Skeletal	B
muscle	I
type	I
ryanodine	I
receptor	I
is	O
involved	O
in	O
calcium	O
signaling	O
in	O
human	O
B	O
lymphocytes	O
.	O

The	O
regulation	O
of	O
intracellular	O
free	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
in	O
B	O
cells	O
remains	O
poorly	O
understood	O
and	O
is	O
presently	O
explained	O
almost	O
solely	O
by	O
inositol	O
1,4,5-triphosphate	O
(	O
IP3	O
)	O
-	O
mediated	O
Ca2	O
+	O
release	O
,	O
followed	O
by	O
activation	O
of	O
a	O
store	O
-	O
operated	O
channel	O
mechanism	O
.	O

In	O
fact	O
,	O
there	O
are	O
reports	O
indicating	O
that	O
IP3	O
production	O
does	O
not	O
always	O
correlate	O
with	O
the	O
magnitude	O
of	O
Ca2	O
+	O
release	O
.	O

We	O
demonstrate	O
here	O
that	O
human	O
B	O
cells	O
express	O
a	O
ryanodine	B
receptor	I
(	O
RYR	B
)	O
that	O
functions	O
as	O
a	O
Ca2	O
+	O
release	O
channel	O
during	O
the	O
B	B
cell	I
antigen	I
receptor	I
(	O
BCR	B
)	O
-	O
stimulated	O
Ca2	O
+	O
signaling	O
process	O
.	O

Immunoblotting	O
studies	O
showed	O
that	O
both	O
human	O
primary	O
CD19	B
(	O
+	O
)	O
B	O
and	O
DAKIKI	O
cells	O
express	O
a	O
565	O
-	O
kDa	O
immunoreactive	O
protein	O
that	O
is	O
indistinguishable	O
in	O
molecular	O
size	O
and	O
immunoreactivity	O
from	O
the	O
RYR	B
.	O

Selective	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
restriction	O
fragment	O
length	O
polymorphism	O
,	O
and	O
sequencing	O
of	O
cloned	O
cDNA	O
indicated	O
that	O
the	O
major	O
isoform	O
of	O
the	O
RYR	B
expressed	O
in	O
primary	O
CD19	B
(	O
+	O
)	O
B	O
and	O
DAKIKI	O
cells	O
is	O
identical	O
to	O
the	O
skeletal	B
muscle	I
type	I
(	O
RYR1	B
)	O
.	O

Saturation	O
analysis	O
of	O
[	O
3H	O
]	O
ryanodine	O
binding	O
yielded	O
Bmax	O
=	O
150	O
fmol	O
/	O
mg	O
of	O
protein	O
and	O
Kd	O
=	O
110	O
nM	O
in	O
DAKIKI	O
cells	O
.	O

In	O
fluo-3-loaded	O
CD19	B
(	O
+	O
)	O
B	O
and	O
DAKIKI	O
cells	O
,	O
4-chloro	O
-	O
m	O
-	O
cresol	O
,	O
a	O
potent	O
activator	O
of	O
Ca2	O
+	O
release	O
mediated	O
by	O
the	O
ryanodine	O
-	O
sensitive	O
Ca2	O
+	O
release	O
channel	O
,	O
induced	O
Ca2	O
+	O
release	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
ryanodine	O
-	O
sensitive	O
fashion	O
.	O

Furthermore	O
,	O
BCR	B
-	O
mediated	O
Ca2	O
+	O
release	O
in	O
CD19	B
(	O
+	O
)	O
B	O
cells	O
was	O
significantly	O
altered	O
by	O
4-chloro	O
-	O
m	O
-	O
cresol	O
and	O
ryanodine	O
.	O

These	O
results	O
indicate	O
that	O
RYR1	B
functions	O
as	O
a	O
Ca2	O
+	O
release	O
channel	O
during	O
BCR	B
-	O
stimulated	O
Ca2	O
+	O
signaling	O
and	O
suggest	O
that	O
complex	O
Ca2	O
+	O
signals	O
that	O
control	O
the	O
cellular	O
activities	O
of	O
B	O
cells	O
may	O
be	O
generated	O
by	O
cooperation	O
of	O
the	O
IP3	B
receptor	I
and	O
RYR1	B
.	O

An	O
interluekin	B
1B	I
allele	O
,	O
which	O
correlates	O
with	O
a	O
high	O
secretor	O
phenotype	O
,	O
is	O
associated	O
with	O
diabetic	O
nephropathy	O
.	O

Induction	O
of	O
interleukin	B
1	I
activates	O
vascular	O
endothelial	O
and	O
kidney	O
mesangial	O
cells	O
,	O
and	O
increases	O
production	O
of	O
type	O
IV	O
(	O
basement	O
membrane	O
)	O
collagen	B
.	O

Hence	O
,	O
genes	O
within	O
the	O
interleukin	B
1	I
gene	O
cluster	O
are	O
potential	O
candidates	O
in	O
the	O
pathogenesis	O
of	O
diabetic	O
nephropathy	O
.	O

In	O
a	O
previously	O
validated	O
case	O
-	O
control	O
study	O
from	O
Northern	O
Ireland	O
,	O
consisting	O
of	O
95	O
patients	O
with	O
insulin	B
-	O
dependent	O
(	O
type	O
1	O
)	O
diabetes	O
and	O
nephropathy	O
(	O
cases	O
)	O
and	O
96	O
patients	O
with	O
insulin	B
-	O
dependent	O
(	O
type	O
1	O
)	O
diabetes	O
without	O
nephropathy	O
(	O
controls	O
)	O
,	O
the	O
authors	O
performed	O
PCR	O
-	O
based	O
genotyping	O
of	O
specific	O
DNA	O
polymorphisms	O
within	O
the	O
interleukin	B
1A	I
,	O
interleukin	B
1B	I
,	O
interleukin	B
1	I
(	I
type	I
1	I
)	I
receptor	I
and	O
interleukin	B
1	I
receptor	I
antagonist	I
genes	O
.	O

The	O
groups	O
were	O
matched	O
for	O
age	O
at	O
onset	O
and	O
duration	O
of	O
diabetes	O
.	O

A	O
statistically	O
significant	O
increase	O
was	O
found	O
in	O
the	O
allele	O
frequency	O
of	O
the	O
interleukin	B
1B*2	I
allele	O
in	O
cases	O
compared	O
to	O
controls	O
(	O
chi2	O
=	O
7	O
.	O
19	O
,	O
df	O
.	O
=	O
1	O
;	O
P	O
=	O
0.007	O
,	O
Pcorr	O
=	O
0.028	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
interleukin	B
1B*2	I
allele	O
,	O
or	O
a	O
susceptibility	O
factor	O
in	O
linkage	O
disequilibrium	O
with	O
this	O
allele	O
,	O
is	O
associated	O
with	O
diabetic	O
nephropathy	O
in	O
the	O
Northern	O
Ireland	O
population	O
.	O

Massive	O
presence	O
of	O
the	O
Escherichia	O
coli	O
'	O
major	O
cold	B
-	I
shock	I
protein	I
'	O
CspA	B
under	O
non	O
-	O
stress	O
conditions	O
.	O

The	O
most	O
characteristic	O
event	O
of	O
cold	O
-	O
shock	O
activation	O
in	O
Escherichia	O
coli	O
is	O
believed	O
to	O
be	O
the	O
de	O
novo	O
synthesis	O
of	O
CspA	B
.	O

We	O
demonstrate	O
,	O
however	O
,	O
that	O
the	O
cellular	O
concentration	O
of	O
this	O
protein	O
is	O
>	O
or	O
=	O
50	O
microM	O
during	O
early	O
exponential	O
growth	O
at	O
37	O
degrees	O
C	O
;	O
therefore	O
,	O
its	O
designation	O
as	O
a	O
major	O
cold	B
-	I
shock	I
protein	I
is	O
a	O
misnomer	O
.	O

The	O
cspA	B
mRNA	O
level	O
decreases	O
rapidly	O
with	O
increasing	O
cell	O
density	O
,	O
becoming	O
virtually	O
undetectable	O
by	O
mid	O
-	O
to	O
-	O
late	O
exponential	O
growth	O
phase	O
while	O
the	O
CspA	B
level	O
declines	O
,	O
although	O
always	O
remaining	O
clearly	O
detectable	O
.	O

A	O
burst	O
of	O
cspA	B
expression	O
followed	O
by	O
a	O
renewed	O
decline	O
ensues	O
upon	O
dilution	O
of	O
stationary	O
phase	O
cultures	O
with	O
fresh	O
medium	O
.	O

The	O
extent	O
of	O
cold	O
-	O
shock	O
induction	O
of	O
cspA	B
varies	O
as	O
a	O
function	O
of	O
the	O
growth	O
phase	O
,	O
being	O
inversely	O
proportional	O
to	O
the	O
pre	O
-	O
existing	O
level	O
of	O
CspA	B
which	O
suggests	O
feedback	O
autorepression	O
by	O
this	O
protein	O
.	O

Both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
controls	O
regulate	O
cspA	B
expression	O
under	O
non	O
-	O
stress	O
conditions	O
;	O
transcription	O
of	O
cspA	B
mRNA	O
is	O
under	O
the	O
antagonistic	O
control	O
of	O
DNA	O
-	O
binding	O
proteins	O
Fis	B
and	O
H	B
-	I
NS	I
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
while	O
its	O
decreased	O
half	O
-	O
life	O
with	O
increasing	O
cell	O
density	O
contributes	O
to	O
its	O
rapid	O
disappearance	O
.	O

The	O
cspA	B
mRNA	O
instability	O
is	O
due	O
to	O
its	O
5	O
'	O
untranslated	O
leader	O
and	O
is	O
counteracted	O
in	O
vivo	O
by	O
the	O
cold	B
-	I
shock	I
DeaD	I
box	I
RNA	I
helicase	I
(	O
CsdA	B
)	O
.	O

Gene	O
expression	O
during	O
differentiation	O
of	O
human	O
dendritic	O
cells	O
from	O
cord	O
blood	O
cd34	B
stem	O
cells	O
.	O

Human	O
cord	O
blood	O
CD34	B
(	O
+	O
)	O
stem	O
cells	O
were	O
allowed	O
to	O
differentiate	O
in	O
the	O
presence	O
of	O
cytokines	B
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
into	O
functional	O
CD1a	B
+	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O

A	O
maximum	O
of	O
1.9	O
x	O
10	O
(	O
6	O
)	O
CD1a	B
+	O
cells	O
were	O
separated	O
from	O
the	O
cells	O
generated	O
from	O
1.2	O
x	O
10	O
(	O
6	O
)	O
CD34	B
(	O
+	O
)	O
stem	O
cells	O
from	O
an	O
individual	O
donor	O
.	O

The	O
percentage	O
of	O
CD1a	B
+	O
cells	O
separated	O
rose	O
to	O
a	O
maximum	O
of	O
27	O
%	O
at	O
day	O
11	O
and	O
fell	O
to	O
8	O
%	O
at	O
21	O
days	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
showed	O
that	O
interleukin	B
2	I
receptor	I
,	O
interleukin	B
3	I
receptor	I
,	O
interleukin	B
6	I
receptor	I
,	O
interleukin	B
12	I
receptor	I
(	O
IL-12R	B
)	O
and	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
3	I
,	O
STAT	B
4	I
mRNA	O
was	O
expressed	O
in	O
all	O
CD1a	B
+	O
cell	O
populations	O
throughout	O
and	O
appears	O
to	O
be	O
constitutive	O
.	O

Expression	O
of	O
IL-12RmRNA	B
was	O
unexpected	O
in	O
CD1a	B
+	O
DC	O
normally	O
considered	O
to	O
be	O
of	O
myeloid	O
lineage	O
.	O

Expression	O
of	O
interleukin	B
12	I
(	I
IL-12	I
)	I
p40	I
subunit	O
mRNA	O
was	O
not	O
detected	O
.	O

Intermittent	O
expression	O
of	O
the	O
IL-12p35	B
subunit	O
and	O
IL-4R	B
mRNA	O
suggested	O
that	O
gene	O
expression	O
is	O
inducible	O
,	O
but	O
not	O
obviously	O
correlated	O
with	O
progressive	O
DC	O
development	O
.	O

Expression	O
of	O
mRNA	O
for	O
a	O
spectrum	O
of	O
cytokine	B
receptors	O
indicates	O
that	O
CD1a	B
+	O
DC	O
have	O
the	O
potential	O
to	O
respond	O
to	O
a	O
variety	O
of	O
maturational	O
signals	O
.	O

Involvement	O
of	O
receptor	O
-	O
bound	O
protein	O
methyltransferase	B
PRMT1	B
in	O
antiviral	O
and	O
antiproliferative	O
effects	O
of	O
type	B
I	I
interferons	I
.	O

Protein	B
arginine	I
N	I
-	I
methyltransferase	I
(	O
PRMT1	B
)	O
is	O
one	O
of	O
the	O
proteins	O
that	O
bind	O
to	O
the	O
intracytoplasmatic	O
domain	O
of	O
the	O
IFNAR-1	B
chain	O
of	O
the	O
type	B
I	I
interferon	I
(	I
IFN	I
)	I
receptor	I
system	O
.	O

The	O
attachment	O
is	O
specific	O
and	O
is	O
not	O
seen	O
with	O
PRMT2	B
,	O
another	O
member	O
of	O
this	O
protein	O
family	O
.	O

Antisense	O
PRMT1	B
cDNA	O
constructs	O
expressed	O
under	O
the	O
early	O
cytomegalovirus	O
(	O
CMV	O
)	O
promoter	O
were	O
transfected	O
into	O
HeLa	O
cells	O
,	O
and	O
stable	O
transformants	O
were	O
selected	O
.	O

Antibodies	O
to	O
PRMT1	B
were	O
used	O
to	O
identify	O
clones	O
with	O
reduced	O
PRMT1	B
expression	O
.	O

In	O
such	O
clones	O
,	O
IFN	B
-	I
beta	I
inhibited	O
three	O
to	O
five	O
times	O
less	O
the	O
replication	O
of	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
than	O
in	O
the	O
original	O
HeLa	O
cells	O
.	O

The	O
antiproliferative	O
effect	O
of	O
IFN	B
-	I
beta	I
was	O
also	O
reduced	O
up	O
to	O
fivefold	O
in	O
the	O
clones	O
with	O
low	O
PRMT1	B
expression	O
.	O

No	O
difference	O
was	O
seen	O
when	O
IFN	B
-	I
gamma	I
was	O
used	O
alone	O
to	O
inhibit	O
cell	O
growth	O
.	O

The	O
protein	O
methylating	O
enzyme	O
,	O
bound	O
to	O
IFNAR-1	B
,	O
appears	O
to	O
regulate	O
positively	O
the	O
biologic	O
activity	O
of	O
type	B
I	I
IFN	I
.	O

Crystal	O
structure	O
of	O
the	O
HLA	B
-	I
Cw3	I
allotype	O
-	O
specific	O
killer	O
cell	O
inhibitory	O
receptor	O
KIR2DL2	B
.	O

Killer	O
cell	O
inhibitory	O
receptors	O
(	O
KIR	B
)	O
protect	O
class	B
I	I
HLAs	I
expressing	O
target	O
cells	O
from	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
-	O
mediated	O
lysis	O
.	O

To	O
understand	O
the	O
molecular	O
basis	O
of	O
this	O
receptor	O
-	O
ligand	O
recognition	O
,	O
we	O
have	O
crystallized	O
the	O
extracellular	O
ligand	O
-	O
binding	O
domains	O
of	O
KIR2DL2	B
,	O
a	O
member	O
of	O
the	O
Ig	B
superfamily	I
receptors	O
that	O
recognize	O
HLA	B
-	I
Cw1	I
,	I
3	I
,	I
7	I
,	I
and	I
8	I
allotypes	O
.	O

The	O
structure	O
was	O
determined	O
in	O
two	O
different	O
crystal	O
forms	O
,	O
an	O
orthorhombic	O
P212121	O
and	O
a	O
trigonal	O
P3221	O
space	O
group	O
,	O
to	O
resolutions	O
of	O
3.0	O
and	O
2.9	O
A	O
,	O
respectively	O
.	O

The	O
overall	O
fold	O
of	O
this	O
structure	O
,	O
like	O
KIR2DL1	B
,	O
exhibits	O
K	O
-	O
type	O
Ig	B
topology	O
with	O
cis	O
-	O
proline	O
residues	O
in	O
both	O
domains	O
that	O
define	O
beta	O
-	O
strand	O
switching	O
,	O
which	O
sets	O
KIR	B
apart	O
from	O
the	O
C2	O
-	O
type	O
hematopoietic	O
growth	B
hormone	I
receptor	I
fold	O
.	O

The	O
hinge	O
angle	O
of	O
KIR2DL2	B
is	O
approximately	O
80	O
degrees	O
,	O
14	O
degrees	O
larger	O
than	O
that	O
observed	O
in	O
KIR2DL1	B
despite	O
the	O
existence	O
of	O
conserved	O
hydrophobic	O
residues	O
near	O
the	O
hinge	O
region	O
.	O

There	O
is	O
also	O
a	O
5	O
degrees	O
difference	O
in	O
the	O
observed	O
hinge	O
angles	O
in	O
two	O
crystal	O
forms	O
of	O
2DL2	B
,	O
suggesting	O
that	O
the	O
interdomain	O
hinge	O
angle	O
is	O
not	O
fixed	O
.	O

The	O
putative	O
ligand	O
-	O
binding	O
site	O
is	O
formed	O
by	O
residues	O
from	O
several	O
variable	O
loops	O
with	O
charge	O
distribution	O
apparently	O
complementary	O
to	O
that	O
of	O
HLA	B
-	I
C	I
.	O

The	O
packing	O
of	O
the	O
receptors	O
in	O
the	O
orthorhombic	O
crystal	O
form	O
offers	O
an	O
intriguing	O
model	O
for	O
receptor	O
aggregation	O
on	O
the	O
cell	O
surface	O
.	O

Identification	O
of	O
the	O
enzyme	O
required	O
for	O
activation	O
of	O
the	O
small	O
ubiquitin	B
-	O
like	O
protein	O
SUMO-1	B
.	O

The	O
ubiquitin	B
-	O
like	O
protein	O
SUMO-1	B
is	O
conjugated	O
to	O
a	O
variety	O
of	O
proteins	O
including	O
Ran	B
GTPase	I
-	I
activating	I
protein	I
1	I
(	O
RanGAP1	B
)	O
,	O
IkappaBalpha	B
,	O
and	O
PML	B
.	O

SUMO-1	B
-	O
modified	O
proteins	O
display	O
altered	O
subcellular	O
targeting	O
and/or	O
stability	O
.	O

We	O
have	O
purified	O
the	O
SUMO-1	B
-	O
activating	O
enzyme	O
from	O
human	O
cells	O
and	O
shown	O
that	O
it	O
contains	O
two	O
subunits	O
of	O
38	O
and	O
72	O
kDa	O
.	O

Isolation	O
of	O
cDNAs	O
for	O
each	O
subunit	O
indicates	O
that	O
they	O
are	O
homologous	O
to	O
ubiquitin	B
-	O
activating	O
enzymes	O
and	O
to	O
the	O
Saccharomyces	O
cerevisiae	O
enzymes	O
responsible	O
for	O
conjugation	O
of	O
Smt3p	B
and	O
Rub-1p	B
.	O

In	O
vitro	O
,	O
recombinant	O
SAE1	B
/	O
SAE2	B
(	O
SUMO-1	B
-	I
activating	I
enzyme	I
)	O
was	O
capable	O
of	O
catalyzing	O
the	O
ATP	O
-	O
dependent	O
formation	O
of	O
a	O
thioester	O
linkage	O
between	O
SUMO-1	B
and	O
SAE2	B
.	O

The	O
addition	O
of	O
the	O
SUMO-1	B
-	O
conjugating	O
enzyme	O
Ubch9	B
resulted	O
in	O
efficient	O
transfer	O
of	O
the	O
thioester	O
-	O
linked	O
SUMO-1	B
from	O
SAE2	B
to	O
Ubch9	B
.	O

In	O
the	O
presence	O
of	O
SAE1	B
/	O
SAE2	B
,	O
Ubch9	B
,	O
and	O
ATP	O
,	O
SUMO-1	B
was	O
efficiently	O
conjugated	O
to	O
the	O
protein	O
substrate	O
IkappaBalpha	B
.	O

As	O
SAE1	B
/	O
SAE2	B
,	O
Ubch9	B
,	O
SUMO-1	B
,	O
and	O
IkappaBalpha	B
are	O
all	O
homogeneous	O
,	O
recombinant	O
proteins	O
,	O
it	O
appears	O
that	O
SUMO-1	B
conjugation	O
of	O
IkappaBalpha	B
in	O
vitro	O
does	O
not	O
require	O
the	O
equivalent	O
of	O
an	O
E3	B
ubiquitin	I
protein	I
ligase	I
activity	O
.	O

Comparison	O
of	O
clinical	O
staging	O
algorithms	O
and	O
111indium	O
-	O
capromab	O
pendetide	O
immunoscintigraphy	O
in	O
the	O
prediction	O
of	O
lymph	O
node	O
involvement	O
in	O
high	O
risk	O
prostate	O
carcinoma	O
patients	O
.	O

BACKGROUND	O
:	O

The	O
pretherapy	O
prediction	O
of	O
occult	O
lymph	O
node	O
involvement	O
and	O
the	O
avoidance	O
of	O
otherwise	O
futile	O
and	O
potentially	O
morbid	O
definitive	O
local	O
therapy	O
is	O
paramount	O
in	O
men	O
with	O
newly	O
diagnosed	O
prostate	O
carcinoma	O
.	O

To	O
identify	O
patients	O
with	O
prostate	O
carcinoma	O
who	O
likely	O
have	O
lymph	O
node	O
involvement	O
and	O
would	O
benefit	O
from	O
staging	O
lymphadenectomy	O
prior	O
to	O
definitive	O
local	O
therapy	O
,	O
the	O
authors	O
compared	O
the	O
ability	O
of	O
several	O
predictive	O
staging	O
algorithms	O
and	O
a	O
radiolabeled	O
monoclonal	O
antibody	O
scan	O
to	O
predict	O
lymphatic	O
metastases	O
prior	O
to	O
treatment	O
.	O

METHODS	O
:	O

Between	O
August	O
1991	O
and	O
June	O
1994	O
,	O
198	O
men	O
with	O
clinical	O
T2	O
or	O
T3	O
classified	O
(	O
TNM	O
)	O
prostate	O
carcinoma	O
(	O
bone	O
scan	O
negative	O
)	O
who	O
were	O
at	O
high	O
risk	O
of	O
lymph	O
node	O
involvement	O
underwent	O
a	O
111In	O
-	O
capromab	O
pendetide	O
scan	O
prior	O
to	O
staging	O
lymphadenectomy	O
.	O

Several	O
predictive	O
models	O
based	O
on	O
preoperative	O
prostate	O
specific	O
antigen	O
level	O
,	O
biopsy	O
Gleason	O
score	O
,	O
and	O
clinical	O
stage	O
were	O
selected	O
to	O
predict	O
those	O
men	O
having	O
a	O
>	O
or	O
=	O
20	O
%	O
probability	O
of	O
lymph	O
node	O
involvement	O
.	O

The	O
ability	O
to	O
predict	O
pathologic	O
stage	O
using	O
several	O
clinical	O
algorithms	O
and	O
the	O
monoclonal	O
antibody	O
scan	O
was	O
compared	O
with	O
pathologic	O
examination	O
of	O
the	O
lymph	O
nodes	O
.	O

RESULTS	O
:	O

Overall	O
,	O
39	O
%	O
of	O
the	O
pelvic	O
lymph	O
node	O
specimens	O
were	O
positive	O
for	O
metastatic	O
disease	O
by	O
pathologic	O
analysis	O
.	O

Published	O
algorithms	O
predicting	O
lymph	O
node	O
metastases	O
had	O
a	O
positive	O
predictive	O
value	O
(	O
PPV	O
)	O
ranging	O
from	O
40.5	O
%	O
to	O
46.6	O
%	O
and	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AUC	O
)	O
ranging	O
from	O
0.52	O
to	O
0.61	O
.	O

The	O
monoclonal	O
antibody	O
scan	O
had	O
a	O
PPV	O
of	O
66.7	O
%	O
and	O
an	O
AUC	O
of	O
0.71	O
.	O

The	O
differences	O
between	O
the	O
PPV	O
and	O
the	O
AUC	O
for	O
the	O
individual	O
clinical	O
algorithms	O
when	O
compared	O
with	O
immunoscintigraphy	O
were	O
statistically	O
significant	O
.	O

Combining	O
the	O
radiolabeled	O
monoclonal	O
antibody	O
scan	O
with	O
clinical	O
predictive	O
models	O
,	O
a	O
PPV	O
of	O
up	O
to	O
72.1	O
%	O
could	O
be	O
obtained	O
.	O

CONCLUSIONS	O
:	O

These	O
data	O
suggest	O
that	O
the	O
PPVs	O
for	O
the	O
clinical	O
predictive	O
algorithms	O
are	O
similar	O
and	O
that	O
the	O
PPV	O
of	O
the	O
radiolabeled	O
monoclonal	O
antibody	O
scan	O
alone	O
or	O
in	O
combination	O
with	O
the	O
algorithms	O
has	O
additional	O
value	O
in	O
predicting	O
lymph	O
node	O
involvement	O
in	O
prostate	O
carcinoma	O
patients	O
at	O
high	O
risk	O
of	O
regional	O
disease	O
spread	O
.	O

These	O
algorithms	O
and	O
the	O
111In	O
-	O
capromab	O
pendetide	O
scan	O
may	O
be	O
used	O
for	O
the	O
appropriate	O
selection	O
of	O
candidates	O
for	O
definitive	O
local	O
therapy	O
in	O
men	O
with	O
clinically	O
localized	O
prostate	O
carcinoma	O
and	O
significant	O
risk	O
of	O
lymph	O
node	O
involvement	O
.	O

Crystal	O
structure	O
of	O
the	O
human	O
p58	B
killer	I
cell	I
inhibitory	I
receptor	I
(	O
KIR2DL3	B
)	O
specific	O
for	O
HLA	B
-	I
Cw3	I
-	O
related	O
MHC	B
class	I
I	I
.	O

BACKGROUND	O
:	O

T	O
cells	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
perform	O
complementary	O
roles	O
in	O
the	O
cellular	O
immune	O
system	O
.	O

T	O
cells	O
identify	O
infected	O
cells	O
directly	O
through	O
recognition	O
of	O
antigenic	O
peptides	O
that	O
are	O
displayed	O
at	O
the	O
target	O
cell	O
surface	O
by	O
the	O
classical	B
major	I
histocompatibility	I
complex	I
(	B
MHC	I
)	I
class	I
I	I
molecules	O
.	O

NK	O
cells	O
monitor	O
the	O
target	O
cell	O
surface	O
for	O
malfunction	O
of	O
this	O
display	O
system	O
,	O
lysing	O
potentially	O
infected	O
cells	O
that	O
might	O
otherwise	O
evade	O
recognition	O
by	O
the	O
T	O
cells	O
.	O

Human	O
killer	B
cell	I
inhibitory	I
receptors	I
(	O
KIRs	B
)	O
control	O
this	O
process	O
by	O
either	O
inhibiting	O
or	O
activating	O
the	O
cytotoxic	O
activity	O
of	O
NK	O
cells	O
via	O
specific	O
binding	O
to	O
MHC	B
class	I
I	I
molecules	O
on	O
the	O
target	O
cell	O
.	O

RESULTS	O
:	O

We	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
extracellular	O
region	O
of	O
the	O
human	O
p58	B
KIR	I
(	O
KIR2DL3	B
)	O
,	O
which	O
is	O
specific	O
for	O
the	O
human	O
MHC	B
class	I
I	I
molecule	O
HLA	B
-	I
Cw3	I
and	O
related	O
alleles	O
.	O

The	O
structure	O
shows	O
the	O
predicted	O
topology	O
of	O
two	O
tandem	O
immunoglobulin	B
-	O
like	O
domains	O
,	O
but	O
comparison	O
with	O
the	O
previously	O
reported	O
structure	O
of	O
the	O
related	O
receptor	O
KIR2DL1	B
reveals	O
an	O
unexpected	O
change	O
of	O
23	O
degrees	O
in	O
the	O
relative	O
orientation	O
of	O
these	O
domains	O
.	O

CONCLUSIONS	O
:	O

The	O
altered	O
orientation	O
of	O
the	O
immunoglobulin	B
-	O
like	O
domains	O
maintains	O
an	O
unusually	O
acute	O
interdomain	O
elbow	O
angle	O
,	O
which	O
therefore	O
appears	O
to	O
be	O
a	O
distinctive	O
feature	O
of	O
the	O
KIRs	B
.	O

The	O
putative	O
MHC	B
class	I
I	I
binding	O
site	O
is	O
located	O
on	O
the	O
outer	O
surface	O
of	O
the	O
elbow	O
,	O
spanning	O
both	O
domains	O
.	O

The	O
unexpected	O
observation	O
that	O
this	O
binding	O
site	O
can	O
be	O
modulated	O
by	O
differences	O
in	O
the	O
relative	O
domain	O
orientations	O
has	O
implications	O
for	O
the	O
general	O
mechanism	O
of	O
KIR	B
-	O
MHC	B
class	I
I	I
complex	O
formation	O
.	O

The	O
SpoIIE	B
phosphatase	B
,	O
the	O
sporulation	O
septum	O
and	O
the	O
establishment	O
of	O
forespore	O
-	O
specific	O
transcription	O
in	O
Bacillus	O
subtilis	O
:	O
a	O
reassessment	O
.	O

Making	O
a	O
spore	O
in	O
Bacillus	O
subtilis	O
requires	O
the	O
formation	O
of	O
two	O
cells	O
,	O
the	O
forespore	O
and	O
the	O
mother	O
cell	O
,	O
which	O
follow	O
dissimilar	O
patterns	O
of	O
gene	O
expression	O
.	O

Cell	O
specificity	O
is	O
first	O
established	O
in	O
the	O
forespore	O
under	O
the	O
control	O
of	O
the	O
sigma	B
F	I
factor	I
,	O
which	O
is	O
itself	O
activated	O
through	O
the	O
action	O
of	O
the	O
SpoIIE	B
serine	B
phosphatase	I
,	O
an	O
enzyme	O
targeted	O
to	O
the	O
septum	O
between	O
the	O
two	O
cells	O
.	O

Deletion	O
of	O
the	O
10	O
transmembrane	O
segments	O
of	O
the	O
SpoIIE	B
protein	O
leads	O
to	O
random	O
distribution	O
of	O
SpoIIE	B
in	O
the	O
cytoplasm	O
.	O

Activation	O
of	O
sigma	B
F	I
is	O
slightly	O
delayed	O
and	O
less	O
efficient	O
than	O
in	O
wild	O
type	O
,	O
but	O
it	O
remains	O
restricted	O
to	O
the	O
forespore	O
in	O
a	O
large	O
proportion	O
of	O
cells	O
and	O
the	O
bacteria	O
sporulate	O
with	O
30	O
%	O
efficiency	O
.	O

Overexpression	O
of	O
the	O
complete	O
SpoIIE	B
protein	O
in	O
a	O
divIC	B
mutant	O
leads	O
to	O
significant	O
sigma	B
F	I
activity	O
,	O
indicating	O
that	O
the	O
septum	O
requirement	O
for	O
activating	O
sigma	B
F	I
can	O
be	O
bypassed	O
.	O

In	O
contradiction	O
to	O
current	O
models	O
,	O
we	O
propose	O
that	O
genetic	O
asymmetry	O
is	O
not	O
created	O
by	O
unequal	O
distribution	O
of	O
SpoIIE	B
within	O
the	O
sporangium	O
,	O
but	O
by	O
exclusion	O
of	O
an	O
inhibitor	O
of	O
SpoIIE	B
from	O
the	O
forespore	O
.	O

This	O
putative	O
inhibitor	O
would	O
be	O
a	O
cytoplasmic	O
molecule	O
that	O
interacts	O
with	O
SpoIIE	B
and	O
shuts	O
off	O
its	O
phosphatase	B
activity	O
until	O
it	O
disappears	O
specifically	O
from	O
the	O
forespore	O
.	O

Post	O
-	O
streptococcal	O
reactive	O
arthritis	O
:	O
a	O
clinical	O
and	O
serological	O
description	O
,	O
revealing	O
its	O
distinction	O
from	O
acute	O
rheumatic	O
fever	O
.	O

OBJECTIVE	O
:	O

To	O
follow	O
-	O
up	O
prospectively	O
patients	O
with	O
arthritis	O
after	O
infection	O
with	O
beta	O
-	O
haemolytic	O
streptococci	O
of	O
Lancefield	O
group	O
A	O
(	O
beta	O
HSA	O
)	O
,	O
with	O
emphasis	O
on	O
clinical	O
characteristics	O
and	O
serological	O
features	O
.	O

We	O
additionally	O
investigated	O
whether	O
these	O
patients	O
,	O
though	O
often	O
fulfilling	O
the	O
Jones	O
'	O
criteria	O
for	O
acute	O
rheumatic	O
fever	O
(	O
ARF	O
)	O
,	O
had	O
a	O
disease	O
with	O
clinical	O
characteristics	O
different	O
from	O
ARF	O
.	O

DESIGN	O
:	O

We	O
performed	O
a	O
systematic	O
prospective	O
observational	O
study	O
of	O
consecutive	O
patients	O
at	O
a	O
Dutch	O
Outpatient	O
Clinic	O
and	O
Department	O
of	O
Rheumatology	O
,	O
with	O
arthritis	O
after	O
throat	O
infection	O
with	O
beta	O
HSA	O
presenting	O
to	O
rheumatologist	O
or	O
internist	O
from	O
September	O
1992	O
until	O
September	O
1996	O
.	O

Main	O
outcome	O
measures	O
were	O
clinical	O
and	O
biochemical	O
characteristics	O
with	O
special	O
reference	O
to	O
carditis	O
.	O

RESULTS	O
:	O

A	O
total	O
of	O
23	O
patients	O
(	O
21	O
Dutch	O
,	O
two	O
Turkish	O
;	O
female	O
/	O
male	O
ratio	O
15	O
/	O
8	O
;	O
mean	O
(	O
SD	O
)	O
age	O
42	O
(	O
14	O
)	O
years	O
)	O
with	O
predominantly	O
non	O
-	O
migratory	O
arthritis	O
were	O
included	O
.	O

A	O
positive	O
throat	O
swab	O
culture	O
was	O
obtained	O
in	O
17	O
%	O
.	O

All	O
patients	O
showed	O
a	O
significant	O
rise	O
of	O
antistreptolysine	O
-	O
O	O
(	O
ASO	O
;	O
normal	O
<	O
200	O
i.u	O
.	O
mL-1	O
)	O
and	O
antideoxyribonuclease	O
-	O
B	O
(	O
anti	O
-	O
DNase	B
-	I
B	I
;	O
normal	O
<	O
200	O
i.u	O
.	O
mL-1	O
)	O
titre	O
.	O

The	O
mean	O
(	O
SEM	O
)	O
maximal	O
ASO	O
was	O
1305	O
(	O
195	O
)	O
i.u	O
.	O
mL-1	O
,	O
and	O
anti	O
-	O
DNase	B
-	I
B	I
titre	O
980	O
(	O
115	O
)	O
i.u	O
.	O
mL-1	O
.	O

Arthritis	O
was	O
present	O
in	O
mean	O
(	O
SEM	O
)	O
5.4	O
(	O
0.9	O
)	O
joints	O
:	O
2.2	O
(	O
0.7	O
)	O
small	O
,	O
3.2	O
(	O
0.4	O
)	O
larger	O
joints	O
.	O

The	O
arthritis	O
was	O
monarticular	O
in	O
23	O
%	O
of	O
the	O
patients	O
,	O
oligoarticular	O
in	O
35	O
%	O
,	O
and	O
polyarticular	O
in	O
43	O
%	O
.	O

Skin	O
abnormalities	O
were	O
present	O
in	O
12	O
patients	O
:	O
erythema	O
nodosum	O
in	O
seven	O
patients	O
(	O
30	O
%	O
)	O
,	O
and	O
erythema	O
multiforme	O
in	O
five	O
patients	O
(	O
22	O
%	O
)	O
.	O

A	O
transient	O
cholestatic	O
hepatitis	O
was	O
found	O
in	O
four	O
patients	O
(	O
17	O
%	O
)	O
.	O

In	O
two	O
patients	O
a	O
transient	O
first	O
-	O
degree	O
conduction	O
block	O
was	O
found	O
;	O
however	O
,	O
neither	O
echocardiography	O
nor	O
clinical	O
course	O
supported	O
carditis	O
.	O

All	O
patients	O
were	O
advised	O
to	O
receive	O
monthly	O
penicillin	O
prophylaxis	O
during	O
a	O
period	O
of	O
2	O
years	O
.	O

Two	O
patients	O
refused	O
to	O
follow	O
medical	O
advice	O
:	O
in	O
one	O
a	O
non	O
-	O
migratory	O
arthritis	O
recurred	O
15	O
months	O
after	O
the	O
first	O
episode	O
of	O
arthritis	O
.	O

CONCLUSION	O
:	O

Commonly	O
,	O
arthritis	O
secondary	O
to	O
beta	O
HSA	O
infection	O
in	O
the	O
Netherlands	O
,	O
a	O
prosperous	O
West	O
-	O
European	O
country	O
with	O
State	O
Welfare	O
,	O
is	O
not	O
accompanied	O
by	O
carditis	O
,	O
contrary	O
to	O
literature	O
on	O
classical	O
ARF	O
.	O

Other	O
factors	O
discriminating	O
it	O
from	O
ARF	O
are	O
the	O
age	O
of	O
onset	O
,	O
the	O
non	O
-	O
migratory	O
character	O
of	O
the	O
arthritis	O
,	O
the	O
high	O
frequency	O
of	O
erythema	O
nodosum	O
and	O
multiforme	O
,	O
as	O
well	O
as	O
the	O
presence	O
of	O
transient	O
hepatitis	O
.	O

As	O
arthritis	O
is	O
the	O
hallmark	O
of	O
this	O
syndrome	O
,	O
post	O
-	O
streptococcal	O
reactive	O
arthritis	O
(	O
PSRA	O
)	O
is	O
the	O
most	O
proper	O
name	O
for	O
this	O
disease	O
entity	O
.	O

Whether	O
penicillin	O
profylaxis	O
is	O
needed	O
in	O
PSRA	O
,	O
as	O
it	O
is	O
in	O
ARF	O
,	O
warrants	O
further	O
prospective	O
investigation	O
.	O

Transcriptional	O
regulation	O
of	O
molybdoenzyme	O
synthesis	O
in	O
Escherichia	O
coli	O
in	O
response	O
to	O
molybdenum	O
:	O
ModE	B
-	O
molybdate	O
,	O
a	O
repressor	O
of	O
the	O
modABCD	B
(	I
molybdate	I
transport	I
)	I
operon	I
is	O
a	O
secondary	O
transcriptional	O
activator	O
for	O
the	O
hyc	B
and	I
nar	I
operons	I
.	O

Escherichia	O
coli	O
growing	O
under	O
anaerobic	O
conditions	O
produces	O
several	O
molybdoenzymes	O
,	O
such	O
as	O
formate	B
hydrogenlyase	I
(	O
formate	O
to	O
H2	O
and	O
CO2	O
;	O
hyc	B
and	O
fdhF	B
genes	O
)	O
and	O
nitrate	B
reductase	I
(	O
narGHJI	B
genes	O
)	O
.	O

Synthesis	O
of	O
these	O
molybdoenzymes	O
,	O
even	O
in	O
the	O
presence	O
of	O
the	O
cognate	O
transcriptional	O
activators	O
and	O
effectors	O
,	O
requires	O
molybdate	O
in	O
the	O
medium	O
.	O

Besides	O
the	O
need	O
for	O
molybdopterin	O
cofactor	O
synthesis	O
,	O
molybdate	O
is	O
also	O
required	O
for	O
transcription	O
of	O
the	O
genes	O
encoding	O
these	O
molybdoenzymes	O
.	O

In	O
E.	O
coli	O
,	O
ModE	B
was	O
previously	O
identified	O
as	O
a	O
repressor	O
controlling	O
transcription	O
of	O
the	O
operon	O
encoding	O
molybdate	O
transport	O
components	O
(	O
modABCD	B
)	O
.	O

In	O
this	O
work	O
,	O
the	O
ModE	B
protein	O
was	O
also	O
found	O
to	O
be	O
a	O
required	O
component	O
in	O
the	O
activation	O
of	O
hyc	B
-	O
lacZ	B
to	O
an	O
optimum	O
level	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
molybdate	O
.	O

Mutant	O
ModE	B
proteins	O
which	O
are	O
molybdate	O
-	O
independent	O
for	O
repression	O
of	O
modA	B
-	O
lacZ	B
also	O
restored	O
hyc	B
-	O
lacZ	B
expression	O
to	O
the	O
wild	O
-	O
type	O
level	O
even	O
in	O
the	O
absence	O
of	O
molybdate	O
.	O

Nitrate	O
-	O
dependent	O
enhancement	O
of	O
transcription	O
of	O
narX	B
-	O
lacZ	B
was	O
completely	O
abolished	O
in	O
a	O
modE	B
mutant	O
.	O

Nitrate	O
-	O
response	O
by	O
narG	B
-	O
lacZ	B
and	O
narK	B
-	O
lacZ	B
was	O
reduced	O
by	O
about	O
50	O
%	O
in	O
a	O
modE	B
mutant	O
.	O

DNase	B
I	I
footprinting	O
experiments	O
revealed	O
that	O
the	O
ModE	B
protein	O
binds	O
the	O
hyc	B
promoter	O
DNA	O
in	O
the	O
presence	O
of	O
molybdate	O
.	O

ModE	B
-	O
molybdate	O
also	O
protected	O
DNA	O
in	O
the	O
intergenic	O
region	O
between	O
narXL	B
and	O
narK	B
from	O
DNase	B
I	I
hydrolysis	O
.	O

DNA	O
sequences	O
(	O
5	O
'	O
TAYAT	O
3	O
'	O
and	O
5	O
'	O
GTTA	O
3	O
'	O
)	O
found	O
in	O
ModE	B
-	O
molybdate	O
-	O
protected	O
modABCD	B
operator	O
DNA	O
were	O
also	O
found	O
in	O
the	O
ModE	B
-	O
molybdate	O
-	O
protected	O
region	O
of	O
hyc	B
promoter	O
DNA	O
(	O
5	O
'	O
GTTA	O
-	O
7	O
bp	O
-	O
CATAT	O
3	O
'	O
)	O
and	O
narX	B
-	O
narK	B
intergenic	O
region	O
(	O
5	O
'	O
GTTA	O
-	O
7	O
bp	O
-	O
TACAT	O
3	O
'	O
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
a	O
working	O
model	O
is	O
proposed	O
in	O
which	O
ModE	B
-	O
molybdate	O
serves	O
as	O
a	O
secondary	O
transcriptional	O
activator	O
of	O
both	O
the	O
hyc	B
and	I
narXL	I
operons	I
which	O
are	O
activated	O
primarily	O
by	O
the	O
transcriptional	O
activators	O
,	O
FhlA	B
and	O
NarL	B
,	O
respectively	O
.	O

Indian	B
hedgehog	I
in	O
the	O
late	O
-	O
phase	O
differentiation	O
in	O
mouse	O
chondrogenic	O
EC	O
cells	O
,	O
ATDC5	O
:	O
upregulation	O
of	O
type	B
X	I
collagen	I
and	O
osteoprotegerin	B
ligand	I
mRNAs	O
.	O

Endochondral	O
bone	O
formation	O
includes	O
a	O
cascade	O
of	O
cellular	O
events	O
such	O
as	O
proliferation	O
,	O
maturation	O
,	O
hypertrophic	O
conversion	O
and	O
calcification	O
of	O
chondrocytes	O
and	O
the	O
cartilage	O
replacement	O
by	O
bone	O
.	O

During	O
these	O
processes	O
,	O
hypertrophic	O
conversion	O
and	O
calcification	O
of	O
chondrocytes	O
(	O
the	O
late	O
-	O
phase	O
differentiation	O
)	O
is	O
a	O
crucial	O
process	O
of	O
chondrogenic	O
differentiation	O
.	O

Indian	B
hedgehog	I
(	O
Ihh	B
)	O
,	O
a	O
secreted	O
protein	O
expressed	O
in	O
early	O
hypertrophic	O
chondrocytes	O
,	O
is	O
thought	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
hypertrophic	O
conversion	O
via	O
a	O
feedback	O
loop	O
through	O
the	O
perichondrium	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
by	O
Northern	O
analysis	O
and	O
in	O
situ	O
hybridization	O
that	O
Smoothened	B
(	O
Smo	B
)	O
,	O
a	O
key	O
component	O
in	O
hedgehog	B
signal	O
transduction	O
,	O
was	O
expressed	O
in	O
chondrocytes	O
in	O
both	O
adult	O
mice	O
and	O
mouse	O
embryos	O
at	O
16	O
days	O
post	O
-	O
coitum	O
in	O
vivo	O
,	O
suggesting	O
that	O
Ihh	B
directly	O
acts	O
on	O
chondrocytes	O
.	O

We	O
previously	O
reported	O
that	O
Ihh	B
,	O
Patched	B
and	O
Smo	B
were	O
all	O
expressed	O
in	O
differentiated	O
ATDC5	O
cells	O
.	O

Exogenously	O
administered	O
mouse	O
recombinant	O
N	O
-	O
terminal	O
protein	O
of	O
Ihh	B
(	O
mrIhh	B
-	O
N	O
)	O
upregulated	O
the	O
gene	O
expression	O
of	O
type	B
X	I
collagen	I
,	O
a	O
phenotypic	O
marker	O
of	O
hypertrophic	O
chondrocytes	O
,	O
as	O
well	O
as	O
osteoprotegerin	B
ligand	I
(	O
OPGL	B
)	O
,	O
a	O
potent	O
stimulator	O
of	O
osteoclastogenesis	O
and	O
osteoclast	O
activity	O
,	O
while	O
it	O
did	O
not	O
modulate	O
the	O
expression	O
of	O
Ihh	O
itself	O
,	O
bone	B
morphogenetic	I
protein	I
(	I
BMP	I
)	I
-	I
4	I
,	O
BMP-6	B
,	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
beta1	I
and	O
TGF	B
-	I
beta2	I
in	O
differentiated	O
ATDC5	O
cells	O
.	O

Moreover	O
,	O
when	O
added	O
to	O
the	O
osteoclast	O
cultures	O
,	O
mrIhh	O
-	O
N	O
N	O
markedly	O
stimulated	O
the	O
formation	O
of	O
resorption	O
pits	O
on	O
dentine	O
slices	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
Ihh	O
stimulated	O
the	O
late	O
-	O
phase	O
chondrogenic	O
differentiation	O
in	O
differentiated	O
ATDC5	O
cells	O
and	O
upregulated	O
the	O
gene	O
expression	O
of	O
OPGL	B
in	O
these	O
cells	O
.	O

Regulation	O
of	O
the	O
enteric	O
nervous	O
system	O
in	O
the	O
internal	O
anal	O
sphincter	O
in	O
Hirschsprung	O
's	O
disease	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O

The	O
cause	O
of	O
impaired	O
motility	O
of	O
the	O
aganglionic	O
internal	O
anal	O
sphincter	O
(	O
IAS	O
)	O
in	O
Hirschsprung	O
's	O
disease	O
(	O
HD	O
)	O
is	O
unknown	O
.	O

To	O
clarify	O
the	O
physiological	O
significance	O
of	O
non	O
-	O
adrenergic	O
non	O
-	O
cholinergic	O
(	O
NANC	O
)	O
excitatory	O
and	O
inhibitory	O
nerves	O
in	O
the	O
IAS	O
of	O
HD	O
,	O
we	O
investigated	O
the	O
enteric	O
nerve	O
responses	O
on	O
lesional	O
and	O
normal	O
IAS	O
in	O
patients	O
with	O
HD	O
and	O
in	O
patients	O
who	O
had	O
undergone	O
rectal	O
amputation	O
for	O
low	O
rectal	O
cancer	O
.	O

METHODOLOGY	O
:	O

Twelve	O
preparations	O
were	O
taken	O
from	O
the	O
lesional	O
IAS	O
of	O
7	O
patients	O
with	O
HD	O
(	O
5	O
boys	O
and	O
2	O
girls	O
aged	O
between	O
6	O
months	O
and	O
1.5	O
years	O
with	O
a	O
mean	O
age	O
of	O
8	O
months	O
)	O
.	O

Twenty	O
preparations	O
were	O
taken	O
from	O
the	O
normal	O
IAS	O
of	O
10	O
patients	O
with	O
low	O
rectal	O
cancer	O
(	O
6	O
men	O
and	O
2	O
women	O
,	O
aged	O
between	O
48	O
and	O
72	O
years	O
with	O
a	O
mean	O
age	O
of	O
54.6	O
years	O
)	O
.	O

A	O
mechanographic	O
technique	O
was	O
used	O
to	O
evaluate	O
in	O
vitro	O
muscle	O
responses	O
to	O
the	O
electrical	O
field	O
stimulation	O
(	O
EFS	O
)	O
of	O
adrenergic	O
and	O
cholinergic	O
nerves	O
before	O
and	O
after	O
treatment	O
with	O
various	O
autonomic	O
nerve	O
blockers	O
.	O

RESULTS	O
:	O

Cholinergic	O
nerves	O
are	O
mainly	O
involved	O
in	O
the	O
regulation	O
of	O
enteric	O
nerve	O
responses	O
to	O
EFS	O
in	O
the	O
normal	O
IAS	O
.	O

The	O
aganglionic	O
IAS	O
of	O
patients	O
with	O
HD	O
was	O
more	O
strongly	O
innervated	O
by	O
cholinergic	O
nerves	O
than	O
the	O
normal	O
IAS	O
(	O
p	O
<	O
0.05	O
)	O
.	O

NANC	O
excitatory	O
and	O
inhibitory	O
nerves	O
were	O
found	O
to	O
act	O
on	O
the	O
normal	O
IAS	O
,	O
but	O
had	O
no	O
effect	O
on	O
it	O
in	O
aganglionosis	O
.	O

CONCLUSIONS	O
:	O

These	O
findings	O
suggest	O
that	O
NANC	O
excitatory	O
and	O
inhibitory	O
nerves	O
play	O
an	O
important	O
role	O
in	O
the	O
impaired	O
motility	O
observed	O
in	O
the	O
IAS	O
in	O
HD	O
.	O

A	O
newly	O
identified	O
member	O
of	O
tumor	B
necrosis	I
factor	I
receptor	I
superfamily	I
(	O
TR6	B
)	O
suppresses	O
LIGHT	B
-	O
mediated	O
apoptosis	O
.	O

TR6	B
(	O
decoy	B
receptor	I
3	I
(	O
DcR3	B
)	O
)	O
is	O
a	O
new	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
(	I
TNFR	I
)	I
family	I
.	O

TR6	B
mRNA	O
is	O
expressed	O
in	O
lung	O
tissues	O
and	O
colon	O
adenocarcinoma	O
,	O
SW480	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
TR6	B
mRNA	O
was	O
shown	O
in	O
the	O
endothelial	O
cell	O
line	O
and	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
/	O
ionomycin	O
in	O
Jurkat	O
T	O
leukemia	O
cells	O
.	O

The	O
open	O
reading	O
frame	O
of	O
TR6	B
encodes	O
300	O
amino	O
acids	O
with	O
a	O
29	O
-	O
residue	O
signal	O
sequence	O
but	O
no	O
transmembrane	O
region	O
.	O

Using	O
histidine	O
-	O
tagged	O
recombinant	O
TR6	B
,	O
we	O
screened	O
soluble	O
forms	O
of	O
TNF	B
-	O
ligand	O
proteins	O
with	O
immunoprecipitation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
TR6	B
specifically	O
binds	O
two	O
cellular	O
ligands	O
,	O
LIGHT	B
(	O
herpes	B
virus	I
entry	I
mediator	I
(	I
HVEM	I
)	I
-	I
L	I
)	O
and	O
Fas	B
ligand	I
(	O
FasL	B
/	O
CD95L	B
)	O
.	O

These	O
bindings	O
were	O
confirmed	O
with	O
HEK	O
293	O
EBNA	O
cells	O
transfected	O
with	O
LIGHT	B
cDNA	O
by	O
flow	O
cytometry	O
.	O

TR6	B
inhibited	O
LIGHT	B
-	O
induced	O
cytotoxicity	O
in	O
HT29	O
cells	O
.	O

It	O
has	O
been	O
shown	O
that	O
LIGHT	B
triggers	O
apoptosis	O
of	O
various	O
tumor	O
cells	O
including	O
HT29	O
cells	O
that	O
express	O
both	O
lymphotoxin	B
beta	I
receptor	I
(	O
LTbetaR	B
)	O
and	O
HVEM	B
/	O
TR2	B
receptors	O
.	O

Our	O
data	O
suggest	O
that	O
TR6	B
inhibits	O
the	O
interactions	O
of	O
LIGHT	B
with	O
HVEM	B
/	O
TR2	B
and	O
LTbetaR	B
,	O
thereby	O
suppressing	O
LIGHT	B
-	O
mediated	O
HT29	O
cell	O
death	O
.	O

Thus	O
,	O
TR6	B
may	O
play	O
a	O
regulatory	O
role	O
for	O
suppressing	O
in	O
FasL	B
-	O
and	O
LIGHT	B
-	O
mediated	O
cell	O
death	O
.	O

Shared	O
and	O
unique	O
determinants	O
of	O
the	O
erythropoietin	B
(	I
EPO	I
)	I
receptor	I
are	O
important	O
for	O
binding	O
EPO	B
and	O
EPO	B
mimetic	O
peptide	O
.	O

We	O
have	O
shown	O
previously	O
that	O
Phe93	O
in	O
the	O
extracellular	O
domain	O
of	O
the	O
erythropoietin	B
(	I
EPO	I
)	I
receptor	I
(	O
EPOR	B
)	O
is	O
crucial	O
for	O
binding	O
EPO	B
.	O

Substitution	O
of	O
Phe93	O
with	O
alanine	O
resulted	O
in	O
a	O
dramatic	O
decrease	O
in	O
EPO	B
binding	O
to	O
the	O
Escherichia	O
coli	O
-	O
expressed	O
extracellular	O
domain	O
of	O
the	O
EPOR	B
(	O
EPO	B
-	O
binding	O
protein	O
or	O
EBP	O
)	O
and	O
no	O
detectable	O
binding	O
to	O
full	O
-	O
length	O
mutant	O
receptor	O
expressed	O
in	O
COS	O
cells	O
.	O

Remarkably	O
,	O
Phe93	O
forms	O
extensive	O
contacts	O
with	O
a	O
peptide	O
ligand	O
in	O
the	O
crystal	O
structure	O
of	O
the	O
EBP	O
bound	O
to	O
an	O
EPO	B
-	O
mimetic	O
peptide	O
(	O
EMP1	O
)	O
,	O
suggesting	O
that	O
Phe93	O
is	O
also	O
important	O
for	O
EMP1	O
binding	O
.	O

We	O
used	O
alanine	O
substitution	O
of	O
EBP	O
residues	O
that	O
contact	O
EMP1	O
in	O
the	O
crystal	O
structure	O
to	O
investigate	O
the	O
function	O
of	O
these	O
residues	O
in	O
both	O
EMP1	O
and	O
EPO	B
binding	O
.	O

The	O
three	O
largest	O
hydrophobic	O
contacts	O
at	O
Phe93	O
,	O
Met150	O
,	O
and	O
Phe205	O
and	O
a	O
hydrogen	O
bonding	O
interaction	O
at	O
Thr151	O
were	O
examined	O
.	O

Our	O
results	O
indicate	O
that	O
Phe93	O
and	O
Phe205	O
are	O
important	O
for	O
both	O
EPO	B
and	O
EMP1	O
binding	O
,	O
Met150	O
is	O
not	O
important	O
for	O
EPO	B
binding	O
but	O
is	O
critical	O
for	O
EMP1	O
binding	O
,	O
and	O
Thr151	O
is	O
not	O
important	O
for	O
binding	O
either	O
ligand	O
.	O

Thus	O
,	O
Phe93	O
and	O
Phe205	O
are	O
important	O
binding	O
determinants	O
for	O
both	O
EPO	B
and	O
EMP1	O
,	O
even	O
though	O
these	O
ligands	O
share	O
no	O
sequence	O
or	O
structural	O
homology	O
,	O
suggesting	O
that	O
these	O
residues	O
may	O
represent	O
a	O
minimum	O
epitope	O
on	O
the	O
EPOR	B
for	O
productive	O
ligand	O
binding	O
.	O

Interplay	O
of	O
global	O
regulators	O
and	O
cell	O
physiology	O
in	O
the	O
general	O
stress	O
response	O
of	O
Escherichia	O
coli	O
.	O

Under	O
various	O
stress	O
conditions	O
,	O
two	O
sigma	O
subunits	O
of	O
RNA	B
polymerase	I
,	O
sigmaS	B
and	O
sigma70	B
,	O
coexist	O
in	O
Escherichia	O
coli	O
cells	O
.	O

In	O
contrast	O
to	O
sigma70	B
,	O
sigmaS	B
is	O
subject	O
to	O
intricate	O
regulation	O
and	O
coordinates	O
an	O
emergency	O
reaction	O
to	O
stress	O
as	O
well	O
as	O
long	O
term	O
stress	O
adaptation	O
.	O

In	O
vivo	O
,	O
the	O
two	O
sigma	B
factors	I
clearly	O
control	O
different	O
genes	O
.	O

Yet	O
,	O
they	O
are	O
structurally	O
and	O
functionally	O
very	O
similar	O
and	O
basically	O
recognize	O
the	O
same	O
promoter	O
sequences	O
.	O

Recent	O
data	O
suggest	O
that	O
sigma	B
factor	I
specificity	O
at	O
stress	O
-	O
activated	O
promoters	O
is	O
affected	O
by	O
the	O
interplay	O
of	O
the	O
two	O
RNA	O
polymeraseholoenzymes	O
with	O
additional	O
regulatory	O
factors	O
,	O
such	O
as	O
H	B
-	I
NS	I
,	O
Lrp	B
,	O
CRP	B
,	O
IHF	B
or	O
Fis	B
,	O
that	O
differentially	O
affect	O
transcription	O
initiation	O
by	O
sigmaS	B
or	O
sigma70	B
in	O
a	O
promoter	O
-	O
specific	O
manner	O
.	O

Epidemiology	O
of	O
tuberculosis	O
in	O
Sardinia	O
:	O
a	O
comparison	O
of	O
two	O
data	O
-	O
gathering	O
methods	O
.	O

SETTING	O
:	O

A	O
complete	O
surveillance	O
system	O
for	O
tuberculosis	O
should	O
be	O
able	O
to	O
guarantee	O
constant	O
updating	O
of	O
incidence	O
and	O
provide	O
useful	O
data	O
on	O
a	O
variety	O
of	O
problems	O
related	O
to	O
tuberculosis	O
such	O
as	O
drug	O
resistance	O
,	O
co	O
-	O
infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
the	O
geographic	O
origin	O
of	O
patients	O
,	O
and	O
mycobacterial	O
species	O
.	O

OBJECTIVE	O
AND	O
DESIGN	O
:	O

To	O
assess	O
the	O
completeness	O
of	O
the	O
surveillance	O
system	O
currently	O
operating	O
in	O
Sardinia	O
,	O
cases	O
seen	O
by	O
all	O
medical	O
centres	O
between	O
1987	O
and	O
1995	O
were	O
compared	O
with	O
those	O
notified	O
to	O
Sardinian	O
Public	O
Health	O
Services	O
for	O
the	O
same	O
period	O
.	O

RESULTS	O
:	O

Each	O
year	O
,	O
on	O
average	O
39	O
%	O
of	O
cases	O
seen	O
in	O
Sardinia	O
are	O
notified	O
;	O
646	O
(	O
40	O
%	O
)	O
of	O
the	O
1591	O
patients	O
notified	O
during	O
the	O
study	O
period	O
were	O
never	O
seen	O
by	O
regional	O
medical	O
centres	O
.	O

An	O
analysis	O
of	O
the	O
results	O
shows	O
that	O
from	O
1992	O
the	O
decline	O
recorded	O
in	O
incidence	O
rates	O
in	O
previous	O
years	O
ceased	O
:	O
1992	O
(	O
26	O
/	O
100,000	O
)	O
,	O
1993	O
(	O
25	O
/	O
100,000	O
)	O
,	O
1994	O
(	O
28	O
/	O
100,000	O
)	O
,	O
and	O
1995	O
(	O
24	O
/	O
100	O
,	O
000	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
current	O
surveillance	O
system	O
in	O
Sardinia	O
is	O
inadequate	O
for	O
performing	O
an	O
accurate	O
epidemiological	O
survey	O
of	O
the	O
disease	O
.	O

Epidemiological	O
analysis	O
based	O
solely	O
on	O
notification	O
can	O
provide	O
neither	O
reliable	O
incidence	O
rates	O
nor	O
useful	O
information	O
concerning	O
many	O
aspects	O
of	O
tuberculosis	O
.	O

Association	O
of	O
terminal	O
complement	B
proteins	I
in	O
solution	O
and	O
modulation	O
by	O
suramin	O
.	O

The	O
association	O
of	O
terminal	O
complement	B
proteins	I
was	O
investigated	O
by	O
analytical	O
ultracentrifugation	O
and	O
multi	O
-	O
angle	O
laser	O
light	O
scattering	O
.	O

Native	O
C8	B
and	O
C9	B
formed	O
a	O
heterodimer	O
in	O
solution	O
of	O
physiological	O
ionic	O
strength	O
with	O
a	O
free	O
-	O
energy	O
change	O
DeltaG	O
degrees	O
of	O
-	O
8.3	O
kcal	O
/	O
mol	O
and	O
a	O
dissociation	O
constant	O
Kd	O
of	O
0.6	O
microM	O
(	O
at	O
20	O
degrees	O
C	O
)	O
that	O
was	O
ionic	O
strength	O
-	O
and	O
temperature	O
-	O
dependent	O
.	O

A	O
van	O
'	O
t	O
Hoff	O
plot	O
of	O
the	O
change	O
in	O
Kd	O
was	O
linear	O
between	O
10	O
and	O
37	O
degrees	O
C	O
and	O
yielded	O
values	O
of	O
DeltaH	O
degrees	O
=	O
-	O
12.9	O
kcal	O
/	O
mol	O
and	O
DeltaS	O
degrees	O
=	O
-	O
15.9	O
cal	O
mol	O
-	O
1	O
deg-1	O
,	O
suggesting	O
that	O
electrostatic	O
forces	O
play	O
a	O
prominent	O
role	O
in	O
the	O
interaction	O
of	O
C8	B
with	O
C9	B
.	O

Native	O
C8	B
also	O
formed	O
a	O
heterodimer	O
with	O
C5	B
,	O
and	O
low	O
concentrations	O
of	O
polyionic	O
ligands	O
such	O
as	O
protamine	O
and	O
suramin	O
inhibited	O
the	O
interaction	O
.	O

Suramin	O
induced	O
high	O
-	O
affinity	O
trimerization	O
of	O
C8	O
(	O
Kd	O
=	O
0.10	O
microM	O
at	O
20	O
degrees	O
C	O
)	O
and	O
dimerization	O
of	O
C9	B
(	O
Kd	O
=	O
0.86	O
microM	O
at	O
20	O
degrees	O
C	O
)	O
.	O

Suramin	O
-	O
induced	O
C8	B
oligomerization	O
may	O
be	O
the	O
primary	O
reason	O
for	O
the	O
drug	O
's	O
ability	O
to	O
prevent	O
complement	O
-	O
mediated	O
hemolysis	O
.	O

Analysis	O
of	O
sedimentation	O
equilibria	O
and	O
also	O
of	O
the	O
fluorescence	O
enhancement	O
of	O
suramin	O
when	O
bound	O
to	O
protein	O
provided	O
evidence	O
for	O
two	O
suramin	O
-	O
binding	O
sites	O
on	O
each	O
C9	B
and	O
three	O
on	O
each	O
C8	B
in	O
the	O
oligomers	O
.	O

Oligomerization	O
could	O
be	O
reversed	O
by	O
high	O
suramin	O
concentrations	O
,	O
but	O
8-aminonaphthalene-1,3,6-	O
trisulfonate	O
(	O
ANTS2-	O
)	O
,	O
which	O
mimics	O
half	O
a	O
suramin	O
molecule	O
,	O
could	O
not	O
compete	O
with	O
suramin	O
binding	O
and	O
oligomerization	O
suggesting	O
that	O
the	O
drug	O
also	O
binds	O
nonionically	O
to	O
the	O
proteins	O
.	O

Contrast	O
enhanced	O
pulsed	O
Doppler	O
and	O
colour	O
-	O
coded	O
duplex	O
studies	O
of	O
the	O
cranial	O
vasculature	O
.	O

INTRODUCTION	O
:	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
Albunex	O
,	O
a	O
vascular	O
contrast	O
agent	O
based	O
on	O
albumin	B
-	O
coated	O
air	O
microbubbles	O
,	O
on	O
pulsed	O
Doppler	O
and	O
colour	O
-	O
coded	O
duplex	O
sonography	O
of	O
the	O
cranial	O
vasculature	O
.	O

METHODS	O
:	O

Twenty	O
healthy	O
male	O
volunteers	O
received	O
intravenous	O
injections	O
of	O
contrast	O
in	O
single	O
doses	O
ranging	O
from	O
0.08	O
to	O
0.30	O
ml	O
/	O
kg	O
.	O

Pulsed	O
wave	O
Doppler	O
sonography	O
examination	O
and	O
colour	O
-	O
coded	O
duplex	O
sonography	O
were	O
carried	O
out	O
in	O
the	O
right	O
internal	O
carotid	O
artery	O
(	O
ICA	O
)	O
and	O
middle	O
cerebral	O
artery	O
(	O
MCA	O
)	O
before	O
and	O
after	O
i.v	O
.	O
contrast	O
.	O

The	O
relative	O
intensity	O
increase	O
of	O
the	O
Doppler	O
signal	O
was	O
measured	O
in	O
decibels	O
.	O

RESULTS	O
:	O

Transpulmonary	O
passage	O
of	O
contrast	O
occurred	O
in	O
sufficient	O
amounts	O
to	O
enhance	O
the	O
intensity	O
of	O
the	O
Doppler	O
signal	O
significantly	O
,	O
but	O
the	O
duration	O
of	O
this	O
effect	O
was	O
short	O
.	O

Contrast	O
enhancement	O
also	O
improved	O
visualization	O
of	O
both	O
the	O
ICA	O
and	O
MCA	O
in	O
all	O
subjects	O
.	O

For	O
the	O
transcranial	O
examinations	O
,	O
this	O
resulted	O
in	O
visualization	O
of	O
a	O
greater	O
length	O
of	O
the	O
middle	O
cerebral	O
arteries	O
and	O
additional	O
vessels	O
in	O
the	O
Circle	O
of	O
Willis	O
.	O

CONCLUSIONS	O
:	O

These	O
results	O
confirm	O
that	O
contrast	O
enhancement	O
can	O
significantly	O
improve	O
the	O
quality	O
of	O
Doppler	O
examination	O
and	O
colour	O
-	O
coded	O
duplex	O
sonography	O
of	O
both	O
the	O
intracranial	O
and	O
extracranial	O
vessels	O
.	O

However	O
,	O
the	O
use	O
of	O
Albunex	O
in	O
neurosonology	O
will	O
be	O
of	O
limited	O
value	O
due	O
to	O
its	O
relatively	O
short	O
duration	O
.	O

Presenilins	B
interact	O
with	O
Rab11	B
,	O
a	O
small	B
GTPase	I
involved	O
in	O
the	O
regulation	O
of	O
vesicular	O
transport	O
.	O

Presenilin	B
1	I
(	O
PS1	B
)	O
mutations	O
account	O
for	O
the	O
majority	O
of	O
early	O
-	O
onset	O
dominant	O
cases	O
of	O
familial	O
Alzheimer	O
's	O
disease	O
.	O

Presenilins	B
(	O
PSs	B
)	O
are	O
located	O
in	O
many	O
intra	O
-	O
cellular	O
compartments	O
such	O
as	O
the	O
endoplasmic	O
reticulum	O
,	O
Golgi	O
apparatus	O
,	O
nuclear	O
region	O
and	O
vesicular	O
structures	O
.	O

These	O
proteins	O
include	O
from	O
seven	O
to	O
nine	O
putative	O
transmembrane	O
domains	O
,	O
with	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
ends	O
and	O
a	O
large	O
hydrophilic	O
loop	O
orientated	O
towards	O
the	O
cytoplasm	O
.	O

We	O
report	O
an	O
interaction	O
between	O
the	O
human	O
PS1	B
or	O
PS2	B
hydrophilic	O
loop	O
and	O
Rab11	B
,	O
a	O
small	B
GTPase	I
belonging	O
to	O
the	O
Ras	B
-	I
related	I
superfamily	I
.	O

Interaction	O
domains	O
were	O
mapped	O
to	O
codons	O
374	O
-	O
400	O
for	O
PS1	B
and	O
to	O
codons	O
106	O
-	O
179	O
for	O
Rab11	B
,	O
a	O
region	O
including	O
the	O
fourth	O
GTP	O
-	O
binding	O
domain	O
.	O

Considering	O
the	O
implication	O
of	O
Rab	B
proteins	O
in	O
vesicular	O
transport	O
pathways	O
,	O
the	O
PS	B
-	O
Rab11	B
inter	O
-	O
action	O
suggests	O
that	O
PSs	B
might	O
be	O
involved	O
in	O
amyloid	O
precursor	O
protein	O
vesicular	O
routing	O
.	O

Computer	O
analysis	O
of	O
transcription	O
regulatory	O
patterns	O
in	O
completely	O
sequenced	O
bacterial	O
genomes	O
.	O

Recognition	O
of	O
transcription	O
regulation	O
sites	O
(	O
operators	O
)	O
is	O
a	O
hard	O
problem	O
in	O
computational	O
molecular	O
biology	O
.	O

In	O
most	O
cases	O
,	O
small	O
sample	O
size	O
and	O
low	O
degree	O
of	O
sequence	O
conservation	O
preclude	O
the	O
construction	O
of	O
reliable	O
recognition	O
rules	O
.	O

We	O
suggest	O
an	O
approach	O
to	O
this	O
problem	O
based	O
on	O
simultaneous	O
analysis	O
of	O
several	O
related	O
genomes	O
.	O

It	O
appears	O
that	O
as	O
long	O
as	O
a	O
gene	O
coding	O
for	O
a	O
transcription	O
regulator	O
is	O
conserved	O
in	O
the	O
compared	O
bacterial	O
genomes	O
,	O
the	O
regulation	O
of	O
the	O
respective	O
group	O
of	O
genes	O
(	O
regulons	O
)	O
also	O
tends	O
to	O
be	O
maintained	O
.	O

Thus	O
a	O
gene	O
can	O
be	O
confidently	O
predicted	O
to	O
belong	O
to	O
a	O
particular	O
regulon	O
in	O
case	O
not	O
only	O
itself	O
,	O
but	O
also	O
its	O
orthologs	O
in	O
other	O
genomes	O
have	O
candidate	O
operators	O
in	O
the	O
regulatory	O
regions	O
.	O

This	O
provides	O
for	O
a	O
greater	O
sensitivity	O
of	O
operator	O
identification	O
as	O
even	O
relatively	O
weak	O
signals	O
are	O
likely	O
to	O
be	O
functionally	O
relevant	O
when	O
conserved	O
.	O

We	O
use	O
this	O
approach	O
to	O
analyze	O
the	O
purine	O
(	O
PurR	B
)	O
,	O
arginine	O
(	O
ArgR	B
)	O
and	O
aromatic	O
amino	O
acid	O
(	O
TrpR	B
and	O
TyrR	B
)	O
regulons	O
of	O
Escherichia	O
coli	O
and	O
Haemophilus	O
influenzae	O
.	O

Candidate	O
binding	O
sites	O
in	O
regulatory	O
regions	O
of	O
the	O
respective	O
H.influenzae	O
genes	O
are	O
identified	O
,	O
a	O
new	O
family	B
of	I
purine	I
transport	I
proteins	I
predicted	O
to	O
belong	O
to	O
the	O
PurR	B
regulon	O
is	O
described	O
,	O
and	O
probable	O
regulation	O
of	O
arginine	O
transport	O
by	O
ArgR	B
is	O
demonstrated	O
.	O

Differences	O
in	O
the	O
regulation	O
of	O
some	O
orthologous	O
genes	O
in	O
E.coli	O
and	O
H.influenzae	O
,	O
in	O
particular	O
the	O
apparent	O
lack	O
of	O
the	O
autoregulation	O
of	O
the	O
purine	B
repressor	I
gene	O
in	O
H.influenzae	O
,	O
are	O
demonstrated	O
.	O

Assaying	O
RNA	O
chaperone	B
activity	O
in	O
vivo	O
using	O
a	O
novel	O
RNA	O
folding	O
trap	O
.	O

In	O
the	O
absence	O
of	O
proteins	O
,	O
RNAs	O
often	O
misfold	O
in	O
vitro	O
due	O
to	O
alternative	O
base	O
pairings	O
which	O
result	O
from	O
the	O
molecule	O
being	O
trapped	O
in	O
inactive	O
conformations	O
.	O

We	O
identify	O
an	O
in	O
vivo	O
folding	O
trap	O
in	O
the	O
T4	O
phage	O
td	B
gene	O
,	O
caused	O
by	O
nine	O
base	O
pairs	O
between	O
a	O
sequence	O
element	O
in	O
the	O
upstream	O
exon	O
of	O
the	O
td	B
gene	O
and	O
another	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
intron	O
.	O

During	O
translation	O
,	O
the	O
ribosome	O
resolves	O
this	O
interaction	O
;	O
consequently	O
the	O
intron	O
folds	O
correctly	O
and	O
splicing	O
occurs	O
.	O

The	O
introduction	O
of	O
a	O
stop	O
codon	O
upstream	O
of	O
this	O
base	O
pairing	O
prevents	O
resolution	O
of	O
the	O
inactive	O
structure	O
so	O
that	O
splicing	O
can	O
not	O
proceed	O
.	O

We	O
have	O
used	O
this	O
folding	O
trap	O
to	O
probe	O
for	O
RNA	O
binding	O
proteins	O
which	O
,	O
when	O
overexpressed	O
,	O
either	O
resolve	O
the	O
misfolded	O
structure	O
or	O
impede	O
its	O
formation	O
in	O
vivo	O
.	O

We	O
distinguish	O
between	O
proteins	O
which	O
recognize	O
the	O
intron	O
structure	O
and	O
those	O
which	O
bind	O
non	O
-	O
specifically	O
and	O
apparently	O
ignore	O
the	O
intron	O
.	O

The	O
first	O
class	O
,	O
e.g.	O
Neurospora	O
crassa	O
CYT-18	B
,	O
can	O
rescue	O
the	O
exonic	O
trap	O
and	O
intron	O
mutants	O
which	O
cause	O
a	O
structural	O
defect	O
.	O

However	O
,	O
known	O
RNA	O
chaperones	B
such	O
as	O
Escherichia	O
coli	O
StpA	B
and	O
S12	B
and	O
the	O
HIV	O
protein	O
NCp7	B
,	O
only	O
resolve	O
the	O
exonic	O
trap	O
without	O
suppressing	O
intron	O
mutations	O
.	O

Thus	O
,	O
this	O
structural	O
trap	O
enables	O
detection	O
of	O
RNA	O
chaperone	B
activity	O
in	O
vivo	O
.	O

Endogenous	O
presenilin	B
1	I
redistributes	O
to	O
the	O
surface	O
of	O
lamellipodia	O
upon	O
adhesion	O
of	O
Jurkat	O
cells	O
to	O
a	O
collagen	B
matrix	O
.	O

Most	O
familial	O
early	O
-	O
onset	O
Alzheimer	O
's	O
disease	O
cases	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
presenilin	B
1	I
(	O
PS1	B
)	O
gene	O
.	O

Subcellular	O
localization	O
of	O
the	O
endogenous	O
PS1	B
is	O
essential	O
for	O
understanding	O
its	O
function	O
,	O
interactions	O
with	O
proteins	O
,	O
and	O
role	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Although	O
numerous	O
studies	O
revealed	O
predominant	O
localization	O
of	O
PS1	B
to	O
endoplasmic	O
reticulum	O
and	O
Golgi	O
,	O
there	O
are	O
conflicting	O
reports	O
on	O
the	O
localization	O
of	O
PS1	B
to	O
the	O
cell	O
surface	O
.	O

We	O
found	O
that	O
endogenous	O
PS1	B
is	O
highly	O
expressed	O
in	O
T	O
lymphocytes	O
(	O
Jurkat	O
cells	O
)	O
.	O

Using	O
a	O
variety	O
of	O
methods	O
,	O
we	O
present	O
evidence	O
that	O
endogenous	O
PS1	B
is	O
localized	O
to	O
the	O
cell	O
surface	O
in	O
addition	O
to	O
intracellular	O
membrane	O
compartments	O
.	O

Moreover	O
,	O
PS1	B
appeared	O
in	O
high	O
levels	O
on	O
the	O
surface	O
of	O
lamellipodia	O
upon	O
adhesion	O
of	O
the	O
cells	O
to	O
a	O
collagen	B
matrix	O
.	O

The	O
redistribution	O
of	O
PS1	B
in	O
adhered	O
cells	O
was	O
strikingly	O
similar	O
to	O
that	O
of	O
the	O
well	O
characterized	O
adhesion	B
protein	I
CD44	B
.	O

Cell	O
surface	O
PS1	B
formed	O
complexes	O
in	O
vivo	O
with	O
actin	B
-	I
binding	I
protein	I
filamin	B
(	O
ABP-280	B
)	O
,	O
which	O
is	O
known	O
to	O
form	O
bridges	O
between	O
cell	O
surface	O
receptors	O
and	O
cytoskeleton	O
and	O
mediate	O
cell	O
adhesion	O
and	O
cell	O
motility	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
a	O
role	O
of	O
PS1	B
in	O
cell	O
adhesion	O
and/or	O
cell	O
-	O
matrix	O
interaction	O
.	O

A	O
single	O
amino	O
acid	O
substitution	O
in	O
the	O
cyclin	B
D	I
binding	O
domain	O
of	O
the	O
infected	O
cell	O
protein	O
no	O
.	O

0	O
abrogates	O
the	O
neuroinvasiveness	O
of	O
herpes	O
simplex	O
virus	O
without	O
affecting	O
its	O
ability	O
to	O
replicate	O
.	O

The	O
infected	O
cell	O
protein	O
no	O
.	O

0	O
(	O
ICP0	B
)	O
of	O
herpes	O
simplex	O
virus	O
1	O
is	O
a	O
promiscuous	O
transactivator	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
genes	O
introduced	O
into	O
cells	O
by	O
infection	O
or	O
transfection	O
.	O

The	O
protein	O
interacts	O
with	O
several	O
viral	O
and	O
cellular	O
proteins	O
.	O

Earlier	O
studies	O
have	O
shown	O
that	O
ICP0	B
binds	O
and	O
stabilizes	O
cyclin	B
D3	I
but	O
does	O
interfere	O
with	O
the	O
phosphorylation	O
of	O
retinoblastoma	B
protein	I
,	O
its	O
major	O
function	O
.	O

Cyclin	B
D3	I
plays	O
a	O
key	O
role	O
in	O
the	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
.	O

To	O
define	O
the	O
role	O
of	O
cyclin	B
D3	I
in	O
productive	O
infection	O
,	O
the	O
ICP0	B
binding	O
site	O
for	O
cyclin	B
D3	I
was	O
mapped	O
and	O
mutagenized	O
by	O
substitution	O
of	O
aspartic	O
acid	O
codon	O
199	O
with	O
the	O
alanine	O
codon	O
.	O

We	O
report	O
that	O
the	O
substitution	O
precluded	O
the	O
interaction	O
of	O
this	O
protein	O
with	O
cyclin	B
D3	I
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
and	O
the	O
stabilization	O
of	O
cyclin	B
D3	I
in	O
infected	O
cells	O
.	O

A	O
recombinant	O
virus	O
carrying	O
this	O
mutation	O
could	O
not	O
be	O
differentiated	O
from	O
wild	O
-	O
type	O
parent	O
with	O
respect	O
to	O
replication	O
in	O
dividing	O
cells	O
but	O
yielded	O
10	O
-	O
fold	O
less	O
progeny	O
from	O
infected	O
resting	O
cells	O
and	O
serum	O
-	O
deprived	O
or	O
contact	O
-	O
inhibited	O
human	O
fibroblasts	O
.	O

In	O
mice	O
,	O
the	O
mutant	O
was	O
only	O
slightly	O
less	O
pathogenic	O
than	O
the	O
wild	O
-	O
type	O
parent	O
by	O
intracerebral	O
route	O
but	O
was	O
significantly	O
less	O
neuroinvasive	O
after	O
peripheral	O
inoculation	O
.	O

Replacement	O
of	O
the	O
mutated	O
amino	O
acid	O
with	O
aspartic	O
acid	O
restored	O
wild	O
-	O
type	O
phenotype	O
.	O

Stabilization	O
of	O
cyclin	B
D3	I
therefore	O
is	O
linked	O
to	O
higher	O
virus	O
yields	O
in	O
nondividing	O
cells	O
and	O
potentially	O
higher	O
virulence	O
in	O
experimental	O
and	O
natural	O
hosts	O
.	O

One	O
function	O
of	O
ICP0	B
is	O
to	O
scavenge	O
the	O
cell	O
for	O
proteins	O
that	O
could	O
bolster	O
viral	O
replication	O
.	O

Intracellular	O
expression	O
and	O
functional	O
properties	O
of	O
an	O
anti	O
-	O
p21Ras	B
scFv	O
derived	O
from	O
a	O
rat	O
hybridoma	O
containing	O
specific	O
lambda	O
and	O
irrelevant	O
kappa	B
light	I
chains	I
.	O

A	O
rat	O
single	O
-	O
chain	O
Fv	O
(	O
Y238	O
scFv	O
)	O
was	O
derived	O
from	O
the	O
Y13	O
-	O
238	O
monoclonal	O
antibody	B
,	O
a	O
non	O
-	O
neutralizing	O
anti	O
-	O
Ras	B
antibody	B
.	O

The	O
Y13	O
-	O
238	O
hybridoma	O
expresses	O
two	O
functional	O
light	O
chains	O
.	O

N	O
-	O
terminus	O
microsequencing	O
of	O
these	O
chains	O
showed	O
the	O
presence	O
of	O
the	O
Y3	O
Ag1.2.3	O
Vkappa	B
chain	I
derived	O
from	O
the	O
rat	O
fusion	O
partner	O
and	O
of	O
a	O
rat	O
Vlambda	B
chain	I
.	O

Primers	O
designed	O
for	O
rat	O
Vlambda	B
amplification	O
allowed	O
the	O
cloning	O
of	O
a	O
functional	O
scFv	O
that	O
could	O
bind	O
p21Ras	B
.	O

The	O
kinetics	O
of	O
interaction	O
of	O
purified	O
Y238	O
scFv	O
with	O
the	O
p21Ras	B
protein	O
was	O
evaluated	O
by	O
BIAcore	O
with	O
a	O
NTA	O
sensor	O
chip	O
and	O
gave	O
an	O
apparent	O
affinity	O
constant	O
in	O
the	O
nanomolar	O
range	O
(	O
K	O
(	O
D	O
)	O
=	O
4.58	O
+	O
/-	O
0.63	O
nM	O
)	O
.	O

Immunoprecipitation	O
experiments	O
of	O
Y238	O
scFv	O
expressed	O
in	O
Xenopus	O
laevis	O
oocytes	O
confirmed	O
the	O
specificity	O
of	O
the	O
scFv	O
for	O
the	O
Ras	B
protein	O
.	O

Y238	O
scFv	O
could	O
be	O
intracellularly	O
expressed	O
in	O
oocytes	O
and	O
in	O
mammaliam	O
cells	O
without	O
adverse	O
effect	O
on	O
the	O
Ras	B
signalling	O
cascade	O
.	O

This	O
scFv	O
was	O
therefore	O
used	O
as	O
control	O
in	O
experiments	O
where	O
another	O
anti	O
-	O
Ras	B
scFv	O
(	O
Y259	O
scFv	O
,	O
derived	O
from	O
the	O
neutralizing	O
anti	O
-	O
Ras	B
mAb	O
Y13	O
-	O
259	O
)	O
blocked	O
the	O
Ras	B
pathway	O
in	O
vitro	O
and	O
led	O
to	O
tumor	O
regression	O
in	O
a	O
nude	O
mouse	O
model	O
[	O
Cochet	O
,	O
O.	O
,	O
Kenigsberg	O
,	O
M.	O
,	O
Delumeau	O
,	O
I.	O
,	O
Virone	O
-	O
Oddos	O
,	O
A.	O
,	O
Multon	O
,	O
M.C.	O
,	O
Fridman	O
,	O
W.H.	O
,	O
Schweighoffer	O
,	O
F.	O
,	O
Teillaud	O
,	O
J.L.	O
,	O
TocquÃ?Â	O
©	O
,	O
B.	O
,	O
1998	O
.	O
Intracellular	O
expression	O
of	O
an	O
antibody	O
fragment	O
-	O
neutralizing	O
p21	B
ras	I
promotes	O
tumor	O
regression	O
.	O
Cancer	O
Res	O
.	O
58	O
,	O
1170	O
-	O
1176	O
.	O
]	O
.	O

Finally	O
,	O
BIAcore	O
analyses	O
indicated	O
that	O
the	O
epitopes	O
recognized	O
by	O
Y238	O
and	O
Y259	O
scFvs	O
are	O
not	O
overlapping	O
and	O
allowed	O
a	O
more	O
precise	O
definition	O
of	O
the	O
Y13	O
-	O
238	O
epitope	O
.	O

A	O
region	O
of	O
sigmaK	B
involved	O
in	O
promoter	O
activation	O
by	O
GerE	B
in	O
Bacillus	O
subtilis	O
.	O

During	O
endospore	O
formation	O
in	O
Bacillus	O
subtilis	O
,	O
the	O
DNA	O
binding	O
protein	O
GerE	B
stimulates	O
transcription	O
from	O
several	O
promoters	O
that	O
are	O
used	O
by	O
RNA	B
polymerase	I
containing	O
sigmaK	B
.	O

GerE	B
binds	O
to	O
a	O
site	O
on	O
one	O
of	O
these	O
promoters	O
,	O
cotX	B
,	O
that	O
overlaps	O
its	O
-	O
35	O
region	O
.	O

We	O
tested	O
the	O
model	O
that	O
GerE	B
interacts	O
with	O
sigmaK	B
at	O
the	O
cotX	B
promoter	O
by	O
seeking	O
amino	O
acid	O
substitutions	O
in	O
sigmaK	B
that	O
interfered	O
with	O
GerE	B
-	O
dependent	O
activation	O
of	O
the	O
cotX	B
promoter	O
but	O
which	O
did	O
not	O
affect	O
utilization	O
of	O
the	O
sigmaK	B
-	O
dependent	O
,	O
GerE	B
-	O
independent	O
promoter	O
gerE	B
.	O

We	O
identified	O
two	O
amino	O
acid	O
substitutions	O
in	O
sigmaK	B
,	O
E216	O
K	O
and	O
H225Y	O
,	O
that	O
decrease	O
cotX	B
promoter	O
utilization	O
but	O
do	O
not	O
affect	O
gerE	B
promoter	O
activity	O
.	O

Alanine	O
substitutions	O
at	O
these	O
positions	O
had	O
similar	O
effects	O
.	O

We	O
also	O
examined	O
the	O
effects	O
of	O
the	O
E216A	O
and	O
H225Y	O
substitutions	O
in	O
sigmaK	B
on	O
transcription	O
in	O
vitro	O
.	O

We	O
found	O
that	O
these	O
substitutions	O
specifically	O
reduced	O
utilization	O
of	O
the	O
cotX	B
promoter	O
.	O

These	O
and	O
other	O
results	O
suggest	O
that	O
the	O
amino	O
acid	O
residues	O
at	O
positions	O
216	O
and	O
225	O
are	O
required	O
for	O
GerE	B
-	O
dependent	O
cotX	B
promoter	O
activity	O
,	O
that	O
the	O
histidine	O
at	O
position	O
225	O
of	O
sigmaK	B
may	O
interact	O
with	O
GerE	B
at	O
the	O
cotX	B
promoter	O
,	O
and	O
that	O
this	O
interaction	O
may	O
facilitate	O
the	O
initial	O
binding	O
of	O
sigmaK	B
RNA	B
polymerase	I
to	O
the	O
cotX	B
promoter	O
.	O

We	O
also	O
found	O
that	O
the	O
alanine	O
substitutions	O
at	O
positions	O
216	O
and	O
225	O
of	O
sigmaK	B
had	O
no	O
effect	O
on	O
utilization	O
of	O
the	O
GerE	B
-	O
dependent	O
promoter	O
cotD	B
,	O
which	O
contains	O
GerE	B
binding	O
sites	O
that	O
do	O
not	O
overlap	O
with	O
its	O
-	O
35	O
region	O
.	O

The	O
nuclear	O
receptor	O
corepressor	O
N	B
-	I
CoR	I
regulates	O
differentiation	O
:	O
N	B
-	I
CoR	I
directly	O
interacts	O
with	O
MyoD	B
.	O

Classical	O
ligand	O
-	O
activated	O
nuclear	O
receptors	O
(	O
e.g.	O
thyroid	B
hormone	I
receptor	I
,	O
retinoic	B
acid	I
receptor	I
)	O
,	O
orphan	O
nuclear	O
receptors	O
(	O
e.g.	O
Rev	B
-	I
erbAalpha	I
/	I
beta	I
)	O
,	O
Mad	B
/	O
Max	B
bHLH	O
(	O
basic	O
helix	O
loop	O
helix	O
)	O
-	O
LZ	O
proteins	O
,	O
and	O
oncoproteins	O
,	O
PLZF	B
and	O
LAZ3	B
/	O
BCL6	B
,	O
bind	O
DNA	O
and	O
silence	O
transcription	O
by	O
recruiting	O
a	O
repressor	O
complex	O
that	O
contains	O
N	B
-	I
CoR	I
(	O
nuclear	B
receptor	I
corepressor	I
)	O
/	O
SMRT	B
(	O
silencing	B
mediator	I
of	I
retinoic	I
acid	I
and	I
thyroid	I
hormone	I
receptor	I
)	O
,	O
Sin3A	B
/	I
B	I
,	O
and	O
HDAc-1	B
/	I
-	I
2	I
proteins	O
.	O

The	O
function	O
of	O
the	O
corepressor	O
,	O
N	B
-	I
CoR	I
,	O
in	O
the	O
process	O
of	O
cellular	O
differentiation	O
and	O
coupled	O
phenotypic	O
acquisition	O
,	O
has	O
not	O
been	O
investigated	O
.	O

We	O
examined	O
the	O
functional	O
role	O
of	O
N	B
-	I
CoR	I
in	O
myogenesis	O
(	O
muscle	O
differentiation	O
)	O
,	O
an	O
ideal	O
paradigm	O
for	O
the	O
analysis	O
of	O
the	O
determinative	O
events	O
that	O
govern	O
the	O
cell	O
's	O
decision	O
to	O
divide	O
or	O
differentiate	O
.	O

We	O
observed	O
that	O
the	O
mRNA	O
encoding	O
N	B
-	I
CoR	I
was	O
suppressed	O
as	O
proliferating	O
myoblasts	O
exited	O
the	O
cell	O
cycle	O
,	O
and	O
formed	O
morphologically	O
and	O
biochemically	O
differentiated	O
myotubes	O
.	O

Exogenous	O
expression	O
of	O
N	B
-	I
CoR	I
(	O
but	O
not	O
RIP13	B
)	O
in	O
myogenic	O
cells	O
ablated	O
1	O
)	O
myogenic	O
differentiation	O
,	O
2	O
)	O
the	O
expression	O
of	O
the	O
myoD	B
gene	I
family	I
that	O
encode	O
the	O
myogenic	O
specific	O
bHLH	O
proteins	O
,	O
and	O
3	O
)	O
the	O
crucial	O
cell	O
cycle	O
regulator	O
,	O
p21Waf-1	B
/	O
Cip-1	B
mRNA	O
.	O

Furthermore	O
,	O
N	B
-	I
CoR	I
expression	O
efficiently	O
inhibits	O
the	O
myoD	B
-	O
mediated	O
myogenic	O
conversion	O
of	O
pluripotential	O
C3H10T1	O
/	O
2	O
cells	O
.	O

We	O
demonstrate	O
that	O
MyoD	B
-	O
mediated	O
transactivation	O
and	O
activity	O
are	O
repressed	O
by	O
N	B
-	I
CoR	I
.	O

The	O
mechanism	O
involves	O
direct	O
interactions	O
between	O
MyoD	B
and	O
N	B
-	I
CoR	I
;	O
moreover	O
,	O
the	O
interaction	O
was	O
dependent	O
on	O
the	O
amino	O
-	O
terminal	O
repression	O
domain	O
(	O
RD1	O
)	O
of	O
N	B
-	I
CoR	I
and	O
the	O
bHLH	O
region	O
of	O
MyoD	B
.	O

Trichostatin	O
A	O
treatment	O
significantly	O
stimulated	O
the	O
activity	O
of	O
MyoD	B
by	O
approximately	O
10	O
-	O
fold	O
and	O
inhibited	O
the	O
ability	O
of	O
N	B
-	I
CoR	I
to	O
repress	O
MyoD	B
-	O
mediated	O
transactivation	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
the	O
corepressor	O
and	O
the	O
recruitment	O
of	O
a	O
histone	B
deacteylase	I
activity	O
in	O
the	O
process	O
.	O

This	O
work	O
demonstrates	O
that	O
the	O
corepressor	O
N	B
-	I
CoR	I
is	O
a	O
key	O
regulator	O
of	O
MyoD	B
activity	O
and	O
mammalian	O
differentiation	O
,	O
and	O
that	O
N	B
-	I
CoR	I
has	O
a	O
multifaceted	O
role	O
in	O
myogenesis	O
.	O

Role	O
of	O
lon	B
and	O
ClpX	B
in	O
the	O
post	O
-	O
translational	O
regulation	O
of	O
a	O
sigma	B
subunit	I
of	I
RNA	I
polymerase	I
required	O
for	O
cellular	O
differentiation	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
RNA	B
polymerase	I
sigma	I
subunit	I
,	O
sigmaH	B
(	O
Spo0H	B
)	O
of	O
Bacillus	O
subtilis	O
,	O
is	O
essential	O
for	O
the	O
transcription	O
of	O
genes	O
that	O
function	O
in	O
sporulation	O
and	O
genetic	O
competence	O
.	O

Although	O
spo0H	B
is	O
transcriptionally	O
regulated	O
by	O
the	O
key	O
regulatory	O
device	O
that	O
controls	O
sporulation	O
initiation	O
,	O
the	O
Spo0	B
phosphorelay	O
,	O
there	O
is	O
considerable	O
evidence	O
implicating	O
a	O
mechanism	O
of	O
post	O
-	O
translational	O
control	O
that	O
governs	O
the	O
activity	O
and	O
concentration	O
of	O
sigmaH	B
.	O

Post	O
-	O
translational	O
control	O
of	O
spo0H	B
is	O
responsible	O
for	O
the	O
reduced	O
expression	O
of	O
genes	O
requiring	O
sigmaH	B
under	O
conditions	O
of	O
low	O
environmental	O
pH	O
.	O

It	O
is	O
also	O
responsible	O
for	O
heightened	O
sigmaH	B
activity	O
upon	O
relief	O
of	O
acid	O
stress	O
and	O
during	O
nutritional	O
depletion	O
.	O

In	O
this	O
study	O
,	O
the	O
ATP	O
-	O
dependent	O
proteases	O
LonA	B
and	I
B	I
and	O
the	O
regulatory	O
ATPase	B
ClpX	B
were	O
found	O
to	O
function	O
in	O
the	O
post	O
-	O
translational	O
control	O
of	O
sigmaH	B
.	O

Mutations	O
in	O
lonA	B
and	O
lonB	B
result	O
in	O
elevated	O
sigmaH	B
protein	O
concentrations	O
in	O
low	O
-	O
pH	O
cultures	O
.	O

However	O
,	O
this	O
is	O
not	O
sufficient	O
to	O
increase	O
sigmaH	B
-	O
dependent	O
transcription	O
.	O

Activation	O
of	O
sigmaH	B
-	O
dependent	O
transcription	O
upon	O
raising	O
medium	O
pH	O
and	O
in	O
cells	O
undergoing	O
sporulation	O
requires	O
clpX	B
,	O
as	O
shown	O
by	O
measuring	O
the	O
expression	O
of	O
lacZ	B
fusions	O
that	O
require	O
sigmaH	B
for	O
transcription	O
and	O
by	O
complementation	O
of	O
a	O
clpX	B
null	O
mutation	O
.	O

A	O
hypothesis	O
is	O
presented	O
that	O
low	O
environmental	O
pH	O
results	O
in	O
the	O
Lon	B
-	O
dependent	O
degradation	O
of	O
sigmaH	B
,	O
but	O
the	O
activity	O
of	O
sigmaH	B
in	O
sporulating	O
cells	O
and	O
in	O
cultures	O
at	O
neutral	O
pH	O
is	O
stimulated	O
by	O
a	O
ClpX	B
-	O
dependent	O
mechanism	O
in	O
response	O
to	O
nutritional	O
stress	O
.	O

Cardiopulmonary	O
and	O
CD4	B
cell	O
changes	O
in	O
response	O
to	O
exercise	O
training	O
in	O
early	O
symptomatic	O
HIV	O
infection	O
.	O

PURPOSE	O
:	O

The	O
purposes	O
of	O
the	O
present	O
study	O
were	O
to	O
assess	O
the	O
effects	O
of	O
a	O
12	O
-	O
wk	O
laboratory	O
based	O
aerobic	O
exercise	O
program	O
on	O
cardiopulmonary	O
function	O
,	O
CD4	B
cell	O
count	O
,	O
and	O
physician	O
-	O
assessed	O
health	O
status	O
among	O
symptomatic	O
pre	O
-	O
AIDS	O
HIV	O
-	O
infected	O
individuals	O
(	O
N	O
=	O
28	O
)	O
and	O
to	O
assess	O
the	O
degree	O
to	O
which	O
ill	O
health	O
was	O
associated	O
with	O
exercise	O
relapse	O
.	O

METHODS	O
:	O

Responses	O
to	O
graded	O
exercise	O
test	O
,	O
physician	O
-	O
assessed	O
health	O
status	O
,	O
and	O
CD4	B
cell	O
counts	O
were	O
determined	O
at	O
baseline	O
and	O
12	O
-	O
wk	O
follow	O
-	O
up	O
for	O
participants	O
randomly	O
assigned	O
to	O
exercise	O
or	O
control	O
conditions	O
,	O
and	O
reasons	O
for	O
exercise	O
noncompliance	O
were	O
recorded	O
.	O

RESULTS	O
:	O

Approximately	O
61	O
%	O
of	O
exercise	O
-	O
assigned	O
participants	O
complied	O
(	O
>	O
50	O
%	O
attendance	O
)	O
with	O
the	O
exercise	O
program	O
,	O
and	O
analyses	O
of	O
exercise	O
relapse	O
data	O
indicated	O
that	O
obesity	O
and	O
smoking	O
status	O
,	O
but	O
not	O
exercise	O
-	O
associated	O
illness	O
,	O
differentiated	O
compliant	O
from	O
noncompliant	O
exercisers	O
.	O

Compliant	O
exercisers	O
significantly	O
improved	O
peak	O
oxygen	O
consumption	O
(	O
VO2peak	O
;	O
12	O
%	O
)	O
,	O
oxygen	O
pulse	O
(	O
O2pulse	O
;	O
13	O
%	O
)	O
,	O
tidal	O
volume	O
(	O
TV	O
;	O
8	O
%	O
)	O
,	O
ventilation	O
(	O
VE	O
;	O
17	O
%	O
)	O
,	O
and	O
leg	O
power	O
(	O
25	O
%	O
)	O
to	O
a	O
greater	O
degree	O
than	O
control	O
participants	O
and	O
noncompliant	O
exercisers	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

Although	O
no	O
group	O
differences	O
in	O
health	O
status	O
were	O
found	O
,	O
a	O
significant	O
interaction	O
effect	O
indicated	O
that	O
noncompliant	O
exercisers	O
'	O
CD4	B
cells	O
declined	O
(	O
18	O
%	O
)	O
significantly	O
,	O
whereas	O
compliant	O
exercisers	O
'	O
cell	O
counts	O
significantly	O
increased	O
(	O
13	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O

We	O
conclude	O
that	O
although	O
aerobic	O
exercise	O
can	O
improve	O
cardiopulmonary	O
functioning	O
in	O
symptomatic	O
HIV	O
-	O
infected	O
individuals	O
with	O
minimal	O
health	O
risks	O
,	O
attention	O
to	O
factors	O
associated	O
with	O
exercise	O
adherence	O
is	O
warranted	O
.	O

Multifocal	O
neural	O
conduction	O
impairment	O
in	O
forestry	O
workers	O
exposed	O
and	O
not	O
exposed	O
to	O
vibration	O
.	O

OBJECTIVE	O
:	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
peripheral	O
neural	O
involvement	O
induced	O
by	O
exposure	O
to	O
hand	O
-	O
arm	O
vibration	O
.	O

METHODS	O
:	O

Twenty	O
lumberjacks	O
,	O
working	O
regularly	O
with	O
chain	O
-	O
saws	O
and	O
exposed	O
to	O
hand	O
-	O
arm	O
vibration	O
(	O
group	O
E	O
)	O
and	O
20	O
forestry	O
workers	O
performing	O
heavy	O
manual	O
work	O
and	O
not	O
exposed	O
to	O
vibration	O
(	O
group	O
NE	O
)	O
were	O
matched	O
with	O
a	O
control	O
group	O
of	O
20	O
healthy	O
non	O
-	O
manual	O
workers	O
(	O
group	O
C	O
)	O
.	O

The	O
subjects	O
of	O
groups	O
E	O
and	O
NE	O
,	O
all	O
symptomatic	O
,	O
and	O
of	O
group	O
C	O
underwent	O
extensive	O
bilateral	O
neurophysiological	O
examination	O
consisting	O
of	O
:	O
sensory	O
conduction	O
(	O
velocity	O
and	O
amplitude	O
)	O
of	O
radial	O
,	O
median	O
and	O
ulnar	O
nerves	O
in	O
digit	O
-	O
wrist	O
segments	O
;	O
sensory	O
conduction	O
(	O
velocity	O
)	O
of	O
median	O
nerve	O
in	O
wrist	O
-	O
elbow	O
segment	O
;	O
mixed	O
conduction	O
(	O
velocity	O
and	O
amplitude	O
)	O
of	O
median	O
and	O
ulnar	O
nerves	O
in	O
palm	O
-	O
wrist	O
segments	O
;	O
motor	O
conduction	O
velocity	O
,	O
including	O
distal	O
motor	O
latencies	O
,	O
and	O
amplitude	O
of	O
median	O
(	O
elbow	O
-	O
wrist	O
)	O
and	O
ulnar	O
(	O
elbow	O
-	O
wrist	O
and	O
across	O
the	O
elbow	O
)	O
nerves	O
.	O

RESULTS	O
:	O

Electrophysiological	O
abnormalities	O
were	O
found	O
in	O
85	O
%	O
of	O
group	O
E	O
's	O
limbs	O
,	O
versus	O
62.5	O
%	O
of	O
group	O
NE	O
's	O
limbs	O
.	O

The	O
most	O
frequent	O
pathological	O
pattern	O
in	O
group	O
E	O
was	O
a	O
'	O
multifocal	O
'	O
impairment	O
(	O
multiple	O
sites	O
of	O
several	O
nerve	O
segments	O
)	O
,	O
with	O
a	O
prevalent	O
involvement	O
of	O
sensory	O
rather	O
than	O
motor	O
fibres	O
in	O
the	O
hand	O
,	O
seldom	O
extending	O
to	O
the	O
forearm	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
the	O
neurographic	O
parameters	O
which	O
better	O
characterized	O
workers	O
exposed	O
to	O
hand	O
-	O
arm	O
vibration	O
had	O
a	O
pattern	O
different	O
from	O
that	O
usually	O
found	O
in	O
idiopathic	O
carpal	O
tunnel	O
syndrome	O
(	O
CTS	O
)	O
.	O

CONCLUSION	O
:	O

These	O
results	O
suggest	O
that	O
vibration	O
-	O
induced	O
neural	O
involvement	O
can	O
be	O
considered	O
neither	O
pure	O
digital	O
neuropathy	O
,	O
nor	O
definite	O
CTS	O
,	O
as	O
previously	O
described	O
.	O

Diversity	O
of	O
the	O
repertoire	O
of	O
p58	B
killer	I
cell	I
inhibitory	I
receptors	I
in	O
a	O
single	O
individual	O
.	O

p58	B
Killer	I
cell	I
inhibitory	I
receptors	I
(	O
KIRs	B
)	O
recognize	O
HLA	B
-	I
C	I
molecules	O
on	O
target	O
cell	O
surface	O
and	O
transmit	O
an	O
inhibitory	O
signal	O
to	O
prevent	O
cell	O
-	O
mediated	O
cytotoxicity	O
.	O

p58	B
KIR	I
family	I
is	O
composed	O
of	O
multiple	O
receptors	O
whose	O
amino	O
acid	O
sequences	O
are	O
similar	O
but	O
their	O
ligand	O
specificity	O
is	O
different	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
how	O
diverse	O
the	O
repertoire	O
of	O
p58	B
KIR	I
is	O
,	O
particularly	O
in	O
a	O
single	O
individual	O
.	O

To	O
address	O
this	O
question	O
,	O
cDNAs	O
were	O
cloned	O
encoding	O
the	O
extracellular	O
domain	O
of	O
p58	B
KIR	I
from	O
a	O
single	O
individual	O
.	O

Twelve	O
different	O
p58	B
KIRs	I
were	O
identified	O
suggesting	O
that	O
the	O
repertoire	O
in	O
a	O
single	O
individual	O
is	O
highly	O
diverse	O
.	O

Interestingly	O
,	O
seven	O
of	O
them	O
have	O
hybrid	O
sequences	O
of	O
three	O
previously	O
reported	O
p58	B
KIRs	I
.	O

Using	O
an	O
RNase	B
protection	O
assay	O
,	O
it	O
was	O
demonstrated	O
that	O
the	O
mRNA	O
transcripts	O
of	O
the	O
hybrid	O
KIRs	B
are	O
present	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O

Four	O
differently	O
spliced	O
forms	O
of	O
p58	B
KIR	I
were	O
also	O
identified	O
indicating	O
that	O
the	O
repertoire	O
is	O
diverse	O
in	O
size	O
as	O
well	O
as	O
in	O
sequence	O
.	O

Putative	O
splicing	O
sites	O
found	O
in	O
p58	B
KIR	I
cDNAs	O
suggest	O
that	O
the	O
differently	O
spliced	O
forms	O
are	O
produced	O
by	O
alternative	O
splicing	O
mechanism	O
,	O
and	O
that	O
the	O
hybrid	O
KIRs	B
may	O
also	O
be	O
generated	O
by	O
alternative	O
splicing	O
of	O
two	O
consecutive	O
genes	O
and/or	O
by	O
trans	O
-	O
splicing	O
mechanism	O
found	O
in	O
Ig	B
genes	O
in	O
B	O
cells	O
.	O

[	O
Biopsy	O
of	O
labial	O
salivary	O
glands	O
and	O
lacrimal	O
glands	O
in	O
the	O
diagnosis	O
of	O
SjÃ?Â¶gren	O
's	O
syndrome	O
]	O

OBJECTIVES	O
:	O

To	O
determine	O
the	O
diagnostic	O
value	O
for	O
SjÃ?Â¶gren	O
's	O
syndrome	O
(	O
SS	O
)	O
by	O
evaluating	O
the	O
presence	O
of	O
focal	O
adenitis	O
in	O
labial	O
salivary	O
gland	O
(	O
LSG	O
)	O
and	O
lacrimal	O
gland	O
(	O
LG	O
)	O
biopsy	O
specimens	O
.	O

METHODS	O
:	O

109	O
suspected	O
cases	O
with	O
SS	O
underwent	O
the	O
biopsies	O
.	O

The	O
diagnostic	O
criteria	O
of	O
Fox	O
et	O
al.	O
were	O
followed	O
.	O

Both	O
Chisholm	O
-	O
Manson	O
's	O
grading	O
standard	O
and	O
Greenspan	O
's	O
focus	O
score	O
were	O
used	O
for	O
the	O
evaluation	O
.	O

RESULTS	O
:	O

Myoepithelial	O
islands	O
and	O
severe	O
lymphocyte	O
infiltration	O
with	O
germinal	O
centers	O
were	O
observed	O
only	O
in	O
LG	O
biopsy	O
specimens	O
.	O

The	O
lymphocytic	O
foci	O
scored	O
of	O
LG	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
LSG	O
in	O
23	O
cases	O
having	O
both	O
biopsy	O
results	O
.	O

The	O
evaluation	O
of	O
both	O
kinds	O
of	O
specimen	O
for	O
such	O
a	O
patient	O
was	O
significantly	O
more	O
effective	O
in	O
diagnosing	O
SS	O
than	O
using	O
either	O
one	O
of	O
them	O
alone	O
.	O

CONCLUSION	O
:	O

We	O
recommend	O
that	O
both	O
LSG	O
and	O
LG	O
biopsies	O
be	O
performed	O
in	O
patients	O
suspected	O
of	O
having	O
SS	O
to	O
reduce	O
false	O
negative	O
results	O
and	O
improve	O
diagnostic	O
accuracy	O
.	O

Localization	O
of	O
a	O
new	O
prostate	B
-	I
specific	I
antigen	I
-	O
related	O
serine	B
protease	I
gene	O
,	O
KLK4	B
,	O
is	O
evidence	O
for	O
an	O
expanded	O
human	O
kallikrein	B
gene	I
family	I
cluster	O
on	O
chromosome	O
19q13.3	O
-	O
13.4	O
.	O

The	O
human	O
tissue	B
kallikrein	I
(	I
KLK	I
)	I
family	I
of	I
serine	I
proteases	I
,	O
which	O
is	O
important	O
in	O
post	O
-	O
translational	O
processing	O
events	O
,	O
currently	O
consists	O
of	O
just	O
three	O
genes	O
-	O
tissue	B
kallikrein	I
(	O
KLK1	B
)	O
,	O
KLK2	B
,	O
and	O
prostate	B
-	I
specific	I
antigen	I
(	O
PSA	B
)	O
(	O
KLK3	B
)	O
-	O
clustered	O
at	O
chromosome	O
19q13	O
.	O
3	O
-	O
13.4	O
.	O

We	O
identified	O
an	O
expressed	O
sequence	O
tag	O
from	O
an	O
endometrial	O
carcinoma	O
cDNA	O
library	O
with	O
50	O
%	O
identity	O
to	O
the	O
three	O
known	O
KLK	B
genes	O
.	O

Primers	O
designed	O
to	O
putative	O
exon	O
2	O
and	O
exon	O
3	O
regions	O
from	O
this	O
novel	O
kallikrein	B
-	O
related	O
sequence	O
were	O
used	O
to	O
polymerase	O
chain	O
reaction	O
-	O
screen	O
five	O
cosmids	O
spanning	O
130	O
kb	O
around	O
the	O
KLK	B
locus	O
on	O
chromosome	O
19	O
.	O

This	O
new	O
gene	O
,	O
which	O
we	O
have	O
named	O
KLK4	B
,	O
is	O
25	O
kb	O
downstream	O
of	O
the	O
KLK2	B
gene	O
and	O
follows	O
a	O
region	O
that	O
includes	O
two	O
other	O
putative	O
KLK	B
-	O
like	O
gene	O
fragments	O
.	O

KLK4	B
spans	O
5.2	O
kb	O
,	O
has	O
an	O
identical	O
genomic	O
structure	O
-	O
five	O
exons	O
and	O
four	O
introns	O
-	O
to	O
the	O
other	O
KLK	B
genes	O
and	O
is	O
transcribed	O
on	O
the	O
reverse	O
strand	O
,	O
in	O
the	O
same	O
direction	O
as	O
KLK1	B
but	O
opposite	O
to	O
that	O
of	O
KLK2	B
and	O
KLK3	B
.	O

It	O
encodes	O
a	O
254	O
-	O
amino	O
acid	O
prepro	O
-	O
serine	B
protease	I
that	O
is	O
most	O
similar	O
(	O
78	O
%	O
identical	O
)	O
to	O
pig	O
enamel	B
matrix	I
serine	I
protease	I
but	O
is	O
also	O
37	O
%	O
identical	O
to	O
PSA	B
.	O

These	O
data	O
suggest	O
that	O
the	O
human	O
kallikrein	B
gene	I
family	I
locus	O
on	O
chromosome	O
19	O
is	O
larger	O
than	O
previously	O
thought	O
and	O
also	O
indicate	O
a	O
greater	O
sequence	O
divergence	O
within	O
this	O
family	O
compared	O
with	O
the	O
highly	O
conserved	O
rodent	O
kallikrein	B
genes	O
.	O

Functional	O
analysis	O
of	O
DNA	O
sequences	O
required	O
for	O
conidium	O
-	O
specific	O
expression	O
of	O
the	O
SpoC1-C1C	B
gene	O
of	O
Aspergillus	O
nidulans	O
.	O

The	O
SpoC1-C1C	B
gene	O
is	O
centrally	O
located	O
within	O
the	O
A.	O
nidulans	O
conidium	O
-	O
specific	O
SpoC1	B
gene	O
cluster	O
.	O

With	O
one	O
exception	O
,	O
the	O
14	O
genes	O
within	O
the	O
cluster	O
are	O
coordinately	O
regulated	O
.	O

C1C	B
transcript	O
is	O
first	O
detected	O
late	O
in	O
conidiation	O
,	O
coincidental	O
with	O
the	O
appearance	O
of	O
mature	O
conidia	O
,	O
and	O
accumulates	O
approximately	O
1000	O
-	O
fold	O
in	O
conidia	O
.	O

We	O
show	O
that	O
C1C	B
expression	O
is	O
restricted	O
to	O
conidia	O
,	O
with	O
mRNA	O
abundance	O
decreasing	O
immediately	O
after	O
induction	O
of	O
germination	O
.	O

C1C	B
transcription	O
and	O
translation	O
are	O
not	O
temporally	O
separated	O
and	O
,	O
similar	O
to	O
C1C	B
RNA	O
abundance	O
,	O
a	O
C1C	B
:	O
:	O
beta	B
-	I
galactosidase	I
fusion	O
protein	O
is	O
first	O
detected	O
with	O
the	O
appearance	O
of	O
mature	O
conidia	O
and	O
decreases	O
after	O
induction	O
of	O
germination	O
.	O

Cell	O
-	O
specific	O
C1C	B
expression	O
requires	O
both	O
a	O
position	O
-	O
dependent	O
mechanism	O
of	O
regulation	O
,	O
responsible	O
for	O
repression	O
in	O
hyphae	O
,	O
and	O
a	O
position	O
-	O
independent	O
mechanism	O
of	O
regulation	O
,	O
responsible	O
for	O
developmental	O
expression	O
.	O

We	O
show	O
by	O
functional	O
analysis	O
of	O
upstream	O
DNA	O
sequences	O
that	O
a	O
10	O
-	O
bp	O
sequence	O
and	O
two	O
adjacent	O
6	O
-	O
bp	O
direct	O
repeats	O
are	O
necessary	O
for	O
position	O
-	O
independent	O
,	O
condium	O
-	O
specific	O
expression	O
of	O
both	O
the	O
intact	O
C1C	B
gene	O
and	O
the	O
reporter	O
gene	O
.	O

At	O
least	O
one	O
repeat	O
(	O
CAACAT	O
)	O
is	O
required	O
for	O
normal	O
levels	O
of	O
expression	O
.	O

We	O
find	O
that	O
the	O
C1C	B
gene	O
is	O
not	O
a	O
direct	O
target	O
of	O
the	O
BrlAp	B
and	O
AbaAp	B
developmental	O
regulators	O
,	O
but	O
of	O
a	O
yet	O
unidentified	O
conidium	O
-	O
specific	O
transcriptional	O
activator	O
.	O

Binge	O
drinking	O
and	O
bone	O
metabolism	O
in	O
a	O
young	O
actively	O
growing	O
rat	O
model	O
.	O

BACKGROUND	O
:	O

Chronic	O
alcohol	O
consumption	O
has	O
been	O
demonstrated	O
to	O
be	O
deleterious	O
to	O
bone	O
health	O
.	O

However	O
,	O
binge	O
drinking	O
is	O
the	O
prevalent	O
form	O
of	O
drinking	O
in	O
young	O
people	O
,	O
which	O
was	O
the	O
impetus	O
for	O
the	O
present	O
study	O
to	O
determine	O
the	O
effect	O
of	O
week	O
-	O
end	O
and	O
week	O
-	O
long	O
binge	O
drinking	O
on	O
bone	O
health	O
in	O
a	O
young	O
actively	O
growing	O
animal	O
model	O
.	O

METHODS	O
:	O

Four	O
-	O
week	O
-	O
old	O
,	O
female	O
,	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
given	O
the	O
amount	O
of	O
5	O
%	O
alcohol	O
by	O
gavage	O
to	O
be	O
equivalent	O
to	O
a	O
63	O
kg	O
woman	O
drinking	O
six	O
beers	O
a	O
day	O
for	O
either	O
2	O
or	O
5	O
consecutive	O
days	O
per	O
week	O
.	O

RESULTS	O
:	O

There	O
were	O
no	O
changes	O
in	O
the	O
5	O
-	O
day	O
binge	O
animals	O
,	O
but	O
the	O
2	O
-	O
day	O
binge	O
animals	O
were	O
hypocalcemic	O
.	O

Similarly	O
,	O
2	O
-	O
day	O
binge	O
animals	O
had	O
slightly	O
increased	O
bone	O
chemistry	O
and	O
histomorphometric	O
values	O
for	O
both	O
tibia	O
and	O
femur	O
,	O
but	O
only	O
femur	O
length	O
,	O
dry	O
weight	O
,	O
and	O
ash	O
weight	O
as	O
well	O
as	O
femur	O
density	O
,	O
presented	O
either	O
as	O
g	O
/	O
ml	O
or	O
ash	O
weight	O
per	O
unit	O
volume	O
,	O
were	O
increased	O
by	O
a	O
statistically	O
significant	O
level	O
.	O

Cross	O
-	O
section	O
periosteal	O
Mineral	O
Apposition	O
Rate	O
(	O
MAR	O
)	O
was	O
significantly	O
decreased	O
in	O
the	O
2	O
-	O
day	O
alcohol	O
fed	O
animals	O
.	O

CONCLUSIONS	O
:	O

Actively	O
growing	O
rats	O
given	O
5	O
%	O
alcohol	O
by	O
gavage	O
for	O
2	O
days	O
per	O
week	O
have	O
an	O
increased	O
bone	O
length	O
,	O
bone	O
weight	O
,	O
and	O
bone	O
density	O
.	O

The	O
interpretation	O
of	O
these	O
results	O
must	O
be	O
viewed	O
with	O
great	O
caution	O
because	O
studies	O
of	O
chronic	O
alcohol	O
consumption	O
,	O
and	O
many	O
studies	O
of	O
acute	O
drinking	O
,	O
clearly	O
indicate	O
deleterious	O
effects	O
of	O
alcohol	O
on	O
bone	O
health	O
.	O

Those	O
fed	O
alcohol	O
for	O
5	O
days	O
per	O
week	O
showed	O
no	O
change	O
.	O

Efficacy	O
of	O
misoprostol	O
in	O
prevention	O
of	O
gastric	O
hemorrhage	O
in	O
dogs	O
treated	O
with	O
high	O
doses	O
of	O
methylprednisolone	O
sodium	O
succinate	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
whether	O
administration	O
of	O
misoprostol	O
prevents	O
gastric	O
hemorrhage	O
in	O
healthy	O
dogs	O
treated	O
with	O
high	O
doses	O
of	O
methylprednisolone	O
sodium	O
succinate	O
(	O
MPSS	O
)	O
.	O

ANIMALS	O
:	O

18	O
healthy	O
hound	O
-	O
type	O
dogs	O
of	O
both	O
sexes	O
.	O

PROCEDURE	O
:	O

All	O
dogs	O
were	O
given	O
high	O
doses	O
of	O
MPSS	O
(	O
30	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
,	O
initially	O
,	O
then	O
15	O
mg	O
/	O
kg	O
2	O
and	O
6	O
hours	O
later	O
,	O
and	O
,	O
subsequently	O
,	O
q	O
6	O
h	O
for	O
a	O
total	O
of	O
48	O
hours	O
)	O
IV	O
.	O

Dogs	O
were	O
assigned	O
randomly	O
to	O
receive	O
concurrent	O
treatment	O
with	O
misoprostol	O
(	O
4	O
to	O
6	O
microg	O
/	O
kg	O
,	O
PO	O
,	O
q	O
8	O
h	O
;	O
n	O
=	O
9	O
)	O
or	O
an	O
empty	O
gelatin	O
capsule	O
(	O
9	O
)	O
.	O

Gastroduodenoscopy	O
was	O
performed	O
before	O
and	O
after	O
treatment	O
.	O

Hemorrhage	O
was	O
graded	O
from	O
none	O
(	O
0	O
)	O
to	O
severe	O
(	O
3	O
)	O
for	O
each	O
cardia	O
,	O
fundus	O
,	O
antrum	O
,	O
and	O
duodenum	O
.	O

A	O
total	O
stomach	O
score	O
was	O
calculated	O
as	O
the	O
sum	O
of	O
the	O
regional	O
stomach	O
scores	O
.	O

Food	O
retention	O
was	O
recorded	O
,	O
and	O
pH	O
of	O
gastric	O
fluid	O
was	O
determined	O
.	O

Gastric	O
and	O
fecal	O
occult	O
blood	O
was	O
measured	O
.	O

RESULTS	O
:	O

Gastric	O
hemorrhage	O
was	O
evident	O
in	O
all	O
dogs	O
after	O
MPSS	O
administration	O
,	O
and	O
its	O
severity	O
was	O
similar	O
in	O
both	O
groups	O
.	O

Median	O
total	O
stomach	O
score	O
was	O
6	O
for	O
misoprostol	O
-	O
treated	O
dogs	O
and	O
5.5	O
for	O
dogs	O
given	O
the	O
gelatin	O
capsule	O
.	O

Difference	O
in	O
gastric	O
acidity	O
,	O
frequency	O
of	O
food	O
retention	O
,	O
and	O
incidence	O
of	O
occult	O
blood	O
in	O
gastric	O
fluid	O
and	O
feces	O
was	O
not	O
apparent	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O

Administration	O
of	O
misoprostol	O
(	O
4	O
to	O
6	O
microg	O
/	O
kg	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
does	O
not	O
prevent	O
gastric	O
hemorrhage	O
caused	O
by	O
high	O
doses	O
of	O
MPSS	O
.	O

Alternative	O
prophylactic	O
treatment	O
should	O
be	O
considered	O
.	O

Grb10	B
,	O
a	O
positive	O
,	O
stimulatory	O
signaling	O
adapter	O
in	O
platelet	B
-	I
derived	I
growth	I
factor	I
BB	I
-	O
,	O
insulin	B
-	I
like	I
growth	I
factor	I
I	I
-	O
,	O
and	O
insulin	B
-	O
mediated	O
mitogenesis	O
.	O

Grb10	B
has	O
been	O
described	O
as	O
a	O
cellular	O
partner	O
of	O
several	O
receptor	B
tyrosine	I
kinases	I
,	O
including	O
the	O
insulin	B
receptor	I
(	O
IR	B
)	O
and	O
the	O
insulin	B
-	I
like	I
growth	I
factor	I
I	I
(	I
IGF	I
-	I
I	I
)	I
receptor	I
(	O
IGF	B
-	I
IR	I
)	O
.	O

Its	O
cellular	O
role	O
is	O
still	O
unclear	O
and	O
a	O
positive	O
as	O
well	O
as	O
an	O
inhibitory	O
role	O
in	O
mitogenesis	O
depending	O
on	O
the	O
cell	O
context	O
has	O
been	O
implicated	O
.	O

We	O
have	O
tested	O
other	O
mitogenic	O
receptor	B
tyrosine	I
kinases	I
as	O
putative	O
Grb10	B
partners	O
and	O
have	O
identified	O
the	O
activated	O
forms	O
of	O
platelet	B
-	I
derived	I
growth	I
factor	I
(	I
PDGF	I
)	I
receptor	I
beta	I
(	O
PDGFRbeta	B
)	O
,	O
hepatocyte	B
growth	I
factor	I
receptor	I
(	O
Met	B
)	O
,	O
and	O
fibroblast	B
growth	I
factor	I
receptor	I
as	O
candidates	O
.	O

We	O
have	O
mapped	O
Y771	O
as	O
a	O
PDFGRbeta	B
site	O
that	O
is	O
involved	O
in	O
the	O
association	O
with	O
Grb10	B
via	O
its	O
SH2	O
domain	O
.	O

We	O
have	O
further	O
investigated	O
the	O
putative	O
role	O
of	O
Grb10	B
in	O
mitogenesis	O
with	O
four	O
independent	O
experimental	O
strategies	O
and	O
found	O
that	O
all	O
consistently	O
suggested	O
a	O
role	O
as	O
a	O
positive	O
,	O
stimulatory	O
signaling	O
adaptor	O
in	O
normal	O
fibroblasts	O
.	O

(	O
i	O
)	O

Complete	O
Grb10	B
expression	O
from	O
cDNA	O
with	O
an	O
ecdysone	O
-	O
regulated	O
transient	O
expression	O
system	O
stimulated	O
PDGF	B
-	I
BB	I
-	O
,	O
IGF	B
-	I
I	I
,	O
and	O
insulin	B
-	O
but	O
not	O
epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
-	O
induced	O
DNA	O
synthesis	O
in	O
an	O
ecdysone	O
dose	O
-	O
responsive	O
fashion	O
.	O

(	O
ii	O
)	O
Microinjection	O
of	O
the	O
(	O
dominant	O
-	O
negative	O
)	O
Grb10	B
SH2	O
domain	O
interfered	O
with	O
PDGF	B
-	I
BB	I
-	O
and	O
insulin	B
-	O
induced	O
DNA	O
synthesis	O
.	O

(	O
iii	O
)	O
Alternative	O
experiments	O
were	O
based	O
on	O
cell	O
-	O
permeable	O
fusion	O
peptides	O
with	O
the	O
Drosophila	O
antennapedia	O
homeodomain	O
which	O
effectively	O
traverse	O
the	O
plasma	O
membrane	O
of	O
cultured	O
cells	O
.	O

A	O
cell	O
-	O
permeable	O
Grb10	B
SH2	O
domain	O
similarly	O
interfered	O
with	O
PDGF	B
-	I
BB	I
-	O
,	O
IGF	B
-	I
I	I
-	O
,	O
and	O
insulin	B
-	O
induced	O
DNA	O
synthesis	O
.	O

In	O
contrast	O
,	O
a	O
cell	O
-	O
permeable	O
Grb10	B
Pro	O
-	O
rich	O
putative	O
SH3	O
domain	O
binding	O
region	O
interfered	O
with	O
IGF	B
-	I
I	I
-	O
and	O
insulin	B
-	O
but	O
not	O
with	O
PDGF	B
-	I
BB	I
-	O
or	O
EGF	B
-	O
induced	O
DNA	O
synthesis	O
.	O

(	O
iv	O
)	O
Transient	O
overexpression	O
of	O
complete	O
Grb10	B
increased	O
whereas	O
cell	O
-	O
permeable	O
Grb10	B
SH2	O
domain	O
fusion	O
peptides	O
substantially	O
decreased	O
the	O
cell	O
proliferation	O
rate	O
(	O
as	O
measured	O
by	O
cell	O
numbers	O
)	O
in	O
normal	O
fibroblasts	O
.	O

These	O
experimental	O
strategies	O
independently	O
suggest	O
that	O
Grb10	B
functions	O
as	O
a	O
positive	O
,	O
stimulatory	O
,	O
mitogenic	O
signaling	O
adapter	O
in	O
PDGF	B
-	I
BB	I
,	O
IGF	B
-	I
I	I
,	O
and	O
insulin	B
action	O
.	O

This	O
function	O
appears	O
to	O
involve	O
the	O
Grb10	B
SH2	O
domain	O
,	O
a	O
novel	O
sequence	O
termed	O
BPS	O
,	O
and	O
the	O
Pro	O
-	O
rich	O
putative	O
SH3	O
domain	O
binding	O
region	O
in	O
IGF	B
-	I
I	I
-	O
and	O
insulin	B
-	O
mediated	O
mitogenesis	O
.	O

In	O
contrast	O
,	O
PDGF	B
-	I
BB	I
-	O
mediated	O
mitogenesis	O
appears	O
to	O
depend	O
on	O
the	O
SH2	O
but	O
not	O
on	O
the	O
Pro	O
-	O
rich	O
region	O
and	O
may	O
involve	O
other	O
,	O
unidentified	O
Grb10	B
domains	O
.	O

Distinct	O
protein	O
domains	O
may	O
help	O
to	O
define	O
specific	O
Grb10	B
functions	O
in	O
different	O
signaling	O
pathways	O
.	O

An	O
autoregulatory	O
circuit	O
affecting	O
peptide	O
signaling	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
competence	B
and	I
sporulation	I
factor	I
(	O
CSF	B
)	O
of	O
Bacillus	O
subtilis	O
is	O
an	O
extracellular	O
pentapeptide	O
produced	O
from	O
the	O
product	O
of	O
phrC	B
.	O

CSF	B
has	O
at	O
least	O
three	O
activities	O
:	O
(	O
i	O
)	O
at	O
low	O
concentrations	O
,	O
it	O
stimulates	O
expression	O
of	O
genes	O
activated	O
by	O
the	O
transcription	B
factor	I
ComA	B
;	O
at	O
higher	O
concentrations	O
,	O
it	O
(	O
ii	O
)	O
inhibits	O
expression	O
of	O
those	O
same	O
genes	O
and	O
(	O
iii	O
)	O
stimulates	O
sporulation	O
.	O

Because	O
the	O
activities	O
of	O
CSF	B
are	O
concentration	O
dependent	O
,	O
we	O
measured	O
the	O
amount	O
of	O
extracellular	O
CSF	B
produced	O
by	O
cells	O
.	O

We	O
found	O
that	O
by	O
mid	O
-	O
exponential	O
phase	O
,	O
CSF	B
accumulated	O
to	O
concentrations	O
(	O
1	O
to	O
5	O
nM	O
)	O
that	O
stimulate	O
ComA	B
-	O
dependent	O
gene	O
expression	O
.	O

Upon	O
entry	O
into	O
stationary	O
phase	O
,	O
CSF	B
reached	O
50	O
to	O
100	O
nM	O
,	O
concentrations	O
that	O
stimulate	O
sporulation	O
and	O
inhibit	O
ComA	B
-	O
dependent	O
gene	O
expression	O
.	O

Transcription	O
of	O
phrC	B
was	O
found	O
to	O
be	O
controlled	O
by	O
two	O
promoters	O
:	O
P1	O
,	O
which	O
precedes	O
rapC	B
,	O
the	O
gene	O
upstream	O
of	O
phrC	B
;	O
and	O
P2	O
,	O
which	O
directs	O
transcription	O
of	O
phrC	B
only	O
.	O

Both	O
RapC	B
and	O
CSF	B
were	O
found	O
to	O
be	O
part	O
of	O
autoregulatory	O
loops	O
that	O
affect	O
transcription	O
from	O
P1	O
,	O
which	O
we	O
show	O
is	O
activated	O
by	O
ComA	B
approximately	O
P.	O
RapC	B
negatively	O
regulates	O
its	O
own	O
expression	O
,	O
presumably	O
due	O
to	O
its	O
ability	O
to	O
inhibit	O
accumulation	O
of	O
ComA	B
approximately	O
P.	O
CSF	B
positively	O
regulates	O
its	O
own	O
expression	O
,	O
presumably	O
due	O
to	O
its	O
ability	O
to	O
inhibit	O
RapC	B
activity	O
.	O

Transcription	O
from	O
P2	O
,	O
which	O
is	O
controlled	O
by	O
the	O
alternate	O
sigma	B
factor	I
sigma	B
(	I
H	I
)	I
,	O
increased	O
as	O
cells	O
entered	O
stationary	O
phase	O
,	O
contributing	O
to	O
the	O
increase	O
in	O
extracellular	O
CSF	B
at	O
this	O
time	O
.	O

In	O
addition	O
to	O
controlling	O
transcription	O
of	O
phrC	B
,	O
sigmaH	B
appears	O
to	O
control	O
expression	O
of	O
at	O
least	O
one	O
other	O
gene	O
required	O
for	O
production	O
of	O
CSF	B
.	O

The	O
Escherichia	O
coli	O
NadR	B
regulator	O
is	O
endowed	O
with	O
nicotinamide	B
mononucleotide	I
adenylyltransferase	I
activity	O
.	O

The	O
first	O
identification	O
and	O
characterization	O
of	O
a	O
catalytic	O
activity	O
associated	O
with	O
NadR	B
protein	O
is	O
reported	O
.	O

A	O
computer	O
-	O
aided	O
search	O
for	O
sequence	O
similarity	O
revealed	O
the	O
presence	O
in	O
NadR	B
of	O
a	O
29	O
-	O
residue	O
region	O
highly	O
conserved	O
among	O
known	O
nicotinamide	B
mononucleotide	I
adenylyltransferases	I
.	O

The	O
Escherichia	O
coli	O
nadR	B
gene	O
was	O
cloned	O
into	O
a	O
T7	O
-	O
based	O
vector	O
and	O
overexpressed	O
.	O

In	O
addition	O
to	O
functionally	O
specific	O
DNA	O
binding	O
properties	O
,	O
the	O
homogeneous	O
recombinant	O
protein	O
catalyzes	O
NAD	O
synthesis	O
from	O
nicotinamide	O
mononucleotide	O
and	O
ATP	O
.	O

An	O
enhancer	O
element	O
located	O
downstream	O
of	O
the	O
major	O
glutamate	B
dehydrogenase	I
gene	O
of	O
Bacillus	O
subtilis	O
.	O

The	O
rocG	B
gene	O
of	O
Bacillus	O
subtilis	O
,	O
encoding	O
a	O
catabolic	O
glutamate	B
dehydrogenase	I
,	O
is	O
transcribed	O
by	O
SigL	B
(	O
sigma	B
(	I
54	I
)	I
)	O
-	O
containing	O
RNA	B
polymerase	I
and	O
requires	O
for	O
its	O
expression	O
RocR	B
,	O
a	O
member	O
of	O
the	O
NtrC	B
/	I
NifA	I
family	I
of	O
proteins	O
that	O
bind	O
to	O
enhancer	O
-	O
like	O
elements	O
,	O
called	O
upstream	O
activating	O
sequences	O
(	O
UAS	O
)	O
.	O

Unlike	O
the	O
case	O
for	O
other	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
genes	O
,	O
rocG	B
has	O
no	O
UAS	O
;	O
instead	O
,	O
its	O
expression	O
depends	O
on	O
a	O
sequence	O
located	O
1.5	O
kilobases	O
downstream	O
of	O
the	O
rocG	B
promoter	O
,	O
beyond	O
the	O
end	O
of	O
the	O
rocG	B
coding	O
region	O
.	O

The	O
same	O
sequence	O
also	O
serves	O
as	O
the	O
UAS	O
for	O
the	O
downstream	O
rocABC	B
operon	I
and	O
can	O
activate	O
rocG	B
if	O
moved	O
upstream	O
of	O
its	O
promoter	O
.	O

Furthermore	O
,	O
the	O
activating	O
sequence	O
can	O
be	O
moved	O
as	O
far	O
as	O
15	O
kilobases	O
downstream	O
of	O
the	O
rocG	B
promoter	O
and	O
still	O
retain	O
partial	O
activity	O
.	O

Signal	O
joint	O
formation	O
is	O
inhibited	O
in	O
murine	O
scid	O
preB	O
cells	O
and	O
fibroblasts	O
in	O
substrates	O
with	O
homopolymeric	O
coding	O
ends	O
.	O

During	O
B	O
and	O
T	O
lymphocyte	O
development	O
,	O
immunoglobulin	B
and	O
T	B
cell	I
receptor	I
genes	O
are	O
assembled	O
from	O
the	O
germline	O
V	O
,	O
(	O
D	O
)	O
and	O
J	O
gene	O
segments	O
(	O
Lewis	O
,	O
S.M.	O
,	O
1994	O
.	O
The	O
mechanism	O
of	O
V	O
(	O
D	O
)	O
J	O
joining	O
:	O
lessons	O
from	O
molecular	O
,	O
immunological	O
and	O
comparative	O
analyses	O
.	O
Adv	O
.	O
Immunol	O
.	O
56	O
,	O
27	O
-	O
150	O
)	O
.	O

These	O
DNA	O
rearrangements	O
,	O
responsible	O
for	O
immune	O
system	O
diversity	O
,	O
are	O
mediated	O
by	O
a	O
site	O
specific	O
recombination	O
machinery	O
via	O
recognition	O
signal	O
sequences	O
(	O
RSSs	O
)	O
composed	O
of	O
conserved	O
heptamers	O
and	O
nonamers	O
separated	O
by	O
spacers	O
of	O
12	O
or	O
23	O
nucleotides	O
(	O
Lewis	O
,	O
S.M.	O
,	O
1994	O
.	O
The	O
mechanism	O
of	O
V	O
(	O
D	O
)	O
J	O
joining	O
:	O
lessons	O
from	O
molecular	O
,	O
immunological	O
and	O
comparative	O
analyses	O
.	O
Adv	O
.	O
Immunol	O
.	O
56	O
,	O
27	O
-	O
150	O
)	O
.	O

Recombination	O
occurs	O
only	O
between	O
a	O
RSS	O
with	O
a	O
12mer	O
spacer	O
and	O
a	O
RSS	O
with	O
a	O
23mer	O
spacer	O
(	O
Lewis	O
,	O
S.M.	O
,	O
1994	O
.	O
The	O
mechanism	O
of	O
V	O
(	O
D	O
)	O
J	O
joining	O
:	O
lessons	O
from	O
molecular	O
,	O
immunological	O
and	O
comparative	O
analyses	O
.	O

Adv	O
.	O

Immunol	O
.	O
56	O
,	O
27	O
-	O
150	O
)	O
.	O

RAG1	B
and	O
RAG2	B
proteins	O
cleave	O
precisely	O
at	O
the	O
RSS	O
-	O
coding	O
sequence	O
border	O
leading	O
to	O
flush	O
signal	O
ends	O
and	O
coding	O
ends	O
with	O
a	O
hairpin	O
structure	O
(	O
Eastman	O
,	O
M.	O
,	O
Leu	O
,	O
T.	O
,	O
Schatz	O
,	O
D.	O
,	O
1996	O
.	O

Initiation	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
in	O
vitro	O
obeying	O
the	O
12	O
/	O
23	O
rule	O
.	O

Nature	O
380	O
,	O
85	O
-	O
88	O
;	O
Roth	O
,	O
D.B.	O
,	O
Menetski	O
,	O
J.P.	O
,	O
Nakajima	O
,	O
P.B.	O
,	O
Bosma	O
,	O
M.J.	O
,	O
Gellert	O
,	O
M.	O
,	O
1992	O
.	O
V	O
(	O
D	O
)	O
J	O
recombination	O
:	O
broken	O
DNA	O
molecules	O
with	O
covalently	O
sealed	O
(	O
hairpin	O
)	O
coding	O
ends	O
in	O
scid	O
mouse	O
thymocytes	O
.	O

Cell	O
983	O
-	O
991	O
:	O
Roth	O
,	O
D.B.	O
,	O
Zhu	O
,	O
C.	O
,	O
Gellert	O
.	O
M.	O
,	O
1993	O
.	O

Characterization	O
of	O
broken	O
DNA	O
molecules	O
associated	O
with	O
V	O
(	O
D	O
)	O
J	O
recombination	O
.	O

Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
90	O
,	O
10	O
,	O
788	O
-	O
10	O
,	O
792	O
;	O
van	O
Gent	O
,	O
D.	O
,	O
McBlane	O
,	O
J.	O
.	O

Sadofsky	O
,	O
M.	O
,	O
Hesse	O
,	O
J.	O
,	O
Gellert	O
,	O
M.	O
,	O
1995	O
.	O

Initiation	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

Cell	O
81	O
,	O
925	O
-	O
934	O
)	O
.	O

Signal	O
ends	O
join	O
,	O
forming	O
a	O
signal	O
joint	O
.	O

The	O
hairpin	O
coding	O
ends	O
are	O
opened	O
by	O
a	O
yet	O
unknown	O
endonuclease	B
,	O
and	O
are	O
further	O
processed	O
to	O
form	O
the	O
coding	O
joint	O
(	O
Lewis	O
,	O
S.M.	O
,	O
1994	O
.	O

The	O
mechanism	O
of	O
V	O
(	O
D	O
)	O
J	O
joining	O
:	O
lessons	O
from	O
molecular	O
,	O
immunological	O
and	O
comparative	O
analyses	O
.	O

Ad	O
.	O

Immunol	O
.	O
56	O
,	O
27	O
-	O
150	O
.	O
)	O
The	O
murine	O
scid	O
mutation	O
has	O
been	O
shown	O
to	O
affect	O
coding	O
joints	O
,	O
but	O
much	O
less	O
signal	O
joint	O
formation	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
the	O
murine	O
scid	O
mutation	O
inhibits	O
correct	O
signal	O
joint	O
formation	O
when	O
both	O
coding	O
ends	O
contain	O
homopolymeric	O
sequences	O
.	O

We	O
suggest	O
that	O
this	O
finding	O
may	O
be	O
due	O
to	O
the	O
function	O
of	O
the	O
SCID	O
protein	O
as	O
an	O
assembly	O
component	O
in	O
V	O
(	O
D	O
)	O
J	O
recombination	O
.	O

Modulation	O
of	O
haematopoietic	O
progenitor	O
development	O
by	O
FLT-3	B
ligand	I
.	O

The	O
Flt-3	B
receptor	O
is	O
expressed	O
in	O
primitive	O
haematopoietic	O
cells	O
and	O
its	O
ligand	O
exerts	O
proliferative	O
effects	O
on	O
these	O
cells	O
in	O
vitro	O
in	O
synergy	O
with	O
other	O
cytokines	B
.	O

To	O
increase	O
our	O
knowledge	O
of	O
the	O
functional	O
properties	O
of	O
the	O
human	O
Flt-3	B
ligand	I
(	O
FL	B
)	O
as	O
relating	O
to	O
in	O
vitro	O
expansion	O
of	O
haematopoietic	O
stem	O
cells	O
,	O
the	O
effects	O
on	O
murine	O
haematopoiesis	O
of	O
FL	B
alone	O
or	O
in	O
combination	O
with	O
other	O
growth	B
factors	I
were	O
studied	O
.	O

Analysis	O
of	O
Flk-2	B
/	O
Flt-3	B
mRNA	O
expression	O
indicated	O
that	O
Flk-2	B
/	O
Flt-3	B
was	O
preferentially	O
expressed	O
in	O
primitive	O
haematopoietic	O
cell	O
populations	O
.	O

To	O
examine	O
the	O
expression	O
of	O
the	O
Flk-2	B
/	O
Flt-3	B
receptor	O
on	O
megakaryocyte	O
progenitors	O
(	O
CFU	O
-	O
Meg	O
)	O
,	O
Flk-2	B
/	O
Flt-3	B
positive	O
and	O
negative	O
CD34	B
(	O
+	O
)	O
populations	O
were	O
separated	O
from	O
human	O
bone	O
marrow	O
and	O
cultured	O
in	O
a	O
plasma	O
clot	O
culture	O
system	O
.	O

CFU	O
-	O
Meg	O
colonies	O
were	O
found	O
in	O
the	O
Flk-2	B
/	O
Flt-3	B
negative	O
fraction	O
.	O

Myeloid	O
(	O
CFU	O
-	O
GM	O
)	O
derived	O
colonies	O
appeared	O
in	O
the	O
presence	O
of	O
FL	B
alone	O
.	O

Neither	O
FL	B
+	O
IL-3	B
nor	O
FL	B
+	O
IL-3	B
+	O
IL-6	B
had	O
any	O
effect	O
on	O
the	O
generation	O
of	O
megakaryocyte	O
colonies	O
(	O
CFU	O
-	O
MK	O
)	O
,	O
due	O
to	O
the	O
lack	O
of	O
FL	B
receptor	I
expression	O
on	O
megakaryocyte	O
progenitors	O
.	O

Bone	O
marrow	O
cells	O
remaining	O
after	O
5-fluorouracil	O
(	O
5-FU	O
)	O
treatment	O
of	O
mice	O
represent	O
a	O
very	O
primitive	O
population	O
of	O
progenitors	O
enriched	O
for	O
reconstituting	O
stem	O
cells	O
.	O

This	O
cell	O
population	O
expressed	O
FL	B
receptors	I
,	O
as	O
revealed	O
by	O
RT	O
-	O
PCR	O
analysis	O
.	O

Addition	O
of	O
FL	B
alone	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
such	O
cells	O
in	O
liquid	O
cultures	O
as	O
compared	O
to	O
controls	O
.	O

However	O
,	O
a	O
significantly	O
greater	O
generation	O
of	O
myeloid	O
progenitors	O
(	O
CFU	O
-	O
GM	O
)	O
in	O
clonogenic	O
assays	O
was	O
observed	O
in	O
the	O
presence	O
of	O
FL	B
+	O
IL-3	B
,	O
FL	B
+	O
GM	B
-	I
CSF	I
or	O
FL	B
+	O
CSF-1	B
.	O

In	O
addition	O
,	O
the	O
effects	O
of	O
FL	B
on	O
in	O
vitro	O
expansion	O
of	O
murine	O
haematopoietic	O
stem	O
cells	O
were	O
studied	O
using	O
lineage	O
-	O
negative	O
(	O
lin	O
(	O
-	O
)	O
)	O
Sca-1	B
positive	O
(	O
Sca-1	B
(	O
+	O
)	O
)	O
c	B
-	I
kit	I
positive	O
(	O
c	B
-	I
kit	I
(	O
+	O
)	O
)	O
marrow	O
cells	O
from	O
5-FU	O
treated	O
mice	O
.	O

FL	B
enhanced	O
the	O
survival	O
of	O
primitive	O
murine	O
lin	O
(	O
-	O
)	O
Sca-1	B
(	O
+	O
)	O
c	B
-	I
kit	I
(	O
+	O
)	O
cells	O
.	O

FL	B
and	O
IL-6	B
were	O
able	O
to	O
significantly	O
expand	O
murine	O
progenitor	O
stem	O
cells	O
in	O
vitro	O
and	O
promote	O
their	O
survival	O
.	O

These	O
studies	O
strongly	O
suggest	O
that	O
FL	B
significantly	O
and	O
selectively	O
enhanced	O
the	O
generation	O
of	O
myeloid	O
progenitors	O
in	O
vitro	O
and	O
increased	O
myeloid	O
progenitor	O
responsiveness	O
to	O
later	O
acting	O
growth	B
factors	I
.	O

In	O
addition	O
,	O
FL	B
synergized	O
with	O
IL-6	B
to	O
support	O
in	O
vitro	O
expansion	O
of	O
haematopoietic	O
progenitors	O
and	O
promoted	O
the	O
survival	O
of	O
lin	O
(	O
-	O
)	O
Sca-1	B
(	O
+	O
)	O
c	B
-	I
kit	I
(	O
+	O
)	O
cells	O
.	O

Cxc	B
chemokine	I
receptor	I
expression	O
on	O
human	O
endothelial	O
cells	O
.	O

CXC	B
chemokines	I
play	O
a	O
important	O
role	O
in	O
the	O
process	O
of	O
leukocyte	O
recruitment	O
and	O
activation	O
at	O
sites	O
of	O
inflammation	O
.	O

However	O
,	O
recent	O
evidence	O
suggests	O
that	O
these	O
molecules	O
can	O
also	O
regulate	O
endothelial	O
cell	O
functions	O
such	O
as	O
migration	O
,	O
angiogenesis	O
and	O
proliferation	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
CXC	B
chemokine	I
receptor	I
expression	O
in	O
both	O
primary	O
cultures	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
and	O
the	O
spontaneously	O
transformed	O
HUVEC	O
cell	O
line	O
,	O
ECV304	O
.	O

We	O
found	O
that	O
both	O
cell	O
types	O
express	O
mRNA	O
for	O
chemokine	O
receptors	O
CXCR1	B
,	O
CXCR2	B
and	O
CXCR4	B
,	O
but	O
not	O
CXCR3	B
.	O

Flow	O
cytometric	O
analysis	O
revealed	O
low	O
levels	O
of	O
CXCR1	B
but	O
higher	O
levels	O
of	O
CXCR4	B
cell	O
surface	O
expression	O
.	O

HUVECs	O
responded	O
to	O
SDF-1alpha	B
with	O
a	O
rapid	O
and	O
robust	O
calcium	O
flux	O
,	O
however	O
no	O
calcium	O
flux	O
was	O
seen	O
with	O
either	O
IL-8	B
or	O
Gro	B
-	I
alpha	I
.	O

HUVECs	O
and	O
ECV304	O
cells	O
did	O
not	O
proliferate	O
in	O
response	O
to	O
CXC	B
chemokines	I
,	O
although	O
ECV304	O
cells	O
did	O
migrate	O
towards	O
SDF-1alpha	B
and	O
IL-8	B
.	O

These	O
data	O
demonstrate	O
that	O
HUVECs	O
and	O
the	O
endothelial	O
cell	O
line	O
,	O
ECV304	O
express	O
functional	O
CXC	B
chemokine	I
receptors	I
.	O

Characterization	O
of	O
the	O
targeting	O
,	O
binding	O
,	O
and	O
phosphorylation	O
site	O
domains	O
of	O
an	O
A	B
kinase	I
anchor	I
protein	I
and	O
a	O
myristoylated	B
alanine	I
-	I
rich	I
C	I
kinase	I
substrate	I
-	O
like	O
analog	O
that	O
are	O
encoded	O
by	O
a	O
single	O
gene	O
.	O

A	O
novel	O
Drosophila	O
A	B
kinase	I
anchor	I
protein	I
,	O
Drosophila	O
A	B
kinase	I
anchor	I
protein	I
200	I
(	O
DAKAP200	B
)	O
,	O
is	O
predicted	O
to	O
be	O
involved	O
in	O
routing	O
,	O
mediating	O
,	O
and	O
integrating	O
signals	O
carried	O
by	O
cAMP	O
,	O
Ca	O
(	O
2	O
+	O
)	O
,	O
and	O
diacylglycerol	O
(	O
Li	O
,	O
Z.	O
,	O
Rossi	O
,	O
E.	O
A.	O
,	O
Hoheisel	O
,	O
J.	O
D.	O
,	O
Kalderon	O
,	O
D.	O
,	O
and	O
Rubin	O
,	O
C.	O
S.	O
(	O
1999	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
274	O
,	O
27191	O
-	O
27200	O
)	O
.	O

Experiments	O
designed	O
to	O
assess	O
this	O
hypothesis	O
now	O
(	O
a	O
)	O
establish	O
the	O
function	O
,	O
boundaries	O
and	O
identity	O
of	O
critical	O
amino	O
acids	O
of	O
the	O
protein	B
kinase	I
AII	I
(	O
PKAII	B
)	O
tethering	O
site	O
of	O
DAKAP200	B
;	O
(	O
b	O
)	O
demonstrate	O
that	O
residues	O
119	O
-	O
148	O
mediate	O
binding	O
with	O
Ca	O
(	O
2	O
+	O
)	O
-	O
calmodulin	B
and	O
F	B
-	I
actin	I
;	O
(	O
c	O
)	O
show	O
that	O
a	O
polybasic	O
region	O
of	O
DAKAP200	B
is	O
a	O
substrate	O
for	O
protein	B
kinase	I
C	I
;	O
(	O
d	O
)	O
reveal	O
that	O
phosphorylation	O
of	O
the	O
polybasic	O
domain	O
regulates	O
affinity	O
for	O
F	B
-	I
actin	I
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
calmodulin	B
;	O
and	O
(	O
e	O
)	O
indicate	O
that	O
DAKAP200	B
is	O
myristoylated	O
and	O
that	O
this	O
modification	O
promotes	O
targeting	O
of	O
DAKAP200	B
to	O
plasma	O
membrane	O
.	O

DeltaDAKAP200	B
,	O
a	O
second	O
product	O
of	O
the	O
DAKAP200	B
gene	O
,	O
can	O
not	O
tether	O
PKAII	B
.	O

However	O
,	O
DeltaDAKAP200	B
is	O
myristoylated	O
and	O
contains	O
a	O
phosphorylation	O
site	O
domain	O
that	O
binds	O
Ca	O
(	O
2	O
+	O
)	O
-	O
calmodulin	B
and	O
F	B
-	I
actin	I
.	O

An	O
atypical	O
amino	O
acid	O
composition	O
,	O
a	O
high	O
level	O
of	O
negative	O
charge	O
,	O
exceptional	O
thermostability	O
,	O
unusual	O
hydrodynamic	O
properties	O
,	O
properties	O
of	O
the	O
phosphorylation	O
site	O
domain	O
,	O
and	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
38,000	O
suggest	O
that	O
DeltaDAKAP200	B
is	O
a	O
new	O
member	O
of	O
the	O
myristoylated	B
alanine	I
-	I
rich	I
C	I
kinase	I
substrate	I
protein	I
family	I
.	O

DAKAP200	B
is	O
a	O
potentially	O
mobile	O
,	O
chimeric	O
A	B
kinase	I
anchor	I
protein	I
-	O
myristoylated	B
alanine	I
-	I
rich	I
C	I
kinase	I
substrate	I
protein	O
that	O
may	O
facilitate	O
localized	O
reception	O
and	O
targeted	O
transmission	O
of	O
signals	O
carried	O
by	O
cAMP	O
,	O
Ca	O
(	O
2	O
+	O
)	O
,	O
and	O
diacylglycerol	O
.	O

Biochemistry	O
of	O
the	O
infarcted	O
heart	O
.	O

I	O
am	O
honored	O
by	O
the	O
invitation	O
to	O
contribute	O
to	O
a	O
volume	O
in	O
Neuroscience	O
,	O
dedicated	O
to	O
Professor	O
Galoyan	O
,	O
whose	O
accomplishments	O
in	O
the	O
field	O
of	O
neuroscience	O
and	O
circulation	O
have	O
been	O
unique	O
.	O

In	O
his	O
book	O
,	O
Dr.	O
Galoyan	O
has	O
summarized	O
the	O
results	O
of	O
his	O
discovery	O
of	O
cardioactive	O
neurohormones	O
.	O

His	O
discovery	O
of	O
biosynthesis	O
of	O
cytokines	B
in	O
the	O
neurosecretory	O
cells	O
of	O
the	O
hypothalamus	O
have	O
opened	O
a	O
new	O
page	O
in	O
immunology	O
.	O

Solution	O
conformation	O
of	O
the	O
(	O
+	O
)	O
-trans	O
-	O
anti	O
-	O
benzo	O
[	O
g	O
]	O
chrysene	O
-	O
dA	O
adduct	O
opposite	O
dT	O
in	O
a	O
DNA	O
duplex	O
.	O

The	O
solution	O
structure	O
of	O
the	O
adduct	O
derived	O
from	O
the	O
covalent	O
bonding	O
of	O
the	O
fjord	O
region	O
(	O
+	O
)	O
-	O
(	O
11S	O
,	O
12R	O
,	O
13R	O
,	O
14S	O
)	O
stereoisomer	O
of	O
anti	O
-	O
11	O
,	O
12	O
-	O
dihydroxy	O
-	O
13	O
,	O
14	O
-	O
epoxy	O
-	O
11	O
,	O
12	O
,	O
13	O
,	O
14	O
-	O
tetrahydrobenzo	O
[	O
g	O
]	O
chrysene	O
,	O
(	O
+	O
)	O
-	O
anti	O
-	O
B	O
[	O
g	O
]	O
CDE	O
,	O
to	O
the	O
exocyclic	O
N	O
(	O
6	O
)	O
amino	O
group	O
of	O
the	O
adenine	O
residue	O
dA6	O
,	O
(	O
designated	O
(	O
+	O
)	O
-	O
trans	O
-	O
anti	O
-	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
dA6	O
)	O
,	O
positioned	O
opposite	O
a	O
thymine	O
residue	O
dT17	O
in	O
the	O
DNA	O
sequence	O
context	O
d	O
(	O
C1-T2	O
-	O
C3	O
-	O
T4	O
-	O
C5	O
-	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
A6	O
-	O
C7	O
-	O
T8	O
-	O
T9	O
-	O
C10	O
-	O
C11	O
)	O
.	O

d	O
(	O
G12-G13-A14-A15-G16-T17-G18-A19-G20	O
+	O
+	O
+	O
-A21-G22	O
)	O
(	O
designated	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
dA.	O
dT	O
11-mer	O
duplex	O
)	O
,	O
has	O
been	O
studied	O
using	O
structural	O
information	O
derived	O
from	O
NMR	O
data	O
in	O
combination	O
with	O
molecular	O
dynamics	O
(	O
MD	O
)	O
calculations	O
.	O

The	O
solution	O
structure	O
of	O
the	O
(	O
+	O
)	O
-	O
trans	O
-	O
anti	O
-	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
dA.dT	O
11-mer	O
duplex	O
has	O
been	O
determined	O
using	O
an	O
MD	O
protocol	O
where	O
both	O
interproton	O
distance	O
and	O
dihedral	O
angle	O
restraints	O
deduced	O
from	O
NOESY	O
and	O
COSY	O
spectra	O
are	O
used	O
during	O
the	O
refinement	O
process	O
,	O
followed	O
by	O
additional	O
relaxation	O
matrix	O
refinement	O
to	O
the	O
observed	O
NOESY	O
intensities	O
to	O
account	O
for	O
spin	O
diffusion	O
effects	O
.	O

The	O
results	O
established	O
that	O
the	O
covalently	O
attached	O
benzo	O
[	O
g	O
]	O
chrysene	O
ring	O
intercalates	O
into	O
the	O
DNA	O
helix	O
directed	O
towards	O
the	O
5	O
'	O
-	O
side	O
of	O
the	O
modified	O
strand	O
and	O
stacks	O
predominantly	O
with	O
dT17	O
when	O
intercalated	O
between	O
dC5.dG18	O
and	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
dA6.dT17	O
base	O
-	O
pairs	O
.	O

All	O
base	O
-	O
pairs	O
,	O
including	O
the	O
modified	O
(	O
B	O
[	O
g	O
]	O
C	O
)	O
dA6.dT17	O
base	O
-	O
pair	O
,	O
are	O
aligned	O
through	O
Watson	O
-	O
Crick	O
pairing	O
as	O
in	O
normal	O
B	O
-	O
DNA	O
.	O

In	O
addition	O
,	O
the	O
potential	O
strain	O
associated	O
with	O
the	O
highly	O
sterically	O
hindered	O
fjord	O
region	O
of	O
the	O
aromatic	O
portion	O
of	O
the	O
benzo	O
[	O
g	O
]	O
chrysenyl	O
ring	O
is	O
relieved	O
through	O
the	O
adoption	O
of	O
a	O
non	O
-	O
planar	O
,	O
propeller	O
-	O
like	O
geometry	O
within	O
the	O
chrysenyl	O
ring	O
system	O
.	O

This	O
conformation	O
shares	O
common	O
structural	O
features	O
with	O
the	O
related	O
(	O
+	O
)	O
-	O
trans	O
-	O
anti	O
-	O
(	O
B	O
[	O
c	O
]	O
Ph	O
)	O
dA	O
adduct	O
in	O
the	O
identical	O
base	O
sequence	O
context	O
,	O
derived	O
from	O
the	O
fjord	O
region	O
(	O
+	O
)	O
-	O
(	O
1S,2R,3R,4S	O
)	O
-3	O
,	O
4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrobenzo	O
[	O
c	O
]	O
phenanthrene	O
stereoisomer	O
,	O
in	O
which	O
intercalation	O
is	O
also	O
observed	O
towards	O
the	O
5	O
'	O
-	O
side	O
of	O
the	O
modified	O
dA6.dT17	O
base	O
-	O
pair	O
.	O

A	O
phylogenetic	O
approach	O
to	O
target	O
selection	O
for	O
structural	O
genomics	O
:	O
solution	O
structure	O
of	O
YciH	B
.	O

Structural	O
genomics	O
presents	O
an	O
enormous	O
challenge	O
with	O
up	O
to	O
100	O
000	O
protein	O
targets	O
in	O
the	O
human	O
genome	O
alone	O
.	O

At	O
current	O
rates	O
of	O
structure	O
deter	O
-	O
mination	O
,	O
judicious	O
selection	O
of	O
targets	O
is	O
necessary	O
.	O

Here	O
,	O
a	O
phylogenetic	O
approach	O
to	O
target	O
selection	O
is	O
described	O
which	O
makes	O
use	O
of	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
database	O
of	O
Clusters	O
of	O
Orthologous	O
Groups	O
(	O
COGS	O
)	O
.	O

The	O
strategy	O
is	O
designed	O
so	O
that	O
each	O
new	O
protein	O
structure	O
is	O
likely	O
to	O
provide	O
novel	O
sequence	O
-	O
fold	O
information	O
.	O

To	O
demonstrate	O
this	O
approach	O
,	O
the	O
NMR	O
solution	O
structure	O
of	O
YciH	B
(	O
COG0023	O
)	O
,	O
a	O
putative	O
translation	O
initiation	O
factor	O
from	O
Escherichia	O
coli	O
,	O
has	O
been	O
determined	O
and	O
its	O
fold	O
classified	O
.	O

YciH	B
is	O
an	O
ortholog	O
of	O
eIF-1	B
/	O
SUI1	B
,	O
an	O
integral	O
component	O
of	O
the	O
translation	O
initiation	O
complex	O
in	O
eukaryotes	O
.	O

The	O
structure	O
consists	O
of	O
two	O
antiparallel	O
alpha	O
-	O
helices	O
packed	O
against	O
the	O
same	O
side	O
of	O
a	O
five	O
-	O
stranded	O
beta	O
-	O
sheet	O
.	O

The	O
first	O
31	O
residues	O
of	O
the	O
11.5	O
kDa	O
protein	O
are	O
unstructured	O
in	O
solution	O
.	O

Comparative	O
analysis	O
indicates	O
that	O
the	O
folded	O
portion	O
of	O
YciH	B
resembles	O
a	O
number	O
of	O
structures	O
with	O
the	O
alpha	O
-	O
beta	O
plait	O
topology	O
,	O
though	O
its	O
sequence	O
is	O
not	O
homologous	O
to	O
any	O
of	O
them	O
.	O

Thus	O
,	O
the	O
phylogenetic	O
approach	O
to	O
target	O
selection	O
described	O
here	O
was	O
used	O
successfully	O
to	O
identify	O
a	O
new	O
homologous	O
superfamily	O
within	O
this	O
topology	O
.	O

The	O
c	B
-	I
kit	I
receptor	I
and	O
its	O
ligand	O
stem	B
cell	I
factor	I
in	O
childhood	O
malignant	O
lymphoid	O
precursors	O
.	O

The	O
c	B
-	I
kit	I
receptor	I
(	O
CD117	B
)	O
and	O
its	O
ligand	O
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
,	O
differentiation	O
,	O
and	O
survival	O
of	O
normal	O
and	O
malignant	O
hematopoietic	O
cells	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
review	O
the	O
cellular	O
distribution	O
of	O
this	O
receptor	O
and	O
the	O
effect	O
of	O
SCF	B
on	O
the	O
hematopoietic	O
system	O
,	O
particularly	O
among	O
lymphoid	O
lineage	O
,	O
either	O
in	O
normal	O
or	O
malignant	O
cell	O
progenitors	O
.	O

We	O
examined	O
reports	O
and	O
results	O
in	O
the	O
field	O
and	O
articles	O
or	O
abstracts	O
published	O
in	O
journals	O
covered	O
by	O
MEDLINE	O
.	O

Additionally	O
,	O
we	O
evaluated	O
CD117	B
expression	O
on	O
fresh	O
blast	O
cells	O
of	O
376	O
newly	O
diagnosed	O
cases	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
that	O
were	O
referred	O
to	O
centers	O
affiliated	O
with	O
the	O
Italian	O
Association	O
for	O
Pediatric	O
Hematology	O
and	O
Oncology	O
(	O
AIEOP	O
)	O
.	O

In	O
view	O
of	O
our	O
data	O
,	O
approximately	O
11	O
%	O
of	O
ALL	O
are	O
CD117	B
positive	O
.	O

In	O
particular	O
,	O
this	O
receptor	O
can	O
be	O
expressed	O
in	O
10	O
%	O
and	O
11.5	O
%	O
of	O
T	O
-	O
lineage	O
and	O
B	O
-	O
lineage	O
ALL	O
,	O
respectively	O
.	O

Its	O
expression	O
is	O
associated	O
with	O
an	O
intermediate	O
/	O
mature	O
phenotype	O
in	O
T	O
-	O
lineage	O
ALL	O
,	O
whereas	O
in	O
B	O
-	O
lineage	O
ALL	O
,	O
the	O
majority	O
of	O
the	O
positive	O
cases	O
are	O
classified	O
as	O
early	O
B	O
ALL	O
.	O

The	O
effect	O
of	O
SCF	B
on	O
malignant	O
hematopoiesis	O
and	O
its	O
potential	O
clinical	O
uses	O
are	O
reviewed	O
.	O

Zinc	O
finger	O
of	O
replication	B
protein	I
A	I
,	O
a	O
non	O
-	O
DNA	O
binding	O
element	O
,	O
regulates	O
its	O
DNA	O
binding	O
activity	O
through	O
redox	O
.	O

Eukaryotic	O
replication	B
protein	I
A	I
(	O
RPA	B
)	O
is	O
a	O
single	O
-	O
stranded	O
DNA	O
-	O
binding	O
protein	O
with	O
multiple	O
functions	O
in	O
DNA	O
replication	O
,	O
repair	O
,	O
and	O
genetic	O
recombination	O
.	O

RPA	B
contains	O
an	O
evolutionarily	O
conserved	O
4	O
-	O
cysteine	O
-	O
type	O
zinc	O
finger	O
motif	O
(	O
X	O
(	O
3	O
)	O
CX	O
(	O
2	O
-	O
4	O
)	O
CX	O
(	O
12	O
-	O
15	O
)	O
CX	O
(	O
2	O
)	O
C	O
)	O
that	O
has	O
a	O
potential	O
role	O
in	O
regulation	O
of	O
DNA	O
replication	O
and	O
repair	O
(	O
Dong	O
,	O
J.	O
,	O
Park	O
,	O
J	O
-	O
S.	O
,	O
and	O
Lee	O
,	O
S	O
-	O
H.	O
(	O
1999	O
)	O
Biochem	O
.	O
J.	O
337	O
,	O
311	O
-	O
317	O
and	O
Lin	O
,	O
Y.	O
-	O
L.	O
,	O
Shivji	O
,	O
M.	O
K.	O
K.	O
,	O
Chen	O
,	O
C.	O
,	O
Kolodner	O
,	O
R.	O
,	O
Wood	O
,	O
R.	O
D.	O
,	O
and	O
Dutta	O
,	O
A.	O
(	O
1998	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
273	O
,	O
1453	O
-	O
1461	O
)	O
,	O
even	O
though	O
the	O
zinc	O
finger	O
itself	O
is	O
not	O
essential	O
for	O
its	O
DNA	O
binding	O
activity	O
(	O
Kim	O
,	O
D.	O
K.	O
,	O
Stigger	O
,	O
E.	O
,	O
and	O
Lee	O
,	O
S.	O
-	O
H.	O
(	O
1996	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
271	O
,	O
15124	O
-	O
15129	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
RPA	B
single	O
-	O
stranded	O
DNA	O
(	O
ssDNA	O
)	O
binding	O
activity	O
is	O
regulated	O
by	O
reduction	O
-	O
oxidation	O
(	O
redox	O
)	O
through	O
its	O
zinc	O
finger	O
domain	O
.	O

RPA	B
-	O
ssDNA	O
interaction	O
was	O
stimulated	O
10	O
-	O
fold	O
by	O
the	O
reducing	O
agent	O
,	O
dithiothreitol	O
(	O
DTT	O
)	O
,	O
whereas	O
treatment	O
of	O
RPA	B
with	O
oxidizing	O
agent	O
,	O
diazene	O
dicarboxylic	O
acid	O
bis	O
[	O
N	O
,	O
N	O
-	O
dimethylamide	O
]	O
(	O
diamide	O
)	O
,	O
significantly	O
reduced	O
this	O
interaction	O
.	O

The	O
effect	O
of	O
diamide	O
was	O
reversed	O
by	O
the	O
addition	O
of	O
excess	O
DTT	O
,	O
suggesting	O
that	O
RPA	B
ssDNA	O
binding	O
activity	O
is	O
regulated	O
by	O
redox	O
.	O

Redox	O
regulation	O
of	O
RPA	B
-	O
ssDNA	O
interaction	O
was	O
more	O
effective	O
in	O
the	O
presence	O
of	O
0.2	O
M	O
NaCl	O
or	O
higher	O
.	O

Cellular	O
redox	O
factor	O
,	O
thioredoxin	O
,	O
was	O
able	O
to	O
replace	O
DTT	O
in	O
stimulation	O
of	O
RPA	B
DNA	O
binding	O
activity	O
,	O
suggesting	O
that	O
redox	O
protein	O
may	O
be	O
involved	O
in	O
RPA	B
modulation	O
in	O
vivo	O
.	O

In	O
contrast	O
to	O
wild	O
-	O
type	O
RPA	B
,	O
zinc	O
finger	O
mutant	O
(	O
cysteine	O
to	O
alanine	O
mutation	O
at	O
amino	O
acid	O
486	O
)	O
did	O
not	O
require	O
DTT	O
for	O
its	O
ssDNA	O
binding	O
activity	O
and	O
is	O
not	O
affected	O
by	O
redox	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
a	O
novel	O
function	O
for	O
a	O
putative	O
zinc	O
finger	O
in	O
the	O
regulation	O
of	O
RPA	B
DNA	O
binding	O
activity	O
through	O
cellular	O
redox	O
.	O

Congenital	O
horizontal	O
tarsal	O
kink	O
:	O
clinical	O
characteristics	O
from	O
a	O
large	O
series	O
.	O

PURPOSE	O
:	O

To	O
describe	O
the	O
clinical	O
characteristics	O
of	O
congenital	O
horizontal	O
tarsal	O
kink	O
.	O

METHODS	O
:	O

Retrospective	O
clinical	O
series	O
derived	O
from	O
a	O
literature	O
review	O
and	O
mail	O
survey	O
.	O

Characteristics	O
included	O
sex	O
,	O
race	O
,	O
association	O
with	O
systemic	O
diseases	O
,	O
interval	O
between	O
birth	O
and	O
diagnosis	O
,	O
laterality	O
,	O
presence	O
of	O
corneal	O
ulcer	O
and	O
causative	O
infectious	O
agent	O
,	O
treatment	O
,	O
and	O
visual	O
outcome	O
.	O

RESULTS	O
:	O

Twenty	O
-	O
five	O
cases	O
were	O
reviewed	O
.	O

The	O
typical	O
patient	O
is	O
a	O
white	O
male	O
diagnosed	O
at	O
7.2	O
weeks	O
of	O
age	O
.	O

Right	O
-	O
sided	O
and	O
bilateral	O
cases	O
were	O
most	O
common	O
.	O

Ulcers	O
were	O
present	O
in	O
12	O
/	O
24	O
patients	O
;	O
most	O
were	O
culture	O
negative	O
.	O

Various	O
methods	O
of	O
surgical	O
repair	O
were	O
successful	O
.	O

Visual	O
outcomes	O
,	O
in	O
general	O
,	O
were	O
favorable	O
although	O
amblyopia	O
developed	O
in	O
4	O
/	O
15	O
patients	O
.	O

CONCLUSIONS	O
:	O

Congenital	O
horizontal	O
tarsal	O
kink	O
is	O
rare	O
and	O
its	O
cause	O
is	O
unknown	O
.	O

A	O
poor	O
visual	O
outcome	O
usually	O
results	O
from	O
a	O
corneal	O
ulcer	O
scar	O
and	O
a	O
delay	O
in	O
diagnosis	O
.	O

Amblyopia	O
not	O
related	O
to	O
corneal	O
opacification	O
can	O
also	O
occur	O
.	O

Characterization	O
of	O
a	O
new	O
sigma	B
-	I
K	I
-	O
dependent	O
peptidoglycan	B
hydrolase	I
gene	O
that	O
plays	O
a	O
role	O
in	O
Bacillus	O
subtilis	O
mother	O
cell	O
lysis	O
.	O

Bacillus	O
subtilis	O
produces	O
a	O
30	O
-	O
kDa	O
peptidoglycan	B
hydrolase	I
,	O
CwlH	B
,	O
during	O
the	O
late	O
sporulation	O
phase	O
.	O

Disruption	O
of	O
yqeE	B
led	O
to	O
a	O
complete	O
loss	O
of	O
CwlH	B
formation	O
,	O
indicating	O
the	O
identity	O
of	O
yqeE	B
with	O
cwlH	B
.	O

Northern	O
blot	O
analysis	O
of	O
cwlH	B
revealed	O
a	O
0.8	O
-	O
kb	O
transcript	O
after	O
6	O
to	O
7.5	O
h	O
for	O
the	O
wild	O
-	O
type	O
strain	O
but	O
not	O
for	O
the	O
sigma	B
(	I
F	I
)	I
,	O
sigma	B
(	I
E	I
)	I
,	O
sigma	B
(	I
G	I
)	I
,	O
and	O
sigma	B
(	I
K	I
)	I
mutants	O
.	O

Expression	O
of	O
the	O
sigma	B
(	I
K	I
)	I
-	O
dependent	O
cwlH	B
gene	O
depended	O
on	O
gerE	B
.	O

Primer	O
extension	O
analysis	O
also	O
suggested	O
that	O
cwlH	B
is	O
transcribed	O
by	O
Esigma	B
(	I
K	I
)	I
RNA	B
polymerase	I
.	O

CwlH	B
produced	O
in	O
Escherichia	O
coli	O
harboring	O
a	O
cwlH	B
plasmid	O
is	O
an	O
N	B
-	I
acetylmuramoyl	I
-	I
L	I
-	I
alanine	I
amidase	I
(	O
EC	B
3.5.1.28	I
)	O
and	O
exhibited	O
an	O
optimum	O
pH	O
of	O
7.0	O
and	O
high	O
-	O
level	O
binding	O
to	O
the	O
B.	O
subtilis	O
cell	O
wall	O
.	O

A	O
cwlC	B
cwlH	B
double	O
mutation	O
led	O
to	O
a	O
lack	O
of	O
mother	O
cell	O
lysis	O
even	O
after	O
7	O
days	O
of	O
incubation	O
in	O
DSM	O
medium	O
,	O
but	O
the	O
single	O
mutations	O
led	O
to	O
mother	O
cell	O
lysis	O
after	O
24	O
h	O
.	O

rpoS	B
function	O
is	O
essential	O
for	O
bgl	B
silencing	O
caused	O
by	O
C	O
-	O
terminally	O
truncated	O
H	B
-	I
NS	I
in	O
Escherichia	O
coli	O
.	O

From	O
evolutionary	O
and	O
physiological	O
viewpoints	O
,	O
the	O
Escherichia	O
coli	O
bgl	B
operon	I
is	O
intriguing	O
because	O
its	O
expression	O
is	O
silent	O
(	O
Bgl	B
(	O
-	O
)	O
phenotype	O
)	O
,	O
at	O
least	O
under	O
several	O
laboratory	O
conditions	O
.	O

H	B
-	I
NS	I
,	O
a	O
nucleoid	O
protein	O
,	O
is	O
known	O
as	O
a	O
DNA	O
-	O
binding	O
protein	O
involved	O
in	O
bgl	B
silencing	O
.	O

However	O
,	O
we	O
previously	O
found	O
that	O
bgl	B
expression	O
is	O
still	O
silent	O
in	O
a	O
certain	O
subset	O
of	O
hns	B
mutations	O
,	O
each	O
of	O
which	O
results	O
in	O
a	O
defect	O
in	O
its	O
DNA	O
-	O
binding	O
ability	O
.	O

Based	O
on	O
this	O
fact	O
,	O
we	O
proposed	O
a	O
model	O
in	O
which	O
a	O
postulated	O
DNA	O
-	O
binding	O
protein	O
(	O
s	O
)	O
has	O
an	O
adapter	O
function	O
by	O
interacting	O
with	O
both	O
the	O
cis	O
-	O
acting	O
element	O
of	O
the	O
bgl	B
promoter	O
and	O
the	O
mutated	O
H	B
-	I
NS	I
.	O

To	O
identify	O
such	O
a	O
presumed	O
adapter	O
molecule	O
,	O
we	O
attempted	O
to	O
isolate	O
mutants	O
exhibiting	O
the	O
Bgl	B
(	O
+	O
)	O
phenotype	O
in	O
the	O
background	O
of	O
hns60	B
,	O
encoding	O
the	O
mutant	O
H	B
-	I
NS	I
protein	O
lacking	O
the	O
DNA	O
-	O
binding	O
domain	O
by	O
random	O
insertion	O
mutagenesis	O
with	O
the	O
mini	O
-	O
Tn10cam	O
transposon	O
.	O

These	O
isolated	O
mutations	O
were	O
mapped	O
to	O
five	O
loci	O
on	O
the	O
chromosome	O
.	O

Among	O
these	O
loci	O
,	O
three	O
appeared	O
to	O
be	O
leuO	B
,	O
hns	B
,	O
and	O
bglJ	B
,	O
which	O
were	O
previously	O
characterized	O
,	O
while	O
the	O
other	O
two	O
were	O
novel	O
.	O

Genetic	O
analysis	O
revealed	O
that	O
the	O
two	O
insertions	O
are	O
within	O
the	O
rpoS	B
gene	O
and	O
in	O
front	O
of	O
the	O
lrhA	B
gene	O
,	O
respectively	O
.	O

The	O
former	O
encodes	O
the	O
stationary	O
-	O
phase	O
-	O
specific	O
sigma	B
factor	I
,	O
sigma	B
(	I
S	I
)	I
,	O
and	O
the	O
latter	O
encodes	O
a	O
LysR	B
-	O
like	O
DNA	O
-	O
binding	O
protein	O
.	O

It	O
was	O
found	O
that	O
sigma	B
(	I
S	I
)	I
is	O
defective	O
in	O
both	O
types	O
of	O
mutant	O
cells	O
.	O

These	O
results	O
showed	O
that	O
the	O
rpoS	B
function	O
is	O
involved	O
in	O
the	O
mechanism	O
underlying	O
bgl	B
silencing	O
,	O
at	O
least	O
in	O
the	O
hns60	B
background	O
used	O
in	O
this	O
study	O
.	O

We	O
also	O
examined	O
whether	O
the	O
H	B
-	I
NS	I
homolog	O
StpA	B
has	O
such	O
an	O
adapter	O
function	O
,	O
as	O
was	O
previously	O
proposed	O
.	O

Our	O
results	O
did	O
not	O
support	O
the	O
idea	O
that	O
StpA	B
has	O
an	O
adapter	O
function	O
in	O
the	O
genetic	O
background	O
used	O
.	O

The	O
kissing	O
-	O
loop	O
motif	O
is	O
a	O
preferred	O
site	O
of	O
5	O
'	O
leader	O
recombination	O
during	O
replication	O
of	O
SL3	O
-	O
3	O
murine	O
leukemia	O
viruses	O
in	O
mice	O
.	O

A	O
panel	O
of	O
mouse	O
T	O
-	O
cell	O
lymphomas	O
induced	O
by	O
SL3	O
-	O
3	O
murine	O
leukemia	O
virus	O
(	O
MLV	O
)	O
and	O
three	O
primer	O
binding	O
site	O
mutants	O
thereof	O
(	O
A.	O
H.	O
Lund	O
,	O
J.	O
Schmidt	O
,	O
A.	O
Luz	O
,	O
A.	O
B.	O
Sorensen	O
,	O
M.	O
Duch	O
,	O
and	O
F.	O
S.	O
Pedersen	O
,	O
J.	O
Virol	O
.	O
73	O
:	O
6117	O
-	O
6122	O
,	O
1999	O
)	O
were	O
analyzed	O
for	O
the	O
occurrence	O
of	O
recombination	O
between	O
the	O
exogenous	O
input	O
virus	O
and	O
endogenous	O
MLV	O
-	O
like	O
sequences	O
within	O
the	O
5	O
'	O
leader	O
region	O
.	O

Evidence	O
of	O
recombination	O
within	O
the	O
region	O
studied	O
was	O
found	O
in	O
14	O
of	O
52	O
tumors	O
analyzed	O
.	O

Sequence	O
analysis	O
of	O
a	O
approximately	O
330	O
-	O
bp	O
fragment	O
of	O
44	O
chimeric	O
proviruses	O
,	O
encompassing	O
the	O
U5	O
,	O
the	O
primer	O
binding	O
site	O
,	O
and	O
the	O
upstream	O
part	O
of	O
the	O
5	O
'	O
untranslated	O
region	O
,	O
enabled	O
us	O
to	O
map	O
recombination	O
sites	O
,	O
guided	O
by	O
distinct	O
scattered	O
nucleotide	O
differences	O
.	O

In	O
30	O
of	O
44	O
analyzed	O
sequences	O
,	O
recombination	O
was	O
mapped	O
to	O
a	O
33	O
-	O
nucleotide	O
similarity	O
window	O
coinciding	O
with	O
the	O
kissing	O
-	O
loop	O
stem	O
-	O
loop	O
motif	O
implicated	O
in	O
dimerization	O
of	O
the	O
diploid	O
genome	O
.	O

Interestingly	O
,	O
the	O
recombination	O
pattern	O
preference	O
found	O
in	O
replication	O
-	O
competent	O
viruses	O
from	O
T	O
-	O
cell	O
tumors	O
is	O
very	O
similar	O
to	O
the	O
pattern	O
previously	O
reported	O
for	O
retroviral	O
vectors	O
in	O
cell	O
culture	O
experiments	O
.	O

The	O
data	O
therefore	O
sustain	O
the	O
hypothesis	O
that	O
the	O
kissing	O
loop	O
,	O
presumably	O
via	O
a	O
role	O
in	O
RNA	O
dimer	O
formation	O
,	O
constitutes	O
a	O
hot	O
spot	O
for	O
reverse	B
transcriptase	I
-	O
mediated	O
recombination	O
in	O
MLV	O
.	O

Elevated	O
plasma	O
eotaxin	B
levels	O
in	O
patients	O
with	O
acute	O
asthma	O
.	O

BACKGROUND	O
:	O

The	O
eosinophil	O
chemotactic	O
and	O
activating	O
effects	O
of	O
eotaxin	B
and	O
the	O
known	O
association	O
of	O
eosinophils	O
with	O
asthma	O
suggest	O
that	O
eotaxin	B
expression	O
is	O
increased	O
during	O
asthma	O
exacerbations	O
.	O

OBJECTIVE	O
:	O

We	O
sought	O
to	O
determine	O
whether	O
plasma	O
eotaxin	B
levels	O
are	O
elevated	O
in	O
patients	O
presenting	O
for	O
emergency	O
treatment	O
of	O
acute	O
asthma	O
and	O
to	O
correlate	O
eotaxin	B
levels	O
with	O
disease	O
activity	O
and	O
responses	O
to	O
treatment	O
.	O

METHODS	O
:	O

A	O
case	O
-	O
control	O
study	O
of	O
plasma	O
eotaxin	B
levels	O
was	O
performed	O
in	O
the	O
46	O
patients	O
who	O
presented	O
for	O
emergency	O
asthma	O
treatment	O
and	O
133	O
age	O
-	O
,	O
sex	O
-	O
,	O
and	O
ethnicity	O
-	O
matched	O
subjects	O
with	O
stable	O
asthma	O
.	O

RESULTS	O
:	O

Plasma	O
eotaxin	B
levels	O
were	O
significantly	O
higher	O
in	O
46	O
patients	O
with	O
acute	O
asthma	O
symptoms	O
and	O
airflow	O
obstruction	O
(	O
520	O
pg	O
/	O
mL	O
[	O
250	O
,	O
1100	O
pg	O
/	O
mL	O
]	O
;	O
geometric	O
mean	O
[	O
-1	O
SD	O
,	O
+	O
1	O
SD	O
]	O
)	O
than	O
in	O
133	O
subjects	O
with	O
stable	O
asthma	O
(	O
350	O
pg	O
/	O
mL	O
[	O
190	O
,	O
620	O
pg	O
/	O
mL	O
]	O
;	O
P	O
=	O
.0008	O
)	O
.	O

Among	O
the	O
patients	O
with	O
emergency	O
asthma	O
flares	O
,	O
those	O
who	O
responded	O
to	O
asthma	O
treatment	O
with	O
an	O
increase	O
in	O
peak	O
expiratory	O
flow	O
rate	O
by	O
an	O
amount	O
equal	O
to	O
at	O
least	O
20	O
%	O
of	O
their	O
predicted	O
normal	O
value	O
had	O
lower	O
eotaxin	B
levels	O
than	O
those	O
who	O
did	O
not	O
(	O
410	O
pg	O
/	O
mL	O
[	O
210	O
,	O
800	O
pg	O
/	O
mL	O
]	O
and	O
660	O
pg	O
/	O
mL	O
[	O
300	O
,	O
1480	O
pg	O
/	O
mL	O
]	O
,	O
respectively	O
;	O
P	O
=	O
.04	O
)	O
.	O

CONCLUSION	O
:	O

These	O
findings	O
imply	O
that	O
eotaxin	B
either	O
is	O
mechanistically	O
involved	O
in	O
acute	O
asthma	O
or	O
serves	O
as	O
a	O
biomarker	O
for	O
activity	O
of	O
the	O
CCR3	B
receptor	O
ligand	O
system	O
,	O
which	O
is	O
functionally	O
linked	O
to	O
asthma	O
.	O

FGF-19	B
,	O
a	O
novel	O
fibroblast	B
growth	I
factor	I
with	O
unique	O
specificity	O
for	O
FGFR4	B
.	O

We	O
have	O
identified	O
a	O
novel	O
fibroblast	B
growth	I
factor	I
,	O
FGF-19	B
,	O
the	O
most	O
distant	O
member	O
of	O
the	O
FGF	B
family	I
described	O
to	O
date	O
.	O

FGF-19	B
is	O
a	O
high	O
affinity	O
,	O
heparin	O
dependent	O
ligand	O
for	O
FGFR4	B
and	O
is	O
the	O
first	O
member	O
of	O
the	O
FGF	B
family	I
to	O
show	O
exclusive	O
binding	O
to	O
FGFR4	B
.	O

Human	O
FGF-19	B
maps	O
to	O
chromosome	O
11	O
q13.1	O
,	O
a	O
region	O
associated	O
with	O
an	O
osteoporosis	O
-	O
pseudoglioma	O
syndrome	O
of	O
skeletal	O
and	O
retinal	O
defects	O
.	O

FGF-19	B
message	O
is	O
expressed	O
in	O
several	O
tissues	O
including	O
fetal	O
cartilage	O
,	O
skin	O
,	O
and	O
retina	O
,	O
as	O
well	O
as	O
adult	O
gall	O
bladder	O
and	O
is	O
overexpressed	O
in	O
a	O
colon	O
adenocarcinoma	O
cell	O
line	O
.	O

Smooth	O
pursuit	O
tracking	O
deficits	O
of	O
patients	O
with	O
schizophrenia	O
at	O
specific	O
within	O
-	O
sine	O
wave	O
bins	O
.	O

BACKGROUND	O
:	O

Early	O
information	O
processing	O
deficits	O
are	O
consistently	O
reported	O
for	O
patients	O
with	O
schizophrenia	O
on	O
smooth	O
pursuit	O
tracking	O
tasks	O
.	O

A	O
growing	O
number	O
of	O
studies	O
have	O
applied	O
a	O
transient	O
(	O
magnocellular	O
)	O
or	O
sustained	O
(	O
parvocellular	O
)	O
explanation	O
to	O
account	O
for	O
deficient	O
processing	O
of	O
briefly	O
presented	O
visual	O
stimuli	O
,	O
moving	O
stimuli	O
,	O
and	O
particularly	O
,	O
stimuli	O
requiring	O
smooth	O
tracking	O
eye	O
movements	O
in	O
patients	O
with	O
schizophrenia	O
.	O

OBJECTIVE	O
:	O

Although	O
the	O
preponderance	O
of	O
findings	O
offer	O
support	O
for	O
transient	O
(	O
where	O
is	O
it	O
?	O
)	O
as	O
opposed	O
to	O
sustained	O
(	O
what	O
is	O
it	O
?	O
)	O
deficit	O
,	O
a	O
need	O
remains	O
for	O
specific	O
depiction	O
of	O
the	O
deficit	O
.	O

This	O
was	O
accomplished	O
by	O
applying	O
a	O
unique	O
analytic	O
method	O
to	O
a	O
smooth	O
pursuit	O
tracking	O
task	O
.	O

METHODS	O
:	O

Fourteen	O
patients	O
with	O
schizophrenia	O
and	O
fifteen	O
normal	O
control	O
subjects	O
were	O
tested	O
on	O
smooth	O
pursuit	O
tracking	O
performance	O
at	O
five	O
different	O
""""	O
within	O
-	O
wave	O
""""	O
dot	O
velocity	O
frequencies	O
that	O
ranged	O
from	O
.3	O
to	O
1.1	O
hz	O
.	O

Performance	O
data	O
was	O
extracted	O
from	O
each	O
of	O
the	O
five	O
frequencies	O
and	O
then	O
separated	O
into	O
12	O
discrete	O
components	O
that	O
corresponded	O
to	O
light	O
velocity	O
(	O
i.e.	O
,	O
12	O
bins	O
)	O
.	O

RESULTS	O
:	O

A	O
repeated	O
measures	O
multivariate	O
analysis	O
of	O
covariance	O
indicated	O
that	O
the	O
performance	O
of	O
patients	O
with	O
schizophrenia	O
was	O
significantly	O
poorer	O
than	O
that	O
of	O
their	O
normal	O
counterparts	O
for	O
three	O
separate	O
analyses	O
of	O
the	O
time	O
in	O
smooth	O
pursuit	O
,	O
F	O
(	O
11,594	O
)	O
=	O
8.99	O
;	O
p	O
<	O
0.00001	O
,	O
percentage	O
of	O
time	O
in	O
smooth	O
pursuit	O
,	O
F	O
(	O
11,594	O
)	O
=	O
3.06	O
;	O
p	O
<	O
0.0005	O
,	O
and	O
time	O
in	O
saccade	O
eye	O
movement	O
,	O
F	O
(	O
11,594	O
)	O
=	O
3.11	O
;	O
p	O
<	O
0.0004	O
.	O

A	O
regression	O
analysis	O
revealed	O
that	O
the	O
medication	O
dosage	O
was	O
not	O
significantly	O
associated	O
with	O
performance	O
on	O
any	O
of	O
the	O
critical	O
measures	O
,	O
although	O
trends	O
were	O
observed	O
.	O

CONCLUSIONS	O
:	O

The	O
findings	O
provide	O
support	O
for	O
an	O
early	O
information	O
processing	O
deficit	O
in	O
patients	O
with	O
schizophrenia	O
.	O

In	O
addition	O
,	O
the	O
results	O
support	O
the	O
current	O
neurophysiologic	O
model	O
for	O
abnormal	O
smooth	O
pursuit	O
tracking	O
in	O
patients	O
with	O
schizophrenia	O
,	O
specifically	O
implicating	O
a	O
transient	O
channel	O
deficiency	O
.	O

Lamivudine	O
as	O
initial	O
treatment	O
for	O
chronic	O
hepatitis	O
B	O
in	O
the	O
United	O
States	O
.	O

BACKGROUND	O
AND	O
METHODS	O
:	O

Although	O
the	O
nucleoside	O
analogue	O
lamivudine	O
has	O
shown	O
promise	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
,	O
long	O
-	O
term	O
data	O
on	O
patients	O
from	O
the	O
United	O
States	O
are	O
lacking	O
.	O

We	O
randomly	O
assigned	O
previously	O
untreated	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
to	O
receive	O
either	O
100	O
mg	O
of	O
oral	O
lamivudine	O
or	O
placebo	O
daily	O
for	O
52	O
weeks	O
.	O

We	O
then	O
followed	O
them	O
for	O
an	O
additional	O
16	O
weeks	O
to	O
evaluate	O
post	O
-	O
treatment	O
safety	O
and	O
the	O
durability	O
of	O
responses	O
.	O

The	O
primary	O
end	O
point	O
with	O
respect	O
to	O
efficacy	O
was	O
a	O
reduction	O
of	O
at	O
least	O
2	O
points	O
in	O
the	O
score	O
on	O
the	O
Histologic	O
Activity	O
Index	O
.	O

On	O
this	O
scale	O
,	O
scores	O
can	O
range	O
from	O
0	O
(	O
normal	O
)	O
to	O
22	O
(	O
most	O
severe	O
abnormalities	O
)	O
.	O

RESULTS	O
:	O

Of	O
the	O
143	O
randomized	O
patients	O
,	O
137	O
were	O
included	O
in	O
the	O
efficacy	O
analysis	O
:	O
66	O
in	O
the	O
lamivudine	O
group	O
and	O
71	O
in	O
the	O
placebo	O
group	O
.	O

The	O
other	O
six	O
patients	O
were	O
excluded	O
at	O
the	O
base	O
-	O
line	O
visit	O
because	O
of	O
the	O
absence	O
of	O
a	O
documented	O
history	O
of	O
hepatitis	O
B	O
surface	O
antigen	O
for	O
at	O
least	O
six	O
months	O
.	O

After	O
52	O
weeks	O
of	O
treatment	O
,	O
lamivudine	O
recipients	O
were	O
more	O
likely	O
than	O
placebo	O
recipients	O
to	O
have	O
a	O
histologic	O
response	O
(	O
52	O
percent	O
vs.	O
23	O
percent	O
,	O
P	O
<	O
0.001	O
)	O
,	O
loss	O
of	O
hepatitis	O
B	O
e	B
antigen	I
(	O
HBeAg	B
)	O
in	O
serum	O
(	O
32	O
percent	O
vs.	O
11	O
percent	O
,	O
P	O
=	O
0.003	O
)	O
,	O
sustained	O
suppression	O
of	O
serum	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
DNA	O
to	O
undetectable	O
levels	O
(	O
44	O
percent	O
vs.	O
16	O
percent	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
sustained	O
normalization	O
of	O
serum	O
alanine	B
aminotransferase	I
levels	O
(	O
41	O
percent	O
vs.	O
7	O
percent	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
they	O
were	O
less	O
likely	O
to	O
have	O
increased	O
hepatic	O
fibrosis	O
(	O
5	O
percent	O
vs.	O
20	O
percent	O
,	O
P	O
=	O
0.01	O
)	O
.	O

Lamivudine	O
recipients	O
were	O
also	O
more	O
likely	O
to	O
undergo	O
HBeAg	B
seroconversion	O
,	O
defined	O
as	O
the	O
loss	O
of	O
HBeAg	B
,	O
undetectable	O
levels	O
of	O
serum	O
HBV	O
DNA	O
,	O
and	O
the	O
appearance	O
of	O
antibodies	O
against	O
HBeAg	B
(	O
17	O
percent	O
vs.	O
6	O
percent	O
,	O
P	O
=	O
0.04	O
)	O
.	O

HBeAg	B
responses	O
persisted	O
in	O
most	O
patients	O
for	O
16	O
weeks	O
after	O
the	O
discontinuation	O
of	O
treatment	O
.	O

Lamivudine	O
was	O
well	O
tolerated	O
.	O

Self	O
-	O
limited	O
post	O
-	O
treatment	O
elevations	O
in	O
serum	O
alanine	B
aminotransferase	I
were	O
more	O
common	O
in	O
lamivudine	O
recipients	O
:	O
25	O
percent	O
had	O
serum	O
alanine	B
aminotransferase	I
levels	O
that	O
were	O
at	O
least	O
three	O
times	O
base	O
-	O
line	O
levels	O
,	O
as	O
compared	O
with	O
8	O
percent	O
of	O
placebo	O
recipients	O
(	O
P	O
=	O
0.01	O
)	O
.	O

The	O
clinical	O
condition	O
of	O
all	O
patients	O
remained	O
stable	O
during	O
the	O
study	O
.	O

CONCLUSIONS	O
:	O

In	O
U.S.	O
patients	O
with	O
previously	O
untreated	O
chronic	O
hepatitis	O
B	O
,	O
one	O
year	O
of	O
lamivudine	O
therapy	O
had	O
favorable	O
effects	O
on	O
histologic	O
,	O
virologic	O
,	O
and	O
biochemical	O
features	O
of	O
the	O
disease	O
and	O
was	O
well	O
tolerated	O
.	O

HBeAg	B
responses	O
were	O
generally	O
sustained	O
after	O
treatment	O
.	O

Recombinant	O
human	O
liver	O
betaine	B
-	I
homocysteine	I
S	I
-	I
methyltransferase	I
:	O
identification	O
of	O
three	O
cysteine	O
residues	O
critical	O
for	O
zinc	O
binding	O
.	O

Betaine	B
-	I
homocysteine	I
S	I
-	I
methyltransferase	I
(	O
BHMT	B
;	O
EC	B
2.1.1.5	I
)	O
catalyzes	O
the	O
transfer	O
of	O
an	O
N	O
-	O
methyl	O
group	O
from	O
betaine	O
to	O
homocysteine	O
to	O
produce	O
dimethylglycine	O
and	O
methionine	O
,	O
respectively	O
.	O

The	O
enzyme	O
is	O
found	O
in	O
the	O
pathway	O
of	O
choline	O
oxidation	O
and	O
is	O
abundantly	O
expressed	O
in	O
liver	O
and	O
kidney	O
.	O

We	O
have	O
recently	O
shown	O
that	O
human	O
BHMT	B
is	O
a	O
zinc	O
metalloenzyme	O
[	O
Millian	O
,	O
N.	O
S.	O
,	O
and	O
Garrow	O
,	O
T.	O
A.	O
(	O
1998	O
)	O
Arch	O
.	O
Biochem	O
.	O
Biophys	O
.	O
356	O
,	O
93	O
-	O
98	O
]	O
.	O

To	O
facilitate	O
the	O
rapid	O
purification	O
of	O
human	O
BHMT	B
for	O
further	O
physical	O
and	O
mechanistic	O
studies	O
,	O
including	O
characterizing	O
its	O
metal	O
binding	O
properties	O
,	O
we	O
have	O
overexpressed	O
the	O
enzyme	O
in	O
E.	O
coli	O
as	O
a	O
fusion	O
construct	O
which	O
facilitated	O
its	O
subsequent	O
purification	O
by	O
a	O
self	O
-	O
cleavable	O
affinity	O
tag	O
system	O
(	O
IMPACT	O
T7	O
)	O
.	O

Using	O
this	O
expression	O
and	O
purification	O
system	O
in	O
conjunction	O
with	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
have	O
identified	O
Cys217	O
,	O
Cys299	O
,	O
and	O
Cys300	O
as	O
zinc	O
ligands	O
.	O

Mutating	O
any	O
of	O
these	O
Cys	O
residues	O
to	O
Ala	O
results	O
in	O
the	O
complete	O
loss	O
of	O
activity	O
and	O
a	O
significant	O
reduction	O
in	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
zinc	O
.	O

Comparing	O
the	O
regions	O
of	O
BHMT	B
amino	O
acid	O
sequence	O
surrounding	O
these	O
Cys	O
residues	O
with	O
similar	O
amino	O
acid	O
sequences	O
retrievable	O
from	O
protein	O
databases	O
,	O
we	O
have	O
identified	O
the	O
following	O
motif	O
:	O
G	O
[	O
ILV	O
]	O
NCX	O
(	O
20	O
,	O
100	O
)	O
[	O
ALV	O
]	O
X	O
(	O
2	O
)	O
[	O
ILV	O
]	O
GGCCX	O
(	O
3	O
)	O
PX	O
(	O
2	O
)	O
I	O
,	O
which	O
we	O
propose	O
to	O
be	O
a	O
signature	O
for	O
a	O
family	O
of	O
zinc	O
-	O
dependent	O
methyltransferases	B
that	O
utilize	O
thiols	O
or	O
selenols	O
as	O
methyl	O
acceptors	O
.	O

Some	O
of	O
the	O
members	O
of	O
this	O
family	O
include	O
the	O
vitamin	B
B	I
(	I
12	I
)	I
-	I
dependent	I
methionine	I
synthases	I
,	O
E.	O
coli	O
S	B
-	I
methylmethionine	I
-	I
S	I
-	I
homocysteine	I
methyltransferase	I
,	O
and	O
A.	O
bisulcatus	O
S	B
-	I
methylmethionine	I
-	I
selenocysteine	I
methyltransferase	I
.	O

Interaction	O
of	O
the	O
metalloprotease	B
disintegrins	I
MDC9	B
and	O
MDC15	B
with	O
two	O
SH3	O
domain	O
-	O
containing	O
proteins	O
,	O
endophilin	B
I	I
and	O
SH3PX1	B
.	O

Metalloprotease	B
disintegrins	I
(	O
a	B
disintegrin	I
and	I
metalloprotease	I
(	O
ADAM	B
)	O
and	O
metalloprotease	B
,	I
disintegrin	I
,	I
cysteine	I
-	I
rich	I
proteins	I
(	O
MDC	B
)	O
)	O
are	O
a	O
family	O
of	O
membrane	O
-	O
anchored	O
glycoproteins	O
that	O
function	O
in	O
diverse	O
biological	O
processes	O
,	O
including	O
fertilization	O
,	O
neurogenesis	O
,	O
myogenesis	O
,	O
and	O
ectodomain	O
processing	O
of	O
cytokines	B
and	O
other	O
proteins	O
.	O

The	O
cytoplasmic	O
domains	O
of	O
ADAMs	B
often	O
include	O
putative	O
signaling	O
motifs	O
,	O
such	O
as	O
proline	O
-	O
rich	O
SH3	O
ligand	O
domains	O
,	O
suggesting	O
that	O
interactions	O
with	O
cytoplasmic	O
proteins	O
may	O
affect	O
metalloprotease	B
disintegrin	I
function	O
.	O

Here	O
we	O
report	O
that	O
two	O
SH3	O
domain	O
-	O
containing	O
proteins	O
,	O
endophilin	B
I	I
(	O
SH3GL2	B
,	O
SH3p4	B
)	O
and	O
a	O
novel	O
SH3	O
domain	O
-	O
and	O
phox	O
homology	O
(	O
PX	O
)	O
domain	O
-	O
containing	O
protein	O
,	O
termed	O
SH3PX1	B
,	O
can	O
interact	O
with	O
the	O
cytoplasmic	O
domains	O
of	O
the	O
metalloprotease	B
disintegrins	I
MDC9	B
and	O
MDC15	B
.	O

These	O
interactions	O
were	O
initially	O
identified	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
and	O
then	O
confirmed	O
using	O
bacterial	O
fusion	O
proteins	O
and	O
co	O
-	O
immunoprecipitations	O
from	O
eukaryotic	O
cells	O
expressing	O
both	O
binding	O
partners	O
.	O

SH3PX1	B
and	O
endophilin	B
I	I
both	O
preferentially	O
bind	O
the	O
precursor	O
but	O
not	O
the	O
processed	O
form	O
of	O
MDC9	B
and	O
MDC15	B
in	O
COS-7	O
cells	O
.	O

Since	O
rat	O
endophilin	B
I	I
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
synaptic	O
vesicle	O
endocytosis	O
and	O
SH3PX1	B
has	O
sequence	O
similarity	O
to	O
sorting	B
nexins	I
in	O
yeast	O
,	O
we	O
propose	O
that	O
endophilin	B
I	I
and	O
SH3PX1	B
may	O
have	O
a	O
role	O
in	O
regulating	O
the	O
function	O
of	O
MDC9	B
and	O
MDC15	B
by	O
influencing	O
their	O
intracellular	O
processing	O
,	O
transport	O
,	O
or	O
final	O
subcellular	O
localization	O
.	O

Micrometastases	O
of	O
bone	O
marrow	O
in	O
localized	O
prostate	O
cancer	O
:	O
correlation	O
with	O
established	O
risk	O
factors	O
.	O

PURPOSE	O
:	O

The	O
presence	O
of	O
cytokeratin	O
18	O
-	O
positive	O
cells	O
in	O
bone	O
marrow	O
correlates	O
with	O
conventional	O
risk	O
factors	O
in	O
many	O
tumors	O
.	O

We	O
examined	O
whether	O
this	O
was	O
also	O
valid	O
for	O
localized	O
or	O
lymphatically	O
spread	O
prostate	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O

Immediately	O
before	O
radical	O
prostatectomy	O
,	O
bone	O
marrow	O
aspirates	O
from	O
both	O
sides	O
of	O
the	O
iliac	O
crest	O
were	O
taken	O
from	O
287	O
patients	O
.	O

The	O
presence	O
of	O
cells	O
containing	O
cytokeratin	O
18	O
was	O
interpreted	O
as	O
micrometastasis	O
.	O

RESULTS	O
:	O

In	O
patients	O
with	O
negative	O
lymph	O
nodes	O
(	O
n	O
=	O
219	O
)	O
,	O
conventional	O
risk	O
factors	O
(	O
Gleason	O
score	O
,	O
pathologic	O
stage	O
,	O
ploidy	O
,	O
and	O
preoperative	O
prostate	O
-	O
specific	O
antigen	O
)	O
did	O
not	O
correlate	O
with	O
the	O
preoperative	O
detection	O
of	O
cells	O
containing	O
cytokeratin	O
18	O
.	O

There	O
was	O
also	O
no	O
correlation	O
with	O
lymph	O
node	O
metastases	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
interdependency	O
between	O
the	O
preoperatively	O
detected	O
number	O
of	O
cells	O
and	O
the	O
established	O
risk	O
factors	O
.	O

CONCLUSION	O
:	O

We	O
assume	O
the	O
presence	O
of	O
epithelial	O
cells	O
in	O
bone	O
marrow	O
to	O
be	O
an	O
independent	O
parameter	O
,	O
the	O
clinical	O
importance	O
of	O
which	O
must	O
be	O
substantiated	O
by	O
further	O
studies	O
.	O

Identification	O
of	O
a	O
novel	O
PSD-95	B
/	O
Dlg	B
/	O
ZO-1	B
(	O
PDZ	O
)	O
-	O
like	O
protein	O
interacting	O
with	O
the	O
C	O
terminus	O
of	O
presenilin-1	B
.	O

Presenilin-1	B
(	O
PS-1	B
)	O
is	O
the	O
most	O
causative	O
Alzheimer	O
gene	O
product	O
,	O
and	O
its	O
function	O
is	O
not	O
well	O
understood	O
.	O

In	O
an	O
attempt	O
to	O
elucidate	O
the	O
function	O
of	O
PS-1	B
,	O
we	O
screened	O
a	O
human	O
brain	O
cDNA	O
library	O
for	O
PS-1	B
-	O
interacting	O
proteins	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
and	O
isolated	O
a	O
novel	O
protein	O
containing	O
a	O
PSD	B
-	I
95	I
/	O
Dlg	B
/	O
ZO-1	B
(	O
PDZ	O
)	O
-	O
like	O
domain	O
.	O

This	O
novel	O
PS-1	B
-	I
associated	I
protein	I
(	O
PSAP	B
)	O
shares	O
a	O
significant	O
similarity	O
with	O
a	O
Caenorhabditis	O
elegans	O
protein	O
of	O
unknown	O
function	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
PSAP	B
is	O
predominantly	O
expressed	O
in	O
the	O
brain	O
.	O

Deletion	O
of	O
the	O
first	O
four	O
C	O
-	O
terminal	O
amino	O
acid	O
residues	O
of	O
PS-1	B
,	O
which	O
contain	O
the	O
PDZ	O
domain	O
-	O
binding	O
motif	O
(	O
Gln	O
-	O
Phe	O
-	O
Tyr	O
-	O
Ile	O
)	O
,	O
reduced	O
the	O
binding	O
activity	O
of	O
PS-1	B
toward	O
PSAP	B
4	O
-	O
fold	O
.	O

These	O
data	O
suggest	O
that	O
PS-1	B
may	O
associate	O
with	O
a	O
PDZ	O
-	O
like	O
domain	O
-	O
containing	O
protein	O
in	O
vivo	O
and	O
thus	O
may	O
participate	O
in	O
receptor	O
or	O
channel	O
clustering	O
and	O
intracellular	O
signaling	O
events	O
in	O
the	O
brain	O
.	O

Transmembrane	O
helix	O
M6	O
in	O
sarco	B
(	I
endo	I
)	I
plasmic	I
reticulum	I
Ca	I
(	I
2+	I
)	I
-ATPase	I
forms	O
a	O
functional	O
interaction	O
site	O
with	O
phospholamban	B
.	O

Evidence	O
for	O
physical	O
interactions	O
at	O
other	O
sites	O
.	O

In	O
an	O
earlier	O
study	O
(	O
Kimura	O
,	O
Y.	O
,	O
Kurzydlowski	O
,	O
K.	O
,	O
Tada	O
,	O
M.	O
,	O
and	O
MacLennan	O
,	O
D.	O
H.	O
(	O
1997	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
272	O
,	O
15061	O
-	O
15064	O
)	O
,	O
mutation	O
of	O
amino	O
acids	O
on	O
one	O
face	O
of	O
the	O
phospholamban	B
(	O
PLN	B
)	O
transmembrane	O
helix	O
led	O
to	O
loss	O
of	O
PLN	B
inhibition	O
of	O
sarco	B
(	I
endo	I
)	I
plasmic	I
reticulum	I
Ca	I
(	I
2+	I
)	I
-ATPase	I
(	O
SERCA	B
)	O
molecules	O
.	O

This	O
helical	O
face	O
was	O
proposed	O
to	O
form	O
a	O
site	O
of	O
PLN	B
interaction	O
with	O
a	O
transmembrane	O
helix	O
in	O
SERCA	B
molecules	O
.	O

To	O
determine	O
whether	O
predicted	O
transmembrane	O
helices	O
M4	O
,	O
M5	O
,	O
M6	O
,	O
or	O
M8	O
in	O
SERCA1a	B
interact	O
with	O
PLN	B
,	O
SERCA1a	B
mutants	O
were	O
co	O
-	O
expressed	O
with	O
wild	O
-	O
type	O
PLN	B
and	O
effects	O
on	O
Ca	O
(	O
2	O
+	O
)	O
dependence	O
of	O
Ca	O
(	O
2	O
+	O
)	O
transport	O
were	O
measured	O
.	O

Wild	O
-	O
type	O
inhibitory	O
interactions	O
shifted	O
apparent	O
Ca	O
(	O
2	O
+	O
)	O
affinity	O
of	O
SERCA1a	B
by	O
an	O
average	O
of	O
-	O
0.34	O
pCa	O
units	O
,	O
but	O
four	O
of	O
the	O
seven	O
mutations	O
in	O
M4	O
led	O
to	O
a	O
more	O
inhibitory	O
shift	O
in	O
apparent	O
Ca	O
(	O
2	O
+	O
)	O
affinity	O
,	O
averaging	O
-	O
0.53	O
pCa	O
units	O
.	O

Seven	O
mutations	O
in	O
M5	O
led	O
to	O
an	O
average	O
shift	O
of	O
-	O
0.32	O
pCa	O
units	O
and	O
seven	O
mutations	O
in	O
M8	O
led	O
to	O
an	O
average	O
shift	O
of	O
-	O
0.30	O
pCa	O
units	O
.	O

Among	O
11	O
mutations	O
in	O
M6	O
,	O
1	O
,	O
Q791A	O
,	O
increased	O
the	O
inhibitory	O
shift	O
(	O
-	O
0.59	O
pCa	O
units	O
)	O
and	O
5	O
,	O
V795A	O
(	O
-0.11	O
)	O
,	O
L802A	O
(	O
-	O
0.07	O
)	O
,	O
L802V	O
(	O
-	O
0.04	O
)	O
,	O
T805A	O
(	O
-	O
0.11	O
)	O
,	O
and	O
F809A	O
(	O
-0.12	O
)	O
,	O
reduced	O
the	O
inhibitory	O
shift	O
,	O
consistent	O
with	O
the	O
view	O
that	O
Val	O
(	O
795	O
)	O
,	O
Leu	O
(	O
802	O
)	O
,	O
Thr	O
(	O
805	O
)	O
,	O
and	O
Phe	O
(	O
809	O
)	O
,	O
located	O
on	O
one	O
face	O
of	O
a	O
predicted	O
M6	O
helix	O
,	O
form	O
a	O
site	O
in	O
SERCA1a	B
for	O
interaction	O
with	O
PLN	B
.	O

Those	O
mutations	O
in	O
M4	O
,	O
M6	O
,	O
or	O
M8	O
of	O
SERCA1a	B
that	O
enhanced	O
PLN	B
inhibitory	O
function	O
did	O
not	O
enhance	O
PLN	B
physical	O
association	O
with	O
SERCA1a	B
,	O
but	O
mutants	O
V795A	O
and	O
L802A	O
in	O
M6	O
,	O
which	O
decreased	O
PLN	B
inhibitory	O
function	O
,	O
decreased	O
physical	O
association	O
,	O
as	O
measured	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

In	O
related	O
studies	O
,	O
those	O
PLN	B
mutants	O
that	O
gained	O
inhibitory	O
function	O
also	O
increased	O
levels	O
of	O
co	O
-	O
immunoprecipitation	O
of	O
wild	O
-	O
type	O
SERCA1a	B
and	O
those	O
that	O
lost	O
inhibitory	O
function	O
also	O
reduced	O
association	O
,	O
correlating	O
functional	O
interaction	O
sites	O
with	O
physical	O
interaction	O
sites	O
.	O

Thus	O
,	O
both	O
functional	O
and	O
physical	O
data	O
confirm	O
that	O
PLN	B
interacts	O
with	O
M6	O
SERCA1a	B
.	O

Twelve	O
species	O
of	O
the	O
nucleoid	O
-	O
associated	O
protein	O
from	O
Escherichia	O
coli	O
.	O

Sequence	O
recognition	O
specificity	O
and	O
DNA	O
binding	O
affinity	O
.	O

The	O
genome	O
of	O
Escherichia	O
coli	O
is	O
composed	O
of	O
a	O
single	O
molecule	O
of	O
circular	O
DNA	O
with	O
the	O
length	O
of	O
about	O
47,000	O
kilobase	O
pairs	O
,	O
which	O
is	O
associated	O
with	O
about	O
10	O
major	O
DNA	O
-	O
binding	O
proteins	O
,	O
altogether	O
forming	O
the	O
nucleoid	O
.	O

We	O
expressed	O
and	O
purified	O
12	O
species	O
of	O
the	O
DNA	O
-	O
binding	O
protein	O
,	O
i.e.	O
CbpA	B
(	O
curved	B
DNA	I
-	I
binding	I
protein	I
A	I
)	O
,	O
CbpB	B
or	O
Rob	B
(	O
curved	O
DNA	O
-	O
binding	O
protein	O
B	O
or	O
right	O
arm	O
of	O
the	O
replication	O
origin	O
binding	O
protein	O
)	O
,	O
DnaA	B
(	O
DNA	O
-	O
binding	O
protein	O
A	O
)	O
,	O
Dps	B
(	O
DNA	O
-	O
binding	O
protein	O
from	O
starved	O
cells	O
)	O
,	O
Fis	B
(	O
factor	B
for	I
inversion	I
stimulation	I
)	O
,	O
Hfq	B
(	O
host	O
factor	O
for	O
phage	O
Q	O
(	O
beta	O
)	O
)	O
,	O
H	B
-	I
NS	I
(	O
histone	O
-	O
like	O
nucleoid	O
structuring	O
protein	O
)	O
,	O
HU	B
(	O
heat	O
-	O
unstable	O
nucleoid	O
protein	O
)	O
,	O
IciA	B
(	O
inhibitor	B
of	I
chromosome	I
initiation	I
A	I
)	O
,	O
IHF	B
(	O
integration	B
host	I
factor	I
)	O
,	O
Lrp	B
(	O
leucine	B
-	I
responsive	I
regulatory	I
protein	I
)	O
,	O
and	O
StpA	B
(	O
suppressor	O
of	O
td	O
(	O
-	O
)	O
phenotype	O
A	O
)	O
.	O

The	O
sequence	O
specificity	O
of	O
DNA	O
binding	O
was	O
determined	O
for	O
all	O
the	O
purified	O
nucleoid	O
proteins	O
using	O
gel	O
-	O
mobility	O
shift	O
assays	O
.	O

Five	O
proteins	O
(	O
CbpB	B
,	O
DnaA	B
,	O
Fis	B
,	O
IHF	B
,	O
and	O
Lrp	B
)	O
were	O
found	O
to	O
bind	O
to	O
specific	O
DNA	O
sequences	O
,	O
while	O
the	O
remaining	O
seven	O
proteins	O
(	O
CbpA	B
,	O
Dps	B
,	O
Hfq	B
,	O
H	B
-	I
NS	I
,	O
HU	B
,	O
IciA	B
,	O
and	O
StpA	B
)	O
showed	O
apparently	O
sequence	O
-	O
nonspecific	O
DNA	O
binding	O
activities	O
.	O

Four	O
proteins	O
,	O
CbpA	B
,	O
Hfq	B
,	O
H	B
-	I
NS	I
,	O
and	O
IciA	B
,	O
showed	O
the	O
binding	O
preference	O
for	O
the	O
curved	O
DNA	O
.	O

From	O
the	O
apparent	O
dissociation	O
constant	O
(	O
K	O
(	O
d	O
)	O
)	O
determined	O
using	O
the	O
sequence	O
-	O
specific	O
or	O
nonspecific	O
DNA	O
probes	O
,	O
the	O
order	O
of	O
DNA	O
binding	O
affinity	O
were	O
determined	O
to	O
be	O
:	O
HU	B
>	O
IHF	B
>	O
Lrp	B
>	O
CbpB	B
(	O
Rob	B
)	O
>	O
Fis	B
>	O
H	B
-	I
NS	I
>	O
StpA	B
>	O
CbpA	B
>	O
IciA	B
>	O
Hfq	B
/	O
Dps	B
,	O
ranging	O
from	O
25	O
nM	O
(	O
HU	B
binding	O
to	O
the	O
non	O
-	O
curved	O
DNA	O
)	O
to	O
250	O
nM	O
(	O
Hfq	B
binding	O
to	O
the	O
non	O
-	O
curved	O
DNA	O
)	O
,	O
under	O
the	O
assay	O
conditions	O
employed	O
.	O

Differing	O
susceptibility	O
of	O
echocardiographic	O
contrast	O
agents	O
to	O
adverse	O
effects	O
of	O
biologic	O
factors	O
:	O
multicenter	O
,	O
videodensitometric	O
comparison	O
of	O
octafluoropropane	O
-	O
filled	O
microspheres	O
with	O
air	O
-	O
filled	O
microspheres	O
for	O
left	O
ventricular	O
opacification	O
.	O

BACKGROUND	O
:	O

Echocardiographic	O
contrast	O
enhancement	O
of	O
the	O
left	O
ventricle	O
has	O
diagnostic	O
value	O
in	O
the	O
assessment	O
of	O
regional	O
and	O
global	O
left	O
ventricular	O
(	O
LV	O
)	O
function	O
.	O

The	O
efficacy	O
of	O
both	O
octafluoropropane	O
-	O
filled	O
human	O
albumin	B
microbubbles	O
(	O
OCTA	O
)	O
and	O
of	O
air	O
-	O
filled	O
human	O
albumin	B
microbubbles	O
(	O
AIR	O
)	O
for	O
LV	O
endocardial	O
delineation	O
and	O
qualitative	O
LV	O
opacification	O
has	O
previously	O
been	O
reported	O
.	O

However	O
,	O
pulmonary	O
disease	O
,	O
obesity	O
,	O
impaired	O
LV	O
function	O
,	O
and	O
decreased	O
echogenicity	O
may	O
diminish	O
the	O
efficacy	O
of	O
contrast	O
agents	O
for	O
LV	O
opacification	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
susceptibility	O
of	O
2	O
contrast	O
agents	O
currently	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
to	O
these	O
biologic	O
factors	O
.	O

METHODS	O
:	O

To	O
compare	O
quantitative	O
LV	O
opacification	O
with	O
OCTA	O
(	O
0.2	O
,	O
0	O
.	O
5	O
,	O
3.0	O
,	O
5.0	O
mL	O
)	O
versus	O
AIR	O
(	O
0.08	O
mL	O
/	O
kg	O
,	O
0.22	O
mL	O
/	O
kg	O
)	O
,	O
we	O
performed	O
videodensitometry	O
in	O
199	O
patients	O
(	O
average	O
age	O
59.2	O
+	O
/-	O
13.3	O
years	O
,	O
79	O
%	O
men	O
)	O
studied	O
in	O
2	O
identical	O
,	O
prospective	O
,	O
multicenter	O
,	O
blinded	O
trials	O
,	O
of	O
whom	O
74	O
had	O
impaired	O
LV	O
function	O
,	O
pulmonary	O
disease	O
,	O
or	O
both	O
,	O
70	O
were	O
obese	O
(	O
body	O
mass	O
index	O
>	O
30	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
,	O
and	O
45	O
were	O
nonechogenic	O
(	O
>	O
/	O
=	O
4	O
of	O
6	O
endocardial	O
segments	O
were	O
not	O
seen	O
in	O
the	O
apical	O
4-chamber	O
view	O
)	O
.	O

Changes	O
in	O
videodensity	O
from	O
noncontrast	O
to	O
contrast	O
agent	O
with	O
the	O
same	O
gain	O
settings	O
were	O
determined	O
at	O
end	O
diastole	O
and	O
end	O
systole	O
(	O
gray	O
scale	O
0	O
to	O
255	O
U	O
)	O
for	O
2	O
regions	O
of	O
interest	O
:	O
left	O
ventricle	O
apex	O
-	O
to	O
-	O
mid	O
-	O
cavity	O
and	O
mid	O
-	O
cavity	O
-	O
to	O
-	O
base	O
.	O

The	O
relative	O
influence	O
of	O
clinically	O
evident	O
pulmonary	O
disease	O
,	O
impaired	O
LV	O
function	O
on	O
echocardiography	O
,	O
and	O
echogenicity	O
on	O
LV	O
opacification	O
produced	O
by	O
both	O
contrast	O
agents	O
was	O
determined	O
by	O
multivariate	O
analysis	O
.	O

RESULTS	O
:	O

Significant	O
videodensity	O
increases	O
ranging	O
from	O
67	O
%	O
to	O
143	O
%	O
were	O
observed	O
with	O
both	O
agents	O
.	O

At	O
the	O
recommended	O
initial	O
doses	O
(	O
0.5	O
mL	O
for	O
OCTA	O
,	O
0.22	O
mL	O
/	O
kg	O
for	O
AIR	O
)	O
,	O
OCTA	O
produced	O
greater	O
opacification	O
than	O
AIR	O
in	O
both	O
regions	O
of	O
interest	O
and	O
at	O
both	O
phases	O
of	O
the	O
cardiac	O
cycle	O
.	O

Poor	O
LV	O
function	O
was	O
associated	O
with	O
decreased	O
LV	O
opacification	O
for	O
AIR	O
but	O
not	O
for	O
OCTA	O
.	O

Diminished	O
echogenicity	O
was	O
more	O
strongly	O
associated	O
with	O
impaired	O
opacification	O
for	O
AIR	O
than	O
for	O
OCTA	O
.	O

Obesity	O
and	O
clinically	O
evident	O
pulmonary	O
disease	O
were	O
associated	O
with	O
diminished	O
chamber	O
opacification	O
with	O
both	O
OCTA	O
and	O
AIR	O
.	O

CONCLUSIONS	O
:	O

In	O
addition	O
to	O
the	O
superiority	O
of	O
octafluoropropane	O
-	O
filled	O
microspheres	O
to	O
air	O
-	O
filled	O
microspheres	O
for	O
LV	O
opacification	O
,	O
the	O
efficacy	O
of	O
OCTA	O
is	O
relatively	O
unaffected	O
by	O
impaired	O
LV	O
function	O
and	O
is	O
less	O
susceptible	O
to	O
the	O
effects	O
of	O
poor	O
echogenicity	O
than	O
AIR	O
.	O

Radiographic	O
joint	O
space	O
in	O
rheumatoid	O
acromioclavicular	O
joints	O
:	O
a	O
15	O
year	O
prospective	O
follow	O
-	O
up	O
study	O
in	O
74	O
patients	O
.	O

OBJECTIVE	O
:	O

To	O
evaluate	O
radiographically	O
the	O
acromioclavicular	O
joint	O
space	O
in	O
patients	O
with	O
long	O
-	O
term	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
:	O

A	O
cohort	O
of	O
74	O
patients	O
with	O
RA	O
was	O
followed	O
prospectively	O
for	O
15	O
yr	O
.	O

At	O
the	O
end	O
point	O
,	O
148	O
shoulders	O
were	O
radiographed	O
with	O
a	O
standard	O
method	O
.	O

The	O
acromioclavicular	O
(	O
AC	O
)	O
joint	O
space	O
was	O
examined	O
from	O
the	O
radiographs	O
with	O
a	O
method	O
developed	O
previously	O
for	O
population	O
studies	O
;	O
the	O
joint	O
space	O
was	O
measured	O
at	O
its	O
superior	O
and	O
inferior	O
border	O
,	O
and	O
the	O
average	O
of	O
the	O
two	O
measurements	O
,	O
the	O
integral	O
space	O
,	O
calculated	O
.	O

RESULTS	O
:	O

Mean	O
AC	O
joint	O
space	O
in	O
RA	O
patients	O
was	O
4.9	O
(	O
S.D.	O
3.7	O
)	O
,	O
range	O
0	O
-	O
20.5	O
mm	O
;	O
6.2	O
mm	O
(	O
S.D.	O
5.1	O
)	O
in	O
men	O
and	O
4.5	O
mm	O
(	O
S.D.	O
3	O
.	O
0	O
)	O
in	O
women	O
.	O

An	O
AC	O
joint	O
space	O
wider	O
than	O
7	O
mm	O
in	O
men	O
was	O
found	O
in	O
11	O
(	O
31	O
%	O
)	O
out	O
of	O
36	O
joints	O
and	O
wider	O
than	O
6	O
mm	O
in	O
women	O
in	O
17	O
(	O
15	O
%	O
)	O
out	O
of	O
112	O
joints	O
.	O

Joint	O
space	O
widening	O
was	O
associated	O
(	O
r	O
=	O
0.87	O
,	O
95	O
%	O
CI	O
0.82	O
-	O
0.90	O
)	O
with	O
increasing	O
destruction	O
(	O
Larsen	O
grading	O
)	O
of	O
the	O
joint	O
and	O
it	O
seems	O
to	O
be	O
an	O
inevitable	O
consequence	O
of	O
AC	O
joint	O
affection	O
in	O
RA	O
.	O

Joint	O
space	O
widening	O
is	O
more	O
progressive	O
on	O
the	O
caudal	O
side	O
because	O
of	O
the	O
nature	O
of	O
the	O
erosive	O
destruction	O
.	O

Degeneration	O
with	O
joint	O
space	O
narrowing	O
was	O
observed	O
in	O
8	O
(	O
11	O
%	O
)	O
patients	O
(	O
11	O
joints	O
,	O
7	O
%	O
;	O
three	O
bilateral	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
largest	O
value	O
of	O
the	O
joint	O
space	O
may	O
be	O
used	O
when	O
evaluating	O
rheumatoid	O
AC	O
joint	O
space	O
.	O

In	O
RA	O
patients	O
,	O
a	O
joint	O
space	O
of	O
>	O
7	O
mm	O
in	O
men	O
and	O
>	O
5	O
mm	O
in	O
women	O
is	O
a	O
sign	O
of	O
destructive	O
AC	O
joint	O
affection	O
.	O

Structure	O
and	O
transcriptional	O
control	O
of	O
the	O
flagellar	O
master	O
operon	O
of	O
Salmonella	O
typhimurium	O
.	O

The	O
flhD	B
and	O
flhC	B
genes	O
constitute	O
the	O
flagellar	O
master	O
operon	O
whose	O
products	O
are	O
required	O
for	O
expression	O
of	O
all	O
the	O
remaining	O
flagellar	O
operons	O
in	O
Salmonella	O
typhimurium	O
.	O

Here	O
we	O
report	O
the	O
molecular	O
structure	O
and	O
in	O
vivo	O
and	O
in	O
vitro	O
expression	O
of	O
the	O
flhD	B
operon	I
.	O

Nucleotide	O
sequence	O
analysis	O
revealed	O
that	O
the	O
upstream	O
region	O
of	O
this	O
operon	O
contains	O
the	O
consensus	O
sequence	O
for	O
the	O
cAMP	O
-	O
CRP	B
binding	O
site	O
.	O

Primer	O
extension	O
analysis	O
demonstrated	O
six	O
possible	O
transcription	O
start	O
sites	O
for	O
this	O
operon	O
.	O

They	O
include	O
CRP	B
-	O
dependent	O
and	O
CRP	B
-	O
repressible	O
transcription	O
start	O
sites	O
.	O

The	O
CRP	B
-	O
dependent	O
transcription	O
start	O
site	O
is	O
located	O
203	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
of	O
the	O
flhD	B
gene	O
and	O
preceded	O
by	O
the	O
consensus	O
sequences	O
of	O
the	O
-	O
10	O
and	O
-	O
35	O
regions	O
of	O
the	O
sigma	B
70	I
-	O
dependent	O
promoter	O
.	O

The	O
putative	O
cAMP	O
-	O
CRP	B
binding	O
site	O
is	O
located	O
centered	O
70	O
bp	O
upstream	O
of	O
this	O
start	O
site	O
.	O

The	O
CRP	B
-	O
repressible	O
transcription	O
start	O
site	O
is	O
located	O
within	O
this	O
putative	O
cAMP	O
-	O
CRP	B
binding	O
site	O
.	O

These	O
two	O
start	O
sites	O
were	O
confirmed	O
by	O
in	O
vitro	O
transcription	O
experiments	O
using	O
sigma	B
70	I
-	O
RNA	B
polymerase	I
with	O
or	O
without	O
cAMP	O
-	O
CRP	B
.	O

Reaction	O
mechanism	O
of	O
recombinant	O
3-oxoacyl-	B
(	I
acyl	I
-	I
carrier	I
-	I
protein	I
)	I
synthase	I
III	I
from	O
Cuphea	O
wrightii	O
embryo	O
,	O
a	O
fatty	B
acid	I
synthase	I
type	I
II	I
condensing	O
enzyme	O
.	O

A	O
unique	O
feature	O
of	O
fatty	B
acid	I
synthase	I
(	I
FAS	I
)	I
type	I
II	I
of	O
higher	O
plants	O
and	O
bacteria	O
is	O
3-oxoacyl-	B
[	I
acyl	I
-	I
carrier	I
-	I
protein	I
(	I
ACP	I
)	I
]	I
synthase	I
III	I
(	O
KAS	B
III	I
)	O
,	O
which	O
catalyses	O
the	O
committing	O
condensing	O
reaction	O
.	O

Working	O
with	O
KAS	B
IIIs	I
from	O
Cuphea	O
seeds	O
we	O
obtained	O
kinetic	O
evidence	O
that	O
KAS	B
III	I
catalysis	O
follows	O
a	O
Ping	O
-	O
Pong	O
mechanism	O
and	O
that	O
these	O
enzymes	O
have	O
substrate	O
-	O
binding	O
sites	O
for	O
acetyl	O
-	O
CoA	O
and	O
malonyl	O
-	O
ACP	O
.	O

It	O
was	O
the	O
aim	O
of	O
the	O
present	O
study	O
to	O
identify	O
these	O
binding	O
sites	O
and	O
to	O
elucidate	O
the	O
catalytic	O
mechanism	O
of	O
recombinant	O
Cuphea	O
wrightii	O
KAS	B
III	I
,	O
which	O
we	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

We	O
engineered	O
mutants	O
,	O
which	O
allowed	O
us	O
to	O
dissect	O
the	O
condensing	O
reaction	O
into	O
three	O
stages	O
,	O
i.e.	O
formation	O
of	O
acyl	O
-	O
enzyme	O
,	O
decarboxylation	O
of	O
malonyl	O
-	O
ACP	O
,	O
and	O
final	O
Claisen	O
condensation	O
.	O

Incubation	O
of	O
recombinant	O
enzyme	O
with	O
[	O
1-	O
(	O
14	O
)	O
C	O
]	O
acetyl	O
-	O
CoA	O
-	O
labelled	O
Cys	O
(	O
111	O
)	O
,	O
and	O
the	O
replacement	O
of	O
this	O
residue	O
by	O
Ala	O
and	O
Ser	O
resulted	O
in	O
loss	O
of	O
overall	O
condensing	O
activity	O
.	O

The	O
Cys	O
(	O
111	O
)	O
Ser	O
mutant	O
,	O
however	O
,	O
still	O
was	O
able	O
to	O
bind	O
acetyl	O
-	O
CoA	O
and	O
to	O
catalyse	O
subsequent	O
binding	O
and	O
decarboxylation	O
of	O
malonyl	O
-	O
ACP	O
to	O
acetyl	O
-	O
ACP	O
.	O

We	O
replaced	O
His	O
(	O
261	O
)	O
with	O
Ala	O
and	O
Arg	O
and	O
found	O
that	O
the	O
former	O
lost	O
activity	O
,	O
whereas	O
the	O
latter	O
retained	O
overall	O
condensing	O
activity	O
,	O
which	O
indicated	O
a	O
general	O
-	O
base	O
action	O
of	O
His	O
(	O
261	O
)	O
.	O

Double	O
mutants	O
Cys	O
(	O
111	O
)	O
Ser	O
/	O
His	O
(	O
261	O
)	O
Ala	O
and	O
Cys	O
(	O
111	O
)	O
Ser	O
/	O
His	O
(	O
261	O
)	O
Arg	O
were	O
not	O
able	O
to	O
catalyse	O
overall	O
condensation	O
,	O
but	O
the	O
double	O
mutant	O
containing	O
Arg	O
induced	O
decarboxylation	O
of	O
[	O
2-	O
(	O
14	O
)	O
C	O
]	O
malonyl	O
-	O
ACP	O
,	O
a	O
reaction	O
indicating	O
the	O
role	O
of	O
His	O
(	O
261	O
)	O
in	O
general	O
-	O
acid	O
catalysis	O
.	O

Finally	O
,	O
alanine	O
scanning	O
revealed	O
the	O
involvement	O
of	O
Arg	O
(	O
150	O
)	O
and	O
Arg	O
(	O
306	O
)	O
in	O
KAS	B
III	I
catalysis	O
.	O

The	O
results	O
offer	O
for	O
the	O
first	O
time	O
a	O
detailed	O
mechanism	O
for	O
a	O
condensing	O
reaction	O
catalysed	O
by	O
a	O
FAS	B
type	I
II	I
condensing	O
enzyme	O
.	O

Genetic	O
analysis	O
of	O
a	O
chromosomal	O
region	O
containing	O
genes	O
required	O
for	O
assimilation	O
of	O
allantoin	O
nitrogen	O
and	O
linked	O
glyoxylate	O
metabolism	O
in	O
Escherichia	O
coli	O
.	O

Growth	O
experiments	O
with	O
Escherichia	O
coli	O
have	O
shown	O
that	O
this	O
organism	O
is	O
able	O
to	O
use	O
allantoin	O
as	O
a	O
sole	O
nitrogen	O
source	O
but	O
not	O
as	O
a	O
sole	O
carbon	O
source	O
.	O

Nitrogen	O
assimilation	O
from	O
this	O
compound	O
was	O
possible	O
only	O
under	O
anaerobic	O
conditions	O
,	O
in	O
which	O
all	O
the	O
enzyme	O
activities	O
involved	O
in	O
allantoin	O
metabolism	O
were	O
detected	O
.	O

Of	O
the	O
nine	O
genes	O
encoding	O
proteins	O
required	O
for	O
allantoin	O
degradation	O
,	O
only	O
the	O
one	O
encoding	O
glyoxylate	B
carboligase	I
(	O
gcl	B
)	O
,	O
the	O
first	O
enzyme	O
of	O
the	O
pathway	O
leading	O
to	O
glycerate	O
,	O
had	O
been	O
identified	O
and	O
mapped	O
at	O
centisome	O
12	O
on	O
the	O
chromosome	O
map	O
.	O

Phenotypic	O
complementation	O
of	O
mutations	O
in	O
the	O
other	O
two	O
genes	O
of	O
the	O
glycerate	O
pathway	O
,	O
encoding	O
tartronic	B
semialdehyde	I
reductase	I
(	O
glxR	B
)	O
and	O
glycerate	B
kinase	I
(	O
glxK	B
)	O
,	O
allowed	O
us	O
to	O
clone	O
and	O
map	O
them	O
closely	O
linked	O
to	O
gcl	B
.	O

Complete	O
sequencing	O
of	O
a	O
15.8	O
-	O
kb	O
fragment	O
encompassing	O
these	O
genes	O
defined	O
a	O
regulon	O
with	O
12	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
.	O

Due	O
to	O
the	O
high	O
similarity	O
of	O
the	O
products	O
of	O
two	O
of	O
these	O
ORFs	O
with	O
yeast	O
allantoinase	B
and	O
yeast	O
allantoate	B
amidohydrolase	I
,	O
a	O
systematic	O
analysis	O
of	O
the	O
gene	O
cluster	O
was	O
undertaken	O
to	O
identify	O
genes	O
involved	O
in	O
allantoin	O
utilization	O
.	O

A	O
BLASTP	O
search	O
predicted	O
four	O
of	O
the	O
genes	O
that	O
we	O
sequenced	O
to	O
encode	O
allantoinase	B
(	O
allB	B
)	O
,	O
allantoate	B
amidohydrolase	I
(	O
allC	B
)	O
,	O
ureidoglycolate	B
hydrolase	I
(	O
allA	B
)	O
,	O
and	O
ureidoglycolate	B
dehydrogenase	I
(	O
allD	B
)	O
.	O

The	O
products	O
of	O
these	O
genes	O
were	O
overexpressed	O
and	O
shown	O
to	O
have	O
the	O
predicted	O
corresponding	O
enzyme	O
activities	O
.	O

Transcriptional	O
fusions	O
to	O
lacZ	B
permitted	O
the	O
identification	O
of	O
three	O
functional	O
promoters	O
corresponding	O
to	O
three	O
transcriptional	O
units	O
for	O
the	O
structural	O
genes	O
and	O
another	O
promoter	O
for	O
the	O
regulatory	O
gene	O
allR	B
.	O

Deletion	O
of	O
this	O
regulatory	O
gene	O
led	O
to	O
constitutive	O
expression	O
of	O
the	O
regulon	O
,	O
indicating	O
a	O
negatively	O
acting	O
function	O
.	O

Cloning	O
,	O
expression	O
,	O
and	O
fatty	O
acid	O
regulation	O
of	O
the	O
human	O
delta-5	B
desaturase	I
.	O

Arachidonic	O
(	O
20:4	O
(	O
n-6	O
)	O
)	O
,	O
eicosapentaenoic	O
(	O
20	O
:	O
5	O
(	O
n-3	O
)	O
)	O
,	O
and	O
docosahexaenoic	O
(	O
22	O
:	O
6	O
(	O
n-3	O
)	O
)	O
acids	O
are	O
major	O
components	O
of	O
brain	O
and	O
retina	O
phospholipids	O
,	O
substrates	O
for	O
eicosanoid	O
production	O
,	O
and	O
regulators	O
of	O
nuclear	O
transcription	B
factors	I
.	O

One	O
of	O
the	O
two	O
rate	O
-	O
limiting	O
steps	O
in	O
the	O
production	O
of	O
these	O
polyenoic	O
fatty	O
acids	O
is	O
the	O
desaturation	O
of	O
20:3	O
(	O
n-6	O
)	O
and	O
20	O
:	O
4	O
(	O
n-3	O
)	O
by	O
Delta-5	B
desaturase	I
.	O

This	O
report	O
describes	O
the	O
cloning	O
and	O
expression	O
of	O
the	O
human	O
Delta-5	B
desaturase	I
,	O
and	O
it	O
compares	O
the	O
structural	O
characteristics	O
and	O
nutritional	O
regulation	O
of	O
the	O
Delta-5	B
and	I
Delta-6	I
desaturases	I
.	O

The	O
open	O
reading	O
frame	O
of	O
the	O
human	O
Delta-5	B
desaturase	I
encodes	O
a	O
444	O
-	O
amino	O
acid	O
peptide	O
which	O
is	O
identical	O
in	O
size	O
to	O
the	O
Delta-6	B
desaturase	I
and	O
which	O
shares	O
61	O
%	O
identity	O
with	O
the	O
human	O
Delta-6	B
desaturase	I
.	O

The	O
Delta-5	B
desaturase	I
contains	O
two	O
membrane	O
-	O
spanning	O
domains	O
,	O
three	O
histidine	O
-	O
rich	O
regions	O
,	O
and	O
a	O
cytochrome	O
b	O
(	O
5	O
)	O
domain	O
that	O
all	O
align	O
perfectly	O
with	O
the	O
same	O
domains	O
located	O
in	O
the	O
Delta	B
-	I
6	I
desaturase	I
.	O

Expression	O
of	O
the	O
open	O
reading	O
frame	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
instilled	O
the	O
ability	O
to	O
convert	O
20	O
:	O
3	O
(	O
n-6	O
)	O
to	O
20	O
:	O
4	O
(	O
n-6	O
)	O
.	O

Northern	O
analysis	O
revealed	O
that	O
many	O
human	O
tissues	O
including	O
skeletal	O
muscle	O
,	O
lung	O
,	O
placenta	O
,	O
kidney	O
,	O
and	O
pancreas	O
expressed	O
Delta-5	B
desaturase	I
mRNA	O
,	O
but	O
Delta	B
-	I
5	I
desaturase	I
was	O
most	O
abundant	O
in	O
the	O
liver	O
,	O
brain	O
,	O
and	O
heart	O
.	O

However	O
,	O
in	O
all	O
tissues	O
,	O
the	O
abundance	O
of	O
Delta-5	B
desaturase	I
mRNA	O
was	O
much	O
lower	O
than	O
that	O
observed	O
for	O
the	O
Delta	B
-	I
6	I
desaturase	I
.	O

When	O
rats	O
were	O
fed	O
a	O
diet	O
containing	O
10	O
%	O
safflower	O
oil	O
or	O
menhaden	O
fish	O
oil	O
,	O
the	O
level	O
of	O
hepatic	O
mRNA	O
for	O
Delta-5	B
and	I
Delta-6	I
desaturase	I
was	O
only	O
25	O
%	O
of	O
that	O
found	O
in	O
the	O
liver	O
of	O
rats	O
fed	O
a	O
fat	O
-	O
free	O
diet	O
or	O
a	O
diet	O
containing	O
triolein	O
.	O

Finally	O
,	O
a	O
BLAST	O
and	O
Genemap	O
search	O
of	O
the	O
human	O
genome	O
revealed	O
that	O
the	O
Delta-5	B
and	I
Delta-6	I
desaturase	I
genes	O
reside	O
in	O
reverse	O
orientation	O
on	O
chromosome	O
11	O
and	O
that	O
they	O
are	O
separated	O
by	O
<	O
11,000	O
base	O
pairs	O
.	O

Identification	O
and	O
characterization	O
of	O
an	O
active	O
plasmid	O
partition	O
mechanism	O
for	O
the	O
novel	O
Lactococcus	O
lactis	O
plasmid	O
pCI2000	O
.	O

The	O
replication	O
region	O
of	O
the	O
lactococcal	O
plasmid	O
pCI2000	O
was	O
subcloned	O
and	O
analyzed	O
.	O

The	O
nucleotide	O
sequence	O
of	O
one	O
5.6	O
-	O
kb	O
EcoRI	B
fragment	O
which	O
was	O
capable	O
of	O
supporting	O
replication	O
when	O
cloned	O
on	O
a	O
replication	O
probe	O
vector	O
revealed	O
the	O
presence	O
of	O
seven	O
putative	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
.	O

One	O
ORF	O
exhibited	O
significant	O
homology	O
to	O
several	O
replication	O
proteins	O
from	O
plasmids	O
considered	O
to	O
replicate	O
via	O
a	O
theta	O
mode	O
.	O

Deletion	O
analysis	O
showed	O
that	O
this	O
ORF	O
,	O
designated	O
repA	B
,	O
is	O
indeed	O
required	O
for	O
replication	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
origin	O
of	O
replication	O
is	O
located	O
outside	O
repA	B
.	O

Upstream	O
and	O
divergently	O
transcribed	O
from	O
repA	B
,	O
an	O
ORF	O
that	O
showed	O
significant	O
(	O
48	O
to	O
64	O
%	O
)	O
homology	O
to	O
a	O
number	O
of	O
proteins	O
that	O
are	O
required	O
for	O
faithful	O
segregation	O
of	O
chromosomal	O
or	O
plasmid	O
DNA	O
of	O
gram	O
-	O
negative	O
bacteria	O
was	O
identified	O
.	O

Gene	O
interruption	O
and	O
transcomplementation	O
experiments	O
showed	O
that	O
this	O
ORF	O
,	O
designated	O
parA	B
,	O
is	O
required	O
for	O
stable	O
inheritance	O
of	O
pCI2000	O
and	O
is	O
active	O
in	O
trans	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
such	O
a	O
partitioning	O
mechanism	O
for	O
plasmids	O
in	O
gram	O
-	O
positive	O
bacteria	O
.	O

Structural	O
interactions	O
of	O
fibroblast	B
growth	I
factor	I
receptor	I
with	O
its	O
ligands	O
.	O

Fibroblast	B
growth	I
factors	I
(	O
FGFs	B
)	O
effect	O
cellular	O
responses	O
by	O
binding	O
to	O
FGF	B
receptors	I
(	O
FGFRs	B
)	O
.	O

FGF	B
bound	O
to	O
extracellular	O
domains	O
on	O
the	O
FGFR	B
in	O
the	O
presence	O
of	O
heparin	O
activates	O
the	O
cytoplasmic	O
receptor	B
tyrosine	I
kinase	I
through	O
autophosphorylation	O
.	O

We	O
have	O
crystallized	O
a	O
complex	O
between	O
human	O
FGF1	B
and	O
a	O
two	O
-	O
domain	O
extracellular	O
fragment	O
of	O
human	O
FGFR2	B
.	O

The	O
crystal	O
structure	O
,	O
determined	O
by	O
multiwavelength	O
anomalous	O
diffraction	O
analysis	O
of	O
the	O
selenomethionyl	O
protein	O
,	O
is	O
a	O
dimeric	O
assemblage	O
of	O
1	O
:	O
1	O
ligand	O
:	O
receptor	O
complexes	O
.	O

FGF	B
is	O
bound	O
at	O
the	O
junction	O
between	O
the	O
two	O
domains	O
of	O
one	O
FGFR	B
,	O
and	O
two	O
such	O
units	O
are	O
associated	O
through	O
receptor	O
:	O
receptor	O
and	O
secondary	O
ligand	O
:	O
receptor	O
interfaces	O
.	O

Sulfate	O
ion	O
positions	O
appear	O
to	O
mark	O
the	O
course	O
of	O
heparin	O
binding	O
between	O
FGF	B
molecules	O
through	O
a	O
basic	O
region	O
on	O
receptor	O
D2	O
domains	O
.	O

This	O
dimeric	O
assemblage	O
provides	O
a	O
structural	O
mechanism	O
for	O
FGF	B
signal	O
transduction	O
.	O

Regulation	O
of	O
HMG	B
-	I
CoA	I
synthase	I
and	O
HMG	B
-	I
CoA	I
reductase	I
by	O
insulin	B
and	O
epidermal	B
growth	I
factor	I
in	O
HaCaT	O
keratinocytes	O
.	O

Synthesis	O
of	O
cholesterol	O
,	O
via	O
the	O
isoprenoid	O
/	O
mevalonate	O
pathway	O
,	O
is	O
required	O
for	O
keratinocyte	O
growth	O
and	O
differentiation	O
,	O
and	O
maintenance	O
of	O
the	O
stratum	O
corneum	O
lipid	O
lamellae	O
.	O

3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
synthase	I
catalyzes	O
the	O
first	O
step	O
in	O
isoprenoid	O
/	O
mevalonate	O
synthesis	O
and	O
under	O
some	O
conditions	O
controls	O
the	O
flux	O
into	O
the	O
pathway	O
.	O

We	O
have	O
investigated	O
whether	O
selected	O
growth	B
factors	I
and	O
hormones	O
could	O
increase	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
synthase	I
mRNA	O
in	O
keratinocytes	O
.	O

Northern	O
blotting	O
was	O
used	O
to	O
demonstrate	O
that	O
10	O
microg	O
per	O
ml	O
insulin	B
and	O
0.1	O
microg	O
per	O
ml	O
epidermal	B
growth	I
factor	I
both	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
synthase	I
mRNA	O
by	O
2.5	O
and	O
6	O
-	O
fold	O
,	O
respectively	O
.	O

Epidermal	B
growth	I
factor	I
and	O
insulin	B
also	O
increased	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
reductase	I
enzyme	O
activity	O
.	O

3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
synthase	I
promoter	O
activity	O
in	O
a	O
luciferase	B
reporter	O
construct	O
was	O
increased	O
2	O
-	O
fold	O
by	O
insulin	B
and	O
2.9	O
-	O
fold	O
by	O
epidermal	B
growth	I
factor	I
.	O

When	O
a	O
mutation	O
in	O
the	O
sterol	O
regulatory	O
element	O
was	O
introduced	O
into	O
the	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
synthase	I
promoter	O
,	O
activity	O
was	O
not	O
increased	O
by	O
insulin	B
,	O
but	O
was	O
increased	O
by	O
epidermal	B
growth	I
factor	I
.	O

Mutation	O
of	O
an	O
AP-1	B
site	O
in	O
the	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
synthase	I
promoter	O
did	O
not	O
affect	O
the	O
increase	O
in	O
activity	O
following	O
treatment	O
with	O
insulin	B
or	O
epidermal	B
growth	I
factor	I
.	O

Therefore	O
,	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
synthase	I
expression	O
in	O
keratinocytes	O
is	O
regulated	O
by	O
insulin	B
and	O
epidermal	B
growth	I
factor	I
by	O
different	O
mechanisms	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
hormones	O
and	O
growth	B
factors	I
in	O
the	O
control	O
of	O
epidermal	O
cholesterol	O
synthesis	O
.	O

Use	O
of	O
an	O
antibody	O
against	O
the	O
soluble	O
interleukin	B
2	I
receptor	I
alpha	I
subunit	O
can	O
modulate	O
the	O
stability	O
and	O
biodistribution	O
of	O
interleukin-2	B
.	O

The	O
authors	O
have	O
previously	O
reported	O
that	O
the	O
soluble	O
serum	O
form	O
of	O
the	O
alpha	B
subunit	I
of	I
the	I
IL-2	I
receptor	I
(	O
sIL-2Ralpha	B
)	O
,	O
whose	O
natural	O
half	O
-	O
life	O
is	O
approximately	O
40	O
min	O
,	O
survived	O
much	O
longer	O
in	O
the	O
circulation	O
when	O
bound	O
by	O
a	O
specific	O
antibody	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
evaluated	O
the	O
extent	O
to	O
which	O
sIL-2Ralpha	B
protected	O
IL-2	B
in	O
freshly	O
collected	O
serum	O
using	O
biochemical	O
analyses	O
,	O
and	O
a	O
functional	O
CTLL-2	O
assay	O
.	O

In	O
particular	O
,	O
sIL-2Ralpha	B
protected	O
IL-2	B
from	O
forming	O
complexes	O
with	O
alpha	B
(	I
2	I
)	I
-macroglobulin	I
and	O
from	O
inactivation	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
the	O
authors	O
demonstrated	O
that	O
the	O
anti	O
-	O
IL-2Ralpha	B
monoclonal	O
antibody	O
7G7	O
/	O
B6	O
,	O
which	O
does	O
not	O
inhibit	O
the	O
binding	O
of	O
IL-2	B
to	O
its	O
binding	O
site	O
on	O
sIL-2Ralpha	B
,	O
protected	O
IL-2	B
from	O
degradation	O
and	O
inactivation	O
in	O
vivo	O
in	O
the	O
presence	O
of	O
sIL-2Ralpha	B
.	O

Both	O
(	O
125	O
)	O
I	O
-	O
labelled	O
and	O
unlabelled	O
IL-2	B
were	O
injected	O
into	O
mice	O
preinjected	O
with	O
humanized	O
anti	O
-	O
Tac	B
(	O
hTac	B
)	O
or	O
7G7	O
/	O
B6	O
and	O
sIL-2Ralpha	B
,	O
or	O
sIL-2Ralpha	B
alone	O
.	O

Using	O
size	O
-	O
exclusion	O
HPLC	O
,	O
ELISA	O
,	O
and	O
CTLL-2	O
cell	O
proliferation	O
assays	O
,	O
we	O
observed	O
that	O
the	O
presence	O
of	O
7G7	O
/	O
B6	O
led	O
to	O
formation	O
of	O
complexes	O
with	O
sIL-2Ralpha	B
and	O
increased	O
the	O
serum	O
levels	O
of	O
IL-2	B
more	O
than	O
3	O
-	O
to	O
40	O
-	O
fold	O
those	O
of	O
groups	O
receiving	O
IL-2	B
alone	O
,	O
sIL-2Ralpha	B
,	O
or	O
hTac	B
.	O

Taken	O
as	O
a	O
whole	O
,	O
these	O
results	O
suggest	O
that	O
the	O
complex	O
of	O
7G7	O
/	O
B6	O
and	O
sIL-2Ralpha	B
not	O
only	O
prolongs	O
the	O
survival	O
of	O
IL-2	B
in	O
vivo	O
,	O
but	O
also	O
maintains	O
the	O
bioactivity	O
of	O
IL-2	B
.	O

The	O
use	O
of	O
antibodies	O
against	O
endogenous	O
soluble	O
receptors	O
could	O
increase	O
the	O
in	O
vivo	O
survival	O
of	O
cytokines	B
,	O
protect	O
their	O
bioactivity	O
and	O
thereby	O
facilitate	O
their	O
clinical	O
use	O
in	O
the	O
treatment	O
of	O
various	O
malignancies	O
and	O
AIDS	O
.	O

Human	O
CD8	B
beta	I
,	O
but	O
not	O
mouse	O
CD8	B
beta	I
,	O
can	O
be	O
expressed	O
in	O
the	O
absence	O
of	O
CD8	B
alpha	I
as	O
a	O
beta	O
beta	O
homodimer	O
.	O

The	O
T	O
cell	O
coreceptor	O
CD8	B
exists	O
on	O
mature	O
T	O
cells	O
as	O
disulfide	O
-	O
linked	O
homodimers	O
of	O
CD8	B
alpha	I
polypeptide	O
chains	O
and	O
heterodimers	O
of	O
CD8	B
alpha	I
-	O
and	O
CD8	B
beta	I
-	O
chains	O
.	O

The	O
function	O
of	O
the	O
CD8	B
alpha	I
-	O
chain	O
for	O
binding	O
to	O
MHC	B
class	I
I	I
and	O
associating	O
with	O
the	O
tyrosine	B
kinase	I
p56lck	B
was	O
demonstrated	O
with	O
CD8	B
alpha	I
alpha	O
homodimers	O
.	O

CD8	B
alpha	I
beta	I
functions	O
as	O
a	O
better	O
coreceptor	O
,	O
but	O
the	O
actual	O
function	O
of	O
CD8	B
beta	I
is	O
less	O
clear	O
.	O

Addressing	O
this	O
issue	O
has	O
been	O
hampered	O
by	O
the	O
apparent	O
inability	O
of	O
CD8	B
beta	I
to	O
be	O
expressed	O
without	O
CD8	B
alpha	I
.	O

This	O
study	O
demonstrates	O
that	O
human	O
,	O
but	O
not	O
mouse	O
,	O
CD8	B
beta	I
can	O
be	O
expressed	O
on	O
the	O
cell	O
surface	O
without	O
CD8	B
alpha	I
in	O
both	O
transfected	O
COS-7	O
cells	O
and	O
murine	O
lymphocytes	O
.	O

By	O
creating	O
chimeric	O
proteins	O
,	O
we	O
show	O
that	O
the	O
murine	O
Ig	B
domain	O
of	O
CD8	B
beta	I
is	O
responsible	O
for	O
the	O
lack	O
of	O
expression	O
of	O
murine	O
CD8	B
beta	I
beta	O
dimers	O
.	O

In	O
contrast	O
to	O
CD8	B
alpha	I
alpha	O
,	O
CD8	B
beta	I
beta	O
is	O
unable	O
to	O
bind	O
MHC	B
class	I
I	I
in	O
a	O
cell	O
-	O
cell	O
adhesion	O
assay	O
.	O

Detection	O
of	O
this	O
form	O
of	O
CD8	B
should	O
facilitate	O
studies	O
on	O
the	O
function	O
of	O
the	O
CD8	B
beta	I
-	O
chain	O
and	O
indicates	O
that	O
caution	O
should	O
be	O
used	O
when	O
interpreting	O
studies	O
on	O
CD8	B
function	O
using	O
chimeric	O
protein	O
with	O
the	O
murine	O
CD8	B
beta	I
beta	O
Ig	B
domain	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
Ig	B
domains	O
of	O
CD8	B
alpha	I
are	O
also	O
involved	O
in	O
controlling	O
the	O
ability	O
of	O
CD8	B
to	O
be	O
expressed	O
.	O

Mutation	O
of	O
B	O
-	O
and	O
F	O
-	O
strand	O
cysteine	O
residues	O
in	O
CD8	B
alpha	I
reduced	O
the	O
ability	O
of	O
the	O
protein	O
to	O
fold	O
properly	O
and	O
,	O
therefore	O
,	O
to	O
be	O
expressed	O
.	O

Substrate	O
specificities	O
of	O
peroxisomal	O
members	O
of	O
short	B
-	I
chain	I
alcohol	I
dehydrogenase	I
superfamily	I
:	O
expression	O
and	O
characterization	O
of	O
dehydrogenase	B
part	O
of	O
Candida	O
tropicalis	O
multifunctional	O
enzyme	O
.	O

In	O
addition	O
to	O
several	O
other	O
enzymes	O
,	O
the	O
short	B
-	I
chain	I
alcohol	I
dehydrogenase	I
superfamily	I
includes	O
a	O
group	O
of	O
peroxisomal	O
multifunctional	O
enzymes	O
involved	O
in	O
fatty	O
acid	O
and	O
cholesterol	O
side	O
-	O
chain	O
beta	O
-	O
oxidation	O
.	O

Mammalian	O
peroxisomal	B
multifunctional	I
enzyme	I
type	I
2	I
(	O
perMFE-2	B
)	O
is	O
a	O
2-enoyl	B
-	I
CoA	I
hydratase-2	I
/	I
(	I
R	I
)	I
-3-hydroxyacyl	I
-	I
CoA	I
dehydrogenase	I
.	O

As	O
has	O
been	O
shown	O
previously	O
,	O
perMFE-2	B
hydrates	O
(	O
24E	O
)	O
-3alpha,7alpha	O
,	O
12alpha	O
-	O
trihydroxy-5beta	O
-	O
cholest-24-enoyl	O
-	O
CoA	O
to	O
(	O
24R	O
,	O
25R	O
)	O
-3alpha	O
,	O
7alpha,12alpha,24xi	O
-	O
tetrahydroxy-5beta	O
-	O
choles	O
tanoyl	O
-	O
CoA	O
,	O
which	O
has	O
been	O
characterized	O
as	O
a	O
physiological	O
intermediate	O
in	O
cholic	O
acid	O
synthesis	O
.	O

Out	O
of	O
four	O
possible	O
stereoisomers	O
of	O
3alpha,7alpha	O
,	O
12alpha,24xi	O
-	O
tetrahydroxy-5beta	O
-	O
cholestanoyl	O
-	O
CoA	O
,	O
the	O
mammalian	O
perMFE-2	B
dehydrogenates	O
only	O
the	O
(	O
24R,25R	O
)	O
-isomer	O
.	O

The	O
yeast	O
peroxisomal	B
multifunctional	I
enzyme	I
(	O
MFE	B
)	O
was	O
first	O
described	O
as	O
2-enoyl	B
-	I
CoA	I
hydratase-2	I
/	I
(	I
R	I
)	I
-3-hydroxyacyl	I
-	I
CoA	I
dehydrogenase	I
.	O

To	O
investigate	O
the	O
stereospecificity	O
of	O
yeast	O
peroxisomal	B
MFE	I
,	O
the	O
two	O
dehydrogenase	B
domains	O
of	O
C.	O
tropicalis	O
MFE	B
were	O
expressed	O
in	O
E.	O
coli	O
as	O
a	O
65	O
kDa	O
recombinant	O
protein	O
.	O

This	O
protein	O
catalyzes	O
the	O
dehydrogenation	O
of	O
straight	O
-	O
chain	O
(	O
R	O
)	O
-3-hydroxyacyl	O
-	O
CoAs	O
,	O
but	O
it	O
is	O
devoid	O
of	O
(	B
S	I
)	I
-3-hydroxyacyl	I
-	I
CoA	I
dehydrogenase	I
and	O
2-enoyl	B
-	I
CoA	I
hydratase	I
activities	O
.	O

The	O
protein	O
dehydrogenates	O
(	O
24R,25R	O
)	O
-	O
and	O
(	O
24R	O
,	O
25S	O
)	O
-	O
isomers	O
of	O
3alpha,7alpha	O
,	O
12alpha	O
,	O
24xi	O
-	O
tetrahydroxy-5beta	O
-	O
cholestanoyl	O
-	O
CoA	O
.	O

Interestingly	O
,	O
the	O
protein	O
also	O
shows	O
17beta	B
-	I
estradiol	I
dehydrogenase	I
activity	O
.	O
As	O
a	O
monofunctional	O
(	O
R	O
)	O
-	O
specific	O
3-hydroxyacyl	B
-	I
CoA	I
dehydrogenase	I
is	O
currently	O
unavailable	O
,	O
this	O
recombinant	O
enzyme	O
can	O
be	O
used	O
to	O
study	O
the	O
stereochemistry	O
of	O
bile	O
acid	O
synthesis	O
.	O

FRS2	B
proteins	O
recruit	O
intracellular	O
signaling	O
pathways	O
by	O
binding	O
to	O
diverse	O
targets	O
on	O
fibroblast	B
growth	I
factor	I
and	I
nerve	I
growth	I
factor	I
receptors	I
.	O

The	O
docking	O
protein	O
FRS2	B
was	O
implicated	O
in	O
the	O
transmission	O
of	O
extracellular	O
signals	O
from	O
the	O
fibroblast	B
growth	I
factor	I
(	I
FGF	I
)	I
or	I
nerve	I
growth	I
factor	I
(	I
NGF	I
)	I
receptors	I
to	O
the	O
Ras	B
/	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
signaling	O
cascade	O
.	O

The	O
two	O
members	O
of	O
the	O
FRS2	B
family	I
,	O
FRS2alpha	B
and	O
FRS2beta	B
,	O
are	O
structurally	O
very	O
similar	O
.	O

Each	O
is	O
composed	O
of	O
an	O
N	O
-	O
terminal	O
myristylation	O
signal	O
,	O
a	O
phosphotyrosine	O
-	O
binding	O
(	O
PTB	O
)	O
domain	O
,	O
and	O
a	O
C	O
-	O
terminal	O
tail	O
containing	O
multiple	O
binding	O
sites	O
for	O
the	O
SH2	O
domains	O
of	O
the	O
adapter	B
protein	I
Grb2	B
and	O
the	O
protein	B
tyrosine	I
phosphatase	I
Shp2	B
.	O

Here	O
we	O
show	O
that	O
the	O
PTB	O
domains	O
of	O
both	O
the	O
alpha	B
and	I
beta	I
isoforms	I
of	I
FRS2	I
bind	O
directly	O
to	O
the	O
FGF	B
or	I
NGF	I
receptors	I
.	O

The	O
PTB	O
domains	O
of	O
the	O
FRS2	B
proteins	O
bind	O
to	O
a	O
highly	O
conserved	O
sequence	O
in	O
the	O
juxtamembrane	O
region	O
of	O
FGFR1	B
.	O

While	O
FGFR1	B
interacts	O
with	O
FRS2	B
constitutively	O
,	O
independent	O
of	O
ligand	O
stimulation	O
and	O
tyrosine	O
phosphorylation	O
,	O
NGF	B
receptor	I
(	O
TrkA	B
)	O
binding	O
to	O
FRS2	B
is	O
strongly	O
dependent	O
on	O
receptor	O
activation	O
.	O

Complex	O
formation	O
with	O
TrkA	B
is	O
dependent	O
on	O
phosphorylation	O
of	O
Y490	O
,	O
a	O
canonical	O
PTB	O
domain	O
binding	O
site	O
that	O
also	O
functions	O
as	O
a	O
binding	O
site	O
for	O
Shc	B
(	O
NPXpY	O
)	O
.	O

Using	O
deletion	O
and	O
alanine	O
scanning	O
mutagenesis	O
as	O
well	O
as	O
peptide	O
competition	O
assays	O
,	O
we	O
demonstrate	O
that	O
the	O
PTB	O
domains	O
of	O
the	O
FRS2	B
proteins	O
specifically	O
recognize	O
two	O
different	O
primary	O
structures	O
in	O
two	O
different	O
receptors	O
in	O
a	O
phosphorylation	O
-	O
dependent	O
or	O
-	O
independent	O
manner	O
.	O

In	O
addition	O
,	O
NGF	B
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
FRS2alpha	B
is	O
diminished	O
in	O
cells	O
that	O
overexpress	O
a	O
kinase	B
-	O
inactive	O
mutant	O
of	O
FGFR1	B
.	O

This	O
experiment	O
suggests	O
that	O
FGFR1	B
may	O
regulate	O
signaling	O
via	O
NGF	B
receptors	I
by	O
sequestering	O
a	O
common	O
key	O
element	O
which	O
both	O
receptors	O
utilize	O
for	O
transmitting	O
their	O
signals	O
.	O

The	O
multiple	O
interactions	O
mediated	O
by	O
FRS2	B
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
target	O
selection	O
and	O
in	O
defining	O
the	O
specificity	O
of	O
several	O
families	O
of	O
receptor	B
tyrosine	I
kinases	I
.	O

Identification	O
and	O
characterization	O
of	O
a	O
new	O
prespore	O
-	O
specific	O
regulatory	O
gene	O
,	O
rsfA	B
,	O
of	O
Bacillus	O
subtilis	O
.	O

Differential	O
gene	O
expression	O
during	O
Bacillus	O
subtilis	O
sporulation	O
is	O
controlled	O
by	O
sigma	B
factors	I
and	O
other	O
regulatory	O
effectors	O
.	O

The	O
first	O
compartmentalized	O
sigma	B
factor	I
,	O
sigma	B
(	I
F	I
)	I
,	O
is	O
active	O
specifically	O
in	O
the	O
prespore	O
compartment	O
.	O

During	O
our	O
screening	O
for	O
new	O
chromosome	O
segregation	O
mutants	O
using	O
a	O
sigma	B
(	I
F	I
)	I
-	O
dependent	O
gpr	B
-	O
lacZ	B
reporter	O
as	O
a	O
probe	O
,	O
we	O
identified	O
a	O
new	O
gene	O
(	O
ywfN	B
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
reporter	O
and	O
named	O
it	O
rsfA	B
.	O

The	O
product	O
of	O
rsfA	B
has	O
features	O
of	O
gene	O
regulatory	O
proteins	O
,	O
and	O
the	O
protein	O
colocalizes	O
with	O
DNA	O
.	O

The	O
expression	O
of	O
rsfA	B
is	O
under	O
the	O
control	O
of	O
both	O
sigma	B
(	I
F	I
)	I
and	O
sigma	B
(	I
G	I
)	I
.	O

Null	O
mutations	O
in	O
rsfA	B
have	O
different	O
effects	O
on	O
the	O
expression	O
of	O
sigma	B
(	I
F	I
)	I
-	O
dependent	O
genes	O
,	O
suggesting	O
that	O
the	O
RsfA	B
protein	O
is	O
a	O
regulator	O
of	O
transcription	O
that	O
fine	O
-	O
tunes	O
gene	O
expression	O
in	O
the	O
prespore	O
.	O

Flt-3	B
ligand	I
,	O
in	O
combination	O
with	O
bovine	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
and	O
interleukin	B
-	I
4	I
,	O
promotes	O
the	O
growth	O
of	O
bovine	O
bone	O
marrow	O
derived	O
dendritic	O
cells	O
.	O

Culture	O
of	O
bone	O
marrow	O
precursor	O
cells	O
with	O
cytokines	B
,	O
including	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
interleukin	B
-	I
4	I
(	O
IL-4	B
)	O
and	O
the	O
tyrosine	B
kinase	I
receptor	I
binding	O
proteins	O
Flt	B
-	I
3	I
ligand	I
(	B
Flt	I
-	I
3L	I
)	O
and	O
stem	B
-	I
cell	I
factor	I
(	O
SCF	B
)	O
,	O
has	O
previously	O
been	O
shown	O
,	O
in	O
both	O
mouse	O
and	O
human	O
,	O
to	O
result	O
in	O
the	O
generation	O
of	O
large	O
numbers	O
of	O
dendritic	O
cells	O
.	O

We	O
extend	O
these	O
findings	O
to	O
bovine	O
dendritic	O
cells	O
.	O

Culture	O
of	O
bovine	O
bone	O
marrow	O
cells	O
with	O
GM	B
-	I
CSF	I
,	O
IL-4	B
and	O
either	O
Flt-3L	B
or	O
SCF	B
enhanced	O
the	O
generation	O
of	O
low	O
buoyant	O
-	O
density	O
dendritic	O
cells	O
.	O

However	O
,	O
only	O
the	O
addition	O
of	O
Flt	B
-	I
3L	I
to	O
cells	O
cultured	O
with	O
GM	B
-	I
CSF	I
and	O
IL-4	B
was	O
shown	O
to	O
increase	O
the	O
number	O
of	O
dendritic	O
cells	O
and	O
induce	O
the	O
differentiation	O
of	O
dendritic	O
cells	O
with	O
potent	O
capacity	O
to	O
stimulate	O
allogeneic	O
T	O
cells	O
and	O
resting	O
CD4	B
+	O
memory	O
T	O
cells	O
.	O

The	O
effective	O
ability	O
to	O
stimulate	O
T	O
cells	O
was	O
associated	O
with	O
the	O
expression	O
of	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
molecules	O
and	O
CD80	B
/	I
86	I
by	O
dendritic	O
cells	O
.	O

Bovine	O
bone	O
marrow	O
derived	O
dendritic	O
cells	O
appeared	O
to	O
be	O
exclusively	O
of	O
myeloid	O
origin	O
because	O
they	O
expressed	O
the	O
myeloid	O
-	O
related	O
antigens	O
CD14	B
,	O
MyD-1	B
and	O
CD11b	B
.	O

Vps52p	B
,	O
Vps53p	B
,	O
and	O
Vps54p	B
form	O
a	O
novel	O
multisubunit	O
complex	O
required	O
for	O
protein	O
sorting	O
at	O
the	O
yeast	O
late	O
Golgi	O
.	O

The	O
late	O
Golgi	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
receives	O
membrane	O
traffic	O
from	O
the	O
secretory	O
pathway	O
as	O
well	O
as	O
retrograde	O
traffic	O
from	O
post	O
-	O
Golgi	O
compartments	O
,	O
but	O
the	O
machinery	O
that	O
regulates	O
these	O
vesicle	O
-	O
docking	O
and	O
fusion	O
events	O
has	O
not	O
been	O
characterized	O
.	O

We	O
have	O
identified	O
three	O
components	O
of	O
a	O
novel	O
protein	O
complex	O
that	O
is	O
required	O
for	O
protein	O
sorting	O
at	O
the	O
yeast	O
late	O
Golgi	O
compartment	O
.	O

Mutation	O
of	O
VPS52	B
,	O
VPS53	B
,	O
or	O
VPS54	B
results	O
in	O
the	O
missorting	O
of	O
70	O
%	O
of	O
the	O
vacuolar	O
hydrolase	B
carboxypeptidase	B
Y	I
as	O
well	O
as	O
the	O
mislocalization	O
of	O
late	O
Golgi	O
membrane	O
proteins	O
to	O
the	O
vacuole	O
,	O
whereas	O
protein	O
traffic	O
through	O
the	O
early	O
part	O
of	O
the	O
Golgi	O
complex	O
is	O
unaffected	O
.	O

A	O
vps52	B
/	I
53	I
/	I
54	I
triple	O
mutant	O
strain	O
is	O
phenotypically	O
indistinguishable	O
from	O
each	O
of	O
the	O
single	O
mutants	O
,	O
consistent	O
with	O
the	O
model	O
that	O
all	O
three	O
are	O
required	O
for	O
a	O
common	O
step	O
in	O
membrane	O
transport	O
.	O

Native	O
coimmunoprecipitation	O
experiments	O
indicate	O
that	O
Vps52p	B
,	O
Vps53p	B
,	O
and	O
Vps54p	B
are	O
associated	O
in	O
a	O
1	O
:	O
1	O
:	O
1	O
complex	O
that	O
sediments	O
as	O
a	O
single	O
peak	O
on	O
sucrose	O
velocity	O
gradients	O
.	O

This	O
complex	O
,	O
which	O
exists	O
both	O
in	O
a	O
soluble	O
pool	O
and	O
as	O
a	O
peripheral	O
component	O
of	O
a	O
membrane	O
fraction	O
,	O
colocalizes	O
with	O
markers	O
of	O
the	O
yeast	O
late	O
Golgi	O
by	O
immunofluorescence	O
microscopy	O
.	O

Together	O
,	O
the	O
phenotypic	O
and	O
biochemical	O
data	O
suggest	O
that	O
VPS52	B
,	O
VPS53	B
,	O
and	O
VPS54	B
are	O
required	O
for	O
the	O
retrograde	O
transport	O
of	O
Golgi	O
membrane	O
proteins	O
from	O
an	O
endosomal	O
/	O
prevacuolar	O
compartment	O
.	O

The	O
Vps52	B
/	I
53	I
/	I
54	I
complex	I
joins	O
a	O
growing	O
list	O
of	O
distinct	O
multisubunit	O
complexes	O
that	O
regulate	O
membrane	O
-	O
trafficking	O
events	O
.	O

Cytokine	B
production	O
from	O
murine	O
CD4	B
and	O
CD8	B
cells	O
after	O
mannan	O
-	O
MUC1	B
immunization	O
.	O

Immunotherapy	O
with	O
oxidized	O
mannan	O
-	O
MUC1	B
fusion	O
protein	O
(	O
M	O
-	O
FP	O
)	O
leads	O
to	O
a	O
T1	O
immune	O
response	O
characterized	O
by	O
the	O
generation	O
of	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
,	O
few	O
antibodies	O
,	O
secretion	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
,	O
IL-12	B
,	O
and	O
interferon	B
-	I
gamma	I
and	O
tumor	O
protection	O
.	O

Immunotherapy	O
with	O
reduced	O
M	O
-	O
FP	O
or	O
fusion	O
protein	O
(	O
FP	O
)	O
alone	O
leads	O
to	O
a	O
T2	O
immune	O
response	O
characterized	O
by	O
the	O
generation	O
of	O
MUC1	B
antibodies	O
,	O
few	O
CTL	O
,	O
IL-4	B
secretion	O
,	O
and	O
no	O
tumor	O
protection	O
.	O

In	O
these	O
studies	O
,	O
cytokine	B
production	O
from	O
T	O
cells	O
was	O
measured	O
from	O
cultures	O
containing	O
whole	O
spleens	O
.	O

We	O
now	O
report	O
the	O
cytokine	B
secretion	O
patterns	O
from	O
spleen	O
cells	O
separated	O
into	O
CD4	B
+	O
and	O
CD8	B
+	O
T	O
cells	O
obtained	O
from	O
mice	O
immunized	O
with	O
either	O
oxidized	O
M	O
-	O
FP	O
,	O
reduced	O
M	O
-	O
FP	O
or	O
FP	O
,	O
or	O
the	O
simultaneous	O
administration	O
of	O
oxidized	O
M	O
-	O
FP	O
and	O
FP	O
.	O

Immunization	O
with	O
oxidized	O
M	O
-	O
FP	O
led	O
to	O
the	O
secretion	O
of	O
T1	O
cytokines	B
from	O
CD8	B
+	O
T	O
cells	O
(	O
IL-2	B
,	O
IFN	B
-	I
gamma	I
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
[	O
TNF	B
-	I
alpha	I
]	O
)	O
and	O
from	O
CD4	B
+	O
T	O
cells	O
(	O
IL-2	B
and	O
IFN	B
-	I
gamma	I
)	O
.	O

IL-12	B
production	O
,	O
presumably	O
from	O
activated	O
macrophages	O
,	O
was	O
observed	O
in	O
CD8	B
+	O
but	O
not	O
CD4	B
+	O
cultures	O
.	O

Immunization	O
with	O
either	O
reduced	O
M	O
-	O
FP	O
or	O
FP	O
led	O
to	O
the	O
secretion	O
of	O
predominantly	O
T2	O
cytokines	B
from	O
CD4	B
+	O
T	O
cells	O
(	O
IL-4	B
and	O
IL-10	B
)	O
and	O
IL-2	B
production	O
in	O
both	O
CD4	B
+	O
and	O
CD8	B
+	O
T	O
cell	O
cultures	O
.	O

The	O
simultaneous	O
immunization	O
of	O
both	O
oxidized	O
M	O
-	O
FP	O
and	O
FP	O
led	O
to	O
the	O
production	O
of	O
both	O
T1	O
and	O
T2	O
cytokines	B
from	O
CD8	B
+	O
T	O
cells	O
(	O
IL-2	B
,	O
IFN	B
-	I
gamma	I
,	O
and	O
TNF	B
-	I
alpha	I
)	O
and	O
CD4	B
+	O
cells	O
(	O
IL-2	B
,	O
IFN	B
-	I
gamma	I
,	O
IL-4	B
,	O
and	O
IL-10	B
)	O
and	O
IL-12	B
production	O
in	O
CD8	B
+	O
cultures	O
that	O
is	O
,	O
both	O
types	O
of	O
immune	O
responses	O
could	O
occur	O
together	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
cellular	O
immune	O
response	O
observed	O
in	O
oxidized	O
M	O
-	O
FP	O
-	O
immunized	O
mice	O
is	O
indeed	O
dependent	O
on	O
the	O
T1	O
cytokine	B
profile	O
secreted	O
by	O
CD8	B
+	O
T	O
cells	O
,	O
and	O
the	O
simultaneous	O
production	O
of	O
both	O
T1	O
and	O
T2	O
cytokines	B
is	O
not	O
cross	O
-	O
inhibitory	O
.	O

Crystal	O
structure	O
of	O
the	O
hereditary	B
haemochromatosis	I
protein	I
HFE	B
complexed	O
with	O
transferrin	B
receptor	I
.	O

HFE	B
is	O
related	O
to	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
I	I
proteins	O
and	O
is	O
mutated	O
in	O
the	O
iron	O
-	O
overload	O
disease	O
hereditary	O
haemochromatosis	O
.	O

HFE	B
binds	O
to	O
the	O
transferrin	B
receptor	I
(	O
TfR	B
)	O
,	O
a	O
receptor	O
by	O
which	O
cells	O
acquire	O
iron	O
-	O
loaded	O
transferrin	B
.	O

The	O
2.8	O
A	O
crystal	O
structure	O
of	O
a	O
complex	O
between	O
the	O
extracellular	O
portions	O
of	O
HFE	B
and	O
TfR	B
shows	O
two	O
HFE	B
molecules	O
which	O
grasp	O
each	O
side	O
of	O
a	O
twofold	O
symmetric	O
TfR	B
dimer	O
.	O

On	O
a	O
cell	O
membrane	O
containing	O
both	O
proteins	O
,	O
HFE	B
would	O
'	O
lie	O
down	O
'	O
parallel	O
to	O
the	O
membrane	O
,	O
such	O
that	O
the	O
HFE	B
helices	O
that	O
delineate	O
the	O
counterpart	O
of	O
the	O
MHC	B
peptide	O
-	O
binding	O
groove	O
make	O
extensive	O
contacts	O
with	O
helices	O
in	O
the	O
TfR	B
dimerization	O
domain	O
.	O

The	O
structures	O
of	O
TfR	B
alone	O
and	O
complexed	O
with	O
HFE	B
differ	O
in	O
their	O
domain	O
arrangement	O
and	O
dimer	O
interfaces	O
,	O
providing	O
a	O
mechanism	O
for	O
communicating	O
binding	O
events	O
between	O
TfR	B
chains	O
.	O

The	O
HFE	B
-	O
TfR	B
complex	O
suggests	O
a	O
binding	O
site	O
for	O
transferrin	O
on	O
TfR	B
and	O
sheds	O
light	O
upon	O
the	O
function	O
of	O
HFE	B
in	O
regulating	O
iron	O
homeostasis	O
.	O

Characterization	O
of	O
a	O
second	O
member	O
of	O
the	O
subfamily	O
of	O
calcium	O
-	O
binding	O
mitochondrial	O
carriers	O
expressed	O
in	O
human	O
non	O
-	O
excitable	O
tissues	O
.	O

We	O
have	O
recently	O
identified	O
a	O
subfamily	O
of	O
mitochondrial	O
carriers	O
that	O
bind	O
calcium	O
,	O
and	O
cloned	O
ARALAR1	B
,	O
a	O
member	O
of	O
this	O
subfamily	O
expressed	O
in	O
human	O
muscle	O
and	O
brain	O
.	O

We	O
have	O
now	O
cloned	O
a	O
second	O
human	O
ARALAR	B
gene	O
(	O
ARALAR2	B
)	O
coding	O
for	O
a	O
protein	O
78.3	O
%	O
identical	O
to	O
Aralar1	B
,	O
but	O
expressed	O
in	O
liver	O
and	O
non	O
-	O
excitable	O
tissues	O
.	O

Aralar2	B
is	O
identical	O
to	O
citrin	B
,	O
the	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
type	O
-	O
II	O
citrullinaemia	O
[	O
Kobayashi	O
,	O
Sinasac	O
,	O
Iijima	O
,	O
Boright	O
,	O
Begum	O
,	O
Lee	O
,	O
Yasuda	O
,	O
Ikeda	O
,	O
Hirano	O
,	O
Terazono	O
et	O
al.	O
(	O
1999	O
)	O
Nat	O
.	O
Genet	O
.	O
22	O
,	O
159	O
-	O
163	O
]	O
.	O

A	O
related	O
protein	O
,	O
DmAralar	B
,	O
69	O
%	O
identical	O
to	O
Aralar1	B
,	O
was	O
found	O
in	O
Drosophila	O
melanogaster	O
,	O
the	O
DMARALAR	B
locus	O
lying	O
on	O
the	O
right	O
arm	O
of	O
the	O
third	O
chromosome	O
,	O
band	O
99F	O
.	O

The	O
N	O
-	O
terminal	O
half	O
of	O
Aralar2	B
/	O
citrin	B
is	O
able	O
to	O
bind	O
calcium	O
and	O
this	O
requires	O
the	O
presence	O
of	O
the	O
two	O
most	O
distal	O
EF	O
-	O
hands	O
.	O

The	O
localization	O
of	O
Aralar2	B
/	O
citrin	B
expressed	O
in	O
human	O
cell	O
lines	O
is	O
mitochondrial	O
,	O
the	O
C	O
-	O
terminal	O
half	O
containing	O
sufficient	O
information	O
for	O
import	O
and	O
assembly	O
into	O
mitochondria	O
.	O

The	O
C	O
-	O
terminal	O
half	O
of	O
Aralar	B
proteins	O
is	O
related	O
to	O
the	O
yeast	O
YPR020c	B
gene	O
,	O
with	O
a	O
very	O
high	O
sequence	O
conservation	O
(	O
54.3	O
%	O
identity	O
)	O
,	O
suggesting	O
that	O
these	O
proteins	O
play	O
an	O
important	O
role	O
.	O

Thus	O
Aralar	B
proteins	O
are	O
probably	O
expressed	O
in	O
all	O
tissues	O
in	O
an	O
isoform	O
-	O
specific	O
fashion	O
,	O
where	O
they	O
function	O
as	O
calcium	O
-	O
regulated	O
metabolite	O
(	O
possibly	O
anionic	O
)	O
carriers	O
.	O

Cloning	O
,	O
expression	O
,	O
and	O
functional	O
characterization	O
of	O
the	O
beta	B
regulatory	I
subunit	I
of	I
human	I
methionine	I
adenosyltransferase	I
(	O
MAT	B
II	I
)	O
.	O

MAT	B
II	I
,	O
the	O
extrahepatic	O
form	O
of	O
methionine	B
adenosyltransferase	I
(	O
MAT	B
)	O
,	O
consists	O
of	O
catalytic	O
alpha	O
(	O
2	O
)	O
/	O
alpha	O
(	O
2	O
'	O
)	O
subunits	O
and	O
a	O
noncatalytic	O
beta	O
subunit	O
,	O
believed	O
to	O
have	O
a	O
regulatory	O
function	O
.	O

The	O
full	O
-	O
length	O
cDNA	O
that	O
encodes	O
the	O
beta	O
subunit	O
of	O
human	O
MAT	B
II	I
was	O
cloned	O
and	O
found	O
to	O
encode	O
for	O
a	O
334	O
-	O
amino	O
acid	O
protein	O
with	O
a	O
calculated	O
molecular	O
weight	O
of	O
37	O
,	O
552	O
.	O

Analysis	O
of	O
sequence	O
homology	O
showed	O
similarity	O
with	O
bacterial	O
enzymes	O
that	O
catalyze	O
the	O
reduction	O
of	O
TDP	O
-	O
linked	O
sugars	O
.	O

The	O
beta	O
subunit	O
cDNA	O
was	O
cloned	O
into	O
the	O
pQE-30	O
expression	O
vector	O
,	O
and	O
the	O
recombinant	O
His	O
tagged	O
protein	O
,	O
which	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
was	O
recognized	O
by	O
antibodies	O
to	O
the	O
human	O
MAT	B
II	I
,	O
to	O
synthetic	O
peptides	O
copying	O
the	O
sequence	O
of	O
native	O
beta	O
subunit	O
protein	O
,	O
and	O
to	O
the	O
rbeta	O
protein	O
.	O

There	O
is	O
no	O
cross	O
-	O
reactivity	O
between	O
the	O
MAT	B
II	I
alpha	I
(	I
2	I
)	I
or	I
beta	I
subunits	O
.	O

None	O
of	O
the	O
anti	O
-	O
beta	O
subunit	O
antibodies	O
reacted	O
with	O
protein	O
extracts	O
of	O
E.	O
coli	O
host	O
cells	O
,	O
suggesting	O
that	O
these	O
bacteria	O
have	O
no	O
beta	O
subunit	O
protein	O
.	O

Interestingly	O
,	O
the	O
rbeta	O
subunit	O
associated	O
with	O
E.	O
coli	O
as	O
well	O
as	O
human	O
MAT	B
alpha	I
subunits	O
.	O

This	O
association	O
changed	O
the	O
kinetic	O
properties	O
of	O
both	O
enzymes	O
and	O
lowered	O
the	O
K	O
(	O
m	O
)	O
of	O
MAT	B
for	O
L	O
-	O
methionine	O
.	O

Together	O
,	O
the	O
data	O
show	O
that	O
we	O
have	O
cloned	O
and	O
expressed	O
the	O
human	O
MAT	B
II	I
beta	I
subunit	O
and	O
confirmed	O
its	O
long	O
suspected	O
regulatory	O
function	O
.	O

This	O
knowledge	O
affords	O
a	O
molecular	O
means	O
by	O
which	O
MAT	B
activity	O
and	O
consequently	O
the	O
levels	O
of	O
AdoMet	O
may	O
be	O
modulated	O
in	O
mammalian	O
cells	O
.	O

ESE-3	B
,	O
a	O
novel	O
member	O
of	O
an	O
epithelium	B
-	I
specific	I
ets	I
transcription	I
factor	I
subfamily	I
,	O
demonstrates	O
different	O
target	O
gene	O
specificity	O
from	O
ESE-1	B
.	O

Most	O
cancers	O
originate	O
as	O
a	O
result	O
of	O
aberrant	O
gene	O
expression	O
in	O
mainly	O
glandular	O
epithelial	O
tissues	O
leading	O
to	O
defects	O
in	O
epithelial	O
cell	O
differentiation	O
.	O

The	O
latter	O
is	O
governed	O
by	O
distinct	O
sets	O
of	O
transcriptional	O
regulators	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
epithelium	B
-	I
specific	I
Ets	I
factor	I
,	I
family	I
member	I
3	I
(	O
ESE-3	B
)	O
,	O
a	O
novel	O
member	O
of	O
the	O
ESE	B
subfamily	I
of	I
Ets	I
transcription	I
factors	I
.	O

ESE-3	B
shows	O
highest	O
homology	O
to	O
two	O
other	O
epithelium	O
restricted	O
Ets	B
factors	O
,	O
ESE-1	B
and	O
ESE-2	B
.	O

ESE-3	B
,	O
like	O
ESE-1	B
and	O
ESE-2	B
,	O
is	O
exclusively	O
expressed	O
in	O
a	O
subset	O
of	O
epithelial	O
cells	O
with	O
highest	O
expression	O
in	O
glandular	O
epithelium	O
such	O
as	O
prostate	O
,	O
pancreas	O
,	O
salivary	O
gland	O
,	O
and	O
trachea	O
.	O

A	O
potential	O
role	O
in	O
branching	O
morphogenesis	O
is	O
suggested	O
,	O
since	O
ESE-3	B
transactivates	O
the	O
c	B
-	I
MET	I
promoter	O
via	O
three	O
high	O
affinity	O
binding	O
sites	O
.	O

Additionally	O
,	O
ESE-3	B
binding	O
to	O
DNA	O
sequences	O
in	O
the	O
promoters	O
of	O
several	O
glandular	O
epithelium	O
-	O
specific	O
genes	O
suggests	O
a	O
role	O
for	O
ESE-3	B
in	O
later	O
stages	O
of	O
glandular	O
epithelium	O
differentiation	O
.	O

Although	O
ESE-3	B
and	O
ESE-1	B
bind	O
with	O
similar	O
affinity	O
to	O
various	O
Ets	B
binding	O
sites	O
,	O
ESE-3	B
and	O
ESE-1	B
differ	O
significantly	O
in	O
their	O
ability	O
to	O
transactivate	O
the	O
promoters	O
containing	O
these	O
sites	O
.	O

Our	O
results	O
support	O
the	O
notion	O
that	O
ESE-1	B
,	O
ESE-2	B
,	O
and	O
ESE-3	B
represent	O
a	O
unique	O
epithelium	B
-	I
specific	I
subfamily	I
of	I
Ets	I
factors	I
that	O
have	O
critical	O
but	O
distinct	O
functions	O
in	O
epithelial	O
cell	O
differentiation	O
and	O
proliferation	O
.	O

Sustained	O
expression	O
of	O
human	O
apolipoprotein	B
A	I
-	I
I	I
after	O
adenoviral	O
gene	O
transfer	O
in	O
C57BL	O
/	O
6	O
mice	O
:	O
role	O
of	O
apolipoprotein	B
A	I
-	I
I	I
promoter	O
,	O
apolipoprotein	B
A	I
-	I
I	I
introns	O
,	O
and	O
human	O
apolipoprotein	B
E	I
enhancer	O
.	O

Elevation	O
of	O
HDL	B
cholesterol	O
,	O
after	O
adenoviral	O
apolipoprotein	B
A	I
-	I
I	I
(	O
apo	B
A	I
-	I
I	I
)	O
gene	O
transfer	O
,	O
may	O
delay	O
or	O
revert	O
ischemic	O
cardiovascular	O
disease	O
,	O
provided	O
transgene	O
expression	O
is	O
persistent	O
.	O

Previously	O
,	O
we	O
observed	O
transient	O
human	O
apo	B
A	I
-	I
I	I
expression	O
after	O
adenoviral	O
gene	O
transfer	O
with	O
a	O
cytomegalovirus	O
(	O
CMV	O
)	O
-	O
driven	O
construct	O
containing	O
the	O
human	O
apo	B
A	I
-	I
I	I
cDNA	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
promoters	O
(	O
CMV	O
or	O
256	O
base	O
pairs	O
of	O
the	O
human	O
apo	B
A	I
-	I
I	I
promoter	O
)	O
,	O
introns	O
of	O
the	O
human	O
apo	B
A	I
-	I
I	I
gene	O
,	O
and	O
the	O
liver	O
-	O
specific	O
human	O
apolipoprotein	B
E	I
(	O
apo	B
E	I
)	O
enhancer	O
on	O
adenovirus	O
-	O
mediated	O
human	O
apo	B
A	I
-	I
I	I
expression	O
were	O
evaluated	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

In	O
the	O
presence	O
of	O
the	O
CMV	O
promoter	O
,	O
human	O
apo	B
A	I
-	I
I	I
introns	O
prolonged	O
expression	O
above	O
20	O
mg	O
/	O
dl	O
from	O
14	O
to	O
35	O
days	O
.	O

Addition	O
of	O
one	O
,	O
two	O
,	O
or	O
four	O
copies	O
of	O
the	O
human	O
apo	B
E	I
enhancer	O
in	O
these	O
constructs	O
resulted	O
in	O
a	O
copy	O
-	O
dependent	O
but	O
transient	O
increase	O
in	O
expression	O
for	O
14	O
days	O
.	O

The	O
apo	B
A	I
-	I
I	I
promoter	O
induced	O
3.2	O
-	O
fold	O
lower	O
peak	O
levels	O
of	O
human	O
apo	B
A	I
-	I
I	I
than	O
did	O
the	O
CMV	O
promoter	O
,	O
but	O
insertion	O
of	O
four	O
apo	B
E	I
enhancers	O
in	O
the	O
apo	B
A	I
-	I
I	I
promoter	O
-	O
driven	O
construct	O
resulted	O
in	O
human	O
apo	B
A	I
-	I
I	I
levels	O
above	O
20	O
mg	O
/	O
dl	O
for	O
6	O
months	O
.	O

The	O
decline	O
between	O
day	O
6	O
and	O
day	O
35	O
of	O
human	O
apo	B
A	I
-	I
I	I
expression	O
driven	O
by	O
the	O
CMV	O
promoter	O
was	O
due	O
to	O
(	O
1	O
)	O
a	O
2.5	O
-	O
fold	O
decline	O
in	O
transgene	O
DNA	O
levels	O
that	O
is	O
not	O
observed	O
with	O
apo	B
A	I
-	I
I	I
promoter	O
-	O
driven	O
constructs	O
,	O
and	O
(	O
2	O
)	O
CMV	O
promoter	O
attenuation	O
as	O
evidenced	O
by	O
a	O
7.6	O
-	O
fold	O
decline	O
in	O
the	O
human	O
apo	B
A	I
-	I
I	I
mRNA	O
/	O
human	O
apo	B
A	I
-	I
I	I
DNA	O
copy	O
number	O
ratio	O
between	O
day	O
6	O
and	O
day	O
35	O
.	O

Hepatotoxicity	O
,	O
as	O
evidenced	O
by	O
up	O
to	O
10	O
-	O
fold	O
higher	O
serum	O
levels	O
of	O
transaminases	B
on	O
day	O
6	O
after	O
gene	O
transfer	O
with	O
CMV	O
promoter	O
-	O
driven	O
constructs	O
than	O
with	O
apo	B
A	I
-	I
I	I
promoter	O
-	O
driven	O
constructs	O
,	O
probably	O
caused	O
the	O
accelerated	O
decline	O
of	O
transgene	O
DNA	O
.	O

In	O
conclusion	O
,	O
gene	O
transfer	O
with	O
an	O
adenovirus	O
comprising	O
the	O
256	O
-	O
bp	O
apo	B
A	I
-	I
I	I
promoter	O
,	O
the	O
genomic	O
apo	B
A	I
-	I
I	I
DNA	O
,	O
and	O
four	O
apo	B
E	I
enhancers	O
,	O
all	O
of	O
human	O
origin	O
,	O
is	O
associated	O
with	O
low	O
hepatotoxicity	O
and	O
with	O
the	O
absence	O
of	O
promoter	O
shutoff	O
resulting	O
in	O
human	O
apo	B
A	I
-	I
I	I
expression	O
above	O
20	O
mg	O
/	O
dl	O
for	O
up	O
to	O
6	O
months	O
.	O

Impact	O
of	O
restriction	O
of	O
placental	O
and	O
fetal	O
growth	O
on	O
expression	O
of	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
and	I
type	I
2	I
messenger	O
ribonucleic	O
acid	O
in	O
the	O
liver	O
,	O
kidney	O
,	O
and	O
adrenal	O
of	O
the	O
sheep	O
fetus	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
fetal	O
growth	O
restriction	O
,	O
induced	O
by	O
restriction	O
of	O
placental	O
growth	O
and	O
function	O
(	O
PR	O
)	O
,	O
on	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11betaHSD-1	B
)	O
and	O
11betaHSD-2	B
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
in	O
fetal	O
tissues	O
in	O
the	O
sheep	O
,	O
using	O
Northern	O
blot	O
analysis	O
.	O

Fetal	O
liver	O
,	O
kidney	O
,	O
and	O
adrenals	O
were	O
collected	O
from	O
normally	O
grown	O
fetuses	O
at	O
90	O
days	O
(	O
n	O
=	O
6	O
)	O
,	O
125	O
days	O
(	O
n	O
=	O
6	O
)	O
,	O
and	O
141	O
-	O
145	O
days	O
(	O
n	O
=	O
7	O
)	O
and	O
from	O
PR	O
fetuses	O
at	O
141	O
-	O
145	O
days	O
(	O
n	O
=	O
6	O
)	O
.	O

Expression	O
of	O
11betaHSD-1	B
mRNA	O
in	O
the	O
fetal	O
liver	O
increased	O
significantly	O
between	O
125	O
days	O
(	O
7.4	O
+	O
/-	O
0.8	O
)	O
and	O
141	O
-	O
145	O
days	O
gestation	O
(	O
27	O
+	O
/	O
-	O
5.3	O
)	O
.	O

There	O
was	O
also	O
an	O
approximately	O
2	O
-	O
fold	O
increase	O
in	O
the	O
ratio	O
of	O
11betaHSD-1	B
mRNA	O
/	O
18S	O
rRNA	O
expression	O
in	O
the	O
PR	O
group	O
(	O
53.8	O
+	O
/-	O
7.9	O
)	O
compared	O
with	O
that	O
in	O
control	O
animals	O
at	O
141	O
-	O
145	O
days	O
gestation	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
11betaHSD-2	B
mRNA	O
in	O
fetal	O
adrenals	O
between	O
125	O
days	O
(	O
41.6	O
+	O
/-	O
2.4	O
)	O
and	O
141	O
-	O
145	O
days	O
(	O
26.7	O
+	O
/-	O
1.1	O
)	O
gestation	O
,	O
but	O
there	O
was	O
no	O
effect	O
of	O
PR	O
on	O
the	O
expression	O
of	O
adrenal	O
11betaHSD-2	B
mRNA	O
.	O

11betaHSD-2	B
mRNA	O
expression	O
in	O
the	O
fetal	O
kidney	O
increased	O
between	O
90	O
days	O
(	O
16.8	O
+	O
/-	O
1.7	O
)	O
and	O
141	O
-	O
145	O
days	O
gestation	O
(	O
31.7	O
+	O
/-	O
4.3	O
)	O
,	O
but	O
there	O
was	O
no	O
effect	O
of	O
PR	O
on	O
the	O
levels	O
of	O
11betaHSD-2	B
mRNA	O
in	O
the	O
fetal	O
kidney	O
.	O

In	O
summary	O
,	O
11betaHSD-2	B
mRNA	O
is	O
differentially	O
regulated	O
in	O
the	O
fetal	O
adrenal	O
and	O
kidney	O
in	O
the	O
sheep	O
fetus	O
during	O
late	O
gestation	O
.	O

There	O
is	O
also	O
a	O
specific	O
increase	O
in	O
the	O
expression	O
of	O
11betaHSD-1	B
mRNA	O
in	O
the	O
liver	O
of	O
growth	O
-	O
restricted	O
fetuses	O
in	O
late	O
gestation	O
.	O

This	O
suggests	O
that	O
there	O
is	O
increased	O
hepatic	O
exposure	O
to	O
cortisol	O
in	O
the	O
growth	O
-	O
restricted	O
fetus	O
,	O
which	O
may	O
be	O
important	O
in	O
the	O
reprogramming	O
of	O
hepatic	O
physiology	O
that	O
occurs	O
after	O
growth	O
restriction	O
in	O
utero	O
.	O

Enhancement	O
of	O
secretion	O
and	O
extracellular	O
stability	O
of	O
staphylokinase	B
in	O
Bacillus	O
subtilis	O
by	O
wprA	B
gene	O
disruption	O
.	O

Staphylokinase	B
(	O
SAK	B
)	O
,	O
a	O
polypeptide	O
secreted	O
by	O
Staphylococcus	O
aureus	O
,	O
is	O
a	O
plasminogen	B
activator	O
with	O
a	O
therapeutic	O
potential	O
in	O
thrombosis	O
diseases	O
.	O

A	O
Bacillus	O
subtilis	O
strain	O
which	O
is	O
multiply	O
deficient	O
in	O
exoproteases	B
was	O
transformed	O
by	O
an	O
expression	O
plasmid	O
carrying	O
a	O
promoter	O
and	O
a	O
signal	O
sequence	O
of	O
subtilisin	B
fused	O
in	O
frame	O
with	O
the	O
sak	B
open	O
reading	O
frame	O
.	O

However	O
,	O
the	O
amount	O
of	O
SAK	B
secretion	O
was	O
marginal	O
(	O
45	O
mg	O
/	O
liter	O
)	O
.	O

In	O
contrast	O
,	O
disruption	O
of	O
the	O
wprA	B
gene	O
,	O
which	O
encodes	O
a	O
subtilisin	B
-	O
type	O
protease	B
,	O
strongly	O
promoted	O
the	O
production	O
of	O
SAK	B
in	O
the	O
stationary	O
phase	O
(	O
181	O
mg	O
/	O
liter	O
)	O
.	O

In	O
addition	O
,	O
the	O
extracellular	O
stability	O
of	O
mature	O
SAK	B
was	O
dramatically	O
enhanced	O
.	O

These	O
data	O
indicate	O
a	O
significant	O
role	O
of	O
the	O
wprA	B
gene	O
product	O
in	O
degrading	O
foreign	O
proteins	O
,	O
both	O
during	O
secretion	O
and	O
in	O
the	O
extracellular	O
milieu	O
.	O

Targeted	O
disruption	O
of	O
the	O
murine	O
junD	B
gene	O
results	O
in	O
multiple	O
defects	O
in	O
male	O
reproductive	O
function	O
.	O

JunD	B
is	O
one	O
of	O
three	O
mammalian	O
Jun	B
proteins	O
that	O
contribute	O
to	O
the	O
AP-1	B
transcription	B
factor	I
complex	O
.	O

Distinct	O
regulation	O
and	O
functions	O
have	O
been	O
proposed	O
for	O
each	O
Jun	B
member	O
,	O
but	O
less	O
is	O
known	O
about	O
the	O
biological	O
functions	O
of	O
each	O
of	O
these	O
proteins	O
in	O
vivo	O
.	O

To	O
investigate	O
the	O
role	O
of	O
JunD	B
,	O
we	O
have	O
inactivated	O
the	O
murine	O
gene	O
by	O
replacement	O
with	O
a	O
bacterial	O
lacZ	B
reporter	O
gene	O
.	O

Embryonic	O
JunD	B
expression	O
was	O
initially	O
detected	O
in	O
the	O
developing	O
heart	O
and	O
cardiovascular	O
system	O
.	O

Subsequent	O
broadening	O
phases	O
of	O
JunD	B
expression	O
were	O
observed	O
during	O
embryonic	O
development	O
and	O
expression	O
in	O
the	O
adult	O
was	O
widespread	O
in	O
many	O
tissues	O
and	O
cell	O
lineages	O
.	O

Mutant	O
animals	O
lack	O
JunD	B
mRNA	O
and	O
protein	O
and	O
showed	O
no	O
evidence	O
of	O
upregulation	O
of	O
c	B
-	I
Jun	I
and	O
JunB	B
mRNA	O
levels	O
.	O

In	O
contrast	O
to	O
the	O
other	O
two	O
Jun	B
members	O
,	O
homozygous	O
JunD	B
-	O
/	O
-	O
mutant	O
animals	O
were	O
viable	O
and	O
appeared	O
healthy	O
.	O

However	O
,	O
homozygous	O
JunD	B
-	O
/	O
-	O
animals	O
showed	O
a	O
reduced	O
postnatal	O
growth	O
.	O

Furthermore	O
,	O
JunD	B
-	O
/	O
-	O
males	O
exhibited	O
multiple	O
age	O
-	O
dependent	O
defects	O
in	O
reproduction	O
,	O
hormone	O
imbalance	O
and	O
impaired	O
spermatogenesis	O
with	O
abnormalities	O
in	O
head	O
and	O
flagellum	O
sperm	O
structures	O
.	O

No	O
defects	O
in	O
fertility	O
were	O
observed	O
in	O
JunD	B
-	O
/	O
-	O
female	O
animals	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
redundant	O
functions	O
for	O
members	O
of	O
the	O
Jun	B
family	I
during	O
development	O
and	O
specific	O
functions	O
for	O
JunD	B
in	O
male	O
reproductive	O
function	O
.	O

Palindromes	O
as	O
substrates	O
for	O
multiple	O
pathways	O
of	O
recombination	O
in	O
Escherichia	O
coli	O
.	O

A	O
246	O
-	O
bp	O
imperfect	O
palindrome	O
has	O
the	O
potential	O
to	O
form	O
hairpin	O
structures	O
in	O
single	O
-	O
stranded	O
DNA	O
during	O
replication	O
.	O

Genetic	O
evidence	O
suggests	O
that	O
these	O
structures	O
are	O
converted	O
to	O
double	O
-	O
strand	O
breaks	O
by	O
the	O
SbcCD	B
nuclease	I
and	O
that	O
the	O
double	O
-	O
strand	O
breaks	O
are	O
repaired	O
by	O
recombination	O
.	O

We	O
investigated	O
the	O
role	O
of	O
a	O
range	O
of	O
recombination	O
mutations	O
on	O
the	O
viability	O
of	O
cells	O
containing	O
this	O
palindrome	O
.	O

The	O
palindrome	O
was	O
introduced	O
into	O
the	O
Escherichia	O
coli	O
chromosome	O
by	O
phage	O
lambda	O
lysogenization	O
.	O

This	O
was	O
done	O
in	O
both	O
wt	O
and	O
sbcC	B
backgrounds	O
.	O

Repair	O
of	O
the	O
SbcCD	B
-	O
induced	O
double	O
-	O
strand	O
breaks	O
requires	O
a	O
large	O
number	O
of	O
proteins	O
,	O
including	O
the	O
components	O
of	O
both	O
the	O
RecB	B
and	O
RecF	B
pathways	O
.	O

Repair	O
does	O
not	O
involve	O
PriA	B
-	O
dependent	O
replication	O
fork	O
restart	O
,	O
which	O
suggests	O
that	O
the	O
double	O
-	O
strand	O
break	O
occurs	O
after	O
the	O
replication	O
fork	O
has	O
passed	O
the	O
palindrome	O
.	O

In	O
the	O
absence	O
of	O
SbcCD	B
,	O
recombination	O
still	O
occurs	O
,	O
probably	O
using	O
a	O
gap	O
substrate	O
.	O

This	O
process	O
is	O
also	O
PriA	B
independent	O
,	O
suggesting	O
that	O
there	O
is	O
no	O
collapse	O
of	O
the	O
replication	O
fork	O
.	O

In	O
the	O
absence	O
of	O
RecA	B
,	O
the	O
RecQ	B
helicase	B
is	O
required	O
for	O
palindrome	O
viability	O
in	O
a	O
sbcC	B
mutant	O
,	O
suggesting	O
that	O
a	O
helicase	B
-	O
dependent	O
pathway	O
exists	O
to	O
allow	O
replicative	O
bypass	O
of	O
secondary	O
structures	O
.	O

alpha5beta1	B
integrin	I
expression	O
and	O
luminal	O
edge	O
fibronectin	B
matrix	O
assembly	O
by	O
smooth	O
muscle	O
cells	O
after	O
arterial	O
injury	O
.	O

Fibronectin	B
is	O
secreted	O
from	O
the	O
cell	O
as	O
a	O
soluble	O
protein	O
that	O
must	O
then	O
polymerize	O
to	O
regulate	O
cell	O
function	O
.	O

To	O
elucidate	O
the	O
process	O
of	O
fibronectin	B
matrix	O
assembly	O
in	O
vascular	O
disease	O
,	O
we	O
immunostained	O
sections	O
of	O
balloon	O
-	O
injured	O
rat	O
carotid	O
artery	O
for	O
the	O
fibronectin	B
-	O
binding	O
alpha5beta1	B
integrin	I
.	O

Whereas	O
alpha5beta1	B
integrin	I
was	O
not	O
evident	O
in	O
the	O
normal	O
carotid	O
artery	O
,	O
its	O
expression	O
was	O
induced	O
after	O
a	O
vascular	O
injury	O
.	O

By	O
14	O
days	O
,	O
the	O
alpha5beta1	B
integrin	I
was	O
localized	O
exclusively	O
to	O
the	O
less	O
differentiated	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
at	O
the	O
luminal	O
surface	O
of	O
the	O
neointima	O
.	O

Platelet	B
-	I
derived	I
growth	I
factor	I
-	I
BB	I
,	O
dominant	O
in	O
neointimal	O
formation	O
,	O
selectively	O
increased	O
the	O
expression	O
of	O
the	O
alpha5beta1	B
integrin	I
by	O
human	O
SMCs	O
in	O
culture	O
.	O

To	O
track	O
the	O
assembly	O
of	O
fibronectin	B
fibers	O
,	O
fluorescence	O
-	O
labeled	O
soluble	O
fibronectin	B
protomers	O
were	O
added	O
to	O
cultured	O
SMCs	O
and	O
to	O
fresh	O
segments	O
of	O
normal	O
and	O
balloon	O
-	O
injured	O
rat	O
carotid	O
arteries	O
.	O

Fibronectin	B
fiber	O
formation	O
in	O
cultured	O
SMCs	O
could	O
be	O
detected	O
within	O
10	O
minutes	O
,	O
and	O
was	O
blocked	O
by	O
an	O
RGD	O
peptide	O
,	O
an	O
anti	O
-	O
beta1	B
integrin	I
antibody	O
,	O
and	O
an	O
anti	O
-	O
alpha5beta1	B
integrin	I
antibody	O
,	O
but	O
not	O
by	O
an	O
anti	O
-	O
beta3	B
integrin	I
antibody	O
.	O

En	O
face	O
confocal	O
microscopy	O
of	O
arterial	O
segments	O
revealed	O
that	O
soluble	O
fibronectin	B
had	O
polymerized	O
on	O
the	O
alpha5beta1	B
integrin	I
-	O
expressing	O
SMCs	O
of	O
the	O
luminal	O
surface	O
of	O
the	O
injured	O
arterial	O
neointima	O
,	O
but	O
not	O
on	O
the	O
alpha5beta1	B
integrin	I
-	O
negative	O
neointimal	O
SMCs	O
below	O
this	O
or	O
on	O
the	O
endothelial	O
cells	O
of	O
uninjured	O
arteries	O
.	O

Furthermore	O
,	O
in	O
situ	O
fibronectin	B
assembly	O
by	O
the	O
neointimal	O
SMCs	O
was	O
inhibited	O
by	O
an	O
RGD	O
peptide	O
and	O
by	O
an	O
anti	O
-	O
beta1	B
integrin	I
antibody	O
.	O

These	O
studies	O
indicate	O
that	O
a	O
subpopulation	O
of	O
SMCs	O
in	O
the	O
repairing	O
artery	O
wall	O
orchestrates	O
integrin	B
-	O
mediated	O
fibronectin	B
assembly	O
.	O

Pattern	O
of	O
morphological	O
diversification	O
in	O
the	O
Leptocarabus	O
ground	O
beetles	O
(	O
Coleoptera	O
:	O
Carabidae	O
)	O
as	O
deduced	O
from	O
mitochondrial	O
ND5	B
gene	O
and	O
nuclear	O
28S	O
rDNA	O
sequences	O
.	O

Most	O
of	O
the	O
mitochondrial	O
NADH	B
dehydrogenase	I
subunit	I
5	I
(	O
ND5	B
)	O
gene	O
and	O
a	O
part	O
of	O
nuclear	O
28S	O
ribosomal	O
RNA	O
gene	O
were	O
sequenced	O
for	O
14	O
species	O
of	O
ground	O
beetles	O
belonging	O
to	O
the	O
genus	O
Leptocarabus	O
.	O

In	O
both	O
the	O
ND5	B
and	O
the	O
28S	O
rDNA	O
phylogenetic	O
trees	O
of	O
Leptocarabus	O
,	O
three	O
major	O
lineages	O
were	O
recognized	O
:	O
(	O
1	O
)	O
L.	O
marcilhaci	O
/	O
L.	O
yokoael	O
/	O
Leptocarabus	O
sp.	O
from	O
China	O
,	O
(	O
2	O
)	O
L.	O
koreanus	O
/	O
L.	O
truncaticollis	O
/	O
L.	O
seishinensis	O
/	O
L.	O
semiopacus	O
/	O
L.	O
canaliculatus	O
/	O
L.	O
kurilensis	O
from	O
the	O
northern	O
Eurasian	O
continent	O
including	O
Korea	O
and	O
Hokkaido	O
,	O
Japan	O
,	O
and	O
(	O
3	O
)	O
all	O
of	O
the	O
Japanese	O
species	O
except	O
L.	O
kurilensis	O
.	O

Clustering	O
of	O
the	O
species	O
in	O
the	O
trees	O
is	O
largely	O
linked	O
to	O
their	O
geographic	O
distribution	O
and	O
does	O
not	O
correlate	O
with	O
morphological	O
characters	O
.	O

The	O
species	O
belonging	O
to	O
different	O
species	O
groups	O
are	O
clustered	O
in	O
the	O
same	O
lineages	O
,	O
and	O
those	O
in	O
the	O
same	O
species	O
group	O
are	O
scattered	O
among	O
the	O
different	O
lineages	O
.	O

One	O
of	O
the	O
possible	O
interpretations	O
of	O
the	O
present	O
results	O
would	O
be	O
that	O
morphological	O
transformations	O
independently	O
took	O
place	O
in	O
the	O
different	O
lineages	O
,	O
sometimes	O
with	O
accompanying	O
parallel	O
morphological	O
evolution	O
,	O
resulting	O
in	O
the	O
occurrence	O
of	O
the	O
morphological	O
species	O
belonging	O
to	O
the	O
same	O
species	O
group	O
(	O
=	O
type	O
)	O
in	O
the	O
different	O
lineages	O
.	O

Identification	O
of	O
the	O
Nogo	B
inhibitor	O
of	O
axon	O
regeneration	O
as	O
a	O
Reticulon	B
protein	O
.	O

Adult	O
mammalian	O
axon	O
regeneration	O
is	O
generally	O
successful	O
in	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
but	O
is	O
dismally	O
poor	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

However	O
,	O
many	O
classes	O
of	O
CNS	O
axons	O
can	O
extend	O
for	O
long	O
distances	O
in	O
peripheral	O
nerve	O
grafts	O
.	O

A	O
comparison	O
of	O
myelin	O
from	O
the	O
CNS	O
and	O
the	O
PNS	O
has	O
revealed	O
that	O
CNS	O
white	O
matter	O
is	O
selectively	O
inhibitory	O
for	O
axonal	O
outgrowth	O
.	O

Several	O
components	O
of	O
CNS	O
white	O
matter	O
,	O
NI35	O
,	O
NI250	O
(	O
Nogo	B
)	O
and	O
MAG	B
,	O
that	O
have	O
inhibitory	O
activity	O
for	O
axon	O
extension	O
have	O
been	O
described	O
.	O

The	O
IN-1	O
antibody	O
,	O
which	O
recognizes	O
NI35	O
and	O
NI250	O
(	O
Nogo	B
)	O
,	O
allows	O
moderate	O
degrees	O
of	O
axonal	O
regeneration	O
and	O
functional	O
recovery	O
after	O
spinal	O
cord	O
injury	O
.	O

Here	O
we	O
identify	O
Nogo	B
as	O
a	O
member	O
of	O
the	O
Reticulon	B
family	I
,	O
Reticulon	B
4-A	I
.	O

Nogo	B
is	O
expressed	O
by	O
oligodendrocytes	O
but	O
not	O
by	O
Schwann	O
cells	O
,	O
and	O
associates	O
primarily	O
with	O
the	O
endoplasmic	O
reticulum	O
.	O

A	O
66	O
-	O
residue	O
lumenal	O
/	O
extracellular	O
domain	O
inhibits	O
axonal	O
extension	O
and	O
collapses	O
dorsal	O
root	O
ganglion	O
growth	O
cones	O
.	O

In	O
contrast	O
to	O
Nogo	B
,	O
Reticulon	B
1	I
and	I
3	I
are	O
not	O
expressed	O
by	O
oligodendrocytes	O
,	O
and	O
the	O
66	O
-	O
residue	O
lumenal	O
/	O
extracellular	O
domains	O
from	O
Reticulon	B
1	I
,	I
2	I
and	I
3	I
do	O
not	O
inhibit	O
axonal	O
regeneration	O
.	O

These	O
data	O
provide	O
a	O
molecular	O
basis	O
to	O
assess	O
the	O
contribution	O
of	O
Nogo	B
to	O
the	O
failure	O
of	O
axonal	O
regeneration	O
in	O
the	O
adult	O
CNS	O
.	O

Restoration	O
of	O
cytotoxic	O
T	O
lymphocyte	O
function	O
in	O
malignant	O
pleural	O
effusion	O
:	O
interleukin-15	B
vs.	O
interleukin-2	B
.	O

The	O
present	O
study	O
attempts	O
to	O
define	O
the	O
role	O
of	O
interleukin-15	B
(	O
IL-15	B
)	O
,	O
as	O
compared	O
with	O
IL-2	B
,	O
in	O
generating	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
from	O
the	O
malignant	O
effusions	O
of	O
cancer	O
patients	O
.	O

Effusion	O
-	O
associated	O
lymphocytes	O
(	O
EAL	O
)	O
from	O
malignant	O
effusion	O
were	O
incubated	O
with	O
IL-15	B
or	O
IL-2	B
with	O
or	O
without	O
alphaCD3	B
.	O

Proliferation	O
and	O
cytotoxicity	O
assays	O
were	O
performed	O
.	O

IL-15	B
was	O
found	O
to	O
have	O
at	O
least	O
an	O
equivalent	O
,	O
if	O
not	O
higher	O
,	O
activity	O
to	O
IL-2	B
in	O
terms	O
of	O
lymphocyte	O
proliferation	O
and	O
generation	O
of	O
CTL	O
from	O
EAL	O
.	O

The	O
proliferative	O
response	O
of	O
EAL	O
,	O
cocultured	O
with	O
IL-15	B
,	O
with	O
or	O
without	O
alphaCD3	B
,	O
was	O
partly	O
inhibited	O
by	O
pretreatment	O
with	O
an	O
anti	O
-	O
IL2	B
receptor	I
beta	I
chain	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
.	O

The	O
proliferative	O
response	O
of	O
EAL	O
,	O
cocultured	O
with	O
alphaCD3	B
,	O
IL-2	B
,	O
or	O
both	O
,	O
was	O
partly	O
inhibited	O
by	O
pretreatment	O
with	O
an	O
anti	O
-	O
IL-2	B
receptor	I
alpha	I
chain	O
mAb	O
.	O

Overnight	O
[	O
5lCr	O
]	O
release	O
assays	O
against	O
K562	O
,	O
Daudi	O
,	O
and	O
the	O
patients	O
'	O
autologous	O
tumor	O
cells	O
were	O
done	O
to	O
evaluate	O
EAL	O
's	O
cytolytic	O
activity	O
.	O

MHC	B
class	I
I	I
Ab	O
blocked	O
the	O
stimulated	O
cytolytic	O
activity	O
of	O
EAL	O
against	O
autologous	O
tumors	O
.	O

An	O
mAb	O
depletion	O
assay	O
showed	O
that	O
the	O
phenotype	O
of	O
the	O
restored	O
EAL	O
was	O
CD16	B
-	O
CD4	B
-	O
CD8	B
+	O
;	O
thus	O
,	O
the	O
restored	O
activity	O
of	O
EAL	O
was	O
CTL	O
activity	O
.	O

The	O
results	O
suggest	O
that	O
both	O
IL-15	B
and	O
IL-2	B
can	O
restore	O
CTL	O
activity	O
from	O
EAL	O
in	O
the	O
presence	O
of	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
-	O
CD3	B
engagement	O
,	O
but	O
the	O
effect	O
of	O
IL-15	B
was	O
superior	O
.	O

Tyrosine	O
462	O
of	O
the	O
membrane	O
-	O
proximal	O
F'-G	O
'	O
loop	O
of	O
murine	O
Mpl	B
is	O
not	O
essential	O
for	O
high	O
-	O
affinity	O
binding	O
of	O
thrombopoietin	B
.	O

The	O
ligand	O
binding	O
site	O
of	O
Mpl	B
,	O
the	O
thrombopoietin	B
(	I
Tpo	I
)	I
receptor	I
,	O
has	O
not	O
been	O
determined	O
.	O

Tyr	O
(	O
462	O
)	O
of	O
murine	O
Mpl	B
corresponds	O
to	O
Tyr	O
(	O
421	O
)	O
of	O
the	O
common	B
beta	I
chain	I
of	I
the	I
human	I
IL-3	I
,	I
IL-5	I
and	I
GM	I
-	I
CSF	I
receptors	I
.	O

Tyr	O
(	O
421	O
)	O
has	O
been	O
identified	O
as	O
essential	O
for	O
high	O
-	O
affinity	O
ligand	O
binding	O
.	O

To	O
determine	O
whether	O
Tyr	O
(	O
462	O
)	O
is	O
similarly	O
required	O
for	O
Tpo	B
binding	O
,	O
wild	O
-	O
type	O
murine	O
Mpl	B
(	O
Mpl	B
-	O
WT	O
)	O
or	O
mutant	O
receptors	O
containing	O
an	O
alanine	O
(	O
Y462A	O
)	O
or	O
lysine	O
(	O
Y462	O
K	O
)	O
in	O
place	O
of	O
Tyr	O
(	O
462	O
)	O
were	O
expressed	O
in	O
BaF3	O
cells	O
.	O

In	O
proliferation	O
studies	O
,	O
the	O
Y462A	O
mutation	O
had	O
no	O
effect	O
on	O
Tpo	B
-	O
induced	O
growth	O
.	O

In	O
contrast	O
,	O
the	O
Y462	O
K	O
mutation	O
led	O
to	O
an	O
attenuated	O
proliferative	O
response	O
to	O
Tpo	B
.	O

In	O
single	O
-	O
point	O
binding	O
studies	O
,	O
both	O
Mpl	B
-	O
WT	O
and	O
Y462A	O
cells	O
were	O
able	O
to	O
bind	O
[	O
(	O
125	O
)	O
I	O
]	O
Tpo	B
in	O
a	O
specific	O
manner	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
marked	O
reduction	O
in	O
binding	O
of	O
[	O
(	O
125	O
)	O
I	O
]	O
Tpo	B
by	O
Y462	O
K	O
cells	O
.	O

Mpl	B
-	O
WT	O
cells	O
bound	O
Tpo	B
with	O
a	O
K	O
(	O
d	O
)	O
of	O
approximately	O
330	O
pM	O
,	O
while	O
Y462A	O
cells	O
bound	O
Tpo	B
with	O
a	O
K	O
(	O
d	O
)	O
of	O
approximately	O
268	O
pM	O
.	O

The	O
binding	O
affinity	O
of	O
Y462	O
K	O
cells	O
was	O
below	O
that	O
quantifiable	O
by	O
Scatchard	O
analysis	O
.	O

This	O
study	O
suggests	O
that	O
unlike	O
the	O
corresponding	O
Tyr	O
(	O
421	O
)	O
of	O
the	O
common	O
human	O
beta	O
chain	O
,	O
Tyr	O
(	O
462	O
)	O
of	O
murine	O
Mpl	B
is	O
not	O
required	O
for	O
high	O
-	O
affinity	O
ligand	O
binding	O
,	O
although	O
it	O
may	O
be	O
located	O
in	O
proximity	O
to	O
the	O
ligand	O
binding	O
site	O
.	O

Introduction	O
of	O
polyphosphate	O
as	O
a	O
novel	O
phosphate	O
pool	O
in	O
the	O
chloroplast	O
of	O
transgenic	O
potato	O
plants	O
modifies	O
carbohydrate	O
partitioning	O
.	O

Potato	O
plants	O
(	O
Solanum	O
tuberosum	O
L.	O
,	O
cv	O
.	O
DÃ?Â	O
©	O
sirÃ?Â	O
©	O
e	O
)	O
were	O
transformed	O
with	O
the	O
polyphosphate	B
kinase	I
gene	O
from	O
Escherichia	O
coli	O
fused	O
to	O
the	O
leader	O
sequence	O
of	O
the	O
ferredoxin	B
oxidoreductase	I
gene	O
(	O
FNR	B
)	O
from	O
Spinacea	O
oleracea	O
under	O
the	O
control	O
of	O
the	O
leaf	O
specific	O
St	O
-	O
LS1	B
promoter	O
to	O
introduce	O
a	O
novel	O
phosphate	O
pool	O
in	O
the	O
chloroplasts	O
of	O
green	O
tissues	O
.	O

Transgenic	O
plants	O
(	O
cpPPK	O
)	O
in	O
tissue	O
culture	O
developed	O
necrotic	O
lesions	O
in	O
older	O
leaves	O
and	O
showed	O
earlier	O
leaf	O
senescence	O
while	O
greenhouse	O
plants	O
showed	O
no	O
noticeable	O
phenotype	O
.	O

Leaves	O
of	O
cpPPK	O
plants	O
contained	O
less	O
starch	O
but	O
higher	O
concentrations	O
of	O
soluble	O
sugars	O
.	O

The	O
presence	O
of	O
polyphosphate	O
in	O
cpPPK	O
leaves	O
was	O
demonstrated	O
by	O
toluidine	O
blue	O
staining	O
and	O
unambiguously	O
verified	O
and	O
quantified	O
by	O
in	O
vitro	O
31P	O
-	O
NMR	O
of	O
extracts	O
.	O

Polyphosphate	O
accumulated	O
during	O
leaf	O
development	O
from	O
0.06	O
in	O
juvenile	O
leaves	O
to	O
0.83	O
mg	O
P	O
g-1	O
DW	O
in	O
old	O
leaves	O
and	O
had	O
an	O
average	O
chain	O
length	O
of	O
18	O
residues	O
in	O
mature	O
leaves	O
.	O

In	O
situ	O
31P	O
-	O
NMR	O
on	O
small	O
leaf	O
pieces	O
perfused	O
with	O
well	O
-	O
oxygenated	O
medium	O
showed	O
only	O
0.036	O
mg	O
P	O
g-1	O
DW	O
polyphosphate	O
that	O
was	O
,	O
however	O
,	O
greatly	O
increased	O
upon	O
treatment	O
with	O
50	O
mM	O
ammonium	O
sulfate	O
at	O
pH	O
7.3	O
.	O

This	O
phenomenon	O
along	O
with	O
a	O
yield	O
of	O
0.47	O
mg	O
P	O
g-1	O
DW	O
polyphosphate	O
from	O
an	O
extract	O
of	O
the	O
same	O
leaf	O
material	O
suggests	O
that	O
93	O
%	O
of	O
the	O
polyphosphate	O
pool	O
is	O
immobile	O
.	O

This	O
conclusion	O
is	O
substantiated	O
by	O
the	O
observation	O
that	O
no	O
differences	O
in	O
polyphosphate	O
pool	O
sizes	O
could	O
be	O
discerned	O
between	O
darkened	O
and	O
illuminated	O
leaves	O
,	O
leaves	O
treated	O
with	O
methylviologen	O
or	O
anaerobis	O
and	O
control	O
leaves	O
,	O
treatments	O
causing	O
a	O
change	O
in	O
the	O
pool	O
of	O
ATP	O
available	O
for	O
polyPi	O
synthesis	O
.	O

Results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
the	O
chelating	O
properties	O
of	O
polyphosphates	O
for	O
cations	O
and	O
its	O
consequences	O
for	O
the	O
partitioning	O
of	O
photoassimilate	O
between	O
starch	O
and	O
soluble	O
sugars	O
.	O

Distribution	O
of	O
PDE4A	B
and	O
G	B
(	I
o	I
)	I
alpha	I
immunoreactivity	O
in	O
the	O
accessory	O
olfactory	O
system	O
of	O
the	O
mouse	O
.	O

Distribution	O
of	O
the	O
cAMP	O
-	O
specific	O
phosphodiesterase	B
PDE4A	B
was	O
examined	O
in	O
the	O
accessory	O
olfactory	O
system	O
by	O
immunohistochemistry	O
.	O

Adjacent	O
sections	O
through	O
the	O
vomeronasal	O
organ	O
(	O
VNO	O
)	O
and	O
accessory	O
olfactory	O
bulb	O
(	O
AOB	O
)	O
were	O
alternately	O
immunostained	O
with	O
antibodies	O
against	O
PDE4A	B
or	O
the	O
G	B
-	I
protein	I
alpha	I
subunit	O
G	B
(	I
o	I
)	I
alpha	I
,	O
which	O
labels	O
basal	O
VNO	O
neurons	O
,	O
in	O
order	O
to	O
determine	O
whether	O
PDE4A	B
occurs	O
preferentially	O
in	O
one	O
of	O
two	O
segregated	O
VNO	O
pathways	O
.	O

We	O
found	O
that	O
PDE4A	B
strongly	O
labeled	O
apical	O
VNO	O
neurons	O
and	O
rostral	O
AOB	O
glomeruli	O
.	O

There	O
was	O
virtually	O
no	O
overlap	O
in	O
G	B
(	I
o	I
)	I
alpha	I
and	O
PDE4A	B
staining	O
,	O
and	O
there	O
were	O
no	O
regions	O
of	O
the	O
VNO	O
neuroepithelium	O
or	O
AOB	O
glomeruli	O
not	O
labeled	O
by	O
either	O
antibody	O
.	O

These	O
results	O
identify	O
a	O
potential	O
member	O
of	O
the	O
pheromone	O
transduction	O
cascade	O
in	O
apical	O
neurons	O
,	O
and	O
provide	O
further	O
evidence	O
that	O
the	O
VNO	O
consists	O
of	O
functionally	O
distinct	O
pathways	O
.	O

Cloning	O
and	O
characterization	O
of	O
additional	O
members	O
of	O
the	O
G	B
protein	I
-	I
coupled	I
receptor	I
family	I
.	O

A	O
search	O
of	O
the	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
database	O
retrieved	O
a	O
human	O
cDNA	O
sequence	O
which	O
partially	O
encoded	O
a	O
novel	O
G	B
protein	I
-	I
coupled	I
receptor	I
(	O
GPCR	B
)	O
GPR26	B
.	O

A	O
human	O
genomic	O
DNA	O
fragment	O
encoding	O
a	O
partial	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
and	O
a	O
rat	O
cDNA	O
encoding	O
the	O
full	O
length	O
ORF	O
of	O
GPR26	B
were	O
obtained	O
by	O
library	O
screening	O
.	O

The	O
rat	O
GPR26	B
cDNA	O
encoded	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
,	O
most	O
similar	O
(	O
albeit	O
distantly	O
related	O
)	O
to	O
the	O
serotonin	B
5-HT	I
(	I
5A	I
)	I
and	O
gastrin	B
releasing	I
hormone	I
BB2	I
receptors	I
.	O

GPR26	B
mRNA	O
expression	O
analysis	O
revealed	O
signals	O
in	O
the	O
striatum	O
,	O
pons	O
,	O
cerebellum	O
and	O
cortex	O
.	O

HEK293	O
and	O
Rh7777	O
cells	O
transfected	O
with	O
GPR26	B
cDNA	O
displayed	O
high	O
basal	O
cAMP	O
levels	O
,	O
slow	O
growth	O
rate	O
of	O
clonal	O
populations	O
and	O
derangements	O
of	O
normal	O
cell	O
shape	O
.	O

We	O
also	O
used	O
a	O
sequence	O
reported	O
only	O
in	O
the	O
patent	O
literature	O
encoding	O
GPR57	B
(	O
a.k.a	O
.	O
HNHCI32	O
)	O
to	O
PCR	O
amplify	O
a	O
DNA	O
fragment	O
which	O
was	O
used	O
to	O
screen	O
a	O
human	O
genomic	O
library	O
.	O

This	O
resulted	O
in	O
the	O
cloning	O
of	O
a	O
genomic	O
fragment	O
containing	O
a	O
pseudogene	O
,	O
psiGPR57	B
,	O
with	O
a	O
99.6	O
%	O
nucleotide	O
identity	O
to	O
GPR57	B
.	O

Based	O
on	O
shared	O
sequence	O
identities	O
,	O
the	O
receptor	O
encoded	O
by	O
GPR57	B
was	O
predicted	O
to	O
belong	O
to	O
a	O
novel	O
subfamily	O
of	O
GPCRs	B
together	O
with	O
GPR58	B
(	O
a.k.a	O
.	O
phBL5	O
,	O
reported	O
only	O
in	O
the	O
patent	O
literature	O
)	O
,	O
putative	B
neurotransmitter	I
receptor	I
(	O
PNR	B
)	O
and	O
a	O
5-HT	B
(	I
4	I
)	I
pseudogene	I
.	O

Analysis	O
of	O
this	O
subfamily	O
revealed	O
greatest	O
identities	O
(	O
approximately	O
56	O
%	O
)	O
between	O
the	O
receptors	O
encoded	O
by	O
GPR57	B
and	O
GPR58	B
,	O
each	O
with	O
shared	O
identities	O
of	O
approximately	O
40	O
%	O
with	O
PNR	B
.	O

Furthermore	O
,	O
psiGPR57	B
,	O
GPR58	B
,	O
PNR	B
and	O
the	O
5-HT	B
(	I
4	I
)	I
pseudogene	I
were	O
mapped	O
in	O
a	O
cluster	O
localized	O
to	O
chromosome	O
6q22	O
-	O
24	O
.	O

PNR	B
and	O
GPR58	B
were	O
expressed	O
in	O
COS	O
cells	O
,	O
however	O
no	O
specific	O
binding	O
was	O
observed	O
for	O
various	O
serotonin	B
receptor	I
-	O
specific	O
ligands	O
.	O

Antirestriction	B
protein	I
Ard	I
(	I
Type	I
C	I
)	I
encoded	O
by	O
IncW	O
plasmid	O
pSa	O
has	O
a	O
high	O
similarity	O
to	O
the	O
""""	O
protein	O
transport	O
""""	O
domain	O
of	O
TraC1	B
primase	I
of	O
promiscuous	O
plasmid	O
RP4	O
.	O

The	O
IncW	O
plasmid	O
pSa	O
contains	O
the	O
gene	O
ard	B
encoding	O
an	O
antirestriction	O
function	O
that	O
is	O
specific	O
for	O
type	O
I	O
restriction	O
and	O
modification	O
systems	O
.	O

The	O
nucleotide	O
sequence	O
of	O
ard	B
was	O
determined	O
and	O
an	O
appropriate	O
polypeptide	O
of	O
about	O
33	O
kDa	O
was	O
identified	O
in	O
Escherichia	O
coli	O
T7	O
expression	O
system	O
.	O

Analysis	O
of	O
deduced	O
amino	O
acid	O
sequence	O
of	O
Ard	B
encoded	O
by	O
pSa	O
revealed	O
that	O
this	O
protein	O
has	O
no	O
significant	O
similarities	O
with	O
the	O
known	O
Ard	B
proteins	O
(	O
ArdA	B
and	O
ArdB	B
types	O
)	O
except	O
the	O
""""	O
antirestriction	O
""""	O
motif	O
(	O
14	O
amino	O
acid	O
residues	O
in	O
length	O
)	O
conserved	O
for	O
all	O
known	O
Ard	B
proteins	O
.	O

This	O
finding	O
suggests	O
that	O
pSa	O
Ard	B
may	O
be	O
classified	O
as	O
a	O
new	O
type	O
of	O
Ard	B
proteins	O
which	O
we	O
designated	O
ArdC	B
.	O

The	O
remarkable	O
feature	O
of	O
ArdC	B
is	O
that	O
it	O
has	O
a	O
high	O
degree	O
of	O
similarity	O
(	O
about	O
38	O
%	O
identity	O
)	O
to	O
the	O
N	O
-	O
terminal	O
region	O
of	O
RP4	O
TraC1	B
primase	I
which	O
includes	O
about	O
300	O
amino	O
acid	O
residues	O
and	O
seems	O
to	O
be	O
essential	O
for	O
binding	O
to	O
the	O
single	O
-	O
stranded	O
DNA	O
and	O
TraC1	B
protein	O
transport	O
to	O
the	O
recipient	O
cells	O
during	O
the	O
conjugal	O
transfer	O
of	O
plasmid	O
DNA	O
.	O

ArdC	B
also	O
binds	O
to	O
single	O
-	O
stranded	O
DNA	O
.	O

In	O
addition	O
,	O
this	O
protein	O
is	O
able	O
in	O
vitro	O
to	O
protect	O
the	O
single	O
-	O
stranded	O
but	O
not	O
double	O
-	O
stranded	O
plasmid	O
DNA	O
against	O
the	O
activity	O
of	O
type	B
II	I
restriction	I
endonuclease	I
HhaI	B
that	O
cleaves	O
both	O
single	O
and	O
double	O
-	O
stranded	O
DNA	O
.	O

We	O
suggest	O
that	O
like	O
TraC1	B
,	O
ArdC	B
would	O
be	O
transported	O
as	O
a	O
result	O
of	O
their	O
interaction	O
with	O
the	O
single	O
-	O
stranded	O
DNA	O
of	O
transferred	O
plasmid	O
strand	O
during	O
conjugative	O
passage	O
through	O
the	O
cell	O
envelope	O
to	O
the	O
recipient	O
bacterium	O
.	O

Such	O
properties	O
of	O
ArdC	B
protein	O
might	O
be	O
useful	O
to	O
protect	O
immediately	O
the	O
incoming	O
single	O
-	O
stranded	O
DNA	O
from	O
the	O
host	O
endonucleases	B
.	O

Plasma	O
fibrinogen	B
,	O
haemostatic	O
factors	O
and	O
prediction	O
of	O
peripheral	O
arterial	O
disease	O
in	O
the	O
Edinburgh	O
Artery	O
Study	O
.	O

The	O
role	O
of	O
fibrinogen	B
and	O
other	O
haemostatic	O
factors	O
in	O
prediction	O
of	O
peripheral	O
arterial	O
disease	O
(	O
PAD	O
)	O
has	O
not	O
been	O
established	O
.	O

We	O
examined	O
the	O
associations	O
of	O
plasma	O
fibrinogen	B
,	O
von	B
Willebrand	I
Factor	I
(	O
vWF	B
)	O
,	O
tissue	B
plasminogen	I
activator	I
(	O
t	B
-	I
PA	I
)	O
antigen	O
,	O
fibrin	B
D	O
-	O
dimer	O
,	O
and	O
factor	B
VII	I
with	O
the	O
development	O
and	O
clinical	O
progression	O
of	O
PAD	O
.	O

In	O
the	O
Edinburgh	O
Artery	O
Study	O
,	O
1592	O
men	O
and	O
women	O
,	O
aged	O
between	O
55	O
and	O
74	O
years	O
,	O
were	O
followed	O
prospectively	O
over	O
5	O
years	O
to	O
detect	O
the	O
onset	O
of	O
PAD	O
,	O
and	O
the	O
deterioration	O
of	O
established	O
PAD	O
.	O

At	O
baseline	O
,	O
418	O
individuals	O
had	O
evidence	O
of	O
PAD	O
and	O
60	O
(	O
14.4	O
%	O
)	O
subsequently	O
deteriorated	O
.	O

1080	O
subjects	O
had	O
no	O
baseline	O
disease	O
,	O
but	O
59	O
(	O
5.5	O
%	O
)	O
developed	O
PAD	O
during	O
follow	O
-	O
up	O
.	O

Median	O
levels	O
of	O
fibrinogen	B
and	O
vWF	B
were	O
higher	O
in	O
the	O
group	O
developing	O
disease	O
compared	O
with	O
the	O
group	O
which	O
did	O
not	O
(	O
2.78	O
g	O
/	O
l	O
versus	O
2.57	O
g	O
/	O
l	O
,	O
P	O
<	O
or	O
=	O
0.01	O
;	O
116	O
IU	O
/	O
dl	O
versus	O
104	O
IU	O
/	O
dl	O
,	O
P	O
<	O
or	O
=	O
0.05	O
;	O
respectively	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
fibrinogen	B
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
and	O
vWF	B
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
were	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
developing	O
PAD	O
.	O

The	O
association	O
between	O
fibrinogen	B
and	O
development	O
of	O
disease	O
remained	O
after	O
adjusting	O
for	O
cardiovascular	O
risk	O
factors	O
and	O
baseline	O
ischaemic	O
heart	O
disease	O
(	O
relative	O
risk	O
,	O
1.35	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
1.05	O
,	O
1.73	O
;	O
P	O
<	O
or	O
=	O
0.05	O
)	O
.	O

None	O
of	O
the	O
haemostatic	O
factors	O
were	O
significantly	O
associated	O
with	O
progression	O
of	O
PAD	O
.	O

In	O
conclusion	O
,	O
plasma	O
fibrinogen	B
levels	O
are	O
related	O
to	O
the	O
future	O
onset	O
of	O
PAD	O
,	O
providing	O
further	O
evidence	O
of	O
a	O
possible	O
role	O
of	O
elevated	O
fibrinogen	B
in	O
the	O
development	O
of	O
atherosclerotic	O
disease	O
.	O

High	O
altitude	O
increases	O
circulating	O
interleukin-6	B
,	O
interleukin-1	B
receptor	I
antagonist	I
and	O
C	B
-	I
reactive	I
protein	I
.	O

Hypoxic	O
pulmonary	O
vasoconstriction	O
is	O
associated	O
with	O
but	O
may	O
not	O
be	O
sufficient	O
for	O
the	O
development	O
of	O
high	O
-	O
altitude	O
pulmonary	O
oedema	O
(	O
HAPO	O
)	O
.	O

Hypoxia	O
is	O
known	O
to	O
induce	O
an	O
inflammatory	O
response	O
in	O
immune	O
cells	O
and	O
endothelial	O
cells	O
.	O

It	O
has	O
been	O
speculated	O
that	O
hypoxia	O
-	O
induced	O
inflammatory	O
cytokines	B
at	O
high	O
altitude	O
may	O
contribute	O
to	O
the	O
development	O
of	O
HAPO	O
by	O
causing	O
capillary	O
leakage	O
in	O
the	O
lung	O
.	O

We	O
were	O
interested	O
if	O
such	O
an	O
inflammatory	O
response	O
,	O
possibly	O
involved	O
in	O
a	O
later	O
development	O
of	O
HAPO	O
,	O
is	O
detectable	O
at	O
high	O
altitude	O
in	O
individuals	O
without	O
HAPO	O
.	O

We	O
examined	O
the	O
plasma	O
levels	O
of	O
interleukin	B
6	I
(	O
IL-6	B
)	O
,	O
interleukin	B
1	I
receptor	I
antagonist	I
(	O
IL-1ra	B
)	O
and	O
C	B
-	I
reactive	I
protein	I
(	O
CRP	B
)	O
in	O
two	O
independent	O
studies	O
:	O
study	O
A	O
,	O
Jungfraujoch	O
,	O
Switzerland	O
,	O
three	O
overnight	O
stays	O
at	O
3458	O
m	O
,	O
n	O
=	O
12	O
;	O
study	O
B	O
:	O
Capanna	O
Regina	O
Margherita	O
,	O
Italy	O
,	O
3	O
overnight	O
stays	O
at	O
3647	O
m	O
and	O
one	O
overnight	O
stay	O
at	O
4559	O
m	O
,	O
n	O
=	O
10	O
.	O

In	O
both	O
studies	O
,	O
probands	O
showed	O
symptoms	O
of	O
acute	O
mountain	O
sickness	O
but	O
no	O
signs	O
of	O
HAPO	O
.	O

At	O
the	O
Jungfraujoch	O
,	O
IL-6	B
increased	O
from	O
0.1	O
+	O
/-	O
0.03	O
pg	O
/	O
ml	O
to	O
2	O
.	O

0	O
+	O
/-	O
0.5	O
pg	O
/	O
ml	O
(	O
day	O
2	O
,	O
P	O
=	O
0.03	O
)	O
,	O
IL-1ra	B
from	O
101	O
+	O
/-	O
21	O
to	O
284	O
+	O
/-	O
73	O
pg	O
/	O
ml	O
(	O
day	O
2	O
,	O
P	O
=	O
0.01	O
)	O
,	O
and	O
CRP	B
from	O
1.0	O
+	O
/-	O
0.4	O
to	O
5.8	O
+	O
/-	O
1.5	O
micrograms	O
/	O
ml	O
(	O
day	O
4	O
,	O
P	O
=	O
0.01	O
)	O
.	O

At	O
the	O
Capanna	O
Margherita	O
,	O
IL-6	B
increased	O
from	O
0	O
.	O
5	O
+	O
/-	O
0.2	O
pg	O
/	O
ml	O
to	O
2.0	O
+	O
/-	O
0.8	O
pg	O
/	O
ml	O
(	O
P	O
=	O
0.02	O
)	O
,	O
IL-1ra	B
from	O
118	O
+	O
/-	O
25	O
to	O
213	O
+	O
/-	O
28	O
pg	O
/	O
ml	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
CRP	B
from	O
0.4	O
+	O
/-	O
0.03	O
to	O
3.5	O
+	O
/-	O
1.1	O
micrograms	O
/	O
ml	O
(	O
P	O
=	O
0.03	O
)	O
.	O

IL-8	B
was	O
below	O
the	O
detection	O
limit	O
of	O
the	O
ELISA	O
(	O
<	O
25	O
pg	O
/	O
ml	O
)	O
in	O
both	O
studies	O
.	O

The	O
increase	O
of	O
IL-6	B
and	O
IL-1ra	B
in	O
response	O
to	O
high	O
altitude	O
was	O
delayed	O
and	O
preceded	O
the	O
increase	O
of	O
CRP	B
.	O

We	O
conclude	O
that	O
:	O
(	O
1	O
)	O
circulating	O
IL-6	B
,	O
IL-1ra	B
and	O
CRP	B
are	O
upregulated	O
in	O
response	O
to	O
hypobaric	O
hypoxic	O
conditions	O
at	O
high	O
altitude	O
,	O
and	O
(	O
2	O
)	O
the	O
moderate	O
systemic	O
increase	O
of	O
these	O
inflammatory	O
markers	O
may	O
reflect	O
considerable	O
local	O
inflammation	O
.	O

The	O
existence	O
and	O
the	O
kinetics	O
of	O
high	O
altitude	O
-	O
induced	O
cytokines	B
found	O
in	O
this	O
study	O
support	O
the	O
hypothesis	O
that	O
inflammation	O
is	O
involved	O
in	O
the	O
development	O
of	O
HAPO	O
.	O

Stem	B
cell	I
factor	I
(	O
SCF	B
)	O
can	O
regulate	O
the	O
activation	O
and	O
expansion	O
of	O
murine	O
intraepithelial	O
lymphocytes	O
.	O

Murine	O
intraepithelial	O
lymphocytes	O
(	O
IEL	O
)	O
express	O
c	B
-	I
kit	I
,	O
the	O
receptor	B
for	I
stem	I
cell	I
factor	I
(	O
SCF	B
)	O
.	O

SCF	B
induced	O
a	O
low	O
but	O
significant	O
proliferative	O
response	O
in	O
IEL	O
,	O
but	O
not	O
in	O
splenic	O
T	O
cells	O
.	O

SCF	B
stimulation	O
of	O
IEL	O
resulted	O
in	O
an	O
expansion	O
of	O
the	O
c	B
-	I
kit	I
(	O
+	O
)	O
,	O
TCRgammadelta	B
(	O
+	O
)	O
cell	O
population	O
.	O

SCF	B
-	O
induced	O
proliferation	O
was	O
dependent	O
upon	O
SCF	B
-	O
c	B
-	I
kit	I
interactions	O
,	O
since	O
antibody	O
to	O
c	B
-	I
kit	I
blocked	O
this	O
response	O
,	O
and	O
IEL	O
obtained	O
from	O
c	B
-	I
kit	I
mutant	O
(	O
W	O
/	O
W	O
(	O
v	O
)	O
)	O
mice	O
failed	O
to	O
respond	O
to	O
SCF	B
.	O

SCF	B
acted	O
synergistically	O
with	O
anti	O
-	O
TCRgammadelta	B
and	O
with	O
concavalin	O
A	O
(	O
Con	O
A	O
)	O
to	O
induce	O
proliferation	O
and	O
interferon	B
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
production	O
in	O
IEL	O
.	O

Finally	O
,	O
mice	O
injected	O
with	O
SCF	B
had	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
IEL	O
in	O
the	O
small	O
intestine	O
.	O

SCF	B
-	O
treated	O
mice	O
had	O
increased	O
numbers	O
of	O
TCRalphabeta	B
(	O
+	O
)	O
and	O
TCRgammadelta	B
(	O
+	O
)	O
cell	O
populations	O
,	O
as	O
well	O
as	O
increased	O
numbers	O
of	O
c	B
-	I
kit	I
(	O
+	O
)	O
and	O
c	B
-	I
kit	I
(	O
-	O
)	O
IEL	O
.	O

These	O
data	O
suggest	O
that	O
SCF	B
-	O
c	B
-	I
kit	I
interactions	O
play	O
an	O
important	O
role	O
in	O
regulating	O
IEL	O
expansion	O
and	O
activation	O
.	O

A	O
new	O
single	O
-	O
copy	O
mycobacterial	O
plasmid	O
,	O
pMF1	O
,	O
from	O
Mycobacterium	O
fortuitum	O
which	O
is	O
compatible	O
with	O
the	O
pAL5000	O
replicon	O
.	O

A	O
9.2	O
kb	O
cryptic	O
Mycobacterium	O
fortuitum	O
plasmid	O
,	O
pMF1	O
,	O
was	O
isolated	O
from	O
strain	O
110	O
and	O
its	O
restriction	O
map	O
constructed	O
.	O

A	O
4.2	O
kb	O
HindIII	B
fragment	O
of	O
pMF1	O
was	O
found	O
to	O
support	O
replication	O
in	O
mycobacteria	O
and	O
this	O
fragment	O
was	O
cloned	O
and	O
sequenced	O
to	O
characterize	O
the	O
replication	O
elements	O
of	O
the	O
plasmid	O
.	O

Computer	O
analysis	O
identified	O
a	O
putative	O
Rep	B
protein	O
(	O
362	O
amino	O
acids	O
)	O
with	O
high	O
homology	O
to	O
the	O
putative	O
Rep	B
protein	O
of	O
the	O
Mycobacterium	O
celatum	O
plasmid	O
pCLP	O
and	O
limited	O
homology	O
,	O
mostly	O
in	O
the	O
N	O
-	O
terminal	O
region	O
,	O
to	O
the	O
Rep	B
proteins	O
of	O
Mycobacterium	O
avium	O
pLR7	O
,	O
M.	O
fortuitum	O
pJAZ38	O
and	O
Mycobacterium	O
scrofulaceum	O
pMSC262	O
.	O

A	O
region	O
containing	O
a	O
putative	O
ori	O
site	O
was	O
located	O
upstream	O
of	O
the	O
rep	B
gene	O
;	O
this	O
region	O
displayed	O
high	O
homology	O
at	O
the	O
nucleotide	O
level	O
with	O
the	O
predicted	O
ori	O
of	O
pCLP	O
and	O
pJAZ38	O
.	O

A	O
plasmid	O
carrying	O
the	O
4.2	O
kb	O
HindIII	B
fragment	O
and	O
a	O
kanamycin	O
resistance	O
marker	O
,	O
designated	O
pBP4	O
,	O
was	O
maintained	O
as	O
a	O
single	O
-	O
copy	O
plasmid	O
in	O
Mycobacterium	O
smegmatis	O
and	O
was	O
stably	O
inherited	O
in	O
the	O
absence	O
of	O
antibiotic	O
selection	O
.	O

Plasmid	O
pBP4	O
was	O
incompatible	O
with	O
the	O
pJAZ38	O
replicon	O
but	O
was	O
compatible	O
with	O
the	O
widely	O
used	O
pAL5000	O
replicon	O
,	O
indicating	O
that	O
among	O
the	O
mycobacterial	O
vectors	O
now	O
available	O
there	O
are	O
two	O
incompatibility	O
groups	O
.	O

Significantly	O
,	O
the	O
plasmid	O
was	O
able	O
to	O
replicate	O
in	O
the	O
pathogen	O
Mycobacterium	O
tuberculosis	O
,	O
making	O
it	O
a	O
useful	O
tool	O
for	O
gene	O
expression	O
studies	O
.	O

To	O
provide	O
a	O
choice	O
of	O
restriction	O
sites	O
and	O
easy	O
manipulation	O
,	O
a	O
2.1	O
kb	O
fragment	O
containing	O
the	O
minimal	O
replication	O
region	O
was	O
cloned	O
to	O
make	O
the	O
mycobacterial	O
shuttle	O
vector	O
pBP10	O
,	O
which	O
showed	O
similar	O
stability	O
to	O
pBP4	O
.	O

Agonist	O
peptide	O
from	O
a	O
cytotoxic	O
t	O
-	O
lymphocyte	O
epitope	O
of	O
human	O
carcinoembryonic	B
antigen	I
stimulates	O
production	O
of	O
tc1	O
-	O
type	O
cytokines	B
and	O
increases	O
tyrosine	O
phosphorylation	O
more	O
efficiently	O
than	O
cognate	O
peptide	O
.	O

The	O
identification	O
of	O
an	O
agonist	O
peptide	O
(	O
YLSGADLNL	O
,	O
designated	O
CAP1	O
-	O
6D	O
)	O
to	O
an	O
immunodominant	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
epitope	O
(	O
designated	O
CAP1	O
)	O
of	O
human	O
carcinoembryonic	B
antigen	I
(	O
CEA	B
)	O
has	O
previously	O
been	O
reported	O
.	O

The	O
agonist	O
peptide	O
harbors	O
a	O
single	O
amino	O
acid	O
substitution	O
at	O
a	O
non	O
-	O
MHC	B
anchor	O
residue	O
and	O
is	O
proposed	O
to	O
exert	O
its	O
effects	O
at	O
the	O
level	O
of	O
the	O
T	B
-	I
cell	I
receptor	I
(	O
TCR	B
)	O
.	O

The	O
type	O
and	O
magnitude	O
of	O
cytokines	B
produced	O
by	O
CAP1	O
-	O
reactive	O
CTL	O
upon	O
stimulation	O
with	O
the	O
agonist	O
peptide	O
,	O
CAP1	O
-	O
6D	O
,	O
were	O
compared	O
to	O
those	O
obtained	O
upon	O
stimulation	O
with	O
the	O
cognate	O
CAP1	O
peptide	O
.	O

In	O
addition	O
,	O
early	O
events	O
in	O
the	O
TCR	B
signaling	O
pathway	O
were	O
examined	O
for	O
differences	O
in	O
tyrosine	O
phosphorylation	O
.	O

Upon	O
stimulation	O
with	O
the	O
agonist	O
peptide	O
CAP1	O
-	O
6D	O
,	O
several	O
different	O
CEA	B
-	O
specific	O
CTL	O
lines	O
exhibited	O
a	O
marked	O
shift	O
in	O
the	O
peptide	O
dose	O
response	O
,	O
which	O
resulted	O
in	O
as	O
much	O
as	O
a	O
1,000	O
-	O
fold	O
increase	O
in	O
the	O
levels	O
of	O
GM	B
-	I
CSF	I
and	O
gamma	B
-	I
IFN	I
produced	O
as	O
compared	O
with	O
the	O
use	O
of	O
the	O
CAP1	O
peptide	O
.	O

However	O
,	O
levels	O
of	O
IL-4	B
and	O
IL	B
-	I
10	I
,	O
which	O
are	O
associated	O
with	O
anti	O
-	O
inflammatory	O
effects	O
,	O
were	O
very	O
low	O
or	O
non	O
-	O
existent	O
.	O

The	O
cytokine	B
profile	O
of	O
CAP1	O
-	O
and	O
CAP1	O
-	O
6D	O
-	O
specific	O
CTL	O
is	O
consistent	O
with	O
a	O
Tc1	O
-	O
type	O
CTL	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
CEA	B
-	O
specific	O
CTL	O
showed	O
increased	O
tyrosine	O
phosphorylation	O
of	O
TCR	B
signaling	O
proteins	O
ZAP	B
-	I
70	I
and	O
TCR	B
zeta	I
chains	O
in	O
response	O
to	O
both	O
peptides	O
.	O

However	O
,	O
when	O
CAP1	O
-	O
6D	O
was	O
compared	O
with	O
the	O
wild	O
-	O
type	O
peptide	O
,	O
the	O
increase	O
in	O
ZAP	B
-	I
70	I
phosphorylation	O
was	O
greater	O
than	O
the	O
increase	O
in	O
zeta	O
phosphorylation	O
.	O

CTL	O
generated	O
with	O
the	O
CAP1	O
-	O
6D	O
agonist	O
were	O
shown	O
capable	O
of	O
lysis	O
of	O
human	O
carcinoma	O
cells	O
expressing	O
native	O
CEA	B
.	O

The	O
ability	O
to	O
upregulate	O
the	O
production	O
of	O
GM	B
-	I
CSF	I
,	O
gamma	B
-	I
IFN	I
,	O
TNFalpha	B
and	O
IL-2	B
with	O
the	O
agonist	O
peptide	O
,	O
as	O
compared	O
with	O
CAP1	O
,	O
may	O
help	O
in	O
initiating	O
or	O
sustaining	O
anti	O
-	O
tumor	O
immune	O
responses	O
and	O
thus	O
potentially	O
prove	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
CEA	B
-	O
positive	O
tumors	O
.	O

Bone	B
morphogenetic	I
protein	I
receptor	I
complexes	O
on	O
the	O
surface	O
of	O
live	O
cells	O
:	O
a	O
new	O
oligomerization	O
mode	O
for	O
serine	B
/	I
threonine	I
kinase	I
receptors	I
.	O

The	O
bone	B
morphogenetic	I
proteins	I
(	O
BMPs	B
)	O
play	O
important	O
roles	O
in	O
embryogenesis	O
and	O
normal	O
cell	O
growth	O
.	O

The	O
BMP	B
receptors	I
belong	O
to	O
the	O
family	B
of	I
serine	I
/	I
threonine	I
kinase	I
receptors	I
,	O
whose	O
activation	O
has	O
been	O
investigated	O
intensively	O
for	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	I
TGF	I
-	I
beta	I
)	I
receptor	I
subfamily	I
.	O

However	O
,	O
the	O
interactions	O
between	O
the	O
BMP	B
receptors	I
,	O
the	O
composition	O
of	O
the	O
active	O
receptor	O
complex	O
,	O
and	O
the	O
role	O
of	O
the	O
ligand	O
in	O
its	O
formation	O
have	O
not	O
yet	O
been	O
investigated	O
and	O
were	O
usually	O
assumed	O
to	O
follow	O
the	O
same	O
pattern	O
as	O
the	O
TGF	B
-	I
beta	I
receptors	I
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
oligomerization	O
pattern	O
of	O
the	O
BMP	B
receptors	I
is	O
different	O
and	O
is	O
more	O
flexible	O
and	O
susceptible	O
to	O
modulation	O
by	O
ligand	O
.	O

Using	O
several	O
complementary	O
approaches	O
,	O
we	O
investigated	O
the	O
formation	O
of	O
homomeric	O
and	O
heteromeric	O
complexes	O
between	O
the	O
two	O
known	O
BMP	B
type	I
I	I
receptors	I
(	O
BR	B
-	I
Ia	I
and	O
BR	B
-	I
Ib	I
)	O
and	O
the	O
BMP	B
type	I
II	I
receptor	I
(	O
BR	B
-	I
II	I
)	O
.	O

Coimmunoprecipitation	O
studies	O
detected	O
the	O
formation	O
of	O
heteromeric	O
and	O
homomeric	O
complexes	O
among	O
all	O
the	O
BMP	B
receptor	I
types	O
even	O
in	O
the	O
absence	O
of	O
ligand	O
.	O

These	O
complexes	O
were	O
also	O
detected	O
at	O
the	O
cell	O
surface	O
after	O
BMP-2	B
binding	O
and	O
cross	O
-	O
linking	O
.	O

Using	O
antibody	O
-	O
mediated	O
immunofluorescence	O
copatching	O
of	O
epitope	O
-	O
tagged	O
receptors	O
,	O
we	O
provide	O
evidence	O
in	O
live	O
cells	O
for	O
preexisting	O
heteromeric	O
(	O
BR	B
-	I
II	I
/	O
BR	B
-	I
Ia	I
and	O
BR	B
-	I
II	I
/	O
BR	B
-	I
Ib	I
)	O
and	O
homomeric	O
(	O
BR	B
-	I
II	I
/	O
BR	B
-	I
II	I
,	O
BR	B
-	I
Ia	I
/	O
BR	B
-	I
Ia	I
,	O
BR	B
-	I
Ib	I
/	O
BR	B
-	I
Ib	I
,	O
and	O
also	O
BR	B
-	I
Ia	I
/	O
BR	B
-	I
Ib	I
)	O
oligomers	O
in	O
the	O
absence	O
of	O
ligand	O
.	O

BMP-2	B
binding	O
significantly	O
increased	O
hetero	O
-	O
and	O
homo	O
-	O
oligomerization	O
(	O
except	O
for	O
the	O
BR	B
-	I
II	I
homo	O
-	O
oligomer	O
,	O
which	O
binds	O
ligand	O
poorly	O
in	O
the	O
absence	O
of	O
BR	B
-	I
I	I
)	O
.	O

In	O
contrast	O
to	O
previous	O
observations	O
on	O
TGF	B
-	I
beta	I
receptors	I
,	O
which	O
were	O
found	O
to	O
be	O
fully	O
homodimeric	O
in	O
the	O
absence	O
of	O
ligand	O
,	O
the	O
BMP	O
receptors	O
show	O
a	O
much	O
more	O
flexible	O
oligomerization	O
pattern	O
.	O

This	O
novel	O
feature	O
in	O
the	O
oligomerization	O
mode	O
of	O
the	O
BMP	B
receptors	I
allows	O
higher	O
variety	O
and	O
flexibility	O
in	O
their	O
responses	O
to	O
various	O
ligands	O
as	O
compared	O
with	O
the	O
TGF	B
-	I
beta	I
receptors	I
.	O

Modulation	O
of	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
responses	O
by	O
dietary	O
lutein	O
in	O
cats	O
.	O

The	O
immuno	O
-	O
modulatory	O
role	O
of	O
dietary	O
lutein	O
in	O
domestic	O
cats	O
is	O
unknown	O
.	O

Female	O
Tabby	O
cats	O
(	O
10	O
-	O
month	O
old	O
;	O
n	O
=	O
56	O
)	O
were	O
supplemented	O
daily	O
for	O
12	O
weeks	O
with	O
0	O
,	O
1	O
,	O
5	O
or	O
10	O
mg	O
lutein	O
.	O

Blood	O
was	O
collected	O
on	O
Weeks	O
0	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
12	O
to	O
assess	O
the	O
following	O
:	O
(	O
1	O
)	O
mitogen	O
-	O
induced	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
proliferation	O
,	O
(	O
2	O
)	O
changes	O
in	O
PBMC	O
subpopulations	O
,	O
(	O
3	O
)	O
interleukin-2	B
(	O
IL-2	B
)	O
production	O
and	O
(	O
4	O
)	O
plasma	O
immunoglobulin	B
(	I
Ig	I
)	I
G	I
production	O
.	O

In	O
addition	O
,	O
delayed	O
-	O
type	O
hypersensitivity	O
(	O
DTH	O
)	O
response	O
to	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
or	O
a	O
polyvalent	O
vaccine	O
was	O
performed	O
on	O
Weeks	O
0	O
,	O
6	O
and	O
12	O
.	O

Dietary	O
lutein	O
increased	O
plasma	O
lutein	O
concentrations	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
p	O
<	O
0.001	O
)	O
and	O
concentrations	O
had	O
not	O
reached	O
steady	O
state	O
after	O
12	O
weeks	O
of	O
feeding	O
in	O
cats	O
given	O
5	O
or	O
10	O
mg	O
lutein	O
.	O

Concentrations	O
of	O
plasma	O
retinol	O
and	O
alpha	O
-	O
tocopherol	O
were	O
not	O
influenced	O
by	O
diet	O
.	O

The	O
DTH	O
response	O
to	O
vaccine	O
but	O
not	O
to	O
Con	O
A	O
increased	O
(	O
p	O
<	O
0.05	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
on	O
Week	O
6	O
.	O

Compared	O
to	O
control	O
,	O
cats	O
fed	O
lutein	O
also	O
showed	O
enhanced	O
Con	O
A	O
-	O
and	O
pokeweed	O
mitogen	O
-	O
stimulated	O
PBMCs	O
proliferation	O
.	O

Dietary	O
lutein	O
also	O
increased	O
the	O
percentages	O
of	O
CD4	B
+	O
and	O
CD21	B
+	O
lymphocytes	O
on	O
Week	O
12	O
but	O
had	O
no	O
significant	O
effect	O
on	O
pan	O
T	O
,	O
CD8	B
and	O
MHC	B
class	I
II	I
markers	O
.	O

Plasma	O
IgG	B
was	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
in	O
cats	O
fed	O
10	O
mg	O
lutein	O
on	O
Weeks	O
8	O
and	O
12	O
.	O

These	O
results	O
support	O
the	O
immuno	O
-	O
modulatory	O
action	O
of	O
lutein	O
in	O
domestic	O
cats	O
.	O

Nucleotide	O
sequence	O
and	O
differential	O
expression	O
of	O
the	O
human	O
3-phosphoglycerate	B
dehydrogenase	I
gene	O
.	O

The	O
nucleotide	O
sequence	O
of	O
Hs	O
3-PGDH	B
gene	O
,	O
encoding	O
human	O
3-phosphoglycerate	B
dehydrogenase	I
that	O
catalyzes	O
the	O
initiating	O
step	O
in	O
the	O
phosphorylated	O
pathway	O
of	O
serine	O
biosynthesis	O
,	O
has	O
been	O
determined	O
.	O

The	O
3-PGDH	B
gene	O
has	O
a	O
predicted	O
533	O
amino	O
acid	O
open	O
reading	O
frame	O
,	O
encoding	O
a	O
56.8kDa	O
protein	O
that	O
shares	O
94.0	O
%	O
similarity	O
with	O
rat	O
-	O
liver	O
3-PGDH	B
.	O

Two	O
different	O
transcripts	O
corresponding	O
to	O
3-PGDH	B
mRNA	O
were	O
detected	O
in	O
human	O
normal	O
tissues	O
.	O

A	O
dominant	O
2.1	O
kb	O
transcript	O
was	O
expressed	O
at	O
high	O
levels	O
in	O
prostate	O
,	O
testis	O
,	O
ovary	O
,	O
brain	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
pancreas	O
,	O
and	O
weakly	O
expressed	O
in	O
thymus	O
,	O
colon	O
,	O
and	O
heart	O
.	O

A	O
710bp	O
transcript	O
also	O
appeared	O
as	O
a	O
weaker	O
band	O
where	O
the	O
2.1	O
kb	O
mRNA	O
was	O
expressed	O
,	O
and	O
it	O
was	O
more	O
significant	O
than	O
the	O
2.1	O
kb	O
mRNA	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

The	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
U937	O
,	O
which	O
also	O
resulted	O
in	O
growth	O
arrest	O
,	O
abruptly	O
downregulated	O
the	O
expression	O
of	O
3-PGDH	B
.	O

Removal	O
of	O
TPA	O
restored	O
cell	O
growth	O
through	O
the	O
retrodifferentiation	O
process	O
and	O
subsequent	O
expression	O
of	O
3-PGDH	B
.	O

The	O
3-PGDH	B
mRNA	O
was	O
markedly	O
expressed	O
in	O
human	O
leukemias	O
,	O
lymphoma	O
Sup	O
-	O
T1	O
,	O
colon	O
adenocarcinoma	O
COLO	O
320DM	O
,	O
epitheloid	O
carcinoma	O
HeLa	O
S3	O
,	O
and	O
murine	O
lymphoma	O
BW5147.G.1.4	O
,	O
but	O
not	O
in	O
human	O
leukemia	O
K562	O
.	O

This	O
report	O
demonstrates	O
that	O
the	O
human	O
3-PGDH	B
gene	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
depending	O
on	O
tissue	O
specificty	O
and	O
cellular	O
proliferative	O
status	O
,	O
and	O
its	O
transcriptional	O
regulation	O
mechanism	O
may	O
be	O
a	O
useful	O
target	O
for	O
diagnosis	O
and	O
therapy	O
of	O
cancer	O
.	O

Partial	O
IFN	B
-	I
alpha	I
/	I
beta	I
and	I
IFN	I
-	I
gamma	I
receptor	I
knockout	O
trisomy	O
16	O
mouse	O
fetuses	O
show	O
improved	O
growth	O
and	O
cultured	O
neuron	O
viability	O
.	O

The	O
trisomy	O
16	O
mouse	O
fetus	O
is	O
a	O
well	O
-	O
studied	O
model	O
for	O
Down	O
syndrome	O
(	O
trisomy	O
21	O
)	O
,	O
the	O
leading	O
genetic	O
cause	O
of	O
mental	O
retardation	O
in	O
the	O
newborn	O
population	O
.	O

Human	O
chromosome	O
21	O
and	O
mouse	O
chromosome	O
16	O
each	O
carry	O
a	O
large	O
cluster	O
of	O
genes	O
that	O
code	O
for	O
components	O
of	O
the	O
interferon	B
(	I
IFN	I
)	I
-alpha	I
/	I
beta	I
and	I
IFN	I
-	I
gamma	I
receptors	I
,	O
and	O
Down	O
syndrome	O
cells	O
display	O
significantly	O
increased	O
sensitivity	O
to	O
IFN	B
action	O
.	O

We	O
have	O
previously	O
reported	O
that	O
in	O
utero	O
anti	O
-	O
IFN	B
IgG	B
treatment	O
of	O
mice	O
pregnant	O
with	O
trisomy	O
16	O
fetuses	O
results	O
in	O
a	O
significant	O
improvement	O
in	O
trisomy	O
16	O
fetus	O
growth	O
and	O
morphology	O
and	O
that	O
anti	O
-	O
IFN	B
-	I
gamma	I
IgG	B
treatment	O
can	O
prevent	O
the	O
premature	O
death	O
of	O
trisomy	O
16	O
fetal	O
mouse	O
cortical	O
neurons	O
in	O
culture	O
.	O

We	O
have	O
now	O
used	O
IFN	B
receptor	I
subunit	O
knockout	O
mice	O
to	O
produce	O
mouse	O
fetuses	O
that	O
carry	O
three	O
No.	O
16	O
chromosomes	O
and	O
one	O
copy	O
each	O
of	O
disabled	O
IFN	B
-	I
gamma	I
receptor	I
(	O
IFNGR	B
)	O
and	O
IFN	B
-	I
alpha	I
/	I
beta	I
receptor	I
(	O
IFNAR-2	B
)	O
component	O
genes	O
.	O

We	O
report	O
here	O
that	O
this	O
partial	O
IFN	B
receptor	I
knockout	O
trisomy	O
(	O
PIRKOT	O
)	O
mouse	O
fetus	O
has	O
significantly	O
improved	O
growth	O
and	O
yields	O
cortical	O
neurons	O
whose	O
viability	O
is	O
the	O
equivalent	O
of	O
that	O
seen	O
in	O
their	O
euploid	O
counterparts	O
.	O

Corrective	O
effects	O
of	O
interleukin-12	B
on	O
age	O
-	O
related	O
deficiencies	O
in	O
IFN	B
-	I
gamma	I
production	O
and	O
IL-12Rbeta2	B
expression	O
in	O
virus	O
-	O
specific	O
CD8	B
+	O
T	O
cells	O
.	O

Interleukin-12	B
receptor	I
beta2	I
(	O
IL-12Rbeta2	B
)	O
has	O
been	O
shown	O
to	O
be	O
selectively	O
expressed	O
on	O
Th1	O
T	O
cell	O
subsets	O
,	O
and	O
we	O
have	O
previously	O
shown	O
that	O
influenza	O
-	O
specific	O
CD8	B
+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
deficiency	O
in	O
old	O
mice	O
was	O
associated	O
with	O
deficient	O
Th1	O
(	O
interferon	B
-	I
gamma	I
[	O
IFN	B
-	I
gamma	I
]	I
)	I
cytokine	B
production	O
.	O

This	O
study	O
tested	O
whether	O
IL-12Rbeta2	B
expression	O
was	O
also	O
deficient	O
in	O
CD8	B
+	O
CTL	O
from	O
old	O
mice	O
and	O
the	O
effect	O
of	O
IL-12	B
treatment	O
on	O
these	O
responses	O
.	O

Splenic	O
lymphocytes	O
from	O
influenza	O
-	O
primed	O
old	O
and	O
young	O
BALB	O
/	O
c	O
mice	O
were	O
stimulated	O
with	O
influenza	O
virus	O
in	O
vitro	O
with	O
and	O
without	O
IL-12	B
and	O
then	O
enriched	O
for	O
CD8	B
+	O
T	O
cells	O
.	O

IFN	B
-	I
gamma	I
was	O
significantly	O
reduced	O
,	O
whereas	O
IL-4	B
and	O
IL-12p40	B
(	O
an	O
antagonist	O
of	O
IL-12	B
function	O
)	O
were	O
evaluated	O
in	O
old	O
when	O
compared	O
with	O
young	O
mice	O
.	O

This	O
was	O
true	O
for	O
secreted	O
protein	O
measured	O
by	O
ELISA	O
and	O
for	O
mRNA	O
levels	O
quantitated	O
by	O
RT	O
-	O
PCR	O
.	O

IL-12Rbeta2	B
mRNA	O
expression	O
in	O
CD8	B
+	O
CTL	O
was	O
also	O
significantly	O
reduced	O
in	O
old	O
mice	O
.	O

IL-12	B
treatment	O
in	O
vitro	O
caused	O
significant	O
upregulation	O
of	O
IFN	B
-	I
gamma	I
and	O
IL-12Rbeta2	B
and	O
downregulation	O
of	O
IL-4	B
in	O
CD8	B
+	O
T	O
cells	O
from	O
old	O
mice	O
and	O
young	O
mice	O
.	O

The	O
present	O
demonstration	O
of	O
an	O
age	O
-	O
related	O
downregulation	O
in	O
IL-12Rbeta2	B
expression	O
and	O
our	O
previous	O
data	O
showing	O
reduced	O
IFN	B
-	I
gamma	I
and	O
elevated	O
IL-4	B
production	O
provide	O
strong	O
evidence	O
that	O
CD8	B
+	O
CTL	O
deficiency	O
in	O
aging	O
results	O
from	O
a	O
Th1	O
/	O
Th2	O
cytokine	B
production	O
switch	O
.	O

Agents	O
that	O
increase	O
IL-12Rbeta2	B
expression	O
and	O
redirect	O
Th2	O
to	O
Thl	O
immune	O
responses	O
are	O
likely	O
to	O
enhance	O
CD8	B
+	O
CTL	O
-	O
mediated	O
control	O
of	O
viral	O
infections	O
in	O
aging	O
.	O

Recombinant	O
expression	O
and	O
neutralizing	O
activity	O
of	O
an	O
MHC	B
class	I
II	I
binding	O
epitope	O
of	O
toxic	B
shock	I
syndrome	I
toxin-1	I
.	O

Toxic	O
shock	O
syndrome	O
(	O
TSS	O
)	O
is	O
caused	O
by	O
the	O
staphylococcal	O
superantigen	B
,	O
TSST-1	B
.	O

The	O
MHC	B
class	I
II	I
binding	O
domain	O
of	O
TSST-1	B
containing	O
a	O
conserved	O
sequence	O
with	O
other	O
related	O
staphylococcal	O
enterotoxins	O
,	O
comprising	O
TSST	B
-	I
1	I
residues	O
47	O
-	O
64	O
[	O
(	O
T	O
(	O
47	O
-	O
64	O
)	O
]	O
,	O
was	O
expressed	O
as	O
a	O
fusion	O
protein	O
with	O
either	O
glutathione	B
-	I
S	I
-	I
transferase	I
(	O
GST	B
(	O
47	O
-	O
64	O
)	O
)	O
,	O
filamentous	O
phage	O
coat	B
protein	I
(	O
pIII	O
(	O
47	O
-	O
64	O
)	O
)	O
,	O
or	O
E.	O
coli	O
outer	O
membrane	O
porin	B
protein	O
(	O
OprF	B
(	O
47	O
-	O
64	O
)	O
)	O
,	O
or	O
synthesized	O
as	O
a	O
peptide	O
conjugated	O
to	O
bovine	O
serum	B
albumin	I
,	O
BSA	B
(	O
47	O
-	O
64	O
)	O
.	O
GST	B
(	O
47	O
-	O
64	O
)	O
,	O
OprF	B
(	O
47	O
-	O
64	O
)	O
and	O
BSA	B
(	O
47	O
-	O
64	O
)	O
,	O
but	O
not	O
pIII	O
(	O
47	O
-	O
64	O
)	O
,	O
all	O
induced	O
high	O
-	O
titer	O
T	O
(	O
47	O
-	O
64	O
)	O
-	O
specific	O
antibodies	O
in	O
Balb	O
/	O
c	O
mice	O
.	O
However	O
,	O
only	O
anti	O
-	O
GST	B
(	O
47	O
-	O
64	O
)	O
antibodies	O
inhibited	O
(	O
125	O
)	O
I	O
-	O
TSST	B
-	I
1	I
binding	O
to	O
MHC	B
class	I
II	I
and	O
abrogated	O
TSST	B
-	I
1	I
-	O
induced	O
T	O
cell	O
mitogenesis	O
and	O
TNFalpha	B
secretion	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Purified	O
GST	B
(	O
47	O
-	O
64	O
)	O
also	O
inhibited	O
(	O
125	O
)	O
I	O
-	O
TSST	B
-	I
1	I
binding	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
findings	O
suggest	O
that	O
GST	B
(	O
47	O
-	O
64	O
)	O
may	O
have	O
potential	O
as	O
a	O
recombinant	O
peptide	O
vaccine	O
or	O
TSST	B
-	I
1	I
receptor	O
inhibitor	O
against	O
TSS	O
.	O

Glycochelates	O
and	O
the	O
etiology	O
of	O
diabetic	O
peripheral	O
neuropathy	O
.	O

People	O
with	O
diabetes	O
are	O
prone	O
to	O
develop	O
peripheral	O
vascular	O
and	O
nerve	O
abnormalities	O
which	O
,	O
in	O
extreme	O
cases	O
,	O
can	O
lead	O
to	O
limb	O
amputations	O
.	O

Although	O
numerous	O
theories	O
have	O
been	O
advanced	O
for	O
these	O
complications	O
,	O
no	O
firm	O
explanation	O
is	O
yet	O
available	O
.	O

Recently	O
,	O
evidence	O
has	O
appeared	O
suggesting	O
that	O
these	O
vascular	O
and	O
nerve	O
abnormalities	O
may	O
involve	O
transition	O
metals	O
;	O
administration	O
of	O
chelators	O
such	O
as	O
desferrioxamine	O
has	O
been	O
shown	O
to	O
prevent	O
or	O
actually	O
reverse	O
slowed	O
peripheral	O
nerve	O
conduction	O
and	O
neuronal	O
blood	O
flow	O
,	O
as	O
well	O
as	O
impaired	O
endothelium	O
-	O
dependent	O
arterial	O
relaxation	O
.	O

Here	O
,	O
we	O
argue	O
that	O
(	O
i	O
)	O
the	O
heavily	O
glycated	O
proteins	O
known	O
to	O
accumulate	O
in	O
people	O
with	O
diabetes	O
gain	O
an	O
increased	O
affinity	O
for	O
transition	O
metals	O
such	O
as	O
iron	O
and	O
copper	O
,	O
(	O
ii	O
)	O
as	O
a	O
result	O
,	O
proteins	O
such	O
as	O
elastin	B
and	O
collagen	B
within	O
the	O
arterial	O
wall	O
-	O
which	O
are	O
known	O
to	O
be	O
particularly	O
heavily	O
glycosylated	O
in	O
diabetes	O
-	O
may	O
accumulate	O
bound	O
metal	O
,	O
especially	O
copper	O
,	O
(	O
iii	O
)	O
the	O
bound	O
metal	O
causes	O
the	O
catalytic	O
destruction	O
of	O
endothelium	O
derived	O
relaxing	O
factor	O
(	O
nitric	O
oxide	O
or	O
a	O
derivative	O
thereof	O
)	O
,	O
thereby	O
engendering	O
a	O
state	O
of	O
chronic	O
vasoconstriction	O
.	O

The	O
resulting	O
impairment	O
of	O
blood	O
flow	O
to	O
peripheral	O
nerves	O
restricts	O
the	O
delivery	O
of	O
oxygen	O
and	O
nutrients	O
and	O
,	O
in	O
extremis	O
,	O
nerve	O
death	O
eventuates	O
.	O

If	O
this	O
hypothesis	O
is	O
proved	O
correct	O
,	O
there	O
are	O
important	O
implications	O
for	O
the	O
development	O
of	O
novel	O
pharmaceuticals	O
for	O
the	O
treatment	O
of	O
diabetic	O
peripheral	O
neuropathy	O
.	O

Single	O
effects	O
of	O
apolipoprotein	B
B	I
,	I
(	I
a	I
)	I
,	I
and	I
E	I
polymorphisms	O
and	O
interaction	O
between	O
plasminogen	B
activator	I
inhibitor-1	I
and	O
apolipoprotein	B
(	I
a	I
)	I
genotypes	O
and	O
the	O
risk	O
of	O
coronary	O
artery	O
disease	O
in	O
Czech	O
male	O
caucasians	O
.	O

To	O
evaluate	O
whether	O
polymorphisms	O
in	O
genes	O
whose	O
products	O
are	O
involved	O
in	O
lipid	O
metabolism	O
and	O
fibrinolysis	O
alter	O
the	O
risk	O
of	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
,	O
allele	O
frequencies	O
of	O
four	O
genetic	O
polymorphisms	O
were	O
ascertained	O
by	O
PCR	O
-	O
based	O
methods	O
in	O
175	O
Czech	O
male	O
patients	O
with	O
coronary	O
artery	O
disease	O
and	O
in	O
222	O
Czech	O
men	O
with	O
no	O
symptoms	O
of	O
CAD	O
.	O

The	O
following	O
polymorphisms	O
were	O
studied	O
:	O
apolipoprotein	B
B	I
(	O
apo	B
B	I
)	O
signal	O
peptide	O
insertion	O
/	O
deletion	O
polymorphism	O
,	O
5	O
'	O
apolipoprotein	B
(	I
a	I
)	I
[	O
apo	B
(	I
a	I
)	I
]	O

TTTTA	O
repeat	O
polymorphism	O
,	O
apolipoprotein	B
E	I
(	O
apo	B
E	I
)	O
varepsilon2	O
,	O
varepsilon3	O
,	O
varepsilon4	O
polymorphism	O
,	O
and	O
plasminogen	B
activator	I
inhibitor-1	I
(	O
PAI-1	B
)	O
4	O
G	O
/	O
5	O
G	O
promoter	O
polymorphism	O
.	O

Apo	B
B	I
and	O
apo	B
(	I
a	I
)	I
allele	O
frequencies	O
differed	O
significantly	O
between	O
the	O
CAD	O
and	O
the	O
control	O
groups	O
(	O
P	O
<	O
0.01	O
each	O
)	O
,	O
with	O
higher	O
frequencies	O
of	O
apo	B
B	I
deletion	O
and	O
apo	B
(	I
a	I
)	I
shorter	O
repeat	O
alleles	O
in	O
the	O
CAD	O
group	O
.	O

We	O
did	O
not	O
observe	O
any	O
differences	O
in	O
allele	O
frequencies	O
of	O
either	O
PAI-1	B
or	O
apo	B
E	I
polymorphisms	O
but	O
the	O
genotype	O
frequencies	O
of	O
apo	B
E	I
were	O
slightly	O
different	O
between	O
the	O
two	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
we	O
observed	O
a	O
gene	O
-	O
gene	O
interaction	O
between	O
the	O
PAI-1	B
and	O
apo	B
(	I
a	I
)	I
polymorphisms	O
with	O
respect	O
to	O
the	O
risk	O
of	O
CAD	O
.	O

None	O
of	O
the	O
polymorphisms	O
studied	O
were	O
associated	O
with	O
the	O
severity	O
of	O
CAD	O
or	O
a	O
history	O
of	O
myocardial	O
infarction	O
.	O

Our	O
findings	O
support	O
the	O
idea	O
that	O
several	O
polymorphisms	O
in	O
apolipoprotein	B
genes	O
may	O
by	O
themselves	O
and/or	O
in	O
interaction	O
with	O
other	O
polymorphisms	O
contribute	O
to	O
risk	O
factors	O
for	O
CAD	O
in	O
men	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
novel	O
histone	B
acetyltransferase	I
homologue	O
from	O
the	O
protozoan	O
parasite	O
Toxoplasma	O
gondii	O
reveals	O
a	O
distinct	O
GCN5	B
family	I
member	O
.	O

In	O
an	O
effort	O
to	O
identify	O
gene	O
products	O
involved	O
in	O
transcriptional	O
regulation	O
in	O
apicomplexan	O
parasites	O
,	O
the	O
Toxoplasma	O
gondii	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
database	O
was	O
examined	O
for	O
sequences	O
containing	O
similarity	O
to	O
known	O
transcriptional	O
components	O
.	O

One	O
EST	O
(	O
dbEST	O
ID	O
#	O
466792	O
)	O
exhibited	O
strong	O
similarity	O
to	O
yeast	O
GCN5	B
and	O
other	O
histone	B
acetyltransferases	I
(	O
HATs	B
)	O
.	O

Primers	O
were	O
designed	O
based	O
on	O
the	O
EST	O
sequence	O
and	O
used	O
to	O
amplify	O
an	O
850	O
bp	O
fragment	O
(	O
containing	O
an	O
intron	O
)	O
from	O
T.	O
gondii	O
genomic	O
DNA	O
which	O
was	O
used	O
to	O
identify	O
four	O
cDNA	O
clones	O
from	O
a	O
tachyzoite	O
cDNA	O
library	O
.	O

The	O
complete	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
3.5	O
kb	O
was	O
elucidated	O
using	O
5	O
'	O
RACE	O
and	O
genomic	O
sequence	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
coding	O
region	O
shows	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
possesses	O
unequivocal	O
similarity	O
to	O
GCN5	B
family	I
members	O
.	O

However	O
,	O
unlike	O
other	O
lower	O
eukaryotes	O
,	O
T.	O
gondii	O
GCN5	B
has	O
an	O
extended	O
N	O
-	O
terminal	O
domain	O
similar	O
in	O
length	O
,	O
but	O
not	O
in	O
composition	O
,	O
to	O
metazoan	O
HAT	B
proteins	O
.	O

These	O
features	O
distinguish	O
T.	O
gondii	O
GCN5	B
as	O
a	O
novel	O
member	O
of	O
the	O
GCN5	B
family	I
.	O

A	O
portion	O
of	O
the	O
cDNA	O
sequence	O
was	O
used	O
as	O
a	O
probe	O
to	O
isolate	O
three	O
overlapping	O
clones	O
from	O
a	O
T.	O
gondii	O
genomic	O
library	O
,	O
generating	O
a	O
approximately	O
7.5	O
kb	O
map	O
of	O
the	O
GCN5	B
locus	O
which	O
contains	O
seven	O
exons	O
separated	O
by	O
six	O
introns	O
.	O

Southern	O
analysis	O
verifies	O
the	O
predicted	O
map	O
and	O
suggests	O
that	O
a	O
similar	O
locus	O
may	O
be	O
present	O
elsewhere	O
in	O
the	O
genome	O
.	O

Relationship	O
between	O
ataxin-1	B
nuclear	O
inclusions	O
and	O
Purkinje	O
cell	O
specific	O
proteins	O
in	O
SCA-1	O
transgenic	O
mice	O
.	O

Spinocerebellar	O
ataxia-1	O
(	O
SCA-1	O
)	O
,	O
like	O
other	O
polyglutamine	O
diseases	O
,	O
is	O
associated	O
with	O
aggregation	O
of	O
mutant	O
protein	O
ataxin	B
-	I
1	I
in	O
the	O
nuclei	O
of	O
susceptible	O
neurons	O
.	O

The	O
role	O
of	O
ataxin-1	B
aggregates	O
in	O
the	O
pathogenesis	O
of	O
susceptible	O
neurons	O
,	O
especially	O
cerebellar	O
Purkinje	O
cells	O
,	O
is	O
unknown	O
.	O

The	O
present	O
study	O
was	O
initiated	O
to	O
determine	O
the	O
temporal	O
relationship	O
between	O
ataxin-1	B
aggregation	O
and	O
the	O
sequence	O
of	O
specific	O
biochemical	O
changes	O
in	O
Purkinje	O
cells	O
in	O
SCA-1	O
transgenic	O
mice	O
(	O
TM	O
)	O
.	O

Earlier	O
,	O
we	O
demonstrated	O
that	O
SCA-1	O
TM	O
with	O
no	O
Purkinje	O
cell	O
loss	O
and	O
no	O
alterations	O
in	O
home	O
cage	O
behavior	O
show	O
decreased	O
expression	O
of	O
calcium	O
-	O
binding	O
proteins	O
calbindin	B
-	I
D28k	I
(	O
CaB	B
)	O
and	O
parvalbumin	B
(	O
PV	B
)	O
in	O
Purkinje	O
cells	O
.	O

To	O
determine	O
if	O
increased	O
expression	O
of	O
mutant	O
ataxin-1	B
in	O
TM	O
is	O
also	O
associated	O
with	O
earlier	O
biochemical	O
changes	O
in	O
Purkinje	O
cells	O
,	O
both	O
heterozygous	O
and	O
homozygous	O
(	O
B05	O
line	O
of	O
SCA-1	O
)	O
TM	O
were	O
used	O
.	O

The	O
age	O
of	O
onset	O
of	O
ataxia	O
in	O
SCA-1	O
TM	O
was	O
at	O
12	O
weeks	O
in	O
heterozygotes	O
and	O
6	O
weeks	O
in	O
homozygotes	O
.	O

In	O
6	O
week	O
old	O
heterozygous	O
TM	O
,	O
Western	O
blot	O
analysis	O
of	O
growth	B
associated	I
protein	I
43	I
(	O
GAP-43	B
)	O
and	O
synaptophysin	B
revealed	O
no	O
significant	O
alterations	O
as	O
compared	O
with	O
the	O
age	O
-	O
matched	O
nontransgenic	O
mice	O
(	O
nTM	O
)	O
,	O
whereas	O
CaB	B
was	O
significantly	O
reduced	O
.	O

beta	B
-	I
III	I
-	I
Tubulin	I
was	O
used	O
as	O
a	O
specific	O
Purkinje	O
cell	O
marker	O
protein	O
,	O
immunohistochemical	O
localization	O
showed	O
strong	O
beta	B
-	I
III	I
-	I
tubulin	I
immunoreactivity	O
(	O
IR	O
)	O
in	O
Purkinje	O
cells	O
in	O
6	O
week	O
old	O
heterozygous	O
TM	O
,	O
whereas	O
CaB	B
and	O
PV	B
IR	O
were	O
markedly	O
reduced	O
in	O
the	O
same	O
neurons	O
(	O
double	O
immunofluorescence	O
staining	O
)	O
.	O

Most	O
Purkinje	O
cells	O
from	O
heterozygous	O
(	O
12	O
weeks	O
old	O
)	O
and	O
homozygous	O
(	O
6	O
weeks	O
old	O
)	O
TM	O
contained	O
ataxin	B
-	I
1	I
nuclear	O
inclusions	O
(	O
NIs	O
)	O
.	O

Cells	O
with	O
and	O
without	O
visible	O
NIs	O
revealed	O
reduced	O
PV	B
and	O
CaB	B
IR	O
;	O
however	O
,	O
the	O
changes	O
were	O
overtly	O
more	O
severe	O
in	O
cells	O
with	O
visible	O
NIs	O
.	O

In	O
contrast	O
,	O
the	O
same	O
cells	O
were	O
strongly	O
immunoreactive	O
to	O
beta	B
-	I
III	I
-	I
tubulin	I
.	O

CaB	B
,	O
which	O
is	O
also	O
present	O
in	O
the	O
nucleus	O
,	O
colocalized	O
with	O
ataxin	B
-	I
1	I
and	O
ubiquitin	O
positive	O
NIs	O
.	O

Further	O
,	O
RT	O
-	O
PCR	O
analysis	O
of	O
CaB	B
mRNA	O
in	O
the	O
cerebellum	O
in	O
6	O
week	O
old	O
heterozygous	O
TM	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
mRNA	O
in	O
comparison	O
with	O
the	O
aged	O
-	O
matched	O
nTM	O
.	O

These	O
data	O
suggest	O
that	O
there	O
are	O
selective	O
alterations	O
in	O
the	O
expression	O
of	O
CaB	B
and	O
PV	B
in	O
Purkinje	O
cells	O
which	O
possibly	O
occur	O
earlier	O
than	O
ataxin-1	B
aggregation	O
.	O

Further	O
,	O
we	O
speculate	O
that	O
ataxin-1	B
aggregates	O
may	O
not	O
be	O
toxic	O
in	O
general	O
;	O
however	O
,	O
they	O
may	O
deplete	O
specific	O
proteins	O
essential	O
for	O
Purkinje	O
cell	O
viability	O
in	O
SCA-1	O
TM	O
.	O

Efficient	O
incorporation	O
of	O
HLA	B
class	I
II	I
onto	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
requires	O
envelope	O
glycoprotein	O
packaging	O
.	O

HLA	B
class	I
II	I
DR	B
is	O
one	O
of	O
the	O
most	O
abundant	O
cell	O
surface	O
proteins	O
incorporated	O
onto	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
during	O
budding	O
.	O

The	O
mechanism	O
for	O
HLA	B
class	I
II	I
protein	O
incorporation	O
is	O
not	O
known	O
and	O
may	O
involve	O
a	O
viral	O
protein	O
.	O

To	O
determine	O
whether	O
Env	B
affects	O
HLA	B
class	I
II	I
protein	O
incorporation	O
,	O
HIV-1	O
virions	O
,	O
either	O
with	O
or	O
without	O
Env	B
on	O
their	O
surface	O
,	O
were	O
produced	O
from	O
HLA	B
class	I
II	I
-	O
expressing	O
cells	O
and	O
analyzed	O
by	O
whole	O
-	O
virus	O
immunoprecipitation	O
with	O
antisera	O
against	O
HLA	B
class	I
II	I
proteins	O
.	O

HLA	B
class	I
II	I
proteins	O
were	O
detected	O
on	O
virions	O
only	O
when	O
wild	O
-	O
type	O
Env	B
was	O
incorporated	O
,	O
while	O
similar	O
experiments	O
showed	O
that	O
HLA	B
class	I
I	I
proteins	O
were	O
incorporated	O
independent	O
of	O
Env	B
packaging	O
.	O

Therefore	O
,	O
the	O
packaging	O
of	O
HIV-1	O
Env	B
protein	O
is	O
required	O
for	O
the	O
efficient	O
incorporation	O
of	O
HLA	B
class	I
II	I
but	O
not	O
class	O
I	O
proteins	O
into	O
the	O
virion	O
.	O

Analysis	O
of	O
two	O
Env	B
mutants	O
revealed	O
that	O
the	O
presence	O
of	O
a	O
43	O
-	O
amino	O
-	O
acid	O
sequence	O
between	O
amino	O
acids	O
708	O
and	O
750	O
in	O
the	O
gp41	B
(	O
TM	O
)	O
cytoplasmic	O
tail	O
was	O
required	O
for	O
efficient	O
incorporation	O
of	O
HLA	B
class	I
II	I
proteins	O
.	O

These	O
data	O
show	O
that	O
HIV-1	O
actively	O
incorporates	O
HLA	B
class	I
II	I
proteins	O
in	O
a	O
process	O
that	O
,	O
either	O
directly	O
or	O
indirectly	O
,	O
requires	O
Env	B
.	O

Choline	O
plus	O
cytidine	O
stimulate	O
phospholipid	O
production	O
,	O
and	O
the	O
expression	O
and	O
secretion	O
of	O
amyloid	B
precursor	I
protein	I
in	O
rat	O
PC12	O
cells	O
.	O

The	O
amyloid	B
precursor	I
protein	I
(	O
APP	B
)	O
is	O
a	O
transmembrane	O
protein	O
anchored	O
in	O
the	O
membrane	O
lipid	O
bilayer	O
.	O

Choline	O
and	O
cytidine	O
are	O
major	O
precursors	O
of	O
cell	O
membranes	O
,	O
and	O
are	O
regulatory	O
elements	O
in	O
membrane	O
biosynthesis	O
.	O

We	O
examined	O
the	O
levels	O
of	O
cellular	O
APP	B
holoprotein	O
and	O
secreted	O
APPs	B
when	O
rat	O
PC12	O
cells	O
are	O
stimulated	O
to	O
undergo	O
increase	O
in	O
membrane	O
phospholipids	O
by	O
choline	O
+	O
cytidine	O
(	O
2	O
+	O
2,5	O
+	O
5,10	O
+	O
10	O
or	O
50	O
+	O
50	O
microM	O
)	O
treatment	O
.	O

We	O
now	O
show	O
that	O
as	O
phospholipids	O
levels	O
are	O
increased	O
by	O
supplemental	O
choline	O
and	O
cytidine	O
treatment	O
,	O
the	O
levels	O
of	O
cell	O
-	O
associated	O
APP	B
also	O
rise	O
stoichiometrically	O
;	O
these	O
treatments	O
also	O
caused	O
major	O
(	O
up	O
to	O
6	O
.	O
8	O
-	O
fold	O
)	O
increases	O
in	O
the	O
amounts	O
of	O
secreted	O
APP	B
released	O
into	O
the	O
cell	O
medium	O
,	O
and	O
also	O
stimulated	O
increased	O
process	O
formation	O
.	O

These	O
results	O
show	O
that	O
choline	O
plus	O
cytidine	O
increase	O
both	O
phospholipid	O
levels	O
,	O
and	O
the	O
expression	O
and	O
secretion	O
in	O
PC12	O
cells	O
.	O

It	O
appears	O
that	O
agents	O
that	O
stimulate	O
cellular	O
membrane	O
biosynthesis	O
may	O
be	O
used	O
to	O
stimulate	O
the	O
secretion	O
of	O
neurotrophic	O
APPs	B
and	O
neurite	O
formation	O
in	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
.	O

Serum	O
antibody	O
responses	O
of	O
cats	O
to	O
soluble	O
whole	O
cell	O
antigens	O
of	O
feline	O
Porphyromonas	O
gingivalis	O
.	O

The	O
whole	O
cell	O
soluble	O
antigens	O
of	O
two	O
strains	O
(	O
VPB	O
3457	O
and	O
VPB	O
3492	O
)	O
of	O
feline	O
Porphyromonas	O
gingivalis	O
were	O
analysed	O
by	O
Western	O
blotting	O
using	O
serum	O
taken	O
from	O
40	O
domestic	O
cats	O
with	O
various	O
grades	O
of	O
periodontal	O
disease	O
.	O

Five	O
strongly	O
immunogenic	O
protein	O
bands	O
(	O
70	O
,	O
34	O
,	O
27	O
,	O
24	O
and	O
19kDa	O
)	O
from	O
VPB	O
3457	O
and	O
seven	O
from	O
VPB	O
3492	O
(	O
58	O
,	O
44	O
,	O
34	O
,	O
27	O
,	O
25	O
,	O
24	O
and	O
21kDa	O
)	O
were	O
selected	O
for	O
further	O
study	O
.	O

A	O
significant	O
positive	O
correlation	O
was	O
found	O
between	O
the	O
serum	O
antibody	O
response	O
to	O
the	O
70	O
,	O
34	O
,	O
27	O
,	O
24	O
and	O
19kDa	O
bands	O
of	O
VPB	O
3457	O
and	O
the	O
58	O
,	O
44	O
,	O
25	O
,	O
24	O
and	O
21kDa	O
bands	O
of	O
VPB	O
3492	O
and	O
the	O
overall	O
periodontal	O
grade	O
.	O

A	O
significant	O
positive	O
correlation	O
was	O
also	O
found	O
between	O
the	O
serum	O
antibody	O
response	O
to	O
the	O
24kDa	O
band	O
of	O
VPB	O
3457	O
and	O
the	O
total	O
colony	O
forming	O
units	O
of	O
P.	O
gingivalis	O
.	O

N	O
-	O
terminal	O
sequencing	O
of	O
the	O
44kDa	O
band	O
of	O
VPB	O
3492	O
showed	O
75	O
%	O
identity	O
with	O
the	O
translated	O
amino	O
acids	O
from	O
the	O
hag	B
A	I
(	O
haemagglutinin	B
)	O
gene	O
of	O
a	O
human	O
strain	O
of	O
P.	O
gingivalis	O
and	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
the	O
27kDa	O
band	O
of	O
VPB	O
3457	O
showed	O
88	O
%	O
identity	O
with	O
the	O
amino	O
acid	O
sequences	O
translated	O
from	O
DNA	O
of	O
purported	O
genes	O
coding	O
for	O
variously	O
named	O
proteinases	B
of	O
human	O
strains	O
of	O
P.	O
gingivalis	O
.	O

Proline	B
-	I
and	I
alanine	I
-	I
rich	I
Ste20	I
-	I
related	I
kinase	I
associates	O
with	O
F	O
-	O
actin	B
and	O
translocates	O
from	O
the	O
cytosol	O
to	O
cytoskeleton	O
upon	O
cellular	O
stresses	O
.	O

Proline	B
-	I
and	I
alanine	I
-	I
rich	I
Ste20	I
-	I
related	I
kinase	I
(	O
PASK	B
)	O
is	O
a	O
Ste20	B
-	O
related	O
protein	B
kinase	I
isolated	O
from	O
rat	O
brain	O
.	O

Cell	O
fractionation	O
studies	O
showed	O
that	O
PASK	B
was	O
present	O
both	O
in	O
the	O
cytosol	O
and	O
in	O
Triton	O
X-100	O
-	O
insoluble	O
cytoskeletal	O
fraction	O
in	O
rat	O
tissues	O
.	O

In	O
brain	O
,	O
PASK	B
associated	O
with	O
protein	O
complexes	O
that	O
contained	O
actin	B
and	O
tubulin	B
,	O
confirming	O
the	O
association	O
of	O
PASK	B
with	O
the	O
cytoskeleton	O
in	O
vivo	O
.	O

Glutathione	B
S	I
-	I
transferase	I
-	O
PASK	B
fusion	O
protein	O
cosedimented	O
with	O
F	B
-	I
actin	I
,	O
indicating	O
that	O
PASK	B
binds	O
to	O
F	O
-	O
actin	B
.	O

In	O
contrast	O
to	O
rat	O
tissues	O
,	O
PASK	B
was	O
detected	O
only	O
in	O
the	O
Triton	O
X	O
-	O
100	O
-	O
soluble	O
cytosolic	O
fraction	O
in	O
cultured	O
PC12	O
and	O
NIH	O
3T3	O
cells	O
.	O

Cytosolic	O
PASK	B
translocated	O
to	O
the	O
cytoskeleton	O
when	O
these	O
cells	O
were	O
stimulated	O
with	O
severe	O
cellular	O
stresses	O
such	O
as	O
hypertonic	O
sodium	O
chloride	O
,	O
hydrogen	O
peroxide	O
,	O
and	O
heat	O
shock	O
at	O
45	O
degrees	O
C	O
.	O

Our	O
results	O
suggest	O
that	O
PASK	B
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
cytoskeleton	O
in	O
response	O
to	O
cellular	O
stresses	O
such	O
as	O
hyperosmotic	O
shock	O
.	O

Expression	O
of	O
15	O
glutamate	B
receptor	I
subunits	O
and	O
various	O
splice	O
variants	O
in	O
tissue	O
slices	O
and	O
single	O
neurons	O
of	O
brainstem	O
nuclei	O
and	O
potential	O
functional	O
implications	O
.	O

Brainstem	O
nuclei	O
serve	O
a	O
diverse	O
array	O
of	O
functions	O
in	O
many	O
of	O
which	O
ionotropic	O
glutamate	B
receptors	I
are	O
known	O
to	O
be	O
involved	O
.	O

However	O
,	O
little	O
detailed	O
information	O
is	O
available	O
on	O
the	O
expression	O
of	O
different	O
glutamate	B
receptor	I
subunits	O
in	O
specific	O
nuclei	O
.	O

We	O
used	O
RT	O
-	O
PCR	O
in	O
mice	O
to	O
analyze	O
the	O
glutamate	B
receptor	I
subunit	O
composition	O
of	O
the	O
pre	O
-	O
BÃ?Â¶tzinger	O
complex	O
,	O
the	O
hypoglossal	O
nucleus	O
,	O
the	O
nucleus	O
of	O
the	O
solitary	O
tract	O
,	O
and	O
the	O
inferior	O
olive	O
.	O

Analyzing	O
15	O
receptor	O
subunits	O
and	O
five	O
variants	O
,	O
we	O
found	O
all	O
four	O
alpha	O
-	O
amino	O
-	O
3	O
-	O
hydroxy	O
-	O
5	O
-	O
methyl	O
-	O
4	O
-	O
propionic	O
acid	O
(	O
AMPA	O
)	O
and	O
six	O
NMDA	B
receptor	I
(	O
NR	B
)	O
subunits	O
as	O
well	O
as	O
three	O
of	O
five	O
kainate	B
(	I
KA	I
)	I
receptors	I
(	O
GluR5	B
,	O
GluR6	B
,	O
and	O
KA1	B
)	O
to	O
be	O
expressed	O
in	O
all	O
nuclei	O
.	O

However	O
,	O
some	O
distinct	O
differences	O
were	O
observed	O
:	O

The	O
inferior	O
olive	O
preferentially	O
expresses	O
flop	O
variants	O
of	O
AMPA	B
receptors	I
,	O
GluR7	B
is	O
more	O
abundant	O
in	O
the	O
pre	O
-	O
BÃ?Â¶tzinger	O
complex	O
than	O
in	O
the	O
other	O
nuclei	O
,	O
and	O
NR2C	B
is	O
most	O
prominent	O
in	O
the	O
nucleus	O
of	O
the	O
solitary	O
tract	O
.	O

In	O
single	O
hypoglossal	O
motoneurons	O
and	O
interneurons	O
of	O
the	O
pre	O
-	O
BÃ?Â¶tzinger	O
complex	O
investigation	O
of	O
GluR2	B
editing	O
revealed	O
strong	O
expression	O
of	O
the	O
GluR2	B
-	O
R	O
editing	O
variant	O
,	O
suggesting	O
low	O
Ca2	O
+	O
permeability	O
of	O
AMPA	B
receptors	I
.	O

Thus	O
,	O
Ca2	O
+	O
-	O
permeable	O
AMPA	B
receptors	I
are	O
unlikely	O
to	O
be	O
the	O
cause	O
for	O
the	O
reported	O
selective	O
vulnerability	O
of	O
hypoglossal	O
motoneurons	O
during	O
excitotoxic	O
events	O
.	O

Allene	B
oxide	I
synthases	I
of	O
barley	O
(	O
Hordeum	O
vulgare	O
cv	O
.	O
Salome	O
)	O
:	O
tissue	O
specific	O
regulation	O
in	O
seedling	O
development	O
.	O

Allene	B
oxide	I
synthase	I
(	O
AOS	B
)	O
is	O
the	O
first	O
enzyme	O
in	O
the	O
lipoxygenase	B
(	O
LOX	B
)	O
pathway	O
which	O
leads	O
to	O
formation	O
of	O
jasmonic	O
acid	O
(	O
JA	O
)	O
.	O

Two	O
full	O
-	O
length	O
cDNAs	O
of	O
AOS	B
designated	O
as	O
AOS1	B
and	O
AOS2	B
,	O
respectively	O
,	O
were	O
isolated	O
from	O
barley	O
(	O
H.	O
vulgare	O
cv	O
.	O
Salome	O
)	O
leaves	O
,	O
which	O
represent	O
the	O
first	O
AOS	B
clones	O
from	O
a	O
monocotyledonous	O
species	O
.	O

For	O
AOS1	B
,	O
the	O
open	O
reading	O
frame	O
encompasses	O
1461	O
bp	O
encoding	O
a	O
polypeptide	O
of	O
487	O
amino	O
acids	O
with	O
calculated	O
molecular	O
mass	O
of	O
53.4	O
kDa	O
and	O
an	O
isoelectric	O
point	O
of	O
9.3	O
,	O
whereas	O
the	O
corresponding	O
data	O
of	O
AOS2	B
are	O
1443	O
bp	O
,	O
480	O
amino	O
acids	O
,	O
52.7	O
kDa	O
and	O
7.9	O
.	O

Southern	O
blot	O
analysis	O
revealed	O
at	O
least	O
two	O
genes	O
.	O

Despite	O
the	O
lack	O
of	O
a	O
putative	O
chloroplast	O
signal	O
peptide	O
in	O
both	O
sequences	O
,	O
the	O
protein	O
co	O
-	O
purified	O
with	O
chloroplasts	O
and	O
was	O
localized	O
within	O
chloroplasts	O
by	O
immunocytochemical	O
analysis	O
.	O

The	O
barley	O
AOSs	B
,	O
expressed	O
in	O
bacteria	O
as	O
active	O
enzymes	O
,	O
catalyze	O
the	O
dehydration	O
of	O
LOX	B
-	O
derived	O
9	O
-	O
as	O
well	O
as	O
13-hydroperoxides	O
of	O
polyenoic	O
fatty	O
acids	O
to	O
the	O
unstable	O
allene	O
oxides	O
.	O

In	O
leaves	O
,	O
AOS	B
mRNA	O
accumulated	O
upon	O
treatment	O
with	O
jasmonates	O
,	O
octadecanoids	O
and	O
metabolizable	O
carbohydrates	O
,	O
but	O
not	O
upon	O
floating	O
on	O
abscisic	O
acid	O
,	O
NaCl	O
,	O
Na	O
-	O
salicylate	O
or	O
infection	O
with	O
powdery	O
mildew	O
.	O

In	O
developing	O
seedlings	O
,	O
AOS	B
mRNA	O
strongly	O
accumulated	O
in	O
the	O
scutellar	O
nodule	O
,	O
but	O
less	O
in	O
the	O
leaf	O
base	O
.	O

Both	O
tissues	O
exhibited	O
elevated	O
JA	O
levels	O
.	O

In	O
situ	O
hybridizations	O
revealed	O
the	O
preferential	O
occurrence	O
of	O
AOS	B
mRNA	O
in	O
parenchymatic	O
cells	O
surrounding	O
the	O
vascular	O
bundles	O
of	O
the	O
scutellar	O
nodule	O
and	O
in	O
the	O
young	O
convoluted	O
leaves	O
as	O
well	O
as	O
within	O
the	O
first	O
internode	O
.	O

The	O
properties	O
of	O
both	O
barley	O
AOSs	B
,	O
their	O
up	O
-	O
regulation	O
of	O
their	O
mRNAs	O
and	O
their	O
tissue	O
specific	O
expression	O
suggest	O
a	O
role	O
during	O
seedling	O
development	O
and	O
jasmonate	O
biosynthesis	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
mouse	O
CD97	B
.	O

The	O
EGF	B
-	I
TM7	I
family	I
(	O
CD97	B
and	O
EMR1	B
)	O
is	O
a	O
group	O
of	O
class	O
II	O
seven	B
-	I
span	I
transmembrane	I
receptors	I
predominantly	O
expressed	O
by	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Recently	O
,	O
we	O
have	O
identified	O
CD55	B
,	O
a	O
regulatory	O
molecule	O
of	O
the	O
complement	O
cascade	O
,	O
as	O
a	O
cellular	O
ligand	O
of	O
human	O
CD97	B
(	O
hCD97	B
)	O
.	O

In	O
this	O
study	O
,	O
the	O
molecular	O
properties	O
of	O
mouse	O
CD97	B
(	O
mCD97	B
)	O
are	O
described	O
.	O

Like	O
hCD97	B
,	O
mCD97	B
has	O
an	O
extended	O
extracellular	O
region	O
with	O
several	O
epidermal	B
growth	I
factor	I
-	O
like	O
(	O
EGF	B
)	O
domains	O
.	O

Due	O
to	O
alternative	O
RNA	O
splicing	O
,	O
isoforms	O
with	O
three	O
and	O
four	O
EGF	B
domains	O
exist	O
,	O
designated	O
mCD97	B
(	O
EGF1	O
,	O
2,4	O
)	O
and	O
mCD97	O
(	O
EGF1	O
,	O
2	O
,	O
3,4	O
)	O
respectively	O
.	O

All	O
EGF	B
domains	O
,	O
except	O
for	O
the	O
N	O
-	O
terminal	O
one	O
,	O
possess	O
a	O
calcium	O
-	O
binding	O
site	O
.	O

In	O
a	O
third	O
isoform	O
mCD97	B
(	O
EGF1,2,X,3,4	O
)	O
,	O
a	O
sequence	O
of	O
45	O
amino	O
acids	O
was	O
found	O
between	O
the	O
second	O
and	O
third	O
EGF	B
domain	O
that	O
does	O
not	O
correspond	O
to	O
any	O
known	O
protein	O
module	O
.	O

Using	O
newly	O
generated	O
mCD97	B
mAb	O
,	O
we	O
show	O
that	O
analogous	O
to	O
the	O
blood	O
expression	O
pattern	O
of	O
hCD97	B
,	O
mCD97	B
can	O
be	O
found	O
on	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O

Adhesion	O
of	O
mouse	O
erythrocytes	O
and	O
splenocytes	O
to	O
COS	O
cells	O
expressing	O
mCD97	B
(	O
EGF1,2,4	O
)	O
or	O
mCD97	B
(	O
EGF1	O
,	O
2	O
,	O
3	O
,	O
4	O
)	O
could	O
be	O
blocked	O
by	O
mouse	O
CD55	B
(	O
mCD55	B
)	O
antibody	O
,	O
identifying	O
mCD55	B
as	O
a	O
cellular	O
ligand	O
for	O
mCD97	B
.	O

Consistent	O
with	O
the	O
necessity	O
of	O
directly	O
linked	O
EGF	B
domains	O
for	O
the	O
integrity	O
of	O
the	O
CD55	B
-	O
binding	O
site	O
on	O
hCD97	B
,	O
no	O
adhesion	O
was	O
detected	O
to	O
the	O
largest	O
mouse	O
isoform	O
mCD97	B
(	O
EGF1	O
,	O
2	O
,	O
X,3,4	O
)	O
.	O

Remarkably	O
,	O
we	O
found	O
that	O
the	O
interaction	O
between	O
CD97	B
and	O
CD55	B
is	O
phylogenetically	O
restricted	O
,	O
as	O
indicated	O
by	O
the	O
selective	O
adhesion	O
of	O
primate	O
erythrocytes	O
to	O
hCD97	B
transfectants	O
,	O
and	O
of	O
mouse	O
and	O
rat	O
erythrocytes	O
to	O
mCD97	B
transfectants	O
respectively	O
.	O

Direct	O
interaction	O
between	O
the	O
cell	O
division	O
protein	O
FtsZ	B
and	O
the	O
cell	O
differentiation	O
protein	O
SpoIIE	B
.	O

SpoIIE	B
is	O
a	O
bifunctional	O
protein	O
with	O
two	O
critical	O
roles	O
in	O
the	O
establishment	O
of	O
cell	O
fate	O
in	O
Bacillus	O
subtilis	O
.	O

First	O
,	O
SpoIIE	B
is	O
needed	O
for	O
the	O
normal	O
formation	O
of	O
the	O
asymmetrically	O
positioned	O
septum	O
that	O
forms	O
early	O
in	O
sporulation	O
and	O
separates	O
the	O
mother	O
cell	O
from	O
the	O
prespore	O
compartment	O
.	O

Secondly	O
,	O
SpoIIE	B
is	O
essential	O
for	O
the	O
activation	O
of	O
the	O
first	O
compartment	O
-	O
specific	O
transcription	B
factor	I
sigma	B
(	I
F	I
)	I
in	O
the	O
prespore	O
.	O

After	O
initiation	O
of	O
sporulation	O
,	O
SpoIIE	B
localizes	O
to	O
the	O
potential	O
asymmetric	O
cell	O
division	O
sites	O
near	O
one	O
or	O
both	O
cell	O
poles	O
.	O

Localization	O
of	O
SpoIIE	B
was	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
essential	O
cell	O
division	O
protein	O
FtsZ	B
.	O

To	O
understand	O
how	O
SpoIIE	B
is	O
targeted	O
to	O
the	O
asymmetric	O
septum	O
we	O
have	O
now	O
analysed	O
its	O
interaction	O
with	O
FtsZ	B
in	O
vitro	O
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
and	O
purified	O
FtsZ	B
,	O
and	O
full	O
-	O
length	O
and	O
truncated	O
SpoIIE	B
proteins	O
,	O
we	O
demonstrate	O
that	O
the	O
two	O
proteins	O
interact	O
directly	O
and	O
that	O
domain	O
II	O
and	O
possibly	O
domain	O
I	O
of	O
SpoIIE	B
are	O
required	O
for	O
the	O
interaction	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
SpoIIE	B
interacts	O
with	O
itself	O
and	O
suggest	O
that	O
this	O
self	O
-	O
interaction	O
plays	O
a	O
role	O
in	O
assembly	O
of	O
SpoIIE	B
into	O
the	O
division	O
machinery	O
.	O

Probing	O
contacts	O
between	O
the	O
ribonuclease	B
H	I
domain	O
of	O
HIV-1	O
reverse	B
transcriptase	I
and	O
nucleic	O
acid	O
by	O
site	O
-	O
specific	O
photocross	O
-	O
linking	O
.	O

Cys	O
(	O
38	O
)	O
and	O
Cys	O
(	O
280	O
)	O
of	O
p66	B
/	O
p51	B
human	O
immunodeficiency	O
virus	O
type	O
1	O
reverse	B
transcriptase	I
(	O
HIV-1	O
RT	B
)	O
can	O
be	O
converted	O
to	O
Ser	O
without	O
affecting	O
enzyme	O
function	O
.	O

We	O
have	O
exploited	O
this	O
feature	O
to	O
construct	O
and	O
purify	O
""""	O
monocysteine	O
""""	O
RT	B
derivatives	O
for	O
site	O
-	O
specific	O
modification	O
with	O
the	O
photoactivable	O
cross	O
-	O
linking	O
agent	O
,	O
p	O
-	O
azidophenacyl	O
bromide	O
.	O

Acylation	O
of	O
a	O
unique	O
cysteine	O
residue	O
introduced	O
at	O
the	O
extreme	O
C	O
terminus	O
of	O
the	O
p66	B
subunit	O
(	O
C	O
(	O
561	O
)	O
)	O
with	O
an	O
azidophenacyl	O
group	O
allowed	O
us	O
to	O
probe	O
contacts	O
between	O
residues	O
C	O
-	O
terminal	O
to	O
alpha	O
-	O
helix	O
E	O
'	O
of	O
the	O
RNase	B
H	I
domain	O
and	O
structurally	O
divergent	O
nucleic	O
acid	O
duplexes	O
.	O

In	O
a	O
binary	O
complex	O
of	O
RT	B
and	O
template	O
-	O
primer	O
,	O
we	O
demonstrate	O
efficient	O
cross	O
-	O
linking	O
to	O
primer	O
nucleotides	O
-	O
21	O
to	O
-	O
24	O
/	O
-	O
25	O
,	O
and	O
template	O
nucleotides	O
-	O
18	O
to	O
-	O
21	O
.	O

Cross	O
-	O
linking	O
specificity	O
was	O
confirmed	O
by	O
an	O
analogous	O
evaluation	O
following	O
limited	O
primer	O
extension	O
,	O
where	O
the	O
profile	O
is	O
displaced	O
by	O
the	O
register	O
of	O
DNA	O
synthesis	O
.	O

Finally	O
,	O
contact	O
with	O
a	O
DNA	O
primer	O
hybridized	O
to	O
an	O
isogenic	O
RNA	O
or	O
DNA	O
template	O
indicates	O
subtle	O
alterations	O
in	O
cross	O
-	O
linking	O
specificity	O
,	O
suggesting	O
differences	O
in	O
nucleic	O
acid	O
geometry	O
between	O
duplex	O
DNA	O
and	O
RNA	O
/	O
DNA	O
hybrids	O
at	O
the	O
RNase	B
H	I
domain	O
.	O

These	O
data	O
exemplify	O
how	O
site	O
-	O
specific	O
acylation	O
of	O
HIV-1	O
RT	B
can	O
be	O
used	O
to	O
provide	O
high	O
resolution	O
structural	O
data	O
to	O
complement	O
crystallographic	O
studies	O
.	O

Reverse	O
transcriptase	O
(	O
RT	O
)	O
-	O
independent	O
as	O
well	O
as	O
RT	O
-	O
dependent	O
HIV-1	O
replication	O
exists	O
in	O
syncytia	O
following	O
cell	O
fusion	O
.	O

We	O
studied	O
the	O
role	O
of	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
1	O
replication	O
in	O
syncytia	O
following	O
cell	O
fusion	O
.	O

A	O
chronically	O
HIV-1	O
-	O
infected	O
MOLT-4	O
(	O
MOLT	O
-	O
4	O
/	O
IIIB	O
)	O
cells	O
allow	O
HIV-1	O
replication	O
and	O
induce	O
syncytium	O
formation	O
between	O
uninfected	O
MOLT-4	O
cells	O
.	O

AZT	O
(	O
3'-azido-3'-deoxythymidine	O
,	O
1	O
microM	O
)	O
inhibited	O
neither	O
HIV-1	O
replication	O
in	O
MOLT-4	O
/	O
IIIB	O
cells	O
nor	O
the	O
syncytium	O
formation	O
induced	O
by	O
concultivation	O
of	O
MOLT-4	O
/	O
IIIB	O
cells	O
with	O
uninfected	O
MOLT-4	O
cells	O
.	O

In	O
the	O
supernatant	O
of	O
the	O
syncytium	O
containing	O
culture	O
a	O
remarkably	O
higher	O
titer	O
of	O
p24	B
antigen	O
was	O
produced	O
than	O
in	O
that	O
of	O
MOLT	O
/	O
IIIB	O
cell	O
culture	O
.	O

AZT	O
inhibited	O
p24	B
antigen	O
production	O
by	O
HIV-1	O
in	O
the	O
syncytia	O
to	O
levels	O
to	O
comparable	O
to	O
that	O
in	O
MOLT-4	O
/	O
IIIB	O
cells	O
which	O
were	O
treated	O
with	O
AZT	O
.	O

In	O
addition	O
,	O
p24	B
production	O
by	O
HIV-1	O
in	O
the	O
syncytia	O
formed	O
by	O
cocultivation	O
of	O
CL-2	O
cells	O
,	O
which	O
are	O
chronically	O
infected	O
with	O
HIV-1	O
but	O
lack	O
functional	O
RT	B
,	O
with	O
uninfected	O
MOLT-4	O
cells	O
was	O
not	O
different	O
from	O
that	O
in	O
CL-2	O
cells	O
alone	O
.	O

The	O
results	O
suggest	O
that	O
HIV-1	O
RT	B
plays	O
an	O
important	O
role	O
in	O
HIV-1	O
replication	O
within	O
the	O
syncytia	O
but	O
an	O
RT	B
-	O
independent	O
replication	O
process	O
which	O
is	O
essential	O
for	O
syncytium	O
formation	O
also	O
exists	O
in	O
the	O
syncytia	O
.	O

These	O
results	O
indicate	O
that	O
not	O
only	O
RT	B
inhibitors	O
but	O
also	O
inhibitors	O
of	O
syncytium	O
formation	O
are	O
essential	O
for	O
anti	O
-	O
HIV	O
therapy	O
.	O

Regulation	O
of	O
expression	O
of	O
the	O
human	O
beta-1,2-N	B
-	I
acetylglucosaminyltransferase	I
II	I
gene	O
(	O
MGAT2	B
)	O
by	O
Ets	B
transcription	B
factors	I
.	O

Oncogenic	O
transformation	O
of	O
fibroblasts	O
by	O
the	O
src	B
oncogene	O
has	O
long	O
been	O
known	O
to	O
cause	O
an	O
increase	O
in	O
the	O
size	O
of	O
cell	O
-	O
surface	O
protein	O
-	O
bound	O
oligosaccharides	O
,	O
owing	O
primarily	O
to	O
increased	O
N	O
-	O
glycan	O
branching	O
mediated	O
by	O
increased	O
beta-1,6-N	B
-	I
acetylglucosaminyltransferase	I
V	I
(	O
GnT	B
V	I
)	O
activity	O
.	O

The	O
src	B
-	O
responsive	O
element	O
of	O
the	O
GnT	B
V	I
promoter	O
was	O
localized	O
to	O
Ets	B
-	O
binding	O
sites	O
and	O
the	O
promoter	O
was	O
transcriptionally	O
stimulated	O
by	O
both	O
ets-1	B
and	O
ets-2	B
expression	O
[	O
Buckhaults	O
,	O
Chen	O
,	O
Fregien	O
and	O
Pierce	O
(	O
1997	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
272	O
,	O
19575	O
-	O
19581	O
;	O
Kang	O
,	O
Saito	O
,	O
Ihara	O
,	O
Miyoshi	O
,	O
Koyama	O
,	O
Sheng	O
and	O
Taniguchi	O
(	O
1996	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
271	O
,	O
26706	O
-	O
26712	O
]	O
.	O

Because	O
GnT	B
V	I
action	O
requires	O
the	O
prior	O
action	O
of	O
beta-1,2-N	B
-	I
acetylglucosaminyltransferase	I
II	I
(	O
GnT	B
II	I
)	O
and	O
the	O
human	O
GnT	B
II	I
promoter	O
contains	O
four	O
putative	O
Ets	B
-	O
binding	O
sites	O
[	O
Chen	O
,	O
Zhou	O
,	O
Tan	O
and	O
Schachter	O
(	O
1998	O
)	O
Glycoconj	O
.	O
J.	O
15	O
,	O
301	O
-	O
308	O
]	O
,	O
GnT	B
II	I
might	O
also	O
be	O
under	O
oncogenic	O
control	O
via	O
Ets	B
transcription	B
factors	I
.	O

We	O
now	O
report	O
that	O
co	O
-	O
transfection	O
into	O
HepG2	O
or	O
COS-1	O
cells	O
of	O
either	O
ets-1	B
or	O
ets-2	B
expression	O
plasmids	O
together	O
with	O
chimaeric	O
GnT	B
II	I
promoter	O
-	O
chloramphenicol	B
acetyltransferase	I
plasmids	O
results	O
in	O
a	O
2	O
-	O
4	O
-	O
fold	O
stimulation	O
of	O
promoter	O
activity	O
.	O

Mobility	O
-	O
shift	O
assays	O
and	O
South	O
-	O
Western	O
blots	O
localized	O
the	O
functional	O
Ets	B
-	O
binding	O
site	O
to	O
one	O
of	O
the	O
four	O
putative	O
sites	O
on	O
the	O
GnT	B
II	I
promoter	O
.	O

The	O
GnT	B
II	I
promoter	O
,	O
unlike	O
the	O
GnT	B
V	I
promoter	O
,	O
is	O
not	O
activated	O
by	O
either	O
src	B
or	O
neu	B
.	O

Therefore	O
although	O
both	O
promoters	O
are	O
stimulated	O
by	O
a	O
member	O
of	O
the	O
Ets	B
family	I
of	O
transcription	B
factors	I
,	O
the	O
functional	O
role	O
of	O
this	O
Ets	B
transcriptional	O
control	O
seems	O
to	O
be	O
different	O
for	O
the	O
two	O
genes	O
.	O

Fine	O
characterization	O
of	O
the	O
antigenic	O
site	O
within	O
the	O
flap	O
region	O
in	O
the	O
protease	B
protein	O
of	O
HIV-1	O
.	O

The	O
aspartate	B
protease	I
encoded	O
by	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
is	O
essential	O
for	O
cleavage	O
of	O
the	O
gag	B
and	O
gag	B
-	I
pol	I
precursor	O
proteins	O
.	O

The	O
majority	O
of	O
HIV-1	O
-	O
antibody	O
-	O
positive	O
sera	O
react	O
with	O
the	O
protease	B
.	O

In	O
this	O
study	O
we	O
used	O
a	O
substitution	O
set	O
of	O
peptides	O
for	O
detailed	O
characterization	O
of	O
the	O
earlier	O
defined	O
antigenic	O
site	O
(	O
aa	O
44	O
-	O
58	O
)	O
within	O
the	O
central	O
""""	O
flap	O
""""	O
region	O
,	O
also	O
important	O
in	O
the	O
context	O
of	O
conformational	O
flexibility	O
during	O
protease	B
inhibitor	O
binding	O
.	O

We	O
found	O
that	O
isoleucine	O
at	O
position	O
54	O
was	O
important	O
for	O
creating	O
an	O
antigenic	O
site	O
required	O
for	O
binding	O
of	O
anti	O
-	O
HIV-1	O
sera	O
.	O

The	O
identification	O
of	O
structurally	O
essential	O
amino	O
acids	O
in	O
the	O
flap	O
region	O
of	O
HIV-1	O
PR	O
may	O
have	O
important	O
implications	O
in	O
future	O
development	O
of	O
antiviral	O
drugs	O
.	O

Epitope	O
spreading	O
and	O
a	O
varying	O
but	O
not	O
disease	O
-	O
specific	O
GAD65	B
antibody	O
response	O
in	O
Type	O
I	O
diabetes	O
.	O

The	O
Childhood	O
Diabetes	O
in	O
Finland	O
Study	O
Group	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
conformational	O
and	O
linear	O
epitope	O
profiles	O
of	O
glutamic	B
acid	I
decarboxylase	I
antibody	O
(	O
GAD65	B
-	O
ab	O
)	O
-	O
positive	O
sera	O
to	O
find	O
disease	O
-	O
specific	O
epitope	O
profiles	O
and	O
to	O
study	O
,	O
whether	O
GAD65	B
-	O
ab	O
epitope	O
recognition	O
changes	O
or	O
spreads	O
during	O
the	O
prediabetic	O
period	O
and	O
,	O
thus	O
,	O
can	O
provide	O
markers	O
to	O
differentiate	O
early	O
from	O
later	O
stages	O
of	O
progression	O
to	O
diabetes	O
.	O

METHODS	O
:	O

Sera	O
from	O
subjects	O
before	O
(	O
n	O
=	O
21	O
)	O
,	O
at	O
onset	O
(	O
n	O
=	O
44	O
)	O
,	O
or	O
at	O
increased	O
risk	O
of	O
Type	O
I	O
(	O
insulin	B
-	O
dependent	O
)	O
diabetes	O
mellitus	O
(	O
n	O
=	O
20	O
)	O
and	O
from	O
patients	O
with	O
stiff	O
-	O
man	O
syndrome	O
(	O
SMS	O
,	O
n	O
=	O
18	O
)	O
or	O
polyendocrine	O
autoimmune	O
syndrome	O
(	O
PAS	O
,	O
n	O
=	O
21	O
)	O
were	O
analysed	O
for	O
conformational	O
and	O
linear	O
GAD65	B
epitope	O
recognition	O
by	O
an	O
immunohistochemical	O
blocking	O
test	O
based	O
on	O
human	O
monoclonal	O
GAD65	B
-	O
ab	O
(	O
MICA	O
1	O
-	O
10	O
)	O
and	O
western	O
blotting	O
of	O
a	O
GAD65	B
epitope	O
-	O
cDNA	O
-	O
library	O
.	O

RESULTS	O
:	O

A	O
redundant	O
reactivity	O
of	O
many	O
GAD65	B
-	O
ab	O
positive	O
sera	O
to	O
three	O
major	O
conformational	O
(	O
EP-1	O
,	O
EP-2	O
,	O
EP-3	O
)	O
and	O
two	O
dominant	O
linear	O
epitope	O
clusters	O
(	O
amino	O
acid	O
1	O
-	O
124	O
and	O
535	O
-	O
585	O
)	O
was	O
observed	O
in	O
diabetes	O
,	O
polyendocrine	O
autoimmune	O
syndrome	O
and	O
stiff	O
-	O
man	O
syndrome	O
and	O
no	O
disease	O
-	O
specific	O
epitopes	O
or	O
epitope	O
-	O
profiles	O
were	O
detected	O
.	O

Epitope	O
recognition	O
broadened	O
with	O
higher	O
titres	O
and	O
with	O
the	O
vulnerability	O
of	O
patients	O
to	O
acquire	O
additional	O
autoimmune	O
diseases	O
apart	O
from	O
diabetes	O
.	O

Low	O
GAD65	B
-	O
ab	O
serum	O
titres	O
(	O
<	O
1200	O
arbitrary	O
units	O
)	O
and	O
EP-1	O
recognition	O
in	O
the	O
absence	O
of	O
EP	O
-	O
2	O
binding	O
characterised	O
the	O
early	O
immune	O
response	O
.	O

Changing	O
epitope	O
profiles	O
combined	O
stable	O
recognition	O
of	O
EP-1	O
with	O
gain	O
or	O
loss	O
of	O
reactivity	O
to	O
C	O
-	O
terminal	O
epitopes	O
during	O
follow	O
-	O
up	O
.	O

CONCLUSION	O
/	O
INTERPRETATION	O
:	O

A	O
maturing	O
autoantibody	O
response	O
,	O
which	O
could	O
spread	O
from	O
EP	O
-	O
1	O
-	O
recognition	O
to	O
other	O
regions	O
of	O
GAD65	B
,	O
resulted	O
in	O
titre	O
-	O
related	O
rather	O
than	O
disease	O
-	O
specific	O
epitope	O
profiles	O
which	O
were	O
not	O
sufficient	O
to	O
predict	O
whether	O
GAD65	B
-	O
ab	O
positive	O
subjects	O
will	O
progress	O
to	O
Type	O
I	O
diabetes	O
,	O
autoimmune	O
polyendocrine	O
syndrome	O
or	O
stiff	O
-	O
man	O
syndrome	O
.	O

delta	B
-	I
catenin	I
is	O
a	O
nervous	O
system	O
-	O
specific	O
adherens	O
junction	O
protein	O
which	O
undergoes	O
dynamic	O
relocalization	O
during	O
development	O
.	O

delta	B
-	I
catenin	I
is	O
a	O
member	O
of	O
the	O
Armadillo	B
repeat	I
family	I
and	O
component	O
of	O
the	O
adherens	O
junction	O
discovered	O
in	O
a	O
two	O
-	O
hybrid	O
assay	O
as	O
a	O
bona	O
fide	O
interactor	O
with	O
presenilin-1	B
(	O
Zhou	O
et	O
al.	O
,	O
[	O
1997	O
]	O
,	O
NeuroReport	O
8	O
:	O
2085	O
-	O
2090	O
)	O
,	O
a	O
protein	O
which	O
carries	O
mutations	O
that	O
cause	O
familial	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
expression	O
pattern	O
of	O
delta	B
-	I
catenin	I
was	O
mapped	O
between	O
embryonic	O
day	O
10	O
(	O
E10	O
)	O
and	O
adulthood	O
by	O
Northern	O
blots	O
,	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
in	O
the	O
mouse	O
.	O

In	O
development	O
,	O
delta	B
-	I
catenin	I
is	O
dynamically	O
regulated	O
with	O
respect	O
to	O
its	O
site	O
of	O
expression	O
.	O

It	O
is	O
first	O
expressed	O
within	O
proliferating	O
neuronal	O
progenitor	O
cells	O
of	O
the	O
neuroepithelium	O
,	O
becomes	O
down	O
-	O
regulated	O
during	O
neuronal	O
migration	O
,	O
and	O
is	O
later	O
reexpressed	O
in	O
the	O
dendritic	O
compartment	O
of	O
postmitotic	O
neurons	O
.	O

In	O
the	O
mouse	O
,	O
delta	B
-	I
catenin	I
mRNA	O
is	O
expressed	O
by	O
E10	O
,	O
increases	O
and	O
peaks	O
at	O
postnatal	O
day	O
(	O
P	O
)	O
7	O
,	O
with	O
lower	O
levels	O
in	O
adulthood	O
.	O

In	O
the	O
developing	O
neocortex	O
,	O
delta	B
-	I
catenin	I
mRNA	O
is	O
strongly	O
expressed	O
in	O
the	O
proliferative	O
ventricular	O
zone	O
and	O
the	O
developing	O
cortical	O
plate	O
,	O
yet	O
is	O
conspicuously	O
less	O
prominent	O
in	O
the	O
intermediate	O
zone	O
,	O
which	O
contains	O
migrating	O
cortical	O
neurons	O
,	O
delta	B
-	I
catenin	I
protein	O
forms	O
a	O
honeycomb	O
pattern	O
in	O
the	O
neuroepithelium	O
by	O
labeling	O
the	O
cell	O
periphery	O
in	O
a	O
typical	O
adherens	O
junction	O
pattern	O
.	O

By	O
E18	O
,	O
delta	B
-	I
catenin	I
expression	O
shifts	O
primarily	O
to	O
nascent	O
apical	O
dendrites	O
,	O
a	O
pattern	O
that	O
continues	O
through	O
adulthood	O
.	O

The	O
dynamic	O
relocalization	O
of	O
delta	B
-	I
catenin	I
expression	O
during	O
development	O
,	O
taken	O
together	O
with	O
previously	O
published	O
data	O
which	O
described	O
a	O
role	O
for	O
delta	B
-	I
catenin	I
in	O
cell	O
motility	O
(	O
Lu	O
et	O
al.	O
,	O
[	O
1999	O
]	O
J.	O
Cell	O
.	O
Biol	O
.	O
144	O
:	O
519	O
-	O
532	O
)	O
,	O
suggests	O
the	O
hypothesis	O
that	O
delta	B
-	I
catenin	I
regulation	O
is	O
closely	O
linked	O
to	O
neuronal	O
migration	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
establishment	O
of	O
mature	O
dendritic	O
relationships	O
in	O
the	O
neuropil	O
.	O

Haemophilus	O
influenzae	O
stimulates	O
ICAM-1	B
expression	O
on	O
respiratory	O
epithelial	O
cells	O
.	O

Epithelial	O
cells	O
interact	O
directly	O
with	O
bacteria	O
in	O
the	O
environment	O
and	O
play	O
a	O
critical	O
role	O
in	O
airway	O
defense	O
against	O
microbial	O
pathogens	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
response	O
of	O
respiratory	O
epithelial	O
cells	O
to	O
infection	O
with	O
nontypable	O
Haemophilus	O
influenzae	O
.	O

Using	O
an	O
in	O
vitro	O
cell	O
culture	O
model	O
,	O
we	O
found	O
that	O
epithelial	O
cell	O
monolayers	O
released	O
significant	O
quantities	O
of	O
IL-8	B
and	O
expressed	O
increased	O
levels	O
of	O
ICAM-1	B
mRNA	O
and	O
surface	O
protein	O
in	O
response	O
to	O
H.	O
influenzae	O
.	O

In	O
contrast	O
,	O
levels	O
of	O
IL-1beta	B
,	O
TNF	B
-	I
alpha	I
,	O
and	O
MHC	B
class	I
I	I
were	O
not	O
significantly	O
affected	O
,	O
suggesting	O
preferential	O
activation	O
of	O
a	O
specific	O
subset	O
of	O
epithelial	O
genes	O
directed	O
toward	O
defense	O
against	O
bacteria	O
.	O

Induction	O
of	O
ICAM-1	B
required	O
direct	O
bacterial	O
interaction	O
with	O
the	O
epithelial	O
cell	O
surface	O
and	O
was	O
not	O
reproduced	O
by	O
purified	O
H.	O
influenzae	O
lipooligosaccharide	O
.	O

Consistent	O
with	O
a	O
functional	O
role	O
for	O
this	O
response	O
,	O
induction	O
of	O
ICAM-1	B
by	O
H.	O
influenzae	O
mediated	O
increased	O
neutrophil	O
adherence	O
to	O
the	O
epithelial	O
cell	O
surface	O
.	O

Furthermore	O
,	O
in	O
an	O
in	O
vivo	O
murine	O
model	O
of	O
airway	O
infection	O
with	O
H.	O
influenzae	O
,	O
increased	O
epithelial	O
cell	O
ICAM-1	B
expression	O
coincided	O
with	O
increased	O
chemokine	B
levels	O
and	O
neutrophil	O
recruitment	O
in	O
the	O
airway	O
.	O

These	O
results	O
indicate	O
that	O
ICAM-1	B
expression	O
on	O
human	O
respiratory	O
epithelial	O
cells	O
is	O
induced	O
by	O
epithelial	O
cell	O
interaction	O
with	O
H.	O
influenzae	O
and	O
suggest	O
that	O
an	O
ICAM-1	B
-	O
dependent	O
mechanism	O
can	O
mediate	O
neutrophil	O
adherence	O
to	O
these	O
cells	O
independent	O
of	O
inflammatory	O
mediator	O
release	O
by	O
other	O
cell	O
types	O
.	O

Direct	O
induction	O
of	O
specific	O
epithelial	O
cell	O
genes	O
(	O
such	O
as	O
ICAM-1	B
and	O
IL-8	B
)	O
by	O
bacterial	O
infection	O
may	O
allow	O
for	O
rapid	O
and	O
efficient	O
innate	O
defense	O
in	O
the	O
airway	O
.	O

Alterations	O
in	O
cathepsin	B
H	I
activity	O
and	O
protein	O
patterns	O
in	O
human	O
colorectal	O
carcinomas	O
.	O

Our	O
analyses	O
of	O
cathepsin	B
H	I
activity	O
levels	O
and	O
protein	O
forms	O
in	O
human	O
colorectal	O
cancers	O
compared	O
to	O
matched	O
control	O
mucosa	O
support	O
the	O
concept	O
that	O
altered	O
proteinase	B
expression	O
patterns	O
may	O
reflect	O
both	O
cancer	O
stage	O
and	O
site	O
.	O

Cathepsin	B
H	I
-	O
specific	O
activity	O
was	O
significantly	O
increased	O
in	O
colorectal	O
cancers	O
compared	O
to	O
control	O
mucosa	O
(	O
P	O
=	O
0.003	O
;	O
n	O
=	O
77	O
)	O
.	O

Highest	O
specific	O
activities	O
and	O
cancer	O
/	O
normal	O
ratios	O
(	O
C	O
/	O
N	O
)	O
for	O
activity	O
were	O
measured	O
in	O
Dukes	O
'	O
B	O
and	O
C	O
stage	O
carcinomas	O
,	O
cancers	O
involved	O
in	O
local	O
spread	O
and	O
invasion	O
to	O
lymph	O
nodes	O
.	O

In	O
contrast	O
,	O
cathepsin	B
B	I
and	I
L	I
activities	O
analysed	O
in	O
the	O
same	O
paired	O
extracts	O
had	O
been	O
shown	O
to	O
be	O
most	O
frequently	O
elevated	O
in	O
earlier	O
stage	O
carcinomas	O
(	O
Dukes	O
'	O
A	O
and	O
B	O
)	O
,	O
confirming	O
that	O
cathepsin	B
H	I
demonstrates	O
a	O
distinct	O
pattern	O
of	O
expression	O
during	O
colorectal	O
cancer	O
progression	O
.	O

Although	O
cathepsin	B
H	I
activities	O
were	O
most	O
commonly	O
elevated	O
in	O
Dukes	O
'	O
C	O
cancers	O
at	O
all	O
colon	O
sites	O
,	O
both	O
specific	O
activity	O
and	O
C	O
/	O
N	O
ratios	O
were	O
significantly	O
higher	O
for	O
cancers	O
of	O
the	O
left	O
colon	O
compared	O
to	O
other	O
colon	O
locations	O
.	O

A	O
subset	O
of	O
43	O
paired	O
extracts	O
analysed	O
on	O
Western	O
blots	O
also	O
revealed	O
consistent	O
changes	O
in	O
cathepsin	B
H	I
protein	O
forms	O
in	O
cancers	O
.	O

Normal	O
mucosa	O
typically	O
showed	O
a	O
strong	O
protein	O
doublet	O
at	O
31	O
and	O
29	O
kDa	O
while	O
cancers	O
demonstrated	O
decreased	O
expression	O
or	O
total	O
loss	O
of	O
the	O
31	O
kDa	O
protein	O
(	O
90	O
%	O
of	O
cases	O
)	O
,	O
equal	O
or	O
increased	O
expression	O
of	O
the	O
29	O
-	O
kDa	O
protein	O
(	O
67	O
%	O
of	O
cases	O
)	O
and	O
the	O
new	O
appearance	O
or	O
up	O
-	O
regulation	O
of	O
a	O
cathepsin	B
H	I
band	O
at	O
22	O
kDa	O
(	O
78	O
%	O
of	O
cases	O
)	O
.	O

C	O
/	O
N	O
ratios	O
for	O
cathepsin	B
H	I
enzyme	O
activity	O
correlated	O
significantly	O
with	O
C	O
/	O
N	O
ratios	O
for	O
the	O
29	O
kDa	O
mature	O
single	O
-	O
chain	O
protein	O
form	O
(	O
P	O
<	O
0.001	O
)	O
,	O
with	O
increased	O
activity	O
most	O
commonly	O
associated	O
with	O
elevated	O
expression	O
of	O
29	O
-	O
kDa	O
cathepsin	B
H	I
but	O
also	O
with	O
up	O
-	O
regulation	O
of	O
the	O
22	O
-	O
kDa	O
band	O
,	O
suggesting	O
a	O
shift	O
to	O
more	O
fully	O
processed	O
,	O
mature	O
active	O
cathepsin	B
H	I
protein	O
forms	O
in	O
cancers	O
.	O

Changes	O
in	O
cathepsin	B
H	I
expression	O
were	O
also	O
detected	O
by	O
immunohistochemistry	O
as	O
elevated	O
cathepsin	B
H	I
staining	O
in	O
tumour	O
epithelial	O
cells	O
.	O

Dual	O
control	O
of	O
muscle	O
cell	O
survival	O
by	O
distinct	O
growth	B
factor	I
-	O
regulated	O
signaling	O
pathways	O
.	O

In	O
addition	O
to	O
their	O
ability	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
polypeptide	O
growth	B
factors	I
are	O
able	O
to	O
maintain	O
cell	O
survival	O
under	O
conditions	O
that	O
otherwise	O
lead	O
to	O
apoptotic	O
death	O
.	O

Growth	B
factors	I
control	O
cell	O
viability	O
through	O
regulation	O
of	O
critical	O
intracellular	O
signal	O
transduction	O
pathways	O
.	O

We	O
previously	O
characterized	O
C2	O
muscle	O
cell	O
lines	O
that	O
lacked	O
endogenous	O
expression	O
of	O
insulin	B
-	I
like	I
growth	I
factor	I
II	I
(	O
IGF	B
-	I
II	I
)	O
.	O

These	O
cells	O
did	O
not	O
differentiate	O
but	O
underwent	O
apoptotic	O
death	O
in	O
low	O
-	O
serum	O
differentiation	O
medium	O
.	O

Death	O
could	O
be	O
prevented	O
by	O
IGF	B
analogues	O
that	O
activated	O
the	O
IGF	B
-	I
I	I
receptor	I
or	O
by	O
unrelated	O
growth	B
factors	I
such	O
as	O
platelet	B
-	I
derived	I
growth	I
factor	I
BB	I
(	O
PDGF	B
-	I
BB	I
)	O
.	O

Here	O
we	O
analyze	O
the	O
signaling	O
pathways	O
involved	O
in	O
growth	B
factor	I
-	O
mediated	O
myoblast	O
survival	O
.	O

PDGF	B
treatment	O
caused	O
sustained	O
activation	O
of	O
extracellular	B
-	I
regulated	I
kinases	I
1	I
and	I
2	I
(	O
ERK1	B
and	I
-	I
2	I
)	O
,	O
while	O
IGF	B
-	I
I	I
only	O
transiently	O
induced	O
these	O
enzymes	O
.	O

Transient	O
transfection	O
of	O
a	O
constitutively	O
active	O
Mek1	B
,	O
a	O
specific	O
upstream	O
activator	O
of	O
ERKs	B
,	O
maintained	O
myoblast	O
viability	O
in	O
the	O
absence	O
of	O
growth	B
factors	I
,	O
while	O
inhibition	O
of	O
Mek1	B
by	O
the	O
drug	O
UO126	O
blocked	O
PDGF	B
-	O
mediated	O
but	O
not	O
IGF	B
-	O
stimulated	O
survival	O
.	O

Although	O
both	O
growth	B
factors	I
activated	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3-kinase	B
)	O
to	O
similar	O
extents	O
,	O
only	O
IGF	B
-	I
I	I
treatment	O
led	O
to	O
sustained	O
stimulation	O
of	O
its	O
downstream	O
kinase	B
,	O
Akt	B
.	O

Transient	O
transfection	O
of	O
a	O
constitutively	O
active	O
PI3	B
-	I
kinase	I
or	O
an	O
inducible	O
Akt	B
promoted	O
myoblast	O
viability	O
in	O
the	O
absence	O
of	O
growth	B
factors	I
,	O
while	O
inhibition	O
of	O
PI3	B
-	I
kinase	I
activity	O
by	O
the	O
drug	O
LY294002	O
selectively	O
blocked	O
IGF	B
-	O
but	O
not	O
PDGF	B
-	O
mediated	O
muscle	O
cell	O
survival	O
.	O

In	O
aggregate	O
,	O
these	O
observations	O
demonstrate	O
that	O
distinct	O
growth	B
factor	I
-	O
regulated	O
signaling	O
pathways	O
independently	O
control	O
myoblast	O
survival	O
.	O

Since	O
IGF	B
action	O
also	O
stimulates	O
muscle	O
differentiation	O
,	O
these	O
results	O
suggest	O
a	O
means	O
to	O
regulate	O
myogenesis	O
through	O
selective	O
manipulation	O
of	O
different	O
signal	O
transduction	O
pathways	O
.	O

DNA	B
methyltransferase	I
levels	O
and	O
altered	O
CpG	O
methylation	O
in	O
the	O
total	O
genome	O
and	O
in	O
the	O
GSTP1	B
gene	O
in	O
human	O
glioma	O
cells	O
transfected	O
with	O
sense	O
and	O
antisense	O
DNA	O
methyltransferase	B
cDNA	O
.	O

This	O
study	O
examines	O
the	O
efficacy	O
of	O
using	O
plasmid	O
expression	O
vectors	O
containing	O
sense	O
and	O
antisense	O
DNA	B
MTase	I
cDNA	O
to	O
both	O
up	O
-	O
and	O
downregulate	O
intracellular	O
DNA	B
MTase	I
levels	O
in	O
human	O
glioma	O
cells	O
.	O

The	O
effects	O
of	O
the	O
changes	O
in	O
MTase	B
levels	O
on	O
global	O
genomic	O
DNA	O
methylation	O
and	O
on	O
the	O
methylation	O
status	O
of	O
CpG	O
dinucleotides	O
in	O
the	O
GSTP1	B
gene	O
were	O
determined	O
in	O
a	O
glioma	O
cell	O
line	O
that	O
overexpresses	O
the	O
GSTP1	B
gene	O
.	O

In	O
cells	O
transfected	O
with	O
sense	O
DNA	B
MTase	I
cDNA	O
,	O
MTase	B
gene	O
transcripts	O
increased	O
to	O
a	O
maximum	O
of	O
2	O
.	O

5	O
-	O
fold	O
at	O
24	O
h	O
,	O
while	O
MTase	B
activity	O
increased	O
to	O
a	O
maximum	O
of	O
3	O
.	O

6	O
-	O
fold	O
at	O
48	O
h	O
.	O

The	O
effects	O
of	O
antisense	O
MTase	B
cDNA	O
transfections	O
were	O
less	O
pronounced	O
,	O
and	O
levels	O
of	O
MTase	B
gene	O
transcripts	O
and	O
enzyme	O
activity	O
in	O
transfectants	O
were	O
decreased	O
to	O
only	O
,	O
approximately	O
,	O
one	O
-	O
half	O
the	O
levels	O
of	O
controls	O
.	O

The	O
alterations	O
in	O
DNA	B
MTase	I
expression	O
were	O
associated	O
with	O
corresponding	O
changes	O
in	O
the	O
level	O
of	O
global	O
DNA	O
methylation	O
and	O
in	O
the	O
methylation	O
of	O
the	O
GSTP1	B
gene	O
in	O
the	O
cells	O
,	O
however	O
,	O
with	O
no	O
detectable	O
morphological	O
or	O
cytotoxic	O
effects	O
on	O
the	O
cells	O
.	O

No	O
significant	O
changes	O
in	O
GSTP1	B
gene	O
expression	O
were	O
detected	O
after	O
the	O
transfections	O
,	O
presumably	O
because	O
of	O
the	O
high	O
levels	O
of	O
basal	O
GSTP1	B
expression	O
in	O
the	O
cells	O
.	O

Consequently	O
,	O
the	O
p16	B
gene	O
,	O
known	O
to	O
be	O
repressed	O
transcriptionally	O
by	O
DNA	O
methylation	O
,	O
was	O
examined	O
for	O
the	O
functional	O
effects	O
of	O
the	O
altered	O
MTase	B
levels	O
.	O

The	O
results	O
showed	O
a	O
2	O
-	O
fold	O
decrease	O
in	O
p16	B
gene	O
transcripts	O
with	O
the	O
sense	O
MTase	B
transfectants	O
,	O
while	O
in	O
the	O
MTase	B
antisense	O
-	O
transfected	O
cells	O
p16	B
transcript	O
levels	O
increased	O
by	O
30	O
%	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
the	O
feasibility	O
of	O
using	O
both	O
sense	O
and	O
antisense	O
DNA	B
MTase	I
expression	O
vectors	O
to	O
regulate	O
DNA	B
MTase	I
levels	O
in	O
glioma	O
cells	O
and	O
that	O
,	O
over	O
relatively	O
short	O
periods	O
of	O
time	O
,	O
the	O
alterations	O
in	O
MTase	B
activities	O
are	O
not	O
deleterious	O
to	O
the	O
cells	O
.	O

The	O
system	O
provides	O
a	O
model	O
with	O
which	O
the	O
role	O
of	O
DNA	O
methylation	O
in	O
critical	O
genes	O
and	O
DNA	O
sequences	O
can	O
be	O
investigated	O
in	O
glioma	O
cells	O
.	O

p53	B
-	O
independent	O
induction	O
of	O
p21	B
(	O
WAF1	B
/	O
CIP1	B
)	O
,	O
reduction	O
of	O
cyclin	B
B1	I
and	O
G2	O
/	O
M	O
arrest	O
by	O
the	O
isoflavone	O
genistein	O
in	O
human	O
prostate	O
carcinoma	O
cells	O
.	O

Genistein	O
,	O
a	O
natural	O
isoflavonoid	O
phytoestrogen	O
,	O
is	O
a	O
strong	O
inhibitor	O
of	O
protein	B
tyrosine	I
kinase	I
and	O
DNA	B
topoisomerase	I
II	I
activities	O
.	O

Genistein	O
has	O
been	O
shown	O
to	O
have	O
anticancer	O
proliferation	O
,	O
differentiation	O
and	O
chemopreventive	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
addressed	O
the	O
mechanism	O
of	O
action	O
by	O
which	O
genistein	O
suppressed	O
the	O
proliferation	O
of	O
p53	B
-	O
null	O
human	O
prostate	O
carcinoma	O
cells	O
.	O

Genistein	O
significantly	O
inhibited	O
the	O
cell	O
growth	O
,	O
which	O
effect	O
was	O
reversible	O
,	O
and	O
induced	O
dendrite	O
-	O
like	O
structure	O
.	O

The	O
inhibitory	O
effects	O
of	O
genistein	O
on	O
cell	O
growth	O
proliferation	O
were	O
associated	O
with	O
a	O
G2	O
/	O
M	O
arrest	O
in	O
cell	O
cycle	O
progression	O
concomitant	O
with	O
a	O
marked	O
inhibition	O
of	O
cyclin	B
B1	I
and	O
an	O
induction	O
of	O
Cdk	B
inhibitor	I
p21	B
(	O
WAF1	B
/	O
CIP1	B
)	O
in	O
a	O
p53	B
-	O
independent	O
manner	O
.	O

Following	O
genistein	O
treatment	O
of	O
cells	O
,	O
an	O
increased	O
binding	O
of	O
p21	B
with	O
Cdk2	B
and	O
Cdc2	B
paralleled	O
a	O
significant	O
decrease	O
in	O
Cdc2	B
and	O
Cdk2	B
kinase	B
activity	O
with	O
no	O
change	O
in	O
Cdk2	B
and	O
Cdc2	B
expression	O
.	O

Genistein	O
also	O
induced	O
the	O
activation	O
of	O
a	O
p21	B
promoter	O
reporter	O
construct	O
,	O
utilizing	O
a	O
sequence	O
distinct	O
from	O
the	O
p53	B
-	O
binding	O
site	O
.	O

Analysis	O
of	O
deletion	O
constructs	O
of	O
the	O
p21	B
promoter	O
indicated	O
that	O
the	O
response	O
to	O
genistein	O
could	O
be	O
localized	O
to	O
the	O
300	O
base	O
pairs	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
.	O

These	O
data	O
suggest	O
that	O
genistein	O
may	O
exert	O
a	O
strong	O
anticarcinogenic	O
effect	O
,	O
and	O
that	O
this	O
effect	O
possibly	O
involves	O
an	O
induction	O
of	O
p21	B
,	O
which	O
inhibits	O
the	O
threshold	O
kinase	B
activities	O
of	O
Cdks	B
and	O
associated	O
cyclins	B
,	O
leading	O
to	O
a	O
G2	O
/	O
M	O
arrest	O
in	O
the	O
cell	O
cycle	O
progression	O
.	O

Tunicamycin	O
enhances	O
the	O
anticellular	O
activity	O
of	O
interferon	B
by	O
inhibiting	O
G1	O
/	O
S	O
phase	O
progression	O
in	O
3T3	O
cells	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
the	O
cell	O
growth	O
inhibitory	O
activity	O
of	O
interferon	B
(	O
IFN	B
)	O
is	O
significantly	O
enhanced	O
by	O
tunicamycin	O
(	O
TM	O
)	O
(	O
Maheshwari	O
et	O
al.	O
,	O
Science	O
219	O
,	O
1339	O
-	O
1341	O
,	O
1983	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
investigated	O
various	O
regulatory	O
points	O
of	O
synergistic	O
action	O
between	O
TM	O
and	O
IFN	B
-	I
alpha	I
/	I
beta	I
that	O
inhibit	O
cell	O
growth	O
in	O
NIH	O
3T3	O
cells	O
.	O

The	O
MTT	O
(	O
3-	O
[	O
4,5-dimethylthiazol-2-yl	O
]	O
-2,5-diphenyl	O
tetrazolium	O
bromide	O
)	O
viability	O
assays	O
showed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
percentage	O
inhibition	O
of	O
the	O
cells	O
when	O
treated	O
with	O
either	O
TM	O
or	O
IFN	B
.	O

When	O
doses	O
of	O
TM	O
and	O
IFN	B
that	O
had	O
no	O
significant	O
inhibition	O
on	O
cell	O
viability	O
were	O
used	O
in	O
combination	O
,	O
there	O
was	O
a	O
pronounced	O
suppression	O
of	O
DNA	O
synthesis	O
(	O
tritiated	O
thymidine	O
incorporation	O
)	O
.	O

Flow	O
cytometry	O
studies	O
revealed	O
that	O
individual	O
treatments	O
with	O
either	O
IFN	B
or	O
TM	O
that	O
did	O
not	O
alter	O
the	O
cell	O
cycle	O
profile	O
,	O
when	O
combined	O
,	O
resulted	O
in	O
an	O
impaired	O
cell	O
cycle	O
by	O
inhibiting	O
G1	O
/	O
S	O
progression	O
.	O

The	O
blockage	O
of	O
G1	O
/	O
S	O
transition	O
was	O
associated	O
with	O
reduction	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
(	O
CDK4	B
)	O
activity	O
.	O

The	O
mRNA	O
(	O
analyzed	O
by	O
ribonuclease	B
protection	O
assay	O
)	O
and	O
protein	O
levels	O
(	O
assayed	O
by	O
Western	O
blotting	O
)	O
of	O
cyclins	B
D1	I
,	I
D3	I
,	O
and	O
CDK4	B
were	O
downregulated	O
by	O
combined	O
treatment	O
with	O
IFN	B
and	O
TM	O
.	O

An	O
increase	O
in	O
the	O
expression	O
of	O
p27	B
/	I
kipl	I
,	O
an	O
inhibitor	O
of	O
CDK4	B
,	O
was	O
observed	O
in	O
cells	O
that	O
were	O
treated	O
with	O
both	O
IFN	B
and	O
TM	O
.	O

These	O
studies	O
suggest	O
that	O
insufficient	O
formation	O
of	O
the	O
active	O
cyclin	B
/	O
CDK	B
complex	O
could	O
possibly	O
be	O
deferring	O
the	O
cells	O
from	O
normal	O
cycling	O
and	O
may	O
be	O
responsible	O
for	O
the	O
ability	O
of	O
TM	O
to	O
enhance	O
cell	O
growth	O
inhibition	O
induced	O
by	O
IFN	B
.	O

Identification	O
of	O
two	O
polyketide	B
synthase	I
gene	O
clusters	O
on	O
the	O
linear	O
plasmid	O
pSLA2-L	O
in	O
Streptomyces	O
rochei	O
.	O

The	O
200	O
kb	O
linear	O
plasmid	O
pSLA2-L	O
was	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
production	O
of	O
two	O
macrolide	O
antibiotics	O
,	O
lankamycin	O
(	O
Lm	O
)	O
and	O
lankacidin	O
(	O
Lc	O
)	O
,	O
in	O
Streptomyces	O
rochei	O
7434AN4	O
.	O

Hybridization	O
experiments	O
with	O
the	O
polyketide	B
synthase	I
(	O
PKS	B
)	O
genes	O
for	O
erythromycin	O
and	O
actinorhodin	O
identified	O
two	O
eryAI	B
-	O
homologous	O
regions	O
and	O
an	O
actI	B
-	O
homologous	O
region	O
on	O
pSLA2-L	O
.	O

The	O
nucleotide	O
sequence	O
of	O
a	O
3.6	O
kb	O
SacI	B
fragment	O
carrying	O
one	O
of	O
the	O
eryAI	B
-	O
homologs	O
revealed	O
that	O
it	O
codes	O
for	O
part	O
of	O
a	O
large	O
protein	O
with	O
four	O
domains	O
for	O
ketoreductase	B
,	O
acyl	B
carrier	I
protein	I
,	O
ketosynthase	B
,	O
and	O
acyltransferase	B
.	O

Gene	O
disruption	O
confirmed	O
that	O
the	O
two	O
eryAI	B
-	O
homologs	O
are	O
parts	O
of	O
a	O
large	O
type	O
-	O
I	O
PKS	B
gene	O
cluster	O
for	O
Lm	O
.	O

A	O
4.8	O
kb	O
DNA	O
carrying	O
the	O
actI	B
-	O
homologous	O
region	O
contains	O
four	O
open	O
reading	O
frames	O
(	O
ORF1	O
-	O
ORF4	O
)	O
as	O
well	O
as	O
an	O
additional	O
ORF	O
,	O
i.e.	O
ORF5	O
,	O
which	O
might	O
code	O
for	O
a	O
thioesterase	B
.	O

Deletion	O
of	O
the	O
ORF2	O
-	O
ORF4	O
region	O
showed	O
that	O
it	O
is	O
not	O
involved	O
in	O
the	O
synthesis	O
of	O
Lm	O
or	O
Lc	O
.	O

Thus	O
,	O
it	O
was	O
confirmed	O
that	O
pSLA2-L	O
contains	O
two	O
PKS	B
gene	O
clusters	O
for	O
Lm	O
and	O
an	O
unknown	O
type	O
-	O
II	O
polyketide	O
.	O

Characterization	O
of	O
ywhE	B
,	O
which	O
encodes	O
a	O
putative	O
high	O
-	O
molecular	O
-	O
weight	O
class	O
A	O
penicillin	O
-	O
binding	O
protein	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
Bacillus	O
subtilis	O
genome	O
sequencing	O
project	O
[	O
Kunst	O
et	O
al.	O
,	O
Nature	O
390	O
(	O
1997	O
)	O
249	O
-	O
256	O
]	O
identified	O
ywhE	B
as	O
a	O
gene	O
that	O
potentially	O
encodes	O
a	O
high	O
-	O
molecular	O
-	O
weight	O
class	O
A	O
penicillin	O
-	O
binding	O
protein	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
a	O
translational	O
ywhE	B
-	O
lacZ	B
fusion	O
showed	O
that	O
ywhE	B
expression	O
is	O
sporulation	O
-	O
specific	O
,	O
and	O
is	O
controlled	O
predominantly	O
by	O
the	O
forespore	O
-	O
specific	O
sigma	B
factor	I
sigma	B
(	I
F	I
)	I
,	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
sigma	B
(	I
G	I
)	I
.	O

Primer	O
extension	O
analysis	O
identified	O
two	O
transcription	O
start	O
sites	O
located	O
26	O
and	O
27	O
nucleotides	O
upstream	O
of	O
the	O
ywhE	B
translational	O
initiation	O
codon	O
.	O

Sequences	O
located	O
in	O
the	O
-	O
10	O
and	O
-	O
35	O
regions	O
relative	O
to	O
the	O
transcription	O
start	O
sites	O
showed	O
good	O
homology	O
to	O
the	O
consensus	O
sequences	O
for	O
promoter	O
elements	O
of	O
sigma	B
(	I
F	I
)	I
-	O
dependent	O
genes	O
.	O

An	O
insertional	O
mutation	O
in	O
ywhE	B
had	O
no	O
significant	O
effect	O
on	O
growth	O
,	O
morphology	O
,	O
and	O
sporulation	O
,	O
and	O
ywhE	B
spores	O
had	O
normal	O
heat	O
-	O
resistance	O
,	O
cortex	O
structure	O
,	O
and	O
germination	O
and	O
outgrowth	O
properties	O
.	O

However	O
,	O
overexpression	O
of	O
ywhE	B
in	O
Escherichia	O
coli	O
resulted	O
in	O
cell	O
lysis	O
.	O

Mechanism	O
of	O
atherosclerotic	O
calcification	O
.	O

Calcification	O
is	O
almost	O
invariably	O
associated	O
with	O
atherosclerotic	O
plaque	O
lesions	O
.	O

Recent	O
data	O
suggest	O
that	O
plaque	O
calcification	O
is	O
an	O
active	O
,	O
regulated	O
process	O
similar	O
to	O
osteogenesis	O
.	O

In	O
order	O
to	O
clarify	O
the	O
mechanism	O
of	O
plaque	O
calcification	O
,	O
we	O
developed	O
an	O
in	O
vitro	O
model	O
of	O
vascular	O
calcification	O
by	O
utilizing	O
bovine	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
BVSMCs	O
)	O
.	O

This	O
model	O
is	O
useful	O
in	O
that	O
diffuse	O
and	O
massive	O
calcification	O
can	O
be	O
induced	O
within	O
2	O
weeks	O
and	O
thereby	O
biochemical	O
analyses	O
of	O
vascular	O
calcification	O
can	O
be	O
performed	O
.	O

We	O
have	O
analyzed	O
several	O
aspects	O
of	O
vascular	O
calcification	O
by	O
using	O
this	O
model	O
and	O
demonstrated	O
as	O
follows	O
:	O
1	O
)	O
in	O
vitro	O
calcification	O
of	O
BVSMCs	O
is	O
regulated	O
by	O
calciotropic	O
hormones	O
and	O
BVSMCs	O
are	O
equipped	O
with	O
a	O
unique	O
autocrine	O
and/or	O
paracrine	O
system	O
regulating	O
calcium	O
metabolism	O
.	O

2	O
)	O
Sodium	O
-	O
dependent	O
phosphate	O
cotransport	O
plays	O
a	O
crucial	O
role	O
in	O
BVSMC	O
calcification	O
as	O
well	O
as	O
in	O
mineralization	O
of	O
skeletal	O
tissues	O
.	O

3	O
)	O
BVSMCs	O
acquire	O
osteoblastic	O
phenotype	O
under	O
certain	O
conditions	O
.	O

Finally	O
,	O
we	O
discuss	O
the	O
roles	O
of	O
macrophages	O
in	O
the	O
development	O
of	O
atherosclerotic	O
calcification	O
.	O

Interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
induces	O
gene	O
expression	O
of	O
25-hydrovitamin	B
D-1	I
alpha	I
-	I
hydroxylase	I
(	O
1	B
alpha	I
OHase	I
)	O
and	O
its	O
activity	O
in	O
macrophages	O
.	O

Since	O
1	B
alpha	I
OHase	I
can	O
locally	O
convert	O
25-hydroxyvitamin	O
D	O
into	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D	O
(	O
1,25	O
(	O
OH	O
)	O
2D	O
)	O
,	O
an	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
it	O
is	O
suggested	O
that	O
local	O
production	O
of	O
1,25	O
(	O
OH	O
)	O
2D	O
by	O
macrophages	O
may	O
promote	O
atherosclerotic	O
calcification	O
.	O

Moreover	O
,	O
macrophages	O
may	O
be	O
involved	O
in	O
the	O
phenotypic	O
changes	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
to	O
acquire	O
calcifying	O
capacity	O
.	O

Therefore	O
,	O
the	O
phenotypic	O
changes	O
of	O
VSMCs	O
in	O
atherosclerotic	O
plaque	O
may	O
contribute	O
to	O
the	O
development	O
of	O
atherosclerotic	O
calcification	O
.	O

Novel	O
beta	B
-	I
lactamase	I
genes	O
from	O
two	O
environmental	O
isolates	O
of	O
Vibrio	O
harveyi	O
.	O

Two	O
ampicillin	O
-	O
resistant	O
(	O
Amp	O
(	O
r	O
)	O
)	O
isolates	O
of	O
Vibrio	O
harveyi	O
,	O
W3B	O
and	O
HB3	O
,	O
were	O
obtained	O
from	O
the	O
coastal	O
waters	O
of	O
the	O
Indonesian	O
island	O
of	O
Java	O
.	O

Strain	O
W3B	O
was	O
isolated	O
from	O
marine	O
water	O
near	O
a	O
shrimp	O
farm	O
in	O
North	O
Java	O
while	O
HB3	O
was	O
from	O
pristine	O
seawater	O
in	O
South	O
Java	O
.	O

In	O
this	O
study	O
,	O
novel	O
beta	B
-	I
lactamase	I
genes	O
from	O
W3B	O
(	O
bla	B
(	O
VHW-1	O
)	O
)	O
and	O
HB3	O
(	O
bla	B
(	O
VHH-1	O
)	O
)	O
were	O
cloned	O
and	O
their	O
nucleotide	O
sequences	O
were	O
determined	O
.	O

An	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
870	O
bp	O
encoding	O
a	O
deduced	O
protein	O
of	O
290	O
amino	O
acids	O
(	O
VHW-1	O
)	O
was	O
revealed	O
for	O
the	O
bla	B
gene	O
of	O
strain	O
W3B	O
while	O
an	O
ORF	O
of	O
849	O
bp	O
encoding	O
a	O
283-amino	O
-	O
acid	O
protein	O
(	O
VHH-1	O
)	O
was	O
deduced	O
for	O
bla	B
(	O
VHH-1	O
)	O
.	O

At	O
the	O
DNA	O
level	O
,	O
genes	O
for	O
VHW-1	O
and	O
VHH-1	O
have	O
a	O
97	O
%	O
homology	O
,	O
while	O
at	O
the	O
protein	O
level	O
they	O
have	O
a	O
91	O
%	O
homology	O
of	O
amino	O
acid	O
sequences	O
.	O

Neither	O
gene	O
sequence	O
showed	O
homology	O
to	O
any	O
other	O
beta	B
-	I
lactamases	I
in	O
the	O
databases	O
.	O

The	O
deduced	O
proteins	O
were	O
found	O
to	O
be	O
class	O
A	O
beta	B
-	I
lactamases	I
bearing	O
low	O
levels	O
of	O
homology	O
(	O
<	O
50	O
%	O
)	O
to	O
other	O
beta	B
-	I
lactamases	I
of	O
the	O
same	O
class	O
.	O

The	O
highest	O
level	O
of	O
identity	O
was	O
obtained	O
with	O
beta	B
-	I
lactamases	I
from	O
Pseudomonas	O
aeruginosa	O
,	O
i.e.	O
,	O
PSE-1	B
,	O
PSE-4	B
,	O
and	O
CARB	B
-	I
3	I
,	O
and	O
Vibrio	O
cholerae	O
CARB-6	B
.	O

Our	O
study	O
showed	O
that	O
both	O
strains	O
W3B	O
and	O
HB3	O
possess	O
an	O
endogenous	O
plasmid	O
of	O
approximately	O
60	O
kb	O
in	O
size	O
.	O

However	O
,	O
Southern	O
hybridization	O
analysis	O
employing	O
bla	B
(	O
VHW-1	O
)	O
as	O
a	O
gene	O
probe	O
demonstrated	O
that	O
the	O
bla	B
gene	O
was	O
not	O
located	O
in	O
the	O
plasmid	O
.	O

A	O
total	O
of	O
nine	O
ampicillin	O
-	O
resistant	O
V.	O
harveyi	O
strains	O
,	O
including	O
W3B	O
and	O
HB3	O
,	O
were	O
examined	O
by	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
of	O
NotI	B
-	O
digested	O
genomic	O
DNA	O
.	O

Despite	O
a	O
high	O
level	O
of	O
intrastrain	O
genetic	O
diversity	O
,	O
the	O
bla	B
(	O
VHW-1	O
)	O
probe	O
hybridized	O
only	O
to	O
an	O
80	O
-	O
or	O
160	O
-	O
kb	O
NotI	B
genomic	O
fragment	O
in	O
different	O
isolates	O
.	O

The	O
bHLH	O
gene	O
Hes1	B
regulates	O
differentiation	O
of	O
multiple	O
cell	O
types	O
.	O

For	O
embryos	O
that	O
have	O
small	O
pancreas	O
and	O
lack	O
brain	O
,	O
eyes	O
and	O
thymus	O
,	O
the	O
defects	O
are	O
caused	O
by	O
mutation	O
of	O
a	O
single	O
gene	O
,	O
Hes1	B
.	O

Hes1	B
encodes	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcriptional	O
repressor	O
and	O
functionally	O
antagonizes	O
positive	O
bHLH	O
genes	O
such	O
as	O
the	O
neuronal	O
determination	O
gene	O
,	O
Mash1	B
.	O

Misexpression	O
of	O
Hes1	B
inhibits	O
cell	O
differentiation	O
and	O
keeps	O
cells	O
at	O
the	O
precursor	O
stage	O
or	O
proliferative	O
stage	O
.	O

Conversely	O
,	O
in	O
the	O
absence	O
of	O
Hes1	B
,	O
the	O
expression	O
of	O
positive	O
bHLH	O
genes	O
is	O
upregulated	O
and	O
cells	O
differentiate	O
prematurely	O
without	O
sufficient	O
cell	O
growth	O
.	O

As	O
a	O
result	O
,	O
the	O
development	O
of	O
many	O
tissues	O
such	O
as	O
the	O
brain	O
,	O
eye	O
and	O
pancreas	O
is	O
severely	O
affected	O
.	O

Thus	O
,	O
Hes1	B
regulates	O
tissue	O
morphogenesis	O
by	O
maintaining	O
undifferentiated	O
cells	O
.	O

In	O
the	O
case	O
of	O
T	O
cell	O
development	O
,	O
Hes1	B
mutation	O
leads	O
to	O
defects	O
of	O
expansion	O
of	O
early	O
T	O
cell	O
precursors	O
and	O
thereby	O
suppresses	O
T	O
cell	O
fate	O
specification	O
.	O

Thus	O
,	O
Hes1	B
promotes	O
differentiation	O
of	O
some	O
cell	O
types	O
in	O
addition	O
to	O
maintenance	O
of	O
the	O
undifferentiated	O
state	O
.	O

Interestingly	O
,	O
Hes1	B
expression	O
is	O
controlled	O
by	O
the	O
transmembrane	O
protein	O
Notch	B
,	O
which	O
is	O
activated	O
by	O
the	O
ligands	O
expressed	O
on	O
the	O
surface	O
of	O
neighboring	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
Notch	B
-	O
Hes1	B
pathway	O
,	O
which	O
is	O
controlled	O
by	O
cell	O
-	O
cell	O
interaction	O
,	O
plays	O
an	O
essential	O
role	O
in	O
differentiation	O
of	O
many	O
cell	O
types	O
.	O

Diversity	O
of	O
the	O
p70	B
killer	I
cell	I
inhibitory	I
receptor	I
(	I
KIR3DL	I
)	I
family	I
members	O
in	O
a	O
single	O
individual	O
.	O

NK	O
cells	O
and	O
some	O
T	O
cells	O
express	O
members	O
of	O
a	O
multigenic	O
family	O
of	O
killer	O
cell	O
inhibitory	O
receptors	O
(	O
KIRs	B
)	O
including	O
p70	B
KIR	I
(	O
KIR3DL	B
)	O
and	O
p58	B
KIR	I
(	I
KIR2DL	I
)	I
family	I
that	O
recognize	O
polymorphic	O
class	B
I	I
MHC	I
molecules	O
on	O
target	O
cells	O
and	O
transmit	O
an	O
inhibitory	O
signal	O
to	O
prevent	O
killer	O
cell	O
-	O
mediated	O
cytoxicity	O
.	O

The	O
cDNA	O
sequences	O
of	O
p70	B
KIR	I
family	I
members	O
reported	O
so	O
far	O
suggest	O
that	O
the	O
p70	B
KIR	I
gene	O
consists	O
of	O
a	O
multigene	O
complex	O
and	O
that	O
each	O
gene	O
may	O
exhibit	O
certain	O
degrees	O
of	O
polymorphism	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
how	O
diverse	O
the	O
repertoire	O
of	O
the	O
p70	B
KIR	I
family	I
is	O
,	O
particularly	O
in	O
a	O
single	O
individual	O
.	O

To	O
address	O
this	O
question	O
in	O
more	O
detail	O
and	O
to	O
determine	O
some	O
indication	O
as	O
to	O
the	O
origin	O
of	O
the	O
diversity	O
,	O
we	O
cloned	O
p70	B
KIR	I
cDNAs	O
from	O
a	O
single	O
individual	O
.	O

We	O
identified	O
nine	O
new	O
KIRs	B
that	O
are	O
different	O
from	O
the	O
previously	O
reported	O
ones	O
.	O

A	O
comparison	O
of	O
the	O
amino	O
acid	O
sequences	O
with	O
published	O
sequences	O
of	O
p70	B
KIRs	I
showed	O
that	O
two	O
clones	O
belonged	O
to	O
the	O
KIR3DL1	B
family	I
,	O
five	O
clones	O
belonged	O
to	O
the	O
KIR3DL2	B
family	I
,	O
one	O
clone	O
belonged	O
to	O
the	O
KIR2DL4	B
family	I
,	O
and	O
one	O
clone	O
appeared	O
to	O
be	O
an	O
alternatively	O
spliced	O
form	O
of	O
p70	B
KIR	I
.	O

These	O
results	O
suggested	O
that	O
the	O
repertoire	O
of	O
p70	B
KIR	I
family	I
members	O
in	O
a	O
single	O
individual	O
is	O
highly	O
diverse	O
.	O

It	O
is	O
not	O
clear	O
how	O
the	O
diverse	O
receptors	O
are	O
generated	O
in	O
a	O
single	O
individual	O
,	O
but	O
a	O
comparison	O
of	O
amino	O
acid	O
sequences	O
of	O
p70	B
KIR	I
family	I
members	O
suggested	O
that	O
some	O
of	O
them	O
may	O
be	O
encoded	O
by	O
distinct	O
genes	O
or	O
their	O
alleles	O
,	O
while	O
others	O
may	O
be	O
generated	O
by	O
a	O
recombination	O
mechanism	O
and/or	O
an	O
alternative	O
splicing	O
mechanism	O
at	O
the	O
maturation	O
of	O
the	O
mRNA	O
transcripts	O
.	O

Functional	O
differences	O
between	O
human	O
and	O
bovine	O
immunodeficiency	O
virus	O
Tat	B
transcription	B
factors	I
.	O

Transcriptional	O
transactivation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
element	O
by	O
the	O
essential	O
viral	O
Tat	B
protein	O
requires	O
recruitment	O
of	O
positive	B
transcription	I
elongation	I
factor	I
b	I
(	O
P	B
-	I
TEFb	I
)	O
to	O
the	O
viral	O
TAR	O
RNA	O
target	O
.	O

The	O
recruitment	O
of	O
P	B
-	I
TEFb	I
,	O
which	O
has	O
been	O
proposed	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
activation	O
of	O
viral	O
gene	O
expression	O
,	O
is	O
mediated	O
by	O
the	O
highly	O
cooperative	O
interaction	O
of	O
Tat	B
and	O
cyclin	B
T1	I
,	O
an	O
essential	O
component	O
of	O
P	B
-	I
TEFb	I
,	O
with	O
the	O
HIV-1	O
TAR	O
element	O
.	O

Species	O
,	O
such	O
as	O
rodents	O
,	O
that	O
encode	O
cyclin	B
T1	I
variants	O
that	O
are	O
unable	O
to	O
support	O
TAR	O
binding	O
by	O
the	O
Tat	B
-	O
cyclin	B
T1	I
heterodimer	O
are	O
also	O
unable	O
to	O
support	O
HIV-1	O
Tat	B
function	O
.	O

In	O
contrast	O
,	O
we	O
here	O
demonstrate	O
that	O
the	O
bovine	O
immunodeficiency	O
virus	O
(	O
BIV	O
)	O
Tat	B
protein	O
is	O
fully	O
able	O
to	O
bind	O
to	O
BIV	O
TAR	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
cofactor	O
.	O

Nevertheless	O
,	O
BIV	O
Tat	B
can	O
specifically	O
recruit	O
cyclin	B
T1	I
to	O
the	O
BIV	O
TAR	O
element	O
,	O
and	O
this	O
recruitment	O
is	O
as	O
essential	O
for	O
BIV	O
Tat	B
function	O
as	O
it	O
is	O
for	O
HIV-1	O
Tat	B
activity	O
.	O

However	O
,	O
because	O
the	O
cyclin	B
T1	I
protein	O
does	O
not	O
contribute	O
to	O
TAR	O
binding	O
,	O
BIV	O
Tat	B
is	O
able	O
to	O
function	O
effectively	O
in	O
cells	O
from	O
several	O
species	O
that	O
do	O
not	O
support	O
HIV-1	O
Tat	B
function	O
.	O

Thus	O
,	O
BIV	O
Tat	B
,	O
while	O
apparently	O
dependent	O
on	O
the	O
same	O
cellular	O
cofactor	O
as	O
the	O
Tat	B
proteins	O
encoded	O
by	O
other	O
lentiviruses	O
,	O
is	O
nevertheless	O
unique	O
in	O
terms	O
of	O
the	O
mechanism	O
used	O
to	O
recruit	O
the	O
BIV	O
Tat	B
-	O
cyclin	B
T1	I
complex	O
to	O
the	O
viral	O
LTR	O
promoter	O
.	O

A	O
novel	O
3-methyladenine	B
DNA	I
glycosylase	I
from	O
helicobacter	O
pylori	O
defines	O
a	O
new	O
class	O
within	O
the	O
endonuclease	B
III	I
family	I
of	I
base	I
excision	I
repair	I
glycosylases	I
.	O

The	O
cloning	O
,	O
purification	O
,	O
and	O
characterization	O
of	O
MagIII	B
,	O
a	O
3	B
-	I
methyladenine	I
DNA	I
glycosylase	I
from	O
Helicobacter	O
pylori	O
,	O
is	O
presented	O
in	O
this	O
paper	O
.	O

Sequence	O
analysis	O
of	O
the	O
genome	O
of	O
this	O
pathogen	O
failed	O
to	O
identify	O
open	O
reading	O
frames	O
potentially	O
coding	O
for	O
proteins	O
with	O
a	O
3-methyladenine	B
DNA	I
glycosylase	I
activity	O
.	O

The	O
putative	O
product	O
of	O
the	O
HP602	O
open	O
reading	O
frame	O
,	O
reported	O
as	O
an	O
endonuclease	B
III	I
,	O
shares	O
extensive	O
amino	O
acid	O
sequence	O
homology	O
with	O
some	O
bacterial	O
members	O
of	O
this	O
family	O
and	O
has	O
the	O
canonic	O
active	O
site	O
helix	O
-	O
hairpin	O
-	O
helix	O
-	O
GPD	O
motif	O
.	O

Surprisingly	O
,	O
this	O
predicted	O
H.	O
pylori	O
endonuclease	B
III	I
encodes	O
a	O
25,220-Da	O
protein	O
able	O
to	O
release	O
3-methyladenine	O
,	O
but	O
not	O
oxidized	O
bases	O
,	O
from	O
modified	O
DNA	O
.	O

MagIII	B
has	O
no	O
abasic	B
site	I
lyase	I
activity	O
and	O
displays	O
the	O
substrate	O
specificity	O
of	O
the	O
3-methyladenine	B
-	I
DNA	I
glycosylase	I
type	I
I	I
of	O
Escherichia	O
coli	O
(	O
Tag	O
)	O
because	O
it	O
is	O
not	O
able	O
to	O
recognize	O
7-methylguanine	O
or	O
hypoxanthine	O
as	O
substrates	O
.	O

The	O
expression	O
of	O
the	O
magIII	B
open	O
reading	O
frame	O
in	O
null	O
3-methyladenine	B
glycosylase	I
E.	O
coli	O
(	O
tag	O
alkA	B
)	O
restores	O
to	O
this	O
mutant	O
partial	O
resistance	O
to	O
alkylating	O
agents	O
.	O

MagIII	B
-	O
deficient	O
H.	O
pylori	O
cells	O
show	O
an	O
alkylation	O
-	O
sensitive	O
phenotype	O
.	O

H.	O
pylori	O
wild	O
type	O
cells	O
exposed	O
to	O
alkylating	O
agents	O
present	O
an	O
adaptive	O
response	O
by	O
inducing	O
the	O
expression	O
of	O
magIII	B
.	O

MagIII	B
is	O
thus	O
a	O
novel	O
bacterial	O
member	O
of	O
the	O
endonuclease	B
III	I
family	I
,	O
which	O
displays	O
biochemical	O
properties	O
not	O
described	O
for	O
any	O
of	O
the	O
members	O
of	O
this	O
group	O
until	O
now	O
.	O

Aquaporin	B
adipose	I
,	O
a	O
putative	O
glycerol	B
channel	I
in	O
adipocytes	O
.	O

Adipose	O
tissue	O
is	O
a	O
major	O
site	O
of	O
glycerol	O
production	O
in	O
response	O
to	O
energy	O
balance	O
.	O

However	O
,	O
molecular	O
basis	O
of	O
glycerol	O
release	O
from	O
adipocytes	O
has	O
not	O
yet	O
been	O
elucidated	O
.	O

We	O
recently	O
cloned	O
a	O
novel	O
member	O
of	O
the	O
aquaporin	B
family	I
,	O
aquaporin	B
adipose	I
(	O
AQPap	B
)	O
,	O
which	O
has	O
glycerol	O
permeability	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
examine	O
the	O
hypothesis	O
that	O
AQPap	B
serves	O
as	O
a	O
glycerol	B
channel	I
in	O
adipocytes	O
.	O

Adipose	O
tissue	O
expressed	O
AQPap	B
mRNA	O
in	O
high	O
abundance	O
,	O
but	O
not	O
the	O
mRNAs	O
for	O
the	O
other	O
aquaglyceroporins	B
,	O
AQP3	B
and	O
AQP9	B
,	O
indicating	O
that	O
AQPap	B
is	O
the	O
only	O
known	O
aquaglyceroporin	B
expressed	O
in	O
adipose	O
tissue	O
.	O

Glycerol	O
release	O
from	O
3T3-L1	O
cells	O
was	O
increased	O
during	O
differentiation	O
in	O
parallel	O
with	O
AQPap	B
mRNA	O
levels	O
and	O
suppressed	O
by	O
mercury	O
ion	O
,	O
which	O
inhibits	O
the	O
function	O
of	O
AQPs	B
,	O
supporting	O
AQPap	B
functions	O
as	O
a	O
glycerol	B
channel	I
in	O
adipocytes	O
.	O

Fasting	O
increased	O
and	O
refeeding	O
suppressed	O
adipose	O
AQPap	B
mRNA	O
levels	O
in	O
accordance	O
with	O
plasma	O
glycerol	O
levels	O
and	O
oppositely	O
to	O
plasma	O
insulin	B
levels	O
in	O
mice	O
.	O

Insulin	B
dose	O
-	O
dependently	O
suppressed	O
AQPap	B
mRNA	O
expression	O
in	O
3T3-L1	O
cells	O
.	O

AQPap	B
mRNA	O
levels	O
and	O
adipose	O
glycerol	O
concentrations	O
measured	O
by	O
the	O
microdialysis	O
technique	O
were	O
increased	O
in	O
obese	O
mice	O
with	O
insulin	B
resistance	O
.	O

Accordingly	O
,	O
negative	O
regulation	O
of	O
AQPap	B
expression	O
by	O
insulin	B
was	O
impaired	O
in	O
the	O
insulin	B
-	O
resistant	O
state	O
.	O

Exposure	O
of	O
epinephrine	O
translocated	O
AQPap	B
protein	O
from	O
perinuclear	O
cytoplasm	O
to	O
the	O
plasma	O
membrane	O
in	O
3T3-L1	O
adipocytes	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
AQPap	B
plays	O
an	O
important	O
role	O
in	O
glycerol	O
release	O
from	O
adipocytes	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
ATP	B
citrate	I
-	I
lyase	I
gene	O
by	O
sterol	B
regulatory	I
element	I
-	I
binding	I
proteins	I
.	O

In	O
an	O
attempt	O
to	O
identify	O
unknown	O
target	O
genes	O
for	O
SREBP-1	B
,	O
total	O
RNA	O
from	O
a	O
stable	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
(	O
CHO-487	O
)	O
expressing	O
a	O
mature	O
form	O
of	O
human	O
SREBP-1a	B
(	O
amino	O
acids	O
1	O
-	O
487	O
)	O
with	O
a	O
LacSwitch	O
Inducible	O
Mammalian	O
Expression	O
System	O
was	O
subjected	O
to	O
a	O
polymerase	O
chain	O
reaction	O
subtraction	O
method	O
.	O

One	O
of	O
the	O
fragments	O
was	O
found	O
to	O
have	O
90	O
and	O
86	O
%	O
homology	O
with	O
rat	O
and	O
human	O
ATP	B
citrate	I
-	I
lyase	I
(	O
ACL	B
)	O
cDNA	O
,	O
respectively	O
.	O

When	O
Hep	O
G2	O
cells	O
are	O
cultured	O
under	O
either	O
sterol	O
-	O
loaded	O
or	O
-	O
depleted	O
conditions	O
,	O
expression	O
of	O
the	O
gene	O
is	O
induced	O
approximately	O
2	O
-	O
3-fold	O
by	O
sterol	O
depletion	O
.	O

To	O
investigate	O
the	O
direct	O
effect	O
of	O
SREBP-1a	B
on	O
transcription	O
,	O
luciferase	B
assays	O
using	O
the	O
promoter	O
of	O
the	O
human	O
ACL	B
gene	O
were	O
performed	O
.	O

These	O
deletion	O
studies	O
indicated	O
that	O
a	O
minimum	O
160	O
-	O
base	O
pair	O
segment	O
contains	O
the	O
information	O
required	O
for	O
the	O
transcriptional	O
regulation	O
brought	O
about	O
by	O
enforced	O
expression	O
of	O
SREBP-1a	B
.	O

Luciferase	B
assays	O
using	O
mutant	O
reporter	O
genes	O
revealed	O
that	O
SREBP	B
-	O
dependent	O
transcriptional	O
regulation	O
is	O
mediated	O
by	O
two	O
nearby	O
motifs	O
,	O
the	O
SREBP	B
-	O
binding	O
site	O
(	O
a	O
TCAGGCTAG	O
sequence	O
)	O
and	O
the	O
NF	B
-	I
Y	I
-	O
binding	O
site	O
(	O
a	O
CCAAT	O
box	O
)	O
.	O

It	O
was	O
confirmed	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
recombinant	O
SREBP-1a	B
binds	O
to	O
the	O
sequence	O
.	O

Data	O
from	O
studies	O
with	O
transgenic	O
mice	O
and	O
reporter	O
assays	O
show	O
that	O
the	O
ACL	B
gene	O
promoter	O
is	O
activated	O
by	O
SREBP-1a	B
more	O
strongly	O
than	O
SREBP-2	B
in	O
contrast	O
to	O
the	O
HMG	B
CoA	I
synthase	I
and	O
LDL	B
receptor	I
gene	O
promoters	O
,	O
which	O
exhibit	O
the	O
same	O
preference	O
for	O
the	O
two	O
factors	O
.	O

Therefore	O
,	O
SREBPs	B
transcriptionally	O
regulates	O
ACL	B
enzyme	O
activity	O
,	O
which	O
generates	O
the	O
cytosolic	O
acetyl	O
CoA	O
required	O
for	O
both	O
cholesterol	O
and	O
fatty	O
acid	O
synthesis	O
.	O

Selective	O
regulation	O
of	O
endogenous	O
G	B
protein	I
-	I
coupled	I
receptors	I
by	O
arrestins	B
in	O
HEK293	O
cells	O
.	O

Arrestins	B
play	O
an	O
important	O
role	O
in	O
regulating	O
desensitization	O
and	O
trafficking	O
of	O
G	B
protein	I
-	I
coupled	I
receptors	I
(	O
GPCRs	B
)	O
.	O

However	O
,	O
limited	O
insight	O
into	O
the	O
specificity	O
of	O
arrestin	B
-	O
mediated	O
regulation	O
of	O
GPCRs	B
is	O
currently	O
available	O
.	O

Recently	O
,	O
we	O
used	O
an	O
antisense	O
strategy	O
to	O
reduce	O
arrestin	B
levels	O
in	O
HEK293	O
cells	O
and	O
characterize	O
the	O
role	O
of	O
arrestins	B
on	O
endogenous	O
G	B
(	I
s	I
)	I
-coupled	I
receptors	I
(	O
Mundell	O
,	O
S.	O
J.	O
,	O
Loudon	O
,	O
R.	O
B.	O
,	O
and	O
Benovic	O
,	O
J.	O
L.	O
(	O
1999	O
)	O
Biochemistry	O
38	O
,	O
8723	O
-	O
8732	O
)	O
.	O

Here	O
,	O
we	O
characterized	O
GPCRs	B
coupled	O
to	O
either	O
G	B
(	I
q	I
)	I
(	O
M	B
(	I
1	I
)	I
muscarinic	I
acetylcholine	I
receptor	I
(	O
M	B
(	I
1	I
)	I
AchR	I
)	O
and	O
P2y	B
(	I
1	I
)	I
and	O
P2y	B
(	I
2	I
)	I
purinergic	I
receptors	I
)	O
or	O
G	B
(	I
i	I
)	I
(	O
somatostatin	B
and	I
AT1	I
angiotensin	I
receptors	I
)	O
in	O
wild	O
type	O
and	O
arrestin	B
antisense	O
HEK293	O
cells	O
.	O

The	O
agonist	O
-	O
specific	O
desensitization	O
of	O
the	O
M	B
(	I
1	I
)	I
Ach	I
and	I
somatostatin	I
receptors	I
was	O
significantly	O
attenuated	O
in	O
antisense	O
-	O
expressing	O
cells	O
,	O
whereas	O
desensitization	O
of	O
P2y	B
(	I
1	I
)	I
and	O
P2y	B
(	I
2	I
)	I
purinergic	O
and	O
AT1	B
angiotensin	I
receptors	I
was	O
unaffected	O
by	O
reduced	O
arrestin	B
levels	O
.	O

To	O
further	O
examine	O
arrestin	B
/	O
GPCR	B
specificity	O
,	O
we	O
studied	O
the	O
effects	O
of	O
endogenous	O
GPCR	B
activation	O
on	O
the	O
redistribution	O
of	O
arrestin-2	B
epitope	O
tagged	O
with	O
the	O
green	B
fluorescent	I
protein	I
(	O
arrestin-2	B
-	O
GFP	B
)	O
.	O

These	O
studies	O
revealed	O
a	O
receptor	O
-	O
specific	O
movement	O
of	O
arrestin-2	B
-	O
GFP	B
that	O
mirrored	O
the	O
arrestin	B
-	O
receptor	O
specificity	O
observed	O
in	O
the	O
antisense	O
cells	O
.	O

Thus	O
,	O
agonist	O
-	O
induced	O
activation	O
of	O
endogenous	O
beta	B
(	I
2	I
)	I
-adrenergic	I
,	I
prostaglandin	I
E	I
(	I
2	I
)	I
,	I
M	I
(	I
1	I
)	I
Ach	I
,	I
and	I
somatostatin	I
receptors	I
induced	O
arrestin-2	B
-	O
GFP	B
redistribution	O
to	O
early	O
endosomes	O
,	O
whereas	O
P2y	B
(	I
1	I
)	I
and	O
P2y	B
(	I
2	I
)	I
purinergic	O
and	O
AT1	B
angiotensin	I
receptor	I
activation	O
did	O
not	O
.	O

Thus	O
,	O
endogenous	O
arrestins	B
mediate	O
the	O
regulation	O
of	O
selective	O
G	B
(	I
q	I
)	I
-	O
and	O
G	B
(	I
i	I
)	I
-	O
coupled	O
receptors	O
in	O
HEK293	O
cells	O
.	O

PDZ	O
domain	O
-	O
dependent	O
suppression	O
of	O
NF	B
-	I
kappaB	I
/	O
p65	B
-	O
induced	O
Abeta42	B
production	O
by	O
a	O
neuron	O
-	O
specific	B
X11	I
-	I
like	I
protein	I
.	O

It	O
is	O
widely	O
believed	O
that	O
one	O
of	O
the	O
causes	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
the	O
generation	O
and	O
secretion	O
of	O
beta	B
-	I
amyloid	I
(	O
Abeta	B
)	O
from	O
amyloid	B
precursor	I
protein	I
in	O
the	O
brain	O
.	O

Here	O
we	O
report	O
that	O
a	O
transcription	B
factor	I
,	O
NF	B
-	I
kappaB	I
/	O
p65	B
,	O
induces	O
increased	O
secretion	O
of	O
amyloidogenic	O
Abeta42	B
but	O
not	O
Abeta40	B
.	O

The	O
kappaB	O
motif	O
-	O
dependent	O
production	O
of	O
Abeta42	B
was	O
suppressed	O
by	O
binding	O
of	O
NF	B
-	I
kappaB	I
/	O
p65	B
to	O
the	O
PDZ	O
domain	O
of	O
the	B
X11	I
-	I
like	I
protein	I
(	O
X11L	B
)	O
,	O
which	O
a	O
human	O
homologue	O
protein	O
of	O
LIN	B
-	I
10	I
.	O

The	O
results	O
suggest	O
that	O
the	O
PDZ	O
domain	O
of	O
X11L	B
can	O
control	O
the	O
ability	O
of	O
NF	B
-	I
kappaB	I
/	O
p65	B
to	O
induce	O
expression	O
of	O
protein	O
(	O
s	O
)	O
involved	O
in	O
Abeta42	B
production	O
.	O

The	O
amino	O
acids	O
161	O
-	O
163	O
in	O
Rel	B
homology	O
domain	O
(	O
RHD	O
)	O
of	O
NF	B
-	I
kappaB	I
/	O
p65	B
is	O
important	O
in	O
interaction	O
of	O
NF	B
-	I
kappaB	I
/	O
p65	B
with	O
X11L	B
.	O

Another	O
subunit	O
NF	B
-	I
kappaB	I
/	O
p50	B
and	O
heterodimers	O
of	O
p65	B
and	O
p50	B
do	O
not	O
bind	O
to	O
X11L	B
.	O

Our	O
finding	O
indicates	O
NF	B
-	I
kappaB	I
and	O
X11L	B
may	O
,	O
in	O
novel	O
way	O
,	O
regulate	O
Abeta	B
production	O
in	O
neuronal	O
cells	O
.	O

Targeting	O
X11L	B
by	O
specific	O
therapy	O
may	O
provide	O
the	O
possibility	O
to	O
control	O
the	O
progression	O
of	O
AD	O
.	O

The	O
differential	O
expression	O
of	O
apoptosis	O
factors	O
in	O
the	O
alveolar	O
epithelium	O
is	O
redox	O
sensitive	O
and	O
requires	O
NF	B
-	I
kappaB	I
(	O
RelA	B
)	O
-	O
selective	O
targeting	O
.	O

Fetal	O
alveolar	O
type	O
II	O
(	O
fATII	O
)	O
epithelial	O
cells	O
were	O
used	O
to	O
evaluate	O
the	O
role	O
of	O
signaling	O
factors	O
involved	O
in	O
oxidative	O
stress	O
-	O
induced	O
programmed	O
cell	O
death	O
(	O
PCD	O
;	O
apoptosis	O
)	O
.	O

Bcl-2	B
,	O
an	O
antiapoptotic	O
proto	O
-	O
oncogene	O
,	O
showed	O
maximum	O
abundance	O
in	O
hypoxia	O
and	O
mild	O
reoxygenation	O
,	O
but	O
declined	O
thereafter	O
.	O

The	O
Bcl-2	B
counterpart	O
,	O
Bax	B
,	O
which	O
promotes	O
PCD	O
,	O
displayed	O
an	O
increasing	O
logarithmic	O
profile	O
with	O
ascending	O
DeltapO	O
(	O
2	O
)	O
regimen	O
,	O
such	O
that	O
the	O
ratio	O
of	O
Bcl	B
-	I
2	I
/	O
Bax	B
decreased	O
as	O
pO	O
(	O
2	O
)	O
increased	O
.	O

The	O
expression	O
of	O
p53	B
,	O
a	O
cell	O
cycle	O
regulator	O
,	O
paralleled	O
Bax	B
abundance	O
.	O

Pretreatment	O
of	O
fATII	O
cells	O
with	O
l	O
-	O
buthionine-	O
(	O
S	O
,	O
R	O
)	O
-sulfoximine	O
,	O
an	O
irreversible	O
inhibitor	O
of	O
gamma	B
-	I
glutamylcysteine	I
synthetase	I
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
biosynthesis	O
of	O
glutathione	O
(	O
GSH	O
)	O
,	O
enhanced	O
Bax	B
and	O
p53	B
expression	O
over	O
Bcl-2	B
.	O

The	O
GSH	O
analogue	O
,	O
gamma	O
-	O
glutamylcysteinyl	O
-	O
ethyl	O
ester	O
,	O
down	O
-	O
regulated	O
Bax	B
/	O
p53	B
abundance	O
but	O
restored	O
that	O
of	O
Bcl-2	B
,	O
thereby	O
increasing	O
Bcl-2	B
/	O
Bax	B
.	O

The	O
antioxidant	O
and	O
GSH	O
precursor	O
N	O
-	O
acetyl	O
-	O
l	O
-	O
cysteine	O
favored	O
Bcl-2	B
at	O
the	O
expense	O
of	O
Bax	B
/	O
p53	B
,	O
whereas	O
pyrrolidine	O
dithiocarbamate	O
induced	O
Bax	B
against	O
Bcl	B
-	I
2	I
,	O
with	O
mild	O
effect	O
on	O
p53	B
.	O

Sulfasalazine	O
,	O
a	O
potent	O
and	O
specific	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
,	O
induced	O
Bax	B
at	O
the	O
expense	O
of	O
Bcl	B
-	I
2	I
,	O
in	O
a	O
p53	B
-	O
dependent	O
manner	O
.	O

We	O
conclude	O
that	O
the	O
differential	O
expression	O
of	O
signaling	O
factors	O
involved	O
in	O
PCD	O
in	O
the	O
alveolar	O
epithelium	O
is	O
redox	O
-	O
sensitive	O
and	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
negative	O
feedback	O
mechanism	O
transduced	O
by	O
NF	B
-	I
kappaB	I
.	O

Molecular	O
cloning	O
and	O
expression	O
of	O
two	O
distinct	O
human	O
chondroitin	B
4-O	I
-	I
sulfotransferases	I
that	O
belong	O
to	O
the	O
HNK-1	B
sulfotransferase	I
gene	I
family	I
.	O

Using	O
an	O
expression	O
cloning	O
strategy	O
,	O
the	O
cDNA	O
encoding	O
the	O
human	O
HNK-1	B
sulfotransferase	I
(	O
HNK-1ST	B
)	O
has	O
been	O
cloned	O
.	O

During	O
this	O
cloning	O
we	O
found	O
that	O
HNK-1ST	B
and	O
other	O
Golgi	O
-	O
associated	O
sulfotransferases	B
cloned	O
before	O
share	O
homologous	O
sequences	O
including	O
the	O
RDP	O
motif	O
(	O
Ong	O
,	O
E.	O
,	O
Yeh	O
,	O
J.	O
-	O
C.	O
,	O
Ding	O
,	O
Y.	O
,	O
Hindsgaul	O
,	O
O.	O
,	O
and	O
Fukuda	O
,	O
M.	O
(	O
1998	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
223	O
,	O
5190	O
-	O
5195	O
)	O
.	O

Using	O
this	O
conserved	O
sequence	O
in	O
HNK-1ST	B
as	O
a	O
probe	O
,	O
we	O
identified	O
two	O
expressed	O
sequence	O
tags	O
in	O
EST	O
data	O
base	O
which	O
have	O
31.6	O
and	O
30.7	O
%	O
identity	O
with	O
HNK-1ST	B
at	O
the	O
amino	O
acid	O
levels	O
.	O

Expression	O
of	O
these	O
two	O
full	O
-	O
length	O
cDNAs	O
failed	O
to	O
form	O
HNK-1	B
glycan	O
nor	O
to	O
add	O
sulfate	O
to	O
CD34	B
or	O
NCAM	B
.	O

Surprisingly	O
,	O
proteins	O
expressed	O
by	O
these	O
cDNAs	O
transferred	O
sulfate	O
to	O
the	O
C-4	O
position	O
of	O
N	O
-	O
acetylgalactosamine	O
in	O
chondroitin	O
and	O
desulfated	O
dermatan	O
sulfate	O
,	O
thus	O
we	O
named	O
these	O
two	O
enzymes	O
,	O
chondroitin	B
4-O	I
-	I
sulfotransferase	I
1	I
and	I
-	I
2	I
(	O
C4ST-1	B
and	O
C4ST-2	B
)	O
.	O

Both	O
C4ST-1	B
and	O
C4ST-2	B
,	O
however	O
,	O
did	O
not	O
form	O
4	O
,	O
6-di	O
-	O
O	O
-	O
sulfated	O
N	O
-	O
acetylgalactosamine	O
when	O
chondroitin	O
sulfate	O
C	O
was	O
used	O
as	O
an	O
acceptor	O
.	O

Moreover	O
,	O
analysis	O
of	O
(	O
35	O
)	O
S	O
-	O
labeled	O
dermatan	O
sulfate	O
formed	O
by	O
C4ST-1	B
indicate	O
that	O
sulfation	O
preferentially	O
took	O
place	O
in	O
GlcA	O
--	O
>	O
GalNAc	O
unit	O
than	O
in	O
IdoA	O
--	O
>	O
GalNAc	O
unit	O
,	O
suggesting	O
that	O
4-O	O
-	O
sulfation	O
at	O
N	O
-	O
acetylgalactosamine	O
may	O
precede	O
epimerization	O
of	O
glucuronic	O
acid	O
to	O
iduronic	O
acid	O
during	O
dermatan	O
sulfate	O
biosynthesis	O
.	O

Northern	O
analysis	O
demonstrated	O
that	O
the	O
transcript	O
for	O
C4ST-1	B
is	O
predominantly	O
expressed	O
in	O
peripheral	O
leukocytes	O
and	O
hematopoietic	O
tissues	O
while	O
the	O
C4ST-2	B
transcript	O
is	O
more	O
widely	O
expressed	O
in	O
various	O
tissues	O
.	O

These	O
results	O
indicate	O
C4ST-1	B
and	O
C4ST-2	B
play	O
complementary	O
roles	O
in	O
chondroitin	O
and	O
dermatan	O
sulfate	O
synthesis	O
in	O
different	O
tissues	O
.	O

Postprandial	O
metabolism	O
of	O
apolipoprotein	B
B-48	I
-	I
and	I
B-100	I
-	O
containing	O
particles	O
in	O
type	O
2	O
diabetes	O
mellitus	O
:	O
relations	O
to	O
angiographically	O
verified	O
severity	O
of	O
coronary	O
artery	O
disease	O
.	O

The	O
aim	O
of	O
the	O
present	O
cross	O
-	O
sectional	O
angiographic	O
study	O
was	O
to	O
examine	O
if	O
there	O
is	O
a	O
relationship	O
between	O
the	O
severity	O
of	O
CAD	O
and	O
postprandial	O
lipemia	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Special	O
emphasis	O
was	O
directed	O
to	O
determining	O
the	O
contribution	O
of	O
apolipoprotein	B
B-48	I
(	O
apoB	B
-	I
48	I
)	O
-	O
containing	O
and	O
B-100	B
(	O
apoB	B
-	I
100	I
)	O
-	O
containing	O
triglyceride	O
-	O
rich	O
particles	O
to	O
the	O
magnitude	O
of	O
postprandial	O
lipemia	O
and	O
degree	O
of	O
CAD	O
.	O

The	O
role	O
of	O
apolipoprotein	B
E	I
(	O
apoE	B
)	O
phenotype	O
as	O
a	O
modulator	O
of	O
postprandial	O
lipemia	O
was	O
also	O
evaluated	O
.	O

The	O
severity	O
of	O
CAD	O
was	O
determined	O
by	O
a	O
quantitative	O
coronary	O
angiography	O
and	O
the	O
subjects	O
were	O
classified	O
into	O
two	O
groups	O
based	O
on	O
the	O
presence	O
(	O
severe	O
CAD	O
)	O
or	O
absence	O
(	O
mild	O
CAD	O
)	O
of	O
at	O
least	O
50	O
%	O
stenosis	O
in	O
a	O
major	O
coronary	O
vessel	O
.	O

The	O
study	O
population	O
consisted	O
of	O
43	O
subjects	O
(	O
31	O
men	O
and	O
12	O
women	O
)	O
with	O
fair	O
glycemic	O
control	O
and	O
comparable	O
fasting	O
lipids	O
and	O
body	O
mass	O
index	O
.	O

Postprandial	O
responses	O
of	O
TG	O
,	O
apoB	B
-	I
48	I
and	O
apoB	B
-	I
100	I
in	O
lipoprotein	B
subfractions	O
(	O
chylomicrons	B
,	O
VLDL1	B
,	O
VLDL2	B
and	O
IDL	B
)	O
were	O
determined	O
after	O
a	O
fat	O
load	O
.	O

Type	O
2	O
diabetic	O
patients	O
exhibited	O
the	O
classical	O
dyslipidemia	O
of	O
the	O
insulin	B
resistance	O
syndrome	O
and	O
delayed	O
clearance	O
of	O
both	O
hepatic	O
and	O
intestinal	O
particles	O
.	O

Fasting	O
or	O
postprandial	O
lipid	O
or	O
lipoprotein	B
measurements	O
,	O
including	O
apoB	B
-	I
48	I
and	O
apoB	B
-	I
100	I
concentrations	O
,	O
did	O
not	O
differ	O
between	O
the	O
groups	O
.	O

The	O
presence	O
or	O
absence	O
of	O
apoE-4	B
allele	O
did	O
not	O
significantly	O
influence	O
postprandial	O
lipemia	O
.	O

The	O
severity	O
of	O
the	O
most	O
significant	O
coronary	O
stenosis	O
in	O
angiography	O
correlated	O
with	O
plasma	O
and	O
with	O
chylomicron	B
area	O
under	O
curve	O
(	O
AUC	O
)	O
for	O
TG	O
(	O
n	O
=	O
27	O
)	O
and	O
chylomicron	B
AUC	O
for	O
apoB-48	B
(	O
n	O
=	O
20	O
)	O
.	O

The	O
strongest	O
correlate	O
of	O
maximal	O
stenosis	O
was	O
area	O
under	O
incremental	O
curve	O
(	O
AUIC	O
)	O
for	O
apoB-100	B
in	O
IDL	B
fraction	O
(	O
r	O
=	O
0.548	O
,	O
P	O
=	O
0	O
.	O
012	O
,	O
n	O
=	O
20	O
)	O
.	O

In	O
conclusion	O
,	O
postprandial	O
apoB	B
-	I
48	I
and	O
apoB	B
-	I
100	I
metabolism	O
in	O
triglyceride	O
rich	O
lipoproteins	B
is	O
distorted	O
in	O
type	O
2	O
diabetic	O
patients	O
,	O
even	O
in	O
those	O
with	O
only	O
mild	O
CAD	O
.	O

The	O
data	O
suggest	O
that	O
postprandial	O
change	O
in	O
small	O
remnant	O
particle	O
numbers	O
may	O
contribute	O
to	O
the	O
severity	O
of	O
CAD	O
in	O
type	O
2	O
diabetes	O
.	O

Combined	O
action	O
of	O
two	O
transcription	B
factors	I
regulates	O
genes	O
encoding	O
spore	O
coat	O
proteins	O
of	O
Bacillus	O
subtilis	O
.	O

During	O
sporulation	O
of	O
Bacillus	O
subtilis	O
,	O
spore	O
coat	O
proteins	O
encoded	O
by	O
cot	B
genes	O
are	O
expressed	O
in	O
the	O
mother	O
cell	O
and	O
deposited	O
on	O
the	O
forespore	O
.	O

Transcription	O
of	O
the	O
cotB	B
,	O
cotC	B
,	O
and	O
cotX	B
genes	O
by	O
final	O
sigma	B
(	I
K	I
)	I
RNA	B
polymerase	I
is	O
activated	O
by	O
a	O
small	O
,	O
DNA	O
-	O
binding	O
protein	O
called	O
GerE	B
.	O

The	O
promoter	O
region	O
of	O
each	O
of	O
these	O
genes	O
has	O
two	O
GerE	B
binding	O
sites	O
.	O

5	O
'	O
deletions	O
that	O
eliminated	O
the	O
more	O
upstream	O
GerE	B
site	O
decreased	O
expression	O
of	O
lacZ	B
fused	O
to	O
cotB	B
and	O
cotX	B
by	O
approximately	O
80	O
%	O
and	O
60	O
%	O
,	O
respectively	O
but	O
had	O
no	O
effect	O
on	O
cotC	B
-	O
lacZ	B
expression	O
.	O

The	O
cotC	B
-	O
lacZ	B
fusion	O
was	O
expressed	O
later	O
during	O
sporulation	O
than	O
the	O
other	O
two	O
fusions	O
.	O

Primer	O
extension	O
analysis	O
confirmed	O
that	O
cotB	B
mRNA	O
increases	O
first	O
during	O
sporulation	O
,	O
followed	O
by	O
cotX	B
and	O
cotC	B
mRNAs	O
over	O
a	O
2	O
-	O
h	O
period	O
.	O

In	O
vitro	O
transcription	O
experiments	O
suggest	O
that	O
the	O
differential	O
pattern	O
of	O
cot	B
gene	O
expression	O
results	O
from	O
the	O
combined	O
action	O
of	O
GerE	B
and	O
another	O
transcription	B
factor	I
,	O
SpoIIID	B
.	O

A	O
low	O
concentration	O
of	O
GerE	B
activated	O
cotB	B
transcription	O
by	O
final	O
sigma	B
(	I
K	I
)	I
RNA	B
polymerase	I
,	O
whereas	O
a	O
higher	O
concentration	O
was	O
needed	O
to	O
activate	O
transcription	O
of	O
cotX	B
or	O
cotC	B
.	O

SpoIIID	B
at	O
low	O
concentration	O
repressed	O
cotC	B
transcription	O
,	O
whereas	O
a	O
higher	O
concentration	O
only	O
partially	O
repressed	O
cotX	B
transcription	O
and	O
had	O
little	O
effect	O
on	O
cotB	B
transcription	O
.	O

DNase	B
I	I
footprinting	O
showed	O
that	O
SpoIIID	B
binds	O
strongly	O
to	O
two	O
sites	O
in	O
the	O
cotC	B
promoter	O
region	O
,	O
binds	O
weakly	O
to	O
one	O
site	O
in	O
the	O
cotX	B
promoter	O
,	O
and	O
does	O
not	O
bind	O
specifically	O
to	O
cotB	B
.	O

We	O
propose	O
that	O
late	O
in	O
sporulation	O
the	O
rising	O
level	O
of	O
GerE	B
and	O
the	O
falling	O
level	O
of	O
SpoIIID	B
,	O
together	O
with	O
the	O
position	O
and	O
affinity	O
of	O
binding	O
sites	O
for	O
these	O
transcription	B
factors	I
in	O
cot	B
gene	O
promoters	O
,	O
dictates	O
the	O
timing	O
and	O
level	O
of	O
spore	O
coat	O
protein	O
synthesis	O
,	O
ensuring	O
optimal	O
assembly	O
of	O
the	O
protein	O
shell	O
on	O
the	O
forespore	O
surface	O
.	O

Identification	O
of	O
a	O
novel	O
four	O
-	O
domain	O
member	O
of	O
the	O
proteinase	B
inhibitor	I
II	I
family	I
from	O
the	O
stigmas	O
of	O
Nicotiana	O
alata	O
.	O

Proteinase	B
inhibitors	I
(	I
PIs	I
)	I
of	I
the	I
potato	I
type	I
II	I
family	I
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
solanaceous	O
species	O
.	O

Most	O
family	O
members	O
have	O
two	O
PI	O
domains	O
which	O
are	O
specific	O
for	O
either	O
chymotrypsin	B
or	O
trypsin	B
.	O

More	O
recently	O
family	O
members	O
have	O
been	O
described	O
with	O
three	O
or	O
six	O
repeated	O
PI	O
domains	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
four	O
-	O
domain	O
family	O
member	O
produced	O
in	O
the	O
stigmas	O
and	O
leaves	O
of	O
the	O
ornamental	O
tobacco	O
,	O
Nicotiana	O
alata	O
,	O
which	O
has	O
high	O
sequence	O
identity	O
with	O
a	O
six	O
-	O
domain	O
member	O
from	O
the	O
same	O
species	O
.	O

Both	O
proteins	O
are	O
produced	O
as	O
precursors	O
that	O
enter	O
the	O
secretory	O
pathway	O
and	O
are	O
subsequently	O
processed	O
into	O
a	O
series	O
of	O
6	O
kDa	O
Pis	O
.	O

The	O
four	O
-	O
and	O
six	O
-	O
domain	O
precursor	O
proteins	O
were	O
isolated	O
from	O
immature	O
stigmas	O
and	O
characterised	O
by	O
mass	O
spectrometry	O
which	O
revealed	O
that	O
both	O
proteins	O
had	O
been	O
trimmed	O
at	O
the	O
N	O
-	O
terminus	O
,	O
at	O
a	O
position	O
corresponding	O
to	O
the	O
predicted	O
signal	O
peptide	O
cleavage	O
site	O
.	O

Furthermore	O
,	O
no	O
post	O
-	O
translational	O
modifications	O
were	O
apparent	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
a	O
putative	O
sodium	B
channel	I
auxiliary	O
subunit	O
gene	O
from	O
the	O
house	O
fly	O
(	O
Musca	O
domestica	O
)	O
.	O

The	O
functional	O
expression	O
of	O
cloned	O
Drosophila	O
melanogaster	O
and	O
house	O
fly	O
(	O
Musca	O
domestica	O
)	O
voltage	B
-	I
sensitive	I
sodium	I
channels	O
in	O
Xenopus	O
oocytes	O
is	O
enhanced	O
,	O
and	O
the	O
inactivation	O
kinetics	O
of	O
the	O
expressed	O
channels	O
are	O
accelerated	O
,	O
by	O
coexpression	O
with	O
the	O
tipE	B
protein	O
,	O
a	O
putative	O
sodium	B
channel	I
auxiliary	O
subunit	O
encoded	O
by	O
the	O
tipE	B
gene	O
of	O
D.	O
melanogaster	O
.	O

These	O
results	O
predict	O
the	O
existence	O
of	O
a	O
tipE	B
ortholog	O
in	O
the	O
house	O
fly	O
.	O

Using	O
a	O
PCR	O
-	O
based	O
homology	O
probing	O
approach	O
,	O
we	O
isolated	O
cDNA	O
clones	O
encoding	O
an	O
ortholog	O
of	O
tipE	B
(	O
designated	O
Vssc	B
beta	O
)	O
from	O
adult	O
house	O
fly	O
heads	O
.	O

Clones	O
comprising	O
3444	O
bp	O
of	O
cDNA	O
sequence	O
contained	O
a	O
1317	O
bp	O
open	O
-	O
reading	O
frame	O
encoding	O
a	O
438	O
amino	O
acid	O
protein	O
.	O

The	O
predicted	O
Vssc	B
beta	O
protein	O
exhibited	O
72	O
%	O
amino	O
acid	O
sequence	O
identity	O
to	O
the	O
entire	O
D.	O
melanogaster	O
tipE	B
protein	O
sequence	O
and	O
97	O
%	O
identity	O
within	O
the	O
two	O
hydrophobic	O
segments	O
identified	O
as	O
probable	O
transmembrane	O
domains	O
.	O

Coexpression	O
of	O
Vssc	B
beta	O
with	O
the	O
house	O
fly	O
sodium	B
channel	I
alpha	O
subunit	O
(	O
Vssc1	B
)	O
in	O
oocytes	O
enhanced	O
the	O
level	O
of	O
sodium	O
current	O
expression	O
five	O
-	O
fold	O
and	O
accelerated	O
the	O
rate	O
of	O
sodium	O
current	O
inactivation	O
2.2	O
-	O
fold	O
.	O

Both	O
of	O
these	O
effects	O
were	O
significantly	O
larger	O
in	O
magnitude	O
than	O
the	O
corresponding	O
effects	O
of	O
the	O
D.	O
melanogaster	O
tipE	B
protein	O
on	O
the	O
expression	O
and	O
kinetics	O
of	O
Vssc1	B
sodium	B
channels	I
.	O

These	O
results	O
identify	O
a	O
second	O
example	O
of	O
a	O
putative	O
sodium	B
channel	I
auxiliary	O
subunit	O
from	O
an	O
insect	O
having	O
functional	O
but	O
not	O
structural	O
homology	O
to	O
vertebrate	O
sodium	B
channel	I
beta	O
subunits	O
.	O

Crystal	O
structure	O
of	O
the	O
Escherichia	O
coli	O
Rob	B
transcription	B
factor	I
in	O
complex	O
with	O
DNA	O
.	O

The	O
Escherichia	O
coli	O
Rob	B
protein	O
is	O
a	O
transcription	B
factor	I
belonging	O
to	O
the	O
AraC	B
/	I
XylS	I
protein	I
family	I
that	O
regulates	O
genes	O
involved	O
in	O
resistance	O
to	O
antibiotics	O
,	O
organic	O
solvents	O
and	O
heavy	O
metals	O
.	O

The	O
genes	O
encoding	O
these	O
proteins	O
are	O
activated	O
by	O
the	O
homologous	O
proteins	O
MarA	B
and	O
SoxS	B
,	O
although	O
the	O
level	O
of	O
activation	O
can	O
vary	O
for	O
the	O
different	O
transcription	B
factors	I
.	O

Here	O
we	O
report	O
a	O
2.7	O
A	O
crystal	O
structure	O
of	O
Rob	B
in	O
complex	O
with	O
the	O
micF	B
promoter	O
that	O
reveals	O
an	O
unusual	O
mode	O
of	O
binding	O
to	O
DNA	O
.	O

The	O
Rob	B
-	O
DNA	O
complex	O
differs	O
from	O
the	O
previously	O
reported	O
structure	O
of	O
MarA	B
bound	O
to	O
the	O
mar	O
promoter	O
,	O
in	O
that	O
only	O
one	O
of	O
Rob	B
'	O
s	O
dual	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
HTH	O
)	O
motifs	O
engages	O
the	O
major	O
groove	O
of	O
the	O
binding	O
site	O
.	O

Biochemical	O
studies	O
show	O
that	O
sequence	O
specific	O
interactions	O
involving	O
only	O
one	O
of	O
Rob	B
's	O
HTH	O
motifs	O
are	O
sufficient	O
for	O
high	O
affinity	O
binding	O
to	O
DNA	O
.	O

The	O
two	O
different	O
modes	O
of	O
DNA	O
binding	O
seen	O
in	O
crystal	O
structures	O
of	O
Rob	B
and	O
MarA	B
also	O
match	O
the	O
distinctive	O
patterns	O
of	O
DNA	O
protection	O
by	O
AraC	B
at	O
several	O
sites	O
within	O
the	O
pBAD	O
promoter	O
.	O

These	O
and	O
other	O
findings	O
suggest	O
that	O
gene	O
activation	O
by	O
AraC	B
/	O
XylS	B
transcription	B
factors	I
might	O
involve	O
two	O
alternative	O
modes	O
of	O
binding	O
to	O
DNA	O
in	O
different	O
promoter	O
contexts	O
.	O

Dual	O
effect	O
of	O
IL-4	B
on	O
resistance	O
to	O
systemic	O
gram	O
-	O
negative	O
infection	O
and	O
production	O
of	O
TNF	B
-	I
alpha	I
.	O

To	O
determine	O
the	O
effect	O
of	O
interleukin	B
4	I
(	O
IL-4	B
)	O
administration	O
in	O
a	O
live	O
sepsis	O
model	O
characterised	O
by	O
high	O
-	O
level	O
production	O
of	O
tumour	B
necrosis	I
factor	I
a	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
mice	O
infected	O
systemically	O
with	O
lethal	O
or	O
sublethal	O
inocula	O
of	O
Pseudomonas	O
aeruginosa	O
were	O
given	O
the	O
recombinant	O
cytokine	B
at	O
different	O
times	O
before	O
infection	O
.	O

Improved	O
survival	O
and	O
decreased	O
TNF	B
-	I
alpha	I
production	O
were	O
observed	O
in	O
lethally	O
infected	O
mice	O
treated	O
with	O
the	O
cytokine	B
1	O
day	O
before	O
challenge	O
.	O

In	O
contrast	O
,	O
increased	O
mortality	O
and	O
overproduction	O
of	O
TNF	B
-	I
alpha	I
were	O
observed	O
in	O
sublethally	O
infected	O
mice	O
given	O
IL-4	B
at	O
the	O
time	O
of	O
infection	O
.	O

ARP3beta	B
,	O
the	O
gene	O
encoding	O
a	O
new	O
human	O
actin	B
-	I
related	I
protein	I
,	O
is	O
alternatively	O
spliced	O
and	O
predominantly	O
expressed	O
in	O
brain	O
neuronal	O
cells	O
.	O

A	O
cDNA	O
encoding	O
a	O
new	O
human	O
actin	B
-	I
related	I
protein	I
(	O
ARP	B
)	O
was	O
cloned	O
.	O

The	O
corresponding	O
protein	O
is	O
highly	O
conserved	O
with	O
the	O
previously	O
described	O
ARP3	B
protein	O
,	O
suggesting	O
that	O
it	O
represents	O
a	O
second	O
isoform	O
of	O
the	O
human	O
ARP3	B
subfamily	O
.	O

This	O
new	O
actin	B
-	I
related	I
protein	I
was	O
subsequently	O
named	O
ARP3beta	B
and	O
represents	O
the	O
second	O
example	O
of	O
multiple	O
isoforms	O
of	O
an	O
actin	B
-	I
related	I
protein	I
in	O
a	O
single	O
organism	O
.	O

The	O
ARP3beta	B
gene	O
was	O
mapped	O
to	O
chromosome	O
band	O
7q34	O
,	O
centromeric	O
to	O
Sonic	B
Hedgehog	I
.	O

Gene	O
structure	O
analysis	O
revealed	O
that	O
at	O
least	O
part	O
of	O
the	O
observed	O
ARP3beta	B
mRNA	O
heterogeneity	O
is	O
caused	O
by	O
alternative	O
splicing	O
resulting	O
in	O
exon	O
skipping	O
.	O

Transcripts	O
produced	O
after	O
exon	O
2	O
skipping	O
are	O
predicted	O
to	O
encode	O
truncated	O
products	O
,	O
whose	O
functionality	O
is	O
still	O
unclear	O
.	O

An	O
ARP3beta	B
pseudogene	O
was	O
detected	O
on	O
chromosome	O
2p11	O
by	O
database	O
searching	O
.	O

Several	O
ARP3beta	B
mRNA	O
species	O
were	O
detected	O
by	O
Northern	O
blotting	O
and	O
their	O
abundance	O
varied	O
importantly	O
among	O
tissues	O
:	O
the	O
highest	O
expression	O
levels	O
were	O
detected	O
in	O
fetal	O
and	O
adult	O
brain	O
,	O
whereas	O
lower	O
levels	O
were	O
observed	O
in	O
liver	O
,	O
muscle	O
and	O
pancreas	O
.	O

In	O
contrast	O
,	O
ARP3	B
mRNAs	O
were	O
detected	O
in	O
all	O
tissues	O
tested	O
.	O

Using	O
in	O
situ	O
hybridization	O
,	O
the	O
expression	O
of	O
ARP3beta	B
in	O
brain	O
was	O
shown	O
to	O
be	O
restricted	O
to	O
neurons	O
and	O
epithelial	O
cells	O
from	O
choroid	O
plexus	O
.	O

This	O
suggests	O
a	O
specific	O
function	O
for	O
ARP3beta	B
in	O
the	O
physiology	O
of	O
the	O
development	O
and/or	O
maintenance	O
of	O
distinct	O
subsets	O
of	O
nerve	O
cells	O
.	O

Expression	O
and	O
localization	O
of	O
enzymes	O
of	O
arginine	O
metabolism	O
in	O
the	O
rat	O
eye	O
.	O

PURPOSE	O
:	O

Production	O
of	O
NO	O
may	O
be	O
regulated	O
by	O
argininosuccinate	B
synthetase	I
and	O
argininosuccinate	B
lyase	I
which	O
recycle	O
citrulline	O
to	O
arginine	O
,	O
and	O
by	O
arginase	O
which	O
hydrolyzes	O
arginine	O
to	O
urea	O
and	O
ornithine	O
.	O

Expression	O
of	O
these	O
and	O
related	O
enzymes	O
in	O
rat	O
eye	O
was	O
studied	O
.	O

METHODS	O
:	O

mRNAs	O
for	O
the	O
enzymes	O
were	O
analyzed	O
by	O
reverse	O
transcription	O
-	O
polymerase	B
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Localization	O
of	O
the	O
enzyme	O
proteins	O
and	O
mRNAs	O
was	O
analyzed	O
by	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
,	O
respectively	O
.	O

RESULTS	O
:	O

In	O
RT	O
-	O
PCR	O
analysis	O
,	O
arginase	B
II	I
(	O
nonhepatic	O
type	O
)	O
mRNA	O
was	O
detected	O
in	O
retina	O
and	O
weakly	O
in	O
cornea	O
,	O
whereas	O
arginase	B
I	I
(	O
hepatic	O
type	O
)	O
mRNA	O
was	O
not	O
detected	O
in	O
any	O
area	O
.	O

mRNAs	O
for	O
argininosuccinate	B
synthetase	I
,	O
argininosuccinate	B
lyase	I
,	O
ornithine	B
aminotransferase	I
and	O
ornithine	B
decarboxylase	I
were	O
present	O
in	O
all	O
areas	O
.	O

In	O
immunohistochemical	O
analysis	O
,	O
arginase	B
II	I
was	O
stained	O
in	O
cornea	O
,	O
epithelium	O
of	O
iris	O
and	O
ciliary	O
process	O
,	O
inner	O
part	O
of	O
neural	O
retina	O
and	O
retinal	O
pigment	O
epithelium	O
.	O

Immunostaining	O
of	O
ornithine	B
aminotransferase	I
resembled	O
that	O
of	O
arginase	B
II	I
.	O

In	O
in	O
situ	O
hybridization	O
,	O
arginase	B
II	I
and	O
ornithine	B
aminotransferase	I
mRNAs	O
were	O
located	O
much	O
as	O
seen	O
with	O
the	O
enzyme	O
proteins	O
.	O

CONCLUSIONS	O
:	O

These	O
results	O
indicate	O
that	O
arginine	O
recycling	O
activity	O
from	O
citrulline	O
is	O
present	O
widely	O
in	O
ocular	O
tissues	O
,	O
whereas	O
expression	O
of	O
arginase	B
II	I
differs	O
among	O
the	O
tissues	O
.	O

We	O
suggest	O
that	O
NO	O
production	O
may	O
be	O
regulated	O
by	O
these	O
enzymes	O
in	O
the	O
cells	O
where	O
NO	B
synthase	I
is	O
colocalized	O
.	O

Colocalization	O
of	O
arginase	B
II	I
and	O
ornithine	B
aminotransferase	I
suggests	O
a	O
role	O
for	O
arginase	B
II	I
in	O
collagen	B
synthesis	O
in	O
the	O
eye	O
.	O

Bradykinin	B
B2	I
-	I
receptor	I
antagonism	O
attenuates	O
fatal	O
cardiocirculatory	O
breakdown	O
induced	O
by	O
severe	O
experimental	O
pancreatitis	O
.	O

OBJECTIVES	O
:	O

To	O
investigate	O
the	O
impact	O
of	O
the	O
long	O
-	O
acting	O
bradykinin	B
B2	I
receptor	I
antagonist	O
HOE	O
140	O
(	O
Icatibant	O
)	O
on	O
survival	O
time	O
in	O
a	O
model	O
of	O
severe	O
porcine	O
pancreatitis	O
.	O

DESIGN	O
:	O

Randomized	O
,	O
controlled	O
intervention	O
trial	O
.	O

SUBJECTS	O
:	O

Thirty	O
domestic	O
pigs	O
of	O
either	O
gender	O
anesthetized	O
by	O
intravenous	O
application	O
of	O
piritramide	O
,	O
midazolam	O
,	O
and	O
pancuronium	O
and	O
mechanically	O
ventilated	O
.	O

INTERVENTIONS	O
:	O

Pancreatitis	O
was	O
induced	O
by	O
an	O
injection	O
of	O
sodium	O
taurocholate	O
(	O
5	O
%	O
,	O
1	O
mL	O
/	O
kg	O
body	O
weight	O
[	O
BW	O
]	O
)	O
and	O
enterokinase	B
(	O
10	O
U	O
/	O
kg	O
BW	O
)	O
.	O

Control	O
animals	O
(	O
group	O
1	O
,	O
n	O
=	O
10	O
)	O
underwent	O
the	O
spontaneous	O
course	O
of	O
the	O
disease	O
.	O

In	O
two	O
treatment	O
groups	O
,	O
Icatibant	O
was	O
administered	O
either	O
in	O
a	O
low	O
(	O
100	O
nmol	O
/	O
kg	O
BW	O
;	O
group	O
2	O
,	O
n	O
=	O
10	O
)	O
or	O
in	O
a	O
high	O
dosage	O
(	O
5000	O
nmol	O
/	O
kg	O
BW	O
;	O
group	O
3	O
,	O
n	O
=	O
10	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O

Mean	O
survival	O
time	O
was	O
significantly	O
prolonged	O
by	O
Icatibant	O
(	O
controls	O
,	O
6.6	O
hrs	O
;	O
group	O
2	O
,	O
9.8	O
hrs	O
;	O
p	O
=	O
.022	O
;	O
group	O
3	O
,	O
10.9	O
hrs	O
;	O
p	O
=	O
.007	O
)	O
.	O

Six	O
hours	O
postinduction	O
,	O
the	O
decline	O
of	O
total	O
peripheral	O
resistance	O
(	O
52	O
%	O
of	O
baseline	O
)	O
and	O
cardiac	O
index	O
(	O
92	O
%	O
of	O
baseline	O
)	O
in	O
controls	O
was	O
significantly	O
improved	O
by	O
Icatibant	O
,	O
both	O
in	O
the	O
low	O
(	O
16	O
%	O
and	O
44	O
%	O
;	O
p	O
<	O
.05	O
)	O
and	O
high	O
(	O
6	O
%	O
and	O
45	O
%	O
;	O
p	O
<	O
.05	O
)	O
dosage	O
.	O

The	O
concentrations	O
of	O
free	O
,	O
nonreceptor	O
-	O
bound	O
kinin	B
in	O
plasma	O
6	O
hrs	O
postinduction	O
were	O
significantly	O
lower	O
in	O
controls	O
than	O
in	O
groups	O
2	O
and	O
3	O
animals	O
(	O
111	O
+	O
/	O
-	O
50	O
vs.	O
208	O
+	O
/-	O
40	O
and	O
237	O
+	O
/	O
-	O
52	O
fmol	O
/	O
mL	O
,	O
respectively	O
)	O
.	O

Six	O
hours	O
postinduction	O
,	O
the	O
pretreatment	O
with	O
Icatibant	O
was	O
associated	O
with	O
significantly	O
higher	O
plasma	O
concentrations	O
of	O
phospholipase	B
A2	I
(	O
controls	O
,	O
+	O
1194	O
%	O
;	O
group	O
2	O
,	O
+	O
2000	O
%	O
;	O
group	O
3	O
,	O
+	O
2285	O
%	O
of	O
baseline	O
values	O
)	O
and	O
interleukin-1	B
receptor	I
antagonist	I
(	O
controls	O
,	O
1900	O
+	O
/	O
-	O
800	O
;	O
group	O
2	O
,	O
3100	O
+	O
/	O
-	O
800	O
;	O
group	O
3	O
,	O
3600	O
+	O
/	O
-	O
800	O
pg	O
/	O
mL	O
)	O
.	O

In	O
contrast	O
,	O
the	O
increase	O
of	O
urinary	O
trypsinogen	B
activation	O
peptides	O
indicating	O
local	O
pancreatic	O
damage	O
(	O
589	O
+	O
/	O
-	O
114	O
nmol	O
/	O
L	O
in	O
controls	O
)	O
was	O
substantially	O
attenuated	O
by	O
pretreatment	O
with	O
Icatibant	O
(	O
group	O
2	O
,	O
467	O
+	O
/	O
-	O
102	O
,	O
NS	O
;	O
352	O
+	O
/	O
-	O
91	O
nmol	O
/	O
L	O
in	O
group	O
3	O
;	O
p	O
=	O
.022	O
vs.	O
controls	O
)	O
.	O

Systemic	O
inflammatory	O
reactions	O
,	O
however	O
,	O
as	O
quantified	O
by	O
C	B
-	I
reactive	I
protein	I
and	O
the	O
extracellularly	O
discharged	O
neutrophil	O
cytosolic	O
inhibitor	O
leukocyte	O
neutral	B
proteinase	I
inhibitor	O
were	O
not	O
influenced	O
by	O
the	O
bradykinin	B
B2	I
-	I
receptor	I
antagonist	O
.	O

CONCLUSIONS	O
:	O

Pretreatment	O
with	O
the	O
bradykinin	B
B2	I
receptor	I
antagonist	O
Icatibant	O
resulted	O
in	O
prolonged	O
survival	O
time	O
and	O
in	O
delayed	O
impairment	O
of	O
major	O
macrocirculatory	O
and	O
pulmonary	O
variables	O
.	O

Icatibant	O
resulted	O
in	O
elevated	O
concentrations	O
of	O
free	O
,	O
circulating	O
kinin	B
.	O

This	O
was	O
associated	O
with	O
increased	O
concentrations	O
of	O
phospholipase	B
A2	I
and	O
interleukin-1	B
receptor	I
antagonist	I
,	O
suggesting	O
that	O
circulating	O
kinins	B
strengthen	O
the	O
activation	O
of	O
some	O
mediator	O
cascades	O
,	O
the	O
association	O
of	O
which	O
with	O
the	O
kinin	B
metabolism	O
requires	O
further	O
experimental	O
clarification	O
.	O

Other	O
variables	O
indicating	O
a	O
systemic	O
inflammatory	O
response	O
(	O
C	B
-	I
reactive	I
protein	I
,	O
leukocyte	O
neutral	B
proteinase	I
inhibitor	O
)	O
remained	O
unaffected	O
by	O
Icatibant	O
.	O

Bradykinin	B
antagonism	O
distinctly	O
ameliorated	O
the	O
local	O
pancreatic	O
damage	O
,	O
indicated	O
by	O
increased	O
urinary	O
concentrations	O
of	O
trypsinogen	B
activation	O
peptides	O
.	O

It	O
is	O
concluded	O
that	O
the	O
kinin	B
metabolism	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
systemic	O
complications	O
after	O
severe	O
experimental	O
pancreatitis	O
.	O

Regulation	O
of	O
human	O
GH	B
receptor	I
gene	O
transcription	O
by	O
20	O
and	O
22	O
kDa	O
GH	B
in	O
a	O
human	O
hepatoma	O
cell	O
line	O
.	O

The	O
human	O
GH	B
gene	O
is	O
1.7	O
kilobase	O
pairs	O
(	O
kb	O
)	O
in	O
length	O
and	O
is	O
composed	O
of	O
five	O
exons	O
and	O
four	O
introns	O
.	O

This	O
gene	O
is	O
expressed	O
in	O
the	O
pituitary	O
gland	O
and	O
encodes	O
a	O
22	O
kDa	O
protein	O
.	O

In	O
addition	O
to	O
this	O
predominant	O
(	O
75	O
%	O
)	O
form	O
,	O
5	O
-	O
10	O
%	O
of	O
pituitary	O
GH	B
is	O
present	O
as	O
a	O
20	O
kDa	O
protein	O
that	O
has	O
an	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
identical	O
to	O
the	O
22	O
kDa	O
form	O
except	O
for	O
a	O
15	O
aa	O
internal	O
deletion	O
of	O
residues	O
32	O
-	O
46	O
as	O
a	O
result	O
of	O
an	O
alternative	O
splicing	O
event	O
.	O

Because	O
it	O
has	O
been	O
reported	O
that	O
non	O
-	O
22	O
-	O
kDa	O
GH	B
isoforms	O
might	O
be	O
partly	O
responsible	O
for	O
short	O
stature	O
and	O
growth	O
retardation	O
in	O
children	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
impact	O
of	O
both	O
22	O
kDa	O
and	O
20	O
kDa	O
GH	B
on	O
GH	B
receptor	I
gene	O
(	O
GH	B
receptor	I
/	O
GH	B
binding	I
protein	I
(	O
GHR	B
/	O
GHBP	B
)	O
)	O
expression	O
.	O

Various	O
concentrations	O
of	O
20	O
kDa	O
and	O
22	O
kDa	O
GH	B
(	O
0	O
,	O
2	O
,	O
5	O
,	O
12.5	O
,	O
25	O
,	O
50	O
and	O
150	O
ng	O
/	O
ml	O
)	O
were	O
added	O
to	O
human	O
hepatoma	O
(	O
HuH7	O
)	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
hormonally	O
defined	O
medium	O
for	O
0	O
,	O
1	O
and	O
2	O
h	O
.	O

Thereafter	O
GHR	B
/	O
GHBP	B
mRNA	O
expression	O
was	O
measured	O
by	O
quantitative	O
PCR	O
.	O

Addition	O
of	O
either	O
20	O
kDa	O
or	O
22	O
kDa	O
GH	B
,	O
at	O
low	O
or	O
normal	O
physiological	O
concentrations	O
(	O
0	O
,	O
2	O
,	O
5	O
,	O
12.5	O
,	O
25	O
or	O
50	O
ng	O
/	O
ml	O
)	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
GHR	B
/	O
GHBP	B
expression	O
.	O

However	O
,	O
a	O
supraphysiological	O
concentration	O
of	O
20	O
kDa	O
GH	B
(	O
150	O
ng	O
/	O
ml	O
)	O
resulted	O
in	O
a	O
significantly	O
lower	O
(	O
P	O
<	O
0.05	O
)	O
downregulation	O
of	O
GHR	B
/	O
GHBP	B
gene	O
transcription	O
compared	O
with	O
the	O
downregulation	O
achieved	O
by	O
this	O
concentration	O
of	O
22	O
kDa	O
GH	B
.	O

This	O
difference	O
might	O
be	O
explained	O
by	O
a	O
decreased	O
ability	O
to	O
form	O
a	O
1	O
:	O
1	O
complex	O
with	O
GHR	B
and/or	O
GHBP	B
,	O
which	O
normally	O
occurs	O
at	O
high	O
concentrations	O
of	O
GH	B
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
and	O
GHBP	B
determinations	O
confirmed	O
the	O
changes	O
in	O
GHR	B
/	O
GHBP	B
mRNA	O
levels	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
that	O
both	O
20	O
kDa	O
and	O
22	O
kDa	O
GH	B
,	O
in	O
low	O
and	O
normal	O
physiological	O
concentrations	O
,	O
have	O
the	O
same	O
effect	O
on	O
regulation	O
of	O
GHR	B
/	O
GHBP	B
gene	O
transcription	O
in	O
a	O
human	O
hepatoma	O
cell	O
line	O
.	O

At	O
a	O
supraphysiological	O
concentration	O
of	O
150	O
ng	O
/	O
ml	O
,	O
however	O
,	O
20	O
kDa	O
GH	B
has	O
a	O
less	O
self	O
-	O
inhibitory	O
effect	O
than	O
the	O
22	O
kDa	O
form	O
.	O

Effective	O
fragment	O
potentials	O
and	O
the	O
enzyme	O
active	O
site	O
.	O

Optimization	O
of	O
the	O
binding	O
conformation	O
of	O
a	O
substrate	O
in	O
an	O
enzyme	O
active	O
site	O
using	O
ab	O
initio	O
quantum	O
chemistry	O
methods	O
are	O
intractable	O
since	O
the	O
active	O
site	O
comprises	O
several	O
hundred	O
atoms	O
.	O

However	O
,	O
the	O
active	O
site	O
can	O
be	O
decomposed	O
into	O
an	O
active	O
and	O
spectator	O
region	O
where	O
the	O
spectator	O
residues	O
are	O
represented	O
by	O
effective	O
fragment	O
potentials	O
and	O
reducing	O
the	O
number	O
of	O
all	O
-	O
electron	O
atoms	O
involved	O
in	O
the	O
chemistry	O
to	O
a	O
reasonable	O
level	O
.	O

The	O
effective	O
fragment	O
potentials	O
for	O
electrostatics	O
and	O
polarization	O
are	O
implemented	O
in	O
GAMESS	O
but	O
the	O
repulsive	O
and	O
charge	O
transfer	O
potentials	O
are	O
fit	O
to	O
interaction	O
energies	O
of	O
water	O
with	O
models	O
of	O
the	O
residues	O
.	O

These	O
repulsive	O
/	O
charge	O
transfer	O
potentials	O
are	O
generated	O
for	O
the	O
protein	O
residues	O
and	O
the	O
EFP	O
are	O
then	O
used	O
to	O
optimize	O
binding	O
of	O
a	O
transition	O
state	O
analogue	O
to	O
chorismate	B
mutase	I
(	O
B.	O
subtilis	O
)	O
and	O
small	O
dianions	O
to	O
ribonuclease	B
A	I
.	O

For	O
chorismate	B
mutase	I
the	O
calculated	O
binding	O
conformation	O
compares	O
well	O
to	O
the	O
comparable	O
X	O
-	O
ray	O
structure	O
.	O

The	O
binding	O
of	O
the	O
inhibitor	O
to	O
the	O
glutamate	O
/	O
glutamine	O
mutant	O
active	O
site	O
is	O
then	O
predicted	O
with	O
the	O
optimization	O
including	O
the	O
glutamine	O
residue	O
constrained	O
only	O
at	O
the	O
C	O
alpha	O
atom	O
.	O

The	O
binding	O
conformations	O
suggest	O
important	O
roles	O
for	O
tyr108	O
and	O
arg63	O
,	O
which	O
have	O
not	O
been	O
noted	O
earlier	O
.	O

The	O
electrostatic	O
stabilization	O
of	O
the	O
transition	O
state	O
by	O
the	O
active	O
site	O
charge	O
distribution	O
has	O
to	O
be	O
augmented	O
by	O
a	O
specific	O
electronic	O
activation	O
by	O
glu78	O
.	O

In	O
ribonuclease	B
A	I
,	O
the	O
protons	O
are	O
found	O
to	O
move	O
to	O
provide	O
a	O
clustering	O
of	O
the	O
charges	O
to	O
bind	O
the	O
small	O
dianions	O
,	O
phosphate	O
,	O
thiophosphate	O
,	O
and	O
sulfate	O
.	O

Identification	O
and	O
localization	O
of	O
the	O
carboxysome	O
peptide	O
Csos3	B
and	O
its	O
corresponding	O
gene	O
in	O
Thiobacillus	O
neapolitanus	O
.	O

Four	O
genes	O
encoding	O
carboxysome	B
shell	I
peptides	I
(	O
csoS1A	B
,	O
csoS1B	B
,	O
csoS1C	B
,	O
csoS2	B
)	O
,	O
the	O
genes	O
encoding	O
the	O
large	O
and	O
small	O
subunits	O
of	O
RuBisCO	B
(	O
cbbL	B
,	O
cbbS	B
)	O
,	O
and	O
three	O
unidentified	O
ORFs	O
constitute	O
an	O
operon	O
in	O
Thiobacillus	O
neapolitanus	O
.	O

An	O
unidentified	O
ORF	O
1.54	O
kb	O
in	O
size	O
is	O
predicted	O
from	O
sequence	O
analysis	O
to	O
encode	O
a	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
57	O
kDa	O
.	O

When	O
this	O
ORF	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
under	O
the	O
control	O
of	O
its	O
endogenous	O
ribosome	O
-	O
binding	O
site	O
,	O
no	O
peptide	O
product	O
was	O
observed	O
.	O

In	O
order	O
to	O
correlate	O
this	O
ORF	O
with	O
a	O
carboxysome	O
peptide	O
,	O
the	O
ORF	O
was	O
overexpressed	O
in	O
E.	O
coli	O
by	O
cloning	O
it	O
into	O
pProExHTb	O
,	O
a	O
prokaryotic	O
expression	O
vector	O
containing	O
an	O
E.	O
coli	O
ribosome	O
binding	O
site	O
.	O

When	O
antibodies	O
raised	O
against	O
the	O
recombinant	O
protein	O
were	O
used	O
to	O
probe	O
an	O
immunoblot	O
containing	O
carboxysome	O
peptides	O
,	O
a	O
60	O
-	O
kDa	O
peptide	O
was	O
recognized	O
.	O

The	O
peptide	O
was	O
subsequently	O
named	O
CsoS3	B
.	O

CsoS3	B
is	O
a	O
minor	O
component	O
of	O
the	O
carboxysome	O
;	O
a	O
peptide	O
of	O
this	O
size	O
is	O
commonly	O
not	O
observed	O
or	O
is	O
very	O
faint	O
on	O
Coomassie	O
blue	O
-	O
stained	O
SDS	O
-	O
polyacrylamide	O
gels	O
of	O
purified	O
carboxysomes	O
.	O

Immunogold	O
labeling	O
established	O
CsoS3	B
to	O
be	O
a	O
component	O
of	O
the	O
carboxysome	O
shell	O
.	O

The	O
zinc	O
-	O
responsive	O
regulator	O
Zur	B
and	O
its	O
control	O
of	O
the	O
znu	B
gene	O
cluster	O
encoding	O
the	O
ZnuABC	B
zinc	O
uptake	O
system	O
in	O
Escherichia	O
coli	O
.	O

The	O
synthesis	O
of	O
the	O
Escherichia	O
coli	O
zinc	O
transporter	O
,	O
encoded	O
by	O
the	O
znuACB	B
gene	O
cluster	O
,	O
is	O
regulated	O
in	O
response	O
to	O
the	O
intracellular	O
zinc	O
concentration	O
by	O
the	O
zur	B
gene	O
product	O
.	O

Inactivation	O
of	O
the	O
zur	B
gene	O
demonstrated	O
that	O
Zur	B
acts	O
as	O
a	O
repressor	O
when	O
binding	O
Zn	O
(	O
2	O
+	O
)	O
.	O

Eight	O
chromosomal	O
mutant	O
zur	B
alleles	O
were	O
sequenced	O
to	O
correlate	O
the	O
loss	O
of	O
Zur	B
function	O
with	O
individual	O
mutations	O
.	O

Wild	O
-	O
type	O
Zur	B
and	O
ZurDelta46	B
-	O
91	O
formed	O
homo	O
-	O
and	O
heterodimers	O
.	O

Dimerization	O
was	O
independent	O
of	O
metal	O
ions	O
since	O
it	O
also	O
occurred	O
in	O
the	O
presence	O
of	O
metal	O
chelators	O
.	O

Using	O
an	O
in	O
vivo	O
titration	O
assay	O
,	O
the	O
znu	B
operator	O
was	O
narrowed	O
down	O
to	O
a	O
31	O
-	O
base	O
pair	O
region	O
overlapping	O
the	O
translational	O
start	O
site	O
of	O
znuA	B
.	O

This	O
location	O
was	O
confirmed	O
by	O
footprinting	O
assays	O
.	O

Zur	B
directly	O
binds	O
to	O
a	O
single	O
region	O
comprising	O
a	O
nearly	O
perfect	O
palindrome	O
.	O

Zinc	O
chelators	O
completely	O
inhibited	O
and	O
Zn	O
(	O
2	O
+	O
)	O
in	O
low	O
concentrations	O
enhanced	O
DNA	O
binding	O
of	O
Zur	B
.	O

No	O
evidence	O
for	O
autoregulation	O
of	O
Zur	B
was	O
found	O
.	O

Zur	B
binds	O
at	O
least	O
2	O
zinc	O
ions	O
/	O
dimer	O
specifically	O
.	O

Although	O
most	O
of	O
the	O
mutant	O
Zur	B
proteins	O
bound	O
to	O
the	O
znu	B
operator	O
in	O
vitro	O
,	O
no	O
protection	O
was	O
observed	O
in	O
in	O
vivo	O
footprinting	O
experiments	O
.	O

Analysis	O
of	O
the	O
mutant	O
Zur	B
proteins	O
suggested	O
an	O
amino	O
-	O
terminal	O
DNA	O
contact	O
domain	O
around	O
residue	O
65	O
and	O
a	O
dimerization	O
and	O
Zn	O
(	O
2	O
+	O
)	O
-	O
binding	O
domain	O
toward	O
the	O
carboxyl	O
-	O
terminal	O
end	O
.	O

Modular	O
organization	O
and	O
identification	O
of	O
a	O
mononuclear	O
iron	O
-	O
binding	O
site	O
within	O
the	O
NifU	B
protein	O
.	O

The	O
NifS	B
and	O
NifU	B
nitrogen	O
fixation	O
-	O
specific	O
gene	O
products	O
are	O
required	O
for	O
the	O
full	O
activation	O
of	O
both	O
the	O
Fe	B
-	I
protein	I
and	I
MoFe	I
-	I
protein	I
of	I
nitrogenase	I
from	O
Azotobacter	O
vinelandii	O
.	O

Because	O
the	O
two	O
nitrogenase	B
component	O
proteins	O
both	O
require	O
the	O
assembly	O
of	O
[	O
Fe	O
-	O
S	O
]	O
-containing	O
clusters	O
for	O
their	O
activation	O
,	O
it	O
has	O
been	O
suggested	O
that	O
NifS	B
and	O
NifU	B
could	O
have	O
complementary	O
functions	O
in	O
the	O
mobilization	O
of	O
sulfur	O
and	O
iron	O
necessary	O
for	O
nitrogenase	B
-	O
specific	O
[	O
Fe	O
-	O
S	O
]	O
cluster	O
assembly	O
.	O

The	O
NifS	B
protein	O
has	O
been	O
shown	O
to	O
have	O
cysteine	B
desulfurase	I
activity	O
and	O
can	O
be	O
used	O
to	O
supply	O
sulfide	O
for	O
the	O
in	O
vitro	O
catalytic	O
formation	O
of	O
[	O
Fe	O
-	O
S	O
]	O
clusters	O
.	O

The	O
NifU	B
protein	O
was	O
previously	O
purified	O
and	O
shown	O
to	O
be	O
a	O
homodimer	O
with	O
a	O
[	O
2Fe-2S	O
]	O
cluster	O
in	O
each	O
subunit	O
.	O

In	O
the	O
present	O
work	O
,	O
primary	O
sequence	O
comparisons	O
,	O
amino	O
acid	O
substitution	O
experiments	O
,	O
and	O
optical	O
and	O
resonance	O
Raman	O
spectroscopic	O
characterization	O
of	O
recombinantly	O
produced	O
NifU	B
and	O
NifU	B
fragments	O
are	O
used	O
to	O
show	O
that	O
NifU	B
has	O
a	O
modular	O
structure	O
.	O

One	O
module	O
is	O
contained	O
in	O
approximately	O
the	O
N	O
-	O
terminal	O
third	O
of	O
NifU	B
and	O
is	O
shown	O
to	O
provide	O
a	O
labile	O
rubredoxin	O
-	O
like	O
ferric	O
-	O
binding	O
site	O
.	O

Cysteine	O
residues	O
Cys35	O
,	O
Cys62	O
,	O
and	O
Cys106	O
are	O
necessary	O
for	O
binding	O
iron	O
in	O
the	O
rubredoxin	O
-	O
like	O
mode	O
and	O
visible	O
extinction	O
coefficients	O
indicate	O
that	O
up	O
to	O
one	O
ferric	O
ion	O
can	O
be	O
bound	O
per	O
NifU	B
monomer	O
.	O

The	O
second	O
module	O
is	O
contained	O
in	O
approximately	O
the	O
C	O
-	O
terminal	O
half	O
of	O
NifU	B
and	O
provides	O
the	O
[	O
2Fe-2S	O
]	O
cluster	O
-	O
binding	O
site	O
.	O

Cysteine	O
residues	O
Cys137	O
,	O
Cys139	O
,	O
Cys172	O
,	O
and	O
Cys175	O
provide	O
ligands	O
to	O
the	O
[	O
2Fe	O
-	O
2S	O
]	O
cluster	O
.	O

The	O
cysteines	O
involved	O
in	O
ligating	O
the	O
mononuclear	O
Fe	O
in	O
the	O
rubredoxin	O
-	O
like	O
site	O
and	O
those	O
that	O
provide	O
the	O
[	O
2Fe-2S	O
]	O
cluster	O
ligands	O
are	O
all	O
required	O
for	O
the	O
full	O
physiological	O
function	O
of	O
NifU	B
.	O

The	O
only	O
two	O
other	O
cysteines	O
contained	O
within	O
NifU	B
,	O
Cys272	O
and	O
Cys275	O
,	O
are	O
not	O
necessary	O
for	O
iron	O
binding	O
at	O
either	O
site	O
,	O
nor	O
are	O
they	O
required	O
for	O
the	O
full	O
physiological	O
function	O
of	O
NifU	B
.	O

The	O
results	O
provide	O
the	O
basis	O
for	O
a	O
model	O
where	O
iron	O
bound	O
in	O
labile	O
rubredoxin	O
-	O
like	O
sites	O
within	O
NifU	B
is	O
used	O
for	O
[	O
Fe	O
-	O
S	O
]	O
cluster	O
formation	O
.	O

The	O
[	O
2Fe-2S	O
]	O
clusters	O
contained	O
within	O
NifU	B
are	O
proposed	O
to	O
have	O
a	O
redox	O
function	O
involving	O
the	O
release	O
of	O
Fe	O
from	O
bacterioferritin	B
and	O
/	O
or	O
the	O
release	O
of	O
Fe	O
or	O
an	O
[	O
Fe	O
-	O
S	O
]	O
cluster	O
precursor	O
from	O
the	O
rubredoxin	O
-	O
like	O
binding	O
site	O
.	O

ATPase	B
kinetic	O
characterization	O
and	O
single	O
molecule	O
behavior	O
of	O
mutant	O
human	O
kinesin	B
motors	O
defective	O
in	O
microtubule	O
-	O
based	O
motility	O
.	O

Conventional	B
kinesin	I
is	O
a	O
microtubule	O
-	O
based	O
motor	B
protein	I
that	O
is	O
an	O
important	O
model	O
system	O
for	O
understanding	O
mechanochemical	O
transduction	O
.	O

To	O
identify	O
regions	O
of	O
the	O
kinesin	B
protein	O
that	O
participate	O
in	O
microtubule	O
binding	O
and	O
force	O
production	O
,	O
Woehlke	O
et	O
al.	O
[	O
(	O
1997	O
)	O
Cell	O
90	O
,	O
207	O
-	O
216	O
]	O
generated	O
35	O
alanine	O
mutations	O
in	O
solvent	O
-	O
exposed	O
residues	O
.	O

Here	O
,	O
we	O
have	O
performed	O
presteady	O
-	O
state	O
kinetic	O
and	O
single	O
molecule	O
motility	O
analyses	O
on	O
three	O
of	O
these	O
mutants	O
[	O
Y138A	O
,	O
loop	O
11	O
triple	O
(	O
L248A	O
/	O
D249A	O
/	O
E250A	O
)	O
,	O
and	O
E311A	O
]	O
that	O
exhibited	O
a	O
similar	O
approximately	O
3	O
-	O
fold	O
reduction	O
in	O
both	O
microtubule	O
gliding	O
velocity	O
and	O
microtubule	O
-	O
stimulated	O
ATPase	B
activity	O
.	O

All	O
mutants	O
showed	O
normal	O
second	O
-	O
order	O
ATP	O
binding	O
kinetics	O
,	O
indicating	O
correct	O
folding	O
of	O
the	O
active	O
site	O
.	O

The	O
Y138A	O
and	O
loop	O
11	O
triple	O
mutants	O
were	O
defective	O
both	O
in	O
nucleotide	O
hydrolysis	O
and	O
in	O
microtubule	O
-	O
stimulated	O
ADP	O
release	O
rates	O
,	O
the	O
latter	O
suggesting	O
a	O
defect	O
in	O
allosteric	O
communication	O
between	O
the	O
microtubule	O
and	O
the	O
active	O
site	O
.	O

A	O
single	O
molecule	O
fluorescence	O
assay	O
further	O
revealed	O
that	O
the	O
loop	O
11	O
mutant	O
is	O
defective	O
in	O
initiating	O
processive	O
motion	O
,	O
suggesting	O
that	O
this	O
loop	O
is	O
important	O
for	O
the	O
initial	O
contact	O
between	O
kinesin	B
and	O
the	O
microtubule	O
.	O

Y138A	O
,	O
on	O
the	O
other	O
hand	O
,	O
can	O
bind	O
to	O
the	O
microtubule	O
normally	O
but	O
can	O
not	O
move	O
processively	O
.	O

For	O
E311A	O
,	O
neither	O
the	O
rate	O
of	O
nucleotide	O
hydrolysis	O
nor	O
ADP	O
release	O
could	O
account	O
for	O
its	O
slower	O
ATPase	B
and	O
gliding	O
velocity	O
,	O
which	O
suggests	O
that	O
either	O
phosphate	O
release	O
or	O
a	O
conformational	O
transition	O
is	O
rate	O
-	O
limiting	O
in	O
this	O
mutant	O
.	O

The	O
single	O
molecule	O
assay	O
showed	O
that	O
E311A	O
has	O
a	O
reduced	O
velocity	O
of	O
movement	O
,	O
but	O
is	O
not	O
defective	O
in	O
processivity	O
.	O

Thus	O
,	O
while	O
these	O
mutants	O
behave	O
similarly	O
in	O
solution	O
ATPase	B
and	O
multiple	O
motor	O
gliding	O
assays	O
,	O
kinetic	O
and	O
single	O
molecule	O
analyses	O
reveal	O
defects	O
in	O
distinct	O
processes	O
in	O
kinesin	B
'	O
s	O
mechanochemical	O
cycle	O
.	O

Interactions	O
between	O
the	O
soluble	O
domain	O
I	O
of	O
nicotinamide	B
nucleotide	I
transhydrogenase	I
from	O
Rhodospirillum	O
rubrum	O
and	O
transhydrogenase	B
from	O
Escherichia	O
coli	O
.	O

Effects	O
on	O
catalytic	O
and	O
H	O
+	O
-	O
pumping	O
activities	O
.	O

Nicotinamide	B
nucleotide	I
transhydrogenase	I
from	O
Escherichia	O
coli	O
is	O
composed	O
of	O
two	O
subunits	O
,	O
the	O
alpha	O
and	O
the	O
beta	O
subunits	O
,	O
each	O
of	O
which	O
contains	O
a	O
hydrophilic	O
domain	O
,	O
domain	O
I	O
and	O
III	O
,	O
respectively	O
,	O
as	O
well	O
as	O
several	O
transmembrane	O
helices	O
,	O
collectively	O
denoted	O
domain	O
II	O
.	O

The	O
interactions	O
between	O
domain	O
I	O
from	O
Rhodospirillum	O
rubrum	O
(	O
rrI	O
)	O
and	O
the	O
intact	O
or	O
the	O
protease	B
-	O
treated	O
enzyme	O
from	O
E.	O
coli	O
was	O
investigated	O
using	O
the	O
separately	O
expressed	O
and	O
purified	O
domain	O
I	O
from	O
R.	O
rubrum	O
,	O
and	O
His	O
-	O
tagged	O
intact	O
and	O
trypsin	B
-	O
treated	O
E.	O
coli	O
transhydrogenase	B
.	O

Despite	O
harsh	O
treatments	O
with	O
,	O
e.g.	O
detergents	O
and	O
denaturing	O
agents	O
,	O
the	O
alpha	O
and	O
beta	O
subunits	O
remained	O
tightly	O
associated	O
.	O

A	O
monoclonal	O
antibody	O
directed	O
towards	O
the	O
alpha	O
subunit	O
was	O
strongly	O
inhibitory	O
,	O
an	O
effect	O
that	O
was	O
relieved	O
by	O
added	O
rrI	O
.	O

In	O
addition	O
,	O
rrI	O
also	O
reactivated	O
the	O
trypsin	B
-	O
digested	O
E.	O
coli	O
enzyme	O
in	O
which	O
domain	O
I	O
had	O
been	O
partly	O
removed	O
.	O

This	O
suggests	O
that	O
the	O
hydrophilic	O
domains	O
I	O
and	O
III	O
are	O
not	O
in	O
permanent	O
contact	O
but	O
are	O
mobile	O
during	O
catalysis	O
while	O
being	O
anchored	O
to	O
domain	O
II	O
.	O

Replacement	O
of	O
domain	O
I	O
of	O
intact	O
,	O
as	O
well	O
as	O
trypsin	B
-	O
digested	O
,	O
E.	O
coli	O
transhydrogenase	B
with	O
rrI	O
resulted	O
in	O
a	O
markedly	O
different	O
pH	O
dependence	O
of	O
the	O
cyclic	O
reduction	O
of	O
3	O
-	O
acetyl	O
-	O
pyridine	O
-	O
NAD	O
+	O
by	O
NADH	O
in	O
the	O
presence	O
of	O
NADP	O
(	O
H	O
)	O
,	O
suggesting	O
that	O
the	O
protonation	O
of	O
one	O
or	O
more	O
protonable	O
groups	O
in	O
domain	O
I	O
is	O
controlling	O
this	O
reaction	O
.	O

The	O
reverse	O
reaction	O
and	O
proton	O
pumping	O
showed	O
a	O
less	O
pronounced	O
change	O
in	O
pH	O
dependence	O
,	O
demonstrating	O
the	O
regulatory	O
role	O
of	O
domain	O
II	O
in	O
these	O
reactions	O
.	O

Polymorphisms	O
in	O
the	O
CBS	B
gene	O
associated	O
with	O
decreased	O
risk	O
of	O
coronary	O
artery	O
disease	O
and	O
increased	O
responsiveness	O
to	O
total	O
homocysteine	O
lowering	O
by	O
folic	O
acid	O
.	O

Elevated	O
total	O
plasma	O
homocysteine	O
(	O
tHcy	O
)	O
is	O
an	O
established	O
risk	O
factor	O
for	O
the	O
development	O
of	O
vascular	O
disease	O
and	O
neural	O
tube	O
defects	O
.	O

Total	O
homocysteine	O
levels	O
can	O
be	O
lowered	O
by	O
folic	O
acid	O
supplements	O
but	O
individual	O
response	O
is	O
highly	O
variable	O
.	O

In	O
this	O
case	O
-	O
control	O
study	O
,	O
involving	O
142	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
patients	O
and	O
102	O
controls	O
,	O
we	O
have	O
typed	O
six	O
genetic	O
polymorphisms	O
in	O
three	O
homocysteine	O
metabolizing	O
genes	O
and	O
examined	O
their	O
relationship	O
to	O
the	O
incidence	O
of	O
CAD	O
,	O
tHcy	O
levels	O
,	O
and	O
lowering	O
of	O
tHcy	O
levels	O
in	O
response	O
to	O
folic	O
acid	O
supplementation	O
.	O

We	O
found	O
that	O
two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
cystathionine	B
beta	I
synthase	I
(	O
CBS	B
)	O
gene	O
,	O
699C	O
--	O
>	O
T	O
and	O
1080	O
T	O
--	O
>	O
C	O
,	O
are	O
associated	O
with	O
decreased	O
risk	O
of	O
CAD	O
and	O
increased	O
responsiveness	O
to	O
the	O
tHcy	O
lowering	O
effects	O
of	O
folic	O
acid	O
.	O

Individuals	O
homozygous	O
for	O
699	O
T	O
were	O
significantly	O
underrepresented	O
in	O
CAD	O
patients	O
as	O
compared	O
to	O
controls	O
(	O
4.9	O
%	O
vs	O
17.3	O
%	O
,	O
P	O
=	O
0.0015	O
)	O
,	O
as	O
were	O
individuals	O
homozygous	O
for	O
the	O
1080C	O
(	O
29.6	O
%	O
vs	O
44.2	O
%	O
,	O
P	O
=	O
0.018	O
)	O
.	O

Additionally	O
,	O
699	O
T	O
and	O
1080C	O
homozygous	O
individuals	O
were	O
the	O
most	O
responsive	O
to	O
folate	O
supplementation	O
.	O

699	O
T	O
homozygotes	O
lowered	O
tHcy	O
levels	O
13.6	O
%	O
on	O
average	O
,	O
compared	O
to	O
4.8	O
%	O
lowering	O
in	O
699C	O
homozygotes	O
(	O
P	O
=	O
0.009	O
)	O
,	O
while	O
1080C	O
homozygotes	O
lowered	O
12.9	O
%	O
compared	O
to	O
just	O
2.7	O
%	O
for	O
1080	O
T	O
homozygotes	O
(	O
P	O
=	O
0.005	O
)	O
.	O

The	O
two	O
polymorphisms	O
in	O
CBS	B
are	O
third	O
codon	O
changes	O
and	O
would	O
not	O
be	O
predicted	O
to	O
affect	O
the	O
underlying	O
protein	O
.	O

However	O
,	O
there	O
is	O
strong	O
linkage	O
disequilibrium	O
between	O
these	O
two	O
positions	O
,	O
suggesting	O
that	O
they	O
may	O
also	O
be	O
linked	O
to	O
other	O
as	O
yet	O
unidentified	O
polymorphisms	O
within	O
the	O
CBS	B
gene	O
.	O

These	O
observations	O
suggest	O
that	O
specific	O
CBS	B
alleles	O
are	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
vascular	O
disease	O
and	O
that	O
genetic	O
information	O
could	O
be	O
predictive	O
of	O
individual	O
response	O
to	O
folic	O
acid	O
supplementation	O
.	O

Basal	O
metabolic	O
rate	O
in	O
anorexia	O
nervosa	O
:	O
relation	O
to	O
body	O
composition	O
and	O
leptin	B
concentrations	O
.	O

BACKGROUND	O
:	O

Leptin	B
is	O
thought	O
to	O
represent	O
a	O
peripheral	O
signal	O
involved	O
in	O
the	O
regulation	O
of	O
energy	O
balance	O
.	O

Its	O
action	O
has	O
been	O
studied	O
in	O
animals	O
and	O
obese	O
subjects	O
.	O

Little	O
is	O
known	O
about	O
leptin	B
's	O
role	O
during	O
negative	O
energy	O
balance	O
.	O

OBJECTIVE	O
:	O

The	O
objective	O
was	O
to	O
evaluate	O
the	O
relation	O
between	O
energy	O
turnover	O
,	O
body	O
composition	O
,	O
and	O
plasma	O
leptin	B
concentrations	O
in	O
anorexia	O
nervosa	O
(	O
AN	O
)	O
.	O

DESIGN	O
:	O

Sixteen	O
weight	O
-	O
stable	O
women	O
with	O
AN	O
were	O
compared	O
with	O
22	O
control	O
subjects	O
and	O
14	O
rehabilitated	O
AN	O
patients	O
(	O
R	O
-	O
AN	O
)	O
.	O

Basal	O
metabolic	O
rate	O
(	O
BMR	O
)	O
was	O
measured	O
by	O
indirect	O
calorimetry	O
;	O
fat	O
-	O
free	O
mass	O
(	O
FFM	O
)	O
and	O
fat	O
mass	O
(	O
FM	O
)	O
were	O
calculated	O
according	O
to	O
a	O
4	O
-	O
compartment	O
model	O
.	O

Plasma	O
leptin	B
was	O
determined	O
by	O
radioimmunoassay	O
.	O

RESULTS	O
:	O

The	O
BMR	O
of	O
AN	O
patients	O
(	O
2.73	O
+	O
/-	O
0.37	O
kJ	O
/	O
min	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
control	O
subjects	O
(	O
3.45	O
+	O
/-	O
0.34	O
kJ	O
/	O
min	O
)	O
(	O
P	O
<	O
0.001	O
)	O
,	O
even	O
after	O
adjustment	O
for	O
FFM	O
(	O
2.92	O
+	O
/-	O
0.33	O
kJ	O
/	O
min	O
in	O
AN	O
patients	O
and	O
3.30	O
+	O
/-	O
0.26	O
kJ	O
/	O
min	O
in	O
control	O
subjects	O
;	O
P	O
<	O
0.004	O
)	O
.	O

Plasma	O
leptin	B
concentrations	O
in	O
AN	O
patients	O
were	O
76	O
%	O
lower	O
than	O
in	O
control	O
subjects	O
,	O
even	O
after	O
body	O
fat	O
was	O
controlled	O
for	O
.	O

In	O
R	O
-	O
AN	O
patients	O
,	O
BMR	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
control	O
subjects	O
and	O
leptin	B
concentrations	O
were	O
generally	O
close	O
to	O
normal	O
.	O

Plasma	O
leptin	B
concentrations	O
correlated	O
significantly	O
with	O
FM	O
(	O
r	O
(	O
2	O
)	O
=	O
0.53	O
,	O
P	O
<	O
0.0000	O
)	O
and	O
BMR	O
,	O
even	O
after	O
adjustment	O
for	O
FFM	O
(	O
r	O
(	O
2	O
)	O
=	O
0.21	O
,	O
P	O
<	O
0.0003	O
)	O
.	O

CONCLUSIONS	O
:	O

BMR	O
and	O
plasma	O
leptin	B
concentrations	O
are	O
depressed	O
in	O
patients	O
with	O
AN	O
;	O
this	O
is	O
not	O
explained	O
by	O
body	O
-	O
composition	O
changes	O
.	O

The	O
relation	O
between	O
leptin	B
and	O
BMR	O
suggests	O
that	O
leptin	O
plays	O
a	O
role	O
in	O
the	O
energy	O
sparing	O
response	O
to	O
exposure	O
to	O
chronic	O
energy	O
deficiency	O
.	O

The	O
return	O
of	O
BMR	O
to	O
normal	O
and	O
the	O
significant	O
increase	O
in	O
leptin	B
concentrations	O
in	O
R	O
-	O
AN	O
patients	O
suggests	O
a	O
full	O
reversibility	O
of	O
this	O
adaptation	O
mechanism	O
.	O

Lung	O
overexpression	O
of	O
the	O
vascular	B
endothelial	I
growth	I
factor	I
gene	O
induces	O
pulmonary	O
edema	O
.	O

We	O
hypothesized	O
that	O
the	O
angiogenic	O
mediator	O
,	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
,	O
known	O
to	O
be	O
expressed	O
in	O
the	O
lung	O
and	O
to	O
be	O
capable	O
of	O
inducing	O
local	O
edema	O
in	O
skin	O
,	O
might	O
evoke	O
the	O
development	O
of	O
lung	O
edema	O
if	O
expressed	O
in	O
excess	O
amounts	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
developed	O
an	O
in	O
vivo	O
model	O
of	O
VEGF	B
overexpression	O
in	O
the	O
lung	O
on	O
the	O
basis	O
of	O
delivery	O
to	O
the	O
respiratory	O
epithelium	O
of	O
the	O
VEGF165	B
complementary	O
DNA	O
by	O
an	O
E1	O
(	O
-	O
)	O
adenovirus	O
vector	O
(	O
AdVEGF165	B
)	O
.	O

Administration	O
of	O
AdVEGF165	B
by	O
the	O
intratracheal	O
route	O
(	O
10	O
(	O
9	O
)	O
plaque	O
-	O
forming	O
units	O
[	O
pfu	O
]	O
)	O
to	O
C57Bl	O
/	O
6	O
mice	O
showed	O
increased	O
expression	O
of	O
VEGF	B
messenger	O
RNA	O
in	O
lung	O
tissue	O
by	O
Northern	O
analysis	O
.	O

Overexpression	O
of	O
VEGF	B
protein	O
in	O
the	O
lung	O
at	O
Days	O
1	O
to	O
10	O
was	O
confirmed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Intratracheal	O
administration	O
of	O
AdVEGF165	B
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
lung	O
wet	O
/	O
dry	O
weight	O
ratios	O
over	O
time	O
,	O
lung	O
histology	O
showed	O
widespread	O
intra	O
-	O
alveolar	O
edema	O
,	O
and	O
pulmonary	O
capillary	O
permeability	O
was	O
significantly	O
increased	O
as	O
quantified	O
by	O
the	O
Evans	O
blue	O
dye	O
assay	O
and	O
[	O
(	O
131	O
)	O
I	O
]	O
albumin	B
permeability	O
.	O

To	O
confirm	O
the	O
specificity	O
of	O
these	O
observations	O
,	O
mice	O
were	O
pretreated	O
with	O
intranasal	O
administration	O
of	O
an	O
adenovirus	O
vector	O
expressing	O
a	O
truncated	O
soluble	O
form	O
of	O
the	O
VEGF	B
receptor	I
flt-1	I
(	O
Adsflt	O
)	O
.	O

Adsflt	O
(	O
10	O
(	O
9	O
)	O
pfu	O
)	O
pretreatment	O
completely	O
abrogated	O
the	O
increased	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
caused	O
by	O
AdVEGF165	B
administration	O
,	O
whereas	O
an	O
identical	O
adenovirus	O
vector	O
with	O
an	O
irrelevant	O
transgene	O
had	O
no	O
effect	O
upon	O
subsequent	O
AdVEGF165	B
-	O
induced	O
pulmonary	O
edema	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
overexpression	O
of	O
VEGF	B
in	O
the	O
lung	O
may	O
be	O
one	O
mechanism	O
of	O
increased	O
pulmonary	O
vascular	O
permeability	O
in	O
the	O
early	O
stages	O
of	O
acute	O
lung	O
injury	O
.	O

Development	O
of	O
a	O
polynucleotide	O
vaccine	O
from	O
melanoma	B
antigen	I
recognized	I
by	I
T	I
cells-1	I
and	O
recombinant	O
protein	O
from	O
melanoma	B
antigen	I
recognized	I
by	I
T	I
cells-1	I
for	O
melanoma	O
vaccine	O
clinical	O
trials	O
.	O

MART-1	B
,	O
a	O
melanoma	B
antigen	I
recognized	I
by	I
T	I
cells	I
-	I
1	I
,	O
is	O
a	O
melanocyte	O
lineage	O
-	O
differentiation	O
antigen	O
expressed	O
only	O
in	O
melanocytes	O
and	O
melanoma	O
cells	O
.	O

This	O
protein	O
is	O
recognized	O
by	O
many	O
T	O
-	O
lymphocyte	O
lines	O
that	O
are	O
human	B
leukocyte	I
antigen	I
(	I
HLA	I
)	I
-	I
A2	I
restricted	O
and	O
melanoma	O
reactive	O
.	O

These	O
observations	O
have	O
culminated	O
in	O
an	O
array	O
of	O
clinical	O
trials	O
of	O
MART-1	B
immunization	O
using	O
recombinant	O
viruses	O
or	O
MART-1	B
immunodominant	O
peptides	O
.	O

Polynucleotide	O
immunization	O
is	O
a	O
promising	O
alternative	O
to	O
recombinant	O
viral	O
vaccines	O
that	O
allows	O
delivery	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
encoding	O
all	O
potential	O
peptide	O
epitopes	O
in	O
a	O
vector	O
that	O
is	O
uncompromised	O
by	O
anti	O
-	O
viral	O
immunity	O
.	O

In	O
preparation	O
for	O
a	O
phase	O
I	O
clinical	O
trial	O
of	O
MART-1	B
polynucleotide	O
immunization	O
in	O
patients	O
with	O
resected	O
melanoma	O
who	O
were	O
at	O
significant	O
risk	O
for	O
recurrence	O
,	O
the	O
authors	O
constructed	O
a	O
plasmid	O
DNA	O
encoding	O
the	O
MART-1	B
cDNA	O
under	O
transcriptional	O
regulatory	O
control	O
of	O
the	O
cytomegalovirus	O
immediate	O
early	O
promoter	O
-	O
enhancer	O
and	O
partially	O
deleted	O
intron	O
A	O
.	O

This	O
plasmid	O
directs	O
high	O
-	O
level	O
MART-1	B
expression	O
in	O
transduced	O
myoblasts	O
and	O
maturing	O
myocytes	O
diffusely	O
throughout	O
the	O
cytoplasm	O
.	O

Immunization	O
of	O
mice	O
with	O
this	O
construct	O
by	O
intramuscular	O
injection	O
elicited	O
MART-1	B
-	O
specific	O
immune	O
responses	O
in	O
all	O
animals	O
.	O

Previous	O
trials	O
of	O
MART-1	B
immunization	O
have	O
been	O
unable	O
to	O
examine	O
the	O
humoral	O
immune	O
response	O
to	O
MART-1	B
because	O
of	O
a	O
lack	O
of	O
sufficient	O
,	O
highly	O
purified	O
protein	O
.	O

We	O
have	O
produced	O
and	O
purified	O
Escherichia	O
coli	O
recombinant	O
MART-1	B
protein	O
using	O
a	O
glutathione	B
-	I
S	I
-	I
transferase	I
fusion	O
protein	O
expression	O
system	O
.	O

Protein	O
staining	O
of	O
a	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
revealed	O
a	O
band	O
of	O
MART-1	B
protein	O
at	O
approximately	O
20	O
kD	O
;	O
and	O
Western	O
immunoblotting	O
with	O
an	O
anti	O
-	O
MART	B
-	I
1	I
monoclonal	O
antibody	O
confirmed	O
a	O
doublet	O
at	O
approximately	O
20	O
kD	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
previous	O
reports	O
using	O
different	O
expression	O
systems	O
for	O
recombinant	O
MART-1	B
.	O

This	O
protein	O
preparation	O
functioned	O
well	O
in	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
to	O
detect	O
anti	O
-	O
MART	B
-	I
1	I
antibody	O
responses	O
in	O
a	O
mouse	O
model	O
;	O
and	O
a	O
panel	O
of	O
healthy	O
donor	O
human	O
sera	O
showed	O
minimal	O
binding	O
to	O
ELISA	O
plates	O
coated	O
with	O
the	O
protein	O
,	O
supporting	O
its	O
utility	O
in	O
monitoring	O
human	O
anti	O
-	O
MART	B
-	I
1	I
antibody	O
responses	O
.	O

The	O
glutathione	B
-	I
S	I
-	I
transferase	I
fusion	O
method	O
yielded	O
approximately	O
200	O
micrograms	O
MART-1	B
per	O
2-L	O
bacterial	O
culture	O
,	O
enough	O
to	O
coat	O
100	O
ELISA	O
plates	O
.	O

Molecular	O
mechanism	O
of	O
ultraviolet	O
-	O
induced	O
keratinocyte	O
apoptosis	O
.	O

This	O
article	O
reviews	O
advances	O
in	O
the	O
study	O
of	O
the	O
molecular	O
mechanisms	O
for	O
ultraviolet	O
(	O
UV	O
)	O
-	O
induced	O
keratinocyte	O
apoptosis	O
,	O
with	O
particular	O
reference	O
to	O
the	O
cytokines	B
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
Fas	B
ligand	I
(	O
FasL	B
)	O
.	O

TNF	B
-	I
alpha	I
and	O
FasL	B
induce	O
their	O
respective	O
receptors	O
and	O
then	O
activate	O
caspase	B
enzymes	O
that	O
are	O
critically	O
involved	O
in	O
the	O
apoptotic	O
process	O
.	O

This	O
activation	O
is	O
further	O
amplified	O
by	O
intracellular	O
mitochondria	O
-	O
associated	O
mechanisms	O
.	O

Using	O
gene	O
-	O
targeted	O
knockout	O
mice	O
lacking	O
either	O
the	O
TNF	B
-	I
Rp55	I
or	O
the	O
TNF	B
-	I
Rp75	I
,	O
we	O
have	O
shown	O
that	O
TNF	B
-	I
alpha	I
plays	O
an	O
important	O
role	O
in	O
UV	O
-	O
induced	O
keratinocyte	O
apoptosis	O
via	O
TNF	B
-	I
Rp55	I
.	O

TNF	B
-	I
Rp55	I
shares	O
homology	O
with	O
Fas	B
and	O
contains	O
an	O
intracellular	O
death	O
domain	O
.	O

UV	O
seems	O
to	O
directly	O
stimulate	O
cross	O
-	O
linking	O
of	O
Fas	B
,	O
resulting	O
in	O
the	O
engagement	O
of	O
the	O
death	O
machinery	O
.	O

Fas	B
-	I
associated	I
death	I
domain	I
protein	I
(	O
FADD	B
)	O
acts	O
as	O
an	O
adapter	B
protein	I
in	O
both	O
the	O
TNF	B
-	I
Rp55	I
and	O
Fas	B
death	O
-	O
inducing	O
cascades	O
and	O
is	O
responsible	O
for	O
downstream	O
signal	O
transduction	O
by	O
recruiting	O
caspases	O
.	O

Moreover	O
,	O
signaling	O
of	O
p53	B
contributes	O
to	O
the	O
induction	O
of	O
apoptosis	O
by	O
regulating	O
Bcl-2	B
family	I
expression	O
and	O
increasing	O
surface	O
Fas	B
expression	O
.	O

In	O
addition	O
to	O
induction	O
mechanisms	O
of	O
apoptosis	O
,	O
there	O
are	O
numerous	O
inhibitory	O
molecules	O
that	O
play	O
a	O
role	O
in	O
restricting	O
the	O
apoptotic	O
pathway	O
.	O

Thus	O
,	O
the	O
ultimate	O
determination	O
of	O
whether	O
or	O
not	O
a	O
cell	O
undergoes	O
apoptosis	O
after	O
UV	O
radiation	O
is	O
based	O
on	O
the	O
balance	O
between	O
agonist	O
and	O
antagonist	O
pathways	O
.	O

Inhibitory	O
effects	O
of	O
IFN	B
-	I
gamma	I
and	O
acyclovir	O
on	O
the	O
glioblastoma	O
cell	O
cycle	O
.	O

Glioblastoma	O
multiforme	O
is	O
one	O
of	O
the	O
most	O
aggressive	O
and	O
frequently	O
occurring	O
forms	O
of	O
brain	O
cancer	O
.	O

It	O
originates	O
from	O
astrocytes	O
and	O
is	O
characterized	O
by	O
a	O
loss	O
of	O
cell	O
cycle	O
control	O
frequently	O
involving	O
mutations	O
in	O
tumor	O
suppressor	O
genes	O
,	O
such	O
as	O
p53	B
and	O
p16	B
.	O

Nucleoside	O
analogs	O
,	O
such	O
as	O
acyclovir	O
(	O
ACV	O
)	O
,	O
are	O
currently	O
being	O
used	O
in	O
the	O
treatment	O
of	O
viral	O
diseases	O
,	O
such	O
as	O
those	O
caused	O
by	O
members	O
of	O
the	O
herpes	O
family	O
.	O

Further	O
,	O
ACV	O
in	O
combination	O
with	O
type	B
I	I
interferons	I
(	O
IFN	B
)	O
has	O
been	O
shown	O
to	O
be	O
more	O
effective	O
at	O
lower	O
doses	O
in	O
treatment	O
of	O
viral	O
diseases	O
.	O

We	O
show	O
here	O
that	O
ACV	O
at	O
high	O
concentrations	O
(	O
up	O
to	O
500	O
microg	O
/	O
ml	O
)	O
inhibited	O
growth	O
in	O
tissue	O
culture	O
of	O
the	O
human	O
glioblastoma	O
cell	O
lines	O
T98	O
G	O
,	O
SNB-19	O
,	O
and	O
U-373	O
by	O
as	O
much	O
as	O
68.3	O
%	O
while	O
inhibiting	O
normal	O
human	O
astrocytes	O
by	O
only	O
38.3	O
%	O
.	O

Related	O
to	O
this	O
,	O
the	O
tumor	O
cells	O
were	O
more	O
than	O
sevenfold	O
more	O
efficient	O
in	O
phosphorylation	O
of	O
ACV	O
to	O
the	O
active	O
phosphate	O
form	O
than	O
normal	O
human	O
astrocytes	O
.	O

Analogous	O
to	O
treatment	O
of	O
virus	O
-	O
infected	O
cells	O
,	O
suboptimal	O
concentrations	O
of	O
ACV	O
were	O
as	O
effective	O
as	O
high	O
concentrations	O
when	O
used	O
in	O
conjunction	O
with	O
low	O
concentrations	O
of	O
IFN	B
-	I
gamma	I
in	O
inhibition	O
of	O
tumor	O
cell	O
growth	O
.	O

At	O
the	O
cellular	O
level	O
,	O
ACV	O
and	O
IFN	B
-	I
gamma	I
inhibited	O
the	O
cell	O
cycle	O
in	O
both	O
the	O
G1	O
and	O
S	O
phases	O
.	O

The	O
cooperative	O
effect	O
of	O
ACV	O
and	O
IFN	B
-	I
gamma	I
against	O
the	O
glioblastomas	O
appears	O
to	O
be	O
due	O
to	O
direct	O
inhibition	O
of	O
DNA	O
synthesis	O
by	O
ACV	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
induction	O
by	O
IFN	B
-	I
gamma	I
of	O
the	O
tumor	O
suppressor	O
gene	O
p21wAF1	B
/	O
CIP1	B
,	O
which	O
in	O
turn	O
acts	O
at	O
the	O
level	O
of	O
proliferating	B
cell	I
nuclear	I
antigen	I
(	O
PCNA	B
)	O
and	O
cyclin	B
E	I
/	O
cyclin	B
-	I
dependent	I
kinase	I
2	I
(	O
Cdk2	B
)	O
binding	O
and	O
inhibition	O
of	O
function	O
.	O

These	O
studies	O
show	O
that	O
the	O
combination	O
of	O
IFN	B
-	I
gamma	I
and	O
ACV	O
at	O
suboptimal	O
concentrations	O
elicits	O
significant	O
antiproliferative	O
effects	O
on	O
the	O
glioblastoma	O
cell	O
lines	O
T98	O
G	O
,	O
SNB-19	O
,	O
and	O
U-373	O
while	O
having	O
very	O
little	O
effect	O
on	O
normal	O
human	O
astrocyte	O
cell	O
proliferation	O
.	O

Stimulation	O
of	O
osteoclast	O
differentiation	O
in	O
vitro	O
by	O
mouse	O
oncostatin	B
M	I
,	O
leukaemia	B
inhibitory	I
factor	I
,	O
cardiotrophin-1	B
and	O
interleukin	B
6	I
:	O
synergy	O
with	O
dexamethasone	O
.	O

The	O
role	O
of	O
oncostatin	B
M	I
in	O
bone	O
metabolism	O
is	O
not	O
clearly	O
defined	O
,	O
and	O
the	O
actions	O
of	O
mouse	O
oncostatin	B
M	I
(	O
mOSM	B
)	O
on	O
osteoclast	O
development	O
has	O
not	O
been	O
previously	O
determined	O
.	O

We	O
therefore	O
examined	O
the	O
ability	O
of	O
recombinant	O
mOSM	B
to	O
stimulate	O
osteoclast	O
formation	O
and	O
activity	O
using	O
cocultures	O
of	O
murine	O
calvaria	O
and	O
bone	O
marrow	O
cells	O
,	O
and	O
compared	O
the	O
responses	O
to	O
other	O
members	O
of	O
the	O
interleukin	B
6	I
family	I
of	I
cytokines	I
including	O
mouse	O
leukaemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
,	O
cardiotrophin-1	B
(	O
CT-1	B
)	O
and	O
IL-6	B
.	O

Mouse	O
OSM	B
,	O
LIF	B
and	O
CT-1	B
strongly	O
induced	O
the	O
formation	O
of	O
tartrate	B
resistant	I
acid	I
phosphatase	I
positive	O
(	O
TRAP	B
(	O
+	O
)	O
)	O
multinucleated	O
cells	O
(	O
MNC	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

OSM	B
,	O
LIF	B
or	O
CT-1	B
also	O
elevated	O
the	O
number	O
and	O
size	O
of	O
resorptive	O
pits	O
when	O
cocultures	O
were	O
added	O
to	O
smooth	O
cortical	O
bone	O
slices	O
,	O
indicating	O
enhancement	O
of	O
osteoclast	O
activity	O
.	O

The	O
activity	O
of	O
OSM	B
was	O
reduced	O
by	O
indomethacin	O
(	O
10	O
(	O
-8	O
)	O
-	O
10	O
(	O
-6	O
)	O
M	O
)	O
,	O
whereas	O
addition	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
at	O
10	O
(	O
-7	O
)	O
-10	O
(	O
-5	O
)	O
M	O
synergistically	O
enhanced	O
OSM	B
-	O
induced	O
numbers	O
of	O
TRAP	B
(	O
+	O
)	O
MNC	O
.	O

DEX	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
costimulation	O
also	O
synergistically	O
enhanced	O
TRAP	B
(	O
+	O
)	O
cell	O
numbers	O
of	O
LIF	B
,	O
and	O
CT-1	B
treated	O
cocultures	O
.	O

IL-6	B
had	O
no	O
activity	O
alone	O
,	O
but	O
further	O
enhanced	O
TRAP	B
(	O
+	O
)	O
cell	O
formation	O
in	O
mOSM	B
or	O
DEX	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
treated	O
cocultures	O
.	O

When	O
added	O
to	O
mouse	O
calvarial	O
osteoblast	O
cultures	O
,	O
mOSM	B
induced	O
secretion	O
of	O
IL-6	B
protein	O
and	O
elevation	O
of	O
mRNA	O
whereas	O
LIF	B
or	O
CT-1	B
did	O
not	O
.	O

IL-6	B
mRNA	O
levels	O
and	O
protein	O
secretion	O
were	O
reduced	O
in	O
osteoblasts	O
by	O
costimulation	O
with	O
DEX	O
.	O

These	O
results	O
show	O
that	O
mouse	O
OSM	B
,	O
LIF	B
and	O
CT-1	B
induce	O
osteoclast	O
differentiation	O
and	O
activation	O
,	O
that	O
DEX	O
synergizes	O
with	O
each	O
in	O
this	O
activity	O
,	O
and	O
that	O
mouse	O
OSM	B
induces	O
responses	O
in	O
osteoblasts	O
that	O
are	O
not	O
shown	O
by	O
LIF	B
or	O
CT-1	B
.	O

Collectively	O
these	O
data	O
suggest	O
an	O
important	O
role	O
of	O
these	O
cytokines	B
in	O
osteoporosis	O
caused	O
by	O
high	O
levels	O
of	O
corticosteroid	O
.	O

The	O
effect	O
of	O
interleukin-6	B
(	O
IL-6	B
)	O
/	O
gp130	B
signalling	O
on	O
biliary	O
epithelial	O
cell	O
growth	O
,	O
in	O
vitro	O
.	O

The	O
effect	O
of	O
IL-6	B
on	O
the	O
growth	O
of	O
mouse	O
biliary	O
epithelial	O
cells	O
(	O
BEC	O
)	O
,	O
in	O
vitro	O
,	O
was	O
tested	O
by	O
comparing	O
BEC	O
obtained	O
IL-6	B
-	O
deficient	O
mice	O
(	O
IL-6	B
(	O
-	O
/	O
-	O
)	O
)	O
to	O
wild	O
-	O
type	O
littermate	O
controls	O
(	O
IL-6	B
(	O
+	O
/+	O
)	O
)	O
,	O
in	O
two	O
different	O
media	O
:	O
simple	O
serum	O
-	O
free	O
media	O
(	O
S	O
-	O
SFM	O
)	O
,	O
and	O
complete	O
serum	O
-	O
free	O
media	O
(	O
C	O
-	O
SFM	O
)	O
containing	O
forskolin	O
,	O
which	O
stimulates	O
BEC	O
IL-6	B
production	O
.	O

In	O
S	O
-	O
SFM	O
,	O
neither	O
IL-6	B
(	O
+	O
/+	O
)	O
nor	O
IL-6	B
(	O
-	O
/	O
-	O
)	O
BEC	O
constitutively	O
produced	O
IL-6	B
mRNA	O
or	O
protein	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
IL-6	B
(	O
+	O
/+	O
)	O
and	O
IL-6	B
(	O
-	O
/	O
-	O
)	O
BEC	O
growth	O
.	O

In	O
contrast	O
,	O
when	O
the	O
BEC	O
were	O
maintained	O
in	O
C	O
-	O
SFM	O
,	O
over	O
48	O
h	O
,	O
the	O
growth	O
of	O
IL-6	B
(	O
+	O
/+	O
)	O
BEC	O
was	O
40	O
%	O
greater	O
than	O
IL-6	B
(	O
-	O
/	O
-	O
)	O
BEC	O
(	O
P	O
<	O
0.006	O
)	O
.	O

Enhanced	O
IL-6	B
(	O
+	O
/+	O
)	O
BEC	O
growth	O
in	O
C	O
-	O
SFM	O
was	O
associated	O
with	O
induced	O
expression	O
of	O
IL-6	B
mRNA	O
and	O
IL-6	B
protein	O
secretion	O
into	O
the	O
medium	O
,	O
upregulation	O
of	O
the	O
IL-6Ralpha	B
(	O
gp80	B
)	O
and	O
phosphorylation	O
of	O
the	O
signal	O
transducing	O
molecule	O
gp130	B
.	O

In	O
C	O
-	O
SFM	O
,	O
anti	O
-	O
IL-6	B
neutralizing	O
antibodies	O
blocked	O
enhanced	O
IL-6	B
(	O
+	O
/+	O
)	O
BEC	O
growth	O
,	O
whereas	O
exogenous	O
rhIL-6	B
stimulated	O
retarded	O
growth	O
of	O
IL-6	B
(	O
-	O
/	O
-	O
)	O
BEC	O
.	O

Thus	O
,	O
under	O
conditions	O
that	O
mimic	O
an	O
inflammatory	O
or	O
stressful	O
microenvironment	O
in	O
vivo	O
,	O
BEC	O
produce	O
,	O
secrete	O
and	O
respond	O
to	O
IL-6	B
,	O
via	O
upregulation	O
and	O
activation	O
of	O
the	O
IL-6Ralpha	B
(	O
gp80	B
)	O
/	O
gp130	B
signaling	O
system	O
in	O
an	O
autocrine	O
/	O
paracrine	O
manner	O
.	O

Characterization	O
of	O
the	O
zinc	O
binding	O
activity	O
of	O
the	O
rubella	O
virus	O
nonstructural	B
protease	I
.	O

The	O
rubella	O
virus	O
(	O
RUB	O
)	O
nonstructural	B
(	I
NS	I
)	I
protein	I
(	O
NSP	B
)	O
ORF	O
encodes	O
a	O
protease	B
that	O
cleaves	O
the	O
NSP	B
precursor	O
(	O
240	O
kDa	O
)	O
at	O
a	O
single	O
site	O
to	O
produce	O
two	O
products	O
.	O

A	O
cleavage	O
site	O
mutation	O
was	O
introduced	O
into	O
a	O
RUB	O
infectious	O
cDNA	O
clone	O
and	O
found	O
to	O
be	O
lethal	O
,	O
demonstrating	O
that	O
cleavage	O
of	O
the	O
NSP	B
precursor	O
is	O
necessary	O
for	O
RUB	O
replication	O
.	O

Based	O
on	O
computer	O
alignments	O
,	O
the	O
RUB	O
NS	B
protease	I
was	O
predicted	O
to	O
be	O
a	O
papain	B
-	O
like	O
cysteine	B
protease	I
(	O
PCP	O
)	O
with	O
the	O
residues	O
Cys1152	O
and	O
His1273	O
as	O
the	O
catalytic	O
dyad	O
;	O
however	O
,	O
the	O
RUB	O
NS	B
protease	I
was	O
recently	O
found	O
to	O
require	O
divalent	O
cations	O
such	O
as	O
Zn	O
,	O
Co	O
,	O
and	O
Cd	O
for	O
activity	O
(	O
X.	O
Liu	O
,	O
S.	O
L.	O
Ropp	O
,	O
R.	O
J.	O
Jackson	O
,	O
and	O
T.	O
K.	O
Frey	O
,	O
J.	O
Virol	O
.	O
72	O
:	O
4463	O
-	O
4466	O
,	O
1998	O
)	O
.	O

To	O
analyze	O
the	O
function	O
of	O
metal	O
cation	O
binding	O
in	O
protease	B
activity	O
,	O
Zn	O
binding	O
studies	O
were	O
performed	O
using	O
the	O
minimal	O
NS	B
protease	I
domain	O
within	O
the	O
NSP	B
ORF	O
.	O

When	O
expressed	O
as	O
a	O
maltose	B
binding	I
protein	I
(	O
MBP	B
)	O
fusion	O
protein	O
by	O
bacteria	O
,	O
the	O
NS	B
protease	I
exhibited	O
activity	O
both	O
in	O
the	O
bacteria	O
and	O
in	O
vitro	O
following	O
purification	O
when	O
denatured	O
and	O
refolded	O
in	O
the	O
presence	O
of	O
Zn	O
.	O

Atomic	O
absorption	O
analysis	O
detected	O
1.6	O
mol	O
of	O
Zn	O
bound	O
per	O
mol	O
of	O
protein	O
refolded	O
in	O
this	O
manner	O
.	O

Expression	O
of	O
individual	O
domains	O
within	O
the	O
protease	B
as	O
MBP	B
fusions	O
and	O
analysis	O
by	O
a	O
Zn	O
(	O
65	O
)	O
binding	O
assay	O
revealed	O
two	O
Zn	O
binding	O
domains	O
:	O
one	O
located	O
at	O
a	O
predicted	O
metal	O
binding	O
motif	O
beginning	O
at	O
Cys1175	O
and	O
the	O
other	O
one	O
close	O
to	O
the	O
cleavage	O
site	O
.	O

Mutagenesis	O
studies	O
showed	O
that	O
Cys1175	O
and	O
Cys1178	O
in	O
the	O
first	O
domain	O
and	O
Cys1227	O
and	O
His1273	O
,	O
the	O
His	O
in	O
the	O
predicted	O
catalytic	O
site	O
,	O
in	O
the	O
second	O
domain	O
are	O
essential	O
for	O
zinc	O
binding	O
.	O

All	O
of	O
these	O
residues	O
are	O
also	O
necessary	O
for	O
the	O
protease	B
activity	O
,	O
as	O
were	O
several	O
other	O
Cys	O
residues	O
not	O
involved	O
in	O
Zn	O
binding	O
.	O

Far	O
-	O
UV	O
circular	O
dichroism	O
(	O
CD	O
)	O
analysis	O
of	O
the	O
MBP	B
-	O
NS	B
protease	I
fusion	O
protein	O
showed	O
that	O
the	O
protease	B
domain	O
contained	O
a	O
large	O
amount	O
of	O
alpha	O
-	O
helical	O
structure	O
,	O
which	O
is	O
consistent	O
with	O
the	O
results	O
of	O
secondary	O
-	O
structural	O
prediction	O
.	O

Both	O
far	O
-	O
UV	O
-	O
CD	O
and	O
fluorescence	O
studies	O
suggested	O
that	O
Zn	O
did	O
not	O
exert	O
a	O
major	O
effect	O
on	O
the	O
overall	O
structure	O
of	O
the	O
fusion	O
protein	O
.	O

Finally	O
,	O
protease	B
inhibitor	O
assays	O
found	O
that	O
the	O
protease	B
activity	O
can	O
be	O
blocked	O
by	O
both	O
metal	O
ion	O
chelators	O
and	O
the	O
metalloprotease	B
inhibitor	O
captopril	O
.	O

In	O
conjunction	O
with	O
the	O
finding	O
that	O
the	O
previously	O
predicted	O
catalytic	O
site	O
,	O
His1273	O
,	O
is	O
essential	O
for	O
zinc	O
binding	O
,	O
this	O
suggests	O
that	O
the	O
RUB	O
NS	B
protease	I
is	O
actually	O
a	O
novel	O
virus	O
metalloprotease	B
rather	O
than	O
a	O
PCP	O
.	O

Amino	O
-	O
and	O
carboxy	O
-	O
terminal	O
PEST	O
domains	O
mediate	O
gastrin	B
stabilization	O
of	O
rat	O
L	B
-	I
histidine	I
decarboxylase	I
isoforms	O
.	O

Control	O
of	O
enzymatic	O
function	O
by	O
peptide	O
hormones	O
can	O
occur	O
at	O
a	O
number	O
of	O
different	O
levels	O
and	O
can	O
involve	O
diverse	O
pathways	O
that	O
regulate	O
cleavage	O
,	O
intracellular	O
trafficking	O
,	O
and	O
protein	O
degradation	O
.	O

Gastrin	B
is	O
a	O
peptide	B
hormone	I
that	O
binds	O
to	O
the	O
cholecystokinin	B
B	I
-	I
gastrin	I
receptor	I
and	O
regulates	O
the	O
activity	O
of	O
L	B
-	I
histidine	I
decarboxylase	I
(	O
HDC	B
)	O
,	O
the	O
enzyme	O
that	O
produces	O
histamine	O
.	O

Here	O
we	O
show	O
that	O
gastrin	B
can	O
increase	O
the	O
steady	O
-	O
state	O
levels	O
of	O
at	O
least	O
six	O
HDC	B
isoforms	O
without	O
affecting	O
HDC	B
mRNA	O
levels	O
.	O

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
HDC	B
isoforms	O
are	O
rapidly	O
degraded	O
and	O
that	O
gastrin	B
-	O
dependent	O
increases	O
are	O
due	O
to	O
enhanced	O
isoform	O
stability	O
.	O

Deletion	O
analysis	O
identified	O
two	O
PEST	O
domains	O
(	O
PEST1	O
and	O
PEST2	O
)	O
and	O
an	O
intracellular	O
targeting	O
domain	O
(	O
ER2	O
)	O
which	O
regulate	O
HDC	B
protein	O
expression	O
levels	O
.	O

Experiments	O
with	O
PEST	O
domain	O
fusion	O
proteins	O
demonstrated	O
that	O
PEST1	O
and	O
PEST2	O
are	O
strong	O
and	O
portable	O
degradation	O
-	O
promoting	O
elements	O
which	O
are	O
positively	O
regulated	O
by	O
both	O
gastrin	B
stimulation	O
and	O
proteasome	O
inhibition	O
.	O

A	O
chimeric	O
protein	O
containing	O
the	O
PEST	O
domain	O
of	O
ornithine	B
decarboxylase	I
was	O
similarly	O
affected	O
,	O
indicating	O
that	O
gastrin	B
can	O
regulate	O
the	O
stability	O
of	O
other	O
PEST	O
domain	O
-	O
containing	O
proteins	O
and	O
does	O
so	O
independently	O
of	O
antizyme	B
/	O
antizyme	B
inhibitor	I
regulation	O
.	O

At	O
the	O
same	O
time	O
,	O
endoplasmic	O
reticulum	O
localization	O
of	O
a	O
fluorescent	O
chimera	O
containing	O
the	O
ER2	O
domain	O
of	O
HDC	B
was	O
unaltered	O
by	O
gastrin	B
stimulation	O
.	O

We	O
conclude	O
that	O
gastrin	B
stabilization	O
of	O
HDC	B
isoforms	O
is	O
dependent	O
upon	O
two	O
transferable	O
and	O
sequentially	O
unrelated	O
PEST	O
domains	O
that	O
regulate	O
degradation	O
.	O

These	O
experiments	O
revealed	O
a	O
novel	O
regulatory	O
mechanism	O
by	O
which	O
a	O
peptide	O
hormone	O
such	O
as	O
gastrin	B
can	O
disrupt	O
the	O
degradation	O
function	O
of	O
multiple	O
PEST	O
-	O
domain	O
-	O
containing	O
proteins	O
.	O

Snail	B
is	O
an	O
immediate	O
early	O
target	O
gene	O
of	O
parathyroid	B
hormone	I
related	I
peptide	I
signaling	O
in	O
parietal	O
endoderm	O
formation	O
.	O

In	O
mouse	O
development	O
,	O
parietal	O
endoderm	O
(	O
PE	O
)	O
is	O
formed	O
from	O
both	O
primitive	O
endoderm	O
(	O
PrE	O
)	O
and	O
visceral	O
endoderm	O
(	O
VE	O
)	O
.	O

This	O
process	O
can	O
be	O
mimicked	O
in	O
vitro	O
by	O
using	O
F9	O
embryonal	O
carcinoma	O
cells	O
(	O
EC	O
)	O
cells	O
,	O
differentiated	O
to	O
PrE	O
or	O
VE	O
cells	O
,	O
and	O
treating	O
these	O
with	O
Parathyroid	B
Hormone	I
related	I
Peptide	I
(	O
PTHrP	B
)	O
.	O

By	O
means	O
of	O
differential	O
display	O
RT	O
-	O
PCR	O
,	O
we	O
identified	O
Snail	B
(	O
Sna	B
)	O
as	O
a	O
gene	O
upregulated	O
during	O
the	O
differentiation	O
from	O
F9	O
PrE	O
to	O
PE	O
.	O

We	O
show	O
that	O
Sna	B
is	O
an	O
immediate	O
early	O
target	O
gene	O
of	O
PTHrP	B
action	O
in	O
the	O
formation	O
of	O
F9	O
PE	O
cells	O
.	O

Using	O
RT	O
-	O
PCR	O
,	O
we	O
detected	O
Sna	B
transcripts	O
in	O
pre	O
-	O
implantation	O
mouse	O
embryos	O
from	O
the	O
zygote	O
-	O
stage	O
onwards	O
.	O

Sna	B
was	O
strongly	O
upregulated	O
in	O
parallel	O
with	O
type	B
1	I
PTH	I
/	I
PTHrP	I
Receptor	I
(	O
PTH	B
(	I
rP	I
)	I
-R1	I
)	O
mRNA	O
in	O
mouse	O
blastocysts	O
plated	O
in	O
culture	O
,	O
concomitant	O
with	O
detection	O
of	O
the	O
PE	O
-	O
marker	O
Follistatin	B
and	O
appearance	O
of	O
PE	O
cells	O
.	O

By	O
radioactive	O
in	O
situ	O
hybridization	O
on	O
sections	O
of	O
mouse	O
embryos	O
,	O
we	O
found	O
Sna	B
expression	O
in	O
the	O
earliest	O
PE	O
cells	O
at	O
E5.5	O
.	O

Sna	O
remained	O
expressed	O
until	O
at	O
least	O
E7.5	O
.	O

At	O
this	O
stage	O
,	O
we	O
also	O
observed	O
clear	O
expression	O
in	O
endoderm	O
cells	O
delaminating	O
from	O
the	O
epithelial	O
sheet	O
of	O
VE	O
cells	O
in	O
the	O
marginal	O
zone	O
.	O

We	O
conclude	O
that	O
PTH	B
(	I
rP	I
)	I
-	I
R1	I
and	O
Sna	B
are	O
expressed	O
in	O
endodermal	O
cells	O
that	O
change	O
from	O
an	O
epithelial	O
to	O
a	O
mesenchymal	O
phenotype	O
.	O

Since	O
Sna	B
expression	O
has	O
been	O
described	O
at	O
other	O
sites	O
where	O
epithelio	O
-	O
mesenchymal	O
transitions	O
(	O
EMT	O
)	O
occur	O
,	O
such	O
as	O
the	O
primitive	O
streak	O
at	O
gastrulation	O
and	O
in	O
pre	O
-	O
migratory	O
neural	O
crest	O
cells	O
,	O
we	O
hypothesize	O
that	O
Sna	O
is	O
instrumental	O
in	O
the	O
action	O
of	O
PTHrP	B
inducing	O
PE	O
formation	O
,	O
which	O
we	O
propose	O
to	O
be	O
the	O
first	O
EMT	O
in	O
mouse	O
development	O
.	O

Identification	O
and	O
functional	O
characterization	O
of	O
human	O
soluble	B
epoxide	I
hydrolase	I
genetic	O
polymorphisms	O
.	O

Human	O
soluble	B
epoxide	I
hydrolase	I
(	O
sEH	B
)	O
,	O
an	O
enzyme	O
directing	O
the	O
functional	O
disposition	O
of	O
a	O
variety	O
of	O
endogenous	O
and	O
xenobiotic	O
-	O
derived	O
chemical	O
epoxides	O
,	O
was	O
characterized	O
at	O
the	O
genomic	O
level	O
for	O
interindividual	O
variation	O
capable	O
of	O
impacting	O
function	O
.	O

RNA	O
was	O
isolated	O
from	O
25	O
human	O
liver	O
samples	O
and	O
used	O
to	O
generate	O
full	O
-	O
length	O
copies	O
of	O
soluble	B
epoxide	I
hydrolase	I
cDNA	O
.	O

The	O
resulting	O
cDNAs	O
were	O
polymerase	O
chain	O
reaction	O
amplified	O
,	O
sequenced	O
,	O
and	O
eight	O
variant	O
loci	O
were	O
identified	O
.	O

The	O
coding	O
region	O
contained	O
five	O
silent	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
two	O
variant	O
loci	O
resulting	O
in	O
altered	O
protein	O
sequence	O
.	O

An	O
amino	O
acid	O
substitution	O
was	O
identified	O
at	O
residue	O
287	O
in	O
exon	O
8	O
,	O
where	O
the	O
more	O
common	O
arginine	O
was	O
replaced	O
by	O
glutamine	O
.	O

A	O
second	O
variant	O
locus	O
was	O
identified	O
in	O
exon	O
13	O
where	O
an	O
arginine	O
residue	O
was	O
inserted	O
following	O
serine	O
402	O
resulting	O
in	O
the	O
sequence	O
,	O
arginine	O
403	O
-	O
404	O
,	O
instead	O
of	O
the	O
more	O
common	O
,	O
arginine	O
403	O
.	O

This	O
amino	O
acid	O
insertion	O
was	O
confirmed	O
by	O
analyzing	O
genomic	O
DNA	O
from	O
individuals	O
harboring	O
the	O
polymorphic	O
allele	O
.	O

Slot	O
blot	O
hybridization	O
analyses	O
of	O
the	O
liver	O
samples	O
indicated	O
that	O
sEH	B
mRNA	O
steady	O
-	O
state	O
expression	O
varied	O
approximately	O
10	O
-	O
fold	O
.	O

Transient	O
transfection	O
experiments	O
with	O
CHO	O
and	O
COS-7	O
cells	O
were	O
used	O
to	O
demonstrate	O
that	O
the	O
two	O
new	O
alleles	O
possess	O
catalytic	O
activity	O
using	O
trans	O
-	O
stilbene	O
oxide	O
as	O
a	O
model	O
substrate	O
.	O

Although	O
the	O
activity	O
of	O
the	O
glutamine	O
287	O
variant	O
was	O
similar	O
to	O
the	O
sEH	B
wild	O
type	O
allele	O
,	O
proteins	O
containing	O
the	O
arginine	O
insertion	O
exhibited	O
strikingly	O
lower	O
activity	O
.	O

Allelic	O
forms	O
of	O
human	O
sEH	B
,	O
with	O
markedly	O
different	O
enzymatic	O
profiles	O
,	O
may	O
have	O
important	O
physiological	O
implications	O
with	O
respect	O
to	O
the	O
disposition	O
of	O
epoxides	O
formed	O
from	O
the	O
oxidation	O
of	O
fatty	O
acids	O
,	O
such	O
as	O
arachidonic	O
acid	O
-	O
derived	O
intermediates	O
,	O
as	O
well	O
in	O
the	O
regulation	O
of	O
toxicity	O
due	O
to	O
xenobiotic	O
epoxide	O
exposures	O
.	O

Rrp8p	B
is	O
a	O
yeast	O
nucleolar	O
protein	O
functionally	O
linked	O
to	O
Gar1p	B
and	O
involved	O
in	O
pre	O
-	O
rRNA	O
cleavage	O
at	O
site	O
A2	O
.	O

Chemical	O
modifications	O
and	O
processing	O
of	O
the	O
18S	O
,	O
5.8S	O
,	O
and	O
25S	O
ribosomal	O
RNAs	O
from	O
the	O
35S	O
pre	O
-	O
ribosomal	O
RNA	O
depend	O
on	O
an	O
important	O
set	O
of	O
small	O
nucleolar	O
ribonucleoprotein	O
particles	O
(	O
snoRNPs	O
)	O
.	O

Genetic	O
depletion	O
of	O
yeast	O
Gar1p	B
,	O
an	O
essential	O
common	O
component	O
of	O
H	O
/	O
ACA	O
snoRNPs	O
,	O
leads	O
to	O
inhibition	O
of	O
uridine	O
isomerizations	O
to	O
pseudo	O
-	O
uridines	O
on	O
the	O
35S	O
pre	O
-	O
rRNA	O
and	O
of	O
the	O
early	O
pre	O
-	O
rRNA	O
cleavages	O
at	O
sites	O
A1	O
and	O
A2	O
,	O
resulting	O
in	O
a	O
loss	O
of	O
mature	O
18S	O
rRNA	O
synthesis	O
.	O

To	O
identify	O
Gar1p	B
functional	O
partners	O
,	O
we	O
screened	O
for	O
mutations	O
that	O
are	O
synthetically	O
lethal	O
with	O
a	O
gar1	B
mutant	O
allele	O
encoding	O
a	O
Gar1p	B
mutant	O
protein	O
lacking	O
its	O
two	O
glycine	O
/	O
arginine	O
-	O
rich	O
(	O
GAR	O
)	O
domains	O
.	O

We	O
identified	O
a	O
previously	O
uncharacterized	O
Saccharomyces	O
cerevisiae	O
open	O
reading	O
frame	O
,	O
YDR083W	B
(	O
now	O
designated	O
RRP8	B
)	O
,	O
that	O
encodes	O
a	O
highly	O
conserved	O
protein	O
containing	O
motifs	O
found	O
in	O
methyltransferases	B
.	O

Rrp8p	B
localizes	O
to	O
the	O
nucleolus	O
.	O

A	O
yeast	O
strain	O
lacking	O
this	O
protein	O
is	O
viable	O
at	O
30	O
degrees	O
C	O
but	O
displays	O
strong	O
growth	O
impairment	O
at	O
lower	O
temperatures	O
.	O

In	O
this	O
strain	O
,	O
cleavage	O
of	O
the	O
pre	O
-	O
rRNA	O
at	O
site	O
A2	O
is	O
strongly	O
affected	O
whereas	O
cleavages	O
at	O
sites	O
A0	O
and	O
A1	O
are	O
only	O
slightly	O
inhibited	O
or	O
delayed	O
.	O

Src	B
homology	I
domain	I
2	I
-	I
containing	I
tyrosine	I
phosphatase	I
2	I
associates	O
with	O
intercellular	B
adhesion	I
molecule	I
1	I
to	O
regulate	O
cell	O
survival	O
.	O

Intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
binds	O
to	O
the	O
plasma	O
protein	O
fibrinogen	B
(	O
Fg	B
)	O
to	O
mediate	O
leukocyte	O
/	O
endothelial	O
cell	O
interactions	O
.	O

In	O
our	O
studies	O
,	O
the	O
ligation	O
of	O
Fg	B
to	O
ICAM-1	B
on	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
-	O
stimulated	O
endothelial	O
cells	O
resulted	O
in	O
the	O
tyrosine	O
phosphorylation	O
of	O
Src	B
homology	I
domain	I
2	I
(	I
SH2	I
)	I
-	I
containing	I
phosphatase-2	I
(	O
SHP-2	B
)	O
.	O

The	O
ICAM-1	B
cytoplasmic	O
sequence	O
IKKYRLQ	O
conforms	O
poorly	O
to	O
the	O
concensus	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motifs	O
found	O
in	O
receptors	O
that	O
bind	O
SHP-2	B
.	O

Nevertheless	O
,	O
the	O
tyrosine	O
phosphorylated	O
sequence	O
(	O
IKKpYRLQ	O
)	O
bound	O
specifically	O
to	O
the	O
SH2	O
domain	O
proximal	O
to	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
of	O
SHP-2	B
(	O
SHP-2	B
-	O
N	O
)	O
but	O
not	O
to	O
the	O
SH2	O
domain	O
proximal	O
on	O
the	O
COOH	O
-	O
terminal	O
side	O
(	O
SHP-2	B
-	O
C	O
)	O
.	O

Phosphorylated	O
ICAM-1	B
bound	O
SHP-2	B
-	O
N	O
.	O

In	O
immunoprecipitation	O
experiments	O
,	O
SHP-2	B
associated	O
with	O
phosphorylated	O
ICAM-1	B
.	O

Cells	O
expressing	O
truncated	O
ICAM-1	B
that	O
lacked	O
the	O
cytoplasmic	O
sequence	O
(	O
ICAM-1	B
(	O
TR	O
)	O
)	O
failed	O
to	O
associate	O
with	O
SHP-2	B
.	O

ICAM-1	B
containing	O
the	O
tyrosine	O
to	O
alanine	O
substitution	O
at	O
position	O
485	O
(	O
ICAM-1	B
(	O
Y485A	O
)	O
)	O
associated	O
weakly	O
with	O
SHP-2	B
.	O

Cells	O
expressing	O
ICAM-1	B
(	O
TR	O
)	O
and	O
ICAM-1	B
(	O
Y485A	O
)	O
underwent	O
apoptosis	O
upon	O
adhesion	O
to	O
Fg	B
,	O
whereas	O
the	O
wild	O
type	O
ICAM-1	B
maintained	O
cell	O
survival	O
.	O

These	O
results	O
indicate	O
that	O
ICAM-1	B
interactions	O
with	O
SHP-2	B
allow	O
better	O
cellular	O
survival	O
mediated	O
through	O
Fg	B
-	O
ICAM-1	B
ligation	O
.	O

Interaction	O
of	O
the	O
iron	B
-	I
sulfur	I
cluster	I
assembly	I
protein	I
IscU	B
with	O
the	O
Hsc66	B
/	O
Hsc20	B
molecular	O
chaperone	B
system	O
of	O
Escherichia	O
coli	O
.	O

The	O
iscU	B
gene	O
in	O
bacteria	O
is	O
located	O
in	O
a	O
gene	O
cluster	O
encoding	O
proteins	O
implicated	O
in	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
and	O
an	O
hsc70	B
-	O
type	O
(	O
heat	O
shock	O
cognate	O
)	O
molecular	O
chaperone	B
system	O
,	O
iscSUA	B
-	I
hscBA	I
.	O

To	O
investigate	O
possible	O
interactions	O
between	O
these	O
systems	O
,	O
we	O
have	O
overproduced	O
and	O
purified	O
the	O
IscU	B
protein	O
from	O
Escherichia	O
coli	O
and	O
have	O
studied	O
its	O
interactions	O
with	O
the	O
hscA	B
and	O
hscB	B
gene	O
products	O
Hsc66	B
and	O
Hsc20	B
.	O

IscU	B
and	O
its	O
iron	O
-	O
sulfur	O
complex	O
(	O
IscU	B
-	O
Fe	O
/	O
S	O
)	O
stimulated	O
the	O
basal	O
steady	O
-	O
state	O
ATPase	B
activity	O
of	O
Hsc66	B
weakly	O
in	O
the	O
absence	O
of	O
Hsc20	B
but	O
,	O
in	O
the	O
presence	O
of	O
Hsc20	B
,	O
increased	O
the	O
ATPase	B
activity	O
up	O
to	O
480	O
-	O
fold	O
.	O

Hsc20	B
also	O
decreased	O
the	O
apparent	O
K	O
(	O
m	O
)	O
for	O
IscU	B
stimulation	O
of	O
Hsc66	B
ATPase	B
activity	O
,	O
and	O
surface	O
plasmon	O
resonance	O
studies	O
revealed	O
that	O
Hsc20	B
enhances	O
binding	O
of	O
IscU	B
to	O
Hsc66	B
.	O

Surface	O
plasmon	O
resonance	O
and	O
isothermal	O
titration	O
calorimetry	O
further	O
showed	O
that	O
IscU	B
and	O
Hsc20	B
form	O
a	O
complex	O
,	O
and	O
Hsc20	B
may	O
thereby	O
aid	O
in	O
the	O
targeting	O
of	O
IscU	B
to	O
Hsc66	B
.	O

These	O
results	O
establish	O
a	O
direct	O
and	O
specific	O
role	O
for	O
the	O
Hsc66	B
/	O
Hsc20	B
chaperone	B
system	O
in	O
functioning	O
with	O
isc	B
gene	O
components	O
for	O
the	O
assembly	O
of	O
iron	O
-	O
sulfur	O
cluster	O
proteins	O
.	O

The	O
aquaporin	B
sidedness	O
revisited	O
.	O

Aquaporins	B
are	O
transmembrane	O
water	B
channel	I
proteins	O
,	O
which	O
play	O
important	O
functions	O
in	O
the	O
osmoregulation	O
and	O
water	O
balance	O
of	O
micro	O
-	O
organisms	O
,	O
plants	O
,	O
and	O
animal	O
tissues	O
.	O

All	O
aquaporins	B
studied	O
to	O
date	O
are	O
thought	O
to	O
be	O
tetrameric	O
assemblies	O
of	O
four	O
subunits	O
each	O
containing	O
its	O
own	O
aqueous	O
pore	O
.	O

Moreover	O
,	O
the	O
subunits	O
contain	O
an	O
internal	O
sequence	O
repeat	O
forming	O
two	O
obversely	O
symmetric	O
hemichannels	O
predicted	O
to	O
resemble	O
an	O
hour	O
-	O
glass	O
.	O

This	O
unique	O
arrangement	O
of	O
two	O
highly	O
related	O
protein	O
domains	O
oriented	O
at	O
180	O
degrees	O
to	O
each	O
other	O
poses	O
a	O
significant	O
challenge	O
in	O
the	O
determination	O
of	O
sidedness	O
.	O

Aquaporin	B
Z	I
(	O
AqpZ	B
)	O
from	O
Escherichia	O
coli	O
was	O
reconstituted	O
into	O
highly	O
ordered	O
two	O
-	O
dimensional	O
crystals	O
.	O

They	O
were	O
freeze	O
-	O
dried	O
and	O
metal	O
-	O
shadowed	O
to	O
establish	O
the	O
relationship	O
between	O
surface	O
structure	O
and	O
underlying	O
protein	O
density	O
by	O
electron	O
microscopy	O
.	O

The	O
shadowing	O
of	O
some	O
surfaces	O
was	O
prevented	O
by	O
protruding	O
aggregates	O
.	O

Thus	O
,	O
images	O
collected	O
from	O
freeze	O
-	O
dried	O
crystals	O
that	O
exhibited	O
both	O
metal	O
-	O
coated	O
and	O
uncoated	O
regions	O
allowed	O
surface	O
relief	O
reconstructions	O
and	O
projection	O
maps	O
to	O
be	O
obtained	O
from	O
the	O
same	O
crystal	O
.	O

Cross	O
-	O
correlation	O
peak	O
searches	O
along	O
lattices	O
crossing	O
metal	O
-	O
coated	O
and	O
uncoated	O
regions	O
allowed	O
an	O
unambiguous	O
alignment	O
of	O
the	O
surface	O
reliefs	O
to	O
the	O
underlying	O
density	O
maps	O
.	O

AqpZ	B
topographs	O
previously	O
determined	O
by	O
AFM	O
could	O
then	O
be	O
aligned	O
with	O
projection	O
maps	O
of	O
AqpZ	B
,	O
and	O
finally	O
with	O
human	O
erythrocyte	O
aquaporin-1	B
(	O
AQP1	B
)	O
.	O

Thereby	O
features	O
of	O
the	O
AqpZ	B
topography	O
could	O
be	O
interpreted	O
by	O
direct	O
comparison	O
to	O
the	O
6	O
A	O
three	O
-	O
dimensional	O
structure	O
of	O
AQP1	B
.	O

We	O
conclude	O
that	O
the	O
sidedness	O
we	O
originally	O
proposed	O
for	O
aquaporin	B
density	O
maps	O
was	O
inverted	O
.	O

Isolation	O
of	O
two	O
novel	O
human	O
RhoGEFs	B
,	O
ARHGEF3	B
and	O
ARHGEF4	B
,	O
in	O
3p13	O
-	O
21	O
and	O
2q22	O
.	O

RhoGEFs	B
play	O
an	O
important	O
role	O
in	O
various	O
signaling	O
cascades	O
and	O
are	O
implicated	O
in	O
human	O
conditions	O
like	O
cancer	O
and	O
mental	O
retardation	O
.	O

A	O
database	O
search	O
combined	O
with	O
screening	O
of	O
a	O
human	O
neuronal	O
teratocarcinoma	O
library	O
identified	O
two	O
novel	O
RhoGEFs	B
,	O
ARHGEF3	B
and	O
ARHGEF4	B
(	O
HGMW	O
-	O
approved	O
symbols	O
)	O
.	O

The	O
widely	O
expressed	O
ARHGEF3	B
transcript	O
of	O
3561	O
nucleotides	O
encodes	O
a	O
polypeptide	O
of	O
526	O
amino	O
acids	O
with	O
homology	O
to	O
NET1	B
.	O

The	O
ARHGEF4	B
gene	O
generates	O
two	O
transcripts	O
of	O
3665	O
and	O
4000	O
nucleotides	O
that	O
translate	O
into	O
720	O
amino	O
acid	O
residues	O
.	O

Expression	O
of	O
ARHGEF4	B
is	O
restricted	O
to	O
brain	O
and	O
the	O
encoded	O
protein	O
shows	O
homology	O
to	O
collybistin	B
.	O

FISH	O
analysis	O
of	O
genomic	O
clones	O
mapped	O
ARHGEF3	B
to	O
3p13	O
-	O
21	O
and	O
ARHGEF4	B
to	O
2q22	O
.	O

The	O
HIV-1	O
Env	B
protein	O
signal	O
sequence	O
retards	O
its	O
cleavage	O
and	O
down	O
-	O
regulates	O
the	O
glycoprotein	O
folding	O
.	O

Secretory	O
proteins	O
and	O
most	O
membrane	O
proteins	O
are	O
synthesized	O
with	O
a	O
signal	O
sequence	O
that	O
is	O
usually	O
cleaved	O
from	O
the	O
nascent	O
polypeptide	O
chain	O
,	O
during	O
its	O
transport	O
,	O
into	O
the	O
lumen	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

We	O
have	O
analyzed	O
the	O
kinetics	O
of	O
the	O
cleavage	O
of	O
the	O
HIV-1	O
Env	B
protein	O
signal	O
sequence	O
from	O
gp160	B
and	O
gp120	B
in	O
HeLa	O
,	O
BHK	O
,	O
and	O
Jurkat	O
cells	O
.	O

Furthermore	O
,	O
we	O
have	O
determined	O
the	O
effects	O
of	O
this	O
cleavage	O
on	O
the	O
association	O
of	O
the	O
gp160	B
and	O
gp120	B
glycoproteins	O
with	O
the	O
ER	O
protein	O
calnexin	B
and	O
the	O
effects	O
of	O
the	O
signal	O
sequence	O
cleavage	O
on	O
protein	O
folding	O
.	O

The	O
cleavage	O
of	O
the	O
HIV-1	O
Env	B
protein	O
signal	O
sequence	O
on	O
both	O
gp160	B
and	O
gp120	B
occurred	O
very	O
slowly	O
in	O
all	O
three	O
cell	O
lines	O
with	O
a	O
t	O
(	O
1	O
/	O
2	O
)	O
of	O
45	O
-	O
60	O
min	O
.	O

The	O
core	O
glycosylated	O
and	O
signal	O
-	O
sequence	O
-	O
retained	O
forms	O
of	O
gp160	B
and	O
gp120	B
associated	O
with	O
calnexin	B
while	O
the	O
signal	O
-	O
sequence	O
-	O
cleaved	O
forms	O
of	O
gp160	B
and	O
gp120	B
had	O
disassociated	O
from	O
calnexin	B
and	O
correctly	O
folded	O
as	O
determined	O
by	O
their	O
ability	O
to	O
associate	O
with	O
the	O
CD4	B
cellular	O
receptor	O
.	O

Further	O
analysis	O
of	O
the	O
folding	O
state	O
of	O
gp160	B
and	O
gp120	B
in	O
nonreducing	O
SDS	O
-	O
PAGE	O
revealed	O
that	O
the	O
signal	O
-	O
sequence	O
-	O
retained	O
and	O
calnexin	B
-	O
associated	O
forms	O
of	O
gp160	B
and	O
gp120	B
migrated	O
as	O
broad	O
,	O
diffuse	O
bands	O
,	O
whereas	O
the	O
signal	O
-	O
sequence	O
-	O
cleaved	O
or	O
CD4	B
-	O
associated	O
forms	O
of	O
gp160	B
and	O
gp120	B
migrated	O
as	O
single	O
sharper	O
bands	O
.	O

The	O
cause	O
of	O
this	O
retardation	O
in	O
the	O
rate	O
of	O
folding	O
and	O
intracellular	O
transport	O
of	O
HIV-1	O
glycoproteins	O
was	O
localized	O
to	O
their	O
signal	O
sequences	O
by	O
fusing	O
the	O
vesicular	O
stomatitis	O
virus	O
G	O
protein	O
with	O
the	O
HIV-1	O
Env	B
protein	O
signal	O
sequence	O
and	O
expressing	O
this	O
chimeric	O
protein	O
in	O
mammalian	O
cells	O
.	O

The	O
HIV-1	O
Env	B
protein	O
signal	O
sequence	O
on	O
the	O
VSV	O
-	O
G	O
protein	O
also	O
confers	O
a	O
reduced	O
rate	O
of	O
cleavage	O
and	O
slow	O
intracellular	O
transport	O
and	O
folding	O
of	O
the	O
chimeric	O
G	O
protein	O
.	O

These	O
results	O
provide	O
direct	O
evidence	O
that	O
in	O
vivo	O
the	O
HIV-1	O
glycoprotein	O
signal	O
sequence	O
inhibits	O
the	O
folding	O
of	O
HIV-1	O
Env	B
protein	O
.	O

Our	O
data	O
also	O
suggest	O
a	O
direct	O
correlation	O
between	O
the	O
rate	O
of	O
the	O
signal	O
sequence	O
cleavage	O
and	O
protein	O
folding	O
.	O

Transcription	O
of	O
the	O
insecticidal	O
crystal	B
protein	I
genes	O
of	O
Bacillus	O
thuringiensis	O
.	O

Production	O
of	O
a	O
large	O
amount	O
of	O
insecticidal	O
crystal	B
proteins	I
encoded	O
on	O
large	O
plasmids	O
is	O
largely	O
dependent	O
upon	O
the	O
mother	O
cell	O
,	O
Bacillus	O
thuringiensis	O
(	O
B.	O
thuringiensis	O
,	O
also	O
Bt	O
)	O
,	O
specific	O
transcription	O
systems	O
attributable	O
to	O
sporulation	O
.	O

In	O
the	O
middle	O
stages	O
of	O
sporulation	O
,	O
cry4A	B
is	O
most	O
actively	O
transcribed	O
from	O
the	O
promoter	O
cry4A	B
-	O
P1	O
.	O

The	O
proximal	O
transcriptional	O
start	O
point	O
of	O
cry4A	B
,	O
which	O
is	O
under	O
the	O
control	O
of	O
the	O
promoter	O
P1	O
,	O
is	O
used	O
in	O
Bacillus	O
subtilis	O
(	O
B.	O
subtilis	O
)	O
in	O
the	O
middle	O
stage	O
of	O
sporulation	O
.	O

The	O
nucleotide	O
sequence	O
that	O
determines	O
the	O
cry4A	B
-	O
P1	O
promoter	O
is	O
homologous	O
to	O
the	O
consensus	O
sequence	O
for	O
the	O
promoter	O
of	O
sigma	B
E	I
-	O
specific	O
genes	O
in	O
B.	O
subtilis	O
,	O
and	O
to	O
those	O
promoters	O
of	O
the	O
insecticidal	O
protein	O
genes	O
that	O
are	O
efficiently	O
transcribed	O
in	O
vitro	O
with	O
the	O
RNA	B
polymerase	I
E	I
sigma	I
35	I
isolated	O
from	O
B.	O
thuringiensis	O
.	O

The	O
sigma	B
factor	I
sigma	B
35	I
of	O
B.	O
thuringiensis	O
is	O
highly	O
homologous	O
and	O
functionally	O
equivalent	O
to	O
sigma	B
E	I
of	O
B.	O
subtilis	O
.	O

These	O
results	O
suggest	O
that	O
the	O
cry4A	B
transcription	O
from	O
P1	O
is	O
under	O
the	O
control	O
of	O
sigma	B
E	I
in	O
B.	O
subtilis	O
,	O
and	O
under	O
the	O
control	O
of	O
sigma	B
35	I
in	O
B.	O
thuringiensis	O
.	O

Loss	O
of	O
a	O
member	O
of	O
the	O
aquaporin	B
gene	O
family	O
,	O
aqpA	B
affects	O
spore	O
dormancy	O
in	O
Dictyostelium	O
.	O

We	O
isolated	O
and	O
characterized	O
a	O
gene	O
from	O
Dictyostelium	O
discoideum	O
,	O
which	O
encodes	O
a	O
protein	O
of	O
279	O
amino	O
acids	O
(	O
30.6kDa	O
)	O
containing	O
six	O
transmembrane	O
domains	O
with	O
two	O
highly	O
conserved	O
motifs	O
of	O
asparagine	O
-	O
proline	O
-	O
alanine	O
(	O
NPA	O
)	O
found	O
in	O
the	O
aquaporin	B
family	I
of	O
water	B
-	I
channel	I
proteins	O
,	O
although	O
the	O
second	O
motif	O
of	O
the	O
protein	O
has	O
been	O
modified	O
into	O
NPV	O
(	O
asparagine	O
-	O
proline	O
-	O
valine	O
)	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
gene	O
,	O
which	O
we	O
have	O
named	O
aqpA	B
,	O
is	O
39	O
%	O
identical	O
to	O
D.	O
discoideum	O
WacA	B
,	O
26	O
%	O
identical	O
to	O
human	O
Aqp5	B
,	O
26	O
%	O
identical	O
to	O
Oryza	O
sativa	O
PIP2a	B
,	O
25	O
%	O
identical	O
to	O
yeast	O
Aqy1	B
and	O
24	O
%	O
identical	O
to	O
E.coli	O
AqpZ	B
.	O

Southern	O
analyses	O
indicated	O
that	O
aqpA	B
is	O
present	O
as	O
a	O
single	O
copy	O
in	O
the	O
genome	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
developmentally	O
regulated	O
1	O
kb	O
mRNA	O
transcript	O
first	O
appears	O
at	O
the	O
tight	O
mound	O
stage	O
(	O
12h	O
)	O
,	O
and	O
is	O
abundant	O
in	O
fingers	O
(	O
16h	O
)	O
and	O
late	O
culminants	O
(	O
20h	O
)	O
.	O

In	O
-	O
situ	O
hybridization	O
of	O
slugs	O
revealed	O
that	O
aqpA	B
mRNA	O
accumulated	O
in	O
cells	O
of	O
the	O
prespore	O
region	O
but	O
not	O
in	O
those	O
of	O
the	O
prestalk	O
region	O
.	O

Disruption	O
of	O
aqpA	B
by	O
homologous	O
recombination	O
did	O
not	O
significantly	O
affect	O
growth	O
or	O
developmental	O
morphogenesis	O
.	O

Although	O
mutant	O
spores	O
were	O
viable	O
,	O
when	O
assayed	O
soon	O
after	O
encapsulation	O
,	O
they	O
became	O
permeable	O
to	O
propidium	O
iodide	O
and	O
lost	O
viability	O
after	O
a	O
week	O
on	O
the	O
top	O
of	O
a	O
fruiting	O
body	O
.	O

Thus	O
,	O
AqpA	B
is	O
essential	O
to	O
maintain	O
spore	O
dormancy	O
perhaps	O
through	O
the	O
regulation	O
of	O
water	O
flow	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
a	O
novel	O
c	B
-	I
mpl	I
variant	O
expressed	O
in	O
human	O
CD34	B
cells	O
and	O
platelets	O
.	O

The	O
thrombopoietin	B
receptor	I
,	O
c	B
-	I
mpl	I
,	O
is	O
a	O
crucial	O
element	O
not	O
only	O
in	O
thrombopoietin	B
(	O
TPO	B
)	O
-	O
initiated	O
signaling	O
pathways	O
but	O
also	O
in	O
the	O
regulation	O
of	O
the	O
circulating	O
amount	O
of	O
TPO	B
.	O

We	O
have	O
identified	O
a	O
new	O
c	B
-	I
mpl	I
isoform	O
,	O
called	O
c	B
-	I
mpl	I
-	O
del	O
,	O
that	O
lacks	O
72	O
bp	O
(	O
24	O
amino	O
acids	O
)	O
in	O
the	O
extracellular	O
region	O
of	O
c	B
-	I
mpl	I
and	O
arises	O
as	O
a	O
consequence	O
of	O
alternative	O
RNA	O
splicing	O
between	O
exons	O
8	O
and	O
9	O
.	O

c	B
-	I
mpl	I
-	O
del	O
is	O
expressed	O
along	O
with	O
c	B
-	I
mpl	I
-	O
wt	O
in	O
blood	O
mononuclear	O
cells	O
,	O
CD34	B
(	O
+	O
)	O
cells	O
,	O
megakaryocytes	O
,	O
and	O
platelets	O
prepared	O
from	O
either	O
normal	O
donors	O
or	O
ET	O
patients	O
,	O
although	O
its	O
relative	O
expression	O
appears	O
to	O
increase	O
with	O
megakaryocyte	O
differentiation	O
.	O

The	O
c	B
-	I
mpl	I
-	O
del	O
-	O
transfected	O
cells	O
expressed	O
greater	O
amounts	O
of	O
c	B
-	I
mpl	I
-	O
del	O
RNA	O
and	O
protein	O
than	O
the	O
comparable	O
c	B
-	I
mpl	I
-	O
wt	O
-	O
transfected	O
cells	O
,	O
however	O
flow	O
cytometry	O
analysis	O
could	O
not	O
detect	O
any	O
c	B
-	I
mpl	I
receptor	O
on	O
the	O
surface	O
of	O
the	O
c	B
-	I
mpl	I
-	O
del	O
-	O
transfected	O
cells	O
.	O

Further	O
evidence	O
for	O
the	O
absence	O
of	O
surface	O
c	B
-	I
mpl	I
-	O
del	O
was	O
that	O
in	O
contrast	O
to	O
cells	O
transfected	O
with	O
c	B
-	I
mpl	I
-	O
wt	O
,	O
those	O
transfected	O
with	O
c	B
-	I
mpl	I
-	O
del	O
did	O
not	O
grow	O
in	O
response	O
to	O
TPO	B
,	O
failed	O
to	O
undergo	O
tyrosine	O
phosphorylation	O
of	O
TPO	B
-	O
specific	O
signal	O
molecules	O
,	O
and	O
did	O
not	O
bind	O
(	O
125	O
)	O
I	O
-	O
rHuTPO	B
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
c	B
-	I
mpl	I
-	O
del	O
,	O
a	O
naturally	O
occurring	O
variant	O
of	O
c	B
-	I
mpl	I
,	O
fails	O
to	O
be	O
incorporated	O
into	O
the	O
cell	O
membrane	O
but	O
might	O
serve	O
as	O
a	O
mechanism	O
to	O
decrease	O
the	O
overall	O
expression	O
of	O
functional	O
c	B
-	I
mpl	I
late	O
in	O
megakaryocyte	O
differentiation	O
.	O

Elevated	O
plasma	O
TGF	B
-	I
beta1	I
in	O
renal	O
diseases	O
:	O
cause	O
or	O
consequence	O
?	O

We	O
previously	O
reported	O
elevated	O
levels	O
of	O
TGF	B
-	I
beta1	I
in	O
patients	O
with	O
renal	O
carcinoma	O
.	O

Certain	O
aspects	O
led	O
us	O
to	O
ask	O
whether	O
they	O
might	O
be	O
caused	O
by	O
chronic	O
damage	O
to	O
the	O
kidney	O
(	O
s	O
)	O
.	O

Here	O
we	O
report	O
on	O
an	O
extended	O
set	O
of	O
patients	O
with	O
various	O
renal	O
diseases	O
,	O
lung	O
cancer	O
,	O
humoral	O
immunodeficiency	O
and	O
controls	O
.	O

For	O
latent	O
TGF	B
-	I
beta1	I
in	O
plasma	O
,	O
we	O
find	O
that	O
the	O
control	O
,	O
immunodeficiency	O
,	O
lung	O
cancer	O
and	O
kidney	O
transplant	O
groups	O
do	O
not	O
differ	O
significantly	O
(	O
means	O
,	O
7.0	O
-	O
8.8	O
ng	O
/	O
ml	O
)	O
.	O

Also	O
,	O
acute	O
short	O
-	O
term	O
renal	O
stress	O
(	O
extracorporal	O
lithotrypsy	O
)	O
does	O
not	O
lead	O
to	O
an	O
increase	O
of	O
TGF	B
-	I
beta1	I
.	O

However	O
,	O
the	O
pyelonephritis	O
patients	O
present	O
with	O
levels	O
of	O
19.0	O
ng	O
/	O
ml	O
,	O
chronic	O
extracorporal	O
dialysis	O
patients	O
with	O
15.5	O
ng	O
/	O
ml	O
,	O
and	O
renal	O
cell	O
carcinoma	O
patients	O
with	O
22.8	O
ng	O
/	O
ml	O
.	O

For	O
active	O
TGF	B
-	I
beta1	I
these	O
findings	O
are	O
exactly	O
recovered	O
.	O

For	O
serum	O
levels	O
,	O
only	O
the	O
renal	O
carcinoma	O
group	O
presents	O
with	O
significantly	O
elevated	O
levels	O
of	O
TGF	B
-	I
beta1	I
.	O

Kidney	O
transplantation	O
seems	O
to	O
normalize	O
TGF	B
-	I
beta1	I
levels	O
,	O
while	O
in	O
the	O
kidney	O
cancer	O
patients	O
surgery	O
has	O
an	O
effect	O
only	O
in	O
part	O
of	O
the	O
group	O
.	O

We	O
conclude	O
that	O
elevated	O
plasma	O
TGF	B
-	I
beta1	I
levels	O
are	O
common	O
in	O
at	O
least	O
two	O
chronic	O
renal	O
disease	O
conditions	O
,	O
and	O
that	O
it	O
normalizes	O
with	O
restoration	O
of	O
renal	O
function	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
chronic	O
elevation	O
of	O
TGF	B
-	I
beta1	I
in	O
these	O
patients	O
may	O
be	O
critically	O
involved	O
in	O
these	O
conditions	O
predisposing	O
to	O
renal	O
cancer	O
.	O

Identification	O
and	O
functional	O
characterization	O
of	O
a	O
novel	O
subtype	O
of	O
neuromedin	B
U	I
receptor	I
.	O

Neuromedin	B
U	I
is	O
a	O
bioactive	O
peptide	O
isolated	O
originally	O
from	O
the	O
porcine	O
spinal	O
cord	O
.	O

We	O
recently	O
identified	O
neuromedin	B
U	I
as	O
the	O
cognate	O
ligand	O
for	O
the	O
orphan	O
G	B
protein	I
-	I
coupled	I
receptor	I
FM-3	B
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
cDNA	O
coding	O
for	O
a	O
novel	O
G	B
protein	I
-	I
coupled	I
receptor	I
,	O
TGR-1	B
,	O
which	O
was	O
highly	O
homologous	O
with	O
FM	B
-	I
3	I
.	O

We	O
found	O
that	O
neuromedin	B
U	I
specifically	O
and	O
clearly	O
elevated	O
the	O
extracellular	O
acidification	O
rates	O
,	O
arachidonic	O
acid	O
metabolite	O
release	O
,	O
and	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
mobilization	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
expressing	O
TGR-1	B
.	O

Radiolabeled	O
neuromedin	B
U	I
specifically	O
bound	O
with	O
high	O
affinity	O
to	O
membrane	O
fractions	O
prepared	O
from	O
these	O
cells	O
.	O

These	O
results	O
show	O
that	O
TGR-1	B
,	O
like	O
FM-3	B
,	O
is	O
a	O
specific	O
and	O
functional	O
receptor	B
for	I
neuromedin	I
U	I
.	O

We	O
analyzed	O
TGR-1	B
mRNA	O
tissue	O
distribution	O
in	O
rats	O
using	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
found	O
it	O
to	O
considerably	O
differ	O
from	O
that	O
of	O
FM-3	B
mRNA	O
.	O

TGR-1	B
mRNA	O
was	O
primarily	O
expressed	O
in	O
the	O
uterus	O
,	O
suggesting	O
that	O
TGR-1	B
mediates	O
the	O
contractile	O
activity	O
of	O
neuromedin	B
U	I
in	O
this	O
tissue	O
.	O

The	O
identification	O
of	O
specific	O
and	O
functional	O
receptor	O
subtypes	O
for	O
neuromedin	B
U	I
will	O
facilitate	O
the	O
study	O
of	O
their	O
physiological	O
roles	O
and	O
the	O
search	O
for	O
their	O
specific	O
agonists	O
and	O
antagonists	O
.	O

Rescue	O
of	O
human	O
T	O
cells	O
by	O
interleukin-9	B
(	O
IL-9	B
)	O
from	O
IL-2	B
deprivation	O
-	O
induced	O
apoptosis	O
:	O
correlation	O
with	O
alpha	O
subunit	O
expression	O
of	O
the	O
IL-9	B
receptor	I
.	O

Interleukin-9	B
(	O
IL-9	B
)	O
is	O
a	O
Th2	O
-	O
derived	O
cytokine	B
that	O
uses	O
the	O
gamma	B
-	I
chain	I
of	I
the	I
IL-2	I
receptor	I
for	O
signaling	O
.	O

Therefore	O
,	O
the	O
responsiveness	O
of	O
human	O
Th1	O
and	O
Th2	O
cell	O
clones	O
to	O
IL-9	B
was	O
measured	O
by	O
examining	O
the	O
ability	O
of	O
this	O
cytokine	B
to	O
prevent	O
apoptosis	O
induced	O
by	O
IL-2	B
deprivation	O
.	O

A	O
time	O
course	O
study	O
demonstrated	O
that	O
both	O
subsets	O
of	O
T	O
cell	O
clones	O
underwent	O
apoptosis	O
with	O
similar	O
kinetics	O
when	O
deprived	O
of	O
IL-2	B
and	O
that	O
viability	O
could	O
be	O
maintained	O
by	O
the	O
addition	O
of	O
either	O
IL-4	B
or	O
IL-7	B
.	O

Interestingly	O
,	O
IL-9	B
prevented	O
apoptosis	O
in	O
only	O
2	O
(	O
Th2	O
)	O
of	O
14	O
clones	O
tested	O
.	O

Analysis	O
of	O
IL-9R	B
alpha	I
subunit	O
expression	O
on	O
18	O
T	O
cell	O
clones	O
revealed	O
that	O
IL-9	B
responsiveness	O
was	O
directly	O
proportional	O
to	O
the	O
expression	O
of	O
the	O
high	O
-	O
affinity	O
receptor	O
.	O

IL-9	B
responsiveness	O
was	O
also	O
dependent	O
on	O
long	O
-	O
term	O
culturing	O
because	O
neither	O
freshly	O
isolated	O
nor	O
3	O
-	O
day	O
phytohemagglutinin	B
(	O
PHA	B
)	O
-	O
stimulated	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
expressed	O
IL-9R	B
alpha	I
.	O

In	O
summary	O
,	O
the	O
data	O
showed	O
that	O
IL-9	B
can	O
rescue	O
only	O
a	O
small	O
subset	O
of	O
Th2	O
cells	O
from	O
apoptosis	O
induced	O
by	O
growth	B
factor	I
withdrawal	O
and	O
that	O
expression	O
of	O
IL-9R	B
alpha	I
is	O
required	O
for	O
the	O
antiapoptotic	O
signals	O
mediated	O
by	O
this	O
cytokine	B
.	O

20	O
kDa	O
human	O
growth	B
hormone	I
(	O
20	O
K	O
hGH	B
)	O
stimulates	O
insulin	B
-	I
like	I
growth	I
factor	I
-	I
I	I
(	O
IGF	B
-	I
I	I
)	O
gene	O
expression	O
at	O
lower	O
concentrations	O
than	O
22	O
K	O
hGH	B
in	O
hGH	B
receptor	I
-	O
expressing	O
Ba	O
/	O
F3	O
cells	O
.	O

Growth	B
hormone	I
(	O
GH	B
)	O
secreted	O
from	O
the	O
pituitary	O
is	O
essential	O
for	O
postnatal	O
growth	O
in	O
animals	O
.	O

GH	B
exerts	O
its	O
actions	O
by	O
a	O
direct	O
effect	O
on	O
target	O
organs	O
and	O
by	O
stimulating	O
insulin	B
-	I
like	I
growth	I
factor	I
I	I
(	O
IGF	B
-	I
I	I
)	O
production	O
.	O

In	O
the	O
human	O
pituitary	O
,	O
there	O
is	O
a	O
naturally	O
occurring	O
variant	O
protein	O
which	O
has	O
a	O
molecular	O
mass	O
of	O
20	O
kDa	O
(	O
20	O
K	O
hGH	B
)	O
besides	O
the	O
major	O
22	O
kDa	O
hGH	B
(	O
22	O
K	O
hGH	B
)	O
,	O
but	O
the	O
physiological	O
actions	O
of	O
20	O
K	O
hGH	B
are	O
still	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
we	O
have	O
examined	O
its	O
effects	O
on	O
the	O
IGF	B
-	I
I	I
mRNA	O
expression	O
in	O
the	O
pro	O
B	O
-	O
cell	O
line	O
Ba	O
/	O
F3	O
cells	O
stably	O
expressing	O
hGH	B
receptor	I
(	O
Ba	O
/	O
F3	O
-	O
hGHR	B
)	O
.	O

Ba	O
/	O
F3	O
-	O
hGHR	B
cells	O
were	O
incubated	O
for	O
2	O
h	O
with	O
a	O
series	O
of	O
various	O
concentrations	O
(	O
10	O
pM	O
to	O
approximately	O
10	O
nM	O
)	O
of	O
20	O
K	O
or	O
22	O
K	O
hGH	B
.	O

The	O
IGF	B
-	I
I	I
mRNA	O
expression	O
in	O
the	O
Ba	O
/	O
F3	O
-	O
hGHR	B
cells	O
was	O
detected	O
by	O
the	O
RT	O
-	O
PCR	O
method	O
.	O

IGF	B
-	I
I	I
gene	O
expression	O
was	O
increased	O
by	O
20	O
K	O
and	O
22	O
K	O
hGH	B
stimulation	O
,	O
but	O
not	O
by	O
PRL	B
or	O
IL-3	B
in	O
the	O
Ba	O
/	O
F3	O
-	O
hGHR	B
.	O

And	O
this	O
effect	O
was	O
not	O
observed	O
in	O
parental	O
Ba	O
/	O
F3	O
cells	O
.	O

Lower	O
concentrations	O
of	O
20	O
K	O
hGH	B
more	O
strongly	O
induced	O
IGF	B
-	I
I	I
gene	O
expression	O
than	O
22	O
K	O
-	O
hGH	B
.	O

These	O
results	O
suggest	O
that	O
20	O
K	O
and	O
22	O
K	O
hGH	B
stimulate	O
the	O
IGF	B
-	I
I	I
gene	O
expression	O
in	O
the	O
Ba	O
/	O
F3	O
-	O
hGHR	B
through	O
hGH	B
receptors	I
,	O
and	O
that	O
the	O
stronger	O
effect	O
of	O
20	O
K	O
hGH	B
than	O
that	O
of	O
22	O
K	O
hGH	B
in	O
enhancing	O
the	O
IGF	B
-	I
I	I
gene	O
expression	O
may	O
be	O
correlated	O
with	O
a	O
20	O
K	O
hGH	B
specific	O
receptor	O
dimerization	O
mechanism	O
.	O

Pemphigus	O
vulgaris	O
antibody	O
identifies	O
pemphaxin	B
.	O

A	O
novel	O
keratinocyte	O
annexin	B
-	O
like	O
molecule	O
binding	O
acetylcholine	O
.	O

Because	O
pemphigus	O
vulgaris	O
(	O
PV	O
)	O
IgGs	B
adsorbed	O
on	O
the	O
rDsg3	B
-	O
Ig	B
-	O
His	O
baculoprotein	O
induced	O
blisters	O
in	O
neonatal	O
mice	O
,	O
it	O
was	O
proposed	O
that	O
anti	O
-	O
desmoglein	B
3	I
(	O
Dsg	B
3	I
)	O
autoantibody	O
causes	O
PV	O
.	O

However	O
,	O
we	O
found	O
that	O
rDsg3	B
-	O
Ig	B
-	O
His	O
absorbs	O
autoantibodies	O
to	O
different	O
antigens	O
,	O
including	O
a	O
non	O
-	O
Dsg	B
3	I
keratinocyte	O
protein	O
of	O
130	O
kDa	O
.	O

This	O
prompted	O
our	O
search	O
for	O
novel	O
targets	O
of	O
PV	O
autoimmunity	O
.	O

The	O
PV	O
IgG	B
eluted	O
from	O
a	O
75	O
-	O
kDa	O
keratinocyte	O
protein	O
band	O
both	O
stained	O
epidermis	O
in	O
a	O
pemphigus	O
-	O
like	O
pattern	O
and	O
induced	O
acantholysis	O
in	O
keratinocyte	O
monolayers	O
.	O

Screening	O
of	O
a	O
keratinocyte	O
lambdagt11	O
cDNA	O
library	O
with	O
this	O
antibody	O
identified	O
clones	O
carrying	O
cDNA	O
inserts	O
encoding	O
a	O
novel	O
molecule	O
exhibiting	O
approximately	O
40	O
%	O
similarity	O
with	O
annexin-2	B
,	O
named	O
pemphaxin	B
(	O
PX	B
)	O
.	O

Recombinant	O
PX	B
(	O
rPX	B
-	O
His	O
)	O
was	O
produced	O
in	O
Escherichia	O
coli	O
M15	O
cells	O
,	O
and	O
,	O
because	O
annexins	B
can	O
act	O
as	O
cholinergic	B
receptors	I
,	O
its	O
conformation	O
was	O
tested	O
in	O
a	O
cholinergic	O
radioligand	O
binding	O
assay	O
.	O

rPX	B
-	O
His	O
specifically	O
bound	O
[	O
(	O
3	O
)	O
H	O
]	O
acetylcholine	O
,	O
suggesting	O
that	O
PX	B
is	O
one	O
of	O
the	O
keratinocyte	O
cholinergic	B
receptors	I
known	O
to	O
be	O
targeted	O
by	O
disease	O
-	O
causing	O
PV	O
antibodies	O
.	O

Preabsorption	O
of	O
PV	O
sera	O
with	O
rPX	B
-	O
His	O
eliminated	O
acantholytic	O
activity	O
,	O
and	O
eluted	O
antibody	O
immunoprecipitated	O
native	O
PX	B
.	O

This	O
antibody	O
alone	O
did	O
not	O
cause	O
skin	O
blisters	O
in	O
vivo	O
,	O
but	O
its	O
addition	O
to	O
the	O
preabsorbed	O
PV	O
IgG	B
fraction	O
restored	O
acantholytic	O
activity	O
,	O
indicating	O
that	O
acantholysis	O
in	O
PV	O
results	O
from	O
synergistic	O
action	O
of	O
antibodies	O
to	O
different	O
keratinocyte	O
self	O
-	O
antigens	O
,	O
including	O
both	O
acetylcholine	B
receptors	I
and	O
desmosomal	O
cadherins	B
.	O

Identification	O
and	O
characterization	O
of	O
two	O
neuromedin	B
U	I
receptors	I
differentially	O
expressed	O
in	O
peripheral	O
tissues	O
and	O
the	O
central	O
nervous	O
system	O
.	O

Two	O
structurally	O
related	O
,	O
G	B
-	I
protein	I
-	I
coupled	I
receptors	I
were	O
identified	O
as	O
receptors	O
for	O
the	O
neuropeptide	B
,	O
neuromedin	B
U	I
.	O

This	O
peptide	O
is	O
found	O
in	O
highest	O
levels	O
in	O
the	O
gut	O
and	O
genitourinary	O
system	O
where	O
it	O
potently	O
contracts	O
smooth	O
muscle	O
but	O
is	O
also	O
expressed	O
in	O
the	O
spinal	O
cord	O
and	O
discrete	O
regions	O
of	O
the	O
brain	O
.	O

Binding	O
sites	O
for	O
neuromedin	B
U	I
have	O
been	O
characterized	O
in	O
rat	O
uterus	O
,	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
activity	O
of	O
this	O
peptide	O
in	O
the	O
regions	O
of	O
the	O
central	O
nervous	O
system	O
where	O
it	O
is	O
expressed	O
.	O

The	O
receptors	O
characterized	O
in	O
this	O
report	O
are	O
activated	O
by	O
neuromedin	B
U	I
at	O
nanomolar	O
potency	O
in	O
heterologous	O
expression	O
systems	O
and	O
bind	O
radiolabeled	O
neuromedin	B
U	I
with	O
high	O
affinity	O
.	O

Localization	O
of	O
the	O
receptor	O
RNA	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
shows	O
distinct	O
expression	O
patterns	O
for	O
the	O
two	O
receptors	O
.	O

NMU1	B
is	O
expressed	O
predominantly	O
in	O
peripheral	O
tissues	O
,	O
whereas	O
NMU2	B
is	O
more	O
highly	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Identification	O
of	O
neuromedin	B
U	I
receptor	I
subtypes	O
will	O
greatly	O
aid	O
in	O
the	O
determination	O
of	O
the	O
physiological	O
roles	O
of	O
this	O
peptide	O
.	O

Thioesterases	O
and	O
the	O
premature	O
termination	O
of	O
polyketide	O
chain	O
elongation	O
in	O
rifamycin	O
B	O
biosynthesis	O
by	O
Amycolatopsis	O
mediterranei	O
S699	O
.	O

The	O
role	O
of	O
two	O
thioesterase	B
genes	O
in	O
the	O
premature	O
release	O
of	O
polyketide	B
synthase	I
intermediates	O
during	O
rifamycin	O
biosynthesis	O
in	O
the	O
Amycolatopsis	O
mediterranei	O
S699	O
strain	O
was	O
investigated	O
.	O

Creation	O
of	O
an	O
in	O
-	O
frame	O
deletion	O
in	O
the	O
rifR	B
gene	O
led	O
to	O
a	O
30	O
approximately	O
60	O
%	O
decrease	O
in	O
the	O
production	O
of	O
both	O
rifamycin	O
B	O
by	O
the	O
S699	O
strain	O
or	O
a	O
series	O
of	O
tetra	O
-	O
to	O
decaketide	O
shunt	O
products	O
of	O
polyketide	O
chain	O
assembly	O
by	O
the	O
rifF	B
strain	O
.	O

Since	O
a	O
similar	O
percentage	O
decrease	O
was	O
seen	O
in	O
both	O
genetic	O
backgrounds	O
,	O
we	O
conclude	O
that	O
the	O
RifR	B
thioesterase	B
2	O
is	O
not	O
involved	O
in	O
premature	O
release	O
of	O
the	O
carbon	O
chain	O
assembly	O
intermediates	O
.	O

Similarly	O
,	O
fusion	O
of	O
the	O
Saccharopolyspora	O
erythraea	O
DEBS3	B
thioesterase	B
I	O
domain	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
RifE	B
PKS	O
subunit	O
did	O
not	O
result	O
in	O
a	O
noticeable	O
increase	O
in	O
the	O
amount	O
of	O
the	O
undecaketide	O
intermediate	O
formed	O
nor	O
in	O
the	O
amounts	O
of	O
the	O
tetra	O
-	O
to	O
decaketide	O
shunt	O
products	O
.	O

Hence	O
,	O
premature	O
release	O
of	O
the	O
carbon	O
chain	O
assembly	O
intermediates	O
is	O
an	O
unusual	O
property	O
of	O
the	O
Rif	B
PKS	O
itself	O
.	O

Glucose	B
transporter	I
mutants	O
of	O
Escherichia	O
coli	O
K-12	O
with	O
changes	O
in	O
substrate	O
recognition	O
of	O
IICB	B
(	I
Glc	I
)	I
and	O
induction	O
behavior	O
of	O
the	O
ptsG	B
gene	O
.	O

In	O
Escherichia	O
coli	O
K-12	O
,	O
the	O
major	O
glucose	B
transporter	I
with	O
a	O
central	O
role	O
in	O
carbon	O
catabolite	O
repression	O
and	O
in	O
inducer	O
exclusion	O
is	O
the	O
phosphoenolpyruvate	B
-	I
dependent	I
glucose	I
:	I
phosphotransferase	I
system	I
(	O
PTS	B
)	O
.	O

Its	O
membrane	O
-	O
bound	O
subunit	O
,	O
IICB	B
(	I
Glc	I
)	I
,	O
is	O
encoded	O
by	O
the	O
gene	O
ptsG	B
;	O
its	O
soluble	O
domain	O
,	O
IIA	B
(	I
Glc	I
)	I
,	O
is	O
encoded	O
by	O
crr	B
,	O
which	O
is	O
a	O
member	O
of	O
the	O
pts	B
operon	I
.	O

The	O
system	O
is	O
inducible	O
by	O
D	O
-	O
glucose	O
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
by	O
L	O
-	O
sorbose	O
.	O

The	O
regulation	O
of	O
ptsG	B
transcription	O
was	O
analyzed	O
by	O
testing	O
the	O
induction	O
of	O
IICB	B
(	I
Glc	I
)	I
transporter	O
activity	O
and	O
of	O
a	O
single	O
-	O
copy	O
Phi	O
(	O
ptsGop	B
-	O
lacZ	B
)	O
fusion	O
.	O

Among	O
mutations	O
found	O
to	O
affect	O
directly	O
ptsG	B
expression	O
were	O
those	O
altering	O
the	O
activity	O
of	O
adenylate	B
cyclase	I
(	O
cyaA	B
)	O
,	O
the	O
repressor	O
DgsA	B
(	O
dgsA	B
;	O
also	O
called	O
Mlc	B
)	O
,	O
the	O
general	O
PTS	B
proteins	I
enzyme	I
I	I
(	O
ptsI	B
)	O
and	O
histidine	O
carrier	O
protein	O
HPr	B
(	O
ptsH	B
)	O
,	O
and	O
the	O
IIA	B
(	I
Glc	I
)	I
and	O
IIB	B
(	I
Glc	I
)	I
domains	O
,	O
as	O
well	O
as	O
several	O
authentic	O
and	O
newly	O
isolated	O
UmgC	B
mutations	O
.	O

The	O
latter	O
,	O
originally	O
thought	O
to	O
map	O
in	O
the	O
repressor	O
gene	O
umgC	B
outside	O
the	O
ptsG	B
locus	O
,	O
were	O
found	O
to	O
represent	O
ptsG	B
alleles	O
.	O

These	O
affected	O
invariably	O
the	O
substrate	O
specificity	O
of	O
the	O
IICB	B
(	I
Glc	I
)	I
domain	O
,	O
thus	O
allowing	O
efficient	O
transport	O
and	O
phosphorylation	O
of	O
substrates	O
normally	O
transported	O
very	O
poorly	O
or	O
not	O
at	O
all	O
by	O
this	O
PTS	B
.	O

Simultaneously	O
,	O
all	O
of	O
these	O
substrates	O
became	O
inducers	O
for	O
ptsG	B
.	O

From	O
the	O
analysis	O
of	O
the	O
mutants	O
,	O
from	O
cis	O
-	O
trans	O
dominance	O
tests	O
,	O
and	O
from	O
the	O
identification	O
of	O
the	O
amino	O
acid	O
residues	O
mutated	O
in	O
the	O
UmgC	B
mutants	O
,	O
a	O
new	O
regulatory	O
mechanism	O
involved	O
in	O
ptsG	B
induction	O
is	O
postulated	O
.	O

According	O
to	O
this	O
model	O
,	O
the	O
phosphorylation	O
state	O
of	O
IIB	B
(	I
Glc	I
)	I
modulates	O
IIC	B
(	I
Glc	I
)	I
which	O
,	O
directly	O
or	O
indirectly	O
,	O
controls	O
the	O
repressor	O
DgsA	B
and	O
hence	O
ptsG	B
expression	O
.	O

By	O
the	O
same	O
mechanism	O
,	O
glucose	O
uptake	O
and	O
phosphorylation	O
also	O
control	O
the	O
expression	O
of	O
the	O
pts	B
operon	I
and	O
probably	O
of	O
all	O
operons	O
controlled	O
by	O
the	O
repressor	O
DgsA	B
.	O

H	B
-	I
NS	I
-	O
Dependent	O
regulation	O
of	O
flagellar	O
synthesis	O
is	O
mediated	O
by	O
a	O
LysR	B
family	I
protein	O
.	O

H	B
-	I
NS	I
regulates	O
the	O
flagellar	O
master	O
operon	O
(	O
flhDC	B
)	O
and	O
thus	O
is	O
necessary	O
for	O
flagellation	O
of	O
Escherichia	O
coli	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
its	O
regulation	O
has	O
remained	O
unknown	O
.	O

Genetic	O
screening	O
of	O
a	O
transposon	O
insertion	O
abolishing	O
the	O
H	B
-	I
NS	I
effect	O
revealed	O
a	O
previously	O
unidentified	O
gene	O
,	O
named	O
hdfR	B
,	O
encoding	O
a	O
LysR	B
family	I
protein	O
.	O

Binding	O
of	O
purified	O
HdfR	B
to	O
the	O
flhDC	B
promoter	O
was	O
demonstrated	O
by	O
a	O
DNA	O
mobility	O
shift	O
assay	O
,	O
indicating	O
that	O
HdfR	B
is	O
a	O
transcriptional	O
regulator	O
for	O
the	O
flagellar	O
master	O
operon	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
the	O
hdfR	B
gene	O
was	O
shown	O
to	O
be	O
negatively	O
regulated	O
by	O
H	B
-	I
NS	I
.	O

Role	O
of	O
A	B
and	I
B	I
blood	I
group	I
antigens	I
in	O
the	O
expression	O
of	O
adhesive	O
activity	O
of	O
von	B
Willebrand	I
factor	I
.	O

ABO	B
(	O
H	O
)	O
blood	O
group	O
antigens	O
are	O
covalently	O
linked	O
to	O
the	O
oligosaccharide	O
side	O
-	O
chains	O
of	O
von	B
Willebrand	I
factor	I
(	O
VWF	B
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
A	O
and	O
B	O
antigens	O
in	O
the	O
expression	O
of	O
VWF	B
adhesive	O
activity	O
.	O

VWF	B
of	O
type	O
A	O
,	O
B	O
or	O
O	O
was	O
purified	O
from	O
fresh	O
frozen	O
plasma	O
.	O

Presence	O
of	O
A	O
or	O
B	O
antigen	O
on	O
the	O
VWF	B
was	O
confirmed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
by	O
immunoblotting	O
with	O
monoclonal	O
anti	O
-	O
A	O
or	O
anti	O
-	O
B	O
.	O

The	O
A	O
or	O
B	O
antigen	O
was	O
also	O
detected	O
in	O
the	O
48	O
/	O
52	O
-	O
kDa	O
fragment	O
of	O
the	O
respective	O
VWF	B
after	O
trypsin	B
digestion	O
.	O

Removal	O
of	O
A	O
antigen	O
with	O
alpha	B
-	I
N	I
-	I
acetylgalactosaminidase	I
or	O
B	O
antigen	O
with	O
alpha	B
-	I
galactosidase	I
did	O
not	O
affect	O
its	O
multimer	O
size	O
or	O
antigenic	O
level	O
,	O
but	O
decreased	O
the	O
ristocetin	O
cofactor	O
(	O
RCoF	O
)	O
activity	O
of	O
the	O
respective	O
VWF	B
by	O
33	O
-	O
39	O
%	O
(	O
P	O
<	O
0.01	O
-	O
0.002	O
)	O
.	O

Removal	O
of	O
A	O
or	O
B	O
antigen	O
from	O
VWF	B
did	O
not	O
affect	O
the	O
binding	O
of	O
the	O
VWF	B
to	O
immobilized	O
type	B
III	I
collagen	I
.	O

A	O
and	O
B	O
antigens	O
were	O
not	O
detected	O
in	O
platelet	O
VWF	B
.	O

These	O
results	O
indicate	O
that	O
AB	O
structures	O
play	O
a	O
role	O
in	O
platelet	O
aggregating	O
activity	O
of	O
VWF	B
.	O

Interleukin	B
secretion	O
,	O
proteoglycan	O
and	O
procollagen	B
alpha	I
(	I
1	I
)	I
(	I
I	I
)	I
gene	O
expression	O
in	O
Crouzon	O
fibroblasts	O
treated	O
with	O
basic	B
fibroblast	I
growth	I
factor	I
.	O

The	O
present	O
study	O
provides	O
the	O
first	O
evidence	O
that	O
fibroblasts	O
obtained	O
from	O
patients	O
affected	O
by	O
Crouzon	O
syndrome	O
,	O
a	O
rare	O
craniosynostosis	O
,	O
despite	O
mutations	O
in	O
the	O
high	O
-	O
affinity	O
bFGF	B
receptor	I
retain	O
their	O
capacity	O
to	O
respond	O
to	O
bFGF	B
.	O

The	O
growth	B
factor	I
reduces	O
IL-1	B
secretion	O
,	O
downregulates	O
biglycan	O
and	O
procollagen	B
alpha	I
(	I
1	I
)	I
(	I
I	I
)	I
,	O
and	O
increases	O
betaglycan	B
expression	O
.	O

Since	O
betaglycan	B
is	O
a	O
co	O
-	O
receptor	O
for	O
bFGF	B
signalling	O
,	O
an	O
alternative	O
signal	O
transduction	O
pathway	O
is	O
suggested	O
in	O
Crouzon	O
fibroblasts	O
,	O
to	O
explain	O
the	O
documented	O
changes	O
in	O
ECM	O
macromolecule	O
production	O
.	O

Analysis	O
of	O
bruchid	O
resistance	O
in	O
the	O
wild	O
common	O
bean	O
accession	O
G02771	O
:	O
no	O
evidence	O
for	O
insecticidal	O
activity	O
of	O
arcelin	B
5	I
.	O

Arcelins	B
are	O
abundant	O
seed	O
storage	O
proteins	O
thought	O
to	O
be	O
implicated	O
in	O
the	O
resistance	O
of	O
wild	O
Phaseolus	O
vulgaris	O
(	O
L.	O
)	O
genotypes	O
against	O
Zabrotes	O
subfasciatus	O
(	O
Boheman	O
)	O
,	O
an	O
important	O
storage	O
insect	O
pest	O
of	O
common	O
bean	O
.	O

Here	O
,	O
the	O
insecticidal	O
activity	O
of	O
the	O
arcelin-5	B
variant	O
that	O
is	O
present	O
in	O
the	O
highly	O
resistant	O
P.	O
vulgaris	O
accession	O
G02771	O
was	O
investigated	O
.	O

No	O
correlation	O
could	O
be	O
established	O
between	O
the	O
presence	O
of	O
arcelin	B
5	I
and	O
the	O
insecticidal	O
effects	O
observed	O
in	O
G02771	O
seeds	O
.	O

Insect	O
feeding	O
assays	O
with	O
artificial	O
seeds	O
into	O
which	O
purified	O
arcelin-5	B
protein	O
was	O
incorporated	O
and	O
with	O
transgenic	O
P.	O
acutifolius	O
(	O
A.	O
Gray	O
)	O
seeds	O
in	O
which	O
the	O
arcelin	B
-	I
5	I
genes	O
were	O
expressed	O
,	O
showed	O
that	O
the	O
presence	O
of	O
arcelin	B
-	I
5	I
proteins	O
,	O
even	O
at	O
elevated	O
levels	O
,	O
was	O
not	O
sufficient	O
to	O
achieve	O
adequate	O
resistance	O
against	O
Z.	O
subfasciatus	O
.	O

The	O
same	O
might	O
apply	O
to	O
other	O
arcelin	B
variants	O
.	O

Nevertheless	O
,	O
as	O
resistance	O
is	O
clearly	O
closely	O
linked	O
to	O
the	O
presence	O
of	O
the	O
arcelin-1	B
or	O
arcelin-5	B
locus	O
,	O
arcelins	B
remain	O
useful	O
markers	O
in	O
breeding	O
programmes	O
aimed	O
at	O
introgressing	O
high	O
levels	O
of	O
resistance	O
to	O
Z.	O
subfasciatus	O
in	O
P.	O
vulgaris	O
cultivars	O
.	O

ApoE	B
polymorphism	O
and	O
fish	O
oil	O
supplementation	O
in	O
subjects	O
with	O
an	O
atherogenic	O
lipoprotein	O
phenotype	O
.	O

The	O
study	O
assessed	O
the	O
efficacy	O
of	O
fish	O
oil	O
supplementation	O
in	O
counteracting	O
the	O
classic	O
dyslipidemia	O
of	O
the	O
atherogenic	O
lipoprotein	O
phenotype	O
(	O
ALP	O
)	O
.	O

In	O
addition	O
,	O
the	O
impact	O
of	O
the	O
common	O
apolipoprotein	B
E	I
(	O
apoE	B
)	O
polymorphism	O
on	O
the	O
fasting	O
and	O
postprandial	O
lipid	O
profile	O
and	O
on	O
responsiveness	O
to	O
the	O
dietary	O
intervention	O
was	O
established	O
.	O

Fifty	O
-	O
five	O
ALP	O
males	O
(	O
aged	O
34	O
to	O
69	O
years	O
,	O
body	O
mass	O
index	O
22	O
to	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
,	O
triglyceride	O
[	O
TG	O
]	O
levels	O
1.5	O
to	O
4.0	O
mmol	O
/	O
L	O
,	O
high	B
density	I
lipoprotein	I
cholesterol	O
[	O
HDL	B
-	O
C	O
]	O
<	O
1.1	O
mmol	O
/	O
l	O
,	O
and	O
percent	O
low	B
density	I
lipoprotein	I
[	I
LDL	I
]	I
-3	I
>	O
40	O
%	O
total	O
LDL	B
)	O
completed	O
a	O
randomized	O
placebo	O
-	O
controlled	O
crossover	O
trial	O
of	O
fish	O
oil	O
(	O
3.0	O
g	O
eicosapentaenoic	O
acid	O
/	O
docosahexaenoic	O
acid	O
per	O
day	O
)	O
and	O
placebo	O
(	O
olive	O
oil	O
)	O
capsules	O
with	O
the	O
6	O
-	O
week	O
treatment	O
arms	O
separated	O
by	O
a	O
12	O
-	O
week	O
washout	O
period	O
.	O

In	O
addition	O
to	O
fasting	O
blood	O
samples	O
,	O
at	O
the	O
end	O
of	O
each	O
intervention	O
arm	O
,	O
a	O
postprandial	O
assessment	O
of	O
lipid	O
metabolism	O
was	O
carried	O
out	O
.	O

Fish	O
oil	O
supplementation	O
resulted	O
in	O
a	O
reduction	O
in	O
fasting	O
TG	O
level	O
of	O
35	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
in	O
postprandial	O
TG	O
response	O
of	O
26	O
%	O
(	O
TG	O
area	O
under	O
the	O
curve	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
in	O
percent	O
LDL-3	B
of	O
26	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
no	O
change	O
in	O
HDL	B
-	O
C	O
levels	O
was	O
evident	O
(	O
P	O
=	O
0.752	O
)	O
.	O

ANCOVA	O
showed	O
that	O
baseline	O
HDL	B
-	O
C	O
levels	O
were	O
significantly	O
lower	O
in	O
apoE4	B
carriers	O
(	O
P	O
=	O
0.035	O
)	O
.	O

The	O
apoE	B
genotype	O
also	O
had	O
a	O
striking	O
impact	O
on	O
lipid	O
responses	O
to	O
fish	O
oil	O
intervention	O
.	O

Individuals	O
with	O
an	O
apoE2	B
allele	O
displayed	O
a	O
marked	O
reduction	O
in	O
postprandial	O
incremental	O
TG	O
response	O
(	O
TG	O
incremental	O
area	O
under	O
the	O
curve	O
,	O
P	O
=	O
0.023	O
)	O
and	O
a	O
trend	O
toward	O
an	O
increase	O
in	O
lipoprotein	B
lipase	I
activity	O
relative	O
to	O
non	O
-	O
E2	O
carriers	O
.	O

In	O
apoE4	B
individuals	O
,	O
a	O
significant	O
increase	O
in	O
total	O
cholesterol	O
and	O
a	O
trend	O
toward	O
a	O
reduction	O
in	O
HDL	B
-	O
C	O
relative	O
to	O
the	O
common	O
homozygous	O
E3	O
/	O
E3	O
profile	O
was	O
evident	O
.	O

Our	O
data	O
demonstrate	O
the	O
efficacy	O
of	O
fish	O
oil	O
fatty	O
acids	O
in	O
counteracting	O
the	O
proatherogenic	O
lipid	O
profile	O
of	O
the	O
ALP	O
but	O
also	O
that	O
the	O
apoE	B
genotype	O
influences	O
responsiveness	O
to	O
this	O
dietary	O
treatment	O
.	O

Decreased	O
NADH	B
glutamate	I
synthase	I
activity	O
in	O
nodules	O
and	O
flowers	O
of	O
alfalfa	O
(	O
Medicago	O
sativa	O
L.	O
)	O
transformed	O
with	O
an	O
antisense	O
glutamate	B
synthase	I
transgene	O
.	O

Legumes	O
obtain	O
a	O
substantial	O
portion	O
of	O
their	O
nitrogen	O
(	O
N	O
)	O
from	O
symbiotic	O
N2	O
fixation	O
in	O
root	O
nodules	O
.	O

The	O
glutamine	B
synthetase	I
(	O
GS	B
,	O
EC	B
6.3.1.2	I
)	O
/	O
glutamate	B
synthase	I
(	O
GOGAT	B
)	O
cycle	O
is	O
responsible	O
for	O
the	O
initial	O
N	O
assimilation	O
.	O

This	O
report	O
describes	O
the	O
analysis	O
of	O
a	O
transgenic	O
alfalfa	O
(	O
Medicago	O
sativa	O
L.	O
)	O
line	O
containing	O
an	O
antisense	O
NADH	B
-	I
GOGAT	I
(	O
EC	B
1.4.1.14	I
)	O
under	O
the	O
control	O
of	O
the	O
nodule	O
-	O
enhanced	O
aspartate	B
amino	I
-	I
transferase	I
(	I
AAT-2	I
)	I
promoter	O
.	O

In	O
one	O
transgenic	O
line	O
,	O
NADH	B
-	I
GOGAT	I
enzyme	O
activity	O
was	O
reduced	O
to	O
approximately	O
50	O
%	O
,	O
with	O
a	O
corresponding	O
reduction	O
in	O
protein	O
and	O
mRNA	O
.	O

The	O
transcript	O
abundance	O
for	O
cytosolic	O
GS	B
,	O
ferredoxin	B
-	I
dependent	I
GOGAT	I
(	O
EC	B
1.4.7.1	I
)	O
,	O
AAT-2	B
(	O
EC	B
2.6.1.1	I
)	O
,	O
asparagine	B
synthase	I
(	O
EC	B
6.3.5.4	I
)	O
,	O
and	O
phosphoenolpyruvate	B
carboxylase	I
(	O
PEPC	B
,	O
EC	B
4.1.1.31	I
)	O
were	O
unaffected	O
,	O
as	O
were	O
enzyme	O
activities	O
for	O
AAT	B
,	O
PEPC	B
and	O
GS	B
.	O

Antisense	O
NADH	B
-	I
GOGAT	I
plants	O
grown	O
under	O
symbiotic	O
conditions	O
were	O
moderately	O
chlorotic	O
and	O
reduced	O
in	O
growth	O
and	O
N	O
content	O
,	O
even	O
though	O
symbiotic	O
N2	O
fixation	O
was	O
not	O
significantly	O
reduced	O
.	O

The	O
addition	O
of	O
nitrate	O
relieved	O
the	O
chlorosis	O
and	O
restored	O
growth	O
and	O
N	O
content	O
.	O

Surprisingly	O
,	O
the	O
antisense	O
NADH	B
-	I
GOGAT	I
plants	O
were	O
male	O
sterile	O
resulting	O
from	O
inviable	O
pollen	O
.	O

A	O
reduction	O
in	O
NADH	B
-	I
GOGAT	I
enzyme	O
activity	O
and	O
transcript	O
abundance	O
in	O
the	O
antisense	O
plants	O
was	O
measured	O
during	O
the	O
early	O
stages	O
of	O
flower	O
development	O
.	O

Inheritance	O
of	O
the	O
transgene	O
was	O
stable	O
and	O
resulted	O
in	O
progeny	O
with	O
a	O
range	O
of	O
NADH	B
-	I
GOGAT	I
activity	O
.	O

These	O
data	O
indicate	O
that	O
NADH	B
-	I
GOGAT	I
plays	O
a	O
critical	O
role	O
in	O
the	O
assimilation	O
of	O
symbiotically	O
fixed	O
N	O
and	O
during	O
pollen	O
development	O
.	O

HIV-1	O
TAR	O
RNA	O
enhances	O
the	O
interaction	O
between	O
Tat	B
and	O
cyclin	B
T1	I
.	O

Human	O
immunodeficiency	O
virus	O
,	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
,	O
Tat	B
activates	O
elongation	O
of	O
RNA	B
polymerase	I
II	I
transcription	O
at	O
the	O
HIV-1	O
promoter	O
through	O
interaction	O
with	O
the	O
cyclin	B
T1	I
(	O
CycT1	B
)	O
subunit	O
of	O
the	O
positive	B
transcription	I
elongation	I
factor	I
complex	I
,	O
P	B
-	I
TEFb	I
.	O

Binding	O
of	O
Tat	B
to	O
CycT1	B
induces	O
cooperative	O
binding	O
of	O
the	O
P	B
-	I
TEFb	I
complex	O
onto	O
nascent	O
HIV-1	O
TAR	O
RNA	O
.	O

Here	O
the	O
specific	O
interaction	O
between	O
Tat	B
protein	O
,	O
human	O
cyclin	B
T1	I
,	O
and	O
HIV-1	O
TAR	O
RNA	O
was	O
analyzed	O
by	O
fluorescence	O
resonance	O
energy	O
transfer	O
,	O
using	O
fluorescein	O
-	O
labeled	O
TAR	O
RNA	O
and	O
a	O
rhodamine	O
-	O
labeled	O
Tat	B
protein	O
synthesized	O
through	O
solid	O
-	O
phase	O
chemistry	O
.	O

We	O
find	O
that	O
CycT1	B
remodels	O
the	O
structure	O
of	O
Tat	B
to	O
enhance	O
its	O
affinity	O
for	O
TAR	O
RNA	O
and	O
that	O
TAR	O
RNA	O
further	O
enhances	O
the	O
interaction	O
between	O
Tat	B
and	O
CycT1	B
.	O

We	O
conclude	O
that	O
TAR	O
RNA	O
nucleates	O
the	O
formation	O
of	O
the	O
Tat	B
.	O
P	B
-	I
TEFb	I
complex	O
through	O
an	O
induced	O
fit	O
mechanism	O
.	O

Fibroblast	B
growth	I
factor	I
-	I
10	I
:	O
a	O
stromal	O
mediator	O
of	O
epithelial	O
function	O
in	O
the	O
ovine	O
uterus	O
.	O

Fibroblast	B
growth	I
factor-10	I
(	O
FGF-10	B
)	O
is	O
a	O
stromal	O
-	O
derived	O
paracrine	O
growth	B
factor	I
considered	O
to	O
be	O
important	O
during	O
embryogenesis	O
;	O
however	O
,	O
its	O
expression	O
by	O
cells	O
in	O
the	O
female	O
reproductive	O
tract	O
has	O
not	O
been	O
investigated	O
.	O

Therefore	O
,	O
an	O
ovine	O
FGF-10	B
cDNA	O
was	O
cloned	O
from	O
an	O
ovine	O
endometrial	O
cDNA	O
library	O
to	O
investigate	O
expression	O
and	O
potential	O
paracrine	O
characteristics	O
of	O
FGF-10	B
in	O
the	O
ovine	O
uterus	O
.	O

The	O
ovine	O
FGF-10	B
cDNA	O
encodes	O
a	O
protein	O
of	O
213	O
amino	O
acids	O
and	O
possesses	O
an	O
unusually	O
long	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
.	O

In	O
situ	O
hybridization	O
demonstrated	O
that	O
ovine	O
FGF-10	B
mRNA	O
was	O
expressed	O
by	O
endometrial	O
stromal	O
cells	O
and	O
by	O
mesenchymal	O
cells	O
of	O
the	O
chorioallantoic	O
placenta	O
.	O

The	O
mRNA	O
for	O
FGF-7	B
,	O
a	O
homologue	O
of	O
FGF-10	B
,	O
was	O
localized	O
in	O
the	O
tunica	O
muscularis	O
of	O
blood	O
vessels	O
in	O
endometrium	O
and	O
myometrium	O
.	O

In	O
contrast	O
,	O
FGF	B
receptor	I
2IIIb	I
,	O
the	O
high	O
-	O
affinity	O
receptor	O
for	O
both	O
FGF-10	B
and	O
FGF-7	B
,	O
was	O
expressed	O
exclusively	O
in	O
luminal	O
epithelium	O
,	O
glandular	O
epithelium	O
,	O
and	O
placental	O
trophectoderm	O
.	O

The	O
in	O
vivo	O
spatial	O
expression	O
pattern	O
suggests	O
that	O
FGF-10	B
is	O
a	O
novel	O
endometrial	O
stromal	O
cell	O
-	O
derived	O
mediator	O
of	O
uterine	O
epithelial	O
and	O
conceptus	O
trophectodermal	O
functions	O
.	O

The	O
nonoverlapping	O
spatial	O
patterns	O
of	O
expression	O
for	O
FGF-10	B
and	O
FGF-7	B
in	O
ovine	O
uterus	O
and	O
conceptus	O
suggest	O
independent	O
roles	O
in	O
uterine	O
function	O
and	O
conceptus	O
development	O
.	O

The	O
impact	O
of	O
the	O
ovulatory	O
cycle	O
on	O
cytokine	B
production	O
:	O
evaluation	O
of	O
systemic	O
,	O
cervicovaginal	O
,	O
and	O
salivary	O
compartments	O
.	O

To	O
understand	O
the	O
impact	O
of	O
the	O
menstrual	O
cycle	O
on	O
immunologic	O
parameters	O
,	O
we	O
measured	O
the	O
level	O
of	O
cytokines	B
and	O
chemokines	B
from	O
plasma	O
,	O
cervicovaginal	O
lavage	O
(	O
CVL	O
)	O
,	O
and	O
saliva	O
samples	O
of	O
6	O
premenopausal	O
women	O
during	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
ovulatory	O
cycle	O
.	O

We	O
demonstrate	O
that	O
the	O
level	O
of	O
plasma	O
interleukin-8	B
(	O
IL-8	B
)	O
was	O
4	O
-	O
fold	O
higher	O
during	O
the	O
follicular	O
phase	O
than	O
the	O
luteal	O
phase	O
(	O
p	O
=	O
0.004	O
)	O
,	O
whereas	O
plasma	O
IL-1beta	B
,	O
IL-4	B
,	O
IL-6	B
,	O
IL-10	B
,	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
,	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	O
TGF	B
-	I
beta	I
)	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
macrophage	B
inflammatory	I
protein-1alpha	I
(	O
MIP-1alpha	B
)	O
,	O
and	O
TNF	B
receptor	I
II	I
(	O
TNFR	B
II	I
)	O
were	O
not	O
altered	O
during	O
the	O
ovulatory	O
cycle	O
.	O

In	O
the	O
vaginal	O
compartment	O
,	O
as	O
measured	O
from	O
CVL	O
samples	O
,	O
the	O
levels	O
of	O
IL-6	B
and	O
IL-1beta	B
were	O
both	O
5	O
-	O
fold	O
higher	O
in	O
the	O
follicular	O
than	O
the	O
luteal	O
phase	O
(	O
p	O
=	O
0.0002	O
and	O
0.03	O
,	O
respectively	O
)	O
.	O

Salivary	O
cytokine	B
and	O
chemokine	B
samples	O
were	O
similar	O
when	O
measured	O
during	O
the	O
luteal	O
and	O
the	O
follicular	O
phases	O
.	O

Additional	O
analysis	O
of	O
lymphocyte	O
subsets	O
for	O
phenotypic	O
and	O
functional	O
markers	O
indicated	O
that	O
they	O
were	O
not	O
influenced	O
by	O
the	O
ovulatory	O
cycle	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
IL-6	B
,	O
IL-8	B
,	O
and	O
IL-1beta	B
are	O
differentially	O
regulated	O
during	O
the	O
ovulatory	O
cycle	O
.	O

Structure	O
-	O
function	O
relationships	O
in	O
an	O
anion	O
-	O
translocating	O
ATPase	B
.	O

The	O
ArsAB	B
ATPase	I
is	O
an	O
efflux	O
pump	O
located	O
in	O
the	O
inner	O
membrane	O
of	O
Escherichia	O
coli	O
.	O

This	O
transport	B
ATPase	I
confers	O
resistance	O
to	O
arsenite	O
and	O
antimonite	O
by	O
their	O
extrusion	O
from	O
the	O
cells	O
.	O

The	O
pump	O
is	O
composed	O
of	O
two	O
subunits	O
,	O
the	O
catalytic	O
ArsA	B
subunit	O
and	O
the	O
membrane	O
subunit	O
ArsB	B
.	O

The	O
complex	O
is	O
similar	O
in	O
many	O
ways	O
to	O
ATP	B
-	I
binding	I
cassette	I
(	I
'	I
ABC	I
'	I
)	I
transporters	I
,	O
which	O
typically	O
have	O
two	O
groups	O
of	O
six	O
transmembrane	O
-	O
spanning	O
helical	O
segments	O
and	O
two	O
nucleotide	O
-	O
binding	O
domains	O
(	O
NBDs	O
)	O
.	O

The	O
45	O
kDa	O
ArsB	B
protein	O
has	O
12	O
transmembrane	O
-	O
spanning	O
segments	O
.	O

ArsB	B
contains	O
the	O
substrate	O
translocation	O
pathway	O
and	O
is	O
capable	O
of	O
functioning	O
as	O
an	O
anion	B
uniporter	I
.	O

The	O
63	O
kDa	O
ArsA	B
protein	O
is	O
a	O
substrate	O
-	O
activated	O
ATPase	B
.	O

It	O
has	O
two	O
homologous	O
halves	O
,	O
A1	O
and	O
A2	O
,	O
which	O
are	O
clearly	O
the	O
result	O
of	O
an	O
ancestral	O
gene	O
duplication	O
and	O
fusion	O
.	O

Each	O
half	O
has	O
a	O
consensus	O
NBD	O
.	O

The	O
mechanism	O
of	O
allosteric	O
activation	O
of	O
the	O
ArsA	B
ATPase	I
has	O
been	O
elucidated	O
by	O
a	O
combination	O
of	O
molecular	O
genetics	O
and	O
biochemical	O
,	O
structural	O
and	O
kinetic	O
analyses	O
.	O

Conformational	O
changes	O
produced	O
by	O
binding	O
of	O
substrates	O
,	O
activator	O
and/or	O
products	O
could	O
be	O
revealed	O
by	O
stopped	O
-	O
flow	O
fluorescence	O
measurements	O
with	O
single	O
-	O
tryptophan	O
derivatives	O
of	O
ArsA	B
.	O

The	O
results	O
demonstrate	O
that	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
overall	O
reaction	O
is	O
a	O
slow	O
isomerization	O
between	O
two	O
conformations	O
of	O
the	O
enzyme	O
.	O

Allosteric	O
activation	O
increases	O
the	O
rate	O
of	O
this	O
isomerization	O
such	O
that	O
product	O
release	O
becomes	O
rate	O
-	O
limiting	O
,	O
thus	O
accelerating	O
catalysis	O
.	O

ABC	B
transporters	I
,	O
which	O
exhibit	O
similar	O
substrate	O
activation	O
of	O
ATPase	B
activity	O
,	O
can	O
undergo	O
similar	O
conformational	O
changes	O
to	O
overcome	O
a	O
rate	O
-	O
limiting	O
step	O
.	O

Thus	O
the	O
ArsAB	B
pump	O
is	O
a	O
useful	O
model	O
for	O
elucidating	O
mechanistic	O
aspects	O
of	O
the	O
ABC	B
superfamily	I
of	I
transport	I
ATPases	I
.	O

Mechanisms	O
of	O
HIV-1	O
to	O
escape	O
from	O
the	O
host	O
immune	O
surveillance	O
.	O

Since	O
the	O
beginning	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
pandemic	O
in	O
1981	O
,	O
research	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
focused	O
on	O
mechanisms	O
by	O
which	O
the	O
virus	O
escapes	O
from	O
immune	O
surveillance	O
.	O

Several	O
human	B
leucocyte	I
antigen	I
haplotypes	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
rapid	O
disease	O
progression	O
or	O
resistance	O
to	O
disease	O
progression	O
.	O

In	O
addition	O
,	O
HIV	O
is	O
able	O
to	O
down	O
-	O
regulate	O
major	B
histocompatibility	I
complex	I
type	I
I	I
(	O
MHC	B
-	I
I	I
)	O
on	O
the	O
surface	O
of	O
the	O
host	O
cell	O
.	O

For	O
this	O
down	O
-	O
regulation	O
HIV	O
seems	O
to	O
use	O
three	O
different	O
mechanisms	O
mediated	O
by	O
three	O
different	O
viral	O
proteins	O
.	O

The	O
viral	O
Tat	B
protein	O
represses	O
transcription	O
of	O
the	O
MHC	B
-	I
I	I
,	O
Vpu	B
retains	O
nascent	O
MHC	B
-	I
I	I
chains	O
in	O
the	O
endoplasmic	O
reticulum	O
and	O
Nef	B
mediates	O
selective	O
internalization	O
of	O
MHC	B
-	I
I	I
molecules	O
from	O
the	O
plasma	O
membrane	O
.	O

The	O
last	O
mechanism	O
also	O
provides	O
protection	O
to	O
natural	O
killer	O
cells	O
that	O
attack	O
cells	O
with	O
little	O
or	O
no	O
MHC	B
-	I
I	I
on	O
the	O
cell	O
surface	O
.	O

Together	O
these	O
mechanisms	O
provide	O
a	O
very	O
efficient	O
escape	O
from	O
the	O
host	O
immune	O
system	O
.	O

Effects	O
of	O
age	O
on	O
gene	O
expression	O
during	O
estrogen	O
-	O
induced	O
synaptic	O
sprouting	O
in	O
the	O
female	O
rat	O
.	O

Age	O
and	O
estrogen	O
treatment	O
influenced	O
fiber	O
outgrowth	O
and	O
compensatory	O
neuronal	O
sprouting	O
after	O
unilateral	O
entorhinal	O
cortex	O
lesions	O
(	O
ECL	O
)	O
which	O
model	O
Alzheimer	O
disease	O
-	O
like	O
deafferentation	O
in	O
the	O
dentate	O
gyrus	O
of	O
the	O
hippocampus	O
.	O

In	O
young	O
F344	O
rats	O
(	O
3	O
months	O
old	O
)	O
,	O
ovariectomy	O
(	O
OVX	O
)	O
decreased	O
reactive	O
fiber	O
outgrowth	O
by	O
60	O
%	O
.	O

Sprouting	O
in	O
middle	O
-	O
aged	O
rats	O
(	O
18	O
months	O
old	O
)	O
was	O
reduced	O
in	O
intact	O
females	O
;	O
no	O
further	O
reduction	O
was	O
caused	O
by	O
OVX	O
.	O

Several	O
astrocyte	O
mRNAs	O
were	O
measured	O
in	O
the	O
dentate	O
gyrus	O
of	O
young	O
and	O
middle	O
-	O
aged	O
female	O
rats	O
in	O
three	O
different	O
estrogen	O
states	O
(	O
sham	O
OVX	O
,	O
OVX	O
,	O
or	O
OVX	O
+	O
estradiol	O
)	O
1	O
week	O
after	O
ECL	O
.	O

Glial	B
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
)	O
mRNA	O
was	O
twofold	O
greater	O
in	O
middle	O
-	O
aged	O
rats	O
than	O
young	O
,	O
although	O
both	O
ages	O
showed	O
threefold	O
increases	O
in	O
response	O
to	O
ECL	O
.	O

In	O
prior	O
studies	O
GFAP	B
was	O
found	O
to	O
be	O
decreased	O
by	O
estradiol	O
treatment	O
3	O
-	O
4	O
days	O
after	O
ECL	O
;	O
in	O
this	O
study	O
GFAP	B
mRNA	O
had	O
returned	O
to	O
sham	O
OVX	O
levels	O
in	O
young	O
rats	O
by	O
7	O
days	O
post	O
-	O
ECL	O
.	O

Surprisingly	O
,	O
estradiol	O
treatment	O
increased	O
GFAP	B
mRNA	O
levels	O
by	O
25	O
%	O
above	O
OVX	O
in	O
middle	O
-	O
aged	O
rats	O
.	O

Apolipoprotein	B
E	I
(	O
apoE	B
)	O
mRNA	O
was	O
decreased	O
20	O
%	O
by	O
age	O
in	O
the	O
dentate	O
,	O
although	O
both	O
age	O
groups	O
showed	O
a	O
25	O
%	O
increase	O
in	O
apoE	B
mRNA	O
in	O
response	O
to	O
ECL	O
.	O

Apolipoprotein	B
J	I
(	O
apoJ	B
)	O
mRNA	O
was	O
increased	O
20	O
%	O
in	O
the	O
dentate	O
gyrus	O
of	O
middle	O
-	O
aged	O
rats	O
,	O
and	O
both	O
age	O
groups	O
responded	O
to	O
ECL	O
with	O
a	O
65	O
%	O
increase	O
in	O
apoJ	B
mRNA	O
.	O

The	O
estrogen	O
state	O
did	O
not	O
alter	O
levels	O
of	O
either	O
apolipoprotein	B
mRNA	O
in	O
the	O
deafferented	O
dentate	O
.	O

The	O
data	O
suggest	O
that	O
the	O
estrogen	O
-	O
induced	O
decrease	O
of	O
GFAP	B
in	O
response	O
to	O
lesions	O
does	O
not	O
persist	O
at	O
7	O
days	O
post	O
-	O
ECL	O
during	O
sprouting	O
.	O

Overall	O
effects	O
of	O
age	O
on	O
the	O
dentate	O
gyrus	O
include	O
elevated	O
GFAP	B
mRNA	O
and	O
decreased	O
apoE	B
mRNA	O
.	O

The	O
cortical	O
wound	O
site	O
showed	O
consistent	O
enhancement	O
of	O
GFAP	B
mRNA	O
in	O
both	O
age	O
groups	O
by	O
estradiol	O
above	O
sham	O
OVX	O
and	O
greater	O
responses	O
in	O
middle	O
-	O
aged	O
rats	O
.	O

Clinical	O
,	O
endocrine	O
,	O
and	O
molecular	O
genetic	O
findings	O
in	O
patients	O
with	O
17beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
deficiency	O
.	O

Mutations	O
in	O
the	O
17beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	I
17beta	I
-	I
HSD	I
)	I
type	I
3	I
gene	O
are	O
associated	O
with	O
the	O
clinical	O
findings	O
of	O
17beta	B
-	I
HSD	I
deficiency	O
.	O

We	O
investigated	O
5	O
patients	O
of	O
German	O
descent	O
with	O
46,XY	O
karyotype	O
and	O
predominantly	O
female	O
phenotype	O
.	O

Androstenedione	O
(	O
A	O
)	O
and	O
testosterone	O
(	O
T	O
)	O
levels	O
in	O
serum	O
were	O
determined	O
before	O
and	O
after	O
stimulation	O
with	O
human	O
chorionic	O
gonadotropin	B
.	O

DNA	O
analysis	O
of	O
the	O
whole	O
coding	O
region	O
of	O
the	O
17beta	B
-	I
HSD	I
type	I
3	I
gene	O
was	O
performed	O
by	O
PCR	O
,	O
single	O
-	O
strand	O
conformation	O
analysis	O
,	O
and	O
direct	O
sequencing	O
.	O

In	O
all	O
patients	O
we	O
found	O
highly	O
variable	O
A	O
and	O
T	O
levels	O
before	O
and	O
after	O
stimulation	O
.	O

However	O
,	O
the	O
A	O
-	O
to	O
-	O
T	O
ratio	O
was	O
abnormal	O
in	O
all	O
cases	O
suggestive	O
of	O
17beta	B
-	I
HSD	I
deficiency	O
.	O

Molecular	O
genetic	O
analysis	O
revealed	O
mutations	O
in	O
all	O
patients	O
.	O

We	O
conclude	O
that	O
A	O
and	O
T	O
levels	O
may	O
be	O
highly	O
variable	O
in	O
patients	O
with	O
17beta	B
-	I
HSD	I
deficiency	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
the	O
17beta	B
-	I
HSD	I
gene	O
may	O
support	O
the	O
diagnosis	O
of	O
this	O
disorder	O
.	O

Identification	O
of	O
transcription	O
activators	O
that	O
regulate	O
gonococcal	O
adaptation	O
from	O
aerobic	O
to	O
anaerobic	O
or	O
oxygen	O
-	O
limited	O
growth	O
.	O

Analysis	O
of	O
the	O
Neisseria	O
gonorrhoeae	O
DNA	O
sequence	O
database	O
revealed	O
the	O
presence	O
of	O
two	O
genes	O
,	O
one	O
encoding	O
a	O
protein	O
predicted	O
to	O
be	O
37	O
.	O

5	O
%	O
identical	O
(	O
50	O
%	O
similar	O
)	O
in	O
amino	O
acid	O
sequence	O
to	O
the	O
Escherichia	O
coli	O
FNR	B
protein	O
and	O
the	O
other	O
encoding	O
a	O
protein	O
41	O
%	O
and	O
42	O
%	O
identical	O
(	O
54	O
and	O
51	O
%	O
sequence	O
similarity	O
)	O
to	O
the	O
E.	O
coli	O
NarL	B
and	O
NarP	B
proteins	O
respectively	O
.	O

Both	O
genes	O
have	O
been	O
cloned	O
into	O
E.	O
coli	O
and	O
insertionally	O
inactivated	O
in	O
vitro	O
.	O

The	O
mutated	O
genes	O
have	O
been	O
transformed	O
into	O
gonococci	O
and	O
recombined	O
into	O
the	O
chromosome	O
.	O

The	O
fnr	B
mutation	O
totally	O
abolished	O
and	O
the	O
narP	B
mutation	O
severely	O
diminished	O
the	O
ability	O
of	O
gonococci	O
to	O
:	O
(	O
i	O
)	O
grow	O
anaerobically	O
;	O
(	O
ii	O
)	O
adapt	O
to	O
oxygen	O
-	O
limited	O
growth	O
;	O
(	O
iii	O
)	O
initiate	O
transcription	O
from	O
the	O
aniA	B
promoter	O
(	O
which	O
directs	O
the	O
expression	O
of	O
a	O
copper	B
-	I
containing	I
nitrite	I
reductase	I
,	O
AniA	B
,	O
in	O
response	O
to	O
the	O
presence	O
of	O
nitrite	O
)	O
;	O
and	O
(	O
iv	O
)	O
reduce	O
nitrite	O
during	O
growth	O
in	O
oxygen	O
-	O
limited	O
media	O
.	O

The	O
product	O
of	O
nitrite	O
reduction	O
was	O
identified	O
to	O
be	O
nitrous	O
oxide	O
.	O

Immediately	O
upstream	O
of	O
the	O
narL	B
/	O
narP	B
gene	O
is	O
an	O
open	O
reading	O
frame	O
that	O
,	O
if	O
translated	O
,	O
would	O
encode	O
a	O
homologue	O
of	O
the	O
E.	O
coli	O
nitrate	O
-	O
and	O
nitrite	O
-	O
sensing	O
proteins	O
NarX	B
and	O
NarQ	B
.	O

As	O
transcription	O
from	O
the	O
aniA	B
promoter	O
was	O
not	O
activated	O
during	O
oxygen	O
-	O
limited	O
growth	O
in	O
the	O
presence	O
of	O
nitrate	O
,	O
the	O
gonococcal	O
two	O
-	O
component	O
regulatory	O
system	O
is	O
designated	O
NarQ	B
-	O
NarP	B
rather	O
than	O
NarX	B
-	O
NarL	B
.	O

As	O
far	O
as	O
we	O
are	O
aware	O
,	O
this	O
is	O
the	O
first	O
well	O
-	O
documented	O
example	O
of	O
a	O
two	O
-	O
component	O
regulatory	O
system	O
working	O
in	O
partnership	O
with	O
a	O
transcription	O
activator	O
in	O
pathogenic	O
neisseria	O
.	O

A	O
45	O
kDa	O
c	B
-	I
type	I
cytochrome	I
that	O
was	O
synthesized	O
during	O
oxygen	O
-	O
limited	O
,	O
but	O
not	O
during	O
oxygen	O
sufficient	O
,	O
growth	O
was	O
identified	O
as	O
a	O
homologue	O
of	O
cytochrome	B
c	I
peroxidases	I
(	O
CCP	B
)	O
of	O
other	O
bacteria	O
.	O

The	O
gene	O
for	O
this	O
cytochrome	B
,	O
designated	O
ccp	B
,	O
was	O
located	O
,	O
and	O
its	O
regulatory	O
region	O
was	O
cloned	O
into	O
the	O
promoter	O
probe	O
vector	O
pLES94	O
.	O

Transcription	O
from	O
the	O
ccp	B
promoter	O
was	O
repressed	O
during	O
aerobic	O
growth	O
and	O
induced	O
during	O
oxygen	O
-	O
limited	O
growth	O
and	O
was	O
totally	O
FNR	B
dependent	O
,	O
suggesting	O
that	O
the	O
gonococcal	O
FNR	B
protein	O
is	O
a	O
transcription	O
activator	O
of	O
at	O
least	O
two	O
genes	O
.	O

However	O
,	O
unlike	O
AniA	B
,	O
synthesis	O
of	O
the	O
CCP	B
homologue	O
was	O
insensitive	O
to	O
the	O
presence	O
of	O
nitrite	O
during	O
oxygen	O
-	O
limited	O
growth	O
.	O

Suppression	O
of	O
FNR	B
-	O
dependent	O
transcription	O
activation	O
at	O
the	O
Escherichia	O
coli	O
nir	B
promoter	O
by	O
Fis	B
,	O
IHF	B
and	O
H	B
-	I
NS	I
:	O
modulation	O
of	O
transcription	O
initiation	O
by	O
a	O
complex	O
nucleo	O
-	O
protein	O
assembly	O
.	O

Expression	O
from	O
the	O
Escherichia	O
coli	O
nir	B
promoter	O
is	O
co	O
-	O
dependent	O
on	O
both	O
the	O
FNR	B
protein	O
(	O
an	O
anaerobically	O
triggered	O
transcription	O
activator	O
)	O
and	O
the	O
NarL	B
or	O
NarP	B
proteins	O
(	O
transcription	O
activators	O
triggered	O
by	O
nitrite	O
and	O
nitrate	O
)	O
.	O

Under	O
anaerobic	O
conditions	O
,	O
FNR	B
binds	O
to	O
a	O
site	O
centred	O
between	O
positions	O
-	O
41	O
and	O
-	O
42	O
,	O
activating	O
transcription	O
of	O
the	O
nir	B
operon	I
.	O

In	O
previous	O
work	O
,	O
we	O
showed	O
that	O
this	O
activation	O
is	O
suppressed	O
by	O
the	O
binding	O
of	O
Fis	B
protein	O
,	O
and	O
at	O
least	O
one	O
other	O
protein	O
,	O
to	O
sequence	O
elements	O
located	O
upstream	O
of	O
the	O
nir	B
promoter	O
.	O

We	O
proposed	O
that	O
the	O
binding	O
of	O
NarL	B
or	O
NarP	B
to	O
a	O
site	O
centred	O
between	O
positions	O
-	O
69	O
and	O
-	O
70	O
counteracts	O
this	O
suppression	O
,	O
resulting	O
in	O
increased	O
transcription	O
in	O
response	O
to	O
nitrite	O
or	O
nitrate	O
.	O

Here	O
we	O
have	O
further	O
investigated	O
the	O
different	O
proteins	O
that	O
downregulate	O
the	O
nir	B
promoter	O
.	O

We	O
show	O
that	O
the	O
nir	B
promoter	O
is	O
repressed	O
by	O
three	O
DNA	O
binding	O
proteins	O
,	O
Fis	B
,	O
IHF	B
and	O
H	B
-	I
NS	I
.	O

We	O
demonstrate	O
that	O
,	O
in	O
addition	O
to	O
binding	O
to	O
its	O
previously	O
characterized	O
upstream	O
site	O
located	O
at	O
position	O
-	O
142	O
,	O
Fis	B
also	O
binds	O
to	O
a	O
second	O
downstream	O
site	O
located	O
at	O
position	O
+	O
23	O
.	O

A	O
second	O
suppressing	O
factor	O
is	O
IHF	B
,	O
that	O
binds	O
to	O
a	O
site	O
located	O
at	O
position	O
-	O
88	O
.	O

Finally	O
,	O
the	O
nucleoid	O
associated	O
protein	O
,	O
H	B
-	I
NS	I
,	O
preferentially	O
binds	O
to	O
upstream	O
sequences	O
at	O
the	O
nir	B
promoter	O
and	O
represses	O
promoter	O
activity	O
.	O

The	O
association	O
of	O
Fis	B
,	O
IHF	B
and	O
H	B
-	I
NS	I
suggests	O
that	O
nir	B
promoter	O
DNA	O
is	O
sequestrated	O
into	O
a	O
highly	O
ordered	O
nucleo	O
-	O
protein	O
structure	O
that	O
represses	O
FNR	B
-	O
dependent	O
transcription	O
activation	O
.	O

NarL	B
and	O
NarP	B
can	O
relieve	O
both	O
IHF	B
-	O
and	O
Fis	B
-	O
mediated	O
repression	O
,	O
but	O
are	O
unable	O
to	O
counteract	O
H	B
-	I
NS	I
-	O
mediated	O
repression	O
.	O

IL-5	B
-	O
Induced	O
JAB	B
-	O
JAK2	B
interaction	O
.	O

Receptor	O
activation	O
by	O
the	O
haematopoietic	O
growth	B
factor	I
proteins	O
interleukin	B
5	I
(	O
IL-5	B
)	O
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
leads	O
to	O
phosphorylation	O
of	O
JAK2	B
as	O
a	O
key	O
trigger	O
of	O
signal	O
transduction	O
.	O

JAB	B
has	O
recently	O
been	O
identified	O
as	O
a	O
regulator	O
of	O
JAK2	B
phosphorylation	O
and	O
activity	O
by	O
binding	O
phosphorylated	O
JAK2	B
and	O
inducing	O
its	O
degradation	O
.	O

As	O
part	O
of	O
our	O
effort	O
to	O
define	O
molecular	O
recognition	O
networks	O
that	O
lead	O
to	O
signalling	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
JAB	B
on	O
both	O
JAK2	B
phosphorylation	O
and	O
JAK2	B
interaction	O
state	O
that	O
ensue	O
upon	O
IL-5	B
stimulation	O
in	O
recombinant	O
293	O
T	O
cells	O
cotransfected	O
293	O
T	O
cells	O
with	O
IL-5R	B
alpha	I
,	O
beta	B
c	I
and	O
hJAK2	B
either	O
with	O
or	O
without	O
JAB	B
.	O

Without	O
JAB	B
,	O
stimulation	O
with	O
wild	O
-	O
type	O
and	O
re	O
-	O
engineered	O
single	O
chain	O
(	O
sc	O
)	O
IL-5	B
induced	O
a	O
time	O
-	O
dependent	O
phosphorylation	O
of	O
JAK2	B
.	O

In	O
the	O
presence	O
of	O
JAB	B
cotransfection	O
,	O
no	O
phospho	O
-	O
JAK2	B
was	O
observed	O
,	O
and	O
JAB	B
was	O
observed	O
co	O
-	O
immunoprecipitated	O
with	O
non	O
-	O
phosphorylated	O
JAK2	B
.	O

The	O
time	O
dependence	O
of	O
JAB	B
co	O
-	O
immunoprecipitation	O
correlated	O
with	O
the	O
time	O
dependence	O
of	O
JAK2	B
phosphorylation	O
when	O
JAB	B
was	O
absent	O
.	O

Since	O
JAB	B
has	O
already	O
been	O
shown	O
to	O
bind	O
JAK2	B
via	O
a	O
phosphorylated	O
tyrosine	O
,	O
the	O
current	O
data	O
suggest	O
that	O
JAB	B
binds	O
to	O
phosphorylated	O
JAK2	B
,	O
enhances	O
JAK2	B
dephosphorylation	O
and	O
remains	O
associated	O
in	O
a	O
complex	O
,	O
with	O
dephosphorylated	O
JAK2	B
,	O
that	O
may	O
be	O
a	O
precursor	O
leading	O
to	O
irreversible	O
JAK2	B
degradation	O
.	O

SURVEY	O
AND	O
SUMMARY	O
:	O
holliday	B
junction	I
resolvases	I
and	O
related	O
nucleases	B
:	O
identification	O
of	O
new	O
families	O
,	O
phyletic	O
distribution	O
and	O
evolutionary	O
trajectories	O
.	O

Holliday	B
junction	I
resolvases	I
(	O
HJRs	B
)	O
are	O
key	O
enzymes	O
of	O
DNA	O
recombination	O
.	O

A	O
detailed	O
computer	O
analysis	O
of	O
the	O
structural	O
and	O
evolutionary	O
relationships	O
of	O
HJRs	B
and	O
related	O
nucleases	B
suggests	O
that	O
the	O
HJR	B
function	O
has	O
evolved	O
independently	O
from	O
at	O
least	O
four	O
distinct	O
structural	O
folds	O
,	O
namely	O
RNase	B
H	I
,	O
endonuclease	B
,	O
endonuclease	B
VII	I
-	O
colicin	B
E	I
and	O
RusA	B
.	O

The	O
endonuclease	B
fold	O
,	O
whose	O
structural	O
prototypes	O
are	O
the	O
phage	O
lambda	O
exonuclease	B
,	O
the	O
very	B
short	I
patch	I
repair	I
nuclease	I
(	O
Vsr	B
)	O
and	O
type	B
II	I
restriction	I
enzymes	I
,	O
is	O
shown	O
to	O
encompass	O
by	O
far	O
a	O
greater	O
diversity	O
of	O
nucleases	B
than	O
previously	O
suspected	O
.	O

This	O
fold	O
unifies	O
archaeal	O
HJRs	B
,	O
repair	B
nucleases	I
such	O
as	O
RecB	B
and	O
Vsr	B
,	O
restriction	B
enzymes	I
and	O
a	O
variety	O
of	O
predicted	O
nucleases	B
whose	O
specific	O
activities	O
remain	O
to	O
be	O
determined	O
.	O

Within	O
the	O
RNase	B
H	I
fold	O
a	O
new	O
family	O
of	O
predicted	O
HJRs	B
,	O
which	O
is	O
nearly	O
ubiquitous	O
in	O
bacteria	O
,	O
was	O
discovered	O
,	O
in	O
addition	O
to	O
the	O
previously	O
characterized	O
RuvC	B
family	I
.	O

The	O
proteins	O
of	O
this	O
family	O
,	O
typified	O
by	O
Escherichia	O
coli	O
YqgF	B
,	O
are	O
likely	O
to	O
function	O
as	O
an	O
alternative	O
to	O
RuvC	B
in	O
most	O
bacteria	O
,	O
but	O
could	O
be	O
the	O
principal	O
HJRs	B
in	O
low	O
-	O
GC	O
Gram	O
-	O
positive	O
bacteria	O
and	O
AQUIFEX	O
:	O

Endonuclease	B
VII	I
of	O
phage	O
T4	O
is	O
shown	O
to	O
serve	O
as	O
a	O
structural	O
template	O
for	O
many	O
nucleases	B
,	O
including	O
MCR	B
:	I
A	I
and	O
other	O
type	B
II	I
restriction	I
enzymes	I
.	O

Together	O
with	O
colicin	B
E7	I
,	O
endonuclease	B
VII	I
defines	O
a	O
distinct	O
metal	O
-	O
dependent	O
nuclease	B
fold	O
.	O

As	O
a	O
result	O
of	O
this	O
analysis	O
,	O
the	O
principal	O
HJRs	B
are	O
now	O
known	O
or	O
confidently	O
predicted	O
for	O
all	O
bacteria	O
and	O
archaea	O
whose	O
genomes	O
have	O
been	O
completely	O
sequenced	O
,	O
with	O
many	O
species	O
encoding	O
multiple	O
potential	O
HJRs	B
.	O

Horizontal	O
gene	O
transfer	O
,	O
lineage	O
-	O
specific	O
gene	O
loss	O
and	O
gene	O
family	O
expansion	O
,	O
and	O
non	O
-	O
orthologous	O
gene	O
displacement	O
seem	O
to	O
have	O
been	O
major	O
forces	O
in	O
the	O
evolution	O
of	O
HJRs	B
and	O
related	O
nucleases	B
.	O

A	O
remarkable	O
case	O
of	O
displacement	O
is	O
seen	O
in	O
the	O
Lyme	O
disease	O
spirochete	O
Borrelia	O
burgdorferi	O
,	O
which	O
does	O
not	O
possess	O
any	O
of	O
the	O
typical	O
HJRs	B
,	O
but	O
instead	O
encodes	O
,	O
in	O
its	O
chromosome	O
and	O
each	O
of	O
the	O
linear	O
plasmids	O
,	O
members	O
of	O
the	O
lambda	B
exonuclease	I
family	I
predicted	O
to	O
function	O
as	O
HJRs	B
.	O

The	O
diversity	O
of	O
HJRs	B
and	O
related	O
nucleases	B
in	O
bacteria	O
and	O
archaea	O
contrasts	O
with	O
their	O
near	O
absence	O
in	O
eukaryotes	O
.	O

The	O
few	O
detected	O
eukaryotic	O
representatives	O
of	O
the	O
endonuclease	B
fold	O
and	O
the	O
RNase	B
H	I
fold	O
have	O
probably	O
been	O
acquired	O
from	O
bacteria	O
via	O
horizontal	O
gene	O
transfer	O
.	O

The	O
identity	O
of	O
the	O
principal	O
HJR	B
(	I
s	I
)	I
involved	O
in	O
recombination	O
in	O
eukaryotes	O
remains	O
uncertain	O
;	O
this	O
function	O
could	O
be	O
performed	O
by	O
topoisomerase	B
IB	I
or	O
by	O
a	O
novel	O
,	O
so	O
far	O
undetected	O
,	O
class	O
of	O
enzymes	O
.	O

Likely	O
HJRs	B
and	O
related	O
nucleases	B
were	O
identified	O
in	O
the	O
genomes	O
of	O
numerous	O
bacterial	O
and	O
eukaryotic	O
DNA	O
viruses	O
.	O

Gene	O
flow	O
between	O
viral	O
and	O
cellular	O
genomes	O
has	O
probably	O
played	O
a	O
major	O
role	O
in	O
the	O
evolution	O
of	O
this	O
class	O
of	O
enzymes	O
.	O

This	O
analysis	O
resulted	O
in	O
the	O
prediction	O
of	O
numerous	O
previously	O
unnoticed	O
nucleases	B
,	O
some	O
of	O
which	O
are	O
likely	O
to	O
be	O
new	O
restriction	B
enzymes	I
.	O

New	O
structural	O
and	O
functional	O
aspects	O
of	O
the	O
type	B
I	I
interferon	I
-	I
receptor	I
interaction	O
revealed	O
by	O
comprehensive	O
mutational	O
analysis	O
of	O
the	O
binding	O
interface	O
.	O

Type	B
I	I
interferons	I
bind	O
to	O
two	O
cell	O
surface	O
receptors	O
,	O
ifnar1	B
and	O
ifnar2	B
,	O
as	O
the	O
first	O
step	O
in	O
the	O
activation	O
of	O
several	O
signal	O
transduction	O
pathways	O
that	O
elicit	O
an	O
anti	O
-	O
viral	O
state	O
and	O
an	O
anti	O
-	O
proliferative	O
response	O
.	O

Here	O
,	O
we	O
quantitatively	O
mapped	O
the	O
complete	O
binding	O
region	O
of	O
ifnar2	B
on	O
interferon	B
(	I
IFN	I
)	I
alpha2	I
by	O
35	O
individual	O
mutations	O
to	O
alanine	O
and	O
isosteric	O
residues	O
.	O

Of	O
the	O
six	O
""""	O
hot	O
-	O
spot	O
""""	O
residues	O
identified	O
(	O
Leu	O
-	O
30	O
,	O
Arg-33	O
,	O
Arg-144	O
,	O
Ala-145	O
,	O
Met-148	O
,	O
and	O
Arg	O
-	O
149	O
)	O
,	O
four	O
are	O
located	O
on	O
the	O
E	O
-	O
helix	O
,	O
which	O
is	O
located	O
at	O
the	O
center	O
of	O
the	O
binding	O
site	O
flanked	O
by	O
residues	O
on	O
the	O
A	O
-	O
helix	O
and	O
the	O
AB	O
-	O
loop	O
.	O

The	O
contribution	O
of	O
residues	O
of	O
the	O
D	O
-	O
helix	O
,	O
which	O
have	O
been	O
previously	O
implicated	O
in	O
binding	O
,	O
proved	O
to	O
be	O
marginal	O
for	O
the	O
interaction	O
with	O
the	O
extracellular	O
domain	O
of	O
ifnar2	B
.	O

Interestingly	O
,	O
the	O
ifnar2	B
binding	O
site	O
overlaps	O
the	O
largest	O
continuous	O
hydrophobic	O
patch	O
on	O
IFNalpha2	B
.	O

Thus	O
,	O
hydrophobic	O
interactions	O
seem	O
to	O
play	O
a	O
significant	O
role	O
stabilizing	O
this	O
interaction	O
,	O
with	O
the	O
charged	O
residues	O
contributing	O
toward	O
the	O
rapid	O
association	O
of	O
the	O
complex	O
.	O

Relating	O
the	O
anti	O
-	O
viral	O
and	O
anti	O
-	O
proliferative	O
activity	O
of	O
the	O
various	O
interferon	O
mutants	O
with	O
their	O
affinity	O
toward	O
ifnar2	B
results	O
in	O
linear	O
function	O
over	O
the	O
whole	O
range	O
of	O
affinities	O
investigated	O
,	O
suggesting	O
that	O
ifnar2	B
binding	O
is	O
the	O
rate	O
-	O
determining	O
step	O
in	O
cellular	O
activation	O
.	O

Dose	O
-	O
time	O
analysis	O
of	O
the	O
anti	O
-	O
viral	O
response	O
revealed	O
that	O
shortening	O
the	O
incubation	O
time	O
of	O
low	O
-	O
level	O
activation	O
can	O
not	O
be	O
compensated	O
by	O
higher	O
IFN	B
doses	O
.	O

Considering	O
the	O
strict	O
dependence	O
of	O
the	O
cellular	O
response	O
on	O
affinity	O
,	O
these	O
results	O
suggest	O
that	O
for	O
maintaining	O
transcription	O
of	O
IFN	B
-	O
responsive	O
genes	O
over	O
a	O
longer	O
time	O
period	O
,	O
low	O
but	O
continuous	O
signaling	O
through	O
the	O
IFN	B
receptor	I
is	O
essential	O
.	O

Purine	O
catabolism	O
in	O
Escherichia	O
coli	O
and	O
function	O
of	O
xanthine	B
dehydrogenase	I
in	O
purine	O
salvage	O
.	O

Escherichia	O
coli	O
is	O
not	O
known	O
to	O
utilize	O
purines	O
,	O
other	O
than	O
adenine	O
and	O
adenosine	O
,	O
as	O
nitrogen	O
sources	O
.	O

We	O
reinvestigated	O
purine	O
catabolism	O
because	O
a	O
computer	O
analysis	O
suggested	O
several	O
potential	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
promoters	O
within	O
a	O
23	O
-	O
gene	O
cluster	O
whose	O
products	O
have	O
homology	O
to	O
purine	O
catabolic	O
enzymes	O
.	O

Our	O
results	O
did	O
not	O
provide	O
conclusive	O
evidence	O
that	O
the	O
sigma	B
(	I
54	I
)	I
-	O
dependent	O
promoters	O
are	O
active	O
.	O

Nonetheless	O
,	O
our	O
results	O
suggest	O
that	O
some	O
of	O
the	O
genes	O
are	O
metabolically	O
significant	O
.	O

We	O
found	O
that	O
even	O
though	O
several	O
purines	O
did	O
not	O
support	O
growth	O
as	O
the	O
sole	O
nitrogen	O
source	O
,	O
they	O
did	O
stimulate	O
growth	O
with	O
aspartate	O
as	O
the	O
nitrogen	O
source	O
.	O

Cells	O
produced	O
(	O
14	O
)	O
CO	O
(	O
2	O
)	O
from	O
minimal	O
medium	O
containing	O
[	O
(	O
14	O
)	O
C	O
]	O
adenine	O
,	O
which	O
implies	O
allantoin	O
production	O
.	O

However	O
,	O
neither	O
ammonia	O
nor	O
carbamoyl	O
phosphate	O
was	O
produced	O
,	O
which	O
implies	O
that	O
purine	O
catabolism	O
is	O
incomplete	O
and	O
does	O
not	O
provide	O
nitrogen	O
during	O
nitrogen	O
-	O
limited	O
growth	O
.	O

We	O
constructed	O
strains	O
with	O
deletions	O
of	O
two	O
genes	O
whose	O
products	O
might	O
catalyze	O
the	O
first	O
reaction	O
of	O
purine	O
catabolism	O
.	O

Deletion	O
of	O
one	O
eliminated	O
(	O
14	O
)	O
CO	O
(	O
2	O
)	O
production	O
from	O
[	O
(	O
14	O
)	O
C	O
]	O
adenine	O
,	O
which	O
implies	O
that	O
its	O
product	O
is	O
necessary	O
for	O
xanthine	B
dehydrogenase	I
activity	O
.	O

We	O
changed	O
the	O
name	O
of	O
this	O
gene	O
to	O
xdhA	B
.	O

The	O
xdhA	B
mutant	O
grew	O
faster	O
with	O
aspartate	O
as	O
a	O
nitrogen	O
source	O
.	O

The	O
mutant	O
also	O
exhibited	O
sensitivity	O
to	O
adenine	O
,	O
which	O
guanosine	O
partially	O
reversed	O
.	O

Adenine	O
sensitivity	O
has	O
been	O
previously	O
associated	O
with	O
defective	O
purine	O
salvage	O
resulting	O
from	O
impaired	O
synthesis	O
of	O
guanine	O
nucleotides	O
from	O
adenine	O
.	O

We	O
propose	O
that	O
xanthine	B
dehydrogenase	I
contributes	O
to	O
this	O
purine	O
interconversion	O
.	O

Amino	O
acid	O
sequence	O
of	O
the	O
protease	B
inhibitor	I
BWI-4a	I
from	O
buckwheat	O
seeds	O
.	O

The	O
complete	O
amino	O
acid	O
sequence	O
of	O
protease	B
inhibitor	I
BWI-4a	I
from	O
buckwheat	O
(	O
Fagopyrum	O
esculentum	O
Moench	O
)	O
seeds	O
,	O
consisting	O
of	O
67	O
amino	O
acid	O
residues	O
with	O
a	O
single	O
disulfide	O
bond	O
,	O
has	O
been	O
established	O
by	O
Edman	O
degradation	O
in	O
combination	O
with	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
.	O

Its	O
N	O
terminus	O
is	O
blocked	O
by	O
a	O
pyroglutamic	O
acid	O
residue	O
.	O

Mass	O
spectrometric	O
analysis	O
revealed	O
that	O
inhibitor	B
BWI-4a	I
is	O
present	O
in	O
buckwheat	O
seeds	O
in	O
two	O
isoforms	O
with	O
a	O
single	O
amino	O
acid	O
substitution	O
of	O
Ala40	O
for	O
Gly40	O
.	O

The	O
reactive	O
site	O
of	O
the	O
inhibitor	O
contains	O
an	O
Arg43	O
-	O
Asp44	O
bond	O
.	O

Analysis	O
of	O
the	O
amino	O
acid	O
sequence	O
suggests	O
that	O
the	O
buckwheat	O
seed	O
protease	O
inhibitor	O
is	O
a	O
member	O
of	O
the	O
potato	B
proteinase	I
inhibitor	I
I	I
family	I
.	O

DNA	O
sequence	O
variation	O
in	O
human	O
apolipoprotein	B
C4	I
gene	O
and	O
its	O
effect	O
on	O
plasma	O
lipid	O
profile	O
.	O

Human	O
apolipoprotein	B
C	I
-	I
IV	I
(	O
apoC	B
-	I
IV	I
,	O
protein	O
;	O
APOC4	B
,	O
gene	O
)	O
is	O
a	O
new	O
member	O
of	O
the	O
APO	B
E	I
/	I
C1	I
/	I
C2	I
gene	O
cluster	O
.	O

In	O
transgenic	O
mice	O
,	O
human	O
apoC	B
-	I
IV	I
is	O
predominantly	O
associated	O
with	O
very	B
low	I
-	I
density	I
lipoprotein	I
(	O
VLDL	B
)	O
and	O
thus	O
may	O
play	O
an	O
important	O
role	O
in	O
lipid	O
metabolism	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
extent	O
and	O
nature	O
of	O
APOC4	B
genetic	O
variation	O
and	O
its	O
role	O
in	O
lipid	O
metabolism	O
are	O
unknown	O
.	O

In	O
this	O
study	O
we	O
have	O
assessed	O
the	O
presence	O
of	O
genetic	O
variation	O
in	O
all	O
three	O
exons	O
of	O
APOC4	B
and	O
their	O
flanking	O
intronic	O
sequence	O
by	O
SSCP	O
and	O
DNA	O
sequencing	O
.	O

A	O
total	O
of	O
five	O
point	O
mutations	O
were	O
observed	O
,	O
including	O
two	O
in	O
the	O
non	O
-	O
coding	O
part	O
of	O
exon	O
1	O
(	O
A609	O
G	O
and	O
G620A	O
)	O
,	O
two	O
in	O
exon	O
2	O
(	O
codons	O
36	O
and	O
52	O
)	O
and	O
one	O
in	O
exon	O
3	O
(	O
codon	O
96	O
)	O
.	O

The	O
three	O
mutations	O
in	O
exons	O
2	O
and	O
3	O
predict	O
amino	O
acid	O
substitutions	O
,	O
Leu36Pro	O
,	O
Gly52Asp	O
,	O
and	O
Leu96Arg	O
.	O

The	O
frequencies	O
of	O
the	O
variant	O
alleles	O
were	O
:	O
0.010	O
for	O
609	O
G	O
,	O
0.039	O
for	O
620A	O
,	O
0.502	O
for	O
Pro36	O
,	O
0.003	O
for	O
Asp52	O
and	O
0.357	O
for	O
Arg96	O
.	O

Significant	O
pairwise	O
linkage	O
disequilibrium	O
was	O
observed	O
between	O
five	O
of	O
the	O
ten	O
APOC4	B
pairs	O
,	O
including	O
nt	O
.	O
620	O
/	O
codon	O
36	O
,	O
nt	O
.	O
620	O
/	O
codon	O
96	O
,	O
codon	O
36	O
/	O
codon	O
52	O
,	O
codon	O
36	O
/	O
codon	O
96	O
and	O
codon	O
52	O
/	O
codon	O
96	O
.	O

A	O
general	O
linear	O
model	O
analysis	O
reveled	O
a	O
significant	O
association	O
of	O
the	O
Leu36Pro	O
and	O
the	O
Leu96Arg	O
polymorphisms	O
with	O
triglyceride	O
levels	O
in	O
women	O
.	O

This	O
is	O
consistent	O
with	O
the	O
proposed	O
role	O
of	O
apoC	B
-	I
IV	I
in	O
triglyceride	O
metabolism	O
.	O

The	O
characterization	O
of	O
APOC4	B
genetic	O
variation	O
may	O
lead	O
to	O
the	O
identification	O
of	O
a	O
specific	O
role	O
of	O
apoC	B
-	I
IV	I
in	O
lipid	O
metabolism	O
or	O
in	O
other	O
physiologic	O
pathways	O
.	O

ASD4	B
,	O
a	O
new	O
GATA	B
factor	I
of	O
Neurospora	O
crassa	O
,	O
displays	O
sequence	O
-	O
specific	O
DNA	O
binding	O
and	O
functions	O
in	O
ascus	O
and	O
ascospore	O
development	O
.	O

A	O
new	O
gene	O
encoding	O
a	O
novel	O
GATA	B
factor	I
,	O
ASD4	B
,	O
of	O
Neurospora	O
crassa	O
was	O
isolated	O
and	O
demonstrated	O
to	O
possess	O
one	O
intron	O
and	O
to	O
specify	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
with	O
427	O
amino	O
acid	O
residues	O
.	O

The	O
ASD4	B
protein	O
contains	O
a	O
single	O
GATA	O
-	O
type	O
zinc	O
finger	O
and	O
a	O
putative	O
coiled	O
-	O
coil	O
domain	O
.	O

Unlike	O
related	O
proteins	O
,	O
DAL80	B
in	O
yeast	O
and	O
NREB	B
in	O
Penicillium	O
,	O
ASD4	B
does	O
not	O
appear	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
nitrogen	O
metabolism	O
.	O

An	O
Asd-4	B
null	O
mutant	O
obtained	O
by	O
the	O
rip	O
procedure	O
did	O
not	O
show	O
any	O
effect	O
upon	O
nitrogen	O
control	O
,	O
but	O
instead	O
resulted	O
in	O
severe	O
defects	O
in	O
ascus	O
and	O
ascospore	O
genesis	O
.	O

The	O
Asd-4	B
rip	O
mutant	O
is	O
dominant	O
to	O
Asd-4	B
+	O
.	O

A	O
cross	O
of	O
the	O
Asd-4	B
mutant	O
with	O
wild	O
-	O
type	O
resulted	O
in	O
fruiting	O
bodies	O
that	O
appeared	O
to	O
be	O
normal	O
macroscopically	O
but	O
which	O
were	O
complete	O
devoid	O
of	O
asci	O
and	O
ascospores	O
.	O

Introduction	O
of	O
the	O
Asd-4	B
+	O
gene	O
into	O
the	O
Asd-4	B
rip	O
mutant	O
corrected	O
the	O
defect	O
in	O
ascus	O
and	O
ascospore	O
development	O
in	O
crosses	O
with	O
wild	O
-	O
type	O
.	O

Mobility	O
shift	O
assays	O
demonstrated	O
that	O
ASD4	B
acts	O
as	O
a	O
sequence	O
-	O
specific	O
DNA	O
binding	O
protein	O
and	O
recognizes	O
DNA	O
fragments	O
that	O
contain	O
GATA	O
core	O
elements	O
.	O

Gel	O
filtration	O
and	O
cross	O
-	O
linking	O
experiments	O
revealed	O
that	O
the	O
ASD4	B
protein	O
exists	O
as	O
a	O
tetramer	O
in	O
solution	O
.	O

These	O
results	O
suggest	O
that	O
the	O
ASD4	B
protein	O
functions	O
positively	O
as	O
a	O
transcriptional	O
regulator	O
of	O
sexual	O
development	O
in	O
Neurospora	O
.	O

Identification	O
of	O
a	O
novel	O
neuromedin	B
U	I
receptor	I
subtype	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Neuromedin	B
U	I
is	O
a	O
neuropeptide	B
prominently	O
expressed	O
in	O
the	O
upper	O
gastrointestinal	O
tract	O
and	O
central	O
nervous	O
system	O
.	O

Recently	O
,	O
GPR66	B
/	O
FM	B
-	I
3	I
(	O
NmU	B
-	I
R1	I
)	O
was	O
identified	O
as	O
a	O
specific	O
receptor	O
for	O
neuromedin	O
U	O
.	O

A	O
BLAST	O
search	O
of	O
the	O
GenBank	O
(	O
TM	O
)	O
genomic	O
database	O
using	O
the	O
NmU	B
-	I
R1	I
cDNA	O
sequence	O
revealed	O
a	O
human	O
genomic	O
fragment	O
encoding	O
a	O
G	B
protein	I
-	I
coupled	I
receptor	I
that	O
we	O
designated	O
NmU	B
-	I
R2	I
based	O
on	O
its	O
homology	O
to	O
NmU	B
-	I
R1	I
.	O

The	O
full	O
-	O
length	O
NmU	B
-	I
R2	I
cDNA	O
was	O
subsequently	O
cloned	O
,	O
stably	O
expressed	O
in	O
293	O
cells	O
,	O
and	O
shown	O
to	O
mobilize	O
intracellular	O
calcium	O
in	O
response	O
to	O
neuromedin	B
U	I
.	O

This	O
response	O
was	O
dose	O
-	O
dependent	O
(	O
EC	O
(	O
50	O
)	O
=	O
5	O
nm	O
)	O
and	O
specific	O
in	O
that	O
other	O
neuromedins	B
did	O
not	O
induce	O
a	O
calcium	O
flux	O
in	O
receptor	O
-	O
transfected	O
cells	O
.	O

Expression	O
analysis	O
of	O
human	O
NmU	B
-	I
R2	I
demonstrated	O
its	O
mRNA	O
to	O
be	O
most	O
highly	O
expressed	O
in	O
central	O
nervous	O
system	O
tissues	O
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
conclude	O
that	O
NmU	B
-	I
R2	I
is	O
a	O
novel	O
neuromedin	B
U	I
receptor	I
subtype	O
that	O
is	O
likely	O
to	O
mediate	O
central	O
nervous	O
system	O
-	O
specific	O
neuromedin	B
U	I
effects	O
.	O

Modulation	O
of	O
amyloid	O
precursor	O
protein	O
metabolism	O
by	O
X11alpha	B
/	O
Mint-1	B
.	O

A	O
deletion	O
analysis	O
of	O
protein	O
-	O
protein	O
interaction	O
domains	O
.	O

Modulation	O
of	O
amyloid	B
precursor	I
protein	I
(	O
APP	B
)	O
metabolism	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
phosphotyrosine	O
-	O
binding	O
/	O
protein	O
interaction	O
(	O
PTB	O
/	O
PI	O
)	O
domain	O
of	O
X11alpha	B
,	O
a	O
neuronal	O
cytosolic	O
adaptor	B
protein	I
,	O
binds	O
to	O
the	O
YENPTY	O
sequence	O
in	O
the	O
cytoplasmic	O
carboxyl	O
terminus	O
of	O
APP	B
.	O

This	O
interaction	O
prolongs	O
the	O
half	O
-	O
life	O
of	O
APP	B
and	O
inhibits	O
Abeta40	B
and	O
Abeta42	B
secretion	O
.	O

X11alpha	B
/	O
Mint-1	B
has	O
multiple	O
protein	O
-	O
protein	O
interaction	O
domains	O
,	O
a	O
Munc	B
-	I
18	I
interaction	O
domain	O
(	O
MID	O
)	O
,	O
a	O
Cask	B
/	O
Lin	B
-	I
2	I
interaction	O
domain	O
(	O
CID	O
)	O
,	O
a	O
PTB	O
/	O
PI	O
domain	O
,	O
and	O
two	O
PDZ	O
domains	O
.	O

These	O
X11alpha	B
protein	O
interaction	O
domains	O
may	O
modulate	O
its	O
effect	O
on	O
APP	B
processing	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
performed	O
a	O
deletion	O
analysis	O
of	O
X11alpha	B
effects	O
on	O
metabolism	O
of	O
APP	B
(	O
695	O
)	O
Swedish	O
(	O
K595N	O
/	O
M596L	O
)	O
(	O
APP	B
(	O
sw	O
)	O
)	O
by	O
transient	O
cotransfection	O
of	O
HEK	O
293	O
cells	O
with	O
:	O
1	O
)	O
X11alpha	B
(	O
X11alpha	B
-	O
wt	O
,	O
N	O
-	O
MID	O
-	O
CID	O
-	O
PTB	O
-	O
PDZ	O
-	O
PDZ	O
-	O
C	O
)	O
,	O
2	O
)	O
amino	O
-	O
terminal	O
deletion	O
(	O
X11alpha	B
-	O
DeltaN	O
,	O
PTB	O
-	O
PDZ	O
-	O
PDZ	O
)	O
,	O
3	O
)	O
carboxyl	O
-	O
terminal	O
deletion	O
(	O
X11alpha	B
-	O
DeltaPDZ	O
,	O
MID	O
-	O
CID	O
-	O
PTB	O
)	O
,	O
or	O
4	O
)	O
deletion	O
of	O
both	O
termini	O
(	O
PTB	O
domain	O
only	O
,	O
PTB	O
)	O
.	O

The	O
carboxyl	O
terminus	O
of	O
X11alpha	B
was	O
required	O
for	O
stabilization	O
of	O
APP	B
(	O
sw	O
)	O
in	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
amino	O
terminus	O
of	O
X11alpha	B
was	O
required	O
to	O
stimulate	O
APPs	B
secretion	O
.	O

X11alpha	B
,	O
X11alpha	B
-	O
DeltaN	O
,	O
and	O
X11alpha	B
-	O
PTB	O
,	O
but	O
not	O
X11alpha	B
-	O
DeltaPDZ	O
,	O
were	O
effective	O
inhibitors	O
of	O
Abeta40	B
and	O
Abeta42	B
secretion	O
.	O

These	O
results	O
suggest	O
that	O
additional	O
protein	O
interaction	O
domains	O
of	O
X11alpha	B
modulate	O
various	O
aspects	O
of	O
APP	B
metabolism	O
.	O

A	O
novel	O
bifunctional	O
phospholipase	B
c	I
that	O
is	O
regulated	O
by	O
Galpha	B
12	I
and	O
stimulates	O
the	O
Ras	B
/	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
.	O

Three	O
families	O
of	O
phospholipase	B
C	I
(	O
PI	B
-	I
PLCbeta	I
,	I
gamma	I
,	I
and	I
delta	I
)	O
are	O
known	O
to	O
catalyze	O
the	O
hydrolysis	O
of	O
polyphosphoinositides	O
such	O
as	O
phosphatidylinositol	O
4,5-bisphosphate	O
(	O
PIP	O
(	O
2	O
)	O
)	O
to	O
generate	O
the	O
second	O
messengers	O
inositol	O
1,4,5	O
trisphosphate	O
and	O
diacylglycerol	O
,	O
leading	O
to	O
a	O
cascade	O
of	O
intracellular	O
responses	O
that	O
result	O
in	O
cell	O
growth	O
,	O
cell	O
differentiation	O
,	O
and	O
gene	O
expression	O
.	O

Here	O
we	O
describe	O
the	O
founding	O
member	O
of	O
a	O
novel	O
,	O
structurally	O
distinct	O
fourth	O
family	B
of	I
PI	I
-	I
PLC	I
.	O

PLCepsilon	B
not	O
only	O
contains	O
conserved	O
catalytic	O
(	O
X	O
and	O
Y	O
)	O
and	O
regulatory	O
domains	O
(	O
C2	O
)	O
common	O
to	O
other	O
eukaryotic	O
PLCs	B
,	O
but	O
also	O
contains	O
two	O
Ras	B
-	O
associating	O
(	O
RA	O
)	O
domains	O
and	O
a	O
Ras	B
guanine	I
nucleotide	I
exchange	I
factor	I
(	O
RasGEF	B
)	O
motif	O
.	O

PLCepsilon	B
hydrolyzes	O
PIP	O
(	O
2	O
)	O
,	O
and	O
this	O
activity	O
is	O
stimulated	O
selectively	O
by	O
a	O
constitutively	O
active	O
form	O
of	O
the	O
heterotrimeric	B
G	I
protein	I
Galpha	B
(	I
12	I
)	I
.	O

PLCepsilon	B
and	O
a	O
mutant	O
(	O
H1144L	O
)	O
incapable	O
of	O
hydrolyzing	O
phosphoinositides	O
promote	O
formation	O
of	O
GTP	O
-	O
Ras	B
.	O

Thus	O
PLCepsilon	B
is	O
a	O
RasGEF	B
.	O

PLCepsilon	B
,	O
the	O
mutant	O
H1144L	O
,	O
and	O
the	O
isolated	O
GEF	B
domain	O
activate	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
in	O
a	O
manner	O
dependent	O
on	O
Ras	B
but	O
independent	O
of	O
PIP	O
(	O
2	O
)	O
hydrolysis	O
.	O

Our	O
findings	O
demonstrate	O
that	O
PLCepsilon	B
is	O
a	O
novel	O
bifunctional	O
enzyme	O
that	O
is	O
regulated	O
by	O
the	O
heterotrimeric	B
G	I
protein	I
Galpha	B
(	I
12	I
)	I
and	O
activates	O
the	O
small	B
G	I
protein	I
Ras	B
/	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
signaling	O
pathway	O
.	O

Regulation	O
of	O
a	O
novel	O
human	O
phospholipase	B
C	I
,	O
PLCepsilon	B
,	O
through	O
membrane	O
targeting	O
by	O
Ras	B
.	O

Phosphoinositide	B
-	I
specific	I
phospholipase	I
C	I
(	O
PI	B
-	I
PLC	I
)	O
plays	O
a	O
pivotal	O
role	O
in	O
regulation	O
of	O
intracellular	O
signal	O
transduction	O
from	O
various	O
receptor	O
molecules	O
.	O

More	O
than	O
10	O
members	O
of	O
human	O
PI	B
-	I
PLC	I
isoforms	O
have	O
been	O
identified	O
and	O
classified	O
into	O
three	O
classes	O
beta	O
,	O
gamma	O
,	O
and	O
delta	O
,	O
which	O
are	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O

Here	O
we	O
report	O
identification	O
of	O
a	O
novel	O
class	O
of	O
human	O
PI	B
-	I
PLC	I
,	O
named	O
PLCepsilon	B
,	O
which	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
Ras	B
-	O
associating	O
domain	O
at	O
its	O
C	O
terminus	O
and	O
a	O
CDC25	B
-	O
like	O
domain	O
at	O
its	O
N	O
terminus	O
.	O

The	O
Ras	B
-	O
associating	O
domain	O
of	O
PLCepsilon	B
specifically	O
binds	O
to	O
the	O
GTP	O
-	O
bound	O
forms	O
of	O
Ha	B
-	I
Ras	I
and	O
Rap1A	B
.	O

The	O
dissociation	O
constant	O
for	O
Ha	B
-	I
Ras	I
is	O
estimated	O
to	O
be	O
approximately	O
40	O
nm	O
,	O
comparable	O
with	O
those	O
of	O
other	O
Ras	B
effectors	O
.	O

Co	O
-	O
expression	O
of	O
an	O
activated	O
Ha	B
-	I
Ras	I
mutant	O
with	O
PLCepsilon	B
induces	O
its	O
translocation	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

Upon	O
stimulation	O
with	O
epidermal	B
growth	I
factor	I
,	O
similar	O
translocation	O
of	O
ectopically	O
expressed	O
PLCepsilon	B
is	O
observed	O
,	O
which	O
is	O
inhibited	O
by	O
co	O
-	O
expression	O
of	O
dominant	O
-	O
negative	O
Ha	B
-	I
Ras	I
.	O

Furthermore	O
,	O
using	O
a	O
liposome	O
-	O
based	O
reconstitution	O
assay	O
,	O
it	O
is	O
shown	O
that	O
the	O
phosphatidylinositol	O
4,5-bisphosphate	O
-	O
hydrolyzing	O
activity	O
of	O
PLCepsilon	B
is	O
stimulated	O
in	O
vitro	O
by	O
Ha	B
-	I
Ras	I
in	O
a	O
GTP	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicate	O
that	O
Ras	B
directly	O
regulates	O
phosphoinositide	O
breakdown	O
through	O
membrane	O
targeting	O
of	O
PLCepsilon	B
.	O

Differential	O
contributions	O
of	O
NADPH	B
-	I
cytochrome	I
P450	I
oxidoreductase	I
FAD	O
binding	O
site	O
residues	O
to	O
flavin	O
binding	O
and	O
catalysis	O
.	O

Transfer	O
of	O
reducing	O
equivalents	O
from	O
NADPH	O
to	O
the	O
cytochromes	B
P450	I
is	O
mediated	O
by	O
NADPH	B
-	I
cytochrome	I
P450	I
oxidoreductase	I
,	O
which	O
contains	O
stoichiometric	O
amounts	O
of	O
tightly	O
bound	O
FMN	O
and	O
FAD	O
.	O

Hydrogen	O
bonding	O
and	O
van	O
der	O
Waals	O
interactions	O
between	O
FAD	O
and	O
amino	O
acid	O
residues	O
in	O
the	O
FAD	O
binding	O
site	O
of	O
the	O
reductase	B
serve	O
to	O
regulate	O
both	O
flavin	O
binding	O
and	O
reactivity	O
.	O

The	O
precise	O
orientation	O
of	O
key	O
residues	O
(	O
Arg	O
(	O
454	O
)	O
,	O
Tyr	O
(	O
456	O
)	O
,	O
Cys	O
(	O
472	O
)	O
,	O
Gly	O
(	O
488	O
)	O
,	O
Thr	O
(	O
491	O
)	O
,	O
and	O
Trp	O
(	O
677	O
)	O
)	O
has	O
been	O
defined	O
by	O
x	O
-	O
ray	O
crystallography	O
(	O
Wang	O
,	O
M.	O
,	O
Roberts	O
,	O
D.	O
L.	O
,	O
Paschke	O
,	O
R.	O
,	O
Shea	O
,	O
T.	O
M.	O
,	O
Masters	O
,	O
B.	O
S.	O
,	O
Kim	O
,	O
J.	O
-	O
J.	O
P.	O
(	O
1997	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U.	O
S.	O
A.	O
94	O
,	O
8411	O
-	O
8416	O
)	O
.	O

The	O
current	O
study	O
examines	O
the	O
relative	O
contributions	O
of	O
these	O
residues	O
to	O
FAD	O
binding	O
and	O
catalysis	O
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
kinetic	O
analysis	O
.	O

Mutation	O
of	O
either	O
Tyr	O
(	O
456	O
)	O
,	O
which	O
makes	O
van	O
der	O
Waals	O
contact	O
with	O
the	O
FAD	O
isoalloxazine	O
ring	O
and	O
also	O
hydrogen	O
-	O
bonds	O
to	O
the	O
ribityl	O
4	O
'	O
-	O
hydroxyl	O
,	O
or	O
Arg	O
(	O
454	O
)	O
,	O
which	O
bonds	O
to	O
the	O
FAD	O
pyrophosphate	O
,	O
decreases	O
the	O
affinity	O
for	O
FAD	O
8000	O
-	O
and	O
25	O
,	O
000	O
-	O
fold	O
,	O
respectively	O
,	O
with	O
corresponding	O
decreases	O
in	O
cytochrome	B
c	I
reductase	I
activity	O
.	O

In	O
contrast	O
,	O
substitution	O
of	O
Thr	O
(	O
491	O
)	O
,	O
which	O
also	O
interacts	O
with	O
the	O
pyrophosphate	O
grouping	O
,	O
had	O
a	O
relatively	O
modest	O
effect	O
on	O
both	O
FAD	O
binding	O
(	O
100	O
-	O
fold	O
decrease	O
)	O
and	O
catalytic	O
activity	O
(	O
2	O
-	O
fold	O
decrease	O
)	O
,	O
while	O
the	O
G488L	O
mutant	O
exhibited	O
,	O
respectively	O
,	O
800	O
-	O
and	O
50	O
-	O
fold	O
decreases	O
in	O
FAD	O
binding	O
and	O
catalytic	O
activity	O
.	O

Enzymic	O
activity	O
of	O
each	O
of	O
these	O
mutants	O
could	O
be	O
restored	O
by	O
addition	O
of	O
FAD	O
.	O

Kinetic	O
properties	O
and	O
the	O
FMN	O
content	O
of	O
these	O
mutants	O
were	O
not	O
affected	O
by	O
these	O
substitutions	O
,	O
with	O
the	O
exception	O
of	O
a	O
3	O
-	O
fold	O
increase	O
in	O
Y456S	O
K	O
(	O
m	O
)	O
(	O
cyt	O
)	O
(	O
c	O
)	O
and	O
a	O
70	O
%	O
decrease	O
in	O
R454E	O
FMN	O
content	O
,	O
suggesting	O
that	O
the	O
FMN	O
-	O
and	O
FAD	O
-	O
binding	O
domains	O
are	O
largely	O
,	O
but	O
not	O
completely	O
,	O
independent	O
.	O

Even	O
though	O
Trp	O
(	O
677	O
)	O
is	O
stacked	O
against	O
the	O
re	O
-	O
face	O
of	O
FAD	O
,	O
suggesting	O
an	O
important	O
role	O
in	O
FAD	O
binding	O
,	O
deletion	O
of	O
both	O
Trp	O
(	O
677	O
)	O
and	O
the	O
carboxyl	O
-	O
terminal	O
Ser	O
(	O
678	O
)	O
decreased	O
catalytic	O
activity	O
50	O
-	O
fold	O
without	O
affecting	O
FAD	O
content	O
.	O

Interleukin	B
8	I
,	O
neutrophil	B
-	I
activating	I
peptide-2	I
and	O
GRO	B
-	I
alpha	I
bind	O
to	O
and	O
elicit	O
cell	O
activation	O
via	O
specific	O
and	O
different	O
amino	O
acid	O
residues	O
of	O
CXCR2	B
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
the	O
amino	O
acid	O
residues	O
of	O
the	O
human	O
neutrophil	O
CXC	B
chemokine	I
receptor-2	I
(	O
CXCR2	B
)	O
that	O
are	O
critical	O
for	O
binding	O
the	O
ligands	O
interleukin	B
8	I
(	O
IL-8	B
)	O
,	O
neutrophil	B
-	I
activating	I
peptide-2	I
(	O
NAP-2	B
)	O
,	O
and	O
growth	B
-	I
related	I
protein	I
alpha	I
(	O
GROalpha	B
)	O
and	O
critical	O
for	O
receptor	O
-	O
mediated	O
signal	O
transduction	O
.	O

Charged	O
residues	O
of	O
the	O
amino	O
terminus	O
and	O
the	O
first	O
extracellular	O
loop	O
of	O
CXCR2	B
were	O
targeted	O
for	O
point	O
mutagenesis	O
studies	O
.	O

Seven	O
separate	O
CXCR2	B
mutants	O
(	O
Glu7	O
,	O
Asp9	O
,	O
Glu12	O
,	O
Asp13	O
,	O
Lys108	O
,	O
Asn110	O
,	O
and	O
Lys120	O
,	O
all	O
to	O
Ala	O
)	O
were	O
generated	O
.	O

Based	O
on	O
the	O
Scatchard	O
analysis	O
of	O
radioligand	O
binding	O
studies	O
,	O
the	O
following	O
amino	O
acids	O
were	O
deemed	O
critical	O
for	O
ligand	O
binding	O
:	O
(	O
i	O
)	O
Asp9	O
,	O
Glu12	O
,	O
Lys108	O
,	O
and	O
Lys120	O
for	O
IL-8	B
and	O
(	O
ii	O
)	O
Glu7	O
,	O
Asp9	O
,	O
and	O
Glu12	O
for	O
GROalpha	B
.	O

Point	O
mutations	O
in	O
the	O
amino	O
terminus	O
domain	O
(	O
Asp9	O
and	O
Glu12	O
)	O
and	O
the	O
first	O
extracellular	O
loop	O
(	O
Lys108	O
,	O
Asn110	O
,	O
and	O
Lys120	O
)	O
of	O
CXCR2	B
reduced	O
cell	O
activation	O
to	O
all	O
three	O
ligands	O
as	O
measured	O
by	O
changes	O
in	O
intracellular	O
calcium	O
concentration	O
.	O

In	O
conclusion	O
,	O
high	O
-	O
affinity	O
binding	O
of	O
IL-8	B
,	O
NAP-2	B
,	O
and	O
GROalpha	B
to	O
CXCR2	B
involves	O
interaction	O
with	O
specific	O
and	O
different	O
amino	O
acid	O
residues	O
of	O
CXCR2	B
.	O

Furthermore	O
,	O
we	O
propose	O
that	O
the	O
CXCR2	B
amino	O
acid	O
residues	O
required	O
for	O
cell	O
activation	O
are	O
not	O
necessarily	O
the	O
same	O
residues	O
required	O
for	O
ligand	O
binding	O
.	O

Cytokines	B
and	O
osteolysis	O
around	O
total	O
hip	O
prostheses	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
assess	O
the	O
correlation	O
between	O
the	O
osteolysis	O
around	O
the	O
prosthesis	O
and	O
the	O
presence	O
of	O
cytokines	B
favouring	O
inflammation	O
in	O
the	O
tissues	O
at	O
the	O
interface	O
between	O
loosened	O
prosthesis	O
and	O
bone	O
.	O

In	O
this	O
study	O
,	O
twenty	O
-	O
nine	O
patients	O
that	O
underwent	O
revision	O
surgery	O
were	O
examined	O
.	O

Bioptic	O
samples	O
were	O
collected	O
at	O
the	O
interface	O
between	O
bone	O
and	O
implant	O
both	O
at	O
the	O
stem	O
and	O
socket	O
level	O
.	O

Semiquantitative	O
immunohistochemistry	O
was	O
performed	O
to	O
detect	O
interleukin	B
1	I
alpha	I
,	O
interleukin	B
1	I
beta	I
,	O
interleukin	B
6	I
and	O
tumour	B
necrosis	I
factor	I
,	O
cytokines	B
that	O
directly	O
cause	O
bone	O
resorption	O
and	O
indirectly	O
induce	O
synthesis	O
of	O
other	O
bone	O
resorbing	O
cytokines	B
.	O

Wear	O
particles	O
were	O
identified	O
and	O
quantified	O
by	O
light	O
microscopy	O
.	O

Radiographic	O
evidence	O
for	O
osteolysis	O
was	O
scored	O
by	O
the	O
Engh	O
and	O
Bobyn	O
score	O
.	O

In	O
tissues	O
collected	O
at	O
the	O
interface	O
,	O
the	O
percentage	O
of	O
cells	O
positive	O
to	O
IL1	B
,	O
IL6	B
and	O
particularly	O
to	O
TNF	B
increased	O
in	O
relation	O
to	O
the	O
tissues	O
collected	O
at	O
the	O
interface	O
with	O
stable	O
components	O
.	O

The	O
cells	O
occurring	O
in	O
the	O
new	O
capsule	O
do	O
not	O
secrete	O
cytokines	B
in	O
quantities	O
that	O
can	O
be	O
related	O
to	O
severity	O
of	O
wear	O
.	O

Cemented	O
prostheses	O
showed	O
higher	O
incidence	O
of	O
severe	O
osteolysis	O
,	O
and	O
higher	O
levels	O
of	O
cytokines	B
.	O

It	O
can	O
be	O
concluded	O
that	O
TNF	B
,	O
and	O
to	O
a	O
lesser	O
extent	O
IL1	B
and	O
IL6	B
,	O
are	O
positively	O
related	O
to	O
the	O
severity	O
of	O
osteolysis	O
around	O
the	O
prosthesis	O
and	O
therefore	O
a	O
pharmacological	O
treatment	O
can	O
be	O
hypothesized	O
with	O
anti	O
-	O
inflammatory	O
or	O
anti	O
-	O
cytokine	B
drugs	O
in	O
order	O
to	O
limit	O
or	O
to	O
avoid	O
prosthesis	O
loosening	O
.	O

Peroxisomal	O
degradation	O
of	O
trans	O
-	O
unsaturated	O
fatty	O
acids	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Degradation	O
of	O
trans	O
-	O
unsaturated	O
fatty	O
acids	O
was	O
studied	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Propagation	O
of	O
yeast	O
cells	O
on	O
trans-9	O
elaidic	O
acid	O
medium	O
resulted	O
in	O
transcriptional	O
up	O
-	O
regulation	O
of	O
the	O
SPS19	B
gene	O
,	O
whose	O
promoter	O
contains	O
an	O
oleate	O
response	O
element	O
.	O

This	O
up	O
-	O
regulation	O
depended	O
on	O
the	O
Pip2p	B
-	O
Oaf1p	B
transcription	B
factor	I
and	O
was	O
accompanied	O
by	O
induction	O
of	O
import	O
-	O
competent	O
peroxisomes	O
.	O

Utilization	O
of	O
trans	O
fatty	O
acids	O
as	O
a	O
single	O
carbon	O
and	O
energy	O
source	O
was	O
evaluated	O
by	O
monitoring	O
the	O
formation	O
of	O
clear	O
zones	O
around	O
cell	O
growth	O
on	O
turbid	O
media	O
containing	O
fatty	O
acids	O
dispersed	O
with	O
Tween	O
80	O
.	O

For	O
metabolizing	O
odd	O
-	O
numbered	O
trans	O
double	O
bonds	O
,	O
cells	O
required	O
the	O
beta	O
-	O
oxidation	O
auxiliary	O
enzyme	O
Delta	B
(	I
3	I
)	I
-	I
Delta	I
(	I
2	I
)	I
-	I
enoyl	I
-	I
CoA	I
isomerase	I
Eci1p	B
.	O

Metabolism	O
of	O
the	O
corresponding	O
even	O
-	O
numbered	O
double	O
bonds	O
proceeded	O
in	O
the	O
absence	O
of	O
Sps19p	B
(	O
2,4-dienoyl	B
-	I
CoA	I
reductase	I
)	O
and	O
Dci1p	B
(	O
Delta	B
(	I
3,5	I
)	I
-Delta	I
(	I
2,4	I
)	I
-dienoyl	I
-	I
CoA	I
isomerase	I
)	O
.	O

trans-2,trans-4-Dienoyl	O
-	O
CoAs	O
could	O
enter	O
beta	O
-	O
oxidation	O
directly	O
via	O
Fox2p	B
(	O
2-enoyl	B
-	I
CoA	I
hydratase	I
2	I
and	O
d	O
-	O
specific	O
3-hydroxyacyl	B
-	I
CoA	I
dehydrogenase	I
)	O
without	O
the	O
involvement	O
of	O
Sps19p	B
,	O
whereas	O
trans-2,cis-4-dienoyl	O
-	O
CoAs	O
could	O
not	O
.	O

This	O
reductase	B
-	O
independent	O
metabolism	O
of	O
trans-2,trans-4-dienoyl	O
-	O
CoAs	O
resembled	O
the	O
situation	O
postulated	O
for	O
mammalian	O
mitochondria	O
in	O
which	O
oleic	O
acid	O
is	O
degraded	O
through	O
a	O
di	O
-	O
isomerase	B
-	O
dependent	O
pathway	O
.	O

In	O
this	O
hypothetical	O
process	O
,	O
trans-2	O
,	O
trans	O
-	O
4	O
-	O
dienoyl	O
-	O
CoA	O
metabolites	O
are	O
generated	O
by	O
Delta	B
(	I
3	I
)	I
-	I
Delta	I
(	I
2	I
)	I
-	I
enoyl	I
-	I
CoA	I
isomerase	I
and	O
Delta	B
(	I
3	I
,	I
5	I
)	I
-	I
Delta	I
(	I
2	I
,	I
4	I
)	I
-	I
dienoyl	I
-	I
CoA	I
isomerase	I
and	O
are	O
degraded	O
by	O
2	B
-	I
enoyl	I
-	I
CoA	I
hydratase	I
1	I
in	O
the	O
absence	O
of	O
2	B
,	I
4	I
-	I
dienoyl	I
-	I
CoA	I
reductase	I
.	O

Growth	O
of	O
a	O
yeast	O
fox2sps19Delta	B
mutant	O
in	O
which	O
Fox2p	B
was	O
exchanged	O
with	O
rat	O
peroxisomal	B
multifunctional	I
enzyme	I
type	I
1	I
on	O
trans-9,trans-12	O
linolelaidic	O
acid	O
medium	O
gave	O
credence	O
to	O
this	O
theory	O
.	O

We	O
propose	O
an	O
amendment	O
to	O
the	O
current	O
scheme	O
of	O
the	O
carbon	O
flux	O
through	O
beta	O
-	O
oxidation	O
taking	O
into	O
account	O
the	O
dispensability	O
of	O
beta	O
-	O
oxidation	O
auxiliary	O
enzymes	O
for	O
metabolizing	O
trans	O
double	O
bonds	O
at	O
even	O
-	O
numbered	O
positions	O
.	O

Homogenous	O
expression	O
of	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
on	O
polyclonal	O
natural	O
killer	O
cells	O
detected	O
by	O
a	O
monoclonal	O
antibody	O
to	O
KIR2D	B
.	O

The	O
activity	O
of	O
human	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
is	O
in	O
part	O
regulated	O
by	O
the	O
expression	O
of	O
killer	B
cell	I
immunoglobulin	I
(	I
Ig	I
)	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
that	O
recognize	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
I	I
and	O
can	O
inhibit	O
NK	O
cell	O
cytotoxicity	O
.	O

A	O
monoclonal	O
anti	O
-	O
KIR	B
antibody	O
was	O
established	O
and	O
designated	O
Lig1	O
.	O

Lig1	O
was	O
shown	O
to	O
be	O
specific	O
for	O
KIR	B
in	O
cell	O
-	O
surface	O
staining	O
and	O
to	O
react	O
with	O
all	O
KIR2D	B
,	O
except	O
KIR2DL4	B
which	O
lacks	O
a	O
D1	O
domain	O
,	O
but	O
not	O
with	O
KIR3D	B
molecules	O
in	O
an	O
enzyme	O
-	O
linked	O
immunoadsorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
Western	O
blotting	O
.	O

Unlike	O
other	O
anti	O
-	O
KIR	B
antibodies	O
,	O
Lig1	O
did	O
not	O
inhibit	O
binding	O
of	O
KIR	B
-	O
Ig	B
-	O
fusion	O
proteins	O
to	O
MHC	B
-	I
class	I
I	I
expressing	O
cells	O
nor	O
did	O
it	O
interfere	O
with	O
KIR	B
-	O
mediated	O
inhibition	O
of	O
NK	O
cell	O
cytotoxicity	O
in	O
a	O
functional	O
assay	O
.	O

Lig1	O
reacted	O
with	O
all	O
NK	O
cells	O
in	O
polyclonal	O
NK	O
populations	O
from	O
different	O
donors	O
,	O
demonstrating	O
that	O
all	O
NK	O
cells	O
express	O
at	O
least	O
one	O
KIR2D	B
receptor	O
.	O

The	O
specificity	O
of	O
antibody	O
responses	O
in	O
cattle	O
naturally	O
exposed	O
to	O
Fasciola	O
hepatica	O
.	O

Fasciola	O
hepatica	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
in	O
dairy	O
cattle	O
in	O
the	O
Andean	O
region	O
of	O
Cajamarca	O
,	O
Peru	O
,	O
where	O
prevalence	O
of	O
infection	O
of	O
up	O
to	O
78	O
%	O
has	O
been	O
reported	O
.	O

ELISA	O
and	O
Western	O
blot	O
analyses	O
were	O
used	O
to	O
characterise	O
antibody	O
responses	O
in	O
dairy	O
cattle	O
to	O
adult	O
F.	O
hepatica	O
to	O
excretory	O
-	O
secretory	O
(	O
E	O
/	O
S	O
)	O
,	O
somatic	O
(	O
SO	O
)	O
and	O
surface	O
(	O
SU	O
)	O
antigens	O
.	O

Three	O
groups	O
of	O
dairy	O
cattle	O
-	O
calves	O
,	O
heifers	O
and	O
adult	O
cows	O
-	O
naturally	O
exposed	O
to	O
F.	O
hepatica	O
in	O
this	O
region	O
,	O
were	O
monitored	O
every	O
2	O
months	O
over	O
a	O
2	O
-	O
year	O
period	O
.	O

Calves	O
,	O
heifers	O
and	O
adult	O
cows	O
all	O
had	O
antibodies	O
which	O
recognised	O
a	O
28kDa	O
protein	O
in	O
the	O
SO	O
preparation	O
,	O
whereas	O
only	O
adult	O
cows	O
had	O
antibodies	O
that	O
recognised	O
a	O
28kDa	O
protein	O
in	O
E	O
/	O
S	O
products	O
.	O

All	O
three	O
groups	O
of	O
cattle	O
responded	O
to	O
a	O
60	O
-	O
66kDa	O
group	O
of	O
proteins	O
in	O
E	O
/	O
S	O
and	O
SU	O
preparations	O
and	O
a	O
17kDa	O
antigen	O
in	O
SO	O
products	O
was	O
recognised	O
by	O
antibodies	O
from	O
cows	O
and	O
heifers	O
but	O
not	O
calves	O
.	O

The	O
total	O
antibody	O
response	O
to	O
E	O
/	O
S	O
antigens	O
measured	O
by	O
ELISA	O
,	O
increased	O
over	O
time	O
in	O
calves	O
and	O
remained	O
constantly	O
high	O
over	O
the	O
2	O
-	O
year	O
period	O
in	O
all	O
three	O
groups	O
of	O
cattle	O
.	O

Slight	O
fluctuations	O
in	O
the	O
antibody	O
response	O
occurred	O
in	O
the	O
group	O
of	O
heifers	O
and	O
cows	O
coinciding	O
with	O
seasonal	O
changes	O
in	O
the	O
level	O
of	O
challenge	O
.	O

Antimicrobial	O
activity	O
of	O
MHC	B
class	I
I	I
-	O
restricted	O
CD8	B
+	O
T	O
cells	O
in	O
human	O
tuberculosis	O
.	O

Studies	O
of	O
mouse	O
models	O
of	O
tuberculosis	O
(	O
TB	O
)	O
infection	O
have	O
indicated	O
a	O
central	O
role	O
for	O
MHC	B
class	I
I	I
-	O
restricted	O
CD8	B
+	O
T	O
cells	O
in	O
protective	O
immunity	O
.	O

To	O
define	O
antigens	O
and	O
epitopes	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
MTB	O
)	O
proteins	O
that	O
are	O
presented	O
by	O
infected	O
cells	O
to	O
CD8	B
+	O
T	O
cells	O
,	O
we	O
screened	O
40	O
MTB	O
proteins	O
for	O
HLA	B
class	I
I	I
A*0201	I
-	O
binding	O
motifs	O
.	O

Peptides	O
that	O
bound	O
with	O
high	O
affinity	O
to	O
purified	O
HLA	B
molecules	O
were	O
subsequently	O
analyzed	O
for	O
recognition	O
by	O
CD8	B
+	O
cytotoxic	O
T	O
lymphocytes	O
.	O

We	O
identified	O
three	O
epitopes	O
recognized	O
by	O
CD8	B
+	O
T	O
cells	O
from	O
patients	O
recovering	O
from	O
TB	O
infection	O
.	O

Those	O
three	O
epitopes	O
were	O
derived	O
from	O
three	O
different	O
antigens	O
:	O
thymidylate	B
synthase	I
(	O
ThyA	B
(	O
30	O
-	O
38	O
)	O
)	O
,	O
RNA	B
polymerase	I
beta	I
-	O
subunit	O
(	O
RpoB	B
(	O
127	O
-	O
135	O
)	O
)	O
,	O
and	O
a	O
putative	O
phosphate	B
transport	I
system	I
permease	I
protein	I
A-1	I
(	O
PstA1	B
(	O
75	O
-	O
83	O
)	O
)	O
.	O

In	O
addition	O
,	O
CD8	B
+	O
T	O
cell	O
lines	O
specific	O
for	O
three	O
peptides	O
(	O
ThyA	B
(	O
30	O
-	O
38	O
)	O
,	O
PstA1	B
(	O
75	O
-	O
83	O
)	O
,	O
and	O
85B	B
(	O
15	O
-	O
23	O
)	O
)	O
were	O
generated	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
normal	O
HLA	B
-	I
A*0201	I
donors	O
.	O

These	O
CD8	B
+	O
T	O
cell	O
lines	O
specifically	O
recognized	O
MTB	O
-	O
infected	O
macrophages	O
,	O
as	O
demonstrated	O
by	O
production	O
of	O
IFN	B
-	I
gamma	I
and	O
lysis	O
of	O
the	O
infected	O
target	O
cells	O
.	O

Finally	O
,	O
CD8	B
+	O
cytotoxic	O
T	O
lymphocytes	O
reduced	O
the	O
viability	O
of	O
the	O
intracellular	O
MTB	O
,	O
providing	O
evidence	O
that	O
CD8	B
+	O
T	O
cell	O
recognition	O
of	O
MHC	B
class	I
I	I
-	O
restricted	O
epitopes	O
of	O
these	O
MTB	O
antigens	O
can	O
contribute	O
to	O
effective	O
immunity	O
against	O
the	O
pathogen	O
.	O

The	O
MAPK	B
kinase	I
kinase	I
TAK1	B
plays	O
a	O
central	O
role	O
in	O
coupling	O
the	O
interleukin-1	B
receptor	I
to	O
both	O
transcriptional	O
and	O
RNA	O
-	O
targeted	O
mechanisms	O
of	O
gene	O
regulation	O
.	O

Mechanisms	O
of	O
fulminant	O
gene	O
induction	O
during	O
an	O
inflammatory	O
response	O
were	O
investigated	O
using	O
expression	O
of	O
the	O
chemoattractant	O
cytokine	B
interleukin-8	B
(	O
IL-8	B
)	O
as	O
a	O
model	O
.	O

Recently	O
we	O
found	O
that	O
coordinate	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
protein	I
kinase	I
(	O
JNK	B
)	O
is	O
required	O
for	O
strong	O
IL-8	B
transcription	O
,	O
whereas	O
the	O
p38	B
MAP	I
kinase	I
(	O
MAPK	B
)	O
pathway	O
stabilizes	O
the	O
IL-8	B
mRNA	O
.	O

It	O
is	O
unclear	O
how	O
these	O
pathways	O
are	O
coupled	O
to	O
the	O
receptor	B
for	I
IL-1	I
,	O
an	O
important	O
physiological	O
inducer	O
of	O
IL-8	B
.	O

Expression	O
of	O
the	O
MAP	B
kinase	I
kinase	I
kinase	I
(	O
MAPKKK	B
)	O
TAK1	B
together	O
with	O
its	O
coactivator	O
TAB1	B
in	O
HeLa	O
cells	O
activated	O
all	O
three	O
pathways	O
and	O
was	O
sufficient	O
to	O
induce	O
IL-8	B
formation	O
,	O
NF	B
-	I
kappaB	I
+	O
JNK2	B
-	O
mediated	O
transcription	O
from	O
a	O
minimal	O
IL-8	B
promoter	O
,	O
and	O
p38	B
MAPK	I
-	O
mediated	O
stabilization	O
of	O
a	O
reporter	O
mRNA	O
containing	O
IL-8	B
-	O
derived	O
regulatory	O
mRNA	O
sequences	O
.	O

Expression	O
of	O
a	O
kinase	B
-	O
inactive	O
mutant	O
of	O
TAK1	B
largely	O
blocked	O
IL-1	B
-	O
induced	O
transcription	O
and	O
mRNA	O
stabilization	O
,	O
as	O
well	O
as	O
formation	O
of	O
endogenous	O
IL-8	B
.	O

Truncated	O
TAB1	B
,	O
lacking	O
the	O
TAK1	B
binding	O
domain	O
,	O
or	O
a	O
TAK1	B
-	O
derived	O
peptide	O
containing	O
a	O
TAK1	B
autoinhibitory	O
domain	O
were	O
also	O
efficient	O
in	O
inhibition	O
.	O

These	O
data	O
indicate	O
that	O
the	O
previously	O
described	O
three	O
-	O
pathway	O
model	O
of	O
IL-8	B
induction	O
is	O
operative	O
in	O
response	O
to	O
a	O
physiological	O
stimulus	O
,	O
IL-1	B
,	O
and	O
that	O
the	O
MAPKKK	B
TAK1	B
couples	O
the	O
IL-1	B
receptor	I
to	O
both	O
transcriptional	O
and	O
RNA	O
-	O
targeted	O
mechanisms	O
mediated	O
by	O
the	O
three	O
pathways	O
.	O

Expression	O
analysis	O
and	O
characterization	O
of	O
alternatively	O
spliced	O
transcripts	O
of	O
human	O
IL-7Ralpha	B
chain	O
encoding	O
two	O
truncated	O
receptor	O
proteins	O
in	O
relapsed	O
childhood	O
all	O
.	O

In	O
the	O
family	O
of	O
cytokines	B
and	O
cytokine	B
receptors	I
,	O
alternative	O
splicing	O
of	O
pre	O
-	O
mRNA	O
is	O
a	O
frequently	O
observed	O
process	O
that	O
generates	O
different	O
protein	O
isoforms	O
from	O
a	O
single	O
genetic	O
locus	O
.	O

The	O
splicing	O
-	O
derived	O
cytokine	B
receptor	I
protein	O
isoforms	O
are	O
mostly	O
soluble	O
receptors	O
or	O
show	O
alterations	O
in	O
their	O
cytoplasmic	O
domain	O
.	O

It	O
is	O
possible	O
that	O
receptor	O
abnormalities	O
or	O
a	O
pathological	O
ratio	O
of	O
different	O
isoforms	O
may	O
contribute	O
to	O
leukaemia	O
by	O
circumventing	O
normal	O
growth	B
factor	I
control	O
or	O
altering	O
the	O
balance	O
of	O
proliferation	O
and	O
differentiation	O
.	O

IL-7	B
plays	O
a	O
critical	O
role	O
in	O
early	O
stages	O
of	O
both	O
B	O
and	O
T	O
cell	O
maturation	O
.	O

Moreover	O
,	O
it	O
stimulates	O
the	O
expansion	O
of	O
mature	O
T	O
cells	O
including	O
anti	O
-	O
tumour	O
reactive	O
cells	O
as	O
well	O
as	O
a	O
number	O
of	O
T	O
and	O
B	O
cell	O
malignancies	O
underlining	O
its	O
potential	O
importance	O
for	O
deregulated	O
lymphoid	O
proliferation	O
and	O
leukaemogenesis	O
.	O

Here	O
,	O
we	O
present	O
detailed	O
data	O
on	O
the	O
expression	O
of	O
the	O
interleukin	B
7	I
receptor	I
alpha	I
chain	O
(	O
IL-7Ralpha	B
)	O
in	O
leukaemic	O
cells	O
from	O
210	O
children	O
with	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
ALL	O
)	O
and	O
describe	O
two	O
novel	O
alternatively	O
spliced	O
transcripts	O
of	O
human	O
IL-7Ralpha	B
coding	O
for	O
truncated	O
receptor	O
proteins	O
which	O
are	O
still	O
capable	O
of	O
binding	O
IL-7	B
.	O

IL-7Ralpha	B
mRNA	O
expression	O
was	O
more	O
frequent	O
in	O
more	O
mature	O
pre	O
-	O
B	O
ALL	O
[	O
91	O
%	O
(	O
30	O
/	O
33	O
)	O
]	O
than	O
in	O
common	O
[	O
81	O
%	O
(	O
81	O
/	O
100	O
)	O
]	O
or	O
pro	O
-	O
B	O
ALL	O
[	O
64	O
%	O
(	O
18	O
/	O
28	O
)	O
]	O
,	O
or	O
even	O
in	O
T	O
ALL	O
[	O
64	O
%	O
(	O
29	O
/	O
45	O
)	O
]	O
.	O

These	O
results	O
are	O
in	O
concordance	O
with	O
flow	O
cytometric	O
analyses	O
on	O
the	O
proportion	O
of	O
IL-7Ralpha	B
bearing	O
cells	O
among	O
total	O
blast	O
cell	O
population	O
.	O

Our	O
results	O
lead	O
us	O
to	O
assume	O
that	O
splicing	O
derived	O
IL-7Ralpha	B
isoforms	O
play	O
a	O
potential	O
role	O
in	O
modulating	O
IL-7	B
signal	O
transduction	O
and	O
might	O
be	O
important	O
for	O
the	O
pathogenesis	O
of	O
leukaemia	O
.	O

Role	O
of	O
type	B
I	I
interferons	I
during	O
macrophage	O
activation	O
by	O
lipopolysaccharide	O
.	O

Activation	O
of	O
macrophages	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
accompanied	O
by	O
the	O
secretion	O
of	O
type	B
I	I
interferons	I
(	O
IFNs	B
)	O
which	O
can	O
act	O
in	O
an	O
autocrine	O
manner	O
.	O

We	O
examined	O
the	O
role	O
of	O
type	B
I	I
IFNs	I
in	O
macrophage	O
responses	O
to	O
LPS	O
using	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMM	O
)	O
from	O
IFNAR1	B
-	O
/	O
-	O
mice	O
,	O
which	O
lack	O
a	O
component	O
of	O
the	O
type	B
I	I
IFN	I
receptor	I
and	O
do	O
not	O
respond	O
to	O
type	B
I	I
IFNs	I
.	O

We	O
found	O
that	O
,	O
unlike	O
wild	O
-	O
type	O
(	O
WT	O
)	O
BMM	O
,	O
LPS	O
-	O
treated	O
IFNAR1	B
-	O
/	O
-	O
cells	O
failed	O
to	O
produce	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
or	O
express	O
inducible	B
NO	I
synthase	I
(	O
iNOS	B
)	O
,	O
indicating	O
that	O
type	B
I	I
IFNs	I
are	O
essential	O
for	O
all	O
LPS	O
-	O
stimulated	O
NO	O
production	O
in	O
BMM	O
.	O

Exogenously	O
added	O
type	B
II	I
IFN	I
(	O
IFNgamma	B
)	O
rescued	O
these	O
responses	O
in	O
LPS	O
-	O
treated	O
IFNAR1	B
-	O
/	O
-	O
BMM	O
.	O

In	O
contrast	O
to	O
effects	O
on	O
NO	O
,	O
type	B
I	I
IFNs	I
negatively	O
regulated	O
respiratory	O
burst	O
activity	O
in	O
LPS	O
-	O
primed	O
BMM	O
.	O

We	O
also	O
found	O
that	O
while	O
type	B
I	I
IFNs	I
mediated	O
the	O
anti	O
-	O
proliferative	O
effects	O
of	O
lower	O
concentrations	O
of	O
LPS	O
,	O
at	O
higher	O
concentrations	O
LPS	O
acted	O
in	O
a	O
type	B
I	I
IFNs	I
-	O
independent	O
manner	O
.	O

Finally	O
,	O
we	O
report	O
that	O
type	B
I	I
IFNs	I
are	O
a	O
survival	O
factor	O
for	O
BMM	O
.	O

Despite	O
this	O
,	O
the	O
ability	O
of	O
LPS	O
to	O
also	O
prevent	O
apoptosis	O
in	O
BMM	O
was	O
independent	O
of	O
type	B
I	I
IFNs	I
.	O

These	O
findings	O
highlight	O
the	O
diverse	O
roles	O
of	O
type	B
I	I
IFNs	I
in	O
mediating	O
LPS	O
-	O
stimulated	O
macrophage	O
responses	O
.	O

Endotoxin	O
and	O
cytokine	B
regulation	O
of	O
toll	B
-	I
like	I
receptor	I
(	I
TLR	I
)	I
2	I
and	O
TLR4	B
gene	O
expression	O
in	O
murine	O
liver	O
and	O
hepatocytes	O
.	O

Toll	B
-	I
like	I
receptor	I
(	I
TLR	I
)	I
2	I
and	O
TLR4	B
are	O
members	O
of	O
the	O
interleukin-1	B
receptor	I
(	I
IL-1R	I
)	I
family	I
and	O
transduce	O
similar	O
signals	O
as	O
IL-1R	B
in	O
response	O
to	O
bacteria	O
and	O
bacterial	O
components	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
their	O
gene	O
expression	O
in	O
murine	O
tissues	O
,	O
especially	O
in	O
the	O
liver	O
and	O
hepatocytes	O
.	O

When	O
mice	O
were	O
administered	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
TLR2	B
mRNA	O
was	O
upregulated	O
in	O
the	O
brain	O
,	O
heart	O
,	O
lung	O
,	O
liver	O
,	O
and	O
kidney	O
.	O

In	O
contrast	O
,	O
it	O
was	O
downregulated	O
in	O
the	O
spleen	O
.	O

TLR4	B
mRNA	O
was	O
decreased	O
in	O
the	O
brain	O
.	O

In	O
the	O
heart	O
and	O
lung	O
,	O
it	O
increased	O
,	O
and	O
it	O
was	O
not	O
affected	O
in	O
the	O
liver	O
,	O
kidney	O
,	O
and	O
spleen	O
.	O

TLR	B
mRNA	O
was	O
further	O
analyzed	O
in	O
the	O
liver	O
and	O
hepatocytes	O
.	O

Like	O
LPS	O
treatment	O
,	O
administration	O
of	O
IL-1	B
,	O
IL-6	B
,	O
or	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
upregulated	O
TLR2	B
mRNA	O
.	O

However	O
,	O
none	O
of	O
them	O
affected	O
the	O
TLR4	B
mRNA	O
level	O
.	O

In	O
primary	O
cultured	O
hepatocytes	O
,	O
TLR2	B
mRNA	O
was	O
upregulated	O
by	O
LPS	O
,	O
IL-1	B
,	O
or	O
TNF	B
but	O
not	O
by	O
IL-6	B
or	O
dexamethasone	O
.	O

None	O
of	O
them	O
affected	O
TLR4	B
mRNA	O
expression	O
.	O

Similar	O
responses	O
were	O
observed	O
in	O
the	O
murine	O
hepatoma	O
cell	O
line	O
Hepa	O
1	O
-	O
6	O
.	O

These	O
results	O
suggest	O
that	O
in	O
infection	O
with	O
gram	O
-	O
negative	O
bacteria	O
,	O
LPS	O
and	O
proinflammatory	O
cytokines	B
differentially	O
regulate	O
gene	O
expression	O
of	O
TLR2	B
and	O
TLR4	B
in	O
murine	O
hepatocytes	O
,	O
which	O
may	O
lead	O
to	O
pathologic	O
and	O
host	O
defense	O
reactions	O
in	O
the	O
liver	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
cDNA	O
and	O
a	O
gene	O
for	O
subtilisin	B
-	I
like	I
serine	I
proteases	I
from	O
rice	O
(	O
Oryza	O
sativa	O
L.	O
)	O
and	O
Arabidopsis	O
thaliana	O
.	O

The	O
complete	O
nucleotide	O
sequences	O
of	O
a	O
cDNA	O
(	O
RSP1	B
)	O
that	O
encodes	O
a	O
subtilisin	B
-	I
like	I
serine	I
protease	I
(	O
subtilase	B
)	O
of	O
rice	O
(	O
Oryza	O
sativa	O
L.	O
)	O
and	O
a	O
gene	O
(	O
ASP48	B
)	O
for	O
Arabidopsis	O
subtilase	B
were	O
analyzed	O
.	O

The	O
RSPI	B
cDNA	O
and	O
ASP48	B
DNA	O
encoded	O
736	O
-	O
and	O
757	O
-	O
residue	O
pre	O
-	O
pro	O
-	O
polypeptides	O
including	O
a	O
signal	O
peptide	O
with	O
molecular	O
masses	O
of	O
78,668	O
Da	O
and	O
79	O
,	O
414	O
Da	O
,	O
respectively	O
.	O

RSP1	B
is	O
the	O
first	O
known	O
serine	B
protease	I
in	O
rice	O
,	O
and	O
ASP48	B
is	O
a	O
gene	O
for	O
ara12	B
cDNA	O
.	O

Sequence	O
comparison	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
RSP1	B
is	O
distantly	O
related	O
to	O
all	O
other	O
plant	O
subtilases	B
and	O
ASP48	B
is	O
closely	O
related	O
to	O
a	O
tomato	O
subtilase	B
,	O
SBT1	B
.	O

The	O
ASP48	B
gene	O
was	O
found	O
to	O
lack	O
introns	O
.	O

The	O
Arabidopsis	O
subtilase	B
gene	O
appears	O
to	O
consist	O
of	O
a	O
small	O
gene	O
family	O
.	O

The	O
RSP1	B
was	O
found	O
to	O
be	O
expressed	O
in	O
seed	O
and	O
shoots	O
of	O
seedlings	O
while	O
ASP48	B
transcripts	O
was	O
found	O
to	O
be	O
accumulated	O
in	O
immature	O
silique	O
and	O
flowers	O
,	O
indicating	O
that	O
both	O
RSP1	B
and	O
ASP48	B
are	O
organ	O
-	O
specific	O
and	O
may	O
be	O
involved	O
in	O
the	O
specific	O
proteolytic	O
events	O
that	O
occur	O
during	O
organ	O
development	O
.	O

An	O
approach	O
to	O
the	O
removal	O
of	O
yeast	O
specific	O
O	O
-	O
linked	O
oligo	O
-	O
mannoses	O
from	O
human	O
midkine	B
expressed	O
in	O
Pichia	O
pastoris	O
using	O
site	O
-	O
specific	O
mutagenesis	O
.	O

Human	O
midkine	B
is	O
expressed	O
and	O
secreted	O
in	O
the	O
medium	O
under	O
the	O
control	O
of	O
an	O
AOX1	B
gene	O
promoter	O
in	O
Pichia	O
pastoris	O
using	O
its	O
own	O
secretion	O
signal	O
.	O

The	O
midkine	B
precursor	O
is	O
properly	O
processed	O
to	O
yield	O
the	O
correct	O
amino	O
-	O
terminus	O
of	O
mature	O
midkine	B
.	O

However	O
,	O
more	O
than	O
half	O
of	O
the	O
product	O
receives	O
yeast	O
specific	O
mannosylations	O
.	O

The	O
sites	O
for	O
the	O
mannosylations	O
were	O
determined	O
to	O
be	O
the	O
three	O
threonine	O
residues	O
in	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
human	O
midkine	B
.	O

In	O
order	O
to	O
obtain	O
non	O
-	O
mannosylated	O
midkine	B
,	O
alanine	O
residues	O
were	O
substituted	O
for	O
the	O
three	O
threonine	O
residues	O
by	O
site	O
specific	O
mutagenesis	O
.	O

HPLC	O
and	O
mass	O
spectrometry	O
confirmed	O
that	O
the	O
mutant	O
midkine	B
contained	O
almost	O
no	O
mannose	O
residues	O
.	O

Despite	O
the	O
amino	O
acid	O
substitutions	O
in	O
the	O
carboxy	O
-	O
terminal	O
region	O
,	O
mutant	O
human	O
midkine	B
,	O
promoted	O
CHO	O
cell	O
proliferation	O
as	O
well	O
as	O
normal	O
midkine	B
.	O

Interaction	O
of	O
CBF	B
alpha	I
/	O
AML	B
/	O
PEBP2	B
alpha	I
transcription	B
factors	I
with	O
nucleosomes	O
containing	O
promoter	O
sequences	O
requires	O
flexibility	O
in	O
the	O
translational	O
positioning	O
of	O
the	O
histone	B
octamer	O
and	O
exposure	O
of	O
the	O
CBF	B
alpha	I
site	O
.	O

Chromatin	O
remodeling	O
at	O
eukaryotic	O
gene	O
promoter	O
sequences	O
accompanies	O
transcriptional	O
activation	O
.	O

Both	O
molecular	O
events	O
rely	O
on	O
specific	O
protein	O
-	O
DNA	O
interactions	O
that	O
occur	O
within	O
these	O
promoter	O
sequences	O
.	O

Binding	O
of	O
CBFalpha	B
/	O
AML	B
/	O
PEBP2alpha	B
(	O
core	B
binding	I
factor	I
alpha	I
/	O
acute	B
myelogenous	I
leukemia	I
/	O
polyoma	B
enhancer	I
binding	I
protein	I
2alpha	I
)	O
proteins	O
is	O
a	O
key	O
event	O
in	O
both	O
tissue	O
-	O
specific	O
and	O
developmentally	O
regulated	O
osteocalcin	B
(	O
OC	B
)	O
promoter	O
activity	O
.	O

To	O
address	O
linkage	O
between	O
chromatin	O
organization	O
and	O
transcription	B
factor	I
binding	O
,	O
we	O
reconstituted	O
segments	O
of	O
the	O
rat	O
OC	B
gene	O
proximal	O
promoter	O
into	O
mononucleosomes	O
and	O
studied	O
binding	O
of	O
CBFalpha	B
proteins	O
.	O

We	O
analyzed	O
binding	O
of	O
bacterially	O
produced	O
Cbfalpha2Alpha	B
and	O
Cbfalpha2B	B
,	O
two	O
splice	O
variants	O
of	O
the	O
human	O
CBFalpha2	B
gene	O
,	O
and	O
determined	O
the	O
effect	O
of	O
heterodimerization	O
with	O
the	O
Cbfbeta	B
subunit	O
on	O
binding	O
activity	O
.	O

Our	O
results	O
indicate	O
that	O
binding	O
of	O
the	O
truncated	O
Cbfalpha2A	B
protein	O
to	O
naked	O
DNA	O
is	O
independent	O
of	O
Cbfbeta	B
whereas	O
Cbfalpha2A	B
binding	O
to	O
nucleosomal	O
DNA	O
was	O
enhanced	O
by	O
Cbfbeta	B
.	O

In	O
contrast	O
,	O
the	O
Cbfalpha2B	B
interaction	O
with	O
either	O
naked	O
or	O
nucleosomal	O
DNA	O
was	O
strongly	O
dependent	O
on	O
heterodimerization	O
with	O
the	O
Cbfbeta	B
subunit	O
.	O

Additionally	O
,	O
our	O
results	O
demonstrate	O
that	O
both	O
Cbfalpha2A	B
alone	O
and	O
Cbfalpha2B	B
complexed	O
with	O
Cbfbeta	B
can	O
interact	O
with	O
nucleosomal	O
DNA	O
only	O
if	O
there	O
is	O
a	O
degree	O
of	O
flexibility	O
in	O
the	O
positioning	O
of	O
the	O
histone	B
octamer	O
on	O
the	O
DNA	O
fragment	O
and	O
exposure	O
of	O
the	O
CBFalpha	B
site	O
.	O

This	O
situation	O
was	O
achieved	O
with	O
a	O
DNA	O
segment	O
of	O
182	O
bp	O
from	O
the	O
rat	O
OC	B
promoter	O
that	O
preferentially	O
positions	O
mononucleosomes	O
upstream	O
of	O
the	O
CBFalpha	B
binding	O
site	O
and	O
leaves	O
this	O
element	O
partially	O
exposed	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
nucleosomal	O
translational	O
positioning	O
is	O
a	O
major	O
determinant	O
of	O
the	O
binding	O
of	O
CBFalpha	B
factors	O
to	O
nucleosomal	O
DNA	O
.	O

Multiple	O
histidine	B
kinases	I
regulate	O
entry	O
into	O
stationary	O
phase	O
and	O
sporulation	O
in	O
Bacillus	O
subtilis	O
.	O

Protein	O
homology	O
studies	O
identified	O
five	O
kinases	B
potentially	O
capable	O
of	O
phosphorylating	O
the	O
Spo0F	B
response	O
regulator	O
and	O
initiating	O
sporulation	O
in	O
Bacillus	O
subtilis	O
.	O

Two	O
of	O
these	O
kinases	B
,	O
KinA	B
and	O
KinB	B
,	O
were	O
known	O
from	O
previous	O
studies	O
to	O
be	O
responsible	O
for	O
sporulation	O
in	O
laboratory	O
media	O
.	O

In	O
vivo	O
studies	O
of	O
the	O
activity	O
of	O
four	O
of	O
the	O
kinases	B
,	O
KinA	B
,	O
KinC	B
,	O
KinD	B
(	O
ykvD	B
)	O
and	O
KinE	B
(	O
ykrQ	B
)	O
,	O
using	O
abrB	B
transcription	O
as	O
an	O
indicator	O
of	O
Spo0A	B
approximately	O
P	O
level	O
,	O
revealed	O
that	O
KinC	B
and	O
KinD	B
were	O
responsible	O
for	O
Spo0A	B
approximately	O
P	O
production	O
during	O
the	O
exponential	O
phase	O
of	O
growth	O
in	O
the	O
absence	O
of	O
KinA	B
and	O
KinB	B
.	O

In	O
vitro	O
,	O
all	O
four	O
kinases	B
dephosphorylated	O
Spo0F	B
approximately	O
P	O
with	O
the	O
production	O
of	O
ATP	O
at	O
approximately	O
the	O
same	O
rate	O
,	O
indicating	O
that	O
they	O
possess	O
approximately	O
equal	O
affinity	O
for	O
Spo0F	B
.	O

All	O
the	O
kinases	B
were	O
expressed	O
during	O
growth	O
and	O
early	O
stationary	O
phase	O
,	O
suggesting	O
that	O
the	O
differential	O
activity	O
observed	O
in	O
growth	O
and	O
sporulation	O
results	O
from	O
differential	O
activation	O
by	O
signal	O
ligands	O
unique	O
to	O
each	O
kinase	B
.	O

Novel	O
G	B
proteins	I
,	O
Rag	B
C	I
and	O
Rag	B
D	I
,	O
interact	O
with	O
GTP	O
-	O
binding	O
proteins	O
,	O
Rag	B
A	I
and	O
Rag	B
B	I
.	O

Rag	B
A	I
/	O
Gtr1p	B
are	O
G	B
proteins	I
and	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
RCC1	B
-	O
Ran	B
pathway	O
.	O

We	O
employed	O
the	O
two	O
-	O
hybrid	O
method	O
using	O
Rag	B
A	I
as	O
the	O
bait	O
to	O
identify	O
proteins	O
binding	O
to	O
Rag	B
A	I
,	O
and	O
we	O
isolated	O
two	O
novel	O
human	O
G	B
proteins	I
,	O
Rag	B
C	I
and	O
Rag	B
D	I
.	O

Rag	B
C	I
demonstrates	O
homology	O
with	O
Rag	B
D	I
(	O
81.1	O
%	O
identity	O
)	O
and	O
with	O
Gtr2p	B
of	O
Saccharomyces	O
cerevisiae	O
(	O
46.1	O
%	O
identity	O
)	O
,	O
and	O
it	O
belongs	O
to	O
the	O
Rag	B
A	I
subfamily	I
of	O
the	O
Ras	B
family	I
.	O

Rag	B
C	I
and	O
Rag	B
D	I
contain	O
conserved	O
GTP	O
-	O
binding	O
motifs	O
(	O
PM-1	O
,	O
-	O
2	O
,	O
and	O
-3	O
)	O
in	O
their	O
N	O
-	O
terminal	O
regions	O
.	O

Recombinant	O
glutathione	B
S	I
-	I
transferase	I
fusion	O
protein	O
of	O
Rag	B
C	I
efficiently	O
bound	O
to	O
both	O
[	O
(	O
3	O
)	O
H	O
]	O
GTP	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
GDP	O
.	O

Rag	B
A	I
was	O
associated	O
with	O
both	O
Rag	B
C	I
and	O
Rag	B
D	I
in	O
their	O
C	O
-	O
terminal	O
regions	O
where	O
a	O
potential	O
leucine	O
zipper	O
motif	O
and	O
a	O
coiled	O
-	O
coil	O
structure	O
were	O
found	O
.	O

Rag	B
C	I
and	I
D	I
were	O
associated	O
with	O
both	O
the	O
GDP	O
and	O
GTP	O
forms	O
of	O
Rag	B
A	I
.	O

Both	O
Rag	B
C	I
and	O
Rag	B
D	I
changed	O
their	O
subcellular	O
localization	O
,	O
depending	O
on	O
the	O
nucleotide	O
-	O
bound	O
state	O
of	O
Rag	B
A	I
.	O

In	O
a	O
similar	O
way	O
,	O
the	O
disruption	O
of	O
S.	O
cerevisiae	O
GTR1	B
resulted	O
in	O
a	O
change	O
in	O
the	O
localization	O
of	O
Gtr2p	B
.	O

Mucin	B
gene	O
expression	O
in	O
Barrett	O
's	O
oesophagus	O
:	O
an	O
in	O
situ	O
hybridisation	O
and	O
immunohistochemical	O
study	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O

Mucin	B
genes	O
are	O
expressed	O
in	O
a	O
site	O
specific	O
manner	O
throughout	O
the	O
gastrointestinal	O
tract	O
.	O

Little	O
is	O
known	O
about	O
the	O
expression	O
pattern	O
in	O
the	O
oesophagus	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
MUC	B
gene	O
expression	O
in	O
both	O
the	O
normal	O
oesophagus	O
and	O
specialised	O
intestinal	O
metaplasia	O
(	O
Barrett	O
's	O
oesophagus	O
)	O
.	O

PATIENTS	O
:	O

Archived	O
paraffin	O
embedded	O
material	O
from	O
eight	O
specimens	O
of	O
normal	O
oesophagus	O
,	O
18	O
Barrett	O
'	O
s	O
oesophagus	O
,	O
eight	O
gastric	O
metaplasia	O
,	O
six	O
high	O
grade	O
dysplasia	O
,	O
and	O
six	O
cases	O
of	O
adenocarcinoma	O
were	O
examined	O
for	O
expression	O
of	O
the	O
mucin	B
genes	O
MUC1	B
-	I
6	I
.	O

METHODS	O
:	O

Mucin	B
mRNA	O
was	O
detected	O
by	O
in	O
situ	O
hybridisation	O
using	O
[	O
(	O
35	O
)	O
S	O
]	O
dATP	O
labelled	O
oligonucleotide	O
probes	O
.	O

Mucin	B
core	O
protein	O
was	O
detected	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O

Normal	O
oesophagus	O
expressed	O
MUC5B	B
in	O
the	O
submucosal	O
glands	O
and	O
MUC1	B
and	O
MUC4	B
in	O
the	O
stratified	O
squamous	O
epithelium	O
.	O

Barrett	O
's	O
oesophagus	O
strongly	O
expressed	O
MUC5AC	B
and	O
MUC3	B
in	O
the	O
superficial	O
columnar	O
epithelium	O
,	O
MUC2	B
in	O
the	O
goblet	O
cells	O
,	O
and	O
MUC6	B
in	O
the	O
glands	O
.	O

In	O
high	O
grade	O
dysplasia	O
and	O
adenocarcinoma	O
there	O
was	O
downregulation	O
of	O
MUC2	B
,	O
MUC3	B
,	O
MUC5AC	B
,	O
and	O
MUC6	B
,	O
but	O
upregulation	O
of	O
MUC1	B
and	O
MUC4	B
in	O
half	O
of	O
the	O
specimens	O
examined	O
.	O

CONCLUSIONS	O
:	O

Normal	O
oesophagus	O
and	O
Barrett	O
's	O
oesophagus	O
have	O
a	O
novel	O
pattern	O
of	O
mucin	B
gene	O
expression	O
.	O

Barrett	O
's	O
oesophagus	O
expressed	O
the	O
mucins	B
associated	O
with	O
normal	O
gastric	O
epithelium	O
and	O
normal	O
intestinal	O
epithelium	O
.	O

While	O
most	O
mucin	B
genes	O
were	O
downregulated	O
in	O
severely	O
dysplastic	O
and	O
neoplastic	O
tissues	O
,	O
there	O
was	O
upregulation	O
of	O
the	O
membrane	O
bound	O
mucins	B
MUC1	B
and	O
MUC4	B
.	O

This	O
may	O
prove	O
useful	O
in	O
detecting	O
early	O
signs	O
of	O
progression	O
to	O
adenocarcinoma	O
of	O
the	O
oesophagus	O
.	O

Crystal	O
structure	O
of	O
the	O
Escherichia	O
coli	O
peptide	O
methionine	B
sulphoxide	I
reductase	I
at	O
1.9	O
A	O
resolution	O
.	O

BACKGROUND	O
:	O

Peptide	O
methionine	B
sulphoxide	I
reductases	I
catalyze	O
the	O
reduction	O
of	O
oxidized	O
methionine	O
residues	O
in	O
proteins	O
.	O

They	O
are	O
implicated	O
in	O
the	O
defense	O
of	O
organisms	O
against	O
oxidative	O
stress	O
and	O
in	O
the	O
regulation	O
of	O
processes	O
involving	O
peptide	O
methionine	O
oxidation	O
/	O
reduction	O
.	O

These	O
enzymes	O
are	O
found	O
in	O
numerous	O
organisms	O
,	O
from	O
bacteria	O
to	O
mammals	O
and	O
plants	O
.	O

Their	O
primary	O
structure	O
shows	O
no	O
significant	O
similarity	O
to	O
any	O
other	O
known	O
protein	O
.	O

RESULTS	O
:	O

The	O
X	O
-	O
ray	O
structure	O
of	O
the	O
peptide	O
methionine	B
sulphoxide	I
reductase	I
from	O
Escherichia	O
coli	O
was	O
determined	O
at	O
3	O
A	O
resolution	O
by	O
the	O
multiple	O
wavelength	O
anomalous	O
dispersion	O
method	O
for	O
the	O
selenomethionine	O
-	O
substituted	O
enzyme	O
,	O
and	O
it	O
was	O
refined	O
to	O
1.9	O
A	O
resolution	O
for	O
the	O
native	O
enzyme	O
.	O

The	O
23	O
kDa	O
protein	O
is	O
folded	O
into	O
an	O
alpha	O
/	O
beta	O
roll	O
and	O
contains	O
a	O
large	O
proportion	O
of	O
coils	O
.	O

Among	O
the	O
three	O
cysteine	O
residues	O
involved	O
in	O
the	O
catalytic	O
mechanism	O
,	O
Cys-51	O
is	O
positioned	O
at	O
the	O
N	O
terminus	O
of	O
an	O
alpha	O
helix	O
,	O
in	O
a	O
solvent	O
-	O
exposed	O
area	O
composed	O
of	O
highly	O
conserved	O
amino	O
acids	O
.	O

The	O
two	O
others	O
,	O
Cys-198	O
and	O
Cys-206	O
,	O
are	O
located	O
in	O
the	O
C	O
-	O
terminal	O
coil	O
.	O

CONCLUSIONS	O
:	O

Sequence	O
alignments	O
show	O
that	O
the	O
overall	O
fold	O
of	O
the	O
peptide	O
methionine	B
sulphoxide	I
reductase	I
from	O
E.	O
coli	O
is	O
likely	O
to	O
be	O
conserved	O
in	O
many	O
species	O
.	O

The	O
characteristics	O
observed	O
in	O
the	O
Cys-51	O
environment	O
are	O
in	O
agreement	O
with	O
the	O
expected	O
accessibility	O
of	O
the	O
active	O
site	O
of	O
an	O
enzyme	O
that	O
reduces	O
methionine	O
sulphoxides	O
in	O
various	O
proteins	O
.	O

Cys-51	O
could	O
be	O
activated	O
by	O
the	O
influence	O
of	O
an	O
alpha	O
helix	O
dipole	O
.	O

The	O
involvement	O
of	O
the	O
two	O
other	O
cysteine	O
residues	O
in	O
the	O
catalytic	O
mechanism	O
requires	O
a	O
movement	O
of	O
the	O
C	O
-	O
terminal	O
coil	O
.	O

Several	O
conserved	O
amino	O
acids	O
and	O
water	O
molecules	O
are	O
discussed	O
as	O
potential	O
participants	O
in	O
the	O
reaction	O
.	O

The	O
role	O
of	O
CD40	B
ligand	I
and	O
tumor	B
necrosis	I
factor	I
alpha	I
signaling	O
in	O
the	O
transgenic	O
K	O
/	O
BxN	O
mouse	O
model	O
of	O
rheumatoid	O
arthritis	O
.	O

OBJECTIVE	O
:	O

Spontaneous	O
arthritis	O
in	O
the	O
KRN	O
transgenic	O
mouse	O
(	O
K	O
/	O
BxN	O
)	O
model	O
is	O
due	O
to	O
the	O
autoreactivity	O
of	O
the	O
transgenic	O
T	B
cell	I
receptor	I
and	O
subsequent	O
induction	O
of	O
autoantibodies	O
directed	O
against	O
glucose-6-phosphate	B
isomerase	I
(	O
G6PI	B
)	O
.	O

This	O
study	O
sought	O
to	O
analyze	O
the	O
potential	O
of	O
anti	O
-	O
CD40	B
ligand	I
(	O
anti	O
-	O
CD40L	B
)	O
and	O
anti	O
-	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
anti	O
-	O
TNFalpha	B
)	O
antibodies	O
in	O
preventing	O
and	O
treating	O
arthritis	O
in	O
this	O
murine	O
model	O
.	O

METHODS	O
:	O

Groups	O
of	O
K	O
/	O
BxN	O
mice	O
were	O
injected	O
with	O
anti	O
-	O
CD40L	B
and	O
anti	O
-	O
TNFalpha	B
antibodies	O
during	O
various	O
stages	O
of	O
arthritis	O
.	O

Disease	O
was	O
assessed	O
by	O
clinical	O
scoring	O
,	O
measurements	O
of	O
paw	O
swelling	O
,	O
and	O
histology	O
.	O

The	O
results	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
autoantibodies	O
in	O
the	O
serum	O
,	O
as	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O

Anti	O
-	O
CD40L	B
antibody	O
treatment	O
was	O
able	O
to	O
diminish	O
significantly	O
the	O
arthritis	O
development	O
in	O
K	O
/	O
BxN	O
mice	O
when	O
given	O
a	O
week	O
before	O
the	O
onset	O
of	O
clinically	O
apparent	O
disease	O
.	O

However	O
,	O
no	O
effect	O
on	O
disease	O
was	O
seen	O
when	O
the	O
antibodies	O
were	O
administered	O
after	O
clinical	O
onset	O
.	O

Surprisingly	O
,	O
neutralizing	O
anti	O
-	O
TNFalpha	B
antibodies	O
were	O
unable	O
to	O
prevent	O
arthritis	O
in	O
K	O
/	O
BxN	O
mice	O
.	O

The	O
success	O
of	O
antibody	O
treatment	O
in	O
preventing	O
disease	O
correlated	O
with	O
low	O
levels	O
of	O
anti	O
-	O
G6PI	B
antibodies	O
in	O
the	O
serum	O
.	O

CONCLUSION	O
:	O

These	O
results	O
suggest	O
that	O
anti	O
-	O
CD40L	B
treatment	O
can	O
prevent	O
arthritis	O
development	O
in	O
a	O
model	O
of	O
immunoglobulin	B
-	O
mediated	O
arthritis	O
,	O
but	O
anti	O
-	O
TNFalpha	B
treatment	O
can	O
not	O
.	O

The	O
unsuccessful	O
treatment	O
of	O
established	O
disease	O
was	O
possibly	O
due	O
to	O
the	O
continued	O
presence	O
of	O
autoreactive	O
antibodies	O
in	O
the	O
arthritic	O
mice	O
.	O

Functional	O
interaction	O
of	O
phytochrome	B
B	I
and	O
cryptochrome	B
2	I
.	O

Light	O
is	O
a	O
crucial	O
environmental	O
signal	O
that	O
controls	O
many	O
photomorphogenic	O
and	O
circadian	O
responses	O
in	O
plants	O
.	O

Perception	O
and	O
transduction	O
of	O
light	O
is	O
achieved	O
by	O
at	O
least	O
two	O
principal	O
groups	O
of	O
photoreceptors	B
,	O
phytochromes	B
and	O
cryptochromes	B
.	O

Phytochromes	B
are	O
red	O
/	O
far	O
-	O
red	O
light	O
-	O
absorbing	O
receptors	O
encoded	O
by	O
a	O
gene	O
family	O
of	O
five	O
members	O
(	O
phyA	B
to	I
phyE	I
)	O
in	O
Arabidopsis	O
.	O

Cryptochrome	B
1	I
(	O
cry1	B
)	O
,	O
cryptochrome	B
2	I
(	O
cry2	B
)	O
and	O
phototropin	B
are	O
the	O
blue	B
/	I
ultraviolet	I
-	I
A	I
light	I
receptors	I
that	O
have	O
been	O
characterized	O
in	O
Arabidopsis	O
.	O

Previous	O
studies	O
showed	O
that	O
modulation	O
of	O
many	O
physiological	O
responses	O
in	O
plants	O
is	O
achieved	O
by	O
genetic	O
interactions	O
between	O
different	O
photoreceptors	B
;	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
nature	O
of	O
these	O
interactions	O
and	O
their	O
roles	O
in	O
the	O
signal	O
transduction	O
pathway	O
.	O

Here	O
we	O
show	O
the	O
genetic	O
interaction	O
that	O
occurs	O
between	O
the	O
Arabidopsis	O
photoreceptors	B
phyB	B
and	O
cry2	B
in	O
the	O
control	O
of	O
flowering	O
time	O
,	O
hypocotyl	O
elongation	O
and	O
circadian	O
period	O
by	O
the	O
clock	O
.	O

PhyB	B
interacts	O
directly	O
with	O
cry2	B
as	O
observed	O
in	O
co	O
-	O
immunoprecipitation	O
experiments	O
with	O
transgenic	O
Arabidopsis	O
plants	O
overexpressing	O
cry2	B
.	O

Using	O
fluorescent	O
resonance	O
energy	O
transfer	O
microscopy	O
,	O
we	O
show	O
that	O
phyB	B
and	O
cry2	B
interact	O
in	O
nuclear	O
speckles	O
that	O
are	O
formed	O
in	O
a	O
light	O
-	O
dependent	O
fashion	O
.	O

Development	O
of	O
a	O
PCR	O
-	O
SSOP	O
approach	O
capable	O
of	O
defining	O
the	O
natural	O
killer	O
cell	O
inhibitory	O
receptor	O
(	O
KIR	B
)	O
gene	O
sequence	O
repertoires	O
.	O

A	O
molecular	O
typing	O
method	O
based	O
on	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
three	O
different	O
target	O
domains	O
(	O
immunoglobulin	B
domains	O
1	O
and	O
3	O
,	O
and	O
the	O
transmembrane	O
-	O
cytoplasmic	O
domain	O
)	O
,	O
followed	O
by	O
hybridisation	O
with	O
26	O
digoxigenin	O
-	O
labelled	O
sequence	O
-	O
specific	O
oligonucleotide	O
probes	O
(	O
SSOP	O
)	O
has	O
been	O
established	O
for	O
the	O
polymorphic	O
killer	O
inhibitory	O
receptor	O
(	O
KIR	B
)	O
genes	O
.	O

In	O
addition	O
to	O
identifying	O
the	O
12	O
KIR	B
subfamilies	I
,	O
our	O
PCR	O
-	O
SSOP	O
typing	O
approach	O
could	O
also	O
distinguish	O
the	O
putative	O
alleles	O
,	O
NKB1	B
and	O
NKAT3	B
,	O
that	O
comprise	O
the	O
KIR3DL1	B
subfamily	I
.	O

Ninety	O
unrelated	O
blood	O
donors	O
and	O
13	O
families	O
(	O
52	O
individuals	O
)	O
,	O
including	O
both	O
parents	O
,	O
were	O
subjected	O
to	O
our	O
KIR	B
PCR	O
-	O
SSOP	O
typing	O
approach	O
.	O

All	O
12	O
KIR	B
subfamilies	I
,	O
including	O
a	O
2DS5	B
variant	O
sequence	O
,	O
were	O
present	O
in	O
the	O
90	O
individuals	O
and	O
displayed	O
varied	O
phenotype	O
frequencies	O
:	O
2DL1	B
(	O
0.96	O
)	O
,	O
2DL2	B
(	O
0.31	O
)	O
,	O
2DL3	B
(	O
0.95	O
)	O
,	O
2DS1	B
(	O
0.56	O
)	O
2DS2	B
(	O
0.51	O
)	O
,	O
2DS3	B
(	O
0.27	O
)	O
,	O
2DS4	B
(	O
0.96	O
)	O
,	O
2DS5v	B
(	O
0.35	O
)	O
,	O
3DS1	B
(	O
0.47	O
)	O
,	O
3DL1	B
(	O
0.96	O
)	O
,	O
3DL2	B
(	O
1.0	O
)	O
and	O
2DL4	B
(	O
1.0	O
)	O
.	O

A	O
total	O
of	O
23	O
different	O
KIR	B
phenotypes	O
were	O
defined	O
in	O
this	O
study	O
,	O
and	O
10	O
of	O
these	O
were	O
only	O
found	O
on	O
one	O
occasion	O
in	O
one	O
individual	O
,	O
indicating	O
considerable	O
diversity	O
in	O
the	O
KIR	B
phenotype	O
profiles	O
within	O
the	O
Irish	O
population	O
.	O

Most	O
individuals	O
(	O
93	O
%	O
)	O
possessed	O
the	O
complement	O
of	O
inhibitory	O
KIR	B
specificities	O
for	O
the	O
three	O
well	O
-	O
defined	O
HLA	B
-	I
B	I
and	I
-	I
C	I
ligands	O
.	O

An	O
unusual	O
probe	O
pattern	O
for	O
3DS1	B
was	O
observed	O
in	O
3	O
individuals	O
indicating	O
a	O
variant	O
3DS1	B
gene	O
sequence	O
with	O
changes	O
at	O
nucleotide	O
positions	O
1185	O
-	O
1186	O
,	O
within	O
the	O
cytoplasmic	O
domain	O
.	O

Sequencing	O
analysis	O
revealed	O
a	O
new	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
3	O
of	O
3DL1	B
NKB1	B
(	O
195	O
,	O
G	O
-	O
A	O
)	O
and	O
a	O
22	O
-	O
bp	O
deletion	O
polymorphism	O
in	O
exon	O
5	O
of	O
2DS4	B
(	O
nucleotides	O
777	O
-	O
798	O
deleted	O
)	O
.	O

A	O
number	O
of	O
strong	O
KIR	B
associations	O
were	O
observed	O
,	O
namely	O
2DL1	B
with	O
2DL3	B
,	O
2DS4	B
with	O
3DL1	B
,	O
2DL2	B
with	O
2DS1	B
/	O
2DS2	B
/	O
2DS3	B
,	O
2DS1	B
with	O
2DS3	B
/	O
2DS5v	B
/	O
3DS1	B
,	O
2DS2	B
with	O
2DS3	B
and	O
2DS5v	B
with	O
3DS1	B
.	O

Analysis	O
of	O
the	O
KIR	B
segregation	O
observed	O
in	O
the	O
13	O
families	O
confirmed	O
these	O
strong	O
associations	O
and	O
permitted	O
the	O
definition	O
of	O
a	O
number	O
of	O
partial	O
KIR	B
haplotypes	O
,	O
e.g.	O
2DL2	B
-	O
2DS1	B
-	O
2DS2	B
-	O
2DS3	B
-	O
3DL1	B
.	O

The	O
segregation	O
analysis	O
concluded	O
that	O
at	O
least	O
3	O
distinct	O
gene	O
loci	O
encode	O
2DL1	B
-	I
4	I
and	O
at	O
least	O
4	O
gene	O
loci	O
encode	O
the	O
non	O
-	O
inhibitory	O
KIR2DS1	B
-	I
2DS5	I
.	O

In	O
the	O
case	O
of	O
3DL1	B
-	I
2	I
and	O
3DS1	B
,	O
our	O
data	O
suggests	O
3	O
gene	O
loci	O
,	O
one	O
for	O
each	O
subfamily	O
.	O

YeiL	B
,	O
the	O
third	O
member	O
of	O
the	O
CRP	B
-	I
FNR	I
family	I
in	O
Escherichia	O
coli	O
.	O

The	O
yeiL	B
open	O
reading	O
frame	O
located	O
at	O
48.5	O
min	O
(	O
2254	O
kb	O
)	O
in	O
the	O
nfo	B
-	O
fruA	B
region	O
of	O
the	O
Escherichia	O
coli	O
chromosome	O
was	O
predicted	O
to	O
encode	O
a	O
CRP	B
and	O
FNR	B
paralogue	O
capable	O
of	O
forming	O
inter	O
-	O
or	O
intra	O
-	O
molecular	O
disulphide	O
bonds	O
and	O
incorporating	O
one	O
iron	O
-	O
sulphur	O
centre	O
per	O
25	O
kDa	O
subunit	O
.	O

Purified	O
MBP	B
-	O
YeiL	B
(	O
a	O
maltose	B
-	I
binding	I
-	I
protein	I
-	O
YeiL	B
fusion	O
protein	O
)	O
was	O
a	O
high	O
-	O
molecular	O
-	O
mass	O
oligomer	O
or	O
aggregate	O
which	O
released	O
unstable	O
monomers	O
(	O
68	O
kDa	O
)	O
under	O
reducing	O
conditions	O
.	O

The	O
MBP	B
-	O
YeiL	B
protein	O
contained	O
substoichiometric	O
amounts	O
of	O
iron	O
and	O
acid	O
-	O
labile	O
sulphide	O
,	O
and	O
an	O
average	O
of	O
one	O
disulphide	O
bond	O
per	O
monomer	O
.	O

The	O
iron	O
and	O
sulphide	O
contents	O
increased	O
consistent	O
with	O
the	O
acquisition	O
of	O
one	O
[	O
4Fe-4S	O
]	O
cluster	O
per	O
monomer	O
after	O
anaerobic	O
NifS	B
-	O
catalysed	O
reconstitution	O
.	O

By	O
analogy	O
with	O
FNR	B
and	O
FLP	B
(	O
the	O
FNR	B
-	O
like	O
protein	O
of	O
Lactobacillus	O
casei	O
)	O
it	O
was	O
suggested	O
that	O
the	O
transcription	O
-	O
regulatory	O
activity	O
of	O
YeiL	B
might	O
be	O
modulated	O
by	O
a	O
sensory	O
iron	O
-	O
sulphur	O
cluster	O
and/or	O
by	O
reversible	O
disulphide	O
bond	O
formation	O
.	O

A	O
yeiL	B
-	O
lacZ	B
transcriptional	O
fusion	O
showed	O
that	O
aerobic	O
yeiL	B
expression	O
increases	O
at	O
least	O
sixfold	O
during	O
stationary	O
phase	O
,	O
requires	O
RpoS	B
,	O
and	O
is	O
positively	O
autoregulated	O
by	O
YeiL	B
,	O
positively	O
activated	O
by	O
Lrp	B
(	O
and	O
IHF	B
in	O
the	O
absence	O
of	O
FNR	B
)	O
and	O
negatively	O
regulated	O
by	O
FNR	B
.	O

A	O
regulatory	O
link	O
between	O
the	O
synthesis	O
of	O
YeiK	B
(	O
a	O
potential	O
nucleoside	B
hydrolase	I
)	O
and	O
YeiL	B
was	O
inferred	O
by	O
showing	O
that	O
the	O
yeiK	B
and	O
yeiL	B
genes	O
are	O
divergently	O
transcribed	O
from	O
overlapping	O
promoters	O
.	O

A	O
10	O
-	O
15	O
%	O
deficiency	O
in	O
aerobic	O
growth	O
yield	O
and	O
an	O
enhanced	O
loss	O
of	O
viability	O
under	O
nitrogen	O
starvation	O
conditions	O
were	O
detected	O
with	O
a	O
yeiL	B
:	O
:	O
kan	O
(	O
R	O
)	O
mutant	O
,	O
suggesting	O
that	O
YeiL	B
might	O
function	O
as	O
a	O
post	O
-	O
exponential	O
-	O
phase	O
nitrogen	O
-	O
starvation	O
regulator	O
.	O

Identification	O
of	O
two	O
putative	O
novel	O
folate	B
receptor	I
genes	O
in	O
humans	O
and	O
mouse	O
.	O

Utilizing	O
a	O
'	O
database	O
mining	O
'	O
strategy	O
to	O
detect	O
novel	O
folate	B
receptors	I
(	O
FR	B
)	O
,	O
we	O
identified	O
two	O
potential	O
novel	O
members	O
in	O
the	O
mouse	O
and	O
human	O
.	O

The	O
mouse	O
gene	O
(	O
Folbp3	B
)	O
was	O
sequenced	O
and	O
found	O
to	O
predict	O
a	O
28.2	O
kDa	O
protein	O
that	O
consists	O
of	O
244	O
amino	O
acids	O
that	O
is	O
highly	O
expressed	O
in	O
both	O
the	O
thymus	O
and	O
spleen	O
,	O
suggesting	O
a	O
potential	O
role	O
in	O
the	O
immune	O
system	O
.	O

The	O
human	O
gene	O
(	O
FR	B
-	I
delta	I
)	O
is	O
mapped	O
to	O
chromosome	O
11q14	O
,	O
and	O
predicts	O
a	O
27.7	O
kDa	O
protein	O
that	O
is	O
comprised	O
of	O
241	O
amino	O
acids	O
.	O

However	O
,	O
expression	O
of	O
the	O
human	O
gene	O
was	O
not	O
detected	O
in	O
59	O
samples	O
from	O
both	O
adult	O
and	O
embryonic	O
tissue	O
sources	O
,	O
suggesting	O
a	O
highly	O
restricted	O
spatial	O
/	O
temporal	O
expression	O
pattern	O
,	O
an	O
alternatively	O
spliced	O
variant	O
or	O
an	O
additional	O
FR	B
pseudogene	I
.	O

Using	O
T31	O
mouse	O
radiation	O
hybrid	O
mapping	O
,	O
Folbp3	B
was	O
mapped	O
to	O
a	O
region	O
on	O
mouse	O
chromosome	O
9	O
that	O
is	O
syntenic	O
to	O
human	O
chromosome	O
19p13	O
.	O

As	O
the	O
chromosomal	O
locations	O
of	O
Folbp1	B
murine	O
and	O
Folbp2	B
genes	O
were	O
previously	O
unknown	O
,	O
we	O
utilized	O
the	O
same	O
approach	O
and	O
mapped	O
both	O
genes	O
to	O
a	O
region	O
of	O
mouse	O
chromosome	O
7	O
that	O
is	O
syntenic	O
to	O
the	O
human	O
FR	B
loci	O
on	O
chromosome	O
11q13	O
.	O

Transcriptional	O
regulation	O
of	O
transport	O
and	O
utilization	O
systems	O
for	O
hexuronides	O
,	O
hexuronates	O
and	O
hexonates	O
in	O
gamma	O
purple	O
bacteria	O
.	O

The	O
comparative	O
approach	O
is	O
a	O
powerful	O
tool	O
for	O
the	O
analysis	O
of	O
gene	O
regulation	O
in	O
bacterial	O
genomes	O
.	O

It	O
can	O
be	O
applied	O
to	O
the	O
analysis	O
of	O
regulons	O
that	O
have	O
been	O
studied	O
experimentally	O
as	O
well	O
as	O
that	O
of	O
regulons	O
for	O
which	O
no	O
known	O
regulatory	O
sites	O
are	O
available	O
.	O

It	O
is	O
assumed	O
that	O
the	O
set	O
of	O
co	O
-	O
regulated	O
genes	O
and	O
the	O
regulatory	O
signal	O
itself	O
are	O
conserved	O
in	O
related	O
genomes	O
.	O

Here	O
,	O
we	O
use	O
genomic	O
comparisons	O
to	O
study	O
the	O
regulation	O
of	O
transport	O
and	O
utilization	O
systems	O
for	O
sugar	O
acids	O
in	O
gamma	O
purple	O
bacteria	O
Escherichia	O
coli	O
,	O
Salmonella	O
typhi	O
,	O
Klebsiella	O
pneumoniae	O
,	O
Yersinia	O
pestis	O
,	O
Erwinia	O
chrysanthemi	O
,	O
Haemophilus	O
influenzae	O
and	O
Vibrio	O
cholerae	O
.	O

The	O
variability	O
of	O
the	O
operon	O
structure	O
and	O
the	O
location	O
of	O
the	O
operator	O
sites	O
for	O
the	O
main	O
transcription	B
factors	I
are	O
demonstrated	O
.	O

The	O
common	O
metabolic	O
map	O
is	O
combined	O
with	O
known	O
and	O
predicted	O
regulatory	O
interactions	O
.	O

It	O
includes	O
all	O
known	O
and	O
predicted	O
members	O
of	O
the	O
GntR	B
,	O
UxuR	B
/	O
ExuR	B
,	O
KdgR	B
,	O
UidR	B
and	O
IdnR	B
regulons	O
.	O

Moreover	O
,	O
most	O
members	O
of	O
these	O
regulons	O
seem	O
to	O
be	O
under	O
catabolite	O
repression	O
mediated	O
by	O
CRP	B
.	O

The	O
candidate	O
UxuR	B
/	O
ExuR	B
signal	O
is	O
proposed	O
,	O
the	O
KdgR	B
consensus	O
is	O
extended	O
,	O
and	O
new	O
operators	O
for	O
all	O
transcription	B
factors	I
are	O
identified	O
in	O
all	O
studied	O
genomes	O
.	O

Two	O
new	O
members	O
of	O
the	O
KdgR	B
regulon	O
,	O
a	O
hypothetical	O
ATP	O
-	O
dependent	O
transport	O
system	O
OgtABCD	B
and	O
YjgK	B
protein	O
with	O
unknown	O
function	O
,	O
are	O
detected	O
.	O

The	O
former	O
is	O
likely	O
to	O
be	O
the	O
transport	O
system	O
for	O
the	O
products	O
of	O
pectin	O
degradation	O
,	O
oligogalacturonides	O
.	O

Effects	O
of	O
a	O
thyromimetic	O
on	O
apolipoprotein	B
B-100	I
in	O
rats	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
a	O
cardiac	O
sparing	O
thyromimetic	O
,	O
CGS	O
23425	O
,	O
on	O
postprandial	O
levels	O
of	O
triglycerides	O
,	O
abundance	O
of	O
apolipoprotein	B
B	I
(	O
apo	B
B	I
)	O
protein	O
and	O
hepatic	O
apo	B
B	I
mRNA	O
expression	O
in	O
rats	O
.	O

When	O
compared	O
with	O
control	O
rats	O
,	O
triglyceride	O
clearance	O
was	O
significantly	O
accelerated	O
by	O
treatment	O
with	O
CGS	O
23425	O
.	O

A	O
full	O
return	O
to	O
baseline	O
values	O
was	O
achieved	O
within	O
8	O
h	O
after	O
ingesting	O
a	O
large	O
quantity	O
of	O
fat	O
,	O
as	O
compared	O
to	O
>	O
24	O
h	O
in	O
control	O
animals	O
.	O

The	O
abundance	O
of	O
apo	B
B-100	I
protein	O
in	O
CGS	O
23425	O
-	O
treated	O
hyperlipidemic	O
rats	O
decreased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
but	O
levels	O
of	O
apo	B
B-48	I
were	O
not	O
significantly	O
affected	O
.	O

Like	O
L	O
-	O
tri	O
-	O
iodothyronine	O
(	O
L	O
-	O
T	O
(	O
3	O
)	O
)	O
,	O
treatment	O
with	O
30	O
microg	O
/	O
kg	O
CGS	O
23425	O
for	O
6	O
or	O
9	O
days	O
decreased	O
the	O
levels	O
of	O
apo	B
B-100	I
protein	O
by	O
80	O
%	O
and	O
40	O
%	O
respectively	O
.	O

This	O
change	O
was	O
paralleled	O
by	O
a	O
27	O
%	O
reduction	O
in	O
hepatic	O
apo	B
B-100	I
mRNA	O
.	O

To	O
investigate	O
a	O
potential	O
mechanism	O
of	O
CGS	O
23425	O
action	O
,	O
we	O
measured	O
in	O
vitro	O
apo	B
B	I
mRNA	O
editing	O
activity	O
in	O
hepatocellular	O
extract	O
from	O
control	O
or	O
CGS	O
23425	O
-	O
treated	O
rats	O
.	O

Treatment	O
with	O
CGS	O
23425	O
increased	O
activity	O
of	O
the	O
hepatic	O
apo	B
B-100	I
editosome	O
,	O
apobec-1	B
.	O

In	O
human	O
hepatoma	O
cells	O
which	O
lack	O
apobec-1	B
activity	O
,	O
apo	B
B-100	I
mRNA	O
levels	O
remained	O
the	O
same	O
in	O
cells	O
treated	O
with	O
or	O
without	O
the	O
agent	O
.	O

In	O
summary	O
,	O
these	O
observations	O
show	O
that	O
CGS	O
23425	O
decreases	O
the	O
levels	O
of	O
apo	B
B-100	I
in	O
rats	O
.	O

This	O
action	O
of	O
CGS	O
23425	O
involves	O
apo	B
B-100	I
mRNA	O
editing	O
activity	O
.	O

Antibodies	O
against	O
keratinocyte	O
antigens	O
other	O
than	O
desmogleins	B
1	I
and	I
3	I
can	O
induce	O
pemphigus	O
vulgaris	O
-	O
like	O
lesions	O
.	O

Pemphigus	O
is	O
an	O
autoimmune	O
disease	O
of	O
skin	O
adhesion	O
associated	O
with	O
autoantibodies	O
against	O
a	O
number	O
of	O
keratinocyte	O
antigens	O
,	O
such	O
as	O
the	O
adhesion	B
molecules	I
desmoglein	I
(	I
Dsg	I
)	I
1	I
and	I
3	I
and	O
acetylcholine	B
receptors	I
.	O

The	O
notion	O
that	O
anti	O
-	O
Dsg	B
antibodies	O
alone	O
are	O
responsible	O
for	O
blisters	O
in	O
patients	O
with	O
pemphigus	O
vulgaris	O
(	O
PV	O
)	O
stems	O
from	O
the	O
ability	O
of	O
rDsg1	B
and	O
rDsg3	B
to	O
absorb	O
antibodies	O
that	O
cause	O
PV	O
-	O
like	O
skin	O
blisters	O
in	O
neonatal	O
mice	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
PV	O
IgGs	B
eluted	O
from	O
rDsg1	B
-	O
Ig	B
-	O
His	O
and	O
rDsg3	B
-	O
Ig	B
-	O
His	O
show	O
similar	O
antigenic	O
profiles	O
,	O
including	O
the	O
38	O
-	O
,	O
43	O
-	O
,	O
115	O
-	O
,	O
and	O
190	O
-	O
kDa	O
keratinocyte	O
proteins	O
and	O
a	O
non	O
-	O
Dsg	B
3	I
130	O
-	O
kDa	O
polypeptide	O
present	O
in	O
keratinocytes	O
from	O
Dsg	B
3	I
knockout	O
mouse	O
.	O

We	O
injected	O
into	O
Dsg	B
3	I
-	O
lacking	O
mice	O
the	O
PV	O
IgGs	B
that	O
did	O
not	O
cross	O
-	O
react	O
with	O
the	O
160	O
-	O
kDa	O
Dsg	B
1	I
or	O
its	O
45	O
-	O
kDa	O
immunoreactive	O
fragment	O
and	O
that	O
showed	O
no	O
reactivity	O
with	O
recombinant	O
Dsg	B
1	I
.	O

We	O
used	O
both	O
the	O
Dsg3	B
(	O
null	O
)	O
mice	O
with	O
a	O
targeted	O
mutation	O
of	O
the	O
Dsg3	B
gene	O
and	O
the	O
""""	O
balding	O
""""	O
Dsg3	B
(	O
bal	O
)	O
/	O
Dsg3	B
(	O
bal	O
)	O
mice	O
that	O
carry	O
a	O
spontaneous	O
null	O
mutation	O
in	O
Dsg3	B
.	O

These	O
PV	O
IgGs	B
caused	O
gross	O
skin	O
blisters	O
with	O
PV	O
-	O
like	O
suprabasal	O
acantholysis	O
and	O
stained	O
perilesional	O
epidermis	O
in	O
a	O
fishnet	O
-	O
like	O
pattern	O
,	O
indicating	O
that	O
the	O
PV	O
phenotype	O
can	O
be	O
induced	O
without	O
anti	O
-	O
Dsg	B
3	I
antibody	O
.	O

The	O
anti	O
-	O
Dsg	B
1	I
antibody	O
also	O
was	O
not	O
required	O
,	O
as	O
its	O
presence	O
in	O
PV	O
IgG	B
does	O
not	O
alter	O
the	O
PV	O
-	O
like	O
phenotype	O
in	O
skin	O
organ	O
cultures	O
and	O
because	O
pemphigus	O
foliaceus	O
IgGs	B
produce	O
a	O
distinct	O
phenotype	O
in	O
Dsg3	B
(	O
null	O
)	O
mice	O
.	O

Therefore	O
,	O
mucocutaneous	O
lesions	O
in	O
PV	O
patients	O
could	O
be	O
caused	O
by	O
non	O
-	O
Dsg	B
antibodies	O
.	O

Loss	O
of	O
fibroblast	B
growth	I
factor	I
receptor	I
2	I
ligand	O
-	O
binding	O
specificity	O
in	O
Apert	O
syndrome	O
.	O

Craniosynostosis	O
syndromes	O
are	O
autosomal	O
dominant	O
human	O
skeletal	O
diseases	O
that	O
result	O
from	O
various	O
mutations	O
in	O
fibroblast	B
growth	I
factor	I
receptor	I
genes	O
(	O
Fgfrs	B
)	O
.	O

Apert	O
syndrome	O
(	O
AS	O
)	O
is	O
one	O
of	O
the	O
most	O
severe	O
craniosynostosis	O
syndromes	O
and	O
is	O
associated	O
with	O
severe	O
syndactyly	O
of	O
the	O
hands	O
and	O
feet	O
and	O
with	O
central	O
nervous	O
system	O
malformations	O
.	O

AS	O
is	O
caused	O
by	O
specific	O
missense	O
mutations	O
in	O
one	O
of	O
two	O
adjacent	O
amino	O
acid	O
residues	O
(	O
S252W	O
or	O
P253R	O
)	O
in	O
the	O
highly	O
conserved	O
region	O
linking	O
Ig	B
-	O
like	O
domains	O
II	O
and	O
III	O
of	O
FGFR2	B
.	O

Here	O
we	O
demonstrate	O
that	O
these	O
mutations	O
break	O
one	O
of	O
the	O
cardinal	O
rules	O
governing	O
ligand	O
specificity	O
of	O
FGFR2	B
.	O

We	O
show	O
that	O
the	O
S252W	O
mutation	O
allows	O
the	O
mesenchymal	O
splice	O
form	O
of	O
FGFR2	B
(	O
FGFR2c	B
)	O
to	O
bind	O
and	O
to	O
be	O
activated	O
by	O
the	O
mesenchymally	O
expressed	O
ligands	O
FGF7	B
or	O
FGF10	B
and	O
the	O
epithelial	O
splice	O
form	O
of	O
FGFR2	B
(	O
FGFR2b	B
)	O
to	O
be	O
activated	O
by	O
FGF2	B
,	O
FGF6	B
,	O
and	O
FGF9	B
.	O

These	O
data	O
demonstrate	O
loss	O
of	O
ligand	O
specificity	O
of	O
FGFR2	B
with	O
retained	O
ligand	O
dependence	O
for	O
receptor	O
activation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
severe	O
phenotypes	O
of	O
AS	O
likely	O
result	O
from	O
ectopic	O
ligand	O
-	O
dependent	O
activation	O
of	O
FGFR2	B
.	O

Development	O
-	O
related	O
increase	O
in	O
cortisol	O
biosynthesis	O
by	O
human	O
granulosa	O
cells	O
.	O

Antiinflammatory	O
mechanisms	O
are	O
important	O
in	O
ovulation	O
and	O
may	O
be	O
regulated	O
by	O
cortisol	O
(	O
F	O
)	O
.	O

We	O
previously	O
showed	O
that	O
after	O
administration	O
of	O
human	O
(	O
h	O
)	O
CG	B
for	O
ovulation	O
induction	O
,	O
luteinized	O
granulosa	O
cells	O
(	O
LGC	O
)	O
abundantly	O
express	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11betaHSD1	B
)	O
messenger	O
RNA	O
but	O
not	O
11betaHSD	B
type	I
2	I
(	O
11betaHSD2	B
)	O
messenger	O
RNA	O
.	O

11ssHSD1	B
is	O
responsible	O
for	O
the	O
reversible	O
formation	O
of	O
antiinflammatory	O
F	O
from	O
its	O
inactive	O
precursor	O
cortisone	O
(	O
E	O
)	O
,	O
whereas	O
11betaHSD2	B
unidirectionally	O
converts	O
F	O
to	O
E	O
through	O
11-oxidation	O
.	O

This	O
pattern	O
of	O
gene	O
expression	O
predicts	O
that	O
LGC	O
from	O
periovulatory	O
follicles	O
would	O
show	O
increased	O
activation	O
of	O
E	O
to	O
F	O
,	O
compared	O
with	O
granulosa	O
cells	O
from	O
immature	O
follicles	O
(	O
IGC	O
)	O
,	O
and	O
that	O
follicular	O
fluid	O
concentrations	O
of	O
E	O
and	O
F	O
would	O
alter	O
accordingly	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
isolated	O
IGC	O
,	O
thecal	O
cells	O
(	O
TC	O
)	O
,	O
and	O
follicular	O
fluid	O
,	O
from	O
ovaries	O
of	O
cyclic	O
women	O
,	O
removed	O
during	O
surgery	O
for	O
benign	O
gynecological	O
disease	O
.	O

LGC	O
and	O
follicular	O
fluid	O
were	O
aspirated	O
from	O
periovulatory	O
follicles	O
,	O
35	O
h	O
after	O
hCG	B
injection	O
,	O
in	O
patients	O
undergoing	O
in	O
vitro	O
fertilization	O
treatment	O
.	O

In	O
an	O
11betaHSD	B
assay	O
based	O
on	O
interconversion	O
of	O
tritiated	O
E	O
and	O
F	O
by	O
cell	O
suspensions	O
in	O
vitro	O
,	O
IGC	O
(	O
%	O
conversion	O
,	O
0.6	O
+	O
/-	O
0.4	O
,	O
mean	O
+	O
/-	O
SEM	O
)	O
and	O
collagenase	B
-	O
dispersed	O
TC	O
(	O
0.2	O
+	O
/-	O
0.1	O
%	O
)	O
were	O
unable	O
to	O
convert	O
E	O
to	O
F	O
,	O
whereas	O
LGC	O
(	O
36.3	O
+	O
/-	O
3.7	O
%	O
)	O
were	O
highly	O
efficient	O
at	O
this	O
reaction	O
.	O

Immature	O
granulosa	O
cells	O
,	O
LGC	O
,	O
and	O
(	O
to	O
a	O
lesser	O
extent	O
)	O
TC	O
were	O
all	O
able	O
to	O
convert	O
F	O
to	O
E	O
.	O

Correspondingly	O
,	O
follicular	O
fluid	O
concentrations	O
of	O
total	O
F	O
and	O
F	O
:	O
E	O
ratios	O
were	O
significantly	O
higher	O
in	O
periovulatory	O
follicles	O
,	O
compared	O
with	O
immature	O
follicles	O
.	O

Culturing	O
IGC	O
for	O
48	O
h	O
in	O
the	O
presence	O
of	O
hFSH	B
resulted	O
in	O
increased	O
11betaHSD1	B
reductase	I
activity	O
,	O
paralleling	O
stimulation	O
of	O
estrogen	O
(	O
aromatase	B
activity	O
)	O
and	O
progesterone	O
biosynthesis	O
.	O

Similar	O
treatment	O
with	O
hLH	B
did	O
not	O
influence	O
11betaHSD1	B
reductase	I
activity	O
,	O
except	O
in	O
a	O
patient	O
with	O
more	O
mature	O
IGC	O
,	O
which	O
also	O
showed	O
a	O
significant	O
increase	O
in	O
E	O
-	O
to	O
-	O
F	O
conversion	O
,	O
as	O
well	O
as	O
progesterone	O
synthesis	O
in	O
response	O
to	O
hLH	B
.	O

These	O
data	O
confirm	O
that	O
11betaHSD	B
activity	O
in	O
the	O
human	O
ovary	O
is	O
developmentally	O
regulated	O
and	O
gonadotropin	B
responsive	O
,	O
favoring	O
metabolism	O
of	O
F	O
to	O
E	O
in	O
immature	O
follicles	O
and	O
E	O
to	O
F	O
in	O
periovulatory	O
follicles	O
.	O

Increased	O
formation	O
of	O
F	O
by	O
LGC	O
in	O
periovulatory	O
follicles	O
is	O
consistent	O
with	O
an	O
antiinflammatory	O
function	O
for	O
this	O
glucocorticoid	O
at	O
ovulation	O
.	O

Cross	O
-	O
reconstitution	O
of	O
various	O
extrinsic	O
proteins	O
and	O
photosystem	B
II	I
complexes	I
from	O
cyanobacteria	O
,	O
red	O
algae	O
and	O
higher	O
plants	O
.	O

Photosystem	B
II	I
(	O
PSII	B
)	O
contains	O
different	O
extrinsic	O
proteins	O
required	O
for	O
oxygen	O
evolution	O
among	O
different	O
organisms	O
.	O

Cyanobacterial	O
PSII	B
contains	O
the	O
33	O
kDa	O
,	O
12	O
kDa	O
proteins	O
and	O
cytochrome	B
(	I
cyt	I
)	I
c-550	I
;	O
red	O
algal	O
PSII	B
contains	O
a	O
20	O
kDa	O
protein	O
in	O
addition	O
to	O
the	O
three	O
homologous	O
cyanobacterial	O
proteins	O
;	O
whereas	O
higher	O
plant	O
PSII	B
contains	O
the	O
33	O
kDa	O
,	O
23	O
kDa	O
and	O
17	O
kDa	O
proteins	O
.	O

In	O
order	O
to	O
understand	O
the	O
binding	O
and	O
functional	O
properties	O
of	O
these	O
proteins	O
,	O
we	O
performed	O
cross	O
-	O
reconstitution	O
experiments	O
with	O
combinations	O
of	O
PSII	B
and	O
extrinsic	O
proteins	O
from	O
three	O
different	O
sources	O
:	O
higher	O
plant	O
(	O
spinach	O
)	O
,	O
red	O
alga	O
(	O
Cyanidium	O
caldarium	O
)	O
and	O
cyanobacterium	O
(	O
Synechococcus	O
vulcanus	O
)	O
.	O

Among	O
all	O
of	O
the	O
extrinsic	O
proteins	O
,	O
the	O
33	O
kDa	O
protein	O
is	O
common	O
to	O
all	O
of	O
the	O
organisms	O
and	O
is	O
totally	O
exchangeable	O
in	O
binding	O
to	O
PSII	B
from	O
any	O
of	O
the	O
three	O
organisms	O
.	O

Oxygen	O
evolution	O
of	O
higher	O
plant	O
and	O
red	O
algal	O
PSII	B
was	O
restored	O
to	O
a	O
more	O
or	O
less	O
similar	O
level	O
by	O
binding	O
of	O
any	O
one	O
of	O
the	O
three	O
33	O
kDa	O
proteins	O
,	O
whereas	O
oxygen	O
evolution	O
of	O
cyanobacterial	O
PSII	B
was	O
restored	O
to	O
a	O
larger	O
extent	O
with	O
its	O
own	O
33	O
kDa	O
protein	O
than	O
with	O
the	O
33	O
kDa	O
protein	O
from	O
other	O
sources	O
.	O

In	O
addition	O
to	O
the	O
33	O
kDa	O
protein	O
,	O
the	O
red	O
algal	O
20	O
kDa	O
,	O
12	O
kDa	O
proteins	O
and	O
cyt	B
c-550	I
were	O
able	O
to	O
bind	O
to	O
cyanobacterial	O
and	O
higher	O
plant	O
PSII	B
,	O
leading	O
to	O
a	O
partial	O
restoration	O
of	O
oxygen	O
evolution	O
in	O
both	O
organisms	O
.	O

The	O
cyanobacterial	O
12	O
kDa	O
protein	O
and	O
cyt	B
c-550	I
partially	O
bound	O
to	O
the	O
red	O
algal	O
PSII	B
,	O
but	O
this	O
binding	O
did	O
not	O
restore	O
oxygen	O
evolution	O
.	O

The	O
higher	O
plant	O
23	O
kDa	O
and	O
17	O
kDa	O
proteins	O
bound	O
to	O
the	O
cyanobacterial	O
and	O
red	O
algal	O
PSII	B
only	O
through	O
non	O
-	O
specific	O
interactions	O
.	O

Thus	O
,	O
only	O
the	O
red	O
algal	O
extrinsic	O
proteins	O
are	O
partially	O
functional	O
in	O
both	O
the	O
cyanobacterial	O
and	O
higher	O
plant	O
PSII	B
,	O
which	O
implies	O
a	O
possible	O
intermediate	O
position	O
of	O
the	O
red	O
algal	O
PSII	B
during	O
its	O
evolution	O
from	O
cyanobacteria	O
to	O
higher	O
plants	O
.	O

Differential	O
regulation	O
of	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
II	I
and	O
17alpha	B
-	I
hydroxylase	I
/	I
lyase	I
P450	I
in	O
human	O
adrenocortical	O
carcinoma	O
cells	O
by	O
epidermal	B
growth	I
factor	I
and	O
basic	B
fibroblast	I
growth	I
factor	I
.	O

Epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
and	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
bFGF	B
)	O
are	O
pluripotent	O
growth	B
factors	I
that	O
stimulate	O
both	O
the	O
proliferation	O
and	O
steroidogenesis	O
of	O
adrenocortical	O
cells	O
.	O

Here	O
we	O
demonstrate	O
that	O
EGF	B
and	O
bFGF	B
specifically	O
induce	O
mRNA	O
of	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
II	I
(	O
3betaHSD	B
II	I
)	O
and	O
suppress	O
that	O
of	O
17alpha	B
-	I
hydroxylase	I
/	I
lyase	I
P450	I
(	O
CYP17	B
)	O
in	O
human	O
adrenocortical	O
H295R	O
cells	O
.	O

The	O
induction	O
of	O
3betaHSD	B
II	I
mRNA	O
did	O
not	O
occur	O
until	O
6	O
h	O
after	O
the	O
growth	O
factor	O
treatment	O
and	O
was	O
completely	O
abolished	O
in	O
the	O
presence	O
of	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
(	O
CHX	O
)	O
,	O
suggesting	O
that	O
the	O
induction	O
required	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
CYP17	B
mRNA	O
suppression	O
began	O
at	O
almost	O
the	O
same	O
time	O
as	O
the	O
induction	O
of	O
the	O
3betaHSD	B
II	I
mRNA	O
.	O

Interestingly	O
,	O
the	O
CYP17	B
mRNA	O
level	O
was	O
increased	O
by	O
the	O
CHX	O
treatment	O
.	O

Both	O
the	O
3betaHSD	B
II	I
and	O
CYP17	B
mRNAs	O
were	O
repressed	O
by	O
treatment	O
with	O
a	O
calmodulin	B
kinase	I
II	I
(	O
CaMK	B
II	I
)	O
inhibitor	O
,	O
KN	O
-	O
93	O
,	O
and	O
were	O
enhanced	O
by	O
a	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
inhibitor	O
,	O
PD98059	O
.	O

The	O
PD98059	O
-	O
mediated	O
induction	O
of	O
the	O
3betaHSD	B
II	I
mRNA	O
was	O
completely	O
blocked	O
by	O
the	O
CHX	O
treatment	O
.	O

Interestingly	O
,	O
treatment	O
with	O
EGF	B
in	O
the	O
presence	O
of	O
both	O
PD98059	O
and	O
CHX	O
produced	O
a	O
greater	O
increase	O
in	O
the	O
CYP17	B
mRNA	O
than	O
did	O
treatment	O
in	O
the	O
presence	O
of	O
PD98059	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
CHX	O
-	O
sensitive	O
factor	O
(	O
s	O
)	O
and	O
CaMK	B
II	I
-	O
and	O
MAPK	B
-	O
signaling	O
pathways	O
may	O
have	O
important	O
roles	O
in	O
both	O
induction	O
of	O
3betaHSD	B
II	I
and	O
suppression	O
of	O
CYP17	B
by	O
EGF	B
or	O
bFGF	B
in	O
H295R	O
cells	O
.	O

Discovery	O
of	O
two	O
novel	O
variants	O
of	O
KIR2DS5	B
reveals	O
this	O
gene	O
to	O
be	O
a	O
common	O
component	O
of	O
human	O
KIR	B
'	O
B	O
'	O
haplotypes	O
.	O

The	O
gene	O
encoding	O
the	O
non	O
-	O
inhibitory	O
receptor	O
KIR2DS5	B
has	O
so	O
far	O
been	O
represented	O
by	O
a	O
single	O
cDNA	O
sequence	O
,	O
NKAT9	B
.	O

A	O
previous	O
study	O
by	O
polymerase	O
chain	O
reaction	O
using	O
sequence	O
-	O
specific	O
primers	O
(	O
PCR	O
-	O
SSP	O
)	O
failed	O
to	O
detect	O
NKAT9	B
in	O
genomic	O
DNA	O
of	O
52	O
donors	O
,	O
which	O
suggested	O
that	O
KIR2DS5	B
could	O
be	O
a	O
rare	O
gene	O
.	O

Here	O
,	O
we	O
have	O
characterized	O
two	O
novel	O
variants	O
of	O
KIR2DS5	B
that	O
differ	O
from	O
NKAT9	B
by	O
8	O
and	O
10	O
nucleotide	O
substitutions	O
.	O

The	O
frequency	O
of	O
KIR2DS5	B
was	O
then	O
re	O
-	O
assessed	O
by	O
PCR	O
-	O
SSP	O
using	O
primers	O
specific	O
for	O
conserved	O
sequences	O
of	O
all	O
three	O
known	O
KIR2DS5	B
variants	O
.	O

We	O
found	O
KIR2DS5	B
is	O
not	O
a	O
rare	O
gene	O
,	O
but	O
one	O
present	O
in	O
26	O
%	O
of	O
34	O
donors	O
representing	O
the	O
major	O
ethnic	O
groups	O
.	O

Like	O
other	O
non	O
-	O
inhibitory	O
KIR	B
,	O
the	O
distribution	O
of	O
KIR2DS5	B
is	O
restricted	O
to	O
the	O
'	O
B	O
'	O
subset	O
of	O
KIR	B
-	O
gene	O
haplotypes	O
.	O

Transcription	O
of	O
the	O
KIR2DS5	B
gene	O
was	O
studied	O
by	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
-	O
PCR	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
from	O
one	O
donor	O
and	O
shown	O
to	O
follow	O
the	O
clonal	O
distribution	O
seen	O
for	O
most	O
other	O
KIR	B
genes	O
.	O

IL-1H	B
,	O
an	O
interleukin	B
1	I
-	O
related	O
protein	O
that	O
binds	O
IL-18	B
receptor	I
/	O
IL-1Rrp	B
.	O

IL-18	B
,	O
or	O
IGIF	B
(	O
interferon	B
-	I
gamma	I
inducing	I
factor	I
)	O
,	O
is	O
an	O
IL-1	B
-	O
related	O
,	O
pro	O
-	O
inflammatory	O
cytokine	B
,	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
systemic	O
and	O
local	O
inflammation	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
IL-1H	B
,	O
a	O
novel	O
IL-1	B
-	O
related	O
molecule	O
.	O

IL-1H	B
appears	O
to	O
be	O
expressed	O
in	O
most	O
tissues	O
with	O
relatively	O
high	O
levels	O
in	O
testis	O
,	O
thymus	O
and	O
uterus	O
.	O

The	O
IL-1H	B
transcripts	O
were	O
stimulated	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
in	O
human	O
cell	O
lines	O
(	O
A431	O
,	O
THP-1	O
and	O
KG-1	O
)	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
HPBMC	O
)	O
and	O
dendritic	O
cells	O
(	O
NHDC	O
)	O
.	O

The	O
protein	O
sequence	O
of	O
IL-1H	B
is	O
mostly	O
related	O
to	O
IL-1ra	B
with	O
a	O
similarity	O
of	O
36	O
%	O
.	O

A	O
short	O
form	O
of	O
IL-1H	B
was	O
identified	O
,	O
and	O
lacks	O
a	O
40	O
-	O
amino	O
acid	O
segment	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
.	O

When	O
expressed	O
in	O
mammalian	O
cells	O
,	O
two	O
secreted	O
polypeptides	O
of	O
IL-1H	B
were	O
identified	O
:	O
an	O
uncleaved	O
and	O
a	O
cleaved	O
form	O
starting	O
with	O
amino	O
acid	O
Val-46	O
.	O

Furthermore	O
,	O
IL-1H	B
binds	O
the	O
IL-18	B
receptor	I
,	O
but	O
not	O
the	O
IL-1	B
receptor	I
.	O

These	O
findings	O
suggest	O
that	O
IL-1H	B
may	O
be	O
another	O
ligand	O
for	O
the	O
IL-18	B
receptor	I
and	O
a	O
new	O
player	O
in	O
the	O
inflammatory	O
and	O
immune	O
responses	O
mediated	O
by	O
the	O
IL-18	B
/	O
IL-18R	B
axis	O
.	O

Localization	O
of	O
human	O
interleukin	B
13	I
receptor	I
in	O
non	O
-	O
haematopoietic	O
cells	O
.	O

Although	O
the	O
functional	O
roles	O
of	O
interleukin	B
(	I
IL-	I
)	I
13	I
in	O
haematopoietic	O
cells	O
are	O
well	O
investigated	O
,	O
those	O
in	O
non	O
-	O
haematopoietic	O
cells	O
remain	O
to	O
be	O
addressed	O
.	O

IL-13	B
exerts	O
its	O
actions	O
by	O
binding	O
to	O
the	O
IL-13	B
receptor	I
(	O
IL-13R	B
)	O
on	O
target	O
cells	O
,	O
which	O
is	O
composed	O
of	O
IL-13Ralpha1	B
and	O
the	O
IL-4	B
receptor	I
alpha	I
chain	O
(	O
IL-4Ralpha	B
)	O
.	O

However	O
,	O
there	O
has	O
been	O
no	O
study	O
of	O
localization	O
of	O
IL-13R	B
in	O
each	O
tissue	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
generated	O
monoclonal	O
anti	O
-	O
IL-13Ralpha1	B
antibody	O
,	O
and	O
performed	O
immunohistochemistry	O
using	O
this	O
antibody	O
and	O
anti	O
-	O
IL-4Ralpha	B
antibody	O
.	O

Distribution	O
of	O
these	O
two	O
components	O
was	O
the	O
same	O
in	O
all	O
examined	O
tissues	O
.	O

Staining	O
was	O
positive	O
in	O
keratinocytes	O
,	O
hair	O
follicles	O
,	O
and	O
sebaceous	O
and	O
sweat	O
glands	O
in	O
skin	O
;	O
in	O
ciliated	O
respiratory	O
epithelial	O
cells	O
in	O
nasal	O
tissue	O
;	O
in	O
heart	O
muscle	O
cells	O
;	O
in	O
foveola	O
cells	O
,	O
gastric	O
glands	O
,	O
and	O
the	O
smooth	O
muscle	O
layer	O
in	O
stomach	O
;	O
and	O
in	O
hepatocytes	O
in	O
liver	O
.	O

However	O
,	O
staining	O
was	O
undetectable	O
in	O
brain	O
and	O
bone	O
marrow	O
.	O

Fibroblasts	O
and	O
endothelial	O
cells	O
were	O
stained	O
in	O
some	O
tissues	O
.	O

These	O
results	O
provide	O
clues	O
to	O
elucidate	O
the	O
known	O
pathological	O
roles	O
of	O
IL-13	B
in	O
atopic	O
dermatitis	O
and	O
allergic	O
rhinitis	O
,	O
as	O
well	O
as	O
its	O
unknown	O
physiological	O
roles	O
.	O

The	O
skeletal	B
muscle	I
ryanodine	I
receptor	I
identified	O
as	O
a	O
molecular	O
target	O
of	O
[	O
3H	O
]	O
azidodantrolene	O
by	O
photoaffinity	O
labeling	O
.	O

Dantrolene	O
is	O
a	O
skeletal	O
muscle	O
relaxant	O
which	O
acts	O
by	O
inhibiting	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
release	O
from	O
sarcoplasmic	O
reticulum	O
(	O
SR	O
)	O
.	O

It	O
is	O
used	O
primarily	O
in	O
the	O
treatment	O
of	O
malignant	O
hyperthermia	O
(	O
MH	O
)	O
,	O
a	O
pharmacogenetic	O
sensitivity	O
to	O
volatile	O
anesthetics	O
resulting	O
in	O
massive	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
release	O
.	O

Determination	O
of	O
the	O
site	O
and	O
mechanism	O
of	O
action	O
of	O
dantrolene	O
should	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
regulation	O
of	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
release	O
in	O
skeletal	O
muscle	O
.	O

Photoaffinity	O
labeling	O
of	O
porcine	O
SR	O
with	O
[	O
(	O
3	O
)	O
H	O
]	O
azidodantrolene	O
,	O
a	O
photoactivatable	O
analogue	O
of	O
dantrolene	O
,	O
has	O
identified	O
a	O
160	O
kDa	O
SR	O
protein	O
with	O
immunologic	O
cross	O
-	O
reactivity	O
to	O
skeletal	B
muscle	I
ryanodine	I
receptor	I
(	O
RyR	B
)	O
as	O
a	O
possible	O
target	O
[	O
Palnitkar	O
et	O
al.	O
(	O
1999	O
)	O
J.	O
Med	O
.	O
Chem	O
.	O
42	O
,	O
1872	O
-	O
1880	O
]	O
.	O

Here	O
we	O
demonstrate	O
specific	O
,	O
AMP	O
-	O
PCP	O
-	O
enhanced	O
,	O
[	O
(	O
3	O
)	O
H	O
]	O
azidodantrolene	O
photolabeling	O
of	O
both	O
the	O
RyR	B
monomer	O
and	O
a	O
160	O
or	O
172	O
kDa	O
protein	O
in	O
porcine	O
and	O
rabbit	O
SR	O
,	O
respectively	O
.	O

The	O
160	O
/	O
172	O
kDa	O
protein	O
is	O
shown	O
to	O
be	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminus	O
of	O
the	O
RyR	B
cleaved	O
from	O
the	O
monomer	O
by	O
an	O
endogenous	O
protease	B
activity	O
consistent	O
with	O
that	O
of	O
n	B
-	I
calpain	I
.	O

MALDI	O
-	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
porcine	O
160	O
kDa	O
protein	O
identifies	O
it	O
as	O
the	O
1400	O
amino	O
acid	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
fragment	O
of	O
the	O
skeletal	B
muscle	I
RyR	I
reportedly	O
generated	O
by	O
n	B
-	I
calpain	I
[	O
Shevchenko	O
et	O
al.	O
(	O
1998	O
)	O
J.	O
Membr	O
.	O
Biol	O
.	O
161	O
,	O
33	O
-	O
34	O
]	O
.	O

Immunoprecipitation	O
of	O
solubilized	O
,	O
[	O
(	O
3	O
)	O
H	O
]	O
azidodantrolene	O
-	O
photolabeled	O
SR	O
protein	O
reveals	O
that	O
the	O
cleaved	O
160	O
/	O
172	O
kDa	O
protein	O
remains	O
associated	O
with	O
the	O
C	O
-	O
terminal	O
,	O
410	O
kDa	O
portion	O
of	O
the	O
RyR	B
.	O

[	O
(	O
3	O
)	O
H	O
]	O
Dantrolene	O
binding	O
to	O
both	O
the	O
intact	O
and	O
the	O
n	B
-	I
calpain	I
-	O
cleaved	O
channel	O
RyR	B
is	O
similarly	O
enhanced	O
by	O
AMP	O
-	O
PCP	O
.	O

n	B
-	I
Calpain	I
cleavage	O
of	O
the	O
RyR	B
does	O
not	O
affect	O
[	O
(	O
3	O
)	O
H	O
]	O
dantrolene	O
binding	O
in	O
the	O
presence	O
of	O
AMP	O
-	O
PCP	O
,	O
but	O
depresses	O
drug	O
binding	O
in	O
the	O
absence	O
of	O
nucleotide	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminus	O
of	O
the	O
RyR	B
is	O
a	O
molecular	O
target	O
for	O
dantrolene	O
,	O
and	O
suggest	O
a	O
regulatory	O
role	O
for	O
both	O
n	B
-	I
calpain	I
activity	O
and	O
ATP	O
in	O
the	O
interaction	O
of	O
dantrolene	O
with	O
the	O
RyR	B
in	O
vivo	O
.	O

Targeting	O
Pyk2	B
to	O
beta	B
1	I
-	I
integrin	I
-	O
containing	O
focal	O
contacts	O
rescues	O
fibronectin	B
-	O
stimulated	O
signaling	O
and	O
haptotactic	O
motility	O
defects	O
of	O
focal	B
adhesion	I
kinase	I
-	O
null	O
cells	O
.	O

Focal	B
adhesion	I
kinase	I
-	O
null	O
(	O
FAK	B
(	O
-	O
/	O
-	O
)	O
fibroblasts	O
exhibit	O
morphological	O
and	O
motility	O
defects	O
that	O
are	O
reversed	O
by	O
focal	B
adhesion	I
kinase	I
(	O
FAK	B
)	O
reexpression	O
.	O
The	O
FAK	B
-	O
related	O
kinase	O
,	O
proline	B
-	I
rich	I
tyrosine	I
kinase	I
2	I
(	O
Pyk2	B
)	O
,	O
is	O
expressed	O
in	O
FAK	B
(	O
-	O
/	O
-	O
)	O
cells	O
,	O
yet	O
it	O
exhibits	O
a	O
perinuclear	O
distribution	O
and	O
does	O
not	O
functionally	O
substitute	O
for	O
FAK	B
.	O
Chimeric	O
Pyk2	B
/	O
FAK	B
proteins	O
were	O
created	O
and	O
expressed	O
in	O
FAK	B
(	O
-	O
/	O
-	O
)	O
cells	O
to	O
determine	O
the	O
impact	O
of	O
Pyk2	B
localization	O
to	O
focal	O
contacts	O
.	O

Whereas	O
an	O
FAK	B
/	O
Pyk2	B
COOH	O
-	O
terminal	O
(	O
CT	O
)	O
domain	O
chimera	O
was	O
perinuclear	O
distributed	O
,	O
stable	O
expression	O
of	O
a	O
Pyk2	B
chimera	O
with	O
the	O
FAK	B
-	O
CT	O
domain	O
(	O
Pyk2	B
/	O
FAK	B
-	O
CT	O
)	O
localized	O
to	O
focal	O
contact	O
sites	O
and	O
enhanced	O
fibronectin	B
(	O
FN	B
)	O
-	O
stimulated	O
haptotactic	O
cell	O
migration	O
equal	O
to	O
FAK	B
-	O
reconstituted	O
cells	O
.	O

Disruption	O
of	O
paxillin	B
binding	O
to	O
the	O
FAK	B
-	O
CT	O
domain	O
(	O
S-1034	O
)	O
inhibited	O
Pyk2	B
/	O
FAK	B
-	O
CT	O
localization	O
to	O
focal	O
contacts	O
and	O
its	O
capacity	O
to	O
promote	O
cell	O
motility	O
.	O

Paxillin	B
binding	O
to	O
the	O
FAK	B
-	O
CT	O
was	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
the	O
indirect	O
association	O
of	O
FAK	B
or	O
Pyk2	B
/	O
FAK	B
-	O
CT	O
with	O
a	O
beta	B
1	I
-	I
integrin	I
-	O
containing	O
complex	O
.	O

Both	O
FAK	B
and	O
Pyk2	B
/	O
FAK	B
-	O
CT	O
but	O
not	O
Pyk2	B
/	O
FAK	B
-	O
CT	O
S-1034	O
reconstituted	O
FAK	B
(	O
-	O
/	O
-	O
)	O
cells	O
,	O
exhibit	O
elevated	O
FN	B
-	O
stimulated	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
2	I
(	O
ERK2	B
)	O
and	O
c	B
-	I
Jun	I
NH	I
(	I
2	I
)	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
kinase	B
activation	O
.	O

FN	B
-	O
stimulated	O
FAK	B
or	O
Pyk2	B
/	O
FAK	B
-	O
CT	O
activation	O
enhanced	O
both	O
the	O
extent	O
and	O
duration	O
of	O
FN	B
-	O
stimulated	O
ERK2	B
activity	O
which	O
was	O
necessary	O
for	O
cell	O
motility	O
.	O

Transient	O
overexpression	O
of	O
the	O
FAK	B
-	O
CT	O
but	O
not	O
FAK	B
-	O
CT	O
S-1034	O
domain	O
inhibited	O
both	O
FN	O
-	O
stimulated	O
ERK2	B
and	O
JNK	B
activation	O
as	O
well	O
as	O
FN	B
-	O
stimulated	O
motility	O
of	O
Pyk2	B
/	O
FAK	B
-	O
CT	O
reconstituted	O
cells	O
.	O

These	O
gain	O
-	O
of	O
-	O
function	O
studies	O
show	O
that	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
and	O
kinase	B
domains	O
of	O
Pyk2	B
can	O
functionally	O
substitute	O
for	O
FAK	B
in	O
promoting	O
FN	B
-	O
stimulated	O
signaling	O
and	O
motility	O
events	O
when	O
localized	O
to	O
beta	B
-	I
integrin	I
-	O
containing	O
focal	O
contact	O
sites	O
via	O
interactions	O
mediated	O
by	O
the	O
FAK	B
-	O
CT	O
domain	O
.	O

Identification	O
of	O
a	O
novel	O
exon	O
in	O
apolipoprotein	B
E	I
receptor	I
2	I
leading	O
to	O
alternatively	O
spliced	O
mRNAs	O
found	O
in	O
cells	O
of	O
the	O
vascular	O
wall	O
but	O
not	O
in	O
neuronal	O
tissue	O
.	O

Novel	O
members	O
of	O
the	O
low	B
density	I
lipoprotein	I
receptor	I
family	I
were	O
identified	O
in	O
human	O
endothelial	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
utilizing	O
a	O
homology	O
-	O
cloning	O
strategy	O
.	O

Four	O
novel	O
mRNA	O
transcripts	O
could	O
be	O
identified	O
as	O
isoforms	O
of	O
the	O
apolipoprotein	B
E	I
receptor	I
2	I
(	O
apoEr2	B
)	O
:	O
one	O
form	O
lacking	O
three	O
ligand	O
binding	O
repeats	O
(	O
nucleotides	O
497	O
-	O
883	O
)	O
but	O
containing	O
a	O
novel	O
ligand	O
binding	O
repeat	O
adjacent	O
to	O
a	O
unique	O
cysteine	O
-	O
rich	O
domain	O
preceding	O
the	O
epidermal	B
growth	I
factor	I
precursor	O
domain	O
of	O
apoEr2	B
,	O
forms	O
lacking	O
the	O
O	O
-	O
linked	O
sugar	O
domain	O
,	O
and	O
forms	O
containing	O
a	O
59	O
-	O
amino	O
acid	O
deletion	O
within	O
the	O
cytoplasmic	O
tail	O
.	O

By	O
fluorescence	O
in	O
situ	O
hybridization	O
for	O
chromosome	O
mapping	O
,	O
we	O
could	O
confirm	O
that	O
the	O
novel	O
alternative	O
forms	O
of	O
apoEr2	B
are	O
splice	O
variants	O
of	O
transcripts	O
from	O
a	O
single	O
copy	O
gene	O
on	O
chromosome	O
1p34	O
.	O

To	O
analyze	O
whether	O
the	O
different	O
splice	O
variants	O
of	O
apoEr2	B
mRNA	O
are	O
expressed	O
in	O
a	O
splice	O
variant	O
-	O
specific	O
pattern	O
,	O
we	O
concentrated	O
on	O
the	O
central	O
nervous	O
system	O
,	O
where	O
high	O
expression	O
of	O
apoEr2	B
has	O
been	O
described	O
originally	O
.	O

By	O
means	O
of	O
splice	O
variant	O
-	O
specific	O
in	O
situ	O
hybridization	O
,	O
we	O
could	O
confirm	O
that	O
apoEr2	B
mRNA	O
is	O
abundantly	O
expressed	O
in	O
brain	O
tissue	O
and	O
,	O
with	O
exception	O
of	O
the	O
newly	O
identified	O
ligand	O
binding	O
domain	O
,	O
all	O
mRNA	O
splice	O
variants	O
exhibited	O
a	O
similar	O
expression	O
pattern	O
.	O

The	O
mRNA	O
of	O
the	O
newly	O
identified	O
ligand	O
binding	O
domain	O
,	O
however	O
,	O
was	O
expressed	O
in	O
brain	O
only	O
in	O
cells	O
of	O
the	O
vascular	O
wall	O
,	O
confirming	O
data	O
from	O
Northern	O
blotting	O
,	O
where	O
the	O
mRNA	O
of	O
the	O
newly	O
identified	O
ligand	O
binding	O
domain	O
was	O
found	O
in	O
several	O
tissues	O
but	O
was	O
absent	O
in	O
brain	O
tissue	O
.	O

Clonal	O
accumulation	O
of	O
T	O
cells	O
bearing	O
V	O
beta	O
6	O
T	B
-	I
cell	I
receptor	I
in	O
chronic	O
inflammatory	O
periodontal	O
disease	O
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
among	O
the	O
various	O
T	O
-	O
cell	O
receptor	O
V	O
beta	O
gene	O
segments	O
,	O
T	B
-	I
cell	I
receptor	I
V	O
beta	O
6	O
gene	O
-	O
bearing	O
T	O
cells	O
are	O
predominant	O
in	O
periodontitis	O
lesions	O
.	O

To	O
explore	O
the	O
clonality	O
of	O
T	O
cells	O
expressing	O
V	O
beta	O
6	O
T	B
-	I
cell	I
receptor	I
,	O
which	O
is	O
determined	O
by	O
the	O
heterogeneity	O
of	O
the	O
complementarity	O
-	O
determining	O
region	O
3	O
(	O
CDR3	O
)	O
,	O
V	O
beta	O
6	O
-	O
C	O
beta	O
polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
gingival	O
tissue	O
and	O
peripheral	O
blood	O
of	O
periodontitis	O
patients	O
were	O
analyzed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequence	O
.	O

Both	O
techniques	O
provided	O
quite	O
similar	O
results	O
in	O
terms	O
of	O
the	O
number	O
of	O
accumulated	O
clones	O
in	O
which	O
clonal	O
accumulation	O
of	O
T	B
-	I
cell	I
receptor	I
V	O
beta	O
6	O
-	O
bearing	O
T	O
cells	O
was	O
found	O
in	O
most	O
periodontitis	O
lesions	O
but	O
not	O
in	O
peripheral	O
blood	O
.	O

From	O
the	O
analysis	O
of	O
deduced	O
amino	O
acid	O
sequences	O
,	O
a	O
possible	O
conserved	O
amino	O
acid	O
residue	O
in	O
the	O
CDR3	O
region	O
of	O
the	O
periodontitis	O
lesion	O
-	O
derived	O
sequences	O
was	O
found	O
in	O
most	O
patients	O
.	O

This	O
conserved	O
amino	O
acid	O
motif	O
however	O
,	O
was	O
not	O
identified	O
.	O

Furthermore	O
,	O
skewed	O
J	O
beta	O
gene	O
segment	O
usage	O
was	O
observed	O
for	O
expanded	O
clones	O
from	O
periodontitis	O
lesions	O
.	O

Our	O
results	O
suggest	O
that	O
T	O
cells	O
infiltrating	O
periodontitis	O
lesions	O
are	O
responding	O
to	O
a	O
restricted	O
number	O
of	O
antigens	O
or	O
epitopes	O
.	O

Parameters	O
underlying	O
successful	O
protection	O
with	O
live	O
attenuated	O
mutants	O
in	O
experimental	O
shigellosis	O
.	O

Because	O
the	O
use	O
of	O
live	O
attenuated	O
mutants	O
of	O
Shigella	O
spp	O
.	O
represents	O
a	O
promising	O
approach	O
to	O
protection	O
against	O
bacillary	O
dysentery	O
(	O
M.	O
E.	O
Etherridge	O
,	O
A.	O
T.	O
M.	O
Shamsul	O
Hoque	O
,	O
and	O
D.	O
A.	O
Sack	O
,	O
Lab	O
.	O
Anim	O
.	O
Sci	O
.	O
46	O
:	O
61	O
-	O
66	O
,	O
1996	O
)	O
,	O
it	O
becomes	O
essential	O
to	O
rationalize	O
this	O
approach	O
in	O
animal	O
models	O
in	O
order	O
to	O
optimize	O
attenuation	O
of	O
virulence	O
in	O
the	O
vaccine	O
candidates	O
,	O
as	O
well	O
as	O
their	O
route	O
and	O
mode	O
of	O
administration	O
,	O
and	O
to	O
define	O
the	O
correlates	O
of	O
protection	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
three	O
strains	O
of	O
Shigella	O
flexneri	O
5	O
-	O
-the	O
wild	O
-	O
type	O
M90	O
T	O
,	O
an	O
aroC	B
mutant	O
,	O
and	O
a	O
double	O
purE	B
aroC	B
mutant	O
--	O
for	O
their	O
pathogenicity	O
,	O
immunogenicity	O
,	O
and	O
protective	O
capacity	O
.	O

Protection	O
against	O
keratoconjunctivitis	O
,	O
induced	O
by	O
wild	O
-	O
type	O
M90	O
T	O
,	O
was	O
used	O
as	O
the	O
protection	O
read	O
out	O
in	O
guinea	O
pigs	O
that	O
were	O
inoculated	O
either	O
intranasally	O
or	O
intragastrically	O
.	O

Following	O
intranasal	O
immunization	O
,	O
the	O
aroC	B
mutant	O
elicited	O
weak	O
nasal	O
tissue	O
destruction	O
compared	O
to	O
M90	O
T	O
and	O
achieved	O
protection	O
correlated	O
with	O
high	O
levels	O
of	O
local	O
anti	O
-	O
lipopolysaccharide	O
immunoglobulin	B
A	I
(	O
IgA	B
)	O
,	O
whereas	O
the	O
purE	B
aroC	B
double	O
mutant	O
,	O
which	O
also	O
elicited	O
weak	O
tissue	O
destruction	O
,	O
was	O
not	O
protective	O
and	O
elicited	O
a	O
low	O
IgA	B
response	O
.	O

Conversely	O
,	O
following	O
intragastric	O
immunization	O
,	O
only	O
the	O
M90	O
T	O
purE	B
aroC	B
double	O
mutant	O
elicited	O
protection	O
compared	O
to	O
both	O
the	O
aroC	B
mutant	O
and	O
the	O
wild	O
-	O
type	O
strain	O
.	O

This	O
mutant	O
caused	O
mild	O
inflammatory	O
destruction	O
,	O
particularly	O
at	O
the	O
level	O
of	O
Peyer	O
's	O
patches	O
,	O
but	O
it	O
persisted	O
much	O
longer	O
within	O
the	O
tissues	O
.	O

This	O
could	O
represent	O
an	O
essential	O
parameter	O
of	O
the	O
protective	O
response	O
that	O
,	O
in	O
this	O
case	O
,	O
did	O
not	O
clearly	O
correlate	O
with	O
high	O
anti	O
-	O
lipopolysaccharide	O
IgA	B
titers	O
.	O

Antigen	O
-	O
specific	O
mediated	O
suppression	O
of	O
beta	O
cell	O
autoimmunity	O
by	O
plasmid	O
DNA	O
vaccination	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
use	O
of	O
plasmid	O
DNA	O
(	O
pDNA	O
)	O
vaccination	O
to	O
elicit	O
Th2	O
effector	O
cell	O
function	O
in	O
an	O
Ag	O
-	O
specific	O
manner	O
and	O
in	O
turn	O
prevent	O
insulin	B
-	O
dependent	O
diabetes	O
mellitus	O
(	O
IDDM	O
)	O
in	O
nonobese	O
diabetic	O
(	O
NOD	O
)	O
mice	O
.	O

pDNA	O
recombinants	O
were	O
engineered	O
encoding	O
a	O
secreted	O
fusion	O
protein	O
consisting	O
of	O
a	O
fragment	O
of	O
glutamic	B
acid	I
decarboxylase	I
65	I
(	O
GAD65	B
)	O
linked	O
to	O
IgGFc	B
,	O
and	O
IL-4	B
.	O

Intramuscular	O
injection	O
of	O
pDNA	O
encoding	O
GAD65	B
-	O
IgGFc	B
and	O
IL-4	B
effectively	O
prevented	O
diabetes	O
in	O
NOD	O
mice	O
treated	O
at	O
early	O
or	O
late	O
preclinical	O
stages	O
of	O
IDDM	O
.	O

This	O
protection	O
was	O
GAD65	B
-	O
specific	O
since	O
NOD	O
mice	O
immunized	O
with	O
pDNA	O
encoding	O
hen	O
egg	O
lysozyme	B
-	O
IgGFc	B
and	O
IL-4	B
continued	O
to	O
develop	O
diabetes	O
.	O

Furthermore	O
,	O
disease	O
prevention	O
correlated	O
with	O
suppression	O
of	O
insulitis	O
and	O
induction	O
of	O
GAD65	B
-	O
specific	O
regulatory	O
Th2	O
cells	O
.	O

Importantly	O
,	O
GAD65	B
-	O
specific	O
immune	O
deviation	O
was	O
dependent	O
on	O
pDNA	O
-	O
encoded	O
IL-4	B
.	O

In	O
fact	O
,	O
GAD65	B
-	O
specific	O
Th1	O
cell	O
reactivity	O
was	O
significantly	O
enhanced	O
in	O
animals	O
immunized	O
with	O
pDNA	O
encoding	O
only	O
GAD65	B
-	O
IgGFc	B
.	O

Finally	O
,	O
NOD	O
.	O
IL4	B
(	O
null	O
)	O
mice	O
treated	O
with	O
pDNA	O
encoding	O
GAD65	B
-	O
IgGFc	B
and	O
IL-4	B
continued	O
to	O
develop	O
diabetes	O
,	O
indicating	O
that	O
endogenous	O
IL-4	B
was	O
also	O
required	O
for	O
disease	O
prevention	O
.	O

These	O
results	O
demonstrate	O
that	O
pDNA	O
vaccination	O
is	O
an	O
effective	O
strategy	O
to	O
elicit	O
beta	O
cell	O
-	O
specific	O
Th2	O
regulatory	O
cell	O
function	O
for	O
the	O
purpose	O
of	O
preventing	O
IDDM	O
even	O
at	O
a	O
late	O
stage	O
of	O
disease	O
development	O
.	O

Interleukin	B
1	I
beta	I
(	O
IL-1	B
beta	I
)	O
action	O
in	O
porcine	O
thyroid	O
cells	O
involves	O
the	O
ceramide	O
signalling	O
pathway	O
.	O

Interleukin	B
1	I
beta	I
(	O
IL-1beta	B
)	O
is	O
often	O
associated	O
with	O
thyroidal	O
autoimmune	O
diseases	O
.	O

This	O
cytokine	B
has	O
been	O
largely	O
described	O
to	O
trigger	O
an	O
important	O
biological	O
signalling	O
pathway	O
:	O
the	O
sphingomyelin	O
/	O
ceramide	O
pathway	O
.	O

In	O
this	O
report	O
we	O
show	O
that	O
IL-1beta	B
induces	O
ceramide	O
formation	O
and	O
sphingomyelin	O
degradation	O
in	O
porcine	O
thyroid	O
cells	O
via	O
the	O
activation	O
of	O
a	O
neutral	B
sphingomyelinase	I
.	O

Among	O
the	O
potential	O
targets	O
of	O
IL-1beta	B
and	O
ceramides	O
action	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
an	O
atypical	B
protein	I
kinase	I
C	I
(	O
PKC	B
)	O
,	O
the	O
PKC	B
zeta	I
.	O

We	O
show	O
that	O
both	O
IL-1beta	B
and	O
ceramides	O
lead	O
to	O
an	O
increase	O
of	O
PKCzeta	B
activity	O
.	O

All	O
these	O
results	O
suggest	O
an	O
important	O
role	O
for	O
ceramides	O
and	O
IL-1beta	B
in	O
regulation	O
of	O
thyroid	O
function	O
,	O
leading	O
to	O
cell	O
survival	O
or	O
to	O
apoptosis	O
.	O

N	O
-	O
linked	O
carbohydrate	O
on	O
human	B
leukocyte	I
antigen	I
-	I
C	I
and	O
recognition	O
by	O
natural	O
killer	O
cell	O
inhibitory	O
receptors	O
.	O

The	O
possible	O
role	O
of	O
carbohydrate	O
in	O
the	O
interaction	O
of	O
HLA	B
-	I
C	I
with	O
a	O
human	O
inhibitory	O
natural	O
Killer	B
cell	I
Immunoglobulin	I
-	I
like	I
Receptor	I
with	O
two	O
Ig	B
domains	O
,	O
KIR2DL1	B
,	O
was	O
investigated	O
.	O

Transfectants	O
of	O
721.221	O
(	O
a	O
class	B
I	I
MHC	I
-	O
negative	O
human	O
B	O
cell	O
line	O
)	O
expressing	O
only	O
HLA	B
-	I
Cw4	I
or	I
-	I
Cw6	I
or	O
their	O
respective	O
non	O
-	O
glycosylated	O
mutants	O
(	O
N86Q	O
,	O
S88A	O
)	O
were	O
made	O
.	O

The	O
binding	O
of	O
a	O
KIR2DL1	B
-	O
Ig	B
fusion	O
protein	O
to	O
the	O
non	O
-	O
glycosylated	O
mutant	O
HLA	B
-	I
Cw4	I
-	I
or	I
-Cw6	I
-	O
expressing	O
cells	O
was	O
markedly	O
decreased	O
compared	O
to	O
the	O
wild	O
type	O
-	O
expressing	O
cells	O
.	O

The	O
ability	O
to	O
induce	O
an	O
inhibitory	O
signal	O
in	O
the	O
NK	O
tumor	O
line	O
YTS	O
transfected	O
with	O
KIR2DL1	B
was	O
also	O
impaired	O
in	O
the	O
nonglycosylated	O
mutant	O
expressing	O
cells	O
.	O

Furthermore	O
,	O
in	O
a	O
second	O
functional	O
assay	O
,	O
mutant	O
HLA	B
-	I
Cw4	I
and	I
-	I
Cw6	I
molecules	O
had	O
impaired	O
ability	O
to	O
induce	O
signal	O
transduction	O
in	O
BW	O
cells	O
expressing	O
a	O
KIR2DL1	B
-	O
CD3	B
zeta	I
chain	O
chimeric	O
protein	O
.	O

Thus	O
,	O
the	O
deletion	O
of	O
the	O
N	O
-	O
linked	O
glycosylation	O
signal	O
in	O
HLA	B
-	I
Cw4	I
and	I
-	I
Cw6	I
greatly	O
reduced	O
recognition	O
by	O
KIR2DL1	B
.	O

Alternative	O
interpretations	O
of	O
the	O
data	O
are	O
discussed	O
.	O

Identification	O
and	O
molecular	O
characterization	O
of	O
a	O
natural	O
mutant	O
of	O
the	O
p50.2	B
/	O
KIR2DS2	B
activating	O
NK	O
receptor	O
that	O
fails	O
to	O
mediate	O
NK	O
cell	O
triggering	O
.	O

P50	B
/	O
KIR2DS	B
molecules	O
represent	O
the	O
activating	O
form	O
of	O
the	O
HLA	B
-	I
C	I
-	O
specific	O
inhibitory	O
NK	O
receptors	O
.	O

They	O
are	O
characterized	O
,	O
in	O
the	O
transmembrane	O
portion	O
,	O
by	O
a	O
charged	O
amino	O
acid	O
that	O
is	O
involved	O
in	O
coupling	O
with	O
signal	O
-	O
transducing	O
adaptor	O
polypeptides	O
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
novel	O
p50.2	B
/	O
KIR2DS2	B
surface	O
molecule	O
,	O
isolated	O
from	O
NK	O
cell	O
clones	O
derived	O
from	O
an	O
otherwise	O
normal	O
donor	O
,	O
that	O
was	O
unable	O
to	O
transduce	O
activating	O
signals	O
.	O

Sequence	O
analysis	O
of	O
the	O
cDNA	O
encoding	O
this	O
molecule	O
revealed	O
six	O
non	O
-	O
conservative	O
codon	O
mutations	O
in	O
the	O
exon	O
coding	O
for	O
the	O
putative	O
transmembrane	O
portion	O
.	O

Notably	O
,	O
one	O
of	O
such	O
mutations	O
involved	O
the	O
charged	O
residue	O
lysine	O
thought	O
to	O
be	O
important	O
for	O
the	O
association	O
with	O
signal	O
-	O
transducing	O
polypeptides	O
.	O

Indeed	O
,	O
co	O
-	O
transfection	O
experiments	O
revealed	O
that	O
this	O
naturally	O
occurring	O
p50.2	B
/	O
KIR2DS2	B
mutant	O
,	O
termed	O
Mp50.2	O
,	O
displayed	O
a	O
sharply	O
reduced	O
ability	O
to	O
associate	O
with	O
DAP12	B
polypeptides	O
.	O

These	O
data	O
provide	O
the	O
first	O
in	O
vivo	O
demonstration	O
of	O
the	O
crucial	O
role	O
played	O
by	O
the	O
transmembrane	O
region	O
of	O
p50.2	B
receptor	O
molecules	O
in	O
the	O
functional	O
association	O
with	O
DAP12	B
adaptor	O
molecules	O
and	O
in	O
the	O
process	O
of	O
activation	O
of	O
NK	O
-	O
mediated	O
cytotoxicity	O
.	O

The	O
molecular	O
basis	O
of	O
3-methylcrotonylglycinuria	O
,	O
a	O
disorder	O
of	O
leucine	O
catabolism	O
.	O

3-Methylcrotonylglycinuria	O
is	O
an	O
inborn	O
error	O
of	O
leucine	O
catabolism	O
and	O
has	O
a	O
recessive	O
pattern	O
of	O
inheritance	O
that	O
results	O
from	O
the	O
deficiency	O
of	O
3-methylcrotonyl	B
-	I
CoA	I
carboxylase	I
(	O
MCC	B
)	O
.	O

The	O
introduction	O
of	O
tandem	O
mass	O
spectrometry	O
in	O
newborn	O
screening	O
has	O
revealed	O
an	O
unexpectedly	O
high	O
incidence	O
of	O
this	O
disorder	O
,	O
which	O
,	O
in	O
certain	O
areas	O
,	O
appears	O
to	O
be	O
the	O
most	O
frequent	O
organic	O
aciduria	O
.	O

MCC	B
,	O
an	O
heteromeric	O
enzyme	O
consisting	O
of	O
alpha	O
(	O
biotin	O
-	O
containing	O
)	O
and	O
beta	O
subunits	O
,	O
is	O
the	O
only	O
one	O
of	O
the	O
four	O
biotin	O
-	O
dependent	O
carboxylases	B
known	O
in	O
humans	O
that	O
has	O
genes	O
that	O
have	O
not	O
yet	O
been	O
characterized	O
,	O
precluding	O
molecular	O
studies	O
of	O
this	O
disease	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
,	O
at	O
the	O
genomic	O
level	O
and	O
at	O
the	O
cDNA	O
level	O
,	O
of	O
both	O
the	O
MCCA	B
gene	O
and	O
the	O
MCCB	B
gene	O
,	O
encoding	O
the	O
MCC	B
alpha	I
and	O
MCC	B
beta	I
subunits	O
,	O
respectively	O
.	O

The	O
19	O
-	O
exon	O
MCCA	B
gene	O
maps	O
to	O
3q25	O
-	O
27	O
and	O
encodes	O
a	O
725	O
-	O
residue	O
protein	O
with	O
a	O
biotin	O
attachment	O
site	O
;	O
the	O
17-exon	O
MCCB	B
gene	O
maps	O
to	O
5q12	O
-	O
q13	O
and	O
encodes	O
a	O
563	O
-	O
residue	O
polypeptide	O
.	O

We	O
show	O
that	O
disease	O
-	O
causing	O
mutations	O
can	O
be	O
classified	O
into	O
two	O
complementation	O
groups	O
,	O
denoted	O
""""	O
CGA	O
""""	O
and	O
""""	O
CGB	O
.	O
""""	O

We	O
detected	O
two	O
MCCA	B
missense	O
mutations	O
in	O
CGA	O
patients	O
,	O
one	O
of	O
which	O
leads	O
to	O
absence	O
of	O
biotinylated	O
MCC	B
alpha	I
.	O

Two	O
MCCB	B
missense	O
mutations	O
and	O
one	O
splicing	O
defect	O
mutation	O
leading	O
to	O
early	O
MCC	B
beta	I
truncation	O
were	O
found	O
in	O
CGB	O
patients	O
.	O

A	O
fourth	O
MCCB	B
mutation	O
also	O
leading	O
to	O
early	O
MCC	B
beta	I
truncation	O
was	O
found	O
in	O
two	O
nonclassified	O
patients	O
.	O

A	O
fungal	O
model	O
carrying	O
an	O
mccA	B
null	O
allele	O
has	O
been	O
constructed	O
and	O
was	O
used	O
to	O
demonstrate	O
,	O
in	O
vivo	O
,	O
the	O
involvement	O
of	O
MCC	B
in	O
leucine	O
catabolism	O
.	O

These	O
results	O
establish	O
that	O
3-methylcrotonylglycinuria	O
results	O
from	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
genes	O
encoding	O
the	O
alpha	B
and	I
beta	I
subunits	I
of	I
MCC	I
and	O
complete	O
the	O
genetic	O
characterization	O
of	O
the	O
four	O
human	O
biotin	O
-	O
dependent	O
carboxylases	B
.	O

Interleukin-6	B
and	O
transforming	B
growth	I
factor	I
-	I
beta	I
1	I
control	O
expression	O
of	O
cathepsins	B
B	I
and	I
L	I
in	O
human	O
lung	O
epithelial	O
cells	O
.	O

Cathepsins	B
B	I
and	I
L	I
are	O
commonly	O
expressed	O
cysteine	B
proteinases	I
that	O
play	O
a	O
major	O
role	O
in	O
lysosomal	O
bulk	O
proteolysis	O
,	O
protein	O
processing	O
,	O
matrix	O
degradation	O
,	O
and	O
tissue	O
remodeling	O
.	O

Cathepsins	B
are	O
also	O
implicated	O
in	O
tumor	O
progression	O
and	O
metastasis	O
,	O
tissue	O
injury	O
,	O
and	O
inflammation	O
.	O

Cells	O
at	O
sites	O
of	O
inflammation	O
often	O
show	O
upregulation	O
and	O
secretion	O
of	O
cathepsins	B
.	O

The	O
regulation	O
of	O
cathepsin	B
expression	O
by	O
inflammatory	O
mediators	O
is	O
not	O
well	O
understood	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
cytokines	B
interleukin-1	B
beta	I
(	O
IL-1	B
beta	I
)	O
,	O
IL-6	B
,	O
IL-10	B
,	O
transforming	B
growth	I
factor	I
-	I
beta	I
1	I
(	O
TGF	B
-	I
beta	I
1	I
)	O
,	O
and	O
hepatocyte	B
growth	I
factor	I
(	O
HGF	B
)	O
on	O
expression	O
of	O
cathepsin	B
B	I
and	O
cathepsin	B
L	I
mRNA	O
(	O
quantitative	O
RT	O
-	O
PCR	O
)	O
,	O
on	O
protein	O
expression	O
(	O
ELISA	O
,	O
Western	O
blot	O
)	O
,	O
and	O
also	O
on	O
enzymatic	O
activity	O
of	O
cathepsins	B
B	I
and	I
L	I
.	O

Investigations	O
were	O
performed	O
using	O
the	O
human	O
lung	O
epithelial	O
cell	O
line	O
A-549	O
.	O

IL-6	B
was	O
found	O
to	O
induce	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
mRNA	O
expression	O
,	O
protein	O
concentration	O
,	O
and	O
enzymatic	O
activity	O
of	O
cathepsin	B
L	I
.	O

Cathepsin	B
B	I
mRNA	O
and	O
protein	O
expression	O
were	O
not	O
affected	O
by	O
IL-6	B
.	O

In	O
contrast	O
,	O
TGF	B
-	I
beta	I
1	I
decreased	O
the	O
amount	O
of	O
cathepsin	B
L	I
mRNA	O
and	O
cathepsin	B
B	I
mRNA	O
.	O

At	O
protein	O
level	O
,	O
it	O
was	O
shown	O
that	O
TGF	B
-	I
beta	I
1	I
clearly	O
reduced	O
the	O
concentration	O
of	O
cathepsin	B
L	I
but	O
not	O
cathepsin	B
B	I
.	O

The	O
cytokines	B
IL-1	B
beta	I
,	O
IL-10	B
,	O
and	O
HGF	B
were	O
found	O
to	O
exert	O
no	O
effect	O
on	O
cathepsin	B
B	I
and	I
L	I
expression	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
are	O
the	O
first	O
to	O
show	O
that	O
IL-6	B
and	O
TGF	B
-	I
beta	I
1	I
have	O
opposite	O
effects	O
on	O
the	O
regulation	O
of	O
expression	O
of	O
cathepsins	B
B	I
and	I
L	I
in	O
A-549	O
human	O
lung	O
epithelial	O
cells	O
.	O

The	O
proinflammatory	O
cytokine	B
IL-6	B
induced	O
an	O
upregulation	O
of	O
cathepsin	B
L	I
,	O
whereas	O
TGF	B
-	I
beta	I
1	I
suppressed	O
cathepsin	B
B	I
and	I
L	I
expression	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
clarify	O
the	O
mechanism	O
that	O
affects	O
cathepsin	B
B	I
and	I
L	I
expression	O
.	O

Identification	O
of	O
clathrin	B
-	I
adaptor	I
medium	I
chains	O
in	O
Dictyostelium	O
discoideum	O
:	O
differential	O
expression	O
during	O
development	O
.	O

Clathrin	B
-	I
adaptor	I
complexes	I
(	O
APs	B
)	O
are	O
vesicle	O
coat	O
components	O
that	O
participate	O
in	O
cargo	O
selectivity	O
and	O
transport	O
vesicle	O
formation	O
.	O

Here	O
we	O
cloned	O
and	O
characterized	O
apm1	B
,	O
apm3	B
and	O
apm4	B
cDNAs	O
encoding	O
AP	B
medium	I
chains	O
(	O
mu	B
)	O
in	O
D.	O
discoideum	O
.	O

Amino	O
acid	O
comparison	O
suggested	O
that	O
predicted	O
proteins	O
were	O
homologous	O
to	O
known	O
mu1	B
,	O
mu3	B
and	O
mu4	B
subunits	O
of	O
mammalian	O
APs	B
as	O
they	O
shared	O
69	O
,	O
51	O
,	O
and	O
26	O
%	O
identity	O
with	O
mouse	O
mu1A	B
,	O
human	O
mu3A	B
and	O
human	O
mu4	B
,	O
respectively	O
.	O

In	O
all	O
chains	O
,	O
amino	O
acid	O
residues	O
predicted	O
to	O
interact	O
with	O
tyrosine	O
based	O
sorting	O
signals	O
were	O
conserved	O
.	O

Southern	O
blot	O
analysis	O
indicated	O
only	O
one	O
copy	O
of	O
each	O
gene	O
in	O
D.	O
discoideum	O
genome	O
.	O

Expression	O
of	O
apm1	B
and	O
apm3	B
mRNAs	O
stayed	O
relatively	O
constant	O
during	O
vegetative	O
growth	O
and	O
throughout	O
development	O
.	O

In	O
contrast	O
,	O
apm4	B
was	O
poorly	O
expressed	O
in	O
amoebae	O
but	O
became	O
well	O
detectable	O
by	O
RT	O
-	O
PCR	O
upon	O
cell	O
differentiation	O
.	O

This	O
regulated	O
expression	O
of	O
coat	O
proteins	O
enlightens	O
the	O
importance	O
of	O
intracellular	O
membrane	O
transport	O
vesicles	O
during	O
development	O
in	O
D.	O
discoideum	O
and	O
strengthens	O
this	O
attractive	O
model	O
organism	O
for	O
studying	O
the	O
function	O
of	O
coat	O
complexes	O
in	O
vivo	O
.	O

Characterization	O
of	O
promoter	O
region	O
and	O
genomic	O
structure	O
of	O
the	O
murine	O
and	O
human	O
genes	O
encoding	O
Src	B
like	I
adapter	I
protein	I
.	O

Src	B
-	I
like	I
adapter	I
protein	I
(	O
SLAP	B
)	O
was	O
identified	O
as	O
a	O
signaling	O
molecule	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
system	O
using	O
the	O
cytoplasmic	O
domain	O
of	O
EphA2	B
,	O
a	O
receptor	B
protein	I
tyrosine	I
kinase	I
(	O
Pandey	O
et	O
al.	O
,	O
1995	O
.	O
Characterization	O
of	O
a	O
novel	O
Src	B
-	I
like	I
adapter	I
protein	I
that	O
associates	O
with	O
the	O
Eck	B
receptor	B
tyrosine	I
kinase	I
.	O
J.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
19201	O
-	O
19204	O
)	O
.	O

It	O
is	O
very	O
similar	O
to	O
members	O
of	O
the	O
Src	B
family	I
of	O
cytoplasmic	O
tyrosine	B
kinases	I
in	O
that	O
it	O
contains	O
very	O
homologous	O
SH3	O
and	O
SH2	O
domains	O
(	O
Abram	O
and	O
Courtneidge	O
,	O
2000	O
.	O
Src	B
family	I
tyrosine	I
kinases	I
and	O
growth	B
factor	I
signaling	O
.	O
Exp	O
.	O
Cell	O
.	O
Res	O
.	O
254	O
,	O
1	O
-	O
13	O
.	O
)	O
.	O

However	O
,	O
instead	O
of	O
a	O
kinase	B
domain	O
at	O
the	O
C	O
-	O
terminus	O
,	O
it	O
contains	O
a	O
unique	O
C	O
-	O
terminal	O
region	O
.	O

In	O
order	O
to	O
exclude	O
the	O
possibility	O
that	O
an	O
alternative	O
form	O
exists	O
,	O
we	O
have	O
isolated	O
genomic	O
clones	O
containing	O
the	O
murine	O
Slap	B
gene	O
as	O
well	O
as	O
the	O
human	O
SLA	B
gene	O
.	O

The	O
coding	O
regions	O
of	O
murine	O
Slap	B
and	O
human	O
SLA	B
genes	O
contain	O
seven	O
exons	O
and	O
six	O
introns	O
.	O

Absence	O
of	O
any	O
kinase	B
domain	O
in	O
the	O
genomic	O
region	O
confirm	O
its	O
designation	O
as	O
an	O
adapter	B
protein	I
.	O

Additionally	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
approximately	O
2.6	O
kb	O
of	O
the	O
region	O
5	O
'	O
to	O
the	O
initiator	O
methionine	O
of	O
the	O
murine	O
Slap	B
gene	O
.	O

When	O
subcloned	O
upstream	O
of	O
a	O
luciferase	B
gene	O
,	O
this	O
fragment	O
increased	O
the	O
transcriptional	O
activity	O
about	O
6	O
-	O
fold	O
in	O
a	O
human	O
Jurkat	O
T	O
cell	O
line	O
and	O
approximately	O
52	O
-	O
fold	O
in	O
a	O
murine	O
T	O
cell	O
line	O
indicating	O
that	O
this	O
region	O
contains	O
promoter	O
elements	O
that	O
dictate	O
SLAP	B
expression	O
.	O

We	O
have	O
also	O
cloned	O
the	O
promoter	O
region	O
of	O
the	O
human	O
SLA	B
gene	O
.	O

Since	O
SLAP	B
is	O
transcriptionally	O
regulated	O
by	O
retinoic	O
acid	O
and	O
by	O
activation	O
of	O
B	O
cells	O
,	O
the	O
cloning	O
of	O
its	O
promoter	O
region	O
will	O
permit	O
a	O
detailed	O
analysis	O
of	O
the	O
elements	O
required	O
for	O
its	O
transcriptional	O
regulation	O
.	O

Nephrogenic	O
diabetes	O
insipidus	O
.	O

Nephrogenic	O
diabetes	O
insipidus	O
,	O
which	O
can	O
be	O
inherited	O
or	O
acquired	O
,	O
is	O
characterized	O
by	O
an	O
inability	O
to	O
concentrate	O
urine	O
despite	O
normal	O
or	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
antidiuretic	O
hormone	O
arginine	B
vasopressin	I
.	O

Polyuria	O
,	O
with	O
hyposthenuria	O
,	O
and	O
polydipsia	O
are	O
the	O
cardinal	O
clinical	O
manifestations	O
of	O
the	O
disease	O
.	O

About	O
90	O
%	O
of	O
patients	O
with	O
congenital	O
nephrogenic	O
diabetes	O
insipidus	O
are	O
males	O
with	O
the	O
X	O
-	O
linked	O
recessive	O
form	O
of	O
the	O
disease	O
(	O
OMIM	O
304800	O
)	O
who	O
have	O
mutations	O
in	O
the	O
arginine	B
vasopressin	I
receptor	I
2	I
gene	O
(	O
AVPR2	B
)	O
,	O
which	O
codes	O
for	O
the	O
vasopressin	B
V2	I
receptor	I
.	O

The	O
gene	O
is	O
located	O
in	O
chromosomal	O
region	O
Xq28	O
.	O

In	O
<	O
10	O
%	O
of	O
the	O
families	O
studied	O
,	O
congenital	O
nephrogenic	O
diabetes	O
insipidus	O
has	O
an	O
autosomal	O
-	O
recessive	O
or	O
autosomal	O
-	O
dominant	O
(	O
OMIM	O
222000	O
and	O
125800	O
,	O
respectively	O
)	O
mode	O
of	O
inheritance	O
.	O

Mutations	O
have	O
been	O
identified	O
in	O
the	O
aquaporin-2	B
gene	O
(	O
AQP2	B
)	O
,	O
which	O
is	O
located	O
in	O
chromosome	O
region	O
12q13	O
and	O
codes	O
for	O
the	O
vasopressin	B
-	O
sensitive	O
water	B
channel	I
.	O

When	O
studied	O
in	O
vitro	O
,	O
most	O
AVPR2	B
mutations	O
result	O
in	O
receptors	O
that	O
are	O
trapped	O
intracellularly	O
and	O
are	O
unable	O
to	O
reach	O
the	O
plasma	O
membrane	O
.	O

A	O
few	O
mutant	O
receptors	O
reach	O
the	O
cell	O
surface	O
but	O
are	O
unable	O
to	O
bind	O
arginine	B
vasopressin	I
or	O
to	O
properly	O
trigger	O
an	O
intracellular	O
cyclic	O
AMP	O
signal	O
.	O

Similarly	O
,	O
aquaporin-2	B
mutant	O
proteins	O
are	O
misrouted	O
and	O
can	O
not	O
be	O
expressed	O
at	O
the	O
luminal	O
membrane	O
.	O

Chemical	O
or	O
pharmacological	O
chaperones	O
have	O
been	O
found	O
to	O
reverse	O
the	O
intracellular	O
retention	O
of	O
aquaporin-2	B
and	O
arginine	B
vasopressin	I
receptor	I
2	I
mutant	O
proteins	O
.	O

Because	O
many	O
hereditary	O
diseases	O
stem	O
from	O
the	O
intracellular	O
retention	O
of	O
otherwise	O
functional	O
proteins	O
,	O
this	O
mechanism	O
may	O
offer	O
a	O
new	O
therapeutic	O
approach	O
to	O
the	O
treatment	O
of	O
those	O
diseases	O
that	O
result	O
from	O
errors	O
in	O
protein	O
kinesis	O
.	O

Trifunctional	B
protein	I
deficiency	O
:	O
three	O
families	O
with	O
significant	O
maternal	O
hepatic	O
dysfunction	O
in	O
pregnancy	O
not	O
associated	O
with	O
E474Q	O
mutation	O
.	O

We	O
report	O
five	O
families	O
with	O
trifunctional	B
protein	I
deficiency	O
in	O
which	O
,	O
during	O
pregnancy	O
,	O
three	O
mothers	O
experienced	O
significant	O
hepatic	O
disease	O
when	O
carrying	O
an	O
affected	O
fetus	O
.	O

Diagnoses	O
were	O
based	O
on	O
increased	O
levels	O
of	O
long	O
-	O
chain	O
hydroxyacylcarnitines	O
and	O
deficiencies	O
of	O
3-hydroxyacyl	B
-	I
CoA	I
dehydrogenase	I
(	O
LCHAD	B
)	O
and	O
3-ketoacyl	B
-	I
CoA	I
thiolase	I
activity	O
in	O
fibroblasts	O
.	O

All	O
affected	O
infants	O
lacked	O
the	O
common	O
E474Q	O
mutation	O
associated	O
with	O
isolated	O
LCHAD	B
deficiency	O
.	O

This	O
mutation	O
is	O
thought	O
to	O
be	O
a	O
predisposing	O
factor	O
for	O
maternal	O
hepatic	O
disease	O
in	O
pregnancy	O
.	O

Our	O
findings	O
suggest	O
that	O
other	O
defects	O
in	O
this	O
enzyme	O
complex	O
might	O
be	O
responsible	O
for	O
maternal	O
hepatic	O
complications	O
in	O
pregnancy	O
.	O

Ku	B
autoantigen	I
(	O
DNA	B
helicase	I
)	O
is	O
required	O
for	O
interleukins	B
-	I
13	I
/	I
-	I
4	I
-	O
induction	O
of	O
15-lipoxygenase-1	B
gene	O
expression	O
in	O
human	O
epithelial	O
cells	O
.	O

As	O
reported	O
previously	O
in	O
human	O
monocytes	O
,	O
a	O
human	O
lung	O
epithelial	O
cell	O
line	O
,	O
A549	O
,	O
showed	O
de	O
novo	O
induction	O
of	O
15-Lipoxygenase-1	B
(	O
15-LO-1	B
)	O
in	O
response	O
to	O
interleukins	B
-	I
13	I
(	I
IL-13	I
)	I
and	I
-	I
4	I
(	O
IL-4	B
)	O
.	O

In	O
this	O
cell	O
line	O
,	O
15-LO-1	B
expression	O
,	O
by	O
RT	O
-	O
PCR	O
and	O
western	O
blotting	O
,	O
was	O
observed	O
following	O
6	O
and	O
24	O
h	O
of	O
exposure	O
to	O
human	O
IL-13	B
(	O
ED50	O
5	O
ng	O
/	O
ml	O
)	O
and	O
IL-4	B
(	O
ED50	O
0.2	O
ng	O
/	O
ml	O
)	O
.	O

We	O
have	O
previously	O
shown	O
that	O
no	O
cis	O
-	O
acting	O
regulatory	O
elements	O
exist	O
within	O
the	O
15-LO-1	B
promoter	O
region	O
.	O

To	O
define	O
IL-13	B
and	O
IL-4	B
responsive	O
trans	O
-	O
acting	O
elements	O
,	O
we	O
identified	O
a	O
region	O
(	O
DP2	O
:	O
-	O
353	O
to	O
-	O
304	O
bp	O
site	O
)	O
within	O
the	O
15-LO-1	B
promoter	O
(	O
by	O
footprinting	O
experiments	O
)	O
to	O
which	O
IL-13	B
-	O
responsive	O
elements	O
(	O
or	O
factors	O
)	O
bind	O
specifically	O
(	O
Kelavkar	O
et	O
al	O
,	O
1998	O
,	O
Mol	O
Biol	O
Rep	O
25	O
,	O
173	O
-	O
182	O
)	O
.	O

To	O
further	O
delineate	O
this	O
region	O
,	O
we	O
constructed	O
(	O
by	O
site	O
-	O
directed	O
mutagenesis	O
)	O
several	O
deletion	O
mutants	O
in	O
the	O
'	O
LOPB5	O
'	O
region	O
containing	O
the	O
29	O
bp	O
within	O
the	O
-	O
353	O
to	O
-	O
304	O
bp	O
of	O
the	O
DP2	O
core	O
element	O
.	O

These	O
were	O
:	O
DP3	O
(	O
site	O
totally	O
deleted	O
)	O
,	O
DP4	O
(	O
5	O
bp	O
deleted	O
at	O
the	O
center	O
of	O
the	O
site	O
)	O
,	O
DP5	O
(	O
8	O
bp	O
at	O
the	O
5'-end	O
of	O
the	O
site	O
)	O
and	O
DP6	O
(	O
13	O
bp	O
at	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
site	O
)	O
.	O

Cotransfection	O
of	O
these	O
deletion	O
constructs	O
(	O
driving	O
luciferase	B
reporter	O
genes	O
)	O
was	O
associated	O
with	O
90	O
%	O
(	O
DP4	O
,	O
DP5	O
and	O
DP6	O
)	O
or	O
100	O
%	O
(	O
DP3	O
)	O
abrogation	O
of	O
promoter	O
activity	O
at	O
24	O
h	O
.	O

Purification	O
of	O
nuclear	O
protein	O
extracts	O
from	O
IL-13	B
and	O
IL-4	B
-	O
stimulated	O
A549	O
cells	O
,	O
using	O
a	O
DP2	O
core	O
containing	O
affinity	O
column	O
,	O
identified	O
a	O
150	O
kDa	O
protein	O
under	O
non	O
-	O
denaturing	O
conditions	O
,	O
and	O
two	O
,	O
70	O
and	O
85	O
kDa	O
proteins	O
under	O
denaturing	O
conditions	O
.	O

These	O
were	O
not	O
detectable	O
by	O
Coomassie	O
blue	O
staining	O
in	O
control	O
nuclear	O
protein	O
extracts	O
.	O

Matrix	O
assisted	O
laser	O
desorption	O
ionization	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
MS	O
)	O
of	O
the	O
tryptic	O
digests	O
of	O
these	O
proteins	O
,	O
identified	O
one	O
as	O
the	O
86	B
kDA	I
Lupus	I
KU	I
autoantigen	I
protein	I
P86	I
and	O
the	O
second	O
as	O
the	O
70	B
kDa	I
Lupus	I
KU	I
autoantigen	I
protein	I
P70	I
.	O

Gel	O
shift	O
and	O
supershift	O
experiments	O
using	O
monoclonal	O
antibodies	O
toward	O
Ku	B
antigen	I
and	O
its	O
individual	O
subunits	O
,	O
and	O
utilizing	O
DP2	O
and	O
other	O
mutant	O
oligonucleotides	O
with	O
purified	O
nuclear	O
protein	O
extracts	O
from	O
control	O
and	O
cytokine	B
-	O
treated	O
A549	O
cells	O
,	O
confirmed	O
our	O
findings	O
.	O

Furthermore	O
,	O
electroporation	O
of	O
neutralizing	O
anti	O
-	O
Ku70	B
,	O
Ku	B
80	I
and	O
Ku70	B
/	I
80	I
antibodies	O
into	O
A549	O
cells	O
totally	O
suppressed	O
IL-13	B
and	O
IL-4	B
-	O
stimulated	O
15-LO-1	B
induction	O
in	O
these	O
cells	O
.	O

Further	O
,	O
immunoprecipitation	O
experiments	O
data	O
suggests	O
that	O
IL-4	B
and	O
IL-13	B
activate	O
Ku	B
antigens	I
and	O
15-LO-1	B
expression	O
through	O
distinct	O
signaling	O
events	O
.	O

In	O
summary	O
,	O
in	O
A549	O
cells	O
,	O
Ku	B
antigen	I
is	O
induced	O
in	O
response	O
to	O
the	O
cytokines	O
,	O
IL-13	B
and	I
-	I
4	I
,	O
and	O
a	O
29	O
bp	O
region	O
within	O
the	O
-	O
353	O
to	O
-	O
304	O
bp	O
region	O
of	O
the	O
15-LO-1	B
promoter	O
is	O
required	O
for	O
its	O
binding	O
and	O
subsequent	O
induction	O
of	O
15-LO-1	B
gene	O
expression	O
.	O

The	O
findings	O
may	O
provide	O
an	O
important	O
link	O
between	O
the	O
established	O
dysregulated	O
function	O
of	O
Ku	B
antigen	I
in	O
auto	O
-	O
immune	O
diseases	O
,	O
such	O
as	O
systemic	O
lupus	O
erythematosus	O
and	O
thyroiditis	O
,	O
and	O
the	O
increasingly	O
recognized	O
'	O
anti	O
-	O
inflammatory	O
'	O
role	O
of	O
15-LO-1	B
.	O

Different	O
NK	O
cell	O
surface	O
phenotypes	O
defined	O
by	O
the	O
DX9	O
antibody	O
are	O
due	O
to	O
KIR3DL1	B
gene	O
polymorphism	O
.	O

KIR3DL1	B
and	O
KIR3DL2	B
are	O
NK	O
cell	O
receptors	O
for	O
polymorphic	O
HLA	B
-	I
B	I
and	I
-	I
A	I
determinants	O
.	O

The	O
proportion	O
of	O
NK	O
cells	O
that	O
bind	O
anti	O
-	O
KIR3DL1	B
-	O
specific	O
Ab	O
DX9	O
and	O
their	O
level	O
of	O
binding	O
vary	O
between	O
individuals	O
.	O

To	O
determine	O
whether	O
these	O
differences	O
are	O
due	O
to	O
KIR	B
polymorphism	O
,	O
we	O
assessed	O
KIR3D	B
gene	O
diversity	O
in	O
unrelated	O
individuals	O
and	O
families	O
.	O

Both	O
KIR3DL1	B
and	O
KIR3DL2	B
are	O
highly	O
polymorphic	O
genes	O
,	O
with	O
KIR3DS1	B
segregating	O
like	O
an	O
allele	O
of	O
KIR3DL1	B
.	O

A	O
KIR	B
haplotype	O
lacking	O
KIR3DL1	B
and	O
KIR3DS1	B
was	O
defined	O
.	O

The	O
two	O
KIR3DL1	B
alleles	O
of	O
a	O
heterozygous	O
donor	O
were	O
expressed	O
by	O
different	O
,	O
but	O
overlapping	O
,	O
subsets	O
of	O
NK	O
cell	O
clones	O
.	O

Sequence	O
variation	O
in	O
KIR3DL1	B
and	O
KIR3DL2	B
appear	O
distinct	O
;	O
recombination	O
is	O
more	O
evident	O
in	O
KIR3DL1	B
,	O
and	O
point	O
mutation	O
is	O
more	O
evident	O
in	O
KIR3DL2	B
.	O

The	O
KIR3DL1	B
genotype	O
correlates	O
well	O
with	O
levels	O
of	O
DX9	O
binding	O
by	O
NK	O
cells	O
,	O
but	O
not	O
with	O
the	O
frequency	O
of	O
DX9	O
-	O
binding	O
cells	O
.	O

Different	O
KIR3DL1	B
alleles	O
determine	O
high	O
,	O
low	O
,	O
and	O
no	O
binding	O
of	O
DX9	O
Ab	O
.	O

Consequently	O
,	O
heterozygotes	O
for	O
high	O
and	O
low	O
binding	O
KIR3DL1	B
alleles	O
have	O
distinct	O
subpopulations	O
of	O
NK	O
cells	O
that	O
bind	O
DX9	O
at	O
high	O
and	O
low	O
levels	O
,	O
giving	O
characteristic	O
bimodal	O
distributions	O
in	O
flow	O
cytometry	O
.	O

The	O
Z27	O
Ab	O
gave	O
binding	O
patterns	O
similar	O
to	O
those	O
of	O
DX9	O
.	O

Four	O
KIR3DL1	B
alleles	O
producing	O
high	O
DX9	O
binding	O
phenotypes	O
were	O
distinguished	O
from	O
four	O
alleles	O
producing	O
low	O
or	O
no	O
binding	O
phenotypes	O
by	O
substitution	O
at	O
one	O
or	O
more	O
of	O
four	O
positions	O
in	O
the	O
encoded	O
protein	O
:	O
182	O
and	O
283	O
in	O
the	O
extracellular	O
Ig	B
-	O
like	O
domains	O
,	O
320	O
in	O
the	O
transmembrane	O
region	O
,	O
and	O
373	O
in	O
the	O
cytoplasmic	O
tail	O
.	O

Significance	O
of	O
endothelial	O
prostacyclin	O
and	O
nitric	O
oxide	O
in	O
peripheral	O
and	O
pulmonary	O
circulation	O
.	O

BACKGROUND	O
:	O

Vasoprotective	O
function	O
of	O
endothelial	O
cells	O
is	O
associated	O
,	O
among	O
others	O
,	O
with	O
biosynthesis	O
and	O
release	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
prostacyclin	O
(	O
PGI2	O
)	O
,	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
carbon	O
monoxide	O
(	O
CO	O
)	O
and	O
plasminogen	B
activator	I
(	O
t	B
-	I
PA	I
)	O
.	O

These	O
endothelial	O
mediators	O
calm	O
down	O
activated	O
platelets	O
and	O
leukocytes	O
,	O
prevent	O
the	O
occurrence	O
of	O
parietal	O
thrombotic	O
events	O
,	O
promote	O
thrombolysis	O
,	O
maintain	O
tissue	O
perfusion	O
and	O
protect	O
vascular	O
wall	O
against	O
acute	O
damage	O
and	O
against	O
chronic	O
remodeling	O
.	O

Endothelial	O
dysfunction	O
in	O
patients	O
suffering	O
from	O
atherosclerosis	O
or	O
diabetes	O
type	O
2	O
is	O
associated	O
not	O
only	O
with	O
suppression	O
in	O
release	O
of	O
the	O
above	O
mediators	O
but	O
also	O
with	O
deleterious	O
discharge	O
of	O
prostaglandin	O
endoperoxides	O
(	O
PGH2	O
,	O
PGG2	O
)	O
,	O
superoxide	O
anion	O
(	O
O2	O
-	O
,	O
peroxynitrite	O
(	O
ONOO-	O
)	O
,	O
and	O
plasminogen	B
activator	I
inhibitor	I
(	O
PAI-1	B
)	O
.	O
We	O
looked	O
for	O
mechanisms	O
of	O
protective	O
endothelial	O
function	O
,	O
with	O
a	O
special	O
respect	O
to	O
the	O
differences	O
between	O
peripheral	O
and	O
pulmonary	O
circulation	O
.	O
METHODS	O
:	O
Cultured	O
endothelial	O
cells	O
of	O
bovine	O
aorta	O
(	O
BAEC	O
)	O
were	O
used	O
to	O
study	O
physiological	O
and	O
pharmacological	O
mechanisms	O
of	O
increasing	O
free	O
cytoplasmic	O
calcium	O
[	O
Ca2+	O
]	O
i	O
.	O

A	O
porphyrinic	O
sensor	O
quantified	O
the	O
release	O
of	O
NO	O
from	O
BAEC	O
.	O

In	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
we	O
looked	O
for	O
induction	O
by	O
bradykinin	B
(	O
Bk	B
)	O
of	O
mRNAs	O
for	O
a	O
number	O
of	O
enzymes	O
.	O

In	O
blood	O
perfused	O
rat	O
lungs	O
we	O
studied	O
protective	O
role	O
of	O
NO	O
against	O
injury	O
inferred	O
by	O
lipopolysaccharide	O
on	O
pulmonary	O
microcirculation	O
that	O
was	O
accomplished	O
by	O
thromboxane	O
A2	O
(	O
TXA2	O
)	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
,	O
cysteinyl	O
-	O
leukotrienes	O
(	O
cyst	O
-	O
LTs	O
)	O
and	O
the	O
complement	O
system	O
.	O

In	O
vivo	O
we	O
analyzed	O
the	O
influence	O
of	O
Bk	B
,	O
perindopril	O
and	O
quinapril	O
(	O
'	O
tissue	O
type	O
'	O
angiotensin	B
converting	I
enzyme	I
inhibitors	O
,	O
ACE	B
-	I
Is	I
)	O
on	O
endothelial	O
function	O
in	O
entire	O
circulation	O
of	O
anaesthetized	O
rats	O
using	O
a	O
thrombolytic	O
bioassay	O
and	O
EIA	O
for	O
6-keto	O
-	O
PGF1	O
alpha	O
and	O
t	B
-	I
PA	I
antigen	O
.	O

RESULTS	O
:	O

In	O
BAEC	O
Bk	B
via	O
kinin	B
B2	I
receptors	I
raised	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
1	O
pM-10	O
nM	O
)	O
free	O
cytoplasmic	O
calcium	O
ions	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
that	O
triggered	O
the	O
release	O
of	O
NO	O
from	O
BAEC	O
.	O

Calcium	O
ionophore	O
(	O
A23187	O
,	O
1	O
-	O
100	O
nM	O
)	O
as	O
well	O
as	O
receptor	O
agonists	O
such	O
as	O
adenosine	O
diphosphate	O
(	O
ADP	O
,	O
10	O
nM-1	O
microM	O
)	O
,	O
adrenaline	O
(	O
Adr	O
,	O
1	O
-	O
10	O
microM	O
)	O
or	O
acetylcholine	O
(	O
Ach	O
,	O
10	O
-	O
100	O
microM	O
)	O
produced	O
a	O
similar	O
rise	O
in	O
endothelial	O
[	O
Ca2	O
+	O
]	O
i	O
as	O
did	O
Bk	B
at	O
a	O
nanomolar	O
concentration	O
.	O

'	O
Tissue	O
type	O
'	O
ACE	B
-	O
Is	O
,	O
e.g.	O
quinapril	O
or	O
perindopril	O
acted	O
through	O
accumulation	O
of	O
endogenous	O
Bk	B
.	O

However	O
,	O
the	O
potency	O
of	O
ACE	B
-	O
I	O
to	O
change	O
endothelial	O
function	O
is	O
by	O
several	O
orders	O
of	O
magnitude	O
lower	O
than	O
that	O
for	O
exogenous	O
Bk	B
.	O

In	O
vivo	O
the	O
major	O
difference	O
between	O
thrombolytic	O
actions	O
by	O
quinapril	O
or	O
perindopril	O
on	O
one	O
hand	O
,	O
and	O
by	O
exogenous	O
Bk	B
on	O
the	O
other	O
was	O
longevity	O
of	O
thrombolysis	O
by	O
ACE	B
I	O
and	O
a	O
distinct	O
hypotensive	O
action	O
of	O
exogenous	O
Bk	B
.	O

Still	O
,	O
the	O
long	O
-	O
lasting	O
isolated	O
thrombolytic	O
effect	O
of	O
ACE	B
I	O
was	O
mediated	O
entirely	O
by	O
endogenous	O
BK	B
as	O
evidenced	O
by	O
the	O
preventive	O
action	O
of	O
icatibant	O
,	O
a	O
kinin	B
B2	I
receptor	I
antagonist	O
.	O

Moreover	O
,	O
in	O
vivo	O
the	O
immediate	O
thrombolysis	O
by	O
ACE	B
-	O
I	O
was	O
mediated	O
by	O
PGI2	O
rather	O
than	O
by	O
NO	O
or	O
t	B
-	I
PA	I
,	O
as	O
shown	O
by	O
pharmacological	O
analysis	O
,	O
and	O
by	O
direct	O
blood	O
assays	O
of	O
6-keto	O
-	O
PGF1	O
alpha	O
and	O
t	B
-	I
PA	I
antigen	O
.	O

Bradykinin	O
as	O
a	O
mediator	O
of	O
pleiotropic	O
endothelial	O
action	O
of	O
several	O
cardiovascular	O
drugs	O
(	O
e.g.	O
ACE	B
-	O
I	O
)	O
may	O
complete	O
its	O
mission	O
not	O
only	O
through	O
B2	B
receptor	I
and	O
[	O
Ca2	O
+	O
]	O
i	O
-	O
-	O
mediated	O
release	O
of	O
PGI2	O
or	O
NO	O
.	O

Here	O
,	O
we	O
describe	O
a	O
new	O
route	O
of	O
the	O
Bk	B
action	O
.	O

Bk	B
mediated	O
induction	O
of	O
the	O
[	O
Ca2+	O
]	O
i	O
-	O
independent	O
,	O
so	O
called	O
'	O
inducible	O
'	O
,	O
endothelial	O
isoenzymes	O
required	O
for	O
generation	O
of	O
CO	O
,	O
PGI2	O
and	O
PGE2	O
.	O

After	O
4	O
hours	O
of	O
incubation	O
of	O
HUVEC	O
with	O
Bk	B
(	O
10	O
nM	O
)	O
it	O
induced	O
mRNAs	O
for	O
haemooxygenase	B
1	I
(	O
HO-1	B
)	O
,	O
cyclooxygenase	B
2	I
(	O
COX-2	B
)	O
,	O
prostaglandin	B
E	I
synthase	I
(	O
PGE	B
-	I
S	I
)	O
whereas	O
mRNA	O
for	O
nitric	B
oxide	I
synthase	I
2	I
(	O
NOS-2	B
)	O
was	O
weakly	O
affected	O
.	O

We	O
proved	O
also	O
that	O
unlike	O
in	O
peripheral	O
circulation	O
,	O
in	O
pulmonary	O
circulation	O
only	O
NO	O
but	O
not	O
PGI2	O
would	O
play	O
a	O
protective	O
role	O
.	O

In	O
the	O
blood	O
-	O
perfused	O
lung	O
,	O
endotoxaemia	O
liberates	O
lipids	O
,	O
such	O
as	O
TXA2	O
,	O
PAF	O
and	O
cyst	O
-	O
LTs	O
.	O

These	O
toxic	O
lipids	O
along	O
with	O
the	O
activated	O
complement	O
mediate	O
pulmonary	O
damage	O
.	O

Pulmonary	O
endothelial	O
nitric	O
oxide	O
is	O
the	O
only	O
local	O
protector	O
against	O
lung	O
injury	O
evoked	O
by	O
the	O
phagocytised	O
bacterial	O
lipopolysaccharide	O
.	O

SUMMARY	O
:	O

Summing	O
up	O
,	O
in	O
peripheral	O
circulation	O
endogenous	O
Bk	B
is	O
the	O
most	O
efficient	O
activator	O
of	O
protective	O
endothelial	O
function	O
.	O

For	O
instance	O
,	O
thrombolytic	O
action	O
of	O
'	O
tissue	O
type	O
'	O
ACE	B
-	O
I	O
depends	O
on	O
the	O
Bk	B
-	O
released	O
PGI2	O
.	O

Acting	O
as	O
an	O
agonist	O
of	O
endothelial	O
B2	B
kinin	I
receptors	I
Bk	B
rises	O
[	O
Ca2+	O
]	O
i	O
with	O
a	O
subsequent	O
activation	O
of	O
constitutive	O
COX	B
1	I
and	O
NOS-3	B
.	O

This	O
is	O
followed	O
by	O
an	O
immediate	O
release	O
of	O
PGI2	O
and	O
NO	O
.	O

Moreover	O
,	O
acting	O
as	O
'	O
microcytokine	O
'	O
Bk	B
induces	O
mRNAs	O
for	O
HO-1	B
,	O
COX-2	B
and	O
PGE	B
S	I
,	O
the	O
isoenzymes	O
responsible	O
for	O
a	O
delayed	O
endothelial	O
biosynthesis	O
of	O
CO	O
,	O
PGI2	O
and	O
PGE2	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
)	O

Phase	O
I	O
trial	O
of	O
intravenous	O
peptide	O
-	O
pulsed	O
dendritic	O
cells	O
in	O
patients	O
with	O
metastatic	O
melanoma	O
.	O

Sixteen	O
patients	O
with	O
metastatic	O
stage	O
IV	O
melanoma	O
were	O
treated	O
with	O
use	O
of	O
intravenous	O
infusions	O
of	O
dendritic	O
cells	O
(	O
DC	O
)	O
derived	O
by	O
incubation	O
of	O
plastic	O
-	O
adherent	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
with	O
IL-4	B
and	O
GM	B
-	I
CSF	I
for	O
8	O
days	O
in	O
serumless	O
AIM	O
-	O
V	O
medium	O
,	O
followed	O
by	O
overnight	O
pulsing	O
with	O
peptides	O
.	O

The	O
tyrosinase368	B
-	I
376	I
(	O
370D	O
)	O
and	O
gp100	B
(	O
209	O
-	O
217	O
(	O
210	O
M	O
)	O
)	O
peptides	O
restricted	O
to	O
HLA	B
class	I
I	I
A*0201	I
each	O
differed	O
from	O
wild	O
type	O
by	O
one	O
amino	O
acid	O
modified	O
to	O
increase	O
HLA	B
binding	O
.	O

Median	O
age	O
was	O
49	O
,	O
with	O
nine	O
men	O
and	O
seven	O
women	O
.	O

All	O
patients	O
,	O
except	O
one	O
,	O
had	O
visceral	O
disease	O
.	O

Patients	O
received	O
escalating	O
doses	O
of	O
peptide	O
-	O
pulsed	O
DCs	O
at	O
10e7	O
,	O
3	O
x	O
10e7	O
,	O
and	O
10e8	O
cells	O
/	O
dose	O
twice	O
at	O
2	O
weeks	O
apart	O
,	O
with	O
toxicity	O
and	O
clinical	O
and	O
immune	O
responses	O
as	O
the	O
principal	O
endpoints	O
.	O

The	O
first	O
infusion	O
of	O
DCs	O
was	O
fresh	O
,	O
and	O
frozen	O
DCs	O
were	O
given	O
for	O
the	O
second	O
infusion	O
of	O
each	O
cycle	O
.	O

Mean	O
DC	O
purity	O
by	O
flow	O
cytometry	O
was	O
49	O
%	O
,	O
with	O
a	O
mean	O
HLA	B
-	I
DR	I
level	O
of	O
57	O
%	O
,	O
CD86	B
of	O
41	O
%	O
,	O
CD58	B
of	O
46	O
%	O
,	O
and	O
mean	O
CD14	B
cells	O
of	O
0.9	O
%	O
.	O

Toxicity	O
was	O
minimal	O
,	O
with	O
two	O
patients	O
having	O
transient	O
grade	O
III	O
DC	O
-	O
related	O
toxicity	O
.	O

Ten	O
patients	O
received	O
one	O
cycle	O
of	O
treatment	O
and	O
six	O
patients	O
received	O
two	O
cycles	O
of	O
treatment	O
.	O

One	O
patient	O
had	O
a	O
complete	O
remission	O
(	O
CR	O
)	O
of	O
lung	O
and	O
pleural	O
disease	O
after	O
two	O
cycles	O
of	O
DC	O
therapy	O
.	O

Two	O
additional	O
patients	O
had	O
stable	O
disease	O
and	O
two	O
patients	O
had	O
mixed	O
responses	O
.	O

Overall	O
immunity	O
was	O
assessed	O
by	O
recall	O
skin	O
testing	O
with	O
peptides	O
,	O
gamma	B
interferon	I
ELISA	O
assays	O
of	O
peptide	O
specific	O
cytolytic	O
T	O
cell	O
(	O
CTL	O
)	O
stimulated	O
twice	O
with	O
peptide	O
,	O
IL-2	B
,	O
and	O
IL	B
-	I
7	I
over	O
24	O
days	O
,	O
and	O
peptide	O
-	O
specific	O
tetramer	O
assays	O
performed	O
before	O
and	O
after	O
vaccination	O
.	O

Five	O
of	O
16	O
patients	O
had	O
an	O
immune	O
response	O
to	O
gp100	B
or	O
tyrosinase	O
by	O
gamma	O
interferon	O
ELISA	O
assay	O
;	O
four	O
of	O
five	O
were	O
clinically	O
stable	O
or	O
had	O
tumor	O
regression	O
.	O

These	O
data	O
suggest	O
that	O
melanoma	O
antigen	O
peptide	O
-	O
pulsed	O
DC	O
given	O
intravenously	O
are	O
not	O
toxic	O
,	O
and	O
regression	O
or	O
stability	O
of	O
tumor	O
appeared	O
to	O
correlate	O
with	O
the	O
detection	O
of	O
a	O
peptide	O
-	O
specific	O
immune	O
response	O
in	O
the	O
peripheral	O
blood	O
.	O

Pretreatment	O
with	O
paclitaxel	O
enhances	O
apo-2	B
ligand	I
/	O
tumor	B
necrosis	I
factor	I
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
-	O
induced	O
apoptosis	O
of	O
prostate	O
cancer	O
cells	O
by	O
inducing	O
death	B
receptors	I
4	I
and	I
5	I
protein	O
levels	O
.	O

We	O
have	O
demonstrated	O
that	O
Apo-2	B
ligand	I
(	O
Apo-2L	B
)	O
/	O
tumor	B
necrosis	I
factor	I
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
(	O
TRAIL	B
)	O
induces	O
apoptosis	O
of	O
human	O
prostate	O
cancer	O
PC-3	O
,	O
DU145	O
,	O
and	O
LNCaP	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
PC-3	O
cells	O
displaying	O
the	O
greatest	O
sensitivity	O
to	O
Apo-2L	B
/	O
TRAIL	B
.	O

Susceptibility	O
of	O
the	O
prostate	O
cancer	O
cell	O
types	O
to	O
Apo-2L	B
/	O
TRAIL	B
-	O
induced	O
apoptosis	O
did	O
not	O
appear	O
to	O
correlate	O
with	O
the	O
levels	O
of	O
the	O
Apo-2L	B
/	I
TRAIL	I
receptors	I
death	B
receptor	I
(	I
DR	I
)	I
4	I
(	O
TRAIL	B
receptor	I
1	I
)	O
or	O
DR5	B
(	O
TRAIL	B
receptor	I
2	I
)	O
,	O
decoy	B
receptor	I
(	I
DcR	I
)	I
1	I
and	O
DcR2	B
,	O
Flame-1	B
,	O
or	O
the	O
inhibitors	B
of	I
apoptosis	I
proteins	I
family	I
of	O
proteins	O
.	O

Apo-2L	B
/	O
TRAIL	B
-	O
induced	O
apoptosis	O
of	O
PC-3	O
cells	O
was	O
associated	O
with	O
the	O
processing	O
of	O
caspase-8	B
,	O
caspase-10	B
,	O
and	O
the	O
proapoptotic	O
Bid	B
protein	O
,	O
resulting	O
in	O
the	O
cytosolic	O
accumulation	O
of	O
cytochrome	B
c	I
as	O
well	O
as	O
the	O
processing	O
of	O
procaspase	B
-	I
9	I
and	O
procaspase	B
-	I
3	I
.	O

Cotreatment	O
with	O
the	O
caspase-8	B
inhibitor	O
z	O
-	O
IETD	O
-	O
fmk	O
or	O
DR4	B
:	O
Fc	O
significantly	O
inhibited	O
Apo-2L	B
/	O
TRAIL	B
-	O
induced	O
apoptosis	O
.	O

Treatment	O
with	O
paclitaxel	O
or	O
taxotere	O
increased	O
DR4	B
and/or	O
DR5	B
protein	O
levels	O
(	O
up	O
to	O
8	O
-	O
fold	O
)	O
without	O
affecting	O
the	O
protein	O
levels	O
of	O
DcR1	B
and	O
DcR2	B
,	O
Apo-2L	B
/	O
TRAIL	B
,	O
Fas	B
,	O
or	O
Fas	B
ligand	I
.	O

Up	O
-	O
regulation	O
of	O
DR4	B
and	O
DR5	B
was	O
not	O
preceded	O
by	O
the	O
induction	O
of	O
their	O
mRNA	O
levels	O
but	O
was	O
inhibited	O
by	O
cotreatment	O
with	O
cycloheximide	O
.	O

Importantly	O
,	O
sequential	O
treatment	O
of	O
PC-3	O
,	O
DU145	O
,	O
and	O
LNCaP	O
cells	O
with	O
paclitaxel	O
followed	O
by	O
Apo-2L	B
/	O
TRAIL	B
induced	O
significantly	O
more	O
apoptosis	O
than	O
Apo-2L	B
/	O
TRAIL	B
treatment	O
alone	O
(	O
P	O
<	O
0.01	O
)	O
.	O

This	O
was	O
also	O
associated	O
with	O
greater	O
processing	O
of	O
procaspase-8	B
and	O
Bid	B
,	O
as	O
well	O
as	O
greater	O
cytosolic	O
accumulation	O
of	O
cytochrome	B
c	I
and	O
the	O
processing	O
of	O
caspase-3	B
.	O

These	O
findings	O
indicate	O
that	O
up	O
-	O
regulation	O
of	O
DR4	B
and	O
DR5	B
protein	O
levels	O
by	O
treatment	O
with	O
paclitaxel	O
enhances	O
subsequent	O
Apo-2L	B
/	O
TRAIL	B
-	O
induced	O
apoptosis	O
of	O
human	O
prostate	O
cancer	O
cells	O
.	O

[	O
Aggregation	O
of	O
human	O
blood	O
platelets	O
by	O
remnant	B
-	I
like	I
lipoprotein	I
particles	O
]	O

The	O
action	O
of	O
lipoprotein	B
lipase	I
on	O
chylomicrons	B
(	O
CM	B
)	O
and	O
very	B
low	I
density	I
lipoproteins	I
(	O
VLDL	B
)	O
produces	O
remnant	B
lipoproteins	I
(	O
RLP	B
)	O
that	O
are	O
rich	O
in	O
triglycerides	O
,	O
cholesterol	O
and	O
apolipoprotein	B
E	I
(	O
apo	B
E	I
)	O
.	O

Apo	B
E	I
serves	O
as	O
a	O
ligand	O
for	O
the	O
LDL	B
receptor	I
and	O
mediates	O
uptake	O
of	O
RLP	B
by	O
macrophages	O
,	O
vascular	O
wall	O
and	O
other	O
cells	O
that	O
express	O
the	O
LDL	B
receptor	I
.	O

Uptake	O
of	O
RLP	B
can	O
profoundly	O
alter	O
the	O
physiology	O
of	O
cells	O
and	O
promote	O
atherosclerosis	O
and	O
thrombosis	O
.	O

Like	O
RLP	B
,	O
blood	O
platelets	O
also	O
have	O
roles	O
in	O
atherosclerosis	O
and	O
thrombosis	O
;	O
hence	O
it	O
is	O
likely	O
that	O
RLP	B
can	O
influence	O
platelet	O
activity	O
as	O
well	O
.	O

Platelet	O
aggregation	O
was	O
assessed	O
by	O
measuring	O
the	O
loss	O
of	O
single	O
platelets	O
.	O

Apo	B
E3	I
/	I
3	I
-	O
rich	O
RLP	B
derived	O
from	O
normal	O
human	O
plasma	O
VLDL	B
and	O
CM	B
were	O
prepared	O
by	O
an	O
immunoseparation	O
method	O
.	O

At	O
2.5	O
to	O
10	O
microliters	O
,	O
RLP	B
induced	O
platelet	O
aggregation	O
that	O
increased	O
with	O
the	O
dose	O
of	O
RLP	B
,	O
but	O
decreased	O
it	O
at	O
25	O
to	O
200	O
microliters	O
.	O

Unlike	O
apo	B
E3	I
/	I
3	I
-	O
rich	O
RLP	B
,	O
apo	B
E4	I
/	I
3	I
(	O
heterozygous	O
phenotype	O
)	O
rich	O
RLP	B
caused	O
platelet	O
aggregation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
without	O
producing	O
a	O
bell	O
-	O
shape	O
dose	O
-	O
response	O
relationship	O
.	O

Scanning	O
electron	O
microscopy	O
revealed	O
that	O
activated	O
platelets	O
had	O
adhered	O
to	O
and	O
formed	O
aggregates	O
on	O
the	O
red	O
cell	O
membrane	O
.	O

The	O
platelet	O
response	O
was	O
unaffected	O
by	O
aspirin	O
,	O
but	O
was	O
inhibited	O
by	O
apyrase	B
(	O
an	O
ADP	O
scavenger	O
)	O
,	O
2-chloroadenosine	O
(	O
a	O
platelet	B
ADP	I
-	I
receptor	I
antagonist	O
)	O
and	O
cilostazol	O
,	O
a	O
phosphodiesterase	B
type	I
III	I
inhibitor	O
.	O

It	O
is	O
thought	O
that	O
RLP	B
cause	O
leakage	O
of	O
ADP	O
from	O
red	O
cells	O
,	O
which	O
then	O
mediates	O
platelet	O
aggregation	O
.	O

121R	B
protein	O
from	O
the	O
E3	O
region	O
of	O
bovine	O
adenovirus-3	O
inhibits	O
cytolysis	O
of	O
mouse	O
cells	O
by	O
human	O
tumor	B
necrosis	I
factor	I
.	O

Based	O
on	O
the	O
DNA	O
sequence	O
and	O
known	O
mRNA	O
structures	O
,	O
the	O
early	O
region	O
3	O
(	O
E3	O
)	O
of	O
bovine	O
adenovirus	O
(	O
BAV	O
)	O
-	O
3	O
has	O
the	O
potential	O
to	O
encode	O
four	O
proteins	O
.	O

One	O
of	O
them	O
(	O
121R	B
)	O
is	O
produced	O
as	O
a	O
14.5	B
-	I
kD	I
protein	I
throughout	O
infection	O
.	O

Analysis	O
of	O
the	O
121R	B
protein	O
showed	O
limited	O
homology	O
to	O
a	O
14.7	B
K	I
protein	O
of	O
human	O
adenovirus	O
(	O
HAV	O
)	O
-	O
5	O
.	O

Interestingly	O
,	O
both	O
anti	O
-	O
14.7	B
K	I
and	O
anti	O
-	O
121R	B
sera	O
immunoprecipitated	O
a	O
14.5	B
-	I
kD	I
protein	I
from	O
cells	O
infected	O
with	O
BAV-3	O
.	O

To	O
determine	O
if	O
121R	B
is	O
functionally	O
related	O
to	O
14.7	B
K	I
,	O
we	O
constructed	O
a	O
recombinant	O
E3-deleted	O
HAV-5	O
(	O
AdKV121	O
)	O
expressing	O
the	O
BAV-3	O
E3	O
121R	B
protein	O
.	O

Mouse	O
C3HA	O
cells	O
infected	O
with	O
HAV-5	O
mutant	O
dl	O
758	O
(	O
deletion	O
of	O
14.7	B
K	I
)	O
were	O
sensitive	O
to	O
TNF	B
lysis	O
.	O

However	O
,	O
wild	O
-	O
type	O
HAV-5	O
-	O
or	O
recombinant	O
AdKV121	O
-	O
infected	O
cells	O
were	O
resistant	O
to	O
TNF	B
-	O
induced	O
cytolysis	O
.	O

Our	O
result	O
show	O
that	O
the	O
BAV-3	O
E3	O
121R	B
protein	O
is	O
serologically	O
and	O
functionally	O
related	O
to	O
the	O
14.7	B
K	I
protein	I
encoded	O
by	O
the	O
E3	O
region	O
of	O
HAV-5	O
.	O

Antisense	O
targeting	O
of	O
c	B
-	I
fos	I
transcripts	O
inhibits	O
serum	O
-	O
and	O
TGF	B
-	I
beta	I
1	I
-	O
stimulated	O
PAI-1	B
gene	O
expression	O
and	O
directed	O
motility	O
in	O
renal	O
epithelial	O
cells	O
.	O

Plasminogen	B
activator	I
inhibitor	I
type-1	I
(	O
PAI-1	B
)	O
,	O
the	O
major	O
regulator	O
of	O
pericellular	O
plasmin	B
generation	O
,	O
and	O
the	O
c	B
-	I
FOS	I
transcription	B
factor	I
are	O
expressed	O
by	O
migrating	O
cells	O
in	O
response	O
to	O
monolayer	O
wounding	O
.	O

Induced	O
c	B
-	I
fos	I
and	O
PAI-1	B
transcripts	O
were	O
evident	O
within	O
30	O
min	O
and	O
2	O
h	O
,	O
respectively	O
,	O
of	O
scrape	O
injury	O
to	O
confluent	O
,	O
growth	O
-	O
arrested	O
,	O
cultures	O
of	O
NRK	O
epithelial	O
cells	O
.	O

Since	O
c	B
-	I
FOS	I
/	O
AP-1	B
DNA	O
-	O
binding	O
activity	O
modulates	O
both	O
basal	O
and	O
inducible	O
modes	O
of	O
PAI-1	B
gene	O
control	O
,	O
and	O
AP-1	B
motif	O
binding	O
factors	O
were	O
present	O
in	O
quiescent	O
as	O
well	O
as	O
stimulated	O
NRK	O
cells	O
,	O
a	O
model	O
of	O
directionally	O
regulated	O
cell	O
movement	O
(	O
migration	O
into	O
scrape	O
-	O
denuded	O
""""	O
wounds	O
""""	O
)	O
was	O
used	O
to	O
assess	O
the	O
consequences	O
of	O
c	B
-	I
fos	I
transcript	O
targeting	O
on	O
PAI-1	B
expression	O
and	O
cell	O
motility	O
.	O

This	O
in	O
vitro	O
model	O
of	O
epithelial	O
injury	O
closely	O
approximated	O
in	O
vivo	O
wound	O
repair	O
with	O
regard	O
to	O
the	O
spatial	O
and	O
temporal	O
emergence	O
of	O
cohorts	O
of	O
cells	O
involved	O
in	O
migration	O
,	O
proliferation	O
,	O
and	O
PAI-1	B
expression	O
.	O

Stable	O
cell	O
lines	O
(	O
NRKsof	O
)	O
were	O
generated	O
by	O
transfection	O
of	O
parental	O
NRK	O
cells	O
with	O
a	O
c	B
-	I
fos	I
antisense	O
expression	O
vector	O
.	O

Serum	O
-	O
inducible	O
c	B
-	I
fos	I
transcripts	O
and	O
PAI-1	B
protein	O
levels	O
were	O
significantly	O
attenuated	O
in	O
NRKsof	O
transfectants	O
relative	O
to	O
parental	O
controls	O
or	O
cells	O
transfected	O
with	O
a	O
neo	O
(	O
R	O
)	O
vector	O
without	O
the	O
sof	O
insert	O
.	O

NRKsof	O
cells	O
had	O
a	O
markedly	O
impaired	O
ability	O
to	O
repair	O
scrape	O
-	O
generated	O
monolayer	O
wounds	O
under	O
basal	O
,	O
serum	O
-	O
stimulated	O
,	O
or	O
TGF	B
-	I
beta	I
1	I
-	O
supplemented	O
culture	O
conditions	O
.	O

Since	O
injury	O
closure	O
and	O
PAI-1	B
induction	O
were	O
attenuated	O
in	O
c	B
-	I
fos	I
antisense	O
cells	O
,	O
it	O
was	O
important	O
to	O
clarify	O
the	O
role	O
of	O
specific	O
AP-1	B
sites	O
in	O
serum	O
-	O
mediated	O
PAI-1	B
transcription	O
.	O

PAI-1	B
""""	O
promoter	O
""""	O
-	O
driven	O
CAT	B
reporter	O
expression	O
was	O
assessed	O
within	O
the	O
real	O
time	O
of	O
serum	O
-	O
stimulated	O
PAI-1	B
induction	O
.	O

A	O
segment	O
of	O
the	O
PAI-1	B
promoter	O
corresponding	O
to	O
nucleotides	O
-	O
533	O
to	O
-	O
764	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
functioned	O
as	O
a	O
prominent	O
serum	O
-	O
responsive	O
region	O
(	O
SSR	O
)	O
.	O

The	O
9	O
-	O
fold	O
increase	O
in	O
CAT	B
mRNA	O
levels	O
attained	O
with	O
the	O
-	O
533	O
to	O
-	O
764	O
bp	O
PAI-1	B
SRR	O
ligated	O
to	O
a	O
minimal	O
PAI-1	B
promoter	O
(	O
i.e.	O
,	O
162	O
bp	O
of	O
5	O
'	O
flanking	O
sequence	O
containing	O
the	O
basal	O
transcription	O
complex	O
)	O
closely	O
approximated	O
the	O
serum	O
-	O
induced	O
transcriptional	O
activity	O
of	O
a	O
fully	O
responsive	O
(	O
1	O
,	O
230	O
bp	O
)	O
PAI-1	B
promoter	O
construct	O
as	O
well	O
as	O
the	O
endogenous	O
PAI-1	B
gene	O
.	O

AP-1	B
-	O
like	O
,	O
CTF	B
/	O
NF-1	B
-	O
like	O
,	O
and	O
AP-2	B
sites	O
were	O
identified	O
in	O
the	O
SRR	O
.	O

The	O
SRR	O
AP-1	B
motif	O
was	O
homologous	O
to	O
the	O
sequence	O
TGACACA	O
that	O
mapped	O
between	O
nucleotides	O
-	O
740	O
and	O
-	O
703	O
in	O
the	O
human	O
PAI-1	B
gene	O
,	O
a	O
region	O
essential	O
for	O
growth	B
factor	I
-	O
inducible	O
PAI-1	B
transcription	O
.	O

While	O
the	O
functionality	O
of	O
this	O
AP-1	B
site	O
in	O
wound	O
-	O
regulated	O
PAI-1	B
synthesis	O
remains	O
to	O
be	O
determined	O
,	O
antisense	O
c	B
-	I
fos	I
transcripts	O
effectively	O
attenuated	O
PAI-1	B
induction	O
and	O
basal	O
as	O
well	O
as	O
growth	B
factor	I
-	O
stimulated	O
cell	O
locomotion	O
,	O
indicating	O
that	O
expression	O
of	O
both	O
the	O
PAI-1	B
and	O
c	B
-	I
fos	I
genes	O
is	O
necessary	O
for	O
wound	O
-	O
initiated	O
NRK	O
cell	O
migration	O
.	O

Petunia	O
Ap2	B
-	O
like	O
genes	O
and	O
their	O
role	O
in	O
flower	O
and	O
seed	O
development	O
.	O

We	O
have	O
isolated	O
three	O
Apetala2	B
(	B
Ap2	I
)	I
-	O
like	O
genes	O
from	O
petunia	O
and	O
studied	O
their	O
expression	O
patterns	O
by	O
in	O
situ	O
hybridization	O
.	O

PhAp2A	B
has	O
a	O
high	O
sequence	O
similarity	O
to	O
the	O
A	O
function	O
gene	O
Ap2	B
from	O
Arabidopsis	O
and	O
a	O
similar	O
expression	O
pattern	O
during	O
flower	O
development	O
,	O
suggesting	O
that	O
they	O
are	O
cognate	O
orthologs	O
.	O

PhAp2B	B
and	O
PhAp2C	B
encode	O
for	O
AP2	B
-	O
like	O
proteins	O
that	O
belong	O
to	O
a	O
different	O
subgroup	O
of	O
the	O
AP2	B
family	I
of	I
transcription	I
factors	I
and	O
exhibit	O
divergent	O
,	O
nearly	O
complementary	O
expression	O
patterns	O
during	O
flower	O
development	O
compared	O
with	O
PhAp2A	B
.	O

In	O
contrast	O
,	O
all	O
three	O
PhAp2	B
genes	O
are	O
strongly	O
expressed	O
in	O
endosperm	O
.	O

The	O
phenotype	O
of	O
the	O
petunia	O
A	O
-	O
type	O
mutant	O
blind	O
can	O
not	O
be	O
attributed	O
to	O
mutations	O
in	O
the	O
petunia	O
Ap2	B
homologs	O
identified	O
in	O
this	O
study	O
,	O
and	O
reverse	O
genetics	O
strategies	O
applied	O
to	O
identify	O
phap2a	B
mutants	O
indicate	O
that	O
PhAp2A	B
might	O
not	O
be	O
essential	O
for	O
normal	O
perianth	O
development	O
in	O
petunia	O
.	O

Nevertheless	O
,	O
we	O
show	O
that	O
PhAp2A	B
is	O
capable	O
of	O
restoring	O
the	O
homeotic	O
transformations	O
observed	O
in	O
flowers	O
and	O
seed	O
of	O
the	O
ap2	B
-	I
1	I
mutant	O
of	O
Arabidopsis	O
.	O

Although	O
the	O
interspecific	O
complementation	O
proves	O
that	O
PhAp2A	B
encodes	O
a	O
genuine	O
Ap2	B
ortholog	O
from	O
petunia	O
,	O
additional	O
factors	O
may	O
be	O
involved	O
in	O
the	O
control	O
of	O
perianth	O
identity	O
in	O
this	O
species	O
.	O

C	B
-	I
reactive	I
protein	I
and	O
interleukin	B
6	I
receptor	I
in	O
post	O
-	O
traumatic	O
stress	O
disorder	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
:	O

it	O
has	O
been	O
reported	O
that	O
psychological	O
stress	O
in	O
humans	O
is	O
associated	O
with	O
a	O
derangement	O
of	O
biological	O
homeostasis	O
.	O

This	O
pilot	O
study	O
aimed	O
to	O
examine	O
the	O
inflammatory	O
response	O
to	O
post	O
-	O
traumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
through	O
measurements	O
of	O
the	O
serum	O
levels	O
of	O
the	O
receptor	B
to	I
interleukin	I
6	I
(	O
sIL-6r	B
)	O
and	O
C	B
-	I
reactive	I
protein	I
(	O
CRP	B
)	O
,	O
in	O
relation	O
to	O
measures	O
of	O
psychological	O
disturbance	O
.	O

METHODS	O
:	O

15	O
patients	O
with	O
established	O
PTSD	O
and	O
eight	O
control	O
patients	O
with	O
musculoskeletal	O
injuries	O
were	O
studied	O
at	O
least	O
three	O
months	O
after	O
their	O
index	O
trauma	O
.	O

All	O
completed	O
revised	O
impact	O
of	O
events	O
scale	O
(	O
RIES	O
)	O
,	O
Davidson	O
's	O
trauma	O
scale	O
(	O
DTS	O
)	O
and	O
the	O
general	O
health	O
questionnaire	O
(	O
GHQ	O
)	O
,	O
and	O
gave	O
blood	O
samples	O
that	O
were	O
assayed	O
for	O
CRP	B
and	O
sIL-6r	B
.	O

Statistical	O
analysis	O
was	O
by	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
Wilcoxon	O
rank	O
sum	O
tests	O
.	O

RESULTS	O
:	O

positive	O
relationships	O
were	O
found	O
between	O
sIL-6r	B
and	O
the	O
RIES	O
intrusion	O
score	O
(	O
P	O
=	O
0.026	O
)	O
,	O
and	O
between	O
CRP	B
and	O
DTS	O
intrusion	O
scores	O
(	O
P	O
=	O
0.016	O
)	O
,	O
GHQ	O
depression	O
(	O
P	O
=	O
0.028	O
)	O
,	O
and	O
RIES	O
intrusion	O
(	O
P	O
=	O
0.044	O
)	O
in	O
the	O
case	O
group	O
.	O

DISCUSSION	O
:	O
we	O
have	O
demonstrated	O
a	O
relationship	O
between	O
post	O
-	O
traumatic	O
psychological	O
and	O
biological	O
disturbance	O
,	O
which	O
provides	O
the	O
basis	O
for	O
further	O
research	O
on	O
the	O
effects	O
of	O
psychological	O
disturbance	O
on	O
physical	O
recovery	O
after	O
injury	O
.	O

Binding	O
free	O
energies	O
and	O
free	O
energy	O
components	O
from	O
molecular	O
dynamics	O
and	O
Poisson	O
-	O
Boltzmann	O
calculations	O
.	O

Application	O
to	O
amino	O
acid	O
recognition	O
by	O
aspartyl	B
-	I
tRNA	I
synthetase	I
.	O

Specific	O
amino	O
acid	O
binding	O
by	O
aminoacyl	B
-	I
tRNA	I
synthetases	I
(	O
aaRS	B
)	O
is	O
necessary	O
for	O
correct	O
translation	O
of	O
the	O
genetic	O
code	O
.	O

Engineering	O
a	O
modified	O
specificity	O
into	O
aminoacyl	B
-	I
tRNA	I
synthetases	I
has	O
been	O
proposed	O
as	O
a	O
means	O
to	O
incorporate	O
artificial	O
amino	O
acid	O
residues	O
into	O
proteins	O
in	O
vivo	O
.	O

In	O
a	O
previous	O
paper	O
,	O
the	O
binding	O
to	O
aspartyl	B
-	I
tRNA	I
synthetase	I
of	O
the	O
substrate	O
Asp	O
and	O
the	O
analogue	O
Asn	O
were	O
compared	O
by	O
molecular	O
dynamics	O
free	O
energy	O
simulations	O
.	O

Molecular	O
dynamics	O
combined	O
with	O
Poisson	O
-	O
Boltzmann	O
free	O
energy	O
calculations	O
represent	O
a	O
less	O
expensive	O
approach	O
,	O
suitable	O
for	O
examining	O
multiple	O
active	O
site	O
mutations	O
in	O
an	O
engineering	O
effort	O
.	O

Here	O
,	O
Poisson	O
-	O
Boltzmann	O
free	O
energy	O
calculations	O
for	O
aspartyl	B
-	I
tRNA	I
synthetase	I
are	O
first	O
validated	O
by	O
their	O
ability	O
to	O
reproduce	O
selected	O
molecular	O
dynamics	O
binding	O
free	O
energy	O
differences	O
,	O
then	O
used	O
to	O
examine	O
the	O
possibility	O
of	O
Asn	O
binding	O
to	O
native	O
and	O
mutant	O
aspartyl	B
-	I
tRNA	I
synthetase	I
.	O

A	O
component	O
analysis	O
of	O
the	O
Poisson	O
-	O
Boltzmann	O
free	O
energies	O
is	O
employed	O
to	O
identify	O
specific	O
interactions	O
that	O
determine	O
the	O
binding	O
affinities	O
.	O

The	O
combined	O
use	O
of	O
molecular	O
dynamics	O
free	O
energy	O
simulations	O
to	O
study	O
one	O
binding	O
process	O
thoroughly	O
,	O
followed	O
by	O
molecular	O
dynamics	O
and	O
Poisson	O
-	O
Boltzmann	O
free	O
energy	O
calculations	O
to	O
study	O
a	O
series	O
of	O
related	O
ligands	O
or	O
mutations	O
is	O
proposed	O
as	O
a	O
paradigm	O
for	O
protein	O
or	O
ligand	O
design	O
.	O
The	O
binding	O
of	O
Asn	O
in	O
an	O
alternate	O
,	O
""""	O
head	O
-	O
to	O
-	O
tail	O
""""	O
orientation	O
observed	O
in	O
the	O
homologous	O
asparagine	B
synthetase	I
is	O
analyzed	O
,	O
and	O
found	O
to	O
be	O
more	O
stable	O
than	O
the	O
""""	O
Asp	O
-	O
like	O
""""	O
orientation	O
studied	O
earlier	O
.	O

The	O
new	O
orientation	O
is	O
probably	O
unsuitable	O
for	O
catalysis	O
.	O

A	O
conserved	O
active	O
site	O
lysine	O
(	O
Lys198	O
in	O
Escherichia	O
coli	O
)	O
that	O
recognizes	O
the	O
Asp	O
side	O
-	O
chain	O
is	O
changed	O
to	O
a	O
leucine	O
residue	O
,	O
found	O
at	O
the	O
corresponding	O
position	O
in	O
asparaginyl	B
-	I
tRNA	I
synthetase	I
.	O

It	O
is	O
interesting	O
that	O
the	O
binding	O
of	O
Asp	O
is	O
calculated	O
to	O
increase	O
slightly	O
(	O
rather	O
than	O
to	O
decrease	O
)	O
,	O
while	O
that	O
of	O
Asn	O
is	O
calculated	O
,	O
as	O
expected	O
,	O
to	O
increase	O
strongly	O
,	O
to	O
the	O
same	O
level	O
as	O
Asp	O
binding	O
.	O

Insight	O
into	O
the	O
origin	O
of	O
these	O
changes	O
is	O
provided	O
by	O
the	O
component	O
analyses	O
.	O

The	O
double	O
mutation	O
(	O
K198L	O
,	O
D233E	O
)	O
has	O
a	O
similar	O
effect	O
,	O
while	O
the	O
triple	O
mutation	O
(	O
K198L	O
,	O
Q199E	O
,	O
D233E	O
)	O
reduces	O
Asp	O
binding	O
strongly	O
.	O

No	O
binding	O
measurements	O
are	O
available	O
,	O
but	O
the	O
three	O
mutants	O
are	O
known	O
to	O
have	O
no	O
ability	O
to	O
adenylate	O
Asn	O
,	O
despite	O
the	O
""""	O
Asp	O
-	O
like	O
""""	O
binding	O
affinities	O
calculated	O
here	O
.	O

In	O
molecular	O
dynamics	O
simulations	O
of	O
all	O
three	O
mutants	O
,	O
the	O
Asn	O
ligand	O
backbone	O
shifts	O
by	O
1	O
-	O
2	O
A	O
compared	O
to	O
the	O
experimental	O
Asp	O
:	O
AspRS	B
complex	O
,	O
and	O
significant	O
side	O
-	O
chain	O
rearrangements	O
occur	O
around	O
the	O
pocket	O
.	O

These	O
could	O
reduce	O
the	O
ATP	O
binding	O
constant	O
and/or	O
the	O
adenylation	O
reaction	O
rate	O
,	O
explaining	O
the	O
lack	O
of	O
catalytic	O
activity	O
in	O
these	O
complexes	O
.	O

Finally	O
,	O
Asn	O
binding	O
to	O
AspRS	B
with	O
neutral	O
K198	O
or	O
charged	O
H449	O
is	O
considered	O
,	O
and	O
shown	O
to	O
be	O
less	O
favorable	O
than	O
with	O
the	O
charged	O
K198	O
and	O
neutral	O
H449	O
used	O
in	O
the	O
analysis	O
.	O

Specific	O
IgA	B
antibody	O
response	O
to	O
coproantigens	O
of	O
Cryptosporidium	O
parvum	O
in	O
serum	O
and	O
saliva	O
of	O
calves	O
after	O
experimental	O
infection	O
.	O

The	O
antibody	O
response	O
to	O
coproantigens	O
of	O
Cryptosporidium	O
parvum	O
was	O
examined	O
in	O
saliva	O
and	O
sera	O
of	O
calves	O
experimentally	O
infected	O
with	O
C.	O
parvum	O
.	O

Coproantigens	O
of	O
C.	O
parvum	O
with	O
approximate	O
molecular	O
masses	O
of	O
17	O
,	O
15	O
and	O
less	O
than	O
14kDa	O
were	O
found	O
in	O
the	O
feces	O
of	O
infected	O
calves	O
on	O
day	O
3	O
or	O
later	O
,	O
and	O
60	O
and	O
23kDa	O
coproantigens	O
observed	O
between	O
days	O
4	O
and	O
9	O
post	O
-	O
infection	O
,	O
respectively	O
.	O

The	O
antibody	O
reactivity	O
to	O
the	O
coproantigens	O
was	O
mainly	O
attributable	O
to	O
IgA	B
class	O
antibodies	O
in	O
saliva	O
and	O
was	O
detectable	O
during	O
the	O
convalescent	O
phase	O
of	O
infection	O
.	O

A	O
15kDa	O
protein	O
isolated	O
from	O
the	O
feces	O
of	O
infected	O
calves	O
by	O
immunoaffinity	O
adsorption	O
using	O
a	O
monoclonal	O
anti	O
C.	O
parvum	O
antibody	O
was	O
recognized	O
by	O
IgA	B
antibodies	O
present	O
in	O
the	O
saliva	O
during	O
the	O
convalescent	O
phase	O
of	O
infection	O
.	O

These	O
results	O
suggest	O
that	O
this	O
coproantigen	O
may	O
be	O
released	O
from	O
C.	O
parvum	O
sporozoites	O
and	O
may	O
induce	O
IgA	B
antibody	O
production	O
in	O
the	O
mucosal	O
immune	O
system	O
of	O
infected	O
calves	O
.	O

Interferon	B
-	I
beta	I
induces	O
the	O
development	O
of	O
type	O
2	O
dendritic	O
cells	O
.	O

Suppression	O
of	O
interleukin	B
12	I
(	O
IL-12	B
)	O
production	O
by	O
dendritic	O
cells	O
(	O
DCs	O
)	O
has	O
been	O
hypothesized	O
to	O
be	O
a	O
principal	O
mechanism	O
underlying	O
the	O
biological	O
action	O
of	O
interferon	B
(	I
IFN	I
)	I
-	I
beta	I
used	O
for	O
treatment	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
a	O
chronic	O
inflammatory	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
with	O
possible	O
autoimmune	O
origin	O
.	O

How	O
IFN	B
-	I
beta	I
interacts	O
with	O
DCs	O
to	O
inhibit	O
IL-12	B
production	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
DCs	O
derived	O
from	O
human	O
blood	O
monocytes	O
,	O
upon	O
culture	O
in	O
the	O
presence	O
of	O
IFN	B
-	I
beta	I
with	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
IL-4	B
,	O
differentiated	O
into	O
a	O
population	O
expressing	O
CD14	B
-	O
CD1a	B
-	O
HLA	B
-	I
DR	I
+	O
.	O

This	O
population	O
expressed	O
CD123	B
(	O
IL-3Ralpha	B
)	O
.	O

IFN	B
-	I
beta	I
dose	O
-	O
dependently	O
increased	O
IL-3Ralpha	B
+	O
DCs	O
and	O
decreased	O
CD1a	B
+	O
DCs	O
.	O

After	O
7	O
days	O
'	O
culture	O
with	O
IFN	B
-	I
beta	I
at	O
a	O
concentration	O
of	O
10	O
000	O
U	O
/	O
ml	O
,	O
more	O
than	O
40	O
%	O
of	O
DCs	O
expressed	O
IL-3Ralpha	B
.	O

IFN	B
-	I
beta	I
,	O
together	O
with	O
GM	B
-	I
CSF	I
and	O
IL-4	B
,	O
also	O
induced	O
maturation	O
of	O
IL-3Ralpha	B
-	O
expressing	O
cells	O
,	O
as	O
reflected	O
by	O
upregulation	O
of	O
HLA	B
-	I
DR	I
and	O
of	O
the	O
costimulatory	O
molecules	O
CD40	B
,	O
CD80	B
and	O
CD86	B
.	O

In	O
contrast	O
to	O
control	O
DCs	O
,	O
IFN	B
-	I
beta	I
-	O
treated	O
DCs	O
produced	O
predominantly	O
IL-10	B
but	O
only	O
low	O
levels	O
of	O
IL-12p40	B
.	O

Correspondingly	O
,	O
IFN	B
-	I
beta	I
-	O
treated	O
DCs	O
strongly	O
suppressed	O
IFN	B
-	I
gamma	I
production	O
but	O
enhanced	O
IL-10	B
production	O
by	O
allogeneic	O
blood	O
mononuclear	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
IFN	B
-	I
beta	I
in	O
vitro	O
can	O
induce	O
the	O
development	O
of	O
DC2	O
,	O
which	O
provide	O
a	O
permissive	O
environment	O
for	O
Th2	O
differentiation	O
.	O

This	O
finding	O
represents	O
a	O
novel	O
mechanism	O
for	O
action	O
of	O
IFN	B
-	I
beta	I
in	O
MS	O
.	O

Growth	B
hormone	I
receptor	I
interaction	O
with	O
Jak	B
proteins	O
differs	O
between	O
tissues	O
.	O

Janus	B
kinases	I
(	O
Jak	B
)	O
play	O
an	O
important	O
role	O
in	O
the	O
initial	O
steps	O
of	O
cytokine	B
receptor	I
signaling	O
.	O

The	O
specificity	O
of	O
the	O
four	O
members	O
of	O
the	O
Jak	B
family	I
(	O
Jak1	B
,	O
Jak2	B
,	O
Jak3	B
,	O
and	O
Tyk2	B
)	O
for	O
different	O
cytokine	B
receptors	I
is	O
not	O
fully	O
understood	O
.	O

Recent	O
studies	O
have	O
indicated	O
that	O
a	O
specific	O
cytokine	B
receptor	I
can	O
activate	O
several	O
Jak	B
and	O
that	O
this	O
may	O
differ	O
between	O
tissues	O
.	O

The	O
growth	B
hormone	I
receptor	I
(	O
GHR	B
)	O
is	O
believed	O
to	O
interact	O
predominantly	O
with	O
Jak2	B
,	O
but	O
studies	O
on	O
cell	O
lines	O
have	O
shown	O
that	O
it	O
may	O
also	O
induce	O
phosphorylation	O
of	O
Jak1	B
and	O
Jak3	B
.	O

Little	O
is	O
known	O
about	O
the	O
interaction	O
between	O
the	O
GHR	B
and	O
Jak	B
in	O
tissues	O
.	O

Our	O
aim	O
,	O
therefore	O
,	O
was	O
to	O
elucidate	O
which	O
Jak	B
interact	O
with	O
the	O
GHR	B
in	O
two	O
target	O
tissues	O
for	O
GH	B
,	O
liver	O
and	O
adipose	O
tissue	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
all	O
four	O
members	O
of	O
the	O
Jak	B
family	I
are	O
present	O
in	O
both	O
rat	O
liver	O
and	O
adipose	O
tissue	O
.	O

However	O
,	O
coprecipitation	O
using	O
an	O
anti	O
-	O
GHR	B
antibody	O
revealed	O
that	O
only	O
Jak1	B
and	O
Jak2	B
were	O
associated	O
with	O
the	O
GHR	B
in	O
these	O
tissues	O
.	O

The	O
relative	O
amount	O
of	O
Jak1	B
and	O
Jak2	B
that	O
coprecipitated	O
with	O
the	O
GHR	B
differed	O
markedly	O
between	O
tissues	O
.	O

In	O
the	O
liver	O
,	O
Jak2	B
dominated	O
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
Jak1	B
was	O
detected	O
.	O

In	O
adipose	O
tissue	O
,	O
at	O
least	O
one	O
third	O
of	O
the	O
coprecipitated	O
Jak	B
was	O
Jak1	B
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
that	O
both	O
Jak1	B
and	O
Jak2	B
are	O
associated	O
with	O
the	O
GHR	B
in	O
rat	O
tissues	O
.	O

The	O
difference	O
in	O
the	O
ratio	O
between	O
GHR	B
-	O
associated	O
Jak1	B
and	O
Jak2	B
in	O
liver	O
and	O
adipose	O
tissue	O
may	O
indicate	O
that	O
GHR	B
signaling	O
in	O
different	O
tissues	O
could	O
differ	O
in	O
terms	O
of	O
Jak	B
specificity	O
.	O

In70	O
of	O
plasmid	O
pAX22	O
,	O
a	O
bla	B
(	I
VIM-1	I
)	I
-	O
containing	O
integron	O
carrying	O
a	O
new	O
aminoglycoside	B
phosphotransferase	I
gene	O
cassette	O
.	O

An	O
Achromobacter	O
xylosoxydans	O
strain	O
showing	O
broad	O
-	O
spectrum	O
resistance	O
to	O
beta	O
-	O
lactams	O
(	O
including	O
carbapenems	O
)	O
and	O
aminoglycosides	O
was	O
isolated	O
at	O
the	O
University	O
Hospital	O
of	O
Verona	O
(	O
Verona	O
,	O
Italy	O
)	O
.	O

This	O
strain	O
was	O
found	O
to	O
produce	O
metallo	B
-	I
beta	I
-	I
lactamase	I
activity	O
and	O
to	O
harbor	O
a	O
30	O
-	O
kb	O
nonconjugative	O
plasmid	O
,	O
named	O
pAX22	O
,	O
carrying	O
a	O
bla	B
(	I
VIM-1	I
)	I
determinant	O
inserted	O
into	O
a	O
class	O
1	O
integron	O
.	O

Characterization	O
of	O
this	O
integron	O
,	O
named	O
In70	O
,	O
revealed	O
an	O
original	O
array	O
of	O
four	O
gene	O
cassettes	O
containing	O
,	O
respectively	O
,	O
the	O
bla	B
(	I
VIM-1	I
)	I
gene	O
and	O
three	O
different	O
aminoglycoside	O
resistance	O
determinants	O
,	O
including	O
an	O
aacA4	B
allele	O
,	O
a	O
new	O
aph	B
-	O
like	O
gene	O
named	O
aphA15	B
,	O
and	O
an	O
aadA1	B
allele	O
.	O

The	O
aphA15	B
gene	O
is	O
the	O
first	O
example	O
of	O
an	O
aph	B
-	O
like	O
gene	O
carried	O
on	O
a	O
mobile	O
gene	O
cassette	O
,	O
and	O
its	O
product	O
exhibits	O
close	O
similarity	O
to	O
the	O
APH	B
(	I
3'	I
)	I
-IIa	I
aminoglycoside	I
phosphotransferase	I
encoded	O
by	O
Tn5	O
(	O
36	O
%	O
amino	O
acid	O
identity	O
)	O
and	O
to	O
an	O
APH	B
(	I
3	I
'	I
)	I
-	I
IIb	I
enzyme	O
from	O
Pseudomonas	O
aeruginosa	O
(	O
38	O
%	O
amino	O
acid	O
identity	O
)	O
.	O

Expression	O
of	O
the	O
cloned	O
aphA15	B
gene	O
in	O
Escherichia	O
coli	O
reduced	O
the	O
susceptibility	O
to	O
kanamycin	O
and	O
neomycin	O
as	O
well	O
as	O
(	O
slightly	O
)	O
to	O
amikacin	O
,	O
netilmicin	O
,	O
and	O
streptomycin	O
.	O

Characterization	O
of	O
the	O
5	O
'	O
and	O
3	O
'	O
conserved	O
segments	O
of	O
In70	O
and	O
of	O
their	O
flanking	O
regions	O
showed	O
that	O
In70	O
belongs	O
to	O
the	O
group	O
of	O
class	O
1	O
integrons	O
associated	O
with	O
defective	O
transposon	O
derivatives	O
originating	O
from	O
Tn402	O
-	O
like	O
elements	O
.	O

The	O
structure	O
of	O
the	O
3	O
'	O
conserved	O
segment	O
indicates	O
the	O
closest	O
ancestry	O
with	O
members	O
of	O
the	O
In0-In2	O
lineage	O
.	O

In70	O
,	O
with	O
its	O
array	O
of	O
cassette	O
-	O
borne	O
resistance	O
genes	O
,	O
can	O
mediate	O
broad	O
-	O
spectrum	O
resistance	O
to	O
most	O
beta	O
-	O
lactams	O
and	O
aminoglycosides	O
.	O

Transcription	B
factors	I
TFIIF	B
,	O
ELL	B
,	O
and	O
Elongin	B
negatively	O
regulate	O
SII	B
-	O
induced	O
nascent	O
transcript	O
cleavage	O
by	O
non	O
-	O
arrested	O
RNA	B
polymerase	I
II	I
elongation	O
intermediates	O
.	O

TFIIF	B
,	O
ELL	B
,	O
and	O
Elongin	B
belong	O
to	O
a	O
class	O
of	O
RNA	B
polymerase	I
II	I
transcription	B
factors	I
that	O
function	O
similarly	O
to	O
activate	O
the	O
rate	O
of	O
elongation	O
by	O
suppressing	O
transient	O
pausing	O
by	O
polymerase	B
at	O
many	O
sites	O
along	O
DNA	O
templates	O
.	O

SII	B
is	O
a	O
functionally	O
distinct	O
RNA	B
polymerase	I
II	I
elongation	B
factor	I
that	O
promotes	O
elongation	O
by	O
reactivating	O
arrested	O
polymerase	B
.	O

Studies	O
of	O
the	O
mechanism	O
of	O
SII	B
action	O
have	O
shown	O
(	O
i	O
)	O
that	O
arrest	O
of	O
RNA	B
polymerase	I
II	I
results	O
from	O
irreversible	O
displacement	O
of	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
nascent	O
transcript	O
from	O
the	O
polymerase	B
catalytic	O
site	O
and	O
(	O
ii	O
)	O
that	O
SII	B
reactivates	O
arrested	O
polymerase	B
by	O
inducing	O
endonucleolytic	O
cleavage	O
of	O
the	O
nascent	O
transcript	O
by	O
the	O
polymerase	B
catalytic	O
site	O
thereby	O
creating	O
a	O
new	O
transcript	O
3	O
'	O
-	O
end	O
that	O
is	O
properly	O
aligned	O
with	O
the	O
catalytic	O
site	O
and	O
can	O
be	O
extended	O
.	O

SII	B
also	O
induces	O
nascent	O
transcript	O
cleavage	O
by	O
paused	O
but	O
non	O
-	O
arrested	O
RNA	B
polymerase	I
II	I
elongation	O
intermediates	O
,	O
leading	O
to	O
the	O
proposal	O
that	O
pausing	O
may	O
result	O
from	O
reversible	O
displacement	O
of	O
the	O
3	O
'	O
-	O
end	O
of	O
nascent	O
transcripts	O
from	O
the	O
polymerase	B
catalytic	O
site	O
.	O

On	O
the	O
basis	O
of	O
evidence	O
consistent	O
with	O
the	O
model	O
that	O
TFIIF	B
,	O
ELL	B
,	O
and	O
Elongin	B
suppress	O
pausing	O
by	O
preventing	O
displacement	O
of	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
nascent	O
transcript	O
from	O
the	O
polymerase	B
catalytic	O
site	O
,	O
we	O
investigated	O
the	O
possibility	O
of	O
cross	O
-	O
talk	O
between	O
SII	B
and	O
transcription	B
factors	I
TFIIF	B
,	O
ELL	B
,	O
and	O
Elongin	B
.	O

These	O
studies	O
led	O
to	O
the	O
discovery	O
that	O
TFIIF	B
,	O
ELL	B
,	O
and	O
Elongin	B
are	O
all	O
capable	O
of	O
inhibiting	O
SII	B
-	O
induced	O
nascent	O
transcript	O
cleavage	O
by	O
non	O
-	O
arrested	O
RNA	B
polymerase	I
II	I
elongation	O
intermediates	O
.	O

Here	O
we	O
present	O
these	O
findings	O
,	O
which	O
bring	O
to	O
light	O
a	O
novel	O
activity	O
associated	O
with	O
TFIIF	B
,	O
ELL	B
,	O
and	O
Elongin	B
and	O
suggest	O
that	O
these	O
transcription	B
factors	I
may	O
expedite	O
elongation	O
not	O
only	O
by	O
increasing	O
the	O
forward	O
rate	O
of	O
nucleotide	O
addition	O
by	O
RNA	B
polymerase	I
II	I
,	O
but	O
also	O
by	O
inhibiting	O
SII	B
-	O
induced	O
nascent	O
transcript	O
cleavage	O
by	O
non	O
-	O
arrested	O
RNA	B
polymerase	I
II	I
elongation	O
intermediates	O
.	O

Brachytelephalangic	O
dwarfism	O
due	O
to	O
the	O
loss	O
of	O
ARSE	B
and	O
SHOX	B
genes	O
resulting	O
from	O
an	O
X	O
;	O
Y	O
translocation	O
.	O

Here	O
we	O
report	O
an	O
8	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
had	O
mesomelic	O
shortening	O
of	O
forearms	O
and	O
legs	O
,	O
brachytelephalangia	O
and	O
ichthyotic	O
skin	O
lesions	O
.	O

Chromosomal	O
analysis	O
showed	O
an	O
X	O
;	O
Y	O
translocation	O
involving	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
(	O
Xp	O
)	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
and	O
molecular	O
studies	O
localized	O
the	O
breakpoints	O
on	O
Xp22.3	O
in	O
the	O
immediate	O
vicinity	O
of	O
the	O
KAL	B
gene	O
demonstrating	O
deletions	O
of	O
steroid	B
sulfatase	I
(	O
STS	B
)	O
,	O
arylsulfatase	B
E	I
(	O
ARSE	B
)	O
,	O
and	O
short	B
stature	I
homeo	I
box	I
(	O
SHOX	B
)	O
genes	O
.	O

It	O
was	O
suspected	O
that	O
the	O
patient	O
was	O
suffering	O
from	O
chondrodysplasia	O
punctata	O
because	O
of	O
a	O
loss	O
of	O
the	O
arylsulfatase	B
E	I
(	O
ARSE	B
)	O
gene	O
.	O

However	O
,	O
no	O
stippled	O
epiphyses	O
were	O
to	O
be	O
seen	O
in	O
the	O
neonatal	O
radiograph	O
.	O

Interestingly	O
,	O
this	O
patient	O
is	O
the	O
first	O
case	O
with	O
a	O
proven	O
loss	O
of	O
the	O
ARSE	B
gene	O
without	O
chondrodysplasia	O
punctata	O
,	O
assuming	O
that	O
chondrodysplasia	O
punctata	O
is	O
not	O
an	O
obligatory	O
sign	O
of	O
ARSE	B
gene	O
loss	O
.	O

Brachytelephalangia	O
was	O
the	O
only	O
result	O
of	O
ARSE	B
gene	O
deletion	O
in	O
this	O
case	O
.	O

The	O
patient	O
's	O
mother	O
also	O
had	O
dwarfism	O
and	O
showed	O
Madelung	O
deformity	O
of	O
the	O
forearms	O
.	O

She	O
was	O
detected	O
as	O
a	O
carrier	O
of	O
the	O
same	O
aberrant	O
X	O
chromosome	O
.	O

The	O
male	O
patient	O
did	O
not	O
show	O
Madelung	O
deformity	O
,	O
demonstrating	O
that	O
Lerri	O
-	O
Weill	O
syndrome	O
phenotype	O
may	O
be	O
still	O
incomplete	O
in	O
children	O
with	O
SHOX	B
gene	O
deletion	O
.	O

The	O
wide	O
clinical	O
spectrum	O
in	O
the	O
male	O
and	O
the	O
Leri	O
-	O
Weill	O
phenotype	O
in	O
his	O
mother	O
are	O
the	O
results	O
of	O
both	O
a	O
deletion	O
involving	O
several	O
sulfatase	B
genes	O
in	O
Xp22.3	O
and	O
the	O
SHOX	B
gene	O
located	O
in	O
the	O
pseudoautosomal	O
region	O
.	O

Nevertheless	O
,	O
there	O
is	O
no	O
explanation	O
for	O
the	O
absence	O
of	O
chondrodysplasia	O
punctata	O
despite	O
the	O
total	O
loss	O
of	O
the	O
ARSE	B
gene	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
genotype	O
/	O
phenotype	O
correlation	O
in	O
cases	O
with	O
translocations	O
or	O
microdeletions	O
on	O
Xp22.3	O
,	O
including	O
the	O
ARSE	B
and	O
the	O
SHOX	B
gene	O
loci	O
.	O

The	O
human	O
tumor	O
suppressor	O
arf	B
interacts	O
with	O
spinophilin	B
/	O
neurabin	B
II	I
,	O
a	O
type	O
1	O
protein	B
-	I
phosphatase	I
-	O
binding	O
protein	O
.	O

The	O
INK4a	B
gene	O
,	O
one	O
of	O
the	O
most	O
often	O
disrupted	O
loci	O
in	O
human	O
cancer	O
,	O
encodes	O
two	O
unrelated	O
proteins	O
,	O
p16	B
(	I
INK4a	I
)	I
and	O
p14	B
(	I
ARF	I
)	I
(	O
ARF	B
)	O
both	O
capable	O
of	O
inducing	O
cell	O
cycle	O
arrest	O
.	O

Although	O
it	O
has	O
been	O
clearly	O
demonstrated	O
that	O
ARF	B
inhibits	O
cell	O
cycle	O
via	O
p53	B
stabilization	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
involvement	O
of	O
ARF	B
in	O
other	O
cell	O
cycle	O
regulatory	O
pathways	O
,	O
as	O
well	O
as	O
on	O
the	O
mechanisms	O
responsible	O
for	O
activating	O
ARF	B
following	O
oncoproliferative	O
stimuli	O
.	O

In	O
search	O
of	O
factors	O
that	O
might	O
associate	O
with	O
ARF	B
to	O
control	O
its	O
activity	O
or	O
its	O
specificity	O
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
.	O

We	O
report	O
here	O
that	O
the	O
human	O
homologue	O
of	O
spinophilin	B
/	O
neurabin	B
II	I
,	O
a	O
regulatory	O
subunit	O
of	O
protein	B
phosphatase	I
1	I
catalytic	I
subunit	I
specifically	O
interacts	O
with	O
ARF	B
,	O
both	O
in	O
yeast	O
and	O
in	O
mammalian	O
cells	O
.	O

We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
spinophilin	B
/	O
neurabin	B
II	I
inhibits	O
the	O
formation	O
of	O
G418	O
-	O
resistant	O
colonies	O
when	O
transfected	O
into	O
human	O
and	O
mouse	O
cell	O
lines	O
,	O
regardless	O
of	O
p53	B
and	O
ARF	B
status	O
.	O

Moreover	O
,	O
spinophilin	B
/	O
ARF	B
coexpression	O
in	O
Saos-2	O
cells	O
,	O
where	O
ARF	B
ectopic	O
expression	O
is	O
ineffective	O
,	O
somehow	O
results	O
in	O
a	O
synergic	O
effect	O
.	O

These	O
data	O
demonstrate	O
a	O
role	O
for	O
spinophilin	B
in	O
cell	O
growth	O
and	O
suggest	O
that	O
ARF	B
and	O
spinophilin	B
could	O
act	O
in	O
partially	O
overlapping	O
pathways	O
.	O

Thrombin	B
regulates	O
vascular	O
smooth	O
muscle	O
cell	O
growth	O
and	O
heat	B
shock	I
proteins	I
via	O
the	O
JAK	B
-	O
STAT	B
pathway	O
.	O

The	O
growth	O
-	O
stimulating	O
effects	O
of	O
thrombin	B
are	O
mediated	O
primarily	O
via	O
activation	O
of	O
a	O
G	B
protein	I
-	I
coupled	I
receptor	I
,	O
PAR-1	B
.	O

Because	O
PAR-1	B
has	O
no	O
intrinsic	O
tyrosine	B
kinase	I
activity	O
,	O
yet	O
requires	O
tyrosine	O
phosphorylation	O
events	O
to	O
induce	O
mitogenesis	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
Janus	B
tyrosine	I
kinases	I
(	O
JAKs	B
)	O
in	O
thrombin	B
-	O
mediated	O
signaling	O
.	O

JAK2	B
was	O
activated	O
rapidly	O
in	O
rat	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMC	O
)	O
treated	O
with	O
thrombin	B
,	O
and	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
STAT1	B
and	O
STAT3	B
)	O
were	O
phosphorylated	O
and	O
translocated	O
to	O
the	O
nucleus	O
in	O
a	O
JAK2	B
-	O
dependent	O
manner	O
.	O

AG-490	O
,	O
a	O
JAK2	B
-	O
specific	O
inhibitor	O
,	O
and	O
a	O
dominant	O
negative	O
JAK2	B
mutant	O
inhibited	O
thrombin	B
-	O
induced	O
ERK2	B
activity	O
and	O
VSMC	O
proliferation	O
suggesting	O
that	O
JAK2	B
is	O
upstream	O
of	O
the	O
Ras	B
/	O
Raf	B
/	O
MEK	B
/	O
ERK	B
pathway	O
.	O

To	O
elucidate	O
the	O
functional	O
significance	O
of	O
JAK	B
-	O
STAT	B
activation	O
,	O
we	O
studied	O
the	O
effect	O
of	O
thrombin	B
on	O
heat	B
shock	I
protein	I
(	O
Hsp	B
)	O
expression	O
,	O
based	O
upon	O
the	O
following	O
:	O
1	O
)	O
reports	O
that	O
thrombin	B
stimulates	O
reactive	O
oxygen	O
species	O
production	O
in	O
VSMC	O
;	O
2	O
)	O
the	O
putative	O
role	O
of	O
Hsps	B
in	O
modulating	O
cellular	O
responses	O
to	O
reactive	O
oxygen	O
species	O
;	O
and	O
3	O
)	O
the	O
presence	O
of	O
functional	O
STAT1	B
/	I
3	I
-	O
binding	O
sites	O
in	O
Hsp70	B
and	O
Hsp90beta	B
promoters	O
.	O

Indeed	O
,	O
thrombin	O
up	O
-	O
regulated	O
Hsp70	B
and	O
Hsp90	B
protein	O
expression	O
via	O
enhanced	O
binding	O
of	O
STATs	B
to	O
cognate	O
binding	O
sites	O
in	O
the	O
Hsp70	B
and	O
Hsp90	B
promoters	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
JAK	B
-	O
STAT	B
pathway	O
activation	O
is	O
necessary	O
for	O
thrombin	B
-	O
induced	O
VSMC	O
growth	O
and	O
Hsp	B
gene	O
expression	O
.	O

Gaf-1	B
,	O
a	O
gamma	B
-	I
SNAP	I
-	O
binding	O
protein	O
associated	O
with	O
the	O
mitochondria	O
.	O

The	O
role	O
of	O
alpha	B
/	I
beta	I
-	I
SNAP	I
(	O
Soluble	B
NSF	I
Attachment	I
Protein	I
)	O
in	O
vesicular	O
trafficking	O
is	O
well	O
established	O
;	O
however	O
,	O
the	O
function	O
of	O
the	O
ubiquitously	O
expressed	O
gamma	B
-	I
SNAP	I
remains	O
unclear	O
.	O

To	O
further	O
characterize	O
the	O
cellular	O
role	O
of	O
this	O
enigmatic	O
protein	O
,	O
a	O
two	O
-	O
hybrid	O
screen	O
was	O
used	O
to	O
identify	O
new	O
,	O
gamma	B
-	I
SNAP	I
-	O
binding	O
proteins	O
and	O
to	O
uncover	O
potentially	O
novel	O
functions	O
for	O
gamma	B
-	I
SNAP	I
.	O

One	O
such	O
SNAP	B
-	O
binding	O
protein	O
,	O
termed	O
Gaf-1	B
(	O
gamma	B
-	I
SNAP	I
associate	I
factor-1	I
)	I
specifically	O
binds	O
gamma	B
-	I
but	I
not	I
alpha	I
-	I
SNAP	I
.	O

The	O
full	O
-	O
length	O
Gaf-1	B
(	O
75	O
kDa	O
)	O
is	O
ubiquitously	O
expressed	O
and	O
is	O
found	O
stoichiometrically	O
associated	O
with	O
gamma	B
-	I
SNAP	I
in	O
cellular	O
extracts	O
.	O

This	O
binding	O
is	O
distinct	O
from	O
other	O
SNAP	B
interactions	O
since	O
no	O
alpha	B
-	I
SNAP	I
or	O
NSF	B
coprecipitated	O
with	O
Gaf-1	B
.	O

Subcellular	O
fractionation	O
and	O
immunofluorescence	O
analysis	O
show	O
that	O
Gaf-1	B
is	O
peripherally	O
associated	O
with	O
the	O
outer	O
mitochondrial	O
membrane	O
.	O

Only	O
a	O
fraction	O
of	O
gamma	B
-	I
SNAP	I
was	O
mitochondrial	O
with	O
the	O
balance	O
being	O
either	O
cytosolic	O
or	O
associated	O
with	O
other	O
membrane	O
fractions	O
.	O

gamma	B
-	I
SNAP	I
and	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
Gaf-1	B
both	O
show	O
a	O
reticular	O
distribution	O
in	O
HEK-293	O
cells	O
.	O

This	O
reticular	O
structure	O
colocalizes	O
with	O
Gaf-1	B
and	O
mitochondria	O
as	O
well	O
as	O
with	O
microtubules	O
but	O
not	O
with	O
other	O
cytoskeletal	O
elements	O
.	O

These	O
data	O
identify	O
a	O
class	O
of	O
gamma	B
-	I
SNAP	I
interactions	O
that	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
SNAP	B
family	I
and	O
point	O
to	O
a	O
potential	O
role	O
for	O
gamma	B
-	I
SNAP	I
in	O
mitochondrial	O
dynamics	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
mammalian	O
enzyme	O
catalyzing	O
the	O
asymmetric	O
oxidative	O
cleavage	O
of	O
provitamin	O
A	O
.	O

In	O
vertebrates	O
,	O
symmetric	O
versus	O
asymmetric	O
cleavage	O
of	O
beta	O
-	O
carotene	O
in	O
the	O
biosynthesis	O
of	O
vitamin	O
A	O
and	O
its	O
derivatives	O
has	O
been	O
controversially	O
discussed	O
.	O

Recently	O
we	O
have	O
been	O
able	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
metazoan	O
beta	B
,	I
beta	I
-	I
carotene-15,15'-dioxygenase	I
from	O
the	O
fruit	O
fly	O
Drosophila	O
melanogaster	O
.	O

This	O
enzyme	O
catalyzes	O
the	O
key	O
step	O
in	O
vitamin	O
A	O
biosynthesis	O
,	O
symmetrically	O
cleaving	O
beta	O
-	O
carotene	O
to	O
give	O
two	O
molecules	O
of	O
retinal	O
.	O

Mutations	O
in	O
the	O
corresponding	O
gene	O
are	O
known	O
to	O
lead	O
to	O
a	O
blind	O
,	O
vitamin	O
A	O
-	O
deficient	O
phenotype	O
.	O

Orthologs	O
of	O
this	O
enzyme	O
have	O
very	O
recently	O
been	O
found	O
also	O
in	O
vertebrates	O
and	O
molecularly	O
characterized	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
cDNA	O
from	O
mouse	O
encoding	O
a	O
second	O
type	O
of	O
carotene	B
dioxygenase	I
catalyzing	O
exclusively	O
the	O
asymmetric	O
oxidative	O
cleavage	O
of	O
beta	O
-	O
carotene	O
at	O
the	O
9	O
'	O
,	O
10	O
'	O
double	O
bond	O
of	O
beta	O
-	O
carotene	O
and	O
resulting	O
in	O
the	O
formation	O
of	O
beta	O
-	O
apo-10'-carotenal	O
and	O
beta	O
-	O
ionone	O
,	O
a	O
substance	O
known	O
as	O
a	O
floral	O
scent	O
from	O
roses	O
,	O
for	O
example	O
.	O

Besides	O
beta	O
-	O
carotene	O
,	O
lycopene	O
is	O
also	O
oxidatively	O
cleaved	O
by	O
the	O
enzyme	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
shares	O
significant	O
sequence	O
identity	O
with	O
the	O
beta	B
,	I
beta	I
-	I
carotene-15,15'-dioxygenases	I
,	O
and	O
the	O
two	O
enzyme	O
types	O
have	O
several	O
conserved	O
motifs	O
.	O

To	O
establish	O
its	O
occurrence	O
in	O
different	O
vertebrates	O
,	O
we	O
then	O
attempted	O
and	O
succeeded	O
in	O
cloning	O
cDNAs	O
encoding	O
this	O
new	O
type	O
of	O
carotene	B
dioxygenase	I
from	O
human	O
and	O
zebrafish	O
as	O
well	O
.	O

As	O
regards	O
their	O
possible	O
role	O
,	O
the	O
apocarotenals	O
formed	O
by	O
this	O
enzyme	O
may	O
be	O
the	O
precursors	O
for	O
the	O
biosynthesis	O
of	O
retinoic	O
acid	O
or	O
exert	O
unknown	O
physiological	O
effects	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
Drosophila	O
,	O
in	O
vertebrates	O
both	O
symmetric	O
and	O
asymmetric	O
cleavage	O
pathways	O
exist	O
for	O
carotenes	O
,	O
revealing	O
a	O
greater	O
complexity	O
of	O
carotene	O
metabolism	O
.	O

Thiazolidinediones	O
but	O
not	O
metformin	O
directly	O
inhibit	O
the	O
steroidogenic	O
enzymes	O
P450c17	B
and	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
.	O

Androgen	O
biosynthesis	O
requires	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
II	I
(	O
3betaHSDII	B
)	O
and	O
the	O
17alpha	B
-	I
hydroxylase	I
and	O
17,20-lyase	B
activities	O
of	O
cytochrome	B
P450c17	I
.	O

Thiazolidinedione	O
and	O
biguanide	O
drugs	O
,	O
which	O
are	O
used	O
to	O
increase	O
insulin	B
sensitivity	O
in	O
type	O
2	O
diabetes	O
,	O
lower	O
serum	O
androgen	O
concentrations	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
this	O
is	O
secondary	O
to	O
increased	O
insulin	B
sensitivity	O
or	O
to	O
direct	O
effects	O
on	O
steroidogenesis	O
.	O

To	O
investigate	O
potential	O
actions	O
of	O
these	O
drugs	O
on	O
P450c17	B
and	O
3betaHSDII	B
,	O
we	O
used	O
""""	O
humanized	O
yeast	O
""""	O
that	O
express	O
these	O
steroidogenic	O
enzymes	O
in	O
microsomal	O
environments	O
.	O

The	O
biguanide	O
metformin	O
had	O
no	O
effect	O
on	O
either	O
enzyme	O
,	O
whereas	O
the	O
thiazolidinedione	O
troglitazone	O
inhibited	O
3betaHSDII	B
(	O
K	O
(	O
I	O
)	O
=	O
25.4	O
+	O
/-	O
5.1	O
microm	O
)	O
and	O
both	O
activities	O
of	O
P450c17	B
(	O
K	O
(	O
I	O
)	O
for	O
17alpha	O
-	O
hydroxylase	O
,	O
8.4	O
+	O
/-	O
0.6	O
microm	O
;	O
K	O
(	O
I	O
)	O
for	O
17,20-lyase	O
,	O
5.3	O
+	O
/-	O
0.7	O
microm	O
)	O
.	O

The	O
action	O
of	O
troglitazone	O
on	O
P450c17	B
was	O
competitive	O
,	O
but	O
it	O
was	O
mainly	O
a	O
noncompetitive	O
inhibitor	O
of	O
3betaHSDII	B
.	O

The	O
thiazolidinediones	O
rosiglitazone	O
and	O
pioglitazone	O
exerted	O
direct	O
but	O
weaker	O
inhibitory	O
effects	O
on	O
both	O
P450c17	B
and	O
3betaHSDII	B
.	O

These	O
differential	O
effects	O
of	O
the	O
thiazolidinediones	O
do	O
not	O
correlate	O
with	O
their	O
effects	O
on	O
insulin	B
sensitivity	O
,	O
suggesting	O
that	O
distinct	O
regions	O
of	O
the	O
thiazolidinedione	O
molecule	O
mediate	O
these	O
two	O
actions	O
.	O

Thus	O
,	O
thiazolidinediones	O
inhibit	O
two	O
key	O
enzymes	O
in	O
human	O
androgen	O
synthesis	O
contributing	O
to	O
their	O
androgen	O
-	O
lowering	O
effects	O
,	O
whereas	O
metformin	O
affects	O
androgen	O
synthesis	O
indirectly	O
,	O
probably	O
by	O
lowering	O
circulating	O
insulin	B
concentrations	O
.	O

The	O
AraC	B
transcriptional	O
activators	O
.	O

The	O
AraC	B
family	I
of	O
bacterial	O
transcriptional	O
activators	O
regulate	O
diverse	O
genetic	O
systems	O
.	O

Recent	O
X	O
-	O
ray	O
diffraction	O
studies	O
show	O
that	O
the	O
monomeric	O
MarA	B
and	O
Rob	B
activators	O
bind	O
to	O
their	O
asymmetric	O
degenerate	O
DNA	O
sites	O
via	O
two	O
different	O
helix	O
-	O
turn	O
-	O
helix	O
elements	O
.	O

Activation	O
by	O
MarA	B
,	O
SoxS	B
or	O
Rob	B
requires	O
a	O
particular	O
orientation	O
of	O
the	O
asymmetric	O
binding	O
sequence	O
(	O
and	O
hence	O
the	O
activator	O
)	O
,	O
depending	O
on	O
its	O
distance	O
from	O
the	O
-	O
10	O
RNAP	B
signal	O
.	O

Genetic	O
studies	O
are	O
beginning	O
to	O
clarify	O
how	O
the	O
activators	O
interact	O
with	O
RNAP	B
.	O

Growing	O
evidence	O
suggests	O
that	O
for	O
the	O
sugar	O
metabolism	O
activators	O
,	O
multiple	O
binding	O
sites	O
upstream	O
of	O
the	O
promoter	O
anchor	O
the	O
activator	O
in	O
a	O
repressing	O
or	O
nonactivating	O
configuration	O
.	O

By	O
interaction	O
with	O
the	O
sugar	O
and/or	O
CRP	B
,	O
the	O
activator	O
is	O
allosterically	O
altered	O
so	O
it	O
can	O
bind	O
a	O
new	O
set	O
of	O
sites	O
that	O
enable	O
it	O
to	O
activate	O
the	O
promoter	O
.	O

Surprisingly	O
,	O
the	O
virulence	O
activator	O
,	O
Rns	B
,	O
must	O
bind	O
to	O
both	O
upstream	O
and	O
downstream	O
sites	O
in	O
order	O
to	O
activate	O
the	O
rns	B
promoter	O
.	O

Involvement	O
of	O
Rel	B
/	O
NF	B
-	I
kappaB	I
in	O
regulation	O
of	O
ascidian	O
notochord	O
formation	O
.	O

The	O
Rel	B
/	I
NF	I
-	I
kappaB	I
family	I
is	O
known	O
to	O
be	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
biological	O
processes	O
,	O
including	O
morphogenesis	O
.	O

In	O
the	O
present	O
study	O
,	O
two	O
protochordate	O
cDNA	O
clones	O
encoding	O
Rel	B
/	O
NF	B
-	I
kappaB	I
proteins	O
,	O
named	O
As	O
-	O
rel1	B
and	O
As	O
-	O
rel2	B
,	O
were	O
isolated	O
from	O
a	O
fertilized	O
egg	O
cDNA	O
library	O
of	O
the	O
ascidian	O
Halocynthia	O
roretzi	O
.	O

The	O
As	O
-	O
rel1	B
protein	O
is	O
a	O
typical	O
Rel	B
/	I
NF	I
-	I
kappaB	I
family	I
member	O
,	O
containing	O
a	O
Rel	B
homology	O
domain	O
,	O
a	O
nuclear	O
localization	O
sequence	O
and	O
a	O
C	O
-	O
terminal	O
putative	O
transcription	O
activation	O
domain	O
,	O
while	O
the	O
As	O
-	O
rel2	B
protein	O
is	O
a	O
novel	O
Rel	B
/	I
NF	I
-	I
kappaB	I
family	I
member	O
that	O
lacks	O
a	O
nuclear	O
localization	O
sequence	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

Northern	O
blot	O
analyses	O
showed	O
that	O
both	O
transcripts	O
were	O
maternally	O
expressed	O
and	O
that	O
their	O
expression	O
changed	O
during	O
development	O
of	O
H.	O
roretzi	O
embryos	O
.	O

Although	O
injection	O
of	O
the	O
As	O
-	O
rel2	B
mRNA	O
into	O
H.	O
roretzi	O
fertilized	O
eggs	O
had	O
little	O
effect	O
on	O
embryonic	O
development	O
,	O
injection	O
of	O
the	O
As	O
-	O
rel1	B
mRNA	O
interfered	O
greatly	O
with	O
notochord	O
formation	O
,	O
resulting	O
in	O
a	O
shortened	O
tail	O
with	O
a	O
reduced	O
number	O
of	O
notochord	O
cells	O
.	O

In	O
contrast	O
,	O
embryos	O
co	O
-	O
injected	O
with	O
As	O
-	O
rel1	B
and	O
As	O
-	O
rel2	B
mRNA	O
developed	O
normally	O
,	O
indicating	O
that	O
the	O
As	O
-	O
rel2	B
protein	O
rescued	O
the	O
defect	O
in	O
notochord	O
formation	O
induced	O
by	O
the	O
injection	O
of	O
As	O
-	O
rel1	B
mRNA	O
alone	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
As	O
-	O
rel1	B
protein	O
functions	O
as	O
a	O
suppressor	O
in	O
ascidian	O
notochord	O
formation	O
,	O
while	O
the	O
As	O
-	O
rel2	B
protein	O
has	O
an	O
antagonistic	O
effect	O
on	O
the	O
action	O
of	O
the	O
As	O
-	O
rel1	B
protein	O
.	O

Identification	O
of	O
EPI64	B
,	O
a	O
TBC	O
/	O
rabGAP	B
domain	O
-	O
containing	O
microvillar	O
protein	O
that	O
binds	O
to	O
the	O
first	O
PDZ	O
domain	O
of	O
EBP50	B
and	O
E3KARP	B
.	O

The	O
cortical	O
scaffolding	O
proteins	O
EBP50	B
(	O
ERM	B
-	I
binding	I
phosphoprotein-50	I
)	O
and	O
E3KARP	B
(	O
NHE3	B
kinase	I
A	I
regulatory	I
protein	I
)	O
contain	O
two	O
PDZ	O
(	O
PSD-95	B
/	O
DlgA	B
/	O
ZO-1	B
-	O
like	O
)	O
domains	O
followed	O
by	O
a	O
COOH	O
-	O
terminal	O
sequence	O
that	O
binds	O
to	O
active	O
ERM	O
family	O
members	O
.	O

Using	O
affinity	O
chromatography	O
,	O
we	O
identified	O
polypeptides	O
from	O
placental	O
microvilli	O
that	O
bind	O
the	O
PDZ	O
domains	O
of	O
EBP50	B
.	O

Among	O
these	O
are	O
64	O
-	O
and/or	O
65	O
-	O
kD	O
differentially	O
phosphorylated	O
polypeptides	O
that	O
bind	O
preferentially	O
to	O
the	O
first	O
PDZ	O
domain	O
of	O
EBP50	B
,	O
as	O
well	O
as	O
to	O
E3KARP	B
,	O
and	O
that	O
we	O
call	O
EPI64	B
(	O
EBP50	B
-	I
PDZ	I
interactor	I
of	I
64	I
kD	I
)	O
.	O

The	O
gene	O
for	O
human	O
EPI64	B
lies	O
on	O
chromosome	O
22	O
where	O
nine	O
exons	O
specify	O
a	O
protein	O
of	O
508	O
residues	O
that	O
contains	O
a	O
Tre	B
/	O
Bub2	B
/	O
Cdc16	B
(	O
TBC	O
)	O
/	O
rab	B
GTPase	I
-	I
activating	I
protein	I
(	O
GAP	B
)	O
domain	O
.	O

EPI64	B
terminates	O
in	O
DTYL	O
,	O
which	O
is	O
necessary	O
for	O
binding	O
to	O
the	O
PDZ	O
domains	O
of	O
EBP50	B
,	O
as	O
a	O
mutant	O
ending	O
in	O
DTYLA	O
no	O
longer	O
interacts	O
.	O

EPI64	B
colocalizes	O
with	O
EBP50	B
and	O
ezrin	B
in	O
syncytiotrophoblast	O
and	O
cultured	O
cell	O
microvilli	O
,	O
and	O
this	O
localization	O
in	O
cultured	O
cells	O
is	O
abolished	O
by	O
introduction	O
of	O
the	O
DTYLA	O
mutation	O
.	O

In	O
addition	O
to	O
EPI64	B
,	O
immobilized	O
EBP50	B
PDZ	O
domains	O
retain	O
several	O
polypeptides	O
from	O
placental	O
microvilli	O
,	O
including	O
an	O
isoform	O
of	O
nadrin	B
,	O
a	O
rhoGAP	B
domain	O
-	O
containing	O
protein	O
implicated	O
in	O
regulating	O
vesicular	O
transport	O
.	O

Nadrin	B
binds	O
EBP50	B
directly	O
,	O
probably	O
through	O
its	O
COOH	O
-	O
terminal	O
STAL	O
sequence	O
.	O

Thus	O
,	O
EBP50	B
appears	O
to	O
bind	O
membrane	O
proteins	O
as	O
well	O
as	O
factors	O
potentially	O
involved	O
in	O
regulating	O
membrane	O
traffic	O
.	O

Apolipoprotein	B
L	I
gene	I
family	I
:	O
tissue	O
-	O
specific	O
expression	O
,	O
splicing	O
,	O
promoter	O
regions	O
;	O
discovery	O
of	O
a	O
new	O
gene	O
.	O

Previously	O
we	O
identified	O
and	O
cloned	O
the	O
cDNA	O
for	O
a	O
new	O
protein	O
,	O
apolipoprotein	B
L	I
(	O
apoL	B
)	O
,	O
present	O
in	O
plasma	O
and	O
mainly	O
associated	O
with	O
large	B
high	I
density	I
lipoprotein	I
particles	O
.	O

Using	O
5	O
'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
,	O
RT	O
-	O
PCR	O
and	O
comparison	O
with	O
three	O
Human	O
Genome	O
Project	O
and	O
three	O
expressed	O
sequence	O
tag	O
sequences	O
,	O
we	O
have	O
characterized	O
the	O
gene	O
for	O
apoL	B
and	O
for	O
three	O
additional	O
,	O
highly	O
homologous	O
proteins	O
that	O
constitute	O
a	O
new	O
family	O
of	O
proteins	O
that	O
display	O
no	O
homology	O
with	O
previously	O
described	O
apolipoproteins	B
.	O

The	O
genes	O
for	O
all	O
four	O
proteins	O
,	O
apoL	B
-	I
I	I
,	O
apoL	B
-	I
II	I
,	O
apoL	B
-	I
III	I
,	O
and	O
apoL	B
-	I
IV	I
,	O
are	O
located	O
at	O
chromosome	O
22q12.1	O
-	O
13.1	O
within	O
a	O
127,000	O
-	O
bp	O
region	O
.	O

The	O
apoL	B
-	I
I	I
gene	O
is	O
in	O
the	O
opposite	O
orientation	O
to	O
the	O
other	O
three	O
.	O

All	O
four	O
genes	O
have	O
TATA	O
-	O
less	O
promoters	O
,	O
which	O
contain	O
putative	O
sterol	O
regulatory	O
elements	O
,	O
suggesting	O
that	O
transcription	O
of	O
these	O
genes	O
may	O
be	O
coordinated	O
with	O
that	O
of	O
the	O
low	B
density	I
lipoprotein	I
receptor	I
and	O
genes	O
in	O
pathways	O
involving	O
the	O
synthesis	O
of	O
triglycerides	O
and	O
cholesterol	O
.	O

The	O
gene	O
family	O
has	O
a	O
consensus	O
eight	O
-	O
exon	O
structure	O
with	O
alternative	O
splice	O
sites	O
that	O
could	O
produce	O
as	O
many	O
as	O
eight	O
distinct	O
gene	O
products	O
.	O

The	O
apoL	B
-	I
II	I
and	O
apoL	B
-	I
III	I
genes	O
have	O
alternative	O
transcriptional	O
start	O
sites	O
as	O
a	O
result	O
of	O
additional	O
5	O
'	O
exons	O
.	O

apoL	B
-	I
I	I
,	O
apoL	B
-	I
II	I
,	O
and	O
apoL	B
-	I
III	I
are	O
expressed	O
to	O
the	O
highest	O
degree	O
in	O
the	O
lung	O
.	O

Other	O
tissues	O
with	O
high	O
expression	O
are	O
the	O
pancreas	O
,	O
prostate	O
,	O
spleen	O
,	O
liver	O
,	O
and	O
placenta	O
.	O

Four	O
clustered	O
common	O
polymorphisms	O
,	O
three	O
of	O
which	O
altered	O
the	O
protein	O
sequence	O
,	O
were	O
found	O
in	O
apoL	B
-	I
I	I
,	O
all	O
in	O
linkage	O
disequilibrium	O
,	O
and	O
describing	O
two	O
haplotypes	O
:	O
the	O
more	O
common	O
Lys166	O
/	O
Ile244	O
/	O
Lys271	O
and	O
the	O
rarer	O
Glu166	O
/	O
Met244	O
/	O
Arg271	O
.	O

Platelet	B
-	I
derived	I
growth	I
factor	I
C	I
(	O
PDGF	B
-	I
C	I
)	O
,	O
a	O
novel	O
growth	B
factor	I
that	O
binds	O
to	O
PDGF	B
alpha	I
and	I
beta	I
receptor	I
.	O

We	O
have	O
characterized	O
platelet	B
-	I
derived	I
growth	I
factor	I
(	I
PDGF	I
)	I
C	I
,	O
a	O
novel	O
growth	B
factor	I
belonging	O
to	O
the	O
PDGF	B
family	I
.	O

PDGF	B
-	I
C	I
is	O
a	O
multidomain	O
protein	O
with	O
the	O
N	O
-	O
terminal	O
region	O
homologous	O
to	O
the	O
extracellular	O
CUB	O
domain	O
of	O
neuropilin-1	B
,	O
and	O
the	O
C	O
-	O
terminal	O
region	O
consists	O
of	O
a	O
growth	B
factor	I
domain	O
(	O
GFD	O
)	O
with	O
homology	O
to	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
25	O
%	O
)	O
and	O
PDGF	B
A	I
-	O
chain	O
(	O
23	O
%	O
)	O
.	O

A	O
serum	O
-	O
sensitive	O
cleavage	O
site	O
between	O
the	O
two	O
domains	O
allows	O
release	O
of	O
the	O
GFD	O
from	O
the	O
CUB	O
domain	O
.	O

Competition	O
binding	O
and	O
immunoprecipitation	O
studies	O
on	O
cells	O
bearing	O
both	O
PDGF	B
alpha	I
and	I
beta	I
receptors	I
reveal	O
a	O
high	O
affinity	O
binding	O
of	O
recombinant	O
GFD	O
(	O
PDGF	B
-	I
CC	I
)	O
to	O
PDGF	B
receptor	I
-	I
alpha	I
homodimers	O
and	O
PDGF	B
receptor	I
-	I
alpha	I
/	I
beta	I
heterodimers	O
.	O

PDGF	B
-	I
CC	I
exhibits	O
greater	O
mitogenic	O
potency	O
than	O
PDGF	B
-	I
AA	I
and	O
comparable	O
or	O
greater	O
mitogenic	O
activity	O
than	O
PDGF	B
-	I
AB	I
and	O
PDGF	B
-	I
BB	I
on	O
several	O
mesenchymal	O
cell	O
types	O
.	O

Analysis	O
of	O
PDGF	B
-	I
CC	I
in	O
vivo	O
in	O
a	O
diabetic	O
mouse	O
model	O
of	O
delayed	O
wound	O
healing	O
showed	O
that	O
PDGF	B
-	I
CC	I
significantly	O
enhanced	O
repair	O
of	O
a	O
full	O
-	O
thickness	O
skin	O
excision	O
.	O

Together	O
,	O
these	O
studies	O
describe	O
a	O
third	O
member	O
of	O
the	O
PDGF	B
family	I
(	O
PDGF	B
-	I
C	I
)	O
as	O
a	O
potent	O
mitogen	O
for	O
cells	O
of	O
mesenchymal	O
origin	O
in	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
with	O
a	O
binding	O
pattern	O
similar	O
to	O
PDGF	B
-	I
AB	I
.	O

IL-10	B
mediation	O
of	O
activation	O
-	O
induced	O
TH1	O
cell	O
apoptosis	O
and	O
lymphoid	O
dysfunction	O
in	O
polymicrobial	O
sepsis	O
.	O

Recent	O
studies	O
suggest	O
that	O
increased	O
activation	O
-	O
induced	O
lymphocyte	O
apoptosis	O
(	O
AICD	O
)	O
is	O
detected	O
in	O
mouse	O
splenocytes	O
during	O
polymicrobial	O
sepsis	O
which	O
may	O
contribute	O
to	O
lymphocyte	O
immune	O
dysfunction	O
[	O
i.e.	O
,	O
decreased	O
interleukin	B
(	I
IL-	I
)	I
2	I
and	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
production	O
]	O
leading	O
to	O
the	O
associated	O
morbidity	O
seen	O
in	O
those	O
animals	O
.	O

Thus	O
,	O
we	O
wanted	O
to	O
examine	O
the	O
hypothesis	O
that	O
immune	O
suppressive	O
agents	O
,	O
such	O
as	O
IL-4	B
,	O
IL-10	B
or	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
known	O
to	O
be	O
elevated	O
in	O
septic	O
animals	O
,	O
also	O
contribute	O
to	O
this	O
increase	O
in	O
AICD	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
inclusion	O
of	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
to	O
IL-10	B
,	O
but	O
not	O
anti	O
-	O
IL-4	B
or	O
ibuprofen	O
(	O
IBU	O
)	O
,	O
blunted	O
this	O
sepsis	O
induced	O
increase	O
in	O
splenocyte	O
AICD	O
.	O

Additionally	O
,	O
septic	O
mice	O
deficient	O
in	O
the	O
IL-10	B
gene	O
product	O
(	O
-	O
/	O
-	O
)	O
showed	O
neither	O
an	O
increase	O
in	O
AICD	O
nor	O
a	O
loss	O
of	O
IL-2	B
/	O
IFN	B
-	I
gamma	I
release	O
capacity	O
.	O

Interestingly	O
,	O
mAb	O
to	O
IL-10	B
did	O
not	O
altered	O
the	O
extent	O
of	O
AICD	O
in	O
a	O
Th2	O
-	O
cell	O
line	O
,	O
but	O
exogenous	O
IL-10	B
did	O
potentiate	O
Th1	O
-	O
like	O
cell	O
line	O
AICD	O
.	O

This	O
was	O
consistent	O
with	O
the	O
finding	O
that	O
the	O
increased	O
AICD	O
seen	O
in	O
septic	O
mouse	O
splenocytes	O
was	O
restricted	O
largely	O
to	O
the	O
CD4	B
+	O
cells	O
producing	O
IL-2	B
(	O
Th1	O
-	O
cells	O
)	O
and	O
that	O
mAb	O
to	O
IL-10	B
treatment	O
suppressed	O
this	O
change	O
.	O

Furthermore	O
,	O
IL-10	B
appears	O
to	O
mediate	O
its	O
AICD	O
effect	O
by	O
upregulation	O
of	O
the	O
Fas	B
receptor	O
and	O
Fas	B
receptor	O
signaling	O
protein	O
components	O
,	O
but	O
not	O
by	O
altered	O
expression	O
of	O
Bcl	B
/	I
Bax	I
/	I
Bad	I
family	I
members	O
,	O
in	O
septic	O
mouse	O
splenocytes	O
.	O

To	O
the	O
extent	O
that	O
these	O
processes	O
contribute	O
in	O
a	O
pathological	O
fashion	O
to	O
the	O
animal	O
's	O
capacity	O
to	O
survive	O
sepsis	O
we	O
have	O
previously	O
observed	O
that	O
in	O
vivo	O
post	O
-	O
treatment	O
of	O
mice	O
with	O
mAb	O
IL-10	B
markedly	O
attenuated	O
septic	O
mortality	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
in	O
the	O
septic	O
mouse	O
the	O
Th2	O
cytokine	B
IL-10	B
not	O
only	O
serves	O
to	O
actively	O
induce	O
Th1	O
lymphocyte	O
immune	O
dysfunction	O
but	O
also	O
plays	O
a	O
role	O
in	O
their	O
apoptotic	O
depletion	O
.	O

These	O
processes	O
in	O
turn	O
appear	O
to	O
contribute	O
to	O
the	O
animal	O
's	O
inability	O
to	O
ward	O
off	O
lethal	O
septic	O
challenge	O
.	O

Molecular	O
characterization	O
of	O
tomato	O
3-dehydroquinate	B
dehydratase	I
-	I
shikimate	I
:	I
NADP	I
oxidoreductase	I
.	O

Analysis	O
of	O
cDNAs	O
encoding	O
the	O
bifunctional	O
3-dehydroquinate	B
dehydratase	I
-	I
shikimate	I
:	I
NADP	I
oxidoreductase	I
(	O
DHQase	B
-	I
SORase	I
)	O
from	O
tomato	O
(	O
Lycopersicon	O
esculentum	O
)	O
revealed	O
two	O
classes	O
of	O
cDNAs	O
that	O
differed	O
by	O
57	O
bp	O
within	O
the	O
coding	O
regions	O
,	O
but	O
were	O
otherwise	O
identical	O
.	O

Comparison	O
of	O
these	O
cDNA	O
sequences	O
with	O
the	O
sequence	O
of	O
the	O
corresponding	O
single	O
gene	O
unequivocally	O
proved	O
that	O
the	O
primary	O
transcript	O
is	O
differentially	O
spliced	O
,	O
potentially	O
giving	O
rise	O
to	O
two	O
polypeptides	O
that	O
differ	O
by	O
19	O
amino	O
acids	O
.	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
revealed	O
that	O
the	O
longer	O
transcript	O
constitutes	O
at	O
most	O
1	O
%	O
to	O
2	O
%	O
of	O
DHQase	B
-	I
SORase	I
transcripts	O
.	O

Expression	O
of	O
the	O
respective	O
polypeptides	O
in	O
Escherichia	O
coli	O
mutants	O
lacking	O
the	O
DHQase	B
or	O
the	O
SORase	B
activity	O
gave	O
functional	O
complementation	O
only	O
in	O
case	O
of	O
the	O
shorter	O
polypeptide	O
,	O
indicating	O
that	O
skipping	O
of	O
a	O
potential	O
exon	O
is	O
a	O
prerequisite	O
for	O
the	O
production	O
of	O
an	O
enzymatically	O
active	O
protein	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
revealed	O
that	O
the	O
DHQase	B
-	I
SORase	I
is	O
most	O
likely	O
synthesized	O
as	O
a	O
precursor	O
with	O
a	O
very	O
short	O
(	O
13-amino	O
acid	O
)	O
plastid	O
-	O
specific	O
transit	O
peptide	O
.	O

Like	O
other	O
genes	O
encoding	O
enzymes	O
of	O
the	O
prechorismate	O
pathway	O
in	O
tomato	O
,	O
this	O
gene	O
is	O
elicitor	O
-	O
inducible	O
.	O

Tissue	O
-	O
specific	O
expression	O
resembles	O
the	O
patterns	O
obtained	O
for	O
3-deoxy	B
-	I
D	I
-	I
arabino	I
-	I
heptulosonate	I
7-phosphate	I
synthase	I
2	I
and	O
dehydroquinate	B
synthase	I
genes	O
.	O

This	O
work	O
completes	O
our	O
studies	O
of	O
the	O
prechorismate	O
pathway	O
in	O
that	O
cDNAs	O
for	O
all	O
seven	O
enzymes	O
(	O
including	O
isozymes	O
)	O
of	O
the	O
prechorismate	O
pathway	O
from	O
tomato	O
have	O
now	O
been	O
characterized	O
.	O

A	O
novel	O
actin	B
-	I
related	I
protein	I
gene	O
of	O
Colletotrichum	O
gloeosporioides	O
f.	O
sp.	O
malvae	O
shows	O
altered	O
expression	O
corresponding	O
with	O
spore	O
production	O
.	O

A	O
novel	O
actin	B
-	I
related	I
protein	I
(	O
arp	B
)	O
was	O
found	O
in	O
the	O
plant	O
pathogenic	O
fungus	O
,	O
Colletotrichum	O
gloeosporioides	O
f.	O
sp.	O
malvae	O
(	O
Cgm	O
)	O
,	O
which	O
causes	O
anthracnose	O
disease	O
of	O
round	O
-	O
leaved	O
mallow	O
(	O
Malva	O
pusilla	O
)	O
.	O

Sequence	O
comparisons	O
showed	O
that	O
this	O
gene	O
,	O
arpA	B
,	O
belongs	O
to	O
the	O
highly	O
divergent	O
'	O
other	O
arps	B
'	O
category	O
in	O
the	O
current	O
arp	B
classification	O
system	O
.	O

ArpA	B
is	O
most	O
similar	O
to	O
the	O
arp11	B
gene	O
of	O
Mus	O
musculus	O
but	O
has	O
a	O
unique	O
structure	O
with	O
deletions	O
at	O
the	O
C	O
-	O
terminus	O
similar	O
to	O
that	O
of	O
the	O
arp10	B
gene	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

A	O
portion	O
of	O
another	O
putative	O
arp	B
gene	O
,	O
arpB	B
,	O
was	O
found	O
immediately	O
downstream	O
of	O
arpA	B
.	O

Expression	O
of	O
arpA	B
was	O
compared	O
to	O
the	O
constitutively	O
expressed	O
Cgm	O
actin	B
gene	O
,	O
actA	B
.	O

In	O
culture	O
,	O
the	O
relative	O
expression	O
of	O
arpA	B
increased	O
when	O
growth	O
conditions	O
favored	O
sporulation	O
.	O

During	O
infection	O
,	O
arpA	B
expression	O
was	O
greatest	O
at	O
the	O
late	O
necrotrophic	O
phase	O
,	O
when	O
sporulation	O
occurred	O
.	O

Arps	B
have	O
been	O
shown	O
to	O
be	O
important	O
in	O
nuclear	O
migration	O
in	O
fungal	O
hyphae	O
,	O
and	O
the	O
expression	O
pattern	O
of	O
arpA	B
indicates	O
that	O
it	O
may	O
have	O
a	O
particular	O
role	O
during	O
sporulation	O
.	O

High	O
-	O
level	O
production	O
of	O
heme	O
-	O
containing	O
holoproteins	O
in	O
Escherichia	O
coli	O
.	O

The	O
expression	O
of	O
recombinant	O
protein	O
is	O
essential	O
for	O
the	O
investigation	O
of	O
the	O
functions	O
and	O
properties	O
of	O
heme	O
-	O
containing	O
protein	O
as	O
an	O
electron	O
carrier	O
.	O

For	O
the	O
expression	O
of	O
fully	O
active	O
recombinant	O
protein	O
,	O
conversion	O
of	O
the	O
expressed	O
apoprotein	O
into	O
holoprotein	O
is	O
the	O
most	O
important	O
and	O
difficult	O
problem	O
.	O

In	O
this	O
study	O
,	O
a	O
system	O
was	O
developed	O
for	O
the	O
production	O
of	O
heme	O
-	O
containing	O
protein	O
in	O
a	O
pure	O
,	O
recombinant	O
holoprotein	O
form	O
,	O
using	O
the	O
bovine	O
cytochrome	B
b5	I
tryptic	O
fragment	O
and	O
Escherichia	O
coli	O
bacterioferritin	B
as	O
heterologous	O
and	O
homologous	O
heme	O
-	O
containing	O
model	O
proteins	O
,	O
respectively	O
.	O

This	O
system	O
is	O
based	O
on	O
the	O
slow	O
synthesis	O
of	O
recombinant	O
apoprotein	O
,	O
which	O
can	O
maintain	O
the	O
balanced	O
consumption	O
of	O
amino	O
acids	O
between	O
protein	O
synthesis	O
and	O
heme	O
synthesis	O
,	O
so	O
that	O
the	O
synthesized	O
apoprotein	O
continues	O
to	O
act	O
as	O
a	O
heme	O
sink	O
.	O

From	O
a	O
1	O
-	O
1	O
culture	O
,	O
15	O
mg	O
of	O
cytochrome	B
b5	I
and	O
40	O
mg	O
of	O
bacterioferritin	B
were	O
purified	O
as	O
pure	O
holoprotein	O
forms	O
.	O

Our	O
expression	O
system	O
provides	O
a	O
rapid	O
and	O
simple	O
method	O
for	O
obtaining	O
large	O
quantities	O
of	O
the	O
active	O
holo	O
-	O
form	O
of	O
heme	O
-	O
containing	O
proteins	O
.	O

Cloning	O
of	O
a	O
novel	O
phosphatidylinositol	B
kinase	I
-	O
related	O
kinase	B
:	O
characterization	O
of	O
the	O
human	O
SMG-1	B
RNA	O
surveillance	O
protein	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
new	O
member	O
of	O
the	O
phosphatidylinositol	B
kinase	I
(	I
PIK	I
)	I
-	I
related	I
kinase	I
family	I
.	O

This	O
gene	O
,	O
which	O
we	O
term	O
human	O
SMG-1	B
(	O
hSMG-1	B
)	O
,	O
is	O
orthologous	O
to	O
Caenorhabditis	O
elegans	O
SMG-1	B
,	O
a	O
protein	O
that	O
functions	O
in	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)	O
.	O

cDNA	O
sequencing	O
revealed	O
that	O
hSMG-1	B
encodes	O
a	O
protein	O
of	O
3031	O
amino	O
acids	O
containing	O
a	O
conserved	O
kinase	B
domain	O
,	O
a	O
C	O
-	O
terminal	O
domain	O
unique	O
to	O
the	O
PIK	B
-	O
related	O
kinases	B
and	O
an	O
FKBP12	B
-	O
rapamycin	O
binding	O
-	O
like	O
domain	O
similar	O
to	O
that	O
found	O
in	O
the	O
PIK	B
-	O
related	O
kinase	O
mTOR	B
.	O

Immunopurified	O
FLAG	O
-	O
tagged	O
hSMG-1	B
exhibits	O
protein	B
kinase	I
activity	O
as	O
measured	O
by	O
autophosphorylation	O
and	O
phosphorylation	O
of	O
the	O
generic	O
PIK	B
-	O
related	O
kinase	O
substrate	O
PHAS-1	B
.	O

hSMG-1	B
kinase	B
activity	O
is	O
inhibited	O
by	O
high	O
nanomolar	O
concentrations	O
of	O
wortmannin	O
(	O
IC	O
(	O
50	O
)	O
=	O
105	O
nm	O
)	O
but	O
is	O
not	O
inhibited	O
by	O
a	O
FKBP12	B
-	O
rapamycin	O
complex	O
.	O

Mutation	O
of	O
conserved	O
residues	O
within	O
the	O
kinase	B
domain	O
of	O
hSMG-1	B
abolishes	O
both	O
autophosphorylation	O
and	O
substrate	O
phosphorylation	O
,	O
demonstrating	O
that	O
hSMG-1	B
exhibits	O
intrinsic	O
protein	O
kinase	B
activity	O
.	O

hSMG-1	B
phosphorylates	O
purified	O
hUpf1	B
protein	O
,	O
a	O
phosphoprotein	O
that	O
plays	O
a	O
critical	O
role	O
in	O
NMD	O
,	O
at	O
sites	O
that	O
are	O
also	O
phosphorylated	O
in	O
whole	O
cells	O
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
conclude	O
that	O
hSMG-1	B
is	O
the	O
human	O
orthologue	O
to	O
C.	O
elegans	O
SMG-1	B
.	O

Our	O
data	O
indicate	O
that	O
hSMG-1	B
may	O
function	O
in	O
NMD	O
by	O
directly	O
phosphorylating	O
hUpf1	B
protein	O
at	O
physiologically	O
relevant	O
sites	O
.	O

Ontogenetic	O
changes	O
in	O
protein	O
level	O
of	O
amyloid	B
precursor	I
protein	I
(	O
APP	B
)	O
in	O
growth	O
cones	O
and	O
synaptosomes	O
from	O
rat	O
brain	O
and	O
prenatal	O
expression	O
pattern	O
of	O
APP	B
mRNA	O
isoforms	O
in	O
developing	O
rat	O
embryo	O
.	O

To	O
elucidate	O
the	O
functional	O
role	O
of	O
the	O
amyloid	B
precursor	I
protein	I
(	O
APP	B
)	O
during	O
brain	O
ontogeny	O
,	O
developmental	O
changes	O
of	O
APP	B
levels	O
in	O
growth	O
cones	O
and	O
synaptosomes	O
were	O
studied	O
from	O
embryonic	O
day	O
14	O
up	O
to	O
postnatal	O
day	O
(	O
PD	O
)	O
400	O
using	O
Western	O
analysis	O
.	O

APP	B
level	O
in	O
growth	O
cones	O
was	O
low	O
during	O
prenatal	O
stages	O
of	O
development	O
,	O
but	O
demonstrating	O
a	O
continuous	O
increase	O
from	O
PD	O
3	O
up	O
to	O
PD	O
10	O
.	O

Highest	O
concentration	O
of	O
APP	B
in	O
synaptosomes	O
was	O
found	O
between	O
PD	O
7	O
and	O
10	O
,	O
followed	O
by	O
a	O
considerable	O
decrease	O
up	O
to	O
PD	O
30	O
and	O
persisting	O
at	O
this	O
level	O
up	O
to	O
PD	O
400	O
.	O

In	O
situ	O
hybridization	O
to	O
differentiate	O
between	O
APP695	B
mRNA	O
,	O
APP751	B
mRNA	O
and	O
APP770	B
mRNA	O
revealed	O
distinct	O
age	O
-	O
related	O
expression	O
pattern	O
of	O
various	O
APP	B
isoforms	O
.	O

During	O
prenatal	O
brain	O
development	O
APP695	B
mRNA	O
is	O
maximally	O
expressed	O
in	O
brain	O
structures	O
,	O
containing	O
differentiating	O
nerve	O
cells	O
.	O

APP751	B
and	O
APP770	B
mRNA	O
isoforms	O
are	O
diffusely	O
distributed	O
in	O
the	O
embryo	O
throughout	O
the	O
prenatal	O
period	O
examined	O
and	O
their	O
expression	O
is	O
higher	O
in	O
peripheral	O
organs	O
such	O
as	O
skin	O
,	O
lung	O
,	O
liver	O
and	O
bones	O
as	O
compared	O
to	O
the	O
brain	O
.	O

The	O
increase	O
of	O
APP	B
level	O
during	O
synaptogenesis	O
suggests	O
a	O
functional	O
role	O
of	O
APP	B
in	O
the	O
processes	O
of	O
neurite	O
outgrowth	O
and	O
cell	O
targeting	O
as	O
well	O
as	O
in	O
the	O
maintenance	O
of	O
the	O
functional	O
integrity	O
of	O
synapses	O
in	O
the	O
mature	O
brain	O
.	O

The	O
APP695	B
isoform	O
seems	O
to	O
be	O
the	O
major	O
form	O
involved	O
in	O
embryonic	O
brain	O
maturation	O
.	O

A	O
novel	O
nucleolar	O
protein	O
,	O
NIFK	B
,	O
interacts	O
with	O
the	O
forkhead	O
associated	O
domain	O
of	O
Ki-67	B
antigen	I
in	O
mitosis	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
forkhead	O
associated	O
(	O
FHA	O
)	O
domain	O
of	O
pKi-67	B
interacts	O
with	O
the	O
novel	O
kinesin	B
-	O
like	O
protein	O
,	O
Hklp2	B
(	O
Sueishi	O
,	O
M.	O
,	O
Takagi	O
,	O
M.	O
,	O
and	O
Yoneda	O
,	O
Y.	O
(	O
2000	O
)	O
J.	O
Biol	O
.	O
Chem	O
.	O
275	O
,	O
28888	O
-	O
28892	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
a	O
putative	O
RNA	O
-	O
binding	O
protein	O
of	O
293	O
residues	O
as	O
another	O
binding	O
partner	O
of	O
the	O
FHA	O
domain	O
of	O
pKi-67	B
(	O
referred	O
to	O
as	O
NIFK	B
for	O
nucleolar	B
protein	I
interacting	I
with	I
the	I
FHA	I
domain	I
of	I
pKi-67	I
)	O
.	O

Human	O
NIFK	B
(	O
hNIFK	B
)	O
interacted	O
with	O
the	O
FHA	O
domain	O
of	O
pKi-67	B
(	O
Ki	O
-	O
FHA	O
)	O
efficiently	O
in	O
vitro	O
when	O
hNIFK	B
was	O
derived	O
from	O
mitotically	O
arrested	O
cells	O
.	O

In	O
addition	O
,	O
a	O
moiety	O
of	O
hNIFK	B
was	O
co	O
-	O
localized	O
with	O
pKi-67	B
at	O
the	O
peripheral	O
region	O
of	O
mitotic	O
chromosomes	O
.	O

The	O
hNIFK	B
domain	O
that	O
interacts	O
with	O
Ki	O
-	O
FHA	O
was	O
mapped	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
to	O
a	O
portion	O
encompassed	O
by	O
residues	O
226	O
-	O
269	O
.	O

In	O
a	O
binding	O
assay	O
utilizing	O
Xenopus	O
egg	O
extracts	O
,	O
it	O
was	O
found	O
that	O
the	O
mitosis	O
-	O
specific	O
environment	O
and	O
two	O
threonine	O
residues	O
within	O
this	O
portion	O
of	O
hNIFK	B
(	O
Thr-234	O
and	O
Thr-238	O
)	O
were	O
crucial	O
for	O
the	O
efficient	O
interaction	O
of	O
hNIFK	B
and	O
Ki	O
-	O
FHA	O
,	O
suggesting	O
that	O
hNIFK	B
interacts	O
with	O
Ki	O
-	O
FHA	O
in	O
a	O
mitosis	O
-	O
specific	O
and	O
phosphorylation	O
-	O
dependent	O
manner	O
.	O

These	O
findings	O
provide	O
a	O
new	O
clue	O
to	O
our	O
understanding	O
of	O
the	O
cellular	O
function	O
of	O
pKi-67	B
.	O

Tobacco	O
and	O
Arabidiopsis	O
SLT1	B
mediate	O
salt	O
tolerance	O
of	O
yeast	O
.	O

A	O
tobacco	O
cDNA	O
(	O
NtSLT1	B
,	O
for	O
Nicotiana	O
tabacum	O
sodium	B
-	I
and	I
lithium	I
-	I
tolerant	I
)	O
was	O
isolated	O
by	O
functional	O
complementation	O
of	O
the	O
salt	O
-	O
sensitive	O
phenotype	O
of	O
a	O
calcineurin	B
(	O
CaN	B
)	O
-	O
deficient	O
yeast	O
mutant	O
(	O
cnb	B
delta	O
,	O
regulatory	O
subunit	O
null	O
)	O
.	O

CaN	B
is	O
a	O
Ca2	B
+	I
/	I
calmodulin	I
-	I
dependent	I
type	I
2B	I
protein	I
phosphatase	I
that	O
regulates	O
Na+	O
homeostasis	O
in	O
yeast	O
.	O

This	O
phosphatase	B
modulates	O
plasma	O
membrane	O
K	O
+	O
/	O
Na	O
+	O
selectivity	O
through	O
the	O
activation	O
of	O
high	O
-	O
affinity	O
K	O
+	O
transport	O
,	O
and	O
increaseses	O
extracellular	O
Na	O
+	O
efflux	O
by	O
activation	O
and	O
transcriptional	O
induction	O
of	O
the	O
Na	O
+	O
/	O
Li	O
+	O
translocating	O
P	B
-	I
type	I
ATPase	I
encoded	O
by	O
ENA1	B
.	O

Expression	O
of	O
N	O
-	O
terminally	O
truncated	O
NtSLT1	B
(	O
Met-304	O
)	O
,	O
but	O
not	O
full	O
-	O
length	O
protein	O
,	O
suppressed	O
salt	O
sensitivity	O
of	O
cnb1	B
.	O

Truncated	O
NtSLT1	B
also	O
increased	O
salt	O
tolerance	O
of	O
wild	O
-	O
type	O
yeast	O
,	O
indicating	O
functional	O
sufficiency	O
.	O

NtSLT1	B
encodes	O
a	O
protein	O
of	O
yet	O
unknown	O
function	O
but	O
experimentation	O
in	O
yeast	O
confirms	O
it	O
as	O
a	O
salt	O
tolerance	O
determinant	O
.	O

The	O
Arabidopsis	O
thaliana	O
orthologue	O
,	O
AtSLT1	B
,	O
also	O
suppressed	O
salt	O
sensitivity	O
of	O
cnb	B
delta	O
but	O
only	O
when	O
expressed	O
without	O
the	O
N	O
-	O
terminus	O
(	O
Met	O
-	O
301	O
)	O
,	O
suggesting	O
that	O
this	O
region	O
of	O
the	O
proteins	O
from	O
these	O
evolutionarily	O
diverse	O
plant	O
species	O
contains	O
an	O
autoinhibitory	O
domain	O
.	O

NtSLT1	B
enhanced	O
transcription	O
of	O
the	O
CaN	B
-	O
dependent	O
ENA1	B
gene	O
promoter	O
and	O
compensated	O
the	O
salt	O
sensitivity	O
of	O
a	O
mutant	O
deficient	O
in	O
TCN1	B
--	O
a	O
transcription	B
factor	I
that	O
is	O
activated	O
by	O
CaN	B
and	O
then	O
induces	O
ENA1	B
expression	O
.	O

NtSLT1	B
partially	O
suppressed	O
the	O
salt	O
sensitivity	O
of	O
ena1	B
-	I
4	I
indicating	O
that	O
NtSLT1	B
has	O
both	O
ENA	B
-	O
dependent	O
and	O
independent	O
functions	O
.	O

NtSLT1	B
suppressed	O
spk1	B
hal4	B
(	O
SPK1	B
/	O
HAL4	B
which	O
encodes	O
a	O
serine	B
-	I
threonine	I
kinase	I
that	O
regulates	O
TRK1	B
-	I
2	I
transporters	O
to	O
have	O
high	O
K	O
+	O
/	O
Na	O
+	O
selectivity	O
)	O
but	O
not	O
ena1	B
-	I
4	I
trk1	B
-	I
2	I
implicating	O
the	O
ENA	B
-	O
independent	O
function	O
to	O
be	O
through	O
TRK1	B
-	I
2	I
.	O

Together	O
,	O
these	O
results	O
implicate	O
SLT1	B
as	O
a	O
signal	O
regulatory	O
molecule	O
that	O
mediates	O
salt	O
tolerance	O
by	O
modulating	O
Na	O
+	O
homeostasis	O
.	O

Hypokalaemic	O
periodic	O
paralysis	O
type	O
2	O
caused	O
by	O
mutations	O
at	O
codon	O
672	O
in	O
the	O
muscle	O
sodium	B
channel	I
gene	O
SCN4A	B
.	O

Hypokalaemic	O
periodic	O
paralysis	O
(	O
hypoPP	O
)	O
is	O
an	O
autosomal	O
dominant	O
muscle	O
disorder	O
characterized	O
by	O
episodic	O
attacks	O
of	O
muscle	O
weakness	O
associated	O
with	O
a	O
decrease	O
in	O
blood	O
potassium	O
levels	O
.	O

Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
skeletal	O
muscle	O
voltage	O
-	O
gated	O
calcium	B
channel	I
alpha-1	I
subunit	O
(	O
CACNL1A3	B
)	O
account	O
for	O
the	O
majority	O
of	O
cases	O
.	O

Recently	O
,	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
the	O
skeletal	O
muscle	O
voltage	O
-	O
gated	O
sodium	B
channel	I
alpha	I
subunit	O
(	O
SCN4A	B
)	O
have	O
been	O
reported	O
in	O
a	O
small	O
number	O
of	O
hypoPP	O
families	O
.	O

In	O
order	O
to	O
determine	O
the	O
relative	O
frequency	O
of	O
the	O
CANCL1A3	B
and	O
SCN4A	B
mutations	O
in	O
a	O
large	O
population	O
of	O
hypoPP	O
patients	O
,	O
and	O
to	O
specify	O
the	O
clinical	O
and	O
pathological	O
features	O
associated	O
with	O
each	O
of	O
them	O
,	O
we	O
searched	O
for	O
mutations	O
in	O
58	O
independent	O
hypoPP	O
index	O
cases	O
.	O

We	O
detected	O
the	O
causative	O
mutation	O
in	O
45	O
cases	O
:	O
40	O
were	O
linked	O
to	O
the	O
CACNL1A3	B
gene	O
and	O
five	O
to	O
the	O
SCN4A	B
gene	O
.	O

One	O
mutation	O
has	O
not	O
been	O
described	O
before	O
.	O

Some	O
remarkable	O
clinical	O
features	O
were	O
observed	O
in	O
a	O
large	O
hypoPP	O
family	O
carrying	O
an	O
SCN4A	B
mutation	O
:	O
a	O
complete	O
penetrance	O
in	O
men	O
and	O
women	O
,	O
an	O
early	O
age	O
at	O
onset	O
,	O
postcritic	O
myalgias	O
and	O
an	O
increased	O
number	O
and	O
severity	O
of	O
attacks	O
induced	O
by	O
acetazolamide	O
.	O

A	O
muscle	O
biopsy	O
,	O
performed	O
in	O
two	O
members	O
of	O
this	O
family	O
,	O
revealed	O
a	O
peculiar	O
myopathy	O
characterized	O
by	O
tubular	O
aggregates	O
.	O

In	O
contrast	O
,	O
vacuoles	O
were	O
predominant	O
in	O
muscles	O
from	O
hypoPP	O
patients	O
carrying	O
CACNL1A3	B
mutations	O
.	O

Our	O
findings	O
point	O
to	O
the	O
usefulness	O
of	O
a	O
molecular	O
characterization	O
of	O
hypoPP	O
patients	O
in	O
clinical	O
practice	O
.	O

They	O
also	O
provide	O
new	O
clues	O
for	O
understanding	O
the	O
mechanisms	O
behind	O
functional	O
and	O
structural	O
alterations	O
of	O
the	O
skeletal	O
muscle	O
in	O
hypoPP	O
.	O

Control	O
of	O
electron	O
transfer	O
in	O
neuronal	B
NO	I
synthase	I
.	O

The	O
nitric	B
oxide	I
synthases	I
(	O
NOSs	B
)	O
are	O
dimeric	O
flavocytochromes	O
consisting	O
of	O
an	O
oxygenase	B
domain	O
with	O
cytochrome	B
P450	I
-	O
like	O
Cys	O
-	O
ligated	O
haem	O
,	O
coupled	O
to	O
a	O
diflavin	O
reductase	B
domain	O
,	O
which	O
is	O
related	O
to	O
cytochrome	B
P450	I
reductase	I
.	O

The	O
NOSs	B
catalyse	O
the	O
sequential	O
mono	O
-	O
oxygenation	O
of	O
arginine	O
to	O
N	O
-	O
hydroxyarginine	O
and	O
then	O
to	O
citrulline	O
and	O
NO	O
.	O

The	O
constitutive	B
NOS	I
isoforms	O
(	O
cNOSs	B
)	O
are	O
regulated	O
by	O
calmodulin	B
(	O
CaM	B
)	O
,	O
which	O
binds	O
at	O
elevated	O
concentrations	O
of	O
free	O
Ca	O
(	O
2	O
+	O
)	O
,	O
whereas	O
the	O
inducible	O
isoform	O
binds	O
CaM	B
irreversibly	O
.	O

One	O
of	O
the	O
main	O
structural	O
differences	O
between	O
the	O
constitutive	O
and	O
inducible	O
isoforms	O
is	O
an	O
insert	O
of	O
40	O
-	O
50	O
amino	O
acids	O
in	O
the	O
FMN	O
-	O
binding	O
domain	O
of	O
the	O
cNOSs	B
.	O

Deletion	O
of	O
the	O
insert	O
in	O
rat	O
neuronal	B
NOS	I
(	O
nNOS	B
)	O
led	O
to	O
a	O
mutant	O
enzyme	O
which	O
binds	O
CaM	B
at	O
lower	O
Ca	O
(	O
2	O
+	O
)	O
concentrations	O
and	O
which	O
retains	O
activity	O
in	O
the	O
absence	O
of	O
CaM	B
.	O

In	O
order	O
to	O
resolve	O
the	O
mechanism	O
of	O
action	O
of	O
CaM	B
activation	O
we	O
determined	O
reduction	O
potentials	O
for	O
the	O
FMN	O
and	O
FAD	O
cofactors	O
of	O
rat	O
nNOS	B
in	O
the	O
presence	O
and	O
absence	O
of	O
CaM	B
using	O
a	O
recombinant	O
form	O
of	O
the	O
reductase	B
domain	O
.	O

The	O
results	O
indicate	O
that	O
CaM	B
binding	O
does	O
not	O
modulate	O
the	O
reduction	O
potentials	O
of	O
the	O
flavins	O
,	O
but	O
appears	O
to	O
control	O
electron	O
transfer	O
primarily	O
via	O
a	O
large	O
structural	O
rearrangement	O
.	O

We	O
also	O
report	O
the	O
creation	O
of	O
chimaeric	O
enzymes	O
in	O
which	O
the	O
reductase	B
domains	O
of	O
nNOS	B
and	O
flavocytochrome	B
P450	I
BM3	I
(	O
Bacillus	O
megaterium	O
III	O
)	O
have	O
been	O
exchanged	O
.	O

Despite	O
its	O
very	O
different	O
flavin	O
redox	O
potentials	O
,	O
the	O
BM3	B
reductase	I
domain	O
was	O
able	O
to	O
support	O
low	O
levels	O
of	O
CaM	B
-	O
dependent	O
NO	O
synthesis	O
,	O
whereas	O
the	O
NOS	B
reductase	I
domain	O
did	O
not	O
effectively	O
substitute	O
for	O
that	O
of	O
cytochrome	B
P450	I
BM3	I
.	O

HMGN3a	B
and	O
HMGN3b	B
,	O
two	O
protein	O
isoforms	O
with	O
a	O
tissue	O
-	O
specific	O
expression	O
pattern	O
,	O
expand	O
the	O
cellular	O
repertoire	O
of	O
nucleosome	O
-	O
binding	O
proteins	O
.	O

HMGN1	B
(	O
HMG-14	B
)	O
and	O
HMGN2	B
(	O
HMG-17	B
)	O
are	O
nuclear	O
proteins	O
that	O
bind	O
specifically	O
to	O
nucleosomes	O
,	O
reduce	O
the	O
compactness	O
of	O
the	O
chromatin	O
fiber	O
,	O
and	O
enhance	O
transcription	O
from	O
chromatin	O
templates	O
.	O

Here	O
we	O
report	O
that	O
many	O
vertebrates	O
contain	O
an	O
additional	O
type	O
of	O
HMGN	B
protein	O
named	O
HMGN3	B
(	O
Trip	B
7	I
)	O
.	O

The	O
human	O
HMGN3	B
gene	O
is	O
located	O
on	O
chromosome	O
6	O
and	O
spans	O
32	O
kilobase	O
pairs	O
,	O
which	O
is	O
nearly	O
10	O
-	O
fold	O
longer	O
than	O
the	O
closely	O
related	O
HMGN2	B
gene	O
.	O

However	O
,	O
the	O
intron	O
/	O
exon	O
boundaries	O
of	O
the	O
HMGN3	B
gene	O
are	O
identical	O
to	O
those	O
of	O
HMGN1	B
and	O
HMGN2	B
.	O

Unique	O
within	O
the	O
HMGN	B
family	I
,	O
the	O
HMGN3	B
transcript	O
undergoes	O
alternative	O
splicing	O
and	O
generates	O
two	O
different	O
variants	O
,	O
HMGN3a	B
and	O
HMGN3b	B
.	O

The	O
shorter	O
variant	O
,	O
HMGN3b	B
,	O
arises	O
from	O
an	O
additional	O
splice	O
site	O
that	O
truncates	O
exon	O
V	O
and	O
causes	O
a	O
frameshift	O
.	O

The	O
resulting	O
HMGN3b	B
protein	O
lacks	O
the	O
majority	O
of	O
the	O
C	O
-	O
terminal	O
chromatin	O
-	O
unfolding	O
domain	O
.	O

Both	O
splice	O
variants	O
are	O
found	O
in	O
many	O
vertebrates	O
from	O
frogs	O
to	O
man	O
and	O
are	O
expressed	O
in	O
many	O
tissues	O
.	O

The	O
pattern	O
of	O
tissue	O
-	O
specific	O
expression	O
differs	O
considerably	O
from	O
those	O
of	O
HMGN1	B
and	O
HMGN2	B
at	O
both	O
the	O
mRNA	O
and	O
the	O
protein	O
level	O
.	O

Our	O
results	O
expand	O
the	O
multiplicity	O
of	O
the	O
HMGN	B
protein	I
family	I
and	O
raise	O
the	O
possibility	O
that	O
these	O
nucleosome	O
-	O
binding	O
proteins	O
function	O
as	O
co	O
-	O
activators	O
in	O
tissue	O
-	O
specific	O
gene	O
expression	O
.	O

BALB	O
/	O
c	O
mice	O
bearing	O
a	O
transgenic	O
IL-12	B
receptor	I
beta	I
2	I
gene	O
exhibit	O
a	O
nonhealing	O
phenotype	O
to	O
Leishmania	O
major	O
infection	O
despite	O
intact	O
IL-12	B
signaling	O
.	O

In	O
BALB	O
/	O
c	O
mice	O
infected	O
with	O
Leishmania	O
major	O
,	O
early	O
secretion	O
of	O
IL-4	B
leads	O
to	O
a	O
Th2	O
-	O
type	O
response	O
and	O
nonhealing	O
.	O

We	O
explored	O
the	O
role	O
of	O
IL-4	B
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
IL-12Rbeta2	B
chain	O
in	O
the	O
establishment	O
of	O
this	O
Th2	O
response	O
.	O

First	O
,	O
we	O
showed	O
that	O
the	O
draining	O
lymph	O
nodes	O
of	O
resistant	O
C57BL	O
/	O
6	O
mice	O
infected	O
with	O
L.	O
major	O
were	O
enriched	O
in	O
CD4	B
+	O
/	O
IL	B
-	I
12Rbeta2	I
chain	O
+	O
cells	O
producing	O
IFN	B
-	I
gamma	I
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
BALB	O
/	O
c	O
background	O
mice	O
bearing	O
an	O
IL	B
-	I
12Rbeta2	I
-	O
chain	O
transgene	O
manifested	O
a	O
nonhealing	O
phenotype	O
similar	O
to	O
wild	O
-	O
type	O
littermates	O
despite	O
the	O
persistence	O
of	O
their	O
ability	O
to	O
undergo	O
STAT4	B
activation	O
.	O

Finally	O
,	O
we	O
found	O
that	O
such	O
transgenic	O
mice	O
display	O
more	O
severe	O
infection	O
than	O
wild	O
-	O
type	O
littermates	O
when	O
treated	O
with	O
IL-12	B
7	O
days	O
after	O
infection	O
,	O
and	O
under	O
this	O
condition	O
,	O
the	O
mice	O
display	O
increased	O
Leishmania	O
Ag	O
-	O
induced	O
IL	B
-	I
4	I
secretion	O
.	O

These	O
studies	O
indicate	O
that	O
although	O
CD4	B
+	O
/	O
IL-12Rbeta2	B
chain	O
+	O
T	O
cells	O
are	O
important	O
components	O
of	O
the	O
Th1	O
response	O
,	O
maintenance	O
of	O
IL-12Rbeta2	B
chain	O
expression	O
is	O
not	O
sufficient	O
to	O
change	O
a	O
Th2	O
response	O
to	O
a	O
Th1	O
response	O
in	O
vivo	O
and	O
thus	O
to	O
allow	O
BALB	O
/	O
c	O
mice	O
to	O
heal	O
L.	O
major	O
infection	O
.	O

Functionality	O
of	O
aquaporin-2	B
missense	O
mutants	O
in	O
recessive	O
nephrogenic	O
diabetes	O
insipidus	O
.	O

Aquaporin-2	B
(	O
AQP2	B
)	O
missense	O
mutants	O
in	O
recessive	O
nephrogenic	O
diabetes	O
insipidus	O
(	O
NDI	O
)	O
are	O
all	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
,	O
but	O
some	O
could	O
function	O
as	O
water	B
channels	I
.	O

No	O
conclusions	O
could	O
be	O
drawn	O
about	O
the	O
water	O
permeability	O
(	O
Pf	O
)	O
of	O
others	O
,	O
because	O
there	O
was	O
no	O
method	O
for	O
quantifying	O
AQP2	B
expression	O
in	O
the	O
plasma	O
membrane	O
.	O

We	O
recently	O
developed	O
such	O
a	O
method	O
,	O
which	O
has	O
allowed	O
us	O
to	O
study	O
the	O
functionality	O
of	O
these	O
AQP2	B
mutants	O
.	O

Immunoblot	O
analysis	O
of	O
membranes	O
of	O
injected	O
oocytes	O
revealed	O
that	O
all	O
mutants	O
(	O
AQP2	B
-	O
G64R	O
,	O
AQP2	B
-	O
N68S	O
,	O
AQP2	B
T126	O
M	O
,	O
AQP2	B
-	O
A147	O
T	O
,	O
AQP2	B
-	O
R187C	O
,	O
AQP2	B
-	O
S216P	O
)	O
are	O
expressed	O
as	O
unglycosylated	O
and	O
high	O
-	O
mannose	O
glycosylated	O
AQP2	B
.	O

The	O
level	O
of	O
the	O
high	O
-	O
mannose	O
form	O
of	O
AQP2	B
-	O
A147	O
T	O
in	O
the	O
plasma	O
membranes	O
was	O
low	O
,	O
indicating	O
that	O
this	O
mutation	O
has	O
a	O
less	O
severe	O
effect	O
on	O
proper	O
folding	O
.	O

Analysis	O
of	O
Pf	O
values	O
and	O
plasma	O
membrane	O
expression	O
levels	O
reveals	O
that	O
AQP2	B
-	O
N68S	O
,	O
AQP2	B
-	O
R187C	O
and	O
AQP2	B
-	O
S216P	O
are	O
non	O
-	O
functional	O
,	O
AQP2	B
-	O
A147	O
T	O
is	O
as	O
functional	O
as	O
wt	O
-	O
AQP2	B
,	O
while	O
AQP2	B
-	O
T126	O
M	O
and	O
AQP2	B
-	O
G64R	O
retain	O
20	O
%	O
of	O
the	O
permeability	O
of	O
wt	O
-	O
AQP2	B
.	O

Since	O
G64	O
is	O
highly	O
conserved	O
between	O
AQPs	B
and	O
expected	O
to	O
form	O
essential	O
interactions	O
with	O
other	O
amino	O
acids	O
within	O
AQP1	B
,	O
the	O
residual	O
functionality	O
of	O
AQP2	B
-	O
G64R	O
is	O
surprising	O
.	O

Our	O
data	O
furthermore	O
indicate	O
that	O
an	O
eventual	O
therapy	O
with	O
chemical	O
chaperones	O
that	O
restores	O
the	O
routing	O
of	O
AQP2	B
mutants	O
to	O
the	O
apical	O
membrane	O
of	O
collecting	O
ducts	O
cells	O
might	O
relieve	O
NDI	O
in	O
patients	O
encoding	O
AQP2	B
-	O
A147	O
T	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
AQP2	B
-	O
T126	O
M	O
and	O
AQP2	B
-	O
G64R	O
,	O
but	O
not	O
in	O
patients	O
encoding	O
AQP2	B
-	O
N68S	O
,	O
AQP2	B
-	O
R187C	O
or	O
AQP2	B
-	O
S216P	O
.	O

Cloning	O
of	O
a	O
mouse	O
beta	B
1	I
,	I
3	I
N	I
-	I
acetylglucosaminyltransferase	I
GlcNAc	I
(	I
beta	I
1,3	I
)	I
Gal	I
(	I
beta	I
1,4	I
)	I
Glc	I
-	I
ceramide	I
synthase	I
gene	O
encoding	O
the	O
key	O
regulator	O
of	O
lacto	O
-	O
series	O
glycolipid	O
biosynthesis	O
.	O

The	O
distinction	O
between	O
the	O
different	O
classes	O
of	O
glycolipids	O
is	O
conditioned	O
by	O
the	O
action	O
of	O
specific	O
core	O
transferases	B
.	O

The	O
entry	O
point	O
for	O
lacto	O
-	O
series	O
glycolipids	O
is	O
catalyzed	O
by	O
the	O
beta1	B
,	I
3	I
N	I
-	I
acetylglucosaminyltransferase	I
GlcNAc	I
(	I
beta1,3	I
)	I
Gal	I
(	I
beta1,4	I
)	I
Glc	I
-	I
ceramide	I
(	I
Lc3	I
)	I
synthase	I
enzyme	O
.	O

The	O
Lc3	B
synthase	I
activity	O
has	O
been	O
shown	O
to	O
be	O
regulated	O
during	O
development	O
,	O
especially	O
during	O
brain	O
morphogenesis	O
.	O

Here	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
of	O
a	O
mouse	O
gene	O
encoding	O
an	O
Lc3	B
synthase	I
enzyme	O
.	O

The	O
mouse	O
cDNA	O
included	O
an	O
open	O
reading	O
frame	O
of	O
1131	O
base	O
pairs	O
encoding	O
a	O
protein	O
of	O
376	O
amino	O
acids	O
.	O

The	O
Lc3	B
synthase	I
protein	O
shared	O
several	O
structural	O
motifs	O
previously	O
identified	O
in	O
the	O
members	O
of	O
the	O
beta1	B
,	I
3	I
glycosyltransferase	I
superfamily	I
.	O

The	O
Lc3	B
synthase	I
enzyme	O
efficiently	O
utilized	O
the	O
lactosyl	O
ceramide	O
glycolipid	O
acceptor	O
.	O

The	O
identity	O
of	O
the	O
reaction	O
products	O
of	O
Lc3	B
synthase	I
-	O
transfected	O
CHOP2	O
/	O
1	O
cells	O
was	O
confirmed	O
by	O
thin	O
-	O
layer	O
chromatography	O
immunostaining	O
using	O
antibodies	O
TE-8	O
and	O
1B2	O
that	O
recognize	O
Lc3	O
and	O
Gal	O
(	O
beta1,4	O
)	O
GlcNAc	O
(	O
beta1,3	O
)	O
Gal	O
(	O
beta1,4	O
)	O
Glc	O
-	O
ceramide	O
(	O
nLc4	O
)	O
structures	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
the	O
initiating	O
activity	O
for	O
lacto	O
-	O
chain	O
synthesis	O
,	O
the	O
Lc3	B
synthase	I
could	O
extend	O
the	O
terminal	O
N	O
-	O
acetyllactosamine	O
unit	O
of	O
nLc4	O
and	O
also	O
had	O
a	O
broad	O
specificity	O
for	O
gangliosides	O
GA1	O
,	O
GM1	O
,	O
and	O
GD1b	O
to	O
generate	O
neolacto	O
-	O
ganglio	O
hybrid	O
structures	O
.	O

The	O
mouse	O
Lc3	B
synthase	I
gene	O
was	O
mainly	O
expressed	O
during	O
embryonic	O
development	O
.	O

In	O
situ	O
hybridization	O
analysis	O
revealed	O
that	O
that	O
the	O
Lc3	B
synthase	I
was	O
expressed	O
in	O
most	O
tissues	O
at	O
embryonic	O
day	O
11	O
with	O
elevated	O
expression	O
in	O
the	O
developing	O
central	O
nervous	O
system	O
.	O

Postnatally	O
,	O
the	O
expression	O
was	O
restricted	O
to	O
splenic	O
B	O
-	O
cells	O
,	O
the	O
placenta	O
,	O
and	O
cerebellar	O
Purkinje	O
cells	O
where	O
it	O
colocalized	O
with	O
HNK-1	B
reactivity	O
.	O

These	O
data	O
support	O
a	O
key	O
role	O
for	O
the	O
Lc3	B
synthase	I
in	O
regulating	O
neolacto	O
-	O
series	O
glycolipid	O
synthesis	O
during	O
embryonic	O
development	O
.	O

AXOR12	B
,	O
a	O
novel	O
human	O
G	B
protein	I
-	I
coupled	I
receptor	I
,	O
activated	O
by	O
the	O
peptide	O
KiSS-1	B
.	O

A	O
novel	O
human	O
G	B
protein	I
-	I
coupled	I
receptor	I
named	O
AXOR12	B
,	O
exhibiting	O
81	O
%	O
homology	O
to	O
the	O
rat	O
orphan	O
receptor	O
GPR54	B
,	O
was	O
cloned	O
from	O
a	O
human	O
brain	O
cDNA	O
library	O
.	O

Heterologous	O
expression	O
of	O
AXOR12	B
in	O
mammalian	O
cells	O
permitted	O
the	O
identification	O
of	O
three	O
surrogate	O
agonist	O
peptides	O
,	O
all	O
with	O
a	O
common	O
C	O
-	O
terminal	O
amidated	O
motif	O
.	O

High	O
potency	O
agonism	O
,	O
indicative	O
of	O
a	O
cognate	O
ligand	O
,	O
was	O
evident	O
from	O
peptides	O
derived	O
from	O
the	O
gene	O
KiSS-1	B
,	O
the	O
expression	O
of	O
which	O
prevents	O
metastasis	O
in	O
melanoma	O
cells	O
.	O

Quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
study	O
the	O
expression	O
of	O
AXOR12	B
and	O
KiSS-1	B
in	O
a	O
variety	O
of	O
tissues	O
.	O

The	O
highest	O
levels	O
of	O
expression	O
of	O
AXOR12	B
mRNA	O
were	O
observed	O
in	O
brain	O
,	O
pituitary	O
gland	O
,	O
and	O
placenta	O
.	O

The	O
highest	O
levels	O
of	O
KiSS-1	B
gene	O
expression	O
were	O
observed	O
in	O
placenta	O
and	O
brain	O
.	O

A	O
polyclonal	O
antibody	O
raised	O
to	O
the	O
C	O
terminus	O
of	O
AXOR12	B
was	O
generated	O
and	O
used	O
to	O
show	O
localization	O
of	O
the	O
receptor	O
to	O
neurons	O
in	O
the	O
cerebellum	O
,	O
cerebral	O
cortex	O
,	O
and	O
brainstem	O
.	O

The	O
biological	O
significance	O
of	O
these	O
expression	O
patterns	O
and	O
the	O
nature	O
of	O
the	O
putative	O
cognate	O
ligand	O
for	O
AXOR12	B
are	O
discussed	O
.	O

The	O
role	O
of	O
antibodies	O
to	O
Bacillus	O
anthracis	O
and	O
anthrax	O
toxin	O
components	O
in	O
inhibiting	O
the	O
early	O
stages	O
of	O
infection	O
by	O
anthrax	O
spores	O
.	O

Vaccines	O
which	O
are	O
efficacious	O
against	O
anthrax	O
,	O
such	O
as	O
the	O
human	O
vaccine	O
,	O
Anthrax	O
Vaccine	O
Absorbed	O
(	O
AVA	O
)	O
,	O
contain	O
the	O
protective	B
antigen	I
(	O
PA	B
)	O
component	O
of	O
the	O
anthrax	O
toxins	O
as	O
the	O
major	O
protective	O
immunogen	O
.	O

Although	O
AVA	O
protects	O
against	O
inhalational	O
anthrax	O
,	O
the	O
immune	O
responses	O
to	O
and	O
role	O
in	O
protection	O
of	O
PA	B
and	O
possibly	O
other	O
antigens	O
have	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

Sera	O
from	O
animals	O
immunized	O
with	O
a	O
toxin	O
-	O
producing	O
,	O
unencapsulated	O
live	O
vaccine	O
strain	O
of	O
Bacillus	O
anthracis	O
have	O
been	O
reported	O
to	O
have	O
anti	O
-	O
spore	O
activities	O
associated	O
with	O
the	O
antitoxin	O
humoral	O
response	O
.	O

The	O
authors	O
performed	O
studies	O
to	O
determine	O
whether	O
anti	O
-	O
PA	B
antibody	O
(	O
Ab	O
)	O
-	O
containing	O
preparations	O
stimulated	O
spore	O
uptake	O
by	O
phagocytes	O
and	O
suppressed	O
the	O
germination	O
of	O
spores	O
in	O
vitro	O
.	O

AVA	O
-	O
and	O
PA	B
-	O
immune	O
sera	O
from	O
several	O
species	O
enhanced	O
the	O
phagocytosis	O
by	O
murine	O
peritoneal	O
macrophages	O
of	O
spores	O
of	O
the	O
virulent	O
Ames	O
and	O
the	O
Sterne	O
vaccine	O
strains	O
.	O

Antitoxin	O
Abs	O
appeared	O
to	O
contribute	O
significantly	O
,	O
although	O
not	O
solely	O
,	O
to	O
the	O
enhanced	O
uptake	O
.	O

Rabbit	O
antisera	O
to	O
PA	B
purified	O
from	O
either	O
Sterne	O
or	O
a	O
PA	B
-	O
producing	O
pX01	O
-	O
cured	O
recombinant	O
,	O
affinity	O
-	O
purified	O
anti	O
-	O
PA	B
IgG	B
,	O
and	O
monkey	O
antisera	O
to	O
AVA	O
were	O
used	O
to	O
assess	O
the	O
role	O
of	O
anti	O
-	O
PA	B
ABS	O
:	O

Rabbit	O
anti	O
-	O
PA	B
Abs	O
promoted	O
the	O
uptake	O
of	O
spores	O
of	O
the	O
PA	B
-	O
producing	O
strains	O
Sterne	O
,	O
Ames	O
and	O
RP42	O
,	O
a	O
mutant	O
of	O
Sterne	O
producing	O
only	O
PA	B
,	O
but	O
not	O
of	O
the	O
pX01	O
-	O
Sterne	O
-	O
1	O
strain	O
,	O
Ames	O
strain	O
,	O
or	O
RP4	O
,	O
a	O
mutant	O
of	O
Sterne	O
with	O
deletions	O
in	O
the	O
loci	O
encoding	O
PA	B
and	O
the	O
oedema	B
factor	I
(	O
EF	B
)	O
toxin	O
component	O
and	O
producing	O
only	O
the	O
lethal	B
factor	I
toxin	O
component	O
.	O

Rabbit	O
anti	O
-	O
PA	B
and	O
monkey	O
anti	O
-	O
AVA	O
Abs	O
also	O
significantly	O
inhibited	O
spore	O
germination	O
in	O
vitro	O
compared	O
to	O
preimmune	O
serum	O
or	O
medium	O
.	O

Spore	O
-	O
associated	O
proteins	O
recognized	O
by	O
anti	O
-	O
PA	B
Abs	O
were	O
detected	O
by	O
electron	O
microscopy	O
and	O
confirmed	O
by	O
immunoblotting	O
of	O
spore	O
coat	O
extracts	O
.	O

Thus	O
,	O
the	O
anti	O
-	O
PA	B
Ab	O
-	O
specific	O
immunity	O
induced	O
by	O
AVA	O
has	O
anti	O
-	O
spore	O
activity	O
and	O
might	O
have	O
a	O
role	O
in	O
impeding	O
the	O
early	O
stages	O
of	O
infection	O
with	O
B.	O
anthracis	O
spores	O
.	O

In	O
vitro	O
processing	O
of	O
the	O
16S	O
rRNA	O
of	O
the	O
thermophilic	O
archaeon	O
Sulfolobus	O
solfataricus	O
.	O

In	O
this	O
paper	O
we	O
have	O
analyzed	O
the	O
processing	O
in	O
vitro	O
of	O
the	O
16S	O
rRNA	O
of	O
the	O
thermophilic	O
archaeon	O
Sulfolobus	O
solfataricus	O
,	O
using	O
pre	O
-	O
rRNA	O
substrates	O
transcribed	O
in	O
vitro	O
and	O
different	O
protein	O
preparations	O
as	O
the	O
source	O
of	O
processing	O
enzymes	O
.	O

We	O
show	O
that	O
the	O
5	O
'	O
external	O
transcribed	O
spacer	O
of	O
the	O
S.	O
solfataricus	O
pre	O
-	O
rRNA	O
transcript	O
contains	O
a	O
target	O
site	O
for	O
a	O
specific	O
endonuclease	B
,	O
which	O
recognizes	O
a	O
conserved	O
sequence	O
also	O
existing	O
in	O
the	O
early	O
A0	O
and	O
0	O
processing	O
sites	O
of	O
Saccharomyces	O
cerevisiae	O
and	O
vertebrates	O
.	O

This	O
site	O
is	O
present	O
in	O
other	O
members	O
of	O
the	O
kingdom	O
Crenarchaeota	O
but	O
apparently	O
not	O
in	O
the	O
Euryarchaeota	O
.	O

Furthermore	O
,	O
S.	O
solfataricus	O
pre	O
-	O
16S	O
RNA	O
is	O
processed	O
within	O
the	O
double	O
-	O
helical	O
stem	O
formed	O
by	O
the	O
inverted	O
repeats	O
flanking	O
the	O
16S	O
RNA	O
sequence	O
,	O
in	O
correspondence	O
with	O
a	O
bulge	O
-	O
helix	O
-	O
bulge	O
motif	O
.	O

The	O
endonuclease	B
responsible	O
for	O
this	O
cleavage	O
is	O
present	O
in	O
both	O
the	O
Crenarchaeota	O
and	O
the	O
Euryarchaeota	O
.	O

The	O
processing	O
pattern	O
remained	O
the	O
same	O
when	O
the	O
substrate	O
was	O
a	O
30S	O
ribonucleoprotein	O
particle	O
instead	O
of	O
the	O
naked	O
RNA	O
.	O

Maturation	O
of	O
either	O
the	O
5	O
'	O
or	O
the	O
3	O
'	O
end	O
of	O
the	O
16S	O
RNA	O
molecule	O
was	O
not	O
observed	O
,	O
suggesting	O
either	O
that	O
maturation	O
requires	O
conditions	O
not	O
easily	O
reproducible	O
in	O
vitro	O
or	O
that	O
the	O
responsible	O
endonucleases	B
are	O
scarcely	O
represented	O
in	O
cell	O
extracts	O
.	O

Upregulation	O
of	O
bone	B
morphogenetic	I
protein	I
GDF-3	B
/	O
Vgr-2	B
expression	O
in	O
adipose	O
tissue	O
of	O
FABP4	B
/	O
aP2	B
null	O
mice	O
.	O

High	O
-	O
fat	O
-	O
fed	O
C57Bl	O
/	O
6J	O
FABP4	B
/	O
aP2	B
null	O
mice	O
develop	O
obesity	O
but	O
not	O
the	O
related	O
hyperglycemia	O
or	O
hyperinsulinemia	O
characteristic	O
of	O
type	O
II	O
diabetes	O
.	O

FABP4	B
/	O
aP2	B
protein	O
's	O
function	O
to	O
bind	O
fatty	O
acids	O
in	O
the	O
adipocytes	O
may	O
promote	O
total	O
body	O
energy	O
homeostasis	O
by	O
linking	O
energy	O
depots	O
to	O
the	O
ability	O
to	O
express	O
signaling	O
molecules	O
similar	O
to	O
leptin	B
.	O

To	O
test	O
this	O
hypothesis	O
,	O
proteomic	O
analysis	O
of	O
serum	O
proteins	O
from	O
high	O
-	O
fat	O
-	O
fed	O
wild	O
-	O
type	O
and	O
FABP4	B
/	O
aP2	B
null	O
mice	O
revealed	O
that	O
the	O
GDF-3	B
/	O
Vgr-2	B
protein	O
,	O
a	O
bone	B
morphogenetic	I
protein	I
,	O
was	O
upregulated	O
in	O
C57Bl	O
/	O
6J	O
FABP4	B
/	O
aP2	B
null	O
mice	O
.	O

The	O
increase	O
in	O
serum	O
GDF-3	B
/	O
Vgr-2	B
protein	O
was	O
correlated	O
with	O
a	O
27	O
-	O
fold	O
increase	O
in	O
adipose	O
GDF-3	B
/	O
Vgr-2	B
mRNA	O
.	O

In	O
contrast	O
,	O
leptin	B
expression	O
was	O
unaltered	O
between	O
FABP4	B
/	O
aP2	B
null	O
and	O
wild	O
-	O
type	O
animals	O
.	O

The	O
expression	O
of	O
GDF-3	B
/	O
Vgr-2	B
mRNA	O
was	O
not	O
substantially	O
different	O
in	O
adipose	O
tissue	O
of	O
db	O
/	O
db	O
and	O
tb	O
/	O
tb	O
mice	O
compared	O
to	O
wild	O
-	O
type	O
controls	O
.	O

The	O
expression	O
of	O
GDF-3	B
/	O
Vgr-2	B
mRNA	O
was	O
dependent	O
upon	O
the	O
age	O
and	O
diet	O
of	O
the	O
animals	O
,	O
declining	O
as	O
a	O
function	O
of	O
age	O
in	O
high	O
-	O
fat	O
-	O
fed	O
wild	O
-	O
type	O
animals	O
while	O
increasing	O
in	O
the	O
FABP4	B
/	O
aP2	B
null	O
strain	O
.	O

These	O
results	O
identify	O
GDF-3	B
/	O
Vgr-2	B
as	O
an	O
age	O
-	O
and	O
fat	O
-	O
regulated	O
,	O
adipose	O
-	O
derived	O
cytokine	B
suggesting	O
a	O
linkage	O
between	O
adipocyte	O
fatty	O
acid	O
metabolism	O
and	O
the	O
expression	O
of	O
the	O
bone	B
morphogenetic	I
family	I
of	O
differentiation	O
regulators	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
new	O
mammalian	O
glutaredoxin	B
(	O
thioltransferase	B
)	O
,	O
Grx2	B
.	O

A	O
thiol	B
/	I
disulfide	I
oxidoreductase	I
component	O
of	O
the	O
GSH	O
system	O
,	O
glutaredoxin	B
(	O
Grx	B
)	O
,	O
is	O
involved	O
in	O
the	O
reduction	O
of	O
GSH	O
-	O
based	O
mixed	O
disulfides	O
and	O
participates	O
in	O
a	O
variety	O
of	O
cellular	O
redox	O
pathways	O
.	O

A	O
single	O
cytosolic	O
Grx	B
(	O
Grx1	B
)	O
was	O
previously	O
described	O
in	O
mammals	O
.	O

We	O
now	O
report	O
identification	O
and	O
characterization	O
of	O
a	O
second	O
mammalian	O
Grx	B
,	O
designated	O
Grx2	B
.	O

Grx2	B
exhibited	O
36	O
%	O
identity	O
with	O
Grx1	B
and	O
had	O
a	O
disulfide	O
active	O
center	O
containing	O
the	O
Cys	O
-	O
Ser	O
-	O
Tyr	O
-	O
Cys	O
motif	O
.	O

Grx2	B
was	O
encoded	O
in	O
the	O
genomes	O
of	O
mammals	O
and	O
birds	O
and	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

The	O
gene	O
for	O
human	O
Grx2	B
consisted	O
of	O
four	O
exons	O
and	O
three	O
introns	O
,	O
spanned	O
10	O
kilobase	O
pairs	O
,	O
and	O
localized	O
to	O
chromosome	O
1q31.2	O
-	O
31.3	O
.	O

The	O
coding	O
sequence	O
was	O
present	O
in	O
all	O
exons	O
,	O
with	O
the	O
first	O
exon	O
encoding	O
a	O
mitochondrial	O
signal	O
peptide	O
.	O

The	O
mitochondrial	O
leader	O
sequence	O
was	O
also	O
present	O
in	O
mouse	O
and	O
rat	O
Grx2	B
sequences	O
and	O
was	O
shown	O
to	O
direct	O
either	O
Grx2	B
or	O
green	B
fluorescent	I
protein	I
to	O
mitochondria	O
.	O

Alternative	O
splicing	O
forms	O
of	O
mammalian	O
Grx2	B
mRNAs	O
were	O
identified	O
that	O
differed	O
in	O
sequences	O
upstream	O
of	O
exon	O
2	O
.	O

To	O
functionally	O
characterize	O
the	O
new	O
protein	O
,	O
human	O
and	O
mouse	O
Grx2	B
proteins	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
and	O
the	O
purified	O
proteins	O
were	O
shown	O
to	O
reduce	O
mixed	O
disulfides	O
formed	O
between	O
GSH	O
and	O
S	O
-	O
sulfocysteine	O
,	O
hydroxyethyldisulfide	O
,	O
or	O
cystine	O
.	O

Grx1	B
and	O
Grx2	B
were	O
sensitive	O
to	O
inactivation	O
by	O
iodoacetamide	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
and	O
exhibited	O
similar	O
pH	O
dependence	O
of	O
catalytic	O
activity	O
.	O

However	O
,	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
-inactivated	O
Grx2	B
could	O
only	O
be	O
reactivated	O
with	O
5	O
mm	O
GSH	O
,	O
whereas	O
Grx1	B
could	O
also	O
be	O
reactivated	O
with	O
dithiothreitol	O
or	O
thioredoxin	B
/	I
thioredoxin	I
reductase	I
.	O

The	O
Grx2	B
structural	O
model	O
suggested	O
a	O
common	O
reaction	O
mechanism	O
for	O
this	O
class	O
of	O
proteins	O
.	O

The	O
data	O
provide	O
the	O
first	O
example	O
of	O
a	O
mitochondrial	O
Grx	B
and	O
also	O
indicate	O
the	O
occurrence	O
of	O
a	O
second	O
functional	O
Grx	B
in	O
mammals	O
.	O

Retinoid	B
receptors	I
in	O
the	O
human	O
endometrium	O
and	O
its	O
disorders	O
:	O
a	O
possible	O
modulator	O
of	O
17	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
.	O

Retinoids	O
have	O
recently	O
been	O
proposed	O
to	O
modulate	O
estrogenic	O
actions	O
in	O
various	O
sex	O
steroid	O
-	O
dependent	O
neoplasms	O
,	O
but	O
little	O
has	O
been	O
studied	O
in	O
human	O
endometrial	O
disorders	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
first	O
examined	O
the	O
immunolocalization	O
of	O
retinoic	B
acid	I
receptor	I
alpha	I
,	I
beta	I
,	I
and	I
gamma	I
,	O
and	O
retinoid	B
X	I
receptor	I
(	I
RXR	I
)	I
alpha	I
,	I
beta	I
,	I
and	I
gamma	I
in	O
20	O
normal	O
cycling	O
human	O
endometria	O
,	O
34	O
endometrial	O
hyperplasia	O
,	O
and	O
46	O
endometrioid	O
endometrial	O
adenocarcinomas	O
.	O

We	O
then	O
correlated	O
these	O
findings	O
with	O
other	O
clinicopathological	O
parameters	O
,	O
especially	O
in	O
the	O
correlation	O
between	O
retinoid	O
receptor	O
subtypes	O
and	O
the	O
status	O
of	O
steroid	B
hormone	I
receptors	I
,	O
17	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
17	B
beta	I
-	I
HSD	I
)	O
and	O
aromatase	B
.	O

We	O
also	O
then	O
examined	O
the	O
effects	O
of	O
retinoic	O
acid	O
on	O
the	O
expression	O
of	O
17	B
beta	I
-	I
HSD	I
type	I
2	I
in	O
cell	O
lines	O
derived	O
from	O
endometrial	O
carcinoma	O
using	O
Northern	O
blotting	O
analysis	O
to	O
examine	O
the	O
possible	O
roles	O
of	O
retinoids	O
in	O
in	O
situ	O
endometrial	O
estrogen	O
metabolism	O
.	O

Among	O
these	O
six	O
retinoid	B
receptors	I
examined	O
,	O
RXR	B
gamma	I
immunoreactivity	O
was	O
exclusively	O
detected	O
in	O
the	O
epithelial	O
cells	O
of	O
the	O
secretory	O
phase	O
endometrium	O
but	O
not	O
of	O
the	O
proliferative	O
phase	O
,	O
which	O
was	O
well	O
correlated	O
with	O
17	B
beta	I
-	I
HSD	I
type	I
2	I
immunolocalization	O
.	O

However	O
,	O
in	O
endometrial	O
hyperplasia	O
,	O
RXR	B
gamma	I
was	O
not	O
correlated	O
with	O
17	B
beta	I
-	I
HSD	I
type	I
2	I
.	O

In	O
endometrioid	O
endometrial	O
adenocarcinoma	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
correlation	O
between	O
17	B
beta	I
-	I
HSD	I
type	I
2	I
immunoreactivity	O
and	O
RXR	B
gamma	I
labeling	O
index	O
(	O
LI	O
)	O
(	O
P	O
<	O
0.001	O
)	O
and	O
between	O
RXR	B
gamma	I
LI	O
and	O
progesterone	B
receptor	I
LI	O
(	O
r	O
=	O
0.501	O
,	O
P	O
=	O
0.003	O
)	O
.	O

A	O
significant	O
inverse	O
correlation	O
was	O
also	O
detected	O
between	O
RXR	B
gamma	I
LI	O
and	O
patient	O
age	O
(	O
r	O
=	O
0.449	O
,	O
P	O
=	O
0.015	O
)	O
.	O

No	O
statistically	O
significant	O
correlation	O
was	O
obtained	O
between	O
LIs	O
of	O
receptors	O
and	O
other	O
clinicopathological	O
parameters	O
including	O
the	O
status	O
of	O
intratumoral	O
aromatase	B
examined	O
by	O
immunohistochemistry	O
.	O

In	O
the	O
endometrial	O
carcinoma	O
cell	O
line	O
,	O
RL95	O
-	O
2	O
,	O
retinoic	O
acid	O
markedly	O
increased	O
the	O
level	O
of	O
17	B
beta	I
-	I
HSD	I
type	I
2	I
messenger	O
RNA	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
all	O
suggest	O
that	O
retinoic	O
acids	O
may	O
be	O
involved	O
in	O
modulation	O
of	O
in	O
situ	O
estrogen	O
metabolism	O
in	O
both	O
normal	O
and	O
neoplastic	O
human	O
endometrium	O
possibly	O
through	O
RXR	B
gamma	I
by	O
stimulating	O
the	O
expression	O
of	O
17	B
beta	I
-	I
HSD	I
type	I
2	I
.	O

Expression	O
of	O
11	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
isoenzymes	O
in	O
the	O
human	O
pituitary	O
:	O
induction	O
of	O
the	O
type	O
2	O
enzyme	O
in	O
corticotropinomas	O
and	O
other	O
pituitary	O
tumors	O
.	O

One	O
of	O
the	O
defining	O
biochemical	O
features	O
of	O
Cushing	O
's	O
disease	O
is	O
a	O
relative	O
insensitivity	O
to	O
glucocorticoid	O
(	O
GC	O
)	O
feedback	O
,	O
but	O
an	O
analysis	O
of	O
the	O
GC	B
receptor	I
has	O
failed	O
to	O
detect	O
any	O
major	O
abnormalities	O
.	O

However	O
,	O
two	O
isoenzymes	O
of	O
11	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
11	B
beta	I
HSD	I
)	O
,	O
either	O
by	O
converting	O
cortisone	O
(	O
E	O
)	O
to	O
cortisol	O
(	O
F	O
)	O
(	O
type	O
1	O
)	O
or	O
conversely	O
by	O
converting	O
F	O
to	O
E	O
(	O
type	O
2	O
)	O
,	O
play	O
an	O
important	O
prereceptor	O
role	O
in	O
regulating	O
corticosteroid	O
hormone	O
action	O
at	O
several	O
sites	O
.	O

11	B
beta	I
HSD1	I
and	I
-	I
2	I
expression	O
within	O
the	O
anterior	O
pituitary	O
gland	O
itself	O
may	O
modulate	O
GC	O
feedback	O
at	O
an	O
autocrine	O
level	O
,	O
and	O
we	O
have	O
speculated	O
that	O
this	O
may	O
be	O
deranged	O
in	O
Cushing	O
's	O
disease	O
.	O

Detection	O
of	O
11	B
beta	I
HSD	I
type	I
1	I
and	I
2	I
immunoreactive	O
protein	O
was	O
performed	O
using	O
fluorescence	O
immunohistochemistry	O
.	O

Double	O
immunofluorescent	O
studies	O
were	O
undertaken	O
on	O
normal	O
pituitary	O
to	O
define	O
the	O
cellular	O
localization	O
of	O
11	B
beta	I
HSD	I
isoenzymes	O
using	O
antisera	O
against	O
GH	B
,	O
ACTH	B
,	O
LH	B
,	O
FSH	B
,	O
PRL	B
,	O
and	O
S100	B
,	O
a	O
nonhormonal	O
marker	O
of	O
folliculo	O
-	O
stellate	O
cells	O
.	O

In	O
normal	O
pituitary	O
,	O
positive	O
staining	O
for	O
11	B
beta	I
HSD1	I
-	O
immunoreactive	O
protein	O
was	O
observed	O
in	O
GH	B
-	O
and	O
PRL	B
-	O
secreting	O
cells	O
and	O
in	O
folliculo	O
-	O
stellate	O
cells	O
;	O
gonadotrophs	O
,	O
thyrotrophs	O
,	O
and	O
ACTH	B
-	O
positive	O
cells	O
were	O
negative	O
.	O

11	B
beta	I
HSD2	I
immunoreactivity	O
was	O
absent	O
in	O
all	O
cell	O
types	O
.	O

RT	O
-	O
PCR	O
detected	O
11	B
beta	I
HSD1	I
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
expression	O
in	O
the	O
normal	O
pituitary	O
;	O
11	B
beta	I
HSD2	I
mRNA	O
expression	O
was	O
also	O
seen	O
in	O
most	O
normal	O
tissue	O
.	O

By	O
contrast	O
,	O
in	O
ACTH	B
-	O
secreting	O
adenomas	O
11	B
beta	I
HSD2	I
immunostaining	O
was	O
strongly	O
positive	O
in	O
every	O
case	O
of	O
corticotroph	O
adenoma	O
.	O

11	B
beta	I
HSD1	I
immunoreactivity	O
was	O
also	O
observed	O
occasionally	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
.	O

In	O
other	O
pituitary	O
tumors	O
,	O
both	O
functional	O
and	O
nonfunctional	O
,	O
11	B
beta	I
HSD	I
expression	O
was	O
variable	O
in	O
terms	O
of	O
isoenzyme	O
mRNA	O
and	O
intensity	O
of	O
protein	O
staining	O
.	O

The	O
expression	O
of	O
11	B
beta	I
HSD1	I
(	O
which	O
generates	O
F	O
from	O
E	O
)	O
in	O
somatotrophs	O
and	O
lactotrophs	O
suggests	O
an	O
autocrine	O
role	O
for	O
this	O
isoenzyme	O
in	O
the	O
glucocorticoid	O
regulation	O
of	O
pituitary	O
GH	B
and	O
PRL	B
secretion	O
.	O

11	B
beta	I
HSD2	I
expression	O
is	O
markedly	O
induced	O
in	O
ACTH	B
-	O
secreting	O
pituitary	O
tumors	O
and	O
,	O
by	O
converting	O
F	O
to	O
E	O
,	O
may	O
explain	O
the	O
resetting	O
of	O
glucocorticoid	O
feedback	O
control	O
in	O
Cushing	O
's	O
disease	O
.	O

Pharmacokinetics	O
and	O
safety	O
of	O
amprenavir	O
and	O
ritonavir	O
following	O
multiple	O
-	O
dose	O
,	O
co	O
-	O
administration	O
to	O
healthy	O
volunteers	O
.	O

OBJECTIVE	O
:	O

To	O
evaluate	O
the	O
safety	O
and	O
pharmacokinetic	O
interaction	O
between	O
amprenavir	O
(	O
APV	O
)	O
and	O
ritonavir	O
(	O
RTV	O
)	O
.	O

METHODS	O
:	O

Three	O
open	O
-	O
label	O
,	O
randomized	O
,	O
two	O
-	O
sequence	O
,	O
multiple	O
-	O
dose	O
studies	O
having	O
the	O
same	O
design	O
(	O
7	O
days	O
of	O
APV	O
or	O
RTV	O
alone	O
followed	O
by	O
7	O
days	O
of	O
both	O
drugs	O
together	O
)	O
used	O
450	O
or	O
900	O
mg	O
APV	O
with	O
100	O
or	O
300	O
mg	O
RTV	O
every	O
12	O
h	O
with	O
pharmacokinetic	O
assessments	O
on	O
days	O
7	O
and	O
14	O
.	O

Safety	O
was	O
monitored	O
as	O
clinical	O
adverse	O
events	O
(	O
AEs	O
)	O
and	O
laboratory	O
abnormalities	O
.	O

RESULTS	O
:	O

Relative	O
to	O
APV	O
alone	O
,	O
RTV	O
co	O
-	O
administration	O
resulted	O
in	O
a	O
3.3	O
-	O
to	O
4	O
-	O
fold	O
and	O
10.84	O
to	O
14.25	O
-	O
fold	O
increase	O
in	O
the	O
geometric	O
least	O
-	O
square	O
(	O
GLS	O
)	O
mean	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
-	O
time	O
curve	O
(	O
AUC	O
(	O
tau	O
,	O
ss	O
)	O
)	O
and	O
minimum	O
concentration	O
(	O
C	O
(	O
min	O
,	O
ss	O
)	O
)	O
,	O
respectively	O
.	O

APV	O
900	O
mg	O
with	O
RTV	O
100	O
mg	O
resulted	O
in	O
a	O
2.09	O
-	O
fold	O
and	O
6.85	O
-	O
fold	O
increase	O
in	O
the	O
GLS	O
mean	O
AUC	O
(	O
tau	O
,	O
ss	O
)	O
and	O
C	O
(	O
min	O
,	O
ss	O
)	O
,	O
respectively	O
.	O

On	O
day	O
14	O
,	O
the	O
geometric	O
mean	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
for	O
450	O
mg	O
APV	O
AUC	O
(	O
tau	O
,	O
ss	O
)	O
(	O
micro	O
x	O
h	O
/	O
mL	O
)	O
was	O
23.49	O
(	O
19.32	O
-	O
-	O
28.57	O
)	O
with	O
300	O
mg	O
RTV	O
and	O
35.42	O
(	O
30.46	O
--44.42	O
)	O
with	O
100	O
microg	O
RTV	O
,	O
and	O
for	O
the	O
900	O
mg	O
APV	O
with	O
100	O
mg	O
RTV	O
47.11	O
(	O
39.47	O
-	O
-	O
61.24	O
)	O
.	O

The	O
450	O
mg	O
APV	O
C	O
(	O
min	O
,	O
ss	O
)	O
(	O
microg	O
/	O
ml	O
)	O
were	O
1.32	O
(	O
1.05	O
--	O
1.67	O
)	O
and	O
2.01	O
(	O
1.70	O
--	O
2.61	O
)	O
,	O
and	O
2.47	O
(	O
2.08	O
-	O
-	O
3.32	O
)	O
for	O
900	O
mg	O
APV	O
.	O

The	O
most	O
common	O
AEs	O
were	O
mild	O
and	O
included	O
diarrhea	O
,	O
nausea	O
/	O
vomiting	O
,	O
oral	O
parasthesias	O
,	O
and	O
rash	O
.	O

The	O
triglyceride	O
and	O
cholesterol	O
increased	O
significantly	O
from	O
RTV	O
exposure	O
.	O

CONCLUSION	O
:	O

Adding	O
RTV	O
to	O
APV	O
resulted	O
in	O
clinically	O
and	O
statistically	O
significant	O
increases	O
in	O
APV	O
AUC	O
and	O
C	O
(	O
min	O
)	O
with	O
variable	O
effects	O
on	O
maximum	O
concentration	O
.	O

The	O
two	O
RTV	O
doses	O
had	O
similar	O
effects	O
on	O
APV	O
but	O
AEs	O
were	O
more	O
frequent	O
with	O
300	O
mg	O
RTV	O
.	O

Expression	O
of	O
AP-2	B
alpha	I
in	O
SV40	O
immortalized	O
human	O
lung	O
fibroblasts	O
is	O
associated	O
with	O
a	O
distinct	O
pattern	O
of	O
cytosine	O
methylation	O
in	O
the	O
AP-2	B
alpha	I
promoter	O
.	O

Activator	B
protein-2	I
alpha	I
(	O
AP-2	B
alpha	I
)	O
is	O
a	O
cell	O
type	O
-	O
specific	O
,	O
developmentally	O
regulated	O
,	O
transcription	B
factor	I
that	O
has	O
been	O
implicated	O
as	O
a	O
critical	O
regulator	O
of	O
gene	O
expression	O
during	O
vertebrate	O
development	O
and	O
carcinogenesis	O
.	O

We	O
found	O
that	O
AP-2	B
alpha	I
was	O
differentially	O
expressed	O
in	O
the	O
normal	O
human	O
lung	O
fibroblast	O
cell	O
strains	O
WI38	O
,	O
MRC-5	O
and	O
their	O
respective	O
SV40	O
-	O
transformed	O
cell	O
counterparts	O
WI38	O
-	O
VA	O
,	O
MRC-5VA	O
.	O

Since	O
CpG	O
methylation	O
within	O
genetic	O
regulatory	O
regions	O
has	O
been	O
implicated	O
as	O
a	O
mechanism	O
of	O
gene	O
regulation	O
,	O
we	O
investigated	O
the	O
CpG	O
methylation	O
status	O
of	O
the	O
AP-2	B
alpha	I
gene	O
promoter	O
in	O
these	O
cells	O
.	O

High	O
resolution	O
mapping	O
of	O
methylated	O
cytosines	O
revealed	O
that	O
differential	O
expression	O
of	O
the	O
AP-2	B
alpha	I
gene	O
in	O
normal	O
human	O
lung	O
fibroblasts	O
and	O
their	O
SV40	O
-	O
transformed	O
counterparts	O
was	O
associated	O
with	O
distinct	O
patterns	O
of	O
cytosine	O
methylation	O
in	O
the	O
AP-2	B
alpha	I
promoter	O
just	O
5	O
'	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O

Site	O
-	O
specific	O
methylation	O
was	O
positively	O
correlated	O
with	O
increased	O
AP-2	B
alpha	I
gene	O
expression	O
in	O
both	O
transformed	O
cell	O
lines	O
investigated	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
two	O
major	O
centers	O
of	O
hypermethylation	O
in	O
the	O
transformed	O
cells	O
encompassed	O
the	O
cis	O
-	O
element	O
for	O
the	O
AP-2	B
repressing	I
transcription	I
factor	I
AP-2rep	B
(	O
KLF12	B
)	O
.	O

Finally	O
,	O
a	O
sequence	O
variation	O
in	O
human	O
lung	O
fibroblasts	O
relative	O
to	O
the	O
published	O
sequence	O
revealed	O
a	O
previously	O
unidentified	O
AP-2	B
binding	O
site	O
at	O
position	O
-	O
528	O
with	O
respect	O
to	O
the	O
transcription	O
initiation	O
site	O
that	O
overlapped	O
the	O
AP-2rep	B
site	O
.	O

Our	O
results	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
AP-2	B
alpha	I
in	O
the	O
SV40	O
-	O
transformed	O
cells	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
site	O
-	O
specific	O
methylation	O
of	O
a	O
negative	O
regulatory	O
cis	O
-	O
element	O
in	O
the	O
AP-2	B
alpha	I
promoter	O
.	O

Maternal	O
undernutrition	O
during	O
early	O
to	O
midgestation	O
programs	O
tissue	O
-	O
specific	O
alterations	O
in	O
the	O
expression	O
of	O
the	O
glucocorticoid	B
receptor	I
,	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
isoforms	O
,	O
and	O
type	B
1	I
angiotensin	I
ii	I
receptor	I
in	O
neonatal	O
sheep	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
maternal	O
nutrient	O
restriction	O
in	O
the	O
sheep	O
during	O
the	O
period	O
of	O
rapid	O
placental	O
growth	O
(	O
i.e.	O
28	O
-	O
77	O
days	O
gestation	O
;	O
term	O
=	O
147	O
days	O
)	O
on	O
feto	O
-	O
placental	O
growth	O
and	O
expression	O
of	O
the	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
,	O
types	B
1	I
and	I
2	I
11beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
11betaHSD1	B
,	O
11betaHSD2	B
)	O
,	O
and	O
types	B
1	I
and	I
2	I
angiotensin	I
II	I
receptor	I
(	O
AT1	B
,	O
AT2	B
)	O
in	O
fetal	O
and	O
neonatal	O
offspring	O
.	O

Ewes	O
(	O
n	O
=	O
63	O
)	O
of	O
similar	O
age	O
,	O
body	O
weight	O
,	O
and	O
body	O
composition	O
were	O
randomly	O
allocated	O
to	O
a	O
nutrient	O
-	O
restricted	O
(	O
NR	O
)	O
group	O
in	O
which	O
they	O
consumed	O
3.2	O
MJ	O
/	O
day	O
metabolizable	O
energy	O
(	O
ME	O
;	O
equivalent	O
to	O
50	O
%	O
of	O
predicted	O
requirements	O
)	O
or	O
to	O
a	O
control	O
group	O
in	O
which	O
they	O
consumed	O
6.7	O
MJ	O
/	O
day	O
ME	O
(	O
equivalent	O
to	O
110	O
%	O
of	O
predicted	O
requirements	O
)	O
.	O

After	O
77	O
days	O
gestation	O
,	O
ewes	O
from	O
both	O
dietary	O
groups	O
consumed	O
close	O
to	O
100	O
%	O
of	O
ME	O
requirements	O
up	O
to	O
term	O
.	O

Newborn	O
offspring	O
of	O
NR	O
ewes	O
were	O
of	O
similar	O
body	O
weight	O
,	O
but	O
had	O
increased	O
crown	O
-	O
rump	O
length	O
,	O
greater	O
placental	O
weight	O
,	O
and	O
increased	O
placental	O
/	O
body	O
weight	O
ratio	O
(	O
P	O
<	O
0.01	O
)	O
compared	O
with	O
controls	O
.	O

Their	O
kidneys	O
were	O
heavier	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
shorter	O
in	O
length	O
,	O
with	O
increased	O
ratios	O
of	O
transverse	O
width	O
to	O
length	O
(	O
P	O
<	O
0.001	O
)	O
.	O

GR	B
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
in	O
neonatal	O
offspring	O
from	O
NR	O
ewes	O
was	O
increased	O
in	O
adrenal	O
,	O
kidney	O
,	O
liver	O
,	O
lung	O
,	O
and	O
perirenal	O
adipose	O
tissue	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Conversely	O
,	O
11betaHSD1	B
mRNA	O
expression	O
was	O
unaffected	O
,	O
except	O
in	O
perirenal	O
adipose	O
tissue	O
,	O
where	O
it	O
was	O
higher	O
in	O
lambs	O
born	O
to	O
NR	O
ewes	O
(	O
P	O
<	O
0.01	O
)	O
.	O

11betaHSD2	B
mRNA	O
expression	O
was	O
decreased	O
in	O
adrenals	O
and	O
kidney	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Maternal	O
NR	O
also	O
resulted	O
in	O
significantly	O
increased	O
AT1	B
expression	O
in	O
those	O
tissues	O
in	O
which	O
expression	O
of	O
GR	B
was	O
increased	O
and/or	O
11betaHSD2	B
was	O
decreased	O
,	O
i.e.	O
adrenals	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
lung	O
.	O

AT2	B
expression	O
was	O
unaffected	O
by	O
maternal	O
NR	O
.	O

Although	O
11betaHSD2	B
mRNA	O
was	O
undetectable	O
in	O
term	O
placenta	O
,	O
it	O
was	O
abundant	O
in	O
midgestation	O
placenta	O
and	O
was	O
lower	O
after	O
maternal	O
NR	O
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
close	O
agreement	O
between	O
levels	O
of	O
11betaHSD	B
enzyme	O
(	O
i.e.	O
11beta	B
-	I
dehydrogenase	I
and	O
11-oxoreductase	B
)	O
activities	O
and	O
abundance	O
of	O
11betaHSD1	B
mRNA	O
and	O
11betaHSD2	B
mRNA	O
expression	O
.	O

The	O
persistence	O
of	O
tissue	O
-	O
specific	O
increases	O
in	O
the	O
expression	O
of	O
GR	B
,	O
11betaHSD1	B
and	O
AT1	B
and	O
decreases	O
in	O
the	O
expression	O
of	O
11betaHSD2	B
in	O
adrenals	O
and	O
kidney	O
in	O
newborn	O
offspring	O
in	O
response	O
to	O
a	O
defined	O
period	O
of	O
maternal	O
nutrient	O
restriction	O
during	O
early	O
to	O
midgestation	O
suggests	O
that	O
gene	O
expression	O
has	O
been	O
programmed	O
by	O
nutrient	O
availability	O
to	O
the	O
fetus	O
before	O
birth	O
.	O

These	O
data	O
suggest	O
key	O
potential	O
mechanisms	O
by	O
which	O
maternal	O
nutrition	O
prenatally	O
programs	O
physiological	O
pathways	O
,	O
such	O
as	O
the	O
renin	B
-	O
angiotensin	B
system	O
,	O
in	O
the	O
offspring	O
that	O
may	O
lead	O
to	O
raised	O
blood	O
pressure	O
and	O
other	O
cardiovascular	O
disease	O
risk	O
factors	O
in	O
later	O
life	O
.	O

Therapeutic	O
alteration	O
of	O
insulin	B
-	O
dependent	O
diabetes	O
mellitus	O
progression	O
by	O
T	O
cell	O
tolerance	O
to	O
glutamic	B
acid	I
decarboxylase	I
65	I
peptides	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
have	O
reported	O
previously	O
that	O
nonobese	O
diabetic	O
(	O
NOD	O
)	O
fetal	O
pancreas	O
organ	O
cultures	O
lose	O
the	O
ability	O
to	O
produce	O
insulin	B
when	O
maintained	O
in	O
contact	O
with	O
NOD	O
fetal	O
thymus	O
organ	O
cultures	O
(	O
FTOC	O
)	O
.	O

Initial	O
studies	O
indicated	O
that	O
exposure	O
to	O
glutamic	B
acid	I
decarboxylase	I
(	O
GAD65	B
)	O
peptides	O
in	O
utero	O
resulted	O
in	O
delay	O
or	O
transient	O
protection	O
from	O
insulin	B
-	O
dependent	O
diabetes	O
mellitus	O
(	O
IDDM	O
)	O
in	O
NOD	O
mice	O
.	O

We	O
also	O
found	O
that	O
exposure	O
of	O
young	O
adult	O
NOD	O
mice	O
to	O
the	O
same	O
peptides	O
could	O
result	O
in	O
acceleration	O
of	O
the	O
disease	O
.	O

To	O
more	O
closely	O
examine	O
the	O
effects	O
of	O
early	O
and	O
late	O
exposure	O
to	O
diabetogenic	O
Ags	O
on	O
T	O
cells	O
,	O
we	O
applied	O
peptides	O
derived	O
from	O
GAD65	B
(	O
GAD	B
AA	O
246	O
-	O
266	O
,	O
509	O
-	O
528	O
,	O
and	O
524	O
-	O
543	O
)	O
,	O
to	O
our	O
""""	O
in	O
vitro	O
IDDM	O
""""	O
(	O
ivIDDM	O
)	O
model	O
.	O

T	O
cells	O
derived	O
from	O
NOD	O
FTOC	O
primed	O
during	O
the	O
latter	O
stages	O
of	O
organ	O
culture	O
,	O
when	O
mature	O
T	O
cell	O
phenotypes	O
are	O
present	O
,	O
had	O
the	O
ability	O
to	O
proliferate	O
to	O
GAD	B
peptides	O
.	O

ivIDDM	O
was	O
exacerbated	O
under	O
these	O
conditions	O
,	O
suggesting	O
that	O
GAD	B
responsiveness	O
correlates	O
with	O
the	O
ivIDDM	O
phenotype	O
,	O
and	O
parallels	O
the	O
acceleration	O
of	O
IDDM	O
we	O
had	O
seen	O
in	O
young	O
adult	O
NOD	O
mice	O
.	O

When	O
GAD	B
peptides	O
were	O
present	O
during	O
the	O
initiation	O
of	O
FTOC	O
,	O
GAD	B
proliferative	O
responses	O
were	O
inhibited	O
,	O
and	O
ivIDDM	O
was	O
reduced	O
.	O

This	O
result	O
suggests	O
that	O
tolerance	O
to	O
GAD	B
peptides	O
may	O
reduce	O
the	O
production	O
of	O
diabetogenic	O
T	O
cells	O
or	O
their	O
capacity	O
to	O
respond	O
,	O
as	O
suggested	O
by	O
the	O
in	O
utero	O
therapies	O
studied	O
in	O
NOD	O
mice	O
.	O

Structure	O
of	O
aspergillopepsin	B
I	I
from	O
Aspergillus	O
phoenicis	O
:	O
variations	O
of	O
the	O
S1'-S2	O
subsite	O
in	O
aspartic	B
proteinases	I
.	O

The	O
crystal	O
structure	O
of	O
aspergillopepsin	B
I	I
(	O
AP	B
)	O
from	O
Aspergillus	O
phoenicis	O
has	O
been	O
determined	O
at	O
2.18	O
A	O
resolution	O
and	O
refined	O
to	O
R	O
and	O
R	O
(	O
free	O
)	O
factors	O
of	O
21.5	O
and	O
26.0	O
%	O
,	O
respectively	O
.	O

AP	B
has	O
the	O
typical	O
two	O
beta	O
-	O
barrel	O
domain	O
structure	O
of	O
aspartic	B
proteinases	I
.	O

The	O
structures	O
of	O
the	O
two	O
independent	O
molecules	O
are	O
partly	O
different	O
,	O
exemplifying	O
the	O
flexible	O
nature	O
of	O
the	O
aspartic	B
proteinase	I
structure	O
.	O

Notably	O
,	O
the	O
'	O
flap	O
'	O
in	O
one	O
molecule	O
is	O
closer	O
,	O
with	O
a	O
largest	O
separation	O
of	O
4.0	O
A	O
,	O
to	O
the	O
active	O
site	O
than	O
in	O
the	O
other	O
molecule	O
.	O

AP	B
is	O
most	O
structurally	O
homologous	O
to	O
penicillopepsin	B
(	O
PP	B
)	O
and	O
then	O
to	O
endothiapepsin	B
(	O
EP	B
)	O
,	O
which	O
share	O
sequence	O
identities	O
of	O
68	O
and	O
56	O
%	O
,	O
respectively	O
.	O

However	O
,	O
AP	B
is	O
similar	O
to	O
EP	B
but	O
differs	O
from	O
PP	B
in	O
the	O
combined	O
S1	O
'	O
-S2	O
subsite	O
that	O
is	O
delineated	O
by	O
a	O
flexible	O
psi	O
-	O
loop	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

The	O
S1	O
'	O
and	O
S2	O
subsites	O
are	O
well	O
defined	O
and	O
small	O
in	O
AP	B
,	O
while	O
there	O
is	O
no	O
definite	O
border	O
between	O
S1	O
'	O
and	O
S2	O
and	O
the	O
open	O
space	O
for	O
the	O
S2	O
subsite	O
is	O
larger	O
in	O
PP	B
.	O

Comparison	O
of	O
the	O
structures	O
indicates	O
that	O
the	O
two	O
amino	O
-	O
acid	O
residues	O
equivalent	O
to	O
Leu295	O
and	O
Leu297	O
of	O
AP	B
are	O
the	O
major	O
determining	O
factors	O
in	O
shaping	O
the	O
S1'-S2	O
subsite	O
in	O
the	O
fungal	O
aspartic	B
proteinases	I
.	O

Recombinant	O
,	O
soluble	O
LIGHT	B
(	O
HVEM	B
ligand	I
)	O
induces	O
increased	O
IL-8	B
secretion	O
and	O
growth	O
arrest	O
in	O
A375	O
melanoma	O
cells	O
.	O

The	O
heterotrimeric	O
lymphotoxin	B
alpha	I
(	I
1	I
)	I
beta	I
(	I
2	I
)	I
(	O
LTalpha	B
(	I
1	I
)	I
beta	I
(	I
2	I
)	I
)	O
complex	O
and	O
LIGHT	B
,	O
a	O
new	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
superfamily	I
,	O
have	O
been	O
identified	O
as	O
membrane	O
-	O
anchored	O
ligands	O
for	O
the	O
LTbeta	B
receptor	I
(	O
LTbetaR	B
)	O
,	O
a	O
member	O
of	O
the	O
TNF	B
receptor	I
(	I
TNFR	I
)	I
superfamily	I
.	O

Although	O
some	O
of	O
the	O
biologic	O
activities	O
of	O
this	O
receptor	O
have	O
been	O
described	O
using	O
either	O
soluble	O
LTalpha	B
(	I
1	I
)	I
beta	I
(	I
2	I
)	I
as	O
a	O
ligand	O
or	O
agonistic	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
signaling	O
of	O
LIGHT	B
via	O
the	O
LTbetaR	B
.	O

To	O
gain	O
more	O
insight	O
into	O
the	O
biologic	O
functions	O
of	O
LIGHT	B
,	O
we	O
generated	O
a	O
recombinant	O
soluble	O
form	O
of	O
human	O
LIGHT	B
(	O
rsHuLIGHT	B
)	O
.	O

We	O
demonstrate	O
here	O
that	O
this	O
rsHuLIGHT	B
is	O
capable	O
of	O
binding	O
to	O
the	O
LTbetaR	B
.	O

Interestingly	O
,	O
receptor	O
-	O
mediated	O
ligand	O
precipitation	O
analysis	O
revealed	O
that	O
rsHuLIGHT	B
bound	O
only	O
to	O
human	O
LTbetaR	B
but	O
not	O
to	O
mouse	O
LTbetaR	B
,	O
indicating	O
a	O
species	O
-	O
specific	O
receptor	O
ligand	O
interaction	O
.	O

Activation	O
of	O
A375	O
human	O
melanoma	O
cells	O
by	O
rsHuLIGHT	B
induced	O
an	O
increased	O
secretion	O
of	O
interleukin-8	B
(	O
IL-8	B
)	O
.	O

Furthermore	O
,	O
rsHuLIGHT	B
caused	O
growth	O
arrest	O
of	O
A375	O
cells	O
even	O
in	O
the	O
absence	O
of	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
.	O

Breaking	O
through	O
the	O
acid	O
barrier	O
:	O
an	O
orchestrated	O
response	O
to	O
proton	O
stress	O
by	O
enteric	O
bacteria	O
.	O

The	O
ability	O
of	O
enteropathogens	O
such	O
as	O
Salmonella	O
and	O
Escherichia	O
coli	O
to	O
adapt	O
and	O
survive	O
acid	O
stress	O
is	O
fundamental	O
to	O
their	O
pathogenesis	O
.	O

Once	O
inside	O
the	O
host	O
,	O
these	O
organisms	O
encounter	O
life	O
-	O
threatening	O
levels	O
of	O
inorganic	O
acid	O
(	O
H+	O
)	O
in	O
the	O
stomach	O
and	O
a	O
combination	O
of	O
inorganic	O
and	O
organic	O
acids	O
(	O
volatile	O
fatty	O
acids	O
)	O
in	O
the	O
small	O
intestine	O
.	O

To	O
combat	O
these	O
stresses	O
,	O
enteric	O
bacteria	O
have	O
evolved	O
elegant	O
,	O
overlapping	O
strategies	O
that	O
involve	O
both	O
constitutive	O
and	O
inducible	O
defense	O
systems	O
.	O

This	O
article	O
reviews	O
the	O
recent	O
progress	O
made	O
in	O
understanding	O
the	O
pH	O
3	O
acid	O
tolerance	O
systems	O
of	O
Salmonella	O
and	O
the	O
even	O
more	O
effective	O
pH	O
2	O
acid	O
resistance	O
systems	O
of	O
E.	O
coli	O
.	O

Focus	O
is	O
placed	O
on	O
how	O
Salmonella	O
orchestrates	O
acid	O
tolerance	O
by	O
modulating	O
the	O
activities	O
or	O
levels	O
of	O
diverse	O
regulatory	O
proteins	O
in	O
response	O
to	O
pH	O
stress	O
.	O

The	O
result	O
is	O
induction	O
of	O
overlapping	O
arrays	O
of	O
acid	O
shock	O
proteins	O
that	O
protect	O
the	O
cell	O
against	O
acid	O
and	O
other	O
environmental	O
stresses	O
.	O

Most	O
notable	O
among	O
these	O
pH	O
-	O
response	O
regulators	O
are	O
RpoS	B
,	O
Fur	B
,	O
PhoP	B
and	O
OmpR	B
.	O

In	O
addition	O
,	O
we	O
will	O
review	O
three	O
dedicated	O
acid	O
resistance	O
systems	O
of	O
E.	O
coli	O
,	O
not	O
present	O
in	O
Salmonella	O
,	O
that	O
allow	O
this	O
organism	O
to	O
survive	O
extreme	O
(	O
pH	O
2	O
)	O
acid	O
challenge	O
.	O

Mutations	O
of	O
the	O
beta	B
-	I
and	I
gamma	I
-	I
catenin	I
genes	O
are	O
uncommon	O
in	O
human	O
lung	O
,	O
breast	O
,	O
kidney	O
,	O
cervical	O
and	O
ovarian	O
carcinomas	O
.	O

Beta	B
-	I
catenin	I
forms	O
complexes	O
with	O
Tcf	B
and	O
Lef-1	B
and	O
functions	O
as	O
a	O
transcriptional	O
activator	O
in	O
the	O
Wnt	B
signalling	O
pathway	O
.	O

Although	O
recent	O
investigations	O
have	O
been	O
focused	O
on	O
the	O
role	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
/	O
beta	B
-	I
catenin	I
/	O
Tcf	B
pathway	O
in	O
human	O
tumorigenesis	O
,	O
there	O
have	O
been	O
very	O
few	O
reports	O
on	O
mutations	O
of	O
the	O
beta	B
-	I
catenin	I
gene	O
in	O
a	O
variety	O
of	O
tumour	O
types	O
.	O

Using	O
PCR	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
,	O
we	O
examined	O
93	O
lung	O
,	O
9	O
breast	O
,	O
6	O
kidney	O
,	O
19	O
cervical	O
and	O
7	O
ovarian	O
carcinoma	O
cell	O
lines	O
for	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta	B
-	I
catenin	I
gene	O
.	O

In	O
addition	O
,	O
we	O
tested	O
these	O
same	O
samples	O
for	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
region	O
of	O
the	O
gamma	B
-	I
catenin	I
gene	O
.	O

Mutational	O
analysis	O
for	O
the	O
entire	O
coding	O
region	O
of	O
beta	B
-	I
catenin	I
cDNA	O
was	O
also	O
undertaken	O
in	O
20	O
lung	O
,	O
9	O
breast	O
,	O
5	O
kidney	O
and	O
6	O
cervical	O
carcinoma	O
cell	O
lines	O
.	O

Deletion	O
of	O
most	O
beta	B
-	I
catenin	I
coding	O
exons	O
was	O
confirmed	O
in	O
line	O
NCI	O
-	O
H28	O
(	O
lung	O
mesothelioma	O
)	O
and	O
a	O
silent	O
mutation	O
at	O
codon	O
214	O
in	O
exon	O
5	O
was	O
found	O
in	O
HeLa	O
(	O
cervical	O
adenocarcinoma	O
)	O
.	O

A	O
missense	O
mutation	O
at	O
codon	O
19	O
and	O
a	O
silent	O
mutation	O
at	O
codon	O
28	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
region	O
of	O
the	O
gamma	B
-	I
catenin	I
gene	O
were	O
found	O
in	O
H1726	O
(	O
squamous	O
cell	O
lung	O
carcinoma	O
)	O
and	O
H1048	O
(	O
small	O
cell	O
lung	O
carcinoma	O
)	O
,	O
respectively	O
.	O

Neither	O
deletions	O
nor	O
mutations	O
of	O
these	O
genes	O
were	O
detected	O
in	O
the	O
other	O
cell	O
lines	O
examined	O
.	O

These	O
results	O
suggest	O
that	O
beta	B
-	I
and	I
gamma	I
-	I
catenins	I
are	O
infrequent	O
mutational	O
targets	O
during	O
development	O
of	O
human	O
lung	O
,	O
breast	O
,	O
kidney	O
,	O
cervical	O
and	O
ovarian	O
carcinomas	O
.	O

Identification	O
of	O
a	O
cis	O
-	O
regulatory	O
element	O
for	O
L1	O
layer	O
-	O
specific	O
gene	O
expression	O
,	O
which	O
is	O
targeted	O
by	O
an	O
L1	O
-	O
specific	O
homeodomain	B
protein	I
.	O

The	O
Arabidopsis	O
thaliana	O
PROTODERMAL	B
FACTOR1	I
(	O
PDF1	B
)	O
gene	O
encoding	O
a	O
putative	O
extracellular	O
proline	O
-	O
rich	O
protein	O
is	O
exclusively	O
expressed	O
in	O
the	O
L1	O
layer	O
of	O
shoot	O
apices	O
and	O
the	O
protoderm	O
of	O
organ	O
primordia	O
.	O

In	O
order	O
to	O
identify	O
essential	O
cis	O
-	O
regulatory	O
sequences	O
required	O
for	O
the	O
L1	O
layer	O
-	O
specific	O
expression	O
,	O
a	O
series	O
of	O
5	O
'	O
deletions	O
of	O
the	O
PDF1	B
promoter	O
were	O
fused	O
to	O
the	O
beta	B
-	I
glucronidase	I
(	O
GUS	B
)	O
gene	O
and	O
introduced	O
into	O
Arabidopsis	O
plants	O
.	O

Our	O
analysis	O
revealed	O
that	O
the	O
minimum	O
region	O
necessary	O
to	O
confer	O
L1	O
-	O
specific	O
expression	O
of	O
PDF1	B
is	O
confined	O
within	O
a	O
260	O
-	O
bp	O
fragment	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

We	O
identified	O
an	O
8	O
-	O
bp	O
motif	O
in	O
this	O
region	O
that	O
is	O
conserved	O
between	O
promoter	O
regions	O
of	O
all	O
the	O
L1	O
-	O
specific	O
genes	O
so	O
far	O
cloned	O
,	O
and	O
we	O
designated	O
it	O
the	O
L1	O
box	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
the	O
L1	O
-	O
specific	O
homeodomain	B
protein	I
ATML1	B
can	O
bind	O
to	O
the	O
L1	O
box	O
sequence	O
in	O
vitro	O
.	O

The	O
GUS	B
expression	O
in	O
transgenic	O
plants	O
disappeared	O
when	O
a	O
mutation	O
that	O
abolishes	O
binding	O
of	O
ATML1	B
was	O
introduced	O
into	O
the	O
PDF1	B
l1	O
box	O
sequence	O
of	O
the	O
construct	O
.	O

These	O
results	O
suggest	O
that	O
the	O
L1	O
box	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
PDF1	B
expression	O
in	O
L1	O
cells	O
and	O
that	O
ATML1	B
could	O
cooperate	O
to	O
drive	O
L1	O
-	O
specific	O
expression	O
.	O

An	O
anti	O
-	O
inflammatory	O
drug	O
,	O
propagermanium	O
,	O
may	O
target	O
GPI	O
-	O
anchored	O
proteins	O
associated	O
with	O
an	O
MCP-1	B
receptor	I
,	O
CCR2	B
.	O

Monocyte	B
chemoattractant	I
protein-1	I
(	O
MCP-1	B
)	O
promotes	O
the	O
migration	O
and	O
activation	O
of	O
monocytes	O
and	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
chronic	O
inflammation	O
.	O

Propagermanium	O
(	O
3-oxygermylpropionic	O
acid	O
polymer	O
)	O
has	O
been	O
used	O
as	O
a	O
therapeutic	O
agent	O
against	O
chronic	O
hepatitis	O
B	O
in	O
Japan	O
.	O

We	O
report	O
here	O
that	O
propagermanium	O
specifically	O
inhibits	O
in	O
vitro	O
chemotactic	O
migration	O
of	O
monocytes	O
by	O
MCP-1	B
.	O

Propagermanium	O
did	O
not	O
inhibit	O
binding	O
of	O
MCP-1	B
to	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
cells	O
,	O
or	O
affect	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
mobilization	O
or	O
the	O
cAMP	O
concentration	O
in	O
MCP-1	B
-	O
treated	O
THP-1	O
cells	O
.	O

The	O
effect	O
of	O
propagermanium	O
seems	O
to	O
require	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
proteins	O
,	O
as	O
cleavage	O
of	O
GPI	O
anchors	O
by	O
phosphatidylinositol	B
-	I
phospholipase	I
C	I
(	O
PI	B
-	I
PLC	I
)	O
eliminated	O
the	O
inhibitory	O
activity	O
of	O
propagermanium	O
.	O

Anti	O
-	O
GPI	O
-	O
anchored	O
protein	O
antibodies	O
,	O
such	O
as	O
anti	O
-	O
CD55	B
and	O
anti	O
-	O
CD59	B
,	O
reduced	O
staining	O
of	O
C	B
-	I
C	I
chemokine	I
receptor	I
2	I
(	O
CCR2	B
)	O
with	O
an	O
anti	O
-	O
CCR2	B
antibody	O
against	O
the	O
N	O
-	O
terminus	O
of	O
CCR2	B
in	O
a	O
flow	O
cytometric	O
analysis	O
,	O
and	O
these	O
antibodies	O
also	O
selectively	O
inhibited	O
MCP-1	B
-	O
induced	O
migration	O
of	O
THP-1	O
cells	O
.	O

Furthermore	O
,	O
under	O
fluorescence	O
microscopy	O
,	O
GPI	O
-	O
anchored	O
proteins	O
colocalized	O
with	O
CCR2	B
on	O
THP-1	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
propagermanium	O
may	O
target	O
GPI	O
-	O
anchored	O
proteins	O
that	O
are	O
closely	O
associated	O
with	O
CCR2	B
to	O
selectively	O
inhibit	O
the	O
MCP-1	B
-	O
induced	O
chemotaxis	O
,	O
thus	O
providing	O
a	O
mechanistic	O
basis	O
for	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
the	O
drug	O
.	O

Identification	O
and	O
characterization	O
of	O
RRM	B
-	I
containing	I
coactivator	I
activator	I
(	O
CoAA	B
)	O
as	O
TRBP	B
-	O
interacting	O
protein	O
,	O
and	O
its	O
splice	O
variant	O
as	O
a	O
coactivator	O
modulator	O
(	O
CoAM	B
)	O
.	O

We	O
previously	O
cloned	O
and	O
characterized	O
thyroid	B
hormone	I
receptor	I
-	I
binding	I
protein	I
(	O
TRBP	B
)	O
as	O
an	O
LXXLL	O
-	O
containing	O
general	O
coactivator	O
that	O
associates	O
with	O
coactivator	O
complexes	O
through	O
its	O
C	O
terminus	O
.	O

To	O
identify	O
protein	O
cofactors	O
for	O
TRBP	B
action	O
,	O
a	O
Sos	B
-	O
Ras	B
yeast	O
two	O
-	O
hybrid	O
cDNA	O
library	O
was	O
screened	O
using	O
TRBP	B
C	O
terminus	O
as	O
bait	O
.	O

A	O
novel	O
coactivator	O
was	O
isolated	O
,	O
coactivator	O
activator	O
(	O
CoAA	B
)	O
,	O
that	O
specifically	O
associates	O
with	O
TRBP	B
.	O

Human	O
CoAA	B
is	O
composed	O
of	O
669	O
amino	O
acids	O
with	O
a	O
TRBP	B
-	O
interacting	O
domain	O
and	O
two	O
highly	O
conserved	O
RNA	O
recognition	O
motifs	O
(	O
RRM	O
)	O
commonly	O
found	O
in	O
ribonucleoproteins	B
.	O

A	O
splice	O
variant	O
lacking	O
the	O
entire	O
TRBP	B
-	O
interacting	O
domain	O
was	O
also	O
isolated	O
as	O
a	O
coactivator	O
modulator	O
(	O
CoAM	B
)	O
,	O
a	O
156	O
-	O
amino	O
acid	O
protein	O
containing	O
only	O
the	O
RRM	O
region	O
.	O

Human	O
CoAA	B
and	O
CoAM	B
mRNAs	O
are	O
encoded	O
by	O
a	O
single	O
gene	O
located	O
on	O
chromosome	O
11q13	O
;	O
alternative	O
splicing	O
in	O
exon	O
2	O
of	O
CoAA	B
yields	O
CoAM	B
.	O

CoAA	B
interacts	O
with	O
both	O
TRBP	B
and	O
p300	B
in	O
vitro	O
.	O

In	O
addition	O
,	O
CoAA	B
potently	O
coactivates	O
transcription	O
mediated	O
by	O
multiple	O
hormone	O
-	O
response	O
elements	O
and	O
acts	O
synergistically	O
with	O
TRBP	B
and	O
CREB	B
-	I
binding	I
protein	I
(	O
CBP	B
)	O
.	O

Furthermore	O
,	O
CoAA	B
is	O
associated	O
with	O
the	O
DNA	B
-	I
dependent	I
protein	I
kinase	I
-	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
complex	O
.	O

Strikingly	O
,	O
CoAM	B
,	O
which	O
lacks	O
a	O
TRBP	B
-	O
interacting	O
domain	O
,	O
strongly	O
represses	O
both	O
TRBP	B
and	O
CBP	B
action	O
suggesting	O
that	O
CoAM	B
may	O
modulate	O
endogenous	O
CoAA	B
function	O
.	O

These	O
data	O
suggest	O
that	O
CoAA	B
may	O
serve	O
as	O
a	O
mediator	O
of	O
coactivators	O
such	O
as	O
TRBP	B
in	O
gene	O
activation	O
.	O

YfiD	B
of	O
Escherichia	O
coli	O
and	O
Y06I	B
of	O
bacteriophage	O
T4	O
as	O
autonomous	O
glycyl	O
radical	O
cofactors	O
reconstituting	O
the	O
catalytic	O
center	O
of	O
oxygen	O
-	O
fragmented	O
pyruvate	B
formate	I
-	I
lyase	I
.	O

Reaction	O
of	O
oxygen	O
with	O
the	O
glycyl	O
radical	O
in	O
pyruvate	B
formate	I
-	I
lyase	I
(	O
PFL	B
)	O
leads	O
to	O
cleavage	O
of	O
the	O
polypeptide	O
backbone	O
between	O
N	O
-	O
Calpha	O
of	O
Gly734	O
.	O

A	O
recombinant	O
protein	O
comprising	O
the	O
core	O
of	O
PFL	B
(	O
Ser1	O
-	O
Ser733	O
)	O
is	O
shown	O
here	O
to	O
associate	O
with	O
the	O
YfiD	B
protein	O
(	O
14	O
kDa	O
)	O
of	O
Escherichia	O
coli	O
and	O
likewise	O
with	O
the	O
homologous	O
T4	O
encoded	O
Y06I	B
protein	O
,	O
yielding	O
upon	O
reaction	O
with	O
PFL	B
activase	I
a	O
heterooligomeric	O
PFL	B
enzyme	O
that	O
has	O
full	O
catalytic	O
activity	O
(	O
35	O
U	O
/	O
nmol	O
)	O
.	O

Treatment	O
of	O
the	O
activated	O
complexes	O
with	O
oxygen	O
led	O
to	O
cleavage	O
of	O
the	O
14	O
kDa	O
proteins	O
into	O
11	O
and	O
3	O
kDa	O
polypeptides	O
as	O
expected	O
for	O
the	O
localization	O
of	O
the	O
putative	O
glycyl	O
radical	O
at	O
Gly102	O
(	O
YfiD	B
)	O
or	O
Gly95	O
(	O
Y06I	B
)	O
.	O

For	O
the	O
isolated	O
fragments	O
from	O
Y06I	B
,	O
mass	O
spectrometric	O
analysis	O
(	O
nanoESI	O
-	O
MS	O
)	O
determined	O
a	O
C	O
-	O
terminal	O
serine	O
carboxamide	O
in	O
the	O
11	O
kDa	O
fragment	O
,	O
and	O
a	O
N	O
-	O
terminal	O
oxalyl	O
modification	O
in	O
the	O
3	O
kDa	O
fragment	O
.	O

We	O
speculate	O
that	O
YfiD	B
in	O
E.	O
coli	O
and	O
other	O
facultative	O
anaerobic	O
bacteria	O
has	O
evolved	O
as	O
a	O
""""	O
spare	O
part	O
""""	O
for	O
PFL	B
's	O
glycyl	O
radical	O
domain	O
,	O
utilized	O
for	O
rapid	O
recovery	O
of	O
PFL	B
activity	O
(	O
and	O
thus	O
ATP	O
generation	O
)	O
in	O
cells	O
that	O
have	O
experienced	O
oxidative	O
stress	O
.	O

Developmental	O
expression	O
of	O
two	O
CXC	B
chemokines	I
,	O
MIP-2	B
and	O
KC	B
,	O
and	O
their	O
receptors	O
.	O

CXC	B
chemokines	I
,	O
macrophage	B
inflammatory	I
protein-2	I
(	O
MIP-2	B
)	O
and	O
KC	B
,	O
(	O
a	O
cloning	O
designation	O
based	O
on	O
ordinate	O
and	O
abscissa	O
position	O
)	O
as	O
well	O
as	O
the	O
CXC	B
chemokine	I
receptor	O
,	O
CXCR2	B
,	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cells	O
and	O
tissues	O
in	O
adult	O
mice	O
.	O

Targeted	O
deletion	O
of	O
the	O
gene	O
encoding	O
murine	O
CXCR2	B
does	O
not	O
result	O
in	O
obvious	O
changes	O
in	O
the	O
development	O
of	O
the	O
organ	O
system	O
of	O
the	O
mouse	O
,	O
though	O
the	O
CXCR2	B
-	O
/	O
-	O
mouse	O
is	O
compromised	O
with	O
regard	O
to	O
its	O
ability	O
to	O
resist	O
infection	O
,	O
heal	O
wounds	O
,	O
and	O
maintain	O
homeostasis	O
when	O
challenged	O
with	O
microbes	O
and/or	O
chemicals	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
insight	O
into	O
additional	O
possible	O
subtle	O
roles	O
of	O
CXCR2	B
and	O
its	O
ligands	O
in	O
the	O
development	O
of	O
the	O
mouse	O
,	O
we	O
examined	O
the	O
expression	O
of	O
MIP-2	B
,	O
KC	B
,	O
CXCR2	B
,	O
as	O
well	O
as	O
the	O
Duffy	B
antigen	I
binding	O
protein	O
for	O
chemokines	B
during	O
embryonic	O
(	O
p.c	O
.	O
)	O
days	O
11.5	O
through	O
14.5	O
in	O
the	O
mouse	O
.	O

We	O
observed	O
strong	O
correlation	O
between	O
the	O
expression	O
of	O
MIP-2	B
and	O
CXCR2	B
in	O
the	O
developing	O
brain	O
,	O
cardiovascular	O
system	O
and	O
condensing	O
mesenchyme	O
between	O
11.5	O
and	O
13.5	O
days	O
.	O

Moreover	O
,	O
the	O
expression	O
of	O
KC	B
was	O
parallel	O
to	O
the	O
expression	O
of	O
the	O
Duffy	B
antigen	I
binding	O
protein	O
for	O
chemokines	B
with	O
regard	O
to	O
temporal	O
pattern	O
and	O
tissue	O
localization	O
.	O

MIP-2	B
and	O
CXCR2	B
are	O
highly	O
expressed	O
in	O
the	O
brain	O
,	O
first	O
in	O
the	O
cerebellum	O
and	O
in	O
the	O
head	O
mesenchyme	O
,	O
the	O
meninges	O
and	O
the	O
floor	O
plate	O
,	O
and	O
by	O
14.5	O
days	O
are	O
also	O
present	O
in	O
the	O
telencephalon	O
,	O
thalamus	O
and	O
hypothalamus	O
.	O

In	O
the	O
developing	O
brain	O
KC	B
and	O
Duffy	B
were	O
prominently	O
expressed	O
in	O
the	O
neuronal	O
tracts	O
,	O
the	O
forebrain	O
,	O
sympathetic	O
ganglia	O
,	O
and	O
along	O
the	O
periphery	O
of	O
the	O
neural	O
tube	O
.	O

However	O
,	O
KC	B
and	O
Duffy	B
were	O
less	O
prevalent	O
in	O
the	O
developing	O
cardiovascular	O
system	O
,	O
lung	O
and	O
other	O
organs	O
,	O
muscle	O
and	O
bone	O
,	O
than	O
are	O
CXCR2	B
and	O
MIP-2	B
.	O

These	O
data	O
suggest	O
that	O
the	O
roles	O
for	O
these	O
chemokines	B
and	O
their	O
receptors	O
during	O
development	O
may	O
be	O
more	O
significant	O
than	O
was	O
initially	O
thought	O
based	O
upon	O
the	O
phenotype	O
of	O
the	O
mice	O
with	O
targeted	O
deletion	O
of	O
CXCR2	B
and	O
Duffy	B
.	O

Astrocyte	O
differentiation	O
of	O
fetal	O
neuroepithelial	O
cells	O
involving	O
cardiotrophin-1	B
-	O
induced	O
activation	O
of	O
STAT3	B
.	O

Cardiotrophin-1	B
(	O
CT-1	B
)	O
belongs	O
to	O
the	O
interleukin	B
(	I
IL-	I
)	I
6	I
family	I
of	I
cytokines	I
that	O
share	O
membrane	O
glycoprotein	B
130	I
(	O
gp130	B
)	O
as	O
a	O
receptor	O
component	O
critical	O
for	O
signal	O
transduction	O
.	O

We	O
here	O
observed	O
that	O
CT-1	B
was	O
expressed	O
in	O
mouse	O
fetal	O
neuroepithelial	O
cells	O
,	O
and	O
was	O
capable	O
of	O
inducing	O
astrocyte	O
differentiation	O
from	O
these	O
cells	O
in	O
a	O
synergistic	O
manner	O
with	O
bone	B
morphogenetic	I
protein	I
(	I
BMP	I
)	I
-	I
2	I
,	O
whose	O
expression	O
was	O
also	O
found	O
in	O
the	O
fetal	O
brain	O
.	O

CT-1	B
-	O
induced	O
astrocyte	O
differentiation	O
was	O
solely	O
gp130	B
-	O
dependent	O
.	O

CT-1	B
-	O
stimulation	O
led	O
to	O
promoter	O
activation	O
of	O
the	O
gene	O
for	O
an	O
astrocyte	O
marker	O
,	O
glial	B
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
)	O
,	O
which	O
was	O
clearly	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
a	O
gp130	B
-	O
downstream	O
transcription	B
factor	I
,	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
STAT3	B
)	O
,	O
or	O
by	O
introduction	O
of	O
a	O
mutation	O
in	O
a	O
single	O
STAT3	B
-	O
binding	O
site	O
in	O
the	O
promoter	O
,	O
suggesting	O
a	O
critical	O
role	O
of	O
STAT3	B
in	O
the	O
CT-1	B
-	O
induced	O
GFAP	B
transcription	O
.	O

These	O
results	O
suggest	O
that	O
astrocyte	O
differentiation	O
in	O
the	O
developing	O
brain	O
involves	O
CT-1	B
-	O
signaling	O
which	O
cooperates	O
with	O
BMP2	B
.	O

Regulation	O
of	O
microcin	B
C51	I
operon	I
expression	O
:	O
the	O
role	O
of	O
global	O
regulators	O
of	O
transcription	O
.	O

Expression	O
of	O
the	O
microcin	B
C51	I
operon	I
in	O
Escherichia	O
coli	O
cells	O
is	O
regulated	O
as	O
a	O
function	O
of	O
the	O
phase	O
of	O
growth	O
;	O
it	O
is	O
stimulated	O
during	O
the	O
decelerating	O
phase	O
of	O
growth	O
.	O

Using	O
single	O
-	O
copy	O
P	O
(	O
mcc	B
)	O
-	O
lac	B
transcriptional	O
fusion	O
(	O
the	O
promoter	O
region	O
of	O
the	O
microcin	B
C51	I
operon	I
fused	O
to	O
a	O
promoterless	O
lac	B
operon	I
in	O
lambda	O
phage	O
)	O
,	O
we	O
showed	O
that	O
transcription	O
from	O
the	O
microcin	B
operon	I
promoter	O
is	O
dependent	O
on	O
sigma	B
(	I
s	I
)	I
(	O
RpoS	B
)	O
factor	O
.	O

However	O
,	O
some	O
level	O
of	O
P	O
(	O
mcc	B
)	O
-	O
lac	B
expression	O
is	O
possible	O
in	O
rpoS	B
null	O
mutants	O
,	O
indicating	O
that	O
another	O
sigma	B
factor	I
might	O
be	O
involved	O
in	O
transcription	O
of	O
the	O
microcin	B
C51	I
operon	I
.	O

Overproduction	O
of	O
sigma70	B
decreased	O
Pmcc	O
-	O
directed	O
transcription	O
,	O
presumably	O
as	O
a	O
result	O
of	O
competition	O
of	O
sigma	B
factors	I
for	O
the	O
limited	O
amount	O
of	O
core	O
RNA	B
polymerase	I
.	O

The	O
cyclic	O
AMP	O
-	O
CRP	B
complex	O
was	O
shown	O
to	O
stimulate	O
transcription	O
from	O
Pmcc	O
:	O
the	O
absence	O
of	O
CRP	B
or	O
cAMP	O
in	O
crp	B
or	O
cya	B
mutant	O
cells	O
strongly	O
decreased	O
the	O
level	O
of	O
P	O
(	O
mcc	B
)	O
-	O
lac	B
expression	O
.	O

The	O
production	O
of	O
C51	O
microcin	O
decreased	O
or	O
was	O
absent	O
in	O
rpoS	B
,	O
crp	B
and	O
cya	B
mutant	O
cells	O
.	O

Leucine	B
-	I
responsive	I
protein	I
Lrp	B
and	O
histone	B
-	O
like	O
protein	O
H	B
-	I
NS	I
repressed	O
P	O
(	O
mcc	B
)	O
-	O
lac	B
expression	O
in	O
the	O
exponential	O
and	O
decelerating	O
phases	O
of	O
growth	O
.	O

In	O
studies	O
of	O
P	O
(	O
mcc	B
)	O
-	O
lac	B
expression	O
in	O
double	O
mutant	O
cells	O
,	O
we	O
showed	O
that	O
proteins	O
CRP	B
,	O
Lrp	B
and	O
H	B
-	I
NS	I
acted	O
in	O
rpoS	B
-	O
dependent	O
and	O
rpoS	B
-	O
independent	O
ways	O
in	O
transcription	O
of	O
the	O
microcin	B
C51	I
operon	I
.	O

Mutation	O
hns	B
(	O
-	O
)	O
resulted	O
in	O
an	O
increase	O
in	O
P	O
(	O
mcc	B
)	O
-	O
lac	B
expression	O
in	O
crp	B
,	O
rpoS	B
and	O
lrp	B
mutant	O
cells	O
,	O
as	O
in	O
wild	O
-	O
type	O
cells	O
.	O

Specific	O
inhibition	O
of	O
the	O
rat	O
ligand	O
-	O
gated	O
ion	B
channel	I
P2X3	B
function	O
via	O
methoxyethoxy	O
-	O
modified	O
phosphorothioated	O
antisense	O
oligonucleotides	O
.	O

P2X3	B
is	O
one	O
receptor	O
of	O
a	O
family	O
of	O
seven	O
ligand	O
-	O
gated	O
ion	B
channels	I
responding	O
to	O
purines	O
.	O

Increasing	O
evidence	O
indicates	O
its	O
involvement	O
in	O
neuronal	O
signaling	O
and	O
in	O
pain	O
.	O

However	O
,	O
there	O
is	O
currently	O
no	O
selective	O
inhibitor	O
known	O
for	O
this	O
subtype	O
.	O

In	O
order	O
to	O
obtain	O
such	O
a	O
specific	O
inhibitor	O
,	O
a	O
variety	O
of	O
antisense	O
oligonucleotides	O
(	O
ASO	O
)	O
against	O
rat	O
P2X3	B
was	O
tested	O
,	O
and	O
dose	O
-	O
dependent	O
,	O
sequence	O
-	O
specific	O
downregulation	O
of	O
the	O
rat	O
P2X3	B
receptor	O
(	O
expressed	O
in	O
a	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
[	O
CHO	O
-	O
K1	O
]	O
)	O
on	O
the	O
mRNA	O
,	O
protein	O
,	O
and	O
functional	O
levels	O
was	O
observed	O
.	O

Using	O
real	O
-	O
time	O
quantitative	O
PCR	O
,	O
a	O
dose	O
-	O
dependent	O
downregulation	O
of	O
P2X3	B
mRNA	O
by	O
ASO	O
,	O
as	O
compared	O
with	O
untreated	O
and	O
mismatch	O
controls	O
,	O
was	O
demonstrated	O
.	O

Subsequently	O
,	O
downregulation	O
by	O
the	O
two	O
most	O
potent	O
ASO	O
was	O
confirmed	O
at	O
the	O
protein	O
level	O
by	O
Western	O
blot	O
.	O

Sequence	O
specificity	O
was	O
shown	O
by	O
titration	O
of	O
mismatches	O
to	O
the	O
original	O
selected	O
oligonucleotide	O
,	O
and	O
this	O
correlated	O
with	O
progressive	O
loss	O
of	O
P2X3	B
inhibition	O
.	O

The	O
functional	O
response	O
of	O
the	O
P2X3	B
receptor	O
was	O
examined	O
using	O
whole	O
-	O
cell	O
voltage	O
clamping	O
.	O

Upon	O
application	O
of	O
10	O
microM	O
of	O
a	O
nonspecific	O
agonist	O
,	O
alpha	O
,	O
beta	O
-	O
methylene	O
-	O
ATP	O
(	O
alphabeta	O
meATP	O
)	O
,	O
pretreatment	O
with	O
increasing	O
amounts	O
of	O
the	O
most	O
active	O
ASO	O
5037	O
correlated	O
with	O
a	O
decrease	O
in	O
depolarization	O
.	O

The	O
ability	O
to	O
specifically	O
downregulate	O
the	O
P2X3	B
receptor	O
by	O
ASO	O
treatment	O
will	O
allow	O
investigation	O
of	O
the	O
biologic	O
role	O
of	O
this	O
receptor	O
in	O
neuronal	O
tissues	O
and	O
eventually	O
in	O
in	O
vivo	O
models	O
of	O
chronic	O
pain	O
.	O

Involvement	O
of	O
TRAIL	B
/	O
TRAIL	B
-	I
R	I
interaction	O
in	O
IFN	B
-	I
alpha	I
-	O
induced	O
apoptosis	O
of	O
Daudi	O
B	O
lymphoma	O
cells	O
.	O

Interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
exerts	O
the	O
anti	O
-	O
tumour	O
effect	O
on	O
various	O
tumours	O
at	O
least	O
partly	O
through	O
induction	O
of	O
apoptosis	O
.	O

Apoptosis	O
is	O
induced	O
by	O
members	O
of	O
the	O
tumour	B
necrosis	I
factor	I
(	I
TNF	I
)	I
family	I
,	O
including	O
Fas	B
(	O
CD95	B
)	O
and	O
TNF	B
-	I
related	I
apoptosis	I
-	I
inducing	I
ligand	I
(	O
TRAIL	B
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
the	O
TRAIL	B
/	O
TRAIL	B
-	I
R	I
system	O
is	O
involved	O
in	O
IFN	B
-	I
alpha	I
-	O
induced	O
apoptosis	O
using	O
Daudi	O
B	O
lymphoma	O
cells	O
.	O

IFN	B
-	I
alpha	I
upregulated	O
the	O
expression	O
of	O
TRAIL	B
within	O
12	O
h	O
,	O
as	O
assessed	O
by	O
flow	O
cytometry	O
and	O
RT	O
-	O
PCR	O
,	O
and	O
the	O
level	O
increased	O
with	O
time	O
until	O
72	O
h	O
.	O

The	O
levels	O
of	O
both	O
TRAIL	B
-	I
R1	I
and	O
TRAIL	B
-	I
R2	I
,	O
low	O
in	O
Daudi	O
cells	O
,	O
were	O
enhanced	O
by	O
IFN	B
-	I
alpha	I
.	O

The	O
enhanced	O
TRAIL	B
-	I
R1	I
/	I
-	I
R2	I
appeared	O
to	O
function	O
as	O
a	O
death	O
-	O
inducing	O
molecule	O
since	O
IFN	B
-	I
alpha	I
-	O
stimulated	O
cells	O
were	O
more	O
susceptible	O
to	O
TRAIL	B
-	O
induced	O
cell	O
death	O
.	O

The	O
IFN	B
-	I
alpha	I
-	O
stimulated	O
Daudi	O
cells	O
or	O
their	O
derived	O
culture	O
supernatants	O
displayed	O
cytotoxicity	O
against	O
TRAIL	B
-	O
sensitive	O
,	O
but	O
not	O
resistant	O
lines	O
.	O

Moreover	O
,	O
the	O
IFN	B
-	I
alpha	I
-	O
induced	O
reduction	O
in	O
mitochondrial	O
membrane	O
potential	O
preceding	O
the	O
induction	O
of	O
apoptosis	O
was	O
substantially	O
prevented	O
by	O
neutralizing	O
anti	O
-	O
TRAIL	B
monoclonal	O
antibody	O
.	O

Taken	O
together	O
,	O
IFN	B
-	I
alpha	I
-	O
induced	O
apoptosis	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
autocrine	O
and/or	O
paracrine	O
loop	O
involving	O
TRAIL	B
/	O
TRAIL	B
-	I
R	I
.	O

IL-8	B
and	O
MCP-1	B
secretion	O
is	O
enhanced	O
by	O
the	O
peptide	O
-	O
nucleic	O
acid	O
immunomodulator	O
,	O
Product	O
R	O
,	O
in	O
U937	O
cells	O
and	O
primary	O
human	O
monocytes	O
.	O

Product	O
R	O
(	O
Reticulose	O
)	O
is	O
a	O
peptide	O
-	O
nucleic	O
acid	O
immunomodulator	O
recently	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
mRNAs	O
encoding	O
pro	O
-	O
inflammatory	O
cytokines	B
.	O

Interleukin	B
8	I
(	O
IL-8	B
)	O
and	O
macrophage	B
chemoattractant	I
protein-1	I
(	O
MCP-1	B
)	O
are	O
pro	O
-	O
inflammatory	O
chemokines	B
involved	O
in	O
immune	O
cell	O
mobilization	O
and	O
stimulation	O
.	O

To	O
determine	O
whether	O
Product	O
R	O
acts	O
by	O
upregulating	O
these	O
chemokines	B
,	O
we	O
assayed	O
its	O
effects	O
on	O
the	O
expression	O
of	O
IL-8	B
and	O
MCP-1	B
mRNAs	O
and	O
proteins	O
by	O
human	O
monocytic	O
U937	O
cells	O
and	O
by	O
adherent	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O

U937	O
cells	O
were	O
cultured	O
for	O
0	O
-	O
21	O
days	O
in	O
media	O
containing	O
0	O
-	O
20	O
%	O
Product	O
R	O
or	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
.	O

Compared	O
to	O
control	O
cultures	O
,	O
cells	O
cultured	O
in	O
Product	O
R	O
expressed	O
increased	O
amounts	O
of	O
IL-8	B
and	O
MCP-1	B
mRNAs	O
,	O
as	O
measured	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Product	O
R	O
also	O
increased	O
secretion	O
of	O
IL-8	B
and	O
MCP-1	B
,	O
as	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
boosted	O
secretion	O
induced	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
adherent	O
PBMCs	O
,	O
Product	O
R	O
increased	O
IL-8	B
and	O
MCP-1	B
secretion	O
,	O
but	O
reduced	O
LPS	O
-	O
induced	O
MCP-1	B
secretion	O
.	O

While	O
mRNAs	O
encoding	O
the	O
IL-8	B
receptor	I
,	O
CXCR2	B
,	O
and	O
the	O
MCP-1	B
receptor	I
,	O
CCR2	B
,	O
were	O
increased	O
in	O
U937	O
cells	O
cultured	O
in	O
5	O
-	O
10	O
%	O
Product	O
R	O
,	O
we	O
observed	O
no	O
change	O
in	O
binding	O
of	O
receptor	O
-	O
specific	O
antibodies	O
.	O

These	O
findings	O
suggest	O
that	O
Product	O
R	O
upregulates	O
the	O
expression	O
of	O
IL-8	B
and	O
MCP-1	B
,	O
which	O
may	O
boost	O
immune	O
system	O
activity	O
in	O
virally	O
-	O
infected	O
patients	O
.	O

Peptidoglycan	B
recognition	I
proteins	I
:	O
a	O
novel	O
family	O
of	O
four	O
human	O
innate	O
immunity	O
pattern	O
recognition	O
molecules	O
.	O

The	O
innate	O
immune	O
system	O
recognizes	O
microorganisms	O
through	O
a	O
series	O
of	O
pattern	O
recognition	O
receptors	O
that	O
are	O
highly	O
conserved	O
in	O
evolution	O
.	O

Insects	O
have	O
a	O
family	O
of	O
12	O
peptidoglycan	B
recognition	I
proteins	I
(	O
PGRPs	B
)	O
that	O
recognize	O
peptidoglycan	O
,	O
a	O
ubiquitous	O
component	O
of	O
bacterial	O
cell	O
walls	O
.	O

We	O
report	O
cloning	O
of	O
three	O
novel	O
human	O
PGRPs	B
(	O
PGRP	B
-	I
L	I
,	O
PGRP	B
-	I
Ialpha	I
,	O
and	O
PGRP	B
-	I
Ibeta	I
)	O
that	O
together	O
with	O
the	O
previously	O
cloned	O
PGRP	B
-	I
S	I
,	O
define	O
a	O
new	O
family	O
of	O
human	O
pattern	O
recognition	O
molecules	O
.	O

PGRP	B
-	I
L	I
,	O
PGRP	B
-	I
Ialpha	I
,	O
and	O
PGRP	B
-	I
Ibeta	I
have	O
576	O
,	O
341	O
,	O
and	O
373	O
amino	O
acids	O
coded	O
by	O
five	O
,	O
seven	O
,	O
and	O
eight	O
exons	O
on	O
chromosomes	O
19	O
and	O
1	O
,	O
and	O
they	O
all	O
have	O
two	O
predicted	O
transmembrane	O
domains	O
.	O

All	O
mammalian	O
and	O
insect	O
PGRPs	B
have	O
at	O
least	O
three	O
highly	O
conserved	O
C	O
-	O
terminal	O
PGRP	B
domains	O
located	O
either	O
in	O
the	O
extracellular	O
or	O
in	O
the	O
cytoplasmic	O
(	O
or	O
in	O
both	O
)	O
portions	O
of	O
the	O
molecules	O
.	O

PGRP	B
-	I
L	I
is	O
expressed	O
in	O
liver	O
,	O
PGRP	B
-	I
Ialpha	I
and	O
PGRP	B
-	I
Ibeta	I
in	O
esophagus	O
(	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
tonsils	O
and	O
thymus	O
)	O
,	O
and	O
PGRP	B
-	I
S	I
in	O
bone	O
marrow	O
(	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
neutrophils	O
and	O
fetal	O
liver	O
)	O
.	O

All	O
four	O
human	O
PGRPs	B
bind	O
peptidoglycan	O
and	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Thus	O
,	O
these	O
PGRPs	B
may	O
play	O
a	O
role	O
in	O
recognition	O
of	O
bacteria	O
in	O
these	O
organs	O
.	O

ASH2L	B
:	O
alternative	O
splicing	O
and	O
downregulation	O
during	O
induced	O
megakaryocytic	O
differentiation	O
of	O
multipotential	O
leukemia	O
cell	O
lines	O
.	O

Abstract	O
Drosophila	O
ash2	B
is	O
a	O
member	O
of	O
the	O
trxG	B
gene	I
super	I
family	I
,	O
some	O
human	O
homologues	O
of	O
which	O
are	O
involved	O
in	O
hematopoiesis	O
and	O
leukemia	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
the	O
human	O
homologue	O
of	O
Drosophila	O
ash2	B
and	O
its	O
alternative	O
splicing	O
isoform	O
,	O
ASH2L1	B
and	O
ASH2L2	B
.	O

ASH2L	B
proteins	O
are	O
60	O
%	O
homologous	O
to	O
Drosophila	O
ash2	B
.	O

ASH2L	B
also	O
has	O
a	O
zinc	O
finger	O
motif	O
(	O
C2C2	O
)	O
although	O
it	O
is	O
not	O
identical	O
to	O
that	O
in	O
ASH2	B
.	O

Expression	O
profile	O
analysis	O
showed	O
that	O
the	O
amount	O
of	O
ASH2L	B
transcripts	O
is	O
extremely	O
high	O
in	O
fetal	O
liver	O
,	O
testis	O
,	O
and	O
leukemia	O
cell	O
lines	O
with	O
erythroid	O
and	O
megakaryocytic	O
potential	O
such	O
as	O
K562	O
,	O
Hel	O
,	O
and	O
Dami	O
.	O

We	O
treated	O
these	O
cells	O
with	O
differentiation	O
inducers	O
phorbol	O
ester	O
and	O
hemin	O
.	O

We	O
found	O
that	O
ASH2L	B
is	O
downregulated	O
rapidly	O
and	O
dramatically	O
in	O
K562	O
,	O
Hel	O
,	O
and	O
Dami	O
cells	O
during	O
phorbol	O
ester	O
induced	O
differentiation	O
with	O
megakaryocytic	O
features	O
.	O

However	O
,	O
its	O
expression	O
is	O
maintained	O
at	O
a	O
high	O
level	O
during	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
induced	O
with	O
hemin	O
.	O

These	O
results	O
suggest	O
that	O
ASH2L	B
plays	O
a	O
role	O
in	O
hematopoiesis	O
and	O
is	O
associated	O
with	O
some	O
special	O
kinds	O
of	O
leukemia	O
.	O

Regulation	O
of	O
the	O
plant	O
-	O
type	O
5'-adenylyl	B
sulfate	I
reductase	I
by	O
oxidative	O
stress	O
.	O

5'-Adenylyl	B
sulfate	I
(	I
APS	I
)	I
reductase	I
(	O
EC	B
1.8.4.9	I
)	O
catalyzes	O
a	O
key	O
reaction	O
in	O
the	O
plant	O
sulfate	O
assimilation	O
pathway	O
leading	O
to	O
the	O
synthesis	O
of	O
cysteine	O
and	O
the	O
antioxidant	O
glutathione	O
.	O

In	O
Arabidopsis	O
thaliana	O
APS	B
reductase	I
is	O
encoded	O
by	O
a	O
family	O
of	O
three	O
genes	O
.	O

In	O
vitro	O
biochemical	O
studies	O
revealed	O
that	O
the	O
enzyme	O
product	O
derived	O
from	O
one	O
of	O
them	O
(	O
APR1	B
)	O
is	O
activated	O
by	O
oxidation	O
,	O
probably	O
through	O
the	O
formation	O
of	O
a	O
disulfide	O
bond	O
.	O

The	O
APR1	B
enzyme	O
is	O
45	O
-	O
fold	O
more	O
active	O
when	O
expressed	O
in	O
a	O
trxB	B
strain	O
of	O
Escherichia	O
coli	O
than	O
in	O
a	O
trxB	B
(	O
+	O
)	O
wild	O
type	O
.	O

The	O
enzyme	O
is	O
inactivated	O
in	O
vitro	O
by	O
treatment	O
with	O
disulfide	O
reductants	O
and	O
is	O
reactivated	O
with	O
thiol	O
oxidants	O
.	O

Redox	O
titrations	O
show	O
that	O
the	O
regulation	O
site	O
has	O
a	O
midpoint	O
potential	O
of	O
-	O
330	O
mV	O
at	O
pH	O
8.5	O
and	O
involves	O
a	O
two	O
-	O
electron	O
redox	O
reaction	O
.	O

Exposure	O
of	O
a	O
variety	O
of	O
plants	O
to	O
ozone	O
induces	O
a	O
rapid	O
increase	O
in	O
APS	B
reductase	I
activity	O
that	O
correlates	O
with	O
the	O
oxidation	O
of	O
the	O
glutathione	O
pool	O
and	O
is	O
followed	O
by	O
an	O
increase	O
in	O
free	O
cysteine	O
and	O
total	O
glutathione	O
.	O

During	O
the	O
response	O
to	O
ozone	O
,	O
the	O
level	O
of	O
immunodetectable	O
APS	B
reductase	I
enzyme	O
does	O
not	O
increase	O
.	O

Treatment	O
of	O
A.	O
thaliana	O
seedlings	O
with	O
oxidized	O
glutathione	O
or	O
paraquat	O
induces	O
APS	B
reductase	I
activity	O
even	O
when	O
transcription	O
or	O
translation	O
is	O
blocked	O
with	O
inhibitors	O
.	O

The	O
results	O
suggest	O
that	O
a	O
posttranslational	O
mechanism	O
controls	O
APS	B
reductase	I
.	O

A	O
model	O
is	O
proposed	O
whereby	O
redox	O
regulation	O
of	O
APS	B
reductase	I
provides	O
a	O
rapidly	O
responding	O
,	O
self	O
-	O
regulating	O
mechanism	O
to	O
control	O
the	O
glutathione	O
synthesis	O
necessary	O
to	O
combat	O
oxidative	O
stress	O
.	O

Human	O
CC	B
chemokine	I
liver	B
-	I
expressed	I
chemokine	I
/	O
CCL16	B
is	O
a	O
functional	O
ligand	O
for	O
CCR1	B
,	O
CCR2	B
and	O
CCR5	B
,	O
and	O
constitutively	O
expressed	O
by	O
hepatocytes	O
.	O

Liver	B
-	I
expressed	I
chemokine	I
(	O
LEC	B
)	O
/	O
CCL16	B
is	O
a	O
human	O
CC	B
chemokine	I
selectively	O
expressed	O
in	O
the	O
liver	O
.	O

Here	O
,	O
we	O
investigated	O
its	O
receptor	O
usage	O
by	O
calcium	O
mobilization	O
and	O
chemotactic	O
assays	O
using	O
mouse	O
L1.2	O
pre	O
-	O
B	O
cell	O
lines	O
stably	O
expressing	O
a	O
panel	O
of	O
12	O
human	O
chemokine	O
receptors	O
.	O

At	O
relatively	O
high	O
concentrations	O
,	O
LEC	B
induced	O
calcium	O
mobilization	O
and	O
chemotaxis	O
via	O
CCR1	B
and	O
CCR2	B
.	O

LEC	B
also	O
induced	O
calcium	O
mobilization	O
,	O
but	O
marginal	O
chemotaxis	O
via	O
CCR5	B
.	O

Consistently	O
,	O
LEC	B
was	O
found	O
to	O
bind	O
to	O
CCR1	B
,	O
CCR2	B
and	O
CCR5	B
with	O
relatively	O
low	O
affinities	O
.	O

The	O
binding	O
of	O
LEC	B
to	O
CCR8	B
was	O
much	O
less	O
significant	O
.	O

In	O
spite	O
of	O
its	O
binding	O
to	O
CCR5	B
,	O
LEC	B
was	O
unable	O
to	O
inhibit	O
infection	O
of	O
an	O
R5	O
-	O
type	O
HIV-1	O
to	O
activated	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
even	O
at	O
high	O
concentrations	O
.	O

In	O
human	O
liver	O
sections	O
,	O
hepatocytes	O
were	O
strongly	O
stained	O
by	O
anti	O
-	O
LEC	B
antibody	O
.	O

HepG2	O
,	O
a	O
human	O
hepatocarcinoma	O
cell	O
line	O
,	O
was	O
found	O
to	O
constitutively	O
express	O
LEC	B
.	O

LEC	B
was	O
also	O
present	O
in	O
the	O
plasma	O
samples	O
from	O
healthy	O
adult	O
donors	O
at	O
relatively	O
high	O
concentrations	O
(	O
0.3	O
--	O
4	O
nM	O
)	O
.	O

Taken	O
together	O
,	O
LEC	B
is	O
a	O
new	O
low	O
-	O
affinity	O
functional	O
ligand	O
for	O
CCR1	B
,	O
CCR2	B
and	O
CCR5	B
,	O
and	O
is	O
constitutively	O
expressed	O
by	O
liver	O
parenchymal	O
cells	O
.	O

The	O
presence	O
of	O
LEC	B
in	O
normal	O
plasma	O
at	O
relatively	O
high	O
concentrations	O
may	O
modulate	O
inflammatory	O
responses	O
.	O

An	O
isoform	O
-	O
specific	O
inhibitory	O
domain	O
regulates	O
the	O
LHX3	B
LIM	O
homeodomain	O
factor	O
holoprotein	O
and	O
the	O
production	O
of	O
a	O
functional	O
alternate	O
translation	O
form	O
.	O

The	O
LHX3	B
LIM	O
homeodomain	O
transcription	B
factor	I
is	O
required	O
for	O
pituitary	O
development	O
and	O
motor	O
neuron	O
specification	O
.	O

The	O
Lhx3	B
gene	O
encodes	O
two	O
isoforms	O
,	O
LHX3a	B
and	O
LHX3b	B
,	O
that	O
differ	O
in	O
their	O
amino	O
-	O
terminal	O
sequences	O
.	O

Humans	O
and	O
mice	O
with	O
defective	O
Lhx3	B
genes	O
are	O
deficient	O
in	O
gonadotrope	O
,	O
lactotrope	O
,	O
somatotrope	O
,	O
and	O
thyrotrope	O
pituitary	O
cells	O
.	O

We	O
show	O
that	O
,	O
whereas	O
Lhx3b	B
is	O
highly	O
expressed	O
in	O
these	O
Lhx3	B
-	O
dependent	O
cell	O
types	O
,	O
high	O
levels	O
of	O
Lhx3a	B
expression	O
are	O
restricted	O
to	O
alpha	O
glycoprotein	O
subunit	O
-	O
expressing	O
thyrotropes	O
and	O
gonadotropes	O
.	O

Cross	O
-	O
species	O
comparison	O
reveals	O
the	O
LHX3b	B
-	O
specific	O
domain	O
is	O
more	O
conserved	O
than	O
the	O
LHX3a	B
-	O
specific	O
domain	O
.	O

We	O
demonstrate	O
that	O
the	O
LHX3b	B
-	O
specific	O
domain	O
is	O
a	O
transferable	O
inhibitor	O
that	O
reduces	O
gene	O
activation	O
and	O
DNA	O
binding	O
by	O
homeodomain	O
proteins	O
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
novel	O
LHX3	B
protein	O
(	O
M2-LHX3	B
)	O
and	O
determine	O
that	O
this	O
molecule	O
is	O
generated	O
by	O
an	O
internal	O
translation	O
initiation	O
codon	O
.	O

The	O
LHX3a	B
-	O
and	O
LHX3b	B
-	O
specific	O
coding	O
sequences	O
regulate	O
differential	O
usage	O
of	O
this	O
internal	O
start	O
codon	O
.	O

Further	O
,	O
we	O
identify	O
the	O
major	O
activation	O
domain	O
of	O
LHX3	B
in	O
the	O
carboxyl	O
terminus	O
of	O
the	O
molecule	O
.	O

M2-LHX3	B
is	O
active	O
because	O
it	O
retains	O
this	O
domain	O
and	O
binds	O
DNA	O
better	O
than	O
LHX3a	B
or	O
LHX3b	B
.	O

Other	O
LIM	O
homeodomain	O
genes	O
,	O
including	O
Lhx4	B
,	O
generate	O
similar	O
truncated	O
proteins	O
.	O

These	O
studies	O
describe	O
how	O
transcriptional	O
regulatory	O
genes	O
can	O
generate	O
multiple	O
functional	O
proteins	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
dermatan	B
-	I
specific	I
N	I
-	I
acetylgalactosamine	I
4-O	I
-	I
sulfotransferase	I
.	O

We	O
have	O
identified	O
and	O
characterized	O
an	O
N	B
-	I
acetylgalactosamine-4-O	I
-	I
sulfotransferase	I
designated	O
dermatan-4-sulfotransferase-1	B
(	O
D4ST-1	B
)	O
(	O
GenBank	O
(	O
TM	O
)	O
accession	O
number	O
AF401222	O
)	O
based	O
on	O
its	O
homology	O
to	O
HNK-1	B
sulfotransferase	I
.	O

The	O
cDNA	O
predicts	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
type	O
II	O
membrane	O
protein	O
of	O
376	O
amino	O
acids	O
with	O
a	O
43	O
-	O
amino	O
acid	O
cytoplasmic	O
domain	O
and	O
a	O
316	O
-	O
amino	O
acid	O
luminal	O
domain	O
containing	O
two	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
.	O

D4ST-1	B
has	O
significant	O
amino	O
acid	O
identity	O
with	O
HNK-1	B
sulfotransferase	I
(	O
21.4	O
%	O
)	O
,	O
N	B
-	I
acetylgalactosamine-4-O	I
-	I
sulfotransferase	I
1	I
(	O
GalNAc-4-ST1	B
)	O
(	O
24.7	O
%	O
)	O
,	O
N	B
-	I
acetylgalactosamine-4-O	I
-	I
sulfotransferase	I
2	I
(	O
GalNAc-4-ST2	B
)	O
(	O
21.0	O
%	O
)	O
,	O
chondroitin-4-O	B
-	I
sulfotransferase	I
1	I
(	O
27.3	O
%	O
)	O
,	O
and	O
chondroitin-4-O	B
-	I
sulfotransferase	I
2	I
(	O
22.8	O
%	O
)	O
.	O

D4ST-1	B
transfers	O
sulfate	O
to	O
the	O
C-4	O
hydroxyl	O
of	O
beta1,4-linked	O
GalNAc	O
that	O
is	O
substituted	O
with	O
an	O
alpha	O
-	O
linked	O
iduronic	O
acid	O
(	O
IdoUA	O
)	O
at	O
the	O
C-3	O
hydroxyl	O
.	O

D4ST-1	B
shows	O
a	O
strong	O
preference	O
in	O
vitro	O
for	O
sulfate	O
transfer	O
to	O
IdoUAalpha1	O
,	O
3GalNAcbeta1	O
,	O
4	O
that	O
is	O
flanked	O
by	O
GlcUAbeta1	O
,	O
3GalNAcbeta1	O
,	O
4	O
as	O
compared	O
with	O
IdoUAalpha1	O
,	O
3GalNAcbeta1	O
,	O
4	O
flanked	O
by	O
IdoUAalpha1	O
,	O
3GalNAcbeta1	O
,	O
4	O
.	O

The	O
specificity	O
of	O
D4ST-1	B
when	O
assayed	O
in	O
vitro	O
suggests	O
that	O
the	O
addition	O
of	O
sulfate	O
to	O
GalNAc	O
occurs	O
immediately	O
after	O
epimerization	O
of	O
GlcUA	O
to	O
IdoUA	O
.	O

The	O
open	O
reading	O
frame	O
of	O
D4ST-1	B
is	O
encoded	O
by	O
a	O
single	O
exon	O
located	O
on	O
human	O
chromosome	O
15q14	O
.	O

Northern	O
blot	O
analysis	O
reveals	O
a	O
single	O
2.4	O
-	O
kilobase	O
transcript	O
.	O

D4ST-1	B
message	O
is	O
expressed	O
in	O
virtually	O
all	O
tissues	O
at	O
some	O
level	O
but	O
is	O
most	O
highly	O
expressed	O
in	O
pituitary	O
,	O
placenta	O
,	O
uterus	O
,	O
and	O
thyroid	O
.	O

The	O
properties	O
of	O
D4ST-1	B
indicate	O
that	O
sulfation	O
of	O
the	O
GalNAc	O
moieties	O
in	O
dermatan	O
is	O
mediated	O
by	O
a	O
distinct	O
GalNAc-4-O	B
-	I
sulfotransferase	I
and	O
occurs	O
following	O
epimerization	O
of	O
GlcUA	O
to	O
IdoUA	O
.	O

Identification	O
of	O
a	O
novel	O
kinesin	B
-	I
related	I
protein	I
,	O
KRMP1	B
,	O
as	O
a	O
target	O
for	O
mitotic	O
peptidyl	B
-	I
prolyl	I
isomerase	I
Pin1	B
.	O

Mitosis	O
utilizes	O
a	O
number	O
of	O
kinesin	B
-	I
related	I
proteins	I
(	O
KRPs	B
)	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
KRP	B
termed	O
KRMP1	B
,	O
which	O
has	O
a	O
deduced	O
1780	O
-	O
amino	O
acid	O
sequence	O
composed	O
of	O
ternary	O
domains	O
.	O

The	O
amino	O
-	O
terminal	O
head	O
domain	O
is	O
most	O
similar	O
to	O
the	O
kinesin	B
motor	O
domain	O
of	O
the	O
MKLP-1	B
subfamily	I
and	O
has	O
an	O
intrinsic	O
ATPase	B
activity	O
that	O
is	O
diminished	O
by	O
substituting	O
the	O
consensus	O
Lys-168	O
with	O
Arg	O
.	O

The	O
central	O
stalk	O
domain	O
is	O
predicted	O
to	O
form	O
a	O
long	O
alpha	O
-	O
helical	O
coiled	O
-	O
coil	O
,	O
and	O
can	O
interact	O
with	O
each	O
other	O
in	O
vivo	O
.	O

An	O
in	O
vivo	O
labeling	O
experiment	O
revealed	O
that	O
KRMP1	B
is	O
phosphorylated	O
,	O
and	O
we	O
also	O
found	O
that	O
the	O
region	O
within	O
the	O
tail	O
domain	O
containing	O
Thr-1604	O
as	O
the	O
cdc2	B
kinase	B
phosphorylation	O
site	O
differs	O
from	O
the	O
bimC	B
box	O
conserved	O
in	O
the	O
bimC	B
subfamily	I
of	I
KRPs	I
.	O

Immunofluorescence	O
analysis	O
showed	O
that	O
endogenous	O
KRMP1	B
was	O
localized	O
predominantly	O
to	O
the	O
cytoplasm	O
during	O
interphase	O
and	O
dispersed	O
throughout	O
the	O
cell	O
during	O
mitosis	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
overexpressed	O
KRMP1	B
was	O
detected	O
in	O
a	O
complicated	O
nuclear	O
or	O
cytoplasmic	O
pattern	O
reflecting	O
multiple	O
nuclear	O
localization	O
/	O
export	O
signals	O
.	O

Furthermore	O
,	O
KRMP1	B
interacted	O
with	O
the	O
mitotic	O
peptidyl	B
-	I
prolyl	I
isomerase	I
Pin1	B
in	O
vivo	O
,	O
and	O
an	O
in	O
vitro	O
interaction	O
was	O
detected	O
between	O
the	O
tail	O
domain	O
of	O
KRMP1	B
and	O
the	O
WW	O
domain	O
of	O
Pin1	B
.	O

Overexpression	O
of	O
KRMP1	B
caused	O
COS-7	O
cells	O
to	O
arrest	O
at	O
G	O
(	O
2	O
)	O
-M	O
,	O
and	O
co	O
-	O
expression	O
of	O
Pin1	B
reversed	O
this	O
effect	O
,	O
indicating	O
their	O
physiological	O
interaction	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
that	O
KRMP1	B
is	O
a	O
mitotic	O
target	O
regulated	O
by	O
Pin1	B
and	O
vice	O
versa	O
.	O

Energetically	O
most	O
likely	O
substrate	O
and	O
active	O
-	O
site	O
protonation	O
sites	O
and	O
pathways	O
in	O
the	O
catalytic	O
mechanism	O
of	O
dihydrofolate	B
reductase	I
.	O

Despite	O
much	O
experimental	O
and	O
computational	O
study	O
,	O
key	O
aspects	O
of	O
the	O
mechanism	O
of	O
reduction	O
of	O
dihydrofolate	O
(	O
DHF	O
)	O
by	O
dihydrofolate	B
reductase	I
(	O
DHFR	B
)	O
remain	O
unresolved	O
,	O
while	O
the	O
secondary	O
DHFR	B
-	O
catalyzed	O
reduction	O
of	O
folate	O
has	O
been	O
little	O
studied	O
.	O

Major	O
differences	O
between	O
proposed	O
DHF	O
mechanisms	O
are	O
whether	O
the	O
carboxylate	O
group	O
of	O
the	O
conserved	O
active	O
-	O
site	O
Asp	O
or	O
Glu	O
residue	O
is	O
protonated	O
or	O
ionized	O
during	O
the	O
reaction	O
,	O
and	O
whether	O
there	O
is	O
direct	O
protonation	O
of	O
N5	O
or	O
a	O
proton	O
shuttle	O
from	O
an	O
initially	O
protonated	O
carboxylate	O
group	O
via	O
O4	O
.	O

We	O
have	O
addressed	O
these	O
questions	O
for	O
both	O
reduction	O
steps	O
with	O
a	O
comprehensive	O
set	O
of	O
ab	O
initio	O
quantum	O
chemical	O
calculations	O
on	O
active	O
-	O
site	O
fragment	O
complexes	O
,	O
including	O
the	O
carboxyl	O
side	O
chain	O
and	O
,	O
progressively	O
,	O
all	O
other	O
polar	O
active	O
-	O
site	O
residue	O
groups	O
including	O
conserved	O
water	O
molecules	O
.	O

Addition	O
of	O
two	O
protons	O
in	O
two	O
steps	O
was	O
considered	O
.	O

The	O
polarization	O
effects	O
of	O
the	O
remainder	O
of	O
the	O
enzyme	O
system	O
were	O
approximated	O
by	O
a	O
dielectric	O
continuum	O
self	O
-	O
consistent	O
reaction	O
field	O
(	O
SCRF	O
)	O
model	O
using	O
an	O
effective	O
dielectric	O
constant	O
(	O
epsilon	O
)	O
of	O
2	O
.	O

Optimized	O
geometries	O
were	O
calculated	O
using	O
the	O
density	O
functional	O
(	O
B3LYP	O
)	O
method	O
and	O
Onsager	O
SCRF	O
model	O
with	O
the	O
6	O
-	O
31	O
G	O
basis	O
.	O

Single	O
-	O
point	O
energy	O
calculations	O
were	O
then	O
carried	O
out	O
at	O
the	O
B3LYP	O
/	O
6	O
-	O
311+G	O
level	O
with	O
either	O
the	O
Onsager	O
or	O
dielectric	O
polarizable	O
continuum	O
model	O
.	O

Additional	O
checking	O
calculations	O
at	O
MP2	O
and	O
HF	O
levels	O
,	O
or	O
with	O
other	O
basis	O
sets	O
or	O
values	O
of	O
epsilon	O
,	O
were	O
also	O
done	O
.	O

From	O
the	O
results	O
,	O
the	O
conserved	O
water	O
molecule	O
,	O
corresponding	O
to	O
W206	O
in	O
the	O
E.	O
coli	O
DHFR	B
complexes	O
,	O
that	O
is	O
H	O
-	O
bonded	O
to	O
both	O
the	O
OD2	O
oxygen	O
atom	O
of	O
the	O
carboxyl	O
(	O
Asp	O
)	O
side	O
chain	O
and	O
O4	O
of	O
the	O
pterin	O
/	O
dihydropterin	O
ring	O
,	O
appears	O
critically	O
important	O
and	O
may	O
determine	O
the	O
protonation	O
site	O
for	O
the	O
enzyme	O
-	O
bound	O
substrates	O
.	O

In	O
the	O
absence	O
of	O
W206	O
,	O
the	O
most	O
stable	O
monoprotonated	O
species	O
are	O
the	O
neutral	O
-	O
pair	O
4	O
-	O
enol	O
forms	O
of	O
substrates	O
with	O
the	O
carboxyl	O
group	O
OD2	O
oxygen	O
protonated	O
and	O
H	O
-	O
bonded	O
to	O
N3	O
.	O

If	O
W206	O
is	O
included	O
,	O
then	O
the	O
most	O
stable	O
forms	O
are	O
still	O
the	O
neutral	O
-	O
pair	O
complexes	O
but	O
now	O
for	O
the	O
N3-H	O
keto	O
forms	O
with	O
the	O
protonated	O
OD2	O
atom	O
H	O
-	O
bonding	O
with	O
W206	O
.	O

A	O
second	O
proton	O
addition	O
to	O
these	O
complexes	O
gives	O
protonations	O
at	O
N8	O
(	O
folate	O
)	O
or	O
N5	O
(	O
DHF	O
)	O
.	O

Calculated	O
H	O
-	O
bond	O
distances	O
correlate	O
well	O
with	O
those	O
for	O
the	O
conserved	O
W206	O
observed	O
in	O
many	O
X	O
-	O
ray	O
structures	O
.	O

For	O
all	O
structures	O
with	O
occluded	O
M20	O
loop	O
conformations	O
(	O
closed	O
active	O
site	O
)	O
,	O
OD2-N3	O
distances	O
are	O
less	O
than	O
OD2	O
-	O
NA2	O
distances	O
,	O
which	O
is	O
consistent	O
with	O
those	O
calculated	O
for	O
protonated	O
OD2	O
complexes	O
.	O

Thus	O
,	O
the	O
results	O
(	O
B3LYP	O
;	O
epsilon	O
=	O
2	O
calculations	O
)	O
support	O
a	O
mechanism	O
for	O
both	O
folate	O
and	O
DHF	O
reduction	O
in	O
which	O
the	O
OD2	O
carboxyl	O
oxygen	O
is	O
first	O
protonated	O
,	O
followed	O
by	O
a	O
direct	O
protonation	O
at	O
N8	O
(	O
folate	O
)	O
and	O
N5	O
(	O
DHF	O
)	O
to	O
obtain	O
the	O
active	O
cation	O
complexes	O
,	O
i.e.	O
,	O
doubly	O
protonated	O
.	O

The	O
results	O
do	O
not	O
support	O
a	O
proposed	O
protonated	O
carboxyl	O
with	O
DHF	O
in	O
the	O
enol	O
form	O
for	O
the	O
Michaelis	O
complex	O
,	O
nor	O
an	O
ionized	O
carboxyl	O
with	O
protonated	O
enol	O
-	O
DHF	O
as	O
a	O
catalytic	O
intermediate	O
.	O

However	O
,	O
as	O
additional	O
calculations	O
for	O
the	O
monoprotonated	O
complete	O
complexes	O
show	O
a	O
reduction	O
in	O
the	O
energy	O
differences	O
between	O
the	O
neutral	O
-	O
pair	O
keto	O
and	O
ion	O
-	O
pair	O
keto	O
(	O
N8	O
-	O
or	O
N5	O
-	O
protonated	O
)	O
forms	O
,	O
we	O
are	O
extending	O
the	O
treatment	O
using	O
combined	O
quantum	O
mechanics	O
and	O
molecular	O
mechanics	O
(	O
QM	O
/	O
MM	O
)	O
and	O
molecular	O
dynamics	O
simulation	O
methods	O
to	O
refine	O
the	O
description	O
of	O
the	O
protein	O
/	O
solvent	O
environment	O
and	O
prediction	O
of	O
the	O
relative	O
stabilization	O
free	O
energies	O
of	O
the	O
various	O
(	O
OD2	O
,	O
O4	O
,	O
N5	O
,	O
and	O
N8	O
)	O
protonation	O
sites	O
.	O

Folding	O
of	O
malate	B
dehydrogenase	I
inside	O
the	O
GroEL	B
-	O
GroES	B
cavity	O
.	O

The	O
chaperonin	B
GroEL	B
binds	O
nonnative	O
substrate	O
protein	O
in	O
the	O
hydrophobic	O
central	O
cavity	O
of	O
an	O
open	O
ring	O
.	O

ATP	O
and	O
GroES	B
binding	O
to	O
the	O
same	O
ring	O
converts	O
this	O
cavity	O
into	O
an	O
encapsulated	O
,	O
hydrophilic	O
chamber	O
that	O
mediates	O
productive	O
folding	O
.	O

A	O
'	O
rack	O
'	O
mechanism	O
of	O
initial	O
protein	O
unfolding	O
proposes	O
that	O
,	O
upon	O
GroES	B
and	O
ATP	O
binding	O
,	O
the	O
polypeptide	O
is	O
stretched	O
between	O
the	O
binding	O
sites	O
on	O
the	O
twisting	O
apical	O
domains	O
of	O
GroEL	B
before	O
complete	O
release	O
into	O
the	O
chamber	O
.	O

Here	O
,	O
the	O
structure	O
of	O
malate	B
dehydrogenase	I
(	O
MDH	B
)	O
subunit	O
during	O
folding	O
is	O
monitored	O
by	O
deuterium	O
exchange	O
,	O
peptic	O
fragment	O
production	O
and	O
mass	O
spectrometry	O
.	O

When	O
bound	O
to	O
GroEL	B
,	O
MDH	B
exhibits	O
a	O
core	O
of	O
partially	O
protected	O
secondary	O
structure	O
that	O
is	O
only	O
modestly	O
deprotected	O
upon	O
ATP	O
and	O
GroES	B
binding	O
.	O

Moreover	O
,	O
deprotection	O
is	O
broadly	O
distributed	O
throughout	O
MDH	B
,	O
suggesting	O
that	O
it	O
results	O
from	O
breaking	O
hydrogen	O
bonds	O
between	O
MDH	B
and	O
the	O
cavity	O
wall	O
or	O
global	O
destabilization	O
,	O
as	O
opposed	O
to	O
forced	O
mechanical	O
unfolding	O
.	O

CD89	B
:	O
the	O
human	O
myeloid	O
IgA	B
Fc	I
receptor	I
.	O

CD89	B
(	O
Fc	B
alphaRI	I
)	O
is	O
the	O
human	O
myeloid	O
IgA	B
Fc	I
receptor	I
expressed	O
on	O
cells	O
,	O
such	O
as	O
neutrophils	O
,	O
eosinophils	O
and	O
monocytes	O
/	O
macrophages	O
.	O

Cross	O
-	O
linking	O
of	O
CD89	B
on	O
these	O
cells	O
,	O
by	O
IgA	B
-	O
opsonised	O
particles	O
(	O
e.g.	O
bacteria	O
,	O
viruses	O
)	O
or	O
anti	O
-	O
CD89	B
monoclonal	O
antibodies	O
,	O
can	O
trigger	O
various	O
immunological	O
effector	O
functions	O
which	O
are	O
generally	O
protective	O
but	O
may	O
also	O
cause	O
harm	O
to	O
the	O
body	O
.	O

CD89	B
is	O
a	O
transmembrane	O
glycoprotein	O
that	O
binds	O
both	O
subclasses	O
of	O
IgA	B
in	O
all	O
its	O
molecular	O
forms	O
(	O
i.e.	O
monomeric	O
,	O
dimeric	O
and	O
secretory	O
IgA	B
)	O
via	O
a	O
region	O
of	O
its	O
membrane	O
-	O
distal	O
EC1	O
domain	O
.	O

DNA	O
studies	O
have	O
shown	O
that	O
the	O
CD89	B
gene	O
is	O
located	O
within	O
the	O
newly	O
described	O
leukocyte	O
receptor	O
cluster	O
(	O
LRC	O
)	O
on	O
chromosome	O
19	O
.	O

CD89	B
is	O
more	O
closely	O
related	O
to	O
the	O
KIR	B
and	O
MIR	B
proteins	O
,	O
whose	O
genes	O
are	O
also	O
found	O
in	O
the	O
LRC	O
,	O
than	O
to	O
other	O
human	O
Fc	B
receptors	I
(	O
FcRs	B
)	O
.	O

On	O
myeloid	O
cells	O
,	O
CD89	B
is	O
able	O
to	O
associate	O
with	O
the	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
(	O
ITAM	O
)	O
-	O
containing	O
the	O
FcR	B
gamma	I
chain	O
,	O
which	O
is	O
responsible	O
for	O
intracellular	O
signaling	O
via	O
CD89	B
.	O

Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
some	O
cells	O
express	O
CD89	B
in	O
a	O
form	O
that	O
does	O
not	O
associate	O
with	O
the	O
FcR	B
gamma	I
chain	O
.	O

Although	O
the	O
biological	O
relevance	O
of	O
this	O
observation	O
is	O
not	O
yet	O
clear	O
,	O
it	O
may	O
explain	O
certain	O
anti	O
-	O
inflammatory	O
/	O
inhibitory	O
effects	O
attributed	O
to	O
IgA	B
.	O

Here	O
we	O
review	O
current	O
knowledge	O
concerning	O
the	O
genetics	O
,	O
structure	O
and	O
biological	O
function	O
of	O
CD89	B
.	O

Effects	O
of	O
tri	O
-	O
iodothyronine	O
on	O
alternative	O
splicing	O
events	O
in	O
the	O
coding	O
region	O
of	O
cytochrome	B
P450	I
aromatase	I
in	O
immature	O
rat	O
Sertoli	O
cells	O
.	O

Transient	O
postnatal	O
hypothyroidism	O
in	O
male	O
rats	O
induces	O
a	O
prolonged	O
proliferation	O
of	O
immature	O
Sertoli	O
cells	O
.	O

This	O
change	O
in	O
Sertoli	O
cell	O
replication	O
at	O
young	O
ages	O
is	O
coincident	O
with	O
enhanced	O
and	O
prolonged	O
aromatase	B
activity	O
that	O
leads	O
to	O
a	O
marked	O
increase	O
in	O
the	O
conversion	O
of	O
androgens	O
into	O
estrogens	O
.	O

Both	O
events	O
are	O
drastically	O
inhibited	O
by	O
tri	O
-	O
iodothyronine	O
(	O
T	O
(	O
3	O
)	O
)	O
replacement	O
either	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O

This	O
study	O
,	O
after	O
the	O
immunolocalization	O
of	O
aromatase	B
in	O
cultured	O
rat	O
Sertoli	O
cells	O
,	O
examined	O
the	O
effects	O
elicited	O
by	O
T	O
(	O
3	O
)	O
on	O
this	O
enzyme	O
,	O
by	O
simultaneously	O
investigating	O
three	O
functional	O
levels	O
of	O
aromatase	B
:	O
mRNA	O
expression	O
,	O
protein	O
content	O
,	O
and	O
enzymatic	O
activity	O
.	O

The	O
immunolocalization	O
of	O
cytochrome	B
P450	I
aromatase	I
(	O
P450	B
arom	I
)	O
was	O
shown	O
in	O
the	O
cytoplasm	O
of	O
cultured	O
Sertoli	O
cells	O
from	O
15	O
-	O
and	O
21	O
-	O
day	O
-	O
old	O
rats	O
.	O

Western	O
blot	O
analysis	O
revealed	O
an	O
enhancement	O
of	O
aromatase	B
protein	O
content	O
upon	O
stimulation	O
with	O
N	O
(	O
6	O
)	O
,2'-O	O
-	O
dibutyryladenosine-3':5'-cyclic	O
monophosphate	O
(	O
(	O
Bu	O
)	O
(	O
2	O
)	O
cAMP	O
)	O
that	O
was	O
clearly	O
down	O
-	O
regulated	O
by	O
T	O
(	O
3	O
)	O
.	O

The	O
presence	O
of	O
a	O
functional	O
P450	B
arom	I
protein	O
in	O
purified	O
Sertoli	O
cells	O
was	O
confirmed	O
by	O
the	O
measurement	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
H	O
(	O
2	O
)	O
O	O
released	O
after	O
incubation	O
with	O
[	O
1	O
beta-	O
(	O
3	O
)	O
H	O
]	O
androst-4-ene-3,17-dione	O
.	O

With	O
100	O
nM	O
T3	O
,	O
a	O
decrease	O
in	O
both	O
P450	B
arom	I
mRNA	O
levels	O
and	O
aromatase	O
activity	O
was	O
observed	O
.	O

The	O
aromatase	B
enzymatic	O
activity	O
was	O
strongly	O
stimulated	O
by	O
(	O
Bu	O
)	O
(	O
2	O
)	O
cAMP	O
and	O
markedly	O
down	O
-	O
regulated	O
by	O
T	O
(	O
3	O
)	O
.	O

In	O
contrast	O
,	O
the	O
strong	O
increase	O
in	O
aromatase	B
mRNA	O
upon	O
(	O
Bu	O
)	O
(	O
2	O
)	O
cAMP	O
stimulation	O
was	O
apparently	O
unaffected	O
by	O
T	O
(	O
3	O
)	O
administration	O
.	O

This	O
paper	O
shows	O
how	O
the	O
identification	O
of	O
an	O
altered	O
transcript	O
induced	O
by	O
T	O
(	O
3	O
)	O
coding	O
for	O
putative	O
truncated	O
and	O
inactive	O
aromatase	B
protein	O
might	O
explain	O
such	O
a	O
decrease	O
in	O
aromatase	B
activity	O
in	O
T	O
(	O
3	O
)	O
-	O
treated	O
cells	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
it	O
is	O
concluded	O
that	O
at	O
least	O
two	O
mechanisms	O
could	O
be	O
involved	O
in	O
the	O
down	O
-	O
regulatory	O
effect	O
of	O
T	O
(	O
3	O
)	O
on	O
aromatase	B
activity	O
in	O
prepuberal	O
Sertoli	O
cells	O
.	O

The	O
first	O
mechanism	O
is	O
linked	O
to	O
a	O
possible	O
direct	O
modulatory	O
role	O
for	O
T	O
(	O
3	O
)	O
in	O
the	O
regulation	O
of	O
the	O
aromatase	B
promoter	O
,	O
whilst	O
the	O
second	O
one	O
is	O
represented	O
by	O
the	O
induction	O
of	O
altered	O
transcripts	O
coding	O
for	O
truncated	O
and	O
inactive	O
aromatase	B
proteins	O
.	O

Sulfonate	O
-	O
sulfur	O
metabolism	O
and	O
its	O
regulation	O
in	O
Escherichia	O
coli	O
.	O

In	O
the	O
absence	O
of	O
sulfate	O
and	O
cysteine	O
,	O
Escherichia	O
coli	O
can	O
use	O
aliphatic	O
sulfonates	O
as	O
a	O
source	O
of	O
sulfur	O
for	O
growth	O
.	O

Starvation	O
for	O
sulfate	O
leads	O
to	O
the	O
expression	O
of	O
the	O
tauABCD	B
and	O
ssuEADCB	B
genes	O
.	O

Each	O
of	O
these	O
gene	O
clusters	O
encodes	O
an	O
ABC	O
-	O
type	O
transport	O
system	O
required	O
for	O
uptake	O
of	O
aliphatic	O
sulfonates	O
and	O
a	O
desulfonation	O
enzyme	O
.	O

The	O
TauD	B
protein	O
is	O
an	O
alpha	B
-	I
ketoglutarate	I
-	I
dependent	I
dioxygenase	I
that	O
preferentially	O
liberates	O
sulfite	O
from	O
taurine	O
(	O
2-aminoethanesulfonic	O
acid	O
)	O
.	O

SsuD	B
is	O
a	O
monooxygenase	B
that	O
catalyzes	O
the	O
oxygenolytic	O
desulfonation	O
of	O
a	O
range	O
of	O
aliphatic	O
sulfonates	O
other	O
than	O
taurine	O
.	O

Its	O
cosubstrate	O
is	O
FMNH2	O
,	O
which	O
is	O
provided	O
by	O
SsuE	B
,	O
an	O
NAD	O
(	O
P	O
)	O
H	O
-	O
dependent	O
FMN	B
reductase	I
.	O

In	O
contrast	O
to	O
many	O
other	O
bacteria	O
,	O
E.	O
coli	O
is	O
unable	O
to	O
grow	O
with	O
arylsulfonates	O
or	O
with	O
sulfate	O
esters	O
as	O
sulfur	O
source	O
.	O

The	O
tau	B
and	O
ssu	B
systems	O
thus	O
provide	O
all	O
genes	O
for	O
the	O
utilization	O
of	O
known	O
organosulfur	O
sources	O
by	O
this	O
organism	O
,	O
except	O
the	O
as	O
yet	O
unidentified	O
gene	O
(	O
s	O
)	O
that	O
enable	O
some	O
E.	O
coli	O
strains	O
to	O
grow	O
with	O
methanesulfonate	O
or	O
cysteate	O
as	O
a	O
sulfur	O
source	O
.	O

Expression	O
of	O
the	O
tau	B
and	O
ssu	B
genes	O
requires	O
the	O
LysR	B
-	O
type	O
transcriptional	O
regulatory	O
proteins	O
CysB	B
and	O
Cbl	B
.	O

Synthesis	O
of	O
Cbl	B
itself	O
is	O
under	O
control	O
of	O
the	O
CysB	B
protein	O
,	O
and	O
the	O
CysB	B
protein	O
may	O
therefore	O
be	O
regarded	O
as	O
the	O
master	O
regulator	O
for	O
sulfur	O
assimilation	O
in	O
E.	O
coli	O
,	O
while	O
the	O
Cbl	B
protein	O
functions	O
as	O
an	O
accessory	O
element	O
specific	O
for	O
utilization	O
of	O
sulfur	O
from	O
organosulfur	O
sources	O
.	O

A	O
Ca	O
(	O
2	O
+	O
)	O
-	O
activated	O
NADPH	B
oxidase	I
in	O
testis	O
,	O
spleen	O
,	O
and	O
lymph	O
nodes	O
.	O

Superoxide	O
and	O
its	O
derivatives	O
are	O
increasingly	O
implicated	O
in	O
the	O
regulation	O
of	O
physiological	O
functions	O
from	O
oxygen	O
sensing	O
and	O
blood	O
pressure	O
regulation	O
to	O
lymphocyte	O
activation	O
and	O
sperm	O
-	O
oocyte	O
fusion	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
superoxide	O
-	O
generating	O
NADPH	B
oxidase	I
referred	O
to	O
as	O
NADPH	B
oxidase	I
5	I
(	O
NOX5	B
)	O
.	O

NOX5	B
is	O
distantly	O
related	O
to	O
the	O
gp91	B
(	I
phox	I
)	I
subunit	O
of	O
the	O
phagocyte	O
NADPH	B
oxidase	I
with	O
conserved	O
regions	O
crucial	O
for	O
the	O
electron	O
transport	O
(	O
NADPH	O
,	O
FAD	O
and	O
heme	O
binding	O
sites	O
)	O
.	O

However	O
,	O
NOX5	B
has	O
a	O
unique	O
N	O
-	O
terminal	O
extension	O
that	O
contains	O
three	O
EF	O
hand	O
motifs	O
.	O

The	O
mRNA	O
of	O
NOX5	B
is	O
expressed	O
in	O
pachytene	O
spermatocytes	O
of	O
testis	O
and	O
in	O
B	O
-	O
and	O
T	O
-	O
lymphocyte	O
-	O
rich	O
areas	O
of	O
spleen	O
and	O
lymph	O
nodes	O
.	O

When	O
heterologously	O
expressed	O
,	O
NOX5	B
was	O
quiescent	O
in	O
unstimulated	O
cells	O
.	O

However	O
,	O
in	O
response	O
to	O
elevations	O
of	O
the	O
cytosolic	O
Ca	O
(	O
2	O
+	O
)	O
concentration	O
it	O
generated	O
large	O
amounts	O
of	O
superoxide	O
.	O

Upon	O
Ca	O
(	O
2	O
+	O
)	O
activation	O
,	O
NOX5	B
also	O
displayed	O
a	O
second	O
function	O
:	O
it	O
became	O
a	O
proton	O
channel	O
,	O
presumably	O
to	O
compensate	O
charge	O
and	O
pH	O
alterations	O
due	O
to	O
electron	O
export	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
novel	O
NADPH	B
oxidase	I
that	O
generates	O
superoxide	O
and	O
functions	O
as	O
a	O
H	B
(	I
+	I
)	I
channel	I
in	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
manner	O
.	O

NOX5	B
is	O
likely	O
to	O
be	O
involved	O
in	O
Ca	O
(	O
2+	O
)	O
-activated	O
,	O
redox	O
-	O
dependent	O
processes	O
of	O
spermatozoa	O
and	O
lymphocytes	O
such	O
as	O
sperm	O
-	O
oocyte	O
fusion	O
,	O
cell	O
proliferation	O
,	O
and	O
cytokine	B
secretion	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
two	O
sterol	O
esterification	O
genes	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Saccharomyces	O
cerevisiae	O
transcribes	O
two	O
genes	O
,	O
ARE1	B
and	O
ARE2	B
,	O
that	O
contribute	O
disproportionately	O
to	O
the	O
esterification	O
of	O
sterols	O
.	O

Are2p	B
is	O
the	O
major	O
enzyme	O
isoform	O
in	O
a	O
wild	O
-	O
type	O
cell	O
growing	O
aerobically	O
.	O

This	O
likely	O
results	O
from	O
a	O
combination	O
of	O
differential	O
transcription	O
initiation	O
and	O
transcript	O
stability	O
.	O

By	O
using	O
ARE1	B
and	O
ARE2	B
promoter	O
fusions	O
to	O
lacZ	B
reporters	O
,	O
we	O
demonstrated	O
that	O
transcriptional	O
initiation	O
from	O
the	O
ARE1	B
promoter	O
is	O
significantly	O
reduced	O
compared	O
to	O
that	O
from	O
the	O
ARE2	B
promoter	O
.	O

Furthermore	O
,	O
the	O
half	O
-	O
life	O
of	O
the	O
ARE2	B
mRNA	O
is	O
approximately	O
12	O
times	O
as	O
long	O
as	O
that	O
of	O
the	O
ARE1	B
transcript	O
.	O

We	O
present	O
evidence	O
that	O
the	O
primary	O
role	O
of	O
the	O
minor	O
sterol	O
esterification	O
isoform	O
encoded	O
by	O
ARE1	B
is	O
to	O
esterify	O
sterol	O
intermediates	O
,	O
whereas	O
the	O
role	O
of	O
the	O
ARE2	B
enzyme	O
is	O
to	O
esterify	O
ergosterol	O
,	O
the	O
end	O
product	O
of	O
the	O
pathway	O
.	O

Accordingly	O
,	O
the	O
ARE1	B
promoter	O
is	O
upregulated	O
in	O
strains	O
that	O
accumulate	O
ergosterol	O
precursors	O
.	O

Furthermore	O
,	O
ARE1	B
and	O
ARE2	B
are	O
oppositely	O
regulated	O
by	O
heme	O
.	O

Under	O
heme	O
-	O
deficient	O
growth	O
conditions	O
,	O
ARE1	B
was	O
upregulated	O
fivefold	O
while	O
ARE2	B
was	O
down	O
-	O
regulated	O
.	O

ARE2	B
requires	O
the	O
HAP1	B
transcription	B
factor	I
for	O
optimal	O
expression	O
,	O
and	O
both	O
ARE	B
genes	O
are	O
derepressed	O
in	O
a	O
rox1	B
(	O
repressor	B
of	I
oxygen	I
)	O
mutant	O
genetic	O
background	O
.	O

We	O
further	O
report	O
that	O
the	O
ARE	B
genes	O
are	O
not	O
subject	O
to	O
end	O
product	O
inhibition	O
;	O
neither	O
ARE1	B
nor	O
ARE2	B
transcription	O
is	O
altered	O
in	O
an	O
are	O
mutant	O
background	O
,	O
nor	O
does	O
overexpression	O
of	O
either	O
ARE	B
gene	O
alter	O
the	O
response	O
of	O
the	O
ARE	B
-	O
lacZ	B
reporter	O
constructs	O
.	O

Our	O
observations	O
are	O
consistent	O
with	O
an	O
important	O
physiological	O
role	O
for	O
Are1p	B
during	O
anaerobic	O
growth	O
when	O
heme	O
is	O
limiting	O
and	O
sterol	O
precursors	O
may	O
accumulate	O
.	O

Conversely	O
,	O
Are2p	B
is	O
optimally	O
required	O
during	O
aerobiosis	O
when	O
ergosterol	O
is	O
plentiful	O
.	O

Peptide	O
insertions	O
in	O
domain	O
4	O
of	O
hbeta	B
(	I
c	I
)	I
,	O
the	O
shared	O
signalling	O
receptor	O
subunit	O
for	O
GM	B
-	I
CSF	I
,	O
IL3	B
and	O
IL5	B
,	O
induce	O
ligand	O
-	O
independent	O
activation	O
.	O

A	O
mutant	O
form	O
of	O
the	O
common	B
beta	I
-	I
subunit	I
of	I
the	I
GM	I
-	I
CSF	I
,	I
interleukin-3	I
(	I
IL3	I
)	I
and	I
IL5	I
receptors	I
is	O
activated	O
by	O
a	O
37	O
residue	O
duplicated	O
segment	O
which	O
includes	O
the	O
WSXWS	O
motif	O
and	O
an	O
adjacent	O
,	O
highly	O
conserved	O
,	O
aliphatic	O
/	O
basic	O
element	O
.	O

Haemopoietic	O
expression	O
of	O
this	O
mutant	O
,	O
hbeta	B
(	I
c	I
)	I
FIDelta	O
,	O
in	O
mice	O
leads	O
to	O
myeloproliferative	O
disease	O
.	O

To	O
examine	O
the	O
mechanism	O
of	O
activation	O
of	O
this	O
mutant	O
we	O
targetted	O
the	O
two	O
conserved	O
motifs	O
in	O
each	O
repeat	O
for	O
mutagenesis	O
.	O

Here	O
we	O
show	O
that	O
this	O
mutant	O
exhibits	O
constitutive	O
activity	O
in	O
BaF	O
-	O
B03	O
cells	O
in	O
the	O
presence	O
of	O
mouse	O
or	O
human	O
GM	B
-	I
CSF	I
receptor	I
alpha	I
-	O
subunit	O
(	O
GMRalpha	B
)	O
and	O
this	O
activity	O
is	O
disrupted	O
by	O
mutations	O
of	O
the	O
conserved	O
motifs	O
in	O
the	O
first	O
repeat	O
.	O

In	O
the	O
presence	O
of	O
these	O
mutations	O
the	O
receptor	O
reverts	O
to	O
an	O
alternative	O
conformation	O
which	O
retains	O
responsiveness	O
to	O
human	O
IL3	B
in	O
a	O
CTLL	O
cell	O
line	O
co	O
-	O
expressing	O
the	O
human	O
IL3	B
receptor	I
alpha	I
-	O
subunit	O
(	O
hIL3Ralpha	B
)	O
.	O

Remarkably	O
,	O
the	O
activated	O
conformation	O
is	O
maintained	O
in	O
the	O
presence	O
of	O
substitutions	O
,	O
deletions	O
or	O
replacement	O
of	O
the	O
second	O
repeat	O
.	O

This	O
suggests	O
that	O
activation	O
occurs	O
due	O
to	O
insertion	O
of	O
extra	O
sequence	O
after	O
the	O
WSXWS	O
motif	O
and	O
is	O
not	O
dependent	O
on	O
the	O
length	O
or	O
specific	O
sequence	O
of	O
the	O
insertion	O
.	O

Thus	O
hbeta	B
(	I
c	I
)	I
displays	O
an	O
ability	O
to	O
fold	O
into	O
functional	O
receptor	O
conformations	O
given	O
insertion	O
of	O
up	O
to	O
37	O
residues	O
in	O
the	O
membrane	O
-	O
proximal	O
region	O
.	O

Constitutive	O
activation	O
most	O
likely	O
results	O
from	O
a	O
specific	O
conformational	O
change	O
which	O
alters	O
a	O
dormant	O
,	O
inactive	O
receptor	O
complex	O
,	O
permitting	O
functional	O
association	O
with	O
GMRalpha	B
and	O
ligand	O
-	O
independent	O
mitogenic	O
signalling	O
.	O

Evidence	O
for	O
a	O
novel	O
thrombopoietin	B
signalling	O
event	O
:	O
activation	O
of	O
protein	B
kinase	I
A	I
in	O
human	O
megakaryoblastic	O
CMK	O
cells	O
.	O

Thrombopoietin	B
(	O
TPO	B
)	O
plays	O
a	O
crucial	O
role	O
in	O
megakaryocyte	O
development	O
.	O

TPO	B
signalling	O
,	O
which	O
is	O
mediated	O
by	O
its	O
receptor	O
Mpl	B
,	O
includes	O
Janus	B
kinase	I
,	O
(	O
JAK	B
)	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	O
STAT	B
)	O
and	O
Shc	B
/	O
Ras	B
/	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
pathways	O
.	O

The	O
precise	O
nature	O
of	O
these	O
signalling	O
routes	O
has	O
not	O
been	O
clarified	O
in	O
detail	O
up	O
until	O
now	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
TPO	B
on	O
activation	O
of	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
(	O
PKA	B
)	O
and	O
its	O
involvement	O
in	O
MAPK	B
signalling	O
in	O
human	O
megakaryoblastic	O
leukaemia	O
CMK	O
cells	O
.	O

For	O
estimation	O
of	O
PKA	B
activity	O
,	O
phosphorylation	O
of	O
a	O
PKA	B
-	O
specific	O
peptide	O
substrate	O
was	O
assayed	O
in	O
CMK	O
cell	O
lysates	O
.	O

Since	O
activation	O
of	O
PKA	B
is	O
associated	O
with	O
translocation	O
of	O
its	O
catalytic	O
subunit	O
alpha	O
(	O
C	O
-	O
PKA	B
)	O
into	O
the	O
cell	O
nucleus	O
,	O
Western	O
blot	O
analysis	O
of	O
nuclear	O
fractions	O
with	O
an	O
anti	O
-	O
C	O
-	O
PKA	B
antibody	O
was	O
additionally	O
performed	O
.	O

The	O
activation	O
of	O
TPO	B
-	O
induced	O
MAPK	B
activation	O
and	O
the	O
effect	O
of	O
the	O
PKA	B
inhibitor	O
H-89	O
was	O
measured	O
using	O
immunoblotting	O
with	O
a	O
monoclonal	O
anti	O
-	O
pERK	B
antibody	O
.	O

TPO	B
enhanced	O
cAMP	O
and	O
induced	O
activation	O
of	O
PKA	B
in	O
CMK	O
cells	O
.	O

In	O
addition	O
,	O
H-89	O
partly	O
blocked	O
TPO	B
-	O
induced	O
MAPK	B
activation	O
in	O
CMK	O
cells	O
.	O

Our	O
results	O
indicate	O
a	O
novel	O
TPO	B
-	O
triggered	O
signalling	O
event	O
,	O
activation	O
of	O
the	O
cAMP	O
/	O
PKA	B
pathway	O
in	O
human	O
megakaryoblastic	O
CMK	O
cells	O
.	O

This	O
signal	O
transduction	O
route	O
seems	O
to	O
be	O
involved	O
in	O
TPO	B
-	O
induced	O
MAPK	B
signaling	O
.	O

Genomic	O
organization	O
and	O
promoter	O
analysis	O
of	O
human	O
KCNN3	B
gene	O
.	O

KCNN3	B
is	O
a	O
member	O
of	O
the	O
gene	O
family	O
,	O
KCNN1	B
-	I
4	I
,	O
encoding	O
the	O
small	O
and	O
intermediate	O
conductance	O
calcium	O
-	O
activated	O
potassium	O
channels	O
.	O

Long	O
CAG	O
-	O
repeat	O
alleles	O
of	O
this	O
gene	O
have	O
been	O
found	O
to	O
be	O
over	O
-	O
represented	O
in	O
patients	O
with	O
schizophrenia	O
in	O
a	O
number	O
of	O
population	O
-	O
based	O
association	O
studies	O
,	O
and	O
this	O
gene	O
maps	O
to	O
human	O
chromosome	O
1q21	O
,	O
a	O
region	O
recently	O
implicated	O
in	O
schizophrenia	O
by	O
linkage	O
.	O

To	O
set	O
the	O
stage	O
for	O
a	O
further	O
functional	O
evaluation	O
of	O
KCNN3	B
,	O
we	O
defined	O
the	O
nature	O
of	O
the	O
genomic	O
locus	O
in	O
the	O
size	O
,	O
structure	O
,	O
and	O
sequence	O
of	O
its	O
introns	O
and	O
exons	O
and	O
the	O
function	O
of	O
potential	O
upstream	O
regulatory	O
regions	O
.	O

We	O
isolated	O
P1	O
-	O
derived	O
artificial	O
chromosome	O
(	O
PAC	O
)	O
clones	O
from	O
a	O
genomic	O
library	O
and	O
identified	O
an	O
overlapping	O
available	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
clone	O
.	O

Cosmids	O
subcloned	O
from	O
the	O
PAC	O
and	O
BAC	O
clones	O
were	O
then	O
sequenced	O
and	O
merged	O
with	O
the	O
sequence	O
in	O
the	O
public	O
database	O
.	O

The	O
KCNN3	B
gene	O
spans	O
over	O
163.1	O
kb	O
and	O
is	O
composed	O
of	O
eight	O
exons	O
and	O
seven	O
introns	O
.	O

All	O
of	O
the	O
exon	O
-	O
intron	O
junctions	O
conform	O
closely	O
to	O
consensus	O
splice	O
sites	O
.	O

The	O
proximal	O
2.5	O
kb	O
of	O
the	O
5	O
'	O
-	O
flanking	O
sequence	O
was	O
obtained	O
and	O
analyzed	O
for	O
potential	O
transcription	B
factor	I
binding	O
sites	O
.	O

In	O
the	O
proximal	O
2.5	O
kb	O
upstream	O
region	O
,	O
potential	O
sites	O
for	O
the	O
Ikaros	B
factor	I
(	O
IK2	B
)	O
,	O
homeodomain	O
factor	O
Nkx-2.5	B
/	O
Csx	B
(	O
NKX25	B
)	O
,	O
nuclear	B
factor	I
of	I
activated	I
T	I
-	I
cells	I
(	O
NFAT	B
)	O
,	O
upstream	B
stimulating	I
factor	I
(	O
USF	B
)	O
,	O
c	B
-	I
AMP	I
responsive	I
element	I
binding	I
protein	I
(	O
CREB	B
)	O
,	O
POU	O
factor	O
Brn2	B
(	O
BRN-2	B
)	O
,	O
myeloid	B
zinc	I
finger	I
protein	I
(	O
MZF1	B
)	O
,	O
vitellogenin	B
binding	I
protein	I
(	O
VBP	B
)	O
,	O
HNF3	B
forkhead	I
homologue	I
2	I
(	O
HFH2	B
)	O
,	O
and	O
transcription	O
initiation	O
were	O
identified	O
,	O
as	O
well	O
as	O
several	O
potential	O
AP-1	B
and	O
AP-4	B
sites	O
.	O

Finally	O
,	O
a	O
2261	O
-	O
bp	O
fragment	O
of	O
this	O
upstream	O
region	O
was	O
cloned	O
into	O
a	O
promoterless	O
pGL3	O
-	O
luciferase	B
vector	O
,	O
where	O
it	O
produced	O
orientation	O
-	O
dependent	O
expression	O
of	O
the	O
reporter	O
gene	O
in	O
transiently	O
transfected	O
PC12	O
cells	O
,	O
cells	O
which	O
natively	O
express	O
functional	O
KCNN3	B
channels	O
,	O
suggesting	O
that	O
this	O
cloned	O
fragment	O
includes	O
competent	O
promoter	O
elements	O
of	O
this	O
gene	O
.	O

Inhibition	O
of	O
natural	O
killer	O
cell	O
activation	O
signals	O
by	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
(	O
CD158	B
)	O
.	O

The	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
(	I
KIR	I
)	I
family	I
includes	O
receptors	O
that	O
bind	O
to	O
HLA	B
class	I
I	I
molecules	O
on	O
target	O
cells	O
and	O
inhibit	O
natural	O
killer	O
(	O
NK	O
)	O
-	O
cell	O
cytotoxicity	O
,	O
and	O
receptors	O
such	O
as	O
KIR3DL7	B
with	O
no	O
known	O
ligand	O
and	O
function	O
.	O

Inhibitory	O
KIR	B
recruit	O
the	O
tyrosine	B
phosphatase	I
SHP-1	B
to	O
block	O
signals	O
transduced	O
by	O
any	O
one	O
of	O
a	O
number	O
of	O
activation	O
receptors	O
.	O

Inhibition	O
of	O
overall	O
protein	O
tyrosine	O
phosphorylation	O
by	O
SHP-1	B
during	O
binding	O
of	O
KIR	B
to	O
MHC	B
class	I
I	I
on	O
target	O
cells	O
is	O
selective	O
,	O
suggesting	O
that	O
a	O
limited	O
number	O
of	O
substrates	O
are	O
dephosphorylated	O
by	O
SHP-1	B
.	O

We	O
have	O
chosen	O
to	O
study	O
KIR	B
inhibition	O
as	O
it	O
occurs	O
during	O
binding	O
of	O
KIR	B
to	O
MHC	B
class	I
I	I
on	O
target	O
cells	O
,	O
despite	O
the	O
technical	O
limitations	O
inherent	O
to	O
studies	O
of	O
processes	O
regulated	O
by	O
cell	O
contact	O
.	O

KIR	O
binding	O
to	O
MHC	B
class	I
I	I
on	O
target	O
cells	O
inhibits	O
tyrosine	O
phosphorylation	O
of	O
the	O
activation	O
receptor	O
2B4	B
(	O
CD244	B
)	O
and	O
disrupts	O
adhesion	O
of	O
NK	O
cells	O
to	O
target	O
cells	O
.	O

Inhibition	O
of	O
proximal	O
events	O
in	O
NK	O
activation	O
may	O
increase	O
the	O
availability	O
of	O
NK	O
cells	O
by	O
liberating	O
them	O
from	O
non	O
-	O
productive	O
interactions	O
with	O
resistant	O
target	O
cells	O
.	O

As	O
the	O
receptors	O
and	O
the	O
signaling	O
pathways	O
that	O
induce	O
NK	O
cytotoxicity	O
are	O
not	O
fully	O
characterized	O
,	O
elucidation	O
of	O
the	O
inhibitory	O
mechanism	O
employed	O
by	O
KIR	B
may	O
provide	O
insight	O
into	O
NK	O
activation	O
.	O

Two	O
similar	O
gene	O
clusters	O
coding	O
for	O
enzymes	O
of	O
a	O
new	O
type	O
of	O
aerobic	O
2-aminobenzoate	O
(	O
anthranilate	O
)	O
metabolism	O
in	O
the	O
bacterium	O
Azoarcus	O
evansii	O
.	O

In	O
the	O
beta	O
-	O
proteobacterium	O
Azoarcus	O
evansii	O
,	O
the	O
aerobic	O
metabolism	O
of	O
2-aminobenzoate	O
(	O
anthranilate	O
)	O
,	O
phenylacetate	O
,	O
and	O
benzoate	O
proceeds	O
via	O
three	O
unprecedented	O
pathways	O
.	O

The	O
pathways	O
have	O
in	O
common	O
that	O
all	O
three	O
substrates	O
are	O
initially	O
activated	O
to	O
coenzyme	O
A	O
(	O
CoA	O
)	O
thioesters	O
and	O
further	O
processed	O
in	O
this	O
form	O
.	O

The	O
two	O
initial	O
steps	O
of	O
2-aminobenzoate	O
metabolism	O
are	O
catalyzed	O
by	O
a	O
2-aminobenzoate	B
-	I
CoA	I
ligase	I
forming	O
2-aminobenzoyl	O
-	O
CoA	O
and	O
by	O
a	O
2-aminobenzoyl	B
-	I
CoA	I
monooxygenase	I
/	I
reductase	I
(	O
ACMR	B
)	O
forming	O
2-amino-5-oxo	O
-	O
cyclohex-1-ene-1-carbonyl	O
-	O
CoA	O
.	O

Eight	O
genes	O
possibly	O
involved	O
in	O
this	O
pathway	O
,	O
including	O
the	O
genes	O
encoding	O
2-aminobenzoate	B
-	I
CoA	I
ligase	I
and	O
ACMR	B
,	O
were	O
detected	O
,	O
cloned	O
,	O
and	O
sequenced	O
.	O

The	O
sequence	O
of	O
the	O
ACMR	B
gene	O
showed	O
that	O
this	O
enzyme	O
is	O
an	O
87	O
-	O
kDa	O
fusion	O
protein	O
of	O
two	O
flavoproteins	O
,	O
a	O
monooxygenase	B
(	O
similar	O
to	O
salicylate	B
monooxygenase	I
)	O
and	O
a	O
reductase	B
(	O
similar	O
to	O
old	B
yellow	I
enzyme	I
)	O
.	O

Besides	O
the	O
genes	O
for	O
the	O
initial	O
two	O
enzymes	O
,	O
genes	O
for	O
three	O
enzymes	O
of	O
a	O
beta	O
-	O
oxidation	O
pathway	O
were	O
found	O
.	O

A	O
substrate	O
binding	O
protein	O
of	O
an	O
ABC	O
transport	O
system	O
,	O
a	O
MarR	B
-	O
like	O
regulator	O
,	O
and	O
a	O
putative	O
translation	O
inhibitor	O
protein	O
were	O
also	O
encoded	O
by	O
the	O
gene	O
cluster	O
.	O

The	O
data	O
suggest	O
that	O
,	O
after	O
monooxygenation	O
/	O
reduction	O
of	O
2-aminobenzoyl	O
-	O
CoA	O
,	O
the	O
nonaromatic	O
CoA	O
thioester	O
intermediate	O
is	O
metabolized	O
further	O
by	O
beta	O
-	O
oxidation	O
.	O

This	O
implies	O
that	O
all	O
subsequent	O
intermediates	O
are	O
CoA	O
thioesters	O
and	O
that	O
the	O
alicyclic	O
carbon	O
ring	O
is	O
not	O
cleaved	O
oxygenolytically	O
.	O

Surprisingly	O
,	O
the	O
cluster	O
of	O
eight	O
genes	O
,	O
which	O
form	O
an	O
operon	O
,	O
is	O
duplicated	O
.	O

The	O
two	O
copies	O
differ	O
only	O
marginally	O
within	O
the	O
coding	O
regions	O
but	O
differ	O
substantially	O
in	O
the	O
respective	O
intergenic	O
regions	O
.	O

Both	O
copies	O
of	O
the	O
genes	O
are	O
coordinately	O
expressed	O
in	O
cells	O
grown	O
aerobically	O
on	O
2-aminobenzoate	O
.	O

Sac1	B
lipid	B
phosphatase	I
and	O
Stt4	B
phosphatidylinositol	B
4-kinase	I
regulate	O
a	O
pool	O
of	O
phosphatidylinositol	O
4-phosphate	O
that	O
functions	O
in	O
the	O
control	O
of	O
the	O
actin	B
cytoskeleton	O
and	O
vacuole	O
morphology	O
.	O

Synthesis	O
and	O
turnover	O
of	O
phosphoinositides	O
are	O
tightly	O
regulated	O
processes	O
mediated	O
by	O
a	O
set	O
of	O
recently	O
identified	O
kinases	B
and	O
phosphatases	B
.	O

We	O
analyzed	O
the	O
primary	O
role	O
of	O
the	O
phosphoinositide	B
phosphatase	I
Sac1p	B
in	O
Saccharomyces	O
cerevisiae	O
with	O
the	O
use	O
of	O
a	O
temperature	O
-	O
sensitive	O
allele	O
of	O
this	O
gene	O
.	O

Our	O
analysis	O
demonstrates	O
that	O
inactivation	O
of	O
Sac1p	B
leads	O
to	O
a	O
specific	O
increase	O
in	O
the	O
cellular	O
levels	O
of	O
phosphatidylinositol	O
4-phosphate	O
(	O
PtdIns	O
(	O
4	O
)	O
P	O
)	O
,	O
accompanied	O
by	O
changes	O
in	O
vacuole	O
morphology	O
and	O
an	O
accumulation	O
of	O
lipid	O
droplets	O
.	O

We	O
have	O
found	O
that	O
the	O
majority	O
of	O
Sac1p	B
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
,	O
and	O
this	O
localization	O
is	O
crucial	O
for	O
the	O
efficient	O
turnover	O
of	O
PtdIns	O
(	O
4	O
)	O
P	O
.	O

By	O
generating	O
double	O
mutant	O
strains	O
harboring	O
the	O
sac1	B
(	O
ts	O
)	O
allele	O
and	O
one	O
of	O
two	O
temperature	O
-	O
sensitive	O
PtdIns	B
4-kinase	I
genes	O
,	O
stt4	B
(	O
ts	O
)	O
or	O
pik1	B
(	O
ts	O
)	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
bulk	O
of	O
PtdIns	O
(	O
4	O
)	O
P	O
that	O
accumulates	O
in	O
sac1	B
mutant	O
cells	O
is	O
generated	O
by	O
the	O
Stt4	B
PtdIns	B
4-kinase	I
,	O
and	O
not	O
Pik1p	B
.	O

Consistent	O
with	O
these	O
findings	O
,	O
inactivation	O
of	O
Sac1p	B
partially	O
rescued	O
defects	O
associated	O
with	O
stt4	B
(	O
ts	O
)	O
but	O
not	O
pik1	B
(	O
ts	O
)	O
mutant	O
cells	O
.	O

To	O
analyze	O
potential	O
overlapping	O
functions	O
between	O
Sac1p	B
and	O
other	O
homologous	O
phosphoinositide	B
phosphatases	I
,	O
sac1	B
(	O
ts	O
)	O
mutant	O
cells	O
lacking	O
various	O
other	O
synaptojanin	B
-	O
like	O
phosphatases	B
were	O
generated	O
.	O

These	O
double	O
and	O
triple	O
mutants	O
exacerbated	O
the	O
accumulation	O
of	O
intracellular	O
phosphoinositides	O
and	O
caused	O
defects	O
in	O
Golgi	O
function	O
.	O

Together	O
,	O
our	O
results	O
demonstrate	O
that	O
Sac1p	B
primarily	O
turns	O
over	O
Stt4p	B
-	O
generated	O
PtdIns	O
(	O
4	O
)	O
P	O
and	O
that	O
the	O
membrane	O
localization	O
of	O
Sac1p	B
is	O
important	O
for	O
its	O
function	O
in	O
vivo	O
.	O

Regulation	O
of	O
this	O
PtdIns	O
(	O
4	O
)	O
P	O
pool	O
appears	O
to	O
be	O
crucial	O
for	O
the	O
maintenance	O
of	O
vacuole	O
morphology	O
,	O
regulation	O
of	O
lipid	O
storage	O
,	O
Golgi	O
function	O
,	O
and	O
actin	B
cytoskeleton	O
organization	O
.	O

The	O
ASK1	B
gene	O
regulates	O
B	O
function	O
gene	O
expression	O
in	O
cooperation	O
with	O
UFO	B
and	O
LEAFY	B
in	O
Arabidopsis	O
.	O

The	O
Arabidopsis	O
floral	O
regulatory	O
genes	O
APETALA3	B
(	O
AP3	B
)	O
and	O
PISTILLATA	B
(	O
PI	B
)	O
are	O
required	O
for	O
the	O
B	O
function	O
according	O
to	O
the	O
ABC	O
model	O
for	O
floral	O
organ	O
identity	O
.	O

AP3	B
and	O
PI	B
expression	O
are	O
positively	O
regulated	O
by	O
the	O
LEAFY	B
(	O
LFY	B
)	O
and	O
UNUSUAL	B
FLORAL	I
ORGANS	I
(	O
UFO	B
)	O
genes	O
.	O

UFO	B
encodes	O
an	O
F	O
-	O
box	O
protein	O
,	O
and	O
we	O
have	O
shown	O
previously	O
that	O
UFO	B
genetically	O
interacts	O
with	O
the	O
ASK1	B
gene	O
encoding	O
a	O
SKP1	B
homologue	O
;	O
both	O
the	O
F	O
-	O
box	O
containing	O
protein	O
and	O
SKP1	B
are	O
subunits	O
of	O
ubiquitin	B
ligases	I
.	O

We	O
show	O
here	O
that	O
the	O
ask1	B
-	O
1	O
mutation	O
can	O
enhance	O
the	O
floral	O
phenotypes	O
of	O
weak	O
lfy	B
and	O
ap3	B
mutants	O
;	O
therefore	O
,	O
like	O
UFO	B
,	O
ASK1	B
also	O
interacts	O
with	O
LFY	B
and	O
AP3	B
genetically	O
.	O

Furthermore	O
,	O
our	O
results	O
from	O
RNA	O
in	O
situ	O
hybridizations	O
indicate	O
that	O
ASK1	B
regulates	O
early	O
AP3	B
and	O
PI	B
expression	O
.	O

These	O
results	O
support	O
the	O
idea	O
that	O
UFO	B
and	O
ASK1	B
together	O
positively	O
regulate	O
AP3	B
and	O
PI	B
expression	O
.	O

We	O
propose	O
that	O
the	O
UFO	B
and	O
ASK1	B
proteins	O
are	O
components	O
of	O
a	O
ubiquitin	B
ligase	I
that	O
mediates	O
the	O
proteolysis	O
of	O
a	O
repressor	O
of	O
AP3	B
and	O
PI	B
expression	O
.	O

Our	O
genetic	O
studies	O
also	O
indicate	O
that	O
ASK1	B
and	O
UFO	B
play	O
a	O
role	O
in	O
regulating	O
the	O
number	O
of	O
floral	O
organ	O
primordia	O
,	O
and	O
we	O
discuss	O
possible	O
mechanisms	O
for	O
such	O
a	O
regulation	O
.	O

Structure	O
of	O
the	O
C	O
-	O
terminal	O
RNA	O
-	O
binding	O
domain	O
of	O
hnRNP	B
D0	I
(	O
AUF1	B
)	O
,	O
its	O
interactions	O
with	O
RNA	O
and	O
DNA	O
,	O
and	O
change	O
in	O
backbone	O
dynamics	O
upon	O
complex	O
formation	O
with	O
DNA	O
.	O

Heterogeneous	B
nuclear	I
ribonucleoprotein	I
(	I
hnRNP	I
)	I
D0	I
has	O
two	O
ribonucleoprotein	O
(	O
RNP	O
)	O
-	O
type	O
RNA	O
-	O
binding	O
domains	O
(	O
RBDs	O
)	O
,	O
each	O
of	O
which	O
can	O
specifically	O
bind	O
to	O
the	O
UUAG	O
-	O
sequence	O
.	O

hnRNP	B
D0	I
also	O
binds	O
specifically	O
to	O
single	O
-	O
stranded	O
d	O
(	O
TTAGGG	O
)	O
(	O
n	O
)	O
,	O
the	O
human	O
telomeric	O
DNA	O
repeat	O
.	O

We	O
have	O
already	O
reported	O
the	O
structure	O
and	O
interactions	O
with	O
RNA	O
of	O
the	O
N	O
-	O
terminal	O
RBD	O
(	O
RBD1	O
)	O
.	O

Here	O
,	O
the	O
structure	O
of	O
the	O
C	O
-	O
terminal	O
RBD	O
(	O
RBD2	O
)	O
determined	O
by	O
NMR	O
is	O
presented	O
.	O

It	O
folds	O
into	O
a	O
compact	O
alpha	O
beta	O
structure	O
comprising	O
an	O
antiparallel	O
beta	O
-	O
sheet	O
packed	O
against	O
two	O
alpha	O
-	O
helices	O
,	O
which	O
is	O
characteristic	O
of	O
RNP	O
-	O
type	O
RBDs	O
.	O

In	O
addition	O
to	O
the	O
four	O
beta	O
-	O
strands	O
commonly	O
found	O
in	O
RNP	O
-	O
type	O
RBDs	O
,	O
an	O
extra	O
beta	O
-	O
strand	O
,	O
termed	O
beta	O
4	O
(	O
-	O
)	O
,	O
was	O
found	O
just	O
before	O
the	O
fourth	O
beta	O
-	O
strand	O
,	O
yielding	O
a	O
five	O
-	O
stranded	O
beta	O
-	O
sheet	O
.	O

Candidate	O
residues	O
of	O
RBD2	O
involved	O
in	O
the	O
interactions	O
with	O
RNA	O
were	O
identified	O
by	O
chemical	O
shift	O
perturbation	O
analysis	O
.	O

Perturbation	O
was	O
detected	O
on	O
the	O
beta	O
-	O
sheet	O
side	O
,	O
not	O
on	O
the	O
opposite	O
alpha	O
-	O
helix	O
side	O
,	O
as	O
observed	O
for	O
RBD1	O
.	O

It	O
is	O
notable	O
that	O
the	O
beta	O
4	O
(	O
-	O
)	O
to	O
beta	O
4	O
region	O
of	O
RBD2	O
is	O
involved	O
in	O
the	O
interactions	O
in	O
contrast	O
to	O
the	O
case	O
of	O
RBD1	O
.	O

The	O
chemical	O
shift	O
perturbation	O
analysis	O
also	O
showed	O
that	O
RBD2	O
interacts	O
with	O
DNA	O
in	O
essentially	O
the	O
same	O
way	O
as	O
with	O
RNA	O
.	O

Changes	O
in	O
the	O
backbone	O
dynamics	O
upon	O
complex	O
formation	O
with	O
DNA	O
were	O
examined	O
by	O
means	O
of	O
model	O
free	O
analysis	O
of	O
relaxation	O
data	O
.	O

In	O
free	O
RBD2	O
,	O
the	O
beta	O
4	O
(	O
-	O
)	O
to	O
beta	O
4	O
region	O
exhibits	O
slow	O
conformational	O
exchange	O
on	O
the	O
milli	O
-	O
to	O
microsecond	O
time	O
scale	O
.	O

The	O
exchange	O
is	O
quenched	O
upon	O
complex	O
formation	O
.	O

The	O
flexibility	O
of	O
free	O
RBD2	O
may	O
be	O
utilized	O
in	O
the	O
recognition	O
process	O
by	O
allowing	O
different	O
conformational	O
states	O
to	O
be	O
accessed	O
and	O
facilitating	O
induced	O
fit	O
.	O

Additionally	O
,	O
faster	O
flexibility	O
on	O
the	O
nano	O
-	O
to	O
picosecond	O
time	O
scale	O
was	O
observed	O
for	O
loop	O
3	O
located	O
between	O
beta	O
2	O
and	O
beta	O
3	O
in	O
free	O
RBD2	O
,	O
which	O
is	O
retained	O
by	O
the	O
complex	O
as	O
well	O
.	O

Ara6	B
,	O
a	O
plant	O
-	O
unique	O
novel	O
type	O
Rab	B
GTPase	I
,	O
functions	O
in	O
the	O
endocytic	O
pathway	O
of	O
Arabidopsis	O
thaliana	O
.	O

Ara6	B
of	O
Arabidopsis	O
thaliana	O
is	O
a	O
novel	O
member	O
of	O
the	O
Rab	B
/	I
Ypt	I
GTPase	I
family	I
with	O
unique	O
structural	O
features	O
.	O

It	O
resembles	O
Rab5	B
GTPases	B
best	O
,	O
but	O
lacks	O
a	O
large	O
part	O
of	O
the	O
C	O
-	O
terminal	O
hypervariable	O
region	O
and	O
the	O
cysteine	O
motif	O
,	O
and	O
instead	O
harbors	O
an	O
extra	O
stretch	O
of	O
amino	O
acid	O
residues	O
containing	O
myristoylation	O
and	O
palmitoylation	O
sites	O
at	O
the	O
N	O
-	O
terminus	O
.	O

Ara6	B
is	O
tightly	O
associated	O
with	O
membranes	O
and	O
is	O
expressed	O
constitutively	O
.	O

In	O
contrast	O
,	O
the	O
conventional	O
Rab5	B
ortholog	O
,	O
Ara7	B
,	O
is	O
highly	O
expressed	O
only	O
in	O
actively	O
dividing	O
cells	O
.	O

Examination	O
of	O
green	B
fluorescent	I
protein	I
(	O
GFP	B
)	O
-	O
tagged	O
proteins	O
indicates	O
that	O
both	O
Ara6	B
and	O
Ara7	B
are	O
distributed	O
on	O
a	O
subpopulation	O
of	O
endosomes	O
and	O
suggests	O
their	O
roles	O
in	O
endosomal	O
fusion	O
.	O

The	O
endosomal	O
localization	O
of	O
Ara6	B
requires	O
N	O
-	O
terminal	O
fatty	O
acylation	O
,	O
nucleotide	O
binding	O
and	O
the	O
C	O
-	O
terminal	O
amino	O
acid	O
sequence	O
coordinately	O
.	O

Proteins	O
similar	O
to	O
Ara6	B
are	O
found	O
only	O
in	O
higher	O
plants	O
and	O
thus	O
represent	O
a	O
novel	O
class	O
of	O
Rab	B
GTPases	I
regulating	O
endocytic	O
function	O
in	O
a	O
plant	O
-	O
specific	O
manner	O
.	O

Endofin	B
,	O
an	O
endosomal	O
FYVE	O
domain	O
protein	O
.	O

KIAA0305	B
is	O
an	O
uncharacterized	O
member	O
of	O
the	O
FYVE	B
domain	I
protein	I
family	I
.	O

It	O
is	O
closely	O
related	O
to	O
SARA	B
,	O
with	O
about	O
50	O
%	O
identity	O
in	O
the	O
carboxyl	O
-	O
terminal	O
800	O
-	O
amino	O
acid	O
region	O
.	O

Indirect	O
immunofluorescence	O
microscopy	O
using	O
polyclonal	O
antibodies	O
raised	O
against	O
KIAA0305	B
revealed	O
that	O
it	O
is	O
enriched	O
in	O
early	O
endosomes	O
.	O

The	O
Myc	B
-	O
tagged	O
version	O
is	O
also	O
faithfully	O
targeted	O
to	O
the	O
early	O
endosome	O
.	O

We	O
have	O
tentatively	O
called	O
KIAA0305	B
endofin	B
(	O
for	O
endosome	B
-	I
associated	I
FYVE	I
-	I
domain	I
protein	I
)	O
.	O

The	O
association	O
of	O
endofin	B
with	O
endosomes	O
is	O
mediated	O
by	O
its	O
FYVE	O
domain	O
because	O
deletion	O
mutants	O
lacking	O
the	O
central	O
FYVE	O
finger	O
motif	O
are	O
distributed	O
in	O
the	O
cytoplasm	O
.	O

In	O
addition	O
,	O
a	O
single	O
point	O
mutation	O
in	O
the	O
FYVE	O
finger	O
motif	O
at	O
cysteine	O
residue	O
753	O
(	O
C753S	O
)	O
is	O
sufficient	O
to	O
abolish	O
its	O
endosomal	O
association	O
.	O

Its	O
endosomal	O
localization	O
is	O
also	O
sensitive	O
to	O
the	O
phosphatidylinositol	B
3-kinase	I
inhibitor	O
,	O
wortmannin	O
.	O

Using	O
in	O
vitro	O
liposome	O
binding	O
assays	O
,	O
we	O
demonstrate	O
that	O
Myc	B
-	O
tagged	O
endofin	B
associates	O
preferentially	O
with	O
phosphatidylinositol	O
3-phosphate	O
,	O
whereas	O
the	O
C753S	O
point	O
mutant	O
was	O
unable	O
to	O
do	O
so	O
.	O

We	O
also	O
show	O
that	O
endofin	B
co	O
-	O
localizes	O
with	O
SARA	B
but	O
that	O
they	O
are	O
not	O
associated	O
in	O
a	O
common	O
complex	O
because	O
they	O
failed	O
to	O
co	O
-	O
immunoprecipitate	O
in	O
co	O
-	O
expressing	O
cells	O
.	O

Endofin	B
also	O
does	O
not	O
associate	O
with	O
Smad2	B
nor	O
behave	O
like	O
SARA	B
in	O
affecting	O
transforming	B
growth	I
factor	I
-	I
beta	I
signaling	O
.	O

At	O
high	O
levels	O
of	O
expression	O
,	O
both	O
endofin	B
and	O
SARA	B
can	O
cause	O
an	O
endosome	O
aggregation	O
/	O
fusion	O
effect	O
.	O

In	O
COS7	O
cells	O
,	O
which	O
can	O
support	O
high	O
levels	O
of	O
exogenous	O
protein	O
expression	O
,	O
both	O
proteins	O
can	O
also	O
cause	O
other	O
structural	O
anomalies	O
in	O
the	O
endocytic	O
pathway	O
,	O
as	O
represented	O
by	O
enlarged	O
vesicular	O
structures	O
.	O

These	O
endosomal	O
aggregates	O
/	O
fusions	O
accumulated	O
endocytosed	O
epidermal	B
growth	I
factor	I
.	O

Taken	O
together	O
,	O
this	O
report	O
provides	O
evidence	O
to	O
suggest	O
that	O
endofin	B
and	O
the	O
highly	O
related	O
SARA	B
are	O
endosomal	O
proteins	O
with	O
potential	O
roles	O
in	O
regulating	O
membrane	O
traffic	O
.	O

Protease	B
inhibitors	O
as	O
potential	O
antiviral	O
agents	O
for	O
the	O
treatment	O
of	O
picornaviral	O
infections	O
.	O

The	O
picornavirus	O
family	O
contains	O
several	O
human	O
pathogens	O
including	O
human	O
rhinovirus	O
(	O
HRV	O
)	O
and	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
.	O

In	O
the	O
case	O
of	O
HRVs	O
,	O
these	O
small	O
single	O
-	O
stranded	O
positive	O
-	O
sense	O
RNA	O
viruses	O
translate	O
their	O
genetic	O
information	O
into	O
a	O
polyprotein	O
precursor	O
which	O
is	O
further	O
processed	O
mainly	O
by	O
two	O
viral	O
proteases	B
designated	O
2A	B
and	O
3C	B
.	O

The	O
2A	B
protease	I
(	O
2Apro	B
)	O
makes	O
the	O
first	O
cleavage	O
between	O
the	O
structural	B
and	I
non	I
-	I
structural	I
proteins	I
,	O
while	O
3C	B
protease	I
(	O
3Cpro	B
)	O
catalyzes	O
most	O
of	O
the	O
remaining	O
internal	O
cleavages	O
.	O

It	O
has	O
been	O
shown	O
that	O
both	O
2Apro	B
and	O
3Cpro	B
are	O
cysteine	B
proteases	I
but	O
their	O
overall	O
protein	O
folding	O
is	O
more	O
like	O
trypsin	B
-	I
type	I
serine	I
proteases	I
.	O

Due	O
to	O
their	O
unique	O
protein	O
structure	O
and	O
essential	O
roles	O
in	O
viral	O
replication	O
,	O
2Apro	B
and	O
3Cpro	B
have	O
been	O
viewed	O
as	O
excellent	O
targets	O
for	O
antiviral	O
intervention	O
.	O

In	O
recent	O
years	O
,	O
considerable	O
efforts	O
have	O
been	O
made	O
in	O
the	O
development	O
of	O
antiviral	O
compounds	O
targeting	O
these	O
proteases	B
.	O

This	O
article	O
summarizes	O
the	O
recent	O
approaches	O
in	O
the	O
design	O
of	O
novel	O
2A	B
and	I
3C	I
protease	I
inhibitors	O
as	O
potential	O
antiviral	O
agents	O
for	O
the	O
treatment	O
of	O
picornaviral	O
infections	O
.	O

Developmental	O
regulation	O
and	O
overexpression	O
of	O
the	O
transcription	B
factor	I
AP-2	I
,	O
a	O
potential	O
regulator	O
of	O
the	O
timing	O
of	O
Schwann	O
cell	O
generation	O
.	O

There	O
is	O
now	O
evidence	O
from	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
that	O
the	O
rate	O
of	O
Schwann	O
cell	O
generation	O
is	O
regulated	O
by	O
the	O
balance	O
of	O
two	O
opposing	O
signals	O
,	O
beta	B
neuregulins	I
and	O
endothelins	B
.	O

The	O
beta	B
neuregulins	I
promote	O
the	O
development	O
of	O
precursors	O
to	O
Schwann	O
cells	O
whereas	O
endothelins	B
retard	O
it	O
through	O
an	O
action	O
on	O
endothelin	B
-	I
B	I
receptors	I
.	O

The	O
present	O
work	O
has	O
shown	O
additional	O
controls	O
of	O
this	O
transition	O
,	O
and	O
implicates	O
AP-2	B
transcription	I
factors	I
,	O
in	O
particular	O
AP-2	B
alpha	I
,	O
as	O
negative	O
regulators	O
of	O
Schwann	O
cell	O
generation	O
.	O

We	O
found	O
that	O
both	O
AP-2	B
alpha	I
and	O
AP-2	B
gamma	I
are	O
present	O
in	O
early	O
embryonic	O
nerves	O
,	O
whereas	O
AP-2	B
beta	I
was	O
not	O
.	O

Isoform	O
-	O
specific	O
analysis	O
of	O
AP-2	B
alpha	I
showed	O
that	O
isoform	O
3	O
was	O
most	O
abundant	O
with	O
isoforms	O
1	O
and	O
2	O
present	O
in	O
lesser	O
amounts	O
;	O
isoform	O
4	O
was	O
absent	O
.	O

Maximal	O
AP-2	B
alpha	I
and	O
AP-2	B
gamma	I
mRNA	O
expression	O
occurred	O
at	O
embryonic	O
day	O
(	O
E	O
)	O
12	O
/	O
13	O
in	O
the	O
mouse	O
and	O
at	O
E14	O
/	O
15	O
in	O
the	O
rat	O
,	O
which	O
correlates	O
with	O
the	O
presence	O
of	O
Schwann	O
cell	O
precursors	O
in	O
the	O
nerve	O
.	O

In	O
both	O
rats	O
and	O
in	O
mice	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
downregulation	O
of	O
AP-2	B
alpha	I
mRNA	O
and	O
protein	O
coincided	O
with	O
one	O
of	O
the	O
main	O
steps	O
in	O
Schwann	O
cell	O
development	O
,	O
the	O
precursor	O
-	O
Schwann	O
cell	O
transition	O
.	O

Moreover	O
,	O
Schwann	O
cell	O
generation	O
was	O
delayed	O
if	O
this	O
downregulation	O
was	O
prevented	O
by	O
enforced	O
expression	O
of	O
AP-2	B
alpha	I
in	O
precursors	O
.	O

These	O
studies	O
suggest	O
that	O
AP-2	B
is	O
involved	O
in	O
the	O
control	O
of	O
the	O
timing	O
of	O
Schwann	O
cell	O
development	O
.	O

Characterization	O
of	O
the	O
human	O
beta	B
-	I
glucan	I
receptor	I
and	O
its	O
alternatively	O
spliced	O
isoforms	O
.	O

beta-1,3-d	O
-	O
Glucans	O
are	O
biological	O
response	O
modifiers	O
with	O
potent	O
effects	O
on	O
the	O
immune	O
system	O
.	O

A	O
number	O
of	O
receptors	O
are	O
thought	O
to	O
play	O
a	O
role	O
in	O
mediating	O
these	O
responses	O
,	O
including	O
murine	O
Dectin-1	B
,	O
which	O
we	O
recently	O
identified	O
as	O
a	O
beta	B
-	I
glucan	I
receptor	I
.	O

In	O
this	O
study	O
we	O
describe	O
the	O
characterization	O
of	O
the	O
human	O
homologue	O
of	O
this	O
receptor	O
and	O
show	O
that	O
it	O
is	O
structurally	O
and	O
functionally	O
similar	O
to	O
the	O
mouse	O
receptor	O
.	O

The	O
human	O
beta	B
-	I
glucan	I
receptor	I
is	O
a	O
type	O
II	O
transmembrane	O
receptor	O
with	O
a	O
single	O
extracellular	O
carbohydrate	O
recognition	O
domain	O
and	O
an	O
immunoreceptor	O
tyrosine	O
activation	O
motif	O
in	O
its	O
cytoplasmic	O
tail	O
.	O

The	O
human	O
beta	B
-	I
glucan	I
receptor	I
is	O
widely	O
expressed	O
and	O
functions	O
as	O
a	O
pattern	O
recognition	O
receptor	O
,	O
recognizing	O
a	O
variety	O
of	O
beta-1,3-	O
and/or	O
beta-1	O
,	O
6	O
-	O
linked	O
glucans	O
as	O
well	O
as	O
intact	O
yeast	O
.	O

In	O
contrast	O
to	O
the	O
murine	O
receptor	O
,	O
the	O
human	O
receptor	O
mRNA	O
is	O
alternatively	O
spliced	O
,	O
resulting	O
in	O
two	O
major	O
(	O
A	O
and	O
B	O
)	O
and	O
six	O
minor	O
isoforms	O
.	O

The	O
two	O
major	O
isoforms	O
differ	O
by	O
the	O
presence	O
of	O
a	O
stalk	O
region	O
separating	O
the	O
carbohydrate	O
recognition	O
domain	O
from	O
the	O
transmembrane	O
region	O
and	O
are	O
the	O
only	O
isoforms	O
that	O
are	O
functional	O
for	O
beta	O
-	O
glucan	O
binding	O
.	O

The	O
human	O
receptor	O
also	O
binds	O
T	O
-	O
lymphocytes	O
at	O
a	O
site	O
distinct	O
from	O
the	O
beta	O
-	O
glucan	O
binding	O
site	O
,	O
indicating	O
that	O
this	O
receptor	O
can	O
recognize	O
both	O
endogenous	O
and	O
exogenous	O
ligands	O
.	O

Mutations	O
in	O
the	O
human	O
orthologue	O
of	O
the	O
mouse	O
underwhite	B
gene	O
(	O
uw	B
)	O
underlie	O
a	O
new	O
form	O
of	O
oculocutaneous	O
albinism	O
,	O
OCA4	O
.	O

Oculocutaneous	O
albinism	O
(	O
OCA	O
)	O
affects	O
approximately	O
1	O
/	O
20,000	O
people	O
worldwide	O
.	O

All	O
forms	O
of	O
OCA	O
exhibit	O
generalized	O
hypopigmentation	O
.	O

Reduced	O
pigmentation	O
during	O
eye	O
development	O
results	O
in	O
misrouting	O
of	O
the	O
optic	O
nerves	O
,	O
nystagmus	O
,	O
alternating	O
strabismus	O
,	O
and	O
reduced	O
visual	O
acuity	O
.	O

Loss	O
of	O
pigmentation	O
in	O
the	O
skin	O
leads	O
to	O
an	O
increased	O
risk	O
for	O
skin	O
cancer	O
.	O

Two	O
common	O
forms	O
and	O
one	O
infrequent	O
form	O
of	O
OCA	O
have	O
been	O
described	O
.	O

OCA1	O
(	O
MIM	O
203100	O
)	O
is	O
associated	O
with	O
mutations	O
of	O
the	O
TYR	B
gene	O
encoding	O
tyrosinase	B
(	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
production	O
of	O
melanin	O
pigment	O
)	O
and	O
accounts	O
for	O
approximately	O
40	O
%	O
of	O
OCA	O
worldwide	O
.	O

OCA2	O
(	O
MIM	O
203200	O
)	O
,	O
the	O
most	O
common	O
form	O
of	O
OCA	O
,	O
is	O
associated	O
with	O
mutations	O
of	O
the	O
P	B
gene	O
and	O
accounts	O
for	O
approximately	O
50	O
%	O
of	O
OCA	O
worldwide	O
.	O

OCA3	O
(	O
MIM	O
203290	O
)	O
,	O
a	O
rare	O
form	O
of	O
OCA	O
and	O
also	O
known	O
as	O
""""	O
rufous	O
/	O
red	O
albinism	O
,	O
""""	O
is	O
associated	O
with	O
mutations	O
in	O
TYRP1	B
(	O
encoding	O
tyrosinase	B
-	I
related	I
protein	I
1	I
)	O
.	O

Analysis	O
of	O
the	O
TYR	B
and	O
P	B
genes	O
in	O
patients	O
with	O
OCA	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
associated	O
with	O
OCA	O
.	O

We	O
have	O
identified	O
the	O
mouse	O
underwhite	B
gene	O
(	O
uw	B
)	O
and	O
its	O
human	O
orthologue	O
,	O
which	O
underlies	O
a	O
new	O
form	O
of	O
human	O
OCA	O
,	O
termed	O
""""	O
OCA4	O
.	O
""""	O

The	O
encoded	O
protein	O
,	O
MATP	B
(	O
for	O
""""	O
membrane	B
-	I
associated	I
transporter	I
protein	I
""""	O
)	O
is	O
predicted	O
to	O
span	O
the	O
membrane	O
12	O
times	O
and	O
likely	O
functions	O
as	O
a	O
transporter	O
.	O

Immune	O
responsiveness	O
following	O
academic	O
stress	O
in	O
first	O
-	O
year	O
medical	O
students	O
.	O

Many	O
studies	O
illustrate	O
that	O
physical	O
or	O
psychologic	O
stressors	O
can	O
alter	O
human	O
immune	O
function	O
,	O
which	O
might	O
predispose	O
one	O
to	O
an	O
increased	O
susceptibility	O
to	O
infections	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
immune	O
responsiveness	O
in	O
16	O
first	O
-	O
year	O
medical	O
students	O
(	O
age	O
23.8	O
+	O
/-	O
2.2	O
years	O
)	O
during	O
the	O
first	O
examination	O
session	O
.	O

Baseline	O
blood	O
samples	O
were	O
collected	O
30	O
days	O
prior	O
to	O
the	O
first	O
examination	O
session	O
.	O

Subsequently	O
,	O
subjects	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
,	O
and	O
blood	O
samples	O
were	O
collected	O
at	O
24	O
h	O
(	O
POST24h	O
)	O
or	O
48	O
h	O
(	O
POST48h	O
)	O
after	O
an	O
examination	O
.	O

The	O
percentage	O
of	O
CD3	B
(	O
+	O
)	O
,	O
CD3	B
(	O
+	O
)	O
CD4	B
(	O
+	O
)	O
,	O
CD3	B
(	O
+	O
)	O
CD8	B
(	O
+	O
)	O
,	O
CD3	B
(	O
+	O
)	O
CD45RO	B
(	O
+	O
)	O
,	O
CD3	B
(	O
+	O
)	O
CD45RA	B
(	O
+	O
)	O
,	O
CD3	B
(	O
-	O
)	O
CD16	B
(	O
+	O
)	O
56	O
(	O
+	O
)	O
,	O
CD19	B
(	O
+	O
)	O
,	O
and	O
CD14	B
(	O
+	O
)	O
cells	O
in	O
whole	O
blood	O
was	O
examined	O
to	O
determine	O
changes	O
in	O
circulating	O
immune	O
cell	O
populations	O
.	O

Activation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
with	O
a	O
mixture	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
ionomycin	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
for	O
4	O
h	O
was	O
used	O
to	O
assess	O
the	O
distribution	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
-	O
secreting	O
or	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
-	O
secreting	O
CD4	B
(	O
+	O
)	O
and	O
CD8	B
(	O
+	O
)	O
cells	O
,	O
as	O
well	O
as	O
IL-1alpha	B
-	O
secreting	O
CD14	B
(	O
+	O
)	O
cells	O
.	O

Activation	O
with	O
a	O
combination	O
of	O
phytohemagglutinin	O
(	O
PHA	O
)	O
and	O
LPS	O
was	O
used	O
to	O
assess	O
secretion	O
of	O
IL-2	B
,	O
IFN	B
-	I
gamma	I
,	O
IL-4	B
,	O
IL-10	B
,	O
soluble	O
IL-2	B
receptor	I
-	I
alpha	I
(	O
sIL-2Ralpha	B
)	O
,	O
IL-1beta	B
,	O
and	O
IL-1R	B
antagonist	I
(	O
IL-1Ra	B
)	O
by	O
PBMC	O
in	O
48	O
-	O
h	O
cell	O
culture	O
.	O

A	O
significantly	O
higher	O
level	O
of	O
total	O
T	O
cells	O
was	O
found	O
at	O
POST24h	O
,	O
and	O
CD14	B
(	O
+	O
)	O
was	O
elevated	O
at	O
both	O
POST24h	O
and	O
POST48h	O
.	O

The	O
percentage	O
of	O
CD4	B
(	O
+	O
)	O
and	O
CD8	B
(	O
+	O
)	O
cells	O
significantly	O
declined	O
at	O
POST24	O
and	O
POST48h	O
.	O

A	O
significant	O
elevation	O
in	O
the	O
percentage	O
of	O
memory	O
T	O
cells	O
was	O
observed	O
at	O
POST48h	O
,	O
whereas	O
the	O
percentage	O
of	O
naive	O
T	O
cells	O
was	O
elevated	O
at	O
POST24h	O
and	O
POST48h	O
.	O

These	O
changes	O
were	O
accompanied	O
by	O
a	O
significant	O
decline	O
in	O
percentage	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
24	O
h	O
after	O
the	O
examination	O
.	O

The	O
percentage	O
of	O
IL-2	B
-	O
producing	O
CD4	B
(	O
+	O
)	O
and	O
CD8	B
(	O
+	O
)	O
cells	O
was	O
significantly	O
lower	O
at	O
POST24h	O
,	O
and	O
the	O
percentage	O
of	O
CD8	B
(	O
+	O
)	O
IFN	B
-	I
gamma	I
(	O
+	O
)	O
cells	O
significantly	O
declined	O
at	O
POST48h	O
.	O

The	O
percentage	O
of	O
CD14	B
(	O
+	O
)	O
IL-1alpha	B
(	O
+	O
)	O
significantly	O
declined	O
at	O
both	O
POST24	O
and	O
POST48h	O
.	O

A	O
significant	O
decrease	O
was	O
observed	O
in	O
IL-2	B
secretion	O
24	O
h	O
after	O
the	O
examinations	O
,	O
and	O
the	O
secretion	O
of	O
IL-4	B
and	O
IL-1beta	B
significantly	O
declined	O
at	O
POST48h	O
.	O

No	O
changes	O
in	O
IFN	B
-	I
gamma	I
,	O
IL-10	B
,	O
sIL-2Ralpha	B
,	O
and	O
IL-1Ra	B
secretion	O
were	O
observed	O
.	O

We	O
conclude	O
that	O
the	O
stress	O
outcomes	O
of	O
academic	O
examinations	O
in	O
first	O
-	O
year	O
medical	O
students	O
can	O
significantly	O
alter	O
immune	O
cell	O
distribution	O
and	O
in	O
vitro	O
production	O
and	O
secretion	O
of	O
specific	O
cytokines	B
.	O

Alpha	B
-	I
B	I
crystallin	I
gene	O
(	O
CRYAB	B
)	O
mutation	O
causes	O
dominant	O
congenital	O
posterior	O
polar	O
cataract	O
in	O
humans	O
.	O

Congenital	O
cataracts	O
are	O
an	O
important	O
cause	O
of	O
bilateral	O
visual	O
impairment	O
in	O
infants	O
.	O

In	O
a	O
four	O
-	O
generation	O
family	O
of	O
English	O
descent	O
,	O
we	O
mapped	O
dominant	O
congenital	O
posterior	O
polar	O
cataract	O
to	O
chromosome	O
11q22	O
-	O
q22.3	O
.	O

The	O
maximum	O
LOD	O
score	O
,	O
3.92	O
at	O
recombination	O
fraction	O
0	O
,	O
was	O
obtained	O
for	O
marker	O
D11S898	O
,	O
near	O
the	O
gene	O
that	O
encodes	O
crystallin	B
alpha	I
-	I
B	I
protein	O
(	O
CRYAB	B
)	O
.	O

By	O
sequencing	O
the	O
coding	O
regions	O
of	O
CRYAB	B
,	O
we	O
found	O
in	O
exon	O
3	O
a	O
deletion	O
mutation	O
,	O
450delA	O
,	O
that	O
is	O
associated	O
with	O
cataract	O
in	O
this	O
family	O
.	O

The	O
mutation	O
resulted	O
in	O
a	O
frameshift	O
in	O
codon	O
150	O
and	O
produced	O
an	O
aberrant	O
protein	O
consisting	O
of	O
184	O
residues	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
mutation	O
,	O
in	O
this	O
gene	O
,	O
resulting	O
in	O
isolated	O
congenital	O
cataract	O
.	O

Cortical	O
dysplasia	O
:	O
electroclinical	O
,	O
imaging	O
,	O
and	O
neuropathologic	O
study	O
of	O
13	O
patients	O
.	O

PURPOSE	O
:	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
correlate	O
the	O
electroclinical	O
and	O
radiologic	O
data	O
with	O
the	O
neuropathologic	O
findings	O
and	O
surgical	O
outcome	O
in	O
epileptic	O
patients	O
with	O
epilepsy	O
and	O
Taylor	O
's	O
focal	O
cortical	O
dysplasia	O
(	O
TFCD	O
)	O
and	O
to	O
characterize	O
further	O
the	O
abnormal	O
intermediate	O
filaments	O
expression	O
in	O
the	O
balloon	O
cell	O
present	O
in	O
the	O
peculiar	O
dysplasia	O
.	O

METHODS	O
:	O

We	O
retrospectively	O
selected	O
13	O
TFCD	O
patients	O
who	O
underwent	O
surgery	O
for	O
intractable	O
epilepsy	O
with	O
the	O
aim	O
of	O
removing	O
the	O
magnetic	O
resonance	O
(	O
MR	O
)	O
-	O
detectable	O
lesion	O
and/or	O
the	O
epileptogenic	O
zone	O
defined	O
by	O
stereoelectroencephalographic	O
recordings	O
.	O

The	O
surgical	O
specimens	O
were	O
analyzed	O
by	O
means	O
of	O
routine	O
neuropathologic	O
and	O
immunocytochemical	O
studies	O
.	O

Antisera	O
against	O
different	O
intermediate	O
filaments	O
also	O
were	O
used	O
in	O
serial	O
adjacent	O
sections	O
to	O
evaluate	O
their	O
coexpression	O
in	O
balloon	O
cells	O
.	O

RESULTS	O
:	O

Histopathologic	O
abnormalities	O
typical	O
of	O
TFCD	O
were	O
found	O
not	O
only	O
within	O
the	O
MR	O
-	O
visible	O
lesions	O
but	O
also	O
in	O
most	O
of	O
the	O
epileptogenic	O
zones	O
with	O
no	O
MR	O
signal	O
alterations	O
.	O

Furthermore	O
,	O
the	O
MR	O
-	O
visible	O
lesions	O
contained	O
a	O
high	O
proportion	O
of	O
cells	O
with	O
an	O
abnormal	O
expression	O
of	O
intermediate	O
filament	O
proteins	O
.	O

After	O
a	O
long	O
follow	O
-	O
up	O
,	O
10	O
of	O
the	O
patients	O
are	O
now	O
seizure	O
free	O
.	O

CONCLUSIONS	O
:	O

Our	O
findings	O
indicate	O
that	O
highly	O
epileptogenic	O
zones	O
may	O
correspond	O
to	O
tissue	O
alterations	O
not	O
revealed	O
by	O
neuroimaging	O
.	O

Furthermore	O
,	O
the	O
immunocytochemical	O
data	O
show	O
that	O
the	O
dysplastic	O
tissue	O
detected	O
by	O
MR	O
contained	O
high	O
concentrations	O
of	O
cells	O
filled	O
with	O
abnormal	O
intermediate	O
filaments	O
.	O

The	O
detected	O
colocalization	O
of	O
neuronal	O
and	O
glial	O
markers	O
in	O
balloon	O
cells	O
indicates	O
a	O
failure	O
of	O
cellular	O
commitment	O
during	O
development	O
.	O

Effect	O
of	O
bilateral	O
subthalamic	O
electrical	O
stimulation	O
in	O
Parkinson	O
's	O
disease	O
.	O

BACKGROUND	O
:	O

Bilateral	O
high	O
frequency	O
subthalamic	O
stimulation	O
has	O
been	O
reported	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
and	O
levodopa	O
-	O
induced	O
dyskinesias	O
.	O

To	O
analyze	O
the	O
results	O
of	O
this	O
surgical	O
procedure	O
we	O
critically	O
reviewed	O
17	O
parkinsonian	O
patients	O
with	O
advanced	O
disease	O
complicated	O
by	O
motor	O
fluctuations	O
and	O
dyskinesias	O
.	O

METHODS	O
:	O

Between	O
January	O
1998	O
and	O
June	O
1999	O
these	O
17	O
consecutive	O
patients	O
(	O
age	O
48	O
-	O
68	O
years	O
;	O
illness	O
duration	O
8	O
-	O
27	O
years	O
)	O
underwent	O
bilateral	O
stereotactically	O
guided	O
implantation	O
of	O
electrodes	O
into	O
the	O
subthalamic	O
nucleus	O
in	O
the	O
Department	O
of	O
Neurosurgery	O
of	O
the	O
Istituto	O
Nazionale	O
Neurologico	O
""""	O
C.	O
Besta	O
.	O
""""	O

Parameters	O
used	O
for	O
continuous	O
high	O
-	O
frequency	O
stimulation	O
were	O
:	O
frequency	O
160	O
Hz	O
,	O
pulse	O
width	O
90	O
microsec	O
,	O
mean	O
amplitude	O
2.05	O
+	O
/-	O
0.45	O
V	O
.	O

Parts	O
II	O
and	O
III	O
of	O
the	O
UPDRS	O
were	O
used	O
to	O
assess	O
motor	O
performance	O
before	O
and	O
after	O
operation	O
by	O
the	O
neurologic	O
team	O
.	O

The	O
follow	O
-	O
up	O
ranged	O
between	O
6	O
and	O
18	O
months	O
.	O

RESULTS	O
:	O

At	O
latest	O
examination	O
,	O
mean	O
UPDRS	O
II	O
and	O
III	O
scores	O
had	O
improved	O
by	O
30	O
%	O
(	O
on	O
stimulation	O
,	O
off	O
therapy	O
)	O
with	O
mean	O
50	O
%	O
reduction	O
in	O
daily	O
off	O
time	O
.	O

Peak	O
dyskinesias	O
and	O
early	O
morning	O
dystonias	O
also	O
improved	O
in	O
relation	O
to	O
therapy	O
reduction	O
.	O

Side	O
effects	O
were	O
persistent	O
postoperative	O
supranuclear	O
oculomotor	O
palsy	O
and	O
postural	O
instability	O
in	O
one	O
case	O
,	O
worsened	O
off	O
-	O
medication	O
hypophonia	O
in	O
three	O
,	O
and	O
temporary	O
nocturnal	O
confusion	O
episodes	O
in	O
three	O
.	O

Postoperative	O
MRI	O
revealed	O
a	O
clinically	O
silent	O
intracerebral	O
haematoma	O
in	O
one	O
case	O
.	O

One	O
electrode	O
required	O
repositioning	O
.	O

CONCLUSIONS	O
:	O

Continuous	O
high	O
frequency	O
STN	O
stimulation	O
is	O
an	O
effective	O
treatment	O
for	O
advanced	O
PD	O
.	O

A	O
functionally	O
useful	O
and	O
safe	O
electrode	O
placement	O
can	O
be	O
performed	O
without	O
microrecording	O
.	O

Dietary	O
adipic	O
acid	O
reduces	O
ammonia	O
emission	O
from	O
swine	O
excreta	O
.	O

Adipic	O
acid	O
is	O
only	O
partially	O
catabolized	O
when	O
it	O
is	O
fed	O
to	O
animals	O
,	O
and	O
a	O
portion	O
of	O
it	O
is	O
excreted	O
in	O
urine	O
.	O

The	O
excreted	O
portion	O
may	O
lower	O
urinary	O
pH	O
and	O
,	O
as	O
a	O
result	O
,	O
ammonia	O
emission	O
.	O

The	O
present	O
study	O
tested	O
this	O
hypothesis	O
.	O

In	O
Exp	O
.	O
1	O
,	O
nursery	O
pigs	O
(	O
n	O
=	O
14	O
)	O
were	O
fed	O
(	O
for	O
a	O
period	O
of	O
7	O
d	O
)	O
either	O
a	O
standard	O
nursery	O
diet	O
or	O
the	O
same	O
diet	O
supplemented	O
with	O
1	O
%	O
adipic	O
acid	O
to	O
assess	O
effects	O
on	O
urinary	O
pH	O
(	O
collected	O
on	O
d	O
5	O
or	O
6	O
)	O
and	O
in	O
vitro	O
ammonia	O
emission	O
from	O
the	O
collected	O
urine	O
samples	O
that	O
were	O
mixed	O
with	O
control	O
feces	O
.	O

In	O
Exp	O
.	O
2	O
,	O
grower	O
pigs	O
housed	O
10	O
each	O
in	O
one	O
of	O
two	O
chambers	O
were	O
fed	O
a	O
control	O
diet	O
or	O
the	O
same	O
diet	O
supplemented	O
with	O
1	O
%	O
adipic	O
acid	O
.	O

Ventilated	O
air	O
was	O
quantified	O
and	O
analyzed	O
for	O
ammonia	O
using	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
to	O
determine	O
the	O
effects	O
of	O
feeding	O
1	O
%	O
adipic	O
acid	O
on	O
ammonia	O
emission	O
.	O

The	O
results	O
from	O
Exp	O
.	O

1	O
showed	O
that	O
adipic	O
acid	O
strongly	O
reduced	O
urinary	O
pH	O
(	O
from	O
7.7	O
to	O
5.5	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
vitro	O
ammonia	O
emission	O
from	O
these	O
urine	O
samples	O
was	O
significantly	O
reduced	O
at	O
all	O
the	O
time	O
points	O
evaluated	O
(	O
1	O
,	O
3	O
,	O
18	O
,	O
and	O
46	O
h	O
with	O
reductions	O
of	O
94	O
,	O
93	O
,	O
70	O
,	O
and	O
39	O
%	O
,	O
respectively	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Experiment	O
2	O
showed	O
that	O
adipic	O
acid	O
supplementation	O
reduced	O
ammonia	O
emission	O
by	O
25	O
%	O
(	O
P	O
<	O
0.05	O
)	O
,	O
which	O
corresponded	O
to	O
the	O
predicted	O
reduction	O
in	O
ammonia	O
emission	O
based	O
on	O
the	O
reduction	O
in	O
manure	O
pH	O
observed	O
.	O

In	O
conclusion	O
,	O
feeding	O
adipic	O
acid	O
lowers	O
urinary	O
pH	O
and	O
reduces	O
ammonia	O
emission	O
.	O

The	O
reduction	O
in	O
ammonia	O
emission	O
,	O
though	O
,	O
does	O
not	O
correspond	O
to	O
the	O
reduction	O
in	O
urinary	O
pH	O
but	O
corresponds	O
to	O
the	O
reduction	O
in	O
fecal	O
pH	O
as	O
a	O
result	O
of	O
mixing	O
the	O
urine	O
and	O
feces	O
,	O
in	O
which	O
feces	O
act	O
as	O
a	O
strong	O
buffer	O
.	O

Identification	O
of	O
hTAF	B
(	I
II	I
)	I
80	I
delta	O
links	O
apoptotic	O
signaling	O
pathways	O
to	O
transcription	B
factor	I
TFIID	B
function	O
.	O

Apoptotic	O
cell	O
death	O
is	O
associated	O
with	O
altered	O
levels	O
of	O
mRNA	O
expression	O
,	O
yet	O
the	O
mechanisms	O
that	O
coordinate	O
changes	O
in	O
gene	O
expression	O
with	O
activation	O
of	O
the	O
cell	O
death	O
machinery	O
remain	O
obscure	O
.	O

Here	O
,	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
hTAF	B
(	I
II	I
)	I
80	I
delta	O
,	O
a	O
specialized	O
isoform	O
of	O
the	O
general	O
transcription	B
factor	I
TFIID	B
subunit	O
hTAF	B
(	I
II	I
)	I
80	I
.	O

Several	O
distinct	O
apoptotic	O
stimuli	O
induce	O
the	O
expression	O
and	O
caspase	O
-	O
dependent	O
cleavage	O
of	O
hTAF	B
(	I
II	I
)	I
80	I
delta	O
.	O

hTAF	B
(	I
II	I
)	I
80	I
delta	O
,	O
unlike	O
hTAF	B
(	I
II	I
)	I
80	I
,	O
forms	O
a	O
TFIID	B
-	O
like	O
complex	O
lacking	O
hTAF	B
(	I
II	I
)	I
31	I
.	O

Elevated	O
expression	O
of	O
hTAF	B
(	I
II	I
)	I
80	I
delta	O
in	O
HeLa	O
cells	O
is	O
sufficient	O
to	O
trigger	O
apoptotic	O
cell	O
death	O
and	O
selectively	O
alters	O
cellular	O
transcription	O
,	O
including	O
the	O
induction	O
of	O
the	O
target	O
genes	O
gadd45	B
and	O
p21	B
.	O

These	O
data	O
define	O
a	O
signaling	O
pathway	O
that	O
couples	O
apoptotic	O
signals	O
to	O
a	O
reprogramming	O
of	O
RNA	B
polymerase	I
II	I
transcription	O
.	O

Direct	O
ligand	O
-	O
receptor	O
complex	O
interaction	O
controls	O
Brassica	O
self	O
-	O
incompatibility	O
.	O

Many	O
higher	O
plants	O
have	O
evolved	O
self	O
-	O
incompatibility	O
mechanisms	O
to	O
prevent	O
self	O
-	O
fertilization	O
.	O

In	O
Brassica	O
self	O
-	O
incompatibility	O
,	O
recognition	O
between	O
pollen	O
and	O
the	O
stigma	O
is	O
controlled	O
by	O
the	O
S	O
locus	O
,	O
which	O
contains	O
three	O
highly	O
polymorphic	O
genes	O
:	O
S	B
-	I
receptor	I
kinase	I
(	O
SRK	B
)	O
,	O
S	B
-	I
locus	I
protein	I
11	I
(	O
SP11	B
)	O
(	O
also	O
called	O
S	B
-	I
locus	I
cysteine	I
-	I
rich	I
protein	I
;	O
SCR	B
)	O
and	O
S	B
-	I
locus	I
glycoprotein	I
(	O
SLG	B
)	O
.	O

SRK	B
encodes	O
a	O
membrane	O
-	O
spanning	O
serine	B
/	I
threonine	I
kinase	I
that	O
determines	O
the	O
S	O
-	O
haplotype	O
specificity	O
of	O
the	O
stigma	O
,	O
and	O
SP11	B
encodes	O
a	O
small	O
cysteine	O
-	O
rich	O
protein	O
that	O
determines	O
the	O
S	O
-	O
haplotype	O
specificity	O
of	O
pollen	O
.	O

SP11	B
is	O
localized	O
in	O
the	O
pollen	O
coat	O
.	O

It	O
is	O
thought	O
that	O
,	O
during	O
self	O
-	O
pollination	O
,	O
SP11	B
is	O
secreted	O
from	O
the	O
pollen	O
coat	O
and	O
interacts	O
with	O
its	O
cognate	O
SRK	B
in	O
the	O
papilla	O
cell	O
of	O
the	O
stigma	O
to	O
elicit	O
the	O
self	O
-	O
incompatibility	O
response	O
.	O

SLG	B
is	O
a	O
secreted	O
stigma	O
protein	O
that	O
is	O
highly	O
homologous	O
to	O
the	O
SRK	B
extracellular	O
domain	O
.	O

Although	O
it	O
is	O
not	O
required	O
for	O
S	O
-	O
haplotype	O
specificity	O
of	O
the	O
stigma	O
,	O
SLG	B
enhances	O
the	O
self	O
-	O
incompatibility	O
response	O
;	O
however	O
,	O
how	O
this	O
is	O
accomplished	O
remains	O
controversial	O
.	O

Here	O
we	O
show	O
that	O
a	O
single	O
form	O
of	O
SP11	B
of	O
the	O
S8	O
haplotype	O
(	O
S8	O
-	O
SP11	B
)	O
stabilized	O
with	O
four	O
intramolecular	O
disulphide	O
bonds	O
specifically	O
binds	O
the	O
stigma	O
membrane	O
of	O
the	O
S8	O
haplotype	O
to	O
induce	O
autophosphorylation	O
of	O
SRK8	B
,	O
and	O
that	O
SRK8	B
and	O
SLG8	B
together	O
form	O
a	O
high	O
-	O
affinity	O
receptor	O
complex	O
for	O
S8	O
-	O
SP11	B
on	O
the	O
stigma	O
membrane	O
.	O

Hermansky	O
-	O
Pudlak	O
syndrome	O
type	O
3	O
in	O
Ashkenazi	O
Jews	O
and	O
other	O
non	O
-	O
Puerto	O
Rican	O
patients	O
with	O
hypopigmentation	O
and	O
platelet	O
storage	O
-	O
pool	O
deficiency	O
.	O

Hermansky	O
-	O
Pudlak	O
syndrome	O
(	O
HPS	O
)	O
,	O
consisting	O
of	O
oculocutaneous	O
albinism	O
and	O
a	O
bleeding	O
diathesis	O
due	O
to	O
the	O
absence	O
of	O
platelet	O
dense	O
granules	O
,	O
displays	O
extensive	O
locus	O
heterogeneity	O
.	O

HPS1	B
mutations	O
cause	O
HPS-1	O
disease	O
,	O
and	O
ADTB3A	O
mutations	O
cause	O
HPS-2	O
disease	O
,	O
which	O
is	O
known	O
to	O
involve	O
abnormal	O
intracellular	O
vesicle	O
formation	O
.	O

A	O
third	O
HPS	O
-	O
causing	O
gene	O
,	O
HPS3	B
,	O
was	O
recently	O
identified	O
on	O
the	O
basis	O
of	O
homozygosity	O
mapping	O
of	O
a	O
genetic	O
isolate	O
of	O
HPS	O
in	O
central	O
Puerto	O
Rico	O
.	O

We	O
now	O
describe	O
the	O
clinical	O
and	O
molecular	O
characteristics	O
of	O
eight	O
patients	O
with	O
HPS-3	O
who	O
are	O
of	O
non	O
-	O
Puerto	O
Rican	O
heritage	O
.	O

Five	O
are	O
Ashkenazi	O
Jews	O
;	O
three	O
of	O
these	O
are	O
homozygous	O
for	O
a	O
1303	O
+	O
1	O
G	O
--	O
>	O
A	O
splice	O
-	O
site	O
mutation	O
that	O
causes	O
skipping	O
of	O
exon	O
5	O
,	O
deleting	O
an	O
RsaI	B
restriction	O
site	O
and	O
decreasing	O
the	O
amounts	O
of	O
mRNA	O
found	O
on	O
northern	O
blotting	O
.	O

The	O
other	O
two	O
are	O
heterozygous	O
for	O
the	O
1303	O
+	O
1	O
G	O
--	O
>	O
A	O
mutation	O
and	O
for	O
either	O
an	O
1831	O
+	O
2	O
T	O
--	O
>	O
G	O
or	O
a	O
2621	O
-2A	O
--	O
>	O
G	O
splicing	O
mutation	O
.	O

Of	O
235	O
anonymous	O
Ashkenazi	O
Jewish	O
DNA	O
samples	O
,	O
one	O
was	O
heterozygous	O
for	O
the	O
1303	O
+	O
1	O
G	O
--	O
>	O
A	O
mutation	O
.	O

One	O
seven	O
-	O
year	O
-	O
old	O
boy	O
of	O
German	O
/	O
Swiss	O
extraction	O
was	O
compound	O
heterozygous	O
for	O
a	O
2729	O
+	O
1	O
G	O
--	O
>	O
C	O
mutation	O
,	O
causing	O
skipping	O
of	O
exon	O
14	O
,	O
and	O
resulting	O
in	O
a	O
C1329	O
T	O
missense	O
(	O
R396W	O
)	O
,	O
with	O
decreased	O
mRNA	O
production	O
.	O

A	O
15	O
-	O
year	O
-	O
old	O
Irish	O
/	O
English	O
boy	O
was	O
heterozygous	O
for	O
an	O
89	O
-	O
bp	O
insertion	O
between	O
exons	O
16	O
and	O
17	O
resulting	O
from	O
abnormal	O
splicing	O
;	O
his	O
fibroblast	O
HPS3	B
mRNA	O
is	O
normal	O
in	O
amount	O
but	O
is	O
increased	O
in	O
size	O
.	O

A	O
12	O
-	O
year	O
-	O
old	O
girl	O
of	O
Puerto	O
Rican	O
and	O
Italian	O
background	O
has	O
the	O
3,904-bp	O
founder	O
deletion	O
from	O
central	O
Puerto	O
Rico	O
on	O
one	O
allele	O
.	O

All	O
eight	O
patients	O
have	O
mild	O
symptoms	O
of	O
HPS	O
;	O
two	O
Jewish	O
patients	O
had	O
received	O
the	O
diagnosis	O
of	O
ocular	O
,	O
rather	O
than	O
oculocutaneous	O
,	O
albinism	O
.	O

These	O
findings	O
expand	O
the	O
molecular	O
diagnosis	O
of	O
HPS	O
,	O
provide	O
a	O
screening	O
method	O
for	O
a	O
mutation	O
common	O
among	O
Jews	O
,	O
and	O
suggest	O
that	O
other	O
patients	O
with	O
mild	O
hypopigmentation	O
and	O
decreased	O
vision	O
should	O
be	O
examined	O
for	O
HPS	O
.	O

Effect	O
of	O
orally	O
administered	O
cimetidine	O
and	O
ranitidine	O
on	O
abomasal	O
luminal	O
pH	O
in	O
clinically	O
normal	O
milk	O
-	O
fed	O
calves	O
.	O

OBJECTIVE	O
:	O

To	O
characterize	O
the	O
change	O
of	O
pH	O
in	O
the	O
abomasal	O
lumen	O
throughout	O
a	O
24	O
-	O
hour	O
period	O
,	O
to	O
determine	O
whether	O
pH	O
of	O
the	O
abomasal	O
body	O
differs	O
from	O
pH	O
of	O
the	O
pyloric	O
antrum	O
,	O
and	O
to	O
determine	O
whether	O
oral	O
administration	O
of	O
cimetidine	O
and	O
ranitidine	O
alters	O
pH	O
of	O
the	O
abomasal	O
lumen	O
in	O
milk	O
-	O
fed	O
calves	O
.	O

ANIMALS	O
:	O

5	O
male	O
dairy	O
calves	O
(	O
4	O
Holsteins	O
-	O
Friesian	O
,	O
1	O
Ayrshire	O
)	O
,	O
5	O
to	O
15	O
days	O
old	O
.	O

PROCEDURE	O
:	O

Cannulas	O
were	O
surgically	O
positioned	O
in	O
the	O
abomasal	O
body	O
and	O
pyloric	O
antrum	O
of	O
each	O
calf	O
.	O

Calves	O
received	O
the	O
following	O
treatments	O
in	O
a	O
randomized	O
crossover	O
design	O
:	O
milk	O
replacer	O
(	O
60	O
ml	O
/	O
kg	O
of	O
body	O
weight	O
,	O
q	O
12	O
h	O
[	O
untreated	O
control	O
calves	O
]	O
)	O
,	O
milk	O
replacer	O
and	O
cimetidine	O
(	O
50	O
or	O
100	O
mg	O
/	O
kg	O
,	O
q	O
8	O
h	O
)	O
,	O
or	O
milk	O
replacer	O
and	O
ranitidine	O
(	O
10	O
or	O
50	O
mg	O
/	O
kg	O
,	O
q	O
8	O
h	O
)	O
.	O

The	O
pH	O
of	O
the	O
abomasal	O
body	O
and	O
pyloric	O
antrum	O
was	O
measured	O
for	O
24	O
hours	O
,	O
using	O
miniature	O
glass	O
pH	O
electrodes	O
.	O

RESULTS	O
:	O

Suckling	O
of	O
milk	O
replacer	O
immediately	O
increased	O
abomasal	O
luminal	O
pH	O
from	O
1.4	O
to	O
6.0	O
,	O
followed	O
by	O
a	O
gradual	O
decrease	O
to	O
preprandial	O
values	O
by	O
6	O
hours	O
.	O

Preprandial	O
and	O
postprandial	O
pH	O
values	O
were	O
not	O
significantly	O
different	O
between	O
the	O
abomasal	O
body	O
and	O
pyloric	O
antrum	O
,	O
indicating	O
lack	O
of	O
pH	O
compartmentalization	O
in	O
the	O
abomasum	O
of	O
milk	O
-	O
fed	O
calves	O
.	O

Administration	O
of	O
cimetidine	O
and	O
ranitidine	O
caused	O
a	O
significant	O
dose	O
-	O
dependent	O
increase	O
in	O
mean	O
24-hour	O
abomasal	O
luminal	O
pH	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O

Abomasal	O
acid	O
secretion	O
in	O
milk	O
-	O
fed	O
calves	O
is	O
mediated	O
in	O
part	O
by	O
histamine	B
type-2	I
receptors	I
.	O

Cimetidine	O
and	O
ranitidine	O
may	O
be	O
efficacious	O
in	O
the	O
treatment	O
of	O
abomasal	O
ulcers	O
in	O
milk	O
-	O
fed	O
calves	O
.	O

Evaluation	O
of	O
glaucomatous	O
visual	O
field	O
loss	O
with	O
locally	O
condensed	O
grids	O
using	O
fundus	O
-	O
oriented	O
perimetry	O
(	O
FOP	O
)	O
.	O

PURPOSE	O
:	O

We	O
compared	O
detection	O
rates	O
of	O
glaucomatous	O
visual	O
field	O
defects	O
(	O
VFDs	O
)	O
between	O
a	O
conventional	O
rectangular	O
stimulus	O
grid	O
and	O
locally	O
condensed	O
test	O
point	O
arrangements	O
in	O
morphologically	O
suspicious	O
regions	O
.	O

METHODS	O
:	O

Humphrey	O
Field	O
Analyzer	O
model	O
630	O
(	O
HFA	O
I	O
,	O
program	O
30	O
-	O
2	O
with	O
a	O
rectangular	O
6	O
degrees	O
x	O
6	O
degrees	O
grid	O
)	O
was	O
used	O
as	O
the	O
conventional	O
perimetric	O
method	O
.	O

Individual	O
local	O
test	O
-	O
point	O
condensation	O
was	O
realized	O
by	O
fundus	O
-	O
oriented	O
perimetry	O
(	O
FOP	O
)	O
on	O
the	O
Tuebingen	O
Computer	O
Campimeter	O
(	O
TCC	O
)	O
.	O

RESULTS	O
:	O

Of	O
a	O
total	O
of	O
66	O
glaucoma	O
patients	O
,	O
or	O
suspected	O
sufferers	O
,	O
23	O
showed	O
normal	O
findings	O
and	O
27	O
showed	O
pathological	O
findings	O
with	O
both	O
methods	O
.	O

In	O
15	O
cases	O
we	O
found	O
normal	O
visual	O
fields	O
in	O
HFA	O
30	O
-	O
2	O
,	O
whereas	O
FOP	O
revealed	O
early	O
glaucomatous	O
functional	O
damage	O
.	O

Only	O
one	O
case	O
showed	O
pathological	O
HFA	O
results	O
,	O
while	O
FOP	O
was	O
normal	O
.	O

Detection	O
rates	O
of	O
VFDs	O
significantly	O
differed	O
between	O
the	O
two	O
methods	O
(	O
p	O
<	O
0.001	O
;	O
sign	O
test	O
)	O
.	O

CONCLUSIONS	O
:	O

FOP	O
,	O
using	O
individually	O
condensed	O
test	O
grids	O
,	O
significantly	O
increases	O
detection	O
rates	O
of	O
glaucomatous	O
VFDs	O
in	O
morphologically	O
suspicuous	O
areas	O
compared	O
with	O
a	O
conventional	O
HFA	O
30	O
-	O
2	O
technique	O
using	O
equidistant	O
rectangular	O
(	O
6	O
degrees	O
x	O
6	O
degrees	O
)	O
test	O
point	O
arrangements	O
.	O

The	O
rat	O
interleukin	B
10	I
receptor	I
:	O
cloning	O
and	O
sequencing	O
of	O
cDNA	O
coding	O
for	O
the	O
alpha	O
-	O
chain	O
protein	O
sequence	O
,	O
and	O
demonstration	O
by	O
western	O
blotting	O
of	O
expression	O
in	O
the	O
rat	O
brain	O
.	O

cDNA	O
coding	O
for	O
the	O
alpha	B
chain	I
of	I
the	I
rat	I
interleukin	I
10	I
(	I
IL-10	I
)	I
receptor	I
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
cloned	O
and	O
sequenced	O
.	O

The	O
nucleic	O
acid	O
coding	O
sequence	O
exhibited	O
88	O
%	O
and	O
68	O
%	O
homology	O
with	O
the	O
mouse	O
and	O
human	O
IL-10	B
receptor	I
sequences	O
,	O
respectively	O
.	O

The	O
translated	O
protein	O
exhibited	O
83	O
%	O
and	O
61	O
%	O
homology	O
with	O
the	O
mouse	O
and	O
human	O
IL-10	B
receptor	I
proteins	O
.	O

Specific	O
antibodies	O
were	O
raised	O
to	O
the	O
extracellular	O
domain	O
of	O
the	O
rat	O
IL-10	B
receptor	I
expressed	O
as	O
a	O
secreted	O
protein	O
in	O
recombinant	O
Drosophila	O
S2	O
cells	O
.	O

Western	O
blotting	O
using	O
these	O
antibodies	O
demonstrated	O
the	O
presence	O
of	O
the	O
IL-10	B
receptor	I
in	O
five	O
major	O
regions	O
of	O
the	O
rat	O
brain	O
(	O
cortex	O
,	O
cerebellum	O
,	O
hippocampus	O
,	O
hypothalamus	O
and	O
pituitary	O
)	O
,	O
supporting	O
a	O
role	O
for	O
IL-10	B
as	O
a	O
central	O
regulator	O
of	O
inflammation	O
.	O

A20	B
inhibits	O
NF	B
-	I
kappa	I
B	I
activation	O
downstream	O
of	O
multiple	O
Map3	B
kinases	I
and	O
interacts	O
with	O
the	O
I	B
kappa	I
B	I
signalosome	O
.	O

A20	B
,	O
a	O
TNF	O
inducible	O
gene	O
,	O
inhibits	O
TNF	B
-	O
mediated	O
apoptosis	O
as	O
well	O
as	O
NF	B
-	I
kappa	I
B	I
induced	O
by	O
this	O
cytokine	B
.	O

Reporter	O
assay	O
experiments	O
revealed	O
that	O
A20	B
is	O
a	O
very	O
effective	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
signaling	O
induced	O
by	O
TRAFs	B
and	O
several	O
Map3	B
kinases	I
,	O
including	O
NIK	B
,	O
MEKK1	B
,	O
COT	B
,	O
and	O
TAK1	B
.	O

Similarly	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
inducing	O
activity	O
of	O
TAX	B
,	O
an	O
activator	O
of	O
the	O
I	B
kappa	I
B	I
kinase	I
complex	I
,	O
is	O
also	O
abrogated	O
by	O
A20	B
.	O

Inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
specific	O
as	O
A20	B
has	O
no	O
effect	O
on	O
TNF	B
-	I
alpha	I
-	O
induced	O
JNK	B
activation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
target	O
of	O
A20	B
is	O
more	O
distal	O
to	O
the	O
receptor	O
than	O
TRAFs	B
as	O
previously	O
proposed	O
.	O

A20	B
inhibits	O
NF	B
-	I
kappa	I
B	I
-	O
dependent	O
transcription	O
without	O
a	O
concomitant	O
decrease	O
in	O
nuclear	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
or	O
nuclear	O
translocation	O
of	O
p65	B
.	O

This	O
apparent	O
discrepancy	O
between	O
transcriptional	O
readout	O
and	O
gel	O
shift	O
experiments	O
is	O
observed	O
with	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
expression	O
of	O
IKK	B
beta	I
.	O

Therefore	O
,	O
in	O
addition	O
to	O
the	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
,	O
another	O
signal	O
is	O
needed	O
for	O
transcriptional	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

A20	B
inhibits	O
this	O
non	O
-	O
redundant	O
signal	O
.	O

The	O
observation	O
that	O
A20	B
associates	O
with	O
IKK	B
alpha	I
and	O
is	O
phosphorylated	O
upon	O
IKK	B
beta	I
co	O
-	O
expression	O
may	O
suggest	O
that	O
A20	B
interferes	O
with	O
some	O
aspects	O
of	O
signalosome	O
function	O
.	O

Genetic	O
factors	O
in	O
the	O
development	O
of	O
gastric	O
precancerous	O
lesions	O
--	O
a	O
role	O
of	O
Helicobacter	O
pylori	O
?	O

Helicobacter	O
pylori	O
is	O
believed	O
to	O
predispose	O
to	O
gastric	O
cancer	O
by	O
inducing	O
gastric	O
precancerous	O
alterations	O
.	O

There	O
is	O
a	O
well	O
known	O
predisposition	O
to	O
gastric	O
cancer	O
and	O
the	O
risk	O
of	O
developing	O
it	O
is	O
greater	O
in	O
relatives	O
of	O
patients	O
with	O
familial	O
cases	O
of	O
this	O
malignancy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
gastric	O
precancerous	O
lesions	O
(	O
atrophy	O
and	O
intestinal	O
metaplasia	O
)	O
and	O
their	O
association	O
with	O
Hp	O
infection	O
in	O
first	O
-	O
degree	O
relatives	O
in	O
patients	O
with	O
noncardia	O
gastric	O
cancer	O
.	O

METHODS	O
:	O

Hp	O
status	O
and	O
gastric	O
histology	O
assessed	O
by	O
upper	O
gastrointestinal	O
endoscopy	O
,	O
biopsies	O
from	O
the	O
antral	O
and	O
body	O
region	O
,	O
the	O
rapid	O
urease	O
test	O
and	O
staining	O
for	O
Hp	O
,	O
inflammation	O
,	O
activity	O
,	O
atrophy	O
and	O
intestinal	O
metaplasia	O
(	O
prevalence	O
and	O
grading	O
)	O
were	O
studied	O
in	O
108	O
first	O
-	O
degree	O
relatives	O
of	O
patients	O
with	O
noncardia	O
gastric	O
cancer	O
and	O
compared	O
with	O
73	O
controls	O
with	O
mild	O
non	O
-	O
ulcer	O
dyspepsia	O
who	O
had	O
no	O
cancer	O
relatives	O
and	O
were	O
examined	O
in	O
the	O
same	O
way	O
.	O

RESULTS	O
:	O

subjects	O
with	O
and	O
without	O
cancer	O
relatives	O
had	O
a	O
similar	O
prevalence	O
of	O
Hp	O
infection	O
(	O
49	O
vs.	O
47	O
%	O
)	O
.	O

Endoscopy	O
revealed	O
a	O
few	O
asymptomatic	O
duodenal	O
ulcers	O
and	O
small	O
hiatus	O
hernias	O
in	O
Hp	O
positive	O
subjects	O
of	O
both	O
groups	O
.	O

Hp	O
positive	O
relatives	O
of	O
gastric	O
cancer	O
had	O
a	O
markedly	O
higher	O
prevalence	O
of	O
atrophy	O
than	O
those	O
with	O
Hp	O
negativity	O
without	O
cancer	O
relatives	O
(	O
29	O
vs.	O
9	O
%	O
)	O
and	O
those	O
with	O
Hp	O
negativity	O
and	O
cancer	O
relatives	O
(	O
29	O
vs.	O
3	O
%	O
.	O
Prevalence	O
of	O
intestinal	O
metaplasia	O
was	O
also	O
higher	O
in	O
those	O
with	O
Hp	O
positivity	O
and	O
cancer	O
relatives	O
than	O
in	O
those	O
without	O
cancer	O
relatives	O
(	O
15	O
vs.	O
5	O
%	O
and	O
was	O
not	O
present	O
in	O
Hp	O
negative	O
subjects	O
with	O
cancer	O
relatives	O
.	O
Inflammation	O
and	O
activity	O
showed	O
similar	O
scores	O
in	O
subjects	O
with	O
and	O
without	O
cancer	O
relatives	O
with	O
higher	O
scores	O
in	O
both	O
Hp	O
positive	O
groups	O
.	O

The	O
prevalence	O
of	O
precancerous	O
lesions	O
in	O
the	O
relatives	O
of	O
gastric	O
cancer	O
was	O
nearly	O
always	O
confined	O
to	O
those	O
with	O
Hp	O
positivity	O
.	O

One	O
year	O
after	O
eradication	O
the	O
prevalence	O
of	O
atrophy	O
in	O
cancer	O
relatives	O
decreased	O
from	O
29	O
to	O
14	O
%	O
;	O
prevalence	O
of	O
intestinal	O
metaplasia	O
remained	O
without	O
substantial	O
changes	O
.	O

Scores	O
for	O
inflammation	O
and	O
activity	O
were	O
also	O
lower	O
after	O
eradication	O
.	O

CONCLUSIONS	O
:	O

First	O
-	O
degree	O
relatives	O
of	O
patients	O
with	O
gastric	O
cancer	O
have	O
an	O
increased	O
prevalence	O
of	O
gastric	O
precancerous	O
abnormalities	O
which	O
are	O
strongly	O
confined	O
to	O
those	O
with	O
Hp	O
infection	O
.	O

Eradication	O
of	O
Hp	O
in	O
these	O
subjects	O
with	O
cancer	O
relatives	O
reduces	O
the	O
prevalence	O
of	O
precancerous	O
lesions	O
(	O
atrophy	O
)	O
and	O
grades	O
of	O
inflammation	O
and	O
activity	O
.	O

In	O
view	O
of	O
these	O
results	O
,	O
eradication	O
of	O
Hp	O
should	O
be	O
offered	O
to	O
such	O
subjects	O
.	O

Cloning	O
and	O
characterization	O
of	O
Plx2	B
and	O
Plx3	B
,	O
two	O
additional	O
Polo	B
-	I
like	I
kinases	I
from	O
Xenopus	O
laevis	O
.	O

Members	O
of	O
the	O
family	B
of	I
Polo	I
-	I
like	I
kinases	I
are	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
progression	O
in	O
all	O
eukaryotes	O
.	O

In	O
Xenopus	O
laevis	O
,	O
only	O
one	O
member	O
of	O
this	O
family	O
,	O
Plx1	B
,	O
has	O
previously	O
been	O
described	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
X.	O
laevis	O
Plx2	B
and	O
Plx3	B
,	O
the	O
likely	O
homologs	O
of	O
mammalian	O
Plk2	B
(	O
Snk	B
)	O
and	O
Plk3	B
(	O
Fnk	B
/	O
Prk	B
)	O
,	O
respectively	O
.	O

RNA	O
expression	O
studies	O
indicate	O
that	O
all	O
three	O
Xenopus	O
Plks	B
are	O
present	O
in	O
both	O
oocytes	O
and	O
unfertilized	O
eggs	O
.	O

Further	O
analysis	O
by	O
in	O
situ	O
hybridization	O
revealed	O
that	O
Plx1	B
RNA	O
is	O
ubiquitously	O
expressed	O
in	O
early	O
embryos	O
,	O
but	O
shows	O
more	O
restricted	O
expression	O
at	O
later	O
stages	O
.	O

In	O
contrast	O
,	O
Plx2	B
and	O
Plx3	B
expression	O
is	O
highly	O
restricted	O
in	O
both	O
early	O
and	O
late	O
-	O
stage	O
embryos	O
.	O

Using	O
Plx	B
-	O
specific	O
antisera	O
,	O
Plx1	B
and	O
Plx3	B
polypeptides	O
could	O
readily	O
be	O
detected	O
on	O
immunoblots	O
of	O
oocyte	O
and	O
egg	O
extracts	O
.	O

Both	O
Plx1	B
and	O
Plx3	B
protein	O
levels	O
remained	O
virtually	O
constant	O
during	O
oocyte	O
maturation	O
.	O

However	O
,	O
whereas	O
Plx1	B
is	O
more	O
active	O
in	O
M	O
phase	O
than	O
in	O
I	O
phase	O
(	O
P.	O
Descombes	O
and	O
E.	O
A.	O
Nigg	O
(	O
1998	O
)	O
EMBO	O
J.	O
17	O
,	O
1328	O
-	O
1335	O
)	O
,	O
Plx3	B
protein	O
and	O
activity	O
levels	O
remained	O
constant	O
upon	O
release	O
of	O
meiotic	O
metaphase	O
II	O
-	O
arrested	O
egg	O
extracts	O
into	O
interphase	O
.	O

Finally	O
,	O
microinjection	O
of	O
in	O
vitro	O
-	O
transcribed	O
RNAs	O
for	O
Plx1	B
,	O
Plx2	B
,	O
and	O
Plx3	B
increased	O
the	O
rate	O
of	O
progesterone	O
-	O
induced	O
oocyte	O
maturation	O
,	O
and	O
concomitantly	O
,	O
all	O
three	O
kinases	B
became	O
activated	O
.	O

Conversely	O
,	O
overexpression	O
of	O
the	O
corresponding	O
catalytically	O
inactive	O
kinases	B
delayed	O
maturation	O
.	O

This	O
suggests	O
that	O
,	O
at	O
least	O
in	O
oocytes	O
,	O
all	O
three	O
kinases	B
may	O
be	O
regulated	O
by	O
similar	O
mechanisms	O
,	O
and	O
they	O
may	O
also	O
share	O
common	O
substrates	O
.	O

However	O
,	O
the	O
strikingly	O
restricted	O
pattern	O
of	O
expression	O
of	O
Plx2	B
and	O
Plx3	B
observed	O
in	O
embryos	O
strongly	O
suggests	O
that	O
individual	O
Plk	B
family	I
members	O
perform	O
at	O
least	O
partly	O
distinct	O
functions	O
at	O
later	O
stages	O
of	O
development	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
novel	O
cDNA	O
,	O
UBAP1	B
,	O
derived	O
from	O
the	O
tumor	O
suppressor	O
locus	O
in	O
human	O
chromosome	O
9p21	O
-	O
22	O
.	O

PURPOSE	O
:	O

To	O
clone	O
the	O
putative	O
tumor	O
suppressor	O
gene	O
(	O
s	O
)	O
in	O
a	O
refined	O
region	O
at	O
9p21	O
-	O
22	O
undergoing	O
loss	O
of	O
heterozygosity	O
in	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O

METHODS	O
:	O

We	O
systematically	O
screened	O
the	O
expression	O
patterns	O
of	O
25	O
novel	O
ESTs	O
(	O
expressed	O
sequence	O
tags	O
)	O
in	O
a	O
minimal	O
common	O
deleted	O
region	O
of	O
9p21	O
-	O
22	O
in	O
NPC	O
.	O

One	O
of	O
these	O
ESTs	O
was	O
found	O
down	O
-	O
regulated	O
in	O
NPC	O
.	O

Subsequently	O
,	O
the	O
corresponding	O
gene	O
sequence	O
of	O
this	O
EST	O
was	O
established	O
by	O
cDNA	O
cloning	O
and	O
RACE	O
(	O
rapid	O
amplification	O
of	O
cDNA	O
end	O
)	O
procedures	O
.	O

Furthermore	O
,	O
a	O
mouse	O
homologue	O
of	O
this	O
gene	O
was	O
identified	O
.	O

The	O
expression	O
of	O
this	O
gene	O
was	O
examined	O
using	O
Northern	O
blot	O
or	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
various	O
human	O
and	O
mouse	O
tissues	O
.	O

A	O
limited	O
screen	O
for	O
mutation	O
of	O
coding	O
sequence	O
of	O
this	O
novel	O
human	O
gene	O
was	O
undertaken	O
using	O
RT	O
-	O
PCR	O
and	O
direct	O
sequencing	O
analysis	O
.	O

RESULTS	O
:	O

A	O
novel	O
gene	O
was	O
cloned	O
.	O

This	O
gene	O
is	O
a	O
new	O
member	O
of	O
the	O
UBA	O
domain	O
family	O
,	O
so	O
we	O
named	O
it	O
UBAPI	B
for	O
ubiquitin	B
-	I
associated	I
protein	I
1	I
(	O
HUGO	O
Gene	O
Nomenclature	O
Committee	O
-	O
approved	O
symbol	O
)	O
.	O

Northern	O
blot	O
and	O
RT	O
-	O
PCR	O
analysis	O
demonstrate	O
a	O
ubiquitous	O
pattern	O
of	O
gene	O
expression	O
in	O
human	O
and	O
mouse	O
tissues	O
.	O

The	O
direct	O
sequencing	O
analysis	O
of	O
the	O
coding	O
region	O
of	O
hUBAP1	B
following	O
RT	O
-	O
PCR	O
failed	O
to	O
reveal	O
any	O
mutations	O
in	O
a	O
preliminary	O
screen	O
of	O
NPC	O
cell	O
line	O
HNE1	O
and	O
primary	O
nasopharyngeal	O
carcinoma	O
samples	O
.	O

CONCLUSIONS	O
:	O

We	O
cloned	O
a	O
novel	O
gene	O
UBAPI	B
,	O
which	O
is	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

Clearly	O
,	O
as	O
a	O
novel	O
member	O
of	O
UBA	O
domain	O
protein	O
family	O
and	O
taking	O
its	O
map	O
location	O
into	O
account	O
,	O
a	O
more	O
extensive	O
analysis	O
is	O
essential	O
to	O
establish	O
whether	O
subtle	O
mutations	O
are	O
present	O
in	O
nasopharyngeal	O
carcinomas	O
.	O

Sequence	O
analysis	O
of	O
a	O
fish	O
vitellogenin	B
cDNA	O
with	O
a	O
large	O
phosvitin	B
domain	O
.	O

Vitellogenins	B
(	O
Vtg	O
)	O
are	O
egg	O
-	O
yolk	O
precursor	O
proteins	O
crucial	O
for	O
reproductive	O
success	O
in	O
oviparous	O
animals	O
.	O

We	O
have	O
cloned	O
the	O
first	O
complete	O
cichlid	O
Vtg	B
cDNA	O
from	O
the	O
tilapia	O
fish	O
,	O
Oreochromis	O
aureus	O
.	O

This	O
cDNA	O
has	O
the	O
largest	O
phosvitin	B
(	O
PV	B
)	O
domain	O
amongst	O
piscine	O
Vtgs	B
,	O
being	O
comparable	O
to	O
those	O
of	O
lamprey	O
,	O
Xenopus	O
,	O
and	O
chicken	O
.	O

Thus	O
,	O
the	O
size	O
of	O
PV	B
is	O
independent	O
of	O
the	O
evolutionary	O
advancement	O
of	O
a	O
species	O
.	O

The	O
closer	O
interspecific	O
relationship	O
between	O
O.	O
aureus	O
Vtg1	B
and	O
Fundulus	O
VtgII	B
than	O
the	O
intraspecific	O
relationship	O
between	O
Fundulus	O
VtgI	B
and	I
II	I
isoforms	O
suggests	O
that	O
teleost	O
ancestors	O
had	O
at	O
least	O
two	O
Vtg	B
isoforms	O
.	O

Contrary	O
to	O
the	O
results	O
of	O
previous	O
phylogenetic	O
inference	O
using	O
Vtgs	B
which	O
indicate	O
that	O
insect	O
lineage	O
is	O
most	O
diverged	O
and	O
nematodes	O
are	O
closer	O
to	O
vertebrate	O
lineage	O
,	O
our	O
results	O
show	O
that	O
nematodes	O
and	O
hexapods	O
form	O
two	O
monophyletic	O
sister	O
groups	O
.	O

Another	O
arthropod	O
taxon	O
,	O
represented	O
by	O
a	O
malacostracan	O
crustacean	O
,	O
Penaeus	O
japonicus	O
,	O
appears	O
to	O
be	O
more	O
closely	O
related	O
to	O
the	O
vertebrates	O
than	O
the	O
hexapods	O
.	O

NHE6	B
protein	O
possesses	O
a	O
signal	O
peptide	O
destined	O
for	O
endoplasmic	O
reticulum	O
membrane	O
and	O
localizes	O
in	O
secretory	O
organelles	O
of	O
the	O
cell	O
.	O

The	O
NHE6	B
protein	O
is	O
a	O
unique	O
Na	B
(	I
+	I
)	I
/	I
H	I
(	I
+	I
)	I
exchanger	I
isoform	O
believed	O
to	O
localize	O
in	O
mitochondria	O
.	O

It	O
possesses	O
a	O
hydrophilic	O
N	O
-	O
terminal	O
portion	O
that	O
is	O
rich	O
in	O
positively	O
charged	O
residues	O
and	O
many	O
hydrophobic	O
segments	O
.	O

In	O
the	O
present	O
study	O
,	O
signal	O
sequences	O
in	O
the	O
NHE6	B
molecule	O
were	O
examined	O
for	O
organelle	O
localization	O
and	O
membrane	O
topogenesis	O
.	O

When	O
the	O
full	O
-	O
length	O
protein	O
was	O
expressed	O
in	O
COS7	O
cells	O
,	O
it	O
localized	O
in	O
the	O
endoplasmic	O
reticulum	O
and	O
on	O
the	O
cell	O
surface	O
.	O

Furthermore	O
,	O
the	O
protein	O
was	O
fully	O
N	O
-	O
glycosylated	O
.	O

When	O
green	B
fluorescent	I
protein	I
was	O
fused	O
after	O
the	O
second	O
(	O
H2	O
)	O
or	O
third	O
(	O
H3	O
)	O
hydrophobic	O
segment	O
,	O
the	O
fusion	O
proteins	O
were	O
targeted	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
membrane	O
.	O

The	O
localization	O
pattern	O
was	O
the	O
same	O
as	O
that	O
of	O
fusion	O
proteins	O
in	O
which	O
green	B
fluorescent	I
protein	I
was	O
fused	O
after	O
H2	O
of	O
NHE1	B
.	O

In	O
an	O
in	O
vitro	O
system	O
,	O
H1	O
behaved	O
as	O
a	O
signal	O
peptide	O
that	O
directs	O
the	O
translocation	O
of	O
the	O
following	O
polypeptide	O
chain	O
and	O
is	O
then	O
processed	O
off	O
.	O

The	O
next	O
hydrophobic	O
segment	O
(	O
H2	O
)	O
halted	O
translocation	O
and	O
eventually	O
became	O
a	O
transmembrane	O
segment	O
.	O

The	O
N	O
-	O
terminal	O
hydrophobic	O
segment	O
(	O
H1	O
)	O
of	O
NHE1	B
also	O
behaved	O
as	O
a	O
signal	O
peptide	O
.	O

Cell	O
fractionation	O
studies	O
using	O
antibodies	O
against	O
the	O
15	O
C	O
-	O
terminal	O
residues	O
indicated	O
that	O
NHE6	B
protein	O
localized	O
in	O
the	O
microsomal	O
membranes	O
of	O
rat	O
liver	O
cells	O
.	O

All	O
of	O
the	O
NHE6	B
molecules	O
in	O
liver	O
tissue	O
possess	O
an	O
endoglycosidase	B
H	I
-	O
resistant	O
sugar	O
chain	O
.	O

These	O
findings	O
indicate	O
that	O
NHE6	B
protein	O
is	O
targeted	O
to	O
the	O
ER	O
membrane	O
via	O
the	O
N	O
-	O
terminal	O
signal	O
peptide	O
and	O
is	O
sorted	O
to	O
organelle	O
membranes	O
derived	O
from	O
the	O
ER	O
membrane	O
.	O

17	B
beta	I
-	I
Hydroxysteroid	I
dehydrogenase	I
type	I
2	I
expression	O
and	O
enzyme	O
activity	O
in	O
the	O
human	O
gastrointestinal	O
tract	O
.	O

The	O
17	B
beta	I
-	I
hydroxysteroid	I
dehydrogenases	I
(	O
17	B
beta	I
HSDs	I
)	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
intracellular	O
levels	O
of	O
biologically	O
active	O
sex	O
steroid	O
hormones	O
in	O
various	O
human	O
tissues	O
.	O

To	O
date	O
,	O
eight	O
distinctive	O
17	B
beta	I
HSD	I
enzymes	O
have	O
been	O
cloned	O
and	O
characterized	O
in	O
humans	O
.	O

Among	O
these	O
isoenzymes	O
,	O
17	B
beta	I
HSD	I
type	I
2	I
(	O
17	B
beta	I
HSD2	I
)	O
catalyses	O
the	O
conversion	O
of	O
testosterone	O
into	O
androstenedione	O
and/or	O
oestradiol	O
into	O
oestrone	O
in	O
various	O
tissues	O
,	O
and	O
it	O
has	O
thus	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
biological	O
inactivation	O
of	O
these	O
sex	O
steroids	O
.	O

The	O
human	O
gastrointestinal	O
tract	O
and	O
liver	O
are	O
considered	O
as	O
the	O
principle	O
sites	O
of	O
inactivation	O
and	O
metabolism	O
of	O
various	O
forms	O
of	O
orally	O
administered	O
sex	O
steroids	O
.	O

We	O
therefore	O
examined	O
17	B
beta	I
HSD2	I
expression	O
and	O
activity	O
in	O
human	O
adult	O
non	O
-	O
pathological	O
gastrointestinal	O
tract	O
in	O
order	O
to	O
clarify	O
further	O
the	O
biological	O
significance	O
of	O
this	O
enzyme	O
.	O

A	O
total	O
of	O
80	O
specimens	O
(	O
40	O
from	O
males	O
and	O
40	O
from	O
females	O
)	O
of	O
normal	O
oesophageal	O
,	O
stomach	O
,	O
duodenal	O
,	O
ileal	O
,	O
colonic	O
and	O
rectal	O
tissues	O
were	O
examined	O
for	O
immunohistochemistry	O
.	O

Altogether	O
,	O
17	O
tissue	O
specimens	O
were	O
used	O
for	O
enzyme	O
assay	O
,	O
and	O
eight	O
for	O
RNA	O
analysis	O
.	O

17	B
beta	I
HSD2	I
activity	O
was	O
detected	O
in	O
the	O
stomach	O
,	O
duodenum	O
,	O
ileum	O
,	O
colon	O
and	O
rectum	O
.	O

17	B
beta	I
HSD2	I
mRNA	O
was	O
most	O
abundant	O
in	O
the	O
small	O
intestine	O
.	O

17	B
beta	I
HSD2	I
immunoreactivity	O
was	O
localized	O
almost	O
exclusively	O
to	O
the	O
absorptive	O
epithelium	O
,	O
which	O
may	O
be	O
involved	O
in	O
the	O
inactivation	O
of	O
excessive	O
endogenous	O
and	O
exogenous	O
active	O
sex	O
steroids	O
.	O

Results	O
from	O
the	O
present	O
study	O
thus	O
suggest	O
that	O
the	O
human	O
gastrointestinal	O
tract	O
is	O
an	O
important	O
sex	O
steroid	O
metabolizing	O
organ	O
in	O
humans	O
.	O

The	O
presence	O
of	O
chemokine	B
receptor	I
(	O
CCR5	B
,	O
CXCR3	B
,	O
CCR3	B
)	O
-	O
positive	O
cells	O
and	O
chemokine	B
(	O
MCP1	B
,	O
MIP-1alpha	B
,	O
MIP-1beta	B
,	O
IP-10	B
)	O
-	O
positive	O
cells	O
in	O
human	O
periapical	O
granulomas	O
.	O

The	O
infiltration	O
of	O
leukocytes	O
into	O
inflammation	O
sites	O
such	O
as	O
observed	O
in	O
human	O
periapical	O
granulomas	O
is	O
considered	O
to	O
be	O
mediated	O
by	O
chemotactic	O
factors	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
presence	O
of	O
chemokine	B
-	O
and	O
chemokine	B
receptor	I
-	O
positive	O
cells	O
in	O
samples	O
obtained	O
from	O
human	O
subjects	O
by	O
means	O
of	O
immunohistochemical	O
methods	O
.	O

Macrophage	B
chemotactic	I
protein-1	I
(	O
MCP-1	B
)	O
,	O
macrophage	B
inflammatory	I
protein	I
(	I
MIP	I
)	I
-	I
1alpha	I
,	O
MIP-1beta	B
and	O
IFN	B
-	I
inducible	I
protein	I
10	I
(	O
IP-10	B
)	O
-	O
producing	O
cells	O
were	O
present	O
in	O
periapical	O
granulomas	O
.	O

In	O
addition	O
,	O
chemokine	B
receptor	I
CCR3	B
-	O
,	O
CCR5	B
-	O
,	O
and	O
CXCR3	B
-	O
positive	O
cells	O
were	O
also	O
present	O
.	O

In	O
contrast	O
,	O
no	O
factor	O
expression	O
was	O
observed	O
in	O
clinically	O
healthy	O
periodontal	O
ligament	O
,	O
serving	O
as	O
a	O
negative	O
control	O
.	O

Our	O
findings	O
suggest	O
that	O
these	O
chemokines	B
are	O
responsible	O
for	O
modulating	O
the	O
process	O
of	O
disease	O
,	O
such	O
as	O
human	O
apical	O
periodontitis	O
.	O

Serine	O
-	O
arginine	O
(	O
SR	O
)	O
protein	O
-	O
like	O
factors	O
that	O
antagonize	O
authentic	O
SR	O
proteins	O
and	O
regulate	O
alternative	O
splicing	O
.	O

We	O
have	O
characterized	O
two	O
RNA	O
-	O
binding	O
proteins	O
,	O
of	O
apparent	O
molecular	O
masses	O
of	O
approximately	O
40	O
and	O
35	O
kDa	O
,	O
which	O
possess	O
a	O
single	O
N	O
-	O
terminal	O
RNA	O
-	O
recognition	O
motif	O
(	O
RRM	O
)	O
followed	O
by	O
a	O
C	O
-	O
terminal	O
domain	O
rich	O
in	O
serine	O
-	O
arginine	O
dipeptides	O
.	O

Their	O
primary	O
structures	O
resemble	O
the	O
single	O
-	O
RRM	O
serine	O
-	O
arginine	O
(	O
SR	O
)	O
protein	O
,	O
SC35	B
;	O
however	O
their	O
functional	O
effects	O
are	O
quite	O
distinctive	O
.	O

The	O
40	O
-	O
kDa	O
protein	O
can	O
not	O
complement	O
SR	O
protein	O
-	O
deficient	O
HeLa	O
cell	O
S100	O
extract	O
and	O
showed	O
a	O
dominant	O
negative	O
effect	O
in	O
vitro	O
against	O
the	O
authentic	O
SR	O
proteins	O
,	O
SF2	B
/	O
ASF	B
and	O
SC35	B
.	O

Interestingly	O
,	O
the	O
40	O
-	O
and	O
35	O
-	O
kDa	O
proteins	O
antagonize	O
SR	O
proteins	O
and	O
activate	O
the	O
most	O
distal	O
alternative	O
5	O
'	O
splice	O
site	O
of	O
adenovirus	O
E1A	B
pre	O
-	O
mRNA	O
in	O
vivo	O
,	O
an	O
activity	O
that	O
is	O
similar	O
to	O
that	O
characterized	O
previously	O
for	O
the	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
particles	O
A	O
/	O
B	O
group	O
of	O
proteins	O
.	O

A	O
series	O
of	O
recombinant	O
chimeric	O
proteins	O
consisting	O
of	O
domains	O
from	O
these	O
proteins	O
and	O
SC35	B
in	O
various	O
combinations	O
showed	O
that	O
the	O
RRM	O
,	O
but	O
not	O
the	O
C	O
-	O
terminal	O
domain	O
rich	O
in	O
serine	O
-	O
arginine	O
dipeptides	O
,	O
has	O
a	O
dominant	O
role	O
in	O
this	O
activity	O
.	O

Because	O
of	O
the	O
similarity	O
to	O
SR	O
proteins	O
we	O
have	O
named	O
these	O
proteins	O
SRrp40	B
and	O
SRrp35	B
,	O
respectively	O
,	O
for	O
SR	O
-	O
repressor	O
proteins	O
of	O
approximately	O
40	O
and	O
approximately	O
35	O
kDa	O
.	O

Both	O
factors	O
show	O
tissue	O
-	O
and	O
cell	O
type	O
-	O
specific	O
patterns	O
of	O
expression	O
.	O

We	O
propose	O
that	O
these	O
two	O
proteins	O
are	O
SR	O
protein	O
-	O
like	O
alternative	O
splicing	O
regulators	O
that	O
antagonize	O
authentic	O
SR	O
proteins	O
in	O
the	O
modulation	O
of	O
alternative	O
5	O
'	O
splice	O
site	O
choice	O
.	O

Expression	O
pattern	O
of	O
human	O
P2Y	B
receptor	I
subtypes	O
:	O
a	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
study	O
.	O

The	O
diverse	O
biological	O
actions	O
of	O
extracellular	O
nucleotides	O
in	O
tissues	O
and	O
cells	O
are	O
mediated	O
by	O
two	O
distinct	O
classes	O
of	O
P2	B
receptor	I
,	O
P2X	B
and	O
P2Y	B
.	O

The	O
G	B
protein	I
-	O
coupled	O
P2Y	B
receptors	I
comprise	O
at	O
least	O
six	O
mammalian	O
subtypes	O
(	O
P2Y	B
(	I
1,2,4,6,11,12	I
)	I
)	O
,	O
all	O
of	O
which	O
have	O
been	O
cloned	O
from	O
human	O
tissues	O
,	O
as	O
well	O
as	O
other	O
species	O
.	O

The	O
P2Y	B
receptor	I
subtypes	O
differ	O
in	O
their	O
pharmacological	O
selectivity	O
for	O
various	O
adenosine	O
and	O
uridine	O
nucleotides	O
,	O
which	O
overlap	O
in	O
some	O
cases	O
.	O

Data	O
concerning	O
the	O
mRNA	O
expression	O
patterns	O
of	O
five	O
P2Y	B
receptors	I
(	O
P2Y	B
(	I
1,2,4,6,11	I
)	I
)	O
in	O
different	O
human	O
tissues	O
and	O
cells	O
are	O
currently	O
quite	O
limited	O
,	O
while	O
P2Y	B
mRNA	O
distribution	O
in	O
the	O
human	O
brain	O
has	O
not	O
previously	O
been	O
studied	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
addressed	O
this	O
deficiency	O
in	O
receptor	O
expression	O
data	O
by	O
using	O
a	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
approach	O
to	O
measure	O
the	O
precise	O
mRNA	O
expression	O
pattern	O
of	O
each	O
P2Y	B
receptor	I
subtype	O
in	O
a	O
number	O
of	O
human	O
peripheral	O
tissues	O
and	O
brain	O
regions	O
,	O
from	O
multiple	O
individuals	O
,	O
as	O
well	O
as	O
numerous	O
human	O
cell	O
lines	O
and	O
primary	O
cells	O
.	O

All	O
five	O
P2Y	B
receptors	I
exhibited	O
widespread	O
yet	O
subtype	O
-	O
selective	O
mRNA	O
expression	O
profiles	O
throughout	O
the	O
human	O
tissues	O
,	O
brain	O
regions	O
and	O
cells	O
used	O
.	O

Our	O
extensive	O
expression	O
data	O
indicate	O
the	O
many	O
potentially	O
important	O
roles	O
of	O
P2Y	B
receptors	I
throughout	O
the	O
human	O
body	O
,	O
and	O
will	O
help	O
in	O
elucidating	O
the	O
physiological	O
function	O
of	O
each	O
receptor	O
subtype	O
in	O
a	O
wide	O
variety	O
of	O
human	O
systems	O
.	O

Expression	O
and	O
function	O
of	O
adrenomedullin	B
and	O
its	O
receptors	O
in	O
Conn	O
's	O
adenoma	O
cells	O
.	O

Adrenomedullin	B
(	O
ADM	B
)	O
is	O
a	O
hypotensive	O
peptide	O
,	O
that	O
derives	O
from	O
the	O
proteolytic	O
cleavage	O
of	O
pro	O
(	O
p	O
)	O
ADM	B
and	O
acts	O
through	O
two	O
subtypes	O
of	O
receptors	O
,	O
called	O
L1	B
-	I
receptor	I
(	O
L1-R	B
)	O
and	O
calcitonin	B
receptor	I
-	I
like	I
receptor	I
(	O
CRLR	B
)	O
.	O

CRLR	B
may	O
function	O
as	O
a	O
calcitonin	B
gene	I
-	I
related	I
peptide	I
or	O
a	O
selective	O
ADM	B
receptor	O
depending	O
on	O
the	O
expression	O
of	O
the	O
subtype	O
1	O
or	O
the	O
subtypes	O
2	O
and	O
3	O
of	O
a	O
family	O
of	O
proteins	O
,	O
named	O
receptor	B
-	I
activity	I
modifying	I
proteins	I
(	O
RAMPs	B
)	O
.	O

Reverse	O
transcription	O
(	O
RT	O
)	O
-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
allowed	O
the	O
detection	O
of	O
pADM	B
mRNA	O
in	O
dispersed	O
cells	O
of	O
eight	O
Conn	O
's	O
adenomas	O
(	O
aldosteronomas	O
)	O
.	O

These	O
cells	O
also	O
expressed	O
peptidyl	B
-	I
glycine	I
alpha	I
-	I
amidating	I
monooxigenase	I
,	O
the	O
enzyme	O
converting	O
immature	O
ADM	B
to	O
the	O
mature	O
form	O
,	O
and	O
contained	O
sizeable	O
amounts	O
of	O
ADM	B
-	O
immunoreactivity	O
as	O
measured	O
by	O
radioimmunoassay	O
.	O

RT	O
-	O
PCR	O
also	O
demonstrated	O
the	O
presence	O
in	O
aldosteronoma	O
cells	O
of	O
the	O
specific	O
mRNAs	O
of	O
L1-R	B
,	O
CRLR	B
and	O
RAMPs	B
1	I
-	I
3	I
.	O

ADM	B
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
inhibited	O
angiotensin	B
-	I
II	I
(	O
10	O
(	O
-9	O
)	O
M	O
)	O
-	O
simulated	O
aldosterone	O
secretion	O
from	O
cultured	O
aldosteronoma	O
cells	O
,	O
without	O
affecting	O
basal	O
production	O
.	O

ADM	B
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
also	O
enhanced	O
basal	O
proliferation	O
rate	O
of	O
cultured	O
cells	O
,	O
as	O
estimated	O
by	O
the	O
5-bromo-2	O
'	O
-	O
deoxyuridine	O
immunocytochemical	O
technique	O
.	O

Both	O
effects	O
of	O
ADM	B
were	O
annulled	O
by	O
the	O
ADM	B
-	O
receptor	O
selective	O
antagonist	O
ADM22	B
-	I
52	I
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
provides	O
evidence	O
that	O
aldosteronoma	O
cells	O
express	O
both	O
ADM	B
and	O
ADM22	B
-	O
52	O
-	O
sensitive	O
receptors	O
.	O

These	O
findings	O
,	O
coupled	O
with	O
the	O
demonstration	O
that	O
ADM	B
exerts	O
an	O
aldosterone	O
antisecretagogue	O
action	O
and	O
a	O
proliferogenic	O
effect	O
on	O
cultured	O
aldosteronoma	O
cells	O
,	O
make	O
it	O
likely	O
that	O
endogenous	O
ADM	B
system	O
plays	O
a	O
potentially	O
important	O
role	O
in	O
the	O
paracrine	O
or	O
autocrine	O
functional	O
control	O
of	O
Conn	O
's	O
adenomas	O
.	O

Genetic	O
influences	O
on	O
lipid	O
metabolism	O
trait	O
variability	O
within	O
the	O
Stanislas	O
Cohort	O
.	O

The	O
contribution	O
of	O
17	O
polymorphisms	O
within	O
13	O
candidate	O
genes	O
on	O
lipid	O
trait	O
variability	O
was	O
investigated	O
by	O
a	O
multiplex	O
assay	O
in	O
772	O
men	O
and	O
780	O
women	O
coming	O
for	O
a	O
health	O
checkup	O
examination	O
.	O

The	O
studied	O
genes	O
were	O
APOE	B
,	O
APOB	B
,	O
APOC3	B
,	O
CETP	B
,	O
LPL	B
,	O
PON	B
,	O
MTHFR	B
,	O
FGB	B
,	O
GpIIIa	B
,	O
SELE	B
,	O
ACE	B
,	O
and	O
AGT	B
.	O

We	O
found	O
that	O
APOB	B
-	O
Thr71Ile	O
,	O
APOE	B
-	O
(	O
112	O
/	O
158	O
)	O
,	O
APOC3	B
-	O
1100C	O
/	O
T	O
,	O
and	O
SELE	B
-	O
98	O
G	O
/	O
T	O
polymorphisms	O
had	O
a	O
significant	O
effect	O
on	O
lipid	O
traits	O
(	O
P	O
<	O
or	O
=	O
0.001	O
to	O
P	O
<	O
or	O
=	O
0.01	O
)	O
.	O

Genetic	O
effects	O
accounted	O
for	O
3.5	O
-	O
5.7	O
%	O
of	O
variation	O
in	O
apolipoprotein	B
B	I
(	O
apoB	B
)	O
-	O
related	O
traits	O
among	O
men	O
,	O
and	O
for	O
5.7	O
-	O
9.0	O
%	O
among	O
women	O
.	O

The	O
contribution	O
of	O
APOE	B
polymorphism	O
on	O
apoB	B
-	O
related	O
traits	O
variability	O
was	O
two	O
to	O
three	O
times	O
more	O
important	O
in	O
women	O
than	O
in	O
men	O
.	O

We	O
found	O
suggestive	O
evidence	O
for	O
interactive	O
effects	O
between	O
genetics	O
and	O
age	O
,	O
smoking	O
status	O
,	O
and	O
oral	O
contraceptives	O
.	O

Increase	O
of	O
LDL	B
-	O
cholesterol	O
and	O
apoB	B
concentrations	O
with	O
age	O
was	O
stronger	O
among	O
the	O
epsilon4	O
carriers	O
in	O
women	O
,	O
and	O
apolipoprotein	B
A	I
-	I
I	I
(	O
apoA	B
-	I
I	I
)	O
concentration	O
decreased	O
with	O
age	O
in	O
epsilon4	O
male	O
carriers	O
.	O

The	O
effect	O
of	O
epsilon2	O
allele	O
on	O
LDL	B
-	O
cholesterol	O
was	O
more	O
important	O
in	O
the	O
oral	O
contraceptive	O
users	O
.	O

In	O
nonsmokers	O
only	O
,	O
the	O
APOC3	B
-	O
1100C	O
allele	O
in	O
women	O
was	O
related	O
to	O
lower	O
apoB	B
-	O
related	O
traits	O
concentrations	O
,	O
and	O
in	O
men	O
to	O
higher	O
apoA	B
-	I
I	I
and	O
HDL	B
-	O
cholesterol	O
concentrations	O
.	O

In	O
conclusion	O
,	O
this	O
work	O
,	O
in	O
addition	O
to	O
the	O
reinforcement	O
of	O
the	O
already	O
known	O
associations	O
between	O
APOB	B
,	O
APOE	B
,	O
and	O
APOC3	B
genes	O
and	O
lipids	O
,	O
leads	O
to	O
new	O
perspectives	O
in	O
the	O
complex	O
relationships	O
among	O
genes	O
and	O
environmental	O
factors	O
.	O

The	O
newly	O
observed	O
relationships	O
between	O
E	B
-	I
selectine	I
gene	O
and	O
lipid	O
concentrations	O
support	O
the	O
hypotheses	O
of	O
multiple	O
metabolic	O
pathways	O
contributing	O
to	O
the	O
complexity	O
of	O
lipids	O
variability	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
the	O
human	O
diacylglycerol	B
kinase	I
beta	I
(	O
DGKbeta	B
)	O
gene	O
:	O
alternative	O
splicing	O
generates	O
DGKbeta	B
isotypes	O
with	O
different	O
properties	O
.	O

Diacylglycerol	B
kinases	I
are	O
key	O
modulators	O
of	O
levels	O
of	O
diacylglycerol	O
,	O
a	O
second	O
messenger	O
involved	O
in	O
a	O
variety	O
of	O
cellular	O
responses	O
to	O
extracellular	O
stimuli	O
.	O

A	O
number	O
of	O
diacylglycerol	B
kinases	I
encoded	O
by	O
separate	O
genes	O
are	O
present	O
in	O
mammalian	O
genomes	O
.	O

We	O
have	O
cloned	O
cDNAs	O
encoding	O
several	O
isoforms	O
of	O
the	O
human	O
homologue	O
of	O
the	O
rat	O
diacylglycerol	B
kinase	I
beta	I
gene	O
and	O
characterized	O
two	O
such	O
isoforms	O
that	O
differ	O
at	O
their	O
carboxyl	O
terminus	O
through	O
alternative	O
splicing	O
and	O
the	O
usage	O
of	O
different	O
polyadenylation	O
signals	O
.	O

Quantitative	O
analysis	O
of	O
gene	O
expression	O
in	O
a	O
panel	O
of	O
human	O
tissue	O
cDNAs	O
revealed	O
that	O
transcripts	O
corresponding	O
to	O
both	O
isoforms	O
are	O
co	O
-	O
expressed	O
in	O
central	O
nervous	O
system	O
tissues	O
and	O
in	O
the	O
uterus	O
,	O
with	O
one	O
variant	O
being	O
expressed	O
at	O
relatively	O
higher	O
levels	O
.	O

As	O
green	B
fluorescent	I
protein	I
fusions	O
,	O
the	O
two	O
isoforms	O
displayed	O
localization	O
to	O
different	O
subcellular	O
compartments	O
,	O
with	O
one	O
variant	O
being	O
associated	O
with	O
the	O
plasma	O
membrane	O
,	O
while	O
the	O
other	O
isoform	O
was	O
predominantly	O
localized	O
within	O
the	O
cytoplasm	O
.	O

Differences	O
were	O
also	O
observed	O
in	O
their	O
subcellular	O
localization	O
in	O
response	O
to	O
phorbol	O
ester	O
stimulation	O
.	O

Enzymatic	O
assays	O
demonstrated	O
that	O
the	O
two	O
isoforms	O
display	O
comparable	O
diacylglycerol	B
kinase	I
activities	O
.	O

Therefore	O
,	O
the	O
human	O
diacylglycerol	B
kinase	I
beta	I
gene	O
can	O
generate	O
several	O
enzyme	O
isoforms	O
,	O
which	O
can	O
display	O
different	O
expression	O
levels	O
and	O
subcellular	O
localization	O
but	O
similar	O
enzymatic	O
activities	O
in	O
vitro	O
.	O

[	O
Clinical	O
and	O
epidemiological	O
characteristics	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oral	O
cavity	O
in	O
women	O
]	O

BACKGROUND	O
:	O

Squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
of	O
the	O
oral	O
cavity	O
occurs	O
mainly	O
in	O
the	O
male	O
population	O
.	O

The	O
objective	O
of	O
the	O
study	O
is	O
to	O
identify	O
the	O
main	O
clinical	O
and	O
epidemiological	O
differences	O
of	O
the	O
oral	O
SCC	O
between	O
men	O
and	O
women	O
.	O

METHODS	O
:	O

Retrospective	O
analysis	O
of	O
the	O
charts	O
of	O
228	O
cases	O
of	O
SCC	O
of	O
the	O
oral	O
cavity	O
in	O
women	O
treated	O
at	O
the	O
Head	O
&	O
Neck	O
Surgery	O
Service	O
,	O
Heliopolis	O
Hospital	O
,	O
SÃ?Â£o	O
Paulo	O
,	O
Brazil	O
from	O
1977	O
to	O
1996	O
.	O

The	O
clinical	O
and	O
epidemiological	O
characteristics	O
of	O
these	O
cases	O
were	O
compared	O
with	O
those	O
of	O
849	O
male	O
patients	O
.	O

RESULTS	O
:	O

The	O
mean	O
age	O
of	O
women	O
was	O
60.7	O
years	O
(	O
ranging	O
2	O
to	O
100	O
years	O
)	O
and	O
in	O
the	O
male	O
group	O
was	O
55.6	O
years	O
(	O
p	O
<	O
0.00001	O
)	O
.	O

In	O
cases	O
where	O
the	O
alcohol	O
intake	O
and	O
tobacco	O
use	O
were	O
absent	O
,	O
the	O
tumors	O
ocurred	O
in	O
older	O
patients	O
.	O

The	O
isolated	O
tobacco	O
use	O
didn	O
'	O
t	O
affect	O
the	O
distribuction	O
by	O
age	O
but	O
for	O
the	O
alcohol	O
intake	O
(	O
alone	O
or	O
combined	O
with	O
tobacco	O
)	O
the	O
patients	O
were	O
younger	O
.	O

On	O
the	O
alcohol	O
intake	O
,	O
71	O
%	O
of	O
the	O
women	O
and	O
8	O
%	O
of	O
the	O
man	O
used	O
no	O
alcohol	O
.	O

The	O
most	O
common	O
sites	O
of	O
tumors	O
were	O
tongue	O
and	O
floor	O
of	O
the	O
mouth	O
but	O
in	O
the	O
women	O
group	O
the	O
incidence	O
of	O
tumors	O
in	O
these	O
sites	O
were	O
43	O
%	O
compared	O
with	O
61	O
%	O
in	O
the	O
men	O
.	O

CONCLUSIONS	O
:	O

The	O
highest	O
incidence	O
of	O
SCC	O
the	O
of	O
oral	O
cavity	O
occurs	O
later	O
in	O
women	O
,	O
than	O
in	O
men	O
.	O

This	O
could	O
be	O
explained	O
by	O
a	O
lesser	O
exposure	O
to	O
alcohol	O
and	O
tobacco	O
in	O
women	O
.	O

Other	O
factors	O
seem	O
to	O
be	O
involved	O
in	O
this	O
issue	O
.	O

Skill	O
transfer	O
from	O
virtual	O
reality	O
to	O
a	O
real	O
laparoscopic	O
task	O
.	O

BACKGROUND	O
:	O

To	O
validate	O
the	O
usefulness	O
of	O
virtual	O
reality	O
surgical	O
simulators	O
,	O
we	O
investigated	O
the	O
transfer	O
of	O
skills	O
achieved	O
by	O
their	O
use	O
to	O
real	O
tasks	O
.	O

METHODS	O
:	O

Thirty	O
medical	O
students	O
underwent	O
a	O
pretest	O
using	O
a	O
real	O
laparoscopic	O
trainer	O
.	O

They	O
were	O
then	O
randomized	O
to	O
the	O
following	O
three	O
groups	O
:	O
group	O
I	O
received	O
no	O
training	O
;	O
group	O
II	O
received	O
training	O
using	O
the	O
Minimal	O
Invasive	O
Surgical	O
Trainer	O
in	O
Virtual	O
Reality	O
(	O
MIST	O
-	O
VR	O
)	O
;	O
and	O
group	O
III	O
received	O
training	O
using	O
conventional	O
training	O
exercises	O
.	O

Each	O
group	O
then	O
underwent	O
a	O
posttest	O
.	O

Using	O
the	O
Imperial	O
College	O
Surgical	O
Assessment	O
Device	O
(	O
ICSAD	O
)	O
,	O
scores	O
were	O
generated	O
for	O
time	O
taken	O
,	O
distance	O
traveled	O
,	O
number	O
of	O
movements	O
made	O
,	O
and	O
speed	O
of	O
instrument	O
movement	O
.	O

RESULTS	O
:	O

Significant	O
changes	O
between	O
the	O
MIST	O
-	O
VR	O
group	O
(	O
group	O
II	O
)	O
and	O
the	O
conventionally	O
trained	O
group	O
(	O
group	O
III	O
)	O
,	O
were	O
observed	O
in	O
the	O
speed	O
of	O
movement	O
of	O
the	O
left	O
hand	O
and	O
the	O
numbers	O
of	O
movements	O
taken	O
by	O
each	O
hand	O
,	O
when	O
compared	O
to	O
the	O
untrained	O
group	O
(	O
group	O
I	O
)	O
.	O

CONCLUSION	O
:	O

The	O
training	O
of	O
novices	O
using	O
MIST	O
-	O
VR	O
yields	O
quantifiable	O
changes	O
in	O
skill	O
that	O
are	O
transferable	O
to	O
a	O
simple	O
real	O
task	O
and	O
are	O
similar	O
to	O
the	O
results	O
achieved	O
with	O
conventional	O
training	O
.	O

MUC4	B
expression	O
is	O
increased	O
in	O
dysplastic	O
cervical	O
disorders	O
.	O

The	O
female	O
uterine	O
cervix	O
has	O
2	O
characteristic	O
populations	O
of	O
epithelial	O
cells	O
:	O
the	O
endocervix	O
is	O
composed	O
by	O
mucus	O
-	O
secreting	O
cells	O
that	O
express	O
several	O
mucin	B
genes	O
,	O
and	O
the	O
exocervix	O
has	O
a	O
typical	O
stratified	O
squamous	O
epithelium	O
and	O
does	O
not	O
express	O
secreted	O
mucins	B
.	O

Among	O
human	O
mucin	B
genes	O
,	O
the	O
MUC4	B
sequence	O
has	O
a	O
transmembrane	O
domain	O
,	O
and	O
its	O
molecular	O
structure	O
suggests	O
that	O
it	O
has	O
a	O
protective	O
role	O
and	O
also	O
may	O
be	O
implicated	O
in	O
intracellular	O
signalling	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
analyze	O
whether	O
changes	O
in	O
the	O
expression	O
of	O
MUC4	B
can	O
be	O
detected	O
associated	O
with	O
the	O
squamous	O
dysplastic	O
transformation	O
of	O
exocervical	O
epithelium	O
.	O

MUC4	B
expression	O
has	O
been	O
analyzed	O
by	O
immunohistochemistry	O
,	O
Western	O
blotting	O
,	O
and	O
in	O
situ	O
hybridization	O
.	O

Using	O
immunohistochemical	O
techniques	O
,	O
MUC4	B
is	O
found	O
in	O
normal	O
endocervix	O
(	O
n	O
=	O
11	O
)	O
and	O
is	O
absent	O
or	O
only	O
focally	O
detected	O
in	O
the	O
normal	O
stratified	O
cervical	O
epithelium	O
(	O
n	O
=	O
18	O
)	O
.	O

In	O
samples	O
from	O
squamous	O
metaplasia	O
(	O
n	O
=	O
9	O
)	O
,	O
MUC4	B
is	O
variably	O
expressed	O
(	O
10	O
%	O
to	O
50	O
%	O
positive	O
cells	O
)	O
,	O
whereas	O
MUC4	B
is	O
strongly	O
detected	O
in	O
dysplastic	O
cervical	O
epithelia	O
.	O

The	O
greatest	O
number	O
of	O
positive	O
cells	O
is	O
found	O
in	O
samples	O
with	O
moderate	O
and	O
severe	O
dysplasia	O
in	O
which	O
MUC4	B
is	O
detected	O
in	O
100	O
%	O
of	O
the	O
analyzed	O
samples	O
(	O
n	O
=	O
16	O
)	O
.	O

These	O
results	O
have	O
been	O
confirmed	O
by	O
Western	O
blotting	O
and	O
by	O
detection	O
of	O
MUC4	B
transcripts	O
using	O
in	O
situ	O
hybridization	O
.	O

The	O
present	O
data	O
suggest	O
that	O
MUC4	B
is	O
activated	O
during	O
the	O
process	O
of	O
squamous	O
dysplastic	O
transformation	O
and	O
may	O
be	O
used	O
as	O
a	O
marker	O
for	O
this	O
pathologic	O
process	O
.	O

Expression	O
of	O
multidrug	B
resistance	I
1	I
and	O
glutathione	B
-	I
S	I
-	I
transferase	I
-	I
Pi	I
protein	O
in	O
nasopharyngeal	O
carcinoma	O
.	O

Radiotherapy	O
is	O
the	O
modality	O
of	O
choice	O
for	O
the	O
treatment	O
of	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O

However	O
,	O
systemic	O
chemotherapy	O
has	O
recently	O
been	O
found	O
to	O
play	O
an	O
increasing	O
role	O
in	O
the	O
treatment	O
of	O
advanced	O
or	O
metastatic	O
disease	O
.	O

The	O
status	O
of	O
drug	O
resistance	O
gene	O
expression	O
that	O
has	O
crucial	O
impact	O
on	O
chemotherapy	O
has	O
not	O
been	O
fully	O
addressed	O
for	O
patients	O
with	O
NPC	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
multidrug	B
resistance	I
1	I
(	O
MDR-1	B
)	O
and	O
glutathione	B
-	I
S	I
-	I
transferase	I
-	I
Pi	I
(	O
GST	B
-	I
Pi	I
)	O
in	O
primary	O
,	O
recurrent	O
,	O
and	O
metastatic	O
NPC	O
using	O
results	O
of	O
immunohistochemical	O
examinations	O
.	O

The	O
results	O
were	O
correlated	O
with	O
the	O
expression	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latent	O
protein	O
,	O
latent	B
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
,	O
and	O
clinicopathologic	O
features	O
,	O
including	O
stage	O
,	O
histopathologic	O
types	O
,	O
and	O
survival	O
rates	O
.	O

MDR-1	B
protein	O
expression	O
was	O
detected	O
in	O
18	O
(	O
12.6	O
%	O
)	O
of	O
143	O
patients	O
with	O
primary	O
NPC	O
,	O
14	O
(	O
32.6	O
%	O
)	O
of	O
43	O
with	O
recurrent	O
NPC	O
,	O
and	O
O	O
(	O
0	O
%	O
)	O
of	O
20	O
with	O
metastatic	O
NPC	O
,	O
whereas	O
83	O
(	O
58	O
%	O
)	O
of	O
143	O
patients	O
with	O
primary	O
NPC	O
,	O
30	O
(	O
69.8	O
%	O
)	O
of	O
43	O
with	O
recurrent	O
NPC	O
,	O
and	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
with	O
metastatic	O
NPC	O
expressed	O
GST	B
-	I
Pi	I
.	O

EBV	O
-	O
LMP1	B
was	O
expressed	O
in	O
59	O
(	O
41.3	O
%	O
)	O
of	O
143	O
patients	O
with	O
primary	O
NPC	O
,	O
23	O
(	O
53.5	O
%	O
)	O
of	O
43	O
with	O
recurrent	O
NPC	O
,	O
and	O
9	O
(	O
45	O
%	O
)	O
of	O
20	O
with	O
metastatic	O
NPC	O
.	O

Simultaneous	O
expression	O
of	O
MDR1	B
and	O
GST	B
-	I
Pi	I
was	O
observed	O
in	O
13	O
(	O
72.2	O
%	O
)	O
of	O
18	O
patients	O
with	O
primary	O
NPC	O
and	O
12	O
(	O
85.7	O
%	O
)	O
of	O
14	O
with	O
recurrent	O
NPC	O
.	O

The	O
expression	O
of	O
LMP1	B
was	O
detected	O
in	O
only	O
6	O
of	O
the	O
13	O
patients	O
with	O
primary	O
NPC	O
and	O
6	O
of	O
the	O
12	O
with	O
recurrent	O
NPC	O
.	O

We	O
concluded	O
that	O
the	O
expression	O
of	O
GST	B
-	I
Pi	I
was	O
more	O
frequent	O
in	O
NPC	O
tumor	O
tissues	O
than	O
the	O
expression	O
of	O
MDR-1	B
.	O

The	O
expression	O
of	O
MDR-1	B
correlated	O
with	O
clinicopathologic	O
features	O
of	O
primary	O
NPC	O
,	O
including	O
the	O
histopathologic	O
types	O
and	O
survival	O
rates	O
,	O
but	O
not	O
with	O
disease	O
stage	O
.	O

The	O
expression	O
of	O
GST	B
-	I
Pi	I
did	O
not	O
correlate	O
with	O
clinicopathologic	O
features	O
.	O

The	O
expression	O
of	O
MDR-1	B
and	O
GST	B
-	I
Pi	I
did	O
not	O
correlate	O
with	O
expression	O
of	O
EBV	O
-	O
LMP1	B
for	O
patients	O
with	O
NPC	O
.	O

Delineation	O
of	O
mRNA	O
export	O
pathways	O
by	O
the	O
use	O
of	O
cell	O
-	O
permeable	O
peptides	O
.	O

The	O
transport	O
of	O
messenger	O
RNAs	O
(	O
mRNAs	O
)	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
involves	O
adapter	O
proteins	O
that	O
bind	O
the	O
mRNA	O
as	O
well	O
as	O
receptor	O
proteins	O
that	O
interact	O
with	O
the	O
nuclear	O
pore	O
complex	O
.	O

We	O
demonstrate	O
the	O
utility	O
of	O
cell	O
-	O
permeable	O
peptides	O
designed	O
to	O
interfere	O
with	O
interactions	O
between	O
potential	O
adapter	O
and	O
receptor	O
proteins	O
to	O
define	O
the	O
pathways	O
accessed	O
by	O
particular	O
mRNAs	O
.	O

We	O
show	O
that	O
HuR	B
,	O
a	O
protein	O
implicated	O
in	O
the	O
stabilization	O
of	O
short	O
-	O
lived	O
mRNAs	O
containing	O
AU	O
-	O
rich	O
elements	O
(	O
AREs	O
)	O
,	O
serves	O
as	O
an	O
adapter	O
for	O
c	B
-	I
fos	I
mRNA	O
export	O
through	O
two	O
pathways	O
.	O

One	O
involves	O
the	O
HuR	B
shuttling	O
domain	O
,	O
HNS	O
,	O
which	O
exhibits	O
a	O
heat	O
shock	O
-	O
sensitive	O
interaction	O
with	O
transportin	B
2	I
(	O
Trn2	B
)	O
;	O
the	O
other	O
involves	O
two	O
protein	O
ligands	O
of	O
HuR	B
-	O
pp32	B
and	O
APRIL	B
-	O
which	O
contain	O
leucine	O
-	O
rich	O
nuclear	O
export	O
signals	O
(	O
NES	O
)	O
recognized	O
by	O
the	O
export	O
receptor	O
CRM1	B
.	O

Heterokaryon	O
and	O
in	O
situ	O
hybridization	O
experiments	O
reveal	O
that	O
the	O
peptides	O
selectively	O
block	O
the	O
nucleocytoplasmic	O
shuttling	O
of	O
their	O
respective	O
adapter	B
proteins	I
without	O
perturbing	O
the	O
overall	O
cellular	O
distribution	O
of	O
polyadenylated	O
mRNAs	O
.	O

Hepatocyte	B
nuclear	I
factor	I
1alpha	I
controls	O
the	O
expression	O
of	O
terminal	O
complement	O
genes	O
.	O

The	O
terminal	O
components	O
of	O
the	O
complement	O
system	O
contribute	O
to	O
host	O
defense	O
by	O
forming	O
the	O
multiprotein	O
membrane	B
attack	I
complex	I
(	O
MAC	B
)	O
which	O
is	O
responsible	O
for	O
cell	O
lysis	O
and	O
several	O
noncytotoxic	O
effects	O
.	O

Most	O
of	O
the	O
complement	O
proteins	O
are	O
synthesized	O
in	O
the	O
liver	O
,	O
but	O
the	O
mechanisms	O
controlling	O
their	O
tissue	O
-	O
specific	O
expression	O
have	O
not	O
been	O
elucidated	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
mice	O
lacking	O
the	O
hepatic	O
transcription	B
factor	I
hepatocyte	B
nuclear	I
factor	I
1alpha	I
(	O
HNF1alpha	B
)	O
fail	O
to	O
transcribe	O
C5	B
and	O
C8A	B
complement	O
genes	O
.	O

In	O
addition	O
,	O
mRNAs	O
encoding	O
for	O
several	O
other	O
terminal	O
complement	B
components	I
or	O
subunits	O
are	O
expressed	O
at	O
lower	O
levels	O
,	O
including	O
C8beta	B
,	O
C8gamma	B
,	O
and	O
C9	B
.	O

We	O
next	O
used	O
a	O
reconstitution	O
assay	O
involving	O
human	O
sera	O
with	O
selective	O
complement	O
deficiencies	O
to	O
assess	O
mouse	O
complement	O
activity	O
.	O

Sera	O
from	O
HNF1alpha	B
-	O
deficient	O
mice	O
showed	O
negligible	O
hemolytic	O
activity	O
of	O
both	O
C5	B
and	O
C8alpha	B
-	I
gamma	I
subunits	O
.	O

The	O
activity	O
of	O
C8beta	B
was	O
severely	O
affected	O
despite	O
only	O
a	O
50	O
%	O
reduction	O
in	O
C8beta	B
mRNA	O
levels	O
in	O
the	O
liver	O
.	O

This	O
is	O
reminiscent	O
of	O
C8alpha	B
-	I
gamma	I
-	O
deficient	O
patients	O
who	O
accumulate	O
extremely	O
low	O
levels	O
of	O
the	O
C8beta	B
subunit	O
.	O

Our	O
results	O
demonstrate	O
that	O
HNF1alpha	B
plays	O
a	O
key	O
role	O
in	O
the	O
expression	O
of	O
C5	B
and	O
C8A	B
genes	O
,	O
two	O
terminal	O
complement	O
component	O
genes	O
that	O
are	O
essential	O
for	O
the	O
assembly	O
of	O
MAC	B
as	O
a	O
result	O
of	O
complement	O
activation	O
.	O

Nucleotide	O
sequence	O
,	O
genomic	O
organization	O
,	O
and	O
chromosomal	O
localization	O
of	O
genes	O
encoding	O
the	O
human	O
NMDA	B
receptor	I
subunits	O
NR3A	B
and	O
NR3B	B
.	O

The	O
N	B
-	I
methyl	I
-	I
D	I
-	I
aspartate	I
(	I
NMDA	I
)	I
receptors	I
are	O
glutamate	O
-	O
regulated	O
ion	B
channels	I
that	O
are	O
critically	O
involved	O
in	O
important	O
physiological	O
and	O
pathological	O
functions	O
of	O
the	O
mammalian	O
central	O
nervous	O
system	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
the	O
gene	O
encoding	O
the	O
human	O
NMDA	B
receptor	I
subunit	O
NR3A	B
(	O
GRIN3A	B
)	O
,	O
as	O
well	O
as	O
the	O
gene	O
(	O
GRIN3B	B
)	O
encoding	O
an	O
entirely	O
novel	O
subunit	O
that	O
we	O
named	O
NR3B	B
,	O
as	O
it	O
is	O
most	O
closely	O
related	O
to	O
NR3A	B
(	O
57.4	O
%	O
identity	O
)	O
.	O

GRIN3A	B
localizes	O
to	O
chromosome	O
9q34	O
,	O
in	O
the	O
region	O
13	O
-	O
34	O
,	O
and	O
consists	O
of	O
nine	O
coding	O
exons	O
.	O

The	O
deduced	O
protein	O
contains	O
1115	O
amino	O
acids	O
and	O
shows	O
92.7	O
%	O
identity	O
to	O
rat	O
NR3A	B
.	O

GRIN3B	B
localizes	O
to	O
chromosome	O
19p13.3	O
and	O
contains	O
,	O
as	O
does	O
the	O
mouse	O
NR3B	B
gene	O
(	O
Grin3b	B
)	O
,	O
eight	O
coding	O
exons	O
.	O

The	O
deduced	O
proteins	O
of	O
human	O
and	O
mouse	O
NR3B	B
contain	O
901	O
and	O
900	O
amino	O
acid	O
residues	O
,	O
respectively	O
(	O
81.6	O
%	O
identity	O
)	O
.	O

In	O
situ	O
hybridization	O
shows	O
a	O
widespread	O
distribution	O
of	O
Grin3b	B
mRNA	O
in	O
the	O
brain	O
of	O
the	O
adult	O
rat	O
.	O

The	O
effects	O
of	O
iron	O
deficiency	O
on	O
lymphocyte	O
cytokine	B
production	O
and	O
activation	O
:	O
preservation	O
of	O
hepatic	O
iron	O
but	O
not	O
at	O
all	O
cost	O
.	O

Worldwide	O
,	O
over	O
40	O
%	O
of	O
children	O
have	O
iron	O
deficiency	O
anaemia	O
,	O
frequently	O
associated	O
with	O
infections	O
.	O

Certain	O
cytokines	B
are	O
involved	O
in	O
both	O
immune	O
activation	O
/	O
response	O
to	O
infection	O
and	O
iron	O
transport	O
/	O
metabolism	O
.	O

We	O
therefore	O
assessed	O
the	O
relations	O
among	O
iron	O
deficiency	O
,	O
cytokine	B
production	O
and	O
lymphocyte	O
activation	O
markers	O
in	O
142	O
hospitalized	O
Malawian	O
children	O
.	O

We	O
examined	O
peripheral	O
blood	O
lymphocyte	O
antigens	O
/	O
cytokine	B
production	O
using	O
four	O
-	O
colour	O
flow	O
cytometry	O
and	O
serum	O
transferrin	B
receptor	I
(	O
TfR	B
)	O
levels	O
,	O
an	O
inverse	O
measure	O
of	O
iron	O
status	O
unaffected	O
by	O
acute	O
illness	O
or	O
infection	O
,	O
with	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Wilcoxon	O
rank	O
sum	O
tests	O
and	O
logistic	O
regression	O
analyses	O
(	O
LRA	O
)	O
were	O
performed	O
.	O

Iron	O
deficiency	O
(	O
TfR	B
>	O
or	O
=	O
10	O
microg	O
/	O
ml	O
)	O
versus	O
TfR	B
<	O
10	O
microg	O
/	O
ml	O
,	O
was	O
associated	O
with	O
higher	O
percentages	O
of	O
lymphocytes	O
producing	O
:	O
(	O
a	O
)	O
induced	O
or	O
spontaneous	O
IL-6	B
(	O
medians	O
:	O
induced	O
,	O
15.9	O
%	O
for	O
iron	O
-	O
deficient	O
children	O
versus	O
8.8	O
%	O
for	O
iron	O
-	O
replete	O
children	O
,	O
P	O
=	O
0.002	O
;	O
spontaneous	O
,	O
24.4	O
%	O
versus	O
13.0	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
(	O
b	O
)	O
induced	O
IFN	B
-	I
gamma	I
(	O
medians	O
:	O
18.4	O
%	O
versus	O
12.4	O
%	O
,	O
P	O
=	O
0.006	O
)	O
.	O

The	O
percentages	O
of	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
spontaneously	O
producing	O
IL-6	B
and	O
of	O
all	O
lymphocytes	O
producing	O
induced	O
TNF	B
-	I
alpha	I
and	O
IFN	B
-	I
gamma	I
in	O
the	O
same	O
cell	O
had	O
the	O
strongest	O
relationships	O
to	O
iron	O
deficiency	O
(	O
b	O
=	O
+	O
0.0211	O
,	O
P	O
=	O
0.005	O
and	O
b	O
=	O
+	O
0.1158	O
,	O
P	O
=	O
0.012	O
,	O
respectively	O
,	O
LRA	O
)	O
and	O
were	O
also	O
positively	O
related	O
to	O
the	O
co	O
-	O
expression	O
of	O
the	O
T	O
cell	O
activation	O
markers	O
HLA	B
DR	I
and	O
CD38	B
.	O

Severe	O
iron	O
deficiency	O
(	O
TfR	B
>	O
or	O
=	O
30	O
microg	O
/	O
ml	O
)	O
was	O
associated	O
with	O
the	O
percentage	O
of	O
lymphocytes	O
producing	O
induced	O
IL-4	B
(	O
medians	O
:	O
0.5	O
%	O
versus	O
1.6	O
%	O
,	O
P	O
<	O
0.010	O
)	O
.	O

The	O
cytokine	B
patterns	O
associated	O
with	O
iron	O
deficiency	O
in	O
our	O
study	O
would	O
preserve	O
iron	O
stores	O
but	O
also	O
preferentially	O
retain	O
the	O
activation	O
capabilities	O
of	O
T	O
cells	O
,	O
albeit	O
not	O
necessarily	O
other	O
immune	O
cells	O
,	O
until	O
a	O
critical	O
level	O
of	O
iron	O
depletion	O
is	O
reached	O
.	O

Cloning	O
,	O
characterisation	O
and	O
crystallisation	O
of	O
a	O
diadenosine	B
"5',5""'-P"	I
(	I
1	I
)	I
,P	I
(	I
4	I
)	I
-tetraphosphate	I
pyrophosphohydrolase	I
from	O
Caenorhabditis	O
elegans	O
.	O

Asymmetrically	O
cleaving	O
diadenosine	B
"5',5""'-P"	I
(	I
1	I
)	I
,P	I
(	I
4	I
)	I
-tetraphosphate	I
(	I
Ap4A	I
)	I
hydrolase	I
activity	O
has	O
been	O
detected	O
in	O
extracts	O
of	O
adult	O
Caenorhabditis	O
elegans	O
and	O
the	O
corresponding	O
cDNA	O
amplified	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

As	O
expected	O
,	O
sequence	O
analysis	O
shows	O
the	O
enzyme	O
to	O
be	O
a	O
member	O
of	O
the	O
Nudix	B
hydrolase	I
family	I
.	O

The	O
purified	O
recombinant	O
enzyme	O
behaves	O
as	O
a	O
typical	O
animal	O
Ap4A	B
hydrolase	I
.	O

It	O
hydrolyses	O
Ap4A	O
with	O
a	O
K	O
(	O
m	O
)	O
of	O
7	O
microM	O
and	O
k	O
(	O
cat	O
)	O
of	O
27	O
s	O
(	O
-1	O
)	O
producing	O
AMP	O
and	O
ATP	O
as	O
products	O
.	O

It	O
is	O
also	O
active	O
towards	O
other	O
adenosine	O
and	O
diadenosine	O
polyphosphates	O
with	O
four	O
or	O
more	O
phosphate	O
groups	O
,	O
but	O
not	O
diadenosine	O
triphosphate	O
,	O
always	O
generating	O
ATP	O
as	O
one	O
of	O
the	O
products	O
.	O

It	O
is	O
inhibited	O
non	O
-	O
competitively	O
by	O
fluoride	O
(	O
K	O
(	O
i	O
)	O
=	O
25	O
microM	O
)	O
and	O
competitively	O
by	O
adenosine	O
5'-tetraphosphate	O
with	O
Ap4A	O
as	O
substrate	O
(	O
K	O
(	O
i	O
)	O
=	O
10	O
nM	O
)	O
.	O

Crystals	O
of	O
diffraction	O
quality	O
with	O
the	O
morphology	O
of	O
rectangular	O
plates	O
were	O
readily	O
obtained	O
and	O
preliminary	O
data	O
collected	O
.	O

These	O
crystals	O
diffract	O
to	O
a	O
minimum	O
d	O
-	O
spacing	O
of	O
2	O
A	O
and	O
belong	O
to	O
either	O
space	O
group	O
C222	O
or	O
C222	O
(	O
1	O
)	O
.	O

Phylogenetic	O
analysis	O
of	O
known	O
and	O
putative	O
Ap4A	B
hydrolases	I
of	O
the	O
Nudix	B
family	I
suggests	O
that	O
they	O
fall	O
into	O
two	O
groups	O
comprising	O
plant	O
and	O
Proteobacterial	O
enzymes	O
on	O
the	O
one	O
hand	O
and	O
animal	O
and	O
archaeal	O
enzymes	O
on	O
the	O
other	O
.	O

Complete	O
structural	O
determination	O
of	O
the	O
C.	O
elegans	O
Ap4A	B
hydrolase	I
will	O
help	O
determine	O
the	O
basis	O
of	O
this	O
grouping	O
.	O

The	O
biochemical	O
basis	O
for	O
increased	O
testosterone	O
production	O
in	O
theca	O
cells	O
propagated	O
from	O
patients	O
with	O
polycystic	O
ovary	O
syndrome	O
.	O

Ovarian	O
theca	O
cells	O
propagated	O
from	O
patients	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
convert	O
steroid	O
precursors	O
into	O
T	O
more	O
efficiently	O
than	O
normal	O
theca	O
cells	O
.	O

To	O
identify	O
the	O
basis	O
for	O
increased	O
T	O
production	O
by	O
PCOS	O
theca	O
cells	O
,	O
we	O
examined	O
type	B
I	I
-	I
V	I
17	I
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
17	B
beta	I
HSD	I
)	O
isoform	O
expression	O
in	O
long	O
-	O
term	O
cultures	O
of	O
theca	O
and	O
granulosa	O
cells	O
isolated	O
from	O
normal	O
and	O
PCOS	O
ovaries	O
.	O

RT	O
-	O
PCR	O
analysis	O
demonstrated	O
that	O
theca	O
cells	O
express	O
type	B
V	I
17	I
beta	I
HSD	I
a	O
member	O
of	O
the	O
aldo	B
-	I
keto	I
reductase	I
(	I
AKR	I
)	I
superfamily	I
(	O
17	B
beta	I
HSDV	I
,	O
AKR1C3	B
)	O
,	O
whereas	O
expression	O
of	O
type	B
I	I
,	I
II	I
,	I
and	I
IV	I
17	I
beta	I
HSD	I
,	O
which	O
are	O
members	O
of	O
the	O
short	B
-	I
chain	I
dehydrogenase	I
/	I
reductase	I
superfamily	I
,	O
was	O
limited	O
to	O
granulosa	O
cells	O
.	O

Type	B
III	I
17	I
beta	I
HSD	I
,	O
the	O
testicular	O
isoform	O
,	O
was	O
not	O
detected	O
in	O
either	O
granulosa	O
or	O
theca	O
cells	O
.	O

Northern	O
and	O
real	O
-	O
time	O
PCR	O
analyses	O
demonstrated	O
that	O
17	B
beta	I
HSDV	I
transcripts	O
were	O
not	O
significantly	O
increased	O
in	O
PCOS	O
theca	O
cells	O
compared	O
with	O
normal	O
theca	O
cells	O
.	O

RT	O
-	O
PCR	O
analysis	O
revealed	O
that	O
theca	O
cells	O
also	O
express	O
another	O
AKR	B
,	O
20	B
alpha	I
HSD	I
(	O
AKR1C1	B
)	O
.	O

Both	O
basal	O
and	O
forskolin	O
-	O
stimulated	O
20	B
alpha	I
HSD	I
mRNA	O
levels	O
were	O
increased	O
in	O
PCOS	O
theca	O
cells	O
compared	O
with	O
normal	O
theca	O
cells	O
.	O

However	O
,	O
17	B
beta	I
HSD	I
enzyme	O
activity	O
per	O
theca	O
cell	O
was	O
not	O
significantly	O
increased	O
in	O
PCOS	O
,	O
suggesting	O
that	O
neither	O
AKR1C3	B
nor	O
AKR1C1	B
contributes	O
to	O
the	O
formation	O
of	O
T	O
in	O
this	O
condition	O
.	O

In	O
contrast	O
,	O
17	B
alpha	I
-	I
hydroxylase	I
/	I
C17,20	I
lyase	I
and	O
3	B
beta	I
HSD	I
enzyme	O
activities	O
were	O
elevated	O
in	O
PCOS	O
theca	O
cells	O
,	O
driving	O
increased	O
production	O
of	O
T	O
precursors	O
.	O

These	O
findings	O
indicate	O
that	O
1	O
)	O
increased	O
T	O
production	O
in	O
PCOS	O
theca	O
cells	O
does	O
not	O
result	O
from	O
dysregulation	O
of	O
""""	O
androgenic	O
""""	O
17	B
beta	I
HSD	I
activity	O
or	O
altered	O
expression	O
of	O
AKRs	B
that	O
may	O
express	O
17	B
beta	I
HSD	I
activity	O
;	O
and	O
2	O
)	O
increased	O
synthesis	O
of	O
T	O
precursors	O
is	O
the	O
primary	O
factor	O
driving	O
enhanced	O
T	O
secretion	O
in	O
PCOS	O
.	O

CT-1	B
mediated	O
cardioprotection	O
against	O
ischaemic	O
re	O
-	O
oxygenation	O
injury	O
is	O
mediated	O
by	O
PI3	B
kinase	I
,	O
Akt	B
and	O
MEK1	B
/	I
2	I
pathways	O
.	O

Cardiotrophin-1	B
protects	O
cardiac	O
myocytes	O
from	O
ischaemic	O
re	O
-	O
oxygenation	O
(	O
IR	O
)	O
injury	O
.	O

CT-1	B
activates	O
MEK1	B
/	I
2	I
,	O
p42	B
/	I
44MAPK	I
as	O
well	O
as	O
the	O
phosphatidylinositol	B
(	I
PI	I
)	I
3-OH	I
kinase	I
(	O
PI3	O
)	O
protein	B
kinase	I
B	I
(	O
PKB	B
/	O
Akt	B
)	O
pathway	O
.	O

In	O
this	O
study	O
we	O
investigate	O
the	O
signalling	O
pathways	O
that	O
mediate	O
the	O
anti	O
-	O
apoptotic	O
cell	O
survival	O
effect	O
of	O
CT-1	B
in	O
IR	O
.	O

Dominant	O
negative	O
gene	O
based	O
inhibitors	O
of	O
MEK1	B
/	I
2	I
,	O
PI3	B
-	I
kinase	I
and	O
Akt	B
inhibited	O
CT-1	B
mediated	O
cardioprotection	O
in	O
re	O
-	O
oxygenation	O
as	O
did	O
chemical	O
inhibitors	O
of	O
the	O
PI3	B
-	I
kinase	I
pathway	O
.	O

Hence	O
the	O
PI3-kinase	B
/	O
Akt	B
pathway	O
is	O
required	O
in	O
addition	O
to	O
MEK1	B
/	I
2	I
to	O
mediate	O
CT-1	B
cardioprotection	O
in	O
IR	O
.	O

A	O
lipid	O
-	O
regulated	O
docking	O
site	O
on	O
vinculin	B
for	O
protein	B
kinase	I
C	I
.	O

During	O
cell	O
spreading	O
,	O
binding	O
of	O
actin	B
-	O
organizing	O
proteins	O
to	O
acidic	O
phospholipids	O
and	O
phosphorylation	O
are	O
important	O
for	O
localization	O
and	O
activity	O
of	O
these	O
proteins	O
at	O
nascent	O
cell	O
-	O
matrix	O
adhesion	O
sites	O
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
transient	O
interaction	O
between	O
the	O
lipid	O
-	O
dependent	O
protein	B
kinase	I
Calpha	I
and	O
vinculin	B
,	O
an	O
early	O
component	O
of	O
these	O
sites	O
,	O
during	O
spreading	O
of	O
HeLa	O
cells	O
on	O
collagen	B
.	O

In	O
vitro	O
binding	O
of	O
protein	B
kinase	I
Calpha	I
to	O
vinculin	B
tail	O
was	O
found	O
dependent	O
on	O
free	O
calcium	O
and	O
acidic	O
phospholipids	O
but	O
independent	O
of	O
a	O
functional	O
kinase	B
domain	O
.	O

The	O
interaction	O
was	O
enhanced	O
by	O
conditions	O
that	O
favor	O
the	O
oligomerization	O
of	O
vinculin	B
.	O

Phosphorylation	O
by	O
protein	B
kinase	I
Calpha	I
reached	O
1.5	O
mol	O
of	O
phosphate	O
/	O
mol	O
of	O
vinculin	B
tail	O
and	O
required	O
the	O
C	O
-	O
terminal	O
hydrophobic	O
hairpin	O
,	O
a	O
putative	O
phosphatidylinositol	O
4,5-bisphosphate	O
-	O
binding	O
site	O
.	O

Mass	O
spectroscopy	O
of	O
peptides	O
derived	O
from	O
in	O
vitro	O
phosphorylated	O
vinculin	B
tail	O
identified	O
phosphorylation	O
of	O
serines	O
1033	O
and	O
1045	O
.	O

Inhibition	O
of	O
C	O
-	O
terminal	O
phospholipid	O
binding	O
at	O
the	O
vinculin	B
tail	O
by	O
mutagenesis	O
or	O
deletion	O
reduced	O
the	O
rate	O
of	O
phosphorylation	O
to	O
<	O
or	O
=	O
50	O
%	O
.	O

We	O
suggest	O
a	O
possible	O
mechanism	O
whereby	O
phospholipid	O
-	O
regulated	O
conformational	O
changes	O
in	O
vinculin	B
may	O
lead	O
to	O
exposure	O
of	O
a	O
docking	O
site	O
for	O
protein	B
kinase	I
Calpha	I
and	O
subsequent	O
phosphorylation	O
of	O
vinculin	B
and/or	O
vinculin	B
interaction	O
partners	O
,	O
thereby	O
affecting	O
the	O
formation	O
of	O
cell	O
adhesion	O
complexes	O
.	O

IscR	B
,	O
an	O
Fe	O
-	O
S	O
cluster	O
-	O
containing	O
transcription	B
factor	I
,	O
represses	O
expression	O
of	O
Escherichia	O
coli	O
genes	O
encoding	O
Fe	O
-	O
S	O
cluster	O
assembly	O
proteins	O
.	O

IscR	B
(	O
iron	B
-	I
sulfur	I
cluster	I
regulator	I
)	O
is	O
encoded	O
by	O
an	O
ORF	O
located	O
immediately	O
upstream	O
of	O
genes	O
coding	O
for	O
the	O
Escherichia	O
coli	O
Fe	O
-	O
S	O
cluster	O
assembly	O
proteins	O
,	O
IscS	B
,	O
IscU	B
,	O
and	O
IscA	B
.	O

IscR	B
shares	O
amino	O
acid	O
similarity	O
with	O
MarA	B
,	O
a	O
member	O
of	O
the	O
MarA	B
/	I
SoxS	I
/	I
Rob	I
family	I
of	O
transcription	B
factors	I
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
IscR	B
functions	O
as	O
a	O
repressor	O
of	O
the	O
iscRSUA	B
operon	I
,	O
because	O
strains	O
deleted	O
for	O
iscR	B
have	O
increased	O
expression	O
of	O
this	O
operon	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
transcription	O
reactions	O
established	O
a	O
direct	O
role	O
for	O
IscR	B
in	O
repression	O
of	O
the	O
iscR	B
promoter	O
.	O

Analysis	O
of	O
IscR	B
by	O
electron	O
paramagnetic	O
resonance	O
showed	O
that	O
the	O
anaerobically	O
isolated	O
protein	O
contains	O
a	O
[	O
2Fe-2S	O
]	O
(	O
1	O
+	O
)	O
cluster	O
.	O

The	O
Fe	O
-	O
S	O
cluster	O
appears	O
to	O
be	O
important	O
for	O
IscR	B
function	O
,	O
because	O
repression	O
of	O
iscR	B
expression	O
is	O
significantly	O
reduced	O
in	O
strains	O
containing	O
null	O
mutations	O
of	O
the	O
Fe	O
-	O
S	O
cluster	O
assembly	O
genes	O
iscS	B
or	O
hscA	B
.	O

The	O
finding	O
that	O
IscR	B
activity	O
is	O
decreased	O
in	O
strain	O
backgrounds	O
in	O
which	O
Fe	O
-	O
S	O
cluster	O
assembly	O
is	O
impaired	O
suggests	O
that	O
this	O
protein	O
may	O
be	O
part	O
of	O
a	O
novel	O
autoregulatory	O
mechanism	O
that	O
senses	O
the	O
Fe	O
-	O
S	O
cluster	O
assembly	O
status	O
of	O
cells	O
.	O

Alternate	O
signalling	O
pathways	O
from	O
the	O
interleukin-2	B
receptor	I
.	O

Interleukin-2	B
(	O
IL-2	B
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
proliferation	O
of	O
cell	O
populations	O
during	O
an	O
immune	O
reaction	O
.	O

The	O
beta	B
(	I
c	I
)	I
and	O
gamma	B
(	I
c	I
)	I
subunits	O
of	O
the	O
IL-2	B
receptor	I
(	O
IL-2R	B
)	O
are	O
sufficient	O
and	O
necessary	O
for	O
signal	O
transduction	O
.	O

Despite	O
lacking	O
known	O
catalytic	O
domains	O
,	O
receptor	O
engagement	O
leads	O
to	O
the	O
activation	O
of	O
a	O
diverse	O
array	O
protein	B
tyrosine	I
kinases	I
(	O
PTKs	B
)	O
.	O

In	O
resting	O
or	O
anergised	O
T	O
cells	O
,	O
Jak3	B
is	O
not	O
activated	O
.	O

Signals	O
arising	O
from	O
the	O
PROX	O
domain	O
of	O
the	O
gamma	B
(	I
c	I
)	I
subunit	O
activate	O
p56	B
(	I
lck	I
)	I
(	O
lck	B
)	O
leading	O
to	O
the	O
induction	O
of	O
anti	O
-	O
apoptotic	O
mechanisms	O
.	O

When	O
Jak3	B
is	O
activated	O
,	O
in	O
primed	O
T	O
cells	O
,	O
other	O
PTKs	B
predominantly	O
mediate	O
the	O
induction	O
of	O
anti	O
-	O
apoptotic	O
mechanisms	O
and	O
drive	O
cellular	O
proliferation	O
.	O

This	O
review	O
intends	O
to	O
suggest	O
a	O
role	O
for	O
these	O
differences	O
within	O
the	O
context	O
of	O
the	O
immune	O
system	O
.	O

Direct	O
interaction	O
of	O
YidC	B
with	O
the	O
Sec	B
-	O
independent	O
Pf3	O
coat	B
protein	I
during	O
its	O
membrane	O
protein	O
insertion	O
.	O

YidC	B
is	O
a	O
newly	O
defined	O
translocase	B
component	O
that	O
mediates	O
the	O
insertion	O
of	O
proteins	O
into	O
the	O
membrane	O
bilayer	O
.	O

How	O
YidC	B
functions	O
in	O
the	O
insertion	O
process	O
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
the	O
Sec	B
-	O
independent	O
Pf3	O
coat	B
protein	I
requires	O
the	O
YidC	B
protein	O
specifically	O
for	O
the	O
membrane	O
translocation	O
step	O
.	O

Using	O
photocrosslinking	O
techniques	O
and	O
ribosome	O
-	O
bound	O
Pf3	O
coat	O
derivatives	O
with	O
an	O
extended	O
carboxyl	O
-	O
terminal	O
region	O
,	O
we	O
found	O
that	O
the	O
transmembrane	O
region	O
of	O
the	O
Pf3	O
coat	B
protein	I
physically	O
interacts	O
with	O
YidC	B
and	O
the	O
bacterial	O
signal	O
recognition	O
particle	O
Ffh	B
component	O
.	O

We	O
also	O
find	O
that	O
in	O
the	O
insertion	O
pathway	O
,	O
Pf3	O
coat	O
interacts	O
strongly	O
with	O
YidC	B
only	O
after	O
its	O
transmembrane	O
segment	O
is	O
fully	O
exposed	O
outside	O
the	O
ribosome	O
tunnel	O
.	O

Interaction	O
between	O
Pf3	O
coat	O
and	O
YidC	B
occurs	O
even	O
in	O
the	O
absence	O
of	O
the	O
proton	O
motive	O
force	O
and	O
with	O
a	O
Pf3	O
coat	O
mutant	O
that	O
is	O
defective	O
in	O
transmembrane	O
insertion	O
.	O

Our	O
study	O
demonstrates	O
that	O
YidC	B
can	O
directly	O
interact	O
with	O
a	O
Sec	B
-	O
independent	O
membrane	O
protein	O
,	O
and	O
the	O
role	O
of	O
YidC	B
is	O
at	O
the	O
stage	O
of	O
folding	O
the	O
Pf3	O
protein	O
into	O
a	O
transmembrane	O
configuration	O
.	O

BCR	B
-	O
ABL	B
suppresses	O
C	B
/	I
EBPalpha	I
expression	O
through	O
inhibitory	O
action	O
of	O
hnRNP	B
E2	I
.	O

The	O
arrest	O
of	O
differentiation	O
is	O
a	O
feature	O
of	O
both	O
chronic	O
myelogenous	O
leukemia	O
cells	O
in	O
myeloid	O
blast	O
crisis	O
and	O
myeloid	O
precursors	O
that	O
ectopically	O
express	O
the	O
p210BCR	B
-	O
ABL	B
oncoprotein	O
;	O
however	O
,	O
its	O
underlying	O
mechanisms	O
remain	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
expression	O
of	O
BCR	B
-	O
ABL	B
in	O
myeloid	O
precursor	O
cells	O
leads	O
to	O
transcriptional	O
suppression	O
of	O
the	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
receptor	I
G	B
-	I
CSF	I
-	I
R	I
(	O
encoded	O
by	O
CSF3R	B
)	O
,	O
possibly	O
through	O
down	O
-	O
modulation	O
of	O
C	B
/	I
EBPalpha	I
-	O
the	O
principal	O
regulator	O
of	O
granulocytic	O
differentiation	O
.	O

Expression	O
of	O
C	B
/	I
EBPalpha	I
protein	O
is	O
barely	O
detectable	O
in	O
primary	O
marrow	O
cells	O
taken	O
from	O
individuals	O
affected	O
with	O
chronic	O
myeloid	O
leukemia	O
in	O
blast	O
crisis	O
.	O

In	O
contrast	O
,	O
CEBPA	B
RNA	O
is	O
clearly	O
present	O
.	O

Ectopic	O
expression	O
of	O
C	B
/	I
EBPalpha	I
induces	O
granulocytic	O
differentiation	O
of	O
myeloid	O
precursor	O
cells	O
expressing	O
BCR	B
-	O
ABL	B
.	O

Expression	O
of	O
C	B
/	I
EBPalpha	I
is	O
suppressed	O
at	O
the	O
translational	O
level	O
by	O
interaction	O
of	O
the	O
poly	O
(	O
rC	O
)	O
-	O
binding	O
protein	O
hnRNP	B
E2	I
with	O
CEBPA	B
mRNA	O
,	O
and	O
ectopic	O
expression	O
of	O
hnRNP	B
E2	I
in	O
myeloid	O
precursor	O
cells	O
down	O
-	O
regulates	O
both	O
C	B
/	I
EBPalpha	I
and	O
G	B
-	I
CSF	I
-	I
R	I
and	O
leads	O
to	O
rapid	O
cell	O
death	O
on	O
treatment	O
with	O
G	B
-	I
CSF	I
(	O
encoded	O
by	O
CSF3	B
)	O
.	O

Our	O
results	O
indicate	O
that	O
BCR	B
-	O
ABL	B
regulates	O
the	O
expression	O
of	O
C	B
/	I
EBPalpha	I
by	O
inducing	O
hnRNP	B
E2	I
-	O
which	O
inhibits	O
the	O
translation	O
of	O
CEBPA	B
mRNA	O
.	O

Cloning	O
,	O
mapping	O
and	O
expression	O
analysis	O
of	O
C15orf4	B
,	O
a	O
novel	O
human	O
gene	O
with	O
homology	O
to	O
the	O
yeast	O
mitochondrial	O
ribosomal	O
protein	O
Ym130	B
gene	O
.	O

We	O
have	O
identified	O
C15orf4	B
,	O
a	O
novel	O
human	O
gene	O
showing	O
homology	O
to	O
the	O
yeast	O
mitochondrial	O
ribosomal	O
protein	O
YmL30	B
.	O

C15orf4	B
encodes	O
a	O
transcript	O
of	O
1	O
,	O
006	O
nt	O
with	O
an	O
ORF	O
of	O
279	O
amino	O
acids	O
and	O
a	O
predicted	O
protein	O
size	O
of	O
31.7	O
kDa	O
.	O

Expression	O
of	O
C15orf4	B
is	O
enriched	O
in	O
testis	O
.	O

C15orf4	B
was	O
positioned	O
to	O
chromosome	O
15q24	O
by	O
radiation	O
hybrid	O
mapping	O
.	O

We	O
have	O
identified	O
the	O
C15orf4	B
mouse	O
orthologue	O
as	O
well	O
as	O
homologues	O
in	O
other	O
species	O
.	O

Effect	O
of	O
300	O
-	O
and	O
450	O
-	O
mg	O
clopidogrel	O
loading	O
doses	O
on	O
membrane	O
and	O
soluble	O
P	B
-	I
selectin	I
in	O
patients	O
undergoing	O
coronary	O
stent	O
implantation	O
.	O

BACKGROUND	O
:	O

After	O
coronary	O
artery	O
stent	O
implantation	O
patients	O
are	O
treated	O
with	O
the	O
adenosine	B
diphosphatase	I
(	I
ADP	I
)	I
receptor	I
antagonist	O
clopidogrel	O
to	O
prevent	O
subacute	O
stent	O
thromboses	O
.	O

Today	O
these	O
patients	O
initially	O
receive	O
a	O
loading	O
dose	O
of	O
300	O
mg	O
of	O
clopidogrel	O
to	O
accelerate	O
the	O
complete	O
drug	O
effect	O
.	O

In	O
the	O
current	O
study	O
we	O
investigated	O
whether	O
a	O
higher	O
loading	O
dose	O
can	O
shorten	O
the	O
time	O
until	O
the	O
maximum	O
platelet	O
inhibitory	O
effect	O
of	O
clopidogrel	O
is	O
achieved	O
.	O

METHODS	O
:	O

P	B
-	I
selectin	I
expression	O
of	O
nonstimulated	O
and	O
ADP	O
-	O
stimulated	O
platelets	O
was	O
flow	O
cytometrically	O
measured	O
before	O
the	O
clopidogrel	O
loading	O
dose	O
and	O
on	O
3	O
consecutive	O
days	O
in	O
52	O
patients	O
with	O
coronary	O
artery	O
disease	O
:	O
21	O
patients	O
in	O
group	O
1	O
received	O
300	O
mg	O
of	O
clopidogrel	O
after	O
stent	O
implantation	O
and	O
11	O
patients	O
in	O
group	O
2	O
received	O
the	O
higher	O
450	O
-	O
mg	O
clopidogrel	O
loading	O
dose	O
followed	O
by	O
a	O
daily	O
dose	O
of	O
75	O
mg	O
of	O
clopidogrel	O
for	O
both	O
groups	O
.	O

The	O
control	O
group	O
consisted	O
of	O
20	O
patients	O
who	O
were	O
monitored	O
over	O
2	O
days	O
before	O
coronary	O
intervention	O
.	O

Soluble	O
P	B
-	I
selectin	I
levels	O
in	O
plasma	O
were	O
determined	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O

Inducible	O
P	B
-	I
selectin	I
expression	O
on	O
ADP	O
-	O
stimulated	O
platelets	O
was	O
significantly	O
reduced	O
(	O
P	O
=	O
.05	O
)	O
on	O
days	O
1	O
and	O
2	O
in	O
patient	O
group	O
2	O
(	O
450	O
-	O
mg	O
loading	O
dose	O
)	O
compared	O
with	O
group	O
1	O
(	O
300	O
-	O
mg	O
loading	O
dose	O
)	O
.	O

No	O
influence	O
of	O
clopidogrel	O
on	O
the	O
P	B
-	I
selectin	I
levels	O
in	O
plasma	O
was	O
observed	O
.	O

CONCLUSIONS	O
:	O

In	O
our	O
study	O
the	O
application	O
of	O
450	O
mg	O
of	O
clopidogrel	O
as	O
the	O
loading	O
dose	O
in	O
patients	O
undergoing	O
coronary	O
stenting	O
shortens	O
the	O
period	O
until	O
the	O
maximum	O
effect	O
of	O
the	O
ADP	B
receptor	I
antagonist	O
is	O
achieved	O
and	O
thus	O
may	O
lead	O
to	O
a	O
more	O
successful	O
prevention	O
of	O
subacute	O
coronary	O
stent	O
thromboses	O
.	O

RseB	B
binding	O
to	O
the	O
periplasmic	O
domain	O
of	O
RseA	B
modulates	O
the	O
RseA	B
:	O
sigmaE	B
interaction	O
in	O
the	O
cytoplasm	O
and	O
the	O
availability	O
of	O
sigmaE	B
.	B
RNA	I
polymerase	I
.	O

The	O
Escherichia	O
coli	O
sigmaE	B
regulon	O
has	O
evolved	O
to	O
sense	O
the	O
presence	O
of	O
misfolded	O
proteins	O
in	O
the	O
bacterial	O
envelope	O
.	O

Expression	O
of	O
periplasmic	O
chaperones	B
and	O
folding	O
catalysts	O
is	O
under	O
the	O
control	O
of	O
sigmaE	B
RNA	B
polymerase	I
.	O

The	O
N	O
-	O
terminal	O
domain	O
of	O
RseA	B
sequesters	O
sigmaE	B
in	O
the	O
cytoplasmic	O
membrane	O
,	O
preventing	O
its	O
association	O
with	O
core	O
RNA	B
polymerase	I
.	O

The	O
C	O
-	O
terminal	O
domain	O
of	O
RseA	B
interacts	O
with	O
RseB	B
,	O
a	O
periplasmic	O
protein	O
.	O

The	O
relative	O
concentration	O
of	O
sigmaE	B
:	O
RseA	B
:	O
RseB	B
is	O
2:5:1	O
and	O
this	O
ratio	O
remains	O
unaltered	O
upon	O
heat	O
shock	O
induction	O
of	O
the	O
sigmaE	B
regulon	O
.	O

Purification	O
from	O
crude	O
cellular	O
extracts	O
yields	O
cytoplasmic	O
,	O
soluble	O
sigmaE	B
RNA	B
polymerase	I
as	O
well	O
as	O
membrane	O
sequestered	O
sigmaE	B
.	O
RseA	B
and	O
sigmaE	B
.	O
RseA	B
.	O
RseB	B
.	O

RseB	B
binding	O
to	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
RseA	B
increases	O
the	O
affinity	O
of	O
RseA	B
for	O
sigmaE	B
by	O
2	O
-	O
to	O
3	O
-	O
fold	O
(	O
Kd	O
50	O
-	O
100	O
nM	O
)	O
.	O

RseB	B
binds	O
also	O
to	O
the	O
misfolded	O
aggregates	O
of	O
MalE31	B
,	O
a	O
variant	O
of	O
maltose	O
binding	O
protein	O
that	O
forms	O
inclusion	O
bodies	O
in	O
the	O
periplasm	O
.	O

We	O
discuss	O
a	O
model	O
whereby	O
the	O
RseB	B
-	O
RiseA	B
interaction	O
represents	O
a	O
measure	O
for	O
misfolded	O
polypeptides	O
in	O
the	O
bacterial	O
envelope	O
,	O
modulating	O
the	O
assembly	O
of	O
sigmaE	B
RNA	B
polymerase	I
and	O
the	O
cellular	O
heat	O
shock	O
response	O
.	O

Th1	O
/	O
Th2	O
type	O
cytokines	B
in	O
hepatitis	O
B	O
patients	O
treated	O
with	O
interferon	B
-	I
alpha	I
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
Th1	O
/	O
Th2	O
type	O
cytokines	B
and	O
the	O
effect	O
of	O
interferon	B
-	I
alpha	I
therapy	O
.	O

METHODS	O
:	O

Th1	O
/	O
Th2	O
type	O
cytokines	B
were	O
assayed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
23	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
who	O
were	O
treated	O
with	O
interferon	B
-	I
alpha	I
.	O

RESULTS	O
:	O

Levels	O
of	O
IFN	B
-	I
gamma	I
in	O
the	O
supernatant	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
cultures	O
from	O
the	O
patients	O
with	O
hepatitis	O
B	O
were	O
slightly	O
lower	O
than	O
those	O
of	O
controls	O
(	O
P	O
=	O
0.07	O
)	O
.	O

However	O
,	O
the	O
levels	O
of	O
IL-4	B
were	O
higher	O
than	O
those	O
of	O
controls	O
(	O
P	O
=	O
0.01	O
)	O
.	O

Cytokines	B
measurements	O
during	O
IFN	B
-	I
alpha	I
treatment	O
showed	O
a	O
trend	O
to	O
decreasing	O
levels	O
of	O
IL-4	B
at	O
4	O
,	O
12	O
,	O
and	O
24	O
weeks	O
.	O

Levels	O
of	O
IFN	B
-	I
gamma	I
were	O
slightly	O
increased	O
following	O
IFN	B
-	I
alpha	I
treatment	O
(	O
P	O
=	O
0.09	O
)	O
.	O

In	O
patients	O
with	O
a	O
complete	O
response	O
to	O
IFN	B
-	I
alpha	I
,	O
the	O
levels	O
of	O
IFN	B
-	I
gamma	I
were	O
higher	O
at	O
24	O
weeks	O
following	O
IFN	B
-	I
alpha	I
treatment	O
than	O
that	O
of	O
pre	O
-	O
treatment	O
(	O
P	O
=	O
0.04	O
)	O
,	O
and	O
the	O
levels	O
of	O
IL-4	B
decreased	O
markedly	O
at	O
12	O
and	O
24	O
weeks	O
(	O
P	O
=	O
0.02	O
,	O
0.03	O
,	O
respectively	O
)	O
.	O

mRNA	O
expression	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
Th1	O
/	O
Th2	O
type	O
cytokines	B
in	O
the	O
supernatant	O
.	O

CONCLUSION	O
:	O

The	O
expression	O
of	O
Th2	O
type	O
cytokines	B
is	O
predominant	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
.	O

Interferon	B
-	I
alpha	I
therapy	O
can	O
modulate	O
the	O
balance	O
of	O
Th1	O
/	O
Th2	O
type	O
cytokines	B
,	O
and	O
this	O
is	O
related	O
to	O
its	O
clinical	O
effect	O
.	O

Levels	O
of	O
Th1	O
/	O
Th2	O
type	O
cytokines	B
could	O
be	O
a	O
predictor	O
of	O
clinical	O
response	O
during	O
Interferon	B
-	I
alpha	I
treatment	O
.	O

The	O
molar	O
ratio	O
of	O
serum	O
retinol	B
-	I
binding	I
protein	I
(	O
RBP	B
)	O
to	O
transthyretin	B
(	O
TTR	B
)	O
is	O
not	O
useful	O
to	O
assess	O
vitamin	O
A	O
status	O
during	O
infection	O
in	O
hospitalised	O
children	O
.	O

OBJECTIVE	O
:	O

To	O
assess	O
the	O
usefulness	O
of	O
the	O
molar	O
ratio	O
of	O
serum	O
retinol	B
-	I
binding	I
protein	I
(	O
RBP	B
)	O
to	O
transthyretin	B
(	O
TTR	B
)	O
to	O
determine	O
vitamin	O
A	O
(	O
VA	O
)	O
status	O
during	O
infection	O
.	O

DESIGN	O
:	O

We	O
took	O
advantage	O
of	O
previously	O
collected	O
data	O
during	O
a	O
randomised	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
to	O
conduct	O
a	O
secondary	O
analysis	O
of	O
the	O
RBP	B
/	O
TTR	B
ratio	O
and	O
its	O
relationship	O
to	O
infection	O
and	O
VA	O
status	O
.	O

In	O
this	O
clinical	O
trial	O
,	O
children	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
and	O
received	O
either	O
one	O
single	O
oral	O
high	O
dose	O
of	O
VA	O
(	O
200	O
000	O
IU	O
)	O
on	O
the	O
day	O
of	O
admission	O
and	O
subsequently	O
a	O
placebo	O
daily	O
until	O
discharge	O
or	O
daily	O
oral	O
low	O
doses	O
of	O
VA	O
(	O
5000	O
IU	O
)	O
from	O
admission	O
until	O
discharge	O
or	O
a	O
placebo	O
daily	O
from	O
admission	O
until	O
discharge	O
.	O

SETTING	O
:	O

Lwiro	O
pediatric	O
hospital	O
,	O
Province	O
of	O
South	O
Kivu	O
,	O
Democratic	O
Republic	O
of	O
Congo	O
.	O

SUBJECTS	O
:	O

A	O
total	O
of	O
900	O
children	O
aged	O
0	O
-	O
72	O
months	O
hospitalised	O
consecutively	O
between	O
March	O
1994	O
and	O
March	O
1996	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O

RBP	B
/	O
TTR	B
molar	O
ratio	O
after	O
7	O
days	O
hospitalisation	O
.	O

RESULTS	O
:	O

After	O
7	O
days	O
hospitalisation	O
,	O
molar	O
RBP	B
:	O
TTR	B
ratio	O
(	O
mean	O
+	O
/	O
-	O
s.d	O
.	O
)	O
of	O
infected	O
children	O
(	O
C	O
-	O
reactive	O
proteins	O
>	O
10	O
mg	O
/	O
l	O
)	O
was	O
0.67	O
+	O
/-	O
0.31	O
in	O
the	O
high	O
-	O
dose	O
group	O
(	O
n	O
=	O
81	O
)	O
,	O
0.74	O
+	O
/-	O
0.44	O
in	O
the	O
low	O
dose	O
group	O
(	O
n	O
=	O
71	O
)	O
and	O
0.73	O
+	O
/-	O
0.39	O
in	O
the	O
placebo	O
group	O
(	O
n	O
=	O
81	O
)	O
.	O

These	O
values	O
did	O
not	O
differ	O
significantly	O
(	O
one	O
-	O
way	O
ANOVA	O
P	O
=	O
0.472	O
)	O
.	O

In	O
patients	O
with	O
baseline	O
serum	O
retinol	O
concentrations	O
<	O
0.70	O
micromol	O
/	O
l	O
,	O
changes	O
in	O
RBP	B
:	O
TTR	B
ratio	O
between	O
admission	O
and	O
day	O
7	O
were	O
not	O
statistically	O
different	O
in	O
the	O
three	O
groups	O
(	O
one	O
-	O
way	O
ANOVA	O
P	O
=	O
0.548	O
)	O
.	O

CONCLUSIONS	O
:	O

In	O
this	O
population	O
of	O
malnourished	O
hospitalised	O
children	O
,	O
molar	O
RBP	B
:	O
TTR	B
ratio	O
does	O
not	O
appear	O
to	O
be	O
useful	O
to	O
assess	O
VA	O
status	O
during	O
infection	O
.	O

SPONSORSHIP	O
:	O

Our	O
research	O
was	O
partially	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Fonds	O
de	O
la	O
Recherche	O
Scientifique	O
et	O
MÃ?Â	O
©	O
dicale	O
(	O
contract	O
3.4505.94	O
)	O
and	O
the	O
David	O
and	O
Alice	O
Van	O
Buuren	O
Foundation	O
.	O

Inhibition	O
of	O
nNOS	B
activity	O
in	O
rat	O
brain	O
by	O
synthetic	O
kynurenines	O
:	O
structure	O
-	O
activity	O
dependence	O
.	O

The	O
overstimulation	O
of	O
the	O
N	B
-	I
methyl	I
-	I
D	I
-	I
aspartate	I
(	I
NMDA	I
)	I
subtype	I
of	I
glutamate	I
receptors	I
is	O
involved	O
in	O
excitotoxicity	O
,	O
a	O
process	O
participating	O
in	O
neurodegeneration	O
that	O
characterizes	O
some	O
neurological	O
disorders	O
and	O
acute	O
cerebral	O
insults	O
.	O

In	O
looking	O
for	O
compounds	O
with	O
neuroprotective	O
properties	O
,	O
a	O
series	O
of	O
kynurenine	O
derivatives	O
were	O
synthesized	O
,	O
and	O
their	O
effects	O
on	O
both	O
the	O
NMDA	O
and	O
nNOS	B
activity	O
in	O
rat	O
striatum	O
were	O
evaluated	O
.	O

Two	O
compounds	O
,	O
15a	O
(	O
2-acetamido-4-	O
(	O
2-amino-5-methoxyphenyl	O
)	O
-4-oxobutyric	O
acid	O
)	O
and	O
15c	O
(	O
2-butyramido-4-	O
(	O
2-amino-5-methoxyphenyl	O
)	O
-4-oxobutyric	O
acid	O
)	O
,	O
displayed	O
more	O
potent	O
activities	O
than	O
the	O
other	O
synthetic	O
compounds	O
tested	O
for	O
the	O
inhibition	O
of	O
NMDA	O
excitability	O
and	O
nNOS	B
activity	O
.	O

Two	O
other	O
compounds	O
,	O
18a	O
(	O
2-acetamido-4-	O
(	O
3-methoxyphenyl	O
)	O
-4-oxobutyric	O
acid	O
)	O
and	O
18c	O
(	O
2-butyramido-4-	O
(	O
3-methoxyphenyl	O
)	O
-4-oxobutyric	O
acid	O
)	O
,	O
that	O
have	O
the	O
same	O
structure	O
as	O
15a	O
and	O
15c	O
,	O
except	O
the	O
amino	O
group	O
in	O
R	O
(	O
1	O
)	O
,	O
showed	O
different	O
effects	O
.	O

Whereas	O
compound	O
18a	O
showed	O
lower	O
electrophysiological	O
potency	O
than	O
compounds	O
15a	O
and	O
15c	O
in	O
the	O
inhibition	O
of	O
the	O
NMDA	O
-	O
dependent	O
excitability	O
,	O
compound	O
18c	O
showed	O
the	O
opposite	O
effect	O
.	O

Moreover	O
,	O
compounds	O
18a	O
and	O
18c	O
were	O
unable	O
to	O
modify	O
nNOS	B
activity	O
.	O

The	O
remaining	O
kynurenines	O
tested	O
behave	O
like	O
compound	O
18a	O
.	O

These	O
results	O
suggest	O
that	O
a	O
structure	O
-	O
related	O
activity	O
of	O
these	O
synthetic	O
kynurenines	O
and	O
a	O
N	O
-	O
H	O
bond	O
in	O
a	O
specific	O
direction	O
is	O
necessary	O
for	O
some	O
kynurenine	O
analogues	O
to	O
inhibit	O
nNOS	B
activity	O
.	O

Calpain	B
-	O
mediated	O
cleavage	O
of	O
the	O
cyclin	B
-	I
dependent	I
kinase-5	I
activator	I
p39	I
to	O
p29	O
.	O

The	O
activity	O
of	O
cyclin	B
-	I
dependent	I
kinase-5	I
(	O
Cdk5	B
)	O
is	O
tightly	O
regulated	O
by	O
binding	O
of	O
its	O
neuronal	O
activators	O
p35	B
and	O
p39	B
.	O

Upon	O
neurotoxic	O
insults	O
,	O
p35	B
is	O
cleaved	O
to	O
p25	B
by	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
protease	B
calpain	B
.	O

p25	B
is	O
accumulated	O
in	O
ischemic	O
brains	O
and	O
in	O
brains	O
of	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
.	O

p25	B
deregulates	O
Cdk5	B
activity	O
by	O
causing	O
prolonged	O
activation	O
and	O
mislocalization	O
of	O
Cdk5	B
.	O

It	O
is	O
unknown	O
whether	O
p39	B
,	O
which	O
is	O
expressed	O
throughout	O
the	O
adult	O
rat	O
brain	O
,	O
is	O
cleaved	O
by	O
calpain	B
,	O
and	O
whether	O
this	O
contributes	O
to	O
deregulation	O
of	O
Cdk5	B
.	O

Here	O
,	O
we	O
show	O
that	O
calpain	B
cleaved	O
p39	B
in	O
vitro	O
,	O
resulting	O
in	O
generation	O
of	O
a	O
C	O
-	O
terminal	O
p29	O
fragment	O
.	O

In	O
vivo	O
,	O
p29	O
was	O
generated	O
in	O
ischemic	O
brain	O
concomitant	O
with	O
increased	O
calpain	B
activity	O
.	O

In	O
fresh	O
brain	O
lysates	O
,	O
generation	O
of	O
p29	O
was	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
,	O
and	O
calpain	O
inhibitors	O
abolished	O
p29	O
production	O
.	O

The	O
Ca	O
(	O
2	O
+	O
)	O
ionophore	O
ionomycin	O
and	O
the	O
excitotoxin	O
glutamate	O
induced	O
production	O
of	O
p29	O
in	O
cultures	O
of	O
cortical	O
neurons	O
in	O
a	O
calpain	B
-	O
dependent	O
manner	O
.	O

Like	O
p25	B
,	O
p29	O
was	O
more	O
stable	O
than	O
p39	B
and	O
caused	O
redistribution	O
of	O
Cdk5	B
in	O
cortical	O
neurons	O
.	O

Our	O
data	O
suggest	O
that	O
neurotoxic	O
insults	O
lead	O
to	O
calpain	B
-	O
mediated	O
conversion	O
of	O
p39	B
to	O
p29	B
,	O
which	O
might	O
contribute	O
to	O
deregulation	O
of	O
Cdk5	B
.	O

[	O
Comparative	O
analysis	O
of	O
various	O
techniques	O
of	O
prostatic	O
drainage	O
in	O
patients	O
with	O
chronic	O
obstructive	O
prostatitis	O
]	O

The	O
efficacy	O
of	O
prostatic	O
drainage	O
using	O
transurethral	O
vacuum	O
aspiration	O
(	O
Introl-4	O
unit	O
)	O
and	O
transrectal	O
pneumovibromassage	O
(	O
PVM	O
-	O
R-01	O
)	O
was	O
compared	O
in	O
1511	O
patients	O
with	O
chronic	O
obstructive	O
prostatitis	O
.	O

The	O
drainage	O
was	O
accompanied	O
by	O
local	O
(	O
urethral	O
,	O
rectal	O
and	O
urethral	O
-	O
rectal	O
tripsin	O
or	O
chimotripsin	O
electrophoresis	O
)	O
or	O
systemic	O
enzymic	O
therapy	O
(	O
vobenzim	O
)	O
.	O

The	O
highest	O
effect	O
of	O
the	O
drainage	O
was	O
achieved	O
in	O
patients	O
pretreated	O
for	O
5	O
-	O
7	O
days	O
with	O
systemic	O
enzymes	O
.	O

Transrectal	O
pneumovibromassage	O
proved	O
more	O
effective	O
and	O
safe	O
but	O
the	O
transurethral	O
technique	O
if	O
indicated	O
can	O
be	O
also	O
used	O
in	O
the	O
combined	O
treatment	O
.	O

[	O
Influence	O
of	O
different	O
methods	O
of	O
chemical	O
disinfection	O
on	O
the	O
physical	O
properties	O
of	O
type	O
IV	O
and	O
V	O
gypsum	O
dies	O
]	O

Several	O
instruments	O
and	O
materials	O
frequently	O
used	O
in	O
prosthodontics	O
--	O
such	O
as	O
stone	O
casts	O
,	O
dental	O
impressions	O
,	O
interocclusal	O
records	O
-	O
-	O
are	O
classified	O
,	O
by	O
the	O
dental	O
literature	O
,	O
as	O
vehicles	O
of	O
transmission	O
of	O
infectious	O
diseases	O
to	O
those	O
who	O
handle	O
them	O
.	O

The	O
present	O
study	O
aims	O
at	O
comparing	O
dimensional	O
alteration	O
,	O
superficial	O
texture	O
and	O
compression	O
resistance	O
of	O
stone	O
dies	O
submitted	O
to	O
different	O
disinfection	O
methods	O
:	O
30-minute	O
immersion	O
in	O
1	O
%	O
sodium	O
hypochlorite	O
or	O
in	O
2.2	O
%	O
alkaline	O
glutaraldehyde	O
(	O
with	O
or	O
without	O
previous	O
ultrasonic	O
washing	O
)	O
and	O
addition	O
of	O
2.2	O
%	O
alkaline	O
glutaraldehyde	O
or	O
5	O
%	O
sodium	O
hypochlorite	O
to	O
the	O
gypsum	O
during	O
its	O
preparation	O
.	O

It	O
was	O
possible	O
to	O
conclude	O
that	O
:	O
(	O
1	O
)	O
chemical	O
disinfection	O
did	O
not	O
cause	O
significant	O
dimensional	O
alteration	O
in	O
stone	O
dies	O
;	O
(	O
2	O
)	O
superficial	O
texture	O
was	O
altered	O
according	O
to	O
the	O
disinfection	O
method	O
utilized	O
;	O
(	O
3	O
)	O
immersion	O
in	O
disinfectant	O
solution	O
during	O
30	O
min	O
,	O
as	O
well	O
as	O
the	O
addition	O
of	O
disinfectant	O
to	O
the	O
gypsum	O
during	O
its	O
preparation	O
,	O
reduced	O
the	O
compression	O
resistance	O
of	O
dies	O
.	O

Positive	O
inotropic	O
responses	O
mediated	O
by	O
endothelin	B
ET	I
(	I
A	I
)	I
and	I
ET	I
(	I
B	I
)	I
receptors	I
in	O
human	O
myocardial	O
trabeculae	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
possible	O
inotropic	O
effects	O
mediated	O
by	O
endothelin	B
ET	I
(	I
A	I
)	I
and	I
ET	I
(	I
B	I
)	I
receptors	I
in	O
human	O
myocardial	O
trabeculae	O
from	O
the	O
right	O
atrium	O
and	O
the	O
left	O
ventricle	O
.	O

Isolated	O
trabeculae	O
from	O
human	O
hearts	O
were	O
paced	O
at	O
1.0	O
Hz	O
in	O
tissue	O
baths	O
,	O
and	O
changes	O
in	O
isometric	O
contractile	O
force	O
upon	O
exposure	O
to	O
agonist	O
were	O
studied	O
.	O

Endothelin-1	B
(	O
ET-1	B
)	O
and	O
ET-3	B
had	O
a	O
strong	O
positive	O
inotropic	O
effect	O
in	O
all	O
trabeculae	O
.	O

ET-1	B
was	O
significantly	O
more	O
potent	O
than	O
ET-3	B
in	O
both	O
atrial	O
(	O
P	O
<	O
0.001	O
)	O
and	O
ventricular	O
(	O
P	O
<	O
0.05	O
)	O
trabeculae	O
.	O

Preincubation	O
with	O
the	O
ET	B
(	I
A	I
)	I
receptor	I
antagonist	O
FR139317	O
(	O
1	O
microM	O
)	O
decreased	O
significantly	O
(	O
P	O
<	O
0.005	O
)	O
the	O
potency	O
of	O
ET	B
-	I
I	I
in	O
both	O
atrial	O
and	O
ventricular	O
trabeculae	O
,	O
without	O
any	O
significant	O
changes	O
in	O
Emax	O
(	O
maximum	O
effect	O
obtained	O
with	O
an	O
agonist	O
)	O
.	O

The	O
ET	B
(	I
B	I
)	I
receptor	I
agonist	O
IRL	O
1620	O
had	O
a	O
positive	O
inotropic	O
effect	O
only	O
in	O
some	O
trabeculae	O
,	O
and	O
the	O
ET	B
(	I
B	I
)	I
receptor	I
antagonist	O
BQ	O
788	O
(	O
1	O
microM	O
)	O
almost	O
completely	O
blocked	O
this	O
effect	O
.	O

These	O
results	O
suggest	O
that	O
both	O
ET	B
(	I
A	I
)	I
and	I
ET	I
(	I
B	I
)	I
receptors	I
mediate	O
positive	O
inotropic	O
responses	O
at	O
both	O
the	O
atrial	O
and	O
ventricular	O
level	O
in	O
the	O
human	O
heart	O
.	O

Burn	O
injury	O
upregulates	O
the	O
activity	O
and	O
gene	O
expression	O
of	O
the	O
20	O
S	O
proteasome	O
in	O
rat	O
skeletal	O
muscle	O
.	O

There	O
is	O
evidence	O
that	O
burn	O
injury	O
stimulates	O
ubiquitin	B
-	O
proteasome	O
-	O
dependent	O
protein	O
breakdown	O
in	O
skeletal	O
muscle	O
.	O

In	O
this	O
proteolytic	O
pathway	O
,	O
protein	O
substrates	O
are	O
conjugated	O
to	O
multiple	O
molecules	O
of	O
ubiquitin	B
,	O
whereafter	O
they	O
are	O
recognized	O
,	O
unfolded	O
and	O
degraded	O
by	O
the	O
multicatalytic	O
26	O
S	O
protease	O
complex	O
.	O

The	O
20	O
S	O
proteasome	O
is	O
the	O
catalytic	O
core	O
of	O
the	O
26	O
S	O
protease	O
complex	O
.	O

The	O
influence	O
of	O
burn	O
injury	O
on	O
the	O
expression	O
and	O
activity	O
of	O
the	O
20	O
S	O
proteasome	O
has	O
not	O
been	O
reported	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
burn	O
injury	O
increases	O
20	O
S	O
proteasome	O
activity	O
and	O
the	O
expression	O
of	O
mRNA	O
for	O
the	O
20	O
S	O
proteasome	O
subunits	O
RC3	B
and	O
RC7	B
.	O

Proteolytic	O
activity	O
of	O
isolated	O
20	O
S	O
proteasomes	O
,	O
assessed	O
as	O
activity	O
against	O
fluorogenic	O
peptide	O
substrates	O
,	O
was	O
increased	O
in	O
extensor	O
digitorum	O
longus	O
muscles	O
from	O
burned	O
rats	O
.	O

Northern	O
-	O
blot	O
analysis	O
revealed	O
that	O
the	O
expression	O
of	O
mRNA	O
for	O
RC3	B
and	O
RC7	B
was	O
increased	O
by	O
100	O
%	O
and	O
80	O
%	O
respectively	O
following	O
burn	O
injury	O
.	O

Increased	O
activity	O
and	O
expression	O
of	O
the	O
20	O
S	O
proteasome	O
in	O
muscles	O
from	O
burned	O
rats	O
support	O
the	O
concept	O
that	O
burn	O
-	O
induced	O
muscle	O
cachexia	O
is	O
at	O
least	O
,	O
in	O
part	O
,	O
regulated	O
by	O
the	O
ubiquitin	B
-	O
proteasome	O
proteolytic	O
pathway	O
.	O

Apoptotic	O
proteins	O
.	O

p53	B
and	O
c	B
-	I
myc	I
related	O
pathways	O
.	O

c	B
-	I
Myc	I
and	O
p53	B
are	O
two	O
proteins	O
that	O
have	O
critical	O
roles	O
in	O
the	O
regulation	O
of	O
apoptosis	O
and	O
the	O
cell	O
cycle	O
.	O

The	O
authors	O
review	O
how	O
these	O
two	O
proteins	O
are	O
thought	O
to	O
control	O
the	O
opposing	O
events	O
of	O
proliferation	O
and	O
apoptosis	O
and	O
examine	O
whether	O
their	O
well	O
-	O
documented	O
biological	O
roles	O
in	O
tumorigenesis	O
can	O
be	O
applied	O
to	O
the	O
vascular	O
system	O
.	O

A	O
comparative	O
study	O
of	O
E	B
-	I
cadherin	I
and	O
stromelysin-3	B
expression	O
in	O
de	O
novo	O
and	O
ex	O
adenoma	O
carcinoma	O
of	O
the	O
colorectum	O
.	O

An	O
apparent	O
exception	O
to	O
the	O
colorectal	O
adenoma	O
-	O
carcinoma	O
carcinogenetic	O
pathway	O
is	O
the	O
so	O
-	O
called	O
""""	O
de	O
novo	O
""""	O
carcinoma	O
which	O
has	O
no	O
evidence	O
of	O
adenoma	O
in	O
its	O
vicinity	O
.	O

Despite	O
the	O
fact	O
that	O
they	O
are	O
often	O
quite	O
small	O
,	O
these	O
lesions	O
appear	O
to	O
be	O
more	O
aggressive	O
(	O
i.e.	O
,	O
greater	O
likelihood	O
of	O
lymph	O
-	O
node	O
metastases	O
)	O
than	O
carcinomas	O
that	O
clearly	O
arise	O
from	O
surrounding	O
adenomas	O
exadenoma	O
carcinoma	O
.	O

The	O
purpose	O
of	O
the	O
present	O
comparative	O
immunohistochemical	O
study	O
was	O
to	O
compare	O
rates	O
of	O
cell	B
adhesion	I
molecule	I
(	O
E	B
-	I
cadherin	I
)	O
and	O
protease	B
[	O
stromelysin-3	B
(	O
ST-3	B
)	O
]	O
expression	O
in	O
groups	O
of	O
de	O
novo	O
(	O
n	O
=	O
64	O
)	O
and	O
ex	O
adenoma	O
(	O
n	O
=	O
42	O
)	O
lesions	O
in	O
order	O
to	O
see	O
whether	O
their	O
more	O
aggressive	O
behavior	O
is	O
associated	O
with	O
decreased	O
cell	O
adhesion	O
and	O
increased	O
protease	O
expression	O
.	O

The	O
rates	O
of	O
extensive	O
ST-3	B
expression	O
and	O
decreased	O
E	B
-	I
cadherin	I
expression	O
were	O
significantly	O
higher	O
in	O
the	O
de	O
novo	O
group	O
(	O
P	O
=	O
0.014	O
and	O
0.005	O
,	O
respectively	O
)	O
.	O

Histopathologically	O
,	O
the	O
de	O
novo	O
group	O
also	O
had	O
a	O
significantly	O
higher	O
percentage	O
of	O
cases	O
with	O
an	O
infiltrative	O
invasion	O
pattern	O
.	O

These	O
differences	O
highlight	O
the	O
more	O
aggressive	O
phenotype	O
of	O
the	O
de	O
novo	O
colorectal	O
carcinoma	O
and	O
fit	O
with	O
their	O
greater	O
invasive	O
potential	O
.	O

Human	O
gastrinoma	O
cells	O
express	O
calcium	B
-	I
sensing	I
receptor	I
.	O

The	O
intravenous	O
calcium	O
injection	O
test	O
has	O
been	O
reported	O
to	O
be	O
useful	O
for	O
the	O
diagnosis	O
of	O
gastrinoma	O
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
calcium	O
-	O
evoked	O
gastrin	B
release	O
is	O
not	O
fully	O
understood	O
.	O

We	O
investigated	O
the	O
mechanism	O
of	O
calcium	O
-	O
stimulated	O
gastrin	B
release	O
from	O
gastrinoma	O
cells	O
in	O
vitro	O
with	O
a	O
particular	O
focus	O
on	O
the	O
calcium	B
-	I
sensing	I
receptor	I
(	O
CaR	B
)	O
.	O

Human	O
gastrinoma	O
cells	O
were	O
taken	O
from	O
mechanically	O
minced	O
gastrinoma	O
tissues	O
obtained	O
at	O
surgery	O
.	O

In	O
the	O
perifusion	O
system	O
,	O
high	O
[	O
Ca2	O
+	O
]	O
o	O
induced	O
gastrin	B
release	O
from	O
gastrinoma	O
cells	O
.	O

As	O
[	O
Ca2+	O
]	O
o	O
increased	O
,	O
[	O
Ca2	O
+	O
]	O
i	O
rapidly	O
increased	O
,	O
as	O
monitored	O
by	O
fluorometry	O
.	O

The	O
response	O
was	O
not	O
inhibited	O
by	O
nifedipine	O
,	O
a	O
blocker	O
of	O
the	O
voltage	B
-	I
dependent	I
calcium	I
channel	I
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
subsequent	O
Southern	O
blot	O
hybridization	O
revealed	O
the	O
presence	O
of	O
the	O
CaR	B
gene	O
in	O
human	O
gastrinoma	O
tissues	O
.	O

Moreover	O
,	O
the	O
expression	O
of	O
CaR	B
in	O
gastrinoma	O
tissues	O
was	O
confirmed	O
by	O
immunohistochemistry	O
.	O

Our	O
results	O
demonstrated	O
that	O
CaR	B
was	O
expressed	O
in	O
human	O
gastrinoma	O
cells	O
and	O
could	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
calcium	O
-	O
evoked	O
gastrin	B
release	O
.	O

Consequences	O
of	O
mevalonate	O
depletion	O
.	O

Differential	O
transcriptional	O
,	O
translational	O
,	O
and	O
post	O
-	O
translational	O
up	O
-	O
regulation	O
of	O
Ras	B
,	O
Rap1a	B
,	O
RhoA	B
,	O
AND	O
RhoB	B
.	O

Ras	B
-	O
related	O
proteins	O
are	O
small	B
GTPases	I
that	O
are	O
post	O
-	O
translationally	O
modified	O
with	O
mevalonate	O
-	O
derived	O
isoprenoids	O
.	O

Although	O
the	O
effects	O
of	O
inhibition	O
of	O
isoprenylation	O
on	O
protein	O
function	O
have	O
been	O
examined	O
,	O
the	O
consequences	O
of	O
depletion	O
of	O
isoprenoid	O
pools	O
on	O
regulation	O
of	O
expression	O
of	O
isoprenylated	O
proteins	O
have	O
yet	O
to	O
be	O
investigated	O
.	O

In	O
these	O
studies	O
we	O
have	O
shown	O
that	O
depletion	O
of	O
mevalonate	O
results	O
in	O
increased	O
total	O
levels	O
of	O
Ras	B
,	O
Rap1a	B
,	O
RhoA	B
,	O
and	O
RhoB	B
in	O
K562	O
cells	O
.	O

Cycloheximide	O
and	O
[	O
(	O
35	O
)	O
S	O
]	O
methionine	O
pulse	O
/	O
pulse	O
-	O
chase	O
experiments	O
reveal	O
that	O
mevalonate	O
depletion	O
increases	O
the	O
de	O
novo	O
synthesis	O
of	O
Ras	B
and	O
RhoA	B
and	O
decreases	O
the	O
degradation	O
of	O
existing	O
Ras	B
and	O
RhoA	B
protein	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
completely	O
prevents	O
the	O
induced	O
up	O
-	O
regulation	O
of	O
RhoB	B
and	O
only	O
partially	O
prevents	O
the	O
up	O
-	O
regulation	O
of	O
Ras	B
,	O
Rap1a	B
,	O
and	O
RhoA	B
.	O

Although	O
depletion	O
of	O
mevalonate	O
does	O
not	O
alter	O
steady	O
state	O
levels	O
of	O
Ras	B
mRNA	O
,	O
there	O
is	O
an	O
increase	O
in	O
RhoB	B
mRNA	O
.	O

Our	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
mevalonate	O
depletion	O
induces	O
up	O
-	O
regulation	O
of	O
Ras	B
and	O
Ras	B
-	O
related	O
proteins	O
by	O
discrete	O
mechanisms	O
that	O
include	O
modulation	O
of	O
transcriptional	O
,	O
translational	O
,	O
and	O
post	O
-	O
translational	O
processes	O
.	O

BMP-4	B
and	O
BMP-6	B
involvement	O
in	O
the	O
osteogenic	O
properties	O
of	O
the	O
HeLa	O
cell	O
line	O
.	O

The	O
heterotopically	O
induced	O
ossicles	O
are	O
used	O
in	O
our	O
research	O
on	O
bone	O
tissue	O
.	O

The	O
ossicles	O
are	O
formed	O
in	O
the	O
thigh	O
muscle	O
of	O
BALB	O
/	O
c	O
mice	O
under	O
the	O
influence	O
of	O
injected	O
suspension	O
of	O
3	O
x	O
10	O
(	O
6	O
)	O
HeLa	O
cells	O
.	O

We	O
postulate	O
that	O
the	O
mechanism	O
of	O
bone	O
induction	O
is	O
based	O
on	O
the	O
secretion	O
of	O
bone	B
morphogenetic	I
proteins	I
BMP-4	B
and	O
BMP-6	B
by	O
the	O
grafted	O
HeLa	O
cells	O
.	O

This	O
was	O
proved	O
by	O
the	O
use	O
of	O
specific	O
immunohistochemical	O
reaction	O
and	O
Western	O
blots	O
of	O
conditioned	O
culture	O
medium	O
.	O

It	O
seems	O
that	O
HeLa	O
cells	O
secrete	O
BMPs	B
continuously	O
into	O
the	O
culture	O
medium	O
,	O
even	O
without	O
contact	O
with	O
the	O
mice	O
muscle	O
tissue	O
,	O
were	O
induction	O
of	O
bone	O
tissue	O
is	O
observed	O
.	O

Genetic	O
studies	O
on	O
the	O
role	O
of	O
proteinases	B
and	O
growth	B
factors	I
in	O
atherosclerosis	O
and	O
aneurysm	O
formation	O
.	O

Expression	O
analysis	O
and	O
epidemiologic	O
studies	O
have	O
provided	O
indirect	O
evidence	O
that	O
proteinases	B
and	O
growth	B
factors	I
play	O
a	O
role	O
in	O
the	O
development	O
of	O
atherosclerosis	O
and	O
complications	O
such	O
as	O
aneurysm	O
formation	O
and	O
plaque	O
rupture	O
.	O

Studies	O
using	O
genetically	O
altered	O
mice	O
have	O
proven	O
to	O
be	O
an	O
elegant	O
tool	O
to	O
study	O
the	O
causal	O
involvement	O
of	O
these	O
factors	O
in	O
atherogenesis	O
and	O
to	O
gain	O
insight	O
into	O
the	O
underlying	O
mechanisms	O
.	O

Recently	O
,	O
proteinases	B
of	O
the	O
plasminogen	B
and	O
matrix	B
metalloproteinase	I
(	O
MMP	B
)	O
systems	O
as	O
well	O
as	O
their	O
inhibitors	O
have	O
received	O
much	O
attention	O
,	O
and	O
these	O
studies	O
together	O
have	O
emphasized	O
the	O
complexity	O
of	O
their	O
role	O
in	O
vascular	O
disease	O
.	O

This	O
overview	O
summarizes	O
the	O
current	O
knowledge	O
on	O
plasminogen	B
activator	I
inhibitor-1	I
(	O
PAI-1	B
)	O
in	O
the	O
progression	O
of	O
atherosclerosis	O
and	O
the	O
influence	O
of	O
MMPs	B
in	O
aneurysm	O
formation	O
.	O

In	O
addition	O
,	O
a	O
possible	O
role	O
for	O
Gas6	B
,	O
the	O
product	O
of	O
growth	B
arrest	I
-	I
specific	I
gene	I
6	I
,	O
in	O
atherosclerotic	O
lesion	O
development	O
is	O
put	O
into	O
perspective	O
.	O

Regulated	O
trafficking	O
of	O
neurotransmitter	B
transporters	I
:	O
common	O
notes	O
but	O
different	O
melodies	O
.	O

The	O
activity	O
of	O
biogenic	O
amine	O
and	O
amino	O
acid	O
neurotransmitters	O
is	O
limited	O
by	O
presynaptic	O
and	O
astrocytic	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
transport	O
systems	O
.	O

Their	O
functional	O
importance	O
is	O
underscored	O
by	O
the	O
observation	O
that	O
these	O
transporters	O
are	O
the	O
targets	O
of	O
broad	O
classes	O
of	O
psychotherapeutic	O
agents	O
,	O
including	O
antidepressants	O
and	O
stimulants	O
.	O

Early	O
studies	O
suggested	O
that	O
the	O
activity	O
of	O
these	O
transporters	O
can	O
be	O
fine	O
tuned	O
by	O
a	O
number	O
of	O
different	O
signaling	O
pathways	O
.	O

In	O
the	O
past	O
five	O
years	O
,	O
several	O
groups	O
have	O
provided	O
compelling	O
evidence	O
that	O
changing	O
the	O
cell	O
surface	O
availability	O
of	O
these	O
transporters	O
contributes	O
to	O
this	O
fine	O
tuning	O
.	O

This	O
regulated	O
trafficking	O
can	O
result	O
in	O
rapid	O
(	O
within	O
minutes	O
)	O
increases	O
or	O
decreases	O
in	O
the	O
plasma	O
membrane	O
expression	O
of	O
these	O
transporters	O
and	O
is	O
independent	O
of	O
transcriptional	O
or	O
translational	O
control	O
mechanisms	O
.	O

Many	O
of	O
the	O
same	O
signaling	O
molecules	O
,	O
including	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
tyrosine	B
kinase	I
,	O
phosphatidylinositol	B
3-kinase	I
(	O
P13	B
-	I
K	I
)	O
,	O
and	O
protein	B
phosphatase	I
,	O
regulate	O
the	O
transporters	O
for	O
different	O
neurotransmitters	O
.	O

In	O
addition	O
to	O
these	O
classical	O
receptor	O
activated	O
pathways	O
,	O
transporter	O
substrates	O
also	O
regulate	O
activity	O
and	O
cell	O
surface	O
expression	O
of	O
these	O
transporters	O
.	O

In	O
fact	O
,	O
some	O
of	O
the	O
transporters	O
form	O
complexes	O
with	O
signaling	O
molecules	O
.	O

Given	O
the	O
functional	O
and	O
genetic	O
similarities	O
of	O
these	O
transporters	O
,	O
it	O
is	O
not	O
surprising	O
that	O
the	O
same	O
signaling	O
molecules	O
regulate	O
their	O
trafficking	O
,	O
but	O
except	O
for	O
the	O
molecules	O
,	O
the	O
actual	O
effects	O
on	O
individual	O
transporters	O
are	O
remarkably	O
different	O
.	O

It	O
is	O
as	O
if	O
the	O
same	O
musical	O
notes	O
have	O
been	O
rearranged	O
into	O
several	O
different	O
melodies	O
.	O

Existence	O
of	O
MHC	B
class	I
I	I
-	O
restricted	O
alloreactive	O
CD4	B
+	O
T	O
cells	O
reacting	O
with	O
peptide	B
transporter	I
-	O
deficient	O
cells	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
as	O
the	O
result	O
of	O
positive	O
thymic	O
selection	O
,	O
CD8	B
-	O
expressing	O
T	O
cells	O
recognize	O
peptide	O
antigens	O
presented	O
in	O
the	O
context	O
of	O
MHC	B
class	I
I	I
molecules	O
and	O
CD4	B
-	O
expressing	O
T	O
cells	O
interact	O
with	O
peptide	O
antigens	O
presented	O
by	O
MHC	B
class	I
II	I
molecules	O
.	O

Here	O
we	O
report	O
the	O
generation	O
of	O
TCRalpha	B
/	I
beta	I
(	O
+	O
)	O
,	O
CD3	B
(	O
+	O
)	O
,	O
CD4	B
(	O
+	O
)	O
,	O
CD8	B
(	O
-	O
)	O
,	O
MHC	B
class	I
I	I
-	O
restricted	O
alloreactive	O
T	O
-	O
cell	O
clones	O
which	O
were	O
induced	O
using	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
healthy	O
individuals	O
following	O
in	O
vitro	O
stimulation	O
with	O
transporter	B
associated	I
with	I
antigen	I
processing	I
(	O
TAP	B
)	O
-	O
deficient	O
cell	O
lines	O
T2	O
.	O

The	O
CD4	B
(	O
+	O
)	O
T	O
-	O
cell	O
clones	O
showed	O
an	O
HLA	B
-	I
A2.1	I
-	O
specific	O
proliferative	O
response	O
against	O
T2	O
cells	O
which	O
was	O
inhibited	O
by	O
anti	O
-	O
CD3	B
and	O
anti	O
-	O
CD4	B
monoclonal	O
antibodies	O
.	O

These	O
results	O
suggest	O
that	O
interaction	O
of	O
the	O
TCR	B
with	O
peptide	O
-	O
bound	O
HLA	B
class	I
I	I
molecules	O
contributes	O
to	O
antigen	O
-	O
specific	O
activation	O
of	O
these	O
co	O
-	O
receptor	O
-	O
mismatched	O
T	O
-	O
cell	O
clones	O
.	O

Antigen	O
recognition	O
by	O
alloreactive	O
MHC	B
class	I
I	I
-	O
restricted	O
CD4	B
(	O
+	O
)	O
T	O
cells	O
was	O
inhibited	O
by	O
removing	O
peptides	O
bound	O
to	O
HLA	B
molecules	O
on	O
T2	O
cells	O
suggesting	O
that	O
the	O
alloreactive	O
CD4	B
(	O
+	O
)	O
T	O
cells	O
recognize	O
peptides	O
that	O
bind	O
in	O
a	O
TAP	B
-	O
independent	O
manner	O
to	O
HLA	B
-	I
A2	I
molecules	O
.	O

The	O
existence	O
of	O
such	O
MHC	B
class	I
I	I
-	O
restricted	O
CD4	B
(	O
+	O
)	O
T	O
cells	O
which	O
can	O
recognize	O
HLA	B
-	I
A2	I
molecules	O
in	O
the	O
absence	O
of	O
TAP	B
function	O
may	O
provide	O
a	O
basis	O
for	O
the	O
development	O
of	O
immunotherapy	O
against	O
TAP	B
-	O
deficient	O
tumor	O
variants	O
which	O
would	O
be	O
tolerant	O
to	O
immunosurveillance	O
by	O
conventional	O
MHC	B
class	I
I	I
-	O
restricted	O
cytotoxic	O
lymphocytes	O
.	O

Present	O
data	O
concerning	O
the	O
renin	B
-	O
angiotensin	B
system	O
of	O
extrarenal	O
origin	O
.	O

After	O
a	O
brief	O
historical	O
incursion	O
regarding	O
RAS	O
of	O
renal	O
origin	O
,	O
we	O
present	O
the	O
main	O
extrarenal	O
angiotensin	B
-	O
forming	O
enzymes	O
,	O
starting	O
with	O
isorenin	B
,	O
tonin	B
,	O
D	B
and	I
G	I
cathepsin	I
and	O
ending	O
with	O
the	O
conversion	B
enzyme	I
and	O
chymase	B
.	O

This	O
is	O
followed	O
by	O
a	O
short	O
presentation	O
of	O
data	O
concerning	O
tissue	O
RAS	O
in	O
the	O
heart	O
and	O
vessels	O
,	O
brain	O
and	O
neurocranial	O
accessory	O
glands	O
,	O
cortico	O
-	O
suprarenal	O
and	O
gonadal	O
glandular	O
territory	O
.	O

In	O
the	O
end	O
we	O
refer	O
to	O
the	O
relations	O
between	O
circulating	O
RAS	O
of	O
renal	O
origin	O
and	O
the	O
extrarenal	O
RAS	O
specific	O
to	O
tissue	O
underlying	O
the	O
fact	O
that	O
the	O
two	O
RAS	O
components	O
cooperate	O
and	O
constitute	O
a	O
unitary	O
hormonal	O
system	O
,	O
regulating	O
the	O
major	O
functions	O
of	O
the	O
organism	O
and	O
maintaining	O
the	O
main	O
homeostatic	O
equilibria	O
.	O

While	O
the	O
circulating	O
RAS	O
of	O
renal	O
origin	O
is	O
acutely	O
activated	O
to	O
contribute	O
to	O
the	O
accomplishment	O
of	O
short	O
term	O
homeostatic	O
reactions	O
,	O
tissue	O
RAS	O
,	O
in	O
paracrine	O
or	O
autocrine	O
ways	O
,	O
exerts	O
local	O
-	O
regional	O
adaptive	O
actions	O
of	O
long	O
duration	O
.	O

Molecular	O
mechanics	O
of	O
cardiac	O
titin	B
's	O
PEVK	O
and	O
N2B	O
spring	O
elements	O
.	O

Titin	B
is	O
a	O
giant	O
elastic	O
protein	O
that	O
is	O
responsible	O
for	O
the	O
majority	O
of	O
passive	O
force	O
generated	O
by	O
the	O
myocardium	O
.	O

Titin	B
's	O
force	O
is	O
derived	O
from	O
its	O
extensible	O
I	O
-	O
band	O
region	O
,	O
which	O
,	O
in	O
the	O
cardiac	O
isoform	O
,	O
comprises	O
three	O
main	O
extensible	O
elements	O
:	O
tandem	O
Ig	B
segments	O
,	O
the	O
PEVK	O
domain	O
,	O
and	O
the	O
N2B	O
unique	O
sequence	O
(	O
N2B	O
-	O
Us	O
)	O
.	O

Using	O
atomic	O
force	O
microscopy	O
,	O
we	O
characterized	O
the	O
single	O
molecule	O
force	O
-	O
extension	O
curves	O
of	O
the	O
PEVK	O
and	O
N2B	O
-	O
Us	O
spring	O
elements	O
,	O
which	O
together	O
are	O
responsible	O
for	O
physiological	O
levels	O
of	O
passive	O
force	O
in	O
moderately	O
to	O
highly	O
stretched	O
myocardium	O
.	O

Stretch	O
-	O
release	O
force	O
-	O
extension	O
curves	O
of	O
both	O
the	O
PEVK	O
domain	O
and	O
N2B	O
-	O
Us	O
displayed	O
little	O
hysteresis	O
:	O
the	O
stretch	O
and	O
release	O
data	O
nearly	O
overlapped	O
.	O

The	O
force	O
-	O
extension	O
curves	O
closely	O
followed	O
worm	O
-	O
like	O
chain	O
behavior	O
.	O

Histograms	O
of	O
persistence	O
length	O
(	O
measure	O
of	O
chain	O
bending	O
rigidity	O
)	O
indicated	O
that	O
the	O
single	O
molecule	O
persistence	O
lengths	O
are	O
approximately	O
1.4	O
and	O
approximately	O
0.65	O
nm	O
for	O
the	O
PEVK	O
domain	O
and	O
N2B	O
-	O
Us	O
,	O
respectively	O
.	O

Using	O
these	O
mechanical	O
characteristics	O
and	O
those	O
determined	O
earlier	O
for	O
the	O
tandem	O
Ig	B
segment	O
(	O
assuming	O
folded	O
Ig	B
domains	O
)	O
,	O
we	O
modeled	O
the	O
cardiac	O
titin	B
extensible	O
region	O
in	O
the	O
sarcomere	O
and	O
calculated	O
the	O
extension	O
of	O
the	O
various	O
spring	O
elements	O
and	O
the	O
forces	O
generated	O
by	O
titin	B
,	O
both	O
as	O
a	O
function	O
of	O
sarcomere	O
length	O
.	O

In	O
the	O
physiological	O
sarcomere	O
length	O
range	O
,	O
predicted	O
values	O
and	O
those	O
obtained	O
experimentally	O
were	O
indistinguishable	O
.	O

Expression	O
of	O
glucocorticoid	B
receptors	I
and	O
cyclooxygenase-2	B
in	O
nasal	O
polyps	O
from	O
nonallergic	O
patients	O
.	O

Glucocorticoid	O
treatment	O
has	O
been	O
widely	O
used	O
to	O
suppress	O
inflammatory	O
and	O
immune	O
responses	O
.	O

However	O
,	O
from	O
a	O
clinical	O
point	O
of	O
view	O
,	O
its	O
efficacy	O
in	O
the	O
treatment	O
of	O
nasal	O
polyposis	O
seems	O
to	O
vary	O
individually	O
from	O
patient	O
to	O
patient	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
presence	O
of	O
glucocorticoid	B
receptors	I
(	O
GRs	B
)	O
and	O
cyclooxygenase-2	B
(	O
COX-2	B
)	O
in	O
the	O
nasal	O
polyps	O
of	O
nonallergic	O
patients	O
as	O
compared	O
with	O
normal	O
controls	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analyses	O
revealed	O
the	O
presence	O
of	O
both	O
GR	B
messenger	O
RNA	O
and	O
COX-2	B
messenger	O
RNA	O
expression	O
in	O
nasal	O
polyps	O
from	O
nonallergic	O
patients	O
,	O
as	O
well	O
as	O
in	O
normal	O
nasal	O
mucosa	O
from	O
controls	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
immunohistochemical	O
analysis	O
demonstrated	O
that	O
GRs	B
and	O
COX-2	B
were	O
labeled	O
in	O
both	O
tissues	O
.	O

In	O
nasal	O
polyps	O
,	O
GR	B
labeling	O
was	O
associated	O
with	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
surface	O
mucosa	O
,	O
submucosal	O
glands	O
,	O
endothelial	O
cells	O
,	O
and	O
inflammatory	O
cells	O
.	O

Importantly	O
,	O
COX-2	B
labeling	O
was	O
seen	O
in	O
the	O
cytoplasm	O
of	O
surface	O
mucosa	O
,	O
submucosal	O
glands	O
,	O
and	O
the	O
vascular	O
wall	O
in	O
nasal	O
polyps	O
.	O

In	O
contrast	O
,	O
in	O
normal	O
nasal	O
tissues	O
,	O
COX-2	B
labeling	O
was	O
only	O
found	O
in	O
the	O
vascular	O
wall	O
,	O
and	O
the	O
expression	O
was	O
weaker	O
--	O
a	O
finding	O
demonstrating	O
that	O
COX-2	B
is	O
upregulated	O
in	O
nasal	O
polyps	O
.	O

Therefore	O
,	O
1	O
)	O
the	O
presence	O
of	O
GRs	B
and	O
COX-2	B
in	O
nasal	O
polyps	O
from	O
nonallergic	O
patients	O
,	O
as	O
well	O
as	O
upregulation	O
of	O
COX-2	B
expression	O
,	O
suggests	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
nasal	O
polyps	O
;	O
and	O
2	O
)	O
glucocorticoid	O
could	O
be	O
a	O
potential	O
treatment	O
method	O
for	O
suppressing	O
inflammatory	O
processes	O
.	O

Differential	O
expression	O
of	O
granulysin	B
and	O
perforin	B
by	O
NK	O
cells	O
in	O
cancer	O
patients	O
and	O
correlation	O
of	O
impaired	O
granulysin	B
expression	O
with	O
progression	O
of	O
cancer	O
.	O

Granulysin	B
has	O
been	O
identified	O
as	O
an	O
effector	O
molecule	O
co	O
-	O
localized	O
with	O
perforin	B
in	O
the	O
cytotoxic	O
granules	O
of	O
cytotoxic	O
T	O
lymphocytes	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
and	O
has	O
been	O
reported	O
to	O
kill	O
intracellular	O
pathogens	O
in	O
infected	O
cells	O
in	O
the	O
presence	O
of	O
perforin	B
and	O
to	O
induce	O
a	O
cytotoxic	O
effect	O
against	O
tumor	O
cells	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
elucidate	O
whether	O
intracellular	O
expression	O
of	O
granulysin	B
and	O
perforin	B
by	O
NK	O
cells	O
might	O
be	O
associated	O
with	O
progression	O
of	O
cancer	O
.	O

Flow	O
cytometric	O
analysis	O
demonstrated	O
high	O
levels	O
of	O
perforin	B
and	O
granulysin	B
expression	O
by	O
CD3	B
(	O
-	O
)	O
CD16	B
(	O
+	O
)	O
cells	O
in	O
healthy	O
controls	O
.	O

In	O
contrast	O
,	O
cancer	O
patients	O
exhibited	O
significantly	O
decreased	O
levels	O
of	O
granulysin	B
expression	O
(	O
P	O
<	O
0.005	O
)	O
,	O
despite	O
having	O
equally	O
high	O
levels	O
of	O
perforin	B
expression	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

The	O
tumor	O
-	O
free	O
patients	O
expressed	O
granulysin	B
at	O
levels	O
similar	O
to	O
healthy	O
controls	O
,	O
while	O
the	O
progressive	O
tumor	O
-	O
bearing	O
patients	O
expressed	O
remarkably	O
lower	O
levels	O
of	O
granulysin	B
compared	O
to	O
healthy	O
controls	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

Similarly	O
,	O
patients	O
with	O
an	O
advanced	O
performance	O
status	O
had	O
significantly	O
fewer	O
granulysin	B
-	O
positive	O
NK	O
cells	O
than	O
healthy	O
controls	O
.	O

Meanwhile	O
,	O
a	O
considerable	O
number	O
of	O
the	O
tumor	O
-	O
bearing	O
patients	O
showed	O
a	O
decrease	O
in	O
the	O
number	O
of	O
circulating	O
NK	O
cells	O
,	O
and	O
a	O
correlation	O
between	O
impaired	O
granulysin	B
expression	O
and	O
reduced	O
circulating	O
NK	O
cells	O
was	O
observed	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
tumor	O
-	O
bearing	O
patients	O
with	O
impaired	O
granulysin	B
expression	O
were	O
in	O
an	O
immunosuppressive	O
state	O
.	O

In	O
conclusion	O
,	O
impaired	O
expression	O
of	O
granulysin	B
by	O
NK	O
cells	O
correlates	O
with	O
progression	O
of	O
cancer	O
,	O
and	O
determination	O
of	O
granulysin	B
expression	O
might	O
prove	O
informative	O
for	O
assessing	O
the	O
immunological	O
condition	O
of	O
cancer	O
patients	O
.	O

Insulin	B
-	I
degrading	I
enzyme	I
rapidly	O
removes	O
the	O
beta	B
-	I
amyloid	I
precursor	I
protein	I
intracellular	I
domain	I
(	O
AICD	B
)	O
.	O

The	O
intramembranous	O
gamma	B
-	I
secretase	I
cleavage	O
of	O
the	O
beta	B
-	I
amyloid	I
precursor	I
protein	I
(	O
APP	B
)	O
is	O
dependent	O
on	O
biologically	O
active	O
presenilins	B
(	O
PS	B
)	O
.	O

Notch	B
also	O
undergoes	O
a	O
similar	O
PS	B
-	O
dependent	O
gamma	B
-	I
secretase	I
-	O
like	O
cleavage	O
,	O
resulting	O
in	O
the	O
liberation	O
of	O
the	O
Notch	B
intracellular	I
domain	I
(	O
NICD	B
)	O
,	O
which	O
is	O
critically	O
required	O
for	O
developmental	O
signal	O
transduction	O
.	O

gamma	B
-	I
Secretase	I
processing	O
of	O
APP	B
results	O
in	O
the	O
production	O
of	O
a	O
similar	O
fragment	O
called	O
AICD	B
(	O
APP	B
intracellular	I
domain	I
)	O
,	O
which	O
may	O
function	O
in	O
nuclear	O
signaling	O
as	O
well	O
.	O

AICD	B
,	O
like	O
NICD	B
,	O
is	O
rapidly	O
removed	O
.	O

By	O
using	O
a	O
battery	O
of	O
protease	B
inhibitors	O
we	O
demonstrate	O
that	O
AICD	B
,	O
in	O
contrast	O
to	O
NICD	B
,	O
is	O
degraded	O
by	O
a	O
cytoplasmic	O
metalloprotease	B
.	O

In	O
vitro	O
degradation	O
of	O
AICD	B
can	O
be	O
reconstituted	O
with	O
cytoplasmic	O
fractions	O
obtained	O
from	O
neuronal	O
and	O
non	O
-	O
neuronal	O
cells	O
.	O

Taking	O
into	O
account	O
the	O
inhibition	O
profile	O
and	O
the	O
cytoplasmic	O
localization	O
,	O
we	O
identified	O
three	O
candidate	O
enzymes	O
(	O
neurolysin	B
,	O
thimet	B
oligopeptidase	I
,	O
and	O
insulin	B
-	I
degrading	I
enzyme	I
(	O
IDE	B
)	O
,	O
also	O
known	O
as	O
insulysin	B
)	O
,	O
which	O
all	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
bioactive	O
peptides	O
in	O
the	O
brain	O
.	O

When	O
insulin	B
,	O
a	O
well	O
characterized	O
substrate	O
of	O
IDE	B
,	O
was	O
added	O
to	O
the	O
in	O
vitro	O
degradation	O
assay	O
,	O
removal	O
of	O
AICD	B
was	O
efficiently	O
blocked	O
.	O

Moreover	O
,	O
overexpression	O
of	O
IDE	B
resulted	O
in	O
enhanced	O
degradation	O
of	O
AICD	B
,	O
whereas	O
overexpression	O
of	O
the	O
inactive	O
IDE	B
E111Q	O
mutant	O
did	O
not	O
affect	O
AICD	B
degradation	O
.	O

Finally	O
,	O
immunodepletion	O
of	O
IDE	B
significantly	O
reduced	O
the	O
AICD	B
degrading	O
activity	O
.	O

Therefore	O
our	O
data	O
demonstrate	O
that	O
IDE	B
,	O
which	O
is	O
one	O
of	O
the	O
proteases	B
implicated	O
in	O
the	O
removal	O
of	O
extracellular	O
Abeta	B
,	O
also	O
removes	O
the	O
cytoplasmic	O
product	O
of	O
gamma	B
-	I
secretase	I
cleaved	O
APP	B
.	O

Determining	O
the	O
differences	O
in	O
actin	B
binding	O
by	O
human	O
ADF	B
and	O
cofilin	B
.	O

The	O
actin	B
-	I
depolymerizing	I
factor	I
(	I
ADF	I
)	I
/	I
cofilin	I
family	I
of	O
proteins	O
play	O
an	O
essential	O
role	O
in	O
actin	B
dynamics	O
and	O
cytoskeletal	O
re	O
-	O
organization	O
.	O

Human	O
tissues	O
express	O
two	O
isoforms	O
in	O
the	O
same	O
cells	O
,	O
ADF	B
and	O
cofilin	B
,	O
and	O
these	O
two	O
proteins	O
are	O
more	O
than	O
70	O
%	O
identical	O
in	O
amino	O
acid	O
sequence	O
.	O

We	O
show	O
that	O
ADF	B
is	O
a	O
much	O
more	O
potent	O
actin	B
-	O
depolymerizing	O
agent	O
than	O
cofilin	B
:	O
the	O
maximum	O
level	O
of	O
depolymerization	O
at	O
pH	O
8	O
by	O
ADF	B
is	O
about	O
20	O
microM	O
compared	O
to	O
5	O
microM	O
for	O
cofilin	B
,	O
but	O
little	O
depolymerization	O
occurs	O
at	O
pH	O
6.5	O
with	O
either	O
protein	O
.	O

However	O
,	O
we	O
find	O
little	O
difference	O
between	O
the	O
two	O
proteins	O
in	O
their	O
binding	O
to	O
filaments	O
,	O
their	O
severing	O
activities	O
or	O
their	O
activation	O
of	O
subunit	O
release	O
from	O
the	O
pointed	O
ends	O
of	O
filaments	O
.	O

Likewise	O
,	O
they	O
show	O
no	O
significant	O
differences	O
in	O
their	O
affinities	O
for	O
monomeric	O
actin	B
:	O
both	O
bind	O
15	O
-	O
fold	O
more	O
tightly	O
to	O
actin	B
.	O
ADP	O
than	O
to	O
actin	B
.	O
ATP	O
.	O

Complexes	O
between	O
actin	B
.	O
ADP	O
and	O
ADF	B
or	O
cofilin	B
associate	O
with	O
both	O
barbed	O
and	O
pointed	O
ends	O
of	O
filaments	O
at	O
similar	O
rates	O
(	O
close	O
to	O
those	O
of	O
actin	B
.	O
ATP	O
and	O
much	O
higher	O
than	O
those	O
of	O
actin	B
.	O
ADP	O
)	O
.	O

This	O
explains	O
why	O
high	O
concentrations	O
of	O
both	O
proteins	O
reverse	O
the	O
activation	O
of	O
subunit	O
release	O
at	O
pointed	O
ends	O
.	O

The	O
major	O
difference	O
between	O
the	O
two	O
proteins	O
is	O
that	O
the	O
nucleating	O
activity	O
of	O
cofilin	B
-	O
actin	B
.	O
ADP	O
complexes	O
is	O
twice	O
that	O
of	O
ADF	B
-	O
actin	B
.	O
ADP	O
complexes	O
and	O
this	O
,	O
in	O
turn	O
,	O
is	O
twice	O
that	O
of	O
actin	B
.	O
ATP	O
alone	O
.	O

It	O
is	O
this	O
weaker	O
nucleating	O
potential	O
of	O
ADF	B
-	O
actin	B
.	O
ADP	O
that	O
accounts	O
for	O
the	O
much	O
higher	O
steady	O
-	O
state	O
depolymerizing	O
activity	O
.	O

The	O
pH	O
-	O
sensitivity	O
is	O
due	O
to	O
the	O
nucleating	O
activity	O
of	O
complexes	O
being	O
greater	O
at	O
pH	O
6.5	O
than	O
at	O
pH	O
8	O
.	O

Sequence	O
analysis	O
of	O
mammalian	O
and	O
avian	O
isoforms	O
shows	O
a	O
consistent	O
pattern	O
of	O
charge	O
differences	O
in	O
regions	O
of	O
the	O
protein	O
associated	O
with	O
F	B
-	I
actin	I
-	O
binding	O
that	O
may	O
account	O
for	O
the	O
differences	O
in	O
activity	O
between	O
ADF	B
and	O
cofilin	B
.	O

Evidence	O
for	O
the	O
expression	O
of	O
the	O
EGF	B
receptor	I
on	O
human	O
monocytic	O
cells	O
.	O

Several	O
malignancies	O
over	O
-	O
express	O
the	O
epidermal	B
growth	I
factor	I
receptor	I
,	O
ligation	O
of	O
which	O
results	O
in	O
cellular	O
differentiation	O
and	O
multiplication	O
.	O

Mononuclear	O
phagocytes	O
secrete	O
this	O
cytokine	B
and	O
its	O
receptor	O
has	O
been	O
detected	O
on	O
microglial	O
cells	O
.	O

This	O
communication	O
describes	O
the	O
expression	O
(	O
and	O
its	O
regulation	O
)	O
of	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
EGFR	B
)	O
on	O
U937	O
cells	O
.	O

We	O
have	O
shown	O
that	O
a	O
few	O
are	O
EGFR	B
-	O
positive	O
,	O
with	O
expression	O
being	O
up	O
regulated	O
by	O
interleukin	B
6	I
(	O
IL-6	B
)	O
.	O

Also	O
,	O
when	O
cultured	O
in	O
the	O
presence	O
of	O
serum	O
with	O
the	O
monoclonal	O
anti	O
-	O
EGFR	B
,	O
ICR62	O
,	O
U937s	O
showed	O
a	O
reduced	O
growth	O
rate	O
.	O

By	O
contrast	O
,	O
ICR9	O
caused	O
a	O
significant	O
increase	O
in	O
cellular	O
proliferation	O
.	O

Both	O
antibodies	O
induced	O
cycle	O
arrest	O
in	O
late	O
G	O
(	O
1	O
)	O
/	O
S	O
phase	O
.	O

When	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
absence	O
of	O
serum	O
,	O
low	O
antibody	O
concentration	O
(	O
10	O
microg	O
/	O
ml	O
)	O
showed	O
an	O
early	O
inhibitory	O
effect	O
on	O
cell	O
proliferation	O
.	O

By	O
contrast	O
,	O
at	O
high	O
antibody	O
concentrations	O
(	O
50	O
micro	O
/	O
ml	O
)	O
,	O
ICR62	O
significantly	O
increased	O
the	O
proliferation	O
of	O
U937	O
cells	O
.	O

We	O
suggest	O
that	O
these	O
results	O
provide	O
indirect	O
evidence	O
for	O
an	O
autocrine	O
action	O
of	O
EGF	B
on	O
U937	O
cells	O
.	O

Two	O
proteins	O
essential	O
for	O
apolipoprotein	B
B	I
mRNA	O
editing	O
are	O
expressed	O
from	O
a	O
single	O
gene	O
through	O
alternative	O
splicing	O
.	O

Apolipoprotein	B
B	I
(	O
apoB	B
)	O
mRNA	O
editing	O
involves	O
site	O
-	O
specific	O
deamination	O
of	O
cytidine	O
to	O
form	O
uridine	O
,	O
resulting	O
in	O
the	O
production	O
of	O
an	O
in	O
-	O
frame	O
stop	O
codon	O
.	O

Protein	O
translated	O
from	O
edited	O
mRNA	O
is	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
atherosclerosis	O
,	O
and	O
hence	O
the	O
protein	O
factors	O
that	O
regulate	O
hepatic	O
apoB	B
mRNA	O
editing	O
are	O
of	O
interest	O
.	O

A	O
human	O
protein	O
essential	O
for	O
apoB	B
mRNA	O
editing	O
and	O
an	O
eight	O
-	O
amino	O
acid	O
-	O
longer	O
variant	O
of	O
no	O
known	O
function	O
have	O
been	O
recently	O
cloned	O
.	O

We	O
report	O
that	O
both	O
proteins	O
,	O
henceforth	O
referred	O
to	O
as	O
ACF64	B
and	O
ACF65	B
,	O
supported	O
APOBEC-1	B
(	O
the	O
catalytic	O
subunit	O
of	O
the	O
editosome	O
)	O
equivalently	O
in	O
editing	O
of	O
apoB	B
mRNA	O
.	O

They	O
are	O
encoded	O
by	O
a	O
single	O
82	O
-	O
kb	O
gene	O
on	O
chromosome	O
10	O
.	O

The	O
transcripts	O
are	O
encoded	O
by	O
15	O
exons	O
that	O
are	O
expressed	O
from	O
a	O
tissue	O
-	O
specific	O
promoter	O
minimally	O
contained	O
within	O
the	O
-	O
0.33	O
-	O
kb	O
DNA	O
sequence	O
.	O

ACF64	B
and	O
ACF65	B
mRNAs	O
are	O
expressed	O
in	O
both	O
liver	O
and	O
intestinal	O
cells	O
in	O
an	O
approximate	O
1	O
:	O
4	O
ratio	O
.	O

Exon	O
11	O
is	O
alternatively	O
spliced	O
to	O
include	O
or	O
exclude	O
24	O
nucleotides	O
of	O
exon	O
12	O
,	O
thereby	O
encoding	O
ACF65	B
and	O
ACF64	B
,	O
respectively	O
.	O

Recognition	O
motifs	O
for	O
the	O
serine	O
/	O
arginine	O
-	O
rich	O
(	O
SR	O
)	O
proteins	O
SC35	B
,	O
SRp40	B
,	O
SRp55	B
,	O
and	O
SF2	B
/	O
ASF	B
involved	O
in	O
alternative	O
RNA	O
splicing	O
were	O
predicted	O
in	O
exon	O
12	O
.	O

Overexpression	O
of	O
these	O
SR	O
proteins	O
in	O
liver	O
cells	O
demonstrated	O
that	O
alternative	O
splicing	O
of	O
a	O
minigene	O
-	O
derived	O
transcript	O
to	O
express	O
ACF65	B
was	O
enhanced	O
6	O
-	O
fold	O
by	O
SRp40	B
.	O

The	O
data	O
account	O
for	O
the	O
expression	O
of	O
two	O
editing	O
factors	O
and	O
provide	O
a	O
possible	O
explanation	O
for	O
their	O
different	O
levels	O
of	O
expression	O
.	O

Cytokine	B
signaling	O
:	O
STATS	B
in	O
plasma	O
membrane	O
rafts	O
.	O

STAT	B
transcription	B
factors	I
signal	O
from	O
the	O
plasma	O
membrane	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
growth	B
factors	I
and	O
cytokines	B
.	O

We	O
have	O
investigated	O
whether	O
plasma	O
membrane	O
""""	O
rafts	O
""""	O
are	O
involved	O
in	O
cytokine	B
-	O
activated	O
STAT	B
signaling	O
.	O

Cytokine	B
-	O
free	O
human	O
hepatoma	O
Hep3B	O
cells	O
or	O
cells	O
treated	O
with	O
interleukin-6	B
(	O
IL-6	B
)	O
or	O
orthovanadate	O
(	O
a	O
general	O
activator	O
of	O
STATs	B
)	O
were	O
fractionated	O
,	O
and	O
plasma	O
membrane	O
raft	O
fractions	O
were	O
obtained	O
by	O
equilibrium	O
sedimentation	O
or	O
flotation	O
through	O
discontinuous	O
sucrose	O
gradients	O
using	O
either	O
non	O
-	O
detergent	O
or	O
detergent	O
-	O
based	O
(	O
saponin	O
or	O
Triton	O
X	O
-	O
100	O
)	O
methods	O
.	O

By	O
Western	O
blotting	O
the	O
plasma	O
membrane	O
raft	O
fractions	O
obtained	O
using	O
either	O
non	O
-	O
detergent	O
or	O
detergent	O
-	O
based	O
methods	O
contained	O
significant	O
amounts	O
of	O
STAT1	B
and	O
STAT3	B
(	O
up	O
to	O
approximately	O
10	O
%	O
of	O
the	O
total	O
cytoplasmic	O
amount	O
)	O
as	O
well	O
as	O
the	O
integral	O
raft	O
proteins	O
caveolin-1	B
and	O
flotillin-1	B
,	O
the	O
IL-6	B
-	I
receptor	I
signal	I
transducing	I
chain	I
gp130	B
,	O
the	O
interferon	B
-	I
gamma	I
receptor	I
alpha	I
chain	I
(	O
IFN	B
-	I
gammaRalpha	I
)	O
,	O
and	O
the	O
chaperone	B
glucose	B
-	I
regulated	I
protein	I
58	I
(	O
GRP58	B
/	O
ER	B
-	I
60	I
/	O
ERp57	B
)	O
.	O

Upon	O
activation	O
of	O
signaling	O
by	O
IL-6	B
or	O
orthovanadate	O
the	O
respective	O
Tyr	O
-	O
phosphorylated	O
STAT	B
species	O
were	O
now	O
also	O
observed	O
in	O
the	O
membrane	O
raft	O
fraction	O
but	O
in	O
a	O
form	O
deficient	O
in	O
DNA	O
binding	O
.	O

The	O
data	O
show	O
pre	O
-	O
association	O
of	O
STATs	B
with	O
plasma	O
membrane	O
rafts	O
in	O
flotation	O
fractions	O
,	O
which	O
also	O
contained	O
caveolin-1	B
and	O
flotillin-1	B
,	O
and	O
suggest	O
that	O
Tyr	O
phosphorylation	O
may	O
not	O
in	O
itself	O
be	O
sufficient	O
to	O
cause	O
the	O
departure	O
of	O
PY	O
-	O
STATs	B
from	O
plasma	O
membrane	O
rafts	O
.	O

Methyl	O
-	O
beta	O
-	O
cyclodextrin	O
,	O
which	O
sequesters	O
cholesterol	O
and	O
disrupts	O
plasma	O
membrane	O
rafts	O
,	O
markedly	O
inhibited	O
IL-6	B
-	O
and	O
IFN	B
-	I
gamma	I
-	O
induced	O
STAT	B
signaling	O
.	O

Signaling	O
through	O
specialized	O
raft	O
microdomains	O
may	O
be	O
a	O
general	O
mechanism	O
operating	O
at	O
the	O
level	O
of	O
the	O
plasma	O
membrane	O
through	O
which	O
cytokines	B
and	O
growth	B
factors	I
activate	O
STAT	B
species	O
(	O
the	O
""""	O
raft	O
-	O
STAT	B
signaling	O
hypothesis	O
""""	O
)	O
.	O

Regulation	O
of	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
carcinogenesis	O
by	O
activin	B
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
provide	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
by	O
which	O
activin	B
A	I
modulates	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
carcinogenesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Activin	B
A	I
,	O
a	O
member	O
of	O
the	O
TGFbeta	B
superfamily	I
,	O
has	O
various	O
effects	O
on	O
diverse	O
biological	O
systems	O
,	O
including	O
cell	O
growth	O
inhibition	O
in	O
many	O
cell	O
types	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
activin	B
exerts	O
its	O
inhibitory	O
effects	O
are	O
not	O
yet	O
understood	O
.	O

This	O
review	O
highlights	O
activin	B
's	O
effects	O
on	O
activin	B
receptors	I
and	O
signaling	O
pathway	O
,	O
modulation	O
of	O
activin	B
signaling	O
,	O
and	O
regulation	O
of	O
cell	O
proliferation	O
and	O
apoptosis	O
by	O
activin	B
.	O

Based	O
on	O
the	O
experiences	O
of	O
all	O
the	O
authors	O
,	O
we	O
emphasized	O
cell	O
cycle	O
inhibitors	O
such	O
as	O
p16	B
and	O
p21	B
and	O
regulators	O
of	O
apoptosis	O
such	O
as	O
p53	B
and	O
members	O
of	O
the	O
bcl-2	B
family	I
.	O

Aside	O
from	O
activin	B
's	O
inhibition	O
of	O
cell	O
proliferation	O
and	O
enhancement	O
of	O
apoptosis	O
,	O
other	O
newly	O
developed	O
methods	O
for	O
molecular	O
studies	O
of	O
apoptosis	O
by	O
activin	B
were	O
briefly	O
presented	O
that	O
support	O
the	O
role	O
of	O
activin	B
as	O
an	O
inhibitor	O
of	O
carcinogenesis	O
and	O
cancer	O
progression	O
.	O

These	O
methods	O
include	O
subtractive	O
hybridization	O
based	O
on	O
covalent	O
bonding	O
,	O
a	O
simple	O
and	O
accurate	O
means	O
to	O
determine	O
molecular	O
profile	O
of	O
as	O
few	O
as	O
20	O
cells	O
based	O
on	O
an	O
RNA	O
-	O
PCR	O
approach	O
,	O
and	O
a	O
messenger	O
RNA	O
-	O
antisense	O
DNA	O
interference	O
phenomenon	O
(	O
D	O
-	O
RNAi	O
)	O
,	O
resulting	O
in	O
a	O
long	O
-	O
term	O
gene	O
knockout	O
effects	O
.	O

Expression	O
and	O
modulation	O
of	O
Rho	B
kinase	I
in	O
human	O
pregnant	O
myometrium	O
.	O

There	O
is	O
little	O
information	O
outlining	O
the	O
role	O
of	O
Rho	B
kinase	I
,	O
RhoA	B
,	O
and	O
calcium	O
sensitization	O
in	O
regulation	O
of	O
human	O
uterine	O
contractility	O
during	O
pregnancy	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
the	O
expression	O
of	O
RhoA	B
,	O
and	O
the	O
Rho	B
kinases	I
ROCK	B
I	I
and	O
ROCK	B
II	I
in	O
human	O
pregnant	O
myometrium	O
,	O
to	O
evaluate	O
the	O
effects	O
of	O
Rho	B
kinase	I
inhibition	O
on	O
pregnant	O
human	O
myometrial	O
contractility	O
in	O
vitro	O
,	O
and	O
to	O
compare	O
these	O
effects	O
with	O
those	O
of	O
the	O
calcium	B
channel	I
blocker	O
nifedipine	O
.	O

RT	O
-	O
PCR	O
using	O
primers	O
for	O
RhoA	B
,	O
ROCK	B
I	I
and	O
ROCK	B
II	I
was	O
performed	O
on	O
mRNA	O
isolated	O
from	O
human	O
pregnant	O
myometrium	O
.	O

Isometric	O
recording	O
was	O
performed	O
in	O
isolated	O
myometrial	O
strips	O
obtained	O
at	O
Caesarean	O
section	O
.	O

The	O
effects	O
of	O
the	O
Rho	B
kinase	I
inhibitor	O
Y-27632	O
(	O
1	O
nmol	O
/	O
l	O
to	O
10	O
mmol	O
/	O
l	O
)	O
,	O
and	O
nifedipine	O
(	O
1	O
nmol	O
/	O
l	O
to	O
10	O
mmol	O
/	O
l	O
)	O
,	O
on	O
oxytocin	O
(	O
0.5	O
nmol	O
/	O
l	O
)	O
induced	O
contractions	O
were	O
measured	O
and	O
compared	O
.	O

Expression	O
of	O
RhoA	B
,	O
ROCK	B
I	I
and	O
ROCK	B
II	I
mRNA	O
was	O
identified	O
in	O
human	O
pregnant	O
myometrium	O
(	O
n	O
=	O
3	O
)	O
.	O

Y-27632	O
exerted	O
a	O
potent	O
relaxant	O
effect	O
on	O
myometrial	O
contractility	O
with	O
a	O
pD	O
(	O
2	O
)	O
value	O
(	O
+	O
/-	O
SEM	O
)	O
of	O
7.63	O
+	O
/-	O
0.38	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
maximum	O
net	O
relaxant	O
effect	O
(	O
+	O
/-	O
SEM	O
)	O
was	O
72.3	O
+	O
/-	O
6.1	O
%	O
(	O
n	O
=	O
6	O
)	O
.	O

Corresponding	O
values	O
for	O
nifedipine	O
were	O
7.24	O
+	O
/-	O
0.48	O
(	O
n	O
=	O
6	O
;	O
P	O
=	O
0.469	O
)	O
and	O
93.40	O
+	O
/-	O
3.1	O
%	O
(	O
n	O
=	O
6	O
;	O
P	O
=	O
0.028	O
)	O
.	O

Rho	B
A	I
/	O
Rho	B
kinase	I
-	O
mediated	O
calcium	O
sensitization	O
may	O
play	O
role	O
in	O
the	O
physiology	O
of	O
human	O
parturition	O
,	O
and	O
pharmacological	O
inhibition	O
of	O
this	O
pathway	O
may	O
therefore	O
provide	O
a	O
novel	O
approach	O
to	O
tocolysis	O
for	O
pre	O
-	O
term	O
labour	O
.	O

Nutritional	O
considerations	O
in	O
renal	O
transplant	O
patients	O
.	O

In	O
renal	O
transplant	O
patients	O
,	O
weight	O
gain	O
generally	O
increases	O
after	O
renal	O
transplantation	O
,	O
which	O
will	O
be	O
influenced	O
by	O
improved	O
appetite	O
and	O
a	O
reversal	O
of	O
the	O
uremic	O
state	O
.	O

However	O
,	O
at	O
least	O
in	O
the	O
early	O
posttransplant	O
period	O
,	O
the	O
increase	O
in	O
body	O
weight	O
is	O
mainly	O
due	O
to	O
an	O
increase	O
in	O
body	O
fat	O
mass	O
.	O

This	O
phenomenon	O
may	O
be	O
partly	O
due	O
to	O
relatively	O
high	O
doses	O
of	O
steroids	O
in	O
the	O
early	O
period	O
after	O
renal	O
transplantation	O
,	O
possibly	O
mediated	O
by	O
their	O
inhibiting	O
effect	O
on	O
lipid	O
peroxidation	O
,	O
but	O
also	O
appears	O
to	O
be	O
related	O
to	O
physical	O
inactivity	O
.	O

The	O
increase	O
in	O
body	O
fat	O
mass	O
may	O
contribute	O
to	O
posttransplant	O
hyperlipidemia	O
,	O
which	O
is	O
improved	O
but	O
not	O
completely	O
normalized	O
by	O
dietary	O
intervention	O
.	O

Current	O
dietary	O
recommendations	O
in	O
stable	O
renal	O
transplant	O
patients	O
do	O
not	O
generally	O
differ	O
from	O
those	O
of	O
the	O
general	O
population	O
,	O
although	O
intense	O
dietary	O
counselling	O
may	O
be	O
indicated	O
in	O
patients	O
with	O
excessive	O
posttransplant	O
weight	O
gain	O
.	O

The	O
effect	O
of	O
supervised	O
exercise	O
training	O
on	O
body	O
composition	O
is	O
currently	O
under	O
investigation	O
.	O

Recombinant	O
human	O
laminin-10	B
(	O
alpha5beta1gamma1	O
)	O
.	O

Production	O
,	O
purification	O
,	O
and	O
migration	O
-	O
promoting	O
activity	O
on	O
vascular	O
endothelial	O
cells	O
.	O

The	O
laminin	B
(	I
LN	I
)	I
family	I
of	O
large	O
heterotrimeric	O
extracellular	O
matrix	O
glycoproteins	O
has	O
multiple	O
functions	O
:	O
LNs	B
take	O
part	O
in	O
the	O
regulation	O
of	O
processes	O
such	O
as	O
cell	O
migration	O
,	O
differentiation	O
,	O
and	O
proliferation	O
,	O
in	O
addition	O
to	O
contributing	O
to	O
the	O
structure	O
of	O
basement	O
membranes	O
.	O

LN-10	B
,	O
composed	O
of	O
alpha5	O
,	O
beta1	O
,	O
and	O
gamma1	O
chains	O
,	O
is	O
widely	O
distributed	O
in	O
most	O
basement	O
membranes	O
of	O
both	O
epithelia	O
and	O
endothelia	O
.	O

We	O
determined	O
the	O
complete	O
human	O
cDNA	O
sequence	O
for	O
the	O
LN	B
alpha5	I
chain	O
and	O
produced	O
recombinant	O
human	O
LN-10	B
(	O
rLN-10	B
)	O
in	O
HEK293	O
cells	O
by	O
triple	O
transfection	O
of	O
full	O
-	O
length	O
cDNAs	O
encoding	O
the	O
human	O
LN	B
alpha5	I
,	O
beta1	B
,	I
and	I
gamma1	I
chains	O
.	O

The	O
rLN-10	B
was	O
purified	O
using	O
affinity	O
chromatography	O
and	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
approximately	O
800	O
kDa	O
in	O
SDS	O
-	O
PAGE	O
and	O
a	O
native	O
domain	O
structure	O
in	O
rotary	O
shadowing	O
electron	O
microscopy	O
.	O

By	O
using	O
function	O
-	O
blocking	O
monoclonal	O
antibodies	O
,	O
integrin	B
alpha	I
(	I
3	I
)	I
beta	I
(	I
1	I
)	I
was	O
found	O
to	O
be	O
a	O
major	O
mediator	O
of	O
adhesion	O
of	O
HT-1080	O
and	O
human	O
saphenous	O
vein	O
endothelial	O
cells	O
.	O

Human	O
saphenous	O
vein	O
endothelial	O
cells	O
adhered	O
more	O
strongly	O
to	O
rLN-10	B
than	O
to	O
LN-1	B
and	O
LN-8	B
and	O
showed	O
better	O
migration	O
on	O
rLN-10	B
,	O
compared	O
with	O
several	O
other	O
matrices	O
.	O

Considering	O
the	O
cell	O
adhesive	O
and	O
migration	O
-	O
promoting	O
properties	O
of	O
rLN-10	B
on	O
endothelial	O
cells	O
,	O
this	O
molecule	O
could	O
be	O
useful	O
in	O
improving	O
the	O
biocompatibility	O
and	O
endothelialization	O
of	O
vascular	O
grafts	O
.	O

Biological	O
activities	O
of	O
ecalectin	B
:	O
a	O
novel	O
eosinophil	O
-	O
activating	O
factor	O
.	O

Ecalectin	B
,	O
produced	O
by	O
Ag	O
-	O
stimulated	O
T	O
lymphocytes	O
,	O
is	O
a	O
potent	O
eosinophil	O
-	O
specific	O
chemoattractant	O
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
and	O
thus	O
is	O
implicated	O
in	O
allergic	O
responses	O
.	O

Ecalectin	B
differs	O
structurally	O
from	O
other	O
known	O
eosinophil	O
chemoattractants	O
(	O
ECAs	O
)	O
;	O
ecalectin	B
belongs	O
to	O
the	O
galectin	B
family	I
defined	O
by	O
their	O
affinity	O
for	O
beta	O
-	O
galactosides	O
and	O
by	O
their	O
conserved	O
carbohydrate	O
recognition	O
domains	O
.	O

These	O
characteristic	O
features	O
suggest	O
that	O
ecalectin	B
has	O
unique	O
activities	O
associated	O
with	O
allergic	O
inflammation	O
besides	O
ECA	O
activity	O
.	O

Conversely	O
,	O
ecalectin	B
may	O
mediate	O
ECA	O
activity	O
by	O
binding	O
to	O
a	O
receptor	O
of	O
a	O
known	O
ECA	O
via	O
affinity	O
for	O
the	O
beta	O
-	O
galactosides	O
present	O
on	O
this	O
receptor	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
tested	O
whether	O
ecalectin	B
mediates	O
ECA	O
activity	O
by	O
binding	O
to	O
a	O
receptor	O
of	O
a	O
known	O
ECA	O
,	O
and	O
we	O
have	O
assessed	O
its	O
effects	O
on	O
eosinophils	O
.	O

Ecalectin	B
did	O
not	O
mediate	O
ECA	O
activity	O
by	O
binding	O
to	O
the	O
IL-5R	B
or	O
to	O
CCR3	B
.	O

Also	O
,	O
the	O
ECA	O
activity	O
of	O
ecalectin	B
was	O
mainly	O
chemokinetic	O
.	O

In	O
addition	O
,	O
ecalectin	B
induced	O
concentration	O
-	O
dependent	O
eosinophil	O
aggregation	O
,	O
a	O
marker	O
for	O
eosinophil	O
activation	O
.	O

Ecalectin	B
induced	O
concentration	O
-	O
dependent	O
superoxide	O
production	O
from	O
eosinophils	O
but	O
did	O
not	O
induce	O
degranulation	O
;	O
usually	O
these	O
two	O
events	O
are	O
coupled	O
in	O
eosinophil	O
activation	O
.	O

Moreover	O
,	O
ecalectin	B
directly	O
prolonged	O
eosinophil	O
survival	O
in	O
vitro	O
and	O
did	O
not	O
trigger	O
eosinophils	O
to	O
secrete	O
cytokines	B
that	O
prolong	O
eosinophil	O
survival	O
.	O

These	O
results	O
demonstrate	O
that	O
ecalectin	B
has	O
several	O
unique	O
effects	O
on	O
eosinophils	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
ecalectin	B
is	O
a	O
novel	O
eosinophil	O
-	O
activating	O
factor	O
.	O

Presumably	O
,	O
these	O
effects	O
allow	O
ecalectin	B
to	O
play	O
a	O
distinctive	O
role	O
in	O
allergic	O
inflammation	O
.	O

Developing	O
a	O
taste	O
for	O
sweets	O
.	O

Lymphocytes	O
are	O
covered	O
with	O
sugars	O
.	O

Some	O
of	O
the	O
oligosaccharides	O
on	O
lymphocytes	O
may	O
be	O
recognized	O
by	O
specific	O
lectins	B
such	O
as	O
the	O
selectins	B
,	O
but	O
what	O
other	O
functions	O
do	O
all	O
of	O
these	O
oligosaccharides	O
serve	O
?	O

Two	O
recent	O
papers	O
in	O
Cell	O
(	O
Moody	O
et	O
al.	O
,	O
2001	O
)	O
and	O
Immunity	O
(	O
Daniels	O
et	O
al.	O
,	O
2001	O
)	O
describe	O
a	O
novel	O
role	O
for	O
glycosylation	O
in	O
the	O
thymus	O
--	O
regulating	O
the	O
interaction	O
of	O
MHC	B
class	I
I	I
molecules	O
with	O
CD8	B
during	O
thymocyte	O
maturation	O
.	O

Consequences	O
of	O
CK2	B
signaling	O
to	O
the	O
nuclear	O
matrix	O
.	O

Protein	B
kinase	I
CK2	B
is	O
recognized	O
as	O
one	O
of	O
the	O
key	O
cellular	O
signals	O
for	O
cell	O
growth	O
and	O
proliferation	O
.	O

Its	O
nuclear	O
targeting	O
appears	O
to	O
be	O
critical	O
to	O
its	O
role	O
in	O
these	O
functions	O
.	O

In	O
the	O
nucleus	O
,	O
nuclear	O
matrix	O
(	O
NM	O
)	O
which	O
plays	O
a	O
major	O
role	O
in	O
growth	O
-	O
related	O
activities	O
is	O
a	O
primary	O
locus	O
for	O
CK2	B
signaling	O
.	O

A	O
variety	O
of	O
growth	O
stimuli	O
evoke	O
a	O
rapid	O
translocation	O
of	O
the	O
CK2	B
to	O
the	O
NM	O
whereas	O
removal	O
of	O
these	O
factors	O
has	O
the	O
opposite	O
effect	O
.	O

These	O
studies	O
,	O
employing	O
various	O
experimental	O
models	O
of	O
cell	O
growth	O
(	O
involving	O
different	O
growth	O
-	O
stimulatory	O
factors	O
)	O
,	O
have	O
suggested	O
that	O
rapid	O
shuttling	O
of	O
CK2	B
to	O
the	O
NM	O
is	O
a	O
key	O
feature	O
of	O
early	O
growth	O
control	O
.	O

By	O
contrast	O
,	O
removal	O
of	O
growth	O
-	O
stimulatory	O
factors	O
leading	O
to	O
the	O
loss	O
of	O
cell	O
viability	O
is	O
associated	O
with	O
early	O
loss	O
of	O
CK2	B
from	O
the	O
NM	O
(	O
and	O
chromatin	O
)	O
.	O

This	O
indicates	O
that	O
absence	O
of	O
CK2	B
from	O
the	O
nuclear	O
compartment	O
is	O
contributory	O
to	O
induction	O
of	O
cell	O
death	O
via	O
apoptosis	O
,	O
implying	O
a	O
protective	O
role	O
for	O
CK2	B
against	O
cell	O
death	O
.	O

Here	O
,	O
we	O
review	O
the	O
evidence	O
that	O
suggests	O
that	O
CK2	B
signaling	O
in	O
the	O
NM	O
is	O
not	O
only	O
involved	O
in	O
cell	O
growth	O
but	O
also	O
in	O
cell	O
survival	O
.	O

Suppression	O
of	O
15-lipoxygenase	B
synthesis	O
by	O
hnRNP	B
E1	I
is	O
dependent	O
on	O
repetitive	O
nature	O
of	O
LOX	B
mRNA	O
3'-UTR	O
control	O
element	O
DICE	O
.	O

Cytidine	O
-	O
rich	O
15	B
-	I
lipoxygenase	I
differentiation	O
control	O
element	O
(	O
15-LOX	B
DICE	O
)	O
is	O
a	O
multifunctional	O
cis	O
-	O
element	O
found	O
in	O
the	O
3'-UTR	O
of	O
numerous	O
eukaryotic	O
mRNAs	O
.	O

It	O
binds	O
KH	O
domain	O
proteins	O
of	O
the	O
type	O
hnRNP	B
E	I
and	I
K	I
,	O
thus	O
mediating	O
mRNA	O
stabilization	O
and	O
translational	O
control	O
.	O

Translational	O
silencing	O
is	O
caused	O
by	O
formation	O
of	O
a	O
simple	O
binary	O
complex	O
between	O
DICE	O
and	O
recombinant	O
hnRNP	B
E1	I
(	O
E1	O
)	O
.	O

Electromobility	O
shift	O
assays	O
and	O
sucrose	O
gradient	O
centrifugation	O
demonstrate	O
that	O
rabbit	O
15-LOX	B
DICE	O
,	O
which	O
is	O
composed	O
of	O
ten	O
subunits	O
of	O
the	O
sequence	O
(	O
CCCCPuCCCUCUUCCCCAAG	O
)	O
10	O
=	O
10R	O
,	O
is	O
able	O
to	O
bind	O
up	O
to	O
ten	O
molecules	O
of	O
E1	O
.	O

Protein	O
/	O
RNA	O
interaction	O
was	O
studied	O
with	O
different	O
subunits	O
and	O
submotifs	O
of	O
the	O
10R	O
structure	O
.	O

Binding	O
appears	O
to	O
be	O
dependent	O
on	O
the	O
degree	O
of	O
polymerization	O
of	O
the	O
C	O
-	O
clusters	O
(	O
1R<2R<4R<10R	O
)	O
,	O
but	O
not	O
on	O
their	O
order	O
.	O

The	O
minimal	O
motif	O
,	O
which	O
still	O
functioned	O
in	O
E1	O
binding	O
,	O
contained	O
two	O
C	O
-	O
clusters	O
(	O
CCCCPuCCCUCUU	O
)	O
.	O

For	O
efficient	O
translational	O
control	O
,	O
E1	O
binding	O
is	O
a	O
necessary	O
,	O
but	O
not	O
sufficient	O
,	O
condition	O
.	O

Translational	O
inhibition	O
by	O
E1	O
is	O
only	O
observed	O
when	O
at	O
least	O
a	O
dimeric	O
2R	O
configuration	O
of	O
the	O
DICE	O
is	O
present	O
in	O
the	O
3'-UTR	O
of	O
a	O
reporter	O
mRNA	O
.	O

We	O
conclude	O
that	O
binding	O
of	O
at	O
least	O
two	O
E1	O
molecules	O
activate	O
or	O
expose	O
a	O
binding	O
site	O
to	O
enable	O
the	O
complex	O
to	O
interact	O
with	O
the	O
5'-end	O
of	O
the	O
mRNA	O
and	O
the	O
translational	O
machinery	O
.	O

DICE	O
-	O
motifs	O
are	O
widely	O
distributed	O
in	O
nature	O
.	O

The	O
UTR	O
database	O
UTRnr	O
contains	O
78	O
entries	O
of	O
mRNAs	O
with	O
15-LOX	B
DICEs	O
.	O

Most	O
DICEs	O
were	O
two	O
-	O
to	O
fourfold	O
repetitive	O
,	O
but	O
also	O
highly	O
repetitive	O
structures	O
were	O
found	O
,	O
as	O
in	O
quail	O
myelin	B
protein	I
mRNA	O
(	O
31	O
repeats	O
)	O
and	O
hyperglycemic	B
hormone	I
mRNA	O
of	O
two	O
crayfish	O
species	O
(	O
nine	O
and	O
11	O
repeats	O
)	O
.	O

Crystal	O
structure	O
of	O
extracellular	O
human	O
BAFF	B
,	O
a	O
TNF	B
family	I
member	I
that	O
stimulates	O
B	O
lymphocytes	O
.	O

B	B
cell	I
activating	I
factor	I
(	O
BAFF	B
)	O
,	O
a	O
ligand	O
belonging	O
to	O
the	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
family	I
,	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
survival	O
and	O
activation	O
of	O
peripheral	O
B	O
cell	O
populations	O
and	O
has	O
been	O
associated	O
with	O
autoimmune	O
disease	O
.	O

BAFF	B
is	O
known	O
to	O
interact	O
with	O
three	O
receptors	O
,	O
BCMA	B
,	O
TACI	B
and	O
BAFF	B
-	I
R	I
,	O
that	O
have	O
distant	O
similarities	O
with	O
other	O
receptors	O
of	O
the	O
TNF	B
family	I
.	O

We	O
have	O
determined	O
the	O
crystal	O
structure	O
of	O
the	O
TNF	B
-	O
homologous	O
domain	O
of	O
BAFF	B
at	O
2.8	O
A	O
resolution	O
.	O

The	O
structure	O
reveals	O
significant	O
differences	O
when	O
compared	O
to	O
other	O
TNF	B
family	I
members	O
,	O
including	O
an	O
unusually	O
long	O
D	O
-	O
E	O
loop	O
that	O
participates	O
in	O
the	O
formation	O
of	O
a	O
deep	O
,	O
concave	O
and	O
negatively	O
charged	O
region	O
in	O
the	O
putative	O
receptor	O
binding	O
site	O
.	O

The	O
BAFF	B
structure	O
was	O
further	O
used	O
to	O
generate	O
a	O
homology	O
model	O
of	O
APRIL	B
,	O
a	O
closely	O
related	O
TNF	B
family	I
ligand	O
that	O
also	O
binds	O
to	O
BCMA	B
and	O
TACI	B
,	O
but	O
not	O
BAFF	B
-	I
R	I
.	O

Analysis	O
of	O
the	O
putative	O
receptor	O
binding	O
sites	O
of	O
BAFF	B
and	O
APRIL	B
suggests	O
that	O
differences	O
in	O
the	O
D	O
-	O
E	O
loop	O
structure	O
and	O
electrostatic	O
surface	O
potentials	O
may	O
be	O
important	O
for	O
determining	O
binding	O
specificities	O
for	O
BCMA	B
,	O
TACI	B
and	O
BAFF	B
-	I
R	I
.	O

Expression	O
of	O
the	O
genes	O
of	O
methyl	O
-	O
binding	O
domain	O
proteins	O
in	O
human	O
gliomas	O
.	O

DNA	O
methylation	O
is	O
the	O
most	O
common	O
epigenetic	O
alteration	O
in	O
tumor	O
genomes	O
and	O
might	O
result	O
in	O
transcriptional	O
repression	O
of	O
tumor	O
suppressor	O
genes	O
.	O

Moreover	O
,	O
recent	O
results	O
have	O
demonstrated	O
that	O
both	O
specific	O
methylation	O
patterns	O
and	O
functional	O
components	O
of	O
the	O
mismatch	O
repair	O
system	O
are	O
involved	O
in	O
the	O
development	O
of	O
therapy	O
resistance	O
of	O
tumor	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
genes	O
of	O
methyl	O
binding	O
domain	O
containing	O
proteins	O
(	O
MBD	B
)	O
in	O
human	O
gliomas	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

We	O
found	O
expression	O
of	O
MBDs	B
including	O
MBD1	B
,	O
MBD2	B
,	O
MBD3	B
and	O
MBD4	B
/	O
MED1	B
in	O
all	O
glioma	O
cell	O
lines	O
and	O
glioma	O
biopsies	O
.	O

No	O
differences	O
existed	O
in	O
vitro	O
with	O
regard	O
to	O
individual	O
MBDs	B
and	O
individual	O
cell	O
lines	O
.	O

In	O
vivo	O
,	O
MBD1	B
and	O
MBD2	B
were	O
also	O
expressed	O
in	O
all	O
biopsies	O
with	O
only	O
minor	O
differences	O
between	O
individual	O
tumors	O
.	O

MBD3	B
and	O
MBD4	B
/	O
MED1	B
,	O
however	O
,	O
showed	O
a	O
correlation	O
of	O
expression	O
with	O
the	O
grade	O
of	O
malignancy	O
.	O

Astrocytomas	O
and	O
anaplastic	O
astrocytomas	O
showed	O
a	O
weak	O
expression	O
compared	O
with	O
a	O
high	O
expression	O
in	O
glioblastoma	O
multiforme	O
.	O

[	O
Investigation	O
on	O
skin	O
retrograde	O
degeneration	O
after	O
tissue	O
expansion	O
]	O

OBJECTIVE	O
:	O

To	O
study	O
the	O
effects	O
of	O
tissue	O
expansion	O
on	O
tissue	O
damage	O
and	O
retrograde	O
degeneration	O
.	O

METHODS	O
:	O

9	O
cases	O
of	O
conventional	O
intermittent	O
tissue	O
expansion	O
(	O
CITE	O
)	O
and	O
9	O
cases	O
of	O
continuous	O
pressure	O
-	O
controlled	O
tissue	O
expansion	O
(	O
CPTE	O
)	O
were	O
chosen	O
for	O
the	O
study	O
.	O

In	O
creating	O
of	O
the	O
expanded	O
flaps	O
,	O
tissue	O
samples	O
were	O
taken	O
for	O
histopathology	O
,	O
molecular	O
biology	O
and	O
transmission	O
electron	O
microscope	O
(	O
TEM	O
)	O
examinations	O
.	O

RESULTS	O
:	O

Capillary	O
bleeding	O
,	O
elastic	O
and	O
reticular	O
fiber	O
proliferation	O
,	O
arteriole	O
thrombosis	O
,	O
fibroblast	O
apoptosis	O
and	O
collagenolysis	O
were	O
observed	O
after	O
expansion	O
.	O

Retrograde	O
degeneration	O
was	O
obvious	O
in	O
CITE	O
group	O
and	O
acute	O
lesion	O
was	O
obvious	O
in	O
CPTE	O
group	O
.	O

CONCLUSION	O
:	O

Expansion	O
stimulation	O
induces	O
tissue	O
damage	O
and	O
retrograde	O
degeneration	O
,	O
which	O
indicates	O
that	O
the	O
time	O
for	O
conventional	O
intermittent	O
expansion	O
should	O
be	O
shortened	O
and	O
too	O
fast	O
continuous	O
expansion	O
is	O
harmful	O
.	O

v	B
-	I
Src	I
SH3	O
-	O
enhanced	O
interaction	O
with	O
focal	B
adhesion	I
kinase	I
at	O
beta	B
1	I
integrin	I
-	O
containing	O
invadopodia	O
promotes	O
cell	O
invasion	O
.	O

In	O
viral	B
Src	I
(	O
v	B
-	I
Src	I
)	O
-	O
transformed	O
cells	O
,	O
focal	B
adhesion	I
kinase	I
(	O
FAK	B
)	O
associates	O
with	O
v	B
-	I
Src	I
by	O
combined	O
v	B
-	I
Src	I
SH2	O
and	O
gain	O
-	O
of	O
-	O
function	O
v	B
-	I
Src	I
SH3	O
domain	O
binding	O
to	O
FAK	B
.	O

Here	O
we	O
assess	O
the	O
significance	O
of	O
the	O
Arg-95	O
to	O
Trp	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
the	O
v	B
-	I
Src	I
SH3	O
domain	O
through	O
comparisons	O
of	O
Src	B
-	O
/	O
-	O
fibroblasts	O
transformed	O
with	O
either	O
Prague	O
C	O
v	B
-	I
Src	I
or	O
a	O
point	O
mutant	O
(	O
v	B
-	I
Src	I
-	O
RT	O
)	O
containing	O
a	O
normal	O
(	O
Arg	O
-	O
95	O
)	O
SH3	O
domain	O
.	O

Both	O
v	B
-	I
Src	I
isoforms	O
exhibited	O
equivalent	O
kinase	B
activity	O
,	O
enhanced	O
Src	B
-	O
/	O
-	O
cell	O
motility	O
,	O
and	O
stimulated	O
cell	O
growth	O
in	O
both	O
low	O
serum	O
and	O
soft	O
agar	O
.	O

The	O
stability	O
of	O
a	O
v	B
-	I
Src	I
-	O
RT	O
.	O
FAK	B
signaling	O
complex	O
and	O
FAK	B
phosphorylation	O
at	O
Tyr-861	O
and	O
Tyr-925	O
were	O
reduced	O
in	O
v	B
-	I
Src	I
-	O
RT	O
-	O
compared	O
with	O
v	B
-	I
Src	I
-	O
transformed	O
cells	O
.	O

v	B
-	I
Src	I
but	O
not	O
v	B
-	I
Src	I
-	O
RT	O
promoted	O
Src	B
-	O
/	O
-	O
cell	O
invasion	O
through	O
a	O
reconstituted	O
Matrigel	O
basement	O
membrane	O
barrier	O
and	O
v	B
-	I
Src	I
co	O
-	O
localized	O
with	O
FAK	B
and	O
beta	B
(	I
1	I
)	I
integrin	I
at	O
invadopodia	O
.	O

In	O
contrast	O
,	O
v	B
-	I
Src	I
-	O
RT	O
exhibited	O
a	O
partial	O
perinuclear	O
and	O
focal	O
contact	O
distribution	O
in	O
Src	B
-	O
/	O
-	O
cells	O
.	O

Adenovirus	O
-	O
mediated	O
FAK	B
overexpression	O
promoted	O
v	B
-	I
Src	I
-	O
RT	O
recruitment	O
to	O
invadopodia	O
,	O
the	O
formation	O
of	O
a	O
v	B
-	I
Src	I
-	O
RT	O
.	O
FAK	B
signaling	O
complex	O
,	O
and	O
reversed	O
the	O
v	B
-	I
Src	I
-	O
RT	O
invasion	O
deficit	O
.	O

Adenovirus	O
-	O
mediated	O
inhibition	O
of	O
FAK	B
blocked	O
v	B
-	I
Src	I
-	O
stimulated	O
cell	O
invasion	O
.	O

These	O
studies	O
establish	O
that	O
gain	O
-	O
of	O
-	O
function	O
v	B
-	I
Src	I
SH3	O
targeting	O
interactions	O
with	O
FAK	B
at	O
beta	B
(	I
1	I
)	I
integrin	I
-	O
containing	O
invadopodia	O
act	O
to	O
stabilize	O
a	O
v	B
-	I
Src	I
.	O
FAK	O
signaling	O
complex	O
promoting	O
cell	O
invasion	O
.	O

Lack	O
of	O
association	O
between	O
HoxA1	B
and	O
HoxB1	B
gene	O
variants	O
and	O
autism	O
in	O
110	O
multiplex	O
families	O
.	O

A	O
recent	O
report	O
suggested	O
that	O
the	O
HoxA1	B
and/or	O
HoxB1	B
genes	O
play	O
a	O
role	O
in	O
susceptibility	O
to	O
autism	O
.	O

To	O
determine	O
whether	O
these	O
findings	O
could	O
be	O
confirmed	O
,	O
we	O
screened	O
these	O
genes	O
for	O
DNA	O
polymorphisms	O
by	O
sequencing	O
all	O
exons	O
in	O
24	O
individuals	O
with	O
autism	O
.	O

We	O
identified	O
the	O
same	O
sequence	O
variants	O
in	O
the	O
genes	O
that	O
appeared	O
in	O
this	O
report	O
,	O
which	O
include	O
one	O
single	O
-	O
base	O
substitution	O
variant	O
in	O
HoxA1	B
and	O
a	O
common	O
haplotype	O
in	O
HoxB1	B
.	O

We	O
performed	O
an	O
association	O
study	O
by	O
applying	O
the	O
transmission	O
disequilibrium	O
test	O
to	O
detect	O
possible	O
association	O
of	O
these	O
variants	O
to	O
autism	O
in	O
110	O
multiplex	O
families	O
.	O

Our	O
results	O
demonstrated	O
no	O
deviation	O
from	O
the	O
null	O
hypothesis	O
of	O
no	O
association	O
.	O

We	O
have	O
also	O
separately	O
examined	O
transmissions	O
within	O
individual	O
mating	O
types	O
,	O
for	O
paternal	O
versus	O
maternal	O
alleles	O
,	O
to	O
affected	O
versus	O
unaffected	O
children	O
,	O
and	O
for	O
transmission	O
to	O
affected	O
boys	O
versus	O
girls	O
.	O

None	O
of	O
these	O
subsets	O
revealed	O
significant	O
deviation	O
from	O
the	O
null	O
expectation	O
.	O

Our	O
interpretation	O
of	O
these	O
findings	O
is	O
that	O
it	O
is	O
unlikely	O
that	O
HoxA1	B
and	O
HoxB1	B
play	O
a	O
significant	O
role	O
in	O
the	O
genetic	O
predisposition	O
to	O
autism	O
.	O

Cloning	O
of	O
rhesus	O
monkey	O
killer	B
-	I
cell	I
Ig	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
from	O
early	O
pregnancy	O
decidua	O
.	O

To	O
define	O
the	O
killer	B
-	I
cell	I
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
molecules	O
expressed	O
within	O
the	O
decidua	O
in	O
the	O
rhesus	O
monkey	O
,	O
an	O
early	O
pregnancy	O
rhesus	O
decidual	O
library	O
was	O
screened	O
with	O
an	O
oligonucleotide	O
located	O
within	O
the	O
KIR	B
D2	O
domain	O
.	O

We	O
obtained	O
26	O
full	O
-	O
length	O
clones	O
which	O
represented	O
11	O
mRNAs	O
.	O

The	O
cDNAs	O
encode	O
proteins	O
containing	O
2	O
or	O
3	O
Ig	B
domains	O
,	O
and	O
short	O
or	O
long	O
cytoplasmic	O
domains	O
.	O

The	O
long	O
domains	O
contained	O
immunotyrosine	O
inhibitory	O
motifs	O
(	O
ITIM	O
)	O
motifs	O
indicating	O
inhibitory	O
function	O
.	O

Three	O
clones	O
contained	O
single	O
or	O
dinucleotide	O
deletions	O
within	O
the	O
D1	O
domain	O
,	O
which	O
would	O
result	O
in	O
proteins	O
truncated	O
within	O
this	O
domain	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
Ig	B
domains	O
supports	O
a	O
D0	O
-	O
D2	O
organization	O
of	O
rhesus	O
KIR2DL4.1	B
,	O
similar	O
to	O
human	O
KIR2DL4	B
and	O
KIR2DL5	B
.	O

The	O
rhesus	O
KIR2DL4.1	B
transcript	O
contains	O
a	O
long	O
cytoplasmic	O
tail	O
homologous	O
with	O
human	O
KIR2DL4	B
.	O

Structure	O
and	O
function	O
of	O
IRF-7	B
.	O

Interferon	B
(	I
IFN	I
)	I
regulatory	I
factors	I
(	O
IRF	B
)	O
are	O
a	O
family	O
of	O
transcription	B
factors	I
with	O
multiple	O
functions	O
.	O

IRF-7	B
was	O
initially	O
cloned	O
within	O
the	O
biologic	O
context	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latency	O
and	O
discovered	O
to	O
have	O
an	O
intimate	O
relation	O
with	O
the	O
EBV	O
primary	O
oncogenic	O
protein	O
,	O
latent	B
membrane	I
protein-1	I
(	O
LMP-1	B
)	O
.	O

EBV	O
regulates	O
and	O
uses	O
IRF-7	B
as	O
a	O
secondary	O
mediator	O
for	O
several	O
target	O
genes	O
involved	O
in	O
latency	O
and	O
immune	O
regulation	O
.	O

Other	O
than	O
its	O
functions	O
in	O
EBV	O
latency	O
,	O
IRF-7	B
has	O
been	O
identified	O
as	O
one	O
of	O
the	O
major	O
players	O
in	O
virally	O
induced	O
IFN	B
production	O
that	O
is	O
central	O
to	O
innate	O
immunity	O
.	O

Thus	O
,	O
IRF-7	B
plays	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biologic	O
systems	O
.	O

Alternative	O
type	O
I	O
and	O
I	O
'	O
turn	O
conformations	O
in	O
the	O
beta8	O
/	O
beta9	O
beta	O
-	O
hairpin	O
of	O
human	O
acidic	B
fibroblast	I
growth	I
factor	I
.	O

Human	O
acidic	B
fibroblast	I
growth	I
factor	I
(	O
FGF-1	B
)	O
has	O
a	O
beta	O
-	O
trefoil	O
structure	O
,	O
one	O
of	O
the	O
fundamental	O
protein	O
superfolds	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
wild	O
-	O
type	O
and	O
various	O
mutant	O
forms	O
of	O
FGF-1	B
have	O
been	O
solved	O
in	O
five	O
different	O
space	O
groups	O
:	O
C2	O
,	O
C222	O
(	O
1	O
)	O
,	O
P2	O
(	O
1	O
)	O
(	O
four	O
molecules	O
/	O
asu	O
)	O
,	O
P2	O
(	O
1	O
)	O
(	O
three	O
molecules	O
/	O
asu	O
)	O
,	O
and	O
P2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
.	O

These	O
structures	O
reveal	O
two	O
characteristically	O
different	O
conformations	O
for	O
the	O
beta8	O
/	O
beta9	O
beta	O
-	O
hairpin	O
comprising	O
residue	O
positions	O
90	O
-	O
94	O
.	O

This	O
region	O
in	O
the	O
wild	O
-	O
type	O
FGF-1	B
structure	O
(	O
P2	O
(	O
1	O
)	O
,	O
four	O
molecules	O
/	O
asu	O
)	O
,	O
a	O
his	O
-	O
tagged	O
His93	O
--	O
>	O
Gly	O
mutant	O
(	O
P2	O
(	O
1	O
)	O
,	O
three	O
molecules	O
/	O
asu	O
)	O
and	O
a	O
his	O
-	O
tagged	O
Asn106	O
--	O
>	O
Gly	O
mutant	O
(	O
P2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
)	O
adopts	O
a	O
3	O
:	O
5	O
beta	O
-	O
hairpin	O
known	O
as	O
a	O
type	O
I	O
(	O
1	O
-	O
4	O
)	O
G1	O
beta	O
-	O
bulge	O
(	O
containing	O
a	O
type	O
I	O
turn	O
)	O
.	O

However	O
,	O
a	O
his	O
-	O
tagged	O
form	O
of	O
wild	O
-	O
type	O
FGF-1	B
(	O
C222	O
(	O
1	O
)	O
)	O
and	O
a	O
his	O
-	O
tagged	O
Leu44	O
--	O
>	O
Phe	O
mutant	O
(	O
C2	O
)	O
adopt	O
a	O
3	O
:	O
3	O
beta	O
-	O
hairpin	O
(	O
containing	O
a	O
type	O
I	O
'	O
turn	O
)	O
for	O
this	O
same	O
region	O
.	O

A	O
feature	O
that	O
distinguishes	O
these	O
two	O
types	O
of	O
beta	O
-	O
hairpin	O
structures	O
is	O
the	O
number	O
and	O
location	O
of	O
side	O
chain	O
positions	O
with	O
eclipsed	O
C	O
(	O
beta	O
)	O
and	O
main	O
-	O
chain	O
carbonyl	O
oxygen	O
groups	O
(	O
Psi	O
is	O
equivalent	O
to	O
+	O
60	O
degrees	O
)	O
.	O

The	O
effects	O
of	O
glycine	O
mutations	O
upon	O
stability	O
,	O
at	O
positions	O
within	O
the	O
hairpin	O
,	O
have	O
been	O
used	O
to	O
identify	O
the	O
most	O
likely	O
structure	O
in	O
solution	O
.	O

Type	O
I	O
'	O
turns	O
in	O
the	O
structural	O
data	O
bank	O
are	O
quite	O
rare	O
,	O
and	O
a	O
survey	O
of	O
these	O
turns	O
reveals	O
that	O
a	O
large	O
percentage	O
exhibit	O
crystal	O
contacts	O
within	O
3.0	O
A	O
.	O

This	O
suggests	O
that	O
many	O
of	O
the	O
type	O
I	O
'	O
turns	O
in	O
X	O
-	O
ray	O
structures	O
may	O
be	O
adopted	O
due	O
to	O
crystal	O
packing	O
effects	O
.	O

KRIT1	B
association	O
with	O
the	O
integrin	B
-	O
binding	O
protein	O
ICAP-1	B
:	O
a	O
new	O
direction	O
in	O
the	O
elucidation	O
of	O
cerebral	O
cavernous	O
malformations	O
(	O
CCM1	O
)	O
pathogenesis	O
.	O

Mutations	O
in	O
KRIT1	B
,	O
a	O
protein	O
initially	O
identified	O
based	O
on	O
a	O
yeast	O
two	O
-	O
hybrid	O
interaction	O
with	O
the	O
RAS	B
-	I
family	I
GTPase	I
RAP1A	B
,	O
are	O
responsible	O
for	O
the	O
development	O
of	O
the	O
inherited	O
vascular	O
disorder	O
cerebral	O
cavernous	O
malformations	O
(	O
CCM1	O
)	O
.	O

As	O
the	O
function	O
of	O
the	O
KRIT1	B
protein	O
and	O
its	O
role	O
in	O
CCM	O
pathogenesis	O
remain	O
unknown	O
,	O
we	O
performed	O
yeast	O
two	O
-	O
hybrid	O
screens	O
to	O
identify	O
additional	O
protein	O
binding	O
partners	O
.	O

A	O
fragment	O
containing	O
the	O
N	O
-	O
terminal	O
272	O
amino	O
acid	O
residues	O
of	O
KRIT1	B
,	O
a	O
region	O
lacking	O
similarity	O
to	O
any	O
known	O
protein	O
upon	O
database	O
searches	O
,	O
was	O
used	O
as	O
bait	O
.	O

From	O
parallel	O
screens	O
of	O
human	O
fetal	O
brain	O
and	O
HeLa	O
cDNA	O
libraries	O
,	O
we	O
obtained	O
multiple	O
independent	O
isolates	O
of	O
human	O
integrin	B
cytoplasmic	I
domain	I
-	I
associated	I
protein-1	I
(	O
ICAP-1	B
)	O
as	O
interacting	O
clones	O
.	O

The	O
interaction	O
of	O
KRIT1	B
and	O
ICAP-1	B
was	O
confirmed	O
by	O
GST	B
-	O
KRIT1	B
trapping	O
of	O
endogenous	O
ICAP-1	B
from	O
293	O
T	O
cells	O
.	O

The	O
alpha	O
isoform	O
of	O
ICAP-1	B
is	O
a	O
200	O
amino	O
acid	O
serine	O
/	O
threonine	O
-	O
rich	O
phosphoprotein	O
which	O
binds	O
the	O
cytoplasmic	O
tail	O
of	O
beta1	B
integrins	I
.	O

We	O
show	O
that	O
mutagenesis	O
of	O
the	O
N	O
-	O
terminal	O
KRIT1	B
NPXY	O
amino	O
acid	O
sequence	O
,	O
a	O
motif	O
critical	O
for	O
ICAP-1	B
binding	O
to	O
beta1	B
integrin	I
molecules	O
,	O
completely	O
abrogates	O
the	O
KRIT1	B
/	O
ICAP-1	B
interaction	O
.	O

The	O
interaction	O
between	O
ICAP-1	B
and	O
KRIT1	B
,	O
and	O
the	O
presence	O
of	O
a	O
FERM	O
domain	O
in	O
the	O
latter	O
,	O
suggest	O
that	O
KRIT1	B
might	O
be	O
involved	O
in	O
the	O
bidirectional	O
signaling	O
between	O
integrin	B
molecules	O
and	O
the	O
cytoskeleton	O
.	O

Furthermore	O
,	O
these	O
data	O
suggest	O
that	O
KRIT1	B
might	O
affect	O
cell	O
adhesion	O
processes	O
via	O
integrin	O
signaling	O
in	O
CCM1	O
pathogenesis	O
.	O

The	O
PGC-1	B
-	O
related	O
protein	O
PERC	B
is	O
a	O
selective	O
coactivator	B
of	I
estrogen	I
receptor	I
alpha	I
.	O

Peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
gamma	I
coactivator-1	I
(	O
PGC-1	B
)	O
is	O
a	O
tissue	O
-	O
specific	O
coactivator	O
that	O
enhances	O
the	O
activity	O
of	O
many	O
nuclear	O
receptors	O
and	O
coordinates	O
transcriptional	O
programs	O
important	O
for	O
energy	O
metabolism	O
.	O

We	O
describe	O
here	O
a	O
novel	O
PGC-1	B
-	O
related	O
coactivator	O
that	O
is	O
expressed	O
in	O
a	O
similar	O
tissue	O
-	O
specific	O
manner	O
as	O
PGC-1	B
,	O
with	O
the	O
highest	O
levels	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

In	O
contrast	O
to	O
PGC-1	B
,	O
the	O
new	O
coactivator	O
shows	O
high	O
receptor	O
specificity	O
.	O

It	O
enhances	O
potently	O
the	O
activity	O
of	O
estrogen	B
receptor	I
(	I
ER	I
)	I
alpha	I
,	O
while	O
having	O
only	O
small	O
effects	O
on	O
other	O
receptors	O
.	O

Because	O
of	O
its	O
nuclear	O
receptor	O
selectivity	O
,	O
we	O
have	O
termed	O
the	O
new	O
protein	O
PERC	B
(	O
PGC-1	B
related	I
Estrogen	I
Receptor	I
Coactivator	I
)	O
.	O

We	O
show	O
here	O
that	O
the	O
coactivation	O
function	O
of	O
PERC	B
relies	O
on	O
a	O
bipartite	O
transcriptional	O
activation	O
domain	O
and	O
two	O
LXXLL	O
motifs	O
that	O
interact	O
with	O
the	O
AF2	O
domain	O
of	O
ERalpha	B
in	O
an	O
estrogen	O
-	O
dependent	O
manner	O
.	O

PERC	B
and	O
PGC-1	B
are	O
likely	O
to	O
have	O
different	O
functions	O
in	O
ER	B
signaling	O
.	O

Whereas	O
PERC	B
acts	O
selectively	O
on	O
ERalpha	B
and	O
not	O
on	O
the	O
second	O
estrogen	B
receptor	I
ERbeta	I
,	O
PGC-1	B
coactivates	O
strongly	O
both	O
ERs	B
.	O

Moreover	O
,	O
PERC	B
and	O
PGC-1	B
show	O
distinct	O
preferences	O
for	O
enhancing	O
ERalpha	B
in	O
different	O
promoter	O
contexts	O
.	O

Finally	O
,	O
PERC	B
enhances	O
the	O
ERalpha	B
-	O
mediated	O
response	O
to	O
the	O
partial	O
agonist	O
tamoxifen	O
,	O
while	O
PGC-1	B
modestly	O
represses	O
it	O
.	O

The	O
two	O
coactivators	O
are	O
likely	O
to	O
mediate	O
distinct	O
,	O
tissue	O
-	O
specific	O
responses	O
to	O
estrogens	O
.	O

Role	O
of	O
integrin	B
-	I
linked	I
kinase	I
in	O
leukocyte	O
recruitment	O
.	O

Chemokines	B
modulate	O
leukocyte	O
integrin	B
avidity	O
to	O
coordinate	O
adhesion	O
and	O
subsequent	O
transendothelial	O
migration	O
,	O
although	O
the	O
sequential	O
signaling	O
pathways	O
involved	O
remain	O
poorly	O
characterized	O
.	O

Here	O
we	O
show	O
that	O
integrin	B
-	I
linked	I
kinase	I
(	O
ILK	B
)	O
,	O
a	O
59	O
-	O
kDa	O
serine	B
-	I
threonine	I
protein	I
kinase	I
that	O
interacts	O
principally	O
with	O
beta	B
(	I
1	I
)	I
integrins	I
,	O
is	O
highly	O
expressed	O
in	O
human	O
mononuclear	O
cells	O
and	O
is	O
activated	O
by	O
exposure	O
of	O
leukocytes	O
to	O
the	O
chemokine	B
monocyte	B
chemoattractant	I
protein-1	I
.	O

Biochemical	O
inhibitor	O
studies	O
show	O
that	O
chemokine	B
-	O
triggered	O
activation	O
of	O
ILK	B
is	O
downstream	O
of	O
phosphoinositide	B
3-kinase	I
.	O

In	O
functional	O
assays	O
under	O
physiologically	O
relevant	O
flow	O
conditions	O
,	O
overexpression	O
of	O
wild	O
-	O
type	O
ILK	B
in	O
human	O
monocytic	O
cells	O
diminishes	O
beta	B
(	I
1	I
)	I
integrin	I
/	O
vascular	B
cell	I
adhesion	I
molecule-1	I
-	O
dependent	O
firm	O
adhesion	O
to	O
human	O
endothelial	O
cells	O
.	O

These	O
data	O
implicate	O
ILK	B
in	O
the	O
dynamic	O
signaling	O
events	O
involved	O
in	O
the	O
regulation	O
of	O
leukocyte	O
integrin	B
avidity	O
for	O
endothelial	O
substrates	O
.	O

Expression	O
pattern	O
and	O
further	O
characterization	O
of	O
human	O
MAGED2	B
and	O
identification	O
of	O
rodent	O
orthologues	O
.	O

In	O
a	O
search	O
for	O
genes	O
involved	O
in	O
X	O
-	O
linked	O
mental	O
retardation	O
we	O
have	O
analyzed	O
the	O
expression	O
pattern	O
and	O
genomic	O
structure	O
of	O
human	O
MAGED2	B
.	O

This	O
gene	O
is	O
a	O
member	O
of	O
a	O
new	O
defined	O
MAGE	B
-	I
D	I
cluster	O
in	O
Xp11.2	O
,	O
a	O
hot	O
spot	O
for	O
X	O
-	O
linked	O
mental	O
retardation	O
.	O

Rat	O
and	O
mouse	O
orthologues	O
have	O
been	O
isolated	O
.	O

In	O
contrast	O
to	O
the	O
genes	O
of	O
the	O
MAGE	B
-	I
A	I
,	O
MAGE	B
-	I
B	I
and	O
MAGE	B
-	I
C	I
clusters	O
,	O
MAGED2	B
is	O
expressed	O
ubiquitously	O
.	O

High	O
expression	O
was	O
detected	O
in	O
specific	O
brain	O
regions	O
and	O
in	O
the	O
interstitium	O
of	O
testes	O
.	O

Five	O
SNPs	O
in	O
the	O
coding	O
region	O
of	O
human	O
MAGED2	B
were	O
characterized	O
and	O
their	O
allele	O
frequencies	O
determined	O
in	O
a	O
German	O
and	O
Turkish	O
population	O
.	O

Loss	O
of	O
polysialic	O
residues	O
accelerates	O
CNS	O
neural	O
precursor	O
differentiation	O
in	O
pathological	O
conditions	O
.	O

Using	O
the	O
model	O
of	O
lysolecithin	O
-	O
induced	O
demyelination	O
of	O
the	O
corpus	O
callosum	O
in	O
wild	O
-	O
type	O
,	O
NCAM	B
-	O
deficient	O
,	O
and	O
endoneuraminidase	B
-	O
injected	O
mice	O
,	O
we	O
have	O
analyzed	O
the	O
consequences	O
of	O
the	O
loss	O
of	O
expression	O
of	O
NCAM	B
or	O
PSA	B
residues	O
on	O
the	O
migration	O
and	O
proliferation	O
capacities	O
of	O
neural	O
precursors	O
of	O
the	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
.	O

We	O
showed	O
that	O
the	O
absence	O
of	O
PSA	B
or	O
NCAM	B
delayed	O
migration	O
of	O
neural	O
precursors	O
to	O
the	O
olfactory	O
bulb	O
and	O
consequently	O
enhanced	O
their	O
recruitment	O
at	O
the	O
lesion	O
site	O
.	O

Moreover	O
,	O
after	O
demyelination	O
,	O
the	O
lack	O
of	O
NCAM	B
but	O
not	O
PSA	B
promoted	O
proliferation	O
in	O
the	O
SVZ	O
and	O
the	O
lesion	O
while	O
the	O
lack	O
of	O
PSA	B
favored	O
the	O
differentiation	O
of	O
the	O
traced	O
cells	O
into	O
the	O
oligodendroglial	O
fate	O
both	O
in	O
the	O
SVZ	O
and	O
in	O
the	O
lesion	O
.	O

As	O
previously	O
demonstrated	O
in	O
vitro	O
(	O
L.	O
Decker	O
et	O
al.	O
,	O
2000	O
,	O
Mol	O
.	O
Cell	O
.	O
Neurosci	O
.	O
16	O
,	O
422	O
-	O
439	O
)	O
,	O
these	O
data	O
illustrate	O
the	O
involvement	O
of	O
PSA	B
and	O
NCAM	B
in	O
neural	O
precursor	O
motility	O
and	O
differentiation	O
in	O
the	O
normal	O
and	O
injured	O
central	O
nervous	O
system	O
,	O
suggesting	O
distinct	O
roles	O
for	O
these	O
two	O
molecules	O
under	O
pathophysiological	O
conditions	O
.	O

Four	O
strains	O
of	O
spontaneously	O
hyperlipidemic	O
(	O
SHL	O
)	O
mice	O
:	O
phenotypic	O
distinctions	O
determined	O
by	O
genetic	O
backgrounds	O
.	O

Spontaneously	O
hyperlipidemic	O
(	O
SHL	O
)	O
mice	O
are	O
Japanese	O
wild	O
mice	O
(	O
KOR	O
)	O
with	O
disruption	O
of	O
the	O
apolipoprotein	B
E	I
(	O
Apo	B
E	I
)	O
gene	O
.	O

These	O
mice	O
(	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
)	O
are	O
superhypercholesterolemic	O
and	O
develop	O
severe	O
xanthoma	O
,	O
but	O
their	O
atherosclerosis	O
is	O
relatively	O
mild	O
compared	O
with	O
Apo	B
E	I
knockout	O
mice	O
.	O

First	O
,	O
we	O
tested	O
whether	O
this	O
distinction	O
is	O
due	O
to	O
additional	O
mutation	O
of	O
the	O
Apoc1	B
and/or	O
Apoc2	B
genes	O
in	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
.	O

Southern	O
blot	O
analysis	O
,	O
but	O
found	O
no	O
gross	O
disruption	O
of	O
these	O
genes	O
.	O

Next	O
,	O
we	O
tested	O
whether	O
the	O
phenotypic	O
distinction	O
is	O
due	O
to	O
differences	O
in	O
the	O
genetic	O
background	O
.	O

To	O
this	O
end	O
,	O
we	O
established	O
three	O
lines	O
of	O
congenic	O
SHL	O
mice	O
with	O
a	O
genetic	O
background	O
of	O
C57BL	O
/	O
6	O
,	O
BALB	O
/	O
c	O
or	O
C3H	O
/	O
He	O
,	O
and	O
named	O
them	O
,	O
respectively	O
,	O
C57BL	O
/	O
6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
(	O
B6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
)	O
,	O
BALB	O
/	O
c	O
.	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
(	O
C.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
)	O
and	O
C3H	O
/	O
He	O
.	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
(	O
C3.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
)	O
.	O

Hypercholesterolemia	O
was	O
most	O
severe	O
in	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
followed	O
the	O
by	O
others	O
as	O
follows	O
;	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
>	O
>	O
C3.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
>	O
C.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
>	O
B6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
.	O

In	O
contrast	O
,	O
atherosclerosis	O
was	O
most	O
severe	O
in	O
B6.KOR	O
Apoe	B
(	O
shl	O
)	O
followed	O
by	O
the	O
others	O
:	O
B6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
>	O
C.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
>	O
>	O
C3.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
>	O
or	O
=	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
.	O

This	O
order	O
,	O
however	O
,	O
did	O
not	O
match	O
that	O
in	O
xanthoma	O
,	O
which	O
was	O
highly	O
prominent	O
in	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
but	O
mild	O
in	O
B6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
,	O
C.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
and	O
C3.KORApoe	O
(	O
shl	O
)	O
.	O

This	O
order	O
,	O
however	O
,	O
did	O
not	O
match	O
that	O
in	O
xanthoma	O
,	O
which	O
was	O
highly	O
prominant	O
in	O
KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
but	O
mild	O
in	O
B6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
,	O
C.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
and	O
C3.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
.	O

These	O
distinctions	O
suggest	O
that	O
the	O
severity	O
of	O
each	O
of	O
the	O
phenotypes	O
is	O
determined	O
by	O
distinct	O
genetic	O
backgrounds	O
which	O
probably	O
are	O
composed	O
of	O
polymorphism	O
of	O
lipid	O
metabolism	O
-	O
related	O
proteins	O
.	O

We	O
found	O
that	O
apolipoprotein	B
A	I
-	I
I	I
is	O
decreased	O
in	O
each	O
SHL	O
strain	O
and	O
polymorphic	O
between	O
B6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
and	O
the	O
other	O
strains	O
examined	O
.	O

This	O
polymorphism	O
may	O
be	O
related	O
to	O
the	O
most	O
severe	O
atherosclerosis	O
observed	O
in	O
B6.KOR	O
-	O
Apoe	B
(	O
shl	O
)	O
.	O

It	O
is	O
most	O
likely	O
that	O
combination	O
of	O
such	O
polymorphisms	O
is	O
due	O
to	O
the	O
genetic	O
background	O
accountable	O
for	O
phenotype	O
distinctions	O
.	O

Characterization	O
of	O
a	O
feline	O
homologue	O
of	O
the	O
alphaE	B
integrin	I
subunit	O
(	O
CD103	B
)	O
reveals	O
high	O
specificity	O
for	O
intra	O
-	O
epithelial	O
lymphocytes	O
.	O

The	O
characteristics	O
of	O
a	O
feline	O
homologue	O
of	O
the	O
alphaE	B
integrin	I
(	O
CD103	B
)	O
,	O
defined	O
by	O
two	O
murine	O
monoclonal	O
antibodies	O
,	O
Fe7.1B8	O
(	O
IgG1	B
)	O
and	O
Fe7.2D8	O
(	O
IgG1	B
)	O
,	O
are	O
described	O
.	O

These	O
antibodies	O
recognized	O
75	O
%	O
of	O
intra	O
-	O
epithelial	O
(	O
range	O
59	O
-	O
88	O
%	O
)	O
and	O
40	O
%	O
of	O
lamina	O
proprial	O
(	O
range	O
28	O
-	O
46	O
%	O
)	O
T	O
cells	O
of	O
the	O
intestinal	O
mucosal	O
tissue	O
of	O
the	O
small	O
intestine	O
in	O
contrast	O
with	O
approximately	O
2	O
%	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

Both	O
antibodies	O
immunoprecipitated	O
a	O
180	O
kDa	O
protein	O
from	O
biotinylated	O
feline	O
intra	O
-	O
epithelial	O
mucosal	O
leukocytes	O
consistent	O
with	O
the	O
alphaE	B
integrin	I
subunit	O
in	O
conjunction	O
with	O
a	O
120	O
kDa	O
protein	O
consistent	O
with	O
the	O
beta7	B
subunit	O
.	O

The	O
nucleotide	O
sequence	O
of	O
feline	O
alphaE	B
integrin	I
,	O
generated	O
from	O
molecular	O
cloning	O
of	O
the	O
feline	O
alphaE	B
encoding	O
cDNA	O
,	O
is	O
also	O
reported	O
.	O

This	O
feline	O
molecule	O
shares	O
72	O
%	O
sequence	O
homology	O
with	O
human	O
and	O
69	O
%	O
homology	O
with	O
murine	O
and	O
rat	O
counterparts	O
.	O

Homology	O
includes	O
the	O
presence	O
of	O
an	O
X	O
(	O
extra	O
)	O
domain	O
,	O
that	O
appears	O
unique	O
to	O
alphaE	B
molecules	O
as	O
described	O
for	O
human	O
,	O
rat	O
and	O
mouse	O
,	O
as	O
well	O
as	O
areas	O
of	O
homology	O
common	O
to	O
other	O
alpha	B
integrins	I
.	O

Of	O
note	O
is	O
a	O
typical	O
I	O
(	O
inserted	O
)	O
domain	O
,	O
the	O
presence	O
of	O
seven	O
repeat	O
regions	O
,	O
and	O
highly	O
conserved	O
sequences	O
in	O
the	O
cytoplasmic	O
tail	O
.	O

Transfection	O
studies	O
demonstrated	O
that	O
both	O
antibodies	O
recognized	O
an	O
extracellular	O
component	O
which	O
encompassed	O
the	O
X	O
and	O
I	O
domains	O
of	O
the	O
cloned	O
alphaE	B
integrin	I
subunit	O
.	O

These	O
studies	O
demonstrate	O
that	O
the	O
pattern	O
of	O
tissue	O
distribution	O
,	O
biochemical	O
characteristics	O
,	O
and	O
cDNA	O
sequence	O
of	O
the	O
feline	O
alphaE	B
integrin	I
subunit	O
are	O
largely	O
similar	O
to	O
that	O
described	O
for	O
other	O
species	O
.	O

Macrovascular	O
disease	O
risk	O
factors	O
and	O
insulin	B
resistance	O
in	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
people	O
.	O

It	O
has	O
been	O
proposed	O
that	O
insulin	B
resistance	O
(	O
IR	O
)	O
underlies	O
a	O
cluster	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
risk	O
factors	O
constituting	O
a	O
""""	O
metabolic	O
syndrome	O
.	O
""""	O

CVD	O
is	O
a	O
leading	O
cause	O
of	O
premature	O
mortality	O
among	O
indigenous	O
Australians	O
.	O

In	O
a	O
group	O
of	O
younger	O
(	O
15	O
-	O
44	O
years	O
,	O
fasting	O
glucose	O
<	O
7.8	O
mmol	O
/	O
l	O
)	O
Aboriginal	O
(	O
n	O
=	O
643	O
)	O
and	O
Torres	O
Strait	O
Islander	O
(	O
n	O
=	O
220	O
)	O
people	O
participating	O
in	O
community	O
-	O
based	O
risk	O
factor	O
surveys	O
,	O
we	O
identified	O
high	O
prevalences	O
of	O
metabolic	O
syndrome	O
components	O
:	O
glucose	O
intolerance	O
,	O
dyslipidaemia	O
,	O
hypertension	O
,	O
and	O
IR	O
.	O

There	O
were	O
inconsistent	O
associations	O
of	O
IR	O
with	O
other	O
risk	O
factors	O
,	O
and	O
the	O
data	O
do	O
not	O
support	O
a	O
direct	O
causal	O
relationship	O
between	O
insulin	B
and	O
other	O
metabolic	O
variables	O
.	O

Rather	O
,	O
metabolic	O
syndrome	O
components	O
may	O
arise	O
from	O
social	O
and	O
environmental	O
factors	O
interacting	O
with	O
behavioural	O
and	O
biochemical	O
factors	O
in	O
individuals	O
.	O

Specific	O
identification	O
of	O
three	O
low	O
molecular	O
weight	O
membrane	O
-	O
associated	O
antigens	O
of	O
Helicobacter	O
pylori	O
.	O

BACKGROUND	O
:	O

A	O
large	O
number	O
of	O
Helicobacter	O
pylori	O
proteins	O
are	O
antigenic	O
,	O
but	O
antibodies	O
to	O
these	O
proteins	O
persist	O
in	O
spite	O
of	O
the	O
eradication	O
of	O
the	O
infection	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

The	O
analysis	O
of	O
sera	O
from	O
H.	O
pylori	O
-	O
infected	O
and	O
non	O
-	O
infected	O
patients	O
,	O
before	O
and	O
3	O
and	O
5	O
months	O
after	O
eradication	O
,	O
showed	O
that	O
the	O
antibody	O
response	O
against	O
unknown	O
H.	O
pylori	O
antigens	O
at	O
32	O
,	O
30	O
,	O
22	O
and	O
14	O
kDa	O
in	O
sodium	O
dodecylsulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
decreased	O
by	O
>	O
or	O
=	O
60	O
%	O
at	O
3	O
months	O
and	O
>	O
or	O
=	O
70	O
%	O
at	O
5	O
months	O
after	O
treatment	O
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
allowed	O
the	O
identification	O
of	O
eight	O
proteins	O
at	O
these	O
positions	O
:	O
neuraminyl	O
-	O
lactose	O
-	O
binding	O
haemagglutinin	B
precursor	O
,	O
3-oxoadipate	B
CoA	I
-	I
transferase	I
subunit	I
A	I
,	O
elongation	B
factor	I
P	I
,	O
peptidoglycan	B
-	I
associated	I
lipoprotein	I
precursor	O
,	O
hypothetical	O
protein	O
HP0596	B
,	O
adhesin	B
-	I
thiol	I
peroxidase	I
,	O
50S	B
ribosomal	I
protein	I
L7	I
/	I
L12	I
and	O
subunit	O
b	B
'	I
of	I
the	I
F	I
(	I
0	I
)	I
ATP	I
synthase	I
.	O

Three	O
of	O
these	O
eight	O
,	O
expressed	O
as	O
recombinant	O
proteins	O
(	O
32	O
kDa	O
neuraminyl	O
-	O
lactose	O
-	O
binding	O
haemagglutinin	B
precursor	O
,	O
30	O
kDa	O
peptidoglycan	B
-	I
associated	I
lipoprotein	I
precursor	O
and	O
22	O
kDa	O
hypothetical	O
protein	O
HP0596	B
)	O
,	O
reacted	O
specifically	O
with	O
sera	O
from	O
infected	O
patients	O
,	O
while	O
the	O
14	O
kDa	O
50S	B
ribosomal	I
protein	I
L7	I
/	I
L12	I
cross	O
-	O
reacted	O
with	O
one	O
out	O
of	O
five	O
sera	O
from	O
H.	O
pylori	O
-	O
negative	O
patients	O
.	O

The	O
other	O
recombinant	O
proteins	O
did	O
not	O
show	O
significant	O
immunoreactivity	O
.	O

CONCLUSIONS	O
:	O

Four	O
low	O
molecular	O
weight	O
antigens	O
were	O
identified	O
by	O
these	O
methods	O
,	O
three	O
of	O
which	O
were	O
specific	O
.	O

Immunoreaction	O
with	O
these	O
three	O
proteins	O
(	O
neuraminyl	O
-	O
lactose	O
-	O
binding	O
haemagglutinin	B
precursor	O
,	O
peptidoglycan	B
-	I
associated	I
lipoprotein	I
precursor	O
and	O
hypothetical	O
protein	O
HP0596	B
)	O
could	O
provide	O
a	O
serological	O
assessment	O
not	O
only	O
of	O
H.	O
pylori	O
infection	O
,	O
but	O
also	O
of	O
eradication	O
.	O

Effect	O
of	O
nonoxynol-9	O
gel	O
on	O
urogenital	O
gonorrhea	O
and	O
chlamydial	O
infection	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

CONTEXT	O
:	O

Nonoxynol-9	O
has	O
been	O
suggested	O
as	O
a	O
vaginal	O
microbicide	O
to	O
protect	O
against	O
common	O
sexually	O
transmitted	O
infections	O
.	O

OBJECTIVE	O
:	O

To	O
compare	O
nonoxynol-9	O
gel	O
and	O
condom	O
use	O
(	O
gel	O
group	O
)	O
vs	O
condom	O
use	O
alone	O
(	O
condom	O
group	O
)	O
for	O
the	O
prevention	O
of	O
male	O
-	O
to	O
-	O
female	O
transmission	O
of	O
urogenital	O
gonococcal	O
and	O
chlamydial	O
infection	O
.	O

DESIGN	O
AND	O
SETTING	O
:	O

Randomized	O
controlled	O
trial	O
conducted	O
at	O
10	O
community	O
clinics	O
and	O
10	O
pharmacies	O
in	O
YaoundÃ?Â	O
©	O
,	O
Cameroon	O
,	O
between	O
October	O
1998	O
and	O
September	O
2000	O
,	O
with	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O

PARTICIPANTS	O
:	O

High	O
-	O
risk	O
population	O
of	O
1251	O
women	O
(	O
excluding	O
sex	O
workers	O
)	O
being	O
treated	O
for	O
or	O
who	O
had	O
symptoms	O
of	O
sexually	O
transmitted	O
infections	O
.	O

Three	O
were	O
excluded	O
from	O
the	O
gel	O
group	O
(	O
0.5	O
%	O
)	O
and	O
7	O
from	O
the	O
condom	O
group	O
(	O
1	O
%	O
)	O
because	O
of	O
no	O
follow	O
-	O
up	O
data	O
.	O

INTERVENTIONS	O
:	O

Nonoxynol-9	O
gel	O
(	O
100	O
mg	O
)	O
and	O
condoms	O
or	O
condoms	O
only	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
:	O

A	O
positive	O
test	O
result	O
for	O
gonococcal	O
or	O
chlamydial	O
infection	O
by	O
the	O
ligase	O
chain	O
reaction	O
assay	O
;	O
secondary	O
outcome	O
measure	O
was	O
a	O
positive	O
test	O
result	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

RESULTS	O
:	O

The	O
rate	O
ratio	O
(	O
RR	O
)	O
for	O
new	O
urogenital	O
infections	O
was	O
1.2	O
for	O
the	O
gel	O
group	O
vs	O
condom	O
group	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.9	O
-	O
1.6	O
;	O
P	O
=	O
.21	O
)	O
.	O

The	O
gel	O
group	O
had	O
116	O
diagnosed	O
gonococcal	O
infections	O
,	O
chlamydial	O
infections	O
,	O
or	O
both	O
for	O
a	O
rate	O
of	O
43.6	O
per	O
100	O
person	O
-	O
years	O
,	O
and	O
the	O
condom	O
group	O
had	O
100	O
infections	O
for	O
a	O
rate	O
of	O
36.6	O
per	O
100	O
person	O
-	O
years	O
.	O

The	O
RR	O
for	O
gonococcal	O
infection	O
in	O
the	O
gel	O
group	O
vs	O
the	O
condom	O
group	O
was	O
1.5	O
(	O
95	O
%	O
CI	O
,	O
1.0	O
-	O
2.3	O
)	O
and	O
for	O
chlamydial	O
infection	O
was	O
1.0	O
(	O
95	O
%	O
CI	O
,	O
0.7	O
-	O
1.4	O
)	O
.	O

There	O
were	O
5	O
new	O
cases	O
of	O
HIV	O
infections	O
in	O
the	O
gel	O
group	O
and	O
4	O
in	O
the	O
condom	O
group	O
.	O

Three	O
women	O
in	O
each	O
group	O
became	O
pregnant	O
during	O
the	O
study	O
.	O

CONCLUSION	O
:	O

Nonoxynol-9	O
gel	O
did	O
not	O
protect	O
against	O
urogenital	O
gonococcal	O
or	O
chlamydial	O
infection	O
.	O

RasGRP4	B
is	O
a	O
novel	O
Ras	B
activator	O
isolated	O
from	O
acute	O
myeloid	O
leukemia	O
.	O

Although	O
a	O
number	O
of	O
genetic	O
defects	O
are	O
commonly	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
a	O
large	O
percentage	O
of	O
AML	O
cases	O
are	O
cytogenetically	O
normal	O
.	O

This	O
suggests	O
a	O
functional	O
screen	O
for	O
transforming	O
genes	O
is	O
required	O
to	O
identify	O
genetic	O
mutations	O
that	O
are	O
missed	O
by	O
cytogenetic	O
analyses	O
.	O

We	O
utilized	O
a	O
retrovirus	O
-	O
based	O
cDNA	O
expression	O
system	O
to	O
identify	O
transforming	O
genes	O
expressed	O
in	O
cytogenetically	O
normal	O
AML	O
patients	O
.	O

We	O
identified	O
a	O
new	O
member	O
of	O
the	O
Ras	B
guanyl	I
nucleotide	I
-	I
releasing	I
protein	I
(	I
RasGRP	I
)	I
family	I
of	O
Ras	B
guanine	I
nucleotide	I
exchange	I
factors	I
,	O
designating	O
it	O
RasGRP4	B
.	O

Subsequently	O
,	O
cDNA	O
sequences	O
encoding	O
rodent	O
and	O
human	O
RasGRP4	B
proteins	O
were	O
deposited	O
in	O
GenBank	O
.	O

RasGRP4	B
contains	O
the	O
same	O
protein	O
domain	O
structure	O
as	O
other	O
members	O
of	O
the	O
RasGRP	B
family	I
,	O
including	O
a	O
Ras	B
exchange	O
motif	O
,	O
a	O
CDC25	B
homology	O
domain	O
,	O
a	O
C1	O
/	O
diacyglycerol	O
-	O
binding	O
domain	O
,	O
and	O
putative	O
calcium	O
-	O
binding	O
EF	O
hands	O
.	O

We	O
show	O
that	O
expression	O
of	O
RasGRP4	B
induces	O
anchorage	O
-	O
independent	O
growth	O
of	O
Rat1	O
fibroblasts	O
.	O

RasGRP4	B
is	O
a	O
Ras	B
-	O
specific	O
activator	O
and	O
,	O
interestingly	O
,	O
is	O
highly	O
expressed	O
in	O
peripheral	O
blood	O
leukocytes	O
and	O
myeloid	O
cell	O
lines	O
.	O

Unlike	O
other	O
RasGRP	B
proteins	O
,	O
RasGRP4	B
is	O
not	O
expressed	O
in	O
the	O
brain	O
or	O
in	O
lymphoid	O
cells	O
.	O

We	O
demonstrated	O
that	O
32D	O
myeloid	O
cells	O
expressing	O
RasGRP4	B
have	O
elevated	O
levels	O
of	O
activated	O
Ras	B
compared	O
with	O
control	O
cells	O
,	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
treatment	O
greatly	O
enhanced	O
Ras	B
activation	O
.	O

PMA	O
induced	O
membrane	O
localization	O
of	O
RasGRP4	B
and	O
32D	O
cells	O
expressing	O
RasGRP4	B
were	O
capable	O
of	O
cytokine	B
-	O
independent	O
proliferation	O
in	O
the	O
presence	O
of	O
PMA	O
.	O

We	O
conclude	O
that	O
RasGRP4	B
is	O
a	O
member	O
of	O
the	O
RasGRP	B
family	I
of	O
Ras	B
guanine	I
nucleotide	I
exchange	I
factors	I
that	O
may	O
play	O
a	O
role	O
in	O
myeloid	O
cell	O
signaling	O
growth	O
regulation	O
pathways	O
that	O
are	O
responsive	O
to	O
diacylglycerol	O
levels	O
.	O

Partial	O
characterization	O
of	O
a	O
cerebral	O
thyroid	B
hormone	I
-	I
responsive	I
protein	I
.	O

The	O
thyroid	B
hormone	I
-	I
responsive	I
protein	I
(	O
THRP	B
)	O
is	O
expressed	O
in	O
rat	O
cerebral	O
tissue	O
and	O
has	O
83	O
%	O
overall	O
sequence	O
homology	O
with	O
c	B
-	I
Abl	I
interactor	I
protein	I
,	O
Abi-2	B
,	O
which	O
is	O
a	O
substrate	O
for	O
the	O
tyrosine	B
kinase	I
activity	O
of	O
c	B
-	I
Abl	I
.	O

Within	O
the	O
core	O
region	O
of	O
the	O
two	O
proteins	O
,	O
the	O
sequence	O
similarity	O
approaches	O
99	O
%	O
.	O

To	O
determine	O
whether	O
THRP	B
is	O
a	O
rat	O
homologue	O
of	O
Abi-2	B
or	O
is	O
a	O
distinct	O
protein	O
with	O
unique	O
properties	O
,	O
the	O
tissue	O
distribution	O
of	O
THRP	B
and	O
Abi	B
-	I
2	I
mRNA	O
's	O
was	O
examined	O
using	O
a	O
sensitive	O
ribonuclease	B
protection	O
assay	O
and	O
probes	O
specific	O
for	O
THRP	B
and	O
Abi	B
-	I
2	I
,	O
respectively	O
.	O

The	O
THRP	B
mRNA	O
content	O
of	O
cerebral	O
tissue	O
(	O
1340.0	O
+	O
/-	O
126.5	O
arbitrary	O
units	O
)	O
was	O
2.3	O
-	O
fold	O
higher	O
than	O
Abi	B
-	I
2	I
mRNA	O
(	O
581.3	O
+	O
/	O
-	O
73.7	O
)	O
,	O
while	O
the	O
ratio	O
of	O
hepatic	O
content	O
of	O
THRP	B
mRNA	O
(	O
209.0	O
+	O
/	O
-	O
49.1	O
)	O
to	O
hepatic	O
Abi-2	B
mRNA	O
(	O
2923.0	O
+	O
/	O
-	O
378.7	O
)	O
was	O
only	O
0.07	O
(	O
P	O
<	O
0.004	O
)	O
.	O

Very	O
low	O
levels	O
of	O
Abi-2	B
mRNA	O
,	O
but	O
not	O
THRP	B
mRNA	O
,	O
were	O
also	O
found	O
in	O
the	O
heart	O
and	O
small	O
intestine	O
.	O

Experiments	O
with	O
PC12	O
cells	O
transfected	O
with	O
the	O
full	O
-	O
length	O
THRP	B
cDNA	O
and	O
grown	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
tyrosine	B
kinase	I
inhibitor	O
,	O
along	O
with	O
experiments	O
where	O
PC12	O
cells	O
were	O
cotransfected	O
with	O
the	O
THRP	B
cDNA	O
with	O
or	O
without	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
(	O
tyrosine	B
kinase	I
deficient	O
)	O
c	B
-	I
Abl	I
cDNA	O
,	O
showed	O
that	O
THRP	B
is	O
tyrosine	O
phosphorylated	O
;	O
however	O
,	O
it	O
is	O
not	O
a	O
substrate	O
for	O
c	B
-	I
Abl	I
.	O

These	O
studies	O
demonstrate	O
that	O
THRP	B
and	O
Abi-2	B
have	O
distinct	O
tissue	O
distribution	O
and	O
distinct	O
biological	O
properties	O
.	O

A	O
novel	O
negative	O
regulatory	O
element	O
in	O
the	O
human	O
collagenase-3	B
proximal	O
promoter	O
region	O
.	O

We	O
have	O
identified	O
in	O
the	O
human	O
collagenase-3	B
promoter	O
a	O
novel	O
negative	O
regulatory	O
element	O
,	O
GAAAAGAAAAAG	O
,	O
designated	O
AGRE	O
(	O
AG	O
-	O
Rich	O
Element	O
)	O
.	O

The	O
AGRE	O
site	O
functionality	O
was	O
characterized	O
in	O
human	O
osteoarthritic	O
(	O
OA	O
)	O
chondrocytes	O
as	O
well	O
as	O
four	O
cell	O
lines	O
.	O

The	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
consisting	O
of	O
the	O
first	O
133	O
bp	O
of	O
the	O
collagenase-3	B
promoter	O
and	O
its	O
AGRE	O
mutated	O
or	O
deleted	O
derivatives	O
.	O

The	O
absence	O
of	O
a	O
functional	O
AGRE	B
site	O
resulted	O
in	O
a	O
statistically	O
significant	O
increase	O
of	O
the	O
collagenase-3	B
basal	O
transcription	O
that	O
was	O
not	O
affected	O
by	O
the	O
collagenase-3	B
inducers	O
IL-1beta	B
and	O
TGF	B
-	I
beta1	I
.	O

Two	O
specific	O
protein	O
-	O
AGRE	O
binding	O
complexes	O
were	O
detected	O
by	O
EMSA	O
,	O
and	O
their	O
presence	O
depended	O
on	O
the	O
physiological	O
state	O
of	O
the	O
cell	O
.	O

Indeed	O
,	O
normal	O
chondrocytes	O
and	O
synovial	O
fibroblasts	O
and	O
the	O
four	O
cell	O
lines	O
showed	O
only	O
a	O
slower	O
-	O
migrating	O
complex	O
(	O
complex	O
1	O
)	O
.	O

In	O
OA	O
chondrocytes	O
,	O
the	O
type	O
of	O
complex	O
discriminated	O
two	O
groups	O
--	O
the	O
low	O
-	O
OA	O
chondrocytes	O
,	O
showing	O
low	O
collagenase	B
-	I
3	I
basal	O
levels	O
and	O
high	O
inducibility	O
of	O
IL-1beta	B
stimulation	O
(	O
complex	O
1	O
)	O
,	O
and	O
the	O
high	O
-	O
OA	O
chondrocytes	O
with	O
high	O
collagenase	B
-	I
3	I
basal	O
levels	O
and	O
low	O
IL-1beta	B
inducibility	O
(	O
a	O
faster	O
-	O
migrating	O
complex	O
,	O
designated	O
complex	O
2	O
)	O
.	O

UV	O
cross	O
-	O
linking	O
revealed	O
the	O
presence	O
of	O
48	O
and	O
97	O
kDa	O
proteins	O
in	O
complex	O
1	O
and	O
27	O
,	O
35	O
,	O
and	O
73	O
kDa	O
proteins	O
in	O
complex	O
2	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
AGRE	O
site	O
plays	O
a	O
rate	O
-	O
limiting	O
role	O
in	O
human	O
collagenase-3	B
production	O
.	O

Production	O
and	O
characterization	O
of	O
bifunctional	O
enzymes	O
.	O

Domain	O
swapping	O
to	O
produce	O
new	O
bifunctional	O
enzymes	O
in	O
the	O
aspartate	O
pathway	O
.	O

The	O
bifunctional	O
enzyme	O
aspartokinase	B
-	I
homoserine	I
dehydrogenase	I
I	I
from	O
Escherichia	O
coli	O
catalyzes	O
non	O
-	O
consecutive	O
reactions	O
in	O
the	O
aspartate	O
pathway	O
of	O
amino	O
acid	O
biosynthesis	O
.	O

Both	O
catalytic	O
activities	O
are	O
subject	O
to	O
allosteric	O
regulation	O
by	O
the	O
end	O
product	O
amino	O
acid	O
L	O
-	O
threonine	O
.	O

To	O
examine	O
the	O
kinetics	O
and	O
regulation	O
of	O
the	O
enzymes	O
in	O
this	O
pathway	O
,	O
each	O
of	O
these	O
catalytic	O
domains	O
were	O
separately	O
expressed	O
and	O
purified	O
.	O

The	O
separated	O
catalytic	O
domains	O
remain	O
active	O
,	O
with	O
each	O
of	O
their	O
catalytic	O
activities	O
enhanced	O
in	O
comparison	O
to	O
the	O
native	O
enzyme	O
.	O

The	O
allosteric	O
regulation	O
of	O
the	O
kinase	B
activity	O
is	O
lost	O
,	O
and	O
regulation	O
of	O
the	O
dehydrogenase	B
activity	O
is	O
dramatically	O
decreased	O
in	O
these	O
separate	O
domains	O
.	O

To	O
create	O
a	O
new	O
bifunctional	O
enzyme	O
that	O
can	O
catalyze	O
consecutive	O
metabolic	O
reactions	O
,	O
the	O
aspartokinase	B
I	I
domain	O
was	O
fused	O
to	O
the	O
enzyme	O
that	O
catalyzes	O
the	O
intervening	O
reaction	O
in	O
the	O
pathway	O
,	O
aspartate	B
semialdehyde	I
dehydrogenase	I
.	O

A	O
hybrid	O
bifunctional	O
enzyme	O
was	O
also	O
created	O
between	O
the	O
native	O
monofunctional	O
aspartokinase	B
III	I
,	O
an	O
allosteric	O
enzyme	O
regulated	O
by	O
lysine	O
,	O
and	O
the	O
catalytic	O
domain	O
of	O
homoserine	B
dehydrogenase	I
I	I
with	O
its	O
regulatory	O
interface	O
domain	O
still	O
attached	O
.	O

In	O
this	O
hybrid	O
the	O
kinase	B
activity	O
remains	O
sensitive	O
to	O
lysine	O
,	O
while	O
the	O
dehydrogenase	B
activity	O
is	O
now	O
regulated	O
by	O
both	O
threonine	O
and	O
lysine	O
.	O

The	O
dehydrogenase	B
domain	O
is	O
less	O
thermally	O
stable	O
than	O
the	O
kinase	B
domain	O
and	O
becomes	O
further	O
destabilized	O
upon	O
removal	O
of	O
the	O
regulatory	O
domain	O
.	O

The	O
more	O
stable	O
aspartokinase	B
III	I
is	O
further	O
stabilized	O
against	O
thermal	O
denaturation	O
in	O
the	O
hybrid	O
bifunctional	O
enzyme	O
and	O
was	O
found	O
to	O
retain	O
some	O
catalytic	O
activity	O
even	O
at	O
temperatures	O
approaching	O
100	O
degrees	O
C	O
.	O

Production	O
and	O
characterization	O
of	O
bifunctional	O
enzymes	O
.	O

Substrate	O
channeling	O
in	O
the	O
aspartate	O
pathway	O
.	O

The	O
direct	O
channeling	O
of	O
an	O
intermediate	O
between	O
enzymes	O
that	O
catalyze	O
consecutive	O
reactions	O
in	O
a	O
pathway	O
offers	O
the	O
possibility	O
of	O
an	O
efficient	O
,	O
exclusive	O
,	O
and	O
protected	O
means	O
of	O
metabolite	O
delivery	O
.	O

Aspartokinase	B
-	I
homoserine	I
dehydrogenase	I
I	I
(	O
AK	B
-	I
HDH	I
I	I
)	O
from	O
Escherichia	O
coli	O
is	O
an	O
unusual	O
bifunctional	O
enzyme	O
in	O
that	O
it	O
does	O
not	O
catalyze	O
consecutive	O
reactions	O
.	O

The	O
potential	O
channeling	O
of	O
the	O
intermediate	O
beta	B
-	I
aspartyl	I
phosphate	I
between	O
the	O
aspartokinase	B
of	O
this	O
bifunctional	O
enzyme	O
and	O
aspartate	B
semialdehyde	I
dehydrogenase	I
(	O
ASADH	B
)	O
,	O
the	O
enzyme	O
that	O
catalyzes	O
the	O
intervening	O
reaction	O
,	O
has	O
been	O
examined	O
.	O

The	O
introduction	O
of	O
increasing	O
levels	O
of	O
inactivated	O
ASADH	B
has	O
been	O
shown	O
to	O
compete	O
against	O
enzyme	O
-	O
enzyme	O
interactions	O
and	O
direct	O
intermediate	O
channeling	O
,	O
leading	O
to	O
a	O
decrease	O
in	O
the	O
overall	O
reaction	O
flux	O
through	O
these	O
consecutive	O
enzymes	O
.	O

These	O
same	O
results	O
are	O
obtained	O
whether	O
these	O
experiments	O
are	O
conducted	O
with	O
aspartokinase	B
III	I
,	O
a	O
naturally	O
occurring	O
monofunctional	O
isozyme	O
,	O
with	O
an	O
artificially	O
produced	O
monofunctional	O
aspartokinase	B
I	I
,	O
or	O
with	O
a	O
fusion	O
construct	O
of	O
AK	B
I	I
-	O
ASADH	B
.	O

These	O
results	O
provide	O
definitive	O
evidence	O
for	O
the	O
channeling	O
of	O
beta	O
-	O
aspartyl	O
phosphate	O
between	O
aspartokinase	B
and	O
aspartate	B
semialdehyde	I
dehydrogenase	I
in	O
E.	O
coli	O
and	O
suggest	O
that	O
ASADH	B
may	O
provide	O
a	O
bridge	O
to	O
channel	O
the	O
intermediates	O
between	O
the	O
non	O
-	O
consecutive	O
reactions	O
of	O
AK	B
-	I
HDH	I
I	I
.	O

Serum	O
TA90	O
immune	O
complex	O
assay	O
can	O
predict	O
outcome	O
after	O
resection	O
of	O
thick	O
(	O
>	O
or	O
=	O
4	O
mm	O
)	O
primary	O
melanoma	O
and	O
sentinel	O
lymphadenectomy	O
.	O

BACKGROUND	O
:	O

We	O
hypothesized	O
that	O
the	O
postoperative	O
serum	O
level	O
of	O
TA90-IC	O
,	O
an	O
immune	O
complex	O
of	O
a	O
90	O
-	O
kDa	O
tumor	O
-	O
associated	O
antigen	O
and	O
its	O
antibody	O
,	O
might	O
have	O
a	O
significant	O
correlation	O
with	O
recurrence	O
and	O
survival	O
in	O
patients	O
with	O
thick	O
primary	O
melanomas	O
.	O

METHODS	O
:	O

We	O
used	O
our	O
prospective	O
melanoma	O
database	O
to	O
identify	O
all	O
patients	O
who	O
underwent	O
wide	O
local	O
excision	O
and	O
sentinel	O
lymphadenectomy	O
for	O
primary	O
melanomas	O
>	O
or	O
=	O
4	O
mm	O
and	O
from	O
whom	O
sera	O
had	O
been	O
collected	O
and	O
cryopreserved	O
within	O
6	O
months	O
after	O
surgery	O
.	O

These	O
sera	O
were	O
analyzed	O
in	O
a	O
blinded	O
fashion	O
for	O
TA90-IC	O
status	O
by	O
using	O
our	O
double	O
-	O
determinant	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Results	O
were	O
correlated	O
with	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

Standard	O
prognostic	O
factors	O
for	O
melanoma	O
were	O
then	O
compared	O
with	O
TA90-IC	O
status	O
for	O
the	O
prediction	O
of	O
DFS	O
and	O
OS	O
.	O

RESULTS	O
:	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
TA90	O
-	O
IC	O
assay	O
for	O
predicting	O
recurrence	O
were	O
70	O
%	O
and	O
85	O
%	O
,	O
respectively	O
.	O

Five	O
-	O
year	O
DFS	O
and	O
OS	O
rates	O
were	O
higher	O
for	O
the	O
TA90	O
-	O
IC	O
-	O
negative	O
group	O
than	O
the	O
positive	O
group	O
.	O

The	O
differences	O
in	O
DFS	O
and	O
OS	O
between	O
the	O
TA90	O
-	O
IC	O
-	O
negative	O
and	O
-	O
positive	O
groups	O
were	O
significant	O
.	O

At	O
a	O
median	O
follow	O
-	O
up	O
of	O
25	O
months	O
,	O
multivariate	O
analysis	O
identified	O
postoperative	O
TA90-IC	O
status	O
and	O
sex	O
as	O
significant	O
predictors	O
of	O
DFS	O
.	O

TA90	O
-	O
IC	O
status	O
was	O
the	O
only	O
independent	O
prognostic	O
factor	O
with	O
multivariate	O
analysis	O
.	O

CONCLUSIONS	O
:	O

TA90	O
-	O
IC	O
status	O
after	O
resection	O
of	O
thick	O
primary	O
melanoma	O
accurately	O
predicts	O
outcome	O
.	O

A	O
positive	O
postoperative	O
TA90	O
-	O
IC	O
level	O
might	O
affect	O
a	O
decision	O
regarding	O
adjuvant	O
therapy	O
,	O
regardless	O
of	O
regional	O
nodal	O
status	O
.	O

A	O
switch	O
in	O
dehydrogenase	B
to	O
reductase	B
activity	O
of	O
11	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
upon	O
differentiation	O
of	O
human	O
omental	O
adipose	O
stromal	O
cells	O
.	O

As	O
exemplified	O
in	O
patients	O
with	O
Cushing	O
's	O
syndrome	O
,	O
glucocorticoids	O
play	O
an	O
important	O
role	O
in	O
regulating	O
adipose	O
tissue	O
distribution	O
and	O
function	O
,	O
but	O
circulating	O
cortisol	O
concentrations	O
are	O
normal	O
in	O
most	O
patients	O
with	O
obesity	O
.	O

However	O
,	O
human	O
omental	O
adipose	O
stromal	O
cells	O
(	O
ASCs	O
)	O
can	O
generate	O
glucocorticoid	O
locally	O
through	O
the	O
expression	O
of	O
the	O
enzyme	O
11	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
(	I
11	I
beta	I
-	I
HSD	I
)	I
type	I
1	I
(	O
11	B
beta	I
-	I
HSD1	I
)	O
,	O
which	O
,	O
in	O
intact	O
cells	O
,	O
has	O
been	O
considered	O
to	O
be	O
an	O
oxoreductase	B
,	O
converting	O
inactive	O
cortisone	O
(	O
E	O
)	O
to	O
cortisol	O
(	O
F	O
)	O
.	O

Locally	O
produced	O
F	O
can	O
induce	O
ASC	O
differentiation	O
,	O
but	O
the	O
relationship	O
between	O
11	B
beta	I
-	I
HSD1	I
expression	O
and	O
adipocyte	O
differentiation	O
is	O
unknown	O
.	O

Primary	O
cultures	O
of	O
paired	O
omental	O
(	O
om	O
)	O
and	O
sc	O
ASC	O
and	O
adipocytes	O
were	O
prepared	O
from	O
17	O
patients	O
undergoing	O
elective	O
abdominal	O
surgery	O
and	O
cultured	O
for	O
up	O
to	O
14	O
d	O
.	O

Expression	O
and	O
activity	O
of	O
11	B
beta	I
-	I
HSD	I
isozymes	O
were	O
analyzed	O
together	O
with	O
early	O
(	O
lipoprotein	B
lipase	I
)	O
and	O
terminal	O
(	O
glycerol	B
3	I
phosphate	I
dehydrogenase	I
)	O
markers	O
of	O
adipocyte	O
differentiation	O
.	O

On	O
d	O
1	O
of	O
culture	O
,	O
11	B
beta	I
-	I
HSD1	I
activity	O
in	O
intact	O
om	O
ASCs	O
exceeded	O
oxoreductase	B
activity	O
in	O
every	O
patient	O
(	O
78.9	O
+	O
/-	O
24.9	O
vs.	O
15.8	O
+	O
/-	O
3.7	O
[	O
mean	O
+	O
/-	O
SE	O
]	O
pmol	O
/	O
mg	O
per	O
hour	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
in	O
sc	O
ASCs	O
,	O
relative	O
activities	O
were	O
similar	O
(	O
40.6	O
+	O
/-	O
12.2	O
vs.	O
36.9	O
+	O
/-	O
8.8	O
)	O
.	O

Conversely	O
,	O
in	O
freshly	O
isolated	O
om	O
adipocytes	O
,	O
reductase	B
activity	O
exceeded	O
dehydrogenase	B
activity	O
(	O
23.6	O
+	O
/-	O
1.5	O
vs.	O
6.2	O
+	O
/-	O
0.8	O
pmol	O
/	O
mg	O
per	O
hour	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Following	O
14	O
d	O
of	O
culture	O
in	O
serum	O
-	O
free	O
conditions	O
with	O
addition	O
of	O
10	O
nM	O
insulin	B
(	O
Ctr	O
)	O
or	O
insulin	B
with	O
100	O
nM	O
F	O
(	O
+	O
F	O
)	O
,	O
lipoprotein	B
lipase	I
/	O
18S	O
RNA	O
levels	O
increased	O
in	O
both	O
the	O
Ctr	O
-	O
and	O
+	O
F	O
-	O
treated	O
ASCs	O
,	O
but	O
glycerol	B
3	I
phosphate	I
dehydrogenase	I
increased	O
only	O
in	O
the	O
+	O
F	O
cultures	O
.	O

In	O
both	O
cases	O
,	O
however	O
,	O
11	B
beta	I
-	I
HSD1	I
oxoreductase	B
activity	O
exceeded	O
dehydrogenase	B
activity	O
(	O
Ctr	O
:	O
53.3	O
+	O
/-	O
9.0	O
vs.	O
32.4	O
+	O
/-	O
10.5	O
,	O
P	O
<	O
0.05	O
;	O
+	O
F	O
:	O
65.6	O
+	O
/-	O
15.6	O
vs.	O
37.1	O
+	O
/-	O
11.5	O
pmol	O
/	O
mg	O
per	O
hour	O
,	O
P	O
<	O
0.05	O
)	O
,	O
despite	O
no	O
significant	O
changes	O
in	O
11	B
beta	I
-	I
HSD1	I
mRNA	O
levels	O
.	O

In	O
sc	O
ASCs	O
,	O
dehydrogenase	B
activity	O
was	O
similar	O
to	O
reductase	B
activity	O
in	O
both	O
Ctr	O
-	O
and	O
+	O
F	O
-	O
treated	O
cells	O
.	O

Type	B
2	I
11	I
beta	I
-	I
HSD	I
expression	O
was	O
undetectable	O
in	O
each	O
case	O
.	O

These	O
data	O
show	O
that	O
in	O
intact	O
,	O
undifferentiated	O
om	O
ASCs	O
,	O
11	B
beta	I
-	I
HSD1	I
acts	O
primarily	O
as	O
a	O
dehydrogenase	B
,	O
but	O
in	O
mature	O
adipocytes	O
oxoreductase	B
activity	O
predominates	O
.	O

Because	O
glucocorticoids	O
inhibit	O
cell	O
proliferation	O
,	O
we	O
postulate	O
that	O
11	B
beta	I
-	I
HSD1	I
activity	O
in	O
uncommitted	O
ASCs	O
may	O
facilitate	O
proliferation	O
rather	O
than	O
differentiation	O
.	O

Once	O
early	O
differentiation	O
is	O
initiated	O
,	O
a	O
""""	O
switch	O
""""	O
to	O
11	B
beta	I
-	I
HSD1	I
oxoreductase	B
activity	O
generates	O
F	O
,	O
thus	O
promoting	O
adipogenesis	O
.	O

Site	O
-	O
specific	O
regulation	O
of	O
the	O
set	O
-	O
point	O
of	O
11	B
beta	I
-	I
HSD1	I
activity	O
may	O
be	O
an	O
important	O
mechanism	O
underpinning	O
visceral	O
obesity	O
.	O

Laminin-10	B
/	I
11	I
and	O
fibronectin	B
differentially	O
prevent	O
apoptosis	O
induced	O
by	O
serum	O
removal	O
via	O
phosphatidylinositol	B
3-kinase	I
/	O
Akt	B
-	O
and	O
MEK1	B
/	O
ERK	B
-	O
dependent	O
pathways	O
.	O

Cell	O
adhesion	O
to	O
the	O
extracellular	O
matrix	O
inhibits	O
apoptosis	O
,	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
signals	O
transduced	O
by	O
different	O
matrix	O
components	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
we	O
examined	O
integrin	B
-	O
mediated	O
antiapoptotic	O
signals	O
from	O
laminin	B
-	I
10	I
/	I
11	I
in	O
comparison	O
with	O
those	O
from	O
fibronectin	B
,	O
the	O
best	O
characterized	O
extracellular	O
adhesive	O
ligand	O
.	O

We	O
found	O
that	O
the	O
activation	O
of	O
protein	B
kinase	I
B	I
/	O
Akt	B
in	O
cells	O
adhering	O
to	O
laminin	B
-	I
10	I
/	I
11	I
can	O
rescue	O
cell	O
apoptosis	O
induced	O
by	O
serum	O
removal	O
.	O

Consistent	O
with	O
this	O
,	O
wortmannin	O
,	O
a	O
specific	O
inhibitor	O
of	O
phosphatidylinositol	B
3-kinase	I
,	O
or	O
ectopic	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
Akt	B
selectively	O
accelerated	O
cell	O
death	O
upon	O
serum	O
removal	O
.	O

In	O
contrast	O
to	O
laminin	B
-	I
10	I
/	I
11	I
,	O
fibronectin	B
rescued	O
cells	O
from	O
serum	O
depletion	O
-	O
induced	O
apoptosis	O
mainly	O
through	O
the	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
pathway	O
.	O

Cell	O
survival	O
on	O
fibronectin	B
but	O
not	O
laminin	B
was	O
significantly	O
reduced	O
by	O
treatment	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
mitogen	B
-	I
or	I
extracellular	I
signal	I
-	I
regulated	I
kinase	I
kinase-1	I
(	O
MEK1	B
)	O
and	O
by	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
MEK1	B
.	O

Laminin-10	B
/	I
11	I
was	O
more	O
potent	O
than	O
fibronectin	B
in	O
preventing	O
apoptosis	O
induced	O
by	O
serum	O
depletion	O
.	O

These	O
results	O
,	O
taken	O
together	O
,	O
demonstrate	O
laminin	B
-	I
10	I
/	I
11	I
potency	O
as	O
a	O
survival	O
factor	O
and	O
demonstrate	O
that	O
different	O
extracellular	O
matrix	O
components	O
can	O
transduce	O
distinct	O
survival	O
signals	O
through	O
preferential	O
activation	O
of	O
subsets	O
of	O
multiple	O
integrin	B
-	O
mediated	O
signaling	O
pathways	O
.	O

Characterization	O
of	O
a	O
brain	O
-	O
enriched	O
chaperone	B
,	O
MRJ	B
,	O
that	O
inhibits	O
Huntingtin	O
aggregation	O
and	O
toxicity	O
independently	O
.	O

Molecular	O
chaperones	B
are	O
involved	O
in	O
a	O
wide	O
range	O
of	O
cellular	O
events	O
,	O
such	O
as	O
protein	O
folding	O
and	O
oligomeric	O
protein	O
complex	O
assembly	O
.	O

DnaK	B
-	O
and	O
DnaJ	B
-	O
like	O
proteins	O
are	O
the	O
two	O
major	O
classes	O
of	O
molecular	O
chaperones	B
in	O
mammals	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
DnaJ	B
-	I
like	I
family	I
proteins	O
can	O
inhibit	O
polyglutamine	O
aggregation	O
,	O
a	O
hallmark	O
of	O
many	O
neurodegenerative	O
diseases	O
,	O
including	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
.	O

Although	O
most	O
DnaJ	B
-	O
like	O
proteins	O
studied	O
are	O
ubiquitously	O
expressed	O
,	O
some	O
have	O
restricted	O
expression	O
,	O
so	O
it	O
is	O
possible	O
that	O
some	O
specific	O
chaperones	B
may	O
affect	O
polyglutamine	O
aggregation	O
in	O
specific	O
neurons	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
isolation	O
of	O
a	O
DnaJ	B
-	O
like	O
protein	O
MRJ	B
and	O
the	O
characterization	O
of	O
its	O
chaperone	B
activity	O
.	O

Tissue	O
distribution	O
studies	O
showed	O
that	O
MRJ	B
is	O
highly	O
enriched	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
an	O
in	O
vitro	O
cell	O
model	O
of	O
HD	O
,	O
overexpressed	O
MRJ	B
effectively	O
suppressed	O
polyglutamine	O
-	O
dependent	O
protein	O
aggregation	O
,	O
caspase	B
activity	O
,	O
and	O
cellular	O
toxicity	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
MRJ	B
has	O
a	O
relevant	O
functional	O
role	O
in	O
neurons	O
.	O

Infantile	O
dilated	O
X	O
-	O
linked	O
cardiomyopathy	O
,	O
G4.5	B
mutations	O
,	O
altered	O
lipids	O
,	O
and	O
ultrastructural	O
malformations	O
of	O
mitochondria	O
in	O
heart	O
,	O
liver	O
,	O
and	O
skeletal	O
muscle	O
.	O

Mutations	O
in	O
the	O
Xq28	O
gene	O
G4.5	B
lead	O
to	O
dilated	O
cardiomyopathy	O
(	O
DCM	O
)	O
.	O

Differential	O
splicing	O
of	O
G4.5	B
results	O
in	O
a	O
family	O
of	O
proteins	O
called	O
""""	O
tafazzins	B
""""	O
with	O
homology	O
to	O
acyltransferases	B
.	O

These	O
enzymes	O
assemble	O
fatty	O
acids	O
into	O
membrane	O
lipids	O
.	O

We	O
sequenced	O
G4.5	B
in	O
two	O
kindreds	O
with	O
X	O
-	O
linked	O
DCM	O
and	O
in	O
two	O
unrelated	O
men	O
,	O
one	O
with	O
idiopathic	O
DCM	O
and	O
the	O
other	O
with	O
DCM	O
of	O
arrhythmogenic	O
right	O
ventricular	O
dysplasia	O
.	O

We	O
examined	O
the	O
ultrastructure	O
of	O
heart	O
,	O
liver	O
,	O
and	O
muscle	O
biopsy	O
specimens	O
in	O
these	O
three	O
DCM	O
types	O
;	O
we	O
used	O
gas	O
chromatography	O
to	O
compare	O
fatty	O
acid	O
composition	O
in	O
heart	O
,	O
liver	O
,	O
and	O
muscle	O
autopsy	O
specimens	O
of	O
two	O
patients	O
of	O
kindred	O
1	O
with	O
that	O
of	O
controls	O
.	O

In	O
X	O
-	O
linked	O
DCM	O
,	O
G4.5	B
had	O
a	O
stop	O
codon	O
(	O
E188X	O
)	O
,	O
a	O
nonsense	O
mutation	O
,	O
in	O
kindred	O
1	O
and	O
an	O
amino	O
acid	O
substitution	O
(	O
G240R	O
)	O
,	O
a	O
missense	O
mutation	O
,	O
in	O
kindred	O
2	O
.	O

In	O
the	O
two	O
men	O
with	O
isolated	O
DCM	O
,	O
G4.5	B
was	O
not	O
mutated	O
.	O

Ultrastructural	O
mitochondrial	O
malformations	O
were	O
present	O
in	O
the	O
biopsy	O
tissues	O
of	O
the	O
patients	O
with	O
DCM	O
.	O

Cardiac	O
biopsy	O
specimens	O
of	O
both	O
kindreds	O
with	O
X	O
-	O
linked	O
DCM	O
exhibited	O
greatly	O
enlarged	O
mitochondria	O
with	O
large	O
bundles	O
of	O
stacked	O
,	O
compacted	O
,	O
disarrayed	O
cristae	O
that	O
differed	O
from	O
those	O
of	O
the	O
two	O
types	O
of	O
isolated	O
DCM	O
.	O

Autopsy	O
tissue	O
of	O
patients	O
with	O
X	O
-	O
linked	O
DCM	O
had	O
decreased	O
unsaturated	O
and	O
increased	O
saturated	O
fatty	O
acid	O
concentrations	O
.	O

Seven	O
of	O
13	O
published	O
G4.5	B
missense	O
mutations	O
,	O
including	O
the	O
one	O
presented	O
here	O
,	O
occur	O
in	O
acyltransferase	B
motifs	O
.	O

Impaired	O
acyltransferase	B
function	O
could	O
result	O
in	O
increased	O
fatty	O
acid	O
saturation	O
that	O
would	O
decrease	O
membrane	O
fluidity	O
.	O

Mitochondrial	O
membrane	O
proliferation	O
may	O
be	O
an	O
attempt	O
to	O
compensate	O
for	O
impaired	O
function	O
of	O
acyltransferase	B
.	O

Cardiac	O
ultrastructure	O
separates	O
X	O
-	O
linked	O
DCM	O
with	O
G4.5	B
mutations	O
from	O
the	O
two	O
types	O
of	O
isolated	O
DCM	O
without	O
G4.5	B
mutations	O
.	O

Electron	O
microscopy	O
of	O
promptly	O
fixed	O
myocardial	O
biopsy	O
specimens	O
has	O
a	O
role	O
in	O
defining	O
the	O
differential	O
diagnosis	O
of	O
DCM	O
.	O

Mutational	O
analysis	O
of	O
the	O
G4.5	B
gene	O
also	O
serves	O
this	O
purpose	O
.	O

Three	O
-	O
dimensional	O
nonfluoroscopic	O
mapping	O
and	O
ablation	O
of	O
inappropriate	O
sinus	O
tachycardia	O
.	O

Procedural	O
strategies	O
and	O
long	O
-	O
term	O
outcome	O
.	O

OBJECTIVES	O
:	O

We	O
conducted	O
this	O
study	O
to	O
assess	O
long	O
-	O
term	O
results	O
of	O
three	O
-	O
dimensional	O
(	O
3-D	O
)	O
mapping	O
-	O
guided	O
radiofrequency	O
ablation	O
(	O
RFA	O
)	O
of	O
inappropriate	O
sinus	O
tachycardia	O
(	O
IST	O
)	O
.	O

Change	O
in	O
activation	O
after	O
the	O
administration	O
of	O
esmolol	O
was	O
also	O
assessed	O
and	O
compared	O
to	O
the	O
shift	O
documented	O
with	O
successful	O
sinus	O
node	O
(	O
SN	O
)	O
modification	O
.	O

BACKGROUND	O
:	O

The	O
long	O
-	O
term	O
results	O
after	O
RFA	O
of	O
IST	O
have	O
been	O
reported	O
to	O
vary	O
between	O
27	O
%	O
and	O
66	O
%	O
.	O

METHODS	O
:	O

Thirty	O
-	O
nine	O
patients	O
(	O
35	O
women	O
,	O
mean	O
age	O
31	O
+	O
/-	O
9	O
years	O
)	O
with	O
debilitating	O
IST	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
area	O
around	O
the	O
earliest	O
site	O
of	O
activation	O
recorded	O
using	O
the	O
3-D	O
mapping	O
system	O
was	O
targeted	O
for	O
ablation	O
.	O

The	O
shift	O
in	O
the	O
earliest	O
activation	O
site	O
after	O
administration	O
of	O
esmolol	O
was	O
compared	O
with	O
the	O
shift	O
after	O
RFA	O
.	O

RESULTS	O
:	O

The	O
heart	O
rate	O
at	O
rest	O
and	O
in	O
drug	O
-	O
free	O
state	O
ranged	O
between	O
95	O
and	O
125	O
beats	O
/	O
min	O
(	O
mean	O
99	O
+	O
/-	O
14	O
beats	O
/	O
min	O
)	O
.	O

Sinus	O
node	O
was	O
successfully	O
modified	O
in	O
all	O
patients	O
.	O

Following	O
ablation	O
,	O
the	O
mean	O
heart	O
rate	O
dropped	O
to	O
72	O
+	O
/-	O
8	O
beats	O
/	O
min	O
,	O
p	O
<	O
0.01	O
.	O

The	O
extent	O
of	O
the	O
3-D	O
shift	O
in	O
caudal	O
activation	O
along	O
the	O
crista	O
terminalis	O
was	O
more	O
pronounced	O
after	O
RFA	O
than	O
during	O
esmolol	O
administration	O
(	O
23	O
+	O
/-	O
11	O
mm	O
vs.	O
7	O
+	O
/-	O
5	O
mm	O
,	O
respectively	O
,	O
p	O
<	O
0.05	O
)	O
.	O

No	O
patient	O
required	O
pacemaker	O
implantation	O
after	O
a	O
mean	O
follow	O
-	O
up	O
time	O
of	O
32	O
+	O
/-	O
9	O
months	O
;	O
21	O
%	O
of	O
patients	O
experienced	O
recurrence	O
of	O
IST	O
and	O
were	O
successfully	O
re	O
-	O
ablated	O
.	O

CONCLUSIONS	O
:	O

Three	O
-	O
dimensional	O
electroanatomical	O
mapping	O
seems	O
to	O
facilitate	O
and	O
improve	O
the	O
ablation	O
results	O
of	O
IST	O
.	O

The	O
difference	O
in	O
caudal	O
shift	O
seen	O
after	O
esmolol	O
administration	O
and	O
following	O
SN	O
modification	O
suggests	O
that	O
adrenergic	O
hypersensitivity	O
is	O
not	O
the	O
only	O
mechanism	O
responsible	O
for	O
the	O
inappropriate	O
behavior	O
of	O
the	O
SN	O
.	O

Deregulated	O
human	O
Cdc14A	B
phosphatase	B
disrupts	O
centrosome	O
separation	O
and	O
chromosome	O
segregation	O
.	O

We	O
show	O
that	O
human	O
Cdc14A	B
phosphatase	B
interacts	O
with	O
interphase	O
centrosomes	O
,	O
and	O
that	O
this	O
interaction	O
is	O
independent	O
of	O
microtubules	O
and	O
Cdc14A	B
phosphatase	B
activity	O
,	O
but	O
requires	O
active	O
nuclear	O
export	O
.	O

Disrupting	O
the	O
nuclear	O
export	O
signal	O
(	O
NES	O
)	O
led	O
to	O
Cdc14A	B
being	O
localized	O
in	O
nucleoli	O
,	O
which	O
in	O
unperturbed	O
cells	O
selectively	O
contain	O
Cdc14B	B
(	O
ref	O
.	O
1	O
)	O
.	O

Conditional	O
overproduction	O
of	O
Cdc14A	B
,	O
but	O
not	O
its	O
phosphatase	B
-	O
dead	O
or	O
NES	O
-	O
deficient	O
mutants	O
,	O
or	O
Cdc14B	B
,	O
resulted	O
in	O
premature	O
centrosome	O
splitting	O
and	O
formation	O
of	O
supernumerary	O
mitotic	O
spindles	O
.	O

In	O
contrast	O
,	O
downregulation	O
of	O
endogenous	O
Cdc14A	B
by	O
short	O
inhibitory	O
RNA	O
duplexes	O
(	O
siRNA	O
)	O
induced	O
mitotic	O
defects	O
including	O
impaired	O
centrosome	O
separation	O
and	O
failure	O
to	O
undergo	O
productive	O
cytokinesis	O
.	O

Consequently	O
,	O
both	O
overexpression	O
and	O
downregulation	O
of	O
Cdc14A	B
caused	O
aberrant	O
chromosome	O
partitioning	O
into	O
daughter	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
Cdc14A	B
is	O
a	O
physiological	O
regulator	O
of	O
the	O
centrosome	O
duplication	O
cycle	O
,	O
which	O
,	O
when	O
disrupted	O
,	O
can	O
lead	O
to	O
genomic	O
instability	O
in	O
mammalian	O
cells	O
.	O

Evaluation	O
of	O
risk	O
prediction	O
criteria	O
for	O
episodes	O
of	O
febrile	O
neutropenia	O
in	O
children	O
with	O
cancer	O
.	O

PURPOSE	O
:	O

To	O
evaluate	O
the	O
feasibility	O
of	O
risk	O
stratification	O
of	O
children	O
with	O
cancer	O
and	O
febrile	O
neutropenia	O
using	O
a	O
simple	O
set	O
of	O
criteria	O
from	O
data	O
available	O
to	O
the	O
clinician	O
at	O
the	O
time	O
of	O
the	O
patient	O
's	O
presentation	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O

This	O
study	O
is	O
a	O
retrospective	O
cohort	O
study	O
of	O
all	O
children	O
with	O
cancer	O
admitted	O
to	O
a	O
single	O
institution	O
with	O
fever	O
and	O
neutropenia	O
(	O
defined	O
as	O
an	O
absolute	O
neutrophil	O
count	O
<	O
500	O
cells	O
/	O
mm3	O
)	O
in	O
a	O
1	O
-	O
year	O
period	O
.	O

Patients	O
were	O
defined	O
a	O
priori	O
as	O
low	O
risk	O
if	O
they	O
were	O
outpatients	O
at	O
the	O
time	O
of	O
presentation	O
with	O
febrile	O
neutropenia	O
,	O
had	O
an	O
anticipated	O
duration	O
of	O
neutropenia	O
less	O
than	O
7	O
days	O
,	O
and	O
had	O
no	O
significant	O
comorbidity	O
.	O

All	O
others	O
were	O
considered	O
high	O
risk	O
.	O

Data	O
was	O
analyzed	O
by	O
first	O
admission	O
for	O
each	O
patient	O
and	O
secondarily	O
for	O
all	O
admissions	O
for	O
febrile	O
neutropenia	O
.	O

RESULTS	O
:	O

There	O
were	O
188	O
admissions	O
in	O
104	O
patients	O
for	O
febrile	O
neutropenia	O
during	O
the	O
study	O
period	O
.	O

Of	O
these	O
47	O
%	O
were	O
high	O
risk	O
and	O
53	O
%	O
were	O
low	O
risk	O
.	O

The	O
duration	O
of	O
fever	O
was	O
not	O
significantly	O
different	O
in	O
the	O
two	O
groups	O
.	O

However	O
,	O
the	O
duration	O
of	O
neutropenia	O
and	O
the	O
length	O
of	O
hospital	O
stay	O
were	O
significantly	O
longer	O
in	O
the	O
high	O
-	O
risk	O
group	O
.	O

The	O
frequency	O
of	O
bacteremia	O
,	O
other	O
documented	O
infection	O
,	O
and	O
serious	O
medical	O
complications	O
was	O
significantly	O
different	O
in	O
the	O
two	O
groups	O
.	O

Overall	O
,	O
the	O
rate	O
of	O
any	O
adverse	O
event	O
was	O
4	O
%	O
in	O
the	O
low	O
-	O
risk	O
group	O
versus	O
41	O
%	O
in	O
the	O
high	O
-	O
risk	O
group	O
.	O

CONCLUSIONS	O
:	O

Simple	O
criteria	O
available	O
to	O
the	O
clinician	O
at	O
the	O
time	O
of	O
evaluation	O
of	O
the	O
child	O
with	O
cancer	O
who	O
has	O
fever	O
and	O
neutropenia	O
allow	O
the	O
selection	O
of	O
a	O
population	O
at	O
low	O
risk	O
for	O
bacteremia	O
or	O
serious	O
medical	O
complication	O
.	O

A	O
prospective	O
study	O
is	O
planned	O
using	O
these	O
risk	O
criteria	O
,	O
evaluating	O
outpatient	O
oral	O
antibiotic	O
therapy	O
in	O
low	O
-	O
risk	O
children	O
with	O
cancer	O
.	O

Conformational	O
change	O
and	O
destabilization	O
of	O
cataract	O
gammaC	B
-	I
crystallin	I
T5P	O
mutant	O
.	O

Human	O
lens	O
gammaC	B
-	I
crystallin	I
and	O
T5P	O
mutant	O
were	O
cloned	O
,	O
and	O
their	O
biophysical	O
properties	O
and	O
thermodynamic	O
stability	O
were	O
studied	O
.	O

CRYGC	B
(	O
T5P	O
)	O
is	O
one	O
of	O
the	O
many	O
gamma	B
-	I
crystallin	I
mutant	O
genes	O
for	O
autosomal	O
dominant	O
congenital	O
cataracts	O
.	O

This	O
mutation	O
is	O
associated	O
with	O
Coppock	O
-	O
like	O
cataract	O
,	O
and	O
has	O
the	O
phenotype	O
of	O
a	O
dust	O
-	O
like	O
opacity	O
of	O
the	O
fetal	O
lens	O
nucleus	O
.	O

During	O
cloning	O
and	O
overexpression	O
,	O
the	O
majority	O
of	O
T5P	O
mutant	O
was	O
found	O
in	O
the	O
inclusion	O
body	O
.	O

This	O
property	O
is	O
unique	O
among	O
the	O
many	O
cataract	O
gamma	B
-	I
crystallin	I
mutant	O
genes	O
.	O

It	O
is	O
thus	O
worthwhile	O
to	O
study	O
what	O
factors	O
contribute	O
to	O
this	O
unique	O
property	O
of	O
gammaC	B
-	I
crystallin	I
.	O

One	O
possibility	O
is	O
changes	O
in	O
conformation	O
and	O
stability	O
,	O
which	O
can	O
be	O
studied	O
using	O
spectroscopic	O
measurements	O
.	O

In	O
this	O
study	O
,	O
conformational	O
change	O
was	O
studied	O
by	O
circular	O
dichroism	O
and	O
fluorescence	O
measurements	O
,	O
and	O
conformational	O
stability	O
was	O
determined	O
by	O
thermal	O
unfolding	O
probed	O
by	O
Trp	O
fluorescence	O
and	O
time	O
-	O
dependent	O
light	O
scattering	O
.	O

The	O
T5P	O
mutation	O
obviously	O
changes	O
conformation	O
and	O
decreases	O
conformational	O
stability	O
.	O

Coamplification	O
of	O
DAD	B
-	I
R	I
,	O
SOX5	B
,	O
and	O
EKI1	B
in	O
human	O
testicular	O
seminomas	O
,	O
with	O
specific	O
overexpression	O
of	O
DAD	B
-	I
R	I
,	O
correlates	O
with	O
reduced	O
levels	O
of	O
apoptosis	O
and	O
earlier	O
clinical	O
manifestation	O
.	O

Seminomas	O
and	O
nonseminomas	O
represent	O
the	O
invasive	O
stages	O
of	O
testicular	O
(	O
TGCTs	O
)	O
of	O
adolescents	O
and	O
adults	O
.	O

Although	O
TGCTs	O
are	O
characterized	O
by	O
extra	O
copies	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
12	O
,	O
the	O
genetic	O
basis	O
for	O
gain	O
of	O
12p	O
in	O
the	O
pathogenesis	O
of	O
this	O
cancer	O
is	O
not	O
yet	O
understood	O
.	O

We	O
have	O
demonstrated	O
that	O
gain	O
of	O
12p	O
is	O
related	O
to	O
invasive	O
growth	O
and	O
that	O
amplification	O
of	O
specific	O
12p	O
sequences	O
,	O
i.e.	O
,	O
12p11.2	O
-	O
p12.1	O
,	O
correlates	O
with	O
reduced	O
apoptosis	O
in	O
the	O
tumors	O
.	O

Here	O
we	O
show	O
that	O
three	O
known	O
genes	O
map	O
within	O
the	O
newly	O
determined	O
shortest	O
region	O
of	O
overlap	O
of	O
amplification	O
(	O
SROA	O
)	O
:	O
DAD	B
-	I
R	I
,	O
SOX5	B
,	O
and	O
EKI1	B
.	O

Whereas	O
EKI1	B
maps	O
close	O
to	O
the	O
telomeric	O
region	O
of	O
the	O
SROA	O
,	O
DAD	B
-	I
R	I
is	O
the	O
first	O
gene	O
at	O
the	O
centromeric	O
region	O
within	O
the	O
12p	O
amplicon	O
.	O

Although	O
all	O
three	O
genes	O
are	O
amplified	O
to	O
the	O
same	O
level	O
within	O
the	O
SROA	O
,	O
expression	O
of	O
DAD	B
-	I
R	I
is	O
significantly	O
up	O
-	O
regulated	O
in	O
seminomas	O
with	O
the	O
restricted	O
12p	O
amplification	O
compared	O
with	O
seminomas	O
without	O
this	O
amplicon	O
.	O

DAD	B
-	I
R	I
is	O
also	O
highly	O
expressed	O
in	O
nonseminomas	O
of	O
various	O
histologies	O
and	O
derived	O
cell	O
lines	O
,	O
both	O
lacking	O
such	O
amplification	O
.	O

This	O
finding	O
is	O
of	O
particular	O
interest	O
because	O
seminomas	O
with	O
the	O
restricted	O
12p	O
amplification	O
and	O
nonseminomas	O
are	O
manifested	O
clinically	O
in	O
the	O
third	O
decade	O
of	O
life	O
and	O
show	O
a	O
low	O
degree	O
of	O
apoptosis	O
.	O

In	O
contrast	O
,	O
seminomas	O
lacking	O
a	O
restricted	O
12p	O
amplification	O
,	O
showing	O
significantly	O
lower	O
levels	O
of	O
DAD	B
-	I
R	I
with	O
pronounced	O
apoptosis	O
,	O
manifest	O
clinically	O
in	O
the	O
fourth	O
decade	O
of	O
life	O
.	O

A	O
low	O
level	O
of	O
DAD	B
-	I
R	I
expression	O
is	O
also	O
observed	O
in	O
normal	O
testicular	O
parenchyma	O
and	O
in	O
parenchyma	O
containing	O
the	O
precursor	O
cells	O
of	O
this	O
cancer	O
,	O
i.e.	O
,	O
carcinoma	O
in	O
situ	O
.	O

Therefore	O
,	O
elevated	O
DAD	B
-	I
R	I
expression	O
in	O
seminomas	O
and	O
nonseminomas	O
correlates	O
with	O
invasive	O
growth	O
and	O
a	O
reduced	O
level	O
of	O
apoptosis	O
associated	O
with	O
an	O
earlier	O
clinical	O
presentation	O
.	O

These	O
data	O
implicate	O
DAD	B
-	I
R	I
as	O
a	O
candidate	O
gene	O
responsible	O
in	O
part	O
for	O
the	O
pathological	O
effects	O
resulting	O
from	O
gain	O
of	O
12p	O
sequences	O
in	O
TGCTs	O
.	O

In	O
addition	O
,	O
our	O
results	O
also	O
imply	O
differences	O
in	O
expression	O
regulation	O
of	O
DAD	B
-	I
R	I
between	O
seminomas	O
and	O
nonseminomas	O
.	O

Interaction	O
of	O
Alzheimer	O
's	O
beta	B
-	I
amyloid	I
precursor	I
family	I
proteins	O
with	O
scaffold	O
proteins	O
of	O
the	O
JNK	B
signaling	O
cascade	O
.	O

We	O
have	O
isolated	O
a	O
novel	O
protein	O
based	O
on	O
its	O
association	O
with	O
Drosophila	O
APP	B
-	I
like	I
protein	I
(	O
APPL	B
)	O
,	O
a	O
homolog	O
of	O
the	O
beta	B
-	I
amyloid	I
precursor	I
protein	I
(	O
APP	B
)	O
that	O
is	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
.	O

This	O
novel	O
APPL	B
-	I
interacting	I
protein	I
1	I
(	O
APLIP1	B
)	O
contains	O
a	O
Src	B
homology	O
3	O
domain	O
and	O
a	O
phosphotyrosine	O
interaction	O
domain	O
and	O
is	O
expressed	O
abundantly	O
in	O
neural	O
tissues	O
.	O

The	O
phosphotyrosine	O
interaction	O
domain	O
of	O
APLIP1	B
interacts	O
with	O
a	O
sequence	O
containing	O
GYENPTY	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
APPL	B
.	O

APLIP1	B
is	O
highly	O
homologous	O
to	O
the	O
carboxyl	O
-	O
terminal	O
halves	O
of	O
mammalian	O
c	B
-	I
Jun	I
NH	I
(	I
2	I
)	I
-	I
terminal	I
kinase	I
(	I
JNK	I
)	I
-	I
interacting	I
protein	I
1b	I
(	I
JIP1b	I
)	I
and	I
2	I
(	O
JIP2	B
)	O
,	O
which	O
also	O
contain	O
Src	B
homology	O
3	O
and	O
phosphotyrosine	O
interaction	O
domains	O
.	O

The	O
similarity	O
of	O
APLIP1	B
to	O
JIP1b	B
and	O
JIP2	B
includes	O
interaction	O
with	O
component	O
(	O
s	O
)	O
of	O
the	O
JNK	B
signaling	O
pathway	O
and	O
with	O
the	O
motor	B
protein	I
kinesin	B
and	O
the	O
formation	O
of	O
homo	O
-	O
oligomers	O
.	O

JIP1b	B
interacts	O
strongly	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
APP	B
(	O
APPcyt	B
)	O
,	O
as	O
APLIP1	B
does	O
with	O
APPL	B
,	O
but	O
the	O
interaction	O
of	O
JIP2	B
with	O
APPcyt	B
is	O
weak	O
.	O

Overexpression	O
of	O
JIP1b	B
slightly	O
enhances	O
the	O
JNK	B
-	O
dependent	O
threonine	O
phosphorylation	O
of	O
APP	B
in	O
cultured	O
cells	O
,	O
but	O
that	O
of	O
JIP2	B
suppresses	O
it	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
interactions	O
of	O
APP	B
family	I
proteins	O
with	O
APLIP1	B
,	O
JIP1b	B
,	O
and	O
JIP2	B
are	O
conserved	O
and	O
play	O
important	O
roles	O
in	O
the	O
metabolism	O
and/or	O
the	O
function	O
of	O
APPs	B
including	O
the	O
regulation	O
of	O
APP	B
phosphorylation	O
by	O
JNK	B
.	O

Analysis	O
of	O
APP	B
family	I
proteins	O
and	O
their	O
associated	O
proteins	O
is	O
expected	O
to	O
contribute	O
to	O
understanding	O
the	O
molecular	O
process	O
of	O
neural	O
degeneration	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Concentrations	O
of	O
proinsulin	B
like	O
molecules	O
predict	O
coronary	O
heart	O
disease	O
risk	O
independently	O
of	O
insulin	B
:	O
prospective	O
data	O
from	O
the	O
Caerphilly	O
Study	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O

Higher	O
concentrations	O
of	O
insulin	B
correlate	O
with	O
several	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
risk	O
factors	O
and	O
have	O
been	O
shown	O
to	O
predict	O
incident	O
CHD	O
in	O
several	O
studies	O
,	O
leading	O
to	O
hypotheses	O
concerning	O
the	O
proatherogenic	O
properties	O
of	O
insulin	B
.	O

However	O
,	O
in	O
cross	O
-	O
sectional	O
studies	O
,	O
relationships	O
of	O
concentrations	O
of	O
the	O
insulin	B
precursor	O
molecules	O
,	O
proinsulin	B
and	O
des	O
31	O
,	O
32	O
proinsulin	B
,	O
relate	O
as	O
strongly	O
,	O
or	O
more	O
strongly	O
,	O
to	O
levels	O
of	O
risk	O
factors	O
and	O
to	O
(	O
prevalent	O
)	O
CHD	O
.	O

METHODS	O
:	O

We	O
investigated	O
the	O
relationship	O
between	O
concentrations	O
of	O
insulin	B
,	O
measured	O
with	O
a	O
specific	O
assay	O
,	O
and	O
of	O
proinsulin	B
-	O
like	O
molecules	O
,	O
and	O
risk	O
factors	O
in	O
1181	O
non	O
-	O
diabetic	O
men	O
50	O
-	O
64	O
years	O
old	O
during	O
Phase	O
II	O
of	O
the	O
Caerphilly	O
Study	O
.	O

We	O
also	O
related	O
concentrations	O
of	O
these	O
molecules	O
to	O
incident	O
CHD	O
during	O
the	O
10	O
-	O
14	O
years	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O

The	O
relationship	O
between	O
concentrations	O
of	O
insulin	B
,	O
of	O
proinsulin	B
and	O
of	O
des	O
31	O
,	O
32	O
proinsulin	B
and	O
BMI	O
(	O
r	O
=	O
0.36	O
-	O
0.45	O
)	O
,	O
triglyceride	O
(	O
r	O
=	O
0.25	O
-	O
0.31	O
)	O
,	O
high	B
density	I
lipoprotein	I
-	O
(	O
HDL	B
-	O
)	O
cholesterol	O
(	O
r	O
=	O
-	O
0.17	O
to	O
-	O
0.21	O
)	O
,	O
systolic	O
(	O
r	O
=	O
0.05	O
-	O
0.11	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
r	O
=	O
0.11	O
-	O
0.15	O
)	O
were	O
similarly	O
close	O
,	O
those	O
with	O
risk	O
factors	O
being	O
somewhat	O
and	O
similarly	O
reduced	O
after	O
adjustment	O
for	O
BMI	O
.	O

The	O
correlation	O
between	O
insulin	B
and	O
of	O
proinsulin	B
-	O
like	O
molecules	O
and	O
those	O
plasminogen	B
activator	I
inhibitor-1	I
(	O
PAI-1	B
)	O
antigen	O
was	O
also	O
similar	O
(	O
r	O
=	O
0.28	O
-	O
0.29	O
)	O
.	O

There	O
was	O
a	O
negative	O
correlation	O
between	O
concentrations	O
of	O
proinsulin	B
-	O
like	O
molecules	O
-	O
but	O
not	O
insulin	B
-	O
and	O
birth	O
weight	O
.	O

Insulin	B
concentrations	O
correlated	O
positively	O
with	O
height	O
(	O
r	O
=	O
0.12	O
)	O
.	O

In	O
logistic	O
regression	O
models	O
,	O
concentrations	O
of	O
proinsulin	B
-	O
like	O
molecules	O
,	O
but	O
not	O
insulin	B
,	O
predicted	O
incident	O
of	O
CHD	O
over	O
a	O
follow	O
-	O
up	O
of	O
10	O
-	O
14	O
years	O
(	O
insulin	B
-	O
standardised	O
odds	O
ratio	O
(	O
SOR	O
)	O
1.30	O
(	O
95	O
%	O
-	O
CI	O
)	O
0.91	O
,	O
1.85	O
)	O
,	O
p	O
=	O
0.15	O
;	O
des	O
31	O
,	O
32	O
proinsulin	B
-	O
SOR	O
1.38	O
(	O
95	O
%	O
-	O
CI	O
1.02	O
,	O
1.85	O
)	O
,	O
p	O
=	O
0.034	O
;	O
sum	O
of	O
proinsulin	B
-	O
like	O
molecules	O
-	O
SOR	O
1.54	O
(	O
95	O
%	O
-	O
CI	O
1.07	O
,	O
2.20	O
)	O
,	O
p	O
=	O
0.019	O
after	O
adjusting	O
for	O
age	O
and	O
BMI	O
.	O

The	O
predictive	O
ability	O
of	O
these	O
molecules	O
was	O
reduced	O
by	O
around	O
one	O
third	O
after	O
adjustment	O
for	O
standard	O
risk	O
factors	O
and	O
concentrations	O
of	O
tryglyceride	O
and	O
HDL	B
-	O
cholesterol	O
,	O
and	O
by	O
about	O
half	O
after	O
further	O
adjustment	O
for	O
PAI-1	B
concentrations	O
.	O

CONCLUSION	O
/	O
INTERPRETATION	O
:	O

We	O
conclude	O
that	O
concentrations	O
of	O
proinsulin	B
-	O
like	O
molecules	O
provide	O
a	O
better	O
way	O
to	O
predict	O
the	O
incidence	O
of	O
CHD	O
than	O
those	O
of	O
insulin	B
.	O

However	O
,	O
the	O
lack	O
of	O
biological	O
evidence	O
for	O
a	O
causative	O
relationship	O
suggests	O
an	O
association	O
through	O
a	O
common	O
antecedent	O
,	O
and	O
this	O
antecedent	O
is	O
not	O
likely	O
to	O
be	O
intrauterine	O
growth	O
retardation	O
.	O

Mutation	O
screening	O
and	O
imprinting	O
analysis	O
of	O
four	O
candidate	O
genes	O
for	O
autism	O
in	O
the	O
7q32	O
region	O
.	O

Genetic	O
studies	O
indicate	O
that	O
chromosome	O
7q	O
is	O
likely	O
to	O
contain	O
an	O
autism	O
susceptibility	O
locus	O
(	O
AUTS1	O
)	O
.	O

We	O
have	O
followed	O
a	O
positional	O
candidate	O
gene	O
approach	O
to	O
identify	O
the	O
relevant	O
gene	O
and	O
report	O
the	O
analysis	O
of	O
four	O
adjacent	O
genes	O
localised	O
to	O
a	O
800	O
kb	O
region	O
in	O
7q32	O
that	O
contains	O
an	O
imprinted	O
domain	O
:	O
PEG1	B
/	O
MEST	B
,	O
COPG2	B
,	O
CPA1	B
and	O
CPA5	B
-	O
a	O
previously	O
uncharacterised	O
member	O
of	O
the	O
carboxypeptidase	B
gene	I
family	I
.	O

Screening	O
these	O
genes	O
for	O
DNA	O
changes	O
and	O
association	O
analysis	O
using	O
intragenic	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
provided	O
no	O
evidence	O
for	O
an	O
etiological	O
role	O
in	O
IMGSAC	O
families	O
.	O

We	O
also	O
searched	O
for	O
imprinting	O
mutations	O
potentially	O
implicated	O
in	O
autism	O
:	O
analysis	O
of	O
both	O
DNA	O
methylation	O
and	O
replication	O
timing	O
indicated	O
a	O
normal	O
imprinting	O
regulation	O
of	O
the	O
PEG1	B
/	O
COPG2	B
domain	O
in	O
blood	O
lymphocytes	O
of	O
all	O
patients	O
tested	O
.	O

The	O
analysis	O
of	O
these	O
four	O
genes	O
strongly	O
suggests	O
that	O
they	O
do	O
not	O
play	O
a	O
major	O
role	O
in	O
autism	O
aetiology	O
,	O
and	O
delineates	O
our	O
strategy	O
to	O
screen	O
additional	O
candidate	O
genes	O
in	O
the	O
AUTS1	B
locus	O
.	O

Results	O
of	O
the	O
Lynn	O
Sage	O
Second	O
-	O
Opinion	O
Program	O
for	O
local	O
therapy	O
in	O
patients	O
with	O
breast	O
carcinoma	O
.	O

Changes	O
in	O
management	O
and	O
determinants	O
of	O
where	O
care	O
is	O
delivered	O
.	O

BACKGROUND	O
:	O

The	O
treatment	O
options	O
of	O
breast	O
conservation	O
therapy	O
(	O
BCT	O
)	O
and	O
immediate	O
reconstruction	O
for	O
patients	O
with	O
carcinoma	O
of	O
the	O
breast	O
have	O
not	O
been	O
adopted	O
widely	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
how	O
often	O
a	O
second	O
opinion	O
on	O
the	O
local	O
therapy	O
of	O
breast	O
carcinoma	O
changed	O
patient	O
management	O
and	O
to	O
identify	O
factors	O
predictive	O
of	O
remaining	O
at	O
the	O
second	O
-	O
opinion	O
site	O
for	O
therapy	O
.	O

METHODS	O
:	O

Two	O
hundred	O
thirty	O
-	O
one	O
patients	O
with	O
intraductal	O
carcinoma	O
or	O
Stage	O
I	O
and	O
II	O
breast	O
carcinoma	O
were	O
reviewed	O
retrospectively	O
.	O

At	O
the	O
time	O
of	O
the	O
second	O
opinion	O
,	O
patients	O
completed	O
a	O
questionnaire	O
regarding	O
their	O
initial	O
surgical	O
opinion	O
and	O
the	O
reason	O
for	O
seeking	O
consultation	O
.	O

RESULTS	O
:	O

Only	O
46	O
%	O
of	O
patients	O
had	O
a	O
complete	O
discussion	O
of	O
treatment	O
options	O
prior	O
to	O
the	O
second	O
opinion	O
.	O

The	O
second	O
opinion	O
changed	O
management	O
in	O
54	O
patients	O
(	O
20.3	O
%	O
)	O
.	O

The	O
most	O
common	O
finding	O
was	O
eligibility	O
for	O
BCT	O
in	O
patients	O
who	O
were	O
offered	O
only	O
mastectomy	O
.	O

Definitive	O
local	O
therapy	O
occurred	O
at	O
the	O
second	O
-	O
opinion	O
site	O
in	O
65.8	O
%	O
of	O
patients	O
.	O

The	O
only	O
predictors	O
of	O
remaining	O
at	O
the	O
second	O
-	O
opinion	O
site	O
were	O
insurance	O
type	O
(	O
P	O
=	O
0.008	O
)	O
and	O
the	O
patient	O
's	O
perception	O
that	O
options	O
were	O
not	O
discussed	O
at	O
the	O
initial	O
opinion	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O

Second	O
opinions	O
provide	O
useful	O
information	O
to	O
patients	O
and	O
may	O
change	O
the	O
management	O
of	O
their	O
disease	O
.	O

They	O
result	O
in	O
significant	O
patient	O
capture	O
for	O
an	O
institution	O
.	O

Mutational	O
and	O
haplotype	O
analysis	O
of	O
AGL	O
in	O
patients	O
with	O
glycogen	O
storage	O
disease	O
type	O
III	O
.	O

Glycogen	O
storage	O
disease	O
type	O
III	O
(	O
GSD	O
III	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
inherited	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
the	O
glycogen	B
-	I
debranching	I
enzyme	I
(	O
AGL	B
)	O
.	O

We	O
investigated	O
two	O
GSD	O
III	O
patients	O
and	O
identified	O
four	O
different	O
mutations	O
.	O

Nucleotide	O
sequence	O
analysis	O
revealed	O
patient	O
1	O
of	O
Chinese	O
descent	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
a	O
novel	O
nonsense	O
mutation	O
,	O
R34X	O
,	O
and	O
the	O
splicing	O
mutation	O
(	O
IVS32	O
-12A	O
>	O
G	O
)	O
reported	O
in	O
a	O
Japanese	O
patient	O
.	O

Patient	O
2	O
of	O
Japanese	O
origin	O
was	O
found	O
to	O
be	O
compound	O
heterozygous	O
for	O
a	O
novel	O
nonsense	O
mutation	O
,	O
Y1148X	O
,	O
and	O
the	O
splicing	O
mutation	O
(	O
IVS14	O
+	O
1	O
G	O
>	O
T	O
)	O
that	O
we	O
had	O
described	O
previously	O
.	O

To	O
determine	O
whether	O
splicing	O
mutations	O
occurred	O
independently	O
,	O
we	O
performed	O
intense	O
AGL	B
haplotype	O
analysis	O
using	O
21	O
intragenic	O
polymorphic	O
markers	O
plus	O
a	O
novel	O
polymorphism	O
IVS32	O
-	O
97	O
A	O
/	O
G	O
in	O
the	O
vicinity	O
of	O
the	O
IVS32	O
splicing	O
mutation	O
.	O

Patient	O
1	O
of	O
Chinese	O
origin	O
and	O
the	O
Japanese	O
patient	O
homozygous	O
for	O
the	O
IVS32	O
-	O
12A	O
>	O
G	O
were	O
found	O
to	O
have	O
different	O
haplotypes	O
,	O
indicating	O
the	O
IVS32	O
-	O
12A	O
>	O
G	O
mutation	O
to	O
be	O
a	O
recurrent	O
mutation	O
.	O

This	O
is	O
the	O
first	O
recurrent	O
mutation	O
established	O
by	O
intense	O
haplotyping	O
in	O
the	O
AGL	B
gene	O
.	O

Distinct	O
expression	O
pattern	O
of	O
two	O
related	O
human	O
proteins	O
containing	O
multiple	O
types	O
of	O
protease	B
-	O
inhibitory	O
modules	O
.	O

We	O
have	O
recently	O
identified	O
a	O
gene	O
(	O
the	O
WFIKKN	B
gene	O
)	O
on	O
human	O
chromosome	O
16	O
(	O
16p13.3	O
)	O
that	O
encodes	O
a	O
secreted	O
protein	O
containing	O
WAP	B
-	I
type	I
,	I
Follistatin	I
/	I
Kazal	I
type	I
,	I
Kunitz	I
-	I
type	I
and	I
NTR	I
-	I
type	I
protease	I
-	O
inhibitory	O
modules	O
and	O
an	O
Immunoglobulin	B
domain	O
[	O
Trexler	O
et	O
al.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
98	O
(	O
2001	O
)	O
,	O
3705	O
-	O
3709	O
]	O
.	O

In	O
the	O
present	O
work	O
we	O
show	O
that	O
a	O
gene	O
on	O
chromosome	O
17	O
encodes	O
a	O
WFIKKN	B
-	I
related	I
protein	I
(	O
WFIKKNRP	B
)	O
that	O
has	O
the	O
same	O
domain	O
organization	O
as	O
the	O
WFIKKN	B
protein	O
.	O

The	O
exon	O
-	O
intron	O
structure	O
of	O
the	O
two	O
genes	O
is	O
also	O
similar	O
as	O
both	O
genes	O
have	O
a	O
single	O
phase	O
0	O
intron	O
that	O
splits	O
their	O
WAP	O
domains	O
in	O
equivalent	O
positions	O
.	O

In	O
view	O
of	O
the	O
presence	O
of	O
several	O
protease	B
inhibitory	O
modules	O
in	O
these	O
proteins	O
it	O
seems	O
likely	O
that	O
they	O
serve	O
to	O
control	O
the	O
action	O
of	O
multiple	O
types	O
of	O
proteases	B
.	O

The	O
tissue	O
expression	O
pattern	O
of	O
the	O
two	O
proteins	O
,	O
however	O
,	O
is	O
markedly	O
different	O
suggesting	O
that	O
they	O
have	O
distinct	O
biological	O
roles	O
.	O

Whereas	O
the	O
WFIKKN	B
gene	O
is	O
expressed	O
primarily	O
in	O
adult	O
pancreas	O
,	O
liver	O
and	O
thymus	O
but	O
not	O
in	O
brain	O
and	O
ovary	O
,	O
significant	O
expression	O
of	O
the	O
WFIKKNRP	B
gene	O
is	O
observed	O
in	O
ovary	O
,	O
testis	O
and	O
brain	O
,	O
but	O
not	O
in	O
liver	O
.	O

Pronounced	O
differences	O
could	O
also	O
be	O
seen	O
in	O
the	O
case	O
of	O
fetal	O
tissues	O
:	O
expression	O
of	O
the	O
WFIKKN	B
gene	O
was	O
highest	O
in	O
the	O
lung	O
,	O
skeletal	O
muscle	O
and	O
liver	O
,	O
whereas	O
the	O
WFIKKNRP	B
gene	O
was	O
expressed	O
primarily	O
in	O
brain	O
,	O
skeletal	O
muscle	O
,	O
thymus	O
and	O
kidney	O
.	O

Independent	O
regulation	O
of	O
the	O
divergent	O
Escherichia	O
coli	O
nrfA	B
and	O
acsP1	B
promoters	O
by	O
a	O
nucleoprotein	O
assembly	O
at	O
a	O
shared	O
regulatory	O
region	O
.	O

Expression	O
from	O
the	O
Escherichia	O
coli	O
nrfA	B
promoter	O
(	O
pnrfA	O
)	O
is	O
activated	O
by	O
both	O
the	O
FNR	B
protein	O
(	O
an	O
anaerobically	O
triggered	O
transcription	O
activator	O
)	O
and	O
the	O
NarL	B
or	O
NarP	B
proteins	O
(	O
transcription	O
activators	O
triggered	O
by	O
nitrite	O
and	O
nitrate	O
)	O
.	O

Under	O
anaerobic	O
conditions	O
,	O
FNR	B
binds	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
41.5	O
at	O
pnrfA	O
and	O
activates	O
transcription	O
.	O

Further	O
activation	O
,	O
induced	O
by	O
the	O
presence	O
of	O
nitrite	O
,	O
results	O
from	O
the	O
binding	O
of	O
NarL	B
and	O
NarP	B
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
74.5	O
.	O

A	O
second	O
promoter	O
(	O
pacsP1	O
)	O
,	O
which	O
directs	O
transcription	O
into	O
the	O
adjacent	O
gene	O
encoding	O
acetyl	B
coenzyme	I
A	I
synthetase	I
(	O
acs	B
)	O
,	O
is	O
overlapping	O
and	O
divergent	O
to	O
pnrfA	O
.	O

Despite	O
extensive	O
overlap	O
of	O
regulatory	O
elements	O
,	O
pnrfA	O
and	O
pacsP1	O
are	O
regulated	O
independently	O
.	O

We	O
demonstrate	O
that	O
at	O
least	O
two	O
nucleoid	O
-	O
associated	O
factors	O
bind	O
to	O
the	O
nrfA	B
-	O
acs	B
intergenic	O
region	O
.	O

The	O
Fis	B
protein	O
binds	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
15	O
(	O
in	O
relation	O
to	O
pnrfA	O
transcription	O
)	O
,	O
whereas	O
the	O
IHF	B
protein	O
binds	O
to	O
a	O
site	O
centred	O
at	O
position	O
-	O
54	O
.	O

Both	O
Fis	B
and	O
IHF	B
repress	O
in	O
vivo	O
expression	O
from	O
pacsP1	O
,	O
but	O
have	O
smaller	O
repressive	O
effects	O
on	O
expression	O
from	O
pnrfA	O
.	O

Gel	O
retardation	O
assays	O
were	O
used	O
to	O
investigate	O
the	O
pairwise	O
binding	O
of	O
FNR	B
,	O
NarL	B
,	O
Fis	B
and	O
IHF	B
proteins	O
to	O
the	O
nrfA	B
-	O
acs	B
intergenic	O
region	O
.	O

The	O
binding	O
of	O
NarL	B
and	O
IHF	B
is	O
mutually	O
exclusive	O
,	O
whereas	O
all	O
other	O
combinations	O
can	O
bind	O
simultaneously	O
.	O

Experiments	O
in	O
which	O
deletions	O
and	O
point	O
mutations	O
were	O
introduced	O
into	O
the	O
upstream	O
region	O
of	O
pnrfA	O
demonstrated	O
that	O
an	O
additional	O
factor	O
must	O
bind	O
upstream	O
to	O
inhibit	O
FNR	B
-	O
dependent	O
transcription	O
.	O

We	O
conclude	O
that	O
the	O
nrfA	B
-	O
acs	B
intergenic	O
region	O
is	O
folded	O
into	O
an	O
ordered	O
nucleoprotein	O
structure	O
that	O
permits	O
the	O
two	O
divergent	O
promoters	O
to	O
be	O
regulated	O
independently	O
in	O
response	O
to	O
different	O
physiological	O
signals	O
.	O

Ran	B
-	I
binding	I
protein	I
3	I
links	O
Crm1	B
to	O
the	O
Ran	B
guanine	I
nucleotide	I
exchange	I
factor	I
.	O

Ran	B
-	I
binding	I
protein	I
3	I
(	O
RanBP3	B
)	O
is	O
an	O
approximately	O
55	O
-	O
kDa	O
protein	O
that	O
functions	O
as	O
a	O
cofactor	O
for	O
Crm1	B
-	O
mediated	O
nuclear	O
export	O
.	O

RanBP3	B
stimulates	O
export	O
by	O
enhancing	O
the	O
affinity	O
of	O
Crm1	B
for	O
Ran	B
.	O
GTP	O
and	O
cargo	O
.	O

However	O
,	O
important	O
additional	O
functions	O
for	O
this	O
cofactor	O
may	O
exist	O
.	O

We	O
now	O
report	O
that	O
RanBP3	B
associates	O
with	O
the	O
Ran	B
-	O
specific	O
guanine	B
nucleotide	I
exchange	I
factor	I
,	O
regulator	B
of	I
chromosome	I
condensation	I
1	I
(	O
RCC1	B
)	O
.	O

This	O
interaction	O
was	O
stimulated	O
by	O
the	O
addition	O
of	O
Ran	B
;	O
moreover	O
,	O
Ran	B
.	O
GDP	O
,	O
Ran	B
.	O
GTP	O
,	O
and	O
Ran	B
without	O
nucleotide	O
could	O
all	O
stimulate	O
complex	O
formation	O
between	O
RanBP3	B
and	O
RCC1	B
even	O
though	O
binding	O
of	O
Ran	B
.	O
GDP	O
to	O
RanBP3	B
alone	O
was	O
undetectable	O
.	O

RanBP3	B
could	O
also	O
promote	O
binding	O
of	O
Crm1	B
to	O
RCC1	B
in	O
the	O
presence	O
of	O
Ran	B
.	O

Binding	O
of	O
RanBP3	B
to	O
RCC1	B
increased	O
the	O
catalytic	O
activity	O
of	O
RCC1	B
toward	O
Ran	B
,	O
and	O
importantly	O
,	O
the	O
ability	O
of	O
RanBP3	B
to	O
stimulate	O
RCC1	B
was	O
not	O
affected	O
by	O
the	O
presence	O
of	O
Crm1	B
.	O

These	O
data	O
indicate	O
that	O
RanBP3	B
acts	O
as	O
a	O
scaffold	O
protein	O
to	O
promote	O
the	O
efficient	O
assembly	O
of	O
export	O
complexes	O
.	O

By	O
tethering	O
Crm1	B
to	O
catalytically	O
enhanced	O
RCC1	B
,	O
RanBP3	B
may	O
lower	O
the	O
entropic	O
barrier	O
for	O
the	O
loading	O
of	O
Ran	B
.	O
GTP	O
onto	O
Crm1	B
.	O

We	O
propose	O
that	O
this	O
provides	O
an	O
additional	O
mechanism	O
by	O
which	O
RanBP3	B
facilitates	O
export	O
.	O

The	O
TRIM37	B
gene	O
encodes	O
a	O
peroxisomal	O
RING	O
-	O
B	O
-	O
box	O
-	O
coiled	O
-	O
coil	O
protein	O
:	O
classification	O
of	O
mulibrey	O
nanism	O
as	O
a	O
new	O
peroxisomal	O
disorder	O
.	O

Mulibrey	O
nanism	O
is	O
a	O
rare	O
growth	O
disorder	O
of	O
prenatal	O
onset	O
caused	O
by	O
mutations	O
in	O
the	O
TRIM37	B
gene	O
,	O
which	O
encodes	O
a	O
RING	O
-	O
B	O
-	O
box	O
-	O
coiled	O
-	O
coil	O
protein	O
.	O

The	O
pathogenetic	O
mechanisms	O
of	O
mulibrey	O
nanism	O
are	O
unknown	O
.	O

We	O
have	O
used	O
transiently	O
transfected	O
cells	O
and	O
antibodies	O
raised	O
against	O
the	O
predicted	O
TRIM37	B
protein	O
to	O
characterize	O
the	O
TRIM37	B
gene	O
product	O
and	O
to	O
determine	O
its	O
intracellular	O
localization	O
.	O

We	O
show	O
that	O
the	O
human	O
TRIM37	B
cDNA	O
encodes	O
a	O
peroxisomal	O
protein	O
with	O
an	O
apparent	O
molecular	O
weight	O
of	O
130	O
kD	O
.	O

Peroxisomal	O
localization	O
is	O
compromised	O
in	O
mutant	O
protein	O
representing	O
the	O
major	O
Finnish	O
TRIM37	B
mutation	O
but	O
is	O
retained	O
in	O
the	O
protein	O
representing	O
the	O
minor	O
Finnish	O
mutation	O
.	O

Colocalization	O
of	O
endogenous	O
TRIM37	B
with	O
peroxisomal	O
markers	O
was	O
observed	O
by	O
double	O
immunofluorescence	O
staining	O
in	O
HepG2	O
and	O
human	O
intestinal	O
smooth	O
muscle	O
cell	O
lines	O
.	O

In	O
human	O
tissue	O
sections	O
,	O
TRIM37	B
shows	O
a	O
granular	O
cytoplasmic	O
pattern	O
.	O

Endogenous	O
TRIM37	B
is	O
not	O
imported	O
into	O
peroxisomes	O
in	O
peroxin	B
1	I
(	O
PEX1	B
(	O
-	O
/	O
-	O
)	O
)	O
and	O
peroxin	B
5	I
(	O
PEX5	B
(	O
-	O
/	O
-	O
)	O
)	O
mutant	O
fibroblasts	O
but	O
is	O
imported	O
normally	O
in	O
peroxin	B
7	I
(	O
PEX7	B
(	O
-	O
/	O
-	O
)	O
)	O
deficient	O
fibroblasts	O
,	O
giving	O
further	O
evidence	O
for	O
a	O
peroxisomal	O
localization	O
of	O
TRIM37	B
.	O

Fibroblasts	O
derived	O
from	O
patients	O
with	O
mulibrey	O
nanism	O
lack	O
C	O
-	O
terminal	O
TRIM37	B
immunoreactivity	O
but	O
stain	O
normally	O
for	O
both	O
peroxisomal	O
matrix	O
and	O
membrane	O
markers	O
,	O
suggesting	O
apparently	O
normal	O
peroxisome	O
biogenesis	O
in	O
patient	O
fibroblasts	O
.	O

Taken	O
together	O
,	O
this	O
molecular	O
evidence	O
unequivocally	O
indicates	O
that	O
TRIM37	B
is	O
located	O
in	O
the	O
peroxisomes	O
,	O
and	O
Mulibrey	O
nanism	O
thus	O
can	O
be	O
classified	O
as	O
a	O
new	O
peroxisomal	O
disorder	O
.	O

The	O
apolipoprotein	B
L	I
gene	O
cluster	O
has	O
emerged	O
recently	O
in	O
evolution	O
and	O
is	O
expressed	O
in	O
human	O
vascular	O
tissue	O
.	O

We	O
previously	O
isolated	O
APOL3	B
(	O
CG12	B
-	I
1	I
)	O
cDNA	O
and	O
now	O
describe	O
the	O
isolation	O
of	O
APOL1	B
and	O
APOL2	B
cDNA	O
from	O
an	O
activated	O
endothelial	O
cell	O
cDNA	O
library	O
and	O
show	O
their	O
endothelialspecific	O
expression	O
in	O
human	O
vascular	O
tissue	O
.	O

APOL1	B
-	I
APOL4	I
are	O
clustered	O
on	O
human	O
chromosome	O
22q13.1	O
,	O
as	O
a	O
result	O
of	O
tandem	O
gene	O
duplication	O
,	O
and	O
were	O
detected	O
only	O
in	O
primates	O
(	O
humans	O
and	O
African	O
green	O
monkeys	O
)	O
and	O
not	O
in	O
dogs	O
,	O
pigs	O
,	O
or	O
rodents	O
,	O
showing	O
that	O
this	O
gene	O
cluster	O
has	O
arisen	O
recently	O
in	O
evolution	O
.	O

The	O
specific	O
tissue	O
distribution	O
and	O
gene	O
organization	O
suggest	O
that	O
these	O
genes	O
have	O
diverged	O
rapidly	O
after	O
duplication	O
.	O

This	O
has	O
resulted	O
in	O
the	O
emergence	O
of	O
an	O
additional	O
signal	O
peptide	O
encoding	O
exon	O
that	O
ensures	O
secretion	O
of	O
the	O
plasma	O
high	B
-	I
density	I
lipoprotein	I
-	O
associated	O
APOL1	B
.	O

Our	O
results	O
show	O
that	O
the	O
APOL1	B
-	I
APOL4	I
cluster	O
might	O
contribute	O
to	O
the	O
substantial	O
differences	O
in	O
the	O
lipid	O
metabolism	O
of	O
humans	O
and	O
mice	O
,	O
as	O
dictated	O
by	O
the	O
variable	O
expression	O
of	O
genes	O
involved	O
in	O
this	O
process	O
.	O

Cooperative	O
E	O
-	O
box	O
regulation	O
of	O
human	O
GLI1	B
by	O
TWIST	B
and	O
USF	B
.	O

Sonic	B
hedgehog	I
signaling	O
plays	O
a	O
critical	O
role	O
in	O
vertebrate	O
patterning	O
,	O
and	O
signaling	O
defects	O
are	O
associated	O
with	O
severe	O
birth	O
defects	O
and	O
cancer	O
in	O
man	O
.	O

GLI1	B
encodes	O
a	O
critical	O
transcription	O
activator	O
in	O
this	O
pathway	O
.	O

GLI1	B
is	O
expressed	O
in	O
human	O
basal	O
cell	O
carcinomas	O
and	O
sarcomas	O
.	O

Despite	O
the	O
significance	O
of	O
the	O
GLI1	B
gene	O
in	O
human	O
disease	O
,	O
few	O
immediate	O
upstream	O
regulators	O
of	O
GLI1	B
expression	O
are	O
known	O
.	O

We	O
previously	O
demonstrated	O
that	O
a	O
5	O
'	O
region	O
,	O
including	O
5	O
'	O
flanking	O
sequence	O
,	O
an	O
untranslated	O
exon	O
,	O
and	O
425	O
bp	O
of	O
the	O
first	O
intron	O
,	O
regulates	O
the	O
human	O
GLI1	B
gene	O
.	O

Here	O
we	O
show	O
that	O
inactivating	O
mutations	O
in	O
E	O
-	O
box	O
,	O
GC	O
box	O
,	O
AP-2	B
,	O
GATA	O
,	O
GSG	O
,	O
PuF	B
,	O
and	O
Zeste	B
sites	O
identified	O
three	O
critical	O
regulatory	O
elements	O
,	O
including	O
a	O
GC	O
box	O
that	O
binds	O
Sp1	B
and	O
two	O
intronic	O
E	O
-	O
boxes	O
that	O
bind	O
USF	B
proteins	O
or	O
Twist	B
.	O

Expression	O
of	O
Twist	B
but	O
not	O
a	O
frame	O
shift	O
mutation	O
of	O
Twist	B
activates	O
the	O
wild	O
-	O
type	O
human	O
GLI1	B
regulatory	O
sequences	O
but	O
not	O
with	O
inactivating	O
mutations	O
of	O
the	O
E	O
-	O
boxes	O
.	O

Twist	B
activates	O
GLI1	B
reporter	O
expression	O
through	O
E	O
-	O
box	O
+	O
482	O
but	O
requires	O
binding	O
of	O
USF	B
proteins	O
to	O
E	O
-	O
box	O
+	O
157	O
.	O

Twist	B
mutations	O
cause	O
human	O
birth	O
defects	O
and	O
Twist	B
is	O
overexpressed	O
in	O
many	O
rhabdomyosarcomas	O
,	O
suggesting	O
that	O
one	O
of	O
Twist	B
's	O
primary	O
roles	O
is	O
the	O
regulation	O
of	O
GLI1	B
.	O

Structure	O
of	O
the	O
16S	B
rRNA	I
pseudouridine	I
synthase	I
RsuA	B
bound	O
to	O
uracil	O
and	O
UMP	O
.	O

In	O
Escherichia	O
coli	O
,	O
the	O
pseudouridine	B
synthase	I
RsuA	B
catalyzes	O
formation	O
of	O
pseudouridine	O
(	O
psi	O
)	O
at	O
position	O
516	O
in	O
16S	O
rRNA	O
during	O
assembly	O
of	O
the	O
30S	O
ribosomal	O
subunit	O
.	O

We	O
have	O
determined	O
the	O
crystal	O
structure	O
of	O
RsuA	B
bound	O
to	O
uracil	O
at	O
2.0	O
A	O
resolution	O
and	O
to	O
uridine	O
5'-monophosphate	O
(	O
UMP	O
)	O
at	O
2.65	O
A	O
resolution	O
.	O

RsuA	B
consists	O
of	O
an	O
N	O
-	O
terminal	O
domain	O
connected	O
by	O
an	O
extended	O
linker	O
to	O
the	O
central	O
and	O
C	O
-	O
terminal	O
domains	O
.	O

Uracil	O
and	O
UMP	O
bind	O
in	O
a	O
cleft	O
between	O
the	O
central	O
and	O
C	O
-	O
terminal	O
domains	O
near	O
the	O
catalytic	O
residue	O
Asp	O
102	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
shows	O
structural	O
similarity	O
to	O
the	O
ribosomal	B
protein	I
S4	I
.	O

Despite	O
only	O
15	O
%	O
amino	O
acid	O
identity	O
,	O
the	O
other	O
two	O
domains	O
are	O
structurally	O
similar	O
to	O
those	O
of	O
the	O
tRNA	O
-	O
specific	O
psi	B
-	I
synthase	I
TruA	B
,	O
including	O
the	O
position	O
of	O
the	O
catalytic	O
Asp	O
.	O

Our	O
results	O
suggest	O
that	O
all	O
four	O
families	B
of	I
pseudouridine	I
synthases	I
share	O
the	O
same	O
fold	O
of	O
their	O
catalytic	O
domain	O
(	O
s	O
)	O
and	O
uracil	O
-	O
binding	O
site	O
.	O

Transcriptional	O
control	O
of	O
the	O
human	O
thromboxane	B
synthase	I
gene	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Thromboxane	O
A	O
(	O
2	O
)	O
,	O
a	O
potent	O
mediator	O
of	O
vasoconstriction	O
and	O
platelet	O
aggregation	O
,	O
is	O
synthesized	O
from	O
prostaglandin	O
H	O
(	O
2	O
)	O
by	O
thromboxane	B
synthase	I
(	O
TXAS	B
)	O
.	O

We	O
report	O
here	O
on	O
promoter	O
analyses	O
of	O
human	O
TXAS	B
using	O
in	O
vitro	O
transcription	O
and	O
in	O
vivo	O
transfection	O
methods	O
.	O

The	O
39	O
-	O
bp	O
core	O
promoter	O
,	O
containing	O
both	O
TATA	O
and	O
initiator	O
elements	O
,	O
accurately	O
initiates	O
transcription	O
in	O
an	O
orientation	O
-	O
dependent	O
manner	O
in	O
a	O
cell	O
-	O
free	O
transcription	O
system	O
.	O

Mutation	O
of	O
either	O
TATA	O
or	O
initiator	O
abolished	O
transcriptional	O
activity	O
,	O
but	O
the	O
upstream	O
sequence	O
had	O
no	O
effect	O
on	O
TXAS	B
promoter	O
activities	O
in	O
vitro	O
,	O
suggesting	O
that	O
the	O
core	O
promoter	O
is	O
sufficient	O
for	O
transcriptional	O
activity	O
from	O
a	O
naked	O
DNA	O
template	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
both	O
elements	O
drastically	O
decreased	O
the	O
promoter	O
activity	O
in	O
vivo	O
.	O

Furthermore	O
,	O
TXAS	B
proximal	O
promoter	O
containing	O
the	O
nucleotides	O
-	O
90	O
to	O
-	O
56	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
was	O
necessary	O
for	O
promoter	O
transactivation	O
in	O
vivo	O
.	O

Transcriptional	O
activities	O
from	O
5'-deletion	O
mutants	O
indicated	O
that	O
the	O
effects	O
of	O
the	O
nucleotides	O
-	O
90	O
/	O
-	O
56	O
were	O
more	O
pronounced	O
in	O
stably	O
transfected	O
cells	O
(	O
a	O
150	O
-	O
fold	O
difference	O
)	O
than	O
in	O
the	O
transiently	O
transfected	O
cells	O
(	O
an	O
8	O
-	O
fold	O
difference	O
)	O
,	O
reflecting	O
the	O
effects	O
of	O
TXAS	B
transcriptional	O
activation	O
from	O
replicating	O
and	O
nonreplicating	O
DNA	O
templates	O
.	O

Partial	O
micrococcal	O
nuclease	B
digestion	O
indicated	O
that	O
the	O
sequence	O
-	O
90	O
/	O
-	O
56	O
,	O
where	O
the	O
NF	B
-	I
E2	I
site	O
is	O
located	O
,	O
is	O
associated	O
with	O
alterations	O
of	O
nucleosomal	O
structure	O
at	O
the	O
regions	O
of	O
promoter	O
and	O
reporter	O
gene	O
but	O
not	O
the	O
region	O
further	O
downstream	O
.	O

Mutagenesis	O
and	O
forced	O
expression	O
studies	O
demonstrated	O
a	O
critical	O
role	O
of	O
p45	B
NF	I
-	I
E2	I
in	O
controlling	O
TXAS	B
expression	O
under	O
native	O
chromatin	O
conditions	O
.	O

Band	O
shifting	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
indicated	O
that	O
p45	B
NF	I
-	I
E2	I
was	O
bound	O
to	O
the	O
TXAS	B
promoter	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Indirect	O
end	O
labeling	O
and	O
ligation	O
-	O
mediated	O
PCR	O
analyses	O
further	O
demonstrated	O
that	O
the	O
occupation	O
of	O
TXAS	B
promoter	O
NF	B
-	I
E2	I
site	O
was	O
associated	O
with	O
disruption	O
of	O
nucleosomal	O
structure	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
binding	O
of	O
NF	B
-	I
E2	I
is	O
critical	O
both	O
for	O
alteration	O
of	O
the	O
nucleosomal	O
structure	O
and	O
for	O
activation	O
of	O
the	O
TXAS	B
promoter	O
,	O
whereas	O
the	O
TATA	O
and	O
initiator	O
elements	O
are	O
essential	O
for	O
transcription	O
.	O

Rapid	O
evolution	O
of	O
the	O
male	O
-	O
specific	O
antibacterial	O
protein	O
andropin	B
gene	O
in	O
Drosophila	O
.	O

Andropin	B
,	O
which	O
encodes	O
an	O
antibacterial	O
protein	O
,	O
is	O
closely	O
linked	O
to	O
the	O
Cecropin	B
gene	O
cluster	O
of	O
D.	O
melanogaster	O
.	O

Andropin	B
and	O
Cecropins	B
are	O
considered	O
to	O
have	O
originated	O
from	O
one	O
common	O
ancestor	O
.	O

However	O
,	O
the	O
expression	O
pattern	O
of	O
Andropin	B
is	O
distinct	O
from	O
that	O
of	O
Cecropins	B
,	O
being	O
restricted	O
to	O
the	O
adult	O
male	O
ejaculatory	O
duct	O
.	O

To	O
elucidate	O
the	O
evolutionary	O
process	O
of	O
Andropin	B
,	O
we	O
have	O
sequenced	O
Andropin	B
genes	O
from	O
D.	O
melanogaster	O
and	O
its	O
closely	O
related	O
species	O
.	O

In	O
D.	O
melanogaster	O
,	O
the	O
nucleotide	O
diversity	O
of	O
Andropin	B
is	O
remarkably	O
low	O
compared	O
to	O
that	O
of	O
Cecropin	B
.	O

In	O
contrast	O
,	O
nonsynonymous	O
substitutions	O
of	O
Andropin	B
are	O
conspicuously	O
frequent	O
between	O
species	O
.	O

From	O
genomic	O
Southern	O
analysis	O
,	O
Andropin	B
-	O
like	O
genes	O
are	O
present	O
in	O
at	O
least	O
the	O
melanogaster	O
species	O
subgroup	O
.	O

The	O
series	O
of	O
present	O
results	O
suggests	O
that	O
Andropin	B
was	O
born	O
in	O
the	O
course	O
of	O
constructing	O
the	O
Drosophila	O
Cecropin	B
gene	I
family	I
and	O
then	O
started	O
to	O
evolve	O
rapidly	O
,	O
in	O
contrast	O
to	O
Cecropins	B
.	O

Structural	O
insights	O
into	O
the	O
pro	O
-	O
apoptotic	O
function	O
of	O
mitochondrial	O
serine	B
protease	I
HtrA2	B
/	O
Omi	B
.	O

HtrA2	B
/	O
Omi	B
,	O
a	O
mitochondrial	O
serine	B
protease	I
in	O
mammals	O
,	O
is	O
important	O
in	O
programmed	O
cell	O
death	O
.	O

However	O
,	O
the	O
underlining	O
mechanism	O
of	O
HtrA2	B
/	O
Omi	B
-	O
mediated	O
apoptosis	O
remains	O
unclear	O
.	O

Analogous	O
to	O
the	O
bacterial	O
homolog	O
HtrA	B
(	O
DegP	B
)	O
,	O
the	O
mature	O
HtrA2	B
protein	O
contains	O
a	O
central	O
serine	B
protease	I
domain	O
and	O
a	O
C	O
-	O
terminal	O
PDZ	O
domain	O
.	O

The	O
2.0	O
A	O
crystal	O
structure	O
of	O
HtrA2	B
/	O
Omi	B
reveals	O
the	O
formation	O
of	O
a	O
pyramid	O
-	O
shaped	O
homotrimer	O
mediated	O
exclusively	O
by	O
the	O
serine	B
protease	I
domains	O
.	O

The	O
peptide	O
-	O
binding	O
pocket	O
of	O
the	O
PDZ	O
domain	O
is	O
buried	O
in	O
the	O
intimate	O
interface	O
between	O
the	O
PDZ	O
and	O
the	O
protease	B
domains	O
.	O

Mutational	O
analysis	O
reveals	O
that	O
the	O
monomeric	O
HtrA2	B
/	O
Omi	B
mutants	O
are	O
unable	O
to	O
induce	O
cell	O
death	O
and	O
are	O
deficient	O
in	O
protease	B
activity	O
.	O

The	O
PDZ	O
domain	O
modulates	O
HtrA2	B
/	O
Omi	B
-	O
mediated	O
cell	O
death	O
activity	O
by	O
regulating	O
its	O
serine	B
protease	I
activity	O
.	O

These	O
structural	O
and	O
biochemical	O
observations	O
provide	O
an	O
important	O
framework	O
for	O
deciphering	O
the	O
mechanisms	O
of	O
HtrA2	B
/	O
Omi	B
-	O
mediated	O
apoptosis	O
.	O

The	O
distribution	O
of	O
activin	B
and	O
activin	B
receptors	I
in	O
gestational	O
tissues	O
across	O
human	O
pregnancy	O
and	O
during	O
labour	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
localization	O
and	O
content	O
of	O
activin	B
beta	I
A	I
-	O
subunit	O
and	O
activin	B
receptors	I
in	O
gestational	O
tissues	O
throughout	O
pregnancy	O
and	O
in	O
association	O
with	O
term	O
labour	O
.	O

Placenta	O
and	O
fetal	O
membranes	O
were	O
collected	O
from	O
women	O
undergoing	O
first	O
and	O
second	O
trimester	O
terminations	O
and	O
from	O
women	O
before	O
and	O
after	O
term	O
labour	O
.	O

Activin	B
beta	I
A	I
-	O
subunit	O
and	O
activin	B
receptors	I
IA	I
,	I
IB	I
,	I
IIA	I
and	I
IIB	I
were	O
studied	O
by	O
immunohistochemistry	O
.	O

Term	O
tissues	O
were	O
analysed	O
for	O
activin	B
A	I
and	O
follistatin	B
content	O
by	O
ELISA	O
and	O
the	O
presence	O
of	O
receptor	O
proteins	O
was	O
assessed	O
by	O
Western	O
hybridization	O
.	O

Activin	B
beta	I
A	I
-	O
subunit	O
was	O
localized	O
to	O
the	O
syncytiotrophoblast	O
and	O
cytotrophoblast	O
in	O
placentae	O
from	O
all	O
gestational	O
ages	O
,	O
and	O
to	O
the	O
amniotic	O
epithelial	O
and	O
chorionic	O
trophoblast	O
layer	O
at	O
term	O
.	O

In	O
placentae	O
of	O
first	O
and	O
second	O
trimester	O
,	O
receptor	O
proteins	O
were	O
localized	O
to	O
the	O
syncytium	O
,	O
whereas	O
at	O
term	O
,	O
the	O
distribution	O
was	O
confined	O
predominantly	O
to	O
vascular	O
endothelial	O
cells	O
of	O
villous	O
blood	O
vessels	O
.	O

Receptor	O
proteins	O
in	O
amnion	O
were	O
localized	O
to	O
some	O
epithelial	O
cells	O
,	O
mesenchyme	O
and	O
chorionic	O
trophoblast	O
.	O

These	O
findings	O
suggest	O
that	O
activin	B
A	I
is	O
secreted	O
by	O
and	O
targets	O
the	O
placental	O
syncytium	O
and	O
amniotic	O
epithelium	O
in	O
early	O
pregnancy	O
,	O
but	O
at	O
term	O
targets	O
the	O
vascular	O
endothelium	O
of	O
placenta	O
and	O
the	O
fetal	O
membranes	O
.	O

There	O
were	O
no	O
differences	O
with	O
labour	O
onset	O
.	O

Functional	O
modulation	O
of	O
expanded	O
CD8	B
+	O
synovial	O
fluid	O
T	O
cells	O
by	O
NK	O
cell	O
receptor	O
expression	O
in	O
HLA	B
-	I
B27	I
-	O
associated	O
reactive	O
arthritis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
NK	O
cell	O
receptor	O
(	O
NKR	O
)	O
expression	O
could	O
modulate	O
cytotoxicity	O
of	O
oligoclonal	O
CD8	B
+	O
T	O
cells	O
present	O
in	O
the	O
synovial	O
fluid	O
(	O
SF	O
)	O
of	O
HLA	B
-	I
B27	I
-	O
reactive	O
arthritis	O
(	O
ReA	O
)	O
patients	O
,	O
especially	O
in	O
a	O
TCRBV1	O
population	O
shared	O
among	O
different	O
patients	O
and	O
cytotoxic	O
toward	O
HLA	B
-	I
B27	I
.	O

A	O
CD8	B
+	O
T	O
cell	O
line	O
,	O
two	O
TCRBV1	O
lines	O
and	O
clones	O
were	O
isolated	O
from	O
the	O
SF	O
of	O
an	O
HLA	B
-	I
B27	I
+	O
ReA	O
patient	O
,	O
and	O
tested	O
with	O
mAb	O
specific	O
for	O
Ig	B
-	O
like	O
(	O
KIR2DL1	B
,	O
KIR2DL2	B
,	O
KIR3DL1	B
and	O
ILT2	B
)	O
and	O
CD94	B
C	B
-	I
type	I
lectin	I
NKR	O
.	O

Transcripts	O
for	O
NKG2	B
subunits	O
(	O
NKG2A-2E	B
)	O
associated	O
with	O
CD94	B
were	O
also	O
evaluated	O
.	O

Function	O
was	O
tested	O
in	O
a	O
51Cr	O
-	O
release	O
cytotoxic	O
assay	O
.	O

We	O
found	O
stable	O
but	O
distinct	O
levels	O
of	O
CD94	B
/	O
NKG2	B
complexes	O
at	O
the	O
surface	O
of	O
T	O
cell	O
lines	O
and	O
clones	O
.	O

Different	O
NKG2	B
members	O
could	O
be	O
associated	O
with	O
CD94	B
,	O
either	O
inhibitory	O
(	O
NKG2A	B
/	I
B	I
)	O
or	O
activating	O
(	O
NKG2C	B
)	O
.	O

The	O
inhibitory	O
ILT2	B
receptor	O
could	O
also	O
be	O
differently	O
expressed	O
,	O
but	O
other	O
Ig	B
-	O
like	O
NKR	O
were	O
negative	O
.	O

Functionally	O
,	O
one	O
TCRBV1	O
line	O
and	O
clones	O
with	O
a	O
high	O
CD94	B
/	O
NKG2A	B
expression	O
did	O
not	O
lyse	O
B27	O
+	O
targets	O
.	O

Another	O
TCRBV1	O
line	O
with	O
the	O
same	O
TCRBV1	O
rearrangement	O
had	O
a	O
low	O
expression	O
of	O
CD94	B
/	O
NKG2A	B
,	O
but	O
expressed	O
NKG2C	B
transcripts	O
and	O
was	O
cytotoxic	O
toward	O
HLA	B
-	I
B27	I
.	O

HLA	B
-	I
B27	I
is	O
a	O
ligand	O
for	O
ILT2	B
and	O
we	O
observed	O
an	O
inhibitory	O
effect	O
of	O
ILT2	B
engagement	O
on	O
B*2705	O
targets	O
in	O
blockade	O
experiments	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
a	O
high	O
degree	O
of	O
heterogeneity	O
in	O
the	O
expression	O
of	O
NKR	O
by	O
intrasynovial	O
CD8	B
+	O
T	O
cells	O
which	O
could	O
modulate	O
their	O
cytotoxicity	O
and	O
play	O
a	O
role	O
in	O
the	O
control	O
of	O
this	O
HLA	B
class	I
I	I
-	O
associated	O
autoimmune	O
disease	O
.	O

A	O
novel	O
asparaginase	B
-	I
like	I
protein	I
is	O
a	O
sperm	O
autoantigen	O
in	O
rats	O
.	O

A	O
novel	O
asparaginase	B
-	I
like	I
protein	I
(	O
ALP	B
)	O
of	O
spermatozoa	O
was	O
cloned	O
from	O
rat	O
and	O
human	O
testis	O
cDNA	O
libraries	O
on	O
the	O
basis	O
of	O
reactivity	O
with	O
antibodies	O
produced	O
after	O
vasectomy	O
.	O

Although	O
obstruction	O
of	O
the	O
male	O
reproductive	O
tract	O
is	O
known	O
to	O
cause	O
an	O
immunologic	O
response	O
,	O
few	O
of	O
the	O
sperm	O
antigens	O
responsible	O
for	O
the	O
generation	O
of	O
autoantibodies	O
have	O
been	O
characterized	O
.	O

We	O
are	O
identifying	O
proteins	O
of	O
interest	O
by	O
coring	O
autoantigenic	O
protein	O
spots	O
from	O
two	O
-	O
dimensional	O
(	O
2-D	O
)	O
gels	O
of	O
rat	O
sperm	O
extracts	O
and	O
microsequencing	O
them	O
by	O
mass	O
spectrometry	O
.	O

The	O
peptide	O
sequences	O
from	O
ALP	B
,	O
a	O
28	O
kDa	O
,	O
pI	O
5.7	O
protein	O
,	O
matched	O
to	O
a	O
single	O
partial	O
length	O
rat	O
EST	O
.	O

These	O
peptide	O
sequences	O
were	O
used	O
to	O
clone	O
a	O
cDNA	O
encoding	O
a	O
novel	O
333	O
amino	O
acid	O
open	O
reading	O
frame	O
.	O

The	O
new	O
protein	O
had	O
a	O
similarity	O
to	O
portions	O
of	O
L	B
-	I
asparaginases	I
of	O
plants	O
(	O
43	O
%	O
)	O
and	O
to	O
glycosylasparaginases	B
in	O
animal	O
cells	O
(	O
32	O
%	O
)	O
.	O

Human	O
ALP	B
cDNA	O
was	O
subsequently	O
cloned	O
.	O

It	O
showed	O
77	O
%	O
identity	O
to	O
the	O
rat	O
ALP	B
sequence	O
and	O
the	O
gene	O
,	O
ASRGL1	B
(	O
asparaginase	B
-	I
like	I
1	I
)	O
,	O
mapped	O
to	O
chromosome	O
locus	O
11q12.3	O
.	O

Purified	O
recombinant	O
rat	O
ALP	B
(	O
rALP	B
)	O
,	O
expressed	O
in	O
E.	O
coli	O
,	O
was	O
used	O
to	O
raise	O
polyclonal	O
antiserum	O
in	O
guinea	O
pigs	O
.	O

Two	O
observations	O
verified	O
that	O
the	O
correct	O
protein	O
had	O
been	O
cloned	O
:	O
1	O
)	O
the	O
anti	O
-	O
rALP	B
antibody	O
reacted	O
with	O
both	O
rALP	B
and	O
rat	O
sperm	O
;	O
and	O
2	O
)	O
post	O
-	O
vasectomy	O
sera	O
bound	O
rALP	B
.	O

Anti	O
-	O
rALP	B
antibody	O
stained	O
the	O
midpiece	O
of	O
rat	O
and	O
human	O
sperm	O
coincident	O
with	O
staining	O
by	O
MitoTracker	O
Green	O
FM	O
,	O
suggesting	O
that	O
ALP	B
is	O
associated	O
with	O
the	O
mitochondria	O
.	O

Northern	O
analysis	O
revealed	O
that	O
rat	O
ALP	B
message	O
was	O
abundantly	O
expressed	O
in	O
the	O
testis	O
but	O
was	O
also	O
present	O
in	O
heart	O
,	O
brain	O
,	O
liver	O
,	O
skeletal	O
muscle	O
,	O
and	O
kidney	O
.	O

Proteinase	B
3	I
and	O
dihydrolipoamide	B
dehydrogenase	I
(	O
E3	O
)	O
are	O
major	O
autoantigens	O
in	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
.	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
has	O
been	O
found	O
to	O
be	O
strikingly	O
associated	O
with	O
autoimmune	O
phenomena	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
presence	O
of	O
various	O
autoantibodies	O
in	O
patients	O
with	O
HCV	O
infection	O
.	O

Anti	O
-	O
neutrophil	O
cytoplamic	O
antibody	O
(	O
ANCA	O
)	O
,	O
anti	O
-	O
dihydrolipoamide	B
dehydrogenase	I
(	O
anti	O
-	O
E3	O
)	O
,	O
rheumatoid	B
factor	I
(	O
RF	B
)	O
,	O
anti	O
-	O
dihydrolipoamide	B
acetyltransferase	I
(	O
anti	O
-	O
E2	O
)	O
,	O
anti	O
-	O
SS	B
-	I
A	I
/	O
Ro	B
(	I
60	I
kD	I
)	I
,	O
anti	O
-	O
SS	B
-	I
A	I
/	O
Ro	B
(	I
52	I
kD	I
)	I
,	O
anti	O
-	O
SS	B
-	I
B	I
/	O
La	B
,	O
anti	O
-	O
topoisomerase	B
II	I
(	O
anti	O
-	O
topo	B
II	I
)	O
,	O
anti	O
-	O
cardiolipin	O
(	O
aCL	O
)	O
,	O
anti	O
-	O
dsDNA	O
,	O
anti	O
-	O
ssDNA	O
,	O
anti	O
-	O
nuclear	O
antibodies	O
(	O
ANA	O
)	O
,	O
anti	O
-	O
proteinase	B
3	I
(	O
anti	O
-	O
Pr3	B
)	O
and	O
anti	O
-	O
myeloperoxidase	B
(	O
anti	O
-	O
MPO	B
)	O
were	O
determined	O
in	O
sera	O
from	O
516	O
patients	O
with	O
HCV	O
infection	O
,	O
11	O
with	O
primary	O
biliary	O
cirrhosis	O
(	O
PBC	O
)	O
and	O
44	O
healthy	O
controls	O
.	O

Assays	O
employed	O
were	O
indirect	O
immunofluoresence	O
,	O
the	O
particle	O
latex	O
agglutination	O
test	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
immunoblotting	O
.	O

ANCA	O
,	O
anti	O
-	O
E3	O
antibody	O
and	O
RF	B
were	O
positive	O
in	O
278	O
/	O
516	O
(	O
55.6	O
%	O
)	O
,	O
276	O
/	O
516	O
(	O
53.3	O
%	O
)	O
and	O
288	O
/	O
516	O
(	O
56	O
%	O
)	O
patients	O
with	O
HCV	O
infection	O
,	O
respectively	O
.	O

Positivity	O
for	O
ANA	O
was	O
present	O
in	O
15.8	O
%	O
,	O
anti	O
-	O
ssDNA	O
in	O
15.6	O
%	O
,	O
anti	O
-	O
dsDNA	O
in	O
8.5	O
%	O
,	O
aCL	O
in	O
5	O
%	O
,	O
anti	O
-	O
SS	B
-	I
B	I
/	O
La	B
in	O
4.1	O
%	O
,	O
anti	O
-	O
SS	B
-	I
A	I
/	O
Ro	B
(	I
60	I
kD	I
)	I
in	O
3.9	O
%	O
,	O
anti	O
-	O
E2	O
in	O
3.3	O
%	O
and	O
anti	O
-	O
SSA	B
/	O
Ro	B
(	I
52	I
kD	I
)	I
in	O
1.2	O
%	O
,	O
anti	O
-	O
MPO	B
in	O
4.8	O
%	O
,	O
anti	O
-	O
Topo	B
II	I
and	O
anti	O
-	O
actinin	B
in	O
0	O
%	O
.	O

All	O
sera	O
with	O
ANCA	O
showed	O
c	O
-	O
ANCA	O
patterns	O
and	O
contained	O
anti	O
-	O
PR3	B
specificity	O
.	O

HCV	O
patients	O
with	O
ANCA	O
showed	O
a	O
higher	O
prevalence	O
of	O
skin	O
involvement	O
,	O
anaemia	O
,	O
abnormal	O
liver	O
function	O
and	O
alpha	B
-	I
Fetoprotein	I
(	O
alpha	B
-	I
FP	I
)	O
.	O

HCV	O
patients	O
with	O
anti	O
-	O
E3	O
antibodies	O
showed	O
a	O
higher	O
prevalence	O
of	O
liver	O
cirrhosis	O
,	O
arthritis	O
,	O
abnormal	O
liver	O
function	O
and	O
elevated	O
alpha	B
-	I
FP	I
levels	O
.	O

The	O
prevalence	O
of	O
autoantibodies	O
was	O
not	O
affected	O
by	O
treatment	O
with	O
interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
.	O

In	O
conclusion	O
,	O
autoantibodies	O
are	O
commonly	O
found	O
in	O
patients	O
with	O
HCV	O
infection	O
.	O

There	O
is	O
a	O
high	O
prevalence	O
of	O
anti	O
-	O
E3	O
,	O
ANCA	O
and	O
RF	B
in	O
these	O
patients	O
.	O

Proteinase	B
3	I
and	O
E3	O
are	O
the	O
major	O
target	O
antigens	O
in	O
HCV	O
infection	O
.	O

HCV	O
may	O
be	O
regarded	O
as	O
a	O
possible	O
causative	O
factor	O
in	O
ANCA	O
-	O
related	O
vasculitis	O
.	O

Re	O
-	O
oxygenation	O
of	O
hypoxic	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
-	O
infected	O
CV1	O
cells	O
causes	O
distinct	O
changes	O
of	O
SV40	O
minichromosome	O
-	O
associated	O
replication	O
proteins	O
.	O

Hypoxia	O
interrupts	O
the	O
initiation	O
of	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
replication	O
in	O
vivo	O
at	O
a	O
stage	O
situated	O
before	O
unwinding	O
of	O
the	O
origin	O
region	O
.	O

After	O
re	O
-	O
oxygenation	O
,	O
unwinding	O
followed	O
by	O
a	O
synchronous	O
round	O
of	O
viral	O
replication	O
takes	O
place	O
.	O

To	O
further	O
characterize	O
the	O
hypoxia	O
-	O
induced	O
inhibition	O
of	O
unwinding	O
,	O
we	O
analysed	O
the	O
binding	O
of	O
several	O
replication	O
proteins	O
to	O
the	O
viral	O
minichromosome	O
before	O
and	O
after	O
re	O
-	O
oxygenation	O
.	O

T	B
antigen	I
,	O
the	O
34	B
-	I
kDa	I
subunit	I
of	I
replication	I
protein	I
A	I
(	O
RPA	B
)	O
,	O
topoisomerase	B
I	I
,	O
the	O
48	B
-	I
kDa	I
subunit	I
of	I
primase	I
,	O
the	O
125	B
-	I
kDa	I
subunit	I
of	I
polymerase	I
delta	I
,	O
and	O
the	O
37	B
-	I
kDa	I
subunit	I
of	I
replication	I
factor	I
C	I
(	O
RFC	B
)	O
were	O
present	O
at	O
the	O
viral	O
chromatin	O
already	O
under	O
hypoxia	O
.	O

The	O
70	B
-	I
kDa	I
subunit	I
of	I
RPA	I
,	O
the	O
180	B
-	I
kDa	I
subunit	I
of	I
polymerase	I
alpha	I
,	O
and	O
proliferating	B
cell	I
nuclear	I
antigen	I
(	O
PCNA	B
)	O
were	O
barely	O
detectable	O
at	O
the	O
SV40	O
chromatin	O
under	O
hypoxia	O
and	O
significantly	O
increased	O
after	O
re	O
-	O
oxygenation	O
.	O

Immunoprecipitation	O
of	O
minichromosomes	O
with	O
T	B
antigen	I
-	O
specific	O
antibody	O
and	O
subsequent	O
digestion	O
with	O
micrococcus	O
nuclease	O
revealed	O
that	O
most	O
of	O
the	O
minichromosome	O
-	O
bound	O
T	B
antigen	I
was	O
associated	O
with	O
the	O
viral	O
origin	O
in	O
hypoxic	O
and	O
in	O
re	O
-	O
oxygenated	O
cells	O
.	O

T	B
antigen	I
-	O
catalysed	O
unwinding	O
of	O
the	O
SV40	O
origin	O
occurred	O
,	O
however	O
,	O
only	O
after	O
re	O
-	O
oxygenation	O
as	O
indicated	O
by	O
(	O
a	O
)	O
increased	O
sensitivity	O
of	O
re	O
-	O
oxygenated	O
minichromosomes	O
against	O
digestion	O
with	O
single	O
-	O
stranded	O
DNA	O
-	O
specific	O
nuclease	B
P1	I
;	O
(	O
b	O
)	O
stabilization	O
of	O
RPA-34	B
binding	O
at	O
the	O
SV40	O
minichromosome	O
;	O
and	O
(	O
c	O
)	O
additional	O
phosphorylations	O
of	O
RPA-34	B
after	O
re	O
-	O
oxygenation	O
,	O
probably	O
catalysed	O
by	O
DNA	B
-	I
dependent	I
protein	I
kinase	I
.	O

The	O
results	O
presented	O
suggest	O
that	O
the	O
subunits	O
of	O
the	O
proteins	O
necessary	O
for	O
unwinding	O
,	O
primer	O
synthesis	O
and	O
primer	O
elongation	O
first	O
assemble	O
at	O
the	O
SV40	O
origin	O
in	O
form	O
of	O
stable	O
,	O
active	O
complexes	O
directly	O
before	O
they	O
start	O
to	O
work	O
.	O

Crystal	O
structure	O
of	O
human	O
dehydroepiandrosterone	B
sulphotransferase	I
in	O
complex	O
with	O
substrate	O
.	O

Dehydroepiandrosterone	B
sulphotransferase	I
(	O
DHEA	B
-	I
ST	I
)	O
is	O
an	O
enzyme	O
that	O
converts	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
,	O
and	O
some	O
other	O
steroids	O
,	O
into	O
their	O
sulphonated	O
forms	O
.	O

The	O
enzyme	O
catalyses	O
the	O
sulphonation	O
of	O
DHEA	O
on	O
the	O
3alpha	O
-	O
oxygen	O
,	O
with	O
3'-phosphoadenosine-5'-phosphosulphate	O
contributing	O
the	O
sulphate	O
.	O

The	O
structure	O
of	O
human	O
DHEA	B
-	I
ST	I
in	O
complex	O
with	O
its	O
preferred	O
substrate	O
DHEA	O
has	O
been	O
solved	O
here	O
to	O
1.99	O
A	O
using	O
molecular	O
replacement	O
with	O
oestradiol	B
sulphotransferase	I
(	O
37	O
%	O
sequence	O
identity	O
)	O
as	O
a	O
model	O
.	O

Two	O
alternative	O
substrate	O
-	O
binding	O
orientations	O
have	O
been	O
identified	O
.	O

The	O
primary	O
,	O
catalytic	O
,	O
orientation	O
has	O
the	O
DHEA	O
3alpha	O
-	O
oxygen	O
and	O
the	O
highly	O
conserved	O
catalytic	O
histidine	O
in	O
nearly	O
identical	O
positions	O
as	O
are	O
seen	O
for	O
the	O
related	O
oestradiol	B
sulphotransferase	I
.	O

The	O
substrate	O
,	O
however	O
,	O
shows	O
rotations	O
of	O
up	O
to	O
30	O
degrees	O
,	O
and	O
there	O
is	O
a	O
corresponding	O
rearrangement	O
of	O
the	O
protein	O
loops	O
contributing	O
to	O
the	O
active	O
site	O
.	O

This	O
may	O
also	O
reflect	O
the	O
low	O
identity	O
between	O
the	O
two	O
enzymes	O
.	O

The	O
second	O
orientation	O
penetrates	O
further	O
into	O
the	O
active	O
site	O
and	O
can	O
form	O
a	O
potential	O
hydrogen	O
bond	O
with	O
the	O
desulphonated	O
cofactor	O
3',5'-phosphoadenosine	O
(	O
PAP	O
)	O
.	O

This	O
second	O
site	O
contains	O
more	O
van	O
der	O
Waal	O
interactions	O
with	O
hydrophobic	O
residues	O
than	O
the	O
catalytic	O
site	O
and	O
may	O
also	O
reflect	O
the	O
substrate	O
-	O
inhibition	O
site	O
.	O

The	O
PAP	O
position	O
was	O
obtained	O
from	O
the	O
previously	O
solved	O
structure	O
of	O
DHEA	B
-	I
ST	I
co	O
-	O
crystallized	O
with	O
PAP	O
.	O

This	O
latter	O
structure	O
,	O
due	O
to	O
the	O
arrangement	O
of	O
loops	O
within	O
the	O
active	O
site	O
and	O
monomer	O
interactions	O
,	O
can	O
not	O
bind	O
substrate	O
.	O

The	O
results	O
presented	O
here	O
describe	O
details	O
of	O
substrate	O
binding	O
to	O
DHEA	B
-	I
ST	I
and	O
the	O
potential	O
relationship	O
to	O
substrate	O
inhibition	O
.	O

Cardiac	O
expression	O
and	O
subcellular	O
localization	O
of	O
the	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
member	O
,	O
stress	B
-	I
activated	I
protein	I
kinase-3	I
(	O
SAPK3	B
)	O
.	O

Despite	O
the	O
interest	O
in	O
the	O
roles	O
that	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
(	O
MAPKs	B
)	O
play	O
in	O
the	O
heart	O
,	O
the	O
role	O
of	O
the	O
different	O
MAPK	B
isoforms	O
has	O
been	O
relatively	O
poorly	O
defined	O
.	O

A	O
third	O
isoform	O
of	O
p38	B
MAPK	I
,	O
known	O
variously	O
as	O
stress	B
-	I
activated	I
protein	I
kinase-3	I
(	O
SAPK3	B
)	O
,	O
p38-	B
gamma	I
or	O
ERK6	B
,	O
has	O
been	O
previously	O
shown	O
to	O
differ	O
from	O
p38	B
-	I
alpha	I
/	I
beta	I
both	O
in	O
its	O
molecular	O
weight	O
and	O
its	O
lack	O
of	O
inhibition	O
by	O
the	O
compound	O
SB203580	O
.	O

We	O
have	O
generated	O
monoclonal	O
antibodies	O
with	O
specificity	O
for	O
SAPK3	B
demonstrated	O
by	O
immunoblot	O
analysis	O
,	O
immunofluorescence	O
studies	O
,	O
and	O
cloning	O
of	O
SAPK3	B
from	O
a	O
rat	O
heart	O
cDNA	O
expression	O
library	O
.	O

By	O
immunoblotting	O
,	O
we	O
confirmed	O
high	O
expression	O
of	O
SAPK3	B
in	O
fast	O
,	O
slow	O
and	O
mixed	O
fibre	O
types	O
of	O
murine	O
skeletal	O
muscle	O
and	O
observed	O
significant	O
expression	O
restricted	O
to	O
heart	O
,	O
lung	O
,	O
thymus	O
and	O
testes	O
.	O

In	O
addition	O
to	O
expression	O
in	O
normal	O
heart	O
(	O
human	O
,	O
mouse	O
,	O
rat	O
,	O
dog	O
and	O
pig	O
)	O
,	O
we	O
observed	O
constant	O
expression	O
in	O
diseased	O
human	O
heart	O
,	O
as	O
well	O
as	O
control	O
and	O
hypertrophic	O
cultured	O
neonatal	O
rat	O
cardiac	O
myocytes	O
.	O

Immunolocalization	O
in	O
cultured	O
cardiac	O
myocytes	O
followed	O
by	O
confocal	O
microscopy	O
showed	O
punctate	O
,	O
non	O
-	O
nuclear	O
SAPK3	B
staining	O
.	O

In	O
contrast	O
,	O
p38	B
-	I
alpha	I
/	I
beta	I
staining	O
was	O
non	O
-	O
punctate	O
and	O
distributed	O
throughout	O
the	O
cytosol	O
and	O
nucleus	O
.	O

Whereas	O
treatment	O
with	O
Leptomycin	O
B	O
to	O
prevent	O
nuclear	O
export	O
processes	O
promoted	O
higher	O
levels	O
of	O
p38	B
-	I
alpha	I
/	I
beta	I
staining	O
in	O
cardiac	O
myocyte	O
nuclei	O
,	O
there	O
was	O
no	O
apparent	O
change	O
in	O
SAPK3	B
localization	O
under	O
these	O
conditions	O
.	O

These	O
differences	O
between	O
p38	B
-	I
alpha	I
/	I
beta	I
and	O
SAPK3	B
probably	O
reflect	O
the	O
specialized	O
functions	O
of	O
SAPK3	B
and	O
emphasize	O
the	O
need	O
to	O
evaluate	O
SAPK3	B
upstream	O
activators	O
and	O
downstream	O
targets	O
in	O
the	O
heart	O
.	O

ROCK	B
and	O
Dia	B
have	O
opposing	O
effects	O
on	O
adherens	O
junctions	O
downstream	O
of	O
Rho	B
.	O

Adherens	O
junctions	O
(	O
AJs	O
)	O
are	O
crucial	O
for	O
maintaining	O
the	O
integrity	O
of	O
epithelial	O
tissues	O
and	O
are	O
often	O
disrupted	O
during	O
tumour	O
progression	O
.	O

Rho	B
family	I
proteins	O
have	O
been	O
shown	O
to	O
regulate	O
adherens	O
junctions	O
.	O

We	O
find	O
that	O
activation	O
of	O
the	O
effector	O
kinase	B
ROCK	B
and	O
acto	O
-	O
myosin	B
contraction	O
disrupts	O
AJs	O
downstream	O
of	O
Rho	B
.	O

In	O
contrast	O
,	O
signalling	O
through	O
the	O
Rho	B
effector	O
Dia1	B
is	O
required	O
to	O
ensure	O
a	O
dynamically	O
stable	O
interface	O
between	O
cells	O
and	O
the	O
maintenance	O
of	O
adherens	O
junction	O
complexes	O
.	O

The	O
ability	O
of	O
Dia1	B
to	O
regulate	O
the	O
actin	B
network	O
is	O
crucial	O
for	O
the	O
localization	O
of	O
adherens	O
junction	O
components	O
to	O
the	O
cell	O
periphery	O
.	O

Mutations	O
in	O
COL6A3	B
cause	O
severe	O
and	O
mild	O
phenotypes	O
of	O
Ullrich	O
congenital	O
muscular	O
dystrophy	O
.	O

Ullrich	O
congenital	O
muscular	O
dystrophy	O
(	O
UCMD	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
generalized	O
muscular	O
weakness	O
,	O
contractures	O
of	O
multiple	O
joints	O
,	O
and	O
distal	O
hyperextensibility	O
.	O

Homozygous	O
and	O
compound	O
heterozygous	O
mutations	O
of	O
COL6A2	B
on	O
chromosome	O
21q22	O
have	O
recently	O
been	O
shown	O
to	O
cause	O
UCMD	O
.	O

We	O
performed	O
a	O
genomewide	O
screening	O
with	O
microsatellite	O
markers	O
in	O
a	O
consanguineous	O
family	O
with	O
three	O
sibs	O
affected	O
with	O
UCMD	O
.	O

Linkage	O
of	O
the	O
disease	O
to	O
chromosome	O
2q37	O
was	O
found	O
in	O
this	O
family	O
and	O
in	O
two	O
others	O
.	O

We	O
analyzed	O
COL6A3	B
,	O
which	O
encodes	O
the	O
alpha3	B
chain	I
of	I
collagen	I
VI	I
,	O
and	O
identified	O
one	O
homozygous	O
mutation	O
per	O
family	O
.	O

In	O
family	O
I	O
,	O
the	O
three	O
sibs	O
carried	O
an	O
A	O
--	O
>	O
G	O
transition	O
in	O
the	O
splice	O
-	O
donor	O
site	O
of	O
intron	O
29	O
(	O
6930	O
+	O
5A	O
--	O
>	O
G	O
)	O
,	O
leading	O
to	O
the	O
skipping	O
of	O
exon	O
29	O
,	O
a	O
partial	O
reduction	O
of	O
collagen	B
VI	I
in	O
muscle	O
biopsy	O
,	O
and	O
an	O
intermediate	O
phenotype	O
.	O

In	O
family	O
II	O
,	O
the	O
patient	O
had	O
an	O
unusual	O
mild	O
phenotype	O
,	O
despite	O
a	O
nonsense	O
mutation	O
,	O
R465X	O
,	O
in	O
exon	O
5	O
.	O

Analysis	O
of	O
the	O
patient	O
's	O
COL6A3	B
transcripts	O
showed	O
the	O
presence	O
of	O
various	O
mRNA	O
species	O
-	O
one	O
of	O
which	O
lacked	O
several	O
exons	O
,	O
including	O
the	O
exon	O
containing	O
the	O
nonsense	O
mutation	O
.	O

The	O
deleted	O
splice	O
variant	O
encodes	O
collagen	B
molecules	O
that	O
have	O
a	O
shorter	O
N	O
-	O
terminal	O
domain	O
but	O
that	O
may	O
assemble	O
with	O
other	O
chains	O
and	O
retain	O
a	O
functional	O
role	O
.	O

This	O
could	O
explain	O
the	O
mild	O
phenotype	O
of	O
the	O
patient	O
who	O
was	O
still	O
ambulant	O
at	O
age	O
18	O
years	O
and	O
who	O
showed	O
an	O
unusual	O
combination	O
of	O
hyperlaxity	O
and	O
finger	O
contractures	O
.	O

In	O
family	O
III	O
,	O
the	O
patient	O
had	O
a	O
nonsense	O
mutation	O
,	O
R2342X	O
,	O
causing	O
absence	O
of	O
collagen	B
VI	I
in	O
muscle	O
and	O
fibroblasts	O
,	O
and	O
a	O
severe	O
phenotype	O
,	O
as	O
has	O
been	O
described	O
in	O
patients	O
with	O
UCMD	O
.	O

Mutations	O
in	O
COL6A3	B
are	O
described	O
in	O
UCMD	O
for	O
the	O
first	O
time	O
and	O
illustrate	O
the	O
wide	O
spectrum	O
of	O
phenotypes	O
which	O
can	O
be	O
caused	O
by	O
collagen	B
VI	I
deficiency	O
.	O

The	O
XAGE	B
family	I
of	O
cancer	O
/	O
testis	O
-	O
associated	O
genes	O
:	O
alignment	O
and	O
expression	O
profile	O
in	O
normal	O
tissues	O
,	O
melanoma	O
lesions	O
and	O
Ewing	O
's	O
sarcoma	O
.	O

The	O
existence	O
of	O
XAGE	B
genes	O
was	O
first	O
reported	O
after	O
database	O
homology	O
searches	O
for	O
PAGE	O
-	O
like	O
sequences	O
identified	O
3	O
XAGE	B
EST	O
clusters	O
.	O

One	O
of	O
these	O
clusters	O
,	O
XAGE-1	B
,	O
has	O
in	O
later	O
studies	O
been	O
identified	O
as	O
a	O
cancer	O
/	O
testis	O
-	O
associated	O
gene	O
.	O

Here	O
,	O
we	O
report	O
the	O
expression	O
profiles	O
of	O
all	O
3	O
reported	O
XAGE	B
genes	O
,	O
as	O
well	O
as	O
several	O
splice	O
variants	O
of	O
XAGE-1	B
,	O
in	O
normal	O
human	O
tissues	O
,	O
Ewing	O
's	O
sarcoma	O
and	O
melanocytic	O
tumors	O
.	O

We	O
also	O
provide	O
the	O
genetic	O
structure	O
of	O
the	O
corresponding	O
genes	O
.	O

Moreover	O
,	O
by	O
searching	O
the	O
databases	O
for	O
XAGE	B
homologues	O
,	O
we	O
identified	O
3	O
additional	O
GAGE	B
-	O
like	O
genes	O
.	O

RT	O
-	O
PCR	O
studies	O
showed	O
frequent	O
expression	O
in	O
melanoma	O
metastases	O
and	O
Ewing	O
's	O
sarcoma	O
for	O
2	O
XAGE-1	B
-	O
derived	O
transcripts	O
.	O

XAGE-2	B
was	O
expressed	O
at	O
lower	O
frequency	O
in	O
these	O
tissues	O
,	O
while	O
XAGE-3	B
was	O
seen	O
only	O
in	O
normal	O
placenta	O
.	O

Due	O
to	O
a	O
frameshift	O
,	O
the	O
largest	O
XAGE-1	B
putative	O
protein	O
is	O
far	O
less	O
homologous	O
to	O
GAGE	B
-	O
like	O
proteins	O
than	O
the	O
other	O
XAGEs	B
.	O

Interestingly	O
,	O
all	O
GAGE	B
-	O
like	O
genes	O
contain	O
a	O
large	O
secondary	O
open	O
reading	O
frame	O
,	O
coding	O
for	O
putative	O
proteins	O
homologues	O
to	O
the	O
XAGE-1	B
primary	O
protein	O
.	O

The	O
XAGE	B
family	I
of	O
cancer	O
/	O
testis	O
-	O
associated	O
genes	O
is	O
located	O
on	O
chromosome	O
Xp11.21	O
-	O
Xp11.22	O
.	O

The	O
data	O
outline	O
a	O
superfamily	B
of	I
GAGE	I
-	I
like	I
cancer	I
/	I
testis	I
antigens	I
,	O
consisting	O
of	O
at	O
least	O
19	O
genes	O
.	O

The	O
Tol	B
/	O
Pal	B
system	O
function	O
requires	O
an	O
interaction	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
TolA	B
and	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
TolB	B
.	O

The	O
Tol	B
/	O
Pal	B
system	O
of	O
Escherichia	O
coli	O
is	O
composed	O
of	O
the	O
YbgC	B
,	O
TolQ	B
,	O
TolA	B
,	O
TolR	B
,	O
TolB	B
,	O
Pal	B
and	O
YbgF	B
proteins	O
.	O

It	O
is	O
involved	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
outer	O
membrane	O
,	O
and	O
is	O
required	O
for	O
the	O
uptake	O
of	O
group	O
A	O
colicins	O
and	O
DNA	O
of	O
filamentous	O
bacteriophages	O
.	O

To	O
identify	O
new	O
interactions	O
between	O
the	O
components	O
of	O
the	O
Tol	B
/	O
Pal	B
system	O
and	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
colicin	O
import	O
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
using	O
the	O
different	O
components	O
of	O
the	O
Tol	B
/	O
Pal	B
system	O
and	O
colicin	O
A	O
.	O

Using	O
this	O
system	O
,	O
we	O
confirmed	O
the	O
already	O
known	O
interactions	O
and	O
identified	O
several	O
new	O
interactions	O
.	O

TolB	B
dimerizes	O
and	O
the	O
periplasmic	O
domain	O
of	O
TolA	B
interacts	O
with	O
YbgF	B
and	O
TolB	B
.	O

Our	O
results	O
indicate	O
that	O
the	O
central	O
domain	O
of	O
TolA	B
(	O
TolAII	O
)	O
is	O
sufficient	O
to	O
interact	O
with	O
YbgF	B
,	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
TolA	B
(	O
TolAIII	O
)	O
is	O
sufficient	O
to	O
interact	O
with	O
TolB	B
,	O
and	O
that	O
the	O
amino	O
terminal	O
domain	O
of	O
TolB	B
(	O
D1	O
)	O
is	O
sufficient	O
to	O
bind	O
TolAIII	O
.	O

The	O
TolA	B
/	O
TolB	B
interaction	O
was	O
confirmed	O
by	O
cross	O
-	O
linking	O
experiments	O
on	O
purified	O
proteins	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
interaction	O
between	O
TolA	B
and	O
TolB	B
is	O
required	O
for	O
the	O
uptake	O
of	O
colicin	O
A	O
and	O
for	O
the	O
membrane	O
integrity	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
TolA	B
/	O
TolB	B
interaction	O
allows	O
the	O
formation	O
of	O
a	O
trans	O
-	O
envelope	O
complex	O
that	O
brings	O
the	O
inner	O
and	O
outer	O
membranes	O
in	O
close	O
proximity	O
.	O

SHP-1	B
-	O
and	O
phosphotyrosine	O
-	O
independent	O
inhibitory	O
signaling	O
by	O
a	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
cytoplasmic	O
domain	O
in	O
human	O
NK	O
cells	O
.	O

Killer	B
cell	I
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
are	O
MHC	B
class	I
I	I
-	O
binding	O
immunoreceptors	O
that	O
can	O
suppress	O
activation	O
of	O
human	O
NK	O
cells	O
through	O
recruitment	O
of	O
the	O
Src	B
homology	I
2	I
-	I
containing	I
protein	I
tyrosine	I
phosphatase-1	I
(	O
SHP-1	B
)	O
to	O
two	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motifs	O
(	O
ITIMs	O
)	O
in	O
their	O
cytoplasmic	O
domains	O
.	O

KIR2DL4	B
(	O
2DL4	B
;	O
CD158d	B
)	O
is	O
a	O
structurally	O
distinct	O
member	O
of	O
the	O
KIR	B
family	I
,	O
which	O
is	O
expressed	O
on	O
most	O
,	O
if	O
not	O
all	O
,	O
human	O
NK	O
cells	O
.	O

2DL4	B
contains	O
only	O
one	O
ITIM	O
in	O
its	O
cytoplasmic	O
domain	O
and	O
an	O
arginine	O
in	O
its	O
transmembrane	O
region	O
,	O
suggesting	O
both	O
inhibitory	O
and	O
activating	O
functions	O
.	O

While	O
2DL4	B
can	O
activate	O
IFN	B
-	I
gamma	I
production	O
,	O
dependent	O
upon	O
the	O
transmembrane	O
arginine	O
,	O
the	O
function	O
of	O
the	O
single	O
ITIM	O
of	O
2DL4	B
remains	O
unknown	O
.	O

In	O
this	O
study	O
,	O
tandem	O
ITIMs	O
of	O
KIR3DL1	B
(	O
3DL1	B
)	O
and	O
the	O
single	O
ITIM	O
of	O
2DL4	B
were	O
directly	O
compared	O
in	O
functional	O
and	O
biochemical	O
assays	O
.	O

Using	O
a	O
retroviral	O
transduction	O
method	O
,	O
we	O
show	O
in	O
human	O
NK	O
cell	O
lines	O
that	O
1	O
)	O
the	O
single	O
ITIM	O
of	O
2DL4	B
efficiently	O
inhibits	O
natural	O
cytotoxicity	O
responses	O
;	O
2	O
)	O
the	O
phosphorylated	O
single	O
ITIM	O
recruits	O
SHP-2	B
protein	B
tyrosine	I
phosphatase	I
,	O
but	O
not	O
SHP-1	B
in	O
NK	O
cells	O
;	O
3	O
)	O
expression	O
of	O
dominant	O
-	O
negative	O
SHP-1	B
does	O
not	O
block	O
the	O
ability	O
of	O
2DL4	B
to	O
inhibit	O
natural	O
cytotoxicity	O
;	O
4	O
)	O
surprisingly	O
,	O
mutation	O
of	O
the	O
tyrosine	O
within	O
the	O
single	O
ITIM	O
does	O
not	O
completely	O
abolish	O
inhibitory	O
function	O
;	O
and	O
5	O
)	O
this	O
correlates	O
with	O
weak	O
SHP-2	B
binding	O
to	O
the	O
mutant	O
ITIM	O
of	O
2DL4	B
in	O
NK	O
cells	O
and	O
a	O
corresponding	O
nonphosphorylated	O
ITIM	O
peptide	O
in	O
vitro	O
.	O

These	O
results	O
reveal	O
new	O
aspects	O
of	O
the	O
KIR	B
-	O
inhibitory	O
pathway	O
in	O
human	O
NK	O
cells	O
,	O
which	O
are	O
SHP-1	B
and	O
phosphotyrosine	O
independent	O
.	O

Closing	O
in	O
on	O
the	O
biological	O
functions	O
of	O
Fps	B
/	O
Fes	B
and	O
Fer	B
.	O

Fps	B
/	O
Fes	B
and	O
Fer	B
are	O
the	O
only	O
known	O
members	O
of	O
a	O
distinct	O
subfamily	O
of	O
the	O
non	O
-	O
receptor	O
protein	B
-	I
tyrosine	I
kinase	I
family	I
.	O

Recent	O
studies	O
indicate	O
that	O
these	O
kinases	B
have	O
roles	O
in	O
regulating	O
cytoskeletal	O
rearrangements	O
and	O
inside	O
out	O
signalling	O
that	O
accompany	O
receptor	O
ligand	O
,	O
cell	O
matrix	O
and	O
cell	O
cell	O
interactions	O
.	O

Genetic	O
analysis	O
using	O
transgenic	O
mouse	O
models	O
also	O
implicates	O
these	O
kinases	B
in	O
the	O
regulation	O
of	O
inflammation	O
and	O
innate	O
immunity	O
.	O

Systematic	O
structure	O
-	O
function	O
analysis	O
of	O
the	O
small	B
GTPase	I
Arf1	B
in	O
yeast	O
.	O

Members	O
of	O
the	O
ADP	B
-	I
ribosylation	I
factor	I
(	I
Arf	I
)	I
family	I
of	O
small	B
GTPases	I
are	O
implicated	O
in	O
vesicle	O
traffic	O
in	O
the	O
secretory	O
pathway	O
,	O
although	O
their	O
precise	O
function	O
remains	O
unclear	O
.	O

We	O
generated	O
a	O
series	O
of	O
23	O
clustered	O
charge	O
-	O
to	O
-	O
alanine	O
mutations	O
in	O
the	O
Arf1	B
protein	O
of	O
Saccharomyces	O
cerevisiae	O
to	O
determine	O
the	O
portions	O
of	O
this	O
protein	O
important	O
for	O
its	O
function	O
in	O
cells	O
.	O

These	O
mutants	O
display	O
a	O
number	O
of	O
phenotypes	O
,	O
including	O
conditional	O
lethality	O
at	O
high	O
or	O
low	O
temperature	O
,	O
defects	O
in	O
glycosylation	O
of	O
invertase	B
,	O
dominant	O
lethality	O
,	O
fluoride	O
sensitivity	O
,	O
and	O
synthetic	O
lethality	O
with	O
the	O
arf2	B
null	O
mutation	O
.	O

All	O
mutations	O
were	O
mapped	O
onto	O
the	O
available	O
crystal	O
structures	O
for	O
Arf1p	B
:	O
Arf1p	B
bound	O
to	O
GDP	O
,	O
to	O
GTP	O
,	O
and	O
complexed	O
with	O
the	O
regulatory	O
proteins	O
ArfGEF	B
and	O
ArfGAP	B
.	O

From	O
this	O
systematic	O
structure	O
-	O
function	O
analysis	O
we	O
demonstrate	O
that	O
all	O
essential	O
mutations	O
studied	O
map	O
to	O
one	O
hemisphere	O
of	O
the	O
protein	O
and	O
provide	O
strong	O
evidence	O
in	O
support	O
of	O
the	O
proposed	O
ArfGEF	B
contact	O
site	O
on	O
Arf1p	B
but	O
minimal	O
evidence	O
in	O
support	O
of	O
the	O
proposed	O
ArfGAP	B
-	O
binding	O
site	O
.	O

In	O
addition	O
,	O
we	O
describe	O
the	O
isolation	O
of	O
a	O
spatially	O
distant	O
intragenic	O
suppressor	O
of	O
a	O
dominant	O
lethal	O
mutation	O
in	O
the	O
guanine	O
nucleotide	O
-	O
binding	O
region	O
of	O
Arf1p	B
.	O

Inactivating	O
mutations	O
of	O
CASP10	B
gene	O
in	O
non	O
-	O
Hodgkin	O
lymphomas	O
.	O

Caspase	B
10	I
(	O
Mch4	B
/	O
FLICE2	B
)	O
is	O
a	O
caspase	O
homologous	O
to	O
caspase	B
8	I
.	O

A	O
recent	O
report	O
described	O
that	O
inherited	O
CASP10	B
gene	O
mutations	O
underlie	O
defective	O
lymphocyte	O
and	O
dendritic	O
cell	O
apoptosis	O
in	O
autoimmune	O
lymphoproliferative	O
syndrome	O
(	O
ALPS	O
)	O
.	O

In	O
this	O
study	O
,	O
to	O
explore	O
the	O
possibility	O
that	O
mutation	O
of	O
this	O
gene	O
might	O
be	O
involved	O
in	O
the	O
development	O
of	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
,	O
we	O
have	O
analyzed	O
the	O
entire	O
coding	O
region	O
and	O
all	O
splice	O
sites	O
of	O
the	O
CASP10	B
gene	O
for	O
the	O
detection	O
of	O
somatic	O
mutations	O
in	O
117	O
human	O
NHLs	O
.	O

Overall	O
,	O
17	O
NHLs	O
(	O
14.5	O
%	O
)	O
were	O
found	O
to	O
have	O
CASP10	B
mutations	O
,	O
which	O
were	O
identified	O
in	O
the	O
coding	O
regions	O
of	O
the	O
prodomain	O
(	O
n	O
=	O
3	O
)	O
,	O
the	O
p17	O
large	O
protease	B
subunit	O
(	O
n	O
=	O
11	O
)	O
,	O
and	O
the	O
p12	O
small	O
protease	O
subunit	O
(	O
n	O
=	O
3	O
)	O
.	O

We	O
expressed	O
the	O
tumor	O
-	O
derived	O
caspase	B
10	I
mutants	O
in	O
293	O
cells	O
and	O
found	O
that	O
apoptosis	O
was	O
suppressed	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inactivating	O
mutations	O
of	O
the	O
CASP10	B
gene	O
might	O
lead	O
to	O
the	O
loss	O
of	O
its	O
apoptotic	O
function	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
some	O
human	O
NHLs	O
.	O

Systemic	O
effects	O
in	O
COPD	O
.	O

The	O
pathogenesis	O
and	O
clinical	O
manifestations	O
of	O
COPD	O
are	O
not	O
restricted	O
to	O
pulmonary	O
inflammation	O
and	O
structural	O
remodeling	O
.	O

Rather	O
,	O
this	O
disorder	O
is	O
associated	O
with	O
clinically	O
significant	O
systemic	O
alterations	O
in	O
biochemistry	O
and	O
organ	O
function	O
.	O

The	O
systemic	O
aspects	O
of	O
COPD	O
include	O
oxidative	O
stress	O
and	O
altered	O
circulating	O
levels	O
of	O
inflammatory	O
mediators	O
and	O
acute	O
-	O
phase	O
proteins	O
.	O

Indeed	O
,	O
an	O
impaired	O
endogenous	O
oxidant	O
-	O
antioxidant	O
balance	O
has	O
been	O
reported	O
in	O
patients	O
experiencing	O
exacerbations	O
of	O
COPD	O
,	O
and	O
others	O
have	O
observed	O
altered	O
circulating	O
levels	O
of	O
several	O
cytokines	B
and	O
adhesion	B
molecules	I
in	O
patients	O
with	O
stable	O
disease	O
.	O

As	O
in	O
other	O
chronic	O
inflammatory	O
conditions	O
,	O
weight	O
loss	O
,	O
muscle	O
wasting	O
,	O
and	O
tissue	O
depletion	O
are	O
commonly	O
seen	O
in	O
COPD	O
patients	O
.	O

Selective	O
wasting	O
of	O
fat	O
-	O
free	O
mass	O
coupled	O
with	O
impaired	O
respiratory	O
and	O
peripheral	O
muscle	O
function	O
and	O
a	O
reduced	O
capacity	O
for	O
exercise	O
occur	O
in	O
COPD	O
patients	O
.	O

Indeed	O
,	O
weight	O
loss	O
may	O
directly	O
impact	O
poor	O
prognosis	O
in	O
COPD	O
patients	O
.	O

The	O
mechanisms	O
underlying	O
weight	O
loss	O
and	O
muscle	O
wasting	O
are	O
incompletely	O
understood	O
but	O
likely	O
involve	O
an	O
imbalance	O
in	O
ongoing	O
processes	O
of	O
protein	O
degradation	O
and	O
replacement	O
.	O

This	O
may	O
include	O
alterations	O
in	O
the	O
relative	O
levels	O
or	O
activities	O
of	O
endocrine	O
hormones	O
such	O
as	O
insulin	B
,	O
growth	B
hormone	I
,	O
testosterone	O
,	O
and	O
glucocorticoids	O
.	O

Furthermore	O
,	O
chronic	O
systemic	O
inflammation	O
involving	O
cytokines	B
such	O
as	O
interleukin-1	B
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
may	O
be	O
associated	O
with	O
these	O
hormonal	O
changes	O
and	O
muscle	O
wasting	O
in	O
COPD	O
patients	O
.	O

This	O
review	O
includes	O
a	O
discussion	O
of	O
the	O
mechanisms	O
of	O
skeletal	O
muscle	O
fiber	O
protein	O
metabolism	O
/	O
catabolism	O
,	O
the	O
potential	O
roles	O
of	O
endogenous	O
cytokines	B
in	O
protein	O
loss	O
,	O
and	O
the	O
possibility	O
that	O
novel	O
drugs	O
that	O
inhibit	O
cytokine	B
signaling	O
may	O
provide	O
benefits	O
by	O
reducing	O
muscle	O
wasting	O
and	O
cachexia	O
,	O
thereby	O
improving	O
the	O
prognosis	O
and	O
quality	O
of	O
life	O
among	O
COPD	O
patients	O
.	O

Differences	O
in	O
the	O
regulation	O
of	O
the	O
classical	O
and	O
the	O
alternative	O
pathway	O
for	O
bile	O
acid	O
synthesis	O
in	O
human	O
liver	O
.	O

No	O
coordinate	O
regulation	O
of	O
CYP7A1	B
and	O
CYP27A1	B
.	O

It	O
has	O
been	O
reported	O
that	O
there	O
is	O
a	O
coordinate	O
regulation	O
of	O
sterol	B
27-hydroxylase	I
(	O
CYP27A1	B
)	O
and	O
cholesterol	B
7alpha	I
-	I
hydroxylase	I
(	O
CYP7A1	B
)	O
in	O
rats	O
.	O

Thus	O
,	O
the	O
levels	O
of	O
the	O
mRNA	O
corresponding	O
to	O
these	O
two	O
enzymes	O
were	O
found	O
to	O
change	O
in	O
the	O
same	O
direction	O
in	O
rat	O
liver	O
and	O
in	O
isolated	O
rat	O
hepatocytes	O
.	O

In	O
contrast	O
,	O
other	O
groups	O
have	O
not	O
seen	O
such	O
regulation	O
of	O
CYP27A1	B
in	O
rabbit	O
liver	O
or	O
in	O
rat	O
liver	O
when	O
using	O
an	O
activity	O
assay	O
.	O

In	O
the	O
present	O
work	O
,	O
the	O
effect	O
of	O
bile	O
acid	O
treatment	O
on	O
human	O
CYP27A1	B
/	O
luciferase	B
reporter	O
activity	O
was	O
studied	O
in	O
a	O
transient	O
transfection	O
assay	O
in	O
human	O
liver	O
-	O
derived	O
HepG2	O
cells	O
.	O

Neither	O
the	O
endogenous	O
27-hydroxylase	B
activity	O
nor	O
the	O
CYP27A1	B
/	O
luciferase	B
reporter	O
activity	O
were	O
down	O
-	O
regulated	O
by	O
treatment	O
of	O
HepG2	O
cells	O
with	O
chenodeoxycholic	O
acid	O
or	O
taurochenodeoxycholic	O
acid	O
.	O

We	O
also	O
measured	O
CYP27A1	B
mRNA	O
and	O
CYP7A1	B
mRNA	O
in	O
liver	O
of	O
humans	O
subjected	O
to	O
treatment	O
with	O
chenodeoxycholic	O
acid	O
,	O
ursodeoxycholic	O
acid	O
,	O
hydroxymethylglutaryl	B
(	I
HMG	I
)	I
-	I
CoA	I
reductase	I
inhibitor	O
and	O
a	O
combination	O
of	O
HMG	B
-	I
CoA	I
reductase	I
inhibitor	O
and	O
cholestyramine	O
.	O

There	O
was	O
a	O
60	O
-	O
fold	O
variation	O
in	O
the	O
levels	O
of	O
CYP7A1	B
mRNA	O
but	O
only	O
a	O
5	O
-	O
fold	O
variation	O
in	O
the	O
levels	O
of	O
CYP27A1	B
mRNA	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
two	O
mRNA	O
species	O
.	O

It	O
is	O
concluded	O
that	O
,	O
in	O
humans	O
,	O
there	O
is	O
little	O
or	O
no	O
coordinate	O
regulation	O
of	O
CYP7A1	B
and	O
CYP27A1	B
at	O
the	O
transcriptional	O
level	O
,	O
and	O
that	O
CYP27A1	B
is	O
not	O
subject	O
to	O
a	O
negative	O
feedback	O
control	O
by	O
bile	O
acids	O
.	O

The	O
results	O
underline	O
that	O
marked	O
species	O
differences	O
may	O
exist	O
in	O
mechanisms	O
for	O
control	O
of	O
synthesis	O
of	O
bile	O
acids	O
and	O
cholesterol	O
homeostasis	O
.	O

Extracellular	O
and	O
cytoplasmic	O
domains	O
of	O
endoglin	B
interact	O
with	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
receptors	I
I	I
and	I
II	I
.	O

Endoglin	B
is	O
an	O
auxiliary	O
component	O
of	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	I
TGF	I
-	I
beta	I
)	I
receptor	I
system	O
,	O
able	O
to	O
associate	O
with	O
the	O
signaling	O
receptor	O
types	O
I	O
(	O
TbetaRI	B
)	O
and	O
II	O
(	O
TbetaRII	B
)	O
in	O
the	O
presence	O
of	O
ligand	O
and	O
to	O
modulate	O
the	O
cellular	O
responses	O
to	O
TGF	B
-	I
beta1	I
.	O

Endoglin	B
can	O
not	O
bind	O
ligand	O
on	O
its	O
own	O
but	O
requires	O
the	O
presence	O
of	O
the	O
signaling	O
receptors	O
,	O
supporting	O
a	O
critical	O
role	O
for	O
the	O
interaction	O
between	O
endoglin	B
and	O
TbetaRI	B
or	O
TbetaRII	B
.	O

This	O
study	O
shows	O
that	O
full	O
-	O
length	O
endoglin	B
interacts	O
with	O
both	O
TbetaRI	B
and	O
TbetaRII	B
,	O
independently	O
of	O
their	O
kinase	B
activation	O
state	O
or	O
the	O
presence	O
of	O
exogenous	O
TGF	B
-	I
beta1	I
.	O

Truncated	O
constructs	O
encoding	O
either	O
the	O
extracellular	O
or	O
the	O
cytoplasmic	O
domains	O
of	O
endoglin	B
demonstrated	O
that	O
the	O
association	O
with	O
the	O
signaling	O
receptors	O
occurs	O
through	O
both	O
extracellular	O
and	O
cytoplasmic	O
domains	O
.	O

However	O
,	O
a	O
more	O
specific	O
mapping	O
revealed	O
that	O
the	O
endoglin	B
/	O
TbetaRI	B
interaction	O
was	O
different	O
from	O
that	O
of	O
endoglin	B
/	O
TbetaRII	B
.	O

TbetaRII	B
interacts	O
with	O
the	O
amino	O
acid	O
region	O
437	O
-	O
558	O
of	O
the	O
extracellular	O
domain	O
of	O
endoglin	B
,	O
whereas	O
TbetaRI	B
interacts	O
not	O
only	O
with	O
the	O
region	O
437	O
-	O
558	O
but	O
also	O
with	O
the	O
protein	O
region	O
located	O
between	O
amino	O
acid	O
437	O
and	O
the	O
N	O
terminus	O
.	O

Both	O
TbetaRI	B
and	O
TbetaRII	B
interact	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
endoglin	B
,	O
but	O
TbetaRI	B
only	O
interacts	O
when	O
the	O
kinase	B
domain	O
is	O
inactive	O
,	O
whereas	O
TbetaRII	B
remains	O
associated	O
in	O
its	O
active	O
and	O
inactive	O
forms	O
.	O

Upon	O
association	O
,	O
TbetaRI	B
and	O
TbetaRII	B
phosphorylate	O
the	O
endoglin	O
cytoplasmic	O
domain	O
,	O
and	O
then	O
TbetaRI	B
,	O
but	O
not	O
TbetaRII	B
,	O
kinase	B
dissociates	O
from	O
the	O
complex	O
.	O

Conversely	O
,	O
endoglin	B
expression	O
results	O
in	O
an	O
altered	O
phosphorylation	O
state	O
of	O
TbetaRII	B
,	O
TbetaRI	B
,	O
and	O
downstream	O
Smad	B
proteins	O
as	O
well	O
as	O
a	O
modulation	O
of	O
TGF	B
-	I
beta	I
signaling	O
,	O
as	O
measured	O
by	O
the	O
reporter	O
gene	O
expression	O
.	O

These	O
results	O
suggest	O
that	O
by	O
interacting	O
through	O
its	O
extracellular	O
and	O
cytoplasmic	O
domains	O
with	O
the	O
signaling	O
receptors	O
,	O
endoglin	O
might	O
affect	O
TGF	B
-	I
beta	I
responses	O
.	O

Analysis	O
of	O
human	O
cellular	B
retinol	I
-	I
binding	I
protein	I
II	I
promoter	O
during	O
enterocyte	O
differentiation	O
.	O

Cellular	B
retinol	I
binding	I
protein	I
II	I
(	O
CRBP	B
II	I
)	O
is	O
a	O
vitamin	O
A	O
-	O
binding	O
protein	O
that	O
is	O
expressed	O
specifically	O
in	O
small	O
intestinal	O
villus	O
absorptive	O
cells	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
retinoic	O
acid	O
upregulates	O
endogenous	O
human	O
CRBP	B
II	I
gene	O
expression	O
in	O
differentiated	O
Caco-2	O
cells	O
.	O

To	O
better	O
characterize	O
the	O
regulation	O
of	O
human	O
CRBP	B
II	I
expression	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
receptor	O
-	O
selective	O
agonists	O
to	O
enhance	O
transcription	O
from	O
the	O
5	O
'	O
-	O
upstream	O
flanking	O
region	O
of	O
the	O
human	O
CRBP	B
II	I
gene	O
.	O

Stable	O
transfection	O
experiments	O
showed	O
that	O
the	O
proximal	O
2.8	O
-	O
kb	O
region	O
of	O
the	O
human	O
CRBP	B
II	I
gene	O
is	O
sufficient	O
for	O
retinoic	O
acid	O
inducibility	O
in	O
differentiated	O
Caco-2	O
cells	O
.	O

However	O
,	O
direct	O
sequence	O
analysis	O
and	O
transient	O
transfection	O
experiments	O
indicate	O
that	O
,	O
unlike	O
the	O
rat	O
CRBP	B
II	I
promoter	O
,	O
the	O
human	O
CRBP	B
II	I
promoter	O
is	O
not	O
a	O
direct	O
retinoid	B
X	I
receptor	I
target	O
.	O

The	O
results	O
indicate	O
that	O
the	O
retinoic	O
acid	O
responsiveness	O
of	O
the	O
human	O
CRBP	B
II	I
promoter	O
is	O
mediated	O
by	O
an	O
indirect	O
mechanism	O
and	O
that	O
this	O
mechanism	O
is	O
associated	O
with	O
enterocyte	O
differentiation	O
.	O

PYPAF7	B
,	O
a	O
novel	O
PYRIN	B
-	I
containing	I
Apaf1	I
-	I
like	I
protein	I
that	O
regulates	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
caspase-1	B
-	O
dependent	O
cytokine	B
processing	O
.	O

PYRIN	B
-	I
containing	I
Apaf1	I
-	I
like	I
proteins	I
(	O
PYPAFs	B
)	O
are	O
members	O
of	O
the	O
nucleotide	B
-	I
binding	I
site	I
/	I
leucine	I
-	I
rich	I
repeat	I
(	I
NBS	I
/	I
LRR	I
)	I
family	I
of	O
signal	O
transduction	O
proteins	O
.	O

We	O
report	O
here	O
that	O
PYPAF7	B
is	O
a	O
novel	O
PYPAF	B
protein	O
that	O
activates	O
inflammatory	O
signaling	O
pathways	O
.	O

The	O
expression	O
of	O
PYPAF7	B
is	O
highly	O
restricted	O
to	O
immune	O
cells	O
,	O
and	O
its	O
gene	O
maps	O
to	O
chromosome	O
19q13.4	O
,	O
a	O
locus	O
that	O
contains	O
a	O
cluster	O
of	O
genes	O
encoding	O
numerous	O
PYPAF	B
family	I
members	O
.	O

Co	O
-	O
expression	O
of	O
PYPAF7	B
with	O
ASC	B
results	O
in	O
the	O
recruitment	O
of	O
PYPAF7	B
to	O
distinct	O
cytoplasmic	O
loci	O
and	O
a	O
potent	O
synergistic	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O

To	O
identify	O
other	O
proteins	O
involved	O
in	O
PYPAF7	B
and	O
ASC	B
signaling	O
pathways	O
,	O
we	O
performed	O
a	O
mammalian	O
two	O
-	O
hybrid	O
screen	O
and	O
identified	O
pro	O
-	O
caspase-1	B
as	O
a	O
binding	O
partner	O
of	O
ASC	B
.	O

Co	O
-	O
expression	O
of	O
PYPAF7	B
and	O
ASC	B
results	O
in	O
the	O
synergistic	O
activation	O
of	O
caspase-1	B
and	O
a	O
corresponding	O
increase	O
in	O
secretion	O
of	O
interleukin-1	B
beta	I
.	O

In	O
addition	O
,	O
PYPAF1	B
induces	O
caspase-1	B
-	O
dependent	O
cytokine	B
processing	O
when	O
co	O
-	O
expressed	O
with	O
ASC	B
.	O

These	O
findings	O
indicate	O
that	O
PYPAF	B
family	I
members	O
participate	O
in	O
inflammatory	O
signaling	O
by	O
regulating	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
cytokine	B
processing	O
.	O

Expression	O
of	O
somatostatin	B
receptor	I
types	I
1	I
-	I
5	I
in	O
81	O
cases	O
of	O
gastrointestinal	O
and	O
pancreatic	O
endocrine	O
tumors	O
.	O

A	O
correlative	O
immunohistochemical	O
and	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Somatostatin	B
receptors	I
(	O
SSTRs	B
)	O
have	O
been	O
extensively	O
mapped	O
in	O
human	O
tumors	O
by	O
means	O
of	O
autoradiography	O
,	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
and	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

We	O
analyzed	O
the	O
SSTR	B
type	I
1	I
-	I
5	I
expression	O
by	O
means	O
of	O
RT	O
-	O
PCR	O
and/or	O
IHC	O
in	O
a	O
series	O
of	O
81	O
functioning	O
and	O
non	O
-	O
functioning	O
gastroenteropancreatic	O
(	O
GEP	O
)	O
endocrine	O
tumors	O
and	O
related	O
normal	O
tissues	O
.	O

Moreover	O
,	O
we	O
compared	O
the	O
results	O
with	O
clinical	O
,	O
pathological	O
and	O
hormonal	O
features	O
.	O

Forty	O
-	O
six	O
cases	O
(	O
13	O
intestinal	O
and	O
33	O
pancreatic	O
)	O
were	O
studied	O
for	O
SSTR	B
1	I
-	I
5	I
expression	O
using	O
RT	O
-	O
PCR	O
,	O
IHC	O
with	O
antibodies	O
to	O
SSTR	B
types	I
2	I
,	I
3	I
,	I
5	I
and	O
ISH	O
for	O
SSTR2	B
mRNA	O
.	O

The	O
vast	O
majority	O
of	O
tumors	O
expressed	O
SSTR	B
types	I
1	I
,	I
2	I
,	I
3	I
and	I
5	I
,	O
while	O
SSTR4	B
was	O
detected	O
in	O
a	O
small	O
minority	O
.	O

Due	O
to	O
the	O
good	O
correlation	O
between	O
RT	O
-	O
PCR	O
and	O
IHC	O
data	O
on	O
SSTR	B
types	I
2	I
,	I
3	I
,	I
and	I
5	I
,	O
thirty	O
-	O
five	O
additional	O
GEP	O
endocrine	O
tumors	O
were	O
studied	O
with	O
IHC	O
alone	O
.	O

Pancreatic	O
insulinomas	O
had	O
an	O
heterogeneous	O
SSTR	B
expression	O
,	O
while	O
100	O
%	O
of	O
somatostatinomas	O
expressed	O
SSTR5	B
and	O
100	O
%	O
gastrinomas	O
and	O
glucagonomas	O
expressed	O
SSTR2	B
.	O

Pre	O
-	O
operative	O
biopsy	O
material	O
showed	O
an	O
overlapping	O
immunoreactivity	O
with	O
that	O
of	O
surgical	O
specimens	O
,	O
suggesting	O
that	O
the	O
SSTR	B
status	O
can	O
be	O
detected	O
in	O
the	O
diagnostic	O
work	O
-	O
up	O
.	O

It	O
is	O
concluded	O
that	O
SSTRs	B
1	I
-	I
5	I
are	O
heterogeneously	O
expressed	O
in	O
GEP	O
endocrine	O
tumors	O
and	O
that	O
IHC	O
is	O
a	O
reliable	O
tool	O
to	O
detect	O
SSTR	B
types	I
2	I
,	I
3	I
and	I
5	I
in	O
surgical	O
and	O
biopsy	O
specimens	O
.	O

Cardiotrophin-1	B
and	O
urocortin	B
cause	O
protection	O
by	O
the	O
same	O
pathway	O
and	O
hypertrophy	O
via	O
distinct	O
pathways	O
in	O
cardiac	O
myocytes	O
.	O

Cardiotrophin-1	B
(	O
CT-1	B
)	O
is	O
an	O
Interleukin-6	B
family	I
cytokine	I
with	O
known	O
hypertrophic	O
and	O
protective	O
effects	O
in	O
cardiac	O
cells	O
.	O

CT-1	B
and	O
the	O
corticotrophin	B
releasing	I
hormone	I
-	O
like	O
hormone	O
urocortin	B
protect	O
cardiac	O
myocytes	O
by	O
the	O
same	O
p42	B
/	I
44	I
mitogen	I
activated	I
protein	I
kinase	I
(	O
p42	B
/	I
44	I
MAPK	I
)	O
dependent	O
pathway	O
.	O

We	O
investigated	O
whether	O
urocortin	O
is	O
also	O
hypertrophic	O
in	O
cardiac	O
myocytes	O
and	O
whether	O
it	O
shares	O
a	O
common	O
pathway	O
with	O
CT-1	B
for	O
this	O
effect	O
.	O

Moreover	O
,	O
we	O
also	O
investigated	O
,	O
for	O
the	O
first	O
time	O
whether	O
CT-1	B
and	O
urocortin	B
can	O
induce	O
hypertrophy	O
in	O
cultured	O
adult	O
as	O
opposed	O
to	O
neonatal	O
cardiac	O
cells	O
.	O

Urocortin	O
and	O
CT-1	B
caused	O
hypertrophy	O
(	O
as	O
measured	O
by	O
an	O
increase	O
in	O
cell	O
area	O
and	O
enhanced	O
protein	O
:	O
DNA	O
ratio	O
)	O
in	O
both	O
adult	O
and	O
neonatal	O
rat	O
cultured	O
cardiac	O
myocytes	O
.	O

The	O
hypertrophic	O
effect	O
of	O
CT-1	B
was	O
dependent	O
on	O
the	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
STAT3	B
)	O
pathway	O
but	O
the	O
hypertrophic	O
effect	O
of	O
urocortin	O
was	O
independent	O
of	O
this	O
pathway	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
the	O
protective	O
p42	B
/	I
p44	I
MAPK	I
pathway	O
has	O
no	O
effect	O
on	O
the	O
hypertrophic	O
effect	O
of	O
CT-1	B
or	O
urocortin	O
.	O

Additionally	O
,	O
inhibition	O
of	O
the	O
STAT3	B
pathway	O
has	O
no	O
effect	O
on	O
the	O
protective	O
effect	O
of	O
CT-1	B
or	O
urocortin	O
.	O

These	O
results	O
identify	O
urocortin	B
as	O
a	O
novel	O
hypertrophic	O
and	O
protective	O
agent	O
whose	O
hypertrophic	O
effect	O
is	O
mediated	O
by	O
a	O
distinct	O
pathway	O
to	O
that	O
activated	O
by	O
CT-1	B
,	O
although	O
the	O
two	O
factors	O
mediate	O
protection	O
via	O
the	O
same	O
pathway	O
.	O

Mutation	O
analysis	O
of	O
the	O
PIG	B
-	I
A	I
gene	O
in	O
Korean	O
patients	O
with	O
paroxysmal	O
nocturnal	O
haemoglobinuria	O
.	O

AIM	O
:	O

Paroxysmal	O
nocturnal	O
haemoglobinuria	O
(	O
PNH	O
)	O
is	O
caused	O
by	O
deficient	O
biosynthesis	O
of	O
the	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchor	O
in	O
haemopoietic	O
stem	O
cells	O
.	O

Mutation	O
of	O
the	O
phosphatidylinositol	B
glycan	I
class	I
A	I
(	O
PIG	B
-	I
A	I
)	O
gene	O
,	O
an	O
X	O
linked	O
gene	O
that	O
participates	O
in	O
the	O
first	O
step	O
of	O
GPI	O
anchor	O
biosynthesis	O
,	O
is	O
responsible	O
for	O
PNH	O
.	O

The	O
characteristics	O
of	O
somatic	O
mutation	O
of	O
the	O
PIG	B
-	I
A	I
gene	O
in	O
Korean	O
patients	O
with	O
PNH	O
were	O
studied	O
.	O

METHODS	O
:	O

Twenty	O
four	O
patients	O
with	O
PNH	O
were	O
selected	O
.	O

Ham	O
tests	O
and	O
sucrose	O
haemolysis	O
tests	O
were	O
carried	O
out	O
on	O
all	O
patients	O
.	O

The	O
expression	O
of	O
CD59	B
in	O
erythrocytes	O
and	O
granulocytes	O
was	O
investigated	O
in	O
14	O
and	O
five	O
patients	O
,	O
respectively	O
,	O
to	O
confirm	O
the	O
diagnosis	O
.	O

Dideoxy	O
fingerprinting	O
(	O
ddF	O
)	O
was	O
used	O
to	O
screen	O
mutations	O
,	O
and	O
direct	O
sequencing	O
of	O
DNA	O
was	O
performed	O
to	O
characterise	O
the	O
mutations	O
.	O

RESULTS	O
:	O

Gene	O
mutation	O
was	O
detected	O
in	O
12	O
of	O
the	O
24	O
patients	O
.	O

The	O
other	O
12	O
patients	O
were	O
negative	O
in	O
ddF	O
screening	O
.	O

Ten	O
new	O
mutations	O
and	O
two	O
known	O
mutations	O
were	O
detected	O
.	O

The	O
mutations	O
consisted	O
of	O
five	O
deletions	O
,	O
six	O
substitutions	O
,	O
and	O
one	O
insertion	O
.	O

These	O
mutations	O
resulted	O
in	O
six	O
premature	O
terminations	O
,	O
three	O
abnormal	O
splicings	O
,	O
one	O
missense	O
mutation	O
in	O
exon	O
2	O
,	O
and	O
two	O
nonsense	O
mutations	O
.	O

Two	O
patients	O
with	O
venous	O
thrombosis	O
showed	O
mutations	O
in	O
exon	O
3	O
only	O
.	O

Substitution	O
mutations	O
were	O
seen	O
in	O
six	O
patients	O
and	O
frameshift	O
mutations	O
in	O
the	O
other	O
six	O
.	O

CONCLUSIONS	O
:	O

There	O
were	O
10	O
new	O
mutations	O
among	O
the	O
12	O
mutations	O
in	O
the	O
Korean	O
patients	O
with	O
PNH	O
and	O
the	O
characteristics	O
of	O
the	O
mutations	O
varied	O
,	O
with	O
no	O
significant	O
hot	O
spots	O
in	O
sites	O
or	O
types	O
.	O

CK2	B
-	O
dependent	O
phosphorylation	O
of	O
the	O
E2	B
ubiquitin	I
conjugating	I
enzyme	I
UBC3B	B
induces	O
its	O
interaction	O
with	O
beta	B
-	I
TrCP	I
and	O
enhances	O
beta	B
-	I
catenin	I
degradation	O
.	O

Protein	B
kinase	I
CK2	B
is	O
a	O
ubiquitous	O
and	O
pleiotropic	O
Ser	B
/	I
Thr	I
protein	I
kinase	I
involved	O
in	O
cell	O
growth	O
and	O
transformation	O
.	O

Here	O
we	O
report	O
the	O
identification	O
by	O
yeast	O
interaction	O
trap	O
of	O
a	O
CK2	B
interacting	O
protein	O
,	O
UBC3B	B
,	O
which	O
is	O
highly	O
homologous	O
to	O
the	O
E2	B
ubiquitin	I
conjugating	I
enzyme	I
UBC3	B
/	O
CDC34	B
.	O

UBC3B	B
complements	O
the	O
yeast	O
cdc34	B
-	I
2	I
cell	O
cycle	O
arrest	O
mutant	O
in	O
S.	O
cerevisiae	O
and	O
transfers	O
ubiquitin	O
to	O
a	O
target	O
substrate	O
in	O
vitro	O
.	O

UBC3B	B
is	O
specifically	O
phosphorylated	O
by	O
CK2	B
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
mapped	O
by	O
deletions	O
and	O
site	O
directed	O
mutagenesis	O
the	O
phosphorylation	O
site	O
to	O
a	O
serine	O
residue	O
within	O
the	O
C	O
-	O
terminal	O
domain	O
in	O
position	O
233	O
of	O
UBC3B	B
and	O
in	O
the	O
corresponding	O
serine	O
residue	O
of	O
UBC3	B
.	O

Following	O
CK2	B
-	O
dependent	O
phosphorylation	O
both	O
UBC3B	B
and	O
UBC3	B
bind	O
to	O
the	O
F	O
-	O
box	O
protein	O
beta	B
-	I
TrCP	I
,	O
the	O
substrate	O
recognition	O
subunit	O
of	O
an	O
SCF	O
(	O
Skp1	B
,	O
Cul1	B
,	O
F	B
-	I
box	I
)	O
ubiquitin	B
ligase	I
.	O

Furthermore	O
,	O
we	O
observed	O
that	O
co	O
-	O
transfection	O
of	O
CK2alpha	B
'	I
together	O
with	O
UBC3B	B
,	O
but	O
not	O
with	O
UBC3DeltaC	B
,	O
enhances	O
the	O
degradation	O
of	O
beta	B
-	I
catenin	I
.	O

Taken	O
together	O
these	O
data	O
suggest	O
that	O
CK2	B
-	O
dependent	O
phosphorylation	O
of	O
UBC3	B
and	O
UBC3B	B
functions	O
by	O
regulating	O
beta	B
-	I
TrCP	I
substrate	O
recognition	O
.	O

Acute	O
effects	O
of	O
acephate	O
and	O
methamidophos	O
and	O
interleukin-1	B
on	O
corticotropin	B
-	I
releasing	I
factor	I
(	O
CRF	B
)	O
synthesis	O
in	O
and	O
release	O
from	O
the	O
hypothalamus	O
in	O
vitro	O
.	O

Acute	O
effects	O
of	O
Ace	O
,	O
Meth	O
and	O
IL-1	B
on	O
AChE	B
activity	O
,	O
ACh	O
and	O
CRF	B
mRNA	O
levels	O
in	O
,	O
and	O
CRF	B
-	O
release	O
from	O
the	O
hypothalamus	O
were	O
studied	O
in	O
vitro	O
.	O

The	O
hypothalamus	O
samples	O
were	O
dissected	O
from	O
the	O
rat	O
brain	O
and	O
were	O
incubated	O
in	O
vitro	O
with	O
IL-1	B
,	O
Ace	O
or	O
Meth	O
in	O
the	O
presence	O
or	O
absence	O
of	O
Dex	O
,	O
Atrop	O
,	O
PTL	O
,	O
PROP	O
and	O
GABA	O
.	O

Ace	O
and	O
Meth	O
,	O
but	O
not	O
IL-1	B
,	O
inhibited	O
AChE	B
activity	O
,	O
while	O
all	O
three	O
compounds	O
;	O
(	O
1	O
)	O
increased	O
ACh	O
and	O
CRF	B
mRNA	O
levels	O
in	O
and	O
CRF	B
release	O
from	O
;	O
(	O
2	O
)	O
activated	O
the	O
CRE	O
promoter	O
region	O
of	O
CRF	B
-	O
gene	O
in	O
:	O
and	O
(	O
3	O
)	O
increased	O
cFos	B
binding	O
to	O
the	O
AP-1	B
region	O
of	O
the	O
CRF	B
-	O
gene	O
in	O
the	O
hypothalamus	O
.	O

Dex	O
suppressed	O
the	O
effects	O
of	O
IL-1	B
,	O
possibly	O
by	O
inducing	O
the	O
nGRE	O
regulatory	O
sites	O
of	O
the	O
CRF	B
-	O
gene	O
.	O

Dex	O
,	O
however	O
,	O
did	O
not	O
modulate	O
the	O
effects	O
of	O
Ace	O
and	O
Meth	O
on	O
the	O
hypothalamus	O
,	O
which	O
may	O
be	O
attributed	O
to	O
the	O
failure	O
of	O
Dex	O
to	O
modulate	O
the	O
CRF	B
-	O
gene	O
'	O
s	O
nGRE	O
regulatory	O
sites	O
.	O

Atrop	O
caused	O
80	O
-	O
90	O
%	O
inhibition	O
of	O
the	O
effects	O
of	O
IL-1	B
,	O
but	O
caused	O
only	O
50	O
-	O
65	O
%	O
inhibition	O
of	O
the	O
effects	O
of	O
Ace	O
or	O
Meth	O
on	O
CRF	B
mRNA	O
levels	O
in	O
and	O
CRF	B
release	O
from	O
the	O
hypothalamus	O
.	O

PTL	O
did	O
not	O
affect	O
,	O
while	O
PROP	O
slightly	O
attenuated	O
the	O
effects	O
of	O
IL-1	B
and	O
the	O
insecticides	O
on	O
the	O
hypothalamus	O
.	O

GABA	O
attenuated	O
the	O
effects	O
of	O
the	O
insecticides	O
but	O
not	O
the	O
effects	O
of	O
IL-1	B
on	O
the	O
hypothalamus	O
.	O

This	O
suggests	O
that	O
the	O
IL-1	B
-	O
induced	O
augmentation	O
of	O
CRF	B
synthesis	O
in	O
and	O
release	O
from	O
the	O
hypothalamus	O
is	O
mediated	O
through	O
a	O
cholinergic	O
pathway	O
,	O
while	O
the	O
insecticide	O
-	O
induced	O
augmentation	O
of	O
CRF	B
synthesis	O
in	O
and	O
release	O
from	O
the	O
hypothalamus	O
is	O
mediated	O
through	O
the	O
cholinergic	O
and	O
GABAergic	O
pathways	O
.	O

The	O
insecticides	O
,	O
but	O
not	O
IL-1	B
,	O
disrupt	O
feedback	O
regulation	O
of	O
CRF	B
synthesis	O
in	O
and	O
release	O
from	O
the	O
hypothalamus	O
.	O

Significance	O
of	O
the	O
parkin	B
gene	O
and	O
protein	O
in	O
understanding	O
Parkinson	O
's	O
disease	O
.	O

Mutations	O
in	O
the	O
parkin	B
gene	O
cause	O
autosomal	O
recessive	O
inherited	O
juvenile	O
parkinsonism	O
(	O
ARJP	O
)	O
and	O
account	O
for	O
the	O
majority	O
of	O
cases	O
of	O
inherited	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
of	O
young	O
onset	O
(	O
<	O
45	O
years	O
of	O
age	O
)	O
.	O

Patients	O
with	O
parkin	B
mutations	O
commonly	O
have	O
atypical	O
clinical	O
features	O
such	O
as	O
dystonia	O
at	O
onset	O
,	O
hyper	O
-	O
reflexia	O
,	O
diurnal	O
fluctuations	O
,	O
and	O
sleep	O
benefit	O
;	O
however	O
,	O
parkin	B
mutation	O
patients	O
with	O
both	O
typical	O
PD	O
symptoms	O
and	O
older	O
age	O
of	O
onset	O
have	O
been	O
identified	O
.	O

Parkin	B
is	O
a	O
ubiquitin	B
protein	I
ligase	I
(	I
E3	I
)	I
,	O
a	O
component	O
in	O
the	O
pathway	O
that	O
attaches	O
ubiquitin	B
to	O
specific	O
proteins	O
,	O
designating	O
them	O
for	O
degradation	O
by	O
the	O
proteasome	O
.	O

Several	O
substrates	O
for	O
parkin	B
have	O
been	O
identified	O
(	O
CDCrel-1	B
,	O
o	O
-	O
glycosylated	O
alpha	B
-	I
synuclein	I
,	O
parkin	B
associated	I
endothelin	I
-	I
like	I
cell	I
receptor	I
,	O
and	O
synphilin	B
)	O
.	O

The	O
role	O
of	O
these	O
substrates	O
in	O
the	O
pathogenesis	O
of	O
ARJP	O
is	O
under	O
active	O
study	O
.	O

Most	O
patients	O
with	O
parkin	B
mutations	O
lack	O
Lewy	O
bodies	O
,	O
suggesting	O
that	O
functional	O
parkin	B
is	O
involved	O
in	O
the	O
formation	O
of	O
these	O
highly	O
ubiquitinated	O
inclusions	O
.	O

Furthermore	O
,	O
the	O
recognition	O
that	O
parkin	B
mutations	O
can	O
lead	O
to	O
a	O
disorder	O
clinically	O
similar	O
to	O
sporadic	O
PD	O
,	O
but	O
presumably	O
lacking	O
Lewy	O
bodies	O
,	O
calls	O
into	O
question	O
the	O
necessity	O
of	O
Lewy	O
bodies	O
for	O
the	O
diagnosis	O
of	O
PD	O
and	O
nigral	O
cell	O
death	O
.	O

Studies	O
of	O
parkin	B
are	O
increasing	O
the	O
focus	O
on	O
the	O
role	O
of	O
the	O
ubiquitin	B
-	O
proteasome	O
system	O
in	O
the	O
pathogenesis	O
of	O
both	O
familial	O
and	O
sporadic	O
PD	O
.	O

Normalization	O
of	O
natural	O
killer	O
cell	O
function	O
and	O
phenotype	O
with	O
effective	O
anti	O
-	O
HIV	O
therapy	O
and	O
the	O
role	O
of	O
IL-10	B
.	O

OBJECTIVES	O
:	O

Natural	O
killer	O
(	O
NK	O
)	O
cell	O
function	O
is	O
likely	O
to	O
be	O
important	O
in	O
controlling	O
HIV	O
infection	O
and	O
opportunistic	O
pathogens	O
.	O

We	O
therefore	O
evaluated	O
NK	O
function	O
and	O
phenotype	O
over	O
the	O
course	O
of	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
and	O
examined	O
the	O
potential	O
mechanisms	O
of	O
altered	O
NK	O
activity	O
in	O
HIV	O
infection	O
.	O

METHODS	O
:	O

We	O
measured	O
NK	O
cell	O
percentage	O
,	O
NK	O
cytolytic	O
activity	O
(	O
both	O
by	O
flow	O
cytometry	O
)	O
and	O
plasma	O
IL-10	B
concentrations	O
(	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
)	O
in	O
10	O
HIV	O
-	O
seropositive	O
patients	O
before	O
and	O
over	O
one	O
year	O
of	O
effective	O
ART	O
.	O

To	O
examine	O
potential	O
mechanisms	O
of	O
altered	O
NK	O
activity	O
,	O
we	O
measured	O
NK	O
receptor	O
expression	O
in	O
ART	O
treated	O
and	O
untreated	O
HIV	O
-	O
positive	O
individuals	O
by	O
flow	O
cytometry	O
.	O

As	O
IL-10	B
enhances	O
NK	O
activity	O
,	O
we	O
studied	O
the	O
effect	O
of	O
IL-10	B
on	O
NK	O
receptor	O
expression	O
and	O
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
HIV	O
-	O
seronegative	O
individuals	O
.	O

RESULTS	O
:	O

NK	O
cytolytic	O
activity	O
was	O
elevated	O
in	O
HIV	O
infection	O
and	O
decreased	O
with	O
ART	O
to	O
levels	O
observed	O
in	O
HIV	O
-	O
negative	O
individuals	O
.	O

A	O
greater	O
proportion	O
of	O
NK	O
cells	O
from	O
untreated	O
HIV	O
-	O
positive	O
individuals	O
expressed	O
the	O
NK	O
receptors	O
CD158a	B
and	O
CD161	B
than	O
either	O
HIV	O
-	O
negative	O
volunteers	O
or	O
effectively	O
treated	O
HIV	O
-	O
positive	O
patients	O
.	O

NK	O
cells	O
from	O
PBMC	O
incubated	O
with	O
IL-10	B
demonstrated	O
increases	O
in	O
CD158a	B
,	O
CD161	B
and	O
CD94	B
expression	O
and	O
increases	O
in	O
cytolytic	O
activity	O
.	O

The	O
treatment	O
-	O
associated	O
decrease	O
in	O
NK	O
activity	O
paralleled	O
a	O
decrease	O
in	O
IL-10	B
production	O
.	O

CONCLUSION	O
:	O

The	O
observation	O
that	O
IL-10	B
alters	O
NK	O
receptor	O
expression	O
similar	O
to	O
that	O
observed	O
in	O
HIV	O
infection	O
,	O
and	O
the	O
fact	O
that	O
NK	O
receptor	O
expression	O
and	O
activity	O
normalize	O
in	O
parallel	O
with	O
ART	O
-	O
induced	O
reduction	O
of	O
circulating	O
IL-10	B
levels	O
supports	O
a	O
role	O
for	O
IL-10	B
in	O
NK	O
cell	O
activity	O
and	O
HIV	O
immunopathogenesis	O
.	O

BAG-1	B
,	O
an	O
anti	O
-	O
apoptotic	O
tumour	O
marker	O
.	O

BAG-1	B
is	O
a	O
multifunctional	O
and	O
anti	O
-	O
apoptotic	O
or	O
anti	O
-	O
cell	O
death	O
protein	O
that	O
interacts	O
with	O
a	O
variety	O
of	O
cellular	O
proteins	O
and	O
affects	O
their	O
functions	O
.	O

On	O
the	O
cell	O
surface	O
,	O
it	O
binds	O
to	O
the	O
cytosolic	O
domain	O
of	O
the	O
growth	B
factor	I
receptors	I
and	O
enhances	O
the	O
protection	O
from	O
cell	O
death	O
triggered	O
by	O
growth	B
factor	I
receptors	I
.	O

In	O
the	O
cytosol	O
,	O
it	O
binds	O
to	O
Bcl-2	B
and	O
heat	B
shock	I
protein	I
,	O
and	O
modulates	O
their	O
functions	O
.	O

In	O
the	O
nucleus	O
,	O
it	O
binds	O
to	O
a	O
variety	O
of	O
nuclear	B
hormone	I
receptors	I
and	O
inhibits	O
hormone	O
-	O
induced	O
apoptosis	O
.	O

BAG-1	B
is	O
widely	O
overexpressed	O
in	O
a	O
variety	O
of	O
tumour	O
cell	O
lines	O
and	O
cancer	O
tissues	O
.	O

In	O
addition	O
,	O
differential	O
expression	O
of	O
BAG-1	B
isoforms	O
has	O
been	O
observed	O
.	O

Preclinical	O
studies	O
indicate	O
that	O
overexpression	O
of	O
BAG-1	B
,	O
especially	O
its	O
nuclear	O
and	O
cytoplasmic	O
isoforms	O
,	O
may	O
be	O
useful	O
as	O
a	O
prognostic	O
and/or	O
predictive	O
biomarker	O
.	O

Pilot	O
clinical	O
studies	O
have	O
demonstrated	O
that	O
overexpression	O
of	O
nuclear	O
BAG-1	B
may	O
be	O
associated	O
with	O
a	O
shorter	O
survival	O
in	O
breast	O
and	O
laryngeal	O
carcinomas	O
.	O

Conversely	O
,	O
overexpression	O
of	O
cytoplasmic	O
BAG-1	B
may	O
be	O
associated	O
with	O
a	O
better	O
clinical	O
outcome	O
in	O
early	O
stage	O
breast	O
cancer	O
and	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Further	O
large	O
-	O
scale	O
clinical	O
studies	O
are	O
warranted	O
to	O
establish	O
the	O
role	O
of	O
BAG-1	B
as	O
a	O
novel	O
prognostic	O
and/or	O
predictive	O
biomarker	O
in	O
the	O
clinical	O
management	O
of	O
these	O
common	O
malignancies	O
.	O

Identification	O
of	O
the	O
bacteria	O
-	O
binding	O
peptide	O
domain	O
on	O
salivary	O
agglutinin	B
(	O
gp-340	B
/	O
DMBT1	B
)	O
,	O
a	O
member	O
of	O
the	O
scavenger	B
receptor	I
cysteine	I
-	I
rich	I
superfamily	I
.	O

Salivary	O
agglutinin	B
is	O
encoded	O
by	O
DMBT1	B
and	O
identical	O
to	O
gp-340	B
,	O
a	O
member	O
of	O
the	O
scavenger	B
receptor	I
cysteine	I
-	I
rich	I
(	I
SRCR	I
)	I
superfamily	I
.	O

Salivary	O
agglutinin	B
/	O
DMBT1	B
is	O
known	O
for	O
its	O
Streptococcus	O
mutans	O
agglutinating	O
properties	O
.	O

This	O
300	O
-	O
400	O
kDa	O
glycoprotein	O
is	O
composed	O
of	O
conserved	O
peptide	O
motifs	O
:	O
14	O
SRCR	B
domains	O
that	O
are	O
separated	O
by	O
SRCR	B
-	O
interspersed	O
domains	O
(	O
SIDs	O
)	O
,	O
2	O
CUB	O
(	O
C1r	B
/	O
C1s	B
Uegf	B
Bmp1	B
)	O
domains	O
,	O
and	O
a	O
zona	O
pellucida	O
domain	O
.	O

We	O
have	O
searched	O
for	O
the	O
peptide	O
domains	O
of	O
agglutinin	B
/	O
DMBT1	B
responsible	O
for	O
bacteria	O
binding	O
.	O

Digestion	O
with	O
endoproteinase	B
Lys	B
-	I
C	I
resulted	O
in	O
a	O
protein	O
fragment	O
containing	O
exclusively	O
SRCR	B
and	O
SID	O
domains	O
that	O
binds	O
to	O
S.	O
mutans	O
.	O

To	O
define	O
more	O
closely	O
the	O
S.	O
mutans	O
-	O
binding	O
domain	O
,	O
consensus	O
-	O
based	O
peptides	O
of	O
the	O
SRCR	B
domains	O
and	O
SIDs	O
were	O
designed	O
and	O
synthesized	O
.	O

Only	O
one	O
of	O
the	O
SRCR	B
peptides	O
,	O
designated	O
SRCRP2	O
,	O
and	O
none	O
of	O
the	O
SID	O
peptides	O
bound	O
to	O
S.	O
mutans	O
.	O

Strikingly	O
,	O
this	O
peptide	O
was	O
also	O
able	O
to	O
induce	O
agglutination	O
of	O
S.	O
mutans	O
and	O
a	O
number	O
of	O
other	O
bacteria	O
.	O

The	O
repeated	O
presence	O
of	O
this	O
peptide	O
in	O
the	O
native	O
molecule	O
endows	O
agglutinin	B
/	O
DMBT1	B
with	O
a	O
general	O
bacterial	O
binding	O
feature	O
with	O
a	O
multivalent	O
character	O
.	O

Moreover	O
,	O
our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
the	O
polymorphic	O
SRCR	B
domains	O
of	O
salivary	O
agglutinin	B
/	O
DMBT1	B
mediate	O
ligand	O
interactions	O
.	O

Yeast	O
Ysl2p	B
,	O
homologous	O
to	O
Sec7	B
domain	O
guanine	B
nucleotide	I
exchange	I
factors	I
,	O
functions	O
in	O
endocytosis	O
and	O
maintenance	O
of	O
vacuole	O
integrity	O
and	O
interacts	O
with	O
the	O
Arf	B
-	I
Like	I
small	I
GTPase	I
Arl1p	B
.	O

We	O
previously	O
described	O
the	O
isolation	O
of	O
ysl2	B
-	I
1	I
due	O
to	O
its	O
genetic	O
interaction	O
with	O
Delta	O
ypt51	B
/	O
vps21	B
,	O
a	O
mutant	O
with	O
a	O
deletion	O
of	O
the	O
coding	O
sequence	O
for	O
the	O
yeast	O
Rab5	B
homolog	O
,	O
which	O
regulates	O
endocytic	O
traffic	O
between	O
early	O
and	O
late	O
endosomes	O
.	O

Here	O
we	O
report	O
that	O
Ysl2p	B
is	O
a	O
novel	O
186.8	O
-	O
kDa	O
peripheral	O
membrane	O
protein	O
homologous	O
to	O
members	O
of	O
the	O
Sec7	B
family	I
.	O

We	O
provide	O
multiple	O
genetic	O
and	O
biochemical	O
evidence	O
for	O
an	O
interaction	O
between	O
Ysl12p	B
and	O
the	O
Arf	B
-	I
like	I
protein	I
Arl1p	B
,	O
consistent	O
with	O
a	O
potential	O
function	O
as	O
an	O
Arf	B
guanine	I
nucleotide	I
exchange	I
factor	I
(	I
GEF	I
)	I
.	O

The	O
temperature	O
-	O
sensitive	O
alleles	O
ysl2	B
-	O
307	O
and	O
ysl2	B
-	O
316	O
are	O
specifically	O
defective	O
in	O
ligand	O
-	O
induced	O
degradation	O
of	O
Ste2p	B
and	O
alpha	B
-	I
factor	I
and	O
exhibit	O
vacuole	O
fragmentation	O
directly	O
upon	O
a	O
shift	O
to	O
37	O
degrees	O
C	O
.	O

In	O
living	O
cells	O
,	O
green	B
fluorescent	I
protein	I
(	O
GFP	B
)	O
-	O
Ysl2p	B
colocalizes	O
with	O
endocytic	O
elements	O
that	O
accumulate	O
FM4	O
-	O
64	O
.	O

The	O
GFP	B
-	O
Ysl2p	B
staining	O
is	O
sensitive	O
to	O
a	O
mutation	O
in	O
VPS27	B
resulting	O
in	O
the	O
formation	O
of	O
an	O
aberrant	O
class	O
E	O
compartment	O
,	O
but	O
it	O
is	O
not	O
affected	O
by	O
a	O
sec7	B
mutation	O
.	O

Consistent	O
with	O
the	O
idea	O
that	O
Ysl2p	B
and	O
Arl1p	B
have	O
closely	O
related	O
functions	O
,	O
Delta	O
arl1	B
cells	O
are	O
defective	O
in	O
endocytic	O
transport	O
and	O
in	O
vacuolar	O
protein	O
sorting	O
.	O

Expression	O
of	O
the	O
Musashi1	B
gene	O
encoding	O
the	O
RNA	O
-	O
binding	O
protein	O
in	O
human	O
hepatoma	O
cell	O
lines	O
.	O

Musashi1	B
,	O
a	O
neural	O
RNA	O
-	O
binding	O
protein	O
,	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
cell	O
differentiation	O
in	O
precursor	O
cells	O
.	O

Recently	O
,	O
expression	O
of	O
Musashi1	B
has	O
been	O
detected	O
in	O
human	O
tumor	O
tissues	O
such	O
as	O
gliomas	O
and	O
melanomas	O
,	O
suggesting	O
its	O
involvement	O
in	O
oncogenic	O
development	O
.	O

To	O
determine	O
any	O
association	O
between	O
Musashi1	B
and	O
the	O
development	O
of	O
liver	O
cancer	O
,	O
we	O
investigated	O
its	O
gene	O
expression	O
in	O
seven	O
human	O
hepatoma	O
cell	O
lines	O
:	O
HuH6	O
,	O
HuH7	O
,	O
Hep3B	O
,	O
SK	O
-	O
Hep1	O
,	O
HepG2	O
,	O
HLE	O
,	O
and	O
HLF	O
.	O

Musashi1	B
mRNA	O
expression	O
was	O
analyzed	O
using	O
the	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and	O
the	O
PCR	O
products	O
were	O
sequenced	O
using	O
a	O
subcloning	O
procedure	O
.	O

Musashi1	B
protein	O
expression	O
was	O
analyzed	O
in	O
HuH7	O
and	O
HepG2	O
cells	O
by	O
Western	O
blot	O
and	O
immunofluorescence	O
staining	O
.	O

Musashi1	B
mRNA	O
was	O
detected	O
in	O
the	O
HuH6	O
,	O
HuH7	O
,	O
and	O
Hep3B	O
hepatoma	O
cell	O
lines	O
,	O
but	O
not	O
in	O
the	O
others	O
.	O

Sequencing	O
of	O
the	O
PCR	O
-	O
amplified	O
Musashi1	B
cDNA	O
in	O
these	O
three	O
cell	O
lines	O
showed	O
the	O
expected	O
sequence	O
of	O
the	O
human	O
Musashi1	B
gene	O
.	O

Musashi1	B
protein	O
expression	O
was	O
confirmed	O
in	O
HuH7	O
cells	O
,	O
which	O
were	O
positive	O
for	O
Musashi1	B
mRNA	O
expression	O
,	O
but	O
not	O
in	O
HepG2	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
Musashi1	B
expression	O
may	O
be	O
an	O
important	O
factor	O
in	O
the	O
development	O
of	O
several	O
types	O
of	O
carcinoma	O
such	O
as	O
human	O
hepatoma	O
,	O
and	O
may	O
be	O
a	O
useful	O
molecular	O
marker	O
for	O
tumor	O
detection	O
.	O

Chromosomal	O
organization	O
and	O
localization	O
of	O
the	O
human	O
histone	B
deacetylase	I
9	I
gene	O
(	O
HDAC9	B
)	O
.	O

Epigenetically	O
mediated	O
modulation	O
of	O
gene	O
promoter	O
function	O
through	O
histone	O
acetylation	O
modifying	O
enzymes	O
,	O
which	O
regulate	O
the	O
acetylation	O
state	O
of	O
histone	B
proteins	O
and	O
other	O
promoter	O
-	O
bound	O
transcription	B
factors	I
,	O
is	O
increasingly	O
appreciated	O
as	O
a	O
key	O
component	O
in	O
the	O
regulation	O
of	O
reversible	O
gene	O
expression	O
.	O

While	O
histone	B
acetyltransferases	I
(	O
HATs	B
)	O
,	O
which	O
are	O
frequently	O
part	O
of	O
multisubunit	O
coactivator	O
complexes	O
,	O
lead	O
to	O
the	O
relaxation	O
of	O
chromatin	O
structure	O
and	O
transcriptional	O
activation	O
,	O
histone	B
deacetylases	I
(	O
HDACs	B
)	O
tend	O
to	O
associate	O
with	O
multisubunit	O
corepressor	O
complexes	O
,	O
which	O
result	O
in	O
chromatin	O
condensation	O
and	O
transcriptional	O
repression	O
of	O
specific	O
target	O
genes	O
.	O

We	O
have	O
isolated	O
and	O
characterized	O
the	O
human	O
HDAC9	B
genomic	O
sequence	O
,	O
which	O
spans	O
a	O
region	O
of	O
458	O
kb	O
and	O
which	O
has	O
one	O
single	O
chromosomal	O
locus	O
.	O

Determination	O
of	O
the	O
exon	O
-	O
intron	O
splice	O
-	O
junctions	O
established	O
that	O
HDAC9	B
is	O
encoded	O
by	O
23	O
exons	O
ranging	O
in	O
size	O
from	O
22	O
bp	O
(	O
exon	O
1	O
)	O
to	O
264	O
bp	O
(	O
exon	O
11	O
)	O
.	O

Characterization	O
of	O
the	O
5	O
'	O
flanking	O
genomic	O
region	O
revealed	O
that	O
the	O
human	O
HDAC9	B
promoter	O
lacks	O
both	O
the	O
canonical	O
TATA	O
and	O
CCAAT	O
boxes	O
;	O
CpG	O
elements	O
are	O
missing	O
.	O

The	O
human	O
HDAC9	B
open	O
reading	O
frame	O
is	O
3036	O
bp	O
long	O
and	O
encodes	O
a	O
1011	O
aa	O
protein	O
with	O
a	O
predictive	O
molecular	O
weight	O
of	O
111.3	O
kDa	O
and	O
an	O
isoelectric	O
point	O
of	O
6.41	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
analysis	O
localized	O
the	O
human	O
HDAC9	B
gene	O
to	O
chromosome	O
7p21	O
,	O
a	O
region	O
which	O
has	O
been	O
associated	O
particularly	O
with	O
the	O
pathogenesis	O
of	O
gynecological	O
tumors	O
.	O

Phospholipase	B
C	I
-	I
beta	I
2	I
interacts	O
with	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
3	I
.	O

Phospholipase	B
C	I
(	I
PLC	I
)	I
-	I
beta	I
enzymes	O
(	O
isoenzymes	O
beta	O
1-beta	O
4	O
)	O
are	O
activated	O
by	O
G	B
protein	I
subunits	O
,	O
leading	O
to	O
the	O
generation	O
of	O
intracellular	O
messengers	O
which	O
mobilize	O
calcium	O
and	O
activate	O
protein	B
kinase	I
C	I
.	O

It	O
has	O
recently	O
been	O
recognized	O
that	O
these	O
enzymes	O
interact	O
with	O
and	O
are	O
regulated	O
by	O
proteins	O
other	O
than	O
G	B
proteins	I
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
technique	O
to	O
screen	O
a	O
leukocyte	O
library	O
we	O
identified	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
3	I
(	O
MKK3	B
)	O
as	O
a	O
partner	O
of	O
PLC	B
-	I
beta	I
2	I
.	O

The	O
interaction	O
was	O
confirmed	O
by	O
co	O
-	O
immunoprecipitation	O
assays	O
which	O
indicated	O
that	O
MKK3	B
interacts	O
with	O
PLC	B
-	I
beta	I
2	I
,	O
but	O
not	O
with	O
other	O
PLC	B
-	I
betas	I
.	O

PLC	B
-	I
beta	I
2	I
interacted	O
weakly	O
with	O
MKK6	B
,	O
which	O
is	O
related	O
to	O
MKK3	B
,	O
but	O
not	O
with	O
the	O
other	O
MKK3	B
tested	O
.	O

The	O
region	O
of	O
PLC	B
-	I
beta	I
2	I
involved	O
in	O
the	O
interaction	O
with	O
MKK3	B
was	O
mapped	O
to	O
the	O
C	O
-	O
terminus	O
of	O
PLC	B
-	I
beta	I
2	I
.	O

p38MAPK	B
also	O
co	O
-	O
immunoprecipitated	O
with	O
PLC	B
-	I
beta	I
2	I
.	O

The	O
data	O
suggest	O
that	O
PLC	B
-	I
beta	I
2	I
serves	O
an	O
unappreciated	O
role	O
assembling	O
components	O
of	O
the	O
p38MAPK	B
signaling	O
module	O
.	O

Differential	O
regulation	O
of	O
multiple	O
proteins	O
of	O
Escherichia	O
coli	O
and	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
by	O
the	O
transcriptional	O
regulator	O
SlyA	B
.	O

SlyA	B
is	O
a	O
transcriptional	O
regulator	O
of	O
Escherichia	O
coli	O
,	O
Salmonella	O
enterica	O
,	O
and	O
other	O
bacteria	O
belonging	O
to	O
the	O
ENTEROBACTERIACEAE	O
:	O

The	O
SlyA	B
protein	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
virulence	O
of	O
S.	O
enterica	O
serovar	O
Typhimurium	O
,	O
but	O
its	O
role	O
in	O
E.	O
coli	O
is	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
the	O
proteome	O
technology	O
to	O
analyze	O
the	O
SlyA	B
regulons	O
of	O
enteroinvasive	O
E.	O
coli	O
(	O
EIEC	O
)	O
and	O
Salmonella	O
serovar	O
Typhimurium	O
.	O

In	O
both	O
cases	O
,	O
comparative	O
analysis	O
of	O
the	O
two	O
-	O
dimensional	O
protein	O
maps	O
of	O
a	O
wild	O
-	O
type	O
strain	O
,	O
a	O
SlyA	B
-	O
overproducing	O
derivative	O
,	O
and	O
a	O
corresponding	O
slyA	B
mutant	O
revealed	O
numerous	O
proteins	O
whose	O
expression	O
appeared	O
to	O
be	O
either	O
positively	O
or	O
negatively	O
controlled	O
by	O
SlyA	B
.	O

Twenty	O
of	O
the	O
putative	O
SlyA	B
-	O
induced	O
proteins	O
and	O
13	O
of	O
the	O
putative	O
SlyA	B
-	O
repressed	O
proteins	O
of	O
the	O
tested	O
EIEC	O
strain	O
were	O
identified	O
by	O
mass	O
spectrometry	O
.	O

The	O
former	O
proteins	O
included	O
several	O
molecular	O
chaperones	O
(	O
GroEL	B
,	O
GroES	B
,	O
DnaK	B
,	O
GrpE	B
,	O
and	O
CbpA	B
)	O
,	O
proteins	O
involved	O
in	O
acid	O
resistance	O
(	O
HdeA	B
,	O
HdeB	B
,	O
and	O
GadA	B
)	O
,	O
the	O
""""	O
starvation	O
lipoprotein	O
""""	O
(	O
Slp	B
)	O
,	O
cytolysin	O
ClyA	B
(	O
HlyE	B
or	O
SheA	B
)	O
,	O
and	O
several	O
enzymes	O
involved	O
in	O
metabolic	O
pathways	O
,	O
whereas	O
most	O
of	O
the	O
latter	O
proteins	O
proved	O
to	O
be	O
biosynthetic	O
enzymes	O
.	O

Consistently	O
,	O
the	O
resistance	O
of	O
the	O
EIEC	O
slyA	B
mutant	O
to	O
heat	O
and	O
acid	O
stress	O
was	O
impaired	O
compared	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
strain	O
.	O

Furthermore	O
,	O
the	O
implication	O
of	O
SlyA	B
in	O
the	O
regulation	O
of	O
several	O
of	O
the	O
identified	O
E.	O
coli	O
proteins	O
was	O
confirmed	O
at	O
the	O
level	O
of	O
transcription	O
with	O
lacZ	B
fusions	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
Salmonella	O
serovar	O
Typhimurium	O
proteins	O
found	O
to	O
be	O
affected	O
by	O
SlyA	B
were	O
also	O
identified	O
by	O
mass	O
spectrometry	O
.	O

With	O
the	O
exception	O
of	O
GroEL	B
these	O
differed	O
from	O
those	O
identified	O
in	O
the	O
EIEC	O
strain	O
and	O
included	O
proteins	O
involved	O
in	O
various	O
processes	O
.	O

The	O
data	O
suggest	O
that	O
gene	O
regulation	O
by	O
SlyA	B
might	O
be	O
crucial	O
for	O
intracellular	O
survival	O
and/or	O
replication	O
of	O
both	O
EIEC	O
and	O
Salmonella	O
serovar	O
Typhimurium	O
in	O
phagocytic	O
host	O
cells	O
.	O

Coexpression	O
of	O
oncostatin	B
M	I
and	O
its	O
receptors	O
and	O
evidence	O
for	O
STAT3	B
activation	O
in	O
human	O
ovarian	O
carcinomas	O
.	O

The	O
expression	O
of	O
oncostatin	B
M	I
and	O
leukemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
,	O
JAK	B
-	O
STAT	B
activators	O
and	O
members	O
of	O
the	O
interleukin-6	B
family	I
of	I
cytokines	I
,	O
were	O
examined	O
in	O
a	O
series	O
of	O
primary	O
ovarian	O
carcinomas	O
using	O
immunohistochemistry	O
.	O

The	O
malignant	O
epithelial	O
cells	O
of	O
all	O
29	O
ovarian	O
carcinomas	O
examined	O
expressed	O
oncostatin	B
M	I
;	O
none	O
expressed	O
LIF	B
.	O

Oncostatin	B
M	I
can	O
activate	O
two	O
related	O
receptors	O
,	O
one	O
consisting	O
of	O
a	O
low	O
-	O
affinity	O
LIF	B
receptor	I
subunit	O
,	O
LIFR	B
beta	O
,	O
which	O
forms	O
a	O
heterocomplex	O
with	O
the	O
gp130	B
signal	O
transducing	O
protein	O
and	O
can	O
recognize	O
both	O
oncostatin	B
M	I
and	O
LIF	B
,	O
and	O
a	O
second	O
heterocomplex	O
consisting	O
of	O
a	O
subunit	O
that	O
specifically	O
recognizes	O
oncostatin	B
M	I
,	O
OSMR	B
beta	I
,	O
and	O
the	O
gp130	B
protein	O
.	O

By	O
immunohistochemistry	O
,	O
25	O
of	O
25	O
ovarian	O
carcinomas	O
examined	O
expressed	O
the	O
LIFR	B
beta	O
subunit	O
in	O
the	O
malignant	O
epithelial	O
cells	O
(	O
all	O
samples	O
express	O
gp130	B
)	O
,	O
and	O
two	O
-	O
thirds	O
the	O
ovarian	O
carcinomas	O
studied	O
expressed	O
OSMR	B
beta	I
mRNA	O
as	O
determined	O
by	O
RT	O
-	O
PCR	O
.	O

Thus	O
oncostatin	B
M	I
and	O
its	O
receptors	O
are	O
commonly	O
coexpressed	O
in	O
malignant	O
ovarian	O
epithelial	O
cells	O
,	O
and	O
represent	O
a	O
potential	O
autocrine	O
loop	O
in	O
this	O
tumor	O
type	O
.	O

STAT3	B
,	O
of	O
one	O
the	O
signaling	O
proteins	O
downstream	O
of	O
the	O
oncostatin	B
M	I
/	I
LIF	I
receptors	I
,	O
was	O
found	O
in	O
its	O
phosphorylated	O
,	O
activated	O
form	O
(	O
phosphotyrosine	O
705	O
STAT3	B
)	O
in	O
the	O
malignant	O
epithelial	O
cells	O
of	O
17	O
of	O
23	O
ovarian	O
carcinomas	O
examined	O
(	O
74	O
%	O
)	O
as	O
determined	O
by	O
immunohistochemistry	O
;	O
this	O
suggests	O
that	O
this	O
protein	O
is	O
constitutively	O
activated	O
in	O
most	O
ovarian	O
carcinomas	O
,	O
as	O
it	O
is	O
in	O
many	O
other	O
human	O
malignancies	O
.	O

Recombinant	O
human	O
Oncostatin	B
M	I
(	O
rhOSM	B
)	O
can	O
induce	O
the	O
transient	O
tyrosine	O
705	O
phosphorylation	O
of	O
STAT3	B
in	O
serum	O
-	O
starved	O
LIFR	B
beta	O
/	O
OSMR	B
beta	I
expressing	O
ovarian	O
carcinoma	O
cell	O
lines	O
,	O
but	O
does	O
not	O
alter	O
cell	O
growth	O
and	O
effects	O
only	O
a	O
modest	O
increase	O
in	O
the	O
apoptotic	O
rate	O
in	O
these	O
cultured	O
cells	O
.	O

Oncostatin	B
M	I
and	I
its	O
receptors	O
may	O
be	O
part	O
of	O
a	O
network	O
of	O
cytokine	B
systems	O
within	O
ovarian	O
carcinomas	O
that	O
may	O
act	O
to	O
maintain	O
STAT3	B
in	O
its	O
activated	O
form	O
,	O
a	O
phenomenon	O
associated	O
with	O
the	O
malignant	O
phenotype	O
.	O

The	O
dystrophin	B
gene	O
is	O
alternatively	O
spliced	O
throughout	O
its	O
coding	O
sequence	O
.	O

We	O
have	O
analysed	O
splicing	O
patterns	O
in	O
the	O
human	O
dystrophin	B
gene	O
region	O
encoding	O
the	O
rod	O
and	O
cysteine	O
-	O
rich	O
domains	O
in	O
normal	O
skeletal	O
muscle	O
,	O
brain	O
and	O
heart	O
tissues	O
.	O

Sixteen	O
novel	O
alternative	O
transcripts	O
were	O
identified	O
,	O
the	O
majority	O
of	O
them	O
being	O
present	O
in	O
all	O
three	O
tissues	O
.	O

Tissue	O
-	O
specific	O
variants	O
were	O
also	O
identified	O
,	O
suggesting	O
a	O
functional	O
role	O
of	O
transcriptional	O
diversity	O
.	O

Transcript	O
analysis	O
in	O
dystrophinopathic	O
autoptic	O
and	O
bioptic	O
specimens	O
revealed	O
that	O
pre	O
-	O
mRNAs	O
secondary	O
structure	O
formation	O
and	O
relative	O
strength	O
of	O
exon	O
/	O
exon	O
association	O
play	O
little	O
or	O
no	O
role	O
in	O
directing	O
alternative	O
splicing	O
events	O
.	O

This	O
analysis	O
also	O
showed	O
that	O
independent	O
deletion	O
events	O
leading	O
to	O
the	O
loss	O
of	O
the	O
same	O
exons	O
may	O
be	O
associated	O
with	O
transcriptional	O
variability	O
.	O

14	B
-	I
3	I
-	I
3	I
proteins	I
in	O
Schistosoma	O
mansoni	O
;	O
identification	O
of	O
a	O
second	O
epsilon	O
isoform	O
.	O

A	O
new	O
member	O
of	O
the	O
14	B
-	I
3	I
-	I
3	I
protein	I
family	I
in	O
Schistosoma	O
mansoni	O
has	O
been	O
identified	O
.	O

Sequence	O
analysis	O
demonstrated	O
that	O
this	O
protein	O
is	O
a	O
member	O
of	O
the	O
epsilon	O
sub	O
-	O
group	O
and	O
is	O
the	O
orthologue	O
of	O
Schistosoma	O
japonicum	O
14	B
-	I
3	I
-	I
3epsilon	I
.	O

Since	O
we	O
had	O
previously	O
identified	O
a	O
14	B
-	I
3	I
-	I
3epsilon	I
protein	O
from	O
S.	O
mansoni	O
,	O
we	O
termed	O
the	O
original	O
protein	O
14	B
-	I
3	I
-	I
3epsilon-1	I
and	O
this	O
second	O
epsilon	O
protein	O
14	B
-	I
3	I
-	I
3epsilon-2	I
.	O

Schistosoma	O
mansoni	O
encodes	O
at	O
least	O
four	O
different	O
14	B
-	I
3	I
-	I
3	I
isoforms	O
:	O
the	O
two	O
epsilon	O
proteins	O
and	O
14	B
-	I
3	I
-	I
3	I
protein	I
1	I
and	I
protein	I
2	I
,	O
which	O
are	O
zeta	O
-	O
like	O
isoforms	O
.	O

Phylogenetic	O
analysis	O
demonstrated	O
the	O
early	O
divergence	O
of	O
the	O
epsilon	O
isoforms	O
,	O
and	O
that	O
schistosome	O
proteins	O
1	O
and	O
2	O
are	O
among	O
the	O
oldest	O
non	O
-	O
epsilon	O
14	B
-	I
3	I
-	I
3	I
proteins	I
yet	O
identified	O
.	O

Schistosoma	O
mansoni	O
14	B
-	I
3	I
-	I
3epsilon-1	I
,	O
14	B
-	I
3	I
-	I
3epsilon-2	I
,	O
and	O
protein	O
1	O
are	O
stage	O
specifically	O
expressed	O
in	O
a	O
similar	O
manner	O
,	O
being	O
absent	O
in	O
cercariae	O
and	O
schistosomula	O
,	O
and	O
abundant	O
in	O
lung	O
stage	O
and	O
adult	O
male	O
and	O
female	O
worms	O
.	O

Protein	O
2	O
transcript	O
was	O
not	O
detected	O
at	O
any	O
of	O
the	O
life	O
cycle	O
stages	O
examined	O
.	O

All	O
three	O
detected	O
14	B
-	I
3	I
-	I
3	I
isoforms	O
elicit	O
an	O
immune	O
response	O
during	O
infection	O
,	O
with	O
the	O
greatest	O
response	O
directed	O
against	O
protein	O
1	O
.	O

Binding	O
studies	O
with	O
S.	O
mansoni	O
receptor	B
kinase-1	I
(	O
SmRK1	B
)	O
and	O
human	O
Raf	B
kinase	I
revealed	O
that	O
the	O
three	O
14	B
-	I
3	I
-	I
3epsilon	I
isoforms	O
exhibit	O
a	O
preference	O
for	O
target	O
protein	O
binding	O
.	O

Although	O
all	O
three	O
isoforms	O
do	O
bind	O
to	O
both	O
targets	O
,	O
14	B
-	I
3	I
-	I
3	I
protein	I
1	I
interacts	O
most	O
strongly	O
with	O
Raf	B
,	O
whereas	O
the	O
14	B
-	I
3	I
-	I
3	I
-	I
1	I
isoform	O
binds	O
SmRK1	B
preferentially	O
.	O

These	O
results	O
suggest	O
that	O
the	O
individual	O
14	B
-	I
3	I
-	I
3	I
proteins	I
may	O
have	O
evolved	O
to	O
play	O
isoform	O
-	O
specific	O
roles	O
in	O
the	O
development	O
and	O
survival	O
of	O
S.	O
mansoni	O
within	O
its	O
host	O
.	O

Cryo	O
-	O
electron	O
microscopy	O
of	O
trichocyte	O
(	O
hard	O
alpha	B
-	I
keratin	I
)	O
intermediate	O
filaments	O
reveals	O
a	O
low	O
-	O
density	O
core	O
.	O

Trichocyte	O
intermediate	O
filaments	O
(	O
IF	O
)	O
are	O
the	O
principal	O
components	O
of	O
epidermal	O
appendages	O
such	O
as	O
hair	O
and	O
nail	O
.	O

Based	O
on	O
studies	O
by	O
a	O
variety	O
of	O
techniques	O
,	O
it	O
has	O
been	O
inferred	O
that	O
trichocyte	O
IF	O
are	O
structurally	O
similar	O
to	O
other	O
kinds	O
of	O
IF	O
.	O

However	O
,	O
some	O
basic	O
structural	O
attributes	O
have	O
yet	O
to	O
be	O
established	O
:	O
in	O
particular	O
,	O
it	O
has	O
remained	O
unclear	O
whether	O
IF	O
are	O
hollow	O
.	O

We	O
have	O
examined	O
trichocyte	O
IF	O
isolated	O
from	O
rat	O
vibrissae	O
and	O
human	O
hair	O
follicles	O
by	O
electron	O
microscopy	O
.	O

Scanning	O
transmission	O
electron	O
microscopy	O
of	O
freeze	O
-	O
dried	O
specimens	O
yielded	O
mass	O
-	O
per	O
-	O
unit	O
-	O
length	O
values	O
of	O
approximately	O
32	O
kDa	O
/	O
nm	O
,	O
with	O
the	O
human	O
preparations	O
also	O
containing	O
filaments	O
at	O
half	O
this	O
density	O
,	O
corresponding	O
to	O
two	O
rather	O
than	O
four	O
protofibrils	O
.	O

Radial	O
density	O
profiles	O
calculated	O
from	O
cryo	O
-	O
electron	O
micrographs	O
of	O
vitrified	O
specimens	O
preserved	O
in	O
a	O
near	O
-	O
native	O
state	O
revealed	O
a	O
low	O
-	O
density	O
region	O
of	O
approximately	O
3	O
nm	O
diameter	O
around	O
the	O
filament	O
axis	O
.	O

A	O
minor	O
species	O
of	O
filament	O
with	O
the	O
same	O
internal	O
structure	O
was	O
surface	O
-	O
decorated	O
with	O
material	O
arranged	O
with	O
a	O
helical	O
pitch	O
length	O
of	O
9.3	O
nm	O
.	O

These	O
filaments	O
appear	O
to	O
represent	O
IF	O
coated	O
with	O
associated	O
proteins	O
-	O
perhaps	O
,	O
""""	O
high	O
-	O
sulfur	O
""""	O
proteins	O
-	O
readied	O
for	O
incorporation	O
into	O
the	O
filament	O
-	O
matrix	O
biocomposite	O
of	O
the	O
mature	O
hair	O
.	O

Aberrant	O
methylation	O
of	O
the	O
CDH13	B
(	O
H	B
-	I
cadherin	I
)	O
promoter	O
region	O
in	O
colorectal	O
cancers	O
and	O
adenomas	O
.	O

Expression	O
of	O
the	O
cadherin	B
family	I
member	O
CDH13	B
(	O
H	B
-	I
cadherin	I
)	O
is	O
reduced	O
in	O
several	O
human	O
tumors	O
,	O
and	O
it	O
has	O
been	O
hypothesized	O
that	O
this	O
gene	O
functions	O
as	O
a	O
tumor	O
suppressor	O
gene	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
the	O
5	O
'	O
region	O
of	O
CDH13	B
is	O
frequently	O
methylated	O
in	O
breast	O
and	O
lung	O
cancers	O
.	O

Here	O
we	O
confirmed	O
the	O
promoter	O
activity	O
of	O
5	O
'	O
region	O
of	O
CDH13	B
by	O
luciferase	B
assay	O
and	O
examined	O
its	O
aberrant	O
methylation	O
in	O
colorectal	O
cancers	O
,	O
cell	O
lines	O
,	O
and	O
adenomas	O
.	O

Methylation	O
status	O
was	O
investigated	O
by	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
and	O
by	O
bisulfite	O
DNA	O
sequencing	O
of	O
cloned	O
DNA	O
of	O
PCR	O
amplicons	O
.	O

In	O
cell	O
lines	O
,	O
we	O
examined	O
the	O
correlation	O
between	O
methylation	O
status	O
and	O
mRNA	O
expression	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Aberrant	O
methylation	O
of	O
CDH13	B
was	O
present	O
in	O
7	O
of	O
13	O
(	O
54	O
%	O
)	O
cell	O
lines	O
,	O
and	O
expression	O
was	O
absent	O
in	O
6	O
of	O
13	O
(	O
46	O
%	O
)	O
cell	O
lines	O
.	O

CDH13	B
expression	O
was	O
present	O
in	O
six	O
cell	O
lines	O
that	O
showed	O
only	O
the	O
unmethylated	O
form	O
by	O
MSP	O
and	O
in	O
one	O
cell	O
line	O
that	O
showed	O
both	O
the	O
methylated	O
and	O
unmethylated	O
forms	O
.	O

Treatment	O
with	O
5-aza-2'-deoxycytidine	O
restored	O
CDH13	B
expression	O
in	O
methylated	O
cell	O
lines	O
.	O

In	O
surgically	O
resected	O
samples	O
,	O
17	O
of	O
35	O
(	O
49	O
%	O
)	O
cases	O
of	O
primary	O
colorectal	O
cancer	O
,	O
2	O
of	O
33	O
(	O
6	O
%	O
)	O
cases	O
of	O
corresponding	O
nonmalignant	O
colorectal	O
mucosa	O
,	O
and	O
8	O
of	O
19	O
(	O
42	O
%	O
)	O
adenomas	O
were	O
methylated	O
.	O

Sequence	O
data	O
after	O
bisulfite	O
treatment	O
indicated	O
that	O
primary	O
cancers	O
and	O
two	O
cell	O
lines	O
with	O
loss	O
of	O
expression	O
were	O
highly	O
methylated	O
compared	O
with	O
nonmalignant	O
colorectal	O
epithelial	O
cells	O
,	O
especially	O
at	O
the	O
attachment	O
sites	O
of	O
primers	O
for	O
MSP	O
,	O
although	O
there	O
was	O
heterogeneity	O
in	O
methylation	O
status	O
.	O

Our	O
results	O
suggest	O
that	O
CDH13	B
expression	O
is	O
frequently	O
silenced	O
by	O
aberrant	O
methylation	O
in	O
colorectal	O
cancers	O
and	O
adenomas	O
and	O
that	O
methylation	O
of	O
CDH13	B
commences	O
at	O
an	O
early	O
stage	O
of	O
multistep	O
colorectal	O
tumorigenesis	O
.	O

Further	O
characterization	O
of	O
the	O
molecular	O
interaction	O
between	O
PSD-95	B
and	O
NMDA	B
receptors	I
:	O
the	O
effect	O
of	O
the	O
NR1	B
splice	O
variant	O
and	O
evidence	O
for	O
modulation	O
of	O
channel	O
gating	O
.	O

Coexpression	O
of	O
PSD-95	B
(	O
c	B
-	I
Myc	I
)	O
with	O
NR1	B
-	I
1a	I
/	O
NR2A	B
NMDA	B
receptors	I
in	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
293	O
cells	O
resulted	O
in	O
a	O
decrease	O
in	O
efficacy	O
for	O
the	O
glycine	O
stimulation	O
of	O
[	O
3	O
H	O
]	O
MK801	O
binding	O
similar	O
to	O
that	O
previously	O
described	O
for	O
l	O
-	O
glutamate	O
.	O

The	O
inhibition	O
constants	O
(	O
K	O
(	O
I	O
)	O
s	O
)	O
for	O
the	O
binding	O
of	O
l	O
-	O
glutamate	O
and	O
glycine	O
to	O
NR1	B
-	I
1a	I
/	O
NR2A	B
determined	O
by	O
[	O
3	O
H	O
]	O
CGP	O
39653	O
and	O
[	O
3H	O
]	O
MDL	O
105	O
519	O
displacement	O
assays	O
,	O
respectively	O
,	O
were	O
not	O
significantly	O
different	O
between	O
NR1	B
-	I
1a	I
/	O
NR2A	B
receptors	O
coexpressed	O
+	O
/-	O
PSD-95	B
(	O
c	B
-	I
Myc	I
)	O
.	O

The	O
increased	O
EC	O
(	O
50	O
)	O
for	O
l	O
-	O
glutamate	O
enhancement	O
of	O
[	O
3	O
H	O
]	O
MK801	O
binding	O
was	O
also	O
found	O
for	O
NR1	B
-	I
2a	I
/	O
NR2A	B
and	O
NR1	B
-	I
4b	I
/	O
NRA	O
receptors	O
thus	O
the	O
altered	O
EC	O
(	O
50	O
)	O
is	O
not	O
dependent	O
on	O
the	O
N1	O
,	O
C1	O
or	O
C2	O
exon	O
of	O
the	O
NR1	B
subunit	O
.	O

The	O
NR1	B
-	I
4b	I
but	O
not	O
the	O
NR1	B
-	I
1a	I
subunit	O
was	O
expressed	O
efficiently	O
at	O
the	O
cell	O
surface	O
in	O
the	O
absence	O
of	O
NR2	B
subunits	O
.	O

Total	O
NR1	B
-	I
4b	I
and	O
NR1	B
-	I
4b	I
/	O
NR2A	B
expression	O
was	O
enhanced	O
by	O
PSD-95	B
(	O
c	B
-	I
Myc	I
)	O
but	O
whole	O
cell	O
enzyme	O
-	O
linked	O
immunoadsorbent	O
assays	O
(	O
ELISAs	O
)	O
showed	O
that	O
this	O
increase	O
was	O
not	O
due	O
to	O
increased	O
expression	O
at	O
the	O
cell	O
surface	O
.	O

It	O
is	O
suggested	O
that	O
PSD-95	B
(	O
c	B
-	I
Myc	I
)	O
has	O
a	O
dual	O
effect	O
on	O
NMDA	B
receptors	I
expressed	O
in	O
mammalian	O
cells	O
,	O
a	O
reduction	O
in	O
channel	O
gating	O
and	O
an	O
enhanced	O
expression	O
of	O
NMDA	B
receptor	I
subunits	O
containing	O
C	O
-	O
terminal	O
E	O
(	O
T	O
/	O
S	O
)	O
XV	O
PSD	B
-	I
95	I
binding	O
motifs	O
.	O

NK	O
cell	O
receptors	O
of	O
the	O
orangutan	O
(	O
Pongo	O
pygmaeus	O
)	O
:	O
a	O
pivotal	O
species	O
for	O
tracking	O
the	O
coevolution	O
of	O
killer	B
cell	I
Ig	I
-	I
like	I
receptors	I
with	O
MHC	B
-	I
C	I
.	O

CD94	B
,	O
NKG2	B
,	O
Ly49	B
,	O
and	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
expressed	O
by	O
orangutan	O
peripheral	O
blood	O
cells	O
were	O
examined	O
by	O
cloning	O
and	O
sequencing	O
cDNA	O
from	O
a	O
panel	O
of	O
individuals	O
.	O

Orthologs	O
of	O
human	O
CD94	B
,	O
NKG2A	B
,	I
D	I
,	I
and	I
F	I
were	O
defined	O
.	O

NKG2C	B
and	I
E	I
are	O
represented	O
by	O
one	O
gene	O
,	O
Popy	O
-	O
NKG2CE	B
,	O
that	O
is	O
equidistant	O
from	O
the	O
two	O
human	O
genes	O
.	O

Several	O
Popy	O
-	O
CD94	B
,	O
NKG2A	B
,	O
and	O
NKG2CE	B
alleles	O
were	O
defined	O
.	O

Ly49L	B
is	O
expressed	O
in	O
cultured	O
NK	O
cells	O
and	O
has	O
a	O
sequence	O
consistent	O
with	O
it	O
encoding	O
a	O
functional	O
receptor	O
.	O

Orangutan	O
KIR	B
corresponding	O
to	O
the	O
three	O
KIR	B
lineages	O
expressed	O
in	O
humans	O
and	O
chimpanzees	O
were	O
defined	O
.	O

Popy	O
-	O
KIR2DL4	B
of	O
lineage	O
I	O
is	O
the	O
only	O
ortholog	O
of	O
a	O
human	O
or	O
chimpanzee	O
KIR	B
,	O
but	O
in	O
all	O
individuals	O
examined	O
,	O
the	O
transcripts	O
of	O
this	O
gene	O
produced	O
premature	O
termination	O
,	O
either	O
in	O
the	O
D2	O
domain	O
or	O
at	O
the	O
beginning	O
of	O
the	O
cytoplasmic	O
domain	O
.	O

Ten	O
Popy	O
-	O
KIR3DL	B
and	O
one	O
Popy	O
-	O
KIR3DS	B
of	O
lineage	O
II	O
are	O
all	O
closely	O
related	O
,	O
but	O
represent	O
the	O
products	O
of	O
at	O
least	O
two	O
genes	O
.	O

The	O
two	O
Popy	O
-	O
KIR2DL	B
and	O
four	O
Popy	O
-	O
KIR2DS	B
of	O
lineage	O
III	O
also	O
represent	O
two	O
genes	O
,	O
both	O
being	O
more	O
related	O
to	O
KIR2DS4	B
than	O
to	O
other	O
human	O
and	O
chimpanzee	O
KIR	B
of	O
lineage	O
III	O
.	O

The	O
Popy	O
-	O
KIR2D	B
include	O
ones	O
predicted	O
to	O
be	O
specific	O
for	O
the	O
C1	O
epitope	O
of	O
MHC	B
-	I
C	I
,	O
but	O
none	O
specific	O
for	O
C2	O
.	O

This	O
correlates	O
with	O
the	O
observation	O
that	O
all	O
orangutan	O
MHC	B
-	I
C	I
allotypes	O
examined	O
have	O
the	O
C1	O
motif	O
.	O

Crystallization	O
and	O
preliminary	O
X	O
-	O
ray	O
crystallographic	O
studies	O
on	O
recombinant	O
human	O
carnitine	B
acetyltransferase	I
.	O

In	O
this	O
paper	O
,	O
the	O
purification	O
,	O
crystallization	O
and	O
preliminary	O
X	O
-	O
ray	O
crystallographic	O
studies	O
of	O
human	O
carnitine	B
acetyltransferase	I
are	O
reported	O
.	O

Recombinant	O
human	O
carnitine	B
acetyltransferase	I
crystals	O
were	O
grown	O
by	O
the	O
hanging	O
-	O
drop	O
vapor	O
-	O
diffusion	O
method	O
and	O
belong	O
to	O
the	O
orthorhombic	O
space	O
group	O
P2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
2	O
(	O
1	O
)	O
,	O
with	O
unit	O
-	O
cell	O
parameters	O
a	O
=	O
137.65	O
,	O
b	O
=	O
84.76	O
,	O
c	O
=	O
57.65	O
A	O
and	O
one	O
molecule	O
per	O
asymmetric	O
unit	O
.	O

The	O
intensity	O
data	O
were	O
collected	O
from	O
a	O
cryocooled	O
crystal	O
to	O
1.6	O
A	O
resolution	O
using	O
a	O
conventional	O
X	O
-	O
ray	O
source	O
.	O

Mutations	O
in	O
the	O
cone	O
photoreceptor	O
G	B
-	I
protein	I
alpha	I
-	O
subunit	O
gene	O
GNAT2	B
in	O
patients	O
with	O
achromatopsia	O
.	O

Achromatopsia	O
is	O
an	O
autosomal	O
recessively	O
inherited	O
visual	O
disorder	O
that	O
is	O
present	O
from	O
birth	O
and	O
that	O
features	O
the	O
absence	O
of	O
color	O
discrimination	O
.	O

We	O
here	O
report	O
the	O
identification	O
of	O
five	O
independent	O
families	O
with	O
achromatopsia	O
that	O
segregate	O
protein	O
-	O
truncation	O
mutations	O
in	O
the	O
GNAT2	B
gene	O
,	O
located	O
on	O
chromosome	O
1p13	O
.	O

GNAT2	B
encodes	O
the	O
cone	O
photoreceptor	O
-	O
specific	O
alpha	B
-	I
subunit	I
of	I
transducin	I
,	O
a	O
G	B
-	I
protein	I
of	O
the	O
phototransduction	O
cascade	O
,	O
which	O
couples	O
to	O
the	O
visual	O
pigment	O
(	O
s	O
)	O
.	O

Our	O
results	O
demonstrate	O
that	O
GNAT2	B
is	O
the	O
third	O
gene	O
implicated	O
in	O
achromatopsia	O
.	O

Activation	O
mechanism	O
of	O
CDK2	B
:	O
role	O
of	O
cyclin	B
binding	O
versus	O
phosphorylation	O
.	O

Activation	O
of	O
the	O
cyclin	B
-	I
dependent	I
kinases	I
is	O
a	O
two	O
-	O
step	O
process	O
involving	O
cyclin	B
binding	O
followed	O
by	O
phosphorylation	O
at	O
a	O
conserved	O
threonine	O
residue	O
within	O
the	O
kinase	B
activation	O
loop	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
the	O
separate	O
roles	O
of	O
cyclin	B
A	I
binding	O
versus	O
phosphorylation	O
in	O
the	O
overall	O
activation	O
mechanism	O
of	O
CDK2	B
.	O

Interaction	O
of	O
CDK2	B
with	O
cyclin	B
A	I
results	O
in	O
a	O
partially	O
active	O
complex	O
that	O
is	O
moderately	O
defective	O
in	O
the	O
binding	O
of	O
the	O
protein	O
substrate	O
,	O
but	O
not	O
ATP	O
,	O
and	O
severely	O
defective	O
in	O
both	O
phosphoryl	O
group	O
transfer	O
and	O
turnover	O
.	O

Alternatively	O
,	O
phosphorylation	O
of	O
the	O
CDK2	B
monomer	O
also	O
results	O
in	O
a	O
partially	O
activated	O
species	O
,	O
but	O
one	O
that	O
is	O
severely	O
(	O
>	O
or	O
=	O
480	O
-	O
fold	O
)	O
defective	O
in	O
substrate	O
binding	O
exclusively	O
.	O

Catalytic	O
turnover	O
in	O
the	O
phosphorylated	O
CDK2	B
monomer	O
is	O
largely	O
unimpaired	O
(	O
approximately	O
8	O
-	O
fold	O
lower	O
)	O
.	O

Our	O
data	O
support	O
a	O
model	O
for	O
the	O
activation	O
of	O
CDK2	B
in	O
vivo	O
,	O
in	O
which	O
interaction	O
of	O
unphosphorylated	O
CDK2	B
with	O
cyclin	B
A	I
serves	O
to	O
configure	O
the	O
active	O
site	O
for	O
ground	O
-	O
state	O
binding	O
of	O
both	O
ATP	O
and	O
the	O
protein	O
substrate	O
,	O
and	O
further	O
aligns	O
ATP	O
in	O
the	O
transition	O
state	O
for	O
phosphoryl	O
transfer	O
.	O

Optimizing	O
the	O
alignment	O
of	O
protein	O
substrates	O
in	O
the	O
phosphoryl	O
transfer	O
reaction	O
is	O
the	O
principal	O
role	O
of	O
phosphorylation	O
at	O
Thr	O
(	O
160	O
)	O
.	O

Interaction	O
of	O
p58	B
(	I
PITSLRE	I
)	I
,	O
a	O
G2	O
/	O
M	O
-	O
specific	O
protein	B
kinase	I
,	O
with	O
cyclin	B
D3	I
.	O

The	O
p58	B
(	I
PITSLRE	I
)	I
is	O
a	O
p34	B
(	I
cdc2	I
)	I
-	O
related	O
protein	B
kinase	I
that	O
plays	O
an	O
important	O
role	O
in	O
normal	O
cell	O
cycle	O
progression	O
.	O

Elevated	O
expression	O
of	O
p58	B
(	I
PITSLRE	I
)	I
in	O
eukaryotic	O
cells	O
prevents	O
them	O
from	O
undergoing	O
normal	O
cytokinesis	O
and	O
appears	O
to	O
delay	O
them	O
in	O
late	O
telophase	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
p58	B
(	I
PITSLRE	I
)	I
action	O
,	O
we	O
used	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
screened	O
a	O
human	O
fetal	O
liver	O
cDNA	O
library	O
,	O
and	O
identified	O
cyclin	B
D3	I
as	O
an	O
interacting	O
partner	O
of	O
p58	B
(	I
PITSLRE	I
)	I
.	O

In	O
vitro	O
binding	O
assay	O
,	O
in	O
vivo	O
coimmunoprecipitation	O
,	O
and	O
immunofluorescence	O
cell	O
staining	O
further	O
confirmed	O
the	O
association	O
of	O
p58	B
(	I
PITSLRE	I
)	I
with	O
cyclin	B
D3	I
.	O

This	O
binding	O
was	O
observed	O
only	O
in	O
the	O
G	O
(	O
2	O
)	O
/	O
M	O
phase	O
but	O
not	O
in	O
the	O
G	O
(	O
1	O
)	O
/	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
;	O
meanwhile	O
,	O
no	O
interaction	O
between	O
p110	O
(	O
PITSLRE	B
)	O
and	O
cyclin	B
D3	I
was	O
observed	O
in	O
all	O
the	O
cell	O
cycle	O
.	O

The	O
overexpression	O
of	O
cyclin	B
D3	I
in	O
7721	O
cells	O
leads	O
to	O
an	O
exclusively	O
accumulation	O
of	O
p58	B
(	I
PITSLRE	I
)	I
in	O
the	O
nuclear	O
region	O
,	O
affecting	O
its	O
cellular	O
distribution	O
.	O

Histone	O
H1	O
kinase	B
activity	O
of	O
p58	B
(	I
PITSLRE	I
)	I
was	O
greatly	O
enhanced	O
upon	O
interaction	O
with	O
cyclin	B
D3	I
.	O

Furthermore	O
,	O
kinase	B
activity	O
of	O
p58	B
(	I
PITSLRE	I
)	I
was	O
found	O
to	O
increase	O
greatly	O
in	O
the	O
presence	O
of	O
cyclin	B
D3	I
using	O
a	O
specific	O
substrate	O
,	O
beta-1,4-galactosyltransferase	B
1	I
.	O

These	O
data	O
provide	O
a	O
new	O
clue	O
to	O
our	O
understanding	O
of	O
the	O
cellular	O
function	O
of	O
p58	B
(	I
PITSLRE	I
)	I
and	O
cyclin	B
D3	I
.	O

Cloning	O
and	O
identification	O
of	O
a	O
new	O
member	O
of	O
water	B
channel	I
(	O
AQP10	B
)	O
as	O
an	O
aquaglyceroporin	B
.	O

Recently	O
,	O
a	O
new	O
member	O
of	O
aquaporins	B
was	O
reported	O
as	O
AQP10	B
[	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
287	O
(	O
2001	O
)	O
814	O
]	O
,	O
which	O
is	O
incompletely	O
spliced	O
to	O
lose	O
the	O
sixth	O
transmembrane	O
domain	O
and	O
has	O
poor	O
water	O
and	O
no	O
glycerol	O
/	O
urea	O
permeabilities	O
.	O

Independently	O
,	O
we	O
identified	O
a	O
similar	O
clone	O
in	O
human	O
.	O

Our	O
AQP10	B
consists	O
of	O
301	O
amino	O
acids	O
with	O
a	O
highly	O
conserved	O
sixth	O
transmembrane	O
domain	O
.	O

AQP10	B
has	O
higher	O
identity	O
with	O
aquaglyceroporins	B
(	O
50	O
%	O
with	O
AQP9	B
,	O
48	O
%	O
with	O
AQP3	B
,	O
42	O
%	O
with	O
AQP7	B
)	O
and	O
lower	O
identity	O
with	O
other	O
aquaporins	B
(	O
32	O
%	O
with	O
AQP1	B
and	O
AQP8	B
)	O
.	O

AQP10	B
is	O
expressed	O
only	O
in	O
the	O
small	O
intestine	O
with	O
(	O
approximately	O
2	O
kb	O
)	O
.	O

RNase	B
protection	O
assay	O
revealed	O
the	O
absence	O
of	O
the	O
unspliced	O
form	O
,	O
supporting	O
the	O
authenticity	O
of	O
our	O
clone	O
.	O

When	O
expressed	O
in	O
Xenopus	O
oocytes	O
,	O
AQP10	B
stimulated	O
osmotic	O
water	O
permeability	O
sixfold	O
in	O
a	O
mercury	O
-	O
sensitive	O
manner	O
.	O

Glycerol	O
and	O
urea	O
uptakes	O
were	O
also	O
stimulated	O
,	O
while	O
adenine	O
uptake	O
was	O
not	O
.	O

The	O
genome	O
structure	O
of	O
AQP10	B
is	O
similar	O
to	O
those	O
of	O
other	O
aquaglyceroporins	B
(	O
AQP3	B
,	O
AQP7	B
,	O
AQP9	B
)	O
with	O
six	O
exons	O
.	O

We	O
conclude	O
that	O
AQP10	B
represents	O
a	O
new	O
member	O
of	O
aquaglyceroporins	B
functionally	O
as	O
well	O
as	O
structurally	O
.	O

Identification	O
of	O
human	O
male	B
germ	I
cell	I
-	I
associated	I
kinase	I
,	O
a	O
kinase	B
transcriptionally	O
activated	O
by	O
androgen	O
in	O
prostate	O
cancer	O
cells	O
.	O

Androgen	O
is	O
involved	O
in	O
both	O
normal	O
development	O
and	O
malignant	O
transformation	O
of	O
prostate	O
cells	O
.	O

The	O
signal	O
transduction	O
pathways	O
associated	O
with	O
these	O
processes	O
are	O
not	O
well	O
understood	O
.	O

Using	O
a	O
novel	O
kinase	B
display	O
approach	O
,	O
we	O
have	O
identified	O
a	O
protein	B
kinase	I
,	O
human	O
male	B
germ	I
cell	I
-	I
associated	I
kinase	I
(	O
hMAK	B
)	O
,	O
which	O
is	O
transcriptionally	O
induced	O
by	O
the	O
androgenic	O
hormone	O
5alpha	O
-	O
dihydrotestosterone	O
(	O
DHT	O
)	O
.	O

The	O
kinetics	O
of	O
induction	O
is	O
rapid	O
and	O
dose	O
-	O
dependent	O
,	O
and	O
the	O
induction	O
is	O
not	O
blocked	O
by	O
cycloheximide	O
treatment	O
.	O

Real	O
time	O
reverse	O
transcription	O
-	O
PCR	O
studies	O
demonstrated	O
a	O
9	O
-	O
fold	O
induction	O
of	O
hMAK	B
by	O
10	O
nm	O
DHT	O
at	O
24	O
h	O
post	O
-	O
stimulation	O
.	O

The	O
expression	O
levels	O
of	O
hMAK	B
in	O
prostate	O
cancer	O
cell	O
lines	O
are	O
in	O
general	O
higher	O
than	O
those	O
of	O
normal	O
prostate	O
epithelial	O
cells	O
.	O

A	O
reverse	O
transcription	O
-	O
PCR	O
product	O
encompassing	O
the	O
entire	O
hMAK	B
open	O
reading	O
frame	O
was	O
isolated	O
.	O

The	O
results	O
from	O
sequencing	O
analysis	O
showed	O
that	O
the	O
hMAK	B
protein	O
is	O
623	O
amino	O
acids	O
in	O
length	O
and	O
contains	O
a	O
kinase	B
catalytic	O
domain	O
at	O
its	O
N	O
terminus	O
,	O
followed	O
by	O
a	O
proline	O
/	O
glutamine	O
-	O
rich	O
domain	O
.	O

The	O
catalytic	O
domain	O
of	O
this	O
kinase	B
contains	O
sequence	O
motifs	O
related	O
to	O
both	O
the	O
cyclin	B
-	I
dependent	I
kinase	I
and	I
the	I
mitogen	I
-	I
activated	I
protein	I
kinase	I
families	I
.	O

When	O
expressed	O
in	O
COS1	O
cells	O
,	O
hMAK	B
is	O
kinase	B
-	O
active	O
as	O
demonstrated	O
by	O
autophosphorylation	O
and	O
phosphorylation	O
of	O
exogenous	O
substrate	O
and	O
is	O
localized	O
in	O
the	O
nucleus	O
.	O

A	O
3.7	O
-	O
kilobase	O
pair	O
promoter	O
of	O
the	O
hMAK	B
locus	O
was	O
isolated	O
from	O
a	O
human	O
genomic	O
DNA	O
bacterial	O
artificial	O
chromosome	O
clone	O
and	O
was	O
shown	O
to	O
be	O
activated	O
by	O
DHT	O
.	O

This	O
activation	O
can	O
be	O
blocked	O
by	O
an	O
anti	O
-	O
androgen	O
drug	O
bicalutamide	O
(	O
Casodex	O
)	O
,	O
implicating	O
the	O
involvement	O
of	O
androgen	B
receptor	I
in	O
this	O
process	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hMAK	B
is	O
a	O
protein	B
kinase	I
targeted	O
by	O
androgen	O
that	O
may	O
participate	O
in	O
androgen	O
-	O
mediated	O
signaling	O
in	O
prostate	O
cancer	O
cells	O
.	O

Contrasting	O
nifD	B
and	O
ribosomal	O
gene	O
relationships	O
among	O
Mesorhizobium	O
from	O
Lotus	O
oroboides	O
in	O
northern	O
Mexico	O
.	O

PCR	O
screens	O
for	O
length	O
variation	O
in	O
a	O
5	O
'	O
portion	O
of	O
23S	O
ribosomal	O
RNA	O
and	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
16S	O
rRNA-23S	O
rRNA	O
internal	O
transcribed	O
spacer	O
(	O
ITS	O
)	O
region	O
indicated	O
that	O
nodule	O
bacteria	O
from	O
a	O
Mexican	O
population	O
of	O
Lotus	O
oroboides	O
were	O
diverse	O
on	O
a	O
local	O
scale	O
.	O

Three	O
23S	O
rRNA	O
length	O
variants	O
and	O
five	O
ITS	O
length	O
variants	O
were	O
detected	O
among	O
the	O
22	O
isolates	O
.	O

Sequencing	O
of	O
nearly	O
full	O
-	O
length	O
16S	O
rRNA	O
genes	O
in	O
three	O
isolates	O
indicated	O
that	O
they	O
fell	O
into	O
the	O
genus	O
Mesorhizobium	O
,	O
but	O
comprised	O
two	O
distinct	O
groups	O
.	O

Two	O
isolates	O
were	O
closely	O
related	O
to	O
M.	O
loti	O
LMG	O
6125	O
T	O
,	O
while	O
the	O
other	O
isolate	O
clustered	O
with	O
an	O
assemblage	O
of	O
Mesorhizobium	O
taxa	O
that	O
included	O
M.	O
amorphae	O
,	O
M.	O
plurifarium	O
and	O
M.	O
huakuii	O
.	O

However	O
,	O
a	O
phylogenetic	O
tree	O
based	O
on	O
715	O
bp	O
of	O
the	O
nitrogenase	B
alpha	I
-	I
subunit	I
(	O
nifD	B
)	O
gene	O
was	O
significantly	O
discordant	O
with	O
the	O
relationships	O
inferred	O
from	O
rRNA	O
sequences	O
.	O

Two	O
isolates	O
that	O
were	O
nearly	O
identical	O
for	O
16S	O
rRNA	O
had	O
nifD	B
genes	O
that	O
varied	O
at	O
2	O
%	O
of	O
sites	O
,	O
and	O
one	O
of	O
these	O
nifD	B
sequences	O
was	O
identical	O
to	O
that	O
of	O
another	O
isolate	O
with	O
a	O
strongly	O
divergent	O
16S	O
rRNA	O
gene	O
.	O

A	O
plasmid	O
screen	O
followed	O
by	O
Southern	O
hybridization	O
indicated	O
that	O
only	O
one	O
of	O
these	O
strains	O
harbored	O
a	O
plasmid	O
-	O
borne	O
nifD	B
gene	O
.	O

These	O
results	O
imply	O
that	O
gene	O
transfer	O
events	O
have	O
altered	O
the	O
distribution	O
of	O
nifD	B
sequences	O
among	O
lineages	O
within	O
this	O
natural	O
population	O
of	O
Mesorhizobium	O
strains	O
.	O

Infertility	O
of	O
CD9	B
-	O
deficient	O
mouse	O
eggs	O
is	O
reversed	O
by	O
mouse	O
CD9	B
,	O
human	O
CD9	B
,	O
or	O
mouse	O
CD81	B
;	O
polyadenylated	O
mRNA	O
injection	O
developed	O
for	O
molecular	O
analysis	O
of	O
sperm	O
-	O
egg	O
fusion	O
.	O

CD9	B
is	O
a	O
membrane	O
protein	O
belonging	O
to	O
the	O
tetraspanin	B
family	I
.	O

Despite	O
CD9	B
's	O
broad	O
tissue	O
distribution	O
,	O
the	O
only	O
abnormality	O
observed	O
in	O
CD9	B
-	O
deficient	O
mice	O
was	O
infertility	O
of	O
females	O
,	O
which	O
was	O
responsible	O
for	O
a	O
defect	O
in	O
the	O
sperm	O
-	O
egg	O
fusion	O
process	O
.	O

However	O
,	O
the	O
function	O
of	O
CD9	B
in	O
sperm	O
-	O
egg	O
fusion	O
is	O
not	O
clear	O
at	O
all	O
because	O
the	O
technique	O
to	O
analyze	O
the	O
activity	O
of	O
molecules	O
in	O
sperm	O
-	O
egg	O
fusion	O
has	O
not	O
been	O
established	O
.	O

We	O
demonstrated	O
that	O
the	O
exogenous	O
mouse	O
CD9	B
,	O
expressed	O
by	O
polyadenylated	O
mRNA	O
injection	O
at	O
the	O
germinal	O
-	O
vesicle	O
stage	O
oocytes	O
,	O
was	O
precisely	O
localized	O
to	O
the	O
egg	O
plasma	O
membrane	O
,	O
and	O
the	O
expression	O
reversed	O
the	O
infertility	O
of	O
CD9	B
(	O
-	O
/	O
-	O
)	O
eggs	O
.	O

Then	O
,	O
two	O
other	O
tetraspanins	B
,	O
human	O
CD9	B
and	O
mouse	O
CD81	B
,	O
overexpressed	O
with	O
this	O
technique	O
on	O
CD9	O
(	O
-	O
/	O
-	O
)	O
eggs	O
restored	O
the	O
fertilization	O
rate	O
up	O
to	O
approximately	O
90	O
and	O
approximately	O
50	O
%	O
against	O
that	O
of	O
wild	O
type	O
eggs	O
,	O
respectively	O
.	O

Moreover	O
,	O
in	O
the	O
presence	O
of	O
an	O
anti	O
-	O
mouse	O
CD9	B
mAb	O
,	O
which	O
blocks	O
sperm	O
-	O
egg	O
fusion	O
,	O
expression	O
of	O
human	O
CD9	B
or	O
mouse	O
CD81	B
on	O
eggs	O
also	O
rescued	O
the	O
fusibility	O
.	O

These	O
results	O
suggested	O
that	O
human	O
CD9	B
plays	O
a	O
crucial	O
role	O
in	O
human	O
fertilization	O
,	O
and	O
mouse	O
CD81	B
has	O
the	O
potential	O
to	O
compensate	O
for	O
CD9	B
function	O
in	O
sperm	O
-	O
egg	O
fusion	O
.	O

In	O
addition	O
,	O
the	O
polyadenylated	O
mRNA	O
injection	O
is	O
effective	O
for	O
molecular	O
analysis	O
of	O
sperm	O
-	O
egg	O
fusion	O
.	O

Prostaglandins	O
and	O
mechanisms	O
of	O
preterm	O
birth	O
.	O

Increased	O
uterine	O
contractility	O
at	O
term	O
and	O
preterm	O
results	O
first	O
from	O
activation	O
and	O
then	O
stimulation	O
of	O
the	O
myometrium	O
.	O

Activation	O
can	O
be	O
provoked	O
by	O
mechanical	O
stretch	O
of	O
the	O
uterus	O
,	O
and	O
by	O
an	O
endocrine	O
pathway	O
resulting	O
from	O
increased	O
activity	O
of	O
the	O
fetal	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
.	O

In	O
sheep	O
fetuses	O
,	O
increased	O
cortisol	O
output	O
during	O
pregnancy	O
regulates	O
expression	O
of	O
prostaglandin	B
synthase	I
type	I
2	I
(	O
PGHS-2	B
)	O
in	O
the	O
placenta	O
in	O
an	O
oestrogen	O
-	O
independent	O
manner	O
,	O
resulting	O
in	O
increased	O
concentrations	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
in	O
the	O
fetal	O
circulation	O
.	O

Later	O
increases	O
in	O
maternal	O
uterine	O
expression	O
of	O
PGHS-2	B
require	O
increases	O
in	O
oestrogen	O
and	O
lead	O
to	O
increased	O
concentrations	O
of	O
PGF	O
(	O
2alpha	O
)	O
in	O
the	O
maternal	O
circulation	O
.	O

Thus	O
,	O
regulation	O
of	O
PGHS-2	B
at	O
term	O
is	O
differentially	O
controlled	O
in	O
fetal	O
(	O
trophoblast	O
)	O
and	O
maternal	O
(	O
uterine	O
epithelium	O
)	O
tissue	O
.	O

This	O
difference	O
may	O
reflect	O
expression	O
of	O
glucocorticoid	B
receptor	I
but	O
not	O
oestrogen	B
receptor	I
(	O
ER	B
)	O
in	O
placental	O
trophoblast	O
cells	O
.	O

In	O
women	O
,	O
cortisol	O
also	O
contributes	O
to	O
increased	O
prostaglandin	O
production	O
in	O
fetal	O
tissues	O
through	O
upregulation	O
of	O
PGHS-2	B
(	O
amnion	O
and	O
chorion	O
)	O
and	O
downregulation	O
of	O
15-OH	B
prostaglandin	I
dehydrogenase	I
(	O
PGDH	B
;	O
chorion	O
trophoblasts	O
)	O
.	O

The	O
effect	O
of	O
cortisol	O
on	O
expression	O
of	O
PGDH	B
in	O
the	O
chorion	O
reverses	O
a	O
tonic	O
stimulatory	O
effect	O
of	O
progesterone	O
,	O
potentially	O
through	O
a	O
paracrine	O
or	O
autocrine	O
action	O
.	O

In	O
membranes	O
,	O
cortisol	O
may	O
be	O
derived	O
from	O
cortisone	O
through	O
activity	O
of	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
(	I
11beta	I
-	I
HSD	I
)	I
type	I
1	I
,	O
in	O
addition	O
to	O
secretion	O
from	O
the	O
maternal	O
or	O
fetal	O
adrenal	O
glands	O
.	O

In	O
placenta	O
,	O
11beta	B
-	I
HSD-2	I
oxidase	I
activity	O
predominates	O
and	O
expression	O
of	O
this	O
enzyme	O
is	O
reduced	O
with	O
hypoxaemia	O
and	O
in	O
placentae	O
from	O
pre	O
-	O
eclamptic	O
pregnancies	O
.	O

In	O
these	O
circumstances	O
,	O
increased	O
concentrations	O
of	O
maternal	O
cortisol	O
may	O
cross	O
into	O
the	O
fetal	O
compartment	O
,	O
contributing	O
to	O
growth	O
restriction	O
and	O
programming	O
later	O
life	O
disease	O
.	O

Expression	O
of	O
the	O
leucocyte	B
common	I
antigen	I
-	I
related	I
(	I
LAR	I
)	I
tyrosine	I
phosphatase	I
is	O
regulated	O
by	O
cell	O
density	O
through	O
functional	O
E	B
-	I
cadherin	I
complexes	O
.	O

The	O
leucocyte	B
common	I
antigen	I
-	I
related	I
phosphatase	I
(	O
LAR	B
)	O
has	O
been	O
implicated	O
in	O
receptor	B
tyrosine	I
kinase	I
signalling	O
pathways	O
while	O
also	O
displaying	O
cell	O
-	O
density	O
-	O
dependency	O
and	O
localization	O
to	O
adherens	O
junctions	O
.	O

Whereas	O
physiological	O
substrates	O
for	O
LAR	B
have	O
not	O
been	O
identified	O
unequivocally	O
,	O
beta	B
-	I
catenin	I
associates	O
with	O
LAR	B
and	O
is	O
a	O
substrate	O
in	O
vitro	O
.	O

With	O
the	O
implication	O
that	O
LAR	B
may	O
play	O
a	O
role	O
in	O
regulating	O
E	B
-	I
cadherin	I
-	O
dependent	O
cell	O
-	O
cell	O
communication	O
and	O
contact	O
inhibition	O
,	O
the	O
relationship	O
of	O
LAR	B
with	O
E	B
-	I
cadherin	I
was	O
investigated	O
.	O

LAR	B
expression	O
increased	O
with	O
cell	O
density	O
in	O
the	O
human	O
breast	O
cancer	O
cell	O
line	O
MCF-7	O
and	O
in	O
Ln	O
3	O
cells	O
derived	O
from	O
the	O
13762NF	O
rat	O
mammary	O
adenocarcinoma	O
.	O

LAR	B
protein	O
levels	O
decreased	O
rapidly	O
when	O
cells	O
were	O
replated	O
at	O
a	O
low	O
density	O
after	O
attaining	O
high	O
expression	O
of	O
LAR	B
at	O
high	O
cell	O
density	O
.	O

COS-7	O
cells	O
displayed	O
comparable	O
density	O
-	O
dependent	O
regulation	O
of	O
LAR	B
expression	O
when	O
transiently	O
expressing	O
exogenous	O
LAR	B
under	O
the	O
control	O
of	O
a	O
constitutively	O
active	O
promoter	O
,	O
indicating	O
that	O
the	O
regulation	O
of	O
expression	O
is	O
not	O
at	O
the	O
level	O
of	O
gene	O
regulation	O
.	O

Disrupting	O
homophilic	O
E	B
-	I
cadherin	I
complexes	O
by	O
chelating	O
extracellular	O
calcium	O
caused	O
a	O
marked	O
decrease	O
in	O
LAR	B
protein	O
levels	O
.	O

Similarly	O
,	O
blocking	O
E	B
-	I
cadherin	I
interactions	O
with	O
saturating	O
amounts	O
of	O
E	B
-	I
cadherin	I
antibody	O
(	O
HECD-1	O
)	O
also	O
led	O
to	O
a	O
rapid	O
and	O
pronounced	O
loss	O
of	O
cellular	O
LAR	B
.	O

In	O
contrast	O
,	O
mimicking	O
cell	O
-	O
surface	O
E	B
-	I
cadherin	I
engagement	O
by	O
plating	O
cells	O
at	O
low	O
density	O
on	O
to	O
dishes	O
coated	O
with	O
HECD-1	O
resulted	O
in	O
a	O
2	O
-	O
fold	O
increase	O
in	O
LAR	B
expression	O
compared	O
with	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
density	O
-	O
dependent	O
regulation	O
of	O
LAR	B
expression	O
is	O
mediated	O
by	O
functional	O
E	B
-	I
cadherin	I
and	O
may	O
play	O
a	O
role	O
in	O
density	O
-	O
dependent	O
contact	O
inhibition	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
in	O
E	B
-	I
cadherin	I
complexes	O
.	O

Direct	O
addition	O
of	O
BimL	B
to	O
mitochondria	O
does	O
not	O
lead	O
to	O
cytochrome	B
c	I
release	O
.	O

Pro	O
-	O
apoptotic	O
members	O
of	O
the	O
Bcl-2	B
family	I
can	O
be	O
subdivided	O
in	O
two	O
classes	O
according	O
to	O
their	O
structure	O
:	O
a	O
group	O
including	O
Bax	B
,	O
Bak	B
,	O
and	O
Bok	B
that	O
display	O
Bcl-2	B
homology	O
(	O
BH	O
)	O
1	O
,	O
BH2	O
and	O
BH3	O
domains	O
and	O
a	O
second	O
group	O
including	O
Bid	B
(	O
BH3	O
interacting	O
domain	O
death	O
agonist	O
)	O
,	O
Bad	B
,	O
Bim	B
(	O
Bcl-2	B
interacting	I
mediator	I
of	I
cell	I
death	I
)	O
and	O
several	O
others	O
that	O
contain	O
only	O
a	O
BH3	O
domain	O
,	O
the	O
BH3	O
-	O
only	O
proteins	O
.	O

The	O
BH3	O
-	O
only	O
proteins	O
have	O
been	O
proposed	O
to	O
activate	O
pro	O
-	O
apoptotic	O
members	O
of	O
the	O
Bax	B
subfamily	I
to	O
trigger	O
a	O
mitochondrial	O
pathway	O
that	O
leads	O
to	O
the	O
release	O
of	O
cytochrome	B
c	I
and	O
other	O
apoptogenic	O
factors	O
.	O

Here	O
we	O
report	O
that	O
the	O
mechanism	O
of	O
action	O
of	O
Bim	B
is	O
different	O
from	O
that	O
of	O
Bid	B
.	O

Although	O
overexpression	O
of	O
Bid	B
or	O
Bim	B
in	O
cells	O
leads	O
to	O
cytochrome	B
c	I
release	O
,	O
only	O
Bid	B
is	O
able	O
to	O
trigger	O
the	O
release	O
of	O
cytochrome	B
c	I
through	O
Bax	B
activation	O
when	O
added	O
directly	O
to	O
isolated	O
mitochondria	O
.	O

Bim	B
(	I
L	I
)	I
,	O
although	O
unable	O
to	O
activate	O
Bax	B
,	O
can	O
directly	O
inhibit	O
Bcl-2	B
or	O
Bcl	B
-	I
x	I
(	I
L	I
)	I
.	O

Our	O
data	O
suggest	O
two	O
functional	O
classes	O
of	O
BH3	O
-	O
only	O
proteins	O
:	O
those	O
such	O
as	O
Bid	B
which	O
directly	O
activate	O
Bax	B
-	O
like	O
proteins	O
leading	O
to	O
mitochondrial	O
membrane	O
permeability	O
and	O
apoptosis	O
and	O
those	O
such	O
as	O
Bim	B
which	O
inhibit	O
anti	O
-	O
apoptotic	O
proteins	O
and	O
render	O
the	O
cells	O
more	O
susceptible	O
to	O
apoptogenic	O
stimuli	O
.	O

Relationship	O
of	O
the	O
interleukin-1	B
system	O
with	O
neuroendocrine	O
and	O
exocrine	O
markers	O
in	O
human	O
colon	O
cancer	O
cell	O
lines	O
.	O

Interleukin	B
1	I
(	O
IL-1	B
)	O
is	O
known	O
to	O
regulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
normal	O
and	O
malignant	O
immune	O
cells	O
as	O
well	O
as	O
other	O
cell	O
types	O
.	O

Expression	O
of	O
IL-1	B
(	I
alpha	I
and	I
beta	I
)	I
,	O
IL-1	B
receptors	I
(	I
RI	I
and	I
RII	I
)	I
and	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1RA	B
)	O
was	O
determined	O
by	O
RT	O
-	O
PCR	O
in	O
seven	O
human	O
colon	O
carcinoma	O
cell	O
lines	O
(	O
COLO	O
320DM	O
,	O
LoVo	O
,	O
SW403	O
,	O
SW1116	O
,	O
SW1417	O
,	O
LS123	O
and	O
LS174	O
t	O
)	O
.	O

Influence	O
of	O
IL-1	B
on	O
the	O
secretion	O
of	O
the	O
neuroendocrine	O
(	O
NE	O
)	O
differentiation	O
marker	O
chromogranin	O
A	O
(	O
CGA	O
)	O
and	O
the	O
exocrine	O
marker	O
carcinoembryonic	B
antigen	I
(	O
CEA	B
)	O
was	O
examined	O
by	O
Western	O
blotting	O
.	O

Our	O
data	O
indicate	O
that	O
CGA	O
and	O
IL-1RI	B
are	O
expressed	O
by	O
all	O
seven	O
,	O
IL-1	B
beta	I
by	O
five	O
,	O
IL-1RII	B
and	O
IL-1RA	B
by	O
six	O
lines	O
.	O

IL-1	B
alpha	I
transcripts	O
were	O
found	O
only	O
in	O
three	O
lines	O
(	O
LoVo	O
,	O
SW1116	O
and	O
LS174	O
t	O
)	O
and	O
correlated	O
with	O
high	O
CEA	B
levels	O
and	O
aggressive	O
growth	O
behavior	O
.	O

""""	O
Pure	O
""""	O
NE	O
cell	O
lines	O
(	O
COLO	O
320DM	O
and	O
LS123	O
)	O
secreted	O
the	O
highest	O
levels	O
of	O
CGA	B
,	O
but	O
the	O
lowest	O
levels	O
of	O
CEA	B
and	O
were	O
IL-1	B
(	I
alpha	I
and	I
beta	I
)	I
negative	O
.	O

Exogenously	O
added	O
IL-1	B
caused	O
a	O
decrease	O
in	O
CGA	O
,	O
but	O
an	O
increase	O
in	O
CEA	B
secretion	O
.	O

Our	O
results	O
suggest	O
an	O
inverse	O
relationship	O
between	O
IL-1	B
and	O
NE	O
differentiation	O
,	O
as	O
well	O
as	O
a	O
direct	O
relationship	O
between	O
IL-1	B
and	O
CEA	B
expression	O
in	O
colon	O
carcinoma	O
.	O

Activation	O
of	O
the	O
Escherichia	O
coli	O
nfnB	B
gene	O
by	O
MarA	B
through	O
a	O
highly	O
divergent	O
marbox	O
in	O
a	O
class	O
II	O
promoter	O
.	O

MarA	B
is	O
a	O
global	O
regulator	O
that	O
mediates	O
resistance	O
to	O
multiple	O
environmental	O
hazards	O
such	O
as	O
antibiotics	O
,	O
disinfectants	O
and	O
oxidative	O
stress	O
agents	O
by	O
modulating	O
the	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
in	O
the	O
Escherichia	O
coli	O
chromosome	O
.	O

Two	O
E.	O
coli	O
MarA	B
homologues	O
,	O
SoxS	B
and	O
Rob	B
also	O
control	O
,	O
to	O
different	O
extents	O
,	O
genes	O
in	O
the	O
mar	B
/	O
sox	B
/	O
rob	B
regulon	O
.	O

The	O
controlling	O
element	O
for	O
these	O
proteins	O
is	O
a	O
20	O
bp	O
'	O
marbox	O
'	O
sequence	O
in	O
the	O
promoter	O
region	O
of	O
regulated	O
genes	O
.	O

Using	O
in	O
vitro	O
assays	O
and	O
mutagenesis	O
of	O
promoter	O
fusions	O
in	O
whole	O
cells	O
,	O
we	O
identified	O
the	O
cis	O
regulatory	O
element	O
involved	O
in	O
MarA	B
upregulation	O
of	O
the	O
oxygen	B
-	I
insensitive	I
nitroreductase	I
nfnB	B
gene	O
.	O

MarA	B
binds	O
to	O
a	O
marbox	O
that	O
is	O
highly	O
divergent	O
from	O
the	O
previously	O
proposed	O
consensus	O
(	O
eight	O
differences	O
out	O
of	O
14	O
specified	O
nucleotides	O
)	O
.	O

Although	O
purified	O
SoxS	B
and	O
Rob	B
proteins	O
,	O
like	O
MarA	B
,	O
activated	O
nfnB	B
transcription	O
in	O
vitro	O
,	O
only	O
constitutive	O
expression	O
of	O
chromosomal	O
marA	B
,	O
but	O
not	O
of	O
soxS	B
and	O
rob	B
genes	O
,	O
affected	O
nfnB	B
expression	O
in	O
whole	O
cells	O
.	O

Increased	O
expression	O
,	O
but	O
limited	O
as	O
compared	O
with	O
MarA	B
,	O
was	O
only	O
achieved	O
by	O
plasmid	O
-	O
mediated	O
overexpression	O
of	O
SoxS	B
and	O
Rob	B
.	O

This	O
study	O
shows	O
that	O
MarA	B
can	O
regulate	O
gene	O
expression	O
through	O
a	O
functional	O
marbox	O
that	O
is	O
considerably	O
divergent	O
from	O
the	O
current	O
consensus	O
sequence	O
.	O

The	O
data	O
suggest	O
that	O
MarA	B
is	O
preferred	O
over	O
SoxS	B
and	O
Rob	B
in	O
upregulating	O
nfnB	B
.	O

The	O
findings	O
imply	O
that	O
other	O
different	O
but	O
physiologically	O
important	O
marbox	O
DNA	O
-	O
MarA	B
interactions	O
take	O
place	O
in	O
the	O
regulation	O
of	O
still	O
uncharacterized	O
members	O
of	O
the	O
mar	B
regulon	O
.	O

Complex	O
expression	O
of	O
natural	O
killer	O
receptor	O
genes	O
in	O
single	O
natural	O
killer	O
cells	O
.	O

Human	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
express	O
several	O
inhibitory	O
and	O
non	O
-	O
inhibitory	O
NK	O
receptors	O
per	O
cell	O
.	O

Understanding	O
the	O
expression	O
patterns	O
of	O
these	O
receptor	O
genes	O
in	O
individual	O
cells	O
is	O
important	O
to	O
understanding	O
their	O
function	O
.	O

Using	O
a	O
single	O
-	O
cell	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
,	O
we	O
analysed	O
the	O
expression	O
of	O
nine	O
NK	O
receptor	O
genes	O
in	O
38	O
resting	O
CD56	B
+	O
NK	O
cells	O
from	O
peripheral	O
blood	O
of	O
normal	O
donors	O
.	O

We	O
observed	O
highly	O
diverse	O
patterns	O
of	O
receptor	O
expression	O
in	O
these	O
cells	O
.	O

No	O
NK	O
receptor	O
is	O
expressed	O
universally	O
in	O
every	O
CD56	B
+	O
NK	O
cell	O
.	O

The	O
expressed	O
receptor	O
types	O
per	O
cell	O
varied	O
from	O
two	O
to	O
eight	O
.	O

We	O
specifically	O
analysed	O
the	O
distribution	O
of	O
inhibitory	O
(	O
DL	O
)	O
and	O
non	O
-	O
inhibitory	O
(	O
DS	O
)	O
killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
.	O

The	O
frequency	O
of	O
individual	O
receptor	O
expression	O
varied	O
from	O
26	O
%	O
for	O
2DS2	B
to	O
68	O
%	O
for	O
both	O
2DL1	B
and	O
2DL4	B
.	O

A	O
comparison	O
of	O
the	O
coexpression	O
of	O
DL	O
and	O
DS	O
receptors	O
showed	O
a	O
significant	O
association	O
in	O
the	O
expression	O
of	O
2DL2	B
and	O
2DS2	B
(	O
chi2	O
=	O
16.6	O
;	O
P	O
<	O
0.001	O
)	O
genes	O
but	O
no	O
association	O
between	O
2DL1	B
and	O
2DS1	B
or	O
between	O
3DL1	B
and	O
3DS1	B
genes	O
.	O

Coexpression	O
analysis	O
of	O
the	O
2DL1	B
and	O
2DL2	B
genes	O
in	O
2DL4	B
+	O
and	O
2DL4	B
-	O
cells	O
showed	O
a	O
strong	O
association	O
in	O
2DL4	B
+	O
but	O
not	O
in	O
2DL4	B
-	O
cells	O
,	O
suggesting	O
a	O
differential	O
effect	O
of	O
the	O
2DL4	B
gene	O
on	O
the	O
expression	O
of	O
2DL1	B
and	O
2DL2	B
genes	O
.	O

Single	O
-	O
cell	O
RT	O
-	O
PCR	O
is	O
a	O
powerful	O
tool	O
to	O
study	O
multiple	O
receptor	O
gene	O
expression	O
ex	O
vivo	O
in	O
individual	O
NK	O
cells	O
and	O
provides	O
information	O
about	O
the	O
expression	O
pattern	O
of	O
KIR	B
receptors	O
that	O
may	O
suggest	O
mechanisms	O
of	O
gene	O
expression	O
responsible	O
for	O
generation	O
of	O
the	O
KIR	B
repertoire	O
.	O

Critical	O
evaluation	O
of	O
the	O
role	O
of	O
the	O
Toll	B
-	I
like	I
receptor	I
18-Wheeler	B
in	O
the	O
host	O
defense	O
of	O
Drosophila	O
.	O

Essential	O
aspects	O
of	O
innate	O
immune	O
responses	O
to	O
microbial	O
infections	O
appear	O
to	O
be	O
conserved	O
between	O
insects	O
and	O
mammals	O
.	O

In	O
particular	O
,	O
in	O
both	O
groups	O
,	O
transmembrane	O
receptors	O
of	O
the	O
Toll	B
superfamily	I
play	O
a	O
crucial	O
role	O
in	O
activating	O
immune	O
defenses	O
.	O

The	O
Drosophila	O
Toll	B
family	I
member	O
18-Wheeler	B
had	O
been	O
proposed	O
to	O
sense	O
Gram	O
-	O
negative	O
infection	O
and	O
direct	O
selective	O
expression	O
of	O
peptides	O
active	O
against	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Here	O
we	O
re	O
-	O
examine	O
the	O
role	O
of	O
18-Wheeler	B
and	O
show	O
that	O
in	O
adults	O
it	O
is	O
dispensable	O
for	O
immune	O
responses	O
.	O

In	O
larvae	O
,	O
18wheeler	B
is	O
required	O
for	O
normal	O
fat	O
body	O
development	O
,	O
and	O
in	O
mutant	O
larvae	O
induction	O
of	O
all	O
antimicrobial	O
peptide	O
genes	O
,	O
and	O
not	O
only	O
of	O
those	O
directed	O
against	O
Gram	O
-	O
negative	O
bacteria	O
,	O
is	O
compromised	O
.	O

18-Wheeler	B
does	O
not	O
qualify	O
as	O
a	O
pattern	O
recognition	O
receptor	O
of	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Relationship	O
between	O
plasma	O
malondialdehyde	O
levels	O
and	O
adenosine	B
deaminase	I
activities	O
in	O
preeclampsia	O
.	O

BACKGROUND	O
:	O

Preeclampsia	O
is	O
characterized	O
by	O
endothelial	O
cell	O
dysfunction	O
,	O
and	O
lipid	O
peroxidation	O
and	O
alterations	O
of	O
immune	O
responses	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
changes	O
in	O
plasma	O
malondialdehyde	O
(	O
MDA	O
)	O
level	O
,	O
an	O
indicator	O
of	O
lipid	O
peroxidation	O
,	O
and	O
adenosine	B
deaminase	I
(	O
ADA	B
)	O
activity	O
,	O
as	O
a	O
marker	O
of	O
T	O
-	O
cell	O
activation	O
in	O
preeclampsia	O
,	O
and	O
evaluated	O
the	O
possible	O
relationship	O
between	O
those	O
parameters	O
in	O
the	O
pathogenesis	O
of	O
preeclampsia	O
.	O

METHODS	O
:	O

Plasma	O
levels	O
of	O
MDA	O
,	O
an	O
end	O
product	O
of	O
lipid	O
peroxidation	O
induced	O
by	O
reactive	O
oxygen	O
species	O
,	O
and	O
ADA	B
activities	O
were	O
measured	O
in	O
26	O
women	O
with	O
preeclampsia	O
and	O
26	O
normal	O
pregnancies	O
.	O

RESULTS	O
:	O

In	O
preeclampsia	O
,	O
plasma	O
MDA	O
level	O
and	O
ADA	B
activity	O
averaged	O
0.43	O
+	O
/-	O
0.03	O
micromol	O
/	O
l	O
and	O
15.8	O
+	O
/-	O
0.8	O
U	O
/	O
l	O
,	O
respectively	O
,	O
which	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
normal	O
pregnancy	O
(	O
0.31	O
+	O
/-	O
0.02	O
micromol	O
/	O
l	O
and	O
9.5	O
+	O
/	O
-	O
0.6	O
U	O
/	O
l	O
,	O
respectively	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
plasma	O
MDA	O
level	O
was	O
positively	O
correlated	O
to	O
ADA	B
activity	O
in	O
preeclampsia	O
(	O
r	O
=	O
0.52	O
,	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
:	O

These	O
results	O
suggest	O
that	O
enhanced	O
lipid	O
peroxidation	O
and	O
T	O
-	O
cell	O
activation	O
,	O
and	O
the	O
presence	O
of	O
possible	O
interrelationship	O
and	O
cross	O
talk	O
between	O
those	O
parameters	O
may	O
be	O
related	O
at	O
least	O
partly	O
to	O
the	O
pathogenesis	O
of	O
preeclampsia	O
.	O

Nuclear	O
localization	O
of	O
CDC25B1	B
and	O
serine	O
146	O
integrity	O
are	O
required	O
for	O
induction	O
of	O
mitosis	O
.	O

CDC25B	B
phosphatases	I
are	O
essential	O
regulators	O
that	O
control	O
cyclin	B
-	I
dependent	I
kinases	I
activities	O
at	O
the	O
entry	O
into	O
mitosis	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
serine	O
146	O
is	O
required	O
for	O
two	O
crucial	O
features	O
of	O
CDC25B1	B
.	O

It	O
is	O
essential	O
for	O
CDC25B1	B
to	O
function	O
as	O
a	O
mitotic	O
inducer	O
and	O
to	O
prevent	O
CDC25B1	B
export	O
from	O
the	O
nucleus	O
.	O

We	O
also	O
show	O
that	O
serine	O
146	O
is	O
phosphorylated	O
in	O
vitro	O
by	O
CDK1	B
-	O
cyclin	B
B	I
.	O

However	O
,	O
phosphorylation	O
of	O
CDC25B	B
does	O
not	O
stimulate	O
its	O
phosphatase	B
activity	O
,	O
and	O
mutation	O
of	O
serine	O
146	O
had	O
no	O
effect	O
on	O
its	O
catalytic	O
activity	O
.	O

Serine	O
146	O
phosphorylation	O
is	O
proposed	O
to	O
be	O
a	O
key	O
event	O
in	O
the	O
regulation	O
of	O
the	O
CDC25B	B
function	O
in	O
the	O
initiation	O
of	O
mammalian	O
mitosis	O
.	O

Identification	O
,	O
characterization	O
,	O
and	O
functional	O
study	O
of	O
the	O
two	O
novel	O
human	O
members	O
of	O
the	O
semaphorin	B
gene	I
family	I
.	O

We	O
cloned	O
two	O
novel	O
human	O
transmembrane	O
semaphorins	B
,	O
(	O
HSA	O
)	O
SEMA6C	B
and	O
(	O
HSA	O
)	O
SEMA6D	B
,	O
that	O
belong	O
to	O
the	O
class	O
VI	O
subgroup	O
of	O
the	O
semaphorin	B
family	I
.	O

The	O
genes	O
for	O
SEMA6C	B
and	O
SEMA6D	B
are	O
mapped	O
on	O
chromosome	O
1q12	O
-	O
21.1	O
and	O
15q21.1	O
,	O
respectively	O
.	O

Among	O
the	O
adult	O
tissues	O
,	O
SEMA6C	B
is	O
expressed	O
only	O
in	O
skeletal	O
muscle	O
,	O
whereas	O
SEMA6D	B
is	O
expressed	O
abundantly	O
in	O
kidney	O
,	O
brain	O
,	O
and	O
placenta	O
and	O
moderately	O
in	O
the	O
heart	O
and	O
skeletal	O
muscles	O
.	O

During	O
murine	O
development	O
,	O
neither	O
SEMA6C	B
nor	O
SEMA6D	B
was	O
expressed	O
in	O
embryonic	O
day	O
10.5	O
(	O
E10.5	O
)	O
embryos	O
,	O
but	O
both	O
were	O
highly	O
expressed	O
in	O
the	O
areas	O
of	O
the	O
lateral	O
ventricle	O
,	O
the	O
striatum	O
,	O
the	O
wall	O
of	O
the	O
midbrain	O
,	O
the	O
pons	O
/	O
midbrain	O
junction	O
,	O
and	O
the	O
choroid	O
plexus	O
of	O
E13	O
embryos	O
.	O

Were	O
neurons	O
,	O
neither	O
axons	O
nor	O
astrocytes	O
,	O
highly	O
expressed	O
both	O
semaphorins	B
.	O

Three	O
isoforms	O
of	O
SEMA6C	B
and	O
five	O
isoforms	O
of	O
SEMA6D	B
derived	O
from	O
alternative	O
splicing	O
were	O
identified	O
,	O
and	O
their	O
expression	O
was	O
regulated	O
in	O
a	O
tissue	O
-	O
and	O
development	O
-	O
dependent	O
manner	O
.	O

Deletion	O
analysis	O
indicated	O
that	O
a	O
sema	O
domain	O
and	O
a	O
PSI	O
domain	O
are	O
integrally	O
necessary	O
for	O
correct	O
post	O
-	O
translation	O
modification	O
and	O
subcellular	O
localization	O
.	O

The	O
extracellular	O
domain	O
of	O
SEMA6C	B
inhibited	O
axonal	O
extension	O
of	O
nerve	B
growth	I
factor	I
-	O
differentiated	O
PC12	O
cells	O
and	O
induced	O
the	O
growth	O
cone	O
collapse	O
of	O
chicken	O
dorsal	O
root	O
ganglion	O
,	O
rat	O
hippocampal	O
neurons	O
,	O
and	O
rat	O
cortical	O
neurons	O
in	O
a	O
dose	O
-	O
responsive	O
manner	O
.	O

SEMA6D	B
acted	O
like	O
SEMA6C	B
except	O
it	O
had	O
no	O
significant	O
effect	O
on	O
the	O
growth	O
cones	O
of	O
rat	O
cortical	O
neurons	O
.	O

Synaptotagmins	B
I	I
and	I
IV	I
promote	O
transmitter	O
release	O
independently	O
of	O
Ca	O
(	O
2	O
+	O
)	O
binding	O
in	O
the	O
C	O
(	O
2	O
)	O
A	O
domain	O
.	O

At	O
nerve	O
terminals	O
,	O
a	O
focal	O
and	O
transient	O
increase	O
in	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
triggers	O
the	O
fusion	O
of	O
neurotransmitter	O
-	O
filled	O
vesicles	O
with	O
the	O
plasma	O
membrane	O
.	O

The	O
most	O
extensively	O
studied	O
candidate	O
for	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
sensing	O
trigger	O
is	O
synaptotagmin	B
I	I
,	O
whose	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
interactions	O
with	O
acidic	O
phospholipids	O
and	O
syntaxin	B
have	O
largely	O
been	O
ascribed	O
to	O
its	O
C	O
(	O
2	O
)	O
A	O
domain	O
,	O
although	O
the	O
C	O
(	O
2	O
)	O
B	O
domain	O
also	O
binds	O
Ca	O
(	O
2	O
+	O
)	O
(	O
refs	O
7	O
,	O
8	O
)	O
.	O

Genetic	O
tests	O
of	O
synaptotagmin	B
I	I
have	O
been	O
equivocal	O
as	O
to	O
whether	O
it	O
is	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
sensing	O
trigger	O
of	O
fusion	O
.	O

Synaptotagmin	B
IV	I
,	O
a	O
related	O
isoform	O
that	O
does	O
not	O
bind	O
Ca	O
(	O
2	O
+	O
)	O
in	O
the	O
C	O
(	O
2	O
)	O
A	O
domain	O
,	O
might	O
be	O
an	O
inhibitor	O
of	O
release	O
.	O

We	O
mutated	O
an	O
essential	O
aspartate	O
of	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
binding	O
site	O
of	O
the	O
synaptotagmin	B
I	I
C	O
(	O
2	O
)	O
A	O
domain	O
and	O
expressed	O
it	O
in	O
Drosophila	O
lacking	O
synaptotagmin	B
I	I
.	O

Here	O
we	O
show	O
that	O
,	O
despite	O
the	O
disruption	O
of	O
the	O
binding	O
site	O
,	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
properties	O
of	O
transmission	O
were	O
not	O
altered	O
.	O

Similarly	O
,	O
we	O
found	O
that	O
synaptotagmin	B
IV	I
could	O
substitute	O
for	O
synaptotagmin	B
I	I
.	O

We	O
conclude	O
that	O
the	O
C	O
(	O
2	O
)	O
A	O
domain	O
of	O
synaptotagmin	B
is	O
not	O
required	O
for	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
synaptic	O
transmission	O
,	O
and	O
that	O
synaptotagmin	B
IV	I
promotes	O
rather	O
than	O
inhibits	O
transmission	O
.	O

A	O
novel	O
polymorphism	O
in	O
exon	O
11	O
of	O
the	O
WKL1	B
gene	O
,	O
shows	O
no	O
association	O
with	O
schizophrenia	O
.	O

A	O
missense	O
mutation	O
in	O
exon	O
11	O
of	O
the	O
WKL1	B
gene	O
on	O
chromosome	O
22	O
was	O
found	O
to	O
be	O
associated	O
with	O
cases	O
of	O
catatonic	O
schizophrenia	O
in	O
a	O
single	O
large	O
pedigree	O
.	O

We	O
have	O
screened	O
exon	O
11	O
of	O
the	O
WKL1	B
gene	O
in	O
174	O
cases	O
of	O
schizophrenia	O
,	O
including	O
cases	O
of	O
22	O
cases	O
of	O
catatonic	O
schizophrenia	O
,	O
but	O
could	O
not	O
detect	O
the	O
previously	O
reported	O
mis	O
-	O
sense	O
mutation	O
.	O

However	O
in	O
exon	O
11	O
,	O
we	O
observed	O
an	O
insertion	O
/	O
deletion	O
polymorphism	O
,	O
one	O
-	O
missense	O
substitution	O
and	O
two	O
synonymous	O
substitutions	O
.	O

In	O
addition	O
,	O
we	O
also	O
identified	O
a	O
nucleotide	O
substitution	O
in	O
intron	O
11	O
.	O

All	O
these	O
polymorphisms	O
appeared	O
to	O
be	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
one	O
another	O
.	O

The	O
polymorphisms	O
were	O
also	O
identified	O
in	O
a	O
UK	O
pedigree	O
with	O
schizophrenia	O
,	O
however	O
the	O
polymorphisms	O
did	O
not	O
segregate	O
with	O
the	O
disease	O
.	O

To	O
test	O
for	O
potential	O
association	O
between	O
these	O
polymorphisms	O
and	O
schizophrenia	O
we	O
sequenced	O
an	O
equal	O
number	O
of	O
UK	O
control	O
individuals	O
who	O
were	O
free	O
of	O
all	O
psychiatric	O
symptoms	O
and	O
had	O
negative	O
family	O
histories	O
for	O
mental	O
illness	O
;	O
the	O
frequency	O
of	O
the	O
insertion	O
/	O
deletion	O
polymorphism	O
was	O
not	O
significantly	O
different	O
in	O
schizophrenia	O
cases	O
(	O
42	O
out	O
of	O
348	O
chromosomes	O
,	O
allele	O
frequency	O
12	O
%	O
)	O
compared	O
to	O
normal	O
controls	O
(	O
40	O
out	O
of	O
356	O
chromosomes	O
,	O
allele	O
frequency	O
11	O
%	O
)	O
.	O

The	O
insertion	O
/	O
deletion	O
was	O
found	O
to	O
be	O
in	O
Hardy	O
Weinberg	O
equilibrium	O
in	O
both	O
the	O
schizophrenic	O
and	O
control	O
groups	O
.	O

The	O
insertion	O
/	O
deletion	O
is	O
composed	O
of	O
repeated	O
sequence	O
from	O
exon	O
11	O
and	O
intron	O
11	O
and	O
is	O
predicted	O
to	O
affect	O
WKL1	B
protein	O
structure	O
.	O

HIV-1	O
Tat	B
interaction	O
with	O
RNA	B
polymerase	I
II	I
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
and	O
a	O
dynamic	O
association	O
with	O
CDK2	B
induce	O
CTD	O
phosphorylation	O
and	O
transcription	O
from	O
HIV-1	O
promoter	O
.	O

Human	O
immunodeficiency	O
virus	O
,	O
type	O
1	O
(	O
HIV-1	O
)	O
,	O
Tat	B
protein	O
activates	O
viral	O
gene	O
expression	O
through	O
promoting	O
transcriptional	O
elongation	O
by	O
RNA	B
polymerase	I
II	I
(	O
RNAPII	B
)	O
.	O

In	O
this	O
process	O
Tat	B
enhances	O
phosphorylation	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
RNAPII	B
by	O
activating	O
cell	B
cycle	I
-	I
dependent	I
kinases	I
(	O
CDKs	B
)	O
associated	O
with	O
general	O
transcription	B
factors	I
of	O
the	O
promoter	O
complex	O
,	O
specifically	O
CDK7	B
and	O
CDK9	B
.	O

We	O
reported	O
a	O
Tat	B
-	O
associated	O
T	O
-	O
cell	O
-	O
derived	O
kinase	B
,	O
which	O
contained	O
CDK2	B
.	O

Here	O
,	O
we	O
provide	O
further	O
evidence	O
that	O
CDK2	B
is	O
involved	O
in	O
Tat	B
-	O
mediated	O
CTD	O
phosphorylation	O
and	O
in	O
HIV-1	O
transcription	O
in	O
vitro	O
.	O

Tat	B
-	O
mediated	O
CTD	O
phosphorylation	O
by	O
CDK2	B
required	O
cysteine	O
22	O
in	O
the	O
activation	O
domain	O
of	O
Tat	B
and	O
amino	O
acids	O
42	O
-	O
72	O
of	O
Tat	B
.	O

CDK2	B
phosphorylated	O
Tat	B
itself	O
,	O
apparently	O
by	O
forming	O
dynamic	O
contacts	O
with	O
amino	O
acids	O
15	O
-	O
24	O
and	O
36	O
-	O
49	O
of	O
Tat	B
.	O

Also	O
,	O
amino	O
acids	O
24	O
-	O
36	O
and	O
45	O
-	O
72	O
of	O
Tat	B
interacted	O
with	O
CTD	O
.	O

CDK2	B
associated	O
with	O
RNAPII	B
and	O
was	O
found	O
in	O
elongation	O
complexes	O
assembled	O
on	O
HIV-1	O
long	O
-	O
terminal	O
repeat	O
template	O
.	O

Recombinant	O
CDK2	B
/	O
cyclin	B
E	I
stimulated	O
Tat	B
-	O
dependent	O
HIV-1	O
transcription	O
in	O
reconstituted	O
transcription	O
assay	O
.	O

Immunodepletion	O
of	O
CDK2	B
/	O
cyclin	B
E	I
in	O
HeLa	O
nuclear	O
extract	O
blocked	O
Tat	B
-	O
dependent	O
transcription	O
.	O

We	O
suggest	O
that	O
CDK2	B
is	O
part	O
of	O
a	O
transcription	O
complex	O
that	O
is	O
required	O
for	O
Tat	B
-	O
dependent	O
transcription	O
and	O
that	O
interaction	O
of	O
Tat	B
with	O
CTD	O
and	O
a	O
dynamic	O
association	O
of	O
Tat	B
with	O
CDK2	B
/	O
cyclin	B
E	I
stimulated	O
CTD	O
phosphorylation	O
by	O
CDK2	B
.	O

Inflammatory	O
mediator	O
mRNA	O
expression	O
by	O
adenovirus	O
E1A	B
-	O
transfected	O
bronchial	O
epithelial	O
cells	O
.	O

Lung	O
tissue	O
from	O
patients	O
with	O
emphysema	O
and	O
airway	O
obstruction	O
carries	O
excess	O
adenoviral	O
E1A	B
DNA	O
that	O
is	O
expressed	O
as	O
protein	O
in	O
airway	O
surface	O
epithelium	O
and	O
is	O
associated	O
with	O
an	O
increased	O
inflammatory	O
response	O
.	O

To	O
examine	O
mechanisms	O
by	O
which	O
latent	O
adenoviral	O
infection	O
might	O
amplify	O
the	O
inflammatory	O
process	O
,	O
we	O
transfected	O
primary	O
human	O
bronchial	O
epithelial	O
(	O
HBE	O
)	O
cells	O
from	O
three	O
separate	O
patients	O
undergoing	O
lung	O
resection	O
so	O
that	O
they	O
stably	O
expressed	O
adenovirus	O
E1A	B
.	O

Lipopolysaccharide	O
stimulation	O
of	O
the	O
E1A	B
-	O
transfected	O
HBE	O
cells	O
increased	O
intercellular	B
adhesion	I
molecule-1	I
and	O
interleukin-8	B
mRNA	O
and	O
protein	O
expression	O
compared	O
with	O
control	O
cells	O
from	O
the	O
same	O
patient	O
.	O

It	O
also	O
induced	O
greater	O
intercellular	B
adhesion	I
molecule-1	I
promoter	O
activity	O
and	O
greater	O
nuclear	B
factor	I
-	I
kappa	I
B	I
binding	O
activity	O
of	O
nuclear	O
extracts	O
in	O
E1A	B
transfectants	O
than	O
controls	O
.	O

E1A	B
-	O
positive	O
transfectants	O
constitutively	O
expressed	O
transforming	B
growth	I
factor	I
-	I
beta	I
1	I
mRNA	O
and	O
protein	O
,	O
whereas	O
this	O
expression	O
was	O
either	O
very	O
low	O
or	O
not	O
detected	O
in	O
control	O
cells	O
.	O

We	O
conclude	O
that	O
adenoviral	O
E1A	B
transfection	O
transforms	O
primary	O
HBE	O
cells	O
and	O
upregulates	O
their	O
production	O
of	O
mediators	O
that	O
are	O
clinically	O
relevant	O
to	O
the	O
pathogenesis	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Novel	O
mode	O
of	O
transcription	O
regulation	O
of	O
divergently	O
overlapping	O
promoters	O
by	O
PhoP	B
,	O
the	O
regulator	O
of	O
two	O
-	O
component	O
system	O
sensing	O
external	O
magnesium	O
availability	O
.	O

PhoP	B
is	O
a	O
response	O
regulator	O
of	O
the	O
PhoQ	B
-	O
PhoP	B
two	O
-	O
component	O
system	O
controlling	O
a	O
set	O
of	O
the	O
Mg	O
(	O
II	O
)	O
-	O
response	O
genes	O
in	O
Escherichia	O
coli	O
.	O

Here	O
we	O
demonstrate	O
the	O
mode	O
of	O
transcription	O
regulation	O
by	O
phosphorylated	O
PhoP	B
of	O
divergently	O
transcribed	O
mgtA	B
and	O
treR	B
genes	O
,	O
each	O
encoding	O
a	O
putative	O
Mg	O
(	O
II	O
)	O
transporter	O
and	O
a	O
repressor	O
for	O
the	O
trehalose	O
utilization	O
operon	O
respectively	O
.	O

Under	O
Mg	O
(	O
II	O
)	O
-	O
limiting	O
conditions	O
in	O
vivo	O
,	O
two	O
promoters	O
,	O
the	O
upstream	O
constitutive	O
P2	O
and	O
the	O
downstream	O
inducible	O
P1	O
,	O
were	O
detected	O
for	O
the	O
mgtA	B
gene	O
.	O

Gel	O
-	O
shift	O
analysis	O
in	O
vitro	O
using	O
purified	O
PhoP	B
indicates	O
its	O
binding	O
to	O
a	O
single	O
DNA	O
target	O
,	O
centred	O
between	O
-	O
43	O
and	O
-	O
24	O
of	O
the	O
mgtAP1	O
promoter	O
.	O

This	O
region	O
includes	O
the	O
PhoP	B
box	O
,	O
which	O
consists	O
of	O
a	O
direct	O
repeat	O
of	O
the	O
heptanucleotide	O
sequence	O
(	O
T	O
)	O
G	O
(	O
T	O
)	O
TT	O
(	O
AA	O
)	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
indicate	O
the	O
critical	O
roles	O
for	O
T	O
(	O
position	O
3	O
)	O
,	O
T	O
(	O
position	O
4	O
)	O
and	O
A	O
(	O
position	O
6	O
)	O
for	O
PhoP	B
-	O
dependent	O
transcription	O
from	O
mgtAP1	O
.	O

DNase	B
I	I
footprinting	O
assays	O
reveal	O
weak	O
binding	O
of	O
PhoP	B
to	O
this	O
PhoP	B
box	O
,	O
but	O
the	O
binding	O
becomes	O
stronger	O
in	O
the	O
simultaneous	O
presence	O
of	O
RNA	B
polymerase	I
.	O

Likewise	O
the	O
RNA	B
polymerase	I
binding	O
to	O
the	O
P1	O
promoter	O
becomes	O
stronger	O
in	O
the	O
presence	O
of	O
PhoP	B
.	O

For	O
the	O
PhoP	B
-	O
assisted	O
formation	O
of	O
open	O
complex	O
at	O
the	O
mgtAP1	O
promoter	O
,	O
however	O
,	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
alpha	O
subunit	O
(	O
alpha	O
CTD	O
)	O
is	O
not	O
needed	O
.	O

For	O
transcription	O
in	O
vivo	O
of	O
the	O
treR	B
gene	O
,	O
four	O
promoters	O
were	O
identified	O
.	O

The	O
most	O
upstream	O
promoter	O
treRP4	O
divergently	O
overlaps	O
with	O
the	O
mgtAP1	O
promoter	O
,	O
sharing	O
the	O
same	O
sequence	O
as	O
the	O
respective	O
-	O
10	O
signal	O
in	O
the	O
opposite	O
direction	O
.	O

In	O
vitro	O
transcription	O
using	O
mutant	O
promoters	O
support	O
this	O
prediction	O
.	O

In	O
the	O
presence	O
of	O
PhoP	B
,	O
transcription	O
from	O
the	O
promoter	O
treRP3	O
was	O
repressed	O
with	O
concomitant	O
activation	O
of	O
mgtAP1	O
transcription	O
.	O

The	O
PhoP	B
box	O
is	O
located	O
between	O
-	O
46	O
and	O
-	O
30	O
with	O
respect	O
to	O
treRP3	O
,	O
and	O
the	O
alpha	O
CTD	O
is	O
needed	O
for	O
this	O
repression	O
.	O

CNS	O
myelinogenesis	O
in	O
vitro	O
:	O
myelin	B
basic	I
protein	I
deficient	O
shiverer	O
oligodendrocytes	O
.	O

The	O
shiverer	O
mutant	O
mouse	O
is	O
an	O
autosomal	O
recessive	O
mutant	O
characterized	O
by	O
incomplete	O
myelin	O
sheath	O
formation	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Such	O
mice	O
contain	O
a	O
deletion	O
in	O
the	O
MBP	B
gene	O
,	O
do	O
not	O
produce	O
MBP	B
proteins	O
,	O
and	O
have	O
little	O
or	O
no	O
compact	O
myelin	O
in	O
the	O
CNS	O
.	O

To	O
investigate	O
the	O
myelin	O
sheath	O
formation	O
in	O
shiverer	O
mutant	O
mice	O
resulting	O
from	O
the	O
absence	O
of	O
compact	O
myelin	O
,	O
firstly	O
we	O
developed	O
new	O
methods	O
for	O
generating	O
oligodendrocyte	O
precursor	O
cells	O
(	O
OPCs	O
)	O
from	O
an	O
E17	O
mouse	O
brain	O
,	O
and	O
examined	O
homozygous	O
shiverer	O
(	O
shi	O
/	O
shi	O
)	O
OPCs	O
with	O
respect	O
to	O
myelinogenesis	O
in	O
vitro	O
.	O

After	O
treatment	O
of	O
shi	O
/	O
shi	O
OPCs	O
in	O
vitro	O
with	O
PDGF	B
or	O
bFGF	B
,	O
proliferation	O
of	O
shi	O
/	O
shi	O
OPCs	O
was	O
enhanced	O
similar	O
to	O
that	O
observed	O
in	O
wild	O
-	O
type	O
OPCs	O
.	O

The	O
majority	O
of	O
cells	O
from	O
the	O
shiverer	O
mutant	O
mouse	O
,	O
however	O
,	O
remained	O
as	O
A2B5	O
-	O
immunoreactive	O
early	O
OPCs	O
.	O

To	O
determine	O
which	O
molecular	O
events	O
affect	O
the	O
differentiation	O
of	O
shi	O
/	O
shi	O
OPCs	O
,	O
we	O
determined	O
the	O
signaling	O
pathway	O
that	O
could	O
be	O
responsible	O
for	O
activating	O
myelin	O
sheath	O
-	O
specific	O
proteins	O
.	O

We	O
found	O
that	O
the	O
developmental	O
schedule	O
of	O
shi	O
/	O
shi	O
OPCs	O
in	O
vitro	O
was	O
accelerated	O
by	O
the	O
addition	O
of	O
cyclic	O
AMP	O
analogs	O
,	O
dibutyryl	O
cAMP	O
(	O
dbcAMP	O
)	O
.	O

Treatment	O
of	O
shi	O
/	O
shi	O
OPCs	O
with	O
dbcAMP	O
had	O
significant	O
effect	O
on	O
the	O
differentiation	O
of	O
OPCs	O
that	O
became	O
MAG	B
-	O
expressing	O
oligodendrocytes	O
.	O

To	O
further	O
determine	O
the	O
possible	O
mechanism	O
involved	O
in	O
the	O
activation	O
of	O
MAG	B
by	O
dbcAMP	O
,	O
we	O
examined	O
the	O
cAMP	O
-	O
dependent	O
signaling	O
cascades	O
.	O

The	O
activation	O
of	O
JNK	B
was	O
markedly	O
stimulated	O
by	O
treatment	O
with	O
dbcAMP	O
,	O
and	O
the	O
phosphorylation	O
of	O
transcription	B
factor	I
ATF	B
-	I
2	I
was	O
also	O
stimulated	O
by	O
dbcAMP	O
.	O

We	O
demonstrated	O
that	O
the	O
MAG	B
-	O
positive	O
shi	O
/	O
shi	O
oligodendrocytes	O
extend	O
processes	O
around	O
axons	O
and	O
finally	O
covered	O
the	O
axon	O
,	O
this	O
was	O
clearly	O
observed	O
by	O
immunocytochemistry	O
of	O
shi	O
/	O
shi	O
oligodendrocyte	O
-	O
DRG	O
cocultures	O
.	O

These	O
results	O
suggest	O
that	O
ATF-2	B
coupled	O
to	O
specific	O
signal	O
transduction	O
cascades	O
plays	O
an	O
important	O
regulatory	O
role	O
in	O
MAG	B
expression	O
at	O
a	O
specific	O
stage	O
of	O
shi	O
/	O
shi	O
oligodendrocyte	O
differentiation	O
,	O
and	O
OPCs	O
grow	O
to	O
become	O
myelin	O
-	O
forming	O
cells	O
with	O
numerous	O
cell	O
processes	O
that	O
wraps	O
around	O
an	O
axon	O
to	O
form	O
a	O
thin	O
myelin	O
sheath	O
.	O

Human	O
lactiferous	O
mammary	O
gland	O
cells	O
produce	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
and	O
express	O
the	O
VEGF	B
receptors	I
,	O
Flt-1	B
AND	O
KDR	B
/	O
Flk-1	B
.	O

Human	O
milk	O
contains	O
a	O
variety	O
of	O
growth	B
factors	I
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
was	O
one	O
of	O
them	O
.	O

We	O
investigated	O
milk	O
VEGF	B
isoforms	O
,	O
their	O
functions	O
,	O
and	O
VEGF	B
receptors	I
on	O
mammary	O
gland	O
epithelial	O
cells	O
(	O
MEC	O
)	O
.	O

The	O
VEGF	B
concentration	O
in	O
human	O
milk	O
was	O
74.3	O
+	O
/-34.9ng	O
/	O
ml	O
on	O
the	O
first	O
day	O
after	O
delivery	O
,	O
and	O
rapidly	O
decreased	O
in	O
a	O
couple	O
of	O
days	O
to	O
6.2	O
+	O
/-2.3ng	O
/	O
ml	O
on	O
the	O
fifth	O
day	O
,	O
and	O
matured	O
milk	O
maintained	O
about	O
4ng	O
/	O
ml	O
.	O

In	O
an	O
MTT	O
assay	O
,	O
human	O
milk	O
accelerated	O
HUVEC	O
proliferation	O
and	O
MV303	O
,	O
a	O
neutralizing	O
antibody	O
of	O
VEGF	B
,	O
blocked	O
17.3	O
%	O
of	O
the	O
effect	O
.	O

Immunoprecipitation	O
and	O
Western	O
blotting	O
showed	O
that	O
VEGF121	B
and	O
VEGF165	B
were	O
contained	O
in	O
human	O
colostrums	O
,	O
and	O
RT	O
-	O
PCR	O
of	O
human	O
MEC	O
confirmed	O
that	O
VEGF121	B
,	O
VEGF165	B
and	O
VEGF189	B
were	O
present	O
.	O

By	O
immunostaining	O
of	O
human	O
breast	O
tissues	O
,	O
RT	O
-	O
PCR	O
of	O
MEC	O
from	O
human	O
colostrum	O
and	O
measurement	O
of	O
the	O
VEGF	B
concentrations	O
of	O
conditioned	O
media	O
of	O
cultured	O
human	O
MEC	O
,	O
it	O
was	O
confirmed	O
that	O
VEGF	B
was	O
produced	O
by	O
MEC	O
.	O

MEC	O
was	O
also	O
expressed	O
VEGF	B
receptors	I
,	O
flt-1	B
and	O
Flk-1	B
/	O
KDR	B
.	O

These	O
results	O
speculate	O
us	O
that	O
the	O
existence	O
of	O
autocrine	O
or	O
paracrine	O
system	O
within	O
breast	O
tissue	O
via	O
VEGF	B
receptors	I
on	O
MEC	O
and	O
have	O
a	O
role	O
in	O
lactation	O
.	O

Functional	O
replacement	O
of	O
the	O
tobacco	O
rattle	O
virus	O
cysteine	O
-	O
rich	O
protein	O
by	O
pathogenicity	O
proteins	O
from	O
unrelated	O
plant	O
viruses	O
.	O

Mutation	O
of	O
the	O
16	B
K	I
gene	O
encoded	O
by	O
RNA1	O
of	O
Tobacco	O
rattle	O
virus	O
(	O
TRV	O
)	O
greatly	O
reduced	O
the	O
levels	O
of	O
viral	O
RNA	O
that	O
accumulated	O
in	O
both	O
infected	O
protoplasts	O
and	O
plants	O
,	O
showing	O
that	O
the	O
16	B
K	I
cysteine	O
-	O
rich	O
protein	O
(	O
CRP	O
)	O
is	O
required	O
for	O
efficient	O
multiplication	O
of	O
TRV	O
.	O

Overexpression	O
of	O
the	O
16	B
K	I
protein	I
,	O
either	O
from	O
an	O
additional	O
copy	O
of	O
the	O
gene	O
carried	O
on	O
TRV	O
RNA2	O
or	O
from	O
a	O
PVX	O
vector	O
,	O
led	O
to	O
an	O
increase	O
in	O
the	O
severity	O
of	O
disease	O
symptoms	O
,	O
suggesting	O
that	O
the	O
protein	O
has	O
a	O
role	O
in	O
the	O
pathogenicity	O
of	O
the	O
virus	O
.	O

Mutation	O
of	O
the	O
16	B
K	I
gene	O
could	O
be	O
overcome	O
by	O
expression	O
from	O
RNA2	O
of	O
the	O
Cucumber	O
mosaic	O
virus	O
2b	B
gene	O
,	O
the	O
Soil	O
-	O
borne	O
wheat	O
mosaic	O
virus	O
19	B
K	I
gene	O
,	O
or	O
the	O
Barley	O
stripe	O
mosaic	O
virus	O
gammab	B
gene	O
,	O
indicating	O
that	O
the	O
proteins	O
encoded	O
by	O
these	O
diverse	O
genes	O
may	O
have	O
similar	O
functions	O
.	O

One	O
known	O
function	O
of	O
the	O
CMV	O
2b	B
gene	O
is	O
as	O
a	O
suppressor	O
of	O
posttranscriptional	O
gene	O
silencing	O
,	O
suggesting	O
that	O
the	O
TRV	O
16	B
K	I
protein	O
may	O
also	O
possess	O
this	O
activity	O
.	O

Association	O
of	O
the	O
adaptor	O
TANK	B
with	O
the	O
I	B
kappa	I
B	I
kinase	I
(	O
IKK	B
)	O
regulator	O
NEMO	B
connects	O
IKK	B
complexes	I
with	O
IKK	B
epsilon	I
and	O
TBK1	B
kinases	B
.	O

Canonical	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
mediated	O
via	O
phosphorylation	O
of	O
the	O
inhibitory	O
I	B
kappa	I
B	I
proteins	O
by	O
the	O
I	B
kappa	I
B	I
kinase	I
complex	I
(	O
IKK	B
)	O
.	O

IKK	B
is	O
composed	O
of	O
a	O
heterodimer	O
of	O
the	O
catalytic	O
IKK	B
alpha	I
and	O
IKK	B
beta	I
subunits	O
and	O
a	O
presumed	O
regulatory	O
protein	O
termed	O
NEMO	B
(	O
NF	B
-	I
kappa	I
B	I
essential	I
modulator	I
)	O
or	O
IKK	B
gamma	I
.	O

NEMO	B
/	O
IKK	B
gamma	I
is	O
indispensable	O
for	O
activation	O
of	O
the	O
IKKs	B
in	O
response	O
to	O
many	O
signals	O
,	O
but	O
its	O
mechanism	O
of	O
action	O
remains	O
unclear	O
.	O

Here	O
we	O
identify	O
TANK	B
(	O
TRAF	B
family	I
member	I
-	I
associated	I
NF	I
-	I
kappa	I
B	I
activator	I
)	O
as	O
a	O
NEMO	B
/	O
IKK	B
gamma	I
-	O
interacting	O
protein	O
via	O
yeast	O
two	O
-	O
hybrid	O
analyses	O
.	O

This	O
interaction	O
is	O
confirmed	O
in	O
mammalian	O
cells	O
,	O
and	O
the	O
domains	O
required	O
are	O
mapped	O
.	O

TANK	B
was	O
previously	O
shown	O
to	O
assist	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
a	O
complex	O
with	O
TANK	B
-	I
binding	I
kinase	I
1	I
(	O
TBK1	B
)	O
or	O
IKK	B
epsilon	I
,	O
two	O
kinases	B
distantly	O
related	O
to	O
IKK	B
alpha	I
/	I
beta	I
,	O
but	O
the	O
underlying	O
mechanisms	O
remained	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
TBK1	B
and	O
IKK	B
epsilon	I
synergize	O
with	O
TANK	B
to	O
promote	O
interaction	O
with	O
the	O
IKKs	B
.	O

The	O
TANK	B
binding	O
domain	O
within	O
NEMO	B
/	O
IKK	B
gamma	I
is	O
required	O
for	O
proper	O
functioning	O
of	O
this	O
IKK	B
subunit	O
.	O

These	O
results	O
indicate	O
that	O
TANK	B
can	O
synergize	O
with	O
IKK	B
epsilon	I
or	O
TBK1	B
to	O
link	O
them	O
to	O
IKK	B
complexes	I
,	O
where	O
the	O
two	O
kinases	B
may	O
modulate	O
aspects	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O

Characterization	O
of	O
mammalian	O
eIF2A	B
and	O
identification	O
of	O
the	O
yeast	O
homolog	O
.	O

To	O
begin	O
the	O
physical	O
characterization	O
of	O
eukaryotic	B
initiation	I
factor	I
(	I
eIF	I
)	I
2A	I
,	O
a	O
translation	B
initiation	I
factor	I
that	O
binds	O
Met	O
-	O
tRNA	O
(	O
i	O
)	O
,	O
tryptic	O
peptides	O
from	O
rabbit	O
reticulocyte	O
eIF2A	B
were	O
analyzed	O
to	O
obtain	O
amino	O
acid	O
sequence	O
information	O
.	O

Sequences	O
for	O
8	O
peptides	O
were	O
matched	O
to	O
three	O
different	O
expressed	O
sequence	O
tag	O
clones	O
.	O

The	O
sequence	O
predicted	O
for	O
eIF2A	B
is	O
585	O
amino	O
acids	O
.	O

Matching	O
of	O
the	O
cDNA	O
sequence	O
to	O
the	O
human	O
genome	O
revealed	O
that	O
the	O
eIF2A	B
mRNA	O
is	O
made	O
up	O
of	O
15	O
or	O
16	O
exons	O
,	O
and	O
the	O
gene	O
is	O
contained	O
on	O
chromosome	O
3	O
.	O

A	O
homolog	O
in	O
Saccharomyces	O
cerevisiae	O
was	O
identified	O
,	O
YGR054W	B
,	O
which	O
is	O
a	O
non	O
-	O
essential	O
gene	O
.	O

Hemagglutinin	B
-	O
tagged	O
yeast	O
eIF2A	B
localizes	O
on	O
both	O
40	O
S	O
and	O
80	O
S	O
ribosomes	O
.	O

A	O
knockout	O
of	O
both	O
eIF2A	B
and	O
eIF5B	B
yielded	O
a	O
""""	O
synthetically	O
sick	O
""""	O
yeast	O
strain	O
with	O
a	O
severe	O
slow	O
growth	O
phenotype	O
.	O

The	O
phenotype	O
of	O
this	O
double	O
mutant	O
and	O
the	O
biochemical	O
localization	O
suggest	O
that	O
eIF2A	B
participates	O
in	O
translation	O
initiation	O
.	O

eIF2A	B
does	O
not	O
appear	O
to	O
participate	O
in	O
re	O
-	O
initiation	O
as	O
the	O
DeltaeIF2A	O
strain	O
shows	O
the	O
same	O
level	O
of	O
GCN4	B
induction	O
with	O
amino	O
acid	O
starvation	O
as	O
seen	O
in	O
wild	O
type	O
yeast	O
.	O

The	O
lack	O
of	O
any	O
apparent	O
phenotype	O
in	O
the	O
DeltaeIF2A	O
strain	O
suggests	O
that	O
eIF2A	B
functions	O
in	O
a	O
minor	O
pathway	O
,	O
perhaps	O
internal	O
initiation	O
or	O
in	O
the	O
translation	O
of	O
a	O
small	O
number	O
of	O
specific	O
mRNAs	O
.	O

Unconventional	O
Rac	B
-	I
GEF	I
activity	O
is	O
mediated	O
through	O
the	O
Dock180	B
-	O
ELMO	B
complex	O
.	O

Mammalian	O
Dock180	B
and	O
ELMO	B
proteins	O
,	O
and	O
their	O
homologues	O
in	O
Caenorhabditis	O
elegans	O
and	O
Drosophila	O
melanogaster	O
,	O
function	O
as	O
critical	O
upstream	O
regulators	O
of	O
Rac	B
during	O
development	O
and	O
cell	O
migration	O
.	O

The	O
mechanism	O
by	O
which	O
Dock180	B
or	O
ELMO	B
mediates	O
Rac	B
activation	O
is	O
not	O
understood	O
.	O

Here	O
,	O
we	O
identify	O
a	O
domain	O
within	O
Dock180	B
(	O
denoted	O
Docker	O
)	O
that	O
specifically	O
recognizes	O
nucleotide	O
-	O
free	O
Rac	B
and	O
can	O
mediate	O
GTP	O
loading	O
of	O
Rac	B
in	O
vitro	O
.	O

The	O
Docker	O
domain	O
is	O
conserved	O
among	O
known	O
Dock180	B
family	I
members	O
in	O
metazoans	O
and	O
in	O
a	O
yeast	O
protein	O
.	O

In	O
cells	O
,	O
binding	O
of	O
Dock180	B
to	O
Rac	B
alone	O
is	O
insufficient	O
for	O
GTP	O
loading	O
,	O
and	O
a	O
Dock180	B
ELMO1	B
interaction	O
is	O
required	O
.	O

We	O
can	O
also	O
detect	O
a	O
trimeric	O
ELMO1	B
Dock180	B
Rac1	B
complex	O
and	O
ELMO	B
augments	O
the	O
interaction	O
between	O
Dock180	B
and	O
Rac	B
.	O

We	O
propose	O
that	O
the	O
Dock180	B
ELMO	B
complex	O
functions	O
as	O
an	O
unconventional	O
two	O
-	O
part	O
exchange	B
factor	I
for	I
Rac	I
.	O

Epidermal	B
growth	I
factor	I
and	O
transforming	B
growth	I
factor	I
alpha	I
mimic	O
the	O
effects	O
of	O
insulin	B
in	O
human	O
fat	O
cells	O
and	O
augment	O
downstream	O
signaling	O
in	O
insulin	B
resistance	O
.	O

The	O
ability	O
of	O
the	O
growth	B
factors	I
epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
,	O
transforming	B
growth	I
factor	I
alpha	I
,	O
and	O
platelet	B
-	I
derived	I
growth	I
factor	I
to	O
exert	O
insulin	B
-	O
like	O
effects	O
on	O
glucose	O
transport	O
and	O
lipolysis	O
were	O
examined	O
in	O
human	O
and	O
rat	O
fat	O
cells	O
.	O

No	O
effects	O
were	O
found	O
in	O
rat	O
fat	O
cells	O
,	O
whereas	O
EGF	B
(	O
EC	O
(	O
50	O
)	O
for	O
glucose	O
transport	O
approximately	O
0.02	O
nm	O
)	O
and	O
transforming	B
growth	I
factor	I
alpha	I
(	O
EC	O
(	O
50	O
)	O
approximately	O
0.2	O
nm	O
)	O
,	O
but	O
not	O
platelet	B
-	I
derived	I
growth	I
factor	I
,	O
mimicked	O
the	O
effects	O
of	O
insulin	B
(	O
EC	O
(	O
50	O
)	O
approximately	O
0.2	O
nm	O
)	O
on	O
both	O
pathways	O
.	O

EGF	B
receptors	I
,	O
but	O
not	O
EGF	B
,	O
were	O
abundantly	O
expressed	O
in	O
human	O
fat	O
cells	O
as	O
well	O
as	O
in	O
human	O
skeletal	O
muscle	O
.	O

EGF	B
increased	O
the	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
(	O
the	O
EGF	B
receptor	I
,	O
insulin	B
receptor	I
substrate	I
(	I
IRS	I
)	I
-	I
1	I
,	O
IRS-2	B
,	O
and	O
Grb2	B
-	I
associated	I
binder	I
1	I
)	O
,	O
whereas	O
Shc	B
and	O
Gab2	B
were	O
only	O
weakly	O
and	O
inconsistently	O
phosphorylated	O
.	O

p85	B
,	O
the	O
regulatory	B
subunit	I
of	I
phosphatidylinositol	I
3-kinase	I
(	O
PI	B
3-kinase	I
)	O
,	O
was	O
also	O
found	O
to	O
associate	O
with	O
all	O
of	O
these	O
docking	O
molecules	O
,	O
showing	O
that	O
EGF	B
activated	O
PI	B
3-kinase	I
pools	O
that	O
were	O
additional	O
to	O
those	O
of	O
insulin	B
.	O

EGF	B
and/or	O
insulin	B
increased	O
protein	B
kinase	I
B	I
/	O
Akt	B
serine	O
phosphorylation	O
to	O
a	O
similar	O
extent	O
,	O
whereas	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
phosphorylation	O
was	O
more	O
pronounced	O
for	O
EGF	B
than	O
for	O
insulin	B
.	O

The	O
impaired	O
insulin	B
-	O
stimulated	O
downstream	O
signaling	O
,	O
measured	O
as	O
protein	B
kinase	I
B	I
/	O
Akt	B
serine	O
phosphorylation	O
,	O
in	O
insulin	B
-	O
resistant	O
cells	O
(	O
Type	O
2	O
diabetes	O
)	O
was	O
improved	O
by	O
the	O
addition	O
of	O
EGF	B
.	O

Thus	O
,	O
EGF	B
receptors	I
,	O
but	O
not	O
EGF	B
,	O
are	O
abundantly	O
expressed	O
in	O
human	O
fat	O
cells	O
and	O
skeletal	O
muscle	O
.	O

EGF	B
mimics	O
the	O
effects	O
of	O
insulin	B
on	O
both	O
the	O
metabolic	O
and	O
mitogenic	O
pathways	O
but	O
utilize	O
in	O
part	O
different	O
signaling	O
pathways	O
.	O

Both	O
insulin	B
and	O
EGF	B
increase	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
IRS-1	B
and	O
IRS-2	B
,	O
whereas	O
EGF	B
is	O
also	O
capable	O
of	O
activating	O
additional	O
PI	B
3-kinase	I
pools	O
and	O
,	O
thus	O
,	O
can	O
augment	O
the	O
downstream	O
signaling	O
of	O
insulin	B
in	O
insulin	B
-	O
resistant	O
states	O
like	O
Type	O
2	O
diabetes	O
.	O

Heparan	B
sulfate	I
3-O	I
-	I
sulfotransferase	I
isoform	I
5	I
generates	O
both	O
an	O
antithrombin	B
-	O
binding	O
site	O
and	O
an	O
entry	O
receptor	O
for	O
herpes	O
simplex	O
virus	O
,	O
type	O
1	O
.	O

Heparan	B
sulfate	I
3-O	I
-	I
sulfotransferase	I
transfers	O
sulfate	O
to	O
the	O
3-OH	O
position	O
of	O
a	O
glucosamine	O
residue	O
of	O
heparan	O
sulfate	O
(	O
HS	O
)	O
to	O
form	O
3-O	O
-	O
sulfated	O
HS	O
.	O

The	O
3-O	O
-	O
sulfated	O
glucosamine	O
residue	O
contributes	O
to	O
two	O
important	O
biological	O
functions	O
of	O
HS	O
:	O
binding	O
to	O
antithrombin	B
and	O
thereby	O
carrying	O
anticoagulant	O
activity	O
,	O
and	O
binding	O
to	O
herpes	O
simplex	O
viral	O
envelope	O
glycoprotein	B
D	I
to	O
serve	O
as	O
an	O
entry	O
receptor	O
for	O
herpes	O
simplex	O
virus	O
1	O
.	O

A	O
total	O
of	O
five	O
HS	B
3-O	I
-	I
sulfotransferase	I
isoforms	O
were	O
reported	O
previously	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
novel	O
HS	B
3-O	I
-	I
sulfotransferase	I
isoform	O
,	O
designated	O
as	O
HS	B
3-O	I
-	I
sulfotransferase	I
isoform	I
5	I
(	O
3-OST-5	B
)	O
.	O

3-OST-5	B
cDNA	O
was	O
isolated	O
from	O
a	O
human	O
placenta	O
cDNA	O
library	O
and	O
expressed	O
in	O
COS-7	O
cells	O
.	O

The	O
disaccharide	O
analysis	O
of	O
3-OST-5	B
-	O
modified	O
HS	O
revealed	O
that	O
3-OST-5	B
generated	O
at	O
least	O
three	O
3-O	O
-	O
sulfated	O
disaccharides	O
as	O
follows	O
:	O
IdoUA2S	O
-	O
AnMan3S	O
,	O
GlcUA	O
-	O
AnMan3S6S	O
,	O
and	O
IdoUA2S	O
-	O
AnMan3S6S	O
.	O

Transfection	O
of	O
the	O
plasmid	O
expressing	O
3-OST-5	B
rendered	O
wild	O
type	O
Chinese	O
hamster	O
ovary	O
cells	O
susceptible	O
to	O
the	O
infection	O
by	O
herpes	O
simplex	O
virus	O
1	O
,	O
suggesting	O
that	O
3-OST-5	B
-	O
modified	O
HS	O
serves	O
as	O
an	O
entry	O
receptor	O
for	O
herpes	O
simplex	O
virus	O
1	O
.	O

In	O
addition	O
,	O
3-OST-5	B
-	O
modified	O
HS	O
bound	O
to	O
herpes	O
simplex	O
viral	O
envelope	O
protein	O
glycoprotein	B
D	I
.	O

Furthermore	O
,	O
we	O
found	O
that	O
3-OST-5	B
-	O
modified	O
HS	O
also	O
bound	O
to	O
antithrombin	O
,	O
suggesting	O
that	O
3-OST-5	B
also	O
produces	O
anticoagulant	O
HS	O
.	O

In	O
summary	O
,	O
our	O
results	O
indicate	O
that	O
a	O
new	O
member	O
of	O
3-OST	B
family	I
generates	O
both	O
anticoagulant	O
HS	O
and	O
an	O
entry	O
receptor	O
for	O
herpes	O
simplex	O
virus	O
1	O
.	O

These	O
results	O
provide	O
a	O
new	O
insight	O
regarding	O
the	O
mechanism	O
for	O
the	O
biosynthesis	O
of	O
biologically	O
active	O
HS	O
.	O

Transcription	O
of	O
cholesterol	O
side	O
-	O
chain	O
cleavage	O
cytochrome	B
P450	I
in	O
the	O
placenta	O
:	O
activating	B
protein-2	I
assumes	O
the	O
role	O
of	O
steroidogenic	B
factor-1	I
by	O
binding	O
to	O
an	O
overlapping	O
promoter	O
element	O
.	O

Progesterone	O
is	O
essential	O
to	O
the	O
sustenance	O
of	O
pregnancy	O
in	O
humans	O
and	O
other	O
mammals	O
.	O

From	O
the	O
second	O
trimester	O
on	O
,	O
the	O
human	O
placenta	O
is	O
the	O
sole	O
origin	O
of	O
de	O
novo	O
synthesized	O
steroid	O
hormones	O
.	O

In	O
mice	O
,	O
placentation	O
at	O
midgestation	O
is	O
accompanied	O
by	O
a	O
temporal	O
rise	O
of	O
steroid	O
hormone	O
synthesis	O
commencing	O
in	O
the	O
giant	O
cells	O
of	O
the	O
mouse	O
trophoblast	O
.	O

In	O
doing	O
so	O
,	O
the	O
giant	O
trophoblasts	O
,	O
as	O
any	O
other	O
steroidogenic	O
cell	O
,	O
express	O
high	O
levels	O
of	O
the	O
key	O
steroidogenic	O
enzyme	O
,	O
cholesterol	B
side	I
-	I
chain	I
cleavage	I
cytochrome	I
P450	I
(	O
P450scc	B
)	O
.	O

Because	O
steroidogenic	B
factor	I
1	I
(	O
SF-1	B
)	O
,	O
the	O
transcription	B
factor	I
required	O
for	O
expression	O
of	O
P450scc	B
in	O
the	O
adrenals	O
and	O
the	O
gonads	O
,	O
is	O
not	O
expressed	O
in	O
the	O
placenta	O
,	O
we	O
hypothesized	O
that	O
placenta	O
-	O
specific	O
nuclear	O
factor	O
(	O
s	O
)	O
(	O
PNF	O
)	O
assumes	O
the	O
role	O
of	O
SF-1	B
by	O
binding	O
to	O
the	O
same	O
promoter	O
region	O
that	O
harbors	O
the	O
SF-1	B
recognition	O
site	O
in	O
the	O
P450scc	B
gene	O
.	O

To	O
address	O
this	O
possibility	O
,	O
we	O
used	O
SCC1	B
,	O
a	O
well	O
conserved	O
proximal	O
region	O
in	O
the	O
P450scc	B
genes	O
(	O
-60	O
/	O
-	O
32	O
in	O
the	O
rat	O
gene	O
)	O
to	O
purify	O
PNF	O
from	O
human	O
term	O
placenta	O
.	O

Sequencing	O
of	O
the	O
purified	O
PNF	O
revealed	O
that	O
it	O
is	O
the	O
alpha	B
isoform	I
of	I
the	I
human	I
activating	I
protein-2	I
(	O
AP-2alpha	B
)	O
.	O

Specific	O
antibodies	O
tested	O
in	O
EMSA	O
confirmed	O
that	O
AP-2alpha	B
is	O
the	O
predominant	O
isoform	O
that	O
binds	O
SCC1	B
in	O
the	O
human	O
placenta	O
,	O
whereas	O
AP-2gamma	B
is	O
the	O
only	O
mouse	O
placental	O
protein	O
that	O
binds	O
this	O
oligonucleotide	O
.	O

Functional	O
studies	O
showed	O
that	O
coexpression	O
of	O
the	O
rat	O
P450scc	B
promoter	O
(	O
-	O
378	O
/	O
+	O
8	O
CAT	O
)	O
and	O
AP-2	B
isoforms	O
(	O
alpha	O
or	O
gamma	O
)	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
results	O
in	O
a	O
marked	O
activation	O
of	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
transcription	O
that	O
is	O
dependent	O
on	O
an	O
intact	O
AP-2	B
motif	O
,	O
GCCTTGAGC	O
.	O

This	O
motif	O
conforms	O
with	O
consensus	O
sequences	O
previously	O
determined	O
for	O
binding	O
of	O
the	O
AP-2	B
alpha	I
and	I
gamma	I
isoforms	O
.	O

Mutations	O
of	O
the	O
AP-2	B
element	O
ablated	O
binding	O
of	O
AP-2	B
to	O
SCC1	B
,	O
as	O
well	O
as	O
severely	O
diminished	O
the	O
promoter	O
activity	O
in	O
primary	O
mouse	O
giant	O
trophoblasts	O
and	O
human	O
choriocarcinoma	O
JAR	O
cells	O
.	O

Collectively	O
,	O
these	O
studies	O
suggest	O
that	O
expression	O
of	O
placental	O
P450scc	B
is	O
governed	O
by	O
AP-2	B
factors	O
that	O
bind	O
to	O
a	O
cis	O
-	O
element	O
that	O
largely	O
overlaps	O
the	O
sequence	O
required	O
for	O
recognition	O
of	O
SF-1	B
in	O
other	O
steroidogenic	O
tissues	O
.	O

Evolutionary	O
divergence	O
of	O
the	O
archaeal	O
aspartyl	B
-	I
tRNA	I
synthetases	I
into	O
discriminating	O
and	O
nondiscriminating	O
forms	O
.	O

Asparaginyl	O
-	O
tRNA	O
(	O
Asn	O
-	O
tRNA	O
)	O
is	O
generated	O
in	O
nature	O
via	O
two	O
alternate	O
routes	O
,	O
either	O
direct	O
acylation	O
of	O
tRNA	O
with	O
asparagine	O
by	O
asparaginyl	B
-	I
tRNA	I
synthetase	I
(	O
AsnRS	B
)	O
or	O
in	O
a	O
two	O
-	O
step	O
pathway	O
that	O
requires	O
misacylated	O
Asp	O
-	O
tRNA	O
(	O
Asn	O
)	O
as	O
an	O
intermediate	O
.	O

This	O
misacylated	O
aminoacyl	O
-	O
tRNA	O
is	O
formed	O
by	O
a	O
nondiscriminating	O
aspartyl	B
-	I
tRNA	I
synthetase	I
(	O
AspRS	B
)	O
,	O
an	O
enzyme	O
that	O
in	O
addition	O
to	O
forming	O
Asp	O
-	O
tRNA	O
(	O
Asp	O
)	O
also	O
misacylates	O
tRNA	O
(	O
Asn	O
)	O
.	O

In	O
contrast	O
,	O
a	O
discriminating	O
AspRS	B
can	O
not	O
acylate	O
tRNA	O
(	O
Asn	O
)	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
archaeal	O
AspRS	B
enzymes	O
are	O
nondiscriminating	O
,	O
whereas	O
the	O
bacterial	O
ones	O
discriminate	O
.	O

The	O
archaeal	O
and	O
bacterial	O
AspRS	B
proteins	O
are	O
indeed	O
distinct	O
in	O
sequence	O
and	O
structure	O
.	O

However	O
,	O
we	O
show	O
that	O
both	O
discriminating	O
and	O
nondiscriminating	O
forms	O
of	O
AspRS	B
exist	O
among	O
the	O
archaea	O
.	O

Using	O
unfractionated	O
methanobacterial	O
and	O
pyrococcal	O
tRNA	O
,	O
the	O
Methanothermobacter	O
thermautotrophicus	O
AspRS	B
acylated	O
approximately	O
twice	O
as	O
much	O
tRNA	O
as	O
did	O
AspRS	B
from	O
Pyrococcus	O
kodakaraensis	O
or	O
Ferroplasma	O
acidarmanus	O
.	O

Proof	O
that	O
Asp	O
-	O
tRNA	O
(	O
Asn	O
)	O
was	O
generated	O
by	O
the	O
methanogen	B
synthetase	I
was	O
the	O
conversion	O
of	O
Asp	O
-	O
tRNA	O
formed	O
by	O
M.	O
thermautotrophicus	O
AspRS	B
to	O
Asn	O
-	O
tRNA	O
by	O
M.	O
thermautotrophicus	O
Asp	B
-	I
tRNA	I
(	I
Asn	I
)	I
amidotransferase	I
.	O

In	O
contrast	O
,	O
Asp	O
-	O
tRNA	O
formed	O
by	O
the	O
Pyrococcus	O
or	O
Ferroplasma	O
enzymes	O
was	O
not	O
a	O
substrate	O
for	O
the	O
amidotransferase	B
.	O

Also	O
,	O
although	O
all	O
three	O
AspRS	B
enzymes	O
charged	O
tRNA	O
(	O
Asp	O
)	O
transcripts	O
,	O
only	O
M.	O
thermautotrophicus	O
AspRS	B
aspartylated	O
the	O
tRNA	O
(	O
Asn	O
)	O
transcript	O
.	O

Genomic	O
analysis	O
provides	O
a	O
rationale	O
for	O
the	O
nature	O
of	O
these	O
enzymes	O
.	O

The	O
mischarging	O
AspRS	B
correlates	O
with	O
the	O
absence	O
in	O
the	O
genome	O
of	O
AsnRS	B
and	O
the	O
presence	O
of	O
Asp	B
-	I
tRNA	I
(	I
Asn	I
)	I
amidotransferase	I
,	O
employed	O
by	O
the	O
transamidation	O
pathway	O
.	O

In	O
contrast	O
,	O
the	O
discriminating	O
AspRS	B
correlates	O
with	O
the	O
absence	O
of	O
the	O
amidotransferase	B
and	O
the	O
presence	O
of	O
AsnRS	B
,	O
forming	O
Asn	O
-	O
tRNA	O
by	O
direct	O
aminoacylation	O
.	O

The	O
high	O
sequence	O
identity	O
,	O
up	O
to	O
60	O
%	O
between	O
discriminating	O
and	O
nondiscriminating	O
archaeal	O
AspRSs	B
,	O
suggests	O
that	O
few	O
mutational	O
steps	O
may	O
be	O
necessary	O
to	O
convert	O
the	O
tRNA	O
-	O
discriminating	O
ability	O
of	O
a	O
tRNA	B
synthetase	I
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
AHR2	B
,	O
ARNT2	B
,	O
and	O
CYP1A	B
in	O
zebrafish	O
embryos	O
and	O
larvae	O
:	O
effects	O
of	O
developmental	O
stage	O
and	O
2,3,7,8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
exposure	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
the	O
aryl	B
hydrocarbon	I
receptor	I
(	O
AHR	B
)	O
signaling	O
pathway	O
in	O
causing	O
tissue	O
-	O
specific	O
signs	O
of	O
2,3,7,8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
toxicity	O
in	O
zebrafish	O
,	O
the	O
temporal	O
and	O
spatial	O
expression	O
of	O
the	O
zebrafish	O
aryl	B
hydrocarbon	I
receptor	I
2	I
(	O
zfAHR2	B
)	O
,	O
aryl	B
hydrocarbon	I
receptor	I
nuclear	I
translocator	I
2	I
(	O
zfARNT2	B
)	O
,	O
and	O
an	O
AHR	B
regulated	O
gene	O
,	O
cytochrome	B
P4501A	I
(	O
zfCYP1A	B
)	O
,	O
were	O
assessed	O
in	O
larvae	O
exposed	O
to	O
vehicle	O
or	O
TCDD	O
(	O
1.55	O
nM	O
)	O
from	O
3	O
-	O
4	O
h	O
postfertilization	O
(	O
hpf	O
)	O
.	O

Coexpression	O
of	O
a	O
transcriptionally	O
active	O
AHR	B
pathway	O
was	O
apparent	O
by	O
the	O
expression	O
of	O
zfCYP1A	B
mRNA	O
and	O
protein	O
in	O
certain	O
larval	O
tissues	O
.	O

zfCYP1A	B
protein	O
was	O
first	O
detected	O
in	O
the	O
skin	O
and	O
vasculature	O
of	O
TCDD	O
-	O
exposed	O
larvae	O
at	O
36	O
hpf	O
.	O

Vascular	O
-	O
specific	O
zfCYP1A	B
protein	O
expression	O
continued	O
from	O
36	O
to120	O
hpf	O
at	O
which	O
time	O
it	O
was	O
also	O
detected	O
in	O
the	O
heart	O
,	O
kidney	O
,	O
and	O
liver	O
.	O

zfCYP1A	B
mRNA	O
was	O
observed	O
in	O
TCDD	O
treated	O
larvae	O
as	O
early	O
as	O
24	O
hpf	O
in	O
the	O
developing	O
vascular	O
system	O
.	O

Vascular	O
specific	O
zfCYP1A	B
mRNA	O
expression	O
in	O
the	O
head	O
,	O
trunk	O
,	O
and	O
tail	O
by	O
36	O
hpf	O
in	O
TCDD	O
-	O
exposed	O
larvae	O
,	O
confirmed	O
immunohistochemical	O
localization	O
.	O

The	O
expression	O
of	O
zfAHR2	B
and	O
zfARNT2	B
mRNAs	O
was	O
generally	O
similar	O
in	O
control	O
and	O
TCDD	O
-	O
exposed	O
larvae	O
.	O

Coexpression	O
of	O
zfAHR2	B
,	O
zfARNT2	B
,	O
and	O
zfCYP1A	B
mRNAs	O
was	O
evident	O
in	O
TCDD	O
-	O
exposed	O
larvae	O
by	O
36	O
hpf	O
and	O
in	O
the	O
vasculature	O
,	O
heart	O
,	O
and	O
trunk	O
kidney	O
by	O
48	O
hpf	O
,	O
well	O
before	O
the	O
first	O
signs	O
of	O
overt	O
developmental	O
toxicity	O
are	O
observed	O
.	O

In	O
addition	O
to	O
their	O
function	O
in	O
response	O
to	O
AHR	B
agonists	O
,	O
zfAHR2	B
and	O
zfARNT2	B
may	O
be	O
involved	O
in	O
development	O
and	O
function	O
of	O
the	O
nervous	O
system	O
.	O

zfAHR2	B
and	O
zfARNT2	B
were	O
detected	O
in	O
the	O
brain	O
,	O
spinal	O
cord	O
,	O
and	O
sensory	O
organs	O
.	O

However	O
,	O
TCDD	O
-	O
induced	O
zfCYP1A	B
expression	O
was	O
not	O
detected	O
in	O
these	O
tissues	O
.	O

Taken	O
together	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
the	O
cardiovascular	O
system	O
is	O
a	O
primary	O
target	O
of	O
TCDD	O
developmental	O
toxicity	O
in	O
zebrafish	O
.	O

Regulation	O
of	O
the	O
CDK	B
-	O
related	O
protein	B
kinase	I
PCTAIRE-1	B
and	O
its	O
possible	O
role	O
in	O
neurite	O
outgrowth	O
in	O
Neuro-2A	O
cells	O
.	O

PCTAIRE-1	B
is	O
a	O
CDK	B
-	O
related	O
protein	B
kinase	I
found	O
in	O
terminally	O
differentiated	O
cells	O
in	O
brain	O
and	O
testis	O
,	O
and	O
in	O
many	O
immortalised	O
and	O
transformed	O
cell	O
lines	O
.	O

Bacterially	O
expressed	O
PCTAIRE	B
is	O
completely	O
inactive	O
as	O
a	O
protein	B
kinase	I
,	O
but	O
is	O
a	O
very	O
good	O
substrate	O
for	O
protein	B
kinase	I
A	I
(	O
PKA	B
)	O
,	O
which	O
phosphorylates	O
a	O
total	O
of	O
four	O
sites	O
in	O
the	O
N	O
-	O
terminus	O
of	O
PCTAIRE-1	B
.	O

Phosphorylation	O
of	O
one	O
of	O
these	O
sites	O
,	O
Ser119	O
,	O
generates	O
a	O
14	B
-	I
3	I
-	I
3	I
binding	O
site	O
,	O
which	O
is	O
functional	O
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
.	O

Mutation	O
of	O
another	O
PKA	B
site	O
,	O
Ser153	O
,	O
to	O
an	O
alanine	O
residue	O
generated	O
an	O
activated	O
kinase	B
in	O
transfected	O
mammalian	O
cells	O
.	O

This	O
activity	O
was	O
comparable	O
to	O
that	O
of	O
CDK5	B
activated	O
by	O
a	O
bacterially	O
expressed	O
,	O
truncated	O
version	O
of	O
p35	B
(	O
nck	B
)	O
,	O
p21	O
.	O

Gel	O
filtration	O
analysis	O
of	O
a	O
brain	O
extract	O
suggested	O
that	O
monomeric	O
PCTAIRE-1	B
was	O
the	O
active	O
species	O
,	O
implying	O
that	O
PCTAIRE-1	B
may	O
not	O
be	O
a	O
true	O
CDK	B
,	O
in	O
that	O
it	O
does	O
not	O
require	O
a	O
partner	O
(	O
cyclin	B
-	O
like	O
)	O
subunit	O
for	O
kinase	B
activity	O
.	O

Finally	O
,	O
we	O
found	O
that	O
various	O
forms	O
of	O
PCTAIRE-1	B
transfected	O
into	O
neuroblastoma	O
cell	O
lines	O
could	O
either	O
promote	O
or	O
inhibit	O
neurite	O
outgrowth	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
the	O
PCTAIRE-1	B
gene	O
product	O
in	O
the	O
control	O
of	O
neurite	O
outgrowth	O
.	O

RNAi	O
is	O
activated	O
during	O
Drosophila	O
oocyte	O
maturation	O
in	O
a	O
manner	O
dependent	O
on	O
aubergine	B
and	O
spindle	B
-	I
E	I
.	O

Gene	O
silencing	O
by	O
double	O
-	O
stranded	O
RNA	O
is	O
a	O
widespread	O
phenomenon	O
called	O
RNAi	O
,	O
involving	O
homology	O
-	O
dependent	O
degradation	O
of	O
mRNAs	O
.	O

Here	O
we	O
show	O
that	O
RNAi	O
is	O
established	O
in	O
the	O
Drosophila	O
female	O
germ	O
line	O
.	O

mRNA	O
transcripts	O
are	O
translationally	O
quiescent	O
at	O
the	O
arrested	O
oocyte	O
stage	O
and	O
are	O
insensitive	O
to	O
RNAi	O
.	O

Upon	O
oocyte	O
maturation	O
,	O
transcripts	O
that	O
are	O
translated	O
become	O
sensitive	O
to	O
degradation	O
while	O
untranslated	O
transcripts	O
remain	O
resistant	O
.	O

Mutations	O
in	O
aubergine	B
and	O
spindle	B
-	I
E	I
,	O
members	O
of	O
the	O
PIWI	B
/	I
PAZ	I
and	I
DE	I
-	I
H	I
helicase	I
gene	I
families	I
,	O
respectively	O
,	O
block	O
RNAi	O
activation	O
during	O
egg	O
maturation	O
and	O
perturb	O
translation	O
control	O
during	O
oogenesis	O
,	O
supporting	O
a	O
connection	O
between	O
gene	O
silencing	O
and	O
translation	O
in	O
the	O
oocyte	O
.	O

Regulation	O
of	O
the	O
interleukin-1	B
receptor	I
antagonist	I
in	O
THP-1	O
cells	O
by	O
ligands	O
of	O
the	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
gamma	I
.	O

Monocytes	O
/	O
macrophages	O
(	O
Mphi	O
)	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
persistence	O
of	O
chronic	O
inflammation	O
and	O
local	O
tissue	O
destruction	O
in	O
diseases	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
atherosclerosis	O
.	O

The	O
production	O
by	O
Mphi	O
of	O
cytokines	B
,	O
chemokines	B
,	O
metalloproteinases	B
and	O
their	O
inhibitors	O
is	O
an	O
essential	O
component	O
in	O
this	O
process	O
,	O
which	O
is	O
tightly	O
regulated	O
by	O
multiple	O
factors	O
.	O

The	O
peroxisome	B
proliferator	I
-	I
activated	I
receptors	I
(	O
PPARs	B
)	O
were	O
shown	O
to	O
be	O
involved	O
in	O
modulating	O
inflammation	O
.	O

PPARgamma	B
is	O
activated	O
by	O
a	O
wide	O
variety	O
of	O
ligands	O
such	O
as	O
fatty	O
acids	O
,	O
the	O
anti	O
-	O
diabetic	O
thiazolidinediones	O
(	O
TZDs	O
)	O
,	O
and	O
also	O
by	O
certain	O
prostaglandins	O
of	O
which	O
15-deoxy	O
-	O
Delta	O
(	O
12,14	O
)	O
-PGJ2	O
(	O
PGJ2	O
)	O
.	O

High	O
concentrations	O
of	O
PPARgamma	B
ligands	O
were	O
shown	O
to	O
have	O
anti	O
-	O
inflammatory	O
activities	O
by	O
inhibiting	O
the	O
secretion	O
of	O
interleukin-1	B
(	O
IL-1	B
)	O
,	O
interleukin-6	B
(	O
IL-6	B
)	O
and	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
)	O
by	O
stimulated	O
monocytes	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
PGJ2	O
and	O
TZDs	O
would	O
also	O
exert	O
an	O
immunomodulatory	O
action	O
through	O
the	O
up	O
-	O
regulation	O
of	O
anti	O
-	O
inflammatory	O
cytokines	B
such	O
as	O
the	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1Ra	B
)	O
.	O

THP-1	O
monocytic	O
cells	O
were	O
stimulated	O
with	O
PMA	O
,	O
thereby	O
enhancing	O
the	O
secretion	O
of	O
IL-1	B
,	O
IL-6	B
,	O
TNFalpha	B
,	O
IL-1Ra	B
and	O
metalloproteinases	B
.	O

Addition	O
of	O
PGJ2	O
had	O
an	O
inhibitory	O
effect	O
on	O
IL-1	B
,	O
IL-6	B
and	O
TNFalpha	B
secretion	O
,	O
while	O
increasing	O
IL-1Ra	B
production	O
.	O

In	O
contrast	O
,	O
the	O
bona	O
fide	O
PPARgamma	B
ligands	O
(	O
TZDs	O
;	O
rosiglitazone	O
,	O
pioglitazone	O
and	O
troglitazone	O
)	O
barely	O
inhibited	O
proinflammatory	O
cytokines	B
,	O
but	O
strongly	O
enhanced	O
the	O
production	O
of	O
IL-1Ra	B
from	O
PMA	O
-	O
stimulated	O
THP-1	O
cells	O
.	O

Unstimulated	O
cells	O
did	O
not	O
respond	O
to	O
TZDs	O
in	O
terms	O
of	O
IL-1Ra	B
production	O
,	O
suggesting	O
that	O
in	O
order	O
to	O
be	O
effective	O
,	O
PPAR	B
ligands	O
depend	O
on	O
PMA	O
signalling	O
.	O

Basal	O
levels	O
of	O
PPARgamma	B
are	O
barely	O
detectable	O
in	O
unstimulated	O
THP-1	O
cells	O
,	O
while	O
stimulation	O
with	O
PMA	O
up	O
-	O
regulates	O
its	O
expression	O
,	O
suggesting	O
that	O
higher	O
levels	O
of	O
PPARgamma	B
expression	O
are	O
necessary	O
for	O
receptor	O
ligand	O
effects	O
to	O
occur	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
TZDs	O
may	O
exert	O
an	O
anti	O
-	O
inflammatory	O
activity	O
by	O
inducing	O
the	O
production	O
of	O
the	O
IL-1Ra	B
.	O

Retinoscleral	O
control	O
of	O
scleral	O
remodelling	O
in	O
refractive	O
development	O
:	O
a	O
role	O
for	O
endogenous	O
FGF-2	B
?	O

AIMS	O
:	O

Studies	O
in	O
avian	O
models	O
of	O
myopia	O
have	O
shown	O
that	O
refractive	O
error	O
development	O
can	O
be	O
influenced	O
by	O
exogenously	O
delivered	O
fibroblast	B
growth	I
factor	I
(	I
FGF	I
)	I
-	I
2	I
.	O

The	O
present	O
study	O
sought	O
to	O
determine	O
whether	O
endogenous	O
FGF-2	B
was	O
associated	O
with	O
retinoscleral	O
signalling	O
or	O
scleral	O
remodelling	O
during	O
changes	O
in	O
refractive	O
error	O
in	O
a	O
mammalian	O
model	O
of	O
myopia	O
.	O

METHODS	O
:	O

Myopia	O
was	O
induced	O
in	O
tree	O
shrews	O
over	O
a	O
5	O
-	O
day	O
period	O
.	O

One	O
group	O
of	O
animals	O
was	O
then	O
allowed	O
3	O
days	O
of	O
recovery	O
from	O
the	O
induced	O
myopia	O
.	O

Endogenous	O
levels	O
of	O
FGF-2	B
were	O
measured	O
in	O
scleral	O
and	O
retinal	O
homogenates	O
using	O
ELISA	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
used	O
to	O
investigate	O
scleral	O
FGF-2	B
and	O
FGF	B
receptor	I
(	I
FGFR	I
)	I
-	I
1	I
mRNA	O
expression	O
.	O

RESULTS	O
:	O

No	O
difference	O
in	O
FGF-2	B
content	O
was	O
found	O
in	O
posterior	O
scleral	O
or	O
retinal	O
extracts	O
of	O
myopic	O
eyes	O
(	O
scleral	O
-4+	O
/	O
-	O
9	O
%	O
,	O
retinal	O
+	O
23	O
+	O
/-17	O
%	O
)	O
or	O
recovering	O
eyes	O
(	O
scleral	O
-	O
10+	O
/	O
-	O
18	O
%	O
,	O
retinal	O
+	O
1	O
+	O
/	O
-	O
13	O
%	O
)	O
,	O
when	O
compared	O
with	O
contralateral	O
control	O
eyes	O
.	O

In	O
addition	O
,	O
no	O
significant	O
changes	O
were	O
found	O
in	O
scleral	O
FGF-2	B
mRNA	O
expression	O
in	O
myopic	O
or	O
recovering	O
eyes	O
(	O
+	O
106+	O
/	O
-	O
56	O
%	O
and	O
+	O
14	O
+	O
/-	O
12	O
%	O
respectively	O
,	O
P	O
=	O
0.21	O
)	O
.	O

However	O
,	O
FGF-2	B
concentration	O
was	O
significantly	O
higher	O
in	O
anterior	O
,	O
relative	O
to	O
posterior	O
,	O
scleral	O
regions	O
in	O
all	O
animals	O
(	O
1602	O
+	O
/-	O
105	O
vs	O
1030	O
+	O
/-50pg	O
/	O
mg	O
respectively	O
P	O
<	O
0.001	O
)	O
.	O

Expression	O
of	O
scleral	O
FGFR-1	B
mRNA	O
was	O
upregulated	O
in	O
myopic	O
eyes	O
(	O
+	O
186+	O
/	O
-	O
32	O
%	O
,	O
P	O
=	O
0.01	O
)	O
but	O
returned	O
to	O
control	O
eye	O
levels	O
during	O
recovery	O
(	O
+	O
63+	O
/	O
-20	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
findings	O
indicate	O
that	O
alterations	O
in	O
endogenous	O
retinal	O
or	O
scleral	O
FGF-2	B
levels	O
are	O
not	O
associated	O
with	O
changes	O
in	O
scleral	O
remodelling	O
in	O
this	O
mammalian	O
model	O
of	O
myopia	O
.	O

However	O
,	O
the	O
reversible	O
changes	O
found	O
in	O
FGFR-1	B
expression	O
in	O
the	O
sclera	O
of	O
myopic	O
eyes	O
mean	O
that	O
an	O
indirect	O
role	O
for	O
FGF-2	B
in	O
the	O
control	O
of	O
scleral	O
remodelling	O
is	O
implicated	O
.	O

The	O
anteroposterior	O
difference	O
found	O
in	O
scleral	O
FGF-2	B
concentration	O
indicates	O
a	O
role	O
for	O
this	O
cytokine	B
in	O
the	O
control	O
of	O
normal	O
scleral	O
growth	O
and	O
development	O
and	O
,	O
presumably	O
,	O
eye	O
size	O
.	O

Paylean	O
alters	O
myosin	B
heavy	I
chain	I
isoform	O
content	O
in	O
pig	O
muscle	O
.	O

Feeding	O
beta	O
-	O
adrenergic	O
agonists	O
promotes	O
muscle	O
growth	O
.	O

Early	O
histological	O
techniques	O
failed	O
to	O
show	O
precisely	O
how	O
feeding	O
ractopamine	O
-	O
HCl	O
(	O
Paylean	O
)	O
alters	O
muscle	O
growth	O
in	O
pigs	O
.	O

To	O
understand	O
these	O
effects	O
,	O
an	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
used	O
to	O
determine	O
the	O
abundance	O
of	O
each	O
adult	O
skeletal	O
muscle	O
myosin	B
heavy	I
chain	I
isoform	O
,	O
one	O
means	O
of	O
assigning	O
muscle	O
fiber	O
type	O
,	O
in	O
fast	O
and	O
slow	O
muscles	O
of	O
pigs	O
fed	O
Paylean	O
.	O

Sixty	O
growing	O
pigs	O
(	O
-	O
85	O
kg	O
)	O
were	O
randomly	O
assigned	O
to	O
three	O
Paylean	O
doses	O
(	O
0	O
,	O
20	O
,	O
or	O
60	O
ppm	O
)	O
.	O

At	O
3	O
,	O
7	O
,	O
14	O
,	O
28	O
,	O
and	O
42	O
d	O
of	O
treatment	O
,	O
four	O
pigs	O
per	O
dose	O
were	O
harvested	O
and	O
white	O
(	O
WST	O
)	O
and	O
red	O
(	O
RST	O
)	O
semitendinosus	O
and	O
longissimus	O
(	O
LM	O
)	O
muscles	O
were	O
removed	O
and	O
processed	O
,	O
and	O
myosin	B
heavy	I
chain	I
was	O
quantified	O
by	O
ELISA	O
.	O

Feeding	O
Paylean	O
enhanced	O
(	O
P	O
<	O
0.05	O
)	O
pigs	O
'	O
average	O
daily	O
gain	O
.	O

Muscle	O
myosin	B
heavy	I
chain	I
(	O
slow	O
,	O
2A	O
,	O
2AX	O
,	O
and	O
2B	O
)	O
composition	O
differed	O
(	O
P	O
<	O
0.05	O
)	O
across	O
muscles	O
.	O

Compared	O
with	O
LM	O
,	O
RST	O
contained	O
approximately	O
five	O
times	O
more	O
(	O
P	O
<	O
0.0001	O
)	O
slow	O
and	O
type	O
2A	B
myosin	I
heavy	I
chain	I
and	O
three	O
times	O
more	O
2AX	B
myosin	I
heavy	I
chain	I
but	O
nearly	O
undetectable	O
amounts	O
of	O
2B	B
myosin	I
heavy	I
chain	I
.	O

Myosin	B
heavy	I
chain	I
composition	O
of	O
the	O
WST	O
closely	O
resembled	O
that	O
of	O
the	O
LM	O
(	O
i.e.	O
,	O
greater	O
2AX	O
and	O
2B	O
and	O
less	O
slow	O
and	O
2A	O
)	O
.	O

After	O
42d	O
of	O
60	O
ppm	O
Paylean	O
,	O
the	O
amount	O
of	O
slow	O
,	O
2A	B
,	I
and	I
2AX	I
myosin	I
heavy	I
chain	I
decreased	O
(	O
P	O
<	O
0.05	O
)	O
across	O
the	O
three	O
muscles	O
whereas	O
the	O
amount	O
of	O
2B	B
myosin	I
heavy	I
chain	I
increased	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
contrast	O
,	O
relative	O
amounts	O
of	O
2A	B
and	I
2AX	I
myosin	I
heavy	I
chain	I
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
muscle	O
of	O
control	O
pigs	O
at	O
42d	O
.	O

Changes	O
associated	O
with	O
the	O
20-ppm	O
dose	O
were	O
intermediate	O
to	O
and	O
different	O
from	O
(	O
P	O
<	O
0.05	O
)	O
control	O
and	O
60	O
ppm	O
treatments	O
.	O

Correlations	O
(	O
P	O
<	O
0.05	O
)	O
among	O
various	O
myosin	B
heavy	I
chain	I
within	O
muscles	O
suggest	O
that	O
slow	O
,	O
type	O
2A	O
,	O
and	O
2X	O
decrease	O
with	O
increases	O
in	O
2B	B
myosin	I
heavy	I
chain	I
.	O

These	O
data	O
show	O
that	O
administration	O
of	O
Paylean	O
affects	O
myosin	B
heavy	I
chain	I
isoform	O
composition	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
and	O
provides	O
a	O
mechanism	O
of	O
action	O
for	O
Paylean	O
altering	O
animal	O
growth	O
.	O

Identification	O
and	O
expression	O
analysis	O
of	O
the	O
human	O
mu	B
-	I
protocadherin	I
gene	O
in	O
fetal	O
and	O
adult	O
kidneys	O
.	O

We	O
recently	O
cloned	O
mu	B
-	I
protocadherin	I
,	O
a	O
developmentally	O
regulated	O
cell	O
adhesion	O
molecule	O
that	O
contains	O
an	O
extracellular	O
region	O
with	O
four	O
cadherin	B
-	O
like	O
ectodomains	O
and	O
a	O
triply	O
repeating	O
mucin	B
domain	O
in	O
its	O
longer	O
isoform	O
.	O

Expression	O
of	O
mu	B
-	I
protocadherin	I
in	O
L929	O
cells	O
resulted	O
in	O
cellular	O
aggregation	O
,	O
confirming	O
its	O
role	O
in	O
intercellular	O
adhesion	O
.	O

We	O
now	O
identify	O
the	O
human	O
mu	B
-	I
protocadherin	I
ortholog	O
and	O
study	O
its	O
distribution	O
in	O
vivo	O
and	O
its	O
targeting	O
in	O
polarized	O
epithelia	O
.	O

Basic	O
Local	O
Alignment	O
Search	O
Tool	O
searches	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
on	O
the	O
basis	O
of	O
human	O
-	O
mouse	O
synteny	O
reveal	O
that	O
mu	B
-	I
protocadherin	I
maps	O
to	O
11p15.5	O
,	O
matching	O
a	O
previously	O
identified	O
gene	O
called	O
MUCDHL	B
.	O

At	O
least	O
three	O
different	O
splicing	O
isoforms	O
exist	O
for	O
MUCDHL	B
that	O
vary	O
in	O
expression	O
in	O
the	O
fetal	O
kidney	O
.	O

Mu	B
-	I
protocadherin	I
is	O
apically	O
expressed	O
along	O
the	O
brush	O
border	O
of	O
the	O
proximal	O
convoluted	O
tubule	O
of	O
the	O
adult	O
kidney	O
.	O

Transfection	O
of	O
truncated	O
forms	O
of	O
mu	B
-	I
protocadherin	I
into	O
polarized	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
cells	O
reveals	O
that	O
the	O
NH	O
(	O
2	O
)	O
terminus	O
is	O
essential	O
for	O
targeting	O
to	O
the	O
apical	O
surface	O
.	O

These	O
results	O
suggest	O
that	O
although	O
human	O
mu	B
-	I
protocadherin	I
may	O
mediate	O
a	O
homotypic	O
adhesive	O
interaction	O
,	O
it	O
may	O
have	O
additional	O
functions	O
in	O
terminally	O
differentiated	O
epithelia	O
.	O

Reelin	B
and	O
ApoE	B
receptors	I
cooperate	O
to	O
enhance	O
hippocampal	O
synaptic	O
plasticity	O
and	O
learning	O
.	O

Two	O
apolipoprotein	B
E	I
(	I
apoE	I
)	I
receptors	I
,	O
the	O
very	B
low	I
density	I
lipoprotein	I
(	I
VLDL	I
)	I
receptor	I
and	O
apoE	B
receptor	I
2	I
(	O
apoER2	B
)	O
,	O
are	O
also	O
receptors	O
for	O
Reelin	B
,	O
a	O
signaling	O
protein	O
that	O
regulates	O
neuronal	O
migration	O
during	O
brain	O
development	O
.	O

In	O
the	O
adult	O
brain	O
,	O
Reelin	B
is	O
expressed	O
by	O
GABA	O
-	O
ergic	O
interneurons	O
,	O
suggesting	O
a	O
potential	O
function	O
as	O
a	O
modulator	O
of	O
neurotransmission	O
.	O

ApoE	B
receptors	I
have	O
been	O
indirectly	O
implicated	O
in	O
memory	O
and	O
neurodegenerative	O
disorders	O
because	O
their	O
ligand	O
,	O
apoE	B
,	O
is	O
genetically	O
associated	O
with	O
Alzheimer	O
disease	O
.	O

We	O
have	O
used	O
knockout	O
mice	O
to	O
investigate	O
the	O
role	O
of	O
Reelin	B
and	O
its	O
receptors	O
in	O
cognition	O
and	O
synaptic	O
plasticity	O
.	O

Mice	O
lacking	O
either	O
the	O
VLDL	B
receptor	I
or	O
the	O
apoER2	B
show	O
contextual	O
fear	O
conditioning	O
deficits	O
.	O

VLDL	B
receptor	I
-	O
deficient	O
mice	O
also	O
have	O
a	O
moderate	O
defect	O
in	O
long	O
term	O
potentiation	O
(	O
LTP	O
)	O
,	O
and	O
apoER2	B
knockouts	O
have	O
a	O
pronounced	O
one	O
.	O

The	O
perfusion	O
of	O
mouse	O
hippocampal	O
slices	O
with	O
Reelin	B
has	O
no	O
effect	O
on	O
baseline	O
synaptic	O
transmission	O
but	O
significantly	O
enhances	O
LTP	O
in	O
area	O
CA1	O
.	O

This	O
Reelin	B
-	O
dependent	O
augmentation	O
of	O
LTP	O
is	O
abolished	O
in	O
VLDL	B
receptor	I
and	O
apoER2	B
knockout	O
mice	O
.	O

Our	O
results	O
reveal	O
a	O
role	O
for	O
Reelin	B
in	O
controlling	O
synaptic	O
plasticity	O
in	O
the	O
adult	O
brain	O
and	O
suggest	O
that	O
both	O
of	O
its	O
receptors	O
are	O
necessary	O
for	O
Reelin	B
-	O
dependent	O
enhancement	O
of	O
synaptic	O
transmission	O
in	O
the	O
hippocampus	O
.	O

Thus	O
,	O
the	O
impairment	O
of	O
apoE	B
receptor	I
-	O
dependent	O
neuromodulation	O
may	O
contribute	O
to	O
cognitive	O
impairment	O
and	O
synaptic	O
loss	O
in	O
Alzheimer	O
disease	O
.	O

Transcription	B
factor	I
NF	B
-	I
IL6	I
(	O
C	B
/	I
EBPbeta	I
)	O
activates	O
the	O
expression	O
of	O
the	O
mouse	O
MHC	B
class	I
I	I
H2-Kb	B
gene	O
in	O
response	O
to	O
TNF	B
-	I
alpha	I
via	O
the	O
intragenic	O
downstream	O
regulatory	O
element	O
.	O

The	O
5'-enhancer	O
-	O
deleted	O
genomic	O
construct	O
of	O
the	O
H2-K	B
(	I
b	I
)	I
gene	O
,	O
stably	O
integrated	O
into	O
the	O
genome	O
of	O
L	O
(	O
tk-	O
)	O
fibroblasts	O
,	O
retains	O
full	O
competence	O
to	O
be	O
induced	O
by	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
treatment	O
.	O

The	O
only	O
defined	O
regulatory	O
region	O
in	O
this	O
construct	O
is	O
the	O
intragenic	O
downstream	O
regulatory	O
element	O
(	O
H2DRE	O
)	O
.	O

Computational	O
inspection	O
uncovered	O
two	O
potential	O
NF	B
-	I
IL6	I
(	O
C	B
/	I
EBPbeta	I
)	O
binding	O
motifs	O
within	O
the	O
H2DRE	O
.	O

Chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
reporter	O
gene	O
assay	O
revealed	O
that	O
NF	B
-	I
IL6	I
is	O
able	O
to	O
elevate	O
transcription	O
from	O
H2DRE	O
.	O

Moreover	O
,	O
transient	O
transfection	O
of	O
an	O
NF	B
-	I
IL6	I
expression	O
vector	O
increased	O
both	O
constitutive	O
and	O
TNF	B
-	I
alpha	I
-	O
induced	O
mRNA	O
levels	O
of	O
endogenous	O
H2	B
class	I
I	I
genes	O
,	O
and	O
transfection	O
of	O
an	O
NF	B
-	I
IL6	I
dominant	O
negative	O
construct	O
decreased	O
the	O
expression	O
of	O
endogenous	O
H2	B
class	I
I	I
genes	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
antibody	O
supershift	O
assay	O
,	O
we	O
were	O
able	O
to	O
qualify	O
the	O
two	O
computationally	O
identified	O
NF	B
-	I
IL6	I
binding	O
motifs	O
as	O
one	O
high	O
-	O
affinity	O
and	O
one	O
low	O
-	O
affinity	O
binding	O
site	O
.	O

We	O
conclude	O
that	O
the	O
H2-K	B
(	I
b	I
)	I
gene	O
belongs	O
to	O
target	O
genes	O
of	O
the	O
NF	B
-	I
IL6	I
(	O
C	B
/	I
EBPbeta	I
)	O
in	O
the	O
course	O
of	O
the	O
cellular	O
response	O
to	O
TNF	B
-	I
alpha	I
,	O
and	O
we	O
discuss	O
some	O
consequences	O
of	O
this	O
conclusion	O
in	O
a	O
general	O
framework	O
of	O
inducible	O
expression	O
of	O
the	O
H2-K	B
(	I
b	I
)	I
gene	O
.	O

The	O
beta	O
-	O
barrel	O
finder	O
(	O
BBF	O
)	O
program	O
,	O
allowing	O
identification	O
of	O
outer	O
membrane	O
beta	O
-	O
barrel	O
proteins	O
encoded	O
within	O
prokaryotic	O
genomes	O
.	O

Many	O
outer	O
membrane	O
proteins	O
(	O
OMPs	O
)	O
in	O
Gram	O
-	O
negative	O
bacteria	O
possess	O
known	O
beta	O
-	O
barrel	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
structures	O
.	O

These	O
proteins	O
,	O
including	O
channel	O
-	O
forming	O
transmembrane	O
porins	B
,	O
are	O
diverse	O
in	O
sequence	O
but	O
exhibit	O
common	O
structural	O
features	O
.	O

We	O
here	O
report	O
computational	O
analyses	O
of	O
six	O
outer	O
membrane	O
proteins	O
of	O
known	O
3D	O
structures	O
with	O
respect	O
to	O
(	O
1	O
)	O
secondary	O
structure	O
,	O
(	O
2	O
)	O
hydropathy	O
,	O
and	O
(	O
3	O
)	O
amphipathicity	O
.	O

Using	O
these	O
characteristics	O
,	O
as	O
well	O
as	O
the	O
presence	O
of	O
an	O
N	O
-	O
terminal	O
targeting	O
sequence	O
,	O
a	O
program	O
was	O
developed	O
allowing	O
prediction	O
of	O
integral	O
membrane	O
beta	O
-	O
barrel	O
proteins	O
encoded	O
within	O
any	O
completely	O
sequenced	O
prokaryotic	O
genome	O
.	O

This	O
program	O
,	O
termed	O
the	O
beta	O
-	O
barrel	O
finder	O
(	O
BBF	O
)	O
program	O
,	O
was	O
used	O
to	O
analyze	O
the	O
proteins	O
encoded	O
within	O
the	O
Escherichia	O
coli	O
genome	O
.	O

Out	O
of	O
4290	O
sequences	O
examined	O
,	O
118	O
(	O
2.8	O
%	O
)	O
were	O
retrieved	O
.	O

Of	O
these	O
,	O
almost	O
all	O
known	O
outer	O
membrane	O
proteins	O
with	O
established	O
beta	O
-	O
barrel	O
structures	O
as	O
well	O
as	O
many	O
probable	O
outer	O
membrane	O
proteins	O
were	O
identified	O
.	O

This	O
program	O
should	O
be	O
useful	O
for	O
predicting	O
the	O
occurrence	O
of	O
outer	O
membrane	O
proteins	O
in	O
bacteria	O
with	O
completely	O
sequenced	O
genomes	O
.	O

Identification	O
of	O
neurite	O
outgrowth	O
promoting	O
sites	O
on	O
the	O
laminin	B
alpha	I
3	I
chain	O
G	O
domain	O
.	O

Laminins	B
are	O
expressed	O
in	O
specific	O
tissues	O
and	O
are	O
involved	O
in	O
various	O
biological	O
activities	O
including	O
promoting	O
cell	O
adhesion	O
,	O
growth	O
,	O
migration	O
,	O
neurite	O
outgrowth	O
,	O
and	O
differentiation	O
.	O

The	O
laminin	B
alpha3	I
chain	O
is	O
mainly	O
located	O
in	O
the	O
skin	O
and	O
is	O
also	O
expressed	O
in	O
the	O
floor	O
plate	O
of	O
the	O
developing	O
neural	O
tube	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
human	O
laminin	B
alpha3	I
chain	O
LG4	O
module	O
binds	O
to	O
syndecan-2	B
/	I
4	I
,	O
a	O
membrane	O
-	O
associated	O
proteoglycan	O
,	O
and	O
promotes	O
human	O
fibroblast	O
adhesion	O
.	O

Here	O
,	O
we	O
have	O
evaluated	O
the	O
neurite	O
outgrowth	O
activity	O
of	O
the	O
laminin	B
alpha3	I
chain	O
LG4	O
and	O
LG5	O
modules	O
.	O

Three	O
overlapping	O
recombinant	O
proteins	O
,	O
which	O
contained	O
LG4	O
and/or	O
LG5	O
modules	O
of	O
the	O
human	O
laminin	B
alpha3	I
chain	O
,	O
were	O
prepared	O
using	O
a	O
mammalian	O
cell	O
expression	O
system	O
.	O

Two	O
proteins	O
,	O
rec	O
-	O
alpha3LG4	O
-	O
5	O
and	O
rec	O
-	O
alpha3LG4	O
,	O
promoted	O
cell	O
attachment	O
and	O
neurite	O
outgrowth	O
of	O
rat	O
pheochromocytoma	O
PC12	O
cells	O
,	O
but	O
rec	O
-	O
alpha3LG5	O
was	O
inactive	O
.	O

Twenty	O
-	O
two	O
peptides	O
covering	O
the	O
entire	O
LG4	O
module	O
were	O
synthesized	O
and	O
tested	O
for	O
cell	O
attachment	O
and	O
neurite	O
outgrowth	O
activity	O
to	O
identify	O
active	O
sites	O
of	O
the	O
LG4	O
module	O
.	O

A3G75	O
(	O
KNSFMALYLSKG	O
,	O
alpha3	O
chain	O
1411	O
-	O
1422	O
)	O
and	O
A3G83	O
(	O
GNSTISIRAPVY	O
,	O
alpha3	O
chain	O
1476	O
-	O
1487	O
)	O
promoted	O
PC12	O
cell	O
attachment	O
and	O
neurite	O
outgrowth	O
.	O

Additionally	O
,	O
A3G75	O
and	O
A3G83	O
inhibited	O
PC12	O
cell	O
attachment	O
to	O
rec	O
-	O
alpha3LG4	O
.	O

These	O
results	O
suggest	O
that	O
the	O
A3G75	O
and	O
A3G83	O
sites	O
are	O
important	O
for	O
PC12	O
cell	O
attachment	O
and	O
neurite	O
outgrowth	O
in	O
the	O
laminin	B
alpha3	I
chain	O
LG4	O
module	O
.	O

We	O
also	O
conjugated	O
the	O
A3G75	O
and	O
A3G83	O
peptides	O
on	O
chitosan	O
membranes	O
to	O
test	O
their	O
potential	O
as	O
bio	O
-	O
materials	O
.	O

These	O
peptide	O
-	O
conjugated	O
chitosan	O
membranes	O
were	O
more	O
active	O
for	O
neurite	O
outgrowth	O
than	O
the	O
peptide	O
-	O
coated	O
plates	O
.	O

These	O
results	O
suggest	O
that	O
the	O
A3G75	O
-	O
and	O
A3G83	O
-	O
conjugated	O
chitosan	O
membranes	O
are	O
applicable	O
as	O
bio	O
-	O
medical	O
materials	O
for	O
neural	O
tissue	O
repair	O
and	O
engineering	O
.	O

Role	O
of	O
the	O
C	O
-	O
terminal	O
propeptide	O
in	O
the	O
activity	O
and	O
maturation	O
of	O
gamma	B
-	I
interferon	I
-	I
inducible	I
lysosomal	I
thiol	I
reductase	I
(	O
GILT	B
)	O
.	O

gamma	B
-	I
Interferon	I
-	I
inducible	I
lysosomal	I
thiol	I
reductase	I
(	O
GILT	B
)	O
is	O
constitutively	O
expressed	O
in	O
antigen	O
-	O
presenting	O
cells	O
.	O

GILT	B
facilitates	O
unfolding	O
of	O
endocytosed	O
antigens	O
in	O
MHC	B
class	I
II	I
-	O
containing	O
compartments	O
by	O
enzymatically	O
reducing	O
disulfide	O
bonds	O
.	O

The	O
enzyme	O
is	O
synthesized	O
as	O
a	O
35	O
-	O
kDa	O
precursor	O
.	O

Although	O
a	O
fraction	O
of	O
the	O
precursor	O
is	O
secreted	O
as	O
a	O
disulfide	O
-	O
linked	O
dimer	O
,	O
the	O
majority	O
is	O
directed	O
via	O
the	O
mannose-6-phosphate	B
receptor	I
pathway	O
to	O
endocytic	O
compartments	O
where	O
its	O
N	O
-	O
and	O
C	O
-	O
terminal	O
propeptides	O
are	O
cleaved	O
to	O
generate	O
the	O
30	O
-	O
kDa	O
mature	O
form	O
.	O

Both	O
precursor	O
and	O
mature	O
GILT	B
reduce	O
disulfide	O
bonds	O
with	O
an	O
acidic	O
pH	O
optimum	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
cysteine	O
residues	O
in	O
the	O
C	O
-	O
terminal	O
propeptide	O
,	O
Cys-211	O
and	O
Cys-222	O
,	O
serve	O
key	O
structural	O
roles	O
.	O

Mutation	O
of	O
Cys-222	O
abolishes	O
disulfide	O
-	O
linked	O
dimerization	O
of	O
precursor	O
GILT	B
and	O
decreases	O
the	O
efficiency	O
of	O
GILT	B
maturation	O
.	O

Mutation	O
of	O
Cys-211	O
results	O
in	O
both	O
impaired	O
intracellular	O
maturation	O
and	O
loss	O
of	O
enzymatic	O
activity	O
of	O
the	O
precursor	O
form	O
at	O
an	O
acidic	O
pH	O
.	O

A	O
similar	O
phenotype	O
was	O
obtained	O
upon	O
mutation	O
of	O
Cys-200	O
,	O
which	O
is	O
retained	O
in	O
the	O
mature	O
form	O
.	O

Cys-200	O
and	O
Cys-211	O
seem	O
to	O
form	O
a	O
disulfide	O
bond	O
that	O
links	O
the	O
propeptide	O
and	O
the	O
mature	O
enzyme	O
until	O
reduction	O
in	O
the	O
lysosome	O
.	O

This	O
disulfide	O
bridge	O
is	O
essential	O
for	O
stability	O
of	O
the	O
enzyme	O
at	O
low	O
pH	O
and	O
for	O
its	O
proper	O
maturation	O
in	O
vivo	O
.	O

Linked	O
unresponsiveness	O
:	O
early	O
cytokine	B
gene	O
expression	O
profiles	O
in	O
cardiac	O
allografts	O
following	O
pretreatment	O
of	O
recipients	O
with	O
bone	O
marrow	O
cells	O
expressing	O
donor	O
MHC	B
alloantigen	O
.	O

Linked	O
unresponsiveness	O
operates	O
to	O
induce	O
specific	O
unresponsiveness	O
to	O
fully	O
mismatched	O
vascularized	O
allografts	O
in	O
recipients	O
pretreated	O
with	O
anti	O
-	O
CD4	B
antibody	O
and	O
syngeneic	O
bone	O
marrow	O
cells	O
expressing	O
a	O
single	O
donor	O
MHC	B
class	I
I	I
alloantigen	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
early	O
post	O
transplant	O
cytokine	B
expression	O
in	O
allografts	O
where	O
linked	O
unresponsiveness	O
was	O
required	O
for	O
long	O
term	O
graft	O
survival	O
.	O

CBA	O
(	O
H2	B
(	O
k	O
)	O
)	O
mice	O
were	O
pretreated	O
with	O
CBK	O
(	O
H2	B
(	O
k	O
)	O
+K	O
(	O
b	O
)	O
)	O
bone	O
marrow	O
cells	O
under	O
the	O
cover	O
of	O
anti	O
-	O
CD4	B
antibody	O
28	O
days	O
before	O
transplantation	O
of	O
a	O
CBK	O
or	O
a	O
C57BL	O
/	O
10	O
(	O
H2	B
(	O
b	O
)	O
)	O
cardiac	O
allograft	O
.	O

In	O
both	O
cases	O
graft	O
survival	O
was	O
prolonged	O
(	O
MST	O
=	O
100	O
days	O
)	O
.	O

Intragraft	O
expression	O
for	O
interferon	B
(	I
IFN	I
)	I
-	I
gamma	I
,	O
interleukin	B
(	I
IL	I
)	I
-	I
2	I
,	O
IL-4	B
,	O
IL-10	B
,	O
IL-12	B
(	I
p40	I
)	I
,	O
IL-18	B
,	O
iNOS	B
,	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
beta	I
(	I
1	I
)	I
and	O
C	O
-	O
beta	O
was	O
determined	O
on	O
day	O
1.5	O
,	O
3	O
,	O
7	O
and	O
14	O
after	O
transplantation	O
.	O

Whereas	O
rejecting	O
allografts	O
displayed	O
a	O
sharp	O
peak	O
in	O
IFN	B
-	I
gamma	I
,	O
IL-2	B
,	O
IL-4	B
and	O
IL-10	B
expression	O
,	O
non	O
-	O
rejecting	O
allografts	O
were	O
characterized	O
by	O
an	O
initial	O
TGF	B
-	I
beta	I
(	I
1	I
)	I
and	O
IFN	B
-	I
gamma	I
production	O
.	O

An	O
increasing	O
IL-4	B
expression	O
towards	O
day	O
14	O
was	O
a	O
unique	O
feature	O
of	O
linked	O
unresponsiveness	O
.	O

All	O
non	O
-	O
rejecting	O
allografts	O
were	O
characterized	O
by	O
an	O
increasing	O
IL-12	B
(	I
p40	I
)	I
production	O
towards	O
day	O
14	O
.	O

In	O
summary	O
,	O
the	O
early	O
cytokine	B
expression	O
pattern	O
in	O
allografts	O
after	O
bone	O
marrow	O
induced	O
operational	O
tolerance	O
is	O
influenced	O
by	O
the	O
quantity	O
of	O
donor	O
alloantigens	O
expressed	O
on	O
the	O
graft	O
as	O
well	O
as	O
on	O
the	O
bone	O
marrow	O
inoculum	O
.	O

Identification	O
of	O
the	O
functional	O
elements	O
in	O
the	O
bidirectional	O
promoter	O
of	O
the	O
mouse	O
O	B
-	I
sialoglycoprotein	I
endopeptidase	I
and	O
APEX	B
nuclease	I
genes	O
.	O

The	O
gene	O
for	O
mammalian	O
O	B
-	I
sialoglycoprotein	I
endopeptidase	I
(	O
Osgep	B
)	O
lies	O
immediately	O
adjacent	O
to	O
the	O
gene	O
for	O
the	O
APEX	B
nuclease	I
(	O
Apex	B
)	O
,	O
a	O
multifunctional	O
DNA	B
repair	I
enzyme	I
,	O
in	O
a	O
head	O
-	O
to	O
-	O
head	O
orientation	O
.	O

To	O
clarify	O
the	O
regulation	O
of	O
these	O
divergent	O
genes	O
,	O
we	O
studied	O
their	O
promoter	O
regions	O
with	O
luciferase	B
reporters	O
.	O

Deletion	O
analysis	O
of	O
a	O
fragment	O
containing	O
the	O
entire	O
mouse	O
Apex	B
gene	O
suggested	O
that	O
cis	O
-	O
acting	O
elements	O
driving	O
in	O
the	O
direction	O
of	O
Osgep	B
are	O
widely	O
distributed	O
in	O
the	O
mApex	B
gene	O
,	O
in	O
the	O
antisense	O
orientation	O
.	O

We	O
investigated	O
in	O
detail	O
cis	O
-	O
acting	O
elements	O
near	O
the	O
transcription	O
initiation	O
site	O
of	O
mOsgep	B
.	O

The	O
spacer	O
sequence	O
between	O
mOsgep	B
and	O
mApex	B
was	O
shown	O
to	O
have	O
bidirectional	O
promoter	O
activity	O
and	O
it	O
has	O
been	O
reported	O
that	O
two	O
CCAAT	O
boxes	O
promote	O
basal	O
transcription	O
in	O
the	O
direction	O
of	O
mApex	B
.	O

However	O
,	O
only	O
one	O
of	O
the	O
CCAAT	O
boxes	O
proximal	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
mOsgep	B
was	O
important	O
for	O
transcription	O
towards	O
mOsgep	B
.	O

An	O
Sp1	B
-	O
binding	O
sequence	O
was	O
found	O
to	O
be	O
involved	O
in	O
bidirectional	O
transcription	O
and	O
a	O
CRE	O
/	O
ATF	B
-	O
like	O
sequence	O
was	O
shown	O
to	O
function	O
as	O
a	O
repressor	O
of	O
mOsgep	B
transcription	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
showed	O
that	O
the	O
mApex	B
and	O
mOsgep	B
genes	O
were	O
expressed	O
in	O
all	O
tissues	O
examined	O
and	O
that	O
expression	O
of	O
mOsgep	B
was	O
low	O
compared	O
with	O
mApex	B
.	O

Hypoxia	O
activates	O
beta	B
(	I
1	I
)	I
-integrin	I
via	O
ERK	B
1	I
/	I
2	I
and	O
p38	B
MAP	I
kinase	I
in	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

Hypoxia	O
plays	O
an	O
important	O
role	O
in	O
vascular	O
remodeling	O
and	O
directly	O
affects	O
vascular	O
smooth	O
muscle	O
cell	O
(	O
VSMC	O
)	O
functions	O
.	O

VSMC	O
adhesion	O
participates	O
in	O
changes	O
of	O
vascular	O
structure	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
VSMC	O
adhesion	O
under	O
hypoxic	O
conditions	O
.	O

It	O
was	O
the	O
aim	O
of	O
the	O
present	O
study	O
to	O
investigate	O
the	O
effects	O
of	O
hypoxia	O
on	O
adhesion	O
mechanisms	O
in	O
human	O
VSMCs	O
.	O

Compared	O
to	O
normoxic	O
cells	O
,	O
hypoxia	O
(	O
1	O
%	O
O	O
(	O
2	O
)	O
,	O
24h	O
)	O
significantly	O
increased	O
adhesion	O
of	O
VSMCs	O
to	O
collagen	B
I	I
by	O
30.2	O
%	O
and	O
fibronectin	B
by	O
58.0	O
%	O
.	O

This	O
effect	O
was	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
the	O
pharmacological	O
ERK	B
1	I
/	I
2	I
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
pathway	O
inhibitor	O
PD98059	O
(	O
30	O
microM	O
)	O
or	O
the	O
p38	B
MAPK	I
inhibitor	O
SB203580	O
(	O
1	O
microM	O
)	O
.	O

Basal	O
adhesion	O
of	O
normoxic	O
cells	O
was	O
not	O
affected	O
by	O
pretreatment	O
with	O
PD98059	O
and	O
SB203580	O
.	O

Hypoxia	O
induced	O
a	O
time	O
-	O
dependent	O
activation	O
of	O
ERK	B
1	I
/	I
2	I
and	O
p38	B
MAPK	I
activation	O
in	O
human	O
VSMCs	O
,	O
which	O
were	O
completely	O
abolished	O
by	O
PD98059	O
or	O
SB203580	O
,	O
respectively	O
.	O

Since	O
adhesion	O
of	O
VSMCs	O
to	O
fibronectin	B
and	O
collagen	B
I	I
involves	O
beta	B
(	I
1	I
)	I
-integrin	I
receptors	O
,	O
we	O
used	O
a	O
blocking	O
antibody	O
against	O
beta	B
(	I
1	I
)	I
-integrin	I
(	O
P5D2	O
)	O
to	O
examine	O
potential	O
effects	O
of	O
hypoxia	O
on	O
beta	B
(	I
1	I
)	I
-	I
integrins	I
.	O

P5D2	O
significantly	O
reduced	O
VSMC	O
adhesion	O
to	O
fibronectin	B
and	O
collagen	B
I	I
in	O
normoxia	O
and	O
hypoxia	O
in	O
a	O
comparable	O
manner	O
;	O
however	O
,	O
beta	B
(	I
1	I
)	I
-integrin	I
protein	O
or	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
hypoxia	O
.	O

As	O
evidenced	O
by	O
flow	O
cytometry	O
,	O
hypoxia	O
induced	O
a	O
activation	O
of	O
beta	B
(	I
1	I
)	I
-integrins	I
by	O
exposing	O
an	O
conformationally	O
sensitive	O
epitope	O
on	O
the	O
beta	B
(	I
1	I
)	I
-	O
subunit	O
.	O

These	O
results	O
demonstrate	O
that	O
hypoxia	O
enhances	O
adhesion	O
of	O
VSMC	O
on	O
extracellular	O
matrix	O
proteins	O
by	O
activating	O
beta	B
(	I
1	I
)	I
-integrin	I
.	O

RNA	B
polymerase	I
II	I
large	I
subunit	I
is	O
cleaved	O
by	O
caspases	B
during	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O

UV	O
radiation	O
induces	O
DNA	O
lesions	O
that	O
are	O
repaired	O
by	O
the	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
pathway	O
.	O

Cells	O
that	O
are	O
NER	O
deficient	O
such	O
as	O
those	O
derived	O
from	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
patients	O
are	O
susceptible	O
to	O
apoptosis	O
after	O
10J	O
/	O
m	O
(	O
2	O
)	O
UV	O
radiation	O
,	O
a	O
dose	O
largely	O
survivable	O
by	O
repair	O
proficient	O
cells	O
.	O

Herein	O
,	O
we	O
report	O
that	O
RNA	B
polymerase	I
II	I
large	I
subunit	I
(	O
RNAP	B
II	I
-	I
LS	I
)	O
undergoes	O
caspase	B
-	O
mediated	O
cleavage	O
,	O
yielding	O
a	O
140kDa	O
C	O
-	O
terminal	O
fragment	O
in	O
XP	O
lymphoblasts	O
but	O
not	O
NER	O
proficient	O
lymphoblasts	O
after	O
10J	O
/	O
m	O
(	O
2	O
)	O
UV	O
irradiation	O
.	O

Cleavage	O
could	O
also	O
be	O
induced	O
by	O
cisplatin	O
or	O
oxaliplatin	O
,	O
but	O
not	O
transplatin	O
,	O
an	O
isomer	O
of	O
cisplatin	O
that	O
does	O
not	O
induce	O
DNA	O
adducts	O
.	O

The	O
cleavage	O
of	O
RNAP	B
II	I
-	I
LS	I
was	O
blocked	O
by	O
a	O
panel	O
of	O
caspase	B
inhibitors	O
but	O
not	O
by	O
proteasomal	O
inhibitors	O
or	O
inhibitors	O
of	O
other	O
proteases	B
.	O

In	O
vitro	O
cleavage	O
with	O
caspase	B
8	I
yielded	O
the	O
same	O
140kDa	O
RNAP	B
II	I
-	I
LS	I
fragment	O
observed	O
in	O
vivo	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
the	O
RNAP	B
II	I
-	I
LS	I
cleavage	O
site	O
was	O
localized	O
to	O
an	O
LETD	O
sequence	O
ending	O
at	O
residue	O
1339	O
,	O
which	O
is	O
near	O
its	O
C	O
-	O
terminal	O
domain	O
.	O

Interaction	O
of	O
oncogenic	O
papillomavirus	O
E6	B
proteins	O
with	O
fibulin-1	B
.	O

Human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	O
is	O
the	O
primary	O
risk	O
factor	O
for	O
the	O
development	O
of	O
cervical	O
cancer	O
.	O

The	O
papillomavirus	O
E6	B
gene	O
is	O
essential	O
for	O
virus	O
-	O
induced	O
cellular	O
transformation	O
and	O
the	O
viral	O
life	O
cycle	O
.	O

Important	O
insight	O
into	O
the	O
mechanism	O
of	O
E6	B
function	O
came	O
from	O
the	O
discovery	O
that	O
cancer	O
-	O
related	O
HPV	O
E6	B
proteins	O
promote	O
the	O
degradation	O
of	O
the	O
tumor	B
suppressor	I
p53	I
.	O

However	O
,	O
mounting	O
evidence	O
indicates	O
that	O
interaction	O
with	O
p53	B
does	O
not	O
mediate	O
all	O
E6	B
activities	O
.	O

To	O
explore	O
the	O
p53	B
-	O
independent	O
functions	O
of	O
E6	B
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
and	O
identified	O
fibulin-1	B
as	O
an	O
E6	B
binding	O
protein	O
.	O

Fibulin-1	B
is	O
a	O
calcium	O
-	O
binding	O
plasma	O
and	O
extracellular	O
matrix	O
protein	O
that	O
has	O
been	O
implicated	O
in	O
cellular	O
transformation	O
and	O
tumor	O
invasion	O
.	O

The	O
interaction	O
between	O
E6	B
and	O
fibulin-1	B
was	O
demonstrated	O
by	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
.	O

Fibulin-1	B
is	O
associated	O
specifically	O
with	O
cancer	O
-	O
related	O
HPV	O
E6s	B
and	O
the	O
transforming	O
bovine	O
papillomavirus	O
type	O
1	O
E6	B
.	O

Significantly	O
,	O
overexpression	O
of	O
fibulin-1	B
specifically	O
inhibited	O
E6	B
-	O
mediated	O
transformation	O
.	O

These	O
results	O
suggest	O
that	O
fibulin-1	B
plays	O
an	O
important	O
role	O
in	O
the	O
biological	O
activities	O
of	O
E6	B
.	O

Towards	O
a	O
new	O
T	O
-	O
fold	O
protein	O
?	O
:	O
the	O
coproporphyrinogen	B
III	I
oxidase	I
sequence	O
matches	O
many	O
structural	O
features	O
from	O
urate	B
oxidase	I
.	O

Urate	B
oxidase	I
(	O
UOX	B
)	O
and	O
coproporphyrinogen	B
III	I
oxidase	I
(	O
CPO	B
)	O
are	O
two	O
unusual	O
oxidases	B
as	O
they	O
accomplish	O
their	O
catalytic	O
act	O
with	O
no	O
co	O
-	O
factor	O
nor	O
metal	O
ion	O
.	O

They	O
both	O
require	O
molecular	O
oxygen	O
,	O
and	O
lead	O
to	O
hydrogen	O
peroxide	O
in	O
addition	O
to	O
the	O
product	O
.	O

UOX	B
is	O
composed	O
of	O
two	O
contiguous	O
Tunneling	O
-	O
fold	O
domains	O
and	O
CPO	B
appears	O
to	O
be	O
also	O
divided	O
into	O
two	O
structurally	O
equivalent	O
domains	O
.	O

Moreover	O
,	O
each	O
of	O
these	O
putative	O
domains	O
can	O
be	O
coherently	O
aligned	O
on	O
UOX	B
domains	O
.	O

Although	O
their	O
sequences	O
are	O
very	O
distant	O
,	O
we	O
therefore	O
suggest	O
that	O
functional	O
CPO	B
dimer	O
is	O
built	O
around	O
a	O
tunnel	O
,	O
with	O
the	O
substrate	O
sitting	O
above	O
it	O
,	O
on	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
side	O
.	O

This	O
overall	O
model	O
is	O
supported	O
by	O
mutation	O
data	O
and	O
is	O
coherent	O
with	O
the	O
chemical	O
events	O
expected	O
for	O
substrate	O
processing	O
by	O
CPO	B
.	O

Overexpression	O
of	O
ABCG5	B
and	O
ABCG8	B
promotes	O
biliary	O
cholesterol	O
secretion	O
and	O
reduces	O
fractional	O
absorption	O
of	O
dietary	O
cholesterol	O
.	O

Two	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporters	O
,	O
ABCG5	B
and	O
ABCG8	B
,	O
have	O
been	O
proposed	O
to	O
limit	O
sterol	O
absorption	O
and	O
to	O
promote	O
biliary	O
sterol	O
excretion	O
in	O
humans	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
P1	O
clone	O
containing	O
the	O
human	O
ABCG5	B
and	O
ABCG8	B
genes	O
was	O
used	O
to	O
generate	O
transgenic	O
mice	O
.	O

The	O
transgenes	O
were	O
expressed	O
primarily	O
in	O
the	O
liver	O
and	O
small	O
intestine	O
,	O
mirroring	O
the	O
expression	O
pattern	O
of	O
the	O
endogenous	O
genes	O
.	O

Transgene	O
expression	O
only	O
modestly	O
affected	O
plasma	O
and	O
liver	O
cholesterol	O
levels	O
but	O
profoundly	O
altered	O
cholesterol	O
transport	O
.	O

The	O
fractional	O
absorption	O
of	O
dietary	O
cholesterol	O
was	O
reduced	O
by	O
about	O
50	O
%	O
,	O
and	O
biliary	O
cholesterol	O
levels	O
were	O
increased	O
more	O
than	O
fivefold	O
.	O

Fecal	O
neutral	O
sterol	O
excretion	O
was	O
increased	O
three	O
-	O
to	O
sixfold	O
and	O
hepatic	O
cholesterol	O
synthesis	O
increased	O
two	O
-	O
to	O
fourfold	O
in	O
the	O
transgenic	O
mice	O
.	O

No	O
significant	O
changes	O
in	O
the	O
pool	O
size	O
,	O
composition	O
,	O
and	O
fecal	O
excretion	O
of	O
bile	O
acids	O
were	O
observed	O
in	O
the	O
transgenic	O
mice	O
.	O

Transgene	O
expression	O
attenuated	O
the	O
increase	O
in	O
hepatic	O
cholesterol	O
content	O
induced	O
by	O
consumption	O
of	O
a	O
high	O
cholesterol	O
diet	O
.	O

These	O
results	O
demonstrate	O
that	O
increased	O
expression	O
of	O
ABCG5	B
and	O
ABCG8	B
selectively	O
drives	O
biliary	O
neutral	O
sterol	O
secretion	O
and	O
reduces	O
intestinal	O
cholesterol	O
absorption	O
,	O
leading	O
to	O
a	O
selective	O
increase	O
in	O
neutral	O
sterol	O
excretion	O
and	O
a	O
compensatory	O
increase	O
in	O
cholesterol	O
synthesis	O
.	O

C2PA	B
is	O
a	O
nuclear	O
protein	O
implicated	O
in	O
the	O
heat	O
shock	O
response	O
.	O

C2PA	B
is	O
a	O
protein	O
of	O
unknown	O
function	O
that	O
is	O
expressed	O
in	O
spermatocytes	O
.	O

PDZ	B
-	I
RGS3	I
is	O
a	O
signaling	O
molecule	O
whose	O
PDZ	O
domain	O
binds	O
Ephrin	B
-	I
B2	I
and	O
mediates	O
reverse	O
signaling	O
of	O
this	O
protein	O
.	O

C2PA	B
and	O
PDZ	B
-	I
RGS3	I
have	O
identical	O
PDZ	O
domains	O
.	O

To	O
explore	O
the	O
function	O
of	O
C2PA	B
,	O
we	O
compared	O
it	O
with	O
PDZ	B
-	I
RGS3	I
with	O
respect	O
to	O
tissue	O
distribution	O
,	O
subcellular	O
localization	O
,	O
and	O
biochemistry	O
.	O

C2PA	B
is	O
expressed	O
only	O
in	O
testis	O
,	O
whereas	O
PDZ	B
-	I
RGS3	I
is	O
expressed	O
in	O
various	O
tissues	O
including	O
brain	O
,	O
heart	O
,	O
lung	O
,	O
liver	O
,	O
spleen	O
,	O
kidney	O
,	O
small	O
intestine	O
,	O
skeletal	O
muscles	O
,	O
and	O
testis	O
.	O

These	O
proteins	O
also	O
differ	O
in	O
their	O
subcellular	O
distribution	O
,	O
in	O
that	O
PDZ	B
-	I
RGS3	I
is	O
cytosolic	O
while	O
C2PA	B
is	O
exclusively	O
nuclear	O
.	O

C2PA	B
is	O
distributed	O
diffusely	O
in	O
the	O
nucleus	O
and	O
forms	O
a	O
few	O
foci	O
at	O
37	O
degrees	O
C	O
.	O

However	O
,	O
when	O
cells	O
are	O
exposed	O
to	O
42	O
degrees	O
C	O
,	O
the	O
number	O
of	O
C2PA	B
foci	O
is	O
increased	O
.	O

These	O
heat	O
shock	O
-	O
induced	O
foci	O
colocalize	O
with	O
CREB	B
-	I
binding	I
protein	I
and	O
heat	B
shock	I
factor-1	I
.	O

In	O
contrast	O
,	O
the	O
distribution	O
of	O
PDZ	B
-	I
RGS3	I
does	O
not	O
change	O
during	O
heat	O
stress	O
.	O

When	O
overexpressed	O
,	O
C2PA	B
induces	O
heat	O
shock	O
response	O
element	O
(	O
HSE	O
)	O
-	O
dependent	O
gene	O
transcription	O
,	O
whereas	O
PDZ	B
-	I
RGS3	I
does	O
not	O
.	O

These	O
data	O
suggest	O
that	O
the	O
function	O
of	O
C2PA	B
is	O
distinct	O
from	O
that	O
of	O
PDZ	B
-	I
RGS3	I
,	O
and	O
that	O
C2PA	B
may	O
be	O
involved	O
in	O
the	O
heat	O
shock	O
response	O
in	O
testis	O
.	O

X	O
-	O
linked	O
creatine	O
deficiency	O
syndrome	O
:	O
a	O
novel	O
mutation	O
in	O
creatine	B
transporter	I
gene	O
SLC6A8	B
.	O

Among	O
creatine	O
deficiency	O
syndromes	O
,	O
an	O
X	O
-	O
linked	O
condition	O
related	O
to	O
a	O
defective	O
creatine	O
transport	O
into	O
the	O
central	O
nervous	O
system	O
has	O
been	O
described	O
recently	O
.	O

Hallmarks	O
of	O
the	O
disease	O
are	O
the	O
absence	O
of	O
a	O
creatine	O
signal	O
at	O
brain	O
spectroscopy	O
,	O
increased	O
creatine	O
levels	O
in	O
blood	O
and	O
urine	O
,	O
ineffectiveness	O
of	O
oral	O
supplementation	O
,	O
and	O
a	O
mutation	O
in	O
the	O
SLC6A8	B
(	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	O
[	O
OMIM	O
]	O
300036	O
)	O
creatine	B
transporter	I
gene	O
.	O

We	O
report	O
on	O
a	O
patient	O
in	O
whom	O
a	O
novel	O
mutation	O
(	O
1221	O
-	O
1223delTTC	O
)	O
was	O
identified	O
.	O

Genetic	O
and	O
environmental	O
risk	O
factors	O
for	O
Alzheimer	O
's	O
disease	O
in	O
Israeli	O
Arabs	O
.	O

OBJECTIVE	O
:	O

We	O
studied	O
the	O
genetic	O
and	O
environmental	O
risk	O
factors	O
and	O
prevalence	O
,	O
and	O
incidence	O
of	O
dementia	O
of	O
the	O
Alzheimer	O
type	O
(	O
DAT	O
)	O
among	O
the	O
elderly	O
in	O
an	O
Arab	O
community	O
in	O
Israel	O
.	O

BACKGROUND	O
:	O

Epidemiological	O
and	O
genetic	O
studies	O
of	O
dementia	O
have	O
rarely	O
been	O
reported	O
in	O
an	O
Arab	O
population	O
.	O

METHODS	O
:	O

All	O
persons	O
aged	O
60	O
years	O
or	O
older	O
who	O
were	O
residents	O
of	O
the	O
rural	O
area	O
of	O
Wadi	O
Ara	O
were	O
examined	O
for	O
identification	O
of	O
DAT	O
,	O
vascular	O
dementia	O
(	O
VaD	O
)	O
and	O
conversion	O
from	O
age	O
related	O
cognitive	O
decline	O
(	O
ARCD	O
)	O
to	O
DAT	O
using	O
DSM	O
-	O
IV	O
criteria	O
and	O
a	O
semi	O
-	O
structured	O
questionnaire	O
for	O
collection	O
of	O
demographic	O
and	O
medical	O
data	O
.	O

ApoE	B
genotype	O
was	O
also	O
determined	O
.	O

Total	O
plasma	O
homocysteine	O
(	O
tHcy	O
)	O
was	O
determined	O
using	O
HPLC	O
with	O
fluorescence	O
detection	O
.	O

Vitamins	O
B12	O
and	O
plasma	O
folate	O
were	O
determined	O
using	O
a	O
commercial	O
radioisotope	O
dilution	O
kit	O
assay	O
(	O
ICN	O
)	O
.	O

RESULTS	O
:	O

DAT	O
was	O
diagnosed	O
in	O
20.5	O
%	O
of	O
this	O
population	O
.	O

Its	O
prevalence	O
increased	O
steeply	O
with	O
age	O
.	O

Illiteracy	O
was	O
very	O
common	O
,	O
and	O
strongly	O
associated	O
with	O
higher	O
prevalence	O
of	O
DAT	O
.	O

The	O
annual	O
incidence	O
of	O
DAT	O
among	O
ARCD	O
cases	O
was	O
4.4	O
%	O
.	O

Subjects	O
with	O
ARCD	O
who	O
developed	O
DAT	O
were	O
older	O
than	O
ARCD	O
subjects	O
who	O
did	O
not	O
develop	O
dementia	O
.	O

Hypertension	O
was	O
significantly	O
more	O
common	O
among	O
converted	O
patients	O
than	O
among	O
non	O
-	O
converted	O
.	O

Illiteracy	O
was	O
insignificantly	O
more	O
common	O
among	O
those	O
who	O
developed	O
DAT	O
than	O
among	O
those	O
who	O
remained	O
ARCD	O
.	O

Vascular	O
dementia	O
(	O
VaD	O
)	O
constitutes	O
about	O
22	O
%	O
of	O
the	O
total	O
dementia	O
population	O
.	O

We	O
also	O
confirm	O
the	O
association	O
between	O
VaD	O
,	O
illiteracy	O
and	O
hypertension	O
.	O

Smoking	O
did	O
not	O
represent	O
a	O
risk	O
factor	O
for	O
VaD	O
.	O

The	O
survival	O
rates	O
among	O
the	O
three	O
groups	O
(	O
healthy	O
subjects	O
,	O
ARCD	O
and	O
DAT	O
)	O
was	O
80.5	O
%	O
,	O
58.8	O
%	O
and	O
55.5	O
%	O
respectively	O
.	O

Homocysteine	O
levels	O
were	O
significantly	O
higher	O
than	O
found	O
in	O
studies	O
in	O
Cleveland	O
.	O

Plasma	O
B12	O
and	O
plasma	O
folate	O
levels	O
did	O
not	O
differ	O
significantly	O
between	O
DAT	O
patients	O
and	O
controls	O
after	O
adjusting	O
for	O
year	O
of	O
birth	O
.	O

CONCLUSIONS	O
:	O

Our	O
findings	O
suggest	O
that	O
the	O
Wadi	O
Ara	O
population	O
is	O
unique	O
because	O
of	O
high	O
prevalence	O
rates	O
of	O
dementia	O
.	O

We	O
found	O
old	O
age	O
,	O
female	O
gender	O
and	O
lack	O
of	O
education	O
to	O
be	O
risk	O
factors	O
for	O
the	O
development	O
of	O
DAT	O
.	O

The	O
ApoE	B
epsilon4	O
allele	O
is	O
relatively	O
uncommon	O
in	O
this	O
population	O
and	O
it	O
can	O
not	O
explain	O
the	O
high	O
DAT	O
prevalence	O
.	O

We	O
also	O
confirm	O
the	O
association	O
between	O
VaD	O
,	O
illiteracy	O
and	O
hypertension	O
and	O
older	O
age	O
and	O
hypertension	O
are	O
risk	O
factors	O
for	O
the	O
transformation	O
of	O
ARCD	O
to	O
DAT	O
.	O

Human	O
fallopian	O
tubes	O
express	O
prostacyclin	B
(	I
PGI	I
)	I
synthase	I
and	O
cyclooxygenases	B
and	O
synthesize	O
abundant	O
PGI	O
.	O

Animal	O
studies	O
unequivocally	O
support	O
the	O
indispensable	O
role	O
of	O
prostaglandin	O
(	O
PG	O
)	O
and	O
cyclooxygenase	B
(	O
COX	B
)	O
in	O
ovulation	O
and	O
implantation	O
.	O

Available	O
data	O
also	O
suggest	O
that	O
PG	O
and	O
COX	B
may	O
be	O
important	O
in	O
the	O
transport	O
of	O
embryos	O
.	O

The	O
effects	O
of	O
PGE	O
(	O
2	O
)	O
and	O
PGF	O
(	O
2alpha	O
)	O
on	O
the	O
contractility	O
of	O
human	O
tubal	O
muscle	O
have	O
been	O
studied	O
extensively	O
;	O
the	O
expression	O
of	O
COX	B
in	O
human	O
fallopian	O
tubes	O
was	O
also	O
reported	O
.	O

Despite	O
all	O
these	O
,	O
two	O
fundamentally	O
important	O
questions	O
remained	O
to	O
be	O
answered	O
:	O
1	O
)	O
which	O
PGs	O
are	O
produced	O
by	O
human	O
fallopian	O
tubes	O
;	O
and	O
2	O
)	O
which	O
COX	B
isoform	O
(	O
s	O
)	O
is	O
expressed	O
by	O
the	O
fallopian	O
tubes	O
.	O

We	O
used	O
reverse	O
-	O
phase	O
HPLC	O
to	O
study	O
the	O
metabolism	O
of	O
[	O
1-	O
(	O
14	O
)	O
C	O
]	O
arachidonic	O
acid	O
by	O
the	O
fallopian	O
tubes	O
.	O

We	O
found	O
that	O
6	O
keto	O
-	O
PGF	O
(	O
1alpha	O
)	O
,	O
a	O
stable	O
metabolite	O
of	O
prostacyclin	O
(	O
PGI	O
)	O
,	O
and	O
PGE	O
(	O
2	O
)	O
constituted	O
56	O
%	O
+	O
/-	O
10	O
%	O
and	O
35	O
%	O
+	O
/-	O
10	O
%	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
four	O
samples	O
)	O
,	O
respectively	O
,	O
of	O
total	O
eicosanoids	O
synthesized	O
.	O

Western	O
blot	O
analysis	O
revealed	O
the	O
expression	O
of	O
both	O
COX	B
isoforms	O
.	O

Immunohistochemistry	O
study	O
showed	O
that	O
both	O
COX-1	B
and	I
-	I
2	I
were	O
localized	O
to	O
nonciliated	O
epithelia	O
and	O
tubal	O
smooth	O
muscle	O
.	O

In	O
addition	O
,	O
COX-2	B
was	O
also	O
expressed	O
in	O
ciliated	O
epithelial	O
cells	O
.	O

Western	O
blot	O
analysis	O
revealed	O
the	O
expression	O
of	O
PGI	B
synthase	I
(	O
PGIS	B
)	O
and	O
PGI	B
receptor	I
by	O
fallopian	O
tubes	O
.	O

Immunohistochemistry	O
confirmed	O
the	O
expression	O
of	O
PGIS	B
by	O
luminal	O
epithelia	O
,	O
tubal	O
smooth	O
muscle	O
,	O
vascular	O
endothelial	O
cells	O
,	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

Iloprost	O
,	O
a	O
PGI	O
analog	O
,	O
inhibited	O
the	O
activities	O
of	O
circular	O
and	O
longitudinal	O
muscles	O
of	O
the	O
fallopian	O
tube	O
.	O

Thus	O
,	O
the	O
fallopian	O
tube	O
expresses	O
both	O
COX	B
isoforms	O
and	O
PGIS	B
.	O

Furthermore	O
,	O
it	O
is	O
a	O
source	O
and	O
a	O
target	O
of	O
PGI	O
.	O

PGI	O
and	O
COX	B
may	O
be	O
important	O
to	O
gamete	O
function	O
,	O
embryo	O
transport	O
,	O
and	O
embryo	O
development	O
.	O

A	O
comprehensive	O
alanine	O
scanning	O
mutagenesis	O
of	O
the	O
Escherichia	O
coli	O
transcriptional	O
activator	O
SoxS	B
:	O
identifying	O
amino	O
acids	O
important	O
for	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O

SoxS	B
is	O
the	O
direct	O
transcriptional	O
activator	O
of	O
the	O
superoxide	O
regulon	O
.	O

SoxS	B
recognizes	O
a	O
highly	O
degenerate	O
""""	O
soxbox	O
""""	O
DNA	O
sequence	O
,	O
and	O
activates	O
transcription	O
from	O
class	O
I	O
and	O
class	O
II	O
promoters	O
.	O

SoxS	B
is	O
the	O
smallest	O
member	O
of	O
the	O
AraC	B
/	I
XylS	I
family	I
of	O
transcription	O
regulators	O
whose	O
hallmark	O
is	O
dual	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
HTH	O
)	O
DNA	O
-	O
binding	O
motifs	O
.	O

Evidence	O
suggests	O
that	O
the	O
N	O
-	O
terminal	O
HTH	O
motif	O
of	O
SoxS	B
interacts	O
with	O
a	O
highly	O
conserved	O
region	O
of	O
the	O
soxbox	O
termed	O
recognition	O
element	O
1	O
(	O
RE1	O
)	O
,	O
while	O
the	O
C	O
-	O
terminal	O
HTH	O
motif	O
interacts	O
with	O
the	O
less	O
conserved	O
recognition	O
element	O
2	O
(	O
RE2	O
)	O
.In	O
the	O
work	O
described	O
here	O
,	O
we	O
prepared	O
a	O
complete	O
library	O
of	O
101	O
SoxS	B
mutants	O
containing	O
single	O
alanine	O
substitutions	O
of	O
SoxS	B
,	O
and	O
we	O
characterized	O
the	O
mutant	O
proteins	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

With	O
SoxS	B
being	O
closely	O
related	O
to	O
MarA	B
,	O
we	O
analyzed	O
the	O
effects	O
of	O
the	O
SoxS	B
mutations	O
in	O
the	O
context	O
of	O
the	O
MarA	B
-	O
mar	B
crystal	O
structure	O
and	O
with	O
respect	O
to	O
the	O
NMR	O
study	O
of	O
MarA	B
-	O
DNA	O
complexes	O
in	O
solution	O
.	O

From	O
the	O
properties	O
of	O
the	O
alanine	O
substitutions	O
,	O
we	O
conclude	O
the	O
following	O
.	O

(	O
1	O
)	O

Surface	O
-	O
exposed	O
residues	O
of	O
helix	O
3	O
and	O
helix	O
6	O
,	O
the	O
recognition	O
helices	O
of	O
the	O
dual	O
HTH	O
motifs	O
,	O
are	O
important	O
to	O
DNA	O
binding	O
and	O
transcription	O
activation	O
;	O
however	O
,	O
substitutions	O
of	O
residues	O
predicted	O
from	O
the	O
MarA	B
-	O
mar	B
crystal	O
structure	O
to	O
make	O
contact	O
with	O
the	O
sugar	O
-	O
phosphate	O
backbone	O
are	O
more	O
detrimental	O
to	O
DNA	O
binding	O
than	O
mutations	O
predicted	O
to	O
make	O
base	O
-	O
specific	O
contacts	O
.	O

(	O
2	O
)	O

Substitution	O
of	O
several	O
residues	O
within	O
the	O
recognition	O
helix	O
predicted	O
to	O
make	O
base	O
-	O
specific	O
contacts	O
with	O
RE2	O
have	O
relatively	O
little	O
effect	O
on	O
DNA	O
-	O
binding	O
,	O
suggesting	O
the	O
possibility	O
of	O
alternative	O
protein	O
-	O
DNA	O
interactions	O
than	O
those	O
inferred	O
from	O
the	O
MarA	B
-	O
mar	B
crystal	O
structure	O
.	O

(	O
3	O
)	O

DNA	O
binding	O
and	O
transcription	O
activation	O
were	O
reduced	O
by	O
substitution	O
of	O
conserved	O
amino	O
acid	O
residues	O
comprising	O
the	O
hydrophobic	O
core	O
,	O
presumably	O
because	O
they	O
disrupt	O
the	O
structural	O
integrity	O
of	O
SoxS	B
.	O

(	O
4	O
)	O

Mutant	O
K30A	O
appears	O
to	O
be	O
a	O
positive	O
control	O
mutant	O
defective	O
in	O
a	O
protein	O
-	O
protein	O
interaction	O
with	O
RNA	B
polymerase	I
that	O
is	O
required	O
for	O
transcription	O
activation	O
at	O
all	O
SoxS	B
-	O
dependent	O
promoters	O
because	O
it	O
binds	O
and	O
bends	O
DNA	O
normally	O
but	O
fails	O
to	O
activate	O
transcription	O
from	O
both	O
classes	O
of	O
promoters	O
.	O

Alanine	O
substitutions	O
of	O
surface	O
-	O
exposed	O
residues	O
H3	O
,	O
K5	O
,	O
D9	O
,	O
S31	O
,	O
and	O
V45	O
confer	O
a	O
similar	O
phenotype	O
.	O

Since	O
these	O
residues	O
are	O
near	O
K30	O
on	O
the	O
surface	O
of	O
the	O
protein	O
,	O
the	O
surface	O
formed	O
by	O
the	O
six	O
residues	O
may	O
be	O
used	O
to	O
make	O
protein	O
-	O
protein	O
interactions	O
with	O
RNA	B
polymerase	I
that	O
are	O
required	O
for	O
transcription	O
activation	O
at	O
both	O
class	O
I	O
and	O
class	O
II	O
SoxS	B
-	O
dependent	O
promoters	O
.	O

(	O
5	O
)	O

Mutants	O
F74A	O
,	O
D75A	O
,	O
M78A	O
,	O
D79A	O
and	O
Q85A	O
appear	O
to	O
define	O
a	O
surface	O
required	O
for	O
protein	O
-	O
protein	O
interaction	O
with	O
RNA	B
polymerase	I
specifically	O
at	O
class	O
II	O
promoters	O
because	O
these	O
positive	O
control	O
mutants	O
bind	O
and	O
bend	O
DNA	O
normally	O
but	O
are	O
defective	O
in	O
activation	O
of	O
class	O
II	O
promoters	O
but	O
not	O
class	O
I	O
promoters	O
.	O

These	O
SoxS	B
mutants	O
that	O
bind	O
and	O
bend	O
DNA	O
normally	O
but	O
are	O
defective	O
in	O
transcription	O
activation	O
represent	O
the	O
first	O
positive	O
control	O
mutants	O
with	O
putative	O
defects	O
in	O
protein	O
-	O
protein	O
interactions	O
with	O
RNA	B
polymerase	I
among	O
the	O
SoxS	B
/	O
MarA	B
/	O
Rob	B
subset	O
of	O
the	O
AraC	B
/	I
XylS	I
family	I
of	O
transcription	O
regulators	O
.	O

The	O
Escherichia	O
coli	O
metD	B
locus	O
encodes	O
an	O
ABC	B
transporter	I
which	O
includes	O
Abc	B
(	O
MetN	B
)	O
,	O
YaeE	B
(	O
MetI	B
)	O
,	O
and	O
YaeC	B
(	O
MetQ	B
)	O
.	O

We	O
report	O
that	O
the	O
genes	O
abc	B
,	O
yaeC	B
,	O
and	O
yaeE	B
comprise	O
metD	B
,	O
an	O
Escherichia	O
coli	O
locus	O
encoding	O
a	O
DL	O
-	O
methionine	O
uptake	O
system	O
.	O

MetD	B
is	O
an	O
ABC	B
transporter	I
with	O
Abc	B
the	O
ATPase	B
,	O
YaeE	B
the	O
permease	B
,	O
and	O
YaeC	B
the	O
likely	O
substrate	O
binding	O
protein	O
.	O

Expression	O
of	O
these	O
genes	O
is	O
regulated	O
by	O
L	O
-	O
methionine	O
and	O
MetJ	B
,	O
a	O
common	O
repressor	O
of	O
the	O
methionine	O
regulon	O
.	O

We	O
propose	O
to	O
rename	O
abc	B
,	O
yaeE	B
,	O
and	O
yaeC	B
as	O
metN	B
,	O
metI	B
,	O
and	O
metQ	B
,	O
respectively	O
.	O

IKKalpha	B
,	O
IKKbeta	B
,	O
and	O
NEMO	B
/	O
IKKgamma	B
are	O
each	O
required	O
for	O
the	O
NF	B
-	I
kappa	I
B	I
-	O
mediated	O
inflammatory	O
response	O
program	O
.	O

The	O
IKKbeta	B
and	O
NEMO	B
/	O
IKKgamma	B
subunits	O
of	O
the	O
NF	B
-	I
kappaB	I
-	O
activating	O
signalsome	O
complex	O
are	O
known	O
to	O
be	O
essential	O
for	O
activating	O
NF	B
-	I
kappaB	I
by	O
inflammatory	O
and	O
other	O
stress	O
-	O
like	O
stimuli	O
.	O

However	O
,	O
the	O
IKKalpha	B
subunit	O
is	O
believed	O
to	O
be	O
dispensable	O
for	O
the	O
latter	O
responses	O
and	O
instead	O
functions	O
as	O
an	O
in	O
vivo	O
mediator	O
of	O
other	O
novel	O
NF	B
-	I
kappaB	I
-	O
dependent	O
and	O
-	O
independent	O
functions	O
.	O

In	O
contrast	O
to	O
this	O
generally	O
accepted	O
view	O
of	O
IKKalpha	B
's	O
physiological	O
functions	O
,	O
we	O
demonstrate	O
in	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
that	O
,	O
akin	O
to	O
IKKbeta	B
and	O
NEMO	B
/	O
IKKgamma	B
,	O
IKKalpha	B
is	O
also	O
a	O
global	O
regulator	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
-	O
and	O
IL-1	B
-	O
responsive	O
IKK	B
signalsome	O
-	O
dependent	O
target	O
genes	O
including	O
many	O
known	O
NF	B
-	I
kappaB	I
targets	O
such	O
as	O
serum	B
amyloid	I
A3	I
,	O
C3	B
,	O
interleukin	B
(	I
IL	I
)	I
-6	I
,	O
IL-11	B
,	O
IL-1	B
receptor	I
antagonist	I
,	O
vascular	B
endothelial	I
growth	I
factor	I
,	O
Ptx3	B
,	O
beta	B
(	I
2	I
)	I
-microglobulin	I
,	O
IL-1alpha	B
,	O
Mcp-1	B
and	I
-	I
3	I
,	O
RANTES	B
(	O
regulated	B
on	I
activation	I
normal	I
T	I
cell	I
expressed	I
and	I
secreted	I
)	O
,	O
Fas	B
antigen	I
,	O
Jun	B
-	I
B	I
,	O
c	B
-	I
Fos	I
,	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
,	O
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
.	O

Only	O
a	O
small	O
number	O
of	O
NF	B
-	I
kappaB	I
-	O
dependent	O
target	O
genes	O
were	O
preferentially	O
dependent	O
on	O
IKKalpha	B
or	O
IKKbeta	B
.	O

Constitutive	O
expression	O
of	O
a	O
trans	O
-	O
dominant	O
IkappaBalpha	B
superrepressor	I
(	O
IkappaBalphaSR	B
)	O
in	O
wild	O
type	O
MEFs	O
confirmed	O
that	O
these	O
signalsome	O
-	O
dependent	O
target	O
genes	O
were	O
also	O
dependent	O
on	O
NF	B
-	I
kappaB	I
.	O

A	O
subset	O
of	O
NF	B
-	I
kappaB	I
target	O
genes	O
were	O
IKK	B
-	O
dependent	O
in	O
the	O
absence	O
of	O
exogenous	O
stimuli	O
,	O
suggesting	O
that	O
the	O
signalsome	O
was	O
also	O
required	O
to	O
regulate	O
basal	O
levels	O
of	O
activated	O
NF	B
-	I
kappaB	I
in	O
established	O
MEFs	O
.	O

Overall	O
,	O
a	O
sizable	O
number	O
of	O
novel	O
NF	B
-	I
kappaB	I
/	O
IKK	B
-	O
dependent	O
genes	O
were	O
identified	O
including	O
Secreted	B
Frizzled	I
,	O
cadherin	B
13	I
,	O
protocadherin	B
7	I
,	O
CCAAT	B
/	I
enhancer	I
-	I
binding	I
protein	I
-	I
beta	I
and	I
-	I
delta	I
,	O
osteoprotegerin	B
,	O
FOXC2	B
and	O
FOXF2	B
,	O
BMP-2	B
,	O
p75	B
neurotrophin	I
receptor	I
,	O
caspase-11	B
,	O
guanylate	B
-	I
binding	I
proteins	I
1	I
and	I
2	I
,	O
ApoJ	B
/	O
clusterin	B
,	O
interferon	B
(	I
alpha	I
and	I
beta	I
)	I
receptor	I
2	I
,	O
decorin	B
,	O
osteoglycin	B
,	O
epiregulin	B
,	O
proliferins	B
2	I
and	I
3	I
,	O
stromal	B
cell	I
-	I
derived	I
factor	I
,	O
and	O
cathepsins	B
B	I
,	I
F	I
,	I
and	I
Z.	I
SOCS	B
-	I
3	I
,	O
a	O
negative	O
effector	O
of	O
STAT3	B
signaling	O
,	O
was	O
found	O
to	O
be	O
an	O
NF	B
-	I
kappaB	I
/	O
IKK	B
-	O
induced	O
gene	O
,	O
suggesting	O
that	O
IKK	B
-	O
mediated	O
NF	B
-	I
kappaB	I
activation	O
can	O
coordinately	O
illicit	O
negative	O
effects	O
on	O
STAT	B
signaling	O
.	O

COP9	B
signalosome	I
subunits	I
4	I
and	I
5	I
regulate	O
multiple	O
pleiotropic	O
pathways	O
in	O
Drosophila	O
melanogaster	O
.	O

The	O
COP9	B
signalosome	I
(	O
CSN	B
)	O
is	O
an	O
essential	O
eight	O
-	O
subunit	O
repressor	O
of	O
light	O
-	O
regulated	O
development	O
in	O
ARABIDOPSIS	O
:	O

This	O
complex	O
has	O
also	O
been	O
identified	O
in	O
animals	O
,	O
though	O
its	O
developmental	O
role	O
remains	O
obscure	O
.	O

CSN	B
subunits	O
have	O
been	O
implicated	O
in	O
various	O
cellular	O
processes	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
the	O
CSN	B
as	O
an	O
integrator	O
of	O
multiple	O
signaling	O
pathways	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
function	O
of	O
the	O
CSN	B
in	O
animals	O
,	O
a	O
Drosophila	O
model	O
system	O
has	O
previously	O
been	O
established	O
.	O

Gel	O
-	O
filtration	O
analysis	O
with	O
antibodies	O
against	O
CSN	B
subunits	I
4	I
,	I
5	I
and	I
7	I
revealed	O
that	O
these	O
proteins	O
act	O
as	O
a	O
complex	O
in	O
Drosophila	O
that	O
is	O
similar	O
in	O
size	O
to	O
the	O
plant	O
and	O
mammalian	O
complexes	O
.	O

Null	O
mutations	O
in	O
either	O
one	O
of	O
two	O
subunits	O
,	O
CSN4	B
or	O
CSN5	B
,	O
are	O
larval	O
lethal	O
.	O

Successful	O
embryogenesis	O
appears	O
to	O
be	O
a	O
consequence	O
of	O
maternal	O
contribution	O
of	O
the	O
complex	O
.	O

Biochemical	O
analysis	O
indicates	O
that	O
the	O
different	O
subunits	O
are	O
found	O
in	O
both	O
CSN	B
-	O
dependent	O
and	O
CSN	B
-	O
independent	O
forms	O
,	O
and	O
that	O
these	O
forms	O
are	O
differentially	O
affected	O
by	O
the	O
mutations	O
.	O

Phenotypic	O
characterization	O
of	O
these	O
two	O
mutants	O
indicates	O
that	O
they	O
show	O
both	O
shared	O
and	O
unique	O
phenotypes	O
,	O
which	O
suggest	O
specific	O
roles	O
for	O
each	O
subunit	O
.	O

Both	O
mutants	O
have	O
defective	O
oocyte	O
and	O
embryo	O
patterning	O
,	O
and	O
defects	O
in	O
response	O
to	O
DNA	O
damage	O
,	O
while	O
csn5	B
mutants	O
develop	O
melanotic	O
tumors	O
and	O
csn4	B
mutants	O
have	O
phenotypes	O
reminiscent	O
of	O
defects	O
in	O
ecdysone	O
signaling	O
.	O

Tumor	O
suppressor	O
activity	O
of	O
AP2alpha	B
mediated	O
through	O
a	O
direct	O
interaction	O
with	O
p53	B
.	O

The	O
AP2	B
transcription	I
factor	I
family	I
is	O
a	O
set	O
of	O
developmentally	O
regulated	O
,	O
retinoic	O
acid	O
inducible	O
genes	O
composed	O
of	O
four	O
related	O
factors	O
,	O
AP2alpha	B
,	O
AP2beta	B
,	O
AP2gamma	B
,	O
and	O
AP2delta	B
.	O

AP2	B
factors	I
orchestrate	O
a	O
variety	O
of	O
cell	O
processes	O
including	O
apoptosis	O
,	O
cell	O
growth	O
,	O
and	O
tissue	O
differentiation	O
during	O
embryogenesis	O
.	O

In	O
studies	O
of	O
primary	O
malignancies	O
,	O
AP2alpha	B
has	O
been	O
shown	O
to	O
function	O
as	O
a	O
tumor	O
suppressor	O
in	O
breast	O
cancer	O
,	O
colon	O
cancer	O
,	O
and	O
malignant	O
melanoma	O
.	O

In	O
cell	O
culture	O
models	O
,	O
overexpression	O
of	O
AP2alpha	B
inhibits	O
cell	O
division	O
and	O
stable	O
colony	O
formation	O
,	O
whereas	O
,	O
a	O
dominant	O
-	O
negative	O
AP2alpha	B
mutant	O
increases	O
invasiveness	O
and	O
tumorigenicity	O
.	O

Here	O
we	O
show	O
that	O
AP2alpha	B
targets	O
the	O
p53	B
tumor	I
suppressor	I
protein	O
.	O

Studies	O
with	O
chromatin	O
immunoprecipitation	O
demonstrate	O
that	O
AP2alpha	B
is	O
brought	O
to	O
p53	B
binding	O
sites	O
in	O
p53	B
-	O
regulated	O
promoters	O
.	O

The	O
interaction	O
between	O
AP2alpha	B
and	O
p53	B
augments	O
p53	B
-	O
mediated	O
transcriptional	O
activation	O
,	O
which	O
results	O
in	O
up	O
-	O
regulation	O
of	O
the	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	I
p21	I
(	O
WAF1	B
/	O
CIP1	B
)	O
.	O

AP2alpha	B
is	O
able	O
to	O
induce	O
G	O
(	O
1	O
)	O
and	O
G	O
(	O
2	O
)	O
cell	O
cycle	O
arrest	O
only	O
in	O
the	O
presence	O
of	O
wild	O
-	O
type	O
p53	B
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
tumor	O
suppressor	O
activity	O
of	O
AP2alpha	B
is	O
mediated	O
through	O
a	O
direct	O
interaction	O
with	O
p53	B
.	O

These	O
results	O
also	O
provide	O
a	O
mechanism	O
to	O
explain	O
patterns	O
of	O
gene	O
expression	O
in	O
cancers	O
where	O
AP2alpha	B
is	O
known	O
to	O
function	O
as	O
a	O
tumor	O
suppressor	O
.	O

Transgenic	O
overexpression	O
of	O
human	O
IL-17E	B
results	O
in	O
eosinophilia	O
,	O
B	O
-	O
lymphocyte	O
hyperplasia	O
,	O
and	O
altered	O
antibody	O
production	O
.	O

We	O
have	O
identified	O
and	O
cloned	O
a	O
novel	O
human	O
cytokine	B
with	O
homology	O
to	O
cytokines	B
of	O
the	O
interleukin-17	B
(	I
IL-17	I
)	I
family	I
,	O
which	O
we	O
have	O
termed	O
human	O
IL-17E	B
(	O
hIL-17E	B
)	O
.	O

With	O
the	O
identification	O
of	O
several	O
IL-17	B
family	I
members	O
,	O
it	O
is	O
critical	O
to	O
understand	O
the	O
in	O
vivo	O
function	O
of	O
these	O
molecules	O
.	O

We	O
have	O
generated	O
transgenic	O
mice	O
overexpressing	O
hIL-17E	B
using	O
an	O
apolipoprotein	B
E	I
(	O
ApoE	B
)	O
hepatic	O
promoter	O
.	O

These	O
mice	O
displayed	O
changes	O
in	O
the	O
peripheral	O
blood	O
,	O
particularly	O
,	O
a	O
3	O
-	O
fold	O
increase	O
in	O
total	O
leukocytes	O
consisting	O
of	O
increases	O
in	O
eosinophils	O
,	O
lymphocytes	O
,	O
and	O
neutrophils	O
.	O

Splenomegaly	O
and	O
lymphoadenopathy	O
were	O
predominant	O
and	O
included	O
marked	O
eosinophil	O
infiltrates	O
and	O
lymphoid	O
hyperplasia	O
.	O

CCR3	B
(	O
+	O
)	O
eosinophils	O
increased	O
in	O
the	O
blood	O
and	O
lymph	O
nodes	O
of	O
the	O
transgenic	O
mice	O
by	O
50	O
-	O
and	O
300	O
-	O
fold	O
,	O
respectively	O
.	O

Eosinophils	O
also	O
increased	O
8	O
-	O
to	O
18	O
-	O
fold	O
in	O
the	O
bone	O
marrow	O
and	O
spleen	O
,	O
respectively	O
.	O

In	O
the	O
bone	O
marrow	O
,	O
most	O
of	O
the	O
eosinophils	O
had	O
an	O
immature	O
appearance	O
.	O

CD19	B
(	O
+	O
)	O
B	O
cells	O
increased	O
2	O
-	O
to	O
5	O
-	O
fold	O
in	O
the	O
peripheral	O
blood	O
,	O
2	O
-	O
fold	O
in	O
the	O
spleen	O
,	O
and	O
10	O
-	O
fold	O
in	O
the	O
lymph	O
nodes	O
of	O
transgenic	O
mice	O
,	O
whereas	O
CD4	B
(	O
+	O
)	O
T	O
lymphocytes	O
increased	O
2	O
-	O
fold	O
in	O
both	O
blood	O
and	O
spleen	O
.	O

High	O
serum	O
levels	O
of	O
the	O
cytokines	B
IL-2	B
,	O
IL-4	B
,	O
IL-5	B
,	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
,	O
eotaxin	B
,	O
and	O
interferon	B
gamma	I
were	O
observed	O
.	O

Consistent	O
with	O
B	O
-	O
lymphocyte	O
increases	O
,	O
serum	O
immunoglobulin	B
(	I
Ig	I
)	I
M	I
,	O
IgG	B
,	O
and	O
IgE	B
were	O
significantly	O
elevated	O
.	O

Antigenic	O
challenge	O
of	O
the	O
transgenic	O
mice	O
with	O
keyhole	B
limpet	I
hemocyanin	I
(	O
KLH	B
)	O
resulted	O
in	O
a	O
decrease	O
in	O
anti	O
-	O
KLH	B
IgG	B
accompanied	O
by	O
increases	O
of	O
anti	O
-	O
KLH	B
IgA	B
and	O
IgE	B
.	O

In	O
situ	O
hybridization	O
of	O
transgenic	O
tissues	O
revealed	O
that	O
IL-17Rh1	B
(	O
IL-17BR	B
/	O
Evi27	B
)	O
,	O
a	O
receptor	O
that	O
binds	O
IL-17E	B
,	O
is	O
up	O
-	O
regulated	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
IL-17E	B
regulates	O
hematopoietic	O
and	O
immune	O
functions	O
,	O
stimulating	O
the	O
development	O
of	O
eosinophils	O
and	O
B	O
lymphocytes	O
.	O

The	O
fact	O
that	O
hIL-17E	B
overexpression	O
results	O
in	O
high	O
levels	O
of	O
circulating	O
eosinophils	O
,	O
IL-4	B
,	O
IL-5	B
,	O
eotaxin	B
,	O
and	O
IgE	B
suggests	O
that	O
IL-17E	B
may	O
be	O
a	O
proinflammatory	O
cytokine	B
favoring	O
Th2	O
-	O
type	O
immune	O
responses	O
.	O

Distinctive	O
response	O
of	O
thyroid	O
-	O
infiltrating	O
mononuclear	O
cells	O
to	O
B	O
cell	O
activation	O
through	O
CD40	B
and	O
interleukin-4	B
in	O
Graves	O
'	O
patients	O
.	O

The	O
possible	O
role	O
of	O
abnormal	O
T	O
cell	O
-	O
dependent	O
B	O
-	O
cell	O
activation	O
in	O
Graves	O
'	O
disease	O
was	O
investigated	O
by	O
comparing	O
lymphocyte	O
subset	O
distribution	O
and	O
the	O
production	O
of	O
soluble	O
CD8	B
(	O
sCD8	B
)	O
,	O
sCD23	B
,	O
IL-10	B
and	O
IL-12	B
by	O
peripheral	O
blood	O
cells	O
(	O
PBMC	O
)	O
and	O
thyroid	O
-	O
infiltrating	O
lymphocytes	O
(	O
TL	O
)	O
in	O
vitro	O
.	O

In	O
TL	O
,	O
the	O
percentage	O
of	O
CD8	B
(	O
+	O
)	O
cells	O
was	O
slightly	O
higher	O
and	O
the	O
sCD8	B
concentration	O
was	O
significantly	O
higher	O
than	O
in	O
PBMC	O
.	O

The	O
ratio	O
CD23	B
(	O
+	O
)	O
cells	O
to	O
CD20	B
(	O
+	O
)	O
cells	O
(	O
activated	O
B	O
/	O
pan	O
B	O
cells	O
)	O
was	O
increased	O
in	O
TL	O
compared	O
to	O
PBMC	O
from	O
Graves	O
'	O
or	O
normal	O
controls	O
,	O
although	O
the	O
percentage	O
of	O
CD20	B
(	O
+	O
)	O
cells	O
was	O
decreased	O
.	O

Compared	O
to	O
PBMC	O
in	O
Graves	O
'	O
disease	O
,	O
the	O
relative	O
ratio	O
of	O
IL-10	B
to	O
IL-12	B
release	O
(	O
IL-10	B
/	O
IL-12	B
)	O
by	O
unstimulated	O
TL	O
was	O
increased	O
,	O
despite	O
a	O
lack	O
of	O
significant	O
difference	O
between	O
PBMC	O
and	O
TL	O
in	O
mean	O
values	O
for	O
either	O
IL-10	B
or	O
IL-12	B
secretion	O
.	O

Incubating	O
PBMC	O
with	O
a	O
combination	O
of	O
anti	O
-	O
CD40	B
monoclonal	O
antibodies	O
and	O
interleukin-4	B
(	O
IL-4	B
)	O
resulted	O
in	O
B	O
cell	O
activation	O
,	O
reflected	O
in	O
an	O
increase	O
in	O
the	O
sCD23	B
level	O
in	O
both	O
controls	O
and	O
Graves	O
'	O
patients	O
,	O
but	O
especially	O
prominent	O
in	O
the	O
latter	O
.	O

Stimulation	O
with	O
anti	O
-	O
CD40	B
antibody	O
and	O
IL-4	B
also	O
decreased	O
the	O
percentage	O
of	O
CD8	B
(	O
+	O
)	O
cells	O
in	O
PBMC	O
but	O
not	O
TL	O
from	O
both	O
Graves	O
'	O
disease	O
and	O
normal	O
controls	O
,	O
and	O
the	O
percentage	O
of	O
CD8	B
(	O
+	O
)	O
cells	O
in	O
TL	O
was	O
higher	O
than	O
PBMC	O
after	O
the	O
stimulation	O
.	O

The	O
sCD23	B
concentration	O
in	O
TL	O
was	O
decreased	O
compared	O
to	O
PBMC	O
both	O
in	O
patients	O
with	O
Graves	O
'	O
disease	O
and	O
normal	O
controls	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
increased	O
responses	O
observed	O
in	O
Graves	O
'	O
PBMC	O
or	O
normal	O
controls	O
after	O
stimulation	O
,	O
sCD23	B
levels	O
remained	O
the	O
same	O
in	O
stimulated	O
TL	O
from	O
Graves	O
'	O
patients	O
.	O

This	O
combination	O
of	O
B	O
cell	O
stimulants	O
increased	O
production	O
of	O
IL-10	B
in	O
PBMC	O
but	O
not	O
in	O
TL	O
obtained	O
from	O
patients	O
with	O
Graves	O
'	O
disease	O
,	O
and	O
the	O
increased	O
IL-10	B
/	O
IL-12	B
ratio	O
declined	O
to	O
a	O
value	O
no	O
different	O
from	O
that	O
in	O
PBMC	O
group	O
after	O
stimulation	O
.	O

Thus	O
,	O
T	O
cell	O
-	O
dependent	O
B	O
-	O
cell	O
activation	O
via	O
a	O
CD40	B
pathway	O
may	O
cause	O
a	O
shift	O
in	O
the	O
Th	O
(	O
1	O
)	O
/	O
Th	O
(	O
2	O
)	O
balance	O
to	O
Th	O
(	O
2	O
)	O
dominance	O
in	O
Graves	O
'	O
disease	O
,	O
while	O
increased	O
CD8	B
(	O
+	O
)	O
cells	O
in	O
TL	O
may	O
suppress	O
sCD23	B
production	O
and	O
IL-10	B
-	O
producing	O
Th	O
(	O
2	O
)	O
cells	O
.	O

Evidence	O
for	O
involvement	O
of	O
a	O
hydrophobic	O
patch	O
in	O
framework	O
region	O
1	O
of	O
human	O
V4	O
-	O
34-encoded	O
Igs	B
in	O
recognition	O
of	O
the	O
red	O
blood	O
cell	O
I	O
antigen	O
.	O

The	O
monoclonal	O
IgM	B
cold	B
agglutinins	I
that	O
bind	O
to	O
the	O
I	O
/	O
i	O
carbohydrate	O
Ags	O
on	O
the	O
surface	O
of	O
RBCs	O
all	O
have	O
Ig	B
H	I
chains	O
encoded	O
by	O
the	O
V4	O
-	O
34	O
gene	O
segment	O
.	O

This	O
mandatory	O
use	O
indicates	O
that	O
distinctive	O
amino	O
acid	O
sequences	O
may	O
be	O
involved	O
in	O
recognition	O
.	O

Critical	O
amino	O
acids	O
exist	O
in	O
framework	O
region	O
1	O
(	O
FR1	O
)	O
of	O
V4	O
-	O
34-encoded	O
Ig	B
,	O
and	O
these	O
generate	O
a	O
specific	O
I	O
d	O
determinant	O
which	O
apparently	O
lies	O
close	O
to	O
the	O
I	O
binding	O
site	O
.	O

However	O
,	O
I	O
binding	O
by	O
Id	O
-	O
expressing	O
Ig	B
can	O
be	O
modulated	O
by	O
sequences	O
in	O
complementarity	O
-	O
determining	O
region	O
(	O
CDR	O
)	O
(	O
H	O
)	O
3	O
.	O

Examination	O
of	O
the	O
crystal	O
structure	O
of	O
an	O
anti	O
-	O
I	O
cold	B
agglutinin	I
has	O
revealed	O
a	O
hydrophobic	O
patch	O
in	O
FR1	O
involving	O
residue	O
W7	O
on	O
beta	O
-	O
strand	O
A	O
and	O
the	O
AVY	O
motif	O
(	O
residues	O
23	O
-	O
25	O
)	O
on	O
beta	O
-	O
strand	O
B	O
.	O

In	O
this	O
study	O
we	O
used	O
mutagenesis	O
to	O
show	O
that	O
each	O
of	O
the	O
strand	O
components	O
of	O
the	O
hydrophobic	O
patch	O
is	O
required	O
for	O
binding	O
the	O
I	O
carbohydrate	O
Ag	O
.	O

In	O
addition	O
,	O
the	O
crystal	O
structure	O
reveals	O
that	O
amino	O
acids	O
in	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
CDR	O
(	O
H	O
)	O
3	O
form	O
a	O
surface	O
region	O
adjacent	O
to	O
the	O
hydrophobic	O
patch	O
.	O

We	O
propose	O
that	O
the	O
I	O
carbohydrate	O
Ag	O
interacts	O
simultaneously	O
with	O
the	O
entire	O
hydrophobic	O
patch	O
in	O
FR1	O
and	O
with	O
the	O
outside	O
surface	O
of	O
CDR	O
(	O
H	O
)	O
3	O
.	O

This	O
interaction	O
could	O
leave	O
most	O
of	O
the	O
conventional	O
binding	O
site	O
available	O
for	O
binding	O
other	O
Ags	O
.	O

Identification	O
of	O
a	O
novel	O
family	O
of	O
cell	O
-	O
surface	O
proteins	O
expressed	O
in	O
human	O
vascular	O
endothelium	O
.	O

Vascular	O
endothelial	O
cells	O
(	O
EC	O
)	O
play	O
a	O
key	O
role	O
in	O
a	O
variety	O
of	O
pathophysiologic	O
processes	O
,	O
such	O
as	O
angiogenesis	O
,	O
inflammation	O
,	O
cancer	O
metastasis	O
,	O
and	O
vascular	O
diseases	O
.	O

As	O
part	O
of	O
a	O
strategy	O
to	O
identify	O
all	O
genes	O
expressed	O
in	O
human	O
EC	O
,	O
a	O
full	O
-	O
length	O
cDNA	O
encoding	O
a	O
potential	O
secreted	O
protein	O
harboring	O
10	O
epidermal	B
growth	I
factor	I
(	O
EGF	B
)	O
-	O
like	O
domains	O
and	O
one	O
CUB	O
domain	O
at	O
the	O
carboxyl	O
terminus	O
(	O
termed	O
,	O
SCUBE1	B
for	O
Signal	B
peptide	I
-	I
CUB	I
-	I
EGF	I
-	I
like	I
domain	I
containing	I
protein	I
1	I
)	O
was	O
identified	O
.	O

SCUBE1	B
shares	O
homology	O
with	O
several	O
protein	O
families	O
,	O
including	O
members	O
of	O
the	O
fibrillin	B
and	I
Notch	I
families	I
,	O
and	O
the	O
anticoagulant	O
proteins	O
,	O
thrombomodulin	B
and	O
protein	B
C	I
.	O

SCUBE1	B
mRNA	O
is	O
found	O
in	O
several	O
highly	O
vascularized	O
tissues	O
such	O
as	O
liver	O
,	O
kidney	O
,	O
lung	O
,	O
spleen	O
,	O
and	O
brain	O
and	O
is	O
selectively	O
expressed	O
in	O
EC	O
by	O
in	O
situ	O
hybridization	O
.	O

SCUBE1	B
is	O
a	O
secreted	O
glycoprotein	O
that	O
can	O
form	O
oligomers	O
and	O
manifests	O
a	O
stable	O
association	O
with	O
the	O
cell	O
surface	O
.	O

A	O
second	O
gene	O
encoding	O
a	O
homologue	O
(	O
designated	O
SCUBE2	B
)	O
was	O
also	O
identified	O
and	O
is	O
expressed	O
in	O
EC	O
as	O
well	O
as	O
other	O
cell	O
types	O
.	O

SCUBE2	B
is	O
also	O
a	O
cell	O
-	O
surface	O
protein	O
and	O
can	O
form	O
a	O
heteromeric	O
complex	O
with	O
SCUBE1	B
.	O

Both	O
SCUBE1	B
and	O
SCUBE2	B
are	O
rapidly	O
down	O
-	O
regulated	O
in	O
EC	O
after	O
interleukin-1beta	B
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
treatment	O
in	O
vitro	O
and	O
after	O
lipopolysaccharide	O
injection	O
in	O
vivo	O
.	O

Thus	O
,	O
SCUBE1	B
and	O
SCUBE2	B
define	O
an	O
emerging	O
family	O
of	O
human	O
secreted	O
proteins	O
that	O
are	O
expressed	O
in	O
vascular	O
endothelium	O
and	O
may	O
play	O
important	O
roles	O
in	O
development	O
,	O
inflammation	O
,	O
and	O
thrombosis	O
.	O

Recombinant	O
glucocorticoid	B
induced	I
tumour	I
necrosis	I
factor	I
receptor	I
(	O
rGITR	B
)	O
induced	O
COX-2	B
activity	O
in	O
murine	O
macrophage	O
Raw	O
264.7	O
cells	O
.	O

Stimulation	O
of	O
murine	O
macrophages	O
with	O
recombinant	O
soluble	O
glucocorticoid	B
induced	I
tumour	I
necrosis	I
factor	I
receptor	I
(	O
GITR	B
)	O
induced	O
cyclooxygenase	B
(	I
COX	I
)	I
-	I
2	I
protein	O
and	O
generated	O
significant	O
amounts	O
of	O
PGE	O
(	O
2	O
)	O
.	O

Previous	O
result	O
demonstrated	O
that	O
macrophages	O
express	O
GITR	B
and	O
GITR	B
ligand	I
constitutively	O
.	O

Induction	O
of	O
COX-2	B
was	O
synergistic	O
with	O
interferon	B
(	I
INF	I
)	I
-	I
gamma	I
.	O

GITR	B
/	O
ligand	O
system	O
could	O
deliver	O
an	O
activation	O
signal	O
to	O
macrophages	O
in	O
inflammatory	O
processes	O
.	O

Expression	O
of	O
trophinin	B
in	O
the	O
cycling	O
endometrium	O
and	O
its	O
association	O
with	O
infertility	O
.	O

OBJECTIVE	O
:	O

To	O
observe	O
the	O
expression	O
of	O
trophinin	B
in	O
the	O
cycling	O
endometrium	O
and	O
investigate	O
its	O
relationship	O
with	O
infertility	O
.	O

METHODS	O
:	O

Trophinin	B
expression	O
in	O
the	O
endometrium	O
was	O
observed	O
in	O
39	O
normal	O
cycling	O
women	O
during	O
different	O
menstrual	O
phases	O
and	O
24	O
women	O
with	O
infertility	O
during	O
mid	O
-	O
luteal	O
phase	O
by	O
immunohistochemical	O
technique	O
.	O

RESULTS	O
:	O

Trophinin	B
expression	O
was	O
detected	O
in	O
the	O
luteal	O
-	O
phase	O
endometrium	O
of	O
both	O
normal	O
and	O
infertile	O
women	O
,	O
which	O
peaked	O
in	O
the	O
mid	O
-	O
luteal	O
phase	O
.	O

In	O
comparison	O
with	O
normal	O
women	O
,	O
infertile	O
women	O
with	O
endometriosis	O
or	O
unexplained	O
infertility	O
had	O
significantly	O
weakened	O
trophinin	B
expression	O
in	O
the	O
endometrium	O
in	O
the	O
mid	O
-	O
luteal	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O

Trophinin	B
may	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
implantation	O
,	O
and	O
abnormal	O
endometrial	O
trophinin	B
expression	O
might	O
be	O
one	O
of	O
the	O
major	O
causes	O
of	O
infertility	O
.	O

Mutations	O
in	O
ANKH	B
cause	O
chondrocalcinosis	O
.	O

Chondrocalcinosis	O
(	O
CC	O
)	O
is	O
a	O
common	O
cause	O
of	O
joint	O
pain	O
and	O
arthritis	O
that	O
is	O
caused	O
by	O
the	O
deposition	O
of	O
calcium	O
-	O
containing	O
crystals	O
within	O
articular	O
cartilage	O
.	O

Although	O
most	O
cases	O
are	O
sporadic	O
,	O
rare	O
familial	O
forms	O
have	O
been	O
linked	O
to	O
human	O
chromosomes	O
8	O
(	O
CCAL1	B
)	O
or	O
5p	O
(	O
CCAL2	B
)	O
(	O
Baldwin	O
et	O
al.	O
1995	O
;	O
Hughes	O
et	O
al.	O
1995	O
;	O
Andrew	O
et	O
al.	O
1999	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
two	O
previously	O
described	O
families	O
with	O
CCAL2	B
have	O
mutations	O
in	O
the	O
human	O
homolog	O
of	O
the	O
mouse	O
progressive	B
ankylosis	I
gene	I
(	O
ANKH	B
)	O
.	O

One	O
of	O
the	O
human	O
mutations	O
results	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
amino	O
acid	O
residue	O
within	O
a	O
predicted	O
transmembrane	O
segment	O
.	O

The	O
other	O
creates	O
a	O
new	O
ATG	O
start	O
site	O
that	O
adds	O
four	O
additional	O
residues	O
to	O
the	O
ANKH	B
protein	O
.	O

Both	O
mutations	O
segregate	O
completely	O
with	O
disease	O
status	O
and	O
are	O
not	O
found	O
in	O
control	O
subjects	O
.	O

In	O
addition	O
,	O
1	O
of	O
95	O
U.K.	O
patients	O
with	O
sporadic	O
CC	O
showed	O
a	O
deletion	O
of	O
a	O
single	O
codon	O
in	O
the	O
ANKH	B
gene	O
.	O

The	O
same	O
change	O
was	O
found	O
in	O
a	O
sister	O
who	O
had	O
bilateral	O
knee	O
replacement	O
for	O
osteoarthritis	O
.	O

Each	O
of	O
the	O
three	O
human	O
mutations	O
was	O
reconstructed	O
in	O
a	O
full	O
-	O
length	O
ANK	B
expression	O
construct	O
previously	O
shown	O
to	O
regulate	O
pyrophosphate	O
levels	O
in	O
cultured	O
cells	O
in	O
vitro	O
.	O

All	O
three	O
of	O
the	O
human	O
mutations	O
showed	O
significantly	O
more	O
activity	O
than	O
a	O
previously	O
described	O
nonsense	O
mutation	O
that	O
causes	O
severe	O
hydroxyapatite	O
mineral	O
deposition	O
and	O
widespread	O
joint	O
ankylosis	O
in	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
small	O
sequence	O
changes	O
in	O
ANKH	B
are	O
one	O
cause	O
of	O
CC	O
and	O
joint	O
disease	O
in	O
humans	O
.	O

Increased	O
ANK	B
activity	O
may	O
explain	O
the	O
different	O
types	O
of	O
crystals	O
commonly	O
deposited	O
in	O
human	O
CCAL2	B
families	O
and	O
mutant	O
mice	O
and	O
may	O
provide	O
a	O
useful	O
pharmacological	O
target	O
for	O
treating	O
some	O
forms	O
of	O
human	O
CC	O
.	O

A	O
27	O
bp	O
cis	O
-	O
acting	O
sequence	O
is	O
essential	O
for	O
L	B
-	I
type	I
calcium	I
channel	I
alpha	I
(	I
1C	I
)	I
subunit	O
expression	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

Expression	O
of	O
L	B
-	I
type	I
calcium	I
channels	I
in	O
cardiac	O
myocytes	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMC	O
)	O
critically	O
regulates	O
the	O
contractile	O
state	O
of	O
these	O
cells	O
.	O

In	O
order	O
to	O
discover	O
the	O
elements	O
in	O
the	O
promoter	O
region	O
of	O
the	O
Ca	B
(	I
v	I
)	I
1.2	I
gene	O
encoding	O
the	O
vascular	O
/	O
cardiac	O
calcium	B
channel	I
alpha	I
(	I
1C	I
)	I
subunit	O
that	O
are	O
important	O
for	O
the	O
basal	O
gene	O
expression	O
,	O
approximately	O
2	O
kb	O
of	O
the	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
Ca	B
(	I
v	I
)	I
1.2	I
gene	O
has	O
been	O
cloned	O
in	O
our	O
lab	O
.	O

In	O
this	O
study	O
,	O
using	O
various	O
lengths	O
of	O
the	O
5	O
'	O
-	O
flanking	O
DNA	O
fused	O
with	O
a	O
luciferase	B
gene	O
as	O
a	O
reporter	O
,	O
we	O
have	O
defined	O
a	O
493	O
-	O
bp	O
fragment	O
of	O
the	O
cis	O
-	O
regulatory	O
DNA	O
which	O
carries	O
the	O
majority	O
of	O
promoter	O
activity	O
in	O
pulmonary	O
artery	O
smooth	O
muscle	O
(	O
PAC1	O
)	O
cells	O
.	O

DNase	B
I	I
footprinting	O
analysis	O
of	O
this	O
493	O
-	O
bp	O
DNA	O
using	O
nuclear	O
extracts	O
from	O
PAC1	O
cells	O
revealed	O
a	O
27	O
-	O
bp	O
DNA	O
sequence	O
that	O
contains	O
a	O
c	B
-	I
Ets	I
like	O
motif	O
(	O
CAGGATGC	O
)	O
.	O

Mutation	O
of	O
the	O
Ets	B
-	O
like	O
site	O
and	O
the	O
respective	O
flanking	O
sequence	O
within	O
the	O
DNase	B
I	I
footprinting	O
protection	O
region	O
induced	O
a	O
marked	O
change	O
in	O
the	O
promoter	O
activity	O
in	O
PAC1	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
confirmed	O
the	O
presence	O
of	O
specific	O
binding	O
factor	O
(	O
s	O
)	O
in	O
PAC1	O
cells	O
'	O
nuclear	O
extracts	O
for	O
this	O
27	O
-	O
bp	O
DNA	O
.	O

Competition	O
studies	O
with	O
the	O
wild	O
-	O
type	O
and	O
mutated	O
DNA	O
fragments	O
established	O
the	O
importance	O
of	O
the	O
27	O
bp	O
DNA	O
sequence	O
for	O
high	O
-	O
affinity	O
binding	O
of	O
the	O
nuclear	O
proteins	O
to	O
the	O
promoter	O
.	O

We	O
conclude	O
that	O
there	O
is	O
a	O
27	O
bp	O
region	O
in	O
the	O
promoter	O
of	O
the	O
Ca	B
(	I
v	I
)	I
1.2	I
gene	O
to	O
which	O
nuclear	O
proteins	O
from	O
VSMC	O
bind	O
and	O
strongly	O
regulate	O
the	O
basal	O
promoter	O
activity	O
.	O

Microsomal	B
epoxide	I
hydrolase	I
and	O
glutathione	B
S	I
-	I
transferase	I
polymorphisms	O
in	O
relation	O
to	O
laryngeal	O
carcinoma	O
risk	O
.	O

Two	O
polymorphic	O
sites	O
of	O
the	O
microsomal	B
epoxide	I
hydrolase	I
gene	O
(	O
EPHX1	B
,	O
113Tyr	O
--	O
>	O
113His	O
,	O
139His	O
--	O
>	O
139Arg	O
)	O
and	O
four	O
glutathione	B
S	I
-	I
transferase	I
genes	O
(	O
GSTM1	B
,	O
GSTM3	B
,	O
GSTP1	B
,	O
GSTT1	B
)	O
were	O
genotyped	O
in	O
a	O
group	O
of	O
patients	O
with	O
larynx	O
cancer	O
(	O
N	O
=	O
204	O
)	O
and	O
in	O
a	O
group	O
of	O
healthy	O
controls	O
(	O
N	O
=	O
203	O
)	O
,	O
all	O
Spanish	O
caucasians	O
.	O

After	O
adjusting	O
for	O
gender	O
,	O
age	O
,	O
and	O
tobacco	O
smoking	O
,	O
none	O
of	O
the	O
polymorphisms	O
alone	O
were	O
found	O
to	O
be	O
associated	O
with	O
larynx	O
cancer	O
risk	O
.	O

The	O
analysis	O
of	O
EPHX1	B
/	O
GST	B
combinations	O
,	O
however	O
,	O
showed	O
a	O
significant	O
over	O
-	O
representation	O
of	O
patients	O
with	O
a	O
combination	O
of	O
113Tyr	O
/	O
113Tyr	O
EPHX1	B
and	O
105Ile	O
/	O
105Ile	O
GSTP1	B
(	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
:	O
1.95	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.02	O
-	O
3.78	O
)	O
.	O

The	O
calculation	O
of	O
the	O
predicted	O
epoxide	B
hydrolase	I
(	O
EH	B
)	O
activity	O
also	O
showed	O
an	O
increased	O
risk	O
for	O
the	O
individuals	O
with	O
both	O
predicted	O
high	O
activity	O
EH	B
and	O
105Ile	O
/	O
105Ile	O
GSTP1	B
(	O
OR	O
:	O
2.90	O
;	O
95	O
%	O
CI	O
:	O
1.10	O
-	O
7.67	O
)	O
.	O

These	O
results	O
on	O
larynx	O
cancer	O
tend	O
to	O
confirm	O
a	O
former	O
study	O
on	O
lung	O
cancer	O
(	O
Cancer	O
Lett	O
.	O
173	O
(	O
2001	O
)	O
155	O
)	O
suggesting	O
the	O
existence	O
of	O
an	O
interaction	O
between	O
variants	O
of	O
EH	B
and	O
GSTpi	B
,	O
both	O
enzymes	O
being	O
involved	O
in	O
the	O
metabolism	O
of	O
aromatic	O
hydrocarbons	O
,	O
that	O
may	O
increase	O
susceptibility	O
to	O
tobacco	O
-	O
related	O
cancers	O
.	O

Caspase	B
-	O
mediated	O
cleavage	O
of	O
adenovirus	O
early	B
region	I
1A	I
proteins	O
.	O

Adenovirus	O
2	O
and	O
12	O
early	B
region	I
1A	I
(	O
Ad2	O
and	O
Ad12	O
E1A	B
)	O
proteins	O
were	O
cleaved	O
during	O
cisplatin	O
-	O
induced	O
apoptosis	O
of	O
Ad	O
-	O
transformed	O
rat	O
and	O
human	O
cells	O
.	O

Cleavage	O
was	O
inhibited	O
in	O
the	O
presence	O
of	O
caspase	B
inhibitors	O
such	O
as	O
Z	O
-	O
VAD	O
-	O
FMK	O
.	O

In	O
Ad12	O
transformants	O
both	O
13S	B
and	I
12S	I
E1A	I
proteins	I
were	O
cleaved	O
at	O
a	O
similar	O
rate	O
.	O

In	O
Ad2	O
transformants	O
the	O
E1A	B
13S	I
component	O
was	O
appreciably	O
less	O
stable	O
than	O
the	O
12S	B
component	O
.	O

In	O
in	O
vitro	O
studies	O
Ad2	O
and	O
Ad12	O
E1A	B
13S	I
and	O
Ad2	O
12S	B
proteins	I
were	O
rapidly	O
cleaved	O
by	O
caspase	B
3	I
whereas	O
Ad12	O
12S	B
E1A	I
and	O
Ad12	O
13S	B
E1A	I
were	O
rapidly	O
degraded	O
by	O
caspase	B
7	I
.	O

Cleavage	O
sites	O
in	O
Ad12	O
13S	B
proteins	I
for	O
caspase	B
3	I
have	O
been	O
determined	O
.	O

Initial	O
cleavage	O
occurred	O
at	O
D24	O
and	O
D150	O
;	O
this	O
was	O
followed	O
by	O
cleavage	O
at	O
D204	O
and	O
D242	O
.	O

Caspase-3	B
-	O
mediated	O
cleavage	O
of	O
Ad12	O
13S	B
E1A	I
destroyed	O
its	O
ability	O
to	O
bind	O
to	O
CBP	B
and	O
TBP	B
but	O
interaction	O
between	O
C	O
terminal	O
E1A	B
polypeptides	O
and	O
CtBP	B
was	O
observed	O
.	O

During	O
viral	O
infection	O
Ad5	O
and	O
Ad12	O
E1A	B
12S	I
proteins	I
were	O
markedly	O
more	O
stable	O
than	O
13S	B
proteins	I
but	O
no	O
difference	O
was	O
observed	O
in	O
Ad	O
E1A	B
levels	O
in	O
the	O
absence	O
or	O
presence	O
of	O
the	O
caspase	B
inhibitors	O
Z	O
-	O
VAD	O
-	O
FMK	O
or	O
Z	O
-	O
D	O
(	O
OMe	O
)	O
-E	O
(	O
OMe	O
)	O
-V	O
-	O
D	O
(	O
OMe	O
)	O
-CH	O
(	O
2	O
)	O
F	O
.	O

Limited	O
caspase	B
3	I
and	I
10	I
activation	O
occurred	O
during	O
infection	O
with	O
the	O
E1B	B
19	I
K	I
(	O
-	O
)	O
virus	O
Ad2	O
pm1722	O
but	O
little	O
or	O
no	O
activation	O
of	O
caspase	B
3	I
was	O
observed	O
during	O
wt	O
virus	O
infection	O
.	O

Examination	O
of	O
protein	O
cleavage	O
during	O
viral	O
infection	O
of	O
A549	O
cells	O
showed	O
proteolysis	O
of	O
lamin	B
B	I
and	O
PARP	B
in	O
response	O
to	O
Ad5	O
wt	O
and	O
Ad2	O
pm1722	O
.	O

Protein	O
degradation	O
in	O
response	O
to	O
both	O
viruses	O
was	O
partially	O
inhibited	O
by	O
Z	O
-	O
VAD	O
-	O
FMK	O
.	O

Following	O
infection	O
of	O
human	O
skin	O
fibroblasts	O
lamin	B
B	I
was	O
degraded	O
,	O
although	O
only	O
limited	O
changes	O
in	O
PARP	B
levels	O
were	O
observed	O
.	O

We	O
have	O
concluded	O
that	O
Ad	O
E1A	B
is	O
cleaved	O
by	O
caspases	B
during	O
apoptosis	O
but	O
not	O
during	O
viral	O
infection	O
.	O

However	O
,	O
some	O
of	O
the	O
processes	O
commonly	O
associated	O
with	O
apoptosis	O
occur	O
during	O
viral	O
infection	O
,	O
particularly	O
with	O
E1B	B
19	I
K	I
(	O
-	O
)	O
mutants	O
,	O
although	O
apoptosis	O
per	O
se	O
is	O
not	O
evident	O
.	O

Regulation	O
of	O
HIV-1	O
transcription	O
by	O
NF	B
-	I
IL6	I
in	O
activated	O
Jurkat	O
T	O
cells	O
.	O

To	O
examine	O
the	O
mechanism	O
of	O
HIV-1	O
regulation	O
by	O
NF	B
-	I
IL6	I
in	O
activated	O
human	O
cells	O
,	O
we	O
selected	O
a	O
Jurkat	O
cell	O
line	O
that	O
did	O
not	O
contain	O
endogenous	O
NF	B
-	I
IL6	I
.	O

In	O
this	O
cellular	O
environment	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
exogenous	O
NF	B
-	I
IL6	I
on	O
transcription	O
mediated	O
by	O
native	O
and	O
deleted	O
LTR	O
sequences	O
.	O

In	O
Jurkat	O
cells	O
stimulated	O
with	O
LPS	O
and	O
PMA	O
,	O
LTR	O
-	O
mediated	O
transcription	O
was	O
enhanced	O
by	O
NF	B
-	I
IL6	I
.	O

The	O
results	O
of	O
deletion	O
studies	O
revealed	O
a	O
central	O
role	O
for	O
the	O
basal	O
LTR	O
region	O
and	O
the	O
TATA	O
element	O
in	O
the	O
LTR	O
,	O
in	O
upregulation	O
of	O
reporter	O
gene	O
expression	O
by	O
NF	B
-	I
IL6	I
in	O
activated	O
cells	O
.	O

In	O
the	O
selected	O
cellular	O
environment	O
,	O
regulation	O
of	O
transcription	O
by	O
NF	B
-	I
IL6	I
was	O
not	O
evident	O
in	O
studies	O
of	O
promoter	O
regions	O
of	O
other	O
genes	O
.	O

The	O
results	O
implied	O
that	O
the	O
basal	O
region	O
of	O
HIV-1	O
LTR	O
includes	O
molecular	O
properties	O
that	O
support	O
activation	O
of	O
HIV-1	O
by	O
NF	B
-	I
IL6	I
in	O
stimulated	O
cells	O
.	O

MafA	B
is	O
a	O
glucose	O
-	O
regulated	O
and	O
pancreatic	O
beta	O
-	O
cell	O
-	O
specific	O
transcriptional	O
activator	O
for	O
the	O
insulin	B
gene	O
.	O

The	O
insulin	B
gene	O
is	O
specifically	O
expressed	O
in	O
beta	O
-	O
cells	O
of	O
the	O
Langerhans	O
islets	O
of	O
the	O
pancreas	O
,	O
and	O
its	O
transcription	O
is	O
regulated	O
by	O
the	O
circulating	O
glucose	O
level	O
.	O

Previous	O
reports	O
have	O
shown	O
that	O
an	O
unidentified	O
beta	O
-	O
cell	O
-	O
specific	O
nuclear	O
factor	O
binds	O
to	O
a	O
conserved	O
cis	O
-	O
regulatory	O
element	O
called	O
RIPE3b	B
and	O
is	O
critical	O
for	O
its	O
glucose	O
-	O
regulated	O
expression	O
.	O

Based	O
on	O
the	O
sequence	O
similarity	O
of	O
the	O
RIPE3b	B
element	O
and	O
the	O
consensus	O
binding	O
sequence	O
of	O
the	O
Maf	B
family	I
of	O
basic	O
leucine	O
zipper	O
transcription	B
factors	I
,	O
we	O
here	O
identified	O
mammalian	O
homologue	O
of	O
avian	O
MafA	B
/	O
L	B
-	I
Maf	I
,	O
an	O
eye	O
-	O
specific	O
member	O
of	O
the	O
Maf	B
family	I
,	O
as	O
the	O
RIPE3b	B
-	O
binding	O
transcriptional	O
activator	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
analysis	O
showed	O
that	O
mafA	B
mRNA	O
is	O
detected	O
only	O
in	O
the	O
eyes	O
and	O
in	O
pancreatic	O
beta	O
-	O
cells	O
and	O
not	O
in	O
alpha	O
-	O
cells	O
.	O

MafA	B
protein	O
as	O
well	O
as	O
its	O
mRNA	O
is	O
up	O
-	O
regulated	O
by	O
glucose	O
,	O
consistent	O
with	O
the	O
glucose	O
-	O
regulated	O
binding	O
of	O
MafA	B
to	O
the	O
RIPE3b	B
element	O
in	O
beta	O
-	O
cell	O
nuclear	O
extracts	O
.	O

In	O
transient	O
luciferase	B
assays	O
,	O
we	O
also	O
showed	O
that	O
expression	O
of	O
MafA	B
greatly	O
enhanced	O
insulin	O
promoter	O
activity	O
and	O
that	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
MafA	B
inhibited	O
it	O
.	O

Therefore	O
,	O
MafA	B
is	O
a	O
beta	O
-	O
cell	O
-	O
specific	O
and	O
glucose	O
-	O
regulated	O
transcriptional	O
activator	O
for	O
insulin	B
gene	O
expression	O
and	O
thus	O
may	O
be	O
involved	O
in	O
the	O
function	O
and	O
development	O
of	O
beta	O
-	O
cells	O
as	O
well	O
as	O
in	O
the	O
pathogenesis	O
of	O
diabetes	O
.	O

The	O
common	O
aromatic	O
amino	O
acid	O
biosynthesis	O
pathway	O
is	O
essential	O
in	O
Mycobacterium	O
tuberculosis	O
.	O

Attempts	O
to	O
construct	O
Mycobacterium	O
tuberculosis	O
strains	O
with	O
a	O
defect	O
in	O
the	O
common	O
aromatic	O
amino	O
acid	O
biosynthesis	O
pathway	O
were	O
made	O
.	O

In	O
other	O
bacteria	O
the	O
genes	O
of	O
this	O
pathway	O
(	O
aro	B
)	O
can	O
be	O
disrupted	O
in	O
the	O
presence	O
of	O
suitable	O
media	O
supplements	O
.	O

The	O
genomic	O
organization	O
of	O
the	O
aro	B
genes	O
in	O
M.	O
tuberculosis	O
reveals	O
that	O
there	O
is	O
one	O
operon	O
(	O
aroCKBQ	B
)	O
and	O
three	O
isolated	O
aro	B
genes	O
(	O
aroE	B
,	O
aroG	B
and	O
aroA	B
)	O
.	O

The	O
aroK	B
gene	O
was	O
chosen	O
as	O
a	O
target	O
for	O
disruption	O
;	O
this	O
encodes	O
shikimate	B
kinase	I
,	O
which	O
catalyses	O
the	O
fifth	O
step	O
in	O
chorismate	O
biosynthesis	O
.	O

Attempts	O
to	O
replace	O
the	O
wild	O
-	O
type	O
aroK	B
gene	O
with	O
a	O
disrupted	O
allele	O
(	O
aroKDelta	B
:	O
:	O
hyg	B
)	O
by	O
a	O
two	O
-	O
step	O
homologous	O
recombination	O
procedure	O
were	O
unsuccessful	O
in	O
a	O
wild	O
-	O
type	O
strain	O
.	O

When	O
a	O
second	O
functional	O
copy	O
of	O
aroK	B
was	O
integrated	O
into	O
the	O
chromosome	O
,	O
it	O
was	O
possible	O
to	O
isolate	O
a	O
strain	O
carrying	O
the	O
disrupted	O
gene	O
.	O

Excision	O
of	O
the	O
L5	O
-	O
integrated	O
copy	O
of	O
aroK	B
by	O
the	O
L5	O
excisionase	B
could	O
be	O
not	O
be	O
achieved	O
in	O
the	O
strain	O
carrying	O
the	O
disrupted	O
copy	O
,	O
but	O
was	O
possible	O
in	O
a	O
strain	O
carrying	O
a	O
wild	O
-	O
type	O
copy	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
chorismate	O
pathway	O
is	O
essential	O
for	O
the	O
viability	O
of	O
M.	O
tuberculosis	O
.	O

Mycobacterium	O
tuberculosis	O
-	O
infected	O
human	O
macrophages	O
exhibit	O
enhanced	O
cellular	O
adhesion	O
with	O
increased	O
expression	O
of	O
LFA-1	B
and	O
ICAM-1	B
and	O
reduced	O
expression	O
and/or	O
function	O
of	O
complement	B
receptors	I
,	O
FcgammaRII	B
and	O
the	O
mannose	B
receptor	I
.	O

The	O
entry	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
Mtb	O
)	O
into	O
the	O
host	O
macrophage	O
and	O
its	O
survival	O
in	O
this	O
environment	O
are	O
key	O
components	O
of	O
tuberculosis	O
pathogenesis	O
.	O

Following	O
intracellular	O
replication	O
of	O
the	O
bacterium	O
within	O
alveolar	O
macrophages	O
,	O
there	O
is	O
spread	O
of	O
bacilli	O
to	O
regional	O
lymph	O
nodes	O
in	O
the	O
lungs	O
and	O
subsequent	O
presentation	O
of	O
antigens	O
to	O
the	O
host	O
immune	O
system	O
.	O

How	O
this	O
process	O
occurs	O
remains	O
poorly	O
understood	O
,	O
but	O
one	O
mechanism	O
may	O
involve	O
the	O
migration	O
of	O
macrophages	O
containing	O
Mtb	O
across	O
the	O
alveoli	O
to	O
lymph	O
nodes	O
,	O
where	O
there	O
is	O
development	O
of	O
a	O
protective	O
host	O
response	O
with	O
formation	O
of	O
granulomas	O
composed	O
in	O
part	O
of	O
aggregated	O
and	O
fused	O
,	O
apoptotic	O
,	O
infected	O
macrophages	O
.	O

Leukocyte	O
integrins	B
,	O
including	O
lymphocyte	B
function	I
-	I
associated	I
antigen-1	I
(	O
LFA-1	B
)	O
and	O
complement	B
receptors	I
CR3	B
and	O
CR4	B
,	O
and	O
their	O
counter	O
receptors	O
play	O
a	O
major	O
role	O
in	O
macrophage	O
adhesion	O
processes	O
and	O
phagocytosis	O
.	O

In	O
this	O
study	O
,	O
the	O
appearance	O
of	O
Mtb	O
-	O
infected	O
macrophages	O
over	O
time	O
was	O
examined	O
,	O
using	O
inverted	O
-	O
phase	O
microscopy	O
and	O
an	O
in	O
vitro	O
culture	O
model	O
of	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
.	O

Prior	O
to	O
and	O
immediately	O
following	O
infection	O
of	O
the	O
MDMs	O
with	O
Mtb	O
,	O
the	O
macrophages	O
appeared	O
as	O
individual	O
cells	O
in	O
monolayer	O
culture	O
;	O
however	O
,	O
within	O
24	O
h	O
of	O
infection	O
with	O
Mtb	O
,	O
the	O
MDMs	O
began	O
to	O
migrate	O
and	O
adhere	O
to	O
each	O
other	O
.	O

The	O
kinetics	O
of	O
this	O
response	O
were	O
dependent	O
on	O
both	O
the	O
m.o.i	O
.	O
and	O
the	O
length	O
of	O
infection	O
.	O

Quantitative	O
transmission	O
electron	O
microscopy	O
studies	O
revealed	O
that	O
macrophage	O
adhesion	O
was	O
accompanied	O
by	O
increases	O
in	O
levels	O
of	O
LFA-1	B
and	O
its	O
counter	O
receptor	O
(	O
ICAM-1	B
)	O
,	O
decreases	O
in	O
surface	O
levels	O
of	O
the	O
phagocytic	O
receptors	O
CR3	B
,	O
CR4	B
and	O
FcgammaRII	B
,	O
and	O
an	O
increase	O
in	O
major	B
histocompatibility	I
complex	I
Class	I
II	I
(	O
MHC	B
-	I
II	I
)	O
molecules	O
at	O
72	O
h	O
post	O
-	O
infection	O
.	O

Decreases	O
in	O
surface	O
levels	O
of	O
CR3	B
and	O
CR4	B
had	O
a	O
functional	O
correlate	O
,	O
with	O
macrophages	O
containing	O
live	O
bacilli	O
showing	O
a	O
diminished	O
phagocytic	O
capacity	O
for	O
complement	O
-	O
opsonized	O
sheep	O
erythrocytes	O
;	O
macrophages	O
containing	O
heat	O
-	O
killed	O
bacilli	O
did	O
not	O
show	O
this	O
diminished	O
capacity	O
.	O

The	O
modulation	O
of	O
macrophage	O
adhesion	O
and	O
phagocytic	O
proteins	O
may	O
influence	O
the	O
trafficking	O
of	O
Mtb	O
-	O
infected	O
macrophages	O
within	O
the	O
host	O
,	O
with	O
increases	O
in	O
levels	O
of	O
LFA-1	B
and	O
ICAM-1	B
enhancing	O
the	O
adhesive	O
properties	O
of	O
the	O
macrophage	O
and	O
decreases	O
in	O
phagocytic	O
receptors	O
diminishing	O
the	O
phagocytic	O
capacity	O
of	O
an	O
already	O
-	O
infected	O
cell	O
,	O
potentially	O
allowing	O
for	O
maintenance	O
of	O
the	O
intracellular	O
niche	O
of	O
Mtb	O
.	O

Engineering	O
tolerance	O
and	O
hyperaccumulation	O
of	O
arsenic	O
in	O
plants	O
by	O
combining	O
arsenate	B
reductase	I
and	O
gamma	B
-	I
glutamylcysteine	I
synthetase	I
expression	O
.	O

We	O
have	O
developed	O
a	O
genetics	O
-	O
based	O
phytoremediation	O
strategy	O
for	O
arsenic	O
in	O
which	O
the	O
oxyanion	O
arsenate	O
is	O
transported	O
aboveground	O
,	O
reduced	O
to	O
arsenite	O
,	O
and	O
sequestered	O
in	O
thiol	O
-	O
peptide	O
complexes	O
.	O

The	O
Escherichia	O
coli	O
arsC	B
gene	O
encodes	O
arsenate	B
reductase	I
(	O
ArsC	B
)	O
,	O
which	O
catalyzes	O
the	O
glutathione	O
(	O
GSH	O
)	O
-	O
coupled	O
electrochemical	O
reduction	O
of	O
arsenate	O
to	O
the	O
more	O
toxic	O
arsenite	O
.	O

Arabidopsis	O
thaliana	O
plants	O
transformed	O
with	O
the	O
arsC	B
gene	O
expressed	O
from	O
a	O
light	O
-	O
induced	O
soybean	O
rubisco	B
promoter	O
(	O
SRS1p	B
)	O
strongly	O
express	O
ArsC	B
protein	O
in	O
leaves	O
,	O
but	O
not	O
roots	O
,	O
and	O
were	O
consequently	O
hypersensitive	O
to	O
arsenate	O
.	O

Arabidopsis	O
plants	O
expressing	O
the	O
E.	O
coli	O
gene	O
encoding	O
gamma	B
-	I
glutamylcysteine	I
synthetase	I
(	O
gamma	B
-	I
ECS	I
)	O
from	O
a	O
strong	O
constitutive	O
actin	B
promoter	O
(	O
ACT2p	B
)	O
were	O
moderately	O
tolerant	O
to	O
arsenic	O
compared	O
with	O
wild	O
type	O
.	O

However	O
,	O
plants	O
expressing	O
SRS1p	B
/	O
ArsC	B
and	O
ACT2p	B
/	O
gamma	B
-	I
ECS	I
together	O
showed	O
substantially	O
greater	O
arsenic	O
tolerance	O
than	O
gamma	B
-	I
ECS	I
or	O
wild	O
-	O
type	O
plants	O
.	O

When	O
grown	O
on	O
arsenic	O
,	O
these	O
plants	O
accumulated	O
4	O
-	O
to	O
17	O
-	O
fold	O
greater	O
fresh	O
shoot	O
weight	O
and	O
accumulated	O
2	O
-	O
to	O
3	O
-	O
fold	O
more	O
arsenic	O
per	O
gram	O
of	O
tissue	O
than	O
wild	O
type	O
or	O
plants	O
expressing	O
gamma	B
-	I
ECS	I
or	O
ArsC	B
alone	O
.	O

This	O
arsenic	O
remediation	O
strategy	O
should	O
be	O
applicable	O
to	O
a	O
wide	O
variety	O
of	O
plant	O
species	O
.	O

Truncation	O
analysis	O
of	O
TatA	B
and	O
TatB	B
defines	O
the	O
minimal	O
functional	O
units	O
required	O
for	O
protein	O
translocation	O
.	O

The	O
TatA	B
and	O
TatB	B
proteins	O
are	O
essential	O
components	O
of	O
the	O
twin	O
arginine	O
protein	O
translocation	O
pathway	O
in	O
Escherichia	O
coli	O
.	O

C	O
-	O
terminal	O
truncation	O
analysis	O
of	O
the	O
TatA	B
protein	O
revealed	O
that	O
a	O
plasmid	O
-	O
expressed	O
TatA	B
protein	O
shortened	O
by	O
40	O
amino	O
acids	O
is	O
still	O
fully	O
competent	O
to	O
support	O
protein	O
translocation	O
.	O

Similar	O
truncation	O
analysis	O
of	O
TatB	B
indicated	O
that	O
the	O
final	O
30	O
residues	O
of	O
TatB	B
are	O
dispensable	O
for	O
function	O
.	O

Further	O
deletion	O
experiments	O
with	O
TatB	B
indicated	O
that	O
removal	O
of	O
even	O
70	O
residues	O
from	O
its	O
C	O
terminus	O
still	O
allowed	O
significant	O
transport	O
.	O

These	O
results	O
imply	O
that	O
the	O
transmembrane	O
and	O
amphipathic	O
helical	O
regions	O
of	O
TatA	B
and	O
TatB	B
are	O
critical	O
for	O
their	O
function	O
but	O
that	O
the	O
C	O
-	O
terminal	O
domains	O
are	O
not	O
essential	O
for	O
Tat	B
transport	O
activity	O
.	O

A	O
chimeric	O
protein	O
comprising	O
the	O
N	O
-	O
terminal	O
region	O
of	O
TatA	B
fused	O
to	O
the	O
amphipathic	O
and	O
C	O
-	O
terminal	O
domains	O
of	O
TatB	B
supports	O
a	O
low	O
level	O
of	O
Tat	B
activity	O
in	O
a	O
strain	O
in	O
which	O
the	O
wild	O
-	O
type	O
copy	O
of	O
either	O
tatA	B
or	O
tatB	B
(	O
but	O
not	O
both	O
)	O
is	O
deleted	O
.	O

Regulatory	O
effect	O
of	O
IFN	B
-	I
kappa	I
,	O
a	O
novel	O
type	B
I	I
IFN	I
,	O
on	O
cytokine	B
production	O
by	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
.	O

IFN	B
-	I
kappa	I
is	O
a	O
recently	O
identified	O
type	B
I	I
IFN	I
that	O
exhibits	O
both	O
structural	O
and	O
functional	O
homology	O
with	O
the	O
other	O
type	B
I	I
IFN	I
subclasses	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
IFN	B
-	I
kappa	I
on	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
by	O
comparing	O
cytokine	B
release	O
following	O
treatment	O
of	O
human	O
cells	O
with	O
either	O
IFN	B
-	I
kappa	I
or	O
two	O
recombinant	O
IFN	B
subtypes	O
,	O
IFN	B
-	I
beta	I
and	O
IFN	B
-	I
alpha2a	I
.	O

Although	O
IFN	B
-	I
alpha2a	I
failed	O
to	O
stimulate	O
monocyte	O
cytokine	B
secretion	O
,	O
IFN	B
-	I
kappa	I
,	O
like	O
IFN	B
-	I
beta	I
,	O
induced	O
the	O
release	O
of	O
several	O
cytokines	B
from	O
both	O
monocytes	O
and	O
dendritic	O
cells	O
,	O
without	O
the	O
requirement	O
of	O
a	O
costimulatory	O
signal	O
.	O

IFN	B
-	I
kappa	I
was	O
particularly	O
effective	O
in	O
inhibiting	O
inducible	O
IL-12	B
release	O
from	O
monocytes	O
.	O

Unlike	O
IFN	B
-	I
beta	I
,	O
IFN	B
-	I
kappa	I
did	O
not	O
induce	O
release	O
of	O
IFN	B
-	I
gamma	I
by	O
PBL	O
.	O

Expression	O
of	O
the	O
IFN	B
-	I
kappa	I
mRNA	O
was	O
observed	O
in	O
resting	O
dendritic	O
cells	O
and	O
monocytes	O
,	O
and	O
it	O
was	O
up	O
-	O
regulated	O
by	O
IFN	B
-	I
gamma	I
stimulation	O
in	O
monocytes	O
,	O
while	O
IFN	B
-	I
beta	I
mRNA	O
was	O
minimally	O
detectable	O
under	O
the	O
same	O
conditions	O
.	O

Monocyte	O
and	O
dendritic	O
cell	O
expression	O
of	O
IFN	B
-	I
kappa	I
was	O
also	O
confirmed	O
in	O
vivo	O
in	O
chronic	O
lesions	O
of	O
psoriasis	O
vulgaris	O
and	O
atopic	O
dermatitis	O
.	O

Finally	O
,	O
biosensor	O
-	O
based	O
binding	O
kinetic	O
analysis	O
revealed	O
that	O
IFN	B
-	I
kappa	I
,	O
like	O
IFN	B
-	I
beta	I
,	O
binds	O
strongly	O
to	O
heparin	O
(	O
K	O
(	O
d	O
)	O
:	O
2.1	O
nM	O
)	O
,	O
suggesting	O
that	O
the	O
cytokine	B
can	O
be	O
retained	O
close	O
to	O
the	O
local	O
site	O
of	O
production	O
.	O

The	O
pattern	O
of	O
cytokines	B
induced	O
by	O
IFN	B
-	I
kappa	I
in	O
monocytes	O
,	O
coupled	O
with	O
the	O
unique	O
induction	O
of	O
IFN	B
-	I
kappa	I
mRNA	O
by	O
IFN	B
-	I
gamma	I
,	O
indicates	O
a	O
potential	O
role	O
for	O
IFN	B
-	I
kappa	I
in	O
the	O
regulation	O
of	O
immune	O
cell	O
functions	O
.	O

Killer	B
Ig	I
-	I
like	I
receptor	I
haplotype	O
analysis	O
by	O
gene	O
content	O
:	O
evidence	O
for	O
genomic	O
diversity	O
with	O
a	O
minimum	O
of	O
six	O
basic	O
framework	O
haplotypes	O
,	O
each	O
with	O
multiple	O
subsets	O
.	O

Killer	B
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genes	O
constitute	O
a	O
multigene	O
family	O
whose	O
genomic	O
diversity	O
is	O
achieved	O
through	O
differences	O
in	O
gene	O
content	O
and	O
allelic	O
polymorphism	O
.	O

KIR	B
haplotypes	O
containing	O
a	O
single	O
activating	O
KIR	B
gene	O
(	O
A	O
-	O
haplotypes	O
)	O
,	O
and	O
KIR	B
haplotypes	O
with	O
multiple	O
activating	O
receptor	O
genes	O
(	O
B	O
-	O
haplotypes	O
)	O
have	O
been	O
described	O
.	O

We	O
report	O
the	O
evaluation	O
of	O
KIR	B
gene	O
content	O
in	O
extended	O
families	O
,	O
sibling	O
pairs	O
,	O
and	O
an	O
unrelated	O
Caucasian	O
panel	O
through	O
identification	O
of	O
the	O
presence	O
or	O
absence	O
of	O
14	O
KIR	B
genes	O
and	O
2	O
pseudogenes	O
.	O

Haplotype	O
definition	O
included	O
subtyping	O
for	O
the	O
expressed	O
and	O
nonexpressed	O
KIR2DL5	B
variants	O
,	O
for	O
two	O
alleles	O
of	O
pseudogene	O
3DP1	B
,	O
and	O
for	O
two	O
alleles	O
of	O
2DS4	B
,	O
including	O
a	O
novel	O
2DS4	B
allele	O
,	O
KIR1D	B
.	O

KIR1D	B
appears	O
functionally	O
homologous	O
to	O
the	O
rhesus	O
monkey	O
KIR1D	B
and	O
likely	O
arose	O
as	O
a	O
consequence	O
of	O
a	O
22	O
nucleotide	O
deletion	O
in	O
the	O
coding	O
sequence	O
of	O
2DS4	B
,	O
leading	O
to	O
disruption	O
of	O
Ig	B
-	O
domain	O
2D	O
and	O
a	O
premature	O
termination	O
codon	O
following	O
the	O
first	O
amino	O
acid	O
in	O
the	O
putative	O
transmembrane	O
domain	O
.	O

Our	O
investigations	O
identified	O
11	O
haplotypes	O
within	O
12	O
families	O
.	O

From	O
49	O
sibling	O
pairs	O
and	O
17	O
consanguineous	O
DNA	O
samples	O
,	O
an	O
additional	O
12	O
haplotypes	O
were	O
predicted	O
.	O

Our	O
studies	O
support	O
a	O
model	O
for	O
KIR	B
haplotype	O
diversity	O
based	O
on	O
six	O
basic	O
gene	O
compositions	O
.	O

We	O
suggest	O
that	O
the	O
centromeric	O
half	O
of	O
the	O
KIR	B
genomic	O
region	O
is	O
comprised	O
of	O
three	O
major	O
combinations	O
,	O
while	O
the	O
telomeric	O
half	O
can	O
assume	O
a	O
short	O
form	O
with	O
either	O
2DS4	B
or	O
KIR1D	B
or	O
a	O
long	O
form	O
with	O
multiple	O
combinations	O
of	O
several	O
stimulatory	O
KIR	B
genes	O
.	O

Additional	O
rare	O
haplotypes	O
can	O
be	O
identified	O
,	O
and	O
may	O
have	O
arisen	O
by	O
gene	O
duplication	O
,	O
intergenic	O
recombination	O
,	O
or	O
deletions	O
.	O

[	O
Sequencing	O
and	O
comparative	O
analysis	O
of	O
the	O
lux	B
operon	I
of	O
Photorhabdus	O
luminescens	O
strain	O
ZM1	O
:	O
ERIC	O
elements	O
as	O
putative	O
recombination	O
spots	O
]	O

The	O
EcoRI	B
chromosomal	O
fragment	O
(	O
6782	O
bp	O
)	O
containing	O
the	O
lux	B
operon	I
of	O
Photorhabdus	O
luminescens	O
was	O
cloned	O
in	O
pUC18	O
and	O
completely	O
sequenced	O
.	O

Enteric	O
repetitive	O
intergenic	O
consensus	O
(	O
ERIC	O
)	O
,	O
an	O
imperfect	O
palindrome	O
(	O
125	O
-	O
127	O
bp	O
)	O
characteristics	O
for	O
Enterobacteriaceae	O
genomes	O
,	O
was	O
found	O
in	O
three	O
sites	O
.	O

Strain	O
Zm1	O
proved	O
to	O
differ	O
in	O
ERIC	O
number	O
and	O
location	O
from	O
strains	O
Hb	O
,	O
Hm	O
,	O
and	O
Hw	O
.	O

Nucleotide	O
substitution	O
analysis	O
showed	O
that	O
luxC	B
and	O
luxB	B
,	O
which	O
are	O
more	O
than	O
1	O
kb	O
away	O
from	O
ERIC	O
,	O
are	O
similar	O
to	O
the	O
corresponding	O
Hb	O
genes	O
,	O
whereas	O
luxD	B
,	O
luxA	B
,	O
and	O
luxE	B
,	O
which	O
are	O
close	O
to	O
ERIC	O
,	O
are	O
intermediate	O
between	O
their	O
Hb	O
and	O
Hw	O
counterparts	O
.	O

The	O
Hb	O
/	O
Hw	O
nucleotide	O
substitution	O
ratio	O
was	O
1	O
:	O
1	O
in	O
regions	O
adjacent	O
to	O
ERIC	O
.	O

Hence	O
ERIC	O
were	O
assumed	O
to	O
play	O
a	O
role	O
of	O
recombination	O
hot	O
spots	O
in	O
the	O
bacterial	O
genome	O
.	O

Pharmacological	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
required	O
for	O
mycobacterium	O
tuberculosis	O
-	O
induced	O
IL-8	B
and	O
MCP-1	B
production	O
in	O
human	O
peripheral	O
monocytes	O
.	O

Signalling	O
cascades	O
involved	O
in	O
chemokine	B
production	O
by	O
human	O
phagocytes	O
following	O
infection	O
with	O
Mycobacterium	O
tuberculosis	O
are	O
still	O
not	O
defined	O
.	O

We	O
used	O
specific	O
pharmacologic	O
inhibitors	O
to	O
identify	O
the	O
signalling	O
molecules	O
which	O
lead	O
to	O
interleukin	B
(	I
IL	I
)	I
-	I
8	I
and	O
MCP-1	B
production	O
in	O
human	O
monocytes	O
in	O
response	O
to	O
M.	O
tuberculosis	O
infection	O
.	O

Inhibition	O
of	O
extracellular	B
signal	I
-	I
regulated	I
(	O
ERK	B
)	O
or	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
by	O
PD98059	O
and	O
SB203580	O
respectively	O
,	O
significantly	O
affected	O
chemokine	B
production	O
.	O

However	O
,	O
only	O
the	O
presence	O
of	O
both	O
inhibitors	O
completely	O
blocked	O
the	O
release	O
.	O

A	O
down	O
-	O
regulation	O
of	O
chemokine	O
secretion	O
was	O
found	O
in	O
presence	O
of	O
inhibitors	O
of	O
protein	B
kinase	I
(	I
PK	I
)	I
C	I
and	O
phospholipase	B
C	I
.	O

Moreover	O
,	O
production	O
depended	O
on	O
transcription	O
activation	O
via	O
the	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
as	O
demonstrated	O
by	O
treatment	O
with	O
actinomycin	O
D	O
and	O
caffeic	O
acid	O
phenethyl	O
ester	O
.	O

In	O
addition	O
,	O
activation	O
of	O
PKA	B
and	O
the	O
phosphoinoside	B
3-kinase	I
(	O
PI-3k	B
)	O
/	O
p70	B
ribosomal	I
S6	I
kinase	I
cascade	O
was	O
required	O
to	O
have	O
maximal	O
MCP-1	B
but	O
not	O
IL-8	B
production	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
provides	O
evidence	O
that	O
multiple	O
signal	O
transduction	O
pathways	O
are	O
involved	O
in	O
M.	O
tuberculosis	O
-	O
induced	O
chemokine	B
secretion	O
by	O
human	O
monocytes	O
.	O

Moreover	O
,	O
for	O
the	O
first	O
time	O
this	O
report	O
indicates	O
that	O
inhibitors	O
of	O
some	O
signalling	O
molecules	O
are	O
able	O
to	O
dissociate	O
IL-8	B
from	O
MCP-1	B
secretion	O
.	O

Differences	O
in	O
the	O
regulatory	O
pathways	O
of	O
chemokine	B
production	O
can	O
potentially	O
be	O
exploited	O
therapeutically	O
.	O

Differential	O
roles	O
of	O
SOCS	B
family	I
members	O
in	O
EpoR	B
signal	O
transduction	O
.	O

To	O
elucidate	O
the	O
roles	O
of	O
suppressor	B
of	I
cytokine	I
signaling	I
(	I
SOCS	I
)	I
family	I
members	O
in	O
erythropoietin	B
(	O
EPO	B
)	O
signaling	O
,	O
we	O
explored	O
SOCS	B
gene	O
regulation	O
,	O
mRNA	O
stability	O
,	O
and	O
protein	O
function	O
in	O
two	O
EPO	B
-	O
responsive	O
hematopoietic	O
cell	O
lines	O
.	O

Using	O
two	O
independent	O
approaches	O
,	O
one	O
involving	O
inhibition	O
of	O
specific	O
signaling	O
molecules	O
and	O
the	O
other	O
employing	O
cell	O
lines	O
that	O
express	O
particular	O
EpoR	B
mutants	O
and	O
thereby	O
activate	O
only	O
subsets	O
of	O
signaling	O
cascades	O
,	O
we	O
demonstrate	O
that	O
induction	O
of	O
SOCS1	B
,	O
SOCS2	B
,	O
SOCS3	B
,	O
and	O
cytokine	B
-	I
inducible	I
SH2	I
-	I
containing	I
protein	I
(	O
CIS	B
)	O
in	O
response	O
to	O
EPO	B
stimulation	O
appears	O
to	O
depend	O
on	O
Stat5	B
but	O
not	O
on	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
or	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3	B
K	I
)	O
.	O

SOCS4	B
expression	O
,	O
in	O
contrast	O
,	O
does	O
not	O
appear	O
to	O
be	O
EPO	B
inducible	O
.	O

Furthermore	O
,	O
we	O
show	O
differential	O
stabilities	O
of	O
SOCS	B
transcripts	O
,	O
with	O
SOCS2	B
the	O
longest	O
-	O
lived	O
and	O
SOCS1	B
and	O
CIS	B
the	O
least	O
stable	O
,	O
and	O
provide	O
evidence	O
in	O
support	O
of	O
EPO	B
-	O
independent	O
expression	O
of	O
SOCS3	B
and	O
SOCS4	B
.	O

In	O
order	O
to	O
understand	O
the	O
effects	O
of	O
SOCS	B
on	O
EPO	B
-	O
mediated	O
effects	O
,	O
we	O
generated	O
multiple	O
stable	O
cell	O
lines	O
that	O
inducibly	O
express	O
particular	O
SOCS	B
proteins	O
.	O

Overexpression	O
of	O
SOCS1	B
,	O
SOCS3	B
,	O
or	O
CIS	B
negatively	O
regulates	O
EPO	B
-	O
mediated	O
cell	O
proliferation	O
Stat5	B
phosphorylation	O
,	O
and	O
activation	O
of	O
a	O
Stat	B
-	O
dependent	O
luciferase	B
reporter	O
.	O

In	O
contrast	O
,	O
SOCS2	B
is	O
less	O
effective	O
,	O
and	O
SOCS4	B
is	O
ineffective	O
at	O
counteracting	O
EPO	B
-	O
mediated	O
events	O
.	O

Thus	O
,	O
we	O
have	O
demonstrated	O
differential	O
regulation	O
and	O
function	O
of	O
various	O
SOCS	B
family	I
members	O
in	O
EPO	B
-	O
dependent	O
hematopoietic	O
cells	O
.	O

Association	O
of	O
IL4R	B
haplotypes	O
with	O
type	O
1	O
diabetes	O
.	O

We	O
have	O
investigated	O
,	O
in	O
282	O
multiplex	O
Caucasian	O
families	O
(	O
the	O
Human	O
Biological	O
Data	O
Interchange	O
Repository	O
)	O
,	O
the	O
association	O
of	O
type	O
1	O
diabetes	O
with	O
polymorphisms	O
in	O
the	O
IL4R	B
gene	O
.	O

IL4R	B
encodes	O
a	O
subunit	O
of	O
the	O
interleukin-4	B
receptor	I
,	O
a	O
molecule	O
critical	O
to	O
T	O
-	O
helper	O
cell	O
development	O
.	O

By	O
genotyping	O
eight	O
different	O
IL4R	B
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
identifying	O
haplotypes	O
(	O
complex	O
alleles	O
)	O
in	O
the	O
multiplex	O
type	O
1	O
diabetic	O
families	O
who	O
were	O
stratified	O
for	O
HLA	B
genotype	O
,	O
we	O
have	O
observed	O
significant	O
evidence	O
of	O
linkage	O
and	O
association	O
of	O
the	O
IL4R	B
gene	O
to	O
type	O
1	O
diabetes	O
.	O

In	O
particular	O
,	O
we	O
have	O
identified	O
a	O
specific	O
haplotype	O
that	O
appears	O
to	O
be	O
protective	O
and	O
observed	O
that	O
this	O
protective	O
effect	O
is	O
strongest	O
among	O
individuals	O
not	O
carrying	O
the	O
HLA	B
DR3	I
/	I
DR4	I
genotype	O
(	O
which	O
confers	O
the	O
strongest	O
genetic	O
risk	O
for	O
type	O
1	O
diabetes	O
)	O
.	O

These	O
findings	O
suggest	O
an	O
important	O
role	O
for	O
the	O
IL4R	B
gene	O
in	O
immune	O
-	O
related	O
disease	O
susceptibility	O
and	O
illustrate	O
the	O
value	O
of	O
using	O
multi	O
-	O
SNP	O
haplotype	O
information	O
in	O
association	O
studies	O
.	O

Alternative	O
core	O
promoters	O
regulate	O
tissue	O
-	O
specific	O
transcription	O
from	O
the	O
autoimmune	O
diabetes	O
-	O
related	O
ICA1	B
(	O
ICA69	B
)	O
gene	O
locus	O
.	O

Islet	B
cell	I
autoantigen	I
69	I
-	I
kDa	I
(	O
ICA69	B
)	O
,	O
protein	O
product	O
of	O
the	O
human	O
ICA1	B
gene	O
,	O
is	O
one	O
target	O
of	O
the	O
immune	O
processes	O
defining	O
the	O
pathogenesis	O
of	O
Type	O
1	O
diabetes	O
.	O

We	O
have	O
characterized	O
the	O
genomic	O
structure	O
and	O
functional	O
promoters	O
within	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
of	O
ICA1	B
.	O

5	B
'	I
-	I
RNA	I
ligase	I
-	O
mediated	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
evaluation	O
of	O
ICA1	B
transcripts	O
expressed	O
in	O
human	O
islets	O
,	O
testis	O
,	O
heart	O
,	O
and	O
cultured	O
neuroblastoma	O
cells	O
reveals	O
that	O
three	O
5	O
'	O
-	O
untranslated	O
region	O
exons	O
are	O
variably	O
expressed	O
from	O
the	O
ICA1	B
gene	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
.	O

Surrounding	O
the	O
transcription	O
initiation	O
sites	O
are	O
motifs	O
characteristic	O
of	O
non	O
-	O
TATA	O
,	O
non	O
-	O
CAAT	O
,	O
GC	O
-	O
rich	O
promoters	O
,	O
including	O
consensus	O
Sp1	O
/	O
GC	O
boxes	O
,	O
an	O
initiator	O
element	O
,	O
cAMP	B
-	I
responsive	I
element	I
-	I
binding	I
protein	I
(	O
CREB	B
)	O
sites	O
,	O
and	O
clusters	O
of	O
other	O
putative	O
transcription	B
factor	I
sites	O
within	O
a	O
genomic	O
CpG	O
island	O
.	O

Luciferase	B
reporter	O
constructs	O
demonstrate	O
that	O
the	O
first	O
two	O
ICA1	B
exon	O
promoters	O
reciprocally	O
stimulate	O
luciferase	B
expression	O
within	O
islet	O
-	O
(	O
RIN	O
1046	O
-	O
38	O
cells	O
)	O
and	O
brain	O
-	O
derived	O
(	O
NMB7	O
)	O
cells	O
in	O
culture	O
;	O
the	O
exon	O
A	O
promoter	O
exhibits	O
greater	O
activity	O
in	O
islet	O
cells	O
,	O
whereas	O
the	O
exon	O
B	O
promoter	O
more	O
efficiently	O
activates	O
transcription	O
in	O
neuronal	O
cells	O
.	O

Mutation	O
of	O
a	O
CREB	B
site	O
within	O
the	O
ICA1	B
exon	O
B	O
promoter	O
significantly	O
enhances	O
transcriptional	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

Our	O
basic	O
understanding	O
of	O
expression	O
from	O
the	O
functional	O
core	O
promoter	O
elements	O
of	O
ICA1	B
is	O
an	O
important	O
advance	O
that	O
will	O
not	O
only	O
add	O
to	O
our	O
knowledge	O
of	O
the	O
ICA69	B
autoantigen	O
but	O
will	O
also	O
facilitate	O
a	O
rational	O
approach	O
to	O
discover	O
the	O
function	O
of	O
ICA69	B
and	O
to	O
identify	O
relevant	O
ICA1	B
promoter	O
polymorphisms	O
and	O
their	O
potential	O
associations	O
with	O
disease	O
.	O

alpha	B
1-Adrenergic	I
receptor	I
subtypes	O
differentially	O
control	O
the	O
cell	O
cycle	O
of	O
transfected	O
CHO	O
cells	O
through	O
a	O
cAMP	O
-	O
dependent	O
mechanism	O
involving	O
p27Kip1	B
.	O

Three	O
distinct	O
subtypes	O
of	O
alpha	B
(	I
1	I
)	I
-adrenergic	I
receptors	I
(	O
alpha	B
(	I
1	I
)	I
A-	I
,	I
alpha	I
(	I
1	I
)	I
B	I
-	I
,	I
and	I
alpha	I
(	I
1	I
)	I
D	I
-	I
AR	I
)	O
play	O
a	O
prominent	O
role	O
in	O
cell	O
growth	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
subtype	O
-	O
specific	O
effects	O
on	O
cell	O
proliferation	O
.	O

The	O
activation	O
of	O
alpha	B
(	I
1	I
)	I
A-	I
or	I
alpha	I
(	I
1	I
)	I
B	I
-	I
AR	I
inhibits	O
serum	O
-	O
promoted	O
cell	O
proliferation	O
,	O
whereas	O
alpha	B
(	I
1	I
)	I
D	I
-	I
AR	I
activation	O
does	O
not	O
show	O
such	O
an	O
inhibitory	O
effect	O
.	O

Notably	O
,	O
cell	O
-	O
cycle	O
progression	O
was	O
blocked	O
at	O
G	O
(	O
1	O
)	O
/	O
S	O
transition	O
after	O
activation	O
of	O
alpha	B
(	I
1	I
)	I
A	I
/	I
alpha	I
(	I
1	I
)	I
B	I
-	I
AR	I
but	O
not	O
of	O
alpha	B
(	I
1	I
)	I
D	I
-	I
AR	I
.	O

In	O
agreement	O
with	O
the	O
differential	O
cell	O
proliferation	O
effect	O
,	O
cAMP	O
production	O
was	O
increased	O
after	O
activation	O
of	O
alpha	B
(	I
1	I
)	I
A	I
/	I
alpha	I
(	I
1	I
)	I
B	I
-	I
AR	I
but	O
not	O
alpha	B
(	I
1	I
)	I
D	I
-	I
AR	I
,	O
whereas	O
all	O
alpha	B
(	I
1	I
)	I
-AR	I
subtypes	O
are	O
associated	O
with	O
inositol	O
1,4,5-trisphosphate	O
production	O
and	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
activation	O
in	O
a	O
similar	O
fashion	O
.	O

Furthermore	O
,	O
the	O
serum	O
-	O
induced	O
reduction	O
in	O
the	O
levels	O
of	O
the	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	I
,	O
p27	B
(	I
Kip1	I
)	I
,	O
was	O
blocked	O
after	O
activation	O
of	O
alpha	B
(	I
1	I
)	I
A	I
/	I
alpha	I
(	I
1	I
)	I
B	I
-	I
AR	I
but	O
not	O
alpha	B
(	I
1	I
)	I
D	I
-	I
AR	I
.	O

These	O
results	O
show	O
that	O
alpha	B
(	I
1	I
)	I
-AR	I
subtypes	O
differentially	O
activate	O
the	O
cAMP	O
/	O
p27	B
(	I
Kip1	I
)	I
pathway	O
and	O
thereby	O
have	O
differential	O
inhibitory	O
effects	O
on	O
cell	O
proliferation	O
.	O

Subtype	O
-	O
dependent	O
effects	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
assessing	O
the	O
physiological	O
response	O
of	O
native	O
cells	O
where	O
alpha	B
(	I
1	I
)	I
-AR	I
subtypes	O
are	O
generally	O
co	O
-	O
expressed	O
.	O

A	O
naturally	O
occurring	O
point	O
substitution	O
in	O
Cdc25A	B
,	O
and	O
not	O
Fv2	B
/	O
Stk	B
,	O
is	O
associated	O
with	O
altered	O
cell	O
-	O
cycle	O
status	O
of	O
early	O
erythroid	O
progenitor	O
cells	O
.	O

The	O
Friend	B
virus	I
susceptibility	I
gene	I
2	I
(	O
Fv2	B
)	O
controls	O
the	O
polyclonal	O
expansion	O
of	O
infected	O
cells	O
that	O
occurs	O
early	O
during	O
Friend	O
erythroleukemia	O
virus	O
infection	O
.	O

Fv2	B
has	O
recently	O
been	O
shown	O
to	O
encode	O
a	O
truncated	O
form	O
of	O
the	O
Stk	B
receptor	B
tyrosine	I
kinase	I
(	O
Sf	B
-	I
Stk	I
)	O
.	O

This	O
observation	O
,	O
coupled	O
with	O
earlier	O
work	O
,	O
suggested	O
that	O
Sf	B
-	I
Stk	I
drives	O
the	O
expansion	O
of	O
infected	O
cells	O
by	O
forming	O
a	O
complex	O
with	O
the	O
Friend	O
virus	O
envelope	O
glycoprotein	O
,	O
gp55	B
,	O
and	O
the	O
erythropoietin	B
receptor	I
.	O

Fv2	B
has	O
also	O
been	O
implicated	O
in	O
the	O
control	O
of	O
cell	O
cycling	O
in	O
early	O
erythroid	O
progenitors	O
(	O
erythroid	O
blast	O
-	O
forming	O
units	O
[	O
BFU	O
-	O
Es	O
]	O
)	O
.	O

Mouse	O
strains	O
that	O
are	O
homozygous	O
for	O
the	O
resistant	O
allele	O
of	O
Fv2	B
(	O
Fv2	B
(	O
rr	O
)	O
)	O
have	O
few	O
actively	O
cycling	O
BFU	O
-	O
Es	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
control	O
of	O
BFU	O
-	O
E	O
cycling	O
is	O
encoded	O
by	O
a	O
gene	O
linked	O
to	O
,	O
but	O
distinct	O
from	O
,	O
Fv2	B
,	O
and	O
suggest	O
that	O
this	O
gene	O
is	O
the	O
dual	B
-	I
specific	I
protein	I
phosphatase	I
Cdc25A	B
,	O
which	O
regulates	O
the	O
G1	O
-	O
to	O
S	O
-	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
.	O

We	O
show	O
that	O
a	O
naturally	O
occurring	O
allele	O
of	O
Cdc25A	B
,	O
which	O
increases	O
Cdc25A	B
phosphatase	I
activity	O
and	O
promotes	O
cell	O
-	O
cycle	O
progression	O
,	O
segregates	O
in	O
mouse	O
strains	O
that	O
exhibit	O
high	O
levels	O
of	O
BFU	O
-	O
E	O
cell	O
cycling	O
.	O

In	O
wild	O
-	O
type	O
mice	O
,	O
this	O
allele	O
of	O
Cdc25A	B
does	O
not	O
overtly	O
affect	O
erythropoiesis	O
;	O
however	O
,	O
when	O
this	O
allele	O
is	O
combined	O
with	O
a	O
mutation	O
of	O
the	O
Kit	B
receptor	O
(	O
Kit	B
(	O
WV	O
)	O
)	O
,	O
the	O
anemia	O
of	O
the	O
mice	O
is	O
enhanced	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
Cdc25A	B
in	O
bone	O
marrow	O
cells	O
causes	O
a	O
defect	O
in	O
the	O
BFU	O
-	O
E	O
colony	O
formation	O
.	O

These	O
results	O
suggest	O
that	O
proper	O
regulation	O
of	O
the	O
cell	O
cycle	O
through	O
Cdc25A	B
is	O
required	O
for	O
normal	O
erythropoiesis	O
.	O

Characterization	O
of	O
t	O
(	O
3	O
;	O
6	O
)	O
(	O
q27	O
;	O
p21	O
)	O
breakpoints	O
in	O
B	O
-	O
cell	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
and	O
construction	O
of	O
the	O
histone	B
H4	I
/	O
BCL6	B
fusion	O
gene	O
,	O
leading	O
to	O
altered	O
expression	O
of	O
Bcl-6	B
.	O

A	O
recurrent	O
translocation	O
,	O
t	O
(	O
3	O
;	O
6	O
)	O
(	O
q27	O
;	O
p21	O
)	O
,	O
in	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
results	O
in	O
fusion	O
of	O
BCL6	B
with	O
a	O
particular	O
histone	B
H4	I
gene	O
on	O
6p21	O
.	O

We	O
cloned	O
five	O
H4	B
/	O
BCL6	B
junctions	O
from	O
both	O
der	O
(	O
3	O
)	O
and	O
der	O
(	O
6	O
)	O
chromosomes	O
.	O

The	O
breakpoints	O
on	O
H4	B
were	O
distributed	O
within	O
the	O
single	O
exon	O
or	O
close	O
to	O
the	O
terminal	O
palindrome	O
,	O
and	O
those	O
on	O
BCL6	B
were	O
localized	O
within	O
or	O
close	O
to	O
the	O
translocation	O
hypercluster	O
.	O

Deletions	O
or	O
duplications	O
of	O
variable	O
numbers	O
of	O
nucleotides	O
were	O
identified	O
at	O
the	O
junctions	O
.	O

A	O
total	O
of	O
eight	O
single	O
nucleotide	O
alterations	O
were	O
introduced	O
into	O
the	O
translocation	O
/	O
mutation	O
cluster	O
of	O
BCL6	B
,	O
whereas	O
four	O
single	O
nucleotide	O
substitutions	O
were	O
identified	O
within	O
a	O
360	O
-	O
bp	O
region	O
of	O
H4	B
.	O

Thus	O
,	O
the	O
somatic	O
hypermutation	O
mechanism	O
is	O
likely	O
to	O
target	O
H4	B
,	O
resulting	O
in	O
a	O
predisposition	O
to	O
the	O
development	O
of	O
translocation	O
with	O
BCL6	B
.	O

Lymphoma	O
cells	O
carrying	O
H4	B
/	O
BCL6	B
produced	O
fusion	O
transcripts	O
containing	O
both	O
H4	B
and	O
BCL6	B
messages	O
;	O
however	O
,	O
the	O
cells	O
expressed	O
only	O
moderate	O
levels	O
of	O
BCL6	B
mRNA	O
.	O

We	O
constructed	O
expression	O
plasmids	O
that	O
mimicked	O
the	O
H4	B
/	O
BCL6	B
fusion	O
gene	O
and	O
transiently	O
introduced	O
them	O
into	O
COS-7	O
cells	O
.	O

H4	B
/	O
BCL6	B
-	O
transfected	O
cells	O
expressed	O
markedly	O
higher	O
levels	O
of	O
Bcl-6	B
protein	O
than	O
cells	O
transfected	O
with	O
a	O
plasmid	O
carrying	O
BCL6	B
driven	O
by	O
its	O
normal	O
promoter	O
and	O
displayed	O
bright	O
nuclear	O
staining	O
with	O
a	O
characteristic	O
punctate	O
pattern	O
with	O
an	O
anti	O
-	O
Bcl-6	B
antibody	O
.	O

Deletion	O
analyses	O
revealed	O
that	O
the	O
high	O
-	O
level	O
Bcl-6	B
expression	O
was	O
promoted	O
by	O
the	O
H4	B
regulatory	O
sequences	O
.	O

The	O
levels	O
of	O
expression	O
of	O
activating	B
transcription	I
factor	I
3	I
,	O
prefoldin	B
4	I
,	O
and	O
retinoblastoma	B
-	I
binding	I
protein	I
7	I
significantly	O
increased	O
in	O
accordance	O
with	O
that	O
of	O
BCL6	B
,	O
suggesting	O
that	O
Bcl-6	B
may	O
act	O
as	O
a	O
transcriptional	O
activator	O
.	O

Our	O
study	O
suggested	O
that	O
t	O
(	O
3	O
;	O
6	O
)	O
(	O
q27	O
;	O
p21	O
)	O
leads	O
to	O
BCL6	B
overexpression	O
;	O
however	O
,	O
the	O
high	O
-	O
level	O
BCL6	B
expression	O
may	O
not	O
be	O
required	O
to	O
maintain	O
the	O
malignant	O
phenotype	O
of	O
lymphoma	O
cells	O
.	O

The	O
expression	O
of	O
alpha	B
-	I
dystrobrevin	I
and	O
dystrophin	B
during	O
skeletal	O
muscle	O
regeneration	O
.	O

The	O
expression	O
of	O
alpha	B
-	I
dystrobrevin	I
and	O
dystrophin	B
in	O
rat	O
tibialis	O
anterior	O
muscles	O
was	O
chronologically	O
evaluated	O
during	O
a	O
cycle	O
of	O
regeneration	O
after	O
myonecrosis	O
induced	O
by	O
the	O
injection	O
of	O
cardiotoxin	B
.	O

In	O
immunohistochemical	O
studies	O
,	O
alpha	B
-	I
dystrobrevin	I
and	O
dystrophin	B
were	O
first	O
stained	O
weakly	O
at	O
the	O
sarcolemma	O
of	O
some	O
regenerating	O
muscle	O
fibers	O
on	O
day	O
5	O
.	O

On	O
day	O
7	O
,	O
alpha	B
-	I
dystrobrevin	I
was	O
still	O
stained	O
weakly	O
,	O
whereas	O
dystrophin	B
was	O
stained	O
conspicuously	O
.	O

After	O
day	O
10	O
,	O
alpha	B
-	I
dystrobrevin	I
and	O
dystrophin	B
were	O
both	O
stained	O
conspicuously	O
on	O
almost	O
all	O
regenerating	O
muscle	O
fibers	O
.	O

In	O
the	O
Western	O
blot	O
analysis	O
,	O
alpha	B
-	I
dystrobrevin	I
and	O
dystrophin	B
were	O
first	O
detected	O
as	O
visible	O
bands	O
on	O
days	O
5	O
and	O
7	O
,	O
respectively	O
.	O

The	O
bands	O
of	O
alpha	B
-	I
dystrobrevin	I
and	O
dystrophin	B
both	O
darkened	O
sequentially	O
up	O
to	O
day	O
10	O
.	O

The	O
protein	O
levels	O
based	O
on	O
the	O
densitometrical	O
analysis	O
of	O
the	O
bands	O
on	O
each	O
day	O
were	O
converted	O
to	O
the	O
percentage	O
of	O
the	O
protein	O
level	O
on	O
day	O
28	O
,	O
which	O
was	O
taken	O
as	O
100	O
%	O
.	O

The	O
sequential	O
line	O
based	O
on	O
these	O
data	O
showed	O
that	O
alpha	B
-	I
dystrobrevin	I
and	O
dystrophin	B
reached	O
50	O
%	O
of	O
the	O
protein	O
level	O
on	O
day	O
28	O
by	O
6.6	O
and	O
5.3	O
days	O
,	O
respectively	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
alpha	B
-	I
dystrobrevin	I
regenerates	O
more	O
slowly	O
than	O
dystrophin	B
in	O
skeletal	O
muscle	O
.	O

In	O
vivo	O
interference	O
with	O
Skp1	B
function	O
leads	O
to	O
genetic	O
instability	O
and	O
neoplastic	O
transformation	O
.	O

Skp1	B
is	O
involved	O
in	O
a	O
variety	O
of	O
crucial	O
cellular	O
functions	O
,	O
among	O
which	O
the	O
best	O
understood	O
is	O
the	O
formation	O
together	O
with	O
Cul1	B
of	O
Skp1	B
-	O
cullin	B
-	O
F	O
-	O
box	O
protein	O
ubiquitin	B
ligases	I
.	O

To	O
investigate	O
the	O
role	O
of	O
Skp1	B
,	O
we	O
generated	O
transgenic	O
(	O
Tg	O
)	O
mice	O
expressing	O
a	O
Cul1	B
deletion	O
mutant	O
(	O
Cul1	B
-	O
N252	O
)	O
able	O
to	O
sequestrate	O
and	O
inactivate	O
Skp1	B
.	O

In	O
vivo	O
interference	O
with	O
Skp1	B
function	O
through	O
expression	O
of	O
the	O
Cul1	B
-	O
N252	O
mutant	O
into	O
the	O
T	O
-	O
cell	O
lineage	O
results	O
in	O
lymphoid	O
organ	O
hypoplasia	O
and	O
reduced	O
proliferation	O
.	O

Nonetheless	O
,	O
after	O
a	O
period	O
of	O
latency	O
,	O
Cul1	B
-	O
N252	O
Tg	O
mice	O
succumb	O
to	O
T	O
-	O
cell	O
lymphomas	O
with	O
high	O
penetrance	O
(	O
>	O
80	O
%	O
)	O
.	O

Both	O
T	O
-	O
cell	O
depletion	O
and	O
the	O
neoplastic	O
phenotype	O
of	O
Cul1	B
-	O
N252	O
Tg	O
mice	O
are	O
largely	O
rescued	O
in	O
Cul1	B
-	O
N252	O
,	O
Skp1	B
double	O
-	O
Tg	O
mice	O
,	O
indicating	O
that	O
the	O
effects	O
of	O
Cul1	B
-	O
N252	O
are	O
due	O
to	O
a	O
sequestration	O
of	O
the	O
endogenous	O
Skp1	B
.	O

Analysis	O
of	O
Cul1	B
-	O
N252	O
lymphomas	O
demonstrates	O
striking	O
karyotype	O
heterogeneity	O
associated	O
with	O
c	B
-	I
myc	I
amplification	O
and	O
c	B
-	I
Myc	I
overexpression	O
.	O

We	O
show	O
that	O
the	O
in	O
vitro	O
expression	O
of	O
the	O
Cul1	B
-	O
N252	O
mutant	O
causes	O
a	O
pleiotrophic	O
phenotype	O
,	O
which	O
includes	O
the	O
formation	O
of	O
multinucleated	O
cells	O
,	O
centrosome	O
and	O
mitotic	O
spindle	O
abnormalities	O
,	O
and	O
impaired	O
chromosome	O
segregation	O
.	O

Our	O
findings	O
support	O
a	O
crucial	O
role	O
for	O
Skp1	B
in	O
proper	O
chromosomal	O
segregation	O
,	O
which	O
is	O
required	O
for	O
the	O
maintenance	O
of	O
euploidy	O
and	O
suppression	O
of	O
transformation	O
.	O

Localization	O
of	O
IL-1alpha	B
,	O
IL-1	B
RI	I
,	O
TNF	B
,	O
TNF	B
-	I
RI	I
and	O
TNF	B
-	I
RII	I
during	O
physiological	O
drift	O
of	O
rat	O
molar	O
teeth	O
--	O
an	O
immunohistochemical	O
and	O
in	O
situ	O
hybridization	O
study	O
.	O

Proinflammatory	O
cytokines	B
such	O
as	O
IL-1	B
and	O
TNF	B
play	O
a	O
crucial	O
role	O
in	O
the	O
initiation	O
of	O
an	O
inflammatory	O
response	O
to	O
bacterial	O
irritants	O
and	O
subsequent	O
periodontal	O
tissue	O
destruction	O
.	O

The	O
object	O
of	O
the	O
present	O
investigation	O
was	O
to	O
examine	O
the	O
possible	O
role	O
of	O
these	O
cytokines	B
in	O
the	O
periodontal	O
tissues	O
under	O
physiological	O
conditions	O
.	O

To	O
this	O
end	O
we	O
studied	O
the	O
expression	O
of	O
IL-1alpha	B
and	O
TNF	B
both	O
at	O
the	O
transcription	O
and	O
protein	O
level	O
by	O
means	O
of	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
and	O
investigated	O
the	O
distribution	O
of	O
IL-1RI	B
,	O
TNF	B
-	I
RI	I
and	O
TNF	B
-	I
RII	I
immunohistochemically	O
in	O
10	O
jaw	O
specimens	O
taken	O
from	O
male	O
Wistar	O
rats	O
.	O

We	O
found	O
IL-1alpha	B
and	O
TNF	B
mRNA	O
to	O
be	O
focally	O
transcribed	O
in	O
bone	O
marrow	O
cells	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
in	O
gingival	O
epithelium	O
as	O
well	O
as	O
in	O
single	O
osteoblasts	O
and	O
osteoclasts	O
.	O

Additionally	O
,	O
IL-1alpha	B
mRNA	O
was	O
detected	O
in	O
PDL	O
-	O
fibroblasts	O
and	O
epithelial	O
remnants	O
of	O
Malassez	O
.	O

The	O
IL-1alpha	B
immunohistochemistry	O
observations	O
were	O
corroborated	O
by	O
the	O
in	O
situ	O
hybridization	O
results	O
.	O

TNF	O
and	O
its	O
receptors	O
were	O
not	O
detected	O
at	O
the	O
protein	O
level	O
.	O

These	O
data	O
suggest	O
that	O
IL-1alpha	B
and	O
its	O
receptor	O
are	O
of	O
some	O
importance	O
in	O
the	O
maintenance	O
of	O
tissue	O
homeostasis	O
and	O
remodeling	O
events	O
accompanied	O
by	O
physiological	O
tooth	O
movement	O
.	O

Altered	O
biological	O
activity	O
associated	O
with	O
C	O
-	O
terminal	O
modifications	O
of	O
IL-7	B
.	O

Interleukin	B
7	I
(	O
IL-7	B
)	O
is	O
a	O
pleiotropic	O
cytokine	B
which	O
plays	O
a	O
role	O
in	O
both	O
T	O
and	O
B	O
cell	O
function	O
as	O
well	O
as	O
in	O
establishment	O
and	O
maintenance	O
of	O
immunological	O
barriers	O
in	O
epithelial	O
tissues	O
.	O

The	O
heterodimeric	O
IL-7	B
receptor	I
(	O
IL-7R	B
)	O
consists	O
of	O
the	O
p76	O
IL-7Ralpha	B
subunit	O
and	O
the	O
p64	B
common	I
gamma	I
(	O
gammac	B
)	O
subunit	O
.	O

Ligand	O
-	O
binding	O
induces	O
signal	O
transduction	O
through	O
tyrosine	O
phosphorylation	O
of	O
the	O
janus	B
(	I
Jak	I
)	I
and	I
src	I
-	I
related	I
kinases	I
as	O
well	O
as	O
by	O
activation	O
of	O
phosphatidinositol-3	B
kinase	I
(	O
P13-kinase	B
)	O
.	O

In	O
an	O
effort	O
to	O
further	O
define	O
the	O
requirements	O
for	O
ligand	O
-	O
receptor	O
interactions	O
and	O
to	O
subsequently	O
develop	O
candidate	O
receptor	O
binding	O
antagonists	O
with	O
selective	O
biological	O
activities	O
,	O
we	O
examined	O
a	O
series	O
of	O
IL-7	B
mutants	O
in	O
which	O
the	O
carboxy	O
terminal	O
hydrophobic	O
residues	O
were	O
substituted	O
with	O
aliphatic	O
amino	O
acids	O
.	O

In	O
this	O
study	O
we	O
describe	O
abrogation	O
of	O
IL-7	B
driven	O
proliferation	O
and	O
attenuated	O
phosphotyrosine	O
signaling	O
by	O
IL-7	B
(	O
143	O
)	O
(	O
Trp	O
-	O
Ala	O
)	O
and	O
IL-7	B
(	O
143	O
)	O
(	O
Trp	O
-	O
His	O
)	O
in	O
IL-7R	B
expressing	O
T	O
and	O
B	O
leukemia	O
cells	O
.	O

Decreased	O
phosphorylation	O
of	O
Jak3	B
kinase	B
by	O
IL-7W143A	B
,	O
IL-7W143P	B
and	O
IL-7W143H	B
suggest	O
that	O
alterations	O
in	O
this	O
region	O
of	O
the	O
carboxyterminal	O
region	O
of	O
IL-7	B
affects	O
its	O
interaction	O
with	O
the	O
gammac	B
subunit	O
of	O
the	O
IL-7R	B
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
ammodytoxins	B
is	O
important	O
but	O
not	O
sufficient	O
for	O
neurotoxicity	O
.	O

Ammodytoxins	B
(	O
Atxs	B
)	O
are	O
presynaptically	O
acting	O
snake	O
venom	O
phospholipase	B
A2	I
(	O
PLA2	B
)	O
toxins	O
the	O
molecular	O
mechanism	O
of	O
whose	O
neurotoxicity	O
is	O
not	O
completely	O
understood	O
.	O

Two	O
chimeric	O
PLA2s	B
were	O
prepared	O
by	O
replacing	O
the	O
C	O
-	O
terminal	O
part	O
of	O
a	O
nontoxic	O
venom	O
PLA2	B
,	O
ammodytin	B
I2	I
,	O
with	O
that	O
of	O
AtxA	B
(	O
K108N	O
)	O
.	O

The	O
chimeras	O
were	O
not	O
toxic	O
,	O
but	O
were	O
able	O
to	O
bind	O
strongly	O
to	O
an	O
Atxs	B
-	O
specific	O
neuronal	O
receptor	O
,	O
R25	O
.	O

They	O
also	O
showed	O
an	O
increased	O
affinity	O
for	O
calmodulin	B
,	O
a	O
recently	O
identified	O
high	O
-	O
affinity	O
binding	O
protein	O
for	O
Atxs	B
,	O
whereas	O
affinity	O
for	O
a	O
neuronal	O
M	B
-	I
type	I
PLA2	I
receptor	I
remained	O
largely	O
unchanged	O
.	O

The	O
results	O
show	O
that	O
the	O
C	O
-	O
terminal	O
region	O
of	O
Atxs	B
,	O
which	O
is	O
known	O
to	O
be	O
involved	O
in	O
neurotoxicity	O
,	O
is	O
critical	O
for	O
their	O
interaction	O
with	O
specific	O
binding	O
proteins	O
,	O
but	O
that	O
some	O
other	O
part	O
of	O
the	O
molecule	O
also	O
contributes	O
to	O
toxicity	O
.	O

Collaborative	O
regulation	O
of	O
Escherichia	O
coli	O
glutamate	O
-	O
dependent	O
acid	O
resistance	O
by	O
two	O
AraC	B
-	O
like	O
regulators	O
,	O
GadX	B
and	O
GadW	B
(	O
YhiW	B
)	O
.	O

An	O
important	O
feature	O
of	O
Escherichia	O
coli	O
pathogenesis	O
is	O
an	O
ability	O
to	O
withstand	O
extremely	O
acidic	O
environments	O
of	O
pH	O
2	O
or	O
lower	O
.	O

This	O
acid	O
resistance	O
property	O
contributes	O
to	O
the	O
low	O
infectious	O
dose	O
of	O
pathogenic	O
E.	O
coli	O
species	O
.	O

One	O
very	O
efficient	O
E.	O
coli	O
acid	O
resistance	O
system	O
encompasses	O
two	O
isoforms	O
of	O
glutamate	B
decarboxylase	I
(	O
gadA	B
and	O
gadB	B
)	O
and	O
a	O
putative	O
glutamate	O
:	O
gamma	B
-	I
amino	I
butyric	I
acid	I
(	I
GABA	I
)	I
antiporter	I
(	O
gadC	B
)	O
.	O

The	O
system	O
is	O
subject	O
to	O
complex	O
controls	O
that	O
vary	O
with	O
growth	O
media	O
,	O
growth	O
phase	O
,	O
and	O
growth	O
pH	O
.	O

Previous	O
work	O
has	O
revealed	O
that	O
the	O
system	O
is	O
controlled	O
by	O
two	O
sigma	B
factors	I
,	O
two	O
negative	O
regulators	O
(	O
cyclic	B
AMP	I
receptor	I
protein	I
[	O
CRP	B
]	O
and	O
H	B
-	I
NS	I
)	O
,	O
and	O
an	O
AraC	B
-	O
like	O
regulator	O
called	O
GadX	B
.	O

Earlier	O
evidence	O
suggested	O
that	O
the	O
GadX	B
protein	O
acts	O
both	O
as	O
a	O
positive	O
and	O
negative	O
regulator	O
of	O
the	O
gadA	B
and	O
gadBC	B
genes	O
depending	O
on	O
environmental	O
conditions	O
.	O

New	O
data	O
clarify	O
this	O
finding	O
,	O
revealing	O
a	O
collaborative	O
regulation	O
between	O
GadX	B
and	O
another	O
AraC	B
-	O
like	O
regulator	O
called	O
GadW	B
(	O
previously	O
YhiW	B
)	O
.	O

GadX	B
and	O
GadW	B
are	O
DNA	O
binding	O
proteins	O
that	O
form	O
homodimers	O
in	O
vivo	O
and	O
are	O
42	O
%	O
homologous	O
to	O
each	O
other	O
.	O

GadX	B
activates	O
expression	O
of	O
gadA	B
and	O
gadBC	B
at	O
any	O
pH	O
,	O
while	O
GadW	B
inhibits	O
GadX	B
-	O
dependent	O
activation	O
.	O

Regulation	O
of	O
gadA	B
and	O
gadBC	B
by	O
either	O
regulator	O
requires	O
an	O
upstream	O
,	O
20-bp	O
GAD	B
box	O
sequence	O
.	O

Northern	O
blot	O
analysis	O
further	O
indicates	O
that	O
GadW	B
represses	O
expression	O
of	O
gadX	B
.	O

The	O
results	O
suggest	O
a	O
control	O
circuit	O
whereby	O
GadW	B
interacts	O
with	O
both	O
the	O
gadA	B
and	O
gadX	B
promoters	O
.	O

GadW	B
clearly	O
represses	O
gadX	B
and	O
,	O
in	O
situations	O
where	O
GadX	B
is	O
missing	O
,	O
activates	O
gadA	B
and	O
gadBC	B
.	O

GadX	B
,	O
however	O
,	O
activates	O
only	O
gadA	B
and	O
gadBC	B
expression	O
.	O

CRP	B
also	O
represses	O
gadX	B
expression	O
.	O

It	O
does	O
this	O
primarily	O
by	O
repressing	O
production	O
of	O
sigma	B
S	I
,	O
the	O
sigma	B
factor	I
responsible	O
for	O
gadX	B
expression	O
.	O

In	O
fact	O
,	O
the	O
acid	O
induction	O
of	O
gadA	B
and	O
gadBC	B
observed	O
when	O
rich	O
-	O
medium	O
cultures	O
enter	O
stationary	O
phase	O
corresponds	O
to	O
the	O
acid	O
induction	O
of	O
sigma	B
S	I
production	O
.	O

These	O
complex	O
control	O
circuits	O
impose	O
tight	O
rein	O
over	O
expression	O
of	O
the	O
gadA	B
and	O
gadBC	B
system	O
yet	O
provide	O
flexibility	O
for	O
inducing	O
acid	O
resistance	O
under	O
many	O
conditions	O
that	O
presage	O
acid	O
stress	O
.	O

The	O
DNA	B
methyltransferase	I
-	O
like	O
protein	O
DNMT3L	B
stimulates	O
de	O
novo	O
methylation	O
by	O
Dnmt3a	B
.	O

Dnmt3L	B
is	O
required	O
for	O
the	O
establishment	O
of	O
maternal	O
methylation	O
imprints	O
at	O
imprinting	O
centers	O
(	O
ICs	O
)	O
.	O

Dnmt3L	B
,	O
however	O
,	O
lacks	O
the	O
conserved	O
catalytic	O
domain	O
common	O
to	O
DNA	B
methyltransferases	I
.	O

In	O
an	O
attempt	O
to	O
define	O
its	O
function	O
,	O
we	O
coexpressed	O
DNMT3L	B
with	O
each	O
of	O
the	O
two	O
known	O
de	O
novo	O
methyltransferases	B
,	O
Dnmt3a	B
and	O
DNMT3B	B
,	O
in	O
human	O
cells	O
and	O
monitored	O
de	O
novo	O
methylation	O
by	O
using	O
replicating	O
minichromosomes	O
carrying	O
various	O
ICs	O
as	O
targets	O
.	O

Coexpression	O
of	O
DNMT3L	B
with	O
DNMT3B	B
led	O
to	O
little	O
or	O
no	O
change	O
in	O
target	O
methylation	O
.	O

However	O
,	O
coexpression	O
of	O
DNMT3L	B
with	O
Dnmt3a	B
resulted	O
in	O
a	O
striking	O
stimulation	O
of	O
de	O
novo	O
methylation	O
by	O
Dnmt3a	B
.	O

Stimulation	O
was	O
observed	O
at	O
maternally	O
methylated	O
ICs	O
such	O
as	O
small	B
nuclear	I
ribonucleoprotein	I
polypeptide	I
N	I
(	O
SNRPN	B
)	O
,	O
Snrpn	B
,	O
and	O
Igf2rAir	B
,	O
as	O
well	O
as	O
at	O
various	O
nonimprinted	O
sequences	O
present	O
on	O
the	O
episomes	O
.	O

Stimulation	O
of	O
Dnmt3a	B
by	O
DNMT3L	B
was	O
also	O
observed	O
at	O
endogenous	O
sequences	O
in	O
the	O
genome	O
.	O

Therefore	O
,	O
DNMT3L	B
acts	O
as	O
a	O
general	O
stimulatory	O
factor	O
for	O
de	O
novo	O
methylation	O
by	O
Dnmt3a	B
.	O

The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
function	O
of	O
DNMT3L	B
and	O
Dnmt3a	B
in	O
DNA	O
methylation	O
and	O
genomic	O
imprinting	O
are	O
discussed	O
.	O

Ethylene	O
synthesis	O
regulated	O
by	O
biphasic	O
induction	O
of	O
1-aminocyclopropane-1-carboxylic	B
acid	I
synthase	I
and	O
1-aminocyclopropane-1-carboxylic	B
acid	I
oxidase	I
genes	O
is	O
required	O
for	O
hydrogen	O
peroxide	O
accumulation	O
and	O
cell	O
death	O
in	O
ozone	O
-	O
exposed	O
tomato	O
.	O

We	O
show	O
that	O
above	O
a	O
certain	O
threshold	O
concentration	O
,	O
ozone	O
leads	O
to	O
leaf	O
injury	O
in	O
tomato	O
(	O
Lycopersicon	O
esculentum	O
)	O
.	O

Ozone	O
-	O
induced	O
leaf	O
damage	O
was	O
preceded	O
by	O
a	O
rapid	O
increase	O
in	O
1-aminocyclopropane-1-carboxylic	B
acid	I
(	I
ACC	I
)	I
synthase	I
activity	O
,	O
ACC	O
content	O
,	O
and	O
ethylene	O
emission	O
.	O

Changes	O
in	O
mRNA	O
levels	O
of	O
specific	O
ACC	B
synthase	I
,	O
ACC	B
oxidase	I
,	O
and	O
ethylene	B
receptor	I
genes	O
occurred	O
within	O
1	O
to	O
5	O
h	O
.	O

Expression	O
of	O
the	O
genes	O
encoding	O
components	O
of	O
ethylene	O
biosynthesis	O
and	O
perception	O
,	O
and	O
biochemistry	O
of	O
ethylene	O
synthesis	O
suggested	O
that	O
ozone	O
-	O
induced	O
ethylene	O
synthesis	O
in	O
tomato	O
is	O
under	O
biphasic	O
control	O
.	O

In	O
transgenic	O
plants	O
containing	O
an	O
LE	O
-	O
ACO1	B
promoter	O
-	O
beta	B
-	I
glucuronidase	I
fusion	O
construct	O
,	O
beta	B
-	I
glucuronidase	I
activity	O
increased	O
rapidly	O
at	O
the	O
beginning	O
of	O
the	O
O	O
(	O
3	O
)	O
exposure	O
and	O
had	O
a	O
spatial	O
distribution	O
resembling	O
the	O
pattern	O
of	O
extracellular	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
production	O
at	O
7	O
h	O
,	O
which	O
coincided	O
with	O
the	O
cell	O
death	O
pattern	O
after	O
24	O
h	O
.	O

Ethylene	O
synthesis	O
and	O
perception	O
were	O
required	O
for	O
active	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
production	O
and	O
cell	O
death	O
resulting	O
in	O
visible	O
tissue	O
damage	O
.	O

The	O
results	O
demonstrate	O
a	O
selective	O
ozone	O
response	O
of	O
ethylene	O
biosynthetic	O
genes	O
and	O
suggest	O
a	O
role	O
for	O
ethylene	O
,	O
in	O
combination	O
with	O
the	O
burst	O
of	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
production	O
,	O
in	O
regulating	O
the	O
spread	O
of	O
cell	O
death	O
.	O

Identification	O
of	O
oligomerization	O
and	O
drug	O
-	O
binding	O
domains	O
of	O
the	O
membrane	O
fusion	O
protein	O
EmrA	B
.	O

Many	O
pathogenic	O
Gram	O
-	O
negative	O
bacteria	O
possess	O
tripartite	O
transporters	O
that	O
catalyze	O
drug	O
extrusion	O
across	O
the	O
inner	O
and	O
outer	O
membranes	O
,	O
thereby	O
conferring	O
resistance	O
.	O

These	O
transporters	O
consist	O
of	O
inner	O
(	O
IMP	O
)	O
and	O
outer	O
(	O
OMP	O
)	O
membrane	O
proteins	O
,	O
which	O
are	O
coupled	O
by	O
a	O
periplasmic	O
membrane	B
fusion	I
(	I
MFP	I
)	I
protein	I
.	O

However	O
,	O
it	O
is	O
not	O
know	O
whether	O
the	O
MFP	B
translocates	O
the	O
drug	O
between	O
the	O
membranes	O
,	O
by	O
acting	O
as	O
a	O
channel	O
,	O
or	O
whether	O
it	O
brings	O
the	O
IMP	O
and	O
OMP	O
together	O
,	O
facilitating	O
drug	O
transfer	O
.	O

The	O
MFP	B
EmrA	B
has	O
an	O
elongated	O
periplasmic	O
domain	O
,	O
which	O
binds	O
transported	O
drugs	O
,	O
and	O
is	O
anchored	O
to	O
the	O
inner	O
membrane	O
by	O
a	O
single	O
alpha	O
-	O
helix	O
,	O
which	O
contains	O
a	O
leucine	O
zipper	O
dimerization	O
domain	O
.	O

Consistent	O
with	O
CD	O
and	O
hydrodynamic	O
analyses	O
,	O
the	O
periplasmic	O
domain	O
is	O
predicted	O
to	O
be	O
composed	O
of	O
a	O
beta	O
-	O
sheet	O
subdomain	O
and	O
an	O
alpha	O
-	O
helical	O
coiled	O
-	O
coil	O
.	O

We	O
propose	O
that	O
EmrA	B
forms	O
a	O
trimer	O
in	O
which	O
the	O
coiled	O
-	O
coils	O
radiate	O
across	O
the	O
periplasm	O
,	O
where	O
they	O
could	O
sequester	O
the	O
OMP	O
TolC	B
.	O

The	O
""""	O
free	O
""""	O
leucine	O
zipper	O
in	O
the	O
EmrA	B
trimer	O
might	O
stabilize	O
the	O
interaction	O
with	O
the	O
IMP	O
EmrB	B
,	O
which	O
also	O
possesses	O
leucine	O
zipper	O
motifs	O
in	O
the	O
putative	O
N	O
-	O
and	O
C	O
-	O
terminal	O
helices	O
.	O

The	O
beta	O
-	O
sheet	O
subdomain	O
of	O
EmrA	B
would	O
sit	O
at	O
the	O
membrane	O
surface	O
adjacent	O
to	O
the	O
EmrB	B
,	O
from	O
which	O
it	O
receives	O
the	O
transported	O
drug	O
,	O
inducing	O
a	O
conformational	O
change	O
that	O
triggers	O
the	O
interaction	O
with	O
the	O
OMP	O
.	O

Evidence	O
for	O
a	O
role	O
of	O
p38	B
kinase	I
in	O
hypoxia	B
-	I
inducible	I
factor	I
1	I
-	O
independent	O
induction	O
of	O
vascular	B
endothelial	I
growth	I
factor	I
expression	O
by	O
sodium	O
arsenite	O
.	O

Recently	O
we	O
have	O
demonstrated	O
that	O
sodium	O
arsenite	O
induces	O
the	O
expression	O
of	O
hypoxia	B
-	I
inducible	I
factor	I
1alpha	I
(	O
HIF-1alpha	B
)	O
protein	O
and	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
in	O
OVCAR-3	O
human	O
ovarian	O
cancer	O
cells	O
.	O

We	O
now	O
show	O
that	O
arsenic	O
trioxide	O
,	O
an	O
experimental	O
anticancer	O
drug	O
,	O
exerts	O
the	O
same	O
effects	O
.	O

The	O
involvement	O
of	O
phosphatidylinositol	B
3-kinase	I
and	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
pathways	O
in	O
the	O
effects	O
of	O
sodium	O
arsenite	O
was	O
investigated	O
.	O

By	O
using	O
kinase	O
inhibitors	O
in	O
OVCAR-3	O
cells	O
,	O
both	O
effects	O
of	O
sodium	O
arsenite	O
were	O
found	O
to	O
be	O
independent	O
of	O
phosphatidylinositol	B
3-kinase	I
and	O
p44	B
/	I
p42	I
MAPKS	I
but	O
were	O
attenuated	O
by	O
inhibition	O
of	O
p38	B
MAPK	I
.	O

A	O
role	O
for	O
p38	B
in	O
the	O
regulation	O
of	O
HIF-1alpha	B
and	O
VEGF	B
expression	O
was	O
supported	O
further	O
by	O
analysis	O
of	O
activation	O
kinetics	O
.	O

Experiments	O
in	O
mouse	O
fibroblast	O
cell	O
lines	O
,	O
lacking	O
expression	O
of	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinases	I
1	I
and	I
2	I
,	O
suggested	O
that	O
these	O
kinases	B
are	O
not	O
required	O
for	O
induction	O
of	O
HIF-1alpha	B
protein	O
and	O
VEGF	B
mRNA	O
.	O

Unexpectedly	O
,	O
sodium	O
arsenite	O
did	O
not	O
activate	O
a	O
HIF-1	B
-	O
dependent	O
reporter	O
gene	O
in	O
OVCAR-3	O
cells	O
,	O
indicating	O
that	O
functional	O
HIF-1	B
was	O
not	O
induced	O
.	O

In	O
agreement	O
with	O
this	O
hypothesis	O
,	O
up	O
-	O
regulation	O
of	O
VEGF	B
mRNA	O
was	O
not	O
reduced	O
in	O
HIF-1alpha	B
(	O
-	O
/	O
-	O
)	O
mouse	O
fibroblast	O
cell	O
lines	O
.	O

Altogether	O
,	O
these	O
data	O
suggest	O
that	O
not	O
HIF-1	B
,	O
but	O
rather	O
p38	B
,	O
mediates	O
induction	O
of	O
VEGF	B
mRNA	O
expression	O
by	O
sodium	O
arsenite	O
.	O

The	O
promoter	O
of	O
IL-18	B
binding	I
protein	I
:	O
activation	O
by	O
an	O
IFN	B
-	I
gamma	I
-	O
induced	O
complex	O
of	O
IFN	B
regulatory	I
factor	I
1	I
and	O
CCAAT	B
/	I
enhancer	I
binding	I
protein	I
beta	I
.	O

The	O
IL-18	B
binding	I
protein	I
(	O
IL-18BP	B
)	O
is	O
a	O
circulating	O
inhibitor	O
of	O
the	O
proinflammatory	O
cytokine	B
IL-18	B
.	O

It	O
is	O
constitutively	O
expressed	O
in	O
mononuclear	O
cells	O
,	O
and	O
elevated	O
expression	O
is	O
induced	O
by	O
IFN	B
-	I
gamma	I
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
the	O
IL-18BP	B
promoter	O
.	O

We	O
first	O
showed	O
that	O
induction	O
is	O
at	O
the	O
transcriptional	O
level	O
and	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
IL-18BP	B
promoter	O
resides	O
within	O
1.6	O
kb	O
DNA	O
upstream	O
of	O
the	O
first	O
exon	O
and	O
includes	O
at	O
least	O
six	O
regulatory	O
elements	O
.	O

We	O
identified	O
in	O
the	O
basal	O
promoter	O
a	O
gamma	O
-	O
activated	O
sequence	O
(	O
GAS	O
)	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
(	O
base	O
1	O
)	O
,	O
followed	O
by	O
an	O
IFN	B
regulatory	I
factor	I
1	I
response	O
element	O
(	O
IRF	O
-	O
E	O
)	O
and	O
two	O
CCAATenhancer	B
binding	I
protein	I
beta	I
(	O
CEBPbeta	B
)	O
sites	O
,	O
all	O
of	O
which	O
are	O
essential	O
for	O
basal	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
GAS	O
and	O
IRF	O
-	O
E	O
were	O
essential	O
for	O
IFN	B
-	I
gamma	I
-	O
induced	O
transcription	O
.	O

Indeed	O
,	O
sera	O
of	O
IRF-1	B
-	O
deficient	O
mice	O
lacked	O
basal	O
and	O
IFN	B
-	I
gamma	I
-	O
induced	O
IL-18BP	B
.	O

We	O
found	O
that	O
after	O
induction	O
of	O
IRF-1	B
by	O
IFN	B
-	I
gamma	I
,	O
it	O
formed	O
a	O
complex	O
with	O
CEBPbeta	B
,	O
which	O
bound	O
to	O
the	O
IRF	O
-	O
E	O
and	O
GAS	O
-	O
containing	O
proximal	O
DNA	O
.	O

In	O
contrast	O
,	O
the	O
IFN	B
-	I
gamma	I
-	O
induced	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
1	I
dimer	O
did	O
not	O
associate	O
with	O
this	O
GAS	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
silencer	O
element	O
and	O
a	O
distal	O
enhancer	O
at	O
bases	O
-	O
1081	O
to	O
-	O
1272	O
,	O
which	O
was	O
also	O
physically	O
associated	O
with	O
IRF-1	B
.	O

The	O
IRF-1	B
-	O
CEBPbeta	B
complex	O
described	O
here	O
probably	O
plays	O
a	O
fundamental	O
role	O
in	O
regulating	O
additional	O
IFN	B
-	I
gamma	I
-	O
responsive	O
genes	O
.	O

IFN	B
-	I
lambdas	I
mediate	O
antiviral	O
protection	O
through	O
a	O
distinct	O
class	O
II	O
cytokine	B
receptor	I
complex	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
ligand	O
-	O
receptor	O
system	O
that	O
,	O
upon	O
engagement	O
,	O
leads	O
to	O
the	O
establishment	O
of	O
an	O
antiviral	O
state	O
.	O

Three	O
closely	O
positioned	O
genes	O
on	O
human	O
chromosome	O
19	O
encode	O
distinct	O
but	O
paralogous	O
proteins	O
,	O
which	O
we	O
designate	O
interferon	B
-	I
lambda1	I
(	O
IFN	B
-	I
lambda1	I
)	O
,	O
IFN	B
-	I
lambda2	I
and	O
IFN	B
-	I
lambda3	I
(	O
tentatively	O
designated	O
as	O
IL-29	B
,	O
IL-28A	B
and	O
IL-28B	B
,	O
respectively	O
,	O
by	O
HUGO	O
)	O
.	O

The	O
expression	O
of	O
IFN	B
-	I
lambda	I
mRNAs	O
was	O
inducible	O
by	O
viral	O
infection	O
in	O
several	O
cell	O
lines	O
.	O

We	O
identified	O
a	O
distinct	O
receptor	O
complex	O
that	O
is	O
utilized	O
by	O
all	O
three	O
IFN	B
-	I
lambda	I
proteins	O
for	O
signaling	O
and	O
is	O
composed	O
of	O
two	O
subunits	O
,	O
a	O
receptor	O
designated	O
CRF2	B
-	I
12	I
(	O
also	O
designated	O
as	O
IFN	B
-	I
lambdaR1	I
)	O
and	O
a	O
second	O
subunit	O
,	O
CRF2	B
-	I
4	I
(	O
also	O
known	O
as	O
IL-10R2	B
)	O
.	O

Both	O
receptor	O
chains	O
are	O
constitutively	O
expressed	O
on	O
a	O
wide	O
variety	O
of	O
human	O
cell	O
lines	O
and	O
tissues	O
and	O
signal	O
through	O
the	O
Jak	B
-	O
STAT	B
(	O
Janus	B
kinases	I
-	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
)	O
pathway	O
.	O

This	O
receptor	O
-	O
ligand	O
system	O
may	O
contribute	O
to	O
antiviral	O
or	O
other	O
defenses	O
by	O
a	O
mechanism	O
similar	O
to	O
,	O
but	O
independent	O
of	O
,	O
type	B
I	I
IFNs	I
.	O

Modulation	O
of	O
cystatin	B
C	I
expression	O
impairs	O
the	O
invasive	O
and	O
tumorigenic	O
potential	O
of	O
human	O
glioblastoma	O
cells	O
.	O

Increases	O
in	O
the	O
abundance	O
of	O
cathepsin	B
B	I
transcript	O
and	O
protein	O
with	O
increased	O
tumor	O
grade	O
and	O
changes	O
in	O
subcellular	O
localization	O
and	O
activity	O
of	O
this	O
enzyme	O
.	O

We	O
observed	O
progressive	O
reductions	O
in	O
levels	O
of	O
the	O
protease	O
inhibitor	O
cystatin	B
C	I
,	O
an	O
inhibitor	O
of	O
cathepsin	B
B	I
with	O
corresponding	O
increases	O
in	O
the	O
malignancy	O
of	O
glioma	O
cell	O
lines	O
,	O
implying	O
an	O
inverse	O
correlation	O
between	O
cystatin	B
C	I
and	O
tumor	O
grade	O
.	O

To	O
investigate	O
the	O
role	O
of	O
cystatin	B
C	I
in	O
the	O
invasion	O
of	O
brain	O
tumor	O
cells	O
,	O
we	O
stably	O
transfected	O
SNB19	O
glioblastoma	O
cells	O
with	O
either	O
a	O
0.4	O
-	O
kb	O
cDNA	O
construct	O
of	O
human	O
cystatin	B
C	I
in	O
the	O
sense	O
orientation	O
or	O
an	O
empty	O
vector	O
.	O

Clones	O
expressing	O
sense	O
-	O
cystatin	B
C	I
cDNA	O
had	O
higher	O
cystatin	B
C	I
mRNA	O
and	O
protein	O
levels	O
than	O
did	O
control	O
cells	O
.	O

Sense	O
-	O
transfected	O
cells	O
were	O
also	O
markedly	O
less	O
invasive	O
than	O
control	O
cells	O
in	O
a	O
Matrigel	O
invasion	O
assay	O
and	O
in	O
a	O
coculture	O
assay	O
of	O
SNB19	O
spheroids	O
and	O
fetal	O
rat	O
brain	O
aggregates	O
.	O

Finally	O
,	O
the	O
sense	O
-	O
transfected	O
cells	O
did	O
not	O
form	O
tumors	O
in	O
nude	O
mice	O
upon	O
intracerebral	O
injection	O
.	O

These	O
results	O
strongly	O
implicate	O
cystatin	B
C	I
in	O
the	O
invasiveness	O
of	O
human	O
glioblastoma	O
cells	O
and	O
suggest	O
that	O
sense	O
transcripts	O
of	O
cystatin	B
C	I
may	O
prove	O
useful	O
in	O
cancer	O
therapy	O
.	O

The	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genomic	O
region	O
:	O
gene	O
-	O
order	O
,	O
haplotypes	O
and	O
allelic	O
polymorphism	O
.	O

Recent	O
genetic	O
studies	O
have	O
established	O
that	O
the	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genomic	O
region	O
displays	O
extensive	O
diversity	O
through	O
variation	O
in	O
gene	O
content	O
and	O
allelic	O
polymorphism	O
within	O
individual	O
KIR	B
genes	O
.	O

It	O
is	O
demonstrated	O
by	O
family	O
segregation	O
analysis	O
,	O
genomic	O
sequencing	O
,	O
and	O
gene	O
order	O
determination	O
that	O
genomic	O
diversity	O
by	O
gene	O
content	O
alone	O
gives	O
rise	O
to	O
more	O
than	O
20	O
different	O
KIR	B
haplotypes	O
and	O
at	O
least	O
40	O
-	O
50	O
KIR	B
genotypes	O
.	O

In	O
the	O
most	O
reductionist	O
format	O
,	O
KIR	B
haplotypes	O
can	O
be	O
accommodated	O
within	O
one	O
of	O
10	O
different	O
prototypes	O
,	O
each	O
with	O
multiple	O
permutations	O
.	O

Our	O
haplotype	O
model	O
considers	O
the	O
KIR	B
haplotype	O
as	O
two	O
separate	O
halves	O
:	O
the	O
centromeric	O
half	O
bordered	O
upstream	O
by	O
KIR3DL3	B
and	O
downstream	O
by	O
2DL4	B
,	O
and	O
the	O
telomeric	O
half	O
bordered	O
upstream	O
by	O
2DL4	B
and	O
downstream	O
by	O
3DL2	B
.	O

There	O
are	O
rare	O
KIR	B
haplotypes	O
that	O
do	O
not	O
fit	O
into	O
this	O
model	O
.	O

Recombination	O
,	O
gene	O
duplication	O
,	O
and	O
inversion	O
can	O
however	O
,	O
readily	O
explain	O
these	O
haplotypes	O
.	O

Additional	O
allelic	O
polymorphism	O
imposes	O
extensive	O
individual	O
variability	O
.	O

Accordingly	O
,	O
this	O
segment	O
of	O
the	O
human	O
genome	O
displays	O
a	O
level	O
of	O
diversity	O
similar	O
to	O
the	O
one	O
observed	O
for	O
the	O
human	O
major	B
histocompatibility	I
complex	I
.	O

Recent	O
application	O
of	O
immunogenetic	O
analysis	O
of	O
KIR	B
genes	O
in	O
patient	O
populations	O
implicates	O
these	O
genes	O
as	O
important	O
genetic	O
disease	O
susceptibility	O
factors	O
.	O

Up	O
-	O
regulation	O
of	O
neuronal	B
calcium	I
sensor-1	I
(	O
NCS-1	B
)	O
in	O
the	O
prefrontal	O
cortex	O
of	O
schizophrenic	O
and	O
bipolar	O
patients	O
.	O

The	O
delineation	O
of	O
dopamine	O
dysfunction	O
in	O
the	O
mentally	O
ill	O
has	O
been	O
a	O
long	O
-	O
standing	O
quest	O
of	O
biological	O
psychiatry	O
.	O

The	O
present	O
study	O
focuses	O
on	O
a	O
recently	O
recognized	O
group	O
of	O
dopamine	B
receptor	I
-	O
interacting	O
proteins	O
as	O
possible	O
novel	O
sites	O
of	O
dysfunction	O
in	O
schizophrenic	O
and	O
bipolar	O
patients	O
.	O

We	O
demonstrate	O
that	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
in	O
schizophrenia	O
and	O
bipolar	O
cases	O
from	O
the	O
Stanley	O
Foundation	O
Neuropathology	O
Consortium	O
display	O
significantly	O
elevated	O
levels	O
of	O
the	O
D2	B
dopamine	I
receptor	I
desensitization	O
regulatory	O
protein	O
,	O
neuronal	B
calcium	I
sensor-1	I
.	O

These	O
levels	O
of	O
neuronal	B
calcium	I
sensor-1	I
were	O
not	O
influenced	O
by	O
age	O
,	O
gender	O
,	O
hemisphere	O
,	O
cause	O
of	O
death	O
,	O
postmortem	O
period	O
,	O
alcohol	O
consumption	O
,	O
or	O
antipsychotic	O
and	O
mood	O
stabilizing	O
medications	O
.	O

The	O
present	O
study	O
supports	O
the	O
hypothesis	O
that	O
schizophrenia	O
and	O
bipolar	O
disorder	O
may	O
be	O
associated	O
with	O
abnormalities	O
in	O
dopamine	B
receptor	I
-	O
interacting	O
proteins	O
.	O

Histidine	O
407	O
,	O
a	O
phantom	O
residue	O
in	O
the	O
E1	B
subunit	O
of	O
the	O
Escherichia	O
coli	O
pyruvate	B
dehydrogenase	I
complex	I
,	O
activates	O
reductive	O
acetylation	O
of	O
lipoamide	O
on	O
the	O
E2	B
subunit	O
.	O

An	O
explanation	O
for	O
conservation	O
of	O
active	O
sites	O
between	O
the	O
E1	B
subunit	O
and	O
transketolase	B
.	O

Least	O
squares	O
alignment	O
of	O
the	O
E.	O
coli	O
pyruvate	B
dehydrogenase	I
multienzyme	I
complex	I
E1	I
subunit	O
and	O
yeast	O
transketolase	B
crystal	O
structures	O
indicates	O
a	O
general	O
structural	O
similarity	O
between	O
the	O
two	O
enzymes	O
and	O
provides	O
a	O
plausible	O
location	O
for	O
a	O
short	O
-	O
loop	O
region	O
in	O
the	O
E1	B
structure	O
that	O
was	O
unobserved	O
due	O
to	O
disorder	O
.	O

The	O
residue	O
H407	O
,	O
located	O
in	O
this	O
region	O
,	O
is	O
shown	O
to	O
be	O
able	O
to	O
penetrate	O
the	O
active	O
site	O
.	O

Suggested	O
by	O
this	O
comparison	O
,	O
the	O
H407A	O
E1	B
variant	O
was	O
created	O
,	O
and	O
H407	O
was	O
shown	O
to	O
participate	O
in	O
the	O
reductive	O
acetylation	O
of	O
both	O
an	O
independently	O
expressed	O
lipoyl	O
domain	O
and	O
the	O
intact	O
1	O
-	O
lipoyl	O
E2	B
subunit	O
.	O

While	O
the	O
H407A	O
substitution	O
only	O
modestly	O
affected	O
the	O
reaction	O
through	O
pyruvate	O
decarboxylation	O
(	O
ca	O
.	O
14	O
%	O
activity	O
compared	O
to	O
parental	O
E1	B
)	O
,	O
the	O
overall	O
complex	O
has	O
a	O
much	O
impaired	O
activity	O
,	O
at	O
most	O
0.15	O
%	O
compared	O
to	O
parental	O
E1	B
.	O

Isothermal	O
titration	O
calorimetry	O
measurements	O
show	O
that	O
the	O
binding	O
of	O
the	O
lipoyl	O
domain	O
to	O
the	O
H407A	O
E1	B
variant	O
is	O
much	O
weaker	O
than	O
that	O
to	O
parental	O
E1	B
.	O

At	O
the	O
same	O
time	O
,	O
mass	O
spectrometric	O
measurements	O
clearly	O
demonstrate	O
much	O
impaired	O
reductive	O
acetylation	O
of	O
the	O
independently	O
expressed	O
lipoyl	O
domain	O
and	O
of	O
the	O
intact	O
1	O
-	O
lipoyl	O
E2	B
by	O
the	O
H407A	O
variant	O
compared	O
to	O
the	O
parental	O
E1	B
.	O

A	O
proposal	O
is	O
presented	O
to	O
explain	O
the	O
remarkable	O
conservation	O
of	O
the	O
three	O
-	O
dimensional	O
structure	O
at	O
the	O
active	O
centers	O
of	O
the	O
E.	O
coli	O
E1	B
subunit	O
and	O
transketolase	B
on	O
the	O
basis	O
of	O
the	O
parallels	O
in	O
the	O
ligation	O
-	O
type	O
reactions	O
carried	O
out	O
and	O
the	O
need	O
to	O
protonate	O
a	O
very	O
weak	O
acid	O
,	O
a	O
dithiolane	O
sulfur	O
atom	O
in	O
the	O
former	O
,	O
and	O
a	O
carbonyl	O
oxygen	O
atom	O
in	O
the	O
latter	O
.	O

Genomic	O
structure	O
,	O
expression	O
,	O
and	O
transcriptional	O
regulation	O
of	O
human	O
Gal	B
beta	I
1,3	I
GalNAc	I
alpha	I
2,3-sialyltransferase	I
gene	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
transcriptional	O
regulation	O
of	O
the	O
human	O
Gal	B
beta	I
1	I
,	I
3	I
GalNAc	I
alpha	I
2,3-sialyltransferase	I
II	I
(	O
hST3Gal	B
II	I
)	O
gene	O
.	O

The	O
results	O
of	O
5'-RACE	O
showed	O
that	O
the	O
forms	O
of	O
two	O
mRNAs	O
differed	O
only	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
Types	O
1	O
and	O
2	O
)	O
.	O

According	O
to	O
analysis	O
of	O
the	O
genomic	O
structure	O
,	O
the	O
transcriptional	O
regulation	O
of	O
Type	O
1	O
and	O
Type	O
2	O
mRNA	O
isoforms	O
depended	O
on	O
the	O
p1	O
and	O
p2	O
promoters	O
,	O
respectively	O
.	O

Both	O
the	O
mRNA	O
isoforms	O
were	O
detected	O
in	O
various	O
human	O
tissues	O
except	O
colon	O
,	O
skeletal	O
muscle	O
,	O
and	O
peripheral	O
blood	O
leukocytes	O
by	O
RT	O
-	O
PCR	O
analysis	O
.	O

In	O
colon	O
tissue	O
,	O
the	O
Type	O
2	O
mRNA	O
was	O
detected	O
,	O
however	O
,	O
Type	O
1	O
mRNA	O
was	O
not	O
detected	O
.	O

To	O
elucidate	O
the	O
molecular	O
basis	O
of	O
hST3Gal	B
II	I
gene	O
expression	O
,	O
we	O
isolated	O
and	O
characterized	O
the	O
function	O
of	O
the	O
genomic	O
region	O
of	O
hST3Gal	B
II	I
containing	O
the	O
p1	O
and	O
p2	O
promoters	O
.	O

The	O
activity	O
of	O
p2	O
promoter	O
is	O
much	O
higher	O
than	O
that	O
of	O
the	O
p1	O
promoter	O
in	O
the	O
colon	O
adenocarcinoma	O
cell	O
line	O
,	O
COLO205	O
.	O

These	O
results	O
suggest	O
that	O
the	O
hST3Gal	B
II	I
gene	O
is	O
expressed	O
specifically	O
by	O
alternative	O
promoter	O
utilization	O
and	O
is	O
regulated	O
in	O
a	O
tissue	O
-	O
restricted	O
fashion	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Role	O
of	O
metazoan	O
mediator	O
proteins	O
in	O
interferon	B
-	O
responsive	O
transcription	O
.	O

The	O
interferon	B
(	O
IFN	B
)	O
-	O
induced	O
signal	O
transduction	O
and	O
transcription	O
activation	O
complex	O
,	O
ISGF3	B
,	O
is	O
assembled	O
from	O
three	O
proteins	O
,	O
STAT1	B
,	O
STAT2	B
,	O
and	O
IRF9	B
.	O

Of	O
these	O
components	O
,	O
STAT2	B
provides	O
a	O
fundamental	O
and	O
essential	O
transcriptional	O
activation	O
function	O
for	O
ISGF3	B
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
ISGF3	B
-	O
mediated	O
transcription	O
is	O
dependent	O
on	O
STAT2	B
interactions	O
with	O
DRIP150	B
,	O
a	O
subunit	O
of	O
the	O
multimeric	O
Mediator	B
coactivator	I
complex	I
.	O

Other	O
Mediator	O
subunits	O
,	O
DRIP77	B
and	O
DRIP130	B
,	O
were	O
found	O
either	O
to	O
bind	O
STAT2	B
without	O
augmenting	O
ISGF3	B
transcriptional	O
activity	O
or	O
to	O
enhance	O
ISGF3	B
transcription	O
without	O
binding	O
STAT2	B
,	O
but	O
only	O
DRIP150	B
both	O
enhanced	O
IFN	B
-	O
dependent	O
transcription	O
and	O
coimmunoprecipitated	O
with	O
STAT2	B
.	O

Endogenous	O
DRIP150	B
and	O
STAT2	B
were	O
able	O
to	O
interact	O
in	O
solution	O
,	O
and	O
DNA	O
affinity	O
chromatography	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
demonstrated	O
that	O
DRIP150	B
binds	O
to	O
the	O
mature	O
,	O
activated	O
ISGF3	B
-	O
DNA	O
complex	O
and	O
is	O
recruited	O
to	O
target	O
gene	O
promoters	O
in	O
an	O
IFN	B
-	O
dependent	O
fashion	O
.	O

IFN	B
-	O
dependent	O
recruitment	O
of	O
DRIP130	B
to	O
an	O
ISGF3	B
target	O
promoter	O
and	O
SRB10	B
-	O
STAT2	B
coprecipitation	O
suggest	O
indirect	O
association	O
with	O
a	O
multisubunit	O
Mediator	B
complex	I
.	O

The	O
site	O
of	O
STAT2	B
interaction	O
was	O
mapped	O
to	O
DRIP150	B
residues	O
188	O
to	O
566	O
,	O
which	O
are	O
necessary	O
and	O
sufficient	O
for	O
interaction	O
with	O
STAT2	B
.	O

Expression	O
of	O
this	O
DRIP150	B
fragment	O
,	O
but	O
not	O
DRIP150	B
fragments	O
outside	O
the	O
STAT2	B
interaction	O
region	O
,	O
suppressed	O
ISGF3	B
-	O
mediated	O
transcriptional	O
activity	O
in	O
a	O
dominant	O
-	O
negative	O
fashion	O
,	O
suggesting	O
a	O
direct	O
functional	O
role	O
of	O
this	O
domain	O
in	O
mediating	O
STAT2	B
-	O
DRIP150	B
interactions	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
IFN	B
-	O
activated	O
ISGF3	B
transcription	O
factor	O
regulates	O
transcription	O
through	O
contact	O
with	O
DRIP150	B
and	O
implicate	O
the	O
Mediator	B
coactivator	I
complex	I
in	O
IFN	B
-	O
activated	O
gene	O
regulation	O
.	O

[	O
A	O
new	O
missense	O
mutation	O
of	O
574C	O
>	O
T	O
in	O
the	O
SURF1	B
gene	O
--	O
biochemical	O
and	O
molecular	O
genetic	O
study	O
in	O
seven	O
children	O
with	O
Leigh	O
syndrome	O
]	O

BACKGROUND	O
:	O

Leigh	O
disease	O
,	O
subacute	O
necrotizing	O
encephalopathy	O
,	O
is	O
a	O
serious	O
mitochondrial	O
disorder	O
of	O
energy	O
-	O
providing	O
metabolism	O
.	O

Clinical	O
presentation	O
usually	O
starts	O
in	O
infancy	O
as	O
a	O
progressive	O
neurodegenerative	O
disorder	O
with	O
retardation	O
and	O
regression	O
of	O
psychomotor	O
development	O
.	O

The	O
most	O
common	O
form	O
of	O
the	O
disease	O
is	O
associated	O
with	O
deficiency	O
of	O
the	O
cytochrome	B
c	I
oxidase	I
(	O
COX	B
)	O
due	O
to	O
SURF1	B
gene	O
mutations	O
.	O

SURF1	B
encodes	O
an	O
inner	O
mitochondrial	O
membrane	O
protein	O
involved	O
in	O
the	O
biogenesis	O
and	O
assembly	O
of	O
COX	B
complex	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

The	O
activities	O
of	O
mitochondrial	O
respiratory	O
chain	O
complexes	O
were	O
determined	O
spectrophotometrically	O
in	O
isolated	O
lymphocytes	O
,	O
platelets	O
,	O
muscle	O
mitochondria	O
and	O
cultured	O
fibroblasts	O
.	O

Generalised	O
decrease	O
of	O
COX	B
activity	O
was	O
found	O
in	O
7	O
children	O
with	O
typical	O
symptoms	O
of	O
Leigh	O
disease	O
.	O

Two	O
-	O
dimensional	O
electrophoresis	O
of	O
mitochondrial	O
proteins	O
showed	O
altered	O
assembly	O
pattern	O
of	O
COX	B
.	O

As	O
demonstrated	O
by	O
Western	O
blot	O
analysis	O
of	O
mitochondria	O
or	O
mitoplasts	O
with	O
anti	O
-	O
hSurf1	B
antibodies	O
(	O
gift	O
from	O
Dr.	O
E.	O
A.	O
Shoubridge	O
)	O
,	O
the	O
Surf1	B
protein	O
was	O
absent	O
in	O
all	O
5	O
investigated	O
patients	O
.	O

Molecular	O
analyses	O
in	O
the	O
7	O
patients	O
revealed	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
SURF1	B
gene	O
--six	O
patients	O
harboured	O
previously	O
described	O
SURF1	B
mutations	O
,	O
a	O
new	O
mutation	O
574C	O
>	O
T	O
was	O
found	O
in	O
one	O
patient	O
.	O

CONCLUSIONS	O
:	O

The	O
co	O
-	O
operation	O
among	O
the	O
patient	O
's	O
families	O
,	O
clinicians	O
and	O
specialised	O
laboratories	O
is	O
essential	O
for	O
the	O
diagnostic	O
of	O
mitochondrial	O
disorders	O
.	O

The	O
treatment	O
of	O
Leigh	O
syndrome	O
is	O
only	O
symptomatic	O
and	O
the	O
prognosis	O
of	O
the	O
disease	O
is	O
unfavourable	O
.	O

The	O
diagnostics	O
on	O
biochemical	O
and	O
molecular	O
level	O
is	O
necessary	O
for	O
genetic	O
counselling	O
and	O
prenatal	O
diagnosis	O
in	O
affected	O
families	O
.	O

Ephrin	B
stimulation	O
modulates	O
T	O
cell	O
chemotaxis	O
.	O

Eph	B
receptor	I
tyrosine	I
kinases	I
and	O
their	O
ligands	O
,	O
the	O
ephrins	B
,	O
are	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
cell	O
migration	O
and	O
targeting	O
in	O
neuronal	O
and	O
endothelial	O
cells	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
lymphoid	O
cells	O
also	O
express	O
Eph	B
receptors	I
,	O
raising	O
the	O
possibility	O
that	O
Eph	B
receptors	I
may	O
similarly	O
regulate	O
lymphocyte	O
migration	O
.	O

Chemotaxis	O
in	O
response	O
to	O
soluble	O
chemokine	B
factors	O
is	O
an	O
essential	O
facet	O
of	O
T	O
cell	O
biology	O
.	O

We	O
demonstrate	O
here	O
that	O
T	O
cell	O
chemotaxis	O
in	O
response	O
to	O
both	O
the	O
stromal	B
cell	I
-	I
derived	I
factor	I
(	I
SDF	I
)	I
-	I
1alpha	I
and	O
macrophage	B
inflammatory	I
protein	I
3beta	I
chemokines	B
is	O
modulated	O
by	O
costimulation	O
with	O
ephrins	B
.	O

Both	O
ephrin	B
-	I
A	I
and	O
ephrin	B
-	I
B	I
ligands	O
were	O
found	O
to	O
modify	O
the	O
chemotactic	O
responses	O
of	O
a	O
T	O
cell	O
line	O
and	O
primary	O
T	O
cells	O
.	O

Ephrin	B
-	I
A1	I
,	O
in	O
particular	O
,	O
strongly	O
inhibited	O
chemotaxis	O
.	O

In	O
accordance	O
with	O
the	O
tyrosine	B
kinase	I
activity	O
of	O
EphA	B
receptors	I
,	O
ephrin	B
-	I
A1	I
stimulation	O
induced	O
rapid	O
intracellular	O
tyrosine	O
phosphorylation	O
in	O
T	O
cells	O
.	O

Although	O
strongly	O
inhibiting	O
chemotaxis	O
,	O
ephrin	B
-	I
A1	I
costimulus	O
did	O
not	O
affect	O
many	O
of	O
the	O
signaling	O
events	O
downstream	O
of	O
the	O
SDF-1alpha	B
receptor	I
CXCR4	B
,	O
including	O
calcium	O
flux	O
and	O
activation	O
of	O
MAPK	B
.	O

Rather	O
,	O
ephrin	B
-	I
A1	I
altered	O
the	O
balance	O
of	O
small	B
G	I
protein	I
activity	O
in	O
T	O
cells	O
.	O

Ephrin	B
-	I
A1	I
stimulation	O
prevented	O
SDF-1alpha	B
-	O
induced	O
activation	O
of	O
cdc42	B
,	O
while	O
simultaneously	O
inducing	O
rho	B
activation	O
.	O

Ultimately	O
,	O
ephrin	B
-	I
A1	I
was	O
found	O
to	O
inhibit	O
chemokine	B
-	O
induced	O
actin	B
polymerization	O
,	O
thereby	O
blocking	O
migration	O
.	O

Ubiquitous	O
ephrin	B
expression	O
in	O
vivo	O
creates	O
enormous	O
potential	O
for	O
T	O
cells	O
to	O
encounter	O
these	O
ligands	O
,	O
suggesting	O
that	O
Eph	B
receptors	I
and	O
ephrins	B
may	O
be	O
important	O
regulators	O
of	O
T	O
cell	O
migration	O
.	O

iASPP	B
oncoprotein	O
is	O
a	O
key	O
inhibitor	O
of	O
p53	B
conserved	O
from	O
worm	O
to	O
human	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ASPP1	B
and	O
ASPP2	B
are	O
specific	O
activators	O
of	O
p53	B
;	O
one	O
mechanism	O
by	O
which	O
wild	O
-	O
type	O
p53	B
is	O
tolerated	O
in	O
human	O
breast	O
carcinomas	O
is	O
through	O
loss	O
of	O
ASPP	B
activity	O
.	O

We	O
have	O
further	O
shown	O
that	O
53BP2	B
,	O
which	O
corresponds	O
to	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
ASPP2	B
,	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
p53	B
(	O
ref	O
.	O
1	O
)	O
.	O

Hence	O
,	O
an	O
inhibitory	O
form	O
of	O
ASPP	B
resembling	O
53BP2	B
could	O
allow	O
cells	O
to	O
bypass	O
the	O
tumor	O
-	O
suppressor	O
functions	O
of	O
p53	B
and	O
the	O
ASPP	B
proteins	O
.	O

Here	O
,	O
we	O
characterize	O
such	O
a	O
protein	O
,	O
iASPP	B
(	O
inhibitory	B
member	I
of	I
the	I
ASPP	I
family	I
)	O
,	O
encoded	O
by	O
PPP1R13L	B
in	O
humans	O
and	O
ape-1	B
in	O
Caenorhabditis	O
elegans	O
.	O

iASPP	B
is	O
an	O
evolutionarily	O
conserved	O
inhibitor	O
of	O
p53	B
;	O
inhibition	O
of	O
iASPP	B
by	O
RNA	O
-	O
mediated	O
interference	O
or	O
antisense	O
RNA	O
in	O
C.	O
elegans	O
or	O
human	O
cells	O
,	O
respectively	O
,	O
induces	O
p53	B
-	O
dependent	O
apoptosis	O
.	O

Moreover	O
,	O
iASPP	B
is	O
an	O
oncoprotein	O
that	O
cooperates	O
with	O
Ras	B
,	O
E1A	B
and	O
E7	O
,	O
but	O
not	O
mutant	O
p53	B
,	O
to	O
transform	O
cells	O
in	O
vitro	O
.	O

Increased	O
expression	O
of	O
iASPP	B
also	O
confers	O
resistance	O
to	O
ultraviolet	O
radiation	O
and	O
to	O
cisplatin	O
-	O
induced	O
apoptosis	O
.	O

iASPP	B
expression	O
is	O
upregulated	O
in	O
human	O
breast	O
carcinomas	O
expressing	O
wild	O
-	O
type	O
p53	B
and	O
normal	O
levels	O
of	O
ASPP	B
.	O

Inhibition	O
of	O
iASPP	B
could	O
provide	O
an	O
important	O
new	O
strategy	O
for	O
treating	O
tumors	O
expressing	O
wild	O
-	O
type	O
p53	B
.	O

Traffic	O
at	O
the	O
tmRNA	O
gene	O
.	O

A	O
partial	O
screen	O
for	O
genetic	O
elements	O
integrated	O
into	O
completely	O
sequenced	O
bacterial	O
genomes	O
shows	O
more	O
significant	O
bias	O
in	O
specificity	O
for	O
the	O
tmRNA	O
gene	O
(	O
ssrA	O
)	O
than	O
for	O
any	O
type	O
of	O
tRNA	O
gene	O
.	O

Horizontal	O
gene	O
transfer	O
,	O
a	O
major	O
avenue	O
of	O
bacterial	O
evolution	O
,	O
was	O
assessed	O
by	O
focusing	O
on	O
elements	O
using	O
this	O
single	O
attachment	O
locus	O
.	O

Diverse	O
elements	O
use	O
ssrA	O
;	O
among	O
enterobacteria	O
alone	O
,	O
at	O
least	O
four	O
different	O
integrase	B
subfamilies	O
have	O
independently	O
evolved	O
specificity	O
for	O
ssrA	O
,	O
and	O
almost	O
every	O
strain	O
analyzed	O
presents	O
a	O
unique	O
set	O
of	O
integrated	O
elements	O
.	O

Even	O
elements	O
using	O
essentially	O
the	O
same	O
integrase	B
can	O
be	O
very	O
diverse	O
,	O
as	O
is	O
a	O
group	O
with	O
an	O
ssrA	O
-	O
specific	O
integrase	B
of	O
the	O
P4	O
subfamily	O
.	O

This	O
same	O
integrase	B
appears	O
to	O
promote	O
damage	O
routinely	O
at	O
attachment	O
sites	O
,	O
which	O
may	O
be	O
adaptive	O
.	O

Elements	O
in	O
arrays	O
can	O
recombine	O
;	O
one	O
such	O
event	O
mediated	O
by	O
invertible	O
DNA	O
segments	O
within	O
neighboring	O
elements	O
likely	O
explains	O
the	O
monophasic	O
nature	O
of	O
Salmonella	O
enterica	O
serovar	O
Typhi	O
.	O

One	O
of	O
a	O
limited	O
set	O
of	O
conserved	O
sequences	O
occurs	O
at	O
the	O
attachment	O
site	O
of	O
each	O
enterobacterial	O
element	O
,	O
apparently	O
serving	O
as	O
a	O
transcriptional	O
terminator	O
for	O
ssrA	O
.	O

Elements	O
were	O
usually	O
found	O
integrated	O
into	O
tRNA	O
-	O
like	O
sequence	O
at	O
the	O
3	O
'	O
end	O
of	O
ssrA	O
,	O
at	O
subsites	O
corresponding	O
to	O
those	O
used	O
in	O
tRNA	O
genes	O
;	O
an	O
exception	O
was	O
found	O
at	O
the	O
non	O
-	O
tRNA	O
-	O
like	O
3	O
'	O
end	O
produced	O
by	O
ssrA	O
gene	O
permutation	O
in	O
cyanobacteria	O
,	O
suggesting	O
that	O
,	O
during	O
the	O
evolution	O
of	O
new	O
site	O
specificity	O
by	O
integrases	B
,	O
tropism	O
toward	O
a	O
conserved	O
3	O
'	O
end	O
of	O
an	O
RNA	O
gene	O
may	O
be	O
as	O
strong	O
as	O
toward	O
a	O
tRNA	O
-	O
like	O
sequence	O
.	O

The	O
proximity	O
of	O
ssrA	O
and	O
smpB	B
,	O
which	O
act	O
in	O
concert	O
,	O
was	O
also	O
surveyed	O
.	O

[	O
Serum	O
apolipoprotein	B
A	I
I	I
,	I
B100	I
and	I
E	I
levels	O
and	O
apolipoprotein	B
E	I
polymorphism	O
in	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
and	O
multiple	O
infarction	O
dementia	O
in	O
Chinese	O
population	O
]	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
relationship	O
of	O
serum	O
apolipoprotein	B
(	I
apo	I
)	I
A	I
I	I
,	I
B100	I
and	I
E	I
levels	O
and	O
apo	B
E	I
polymorphism	O
to	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
multiple	O
infarction	O
dementia	O
(	O
MID	O
)	O
in	O
Chinese	O
population	O
.	O

METHODS	O
:	O

The	O
apoE	B
phenotypes	O
were	O
assayed	O
by	O
isoelectric	O
focusing	O
and	O
immunoblotting	O
,	O
and	O
apolipoproteins	B
were	O
determined	O
by	O
radial	O
immunodiffusion	O
assay	O
in	O
75	O
patients	O
with	O
AD	O
,	O
36	O
patients	O
with	O
MID	O
and	O
60	O
control	O
subjects	O
.	O

RESULTS	O
:	O

The	O
frequency	O
of	O
apo	B
E4	I
allele	O
(	O
epsilon	O
4	O
)	O
was	O
significantly	O
higher	O
and	O
the	O
frequency	O
of	O
epsilon	O
2	O
allele	O
was	O
lower	O
in	O
AD	O
group	O
,	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
(	O
0.2333	O
vs	O
0.0666	O
,	O
0.0467	O
vs	O
0.0833	O
,	O
P	O
<	O
0.05	O
)	O
.	O

The	O
frequency	O
of	O
epsilon	O
4	O
allele	O
in	O
MID	O
group	O
was	O
also	O
higher	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
0.2083	O
vs	O
0.0666	O
,	O
P	O
<	O
0.05	O
)	O
.	O

The	O
fasting	O
serum	O
apoA	B
1	I
and	I
E	I
levels	O
in	O
AD	O
and	O
MID	O
groups	O
were	O
remarkably	O
lower	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.001	O
and	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O

Apo	B
E4	I
allele	O
epsilon	O
4	O
was	O
associated	O
with	O
AD	O
and	O
MID	O
.	O

ApoE4	B
might	O
be	O
a	O
risk	O
factor	O
for	O
AD	O
and	O
MID	O
,	O
and	O
apo	B
E2	I
might	O
be	O
a	O
protective	O
factor	O
for	O
AD	O
.	O

The	O
serum	O
apo	B
A	I
I	I
and	O
apoE	B
levels	O
were	O
significantly	O
decreased	O
in	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
and	O
multiple	O
infarction	O
dementia	O
.	O

DNA	O
methylation	O
maintains	O
allele	O
-	O
specific	O
KIR	B
gene	O
expression	O
in	O
human	O
natural	O
killer	O
cells	O
.	O

Killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
bind	O
self	O
-	O
major	B
histocompatibility	I
complex	I
class	I
I	I
molecules	O
,	O
allowing	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
to	O
recognize	O
aberrant	O
cells	O
that	O
have	O
down	O
-	O
regulated	O
class	O
I	O
.	O

NK	O
cells	O
express	O
variable	O
numbers	O
and	O
combinations	O
of	O
highly	O
homologous	O
clonally	O
restricted	O
KIR	B
genes	O
,	O
but	O
uniformly	O
express	O
KIR2DL4	B
.	O

We	O
show	O
that	O
NK	O
clones	O
express	O
both	O
2DL4	B
alleles	O
and	O
either	O
one	O
or	O
both	O
alleles	O
of	O
the	O
clonally	O
restricted	O
KIR	B
3DL1	I
and	O
3DL2	B
genes	O
.	O

Despite	O
allele	O
-	O
independent	O
expression	O
,	O
3DL1	B
alleles	O
differed	O
in	O
the	O
core	O
promoter	O
by	O
only	O
one	O
or	O
two	O
nucleotides	O
.	O

Allele	O
-	O
specific	O
3DL1	B
gene	O
expression	O
correlated	O
with	O
promoter	O
and	O
5	O
'	O
gene	O
DNA	O
hypomethylation	O
in	O
NK	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
DNA	B
methylase	I
inhibitor	O
,	O
5-aza-2'-deoxycytidine	O
,	O
induced	O
KIR	B
DNA	O
hypomethylation	O
and	O
heterogeneous	O
expression	O
of	O
multiple	O
KIR	B
genes	O
.	O

Thus	O
,	O
NK	O
cells	O
use	O
DNA	O
methylation	O
to	O
maintain	O
clonally	O
restricted	O
expression	O
of	O
highly	O
homologous	O
KIR	B
genes	O
and	O
alleles	O
.	O

Apolipoprotein	B
B	I
in	O
cholesterol	O
-	O
containing	O
drusen	O
and	O
basal	O
deposits	O
of	O
human	O
eyes	O
with	O
age	O
-	O
related	O
maculopathy	O
.	O

Lipids	O
accumulate	O
in	O
Bruch	O
's	O
membrane	O
(	O
BrM	O
)	O
,	O
a	O
specialized	O
vascular	O
intima	O
of	O
the	O
eye	O
,	O
and	O
in	O
extracellular	O
lesions	O
associated	O
with	O
aging	O
and	O
age	O
-	O
related	O
maculopathy	O
(	O
ARM	O
)	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
ARM	O
and	O
atherosclerotic	O
cardiovascular	O
disease	O
share	O
molecules	O
and	O
mechanisms	O
pertaining	O
to	O
extracellular	O
lipid	O
accumulation	O
by	O
localizing	O
cholesterol	O
and	O
apolipoprotein	B
B	I
(	O
apo	B
B	I
)	O
in	O
BrM	O
,	O
basal	O
deposits	O
,	O
and	O
drusen	O
.	O

Human	O
donor	O
eyes	O
were	O
preserved	O
<	O
4	O
hours	O
postmortem	O
and	O
cryosectioned	O
.	O

Sections	O
were	O
stained	O
with	O
traditional	O
lipid	O
stains	O
and	O
filipin	O
for	O
esterified	O
and	O
unesterified	O
cholesterol	O
or	O
probed	O
with	O
antibodies	O
to	O
apo	B
B	I
,	O
apo	B
E	I
,	O
and	O
apo	B
C	I
-	I
III	I
.	O

Normal	O
adult	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
was	O
subjected	O
to	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
for	O
apolipoprotein	B
mRNA	O
and	O
protein	O
.	O

Esterified	O
and	O
unesterified	O
cholesterol	O
was	O
present	O
in	O
all	O
drusen	O
and	O
basal	O
deposits	O
of	O
ARM	O
and	O
normal	O
eyes	O
.	O

Both	O
apo	B
B	I
and	O
apo	B
E	I
but	O
not	O
apo	B
C	I
-	I
III	I
were	O
found	O
in	O
BrM	O
,	O
drusen	O
,	O
and	O
basal	O
deposits	O
.	O

Fewer	O
macular	O
drusen	O
were	O
stained	O
by	O
traditional	O
lipid	O
stains	O
and	O
apolipoprotein	B
antibodies	O
than	O
peripheral	O
drusen	O
.	O

RPE	O
contained	O
apo	B
B	I
and	O
apo	B
E	I
mRNA	O
and	O
protein	O
.	O

Finding	O
cholesterol	O
and	O
apo	B
B	I
in	O
sub	O
-	O
RPE	O
deposits	O
links	O
ARM	O
with	O
important	O
molecules	O
and	O
mechanisms	O
in	O
atherosclerosis	O
initiation	O
and	O
progression	O
.	O

The	O
combination	O
of	O
apo	B
B	I
mRNA	O
and	O
protein	O
in	O
RPE	O
raises	O
the	O
possibility	O
that	O
intraocular	O
assembly	O
of	O
apo	B
B	I
-	O
containing	O
lipoproteins	O
is	O
a	O
pathway	O
involved	O
in	O
forming	O
cholesterol	O
-	O
enriched	O
lesions	O
in	O
ARM	O
.	O

Enhanced	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
activity	O
in	O
stress	O
adaptation	O
in	O
the	O
guinea	O
pig	O
.	O

The	O
11beta	B
-	I
hydroxysteroid	I
dehydrogenases	I
(	O
11beta	B
-	I
HSDs	I
)	O
convert	O
cortisol	O
to	O
its	O
inactive	O
metabolite	O
cortisone	O
and	O
vice	O
versa	O
.	O

11beta	B
-	I
HSD	I
type	I
1	I
(	O
11beta	B
-	I
HSD-1	I
)	O
functions	O
as	O
a	O
reductase	B
in	O
vivo	O
,	O
regulating	O
intracellular	O
cortisol	O
levels	O
and	O
its	O
access	O
to	O
the	O
glucocorticoid	B
receptor	I
.	O

In	O
contrast	O
,	O
11beta	B
-	I
HSD-2	I
only	O
mediates	O
oxidation	O
of	O
natural	O
glucocorticoids	O
,	O
and	O
protects	O
the	O
mineralocorticoid	B
receptor	I
from	O
high	O
cortisol	O
concentrations	O
.	O

We	O
investigated	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
ACTH	B
on	O
the	O
recently	O
characterized	O
11beta	B
-	I
HSDs	I
in	O
guinea	O
pig	O
liver	O
and	O
kidney	O
.	O

Tissue	O
slices	O
of	O
untreated	O
guinea	O
pigs	O
were	O
incubated	O
with	O
(	O
3	O
)	O
H	O
-	O
labelled	O
cortisol	O
or	O
cortisone	O
and	O
ACTH	B
(	I
1	I
-	I
24	I
)	I
(	O
10	O
(	O
-10	O
)	O
and	O
10	O
(	O
-9	O
)	O
mol	O
/	O
l	O
)	O
.	O

The	O
11beta	B
-	I
HSD	I
activities	O
in	O
liver	O
and	O
kidney	O
slices	O
were	O
not	O
influenced	O
by	O
in	O
vitro	O
incubation	O
with	O
ACTH	B
(	I
1	I
-	I
24	I
)	I
.	O

In	O
addition	O
,	O
guinea	O
pigs	O
were	O
treated	O
with	O
ACTH	B
(	I
1	I
-	I
24	I
)	O
or	O
saline	O
injections	O
s.c	O
.	O
for	O
3	O
days	O
.	O

Liver	O
and	O
kidney	O
tissue	O
slices	O
of	O
these	O
animals	O
were	O
incubated	O
with	O
(	O
3	O
)	O
H	O
-	O
labelled	O
cortisol	O
or	O
cortisone	O
.	O

In	O
vivo	O
ACTH	B
treatment	O
significantly	O
increased	O
reductase	B
and	O
decreased	O
oxidase	B
activity	O
in	O
liver	O
and	O
kidney	O
.	O

Furthermore	O
,	O
11beta	B
-	I
HSD-1	I
activity	O
assessed	O
by	O
measurement	O
of	O
the	O
urinary	O
ratio	O
of	O
(	O
tetrahydrocortisol	O
(	O
THF	O
)	O
+	O
5alphaTHF	O
)	O
/	O
(	O
tetrahydrocortisone	O
)	O
was	O
significantly	O
increased	O
after	O
ACTH	B
treatment	O
compared	O
with	O
the	O
control	O
group	O
.	O

Plasma	O
levels	O
of	O
cortisol	O
,	O
cortisone	O
,	O
progesterone	O
,	O
17-hydroxyprogesterone	O
and	O
androstenedione	O
increased	O
significantly	O
following	O
in	O
vivo	O
ACTH	B
treatment	O
.	O

The	O
enhanced	O
reductase	B
activity	O
of	O
the	O
hepatic	O
and	O
renal	O
11beta	B
-	I
HSD-1	I
is	O
apparently	O
caused	O
by	O
cortisol	O
or	O
other	O
ACTH	B
-	O
dependent	O
steroids	O
rather	O
than	O
by	O
ACTH	B
itself	O
.	O

This	O
may	O
be	O
an	O
important	O
fine	O
regulation	O
of	O
the	O
glucocorticoid	O
tonus	O
for	O
stress	O
adaptation	O
in	O
every	O
organ	O
,	O
e.g.	O
enhanced	O
gluconeogenesis	O
in	O
liver	O
.	O

Assessment	O
of	O
killer	B
cell	I
immunoglobulinlike	I
receptor	I
expression	O
and	O
corresponding	O
HLA	B
class	I
I	I
phenotypes	O
demonstrates	O
heterogenous	O
KIR	B
expression	O
independent	O
of	O
anticipated	O
HLA	B
class	I
I	I
ligands	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cell	O
-	O
mediated	O
cytolysis	O
is	O
stimulated	O
and	O
downregulated	O
through	O
the	O
interaction	O
of	O
distinct	O
human	B
leukocyte	I
antigen	I
(	I
HLA	I
)	I
class	I
I	I
molecules	O
on	O
target	O
cells	O
with	O
specific	O
killer	B
cell	I
immunoglobulinlike	I
receptors	I
(	O
KIRs	B
)	O
on	O
NK	O
cells	O
.	O

Killer	B
cell	I
immunoglobulinlike	I
receptors	I
are	O
highly	O
polymorphic	O
and	O
are	O
clonally	O
distributed	O
on	O
NK	O
cell	O
populations	O
within	O
individuals	O
.	O

However	O
,	O
the	O
regulation	O
of	O
KIR	B
expression	O
by	O
individual	O
HLA	B
class	I
I	I
phenotypes	O
is	O
not	O
well	O
understood	O
.	O

To	O
examine	O
a	O
potential	O
influence	O
of	O
the	O
HLA	B
class	I
I	I
phenotype	O
on	O
KIR	B
expression	O
patterns	O
we	O
studied	O
the	O
KIR	B
expression	O
in	O
individuals	O
that	O
were	O
subgrouped	O
according	O
to	O
the	O
major	O
HLA	B
-	I
C	I
encoded	O
KIR	B
-	O
epitopes	O
(	O
group	O
C1	O
versus	O
C2	O
)	O
.	O

In	O
these	O
individuals	O
,	O
NK	O
cells	O
were	O
analyzed	O
for	O
KIR	B
expression	O
using	O
flow	O
cytometry	O
and	O
RNA	O
-	O
based	O
expression	O
analysis	O
.	O

Our	O
results	O
demonstrate	O
that	O
KIR	B
genes	O
are	O
transmitted	O
very	O
heterogeneously	O
with	O
two	O
main	O
patterns	O
of	O
KIR	B
genotypes	O
as	O
previously	O
described	O
;	O
group	O
A	O
and	O
group	O
B	O
(	O
with	O
21	O
different	O
genotypes	O
)	O
.	O

There	O
are	O
distinct	O
populations	O
exhibiting	O
different	O
densities	O
of	O
CD158a	B
and/or	O
CD158b	B
positive	O
NK	O
cells	O
that	O
coexist	O
in	O
all	O
individuals	O
.	O

A	O
clear	O
correlation	O
between	O
KIR	B
expression	O
and	O
the	O
currently	O
known	O
HLA	B
class	I
I	I
ligands	O
was	O
not	O
observed	O
.	O

In	O
conclusion	O
,	O
the	O
surface	O
expression	O
of	O
KIRs	B
in	O
individuals	O
with	O
different	O
HLA	B
class	I
I	I
genotypes	O
indicates	O
that	O
other	O
non	O
-	O
HLA	B
class	I
I	I
encoded	O
factors	O
contribute	O
to	O
the	O
shaping	O
of	O
the	O
KIR	B
repertoire	O
.	O

Furin	B
processing	O
and	O
proteolytic	O
activation	O
of	O
Semliki	O
Forest	O
virus	O
.	O

The	O
alphavirus	O
Semliki	O
Forest	O
virus	O
(	O
SFV	O
)	O
infects	O
cells	O
via	O
a	O
low	O
-	O
pH	O
-	O
dependent	O
membrane	O
fusion	O
reaction	O
mediated	O
by	O
the	O
E1	B
envelope	I
protein	I
.	O

Fusion	O
is	O
regulated	O
by	O
the	O
interaction	O
of	O
E1	B
with	O
the	O
receptor	O
-	O
binding	O
protein	O
E2	B
.	O

E2	B
is	O
synthesized	O
as	O
a	O
precursor	O
termed	O
""""	O
p62	B
,	O
""""	O
which	O
forms	O
a	O
stable	O
heterodimer	O
with	O
E1	B
and	O
is	O
processed	O
late	O
in	O
the	O
secretory	O
pathway	O
by	O
a	O
cellular	O
furin	B
-	O
like	O
protease	B
.	O

Once	O
processing	O
to	O
E2	B
occurs	O
,	O
the	O
E1	B
/	O
E2	B
heterodimer	O
is	O
destabilized	O
so	O
that	O
it	O
is	O
more	O
readily	O
dissociated	O
by	O
exposure	O
to	O
low	O
pH	O
,	O
allowing	O
fusion	O
and	O
infection	O
.	O

We	O
have	O
used	O
FD11	O
cells	O
,	O
a	O
furin	B
-	O
deficient	O
CHO	O
cell	O
line	O
,	O
to	O
characterize	O
the	O
processing	O
of	O
p62	B
and	O
its	O
role	O
in	O
the	O
control	O
of	O
virus	O
fusion	O
and	O
infection	O
.	O

p62	B
was	O
not	O
cleaved	O
in	O
FD11	O
cells	O
and	O
cleavage	O
was	O
restored	O
in	O
FD11	O
cell	O
transfectants	O
expressing	O
human	O
furin	B
.	O

Studies	O
of	O
unprocessed	O
virus	O
produced	O
in	O
FD11	O
cells	O
(	O
wt	O
/	O
p62	B
)	O
demonstrated	O
that	O
the	O
p62	B
protein	O
was	O
efficiently	O
cleaved	O
by	O
purified	O
furin	B
in	O
vitro	O
,	O
without	O
requiring	O
prior	O
exposure	O
to	O
low	O
pH	O
.	O

wt	O
/	O
p62	B
virus	O
particles	O
were	O
also	O
processed	O
during	O
their	O
endocytic	O
uptake	O
in	O
furin	B
-	O
containing	O
cells	O
,	O
resulting	O
in	O
more	O
efficient	O
virus	O
infection	O
.	O

wt	O
/	O
p62	B
virus	O
was	O
compared	O
with	O
mutant	O
L	O
,	O
in	O
which	O
p62	B
cleavage	O
was	O
blocked	O
by	O
mutation	O
of	O
the	O
furin	B
-	O
recognition	O
motif	O
.	O

wt	O
/	O
p62	B
and	O
mutant	O
L	O
had	O
similar	O
fusion	O
properties	O
,	O
requiring	O
a	O
much	O
lower	O
pH	O
than	O
control	O
virus	O
to	O
trigger	O
fusion	O
and	O
fusogenic	O
E1	B
conformational	O
changes	O
.	O

However	O
,	O
the	O
in	O
vivo	O
infectivity	O
of	O
mutant	O
L	O
was	O
more	O
strongly	O
inhibited	O
than	O
that	O
of	O
wt	O
/	O
p62	B
,	O
due	O
to	O
additional	O
effects	O
of	O
the	O
mutation	O
on	O
virus	O
-	O
cell	O
binding	O
.	O

Synergism	O
between	O
nuclear	B
receptors	I
bound	O
to	O
specific	O
hormone	O
response	O
elements	O
of	O
the	O
hepatic	O
control	O
region-1	O
and	O
the	O
proximal	O
apolipoprotein	B
C	I
-	I
II	I
promoter	O
mediate	O
apolipoprotein	B
C	I
-	I
II	I
gene	O
regulation	O
by	O
bile	O
acids	O
and	O
retinoids	O
.	O

We	O
have	O
shown	O
previously	O
that	O
the	O
hepatic	O
control	O
region	O
1	O
(	O
HCR-1	O
)	O
enhances	O
the	O
activity	O
of	O
the	O
human	O
apolipoprotein	B
C	I
-	I
II	I
(	O
apoC	B
-	I
II	I
)	O
promoter	O
in	O
HepG2	O
cells	O
via	O
two	O
hormone	O
response	O
elements	O
(	O
HREs	O
)	O
present	O
in	O
the	O
apoC	B
-	I
II	I
promoter	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
report	O
that	O
the	O
HCR-1	O
selectively	O
mediates	O
the	O
transactivation	O
of	O
the	O
apoC	B
-	I
II	I
promoter	O
by	O
chenodeoxycholic	O
acid	O
(	O
CDCA	O
)	O
and	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
.	O

CDCA	O
,	O
which	O
is	O
a	O
natural	O
ligand	O
of	O
farnesoid	B
X	I
receptor	I
alpha	I
(	O
FXRalpha	B
)	O
,	O
increases	O
the	O
steady	O
-	O
state	O
apoC	B
-	I
II	I
mRNA	O
levels	O
in	O
HepG2	O
cells	O
.	O

This	O
increase	O
in	O
transcription	O
requires	O
the	O
binding	O
of	O
retinoid	B
X	I
receptor	I
alpha	I
(	O
RXRalpha	B
)	O
-	O
FXRalpha	B
heterodimers	O
to	O
a	O
novel	O
inverted	O
repeat	O
with	O
one	O
nucleotide	O
spacing	O
(	O
IR-1	O
)	O
present	O
in	O
the	O
HCR-1	O
.	O

This	O
element	O
also	O
binds	O
hepatocyte	B
nuclear	I
factor	I
4	I
and	O
apoA	B
-	I
I	I
regulatory	I
protein-1	I
.	O

Transactivation	O
of	O
the	O
HCR-1	O
/	O
apoC	B
-	I
II	I
promoter	O
cluster	O
by	O
RXRalpha	B
-	O
FXRalpha	B
heterodimers	O
in	O
the	O
presence	O
of	O
CDCA	O
was	O
abolished	O
by	O
mutations	O
either	O
in	O
the	O
IR-1	O
HRE	O
of	O
the	O
HCR-1	O
or	O
in	O
the	O
thyroid	O
HRE	O
of	O
the	O
proximal	O
apoC	B
-	I
II	I
promoter	O
,	O
which	O
binds	O
RXRalpha	B
-	O
thyroid	B
hormone	I
receptor	I
beta	I
(	O
T3Rbeta	B
)	O
heterodimers	O
.	O

The	O
same	O
mutations	O
also	O
abolished	O
transactivation	O
of	O
the	O
HCR-1	O
/	O
apoC	B
-	I
II	I
promoter	O
cluster	O
by	O
RXRalpha	B
-	O
T3Rbeta	B
heterodimers	O
in	O
the	O
presence	O
of	O
tri	O
-	O
iodothyronine	O
.	O

The	O
findings	O
establish	O
synergism	O
between	O
nuclear	B
receptors	I
bound	O
to	O
specific	O
HREs	O
of	O
the	O
proximal	O
apoC	B
-	I
II	I
promoter	O
and	O
the	O
HCR-1	O
,	O
and	O
suggest	O
that	O
this	O
synergism	O
mediates	O
the	O
induction	O
of	O
the	O
HCR-1	O
/	O
apoC	B
-	I
II	I
promoter	O
cluster	O
by	O
bile	O
acids	O
and	O
retinoids	O
.	O

Oestradiol	O
-	O
dependent	O
and	O
-	O
independent	O
modulation	O
of	O
tyrosine	B
hydroxylase	I
mRNA	O
levels	O
in	O
subpopulations	O
of	O
A1	O
and	O
A2	O
neurones	O
with	O
oestrogen	B
receptor	I
(	I
ER	I
)	I
alpha	I
and	O
ER	B
beta	I
gene	O
expression	O
.	O

Oestradiol	O
(	O
E2	O
)	O
induces	O
luteinizing	B
hormone	I
-	I
releasing	I
hormone	I
(	O
LHRH	B
)	O
hypersecretion	O
,	O
thereby	O
triggering	O
LH	B
surge	O
release	O
in	O
ovariectomized	O
(	O
OVX	O
)	O
rats	O
.	O

Neural	O
signals	O
responsible	O
for	O
the	O
surge	O
are	O
marked	O
by	O
a	O
morning	O
increase	O
in	O
LHRH	B
gene	O
expression	O
and	O
an	O
afternoon	O
increase	O
in	O
LHRH	B
release	O
.	O

Evidence	O
suggests	O
that	O
subpopulations	O
of	O
noradrenergic	O
neurones	O
may	O
be	O
responsible	O
for	O
one	O
or	O
both	O
of	O
these	O
signals	O
.	O

To	O
further	O
investigate	O
this	O
issue	O
,	O
we	O
examined	O
effects	O
of	O
E2	O
on	O
the	O
activity	O
of	O
A1	O
and	O
A2	O
noradrenergic	O
neurones	O
,	O
as	O
reflected	O
in	O
changes	O
in	O
tyrosine	B
hydroxylase	I
(	O
TH	B
)	O
mRNA	O
expression	O
,	O
on	O
the	O
day	O
of	O
LH	B
surge	O
release	O
.	O

We	O
then	O
used	O
dual	O
-	O
label	O
in	O
situ	O
hybridization	O
to	O
determine	O
whether	O
E2	O
-	O
induced	O
changes	O
occurred	O
primarily	O
in	O
A1	O
and	O
A2	O
subdivisions	O
wherein	O
most	O
noradrenergic	O
neurones	O
expressed	O
oestrogen	B
receptor	I
(	I
ER	I
)	I
alpha	I
and/or	O
ER	B
beta	I
mRNA	O
.	O

We	O
found	O
that	O
in	O
all	O
subdivisions	O
,	O
levels	O
of	O
TH	B
mRNA	O
were	O
higher	O
in	O
E2	O
-	O
than	O
oil	O
-	O
treated	O
rats	O
at	O
12.00	O
h	O
.	O

These	O
differences	O
resulted	O
from	O
a	O
decline	O
in	O
TH	B
mRNA	O
expression	O
in	O
oil	O
-	O
treated	O
rats	O
,	O
as	O
well	O
as	O
a	O
rise	O
in	O
levels	O
in	O
E2	O
-	O
treated	O
rats	O
between	O
10.00	O
h	O
and	O
12.00	O
h	O
.	O

During	O
the	O
afternoon	O
,	O
TH	B
mRNA	O
expression	O
in	O
most	O
A1	O
and	O
A2	O
subdivisions	O
peaked	O
at	O
14.00	O
h	O
when	O
LH	B
surge	O
release	O
began	O
.	O

However	O
,	O
in	O
all	O
but	O
the	O
middle	O
and	O
caudal	O
A2	O
subdivisons	O
,	O
levels	O
were	O
similar	O
in	O
E2	O
-	O
treated	O
and	O
control	O
rats	O
at	O
this	O
time	O
.	O

This	O
was	O
attributable	O
to	O
a	O
widespread	O
increase	O
in	O
TH	B
mRNA	O
expression	O
between	O
12.00	O
h	O
and	O
14.00	O
h	O
in	O
OVX	O
rats	O
.	O

There	O
was	O
no	O
evidence	O
that	O
E2	O
induced	O
changes	O
in	O
TH	B
mRNA	O
expression	O
preferentially	O
in	O
regions	O
wherein	O
most	O
neurones	O
contained	O
ER	B
alpha	I
or	O
ER	B
beta	I
mRNA	O
.	O

Our	O
findings	O
suggest	O
that	O
E2	O
activation	O
of	O
middle	O
and	O
caudal	O
A2	O
neurones	O
,	O
in	O
conjunction	O
with	O
the	O
widespread	O
E2	O
-	O
independent	O
activation	O
of	O
noradrenergic	O
neurones	O
in	O
other	O
subdivisions	O
,	O
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
LH	B
surge	O
release	O
.	O

Cutting	O
edge	O
:	O
molecular	O
cloning	O
of	O
a	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
in	O
the	O
mouse	O
and	O
rat	O
.	O

We	O
report	O
the	O
molecular	O
cloning	O
of	O
a	O
KIR3DL1	B
receptor	O
in	O
the	O
mouse	O
and	O
the	O
rat	O
,	O
between	O
37.4	O
and	O
45.4	O
%	O
identical	O
with	O
primate	O
killer	B
cell	I
Ig	I
-	I
like	I
receptors	I
(	O
KIRs	B
/	O
CD158	B
)	O
.	O

Both	O
mouse	O
and	O
rat	O
molecules	O
contain	O
a	O
pair	O
of	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motifs	O
in	O
their	O
cytoplasmic	O
regions	O
,	O
suggesting	O
an	O
inhibitory	O
function	O
.	O

Southern	O
blot	O
analysis	O
indicated	O
a	O
single	O
KIR	B
gene	O
in	O
the	O
rat	O
,	O
whereas	O
the	O
mouse	O
genome	O
contains	O
more	O
than	O
one	O
KIR	B
-	O
related	O
element	O
.	O

The	O
rat	O
Kir3dl1	B
locus	O
was	O
mapped	O
to	O
the	O
leukocyte	O
receptor	O
gene	O
complex	O
on	O
chromosome	O
1	O
,	O
whereas	O
mouse	O
Kir3dl1	B
was	O
localized	O
to	O
the	O
X	O
chromosome	O
.	O

RT	O
-	O
PCR	O
demonstrated	O
that	O
KIR3DL1	B
was	O
selectively	O
expressed	O
by	O
NK	O
cells	O
in	O
both	O
rat	O
and	O
mouse	O
.	O

An	O
epitope	O
-	O
tagged	O
expression	O
construct	O
of	O
mouse	O
KIR3DL1	B
transfected	O
into	O
293	O
T	O
cells	O
induced	O
expression	O
of	O
a	O
approximately	O
55	O
-	O
kDa	O
protein	O
.	O

Our	O
data	O
indicate	O
that	O
KIR	B
receptors	O
may	O
contribute	O
to	O
the	O
NK	O
cell	O
receptor	O
repertoire	O
in	O
rodents	O
,	O
alongside	O
the	O
Ly-49	B
family	I
.	O

Influence	O
of	O
interleukin-12	B
receptor	I
beta1	I
polymorphisms	O
on	O
tuberculosis	O
.	O

Host	O
genetic	O
factors	O
may	O
be	O
important	O
determinants	O
of	O
susceptibility	O
to	O
tuberculosis	O
,	O
and	O
several	O
candidate	O
gene	O
polymorphisms	O
have	O
been	O
shown	O
to	O
date	O
.	O

A	O
series	O
of	O
recent	O
reports	O
concerning	O
rare	O
human	O
deficiencies	O
in	O
the	O
type-1	O
cytokine	B
pathway	O
suggest	O
that	O
more	O
subtle	O
variants	O
of	O
relevant	O
genes	O
may	O
also	O
contribute	O
to	O
susceptibility	O
to	O
tuberculosis	O
at	O
the	O
general	O
population	O
level	O
.	O

To	O
investigate	O
whether	O
polymorphisms	O
in	O
the	O
interleukin-12	B
receptor	I
(	O
IL-12R	B
)	O
gene	O
predispose	O
individuals	O
to	O
tuberculosis	O
,	O
we	O
studied	O
these	O
genes	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Although	O
no	O
common	O
polymorphisms	O
could	O
be	O
identified	O
in	O
the	O
IL-12R	B
beta	I
2	I
gene	O
(	O
IL-12RB2	B
)	O
,	O
we	O
confirmed	O
four	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
;	O
641A	O
--	O
>	O
G	O
,	O
684C	O
--	O
>	O
T	O
,	O
1094	O
T	O
--	O
>	O
C	O
,	O
and	O
1132	O
G	O
--	O
>	O
C	O
)	O
causing	O
three	O
missense	O
variants	O
(	O
Q214R	O
,	O
M365	O
T	O
,	O
G378R	O
)	O
and	O
one	O
synonymous	O
substitution	O
in	O
the	O
extracellular	O
domain	O
of	O
the	O
IL-12R	B
beta	I
1	I
gene	O
(	O
IL12RB1	B
)	O
.	O

All	O
SNPs	O
were	O
in	O
almost	O
perfect	O
linkage	O
disequilibrium	O
(	O
D'=	O
0.98	O
)	O
,	O
and	O
two	O
common	O
haplotypes	O
of	O
IL12RB1	B
(	O
allele	O
1	O
:	O
Q214-M365	O
-	O
G378	O
;	O
allele	O
2	O
:	O
R214	O
-	O
T365	O
-	O
R378	O
)	O
were	O
revealed	O
.	O

Polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
sequence	O
analyses	O
were	O
used	O
to	O
type	O
IL12RB1polymorphisms	B
in	O
98	O
patients	O
with	O
tuberculosis	O
and	O
197	O
healthy	O
controls	O
in	O
Japanese	O
populations	O
.	O

In	O
our	O
case	O
-	O
control	O
association	O
study	O
of	O
tuberculosis	O
,	O
the	O
R214	O
-	O
T365	O
-	O
R378	O
allele	O
(	O
allele	O
2	O
)	O
was	O
over	O
-	O
represented	O
in	O
patients	O
with	O
tuberculosis	O
,	O
and	O
homozygosity	O
for	O
R214	O
-	O
T365	O
-	O
R378	O
(	O
the	O
2	O
/	O
2	O
genotype	O
)	O
was	O
significantly	O
associated	O
with	O
tuberculosis	O
(	O
odds	O
ratio	O
:	O
2.45	O
;	O
95	O
%	O
CI	O
:	O
1.20	O
-	O
4.99	O
;	O
P	O
=	O
0.013	O
)	O
.	O

In	O
healthy	O
subjects	O
,	O
homozygotes	O
for	O
R214	O
-	O
T365	O
-	O
R378	O
had	O
lower	O
levels	O
of	O
IL-12	B
-	O
induced	O
signaling	O
,	O
according	O
to	O
differences	O
in	O
cellular	O
responses	O
to	O
IL-12	B
between	O
two	O
haplotypes	O
.	O

These	O
data	O
suggest	O
that	O
the	O
R214	O
-	O
T365	O
-	O
R378	O
allele	O
,	O
i.e.	O
,	O
variation	O
in	O
IL12RB1	B
,	O
contribute	O
to	O
tuberculosis	O
susceptibility	O
in	O
the	O
Japanese	O
population	O
.	O

This	O
genetic	O
variation	O
may	O
predispose	O
individuals	O
to	O
tuberculosis	O
infection	O
by	O
diminishing	O
receptor	O
responsiveness	O
to	O
IL-12	B
and	O
to	O
IL-23	B
,	O
leading	O
to	O
partial	O
dysfunction	O
of	O
interferon	B
-	I
gamma	I
-	O
mediated	O
immunity	O
.	O

[	O
Variation	O
of	O
gene	O
at	O
the	O
apolipoprotein	B
C	I
III	I
locus	O
with	O
the	O
changes	O
of	O
serum	O
lipid	O
profile	O
in	O
school	O
-	O
aged	O
children	O
]	O

The	O
variation	O
of	O
gene	O
at	O
the	O
apolipoprotein	B
C	I
III	I
locus	O
with	O
the	O
changes	O
of	O
serum	O
lipids	O
in	O
children	O
was	O
studied	O
.	O

Blood	O
samples	O
were	O
collected	O
from	O
308	O
normal	O
children	O
aged	O
7	O
-	O
11	O
year	O
-	O
old	O
,	O
including	O
of	O
151	O
boys	O
and	O
157	O
girls	O
.	O

The	O
levels	O
of	O
serum	O
lipids	O
profile	O
,	O
including	O
TC	O
,	O
TG	O
,	O
LDL	B
-	O
C	O
,	O
HDL	B
-	O
C	O
,	O
apoB	B
,	O
apoA	B
I	I
and	O
Lp	B
(	I
a	I
)	I
were	O
detected	O
.	O

The	O
genome	O
DNA	O
was	O
extracted	O
from	O
blood	O
clot	O
,	O
then	O
ApoB	B
-	O
Xba	B
I	I
gene	O
polymorphism	O
were	O
tested	O
by	O
the	O
PCR	O
-	O
RFLP	O
method	O
.	O

The	O
frequency	O
of	O
ApoC	B
III	I
-	O
Sac	B
I	I
heterozygote	O
(	O
+	O
/-	O
)	O
was	O
48.7	O
%	O
,	O
homozygote	O
(	O
+	O
/+	O
)	O
was	O
7.5	O
%	O
,	O
and	O
allele	O
(	O
+	O
)	O
was	O
31.8	O
%	O
of	O
the	O
308	O
children	O
.	O

The	O
frequency	O
of	O
allele	O
(	O
+	O
)	O
was	O
more	O
than	O
the	O
reports	O
in	O
Shanghai	O
(	O
12	O
%	O
)	O
and	O
Guassian	O
(	O
6	O
%	O
)	O
,	O
and	O
closed	O
to	O
the	O
Japanese	O
(	O
34	O
%	O
)	O
.	O

The	O
results	O
showed	O
a	O
population	O
and	O
ethnic	O
difference	O
in	O
the	O
inheritance	O
variation	O
.	O

Comparing	O
the	O
serum	O
lipids	O
levels	O
among	O
different	O
genotypes	O
,	O
the	O
average	O
TG	O
levels	O
of	O
homozygotes	O
(	O
+	O
/+	O
)	O
were	O
more	O
than	O
wildtype	O
(	O
-	O
/	O
+	O
)	O
(	O
1.06	O
mmol	O
/	O
L	O
vs	O
0.85	O
mmol	O
/	O
L	O
,	O
P	O
<	O
0.05	O
)	O
.	O

The	O
frequency	O
of	O
(	O
+	O
/	O
+	O
)	O
genotype	O
in	O
hypertriglyceridemia	O
group	O
was	O
more	O
than	O
control	O
group	O
(	O
30.0	O
%	O
vs	O
6.7	O
%	O
,	O
P	O
<	O
0.05	O
)	O
;	O
The	O
allele	O
(	O
+	O
)	O
could	O
increase	O
the	O
TG	O
level	O
of	O
0.031	O
mmol	O
/	O
L	O
.	O

It	O
suggested	O
that	O
the	O
variation	O
of	O
Apolipoprotein	B
C	I
III	I
-	O
Sac	B
I	I
locus	O
was	O
correlated	O
with	O
the	O
TG	O
level	O
in	O
children	O
.	O

TGFbeta	B
-	I
induced	I
factor	I
:	O
a	O
candidate	O
gene	O
for	O
high	O
myopia	O
.	O

PURPOSE	O
:	O

To	O
investigate	O
the	O
coding	O
exons	O
of	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
beta	I
-	I
induced	I
factor	I
(	O
TGIF	B
)	O
for	O
mutations	O
in	O
Chinese	O
patients	O
with	O
high	O
myopia	O
.	O

METHODS	O
:	O

Seventy	O
-	O
one	O
individuals	O
with	O
high	O
myopia	O
of	O
-	O
6.00	O
D	O
or	O
less	O
and	O
105	O
control	O
subjects	O
were	O
screened	O
by	O
DNA	O
sequencing	O
for	O
sequence	O
alterations	O
.	O

Univariate	O
analysis	O
and	O
logistic	O
regression	O
were	O
performed	O
to	O
identify	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
their	O
interactions	O
in	O
TGIF	B
that	O
may	O
be	O
associated	O
with	O
myopia	O
.	O

RESULTS	O
:	O

Six	O
SNPs	O
showed	O
a	O
significant	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
between	O
patient	O
and	O
control	O
subject	O
in	O
univariate	O
analysis	O
.	O

Four	O
of	O
them	O
cause	O
codon	O
changes	O
:	O
G223R	O
,	O
G231S	O
,	O
P241	O
T	O
,	O
and	O
A262	O
G	O
.	O

Among	O
all	O
the	O
SNPs	O
that	O
entered	O
multivariate	O
analysis	O
,	O
only	O
657	O
(	O
T--	O
>	O
G	O
)	O
showed	O
statistical	O
significance	O
in	O
the	O
logistic	O
regression	O
model	O
(	O
odds	O
ratio	O
0.133	O
;	O
95	O
%	O
confidence	O
interval	O
0.037	O
-	O
0.488	O
;	O
P	O
=	O
0.002	O
)	O
.	O

CONCLUSIONS	O
:	O

TGIF	B
is	O
a	O
probable	O
candidate	O
gene	O
for	O
high	O
myopia	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
underlying	O
mechanism	O
.	O

Transcriptional	O
activation	O
of	O
BMP-4	B
and	O
regulation	O
of	O
mammalian	O
organogenesis	O
by	O
GATA-4	B
and	I
-	I
6	I
.	O

Transcription	B
factors	I
GATA-4	B
,	I
-	I
5	I
,	I
and	I
-	I
6	I
constitute	O
an	O
evolutionary	O
conserved	O
subfamily	O
of	O
vertebrate	O
zinc	O
finger	O
regulators	O
highly	O
expressed	O
in	O
the	O
developing	O
heart	O
and	O
gut	O
.	O

Genetic	O
evidence	O
suggests	O
that	O
each	O
protein	O
is	O
essential	O
for	O
embryonic	O
development	O
,	O
but	O
their	O
exact	O
functions	O
are	O
not	O
fully	O
elucidated	O
.	O

Moreover	O
,	O
because	O
all	O
three	O
proteins	O
share	O
similar	O
transcriptional	O
properties	O
in	O
vitro	O
,	O
and	O
because	O
transcripts	O
for	O
two	O
or	O
more	O
GATA	B
genes	O
are	O
present	O
in	O
similar	O
tissues	O
,	O
the	O
molecular	O
basis	O
underlying	O
in	O
vivo	O
specificity	O
of	O
GATA	B
factors	O
remains	O
undefined	O
.	O

Knowledge	O
of	O
the	O
exact	O
cell	O
types	O
expressing	O
each	O
protein	O
and	O
identification	O
of	O
downstream	O
targets	O
would	O
greatly	O
help	O
define	O
their	O
function	O
.	O

We	O
have	O
used	O
high	O
-	O
resolution	O
immunohistochemistry	O
to	O
precisely	O
determine	O
the	O
cellular	O
distribution	O
of	O
the	O
GATA-4	B
,	I
-	I
5	I
,	I
and	I
-	I
6	I
proteins	O
in	O
murine	O
embryogenesis	O
.	O

The	O
results	O
reveal	O
novel	O
sites	O
of	O
expression	O
in	O
mesodermal	O
and	O
ectodermal	O
cells	O
.	O

In	O
particular	O
,	O
GATA-4	B
and	I
-	I
6	I
expression	O
was	O
closely	O
associated	O
with	O
yolk	O
sac	O
vasculogenesis	O
and	O
early	O
endoderm	O
-	O
mesoderm	O
signaling	O
.	O

Additionally	O
,	O
GATA-6	B
was	O
strongly	O
expressed	O
in	O
the	O
embryonic	O
ectoderm	O
,	O
neural	O
tube	O
,	O
and	O
neural	O
crest	O
-	O
derived	O
cells	O
.	O

This	O
pattern	O
of	O
expression	O
closely	O
paralled	O
that	O
of	O
BMP-4	B
,	O
and	O
the	O
BMP-4	B
gene	O
was	O
identified	O
as	O
a	O
direct	O
downstream	O
target	O
for	O
GATA-4	B
and	I
-	I
6	I
.	O

These	O
findings	O
offer	O
new	O
insight	O
into	O
the	O
function	O
of	O
GATA-4	B
and	I
-	I
6	I
during	O
early	O
stages	O
of	O
embryogenesis	O
and	O
reveal	O
the	O
existence	O
of	O
a	O
positive	O
cross	O
-	O
regulatory	O
loop	O
between	O
BMP-4	B
and	O
GATA-4	B
.	O

They	O
also	O
raise	O
the	O
possibility	O
that	O
part	O
of	O
the	O
early	O
defects	O
in	O
GATA-4	B
and/or	O
GATA-6	B
null	O
embryos	O
may	O
be	O
due	O
to	O
impaired	O
BMP-4	B
signaling	O
.	O

Differential	O
regulation	O
of	O
lipoprotein	O
kinetics	O
by	O
atorvastatin	O
and	O
fenofibrate	O
in	O
subjects	O
with	O
the	O
metabolic	O
syndrome	O
.	O

The	O
metabolic	O
syndrome	O
is	O
characterized	O
by	O
insulin	B
resistance	O
and	O
abnormal	O
apolipoprotein	B
AI	I
(	O
apoAI	B
)	O
and	O
apolipoprotein	B
B-100	I
(	O
apoB	B
)	O
metabolism	O
that	O
may	O
collectively	O
accelerate	O
atherosclerosis	O
.	O

The	O
effects	O
of	O
atorvastatin	O
(	O
40	O
mg	O
/	O
day	O
)	O
and	O
micronised	O
fenofibrate	O
(	O
200	O
mg	O
/	O
day	O
)	O
on	O
the	O
kinetics	O
of	O
apoAI	B
and	O
apoB	B
were	O
investigated	O
in	O
a	O
controlled	O
cross	O
-	O
over	O
trial	O
of	O
11	O
dyslipidemic	O
men	O
with	O
the	O
metabolic	O
syndrome	O
.	O

ApoAI	B
and	O
apoB	B
kinetics	O
were	O
studied	O
following	O
intravenous	O
d	O
(	O
3	O
)	O
-leucine	O
administration	O
using	O
gas	O
-	O
chromatography	O
mass	O
spectrometry	O
with	O
data	O
analyzed	O
by	O
compartmental	O
modeling	O
.	O

Compared	O
with	O
placebo	O
,	O
atorvastatin	O
significantly	O
decreased	O
(	O
P	O
<	O
0.001	O
)	O
plasma	O
concentrations	O
of	O
cholesterol	O
,	O
triglyceride	O
,	O
LDL	B
cholesterol	O
,	O
VLDL	B
apoB	B
,	O
intermediate	B
-	I
density	I
lipoprotein	I
(	O
IDL	B
)	O
apoB	B
,	O
and	O
LDL	B
apoB	B
.	O

Fenofibrate	O
significantly	O
decreased	O
(	O
P	O
<	O
0.001	O
)	O
plasma	O
triglyceride	O
and	O
VLDL	B
apoB	B
and	O
elevated	O
HDL	B
(	I
2	I
)	I
cholesterol	O
(	O
P	O
<	O
0.001	O
)	O
,	O
HDL	B
(	I
3	I
)	I
cholesterol	O
(	O
P	O
<	O
0.01	O
)	O
,	O
apoAI	B
(	O
P	O
=	O
0.01	O
)	O
,	O
and	O
apoAII	B
(	O
P	O
<	O
0.001	O
)	O
concentrations	O
,	O
but	O
it	O
did	O
not	O
significantly	O
alter	O
LDL	B
cholesterol	O
.	O

Atorvastatin	O
significantly	O
increased	O
(	O
P	O
<	O
0.002	O
)	O
the	O
fractional	O
catabolic	O
rate	O
(	O
FCR	O
)	O
of	O
VLDL	B
apoB	B
,	O
IDL	B
apoB	B
,	O
and	O
LDL	B
apoB	B
but	O
did	O
not	O
affect	O
the	O
production	O
of	O
apoB	B
in	O
any	O
lipoprotein	O
fraction	O
or	O
in	O
the	O
turnover	O
of	O
apoAI	B
.	O

Fenofibrate	O
significantly	O
increased	O
(	O
P	O
<	O
0.01	O
)	O
the	O
FCR	O
of	O
VLDL	B
,	O
IDL	B
,	O
and	O
LDL	B
apoB	B
but	O
did	O
not	O
affect	O
the	O
production	O
of	O
VLDL	B
apoB	B
.	O

Relative	O
to	O
placebo	O
and	O
atorvastatin	O
,	O
fenofibrate	O
significantly	O
increased	O
the	O
production	O
(	O
P	O
<	O
0.001	O
)	O
and	O
FCR	O
(	O
P	O
=	O
0.016	O
)	O
of	O
apoAI	B
.	O

Both	O
agents	O
significantly	O
lowered	O
plasma	O
triglycerides	O
and	O
apoCIII	B
concentrations	O
,	O
but	O
only	O
atorvastatin	O
significantly	O
lowered	O
(	O
P	O
<	O
0.001	O
)	O
plasma	O
cholesteryl	O
ester	O
transfer	O
protein	O
activity	O
.	O

Neither	O
treatment	O
altered	O
insulin	B
resistance	O
.	O

In	O
conclusion	O
,	O
these	O
differential	O
effects	O
of	O
atorvastatin	O
and	O
fenofibrate	O
on	O
apoAI	B
and	O
apoB	B
kinetics	O
support	O
the	O
use	O
of	O
combination	O
therapy	O
for	O
optimally	O
regulating	O
dyslipoproteinemia	O
in	O
the	O
metabolic	O
syndrome	O
.	O

Autosomal	O
dominant	O
macular	O
dystrophy	O
in	O
a	O
large	O
Canadian	O
family	O
.	O

BACKGROUND	O
:	O

We	O
studied	O
a	O
large	O
Canadian	O
family	O
(	O
178	O
total	O
family	O
members	O
)	O
spanning	O
seven	O
generations	O
with	O
autosomal	O
dominant	O
macular	O
dystrophy	O
.	O

We	O
performed	O
a	O
study	O
to	O
identify	O
the	O
gene	O
mutation	O
responsible	O
for	O
the	O
disease	O
in	O
the	O
family	O
.	O

METHODS	O
:	O

Participating	O
family	O
members	O
were	O
evaluated	O
clinically	O
.	O

Genetic	O
linkage	O
,	O
genotyping	O
,	O
mutation	O
screening	O
and	O
an	O
extensive	O
genealogic	O
investigation	O
were	O
performed	O
.	O

RESULTS	O
:	O

The	O
common	O
clinical	O
findings	O
in	O
affected	O
family	O
members	O
included	O
progressive	O
early	O
-	O
to	O
mid	O
-	O
onset	O
visual	O
loss	O
and	O
extensive	O
areas	O
of	O
central	O
chorioretinal	O
atrophy	O
.	O

Two	O
-	O
point	O
linkage	O
analysis	O
indicated	O
linkage	O
to	O
chromosome	O
6p	O
.	O

Direct	O
DNA	O
sequencing	O
showed	O
a	O
C	O
/	O
T	O
transition	O
in	O
codon	O
172	O
of	O
the	O
retinal	B
degeneration	I
slow	I
(	O
RDS	B
)	O
gene	O
creating	O
an	O
amino	O
acid	O
change	O
to	O
Arg172Trp	O
.	O

Haplotype	O
analysis	O
of	O
affected	O
family	O
members	O
using	O
microsatellite	O
markers	O
distributed	O
around	O
the	O
RDS	B
gene	O
locus	O
revealed	O
that	O
the	O
markers	O
were	O
not	O
conserved	O
when	O
compared	O
to	O
members	O
of	O
British	O
families	O
with	O
the	O
Arg172Trp	O
mutation	O
.	O

Genealogic	O
studies	O
indicated	O
the	O
family	O
immigrated	O
to	O
Canada	O
from	O
Ireland	O
in	O
1843	O
.	O

INTERPRETATION	O
:	O

A	O
newly	O
identified	O
large	O
family	O
with	O
autosomal	O
dominant	O
macular	O
dystrophy	O
is	O
described	O
.	O

The	O
phenotypic	O
appearance	O
of	O
the	O
fundus	O
is	O
similar	O
to	O
that	O
of	O
previously	O
described	O
patients	O
with	O
an	O
Arg172Trp	O
mutation	O
in	O
the	O
RDS	B
gene	O
.	O

Haplotype	O
analysis	O
of	O
markers	O
spanning	O
the	O
disease	O
locus	O
identified	O
a	O
new	O
founder	O
for	O
this	O
mutation	O
.	O

The	O
identification	O
of	O
the	O
disease	O
-	O
causing	O
gene	O
in	O
this	O
family	O
allows	O
for	O
better	O
genetic	O
counselling	O
for	O
patients	O
with	O
this	O
condition	O
and	O
provides	O
a	O
basis	O
to	O
distinguish	O
clinically	O
similar	O
types	O
of	O
macular	O
dystrophy	O
based	O
on	O
the	O
clinical	O
phenotype	O
.	O

Targeting	O
of	O
p0071	B
to	O
desmosomes	O
and	O
adherens	O
junctions	O
is	O
mediated	O
by	O
different	O
protein	O
domains	O
.	O

p0071	B
,	O
a	O
member	O
of	O
the	O
armadillo	B
protein	I
family	I
,	O
is	O
most	O
closely	O
related	O
to	O
p120	B
(	I
ctn	I
)	I
and	O
the	O
plakophilins	B
1	I
-	I
3	I
.	O

Whereas	O
plakophilins	B
are	O
desmosomal	O
plaque	O
proteins	O
,	O
p120	B
(	I
ctn	I
)	I
localizes	O
to	O
adherens	O
junctions	O
and	O
interacts	O
with	O
classical	O
cadherins	B
.	O

In	O
contrast	O
,	O
p0071	B
has	O
been	O
described	O
as	O
a	O
protein	O
with	O
dual	O
localization	O
in	O
adherens	O
junctions	O
and	O
desmosomes	O
depending	O
on	O
the	O
cell	O
type	O
examined	O
.	O

Here	O
we	O
have	O
analyzed	O
the	O
localization	O
of	O
p0071	B
and	O
its	O
domains	O
in	O
detail	O
.	O

Although	O
by	O
sequence	O
analysis	O
,	O
p0071	B
is	O
more	O
closely	O
related	O
to	O
the	O
adherens	O
junction	O
proteins	O
p120	B
(	I
ctn	I
)	I
,	O
ARVCF	B
and	O
delta	B
-	I
catenin	I
,	O
endogenous	O
p0071	B
associated	O
preferentially	O
with	O
desmosomes	O
in	O
MCF-7	O
epithelial	O
cells	O
.	O

Overexpressed	O
p0071	B
localized	O
along	O
cell	O
borders	O
and	O
overlapped	O
only	O
partially	O
with	O
desmosomal	O
markers	O
but	O
colocalized	O
with	O
non	O
-	O
desmosomal	O
cadherins	B
and	O
recruited	O
cadherins	B
to	O
the	O
membrane	O
.	O

The	O
head	O
domain	O
of	O
p0071	B
was	O
sufficient	O
for	O
desmosomal	O
targeting	O
,	O
whereas	O
the	O
arm	O
repeat	O
domain	O
associated	O
with	O
adherens	O
junctions	O
and	O
enhanced	O
membrane	O
association	O
of	O
classical	O
cadherins	B
.	O

The	O
tail	O
domain	O
localized	O
preferentially	O
to	O
the	O
nucleus	O
and	O
associated	O
with	O
desmosomes	O
.	O

To	O
examine	O
the	O
mechanism	O
underlying	O
this	O
dual	O
localization	O
more	O
closely	O
we	O
determined	O
binding	O
partners	O
of	O
p0071	B
by	O
using	O
yeast	O
-	O
two	O
-	O
hybrid	O
and	O
mom	O
-	O
targeting	O
assays	O
.	O

These	O
approaches	O
show	O
that	O
the	O
head	O
domain	O
interacted	O
with	O
desmosomal	O
proteins	O
desmocollin	B
3a	I
and	O
desmoplakin	B
,	O
whereas	O
the	O
armadillo	B
repeat	O
domain	O
binds	O
to	O
non	O
-	O
desmosomal	O
cadherins	B
.	O

Head	O
and	O
armadillo	B
repeat	O
domains	O
both	O
interacted	O
with	O
plakoglobin	B
by	O
binding	O
to	O
different	O
sites	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
plakoglobin	B
,	O
p0071	B
is	O
the	O
second	O
armadillo	B
protein	I
present	O
in	O
both	O
types	O
of	O
adhesive	O
junctions	O
and	O
may	O
play	O
a	O
role	O
in	O
regulating	O
crosstalk	O
between	O
adherens	O
junctions	O
and	O
desmosomes	O
.	O

Comprehensive	O
studies	O
of	O
drug	O
resistance	O
mediated	O
by	O
overexpression	O
of	O
response	B
regulators	I
of	O
two	O
-	O
component	O
signal	O
transduction	O
systems	O
in	O
Escherichia	O
coli	O
.	O

In	O
Escherichia	O
coli	O
,	O
there	O
are	O
32	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
that	O
are	O
assumed	O
to	O
be	O
response	B
regulator	I
genes	O
of	O
two	O
-	O
component	O
signal	O
transduction	O
systems	O
on	O
the	O
basis	O
of	O
sequence	O
similarities	O
.	O

We	O
cloned	O
all	O
of	O
these	O
32	O
ORFs	O
into	O
a	O
multicopy	O
expression	O
vector	O
and	O
investigated	O
whether	O
or	O
not	O
they	O
confer	O
drug	O
resistance	O
via	O
control	O
of	O
drug	O
resistance	O
determinants	O
.	O

Fifteen	O
of	O
these	O
ORFs	O
,	O
i.e.	O
,	O
baeR	B
,	O
citB	B
,	O
cpxR	B
,	O
evgA	B
,	O
fimZ	B
,	O
kdpE	B
,	O
narL	B
,	O
narP	B
,	O
ompR	B
,	O
rcsB	B
,	O
rstA	B
,	O
torR	B
,	O
yedW	B
,	O
yehT	B
,	O
and	O
dcuR	B
,	O
conferred	O
increased	O
single	O
-	O
or	O
multidrug	O
resistance	O
.	O

Two	O
-	O
thirds	O
of	O
them	O
conferred	O
deoxycholate	O
resistance	O
.	O

Five	O
of	O
them	O
,	O
i.e.	O
,	O
evgA	B
,	O
baeR	B
,	O
ompR	B
,	O
cpxR	B
,	O
and	O
rcsB	B
,	O
modulated	O
the	O
expression	O
of	O
several	O
drug	O
exporter	O
genes	O
.	O

The	O
drug	O
resistance	O
mediated	O
by	O
evgA	B
,	O
baeR	B
,	O
and	O
cpxR	B
could	O
be	O
assigned	O
to	O
drug	O
exporters	O
by	O
using	O
drug	O
exporter	O
gene	O
knockout	O
strains	O
.	O

The	O
L1	B
major	I
capsid	I
protein	I
of	O
human	O
papillomavirus	O
type	O
11	O
interacts	O
with	O
Kap	B
beta2	I
and	O
Kap	B
beta3	I
nuclear	O
import	O
receptors	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
L1	B
major	I
capsid	I
protein	I
of	O
low	O
-	O
risk	O
HPV11	O
binds	O
to	O
the	O
Kap	B
alpha2	I
adapter	O
and	O
enters	O
the	O
nucleus	O
via	O
a	O
Kap	B
alpha2beta1	I
-	O
mediated	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
discovered	O
that	O
HPV11	O
L1	B
capsomeres	O
bind	O
to	O
Kap	B
beta2	I
import	O
receptor	O
,	O
known	O
to	O
mediate	O
nuclear	O
import	O
of	O
hnRNP	B
A1	I
via	O
interaction	O
with	O
its	O
nuclear	O
localization	O
signal	O
termed	O
M9	O
.	O

Significantly	O
,	O
binding	O
of	O
HPV11	O
L1	B
capsomeres	O
to	O
Kap	B
beta2	I
inhibited	O
the	O
nuclear	O
import	O
of	O
Kap	B
beta2	I
,	O
and	O
its	O
specific	O
M9	O
-	O
containing	O
cargo	O
.	O

Interestingly	O
,	O
HPV11	O
L1	B
capsomeres	O
also	O
interacted	O
with	O
Kap	B
beta3	I
import	O
receptor	O
and	O
inhibited	O
Kap	B
beta3	I
nuclear	O
import	O
.	O

Moreover	O
,	O
the	O
L1	B
capsomeres	O
of	O
high	O
-	O
risk	O
HPV-16	O
shared	O
these	O
activities	O
.	O

These	O
data	O
suggest	O
that	O
HPV	O
L1	B
major	I
capsid	I
proteins	I
interact	O
with	O
Kap	B
beta2	I
and	O
Kap	B
beta3	I
,	O
and	O
they	O
may	O
inhibit	O
the	O
Kap	B
beta2	I
-	O
and	O
Kap	B
beta3	I
-	O
mediated	O
nuclear	O
import	O
pathways	O
during	O
the	O
productive	O
phase	O
of	O
the	O
viral	O
life	O
cycle	O
when	O
the	O
virions	O
are	O
assembled	O
and	O
released	O
.	O

Minimal	O
change	O
disease	O
in	O
a	O
patient	O
receiving	O
IFN	B
-	I
alpha	I
therapy	O
for	O
chronic	O
hepatitis	O
C	O
virus	O
infection	O
.	O

Chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
associated	O
with	O
several	O
extrahepatic	O
syndromes	O
.	O

The	O
principal	O
types	O
of	O
renal	O
disorders	O
associated	O
with	O
chronic	O
HCV	O
infection	O
are	O
cryoglobulinemia	O
or	O
noncryoglobulinemic	O
membranoproliferative	O
glomerulonephritis	O
(	O
MPGN	O
)	O
.	O

Interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
may	O
precipitate	O
or	O
exacerbate	O
the	O
occurrence	O
of	O
MPGN	O
.	O

Our	O
patient	O
was	O
a	O
32	O
-	O
year	O
-	O
old	O
man	O
who	O
tested	O
positive	O
for	O
HCV	O
in	O
July	O
1997	O
.	O

The	O
patient	O
was	O
treated	O
with	O
IFN	B
-	I
alpha	I
in	O
another	O
medical	O
center	O
for	O
6	O
months	O
because	O
his	O
liver	O
biopsy	O
showed	O
chronic	O
active	O
hepatitis	O
.	O

In	O
December	O
1998	O
,	O
he	O
applied	O
to	O
our	O
clinic	O
for	O
a	O
follow	O
-	O
up	O
examination	O
.	O

The	O
level	O
of	O
aspartate	B
aminotransferase	I
(	O
AST	B
)	O
was	O
44	O
U	O
/	O
L	O
,	O
and	O
that	O
of	O
alanine	B
aminotransferase	I
(	O
ALT	B
)	O
was	O
69	O
U	O
/	O
L	O
.	O

HCV	O
RNA	O
was	O
positive	O
in	O
serum	O
,	O
and	O
chronic	O
HCV	O
infection	O
was	O
detected	O
by	O
liver	O
biopsy	O
.	O

IFN	B
-	I
alpha	I
therapy	O
(	O
5	O
million	O
U	O
/	O
day	O
)	O
was	O
administered	O
for	O
6	O
months	O
longer	O
.	O

In	O
May	O
1999	O
,	O
the	O
patient	O
came	O
to	O
our	O
polyclinic	O
with	O
edema	O
of	O
the	O
feet	O
and	O
legs	O
.	O

We	O
detected	O
proteinuria	O
,	O
serum	O
cholesterol	O
of	O
269	O
mg	O
/	O
dl	O
,	O
AST	B
of	O
50	O
U	O
/	O
L	O
,	O
ALT	B
of	O
41	O
U	O
/	O
L	O
,	O
serum	O
total	O
protein	O
of	O
3.4	O
g	O
/	O
dl	O
,	O
serum	B
albumin	I
of	O
1.2	O
g	O
/	O
dl	O
,	O
positive	O
cryoglobulin	O
,	O
and	O
urine	O
protein	O
of	O
9.84	O
g	O
/	O
day	O
.	O

Cryoglobulinemic	O
MPGN	O
was	O
suspected	O
and	O
kidney	O
biopsy	O
was	O
performed	O
,	O
resulting	O
in	O
a	O
diagnosis	O
of	O
minimal	O
change	O
disease	O
(	O
MCD	O
)	O
.	O

A	O
novel	O
gene	O
,	O
MSI2	B
,	O
encoding	O
a	O
putative	O
RNA	O
-	O
binding	O
protein	O
is	O
recurrently	O
rearranged	O
at	O
disease	O
progression	O
of	O
chronic	O
myeloid	O
leukemia	O
and	O
forms	O
a	O
fusion	O
gene	O
with	O
HOXA9	B
as	O
a	O
result	O
of	O
the	O
cryptic	O
t	O
(	O
7	O
;	O
17	O
)	O
(	O
p15	O
;	O
q23	O
)	O
.	O

The	O
pathogenetic	O
role	O
of	O
the	O
P210	O
BCR	B
/	O
ABL1	B
fusion	O
gene	O
in	O
the	O
chronic	O
phase	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
has	O
been	O
well	O
established	O
.	O
In	O
contrast	O
,	O
the	O
genetic	O
mechanisms	O
underlying	O
the	O
disease	O
progression	O
into	O
the	O
accelerated	O
phase	O
(	O
AP	O
)	O
and	O
the	O
final	O
blast	O
crisis	O
(	O
BC	O
)	O
remain	O
poorly	O
understood	O
.	O

We	O
have	O
previously	O
identified	O
(	O
A.	O
Barbouti	O
et	O
al.	O
,	O
Genes	O
Chromosomes	O
Cancer	O
,	O
35	O
:	O
127	O
-	O
137	O
,	O
2002	O
)	O
two	O
cryptic	O
balanced	O
translocations	O
,	O
t	O
(	O
7	O
;	O
17	O
)	O
(	O
p15	O
;	O
q23	O
)	O
and	O
t	O
(	O
7	O
;	O
17	O
)	O
(	O
q32	O
-	O
34	O
;	O
q23	O
)	O
,	O
in	O
CML	O
AP	O
/	O
BC	O
using	O
multicolor	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
novel	O
gene	O
in	O
17q23	O
,	O
Musashi-2	B
(	O
MSI2	B
)	O
,	O
encoding	O
a	O
putative	O
RNA	O
-	O
binding	O
protein	O
,	O
is	O
rearranged	O
in	O
both	O
cases	O
and	O
that	O
a	O
MSI2	B
/	O
HOXA9	B
fusion	O
gene	O
is	O
formed	O
in	O
the	O
case	O
with	O
the	O
7p15	O
breakpoint	O
.	O

The	O
identified	O
in	O
-	O
frame	O
MSI2	B
/	O
HOXA9	B
fusion	O
transcript	O
retains	O
both	O
of	O
the	O
RNA	O
recognition	O
motif	O
domains	O
of	O
MSI2	B
,	O
which	O
is	O
fused	O
to	O
the	O
homeobox	O
domain	O
of	O
HOXA9	B
,	O
and	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
disease	O
progression	O
of	O
CML	O
.	O

Arsenic	O
resistance	O
in	O
the	O
archaeon	O
""""	O
Ferroplasma	O
acidarmanus	O
""""	O
:	O
new	O
insights	O
into	O
the	O
structure	O
and	O
evolution	O
of	O
the	O
ars	B
genes	O
.	O

Arsenic	O
resistance	O
in	O
the	O
acidophilic	O
iron	O
-	O
oxidizing	O
archaeon	O
""""	O
Ferroplasma	O
acidarmanus	O
""""	O
was	O
investigated	O
.	O

F.	O
acidarmanus	O
is	O
native	O
to	O
arsenic	O
-	O
rich	O
environments	O
,	O
and	O
culturing	O
experiments	O
confirm	O
a	O
high	O
level	O
of	O
resistance	O
to	O
both	O
arsenite	O
and	O
arsenate	O
.	O

Analyses	O
of	O
the	O
complete	O
genome	O
revealed	O
protein	O
-	O
encoding	O
regions	O
related	O
to	O
known	O
arsenic	B
-	I
resistance	I
genes	I
.	O

Genes	O
encoding	O
for	O
ArsR	B
(	O
arsenite	B
-	I
sensitive	I
regulator	I
)	O
and	O
ArsB	B
(	O
arsenite	B
-	I
efflux	I
pump	I
)	O
homologues	O
were	O
found	O
located	O
on	O
a	O
single	O
operon	O
.	O

A	O
gene	O
encoding	O
for	O
an	O
ArsA	B
relative	O
(	O
anion	B
-	I
translocating	I
ATPase	I
)	O
located	O
apart	O
from	O
the	O
arsRB	B
operon	I
was	O
also	O
identified	O
.	O

Arsenate	B
-	I
resistance	I
genes	I
encoding	O
for	O
proteins	O
homologous	O
to	O
the	O
arsenate	B
reductase	I
ArsC	B
and	O
the	O
phosphate	B
-	I
specific	I
transporter	I
Pst	B
were	O
not	O
found	O
,	O
indicating	O
that	O
additional	O
unknown	O
arsenic	O
-	O
resistance	O
genes	O
exist	O
for	O
arsenate	O
tolerance	O
.	O

Phylogenetic	O
analyses	O
of	O
ArsA	B
-	O
related	O
proteins	O
suggest	O
separate	O
evolutionary	O
lines	O
for	O
these	O
proteins	O
and	O
offer	O
new	O
insights	O
into	O
the	O
formation	O
of	O
the	O
arsA	B
gene	O
.	O

The	O
ArsB	B
-	O
homologous	O
protein	O
of	O
F.	O
acidarmanus	O
had	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
known	O
ArsB	B
proteins	O
.	O

An	O
evolutionary	O
analysis	O
of	O
ArsB	B
homologues	O
across	O
a	O
number	O
of	O
species	O
indicated	O
a	O
clear	O
relationship	O
in	O
close	O
agreement	O
with	O
16S	O
rRNA	O
evolutionary	O
lines	O
.	O

These	O
results	O
support	O
a	O
hypothesis	O
of	O
arsenic	O
resistance	O
developing	O
early	O
in	O
the	O
evolution	O
of	O
life	O
.	O

Crystal	O
structure	O
of	O
the	O
human	O
natural	O
killer	O
cell	O
activating	O
receptor	O
KIR2DS2	B
(	O
CD158j	B
)	O
.	O

Killer	B
cell	I
Ig	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
regulate	O
the	O
function	O
of	O
human	O
natural	O
killer	O
and	O
T	O
cell	O
subsets	O
.	O

A	O
feature	O
of	O
the	O
KIR	B
locus	O
is	O
the	O
clustering	O
of	O
homologous	O
genes	O
encoding	O
for	O
inhibitory	O
and	O
activating	O
KIR	B
.	O

Inhibitory	O
and	O
activating	O
KIR	B
differ	O
for	O
ligand	O
specificities	O
and/or	O
affinities	O
.	O

In	O
particular	O
,	O
we	O
show	O
here	O
with	O
KIR	B
tetramers	O
that	O
activating	O
KIR2DS2	B
does	O
not	O
bind	O
HLA	B
-	I
Cw3	I
molecules	O
recognized	O
by	O
inhibitory	O
KIR2DL2	B
,	O
despite	O
99	O
%	O
extracellular	O
amino	O
acid	O
identity	O
.	O

We	O
also	O
report	O
the	O
2.3	O
-	O
A	O
structure	O
of	O
KIR2DS2	B
,	O
which	O
reveals	O
subtle	O
displacements	O
of	O
two	O
residues	O
(	O
Tyr45	O
and	O
Gln71	O
)	O
involved	O
in	O
the	O
interaction	O
of	O
KIR2DL2	B
with	O
HLA	B
-	I
Cw3	I
.	O

These	O
results	O
show	O
that	O
KIR	B
molecules	O
can	O
not	O
tolerate	O
any	O
variability	O
in	O
their	O
three	O
-	O
dimensional	O
structure	O
without	O
altering	O
their	O
MHC	B
class	I
I	I
recognition	O
capacities	O
.	O

Therefore	O
,	O
the	O
mode	O
of	O
recognition	O
used	O
by	O
KIR	B
largely	O
differs	O
from	O
the	O
conformational	O
changes	O
that	O
characterize	O
T	O
cell	O
receptor	O
or	O
NKG2D	B
interaction	O
with	O
their	O
respective	O
ligands	O
.	O

Natural	O
killer	O
cell	O
receptors	O
in	O
cattle	O
:	O
a	O
bovine	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
multigene	I
family	I
contains	O
members	O
with	O
divergent	O
signaling	O
motifs	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
recognize	O
and	O
kill	O
certain	O
tumor	O
cells	O
,	O
virally	O
infected	O
cells	O
and	O
MHC	B
class	I
I	I
-	O
disparate	O
normal	O
hematopoietic	O
cells	O
.	O

NK	O
cell	O
cytotoxicity	O
is	O
regulated	O
by	O
a	O
multitude	O
of	O
receptors	O
with	O
either	O
activating	O
or	O
inhibitory	O
signaling	O
function	O
.	O

We	O
here	O
report	O
the	O
molecular	O
cloning	O
of	O
bovine	O
CD94	B
[	O
killer	B
cell	I
lectin	I
-	I
like	I
receptor	I
(	I
KLR	I
)	I
-D1	I
]	O
and	O
NKp46	B
orthologues	O
,	O
four	O
members	O
of	O
a	O
bovine	O
CD158	B
[	I
killer	I
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
(	I
KIR	I
)	I
]	I
family	I
,	O
and	O
a	O
novel	O
KLR	B
.	O

This	O
novel	O
receptor	O
was	O
termed	O
KLRJ1	B
and	O
is	O
most	O
similar	O
to	O
Ly-49	B
(	O
KLRA	B
)	O
.	O

The	O
KLRD1	B
and	O
KLRJ1	B
loci	O
were	O
mapped	O
to	O
a	O
bovine	O
NK	O
gene	O
complex	O
on	O
chromosome	O
5	O
by	O
radiation	O
hybrid	O
mapping	O
,	O
whereas	O
KIR2DL1	B
and	O
NKP46	B
were	O
localized	O
to	O
chromosome	O
18	O
.	O

Two	O
of	O
the	O
bovine	O
KIR	B
(	O
KIR2DL1	B
and	O
KIR3DL1	B
)	O
contain	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motifs	O
(	O
ITIM	O
)	O
,	O
suggesting	O
an	O
inhibitory	O
function	O
.	O

Bovine	O
KIR2DS1	B
and	O
KIR3DS1	B
lack	O
ITIM	O
but	O
have	O
an	O
arginine	O
-	O
containing	O
motif	O
in	O
their	O
transmembrane	O
domain	O
,	O
similar	O
to	O
primate	O
KIR2DL4	B
.	O

Thus	O
,	O
KIR	B
multigene	I
families	I
with	O
divergent	O
signaling	O
motifs	O
do	O
not	O
only	O
exist	O
in	O
primates	O
.	O

Based	O
on	O
sequence	O
comparison	O
,	O
it	O
appears	O
that	O
the	O
primate	O
and	O
bovine	O
KIR	B
multigene	O
families	O
may	O
have	O
evolved	O
independently	O
.	O

Superoxide	O
production	O
by	O
peripheral	O
polymorphonuclear	O
leukocytes	O
in	O
patients	O
with	O
COPD	O
.	O

Polymorphonuclear	O
leukocytes	O
(	O
PMNs	O
)	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
COPD	O
,	O
partly	O
because	O
of	O
the	O
release	O
of	O
oxidants	O
,	O
like	O
superoxide	O
anion	O
(	O
SA	O
)	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
measure	O
the	O
spontaneous	O
and	O
stimulated	O
release	O
of	O
SA	O
by	O
peripheral	O
PMN	O
in	O
stable	O
COPD	O
compared	O
with	O
healthy	O
controls	O
.	O

Seventeen	O
patients	O
with	O
stable	O
moderate	O
COPD	O
and	O
17	O
healthy	O
age	O
-	O
matched	O
controls	O
were	O
included	O
.	O

SA	O
release	O
from	O
peripheral	O
PMN	O
was	O
measured	O
spectrophotometrically	O
as	O
the	O
superoxide	B
dismutase	I
(	O
SOD	B
)	O
inhibitable	O
reduction	O
of	O
cytochrome	B
c	I
.	O

PMNs	O
were	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
,	O
1	O
and	O
10	O
ng	O
/	O
ml	O
)	O
,	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
,	O
carbon	O
black	O
(	O
CB	O
)	O
and	O
ultrafine	O
CB	O
(	O
ufCB	O
,	O
125	O
,	O
250	O
and	O
500	O
microg	O
/	O
ml	O
)	O
.	O

The	O
spontaneous	O
SA	O
release	O
(	O
PMA-0	O
)	O
between	O
patients	O
and	O
control	O
subjects	O
was	O
not	O
significantly	O
different	O
.	O

After	O
stimulation	O
with	O
PMA	O
,	O
SA	O
release	O
increased	O
in	O
both	O
patients	O
and	O
controls	O
.	O

The	O
SA	O
release	O
did	O
not	O
increase	O
after	O
stimulation	O
with	O
DEP	O
and	O
CB	O
in	O
patients	O
nor	O
in	O
controls	O
.	O

There	O
was	O
only	O
an	O
increase	O
after	O
stimulation	O
with	O
ufCB	O
in	O
the	O
patient	O
group	O
.	O

The	O
increased	O
SA	O
release	O
in	O
COPD	O
patients	O
after	O
stimulation	O
with	O
ufCB	O
may	O
suggest	O
that	O
PMN	O
of	O
COPD	O
patients	O
are	O
more	O
prone	O
to	O
stimulation	O
and	O
that	O
the	O
smaller	O
particle	O
size	O
of	O
ufCB	O
might	O
be	O
a	O
crucial	O
factor	O
.	O

Induction	O
of	O
Duffy	B
gene	O
(	O
FY	B
)	O
in	O
human	O
endothelial	O
cells	O
and	O
in	O
mouse	O
.	O

Duffy	B
Blood	O
Group	O
protein	O
is	O
a	O
glycoprotein	O
with	O
seven	O
transmembrane	O
domains	O
that	O
binds	O
to	O
C	B
-	I
X	I
-	I
C	I
and	I
C	I
-	I
C	I
chemokines	I
.	O

The	O
antigen	O
is	O
constitutively	O
expressed	O
in	O
endothelial	O
and	O
epithelial	O
cells	O
of	O
several	O
nonerythroid	O
tissues	O
and	O
in	O
Purkinje	O
cells	O
of	O
the	O
cerebellum	O
.	O

We	O
studied	O
the	O
effect	O
of	O
proinflammatory	O
cytokines	B
on	O
Duffy	B
gene	O
expression	O
in	O
endothelial	O
cells	O
from	O
human	O
umbilical	O
vein	O
(	O
HUVEC	O
)	O
and	O
human	O
pulmonary	O
arteries	O
(	O
HPAEC	O
)	O
.	O

Also	O
,	O
we	O
studied	O
the	O
effect	O
of	O
inflammatory	O
agents	O
like	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
Duffy	B
gene	O
induction	O
in	O
mouse	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
and	O
mRNA	O
blot	O
analyses	O
showed	O
that	O
Duffy	B
mRNA	O
was	O
present	O
in	O
these	O
cells	O
in	O
negligible	O
amounts	O
.	O

However	O
,	O
treatment	O
with	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
for	O
6	O
-	O
24h	O
resulted	O
in	O
a	O
5	O
to	O
8	O
-	O
fold	O
increase	O
in	O
Duffy	B
mRNA	O
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
with	O
interleukin-1	B
(	O
IL-1	B
)	O
,	O
IL-6	B
or	O
LPS	O
did	O
not	O
have	O
any	O
effect	O
.	O

Fluorescence	O
microscopy	O
and	O
fluorescence	O
activated	O
cell	O
sorting	O
showed	O
greater	O
expression	O
of	O
Duffy	B
protein	O
in	O
treated	O
cells	O
correlating	O
the	O
increase	O
in	O
mRNA	O
synthesis	O
with	O
an	O
increase	O
in	O
antigen	O
production	O
.	O

In	O
mice	O
,	O
Duffy	B
gene	O
was	O
induced	O
in	O
lungs	O
and	O
brain	O
with	O
LPS	O
treatment	O
indicating	O
that	O
the	O
induction	O
is	O
a	O
physiological	O
event	O
.	O

Vascular	O
endothelial	O
cells	O
may	O
induce	O
Duffy	B
protein	O
to	O
regulate	O
leukocytes	O
and/or	O
chemokine	B
trafficking	O
.	O

14	B
-	I
3	I
-	I
3	I
dimers	O
probe	O
the	O
assembly	O
status	O
of	O
multimeric	O
membrane	O
proteins	O
.	O

BACKGROUND	O
:	O

Arginine	O
-	O
based	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
localization	O
signals	O
are	O
involved	O
in	O
the	O
heteromultimeric	O
assembly	O
of	O
membrane	O
protein	O
complexes	O
like	O
ATP	B
-	I
sensitive	I
potassium	I
channels	I
(	O
K	O
(	O
ATP	O
)	O
)	O
or	O
GABA	B
(	I
B	I
)	I
G	I
protein	I
-	I
coupled	I
receptors	I
.	O

They	O
constitute	O
a	O
trafficking	O
checkpoint	O
that	O
prevents	O
ER	O
exit	O
of	O
unassembled	O
subunits	O
or	O
partially	O
assembled	O
complexes	O
.	O

For	O
K	O
(	O
ATP	O
)	O
channels	O
,	O
the	O
mechanism	O
that	O
leads	O
to	O
masking	O
of	O
the	O
ER	O
localization	O
signals	O
in	O
the	O
fully	O
assembled	O
octameric	O
complex	O
is	O
unknown	O
.	O

RESULTS	O
:	O

By	O
employing	O
a	O
tetrameric	O
affinity	O
construct	O
of	O
the	O
C	O
terminus	O
of	O
the	O
K	O
(	O
ATP	O
)	O
channel	O
alpha	O
subunit	O
,	O
Kir6.2	B
,	O
we	O
found	O
that	O
14	B
-	I
3	I
-	I
3	I
isoforms	I
epsilon	I
and	I
zeta	I
specifically	O
recognize	O
the	O
arginine	O
-	O
based	O
ER	O
localization	O
signal	O
present	O
in	O
this	O
cytosolic	O
tail	O
.	O

The	O
interaction	O
was	O
reconstituted	O
by	O
using	O
purified	O
14	B
-	I
3	I
-	I
3	I
proteins	O
.	O

Competition	O
with	O
a	O
nonphosphorylated	O
14	B
-	I
3	I
-	I
3	I
high	O
-	O
affinity	O
binding	O
peptide	O
implies	O
that	O
the	O
canonical	O
substrate	O
binding	O
groove	O
of	O
14	B
-	I
3	I
-	I
3	I
is	O
involved	O
.	O

Comparison	O
of	O
monomeric	O
CD4	B
,	O
dimeric	O
CD8	B
,	O
and	O
artificially	O
tetramerized	O
CD4	B
fusions	O
correlates	O
the	O
copy	O
number	O
of	O
the	O
tail	O
containing	O
the	O
arginine	O
-	O
based	O
signal	O
with	O
14	B
-	I
3	I
-	I
3	I
binding	O
,	O
resulting	O
in	O
the	O
surface	O
expression	O
of	O
the	O
membrane	O
protein	O
.	O

Binding	O
experiments	O
revealed	O
that	O
the	O
COPI	B
vesicle	O
coat	O
can	O
specifically	O
recognize	O
the	O
arginine	O
-	O
based	O
ER	O
localization	O
signal	O
and	O
competes	O
with	O
14	B
-	I
3	I
-	I
3	I
for	O
the	O
binding	O
site	O
.	O

CONCLUSIONS	O
:	O

The	O
COPI	B
vesicle	O
coat	O
and	O
proteins	O
of	O
the	O
14	B
-	I
3	I
-	I
3	I
family	I
recognize	O
arginine	O
-	O
based	O
ER	O
localization	O
signals	O
on	O
multimeric	O
membrane	O
proteins	O
.	O

The	O
equilibrium	O
between	O
these	O
two	O
competing	O
reactions	O
depends	O
on	O
the	O
valency	O
and	O
spatial	O
arrangement	O
of	O
the	O
signal	O
-	O
containing	O
tails	O
.	O

We	O
propose	O
a	O
mechanism	O
in	O
which	O
14	B
-	I
3	I
-	I
3	I
bound	O
to	O
the	O
correctly	O
assembled	O
multimer	O
mediates	O
release	O
of	O
the	O
complex	O
from	O
the	O
ER	O
.	O

Expression	O
and	O
purification	O
of	O
the	O
angiogenesis	O
inhibitor	O
16	O
-	O
kDa	O
prolactin	B
fragment	O
from	O
insect	O
cells	O
.	O

The	O
16	O
-	O
kDa	O
fragment	O
of	O
prolactin	B
(	O
16	O
-	O
kDa	O
PRL	B
)	O
,	O
derived	O
from	O
proteolytic	O
cleavage	O
of	O
23-kDa	O
PRL	B
,	O
was	O
shown	O
to	O
have	O
antiangiogenic	O
activity	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
recombinant	O
16	O
-	O
kDa	O
PRL	B
produced	O
from	O
bacteria	O
often	O
contained	O
endotoxins	O
,	O
which	O
are	O
cytotoxic	O
to	O
endothelial	O
cells	O
,	O
and	O
varied	O
in	O
its	O
biological	O
activity	O
due	O
to	O
changes	O
in	O
its	O
refolding	O
from	O
inclusion	O
bodies	O
.	O

These	O
problems	O
limited	O
the	O
use	O
of	O
recombinant	O
16	O
-	O
kDa	O
PRL	B
.	O

To	O
improve	O
the	O
generation	O
of	O
recombinant	O
16	O
-	O
kDa	O
PRL	B
,	O
we	O
expressed	O
16	O
-	O
kDa	O
PRL	B
in	O
Sf9	O
insect	O
cells	O
using	O
a	O
baculoviral	O
expression	O
system	O
.	O

The	O
signal	O
sequence	O
of	O
the	O
human	O
PRL	B
gene	O
and	O
codons	O
for	O
seven	O
histidines	O
were	O
added	O
to	O
the	O
N	O
-	O
and	O
C	O
-	O
termini	O
,	O
respectively	O
,	O
of	O
the	O
16-kDa	O
PRL	B
cDNA	O
construct	O
.	O

Recombinant	O
16	O
-	O
kDa	O
PRL	B
was	O
detected	O
in	O
both	O
the	O
cell	O
pellet	O
and	O
the	O
medium	O
.	O

About	O
0.28	O
mg	O
purified	O
protein	O
was	O
isolated	O
from	O
the	O
cell	O
pellet	O
of	O
4	O
x	O
10	O
(	O
7	O
)	O
infected	O
cells	O
using	O
nickel	O
affinity	O
chromatography	O
.	O

Sixteen	O
kilodalton	O
PRL	B
was	O
posttranslationally	O
modified	O
with	O
apparent	O
molecular	O
weights	O
of	O
16	O
and	O
18	O
kDa	O
on	O
SDS	O
-	O
PAGE	O
.	O

The	O
level	O
of	O
18	O
-	O
kDa	O
protein	O
was	O
significantly	O
reduced	O
after	O
digestion	O
with	O
peptidyl	B
-	I
N	I
-	I
glycosidase	I
,	O
suggesting	O
that	O
the	O
heterogeneity	O
was	O
due	O
to	O
glycosylation	O
of	O
16-kDa	O
PRL	B
.	O

N	O
-	O
terminal	O
sequence	O
analysis	O
confirmed	O
the	O
fact	O
that	O
both	O
proteins	O
were	O
human	O
16	O
-	O
kDa	O
PRL	B
and	O
the	O
signal	O
sequences	O
were	O
cleaved	O
at	O
the	O
same	O
position	O
as	O
that	O
of	O
human	O
PRL	B
.	O

Consistent	O
with	O
its	O
role	O
as	O
an	O
angiogenesis	O
inhibitor	O
,	O
purified	O
recombinant	O
16-kDa	O
PRL	B
inhibits	O
the	O
proliferation	O
of	O
endothelial	O
cells	O
with	O
a	O
potency	O
similar	O
to	O
that	O
previously	O
reported	O
for	O
the	O
protein	O
generated	O
in	O
Escherichia	O
coli	O
.	O

This	O
16	O
-	O
kDa	O
PRL	B
expressed	O
in	O
Sf9	O
cells	O
is	O
a	O
useful	O
reagent	O
for	O
functional	O
studies	O
and	O
for	O
the	O
purification	O
and	O
identification	O
of	O
its	O
receptor	O
.	O

Smad3	B
mediates	O
transforming	B
growth	I
factor	I
-	I
beta	I
-	O
induced	O
alpha	O
-	O
smooth	O
muscle	O
actin	B
expression	O
.	O

Transforming	B
growth	I
factor	I
-	I
beta	I
(	O
TGF	B
-	I
beta	I
)	O
-	O
induced	O
alpha	B
-	I
smooth	I
muscle	I
actin	I
(	O
ASMA	B
)	O
expression	O
is	O
a	O
key	O
indicator	O
of	O
myofibroblast	O
differentiation	O
from	O
fibroblasts	O
.	O

Recent	O
studies	O
suggest	O
that	O
a	O
TGF	B
-	I
beta	I
control	O
element	O
is	O
important	O
in	O
the	O
regulation	O
of	O
the	O
ASMA	B
gene	O
promoter	O
by	O
TGF	B
-	I
beta	I
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
Smad3	B
,	O
a	O
key	O
component	O
of	O
the	O
Smad	B
pathway	O
that	O
mediates	O
TGF	B
-	I
beta	I
signaling	O
in	O
regulation	O
of	O
ASMA	B
gene	O
expression	O
,	O
is	O
investigated	O
.	O

All	O
members	O
of	O
the	O
Smad	B
family	I
were	O
expressed	O
in	O
rat	O
lung	O
fibroblasts	O
,	O
and	O
Smad3	B
expression	O
was	O
elevated	O
upon	O
TGF	B
-	I
beta	I
1	I
treatment	O
.	O

Transfection	O
with	O
a	O
Smad3	B
-	O
expressing	O
plasmid	O
markedly	O
increased	O
Smad3	B
and	O
ASMA	B
protein	O
expression	O
,	O
whereas	O
transfection	O
with	O
an	O
antisense	O
Smad3	B
plasmid	O
suppressed	O
Smad3	B
and	O
ASMA	B
expression	O
.	O

Similar	O
effects	O
were	O
noted	O
when	O
the	O
cloned	O
rat	O
ASMA	B
promoter	O
-	O
luciferase	B
reporter	O
gene	O
construct	O
was	O
used	O
to	O
monitor	O
transcriptional	O
activation	O
of	O
the	O
ASMA	B
gene	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNA	O
affinity	O
precipitation	O
indicated	O
Smad3	B
binding	O
to	O
at	O
least	O
two	O
regions	O
of	O
the	O
promoter	O
containing	O
CAGA	O
motifs	O
,	O
termed	O
Smad3	B
-	O
binding	O
elements	O
(	O
SBEs	O
)	O
.	O

Mutation	O
of	O
one	O
of	O
the	O
SBEs	O
decreased	O
promoter	O
activity	O
significantly	O
,	O
indicative	O
of	O
a	O
functional	O
role	O
for	O
this	O
SBE	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
a	O
role	O
for	O
Smad3	B
in	O
TGF	B
-	I
beta	I
regulation	O
of	O
ASMA	B
gene	O
expression	O
in	O
myofibroblast	O
differentiation	O
.	O

2-Amino-3-benzoylthiophene	O
allosteric	O
enhancers	O
of	O
A1	O
adenosine	O
agonist	O
binding	O
:	O
new	O
3	O
,	O
4	O
-	O
,	O
and	O
5	O
-	O
modifications	O
.	O

2-Amino-3-aroylthiophenes	O
are	O
agonist	O
allosteric	O
enhancers	O
(	O
AE	O
)	O
at	O
the	O
A	B
(	I
1	I
)	I
adenosine	I
receptor	I
(	O
A	B
(	I
1	I
)	I
AR	I
)	O
.	O

Here	O
we	O
report	O
the	O
syntheses	O
of	O
three	O
kinds	O
of	O
novel	O
2-aminothiophenes	O
and	O
assays	O
of	O
their	O
AE	O
activity	O
at	O
the	O
human	O
A	B
(	I
1	I
)	I
AR	I
(	O
hA	B
(	I
1	I
)	I
AR	I
)	O
,	O
namely	O
,	O
(	O
1	O
)	O
2-amino-4,5-diphenylthiophene-3-carboxylates	O
,	O
3a	O
-	O
h	O
,	O
(	O
2	O
)	O
2-amino-3-benzoyl-4,5-diphenylthiophenes	O
,	O
7a	O
-	O
p	O
,	O
and	O
(	O
3	O
)	O
2-amino-5-bromo-3-benzoyl-4-phenylthiophenes	O
,	O
10a	O
-	O
h	O
.	O

An	O
in	O
vitro	O
assay	O
employing	O
the	O
A	B
(	I
1	I
)	I
AR	I
agonist	O
[	O
(	O
125	O
)	O
I	O
]	O
ABA	O
and	O
membranes	O
from	O
CHO	O
-	O
K1	O
cells	O
stably	O
expressing	O
the	O
hA	B
(	I
1	I
)	I
AR	I
measured	O
an	O
index	O
of	O
AE	O
activity	O
,	O
the	O
ability	O
of	O
a	O
candidate	O
AE	O
to	O
stabilize	O
the	O
agonist	O
-	O
A	B
(	I
1	I
)	I
AR	I
-	O
G	B
protein	I
ternary	O
complex	O
,	O
scored	O
as	O
the	O
percentage	O
of	O
ternary	O
complex	O
remaining	O
after	O
10	O
min	O
of	O
dissociation	O
initiated	O
by	O
CPX	O
and	O
GTPgammaS	O
.	O

The	O
AE	O
activity	O
score	O
of	O
2-amino-4,5-dimethyl-3-	O
(	O
3-trifluoromethylbenzoyl	O
)	O
thiophene	O
(	O
PD	O
81	O
,	O
723	O
)	O
,	O
which	O
was	O
19	O
%	O
,	O
served	O
as	O
a	O
standard	O
for	O
comparison	O
.	O

Two	O
3-carboxythiophene	O
3-trifluoromethylbenzyl	O
esters	O
,	O
3d	O
(	O
49	O
%	O
)	O
and	O
3f	O
(	O
63	O
%	O
)	O
,	O
had	O
substantial	O
AE	O
activity	O
.	O

The	O
3-	O
(	O
1-naphthoyl	O
)	O
substituent	O
of	O
7e	O
(	O
52	O
%	O
)	O
also	O
supported	O
AE	O
activity	O
.	O

Compounds	O
in	O
series	O
3	O
tended	O
to	O
be	O
more	O
potent	O
,	O
10a	O
and	O
10c	O
having	O
scores	O
of	O
91	O
and	O
80	O
%	O
,	O
respectively	O
.	O

The	O
activity	O
of	O
2-amino-5-bromo-3-ethoxycarbonyl-4-	O
(	O
3-nitrophenyl	O
)	O
thiophene	O
,	O
10h	O
(	O
26	O
%	O
)	O
,	O
is	O
an	O
exception	O
to	O
the	O
rule	O
that	O
a	O
3-ethoxycarbonyl	O
substituent	O
can	O
not	O
support	O
AE	O
activity	O
.	O

Cloning	O
and	O
overexpression	O
of	O
the	O
3-hydroxyisobutyrate	B
dehydrogenase	I
gene	O
from	O
pseudomonas	O
putida	O
E23	O
.	O

The	O
structural	O
gene	O
for	O
NAD+-dependent	O
3-hydroxyisobutyrate	B
dehydrogenase	I
(	O
EC	B
1.1.1.31	I
)	O
from	O
Pseudomonas	O
putida	O
E23	O
was	O
cloned	O
in	O
Escherichia	O
coli	O
cells	O
to	O
obtain	O
a	O
large	O
amount	O
of	O
the	O
enzyme	O
and	O
its	O
nucleotides	O
were	O
sequenced	O
to	O
study	O
its	O
structural	O
relationship	O
with	O
other	O
proteins	O
.	O

The	O
gene	O
encoded	O
a	O
polypeptide	O
containing	O
295	O
amino	O
acid	O
residues	O
and	O
was	O
in	O
a	O
cluster	O
with	O
the	O
gene	O
for	O
methylmalonate	B
semialdehyde	I
dehydrogenase	I
.	O

Transformed	O
E.	O
coli	O
cells	O
overproduced	O
3-hydroxyisobutyrate	B
dehydrogenase	I
,	O
and	O
the	O
recombinant	O
enzyme	O
was	O
purified	O
to	O
homogeneity	O
with	O
a	O
high	O
yield	O
.	O

Lysine	O
and	O
asparagine	O
residues	O
,	O
which	O
are	O
important	O
in	O
catalysis	O
of	O
the	O
3-hydroxyacid	B
dehydrogenase	I
family	I
,	O
are	O
conserved	O
in	O
this	O
enzyme	O
.	O

Cell	O
-	O
specific	O
and	O
hormone	O
-	O
regulated	O
expression	O
of	O
gonadotropin	B
-	I
regulated	I
testicular	I
RNA	I
helicase	I
gene	O
(	O
GRTH	B
/	O
Ddx25	B
)	O
resulting	O
from	O
alternative	O
utilization	O
of	O
translation	O
initiation	O
codons	O
in	O
the	O
rat	O
testis	O
.	O

Gonadotropin	B
-	I
regulated	I
testicular	I
RNA	I
helicase	I
(	O
GRTH	B
)	O
is	O
a	O
novel	O
DEAD	O
-	O
box	O
protein	O
with	O
ATPase	B
and	O
RNA	B
helicase	I
activities	O
.	O

GRTH	B
gene	O
transcription	O
is	O
stimulated	O
by	O
human	B
chorionic	I
gonadotropin	I
(	O
hCG	B
)	O
via	O
cyclic	O
AMP	O
-	O
induced	O
androgen	O
formation	O
in	O
testicular	O
Leydig	O
cells	O
.	O

In	O
this	O
study	O
,	O
immunocytochemical	O
and	O
Western	O
analyses	O
identified	O
GRTH	B
as	O
a	O
developmentally	O
regulated	O
protein	O
in	O
Leydig	O
cells	O
and	O
in	O
germ	O
cells	O
(	O
pachytene	O
spermatocytes	O
and	O
round	O
spermatids	O
)	O
of	O
the	O
rat	O
testis	O
.	O

Three	O
ATGs	O
with	O
the	O
potential	O
for	O
generation	O
of	O
multiple	O
protein	O
species	O
were	O
identified	O
.	O

Germ	O
cells	O
primarily	O
utilized	O
the	O
1st	O
ATG	O
codon	O
(	O
+	O
1	O
)	O
and	O
contained	O
major	O
proteins	O
of	O
61	O
/	O
56	O
kDa	O
,	O
whereas	O
Leydig	O
cells	O
utilized	O
preferentially	O
the	O
2nd	O
ATG	O
codon	O
(	O
+	O
343	O
)	O
with	O
expression	O
of	O
48	O
/	O
43	O
kDa	O
species	O
.	O

A	O
3rd	O
ATG	O
was	O
weakly	O
utilized	O
and	O
yielded	O
a	O
33	O
-	O
kDa	O
protein	O
only	O
in	O
germ	O
cells	O
.	O

The	O
increase	O
in	O
GRTH	B
43	O
-	O
kDa	O
protein	O
in	O
Leydig	O
cells	O
caused	O
by	O
hCG	B
treatment	O
was	O
prevented	O
by	O
the	O
androgen	B
receptor	I
antagonist	O
,	O
flutamide	O
.	O

In	O
round	O
spermatids	O
,	O
hCG	B
caused	O
a	O
significant	O
decrease	O
of	O
61	O
kDa	O
species	O
and	O
an	O
induction	O
48	O
/	O
43	O
kDa	O
species	O
,	O
whereas	O
no	O
changes	O
were	O
observed	O
in	O
pachytene	O
spermatocytes	O
.	O

Reversal	O
of	O
this	O
hormone	O
-	O
induced	O
switch	O
of	O
expression	O
by	O
flutamide	O
indicated	O
a	O
role	O
of	O
androgen	O
in	O
utilization	O
of	O
the	O
2nd	O
ATG	O
.	O

These	O
studies	O
have	O
demonstrated	O
a	O
cell	O
-	O
specific	O
and	O
hormone	O
-	O
dependent	O
alternative	O
usage	O
of	O
ATG	O
codons	O
in	O
the	O
testis	O
.	O

They	O
have	O
also	O
revealed	O
that	O
the	O
androgen	O
-	O
dependent	O
transcription	O
of	O
GRTH	B
expression	O
in	O
Leydig	O
cells	O
is	O
accompanied	O
by	O
a	O
marked	O
increase	O
of	O
43	O
-	O
kDa	O
species	O
.	O

The	O
findings	O
indicate	O
that	O
expression	O
of	O
GRTH	B
proteins	O
is	O
regulated	O
by	O
gonadotropin	B
/	O
androgen	O
at	O
the	O
translational	O
level	O
.	O

Cloning	O
and	O
characterization	O
of	O
porcine	O
common	O
gamma	O
chain	O
gene	O
.	O

The	O
common	O
gamma	O
chain	O
,	O
which	O
was	O
originally	O
identified	O
as	O
a	O
component	O
of	O
interleukin-2	O
receptors	O
(	O
IL-2R	O
)	O
,	O
plays	O
a	O
key	O
role	O
in	O
differentiation	O
of	O
T	O
lymphocytes	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
cDNA	O
of	O
the	O
porcine	O
common	O
gamma	O
chain	O
gene	O
and	O
its	O
genomic	O
DNA	O
were	O
molecularly	O
cloned	O
and	O
characterized	O
.	O

The	O
porcine	O
common	O
gamma	O
chain	O
gene	O
was	O
found	O
to	O
consist	O
of	O
8	O
exons	O
,	O
spanning	O
approximately	O
3.7	O
kb	O
,	O
and	O
to	O
encode	O
a	O
368	O
-	O
amino	O
acid	O
polypeptide	O
.	O

The	O
amino	O
acid	O
sequence	O
showed	O
82.4	O
%	O
,	O
71.1	O
%	O
,	O
86.1	O
%	O
,	O
and	O
84.8	O
%	O
similarities	O
with	O
that	O
of	O
human	O
,	O
murine	O
,	O
bovine	O
,	O
and	O
canine	O
chains	O
,	O
respectively	O
.	O

The	O
common	O
gamma	O
chain	O
gene	O
was	O
assigned	O
to	O
swine	O
chromosome	O
Xq13	O
by	O
FISH	O
analysis	O
and	O
was	O
consistent	O
with	O
the	O
result	O
of	O
radiation	O
hybrid	O
(	O
RH	O
)	O
mapping	O
.	O

When	O
various	O
porcine	O
tissues	O
were	O
examined	O
for	O
the	O
expression	O
of	O
this	O
gene	O
,	O
the	O
expression	O
was	O
observed	O
in	O
lymphocytes	O
and	O
lymphocyte	O
-	O
related	O
tissues	O
.	O

Since	O
GATA	O
,	O
T	O
cell	O
factor-1	O
(	O
TCF-1	O
)	O
,	O
Ets-1	O
,	O
activated	O
protein2	O
(	O
AP-2	O
)	O
,	O
and	O
Ikaros2	O
binding	O
motifs	O
were	O
demonstrated	O
in	O
the	O
5	O
'	O
upstream	O
region	O
of	O
this	O
gene	O
,	O
promoter	O
activity	O
was	O
investigated	O
using	O
luciferase	O
gene	O
as	O
a	O
reporter	O
.	O

The	O
results	O
indicate	O
that	O
the	O
Ets-1	O
binding	O
motif	O
in	O
the	O
segment	O
from	O
-	O
95	O
to	O
-	O
59	O
(	O
major	O
transcription	O
initiation	O
site	O
:	O
+	O
1	O
)	O
was	O
an	O
essential	O
cis	O
-	O
acting	O
regulatory	O
element	O
for	O
the	O
common	O
gamma	O
chain	O
gene	O
in	O
lymphoid	O
cells	O
.	O

Methylation	O
of	O
histone	B
H3	I
by	O
Set2	B
in	O
Saccharomyces	O
cerevisiae	O
is	O
linked	O
to	O
transcriptional	O
elongation	O
by	O
RNA	B
polymerase	I
II	I
.	O

Set2	B
methylates	O
Lys36	O
of	O
histone	B
H3	I
.	O

We	O
show	O
here	O
that	O
yeast	O
Set2	B
copurifies	O
with	O
RNA	B
polymerase	I
II	I
(	O
RNAPII	B
)	O
.	O

Chromatin	O
immunoprecipitation	O
analyses	O
demonstrated	O
that	O
Set2	B
and	O
histone	B
H3	I
Lys36	O
methylation	O
are	O
associated	O
with	O
the	O
coding	O
regions	O
of	O
several	O
genes	O
that	O
were	O
tested	O
and	O
correlate	O
with	O
active	O
transcription	O
.	O

Both	O
depend	O
,	O
as	O
well	O
,	O
on	O
the	O
Paf1	B
elongation	I
factor	I
complex	I
.	O

The	O
C	O
terminus	O
of	O
Set2	B
,	O
which	O
contains	O
a	O
WW	O
domain	O
,	O
is	O
also	O
required	O
for	O
effective	O
Lys36	O
methylation	O
.	O

Deletion	O
of	O
CTK1	B
,	O
encoding	O
an	O
RNAPII	B
CTD	B
kinase	I
,	O
prevents	O
Lys36	O
methylation	O
and	O
Set2	B
recruitment	O
,	O
suggesting	O
that	O
methylation	O
may	O
be	O
triggered	O
by	O
contact	O
of	O
the	O
WW	O
domain	O
or	O
C	O
terminus	O
of	O
Set2	B
with	O
Ser2	O
-	O
phosphorylated	O
CTD	O
.	O

A	O
set2	B
deletion	O
results	O
in	O
slight	O
sensitivity	O
to	O
6-azauracil	O
and	O
much	O
less	O
beta	B
-	I
galactosidase	I
produced	O
by	O
a	O
reporter	O
plasmid	O
,	O
resulting	O
from	O
a	O
defect	O
in	O
transcription	O
.	O

In	O
synthetic	O
genetic	O
array	O
(	O
SGA	O
)	O
analysis	O
,	O
synthetic	O
growth	O
defects	O
were	O
obtained	O
when	O
a	O
set2	B
deletion	O
was	O
combined	O
with	O
deletions	O
of	O
all	O
five	O
components	O
of	O
the	O
Paf1	B
complex	I
,	O
the	O
chromodomain	O
elongation	B
factor	I
Chd1	B
,	O
the	O
putative	O
elongation	B
factor	I
Soh1	B
,	O
the	O
Bre1	B
or	O
Lge1	B
components	O
of	O
the	O
histone	B
H2B	I
ubiquitination	O
complex	O
,	O
or	O
the	O
histone	B
H2A	I
variant	O
Htz1	B
.	O

SET2	B
also	O
interacts	O
genetically	O
with	O
components	O
of	O
the	O
Set1	B
and	O
Set3	B
complexes	O
,	O
suggesting	O
that	O
Set1	B
,	O
Set2	B
,	O
and	O
Set3	B
similarly	O
affect	O
transcription	O
by	O
RNAPII	B
.	O

Cytokine	B
response	O
to	O
endotoxin	O
in	O
individuals	O
heterozygous	O
for	O
the	O
Delta32	O
mutation	O
of	O
chemokine	B
receptor	I
CCR5	B
.	O

Studies	O
of	O
mice	O
with	O
a	O
targeted	O
disruption	O
of	O
the	O
CCR5	B
gene	O
suggest	O
that	O
the	O
CC	B
chemokine	I
receptor	I
5	I
(	O
CCR5	B
)	O
is	O
a	O
determinant	O
of	O
the	O
cytokine	B
response	O
to	O
endotoxin	O
.	O

In	O
humans	O
,	O
a	O
naturally	O
occurring	O
mutation	O
of	O
the	O
CCR5	B
gene	O
is	O
a	O
32	O
-	O
basepair	O
(	O
bp	O
)	O
deletion	O
which	O
precludes	O
the	O
translation	O
of	O
the	O
gene	O
into	O
a	O
functional	O
transmembrane	O
protein	O
.	O

To	O
evaluate	O
the	O
cytokine	B
phenotype	O
of	O
heterozygosity	O
for	O
the	O
32	O
deletion	O
,	O
we	O
studied	O
the	O
endotoxin	O
-	O
stimulated	O
release	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
Interleukin	B
(	I
IL	I
)	I
-	I
6	I
,	O
IL-8	B
,	O
IL-10	B
,	O
and	O
IL-12	B
in	O
whole	O
blood	O
ex	O
-	O
vivo	O
of	O
healthy	O
volunteers	O
and	O
patients	O
undergoing	O
elective	O
cardiac	O
bypass	O
surgery	O
.	O

This	O
operation	O
represents	O
a	O
major	O
surgical	O
trauma	O
associated	O
with	O
ischemia	O
-	O
reperfusion	O
-	O
injury	O
and	O
triggers	O
a	O
profound	O
inflammatory	O
response	O
.	O

In	O
these	O
patients	O
,	O
cytokine	B
plasma	O
concentrations	O
were	O
measured	O
during	O
and	O
after	O
cardiac	O
surgery	O
.	O

No	O
difference	O
was	O
found	O
between	O
the	O
frequencies	O
of	O
the	O
observed	O
and	O
expected	O
CCR5	B
genotypes	O
in	O
the	O
groups	O
of	O
individuals	O
studied	O
.	O

Furthermore	O
,	O
no	O
significant	O
difference	O
in	O
ex	O
-	O
vivo	O
or	O
peri	O
-	O
and	O
postoperative	O
cytokine	B
plasma	O
concentrations	O
was	O
detected	O
between	O
CCR5	B
wild	O
-	O
type	O
homozygotes	O
and	O
individuals	O
carrying	O
one	O
defective	O
CCR5	B
allele	O
.	O

Our	O
results	O
indicate	O
that	O
heterozygosity	O
for	O
the	O
32bp	O
deletion	O
of	O
CCR5	O
is	O
not	O
associated	O
with	O
an	O
altered	O
cytokine	B
response	O
to	O
endotoxin	O
or	O
to	O
a	O
major	O
surgical	O
trauma	O
when	O
compared	O
with	O
individuals	O
homozygous	O
for	O
the	O
wild	O
-	O
type	O
allele	O
.	O

DNA	B
polymerase	I
zeta	I
:	O
new	O
insight	O
into	O
eukaryotic	O
mutagenesis	O
and	O
mammalian	O
embryonic	O
development	O
.	O

Information	O
about	O
the	O
mechanisms	O
that	O
generate	O
mutations	O
in	O
eukaryotes	O
is	O
likely	O
to	O
be	O
useful	O
for	O
understanding	O
human	O
health	O
concerns	O
,	O
such	O
as	O
genotoxicity	O
and	O
cancer	O
.	O

Eukaryotic	O
mutagenesis	O
is	O
largely	O
the	O
outcome	O
of	O
attacks	O
by	O
endogenous	O
and	O
environmental	O
agents	O
.	O

Except	O
for	O
DNA	O
repair	O
,	O
cell	O
cycle	O
checkpoints	O
and	O
DNA	O
damage	O
avoidance	O
,	O
cells	O
have	O
also	O
evolved	O
DNA	O
damage	O
tolerance	O
mechanism	O
,	O
by	O
which	O
lesion	O
-	O
targeted	O
mutation	O
might	O
occur	O
in	O
the	O
genome	O
during	O
replication	O
by	O
specific	O
DNA	B
polymerases	I
to	O
bypass	O
the	O
lesions	O
(	O
translesion	O
DNA	O
synthesis	O
,	O
TLS	O
)	O
,	O
or	O
mutation	O
on	O
undamaged	O
DNA	O
templates	O
(	O
untargeted	O
mutation	O
)	O
might	O
be	O
induced	O
.	O

DNA	B
polymerase	I
zeta	I
(	O
pol	B
zeta	I
)	O
,	O
which	O
was	O
found	O
firstly	O
in	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
and	O
consists	O
of	O
catalytic	O
subunit	O
scRev3	B
and	O
stimulating	O
subunit	O
scRev7	B
,	O
has	O
received	O
more	O
attention	O
in	O
recent	O
years	O
.	O

Pol	B
zeta	I
is	O
a	O
member	O
of	O
DNA	B
polymerase	I
eta	I
subfamily	I
,	O
which	O
belongs	O
to	O
DNA	B
polymerase	I
B	I
family	I
,	O
and	O
exists	O
in	O
almost	O
all	O
eukaryotes	O
.	O

Human	O
homolog	O
of	O
the	O
scRev3	B
gene	O
is	O
located	O
in	O
chromosome	O
region	O
6q21	O
,	O
and	O
the	O
mouse	O
equivalent	O
maps	O
to	O
chromosome	O
10	O
,	O
distal	O
to	O
the	O
c	B
-	I
myb	I
gene	O
and	O
close	O
to	O
the	O
Macs	B
gene	O
.	O

Alternative	O
splicing	O
,	O
upstream	O
out	O
-	O
of	O
frame	O
ATG	O
can	O
be	O
found	O
in	O
yeast	O
scRev3	B
,	O
mouse	O
and	O
human	O
homologs	O
.	O

Furthermore	O
,	O
the	O
sequence	O
from	O
253	O
-	O
323	O
immediate	O
upstream	O
of	O
the	O
AUG	O
initiator	O
codon	O
has	O
the	O
potential	O
to	O
form	O
a	O
stem	O
-	O
loop	O
hairpin	O
secondary	O
structure	O
in	O
REV3	B
mRNA	O
,	O
suggesting	O
that	O
human	O
REV3	B
protein	O
may	O
be	O
expressed	O
at	O
low	O
levels	O
in	O
human	O
cells	O
under	O
normal	O
growth	O
conditions	O
.	O

The	O
functional	O
domain	O
analysis	O
showed	O
that	O
yeast	O
Rev3	B
-	O
980	O
tyrosine	O
in	O
conserved	O
region	O
II	O
is	O
at	O
the	O
polymerase	B
active	O
site	O
.	O

Human	O
REV3	B
amino	O
acid	O
residues	O
1	O
776	O
-	O
2	O
195	O
provide	O
a	O
REV7	B
binding	O
domain	O
,	O
and	O
REV7	B
amino	O
acid	O
residues	O
1	O
-	O
211	O
provide	O
a	O
bind	O
domain	O
for	O
REV1	B
,	O
REV3	B
and	O
REV7	B
itself	O
.	O

More	O
interestingly	O
,	O
REV7	B
interacts	O
with	O
hMAD2	B
and	O
therefore	O
might	O
function	O
in	O
the	O
cell	O
cycle	O
control	O
by	O
affecting	O
the	O
activation	O
of	O
APC	B
(	O
anaphase	B
promoting	I
complex	I
)	O
.	O

Currently	O
it	O
has	O
been	O
known	O
that	O
pol	B
zeta	I
is	O
involved	O
in	O
most	O
spontaneous	O
mutation	O
,	O
lesion	O
-	O
targeted	O
mutation	O
via	O
TLS	O
,	O
chemical	O
carcinogen	O
induced	O
untargeted	O
mutation	O
and	O
somatic	O
hypermutation	O
of	O
antibody	O
genes	O
in	O
mammalian	O
.	O

In	O
TLS	O
pathway	O
,	O
pol	B
zeta	I
acts	O
as	O
a	O
""""	O
mismatch	O
extender	O
""""	O
with	O
combination	O
of	O
other	O
DNA	B
polymerases	I
,	O
such	O
as	O
pol	B
iota	I
.	O

Unlike	O
in	O
yeast	O
,	O
it	O
was	O
found	O
that	O
pol	B
zeta	I
also	O
functioned	O
in	O
mouse	O
embryonic	O
development	O
more	O
recently	O
.	O

It	O
was	O
hypothesized	O
that	O
the	O
roles	O
of	O
pol	B
zeta	I
in	O
TLS	O
and	O
cell	O
cycle	O
control	O
might	O
contribute	O
to	O
mouse	O
embryonic	O
lethality	O
.	O

Gene	O
expression	O
profiling	O
of	O
the	O
effects	O
of	O
castration	O
and	O
estrogen	O
treatment	O
in	O
the	O
rat	O
uterus	O
.	O

The	O
development	O
and	O
functions	O
of	O
female	O
reproductive	O
tissues	O
are	O
regulated	O
by	O
the	O
actions	O
of	O
two	O
major	O
sex	O
steroid	O
hormones	O
,	O
estrogen	O
and	O
progesterone	O
.	O

To	O
investigate	O
estrogen	O
-	O
dependent	O
gene	O
expression	O
in	O
the	O
rat	O
uterus	O
,	O
we	O
studied	O
the	O
effect	O
of	O
ovariectomy	O
with	O
or	O
without	O
estrogen	O
treatment	O
on	O
the	O
uterine	O
expression	O
of	O
3000	O
genes	O
using	O
cDNA	O
microarrays	O
.	O

Many	O
genes	O
were	O
regulated	O
by	O
either	O
treatment	O
,	O
but	O
only	O
few	O
were	O
reciprocally	O
regulated	O
by	O
these	O
contrasting	O
treatments	O
.	O

The	O
present	O
study	O
confirms	O
previous	O
findings	O
and	O
identifies	O
several	O
genes	O
with	O
expressions	O
not	O
previously	O
known	O
to	O
be	O
influenced	O
by	O
estrogen	O
.	O

These	O
genes	O
include	O
follistatin	B
-	I
related	I
protein	I
,	O
Thy-1	B
glycoprotein	I
,	O
alpha	B
-	I
fodrin	I
,	O
CD24	B
,	O
immediate	B
early	I
response	I
5	I
,	O
insulin	B
-	I
like	I
growth	I
factor	I
-	I
binding	I
protein	I
2	I
,	O
growth	B
response	I
protein	I
CL-6	I
(	O
INSIG-1	B
)	O
,	O
ladinin1	B
,	O
class	B
I	I
major	I
histocompatibility	I
complex	I
heavy	I
chain	I
,	O
lactadherin	B
,	O
ezrin	B
,	O
and	O
Fas	B
-	I
activated	I
serine	I
/	I
threonine	I
kinase	I
.	O

Because	O
of	O
their	O
function	O
as	O
regulators	O
of	O
proliferation	O
and	O
apoptosis	O
,	O
CD24	B
,	O
insulin	B
-	I
like	I
growth	I
factor	I
-	I
binding	I
protein	I
2	I
,	O
and	O
Fas	B
/	O
Fas	B
ligand	I
were	O
examined	O
further	O
by	O
immunohistochemical	O
expression	O
and	O
tissue	O
localization	O
analysis	O
.	O

Our	O
analysis	O
confirms	O
a	O
contrasting	O
regulation	O
of	O
these	O
gene	O
products	O
by	O
ovariectomy	O
and	O
estrogen	O
treatment	O
.	O

The	O
present	O
study	O
identifies	O
novel	O
mediators	O
of	O
estrogen	O
actions	O
in	O
the	O
uterus	O
and	O
provides	O
genome	O
-	O
wide	O
expression	O
data	O
from	O
which	O
novel	O
hypotheses	O
regarding	O
uterine	O
function	O
can	O
be	O
generated	O
.	O

Intramembrane	O
proteolysis	O
by	O
presenilin	B
and	O
presenilin	B
-	O
like	O
proteases	B
.	O

Regulated	O
intramembrane	O
proteolysis	O
is	O
a	O
novel	O
mechanism	O
involving	O
proteases	B
that	O
hydrolyze	O
their	O
substrates	O
in	O
a	O
hydrophobic	O
environment	O
.	O

Presenilin	B
(	I
PS	I
)	I
1	I
and	O
PS	B
2	I
are	O
required	O
for	O
intramembrane	O
cleavage	O
of	O
an	O
increasing	O
number	O
of	O
type	O
I	O
membrane	O
proteins	O
,	O
including	O
the	O
amyloid	B
precursor	I
protein	I
of	O
Alzheimer	O
'	O
s	O
disease	O
and	O
the	O
Notch	B
receptor	O
,	O
which	O
signals	O
during	O
differentiation	O
and	O
development	O
.	O

Mutagenesis	O
,	O
affinity	O
labeling	O
,	O
biochemical	O
isolation	O
,	O
and	O
reconstitution	O
in	O
cells	O
reveal	O
that	O
PS	B
,	O
in	O
complex	O
with	O
co	O
-	O
factors	O
nicastrin	B
,	O
APH	B
-	I
1	I
and	O
PEN	B
-	I
2	I
,	O
apparently	O
contains	O
the	O
active	O
site	O
of	O
gamma	B
-	I
secretase	I
,	O
a	O
novel	O
membrane	O
aspartyl	B
protease	I
.	O

In	O
addition	O
,	O
other	O
related	O
aspartyl	B
proteases	I
have	O
been	O
identified	O
.	O

These	O
include	O
members	O
of	O
the	O
type-4	B
prepilin	I
peptidase	I
family	I
in	O
bacteria	O
,	O
which	O
are	O
known	O
proteases	B
and	O
carry	O
a	O
GD	O
motif	O
conserved	O
in	O
PS	B
.	O

A	O
group	O
of	O
multi	O
-	O
pass	O
membrane	O
proteins	O
found	O
in	O
eukaryotes	O
also	O
contain	O
YD	O
and	O
LGXGD	O
motifs	O
in	O
two	O
transmembrane	O
domains	O
that	O
are	O
conserved	O
in	O
PS	B
and	O
postulated	O
to	O
constitute	O
an	O
aspartyl	B
protease	I
active	O
site	O
.	O

Among	O
these	O
is	O
signal	B
peptide	I
peptidase	I
(	O
SPP	B
)	O
,	O
which	O
cleaves	O
remnant	O
signal	O
peptides	O
derived	O
from	O
signal	B
-	I
peptidase	I
-	O
mediated	O
ectodomain	O
shedding	O
.	O

SPP	B
cuts	O
type	O
II	O
membrane	O
proteins	O
,	O
illustrating	O
that	O
PS	B
-	O
like	O
proteases	B
play	O
a	O
key	O
role	O
in	O
intramembrane	O
proteolysis	O
of	O
single	O
-	O
pass	O
membrane	O
proteins	O
oriented	O
in	O
either	O
direction	O
.	O

Molecular	O
analysis	O
of	O
the	O
copper	O
-	O
transporting	O
efflux	O
system	O
CusCFBA	B
of	O
Escherichia	O
coli	O
.	O

The	O
cus	B
determinant	O
of	O
Escherichia	O
coli	O
encodes	O
the	O
CusCFBA	B
proteins	O
that	O
mediate	O
resistance	O
to	O
copper	O
and	O
silver	O
by	O
cation	O
efflux	O
.	O

CusA	B
and	O
CusB	B
were	O
essential	O
for	O
copper	O
resistance	O
,	O
and	O
CusC	B
and	O
CusF	B
were	O
required	O
for	O
full	O
resistance	O
.	O

Replacements	O
of	O
methionine	O
residues	O
573	O
,	O
623	O
,	O
and	O
672	O
with	O
isoleucine	O
in	O
CusA	B
resulted	O
in	O
loss	O
of	O
copper	O
resistance	O
,	O
demonstrating	O
their	O
functional	O
importance	O
.	O

Substitutions	O
for	O
several	O
other	O
methionine	O
residues	O
of	O
this	O
protein	O
did	O
not	O
have	O
any	O
effect	O
.	O

The	O
small	O
10	O
-	O
kDa	O
protein	O
CusF	B
(	O
previously	O
YlcC	B
)	O
was	O
shown	O
to	O
be	O
a	O
periplasmic	O
protein	O
.	O

CusF	B
bound	O
one	O
copper	O
per	O
polypeptide	O
.	O

The	O
pink	O
CusF	B
copper	O
protein	O
complex	O
exhibited	O
an	O
absorption	O
maximum	O
at	O
around	O
510	O
nm	O
.	O

Methionine	O
residues	O
of	O
CusF	B
were	O
involved	O
in	O
copper	O
binding	O
as	O
shown	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

CusF	B
interacted	O
with	O
CusB	B
and	O
CusC	B
polypeptides	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
.	O

In	O
contrast	O
to	O
other	O
well	O
-	O
studied	O
CBA	O
-	O
type	O
heavy	O
metal	O
efflux	O
systems	O
,	O
Cus	B
was	O
shown	O
to	O
be	O
a	O
tetrapartite	O
resistance	O
system	O
that	O
involves	O
the	O
novel	O
periplasmic	O
copper	O
-	O
binding	O
protein	O
CusF	B
.	O

These	O
data	O
provide	O
additional	O
evidence	O
for	O
the	O
hypothesis	O
that	O
Cu	O
(	O
I	O
)	O
is	O
directly	O
transported	O
from	O
the	O
periplasm	O
across	O
the	O
outer	O
membrane	O
by	O
the	O
Cus	B
complex	I
.	O

Chemokine	B
receptor	I
inhibitor	O
,	O
Antileukinate	O
,	O
suppressed	O
ovalbumin	B
-	O
induced	O
eosinophilic	O
inflammation	O
in	O
the	O
airway	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
eosinophils	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

An	O
eosinophil	O
-	O
active	O
chemokine	B
,	O
eotaxin	B
,	O
and	O
its	O
receptor	O
,	O
C	B
-	I
C	I
chemokine	I
receptor	I
3	I
,	O
are	O
particularly	O
attractive	O
as	O
novel	O
targets	O
of	O
immunological	O
intervention	O
for	O
the	O
disease	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
effects	O
of	O
a	O
hexa	O
-	O
peptide	O
(	O
Ac	O
-	O
RRWWCR	O
-	O
NH	O
(	O
2	O
)	O
)	O
,	O
Antileukinate	O
,	O
which	O
we	O
have	O
previously	O
defined	O
as	O
a	O
potent	O
inhibitor	O
of	O
CXC	B
chemokine	I
receptor	I
1	I
and	I
2	I
,	O
on	O
eotaxin	B
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Antileukinate	O
inhibited	O
the	O
binding	O
of	O
125I	O
-	O
labeled	O
human	O
eotaxin	B
to	O
human	O
eosinophils	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
approximately	O
10	O
microM	O
and	O
eosinophil	O
chemotaxis	O
to	O
human	O
eotaxin	B
was	O
significantly	O
inhibited	O
by	O
10	O
microM	O
of	O
Antileukinate	O
.	O

We	O
examined	O
the	O
effects	O
of	O
Antileukinate	O
on	O
eosinophil	O
accumulation	O
induced	O
by	O
intraperitoneal	O
administration	O
of	O
murine	O
eotaxin	B
,	O
and	O
confirmed	O
that	O
Antileukinate	O
is	O
also	O
active	O
in	O
the	O
murine	O
system	O
.	O

When	O
Antileukinate	O
was	O
tested	O
in	O
ovalbumin	B
-	O
induced	O
airway	O
inflammation	O
model	O
in	O
vivo	O
,	O
Antileukinate	O
significantly	O
inhibited	O
eosinophil	O
accumulation	O
and	O
allergen	O
-	O
induced	O
increase	O
in	O
total	O
protein	O
in	O
bronchoalveolar	O
lavage	O
fluids	O
.	O

Furthermore	O
,	O
Antileukinate	O
suppressed	O
fibrous	O
thickening	O
of	O
submucosal	O
tissue	O
induced	O
by	O
chronic	O
antigen	O
challenge	O
.	O

These	O
results	O
suggest	O
that	O
eotaxin	B
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
eosinophilic	O
airway	O
inflammation	O
,	O
and	O
that	O
Antileukinate	O
may	O
be	O
a	O
promising	O
tool	O
to	O
control	O
allergic	O
diseases	O
.	O

Glutamine	O
decreases	O
lipopolysaccharide	O
-	O
induced	O
IL-8	B
production	O
in	O
Caco-2	O
cells	O
through	O
a	O
non	O
-	O
NF	B
-	I
kappaB	I
p50	I
mechanism	O
.	O

Glutamine	O
(	O
Gln	O
)	O
supplementation	O
has	O
been	O
shown	O
to	O
decrease	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	B
by	O
the	O
human	O
intestinal	O
mucosa	O
.	O

The	O
mechanism	O
of	O
this	O
is	O
poorly	O
understood	O
.	O

We	O
hypothesize	O
that	O
Gln	O
down	O
-	O
regulates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
pro	O
-	O
inflammatory	O
cytokine	B
production	O
in	O
Caco-2	O
cells	O
by	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappaB	I
)	O
.	O

Caco-2	O
cells	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
Gln	O
with	O
or	O
without	O
methionine	O
sulfoximine	O
(	O
MS	O
,	O
an	O
inhibitor	O
of	O
glutamine	B
synthetase	I
)	O
before	O
stimulation	O
with	O
LPS	O
.	O

IL-6	B
,	O
IL-8	B
,	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
protein	O
and	O
mRNA	O
level	O
were	O
determined	O
.	O

NF	B
-	I
kappaB	I
translocation	O
was	O
determined	O
using	O
an	O
ELISA	O
-	O
based	O
kit	O
.	O

IL-8	B
was	O
the	O
only	O
detectable	O
cytokine	B
/	O
chemokine	B
.	O

The	O
largest	O
amount	O
of	O
IL-8	B
was	O
secreted	O
by	O
cells	O
in	O
the	O
presence	O
of	O
MS	O
with	O
no	O
Gln	O
in	O
the	O
medium	O
after	O
exposure	O
to	O
LPS	O
.	O

LPS	O
increased	O
IL-8	B
production	O
,	O
peaking	O
10h	O
after	O
LPS	O
administration	O
.	O

The	O
addition	O
of	O
Gln	O
(	O
0.5	O
or	O
5.0mM	O
)	O
decreased	O
IL-8	B
peptide	O
and	O
mRNA	O
expression	O
.	O

LPS	O
increased	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
MS	O
.	O

Neither	O
Gln	O
nor	O
MS	O
altered	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
.	O

These	O
results	O
indicate	O
that	O
the	O
lack	O
of	O
glutamine	O
increases	O
IL-8	B
production	O
by	O
Caco-2	O
cells	O
after	O
LPS	O
stimulation	O
.	O

However	O
,	O
the	O
glutamine	O
-	O
mediated	O
decrease	O
in	O
LPS	O
-	O
stimulated	O
IL-8	B
production	O
is	O
not	O
associated	O
with	O
NF	B
-	I
kappaB	I
p50	I
nuclear	O
binding	O
.	O

IRAK	B
-	O
dependent	O
phosphorylation	O
of	O
Stat1	B
on	O
serine	O
727	O
in	O
response	O
to	O
interleukin-1	B
and	O
effects	O
on	O
gene	O
expression	O
.	O

Interleukin-1	B
(	O
IL-1	B
)	O
induces	O
the	O
phosphorylation	O
of	O
Stat1	B
on	O
serine	O
727	O
but	O
not	O
on	O
tyrosine	O
701	O
.	O

Analyses	O
of	O
mutant	O
I1A	O
cells	O
,	O
which	O
lack	O
the	O
IL-1	B
receptor	I
-	I
associated	I
kinase	I
(	O
IRAK	B
)	O
,	O
and	O
of	O
I1A	O
cells	O
reconstituted	O
with	O
deletion	O
mutants	O
of	O
IRAK	B
show	O
that	O
the	O
IL-1	B
-	O
mediated	O
phosphorylation	O
of	O
Stat1	B
on	O
serine	O
requires	O
the	O
IRAK	B
protein	O
but	O
not	O
its	O
kinase	B
activity	O
and	O
does	O
not	O
involve	O
phosphatidylinositol-3'-kinase	B
(	O
PI3	B
K	I
)	O
or	O
the	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinases	I
p38	B
or	O
ERK	B
.	O

IRAK	B
and	O
Stat1	B
interact	O
in	O
vivo	O
,	O
and	O
this	O
interaction	O
is	O
increased	O
in	O
response	O
to	O
IL-1	B
,	O
suggesting	O
that	O
IRAK	B
may	O
serve	O
to	O
recruit	O
the	O
as	O
yet	O
unknown	O
IL-1	B
-	O
induced	O
Stat1	B
serine	B
kinase	I
.	O

Chemical	O
inhibitors	O
or	O
dominant	O
-	O
negative	O
forms	O
of	O
signaling	O
components	O
required	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
,	O
ATF	B
,	O
or	O
AP-1	B
in	O
response	O
to	O
IL-1	B
do	O
not	O
affect	O
the	O
phosphorylation	O
of	O
Stat1	B
on	O
serine	O
.	O

IL-1	B
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
enhance	O
the	O
serine	O
phosphorylation	O
of	O
Stat1	B
that	O
occurs	O
in	O
response	O
to	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
potentiate	O
IFN	B
-	I
gamma	I
-	O
mediated	O
,	O
Stat1	B
-	O
driven	O
gene	O
expression	O
,	O
thus	O
contributing	O
to	O
the	O
synergistic	O
activities	O
of	O
these	O
proinflammatory	O
cytokines	B
.	O

Structural	O
and	O
biochemical	O
dissection	O
of	O
photorespiration	O
in	O
hybrids	O
differing	O
in	O
genome	O
constitution	O
between	O
Diplotaxis	O
tenuifolia	O
(	O
C3-C4	O
)	O
and	O
radish	O
(	O
C3	O
)	O
.	O

We	O
compared	O
the	O
structural	O
,	O
biochemical	O
,	O
and	O
physiological	O
characteristics	O
involved	O
in	O
photorespiration	O
of	O
intergeneric	O
hybrids	O
differing	O
in	O
genome	O
constitution	O
(	O
DtDtR	O
,	O
DtDtRR	O
,	O
and	O
DtRR	O
)	O
between	O
the	O
C	O
(	O
3	O
)	O
-C	O
(	O
4	O
)	O
intermediate	O
species	O
Diplotaxis	O
tenuifolia	O
(	O
DtDt	O
)	O
and	O
the	O
C	O
(	O
3	O
)	O
species	O
radish	O
(	O
Raphanus	O
sativus	O
;	O
RR	O
)	O
.	O

The	O
bundle	O
sheath	O
(	O
BS	O
)	O
cells	O
in	O
D.	O
tenuifolia	O
included	O
many	O
centripetally	O
located	O
chloroplasts	O
and	O
mitochondria	O
,	O
but	O
those	O
of	O
radish	O
had	O
only	O
a	O
few	O
chloroplasts	O
and	O
mitochondria	O
.	O

In	O
the	O
hybrids	O
,	O
the	O
numbers	O
of	O
chloroplasts	O
and	O
mitochondria	O
,	O
the	O
ratio	O
of	O
centripetally	O
located	O
organelles	O
to	O
total	O
organelles	O
,	O
and	O
the	O
mitochondrial	O
size	O
in	O
the	O
BS	O
cells	O
increased	O
with	O
an	O
increase	O
in	O
the	O
constitution	O
ratio	O
of	O
the	O
Dt	O
:	O
R	O
genome	O
.	O

The	O
P	B
-	I
protein	I
of	I
glycine	I
decarboxylase	I
(	O
GDC	B
)	O
was	O
confined	O
to	O
the	O
BS	O
mitochondria	O
in	O
D.	O
tenuifolia	O
,	O
whereas	O
in	O
radish	O
,	O
it	O
accumulated	O
more	O
densely	O
in	O
the	O
mesophyll	O
than	O
in	O
the	O
BS	O
mitochondria	O
.	O

In	O
the	O
hybrids	O
,	O
more	O
intense	O
accumulation	O
of	O
GDC	B
in	O
the	O
BS	O
relative	O
to	O
the	O
mesophyll	O
mitochondria	O
occurred	O
with	O
an	O
increase	O
in	O
the	O
Dt	O
:	O
R	O
ratio	O
.	O

These	O
structural	O
and	O
biochemical	O
features	O
in	O
the	O
hybrids	O
were	O
reflected	O
in	O
the	O
gas	O
exchange	O
characteristics	O
of	O
leaves	O
,	O
such	O
as	O
the	O
CO	O
(	O
2	O
)	O
compensation	O
point	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
leaf	O
structure	O
,	O
the	O
intercellular	O
pattern	O
of	O
GDC	B
expression	O
,	O
and	O
the	O
gas	O
exchange	O
characteristics	O
of	O
C	O
(	O
3	O
)	O
-	O
C	O
(	O
4	O
)	O
intermediate	O
photosynthesis	O
are	O
inherited	O
in	O
the	O
hybrids	O
depending	O
on	O
the	O
constitution	O
ratio	O
of	O
the	O
parent	O
genomes	O
.	O

Our	O
findings	O
also	O
demonstrate	O
that	O
the	O
apparent	O
reduced	O
photorespiration	O
in	O
C	O
(	O
3	O
)	O
-C	O
(	O
4	O
)	O
intermediate	O
plants	O
is	O
mainly	O
due	O
to	O
the	O
structural	O
differentiation	O
of	O
mitochondria	O
and	O
chloroplasts	O
in	O
the	O
BS	O
cells	O
combined	O
with	O
the	O
BS	O
-	O
dominant	O
expression	O
of	O
GDC	B
.	O

Expression	O
of	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
and	O
P450	B
side	I
chain	I
cleavage	I
enzyme	O
in	O
the	O
human	O
uterine	O
endometrium	O
.	O

The	O
enzyme	O
complex	O
3beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
/	I
Delta5	I
-	I
Delta4	I
-	I
isomerase	I
(	O
3beta	B
-	I
HSD	I
)	O
is	O
involved	O
in	O
the	O
biosynthesis	O
of	O
all	O
classes	O
of	O
active	O
steroids	O
.	O

The	O
expression	O
of	O
3b	B
-	I
HSD	I
in	O
human	O
uterine	O
endometrium	O
during	O
the	O
menstrual	O
cycle	O
and	O
decidua	O
was	O
examined	O
in	O
an	O
effort	O
to	O
understand	O
its	O
role	O
during	O
ova	O
implantation	O
.	O

3beta	B
-	I
HSD	I
was	O
weakly	O
expressed	O
in	O
the	O
glandular	O
epithelium	O
of	O
the	O
proliferative	O
phase	O
and	O
moderately	O
expressed	O
in	O
the	O
glandular	O
epithelium	O
of	O
secretory	O
phase	O
of	O
the	O
endometrium	O
.	O

In	O
the	O
decidua	O
of	O
the	O
ectopic	O
pregnancy	O
,	O
3beta	B
-	I
HSD	I
was	O
strongly	O
expressed	O
.	O

The	O
human	O
uterine	O
endometrial	O
3beta	B
-	I
HSD	I
was	O
identified	O
as	O
being	O
the	O
same	O
type	O
as	O
the	O
placental	O
3beta	B
-	I
HSD	I
by	O
RT	O
-	O
PCR	O
and	O
sequence	O
analysis	O
.	O

In	O
addition	O
to	O
the	O
expression	O
of	O
3beta	B
-	I
HSD	I
,	O
P450scc	B
was	O
expressed	O
in	O
the	O
decidua	O
of	O
the	O
ectopic	O
pregnancy	O
.	O

These	O
results	O
suggest	O
that	O
pregnenolone	O
might	O
be	O
synthesized	O
from	O
cholesterol	O
by	O
P450scc	B
de	O
novo	O
and	O
then	O
,	O
it	O
is	O
converted	O
to	O
progesterone	O
by	O
3beta	B
-	I
HSD	I
in	O
the	O
uterine	O
endometrium	O
.	O

The	O
data	O
implies	O
that	O
the	O
endometrial	O
3beta	B
-	I
HSD	I
can	O
use	O
not	O
only	O
the	O
out	O
-	O
coming	O
pregnenolone	O
from	O
the	O
adrenal	O
gland	O
but	O
also	O
the	O
self	O
-	O
made	O
pregnenolone	O
to	O
produce	O
progesterone	O
.	O

The	O
de	O
novo	O
synthesis	O
of	O
progesterone	O
in	O
the	O
endometrium	O
might	O
be	O
a	O
crucial	O
factor	O
for	O
implantation	O
and	O
maintenance	O
of	O
pregnancy	O
.	O

RcsCDB	B
His	O
-	O
Asp	O
phosphorelay	O
system	O
negatively	O
regulates	O
the	O
flhDC	B
operon	I
in	O
Escherichia	O
coli	O
.	O

The	O
genes	O
involved	O
in	O
flagellum	O
synthesis	O
,	O
motility	O
and	O
chemotaxis	O
in	O
Escherichia	O
coli	O
are	O
expressed	O
in	O
a	O
hierarchical	O
fashion	O
.	O

At	O
the	O
top	O
of	O
the	O
hierarchy	O
lies	O
the	O
master	O
regulator	O
FlhDC	B
,	O
required	O
for	O
the	O
expression	O
of	O
the	O
whole	O
set	O
of	O
genes	O
.	O

The	O
operon	B
flhDC	I
is	O
controlled	O
by	O
numerous	O
regulators	O
including	O
H	B
-	I
NS	I
,	O
CRP	B
,	O
EnvZ	B
/	O
OmpR	B
,	O
QseBC	B
and	O
LrhA	B
.	O

In	O
the	O
present	O
work	O
,	O
we	O
report	O
that	O
the	O
flhDC	B
operon	I
is	O
also	O
negatively	O
regulated	O
by	O
the	O
His	O
-	O
Asp	O
phosphorelay	O
system	O
RcsCDB	B
.	O

The	O
regulation	O
is	O
potentiated	O
by	O
the	O
RcsB	B
cofactor	O
RcsA	B
.	O

Genetic	O
analysis	O
indicates	O
that	O
an	O
RcsAB	B
box	O
,	O
located	O
downstream	O
of	O
the	O
promoter	O
,	O
is	O
required	O
for	O
the	O
regulation	O
.	O

The	O
binding	O
of	O
RcsB	B
and	O
RcsA	B
to	O
this	O
site	O
was	O
demonstrated	O
by	O
gel	O
retardation	O
and	O
DNase	B
I	I
protection	O
assays	O
.	O

In	O
addition	O
,	O
mutation	O
analysis	O
suggests	O
that	O
RcsA	B
-	O
specific	O
determinants	O
lie	O
in	O
the	O
right	O
part	O
of	O
the	O
'	O
RcsAB	B
box	O
'	O
.	O

Transcriptional	O
expression	O
of	O
Escherichia	O
coli	O
glutamate	O
-	O
dependent	O
acid	O
resistance	O
genes	O
gadA	B
and	O
gadBC	B
in	O
an	O
hns	B
rpoS	B
mutant	O
.	O

Resistance	O
to	O
being	O
killed	O
by	O
acidic	O
environments	O
with	O
pH	O
values	O
lower	O
than	O
3	O
is	O
an	O
important	O
feature	O
of	O
both	O
pathogenic	O
and	O
nonpathogenic	O
Escherichia	O
coli	O
.	O

The	O
most	O
potent	O
E.	O
coli	O
acid	O
resistance	O
system	O
utilizes	O
two	O
isoforms	O
of	O
glutamate	B
decarboxylase	I
encoded	O
by	O
gadA	B
and	O
gadB	B
and	O
a	O
putative	O
glutamate	B
:	I
gamma	I
-	I
aminobutyric	I
acid	I
antiporter	I
encoded	O
by	O
gadC	B
.	O

The	O
gad	B
system	O
is	O
controlled	O
by	O
two	O
repressors	O
(	O
H	B
-	I
NS	I
and	O
CRP	B
)	O
,	O
one	O
activator	O
(	O
GadX	B
)	O
,	O
one	O
repressor	O
-	O
activator	O
(	O
GadW	B
)	O
,	O
and	O
two	O
sigma	B
factors	I
(	O
sigma	B
(	I
S	I
)	I
and	O
sigma	B
(	I
70	I
)	I
)	O
.	O

In	O
contrast	O
to	O
results	O
of	O
previous	O
reports	O
,	O
we	O
demonstrate	O
that	O
gad	B
transcription	O
can	O
be	O
detected	O
in	O
an	O
hns	B
rpoS	B
mutant	O
strain	O
of	O
E.	O
coli	O
K-12	O
,	O
indicating	O
that	O
gad	B
promoters	O
can	O
be	O
initiated	O
by	O
sigma	B
(	I
70	I
)	I
in	O
the	O
absence	O
of	O
H	B
-	I
NS	I
.	O

[	O
Construction	O
and	O
stable	O
expression	O
of	O
intracellular	O
antibodies	O
to	O
glycoprotein	O
of	O
hantavirus	O
]	O

OBJECTIVE	O
:	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
hantavirus	O
assembly	O
and	O
maturation	O
by	O
stably	O
expressing	O
the	O
intracellular	O
antibodies	O
to	O
hantavirus	O
glycoprotein	B
G1	I
and	I
G2	I
in	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
cytoplasm	O
(	O
Cyto	O
)	O
of	O
Vero	O
E6	O
cell	O
.	O

METHODS	O
:	O

The	O
genes	O
of	O
VH	O
and	O
VL	O
of	O
antibodies	O
against	O
glycoprotein	O
of	O
hantavirus	O
were	O
amplified	O
by	O
PCR	O
and	O
cloned	O
into	O
pOPE	O
101	O
-	O
215	O
(	O
Yol	O
)	O
vector	O
.	O

The	O
G1	B
and	O
G2	B
proteins	O
specific	O
ScFv	O
genes	O
were	O
first	O
expressed	O
in	O
E.coli	O
and	O
the	O
function	O
and	O
binding	O
properties	O
were	O
identified	O
.	O

The	O
gene	O
of	O
ScFv	O
were	O
further	O
inserted	O
into	O
intracellular	O
expression	O
vectyrs	O
pEF	O
/	O
myc	B
/	O
ER	O
and	O
pEF	O
/	O
myc	B
/	O
CYTO	O
vector	O
and	O
transfected	O
Vero	O
E6	O
cell	O
.	O

The	O
clonal	O
cell	O
line	O
which	O
stabl	O
expresses	O
ScFv	O
were	O
isolated	O
under	O
the	O
pressure	O
of	O
G418	O
.	O

RESULTS	O
:	O

The	O
ScFv	O
genes	O
of	O
hantavirus	O
G1	B
and	O
G2	B
specific	O
antibodies	O
were	O
successfully	O
expressed	O
in	O
subcellular	O
compartment	O
ER	O
and	O
Cyto	O
of	O
Vero	O
E6	O
cells	O
and	O
specifically	O
targeted	O
G1	B
and	O
G2	B
protein	O
after	O
virus	O
infection	O
of	O
the	O
cells	O
.	O

CONCLUSIONS	O
:	O

The	O
recombination	O
of	O
intrabody	O
to	O
Hantann	O
virus	O
glycoprotein	O
was	O
constructed	O
successfully	O
,	O
and	O
it	O
may	O
provide	O
basic	O
material	O
for	O
the	O
studying	O
antiviral	O
gene	O
therapy	O
and	O
the	O
molecular	O
mechanism	O
of	O
viral	O
replication	O
and	O
infection	O
.	O

Cellular	O
mechanisms	O
of	O
the	O
hemostatic	O
effects	O
of	O
desmopressin	O
(	O
DDAVP	O
)	O
.	O

The	O
synthetic	O
analog	O
of	O
vasopressin	B
desmopressin	O
(	O
DDAVP	O
)	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
von	O
Willebrand	O
disease	O
(	O
VWD	O
)	O
,	O
hemophilia	O
A	O
,	O
several	O
platelet	O
disorders	O
,	O
and	O
uremic	O
bleeding	O
.	O

DDAVP	O
induces	O
an	O
increase	O
in	O
plasma	O
levels	O
of	O
von	B
Willebrand	I
factor	I
(	O
VWF	B
)	O
,	O
coagulation	B
factor	I
VIII	I
(	O
FVIII	B
)	O
,	O
and	O
tissue	B
plasminogen	I
activator	I
(	O
t	B
-	I
PA	I
)	O
.	O

It	O
also	O
has	O
a	O
vasodilatory	O
action	O
.	O

In	O
spite	O
of	O
its	O
extensive	O
clinical	O
use	O
,	O
its	O
cellular	O
mechanism	O
of	O
action	O
remains	O
incompletely	O
understood	O
.	O

Its	O
effect	O
on	O
VWF	B
and	O
t	B
-	I
PA	I
as	O
well	O
as	O
its	O
vasodilatory	O
effect	O
are	O
likely	O
explained	O
by	O
a	O
direct	O
action	O
on	O
the	O
endothelium	O
,	O
via	O
activation	O
of	O
endothelial	O
vasopressin	B
V2R	I
receptor	I
and	O
cAMP	O
-	O
mediated	O
signaling	O
.	O

This	O
leads	O
to	O
exocytosis	O
from	O
Weibel	O
Palade	O
bodies	O
where	O
both	O
VWF	B
and	O
t	B
-	I
PA	I
are	O
stored	O
,	O
as	O
well	O
as	O
to	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
via	O
activation	O
of	O
endothelial	B
NO	I
synthase	I
.	O

The	O
mechanism	O
of	O
action	O
of	O
DDAVP	O
on	O
FVIII	B
plasma	O
levels	O
remains	O
to	O
be	O
elucidated	O
.	O

The	O
hemostatic	O
effect	O
of	O
DDAVP	O
likely	O
involves	O
additional	O
cellular	O
effects	O
that	O
remain	O
to	O
be	O
discovered	O
.	O

Abnormal	O
killer	O
inhibitory	O
receptor	O
expression	O
on	O
natural	O
killer	O
cells	O
in	O
patients	O
with	O
BehÃ?Â§et	O
's	O
disease	O
.	O

Viral	O
infection	O
has	O
been	O
assigned	O
some	O
role	O
in	O
the	O
pathogenesis	O
of	O
BehÃ?Â§et	O
's	O
disease	O
(	O
BD	O
)	O
.	O

Defects	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
repertoire	O
may	O
be	O
involved	O
in	O
impaired	O
antiviral	O
immunity	O
,	O
leading	O
to	O
the	O
development	O
of	O
BD	O
.	O

We	O
studied	O
killer	O
inhibitory	O
receptor	O
(	O
KIR	B
)	O
expression	O
in	O
40	O
patients	O
with	O
BD	O
.	O

CD94	B
and	O
CD158b	B
expression	O
of	O
NK	O
cells	O
was	O
normal	O
in	O
a	O
great	O
majority	O
of	O
BD	O
patients	O
.	O

NKB1	B
expression	O
was	O
reduced	O
in	O
eight	O
and	O
increased	O
in	O
six	O
.	O

Twelve	O
of	O
these	O
14	O
patients	O
(	O
86	O
%	O
)	O
had	O
severe	O
eye	O
disease	O
.	O

Some	O
had	O
reduced	O
NKB1	B
and	O
enhanced	O
CD158a	B
expression	O
simultaneously	O
,	O
or	O
enhanced	O
NKB1	B
and	O
reduced	O
CD158a	B
simultaneously	O
,	O
suggesting	O
a	O
skewed	O
NK	O
cell	O
repertoire	O
in	O
BD	O
.	O

Collectively	O
,	O
KIR	B
expression	O
was	O
abnormal	O
in	O
the	O
BD	O
patients	O
with	O
severe	O
eye	O
disease	O
.	O

This	O
may	O
result	O
from	O
genetic	O
predisposition	O
,	O
or	O
certain	O
viruses	O
may	O
affect	O
the	O
KIR	B
repertoire	O
formation	O
in	O
BD	O
patients	O
.	O

Abnormal	O
KIR	B
expression	O
of	O
NK	O
cells	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
BD	O
.	O

Impact	O
of	O
PGE1	O
on	O
cyclosporine	O
A	O
induced	O
up	O
-	O
regulation	O
of	O
TGF	B
-	I
beta1	I
,	O
its	O
receptors	O
,	O
and	O
related	O
matrix	O
production	O
in	O
cultured	O
mesangial	O
cells	O
.	O

Transforming	B
growth	I
factor	I
-	I
beta1	I
(	O
TGF	B
-	I
beta1	I
)	O
plays	O
a	O
major	O
role	O
in	O
cyclosporine	O
A	O
(	O
CsA	O
)	O
induced	O
glomerulosclerosis	O
.	O

We	O
have	O
recently	O
shown	O
that	O
CsA	O
up	O
-	O
regulates	O
the	O
expression	O
of	O
TGF	B
-	I
beta1	I
and	O
its	O
receptors	O
type	O
I	O
(	O
TbetaR	B
-	I
I	I
)	O
and	O
type	O
II	O
(	O
TbetaR	B
-	I
II	I
)	O
in	O
rat	O
mesangial	O
cells	O
(	O
MCs	O
)	O
.	O

Prostaglandins	O
of	O
the	O
E	O
series	O
(	O
PGEs	O
)	O
are	O
known	O
to	O
exert	O
substantial	O
anti	O
-	O
fibrotic	O
effects	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
PGE1	O
on	O
CsA	O
induced	O
up	O
-	O
regulation	O
of	O
TGF	B
-	I
beta1	I
,	O
TbetaR	B
-	I
I	I
,	O
TbetaR	B
-	I
II	I
and	O
related	O
matrix	O
production	O
in	O
MCs	O
.	O

Co	O
-	O
incubation	O
with	O
PGE1	O
reduced	O
CsA	O
induced	O
up	O
-	O
regulation	O
of	O
TGF	B
-	I
beta1	I
and	O
TbetaR	B
-	I
II	I
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

Alike	O
,	O
PGE1	O
reduced	O
TbetaR	B
-	I
I	I
protein	O
expression	O
,	O
which	O
is	O
posttranscriptionally	O
up	O
-	O
regulated	O
by	O
CsA	O
.	O

Whereas	O
a	O
low	O
PGE	O
(	O
1	O
)	O
concentration	O
decreased	O
CsA	O
induced	O
production	O
of	O
fibronectin	B
(	O
FN	B
)	O
and	O
plasminogen	B
activator	I
inhibitor	I
type-1	I
(	O
PAI-1	B
)	O
,	O
a	O
higher	O
PGE1	O
concentration	O
did	O
not	O
change	O
FN	B
production	O
,	O
but	O
further	O
increased	O
PAI-1	B
production	O
.	O

In	O
vivo	O
studies	O
will	O
show	O
,	O
whether	O
treatment	O
with	O
PGE1	O
analogues	O
will	O
be	O
useful	O
in	O
preventing	O
CsA	O
induced	O
glomerulosclerosis	O
.	O

YodA	B
from	O
Escherichia	O
coli	O
is	O
a	O
metal	O
-	O
binding	O
,	O
lipocalin	B
-	O
like	O
protein	O
.	O

We	O
have	O
determined	O
the	O
crystal	O
structure	O
of	O
YodA	B
,	O
an	O
Escherichia	O
coli	O
protein	O
of	O
unknown	O
function	O
.	O

YodA	B
had	O
been	O
identified	O
under	O
conditions	O
of	O
cadmium	O
stress	O
,	O
and	O
we	O
confirm	O
that	O
it	O
binds	O
metals	O
such	O
as	O
cadmium	O
and	O
zinc	O
.	O

We	O
have	O
also	O
found	O
nickel	O
bound	O
in	O
one	O
of	O
the	O
crystal	O
forms	O
.	O

YodA	B
is	O
composed	O
of	O
two	O
domains	O
:	O
a	O
main	O
lipocalin	B
/	O
calycin	B
-	O
like	O
domain	O
and	O
a	O
helical	O
domain	O
.	O

The	O
principal	O
metal	O
-	O
binding	O
site	O
lies	O
on	O
one	O
side	O
of	O
the	O
calycin	B
domain	O
,	O
thus	O
making	O
YodA	B
the	O
first	O
metal	O
-	O
binding	O
lipocalin	B
known	O
.	O

Our	O
experiments	O
suggest	O
that	O
YodA	B
expression	O
may	O
be	O
part	O
of	O
a	O
more	O
general	O
stress	O
response	O
.	O

From	O
sequence	O
analogy	O
with	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
a	O
metal	O
-	O
binding	O
receptor	O
of	O
a	O
member	O
of	O
bacterial	O
ATP	B
-	I
binding	I
cassette	I
transporters	I
,	O
we	O
propose	O
a	O
three	O
-	O
dimensional	O
model	O
for	O
this	O
receptor	O
and	O
suggest	O
that	O
YodA	B
may	O
have	O
a	O
receptor	O
-	O
type	O
partner	O
in	O
E.	O
coli	O
.	O

Identification	O
of	O
mutans	O
streptococci	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
16S	O
ribosomal	O
RNA	O
genes	O
.	O

Mutans	O
streptococci	O
are	O
frequently	O
isolated	O
from	O
dental	O
plaque	O
and	O
carious	O
lesions	O
.	O

These	O
bacteria	O
have	O
been	O
identified	O
by	O
conventional	O
methods	O
such	O
as	O
biochemical	O
and	O
serologic	O
tests	O
followed	O
by	O
the	O
isolation	O
of	O
colonies	O
on	O
the	O
mitis	O
-	O
salivarius	O
agar	O
,	O
which	O
are	O
sometimes	O
inconsistent	O
.	O

Recently	O
,	O
species	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
has	O
been	O
reported	O
to	O
rapidly	O
identify	O
Streptococcus	O
mutans	O
and	O
Streptococcus	O
sobrinus	O
.	O

However	O
,	O
in	O
the	O
case	O
of	O
identification	O
and	O
classification	O
into	O
several	O
species	O
,	O
e.g.	O
within	O
the	O
group	O
of	O
mutans	O
streptococci	O
consisting	O
of	O
seven	O
species	O
,	O
the	O
identification	O
using	O
species	O
-	O
specific	O
PCR	O
seems	O
somewhat	O
inefficient	O
because	O
of	O
need	O
for	O
the	O
development	O
and	O
preparation	O
of	O
specific	O
primers	O
for	O
each	O
species	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
we	O
developed	O
a	O
simple	O
method	O
using	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
PCR	O
-	O
amplified	O
16S	O
ribosomal	O
RNA	O
genes	O
(	O
16S	O
rRNA	O
genes	O
PCR	O
-	O
RFLP	O
)	O
for	O
the	O
identification	O
of	O
seven	O
different	O
species	O
included	O
in	O
the	O
group	O
of	O
mutans	O
streptococci	O
.	O

We	O
amplified	O
16S	O
rRNA	O
gene	O
sequences	O
from	O
genomic	O
DNA	O
samples	O
by	O
PCR	O
using	O
universal	O
primers	O
and	O
digested	O
the	O
PCR	O
products	O
with	O
the	O
restriction	B
endonucleases	I
,	O
HpaII	B
and	O
HaeIII	B
.	O

HpaII	B
produced	O
six	O
RFLP	O
patterns	O
for	O
eight	O
reference	O
strains	O
,	O
since	O
the	O
patterns	O
for	O
S.	O
sobrinus	O
,	O
Streptococcus	O
downei	O
and	O
Streptococcus	O
ferus	O
were	O
similar	O
.	O

RFLP	O
patterns	O
produced	O
with	O
HaeIII	B
could	O
separate	O
these	O
three	O
species	O
.	O

Furthermore	O
,	O
the	O
RFLP	O
patterns	O
predicted	O
from	O
the	O
16S	O
rRNA	O
gene	O
sequences	O
in	O
the	O
GenBank	O
database	O
agreed	O
with	O
the	O
actual	O
RFLP	O
patterns	O
produced	O
in	O
the	O
present	O
study	O
.	O

The	O
16S	O
rRNA	O
sequence	O
comparisons	O
can	O
be	O
used	O
to	O
identify	O
oral	O
mutans	O
streptococci	O
;	O
however	O
,	O
the	O
identification	O
by	O
sequencing	O
is	O
sometimes	O
difficult	O
in	O
large	O
-	O
scale	O
studies	O
and	O
for	O
small	O
laboratories	O
.	O

Therefore	O
,	O
16S	O
rRNA	O
genes	O
PCR	O
-	O
RFLP	O
,	O
using	O
HpaII	B
and	O
HaeIII	B
,	O
could	O
be	O
an	O
alternative	O
method	O
for	O
the	O
identification	O
of	O
mutans	O
streptococci	O
,	O
and	O
may	O
be	O
applicable	O
for	O
large	O
-	O
scale	O
studies	O
on	O
the	O
cariogenicity	O
of	O
mutans	O
streptococci	O
.	O

MyoR	B
is	O
expressed	O
in	O
nonmyogenic	O
cells	O
and	O
can	O
inhibit	O
their	O
differentiation	O
.	O

The	O
development	O
of	O
skeletal	O
muscle	O
in	O
mammals	O
is	O
promoted	O
by	O
the	O
muscle	O
-	O
specific	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factors	O
of	O
the	O
MyoD	B
family	I
.	O

Evidence	O
also	O
suggests	O
that	O
there	O
are	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
that	O
specifically	O
inhibit	O
skeletal	O
myogenesis	O
,	O
including	O
Mtwist	B
,	O
Mist1	B
,	O
and	O
the	O
most	O
recently	O
described	O
,	O
MyoR	B
.	O

It	O
has	O
been	O
suggested	O
that	O
MyoR	B
expression	O
is	O
limited	O
to	O
the	O
precursors	O
of	O
the	O
skeletal	O
muscle	O
lineage	O
and	O
acts	O
as	O
a	O
transcriptional	O
repressor	O
of	O
the	O
muscle	O
differentiation	O
program	O
.	O

However	O
,	O
our	O
results	O
demonstrate	O
that	O
MyoR	B
is	O
expressed	O
in	O
several	O
different	O
,	O
nonmuscle	O
adult	O
tissues	O
.	O

Furthermore	O
,	O
MyoR	B
is	O
expressed	O
in	O
the	O
embryonic	O
ectoderm	O
of	O
blastocyst	O
stage	O
mouse	O
embryos	O
,	O
well	O
before	O
skeletal	O
muscle	O
specification	O
and	O
even	O
before	O
delineation	O
of	O
the	O
mesodermal	O
germ	O
layer	O
.	O

Using	O
embryonic	O
ectoderm	O
analogous	O
stem	O
cells	O
,	O
we	O
demonstrate	O
that	O
in	O
these	O
nonmuscle	O
cells	O
,	O
as	O
in	O
skeletal	O
muscle	O
precursor	O
cells	O
,	O
expression	O
of	O
MyoR	B
is	O
inversely	O
correlated	O
with	O
the	O
extent	O
of	O
cellular	O
differentiation	O
as	O
induced	O
by	O
retinoic	O
acid	O
.	O

Our	O
preliminary	O
results	O
indicate	O
that	O
overexpression	O
of	O
exogenous	O
MyoR	B
inhibits	O
retinoic	O
-	O
acid	O
-	O
induced	O
differentiation	O
in	O
EC	O
cells	O
and	O
is	O
lethal	O
to	O
early	O
mouse	O
embryos	O
.	O

Our	O
results	O
suggest	O
a	O
much	O
broader	O
role	O
for	O
MyoR	B
in	O
the	O
repression	O
and/or	O
determination	O
of	O
embryonic	O
cell	O
differentiation	O
.	O

[	O
Construction	O
of	O
the	O
synthetic	O
genes	O
for	O
protein	O
analogs	O
of	O
spider	O
silk	O
carcass	O
spidroin	B
1	I
and	O
their	O
expression	O
in	O
tobacco	O
plants	O
]	O

To	O
obtain	O
transgenic	O
tobacco	O
plants	O
expressing	O
recombinant	O
analogs	O
of	O
spider	O
dragline	O
silk	O
spidroin	B
1	I
,	O
artificial	O
1f5	O
and	O
1f9	O
coding	O
for	O
spidroin	B
1	I
analogs	O
were	O
3'-fused	O
in	O
-	O
frame	O
with	O
the	O
reporter	O
lichenase	B
gene	O
.	O

The	O
Tr2	O
'	O
weak	O
constitutive	O
promoter	O
of	O
Agrobacterium	O
tumefaciens	O
T	O
-	O
DNA	O
and	O
the	O
strong	O
constitutive	O
promoter	O
of	O
the	O
cauliflower	O
mosaic	O
virus	O
35S	O
RNA	O
gene	O
were	O
used	O
as	O
regulatory	O
elements	O
.	O

The	O
expression	O
cassettes	O
were	O
used	O
to	O
transform	O
agrobacteria	O
and	O
then	O
introduced	O
in	O
tobacco	O
leaf	O
disks	O
.	O

On	O
evidence	O
of	O
Southern	O
hybridization	O
,	O
transgenic	O
plants	O
each	O
carried	O
a	O
single	O
copy	O
of	O
a	O
hybrid	O
gene	O
,	O
which	O
corresponded	O
in	O
size	O
to	O
the	O
constructed	O
one	O
.	O

Zymography	O
and	O
Western	O
blotting	O
revealed	O
full	O
-	O
length	O
hybrid	O
proteins	O
in	O
leaf	O
extracts	O
of	O
transgenic	O
plants	O
.	O

The	O
results	O
testified	O
that	O
plants	O
can	O
maintain	O
and	O
express	O
synthetic	O
genes	O
for	O
spider	O
silks	O
and	O
,	O
consequently	O
,	O
may	O
be	O
used	O
as	O
a	O
convenient	O
producer	O
of	O
recombinant	O
silk	O
analogs	O
.	O

Distinct	O
molecular	O
mechanisms	O
involved	O
in	O
carbon	O
catabolite	O
repression	O
of	O
the	O
arabinose	O
regulon	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
Bacillus	O
subtilis	O
proteins	O
involved	O
in	O
the	O
utilization	O
of	O
L	O
-	O
arabinose	O
are	O
encoded	O
by	O
the	O
araABDLMNPQ	B
-	O
abfA	B
metabolic	O
operon	O
and	O
by	O
the	O
araE	B
/	O
araR	B
divergent	O
unit	O
.	O

Transcription	O
from	O
the	O
ara	B
operon	I
,	O
araE	B
transport	O
gene	O
and	O
araR	B
regulatory	O
gene	O
is	O
induced	O
by	O
L	O
-	O
arabinose	O
and	O
negatively	O
controlled	O
by	O
AraR	B
.	O

Additionally	O
,	O
expression	O
of	O
both	O
the	O
ara	B
operon	I
and	O
the	O
araE	B
gene	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
by	O
glucose	O
repression	O
.	O

Here	O
,	O
by	O
transcriptional	O
fusion	O
analysis	O
in	O
different	O
mutant	O
backgrounds	O
,	O
it	O
is	O
shown	O
that	O
CcpA	B
most	O
probably	O
complexed	O
with	O
HPr	B
-	O
Ser46-P	O
plays	O
the	O
major	O
role	O
in	O
carbon	O
catabolite	O
repression	O
of	O
the	O
ara	B
regulon	O
by	O
glucose	O
and	O
glycerol	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
and	O
deletion	O
analysis	O
indicate	O
that	O
two	O
catabolite	O
responsive	O
elements	O
(	O
cres	O
)	O
present	O
in	O
the	O
ara	B
operon	I
(	O
cre	O
araA	B
and	O
cre	O
araB	B
)	O
and	O
one	O
cre	O
in	O
the	O
araE	B
gene	O
(	O
cre	O
araE	B
)	O
are	O
implicated	O
in	O
this	O
mechanism	O
.	O

Furthermore	O
,	O
cre	O
araA	B
located	O
between	O
the	O
promoter	O
region	O
of	O
the	O
ara	B
operon	I
and	O
the	O
araA	B
gene	O
,	O
and	O
cre	O
araB	B
placed	O
2	O
kb	O
downstream	O
within	O
the	O
araB	B
gene	O
are	O
independently	O
functional	O
and	O
both	O
contribute	O
to	O
glucose	O
repression	O
.	O

In	O
Northern	O
blot	O
analysis	O
,	O
in	O
the	O
presence	O
of	O
glucose	O
,	O
a	O
CcpA	B
-	O
dependent	O
transcript	O
consistent	O
with	O
a	O
message	O
stopping	O
at	O
cre	O
araB	B
was	O
detected	O
,	O
suggesting	O
that	O
transcription	O
'	O
roadblocking	O
'	O
of	O
RNA	B
polymerase	I
elongation	O
is	O
the	O
most	O
likely	O
mechanism	O
operating	O
in	O
this	O
system	O
.	O

Glucose	O
exerts	O
an	O
additional	O
repression	O
of	O
the	O
ara	B
regulon	O
,	O
which	O
requires	O
a	O
functional	O
araR	B
.	O

Gene	O
expression	O
of	O
type	B
2	I
17	I
beta	I
hydroxysteroid	I
dehydrogenase	I
in	O
scalp	O
hairs	O
of	O
hirsute	O
women	O
.	O

Androgens	O
are	O
the	O
main	O
hormonal	O
regulators	O
of	O
human	O
hair	O
growth	O
and	O
they	O
are	O
related	O
to	O
clinical	O
conditions	O
such	O
as	O
hirsutism	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
gene	O
expression	O
of	O
androgen	B
receptor	I
(	O
AR	B
)	O
and	O
type	B
2	I
17	I
beta	I
hydroxysteroid	I
dehydrogenase	I
(	O
17	B
beta	I
-	I
HSD	I
)	O
in	O
keratinocytes	O
of	O
plucked	O
scalp	O
hairs	O
from	O
hirsute	O
patients	O
and	O
normal	O
subjects	O
.	O

We	O
studied	O
58	O
women	O
with	O
hirsutism	O
(	O
31	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
,	O
27	O
with	O
idiopathic	O
hirsutism	O
(	O
IH	O
)	O
)	O
;	O
15	O
control	O
women	O
;	O
and	O
10	O
control	O
men	O
.	O

Hirsutism	O
was	O
assessed	O
by	O
a	O
modified	O
Ferriman	O
-	O
Gallwey	O
method	O
.	O

Hormonal	O
status	O
was	O
assessed	O
between	O
days	O
2	O
and	O
10	O
of	O
the	O
menstrual	O
cycle	O
or	O
on	O
any	O
day	O
when	O
the	O
patients	O
were	O
amenorrheic	O
.	O

AR	B
and	O
type	B
2	I
17	I
beta	I
-	I
HSD	I
mRNA	O
levels	O
were	O
estimated	O
by	O
reverse	O
transcription	O
-	O
polymerase	B
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

AR	B
expression	O
was	O
similar	O
in	O
all	O
groups	O
.	O

Type	B
2	I
17	I
beta	I
-	I
HSD	I
gene	O
expression	O
in	O
untreated	O
hirsute	O
patients	O
was	O
lower	O
(	O
2.1	O
+	O
/-	O
0.10	O
)	O
than	O
in	O
normal	O
women	O
(	O
3.1	O
+	O
/-	O
0.17	O
)	O
,	O
and	O
similar	O
to	O
men	O
(	O
1.8	O
+	O
/-	O
0.22	O
)	O
.	O

Comparing	O
hirsute	O
patients	O
,	O
type	B
2	I
17	I
beta	I
-	I
HSD	I
expression	O
was	O
higher	O
in	O
treated	O
PCOS	O
(	O
3.0	O
+	O
/-	O
0.34	O
versus	O
2.2	O
+	O
/-	O
0.13	O
)	O
and	O
IH	O
patients	O
(	O
2.5	O
+	O
/-	O
0.19	O
versus	O
2.0	O
+	O
/-	O
0.15	O
)	O
;	O
hirsutism	O
score	O
was	O
lower	O
(	O
P	O
=	O
0.003	O
,	O
PCOS	O
;	O
P	O
=	O
0.003	O
,	O
IH	O
)	O
;	O
and	O
SHBG	O
levels	O
were	O
higher	O
(	O
P	O
=	O
0.001	O
,	O
PCOS	O
;	O
P	O
=	O
0.024	O
,	O
IH	O
)	O
in	O
treated	O
patients	O
.	O

The	O
free	O
androgen	O
index	O
was	O
lower	O
in	O
treated	O
women	O
(	O
P	O
=	O
0.024	O
for	O
the	O
IH	O
group	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
lower	O
expression	O
of	O
type	B
2	I
17	I
beta	I
-	I
HSD	I
mRNA	O
in	O
scalp	O
hairs	O
of	O
untreated	O
hirsute	O
patients	O
suggests	O
androgen	O
metabolism	O
disturbances	O
with	O
predominance	O
of	O
more	O
potent	O
androgens	O
,	O
as	O
occurs	O
in	O
men	O
.	O

The	O
enzyme	O
's	O
higher	O
gene	O
expression	O
in	O
treated	O
hirsute	O
patients	O
could	O
be	O
an	O
indirect	O
evidence	O
of	O
restored	O
enzyme	O
activity	O
and	O
intracellular	O
androgen	O
metabolism	O
.	O

Killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
and	O
leukocyte	B
Ig	I
-	I
like	I
receptor	I
transgenic	O
mice	O
exhibit	O
tissue	O
-	O
and	O
cell	O
-	O
specific	O
transgene	O
expression	O
.	O

To	O
generate	O
an	O
experimental	O
model	O
for	O
exploring	O
the	O
function	O
,	O
expression	O
pattern	O
,	O
and	O
developmental	O
regulation	O
of	O
human	O
Ig	B
-	O
like	O
activating	O
and	O
inhibitory	O
receptors	O
,	O
we	O
have	O
generated	O
transgenic	O
mice	O
using	O
two	O
human	O
genomic	O
clones	O
:	O
52N12	O
(	O
a	O
150	O
-	O
Kb	O
clone	O
encompassing	O
the	O
leukocyte	B
Ig	I
-	I
like	I
receptor	I
(	I
LILR	I
)	I
B1	I
(	O
ILT2	B
)	O
,	O
LILRB4	B
(	O
ILT3	B
)	O
,	O
and	O
LILRA1	B
(	O
LIR6	B
)	O
genes	O
)	O
and	O
1060P11	O
(	O
a	O
160	O
-	O
Kb	O
clone	O
that	O
contains	O
ten	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genes	O
)	O
.	O

Both	O
the	O
KIR	B
and	I
LILR	I
families	I
are	O
encoded	O
within	O
the	O
leukocyte	O
receptor	O
complex	O
,	O
and	O
are	O
involved	O
in	O
immune	O
modulation	O
.	O

We	O
have	O
also	O
produced	O
a	O
novel	O
mAb	O
to	O
LILRA1	B
to	O
facilitate	O
expression	O
studies	O
.	O

The	O
LILR	B
transgenes	O
were	O
expressed	O
in	O
a	O
similar	O
,	O
but	O
not	O
identical	O
,	O
pattern	O
to	O
that	O
observed	O
in	O
humans	O
:	O
LILRB1	B
was	O
expressed	O
in	O
B	O
cells	O
,	O
most	O
NK	O
cells	O
,	O
and	O
a	O
small	O
number	O
of	O
T	O
cells	O
;	O
LILRB4	B
was	O
expressed	O
in	O
a	O
B	O
cell	O
subset	O
;	O
and	O
LILRA1	B
was	O
found	O
on	O
a	O
ring	O
of	O
cells	O
surrounding	O
B	O
cell	O
areas	O
on	O
spleen	O
sections	O
,	O
consistent	O
with	O
other	O
data	O
showing	O
monocyte	O
/	O
macrophage	O
expression	O
.	O

KIR	B
transgenic	O
mice	O
showed	O
KIR2DL2	B
expression	O
on	O
a	O
subset	O
of	O
NK	O
cells	O
and	O
T	O
cells	O
,	O
similar	O
to	O
the	O
pattern	O
seen	O
in	O
humans	O
,	O
and	O
expression	O
of	O
KIR2DL4	B
,	O
KIR3DS1	B
,	O
and	O
KIR2DL5	B
by	O
splenic	O
NK	O
cells	O
.	O

These	O
observations	O
indicate	O
that	O
linked	O
regulatory	O
elements	O
within	O
the	O
genomic	O
clones	O
are	O
sufficient	O
to	O
allow	O
appropriate	O
expression	O
of	O
KIRs	B
in	O
mice	O
,	O
and	O
illustrate	O
that	O
the	O
presence	O
of	O
the	O
natural	O
ligands	O
for	O
these	O
receptors	O
,	O
in	O
the	O
form	O
of	O
human	O
MHC	B
class	I
I	I
proteins	O
,	O
is	O
not	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
KIRs	B
observed	O
in	O
these	O
mice	O
.	O

Reduced	O
sulfhydryls	O
maintain	O
specific	O
incision	O
of	O
BPDE	O
-	O
DNA	O
adducts	O
by	O
recombinant	O
thermoresistant	O
Bacillus	O
caldotenax	O
UvrABC	B
endonuclease	I
.	O

Prokaryotic	O
DNA	B
repair	I
nucleases	I
are	O
useful	O
reagents	O
for	O
detecting	O
DNA	O
lesions	O
.	O

Escherichia	O
coli	O
UvrABC	B
endonuclease	I
can	O
incise	O
DNA	O
containing	O
UV	O
photoproducts	O
and	O
bulky	O
chemical	O
adducts	O
.	O

The	O
limited	O
stability	O
of	O
the	O
E.	O
coli	O
UvrABC	B
subunits	O
leads	O
to	O
difficulty	O
in	O
estimating	O
incision	O
efficiency	O
and	O
quantitative	O
adduct	O
detection	O
.	O

To	O
develop	O
a	O
more	O
stable	O
enzyme	O
with	O
greater	O
utility	O
for	O
the	O
detection	O
of	O
DNA	O
adducts	O
,	O
thermoresistant	O
UvrABC	B
endonuclease	I
was	O
cloned	O
from	O
the	O
eubacterium	O
Bacillus	O
caldotenax	O
(	O
Bca	O
)	O
and	O
individual	O
recombinant	O
protein	O
subunits	O
were	O
overexpressed	O
in	O
and	O
purified	O
from	O
E.	O
coli	O
.	O

Here	O
,	O
we	O
show	O
that	O
Bca	O
UvrC	B
that	O
had	O
lost	O
activity	O
or	O
specificity	O
could	O
be	O
restored	O
by	O
dialysis	O
against	O
buffer	O
containing	O
500	O
mM	O
KCl	O
and	O
20mM	O
dithiothreitol	O
.	O

Our	O
data	O
indicate	O
that	O
UvrC	B
solubility	O
depended	O
on	O
high	O
salt	O
concentrations	O
and	O
UvrC	B
nuclease	I
activity	O
and	O
the	O
specificity	O
of	O
incisions	O
depended	O
on	O
the	O
presence	O
of	O
reduced	O
sulfhydryls	O
.	O

Optimal	O
conditions	O
for	O
BCA	O
UvrABC	B
-	O
specific	O
cleavage	O
of	O
plasmid	O
DNAs	O
treated	O
with	O
[	O
3H	O
]	O
(	O
+	O
)	O
-7R,8S	O
-	O
dihydroxy-9S,10R	O
-	O
epoxy-7,8,9,10-tetrahydrobenzo	O
[	O
a	O
]	O
pyrene	O
(	O
BPDE	O
)	O
(	O
1	O
-	O
5	O
lesions	O
/	O
plasmid	O
)	O
were	O
developed	O
.	O

Preincubation	O
of	O
substrates	O
with	O
UvrA	B
and	O
UvrB	B
enhanced	O
incision	O
efficiency	O
on	O
damaged	O
substrates	O
and	O
decreased	O
non	O
-	O
specific	O
nuclease	B
activity	O
on	O
undamaged	O
substrates	O
.	O

Under	O
optimal	O
conditions	O
for	O
damaged	O
plasmid	O
incision	O
,	O
approximately	O
70	O
%	O
of	O
adducts	O
were	O
incised	O
in	O
1	O
nM	O
plasmid	O
DNA	O
(	O
2	O
BPDE	O
adducts	O
/	O
5.4	O
kbp	O
plasmid	O
)	O
with	O
UvrA	B
at	O
2.5	O
nM	O
,	O
UvrB	B
at	O
62.5	O
nM	O
,	O
and	O
UvrC	B
at	O
25	O
nM	O
.	O

These	O
results	O
demonstrate	O
the	O
potential	O
usefulness	O
of	O
the	O
Bca	O
UvrABC	B
for	O
monitoring	O
the	O
distribution	O
of	O
chemical	O
carcinogen	O
-	O
induced	O
lesions	O
in	O
DNA	O
.	O

Differential	O
regulation	O
of	O
TNF	B
-	I
alpha	I
,	O
IL-6	B
and	O
IL-10	B
in	O
UVB	O
-	O
irradiated	O
human	O
keratinocytes	O
via	O
cyclic	B
AMP	I
/	I
protein	I
kinase	I
A	I
pathway	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	B
are	O
important	O
mediators	O
of	O
cutaneous	O
cellular	O
activities	O
during	O
many	O
skin	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
IL-6	B
and	O
IL-10	B
by	O
UVB	O
-	O
irradiated	O
human	O
keratinocytes	O
NCTC	O
2544	O
cell	O
line	O
in	O
the	O
presence	O
of	O
cAMP	O
-	O
elevating	O
agents	O
and	O
we	O
attempted	O
to	O
determine	O
the	O
implication	O
of	O
cyclic	O
AMP	O
/	O
PKA	B
pathway	O
in	O
the	O
regulation	O
of	O
cytokine	B
gene	O
expression	O
.	O

Cytokine	B
mRNA	O
expression	O
levels	O
and	O
cytokine	B
concentrations	O
were	O
investigated	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
and	O
by	O
ELISA	O
method	O
,	O
respectively	O
.	O

Treatment	O
of	O
UVB	O
-	O
irradiated	O
NCTC	O
2544	O
cells	O
with	O
drugs	O
known	O
to	O
enhance	O
cAMP	O
concentration	O
[	O
dibutyryl	O
cAMP	O
,	O
PGE	O
(	O
2	O
)	O
and	O
cholera	B
toxin	I
]	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
TNF	B
-	I
alpha	I
mRNA	O
expression	O
whereas	O
IL-6	B
and	O
IL-10	B
mRNAs	O
were	O
enhanced	O
.	O

In	O
the	O
same	O
experimental	O
conditions	O
,	O
treatment	O
of	O
irradiated	O
keratinocytes	O
with	O
PKA	B
inhibitors	O
[	O
H89	O
and	O
PKA	B
inhibitor	O
(	O
PKAi	O
)	O
]	O
induced	O
a	O
significant	O
inhibition	O
of	O
mRNA	O
expression	O
for	O
all	O
tested	O
cytokines	B
.	O

Except	O
for	O
IL-10	B
,	O
the	O
pharmacological	O
effect	O
of	O
cAMP	O
-	O
elevating	O
agents	O
or	O
PKA	B
inhibitors	O
on	O
radiation	O
-	O
induced	O
TNF	B
-	I
alpha	I
and	O
IL-6	B
mRNA	O
expression	O
was	O
associated	O
with	O
a	O
concomitant	O
regulation	O
of	O
cytokine	B
release	O
.	O

Taken	O
together	O
our	O
results	O
showed	O
:	O
(	O
i	O
)	O
a	O
differential	O
regulation	O
of	O
TNF	B
-	I
alpha	I
,	O
IL-6	B
and	O
IL-10	B
in	O
UVB	O
-	O
irradiated	O
human	O
keratinocytes	O
via	O
cyclic	O
AMP	O
/	O
protein	B
kinase	I
A	I
pathway	O
,	O
and	O
(	O
ii	O
)	O
a	O
possible	O
reduction	O
of	O
deleterious	O
inflammatory	O
effects	O
of	O
cytokine	B
following	O
UVB	O
-	O
irradiation	O
by	O
using	O
pharmacological	O
agents	O
that	O
regulate	O
both	O
the	O
intracellular	O
cAMP	O
levels	O
and	O
the	O
cellular	O
PKA	B
activity	O
.	O

Analysis	O
of	O
plausible	O
downstream	O
target	O
genes	O
of	O
Hoxc8	B
in	O
F9	O
teratocarcinoma	O
cells	O
.	O

Putative	O
downstream	O
target	O
genes	O
of	O
Hoxc8	B
.	O

Although	O
Hox	B
genes	O
are	O
known	O
to	O
mediate	O
developmental	O
decisions	O
involved	O
in	O
pattern	O
formation	O
during	O
embryogenesis	O
,	O
it	O
is	O
still	O
not	O
well	O
understood	O
what	O
Hox	B
regulates	O
.	O

In	O
order	O
to	O
analyze	O
Hoxc8	B
downstream	O
target	O
genes	O
,	O
a	O
stable	O
cell	O
line	O
overexpressing	O
Hoxc8	B
was	O
established	O
using	O
F9	O
murine	O
teratocarcinoma	O
cells	O
,	O
proteom	O
samples	O
were	O
analyzed	O
by	O
2-DE	O
,	O
and	O
compared	O
with	O
controls	O
.	O

The	O
protein	O
spots	O
having	O
differences	O
more	O
than	O
4	O
fold	O
in	O
intensity	O
were	O
selected	O
,	O
analyzed	O
by	O
MALDI	O
-	O
TOF	O
,	O
and	O
grouped	O
in	O
terms	O
of	O
putative	O
function	O
;	O
cytoskeleton	O
and	O
motility	O
(	O
vimentin	B
,	O
gamma	B
-	I
actin	I
,	O
tropomyosin	B
,	O
and	O
tubulin	B
beta-5	I
chain	O
)	O
;	O
folding	O
,	O
modification	O
and	O
degradation	O
of	O
protein	O
(	O
GRP78	B
,	O
proteasome	B
subunit	I
alpha	I
type	I
5	I
,	O
26S	B
proteasome	I
regulatory	I
subunit	I
p27	I
protein	O
,	O
and	O
PDIR	B
)	O
;	O
metabolism	O
(	O
ATP	B
synthase	I
beta	I
subunit	I
,	O
Pgam1	B
,	O
and	O
CAII	B
)	O
;	O
transcription	B
/	I
translation	I
factors	I
and	O
general	O
nucleic	O
acid	O
binding	O
proteins	O
(	O
RbAp46	B
,	O
PCNA	B
,	O
eEF-1-beta	B
,	O
and	O
nucleophosmin	B
)	O
.	O

Although	O
it	O
may	O
not	O
be	O
significant	O
,	O
50	O
%	O
of	O
the	O
genes	O
were	O
located	O
on	O
chromosomes	O
2	O
and	O
3	O
,	O
suggesting	O
the	O
possibility	O
of	O
a	O
non	O
-	O
random	O
distribution	O
of	O
Hox	B
downstream	O
genes	O
.	O

Almost	O
50	O
%	O
of	O
the	O
genes	O
analyzed	O
showed	O
some	O
relation	O
with	O
Hox	B
protein	O
directly	O
or	O
indirectly	O
;	O
i.e.	O
,	O
tubulin	B
beta	I
5	I
,	O
EF-1	B
beta	I
and	O
PCNA	B
have	O
been	O
reported	O
to	O
contain	O
putative	O
Hox	B
binding	O
regulatory	O
sites	O
and	O
genes	O
like	O
vimentin	B
,	O
pgam1	B
and	O
nucleophosmin	B
to	O
be	O
regulated	O
by	O
RA	O
,	O
a	O
potent	O
modulator	O
of	O
Hox	B
expression	O
.	O

These	O
results	O
altogether	O
imply	O
that	O
proteom	O
analysis	O
could	O
be	O
a	O
possible	O
tool	O
for	O
the	O
analysis	O
of	O
the	O
potent	O
Hox	B
realizator	O
genes	O
,	O
which	O
provides	O
a	O
new	O
insight	O
into	O
the	O
function	O
of	O
Hox	B
on	O
pattern	O
formation	O
during	O
embryogenesis	O
.	O

Reconstitution	O
of	O
the	O
multiprotein	O
complex	O
of	O
pp60src	B
,	O
hsp90	B
,	O
and	O
p50	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

A	O
rabbit	O
reticulocyte	O
lysate	O
system	O
that	O
has	O
been	O
used	O
to	O
reconstitute	O
functional	O
complexes	O
between	O
steroid	B
receptors	I
and	O
the	O
90	B
-	I
kDa	I
heat	I
shock	I
protein	I
(	O
hsp90	B
)	O
has	O
been	O
used	O
here	O
to	O
form	O
complexes	O
between	O
the	O
pp60src	B
tyrosine	B
kinase	I
and	O
hsp90	B
.	O

Reticulocyte	O
lysate	O
forms	O
complexes	O
between	O
hsp90	B
and	O
a	O
temperature	O
-	O
sensitive	O
mutant	O
of	O
Rous	O
sarcoma	O
virus	O
pp60v	B
-	I
src	I
,	O
which	O
is	O
normally	O
present	O
in	O
cytosol	O
virtually	O
entirely	O
in	O
the	O
multiprotein	O
complex	O
form	O
.	O

In	O
addition	O
,	O
hsp90	B
in	O
the	O
lysate	O
complexes	O
with	O
wild	O
-	O
type	O
pp60v	B
-	I
src	I
,	O
of	O
which	O
only	O
a	O
small	O
portion	O
is	O
normally	O
recovered	O
in	O
cytosol	O
in	O
the	O
native	O
multiprotein	O
complex	O
,	O
and	O
with	O
the	O
cellular	O
homolog	O
,	O
pp60c	B
-	I
src	I
,	O
which	O
has	O
never	O
been	O
recovered	O
in	O
cytosol	O
in	O
the	O
form	O
of	O
a	O
native	O
multiprotein	O
complex	O
with	O
hsp90	B
.	O

Moreover	O
,	O
the	O
reticulocyte	O
lysate	O
-	O
reconstituted	O
complex	O
also	O
contains	O
the	O
50	O
-	O
kDa	O
phosphoprotein	O
component	O
of	O
the	O
native	O
pp60v	B
-	I
src	I
multiprotein	O
complex	O
.	O

The	O
native	O
and	O
reconstituted	O
pp60src	B
-	O
hsp90	B
complexes	O
have	O
similar	O
thermal	O
stability	O
and	O
,	O
like	O
steroid	B
receptor	I
heterocomplexes	O
,	O
they	O
are	O
stabilized	O
by	O
molybdate	O
.	O

As	O
previously	O
shown	O
with	O
reticulocyte	O
lysate	O
-	O
reconstituted	O
steroid	B
receptor	I
heteroprotein	O
complexes	O
,	O
the	O
reconstituted	O
pp60src	B
multiprotein	O
complex	O
contains	O
hsp70	B
,	O
which	O
is	O
a	O
major	O
candidate	O
for	O
providing	O
the	O
protein	O
unfoldase	O
activity	O
required	O
for	O
hsp90	B
association	O
.	O

Control	O
of	O
enzyme	B
IIscr	I
and	O
sucrose-6-phosphate	B
hydrolase	I
activities	O
in	O
Streptococcus	O
mutans	O
by	O
transcriptional	O
repressor	O
ScrR	B
binding	O
to	O
the	O
cis	O
-	O
active	O
determinants	O
of	O
the	O
scr	B
regulon	O
.	O

In	O
Streptococcus	O
mutans	O
,	O
enzyme	B
II	I
(	I
scr	I
)	I
and	O
sucrose-6-phosphate	B
hydrolase	I
are	O
two	O
important	O
enzymes	O
in	O
the	O
transport	O
and	O
metabolism	O
of	O
dietary	O
sucrose	O
.	O

The	O
scr	B
regulon	O
of	O
S.	O
mutans	O
is	O
composed	O
of	O
three	O
genes	O
,	O
scrA	B
and	O
scrB	B
,	O
which	O
code	O
for	O
enzyme	B
II	I
(	I
scr	I
)	I
and	O
sucrose	B
-	I
6	I
-	I
phosphate	I
hydrolase	I
,	O
respectively	O
,	O
and	O
scrR	B
,	O
which	O
codes	O
for	O
a	O
GalR	B
-	O
LacI	B
-	O
type	O
transcription	O
regulator	O
.	O

It	O
was	O
previously	O
shown	O
that	O
expression	O
of	O
both	O
scrA	B
and	O
scrB	B
is	O
similarly	O
induced	O
by	O
sucrose	O
.	O

Mutation	O
in	O
the	O
scrR	B
gene	O
resulted	O
in	O
increased	O
expression	O
of	O
scrB	B
relative	O
to	O
that	O
in	O
the	O
wild	O
-	O
type	O
strain	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
DNA	O
mobility	O
shift	O
and	O
DNase	B
I	I
protection	O
assays	O
with	O
a	O
purified	O
ScrR	B
-	O
histidine	O
tag	O
fusion	O
protein	O
to	O
examine	O
the	O
DNA	O
binding	O
properties	O
of	O
ScrR	B
to	O
the	O
promoter	O
regions	O
of	O
the	O
scrA	B
and	O
scrB	B
genes	O
.	O

The	O
results	O
showed	O
that	O
ScrR	B
bound	O
specifically	O
to	O
the	O
promoter	O
regions	O
of	O
both	O
scrA	B
and	O
scrB	B
.	O

Two	O
regions	O
with	O
high	O
affinity	O
for	O
ScrR	B
in	O
the	O
promoter	O
sequences	O
of	O
the	O
scrA	B
and	O
scrB	B
genes	O
were	O
identified	O
by	O
DNase	B
I	I
protection	O
assays	O
.	O

One	O
,	O
O	O
(	O
C	O
)	O
,	O
which	O
includes	O
a	O
20	O
-	O
bp	O
imperfect	O
inverted	O
-	O
repeat	O
sequence	O
,	O
is	O
located	O
between	O
the	O
two	O
promoters	O
,	O
and	O
the	O
other	O
,	O
O	O
(	O
B	O
)	O
,	O
is	O
located	O
within	O
the	O
scrB	B
promoter	O
region	O
containing	O
a	O
37	O
-	O
bp	O
imperfect	O
direct	O
-	O
repeat	O
sequence	O
.	O

Mutations	O
of	O
O	O
(	O
B	O
)	O
and	O
O	O
(	O
C	O
)	O
resulted	O
in	O
constitutive	O
transcription	O
and	O
expression	O
of	O
both	O
the	O
scrA	B
and	O
scrB	B
genes	O
.	O

Our	O
results	O
indicated	O
that	O
S.	O
mutans	O
coordinates	O
the	O
activities	O
of	O
enzyme	B
II	I
(	I
scr	I
)	I
and	O
sucrose	B
-	I
6	I
-	I
phosphate	I
hydrolase	I
by	O
transcriptional	O
repressor	O
ScrR	B
binding	O
to	O
the	O
promoter	O
regions	O
of	O
the	O
scr	B
regulon	O
.	O

The	O
cadC	B
gene	O
product	O
of	O
alkaliphilic	O
Bacillus	O
firmus	O
OF4	O
partially	O
restores	O
Na+	O
resistance	O
to	O
an	O
Escherichia	O
coli	O
strain	O
lacking	O
an	O
Na	B
+	I
/H	I
+	I
antiporter	I
(	O
NhaA	B
)	O
.	O

A	O
5.6	O
-	O
kb	O
fragment	O
of	O
alkaliphilic	O
Bacillus	O
firmus	O
OF4	O
DNA	O
was	O
isolated	O
by	O
screening	O
a	O
library	O
of	O
total	O
genomic	O
DNA	O
constructed	O
in	O
pGEM3Zf	O
(	O
+	O
)	O
for	O
clones	O
that	O
reversed	O
the	O
Na+	O
sensitivity	O
of	O
Escherichia	O
coli	O
NM81	O
,	O
in	O
which	O
the	O
gene	O
encoding	O
an	O
Na	B
+	I
/	I
H	I
+	I
antiporter	I
(	O
NhaA	B
)	O
is	O
deleted	O
(	O
E.	O
Padan	O
,	O
N.	O
Maisler	O
,	O
D.	O
Taglicht	O
,	O
R.	O
Karpel	O
,	O
and	O
S.	O
Schuldiner	O
,	O
J.	O
Biol	O
.	O
Chem	O
.	O
264	O
:	O
20297	O
-	O
20302	O
,	O
1989	O
)	O
.	O

The	O
plasmid	O
,	O
designated	O
pJB22	O
,	O
contained	O
two	O
genes	O
that	O
apparently	O
encode	O
transposition	O
functions	O
and	O
two	O
genes	O
that	O
are	O
apparent	O
homologs	O
of	O
the	O
cadA	B
and	O
cadC	B
genes	O
of	O
cadmium	O
resistance	O
-	O
conferring	O
plasmid	O
pI258	O
of	O
Staphylococcus	O
aureus	O
.	O

E.	O
coli	O
NM81	O
transformed	O
with	O
pJB22	O
had	O
enhanced	O
membrane	O
Na+	B
/	I
H	I
+	I
antiporter	I
activity	O
that	O
was	O
cold	O
labile	O
and	O
that	O
decreased	O
very	O
rapidly	O
following	O
isolation	O
of	O
everted	O
vesicles	O
.	O

Subclones	O
of	O
pJB22	O
containing	O
cadC	B
as	O
the	O
only	O
intact	O
gene	O
showed	O
identical	O
complementation	O
patterns	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
cadC	B
gene	O
product	O
of	O
S.	O
aureus	O
has	O
been	O
proposed	O
to	O
act	O
as	O
an	O
accessory	O
protein	O
for	O
the	O
Cd2	B
+	I
efflux	I
ATPase	I
(	O
CadA	B
)	O
(	O
K.	O
P.	O
Yoon	O
and	O
S.	O
Silver	O
,	O
J.	O
Bacteriol	O
.	O
173	O
:	O
7636	O
-	O
7642	O
,	O
1991	O
)	O
;	O
perhaps	O
the	O
alkaliphile	O
CadC	B
also	O
binds	O
Na	O
+	O
and	O
enhances	O
antiporter	O
activity	O
by	O
delivering	O
a	O
substrate	O
to	O
an	O
integral	O
membrane	O
antiporter	B
.	O

A	O
6.0	O
-	O
kb	O
fragment	O
overlapping	O
the	O
pJB22	O
insert	O
was	O
isolated	O
to	O
complete	O
the	O
sequence	O
of	O
the	O
cadA	B
homolog	O
.	O

A	O
partial	O
sequence	O
of	O
a	O
region	O
approximately	O
2	O
kb	O
downstream	O
of	O
the	O
cadA	B
locus	O
shares	O
sequence	O
similarity	O
with	O
plasmids	O
from	O
several	O
gram	O
-	O
positive	O
bacteria	O
.	O

These	O
results	O
suggest	O
that	O
the	O
region	O
of	O
alkaliphile	O
DNA	O
containing	O
the	O
cadCA	B
locus	O
is	O
present	O
on	O
a	O
transposon	O
that	O
could	O
reside	O
on	O
a	O
heretofore	O
-	O
undetected	O
endogenous	O
plasmid	O
.	O

Activation	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
by	O
v	B
-	I
Raf	I
in	O
NIH	O
3T3	O
cells	O
and	O
in	O
vitro	O
.	O

Mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinases	I
are	O
42	O
-	O
and	O
44	O
-	O
kD	O
serine	B
-	I
threonine	I
protein	I
kinases	I
that	O
are	O
activated	O
by	O
tyrosine	O
and	O
threonine	O
phosphorylation	O
in	O
cells	O
stimulated	O
with	O
mitogens	O
and	O
growth	B
factors	I
.	O

MAP	B
kinase	I
and	O
the	O
protein	B
kinase	I
that	O
activates	O
it	O
(	O
MAP	B
kinase	I
kinase	I
)	O
were	O
constitutively	O
activated	O
in	O
NIH	O
3T3	O
cells	O
infected	O
with	O
viruses	O
containing	O
either	O
of	O
two	O
oncogenic	O
forms	O
(	O
p35EC12	O
,	O
p3722W	O
)	O
of	O
the	O
c	B
-	I
Raf-1	I
protein	B
kinase	I
.	O

The	O
v	B
-	I
Raf	I
proteins	O
purified	O
from	O
cells	O
infected	O
with	O
EC12	O
or	O
22W	O
viruses	O
activated	O
MAP	B
kinase	I
kinase	I
from	O
skeletal	O
muscle	O
in	O
vitro	O
.	O

Furthermore	O
,	O
a	O
bacterially	O
expressed	O
v	B
-	I
Raf	I
fusion	O
protein	O
(	O
glutathione	B
S	I
-	I
transferase	I
-	O
p3722W	O
)	O
also	O
activated	O
MAP	B
kinase	I
kinase	I
in	O
vitro	O
.	O

These	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c	B
-	I
Raf-1	I
in	O
mitogenic	O
signaling	O
is	O
to	O
phosphorylate	O
and	O
activate	O
MAP	B
kinase	I
kinase	I
.	O

Biochemical	O
properties	O
of	O
the	O
75	B
-	I
kDa	I
tumor	I
necrosis	I
factor	I
receptor	I
.	O

Characterization	O
of	O
ligand	O
binding	O
,	O
internalization	O
,	O
and	O
receptor	O
phosphorylation	O
.	O

An	O
expression	O
plasmid	O
encoding	O
the	O
human	O
75	B
-	I
kDa	I
tumor	I
necrosis	I
factor	I
(	I
TNF	I
)	I
type	I
2	I
receptor	I
(	O
TNF	B
-	I
R2	I
)	O
was	O
constructed	O
and	O
used	O
to	O
generate	O
a	O
stable	O
human	O
cell	O
line	O
(	O
293	O
/	O
TNF	B
-	I
R2	I
)	O
overexpressing	O
TNF	B
-	I
R2	I
.	O

Ligand	O
binding	O
analysis	O
revealed	O
high	O
affinity	O
binding	O
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
with	O
approximately	O
94,000	O
+	O
/-	O
7	O
,	O
500	O
sites	O
/	O
cell	O
for	O
125I	O
-	O
TNF	B
-	I
alpha	I
and	O
approximately	O
5	O
-	O
fold	O
lower	O
affinity	O
for	O
TNF	B
-	I
beta	I
(	O
Kd	O
=	O
1.1	O
nM	O
)	O
with	O
264,000	O
+	O
/-	O
2,000	O
sites	O
/	O
cell	O
.	O

Cross	O
-	O
linking	O
of	O
125I	O
-	O
TNF	B
-	I
alpha	I
and	O
125I	O
-	O
TNF	B
-	I
beta	I
to	O
293	O
/	O
TNF	B
-	I
R2	I
cells	O
yielded	O
predominant	O
complexes	O
with	O
apparent	O
molecular	O
weights	O
of	O
211,000	O
for	O
TNF	B
-	I
alpha	I
and	O
205,000	O
and	O
244,000	O
for	O
TNF	B
-	I
beta	I
,	O
suggesting	O
these	O
complexes	O
contain	O
two	O
or	O
three	O
TNF	B
-	I
R2	I
molecules	O
.	O

Immunoprecipitation	O
of	O
TNF	B
-	I
R2	I
from	O
32P	O
-	O
labeled	O
293	O
/	O
TNF	B
-	I
R2	I
cells	O
demonstrated	O
that	O
the	O
receptor	O
is	O
phosphorylated	O
.	O

The	O
majority	O
(	O
97	O
%	O
)	O
of	O
32Pi	O
incorporation	O
was	O
found	O
in	O
serine	O
residues	O
with	O
a	O
very	O
low	O
level	O
of	O
incorporation	O
(	O
3	O
%	O
)	O
in	O
threonine	O
residues	O
.	O

TNF	B
-	I
alpha	I
treatment	O
of	O
293	O
/	O
TNF	B
-	I
R2	I
cells	O
did	O
not	O
significantly	O
affect	O
the	O
degree	O
or	O
pattern	O
of	O
phosphorylation	O
.	O

Cell	O
surface	O
-	O
bound	O
125I	O
-	O
TNF	B
-	I
alpha	I
was	O
slowly	O
internalized	O
by	O
the	O
293	O
/	O
TNF	B
-	I
R2	I
cell	O
line	O
with	O
a	O
t1	O
/	O
2	O
=	O
25	O
min	O
.	O

Shedding	O
of	O
the	O
extracellular	O
domain	O
of	O
TNF	B
-	I
R2	I
was	O
induced	O
by	O
4	O
beta	O
-	O
phorbol	O
12-myristate	O
13-acetate	O
but	O
not	O
by	O
TNF	B
-	I
alpha	I
or	O
TNF	B
-	I
beta	I
.	O

DNA	B
deoxyribophosphodiesterase	I
of	O
Escherichia	O
coli	O
is	O
associated	O
with	O
exonuclease	B
I	I
.	O

DNA	B
deoxyribophosphodiesterase	I
(	O
dRpase	B
)	O
of	O
E.	O
coli	O
catalyzes	O
the	O
release	O
of	O
deoxyribose	O
-	O
phosphate	O
moieties	O
following	O
the	O
cleavage	O
of	O
DNA	O
at	O
an	O
apurinic	O
/	O
apyrimidinic	O
(	O
AP	O
)	O
site	O
by	O
either	O
an	O
AP	B
endonuclease	I
or	O
AP	B
lyase	I
.	O

Exonuclease	B
I	I
is	O
a	O
single	O
-	O
strand	O
specific	O
DNA	B
nuclease	I
which	O
affects	O
the	O
expression	O
of	O
recombination	O
and	O
repair	O
pathways	O
in	O
E.	O
coli	O
.	O

We	O
show	O
here	O
that	O
a	O
major	O
dRpase	B
activity	O
in	O
E.	O
coli	O
is	O
associated	O
with	O
the	O
exonuclease	B
I	I
protein	O
.	O

Highly	O
purified	O
exonuclease	B
I	I
isolated	O
from	O
an	O
over	O
-	O
producing	O
stain	O
contains	O
high	O
levels	O
of	O
dRpase	B
activity	O
;	O
it	O
catalyzes	O
the	O
release	O
of	O
deoxyribose-5-phosphate	O
from	O
an	O
AP	O
site	O
incised	O
with	O
endonuclease	B
IV	I
of	O
E.	O
coli	O
and	O
the	O
release	O
of	O
4-hydroxy-2-pentenal-5-phosphate	O
from	O
an	O
AP	O
site	O
incised	O
by	O
the	O
AP	B
lyase	I
activity	O
of	O
endonuclease	B
III	I
of	O
E.	O
coli	O
.	O

A	O
strain	O
containing	O
a	O
deletion	O
of	O
the	O
sbcB	B
gene	O
showed	O
little	O
dRpase	B
activity	O
;	O
the	O
activity	O
could	O
be	O
restored	O
by	O
transformation	O
of	O
the	O
strain	O
with	O
a	O
plasmid	O
containing	O
the	O
sbcB	B
gene	O
.	O

The	O
dRpase	B
activity	O
isolated	O
from	O
an	O
overproducing	O
stain	O
was	O
increased	O
70	O
-	O
fold	O
as	O
compared	O
to	O
a	O
normal	O
sbcB	B
+	O
strain	O
(	O
AB3027	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
dRpase	B
activity	O
may	O
be	O
important	O
in	O
pathways	O
for	O
both	O
DNA	O
repair	O
and	O
recombination	O
.	O

A	O
constitutive	O
expression	O
vector	O
system	O
driven	O
by	O
the	O
deo	B
P1P2	O
promoters	O
of	O
Escherichia	O
coli	O
.	O

The	O
P1P2	O
promoters	O
of	O
Escherichia	O
coli	O
K12	O
deo	B
operon	I
,	O
residing	O
on	O
an	O
AvaII	B
restriction	O
fragment	O
,	O
were	O
used	O
to	O
construct	O
a	O
new	O
expression	O
vector	O
.	O

To	O
evaluate	O
the	O
potential	O
of	O
the	O
P1P2	O
-	O
driven	O
expression	O
system	O
we	O
have	O
inserted	O
the	O
sequence	O
of	O
human	O
superoxide	B
dismutase	I
(	O
hSOD	B
)	O
downstream	O
of	O
the	O
deo	B
ribosome	O
binding	O
site	O
.	O

Expression	O
of	O
hSOD	B
was	O
evaluated	O
by	O
means	O
of	O
sodium	O
dodecyl	O
sulphate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
enzyme	O
activity	O
.	O

In	O
crude	O
cell	O
extracts	O
hSOD	B
expression	O
levels	O
were	O
found	O
to	O
be	O
high	O
in	O
hosts	O
possessing	O
no	O
deoR	B
or	O
cytR	B
repressors	O
.	O

Highest	O
levels	O
of	O
hSOD	B
expression	O
were	O
obtained	O
with	O
a	O
high	O
-	O
copy	O
-	O
number	O
plasmid	O
regardless	O
of	O
the	O
host	O
used	O
.	O

Expressed	O
hSOD	B
can	O
account	O
for	O
35	O
%	O
-	O
40	O
%	O
of	O
total	O
protein	O
in	O
E.	O
coli	O
.	O

The	O
heat	B
-	I
shock	I
protein	I
ClpB	B
in	O
Escherichia	O
coli	O
is	O
a	O
protein	O
-	O
activated	O
ATPase	B
.	O

The	O
clpB	B
gene	O
in	O
Escherichia	O
coli	O
encodes	O
a	O
heat	B
-	I
shock	I
protein	I
that	O
is	O
a	O
close	O
homolog	O
of	O
the	O
clpA	B
gene	O
product	O
.	O

The	O
latter	O
is	O
the	O
ATPase	B
subunit	O
of	O
the	O
multimeric	O
ATP	B
-	I
dependent	I
protease	I
Ti	I
(	I
Clp	I
)	I
in	O
E.	O
coli	O
,	O
which	O
also	O
contains	O
the	O
21	O
-	O
kDa	O
proteolytic	O
subunit	O
(	O
ClpP	B
)	O
.	O

The	O
clpB	B
gene	O
product	O
has	O
been	O
purified	O
to	O
near	O
homogeneity	O
by	O
DEAE	O
-	O
Sepharose	O
and	O
heparin	O
-	O
agarose	O
column	O
chromatographies	O
.	O

The	O
purified	O
ClpB	B
consists	O
of	O
a	O
major	O
93	O
-	O
kDa	O
protein	O
and	O
a	O
minor	O
79	O
-	O
kDa	O
polypeptide	O
as	O
analyzed	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
in	O
the	O
presence	O
of	O
sodium	O
dodecyl	O
sulfate	O
.	O

Upon	O
gel	O
filtration	O
on	O
a	O
Superose	O
-	O
6	O
column	O
,	O
it	O
behaves	O
as	O
a	O
350	O
-	O
kDa	O
protein	O
.	O

Thus	O
,	O
ClpB	B
appears	O
to	O
be	O
a	O
tetrameric	O
complex	O
of	O
the	O
93	O
-	O
kDa	O
subunit	O
.	O

The	O
purified	O
ClpB	B
has	O
ATPase	B
activity	O
which	O
is	O
stimulated	O
5	O
-	O
10	O
-	O
fold	O
by	O
casein	B
.	O

It	O
is	O
also	O
activated	O
by	O
insulin	B
,	O
but	O
not	O
by	O
other	O
proteins	O
,	O
including	O
globin	B
and	O
denatured	O
bovine	B
serum	I
albumin	I
.	O

ClpB	B
cleaves	O
adenosine	O
5'-	O
(	O
alpha	O
,	O
beta	O
-	O
methylene	O
)	O
-triphosphate	O
as	O
rapidly	O
as	O
ATP	O
,	O
but	O
not	O
adenosine	O
5'-	O
(	O
beta	O
,	O
gamma	O
-	O
methylene	O
)	O
-triphosphate	O
.	O

GTP	O
,	O
CTP	O
,	O
and	O
UTP	O
are	O
hydrolyzed	O
15	O
-	O
25	O
%	O
as	O
well	O
as	O
ATP	O
.	O

ADP	O
strongly	O
inhibits	O
ATP	O
hydrolysis	O
with	O
a	O
Ki	O
of	O
34	O
microM	O
.	O

ClpB	B
has	O
a	O
Km	O
for	O
ATP	O
of	O
1.1	O
mM	O
,	O
and	O
casein	B
increases	O
its	O
Vmax	O
for	O
ATP	O
without	O
affecting	O
its	O
Km	O
.	O

A	O
Mg2	O
+	O
concentration	O
of	O
3	O
mM	O
is	O
necessary	O
for	O
half	O
-	O
maximal	O
ATP	O
hydrolysis	O
.	O

Mn2	O
+	O
supports	O
ATPase	B
activity	O
as	O
well	O
as	O
Mg2	O
+	O
,	O
and	O
Ca2	O
+	O
has	O
about	O
20	O
%	O
their	O
activity	O
.	O

Anti	O
-	O
ClpB	B
antiserum	O
does	O
not	O
cross	O
-	O
react	O
with	O
ClpA	B
nor	O
does	O
anti	O
-	O
ClpA	B
antiserum	O
react	O
with	O
ClpB	B
.	O

In	O
addition	O
,	O
ClpB	B
can	O
not	O
replace	O
ClpA	B
in	O
supporting	O
the	O
casein	B
-	O
degrading	O
activity	O
of	O
ClpP	B
.	O

Thus	O
,	O
ClpB	B
is	O
distinct	O
from	O
ClpA	B
in	O
its	O
structural	O
and	O
biochemical	O
properties	O
despite	O
the	O
similarities	O
in	O
their	O
sequences	O
.	O

Overexpression	O
,	O
purification	O
and	O
characterization	O
of	O
the	O
Escherichia	O
coli	O
MelR	B
transcription	O
activator	O
protein	O
.	O

The	O
gene	O
encoding	O
Escherichia	O
coli	O
MelR	B
protein	O
has	O
been	O
cloned	O
in	O
the	O
expression	O
vector	O
pJLA502	O
.	O

MelR	B
has	O
been	O
overexpressed	O
,	O
substantially	O
purified	O
and	O
shown	O
to	O
bind	O
to	O
DNA	O
fragments	O
carrying	O
the	O
melAB	B
promoter	O
.	O

A	O
truncated	O
version	O
of	O
the	O
melR	B
gene	O
,	O
encoding	O
the	O
C	O
-	O
terminal	O
half	O
of	O
MelR	B
,	O
was	O
also	O
cloned	O
into	O
pJLA502	O
;	O
the	O
protein	O
product	O
of	O
this	O
truncated	O
gene	O
binds	O
to	O
the	O
melAB	B
promoter	O
but	O
was	O
not	O
overproduced	O
.	O

A	O
number	O
of	O
amino	O
acid	O
substitutions	O
were	O
made	O
in	O
the	O
recognition	O
helices	O
of	O
two	O
putative	O
helix	O
-	O
turn	O
-	O
helix	O
motifs	O
in	O
the	O
C	O
-	O
terminal	O
part	O
of	O
MelR	B
,	O
and	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
MelR	B
-	O
dependent	O
transcription	O
initiation	O
at	O
the	O
melAB	B
promoter	O
have	O
been	O
measured	O
.	O

IFN	B
-	B
alpha	I
skews	O
monocyte	O
differentiation	O
into	O
Toll	B
-	I
like	I
receptor	I
7	I
-	O
expressing	O
dendritic	O
cells	O
with	O
potent	O
functional	O
activities	O
.	O

IFN	B
-	I
alpha	I
is	O
an	O
important	O
cytokine	B
for	O
the	O
generation	O
of	O
a	O
protective	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
to	O
viruses	O
.	O

In	O
this	O
study	O
,	O
we	O
asked	O
whether	O
IFN	B
-	I
alpha	I
can	O
regulate	O
the	O
functional	O
properties	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
.	O

We	O
show	O
that	O
monocytes	O
cultured	O
in	O
the	O
presence	O
of	O
GM	B
-	I
CSF	I
and	O
IFN	B
-	I
alpha	I
can	O
differentiate	O
into	O
DCs	O
(	O
IFN	B
-	I
alpha	I
-	O
derived	O
DCs	O
(	O
IFN	B
-	O
DCs	O
)	O
)	O
.	O

When	O
compared	O
with	O
DCs	O
generated	O
in	O
the	O
presence	O
of	O
GM	B
-	I
CSF	I
and	O
IL-4	B
(	O
IL-4	B
-	O
derived	O
DCs	O
)	O
,	O
IFN	B
-	O
DCs	O
exhibited	O
a	O
typical	O
DC	O
morphology	O
and	O
expressed	O
,	O
in	O
addition	O
to	O
DC	O
markers	O
CD1a	B
and	O
blood	O
DC	O
Ag	O
4	O
,	O
a	O
similar	O
level	O
of	O
costimulatory	O
and	O
class	B
II	I
MHC	I
molecules	O
,	O
but	O
a	O
significantly	O
higher	O
level	O
of	O
MHC	B
class	I
I	I
molecules	O
.	O

After	O
maturation	O
with	O
CD40	B
ligand	I
,	O
IFN	B
-	O
DCs	O
up	O
-	O
regulated	O
costimulatory	O
,	O
class	B
I	I
and	I
II	I
MHC	I
molecules	O
and	O
expressed	O
mature	O
DC	O
markers	O
such	O
as	O
CD83	B
and	O
DC	O
-	O
lysosome	B
-	I
associated	I
membrane	I
protein	I
.	O

DCs	O
were	O
endowed	O
with	O
potent	O
functional	O
activities	O
.	O

DCs	O
secreted	O
large	O
amounts	O
of	O
the	O
inflammatory	O
cytokines	B
IL-6	B
,	O
IL-10	B
,	O
TNF	B
-	I
alpha	I
,	O
IL-1beta	B
,	O
and	O
IL-18	B
,	O
and	O
promoted	O
a	O
Th1	O
response	O
that	O
was	O
independent	O
of	O
IL	B
-	I
12p70	I
and	O
IL	B
-	I
18	I
,	O
but	O
substantially	O
inhibited	O
by	O
IFN	B
-	I
alpha	I
neutralization	O
.	O

Furthermore	O
,	O
immature	O
IFN	B
-	O
DCs	O
induced	O
a	O
potent	O
autologous	O
Ag	O
-	O
specific	O
immune	O
response	O
,	O
as	O
evaluated	O
by	O
IFN	B
-	I
gamma	I
secretion	O
and	O
expansion	O
of	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
specific	O
for	O
CMV	O
.	O

Also	O
,	O
IFN	B
-	O
DCs	O
expressed	O
a	O
large	O
number	O
of	O
Toll	B
-	I
like	I
receptors	I
(	O
TLRs	B
)	O
,	O
including	O
acquisition	O
of	O
TLR7	B
,	O
which	O
is	O
classically	O
found	O
on	O
the	O
natural	O
type	B
I	I
IFN	I
-	O
producing	O
plasmacytoid	O
DCs	O
.	O

Like	O
plasmacytoid	O
DCs	O
,	O
IFN	B
-	O
DCs	O
could	O
secrete	O
IFN	B
-	I
alpha	I
following	O
viral	O
stimulation	O
or	O
TLR7	B
-	O
specific	O
stimulation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
illustrate	O
the	O
critical	O
role	O
of	O
IFN	B
-	I
alpha	I
at	O
the	O
early	O
steps	O
of	O
immune	O
response	O
to	O
pathogens	O
or	O
in	O
autoimmune	O
diseases	O
.	O

Complexes	O
of	O
RecA	B
with	O
LexA	B
and	O
RecX	B
differentiate	O
between	O
active	O
and	O
inactive	O
RecA	B
nucleoprotein	O
filaments	O
.	O

The	O
bacterial	O
RecA	B
protein	O
has	O
been	O
the	O
dominant	O
model	O
system	O
for	O
understanding	O
homologous	O
genetic	O
recombination	O
.	O

Although	O
a	O
crystal	O
structure	O
of	O
RecA	B
was	O
solved	O
ten	O
years	O
ago	O
,	O
we	O
still	O
do	O
not	O
have	O
a	O
detailed	O
understanding	O
of	O
how	O
the	O
helical	O
filament	O
formed	O
by	O
RecA	B
on	O
DNA	O
catalyzes	O
the	O
recognition	O
of	O
homology	O
and	O
the	O
exchange	O
of	O
strands	O
between	O
two	O
DNA	O
molecules	O
.	O

Recent	O
structural	O
and	O
spectroscopic	O
studies	O
have	O
suggested	O
that	O
subunits	O
in	O
the	O
helical	O
filament	O
formed	O
in	O
the	O
RecA	B
crystal	O
are	O
rotated	O
when	O
compared	O
to	O
the	O
active	O
RecA	B
-	O
ATP	O
-	O
DNA	O
filament	O
.	O

We	O
examine	O
RecA	B
-	O
DNA	O
-	O
ATP	O
filaments	O
complexed	O
with	O
LexA	B
and	O
RecX	B
to	O
shed	O
more	O
light	O
on	O
the	O
active	O
RecA	B
filament	O
.	O

The	O
LexA	B
repressor	I
and	O
RecX	B
,	O
an	O
inhibitor	O
of	O
RecA	B
,	O
both	O
bind	O
within	O
the	O
deep	O
helical	O
groove	O
of	O
the	O
RecA	B
filament	O
.	O

Residues	O
on	O
RecA	B
that	O
interact	O
with	O
LexA	B
can	O
not	O
be	O
explained	O
by	O
the	O
crystal	O
filament	O
,	O
but	O
can	O
be	O
properly	O
positioned	O
in	O
an	O
existing	O
model	O
for	O
the	O
active	O
filament	O
.	O

We	O
show	O
that	O
the	O
strand	O
exchange	O
activity	O
of	O
RecA	B
,	O
which	O
can	O
be	O
inhibited	O
when	O
RecX	B
is	O
present	O
at	O
very	O
low	O
stoichiometry	O
,	O
is	O
due	O
to	O
RecX	B
forming	O
a	O
block	O
across	O
the	O
deep	O
helical	O
groove	O
of	O
the	O
RecA	B
filament	O
,	O
where	O
strand	O
exchange	O
occurs	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
changes	O
in	O
the	O
nucleotide	O
bound	O
to	O
RecA	B
are	O
associated	O
with	O
large	O
motions	O
of	O
RecA	B
's	O
C	O
-	O
terminal	O
domain	O
.	O

Since	O
RecX	B
binds	O
from	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
one	O
subunit	O
to	O
the	O
nucleotide	O
-	O
binding	O
core	O
of	O
another	O
subunit	O
,	O
a	O
stabilization	O
of	O
RecA	B
's	O
C	O
-	O
terminal	O
domain	O
by	O
RecX	B
can	O
likely	O
explain	O
the	O
inhibition	O
of	O
RecA	B
's	O
ATPase	B
activity	O
by	O
RecX	B
.	O

Prospecting	O
for	O
novel	O
biocatalysts	O
in	O
a	O
soil	O
metagenome	O
.	O

The	O
metagenomes	O
of	O
complex	O
microbial	O
communities	O
are	O
rich	O
sources	O
of	O
novel	O
biocatalysts	O
.	O

We	O
exploited	O
the	O
metagenome	O
of	O
a	O
mixed	O
microbial	O
population	O
for	O
isolation	O
of	O
more	O
than	O
15	O
different	O
genes	O
encoding	O
novel	O
biocatalysts	O
by	O
using	O
a	O
combined	O
cultivation	O
and	O
direct	O
cloning	O
strategy	O
.	O

A	O
16S	O
rRNA	O
sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
hitherto	O
uncultured	O
microbes	O
closely	O
related	O
to	O
the	O
genera	O
Pseudomonas	O
,	O
Agrobacterium	O
,	O
Xanthomonas	O
,	O
Microbulbifer	O
,	O
and	O
Janthinobacterium	O
.	O

Total	O
genomic	O
DNA	O
from	O
this	O
bacterial	O
community	O
was	O
used	O
to	O
construct	O
cosmid	O
DNA	O
libraries	O
,	O
which	O
were	O
functionally	O
searched	O
for	O
novel	O
enzymes	O
of	O
biotechnological	O
value	O
.	O

Our	O
searches	O
in	O
combination	O
with	O
cosmid	O
sequencing	O
resulted	O
in	O
identification	O
of	O
four	O
clones	O
encoding	O
12	O
putative	O
agarase	B
genes	O
,	O
most	O
of	O
which	O
were	O
organized	O
in	O
clusters	O
consisting	O
of	O
two	O
or	O
three	O
genes	O
.	O

Interestingly	O
,	O
nine	O
of	O
these	O
agarase	B
genes	O
probably	O
originated	O
from	O
gene	O
duplications	O
.	O

Furthermore	O
,	O
we	O
identified	O
by	O
DNA	O
sequencing	O
several	O
other	O
biocatalyst	O
-	O
encoding	O
genes	O
,	O
including	O
genes	O
encoding	O
a	O
putative	O
stereoselective	O
amidase	B
(	O
amiA	B
)	O
,	O
two	O
cellulases	B
(	O
gnuB	B
and	O
uvs080	B
)	O
,	O
an	O
alpha	B
-	I
amylase	I
(	O
amyA	B
)	O
,	O
a	O
1,4-alpha	B
-	I
glucan	I
branching	I
enzyme	I
(	O
amyB	B
)	O
,	O
and	O
two	O
pectate	B
lyases	I
(	O
pelA	B
and	O
uvs119	B
)	O
.	O

Also	O
,	O
a	O
conserved	O
cluster	O
of	O
two	O
lipase	B
genes	O
was	O
identified	O
,	O
which	O
was	O
linked	O
to	O
genes	O
encoding	O
a	O
type	O
I	O
secretion	O
system	O
.	O

The	O
novel	O
gene	O
aguB	B
was	O
overexpressed	O
in	O
Escherichia	O
coli	O
,	O
and	O
the	O
enzyme	O
activities	O
were	O
determined	O
.	O

Finally	O
,	O
we	O
describe	O
more	O
than	O
162	O
kb	O
of	O
DNA	O
sequence	O
that	O
provides	O
a	O
strong	O
platform	O
for	O
further	O
characterization	O
of	O
this	O
microbial	O
consortium	O
.	O

Analysis	O
of	O
the	O
alternative	B
oxidase	I
promoters	O
from	O
soybean	O
.	O

Alternative	B
oxidase	I
(	O
Aox	B
)	O
is	O
a	O
nuclear	O
-	O
encoded	O
mitochondrial	O
protein	O
.	O

In	O
soybean	O
(	O
Glycine	O
max	O
)	O
,	O
the	O
three	O
members	O
of	O
the	O
gene	O
family	O
have	O
been	O
shown	O
to	O
be	O
differentially	O
expressed	O
during	O
normal	O
plant	O
development	O
and	O
in	O
response	O
to	O
stresses	O
.	O

To	O
examine	O
the	O
function	O
of	O
the	O
Aox	B
promoters	O
,	O
genomic	O
fragments	O
were	O
obtained	O
for	O
all	O
three	O
soybean	O
genes	O
:	O
Aox1	B
,	O
Aox2a	B
,	O
and	O
Aox2b	B
.	O

The	O
regions	O
of	O
these	O
fragments	O
immediately	O
upstream	O
of	O
the	O
coding	O
regions	O
were	O
used	O
to	O
drive	O
beta	B
-	I
glucuronidase	I
(	O
GUS	B
)	O
expression	O
during	O
transient	O
transformation	O
of	O
soybean	O
suspension	O
culture	O
cells	O
and	O
stable	O
transformation	O
of	O
Arabidopsis	O
.	O

The	O
expression	O
patterns	O
of	O
the	O
GUS	B
reporter	O
genes	O
in	O
soybean	O
cells	O
were	O
in	O
agreement	O
with	O
the	O
presence	O
or	O
absence	O
of	O
the	O
various	O
endogenous	O
Aox	B
proteins	O
,	O
determined	O
by	O
immunoblotting	O
.	O

Deletion	O
of	O
different	O
portions	O
of	O
the	O
upstream	O
regions	O
identified	O
sequences	O
responsible	O
for	O
both	O
positive	O
and	O
negative	O
regulation	O
of	O
Aox	B
gene	O
expression	O
in	O
soybean	O
cells	O
.	O

Reporter	O
gene	O
analysis	O
in	O
Arabidopsis	O
plants	O
showed	O
differential	O
tissue	O
expression	O
patterns	O
driven	O
by	O
the	O
three	O
upstream	O
regions	O
,	O
similar	O
to	O
those	O
reported	O
for	O
the	O
endogenous	O
proteins	O
in	O
soybean	O
.	O

The	O
expression	O
profiles	O
of	O
all	O
five	O
members	O
of	O
the	O
Arabidopsis	O
Aox	B
gene	I
family	I
were	O
examined	O
also	O
,	O
to	O
compare	O
with	O
GUS	B
expression	O
driven	O
by	O
the	O
soybean	O
upstream	O
fragments	O
.	O

Even	O
though	O
the	O
promoter	O
activity	O
of	O
the	O
upstream	O
fragments	O
from	O
soybean	O
Aox2a	B
and	O
Aox2b	B
displayed	O
the	O
same	O
tissue	O
specificity	O
in	O
Arabidopsis	O
as	O
they	O
do	O
in	O
soybean	O
,	O
the	O
most	O
prominently	O
expressed	O
endogenous	O
genes	O
in	O
all	O
tissues	O
of	O
Arabidopsis	O
were	O
of	O
the	O
Aox1	B
type	O
.	O

Thus	O
although	O
regulation	O
of	O
Aox	B
expression	O
generally	O
appears	O
to	O
involve	O
the	O
same	O
signals	O
in	O
different	O
species	O
,	O
different	O
orthologs	O
of	O
Aox	B
may	O
respond	O
variously	O
to	O
these	O
signals	O
.	O

A	O
comparison	O
of	O
upstream	O
sequences	O
between	O
soybean	O
Aox	B
genes	O
and	O
similarly	O
expressed	O
Arabidopsis	O
Aox	B
genes	O
identified	O
common	O
motifs	O
.	O

[	O
The	O
role	O
of	O
Smads	B
and	O
related	O
transcription	B
factors	I
in	O
the	O
signal	O
transduction	O
of	O
bone	B
morphogenetic	I
protein	I
inducing	O
bone	O
formation	O
]	O

OBJECTIVE	O
:	O

To	O
clarify	O
the	O
mechanisms	O
of	O
the	O
signal	O
transduction	O
of	O
bone	B
morphogenetic	I
proteins	I
(	O
BMPs	B
)	O
inducing	O
bone	O
formation	O
and	O
to	O
provide	O
theoretical	O
basis	O
for	O
basic	O
and	O
applying	O
research	O
of	O
BMPs	B
.	O

METHOD	O
:	O

We	O
looked	O
up	O
the	O
literature	O
of	O
the	O
role	O
of	O
Smads	B
and	O
related	O
transcription	B
factors	I
in	O
the	O
signal	O
transduction	O
of	O
BMPs	B
inducing	O
bone	O
formation	O
.	O

RESULTS	O
:	O

The	O
signal	O
transduction	O
processes	O
of	O
BMPs	B
included	O
:	O
1	O
.	O

BMPs	B
combined	O
with	O
type	O
II	O
and	O
type	O
I	O
receptors	O
;	O
2	O
.	O
the	O
type	O
I	O
receptor	O
phosphorylated	O
Smads	B
;	O
and	O
3	O
.	O

Smads	B
entered	O
the	O
cell	O
nucleus	O
,	O
interacted	O
with	O
transcription	B
factors	I
and	O
influenced	O
the	O
transcription	O
of	O
related	O
proteins	O
.	O

Smads	B
could	O
be	O
divided	O
into	O
receptor	O
-	O
regulated	O
Smads	B
(	O
R	B
-	I
Smads	I
:	O
Smad1	B
,	O
Smad2	B
,	O
Smad3	B
,	O
Smad5	B
,	O
Smad8	B
and	O
Smad9	B
)	O
,	O
common	O
-	O
mediator	O
Smad	B
(	O
co	O
-	O
Smad	B
:	O
Smad4	B
)	O
,	O
and	O
inhibitory	O
Smads	B
(	O
I-	O
Smads	B
:	O
Smad6	B
and	O
Smad7	B
)	O
.	O

Smad1	B
,	O
Smad5	B
,	O
Smad8	B
,	O
and	O
probable	O
Smad9	B
were	O
involved	O
in	O
the	O
signal	O
transduction	O
of	O
BMPs	B
.	O

Multiple	O
kinases	B
,	O
such	O
as	O
focal	B
adhesion	I
kinase	I
(	O
FAK	B
)	O
,	O
Ras	B
-	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
(	O
ERK	B
)	O
,	O
phosphatidylinositol	B
3	I
-	I
kinase	I
(	O
PI3	B
K	I
)	O
,	O
and	O
Akt	B
serine	I
/	I
threonine	I
kinase	I
were	O
related	O
to	O
Smads	B
signal	O
transduction	O
.	O

Smad1	B
and	O
Smad5	B
related	O
with	O
transcription	B
factors	I
included	O
core	B
binding	I
factor	I
A1	I
(	O
CBFA1	B
)	O
,	O
smad	B
-	I
interacting	I
protein	I
1	I
(	O
SIP1	B
)	O
,	O
ornithine	B
decarboxylase	I
antizyme	I
(	O
OAZ	B
)	O
,	O
activating	B
protein	I
-	I
1	I
(	O
AP-1	B
)	O
,	O
xenopus	O
ventralizing	B
homeobox	I
protein-2	I
(	O
Xvent	B
-	I
2	I
)	O
,	O
sandostatin	O
(	O
Ski	O
)	O
,	O
antiproliferative	O
proteins	O
(	O
Tob	O
)	O
,	O
and	O
homeodomain	B
-	I
containing	I
transcriptian	I
factor	I
-	I
8	I
(	O
Hoxc	B
-	I
8	I
)	O
,	O
et	O
al.	O
CBFA1	B
could	O
interact	O
with	O
Smad1	B
,	O
Smad2	B
,	O
Smad3	B
,	O
and	O
Smad5	B
,	O
so	O
it	O
was	O
involved	O
in	O
TGF	B
-	I
beta	I
and	O
BMP-2	B
signal	O
transduction	O
,	O
and	O
played	O
an	O
important	O
role	O
in	O
the	O
bone	O
formation	O
.	O

Cleidocranial	O
dysplasia	O
(	O
CCD	O
)	O
was	O
thought	O
to	O
be	O
caused	O
by	O
heterozygous	O
mutations	O
in	O
CBFA1	B
.	O

The	O
CBFA1	B
knockout	O
mice	O
showed	O
no	O
osteogenesis	O
and	O
had	O
maturational	O
disturbance	O
of	O
chondrocytes	O
.	O

CONCLUSION	O
:	O

Smads	B
and	O
related	O
transcription	B
factors	I
,	O
especially	O
Smad1	B
,	O
Smad5	B
,	O
Smad8	B
and	O
CBFA1	B
,	O
play	O
an	O
important	O
role	O
in	O
the	O
signal	O
transduction	O
of	O
BMPs	B
inducing	O
bone	O
formation	O
.	O

IL-27	B
and	O
IFN	B
-	I
alpha	I
signal	O
via	O
Stat1	B
and	O
Stat3	B
and	O
induce	O
T	O
-	O
Bet	O
and	O
IL-12Rbeta2	B
in	O
naive	O
T	O
cells	O
.	O

Interleukin-27	B
(	O
IL-27	B
)	O
supports	O
proliferation	O
of	O
naive	O
CD4	B
(	O
+	O
)	O
T	O
cells	O
and	O
enhances	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
production	O
by	O
activated	O
T	O
cells	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

We	O
report	O
here	O
that	O
IL-27	B
induces	O
Stat1	B
and	O
Stat3	B
phosphorylation	O
and	O
activation	O
in	O
human	O
and	O
murine	O
cell	O
lines	O
and	O
primary	O
human	O
T	O
cells	O
.	O

IL-27	B
also	O
induces	O
T	B
-	I
Bet	I
,	O
a	O
Stat1	B
-	O
dependent	O
gene	O
crucial	O
to	O
Th1	O
cell	O
commitment	O
.	O

Similarly	O
,	O
IFN	B
-	I
alpha	I
activates	O
Stat1	B
and	O
Stat3	B
and	O
T	B
-	I
Bet	I
expression	O
in	O
naive	O
T	O
cells	O
.	O

Induction	O
of	O
T	B
-	I
Bet	I
results	O
in	O
upregulation	O
of	O
IL-12Rbeta2	B
on	O
naive	O
T	O
cells	O
,	O
which	O
is	O
essential	O
for	O
responsiveness	O
to	O
IL-12	B
and	O
differentiation	O
to	O
a	O
Th1	O
phenotype	O
.	O

Both	O
IL-27	B
and	O
IFN	B
-	I
alpha	I
induce	O
expression	O
of	O
IL-12Rbeta2	B
in	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
IFN	B
-	I
gamma	I
,	O
which	O
activates	O
Stat1	B
but	O
not	O
Stat3	B
,	O
induces	O
expression	O
of	O
T	B
-	I
Bet	I
but	O
not	O
IL-12Rbeta2	B
in	O
naive	O
T	O
cells	O
.	O

We	O
propose	O
that	O
IL-27	B
and	O
IFN	B
-	I
alpha	I
are	O
important	O
for	O
early	O
Th1	O
commitment	O
and	O
act	O
upstream	O
of	O
IL-12	B
and	O
IFN	B
-	I
gamma	I
in	O
this	O
pathway	O
.	O

CD8	B
(	O
+	O
)	O
CD28	B
(	O
-	O
)	O
T	O
lymphocytes	O
from	O
HIV-1	O
-	O
infected	O
patients	O
secrete	O
factors	O
that	O
induce	O
endothelial	O
cell	O
proliferation	O
and	O
acquisition	O
of	O
Kaposi	O
's	O
sarcoma	O
cell	O
features	O
.	O

Kaposi	O
's	O
sarcoma	O
(	O
KS	O
)	O
develops	O
more	O
frequently	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
-	O
infected	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
molecules	O
released	O
by	O
CD8	B
(	O
+	O
)	O
CD28	B
(	O
-	O
)	O
T	O
lymphocytes	O
from	O
HIV-1	O
-	O
infected	O
patients	O
promote	O
endothelial	O
-	O
cell	O
(	O
EC	O
)	O
growth	O
and	O
induce	O
ECs	O
to	O
acquire	O
spindle	O
cell	O
morphology	O
and	O
upregulation	O
of	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
,	O
E	B
-	I
selectin	I
,	O
and	O
vascular	B
endothelial	I
cell	I
growth	I
factor	I
receptor-3	I
(	O
VEGFR-3	B
)	O
(	O
a	O
typical	O
feature	O
of	O
the	O
KS	O
cell	O
phenotype	O
)	O
.	O

The	O
effects	O
observed	O
on	O
ECs	O
cocultured	O
with	O
in	O
vivo	O
activated	O
CD28	B
(	O
-	O
)	O
cells	O
were	O
partly	O
reproduced	O
when	O
ECs	O
were	O
grown	O
in	O
medium	O
containing	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O

At	O
concentrations	O
similar	O
to	O
those	O
found	O
in	O
the	O
supernatant	O
of	O
in	O
vivo	O
activated	O
CD28	B
(	O
-	O
)	O
cells	O
,	O
the	O
two	O
proinflammatory	O
cytokines	B
sustained	O
EC	O
growth	O
and	O
survival	O
only	O
when	O
combined	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
CD28	B
(	O
-	O
)	O
T	O
lymphocytes	O
from	O
HIV-1	O
-	O
infected	O
patients	O
exert	O
their	O
effect	O
on	O
ECs	O
through	O
a	O
mechanism	O
involving	O
both	O
IFN	B
-	I
gamma	I
and	O
TNF	B
-	I
alpha	I
.	O

This	O
finding	O
may	O
have	O
wide	O
implications	O
for	O
our	O
basic	O
understanding	O
of	O
the	O
immunopathology	O
of	O
KS	O
.	O

Canavan	O
disease	O
:	O
a	O
monogenic	O
trait	O
with	O
complex	O
genomic	O
interaction	O
.	O

Canavan	O
disease	O
(	O
CD	O
)	O
is	O
an	O
inherited	O
leukodystrophy	O
,	O
caused	O
by	O
aspartoacylase	B
(	O
ASPA	B
)	O
deficiency	O
,	O
and	O
accumulation	O
of	O
N	O
-	O
acetylaspartic	O
acid	O
(	O
NAA	O
)	O
in	O
the	O
brain	O
.	O

The	O
gene	O
for	O
ASPA	B
has	O
been	O
cloned	O
and	O
more	O
than	O
40	O
mutations	O
have	O
been	O
described	O
,	O
with	O
two	O
founder	O
mutations	O
among	O
Ashkenazi	O
Jewish	O
patients	O
.	O

Screening	O
of	O
Ashkenazi	O
Jews	O
for	O
these	O
two	O
common	O
mutations	O
revealed	O
a	O
high	O
carrier	O
frequency	O
,	O
approximately	O
1	O
/	O
40	O
,	O
so	O
that	O
programs	O
for	O
carrier	O
testing	O
are	O
currently	O
in	O
practice	O
.	O

The	O
enzyme	O
deficiency	O
in	O
CD	O
interferes	O
with	O
the	O
normal	O
hydrolysis	O
of	O
NAA	O
,	O
which	O
results	O
in	O
disruption	O
of	O
myelin	O
and	O
spongy	O
degeneration	O
of	O
the	O
white	O
matter	O
of	O
the	O
brain	O
.	O

The	O
clinical	O
features	O
of	O
the	O
disease	O
are	O
macrocephaly	O
,	O
head	O
lag	O
,	O
progressive	O
severe	O
mental	O
retardation	O
,	O
and	O
hypotonia	O
in	O
early	O
life	O
,	O
which	O
later	O
changes	O
to	O
spasticity	O
.	O

A	O
knockout	O
mouse	O
for	O
CD	O
has	O
been	O
generated	O
,	O
and	O
used	O
to	O
study	O
the	O
pathophysiological	O
basis	O
for	O
CD	O
.	O

Findings	O
from	O
the	O
knockout	O
mouse	O
indicate	O
that	O
this	O
monogenic	O
trait	O
leads	O
to	O
a	O
series	O
of	O
genomic	O
interaction	O
in	O
the	O
brain	O
.	O

Changes	O
include	O
low	O
levels	O
of	O
glutamate	O
and	O
GABA	O
.	O

Microarray	O
expression	O
analysis	O
showed	O
low	O
level	O
of	O
expression	O
of	O
GABA	B
-	I
A	I
receptor	I
(	O
GABRA6	B
)	O
and	O
glutamate	B
transporter	I
(	O
EAAT4	B
)	O
.	O

The	O
gene	O
Spi2	B
,	O
a	O
gene	O
involved	O
in	O
apoptosis	O
and	O
cell	O
death	O
,	O
showed	O
high	O
level	O
of	O
expression	O
.	O

Such	O
complexity	O
of	O
gene	O
interaction	O
results	O
in	O
the	O
phenotype	O
,	O
the	O
proteome	O
,	O
with	O
spongy	O
degeneration	O
of	O
the	O
brain	O
and	O
neurological	O
impairment	O
of	O
the	O
mouse	O
,	O
similar	O
to	O
the	O
human	O
counterpart	O
.	O

Aspartoacylase	B
gene	O
transfer	O
trial	O
in	O
the	O
mouse	O
brain	O
using	O
adenoassociated	O
virus	O
(	O
AAV	O
)	O
as	O
a	O
vector	O
are	O
encouraging	O
showing	O
improved	O
myelination	O
and	O
decrease	O
in	O
spongy	O
degeneration	O
in	O
the	O
area	O
of	O
the	O
injection	O
and	O
also	O
beyond	O
that	O
site	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
mouse	O
AP-2	B
epsilon	I
gene	O
:	O
a	O
novel	O
family	O
member	O
expressed	O
in	O
the	O
developing	O
olfactory	O
bulb	O
.	O

Members	O
of	O
the	O
mammalian	O
AP-2	B
transcription	I
factor	I
family	I
have	O
critical	O
regulatory	O
roles	O
in	O
many	O
aspects	O
of	O
development	O
and	O
are	O
also	O
implicated	O
in	O
cancer	O
progression	O
.	O

Four	O
AP-2	B
genes	O
have	O
been	O
previously	O
characterized	O
in	O
mouse	O
and	O
human	O
,	O
encoding	O
the	O
AP-2alpha	B
,	O
AP-2beta	B
,	O
AP-2gamma	B
,	O
and	O
AP-2delta	B
proteins	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
the	O
fifth	O
member	O
of	O
the	O
vertebrate	O
AP-2	B
family	I
,	O
AP-2epsilon	B
.	O

The	O
AP-2epsilon	B
protein	O
is	O
very	O
similar	O
to	O
the	O
other	O
family	O
members	O
in	O
its	O
DNA	O
binding	O
and	O
dimerization	O
domain	O
and	O
also	O
contains	O
conserved	O
proline	O
and	O
aromatic	O
amino	O
acid	O
residues	O
in	O
the	O
activation	O
domain	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
AP-2epsilon	B
can	O
bind	O
to	O
the	O
GC	O
-	O
rich	O
AP-2	B
consensus	O
sequence	O
and	O
can	O
dimerize	O
either	O
with	O
itself	O
or	O
with	O
any	O
of	O
the	O
other	O
AP-2	B
proteins	O
.	O

The	O
AP-2epsilon	B
protein	O
is	O
also	O
able	O
to	O
activate	O
transcription	O
in	O
a	O
binding	O
site	O
-	O
dependent	O
manner	O
.	O

However	O
,	O
the	O
mouse	O
AP-2epsilon	B
gene	O
is	O
distinctive	O
from	O
the	O
other	O
AP-2	B
genes	O
in	O
its	O
pattern	O
of	O
expression	O
during	O
embryogenesis	O
.	O

Unlike	O
AP-2alpha	B
,	O
AP-2beta	B
,	O
and	O
AP-2gamma	B
,	O
transcripts	O
corresponding	O
to	O
AP-2epsilon	B
are	O
not	O
found	O
in	O
the	O
neural	O
crest	O
and	O
its	O
derivatives	O
.	O

Instead	O
,	O
AP-2epsilon	B
is	O
expressed	O
most	O
prominently	O
in	O
the	O
mitral	O
cell	O
layer	O
of	O
the	O
developing	O
olfactory	O
bulb	O
.	O

A	O
comparison	O
of	O
AP-2	B
gene	O
family	O
expression	O
in	O
the	O
olfactory	O
system	O
suggests	O
both	O
distinct	O
and	O
overlapping	O
functions	O
for	O
these	O
transcription	B
factors	I
in	O
forebrain	O
development	O
.	O

Expression	O
profiles	O
of	O
peroxiredoxin	B
proteins	O
of	O
the	O
rodent	O
malaria	O
parasite	O
Plasmodium	O
yoelii	O
.	O

Patterns	O
of	O
expression	O
of	O
the	O
2-Cys	B
and	I
1-Cys	I
peroxiredoxin	I
(	O
Prx	B
)	O
proteins	O
of	O
the	O
rodent	O
malaria	O
parasite	O
Plasmodium	O
yoelii	O
during	O
its	O
life	O
cycle	O
were	O
observed	O
by	O
immunofluorescent	O
antibody	O
staining	O
and	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

2-Cys	B
Prx	I
was	O
expressed	O
in	O
the	O
parasite	O
cytoplasm	O
throughout	O
the	O
life	O
cycle	O
,	O
and	O
the	O
thioredoxin	B
(	I
Trx	I
)	I
-	I
peroxidase	I
activity	O
of	O
2-Cys	B
Prx	I
revealed	O
with	O
the	O
recombinant	O
protein	O
suggested	O
that	O
the	O
Prx	B
is	O
constitutively	O
expressed	O
and	O
,	O
thus	O
,	O
likely	O
plays	O
a	O
housekeeping	O
role	O
in	O
the	O
parasite	O
's	O
intracellular	O
redox	O
control	O
.	O

In	O
contrast	O
,	O
1-Cys	B
Prx	I
showed	O
stage	O
-	O
specific	O
expression	O
in	O
blood	O
-	O
stage	O
parasites	O
.	O

The	O
limited	O
expression	O
of	O
1-Cys	B
Prx	I
in	O
the	O
trophozoite	O
cytoplasm	O
suggests	O
that	O
1-Cys	B
Prx	I
may	O
be	O
involved	O
in	O
haemoglobin	O
metabolism	O
by	O
the	O
parasite	O
,	O
which	O
generates	O
a	O
prooxidative	O
haem	O
iron	O
and	O
increases	O
intracellular	O
oxidative	O
stress	O
.	O

The	O
antioxidant	O
activity	O
of	O
1-Cys	B
Prx	I
was	O
tested	O
for	O
its	O
ability	O
to	O
protect	O
yeast	O
enolase	O
against	O
inactivation	O
of	O
the	O
mixed	O
-	O
function	O
oxidation	O
system	O
.	O

Differential	O
expression	O
of	O
the	O
two	O
Prx	B
proteins	O
during	O
the	O
erythrocytic	O
and	O
insect	O
stages	O
suggests	O
the	O
importance	O
of	O
these	O
proteins	O
in	O
protecting	O
parasites	O
against	O
oxidative	O
stress	O
,	O
which	O
is	O
generated	O
by	O
the	O
parasite	O
's	O
metabolism	O
and	O
also	O
from	O
the	O
environment	O
.	O

Evidence	O
that	O
the	O
37	B
kDa	I
protein	I
of	O
Soil	O
-	O
borne	O
wheat	O
mosaic	O
virus	O
is	O
a	O
virus	O
movement	O
protein	O
.	O

Experiments	O
were	O
conducted	O
to	O
determine	O
if	O
the	O
37	B
kDa	I
protein	I
(	O
37	O
K	O
)	O
of	O
Soil	O
-	O
borne	O
wheat	O
mosaic	O
virus	O
(	O
SBWMV	O
)	O
is	O
a	O
virus	O
movement	O
protein	O
.	O

First	O
,	O
evidence	O
was	O
obtained	O
that	O
indicated	O
that	O
37	B
K	I
has	O
the	O
ability	O
to	O
move	O
from	O
cell	O
to	O
cell	O
,	O
similar	O
to	O
other	O
virus	O
movement	O
proteins	O
(	O
MPs	O
)	O
.	O

Plasmids	O
containing	O
the	O
GFP	B
gene	O
fused	O
to	O
the	O
SBWMV	O
37	B
K	I
,	O
the	O
coat	B
protein	I
(	O
CP	B
)	O
or	O
the	O
CP	B
readthrough	O
domain	O
(	O
RT	O
)	O
ORFs	O
were	O
delivered	O
by	O
biolistic	O
bombardment	O
to	O
wheat	O
and	O
tobacco	O
leaves	O
.	O

In	O
wheat	O
leaves	O
,	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
GFP	B
-	O
37	B
K	I
was	O
observed	O
,	O
while	O
GFP	B
,	O
GFP	B
-	O
CP	B
and	O
GFP	B
-	O
RT	O
accumulated	O
primarily	O
in	O
single	O
cells	O
.	O

All	O
fusion	O
proteins	O
accumulated	O
in	O
single	O
cells	O
in	O
tobacco	O
leaves	O
.	O

Thus	O
,	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
is	O
a	O
specific	O
property	O
of	O
37	B
K	I
that	O
occurs	O
in	O
SBWMV	O
host	O
plants	O
.	O

Subcellular	O
accumulation	O
of	O
37	B
K	I
was	O
studied	O
using	O
SBWMV	O
-	O
infected	O
and	O
37	O
K	O
-	O
expressing	O
transgenic	O
wheat	O
.	O

In	O
infected	O
and	O
transgenic	O
wheat	O
leaves	O
,	O
37	B
K	I
accumulated	O
in	O
the	O
cell	O
wall	O
,	O
similar	O
to	O
other	O
virus	O
MPs	O
,	O
and	O
in	O
aggregates	O
in	O
the	O
cytoplasm	O
.	O

Phylogenetic	O
studies	O
were	O
conducted	O
to	O
compare	O
the	O
furovirus	O
37	B
K	I
proteins	I
with	O
members	O
of	O
the	O
30	B
K	I
superfamily	I
of	O
virus	O
MPs	O
.	O

Amino	O
acid	O
sequences	O
of	O
the	O
furovirus	O
37	B
K	I
proteins	I
were	O
aligned	O
with	O
the	O
MPs	O
from	O
43	O
representative	O
viruses	O
.	O

The	O
furovirus	O
37	B
K	I
proteins	I
were	O
found	O
to	O
reside	O
in	O
a	O
clade	O
that	O
also	O
contained	O
the	O
dianthovirus	O
MPs	O
.	O

Combined	O
,	O
these	O
data	O
suggest	O
that	O
SBWMV	O
37	B
K	I
is	O
probably	O
a	O
virus	O
MP	O
.	O

Expression	O
of	O
nucleolar	O
-	O
related	O
proteins	O
in	O
porcine	O
preimplantation	O
embryos	O
produced	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
expression	O
of	O
nucleolar	O
-	O
related	O
proteins	O
was	O
studied	O
as	O
an	O
indirect	O
marker	O
of	O
the	O
ribosomal	O
RNA	O
(	O
rRNA	O
)	O
gene	O
activation	O
in	O
porcine	O
embryos	O
up	O
to	O
the	O
blastocyst	O
stage	O
produced	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

A	O
group	O
of	O
the	O
in	O
vivo	O
-	O
developed	O
embryos	O
were	O
cultured	O
with	O
alpha	O
-	O
amanitin	O
to	O
block	O
the	O
de	O
novo	O
embryonic	O
mRNA	O
transcription	O
.	O

Localization	O
of	O
proteins	O
involved	O
in	O
the	O
rRNA	O
transcription	O
(	O
upstream	B
binding	I
factor	I
[	O
UBF	B
]	O
,	O
topoisomerase	B
I	I
,	O
RNA	B
polymerase	I
I	I
[	O
RNA	B
Pol	I
I	I
]	O
,	O
and	O
the	O
RNA	B
Pol	I
I	I
-	I
associated	I
factor	I
PAF53	I
)	O
and	O
processing	O
(	O
fibrillarin	B
,	O
nucleophosmin	B
,	O
and	O
nucleolin	B
)	O
was	O
assessed	O
by	O
immunocytochemistry	O
and	O
confocal	O
laser	O
-	O
scanning	O
microscopy	O
,	O
and	O
mRNA	O
expression	O
was	O
determined	O
by	O
semiquantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

These	O
findings	O
were	O
correlated	O
with	O
ultrastructural	O
data	O
and	O
autoradiography	O
following	O
20	O
-	O
min	O
[	O
3H	O
]	O
uridine	O
incubation	O
.	O

Additionally	O
,	O
expression	O
of	O
the	O
pocket	B
proteins	I
pRb	B
and	O
p130	B
,	O
which	O
are	O
involved	O
in	O
cell	O
-	O
cycle	O
regulation	O
,	O
was	O
assessed	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
up	O
to	O
the	O
blastocyst	O
stage	O
.	O

Toward	O
the	O
end	O
of	O
third	O
cell	O
cycle	O
,	O
the	O
nuclei	O
in	O
non	O
-	O
alpha	O
-	O
amanitin	O
-	O
treated	O
,	O
in	O
vivo	O
-	O
produced	O
embryos	O
displayed	O
different	O
stages	O
of	O
transformation	O
of	O
the	O
nuclear	O
precursor	O
bodies	O
(	O
NPBs	O
)	O
into	O
fibrillogranular	O
nucleoli	O
associated	O
with	O
autoradiographic	O
labeling	O
.	O

However	O
,	O
on	O
culture	O
with	O
alpha	O
-	O
amanitin	O
,	O
NPBs	O
were	O
not	O
transformed	O
into	O
a	O
fibrillogranular	O
nucleolus	O
during	O
this	O
cell	O
cycle	O
,	O
demonstrating	O
that	O
embryonic	O
nucleogenesis	O
requires	O
de	O
novo	O
mRNA	O
transcription	O
.	O

Moreover	O
,	O
immunolocalization	O
of	O
RNA	B
Pol	I
I	I
,	O
but	O
not	O
of	O
UBF	B
,	O
and	O
the	O
mRNA	O
expression	O
of	O
PAF53	B
and	O
UBF	B
were	O
significantly	O
reduced	O
or	O
absent	O
after	O
culture	O
with	O
alpha	O
-	O
amanitin	O
,	O
indicating	O
that	O
RNA	B
Pol	I
I	I
,	O
PAF53	B
,	O
and	O
presumably	O
,	O
UBF	B
are	O
derived	O
from	O
de	O
novo	O
embryonic	O
transcription	O
.	O

Embryonic	O
genomic	O
activation	O
was	O
delayed	O
in	O
porcine	O
embryos	O
produced	O
in	O
vitro	O
compared	O
to	O
the	O
in	O
vivo	O
-	O
derived	O
counterparts	O
with	O
respect	O
to	O
mRNAs	O
encoding	O
PAF53	B
and	O
UBF	B
.	O

Moreover	O
,	O
differences	O
existed	O
in	O
the	O
mRNA	O
expression	O
patterns	O
of	O
pRb	B
between	O
in	O
vivo	O
-	O
and	O
in	O
vitro	O
-	O
developed	O
embryos	O
.	O

These	O
findings	O
show	O
,	O
to	O
our	O
knowledge	O
for	O
the	O
first	O
time	O
,	O
a	O
nucleolus	O
-	O
related	O
gene	O
expression	O
in	O
the	O
preimplantation	O
porcine	O
embryo	O
,	O
and	O
they	O
highlight	O
the	O
differences	O
in	O
quality	O
between	O
in	O
vivo	O
and	O
in	O
vitro	O
-	O
produced	O
embryos	O
.	O

Identification	O
of	O
two	O
cyclooxygenase	B
active	O
site	O
residues	O
,	O
Leucine	O
384	O
and	O
Glycine	O
526	O
,	O
that	O
control	O
carbon	O
ring	O
cyclization	O
in	O
prostaglandin	O
biosynthesis	O
.	O

The	O
cyclooxygenase	B
(	O
COX	B
)	O
reaction	O
of	O
prostaglandin	O
(	O
PG	O
)	O
biosynthesis	O
begins	O
with	O
the	O
highly	O
specific	O
oxygenation	O
of	O
arachidonic	O
acid	O
in	O
the	O
11R	O
configuration	O
and	O
ends	O
with	O
a	O
15S	O
oxygenation	O
to	O
form	O
PGG2	O
.	O

To	O
obtain	O
new	O
insights	O
into	O
the	O
mechanisms	O
of	O
stereocontrol	O
of	O
oxygenation	O
,	O
we	O
mutated	O
active	O
site	O
residues	O
of	O
human	O
COX-2	B
that	O
have	O
potential	O
contacts	O
with	O
C-11	O
of	O
the	O
reacting	O
substrate	O
.	O

Although	O
the	O
11R	O
oxygenation	O
was	O
not	O
perturbed	O
,	O
changing	O
Leu-384	O
(	O
into	O
Phe	O
,	O
Trp	O
)	O
,	O
Trp-387	O
(	O
Phe	O
,	O
Tyr	O
)	O
,	O
Phe-518	O
(	O
Ile	O
,	O
Trp	O
,	O
Tyr	O
)	O
,	O
and	O
Gly-526	O
(	O
Ala	O
,	O
Ser	O
,	O
Thr	O
,	O
Val	O
)	O
impaired	O
or	O
abrogated	O
PGG2	O
synthesis	O
,	O
and	O
typically	O
11R	O
-	O
HETE	O
was	O
the	O
main	O
product	O
formed	O
.	O

The	O
Gly-526	O
and	O
Leu-384	O
mutants	O
formed	O
,	O
in	O
addition	O
,	O
three	O
novel	O
products	O
identified	O
by	O
LC	O
-	O
MS	O
,	O
NMR	O
,	O
and	O
circular	O
dichroism	O
as	O
8,9	O
-	O
11,12-diepoxy-13R-	O
(	O
or	O
15R	O
)	O
-	O
hydro	O
(	O
pero	O
)	O
xy	O
derivatives	O
of	O
arachidonic	O
acid	O
.	O

Mechanistically	O
,	O
we	O
propose	O
these	O
arise	O
from	O
a	O
free	O
radical	O
intermediate	O
in	O
which	O
a	O
C-8	O
carbon	O
radical	O
displaces	O
the	O
9,11-endoperoxide	O
O	O
-	O
O	O
bond	O
to	O
yield	O
an	O
8,9	O
-	O
11,12-diepoxide	O
that	O
is	O
finally	O
oxygenated	O
stereospecifically	O
in	O
the	O
13R	O
or	O
15R	O
configuration	O
.	O

Formation	O
of	O
these	O
novel	O
products	O
signals	O
an	O
arrest	O
in	O
the	O
normal	O
course	O
of	O
prostaglandin	O
synthesis	O
just	O
prior	O
to	O
closing	O
of	O
the	O
5-membered	O
carbon	O
ring	O
,	O
and	O
points	O
to	O
a	O
crucial	O
role	O
for	O
Leu-384	O
and	O
Gly-526	O
in	O
the	O
correct	O
positioning	O
of	O
the	O
reacting	O
fatty	O
acid	O
intermediate	O
.	O

Some	O
of	O
the	O
Gly-526	O
and	O
Leu-384	O
mutants	O
catalyzed	O
both	O
formation	O
of	O
PGG2	O
(	O
with	O
the	O
normal	O
15S	O
configuration	O
)	O
and	O
the	O
13R	O
-	O
or	O
15R	O
-	O
oxygenated	O
diepoxides	O
.	O

This	O
result	O
suggests	O
that	O
oxygenation	O
specificity	O
can	O
be	O
determined	O
by	O
the	O
orientation	O
of	O
the	O
reacting	O
fatty	O
acid	O
radical	O
and	O
is	O
not	O
a	O
predetermined	O
outcome	O
based	O
solely	O
on	O
the	O
structure	O
of	O
the	O
cyclooxygenase	B
active	O
site	O
.	O

Accumulation	O
of	O
the	O
amyloid	B
precursor	I
-	I
like	I
protein	I
APLP2	B
and	O
reduction	O
of	O
APLP1	B
in	O
retinoic	O
acid	O
-	O
differentiated	O
human	O
neuroblastoma	O
cells	O
upon	O
curcumin	O
-	O
induced	O
neurite	O
retraction	O
.	O

Amyloid	B
precursor	I
protein	I
(	O
APP	B
)	O
belongs	O
to	O
a	O
conserved	O
gene	O
family	O
,	O
also	O
including	O
the	O
amyloid	B
precursor	I
-	I
like	I
proteins	I
,	O
APLP1	B
and	O
APLP2	B
.	O

The	O
function	O
of	O
these	O
three	O
proteins	O
is	O
not	O
yet	O
fully	O
understood	O
.	O

One	O
of	O
the	O
proposed	O
roles	O
of	O
APP	B
is	O
to	O
promote	O
neurite	O
outgrowth	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
regulation	O
of	O
the	O
expression	O
levels	O
of	O
APP	B
family	I
members	O
during	O
neurite	O
outgrowth	O
.	O

We	O
observed	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
-	O
induced	O
neuronal	O
differentiation	O
of	O
human	O
SH	O
-	O
SY5Y	O
cells	O
resulted	O
in	O
increased	O
expression	O
of	O
APP	B
,	O
APLP1	B
and	O
APLP2	B
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
the	O
NFkappaB	B
,	O
AP-1	B
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
inhibitor	O
curcumin	O
(	O
diferuloylmethane	O
)	O
on	O
the	O
RA	O
-	O
induced	O
expression	O
levels	O
of	O
these	O
proteins	O
.	O

We	O
found	O
that	O
treatment	O
with	O
curcumin	O
counteracted	O
the	O
RA	O
-	O
induced	O
mRNA	O
expression	O
of	O
all	O
APP	B
family	I
members	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
curcumin	O
treatment	O
resulted	O
in	O
neurite	O
retraction	O
without	O
any	O
effect	O
on	O
cell	O
viability	O
.	O

Surprisingly	O
,	O
curcumin	O
had	O
differential	O
effects	O
on	O
the	O
APLP	B
protein	O
levels	O
in	O
RA	O
-	O
differentiated	O
cells	O
.	O

RA	O
-	O
induced	O
APLP1	B
protein	O
expression	O
was	O
blocked	O
by	O
curcumin	O
,	O
while	O
the	O
APLP2	B
protein	O
levels	O
were	O
further	O
increased	O
.	O

APP	B
protein	O
levels	O
were	O
not	O
affected	O
by	O
curcumin	O
treatment	O
.	O

We	O
propose	O
that	O
the	O
sustained	O
levels	O
of	O
APP	B
and	O
the	O
elevated	O
levels	O
of	O
APLP2	B
,	O
in	O
spite	O
of	O
the	O
reduced	O
mRNA	O
expression	O
,	O
are	O
due	O
to	O
altered	O
proteolytic	O
processing	O
of	O
these	O
proteins	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
APLP1	B
does	O
not	O
undergo	O
the	O
same	O
type	O
of	O
regulated	O
processing	O
as	O
APP	B
and	O
APLP2	B
.	O

Cloning	O
,	O
sequencing	O
,	O
and	O
expression	O
of	O
the	O
fadD	B
gene	O
of	O
Escherichia	O
coli	O
encoding	O
acyl	B
coenzyme	I
A	I
synthetase	I
.	O

In	O
the	O
enteric	O
bacterium	O
,	O
Escherichia	O
coli	O
,	O
acyl	B
coenzyme	I
A	I
synthetase	I
(	O
fatty	B
acid	I
:	I
CoA	I
ligase	I
(	O
AMP	O
-	O
forming	O
)	O
EC	B
6.2.1.3	I
)	O
activates	O
exogenous	O
long	O
-	O
chain	O
fatty	O
acids	O
concomitant	O
with	O
their	O
transport	O
across	O
the	O
inner	O
membrane	O
into	O
metabolically	O
active	O
CoA	O
thioesters	O
.	O

These	O
compounds	O
serve	O
as	O
substrates	O
for	O
acyl	B
-	I
CoA	I
dehydrogenase	I
in	O
the	O
first	O
step	O
in	O
the	O
process	O
of	O
beta	O
-	O
oxidation	O
.	O

The	O
acyl	B
-	I
CoA	I
synthetase	I
structural	O
gene	O
,	O
fadD	B
,	O
has	O
been	O
identified	O
on	O
clone	O
6D1	O
of	O
the	O
Kohara	O
E.	O
coli	O
gene	O
library	O
and	O
by	O
a	O
process	O
of	O
subcloning	O
and	O
complementation	O
analyses	O
shown	O
to	O
be	O
contained	O
on	O
a	O
2.2	O
-	O
kilobase	O
NcoI	B
-	O
ClaI	B
fragment	O
of	O
genomic	O
DNA	O
.	O

The	O
polypeptide	O
encoded	O
within	O
this	O
DNA	O
fragment	O
was	O
identified	O
following	O
T7	B
RNA	I
polymerase	I
-	O
dependent	O
induction	O
and	O
estimated	O
to	O
be	O
M	O
(	O
r	O
)	O
=	O
62,000	O
using	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

The	O
N	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
acyl	B
-	I
CoA	I
synthetase	I
was	O
determined	O
by	O
automated	O
sequencing	O
to	O
be	O
Met	O
-	O
Lys	O
-	O
Lys	O
-	O
Val	O
-	O
Trp	O
-	O
Leu	O
-	O
Asn	O
-	O
Arg	O
-	O
Tyr	O
-	O
Pro	O
.	O

Sequence	O
analysis	O
of	O
the	O
2.2	O
-	O
kilobase	O
NcoI	B
-	O
ClaI	B
fragment	O
revealed	O
a	O
single	O
open	O
reading	O
frame	O
encoding	O
these	O
amino	O
acids	O
as	O
the	O
first	O
10	O
residues	O
of	O
a	O
protein	O
with	O
a	O
molecular	O
weight	O
of	O
62,028	O
.	O

The	O
initiation	O
codon	O
for	O
methionine	O
was	O
TTG	O
.	O

Primer	O
extension	O
of	O
total	O
in	O
vivo	O
mRNA	O
from	O
two	O
fadD	B
-	O
specific	O
oligonucleotides	O
defined	O
the	O
transcriptional	O
start	O
at	O
an	O
adenine	O
residue	O
60	O
base	O
pairs	O
upstream	O
from	O
the	O
predicted	O
translational	O
start	O
site	O
.	O

Two	O
FadR	B
operator	O
sites	O
of	O
the	O
fadD	B
gene	O
were	O
identified	O
at	O
positions	O
-	O
13	O
to	O
-	O
29	O
(	O
OD1	O
)	O
and	O
positions	O
-	O
99	O
to	O
-	O
115	O
(	O
OD2	O
)	O
by	O
DNase	B
I	I
footprinting	O
.	O

Comparisons	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
E.	O
coli	O
acyl	B
-	I
CoA	I
synthetase	I
to	O
the	O
deduced	O
amino	O
acid	O
sequences	O
of	O
the	O
rat	O
and	O
yeast	O
acyl	B
-	I
CoA	I
synthetases	I
and	O
the	O
firefly	O
luciferase	B
demonstrated	O
that	O
these	O
enzymes	O
shared	O
a	O
significant	O
degree	O
of	O
similarity	O
.	O

Based	O
on	O
the	O
similar	O
reaction	O
mechanisms	O
of	O
these	O
four	O
enzymes	O
,	O
this	O
similarity	O
may	O
define	O
a	O
region	O
required	O
for	O
the	O
same	O
function	O
.	O

pH	O
-	O
Dependent	O
modulation	O
of	O
cyclic	O
AMP	O
levels	O
and	O
GadW	B
-	O
dependent	O
repression	O
of	O
RpoS	B
affect	O
synthesis	O
of	O
the	O
GadX	B
regulator	O
and	O
Escherichia	O
coli	O
acid	O
resistance	O
.	O

Extreme	O
acid	O
resistance	O
is	O
a	O
remarkable	O
property	O
of	O
virulent	O
and	O
avirulent	O
Escherichia	O
coli	O
.	O

The	O
ability	O
to	O
resist	O
environments	O
in	O
which	O
the	O
pH	O
is	O
2.5	O
and	O
below	O
is	O
predicted	O
to	O
contribute	O
significantly	O
to	O
the	O
survival	O
of	O
E.	O
coli	O
during	O
passage	O
through	O
the	O
gastric	O
acid	O
barrier	O
.	O

One	O
acid	O
resistance	O
system	O
imports	O
glutamate	O
from	O
acidic	O
environments	O
and	O
uses	O
it	O
as	O
a	O
proton	O
sink	O
during	O
an	O
intracellular	O
decarboxylation	O
reaction	O
.	O

Transcription	O
of	O
the	O
genes	O
encoding	O
the	O
glutamate	B
decarboxylases	I
and	O
the	O
substrate	O
-	O
product	O
antiporter	B
required	O
for	O
this	O
system	O
is	O
induced	O
under	O
a	O
variety	O
of	O
conditions	O
,	O
including	O
the	O
stationary	O
phase	O
and	O
a	O
low	O
pH	O
.	O

Acid	O
induction	O
during	O
log	O
-	O
phase	O
growth	O
in	O
minimal	O
medium	O
appears	O
to	O
occur	O
through	O
multiple	O
pathways	O
.	O

We	O
recently	O
demonstrated	O
that	O
GadE	B
,	O
the	O
essential	O
activator	O
of	O
the	O
genes	O
,	O
was	O
itself	O
acid	O
induced	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
there	O
is	O
a	O
regulatory	O
loop	O
involving	O
cross	O
-	O
repression	O
of	O
two	O
AraC	B
-	O
like	O
regulators	O
,	O
GadX	B
and	O
GadW	B
,	O
that	O
can	O
either	O
assist	O
or	O
interfere	O
with	O
GadE	B
activation	O
of	O
the	O
gad	B
decarboxylase	I
and	I
antiporter	I
genes	O
,	O
depending	O
on	O
the	O
culture	O
conditions	O
.	O

Balancing	O
cross	O
-	O
repression	O
appears	O
to	O
be	O
dependent	O
on	O
cAMP	O
and	O
the	O
cAMP	B
regulator	I
protein	I
(	O
CRP	B
)	O
.	O

The	O
control	O
loop	O
involves	O
the	O
GadX	B
protein	O
repressing	O
the	O
expression	O
of	O
gadW	B
and	O
the	O
GadW	B
protein	O
repressing	O
or	O
inhibiting	O
RpoS	B
,	O
which	O
is	O
the	O
alternative	O
sigma	B
factor	I
that	O
drives	O
transcription	O
of	O
gadX	B
.	O

CRP	B
and	O
cAMP	O
appear	O
to	O
influence	O
GadX	B
-	O
GadW	B
cross	O
-	O
repression	O
from	O
outside	O
the	O
loop	O
by	O
inhibiting	O
production	O
of	O
RpoS	B
.	O

We	O
found	O
that	O
GadW	B
represses	O
the	O
decarboxylase	B
genes	O
in	O
minimal	O
medium	O
and	O
that	O
growth	O
under	O
acidic	O
conditions	O
lowers	O
the	O
intracellular	O
cAMP	O
levels	O
.	O

These	O
results	O
indicate	O
that	O
CRP	B
and	O
cAMP	O
can	O
mediate	O
pH	O
control	O
over	O
gadX	B
expression	O
and	O
,	O
indirectly	O
,	O
expression	O
of	O
the	O
decarboxylase	B
genes	O
.	O

Mutational	O
or	O
physiological	O
lowering	O
of	O
cAMP	O
levels	O
increases	O
the	O
level	O
of	O
RpoS	B
and	O
thereby	O
increases	O
the	O
production	O
of	O
GadX	B
.	O

Higher	O
GadX	B
levels	O
,	O
in	O
turn	O
,	O
repress	O
gadW	B
and	O
contribute	O
to	O
induction	O
of	O
the	O
gad	B
decarboxylase	I
genes	O
.	O

The	O
presence	O
of	O
multiple	O
pH	O
control	O
pathways	O
governing	O
expression	O
of	O
this	O
acid	O
resistance	O
system	O
is	O
thought	O
to	O
reflect	O
different	O
environmental	O
routes	O
to	O
a	O
low	O
pH	O
.	O

Phosphotransferase	B
-	O
mediated	O
transport	O
of	O
the	O
osmolyte	O
2-O	O
-	O
alpha	O
-	O
mannosyl	O
-	O
D	O
-	O
glycerate	O
in	O
Escherichia	O
coli	O
occurs	O
by	O
the	O
product	O
of	O
the	O
mngA	B
(	O
hrsA	B
)	O
gene	O
and	O
is	O
regulated	O
by	O
the	O
mngR	B
(	O
farR	B
)	O
gene	O
product	O
acting	O
as	O
repressor	O
.	O

2-O	O
-	O
alpha	O
-	O
mannosyl	O
-	O
D	O
-	O
glycerate	O
(	O
MGs	O
)	O
has	O
been	O
recognized	O
as	O
an	O
osmolyte	O
in	O
hyperthermophilic	O
but	O
not	O
mesophilic	O
prokaryotes	O
.	O

We	O
report	O
that	O
MG	O
is	O
taken	O
up	O
and	O
utilized	O
as	O
sole	O
carbon	O
source	O
by	O
Escherichia	O
coli	O
K12	O
,	O
strainMC4100	O
.	O

Uptake	O
is	O
mediated	O
by	O
the	O
P	B
-	I
enolpyruvate	I
-	I
dependent	I
phosphotransferase	I
system	O
with	O
the	O
MG	O
-	O
inducible	O
HrsA	B
(	O
now	O
called	O
MngA	B
)	O
protein	O
as	O
its	O
specific	O
EIIABC	B
complex	I
.	O

The	O
apparent	O
Km	O
of	O
MG	O
uptake	O
in	O
induced	O
cells	O
was	O
10	O
microm	O
,	O
and	O
the	O
Vmax	O
was	O
0.65	O
nmol	O
/	O
min	O
/	O
10	O
(	O
9	O
)	O
cells	O
.	O

Inverted	O
membrane	O
vesicles	O
harboring	O
plasmid	O
-	O
encoded	O
MngA	B
phosphorylated	O
MG	O
in	O
a	O
P	O
-	O
enolpyruvate	O
-	O
dependent	O
manner	O
.	O

A	O
deletion	O
mutant	O
in	O
mngA	B
was	O
devoid	O
of	O
MG	O
transport	O
but	O
is	O
complemented	O
by	O
a	O
plasmid	O
harboring	O
mngA	B
.	O

Uptake	O
of	O
MG	O
in	O
MC4100	O
also	O
caused	O
induction	O
of	O
a	O
regulon	O
specifying	O
the	O
uptake	O
and	O
the	O
metabolism	O
of	O
galactarate	O
and	O
glucarate	O
controlled	O
by	O
the	O
CdaR	B
activator	O
.	O

The	O
ybgG	B
gene	O
(	O
now	O
called	O
mngB	B
)	O
the	O
gene	O
immediately	O
downstream	O
of	O
mngA	B
encodes	O
a	O
protein	O
with	O
alpha	B
-	I
mannosidase	I
activity	O
.	O

farR	B
,	O
the	O
gene	O
upstream	O
of	O
mngA	B
(	O
now	O
called	O
mngR	B
)	O
had	O
previously	O
been	O
characterized	O
as	O
a	O
fatty	O
acyl	O
-	O
responsive	O
regulator	O
;	O
however	O
,	O
deletion	O
of	O
mngR	B
resulted	O
in	O
the	O
up	O
-	O
regulation	O
of	O
only	O
two	O
genes	O
,	O
mngA	B
and	O
mngB	B
.	O

The	O
mngR	B
deletion	O
caused	O
constitutive	O
MG	O
transport	O
that	O
became	O
MG	O
-	O
inducible	O
after	O
transformation	O
with	O
plasmid	O
expressed	O
mngR	B
.	O

Thus	O
,	O
MngR	B
is	O
the	O
regulator	O
(	O
repressor	O
)	O
of	O
the	O
MG	O
transport	O
/	O
metabolism	O
system	O
.	O

Thus	O
,	O
the	O
mngR	B
mngA	B
mngB	B
gene	O
cluster	O
encodes	O
an	O
MG	O
utilizing	O
system	O
.	O

Deregulated	O
expression	O
of	O
interferon	B
regulatory	I
factor-1	I
in	O
oncogene	O
-	O
transformed	O
mouse	O
fibroblasts	O
.	O

Interferon	B
(	I
IFN	I
)	I
regulatory	I
factor-1	I
(	O
IRF-1	B
)	O
is	O
a	O
transcription	B
factor	I
that	O
has	O
been	O
historically	O
associated	O
with	O
type	B
I	I
IFN	I
activation	O
and	O
antioncogenic	O
properties	O
.	O

We	O
studied	O
IRF-1	B
expression	O
and	O
DNA	O
-	O
binding	O
capacity	O
in	O
nontransformed	O
and	O
transformed	O
mouse	O
fibroblasts	O
.	O

A	O
43	O
-	O
kDa	O
nuclear	O
IRF-1	B
protein	O
was	O
expressed	O
biphasically	O
during	O
the	O
cell	O
cycle	O
in	O
primary	O
mouse	O
embryo	O
fibroblasts	O
,	O
nontransformed	O
NIH	O
3T3	O
cells	O
,	O
and	O
ras	B
revertants	O
.	O

IRF-1	B
expression	O
became	O
constitutive	O
in	O
ras	B
-	O
transformed	O
NIH	O
3T3	O
cells	O
and	O
in	O
cells	O
transformed	O
by	O
oncogenes	O
ets	B
,	O
fes	B
,	O
fos	B
,	O
her-2	B
/	O
neu	B
,	O
met	B
,	O
mos	B
,	O
raf	B
,	O
or	O
trk	B
,	O
suggesting	O
that	O
deregulated	O
IRF-1	B
expression	O
may	O
be	O
associated	O
with	O
loss	O
of	O
growth	O
control	O
.	O

Lysyl	B
oxidase	I
(	O
LO	B
)	O
,	O
a	O
ras	O
suppressor	O
that	O
is	O
downregulated	O
in	O
ras	B
transformants	O
,	O
is	O
an	O
IRF-1	B
target	O
gene	O
,	O
but	O
it	O
is	O
not	O
stimulated	O
by	O
abundant	O
IRF-1	B
present	O
in	O
transformants	O
,	O
while	O
another	O
IRF-1	B
target	O
gene	O
(	O
iNOS	B
)	O
is	O
transcribed	O
.	O

IRF-1	B
from	O
either	O
normal	O
or	O
ras	B
-	O
transformed	O
cells	O
bound	O
to	O
IRF	B
elements	O
in	O
the	O
IFN	B
-	I
beta	I
and	O
LO	B
promoters	O
.	O

IRF-1	B
in	O
transformants	O
can	O
,	O
therefore	O
,	O
bind	O
to	O
but	O
not	O
transactivate	O
the	O
LO	B
promoter	O
,	O
and	O
the	O
presence	O
of	O
IRF-1	B
is	O
not	O
sufficient	O
to	O
suppress	O
ras	B
transformation	O
.	O

LO	B
expression	O
may	O
effect	O
the	O
regulated	O
expression	O
of	O
IRF-1	B
:	O
a	O
ras	O
revertant	O
,	O
which	O
was	O
generated	O
by	O
stable	O
transfection	O
of	O
LO	B
cDNA	O
,	O
regained	O
the	O
normal	O
biphasic	O
IRF-1	B
pattern	O
.	O

A	O
mainly	O
cytoplasmic	O
,	O
constitutively	O
expressed	O
46	O
-	O
kDa	O
protein	O
with	O
immunologic	O
identity	O
to	O
the	O
43	O
-	O
kDa	O
nuclear	O
IRF-1	B
was	O
also	O
present	O
in	O
normal	O
and	O
transformed	O
cells	O
,	O
but	O
as	O
it	O
did	O
not	O
bind	O
to	O
the	O
IRF	B
elements	O
,	O
its	O
function	O
is	O
unclear	O
.	O

Calcium	O
regulates	O
the	O
expression	O
of	O
a	O
Dictyostelium	O
discoideum	O
asparaginyl	B
tRNA	I
synthetase	I
gene	O
.	O

In	O
a	O
screen	O
for	O
calcium	O
-	O
regulated	O
gene	O
expression	O
during	O
growth	O
and	O
development	O
of	O
Dictyostelium	O
discoideum	O
we	O
have	O
identified	O
an	O
asparaginyl	B
tRNA	I
synthetase	I
(	O
ddAsnRS	B
)	O
gene	O
,	O
the	O
second	O
tRNA	B
synthetase	I
gene	O
identified	O
in	O
this	O
organism	O
.	O

The	O
ddAsnRS	B
gene	O
shows	O
many	O
unique	O
features	O
.	O

One	O
,	O
it	O
is	O
repressed	O
by	O
lowering	O
cellular	O
calcium	O
,	O
making	O
it	O
the	O
first	O
known	O
calcium	O
-	O
regulated	O
tRNA	B
synthetase	I
.	O

Two	O
,	O
despite	O
the	O
calcium	O
-	O
dependence	O
,	O
its	O
expression	O
is	O
unaltered	O
during	O
the	O
cell	O
cycle	O
,	O
making	O
this	O
the	O
first	O
D.	O
discoideum	O
gene	O
to	O
show	O
a	O
calcium	O
-	O
dependent	O
but	O
cell	O
cycle	O
phase	O
-	O
independent	O
expression	O
.	O

Finally	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
predicted	O
ddAsnRS	B
protein	O
shows	O
higher	O
sequence	O
similarity	O
to	O
Glutaminyl	B
tRNA	I
synthetases	I
than	O
to	O
other	O
Asn	B
tRNA	I
synthetases	I
.	O

These	O
unique	O
features	O
of	O
the	O
AsnRS	B
from	O
this	O
primitive	O
eukaryote	O
not	O
only	O
point	O
to	O
a	O
novel	O
mechanism	O
regulating	O
the	O
components	O
of	O
translation	O
machinery	O
and	O
gene	O
expression	O
by	O
calcium	O
,	O
but	O
also	O
hint	O
at	O
a	O
link	O
between	O
the	O
evolution	O
of	O
GlnRS	B
and	O
AsnRS	B
in	O
eukaryotes	O
.	O

Involvement	O
of	O
p38	B
and	O
p42	B
/	I
44	I
MAP	I
kinases	I
and	O
protein	B
kinase	I
C	I
in	O
the	O
interferon	B
-	I
gamma	I
and	O
interleukin-1alpha	B
-	O
induced	O
phosphorylation	O
of	O
85	O
-	O
kDa	O
cytosolic	B
phospholipase	I
A	I
(	I
2	I
)	I
in	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
interleukin-1	B
(	O
IL-1	B
)	O
play	O
an	O
important	O
role	O
in	O
the	O
modulation	O
of	O
acute	O
and	O
chronic	O
airway	O
inflammation	O
.	O

Both	O
IFN	B
-	I
gamma	I
and	O
IL-1	B
are	O
known	O
to	O
increase	O
the	O
release	O
of	O
arachidonic	O
acid	O
(	O
AA	O
)	O
from	O
airway	O
epithelial	O
cells	O
,	O
suggesting	O
that	O
AA	O
metabolites	O
may	O
mediate	O
the	O
cytokine	B
-	O
induced	O
inflammation	O
.	O

This	O
study	O
was	O
designed	O
to	O
examine	O
the	O
direct	O
effect	O
of	O
IFN	B
-	I
gamma	I
and	O
IL	B
-	I
alpha	I
on	O
the	O
phosphorylation	O
of	O
85	O
-	O
kDa	O
cytosolic	B
phospholipase	I
A	I
(	I
2	I
)	I
(	O
cPLA	B
(	I
2	I
)	I
)	O
and	O
AA	O
release	O
in	O
primary	O
normal	O
human	O
bronchial	O
epithelial	O
(	O
NHBE	O
)	O
cells	O
.	O

Treatment	O
with	O
IFN	B
-	I
gamma	I
and	O
IL-1alpha	B
for	O
15	O
min	O
induced	O
a	O
rapid	O
increase	O
of	O
AA	O
release	O
from	O
NHBE	O
cells	O
,	O
which	O
was	O
blocked	O
by	O
the	O
cPLA	B
(	I
2	I
)	I
inhibitor	O
MAFP	O
(	O
p	O
<	O
0.05	O
)	O
but	O
not	O
by	O
the	O
sPLA	B
(	I
2	I
)	I
inhibitor	O
LY311727	O
or	O
iPLA	B
(	I
2	I
)	I
inhibitor	O
HELSS	O
.	O

Immunoprecipitation	O
and	O
Western	O
blot	O
analysis	O
showed	O
that	O
both	O
IFN	B
-	I
gamma	I
and	O
IL-1alpha	B
induced	O
a	O
rapid	O
phosphorylation	O
of	O
cPLA	B
(	I
2	I
)	I
.	O

The	O
IFN	B
-	I
gamma	I
and	O
IL-1alpha	B
-	O
induced	O
cPLA	B
(	I
2	I
)	I
phosphorylation	O
and	O
AA	O
release	O
in	O
the	O
NHBE	O
cells	O
were	O
inhibited	O
by	O
the	O
p38	B
MAP	I
kinase	I
(	O
MAPK	B
)	O
inhibitor	O
SB203580	O
,	O
p42	B
/	I
44	I
MAPK	I
inhibitor	O
PD98059	O
and	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
inhibitor	O
bisindolylmaleimide	O
I	O
.	O

These	O
results	O
demonstrate	O
the	O
involvement	O
of	O
p38	B
and	O
p42	B
/	I
44	I
MAPKs	I
as	O
well	O
as	O
PKC	B
in	O
the	O
IFN	B
-	I
gamma	I
and	O
IL-1alpha	B
-	O
induced	O
cPLA	B
(	I
2	I
)	I
phosphorylation	O
and	O
AA	O
release	O
in	O
human	O
airway	O
epithelial	O
cells	O
.	O

Molecular	O
characterization	O
of	O
a	O
human	O
rotavirus	O
reveals	O
porcine	O
characteristics	O
in	O
most	O
of	O
the	O
genes	O
including	O
VP6	B
and	O
NSP4	B
.	O

Long	O
electropherotype	O
with	O
Subgroup	O
I	O
specificity	O
is	O
a	O
common	O
feature	O
of	O
animal	O
rotaviruses	O
.	O

In	O
an	O
epidemic	O
of	O
infantile	O
gastroenteritis	O
in	O
Manipur	O
,	O
India	O
,	O
long	O
but	O
SG	O
I	O
strains	O
predominated	O
in	O
the	O
outbreak	O
in	O
the	O
year	O
1987	O
-	O
88	O
.	O

One	O
such	O
strain	O
isolated	O
from	O
that	O
region	O
,	O
following	O
the	O
outbreak	O
had	O
G9P	O
[	O
19	O
]	O
specificity	O
.	O

As	O
this	O
is	O
a	O
rare	O
combination	O
,	O
the	O
gene	O
sequences	O
encoding	O
VP4	B
,	O
VP6	B
,	O
VP7	B
,	O
NSP1	B
,	O
NSP2	B
,	O
NSP3	B
,	O
NSP4	B
and	O
NSP5	B
of	O
this	O
strain	O
were	O
analyzed	O
.	O

All	O
these	O
genes	O
except	O
VP7	B
were	O
closely	O
related	O
to	O
porcine	O
rotaviruses	O
(	O
95	O
-	O
99	O
%	O
identity	O
at	O
amino	O
acid	O
level	O
)	O
and	O
clustered	O
with	O
the	O
porcine	O
strains	O
in	O
phylogenetic	O
analysis	O
.	O

In	O
addition	O
,	O
it	O
had	O
subgroup	O
I	O
nature	O
and	O
belonged	O
to	O
NSP4	B
genotype	O
B	O
which	O
is	O
characteristic	O
of	O
animal	O
rotaviruses	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
rotavirus	O
with	O
VP6	B
and	O
NSP4	B
,	O
two	O
crucial	O
proteins	O
thought	O
to	O
be	O
involved	O
in	O
host	O
range	O
restriction	O
and	O
pathogenicity	O
,	O
were	O
of	O
porcine	O
origin	O
and	O
caused	O
diarrhoea	O
in	O
a	O
human	O
host	O
.	O

Among	O
the	O
genes	O
of	O
this	O
strain	O
sequenced	O
so	O
far	O
,	O
only	O
VP7	B
had	O
highest	O
identity	O
to	O
human	O
strains	O
at	O
amino	O
acid	O
level	O
.	O

This	O
study	O
suggests	O
reassortment	O
may	O
be	O
occurring	O
between	O
human	O
and	O
other	O
animal	O
strains	O
and	O
some	O
of	O
the	O
reassortant	O
viruses	O
may	O
be	O
virulent	O
to	O
humans	O
.	O

Purification	O
and	O
characterization	O
of	O
phytocystatins	B
from	O
kiwifruit	O
cortex	O
and	O
seeds	O
.	O

Kiwifruit	O
cysteine	B
proteinase	I
inhibitors	I
(	O
KCPIs	B
)	O
were	O
purified	O
from	O
the	O
cortex	O
and	O
seeds	O
of	O
kiwifruit	O
after	O
inactivation	O
of	O
the	O
abundant	O
cortex	O
cysteine	B
proteinase	I
actinidain	B
.	O

One	O
major	O
(	O
KCPI1	B
)	O
and	O
four	O
minor	O
cystatins	B
were	O
identified	O
from	O
Actinidia	O
deliciosa	O
ripe	O
mature	O
kiwifruit	O
cortex	O
as	O
well	O
as	O
a	O
seed	O
KCPI	B
from	O
A.	O
chinensis	O
.	O

The	O
predominant	O
cortex	O
cystatin	B
,	O
KCPI1	B
,	O
inhibited	O
clan	B
CA	I
,	I
family	I
C1	I
(	I
papain	I
family	I
)	I
cysteine	I
proteinases	I
(	O
papain	B
,	O
chymopapain	B
,	O
bromelain	B
,	O
ficin	B
,	O
human	O
cathepsins	B
B	I
,	I
H	I
and	I
L	I
,	O
actinidain	B
and	O
the	O
house	O
dust	O
mite	O
endopeptidase	B
1	I
)	O
,	O
while	O
cysteine	B
proteinases	I
belonging	O
to	O
other	O
families	O
,	O
[	O
clostripain	B
(	O
C11	O
)	O
,	O
streptopain	B
(	O
C10	O
)	O
and	O
calpain	B
(	O
C2	O
)	O
]	O
were	O
not	O
inhibited	O
.	O

Inhibition	O
constants	O
(	O
K	O
(	O
I	O
)	O
)	O
ranged	O
between	O
0.001	O
nM	O
for	O
cathepsin	B
L	I
and	O
0.98	O
nM	O
for	O
endopeptidase	B
1	I
.	O

The	O
K	O
(	O
I	O
)	O
(	O
14	O
nM	O
)	O
for	O
KCPI1	B
inhibiting	O
actinidain	B
is	O
at	O
least	O
2	O
orders	O
of	O
magnitude	O
higher	O
than	O
for	O
other	O
plant	O
proteinases	B
measured	O
.	O

The	O
cortex	O
KCPI1	B
and	O
a	O
seed	O
KCPI	B
purified	O
from	O
seeds	O
had	O
the	O
same	O
N	O
-	O
terminal	O
sequence	O
(	O
VAAGGWRPIESLNSAEVQDV	O
)	O
.	O

BLAST	O
-	O
matching	O
the	O
peptide	O
sequence	O
against	O
an	O
in	O
-	O
house	O
generated	O
Actinidia	O
EST	O
database	O
,	O
identified	O
81	O
cDNAs	O
that	O
exactly	O
matched	O
the	O
measured	O
KCPI1	B
peptide	O
sequence	O
.	O

Peptide	O
sequences	O
of	O
two	O
other	O
cortex	O
KCPIs	B
each	O
exactly	O
matched	O
a	O
predicted	O
peptide	O
sequence	O
of	O
a	O
cDNA	O
from	O
kiwifruit	O
.	O

The	O
predicted	O
peptide	O
sequence	O
of	O
KCPI1	B
of	O
116	O
amino	O
acids	O
encodes	O
a	O
signal	O
peptide	O
and	O
does	O
not	O
contain	O
cysteine	O
.	O

Without	O
the	O
signal	O
peptide	O
(	O
mature	O
protein	O
)	O
,	O
KCPI1	B
has	O
a	O
molecular	O
mass	O
of	O
approximately	O
11	O
kDa	O
,	O
possesses	O
the	O
consensus	O
sequence	O
characteristic	O
for	O
the	O
phytocystatins	B
and	O
shows	O
the	O
highest	O
homology	O
to	O
a	O
cystatin	B
from	O
Citrusxparadisi	O
(	O
52	O
%	O
identity	O
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
phytocystatins	B
from	O
the	O
Ericales	O
.	O

Glial	O
activation	O
and	O
TNFR	B
-	I
I	I
upregulation	O
precedes	O
motor	O
dysfunction	O
in	O
the	O
spinal	O
cord	O
of	O
mnd	O
mice	O
.	O

Mice	O
homozygous	O
for	O
the	O
spontaneous	O
motor	O
neuron	O
degeneration	O
mutation	O
(	O
mnd	O
)	O
show	O
at	O
the	O
age	O
of	O
8	O
months	O
a	O
marked	O
impairment	O
of	O
the	O
motor	O
function	O
and	O
accumulation	O
of	O
lipofuscin	O
granules	O
in	O
the	O
cytoplasm	O
of	O
almost	O
all	O
neurons	O
of	O
the	O
central	O
nervous	O
system	O
.	O
We	O
previously	O
reported	O
a	O
significant	O
increase	O
in	O
GFAP	B
protein	O
levels	O
in	O
the	O
lumbar	O
spinal	O
cord	O
homogenates	O
by	O
western	O
blot	O
analysis	O
and	O
upregulation	O
of	O
TNF	B
,	O
a	O
proinflammatory	O
cytokine	B
,	O
in	O
the	O
motor	O
neurons	O
of	O
lumbar	O
spinal	O
cord	O
of	O
mnd	O
mice	O
,	O
already	O
in	O
a	O
presymptomatic	O
stage	O
(	O
4	O
months	O
of	O
age	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
immunohistochemical	O
analysis	O
,	O
we	O
performed	O
a	O
time	O
course	O
in	O
mnd	O
mice	O
(	O
1	O
,	O
4	O
and	O
9	O
months	O
of	O
age	O
)	O
evaluating	O
the	O
expression	O
and	O
the	O
distribution	O
of	O
astroglial	O
and	O
microglial	O
cells	O
and	O
the	O
expression	O
of	O
both	O
TNF	B
receptors	I
,	O
TNFR	B
-	I
I	I
and	O
TNFR	B
-	I
II	I
.	O

We	O
observed	O
a	O
marked	O
increase	O
in	O
astroglial	O
and	O
microglial	O
cells	O
and	O
in	O
TNFR	B
-	I
I	I
immunoreactivity	O
already	O
at	O
the	O
4th	O
month	O
.	O

Since	O
motor	O
neuron	O
dysfunction	O
occurs	O
in	O
mnd	O
mice	O
in	O
the	O
absence	O
of	O
evident	O
loss	O
of	O
spinal	O
motor	O
neurons	O
,	O
the	O
present	O
results	O
indicate	O
that	O
the	O
activation	O
of	O
microglial	O
cells	O
and	O
astrocytes	O
is	O
independent	O
from	O
neuronal	O
degeneration	O
.	O

The	O
role	O
of	O
TNF	B
and	O
TNFR	B
-	I
I	I
on	O
motor	O
neurons	O
is	O
still	O
to	O
be	O
demonstrated	O
.	O

Stat3	B
-	O
dependent	O
induction	O
of	O
interleukin-3	B
receptor	I
expression	O
in	O
leukemia	B
inhibitory	I
factor	I
-	O
stimulated	O
M1	O
mouse	O
leukemia	O
cells	O
.	O

M1	O
mouse	O
leukemia	O
cells	O
differentiate	O
to	O
macrophages	O
/	O
monocytes	O
by	O
the	O
stimulation	O
of	O
interleukin-6	B
(	O
IL-6	B
)	O
/	O
leukemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
.	O

To	O
identify	O
new	O
LIF	B
-	O
induced	O
genes	O
,	O
we	O
have	O
performed	O
representational	O
difference	O
analysis	O
using	O
M1	O
cells	O
and	O
cloned	O
mouse	O
interleukin-3	B
(	I
IL-3	I
)	I
receptor	I
beta	I
subunit	O
gene	O
.	O

The	O
mRNA	O
expression	O
of	O
both	O
IL-3	B
receptor	I
(	I
IL-3R	I
)	I
alpha	I
and	I
beta	I
subunits	O
is	O
upregulated	O
after	O
1	O
h	O
stimulation	O
of	O
LIF	B
and	O
remains	O
to	O
be	O
elevated	O
along	O
the	O
differentiation	O
of	O
M1	O
cells	O
.	O

This	O
induction	O
is	O
almost	O
completely	O
suppressed	O
in	O
M1	O
cells	O
expressing	O
a	O
dominant	O
negative	O
form	O
of	O
Stat3	B
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL-3	B
-	O
induced	O
Stat5	B
phosphorylation	O
increases	O
in	O
LIF	B
-	O
stimulated	O
M1	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
Stat3	B
may	O
play	O
a	O
role	O
in	O
the	O
differentiation	O
of	O
myeloid	O
cells	O
by	O
regulating	O
IL-3R	B
expression	O
.	O

Clinical	O
and	O
biochemical	O
characterisation	O
of	O
patients	O
with	O
autosomal	O
recessive	O
hypercholesterolemia	O
(	O
ARH	O
)	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O

Inherited	O
hypercholesterolemias	O
are	O
common	O
disorders	O
characterised	O
by	O
elevated	O
LDL	B
-	O
C	O
levels	O
and	O
premature	O
coronary	O
heart	O
disease	O
.	O

We	O
have	O
recently	O
described	O
a	O
recessive	O
form	O
of	O
hypercholesterolemia	O
(	O
autosomal	O
recessive	O
hypercholesterolemia	O
,	O
ARH	O
)	O
in	O
which	O
LDL	B
catabolism	O
is	O
reduced	O
because	O
of	O
a	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
an	O
adaptor	B
protein	I
that	O
impairs	O
LDL	B
-	I
receptor	I
(	O
LDL	B
-	I
R	I
)	O
activity	O
in	O
the	O
liver	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterise	O
in	O
detail	O
the	O
phenotypes	O
of	O
subjects	O
with	O
homozygous	O
and	O
heterozygous	O
ARH	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
have	O
so	O
far	O
identified	O
six	O
Italian	O
families	O
with	O
ARH	O
and	O
studied	O
the	O
clinical	O
and	O
biochemical	O
characteristics	O
of	O
11	O
homozygotes	O
(	O
age	O
13	O
-	O
47	O
years	O
)	O
and	O
12	O
obligate	O
heterozygotes	O
(	O
age	O
42	O
-	O
83	O
years	O
)	O
.	O

The	O
study	O
protocol	O
included	O
an	O
evaluation	O
of	O
the	O
lipoprotein	O
profile	O
,	O
LDL	B
-	I
R	I
activity	O
in	O
fibroblasts	O
,	O
LDL	B
binding	O
activity	O
,	O
and	O
apo	B
E	I
genotype	O
;	O
a	O
structured	O
questionnaire	O
(	O
CHD	O
risk	O
factors	O
,	O
medical	O
history	O
,	O
current	O
medications	O
)	O
;	O
a	O
physical	O
examination	O
,	O
resting	O
and	O
stress	O
ECG	O
,	O
ultrasound	O
examinations	O
(	O
heart	O
,	O
carotid	O
arteries	O
,	O
Achilles	O
tendons	O
)	O
and	O
coronary	O
angiography	O
.	O

The	O
pedigrees	O
were	O
characterised	O
by	O
the	O
absence	O
of	O
vertical	O
transmission	O
;	O
consanguinity	O
was	O
documented	O
in	O
two	O
families	O
.	O

Only	O
the	O
two	O
previously	O
described	O
Sardinian	O
mutations	O
,	O
ARH1	O
(	O
c.432insA	O
)	O
and	O
ARH2	O
(	O
c.65	O
G	O
>	O
A	O
)	O
,	O
were	O
identified	O
in	O
the	O
probands	O
.	O

All	O
of	O
the	O
ARH	O
homozygotes	O
had	O
large	O
tendinous	O
xanthomas	O
,	O
two	O
had	O
exertional	O
angina	O
,	O
and	O
four	O
a	O
positive	O
stress	O
ECG	O
.	O

None	O
had	O
experienced	O
myocardial	O
infarction	O
or	O
stroke	O
.	O

More	O
than	O
half	O
had	O
instrumental	O
signs	O
of	O
atherosclerosis	O
such	O
as	O
a	O
positive	O
stress	O
ECG	O
or	O
positive	O
carotid	O
echo	O
-	O
doppler	O
examination	O
.	O

The	O
ARH	O
heterozygotes	O
were	O
consistently	O
normal	O
and	O
had	O
a	O
normal	O
lipid	O
profile	O
.	O

CONCLUSIONS	O
:	O

The	O
ARH	O
phenotype	O
resembles	O
that	O
of	O
familial	O
hypercholesterolemia	O
(	O
FH	O
)	O
homozygotes	O
,	O
but	O
ARH	O
may	O
be	O
a	O
less	O
serious	O
illness	O
.	O

The	O
absence	O
of	O
vertical	O
transmission	O
,	O
and	O
the	O
presence	O
of	O
mild	O
coronary	O
heart	O
disease	O
and	O
consanguinity	O
,	O
can	O
suggest	O
a	O
possible	O
diagnosis	O
of	O
ARH	O
.	O

ARH	O
might	O
be	O
considered	O
a	O
phenocopy	O
of	O
FH	O
but	O
heterozygous	O
subjects	O
seem	O
to	O
have	O
a	O
consistently	O
normal	O
phenotype	O
.	O

Domain	O
-	O
dependent	O
action	O
of	O
urokinase	B
on	O
smooth	O
muscle	O
cell	O
responses	O
.	O

BACKGROUND	O
:	O

Single	O
-	O
chain	O
urokinase	B
-	I
type	I
plasminogen	I
activator	I
(	O
sc	O
-	O
uPA	B
)	O
is	O
one	O
of	O
the	O
key	O
serine	B
proteases	I
involved	O
in	O
modulating	O
cellular	O
and	O
extracellular	O
matrix	O
responses	O
during	O
tissue	O
remodeling	O
.	O

Sc	O
-	O
uPA	B
is	O
composed	O
of	O
three	O
domains	O
:	O
aminoterminal	O
fragment	O
(	O
ATF	O
)	O
,	O
kringle	O
domain	O
,	O
and	O
carboxyterminal	O
fragment	O
(	O
CTF	O
)	O
.	O

uPA	B
is	O
readily	O
cleaved	O
into	O
these	O
three	O
domain	O
fragments	O
in	O
vitro	O
,	O
each	O
of	O
which	O
is	O
biologically	O
active	O
;	O
however	O
,	O
their	O
roles	O
in	O
the	O
microenvironment	O
of	O
the	O
vessel	O
wall	O
are	O
poorly	O
understood	O
.	O

PURPOSE	O
:	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
each	O
domain	O
of	O
sc	O
-	O
uPA	B
on	O
vascular	O
smooth	O
muscle	O
cell	O
(	O
SMC	O
)	O
proliferation	O
and	O
migration	O
.	O

METHODS	O
:	O

SMCs	O
were	O
cultured	O
in	O
vitro	O
.	O

Assays	O
of	O
DNA	O
synthesis	O
,	O
cell	O
proliferation	O
,	O
and	O
migration	O
were	O
performed	O
in	O
response	O
to	O
sc	O
-	O
uPA	B
,	O
ATF	O
,	O
kringle	O
,	O
and	O
CTF	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
plasmin	B
inhibitors	O
epsilon	O
-	O
aminocaproic	O
acid	O
(	O
EACA	O
)	O
and	O
aprotinin	O
,	O
the	O
Galphai	B
inhibitor	O
pertussis	O
toxin	O
,	O
and	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
1	I
(	O
the	O
upstream	O
regulator	O
of	O
the	O
extracellular	B
-	I
signal	I
regulated	I
kinase	I
[	O
ERK	B
]	O
)	O
inhibitor	O
PD98059	O
.	O

RESULTS	O
:	O

sc	O
-	O
uPA	B
produced	O
dose	O
-	O
dependent	O
increases	O
in	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
.	O

These	O
responses	O
were	O
dependent	O
on	O
the	O
CTF	O
domain	O
and	O
were	O
sensitive	O
to	O
plasmin	B
inhibitors	O
,	O
pertussis	B
toxin	I
,	O
and	O
PD98059	O
.	O

Sc	O
-	O
uPA	B
also	O
induced	O
SMC	O
migration	O
,	O
which	O
could	O
be	O
elicited	O
by	O
both	O
ATF	O
and	O
kringle	O
.	O

Migration	O
to	O
sc	O
-	O
uPA	B
,	O
ATF	O
,	O
and	O
kringle	O
was	O
both	O
pertussis	O
toxin	O
and	O
PD98059	O
sensitive	O
,	O
but	O
importantly	O
was	O
plasmin	B
-	O
independent	O
.	O

CONCLUSION	O
:	O

sc	O
-	O
uPA	B
induces	O
SMC	O
proliferation	O
and	O
migration	O
,	O
which	O
are	O
domain	O
-	O
dependent	O
and	O
mediated	O
in	O
part	O
by	O
Galphai	B
-	O
linked	O
,	O
ERK	B
-	O
dependent	O
processes	O
,	O
while	O
only	O
the	O
mitogenic	O
response	O
is	O
protease	O
dependent	O
.	O

These	O
findings	O
suggest	O
that	O
migration	O
is	O
linked	O
to	O
a	O
G	B
-	I
protein	I
coupled	O
nonprotease	O
receptor	O
,	O
while	O
proliferation	O
is	O
associated	O
with	O
a	O
G	B
-	I
protein	I
coupled	O
protease	O
receptor	O
.	O

Oxidative	O
stress	O
-	O
a	O
link	O
between	O
endothelial	O
injury	O
,	O
coagulation	O
activation	O
,	O
and	O
atherosclerosis	O
in	O
haemodialysis	O
patients	O
.	O

BACKGROUND	O
/	O
AIM	O
:	O

Recently	O
emerging	O
evidence	O
suggests	O
that	O
oxidative	O
stress	O
(	O
SOX	O
)	O
may	O
participate	O
in	O
atherogenesis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
establish	O
whether	O
enhanced	O
SOX	O
,	O
involving	O
endothelial	O
injury	O
,	O
activation	O
of	O
coagulation	O
,	O
and	O
inflammatory	O
reaction	O
,	O
could	O
be	O
implicated	O
in	O
atherosclerotic	O
diseases	O
in	O
haemodialysis	O
(	O
HD	O
)	O
patients	O
.	O

METHODS	O
:	O

Markers	O
of	O
SOX	O
,	O
endothelial	O
injury	O
,	O
coagulation	O
,	O
and	O
cytokines	B
,	O
were	O
measured	O
in	O
the	O
plasma	O
of	O
HD	O
patients	O
with	O
and	O
without	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
,	O
and	O
of	O
healthy	O
controls	O
by	O
ELISA	O
methods	O
.	O

Remodeling	O
of	O
the	O
carotid	O
arteries	O
was	O
assessed	O
by	O
measuring	O
the	O
intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
as	O
a	O
surrogate	O
of	O
atherosclerotic	O
disease	O
in	O
all	O
groups	O
.	O

RESULTS	O
:	O

Markers	O
of	O
SOX	O
,	O
endothelial	O
injury	O
,	O
and	O
extrinsic	O
coagulation	O
pathway	O
activation	O
and	O
IMT	O
values	O
were	O
significantly	O
elevated	O
in	O
HD	O
patients	O
,	O
especially	O
in	O
those	O
with	O
CVD	O
when	O
compared	O
with	O
the	O
control	O
group	O
.	O

The	O
von	B
Willebrand	I
factor	I
antigen	O
(	O
vWF	B
:	O
Ag	O
)	O
levels	O
were	O
more	O
increased	O
in	O
the	O
patients	O
with	O
CVD	O
than	O
in	O
those	O
without	O
.	O

Furthermore	O
,	O
the	O
plasma	O
levels	O
of	O
tumour	B
necrosis	I
factor	I
alpha	I
,	O
monocyte	B
chemo	I
-	I
attractant	I
protein	I
1	I
,	O
and	O
macrophage	B
inflammatory	I
protein	I
1	I
beta	I
were	O
significantly	O
higher	O
only	O
in	O
the	O
HD	O
group	O
with	O
CVD	O
when	O
compared	O
with	O
the	O
controls	O
.	O

The	O
IMT	O
was	O
strongly	O
and	O
directly	O
correlated	O
with	O
Cu	B
/	I
Zn	I
superoxide	I
dismutase	I
.	O

Both	O
IMT	O
and	O
Cu	B
/	I
Zn	I
superoxide	I
dismutase	I
were	O
positively	O
correlated	O
with	O
age	O
,	O
thrombomodulin	B
,	O
vWF	B
:	O
Ag	O
,	O
tissue	B
factor	I
,	O
tissue	B
factor	I
pathway	I
inhibitor	I
,	O
prothrombin	B
fragment	O
F1	O
+	O
2	O
,	O
monocte	B
chemo	I
-	I
attractant	I
protein	I
1	I
,	O
macrophage	B
inflammatory	I
protein	I
1	I
beta	I
,	O
and	O
tumour	B
necrosis	I
factor	I
alpha	I
levels	O
.	O

Multivariate	O
analysis	O
identified	O
vWF	B
:	O
Ag	O
as	O
the	O
only	O
independent	O
variable	O
significantly	O
associated	O
with	O
an	O
increased	O
IMT	O
.	O

CONCLUSIONS	O
:	O

The	O
present	O
study	O
suggests	O
that	O
enhanced	O
SOX	O
,	O
involved	O
pro	O
-	O
atherogenic	O
cytokine	B
and	O
chemokines	B
levels	O
,	O
endothelial	O
injury	O
,	O
and	O
coagulation	O
activation	O
may	O
constitute	O
a	O
pathway	O
for	O
accelerated	O
atherosclerosis	O
in	O
HD	O
patients	O
.	O

The	O
significant	O
,	O
independent	O
association	O
between	O
IMT	O
and	O
vWF	B
:	O
Ag	O
should	O
be	O
assessed	O
in	O
future	O
studies	O
to	O
determine	O
whether	O
vWF	B
:	O
Ag	O
elevation	O
is	O
causative	O
or	O
a	O
by	O
-	O
product	O
of	O
the	O
increased	O
IMT	O
.	O

Infection	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
the	O
costimulatory	O
molecule	O
4	B
-	I
1BB	I
in	O
osteoblastic	O
cells	O
and	O
its	O
inhibitory	O
effect	O
on	O
M	B
-	I
CSF	I
/	O
RANKL	B
-	O
induced	O
in	O
vitro	O
osteoclastogenesis	O
.	O

Bacterial	O
infection	O
sometimes	O
impairs	O
bone	O
metabolism	O
.	O

In	O
this	O
study	O
,	O
we	O
infected	O
the	O
osteoblastic	O
cell	O
line	O
MC3T3-E1	O
with	O
Mycobacterium	O
bovis	O
bacillus	O
Calmette	O
-	O
GuÃ?Â	O
©	O
rin	O
(	O
BCG	O
)	O
and	O
identified	O
genes	O
that	O
were	O
up	O
-	O
regulated	O
in	O
the	O
BCG	O
-	O
infected	O
cells	O
by	O
the	O
suppression	O
subtractive	O
hybridization	O
method	O
.	O

A	O
gene	O
encoding	O
4	B
-	I
1BB	I
(	O
CD137	B
)	O
,	O
a	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
receptor	I
family	I
,	O
was	O
found	O
to	O
be	O
one	O
of	O
the	O
up	O
-	O
regulated	O
genes	O
.	O

Up	O
-	O
regulation	O
of	O
4	B
-	I
1BB	I
was	O
also	O
observed	O
by	O
infection	O
with	O
Escherichia	O
coli	O
,	O
Salmonella	O
typhimurium	O
,	O
and	O
Staphylococcus	O
aureus	O
,	O
and	O
by	O
treatment	O
with	O
lipopolysaccharides	O
and	O
heat	O
-	O
killed	O
BCG	O
.	O

Bone	O
marrow	O
cells	O
and	O
the	O
macrophage	O
-	O
like	O
cell	O
lines	O
J774	O
and	O
RAW264.7	O
were	O
found	O
to	O
express	O
4	B
-	I
1BB	I
ligand	I
(	O
4	B
-	I
1BBL	I
)	O
.	O

Recombinant	O
4	B
-	I
1BB	I
(	O
r4	B
-	I
1BB	I
)	O
that	O
was	O
immobilized	O
on	O
culture	O
plates	O
strongly	O
inhibited	O
macrophage	B
colony	I
stimulating	I
factor	I
(	O
M	B
-	I
CSF	I
)	O
/	O
receptor	B
activator	I
of	I
nuclear	I
factor	I
-	I
kappaB	I
ligand	I
(	O
RANKL	B
)	O
-	O
induced	O
in	O
vitro	O
osteoclast	O
formation	O
from	O
bone	O
marrow	O
cells	O
.	O

4	B
-	I
1BBL	I
antibody	O
also	O
inhibited	O
osteoclast	O
formation	O
to	O
a	O
lesser	O
extent	O
,	O
indicating	O
involvement	O
of	O
reverse	O
signaling	O
through	O
4	B
-	I
1BBL	I
during	O
inhibition	O
of	O
osteoclast	O
formation	O
.	O

A	O
casein	B
kinase	I
I	I
(	O
CKI	B
)	O
inhibitor	O
markedly	O
suppressed	O
the	O
inhibitory	O
effect	O
of	O
r4	B
-	I
1BB	I
on	O
M	B
-	I
CSF	I
/	O
RANKL	B
-	O
induced	O
osteoclast	O
formation	O
,	O
suggesting	O
that	O
CKI	B
might	O
be	O
involved	O
in	O
4	B
-	I
1BB	I
/	O
4	B
-	I
1BBL	I
reverse	O
signaling	O
.	O

r4	B
-	I
1BB	I
showed	O
no	O
effects	O
on	O
M	B
-	I
CSF	I
-	O
or	O
RANKL	B
-	O
induced	O
phosphorylation	O
of	O
I	B
-	I
kappaB	I
,	O
ERK1	B
/	I
2	I
,	O
p38	B
,	O
or	O
JNK	B
,	O
whereas	O
RANKL	B
-	O
induced	O
phosphorylation	O
of	O
Akt	B
,	O
a	O
downstream	O
target	O
of	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3	B
K	I
)	O
,	O
was	O
completely	O
abolished	O
by	O
r4	B
-	I
1BB	I
,	O
suggesting	O
that	O
4	B
-	I
1BB	I
/	O
4	B
-	I
1BBL	I
reverse	O
signaling	O
may	O
interfere	O
with	O
PI3	B
K	I
/	O
Akt	B
pathway	O
.	O

r4	B
-	I
1BB	I
also	O
abolished	O
RANKL	B
-	O
mediated	O
induction	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells-2	O
.	O

This	O
study	O
may	O
elucidate	O
a	O
novel	O
role	O
of	O
4	B
-	I
1BB	I
in	O
cell	O
metabolism	O
,	O
especially	O
osteoclastogenesis	O
.	O

A	O
novel	O
role	O
for	O
an	O
insect	O
apolipoprotein	B
(	O
apolipophorin	B
III	I
)	O
in	O
beta-1,3-glucan	O
pattern	O
recognition	O
and	O
cellular	O
encapsulation	O
reactions	O
.	O

Lipoproteins	O
and	O
molecules	O
for	O
pattern	O
recognition	O
are	O
centrally	O
important	O
in	O
the	O
innate	O
immune	O
response	O
of	O
both	O
vertebrates	O
and	O
invertebrates	O
.	O

Mammalian	O
apolipoproteins	B
such	O
as	O
apolipoprotein	B
E	I
(	O
apoE	B
)	O
are	O
involved	O
in	O
LPS	O
detoxification	O
,	O
phagocytosis	O
,	O
and	O
possibly	O
pattern	O
recognition	O
.	O

The	O
multifunctional	O
insect	O
protein	O
,	O
apolipophorin	B
III	I
(	O
apoLp	B
-	I
III	I
)	O
,	O
is	O
homologous	O
to	O
apoE	B
.	O

In	O
this	O
study	O
we	O
describe	O
novel	O
roles	O
for	O
apoLp	B
-	I
III	I
in	O
pattern	O
recognition	O
and	O
multicellular	O
encapsulation	O
reactions	O
in	O
the	O
innate	O
immune	O
response	O
,	O
which	O
may	O
be	O
of	O
direct	O
relevance	O
to	O
mammalian	O
systems	O
.	O

It	O
is	O
known	O
that	O
apoLp	B
-	I
III	I
stimulates	O
antimicrobial	O
peptide	O
production	O
in	O
insect	O
blood	O
,	O
enhances	O
phagocytosis	O
by	O
insect	O
blood	O
cells	O
(	O
hemocytes	O
)	O
,	O
and	O
binds	O
and	O
detoxifies	O
LPS	O
and	O
lipoteichoic	O
acid	O
.	O

In	O
the	O
present	O
study	O
we	O
show	O
that	O
apoLp	B
-	I
III	I
from	O
the	O
greater	O
wax	O
moth	O
,	O
Galleria	O
mellonella	O
,	O
also	O
binds	O
to	O
fungal	O
conidia	O
and	O
beta-1,3-glucan	O
and	O
therefore	O
may	O
act	O
as	O
a	O
pattern	O
recognition	O
molecule	O
for	O
multiple	O
microbial	O
and	O
parasitic	O
invaders	O
.	O

This	O
protein	O
also	O
stimulates	O
increases	O
in	O
cellular	O
encapsulation	O
of	O
nonself	O
particles	O
by	O
the	O
blood	O
cells	O
and	O
exerts	O
shorter	O
term	O
,	O
time	O
-	O
dependent	O
,	O
modulatory	O
effects	O
on	O
cell	O
attachment	O
and	O
spreading	O
.	O

All	O
these	O
responses	O
are	O
dose	O
dependent	O
,	O
occur	O
within	O
physiological	O
levels	O
,	O
and	O
,	O
with	O
the	O
notable	O
exception	O
of	O
beta	O
-	O
glucan	O
binding	O
,	O
are	O
only	O
observed	O
with	O
the	O
lipid	O
-	O
associated	O
form	O
of	O
apoLp	B
-	I
III	I
.	O

Preliminary	O
studies	O
also	O
established	O
a	O
beneficial	O
role	O
for	O
apoLp	B
-	I
III	I
in	O
the	O
in	O
vivo	O
response	O
to	O
an	O
entomopathogenic	O
fungus	O
.	O

These	O
data	O
suggest	O
a	O
wide	O
range	O
of	O
immune	O
functions	O
for	O
a	O
multiple	O
specificity	O
pattern	O
recognition	O
molecule	O
and	O
may	O
provide	O
a	O
useful	O
model	O
for	O
identifying	O
further	O
potential	O
roles	O
for	O
homologous	O
proteins	O
in	O
mammalian	O
immunology	O
,	O
particularly	O
in	O
terms	O
of	O
fungal	O
infections	O
,	O
pneumoconiosis	O
,	O
and	O
granulomatous	O
reactions	O
.	O

Coexpression	O
of	O
genetically	O
engineered	O
3-ketoacyl	B
-	I
ACP	I
synthase	I
III	I
(	O
fabH	B
)	O
and	O
polyhydroxyalkanoate	B
synthase	I
(	O
phaC	B
)	O
genes	O
leads	O
to	O
short	O
-	O
chain	O
-	O
length	O
-	O
medium	O
-	O
chain	O
-	O
length	O
polyhydroxyalkanoate	O
copolymer	O
production	O
from	O
glucose	O
in	O
Escherichia	O
coli	O
JM109	O
.	O

Polyhydroxyalkanoates	O
(	O
PHAs	O
)	O
can	O
be	O
divided	O
into	O
three	O
main	O
types	O
based	O
on	O
the	O
sizes	O
of	O
the	O
monomers	O
incorporated	O
into	O
the	O
polymer	O
.	O

Short	O
-	O
chain	O
-	O
length	O
(	O
SCL	O
)	O
PHAs	O
consist	O
of	O
monomer	O
units	O
of	O
C3	O
to	O
C5	O
,	O
medium	O
-	O
chain	O
-	O
length	O
(	O
MCL	O
)	O
PHAs	O
consist	O
of	O
monomer	O
units	O
of	O
C6	O
to	O
C14	O
,	O
and	O
SCL	O
-	O
MCL	O
PHAs	O
consist	O
of	O
monomers	O
ranging	O
in	O
size	O
from	O
C4	O
to	O
C14	O
.	O

Although	O
previous	O
studies	O
using	O
recombinant	O
Escherichia	O
coli	O
have	O
shown	O
that	O
either	O
SCL	O
or	O
MCL	O
PHA	O
polymers	O
could	O
be	O
produced	O
from	O
glucose	O
,	O
this	O
study	O
presents	O
the	O
first	O
evidence	O
that	O
an	O
SCL	O
-	O
MCL	O
PHA	O
copolymer	O
can	O
be	O
made	O
from	O
glucose	O
in	O
recombinant	O
E.	O
coli	O
.	O

The	O
3-ketoacyl	B
-	I
acyl	I
carrier	I
protein	I
synthase	I
III	I
gene	O
(	O
fabH	B
)	O
from	O
E.	O
coli	O
was	O
modified	O
by	O
saturation	O
point	O
mutagenesis	O
at	O
the	O
codon	O
encoding	O
amino	O
acid	O
87	O
of	O
the	O
FabH	B
protein	O
sequence	O
,	O
and	O
the	O
resulting	O
plasmids	O
were	O
cotransformed	O
with	O
either	O
the	O
pAPAC	O
plasmid	O
,	O
which	O
harbors	O
the	O
Aeromonas	O
caviae	O
PHA	B
synthase	I
gene	O
(	O
phaC	B
)	O
,	O
or	O
the	O
pPPAC	O
plasmid	O
,	O
which	O
harbors	O
the	O
Pseudomonas	O
sp.	O
strain	O
61	O
-	O
3	O
PHA	B
synthase	I
gene	O
(	O
phaC1	B
)	O
,	O
and	O
the	O
abilities	O
of	O
these	O
strains	O
to	O
accumulate	O
PHA	O
from	O
glucose	O
were	O
assessed	O
.	O

It	O
was	O
found	O
that	O
overexpression	O
of	O
several	O
of	O
the	O
mutant	O
fabH	B
genes	O
enabled	O
recombinant	O
E.	O
coli	O
to	O
induce	O
the	O
production	O
of	O
monomers	O
of	O
C4	O
to	O
C10	O
and	O
subsequently	O
to	O
produce	O
unusual	O
PHA	O
copolymers	O
containing	O
SCL	O
and	O
MCL	O
units	O
.	O

The	O
results	O
indicate	O
that	O
the	O
composition	O
of	O
PHA	O
copolymers	O
may	O
be	O
controlled	O
by	O
the	O
monomer	O
-	O
supplying	O
enzyme	O
and	O
further	O
reinforce	O
the	O
idea	O
that	O
fatty	O
acid	O
biosynthesis	O
may	O
be	O
used	O
to	O
supply	O
monomers	O
for	O
PHA	O
production	O
.	O

Poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
inhibition	O
protect	O
neurons	O
and	O
the	O
white	O
matter	O
and	O
regulates	O
the	O
translocation	O
of	O
apoptosis	B
-	I
inducing	I
factor	I
in	O
stroke	O
.	O

Focal	O
cerebral	O
ischemia	O
activates	O
the	O
nuclear	O
protein	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
(	O
PARP	B
)	O
.	O

Apoptosis	B
-	I
inducing	I
factor	I
(	O
AIF	B
)	O
is	O
a	O
flavoprotein	O
that	O
is	O
normally	O
confined	O
to	O
the	O
mitochondria	O
,	O
but	O
translocates	O
to	O
the	O
nucleus	O
,	O
as	O
shown	O
by	O
in	O
vitro	O
models	O
of	O
neuronal	O
injury	O
.	O

Using	O
INO-1001	O
,	O
a	O
novel	O
potent	O
inhibitor	O
of	O
PARP	B
,	O
we	O
determined	O
the	O
role	O
of	O
PARP	B
activation	O
in	O
the	O
process	O
of	O
AIF	B
translocation	O
in	O
a	O
rat	O
model	O
of	O
focal	O
cerebral	O
ischemia	O
.	O

The	O
potency	O
of	O
INO-1001	O
as	O
a	O
PARP	B
inhibitor	O
and	O
its	O
cytoprotective	O
potential	O
in	O
oxidant	O
-	O
challenged	O
human	O
neuronal	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
was	O
first	O
confirmed	O
in	O
vitro	O
.	O

PARP	B
inhibition	O
markedly	O
reduced	O
infarct	O
size	O
and	O
improved	O
neurological	O
status	O
in	O
both	O
transient	O
and	O
permanent	O
models	O
of	O
MCA	O
occlusion	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
with	O
a	O
therapeutic	O
window	O
of	O
6	O
h	O
and	O
2	O
h	O
in	O
the	O
transient	O
and	O
permanent	O
ischemia	O
models	O
,	O
respectively	O
.	O

The	O
PARP	B
inhibitor	O
reduced	O
the	O
accumulation	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
in	O
the	O
ischemic	O
/	O
reperfused	O
hemisphere	O
and	O
reduced	O
the	O
accumulation	O
of	O
APP	B
in	O
the	O
white	O
matter	O
of	O
the	O
affected	O
hemisphere	O
,	O
consistently	O
with	O
protection	O
against	O
neuronal	O
necrosis	O
and	O
axonal	O
damage	O
,	O
respectively	O
.	O

Immunohistochemical	O
analysis	O
showed	O
the	O
appearance	O
of	O
AIF	B
labeling	O
in	O
neuronal	O
nuclei	O
of	O
the	O
border	O
zone	O
ischemic	O
area	O
in	O
the	O
striatum	O
after	O
stroke	O
.	O

Cytoplasmatic	O
(	O
axonal	O
)	O
AIF	B
staining	O
was	O
significantly	O
diminished	O
in	O
the	O
necrotic	O
core	O
of	O
the	O
striatum	O
,	O
while	O
it	O
was	O
somewhat	O
enhanced	O
at	O
the	O
borderline	O
ischemic	O
territories	O
of	O
the	O
white	O
matter	O
.	O

Inhibition	O
of	O
PARP	B
with	O
INO-1001	O
reshifted	O
the	O
location	O
of	O
the	O
apoptotic	O
marker	O
to	O
the	O
axons	O
in	O
the	O
ipsilateral	O
striatum	O
.	O

Thus	O
,	O
PARP	B
inhibition	O
is	O
neuroprotective	O
and	O
regulates	O
the	O
ischemic	O
nuclear	O
translocation	O
of	O
AIF	B
in	O
stroke	O
.	O

PACT	B
-	O
mediated	O
enhancement	O
of	O
reporter	O
gene	O
expression	O
at	O
the	O
translational	O
level	O
.	O

The	O
cellular	O
protein	O
,	O
PACT	B
,	O
can	O
directly	O
activate	O
protein	B
kinase	I
(	O
PKR	B
)	O
in	O
vitro	O
by	O
the	O
interaction	O
of	O
PACT	B
domain	O
3	O
with	O
PKR	B
.	O

In	O
contrast	O
,	O
in	O
vivo	O
,	O
PACT	B
-	O
mediated	O
PKR	B
activation	O
and	O
concomitant	O
inhibition	O
of	O
protein	O
synthesis	O
require	O
additional	O
cellular	O
stresses	O
.	O

We	O
observed	O
that	O
without	O
such	O
stresses	O
,	O
cotransfection	O
of	O
a	O
PACT	B
expression	O
vector	O
with	O
various	O
reporter	O
genes	O
enhances	O
their	O
levels	O
of	O
expression	O
.	O

This	O
effect	O
was	O
promoter	O
and	O
inducer	O
-	O
independent	O
and	O
PACT	B
specific	O
and	O
mediated	O
by	O
PACT	B
domains	O
1	O
and	O
2	O
.	O

PACT	B
did	O
not	O
increase	O
the	O
level	O
of	O
the	O
reporter	O
mRNA	O
but	O
enhanced	O
its	O
translation	O
by	O
suppressing	O
phosphorylation	O
of	O
eukaryotic	B
initiation	I
factor	I
2alpha	I
(	O
eIF2alpha	B
)	O
caused	O
by	O
the	O
transfection	O
process	O
.	O

To	O
further	O
examine	O
the	O
phenomenon	O
,	O
we	O
generated	O
cell	O
lines	O
expressing	O
a	O
PACT	B
mutant	O
containing	O
only	O
domains	O
1	O
and	O
2	O
.	O

Reporter	O
gene	O
expression	O
was	O
higher	O
and	O
eIF2alpha	B
phosphorylation	O
was	O
lower	O
in	O
such	O
cell	O
lines	O
compared	O
with	O
the	O
corresponding	O
control	O
cells	O
.	O

Thus	O
,	O
different	O
domains	O
of	O
PACT	B
can	O
either	O
promote	O
or	O
inhibit	O
translation	O
by	O
appropriately	O
modulating	O
the	O
status	O
of	O
eIF2alpha	B
phosphorylation	O
.	O

Avian	O
interleukin-12beta	B
(	O
p40	B
)	O
:	O
cloning	O
and	O
characterization	O
of	O
the	O
cDNA	O
and	O
gene	O
.	O

We	O
isolated	O
the	O
chicken	O
interleukin-12	B
(	I
ChIL-12	I
)	I
p40	I
cDNA	O
from	O
a	O
concanavalin	O
A	O
(	O
ConA	O
)	O
-	O
stimulated	O
spleen	O
cDNA	O
library	O
using	O
the	O
PCR	O
with	O
primers	O
based	O
on	O
a	O
partial	O
3	O
'	O
EST	O
sequence	O
in	O
a	O
chicken	O
EST	O
library	O
.	O

The	O
cDNA	O
encodes	O
a	O
polypeptide	O
of	O
315	O
amino	O
acids	O
(	O
aa	O
)	O
,	O
with	O
a	O
predicted	O
mature	O
peptide	O
of	O
300	O
aa	O
.	O

ChIL-12	B
p40	I
has	O
46	O
%	O
and	O
41	O
%	O
amino	O
acid	O
identity	O
with	O
human	O
(	O
HuIL-12	B
)	O
and	O
murine	O
IL-12	B
(	I
MuIL	I
-	I
12	I
)	I
p40	I
,	O
respectively	O
.	O

We	O
also	O
isolated	O
a	O
partial	O
turkey	O
IL-12	B
(	I
TuIL-12	I
)	I
p40	I
cDNA	O
sequence	O
with	O
95	O
%	O
predicted	O
aa	O
identity	O
with	O
ChIL-12	B
p40	I
.	O

The	O
structures	O
of	O
the	O
ChIL-12	B
p40	I
gene	O
and	O
its	O
promoter	O
were	O
determined	O
by	O
direct	O
sequencing	O
of	O
a	O
chicken	O
BAC	O
identified	O
by	O
hybridization	O
with	O
the	O
cDNA	O
.	O

The	O
gene	O
structures	O
of	O
HuIL-12	B
,	I
MuIL	I
-	I
12	I
,	I
and	I
ChIL-12	I
p40	I
all	O
differ	O
.	O

The	O
promoter	O
of	O
the	O
ChIL-12	B
p40	I
gene	O
shares	O
some	O
(	O
an	O
ETS	O
consensus	O
sequence	O
,	O
a	O
C	B
/	I
EBP	I
binding	O
site	O
,	O
and	O
a	O
TATA	O
box	O
)	O
but	O
not	O
all	O
(	O
an	O
NF	B
-	I
kappaB	I
binding	O
site	O
and	O
a	O
GA12	O
site	O
are	O
absent	O
)	O
of	O
the	O
transcription	B
factor	I
binding	O
sites	O
identified	O
in	O
the	O
human	O
and	O
murine	O
promoters	O
.	O

IL-12	B
p40	I
mRNA	O
expression	O
was	O
identified	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
and	O
in	O
B	O
,	O
T	O
,	O
and	O
macrophage	O
cell	O
lines	O
by	O
RT	O
-	O
PCR	O
.	O

Simple	O
electrostatic	O
interaction	O
mechanisms	O
in	O
the	O
service	O
of	O
HIV-1	O
pathogenesis	O
.	O

The	O
main	O
cell	O
population	O
affected	O
by	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
infection	O
belongs	O
to	O
the	O
CD4	B
+	O
T	O
-	O
lymphocyte	O
family	O
.	O

Recent	O
convincing	O
evidence	O
indicates	O
that	O
the	O
majority	O
of	O
the	O
cells	O
that	O
die	O
due	O
to	O
HIV-1	O
are	O
not	O
actually	O
infected	O
by	O
the	O
virus	O
.	O

Instead	O
,	O
these	O
cells	O
are	O
being	O
led	O
to	O
programmed	O
cell	O
death	O
after	O
the	O
activation	O
of	O
apoptotic	O
mechanisms	O
by	O
the	O
virus	O
or	O
its	O
components	O
.	O

We	O
propose	O
here	O
from	O
accumulated	O
evidence	O
that	O
the	O
virus	O
appears	O
to	O
deregulate	O
the	O
physiological	O
function	O
of	O
these	O
cells	O
during	O
the	O
process	O
of	O
antigen	O
presentation	O
.	O

Ionic	O
interactions	O
between	O
the	O
variable	O
V3	O
domain	O
of	O
the	O
HIV-1	O
coat	O
glycoprotein	O
gp120	B
and	O
the	O
amino	O
terminal	O
of	O
the	O
chemokine	B
receptor	I
CCR5	B
play	O
a	O
prominent	O
role	O
in	O
this	O
process	O
,	O
and	O
we	O
speculate	O
that	O
nature	O
has	O
evolved	O
simple	O
electrostatic	O
interaction	O
mechanisms	O
which	O
,	O
coupled	O
to	O
specific	O
recognition	O
systems	O
on	O
the	O
cell	O
surface	O
,	O
can	O
initiate	O
and	O
modulate	O
certain	O
cellular	O
events	O
without	O
the	O
need	O
for	O
specific	O
molecular	O
structures	O
.	O

HIV-1	O
utilizes	O
such	O
a	O
mechanism	O
to	O
ensure	O
activation	O
of	O
the	O
target	O
host	O
cell	O
.	O

Anp32e	B
(	O
Cpd1	B
)	O
and	O
related	O
protein	B
phosphatase	I
2	I
inhibitors	O
.	O

Mouse	O
Anp32e	B
(	O
Acidic	B
leucine	I
-	I
rich	I
nuclear	I
phosphoprotein	I
32	I
family	I
,	I
member	I
e	I
:	O
NM_023210	O
,	O
P97822	O
,	O
formerly	O
Cpd1	B
)	O
,	O
a	O
protein	O
identified	O
in	O
postnatal	O
cerebellum	O
by	O
differential	O
display	O
,	O
belongs	O
to	O
the	O
superfamily	B
of	I
leucine	I
rich	I
repeat	I
(	I
LRR	I
)	I
proteins	I
and	O
to	O
the	O
Acidic	B
Nuclear	I
Phosphoprotein	I
32	I
(	I
ANP32	I
)	I
family	I
of	O
protein	B
phosphatase	I
2	I
(	O
PPP2	B
,	O
formerly	O
PP2A	B
)	O
inhibitors	O
.	O

Two	O
families	O
of	O
PPP2	B
inhibitor	O
proteins	O
have	O
been	O
described	O
,	O
ANP32	B
and	O
SET	B
,	O
represented	O
by	O
the	O
human	O
proteins	O
ANP32A	B
(	O
NM_006305	O
,	O
formerly	O
LANP	B
,	O
PP32	B
,	O
I1PPP2	B
,	O
PHAPI	B
,	O
MAPM	B
,	O
mapmodulin	B
)	O
and	O
SET	B
(	O
NM_003011	O
,	O
formerly	O
PHAPII	B
,	O
2PPP2	B
,	O
I2PPP2	B
,	O
TAF-1BETA	B
)	O
.	O

Besides	O
their	O
common	O
PPP2	B
inhibitor	O
activity	O
,	O
described	O
several	O
years	O
ago	O
,	O
these	O
nucleo	O
-	O
cytoplasmic	O
shuttling	O
phosphoproteins	O
have	O
additional	O
and	O
very	O
important	O
functions	O
recently	O
reported	O
.	O

In	O
HeLa	O
cells	O
,	O
ANP32A	B
,	O
SET	B
(	O
isoforms	O
A	O
and	O
B	O
)	O
and	O
ANP32B	B
(	O
APRIL	B
)	O
,	O
form	O
a	O
multi	O
-	O
subunit	O
heterocomplex	O
with	O
ELAVL1	B
(	O
NM_001419	O
,	O
formerly	O
HuR	B
)	O
,	O
a	O
protein	O
that	O
stabilizes	O
short	O
-	O
lived	O
mRNAs	O
containing	O
AU	O
-	O
rich	O
elements	O
(	O
AREs	O
)	O
.	O

A	O
similar	O
heterocomplex	O
,	O
formed	O
by	O
SET	B
(	O
A	O
and	O
B	O
)	O
and	O
ANP32A	B
as	O
major	O
subunits	O
,	O
possess	O
histone	B
acetyltransferase	I
inhibitory	O
activity	O
(	O
INHAT	B
)	O
,	O
and	O
have	O
a	O
role	O
in	O
chromatin	O
remodeling	O
and	O
transcriptional	O
regulation	O
(	O
histone	B
code	O
)	O
.	O

The	O
possible	O
roles	O
of	O
these	O
multifunctional	O
proteins	O
are	O
discussed	O
here	O
,	O
with	O
emphasis	O
on	O
mouse	O
Anp32e	B
and	O
the	O
cerebellar	O
tissue	O
.	O

Transcription	O
activation	O
at	O
the	O
Escherichia	O
coli	O
melAB	B
promoter	O
:	O
interactions	O
of	O
MelR	B
with	O
its	O
DNA	O
target	O
site	O
and	O
with	O
domain	O
4	O
of	O
the	O
RNA	B
polymerase	I
sigma	I
subunit	O
.	O

Activation	O
of	O
transcription	O
initiation	O
at	O
the	O
Escherichia	O
coli	O
melAB	B
promoter	O
is	O
dependent	O
on	O
MelR	B
,	O
a	O
transcription	B
factor	I
belonging	O
to	O
the	O
AraC	B
family	I
.	O

MelR	B
binds	O
to	O
18	O
bp	O
target	O
sites	O
using	O
two	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
HTH	O
)	O
motifs	O
that	O
are	O
both	O
located	O
in	O
its	O
C	O
-	O
terminal	O
domain	O
.	O

The	O
melAB	B
promoter	O
contains	O
four	O
target	O
sites	O
for	O
MelR	B
.	O

Previously	O
,	O
we	O
showed	O
that	O
occupation	O
of	O
two	O
of	O
these	O
sites	O
,	O
centred	O
at	O
positions	O
-	O
42.5	O
and	O
-	O
62.5	O
upstream	O
of	O
the	O
melAB	B
transcription	O
start	O
point	O
,	O
is	O
sufficient	O
for	O
activation	O
.	O

We	O
showed	O
that	O
MelR	B
binds	O
as	O
a	O
direct	O
repeat	O
to	O
these	O
sites	O
,	O
and	O
we	O
proposed	O
a	O
model	O
to	O
describe	O
how	O
the	O
two	O
HTH	O
motifs	O
are	O
positioned	O
.	O

Here	O
,	O
we	O
have	O
used	O
suppression	O
genetics	O
to	O
confirm	O
this	O
model	O
and	O
to	O
show	O
that	O
MelR	B
residue	O
273	O
,	O
which	O
is	O
in	O
HTH	O
2	O
,	O
interacts	O
with	O
basepair	O
13	O
of	O
each	O
target	O
site	O
.	O

As	O
our	O
model	O
for	O
DNA	O
-	O
bound	O
MelR	B
suggests	O
that	O
HTH	O
2	O
must	O
be	O
adjacent	O
to	O
the	O
melAB	B
promoter	O
-	O
35	O
element	O
,	O
we	O
searched	O
this	O
part	O
of	O
MelR	B
for	O
amino	O
acid	O
side	O
-	O
chains	O
that	O
might	O
be	O
able	O
to	O
interact	O
with	O
sigma	B
.	O

We	O
describe	O
genetic	O
evidence	O
to	O
show	O
that	O
MelR	B
residue	O
261	O
is	O
close	O
to	O
residues	O
596	O
and	O
599	O
of	O
the	O
RNA	B
polymerase	I
sigma	I
(	I
70	I
)	I
subunit	O
,	O
and	O
that	O
they	O
can	O
interact	O
.	O

Similarly	O
,	O
MelR	B
residue	O
265	O
is	O
shown	O
to	O
be	O
able	O
to	O
interact	O
with	O
residue	O
596	O
of	O
sigma	B
(	I
70	I
)	I
.	O

In	O
the	O
final	O
part	O
of	O
the	O
work	O
,	O
we	O
describe	O
experiments	O
in	O
which	O
the	O
MelR	B
binding	O
site	O
at	O
position	O
-	O
42.5	O
was	O
improved	O
.	O

We	O
show	O
that	O
this	O
is	O
detrimental	O
to	O
MelR	B
-	O
dependent	O
transcription	O
activation	O
because	O
bound	O
MelR	B
is	O
mispositioned	O
so	O
that	O
it	O
is	O
unable	O
to	O
make	O
'	O
correct	O
'	O
interactions	O
with	O
sigma	B
.	O

Transcription	O
activation	O
at	O
the	O
Escherichia	O
coli	O
melAB	B
promoter	O
:	O
interactions	O
of	O
MelR	B
with	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	O
during	O
MelR	B
-	O
dependent	O
activation	O
of	O
transcription	O
at	O
the	O
Escherichia	O
coli	O
melAB	B
promoter	O
.	O

To	O
do	O
this	O
,	O
we	O
used	O
a	O
simplified	O
melAB	B
promoter	O
derivative	O
that	O
is	O
dependent	O
on	O
MelR	B
binding	O
at	O
two	O
18	O
bp	O
sites	O
,	O
located	O
from	O
position	O
-	O
34	O
to	O
-	O
51	O
and	O
from	O
position	O
-	O
54	O
to	O
-	O
71	O
,	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

Results	O
from	O
experiments	O
with	O
hydroxyl	O
radical	O
footprinting	O
,	O
and	O
with	O
RNA	B
polymerase	I
,	O
carrying	O
alpha	O
subunits	O
that	O
were	O
tagged	O
with	O
a	O
chemical	O
nuclease	B
,	O
show	O
that	O
the	O
C	O
-	O
terminal	O
domains	O
of	O
the	O
RNA	B
polymerase	I
alpha	I
subunits	O
are	O
located	O
near	O
position	O
-	O
52	O
and	O
near	O
position	O
-	O
72	O
during	O
transcription	O
activation	O
.	O

We	O
demonstrate	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	O
is	O
needed	O
for	O
open	O
complex	O
formation	O
,	O
and	O
we	O
describe	O
two	O
experiments	O
showing	O
that	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	O
can	O
interact	O
with	O
MelR	B
.	O

Finally	O
,	O
we	O
used	O
alanine	O
scanning	O
to	O
identify	O
determinants	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
RNA	B
polymerase	I
alpha	I
subunit	O
that	O
are	O
important	O
for	O
MelR	B
-	O
dependent	O
activation	O
of	O
the	O
melAB	B
promoter	O
.	O

Cloning	O
and	O
characterization	O
of	O
Kin5	B
,	O
a	O
novel	O
Tetrahymena	O
ciliary	O
kinesin	B
II	I
.	O

Two	O
Tetrahymena	O
kinesin	B
-	O
like	O
proteins	O
(	O
klps	O
)	O
of	O
the	O
kinesin	B
II	I
subfamily	I
,	O
Kin1	B
and	O
Kin2	B
,	O
were	O
first	O
identified	O
by	O
Brown	O
et	O
al.	O
[	O
1999	O
:	O
Mol	O
Biol	O
Cell	O
10	O
:	O
3081	O
-	O
3096	O
]	O
and	O
shown	O
to	O
be	O
involved	O
in	O
ciliary	O
morphogenesis	O
probably	O
as	O
molecular	O
motors	O
in	O
intraciliary	O
transport	O
(	O
ICT	O
)	O
.	O

Using	O
Tetrahymena	O
genomic	O
DNA	O
as	O
a	O
template	O
,	O
we	O
cloned	O
Kin5	B
,	O
another	O
kinesin	B
II	I
subfamily	I
member	O
.	O

Kin5	B
is	O
upregulated	O
upon	O
deciliation	O
,	O
suggesting	O
that	O
Kin5	B
is	O
a	O
ciliary	O
protein	O
.	O

Kin5	B
is	O
most	O
closely	O
related	O
to	O
Osm3	B
,	O
a	O
Caenorhabditis	O
elegans	O
kinesin	B
II	I
;	O
Osm3	B
and	O
Kin5	B
have	O
a	O
56	O
%	O
identity	O
,	O
which	O
rises	O
to	O
60.4	O
%	O
in	O
the	O
motor	O
domain	O
and	O
a	O
45	O
%	O
identity	O
in	O
a	O
60	O
amino	O
acid	O
region	O
of	O
the	O
C	O
-	O
terminal	O
FERM	O
(	O
4.1	B
,	O
Ezrin	B
,	O
Radixin	B
,	O
Moesin	B
)	O
domain	O
,	O
not	O
present	O
in	O
Kin1	B
or	O
Kin2	B
,	O
which	O
we	O
hypothesize	O
to	O
be	O
a	O
critical	O
domain	O
either	O
for	O
dimerization	O
or	O
for	O
cargo	O
recognition	O
in	O
ICT	O
.	O

An	O
antibody	O
to	O
a	O
peptide	O
sequence	O
from	O
the	O
tail	O
region	O
of	O
Kin5	B
localizes	O
in	O
a	O
punctate	O
pattern	O
along	O
the	O
ciliary	O
axoneme	O
,	O
colocalizing	O
with	O
an	O
antibody	O
to	O
the	O
raft	O
protein	O
IFT139	B
.	O

These	O
findings	O
suggest	O
that	O
Kin5	B
is	O
an	O
ICT	O
motor	O
like	O
Osm3	B
.	O

Osm3	B
orthologs	O
apparently	O
transport	O
membrane	O
proteins	O
and	O
Kin5	B
may	O
be	O
the	O
homodimeric	O
kinesin	B
II	I
that	O
performs	O
this	O
function	O
in	O
Tetrahymena	O
cilia	O
.	O

ARNT	B
gene	O
multiplicity	O
in	O
amphibians	O
:	O
characterization	O
of	O
ARNT2	B
from	O
the	O
frog	O
Xenopus	O
laevis	O
.	O

The	O
aryl	B
hydrocarbon	I
receptor	I
nuclear	I
translocator	I
(	O
ARNT	B
)	O
is	O
a	O
member	O
of	O
the	O
Per	B
-	I
ARNT	I
-	I
Sim	I
(	I
PAS	I
)	I
protein	I
superfamily	I
,	O
transcription	B
factors	I
that	O
mediate	O
the	O
cellular	O
responses	O
to	O
various	O
developmental	O
signals	O
and	O
environmental	O
conditions	O
.	O

A	O
beta	O
-	O
class	O
(	O
""""	O
partner	O
""""	O
)	O
PAS	O
protein	O
,	O
ARNT	B
exhibits	O
the	O
capacity	O
to	O
form	O
transcriptionally	O
active	O
heterodimers	O
with	O
several	O
alpha	O
-	O
class	O
(	O
""""	O
sensor	O
""""	O
)	O
proteins	O
,	O
including	O
the	O
aryl	B
hydrocarbon	I
receptors	I
(	O
AHRs	B
)	O
,	O
the	O
hypoxia	B
-	I
inducible	I
factors	I
(	O
HIFs	B
)	O
,	O
and	O
the	O
Single	B
minded	I
(	O
Sim	B
)	O
proteins	O
.	O

Two	O
genes	O
encode	O
different	O
forms	O
of	O
ARNT	B
in	O
mammals	O
:	O
ARNT1	B
,	O
which	O
is	O
widely	O
expressed	O
,	O
and	O
ARNT2	B
,	O
which	O
is	O
limited	O
to	O
the	O
brain	O
and	O
kidneys	O
of	O
adults	O
and	O
specific	O
neural	O
and	O
branchial	O
tissues	O
of	O
embryos	O
.	O

In	O
contrast	O
,	O
fish	O
apparently	O
express	O
only	O
a	O
single	O
ARNT	B
gene	O
,	O
although	O
in	O
different	O
species	O
,	O
this	O
may	O
be	O
either	O
ARNT1	B
or	O
ARNT2	B
.	O

In	O
efforts	O
to	O
understand	O
the	O
evolution	O
of	O
ARNT	B
proteins	O
throughout	O
the	O
vertebrate	O
lineage	O
,	O
we	O
isolated	O
an	O
ARNT	B
cDNA	O
from	O
early	O
life	O
stages	O
of	O
the	O
amphibian	O
Xenopus	O
laevis	O
.	O

The	O
encoded	O
protein	O
binds	O
cognate	O
DNA	O
sequences	O
in	O
concert	O
with	O
mouse	O
AHR	B
.	O

Phylogenetic	O
analysis	O
reveals	O
that	O
this	O
sequence	O
is	O
orthologous	O
to	O
mammalian	O
ARNT2	B
and	O
paralogous	O
to	O
the	O
recently	O
reported	O
X.	O
laevis	O
ARNT1	B
.	O

ARNT2	B
mRNA	O
expression	O
begins	O
later	O
than	O
ARNT1	B
(	O
stage	O
22	O
vs.	O
stage	O
8	O
)	O
,	O
suggesting	O
the	O
two	O
proteins	O
play	O
distinct	O
roles	O
during	O
development	O
.	O

Hence	O
,	O
in	O
the	O
expression	O
of	O
two	O
well	O
-	O
conserved	O
ARNT	B
paralogs	O
with	O
distinct	O
expression	O
patterns	O
,	O
X.	O
laevis	O
resembles	O
mammals	O
rather	O
than	O
fish	O
.	O

Diversity	O
in	O
the	O
number	O
and	O
function	O
of	O
PAS	O
proteins	O
,	O
including	O
ARNT	B
,	O
may	O
underlie	O
significant	O
species	O
differences	O
in	O
developmental	O
programming	O
and	O
biochemical	O
response	O
to	O
environmental	O
conditions	O
.	O

The	O
identification	O
of	O
multiple	O
amphibian	O
ARNT	B
paralogs	O
represents	O
an	O
important	O
step	O
in	O
the	O
understanding	O
of	O
evolution	O
and	O
functional	O
variation	O
of	O
ARNT	B
in	O
vertebrates	O
.	O

Polymorphisms	O
of	O
mouse	O
apolipoprotein	B
A	I
-	I
II	I
:	O
seven	O
alleles	O
found	O
among	O
41	O
inbred	O
strains	O
of	O
mice	O
.	O

In	O
mice	O
,	O
apolipoprotein	B
A	I
-	I
II	I
(	O
apoA	B
-	I
II	I
)	O
associates	O
to	O
form	O
amyloid	O
fibrils	O
in	O
an	O
age	O
-	O
associated	O
manner	O
.	O

We	O
determined	O
the	O
complete	O
nucleotide	O
sequences	O
of	O
the	O
apoA	B
-	I
II	I
gene	O
(	O
Apoa2	B
)	O
cDNA	O
in	O
41	O
inbred	O
strains	O
of	O
mice	O
including	O
Mus	O
musculus	O
domesticus	O
(	O
laboratory	O
mouse	O
)	O
,	O
Mus	O
musculus	O
castaneus	O
,	O
Mus	O
musculus	O
molossinus	O
,	O
Mus	O
musculus	O
musculus	O
and	O
Mus	O
spretus	O
.	O

Among	O
these	O
strains	O
we	O
identified	O
7	O
alleles	O
(	O
Apoa2a1	B
,	O
Apoa2a2	B
,	O
Apoa2b	B
,	O
Apoa2c	B
,	O
Apoa2d	B
,	O
Apoa2e	B
and	O
Apoa2f	B
)	O
.	O

Polymorphisms	O
of	O
nucleotides	O
at	O
15	O
positions	O
were	O
detected	O
and	O
amino	O
acid	O
substitutions	O
were	O
found	O
at	O
8	O
positions	O
.	O

Apoa2a1	B
was	O
found	O
in	O
all	O
mouse	O
subspecies	O
,	O
but	O
Apoa2b	B
and	O
Apoa2c	B
were	O
found	O
only	O
in	O
Mus	O
musculus	O
domesticus	O
.	O

Two	O
strains	O
of	O
Mus	O
spretus	O
have	O
the	O
unique	O
alleles	O
Apoa2e	B
and	O
Apoa2f	B
which	O
resemble	O
Apoa2c	B
.	O

We	O
confirmed	O
that	O
VICS	O
in	O
which	O
we	O
found	O
severe	O
amyloidosis	O
here	O
and	O
other	O
amyloidoneic	O
strains	O
in	O
published	O
reports	O
have	O
Apoa2c	B
allele	O
.	O

We	O
determined	O
the	O
plasma	O
concentrations	O
of	O
total	O
and	O
HDL	B
cholesterol	O
in	O
the	O
strains	O
of	O
Mus	O
musculus	O
domesticus	O
with	O
the	O
Apoa2a1	B
,	O
Apoa2b	B
and	O
Apoa2c	B
alleles	O
.	O

Significantly	O
higher	O
concentrations	O
of	O
plasma	O
cholesterol	O
were	O
observed	O
in	O
mouse	O
strains	O
with	O
the	O
Apoa2b	B
allele	O
.	O

These	O
findings	O
provide	O
fundamental	O
data	O
on	O
mouse	O
Apoa2	B
alleles	O
.	O

Furthermore	O
,	O
differences	O
in	O
these	O
alleles	O
likely	O
have	O
considerable	O
influence	O
on	O
traits	O
related	O
to	O
amyloidosis	O
and	O
lipid	O
metabolism	O
.	O

Regulation	O
of	O
expression	O
of	O
the	O
divergent	O
ulaG	B
and	O
ulaABCDEF	B
operons	I
involved	O
in	O
LaAscorbate	O
dissimilation	O
in	O
Escherichia	O
coli	O
.	O

The	O
ula	B
regulon	O
,	O
responsible	O
for	O
the	O
utilization	O
of	O
L	O
-	O
ascorbate	O
in	O
Escherichia	O
coli	O
,	O
is	O
formed	O
by	O
two	O
divergently	O
transcribed	O
operons	O
,	O
ulaG	B
and	O
ulaABCDEF	B
.	O

The	O
regulon	O
is	O
negatively	O
regulated	O
by	O
a	O
repressor	O
of	O
the	O
DeoR	B
family	I
which	O
is	O
encoded	O
by	O
the	O
constitutive	O
gene	O
ulaR	B
located	O
downstream	O
of	O
ulaG	B
.	O

Full	O
repression	O
of	O
the	O
ula	B
regulon	O
requires	O
simultaneous	O
interaction	O
of	O
the	O
repressor	O
with	O
both	O
divergent	O
promoters	O
and	O
seems	O
to	O
be	O
dependent	O
on	O
repressor	O
-	O
mediated	O
DNA	O
loop	O
formation	O
,	O
which	O
is	O
helped	O
by	O
the	O
action	O
of	O
integration	B
host	I
factor	I
.	O

Two	O
operator	O
sites	O
have	O
been	O
identified	O
in	O
each	O
promoter	O
.	O

Lack	O
of	O
either	O
of	O
the	O
two	O
sets	O
of	O
operators	O
partially	O
relieved	O
the	O
repression	O
of	O
the	O
other	O
operon	O
;	O
thus	O
,	O
each	O
promoter	O
is	O
dependent	O
on	O
the	O
UlaR	B
operator	O
sites	O
of	O
the	O
other	O
promoter	O
to	O
enhance	O
repression	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
with	O
purified	O
UlaR	B
protein	O
and	O
promoter	O
deletion	O
analyses	O
revealed	O
a	O
conserved	O
sequence	O
,	O
present	O
in	O
each	O
of	O
the	O
four	O
operators	O
,	O
acting	O
as	O
a	O
UlaR	B
binding	O
site	O
.	O

Glucose	O
represses	O
the	O
ula	B
regulon	O
via	O
at	O
least	O
two	O
mechanisms	O
,	O
one	O
dependent	O
on	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
-	O
cAMP	B
receptor	I
protein	I
(	O
CRP	B
)	O
and	O
the	O
other	O
(	O
possibly	O
inducer	O
exclusion	O
)	O
independent	O
of	O
it	O
.	O

Glucose	O
effects	O
mediated	O
by	O
other	O
global	O
regulators	O
can	O
not	O
be	O
ruled	O
out	O
with	O
the	O
present	O
information	O
.	O

Changes	O
in	O
cAMP	O
-	O
CRP	B
levels	O
affected	O
only	O
the	O
expression	O
of	O
the	O
ulaABCDEF	B
operon	I
.	O

Reconstitution	O
of	O
ATP	O
-	O
dependent	O
cGMP	O
transport	O
into	O
proteoliposomes	O
by	O
membrane	O
proteins	O
from	O
human	O
erythrocytes	O
.	O

The	O
cellular	O
efflux	O
of	O
cGMP	O
from	O
human	O
erythrocytes	O
has	O
previously	O
been	O
characterized	O
in	O
functional	O
studies	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
membrane	O
proteins	O
with	O
the	O
ability	O
to	O
restore	O
ATP	O
-	O
dependent	O
uptake	O
of	O
cGMP	O
into	O
proteoliposomes	O
.	O

Human	O
erythrocyte	O
membranes	O
were	O
solubilized	O
with	O
CHAPS	O
(	O
3-	O
(	O
[	O
3-cholamidopropyl	O
]	O
dimethylammonio	O
)	O
-1-propanesulfonate	O
)	O
and	O
gel	O
filtration	O
gave	O
three	O
protein	O
fractions	O
with	O
the	O
ability	O
to	O
restore	O
active	O
transport	O
.	O

Only	O
two	O
of	O
these	O
fractions	O
were	O
retained	O
on	O
a	O
lentil	O
lectin	B
column	O
.	O

By	O
using	O
these	O
two	O
purification	O
steps	O
,	O
active	O
transport	O
was	O
11	O
times	O
higher	O
in	O
the	O
first	O
fraction	O
compared	O
to	O
the	O
original	O
material	O
and	O
SDS	O
-	O
PAGE	O
showed	O
the	O
presence	O
of	O
proteins	O
with	O
sizes	O
of	O
145	O
kDa	O
and	O
165	O
kDa	O
.	O

The	O
second	O
fraction	O
gave	O
20	O
times	O
higher	O
active	O
transport	O
after	O
purification	O
and	O
comprised	O
proteins	O
with	O
sizes	O
of	O
145	O
kDa	O
and	O
180	O
kDa	O
.	O

At	O
present	O
three	O
members	O
of	O
the	O
MRP	B
(	I
multi	I
-	I
resistance	I
associated	I
protein	I
)	I
family	I
have	O
been	O
detected	O
in	O
human	O
erythrocytes	O
:	O
MRPI	B
,	O
MRP4	B
and	O
MRP5	B
.	O

The	O
last	O
two	O
proteins	O
have	O
been	O
shown	O
to	O
transport	O
cyclic	O
nucleotides	O
.	O

The	O
present	O
findings	O
are	O
compatible	O
with	O
MRP4	B
as	O
the	O
145	O
kDa	O
protein	O
,	O
MRP5	B
as	O
the	O
165	O
kDa	O
protein	O
and	O
MRP1	B
as	O
the	O
180	O
kDa	O
protein	O
.	O

However	O
,	O
the	O
145	O
kDa	O
protein	O
could	O
also	O
be	O
SMRP	B
(	O
short	B
multi	I
-	I
resistance	I
protein	I
)	O
,	O
the	O
gene	O
splice	O
variant	O
of	O
MRP5	B
.	O

Immunoprecipitation	O
of	O
MRP5	B
from	O
CHAPS	O
-	O
solubilized	O
extract	O
reduced	O
active	O
transport	O
and	O
specific	O
binding	O
by	O
about	O
45	O
%	O
and	O
40	O
%	O
,	O
respectively	O
.	O

This	O
shows	O
that	O
MRP5	B
is	O
an	O
important	O
cGMP	O
-	O
transporting	O
protein	O
in	O
human	O
erythrocytes	O
.	O

Structure	O
-	O
function	O
of	O
human	O
3	B
alpha	I
-	I
hydroxysteroid	I
dehydrogenases	I
:	O
genes	O
and	O
proteins	O
.	O

Four	O
soluble	O
human	O
3	B
alpha	I
-	I
hydroxysteroid	I
dehydrogenase	I
(	O
HSD	B
)	O
isoforms	O
exist	O
which	O
are	O
aldo	B
-	I
keto	I
reductase	I
(	I
AKR	I
)	I
superfamily	I
members	O
.	O

They	O
share	O
86	O
%	O
sequence	O
identity	O
and	O
correspond	O
to	O
:	O
AKR1C1	B
(	O
20	B
alpha	I
(	I
3	I
alpha	I
)	I
-	I
HSD	I
)	O
;	O
AKR1C2	B
(	O
type	B
3	I
3	I
alpha	I
-	I
HSD	I
and	O
bile	B
-	I
acid	I
binding	I
protein	I
)	O
;	O
AKR1C3	B
(	O
type	B
2	I
3	I
alpha	I
-	I
HSD	I
and	O
type	B
5	I
17	I
beta	I
-	I
HSD	I
)	O
;	O
and	O
AKR1C4	B
(	O
type	B
1	I
3	I
alpha	I
-	I
HSD	I
)	O
.	O

Each	O
of	O
the	O
homogeneous	O
recombinant	O
enzymes	O
are	O
plastic	O
and	O
display	O
3	B
-	I
,	I
17	I
-	I
and	I
20	I
-	I
ketosteroid	I
reductase	I
and	O
3	B
alpha-	I
17	I
beta	I
-	I
and	I
20	I
alpha	I
-	I
hydroxysteroid	I
oxidase	I
activities	O
with	O
different	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
ratios	O
in	O
vitro	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
AKR1C2	B
.	O
NADP	O
(	O
+	O
)	O
.ursodeoxycholate	O
complex	O
provides	O
an	O
explanation	O
for	O
this	O
functional	O
plasticity	O
.	O

Ursodeoxycholate	O
is	O
bound	O
backwards	O
(	O
D	O
-	O
ring	O
in	O
the	O
A	O
-	O
ring	O
position	O
)	O
and	O
upside	O
down	O
(	O
beta	O
-	O
face	O
of	O
steroid	O
inverted	O
)	O
relative	O
to	O
the	O
position	O
of	O
3-ketosteroids	O
in	O
the	O
related	O
rat	O
liver	O
3	B
alpha	I
-	I
HSD	I
(	O
AKR1C9	B
)	O
structure	O
.	O

Transient	O
transfection	O
indicates	O
that	O
in	O
COS-1	O
cells	O
,	O
AKR1C	B
enzymes	O
function	O
as	O
ketosteroid	B
reductases	I
due	O
to	O
potent	O
inhibition	O
of	O
their	O
oxidase	B
activity	O
by	O
NADPH	O
.	O

By	O
acting	O
as	O
ketosteroid	B
reductases	I
they	O
may	O
regulate	O
the	O
occupancy	O
of	O
the	O
androgen	B
,	I
estrogen	I
and	I
progesterone	I
receptors	I
.	O

RT	O
-	O
PCR	O
showed	O
that	O
AKRs	B
are	O
discretely	O
localized	O
.	O

AKR1C4	B
is	O
virtually	O
liver	O
specific	O
,	O
while	O
AKR1C2	B
and	O
AKR1C3	B
are	O
dominantly	O
expressed	O
in	O
prostate	O
and	O
mammary	O
gland	O
.	O

AKR1C	B
genes	O
are	O
highly	O
conserved	O
in	O
structure	O
and	O
may	O
be	O
transcriptionally	O
regulated	O
by	O
steroid	O
hormones	O
and	O
stress	O
.	O

Construction	O
of	O
a	O
soluble	O
human	O
GH	B
-	I
receptor	I
/	O
EGF	B
-	I
receptor	I
hybrid	O
and	O
its	O
activation	O
by	O
GH	B
.	O

To	O
develop	O
a	O
cell	O
-	O
free	O
system	O
that	O
can	O
be	O
used	O
to	O
measure	O
cytokine	B
bioactivity	O
we	O
have	O
designed	O
a	O
soluble	O
hybrid	O
molecule	O
consisting	O
of	O
the	O
extracellular	O
domain	O
of	O
the	O
GH	B
-	I
receptor	I
(	O
GHR	B
)	O
and	O
the	O
intracellular	O
domain	O
of	O
the	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
EGFR	B
)	O
.	O

A	O
DNA	O
construct	O
encoding	O
this	O
hybrid	O
-	O
receptor	O
was	O
inserted	O
into	O
a	O
baculoviral	O
expression	O
vector	O
and	O
expressed	O
in	O
Sf9	O
-	O
cells	O
.	O

Activation	O
of	O
the	O
hybrid	O
-	O
receptor	O
by	O
ligand	O
-	O
induced	O
dimerization	O
can	O
be	O
measured	O
as	O
the	O
incorporation	O
of	O
radiolabeled	O
phosphate	O
into	O
a	O
biotinylated	O
tyrosine	B
kinase	I
peptide	O
substrate	O
.	O

The	O
kinase	B
activity	O
in	O
samples	O
stimulated	O
with	O
GH	B
(	O
10	O
ng	O
/	O
ml	O
)	O
increased	O
5	O
-	O
fold	O
compared	O
to	O
samples	O
without	O
addition	O
of	O
GH	B
.	O

This	O
is	O
the	O
first	O
example	O
of	O
a	O
functional	O
hybrid	O
-	O
receptor	O
where	O
the	O
transmembrane	O
domain	O
has	O
been	O
deleted	O
.	O

Our	O
results	O
suggest	O
that	O
such	O
hybrid	O
-	O
receptors	O
may	O
be	O
used	O
for	O
detection	O
of	O
GH	B
and	O
other	O
cytokine	B
-	I
receptor	I
activating	O
substances	O
in	O
biological	O
fluids	O
.	O

The	O
inner	O
membrane	O
subassembly	O
of	O
the	O
enteropathogenic	O
Escherichia	O
coli	O
bundle	O
-	O
forming	O
pilus	O
machine	O
.	O

Type	O
IV	O
pili	O
(	O
Tfps	O
)	O
are	O
filamentous	O
surface	O
appendages	O
expressed	O
by	O
Gram	O
-	O
negative	O
microorganisms	O
and	O
play	O
numerous	O
roles	O
in	O
bacterial	O
cell	O
biology	O
.	O

Tfp	O
biogenesis	O
machineries	O
are	O
highly	O
conserved	O
and	O
resemble	O
protein	O
secretion	O
and	O
DNA	O
uptake	O
systems	O
.	O

Although	O
components	O
of	O
Tfp	O
biogenesis	O
systems	O
have	O
been	O
identified	O
,	O
it	O
is	O
not	O
known	O
how	O
they	O
interact	O
to	O
form	O
these	O
machineries	O
.	O

Using	O
the	O
bundle	O
-	O
forming	O
pilus	O
(	O
BFP	O
)	O
of	O
enteropathogenic	O
Escherichia	O
coli	O
as	O
a	O
model	O
Tfp	O
system	O
,	O
we	O
provide	O
evidence	O
of	O
a	O
cytoplasmic	O
membrane	O
subassembly	O
of	O
the	O
Tfp	O
assembly	O
machine	O
composed	O
of	O
putative	O
cytoplasmic	O
nucleotide	O
-	O
binding	O
and	O
cytoplasmic	O
membrane	O
proteins	O
.	O

A	O
combination	O
of	O
genetic	O
,	O
biochemical	O
and	O
biophysical	O
approaches	O
revealed	O
interactions	O
among	O
putative	O
cytoplasmic	O
nucleotide	O
-	O
binding	O
proteins	O
BfpD	B
and	O
BfpF	B
and	O
cytoplasmic	O
membrane	O
proteins	O
BfpC	B
and	O
BfpE	B
of	O
the	O
BFP	B
biogenesis	O
machine	O
.	O

The	O
polytopic	O
membrane	O
protein	O
BfpE	B
appears	O
to	O
be	O
a	O
central	O
component	O
of	O
this	O
subassembly	O
as	O
it	O
interacts	O
with	O
BfpC	B
,	O
BfpD	B
and	O
BfpF	B
.	O

We	O
report	O
that	O
BFP	O
biogenesis	O
probably	O
requires	O
interactions	O
among	O
BfpC	B
,	O
BfpD	B
and	O
BfpE	B
,	O
whereas	O
BFP	O
retraction	O
requires	O
interaction	O
of	O
the	O
PilT	B
-	O
like	O
putative	O
ATPase	B
BfpF	B
with	O
a	O
conserved	O
domain	O
of	O
BfpE	B
.	O

BfpE	B
is	O
the	O
first	O
protein	O
that	O
is	O
not	O
a	O
member	O
of	O
the	O
PilT	B
family	I
to	O
be	O
implicated	O
in	O
Tfp	O
retraction	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
putative	O
ATPases	B
BfpD	B
and	O
BfpF	B
play	O
antagonistic	O
roles	O
in	O
BFP	O
biogenesis	O
and	O
retraction	O
,	O
respectively	O
,	O
by	O
interacting	O
with	O
distinct	O
domains	O
of	O
the	O
BFP	O
biogenesis	O
machine	O
.	O

Co	O
-	O
expression	O
of	O
three	O
MEP	O
pathway	O
genes	O
and	O
geraniol	B
10-hydroxylase	I
in	O
internal	O
phloem	O
parenchyma	O
of	O
Catharanthus	O
roseus	O
implicates	O
multicellular	O
translocation	O
of	O
intermediates	O
during	O
the	O
biosynthesis	O
of	O
monoterpene	O
indole	O
alkaloids	O
and	O
isoprenoid	O
-	O
derived	O
primary	O
metabolites	O
.	O

In	O
higher	O
plants	O
,	O
isopentenyl	O
diphosphate	O
(	O
IPP	O
)	O
is	O
synthesised	O
both	O
from	O
the	O
plastidic	O
2-C	O
-	O
methyl	O
-	O
d	O
-	O
erythritol	O
4-phosphate	O
(	O
MEP	O
)	O
and	O
from	O
the	O
cytosolic	O
mevalonate	O
(	O
MVA	O
)	O
pathways	O
.	O

Primary	O
metabolites	O
,	O
such	O
as	O
phytol	O
group	O
of	O
chlorophylls	O
,	O
carotenoids	O
and	O
the	O
plant	O
hormones	O
abscisic	O
acid	O
(	O
ABA	O
)	O
and	O
gibberellins	O
(	O
GAs	O
)	O
are	O
derived	O
directly	O
from	O
the	O
MEP	O
pathway	O
.	O

Many	O
secondary	O
metabolites	O
,	O
such	O
as	O
monoterpene	O
indole	O
alkaloids	O
(	O
MIAs	O
)	O
in	O
Catharanthus	O
roseus	O
,	O
are	O
also	O
synthesised	O
from	O
this	O
source	O
of	O
IPP	O
.	O

Using	O
Northern	O
blot	O
and	O
in	O
situ	O
hybridisation	O
experiments	O
,	O
we	O
show	O
that	O
three	O
MEP	O
pathway	O
genes	O
(	O
1-deoxy	B
-	I
d	I
-	I
xylulose	I
5-phosphate	I
synthase	I
(	O
DXS	B
)	O
,	O
1-deoxy	B
-	I
d	I
-	I
xylulose	I
5-phosphate	I
reductoisomerase	I
(	O
DXR	B
)	O
and	O
2C	B
-	I
methyl	I
-	I
d	I
-	I
erythritol	I
2,4-cyclodiphosphate	I
synthase	I
(	O
MECS	B
)	O
)	O
and	O
the	O
gene	O
encoding	O
geraniol	B
10-hydroxylase	I
(	O
G10H	B
)	O
,	O
a	O
cytochrome	B
P450	I
monooxygenase	I
involved	O
in	O
the	O
first	O
committed	O
step	O
in	O
the	O
formation	O
of	O
iridoid	O
monoterpenoids	O
display	O
identical	O
cell	O
-	O
specific	O
expression	O
patterns	O
.	O

The	O
co	O
-	O
localisation	O
of	O
these	O
four	O
transcripts	O
to	O
internal	O
phloem	O
parenchyma	O
of	O
young	O
aerial	O
organs	O
of	O
C.	O
roseus	O
adds	O
a	O
new	O
level	O
of	O
complexity	O
to	O
the	O
multicellular	O
nature	O
of	O
MIA	O
biosynthesis	O
.	O

We	O
predict	O
the	O
translocation	O
of	O
pathway	O
intermediates	O
from	O
the	O
internal	O
phloem	O
parenchyma	O
to	O
the	O
epidermis	O
and	O
,	O
ultimately	O
,	O
to	O
laticifers	O
and	O
idioblasts	O
during	O
MIA	O
biosynthesis	O
.	O

Similarly	O
,	O
the	O
translocation	O
of	O
intermediates	O
from	O
the	O
phloem	O
parenchyma	O
is	O
probably	O
also	O
required	O
during	O
the	O
biosynthesis	O
of	O
hormones	O
and	O
photosynthetic	O
primary	O
metabolites	O
derived	O
from	O
the	O
MEP	O
pathway	O
.	O

Calcium	O
-	O
regulated	O
changes	O
in	O
mitochondrial	O
phenotype	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Cytochrome	B
c	I
expression	O
and	O
mitochondrial	O
biogenesis	O
can	O
be	O
invoked	O
by	O
elevated	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
in	O
muscle	O
cells	O
.	O

To	O
characterize	O
the	O
potential	O
role	O
of	O
Ca	O
(	O
2	O
+	O
)	O
as	O
a	O
messenger	O
involved	O
in	O
mitochondrial	O
biogenesis	O
in	O
muscle	O
,	O
we	O
determined	O
the	O
effects	O
of	O
the	O
Ca	O
(	O
2	O
+	O
)	O
ionophore	O
A	O
-	O
23187	O
on	O
the	O
expression	O
of	O
nuclear	O
-	O
and	O
mitochondrially	O
encoded	O
genes	O
.	O

Treatment	O
of	O
myotubes	O
with	O
1	O
microM	O
A-23187	O
for	O
48	O
-	O
96	O
h	O
increased	O
nuclear	O
-	O
encoded	O
beta	B
-	I
subunit	I
F	I
(	I
1	I
)	I
ATPase	I
and	O
malate	B
dehydrogenase	I
(	O
MDH	B
)	O
mRNA	O
levels	O
by	O
50	O
-	O
100	O
%	O
(	O
P	O
<	O
0.05	O
)	O
but	O
decreased	O
mRNA	O
levels	O
of	O
glutamate	B
dehydrogenase	I
(	O
GDH	B
)	O
by	O
19	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

mRNA	O
levels	O
of	O
the	O
cytochrome	B
c	I
oxidase	I
(	O
COX	B
)	O
nuclear	O
-	O
encoded	O
subunits	O
IV	O
,	O
Vb	O
,	O
and	O
VIc	O
were	O
unchanged	O
,	O
whereas	O
the	O
mitochondrially	O
encoded	O
subunits	O
COX	B
II	I
and	O
COX	B
III	I
were	O
decreased	O
by	O
30	O
and	O
70	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O

This	O
was	O
paralleled	O
by	O
a	O
20	O
%	O
decrease	O
(	O
P	O
<	O
0.05	O
)	O
in	O
COX	B
activity	O
.	O

These	O
data	O
suggest	O
that	O
cytoplasmic	O
Ca	O
(	O
2	O
+	O
)	O
differentially	O
regulates	O
the	O
mRNA	O
level	O
of	O
nuclear	O
and	O
mitochondrial	O
genes	O
.	O

The	O
decline	O
in	O
COX	B
II	I
and	I
III	I
mRNA	O
may	O
be	O
mediated	O
by	O
Tfam	B
,	O
because	O
A	O
-	O
23187	O
modestly	O
reduced	O
Tfam	B
levels	O
by	O
48	O
h	O
.	O

A-23187	O
induced	O
time	O
-	O
dependent	O
increases	O
in	O
Egr-1	B
mRNA	O
,	O
along	O
with	O
the	O
activation	O
of	O
ERK1	B
/	I
2	I
and	O
AMP	B
-	I
activated	I
protein	I
kinase	I
.	O

MEK	B
inhibition	O
with	O
PD-98059	O
attenuated	O
the	O
increase	O
in	O
Egr-1	B
mRNA	O
.	O

A-23187	O
also	O
increased	O
Egr-1	B
,	O
serum	B
response	I
factor	I
,	O
and	O
Sp1	B
protein	O
expression	O
,	O
transcription	B
factors	I
implicated	O
in	O
mitochondrial	O
biogenesis	O
.	O

Egr-1	B
overexpression	O
increased	O
nuclear	O
-	O
encoded	O
cytochrome	B
c	I
transcriptional	O
activation	O
by	O
1.5	O
-	O
fold	O
(	O
P	O
<	O
0.05	O
)	O
and	O
reduced	O
GDH	B
mRNA	O
by	O
37	O
%	O
(	O
P	O
<	O
0.05	O
)	O
but	O
had	O
no	O
effect	O
on	O
MDH	B
or	O
beta	B
-	I
subunit	I
F	I
(	I
1	I
)	I
ATPase	I
mRNA	O
.	O

These	O
results	O
indicate	O
that	O
changes	O
in	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
can	O
modify	O
mitochondrial	O
phenotype	O
,	O
in	O
part	O
via	O
the	O
involvement	O
of	O
Egr-1	B
.	O

Cyclooxygenase	B
2	I
-	O
derived	O
prostaglandin	O
E2	O
production	O
by	O
corticotropin	B
-	I
releasing	I
hormone	I
contributes	O
to	O
the	O
activated	O
cAMP	B
response	I
element	I
binding	I
protein	I
content	O
in	O
rheumatoid	O
arthritis	O
synovial	O
tissue	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
a	O
mechanism	O
by	O
which	O
corticotropin	B
-	I
releasing	I
hormone	I
(	O
CRH	B
)	O
promotes	O
human	O
inflammatory	O
joint	O
disease	O
progression	O
.	O

METHODS	O
:	O

An	O
ex	O
vivo	O
synovial	O
tissue	O
culture	O
system	O
was	O
established	O
to	O
investigate	O
the	O
functional	O
properties	O
of	O
CRH	B
at	O
peripheral	O
sites	O
of	O
inflammation	O
.	O

CRH	B
-	O
and	O
interleukin-1	B
beta	I
(	O
IL-1	B
beta	I
)	O
-	O
induced	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
production	O
from	O
10	O
fresh	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
synovial	O
tissue	O
(	O
ST	O
)	O
explants	O
was	O
quantified	O
using	O
a	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Modulation	O
of	O
PGE	O
(	O
2	O
)	O
levels	O
was	O
further	O
examined	O
following	O
selective	O
and	O
nonselective	O
cyclooxygenase	B
2	I
(	O
COX-2	B
)	O
inhibition	O
.	O

Nuclear	O
extracts	O
were	O
analyzed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
to	O
determine	O
functional	O
cAMP	B
response	I
element	I
binding	I
protein	I
(	O
CREB	B
)	O
activity	O
in	O
response	O
to	O
CRH	B
and	O
PGE	O
(	O
2	O
)	O
in	O
isolated	O
primary	O
synovial	O
cell	O
populations	O
.	O

Western	O
blot	O
analysis	O
measured	O
levels	O
of	O
total	O
and	O
activated	O
(	O
phosphospecific	O
)	O
CREB	B
/	I
activating	I
transcription	I
factor	I
(	I
ATF	I
)	I
family	I
members	O
prior	O
to	O
and	O
following	O
stimulation	O
.	O

RESULTS	O
:	O

CRH	B
,	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
significantly	O
(	O
P	O
=	O
0.022	O
)	O
up	O
-	O
regulated	O
PGE	O
(	O
2	O
)	O
production	O
from	O
10	O
fresh	O
RA	O
ST	O
explants	O
.	O

Costimulation	O
of	O
RA	O
ST	O
with	O
CRH	B
and	O
IL-1	B
beta	I
significantly	O
augmented	O
(	O
P	O
=	O
0.036	O
)	O
the	O
effects	O
on	O
PGE	O
(	O
2	O
)	O
production	O
additively	O
over	O
24	O
hours	O
.	O

We	O
demonstrated	O
that	O
selective	O
COX-2	B
inhibitors	O
prevent	O
the	O
induction	O
of	O
PGE	O
(	O
2	O
)	O
by	O
both	O
CRH	B
and	O
IL-1	B
beta	I
.	O

Further	O
,	O
we	O
provided	O
evidence	O
that	O
CRH	B
and	O
PGE	O
(	O
2	O
)	O
signal	O
through	O
the	O
induction	O
of	O
CREB	B
and	O
phosphorylated	O
CREB	B
/	I
ATF	I
family	I
members	O
in	O
RA	O
ST	O
and	O
in	O
isolated	O
primary	O
RA	O
cell	O
populations	O
.	O

CONCLUSION	O
:	O

Our	O
findings	O
underscore	O
the	O
pathogenic	O
role	O
that	O
CRH	B
may	O
play	O
in	O
modulating	O
inflammatory	O
joint	O
disease	O
and	O
establish	O
the	O
CREB	B
/	I
ATF	I
family	I
of	O
transcription	B
factors	I
as	O
principal	O
effector	O
molecules	O
of	O
proinflammatory	O
mediator	O
action	O
in	O
RA	O
.	O

Type	O
-	O
A	O
CpG	O
oligonucleotides	O
activate	O
exclusively	O
porcine	O
natural	O
interferon	B
-	O
producing	O
cells	O
to	O
secrete	O
interferon	B
-	I
alpha	I
,	O
tumour	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-12	B
.	O

Natural	O
interferon	B
-	O
producing	O
cells	O
(	O
NIPC	O
)	O
,	O
also	O
referred	O
to	O
as	O
immature	O
plasmacytoid	O
dendritic	O
cells	O
(	O
PDC	O
)	O
,	O
constitute	O
a	O
small	O
population	O
of	O
leucocytes	O
secreting	O
high	O
levels	O
of	O
type	B
I	I
interferons	I
in	O
response	O
to	O
certain	O
danger	O
signals	O
.	O

Amongst	O
these	O
signals	O
are	O
those	O
from	O
DNA	O
containing	O
unmethylated	O
CpG	O
motifs	O
.	O

The	O
present	O
work	O
demonstrated	O
that	O
the	O
CpG	O
oligonucleotides	O
(	O
CpG	O
-	O
ODN	O
)	O
2216	O
,	O
D32	O
and	O
D19	O
induce	O
high	O
amounts	O
of	O
interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
,	O
tumour	B
-	I
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
interleukin	B
(	I
IL	I
)	I
-	I
12	I
in	O
porcine	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O

Swine	B
workshop	I
cluster	I
3	I
(	O
SWC3	B
)	O
1ow	O
CD4high	B
cells	O
,	O
with	O
high	O
IL-3	B
-	O
binding	O
activity	O
,	O
representing	O
NIPC	O
,	O
were	O
the	O
exclusive	O
cytokine	B
-	O
producing	O
cells	O
responding	O
to	O
the	O
CpG	O
-	O
ODN	O
.	O

These	O
cells	O
did	O
not	O
express	O
CD6	B
,	O
CD8	B
or	O
CD45RA	B
.	O

Importantly	O
,	O
monocyte	O
-	O
derived	O
DC	O
did	O
not	O
respond	O
to	O
CpG	O
-	O
ODN	O
by	O
secretion	O
of	O
IFN	B
-	I
alpha	I
or	O
TNF	B
-	I
alpha	I
or	O
by	O
the	O
up	O
-	O
regulation	O
of	O
costimulatory	O
molecule	O
expression	O
.	O

CpG	O
-	O
ODN	O
up	O
-	O
regulated	O
MHC	B
class	I
II	I
and	O
CD80	B
\	I
86	I
expression	O
on	O
the	O
NIPC	O
,	O
but	O
were	O
unable	O
to	O
promote	O
NIPC	O
survival	O
.	O

Interestingly	O
,	O
certain	O
CpG	O
-	O
ODN	O
,	O
incapable	O
of	O
inducing	O
NIPC	O
to	O
secrete	O
IFN	B
-	I
alpha	I
or	O
up	O
-	O
regulate	O
MHC	B
class	I
II	I
and	O
CD80	B
\	I
86	I
,	O
did	O
promote	O
NIPC	O
viability	O
.	O

Taken	O
together	O
,	O
the	O
influence	O
of	O
CpG	O
-	O
ODN	O
on	O
porcine	O
NIPC	O
,	O
monocytes	O
and	O
myeloid	O
DCs	O
relates	O
to	O
that	O
observed	O
with	O
their	O
human	O
equivalents	O
.	O

These	O
results	O
represent	O
an	O
important	O
basis	O
for	O
the	O
application	O
of	O
CpG	O
-	O
ODN	O
as	O
adjuvants	O
for	O
the	O
formulation	O
of	O
novel	O
vaccines	O
and	O
demonstrate	O
the	O
importance	O
of	O
the	O
pig	O
as	O
an	O
alternative	O
animal	O
model	O
for	O
this	O
approach	O
.	O

A	O
suf	B
operon	I
requirement	O
for	O
Fe	O
-	O
S	O
cluster	O
assembly	O
during	O
iron	O
starvation	O
in	O
Escherichia	O
coli	O
.	O

The	O
suf	B
and	I
isc	I
operons	I
of	O
Escherichia	O
coli	O
have	O
been	O
implicated	O
in	O
Fe	O
-	O
S	O
cluster	O
assembly	O
.	O

However	O
,	O
it	O
has	O
been	O
unclear	O
why	O
E.	O
coli	O
has	O
two	O
systems	O
for	O
Fe	O
-	O
S	O
cluster	O
biosynthesis	O
.	O

We	O
have	O
examined	O
the	O
regulatory	O
characteristics	O
and	O
mutant	O
phenotypes	O
of	O
both	O
operons	O
to	O
discern	O
if	O
the	O
two	O
operons	O
have	O
redundant	O
functions	O
or	O
if	O
their	O
cellular	O
roles	O
are	O
divergent	O
.	O

Both	O
operons	O
are	O
similarly	O
induced	O
by	O
hydrogen	O
peroxide	O
and	O
the	O
iron	O
chelator	O
2,2'-dipyridyl	O
,	O
although	O
by	O
different	O
mechanisms	O
.	O

Regulation	O
of	O
the	O
isc	B
operon	I
is	O
mediated	O
by	O
IscR	B
,	O
whereas	O
the	O
suf	B
operon	I
requires	O
OxyR	B
and	O
IHF	B
for	O
the	O
response	O
to	O
oxidative	O
stress	O
and	O
Fur	B
for	O
induction	O
by	O
iron	O
starvation	O
.	O

Simultaneous	O
deletion	O
of	O
iscS	B
and	O
most	O
suf	O
genes	O
is	O
synthetically	O
lethal	O
.	O

However	O
,	O
although	O
the	O
suf	B
and	I
isc	I
operons	I
have	O
overlapping	O
functions	O
,	O
they	O
act	O
as	O
distinct	O
complexes	O
because	O
the	O
SufS	B
desulphurase	I
alone	O
can	O
not	O
substitute	O
for	O
the	O
IscS	B
enzyme	O
.	O

In	O
addition	O
,	O
suf	B
deletion	O
mutants	O
are	O
more	O
sensitive	O
to	O
iron	O
starvation	O
than	O
isc	B
mutants	O
,	O
and	O
the	O
activity	O
of	O
the	O
Fe	O
-	O
S	O
enzyme	O
gluconate	B
dehydratase	I
is	O
diminished	O
in	O
the	O
suf	B
mutant	O
during	O
iron	O
starvation	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
model	O
that	O
the	O
isc	B
operon	I
encodes	O
the	O
housekeeping	O
Fe	O
-	O
S	O
cluster	O
assembly	O
system	O
in	O
E.	O
coli	O
,	O
whereas	O
the	O
suf	B
operon	I
is	O
specifically	O
adapted	O
to	O
synthesize	O
Fe	O
-	O
S	O
clusters	O
when	O
iron	O
or	O
sulphur	O
metabolism	O
is	O
disrupted	O
by	O
iron	O
starvation	O
or	O
oxidative	O
stress	O
.	O

Abnormal	O
in	O
vivo	O
metabolism	O
of	O
apoB	B
-	O
containing	O
lipoproteins	O
in	O
human	O
apoE	B
deficiency	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
elucidate	O
the	O
metabolic	O
basis	O
for	O
the	O
increased	O
remnants	O
and	O
lipoprotein	B
(	I
a	I
)	I
[	O
Lp	B
(	I
a	I
)	I
]	O
and	O
decreased	O
LDL	B
apolipoprotein	B
B	I
(	O
apoB	B
)	O
levels	O
in	O
human	O
apoE	B
deficiency	O
.	O

A	O
primed	O
constant	O
infusion	O
of	O
(	O
13	O
)	O
C	O
(	O
6	O
)	O
-phenylalanine	O
was	O
administered	O
to	O
a	O
homozygous	O
apoE	B
-	O
deficient	O
subject	O
.	O

apoB-100	B
and	O
apoB-48	B
were	O
isolated	O
,	O
and	O
tracer	O
enrichments	O
were	O
determined	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
,	O
then	O
kinetic	O
parameters	O
were	O
calculated	O
by	O
multicompartmental	O
modeling	O
.	O

In	O
the	O
apoE	B
-	O
deficient	O
subject	O
,	O
fractional	O
catabolic	O
rates	O
(	O
FCRs	O
)	O
of	O
apoB	B
-	I
100	I
in	O
VLDL	B
and	O
intermediate	B
density	I
lipoprotein	I
and	O
apoB-48	B
in	O
VLDL	B
were	O
3x	O
,	O
12x	O
,	O
and	O
12x	O
slower	O
than	O
those	O
of	O
controls	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
LDL	B
apoB-100	B
FCR	O
was	O
increased	O
by	O
2.6x	O
.	O

The	O
production	O
rate	O
of	O
VLDL	B
apoB-100	B
was	O
decreased	O
by	O
45	O
%	O
.	O

In	O
the	O
Lp	B
(	I
a	I
)	I
kinetic	O
study	O
,	O
two	O
types	O
of	O
Lp	B
(	I
a	I
)	I
were	O
isolated	O
from	O
plasma	O
with	O
apoE	B
deficiency	O
:	O
buoyant	O
and	O
normal	O
Lp	B
(	I
a	I
)	I
.	O

(	O
125	O
)	O
I	O
-	O
buoyant	O
Lp	B
(	I
a	I
)	I
was	O
catabolized	O
at	O
a	O
slower	O
rate	O
in	O
the	O
patient	O
.	O

However	O
,	O
(	O
125	O
)	O
I	O
-	O
buoyant	O
Lp	B
(	I
a	I
)	I
was	O
catabolized	O
at	O
twice	O
as	O
fast	O
as	O
(	O
131	O
)	O
I	O
-	O
normal	O
Lp	B
(	I
a	I
)	I
in	O
the	O
control	O
subjects	O
.	O

In	O
summary	O
,	O
apoE	B
deficiency	O
results	O
in	O
:	O
1	O
)	O
a	O
markedly	O
impaired	O
catabolism	O
of	O
VLDL	B
/	O
chylomicron	B
and	O
their	O
remnants	O
due	O
to	O
lack	O
of	O
direct	O
removal	O
and	O
impaired	O
lipolysis	O
;	O
2	O
)	O
an	O
increased	O
rate	O
of	O
catabolism	O
of	O
LDL	B
apoB	B
-	I
100	I
,	O
likely	O
due	O
to	O
upregulation	O
of	O
LDL	B
receptor	I
activity	O
;	O
3	O
)	O
reduced	O
VLDL	B
apoB	B
production	O
;	O
and	O
4	O
)	O
a	O
delayed	O
catabolism	O
of	O
a	O
portion	O
of	O
Lp	B
(	I
a	I
)	I
.	O

Fructan	O
metabolising	O
enzymes	O
in	O
rhizophores	O
of	O
Vernonia	O
herbacea	O
upon	O
excision	O
of	O
aerial	O
organs	O
.	O

The	O
activities	O
of	O
fructan	O
metabolising	O
enzymes	O
and	O
fructan	O
contents	O
are	O
reported	O
for	O
rhizophores	O
of	O
Vernonia	O
herbacea	O
(	O
Vell	O
.	O
)	O
Rusby	O
induced	O
to	O
sprouting	O
by	O
shoot	O
excision	O
.	O

The	O
activities	O
of	O
fructan	B
exohydrolase	I
(	O
1-FEH	B
)	O
,	O
sucrose	B
:	I
sucrose	I
fructosyltransferase	I
(	O
1-SST	B
)	O
,	O
fructan	B
:	I
fructan	I
fructosyltransferase	I
(	O
1-FFT	B
)	O
and	O
invertase	B
(	O
INV	B
)	O
and	O
the	O
fructan	O
contents	O
were	O
analysed	O
every	O
3	O
-	O
4	O
days	O
for	O
1	O
month	O
by	O
colorimetric	O
and	O
chromatographic	O
methods	O
.	O

Sprouting	O
of	O
new	O
shoots	O
started	O
on	O
day	O
9	O
.	O

1-FEH	B
activity	O
increased	O
after	O
day	O
13	O
and	O
reached	O
its	O
maximum	O
value	O
20	O
days	O
after	O
shoot	O
excision	O
.	O

A	O
gradual	O
decrease	O
in	O
1-SST	B
activity	O
was	O
detected	O
between	O
days	O
3	O
and	O
9	O
.	O

1-FFT	B
activity	O
exhibited	O
fluctuations	O
throughout	O
the	O
experimental	O
period	O
and	O
a	O
peak	O
of	O
activity	O
for	O
invertase	O
was	O
detected	O
9	O
days	O
after	O
shoot	O
excision	O
.	O

Variation	O
in	O
fructan	O
contents	O
in	O
vivo	O
included	O
a	O
decrease	O
until	O
day	O
13	O
after	O
which	O
,	O
levels	O
remained	O
practically	O
unchanged	O
.	O

Fructan	O
depolymerization	O
and	O
sprouting	O
are	O
concomitant	O
processes	O
in	O
V.	O
herbacea	O
and	O
can	O
be	O
induced	O
by	O
shoot	O
excision	O
at	O
any	O
phenological	O
phase	O
.	O

1-FEH	B
and	O
1-FFT	B
seemed	O
to	O
act	O
in	O
a	O
concerted	O
way	O
to	O
catalyse	O
fructan	O
depolymerization	O
,	O
while	O
1-SST	B
was	O
inhibited	O
,	O
possibly	O
due	O
to	O
interruption	O
of	O
sucrose	O
supply	O
to	O
rhizophores	O
from	O
the	O
aerial	O
organs	O
.	O

Effect	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interferon	B
-	I
gamma	I
on	O
intestinal	O
P	B
-	I
glycoprotein	I
expression	O
,	O
activity	O
,	O
and	O
localization	O
in	O
Caco-2	O
cells	O
.	O

The	O
P	B
-	I
glycoprotein	I
(	O
Pgp	B
)	O
,	O
a	O
drug	O
efflux	O
pump	O
,	O
is	O
expressed	O
in	O
intestinal	O
epithelial	O
cells	O
,	O
where	O
it	O
constitutes	O
a	O
barrier	O
against	O
xenobiotics	O
.	O

In	O
inflammatory	O
bowel	O
disease	O
,	O
a	O
dysregulation	O
in	O
the	O
production	O
of	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
alpha	I
and	O
interferon	B
(	I
IFN	I
)	I
gamma	I
,	O
and	O
an	O
alteration	O
of	O
Pgp	B
expression	O
and	O
activity	O
have	O
been	O
reported	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
TNF	B
alpha	I
and	O
IFN	B
gamma	I
on	O
intestinal	O
Pgp	B
expression	O
,	O
activity	O
,	O
and	O
localization	O
in	O
Caco-2	O
cells	O
grown	O
on	O
filters	O
.	O

TNF	B
alpha	I
induced	O
both	O
a	O
strong	O
time	O
-	O
dependent	O
diminution	O
(	O
-	O
56	O
%	O
)	O
of	O
MDR1	B
mRNA	O
(	O
semiquantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
)	O
and	O
a	O
significant	O
decrease	O
of	O
unidirectional	O
transport	O
of	O
rhodamine	O
123	O
after	O
48	O
h	O
of	O
exposure	O
at	O
10	O
ng	O
/	O
mL	O
.	O

By	O
confocal	O
laser	O
scanning	O
microscopy	O
,	O
the	O
Pgp	B
was	O
mainly	O
localized	O
to	O
the	O
apical	O
plasma	O
membrane	O
of	O
both	O
control	O
and	O
TNF	B
alpha	I
-	O
treated	O
cells	O
.	O

By	O
contrast	O
,	O
IFN	B
gamma	I
induced	O
up	O
-	O
regulation	O
of	O
both	O
mRNA	O
MDR1	B
and	O
Pgp	B
protein	O
expression	O
without	O
incidence	O
on	O
Pgp	B
activity	O
.	O

Interestingly	O
,	O
a	O
colocalization	O
of	O
Pgp	B
with	O
lateral	O
F	B
-	I
actin	I
was	O
observed	O
.	O

Associated	O
with	O
TNF	B
alpha	I
,	O
IFN	B
gamma	I
produced	O
neither	O
an	O
antagonist	O
nor	O
synergistic	O
effect	O
on	O
Pgp	B
activity	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
demonstrate	O
an	O
inhibitory	O
effect	O
of	O
TNF	B
alpha	I
and	O
no	O
effect	O
of	O
IFN	B
gamma	I
on	O
Pgp	B
transport	O
activity	O
using	O
rhodamine	O
123	O
as	O
a	O
substrate	O
.	O

Mechanisms	O
of	O
action	O
of	O
these	O
cytokines	B
remain	O
to	O
be	O
studied	O
.	O

Genetic	O
polymorphisms	O
of	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
are	O
associated	O
with	O
susceptibility	O
to	O
psoriasis	O
vulgaris	O
.	O

To	O
elucidate	O
the	O
association	O
between	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
and	O
psoriasis	O
vulgaris	O
(	O
PV	O
)	O
,	O
we	O
typed	O
14	O
KIR	B
genes	O
in	O
96	O
Japanese	O
cases	O
and	O
50	O
healthy	O
controls	O
using	O
PCR	O
with	O
sequence	O
-	O
specific	O
primers	O
(	O
PCR	O
-	O
SSP	O
)	O
.	O

Here	O
we	O
report	O
an	O
interesting	O
association	O
between	O
certain	O
KIRs	B
and	O
Japanese	O
cases	O
with	O
PV	O
.	O

The	O
frequencies	O
of	O
KIR2DS1	B
and	O
KIR2DL5	B
were	O
significantly	O
increased	O
in	O
PV	O
cases	O
compared	O
with	O
controls	O
(	O
KIR2DS1	B
,	O
43	O
of	O
96	O
(	O
45	O
%	O
)	O
in	O
cases	O
vs	O
14	O
of	O
50	O
(	O
28	O
%	O
)	O
in	O
controls	O
;	O
KIR2DL5	B
,	O
46	O
of	O
96	O
(	O
48	O
%	O
)	O
in	O
cases	O
vs	O
15	O
of	O
50	O
(	O
30	O
%	O
)	O
in	O
controls	O
,	O
p	O
<	O
0.05	O
for	O
both	O
)	O
,	O
and	O
the	O
frequency	O
of	O
carriage	O
of	O
at	O
least	O
one	O
presumed	O
""""	O
B	O
""""	O
haplotype	O
,	O
inferred	O
from	O
patterns	O
including	O
KIR2DL2	B
,	O
KIR2DL5	B
,	O
and/or	O
various	O
combinations	O
of	O
activating	O
KIRs	B
,	O
was	O
also	O
statistically	O
increased	O
in	O
the	O
PV	O
cases	O
(	O
53	O
of	O
96	O
(	O
55	O
%	O
)	O
in	O
cases	O
vs	O
18	O
of	O
50	O
(	O
36	O
%	O
)	O
in	O
controls	O
,	O
p	O
<	O
0.04	O
)	O
.	O

The	O
increase	O
in	O
KIR2DS1	B
has	O
also	O
been	O
observed	O
in	O
psoriatic	O
arthritis	O
,	O
another	O
HLA	B
-	I
Cw6	I
-	O
associated	O
disease	O
(	O
Martin	O
et	O
al	O
,	O
2002	O
)	O
.	O

Accordingly	O
,	O
KIR2DS1	B
may	O
be	O
a	O
common	O
denominator	O
of	O
both	O
diseases	O
.	O

Differential	O
contribution	O
of	O
IL-1Ra	B
isoforms	O
to	O
allele	O
-	O
specific	O
IL-1Ra	B
mRNA	O
accumulation	O
.	O

The	O
interleukin-1	B
(	I
IL-1	I
)	I
receptor	I
antagonist	I
(	O
IL-1Ra	B
)	O
gene	O
produces	O
two	O
isoforms	O
of	O
IL-1Ra	B
,	O
intracellular	O
(	O
icIL-1Ra	B
)	O
and	O
secreted	O
(	O
sIL-1Ra	B
)	O
.	O

Distinct	O
promoter	O
regions	O
control	O
synthesis	O
of	O
each	O
isoform	O
.	O

Five	O
alleles	O
of	O
this	O
gene	O
,	O
defined	O
by	O
sIL-1Ra	B
intron	O
2	O
polymorphism	O
,	O
have	O
been	O
described	O
.	O

Although	O
differences	O
in	O
IL-1Ra	B
protein	O
production	O
have	O
been	O
demonstrated	O
in	O
various	O
tissues	O
and	O
cells	O
obtained	O
from	O
individuals	O
carrying	O
allele	O
1	O
vs.	O
allele	O
2	O
,	O
the	O
underlying	O
mechanisms	O
of	O
this	O
discrepancy	O
remain	O
poorly	O
understood	O
.	O

We	O
hypothesize	O
that	O
one	O
mechanism	O
contributing	O
to	O
differences	O
in	O
protein	O
levels	O
may	O
be	O
allele	O
-	O
specific	O
accumulation	O
of	O
icIL-1Ra	B
or	O
sIL-1Ra	B
mRNA	O
.	O

Quantification	O
of	O
allele	O
-	O
specific	O
differences	O
in	O
mRNA	O
accumulation	O
in	O
colonic	O
biopsies	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
heterozygous	O
individuals	O
shows	O
that	O
the	O
amount	O
of	O
allele	O
1	O
-	O
specific	O
icIL-1Ra	B
mRNA	O
averaged	O
four	O
times	O
higher	O
relative	O
to	O
allele	O
2	O
.	O

In	O
transfection	O
assays	O
,	O
gene	O
expression	O
directed	O
by	O
the	O
allele	O
1	O
-	O
specific	O
icIL-1Ra	B
promoter	O
fragment	O
was	O
found	O
to	O
be	O
greater	O
than	O
that	O
directed	O
by	O
the	O
allele	O
2	O
promoter	O
,	O
suggesting	O
that	O
icIL-1Ra	B
promoter	O
activity	O
contributes	O
to	O
the	O
disparity	O
in	O
the	O
allele	O
-	O
specific	O
icIL-1Ra	B
mRNA	O
accumulation	O
.	O

Our	O
data	O
show	O
that	O
differences	O
in	O
the	O
transcriptional	O
regulation	O
of	O
icIL-1Ra	B
alleles	O
1	O
and	O
2	O
may	O
be	O
involved	O
in	O
the	O
production	O
of	O
icIL-1Ra	B
protein	O
.	O

Disregulated	O
icIL-1Ra	B
production	O
may	O
play	O
a	O
role	O
in	O
chronic	O
inflammatory	O
diseases	O
where	O
the	O
balance	O
between	O
IL-1	B
and	O
IL-1Ra	B
has	O
been	O
implicated	O
as	O
a	O
key	O
pathogenic	O
mechanism	O
.	O

Pathogens	O
and	O
symbionts	O
in	O
ticks	O
:	O
prevalence	O
of	O
Anaplasma	O
phagocytophilum	O
(	O
Ehrlichia	O
sp.	O
)	O
,	O
Wolbachia	O
sp.	O
,	O
Rickettsia	O
sp.	O
,	O
and	O
Babesia	O
sp.	O
in	O
Southern	O
Germany	O
.	O

Tick	O
-	O
transmitted	O
diseases	O
like	O
tick	O
-	O
borne	O
encephalitis	O
and	O
Lyme	O
borreliosis	O
have	O
been	O
well	O
known	O
in	O
Germany	O
for	O
decades	O
.	O

Ongoing	O
research	O
now	O
gives	O
an	O
additional	O
focus	O
to	O
a	O
broad	O
range	O
of	O
other	O
bacteria	O
and	O
parasites	O
in	O
ticks	O
like	O
Anaplasma	O
phagocytophilum	O
,	O
former	O
Ehrlichia	O
sp.	O
,	O
Rickettsia	O
sp.	O
and	O
Babesia	O
sp.	O
Knowledge	O
about	O
the	O
prevalence	O
of	O
these	O
infectious	O
agents	O
in	O
ticks	O
is	O
an	O
important	O
prerequisite	O
for	O
risk	O
assessment	O
of	O
human	O
diseases	O
.	O

Therefore	O
nymphs	O
and	O
adult	O
Ixodes	O
ricinus	O
ticks	O
were	O
collected	O
and	O
examined	O
for	O
Anaplasma	O
phagocytophilum	O
(	O
n	O
=	O
5424	O
ticks	O
)	O
,	O
Rickettsia	O
sp.	O
(	O
n	O
=	O
1187	O
)	O
,	O
and	O
Babesia	O
sp.	O
(	O
n	O
=	O
3113	O
)	O
.	O

For	O
the	O
detection	O
of	O
Anaplasma	O
phagocytophilum	O
,	O
DNA	O
from	O
the	O
16S	O
rDNA	O
gene	O
was	O
amplified	O
by	O
nested	O
PCR	O
and	O
hybridized	O
with	O
a	O
DIG	O
-	O
labeled	O
oligonucleotide	O
probe	O
.	O

The	O
examination	O
of	O
Rickettsia	O
sp.	O
was	O
performed	O
by	O
single	O
PCR	O
.	O

A	O
partial	O
sequence	O
of	O
the	O
citrate	B
synthase	I
gene	O
was	O
amplified	O
.	O

As	O
a	O
target	O
for	O
the	O
detection	O
of	O
Babesia	O
sp.	O
,	O
DNA	O
from	O
the	O
18S	O
rDNA	O
gene	O
was	O
amplified	O
,	O
also	O
by	O
single	O
PCR	O
.	O

All	O
positive	O
PCR	O
products	O
were	O
sequenced	O
to	O
control	O
specificity	O
.	O

Anaplasma	O
phagocytophilum	O
was	O
detected	O
by	O
PCR	O
in	O
n	O
=	O
103	O
(	O
1.9	O
%	O
)	O
out	O
of	O
5,424	O
examined	O
ticks	O
from	O
11	O
investigation	O
areas	O
.	O

However	O
,	O
not	O
all	O
positive	O
PCR	O
products	O
hybridized	O
using	O
DIG	O
-	O
labeled	O
oligonucleotide	O
probe	O
.	O

Thus	O
,	O
the	O
result	O
of	O
sequencing	O
indicated	O
that	O
only	O
1.0	O
%	O
(	O
n	O
=	O
54	O
)	O
belonged	O
to	O
Anaplasma	O
phagocytophilum	O
and	O
nearly	O
half	O
of	O
these	O
PCR	O
products	O
(	O
0.9	O
%	O
)	O
were	O
identified	O
as	O
Wolbachia	O
sp.	O
Rickettsia	O
sp.	O
in	O
Ixodes	O
ricinus	O
ticks	O
from	O
3	O
areas	O
were	O
found	O
in	O
n	O
=	O
105	O
(	O
8.9	O
%	O
)	O
out	O
of	O
1,187	O
ticks	O
examined	O
(	O
range	O
from	O
13.3	O
%	O
to	O
5.6	O
%	O
)	O
.	O

Sequencing	O
showed	O
Rickettsia	O
helvetica	O
exclusively	O
.	O

In	O
about	O
2.6	O
%	O
of	O
Rickettsia	O
-	O
positive	O
ticks	O
,	O
double	O
infection	O
with	O
Anaplasma	O
phagocytophilum	O
was	O
found	O
.	O

Babesia	O
sp.	O
was	O
detected	O
in	O
n	O
=	O
31	O
(	O
1.0	O
%	O
)	O
out	O
of	O
3,113	O
ticks	O
examined	O
,	O
which	O
originated	O
from	O
4	O
different	O
areas	O
.	O

By	O
sequencing	O
,	O
n	O
=	O
28	O
(	O
90.0	O
%	O
)	O
were	O
identified	O
as	O
Babesia	O
divergens	O
.	O

Three	O
of	O
all	O
Babesia	O
-	O
positive	O
ticks	O
were	O
identified	O
as	O
harboring	O
Babesia	O
microti	O
.	O

The	O
detection	O
of	O
Anaplasma	O
phagocytophilum	O
,	O
Rickettsia	O
sp.	O
and	O
Babesia	O
sp.	O
demonstrates	O
their	O
possible	O
role	O
as	O
a	O
source	O
of	O
human	O
infection	O
in	O
Germany	O
.	O

The	O
role	O
of	O
human	O
mast	O
cell	O
-	O
derived	O
cytokines	B
in	O
eosinophil	O
biology	O
.	O

Eosinophil	O
-	O
mediated	O
diseases	O
,	O
such	O
as	O
allergic	O
asthma	O
,	O
eosinophilic	O
fasciitis	O
,	O
and	O
certain	O
hypersensitivity	O
pulmonary	O
disorders	O
,	O
are	O
characterized	O
by	O
eosinophil	O
infiltration	O
and	O
tissue	O
injury	O
.	O

Mast	O
cells	O
and	O
T	O
cells	O
often	O
colocalize	O
to	O
these	O
areas	O
.	O

Recent	O
data	O
suggest	O
that	O
mast	O
cells	O
can	O
contribute	O
to	O
eosinophil	O
-	O
mediated	O
inflammatory	O
responses	O
.	O

Activation	O
of	O
mast	O
cells	O
can	O
occur	O
by	O
antigen	O
and	O
immunoglobulin	B
E	I
(	O
IgE	B
)	O
via	O
the	O
high	B
-	I
affinity	I
receptor	I
(	I
FcepsilonRI	I
)	I
for	I
IgE	I
.	O

The	O
liberation	O
of	O
proteases	O
,	O
leukotrienes	O
,	O
lipid	O
mediators	O
,	O
and	O
histamine	O
can	O
contribute	O
to	O
tissue	O
inflammation	O
and	O
allow	O
recruitment	O
of	O
eosinophils	O
to	O
tissue	O
.	O

In	O
addition	O
,	O
the	O
synthesis	O
and	O
expression	O
of	O
a	O
plethora	O
of	O
cytokines	B
and	O
chemokines	B
(	O
such	O
as	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
[	O
GM	B
-	I
CSF	I
]	O
,	O
interleukin-1	B
[	O
IL-1	B
]	O
,	O
IL-3	B
,	O
IL-5	B
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
[	O
TNF	B
-	I
alpha	I
]	O
,	O
and	O
the	O
chemokines	B
IL-8	B
,	O
regulated	B
upon	I
activation	I
normal	I
T	I
cell	I
expressed	I
and	I
secreted	I
[	O
RANTES	B
]	O
,	O
monocyte	B
chemotactic	I
protein-1	I
[	O
MCP-1	B
]	O
,	O
and	O
eotaxin	B
)	O
by	O
mast	O
cells	O
can	O
influence	O
eosinophil	O
biology	O
.	O

Stem	B
cell	I
factor	I
(	O
SCF	B
)	O
-	O
c	B
-	I
kit	I
,	O
cytokine	B
-	O
cytokine	B
receptor	I
,	O
and	O
chemokine	B
-	O
chemokine	B
receptor	I
(	O
CCR3	B
)	O
interactions	O
leading	O
to	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
expression	O
,	O
and	O
other	O
signaling	O
pathways	O
can	O
modulate	O
eosinophil	O
function	O
.	O

Eosinophil	O
hematopoiesis	O
,	O
activation	O
,	O
survival	O
,	O
and	O
elaboration	O
of	O
mediators	O
can	O
all	O
be	O
regulated	O
thus	O
by	O
mast	O
cells	O
in	O
tissue	O
.	O

Moreover	O
,	O
because	O
eosinophils	O
can	O
secrete	O
SCF	B
,	O
eosinophils	O
can	O
regulate	O
mast	O
cell	O
function	O
in	O
a	O
paracrine	O
manner	O
.	O

This	O
two	O
-	O
way	O
interaction	O
between	O
eosinophils	O
and	O
mast	O
cells	O
can	O
pave	O
the	O
way	O
for	O
chronic	O
inflammatory	O
responses	O
in	O
a	O
variety	O
of	O
human	O
diseases	O
.	O

This	O
review	O
summarizes	O
this	O
pivotal	O
interaction	O
between	O
human	O
mast	O
cells	O
and	O
eosinophils	O
.	O

Comparative	O
genomic	O
analysis	O
,	O
diversity	O
and	O
evolution	O
of	O
two	O
KIR	B
haplotypes	O
A	O
and	O
B	O
.	O

Members	O
of	O
the	O
killer	B
immunoglobulin	I
(	I
Ig	I
)	I
-	I
like	I
receptor	I
(	I
KIR	I
)	I
gene	I
family	I
are	O
tightly	O
clustered	O
on	O
human	O
chromosome	O
19q13.4	O
.	O

Despite	O
considerable	O
variation	O
in	O
KIR	B
gene	O
content	O
and	O
allelic	O
polymorphism	O
,	O
most	O
KIR	B
haplotypes	O
belong	O
to	O
one	O
of	O
two	O
broad	O
groups	O
termed	O
A	O
and	O
B	O
.	O

The	O
availability	O
of	O
contiguous	O
genomic	O
sequences	O
for	O
these	O
haplotypes	O
has	O
allowed	O
us	O
to	O
compare	O
their	O
genomic	O
organization	O
,	O
nucleotide	O
(	O
nt	O
)	O
diversity	O
and	O
reconstruct	O
their	O
evolutionary	O
history	O
.	O

The	O
haplotypes	O
have	O
a	O
framework	O
of	O
three	O
conserved	O
blocks	O
containing	O
(	O
i	O
)	O
KIR3DL3	B
,	O
(	O
ii	O
)	O
KIR3DP1	B
,	O
2DL4	B
,	O
and	O
(	O
iii	O
)	O
KIR3DL2	B
that	O
are	O
interrupted	O
by	O
two	O
variable	O
segments	O
that	O
differ	O
in	O
the	O
number	O
and	O
type	O
of	O
KIR	B
genes	O
.	O

Low	O
(	O
0.05	O
%	O
)	O
nucleotide	O
diversity	O
was	O
detected	O
across	O
the	O
centromeric	O
and	O
telomeric	O
boundaries	O
of	O
the	O
KIR	B
gene	O
cluster	O
while	O
higher	O
SNP	O
density	O
(	O
0.2	O
%	O
)	O
occurred	O
within	O
the	O
central	O
region	O
containing	O
the	O
KIR2DL4	B
gene	O
.	O

Phylogenetic	O
and	O
genomic	O
analyses	O
have	O
permitted	O
the	O
reconstruction	O
of	O
a	O
hypothetical	O
ancestral	O
haplotype	O
that	O
has	O
revealed	O
common	O
groupings	O
and	O
differences	O
between	O
the	O
KIR	B
genes	O
of	O
the	O
two	O
haplotypes	O
.	O

The	O
present	O
phylogenetic	O
and	O
genomic	O
comparison	O
of	O
the	O
two	O
sequenced	O
KIR	B
haplotypes	O
provides	O
a	O
framework	O
for	O
a	O
more	O
thorough	O
examination	O
of	O
KIR	B
haplotype	O
variations	O
,	O
diversity	O
and	O
evolution	O
in	O
human	O
populations	O
and	O
between	O
humans	O
and	O
non	O
-	O
human	O
primates	O
.	O

The	O
interaction	O
of	O
Bex	B
and	O
OMP	B
reveals	O
a	O
dimer	O
of	O
OMP	B
with	O
a	O
short	O
half	O
-	O
life	O
.	O

Olfactory	B
marker	I
protein	I
(	O
OMP	B
)	O
participates	O
in	O
the	O
olfactory	O
signal	O
transduction	O
pathway	O
.	O

This	O
is	O
evident	O
from	O
the	O
behavioral	O
and	O
electrophysiological	O
deficits	O
of	O
OMP	B
-	O
null	O
mice	O
,	O
which	O
can	O
be	O
reversed	O
by	O
intranasal	O
infection	O
of	O
olfactory	O
sensory	O
neurons	O
with	O
an	O
OMP	B
-	O
expressing	O
adenovirus	O
.	O

Bex	B
,	O
brain	B
expressed	I
X	I
-	I
linked	I
protein	I
,	O
has	O
been	O
identified	O
as	O
a	O
protein	O
that	O
interacts	O
with	O
OMP	B
.	O

We	O
have	O
now	O
further	O
characterized	O
the	O
interaction	O
of	O
OMP	B
and	O
Bex1	B
/	I
2	I
by	O
in	O
vitro	O
binding	O
assays	O
and	O
by	O
immuno	O
-	O
coprecipitation	O
experiments	O
.	O

OMP	B
is	O
a	O
19	O
kDa	O
protein	O
but	O
these	O
immunoprecipitation	O
studies	O
have	O
revealed	O
the	O
unexpected	O
presence	O
of	O
a	O
38	O
kDa	O
band	O
in	O
addition	O
to	O
the	O
expected	O
19	O
kDa	O
band	O
.	O

Furthermore	O
,	O
the	O
38	O
kDa	O
form	O
was	O
preferentially	O
co	O
-	O
immunoprecipitated	O
with	O
Bex	B
from	O
cell	O
extracts	O
.	O

In	O
-	O
gel	O
tryptic	O
digestion	O
,	O
mass	O
spectrometry	O
,	O
and	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
indicate	O
that	O
the	O
38	O
kDa	O
protein	O
behaves	O
as	O
a	O
covalently	O
cross	O
-	O
linked	O
OMP	B
-	O
homodimer	O
.	O

The	O
38	O
kDa	O
band	O
was	O
also	O
identified	O
in	O
western	O
blots	O
of	O
olfactory	O
epithelium	O
demonstrating	O
its	O
presence	O
in	O
vivo	O
.	O

The	O
stabilities	O
and	O
subcellular	O
localizations	O
of	O
the	O
OMP	B
-	O
monomer	O
and	O
-	O
dimer	O
were	O
studied	O
in	O
transfected	O
cells	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
OMP	B
-	O
dimer	O
is	O
much	O
less	O
stable	O
than	O
the	O
monomer	O
,	O
and	O
that	O
while	O
the	O
monomer	O
is	O
present	O
both	O
in	O
the	O
nuclear	O
and	O
cytosolic	O
compartments	O
,	O
the	O
dimer	O
is	O
preferentially	O
located	O
in	O
a	O
Triton	O
X-100	O
insoluble	O
cytoskeletal	O
fraction	O
.	O

These	O
novel	O
observations	O
led	O
us	O
to	O
hypothesize	O
that	O
regulation	O
of	O
the	O
level	O
of	O
the	O
rapidly	O
turning	O
-	O
over	O
OMP	B
-	O
dimer	O
and	O
its	O
interaction	O
with	O
Bex1	B
/	I
2	I
is	O
critical	O
for	O
OMP	B
function	O
in	O
sensory	O
transduction	O
.	O

Role	O
of	O
cytokine	B
gene	O
polymorphism	O
and	O
hepatic	O
transforming	B
growth	I
factor	I
beta1	I
expression	O
in	O
recurrent	O
hepatitis	O
C	O
after	O
liver	O
transplantation	O
.	O

Recurrent	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLT	O
)	O
is	O
nearly	O
universal	O
.	O

Cytokines	B
play	O
an	O
important	O
role	O
in	O
the	O
immune	O
response	O
to	O
viral	O
infection	O
,	O
and	O
cytokine	B
gene	O
polymorphism	O
affects	O
the	O
overall	O
expression	O
and	O
secretion	O
of	O
cytokines	B
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
define	O
the	O
relationship	O
between	O
cytokine	B
polymorphism	O
and	O
recurrent	O
hepatitis	O
C	O
after	O
OLT	O
.	O

Blood	O
samples	O
were	O
collected	O
from	O
36	O
patients	O
at	O
a	O
mean	O
of	O
44.6	O
+	O
/-	O
30.4	O
months	O
after	O
OLT	O
for	O
chronic	O
HCV	O
infection	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
and	O
polymerase	O
chain	O
reaction	O
-	O
sequence	O
specific	O
primers	O
(	O
PCR	O
-	O
SSP	O
)	O
analysis	O
was	O
performed	O
on	O
promoter	O
sequences	O
of	O
transforming	B
growth	I
factor	I
beta1	I
(	O
TGF	B
-	I
beta1	I
)	O
,	O
interleukin	B
6	I
(	O
IL-6	B
)	O
interleukin	B
10	I
(	O
IL-10	B
)	O
,	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
interferon	B
gamma	I
(	O
INF	B
-	I
gamma	I
)	O
.	O

Liver	O
biopsies	O
performed	O
at	O
diagnosis	O
of	O
recurrent	O
disease	O
were	O
graded	O
with	O
the	O
Knodell	O
score	O
,	O
and	O
hepatic	O
TGF	B
-	I
beta1	I
expression	O
was	O
determined	O
semiquantitatively	O
by	O
immunohistochemistry	O
.	O

The	O
gene	O
polymorphism	O
of	O
TGF	B
-	I
beta1	I
was	O
correlated	O
with	O
its	O
expression	O
on	O
hepatocytes	O
and	O
sinusoids	O
.	O

Polymorphism	O
in	O
all	O
studied	O
cytokine	B
genes	O
was	O
correlated	O
with	O
recurrence	O
,	O
and	O
interval	O
to	O
recurrence	O
(	O
>	O
12	O
or	O
<	O
or	O
=	O
12	O
months	O
post	O
-	O
OLT	O
)	O
,	O
and	O
clinical	O
(	O
ascites	O
,	O
Child	O
-	O
Pugh	O
score	O
and	O
death	O
)	O
,	O
biochemical	O
parameters	O
of	O
recurrent	O
HCV	O
(	O
serum	B
alanine	I
aminotransferase	I
(	O
ALT	B
)	O
)	O
,	O
INR	O
,	O
albumin	B
,	O
bilirubin	O
)	O
,	O
and	O
virological	O
parameters	O
(	O
HCV	O
genotype	O
and	O
load	O
)	O
.	O

Biopsies	O
revealed	O
recurrent	O
HCV	O
in	O
31	O
patients	O
(	O
86.1	O
%	O
)	O
;	O
in	O
21	O
(	O
67.7	O
%	O
)	O
,	O
the	O
interval	O
to	O
recurrence	O
was	O
12	O
months	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
correlation	O
between	O
TGF	B
-	I
beta1	I
gene	O
polymorphism	O
,	O
i.e.	O
,	O
the	O
genetic	O
ability	O
to	O
produce	O
high	O
levels	O
of	O
TGF	B
-	I
beta1	I
,	O
and	O
the	O
intensity	O
of	O
TGF	B
-	I
beta1	I
staining	O
on	O
hepatocytes	O
(	O
p	O
=	O
0.003	O
)	O
and	O
sinusoids	O
(	O
p	O
=	O
0.003	O
)	O
,	O
and	O
the	O
degree	O
of	O
fibrosis	O
(	O
p	O
=	O
0.02	O
)	O
.	O

A	O
borderline	O
correlation	O
was	O
found	O
with	O
the	O
presence	O
of	O
ascites	O
(	O
p	O
=	O
0.007	O
)	O
,	O
but	O
not	O
with	O
Child	O
-	O
Pugh	O
score	O
,	O
synthetic	O
liver	O
function	O
tests	O
or	O
HCV	O
genotype	O
and	O
load	O
.	O

The	O
genetic	O
ability	O
to	O
produce	O
low	O
levels	O
of	O
IFN	B
-	I
gamma	I
was	O
correlated	O
with	O
recurrent	O
disease	O
(	O
p	O
=	O
0.015	O
)	O
.	O

No	O
such	O
correlation	O
was	O
found	O
for	O
TGF	B
-	I
beta1	I
gene	O
polymorphism	O
.	O

In	O
conclusion	O
,	O
polymorphism	O
in	O
the	O
TGF	B
-	I
beta1	I
gene	O
correlates	O
with	O
its	O
in	O
situ	O
hepatic	O
expression	O
in	O
patients	O
with	O
recurrent	O
HCV	O
after	O
liver	O
transplantation	O
.	O

INF	B
-	I
gamma	I
,	O
but	O
not	O
TGF	B
-	I
beta1	I
gene	O
polymorphism	O
,	O
correlates	O
with	O
early	O
recurrent	O
hepatitis	O
C	O
after	O
transplantation	O
.	O

These	O
findings	O
might	O
help	O
to	O
design	O
preemptive	O
prevention	O
therapy	O
in	O
selected	O
patients	O
at	O
risk	O
.	O

Interleukin-8	B
production	O
by	O
THP-1	O
cells	O
stimulated	O
by	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
porins	O
is	O
mediated	O
by	O
AP-1	B
,	O
NF	B
-	I
kappaB	I
and	O
MAPK	B
pathways	O
.	O

Interleukin-8	B
(	O
IL-8	B
)	O
is	O
released	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
such	O
as	O
bacterial	O
products	O
.	O

Either	O
porins	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulated	O
THP-1	O
cells	O
to	O
release	O
IL-8	B
after	O
24	O
h	O
.	O

We	O
have	O
previously	O
reported	O
that	O
stimulation	O
of	O
monocytic	O
cells	O
with	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
porins	O
led	O
to	O
the	O
activation	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
cascades	O
and	O
of	O
protein	B
tyrosine	I
kinases	I
(	O
PTKs	B
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
,	O
using	O
two	O
potent	O
and	O
selective	O
inhibitors	O
of	O
MEK	B
activation	O
by	O
Raf-1	B
(	O
PD-098059	O
)	O
and	O
p38	B
(	O
SB-203580	O
)	O
,	O
that	O
both	O
ERK1	B
/	I
2	I
and	O
p38	B
pathways	O
play	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
IL-8	B
by	O
porins	O
and	O
LPS	O
.	O

Porin	O
-	O
stimulated	O
expression	O
of	O
activating	B
protein	I
1	I
(	O
AP-1	B
)	O
and	O
correlated	O
IL-8	B
release	O
is	O
also	O
inhibited	O
by	O
PD-098059	O
or	O
SB-203580	O
indicating	O
that	O
the	O
Raf-1	B
/	O
MEK1	B
-	O
MEK2	B
/	O
MAPK	B
cascade	O
is	O
required	O
for	O
their	O
activation	O
.	O

Also	O
PTKs	B
modulate	O
the	O
pathway	O
that	O
control	O
IL-8	B
gene	O
expression	O
,	O
in	O
fact	O
its	O
expression	O
is	O
abolished	O
by	O
tyrphostin	O
.	O

By	O
using	O
N	O
-	O
acetyl	O
-	O
leucinyl	O
-	O
leucinyl	O
-	O
norleucinal	O
-	O
H	O
(	O
ALLN	O
)	O
an	O
inhibitor	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
activity	O
,	O
we	O
also	O
observed	O
IL-8	B
release	O
modulation	O
.	O

Our	O
results	O
elucidate	O
some	O
of	O
the	O
molecular	O
mechanisms	O
by	O
which	O
AP-1	B
and	O
NF	B
-	I
kappaB	I
regulate	O
IL-8	B
release	O
and	O
open	O
new	O
strategies	O
for	O
the	O
design	O
of	O
specific	O
molecules	O
that	O
will	O
modulate	O
IL-8	B
effects	O
in	O
various	O
infectious	O
diseases	O
.	O

Amyloid	B
beta	I
prevents	O
activation	O
of	O
calcium	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
II	I
and	O
AMPA	B
receptor	I
phosphorylation	O
during	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
.	O

Accumulation	O
of	O
amyloid	B
beta	I
-	I
peptides	I
(	O
Abeta	B
)	O
in	O
the	O
brain	O
has	O
been	O
linked	O
with	O
memory	O
loss	O
in	O
Alzheimer	O
'	O
s	O
disease	O
and	O
its	O
animal	O
models	O
.	O

However	O
,	O
the	O
synaptic	O
mechanism	O
by	O
which	O
Abeta	B
causes	O
memory	O
deficits	O
remains	O
unclear	O
.	O

We	O
previously	O
showed	O
that	O
acute	O
application	O
of	O
Abeta	B
inhibited	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
hippocampal	O
perforant	O
path	O
via	O
activation	O
of	O
calcineurin	B
,	O
a	O
Ca2	O
+	O
-	O
dependent	O
protein	B
phosphatase	I
.	O

This	O
study	O
examined	O
whether	O
Abeta	B
could	O
also	O
inhibit	O
Ca2	B
+	I
/	I
calmodulin	I
dependent	I
protein	I
kinase	I
II	I
(	O
CaMKII	B
)	O
,	O
further	O
disrupting	O
the	O
dynamic	O
balance	O
between	O
protein	B
kinase	I
and	I
phosphatase	I
during	O
synaptic	O
plasticity	O
.	O

Immunoblot	O
analysis	O
was	O
conducted	O
to	O
measure	O
autophosphorylation	O
of	O
CaMKII	B
at	O
Thr286	O
and	O
phosphorylation	O
of	O
the	O
GluR1	B
subunit	O
of	O
AMPA	B
receptors	I
in	O
single	O
rat	O
hippocampal	O
slices	O
.	O

A	O
high	O
-	O
frequency	O
tetanus	O
applied	O
to	O
the	O
perforant	O
path	O
significantly	O
increased	O
CaMKII	B
autophosphorylation	O
and	O
subsequent	O
phosphorylation	O
of	O
GluR1	B
at	O
Ser831	O
,	O
a	O
CaMKII	B
-	O
dependent	O
site	O
,	O
in	O
the	O
dentate	O
area	O
.	O

Acute	O
application	O
of	O
Abeta1	B
-	I
42	I
inhibited	O
dentate	O
LTP	O
and	O
associated	O
phosphorylation	O
processes	O
,	O
but	O
was	O
without	O
effect	O
on	O
phosphorylation	O
of	O
GluR1	B
at	O
Ser845	O
,	O
a	O
protein	B
kinase	I
A	I
-	O
dependent	O
site	O
.	O

These	O
results	O
suggest	O
that	O
activity	O
-	O
dependent	O
CaMKII	B
autophosphorylation	O
and	O
AMPA	B
receptor	I
phosphorylation	O
are	O
essential	O
for	O
dentate	O
LTP	O
.	O

Disruption	O
of	O
such	O
mechanisms	O
could	O
directly	O
contribute	O
to	O
Abeta	B
-	O
induced	O
deficits	O
in	O
hippocampal	O
synaptic	O
plasticity	O
and	O
memory	O
.	O

The	O
role	O
of	O
angiotensin	B
-	I
converting	I
enzyme	I
and	O
apolipoprotein	B
-	I
E	I
gene	O
polymorphisms	O
on	O
lipid	O
compositions	O
in	O
newborn	O
infants	O
with	O
intrauterine	O
growth	O
restriction	O
.	O

Recent	O
findings	O
suggest	O
that	O
hypertension	O
,	O
dyslipidemia	O
,	O
diabetes	O
mellitus	O
,	O
coronary	O
heart	O
disease	O
are	O
more	O
common	O
in	O
adults	O
who	O
born	O
with	O
intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
polymorphisms	O
in	O
angiotensin	B
-	I
converting	I
enzyme	I
(	O
ACE	B
)	O
and	O
apolipoprotein	B
-	I
E	I
(	O
Apo	B
-	I
E	I
)	O
are	O
effective	O
in	O
developing	O
the	O
insulin	B
resistance	O
and	O
also	O
in	O
increasing	O
the	O
risk	O
of	O
coronary	O
heart	O
disease	O
.	O

In	O
present	O
study	O
,	O
the	O
frequencies	O
of	O
ACE	B
,	O
Apo	B
-	I
E	I
gene	O
polymorphisms	O
,	O
apolipoprotein	B
-	I
B	I
(	O
Apo	B
-	I
B	I
)	O
mutation	O
and	O
lipid	O
compositions	O
were	O
determined	O
in	O
full	O
-	O
term	O
newborn	O
infants	O
with	O
IUGR	O
.	O

Forty	O
-	O
four	O
newborn	O
infants	O
who	O
had	O
completed	O
36	O
weeks	O
of	O
gestational	O
age	O
,	O
24	O
healthy	O
infants	O
and	O
20	O
with	O
IUGR	O
,	O
were	O
taken	O
into	O
the	O
scope	O
of	O
the	O
study	O
.	O

While	O
total	O
cholesterol	O
(	O
TC	O
)	O
and	O
Apo	B
-	I
B	I
concentrations	O
in	O
infants	O
with	O
IUGR	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
p	O
<	O
0.05	O
)	O
,	O
triglyceride	O
(	O
TG	O
)	O
,	O
low	B
-	I
density	I
lipoproteins	I
(	O
LDL	B
)	O
,	O
high	B
-	I
density	I
lipoproteins	I
(	O
HDL	B
)	O
and	O
Apo	B
-	I
A1	I
levels	O
were	O
similar	O
(	O
p	O
>	O
0.05	O
)	O
.	O

An	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
with	O
a	O
significantly	O
increased	O
frequency	O
was	O
observed	O
in	O
the	O
IUGR	O
group	O
(	O
65	O
%	O
)	O
as	O
compared	O
with	O
the	O
control	O
group	O
(	O
33	O
%	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

When	O
the	O
distribution	O
of	O
the	O
Apo	B
-	I
E	I
gene	O
polymorphism	O
(	O
E2	O
,	O
E3	O
and	O
E4	O
)	O
was	O
studied	O
,	O
no	O
difference	O
was	O
found	O
between	O
the	O
IUGR	O
and	O
control	O
groups	O
with	O
respect	O
to	O
frequency	O
.	O

No	O
Apo	B
-	I
B	I
gene	O
mutation	O
was	O
identified	O
in	O
the	O
study	O
groups	O
.	O

In	O
conclusion	O
,	O
we	O
may	O
suggest	O
that	O
I	O
/	O
D	O
polymorphism	O
is	O
responsible	O
,	O
though	O
in	O
part	O
,	O
for	O
the	O
etiology	O
of	O
intrauterine	O
growth	O
restriction	O
.	O

Levels	O
of	O
total	O
cholesterol	O
and	O
Apo	B
-	I
B	I
are	O
elevated	O
in	O
IUGR	O
infants	O
,	O
suggesting	O
a	O
linkage	O
between	O
low	O
birth	O
weight	O
and	O
atherosclerosis	O
.	O

Aquaporins	B
:	O
water	B
channel	I
proteins	O
of	O
the	O
cell	O
membrane	O
.	O

Aquaporins	B
(	O
AQP	B
)	O
are	O
integral	O
membrane	O
proteins	O
that	O
serve	O
as	O
channels	O
in	O
the	O
transfer	O
of	O
water	O
,	O
and	O
in	O
some	O
cases	O
,	O
small	O
solutes	O
across	O
the	O
membrane	O
.	O

They	O
are	O
conserved	O
in	O
bacteria	O
,	O
plants	O
,	O
and	O
animals	O
.	O

Structural	O
analyses	O
of	O
the	O
molecules	O
have	O
revealed	O
the	O
presence	O
of	O
a	O
pore	O
in	O
the	O
center	O
of	O
each	O
aquaporin	B
molecule	O
.	O

In	O
mammalian	O
cells	O
,	O
more	O
than	O
10	O
isoforms	O
(	O
AQP0-AQP10	B
)	O
have	O
been	O
identified	O
so	O
far	O
.	O

They	O
are	O
differentially	O
expressed	O
in	O
many	O
types	O
of	O
cells	O
and	O
tissues	O
in	O
the	O
body	O
.	O

AQP0	B
is	O
abundant	O
in	O
the	O
lens	O
.	O

AQP1	B
is	O
found	O
in	O
the	O
blood	O
vessels	O
,	O
kidney	O
proximal	O
tubules	O
,	O
eye	O
,	O
and	O
ear	O
.	O

AQP2	B
is	O
expressed	O
in	O
the	O
kidney	O
collecting	O
ducts	O
,	O
where	O
it	O
shuttles	O
between	O
the	O
intracellular	O
storage	O
sites	O
and	O
the	O
plasma	O
membrane	O
under	O
the	O
control	O
of	O
antidiuretic	B
hormone	I
(	O
ADH	B
)	O
.	O

Mutations	O
of	O
AQP2	B
result	O
in	O
diabetes	O
insipidus	O
.	O

AQP3	B
is	O
present	O
in	O
the	O
kidney	O
collecting	O
ducts	O
,	O
epidermis	O
,	O
urinary	O
,	O
respiratory	O
,	O
and	O
digestive	O
tracts	O
.	O

AQP3	B
in	O
organs	O
other	O
than	O
the	O
kidney	O
may	O
be	O
involved	O
in	O
the	O
supply	O
of	O
water	O
to	O
them	O
.	O

AQP4	B
is	O
present	O
in	O
the	O
brain	O
astrocytes	O
,	O
eye	O
,	O
ear	O
,	O
skeletal	O
muscle	O
,	O
stomach	O
parietal	O
cells	O
,	O
and	O
kidney	O
collecting	O
ducts	O
.	O

AQP5	B
is	O
in	O
the	O
secretory	O
cells	O
such	O
as	O
salivary	O
,	O
lacrimal	O
,	O
and	O
sweat	O
glands	O
.	O

AQP5	B
is	O
also	O
expressed	O
in	O
the	O
ear	O
and	O
eye	O
.	O

AQP6	B
is	O
localized	O
intracellular	O
vesicles	O
in	O
the	O
kidney	O
collecting	O
duct	O
cells	O
.	O

AQP7	B
is	O
expressed	O
in	O
the	O
adipocytes	O
,	O
testis	O
,	O
and	O
kidney	O
.	O

AQP8	B
is	O
expressed	O
in	O
the	O
kidney	O
,	O
testis	O
,	O
and	O
liver	O
.	O

AQP9	B
is	O
present	O
in	O
the	O
liver	O
and	O
leukocytes	O
.	O

AQP10	B
is	O
expressed	O
in	O
the	O
intestine	O
.	O

The	O
diverse	O
and	O
characteristic	O
distribution	O
of	O
aquaporins	B
in	O
the	O
body	O
suggests	O
their	O
important	O
and	O
specific	O
roles	O
in	O
each	O
organ	O
.	O

Methylprednisolone	O
favourably	O
alters	O
plasma	O
and	O
urinary	O
cytokine	B
homeostasis	O
and	O
subclinical	O
renal	O
injury	O
at	O
cardiac	O
surgery	O
.	O

Whilst	O
elevated	O
urinary	O
transforming	B
growth	I
factor	I
beta-1	I
(	O
TGFbeta	B
)	O
is	O
associated	O
with	O
chronic	O
renal	O
dysfunction	O
its	O
role	O
in	O
acute	O
peri	O
-	O
operative	O
renal	O
dysfunction	O
is	O
unknown	O
.	O

In	O
contrast	O
,	O
peri	O
-	O
operative	O
increases	O
in	O
urinary	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1ra	B
)	O
and	O
TNF	B
soluble	I
receptor-2	I
(	O
TNFsr-2	B
)	O
mirror	O
pro	O
-	O
inflammatory	O
activity	O
in	O
the	O
nephron	O
and	O
correlate	O
with	O
renal	O
complications	O
.	O

Steroids	O
modulate	O
some	O
plasma	O
cytokines	B
(	O
decreasing	O
TNFalpha	B
,	O
IL-8	B
,	O
IL-6	B
and	O
increasing	O
IL-10	B
)	O
,	O
whereas	O
ability	O
to	O
reduce	O
plasma	O
and	O
urinary	O
TNFsr-2	B
and	O
IL-1ra	B
and	O
peri	O
-	O
operative	O
renal	O
injury	O
is	O
unknown	O
.	O

Patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
with	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
were	O
randomised	O
to	O
receive	O
methylprednisolone	O
(	O
n	O
=	O
18	O
)	O
or	O
placebo	O
(	O
n	O
=	O
17	O
)	O
before	O
induction	O
of	O
anaesthesia	O
.	O

Plasma	O
and	O
urinary	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokine	B
balance	O
was	O
determined	O
along	O
with	O
subclinical	O
proximal	O
tubular	O
injury	O
and	O
dysfunction	O
,	O
measured	O
by	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
d	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
/	O
creatinine	O
and	O
alpha-1-microglobulin	O
/	O
creatinine	O
ratios	O
,	O
respectively	O
.	O

In	O
the	O
control	O
group	O
compared	O
with	O
baseline	O
,	O
plasma	O
IL-8	B
,	O
TNFalpha	B
,	O
IL-10	B
,	O
IL-1ra	B
and	O
TNFsr-2	B
were	O
significantly	O
elevated	O
along	O
with	O
urinary	O
IL-1ra	B
,	O
TNFsr-2	B
and	O
TGFbeta1	B
.	O

Urinary	O
NAG	O
/	O
creatinine	O
and	O
alpha-1-microglobulin	B
/	O
creatinine	O
ratios	O
rose	O
from	O
completion	O
of	O
revascularisation	O
until	O
6	O
h	O
with	O
recovery	O
at	O
24	O
h	O
with	O
a	O
further	O
rise	O
in	O
NAG	O
/	O
creatinine	O
ratio	O
at	O
48	O
h	O
.	O

Compared	O
to	O
placebo	O
,	O
the	O
methylprednisolone	O
group	O
showed	O
significantly	O
reduced	O
plasma	O
IL-8	B
,	O
TNFalpha	B
,	O
IL-1ra	B
and	O
TNFsr-2	B
whereas	O
plasma	O
IL-10	B
increased	O
.	O

Compared	O
to	O
placebo	O
,	O
the	O
methylprednisolone	O
group	O
demonstrated	O
significantly	O
reduced	O
urinary	O
NAG	O
/	O
creatinine	O
ratio	O
,	O
TNFsr-2	B
and	O
TGFbeta1	B
at	O
24	O
h	O
whereas	O
urinary	O
alpha-1-microglobulin	B
/	O
creatinine	O
ratios	O
increased	O
.	O

CONCLUSIONS	O
:	O

Methylprednisolone	O
administration	O
during	O
cardiac	O
surgery	O
significantly	O
reduces	O
plasma	O
and	O
urinary	O
TNFsr-2	B
and	O
IL-1ra	B
,	O
urinary	O
TGFbeta1	B
and	O
subclinical	O
renal	O
injury	O
but	O
not	O
dysfunction	O
.	O

Genetic	O
polymorphism	O
of	O
NK	O
receptors	O
and	O
their	O
ligands	O
in	O
melanoma	O
patients	O
:	O
prevalence	O
of	O
inhibitory	O
over	O
activating	O
signals	O
.	O

Antitumor	O
cytotoxicity	O
of	O
NK	O
cells	O
and	O
T	O
cells	O
expressing	O
NK	O
-	O
associated	O
receptors	O
is	O
regulated	O
by	O
interaction	O
between	O
their	O
cell	O
surface	O
killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
and	O
CD94	B
/	O
NKG2	B
heterodimers	O
with	O
MHC	B
class	I
I	I
ligands	O
on	O
target	O
cells	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
KIR	B
and/or	O
HLA	B
polymorphisms	O
,	O
and	O
KIR	B
/	O
HLA	B
combinations	O
could	O
contribute	O
to	O
the	O
tumorigenesis	O
,	O
association	O
studies	O
were	O
performed	O
in	O
50	O
patients	O
with	O
malignant	O
melanoma	O
(	O
MM	O
)	O
in	O
different	O
stages	O
of	O
disease	O
and	O
54	O
controls	O
.	O

Our	O
data	O
showed	O
that	O
the	O
frequency	O
of	O
inhibitory	O
and	O
activating	O
KIR	B
genes	O
and	O
KIR	B
genotypes	O
did	O
not	O
differ	O
significantly	O
between	O
healthy	O
individuals	O
and	O
melanoma	O
patients	O
.	O

HLA	B
haplotype	O
distribution	O
showed	O
statistically	O
significant	O
increased	O
frequencies	O
of	O
A*01-B*35	O
-	O
Cw*04	O
(	O
0.069	O
vs	O
0.000	O
;	O
pc	O
<	O
0.05	O
;	O
OR	O
=	O
19.9	O
)	O
,	O
A*01-B*08	O
-	O
DRB1	B
*	I
03	I
(	O
0.079	O
vs	O
0.019	O
;	O
pc	O
<	O
0.05	O
;	O
OR	O
=	O
4.5	O
)	O
,	O
and	O
A*24	O
-	O
B*40	O
-	O
DRB1	B
*	I
11	I
(	O
0.026	O
vs	O
0.000	O
;	O
pc	O
<	O
0.05	O
;	O
OR	O
=	O
7.1	O
)	O
in	O
melanoma	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

Individuals	O
homozygous	O
for	O
group	O
2	O
HLA	B
-	I
C	I
ligands	O
were	O
less	O
frequent	O
in	O
the	O
patient	O
group	O
compared	O
with	O
the	O
control	O
cohort	O
(	O
12	O
%	O
vs	O
31.5	O
%	O
;	O
p	O
<	O
0.017	O
)	O
.	O

In	O
addition	O
,	O
we	O
observed	O
an	O
increased	O
frequency	O
(	O
88.0	O
%	O
vs	O
68.5	O
%	O
;	O
p	O
=	O
0.017	O
;	O
OR	O
=	O
2.80	O
)	O
of	O
KIR2DL2	B
/	O
2DL3	B
in	O
combination	O
with	O
their	O
group	O
1	O
HLA	B
-	I
C	I
ligands	O
,	O
while	O
the	O
presence	O
of	O
these	O
KIRs	B
in	O
the	O
absence	O
of	O
the	O
putative	O
ligands	O
was	O
decreased	O
(	O
12.0	O
%	O
vs	O
31.5	O
%	O
;	O
p	O
=	O
0.017	O
)	O
in	O
the	O
patient	O
group	O
.	O

Furthermore	O
,	O
an	O
increased	O
frequency	O
of	O
activating	O
KIR2DS1	B
in	O
the	O
absence	O
of	O
the	O
putative	O
HLA	B
-	I
C	I
(	O
Lys80	O
)	O
ligands	O
was	O
found	O
in	O
melanoma	O
patients	O
(	O
16.0	O
%	O
vs	O
9.2	O
%	O
)	O
.	O

In	O
contrast	O
,	O
KIR2DS2	B
was	O
absent	O
in	O
patients	O
more	O
often	O
(	O
38.0	O
%	O
vs	O
25.9	O
%	O
)	O
when	O
the	O
presumptive	O
HLA	B
-	I
C	I
(	O
Asn80	O
)	O
ligands	O
were	O
present	O
.	O

A	O
slightly	O
higher	O
incidence	O
of	O
KIR3DL1	B
in	O
combination	O
with	O
the	O
less	O
effective	O
Bw4	B
(	O
Thr80	O
)	O
ligands	O
was	O
seen	O
in	O
patients	O
with	O
primary	O
(	O
20.8	O
%	O
)	O
compared	O
with	O
metastatic	O
(	O
4.2	O
%	O
)	O
disease	O
.	O

The	O
data	O
obtained	O
in	O
this	O
study	O
imply	O
that	O
there	O
may	O
not	O
be	O
a	O
direct	O
association	O
between	O
KIR	B
gene	O
content	O
in	O
the	O
genome	O
and	O
the	O
presence	O
of	O
malignant	O
melanoma	O
,	O
or	O
melanoma	O
progression	O
.	O

However	O
,	O
some	O
HLA	B
haplotypes	O
could	O
be	O
predisposing	O
to	O
MM	O
in	O
the	O
Bulgarian	O
population	O
.	O

Furthermore	O
,	O
distinct	O
KIR	B
/	O
HLA	B
ligand	O
combinations	O
may	O
be	O
relevant	O
to	O
the	O
development	O
of	O
malignancy	O
whereby	O
inhibition	O
overrides	O
activation	O
of	O
NK	O
cells	O
and	O
T	O
cells	O
expressing	O
NK	O
-	O
associated	O
receptors	O
,	O
which	O
in	O
turn	O
might	O
facilitate	O
tumor	O
escape	O
and	O
progression	O
.	O

Apoptotic	B
speck	I
protein	I
-	I
like	I
,	O
a	O
highly	O
homologous	O
protein	O
to	O
apoptotic	B
speck	I
protein	I
in	O
the	O
pyrin	B
domain	O
,	O
is	O
silenced	O
by	O
DNA	O
methylation	O
and	O
induces	O
apoptosis	O
in	O
human	O
hepatocellular	O
carcinoma	O
.	O

We	O
have	O
identified	O
a	O
novel	O
gene	O
encoding	O
a	O
pyrin	B
domain	O
protein	O
of	O
89	O
amino	O
acids	O
that	O
is	O
expressed	O
in	O
various	O
tissues	O
including	O
liver	O
,	O
brain	O
,	O
and	O
spleen	O
.	O

The	O
protein	O
is	O
highly	O
homologous	O
to	O
the	O
pyrin	B
domain	O
of	O
apoptosis	B
-	I
associated	I
speck	I
-	I
like	I
protein	I
(	O
ASC	B
)	O
.	O

Therefore	O
,	O
we	O
termed	O
it	O
ASC	B
-	I
like	I
(	O
ASCL	B
)	O
.	O

We	O
found	O
that	O
ASCL	B
gene	O
was	O
densely	O
and	O
frequently	O
(	O
80	O
%	O
)	O
methylated	O
in	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
normal	O
liver	O
samples	O
did	O
not	O
show	O
any	O
significant	O
methylation	O
.	O

This	O
aberrant	O
methylation	O
correlated	O
well	O
with	O
the	O
suppression	O
of	O
RNA	O
expression	O
.	O

Furthermore	O
,	O
a	O
demethylating	O
agent	O
,	O
5-aza-2'-deoxycytidine	O
,	O
reactivated	O
the	O
ASCL	B
expression	O
in	O
the	O
methylation	O
-	O
silenced	O
cells	O
,	O
indicating	O
that	O
ASCL	B
is	O
silenced	O
by	O
the	O
associated	O
DNA	O
methylation	O
.	O

ASCL	B
methylation	O
was	O
also	O
found	O
in	O
primary	O
HCC	O
(	O
4	O
of	O
17	O
samples	O
)	O
,	O
although	O
the	O
frequency	O
was	O
less	O
than	O
that	O
in	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
ASC	B
was	O
also	O
methylated	O
in	O
primary	O
samples	O
(	O
6	O
of	O
the	O
17	O
)	O
.	O

Interestingly	O
,	O
either	O
ASCL	B
or	O
ASC	B
methylation	O
was	O
observed	O
in	O
53	O
%	O
(	O
9	O
of	O
the	O
17	O
)	O
of	O
primary	O
HCC	O
samples	O
.	O

Significantly	O
,	O
the	O
restoration	O
of	O
ASCL	B
in	O
the	O
methylation	O
-	O
silenced	O
cells	O
demonstrated	O
growth	O
suppression	O
in	O
colony	O
formation	O
assay	O
.	O

This	O
growth	O
suppression	O
effect	O
of	O
ASCL	B
was	O
supported	O
by	O
apoptotic	O
changes	O
observed	O
in	O
ASCL	B
-	O
transfected	O
cells	O
in	O
which	O
annexin	B
-	I
V	I
binding	O
was	O
positive	O
and	O
caspase-3	B
was	O
activated	O
.	O

Based	O
on	O
the	O
methylation	O
-	O
silencing	O
and	O
the	O
growth	O
suppression	O
activity	O
,	O
we	O
propose	O
that	O
ASCL	B
plays	O
a	O
significant	O
role	O
in	O
the	O
development	O
of	O
HCC	O
.	O

The	O
omptin	B
family	I
of	I
enterobacterial	I
surface	I
proteases	I
/	I
adhesins	I
:	O
from	O
housekeeping	O
in	O
Escherichia	O
coli	O
to	O
systemic	O
spread	O
of	O
Yersinia	O
pestis	O
.	O

The	O
omptins	B
are	O
a	O
family	B
of	I
enterobacterial	I
surface	I
proteases	I
/	I
adhesins	I
that	O
share	O
high	O
sequence	O
identity	O
and	O
a	O
conserved	O
beta	O
-	O
barrel	O
fold	O
in	O
the	O
outer	O
membrane	O
.	O

The	O
omptins	B
are	O
multifunctional	O
,	O
and	O
the	O
individual	O
omptins	B
exhibit	O
differing	O
virulence	O
-	O
associated	O
functions	O
.	O

The	O
Pla	B
plasminogen	I
activator	I
of	O
Yersinia	O
pestis	O
contributes	O
by	O
several	O
mechanisms	O
to	O
bacterial	O
invasiveness	O
and	O
the	O
systemic	O
,	O
uncontrolled	O
proteolysis	O
in	O
plague	O
.	O

Pla	B
proteolytically	O
activates	O
the	O
human	O
proenzyme	O
plasminogen	B
and	O
inactivates	O
the	O
antiprotease	O
alpha2	B
-	I
antiplasmin	I
,	O
and	O
its	O
binding	O
to	O
laminin	B
localizes	O
the	O
uncontrolled	O
plasmin	B
activity	O
onto	O
basement	O
membranes	O
.	O

These	O
properties	O
enhance	O
bacterial	O
migration	O
through	O
tissue	O
barriers	O
.	O

Pla	B
also	O
degrades	O
circulating	O
complement	B
proteins	I
and	O
functions	O
in	O
bacterial	O
invasion	O
into	O
human	O
epithelial	O
cells	O
.	O

PgtE	B
of	O
Salmonella	O
enterica	O
and	O
OmpT	B
of	O
Escherichia	O
coli	O
have	O
been	O
shown	O
to	O
degrade	O
cationic	O
antimicrobial	O
peptides	O
from	O
epithelial	O
cells	O
or	O
macrophages	O
.	O

PgtE	B
and	O
SopA	B
of	O
Shigella	O
flexneri	O
appear	O
important	O
in	O
the	O
intracellular	O
phases	O
of	O
salmonellosis	O
and	O
shigellosis	O
,	O
whereas	O
functions	O
of	O
OmpT	B
have	O
mainly	O
been	O
associated	O
with	O
protein	O
degradation	O
in	O
E.	O
coli	O
cells	O
.	O

The	O
differing	O
virulence	O
roles	O
and	O
functions	O
have	O
been	O
attributed	O
to	O
minor	O
sequence	O
variations	O
at	O
the	O
surface	O
-	O
exposed	O
regions	O
important	O
for	O
substrate	O
recognition	O
,	O
to	O
the	O
dependence	O
of	O
omptin	B
functions	O
on	O
lipopolysaccharide	O
,	O
and	O
to	O
the	O
different	O
regulation	O
of	O
omptin	B
expression	O
.	O

CD40	B
engagement	O
enhances	O
antigen	O
-	O
presenting	O
langerhans	O
cell	O
priming	O
of	O
IFN	B
-	I
gamma	I
-	O
producing	O
CD4	B
+	O
and	O
CD8	B
+	O
T	O
cells	O
independently	O
of	O
IL-12	B
.	O

The	O
delivery	O
of	O
CD40	B
signaling	O
to	O
APCs	O
during	O
T	O
cell	O
priming	O
enhances	O
many	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

Although	O
CD40	B
signaling	O
up	O
-	O
regulates	O
APC	O
production	O
of	O
IL-12	B
,	O
the	O
impact	O
of	O
this	O
increased	O
production	O
on	O
T	O
cell	O
priming	O
is	O
unclear	O
.	O

In	O
this	O
study	O
an	O
IL-12	B
-	O
independent	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
,	O
contact	O
hypersensitivity	O
(	O
CHS	O
)	O
,	O
was	O
used	O
to	O
further	O
investigate	O
the	O
effect	O
of	O
CD40	B
ligation	O
on	O
the	O
phenotypic	O
development	O
of	O
Ag	O
-	O
specific	O
CD4	B
(	O
+	O
)	O
and	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
.	O

Normally	O
,	O
sensitization	O
for	O
CHS	O
responses	O
induces	O
hapten	O
-	O
specific	O
CD4	B
(	O
+	O
)	O
T	O
cells	O
producing	O
type	O
2	O
cytokines	B
and	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
producing	O
IFN	B
-	I
gamma	I
.	O

Treatment	O
of	O
mice	O
with	O
agonist	O
anti	O
-	O
CD40	B
mAb	O
during	O
sensitization	O
with	O
the	O
hapten	O
2,4-dinitrofluorobenzene	O
resulted	O
in	O
CHS	O
responses	O
of	O
increased	O
magnitude	O
and	O
duration	O
.	O

These	O
augmented	O
responses	O
in	O
anti	O
-	O
CD40	B
Ab	O
-	O
treated	O
mice	O
correlated	O
with	O
increased	O
numbers	O
of	O
hapten	O
-	O
specific	O
CD4	B
(	O
+	O
)	O
and	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
producing	O
IFN	B
-	I
gamma	I
in	O
the	O
skin	O
draining	O
lymph	O
nodes	O
.	O

Identical	O
results	O
were	O
observed	O
using	O
IL-12	B
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
indicating	O
that	O
CD40	B
ligation	O
promotes	O
CHS	O
responses	O
and	O
development	O
of	O
IFN	B
-	I
gamma	I
-	O
producing	O
CD4	B
(	O
+	O
)	O
and	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
in	O
the	O
absence	O
of	O
IL-12	B
.	O

Engagement	O
of	O
CD40	B
on	O
hapten	O
-	O
presenting	O
Langerhans	O
cells	O
(	O
hpLC	O
)	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
both	O
class	B
I	I
and	I
class	I
II	I
MHC	I
and	O
promoted	O
hpLC	O
migration	O
into	O
the	O
T	O
cell	O
priming	O
site	O
.	O

These	O
results	O
indicate	O
that	O
hpLC	O
stimulated	O
by	O
CD40	B
ligation	O
use	O
a	O
mechanism	O
distinct	O
from	O
increased	O
IL-12	B
production	O
to	O
promote	O
Ag	O
-	O
specific	O
T	O
cell	O
development	O
to	O
IFN	B
-	I
gamma	I
-	O
producing	O
cells	O
.	O

alpha	B
-	I
thrombin	I
rapidly	O
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
novel	O
,	O
74	O
-	O
78	O
-	O
kDa	O
stress	O
response	O
protein	O
(	O
s	O
)	O
in	O
lung	O
fibroblast	O
cells	O
.	O

We	O
demonstrated	O
previously	O
that	O
exposure	O
of	O
CCL39	O
lung	O
fibroblasts	O
to	O
alpha	B
-	I
thrombin	I
rapidly	O
inhibits	O
interleukin	B
6	I
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
3	I
(	O
Stat3	B
)	O
.	O

While	O
studying	O
the	O
cross	O
-	O
talk	O
between	O
alpha	B
-	I
thrombin	I
and	O
interleukin	B
6	I
,	O
we	O
observed	O
that	O
the	O
phospho	O
-	O
specific	O
(	O
tyrosine	O
)	O
anti	O
-	O
Stat3	B
antibody	O
specifically	O
cross	O
-	O
reacted	O
with	O
a	O
74	O
-	O
78	O
-	O
kDa	O
protein	O
(	O
s	O
)	O
in	O
alpha	B
-	I
thrombin	I
-	O
treated	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
in	O
alpha	B
-	I
thrombin	I
-	O
treated	O
CCL39	O
cells	O
,	O
the	O
74	O
-	O
78	O
-	O
kDa	O
protein	O
(	O
s	O
)	O
rapidly	O
undergoes	O
tyrosine	O
phosphorylation	O
.	O

The	O
phosphorylation	O
by	O
alpha	B
-	I
thrombin	I
was	O
detected	O
as	O
early	O
as	O
5	O
min	O
and	O
reached	O
a	O
maximum	O
at	O
15	O
min	O
;	O
however	O
,	O
low	O
levels	O
were	O
present	O
at	O
2	O
h	O
.	O

alpha	B
-	I
Thrombin	I
receptor	I
agonist	O
peptide	O
(	O
SFLLRN	O
)	O
induced	O
its	O
tyrosine	O
phosphorylation	O
,	O
suggesting	O
that	O
alpha	B
-	I
thrombin	I
mediates	O
the	O
effects	O
via	O
protease	B
-	I
activated	I
receptor	I
type	I
1	I
.	O

Anti	O
-	O
Stat3	B
antibodies	O
specific	O
to	O
different	O
regions	O
of	O
Stat3	B
failed	O
to	O
recognize	O
the	O
74	O
-	O
78-kDa	O
protein	O
(	O
s	O
)	O
,	O
suggesting	O
that	O
it	O
is	O
unrelated	O
to	O
Stat3	B
.	O

Cell	O
fractionation	O
experiments	O
showed	O
that	O
it	O
is	O
localized	O
to	O
the	O
cytoplasm	O
.	O

Mass	O
spectrometric	O
analysis	O
of	O
the	O
immunoprecipitated	O
protein	O
showed	O
that	O
the	O
74	O
-	O
78-kDa	O
protein	O
(	O
s	O
)	O
is	O
related	O
to	O
glucose	B
-	I
regulated	I
protein	I
75	I
(	O
GRP	B
-	I
75	I
)	O
,	O
a	O
member	O
of	O
the	O
heat	B
shock	I
/	I
stress	I
-	I
response	I
protein	I
family	I
.	O

Consistent	O
with	O
these	O
data	O
,	O
we	O
observed	O
tyrosine	O
phosphorylation	O
of	O
GRP	B
-	I
75	I
in	O
alpha	B
-	I
thrombin	I
-	O
treated	O
cells	O
.	O

Exposure	O
of	O
cells	O
to	O
pervanadate	O
,	O
a	O
stress	O
-	O
inducing	O
agent	O
,	O
stimulated	O
its	O
tyrosine	O
phosphorylation	O
;	O
however	O
,	O
cytokines	B
and	O
growth	B
factors	I
were	O
ineffective	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
tyrosine	O
phosphorylation	O
of	O
GRP-75	B
-	O
related	O
stress	O
protein	O
(	O
s	O
)	O
by	O
alpha	B
-	I
thrombin	I
and	O
suggests	O
that	O
this	O
pathway	O
may	O
contribute	O
to	O
the	O
ability	O
of	O
alpha	B
-	I
thrombin	I
to	O
prevent	O
apoptosis	O
in	O
cells	O
exposed	O
to	O
stress	O
or	O
in	O
the	O
injured	O
tissue	O
.	O

Zinc	O
stabilizes	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
protein	O
levels	O
and	O
induces	O
cell	O
cycle	O
arrest	O
in	O
colon	O
cancer	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
mechanisms	O
by	O
which	O
zinc	O
causes	O
growth	O
arrest	O
in	O
colon	O
cancer	O
cells	O
.	O

The	O
results	O
suggest	O
that	O
zinc	O
treatment	O
stabilizes	O
the	O
levels	O
of	O
the	O
wild	O
-	O
type	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
protein	O
at	O
the	O
post	O
-	O
translational	O
level	O
since	O
the	O
APC	B
mRNA	O
levels	O
and	O
the	O
promoter	O
activity	O
of	O
the	O
APC	B
gene	O
were	O
decreased	O
in	O
HCT-116	O
cells	O
(	O
which	O
express	O
the	O
wild	O
-	O
type	O
APC	B
gene	O
)	O
after	O
treatment	O
with	O
ZnCl2	O
.	O

Increased	O
levels	O
of	O
wild	O
-	O
type	O
but	O
not	O
truncated	O
APC	B
proteins	O
were	O
required	O
for	O
the	O
ZnCl2	O
-	O
mediated	O
G2	O
/	O
M	O
phase	O
arrest	O
in	O
different	O
colon	O
cancer	O
cell	O
lines	O
.	O

We	O
further	O
tested	O
whether	O
serum	O
-	O
stimulation	O
,	O
which	O
induces	O
cell	O
cycle	O
arrest	O
in	O
the	O
S	O
phase	O
,	O
can	O
relieve	O
ZnCl2	O
-	O
induced	O
G2	O
/	O
M	O
phase	O
arrest	O
of	O
HCT-116	O
cells	O
.	O

Results	O
showed	O
that	O
in	O
the	O
HCT-116	O
cells	O
pretreated	O
with	O
ZnCl2	O
,	O
the	O
serum	O
-	O
stimulation	O
neither	O
changed	O
the	O
distribution	O
of	O
G2	O
/	O
M	O
phase	O
arrested	O
cells	O
nor	O
the	O
increased	O
levels	O
of	O
APC	B
protein	O
.	O

The	O
G2	O
/	O
M	O
phase	O
arrest	O
correlated	O
with	O
retarded	O
growth	O
of	O
HCT-116	O
cells	O
.	O

To	O
further	O
establish	O
that	O
wild	O
-	O
type	O
APC	B
protein	O
plays	O
a	O
role	O
in	O
ZnCl2	O
-	O
induced	O
G2	O
/	O
M	O
arrest	O
,	O
we	O
treated	O
SW480	O
colon	O
cancer	O
cells	O
that	O
express	O
truncated	O
APC	B
protein	O
.	O

We	O
found	O
that	O
ZnCl2	O
treatment	O
did	O
not	O
induce	O
G2	O
/	O
M	O
phase	O
arrest	O
in	O
SW480	O
cells	O
;	O
however	O
,	O
the	O
cell	O
growth	O
was	O
retarded	O
due	O
to	O
the	O
loss	O
of	O
E	B
-	I
cadherin	I
and	O
alpha	B
-	I
tubulin	I
levels	O
.	O

These	O
results	O
suggest	O
that	O
ZnCl2	O
inhibits	O
the	O
proliferation	O
of	O
colon	O
cancer	O
cells	O
(	O
which	O
carry	O
the	O
wild	O
-	O
type	O
APC	B
gene	O
)	O
through	O
stabilization	O
of	O
the	O
APC	B
protein	O
and	O
cell	O
cycle	O
arrest	O
in	O
the	O
G2	O
/	O
M	O
phase	O
.	O

On	O
the	O
other	O
hand	O
,	O
ZnCl2	O
inhibits	O
the	O
proliferation	O
of	O
colon	O
cancer	O
cells	O
(	O
which	O
carry	O
the	O
mutant	O
APC	B
gene	O
)	O
by	O
disrupting	O
cellular	O
attachment	O
and	O
microtubule	O
stability	O
.	O

Mechanisms	O
of	O
bacillus	O
Calmette	O
-	O
Guerin	O
mediated	O
natural	O
killer	O
cell	O
activation	O
.	O

PURPOSE	O
:	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
are	O
of	O
crucial	O
importance	O
for	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
mediated	O
antitumor	O
effects	O
.	O

We	O
defined	O
the	O
mechanisms	O
of	O
BCG	O
mediated	O
NK	O
cell	O
activation	O
in	O
vitro	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

A	O
standard	O
Cr	O
release	O
assay	O
was	O
used	O
to	O
measure	O
the	O
cytotoxicity	O
of	O
BCG	O
activated	O
NK	O
cells	O
.	O

Using	O
the	O
MACS	O
system	O
(	O
Miltenyi	O
Biotec	O
,	O
Bergisch	O
-	O
Gladbach	O
,	O
Germany	O
)	O
we	O
depleted	O
various	O
immune	O
cell	O
subpopulations	O
from	O
BCG	O
stimulated	O
peripheral	O
blood	O
mononuclear	O
cells	O
to	O
phenotype	O
activated	O
NK	O
cells	O
.	O

During	O
the	O
stimulation	O
process	O
anticytokine	O
antibodies	O
and	O
recombinant	O
cytokines	B
were	O
added	O
to	O
define	O
their	O
role	O
in	O
NK	O
cell	O
activation	O
.	O

For	O
costimulation	O
studies	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
separated	O
into	O
lymphocytes	O
and	O
monocytes	O
by	O
counterflow	O
-	O
centrifugation	O
(	O
elutriation	O
)	O
.	O

Inhibitory	O
NK	O
cell	O
receptor	O
expression	O
on	O
activated	O
NK	O
cells	O
was	O
measured	O
by	O
flow	O
cytometry	O
by	O
antiCD3	B
,	O
antiCD56	B
and	O
anti	O
-	O
inhibitory	O
NK	O
cell	O
receptor	O
triple	O
staining	O
.	O

RESULTS	O
:	O

The	O
accessory	O
function	O
of	O
monocytes	O
was	O
indispensable	O
for	O
BCG	O
mediated	O
NK	O
cell	O
activation	O
.	O

However	O
,	O
the	O
stimulatory	O
potential	O
of	O
monocytes	O
did	O
not	O
require	O
direct	O
cell	O
-	O
cell	O
contact	O
to	O
NK	O
cells	O
or	O
major	B
histocompatibility	I
complex	I
dependent	O
antigen	O
presentation	O
to	O
T	O
cells	O
.	O

Monocyte	O
derived	O
interleukin	B
(	I
IL	I
)	I
-	I
12	I
and	O
to	O
a	O
lesser	O
extent	O
interferon	B
(	I
IFN	I
)	I
-	I
alpha	I
were	O
key	O
mediators	O
for	O
stimulating	O
BCG	O
induced	O
NK	O
cell	O
cytotoxicity	O
and	O
IFN	B
-	I
gamma	I
production	O
.	O

In	O
contrast	O
,	O
IL-10	B
inhibited	O
NK	O
cell	O
cytotoxicity	O
and	O
IL-18	B
did	O
not	O
show	O
any	O
effect	O
.	O

Exogenous	O
recombinant	O
IFN	B
-	I
alpha	I
and	O
IL-12	B
enhanced	O
BCG	O
mediated	O
secretion	O
of	O
IFN	B
-	I
gamma	I
and	O
yet	O
BCG	O
induced	O
NK	O
cell	O
cytotoxicity	O
remained	O
unchanged	O
.	O

While	O
the	O
CD158a	B
and	O
CD158b	B
subsets	O
did	O
not	O
have	O
a	O
significant	O
role	O
,	O
NKG2A	B
cells	O
represented	O
the	O
predominant	O
cytolytic	O
subset	O
in	O
BCG	O
activated	O
NK	O
cells	O
.	O

CONCLUSIONS	O
:	O

Following	O
BCG	O
stimulation	O
the	O
monocyte	O
derived	O
TH1	O
cytokines	B
IL-12	B
and	O
IFN	B
-	I
alpha	I
activate	O
tumor	O
cytotoxic	O
CD3	B
/	O
CD56	B
/	O
NKG2A	B
NK	O
cells	O
.	O

Our	O
results	O
elucidate	O
NK	O
activating	O
mechanisms	O
that	O
are	O
operative	O
during	O
BCG	O
immunotherapy	O
for	O
bladder	O
cancer	O
and	O
are	O
relevant	O
for	O
an	O
early	O
,	O
innate	O
antimycobacterial	O
immune	O
response	O
.	O

Binding	O
of	O
Spo0A	B
stimulates	O
spoIIG	B
promoter	O
activity	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
spoIIG	B
promoter	O
is	O
used	O
by	O
RNA	B
polymerase	I
containing	O
sigma	B
A	I
(	O
E	B
sigma	I
A	I
)	O
,	O
the	O
primary	O
form	O
of	O
RNA	B
polymerase	I
found	O
in	O
vegetative	O
cells	O
in	O
Bacillus	O
subtilis	O
.	O

However	O
,	O
the	O
spoIIG	B
promoter	O
is	O
active	O
only	O
after	O
the	O
onset	O
of	O
sporulation	O
.	O

Activation	O
of	O
the	O
spoIIG	B
promoter	O
requires	O
the	O
product	O
of	O
the	O
spo0A	B
gene	O
(	O
Spo0A	B
)	O
.	O

Spo0A	B
is	O
a	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
which	O
binds	O
to	O
two	O
sites	O
in	O
the	O
spoIIG	B
promoter	O
that	O
are	O
essential	O
for	O
promoter	O
activity	O
.	O

We	O
found	O
that	O
single	O
-	O
base	O
-	O
pair	O
substitutions	O
in	O
these	O
two	O
regions	O
that	O
reduced	O
promoter	O
activity	O
in	O
vivo	O
caused	O
reduced	O
binding	O
of	O
Spo0A	B
in	O
vitro	O
,	O
and	O
one	O
substitution	O
that	O
increased	O
promoter	O
activity	O
in	O
vivo	O
increased	O
the	O
affinity	O
of	O
Spo0A	B
for	O
this	O
DNA	O
in	O
vitro	O
.	O

Furthermore	O
,	O
Spo0A	B
stimulated	O
transcription	O
from	O
the	O
spoIIG	B
promoter	O
by	O
E	B
sigma	I
A	I
in	O
vitro	O
.	O

These	O
results	O
support	O
the	O
model	O
that	O
binding	O
of	O
Spo0A	B
activates	O
E	B
sigma	I
A	I
-	O
dependent	O
transcription	O
from	O
the	O
spoIIG	B
promoter	O
after	O
the	O
onset	O
of	O
sporulation	O
.	O

The	O
synergetic	O
effects	O
of	O
two	O
CCAAT	O
boxes	O
in	O
Aspergillus	O
niger	O
glaA	B
gene	O
promoter	O
on	O
activation	O
of	O
PglaA	B
transcription	O
.	O

EMSA	O
and	O
footprinting	O
analyses	O
have	O
revealed	O
that	O
the	O
-	O
489	O
--	O
-	O
414	O
bp	O
and	O
the	O
-	O
390	O
-	O
-	O
-	O
345	O
bp	O
(	O
designated	O
DC	O
and	O
PC	O
respectively	O
)	O
upstream	O
of	O
the	O
Aspergillus	O
nigerT21	O
glaA	B
gene	O
were	O
bound	O
by	O
one	O
protein	O
factor	O
in	O
the	O
A.	O
nigerT21	O
whole	O
cell	O
extract	O
.	O

Both	O
DC	O
and	O
PC	O
contained	O
CCAAT	O
pentanucleotides	O
.	O

The	O
functions	O
of	O
DC	O
and	O
PC	O
in	O
regulation	O
of	O
expression	O
of	O
glucoamylase	B
(	O
GLA	B
)	O
were	O
studied	O
.	O

CCAAT	O
pentanucleotides	O
were	O
replaced	O
with	O
CGTAA	O
and	O
the	O
mutated	O
DNA	O
fragments	O
DCm	O
and	O
PCm	O
lost	O
the	O
binding	O
activities	O
of	O
protein	O
factors	O
in	O
vitro	O
.	O

In	O
vivo	O
when	O
either	O
DC	O
or	O
PC	O
was	O
mutated	O
or	O
the	O
relative	O
orientations	O
between	O
them	O
were	O
changed	O
on	O
the	O
PglaA	B
,	O
the	O
transcriptional	O
activity	O
of	O
PglaA	B
decreased	O
to	O
a	O
basal	O
level	O
.	O

Introduction	O
of	O
multi	O
-	O
copies	O
of	O
DC	O
into	O
the	O
original	O
site	O
at	O
the	O
PglaA	B
in	O
A.	O
nigerT21	O
decreased	O
the	O
expression	O
of	O
endogenous	O
GLA	B
expression	O
and	O
the	O
exogenous	O
reporter	O
E.	O
coli	O
uidA	B
gene	O
introduced	O
under	O
the	O
PglaA	B
promoter	O
,	O
while	O
having	O
no	O
effect	O
on	O
the	O
uidA	B
gene	O
under	O
the	O
control	O
of	O
PgpdA	B
.	O

EMSA	O
revealed	O
that	O
the	O
levels	O
of	O
the	O
specific	O
DNA	O
-	O
binding	O
protein	O
factors	O
in	O
the	O
transformants	O
maintained	O
the	O
same	O
meaning	O
that	O
introduction	O
of	O
multi	O
-	O
copies	O
of	O
DC	O
caused	O
the	O
titration	O
effect	O
.	O

AnghapC	B
gene	O
was	O
cloned	O
from	O
A.	O
nigerT21	O
cDNA	O
and	O
introduced	O
into	O
the	O
DC	O
multi	O
-	O
copied	O
strains	O
.	O

The	O
expression	O
of	O
AnghapC	B
improved	O
the	O
expression	O
of	O
the	O
endogenous	O
GLA	B
and	O
the	O
exogenous	O
gene	O
controlled	O
by	O
PglaA	B
.	O

These	O
results	O
showed	O
that	O
both	O
the	O
CCAAT	O
pentanucleotides	O
were	O
necessary	O
for	O
DC	O
and	O
PC	O
binding	O
to	O
the	O
protein	O
factors	O
,	O
and	O
the	O
simultaneous	O
binding	O
of	O
DC	O
and	O
PC	O
to	O
the	O
protein	O
was	O
necessary	O
for	O
promoting	O
the	O
transcriptional	O
activity	O
of	O
PglaA	B
.	O

AngHapC	B
was	O
the	O
specific	O
positive	O
trans	O
-	O
acting	O
protein	O
factor	O
binding	O
to	O
DC	O
.	O

Effect	O
of	O
different	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
reactive	O
agents	O
on	O
reverse	O
signaling	O
of	O
membrane	O
integrated	O
TNF	B
in	O
monocytes	O
.	O

Reverse	O
signaling	O
of	O
transmembrane	O
TNF	B
(	O
mTNF	B
)	O
contributes	O
to	O
the	O
versatility	O
of	O
this	O
cytokine	B
superfamily	I
.	O

Previously	O
,	O
we	O
could	O
demonstrate	O
that	O
mTNF	B
acting	O
as	O
receptor	O
confers	O
resistance	O
to	O
bacterial	O
lipopolysaccharide	O
in	O
monocytes	O
and	O
macrophages	O
(	O
MO	O
/	O
MPhi	O
)	O
.	O

Reverse	O
signaling	O
can	O
be	O
induced	O
by	O
incubation	O
with	O
the	O
monoclonal	O
anti	O
-	O
TNF	B
antibody	O
195F	O
and	O
other	O
TNF	B
antagonists	O
,	O
such	O
as	O
the	O
humanized	O
monoclonal	O
antibody	O
infliximab	O
and	O
the	O
humanized	O
soluble	O
TNF	B
receptor	I
construct	O
etanercept	O
,	O
respectively	O
,	O
all	O
in	O
former	O
or	O
present	O
clinical	O
use	O
.	O

Here	O
,	O
we	O
addressed	O
the	O
question	O
whether	O
there	O
are	O
differences	O
in	O
modulating	O
the	O
LPS	O
response	O
in	O
MO	O
/	O
MPhi	O
among	O
these	O
three	O
antagonists	O
.	O

Whereas	O
195F	O
and	O
infliximab	O
suppress	O
both	O
,	O
the	O
release	O
of	O
an	O
LPS	O
-	O
induced	O
endothelial	O
cell	O
apoptotic	O
factor	O
and	O
proinflammatory	O
cytokines	B
,	O
etanercept	O
only	O
protected	O
against	O
the	O
LPS	O
-	O
triggered	O
apoptosis	O
activity	O
,	O
but	O
left	O
the	O
LPS	O
-	O
induced	O
cytokine	B
release	O
unchanged	O
.	O

These	O
data	O
could	O
have	O
clinical	O
impact	O
with	O
regard	O
to	O
TNF	B
neutralization	O
strategies	O
.	O

Antigenic	O
properties	O
of	O
phage	O
displayed	O
peptides	O
comprising	O
disulfide	O
-	O
bonded	O
loop	O
of	O
the	O
immunodominant	O
region	O
of	O
HIV-1	O
gp41	B
.	O

The	O
HIV-1	O
envelope	O
glycoprotein	O
gp41	B
contains	O
Cys	O
(	O
X	O
)	O
5Cys	O
motif	O
,	O
which	O
has	O
been	O
shown	O
to	O
elicit	O
a	O
strong	O
antibody	O
response	O
in	O
almost	O
all	O
HIV	O
-	O
1	O
infected	O
individuals	O
.	O

This	O
disulfide	O
-	O
bonded	O
loop	O
region	O
is	O
conserved	O
in	O
most	O
retroviruses	O
suggesting	O
the	O
existence	O
of	O
an	O
essential	O
function	O
in	O
virus	O
life	O
cycle	O
.	O

In	O
this	O
study	O
,	O
we	O
displayed	O
the	O
peptides	O
comprising	O
12	O
amino	O
acids	O
of	O
the	O
immunodominant	O
loop	O
of	O
gp41	B
on	O
the	O
surface	O
of	O
M13	O
phage	O
as	O
N	O
-	O
terminal	O
fusions	O
to	O
the	O
minor	B
coat	I
protein	I
pIII	I
and	O
major	B
coat	I
protein	I
pVIII	I
of	O
the	O
phage	O
and	O
demonstrated	O
that	O
cysteine	O
loop	O
containing	O
peptide	O
expressed	O
on	O
phage	O
recognized	O
62	O
out	O
of	O
63	O
(	O
98.4	O
%	O
)	O
HIV-1	O
positive	O
samples	O
but	O
not	O
control	O
negative	O
sera	O
while	O
phage	O
bearing	O
linear	O
peptides	O
detected	O
4	O
-	O
30	O
%	O
of	O
HIV	O
-	O
1	O
-	O
positive	O
sera	O
.	O

The	O
main	O
advantage	O
of	O
phage	O
-	O
based	O
ELISA	O
or	O
other	O
antibody	O
detection	O
-	O
based	O
diagnostic	O
tests	O
of	O
HIV	O
-	O
infection	O
to	O
be	O
used	O
for	O
massive	O
screening	O
in	O
developing	O
countries	O
is	O
the	O
reproducible	O
,	O
simple	O
,	O
rapid	O
and	O
low	O
-	O
cost	O
production	O
of	O
recombinant	O
antigens	O
.	O

Molecular	O
characterization	O
of	O
the	O
MalT	B
-	O
dependent	O
periplasmic	O
alpha	B
-	I
amylase	I
of	O
Escherichia	O
coli	O
encoded	O
by	O
malS	B
.	O

malS	B
,	O
the	O
gene	O
encoding	O
the	O
periplasmic	O
alpha	B
-	I
amylase	I
,	O
is	O
under	O
the	O
regulatory	O
control	O
of	O
the	O
MalT	B
protein	O
,	O
the	O
gene	O
activator	O
of	O
the	O
Escherichia	O
coli	O
maltose	O
system	O
.	O

We	O
sequenced	O
the	O
DNA	O
region	O
encoding	O
malS	B
and	O
its	O
control	O
elements	O
.	O

malS	B
consists	O
of	O
an	O
open	O
reading	O
frame	O
of	O
2	O
,	O
028	O
base	O
pairs	O
encoding	O
a	O
protein	O
of	O
676	O
amino	O
acids	O
with	O
a	O
deduced	O
molecular	O
weight	O
of	O
75	O
,	O
664	O
including	O
a	O
typical	O
amino	O
-	O
terminal	O
signal	O
sequence	O
of	O
17	O
amino	O
acids	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
malS	B
was	O
compared	O
with	O
that	O
of	O
other	O
proteins	O
.	O

We	O
found	O
homologies	O
to	O
alpha	B
-	I
amylases	I
and	O
a	O
cyclodextrin	B
glucanotransferase	I
but	O
not	O
to	O
beta	B
-	I
amylases	I
.	O

In	O
addition	O
,	O
MalS	B
showed	O
significant	O
homology	O
to	O
another	O
maltodextrin	O
-	O
utilizing	O
and	O
MalT	B
-	O
dependent	O
enzyme	O
of	O
E.	O
coli	O
,	O
maltodextrin	B
glucosidase	I
(	O
MalZ	B
)	O
but	O
not	O
to	O
amylomaltase	B
(	O
MalQ	B
)	O
,	O
the	O
major	O
maltodextrin	O
-	O
degrading	O
enzyme	O
.	O

Conserved	O
regions	O
that	O
have	O
been	O
proposed	O
to	O
constitute	O
enzymatically	O
active	O
sites	O
in	O
alpha	B
-	I
amylases	I
are	O
present	O
in	O
MalS	B
.	O

Two	O
of	O
these	O
sequences	O
can	O
also	O
be	O
found	O
in	O
the	O
amino	O
terminus	O
of	O
the	O
lambda	B
-	I
receptor	I
,	O
a	O
maltodextrin	O
-	O
specific	O
channel	O
in	O
the	O
outer	O
membrane	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
control	O
region	O
of	O
malS	B
revealed	O
MalT	B
binding	O
sites	O
correctly	O
spaced	O
for	O
the	O
start	O
of	O
the	O
malS	B
transcript	O
.	O

At	O
the	O
position	O
219	O
base	O
pairs	O
upstream	O
of	O
malS	B
,	O
we	O
found	O
a	O
divergently	O
transcribed	O
gene	O
,	O
bax	B
,	O
which	O
has	O
been	O
recognized	O
previously	O
.	O

Downstream	O
of	O
malS	B
,	O
after	O
a	O
513	O
-	O
base	O
pair	O
intergenic	O
region	O
,	O
lies	O
the	O
convergently	O
transcribed	O
gene	O
avtA	B
,	O
which	O
codes	O
for	O
the	O
alanine	B
/	I
valine	I
transaminase	I
.	O

Cloning	O
and	O
sequencing	O
analysis	O
of	O
the	O
repressor	O
gene	O
of	O
temperate	O
mycobacteriophage	O
L1	O
.	O

The	O
wild	O
-	O
type	O
and	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
repressor	O
genes	O
were	O
cloned	O
from	O
the	O
temperate	O
mycobacteriophage	O
L1	O
and	O
its	O
mutant	O
L1cIts391	O
,	O
respectively	O
.	O

A	O
sequencing	O
analysis	O
revealed	O
that	O
the	O
131st	O
proline	O
residue	O
of	O
the	O
wild	O
-	O
type	O
repressor	O
was	O
changed	O
to	O
leucine	O
in	O
the	O
ts	O
mutant	O
repressor	O
.	O

The	O
100	O
%	O
identity	O
that	O
was	O
discovered	O
between	O
the	O
two	O
DNA	O
regions	O
of	O
phages	O
L1	O
and	O
L5	O
,	O
carrying	O
the	O
same	O
sets	O
of	O
genes	O
including	O
their	O
repressor	O
genes	O
,	O
strengthened	O
the	O
speculation	O
that	O
L1	O
is	O
a	O
minor	O
variant	O
of	O
phage	O
L5	O
or	O
vice	O
versa	O
.	O

A	O
comparative	O
analysis	O
of	O
the	O
repressor	O
proteins	O
of	O
different	O
mycobacteriophages	O
suggests	O
that	O
the	O
mycobacteriophage	O
-	O
specific	O
repressor	O
proteins	O
constitute	O
a	O
new	O
family	O
of	O
repressors	O
,	O
which	O
were	O
possibly	O
evolved	O
from	O
a	O
common	O
ancestor	O
.	O

Alignment	O
of	O
the	O
mycobacteriophage	O
-	O
specific	O
repressor	O
proteins	O
showed	O
at	O
least	O
7	O
blocks	O
(	O
designated	O
I	O
-	O
VII	O
)	O
that	O
carried	O
3	O
-	O
8	O
identical	O
amino	O
acid	O
residues	O
.	O

The	O
amino	O
acid	O
residues	O
of	O
blocks	O
V	O
,	O
VI	O
,	O
and	O
some	O
residues	O
downstream	O
to	O
block	O
VI	O
are	O
crucial	O
for	O
the	O
function	O
of	O
the	O
L1	O
(	O
or	O
L5	O
)	O
repressor	O
.	O

Blocks	O
I	O
and	O
II	O
possibly	O
form	O
the	O
turn	O
and	O
helix	O
2	O
regions	O
of	O
the	O
HTH	O
motif	O
of	O
the	O
repressor	O
.	O

Block	O
IV	O
in	O
the	O
L1	O
repressor	O
is	O
part	O
of	O
the	O
most	O
charged	O
region	O
encompassing	O
amino	O
acid	O
residues	O
72	O
-	O
92	O
,	O
which	O
flanks	O
the	O
putative	O
N	O
-	O
terminal	O
basic	O
(	O
residues	O
1	O
-	O
71	O
)	O
and	O
C	O
-	O
terminal	O
acidic	O
(	O
residues	O
93	O
-	O
183	O
)	O
domains	O
of	O
L1	O
repressor	O
.	O

The	O
effect	O
of	O
IL-5	B
treatment	O
on	O
the	O
stimulation	O
-	O
induced	O
phosphorylation	O
of	O
proteins	O
in	O
blood	O
eosinophils	O
.	O

Eosinophils	O
are	O
selectively	O
primed	O
and	O
activated	O
by	O
the	O
cytokine	B
IL-5	B
.	O

The	O
aim	O
of	O
this	O
investigation	O
was	O
to	O
study	O
the	O
effects	O
of	O
IL-5	B
treatment	O
on	O
stimulation	O
-	O
dependent	O
protein	O
phosphorylations	O
,	O
in	O
human	O
peripheral	O
blood	O
eosinophils	O
.	O

After	O
IL-5	B
treatment	O
,	O
basal	O
phosphorylation	O
patterns	O
showed	O
increases	O
in	O
the	O
phosphorylation	O
of	O
67	O
,	O
80	O
and	O
93	O
kDa	O
proteins	O
.	O

Cell	O
stimulations	O
resulted	O
in	O
the	O
following	O
protein	O
phosphorylation	O
increases	O
:	O
50	O
,	O
60	O
,	O
67	O
,	O
80	O
and	O
93	O
kDa	O
(	O
PMA	O
)	O
;	O
50	O
,	O
67	O
,	O
80	O
and	O
93	O
kDa	O
(	O
STZ	O
)	O
;	O
and	O
67	O
,	O
80	O
and	O
93	O
kDa	O
(	O
IL-5	B
)	O
.	O

The	O
phosphorylation	O
of	O
the	O
50	O
and	O
60	O
kDa	O
proteins	O
was	O
shown	O
to	O
be	O
MEK	B
-	O
independent	O
and	O
dependent	O
on	O
some	O
PKC	B
isoform	O
/	O
s	O
,	O
whereas	O
that	O
of	O
the	O
67	O
,	O
80	O
and	O
93	O
kDa	O
proteins	O
was	O
both	O
MEK	B
-	O
and	O
PKC	B
-	I
alpha	I
,	I
beta	I
,	I
delta	I
,	I
gamma	I
,	I
tau	I
and	I
zeta	I
-	O
independent	O
.	O

A	O
phosphoprotein	O
of	O
50	O
kDa	O
was	O
identified	O
as	O
p47	B
(	I
phox	I
)	I
and	O
another	O
of	O
67	O
kDa	O
protein	O
as	O
the	O
tyrosine	B
phosphatase	I
SHPTP-1	B
.	O

Incubation	O
with	O
IL-5	B
followed	O
by	O
cell	O
stimulation	O
increased	O
the	O
total	O
phosphorylation	O
of	O
p47	B
(	I
phox	I
)	I
.	O

Bidimensional	O
(	O
IEF	O
-	O
SDS	O
/	O
PAGE	O
)	O
analysis	O
showed	O
that	O
the	O
combination	O
of	O
IL-5	B
treatment	O
followed	O
by	O
stimulation	O
with	O
either	O
PMA	O
or	O
STZ	O
induced	O
the	O
formation	O
of	O
an	O
additional	O
,	O
hyperphosphorylated	O
form	O
of	O
p47	B
(	I
phox	I
)	I
.	O

The	O
presence	O
of	O
this	O
form	O
would	O
explain	O
the	O
higher	O
NADPH	B
oxidase	I
activity	O
normally	O
observed	O
after	O
IL-5	B
priming	O
.	O

Identification	O
of	O
a	O
new	O
member	O
of	O
the	O
phage	B
shock	I
protein	I
response	O
in	O
Escherichia	O
coli	O
,	O
the	O
phage	B
shock	I
protein	I
G	I
(	O
PspG	B
)	O
.	O

The	O
phage	B
shock	I
protein	I
operon	I
(	O
pspABCDE	B
)	O
of	O
Escherichia	O
coli	O
is	O
strongly	O
up	O
-	O
regulated	O
in	O
response	O
to	O
overexpression	O
of	O
the	O
filamentous	O
phage	O
secretin	O
protein	B
IV	I
(	O
pIV	B
)	O
and	O
by	O
many	O
other	O
stress	O
conditions	O
including	O
defects	O
in	O
protein	O
export	O
.	O

PspA	B
has	O
an	O
established	O
role	O
in	O
maintenance	O
of	O
the	O
proton	O
-	O
motive	O
force	O
of	O
the	O
cell	O
under	O
stress	O
conditions	O
.	O

Here	O
we	O
present	O
evidence	O
for	O
a	O
new	O
member	O
of	O
the	O
phage	O
shock	O
response	O
in	O
E.	O
coli	O
.	O

Using	O
transcriptional	O
profiling	O
,	O
we	O
show	O
that	O
the	O
synthesis	O
of	O
pIV	B
in	O
E.	O
coli	O
leads	O
to	O
a	O
highly	O
restricted	O
response	O
limited	O
to	O
the	O
up	O
-	O
regulation	O
of	O
the	O
psp	B
operon	I
genes	O
and	O
yjbO	B
.	O

The	O
psp	B
operon	I
and	O
yjbO	B
are	O
also	O
up	O
-	O
regulated	O
in	O
response	O
to	O
pIV	B
in	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
.	O

yjbO	B
is	O
a	O
highly	O
conserved	O
gene	O
found	O
exclusively	O
in	O
bacteria	O
that	O
contain	O
a	O
psp	B
operon	I
but	O
is	O
physically	O
unlinked	O
to	O
the	O
psp	B
operon	I
.	O

yjbO	B
encodes	O
a	O
putative	O
inner	O
membrane	O
protein	O
that	O
is	O
co	O
-	O
controlled	O
with	O
the	O
psp	B
operon	I
genes	O
and	O
is	O
predicted	O
to	O
be	O
an	O
effector	O
of	O
the	O
psp	B
response	O
in	O
E.	O
coli	O
.	O

We	O
present	O
evidence	O
that	O
yjbO	B
expression	O
is	O
driven	O
by	O
sigma	B
(	I
54	I
)	I
-	O
RNA	B
polymerase	I
,	O
activated	O
by	O
PspF	B
and	O
integration	B
host	I
factor	I
,	O
and	O
negatively	O
regulated	O
by	O
PspA	B
.	O

PspF	B
specifically	O
regulates	O
only	O
members	O
of	O
the	O
PspF	B
regulon	O
:	O
pspABCDE	B
and	O
yjbO	B
.	O

We	O
found	O
that	O
increased	O
expression	O
of	O
YjbO	B
results	O
in	O
decreased	O
motility	O
of	O
bacteria	O
.	O

Because	O
yjbO	B
is	O
co	O
-	O
conserved	O
and	O
co	O
-	O
regulated	O
with	O
the	O
psp	B
operon	I
and	O
is	O
a	O
member	O
of	O
the	O
phage	B
shock	I
protein	I
F	I
regulon	O
,	O
we	O
propose	O
that	O
yjbO	B
be	O
renamed	O
pspG	B
.	O

Molecular	O
cloning	O
,	O
expression	O
,	O
and	O
characterization	O
of	O
myo	B
-	I
inositol	I
oxygenase	I
from	O
mouse	O
,	O
rat	O
,	O
and	O
human	O
kidney	O
.	O

myo	B
-	I
Inositol	I
oxygenase	I
(	O
MIOX	B
)	O
is	O
a	O
non	O
-	O
heme	O
iron	O
enzyme	O
,	O
which	O
catalyzes	O
the	O
conversion	O
of	O
myo	O
-	O
inositol	O
to	O
d	O
-	O
glucuronic	O
acid	O
,	O
the	O
first	O
committed	O
step	O
in	O
myo	O
-	O
inositol	O
catabolism	O
.	O

Full	O
-	O
length	O
cDNAs	O
of	O
858bp	O
each	O
coding	O
for	O
33kDa	O
protein	O
were	O
cloned	O
from	O
kidney	O
cDNA	O
libraries	O
of	O
mouse	O
,	O
rat	O
,	O
and	O
human	O
.	O

The	O
individual	O
clones	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
recombinant	O
MIOX	B
proteins	O
were	O
purified	O
to	O
electrophoretic	O
homogeneity	O
.	O

A	O
hydrophobic	O
interaction	O
chromatography	O
step	O
yielded	O
multiple	O
conformers	O
,	O
with	O
mouse	O
and	O
human	O
MIOX	B
showing	O
three	O
peaks	O
and	O
rat	O
enzyme	O
revealing	O
two	O
peaks	O
.	O

Individual	O
MIOX	B
peaks	O
exhibited	O
distinct	O
V	O
(	O
max	O
)	O
and	O
K	O
(	O
m	O
)	O
values	O
.	O

Interestingly	O
,	O
upon	O
storage	O
,	O
the	O
33kDa	O
protein	O
was	O
degraded	O
to	O
a	O
approximately	O
30kDa	O
truncated	O
protein	O
in	O
each	O
species	O
,	O
and	O
formed	O
small	O
amounts	O
of	O
dimers	O
of	O
identical	O
subunits	O
.	O

While	O
MIOX	B
is	O
a	O
highly	O
conserved	O
enzyme	O
in	O
all	O
mammalian	O
species	O
,	O
the	O
labile	O
nature	O
and	O
tendency	O
to	O
degrade	O
in	O
solution	O
may	O
be	O
the	O
source	O
of	O
significant	O
differences	O
in	O
size	O
previously	O
reported	O
in	O
the	O
literature	O
.	O

Regardless	O
of	O
the	O
source	O
,	O
our	O
results	O
strongly	O
dispel	O
previous	O
conflicting	O
literature	O
reports	O
on	O
the	O
size	O
of	O
the	O
protein	O
and	O
confirm	O
that	O
MIOX	B
is	O
a	O
33kDa	O
protein	O
.	O

Isolation	O
and	O
characterization	O
of	O
photosystem	B
II	I
of	O
Porphyra	O
yezoensis	O
Ueda	O
.	O

The	O
thylakoid	O
membranes	O
were	O
isolated	O
and	O
purified	O
from	O
gametophyte	O
of	O
Porphyra	O
yezoensis	O
Ueda	O
(	O
P.	O
yezoensis	O
)	O
by	O
sucrose	O
density	O
gradient	O
ultracentrifugation	O
.	O

After	O
P.	O
yezoensis	O
gametophyte	O
thylakoid	O
membranes	O
were	O
solubilized	O
with	O
SDS	O
,	O
the	O
photosystem	B
II	I
(	O
PSII	B
)	O
particles	O
were	O
isolated	O
and	O
purified	O
.	O

The	O
activity	O
of	O
PSII	B
particles	O
was	O
determined	O
with	O
DCIP	O
(	O
2,6-dichloroindophenol	O
)	O
photoreduction	O
reaction	O
.	O

The	O
composition	O
of	O
purified	O
PSII	B
particles	O
was	O
detected	O
by	O
SDS	O
-	O
PAGE	O
.	O

As	O
a	O
result	O
,	O
seven	O
proteins	O
including	O
55	O
kD	O
protein	O
,	O
47	O
kD	O
protein	O
,	O
43	O
kD	O
protein	O
,	O
33	O
kD	O
protein	O
,	O
31	O
kD	O
protein	O
,	O
29	O
kD	O
protein	O
,	O
and	O
18	O
kD	O
protein	O
were	O
found	O
.	O

Compared	O
with	O
PSII	B
particles	O
of	O
higher	O
plants	O
and	O
other	O
algae	O
,	O
they	O
were	O
identified	O
as	O
D1	B
/	I
D2	I
complex	I
,	O
CP47	B
,	O
CP43	B
,	O
33	O
kD	O
protein	O
,	O
D1	O
,	O
D2	O
and	O
cyt	B
c-550	I
respectively	O
.	O

Besides	O
,	O
other	O
three	O
new	O
proteins	O
of	O
20	O
kD	O
,	O
16	O
kD	O
and	O
14	O
kD	O
respectively	O
were	O
found	O
.	O

Among	O
these	O
extrinsic	O
proteins	O
,	O
the	O
16	O
kD	O
and	O
14	O
kD	O
proteins	O
had	O
not	O
been	O
reported	O
previously	O
,	O
and	O
the	O
20	O
kD	O
protein	O
was	O
found	O
for	O
the	O
first	O
time	O
in	O
multicellular	O
red	O
algae	O
.	O

Binding	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	B
subunit	I
of	I
RNA	I
polymerase	I
to	O
the	O
phage	O
mu	O
middle	O
promoter	O
.	O

The	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	O
subunit	O
(	O
alpha	O
CTD	O
)	O
of	O
Escherichia	O
coli	O
RNA	B
polymerase	I
is	O
often	O
involved	O
in	O
transcriptional	O
regulation	O
.	O

The	O
alpha	O
CTD	O
typically	O
stimulates	O
transcription	O
via	O
interactions	O
with	O
promoter	O
UP	O
element	O
DNA	O
and	O
transcriptional	O
activators	O
.	O

DNase	B
I	I
footprinting	O
and	O
gel	O
mobility	O
shift	O
assays	O
were	O
used	O
to	O
look	O
for	O
potential	O
interaction	O
of	O
the	O
alpha	O
CTD	O
with	O
the	O
phage	O
Mu	O
middle	O
promoter	O
P	O
(	O
m	O
)	O
and	O
its	O
activator	O
protein	O
Mor	B
.	O

Binding	O
of	O
RNA	B
polymerase	I
to	O
P	O
(	O
m	O
)	O
in	O
the	O
presence	O
of	O
Mor	B
resulted	O
in	O
production	O
of	O
a	O
DNase	B
I	I
footprint	O
downstream	O
of	O
Mor	B
due	O
to	O
open	O
complex	O
formation	O
and	O
generation	O
of	O
a	O
second	O
footprint	O
just	O
upstream	O
of	O
the	O
Mor	B
binding	O
site	O
.	O

Generation	O
of	O
the	O
upstream	O
footprint	O
did	O
not	O
require	O
open	O
complex	O
formation	O
and	O
also	O
occurred	O
in	O
reactions	O
in	O
which	O
the	O
alpha	O
CTD	O
or	O
His	O
-	O
alpha	O
proteins	O
were	O
substituted	O
for	O
RNA	B
polymerase	I
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
the	O
formation	O
of	O
a	O
supershifted	O
ternary	O
complex	O
demonstrated	O
that	O
Mor	B
and	O
His	O
-	O
alpha	O
bind	O
synergistically	O
to	O
P	O
(	O
m	O
)	O
DNA	O
.	O

Gel	O
shift	O
assays	O
with	O
short	O
DNA	O
fragments	O
demonstrated	O
that	O
only	O
the	O
Mor	B
binding	O
site	O
and	O
a	O
single	O
upstream	O
alpha	O
CTD	O
binding	O
site	O
were	O
required	O
for	O
ternary	O
complex	O
formation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alpha	O
CTD	O
plays	O
a	O
role	O
in	O
P	O
(	O
m	O
)	O
transcription	O
by	O
binding	O
to	O
P	O
(	O
m	O
)	O
DNA	O
just	O
upstream	O
from	O
Mor	B
and	O
making	O
protein	O
-	O
protein	O
interactions	O
with	O
Mor	B
that	O
stabilize	O
the	O
binding	O
of	O
both	O
proteins	O
.	O

Expression	O
of	O
inhibitory	O
KIR	B
is	O
confined	O
to	O
CD8	B
+	O
effector	O
T	O
cells	O
and	O
limits	O
their	O
proliferative	O
capacity	O
.	O

A	O
subset	O
of	O
effector	O
/	O
memory	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
expresses	O
natural	O
killer	O
cell	O
receptors	O
(	O
NKR	O
)	O
.	O

Expression	O
of	O
inhibitory	O
NKR	O
at	O
that	O
stage	O
of	O
T	O
cell	O
differentiation	O
is	O
poorly	O
understood	O
.	O

Interestingly	O
,	O
recent	O
studies	O
in	O
mice	O
indicated	O
that	O
transgenic	O
expression	O
of	O
an	O
inhibitory	O
NKR	O
induced	O
the	O
accumulation	O
of	O
memory	O
T	O
cells	O
by	O
inhibiting	O
activation	O
-	O
induced	O
cell	O
death	O
(	O
AICD	O
)	O
.	O

To	O
further	O
understand	O
the	O
role	O
of	O
inhibitory	O
NKR	O
on	O
T	O
cells	O
,	O
we	O
characterized	O
the	O
subset	O
of	O
human	O
peripheral	O
T	O
cells	O
expressing	O
the	O
inhibitory	O
NKR	O
,	O
CD158b	B
,	O
and	O
studied	O
the	O
modulation	O
of	O
antigen	O
-	O
driven	O
T	O
cell	O
expansion	O
by	O
an	O
endogenous	O
inhibitory	O
NKR	O
.	O

We	O
found	O
that	O
CD158b	B
expression	O
was	O
confined	O
to	O
a	O
population	O
of	O
CD8	B
(	O
+	O
)	O
TCRalphabeta	B
(	O
+	O
)	O
effector	O
T	O
cells	O
as	O
defined	O
by	O
a	O
CD45RA	B
(	O
+	O
)	O
CCR7	B
(	O
-	O
)	O
phenotype	O
and	O
high	O
constitutive	O
expression	O
of	O
granzyme	B
B1	I
.	O

Few	O
cells	O
expressed	O
the	O
activating	O
form	O
CD158j	B
in	O
the	O
absence	O
of	O
CD158b	B
.	O

Functionally	O
,	O
engagement	O
of	O
CD158b	B
by	O
MHC	B
ligands	O
diminished	O
early	O
TCR	B
signaling	O
,	O
as	O
well	O
as	O
AICD	O
.	O

However	O
,	O
the	O
reduced	O
AICD	O
did	O
not	O
rescue	O
cells	O
for	O
proliferation	O
,	O
since	O
T	O
cell	O
expansion	O
in	O
the	O
presence	O
of	O
CD158b	B
triggering	O
was	O
impaired	O
.	O

Expression	O
of	O
inhibitory	O
NKR	O
on	O
effector	O
CD8	B
(	O
+	O
)	O
T	O
cells	O
may	O
explain	O
in	O
part	O
the	O
poor	O
replicative	O
capacity	O
of	O
T	O
cells	O
at	O
that	O
stage	O
of	O
differentiation	O
.	O

Cytokine	B
gene	O
polymorphisms	O
in	O
endemic	O
pemphigus	O
foliaceus	O
:	O
a	O
possible	O
role	O
for	O
IL6	B
variants	O
.	O

Endemic	O
pemphigus	O
foliaceus	O
(	O
EPF	O
)	O
is	O
a	O
complex	O
autoimmune	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
antibodies	O
against	O
desmoglein	B
1	I
,	O
which	O
lead	O
to	O
the	O
loss	O
of	O
adhesion	O
among	O
keratinocytes	O
(	O
acantholysis	O
)	O
.	O

Variants	O
of	O
HLA	B
class	I
II	I
genes	O
have	O
been	O
the	O
only	O
genetic	O
factors	O
found	O
to	O
modulate	O
susceptibility	O
to	O
EPF	O
.	O

This	O
study	O
aims	O
at	O
investigating	O
the	O
influence	O
of	O
cytokine	B
genetic	O
variants	O
in	O
the	O
pathogenesis	O
of	O
EPF	O
,	O
since	O
they	O
may	O
affect	O
the	O
expression	O
levels	O
of	O
these	O
immunomodulatory	O
molecules	O
.	O

The	O
sample	O
included	O
168	O
patients	O
and	O
189	O
controls	O
and	O
was	O
comprised	O
of	O
mostly	O
Caucasoids	O
and	O
Mulattos	O
.	O

The	O
approach	O
consisted	O
of	O
a	O
case	O
-	O
control	O
association	O
study	O
and	O
the	O
alleles	O
were	O
identified	O
by	O
mismatched	O
PCR	O
-	O
RFLP	O
.	O

No	O
associations	O
were	O
found	O
with	O
variants	O
of	O
IL1A	B
,	O
IL1B	B
,	O
IL1RN	B
,	O
IL4R	B
and	O
IL10	B
.	O

There	O
was	O
a	O
weak	O
negative	O
association	O
with	O
the	O
haplotype	O
-	O
1082	O
G	O
-	O
592C	O
(	O
OR	O
=	O
0.49	O
)	O
of	O
the	O
IL10	B
gene	O
in	O
Mulattos	O
.	O

In	O
regard	O
to	O
polymorphism	O
-	O
590	O
of	O
the	O
IL4	B
gene	O
,	O
a	O
positive	O
association	O
with	O
the	O
T	O
/	O
T	O
genotype	O
(	O
OR	O
=	O
2.71	O
)	O
and	O
a	O
negative	O
association	O
with	O
the	O
C	O
variant	O
(	O
OR	O
=	O
0.37	O
)	O
were	O
found	O
.	O

Associations	O
with	O
IL6	B
-	O
174	O
variants	O
suggest	O
that	O
the	O
C	O
/	O
C	O
genotype	O
has	O
a	O
protective	O
effect	O
(	O
OR	O
=	O
0.13	O
)	O
while	O
carriers	O
of	O
the	O
G	O
allele	O
are	O
more	O
susceptible	O
(	O
OR	O
=	O
7.66	O
)	O
to	O
EPF	O
.	O

Agrobacterium	O
VirB10	B
,	O
an	O
ATP	O
energy	O
sensor	O
required	O
for	O
type	O
IV	O
secretion	O
.	O

Bacteria	O
use	O
type	O
IV	O
secretion	O
systems	O
(	O
T4SS	O
)	O
to	O
translocate	O
DNA	O
and	O
protein	O
substrates	O
to	O
target	O
cells	O
of	O
phylogenetically	O
diverse	O
taxa	O
.	O

Recently	O
,	O
by	O
use	O
of	O
an	O
assay	O
termed	O
transfer	O
DNA	O
immunoprecipitation	O
(	O
TrIP	O
)	O
,	O
we	O
described	O
the	O
translocation	O
route	O
for	O
a	O
DNA	O
substrate	O
[	O
T	O
-	O
DNA	O
,	O
portion	O
of	O
the	O
Ti	O
(	O
tumor	O
-	O
inducing	O
)	O
plasmid	O
that	O
is	O
transferred	O
to	O
plant	O
cells	O
]	O
of	O
the	O
Agrobacterium	O
tumefaciens	O
VirB	B
/	I
D4	I
T4SS	O
in	O
terms	O
of	O
a	O
series	O
of	O
temporally	O
and	O
spatially	O
ordered	O
substrate	O
contacts	O
with	O
subunits	O
of	O
the	O
secretion	O
channel	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
bitopic	O
inner	O
membrane	O
protein	O
VirB10	B
undergoes	O
a	O
structural	O
transition	O
in	O
response	O
to	O
ATP	O
utilization	O
by	O
the	O
VirD4	B
and	O
VirB11	B
ATP	O
-	O
binding	O
subunits	O
,	O
as	O
monitored	O
by	O
protease	B
susceptibility	O
.	O

VirB10	B
interacts	O
with	O
inner	O
membrane	O
VirD4	B
independently	O
of	O
cellular	O
energetic	O
status	O
,	O
whereas	O
the	O
energy	O
-	O
induced	O
conformational	O
change	O
is	O
required	O
for	O
VirB10	B
complex	O
formation	O
with	O
an	O
outer	O
membrane	O
-	O
associated	O
heterodimer	O
of	O
VirB7	B
lipoprotein	O
and	O
VirB9	B
,	O
as	O
shown	O
by	O
coimmunoprecipitation	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
T	O
-	O
DNA	O
substrate	O
is	O
delivered	O
from	O
the	O
inner	O
membrane	O
channel	O
components	O
VirB6	B
and	O
VirB8	B
to	O
periplasmic	O
and	O
outer	O
membrane	O
-	O
associated	O
VirB2	B
pilin	O
and	O
VirB9	B
.	O

We	O
propose	O
that	O
VirD4	B
and	O
VirB11	B
coordinate	O
the	O
ATP	O
-	O
dependent	O
formation	O
of	O
a	O
VirB10	B
""""	O
bridge	O
""""	O
between	O
inner	O
and	O
outer	O
membrane	O
subassemblies	O
of	O
the	O
VirB	B
/	I
D4	I
T4SS	O
,	O
and	O
that	O
this	O
morphogenetic	O
event	O
is	O
required	O
for	O
T	O
-	O
DNA	O
translocation	O
across	O
the	O
A.	O
tumefaciens	O
cell	O
envelope	O
.	O

Stimulation	O
,	O
monitoring	O
,	O
and	O
analysis	O
of	O
pathway	O
dynamics	O
by	O
metabolic	O
profiling	O
in	O
the	O
aromatic	O
amino	O
acid	O
pathway	O
.	O

Using	O
a	O
concerted	O
approach	O
of	O
biochemical	O
standard	O
preparation	O
,	O
analytical	O
access	O
via	O
LC	O
-	O
MS	O
/	O
MS	O
,	O
glucose	O
pulse	O
,	O
metabolic	O
profiling	O
,	O
and	O
statistical	O
data	O
analysis	O
,	O
the	O
metabolism	O
dynamics	O
in	O
the	O
aromatic	O
amino	O
acid	O
pathway	O
has	O
been	O
stimulated	O
,	O
monitored	O
,	O
and	O
analyzed	O
in	O
different	O
tyrosine	O
-	O
auxotrophic	O
L	O
-	O
phenylalanine	O
-	O
producing	O
Escherichia	O
coli	O
strains	O
.	O

During	O
the	O
observation	O
window	O
from	O
-	O
4	O
s	O
(	O
before	O
)	O
up	O
to	O
27	O
s	O
after	O
the	O
glucose	O
pulse	O
,	O
the	O
dynamics	O
of	O
the	O
first	O
five	O
enzymatic	O
reactions	O
in	O
the	O
aromatic	O
amino	O
acid	O
pathway	O
was	O
observed	O
by	O
measuring	O
intracellular	O
concentrations	O
of	O
3-deoxy	O
-	O
d	O
-	O
arabino	O
-	O
heptulosonate	O
7-phosphate	O
DAH	O
(	O
P	O
)	O
,	O
3-dehydroquinate	O
(	O
3-DHQ	O
)	O
,	O
3-dehydroshikimate	O
(	O
3-DHS	O
)	O
,	O
shikimate	O
3-phosphate	O
(	O
S3P	O
)	O
,	O
and	O
shikimate	O
(	O
SHI	O
)	O
,	O
together	O
with	O
the	O
pathway	O
precursors	O
phosphoenolpyruvate	O
(	O
PEP	O
)	O
and	O
P5P	O
,	O
the	O
lumped	O
pentose	O
phosphate	O
pool	O
as	O
an	O
alternative	O
to	O
the	O
nondetectable	O
erythrose	O
4-phosphate	O
(	O
E4P	O
)	O
.	O

Provided	O
that	O
a	O
sufficient	O
fortification	O
of	O
the	O
carbon	O
flux	O
into	O
the	O
pathway	O
of	O
interest	O
is	O
ensured	O
,	O
respective	O
metabolism	O
dynamics	O
can	O
be	O
observed	O
.	O

On	O
the	O
basis	O
of	O
the	O
intracellular	O
pool	O
measurements	O
,	O
the	O
standardized	O
pool	O
velocities	O
were	O
calculated	O
,	O
and	O
a	O
simple	O
,	O
data	O
-	O
driven	O
criterion	O
--called	O
""""	O
pool	O
efflux	O
capacity	O
""""	O
(	O
PEC	O
)	O
--	O
is	O
derived	O
.	O

Despite	O
its	O
simplifying	O
system	O
description	O
,	O
the	O
criterion	O
managed	O
to	O
identify	O
the	O
well	O
-	O
known	O
AroB	B
limitation	O
in	O
the	O
E.	O
coli	O
strain	O
A	O
(	O
genotype	O
delta	O
(	O
pheA	B
tyrA	B
aroF	B
)	O
/	O
pJF119EH	O
aroF	B
(	O
fbr	O
)	O
pheA	B
(	O
fbr	O
)	O
amp	O
)	O
and	O
it	O
also	O
succeeded	O
to	O
identify	O
AroL	B
and	O
AroA	B
(	O
in	O
strain	O
B	O
,	O
genotype	O
delta	O
(	O
pheA	B
tyrA	B
aroF	B
)	O
/	O
pJF119EH	O
aroF	B
(	O
fbr	O
)	O
pheA	B
(	O
fbr	O
)	O
aroB	B
amp	O
)	O
as	O
promising	O
metabolic	O
engineering	O
targets	O
to	O
alleviate	O
respective	O
flux	O
control	O
in	O
subsequent	O
L	O
-	O
Phe	O
producing	O
strains	O
.	O

Furthermore	O
,	O
using	O
of	O
a	O
simple	O
correlation	O
analysis	O
,	O
the	O
reconstruction	O
of	O
the	O
metabolite	O
sequence	O
of	O
the	O
observed	O
pathway	O
was	O
enabled	O
.	O

The	O
results	O
underline	O
the	O
necessity	O
to	O
extend	O
the	O
focus	O
of	O
glucose	O
pulse	O
experiments	O
by	O
studying	O
not	O
only	O
the	O
central	O
metabolism	O
but	O
also	O
anabolic	O
pathways	O
.	O

The	O
silent	O
KIR3DP1	B
gene	O
(	O
CD158c	B
)	O
is	O
transcribed	O
and	O
might	O
encode	O
a	O
secreted	O
receptor	O
in	O
a	O
minority	O
of	O
humans	O
,	O
in	O
whom	O
the	O
KIR3DP1	B
,	O
KIR2DL4	B
and	O
KIR3DL1	B
/	O
KIR3DS1	B
genes	O
are	O
duplicated	O
.	O

Killer	B
-	I
cell	I
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
are	O
structurally	O
and	O
functionally	O
diverse	O
,	O
and	O
enable	O
human	O
NK	O
cells	O
to	O
survey	O
the	O
expression	O
of	O
individual	O
HLA	B
class	I
I	I
molecules	O
,	O
often	O
altered	O
in	O
infections	O
and	O
tumors	O
.	O

Multiple	O
events	O
of	O
non	O
-	O
reciprocal	O
recombination	O
have	O
contributed	O
to	O
the	O
rapid	O
diversification	O
of	O
KIR	B
.	O

We	O
show	O
that	O
approximately	O
4.5	O
%	O
of	O
the	O
individuals	O
of	O
a	O
Caucasoid	O
population	O
bear	O
a	O
recombinant	O
allele	O
of	O
KIR3DP1	B
,	O
officially	O
designed	O
KIR3DP1	B
*	I
004	I
,	O
that	O
associates	O
tightly	O
with	O
gene	O
duplications	O
of	O
KIR3DP1	B
,	O
KIR2DL4	B
and	O
KIR3DL1	B
/	O
KIR3DS1	B
.	O

The	O
KIR3DP1	B
gene	O
is	O
normally	O
silent	O
,	O
but	O
the	O
recombinant	O
allele	O
carries	O
a	O
novel	O
promoter	O
sequence	O
and	O
,	O
as	O
a	O
consequence	O
,	O
is	O
transcribed	O
in	O
all	O
tested	O
individuals	O
.	O

Messenger	O
RNA	O
of	O
KIR3DP1	B
*	I
004	I
is	O
made	O
up	O
of	O
six	O
exons	O
;	O
of	O
these	O
,	O
exons	O
1	O
-	O
5	O
are	O
similar	O
to	O
,	O
and	O
spliced	O
like	O
,	O
those	O
encoding	O
the	O
leader	O
peptide	O
and	O
Ig	B
-	O
domains	O
of	O
KIR3D	B
.	O

By	O
contrast	O
,	O
exon	O
6	O
is	O
homologous	O
to	O
no	O
other	O
human	O
KIR	B
sequence	O
,	O
but	O
only	O
to	O
possible	O
homologs	O
in	O
chimpanzees	O
and	O
rhesus	O
macaques	O
,	O
and	O
encodes	O
a	O
short	O
hydrophilic	O
tail	O
.	O

The	O
putative	O
KIR3DP1	B
*	I
004	I
product	O
,	O
like	O
those	O
of	O
the	O
related	O
genes	O
LAIR-2	B
and	O
LILRA3	B
/	O
ILT6	B
/	O
LIR4	B
,	O
is	O
predicted	O
to	O
be	O
secreted	O
to	O
the	O
extracellular	O
medium	O
rather	O
than	O
anchored	O
to	O
the	O
cell	O
membrane	O
.	O

Proteomic	O
analysis	O
of	O
antiproliferative	O
effects	O
by	O
treatment	O
of	O
5-fluorouracil	O
in	O
cervical	O
cancer	O
cells	O
.	O

The	O
global	O
effects	O
of	O
5-fluorouracil	O
(	O
FU	O
)	O
on	O
cervical	O
carcinoma	O
cells	O
were	O
analyzed	O
using	O
an	O
efficient	O
proteomic	O
method	O
.	O

More	O
than	O
50	O
proteins	O
showed	O
a	O
significant	O
change	O
in	O
5-FU	O
-	O
treated	O
cervical	O
carcinoma	O
cells	O
compared	O
to	O
control	O
cells	O
.	O

Among	O
them	O
,	O
34	O
proteins	O
have	O
been	O
identified	O
by	O
employing	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
and	O
MALDI	O
-	O
TOF	O
-	O
MS	O
using	O
peptide	O
mass	O
fingerprinting	O
.	O

In	O
results	O
,	O
22	O
proteins	O
were	O
upregulated	O
(	O
CIDE	B
-	I
B	I
[	O
cell	B
death	I
-	I
inducing	I
DFFA	I
-	I
like	I
effector	I
B	I
]	O
,	O
caspase	B
-	I
3	I
,	O
caspase	B
-	I
8	I
,	O
Apo	B
-	I
1	I
/	O
CD95	B
(	O
Fas	B
)	O
,	O
etc	O
.	O
)	O
and	O
12	O
proteins	O
were	O
downregulated	O
(	O
mitotic	B
checkpoint	I
protein	I
BUB3	I
,	O
myc	B
proto	O
-	O
oncogene	O
protein	O
[	O
c	B
-	I
myc	I
]	O
,	O
src	B
substrate	I
cortactin	I
,	O
transforming	O
protein	O
p21A	O
,	O
etc	O
.	O
)	O
by	O
5	O
-	O
FU	O
treatment	O
in	O
HeLa	O
cervical	O
carcinoma	O
cells	O
as	O
determined	O
by	O
spot	O
volume	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Our	O
experiments	O
showed	O
that	O
5-FU	O
engaged	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
involving	O
cytosolic	O
cytochrome	B
c	I
release	O
and	O
subsequent	O
activation	O
of	O
caspase-9	B
and	O
caspase-3	B
as	O
well	O
as	O
the	O
membrane	O
death	B
receptor	I
(	O
DR	B
)	O
-	O
mediated	O
apoptotic	O
pathway	O
involving	O
activation	O
of	O
caspase-8	B
with	O
an	O
Apo-1	B
/	O
CD95	B
(	O
Fas	B
)	O
-	O
dependent	O
fashion	O
.	O

In	O
addition	O
,	O
we	O
could	O
observe	O
reduction	O
of	O
HPV	O
-	O
18	O
E6	B
/	O
E7	B
gene	O
expression	O
and	O
activation	O
of	O
p53	B
,	O
pRb	B
,	O
and	O
p21waf1	B
proteins	O
by	O
5-FU	O
treatment	O
in	O
HeLa	O
cervical	O
carcinoma	O
cells	O
.	O

In	O
conclusion	O
,	O
we	O
suggest	O
that	O
5	O
-	O
FU	O
suppresses	O
the	O
growth	O
of	O
cervical	O
cancer	O
cells	O
not	O
only	O
by	O
antiproliferative	O
effect	O
but	O
also	O
antiviral	O
regulation	O
.	O

Our	O
findings	O
may	O
offer	O
new	O
insights	O
into	O
the	O
mechanism	O
of	O
anticancer	O
effect	O
affected	O
by	O
5-FU	O
treatment	O
in	O
cervical	O
cancer	O
cells	O
and	O
its	O
mode	O
of	O
action	O
.	O

Endogenous	O
IL-11	B
is	O
pro	O
-	O
inflammatory	O
in	O
acute	O
methylated	O
bovine	O
serum	B
albumin	I
/	O
interleukin-1	B
-	O
induced	O
(	O
mBSA	B
/	O
IL-1	B
)	O
arthritis	O
.	O

OBJECTIVE	O
:	O

To	O
evaluate	O
the	O
role	O
of	O
interleukin-11	B
(	O
IL-11	B
)	O
in	O
acute	O
mBSA	B
/	O
IL-1	B
-	O
induced	O
inflammatory	O
arthritis	O
.	O

METHODS	O
:	O

IL-11	B
was	O
administered	O
via	O
intra	O
-	O
articular	O
(	O
IA	O
)	O
injection	O
into	O
knee	O
joints	O
of	O
C57BL	O
/	O
6	O
mice	O
and	O
joint	O
histology	O
was	O
assessed	O
.	O

The	O
mitogenic	O
response	O
to	O
IL-11	B
was	O
measured	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
synovial	O
fibroblasts	O
.	O

IL-1	B
was	O
used	O
as	O
a	O
comparator	O
in	O
both	O
the	O
studies	O
.	O

The	O
severity	O
of	O
acute	O
methylated	O
bovine	O
serum	O
albumin	O
(	O
mBSA	O
)	O
/	O
IL-1	B
arthritis	O
was	O
determined	O
in	O
WT	O
and	O
IL-11	B
receptor	I
null	O
(	O
IL-11Ra1	B
-	O
/	O
-	O
)	O
mice	O
.	O

In	O
parallel	O
experiments	O
,	O
a	O
neutralising	O
antibody	O
to	O
IL-11	B
was	O
administered	O
to	O
WT	O
mice	O
throughout	O
this	O
model	O
.	O

RESULTS	O
:	O

IA	O
injections	O
of	O
IL-11	B
resulted	O
in	O
mild	O
-	O
to	O
-	O
moderate	O
joint	O
inflammation	O
which	O
was	O
less	O
than	O
that	O
due	O
to	O
IA	O
IL-1	B
.	O

IL-11	B
had	O
a	O
dose	O
-	O
dependent	O
mitogenic	O
effect	O
on	O
WT	O
synovial	O
fibroblasts	O
(	O
P	O
<	O
0.01	O
)	O
.	O

mBSA	O
/	O
IL-1	B
acute	O
arthritis	O
was	O
reduced	O
in	O
IL-11Ra1	B
-	O
/	O
-	O
versus	O
WT	O
mice	O
(	O
histological	O
arthritis	O
score	O
:	O
10.1	O
+	O
/-	O
0.5	O
versus	O
12.8	O
+	O
/-	O
0.7	O
,	O
respectively	O
;	O
P	O
=	O
0.01	O
)	O
.	O

Administration	O
of	O
an	O
IL-11	B
neutralising	O
antibody	O
to	O
WT	O
mice	O
reduced	O
mBSA	B
/	O
IL-1	B
acute	O
arthritis	O
scores	O
compared	O
to	O
control	O
antibody	O
(	O
10.6	O
+	O
/-	O
0.7	O
versus	O
13.3	O
+	O
/-	O
0.6	O
,	O
respectively	O
;	O
P	O
=	O
0.02	O
)	O
.	O

CONCLUSIONS	O
:	O

These	O
data	O
demonstrate	O
that	O
endogenous	O
IL-11	B
exerts	O
relatively	O
mild	O
but	O
consistent	O
pro	O
-	O
inflammatory	O
effects	O
in	O
acute	O
inflammatory	O
arthritis	O
.	O

Transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
beta	I
in	O
conjunction	O
with	O
H	B
-	I
ras	I
activation	O
promotes	O
malignant	O
progression	O
of	O
MCF10A	O
breast	O
epithelial	O
cells	O
.	O

To	O
address	O
how	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
beta	I
and	O
oncogenic	O
H	B
-	I
ras	I
signal	O
transduction	O
pathways	O
interact	O
with	O
each	O
other	O
in	O
the	O
malignant	O
progression	O
of	O
breast	O
epithelial	O
cells	O
,	O
we	O
investigated	O
the	O
role	O
of	O
TGF	B
-	I
beta	I
signaling	O
pathway	O
in	O
invasive	O
and	O
migrative	O
properties	O
of	O
H	B
-	I
ras	I
-	O
transformed	O
MCF10A	O
human	O
breast	O
epithelial	O
cells	O
in	O
this	O
study	O
.	O

Here	O
we	O
show	O
that	O
TGF	B
-	I
beta	I
treatment	O
significantly	O
enhanced	O
invasion	O
and	O
migration	O
of	O
H	B
-	I
ras	I
MCF10A	O
cells	O
.	O

H	B
-	I
ras	I
-	O
mediated	O
activation	O
of	O
p38	B
MAPK	I
and	O
ERK-1	B
/	I
2	I
was	O
stimulated	O
by	O
TGF	B
-	I
beta	I
.	O

TGF	B
-	I
beta	I
increased	O
expression	O
of	O
matrix	B
metalloproteinase	I
(	I
MMP	I
)	I
-	I
2	I
through	O
transcriptional	O
activation	O
while	O
TGF	B
-	I
beta	I
-	O
stimulated	O
MMP-9	B
up	O
-	O
regulation	O
did	O
not	O
occur	O
at	O
transcription	O
level	O
.	O

Activation	O
of	O
p38	B
MAPK	I
pathway	O
was	O
required	O
for	O
TGF	B
-	I
beta	I
-	O
induced	O
cell	O
migration	O
,	O
invasion	O
and	O
MMP-2	B
/	I
-	I
9	I
up	O
-	O
regulation	O
,	O
indicating	O
a	O
critical	O
role	O
of	O
p38	B
MAPK	I
signaling	O
in	O
TGF	B
-	I
beta	I
-	O
promoted	O
tumor	O
progression	O
of	O
H	B
-	I
ras	I
-	O
activated	O
cells	O
.	O

ERKs	B
signaling	O
was	O
also	O
crucial	O
for	O
TGF	B
-	I
beta	I
-	O
enhanced	O
invasive	O
and	O
migrative	O
phenotypes	O
but	O
the	O
up	O
-	O
regulation	O
of	O
MMP-2	B
/	I
-	I
9	I
was	O
not	O
dependent	O
on	O
ERKs	B
activity	O
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
TGF	B
-	I
beta	I
promotes	O
H	B
-	I
ras	I
-	O
mediated	O
cell	O
migration	O
and	O
invasive	O
phenotypes	O
in	O
which	O
p38	B
MAPK	I
and	O
ERKs	B
signaling	O
pathways	O
are	O
involved	O
.	O

Our	O
findings	O
revealing	O
how	O
H	B
-	I
ras	I
and	O
TGF	B
-	I
beta	I
signal	O
pathways	O
interact	O
with	O
each	O
other	O
in	O
MCF10A	O
human	O
breast	O
cells	O
may	O
provide	O
an	O
insight	O
into	O
molecular	O
mechanisms	O
for	O
contribution	O
of	O
TGF	B
-	I
beta	I
to	O
a	O
malignant	O
progression	O
of	O
breast	O
cancer	O
in	O
collaboration	O
with	O
activated	O
H	B
-	I
ras	I
.	O

Genetic	O
diversity	O
among	O
A	O
-	O
proteins	O
of	O
atypical	O
strains	O
of	O
Aeromonas	O
salmonicida	O
.	O

The	O
virulence	B
array	I
protein	I
gene	I
A	I
(	O
vapA	B
)	O
encoding	O
the	O
A	O
-	O
protein	O
subunit	O
of	O
the	O
surface	O
layer	O
of	O
23	O
typical	O
and	O
atypical	O
strains	O
of	O
Aeromonas	O
salmonicida	O
from	O
salmonids	O
and	O
marine	O
fish	O
species	O
were	O
sequenced	O
,	O
and	O
the	O
deduced	O
A	O
-	O
protein	O
sequences	O
compared	O
.	O

The	O
A	O
-	O
proteins	O
of	O
the	O
typical	O
A.	O
salmonicida	O
ssp	O
.	O
salmonicida	O
strains	O
were	O
shown	O
to	O
be	O
identical	O
,	O
while	O
amino	O
acid	O
variability	O
was	O
revealed	O
among	O
A	O
-	O
proteins	O
of	O
atypical	O
strains	O
.	O

The	O
highest	O
amino	O
acid	O
variability	O
appears	O
to	O
be	O
in	O
a	O
predicted	O
surface	O
exposed	O
region	O
and	O
is	O
believed	O
to	O
result	O
in	O
antigenic	O
differences	O
among	O
the	O
atypical	O
strains	O
of	O
A.	O
salmonicida	O
.	O

Escherichia	O
coli	O
dihydroxyacetone	B
kinase	I
controls	O
gene	O
expression	O
by	O
binding	O
to	O
transcription	B
factor	I
DhaR	B
.	O

Dihydroxyacetone	B
(	I
Dha	I
)	I
kinases	I
are	O
a	O
sequence	O
-	O
conserved	O
family	O
of	O
enzymes	O
,	O
which	O
utilize	O
either	O
ATP	O
(	O
in	O
animals	O
,	O
plants	O
,	O
bacteria	O
)	O
or	O
the	O
bacterial	O
phosphoenolpyruvate	B
carbohydrate	I
phosphotransferase	I
system	O
(	O
PTS	B
)	O
as	O
a	O
source	O
of	O
high	O
-	O
energy	O
phosphate	O
.	O

The	O
PTS	B
-	I
dependent	I
kinase	I
of	O
Escherichia	O
coli	O
consists	O
of	O
three	O
subunits	O
:	O
DhaK	B
contains	O
the	O
Dha	O
binding	O
site	O
,	O
DhaL	B
contains	O
ADP	O
as	O
cofactor	O
for	O
the	O
double	O
displacement	O
of	O
phosphate	O
from	O
DhaM	B
to	O
Dha	O
,	O
and	O
DhaM	B
provides	O
a	O
phospho	O
-	O
histidine	O
relay	O
between	O
the	O
PTS	B
and	O
DhaL	B
:	O
:	O
ADP	O
.	O

DhaR	B
is	O
a	O
transcription	O
activator	O
belonging	O
to	O
the	O
AAA	B
+	I
family	I
of	O
enhancer	O
binding	O
proteins	O
.	O

It	O
stimulates	O
transcription	O
of	O
the	O
dhaKLM	B
operon	I
from	O
a	O
sigma70	B
promoter	O
and	O
autorepresses	O
dhaR	B
transcription	O
.	O

Genetic	O
and	O
biochemical	O
studies	O
indicate	O
that	O
the	O
enzyme	O
subunits	O
DhaL	B
and	O
DhaK	B
act	O
antagonistically	O
as	O
coactivator	O
and	O
corepressor	O
of	O
the	O
transcription	O
activator	O
by	O
mutually	O
exclusive	O
binding	O
to	O
the	O
sensing	O
domain	O
of	O
DhaR	B
.	O

In	O
the	O
presence	O
of	O
Dha	O
,	O
DhaL	B
is	O
dephosphorylated	O
and	O
DhaL	B
:	O
:	O
ADP	O
displaces	O
DhaK	B
and	O
stimulates	O
DhaR	B
activity	O
.	O

In	O
the	O
absence	O
of	O
Dha	O
,	O
DhaL	B
:	O
:	O
ADP	O
is	O
converted	O
by	O
the	O
PTS	B
to	O
DhaL	B
:	O
:	O
ATP	O
,	O
which	O
does	O
not	O
bind	O
to	O
DhaR	B
.	O

Introns	O
in	O
the	O
cytolethal	B
distending	I
toxin	I
gene	O
of	O
Actinobacillus	O
actinomycetemcomitans	O
.	O

In	O
eukaryotic	O
cells	O
,	O
genes	O
are	O
interrupted	O
by	O
intervening	O
sequences	O
called	O
introns	O
.	O

Introns	O
are	O
transcribed	O
as	O
part	O
of	O
a	O
precursor	O
RNA	O
that	O
is	O
subsequently	O
removed	O
by	O
splicing	O
,	O
giving	O
rise	O
to	O
mature	O
mRNA	O
.	O

However	O
,	O
introns	O
are	O
rarely	O
found	O
in	O
bacteria	O
.	O

Actinobacillus	O
actinomycetemcomitans	O
is	O
a	O
periodontal	O
pathogen	O
implicated	O
in	O
aggressive	O
forms	O
of	O
periodontal	O
disease	O
.	O

This	O
organism	O
has	O
been	O
shown	O
to	O
produce	O
cytolethal	B
distending	I
toxin	I
(	O
CDT	B
)	O
,	O
which	O
causes	O
sensitive	O
eukaryotic	O
cells	O
to	O
become	O
irreversibly	O
blocked	O
at	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
presence	O
of	O
introns	O
within	O
the	O
cdt	B
gene	O
of	O
A.	O
actinomycetemcomitans	O
.	O

By	O
use	O
of	O
reverse	O
transcription	O
-	O
PCR	O
,	O
cdt	B
transcripts	O
of	O
2.123	O
,	O
1.572	O
,	O
and	O
0.882	O
kb	O
(	O
RTA1	B
,	O
RTA2	B
,	O
and	O
RTA3	B
,	O
respectively	O
)	O
were	O
detected	O
.	O

In	O
contrast	O
,	O
a	O
single	O
2.123	O
-	O
kb	O
amplicon	O
was	O
obtained	O
by	O
PCR	O
with	O
the	O
genomic	O
DNA	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
plasmid	O
carrying	O
cdt	B
was	O
cloned	O
into	O
Escherichia	O
coli	O
.	O

Sequence	O
analysis	O
of	O
RTA1	B
,	O
RTA2	B
,	O
and	O
RTA3	B
revealed	O
that	O
RTA1	B
had	O
undergone	O
splicing	O
,	O
giving	O
rise	O
to	O
RTA2	B
and	O
RTA3	B
.	O

Two	O
exon	O
-	O
intron	O
boundaries	O
,	O
or	O
splice	O
sites	O
,	O
were	O
identified	O
at	O
positions	O
863	O
to	O
868	O
and	O
1553	O
to	O
1558	O
of	O
RTA1	B
.	O

Site	O
-	O
directed	O
and	O
deletion	O
mutation	O
studies	O
of	O
the	O
splice	O
site	O
sequence	O
indicated	O
that	O
sequence	O
conservation	O
was	O
important	O
in	O
order	O
for	O
accurate	O
splicing	O
to	O
occur	O
.	O

The	O
catalytic	O
region	O
of	O
the	O
cdt	B
RNA	O
was	O
located	O
within	O
the	O
cdtC	B
gene	O
.	O

This	O
0.56	O
-	O
kb	O
RNA	O
behaved	O
independently	O
as	O
a	O
catalytically	O
active	O
RNA	O
molecule	O
(	O
a	O
ribozyme	O
)	O
in	O
vitro	O
,	O
capable	O
of	O
splicing	O
heterologous	O
RNA	O
in	O
both	O
cis	O
and	O
trans	O
configurations	O
.	O

Implication	O
of	O
membrane	O
localization	O
of	O
target	O
mRNA	O
in	O
the	O
action	O
of	O
a	O
small	O
RNA	O
:	O
mechanism	O
of	O
post	O
-	O
transcriptional	O
regulation	O
of	O
glucose	B
transporter	I
in	O
Escherichia	O
coli	O
.	O

Accumulation	O
of	O
phosphosugars	O
such	O
as	O
glucose-6-phosphate	O
causes	O
a	O
rapid	O
degradation	O
of	O
ptsG	B
mRNA	O
encoding	O
the	O
major	O
glucose	B
transporter	I
IICB	I
(	I
Glc	I
)	I
in	O
an	O
RNase	B
E	I
/	O
degradosome	O
-	O
dependent	O
manner	O
.	O

The	O
destabilization	O
of	O
ptsG	B
mRNA	O
is	O
caused	O
by	O
a	O
small	O
antisense	O
RNA	O
(	O
SgrS	O
)	O
that	O
is	O
induced	O
by	O
phosphosugar	O
stress	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
a	O
series	O
of	O
ptsG	B
-	O
crp	B
translational	O
fusions	O
to	O
identify	O
the	O
mRNA	O
region	O
required	O
for	O
the	O
rapid	O
degradation	O
of	O
ptsG	B
mRNA	O
.	O

We	O
found	O
that	O
the	O
ptsG	B
-	O
crp	B
mRNA	O
is	O
destabilized	O
in	O
response	O
to	O
phosphosugar	O
stress	O
when	O
it	O
contains	O
the	O
5	O
'	O
portion	O
of	O
ptsG	B
mRNA	O
corresponding	O
up	O
to	O
the	O
first	O
two	O
transmembrane	O
domains	O
(	O
TM1	O
and	O
TM2	O
)	O
of	O
IICB	B
(	I
Glc	I
)	I
.	O

The	O
destabilization	O
of	O
ptsG	B
-	O
crp	B
mRNA	O
was	O
largely	O
eliminated	O
by	O
frameshift	O
mutations	O
in	O
the	O
transmembrane	O
region	O
.	O

The	O
IICB	B
(	I
Glc	I
)	I
-	O
CRP	B
fusion	O
proteins	O
containing	O
more	O
than	O
two	O
transmembrane	O
domains	O
were	O
localized	O
at	O
the	O
membrane	O
.	O

The	O
efficient	O
destabilization	O
of	O
ptsG	B
-	O
crp	B
mRNA	O
was	O
restored	O
when	O
TM1	O
and	O
TM2	O
of	O
IICB	B
(	I
Glc	I
)	I
were	O
replaced	O
by	O
part	O
of	O
the	O
LacY	B
transmembrane	O
region	O
.	O

We	O
conclude	O
that	O
the	O
membrane	O
-	O
targeting	O
property	O
of	O
IICB	B
(	I
Glc	I
)	I
protein	O
rather	O
than	O
the	O
particular	O
nucleotide	O
or	O
amino	O
acid	O
sequence	O
is	O
required	O
for	O
the	O
efficient	O
degradation	O
of	O
ptsG	B
mRNA	O
in	O
response	O
to	O
metabolic	O
stress	O
.	O

The	O
stimulation	O
of	O
ptsG	B
-	O
crp	B
mRNA	O
degradation	O
was	O
completely	O
eliminated	O
when	O
either	O
the	O
hfq	B
or	O
sgrS	O
gene	O
is	O
inactivated	O
.	O

The	O
efficient	O
mRNA	O
destabilization	O
was	O
observed	O
in	O
the	O
absence	O
of	O
membrane	O
localization	O
when	O
translation	O
was	O
reduced	O
by	O
introducing	O
a	O
mutation	O
in	O
the	O
ribosome	O
-	O
binding	O
site	O
in	O
the	O
cytoplasmic	O
ptsG	B
-	O
crp	B
mRNA	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
mRNA	O
localization	O
to	O
the	O
inner	O
membrane	O
coupled	O
with	O
the	O
membrane	O
insertion	O
of	O
nascent	O
peptide	O
mediates	O
the	O
Hfq	B
/	O
SgrS	O
-	O
dependent	O
ptsG	B
mRNA	O
destabilization	O
presumably	O
by	O
reducing	O
second	O
rounds	O
of	O
translation	O
.	O

Heme	O
oxygenase-1	O
alleviates	O
ischemia	O
/	O
reperfusion	O
injury	O
in	O
aged	O
liver	O
.	O

AIM	O
:	O

To	O
investigate	O
if	O
ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
injury	O
in	O
aged	O
liver	O
could	O
be	O
alleviated	O
by	O
heme	B
oxygenase-1	I
(	O
HO-1	B
)	O
.	O

METHODS	O
:	O

Three	O
groups	O
of	O
SD	O
rats	O
(	O
16	O
mo	O
old	O
)	O
were	O
studied	O
.	O

Group	O
1	O
:	O
control	O
donors	O
received	O
physiological	O
saline	O
24	O
h	O
before	O
their	O
livers	O
were	O
harvested	O
;	O
group	O
2	O
:	O
donors	O
were	O
pretreated	O
with	O
hemin	O
24	O
h	O
before	O
their	O
livers	O
were	O
harvested	O
;	O
and	O
group	O
3	O
:	O
donors	O
received	O
hemin	O
24	O
h	O
before	O
their	O
livers	O
were	O
harvested	O
and	O
zinc	O
protoporphyrin	O
(	O
ZnPP	O
,	O
HO	B
-	I
1	I
inhibitor	O
)	O
was	O
given	O
to	O
recipients	O
at	O
reperfusion	O
.	O

The	O
harvested	O
livers	O
were	O
stored	O
in	O
University	O
of	O
Wisconsin	O
solution	O
(	O
4	O
degrees	O
)	O
for	O
6	O
h	O
,	O
and	O
then	O
transplanted	O
to	O
syngeneic	O
rats	O
.	O

Serum	O
glutamic	B
oxaloacetic	I
transaminase	I
(	O
SGOT	O
)	O
,	O
apoptotic	O
cells	O
,	O
and	O
apoptotic	O
gene	O
were	O
measured	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
48	O
h	O
after	O
reperfusion	O
.	O

We	O
measured	O
the	O
apoptotic	O
index	O
by	O
TUNEL	O
,	O
determined	O
the	O
expression	O
of	O
antiapoptotic	O
Bcl-2	B
and	O
proapoptotic	O
(	O
caspase	B
-	I
3	I
)	O
gene	O
products	O
by	O
Western	O
blot	O
.	O

RESULTS	O
:	O

After	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
48	O
h	O
of	O
reperfusion	O
,	O
the	O
SGOT	O
levels	O
(	O
584.4	O
+	O
/	O
-	O
85.8	O
u	O
/	O
L	O
,	O
999.2	O
+	O
/	O
-	O
125.2	O
u	O
/	O
L	O
,	O
423.4	O
+	O
/	O
-	O
161.3	O
u	O
/	O
L	O
,	O
257.8	O
+	O
/	O
-	O
95.8	O
u	O
/	O
L	O
,	O
and	O
122.4	O
+	O
/-	O
26.4	O
u	O
/	O
L	O
)	O
in	O
hemin	O
group	O
were	O
significantly	O
(	O
all	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
those	O
in	O
saline	O
group	O
(	O
1082.2	O
+	O
/	O
-	O
101.2	O
u	O
/	O
L	O
,	O
1775.2	O
+	O
/	O
-	O
328.3	O
u	O
/	O
L	O
,	O
840.4	O
+	O
/	O
-	O
137.8	O
u	O
/	O
L	O
,	O
448.6	O
+	O
/	O
-	O
74.3	O
u	O
/	O
L	O
,	O
and	O
306.2	O
+	O
/	O
-	O
49.3	O
u	O
/	O
L	O
)	O
.	O

Liver	O
HO-1	B
enzymatic	O
activity	O
correlated	O
with	O
beneficial	O
effects	O
of	O
hemin	O
and	O
deleterious	O
effects	O
of	O
adjunctive	O
ZnPP	O
treatment	O
.	O

Markedly	O
less	O
apoptotic	O
(	O
TUNEL	O
+	O
)	O
liver	O
cells	O
3	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
48	O
h	O
after	O
reperfusion	O
(	O
5.16	O
+	O
/	O
-	O
0.73	O
,	O
10.2	O
+	O
/	O
-	O
0.67	O
,	O
9.28	O
+	O
/	O
-	O
0.78	O
,	O
7.14	O
+	O
/	O
-	O
1.12	O
,	O
and	O
4.78	O
+	O
/	O
-	O
0.65	O
)	O
(	O
P	O
<	O
0.05	O
)	O
could	O
be	O
detected	O
in	O
hemin	O
liver	O
grafts	O
,	O
as	O
compared	O
to	O
controls	O
(	O
7.82	O
+	O
/	O
-	O
1.05	O
,	O
15.94	O
+	O
/	O
-	O
1.82	O
,	O
11.67	O
+	O
/	O
-	O
1.59	O
,	O
8.28	O
+	O
/	O
-	O
1.09	O
,	O
and	O
6.36	O
+	O
/	O
-	O
0.67	O
)	O
.	O

We	O
detected	O
the	O
increased	O
levels	O
of	O
Bcl-2	B
(	O
1.5	O
-	O
fold	O
)	O
expression	O
and	O
compared	O
with	O
saline	O
controls	O
.	O

These	O
differences	O
were	O
most	O
pronounced	O
at	O
12	O
h	O
after	O
transplantation	O
.	O

In	O
contrast	O
,	O
an	O
active	O
form	O
of	O
proapoptotic	O
caspase	B
-	I
3	I
(	O
p20	B
)	O
protein	O
was	O
found	O
to	O
be	O
2.9	O
-	O
fold	O
lower	O
at	O
24	O
h	O
in	O
hemin	O
-	O
pretreated	O
group	O
,	O
as	O
compared	O
to	O
saline	O
liver	O
transplant	O
controls	O
.	O

CONCLUSION	O
:	O

HO-1	B
overexpression	O
can	O
provide	O
potent	O
protection	O
against	O
cold	O
I	O
/	O
R	O
injury	O
.	O

This	O
effect	O
depends	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
HO-1	B
-	O
mediated	O
inhibition	O
of	O
antiapoptotic	O
mechanism	O
.	O

The	O
effect	O
of	O
over	O
-	O
expression	O
of	O
the	O
alternative	B
oxidase	I
in	O
the	O
procyclic	O
forms	O
of	O
Trypanosoma	O
brucei	O
.	O

Trypanosome	O
alternative	B
oxidase	I
(	O
TAO	B
)	O
is	O
the	O
cyanide	O
-	O
resistant	O
but	O
SHAM	B
-	I
sensitive	I
terminal	I
oxidase	I
of	O
the	O
mitochondrial	O
electron	O
transport	O
chain	O
in	O
African	O
trypanosomes	O
.	O

The	O
bloodstream	O
forms	O
of	O
Trypanosoma	O
brucei	O
lack	O
cytochromes	O
and	O
respire	O
exclusively	O
via	O
TAO	B
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
insect	O
,	O
or	O
procyclic	O
form	O
possesses	O
a	O
fully	O
developed	O
cytochrome	B
system	O
,	O
and	O
down	O
regulates	O
TAO	B
several	O
folds	O
by	O
reducing	O
the	O
stability	O
of	O
the	O
TAO	B
transcript	O
.	O

We	O
expressed	O
an	O
ectopic	O
copy	O
of	O
TAO	B
in	O
the	O
procyclic	O
form	O
from	O
a	O
tetracycline	O
regulated	O
stable	O
expression	O
vector	O
,	O
in	O
which	O
the	O
TAO	B
3	O
'	O
-	O
UTR	O
was	O
replaced	O
by	O
T.	O
brucei	O
aldolase	B
3	O
'	O
-	O
UTR	O
.	O

The	O
TAO	B
transcript	O
produced	O
from	O
the	O
ectopic	O
copy	O
was	O
stably	O
accumulated	O
in	O
the	O
procyclic	O
form	O
.	O

Upon	O
induction	O
with	O
doxycycline	O
,	O
TAO	B
protein	O
level	O
was	O
gradually	O
increased	O
about	O
five	O
-	O
fold	O
within	O
72	O
h	O
.	O

TAO	B
over	O
-	O
expression	O
did	O
not	O
show	O
any	O
effect	O
on	O
the	O
growth	O
of	O
the	O
parasite	O
.	O

The	O
rate	O
of	O
respiration	O
and	O
the	O
SHAM	O
-	O
sensitive	O
respiratory	O
pathway	O
capacity	O
was	O
increased	O
about	O
two	O
-	O
and	O
five	O
-	O
fold	O
,	O
respectively	O
,	O
and	O
the	O
cytochrome	B
-	O
mediated	O
respiratory	O
pathway	O
capacity	O
was	O
reduced	O
two	O
-	O
to	O
three	O
-	O
folds	O
within	O
5	O
days	O
after	O
induction	O
of	O
TAO	B
.	O

Doxycycline	O
induced	O
TAO	B
+	O
cells	O
preferentially	O
utilized	O
CN	O
-	O
resistant	O
,	O
SHAM	O
-	O
sensitive	O
pathway	O
of	O
respiration	O
,	O
whereas	O
,	O
in	O
the	O
control	O
cells	O
70	O
-	O
80	O
%	O
of	O
total	O
respiration	O
was	O
via	O
the	O
CN	O
-	O
sensitive	O
pathway	O
.	O

Moreover	O
,	O
we	O
have	O
found	O
that	O
increased	O
expression	O
of	O
TAO	B
caused	O
about	O
two	O
-	O
fold	O
down	O
regulation	O
of	O
cytochrome	B
oxidase	I
subunit	I
IV	I
,	O
and	O
cytochrome	B
c1	I
protein	O
level	O
and	O
also	O
caused	O
a	O
four	O
-	O
fold	O
up	O
-	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
surface	O
coat	O
protein	O
,	O
GPEET	B
procyclin	I
in	O
the	O
procyclic	O
form	O
.	O

This	O
suggests	O
that	O
the	O
expression	O
of	O
two	O
terminal	B
oxidases	I
and	O
the	O
coat	B
protein	I
is	O
linked	O
in	O
T.	O
brucei	O
.	O

Differential	O
contribution	O
of	O
the	O
three	O
Aph1	B
genes	O
to	O
gamma	B
-	I
secretase	I
activity	O
in	O
vivo	O
.	O

Gamma	B
-	I
secretase	I
is	O
the	O
protease	B
responsible	O
for	O
amyloid	B
beta	I
peptide	I
release	O
and	O
is	O
needed	O
for	O
Notch	B
,	O
N	B
-	I
Cadherin	I
,	O
and	O
possibly	O
other	O
signaling	O
pathways	O
.	O

The	O
protease	B
complex	O
consists	O
of	O
at	O
least	O
four	O
subunits	O
,	O
i.e.	O
,	O
Presenilin	B
,	O
Aph1	B
,	O
Pen2	B
,	O
and	O
Nicastrin	B
.	O

Two	O
different	O
genes	O
encode	O
Aph1A	B
and	O
Aph1B	B
in	O
man	O
.	O

A	O
duplication	O
of	O
Aph1B	B
in	O
rodents	O
has	O
given	O
rise	O
to	O
a	O
third	O
gene	O
,	O
Aph1C	B
.	O

Different	O
mixes	O
of	O
gamma	B
-	I
secretase	I
subunits	O
assemble	O
in	O
at	O
least	O
four	O
human	O
and	O
six	O
rodent	O
complexes	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
have	O
different	O
activities	O
in	O
vivo	O
.	O

We	O
report	O
here	O
the	O
inactivation	O
of	O
the	O
three	O
Aph1	B
genes	O
in	O
mice	O
.	O

Aph1A	B
-	O
/	O
-	O
embryos	O
show	O
a	O
lethal	O
phenotype	O
characterized	O
by	O
angiogenesis	O
defects	O
in	O
the	O
yolk	O
sac	O
,	O
neuronal	O
tube	O
malformations	O
,	O
and	O
mild	O
somitogenesis	O
defects	O
.	O

Aph1B	B
-	O
/	O
-	O
or	O
C	O
-	O
/	O
-	O
or	O
the	O
combined	O
Aph1BC	B
-	O
/	O
-	O
mice	O
(	O
which	O
can	O
be	O
considered	O
as	O
a	O
model	O
for	O
total	O
Aph1B	B
loss	O
in	O
human	O
)	O
survive	O
into	O
adulthood	O
.	O

However	O
,	O
Aph1BC	B
-	O
/	O
-	O
deficiency	O
causes	O
a	O
mild	O
but	O
significant	O
reduction	O
in	O
amyloid	B
beta	I
percursor	I
protein	O
processing	O
in	O
selective	O
regions	O
of	O
the	O
adult	O
brain	O
.	O

We	O
conclude	O
that	O
the	O
biochemical	O
and	O
physiological	O
repercussions	O
of	O
genetically	O
reducing	O
gamma	B
-	I
secretase	I
activity	O
via	O
the	O
different	O
Aph1	B
components	O
are	O
quite	O
divergent	O
and	O
tissue	O
specific	O
.	O

Our	O
work	O
provides	O
in	O
vivo	O
evidence	O
for	O
the	O
concept	O
that	O
different	O
gamma	B
-	I
secretase	I
complexes	I
may	O
exert	O
different	O
biological	O
functions	O
.	O

In	O
the	O
context	O
of	O
Alzheimer	O
's	O
disease	O
therapy	O
,	O
this	O
implies	O
the	O
theoretical	O
possibility	O
that	O
targeting	O
specific	O
gamma	B
-	I
secretase	I
subunit	O
combinations	O
could	O
yield	O
less	O
toxic	O
drugs	O
than	O
the	O
currently	O
available	O
general	O
inhibitors	O
of	O
gamma	B
-	I
secretase	I
activity	O
.	O

An	O
essential	O
role	O
for	O
IFN	B
-	I
alpha	I
in	O
the	O
overexpression	O
of	O
Fas	B
ligand	I
on	O
MRL	O
/	O
lpr	O
lymphocytes	O
and	O
on	O
their	O
spontaneous	O
Fas	B
-	O
mediated	O
cytotoxic	O
potential	O
.	O

Lymphocytes	O
from	O
aged	O
autoimmune	O
MRL	O
/	O
lpr	O
mice	O
overexpress	O
Fas	B
ligand	I
(	O
FasL	B
)	O
,	O
and	O
are	O
cytotoxic	O
against	O
Fas	B
+	O
target	O
cells	O
.	O

This	O
cytotoxic	O
potential	O
is	O
only	O
partly	O
due	O
to	O
FasL	B
,	O
as	O
wild	O
-	O
type	O
MRL	O
+	O
/+	O
lymphocytes	O
are	O
not	O
able	O
to	O
kill	O
Fas	B
+	O
targets	O
after	O
induction	O
of	O
FasL	B
.	O

In	O
addition	O
,	O
serum	O
levels	O
of	O
interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
increase	O
in	O
parallel	O
with	O
the	O
Fas	B
-	O
dependent	O
cytotoxic	O
potential	O
of	O
lymphocytes	O
from	O
MRL	O
/	O
lpr	O
mice	O
as	O
they	O
age	O
.	O

To	O
understand	O
the	O
mechanisms	O
underlying	O
these	O
observations	O
,	O
combined	O
suppression	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
and	O
RT	O
-	O
PCR	O
were	O
used	O
to	O
study	O
differential	O
gene	O
expression	O
in	O
splenocytes	O
from	O
MRL	O
/	O
lpr	O
mice	O
compared	O
with	O
splenocytes	O
from	O
MRL	O
+	O
/+	O
mice	O
.	O

Twenty	O
-	O
two	O
genes	O
were	O
upregulated	O
transcriptionally	O
in	O
MRL	O
/	O
lpr	O
splenocytes	O
compared	O
with	O
their	O
MRL	O
+	O
/+	O
counterparts	O
.	O

Furthermore	O
,	O
9	O
of	O
these	O
genes	O
were	O
also	O
upregulated	O
after	O
treatment	O
of	O
MRL	O
/	O
lpr	O
splenocytes	O
with	O
IFN	B
-	I
alpha	I
,	O
and	O
4	O
were	O
strongly	O
downregulated	O
.	O

MRL	O
/	O
lpr	O
lymphocytes	O
were	O
also	O
found	O
to	O
be	O
hyperresponsive	O
to	O
IFN	B
-	I
alpha	I
.	O

Thus	O
,	O
MRL	O
/	O
lpr	O
lymphocytes	O
overexpressed	O
mRNA	O
for	O
the	O
IFN	B
-	I
alpha	I
receptor	I
(	O
IFNAR-1	B
and	O
IFNAR-2	B
)	O
chains	O
of	O
the	O
IFN	B
-	I
alpha	I
/	I
beta	I
receptor	I
and	O
exhibited	O
high	O
endogenous	O
levels	O
of	O
both	O
Stat1	B
and	O
phosphorylated	O
Stat1	B
proteins	O
.	O

Lymphocytes	O
from	O
young	O
MRL	O
/	O
lpr	O
mice	O
,	O
with	O
low	O
Fas	B
-	O
dependent	O
cytotoxic	O
activity	O
,	O
were	O
found	O
to	O
become	O
highly	O
cytotoxic	O
against	O
Fas	B
+	O
targets	O
after	O
treatment	O
with	O
IFN	B
-	I
alpha	I
.	O

These	O
data	O
suggest	O
that	O
IFN	B
-	I
alpha	I
plays	O
an	O
important	O
role	O
in	O
the	O
physiopathology	O
of	O
the	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
-	O
like	O
syndrome	O
that	O
occurs	O
in	O
MRL	O
/	O
lpr	O
mice	O
.	O

Bacillus	O
subtilis	O
early	O
sporulation	O
genes	O
kinA	B
,	O
spo0F	B
,	O
and	O
spo0A	B
are	O
transcribed	O
by	O
the	O
RNA	B
polymerase	I
containing	O
sigma	B
H	I
.	O

The	O
Bacillus	O
subtilis	O
genes	O
kinA	B
(	O
spoIIJ	B
)	O
,	O
spo0F	B
,	O
and	O
spo0A	B
encode	O
components	O
of	O
the	O
sporulation	O
signal	O
transduction	O
pathway	O
.	O

Recent	O
work	O
has	O
suggested	O
that	O
these	O
genes	O
are	O
transcribed	O
by	O
a	O
minor	O
form	O
of	O
RNA	B
polymerase	I
,	O
E	B
sigma	I
H	I
(	O
sigma	B
H	I
is	O
the	O
product	O
of	O
spo0H	B
,	O
another	O
early	O
sporulation	O
gene	O
)	O
.	O

We	O
directly	O
tested	O
this	O
hypothesis	O
by	O
performing	O
in	O
vitro	O
transcription	O
assays	O
with	O
reconstituted	O
E	B
sigma	I
H	I
and	O
a	O
set	O
of	O
plasmids	O
containing	O
the	O
kinA	B
,	O
spo0F	B
,	O
and	O
spo0A	B
promoter	O
regions	O
.	O

We	O
were	O
able	O
to	O
obtain	O
distinct	O
transcripts	O
of	O
the	O
expected	O
sizes	O
with	O
all	O
three	O
genes	O
by	O
using	O
linearized	O
or	O
supercoiled	O
templates	O
.	O

Furthermore	O
,	O
primer	O
extension	O
experiments	O
indicate	O
that	O
the	O
transcription	O
start	O
sites	O
for	O
the	O
three	O
genes	O
in	O
vitro	O
and	O
in	O
vivo	O
are	O
the	O
same	O
.	O

In	O
addition	O
,	O
we	O
measured	O
steady	O
-	O
state	O
levels	O
of	O
kinA	B
,	O
spo0F	B
,	O
and	O
spo0A	B
mRNAs	O
during	O
growth	O
in	O
sporulation	O
medium	O
;	O
all	O
of	O
them	O
were	O
increased	O
at	O
or	O
near	O
the	O
beginning	O
of	O
the	O
stationary	O
phase	O
.	O

Dna	O
probes	O
for	O
identification	O
of	O
leptospires	O
and	O
disease	O
diagnosis	O
.	O

A	O
newly	O
identified	O
1	O
kb	O
DNA	O
fragment	O
amplified	O
by	O
PCR	O
using	O
(	O
AG	O
)	O
8	O
T	O
inter	O
-	O
simple	O
sequence	O
repeats	O
(	O
ISSR	O
)	O
primer	O
and	O
a	O
631	O
bp	O
segment	O
of	O
16S	O
rRNA	O
ribosomal	O
gene	O
amplified	O
by	O
PCR	O
using	O
reported	O
primers	O
were	O
labeled	O
with	O
a	O
alpha32P	O
dCTP	O
for	O
use	O
as	O
DNA	O
probes	O
.	O

These	O
probes	O
were	O
hybridized	O
with	O
DNA	O
extracted	O
from	O
19	O
standard	O
pathogenic	O
serovars	O
,	O
3	O
standard	O
saprophytic	O
serovars	O
,	O
33	O
pathogenic	O
isolates	O
(	O
12	O
from	O
patients	O
,	O
1	O
from	O
a	O
tapwater	O
source	O
,	O
and	O
20	O
from	O
rodents	O
)	O
,	O
and	O
22	O
saprophytic	O
isolates	O
from	O
environmental	O
sources	O
.	O

The	O
pathogen	O
-	O
specific	O
16S	O
rRNA	O
DNA	O
probe	O
specifically	O
hybridized	O
all	O
33	O
standard	O
pathogenic	O
serovars	O
,	O
to	O
13	O
pathogenic	O
isolates	O
.	O

Similarly	O
,	O
the	O
saprophyte	O
specific	O
1	O
kb	O
ISSR	O
DNA	O
probe	O
specifically	O
hybridized	O
the	O
3	O
standard	O
saprophytic	O
serovars	O
and	O
the	O
22	O
saprophytic	O
Leptospira	O
isolates	O
.	O

The	O
sensitivity	O
of	O
the	O
1	O
kb	O
labeled	O
saprophytic	O
Leptospira	O
specific	O
DNA	O
probe	O
was	O
1.95	O
ng	O
,	O
and	O
for	O
the	O
16S	O
rRNA	O
pathogen	O
specific	O
probe	O
3.90	O
ng	O
.	O

The	O
16S	O
rRNA	O
gene	O
segment	O
DNA	O
probe	O
could	O
also	O
identify	O
the	O
leptospiremic	O
stage	O
in	O
mice	O
or	O
guinea	O
pigs	O
infected	O
experimentally	O
with	O
the	O
pathogenic	O
serovars	O
australis	O
,	O
autumnalis	O
or	O
icterohaemorrhagiae	O
.	O

DNA	O
probes	O
therefore	O
,	O
owing	O
to	O
their	O
high	O
specificity	O
and	O
sensitivity	O
,	O
appear	O
useful	O
for	O
easy	O
,	O
rapid	O
,	O
and	O
reliable	O
differentiation	O
of	O
pathogenic	O
Leptospira	O
strains	O
and	O
also	O
hold	O
promise	O
for	O
direct	O
identification	O
of	O
organisms	O
in	O
blood	O
samples	O
to	O
diagnose	O
leptopsirosis	O
.	O

RNA	O
interference	O
-	O
mediated	O
silencing	O
of	O
X11alpha	B
and	O
X11beta	B
attenuates	O
amyloid	B
beta	I
-	I
protein	I
levels	O
via	O
differential	O
effects	O
on	O
beta	B
-	I
amyloid	I
precursor	I
protein	I
processing	O
.	O

Processing	O
of	O
the	O
beta	B
-	I
amyloid	I
precursor	I
protein	I
(	O
APP	B
)	O
plays	O
a	O
key	O
role	O
in	O
Alzheimer	O
disease	O
neuropathogenesis	O
.	O

APP	B
is	O
cleaved	O
by	O
beta	B
-	I
and	I
alpha	I
-	I
secretase	I
to	O
produce	O
APP	B
-	I
C99	I
and	O
APP	B
-	I
C83	I
,	O
which	O
are	O
further	O
cleaved	O
by	O
gamma	B
-	I
secretase	I
to	O
produce	O
amyloid	B
beta	I
-	I
protein	I
(	O
Abeta	B
)	O
and	O
p3	O
,	O
respectively	O
.	O

APP	B
adaptor	O
proteins	O
with	O
phosphotyrosine	O
-	O
binding	O
domains	O
,	O
including	O
X11alpha	B
(	O
MINT1	B
,	O
encoded	O
by	O
gene	O
APBA1	B
)	O
and	O
X11beta	B
(	O
MINT2	B
,	O
encoded	O
by	O
gene	O
APBA2	B
)	O
,	O
can	O
bind	O
to	O
the	O
conserved	O
YENPTY	O
motif	O
in	O
the	O
APP	B
C	O
terminus	O
.	O

Overexpression	O
of	O
X11alpha	B
and	O
X11beta	B
alters	O
APP	B
processing	O
and	O
Abeta	B
production	O
.	O

Here	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
have	O
described	O
the	O
effects	O
of	O
RNA	O
interference	O
(	O
RNAi	O
)	O
silencing	O
of	O
X11alpha	B
and	O
X11beta	B
expression	O
on	O
APP	B
processing	O
and	O
Abeta	B
production	O
.	O

RNAi	O
silencing	O
of	O
APBA1	B
in	O
H4	O
human	O
neuroglioma	O
cells	O
stably	O
transfected	O
to	O
express	O
either	O
full	O
-	O
length	O
APP	B
or	O
APP	B
-	I
C99	I
increased	O
APP	B
C	O
-	O
terminal	O
fragment	O
levels	O
and	O
lowered	O
Abeta	B
levels	O
in	O
both	O
cell	O
lines	O
by	O
inhibiting	O
gamma	B
-	I
secretase	I
cleavage	O
of	O
APP	B
.	O

RNAi	O
silencing	O
of	O
APBA2	B
also	O
lowered	O
Abeta	B
levels	O
,	O
but	O
apparently	O
not	O
via	O
attenuation	O
of	O
gamma	B
-	I
secretase	I
cleavage	O
of	O
APP	B
.	O

The	O
notion	O
of	O
attenuating	O
gamma	B
-	I
secretase	I
cleavage	O
of	O
APP	B
via	O
the	O
APP	B
adaptor	B
protein	I
X11alpha	B
is	O
particularly	O
attractive	O
with	O
regard	O
to	O
therapeutic	O
potential	O
given	O
that	O
side	O
effects	O
of	O
gamma	B
-	I
secretase	I
inhibition	O
due	O
to	O
impaired	O
proteolysis	O
of	O
other	O
gamma	B
-	I
secretase	I
substrates	O
,	O
e.g.	O
Notch	B
,	O
might	O
be	O
avoided	O
.	O

Differential	O
expression	O
of	O
aquaporins	B
in	O
the	O
kidneys	O
of	O
streptozotocin	O
-	O
induced	O
diabetic	O
mice	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O

Aquaporins	B
(	O
AQPs	B
)	O
are	O
members	O
of	O
the	O
water	B
channel	I
family	I
and	O
are	O
important	O
in	O
renal	O
physiology	O
as	O
it	O
affects	O
urinary	O
concentration	O
.	O

The	O
downregulation	O
of	O
aquaporins	B
is	O
often	O
observed	O
in	O
polyuria	O
associated	O
with	O
acquired	O
nephrogenic	O
diabetes	O
insipidus	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
AQP1	B
,	O
AQP2	B
,	O
AQP3	B
and	O
AQP4	B
in	O
streptozotocin	O
(	O
STZ	O
)	O
-	O
induced	O
diabetic	O
mice	O
.	O

RESULTS	O
:	O

By	O
semiquantitative	O
reverse	O
transcription	O
-	O
polymerase	B
chain	O
reaction	O
,	O
we	O
detected	O
no	O
change	O
in	O
the	O
gene	O
expression	O
of	O
AQP1	B
or	O
AQP4	B
in	O
whole	O
kidney	O
among	O
STZ	O
-	O
induced	O
diabetic	O
mice	O
(	O
STZ	O
mice	O
)	O
and	O
sham	O
(	O
control	O
group	O
that	O
received	O
citrate	O
buffer	O
injection	O
only	O
)	O
.	O

In	O
contrast	O
,	O
we	O
found	O
less	O
AQP2	B
or	O
AQP3	B
mRNA	O
expression	O
in	O
the	O
whole	O
kidney	O
from	O
STZ	O
mice	O
.	O

Immunoblotting	O
studies	O
confirmed	O
no	O
difference	O
in	O
AQP1	B
or	O
AQP4	B
protein	O
expression	O
of	O
whole	O
kidney	O
between	O
STZ	O
mice	O
and	O
sham	O
.	O

However	O
,	O
there	O
was	O
less	O
AQP2	B
or	O
AQP3	B
protein	O
expression	O
in	O
the	O
whole	O
kidney	O
from	O
STZ	O
mice	O
as	O
compared	O
to	O
sham	O
.	O

By	O
immunochemical	O
staining	O
,	O
the	O
reduction	O
of	O
AQP2	B
protein	O
was	O
localized	O
to	O
the	O
principle	O
cells	O
of	O
the	O
collecting	O
ducts	O
.	O

The	O
expression	O
of	O
cortical	O
AQP3	B
(	O
especially	O
the	O
outer	O
cortex	O
,	O
the	O
S1	O
and	O
S2	O
segments	O
of	O
the	O
proximal	O
tubules	O
)	O
was	O
downregulated	O
in	O
STZ	O
mice	O
whereas	O
the	O
expression	O
of	O
AQP3	B
protein	O
in	O
medullary	O
collecting	O
ducts	O
was	O
similar	O
to	O
that	O
of	O
sham	O
.	O

CONCLUSION	O
:	O

Our	O
results	O
reveal	O
that	O
the	O
water	O
transport	O
in	O
urinary	O
concentration	O
involves	O
the	O
downregulation	O
of	O
AQP2	B
and	O
AQP3	B
expression	O
in	O
STZ	O
mice	O
.	O

Killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
of	O
the	O
African	O
-	O
origin	O
sabaeus	O
monkey	O
:	O
evidence	O
for	O
recombination	O
events	O
in	O
the	O
evolution	O
of	O
KIR	B
.	O

Killer	B
cell	I
immunoglobulin	I
(	I
Ig	I
)	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
were	O
characterized	O
in	O
the	O
West	O
African	O
sabaeus	O
monkey	O
(	O
Chlorocebus	O
sabaeus	O
)	O
to	O
elucidate	O
the	O
mechanism	O
by	O
which	O
diversity	O
evolves	O
in	O
this	O
family	O
of	O
molecules	O
.	O

Complementary	O
DNA	O
encoding	O
four	O
forms	O
of	O
KIR	B
molecules	O
,	O
including	O
KIR3DL	B
,	O
KIR2DL4	B
,	O
KIR2DL5	B
,	O
and	O
KIR3DH	B
forms	O
,	O
were	O
identified	O
in	O
two	O
unrelated	O
sabaeus	O
monkeys	O
.	O

A	O
novel	O
hybrid	O
form	O
showing	O
features	O
found	O
in	O
both	O
KIR2DL5	B
and	O
KIR3DH	B
was	O
also	O
identified	O
.	O

Both	O
the	O
KIR3DL	B
and	O
KIR3DH	B
forms	O
from	O
the	O
sabaeus	O
monkey	O
were	O
considerably	O
more	O
polymorphic	O
than	O
any	O
KIR	B
form	O
identified	O
in	O
great	O
apes	O
or	O
humans	O
.	O

The	O
polymorphic	O
residues	O
of	O
the	O
three	O
Ig	B
-	O
like	O
domains	O
were	O
frequently	O
located	O
in	O
structural	O
loops	O
,	O
indicating	O
that	O
point	O
mutations	O
have	O
occurred	O
in	O
these	O
regions	O
.	O

The	O
three	O
Ig	B
-	O
like	O
domains	O
of	O
the	O
KIR3D	B
forms	O
of	O
six	O
primate	O
species	O
were	O
found	O
to	O
have	O
different	O
patterns	O
of	O
clustering	O
in	O
phylogenetic	O
trees	O
,	O
suggesting	O
that	O
each	O
Ig	B
-	O
like	O
domain	O
has	O
a	O
distinct	O
phylogenetic	O
history	O
.	O

This	O
variation	O
in	O
relationships	O
suggests	O
that	O
repeated	O
recombination	O
events	O
have	O
occurred	O
between	O
the	O
Ig	B
-	O
like	O
domains	O
during	O
the	O
evolution	O
of	O
the	O
KIR	B
family	I
in	O
primates	O
.	O

Recombination	O
between	O
individual	O
Ig	B
-	O
like	O
domains	O
,	O
in	O
addition	O
to	O
point	O
mutations	O
,	O
provides	O
a	O
mechanism	O
for	O
generating	O
the	O
diversity	O
of	O
the	O
KIR	B
genes	O
.	O

Interaction	O
between	O
ArgR	B
and	O
AhrC	B
controls	O
regulation	O
of	O
arginine	O
metabolism	O
in	O
Lactococcus	O
lactis	O
.	O

The	O
expression	O
of	O
arginine	O
metabolism	O
in	O
Lactococcus	O
lactis	O
is	O
controlled	O
by	O
the	O
two	O
homologous	O
transcriptional	O
regulators	O
ArgR	B
and	O
AhrC	B
.	O

Genome	O
sequence	O
analyses	O
have	O
shown	O
that	O
the	O
occurrence	O
of	O
multiple	O
homologues	O
of	O
the	O
ArgR	B
family	I
of	O
transcriptional	O
regulators	O
is	O
a	O
common	O
feature	O
of	O
many	O
low	O
-	O
G	O
+	O
C	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Detailed	O
studies	O
of	O
ArgR	B
type	O
regulators	O
have	O
previously	O
only	O
been	O
carried	O
out	O
in	O
bacteria	O
containing	O
single	O
regulators	O
.	O

Here	O
,	O
we	O
present	O
a	O
first	O
characterization	O
of	O
the	O
two	O
L.	O
lactis	O
arginine	O
regulators	O
by	O
means	O
of	O
gel	O
retardation	O
and	O
DNase	B
I	I
footprinting	O
.	O

ArgR	B
of	O
L.	O
lactis	O
was	O
shown	O
to	O
bind	O
to	O
the	O
promoter	O
regions	O
of	O
both	O
the	O
arginine	O
biosynthetic	O
argCJDBF	B
operon	I
and	O
the	O
arginine	O
catabolic	O
arcABD1C1C2TD2yvaD	B
operon	I
,	O
but	O
in	O
an	O
arginine	O
-	O
independent	O
manner	O
.	O

Surprisingly	O
,	O
AhrC	B
alone	O
was	O
unable	O
to	O
bind	O
to	O
DNA	O
.	O

Arginine	O
-	O
dependent	O
DNA	O
binding	O
was	O
obtained	O
by	O
mixing	O
the	O
two	O
regulators	O
in	O
gel	O
retardation	O
assays	O
.	O

With	O
both	O
regulators	O
present	O
,	O
the	O
addition	O
of	O
arginine	O
led	O
to	O
increased	O
binding	O
of	O
ArgR	B
-	O
AhrC	B
to	O
the	O
biosynthetic	O
argC	B
promoter	O
but	O
also	O
to	O
diminished	O
binding	O
to	O
the	O
catabolic	O
arcA	B
promoter	O
.	O

Footprinting	O
showed	O
ArgR	B
-	O
AhrC	B
protection	O
of	O
regions	O
containing	O
ARG	B
box	O
operator	O
sequences	O
preceding	O
argC	B
.	O

In	O
the	O
absence	O
of	O
AhrC	B
,	O
ArgR	B
protected	O
sites	O
in	O
the	O
arcA	B
promoter	O
region	O
with	O
similarity	O
to	O
ARG	B
box	O
half	O
-	O
sites	O
,	O
here	O
called	O
ARC	B
boxes	O
.	O

We	O
propose	O
a	O
model	O
for	O
repression	O
of	O
arginine	O
biosynthesis	O
and	O
activation	O
of	O
catabolism	O
by	O
anti	O
-	O
repression	O
,	O
involving	O
arginine	O
-	O
dependent	O
interaction	O
between	O
the	O
two	O
L.	O
lactis	O
regulator	O
proteins	O
,	O
ArgR	B
and	O
AhrC	B
.	O

Compartmentalized	O
transcription	O
and	O
the	O
establishment	O
of	O
cell	O
type	O
during	O
sporulation	O
in	O
Bacillus	O
subtilis	O
.	O

An	O
early	O
step	O
in	O
sporulation	O
of	O
the	O
bacterium	O
Bacillus	O
subtilis	O
,	O
is	O
the	O
formation	O
of	O
two	O
compartments	O
in	O
the	O
developing	O
sporangium	O
:	O
the	O
mother	O
cell	O
and	O
the	O
forespore	O
.	O

These	O
compartments	O
differ	O
in	O
their	O
programs	O
of	O
gene	O
expression	O
and	O
developmental	O
fate	O
.	O

The	O
establishment	O
of	O
cell	O
type	O
within	O
this	O
simple	O
developmental	O
program	O
,	O
is	O
accomplished	O
by	O
the	O
compartmentalization	O
of	O
sigma	O
subunits	O
of	O
RNA	B
polymerase	I
.	O

The	O
localization	O
of	O
these	O
sigma	B
factors	I
results	O
in	O
compartment	O
-	O
specific	O
gene	O
expression	O
.	O

Recent	O
experiments	O
have	O
elucidated	O
some	O
of	O
the	O
early	O
steps	O
in	O
the	O
establishment	O
of	O
cell	O
type	O
.	O

After	O
septum	O
formation	O
,	O
the	O
activity	O
of	O
the	O
sigma	B
factor	I
,	O
sigma	B
F	I
,	O
is	O
confined	O
to	O
the	O
forespore	O
compartment	O
.	O

This	O
,	O
in	O
turn	O
,	O
results	O
in	O
the	O
localized	O
expression	O
of	O
another	O
developmental	O
sigma	B
factor	I
,	O
sigma	B
G	I
.	O

The	O
forespore	O
localization	O
of	O
these	O
two	O
sigma	B
factors	I
,	O
establishes	O
the	O
forespore	O
line	O
of	O
gene	O
expression	O
.	O

sigma	B
F	I
and	O
sigma	B
G	I
also	O
regulate	O
mother	O
cell	O
events	O
.	O

sigma	B
F	I
activity	O
in	O
the	O
forespore	O
regulates	O
the	O
proteolytic	O
processing	O
of	O
sigma	B
E	I
within	O
the	O
mother	O
cell	O
compartment	O
.	O

The	O
localization	O
sigma	B
E	I
activity	O
leads	O
to	O
mother	O
cell	O
expression	O
of	O
another	O
sigma	B
factor	I
,	O
pro	O
-	O
sigma	B
K	I
.	O

The	O
proteolytic	O
processing	O
of	O
pro	O
-	O
sigma	B
K	I
to	O
mature	O
sigma	B
K	I
is	O
controlled	O
by	O
the	O
forespore	O
sigma	B
factor	I
,	O
sigma	B
G	I
.	O

Mature	O
sigma	B
K	I
then	O
directs	O
the	O
transcription	O
of	O
mother	O
cell	O
specific	O
genes	O
.	O

Therefore	O
,	O
the	O
initial	O
localization	O
of	O
sigma	B
F	I
activity	O
to	O
the	O
forespore	O
compartment	O
,	O
orchestrates	O
the	O
establishment	O
of	O
cell	O
type	O
in	O
both	O
forespore	O
and	O
mother	O
cell	O
compartments	O
.	O

Cutting	O
edge	O
:	O
KIR2DL4	B
transduces	O
signals	O
into	O
human	O
NK	O
cells	O
through	O
association	O
with	O
the	O
Fc	B
receptor	I
gamma	I
protein	O
.	O

KIR2DL4	B
(	O
2DL4	B
,	O
CD158d	B
)	O
,	O
a	O
member	O
of	O
the	O
human	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
(	I
KIR	I
)	I
family	I
,	O
triggers	O
potent	O
IFN	B
-	I
gamma	I
responses	O
but	O
weak	O
cytotoxicity	O
in	O
resting	O
NK	O
cells	O
.	O

2DL4	B
mRNA	O
has	O
been	O
detected	O
in	O
most	O
NK	O
cell	O
clones	O
from	O
most	O
humans	O
examined	O
,	O
but	O
surface	O
protein	O
expression	O
is	O
detectable	O
only	O
on	O
CD56	B
(	O
high	O
)	O
NK	O
cells	O
from	O
certain	O
donors	O
.	O

The	O
receptor	O
possesses	O
a	O
transmembrane	O
arginine	O
residue	O
,	O
suggesting	O
association	O
with	O
a	O
signaling	O
accessory	O
protein	O
that	O
has	O
remained	O
elusive	O
.	O

We	O
provide	O
biochemical	O
and	O
functional	O
evidence	O
that	O
FcepsilonRI	B
-	I
gamma	I
(	O
gamma	O
)	O
associates	O
with	O
2DL4	B
to	O
promote	O
surface	O
expression	O
and	O
provide	O
signal	O
transducing	O
function	O
.	O

Weak	O
cytolytic	O
responses	O
triggered	O
through	O
2DL4	B
may	O
result	O
from	O
low	O
stoichiometric	O
association	O
with	O
gamma	O
.	O

Selective	O
association	O
with	O
gamma	O
distinguishes	O
2DL4	B
from	O
all	O
other	O
activating	O
forms	O
of	O
the	O
KIR	B
family	I
,	O
which	O
alternatively	O
associate	O
with	O
DNAX	B
-	I
activating	I
protein	I
(	I
DAP	I
)	I
12	I
.	O

Three	O
structurally	O
and	O
functionally	O
divergent	O
kinds	O
of	O
promoters	O
regulate	O
expression	O
of	O
clonally	O
distributed	O
killer	B
cell	I
Ig	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
,	O
of	O
KIR2DL4	B
,	O
and	O
of	O
KIR3DL3	B
.	O

The	O
generation	O
of	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
expression	O
patterns	O
in	O
NK	O
cells	O
involves	O
variegated	O
silencing	O
of	O
KIR	B
genes	O
by	O
DNA	O
methylation	O
.	O

To	O
identify	O
regulatory	O
elements	O
involved	O
in	O
KIR	B
gene	O
activation	O
,	O
upstream	O
regions	O
of	O
KIR	B
genes	O
were	O
functionally	O
characterized	O
in	O
NK3.3	O
cells	O
as	O
well	O
as	O
in	O
primary	O
NK	O
cells	O
.	O

Three	O
kinds	O
of	O
KIR	B
promoters	O
were	O
defined	O
,	O
controlling	O
clonally	O
expressed	O
KIR	B
genes	O
,	O
the	O
constitutively	O
active	O
KIR2DL4	B
,	O
and	O
the	O
weakly	O
expressed	O
KIR3DL3	B
.	O

Upstream	O
of	O
a	O
short	O
core	O
promoter	O
common	O
to	O
all	O
KIR	B
genes	O
,	O
a	O
region	O
containing	O
functionally	O
divergent	O
elements	O
was	O
characterized	O
.	O

Although	O
this	O
region	O
had	O
no	O
impact	O
on	O
the	O
activity	O
of	O
the	O
KIR2DL3	B
promoter	O
,	O
an	O
inhibitory	O
element	O
was	O
identified	O
in	O
the	O
KIR2DL4	B
promoter	O
and	O
an	O
activating	O
element	O
was	O
found	O
in	O
the	O
KIR3DL3	B
promoter	O
.	O

Upon	O
treatment	O
with	O
a	O
methyltransferase	B
inhibitor	O
,	O
KIR3DL3	B
expression	O
could	O
be	O
readily	O
induced	O
showing	O
that	O
the	O
low	O
levels	O
of	O
KIR3DL3	B
expression	O
in	O
peripheral	O
blood	O
are	O
due	O
to	O
sustained	O
DNA	O
methylation	O
of	O
an	O
otherwise	O
fully	O
functional	O
promoter	O
.	O

Analysis	O
of	O
transcription	B
factor	I
binding	O
sites	O
identified	O
a	O
functional	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
site	O
common	O
to	O
all	O
three	O
KIR	B
promoters	O
.	O

Mutation	O
of	O
this	O
site	O
led	O
to	O
a	O
substantial	O
increase	O
in	O
activity	O
of	O
all	O
KIR	B
promoters	O
.	O

Among	O
the	O
different	O
members	O
of	O
the	O
AML	B
family	I
,	O
AML-2	B
was	O
identified	O
as	O
the	O
predominant	O
KIR	B
binding	O
factor	O
.	O

The	O
present	O
study	O
suggests	O
that	O
AML-2	B
acts	O
as	O
a	O
repressor	O
of	O
KIR	B
expression	O
in	O
mature	O
NK	O
cells	O
and	O
opens	O
the	O
possibility	O
that	O
AML	B
factors	O
and	O
associated	O
cofactors	O
are	O
involved	O
in	O
regulation	O
of	O
KIR	B
expression	O
during	O
NK	O
cell	O
development	O
.	O

Aspartyl	B
-	I
tRNA	I
synthetase	I
requires	O
a	O
conserved	O
proline	O
in	O
the	O
anticodon	O
-	O
binding	O
loop	O
for	O
tRNA	O
(	O
Asn	O
)	O
recognition	O
in	O
vivo	O
.	O

Most	O
prokaryotes	O
require	O
Asp	O
-	O
tRNA	O
(	O
Asn	O
)	O
for	O
the	O
synthesis	O
of	O
Asn	O
-	O
tRNA	O
(	O
Asn	O
)	O
.	O

This	O
misacylated	O
tRNA	O
species	O
is	O
synthesized	O
by	O
a	O
non	O
-	O
discriminating	O
aspartyl	B
-	I
tRNA	I
synthetase	I
(	O
AspRS	B
)	O
that	O
acylates	O
both	O
tRNA	O
(	O
Asp	O
)	O
and	O
tRNA	O
(	O
Asn	O
)	O
with	O
aspartate	O
.	O

In	O
contrast	O
,	O
a	O
discriminating	O
AspRS	B
forms	O
only	O
Asp	O
-	O
tRNA	O
(	O
Asp	O
)	O
.	O

Here	O
we	O
show	O
that	O
a	O
conserved	O
proline	O
(	O
position	O
77	O
)	O
in	O
the	O
L1	O
loop	O
of	O
the	O
non	O
-	O
discriminating	O
Deinococcus	O
radiodurans	O
AspRS2	B
is	O
required	O
for	O
tRNA	O
(	O
Asn	O
)	O
recognition	O
in	O
vivo	O
.	O

Escherichia	O
coli	O
trpA34	O
was	O
transformed	O
with	O
DNA	O
from	O
a	O
library	O
of	O
D.	O
radiodurans	O
aspS2	B
genes	O
with	O
a	O
randomized	O
codon	O
77	O
and	O
then	O
subjected	O
to	O
in	O
vivo	O
selection	O
for	O
Asp	O
-	O
tRNA	O
(	O
Asn	O
)	O
formation	O
by	O
growth	O
in	O
minimal	O
medium	O
.	O

Only	O
proline	O
codons	O
were	O
found	O
at	O
position	O
77	O
in	O
the	O
aspS2	B
genes	O
isolated	O
from	O
21	O
of	O
the	O
resulting	O
viable	O
colonies	O
.	O

However	O
,	O
when	O
the	O
aspS	B
temperature	O
-	O
sensitive	O
E.	O
coli	O
strain	O
CS89	O
was	O
transformed	O
with	O
the	O
same	O
DNA	O
library	O
and	O
then	O
screened	O
for	O
Asp	O
-	O
tRNA	O
(	O
Asp	O
)	O
formation	O
in	O
vivo	O
by	O
growth	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
,	O
codons	O
for	O
seven	O
other	O
amino	O
acids	O
besides	O
proline	O
were	O
identified	O
at	O
position	O
77	O
in	O
the	O
isolates	O
examined	O
.	O

Thus	O
,	O
replacement	O
of	O
proline	O
77	O
by	O
cysteine	O
,	O
isoleucine	O
,	O
leucine	O
,	O
lysine	O
,	O
phenylalanine	O
,	O
serine	O
,	O
or	O
valine	O
resulted	O
in	O
mutant	O
D.	O
radiodurans	O
AspRS2	B
enzymes	O
still	O
capable	O
of	O
forming	O
Asp	O
-	O
tRNA	O
(	O
Asp	O
)	O
but	O
unable	O
to	O
recognize	O
tRNA	O
(	O
Asn	O
)	O
.	O

This	O
strongly	O
suggests	O
that	O
proline	O
77	O
is	O
responsible	O
for	O
the	O
non	O
-	O
discriminatory	O
tRNA	O
recognition	O
properties	O
of	O
this	O
enzyme	O
.	O

Coenzyme	O
q10	O
confers	O
cardiovascular	O
protection	O
against	O
acute	O
mevinphos	O
intoxication	O
by	O
ameliorating	O
bioenergetic	O
failure	O
and	O
hypoxia	O
in	O
the	O
rostral	O
ventrolateral	O
medulla	O
of	O
the	O
rat	O
.	O

Coenzyme	O
Q10	O
(	O
CoQ10	O
,	O
ubiquinone	O
)	O
is	O
a	O
highly	O
mobile	O
electron	O
carrier	O
in	O
the	O
mitochondrial	O
respiratory	O
chain	O
that	O
also	O
acts	O
as	O
an	O
antioxidant	O
.	O

We	O
evaluated	O
the	O
cardiovascular	O
protective	O
efficacy	O
of	O
CoQ10	O
at	O
the	O
rostral	O
ventrolateral	O
medulla	O
(	O
RVLM	O
)	O
,	O
a	O
medullary	O
site	O
where	O
sympathetic	O
vasomotor	O
tone	O
originates	O
and	O
where	O
the	O
organophosphate	O
poison	O
mevinphos	O
(	O
Mev	O
)	O
acts	O
to	O
elicit	O
cardiovascular	O
intoxication	O
.	O

Experiments	O
were	O
carried	O
out	O
in	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
that	O
were	O
maintained	O
under	O
propofol	O
anesthesia	O
.	O

Microinjection	O
bilaterally	O
of	O
Mev	O
(	O
10	O
nmol	O
)	O
into	O
the	O
RVLM	O
induced	O
progressive	O
hypotension	O
and	O
minor	O
bradycardia	O
,	O
alongside	O
significant	O
depression	O
of	O
the	O
activity	O
of	O
NADH	B
cytochrome	I
c	I
reductase	I
(	O
enzyme	O
marker	O
for	O
Complexes	O
I	O
and	O
III	O
)	O
or	O
cytochrome	B
c	I
oxidase	I
(	O
enzyme	O
marker	O
for	O
Complex	O
IV	O
)	O
in	O
the	O
mitochondrial	O
respiratory	O
chain	O
,	O
reduction	O
in	O
ATP	O
concentration	O
,	O
or	O
tissue	O
hypoxia	O
in	O
the	O
RVLM	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
activity	O
of	O
succinate	B
cytochrome	I
c	I
reductase	I
(	O
enzyme	O
marker	O
for	O
Complexes	O
II	O
and	O
III	O
)	O
remained	O
unaltered	O
.	O

The	O
Mev	O
-	O
induced	O
hypotension	O
,	O
bioenergetic	O
failure	O
,	O
or	O
hypoxia	O
was	O
significantly	O
reversed	O
when	O
CoQ10	O
(	O
4	O
microg	O
)	O
was	O
coadministered	O
bilaterally	O
into	O
the	O
RVLM	O
with	O
the	O
organophosphate	O
poison	O
.	O

We	O
conclude	O
that	O
CoQ10	O
confers	O
cardiovascular	O
protection	O
against	O
acute	O
Mev	O
intoxication	O
by	O
acting	O
on	O
the	O
RVLM	O
,	O
whose	O
neuronal	O
activity	O
is	O
intimately	O
related	O
to	O
the	O
""""	O
life	O
-	O
and	O
-	O
death	O
""""	O
process	O
.	O

We	O
also	O
showed	O
that	O
amelioration	O
of	O
the	O
selective	O
dysfunction	O
of	O
respiratory	O
enzyme	O
Complexes	O
I	O
and	O
IV	O
in	O
the	O
mitochondrial	O
respiratory	O
chain	O
,	O
the	O
reduced	O
ATP	O
level	O
,	O
and	O
the	O
induced	O
tissue	O
hypoxia	O
in	O
the	O
RVLM	O
are	O
among	O
some	O
of	O
the	O
underlying	O
mechanisms	O
for	O
the	O
elicited	O
protection	O
.	O

Molecular	O
analysis	O
of	O
the	O
role	O
of	O
two	O
aromatic	B
aminotransferases	I
and	O
a	O
broad	O
-	O
specificity	O
aspartate	B
aminotransferase	I
in	O
the	O
aromatic	O
amino	O
acid	O
metabolism	O
of	O
Pyrococcus	O
furiosus	O
.	O

The	O
genes	O
encoding	O
aromatic	B
aminotransferase	I
II	I
(	O
AroAT	B
II	I
)	O
and	O
aspartate	B
aminotransferase	I
(	O
AspAT	B
)	O
from	O
Pyrococcus	O
furiosus	O
have	O
been	O
identified	O
,	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
the	O
recombinant	O
proteins	O
characterized	O
.	O

The	O
AroAT	B
II	I
enzyme	O
was	O
specific	O
for	O
the	O
transamination	O
reaction	O
of	O
the	O
aromatic	O
amino	O
acids	O
,	O
and	O
uses	O
a	O
-	O
ketoglutarate	O
as	O
the	O
amino	O
acceptor	O
.	O

Like	O
the	O
previously	O
characterized	O
AroAT	B
I	I
,	O
AroAT	B
II	I
has	O
highest	O
efficiency	O
for	O
phenylalanine	O
(	O
k	O
(	O
cat	O
)	O
/	O
Km	O
=	O
923	O
s	O
(	O
-1	O
)	O
mM	O
(	O
-1	O
)	O
)	O
.	O

Northern	O
blot	O
analyses	O
revealed	O
that	O
AroAT	B
I	I
was	O
mainly	O
expressed	O
when	O
tryptone	O
was	O
the	O
primary	O
carbon	O
and	O
energy	O
source	O
.	O

Although	O
the	O
expression	O
was	O
significantly	O
lower	O
,	O
a	O
similar	O
trend	O
was	O
observed	O
for	O
AroAT	B
II	I
.	O

These	O
observations	O
suggest	O
that	O
both	O
AroATs	B
are	O
involved	O
in	O
amino	O
acid	O
degradation	O
.	O

Although	O
AspAT	B
exhibited	O
highest	O
activity	O
with	O
aspartate	O
and	O
alpha	O
-	O
ketoglutarate	O
(	O
k	O
(	O
cat	O
)	O
approximately	O
105	O
s	O
(	O
-1	O
)	O
)	O
,	O
it	O
also	O
showed	O
significant	O
activity	O
with	O
alanine	O
,	O
glutamate	O
and	O
the	O
aromatic	O
amino	O
acids	O
.	O

With	O
aspartate	O
as	O
the	O
amino	O
donor	O
,	O
AspAT	B
catalyzed	O
the	O
amination	O
of	O
alpha	O
-	O
ketoglutarate	O
,	O
pyruvate	O
and	O
phenyl	O
-	O
pyruvate	O
.	O

No	O
activity	O
was	O
detected	O
with	O
either	O
branched	O
-	O
chain	O
amino	O
acids	O
or	O
alpha	O
-	O
keto	O
acids	O
.	O

The	O
AspAT	B
gene	O
(	O
aspC	B
)	O
was	O
expressed	O
as	O
a	O
polycistronic	O
message	O
as	O
part	O
of	O
the	O
aro	B
operon	I
,	O
with	O
expression	O
observed	O
only	O
when	O
the	O
aromatic	O
amino	O
acids	O
were	O
absent	O
from	O
the	O
growth	O
medium	O
,	O
indicating	O
a	O
role	O
in	O
the	O
biosynthesis	O
of	O
the	O
aromatic	O
amino	O
acids	O
.	O

The	O
effect	O
of	O
MCP-1	B
depletion	O
on	O
chemokine	B
and	O
chemokine	B
-	O
related	O
gene	O
expression	O
:	O
evidence	O
for	O
a	O
complex	O
network	O
in	O
acute	O
inflammation	O
.	O

The	O
expression	O
of	O
chemokines	B
has	O
been	O
suggested	O
to	O
involve	O
an	O
interdependent	O
network	O
,	O
with	O
the	O
absence	O
of	O
a	O
single	O
chemokine	B
affecting	O
the	O
expression	O
of	O
multiple	O
other	O
chemokines	B
.	O

Monocyte	B
chemoattractant	I
protein	I
(	O
MCP-1	B
)	O
,	O
a	O
member	O
of	O
C	B
-	I
C	I
chemokine	I
superfamily	I
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
recruitment	O
and	O
activation	O
of	O
leukocytes	O
during	O
acute	O
inflammation	O
.	O

To	O
examine	O
the	O
effect	O
of	O
the	O
loss	O
of	O
MCP-1	B
on	O
expression	O
of	O
the	O
chemokine	B
network	O
,	O
we	O
compared	O
the	O
mRNA	O
expression	O
profiles	O
of	O
MCP-1	B
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
type	O
mice	O
during	O
the	O
acute	O
inflammatory	O
phase	O
of	O
excisional	O
wounds	O
.	O

Utilizing	O
a	O
mouse	O
cDNA	O
array	O
containing	O
514	O
chemokine	B
and	O
chemokine	B
related	O
genes	O
,	O
the	O
loss	O
of	O
MCP-1	B
was	O
observed	O
to	O
cause	O
a	O
significant	O
upregulation	O
of	O
nine	O
genes	O
(	O
Decorin	B
,	O
Persephin	B
,	O
IL-1beta	B
,	O
MIP-2	B
,	O
MSP	B
,	O
IL1ra	B
,	O
CCR5	B
,	O
CCR3	B
,	O
IL-11	B
)	O
and	O
significant	O
downregulation	O
of	O
two	O
genes	O
(	O
CCR4	B
and	O
CD3Z	B
)	O
in	O
acute	O
wounds	O
.	O

The	O
array	O
data	O
was	O
confirmed	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
.	O

The	O
effect	O
of	O
MCP-1	B
deletion	O
on	O
chemokine	O
expression	O
was	O
further	O
examined	O
in	O
isolated	O
macrophages	O
.	O

Compared	O
to	O
wild	O
type	O
,	O
LPS	O
-	O
stimulated	O
peritoneal	O
macrophages	O
from	O
MCP-1	B
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
expression	O
of	O
RANTES	B
,	O
MIP-1beta	B
,	O
MIP-1alpha	B
and	O
MIP-2	B
mRNA	O
.	O

The	O
data	O
suggest	O
that	O
loss	O
of	O
a	O
single	O
chemokine	B
perturbs	O
the	O
chemokine	O
network	O
not	O
only	O
in	O
the	O
setting	O
of	O
acute	O
inflammation	O
but	O
even	O
in	O
an	O
isolated	O
inflammatory	O
cell	O
,	O
the	O
macrophage	O
.	O

Association	O
of	O
nucleotide	O
variations	O
in	O
the	O
apolipoprotein	B
B48	I
receptor	I
gene	O
(	O
APOB48R	B
)	O
with	O
hypercholesterolemia	O
.	O

Factors	O
predisposing	O
to	O
the	O
phenotypic	O
features	O
of	O
high	O
total	O
cholesterol	O
(	O
T	O
-	O
Cho	O
)	O
in	O
human	O
plasma	O
have	O
not	O
been	O
clearly	O
defined	O
.	O

Here	O
we	O
report	O
an	O
association	O
between	O
two	O
variations	O
in	O
the	O
apolipoprotein	B
B48	I
receptor	I
gene	O
(	O
APOB48R	B
)	O
and	O
plasma	O
T	O
-	O
Cho	O
levels	O
among	O
352	O
adult	O
individuals	O
in	O
Japan	O
.	O

By	O
analyzing	O
phenotypic	O
associations	O
between	O
age	O
-	O
and	O
gender	O
-	O
adjusted	O
levels	O
of	O
plasma	O
T	O
-	O
Cho	O
,	O
low	B
-	I
density	I
lipoprotein	I
(	O
LDL	B
)	O
cholesterol	O
(	O
LDL	B
-	O
C	O
)	O
,	O
and	O
high	B
-	I
density	I
lipoprotein	I
(	O
HDL	B
)	O
cholesterol	O
(	O
HDL	B
-	O
C	O
)	O
,	O
we	O
detected	O
a	O
significant	O
correlation	O
between	O
genotypes	O
of	O
the	O
A419P	O
variation	O
and	O
adjusted	O
T	O
-	O
Cho	O
levels	O
.	O

Among	O
homozygous	O
G	O
-	O
allele	O
carriers	O
(	O
n	O
=	O
265	O
)	O
,	O
heterozygous	O
carriers	O
(	O
n	O
=	O
78	O
)	O
,	O
and	O
homozygous	O
minor	O
C	O
-	O
allele	O
carriers	O
(	O
n	O
=	O
9	O
)	O
,	O
T	O
-	O
Cho	O
levels	O
were	O
2.43	O
+	O
/-	O
0.21	O
mg	O
/	O
cm	O
(	O
3	O
)	O
,	O
2.48	O
+	O
/	O
-	O
0.24	O
mg	O
/	O
cm	O
(	O
3	O
)	O
,	O
and	O
2.63	O
+	O
/-	O
0.21	O
mg	O
/	O
cm	O
(	O
3	O
)	O
,	O
respectively	O
,	O
indicating	O
a	O
codominant	O
T	O
-	O
Cho	O
-	O
elevating	O
effect	O
of	O
the	O
minor	O
C	O
-	O
allele	O
(	O
r	O
=	O
0.15	O
,	O
P	O
=	O
0.007	O
)	O
.	O

A	O
similar	O
effect	O
was	O
detected	O
for	O
c.934	O
-	O
960	O
/	O
del	O
(	O
r	O
=	O
0.13	O
,	O
P	O
=	O
0.015	O
)	O
.	O

Linkage	O
disequilibrium	O
(	O
LD	O
)	O
analysis	O
detected	O
significant	O
LD	O
among	O
eight	O
variant	O
sites	O
that	O
included	O
neighboring	O
loci	O
.	O

Our	O
results	O
indicate	O
that	O
variations	O
in	O
APOB48R	B
and	O
nearby	O
genes	O
are	O
among	O
the	O
many	O
factors	O
involved	O
in	O
hypercholesterolemia	O
.	O

The	O
etiological	O
studies	O
should	O
now	O
include	O
consideration	O
of	O
this	O
novel	O
aspect	O
of	O
the	O
mechanism	O
(	O
s	O
)	O
leading	O
to	O
hypercholesterolemic	O
disease	O
.	O

B	O
cell	O
memory	O
to	O
3	O
Plasmodium	O
falciparum	O
blood	O
-	O
stage	O
antigens	O
in	O
a	O
malaria	O
-	O
endemic	O
area	O
.	O

To	O
gain	O
insight	O
into	O
why	O
antibody	O
responses	O
to	O
malarial	O
antigens	O
tend	O
to	O
be	O
short	O
lived	O
,	O
we	O
studied	O
antigen	O
-	O
specific	O
memory	O
B	O
cells	O
from	O
donors	O
in	O
an	O
area	O
where	O
malaria	O
is	O
endemic	O
.	O

We	O
compared	O
antibody	O
and	O
memory	O
B	O
cell	O
responses	O
to	O
tetanus	O
toxoid	O
with	O
those	O
to	O
3	O
Plasmodium	O
falciparum	O
candidate	O
vaccine	O
antigens	O
:	O
the	O
C	O
-	O
terminal	O
portion	O
of	O
merozoite	B
surface	I
protein	I
1	I
(	O
MSP1	B
(	O
19	O
)	O
)	O
,	O
apical	B
membrane	I
antigen	I
1	I
(	O
AMA1	B
)	O
,	O
and	O
the	O
cysteine	O
-	O
rich	O
interdomain	O
region	O
1	O
alpha	O
(	O
CIDR1	O
alpha	O
)	O
of	O
a	O
protein	O
from	O
the	O
P.	B
falciparum	I
erythrocyte	I
membrane	I
protein	I
1	I
(	I
PfEMP1	I
)	I
family	I
.	O

These	O
data	O
are	O
the	O
first	O
to	O
be	O
generated	O
on	O
memory	O
B	O
cells	O
in	O
children	O
who	O
are	O
in	O
the	O
process	O
of	O
acquiring	O
antimalarial	O
immunity	O
,	O
and	O
they	O
reveal	O
defects	O
in	O
B	O
cell	O
memory	O
to	O
P.	O
falciparum	O
antigens	O
.	O

Compared	O
with	O
the	O
results	O
for	O
tetanus	O
toxoid	O
,	O
more	O
donors	O
who	O
were	O
positive	O
for	O
antibody	O
to	O
AMA1	B
and	O
CIDR1	O
alpha	O
were	O
negative	O
for	O
memory	O
B	O
cells	O
.	O

These	O
data	O
imply	O
that	O
some	O
exposures	O
to	O
malaria	O
do	O
not	O
result	O
in	O
the	O
establishment	O
of	O
stable	O
populations	O
of	O
circulating	O
antigen	O
-	O
specific	O
memory	O
B	O
cells	O
,	O
suggesting	O
possible	O
mechanisms	O
for	O
the	O
short	O
-	O
lived	O
nature	O
of	O
many	O
anti	O
-	O
malarial	O
antibody	O
responses	O
.	O

Restoration	O
of	O
aspartoacylase	B
activity	O
in	O
CNS	O
neurons	O
does	O
not	O
ameliorate	O
motor	O
deficits	O
and	O
demyelination	O
in	O
a	O
model	O
of	O
Canavan	O
disease	O
.	O

Canavan	O
disease	O
is	O
an	O
early	O
onset	O
leukodystrophy	O
associated	O
with	O
psychomotor	O
retardation	O
,	O
seizures	O
,	O
and	O
premature	O
death	O
.	O

This	O
disorder	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
enzyme	O
aspartoacylase	B
(	O
ASPA	B
)	O
.	O

Normally	O
,	O
ASPA	B
is	O
enriched	O
in	O
oligodendrocytes	O
and	O
ASPA	B
deficiency	O
results	O
in	O
elevated	O
levels	O
of	O
its	O
substrate	O
molecule	O
,	O
N	O
-	O
acetylaspartate	O
(	O
NAA	O
)	O
,	O
brain	O
edema	O
,	O
and	O
dysmyelination	O
.	O

Using	O
adeno	O
-	O
associated	O
virus	O
,	O
we	O
permanently	O
expressed	O
ASPA	B
in	O
CNS	O
neurons	O
of	O
the	O
tremor	O
rat	O
,	O
a	O
genetic	O
model	O
of	O
Canavan	O
disease	O
,	O
and	O
examined	O
the	O
efficacy	O
of	O
the	O
treatment	O
by	O
monitoring	O
NAA	O
metabolism	O
,	O
myelination	O
,	O
motor	O
behavior	O
,	O
and	O
seizures	O
.	O

Assessment	O
of	O
ASPA	B
protein	O
and	O
enzyme	O
activity	O
in	O
whole	O
brain	O
hemispheres	O
showed	O
restoration	O
to	O
normal	O
levels	O
as	O
long	O
as	O
6	O
months	O
after	O
treatment	O
.	O

This	O
finding	O
correlated	O
with	O
a	O
reduction	O
of	O
NAA	O
levels	O
,	O
along	O
with	O
a	O
rescue	O
of	O
the	O
seizure	O
phenotype	O
.	O

However	O
,	O
gross	O
brain	O
pathology	O
,	O
such	O
as	O
dilated	O
ventricles	O
and	O
spongiform	O
vacuolization	O
,	O
was	O
unchanged	O
.	O

Moreover	O
,	O
hypomyelination	O
and	O
motor	O
deficits	O
were	O
not	O
resolved	O
by	O
ASPA	B
gene	O
transfer	O
.	O

Our	O
data	O
suggest	O
that	O
NAA	O
-	O
mediated	O
neuronal	O
hyperexcitation	O
but	O
not	O
oligodendrocyte	O
dysfunction	O
can	O
be	O
compensated	O
for	O
by	O
neuronal	O
ASPA	B
expression	O
.	O

[	O
Study	O
on	O
p53	B
tetramerization	O
domain	O
in	O
improving	O
functional	O
affinity	O
and	O
biological	O
activity	O
of	O
antibody	O
]	O

OBJECTIVE	O
:	O

To	O
fuse	O
the	O
genes	O
of	O
p53	B
tetramerization	O
domain	O
and	O
anti	O
-	O
CD3	B
/	O
anti	O
-	O
prostate	O
-	O
cancer	O
bispecific	O
single	O
-	O
chain	O
antibody	O
(	O
BsAb	O
)	O
,	O
and	O
exploit	O
a	O
new	O
way	O
to	O
improve	O
the	O
functional	O
affinity	O
and	O
biological	O
activity	O
of	O
antibody	O
.	O

METHODS	O
:	O

Genes	O
of	O
p53	B
tetramerization	O
domain	O
and	O
anti	O
-	O
CD3	B
/	O
anti	O
-	O
prostate	O
-	O
cancer	O
BsAb	O
was	O
fused	O
by	O
technique	O
of	O
DNA	O
sub	O
-	O
cloning	O
.	O

The	O
fusion	O
gene	O
confirmed	O
by	O
sequencing	O
was	O
subcloned	O
into	O
the	O
pSectag2	O
-	O
B	O
plasmid	O
.	O

Then	O
the	O
recombinant	O
plasmid	O
was	O
transfected	O
into	O
HeLa	O
cells	O
.	O

The	O
expression	O
products	O
,	O
which	O
were	O
analyzed	O
by	O
both	O
SDS	O
-	O
PAGE	O
and	O
western	O
blotting	O
,	O
were	O
purified	O
with	O
Ni	O
(	O
2+	O
)	O
-NTA	O
superflow	O
affinity	O
chromatography	O
.	O

mBsAb	O
-	O
pSectag2-B	O
plasmid	O
was	O
added	O
into	O
the	O
suspensions	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
PC-3	O
cells	O
respectively	O
.	O

Flow	O
cytometry	O
was	O
used	O
to	O
examine	O
the	O
binding	O
rate	O
of	O
multivalent	O
anti	O
-	O
prostate	O
-	O
cander	O
/	O
anti	O
-	O
CD3	B
bispecific	O
scFv	O
with	O
PBMCs	O
and	O
PC-3	O
cells	O
.	O

T	O
cells	O
were	O
isolated	O
from	O
the	O
PBMCs	O
.	O

PC-3	O
cells	O
were	O
labeled	O
with	O
Na	O
(	O
2	O
)	O
[	O
(	O
51	O
)	O
Cr	O
]	O
O	O
(	O
4	O
)	O
used	O
as	O
target	O
cells	O
.	O

Labeled	O
PC-3	O
cells	O
,	O
T	O
cells	O
,	O
and	O
different	O
concentrations	O
of	O
mBsAb	O
were	O
mixed	O
.	O

Natural	O
release	O
control	O
well	O
with	O
labeled	O
target	O
cells	O
only	O
and	O
maximum	O
release	O
control	O
well	O
with	O
labeled	O
target	O
cells	O
and	O
10	O
%	O
SDS	O
were	O
prepared	O
.	O

The	O
supernatants	O
were	O
extracted	O
.	O

gamma	O
calculator	O
was	O
used	O
to	O
calculate	O
the	O
counts	O
per	O
minute	O
(	O
cpm	O
)	O
values	O
to	O
calculate	O
the	O
specific	O
release	O
rate	O
of	O
(	O
51	O
)	O
Cr	O
.	O

RESULTS	O
:	O

Sequencing	O
showed	O
a	O
fragment	O
from	O
mBsAb	O
-	O
pSectag2-B	O
with	O
the	O
size	O
of	O
1.7	O
kb	O
corresponding	O
to	O
the	O
predicted	O
value	O
.	O

SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
showed	O
expression	O
of	O
67	O
000	O
D	O
protein	O
in	O
the	O
supernatant	O
of	O
culture	O
fluid	O
of	O
HeLa	O
cells	O
transfected	O
with	O
MBsAb	O
-	O
pSectag2	O
-	O
B	O
plasmid	O
.	O

The	O
binding	O
rates	O
of	O
multivalent	O
anti	O
-	O
prostate	O
-	O
cancer	O
/	O
anti	O
-	O
CD3	B
bispecific	O
scFv	O
with	O
PBMC	O
and	O
PC-3	O
cells	O
were	O
70.4	O
%	O
and	O
81	O
%	O
respectively	O
,	O
significantly	O
higher	O
than	O
those	O
of	O
anti	O
-	O
prostate	O
-	O
cancer	O
/	O
anti	O
-	O
CD3	B
bispecific	O
scFv	O
.	O

In	O
the	O
presence	O
of	O
mBsAb	O
the	O
activated	O
T	O
cells	O
lysed	O
PC-3	O
cells	O
in	O
positive	O
correlation	O
with	O
the	O
antibody	O
concentration	O
and	O
effective	O
cell	O
/	O
target	O
cell	O
ratio	O
and	O
with	O
a	O
lysis	O
rate	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
control	O
groups	O
.	O

CONCLUSION	O
:	O

Multivalent	O
anti	O
-	O
CD3	B
x	O
anti	O
-	O
prostate	O
-	O
cancer	O
BsAb	O
exhibits	O
much	O
higher	O
functional	O
affinity	O
and	O
biological	O
activity	O
than	O
anti	O
-	O
CD3	B
x	O
anti	O
-	O
prostate	O
-	O
cancer	O
BsAb	O
,	O
which	O
may	O
break	O
a	O
new	O
path	O
to	O
the	O
improvement	O
of	O
functional	O
affinity	O
and	O
biological	O
activity	O
of	O
antibody	O
.	O

Packages	O
of	O
vitreous	O
collagen	B
(	I
type	I
II	I
)	I
in	O
the	O
human	O
retina	O
:	O
an	O
indication	O
of	O
postnatal	O
collagen	B
turnover	O
?	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
vitreoretinal	O
border	O
in	O
the	O
(	O
pre	O
-	O
)	O
equatorial	O
area	O
in	O
nonpathologic	O
human	O
donor	O
eyes	O
,	O
because	O
the	O
majority	O
of	O
retinal	O
defects	O
induced	O
by	O
posterior	O
vitreous	O
detachment	O
(	O
PVD	O
)	O
are	O
located	O
there	O
.	O

Nine	O
eyes	O
(	O
24	O
-	O
80	O
years	O
)	O
were	O
fixed	O
and	O
embedded	O
in	O
Technovit	O
8100	O
.	O

After	O
evaluation	O
by	O
light	O
microscope	O
,	O
areas	O
of	O
interest	O
were	O
selected	O
for	O
immunotransmission	O
electron	O
microscope	O
.	O

Anti	O
-	O
type	B
II	I
collagen	I
antibody	O
was	O
used	O
to	O
stain	O
vitreous	O
fibrils	O
and	O
lamellae	O
;	O
anti	O
-	O
type	B
IV	I
collagen	I
antibody	O
was	O
used	O
to	O
identify	O
the	O
internal	O
limiting	O
lamina	O
(	O
ILL	O
)	O
;	O
anti	O
-	O
vimentin	B
and	O
anti	O
-	O
CD-68	B
antibodies	O
stained	O
retinal	O
Muller	O
cells	O
and	O
macrophages	O
,	O
respectively	O
.	O

Observations	O
included	O
fusing	O
of	O
lamellae	O
with	O
the	O
ILL	O
,	O
an	O
intravitreal	O
course	O
of	O
the	O
ILL	O
,	O
and	O
clear	O
focal	O
interruptions	O
in	O
the	O
ILL	O
.	O

In	O
addition	O
,	O
an	O
obvious	O
finding	O
was	O
the	O
presence	O
of	O
intraretinal	O
packages	O
of	O
type	B
II	I
collagen	I
.	O

Interestingly	O
these	O
collagen	O
packages	O
were	O
closely	O
related	O
to	O
Muller	O
cells	O
and	O
,	O
in	O
several	O
eyes	O
,	O
also	O
to	O
macrophages	O
,	O
cell	O
debris	O
and	O
interruptions	O
in	O
the	O
ILL	O
.	O

In	O
our	O
opinion	O
,	O
the	O
collagen	O
packages	O
can	O
reflect	O
the	O
net	O
result	O
of	O
a	O
process	O
of	O
interactive	O
remodelling	O
,	O
in	O
which	O
both	O
breakdown	O
and	O
synthesis	O
of	O
vitreous	O
and	O
ILL	O
collagens	O
take	O
place	O
.	O

Connections	O
between	O
vitreous	O
and	O
intraretinal	O
collagen	B
networks	O
can	O
make	O
the	O
(	O
pre	O
-	O
)	O
equatorial	O
area	O
more	O
vulnerable	O
to	O
tearing	O
and	O
retinal	O
detachment	O
in	O
the	O
case	O
of	O
liquefaction	O
and	O
PVD	O
.	O

Interleukin-12	B
p40	I
promoter	O
activity	O
is	O
regulated	O
by	O
the	O
reversible	O
acetylation	O
mediated	O
by	O
HDAC1	B
and	I
p300	I
.	O

Interleukin-12	B
(	O
IL-12	B
)	O
is	O
a	O
heterodimeric	O
cytokine	O
produced	O
by	O
macrophages	O
in	O
response	O
to	O
intracellular	O
pathogens	O
.	O

The	O
importance	O
of	O
IL-12	B
in	O
generation	O
of	O
Th1	O
response	O
against	O
human	O
pathogens	O
has	O
been	O
characterized	O
.	O

The	O
coactivator	O
p300	B
is	O
an	O
important	O
histone	B
acetyltransferase	I
(	O
HAT	B
)	O
and	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
many	O
genes	O
.	O

Histone	B
deacetylases	I
(	O
HDACs	B
)	O
regulate	O
gene	O
transcription	O
through	O
deacetylation	O
of	O
histones	B
.	O

Whether	O
the	O
reversible	O
histone	B
acetylation	O
/	O
deacetylation	O
modification	O
participates	O
in	O
the	O
regulation	O
of	O
IL-12	B
p40	I
transcription	O
expression	O
has	O
not	O
been	O
investigated	O
before	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
roles	O
of	O
HDAC1	B
and	O
p300	B
in	O
the	O
regulation	O
of	O
human	O
IL-12	B
p40	I
.	O

Co	O
-	O
transfection	O
studies	O
showed	O
that	O
HDAC1	B
had	O
a	O
repressing	O
effect	O
on	O
the	O
activity	O
of	O
IL-12	B
p40	I
promoter	O
.	O

Contrarily	O
,	O
p300	B
was	O
able	O
to	O
reinforce	O
the	O
C	B
/	I
EBPbeta	I
-	O
mediated	O
activation	O
of	O
IL-12	B
p40	I
and	O
it	O
counteracted	O
the	O
HDAC1	B
-	O
mediated	O
repression	O
of	O
the	O
IL-12	B
promoter	O
.	O

Chromatin	O
immunoprecipitation	O
tests	O
(	O
ChIP	O
)	O
revealed	O
that	O
p300	B
had	O
a	O
stimulating	O
effect	O
on	O
the	O
acetylation	O
of	O
the	O
histone	B
H3	I
at	O
IL-12	B
p40	I
promoter	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
p300	B
had	O
a	O
physical	O
interaction	O
with	O
C	B
/	I
EBPbeta	I
and	O
can	O
enhance	O
acetylation	O
of	O
C	B
/	I
EBPbeta	I
.	O

Data	O
presented	O
in	O
this	O
paper	O
indicate	O
that	O
the	O
reversible	O
histone	B
acetylation	O
/	O
deacetylation	O
modification	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
IL-12	B
.	O

IL-6	B
transsignaling	O
:	O
the	O
in	O
vivo	O
consequences	O
.	O

Cytokine	B
receptors	I
exist	O
in	O
membrane	O
-	O
bound	O
and	O
soluble	O
forms	O
.	O

They	O
bind	O
their	O
ligands	O
with	O
comparable	O
affinity	O
.	O

Although	O
most	O
soluble	O
receptors	O
are	O
antagonists	O
because	O
they	O
compete	O
with	O
their	O
membrane	O
counterparts	O
for	O
their	O
ligands	O
,	O
some	O
soluble	O
receptors	O
are	O
agonists	O
.	O

In	O
this	O
case	O
,	O
on	O
target	O
cells	O
,	O
the	O
complex	O
of	O
cytokine	B
and	O
soluble	O
cytokine	B
receptor	I
binds	O
to	O
a	O
second	O
receptor	O
subunit	O
and	O
initiates	O
intracellular	O
signal	O
transduction	O
.	O

The	O
soluble	O
receptors	O
of	O
the	O
interleukin-6	B
(	I
IL-6	I
)	I
family	I
of	I
cytokines	I
--	O
soluble	O
IL-6	B
receptor	I
(	O
sIL-6R	B
)	O
,	O
sIL-11R	B
,	O
and	O
soluble	O
ciliary	B
neurotrophic	I
factor	I
receptor	I
(	O
sCNTFR	B
)	O
--	O
are	O
agonists	O
.	O

In	O
vivo	O
,	O
the	O
IL-6	B
/	O
sIL-6R	B
complex	O
stimulates	O
several	O
types	O
of	O
target	O
cells	O
not	O
stimulated	O
by	O
IL-6	B
alone	O
,	O
as	O
they	O
do	O
not	O
express	O
the	O
membrane	O
-	O
bound	O
IL-6R	B
.	O

This	O
process	O
has	O
been	O
named	O
transsignaling	O
.	O

We	O
have	O
shown	O
recently	O
that	O
in	O
several	O
chronic	O
inflammatory	O
diseases	O
,	O
such	O
as	O
chronic	O
inflammatory	O
bowl	O
disease	O
,	O
peritonitis	O
,	O
and	O
rheumatoid	O
arthritis	O
,	O
as	O
well	O
as	O
in	O
colon	O
cancer	O
,	O
transsignaling	O
via	O
the	O
sIL-6R	B
complexed	O
to	O
IL-6	B
is	O
a	O
crucial	O
point	O
in	O
the	O
maintenance	O
of	O
the	O
disease	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
IL-6	B
/	O
sIL-6R	B
complex	O
regulates	O
the	O
inflammatory	O
or	O
neoplastic	O
state	O
is	O
discussed	O
.	O

Age	O
-	O
related	O
alteration	O
of	O
vitamin	O
D	O
metabolism	O
in	O
response	O
to	O
low	O
-	O
phosphate	O
diet	O
in	O
rats	O
.	O

The	O
responses	O
of	O
renal	O
vitamin	O
D	O
metabolism	O
to	O
its	O
major	O
stimuli	O
alter	O
with	O
age	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
increase	O
in	O
circulating	O
1,25-dihydroxyvitamin	O
D	O
(	O
1,25	O
(	O
OH	O
)	O
2D3	O
)	O
as	O
well	O
as	O
renal	O
25-hydroxyvitamin	B
D3	I
1-alpha	I
hydroxylase	I
(	O
1-OHase	B
)	O
activity	O
in	O
response	O
to	O
dietary	O
Ca	O
or	O
P	O
restriction	O
reduced	O
with	O
age	O
in	O
rats	O
.	O

We	O
hypothesized	O
that	O
the	O
mechanism	O
involved	O
in	O
increasing	O
circulating	O
1,25	O
(	O
OH	O
)	O
2D3	O
in	O
response	O
to	O
mineral	O
deficiency	O
alters	O
with	O
age	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
by	O
studying	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
renal	O
vitamin	O
D	O
metabolism	O
(	O
renal	O
1	B
-	I
OHase	I
,	O
25-hydroxyvitamin	B
D	I
24-hydroxylase	I
(	O
24	B
-	I
OHase	I
)	O
and	O
vitamin	B
D	I
receptor	I
(	O
VDR	B
)	O
)	O
in	O
young	O
(	O
1-month	O
-	O
old	O
)	O
and	O
adult	O
(	O
6	O
-	O
month	O
-	O
old	O
)	O
rats	O
in	O
response	O
to	O
low	O
-	O
phosphate	O
diet	O
(	O
LPD	O
)	O
.	O

As	O
expected	O
,	O
serum	O
1,25	O
(	O
OH	O
)	O
2D3	O
increased	O
in	O
both	O
young	O
and	O
adult	O
rats	O
upon	O
LPD	O
treatment	O
and	O
the	O
increase	O
was	O
much	O
higher	O
in	O
younger	O
rats	O
.	O

In	O
young	O
rats	O
,	O
LPD	O
treatment	O
decreased	O
renal	O
24	B
-	I
OHase	I
(	O
days	O
1	O
-	O
7	O
,	O
P	O
<	O
0.01	O
)	O
and	O
increased	O
renal	O
1	B
-	I
OHase	I
mRNA	O
expression	O
(	O
days	O
1	O
-	O
5	O
,	O
P	O
<	O
0.01	O
)	O
.	O

LPD	O
treatment	O
failed	O
to	O
increase	O
renal	O
1-OHase	B
but	O
did	O
suppress	O
24-OHase	B
mRNA	O
expression	O
(	O
P	O
<	O
0.01	O
)	O
within	O
7	O
d	O
of	O
LPD	O
treatment	O
in	O
adult	O
rats	O
.	O

Renal	O
expression	O
of	O
VDR	B
mRNA	O
decreased	O
with	O
age	O
(	O
P	O
<	O
0.001	O
)	O
and	O
was	O
suppressed	O
by	O
LPD	O
treatment	O
in	O
both	O
age	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Feeding	O
of	O
adult	O
rats	O
with	O
10	O
d	O
of	O
LPD	O
increased	O
1-OHase	O
(	O
P	O
<	O
0.05	O
)	O
and	O
suppressed	O
24-OHase	B
(	O
P	O
<	O
0.001	O
)	O
as	O
well	O
as	O
VDR	B
(	O
P	O
<	O
0.05	O
)	O
mRNA	O
expression	O
.	O

These	O
results	O
indicate	O
that	O
the	O
increase	O
in	O
serum	O
1,25	O
(	O
OH	O
)	O
2D3	O
level	O
in	O
adult	O
rats	O
during	O
short	O
-	O
term	O
LPD	O
treatment	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
a	O
decrease	O
in	O
metabolic	O
clearance	O
via	O
the	O
down	O
-	O
regulation	O
of	O
both	O
renal	O
24-OHase	B
and	O
VDR	B
expression	O
.	O

The	O
induction	O
of	O
renal	O
1-OHase	B
mRNA	O
expression	O
in	O
adult	O
rats	O
requires	O
longer	O
duration	O
of	O
LPD	O
treatment	O
than	O
in	O
younger	O
rats	O
.	O

Two	O
naturally	O
occurring	O
deletion	O
mutants	O
of	O
12S	B
seed	I
storage	I
proteins	I
in	O
Arabidopsis	O
thaliana	O
.	O

Two	O
naturally	O
occurring	O
Arabidopsis	O
mutants	O
,	O
Cape	O
Verde	O
Islands	O
and	O
Monte	O
(	O
Mr-0	O
)	O
,	O
with	O
aberrant	O
12S	B
seed	I
storage	I
protein	I
(	I
SSP	I
)	I
profiles	O
have	O
been	O
identified	O
by	O
SDS	O
-	O
PAGE	O
.	O

In	O
both	O
mutants	O
,	O
one	O
of	O
the	O
12S	B
globulin	I
bands	O
is	O
missing	O
while	O
a	O
new	O
band	O
of	O
lower	O
molecular	O
mass	O
is	O
present	O
.	O

Tandem	O
mass	O
spectrometry	O
-	O
mass	O
spectrometry	O
(	O
MS	O
/	O
MS	O
)	O
analyses	O
of	O
the	O
mutant	O
peptides	O
have	O
revealed	O
that	O
both	O
are	O
shorter	O
variants	O
of	O
12S	B
globulin	I
with	O
deletion	O
sites	O
detected	O
within	O
the	O
alpha	O
-	O
subunits	O
of	O
12S	B
globulin	I
cruciferin	I
B	I
(	I
CRB	I
)	I
and	I
C	I
(	O
CRC	B
)	O
,	O
respectively	O
.	O

Sequence	O
analyses	O
of	O
the	O
genomic	O
DNA	O
flanking	O
the	O
deletion	O
sites	O
have	O
demonstrated	O
that	O
both	O
deletions	O
occurred	O
at	O
the	O
genomic	O
level	O
.	O

These	O
two	O
mutants	O
are	O
referred	O
to	O
as	O
CRBDelta12	O
and	O
CRCDelta13	O
with	O
the	O
delta	O
sign	O
indicating	O
a	O
deletion	O
and	O
the	O
number	O
indicating	O
amino	O
acids	O
deleted	O
.	O

Alignment	O
of	O
these	O
two	O
mutant	O
sequences	O
with	O
that	O
of	O
soybean	O
A3B4	B
subunit	O
,	O
for	O
which	O
the	O
crystal	O
structure	O
was	O
determined	O
recently	O
,	O
have	O
revealed	O
that	O
the	O
CRCDelta13	O
deletion	O
is	O
located	O
in	O
a	O
hypervariable	O
/	O
disordered	O
region	O
,	O
and	O
will	O
probably	O
not	O
affect	O
the	O
structure	O
of	O
the	O
hexameric	O
globulin	O
.	O

The	O
CRBDelta12	O
deletion	O
,	O
however	O
,	O
is	O
located	O
in	O
a	O
binding	O
region	O
that	O
is	O
thought	O
to	O
be	O
important	O
for	O
the	O
hexamer	O
formation	O
.	O

However	O
,	O
CRBDelta12	O
appears	O
to	O
accumulate	O
normally	O
as	O
judged	O
by	O
its	O
band	O
intensity	O
relative	O
to	O
the	O
other	O
SSP	B
subunits	O
on	O
the	O
protein	O
gels	O
.	O

Thus	O
it	O
seems	O
that	O
the	O
seed	O
can	O
,	O
to	O
a	O
certain	O
extent	O
,	O
tolerate	O
some	O
mutations	O
in	O
its	O
storage	O
proteins	O
.	O

Decreased	O
IgG	B
production	O
but	O
increased	O
MIP-1beta	B
expression	O
in	O
collagen	B
-	O
induced	O
arthritis	O
in	O
C	B
-	I
C	I
chemokine	I
receptor	I
5	I
-	O
deficient	O
mice	O
.	O

Collagen	B
-	O
induced	O
arthritis	O
(	O
CIA	O
)	O
is	O
a	O
widely	O
used	O
model	O
of	O
human	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
characterized	O
by	O
chronic	O
inflammation	O
of	O
the	O
synovial	O
joints	O
.	O

The	O
pathogenesis	O
of	O
RA	O
and	O
CIA	O
has	O
not	O
been	O
completely	O
defined	O
,	O
but	O
both	O
involve	O
the	O
recruitment	O
of	O
leukocytes	O
and	O
lymphocytes	O
to	O
the	O
joints	O
and	O
Th1	O
-	O
type	O
cell	O
mediated	O
autoimmune	O
responses	O
.	O

The	O
C	B
-	I
C	I
chemokine	I
receptor	I
5	I
(	O
CCR5	B
)	O
is	O
preferentially	O
expressed	O
on	O
Th1	O
cells	O
and	O
has	O
been	O
strongly	O
implicated	O
in	O
inflammatory	O
process	O
through	O
trafficking	O
of	O
leukocytes	O
and	O
lymphocytes	O
into	O
the	O
sites	O
of	O
inflammation	O
.	O

We	O
investigated	O
the	O
role	O
of	O
the	O
CCR5	B
in	O
CIA	O
using	O
CCR5	B
knockout	O
mice	O
(	O
CCR5	B
-	O
/	O
-	O
)	O
in	O
which	O
we	O
analyzed	O
the	O
consequences	O
of	O
CCR5	B
deficiency	O
for	O
the	O
immune	O
response	O
and	O
inflammation	O
.	O

We	O
found	O
that	O
CCR5	B
-	O
/	O
-	O
mice	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
incidence	O
of	O
CIA	O
after	O
collagen	B
II	I
(	O
CII	B
)	O
-	O
immunization	O
as	O
compared	O
to	O
wild	O
-	O
type	O
(	O
CCR5	B
+	O
/+	O
)	O
mice	O
.	O

The	O
reduced	O
incidence	O
seen	O
in	O
CCR5	B
-	O
/	O
-	O
mice	O
was	O
associated	O
with	O
these	O
animals	O
having	O
significantly	O
lower	O
IgG	B
levels	O
,	O
especially	O
IgG2a	B
and	O
IgG2b	B
antibodies	O
against	O
CII	B
,	O
as	O
well	O
as	O
an	O
obviously	O
augmented	O
IL-10	B
production	O
in	O
splenocytes	O
.	O

Overproduction	O
of	O
MIP-1beta	B
in	O
CCR5	B
-	O
deficient	O
mice	O
after	O
CII	B
-	O
immunization	O
may	O
contribute	O
partially	O
to	O
the	O
occurrence	O
of	O
arthritis	O
.	O

IL-17	B
reduces	O
TNF	B
-	O
induced	O
Rantes	B
and	O
VCAM-1	B
expression	O
.	O

Functional	O
diversity	O
of	O
the	O
memory	O
T	O
-	O
cell	O
-	O
derived	O
cytokine	B
IL-17	B
was	O
explored	O
at	O
the	O
receptor	O
level	O
.	O

IL-17	B
inhibited	O
TNF	B
-	O
induced	O
chemokine	B
Rantes	B
expression	O
in	O
human	O
synovial	O
fibroblasts	O
and	O
mouse	O
lung	O
fibroblasts	O
.	O

This	O
inhibitory	O
activity	O
of	O
IL-17	B
(	O
IC50	O
=	O
0.2	O
ng	O
/	O
ml	O
)	O
was	O
6	O
-	O
fold	O
more	O
potent	O
than	O
its	O
stimulatory	O
activity	O
on	O
TNF	B
-	I
alpha	I
-	O
induced	O
IL-6	B
secretion	O
(	O
ED50	O
=	O
1.2	O
ng	O
/	O
ml	O
)	O
,	O
measured	O
in	O
the	O
same	O
cells	O
.	O

IL-17	B
also	O
inhibited	O
the	O
TNF	B
-	O
mediated	O
expression	O
of	O
adhesion	B
molecule	I
VCAM-1	B
,	O
and	O
the	O
NF	B
-	I
kappaB	I
binding	O
to	O
the	O
VCAM-1	B
promoter	O
-	O
specific	O
site	O
,	O
along	O
with	O
the	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
,	O
IkappaB	B
-	I
beta	I
.	O

Neutralization	O
of	O
the	O
human	O
IL-17	B
receptor	I
(	O
IL-17R	B
)	O
by	O
M202	O
antibody	O
competitively	O
reverses	O
the	O
IL-17	B
-	O
induced	O
IL-6	B
upregulation	O
.	O

However	O
,	O
M202	O
only	O
partially	O
affected	O
the	O
inhibitions	O
by	O
IL-17	B
.	O

Yet	O
,	O
IL-17R	B
was	O
essential	O
for	O
the	O
Rantes	B
inhibition	O
,	O
as	O
assessed	O
in	O
lung	O
-	O
derived	O
fibroblasts	O
from	O
IL-17R	B
gene	O
deficient	O
mice	O
.	O

Therefore	O
,	O
inhibitory	O
and	O
stimulatory	O
functions	O
of	O
IL-17	B
involve	O
receptor	O
IL-17R	B
but	O
show	O
distinct	O
dose	O
-	O
responses	O
and	O
in	O
turn	O
different	O
sensitivities	O
to	O
an	O
IL-17R	B
antagonizing	O
antibody	O
.	O

Lymphocyte	O
subsets	O
and	O
cytokines	B
in	O
women	O
with	O
gestational	O
diabetes	O
mellitus	O
and	O
their	O
newborn	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
potential	O
immunological	O
markers	O
for	O
predicting	O
type	O
1	O
diabetes	O
in	O
patients	O
with	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
and	O
any	O
immunological	O
impairment	O
in	O
their	O
newborn	O
.	O

In	O
62	O
GDM	O
patients	O
and	O
74	O
women	O
with	O
normal	O
glucose	O
tolerance	O
(	O
NGT	O
)	O
,	O
and	O
their	O
babies	O
,	O
we	O
assessed	O
total	O
lymphocytes	O
,	O
T	O
lymphocyte	O
subsets	O
CD3	B
and	O
CD8	B
expressing	O
T	B
cell	I
receptor	I
(	I
TCR	I
)	I
alpha	I
/	I
beta	I
or	I
gamma	I
/	I
delta	I
,	O
CD16	B
and	O
CD19	B
,	O
pancreatic	O
autoantibodies	O
and	O
cytokines	B
(	O
IL-5	B
,	O
IL-2	B
,	O
soluble	O
receptor	B
IL-2	I
)	O
.	O

At	O
delivery	O
,	O
umbilical	O
cord	O
blood	O
samples	O
were	O
taken	O
for	O
lymphocyte	O
subpopulations	O
and	O
cytokine	B
measurements	O
.	O

GDM	O
mothers	O
had	O
higher	O
levels	O
of	O
total	O
lymphocytes	O
,	O
CD8	B
expressing	O
TCR	B
gamma	I
/	I
delta	I
,	O
and	O
lower	O
levels	O
of	O
CD3	B
expressing	O
TCR	B
alpha	I
/	I
beta	I
than	O
NGT	O
controls	O
.	O

Insulin	B
-	O
treated	O
GDM	O
mothers	O
had	O
lower	O
CD4	B
and	O
CD4	B
/	O
CD8	B
ratios	O
,	O
and	O
higher	O
CD8	B
and	O
IL-5	B
than	O
diet	O
-	O
treated	O
GDM	O
or	O
controls	O
.	O

Five	O
women	O
were	O
positive	O
for	O
pancreatic	O
autoantibodies	O
,	O
with	O
lower	O
CD4	B
(	O
p	O
<	O
0.01	O
)	O
and	O
CD4	B
/	O
CD8	B
ratios	O
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
higher	O
CD8	B
(	O
p	O
<	O
0.03	O
)	O
and	O
CD19	B
than	O
GDM	O
and	O
control	O
mothers	O
negative	O
for	O
autoantibodies	O
.	O

GDM	O
newborn	O
had	O
higher	O
CD8	B
gamma	O
/	O
delta	O
and	O
lower	O
CD16	B
than	O
NGT	O
babies	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
TNF	B
-	I
alpha	I
concentrations	O
in	O
the	O
cord	O
blood	O
obtained	O
from	O
the	O
GDM	O
and	O
NGT	O
newborn	O
.	O

In	O
conclusion	O
,	O
GDM	O
women	O
and	O
their	O
newborn	O
have	O
lymphocyte	O
subset	O
impairments	O
,	O
which	O
are	O
more	O
important	O
in	O
patients	O
positive	O
for	O
autoantibodies	O
and/or	O
treated	O
with	O
insulin	B
.	O

New	O
lnu	B
(	I
C	I
)	I
gene	O
conferring	O
resistance	O
to	O
lincomycin	O
by	O
nucleotidylation	O
in	O
Streptococcus	O
agalactiae	O
UCN36	O
.	O

Streptococcus	O
agalactiae	O
UCN36	O
was	O
resistant	O
to	O
lincomycin	O
(	O
MIC	O
=	O
16	O
microg	O
/	O
ml	O
)	O
but	O
susceptible	O
to	O
clindamycin	O
(	O
MIC	O
=	O
0.12	O
microg	O
/	O
ml	O
)	O
and	O
erythromycin	O
(	O
MIC	O
=	O
0.06	O
microg	O
/	O
ml	O
)	O
.	O

A	O
4	O
-	O
kb	O
HindIII	B
fragment	O
was	O
cloned	O
from	O
S.	O
agalactiae	O
UCN36	O
total	O
DNA	O
on	O
plasmid	O
pUC18	O
and	O
introduced	O
into	O
Escherichia	O
coli	O
AG100A	O
,	O
where	O
it	O
conferred	O
resistance	O
to	O
lincomycin	O
.	O

The	O
sequence	O
analysis	O
of	O
the	O
fragment	O
showed	O
the	O
presence	O
of	O
a	O
1,724-bp	O
element	O
delineated	O
by	O
imperfect	O
inverted	O
repeats	O
(	O
22	O
of	O
25	O
bp	O
)	O
and	O
inserted	O
in	O
the	O
operon	O
for	O
capsular	O
synthesis	O
of	O
S.	O
agalactiae	O
UCN36	O
.	O

This	O
element	O
carried	O
two	O
open	O
reading	O
frames	O
(	O
ORF	O
)	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
upstream	O
ORF	O
displayed	O
similarity	O
with	O
transposases	B
from	O
anaerobes	O
and	O
IS1	O
.	O

The	O
downstream	O
ORF	O
,	O
lnu	B
(	I
C	I
)	I
,	O
encoded	O
a	O
164	O
-	O
amino	O
-	O
acid	O
protein	O
with	O
26	O
%	O
to	O
27	O
%	O
identity	O
with	O
the	O
LnuA	B
(	O
N2	O
)	O
,	O
LnuA	B
,	O
and	O
LnuA	B
'	O
lincosamide	O
nucleotidyltransferases	B
reported	O
for	O
Bacteroides	O
and	O
Staphylococcus	O
,	O
respectively	O
.	O

Crude	O
lysates	O
of	O
E.	O
coli	O
AG100A	O
containing	O
the	O
cloned	O
lnu	B
(	I
C	I
)	I
gene	O
inactivated	O
lincomycin	O
and	O
clindamycin	O
in	O
the	O
presence	O
of	O
ATP	O
and	O
MgCl2	O
.	O

Mass	O
spectrometry	O
experiments	O
demonstrated	O
that	O
the	O
LnuC	B
enzyme	O
catalyzed	O
adenylylation	O
of	O
lincomycin	O
.	O

Evolution	O
of	O
3-deoxy	B
-	I
D	I
-	I
arabino	I
-	I
heptulosonate-7-phosphate	I
synthase	I
-	O
encoding	O
genes	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
shikimate	O
pathway	O
resulting	O
in	O
three	O
aromatic	O
amino	O
acids	O
is	O
initiated	O
in	O
different	O
organisms	O
by	O
two	O
and	O
three	O
3-deoxy	B
-	I
d	I
-	I
arabino	I
-	I
heptulosonate-7-phosphate	I
synthases	I
,	O
respectively	O
.	O

Aro3p	B
and	O
Aro4p	B
are	O
the	O
yeast	O
enzymes	O
feedback	O
-	O
inhibited	O
by	O
phenylalanine	O
and	O
tyrosine	O
,	O
respectively	O
.	O

A	O
yeast	O
strain	O
deficient	O
in	O
the	O
general	O
control	O
transcriptional	O
regulatory	O
system	O
of	O
amino	O
acid	O
biosynthesis	O
is	O
unable	O
to	O
live	O
in	O
the	O
presence	O
of	O
high	O
amounts	O
of	O
phenylalanine	O
and	O
tyrosine	O
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
yeast	O
strain	O
can	O
be	O
rescued	O
by	O
the	O
expression	O
of	O
aroH	B
from	O
Escherichia	O
coli	O
encoding	O
the	O
tryptophan	O
-	O
regulated	O
AroH	B
as	O
third	O
isoenzyme	O
.	O

Yeast	O
carrying	O
Ec	O
AroH	B
as	O
the	O
only	O
enzyme	O
for	O
the	O
initial	O
step	O
of	O
the	O
shikimate	O
pathway	O
can	O
grow	O
in	O
the	O
absence	O
of	O
tryptophan	O
.	O

Without	O
aromatic	O
amino	O
acids	O
,	O
this	O
yeast	O
strain	O
survives	O
only	O
when	O
the	O
yeast	O
ARO3	B
promoter	O
instead	O
of	O
the	O
ARO4	B
promoter	O
drives	O
E.	O
coli	O
aroH	B
.	O

The	O
detailed	O
analysis	O
of	O
Aro3p	B
and	O
Aro4p	B
revealed	O
a	O
triple	O
feedback	O
control	O
by	O
tyrosine	O
/	O
phenylalanine	O
and	O
tryptophan	O
.	O

Dissecting	O
this	O
control	O
allowed	O
engineering	O
of	O
Aro4p	B
S195A	O
as	O
an	O
enzyme	O
,	O
which	O
is	O
inhibited	O
like	O
AroH	B
only	O
by	O
tryptophan	O
.	O

In	O
addition	O
,	O
Aro4p	B
variants	O
were	O
constructed	O
that	O
show	O
an	O
equally	O
strong	O
inhibition	O
by	O
tyrosine	O
and	O
tryptophan	O
(	O
Aro4p	B
P165	O
G	O
Q302R	O
)	O
and	O
in	O
which	O
the	O
regulation	O
by	O
tyrosine	O
and	O
tryptophan	O
was	O
reversed	O
(	O
Aro4p	B
P165	O
G	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
yeast	O
possesses	O
only	O
two	O
instead	O
of	O
three	O
isogenes	O
encoding	O
3-deoxy	B
-	I
D	I
-	I
arabino	I
-	I
heptulosonate-7-phosphate	I
synthases	I
because	O
both	O
isoenzymes	O
can	O
be	O
fine	O
tuned	O
by	O
tryptophan	O
as	O
additional	O
effector	O
and	O
because	O
transcriptional	O
regulation	O
by	O
the	O
general	O
control	O
system	O
can	O
be	O
induced	O
as	O
backup	O
when	O
aromatic	O
amino	O
acids	O
in	O
the	O
environment	O
are	O
imbalanced	O
.	O

Dysregulation	O
of	O
the	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
target	O
genes	O
by	O
XPD	B
mutations	O
.	O

Mutations	O
in	O
the	O
XPD	B
subunit	O
of	O
TFIIH	B
give	O
rise	O
to	O
human	O
genetic	O
disorders	O
initially	O
defined	O
as	O
DNA	O
repair	O
syndromes	O
.	O

Nevertheless	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
group	O
D	O
(	O
XP	O
-	O
D	O
)	O
patients	O
develop	O
clinical	O
features	O
such	O
as	O
hypoplasia	O
of	O
the	O
adipose	O
tissue	O
,	O
implying	O
a	O
putative	O
transcriptional	O
defect	O
.	O

Knowing	O
that	O
peroxisome	B
proliferator	I
-	I
activated	I
receptors	I
(	O
PPARs	B
)	O
are	O
implicated	O
in	O
lipid	O
metabolism	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
PPAR	B
target	O
genes	O
in	O
the	O
adipose	O
tissues	O
and	O
the	O
livers	O
of	O
XPD	B
-	O
deficient	O
mice	O
and	O
found	O
that	O
(	O
i	O
)	O
some	O
genes	O
are	O
abnormally	O
overexpressed	O
in	O
a	O
ligand	O
-	O
independent	O
manner	O
which	O
parallels	O
an	O
increase	O
in	O
the	O
recruitment	O
of	O
RNA	B
polymerase	I
(	I
pol	I
)	I
II	I
but	O
not	O
PPARs	B
on	O
their	O
promoter	O
and	O
(	O
ii	O
)	O
upon	O
treatment	O
with	O
PPAR	B
ligands	O
,	O
other	O
genes	O
are	O
much	O
less	O
induced	O
compared	O
to	O
the	O
wild	O
type	O
,	O
which	O
is	O
due	O
to	O
a	O
lower	O
recruitment	O
of	O
both	O
PPARs	B
and	O
RNA	B
pol	I
II	I
.	O

The	O
defect	O
in	O
transactivation	O
by	O
PPARs	B
is	O
likely	O
attributable	O
to	O
their	O
weaker	O
phosphorylation	O
by	O
the	O
cdk7	B
kinase	B
of	O
TFIIH	B
.	O

Having	O
identified	O
the	O
phosphorylated	O
residues	O
in	O
PPAR	B
isotypes	O
,	O
we	O
demonstrate	O
how	O
their	O
transactivation	O
defect	O
in	O
XPD	B
-	O
deficient	O
cells	O
can	O
be	O
circumvented	O
by	O
overexpression	O
of	O
either	O
a	O
wild	O
-	O
type	O
XPD	B
or	O
a	O
constitutively	O
phosphorylated	O
PPAR	B
S	O
/	O
E	O
.	O

This	O
work	O
emphasizes	O
that	O
underphosphorylation	O
of	O
PPARs	B
affects	O
their	O
transactivation	O
and	O
consequently	O
the	O
expression	O
of	O
PPAR	B
target	O
genes	O
,	O
thus	O
contributing	O
in	O
part	O
to	O
the	O
XP	O
-	O
D	O
phenotype	O
.	O

Cloning	O
of	O
a	O
quail	O
homologue	O
of	O
hatching	B
enzyme	I
:	O
its	O
conserved	O
function	O
and	O
additional	O
function	O
in	O
egg	O
envelope	O
digestion	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
reveal	O
molecular	O
entities	O
participating	O
in	O
the	O
digestion	O
of	O
the	O
egg	O
envelope	O
in	O
the	O
Japanese	O
quail	O
,	O
Coturnix	O
japonica	O
.	O

We	O
isolated	O
a	O
1,510-bp	O
cDNA	O
from	O
extraembryonic	O
tissues	O
of	O
developing	O
embryos	O
and	O
designated	O
it	O
quail	B
hatching	I
enzyme	I
(	O
QHE	B
)	O
cDNA	O
.	O

The	O
QHE	B
cDNA	O
was	O
found	O
to	O
code	O
a	O
protein	O
molecule	O
comprising	O
an	O
astacin	B
protease	I
domain	O
in	O
the	O
N	O
-	O
terminal	O
half	O
and	O
a	O
complement	O
subcomponents	O
C1r	B
/	O
C1s	B
,	O
Uegf	B
,	O
Bmp1	B
(	O
CUB	O
)	O
domain	O
in	O
the	O
C	O
-	O
terminal	O
half	O
.	O

A	O
phylogenetic	O
analysis	O
showed	O
that	O
QHE	B
belonged	O
to	O
the	O
hatching	B
enzyme	I
group	I
and	O
was	O
distinct	O
from	O
other	O
proteases	B
in	O
the	O
astacin	B
family	I
.	O

Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
demonstrated	O
that	O
expression	O
of	O
the	O
QHE	B
mRNA	O
occurred	O
twice	O
during	O
the	O
development	O
:	O
first	O
in	O
ectodermal	O
cells	O
of	O
the	O
yolk	O
sac	O
on	O
days	O
0	O
-	O
5	O
,	O
then	O
in	O
those	O
of	O
the	O
albumen	O
sac	O
on	O
days	O
8	O
-	O
13	O
.	O

Zymography	O
revealed	O
that	O
proteolytic	O
activity	O
in	O
extracts	O
of	O
days	O
3	O
-	O
4	O
and	O
9	O
-	O
12	O
embryos	O
appeared	O
at	O
the	O
position	O
of	O
40	O
kDa	O
.	O

Immunoblotting	O
tests	O
showed	O
that	O
anti	O
-	O
QHE	B
antiserum	O
stained	O
a	O
40	O
-	O
kDa	O
molecule	O
in	O
extracts	O
of	O
day	O
3	O
area	O
vitellina	O
.	O

Anti	O
-	O
QHE	B
antibody	O
stained	O
the	O
ectodermal	O
cells	O
of	O
the	O
area	O
opaca	O
on	O
days	O
0	O
-	O
1	O
,	O
those	O
of	O
the	O
area	O
vitellina	O
of	O
the	O
yolk	O
sac	O
on	O
days	O
2	O
-	O
5	O
,	O
and	O
those	O
of	O
the	O
albumen	O
sac	O
on	O
days	O
9	O
-	O
12	O
.	O

The	O
temporal	O
and	O
spatial	O
expression	O
pattern	O
of	O
QHE	B
mRNA	O
was	O
closely	O
associated	O
with	O
digestion	O
of	O
the	O
vitelline	O
membrane	O
occurring	O
on	O
days	O
1	O
-	O
4	O
,	O
and	O
with	O
that	O
of	O
the	O
egg	O
white	O
on	O
days	O
9	O
-	O
12	O
.	O

Control	O
of	O
root	O
cap	O
formation	O
by	O
MicroRNA	O
-	O
targeted	O
auxin	B
response	I
factors	I
in	O
Arabidopsis	O
.	O

The	O
plant	O
root	O
cap	O
mediates	O
the	O
direction	O
of	O
root	O
tip	O
growth	O
and	O
protects	O
internal	O
cells	O
.	O

Root	O
cap	O
cells	O
are	O
continuously	O
produced	O
from	O
distal	O
stem	O
cells	O
,	O
and	O
the	O
phytohormone	O
auxin	O
provides	O
position	O
information	O
for	O
root	O
distal	O
organization	O
.	O

Here	O
,	O
we	O
identify	O
the	O
Arabidopsis	O
thaliana	O
auxin	B
response	I
factors	I
ARF10	B
and	O
ARF16	B
,	O
targeted	O
by	O
microRNA160	O
(	O
miR160	O
)	O
,	O
as	O
the	O
controller	O
of	O
root	O
cap	O
cell	O
formation	O
.	O

The	O
Pro	O
(	O
35S	O
)	O
:	O
MIR160	O
plants	O
,	O
in	O
which	O
the	O
expression	O
of	O
ARF10	B
and	O
ARF16	B
is	O
repressed	O
,	O
and	O
the	O
arf10	B
-	O
2	O
arf16	B
-	O
2	O
double	O
mutants	O
display	O
the	O
same	O
root	O
tip	O
defect	O
,	O
with	O
uncontrolled	O
cell	O
division	O
and	O
blocked	O
cell	O
differentiation	O
in	O
the	O
root	O
distal	O
region	O
and	O
show	O
a	O
tumor	O
-	O
like	O
root	O
apex	O
and	O
loss	O
of	O
gravity	O
-	O
sensing	O
.	O

ARF10	B
and	O
ARF16	B
play	O
a	O
role	O
in	O
restricting	O
stem	O
cell	O
niche	O
and	O
promoting	O
columella	O
cell	O
differentiation	O
;	O
although	O
functionally	O
redundant	O
,	O
the	O
two	O
ARFs	B
are	O
indispensable	O
for	O
root	O
cap	O
development	O
,	O
and	O
the	O
auxin	O
signal	O
can	O
not	O
bypass	O
them	O
to	O
initiate	O
columella	O
cell	O
production	O
.	O

In	O
root	O
,	O
auxin	O
and	O
miR160	O
regulate	O
the	O
expression	O
of	O
ARF10	B
and	O
ARF16	B
genes	O
independently	O
,	O
generating	O
a	O
pattern	O
consistent	O
with	O
root	O
cap	O
development	O
.	O

We	O
further	O
demonstrate	O
that	O
miR160-uncoupled	O
production	O
of	O
ARF16	B
exerts	O
pleiotropic	O
effects	O
on	O
plant	O
phenotypes	O
,	O
and	O
miR160	O
plays	O
an	O
essential	O
role	O
in	O
regulating	O
Arabidopsis	O
development	O
and	O
growth	O
.	O

Deletion	O
of	O
Cg	O
-	O
emb	B
in	O
corynebacterianeae	O
leads	O
to	O
a	O
novel	O
truncated	O
cell	O
wall	O
arabinogalactan	O
,	O
whereas	O
inactivation	O
of	O
Cg	O
-	O
ubiA	B
results	O
in	O
an	O
arabinan	O
-	O
deficient	O
mutant	O
with	O
a	O
cell	O
wall	O
galactan	O
core	O
.	O

The	O
cell	O
wall	O
of	O
Mycobacterium	O
tuberculosis	O
has	O
a	O
complex	O
ultrastructure	O
that	O
consists	O
of	O
mycolic	O
acids	O
connected	O
to	O
peptidoglycan	O
via	O
arabinogalactan	O
(	O
AG	O
)	O
and	O
abbreviated	O
as	O
the	O
mAGP	O
complex	O
.	O

The	O
mAGP	O
complex	O
is	O
crucial	O
for	O
the	O
survival	O
and	O
pathogenicity	O
of	O
M.	O
tuberculosis	O
and	O
is	O
the	O
target	O
of	O
several	O
anti	O
-	O
tubercular	O
agents	O
.	O

Apart	O
from	O
sharing	O
a	O
similar	O
mAGP	O
and	O
the	O
availability	O
of	O
the	O
complete	O
genome	O
sequence	O
,	O
Corynebacterium	O
glutamicum	O
has	O
proven	O
useful	O
in	O
the	O
study	O
of	O
orthologous	O
M.	O
tuberculosis	O
genes	O
essential	O
for	O
viability	O
.	O

Here	O
we	O
examined	O
the	O
effects	O
of	O
particular	O
genes	O
involved	O
in	O
AG	O
polymerization	O
by	O
gene	O
deletion	O
in	O
C.	O
glutamicum	O
.	O

The	O
anti	O
-	O
tuberculosis	O
drug	O
ethambutol	O
is	O
thought	O
to	O
target	O
a	O
set	O
of	O
arabinofuranosyltransferases	B
(	O
Emb	B
)	O
that	O
are	O
involved	O
in	O
arabinan	O
polymerization	O
.	O

Deletion	O
of	O
emb	B
in	O
C.	O
glutamicum	O
results	O
in	O
a	O
slow	O
growing	O
mutant	O
with	O
profound	O
morphological	O
changes	O
.	O

Chemical	O
analysis	O
revealed	O
a	O
dramatic	O
reduction	O
of	O
arabinose	O
resulting	O
in	O
a	O
novel	O
truncated	O
AG	O
structure	O
possessing	O
only	O
terminal	O
arabinofuranoside	O
(	O
t	O
-	O
Araf	O
)	O
residues	O
with	O
a	O
corresponding	O
loss	O
of	O
cell	O
wall	O
bound	O
mycolic	O
acids	O
.	O

Treatment	O
of	O
wild	O
-	O
type	O
C.	O
glutamicum	O
with	O
ethambutol	O
and	O
subsequent	O
cell	O
wall	O
analyses	O
resulted	O
in	O
an	O
identical	O
phenotype	O
comparable	O
to	O
the	O
C.	O
glutamicum	O
emb	B
deletion	O
mutant	O
.	O

Additionally	O
,	O
disruption	O
of	O
ubiA	B
in	O
C.	O
glutamicum	O
,	O
the	O
first	O
enzyme	O
involved	O
in	O
the	O
biosynthesis	O
of	O
the	O
sugar	O
donor	O
decaprenol	O
phosphoarabinose	O
(	O
DPA	O
)	O
,	O
resulted	O
in	O
a	O
complete	O
loss	O
of	O
cell	O
wall	O
arabinan	O
.	O

Herein	O
,	O
we	O
establish	O
for	O
the	O
first	O
time	O
,	O
(	O
i	O
)	O
that	O
in	O
contrast	O
to	O
M.	O
tuberculosis	O
embA	B
and	O
embB	B
mutants	O
,	O
deletion	O
of	O
C.	O
glutamicum	O
emb	B
leads	O
to	O
a	O
highly	O
truncated	O
AG	O
possessing	O
t	O
-	O
Araf	O
residues	O
,	O
(	O
ii	O
)	O
the	O
exact	O
site	O
of	O
attachment	O
of	O
arabinan	O
chains	O
in	O
AG	O
,	O
and	O
(	O
iii	O
)	O
DPA	O
is	O
the	O
only	O
Araf	O
sugar	O
donor	O
in	O
AG	O
biosynthesis	O
suggesting	O
the	O
presence	O
of	O
a	O
novel	O
enzyme	O
responsible	O
for	O
""""	O
priming	O
""""	O
the	O
galactan	O
domain	O
for	O
further	O
elaboration	O
by	O
Emb	B
,	O
resulting	O
in	O
the	O
final	O
maturation	O
of	O
the	O
native	O
AG	O
polysaccharide	O
.	O

Human	O
high	B
density	I
lipoproteins	I
are	O
platforms	O
for	O
the	O
assembly	O
of	O
multi	O
-	O
component	O
innate	O
immune	O
complexes	O
.	O

Human	O
innate	O
immunity	O
to	O
non	O
-	O
pathogenic	O
species	O
of	O
African	O
trypanosomes	O
is	O
provided	O
by	O
human	O
high	B
density	I
lipoprotein	I
(	O
HDL	B
)	O
particles	O
.	O

Here	O
we	O
show	O
that	O
native	O
human	O
HDLs	B
containing	O
haptoglobin	B
-	I
related	I
protein	I
(	O
Hpr	B
)	O
,	O
apolipoprotein	B
L	I
-	I
I	I
(	O
apoL	B
-	I
I	I
)	O
and	O
apolipoprotein	B
A	I
-	I
I	I
(	O
apoA	B
-	I
I	I
)	O
are	O
the	O
principle	O
antimicrobial	O
molecules	O
providing	O
protection	O
from	O
trypanosome	O
infection	O
.	O

Other	O
HDL	B
subclasses	O
containing	O
either	O
apoA	B
-	I
I	I
and	O
apoL	B
-	I
I	I
or	O
apoA	B
-	I
I	I
and	O
Hpr	B
have	O
reduced	O
trypanolytic	O
activity	O
,	O
whereas	O
HDL	B
subclasses	O
lacking	O
apoL	B
-	I
I	I
and	O
Hpr	B
are	O
non	O
-	O
toxic	O
to	O
trypanosomes	O
.	O

Highly	O
purified	O
,	O
lipid	O
-	O
free	O
Hpr	B
and	O
apoL	B
-	I
I	I
were	O
both	O
toxic	O
to	O
Trypanosoma	O
brucei	O
brucei	O
but	O
with	O
specific	O
activities	O
at	O
least	O
500	O
-	O
fold	O
less	O
than	O
those	O
of	O
native	O
HDLs	B
,	O
suggesting	O
that	O
association	O
of	O
these	O
apolipoproteins	B
within	O
the	O
HDL	B
particle	O
was	O
necessary	O
for	O
optimal	O
cytotoxicity	O
.	O

These	O
studies	O
show	O
that	O
HDLs	B
can	O
serve	O
as	O
platforms	O
for	O
the	O
assembly	O
of	O
multiple	O
synergistic	O
proteins	O
and	O
that	O
these	O
assemblies	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
evolution	O
of	O
primate	O
-	O
specific	O
innate	O
immunity	O
to	O
trypanosome	O
infection	O
.	O

Novel	O
brain	O
14	B
-	I
3	I
-	I
3	I
interacting	O
proteins	O
involved	O
in	O
neurodegenerative	O
disease	O
.	O

We	O
isolated	O
two	O
novel	O
14	B
-	I
3	I
-	I
3	I
binding	O
proteins	O
using	O
14	B
-	I
3	I
-	I
3	I
zeta	I
as	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
of	O
a	O
human	O
brain	O
cDNA	O
library	O
.	O

One	O
of	O
these	O
encoded	O
the	O
C	O
-	O
terminus	O
of	O
a	O
neural	O
specific	O
armadillo	B
-	O
repeat	O
protein	O
,	O
delta	B
-	I
catenin	I
(	O
neural	B
plakophilin	I
-	I
related	I
arm	I
-	I
repeat	I
protein	I
or	O
neurojungin	B
)	O
.	O

delta	B
-	I
Catenin	I
from	O
brain	O
lysates	O
was	O
retained	O
on	O
a	O
14	B
-	I
3	I
-	I
3	I
affinity	O
column	O
.	O

Mutation	O
of	O
serine	O
1072	O
in	O
the	O
human	O
protein	O
and	O
serine	O
1094	O
in	O
the	O
equivalent	O
site	O
in	O
the	O
mouse	O
homologue	O
(	O
in	O
a	O
consensus	O
binding	O
motif	O
for	O
14	B
-	I
3	I
-	I
3	I
)	O
abolished	O
14	B
-	I
3	I
-	I
3	I
binding	O
to	O
delta	B
-	I
catenin	I
in	O
vitro	O
and	O
in	O
transfected	O
cells	O
.	O

delta	B
-	I
catenin	I
binds	O
to	O
presenilin-1	B
,	O
encoded	O
by	O
the	O
gene	O
most	O
commonly	O
mutated	O
in	O
familial	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
other	O
clone	O
was	O
identified	O
as	O
the	O
insulin	B
receptor	I
tyrosine	I
kinase	I
substrate	I
protein	I
of	I
53	I
kDa	I
(	O
IRSp53	B
)	O
.	O

Human	O
IRSp53	B
interacts	O
with	O
the	O
gene	O
product	O
implicated	O
in	O
dentatorubral	O
-	O
pallidoluysian	O
atrophy	O
,	O
an	O
autosomal	O
recessive	O
disorder	O
associated	O
with	O
glutamine	O
repeat	O
expansion	O
of	O
atrophin	B
-	I
1	I
.	O

Phosphatidylcholine	B
transfer	I
protein	I
regulates	O
size	O
and	O
hepatic	O
uptake	O
of	O
high	O
-	O
density	O
lipoproteins	O
.	O

Phosphatidylcholine	B
transfer	I
protein	I
(	O
PC	B
-	I
TP	I
)	O
is	O
a	O
steroidogenic	O
acute	O
regulatory	O
-	O
related	O
transfer	O
domain	O
protein	O
that	O
is	O
enriched	O
in	O
liver	O
cytosol	O
and	O
binds	O
phosphatidylcholines	O
with	O
high	O
specificity	O
.	O

In	O
tissue	O
culture	O
systems	O
,	O
PC	B
-	I
TP	I
promotes	O
ATP	O
-	O
binding	O
cassette	O
protein	O
A1	O
-	O
mediated	O
efflux	O
of	O
cholesterol	O
and	O
phosphatidylcholine	O
molecules	O
as	O
nascent	O
pre	O
-	O
beta	O
-	O
high	B
-	I
density	I
lipoprotein	I
(	O
HDL	B
)	O
particles	O
.	O

Here	O
,	O
we	O
explored	O
a	O
role	O
for	O
PC	B
-	I
TP	I
in	O
HDL	B
metabolism	O
in	O
vivo	O
utilizing	O
8	O
-	O
wk	O
-	O
old	O
male	O
Pctp	B
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
littermate	O
C57BL	O
/	O
6J	O
mice	O
that	O
were	O
fed	O
for	O
7	O
days	O
with	O
either	O
chow	O
or	O
a	O
high	O
-	O
fat	O
/	O
high	O
-	O
cholesterol	O
diet	O
.	O

In	O
chow	O
-	O
fed	O
mice	O
,	O
neither	O
plasma	O
cholesterol	O
concentrations	O
nor	O
the	O
concentrations	O
and	O
compositions	O
of	O
plasma	O
phospholipids	O
were	O
influenced	O
by	O
PC	B
-	I
TP	I
expression	O
.	O

However	O
,	O
in	O
Pctp	B
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
there	O
was	O
an	O
accumulation	O
of	O
small	O
alpha	O
-	O
migrating	O
HDL	B
particles	O
.	O

This	O
occurred	O
without	O
changes	O
in	O
hepatic	O
expression	O
of	O
ATP	B
-	I
binding	I
cassette	I
protein	I
A1	I
or	O
in	O
proteins	O
that	O
regulate	O
the	O
intravascular	O
metabolism	O
and	O
clearance	O
of	O
HDL	B
particles	O
.	O

In	O
Pctp	B
(	O
-	O
/	O
-	O
)	O
mice	O
fed	O
the	O
high	O
-	O
fat	O
/	O
high	O
-	O
cholesterol	O
diet	O
,	O
HDL	B
particle	O
sizes	O
were	O
normalized	O
,	O
whereas	O
plasma	O
cholesterol	O
and	O
phospholipid	O
concentrations	O
were	O
increased	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

In	O
the	O
absence	O
of	O
upregulation	O
of	O
hepatic	O
ATP	B
-	I
binding	I
cassette	I
protein	I
A1	I
,	O
reduced	O
HDL	B
uptake	O
from	O
plasma	O
into	O
livers	O
of	O
Pctp	B
(	O
-	O
/	O
-	O
)	O
mice	O
contributed	O
to	O
higher	O
plasma	O
lipid	O
concentrations	O
.	O

These	O
data	O
indicate	O
that	O
PC	B
-	I
TP	I
is	O
not	O
essential	O
for	O
the	O
enrichment	O
of	O
HDL	B
with	O
phosphatidylcholines	O
but	O
that	O
it	O
does	O
modulate	O
particle	O
size	O
and	O
rates	O
of	O
hepatic	O
clearance	O
.	O

Dengue	O
virus	O
nonstructural	B
protein	I
NS5	B
induces	O
interleukin-8	B
transcription	O
and	O
secretion	O
.	O

Elevated	O
circulating	O
levels	O
of	O
chemokines	B
have	O
been	O
reported	O
in	O
patients	O
with	O
dengue	O
fever	O
and	O
are	O
proposed	O
to	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
dengue	O
disease	O
.	O

To	O
establish	O
in	O
vitro	O
models	O
for	O
chemokine	B
induction	O
by	O
dengue	O
2	O
virus	O
(	O
DEN2V	O
)	O
,	O
we	O
studied	O
a	O
variety	O
of	O
human	O
cell	O
lines	O
and	O
primary	O
cells	O
.	O

DEN2V	O
infection	O
of	O
HepG2	O
and	O
primary	O
dendritic	O
cells	O
induced	O
the	O
production	O
of	O
interleukin-8	B
(	O
IL-8	B
)	O
,	O
RANTES	B
,	O
MIP-1alpha	B
,	O
and	O
MIP-1beta	B
,	O
whereas	O
only	O
IL-8	B
and	O
RANTES	B
were	O
induced	O
following	O
dengue	O
virus	O
infection	O
of	O
HEK293	O
cells	O
.	O

Chemokine	B
secretion	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
steady	O
-	O
state	O
mRNA	O
levels	O
.	O

No	O
chemokine	B
induction	O
was	O
observed	O
in	O
HEK293	O
cells	O
treated	O
with	O
poly	O
(	O
I	O
:	O
C	O
)	O
or	O
alpha	B
interferon	I
,	O
suggesting	O
a	O
direct	O
effect	O
of	O
virus	O
infection	O
.	O

To	O
determine	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
in	O
the	O
induction	O
of	O
chemokine	B
production	O
by	O
DEN2V	O
,	O
individual	O
dengue	O
virus	O
genes	O
were	O
cloned	O
into	O
plasmids	O
and	O
expressed	O
in	O
HEK293	O
cells	O
.	O

Transfection	O
of	O
a	O
plasmid	O
expressing	O
NS5	B
or	O
a	O
dengue	O
virus	O
replicon	O
induced	O
IL-8	B
gene	O
expression	O
and	O
secretion	O
.	O

RANTES	B
expression	O
was	O
not	O
induced	O
under	O
these	O
conditions	O
,	O
however	O
.	O

Reporter	O
assays	O
showed	O
that	O
IL-8	B
induction	O
by	O
NS5	B
was	O
principally	O
through	O
CAAT	B
/	I
enhancer	I
binding	I
protein	I
,	O
whereas	O
DEN2V	O
infection	O
also	O
induced	O
NF	B
-	I
kappaB	I
.	O

These	O
results	O
indicate	O
a	O
role	O
for	O
the	O
dengue	O
virus	O
NS5	B
protein	O
in	O
the	O
induction	O
of	O
IL-8	B
by	O
DEN2V	O
infection	O
.	O

Recruitment	O
and	O
activation	O
of	O
potential	O
target	O
cells	O
to	O
sites	O
of	O
DEN2V	O
replication	O
by	O
virus	O
-	O
induced	O
chemokine	B
production	O
may	O
contribute	O
to	O
viral	O
replication	O
as	O
well	O
as	O
to	O
the	O
inflammatory	O
components	O
of	O
dengue	O
virus	O
disease	O
.	O

Hematopoietic	O
progenitor	O
cell	O
mobilization	O
in	O
mice	O
by	O
sustained	O
delivery	O
of	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
.	O

The	O
objective	O
of	O
these	O
studies	O
was	O
to	O
determine	O
the	O
effect	O
of	O
sustained	O
delivery	O
of	O
growth	B
factors	I
(	O
GFs	B
)	O
on	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
in	O
mice	O
.	O

In	O
these	O
studies	O
,	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
was	O
administered	O
using	O
the	O
poloxamer	O
-	O
based	O
matrix	O
,	O
ProGelz	O
(	O
PG	O
)	O
and	O
G	B
-	I
CSF	I
,	O
and	O
pharmacokinetics	O
(	O
PKs	O
)	O
and	O
HPC	O
mobilization	O
was	O
assessed	O
.	O

A	O
single	O
injection	O
of	O
G	B
-	I
CSF	I
formulated	O
in	O
PG	O
(	O
17	O
%	O
poloxamer-407	O
and	O
5	O
%	O
hydroxypropyl	O
methylcellulose	O
[	O
HPMC	O
]	O
)	O
administered	O
to	O
BALB	O
/	O
c	O
mice	O
mobilized	O
HPC	O
significantly	O
more	O
rapidly	O
to	O
the	O
spleen	O
,	O
but	O
not	O
the	O
blood	O
,	O
than	O
multiple	O
injections	O
of	O
saline	O
-	O
formulated	O
G	B
-	I
CSF	I
.	O

Two	O
days	O
after	O
a	O
single	O
injection	O
of	O
PG	O
G	B
-	I
CSF	I
,	O
the	O
frequency	O
of	O
colony	O
-	O
forming	O
unit	O
-	O
culture	O
(	O
CFU	O
-	O
c	O
)	O
in	O
the	O
spleen	O
was	O
increased	O
289	O
-	O
fold	O
compared	O
with	O
an	O
8	O
-	O
fold	O
increase	O
after	O
2	O
days	O
of	O
twice	O
-	O
daily	O
injections	O
of	O
saline	O
-	O
formulated	O
G	B
-	I
CSF	I
.	O

Indeed	O
,	O
4	O
days	O
of	O
twice	O
-	O
daily	O
G	B
-	I
CSF	I
injections	O
were	O
required	O
to	O
achieve	O
the	O
same	O
level	O
of	O
HPC	O
mobilization	O
.	O

In	O
contrast	O
,	O
a	O
similar	O
mobilization	O
of	O
HPC	O
to	O
the	O
blood	O
was	O
observed	O
between	O
PG	O
and	O
saline	O
-	O
formulated	O
G	B
-	I
CSF	I
.	O

The	O
mechanism	O
for	O
the	O
accelerated	O
and	O
increased	O
mobilization	O
to	O
the	O
spleen	O
by	O
the	O
PG	O
-	O
formulation	O
of	O
G	B
-	I
CSF	I
is	O
due	O
,	O
in	O
part	O
,	O
to	O
its	O
increased	O
bioavailability	O
(	O
>	O
1.5	O
-	O
fold	O
)	O
,	O
T	O
(	O
max	O
)	O
(	O
6	O
-	O
fold	O
)	O
,	O
and	O
prolonged	O
elimination	O
(	O
Tbeta	O
)	O
half	O
-	O
life	O
(	O
>	O
3	O
-	O
fold	O
)	O
as	O
compared	O
with	O
a	O
saline	O
formulation	O
.	O

In	O
addition	O
,	O
we	O
observed	O
a	O
more	O
rapid	O
trafficking	O
of	O
the	O
PG	O
G	B
-	I
CSF	I
to	O
the	O
marrow	O
,	O
which	O
could	O
also	O
facilitate	O
mobilization	O
.	O

Systemic	O
and	O
vascular	O
inflammation	O
is	O
elevated	O
in	O
early	O
IgA	B
and	O
type	O
1	O
diabetic	O
nephropathies	O
and	O
relates	O
to	O
vascular	O
disease	O
risk	O
factors	O
and	O
renal	O
function	O
.	O

BACKGROUND	O
:	O

Inflammation	O
is	O
implicated	O
in	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
and	O
mortality	O
in	O
end	O
-	O
stage	O
renal	O
failure	O
(	O
ESRF	O
)	O
.	O

Its	O
importance	O
in	O
early	O
renal	O
disease	O
is	O
yet	O
to	O
be	O
defined	O
.	O

METHODS	O
:	O

Serum	O
levels	O
of	O
systemic	O
and	O
vascular	O
inflammatory	O
markers	O
in	O
early	O
IgA	B
nephropathy	O
(	O
IgAN	O
)	O
and	O
control	O
subjects	O
were	O
measured	O
and	O
related	O
to	O
renal	O
function	O
and	O
vascular	O
risk	O
factors	O
.	O

A	O
parallel	O
study	O
in	O
type	O
1	O
diabetes	O
mellitus	O
subjects	O
with	O
(	O
T1DM	O
Nx	O
)	O
and	O
without	O
nephropathy	O
(	O
T1DM	O
No	O
Nx	O
)	O
was	O
performed	O
.	O

RESULTS	O
:	O

Fifty	O
-	O
one	O
IgAN	O
patients	O
aged	O
46	O
+	O
/-2	O
years	O
(	O
mean	O
+	O
/-SEM	O
)	O
,	O
calculated	O
creatinine	O
clearance	O
(	O
CrCl	O
)	O
88	O
+	O
/	O
-	O
5	O
ml	O
/	O
min	O
,	O
were	O
compared	O
with	O
51	O
matched	O
control	O
subjects	O
.	O

Forty	O
-	O
six	O
T1DM	O
Nx	O
patients	O
aged	O
40	O
+	O
/	O
-	O
2	O
years	O
,	O
CrCl	O
84	O
+	O
/	O
-	O
5	O
ml	O
/	O
min	O
,	O
and	O
73	O
T1DM	O
No	O
Nx	O
patients	O
aged	O
38	O
+	O
/	O
-	O
2	O
years	O
were	O
also	O
compared	O
.	O

High	O
sensitivity	O
C	B
-	I
reactive	I
protein	I
(	O
hsCRP	B
)	O
was	O
elevated	O
in	O
IgAN	O
,	O
T1DM	O
Nx	O
and	O
T1DM	O
No	O
Nx	O
patients	O
compared	O
with	O
controls	O
[	O
4.2	O
+	O
/-	O
0.6	O
(	O
P	O
<	O
0.001	O
)	O
,	O
4.1	O
+	O
/-	O
0.6	O
(	O
P	O
<	O
0.001	O
)	O
,	O
2.6	O
+	O
/-	O
0.4	O
(	O
P	O
<	O
0.05	O
)	O
vs	O
1.6	O
+	O
/	O
-	O
0.3	O
mg	O
/	O
l	O
]	O
.	O

Levels	O
in	O
T1DM	O
Nx	O
patients	O
were	O
higher	O
than	O
in	O
T1DM	O
No	O
Nx	O
patients	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Inflammation	O
and	O
vascular	O
dysfunction	O
as	O
measured	O
by	O
pulse	O
pressure	O
(	O
PP	O
)	O
were	O
related	O
.	O

HsCRP	B
correlated	O
with	O
PP	O
in	O
IgAN	O
and	O
T1DM	O
Nx	O
(	O
r	O
=	O
0.47	O
,	O
P	O
=	O
0.001	O
;	O
r	O
=	O
0.40	O
,	O
P	O
<	O
0.05	O
)	O
.	O

PP	O
was	O
the	O
strongest	O
independent	O
predictor	O
of	O
hsCRP	B
in	O
IgAN	O
(	O
T	O
=	O
2.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
while	O
body	O
mass	O
index	O
(	O
T	O
=	O
7.83	O
,	O
P	O
<	O
0.001	O
)	O
was	O
the	O
strongest	O
predictor	O
in	O
T1DM	O
Nx	O
.	O

Endothelial	O
cell	O
adhesion	B
molecules	I
were	O
increased	O
in	O
T1DM	O
Nx	O
>	O
IgAN	O
>	O
T1DM	O
No	O
Nx	O
vs	O
controls	O
:	O
soluble	O
vascular	B
adhesion	I
molecule-1	I
(	O
sVCAM-1	B
)	O
760	O
+	O
/-	O
30	O
(	O
P	O
<	O
0.001	O
)	O
>	O
663+	O
/	O
-	O
34	O
(	O
P	O
=	O
0.001	O
)	O
>	O
601	O
+	O
/	O
-	O
21	O
(	O
P	O
<	O
0.05	O
)	O
vs	O
536	O
+	O
/	O
-	O
15	O
ng	O
/	O
ml	O
;	O
soluble	O
intracellular	B
adhesion	I
molecule-1	I
(	O
sICAM-1	B
)	O
320	O
+	O
/	O
-	O
8	O
(	O
P	O
<	O
0.001	O
)	O
>	O
313	O
+	O
/	O
-	O
13	O
(	O
P	O
<	O
0.001	O
)	O
>	O
307+	O
/	O
-	O
8	O
(	O
P	O
<	O
0.001	O
)	O
vs	O
244	O
+	O
/	O
-	O
6	O
ng	O
/	O
ml	O
.	O

sVCAM-1	B
levels	O
were	O
higher	O
in	O
T1DM	O
Nx	O
than	O
in	O
T1DM	O
No	O
Nx	O
,	O
P	O
<	O
0.001	O
.	O

In	O
IgAN	O
and	O
T1DM	O
Nx	O
,	O
hsCRP	B
correlated	O
with	O
sICAM-1	B
(	O
r	O
=	O
0.33	O
,	O
P	O
=	O
0.017	O
;	O
r	O
=	O
0.37	O
;	O
P	O
=	O
0.017	O
)	O
.	O

sVCAM-1	B
was	O
related	O
to	O
renal	O
function	O
in	O
IgAN	O
and	O
T1DM	O
Nx	O
:	O
serum	O
cystatin	B
C	I
(	O
r	O
=	O
0.63	O
,	O
P	O
<	O
0.001	O
:	O
r	O
=	O
0.425	O
,	O
P	O
=	O
0.002	O
)	O
,	O
and	O
urine	O
protein	O
:	O
creatinine	O
ratio	O
in	O
IgAN	O
(	O
r	O
=	O
0.48	O
;	O
P	O
=	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O

Systemic	O
and	O
vascular	O
markers	O
of	O
inflammation	O
are	O
increased	O
in	O
early	O
renal	O
disease	O
and	O
relate	O
to	O
renal	O
dysfunction	O
and	O
cardiovascular	O
risk	O
factors	O
.	O

Inflammation	O
may	O
be	O
a	O
common	O
process	O
in	O
various	O
renal	O
diseases	O
and	O
may	O
link	O
and	O
accelerate	O
renal	O
dysfunction	O
and	O
CVD	O
.	O

Apolipoprotein	B
E	I
polymorphism	O
in	O
diabetic	O
and	O
non	O
-	O
diabetic	O
patients	O
:	O
does	O
it	O
really	O
contribute	O
to	O
atherosclerosis	O
?	O

OBJECTIVE	O
:	O

The	O
exact	O
mechanism	O
of	O
the	O
increased	O
cardiovascular	O
morbidity	O
and	O
mortality	O
in	O
type-2	O
diabetes	O
is	O
still	O
undefined	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
impact	O
of	O
apolipoprotein	B
E	I
(	O
apo	B
E	I
)	O
polymorphism	O
and	O
other	O
factors	O
on	O
atherosclerotic	O
vascular	O
disease	O
in	O
type-2	O
diabetic	O
patients	O
.	O

We	O
also	O
examined	O
the	O
association	O
between	O
apo	B
E	I
polymorphism	O
and	O
lipid	O
profile	O
in	O
diabetic	O
patients	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
assessed	O
the	O
apo	B
E	I
polymorphism	O
in	O
295	O
atherosclerotic	O
patients	O
(	O
124	O
of	O
them	O
had	O
diabetes	O
(	O
according	O
to	O
WHO	O
criteria	O
)	O
and	O
171	O
of	O
them	O
had	O
coronary	O
artery	O
narrowing	O
>	O
50	O
)	O
.The	O
detection	O
of	O
apo	B
E	I
polymorphism	O
was	O
made	O
by	O
Real	O
-	O
Time	O
PCR	O
using	O
a	O
Light	O
-	O
Cycler	O
(	O
Roche	O
diagnostics	O
,	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
.	O

Serum	O
triglycerides	O
(	O
TG	O
)	O
,	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
low	B
-	I
density	I
lipoprotein	I
(	O
LDL	B
)	O
,	O
high	B
-	I
density	I
lipoprotein	I
(	O
HDL	B
)	O
,	O
lipoprotein	B
(	I
a	I
)	I
[	O
Lp	B
(	I
a	I
)	I
]	O
,	O
apolipoprotein	B
A	I
(	O
Apo	B
A	I
)	O
and	O
apolipoprotein	B
B	I
(	O
Apo	B
B	I
)	O
levels	O
were	O
determined	O
by	O
biochemical	O
analyser	O
.	O

Genotypic	O
distribution	O
of	O
apo	B
E	I
polymorphism	O
did	O
not	O
differ	O
between	O
diabetic	O
and	O
non	O
-	O
diabetic	O
atherosclerotic	O
patients	O
.	O

The	O
distributions	O
of	O
apo	B
E2	I
/	I
2	I
,	I
E2	I
/	I
3	I
,	I
E2	I
/	I
4	I
,	I
E3	I
/	I
3	I
,	I
E3	I
/	I
4	I
and	I
E4	I
/	I
4	I
genotypes	O
in	O
diabetic	O
and	O
non	O
-	O
diabetic	O
atherosclerotic	O
patients	O
were	O
7.3	O
%	O
:	O
8.2	O
%	O
,	O
15.3	O
%	O
:	O
15.8	O
%	O
,	O
4.0	O
%	O
:	O
5.3	O
%	O
,	O
50.8	O
%	O
:	O
56.7	O
%	O
,	O
16.9	O
%	O
:	O
11.1	O
%	O
and	O
5.6	O
%	O
:	O
2.9	O
%	O
,	O
respectively	O
.	O

Participants	O
were	O
grouped	O
as	O
apo	B
E2	I
(	I
E2	I
/	I
2	I
or	I
E2	I
/	I
3	I
)	I
,	O
apo	B
E3	I
(	I
E3	I
/	I
3	I
)	I
,	O
or	O
apo	B
E4	I
(	I
E4	I
/	I
4	I
or	I
E4	I
/	I
3	I
)	I
.The	O
distributions	O
of	O
apo	B
E2	I
,	I
E3	I
and	I
E4	I
alleles	O
were	O
23.5	O
%	O
,	O
52.9	O
%	O
,	O
23.5	O
%	O
,	O
for	O
diabetic	O
patients	O
,	O
and	O
25.3	O
%	O
,	O
59.9	O
%	O
,	O
14.8	O
%	O
for	O
non	O
-	O
diabetic	O
patients	O
,	O
respectively	O
.	O

The	O
apolipoprotein	B
E	I
genotype	O
was	O
not	O
associated	O
with	O
the	O
lipid	O
levels	O
in	O
diabetic	O
patients	O
.	O

CONCLUSIONS	O
:	O

Our	O
findings	O
imply	O
that	O
apo	B
E	I
polymorphism	O
is	O
not	O
related	O
to	O
the	O
development	O
of	O
atherosclerosis	O
in	O
patients	O
with	O
type-2	O
diabetes	O
.	O

Plasma	O
proteomic	O
analysis	O
of	O
the	O
acute	O
phase	O
response	O
of	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
to	O
intraperitoneal	O
inflammation	O
and	O
LPS	O
injection	O
.	O

Few	O
acute	O
phase	O
proteins	O
are	O
known	O
in	O
fish	O
and	O
better	O
knowledge	O
of	O
them	O
would	O
provide	O
a	O
basis	O
for	O
more	O
reliable	O
methods	O
to	O
objectively	O
assess	O
fish	O
health	O
and	O
welfare	O
.	O

An	O
acute	O
phase	O
response	O
was	O
induced	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
,	O
Walbaum	O
)	O
by	O
inflammation	O
triggered	O
by	O
intraperitoneal	O
administration	O
of	O
purified	O
Aeromonas	O
salmonicida	O
lipopolysaccharide	O
emulsified	O
in	O
Freund	O
's	O
incomplete	O
adjuvant	O
(	O
LPS	O
/	O
FIA	O
)	O
or	O
a	O
commercial	O
oil	O
-	O
based	O
multivalent	O
vaccine	O
.	O

Acute	O
phase	O
proteins	O
were	O
characterized	O
by	O
comparative	O
densitometry	O
of	O
plasma	O
proteins	O
separated	O
by	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
2D	O
-	O
PAGE	O
)	O
and	O
identified	O
by	O
MALDI	O
-	O
TOF	O
and	O
ESI	O
MS	O
/	O
MS	O
mass	O
spectrometry	O
.	O

In	O
one	O
experiment	O
,	O
plasma	O
samples	O
were	O
compared	O
between	O
treatment	O
and	O
control	O
groups	O
in	O
which	O
fish	O
were	O
terminally	O
bled	O
.	O

In	O
another	O
experiment	O
,	O
individual	O
fish	O
were	O
sampled	O
repeatedly	O
.	O

Proteins	O
scored	O
as	O
increased	O
were	O
those	O
whose	O
normalized	O
value	O
increased	O
three	O
-	O
fold	O
or	O
greater	O
between	O
pre	O
-	O
and	O
post	O
-	O
stimulus	O
.	O

Proteins	O
scored	O
as	O
decreased	O
were	O
those	O
whose	O
normalized	O
values	O
decreased	O
two	O
-	O
fold	O
or	O
greater	O
.	O

Unaltered	O
proteins	O
were	O
those	O
that	O
were	O
not	O
altered	O
or	O
did	O
not	O
meet	O
either	O
of	O
these	O
criteria	O
.	O

Proteins	O
that	O
were	O
absent	O
in	O
pre	O
-	O
stimulus	O
gels	O
but	O
present	O
in	O
post	O
-	O
stimulus	O
profiles	O
were	O
considered	O
to	O
be	O
induced	O
.	O

Only	O
those	O
proteins	O
that	O
were	O
altered	O
in	O
all	O
fish	O
for	O
a	O
given	O
treatment	O
were	O
considered	O
.	O

In	O
both	O
experiments	O
,	O
protein	O
p36	O
was	O
increased	O
up	O
to	O
13	O
-	O
fold	O
and	O
several	O
proteins	O
were	O
detected	O
that	O
had	O
not	O
been	O
previously	O
.	O

In	O
all	O
fish	O
treated	O
with	O
LPS	O
/	O
FIA	O
,	O
p9.5	O
was	O
consistently	O
increased	O
an	O
average	O
of	O
75	O
-	O
fold	O
in	O
plasma	O
.	O

We	O
have	O
constructed	O
a	O
plasma	O
protein	O
panel	O
of	O
eight	O
increased	O
or	O
induced	O
proteins	O
(	O
p9.5	O
,	O
p10.5	O
,	O
p24a	O
,	O
p24b	O
,	O
p24c	O
,	O
p25a	O
,	O
p36	O
and	O
p37	O
)	O
,	O
one	O
decreased	O
(	O
p16	O
)	O
and	O
two	O
that	O
are	O
unaltered	O
(	O
p28a	O
,	O
p28b	O
)	O
in	O
rainbow	O
trout	O
following	O
inflammation	O
or	O
injection	O
with	O
LPS	O
/	O
FIA	O
.	O

Proteins	O
from	O
this	O
panel	O
that	O
were	O
similar	O
to	O
previously	O
identified	O
proteins	O
were	O
pre	O
-	O
cerebellin	B
-	O
like	O
(	O
p24a	O
)	O
,	O
transferrin	B
(	O
p37	O
)	O
and	O
apolipoprotein	B
(	O
p10.5	O
,	O
p24c	O
and	O
p28	O
)	O
.	O

Effect	O
of	O
nandrolone	O
decanonate	O
on	O
paraoxonase	B
activity	O
in	O
hemodialysis	O
patients	O
.	O

OBJECTIVES	O
:	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effect	O
of	O
nandrolone	O
decanonate	O
(	O
ND	O
)	O
on	O
HDL	B
-	O
C	O
,	O
apolipoproteins	B
and	O
paraoxonase	B
(	O
PON	B
)	O
activity	O
in	O
stable	O
hemodialysis	O
patients	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O

64	O
hemodialysis	O
patients	O
were	O
treated	O
with	O
ND	O
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
I.M.	O
/	O
week	O
for	O
4	O
months	O
.	O

HDL	B
-	O
C	O
,	O
Apo	B
-	I
AI	I
,	O
Apo	B
B	I
,	O
concentrations	O
and	O
PON	B
activity	O
were	O
measured	O
before	O
and	O
after	O
2	O
and	O
4	O
months	O
of	O
treatment	O
as	O
well	O
as	O
2	O
months	O
after	O
withdrawing	O
the	O
treatment	O
.	O

RESULTS	O
:	O

After	O
4	O
months	O
of	O
treatment	O
,	O
an	O
elevation	O
in	O
the	O
serum	O
levels	O
of	O
Apo	B
B	I
(	O
P	O
<	O
0.0001	O
)	O
and	O
a	O
marked	O
decrease	O
in	O
the	O
concentration	O
of	O
HDL	B
-	O
C	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
Apo	B
-	I
AI	I
(	O
P	O
<	O
0.0001	O
)	O
and	O
PON	B
activity	O
(	O
P	O
<	O
0.0001	O
)	O
were	O
found	O
.	O

A	O
significant	O
correlation	O
between	O
PON	B
and	O
both	O
Apo	B
-	I
AI	I
(	O
r	O
=	O
0.270	O
,	O
P	O
<	O
0.04	O
)	O
and	O
HDL	B
-	O
C	O
(	O
r	O
=	O
0.455	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
also	O
between	O
HDL	B
-	O
C	O
and	O
Apo	B
-	I
AI	I
(	O
r	O
=	O
0.305	O
,	O
P	O
<	O
0.02	O
)	O
were	O
found	O
.	O

CONCLUSION	O
:	O

Results	O
revealed	O
the	O
adverse	O
effects	O
of	O
ND	O
on	O
apolipoprotein	O
levels	O
in	O
our	O
study	O
population	O
.	O

It	O
is	O
possible	O
that	O
ND	O
reduces	O
PON	B
activity	O
mostly	O
by	O
reducing	O
both	O
the	O
HDL	B
-	O
C	O
and	O
Apo	B
-	I
AI	I
levels	O
.	O

Three	O
-	O
dimensional	O
reconstruction	O
of	O
anomalous	O
chloroplasts	O
in	O
transgenic	O
ipt	O
tobacco	O
.	O

Anomalies	O
in	O
the	O
ultrastructure	O
of	O
chloroplasts	O
,	O
from	O
transgenic	O
ipt	O
tobacco	O
,	O
overproducing	O
endogenous	O
cytokinins	B
(	O
CKs	O
)	O
were	O
studied	O
.	O

Detailed	O
analyses	O
of	O
CKs	O
and	O
their	O
metabolites	O
showed	O
that	O
Pssu	O
-	O
ipt	O
tobacco	O
contained	O
enhanced	O
contents	O
of	O
CKs	O
both	O
in	O
leaves	O
and	O
in	O
isolated	O
chloroplasts	O
.	O

The	O
role	O
of	O
CKs	O
in	O
the	O
formation	O
of	O
anomalous	O
structures	O
is	O
suggested	O
.	O

Pssu	O
-	O
ipt	O
chloroplasts	O
frequently	O
formed	O
the	O
distinct	O
peripheral	O
reticulum	O
with	O
a	O
system	O
of	O
caverns	O
that	O
often	O
involved	O
mitochondria	O
and/or	O
peroxisomes	O
.	O

Large	O
crystalloids	O
,	O
which	O
were	O
found	O
in	O
chloroplasts	O
of	O
Pssu	O
-	O
ipt	O
,	O
occupied	O
up	O
to	O
16	O
%	O
of	O
chloroplast	O
volume	O
.	O

We	O
suggested	O
that	O
the	O
crystalloids	O
were	O
formed	O
by	O
LHC	B
II	I
aggregates	O
.	O

This	O
was	O
supported	O
by	O
analysis	O
of	O
the	O
fluorescence	O
emission	O
spectra	O
at	O
77	O
degrees	O
K	O
,	O
chlorophyll	O
a	O
/	O
b	O
ratio	O
,	O
immunogold	O
staining	O
of	O
the	O
structures	O
,	O
and	O
crystallographic	O
unit	O
size	O
analysis	O
.	O

Cloning	O
and	O
sequencing	O
of	O
28	B
kDa	I
outer	I
membrane	I
protein	I
gene	O
of	O
Brucella	O
melitensis	O
Rev.	O
1	O
.	O

Brucella	O
melitensis	O
is	O
an	O
organism	O
of	O
paramount	O
zoonotic	O
importance	O
.	O

The	O
28	B
kDa	I
outer	I
membrane	I
protein	I
(	I
OMP	I
)	I
is	O
one	O
of	O
the	O
immunodominant	O
antigens	O
of	O
B.	O
melitensis	O
.	O

The	O
gene	O
encoding	O
28	B
kDa	I
OMP	I
(	O
omp28	B
)	O
has	O
been	O
amplified	O
from	O
B.	O
melitensis	O
Rev.	O
1	O
strain	O
.	O

A	O
PCR	O
product	O
of	O
753	O
bp	O
,	O
encoding	O
complete	O
omp28	B
gene	O
of	O
B.	O
melitensis	O
,	O
was	O
obtained	O
.	O

The	O
gene	O
was	O
further	O
cloned	O
and	O
sequenced	O
.	O

The	O
nucleotide	O
sequence	O
of	O
B.	O
melitensis	O
Rev.	O
1	O
strain	O
showed	O
substitution	O
of	O
2	O
nucleotides	O
from	O
that	O
of	O
16	O
M	O
strain	O
.	O

Expression	O
of	O
hyaluronan	B
synthases	I
and	O
hyaluronidases	B
in	O
the	O
MG63	O
osteoblast	O
cell	O
line	O
.	O

The	O
expression	O
of	O
hyaluronan	B
synthases	I
(	I
1	I
,	I
2	I
and	I
3	I
)	I
and	O
hyaluronidases	B
(	I
1	I
,	I
2	I
,	I
3	I
,	I
4	I
and	O
PH20	B
)	O
was	O
examined	O
in	O
the	O
MG63	O
osteoblast	O
cell	O
line	O
induced	O
to	O
mineralize	O
in	O
vitro	O
and	O
compared	O
to	O
the	O
rate	O
of	O
glycosaminoglycan	O
production	O
.	O

Real	O
-	O
time	O
PCR	O
analysis	O
demonstrated	O
a	O
13	O
-	O
fold	O
decrease	O
in	O
hyaluronan	B
synthase	I
3	I
expression	O
in	O
mineralising	O
MG63	O
cells	O
;	O
no	O
significant	O
change	O
in	O
hyaluronan	B
synthase	I
2	I
expression	O
in	O
mineralising	O
cells	O
and	O
hyaluronan	B
synthase	I
1	I
was	O
not	O
expressed	O
.	O

In	O
mineralising	O
MG63	O
cells	O
a	O
62	O
-	O
fold	O
increase	O
in	O
hyaluronidase	B
2	I
,	O
a	O
13	O
-	O
fold	O
increase	O
in	O
hyaluronidase	B
3	I
,	O
and	O
a	O
3	O
-	O
fold	O
increase	O
in	O
hyaluronidase	B
4	I
expression	O
were	O
observed	O
when	O
compared	O
to	O
non	O
-	O
mineralising	O
cells	O
;	O
hyaluronidase	B
1	I
and	O
PH20	B
expression	O
was	O
not	O
detected	O
.	O

After	O
5	O
weeks	O
in	O
mineralising	O
culture	O
conditions	O
a	O
2	O
-	O
fold	O
increase	O
in	O
total	O
3H	O
-	O
glucosamine	O
incorporation	O
was	O
observed	O
in	O
cells	O
when	O
compared	O
to	O
24	O
h	O
or	O
5	O
week	O
control	O
cultures	O
.	O

This	O
was	O
made	O
up	O
of	O
a	O
5	O
-	O
fold	O
decrease	O
in	O
hyaluronan	O
production	O
,	O
a	O
2	O
-	O
fold	O
increase	O
in	O
chondroitin	O
sulphate	O
/	O
dermatan	O
sulphate	O
and	O
a	O
10	O
-	O
fold	O
increase	O
in	O
3H	O
-	O
glucosamine	O
incorporation	O
into	O
the	O
non	O
-	O
glycosaminoglycan	O
fraction	O
.	O

A	O
3	O
-	O
fold	O
increase	O
in	O
35SO4	O
incorporation	O
into	O
chondroitin	O
sulphate	O
/	O
dermatan	O
sulphate	O
was	O
also	O
observed	O
.	O

Thus	O
there	O
is	O
co	O
-	O
ordinate	O
expression	O
of	O
genes	O
that	O
control	O
hyaluronan	O
metabolism	O
such	O
that	O
there	O
is	O
a	O
general	O
decrease	O
in	O
the	O
expression	O
of	O
hyaluronan	B
synthases	I
,	O
an	O
increase	O
in	O
the	O
expression	O
of	O
hyaluronidases	B
and	O
a	O
corresponding	O
decrease	O
in	O
hyaluronan	O
production	O
by	O
mineralising	O
MG63	O
cells	O
.	O

Analysis	O
of	O
genes	O
involved	O
in	O
arsenic	O
resistance	O
in	O
Corynebacterium	O
glutamicum	O
ATCC	O
13032	O
.	O

Corynebacterium	O
glutamicum	O
is	O
able	O
to	O
grow	O
in	O
media	O
containing	O
up	O
to	O
12	O
mM	O
arsenite	O
and	O
500	O
mM	O
arsenate	O
and	O
is	O
one	O
of	O
the	O
most	O
arsenic	O
-	O
resistant	O
microorganisms	O
described	O
to	O
date	O
.	O

Two	O
operons	O
(	O
ars1	B
and	O
ars2	B
)	O
involved	O
in	O
arsenate	O
and	O
arsenite	O
resistance	O
have	O
been	O
identified	O
in	O
the	O
complete	O
genome	O
sequence	O
of	O
Corynebacterium	O
glutamicum	O
.	O

The	O
operons	B
ars1	I
and	O
ars2	B
are	O
located	O
some	O
distance	O
from	O
each	O
other	O
in	O
the	O
bacterial	O
chromosome	O
,	O
but	O
they	O
are	O
both	O
composed	O
of	O
genes	O
encoding	O
a	O
regulatory	O
protein	O
(	O
arsR	B
)	O
,	O
an	O
arsenite	B
permease	I
(	O
arsB	B
)	O
,	O
and	O
an	O
arsenate	B
reductase	I
(	O
arsC	B
)	O
;	O
operon	B
ars1	I
contains	O
an	O
additional	O
arsenate	B
reductase	I
gene	O
(	O
arsC1	B
'	I
)	O
located	O
immediately	O
downstream	O
from	O
arsC1	B
.	O

Additional	O
arsenite	B
permease	I
and	O
arsenate	B
reductase	I
genes	O
(	O
arsB3	B
and	O
arsC4	B
)	O
scattered	O
on	O
the	O
chromosome	O
were	O
also	O
identified	O
.	O

The	O
involvement	O
of	O
ars	B
operons	I
in	O
arsenic	O
resistance	O
in	O
C.	O
glutamicum	O
was	O
confirmed	O
by	O
gene	O
disruption	O
experiments	O
of	O
the	O
three	O
arsenite	B
permease	I
genes	O
present	O
in	O
its	O
genome	O
.	O

Wild	O
-	O
type	O
and	O
arsB3	B
insertional	O
mutant	O
C.	O
glutamicum	O
strains	O
were	O
able	O
to	O
grow	O
with	O
up	O
to	O
12	O
mM	O
arsenite	O
,	O
whereas	O
arsB1	B
and	O
arsB2	B
C.	O
glutamicum	O
insertional	O
mutants	O
were	O
resistant	O
to	O
4	O
mM	O
and	O
9	O
mM	O
arsenite	O
,	O
respectively	O
.	O

The	O
double	O
arsB1	B
-	O
arsB2	B
insertional	O
mutant	O
was	O
resistant	O
to	O
only	O
0.4	O
mM	O
arsenite	O
and	O
10	O
mM	O
arsenate	O
.	O

Gene	O
amplification	O
assays	O
of	O
operons	B
ars1	I
and	O
ars2	B
in	O
C.	O
glutamicum	O
revealed	O
that	O
the	O
recombinant	O
strains	O
containing	O
the	O
ars1	B
operon	I
were	O
resistant	O
to	O
up	O
to	O
60	O
mM	O
arsenite	O
,	O
this	O
being	O
one	O
of	O
the	O
highest	O
levels	O
of	O
bacterial	O
resistance	O
to	O
arsenite	O
so	O
far	O
described	O
,	O
whereas	O
recombinant	O
strains	O
containing	O
operon	B
ars2	I
were	O
resistant	O
to	O
only	O
20	O
mM	O
arsenite	O
.	O

Northern	O
blot	O
and	O
reverse	O
transcription	O
-	O
PCR	O
analysis	O
confirmed	O
the	O
presence	O
of	O
transcripts	O
for	O
all	O
the	O
ars	B
genes	O
,	O
the	O
expression	O
of	O
arsB3	B
and	O
arsC4	B
being	O
constitutive	O
,	O
and	O
the	O
expression	O
of	O
arsR1	B
,	O
arsB1	B
,	O
arsC1	B
,	O
arsC1	B
'	I
,	O
arsR2	B
,	O
arsB2	B
,	O
and	O
arsC2	B
being	O
inducible	O
by	O
arsenite	O
.	O

Transient	O
effects	O
of	O
overexpressing	O
anthranilate	B
synthase	I
alpha	I
and	I
beta	I
subunits	O
in	O
Catharanthus	O
roseus	O
hairy	O
roots	O
.	O

Catharanthus	O
roseus	O
produces	O
two	O
economically	O
valuable	O
anticancer	O
drugs	O
,	O
vinblastine	O
and	O
vincristine	O
.	O

These	O
drugs	O
are	O
members	O
of	O
the	O
terpenoid	O
indole	O
alkaloids	O
and	O
accumulate	O
in	O
small	O
quantities	O
within	O
the	O
plant	O
;	O
thus	O
these	O
two	O
drugs	O
are	O
expensive	O
to	O
produce	O
.	O

Metabolic	O
engineering	O
efforts	O
have	O
focused	O
on	O
increasing	O
the	O
alkaloids	O
in	O
this	O
pathway	O
through	O
various	O
means	O
such	O
as	O
elicitation	O
,	O
precursor	O
feeding	O
,	O
and	O
gene	O
overexpression	O
.	O

Recently	O
we	O
successfully	O
expressed	O
Arabidopsis	O
genes	O
encoding	O
a	O
feedback	O
-	O
insensitive	O
anthranilate	B
synthase	I
alpha	I
subunit	O
under	O
the	O
control	O
of	O
the	O
glucocorticoid	O
-	O
inducible	O
promoter	O
system	O
and	O
the	O
anthranilate	B
synthase	I
beta	I
subunit	O
under	O
the	O
control	O
of	O
a	O
constitutive	O
promoter	O
in	O
C.	O
roseus	O
hairy	O
roots	O
.	O

In	O
this	O
work	O
we	O
look	O
at	O
the	O
transient	O
behaviors	O
of	O
terpenoid	O
indole	O
alkaloids	O
over	O
a	O
72	O
h	O
induction	O
period	O
in	O
late	O
exponential	O
growth	O
phase	O
cultures	O
.	O

Upon	O
induction	O
,	O
the	O
tryptophan	O
,	O
tryptamine	O
,	O
and	O
ajmalicine	O
pools	O
accumulated	O
over	O
72	O
h	O
.	O

In	O
contrast	O
,	O
the	O
lochnericine	O
,	O
hÃ?Â¶rhammericine	O
,	O
and	O
tabersonine	O
pools	O
decreased	O
and	O
leveled	O
out	O
over	O
the	O
72	O
h	O
induction	O
period	O
.	O

Visible	O
changes	O
within	O
the	O
individual	O
compounds	O
usually	O
took	O
from	O
4	O
to	O
12	O
h	O
.	O

KIR3DL1	B
polymorphisms	O
that	O
affect	O
NK	O
cell	O
inhibition	O
by	O
HLA	B
-	I
Bw4	I
ligand	O
.	O

The	O
killer	B
cell	I
Ig	I
-	I
like	I
receptor	I
(	I
KIR	I
)	I
gene	I
family	I
encodes	O
MHC	B
class	I
I	I
receptors	O
expressed	O
by	O
NK	O
cells	O
and	O
several	O
T	O
cell	O
subpopulations	O
.	O

Factors	O
contributing	O
to	O
human	O
KIR	B
haplotype	O
diversity	O
are	O
differences	O
in	O
gene	O
number	O
,	O
gene	O
content	O
,	O
and	O
allelic	O
polymorphism	O
.	O

Whereas	O
functional	O
and	O
clinical	O
consequences	O
of	O
the	O
first	O
two	O
factors	O
are	O
established	O
,	O
knowledge	O
of	O
the	O
effects	O
of	O
KIR	B
gene	O
polymorphism	O
is	O
limited	O
to	O
special	O
cases	O
in	O
which	O
signaling	O
function	O
is	O
reversed	O
or	O
cell	O
surface	O
expression	O
lost	O
.	O

In	O
this	O
study	O
we	O
use	O
retrovirally	O
transduced	O
human	O
cell	O
lines	O
to	O
show	O
that	O
3DL1	B
*	I
002	I
is	O
a	O
stronger	O
inhibitory	O
receptor	O
for	O
HLA	B
-	I
Bw4	I
ligands	O
than	O
3DL1	B
*	I
007	I
.	O

Analysis	O
of	O
mutant	O
3DL1	B
*	I
002	I
and	O
3DL1	B
*	I
007	I
molecules	O
demonstrates	O
that	O
residue	O
238	O
in	O
the	O
D2	O
domain	O
and	O
320	O
in	O
the	O
transmembrane	O
region	O
contribute	O
to	O
the	O
difference	O
in	O
receptor	O
strength	O
.	O

Neither	O
position	O
238	O
nor	O
320	O
is	O
predicted	O
to	O
interact	O
directly	O
with	O
HLA	B
-	I
Bw4	I
ligand	O
.	O

This	O
study	O
also	O
revealed	O
that	O
KIR3DL1	B
and	O
LILRB1	B
both	O
contribute	O
to	O
developing	O
an	O
inhibitory	O
response	O
to	O
HLA	B
-	I
Bw4	I
ligands	O
.	O

Role	O
of	O
tumor	B
necrosis	I
factor	I
receptors	I
in	O
an	O
animal	O
model	O
of	O
acute	O
colitis	O
.	O

TNF	B
-	I
alpha	I
is	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
;	O
however	O
,	O
the	O
pathophysiological	O
role	O
of	O
its	O
receptors	O
is	O
still	O
under	O
study	O
.	O

Acute	O
colitis	O
was	O
induced	O
in	O
rats	O
by	O
intracolonic	O
administration	O
of	O
trinitrobenzene	O
sulfonic	O
acid	O
(	O
TNBS	O
)	O
.	O

Control	O
rats	O
received	O
the	O
ethanol	O
vehicle	O
.	O

Rats	O
were	O
sacrificed	O
72	O
h	O
later	O
and	O
samples	O
of	O
tissue	O
and	O
fluids	O
were	O
collected	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
protein	O
levels	O
of	O
sTNF	B
-	I
alpha	I
,	O
sTNFRI	B
,	O
and	O
sTNFRII	B
in	O
the	O
peritoneal	O
fluid	O
(	O
PF	O
)	O
of	O
experimental	O
rats	O
.	O

TNF	B
-	I
alpha	I
,	O
TNFRI	B
,	O
and	O
TNFRII	B
mRNA	O
expression	O
was	O
increased	O
significantly	O
in	O
the	O
colon	O
of	O
experimental	O
animals	O
compared	O
to	O
controls	O
.	O

TRAF3	B
and	O
TRAF5	B
expression	O
was	O
also	O
significantly	O
higher	O
,	O
as	O
was	O
that	O
of	O
the	O
adhesion	B
molecules	I
ICAM-1	B
and	O
E	B
-	I
selectin	I
.	O

The	O
increased	O
expression	O
of	O
TNF	B
-	I
alpha	I
,	O
TNFRs	B
,	O
and	O
the	O
associated	O
signaling	O
factors	O
in	O
the	O
colon	O
of	O
this	O
rat	O
model	O
of	O
IBD	O
provides	O
further	O
evidence	O
for	O
their	O
involvement	O
in	O
the	O
promotion	O
of	O
inflammation	O
and	O
tissue	O
damage	O
.	O

In	O
addition	O
,	O
increased	O
levels	O
of	O
sTNFRs	B
in	O
the	O
PF	O
of	O
experimental	O
rats	O
--	O
particularly	O
sTNFRII	B
--	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
colitis	O
by	O
serving	O
as	O
a	O
reservoir	O
of	O
TNF	B
-	I
alpha	I
,	O
and	O
thus	O
provide	O
a	O
novel	O
therapeutic	O
target	O
for	O
IBD	O
.	O

Cytokine	B
-	O
mediated	O
modulation	O
of	O
leptin	B
and	O
adiponectin	B
secretion	O
during	O
in	O
vitro	O
adipogenesis	O
:	O
evidence	O
that	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
-	O
and	O
interleukin-1beta	B
-	O
treated	O
human	O
preadipocytes	O
are	O
potent	O
leptin	B
producers	O
.	O

Over	O
the	O
last	O
decade	O
,	O
compelling	O
evidence	O
has	O
been	O
presented	O
that	O
cytokines	O
affect	O
adipocyte	O
tissue	O
formation	O
and	O
function	O
.	O

In	O
this	O
study	O
we	O
explored	O
the	O
effect	O
of	O
pro	O
-	O
inflammatory	O
(	O
i.e.	O
interleukin	B
(	I
IL	I
)	I
-	I
1beta	I
,	O
IL-6	B
,	O
interferon	B
(	I
IFN	I
)	I
-	I
gamma	I
,	O
and	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-	I
alpha	I
)	O
versus	O
anti	O
-	O
inflammatory	O
cytokines	B
(	O
i.e.	O
IL-4	B
,	O
IL-10	B
,	O
and	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
beta1	I
)	O
on	O
leptin	B
and	O
adiponectin	B
secretion	O
during	O
in	O
vitro	O
human	O
adipogenesis	O
.	O

Confirmative	O
to	O
previous	O
reports	O
,	O
conversion	O
of	O
precursor	O
preadipocytes	O
into	O
mature	O
adipocytes	O
was	O
completely	O
inhibited	O
upon	O
exposure	O
to	O
TNF	B
-	I
alpha	I
,	O
IL-1beta	B
,	O
IFN	B
-	I
gamma	I
,	O
or	O
TGF	B
-	I
beta1	I
.	O

Hence	O
,	O
all	O
these	O
anti	O
-	O
adipogenic	O
cytokines	B
prevented	O
release	O
of	O
adipocyte	O
-	O
specific	O
adiponectin	B
.	O

IFN	B
-	I
gamma	I
also	O
strongly	O
reduced	O
leptin	B
production	O
(	O
>	O
or	O
=	O
85	O
%	O
)	O
.	O

However	O
,	O
TNF	B
-	I
alpha	I
,	O
IL-1beta	B
,	O
and	O
TGF	B
-	I
beta1	I
stimulated	O
leptin	B
production	O
from	O
preadipocytes	O
in	O
the	O
absence	O
of	O
mature	O
adipocytes	O
(	O
20.6	O
+	O
/-	O
5.4	O
ng	O
/	O
ml	O
,	O
100.8	O
+	O
/-	O
18.2	O
ng	O
/	O
ml	O
,	O
and	O
5.4	O
+	O
/-	O
0.4	O
ng	O
/	O
ml	O
,	O
respectively	O
,	O
compared	O
to	O
6.6	O
+	O
/-	O
0.8	O
ng	O
/	O
ml	O
in	O
control	O
adipocyte	O
cultures	O
on	O
day	O
21	O
;	O
n	O
=	O
4	O
)	O
.	O

IL-4	B
,	O
IL-6	B
and	O
IL-10	B
did	O
not	O
,	O
or	O
only	O
slightly	O
,	O
affect	O
adipocyte	O
differentiation	O
and	O
their	O
hormonal	O
secretion	O
.	O

In	O
conclusion	O
,	O
adiponectin	B
and	O
leptin	B
are	O
both	O
synthesized	O
by	O
adipocytes	O
,	O
whereas	O
leptin	B
is	O
also	O
produced	O
by	O
preadipocytes	O
upon	O
TNF	B
-	I
alpha	I
or	O
IL-1beta	B
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
preadipocytes	O
could	O
contribute	O
more	O
to	O
total	O
circulating	O
leptin	B
levels	O
than	O
has	O
been	O
previously	O
considered	O
,	O
especially	O
in	O
diseased	O
conditions	O
were	O
these	O
pro	O
-	O
inflammatory	O
factors	O
play	O
a	O
prominent	O
role	O
.	O

The	O
docosatriene	O
protectin	O
D1	O
is	O
produced	O
by	O
TH2	O
skewing	O
and	O
promotes	O
human	O
T	O
cell	O
apoptosis	O
via	O
lipid	O
raft	O
clustering	O
.	O

Docosahexaenoic	O
acid	O
,	O
a	O
major	O
omega-3	O
fatty	O
acid	O
in	O
human	O
brain	O
,	O
synapses	O
,	O
retina	O
,	O
and	O
other	O
neural	O
tissues	O
,	O
displays	O
beneficial	O
actions	O
in	O
neuronal	O
development	O
,	O
cancer	O
,	O
and	O
inflammatory	O
diseases	O
by	O
mechanisms	O
that	O
remain	O
to	O
be	O
elucidated	O
.	O

In	O
this	O
study	O
we	O
found	O
,	O
using	O
lipid	O
mediator	O
informatics	O
employing	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
,	O
that	O
(	O
10,17S	O
)	O
-docosatriene	O
/	O
neuroprotectin	O
D1	O
,	O
now	O
termed	O
protectin	O
D1	O
(	O
PD1	O
)	O
,	O
is	O
generated	O
from	O
docosahexaenoic	O
acid	O
by	O
T	O
helper	O
type	O
2	O
-	O
skewed	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
a	O
lipoxygenase	B
-	O
dependent	O
manner	O
.	O

PD1	O
blocked	O
T	O
cell	O
migration	O
in	O
vivo	O
,	O
inhibited	O
tumor	B
necrosis	I
factor	I
alpha	I
and	O
interferon	B
-	I
gamma	I
secretion	O
,	O
and	O
promoted	O
apoptosis	O
mediated	O
by	O
raft	O
clustering	O
.	O

These	O
results	O
demonstrated	O
novel	O
anti	O
-	O
inflammatory	O
roles	O
for	O
PD1	O
in	O
regulating	O
events	O
associated	O
with	O
inflammation	O
and	O
resolution	O
.	O

Serum	O
evaluation	O
of	O
the	O
balance	O
between	O
soluble	O
interleukin-2	B
and	O
interleukin-4	B
receptors	I
.	O

To	O
elucidate	O
the	O
usefulness	O
of	O
the	O
simultaneous	O
analysis	O
of	O
the	O
multiple	O
kinds	O
of	O
soluble	O
cytokine	B
receptors	I
,	O
we	O
determined	O
both	O
the	O
soluble	O
interleukin	B
2	I
receptor	I
(	O
sIL-2R	B
,	O
Th1	O
-	O
type	O
cytokine	B
receptor	I
)	O
and	O
the	O
soluble	O
interleukin	B
4	I
receptor	I
(	O
sIL-4R	B
,	O
Th2	O
-	O
type	O
cytokine	B
receptor	I
)	O
levels	O
in	O
the	O
sera	O
of	O
healthy	O
subjects	O
as	O
reference	O
values	O
and	O
preliminarily	O
applied	O
to	O
evaluate	O
the	O
patients	O
with	O
diarrhea	O
positive	O
(	O
D+	O
)	O
hemolytic	O
uremic	O
syndrome	O
(	O
HUS	O
)	O
as	O
the	O
diagnostic	O
parameter	O
of	O
the	O
severity	O
.	O

Both	O
sIL-2R	B
and	O
sIL-4R	B
levels	O
in	O
the	O
sera	O
of	O
healthy	O
children	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
healthy	O
adults	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
serum	O
sIL-2R	B
level	O
of	O
the	O
patients	O
with	O
severe	O
HUS	O
(	O
n	O
=	O
4	O
)	O
was	O
higher	O
than	O
that	O
of	O
the	O
patients	O
with	O
mild	O
/	O
moderate	O
HUS	O
(	O
n	O
=	O
6	O
)	O
at	O
the	O
initial	O
stage	O
(	O
p	O
<	O
0.01	O
)	O
or	O
healthy	O
children	O
(	O
n	O
=	O
51	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Whereas	O
,	O
the	O
serum	O
sIL-4R	B
level	O
of	O
both	O
the	O
severe	O
and	O
mild	O
/	O
moderate	O
groups	O
was	O
lower	O
than	O
that	O
of	O
the	O
healthy	O
control	O
children	O
,	O
although	O
there	O
was	O
no	O
significant	O
difference	O
among	O
the	O
three	O
groups	O
.	O

Namely	O
,	O
the	O
soluble	O
receptor	O
balance	O
(	O
sIL-2R	B
/	O
sIL-4R	B
)	O
in	O
the	O
patients	O
with	O
severe	O
HUS	O
may	O
shift	O
.	O

We	O
considered	O
that	O
the	O
evaluation	O
of	O
the	O
balance	O
between	O
soluble	O
cytokine	B
receptors	I
might	O
be	O
informative	O
for	O
the	O
evaluation	O
of	O
the	O
immune	O
states	O
,	O
as	O
well	O
as	O
the	O
conventional	O
cytokine	B
balance	O
(	O
Th1	O
/	O
Th2	O
)	O
.	O

F	B
-	I
spondin	I
interaction	O
with	O
the	O
apolipoprotein	B
E	I
receptor	I
ApoEr2	B
affects	O
processing	O
of	O
amyloid	B
precursor	I
protein	I
.	O

A	O
recent	O
study	O
showed	O
that	O
F	B
-	I
spondin	I
,	O
a	O
protein	O
associated	O
with	O
the	O
extracellular	O
matrix	O
,	O
interacted	O
with	O
amyloid	B
precursor	I
protein	I
(	O
APP	B
)	O
and	O
inhibited	O
beta	B
-	I
secretase	I
cleavage	O
.	O

F	B
-	I
spondin	I
contains	O
a	O
thrombospondin	B
domain	O
that	O
we	O
hypothesized	O
could	O
interact	O
with	O
the	O
family	B
of	I
receptors	I
for	I
apolipoprotein	I
E	I
(	O
apoE	B
)	O
.	O

Through	O
coimmunoprecipitation	O
experiments	O
,	O
we	O
demonstrated	O
that	O
F	B
-	I
spondin	I
interacts	O
with	O
an	O
apoE	B
receptor	I
(	O
apoE	B
receptor	I
2	I
[	O
ApoEr2	B
]	O
)	O
through	O
the	O
thrombospondin	B
domain	O
of	O
F	B
-	I
spondin	I
and	O
the	O
ligand	O
binding	O
domain	O
of	O
ApoEr2	B
.	O

Full	O
-	O
length	O
F	B
-	I
spondin	I
increased	O
coimmunoprecipitation	O
of	O
ApoEr2	B
and	O
APP	B
in	O
transfected	O
cells	O
and	O
primary	O
neurons	O
and	O
increased	O
surface	O
expression	O
of	O
APP	B
and	O
ApoEr2	B
.	O

Full	O
-	O
length	O
F	B
-	I
spondin	I
,	O
but	O
none	O
of	O
the	O
individual	O
F	B
-	I
spondin	I
domains	O
,	O
increased	O
cleavage	O
of	O
APP	B
and	O
ApoEr2	B
,	O
resulting	O
in	O
more	O
secreted	O
forms	O
of	O
APP	B
and	O
ApoEr2	B
and	O
more	O
C	O
-	O
terminal	O
fragments	O
(	O
CTF	O
)	O
of	O
these	O
proteins	O
.	O

In	O
addition	O
,	O
full	O
-	O
length	O
F	B
-	I
spondin	I
,	O
but	O
not	O
the	O
individual	O
domains	O
,	O
decreased	O
production	O
of	O
the	O
beta	O
-	O
CTF	O
of	O
APP	B
and	O
Abeta	B
in	O
transfected	O
cells	O
and	O
primary	O
neurons	O
.	O

The	O
reduction	O
in	O
APP	B
beta	I
-	O
CTF	O
was	O
blocked	O
by	O
receptor	B
-	I
associated	I
protein	I
(	O
RAP	B
)	O
,	O
an	O
inhibitor	O
of	O
lipoprotein	B
receptors	I
,	O
implicating	O
ApoEr2	B
in	O
the	O
altered	O
proteolysis	O
of	O
APP	B
.	O

ApoEr2	B
coprecipitated	O
with	O
APP	B
alpha	O
-	O
and	O
beta	O
-	O
CTF	O
,	O
and	O
F	B
-	I
spondin	I
reduced	O
the	O
levels	O
of	O
APP	B
intracellular	O
domain	O
signaling	O
,	O
suggesting	O
that	O
there	O
are	O
also	O
intracellular	O
interactions	O
between	O
APP	B
and	O
ApoEr2	B
,	O
perhaps	O
involving	O
adaptor	B
proteins	I
.	O

These	O
studies	O
suggest	O
that	O
the	O
extracellular	O
matrix	O
molecule	O
F	B
-	I
spondin	I
can	O
cluster	O
APP	B
and	O
ApoEr2	B
together	O
on	O
the	O
cell	O
surface	O
and	O
affect	O
the	O
processing	O
of	O
each	O
,	O
resulting	O
in	O
decreased	O
production	O
of	O
Abeta	B
.	O

Sequence	O
analysis	O
of	O
Arabidopsis	O
thaliana	O
E	O
/	O
ANTH	O
-	O
domain	O
-	O
containing	O
proteins	O
:	O
membrane	O
tethers	O
of	O
the	O
clathrin	B
-	O
dependent	O
vesicle	O
budding	O
machinery	O
.	O

The	O
epsin	B
N	O
-	O
terminal	O
homology	O
(	O
ENTH	O
)	O
domain	O
is	O
a	O
conserved	O
protein	O
module	O
present	O
in	O
cytosolic	O
proteins	O
which	O
are	O
required	O
in	O
clathrin	B
-	O
mediated	O
vesicle	O
budding	O
processes	O
.	O

A	O
highly	O
similar	O
,	O
yet	O
unique	O
module	O
is	O
the	O
AP180	B
N	O
-	O
terminal	O
homology	O
(	O
ANTH	O
)	O
domain	O
,	O
which	O
is	O
present	O
in	O
a	O
set	O
of	O
proteins	O
that	O
also	O
support	O
clathrin	B
-	O
dependent	O
endocytosis	O
.	O

Both	O
ENTH	O
and	O
ANTH	O
(	O
E	O
/	O
ANTH	O
)	O
domains	O
bind	O
to	O
phospholipids	O
and	O
proteins	O
,	O
in	O
order	O
to	O
support	O
the	O
nucleation	O
of	O
clathrin	B
coats	O
on	O
the	O
plasma	O
membrane	O
or	O
the	O
trans	O
-	O
Golgi	O
-	O
network	O
membrane	O
.	O

Therefore	O
,	O
E	O
/	O
ANTH	O
proteins	O
might	O
be	O
considered	O
as	O
universal	O
tethering	O
components	O
of	O
the	O
clathrin	B
-	O
mediated	O
vesicle	O
budding	O
machinery	O
.	O

Since	O
the	O
E	B
/	I
ANTH	I
protein	I
family	I
appears	O
to	O
be	O
crucial	O
in	O
the	O
first	O
steps	O
of	O
clathrin	B
-	O
coated	O
vesicle	O
budding	O
,	O
we	O
performed	O
data	O
base	O
searches	O
of	O
the	O
Arabidopsis	O
thaliana	O
genome	O
.	O

Sequence	O
analysis	O
revealed	O
three	O
proteins	O
containing	O
the	O
ENTH	O
signature	O
motif	O
and	O
eight	O
proteins	O
containing	O
the	O
ANTH	O
signature	O
motif	O
.	O

Another	O
six	O
proteins	O
were	O
found	O
that	O
do	O
not	O
contain	O
either	O
motif	O
but	O
seem	O
to	O
have	O
the	O
same	O
domain	O
structure	O
and	O
might	O
therefore	O
be	O
seen	O
as	O
VHS	O
-	O
domain	O
-	O
containing	O
plant	O
proteins	O
.	O

Functional	O
analysis	O
of	O
plant	O
E	O
/	O
ANTH	O
proteins	O
are	O
rather	O
scarce	O
,	O
since	O
only	O
one	O
ANTH	O
homolog	O
from	O
A.	O
thaliana	O
,	O
At	O
-	O
AP180	B
,	O
has	O
been	O
characterized	O
so	O
far	O
.	O

AP180	B
displays	O
conserved	O
functions	O
as	O
a	O
clathrin	B
assembly	I
protein	I
and	O
as	O
an	O
alpha	B
-	I
adaptin	I
binding	O
partner	O
,	O
and	O
in	O
addition	O
shows	O
features	O
at	O
the	O
molecular	O
level	O
that	O
seem	O
to	O
be	O
plant	O
-	O
specific	O
.	O

Gene	O
cloning	O
and	O
molecular	O
characterization	O
of	O
an	O
extracellular	O
poly	B
(	I
L	I
-	I
lactic	I
acid	I
)	I
depolymerase	I
from	O
Amycolatopsis	O
sp.	O
strain	O
K104	O
-	O
1	O
.	O

We	O
have	O
isolated	O
a	O
polylactide	O
or	O
poly	O
(	O
L	O
-	O
lactic	O
acid	O
)	O
(	O
PLA	O
)	O
-	O
degrading	O
bacterium	O
,	O
Amycolatopsis	O
sp.	O
strain	O
K104	O
-	O
1	O
,	O
and	O
purified	O
PLA	B
depolymerase	I
(	O
PLD	B
)	O
from	O
the	O
culture	O
fluid	O
of	O
the	O
bacterium	O
.	O

Here	O
,	O
we	O
cloned	O
and	O
expressed	O
the	O
pld	B
gene	O
encoding	O
PLD	B
in	O
Streptomyces	O
lividans	O
1326	O
and	O
characterized	O
a	O
recombinant	O
PLD	B
(	O
rPLD	B
)	O
preparation	O
.	O

We	O
also	O
describe	O
the	O
processing	O
mechanism	O
from	O
nascent	O
PLD	B
to	O
mature	O
PLD	B
.	O

The	O
pld	B
gene	O
encodes	O
PLD	B
as	O
a	O
24,225-Da	O
polypeptide	O
consisting	O
of	O
238	O
amino	O
acids	O
.	O

Biochemical	O
and	O
Western	O
immunoblot	O
analyses	O
of	O
PLD	B
and	O
its	O
precursors	O
revealed	O
that	O
PLD	B
is	O
synthesized	O
as	O
a	O
precursor	O
(	O
prepro	O
-	O
type	O
)	O
,	O
requiring	O
proteolytic	O
cleavage	O
of	O
the	O
N	O
-	O
terminal	O
35	O
-	O
amino	O
-	O
acid	O
extension	O
including	O
the	O
26	O
-	O
amino	O
-	O
acid	O
signal	O
sequence	O
and	O
9-residue	O
prosequence	O
to	O
generate	O
the	O
mature	O
enzyme	O
of	O
20,904	O
Da	O
.	O

The	O
cleavage	O
of	O
the	O
prosequence	O
was	O
found	O
to	O
be	O
autocatalytic	O
.	O

PLD	B
showed	O
about	O
45	O
%	O
similarity	O
to	O
many	O
eukaryotic	O
serine	B
proteases	I
.	O

In	O
addition	O
,	O
three	O
amino	O
acid	O
residues	O
,	O
H57	O
,	O
D102	O
,	O
and	O
S195	O
(	O
chymotrypsin	B
numbering	O
)	O
,	O
which	O
are	O
implicated	O
in	O
forming	O
the	O
catalytic	O
triad	O
necessary	O
for	O
cleavage	O
of	O
amide	O
bond	O
of	O
substrates	O
in	O
eukaryotic	O
serine	B
proteases	I
,	O
were	O
conserved	O
in	O
PLD	B
as	O
residues	O
H74	O
,	O
D111	O
,	O
and	O
S197	O
.	O

The	O
G193	O
residue	O
(	O
chymotrypsin	B
numbering	O
)	O
,	O
which	O
is	O
implicated	O
in	O
forming	O
an	O
oxyanion	O
hole	O
with	O
residue	O
S195	O
and	O
forms	O
an	O
important	O
hydrogen	O
bond	O
for	O
interaction	O
with	O
the	O
carbonyl	O
group	O
of	O
the	O
scissile	O
peptide	O
bond	O
,	O
was	O
also	O
conserved	O
in	O
PLD	B
.	O

The	O
functional	O
analysis	O
of	O
the	O
PLD	B
mutants	O
H74A	O
,	O
D111A	O
,	O
and	O
S197A	O
revealed	O
that	O
residues	O
H74	O
,	O
D111	O
,	O
and	O
S197	O
are	O
important	O
for	O
the	O
depolymerase	B
and	O
caseinolytic	O
activities	O
of	O
PLD	B
and	O
for	O
cleavage	O
of	O
the	O
prosequence	O
from	O
pro	O
-	O
type	O
PLD	B
to	O
form	O
the	O
mature	O
one	O
.	O

The	O
PLD	B
preparation	O
had	O
elastase	B
activity	O
which	O
was	O
not	O
inhibited	O
by	O
1	O
mM	O
elastatinal	O
,	O
which	O
is	O
10	O
times	O
higher	O
than	O
needed	O
for	O
complete	O
inhibition	O
of	O
porcine	O
pancreatic	O
elastase	B
.	O

The	O
rPLD	B
preparation	O
degraded	O
PLA	O
with	O
an	O
average	O
molecular	O
mass	O
of	O
220	O
kDa	O
into	O
lactic	O
acid	O
dimers	O
through	O
lactic	O
acid	O
oligomers	O
and	O
finally	O
into	O
lactic	O
acid	O
.	O

The	O
PLD	B
preparation	O
bound	O
to	O
high	O
polymers	O
of	O
3-hydoxybutyrate	O
,	O
epsilon	O
-	O
caprolacton	O
,	O
and	O
butylene	O
succinate	O
as	O
well	O
as	O
PLA	O
,	O
but	O
it	O
degraded	O
only	O
PLA	O
.	O

Global	O
transcriptional	O
profiling	O
demonstrates	O
the	O
combination	O
of	O
type	B
I	I
and	I
type	I
II	I
interferon	I
enhances	O
antiviral	O
and	O
immune	O
responses	O
at	O
clinically	O
relevant	O
doses	O
.	O

A	O
role	O
for	O
type	B
II	I
interferon	I
(	O
IFN	B
-	I
gamma	I
)	O
in	O
resolving	O
viral	O
infection	O
is	O
suggested	O
by	O
the	O
correlation	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
clearance	O
with	O
enhancement	O
of	O
IFN	B
-	I
gamma	I
-	O
producing	O
activated	O
T	O
cells	O
in	O
the	O
resolution	O
of	O
acute	O
HCV	O
infection	O
.	O

Using	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
,	O
a	O
synergistic	O
direct	O
antiviral	O
effect	O
was	O
documented	O
using	O
IFN	B
-	I
gamma1b	I
and	O
a	O
potent	O
,	O
consensus	O
type	B
I	I
IFN	I
(	O
IFN	B
alfacon-1	O
)	O
.	O

Global	O
expression	O
profiling	O
following	O
EC50	O
exposure	O
to	O
IFN	B
alfacon-1	O
,	O
IFN	B
-	I
gamma1b	I
,	O
or	O
a	O
cocktail	O
of	O
the	O
two	O
allowed	O
the	O
antiviral	O
state	O
to	O
be	O
correlated	O
with	O
induction	O
of	O
a	O
subset	O
of	O
IFN	B
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
.	O

Genes	O
identified	O
through	O
this	O
analysis	O
corresponded	O
to	O
classic	O
antiviral	O
components	O
,	O
ISGs	O
more	O
recently	O
associated	O
with	O
direct	O
antiviral	O
functions	O
,	O
as	O
well	O
as	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
and	O
hypothetical	O
proteins	O
.	O

The	O
magnitude	O
of	O
these	O
antiviral	O
EC50	O
-	O
correlated	O
expression	O
events	O
in	O
human	O
hepatoma	O
(	O
Huh7	O
)	O
cells	O
exposed	O
to	O
clinically	O
relevant	O
doses	O
of	O
IFN	B
alfacon-1	O
,	O
IFN	B
-	I
gamma1b	I
,	O
or	O
a	O
cocktail	O
of	O
the	O
two	O
was	O
also	O
probed	O
because	O
the	O
standard	O
of	O
care	O
for	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
is	O
type	B
I	I
IFN	I
-	O
containing	O
regimens	O
.	O

Relative	O
to	O
type	B
I	I
IFNs	I
used	O
alone	O
,	O
the	O
addition	O
of	O
type	B
II	I
IFN	I
caused	O
enhanced	O
expression	O
not	O
only	O
of	O
many	O
of	O
the	O
genes	O
correlated	O
with	O
the	O
direct	O
antiviral	O
state	O
but	O
also	O
of	O
genes	O
involved	O
in	O
(	O
1	O
)	O
antigen	O
presentation	O
to	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
,	O
(	O
2	O
)	O
macrophage	O
,	O
natural	O
killer	O
(	O
NK	O
)	O
,	O
and	O
T	O
helper	O
1	O
(	O
Th1	O
)	O
cell	O
recruitment	O
and	O
activation	O
,	O
(	O
3	O
)	O
complement	O
system	O
function	O
,	O
(	O
4	O
)	O
apoptosis	O
,	O
and	O
(	O
5	O
)	O
ISGs	O
with	O
unknown	O
functions	O
.	O

As	O
many	O
of	O
these	O
processes	O
are	O
correlated	O
clinically	O
with	O
resolution	O
of	O
chronic	O
HCV	O
infection	O
,	O
the	O
combined	O
use	O
of	O
these	O
IFNs	B
could	O
display	O
a	O
beneficial	O
effect	O
on	O
viral	O
clearance	O
in	O
patients	O
infected	O
with	O
HCV	O
and	O
other	O
viruses	O
through	O
enhancement	O
of	O
one	O
of	O
these	O
processes	O
or	O
of	O
the	O
direct	O
antiviral	O
state	O
.	O

In	O
vitro	O
gene	O
expression	O
changes	O
of	O
androgen	B
receptor	I
coactivators	O
after	O
hormone	O
deprivation	O
in	O
an	O
androgen	O
-	O
dependent	O
prostate	O
cancer	O
cell	O
line	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O

Androgen	B
receptor	I
(	O
AR	B
)	O
coactivators	O
modulate	O
the	O
transcriptional	O
activity	O
of	O
AR	B
and	O
may	O
activate	O
AR	B
-	O
associated	O
genes	O
upon	O
androgen	O
deprivation	O
.	O

Changes	O
of	O
expression	O
patterns	O
may	O
help	O
reveal	O
the	O
role	O
of	O
AR	B
cofactors	O
in	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
.	O

This	O
study	O
investigated	O
changes	O
of	O
expression	O
patterns	O
of	O
several	O
AR	B
coactivators	O
after	O
androgen	O
deprivation	O
in	O
an	O
androgen	O
-	O
dependent	O
prostate	O
cancer	O
cell	O
line	O
(	O
LNCaP	O
)	O
.	O

METHODS	O
:	O

LNCaP	O
cells	O
were	O
cultured	O
in	O
RPMI	O
medium	O
with	O
charcoal	O
/	O
dextran	O
-	O
treated	O
fetal	O
bovine	O
serum	O
for	O
28	O
days	O
.	O

Samples	O
of	O
total	O
RNA	O
collected	O
at	O
1	O
-	O
week	O
intervals	O
were	O
analyzed	O
using	O
a	O
non	O
-	O
isotopic	O
multi	O
-	O
probe	O
ribonuclease	B
protection	O
assay	O
system	O
with	O
a	O
human	O
AR	B
multi	O
-	O
probe	O
template	O
set	O
.	O

Expression	O
changes	O
of	O
10	O
mRNAs	O
of	O
interest	O
(	O
AR	B
,	O
Rb	B
,	O
ARA160	B
,	O
ARA24	B
,	O
ARA54	B
,	O
ARA55	B
,	O
ARA70	B
,	O
BRCA1	B
,	O
F	B
-	I
SRC-1	I
,	O
and	O
RAC3	B
)	O
were	O
analyzed	O
simultaneously	O
as	O
AR	B
and	O
AR	B
-	O
associated	O
cofactors	O
in	O
1	O
hybridization	O
reaction	O
.	O

RESULTS	O
:	O

Seven	O
of	O
10	O
cofactors	O
tested	O
were	O
expressed	O
in	O
LNCaP	O
cells	O
.	O

Only	O
Rb	B
,	O
ARA55	B
and	O
BRCA1	B
were	O
not	O
detected	O
.	O

LNCaP	O
cells	O
cultured	O
in	O
charcoal	O
-	O
treated	O
serum	O
for	O
28	O
days	O
clearly	O
showed	O
more	O
than	O
1.5	O
-	O
fold	O
increases	O
in	O
AR	B
,	O
ARA160	B
,	O
and	O
ARA70	B
expression	O
,	O
while	O
expression	O
of	O
ARA24	B
and	O
ARA54	B
increased	O
less	O
than	O
1.5	O
-	O
fold	O
.	O

Only	O
RAC3	B
and	O
F	B
-	I
SRC-1	I
decreased	O
in	O
RNA	O
expression	O
.	O

Cell	O
morphology	O
features	O
changed	O
gradually	O
into	O
neuron	O
-	O
like	O
shapes	O
with	O
elongated	O
cytoplasm	O
during	O
the	O
culture	O
period	O
.	O

Cell	O
growth	O
almost	O
ceased	O
28	O
days	O
after	O
the	O
start	O
of	O
culture	O
.	O

CONCLUSION	O
:	O

The	O
changes	O
in	O
expression	O
pattern	O
of	O
AR	B
and	O
AR	B
cofactors	O
and	O
in	O
particular	O
the	O
remarkable	O
increase	O
in	O
AR	B
,	O
ARA160	B
and	O
ARA70	B
support	O
the	O
role	O
of	O
AR	B
cofactors	O
in	O
modulating	O
prostate	O
cancer	O
cell	O
growth	O
from	O
androgen	O
dependence	O
to	O
androgen	O
independence	O
.	O

Upregulation	O
of	O
neuropilin-1	B
by	O
basic	B
fibroblast	I
growth	I
factor	I
enhances	O
vascular	O
smooth	O
muscle	O
cell	O
migration	O
in	O
response	O
to	O
VEGF	B
.	O

Neuropilin-1	B
(	O
NRP-1	B
)	O
is	O
a	O
co	O
-	O
receptor	O
for	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
.	O

During	O
neovascularization	O
,	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
and	O
pericytes	O
modulate	O
the	O
function	O
of	O
endothelial	O
cells	O
.	O

Factors	O
that	O
mediate	O
NRP-1	B
in	O
human	O
VSMCs	O
(	O
hVSMCs	O
)	O
remain	O
to	O
be	O
elucidated	O
.	O

We	O
studied	O
various	O
angiogenic	O
cytokines	B
to	O
identify	O
factors	O
that	O
increase	O
NRP-1	B
expression	O
in	O
hVSMCs	O
.	O

Treatment	O
of	O
hVSMCs	O
with	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
b	B
-	I
FGF	I
)	O
induced	O
expressions	O
of	O
NRP-1	B
mRNA	O
and	O
protein	O
whereas	O
epidermal	B
growth	I
factor	I
,	O
insulin	B
-	I
like	I
growth	I
factor-1	I
,	O
and	O
interleukin-1beta	B
did	O
not	O
.	O

b	B
-	I
FGF	I
induced	O
phosphorylation	O
of	O
Erk-1	B
/	I
2	I
and	O
JNK	B
.	O

MEK1	B
/	I
2	I
and	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappaB	I
)	O
inhibitors	O
(	O
U0126	O
and	O
TLCK	O
,	O
respectively	O
)	O
blocked	O
the	O
ability	O
of	O
b	B
-	I
FGF	I
to	O
induce	O
NRP-1	B
mRNA	O
expression	O
,	O
but	O
inhibition	O
of	O
JNK	B
(	O
SP600125	O
)	O
or	O
PI3	B
-	I
kinase	I
activity	O
(	O
wortmannin	O
)	O
did	O
not	O
.	O

Further	O
,	O
the	O
increase	O
in	O
NRP-1	B
expression	O
by	O
b	B
-	I
FGF	I
enhanced	O
hVSMCs	O
migration	O
in	O
response	O
to	O
VEGF	B
(	O
165	O
)	O
.	O

This	O
effect	O
was	O
dependent	O
on	O
the	O
binding	O
of	O
VEGF	B
(	O
165	O
)	O
to	O
VEGFR-2	B
,	O
as	O
blocking	O
antibodies	O
to	O
VEGFR-2	B
,	O
but	O
not	O
VEGFR-1	B
,	O
inhibited	O
VEGF	B
(	I
165	I
)	I
-	O
induced	O
migration	O
.	O

In	O
conclusion	O
,	O
b	B
-	I
FGF	I
increased	O
NRP-1	B
expression	O
in	O
hVSMCs	O
that	O
in	O
turn	O
enhance	O
the	O
effect	O
of	O
VEGF	B
(	O
165	O
)	O
on	O
cell	O
migration	O
.	O

The	O
enhanced	O
migration	O
of	O
hVSMCs	O
was	O
mediated	O
through	O
binding	O
of	O
VEGF	B
(	O
165	O
)	O
to	O
both	O
NRP-1	B
and	O
VEGFR-2	B
,	O
as	O
inhibition	O
of	O
VEGFR-2	B
on	O
these	O
cells	O
blocked	O
the	O
effect	O
of	O
VEGF	B
-	O
mediated	O
cell	O
migration	O
.	O

Pathogenesis	O
of	O
antiphospholipid	O
antibodies	O
:	O
impairment	O
of	O
fibrinolysis	O
and	O
monocyte	O
activation	O
via	O
the	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
pathway	O
.	O

Antiphospholipid	O
syndrome	O
(	O
APS	O
)	O
is	O
characterized	O
by	O
recurrent	O
thrombosis	O
or	O
pregnancy	O
morbidity	O
associated	O
with	O
antiphospholipid	O
antibodies	O
(	O
aPL	O
)	O
.	O

Impaired	O
fibrinolysis	O
is	O
a	O
contributing	O
factor	O
for	O
the	O
development	O
of	O
thrombosis	O
,	O
and	O
the	O
effect	O
of	O
aPL	O
in	O
the	O
fibrinolytic	O
system	O
has	O
been	O
investigated	O
.	O

Impaired	O
release	O
of	O
tPA	B
and	O
enhanced	O
release	O
of	O
PAI-1	B
after	O
endothelial	O
activation	O
is	O
reported	O
in	O
patients	O
with	O
APS	O
.	O

Elevated	O
Lipoprotein	B
(	I
a	I
)	I
levels	O
have	O
been	O
found	O
in	O
APS	O
,	O
which	O
results	O
in	O
inhibition	O
of	O
fibrinolytic	O
activity	O
.	O

Phospholipid	O
-	O
bound	O
beta	B
(	I
2	I
)	I
-glycoprotein	I
I	I
(	O
beta	B
(	I
2	I
)	I
GPI	I
)	O
is	O
a	O
major	O
autoantigen	O
for	O
aPLs	O
.	O

beta	B
(	I
2	I
)	I
GPI	I
exerts	O
both	O
anti	O
-	O
coagulant	O
and	O
pro	O
-	O
coagulant	O
properties	O
mainly	O
by	O
interacting	O
with	O
other	O
phospholipid	O
-	O
binding	O
proteins	O
such	O
as	O
coagulation	B
factors	I
and	O
protein	B
C	I
.	O

Dramatic	O
increase	O
in	O
the	O
affinity	O
of	O
beta	B
(	I
2	I
)	I
GPI	I
to	O
the	O
cell	O
surface	O
is	O
induced	O
by	O
binding	O
of	O
pathogenic	O
anti	O
-	O
beta	B
(	I
2	I
)	I
GPI	I
antibodies	O
,	O
which	O
may	O
modify	O
the	O
physiological	O
function	O
of	O
beta	B
(	I
2	I
)	I
GPI	I
and	O
may	O
affect	O
the	O
coagulation	O
/	O
fibrinolysis	O
balance	O
on	O
the	O
cell	O
surface	O
.	O

Using	O
chromogenic	O
assays	O
for	O
measuring	O
fibrinolytic	O
activity	O
,	O
we	O
demonstrated	O
that	O
addition	O
of	O
monoclonal	O
anticardiolipin	O
antibody	O
(	O
aCL	O
)	O
decreases	O
the	O
activity	O
of	O
extrinsic	O
/	O
intrinsic	O
fibrinolysis	O
.	O

Significantly	O
lower	O
activity	O
of	O
intrinsic	O
fibrinolysis	O
was	O
also	O
demonstrated	O
in	O
the	O
euglobulin	O
fractions	O
from	O
APS	O
patients	O
.	O

Endothelial	O
cells	O
and	O
monocytes	O
are	O
activated	O
by	O
aPLs	O
in	O
vitro	O
,	O
resulting	O
in	O
production	O
of	O
tissue	B
factor	I
(	O
TF	B
)	O
,	O
a	O
major	O
initiator	O
of	O
the	O
coagulation	O
system	O
.	O

Recently	O
,	O
aPLs	O
are	O
reported	O
to	O
induce	O
thrombocytes	O
to	O
produce	O
thromboxane	O
.	O

The	O
importance	O
of	O
apoE	B
receptor	I
2	I
on	O
platelets	O
for	O
the	O
binding	O
of	O
artificially	O
dimerized	O
beta	B
(	I
2	I
)	I
GPI	I
was	O
suggested	O
.	O

By	O
investigating	O
aPL	O
-	O
inducible	O
genes	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
we	O
found	O
that	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
pathway	O
was	O
up	O
-	O
regulated	O
.	O

Using	O
a	O
monocyte	O
cell	O
line	O
,	O
phosphorylation	O
of	O
p38	B
MAPK	I
,	O
NF	B
-	I
kappaB	I
translocation	O
to	O
the	O
nuclear	O
fraction	O
,	O
and	O
up	O
-	O
regulated	O
TF	B
mRNA	O
expression	O
were	O
demonstrated	O
after	O
treatment	O
with	O
monoclonal	O
aCL	O
.	O

These	O
phenomena	O
were	O
observed	O
only	O
in	O
the	O
presence	O
of	O
beta	B
(	I
2	I
)	I
GPI	I
.	O

Moreover	O
,	O
a	O
specific	O
p38	B
MAPK	I
inihibitor	O
SB203580	O
decreased	O
aCL	O
/	O
beta	B
(	I
2	I
)	I
GPI	I
-	O
induced	O
TF	B
mRNA	O
expression	O
.	O

Thus	O
,	O
aCL	O
/	O
beta	B
(	I
2	I
)	I
GPI	I
plays	O
dual	O
roles	O
in	O
the	O
pathogenesis	O
of	O
APS	O
,	O
firstly	O
by	O
deranging	O
the	O
fibrinolytic	O
system	O
and	O
secondly	O
by	O
activating	O
monocytes	O
,	O
endothelial	O
cells	O
and	O
thrombocytes	O
to	O
produce	O
TF	B
or	O
thromboxane	O
.	O

Molecular	O
evolution	O
of	O
the	O
AP2	B
subfamily	I
.	O

The	O
AP2	B
(	I
APETALA2	I
)	I
/	I
EREBP	I
(	I
Ethylene	I
Responsive	I
Element	I
Binding	I
Protein	I
)	I
multigene	I
family	I
includes	O
developmentally	O
and	O
physiologically	O
important	O
transcription	B
factors	I
.	O

AP2	B
/	O
EREBP	B
genes	O
are	O
divided	O
into	O
two	O
subfamilies	O
:	O
AP2	B
genes	O
with	O
two	O
AP2	B
domains	O
and	O
EREBP	B
genes	O
with	O
a	O
single	O
AP2	B
/	O
ERF	B
(	O
Ethylene	B
Responsive	I
Element	I
Binding	I
Factor	I
)	O
domain	O
.	O

Based	O
on	O
previous	O
phylogenetic	O
analyses	O
,	O
AP2	B
genes	O
can	O
be	O
divided	O
into	O
two	O
clades	O
,	O
AP2	B
and	I
ANT	I
groups	I
.	O

To	O
clarify	O
the	O
molecular	O
evolution	O
of	O
the	O
AP2	B
subfamily	I
,	O
we	O
isolated	O
and	O
sequenced	O
genes	O
with	O
two	O
AP2	B
domains	O
from	O
three	O
gymnosperms	O
,	O
Cycas	O
revoluta	O
,	O
Ginkgo	O
biloba	O
,	O
and	O
Gnetum	O
parvifolium	O
,	O
as	O
well	O
as	O
from	O
the	O
moss	O
Physcomitrella	O
patens	O
.	O

Expressions	O
of	O
AP2	B
-	O
like	O
genes	O
,	O
including	O
AP2	B
,	O
in	O
Arabidopsis	O
thaliana	O
are	O
regulated	O
by	O
the	O
microRNA	O
miR172	O
.	O

We	O
found	O
that	O
the	O
target	O
site	O
of	O
miR172	O
is	O
significantly	O
conserved	O
in	O
gymnosperm	O
AP2	B
homologs	O
,	O
suggesting	O
that	O
regulatory	O
mechanisms	O
of	O
gene	O
expression	O
using	O
microRNA	O
have	O
been	O
conserved	O
over	O
the	O
three	O
hundred	O
million	O
years	O
since	O
the	O
divergence	O
of	O
gymnosperm	O
and	O
flowering	O
plant	O
lineages	O
.	O

We	O
inferred	O
a	O
phylogenetic	O
relationship	O
of	O
these	O
genes	O
with	O
the	O
green	O
alga	O
Chlamydomonas	O
reinhardtii	O
and	O
seed	O
-	O
plant	O
genes	O
available	O
in	O
public	O
DNA	O
databases	O
.	O

The	O
phylogenetic	O
tree	O
showed	O
that	O
the	O
AP2	B
subfamily	I
diverged	O
into	O
the	O
AP2	B
and	I
ANT	I
groups	I
before	O
the	O
last	O
common	O
ancestor	O
of	O
land	O
plants	O
and	O
after	O
C.	O
reinhardtii	O
diverged	O
from	O
the	O
land	O
-	O
plant	O
lineage	O
.	O

The	O
tree	O
also	O
indicated	O
that	O
each	O
AP2	B
and	I
ANT	I
group	I
further	O
diverged	O
into	O
several	O
clades	O
through	O
gene	O
duplications	O
prior	O
to	O
the	O
divergence	O
of	O
gymnosperms	O
and	O
angiosperms	O
.	O

Endothelin-3-converting	B
enzyme	I
activity	O
of	O
the	O
KEL1	B
and	O
KEL6	B
phenotypes	O
of	O
the	O
Kell	B
blood	I
group	I
system	O
.	O

The	O
Kell	B
blood	I
group	I
protein	I
is	O
a	O
metalloendopeptidase	B
that	O
preferentially	O
cleaves	O
a	O
Trp	O
(	O
21	O
)	O
-Ile	O
(	O
22	O
)	O
bond	O
of	O
big	O
endothelin	B
-	I
3	I
producing	O
bioactive	O
endothelin	B
-	I
3	I
.	O

Kell	B
is	O
a	O
polymorphic	O
protein	O
,	O
and	O
25	O
different	O
phenotypes	O
,	O
because	O
of	O
point	O
mutations	O
resulting	O
in	O
single	O
amino	O
acid	O
substitutions	O
,	O
have	O
been	O
described	O
.	O

It	O
was	O
recently	O
reported	O
that	O
a	O
recombinant	O
form	O
of	O
KEL1	B
(	O
K	O
,	O
K1	O
)	O
phenotype	O
,	O
expressed	O
in	O
K562	O
and	O
HEK293	O
cells	O
,	O
had	O
no	O
endothelin-3	B
-	O
converting	O
activity	O
,	O
in	O
contrast	O
to	O
the	O
common	O
KEL2	B
(	O
k	O
,	O
K2	O
)	O
phenotype	O
.	O

We	O
demonstrate	O
that	O
KEL1	B
red	O
blood	O
cells	O
and	O
also	O
a	O
soluble	O
recombinant	O
form	O
of	O
KEL1	B
protein	O
(	O
s	O
-	O
Kell	B
KEL1	B
)	O
have	O
similar	O
enzymatic	O
activity	O
as	O
the	O
common	O
Kell	B
phenotype	O
.	O

In	O
addition	O
we	O
show	O
that	O
KEL6	B
red	O
blood	O
cells	O
,	O
which	O
are	O
more	O
prevalent	O
in	O
persons	O
of	O
African	O
heritage	O
than	O
in	O
Caucasians	O
also	O
have	O
endothelin	B
-	I
3	I
-	I
converting	I
enzyme	I
activity	O
and	O
that	O
the	O
recombinant	O
soluble	O
form	O
of	O
KEL6	B
protein	O
(	O
s	O
-	O
Kell	O
KEL6	B
)	O
has	O
similar	O
K	O
(	O
m	O
)	O
values	O
as	O
the	O
wild	O
-	O
type	O
.	O

Posttranscriptional	O
regulation	O
of	O
TNFalpha	B
expression	O
via	O
eukaryotic	B
initiation	I
factor	I
4E	I
(	O
eIF4E	B
)	O
phosphorylation	O
in	O
mouse	O
macrophages	O
.	O

Resident	O
mouse	O
macrophages	O
secrete	O
Tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
)	O
upon	O
challenge	O
with	O
LPS	O
.	O

The	O
production	O
of	O
TNFalpha	B
is	O
controlled	O
not	O
only	O
at	O
the	O
transcription	O
of	O
the	O
gene	O
,	O
but	O
also	O
by	O
strong	O
posttranscriptional	O
regulation	O
.	O

When	O
macrophages	O
are	O
stimulated	O
with	O
LPS	O
different	O
signal	O
transduction	O
pathways	O
become	O
activated	O
.	O

Here	O
we	O
show	O
that	O
the	O
combination	O
of	O
the	O
2	O
kinases	B
p38	B
and	O
MEK	B
and	O
presumably	O
ERK1	B
/	I
2	I
regulate	O
translation	O
of	O
TNFalpha	B
,	O
through	O
the	O
downstream	O
kinase	B
Mnk1	B
.	O

TNFalpha	B
production	O
is	O
inhibited	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
by	O
CGP57380	O
(	O
Mnk1	B
inhibitor	O
)	O
.	O

The	O
corresponding	O
mRNA	O
results	O
show	O
that	O
the	O
inhibition	O
targets	O
posttranscriptional	O
regulation	O
and	O
is	O
paralleled	O
by	O
inhibition	O
of	O
the	O
phosphorylation	O
of	O
eukaryotic	B
initiation	I
factor	I
4E	I
(	O
eIF4E	B
)	O
.	O

Unexpectedly	O
,	O
the	O
activation	O
/	O
inhibition	O
of	O
MAPKAP	B
kinase-2	I
(	O
MK2	B
)	O
does	O
not	O
parallel	O
TNFalpha	B
production	O
,	O
arguing	O
against	O
a	O
direct	O
/	O
immediate	O
role	O
for	O
this	O
kinase	B
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
and	O
previous	O
results	O
we	O
propose	O
that	O
ARE	O
-	O
containing	O
TNFalpha	B
mRNA	O
requires	O
phosphorylation	O
of	O
eIF4E	B
for	O
initiation	O
of	O
translation	O
.	O

[	O
Amphiregulin	B
antisense	O
RNA	O
expression	O
inhibits	O
angiogenesis	O
of	O
human	O
breast	O
cancer	O
in	O
nude	O
mice	O
]	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
anti	O
-	O
angiogenic	O
effect	O
of	O
amphiregulin	B
(	O
AR	B
)	O
antisense	O
RNA	O
expression	O
in	O
breast	O
cancer	O
.	O

METHODS	O
:	O

Human	O
AR	B
cDNA	O
antisense	O
plasmid	O
was	O
transfected	O
into	O
NS2T2A1	O
cells	O
(	O
a	O
human	O
breast	O
cancer	O
cell	O
line	O
)	O
.	O

Two	O
selected	O
clones	O
expressed	O
AR	B
antisense	O
RNA	O
(	O
AR	B
AS1	O
and	O
AR	B
AS3	O
cell	O
lines	O
)	O
in	O
which	O
AR	B
protein	O
expression	O
was	O
reduced	O
.	O

Control	O
cell	O
line	O
NS2T2A1	O
V	O
was	O
obtained	O
by	O
empty	O
vector	O
transfection	O
.	O

These	O
cells	O
were	O
injected	O
subcutaneously	O
into	O
nude	O
mice	O
.	O

The	O
effects	O
of	O
conditioned	O
media	O
on	O
proliferation	O
of	O
human	O
microvascular	O
endothelial	O
cells	O
(	O
HMEC	O
)	O
were	O
evaluated	O
and	O
VEGF	B
secreted	O
by	O
the	O
cells	O
was	O
measured	O
by	O
ELISA	O
method	O
.	O

In	O
tumor	O
tissues	O
,	O
VEGF	B
expression	O
levels	O
were	O
measured	O
by	O
quantitative	O
RT	O
-	O
PCR	O
,	O
and	O
CD31	B
-	O
immunostaining	O
was	O
used	O
for	O
intra	O
-	O
tumoral	O
vascular	O
quantification	O
.	O

RESULTS	O
:	O

The	O
proliferation	O
index	O
of	O
HMEC	O
cells	O
grown	O
in	O
conditioned	O
media	O
with	O
AR	B
AS1	O
and	O
AR	B
AS3	O
was	O
significantly	O
reduced	O
in	O
comparison	O
with	O
that	O
of	O
control	O
cells	O
,	O
accompanied	O
by	O
a	O
decreased	O
VEGF	B
secretion	O
.	O

In	O
tumors	O
derived	O
from	O
AR	B
AS1	O
and	O
AR	B
AS3	O
cells	O
,	O
intra	O
-	O
tumoral	O
vascularization	O
was	O
reduced	O
to	O
about	O
50	O
%	O
of	O
that	O
derived	O
from	O
control	O
cell	O
line	O
,	O
accompanied	O
with	O
a	O
decrease	O
of	O
VEGF	B
expression	O
.	O

CONCLUSION	O
:	O

Amphiregulin	B
antisense	O
RNA	O
expression	O
inhibits	O
efficiently	O
the	O
angiogenesis	O
in	O
breast	O
cancer	O
,	O
suggesting	O
this	O
growth	B
factor	I
could	O
represent	O
a	O
novel	O
therapeutic	O
target	O
in	O
breast	O
cancer	O
.	O

[	O
Antiapoptotic	O
functions	O
of	O
the	O
retrovirally	O
transferred	O
API2	B
-	O
MALT1	B
gene	O
]	O
t	O
(	O
11	O
;	O
18	O
)	O
(	O
q21	O
;	O
q21	O
)	O
is	O
a	O
specific	O
chromosomal	O
aberration	O
in	O
mucosa	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
lymphoma	O
,	O
and	O
produces	O
chimeric	O
transcript	O
Apoptosis	B
Inhibitor	I
2	I
(	O
API2	B
)	O
-	O
MALT1	B
.	O

Although	O
it	O
is	O
known	O
that	O
API2	B
has	O
an	O
antiapoptotic	O
effect	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
this	O
also	O
applies	O
to	O
API2	B
-	O
MALT1	B
.	O

To	O
investigate	O
its	O
effects	O
against	O
various	O
apoptotic	O
stimuli	O
,	O
API2	B
-	O
MALT1	B
was	O
expressed	O
by	O
means	O
of	O
retroviral	O
infection	O
on	O
the	O
epithelial	O
cell	O
line	O
HeLa	O
and	O
the	O
murine	O
Pro	O
-	O
B	O
cell	O
line	O
Ba	O
/	O
F3	O
.	O

On	O
both	O
these	O
cell	O
lines	O
,	O
API2	B
-	O
MALT1	B
was	O
found	O
to	O
cause	O
a	O
significant	O
reduction	O
in	O
UV	O
-	O
induced	O
apoptosis	O
.	O

The	O
apoptosis	O
induced	O
by	O
doxorubicin	O
was	O
also	O
inhibited	O
by	O
API2	B
-	O
MALT1	B
,	O
but	O
not	O
that	O
induced	O
by	O
IL-3	B
withdrawal	O
from	O
Ba	O
/	O
F3	O
.	O

These	O
findings	O
suggest	O
that	O
API2	B
-	O
MALT1	B
has	O
an	O
antiapoptotic	O
effect	O
on	O
both	O
epithelial	O
and	O
lymphoid	O
cells	O
and	O
that	O
this	O
effect	O
depends	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

Protective	O
effect	O
of	O
the	O
G-765C	O
COX-2	B
polymorphism	O
on	O
subclinical	O
atherosclerosis	O
and	O
inflammatory	O
markers	O
in	O
asymptomatic	O
subjects	O
with	O
cardiovascular	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O

Cyclooxygenase	B
(	I
COX	I
)	I
-	I
2	I
,	O
a	O
key	O
regulatory	O
enzyme	O
in	O
prostanoid	O
synthesis	O
,	O
plays	O
an	O
important	O
role	O
in	O
inflammatory	O
processes	O
.	O

The	O
-765G	O
>	O
C	O
COX-2	B
polymorphism	O
has	O
been	O
associated	O
with	O
lower	O
promoter	O
activity	O
in	O
vitro	O
and	O
reduced	O
levels	O
of	O
C	B
-	I
reactive	I
protein	I
(	O
CRP	B
)	O
in	O
atherosclerotic	O
carriers	O
of	O
the	O
C	O
allele	O
.	O

However	O
,	O
its	O
pathophysiological	O
relevance	O
in	O
vivo	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
assessed	O
the	O
-765	O
G	O
>	O
C	O
polymorphism	O
and	O
COX-2	B
expression	O
in	O
220	O
asymptomatic	O
subjects	O
free	O
of	O
cardiovascular	O
disease	O
,	O
in	O
relation	O
to	O
global	O
vascular	O
risk	O
,	O
carotid	O
intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
,	O
and	O
inflammatory	O
markers	O
(	O
fibrinogen	B
,	O
C	B
-	I
reactive	I
protein	I
[	O
CRP	B
]	O
,	O
von	B
Willebrand	I
factor	I
[	O
vWF	B
]	O
and	O
interleukin-6	B
[	O
IL-6	B
]	O
)	O
.	O

Genotype	O
frequencies	O
were	O
:	O
CC	O
(	O
7.7	O
%	O
)	O
,	O
CG	O
(	O
34.5	O
%	O
)	O
,	O
GG	O
(	O
57.7	O
%	O
)	O
.	O

Among	O
hypercholesterolemic	O
subjects	O
(	O
n	O
=	O
140	O
)	O
,	O
C	O
allele	O
carriers	O
had	O
lower	O
COX-2	B
expression	O
(	O
p	O
<	O
0.05	O
)	O
,	O
reduced	O
carotid	O
IMT	O
(	O
p	O
<	O
0.01	O
)	O
and	O
diminished	O
levels	O
of	O
inflammatory	O
markers	O
CRP	B
,	O
vWF	B
and	O
IL-6	B
(	O
p	O
<	O
0.05	O
)	O
,	O
as	O
compared	O
to	O
GG	O
homozygous	O
subjects	O
.	O

The	O
association	O
between	O
carotid	O
IMT	O
and	O
COX-2	B
polymorphism	O
remained	O
significant	O
after	O
adjusting	O
for	O
cardiovascular	O
risk	O
factors	O
and	O
inflammatory	O
markers	O
(	O
p	O
=	O
0.008	O
)	O
.	O

CONCLUSIONS	O
:	O

In	O
asymptomatic	O
hypercholesterolemic	O
subjects	O
the	O
C	O
allele	O
of	O
-765G	O
>	O
C	O
COX-2	B
polymorphism	O
was	O
associated	O
with	O
lower	O
COX-2	B
expression	O
,	O
and	O
reduced	O
subclinical	O
atherosclerosis	O
and	O
systemic	O
inflammation	O
compared	O
with	O
GG	O
homozygous	O
,	O
thus	O
conferring	O
atherosclerosis	O
protection	O
in	O
this	O
cardiovascular	O
risk	O
population	O
.	O

Identification	O
of	O
a	O
tandem	O
duplicated	O
array	O
in	O
the	O
Rhox	B
alpha	O
locus	O
on	O
mouse	O
chromosome	O
X	O
.	O

The	O
Rhox	B
family	I
of	O
homeobox	O
-	O
containing	O
genes	O
maps	O
to	O
three	O
gene	O
dense	O
clusters	O
,	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
,	O
on	O
the	O
mouse	O
X	O
chromosome	O
.	O

Rhox	B
genes	O
are	O
expressed	O
primarily	O
in	O
reproductive	O
and	O
extra	O
-	O
embryonic	O
tissues	O
and	O
may	O
be	O
regulated	O
by	O
colinear	O
mechanisms	O
.	O

Uniquely	O
among	O
family	O
members	O
,	O
Rhox4	B
is	O
also	O
expressed	O
in	O
the	O
developing	O
and	O
adult	O
thymus	O
,	O
where	O
its	O
striking	O
restriction	O
to	O
the	O
third	O
pharyngeal	O
pouch	O
has	O
suggested	O
a	O
role	O
in	O
lineage	O
specification	O
.	O

In	O
this	O
article	O
we	O
describe	O
a	O
previously	O
unreported	O
duplication	O
within	O
the	O
Rhox	B
alpha	O
locus	O
that	O
contains	O
seven	O
copies	O
of	O
Rhox4	B
and	O
eight	O
copies	O
of	O
Rhox2	B
and	O
Rhox3	B
in	O
a	O
tandem	O
array	O
.	O

We	O
further	O
show	O
that	O
all	O
seven	O
Rhox4	B
copies	O
are	O
expressed	O
,	O
although	O
preferential	O
expression	O
occurs	O
and	O
differs	O
between	O
tissues	O
.	O

In	O
contrast	O
to	O
reproductive	O
tissues	O
,	O
we	O
found	O
no	O
evidence	O
of	O
colinear	O
expression	O
of	O
the	O
Rhox	B
alpha	O
cluster	O
during	O
thymus	O
development	O
.	O

All	O
subspecies	O
of	O
mice	O
examined	O
contained	O
multiple	O
copies	O
of	O
Rhox4	B
.	O

However	O
,	O
the	O
only	O
predicted	O
ortholog	O
of	O
Rhox4	B
,	O
rat	O
Rhox4	B
,	O
is	O
present	O
in	O
a	O
single	O
copy	O
,	O
suggesting	O
that	O
the	O
duplications	O
arose	O
at	O
the	O
time	O
of	O
rat	O
and	O
mouse	O
lineage	O
divergence	O
.	O

Finally	O
,	O
no	O
changes	O
in	O
Rhox4	B
expression	O
were	O
detected	O
in	O
mice	O
with	O
defects	O
in	O
thymus	O
organogenesis	O
,	O
placing	O
it	O
upstream	O
or	O
outside	O
of	O
established	O
transcriptional	O
pathways	O
.	O

The	O
expansion	O
of	O
megakaryocyte	O
progenitors	O
from	O
CD34	B
+	O
-	O
enriched	O
mobilized	O
peripheral	O
blood	O
stem	O
cells	O
is	O
inhibited	O
by	O
Flt3	B
-	I
L	I
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
optimal	O
growth	B
factor	I
combination	O
for	O
expansion	O
of	O
megakaryocyte	O
(	O
Mk	O
)	O
progenitors	O
with	O
clonogenic	O
potential	O
from	O
CD34	B
+	O
-	O
enriched	O
mobilized	O
peripheral	O
blood	O
stem	O
cells	O
(	O
PBSC	O
)	O
.	O

Mobilized	O
PBSC	O
were	O
monocyte	O
depleted	O
and	O
CD34	B
+	O
enriched	O
,	O
then	O
cultured	O
with	O
various	O
combinations	O
of	O
interleukin-3	B
(	O
IL-3	B
)	O
,	O
IL-6	B
,	O
IL-11	B
,	O
Flt3	B
ligand	I
(	O
Flt3-L	B
)	O
,	O
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
,	O
granulocyte	B
-	I
macrophage	I
colonystimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
and	O
erythropoietin	B
(	O
EPO	B
)	O
,	O
using	O
a	O
2	O
(	O
7	O
-	O
3	O
)	O
IV	O
fractional	O
factorial	O
design	O
.	O

Expansion	O
of	O
Mk	O
committed	O
progenitors	O
(	O
CD41	B
+	O
)	O
and	O
primitive	O
precursors	O
(	O
CD61	B
+	O
CD34	B
+	O
)	O
was	O
determined	O
using	O
FACS	O
and	O
colony	O
-	O
forming	O
assays	O
.	O

Amplification	O
of	O
Mk	O
progenitor	O
production	O
was	O
attributed	O
to	O
IL-3	B
(	O
p	O
<	O
0.002	O
)	O
,	O
SCF	B
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
GM	B
-	I
CSF	I
(	O
p	O
<	O
0.05	O
)	O
.	O

Flt3	B
-	I
L	I
inhibited	O
the	O
production	O
of	O
total	O
CD61	B
+	O
cells	O
(	O
p	O
<	O
0.05	O
)	O
,	O
CD61	B
+	O
CD34	B
+	O
cells	O
(	O
p	O
<	O
0.03	O
)	O
,	O
and	O
total	O
CD41a	B
+	O
cells	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Addition	O
of	O
Flt3	B
-	I
L	I
to	O
the	O
optimum	O
growth	B
factor	I
combination	O
of	O
megakaryocyte	B
growth	I
and	I
development	I
factor	I
(	O
MGDF	B
)	O
,	O
SCF	B
,	O
IL-3	B
,	O
and	O
GM	B
-	I
CSF	I
caused	O
the	O
greatest	O
increase	O
in	O
total	O
nucleated	O
cells	O
but	O
reduced	O
Mk	O
progenitor	O
expansion	O
.	O

There	O
was	O
also	O
a	O
20	O
%	O
reduction	O
in	O
Mk	O
+	O
colonies	O
from	O
cells	O
expanded	O
in	O
the	O
presence	O
of	O
Flt3	B
-	I
L	I
.	O

Factorial	O
analysis	O
identified	O
the	O
optimal	O
combination	O
of	O
growth	B
factors	I
required	O
to	O
expand	O
Mk	O
precursors	O
with	O
clonogenic	O
potential	O
.	O

The	O
addition	O
of	O
Flt3	B
-	I
L	I
to	O
the	O
optimal	O
combination	O
of	O
MGDF	B
,	O
SCF	B
,	O
IL-3	B
,	O
and	O
GM	B
-	I
CSF	I
reduced	O
both	O
the	O
fold	O
expansion	O
of	O
Mk	O
progenitors	O
and	O
Mk	O
colony	O
numbers	O
.	O

LPS	O
-	O
induced	O
release	O
of	O
IL-1beta	B
,	O
IL-1Ra	B
,	O
IL-6	B
,	O
and	O
TNF	B
-	I
alpha	I
in	O
whole	O
blood	O
from	O
patients	O
with	O
familial	O
hypercholesterolemia	O
:	O
no	O
effect	O
of	O
cholesterol	O
-	O
lowering	O
treatment	O
.	O

Proinflammatory	O
cytokines	B
,	O
such	O
as	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
,	O
IL-6	B
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
are	O
suggested	O
to	O
have	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
atherosclerosis	O
.	O

Patients	O
with	O
heterozygous	O
familial	O
hypercholesterolemia	O
(	O
FH	O
)	O
have	O
a	O
marked	O
elevation	O
in	O
the	O
plasma	O
level	O
of	O
low	B
-	I
density	I
lipoproteins	I
(	O
LDL	B
)	O
,	O
and	O
they	O
show	O
early	O
development	O
of	O
atherosclerosis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
with	O
a	O
whole	O
blood	O
culture	O
system	O
if	O
hyperlipoproteinemia	O
is	O
associated	O
with	O
increased	O
cytokine	B
production	O
capacity	O
in	O
these	O
patients	O
and	O
if	O
treatment	O
with	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
(	I
HMG	I
-	I
CoA	I
)	I
reductase	I
inhibitors	O
influences	O
this	O
production	O
capacity	O
of	O
blood	O
cells	O
,	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

The	O
capacity	O
of	O
blood	O
cells	O
in	O
a	O
whole	O
blood	O
culture	O
to	O
produce	O
IL-1beta	B
,	O
IL-6	B
,	O
TNF	B
-	I
alpha	I
,	O
IL-12	B
,	O
IL-18	B
,	O
and	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1Ra	B
)	O
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
appeared	O
to	O
be	O
similar	O
for	O
heterozygous	O
FH	O
patients	O
and	O
healthy	O
volunteers	O
.	O

Furthermore	O
,	O
the	O
capacity	O
to	O
produce	O
IL-1beta	B
,	O
IL-6	B
,	O
and	O
TNF	B
-	I
alpha	I
in	O
response	O
to	O
LPS	O
was	O
not	O
modified	O
by	O
cholesterol	O
synthesis	O
inhibitors	O
at	O
the	O
level	O
of	O
mRNA	O
expression	O
or	O
at	O
the	O
level	O
of	O
release	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
release	O
of	O
IL-1Ra	B
was	O
significantly	O
increased	O
after	O
treatment	O
with	O
HMG	B
-	I
CoA	I
reductase	I
inhibitors	O
,	O
although	O
only	O
at	O
the	O
protein	O
level	O
.	O

This	O
suggests	O
a	O
possible	O
beneficial	O
anti	O
-	O
inflammatory	O
role	O
for	O
this	O
therapy	O
.	O

Association	O
of	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
genotypes	O
with	O
microscopic	O
polyangiitis	O
.	O

OBJECTIVE	O
:	O

Genetic	O
background	O
and	O
infection	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
microscopic	O
polyangiitis	O
(	O
MPA	O
)	O
.	O

Killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
are	O
a	O
diverse	O
family	O
of	O
activating	O
and	O
inhibitory	O
receptors	O
expressed	O
on	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
T	O
cells	O
,	O
the	O
genes	O
of	O
which	O
show	O
extreme	O
polymorphism	O
.	O

Some	O
KIRs	B
bind	O
to	O
HLA	B
class	I
I	I
subgroups	O
,	O
and	O
genetic	O
interactions	O
between	O
KIR	B
genes	O
and	O
their	O
ligand	O
HLA	B
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
several	O
autoimmune	O
and	O
viral	O
diseases	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
possible	O
associations	O
of	O
the	O
presence	O
or	O
absence	O
of	O
KIR	B
loci	O
with	O
a	O
genetic	O
predisposition	O
to	O
MPA	O
.	O

METHODS	O
:	O

The	O
presence	O
or	O
absence	O
of	O
14	O
KIR	B
loci	O
was	O
determined	O
in	O
57	O
myeloperoxidase	B
antineutrophil	O
cytoplasmic	O
antibody	O
-	O
positive	O
Japanese	O
subjects	O
(	O
43	O
patients	O
with	O
MPA	O
and	O
239	O
healthy	O
controls	O
)	O
.	O

RESULTS	O
:	O

The	O
carrier	O
frequency	O
of	O
activating	O
KIR2DS3	B
was	O
significantly	O
decreased	O
among	O
patients	O
with	O
MPA	O
compared	O
with	O
healthy	O
controls	O
(	O
4.7	O
%	O
versus	O
16.7	O
%	O
;	O
P	O
=	O
0.038	O
,	O
odds	O
ratio	O
[	O
OR	O
]	O
0.24	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
0.06	O
-	O
0.94	O
)	O
.	O

When	O
KIRs	B
were	O
analyzed	O
in	O
combination	O
with	O
their	O
HLA	B
ligands	I
,	O
the	O
proportion	O
of	O
individuals	O
carrying	O
inhibitory	O
KIR3DL1	B
and	O
HLA	B
-	I
Bw4	I
but	O
not	O
activating	O
receptor	O
KIR3DS1	B
,	O
a	O
combination	O
presumed	O
to	O
be	O
the	O
most	O
inhibitory	O
of	O
all	O
KIR3DS1	B
/	O
3DL1	B
/	O
HLA	B
-	I
B	I
combinations	O
,	O
was	O
significantly	O
increased	O
in	O
the	O
MPA	O
group	O
compared	O
with	O
the	O
control	O
group	O
(	O
46.5	O
%	O
versus	O
27.0	O
%	O
;	O
P	O
=	O
0.014	O
,	O
OR	O
2.35	O
,	O
95	O
%	O
CI	O
1.18	O
-	O
4.70	O
)	O
.	O

Furthermore	O
,	O
when	O
subjects	O
were	O
classified	O
according	O
to	O
KIR3DL1	B
/	O
3DS1	B
/	O
HLA	B
-	I
B	I
and	O
KIR2DL1	B
/	O
HLA	B
-	I
C	I
combinations	O
,	O
an	O
increasing	O
trend	O
toward	O
susceptibility	O
was	O
observed	O
as	O
combinations	O
became	O
more	O
inhibitory	O
.	O

CONCLUSION	O
:	O

The	O
decreased	O
activation	O
potential	O
of	O
NK	O
and/or	O
T	O
cells	O
associated	O
with	O
KIR	B
/	O
HLA	B
genotypes	O
may	O
predispose	O
to	O
MPA	O
,	O
possibly	O
through	O
insufficient	O
resistance	O
against	O
infections	O
.	O

[	O
SOS	O
-	O
induction	O
in	O
the	O
presence	O
of	O
the	O
plasmid	O
pKM101	O
in	O
the	O
bacterial	O
cells	O
Escherichia	O
coli	O
K12	O
]	O

Induction	O
of	O
transcription	O
by	O
the	O
plasmid	O
pKM101	O
(	O
mutability	O
mediating	O
derivate	O
of	O
the	O
plasmid	O
R46	O
)	O
of	O
the	O
sfiA	B
gene	O
controlling	O
cell	O
division	O
and	O
of	O
the	O
fruA	B
gene	O
encoding	O
the	O
fructose	O
specific	O
enzyme	O
II	O
of	O
the	O
phosphoenolpyruvate	B
-	I
phosphotransferase	I
system	I
in	O
intact	O
cultures	O
of	O
Escherichia	O
coli	O
was	O
studied	O
.	O

The	O
genes	O
under	O
study	O
were	O
fused	O
to	O
the	O
bacteriophage	O
Mu	O
dl	O
(	O
Ap	O
lac	O
)	O
.	O

Activation	O
of	O
the	O
sfiA	B
gene	O
,	O
a	O
typical	O
member	O
of	O
the	O
SOS	O
-	O
regulon	O
,	O
was	O
demonstrated	O
to	O
depend	O
on	O
the	O
key	O
genes	O
of	O
the	O
SOS	O
-	O
system	O
-	O
recA	B
and	O
lexA	B
.	O

In	O
contrast	O
,	O
the	O
fruA	B
gene	O
that	O
is	O
non	O
-	O
inducible	O
by	O
the	O
UV	O
-	O
light	O
,	O
a	O
classical	O
SOS	O
-	O
inducing	O
agent	O
,	O
is	O
not	O
activated	O
by	O
the	O
presence	O
of	O
the	O
plasmid	O
pKMIO1	O
in	O
the	O
bacterial	O
cells	O
.	O

The	O
data	O
obtained	O
suggest	O
that	O
the	O
presence	O
of	O
pKMIO1	O
plasmid	O
in	O
the	O
Escherichia	O
coli	O
cells	O
induces	O
a	O
SOS	O
-	O
signal	O
as	O
a	O
consequence	O
of	O
the	O
plasmid	O
DNA	O
replication	O
or	O
its	O
conjugative	O
transfer	O
.	O

Circulating	O
markers	O
of	O
endothelial	O
function	O
in	O
cardiovascular	O
disease	O
.	O

Endothelial	O
dysfunction	O
is	O
a	O
key	O
event	O
in	O
cardiovascular	O
disease	O
.	O

Measurement	O
of	O
endothelial	O
dysfunction	O
in	O
vivo	O
presents	O
a	O
major	O
challenge	O
,	O
but	O
has	O
important	O
implications	O
since	O
it	O
may	O
identify	O
the	O
clinical	O
need	O
for	O
therapeutic	O
intervention	O
,	O
specifically	O
in	O
primary	O
prevention	O
.	O

Several	O
biological	O
markers	O
have	O
been	O
used	O
as	O
indicators	O
of	O
endothelial	O
dysfunction	O
.	O

The	O
soluble	O
adhesion	B
molecules	I
sICAM-1	B
and	O
sVCAM-1	B
lack	O
specificity	O
and	O
are	O
increased	O
in	O
inflammatory	O
processes	O
.	O

Both	O
markers	O
are	O
increased	O
in	O
coronary	O
artery	O
disease	O
.	O

sICAM-1	B
level	O
predicts	O
the	O
risk	O
for	O
cardiovascular	O
disease	O
or	O
diabetes	O
mellitus	O
in	O
healthy	O
individuals	O
.	O

sE	B
-	I
selectin	I
is	O
specific	O
for	O
the	O
endothelium	O
and	O
is	O
increased	O
in	O
coronary	O
artery	O
disease	O
and	O
diabetes	O
mellitus	O
.	O

sE	B
-	I
selectin	I
is	O
also	O
associated	O
with	O
diabetic	O
risk	O
.	O

The	O
endothelium	O
-	O
specific	O
marker	O
,	O
soluble	O
thrombomodulin	B
,	O
is	O
associated	O
with	O
severity	O
of	O
coronary	O
artery	O
disease	O
,	O
stroke	O
or	O
peripheral	O
occlusive	O
arterial	O
disease	O
and	O
is	O
not	O
increased	O
in	O
healthy	O
or	O
asymptomatic	O
subjects	O
.	O

Interestingly	O
,	O
thrombomodulin	B
decreases	O
during	O
treatment	O
of	O
hypercholesterolemia	O
or	O
hyperhomocysteinemia	O
.	O

In	O
contrast	O
,	O
von	B
Willebrand	I
factor	I
is	O
the	O
best	O
endothelial	O
biomarker	O
and	O
predicts	O
risk	O
for	O
ischemic	O
heart	O
disease	O
or	O
stroke	O
.	O

An	O
N	O
-	O
terminally	O
acetylated	O
Arf	B
-	I
like	I
GTPase	I
is	O
localised	O
to	O
lysosomes	O
and	O
affects	O
their	O
motility	O
.	O

Small	B
GTPases	I
of	I
the	I
Arf	I
and	I
Rab	I
families	I
play	O
key	O
roles	O
in	O
the	O
function	O
of	O
subcellular	O
organelles	O
.	O

Each	O
GTPase	B
is	O
usually	O
found	O
on	O
only	O
one	O
compartment	O
and	O
,	O
hence	O
,	O
they	O
confer	O
organelle	O
specificity	O
to	O
many	O
intracellular	O
processes	O
.	O

However	O
,	O
there	O
has	O
so	O
far	O
been	O
little	O
evidence	O
for	O
specific	O
GTPases	B
present	O
on	O
lysosomes	O
.	O

Here	O
,	O
we	O
report	O
that	O
two	O
closely	O
related	O
human	O
Arf	B
-	I
like	I
GTPases	I
,	O
Arl8a	B
and	O
Arl8b	B
(	O
also	O
known	O
as	O
Arl10b	B
/	I
c	I
and	O
Gie1	B
/	I
2	I
)	O
,	O
localise	O
to	O
lysosomes	O
in	O
mammalian	O
cells	O
,	O
with	O
the	O
single	O
homologue	O
in	O
Drosophila	O
cells	O
having	O
a	O
similar	O
location	O
.	O

Conventionally	O
,	O
membrane	O
binding	O
of	O
Arf	B
and	O
Arl	B
proteins	O
is	O
mediated	O
by	O
both	O
an	O
N	O
-	O
terminal	O
myristoyl	O
group	O
and	O
an	O
N	O
-	O
terminal	O
amphipathic	O
helix	O
that	O
is	O
inserted	O
into	O
the	O
lipid	O
bilayer	O
upon	O
activation	O
of	O
the	O
GTPase	B
.	O

Arl8a	B
and	O
Arl8b	B
do	O
not	O
have	O
N	O
-	O
terminal	O
myristoylation	O
sites	O
,	O
and	O
we	O
find	O
that	O
Arl8b	B
is	O
instead	O
N	O
-	O
terminally	O
acetylated	O
,	O
and	O
an	O
acetylated	O
methionine	O
is	O
necessary	O
for	O
its	O
lysosomal	O
localization	O
.	O

Overexpression	O
of	O
Arl8a	B
or	O
Arl8b	B
results	O
in	O
a	O
microtubule	O
-	O
dependent	O
redistribution	O
of	O
lysosomes	O
towards	O
the	O
cell	O
periphery	O
.	O

Live	O
cell	O
imaging	O
shows	O
that	O
lysosomes	O
move	O
more	O
frequently	O
both	O
toward	O
and	O
away	O
from	O
the	O
cell	O
periphery	O
,	O
suggesting	O
a	O
role	O
for	O
Arl8a	B
and	O
Arl8b	B
as	O
positive	O
regulators	O
of	O
lysosomal	O
transport	O
.	O

Bis	O
selenide	O
alkene	O
derivatives	O
:	O

A	O
class	O
of	O
potential	O
antioxidant	O
and	O
antinociceptive	O
agents	O
.	O

Bis	O
and	O
tris	O
-	O
selenide	O
alkene	O
derivatives	O
,	O
a	O
class	O
of	O
organoselenium	O
compounds	O
,	O
were	O
screened	O
for	O
antinociceptive	O
and	O
antioxidant	O
activities	O
.	O

In	O
vitro	O
,	O
bis	O
-	O
selenide	O
alkene	O
1c	O
(	O
R=2,4,6-Me	O
(	O
3	O
)	O
C	O
(	O
6	O
)	O
H	O
(	O
2	O
)	O
)	O
,	O
1d	O
(	O
R=4-ClC	O
(	O
6	O
)	O
H	O
(	O
4	O
)	O
)	O
and	O
1e	O
(	O
R=4-MeOC	O
(	O
6	O
)	O
H	O
(	O
4	O
)	O
)	O
protected	O
against	O
lipid	O
peroxidation	O
about	O
50	O
%	O
,	O
whereas	O
1b	O
(	O
R	O
=	O
C	O
(	O
6	O
)	O
H	O
(	O
5	O
)	O
)	O
and	O
1a	O
(	O
R	O
=	O
C	O
(	O
4	O
)	O
H	O
(	O
9	O
)	O
)	O
protected	O
only	O
23	O
%	O
.	O

Compound	O
1d	O
presented	O
lesser	O
IC	O
(	O
50	O
)	O
against	O
lipid	O
peroxidation	O
than	O
other	O
bis	O
-	O
selenide	O
alkene	O
compounds	O
(	O
1d>1e	O
>	O
or	O
=	O
1c	O
>	O
1a	O
=	O
1b	O
)	O
.	O

The	O
maximal	O
inhibitory	O
effect	O
of	O
tris	O
-	O
selenide	O
alkenes	O
on	O
lipid	O
peroxidation	O
was	O
in	O
the	O
following	O
order	O
2c	O
>	O
2a	O
=	O
2b	O
.	O

Compound	O
1e	O
increased	O
the	O
rate	O
of	O
GSH	O
,	O
but	O
not	O
DTT	O
,	O
oxidation	O
.	O

Tris	O
-	O
selenide	O
alkene	O
2c	O
(	O
R=4-MeOC	O
(	O
6	O
)	O
H	O
(	O
4	O
)	O
)	O
demonstrated	O
the	O
higher	O
rate	O
of	O
thiol	O
oxidation	O
,	O
while	O
2a	O
(	O
R	O
=	O
C	O
(	O
6	O
)	O
H	O
(	O
5	O
)	O
)	O
did	O
not	O
change	O
DTT	O
oxidation	O
but	O
oxidized	O
GSH	O
.	O

Conversely	O
,	O
compound	O
2b	O
(	O
R=4-ClC	O
(	O
6	O
)	O
H	O
(	O
4	O
)	O
)	O
did	O
not	O
change	O
the	O
rate	O
of	O
GSH	O
oxidation	O
,	O
but	O
oxidized	O
DDT	O
.	O

Bis	O
-	O
selenide	O
alkene	O
derivatives	O
1c	O
,	O
1d	O
and	O
1e	O
were	O
the	O
most	O
promising	O
compounds	O
tested	O
in	O
vitro	O
.	O

In	O
vivo	O
,	O
compounds	O
1c	O
and	O
1d	O
(	O
5	O
-	O
50	O
mg	O
/	O
kg	O
,	O
subcutaneously	O
)	O
produced	O
significant	O
inhibition	O
of	O
acetic	O
acid	O
-	O
and	O
capsaicin	O
-	O
induced	O
pain	O
.	O

Compounds	O
1c	O
and	O
1d	O
increased	O
the	O
tail	O
-	O
flick	O
response	O
latency	O
time	O
.	O

The	O
antinociception	O
effect	O
of	O
1c	O
and	O
1d	O
was	O
not	O
abolished	O
by	O
naloxone	O
(	O
an	O
antagonist	O
of	O
opioid	O
receptor	O
,	O
1	O
mg	O
/	O
kg	O
,	O
subcutaneously	O
)	O
,	O
suggesting	O
that	O
the	O
antinociceptive	O
effect	O
is	O
not	O
influenced	O
by	O
the	O
opioidergic	O
mechanism	O
.	O

[	O
Expression	O
,	O
purification	O
and	O
identification	O
of	O
Echinococcus	O
granulosus	O
recombinant	O
antigen	B
B	I
]	O

OBJECTIVE	O
:	O

To	O
purify	O
and	O
identify	O
recombinant	O
antigen	B
B	I
of	O
hydatid	O
disease	O
.	O

METHODS	O
:	O

The	O
recombinant	O
plasmid	O
pMalc2x	O
-	O
AgB	B
was	O
expressed	O
in	O
E.	O
coli	O
JM109	O
.	O

The	O
fusion	O
protein	O
rAgB	B
-	O
MBP	B
was	O
made	O
up	O
of	O
antigen	B
B	I
and	O
MBP	B
(	O
maltose	B
binding	I
protein	I
)	O
which	O
was	O
designed	O
to	O
absorb	O
the	O
antigen	B
B	I
onto	O
the	O
amylose	O
column	O
.	O

In	O
order	O
to	O
get	O
the	O
pure	O
antigen	O
as	O
the	O
probe	O
for	O
selecting	O
phage	O
displayed	O
antibody	O
library	O
,	O
factor	B
Xa	I
protease	B
was	O
used	O
to	O
digest	O
the	O
fusion	O
protein	O
rAgB	B
-	O
MBP	B
so	O
that	O
MBP	B
was	O
cut	O
off	O
from	O
the	O
special	O
cleavage	O
site	O
.	O

Flowing	O
through	O
the	O
amylose	O
resin	O
column	O
and	O
hydroxyapatite	O
column	O
,	O
rAgB	B
was	O
purified	O
by	O
the	O
method	O
of	O
affinity	O
chromatography	O
.	O

Its	O
specificity	O
was	O
proved	O
by	O
patient	O
sera	O
with	O
Western	O
blotting	O
.	O

RESULTS	O
:	O

The	O
recombinant	O
antigen	B
B	I
was	O
Mr	O
12	O
000	O
,	O
and	O
it	O
showed	O
the	O
capability	O
to	O
combine	O
with	O
the	O
specific	O
antibody	O
.	O

CONCLUSION	O
:	O

Hydatid	O
disease	O
antigen	B
B	I
can	O
be	O
produced	O
by	O
molecular	O
method	O
and	O
applied	O
in	O
monoclonal	O
antibody	O
production	O
and	O
phage	O
antibody	O
library	O
scanning	O
.	O

Anti	O
-	O
HBc	B
&	O
HBV	O
-	O
DNA	O
detection	O
in	O
blood	O
donors	O
negative	O
for	O
hepatitis	B
B	I
virus	I
surface	I
antigen	I
in	O
reducing	O
risk	O
of	O
transfusion	O
associated	O
HBV	O
infection	O
.	O

BACKGROUND	O
&	O
OBJECTIVE	O
:	O

Though	O
sensitive	O
screening	O
assays	O
for	O
detection	O
of	O
hepatitis	B
B	I
virus	I
surface	I
antigen	I
(	O
HBsAg	B
)	O
are	O
available	O
,	O
occasional	O
cases	O
of	O
post	O
-	O
transfusion	O
hepatitis	O
B	O
virus	O
infection	O
(	O
PTH	O
)	O
still	O
occur	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
prevalence	O
of	O
anti	O
-	O
hepatitis	B
B	I
core	I
(	O
anti	O
-	O
HBc	B
)	O
positivity	O
and	O
presence	O
of	O
HBV	O
-	O
DNA	O
in	O
serum	O
sample	O
of	O
healthy	O
blood	O
donors	O
negative	O
for	O
both	O
HBsAg	B
and	O
anti	O
-	O
HCV	O
antibody	O
in	O
Shiraz	O
,	O
Iran	O
.	O

Since	O
anti	O
-	O
HBc	B
detection	O
is	O
not	O
mandatory	O
in	O
Iran	O
,	O
we	O
evaluated	O
whether	O
anti	O
-	O
HBc	B
detection	O
could	O
be	O
adopted	O
as	O
a	O
screening	O
assay	O
for	O
safety	O
of	O
donated	O
blood	O
.	O

METHODS	O
:	O

Two	O
thousands	O
serum	O
samples	O
negative	O
for	O
both	O
HBsAg	B
and	O
anti	O
-	O
HCV	O
collected	O
from	O
healthy	O
blood	O
donors	O
were	O
tested	O
for	O
the	O
presence	O
of	O
anti	O
HBc	B
antibody	O
.	O

All	O
samples	O
positive	O
for	O
anti	O
-	O
HBc	B
antibody	O
were	O
then	O
investigated	O
for	O
determination	O
of	O
anti	O
-	O
HBc	B
titre	O
,	O
anti	O
-	O
HBs	B
titre	O
,	O
HbeAg	B
and	O
anti	O
-	O
HBe	B
antibody	O
by	O
enzyme	O
immunoassay	O
(	O
EIA	O
)	O
.	O

Every	O
sample	O
that	O
tested	O
negative	O
for	O
HBsAg	B
but	O
positive	O
for	O
anti	O
-	O
HBc	B
alone	O
or	O
in	O
combination	O
with	O
other	O
serological	O
markers	O
was	O
also	O
examined	O
for	O
the	O
presence	O
of	O
HBV	O
-	O
DNA	O
by	O
polymerase	B
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

RESULTS	O
:	O

Of	O
the	O
2000	O
samples	O
tested	O
,	O
131	O
(	O
6.55	O
%	O
)	O
blood	O
samples	O
were	O
found	O
to	O
be	O
positive	O
for	O
anti	O
-	O
HBc	B
.	O

HBV	O
DNA	O
was	O
detected	O
among	O
16	O
of	O
131	O
(	O
12.2	O
%	O
)	O
anti	O
-	O
HBc	B
positive	O
specimens	O
.	O

Further	O
,	O
there	O
was	O
an	O
association	O
between	O
the	O
titration	O
of	O
anti	O
-	O
HBc	B
antibody	O
and	O
the	O
intensity	O
of	O
expected	O
PCR	O
product	O
band	O
.	O

The	O
liver	O
function	O
test	O
results	O
were	O
all	O
in	O
normal	O
range	O
except	O
in	O
4	O
of	O
16	O
HBV	O
-	O
DNA	O
positive	O
subjects	O
.	O

The	O
mean	O
levels	O
of	O
alanine	B
aminotransferase	I
(	O
ALT	B
)	O
and	O
aspartate	B
aminotransferase	I
(	O
AST	B
)	O
in	O
HBV	O
-	O
PCR	O
positive	O
subjects	O
were	O
14	O
IU	O
/	O
l	O
and	O
23.7	O
IU	O
/	O
l	O
respectively	O
.	O

INTERPRETATION	O
&	O
CONCLUSION	O
:	O

Anti	O
-	O
HBc	B
antibody	O
should	O
be	O
tested	O
routinely	O
on	O
blood	O
donors	O
volunteers	O
and	O
if	O
the	O
sample	O
found	O
positive	O
regardless	O
of	O
anti	O
-	O
HBs	B
titre	O
,	O
the	O
blood	O
should	O
be	O
discarded	O
.	O

Further	O
testing	O
for	O
HBV	O
-	O
DNA	O
would	O
be	O
appropriate	O
to	O
follow	O
up	O
the	O
donor	O
for	O
HBV	O
infection	O
.	O

Increased	O
expression	O
of	O
renal	O
aquaporin	B
water	I
channels	I
in	O
spontaneously	O
hypertensive	O
rats	O
.	O

AIMS	O
:	O

The	O
present	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
exists	O
an	O
altered	O
regulation	O
of	O
aquaporin	B
(	I
AQP	I
)	I
water	I
channels	I
in	O
hypertension	O
.	O

METHODS	O
:	O

Male	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHR	O
)	O
aged	O
10	O
-	O
12	O
weeks	O
were	O
used	O
.	O

Age	O
-	O
matched	O
Wistar	O
-	O
Kyoto	O
(	O
WKY	O
)	O
rats	O
served	O
as	O
control	O
.	O

The	O
abundance	O
of	O
AQP1	B
-	I
4	I
proteins	O
in	O
the	O
kidney	O
was	O
determined	O
by	O
Western	O
blot	O
analysis	O
.	O

The	O
protein	O
expression	O
and	O
activity	O
of	O
adenylyl	B
cyclase	I
were	O
also	O
determined	O
.	O

RESULTS	O
:	O

The	O
medullary	O
expression	O
of	O
AQP2	B
and	O
AQP3	B
proteins	O
was	O
increased	O
in	O
SHR	O
compared	O
with	O
that	O
in	O
WKY	O
rats	O
.	O

The	O
expression	O
of	O
AQP1	B
protein	O
was	O
also	O
significantly	O
increased	O
in	O
the	O
inner	O
medulla	O
,	O
while	O
that	O
of	O
AQP4	B
was	O
not	O
.	O

Immunohistochemistry	O
of	O
AQP2	B
revealed	O
that	O
principal	O
cells	O
of	O
the	O
collecting	O
duct	O
have	O
strong	O
immunoreactivity	O
,	O
the	O
degree	O
of	O
which	O
was	O
augmented	O
with	O
prominent	O
apical	O
labeling	O
in	O
SHR	O
.	O

The	O
plasma	O
level	O
of	O
arginine	B
vasopressin	I
(	O
AVP	B
)	O
was	O
higher	O
in	O
SHR	O
;	O
the	O
adenylyl	B
cyclase	I
activity	O
stimulated	O
by	O
AVP	B
was	O
augmented	O
,	O
along	O
with	O
increased	O
expression	O
of	O
type	B
VI	I
adenylyl	I
cyclase	I
.	O

The	O
urine	O
was	O
more	O
concentrated	O
with	O
its	O
volume	O
decreased	O
in	O
SHR	O
.	O

CONCLUSION	O
:	O

The	O
expression	O
of	O
AQP1	B
-	I
3	I
channels	O
is	O
increased	O
in	O
the	O
kidney	O
,	O
in	O
association	O
with	O
enhanced	O
activity	O
of	O
the	O
AVP	B
/	O
cAMP	O
pathway	O
,	O
in	O
SHR	O
.	O

Interactions	O
of	O
mRNAs	O
and	O
gRNAs	O
involved	O
in	O
trypanosome	O
mitochondrial	O
RNA	O
editing	O
:	O
structure	O
probing	O
of	O
a	O
gRNA	O
bound	O
to	O
its	O
cognate	O
mRNA	O
.	O

Expression	O
of	O
mitochondrial	O
genes	O
in	O
Trypanosoma	O
brucei	O
requires	O
RNA	O
editing	O
of	O
its	O
mRNA	O
transcripts	O
.	O

During	O
editing	O
,	O
uridylates	O
are	O
precisely	O
inserted	O
and	O
deleted	O
as	O
directed	O
by	O
the	O
gRNA	O
template	O
to	O
create	O
the	O
protein	O
open	O
reading	O
frame	O
.	O

This	O
process	O
involves	O
the	O
bimolecular	O
interaction	O
of	O
the	O
gRNA	O
with	O
its	O
cognate	O
pre	O
-	O
edited	O
mRNA	O
and	O
the	O
assembly	O
of	O
a	O
protein	O
complex	O
with	O
the	O
enzymatic	O
machinery	O
required	O
.	O

While	O
a	O
considerable	O
amount	O
of	O
work	O
has	O
been	O
done	O
identifying	O
the	O
protein	O
components	O
of	O
the	O
editing	O
complex	O
,	O
very	O
little	O
is	O
known	O
about	O
how	O
a	O
functional	O
editosome	O
is	O
assembled	O
.	O

In	O
addition	O
,	O
the	O
importance	O
of	O
RNA	O
structure	O
in	O
establishing	O
a	O
functional	O
editing	O
complex	O
is	O
poorly	O
understood	O
.	O

Work	O
in	O
our	O
lab	O
suggests	O
that	O
different	O
mRNA	O
/	O
gRNA	O
pairs	O
can	O
form	O
similar	O
secondary	O
structures	O
suggesting	O
that	O
a	O
common	O
core	O
architecture	O
may	O
be	O
important	O
for	O
editosome	O
recognition	O
and	O
function	O
.	O

Using	O
solution	O
structure	O
probing	O
,	O
we	O
have	O
investigated	O
the	O
structure	O
of	O
the	O
initiating	O
gRNA	O
,	O
gCYb-558	O
,	O
in	O
the	O
mRNA	O
/	O
gRNA	O
complex	O
with	O
pre	O
-	O
edited	O
apocytochrome	B
b	I
mRNA	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
stem	O
-	O
loop	O
formed	O
by	O
the	O
guiding	O
region	O
of	O
the	O
gRNA	O
alone	O
is	O
maintained	O
in	O
its	O
interaction	O
with	O
the	O
pre	O
-	O
edited	O
message	O
.	O

In	O
addition	O
,	O
our	O
data	O
suggest	O
that	O
a	O
gRNA	O
stem	O
-	O
loop	O
structure	O
is	O
maintained	O
through	O
the	O
first	O
few	O
editing	O
events	O
by	O
the	O
use	O
of	O
alternative	O
base	O
-	O
pairing	O
with	O
the	O
U	O
-	O
tail	O
.	O

Association	O
of	O
the	O
promoter	O
polymorphism	O
-	O
232C	O
/	O
G	O
of	O
the	O
phosphoenolpyruvate	B
carboxykinase	I
gene	O
(	O
PCK1	B
)	O
with	O
Type	O
2	O
diabetes	O
mellitus	O
.	O

AIMS	O
:	O

The	O
phosphoenolpyruvate	B
carboxykinase	I
gene	O
(	O
PCK1	B
)	O
is	O
a	O
potential	O
candidate	O
gene	O
in	O
the	O
pathogenesis	O
of	O
Type	O
2	O
diabetes	O
mellitus	O
.	O

A	O
-	O
232C	O
/	O
G	O
promoter	O
polymorphism	O
of	O
PCK1	B
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
Type	O
2	O
diabetes	O
in	O
a	O
Canadian	O
population	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
this	O
association	O
in	O
a	O
German	O
Caucasian	O
population	O
.	O

METHODS	O
:	O

We	O
investigated	O
397	O
subjects	O
with	O
Type	O
2	O
diabetes	O
[	O
227	O
men	O
,	O
170	O
women	O
,	O
age	O
63	O
+	O
/	O
-	O
11	O
years	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
28.7	O
+	O
/-	O
5.1	O
kg	O
/	O
m2	O
]	O
and	O
431	O
control	O
subjects	O
without	O
diabetes	O
(	O
247	O
men	O
,	O
184	O
women	O
,	O
age	O
64	O
+	O
/-	O
7	O
years	O
,	O
BMI	O
26.5	O
+	O
/-	O
3.7	O
kg	O
/	O
m2	O
)	O
matched	O
for	O
sex	O
and	O
age	O
.	O

RESULTS	O
:	O

In	O
the	O
diabetic	O
and	O
control	O
groups	O
,	O
the	O
CC	O
genotype	O
frequencies	O
were	O
18.1	O
and	O
18.3	O
%	O
,	O
the	O
CG	O
48.6	O
and	O
48.7	O
%	O
and	O
the	O
GG	O
33.2	O
and	O
32.9	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.995	O
)	O
.	O

The	O
allelic	O
frequencies	O
were	O
0.51	O
and	O
0.57	O
for	O
the	O
G	O
allele	O
and	O
0.49	O
and	O
0.43	O
for	O
the	O
C	O
allele	O
,	O
respectively	O
.	O

In	O
a	O
logistic	O
regression	O
model	O
only	O
BMI	O
and	O
family	O
history	O
,	O
but	O
not	O
the	O
polymorphism	O
,	O
were	O
predictors	O
of	O
Type	O
2	O
diabetes	O
.	O

In	O
both	O
the	O
control	O
and	O
diabetic	O
subjects	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
BMI	O
or	O
blood	O
pressure	O
between	O
the	O
groups	O
with	O
or	O
without	O
the	O
polymorphism	O
.	O

The	O
variant	O
also	O
had	O
no	O
significant	O
influence	O
on	O
the	O
presence	O
of	O
atherosclerotic	O
disease	O
,	O
while	O
the	O
influence	O
of	O
other	O
known	O
cardiovascular	O
risk	O
factors	O
was	O
confirmed	O
.	O

CONCLUSIONS	O
:	O

The	O
present	O
data	O
suggest	O
that	O
,	O
in	O
a	O
German	O
Caucasian	O
population	O
,	O
the	O
-	O
232C	O
/	O
G	O
polymorphism	O
of	O
the	O
PEPCK	B
gene	O
is	O
not	O
associated	O
with	O
Type	O
2	O
diabetes	O
.	O

Differential	O
distribution	O
of	O
non	B
-	I
structural	I
proteins	I
of	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
in	O
BHK-21	O
cells	O
.	O

Differences	O
in	O
the	O
kinetics	O
of	O
expression	O
and	O
cell	O
distribution	O
among	O
FMDV	O
non	B
-	I
structural	I
proteins	I
(	O
NSPs	B
)	O
have	O
been	O
observed	O
in	O
BHK-21	O
-	O
infected	O
cells	O
.	O

3D	B
(	I
pol	I
)	I
was	O
the	O
first	O
protein	O
detected	O
by	O
immunofluorescence	O
(	O
1.5	O
h	O
p.i	O
.	O
)	O
,	O
showing	O
a	O
perinuclear	O
distribution	O
.	O

At	O
2	O
-	O
2.5	O
h	O
p.i	O
.	O
,	O
2B	B
,	O
2C	B
,	O
3B	B
and	O
3C	B
were	O
detected	O
,	O
mostly	O
exhibiting	O
a	O
punctuated	O
,	O
scattered	O
pattern	O
,	O
while	O
3A	O
and	O
3D	B
(	I
pol	I
)	I
appeared	O
concentrated	O
at	O
one	O
side	O
of	O
the	O
nucleus	O
.	O

This	O
distribution	O
was	O
exhibited	O
by	O
all	O
the	O
NSPs	B
from	O
3	O
h	O
p.i	O
.	O
,	O
being	O
2C	B
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
precursors	O
2BC	B
and	O
3ABBB	B
,	O
the	O
only	O
proteins	O
detected	O
by	O
Western	O
blotting	O
at	O
that	O
infection	O
time	O
.	O

From	O
4	O
h	O
p.i	O
.	O
,	O
all	O
mature	O
NSPs	B
as	O
well	O
as	O
precursors	O
2BC	B
,	O
3ABBB	B
,	O
3ABB	B
,	O
3AB	B
and	O
3CD	B
(	I
pol	I
)	I
were	O
detected	O
by	O
this	O
technique	O
.	O

In	O
spite	O
of	O
their	O
similar	O
immunofluorescence	O
patterns	O
,	O
2C	B
and	O
3A	B
co	O
-	O
localized	O
partially	O
by	O
confocal	O
microscopy	O
at	O
3.5	O
h	O
p.i	O
.	O
,	O
and	O
3A	B
,	O
but	O
not	O
2C	B
,	O
co	O
-	O
localized	O
with	O
the	O
ER	O
marker	O
calreticulin	O
,	O
suggesting	O
differences	O
in	O
the	O
distribution	O
of	O
these	O
proteins	O
and/or	O
their	O
precursors	O
as	O
infection	O
proceeded	O
.	O

Transient	O
expression	O
of	O
2C	B
and	O
3AB	B
resulted	O
in	O
punctuated	O
fluorescence	O
patterns	O
similar	O
to	O
those	O
found	O
in	O
early	O
infected	O
cells	O
,	O
while	O
3A	B
showed	O
a	O
more	O
diffuse	O
distribution	O
.	O

A	O
shift	O
towards	O
a	O
fibrous	O
pattern	O
was	O
noticed	O
for	O
3ABB	B
,	O
while	O
a	O
major	O
change	O
was	O
observed	O
in	O
cells	O
expressing	O
3ABBB	B
,	O
which	O
displayed	O
a	O
perinuclear	O
fibrous	O
distribution	O
.	O

Interestingly	O
,	O
when	O
co	O
-	O
expressed	O
with	O
3D	B
(	I
pol	I
)	I
,	O
the	O
pattern	O
observed	O
for	O
3ABBB	B
fluorescence	O
was	O
altered	O
,	O
resembling	O
that	O
exhibited	O
by	O
cells	O
transfected	O
with	O
3AB	B
.	O

Transient	O
expression	O
of	O
3D	B
(	I
pol	I
)	I
showed	O
a	O
homogeneous	O
cell	O
distribution	O
that	O
included	O
,	O
as	O
determined	O
by	O
confocal	O
microscopy	O
,	O
the	O
nucleus	O
.	O

This	O
was	O
confirmed	O
by	O
the	O
detection	O
of	O
3D	B
(	I
pol	I
)	I
in	O
nuclear	O
fractions	O
of	O
transfected	O
cells	O
.	O

3D	B
(	I
pol	I
)	I
and	O
its	O
precursor	O
3CD	B
(	I
pol	I
)	I
were	O
also	O
detected	O
in	O
nuclear	O
fractions	O
of	O
infected	O
cells	O
,	O
suggesting	O
that	O
these	O
proteins	O
can	O
directly	O
interact	O
with	O
the	O
nucleus	O
during	O
FMDV	O
infection	O
.	O

T	O
cells	O
to	O
a	O
dominant	O
epitope	O
of	O
GAD65	B
express	O
a	O
public	O
CDR3	O
motif	O
.	O

Non	O
-	O
obese	O
diabetic	O
(	O
NOD	O
)	O
mice	O
spontaneously	O
develop	O
autoimmune	O
diabetes	O
,	O
and	O
serve	O
as	O
a	O
model	O
for	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
and	O
natural	O
autoimmunity	O
.	O

T	O
cell	O
responses	O
to	O
the	O
pancreatic	O
islet	O
antigen	O
glutamic	B
acid	I
decarboxylase	I
65	I
(	O
GAD65	B
)	O
can	O
be	O
detected	O
in	O
the	O
spleens	O
of	O
young	O
prediabetic	O
NOD	O
mice	O
,	O
which	O
display	O
a	O
unique	O
MHC	B
class	I
II	I
molecule	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
distinct	O
TcR	B
beta	I
chain	O
and	O
CDR3	O
motif	O
are	O
utilized	O
by	O
all	O
NOD	O
mice	O
in	O
response	O
to	O
a	O
dominant	O
determinant	O
on	O
GAD65	B
,	O
establishing	O
a	O
public	O
repertoire	O
in	O
the	O
spontaneous	O
autoimmunity	O
to	O
an	O
important	O
islet	O
cell	O
antigen	O
.	O

GAD65	B
530	O
-	O
543	O
(	O
p530	O
)	O
-	O
reactive	O
T	O
cells	O
preferentially	O
utilize	O
the	O
Vbeta4	O
,	O
Dbeta2.1	O
and	O
Jbeta2.7	O
gene	O
segments	O
,	O
with	O
a	O
CDR3	O
that	O
is	O
characterized	O
by	O
a	O
triad	O
of	O
amino	O
acids	O
,	O
DWG	O
,	O
preceded	O
by	O
a	O
polar	O
residue	O
.	O

In	O
addition	O
,	O
we	O
used	O
CDR3	O
length	O
spectratyping	O
,	O
CDR3	O
-	O
specific	O
reverse	O
transcriptase	O
-	O
PCR	O
and	O
direct	O
TcR	B
sequencing	O
to	O
show	O
that	O
the	O
TcR	B
beta	I
chain	O
structural	O
patterns	O
associated	O
with	O
p530	O
-	O
specific	O
T	O
cells	O
consistently	O
appeared	O
in	O
the	O
islets	O
of	O
young	O
NOD	O
mice	O
with	O
insulitis	O
,	O
but	O
not	O
in	O
the	O
inflamed	O
islets	O
of	O
streptozotocin	O
-	O
treated	O
C57BL	O
/	O
6	O
mice	O
,	O
or	O
in	O
inflamed	O
NOD	O
salivary	O
glands	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
that	O
a	O
public	O
T	O
cell	O
repertoire	O
is	O
used	O
in	O
spontaneous	O
autoimmunity	O
to	O
a	O
dominant	O
self	O
-	O
determinant	O
.	O

These	O
findings	O
suggest	O
that	O
defined	O
clonotypes	O
and	O
repertoires	O
may	O
be	O
preferentially	O
selected	O
in	O
haplotypes	O
predisposed	O
to	O
spontaneous	O
autoimmunity	O
.	O

Degradation	O
of	O
the	O
Alzheimer	O
disease	O
amyloid	B
beta	I
-	I
peptide	I
by	O
metal	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
metalloprotease	B
activity	O
.	O

Biometals	O
play	O
an	O
important	O
role	O
in	O
Alzheimer	O
disease	O
,	O
and	O
recent	O
reports	O
have	O
described	O
the	O
development	O
of	O
potential	O
therapeutic	O
agents	O
based	O
on	O
modulation	O
of	O
metal	O
bioavailability	O
.	O

The	O
metal	O
ligand	O
clioquinol	O
(	O
CQ	O
)	O
has	O
shown	O
promising	O
results	O
in	O
animal	O
models	O
and	O
small	O
phase	O
clinical	O
trials	O
;	O
however	O
,	O
the	O
actual	O
mode	O
of	O
action	O
in	O
vivo	O
has	O
not	O
been	O
determined	O
.	O

We	O
now	O
report	O
a	O
novel	O
effect	O
of	O
CQ	O
on	O
amyloid	B
beta	I
-	I
peptide	I
(	O
Abeta	B
)	O
metabolism	O
in	O
cell	O
culture	O
.	O

Treatment	O
of	O
Chinese	O
hamster	O
ovary	O
cells	O
overexpressing	O
amyloid	B
precursor	I
protein	I
with	O
CQ	O
and	O
Cu	O
(	O
2	O
+	O
)	O
or	O
Zn	O
(	O
2	O
+	O
)	O
resulted	O
in	O
an	O
approximately	O
85	O
-	O
90	O
%	O
reduction	O
of	O
secreted	O
Abeta	B
-	O
(	O
1	O
-	O
40	O
)	O
and	O
Abeta	B
-	O
(	O
1	O
-	O
42	O
)	O
compared	O
with	O
untreated	O
controls	O
.	O

Analogous	O
effects	O
were	O
seen	O
in	O
amyloid	B
precursor	I
protein	I
-	O
overexpressing	O
neuroblastoma	O
cells	O
.	O

The	O
secreted	O
Abeta	B
was	O
rapidly	O
degraded	O
through	O
up	O
-	O
regulation	O
of	O
matrix	B
metalloprotease	I
(	I
MMP	I
)	I
-	I
2	I
and	O
MMP-3	B
after	O
addition	O
of	O
CQ	O
and	O
Cu	O
(	O
2	O
+	O
)	O
.	O

MMP	B
activity	O
was	O
increased	O
through	O
activation	O
of	O
phosphoinositol	B
3-kinase	I
and	O
JNK	B
.	O

CQ	O
and	O
Cu	O
(	O
2	O
+	O
)	O
also	O
promoted	O
phosphorylation	O
of	O
glycogen	B
synthase	I
kinase	I
-	I
3	I
,	O
and	O
this	O
potentiated	O
activation	O
of	O
JNK	B
and	O
loss	O
of	O
Abeta	B
-	O
(	O
1	O
-	O
40	O
)	O
.	O

Our	O
findings	O
identify	O
an	O
alternative	O
mechanism	O
of	O
action	O
for	O
CQ	O
in	O
the	O
reduction	O
of	O
Abeta	B
deposition	O
in	O
the	O
brains	O
of	O
CQ	O
-	O
treated	O
animals	O
and	O
potentially	O
in	O
Alzheimer	O
disease	O
patients	O
.	O

Distribution	O
of	O
killer	B
-	I
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
in	O
Comoros	O
and	O
Southeast	O
France	O
.	O

Killer	B
-	I
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
expressed	O
by	O
natural	O
killer	O
cells	O
are	O
cell	O
surface	O
molecules	O
able	O
to	O
recognize	O
groups	O
of	O
HLA	B
class	I
I	I
alleles	O
.	O

The	O
number	O
and	O
distribution	O
of	O
KIR	B
genes	O
vary	O
among	O
individuals	O
and	O
populations	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
analyse	O
the	O
KIR	B
gene	O
content	O
in	O
a	O
Comorian	O
population	O
in	O
order	O
to	O
investigate	O
genetic	O
relationships	O
with	O
other	O
populations	O
and	O
to	O
reconstruct	O
past	O
migration	O
events	O
.	O

The	O
Comorian	O
population	O
consisted	O
of	O
54	O
unrelated	O
immigrants	O
living	O
in	O
France	O
and	O
a	O
control	O
population	O
consisted	O
of	O
38	O
individuals	O
from	O
Southeast	O
France	O
.	O

We	O
investigated	O
the	O
presence	O
or	O
absence	O
of	O
15	O
KIR	B
genes	O
,	O
two	O
pseudogenes	O
expressed	O
and	O
non	O
-	O
expressed	O
forms	O
of	O
KIR2DL5	B
and	O
the	O
two	O
major	O
subtype	O
full	O
-	O
length	O
and	O
deleted	O
forms	O
of	O
KIR2DS4	B
.	O

All	O
individuals	O
were	O
typed	O
positive	O
for	O
the	O
framework	O
genes	O
,	O
i.e.	O
KIR2DL4	B
,	O
KIR3DL2	B
and	O
KIR3DL3	B
,	O
and	O
the	O
two	O
pseudogenes	O
KIR3DP1	B
and	O
KIR2DP1	B
.	O

The	O
frequencies	O
of	O
full	O
-	O
length	O
KIR2DS4	B
(	O
*	O
00101	O
/	O
00102	O
/	O
002	O
)	O
were	O
lower	O
in	O
the	O
French	O
population	O
(	O
F	O
=	O
29	O
%	O
)	O
than	O
in	O
the	O
Comorian	O
population	O
(	O
F	O
=	O
72	O
%	O
)	O
(	O
P	O
(	O
c	O
)	O
<	O
0.05	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
for	O
other	O
KIR	B
genes	O
.	O

A	O
total	O
of	O
11	O
genotypes	O
were	O
identified	O
in	O
the	O
Southeast	O
French	O
population	O
and	O
22	O
genotypes	O
in	O
the	O
Comorian	O
population	O
.	O

The	O
most	O
common	O
genotype	O
(	O
2DL1	B
,	O
2DL3	B
,	O
2DL4	B
,	O
3DL1	B
,	O
3DL2	B
,	O
3DL3	B
and	O
2DS4	B
)	O
accounted	O
for	O
41	O
%	O
in	O
the	O
Comorian	O
population	O
and	O
34	O
%	O
in	O
the	O
Southeast	O
French	O
population	O
.	O

Principal	O
component	O
analysis	O
using	O
KIR	B
gene	O
data	O
from	O
20	O
populations	O
was	O
performed	O
to	O
determine	O
genetic	O
differences	O
and	O
relations	O
between	O
populations	O
.	O

The	O
Comorian	O
population	O
exhibited	O
closest	O
kinship	O
with	O
Africans	O
and	O
Asians	O
.	O

As	O
KIR	B
gene	O
content	O
is	O
heterogeneous	O
among	O
ethnic	O
groups	O
,	O
it	O
can	O
probably	O
be	O
used	O
to	O
assess	O
the	O
genetic	O
relationships	O
among	O
populations	O
from	O
different	O
geographic	O
areas	O
.	O

Avian	O
and	O
canine	O
aldehyde	B
oxidases	I
.	O

Novel	O
insights	O
into	O
the	O
biology	O
and	O
evolution	O
of	O
molybdo	B
-	I
flavoenzymes	I
.	O

Aldehyde	B
oxidases	I
are	O
molybdo	B
-	I
flavoenzymes	I
structurally	O
related	O
to	O
xanthine	B
oxidoreductase	I
.	O

They	O
catalyze	O
the	O
oxidation	O
of	O
aldehydes	O
or	O
N	O
-	O
heterocycles	O
of	O
physiological	O
,	O
pharmacological	O
,	O
and	O
toxicological	O
relevance	O
.	O

Rodents	O
are	O
characterized	O
by	O
four	O
aldehyde	B
oxidases	I
as	O
follows	O
:	O
AOX1	B
and	O
aldehyde	B
oxidase	I
homologs	I
1	I
-	I
3	I
(	O
AOH1	B
,	O
AOH2	B
,	O
and	O
AOH3	B
)	O
.	O

Humans	O
synthesize	O
a	O
single	O
functional	O
aldehyde	B
oxidase	I
,	O
AOX1	B
.	O

Here	O
we	O
define	O
the	O
structure	O
and	O
the	O
characteristics	O
of	O
the	O
aldehyde	B
oxidase	I
genes	O
and	O
proteins	O
in	O
chicken	O
and	O
dog	O
.	O

The	O
avian	O
genome	O
contains	O
two	O
aldehyde	B
oxidase	I
genes	O
,	O
AOX1	B
and	O
AOH	B
,	O
mapping	O
to	O
chromosome	O
7	O
.	O

AOX1	B
and	O
AOH	B
are	O
structurally	O
very	O
similar	O
and	O
code	O
for	O
proteins	O
whose	O
sequence	O
was	O
deduced	O
from	O
the	O
corresponding	O
cDNAs	O
.	O

AOX1	B
is	O
the	O
ortholog	O
of	O
the	O
same	O
gene	O
in	O
mammals	O
,	O
whereas	O
AOH	B
represents	O
the	O
likely	O
ancestor	O
of	O
rodent	O
AOH1	B
,	O
AOH2	B
,	O
and	O
AOH3	B
.	O

The	O
dog	O
genome	O
is	O
endowed	O
with	O
two	O
structurally	O
conserved	O
and	O
active	O
aldehyde	B
oxidases	I
clustering	O
on	O
chromosome	O
37	O
.	O

Cloning	O
of	O
the	O
corresponding	O
cDNAs	O
and	O
tissue	O
distribution	O
studies	O
demonstrate	O
that	O
they	O
are	O
the	O
orthologs	O
of	O
rodent	O
AOH2	B
and	O
AOH3	B
.	O

The	O
vestiges	O
of	O
dog	O
AOX1	B
and	O
AOH1	B
are	O
recognizable	O
upstream	O
of	O
AOH2	B
and	O
AOH3	B
on	O
the	O
same	O
chromosome	O
.	O

Comparison	O
of	O
the	O
complement	O
and	O
the	O
structure	O
of	O
the	O
aldehyde	B
oxidase	I
and	O
xanthine	B
oxidoreductase	I
genes	O
in	O
vertebrates	O
and	O
other	O
animal	O
species	O
indicates	O
that	O
they	O
evolved	O
through	O
a	O
series	O
of	O
duplication	O
and	O
inactivation	O
events	O
.	O

Purification	O
of	O
the	O
chicken	O
AOX1	B
protein	O
to	O
homogeneity	O
from	O
kidney	O
demonstrates	O
that	O
the	O
enzyme	O
possesses	O
retinaldehyde	O
oxidase	B
activity	O
.	O

Unlike	O
humans	O
and	O
most	O
other	O
mammals	O
,	O
dog	O
and	O
chicken	O
are	O
devoid	O
of	O
liver	O
aldehyde	B
oxidase	I
activity	O
.	O

Phosphorylation	O
of	O
the	O
spinach	O
chloroplast	O
24	B
kDa	I
RNA	I
-	I
binding	I
protein	I
(	O
24RNP	B
)	O
increases	O
its	O
binding	O
to	O
petD	B
and	O
psbA	B
3	O
'	O
untranslated	O
regions	O
.	O

The	O
chloroplast	O
24	B
kDa	I
RNA	I
binding	I
protein	I
(	O
24RNP	B
)	O
from	O
Spinacea	O
oleracea	O
is	O
a	O
nuclear	O
encoded	O
protein	O
that	O
binds	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3'UTR	O
)	O
of	O
some	O
chloroplast	O
mRNAs	O
and	O
seems	O
to	O
be	O
involved	O
in	O
some	O
processes	O
of	O
mRNA	O
metabolism	O
,	O
such	O
as	O
3'UTR	O
processing	O
,	O
maturation	O
and	O
stabilization	O
.	O

The	O
24RNP	B
is	O
similar	O
to	O
the	O
28RNP	B
which	O
is	O
involved	O
in	O
the	O
correct	O
maturation	O
of	O
petD	B
and	O
psbA	B
3	O
'	O
UTRs	O
,	O
and	O
when	O
phosphorylated	O
,	O
decreases	O
its	O
binding	O
affinity	O
for	O
RNA	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
determined	O
that	O
the	O
recombinant	O
24RNP	B
was	O
phosphorylated	O
in	O
vitro	O
either	O
by	O
an	O
animal	O
protein	B
kinase	I
C	I
,	O
a	O
plant	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
protein	B
kinase	I
,	O
or	O
a	O
chloroplastic	O
kinase	B
activity	O
present	O
in	O
a	O
protein	O
extract	O
with	O
3'-end	O
processing	O
activity	O
in	O
which	O
the	O
24RNP	B
is	O
also	O
present	O
.	O

Phosphorylation	O
of	O
24RNP	B
increased	O
the	O
binding	O
capacity	O
(	O
B	O
(	O
max	O
)	O
)	O
0.25	O
time	O
for	O
petD	B
3'UTR	O
,	O
and	O
three	O
times	O
for	O
psbA	B
3	O
'	O
UTR	O
;	O
the	O
affinity	O
for	O
P	O
-	O
24RNP	B
only	O
increased	O
when	O
the	O
interaction	O
with	O
petD	B
was	O
tested	O
.	O

Competition	O
experiments	O
suggested	O
that	O
B	O
(	O
max	O
)	O
,	O
not	O
K	O
(	O
d	O
)	O
,	O
might	O
be	O
a	O
more	O
important	O
factor	O
in	O
the	O
P	O
-	O
24RNP	B
-	O
3	O
'	O
UTR	O
interaction	O
.	O

The	O
data	O
suggested	O
that	O
the	O
24RNP	B
role	O
in	O
chloroplast	O
mRNA	O
metabolism	O
may	O
be	O
regulated	O
in	O
vivo	O
by	O
changes	O
in	O
its	O
phosphorylation	O
status	O
carried	O
out	O
by	O
a	O
chloroplastic	O
kinase	B
.	O

Proteasome	O
-	O
mediated	O
proteolysis	O
of	O
the	O
interleukin-10	B
receptor	I
is	O
important	O
for	O
signal	O
downregulation	O
.	O

The	O
cytokine	B
interleukin-10	B
(	O
IL-10	B
)	O
is	O
an	O
important	O
regulator	O
of	O
immune	O
cell	O
function	O
,	O
proliferation	O
,	O
and	O
survival	O
.	O

The	O
IL-10	B
receptor	I
(	O
IL-10R	B
)	O
consists	O
of	O
two	O
subunits	O
,	O
IL-10R1	B
and	O
IL-10R2	B
,	O
both	O
belonging	O
to	O
the	O
class	B
II	I
cytokine	I
receptor	I
superfamily	I
.	O

Like	O
other	O
members	O
of	O
the	O
cytokine	B
receptor	I
superfamily	I
,	O
IL-10R	B
stimulation	O
leads	O
to	O
activation	O
of	O
Jak	B
family	I
kinases	I
and	O
Stat	B
transcription	I
factors	I
.	O

To	O
identify	O
additional	O
signal	O
transduction	O
pathways	O
used	O
by	O
the	O
IL-10R	B
,	O
we	O
purified	O
92	O
-	O
kDa	O
and	O
100	O
-	O
kDa	O
proteins	O
that	O
coprecipitated	O
with	O
IL-10R1	B
from	O
IL-10	B
-	O
stimulated	O
cells	O
.	O

Both	O
proteins	O
were	O
found	O
to	O
be	O
related	O
to	O
the	O
97	O
-	O
kDa	O
subunit	O
of	O
the	O
regulatory	O
component	O
of	O
the	O
26S	O
proteasome	O
.	O

Subsequent	O
studies	O
confirmed	O
that	O
the	O
IL-10R1	B
undergoes	O
ligand	O
-	O
dependent	O
internalization	O
and	O
proteasome	O
-	O
mediated	O
degradation	O
.	O

An	O
IL-10R1	B
cytoplasmic	O
domain	O
mutant	O
deficient	O
for	O
internalization	O
exhibited	O
prolonged	O
signaling	O
through	O
Jak1	B
and	O
Stat3	B
,	O
reinforcing	O
the	O
importance	O
of	O
receptor	O
internalization	O
for	O
signal	O
termination	O
.	O

An	O
approach	O
to	O
analyze	O
mechanisms	O
of	O
intestinal	O
adaptation	O
following	O
total	O
proctocolectomy	O
.	O

We	O
hypothesized	O
that	O
epithelial	O
cells	O
of	O
the	O
remnant	O
small	O
intestine	O
display	O
""""	O
colonic	O
""""	O
phenotype	O
after	O
total	O
proctocolectomy	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
identify	O
preferentially	O
expressed	O
molecules	O
in	O
the	O
colon	O
or	O
in	O
the	O
small	O
intestine	O
and	O
to	O
evaluate	O
mRNA	O
levels	O
of	O
those	O
in	O
the	O
ileal	O
pouch	O
.	O

Differential	O
gene	O
expression	O
was	O
investigated	O
between	O
the	O
small	O
intestine	O
and	O
the	O
colon	O
by	O
using	O
cDNA	O
microarray	O
and	O
was	O
confirmed	O
by	O
Northern	O
blotting	O
.	O

Expression	O
of	O
three	O
colonic	O
mRNAs	O
(	O
3-hydroxy-3-methylglutaryl	B
-	I
coenzyme	I
A	I
synthase	I
2	I
,	O
deleted	B
malignant	I
brain	I
tumors	I
1	I
,	O
carcinoembryonic	B
antigen	I
-	I
related	I
cell	I
adhesion	I
molecule	I
1	I
)	O
and	O
one	O
""""	O
small	O
intestinal	O
""""	O
(	O
microsomal	B
triglyceride	I
transfer	I
protein	I
)	O
mRNA	O
were	O
compared	O
between	O
the	O
control	O
and	O
the	O
ileal	O
pouch	O
mucosae	O
by	O
quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
.	O

Seventy	O
-	O
four	O
clones	O
were	O
differentially	O
expressed	O
with	O
more	O
than	O
a	O
threefold	O
difference	O
.	O

Differential	O
expression	O
was	O
confirmed	O
in	O
all	O
mRNAs	O
examined	O
,	O
including	O
3-hydroxy-3-methylglutaryl	B
-	I
coenzyme	I
A	I
synthase	I
2	I
and	O
microsomal	B
triglyceride	I
transfer	I
protein	I
.	O

The	O
mucosal	O
expression	O
of	O
carcinoembryonic	B
antigen	I
-	I
related	I
cell	I
adhesion	I
molecule	I
1	I
mRNA	O
in	O
the	O
ileal	O
pouch	O
was	O
enhanced	O
in	O
humans	O
.	O

The	O
remnant	O
ileum	O
develops	O
some	O
,	O
but	O
not	O
all	O
,	O
colonic	O
phenotype	O
after	O
total	O
proctocolectomy	O
.	O

Comparative	O
study	O
of	O
epithelial	O
gene	O
expression	O
between	O
the	O
small	O
intestine	O
and	O
the	O
colon	O
enables	O
us	O
to	O
analyze	O
mechanisms	O
of	O
intestinal	O
adaptation	O
after	O
total	O
proctocolectomy	O
.	O

L	O
-	O
arginine	O
chlorination	O
results	O
in	O
the	O
formation	O
of	O
a	O
nonselective	O
nitric	B
-	I
oxide	I
synthase	I
inhibitor	O
.	O

Reduced	O
nitric	O
oxide	O
(	O
NO	O
)	O
bioavailability	O
and	O
impaired	O
vascular	O
function	O
are	O
the	O
key	O
pathological	O
characteristics	O
of	O
inflammatory	O
diseases	O
such	O
as	O
atherosclerosis	O
.	O

We	O
have	O
recently	O
found	O
that	O
leukocyte	O
-	O
derived	O
hypochlorous	O
acid	O
is	O
able	O
to	O
react	O
with	O
the	O
nitric	B
-	I
oxide	I
synthase	I
(	O
NOS	B
)	O
substrate	O
L	O
-	O
arginine	O
to	O
produce	O
chlorinated	O
L	O
-	O
arginine	O
(	O
cl	O
-	O
L	O
-	O
Arg	O
)	O
.	O

Interestingly	O
,	O
cl	O
-	O
L	O
-	O
Arg	O
potently	O
inhibits	O
the	O
formation	O
of	O
NO	O
metabolites	O
in	O
cultured	O
endothelial	O
cells	O
.	O

It	O
is	O
unknown	O
whether	O
cl	O
-	O
L	O
-	O
Arg	O
has	O
a	O
direct	O
inhibitory	O
effect	O
on	O
endothelial	B
NOS	I
(	O
eNOS	B
)	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
cl	O
-	O
L	O
-	O
Arg	O
on	O
the	O
other	O
NOS	B
isoforms	O
,	O
neuronal	B
NOS	I
(	O
nNOS	B
)	O
and	O
inducible	B
NOS	I
(	O
iNOS	B
)	O
,	O
is	O
also	O
unknown	O
.	O

Therefore	O
,	O
we	O
designed	O
the	O
current	O
study	O
to	O
test	O
the	O
effects	O
of	O
cl	O
-	O
L	O
-	O
Arg	O
on	O
eNOS	B
,	O
nNOS	B
,	O
and	O
iNOS	B
.	O

Using	O
recombinant	O
NOS	B
,	O
we	O
found	O
that	O
cl	O
-	O
L	O
-	O
Arg	O
had	O
a	O
direct	O
inhibitory	O
effect	O
on	O
the	O
activity	O
of	O
NOS	B
.	O

The	O
effect	O
of	O
cl	O
-	O
L	O
-	O
Arg	O
on	O
NOS	B
activity	O
is	O
nonselective	O
,	O
as	O
all	O
three	O
NOS	B
isoforms	O
were	O
inhibited	O
with	O
a	O
similar	O
IC	O
(	O
50	O
)	O
.	O

We	O
further	O
determined	O
the	O
effect	O
of	O
cl	O
-	O
L	O
-	O
Arg	O
on	O
the	O
three	O
NOS	B
isoforms	O
at	O
the	O
tissue	O
level	O
.	O

The	O
results	O
demonstrated	O
that	O
cl	O
-	O
L	O
-	O
Arg	O
potently	O
inhibited	O
all	O
three	O
NOS	B
isoform	O
-	O
mediated	O
vessel	O
reactivities	O
,	O
as	O
well	O
as	O
the	O
NOS	B
signaling	O
molecule	O
cGMP	O
.	O

Cl	O
-	O
L	O
-	O
Arg	O
might	O
serve	O
as	O
a	O
novel	O
endogenous	O
NOS	B
inhibitor	O
and	O
an	O
important	O
mediator	O
for	O
vascular	O
dysfunction	O
under	O
inflammatory	O
conditions	O
such	O
as	O
atherosclerosis	O
.	O

Blocking	O
cl	O
-	O
L	O
-	O
Arg	O
formation	O
may	O
be	O
a	O
new	O
therapeutic	O
approach	O
to	O
cardiovascular	O
diseases	O
.	O

TNFalpha	B
induces	O
chromosomal	O
abnormalities	O
independent	O
of	O
ROS	O
through	O
IKK	B
,	O
JNK	B
,	O
p38	B
and	O
caspase	B
pathways	O
.	O

A	O
role	O
for	O
pro	O
-	O
inflammatory	O
cytokines	B
in	O
inflammation	O
-	O
related	O
cancers	O
has	O
been	O
suggested	O
,	O
but	O
mechanisms	O
are	O
not	O
defined	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
treatment	O
of	O
HeLa	O
cells	O
with	O
TNFalpha	B
increases	O
chromosomal	O
aberration	O
.	O

In	O
contrast	O
,	O
IL-1beta	B
did	O
not	O
increase	O
,	O
but	O
rather	O
decreased	O
chromosomal	O
aberration	O
.	O

TNFalpha	B
and	O
IL-1beta	B
increased	O
the	O
production	O
of	O
H2O2	O
to	O
similar	O
levels	O
in	O
cells	O
,	O
suggesting	O
that	O
increased	O
production	O
of	O
reactive	O
oxygen	O
species	O
might	O
not	O
be	O
the	O
premier	O
factor	O
involved	O
.	O

Reducing	O
H2O2	O
through	O
overexpression	O
of	O
catalase	B
or	O
treatment	O
of	O
cells	O
with	O
NAC	O
or	O
BHA	O
did	O
not	O
have	O
an	O
effect	O
on	O
TNF	B
-	O
induced	O
chromosomal	O
aberration	O
.	O

TNFalpha	B
-	O
induced	O
NO	O
production	O
has	O
been	O
implicated	O
in	O
DNA	O
damage	O
.	O

Inhibiting	O
NO	O
did	O
not	O
reduce	O
TNF	B
-	O
induced	O
chromosomal	O
aberration	O
.	O

Inhibiting	O
IKK	B
,	O
JNK	B
,	O
and	O
p38	B
kinase	I
as	O
well	O
as	O
caspases	O
decreased	O
TNF	B
-	O
induced	O
chromosomal	O
aberration	O
,	O
and	O
a	O
correlation	O
between	O
TNF	B
-	O
induced	O
apoptosis	O
and	O
CA	O
generation	O
was	O
not	O
found	O
.	O

Single	O
-	O
strand	O
DNA	O
breaks	O
give	O
rise	O
to	O
double	O
-	O
strand	O
breaks	O
,	O
which	O
then	O
results	O
in	O
chromosomal	O
breaks	O
,	O
when	O
replication	O
forks	O
reach	O
the	O
single	O
-	O
strand	O
breaks	O
during	O
S	O
-	O
phase	O
.	O

In	O
cells	O
progressing	O
through	O
S	O
-	O
phase	O
,	O
TNFalpha	B
activation	O
of	O
IKK	B
,	O
JNK	B
,	O
and	O
p38	B
is	O
significantly	O
reduced	O
.	O

However	O
,	O
these	O
kinases	B
were	O
activated	O
by	O
IL-1beta	B
in	O
S	O
-	O
phase	O
.	O

The	O
possibility	O
that	O
these	O
pathways	O
,	O
in	O
a	O
TNF	B
-	O
specific	O
manner	O
,	O
may	O
regulate	O
either	O
the	O
generation	O
of	O
single	O
-	O
and	O
double	O
-	O
strand	O
breaks	O
or	O
their	O
repair	O
,	O
thereby	O
resulting	O
in	O
increased	O
chromosomal	O
aberration	O
,	O
is	O
discussed	O
.	O

Engineering	O
human	O
IL-18	B
with	O
increased	O
bioactivity	O
and	O
bioavailability	O
.	O

Cytokines	B
in	O
plasmid	O
form	O
can	O
act	O
as	O
potent	O
adjuvants	O
when	O
co	O
-	O
administered	O
with	O
DNA	O
vaccines	O
,	O
resulting	O
in	O
an	O
enhanced	O
immune	O
response	O
to	O
the	O
DNA	O
-	O
encoded	O
antigen	O
.	O

This	O
is	O
true	O
of	O
interleukin-18	B
(	O
IL-18	B
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
serve	O
as	O
an	O
adjuvant	O
in	O
conjunction	O
with	O
certain	O
DNA	O
vaccines	O
.	O

To	O
determine	O
if	O
the	O
properties	O
of	O
IL-18	B
could	O
be	O
optimized	O
for	O
use	O
as	O
a	O
DNA	O
vaccine	O
adjuvant	O
,	O
a	O
model	O
of	O
IL-18	B
/	O
IL-18R	B
binding	O
was	O
developed	O
to	O
identify	O
variants	O
of	O
human	O
IL-18	B
that	O
were	O
predicted	O
to	O
improve	O
receptor	O
interactions	O
and	O
potentially	O
bioactivity	O
.	O

The	O
linkage	O
of	O
mature	O
IL-18	B
to	O
a	O
secretion	O
signal	O
sequence	O
provided	O
improved	O
protein	O
expression	O
from	O
mammalian	O
cells	O
and	O
signal	B
peptidase	I
cleavage	O
of	O
this	O
protein	O
produced	O
the	O
authentic	O
N	O
-	O
terminus	O
.	O

The	O
IL-18	B
variant	O
proteins	O
secreted	O
this	O
way	O
were	O
bioactive	O
,	O
as	O
demonstrated	O
by	O
their	O
ability	O
to	O
induce	O
interferon	B
gamma	I
(	O
IFNgamma	B
)	O
expression	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
to	O
bind	O
to	O
IL-18R	B
,	O
as	O
demonstrated	O
by	O
BIAcore	O
analysis	O
.	O

The	O
IL-18	B
variants	O
were	O
inhibited	O
by	O
IL-18	B
binding	I
protein	I
(	O
IL-18BP	B
)	O
,	O
the	O
soluble	O
inhibitor	O
of	O
IL-18	B
,	O
as	O
measured	O
by	O
neutralization	O
of	O
the	O
IFNgamma	B
response	O
in	O
PBMCs	O
.	O

One	O
variant	O
,	O
V11I	O
/	O
T63A	O
,	O
demonstrated	O
increases	O
both	O
in	O
bioactivity	O
and	O
mammalian	O
cell	O
expression	O
as	O
compared	O
to	O
native	O
IL-18	B
,	O
indicating	O
that	O
this	O
molecule	O
may	O
be	O
particularly	O
well	O
suited	O
for	O
use	O
as	O
a	O
DNA	O
-	O
encoded	O
vaccine	O
adjuvant	O
.	O

The	O
role	O
of	O
the	O
STAS	O
domain	O
in	O
the	O
function	O
and	O
biogenesis	O
of	O
a	O
sulfate	B
transporter	I
as	O
probed	O
by	O
random	O
mutagenesis	O
.	O

Sulfate	B
transporters	I
in	O
plants	O
represent	O
a	O
family	O
of	O
proteins	O
containing	O
transmembrane	O
domains	O
that	O
constitute	O
the	O
catalytic	O
part	O
of	O
the	O
protein	O
and	O
a	O
short	O
linking	O
region	O
that	O
joins	O
this	O
catalytic	O
moiety	O
with	O
a	O
C	O
-	O
terminal	O
STAS	O
domain	O
.	O

The	O
STAS	O
domain	O
resembles	O
an	O
anti	B
-	I
sigma	I
factor	I
antagonist	I
of	O
Bacillus	O
subtilis	O
,	O
which	O
is	O
one	O
distinguishing	O
feature	O
of	O
the	O
SLC26	B
transporter	I
family	I
;	O
this	O
family	O
includes	O
transporters	O
for	O
sulfate	O
and	O
other	O
anions	O
such	O
as	O
iodide	O
and	O
carbonate	O
.	O

Recent	O
work	O
has	O
demonstrated	O
that	O
this	O
domain	O
is	O
critical	O
for	O
the	O
activity	O
of	O
Arabidopsis	O
thaliana	O
sulfate	B
transporters	I
,	O
and	O
specific	O
lesions	O
in	O
this	O
domain	O
,	O
or	O
the	O
exchange	O
of	O
STAS	O
domains	O
between	O
different	O
sulfate	B
transporters	I
,	O
can	O
severely	O
impair	O
transport	O
activity	O
.	O

In	O
this	O
work	O
we	O
generated	O
a	O
Saccharomyces	O
cerevisiae	O
expression	O
library	O
of	O
the	O
A.	O
thaliana	O
Sultr1	B
;	I
2	I
gene	O
with	O
random	O
mutations	O
in	O
the	O
linking	O
region	O
-	O
STAS	O
domain	O
and	O
identified	O
STAS	O
domain	O
lesions	O
that	O
altered	O
Sultr1	B
;	I
2	I
biogenesis	O
and/or	O
function	O
.	O

A	O
number	O
of	O
mutations	O
in	O
the	O
beta	O
-	O
sheet	O
that	O
forms	O
the	O
core	O
of	O
the	O
STAS	O
domain	O
prevented	O
intracellular	O
accumulation	O
of	O
Sultr1	B
;	I
2	I
.	O

In	O
contrast	O
,	O
the	O
linking	O
region	O
and	O
one	O
surface	O
of	O
the	O
STAS	O
domain	O
containing	O
N	O
termini	O
of	O
the	O
first	O
and	O
second	O
alpha	O
-	O
helices	O
have	O
a	O
number	O
of	O
amino	O
acids	O
critical	O
for	O
the	O
function	O
of	O
the	O
protein	O
;	O
mutations	O
in	O
these	O
regions	O
still	O
allow	O
protein	O
accumulation	O
in	O
the	O
plasma	O
membrane	O
,	O
but	O
the	O
protein	O
is	O
no	O
longer	O
capable	O
of	O
efficiently	O
transporting	O
sulfate	O
into	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAS	O
domain	O
is	O
critical	O
for	O
both	O
the	O
activity	O
and	O
biosynthesis	O
/	O
stability	O
of	O
the	O
transporter	O
,	O
and	O
that	O
STAS	O
sub	O
-	O
domains	O
correlate	O
with	O
these	O
specific	O
functions	O
.	O

The	O
G490E	O
mutation	O
in	O
reverse	B
transcriptase	I
does	O
not	O
impact	O
tRNA	O
primer	O
selection	O
by	O
HIV-1	O
with	O
altered	O
PBS	O
and	O
A	O
-	O
loop	O
.	O

The	O
initiation	O
of	O
HIV-1	O
reverse	O
transcription	O
utilizes	O
a	O
cellular	O
tRNA	O
(	O
Lys,3	O
)	O
as	O
a	O
primer	O
.	O

The	O
3	O
'	O
terminal	O
18	O
-	O
nucleotides	O
of	O
the	O
cellular	O
tRNA	O
(	O
Lys,3	O
)	O
are	O
complementary	O
to	O
a	O
region	O
on	O
the	O
viral	O
genome	O
,	O
designated	O
as	O
the	O
primer	O
binding	O
site	O
(	O
PBS	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
forcing	O
HIV-1	O
to	O
utilize	O
alternative	O
tRNA	O
primers	O
through	O
alteration	O
of	O
the	O
PBS	O
results	O
in	O
viruses	O
that	O
revert	O
to	O
utilize	O
tRNA	O
(	O
Lys,3	O
)	O
following	O
in	O
vitro	O
replication	O
.	O

In	O
some	O
instances	O
though	O
,	O
HIV-1	O
has	O
been	O
shown	O
to	O
select	O
alternative	O
tRNAs	O
for	O
initiation	O
of	O
reverse	O
transcription	O
if	O
additional	O
mutations	O
upstream	O
in	O
the	O
U5	O
region	O
(	O
A	O
-	O
loop	O
)	O
were	O
made	O
to	O
be	O
complementary	O
to	O
these	O
alternative	O
tRNAs	O
.	O

Recently	O
,	O
an	O
HIV-1	O
has	O
been	O
described	O
in	O
which	O
the	O
U5	O
region	O
distinct	O
from	O
the	O
A	O
-	O
loop	O
,	O
designated	O
as	O
the	O
primer	O
activation	O
site	O
(	O
PAS	O
)	O
,	O
was	O
mutated	O
in	O
conjunction	O
with	O
the	O
PBS	O
to	O
force	O
the	O
virus	O
to	O
use	O
tRNA	O
(	O
Lys1,2	O
)	O
as	O
a	O
primer	O
.	O

An	O
additional	O
mutation	O
in	O
reverse	B
transcriptase	I
(	O
RT	B
)	O
,	O
G490E	O
,	O
was	O
found	O
to	O
facilitate	O
the	O
forced	O
use	O
of	O
tRNA	O
(	O
Lys1,2	O
)	O
as	O
the	O
primer	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
have	O
investigated	O
the	O
impact	O
of	O
the	O
G490E	O
mutation	O
in	O
RT	B
on	O
the	O
selection	O
and	O
use	O
of	O
alternative	O
primers	O
by	O
HIV-1	O
.	O

Viruses	O
were	O
first	O
constructed	O
in	O
which	O
the	O
PBS	O
and	O
A	O
-	O
loop	O
region	O
were	O
made	O
complementary	O
to	O
tRNA	O
(	O
Trp	O
)	O
.	O

Previous	O
studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
these	O
viruses	O
are	O
unstable	O
and	O
mutate	O
to	O
select	O
tRNA	O
(	O
Met	O
)	O
or	O
tRNA	O
(	O
Lys1,2	O
)	O
.	O

Analysis	O
of	O
the	O
replication	O
of	O
viruses	O
with	O
the	O
U5	O
and	O
PBS	O
complementary	O
to	O
tRNA	O
(	O
Trp	O
)	O
with	O
or	O
without	O
the	O
G490E	O
mutation	O
revealed	O
no	O
significant	O
differences	O
with	O
respect	O
to	O
infectivity	O
and	O
viral	O
growth	O
in	O
SupT1	O
or	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
the	O
G490E	O
mutation	O
did	O
not	O
influence	O
the	O
capacity	O
of	O
this	O
virus	O
to	O
revert	O
to	O
utilize	O
tRNA	O
(	O
Met	O
)	O
as	O
the	O
primer	O
for	O
initiation	O
of	O
reverse	O
transcription	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
have	O
described	O
an	O
HIV-1	O
that	O
has	O
been	O
forced	O
to	O
utilize	O
tRNA	O
(	O
Lys1,2	O
)	O
through	O
mutations	O
in	O
the	O
A	O
-	O
loop	O
and	O
PBS	O
.	O

The	O
G490E	O
RT	B
mutation	O
in	O
this	O
virus	O
did	O
not	O
impact	O
on	O
the	O
virus	O
infectivity	O
or	O
growth	O
in	O
SupT1	O
or	O
PBMC	O
.	O

We	O
did	O
not	O
find	O
a	O
significant	O
fitness	O
advantage	O
to	O
viruses	O
in	O
which	O
the	O
A	O
-	O
loop	O
and	O
PBS	O
were	O
made	O
complementary	O
to	O
tRNA	O
(	O
Lys1,2	O
)	O
that	O
also	O
contained	O
the	O
G490E	O
mutation	O
in	O
RT	B
.	O

The	O
results	O
of	O
these	O
studies	O
then	O
establish	O
that	O
HIV-1	O
can	O
be	O
forced	O
to	O
use	O
alternative	O
primers	O
through	O
mutations	O
in	O
the	O
U5	O
(	O
PAS	O
or	O
A	O
-	O
loop	O
)	O
for	O
certain	O
tRNAs	O
.	O

Furthermore	O
,	O
for	O
mutations	O
in	O
the	O
A	O
-	O
loop	O
and	O
PBS	O
,	O
the	O
RT	B
does	O
not	O
play	O
an	O
important	O
role	O
in	O
dictating	O
the	O
selection	O
of	O
the	O
alternative	O
primers	O
to	O
be	O
used	O
for	O
initiation	O
of	O
reverse	O
transcription	O
.	O

HIV-1	O
infection	O
:	O
is	O
it	O
time	O
to	O
reconsider	O
our	O
concepts	O
?	O

The	O
long	O
asymptomatic	O
phase	O
of	O
HIV	O
infection	O
is	O
critical	O
in	O
the	O
progression	O
to	O
AIDS	O
.	O

It	O
probably	O
reflects	O
an	O
ancestral	O
relationship	O
with	O
lentiviruses	O
stemming	O
from	O
the	O
primate	O
-	O
simian	O
immunodeficiency	O
virus	O
evolutionary	O
pathway	O
leading	O
to	O
an	O
idiosyncratic	O
immune	O
tolerance	O
,	O
which	O
needs	O
to	O
be	O
understood	O
if	O
effective	O
vaccines	O
are	O
to	O
be	O
rationally	O
designed	O
.	O

The	O
majority	O
of	O
CD4	B
+	O
T	O
cells	O
that	O
die	O
due	O
to	O
HIV-1	O
in	O
the	O
asymptomatic	O
phase	O
are	O
not	O
infected	O
with	O
the	O
virus	O
.	O

Transmission	O
of	O
the	O
predominant	O
HIV-1	O
R5	O
variants	O
to	O
T	O
cells	O
is	O
mediated	O
by	O
infected	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

The	O
two	O
cell	O
populations	O
come	O
into	O
intimate	O
contact	O
mainly	O
in	O
the	O
lymph	O
nodes	O
during	O
antigen	O
presentation	O
where	O
there	O
is	O
also	O
active	O
viral	O
replication	O
.	O

We	O
propose	O
that	O
HIV	O
exploits	O
antigen	O
presentation	O
to	O
access	O
target	O
T	O
cells	O
and	O
evade	O
immune	O
surveillance	O
.	O

This	O
is	O
achieved	O
at	O
the	O
assembly	O
point	O
of	O
an	O
immunological	O
synapse	O
between	O
an	O
antigen	O
presenting	O
,	O
HIV-1	O
-	O
infected	O
macrophage	O
and	O
a	O
responding	O
effector	O
/	O
memory	O
CD4	B
+	O
T	O
cell	O
.	O

Viral	O
envelope	O
gp120	B
glycoproteins	O
proximal	O
to	O
MHC	B
II	I
molecules	O
cross	O
-	O
link	O
with	O
T	O
cell	O
CD4	B
molecules	O
,	O
thus	O
establishing	O
a	O
supra	O
molecular	O
immuno	O
-	O
viral	O
synapse	O
.	O

The	O
interaction	O
results	O
in	O
conformational	O
changes	O
of	O
gp120	B
exposing	O
its	O
V3	O
domain	O
.	O

Ionic	O
interaction	O
of	O
this	O
domain	O
with	O
the	O
synapse	O
-	O
recruited	O
chemokine	B
receptor	I
CCR5	B
dimerizes	O
the	O
receptor	O
triggering	O
intracellular	O
signals	O
that	O
contribute	O
to	O
T	B
cell	I
receptor	I
transactivation	O
pathways	O
and	O
subsequent	O
enhancement	O
of	O
T	O
cell	O
activation	O
.	O

HIV	O
-	O
downregulated	O
MHC	B
II	I
gives	O
weak	O
immune	O
complexes	O
.	O

Disruption	O
of	O
the	O
immuno	O
-	O
viral	O
synapse	O
before	O
completion	O
of	O
cell	O
entry	O
is	O
a	O
frequent	O
outcome	O
condemning	O
the	O
responding	O
T	O
cell	O
to	O
a	O
premature	O
activation	O
-	O
induced	O
T	O
cell	O
death	O
.	O

Information	O
on	O
the	O
assembly	O
,	O
mechanistic	O
and	O
functional	O
interactions	O
at	O
the	O
immuno	O
-	O
viral	O
synapses	O
may	O
well	O
assist	O
in	O
elucidating	O
new	O
strategies	O
to	O
combat	O
HIV	O
infection	O
.	O

A	O
novel	O
gene	O
of	O
beta	B
chain	I
of	I
the	I
IFN	I
-	I
gamma	I
receptor	I
of	O
Huiyang	O
chicken	O
:	O
cloning	O
,	O
distribution	O
,	O
and	O
CD	O
assay	O
.	O

The	O
beta	B
chain	I
of	I
the	I
interferon	I
-	I
gamma	I
receptor	I
(	O
IFNGR-2	B
)	O
plays	O
a	O
critical	O
role	O
in	O
signal	O
transmission	O
to	O
the	O
nucleus	O
by	O
IFN	B
-	I
gamma	I
.	O

Here	O
,	O
we	O
cloned	O
the	O
full	O
-	O
length	O
cDNA	O
of	O
IFNGR-2	B
of	O
Huiyang	O
chicken	O
using	O
RACE	O
.	O

mRNA	O
transcripts	O
of	O
IFNGR-2	B
were	O
detected	O
in	O
peripheral	O
blood	O
leukocytes	O
(	O
PBL	O
)	O
and	O
various	O
organs	O
using	O
Northern	O
blot	O
analysis	O
.	O

The	O
extracellular	O
region	O
of	O
IFNGR-2	B
(	O
IFNGR-2EC	B
)	O
was	O
expressed	O
in	O
Pichia	O
pastoris	O
,	O
and	O
its	O
secondary	O
structure	O
was	O
investigated	O
by	O
circular	O
dichroism	O
(	O
CD	O
)	O
.	O

The	O
Huiyang	O
chicken	O
IFNGR-2	B
gene	O
is	O
2221	O
bp	O
with	O
a	O
polyA	O
+	O
tail	O
,	O
and	O
it	O
encodes	O
334	O
amino	O
acids	O
sharing	O
30	O
%	O
-	O
33	O
%	O
identity	O
with	O
that	O
of	O
rat	O
,	O
mouse	O
,	O
and	O
human	O
IFNGR-2	B
.	O

IFNGR-2	B
is	O
localized	O
on	O
chromosome	O
1	O
of	O
chicken	O
in	O
tandem	O
with	O
IFNAR-1	B
,	O
interleukin	B
-	I
10	I
receptor	I
(	O
IL-10R-2	B
)	O
,	O
and	O
IFNAR-2	B
.	O

IFNGR-2	B
was	O
highly	O
expressed	O
in	O
PBL	O
,	O
muscle	O
,	O
spleen	O
,	O
thymus	O
,	O
and	O
cecal	O
tonsil	O
,	O
whereas	O
its	O
expression	O
in	O
cardiac	O
muscle	O
,	O
cloacal	O
bursa	O
,	O
liver	O
,	O
and	O
kidney	O
was	O
comparatively	O
low	O
.	O

Recombinant	O
protein	O
of	O
IFNGR-2EC	B
expressed	O
in	O
P.	O
pastoris	O
formed	O
the	O
secondary	O
structure	O
including	O
19.8	O
%	O
alpha	O
-	O
helix	O
,	O
29.6	O
%	O
beta	O
-	O
sheet	O
,	O
19.7	O
%	O
turn	O
,	O
and	O
30.9	O
%	O
random	O
.	O

The	O
data	O
show	O
that	O
Huiyang	O
chicken	O
IFNGR-2	B
shares	O
properties	O
of	O
the	O
IFN	B
receptor	I
family	I
in	O
gene	O
structure	O
and	O
distribution	O
in	O
multiple	O
tissues	O
and	O
PBL	O
.	O

CD	O
analysis	O
indicated	O
that	O
the	O
recombinant	O
protein	O
of	O
IFNGR-2EC	B
resembles	O
the	O
known	O
structure	O
of	O
human	O
IFN	B
receptors	I
.	O

Expression	O
of	O
multiple	O
isoforms	O
of	O
the	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
(	I
PK	I
-	I
A	I
)	I
catalytic	I
subunit	I
in	O
the	O
nematode	O
,	O
Caenorhabditis	O
elegans	O
.	O

The	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
(	O
protein	B
kinase	I
A	I
,	O
PK	B
-	I
A	I
)	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
many	O
aspects	O
of	O
eukaryotic	O
cellular	O
activity	O
.	O

In	O
the	O
free	O
-	O
living	O
nematode	O
,	O
Caenorhabditis	O
elegans	O
,	O
two	O
genes	O
encode	O
PK	B
-	I
A	I
-	O
like	O
catalytic	O
subunits	O
.	O

The	O
kin-1	B
gene	O
has	O
the	O
potential	O
to	O
generate	O
,	O
through	O
alternative	O
splicing	O
events	O
,	O
a	O
multiplicity	O
of	O
catalytic	O
subunit	O
isoforms	O
;	O
in	O
contrast	O
,	O
the	O
F47F2.1b	B
gene	O
appears	O
to	O
encode	O
just	O
a	O
single	O
authentic	O
catalytic	O
subunit	O
-	O
like	O
protein	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
occurrence	O
of	O
,	O
and	O
developmental	O
changes	O
in	O
the	O
expression	O
of	O
,	O
polypeptide	O
products	O
of	O
these	O
genes	O
in	O
both	O
C.	O
elegans	O
and	O
the	O
closely	O
related	O
nematode	O
,	O
C.	O
briggsae	O
.	O

Polypeptides	O
derived	O
from	O
the	O
F47F2.1	B
gene	O
and	O
its	O
orthologue	O
were	O
detected	O
in	O
mixed	O
stage	O
populations	O
of	O
C.	O
elegans	O
and	O
C.	O
briggsae	O
,	O
respectively	O
.	O

Likewise	O
,	O
a	O
number	O
of	O
polypeptides	O
arising	O
as	O
a	O
result	O
of	O
alternative	O
splicing	O
of	O
transcripts	O
from	O
kin	B
-	I
1	I
,	O
or	O
its	O
orthologue	O
in	O
C.	O
briggsae	O
,	O
were	O
identified	O
in	O
mixed	O
stage	O
populations	O
of	O
nematodes	O
.	O

These	O
isoforms	O
included	O
polypeptides	O
with	O
N	O
-	O
termini	O
encoded	O
by	O
exons	O
N'1	O
or	O
N'4	O
and	O
C	O
-	O
termini	O
encoded	O
by	O
exons	O
7	O
or	O
N	O
.	O

The	O
expression	O
of	O
isoforms	O
with	O
an	O
N	O
-	O
terminus	O
encoded	O
by	O
the	O
N'1	O
exon	O
is	O
of	O
significance	O
because	O
the	O
amino	O
acid	O
sequence	O
encoded	O
by	O
this	O
exon	O
encompasses	O
an	O
N	O
-	O
myristoylation	O
motif	O
.	O

Isoform	O
abundance	O
appears	O
to	O
be	O
related	O
to	O
developmental	O
stage	O
.	O

Substantial	O
differences	O
in	O
polypeptide	O
expression	O
profiles	O
can	O
be	O
seen	O
in	O
embryonic	O
and	O
adult	O
nematodes	O
.	O

The	O
functional	O
significance	O
of	O
this	O
PK	B
-	I
A	I
catalytic	I
subunit	I
isoform	O
diversity	O
is	O
discussed	O
.	O

Differentiation	O
potential	O
of	O
bone	O
marrow	O
stromal	O
cells	O
to	O
enteric	O
neurons	O
in	O
vitro	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
whether	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
enteric	O
neurons	O
and	O
to	O
produce	O
more	O
nerve	B
growth	I
factor	I
(	O
NGF	B
)	O
and	O
glial	B
cell	I
line	I
-	I
derived	I
neurotrophic	I
factor	I
(	O
GDNF	B
)	O
.	O

METHODS	O
:	O

Bone	O
marrow	O
stromal	O
cells	O
were	O
harvested	O
from	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
and	O
cultured	O
in	O
Dulbecco	O
's	O
modified	O
eagle	O
medium	O
supplemented	O
with	O
20	O
%	O
fetal	O
bovine	O
serum	O
.	O

The	O
BMSC	O
were	O
passaged	O
six	O
times	O
and	O
characterized	O
by	O
flow	O
cytometry	O
.	O

The	O
BMSC	O
were	O
pre	O
-	O
induced	O
by	O
basic	B
fibroblast	I
growth	I
factor	I
(	O
10	O
ng	O
/	O
mL	O
)	O
for	O
24	O
h	O
,	O
then	O
induced	O
with	O
GDNF	B
in	O
fetal	O
gut	O
condition	O
medium	O
(	O
FGCM	O
)	O
for	O
10	O
days	O
.	O

The	O
expressions	O
of	O
neuronal	O
markers	O
neural	B
specific	I
enolase	I
(	O
NSE	B
)	O
,	O
neurofilament	B
(	O
NF	B
)	O
,	O
glial	O
cell	O
marker	O
,	O
glial	B
fibrillary	I
acedic	I
protein	I
(	O
GFAP	B
)	O
,	O
and	O
enteric	O
neuronal	O
marker	O
protein	B
gene	I
product	I
9.5	I
(	O
PGP9.5	B
)	O
,	O
neural	B
nitric	I
oxide	I
synthase	I
(	O
nNOS	B
)	O
,	O
and	O
enteric	O
neural	O
transmitter	O
vasoactive	B
intestinal	I
polypeptide	I
(	O
VIP	B
)	O
were	O
detected	O
by	O
fluorescent	O
immunohistochemistry	O
.	O

Expression	O
levels	O
of	O
GDNF	B
and	O
NGF	B
mRNA	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O

The	O
cultured	O
BMSC	O
were	O
CD90	B
(	O
99.7	O
%	O
)	O
positive	O
and	O
CD45	B
negative	O
on	O
flow	O
cytometry	O
.	O

At	O
day	O
10	O
of	O
induction	O
,	O
58.5	O
+	O
/-	O
10.8	O
%	O
cells	O
adopted	O
neuron	O
-	O
like	O
morphological	O
changes	O
and	O
showed	O
expression	O
of	O
NSE	B
(	O
47.6	O
+	O
/-	O
7.5	O
%	O
)	O
,	O
NF	B
(	O
75.6	O
+	O
/-	O
8.4	O
%	O
)	O
,	O
GFAP	B
(	O
negative	O
)	O
,	O
PGP9.5	B
(	O
57.7	O
+	O
/-	O
6.5	O
%	O
)	O
,	O
nNOS	B
(	O
46.6	O
+	O
/-	O
5.4	O
%	O
)	O
and	O
VIP	B
(	O
72.3	O
+	O
/-	O
6.7	O
%	O
)	O
by	O
immunofluorescence	O
.	O

The	O
BMSC	O
expressed	O
low	O
levels	O
of	O
NGF	B
and	O
GDNF	B
mRNA	O
;	O
however	O
,	O
after	O
induction	O
of	O
GDNF	B
in	O
FGCM	O
,	O
the	O
expression	O
levels	O
of	O
NGF	B
and	O
GDNF	B
mRNA	O
were	O
significantly	O
increased	O
.	O

CONCLUSION	O
:	O

Bone	O
marrow	O
stromal	O
cells	O
have	O
the	O
potential	O
to	O
be	O
induced	O
to	O
differentiate	O
into	O
enteric	O
neurons	O
,	O
express	O
enteric	O
neural	O
transmitters	O
,	O
and	O
produce	O
more	O
NGF	B
and	O
GDNF	B
.	O

Therefore	O
,	O
BMSC	O
could	O
be	O
used	O
as	O
new	O
method	O
to	O
treat	O
gastrointestinal	O
motility	O
disorders	O
associated	O
with	O
enteric	O
neural	O
lesions	O
.	O

Evolutionary	O
history	O
of	O
the	O
Asr	B
gene	I
family	I
.	O

The	O
Asr	B
gene	I
family	I
is	O
widespread	O
in	O
higher	O
plants	O
.	O

Most	O
Asr	B
genes	O
are	O
up	O
-	O
regulated	O
under	O
different	O
environmental	O
stress	O
conditions	O
and	O
during	O
fruit	O
ripening	O
.	O

ASR	B
proteins	O
are	O
localized	O
in	O
the	O
nucleus	O
and	O
their	O
likely	O
function	O
is	O
transcriptional	O
regulation	O
.	O

In	O
cultivated	O
tomato	O
,	O
we	O
identified	O
a	O
novel	O
fourth	O
family	O
member	O
,	O
named	O
Asr4	B
,	O
which	O
maps	O
close	O
to	O
its	O
sibling	O
genes	O
Asr1	B
-	O
Asr2	B
-	O
Asr3	B
and	O
displays	O
an	O
unshared	O
region	O
coding	O
for	O
a	O
domain	O
containing	O
a	O
13	O
-	O
amino	O
acid	O
repeat	O
.	O

In	O
this	O
work	O
we	O
were	O
able	O
to	O
expand	O
our	O
previous	O
analysis	O
for	O
Asr2	B
and	O
investigated	O
the	O
coding	O
regions	O
of	O
the	O
four	O
known	O
Asr	B
paralogous	O
genes	O
in	O
seven	O
tomato	O
species	O
from	O
different	O
geographic	O
locations	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
phylogenetic	O
analysis	O
on	O
ASR	B
proteins	O
.	O

The	O
first	O
conclusion	O
drawn	O
from	O
this	O
work	O
is	O
that	O
tomato	O
ASR	B
proteins	O
cluster	O
together	O
in	O
the	O
tree	O
.	O

This	O
observation	O
can	O
be	O
explained	O
by	O
a	O
scenario	O
of	O
concerted	O
evolution	O
or	O
birth	O
and	O
death	O
of	O
genes	O
.	O

Secondly	O
,	O
our	O
study	O
showed	O
that	O
Asr1	B
is	O
highly	O
conserved	O
at	O
both	O
replacement	O
and	O
synonymous	O
sites	O
within	O
the	O
genus	O
Lycopersicon	O
.	O

ASR1	B
protein	O
sequence	O
conservation	O
might	O
be	O
associated	O
with	O
its	O
multiple	O
functions	O
in	O
different	O
tissues	O
while	O
the	O
low	O
rate	O
of	O
synonymous	O
substitutions	O
suggests	O
that	O
silent	O
variation	O
in	O
Asr1	B
is	O
selectively	O
constrained	O
,	O
which	O
is	O
probably	O
related	O
to	O
its	O
high	O
expression	O
levels	O
.	O

Finally	O
,	O
we	O
found	O
that	O
Asr1	B
activation	O
under	O
water	O
stress	O
is	O
not	O
conserved	O
between	O
Lycopersicon	O
species	O
.	O

The	O
role	O
of	O
Schizosaccharomyces	O
pombe	O
DNA	O
repair	O
enzymes	O
Apn1p	B
and	O
Uve1p	B
in	O
the	O
base	O
excision	O
repair	O
of	O
apurinic	O
/	O
apyrimidinic	O
sites	O
.	O

In	O
Schizosaccharomyces	O
pombe	O
the	O
repair	O
of	O
apurinic	O
/	O
apyrimidinic	O
(	O
AP	O
)	O
sites	O
is	O
mainly	O
initiated	O
by	O
AP	B
lyase	I
activity	O
of	O
DNA	B
glycosylase	I
Nth1p	B
.	O

In	O
contrast	O
,	O
the	O
major	O
AP	B
endonuclease	I
Apn2p	B
functions	O
by	O
removing	O
3'-alpha	O
,	O
beta	O
-	O
unsaturated	O
aldehyde	O
ends	O
induced	O
by	O
Nth1p	B
,	O
rather	O
than	O
by	O
incising	O
the	O
AP	O
sites	O
.	O

S.	O
pombe	O
possesses	O
other	O
minor	O
AP	B
endonuclease	I
activities	O
derived	O
from	O
Apn1p	B
and	O
Uve1p	B
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
function	O
of	O
these	O
two	O
enzymes	O
in	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
for	O
methyl	O
methanesulfonate	O
(	O
MMS	O
)	O
damage	O
using	O
the	O
nth1	B
and	O
apn2	B
mutants	O
.	O

Deletion	O
of	O
apn1	B
or	O
uve1	B
from	O
nth1Delta	B
cells	O
did	O
not	O
affect	O
sensitivity	O
to	O
MMS	O
.	O

Exogenous	O
expression	O
of	O
Apn1p	B
failed	O
to	O
suppress	O
the	O
MMS	O
sensitivity	O
of	O
nth1Delta	B
cells	O
.	O

Although	O
Apn1p	B
and	O
Uve1p	B
incised	O
the	O
oligonucleotide	O
containing	O
an	O
AP	O
site	O
analogue	O
,	O
these	O
enzymes	O
could	O
not	O
initiate	O
repair	O
of	O
the	O
AP	O
sites	O
in	O
vivo	O
.	O

Despite	O
this	O
,	O
expression	O
of	O
Apn1p	B
partially	O
restored	O
the	O
MMS	O
sensitivity	O
of	O
apn2Delta	B
cells	O
,	O
indicating	O
that	O
the	O
enzyme	O
functions	O
as	O
a	O
3'-phosphodiesterase	B
to	O
remove	O
3	O
'	O
-	O
blocked	O
ends	O
.	O

Localization	O
of	O
Apn1p	B
in	O
the	O
nucleus	O
and	O
cytoplasm	O
hints	O
at	O
an	O
additional	O
function	O
of	O
the	O
enzyme	O
other	O
than	O
nuclear	O
DNA	O
repair	O
.	O

Heterologous	O
expression	O
of	O
Saccharomyces	O
cerevisiae	O
homologue	O
of	O
Apn1p	B
completely	O
restored	O
the	O
MMS	O
resistance	O
of	O
the	O
nth1Delta	B
and	O
apn2Delta	B
cells	O
.	O

This	O
result	O
confirms	O
a	O
difference	O
in	O
the	O
major	O
pathway	O
for	O
processing	O
the	O
AP	B
site	O
between	O
S.	O
pombe	O
and	O
S.	O
cerevisiae	O
cells	O
.	O

Increased	O
expression	O
of	O
the	O
natural	O
killer	O
cell	O
inhibitory	O
receptor	O
CD94	B
/	O
NKG2A	B
and	O
CD158b	B
on	O
circulating	O
and	O
lesional	O
T	O
cells	O
in	O
patients	O
with	O
chronic	O
plaque	O
psoriasis	O
.	O

BACKGROUND	O
:	O

Psoriasis	O
is	O
a	O
common	O
inflammatory	O
cutaneous	O
disorder	O
characterized	O
by	O
activated	O
T	O
-	O
cell	O
infiltration	O
.	O

T	O
lymphocytes	O
bearing	O
natural	O
killer	O
cell	O
receptors	O
(	O
NKRs	O
)	O
have	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
psoriasis	O
.	O

However	O
,	O
the	O
expression	O
pattern	O
of	O
activating	O
and	O
inhibitory	O
NKRs	O
on	O
T	O
lymphocytes	O
from	O
psoriatic	O
patients	O
and	O
its	O
significance	O
in	O
psoriasis	O
needs	O
further	O
study	O
.	O

OBJECTIVES	O
:	O

To	O
investigate	O
the	O
pathogenesis	O
of	O
NKR	O
-	O
expressing	O
T	O
cells	O
in	O
psoriasis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

Thirty	O
patients	O
with	O
chronic	O
plaque	O
psoriasis	O
and	O
20	O
healthy	O
controls	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

The	O
immunophenotypic	O
profiles	O
of	O
NKRs	O
,	O
including	O
CD56	B
,	O
CD16	B
(	O
activating	O
NKRs	O
)	O
,	O
CD158a	B
,	O
CD158b	B
,	O
CD94	B
and	O
NKG2A	B
(	O
inhibitory	O
NKRs	O
)	O
,	O
were	O
analysed	O
in	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
as	O
well	O
as	O
psoriatic	O
lesional	O
infiltrating	O
T	O
cells	O
,	O
by	O
triple	O
-	O
fluorescence	O
flow	O
cytometry	O
.	O

RESULTS	O
:	O

A	O
significant	O
increase	O
of	O
inhibitory	O
CD8	B
+	O
CD158b	B
+	O
,	O
CD4	B
CD8	B
CD158b	B
+	O
and	O
CD8	B
+	O
CD94	B
/	O
NKG2A	B
+	O
T	O
cells	O
was	O
found	O
in	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
psoriasis	O
when	O
compared	O
with	O
controls	O
.	O

Tissue	O
-	O
infiltrating	O
T	O
lymphocytes	O
expressing	O
inhibitory	O
receptors	O
CD158b	B
,	O
CD94	B
and	O
NKG2A	B
were	O
found	O
in	O
psoriatic	O
lesions	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
the	O
increased	O
percentage	O
of	O
circulating	O
CD8	B
+	O
CD94	B
/	O
NKG2A	B
+	O
T	O
cells	O
and	O
the	O
Psoriasis	O
Area	O
and	O
Severity	O
Index	O
.	O

CONCLUSIONS	O
:	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
increased	O
proportions	O
of	O
particular	O
subsets	O
of	O
inhibitory	O
CD158b	B
+	O
and/or	O
CD94	B
/	O
NKG2A	B
+	O
T	O
cells	O
in	O
patients	O
with	O
psoriasis	O
.	O

The	O
elevation	O
of	O
these	O
inhibitory	O
NKR	O
-	O
expressing	O
T	O
cells	O
was	O
correlated	O
with	O
disease	O
severity	O
,	O
which	O
may	O
signify	O
the	O
possibility	O
of	O
chronic	O
antigen	O
-	O
driven	O
stimulation	O
and	O
dysregulated	O
cytokine	B
production	O
in	O
the	O
pathogenesis	O
of	O
psoriasis	O
.	O

The	O
influence	O
of	O
kainic	O
acid	O
on	O
core	O
temperature	O
and	O
cytokine	B
levels	O
in	O
the	O
brain	O
.	O

Excitotoxic	O
brain	O
injury	O
is	O
associated	O
with	O
hyperthermia	O
,	O
and	O
there	O
are	O
data	O
showing	O
beneficial	O
effects	O
of	O
hypothermia	O
on	O
neurodegeneration	O
and	O
that	O
hyperthermia	O
facilitates	O
the	O
neurodegeneration	O
.	O

Cytokines	B
are	O
inflammatory	O
proteins	O
that	O
seem	O
to	O
be	O
involved	O
in	O
the	O
neuroinflammation	O
associated	O
with	O
epilepsy	O
.	O

Core	O
temperature	O
changes	O
caused	O
by	O
the	O
epileptogenic	O
glutamate	O
analogue	O
kainic	O
acid	O
(	O
KA	O
)	O
were	O
investigated	O
in	O
relation	O
to	O
changes	O
in	O
levels	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	B
interleukin-1beta	B
(	O
IL-1beta	B
)	O
and	O
interleukin-6	B
(	O
IL-6	B
)	O
,	O
and	O
the	O
endogenous	O
interleukin-1	B
receptor	I
antagonist	I
(	O
IL-1ra	B
)	O
.	O

The	O
temperature	O
was	O
measured	O
every	O
10	O
min	O
during	O
the	O
first	O
hour	O
,	O
and	O
at	O
90	O
and	O
120	O
min	O
,	O
and	O
hourly	O
until	O
8	O
h	O
after	O
KA	O
-	O
injection	O
(	O
10	O
mg	O
/	O
kg	O
)	O
.	O

The	O
cytokines	B
were	O
measured	O
in	O
the	O
hypothalamus	O
,	O
a	O
site	O
of	O
temperature	O
regulation	O
,	O
and	O
in	O
hippocampus	O
,	O
cerebellum	O
,	O
and	O
frontal	O
cortex	O
.	O

KA	O
induced	O
a	O
brief	O
hypothermia	O
followed	O
by	O
hyperthermia	O
.	O

IL-1beta	B
levels	O
were	O
increased	O
after	O
KA	O
-	O
administration	O
in	O
all	O
brain	O
regions	O
examined	O
and	O
,	O
excepting	O
hippocampus	O
,	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
h	O
.	O

The	O
hippocampal	O
IL-1ra	B
levels	O
were	O
significantly	O
increased	O
at	O
24	O
h	O
,	O
whereas	O
no	O
changes	O
in	O
IL-6	B
levels	O
were	O
observed	O
.	O

The	O
changes	O
in	O
IL-1beta	B
levels	O
and	O
in	O
ratios	O
between	O
the	O
levels	O
of	O
the	O
three	O
cytokines	B
,	O
may	O
account	O
for	O
some	O
of	O
the	O
temperature	O
changes	O
and	O
the	O
behavioural	O
manifestations	O
induced	O
by	O
KA	O
.	O

Convergence	O
of	O
genes	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
on	O
the	O
cerebral	O
cholesterol	O
shuttle	O
:	O
APP	B
,	O
cholesterol	O
,	O
lipoproteins	O
,	O
and	O
atherosclerosis	O
.	O

Polymorphic	O
genes	O
associated	O
with	O
Alzheimer	O
's	O
disease	O
(	O
see	O
)	O
delineate	O
a	O
clearly	O
defined	O
pathway	O
related	O
to	O
cerebral	O
and	O
peripheral	O
cholesterol	O
and	O
lipoprotein	O
homoeostasis	O
.	O

They	O
include	O
all	O
of	O
the	O
key	O
components	O
of	O
a	O
glia	O
/	O
neurone	O
cholesterol	O
shuttle	O
including	O
cholesterol	O
binding	O
lipoproteins	O
APOA1	B
,	O
APOA4	B
,	O
APOC1	B
,	O
APOC2	B
,	O
APOC3	B
,	O
APOD	B
,	O
APOE	B
and	O
LPA	B
,	O
cholesterol	O
transporters	O
ABCA1	B
,	O
ABCA2	B
,	O
lipoprotein	B
receptors	I
LDLR	B
,	O
LRP1	B
,	O
LRP8	B
and	O
VLDLR	B
,	O
and	O
the	O
cholesterol	O
metabolising	O
enzymes	O
CYP46A1	B
and	O
CH25H	B
,	O
whose	O
oxysterol	O
products	O
activate	O
the	O
liver	B
X	I
receptor	I
NR1H2	B
and	O
are	O
metabolised	O
to	O
esters	O
by	O
SOAT1	B
.	O

LIPA	B
metabolises	O
cholesterol	O
esters	O
,	O
which	O
are	O
transported	O
by	O
the	O
cholesteryl	B
ester	I
transport	I
protein	I
CETP	B
.	O

The	O
transcription	B
factor	I
SREBF1	B
controls	O
the	O
expression	O
of	O
most	O
enzymes	O
of	O
cholesterol	O
synthesis	O
.	O

APP	B
is	O
involved	O
in	O
this	O
shuttle	O
as	O
it	O
metabolises	O
cholesterol	O
to	O
7-betahydroxycholesterol	O
,	O
a	O
substrate	O
of	O
SOAT1	B
and	O
HSD11B1	B
,	O
binds	O
to	O
APOE	B
and	O
is	O
tethered	O
to	O
LRP1	B
via	O
APPB1	B
,	O
APBB2	B
and	O
APBB3	B
at	O
the	O
cytoplasmic	O
domain	O
and	O
via	O
LRPAP1	B
at	O
the	O
extracellular	O
domain	O
.	O

APP	B
cleavage	O
products	O
are	O
also	O
able	O
to	O
prevent	O
cholesterol	O
binding	O
to	O
APOE	B
.	O

BACE	B
cleaves	O
both	O
APP	B
and	O
LRP1	B
.	O

Gamma	B
-	I
secretase	I
(	O
PSEN1	B
,	O
PSEN2	B
,	O
NCSTN	B
)	O
cleaves	O
LRP1	B
and	O
LRP8	B
as	O
well	O
as	O
APP	B
and	O
their	O
degradation	O
products	O
control	O
transcription	B
factor	I
TFCP2	B
,	O
which	O
regulates	O
thymidylate	B
synthase	I
(	O
TS	B
)	O
and	O
GSK3B	B
expression	O
.	O

GSK3B	B
is	O
known	O
to	O
phosphorylate	O
the	O
microtubule	B
protein	I
tau	I
(	O
MAPT	B
)	O
.	O

Dysfunction	O
of	O
this	O
cascade	O
,	O
carved	O
out	O
by	O
genes	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
,	O
may	O
play	O
a	O
major	O
role	O
in	O
its	O
pathology	O
.	O

Many	O
other	O
genes	O
associated	O
with	O
Alzheimer	O
's	O
disease	O
affect	O
cholesterol	O
or	O
lipoprotein	O
function	O
and/or	O
have	O
also	O
been	O
implicated	O
in	O
atherosclerosis	O
,	O
a	O
feature	O
of	O
Alzheimer	O
's	O
disease	O
,	O
and	O
this	O
duality	O
may	O
well	O
explain	O
the	O
close	O
links	O
between	O
vascular	O
and	O
cerebral	O
pathology	O
in	O
Alzheimer	O
's	O
disease	O
.	O

The	O
definition	O
of	O
many	O
of	O
these	O
genes	O
as	O
risk	O
factors	O
is	O
highly	O
contested	O
.	O

However	O
,	O
when	O
polymorphic	O
susceptibility	O
genes	O
belong	O
to	O
the	O
same	O
signaling	O
pathway	O
,	O
the	O
risk	O
associated	O
with	O
multigenic	O
disease	O
is	O
better	O
related	O
to	O
the	O
integrated	O
effects	O
of	O
multiple	O
polymorphisms	O
of	O
genes	O
within	O
the	O
same	O
pathway	O
than	O
to	O
variants	O
in	O
any	O
single	O
gene	O
[	O
Wu	O
,	O
X.	O
,	O
Gu	O
,	O
J.	O
,	O
Grossman	O
,	O
H.B.	O
,	O
Amos	O
,	O
C.I.	O
,	O
Etzel	O
,	O
C.	O
,	O
Huang	O
,	O
M.	O
,	O
Zhang	O
,	O
Q.	O
,	O
Millikan	O
,	O
R.E.	O
,	O
Lerner	O
,	O
S.	O
,	O
Dinney	O
,	O
C.P.	O
,	O
Spitz	O
,	O
M.R.	O
,	O
2006	O
.	O
Bladder	O
cancer	O
predisposition	O
:	O
a	O
multigenic	O
approach	O
to	O
DNA	O
-	O
repair	O
and	O
cell	O
-	O
cycle	O
-	O
control	O
genes	O
.	O
Am	O
.	O
J.	O
Hum	O
.	O
Genet	O
.	O
78	O
,	O
464	O
-	O
479	O
.	O
]	O
.	O

Thus	O
,	O
the	O
fact	O
that	O
Alzheimer	O
's	O
disease	O
susceptibility	O
genes	O
converge	O
on	O
a	O
clearly	O
defined	O
signaling	O
network	O
has	O
important	O
implications	O
for	O
genetic	O
association	O
studies	O
.	O

IL-18	B
expression	O
in	O
pigs	O
following	O
infection	O
with	O
Mycoplasma	O
hyopneumoniae	O
.	O

Little	O
is	O
known	O
about	O
the	O
detail	O
of	O
the	O
immune	O
response	O
during	O
infection	O
of	O
pigs	O
with	O
Mycoplasma	O
hyopneumoniae	O
(	O
Mhp	O
)	O
.	O

To	O
further	O
understand	O
this	O
important	O
porcine	O
pathogen	O
,	O
we	O
examined	O
the	O
interleukin-18	B
(	O
IL	B
-	I
18	I
)	O
response	O
in	O
experimentally	O
infected	O
piglets	O
.	O

We	O
found	O
that	O
large	O
amounts	O
of	O
IL-18	B
were	O
produced	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluids	O
(	O
BALF	O
)	O
of	O
pigs	O
experimentally	O
infected	O
with	O
Mhp	O
.	O

However	O
,	O
the	O
concentration	O
of	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
in	O
the	O
same	O
BALF	O
was	O
negatively	O
correlated	O
with	O
that	O
of	O
IL-18	B
.	O

The	O
antibody	O
response	O
against	O
Mhp	O
was	O
found	O
to	O
be	O
associated	O
with	O
the	O
IL-18	B
concentration	O
in	O
the	O
BALF	O
.	O

Immunohistochemical	O
staining	O
revealed	O
that	O
both	O
IL-18	B
and	O
IL-18	B
receptor	I
alpha	I
chain	I
(	O
IL-18Ralpha	B
)	O
were	O
present	O
in	O
macrophages	O
and	O
plasma	O
cells	O
in	O
the	O
lungs	O
of	O
Mhp	O
-	O
infected	O
pigs	O
.	O

Lung	O
mononuclear	O
cells	O
isolated	O
from	O
pneumonic	O
lesions	O
secreted	O
IL-18	B
and	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
in	O
vitro	O
,	O
and	O
PGE	O
(	O
2	O
)	O
production	O
was	O
enhanced	O
by	O
stimulation	O
with	O
IL-18	B
.	O

These	O
results	O
indicate	O
that	O
IL-18	B
produced	O
in	O
the	O
pig	O
lung	O
contributes	O
to	O
the	O
development	O
of	O
innate	O
and	O
acquired	O
immune	O
responses	O
against	O
Mhp	O
as	O
a	O
proinflammatory	O
cytokine	B
rather	O
than	O
as	O
an	O
IFN	B
-	I
gamma	I
-	I
inducing	I
factor	I
and	O
may	O
be	O
involved	O
in	O
immunomodulation	O
in	O
pigs	O
.	O

Identification	O
of	O
human	O
hepatic	B
stimulator	I
substance	I
gene	O
promoter	O
and	O
demonstration	O
of	O
dual	O
regulation	O
of	O
AP1	B
/	O
AP4	B
cis	O
-	O
acting	O
element	O
in	O
different	O
cell	O
lines	O
.	O

Human	O
hepatic	B
stimulator	I
substance	I
(	O
hHSS	B
)	O
is	O
a	O
newly	O
identified	O
growth	B
-	I
promoting	I
factor	I
in	O
the	O
liver	O
.	O

HSS	B
is	O
capable	O
of	O
stimulating	O
hepatic	O
regeneration	O
in	O
partial	O
hepatectomized	O
rats	O
,	O
thus	O
,	O
promoting	O
growth	O
of	O
hepatic	O
tumor	O
cells	O
.	O

To	O
understand	O
and	O
elucidate	O
the	O
transcriptional	O
regulation	O
of	O
hHSS	B
gene	O
,	O
the	O
4890bp	O
of	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gene	O
have	O
been	O
isolated	O
and	O
sequenced	O
.	O

The	O
transcriptional	O
start	O
site	O
,	O
located	O
at	O
248nt	O
upstream	O
from	O
the	O
ATG	O
starting	O
codon	O
,	O
was	O
identified	O
by	O
5'-rapid	O
amplification	O
cDNA	O
end	O
(	O
5'-RACE	O
)	O
.	O

The	O
classical	O
promoter	O
sequences	O
,	O
such	O
as	O
TATA	O
box	O
or	O
GAATT	O
were	O
not	O
identified	O
in	O
the	O
promoter	O
region	O
,	O
instead	O
a	O
GC	O
-	O
rich	O
segment	O
was	O
formed	O
(	O
>	O
70	O
%	O
)	O
by	O
expanding	O
to	O
a	O
longer	O
than	O
400bp	O
,	O
and	O
immediately	O
upstream	O
from	O
the	O
ATG	O
start	O
codon	O
.	O

The	O
transient	O
transfection	O
assays	O
,	O
using	O
promoter	O
deletion	O
constructs	O
,	O
showed	O
that	O
hHSS	B
promoter	O
was	O
efficiently	O
capable	O
in	O
driving	O
the	O
reporter	O
expression	O
not	O
only	O
in	O
HepG2	O
cells	O
,	O
but	O
also	O
in	O
Cos7	O
cells	O
.	O

A	O
region	O
spanning	O
nucleotides	O
in	O
the	O
range	O
of	O
-	O
447	O
to	O
-	O
358bp	O
revealed	O
a	O
negative	O
regulation	O
on	O
promoter	O
activity	O
in	O
HepG2	O
cells	O
,	O
but	O
with	O
positive	O
regulation	O
in	O
Cos7	O
and	O
Hela	O
cells	O
.	O

The	O
promoter	O
activity	O
was	O
obviously	O
influenced	O
by	O
AP1	B
/	O
AP4	B
(	O
-	O
375	O
/	O
-	O
369nt	O
)	O
mutation	O
in	O
these	O
three	O
cell	O
lines	O
.	O

EMSAs	O
showed	O
that	O
the	O
site	O
was	O
recognized	O
by	O
AP1	B
in	O
HepG2	O
cell	O
,	O
and	O
only	O
by	O
an	O
AP4	B
protein	O
in	O
Cos7	O
cells	O
.	O

The	O
c	B
-	I
Jun	I
bound	O
to	O
the	O
promoter	O
was	O
further	O
verified	O
by	O
supershift	O
in	O
HepG2	O
cells	O
and	O
human	O
liver	O
tissue	O
.	O

Chromatin	O
immuno	O
-	O
precipitation	O
(	O
ChIP	O
)	O
demonstrated	O
that	O
there	O
was	O
a	O
direct	O
association	O
of	O
c	B
-	I
Jun	I
with	O
hHSS	B
promoter	O
in	O
HepG2	O
cells	O
.	O

The	O
c	B
-	I
Jun	I
strongly	O
suppressed	O
hHSS	B
promoter	O
activity	O
in	O
transient	O
expression	O
analyses	O
in	O
HepG2	O
cells	O
.	O

Mutations	O
in	O
the	O
AP1	B
binding	O
sites	O
rescued	O
suppression	O
caused	O
by	O
c	B
-	I
Jun	I
,	O
suggesting	O
this	O
was	O
a	O
direct	O
regulation	O
of	O
the	O
hHSS	B
promoter	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
significant	O
effect	O
in	O
c	B
-	I
Jun	I
over	O
-	O
expressed	O
Cos7	O
and	O
Hela	O
cells	O
.	O

The	O
tissue	O
-	O
specific	O
function	O
of	O
c	B
-	I
Jun	I
in	O
hHSS	B
promoter	O
activity	O
may	O
in	O
part	O
help	O
explain	O
the	O
differences	O
in	O
biology	O
function	O
of	O
hHSS	B
between	O
liver	O
and	O
non	O
-	O
liver	O
cells	O
.	O

Structure	O
of	O
a	O
human	O
ASF1a	B
-	O
HIRA	B
complex	O
and	O
insights	O
into	O
specificity	O
of	O
histone	B
chaperone	I
complex	I
assembly	O
.	O

Human	O
HIRA	B
,	O
ASF1a	B
,	O
ASF1b	B
and	O
CAF-1	B
are	O
evolutionally	O
conserved	O
histone	B
chaperones	I
that	O
form	O
multiple	O
functionally	O
distinct	O
chromatin	B
-	I
assembly	I
complexes	I
,	O
with	O
roles	O
linked	O
to	O
diverse	O
nuclear	O
process	O
,	O
such	O
as	O
DNA	O
replication	O
and	O
formation	O
of	O
heterochromatin	O
in	O
senescent	O
cells	O
.	O

We	O
report	O
the	O
crystal	O
structure	O
of	O
an	O
ASF1a	B
-	O
HIRA	B
heterodimer	O
and	O
a	O
biochemical	O
dissection	O
of	O
ASF1a	B
's	O
mutually	O
exclusive	O
interactions	O
with	O
HIRA	B
and	O
the	O
p60	B
subunit	I
of	I
CAF-1	I
.	O

The	O
HIRA	B
B	O
domain	O
forms	O
an	O
antiparallel	O
beta	O
-	O
hairpin	O
that	O
binds	O
perpendicular	O
to	O
the	O
strands	O
of	O
the	O
beta	O
-	O
sandwich	O
of	O
ASF1a	B
,	O
via	O
beta	O
-	O
sheet	O
,	O
salt	O
bridge	O
and	O
van	O
der	O
Waals	O
contacts	O
.	O

The	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
of	O
ASF1a	B
and	O
ASF1b	B
determine	O
the	O
different	O
affinities	O
of	O
these	O
two	O
proteins	O
for	O
HIRA	B
,	O
by	O
contacting	O
regions	O
outside	O
the	O
HIRA	B
B	O
domain	O
.	O

CAF-1	B
p60	I
also	O
uses	O
B	O
domain	O
-	O
like	O
motifs	O
for	O
binding	O
to	O
ASF1a	B
,	O
thereby	O
competing	O
with	O
HIRA	B
.	O

Together	O
,	O
these	O
studies	O
begin	O
to	O
define	O
the	O
molecular	O
determinants	O
of	O
assembly	O
of	O
functionally	O
diverse	O
macromolecular	O
histone	B
chaperone	I
complexes	I
.	O

Role	O
of	O
cytokines	B
in	O
inflammatory	O
process	O
in	O
Parkinson	O
's	O
disease	O
.	O

We	O
investigated	O
whether	O
the	O
cytokines	B
produced	O
in	O
activated	O
microglia	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
and	O
putamen	O
in	O
sporadic	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
are	O
neuroprotective	O
or	O
neurotoxic	O
.	O

In	O
autopsy	O
brains	O
of	O
PD	O
,	O
the	O
number	O
of	O
MHC	B
class	I
II	I
(	O
CR3	O
/	O
43	O
)	O
-	O
positive	O
activated	O
microglia	O
,	O
which	O
were	O
also	O
ICAM-1	B
(	O
CD	B
54	I
)	O
-	O
,	O
LFA-1	B
(	O
CD	B
11a	I
)	O
-	O
,	O
TNF	B
-	I
alpha	I
-	O
,	O
and	O
IL-6	B
-	O
positive	O
,	O
increased	O
in	O
the	O
SN	O
and	O
putamen	O
during	O
progress	O
of	O
PD	O
.	O

At	O
the	O
early	O
stage	O
activated	O
microglia	O
were	O
mainly	O
associated	O
with	O
tyrosine	B
hydroxylase	I
(	O
TH	B
)	O
-	O
positive	O
neurites	O
in	O
the	O
putamen	O
,	O
and	O
at	O
the	O
advanced	O
stage	O
with	O
damaged	O
TH	B
-	O
positive	O
neurons	O
in	O
the	O
SN	O
.	O

The	O
activated	O
microglia	O
in	O
PD	O
were	O
observed	O
not	O
only	O
in	O
the	O
nigro	O
-	O
striatal	O
region	O
,	O
but	O
also	O
in	O
various	O
brain	O
regions	O
such	O
as	O
the	O
hippocampus	O
and	O
cerebral	O
cortex	O
.	O

We	O
examined	O
the	O
distribution	O
of	O
activated	O
microglia	O
and	O
the	O
expression	O
of	O
cytokines	B
and	O
neurotrophins	B
in	O
the	O
hippocampus	O
of	O
PD	O
and	O
Lewy	O
body	O
disease	O
(	O
LBD	O
)	O
.	O

The	O
levels	O
of	O
IL-6	B
and	O
TNF	B
-	I
alpha	I
mRNAs	O
increased	O
both	O
in	O
PD	O
and	O
LBD	O
,	O
but	O
those	O
of	O
BDNF	B
mRNA	O
and	O
protein	O
drastically	O
decreased	O
specifically	O
in	O
LBD	O
,	O
in	O
which	O
neuronal	O
loss	O
was	O
observed	O
not	O
only	O
in	O
the	O
nigro	O
-	O
striatum	O
but	O
also	O
in	O
the	O
hippocampus	O
.	O

The	O
results	O
suggest	O
activated	O
microglia	O
in	O
the	O
hippocampus	O
to	O
be	O
probably	O
neuroprotective	O
in	O
PD	O
,	O
but	O
those	O
to	O
be	O
neurotoxic	O
in	O
LBD	O
.	O

As	O
an	O
evidence	O
supporting	O
this	O
hypothesis	O
,	O
two	O
subsets	O
of	O
microglia	O
were	O
isolated	O
from	O
mouse	O
brain	O
by	O
cell	O
sorting	O
:	O
one	O
subset	O
with	O
high	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
the	O
other	O
with	O
no	O
production	O
of	O
ROS	O
.	O

When	O
co	O
-	O
cultured	O
with	O
neuronal	O
cells	O
,	O
one	O
microglia	O
clone	O
with	O
high	O
ROS	O
production	O
was	O
neurotoxic	O
,	O
but	O
another	O
clone	O
with	O
no	O
ROS	O
production	O
neuroprotective	O
.	O

On	O
the	O
other	O
hand	O
,	O
Sawada	O
with	O
coworkers	O
found	O
that	O
a	O
neuroprotective	O
microglial	O
clone	O
in	O
a	O
culture	O
experiment	O
converted	O
to	O
a	O
toxic	O
microglial	O
clone	O
by	O
transduction	O
of	O
the	O
HIV-1	O
Nef	B
protein	O
with	O
increasing	O
NADPH	B
oxidase	I
activity	O
.	O

Taken	O
together	O
,	O
all	O
these	O
results	O
suggest	O
that	O
activated	O
microglia	O
may	O
change	O
in	O
vivo	O
from	O
neuroprotective	O
to	O
neurotoxic	O
subtsets	O
as	O
degeneration	O
of	O
dopamine	O
neurons	O
in	O
the	O
SN	O
progresses	O
in	O
PD	O
.	O

We	O
conclude	O
that	O
the	O
cytokines	B
from	O
activated	O
microglia	O
in	O
the	O
SN	O
and	O
putamen	O
may	O
be	O
initially	O
neuroprotective	O
,	O
but	O
may	O
later	O
become	O
neurotoxic	O
during	O
the	O
progress	O
of	O
PD	O
.	O

Toxic	O
change	O
of	O
activated	O
microglia	O
may	O
also	O
occur	O
in	O
Alzheimer	O
's	O
disease	O
and	O
other	O
neurodegenerative	O
diseases	O
in	O
which	O
inflammatory	O
process	O
is	O
found	O
.	O

Metallothionein	B
-	I
I	I
and	I
-	I
III	I
expression	O
in	O
animal	O
models	O
of	O
Alzheimer	O
disease	O
.	O

Previous	O
studies	O
have	O
described	O
altered	O
expression	O
of	O
metallothioneins	B
(	O
MTs	B
)	O
in	O
neurodegenerative	O
diseases	O
like	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
Down	O
syndrome	O
,	O
and	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
the	O
possible	O
role	O
of	O
MTs	B
in	O
neurodegenerative	O
processes	O
and	O
especially	O
in	O
human	O
diseases	O
,	O
the	O
use	O
of	O
animal	O
models	O
is	O
a	O
valuable	O
tool	O
.	O

Several	O
transgenic	O
mouse	O
models	O
of	O
AD	O
amyloid	O
deposits	O
are	O
currently	O
available	O
.	O

These	O
models	O
express	O
human	O
beta	B
-	I
amyloid	I
precursor	I
protein	I
(	O
AbetaPP	B
)	O
carrying	O
different	O
mutations	O
that	O
subsequently	O
result	O
in	O
a	O
varied	O
pattern	O
of	O
beta	O
-	O
amyloid	O
(	O
Abeta	O
)	O
deposition	O
within	O
the	O
brain	O
.	O

We	O
have	O
evaluated	O
the	O
expression	O
of	O
MT	B
-	I
I	I
and	O
MT	B
-	I
III	I
mRNA	O
by	O
in	O
situ	O
hybridization	O
in	O
three	O
different	O
transgenic	O
mice	O
models	O
of	O
AD	O
:	O
Tg2576	O
(	O
carrying	O
AbetaPP	B
harboring	O
the	O
Swedish	O
K670N	O
/	O
M671L	O
mutations	O
)	O
,	O
TgCRND8	O
(	O
Swedish	O
and	O
the	O
Indiana	O
V717F	O
mutations	O
)	O
,	O
and	O
Tg	O
-	O
SwDI	O
(	O
Swedish	O
and	O
Dutch	O
/	O
Iowa	O
E693Q	O
/	O
D694N	O
mutations	O
)	O
.	O

MT	B
-	I
I	I
mRNA	O
levels	O
were	O
induced	O
in	O
all	O
transgenic	O
lines	O
studied	O
,	O
although	O
the	O
pattern	O
of	O
induction	O
differed	O
between	O
the	O
models	O
.	O

In	O
the	O
Tg2576	O
mice	O
MT	B
-	I
I	I
was	O
weakly	O
upregulated	O
in	O
cells	O
surrounding	O
Congo	O
Red	O
-	O
positive	O
plaques	O
in	O
the	O
cortex	O
and	O
hippocampus	O
.	O

A	O
more	O
potent	O
induction	O
of	O
MT	B
-	I
I	I
was	O
observed	O
in	O
the	O
cortex	O
and	O
hippocampus	O
of	O
the	O
TgCRND8	O
mice	O
,	O
likely	O
reflecting	O
their	O
higher	O
amyloid	O
plaques	O
content	O
.	O

MT	B
-	I
I	I
upregulation	O
was	O
also	O
more	O
significant	O
in	O
Tg	O
-	O
SwDI	O
mice	O
,	O
especially	O
in	O
the	O
subiculum	O
and	O
hippocampus	O
CA1	O
area	O
.	O

Immunofluorescence	O
stainings	O
demonstrate	O
that	O
astrocytes	O
and	O
microglia	O
/	O
macrophages	O
surrounding	O
the	O
plaques	O
express	O
MT	B
-	I
I&II	I
.	O

In	O
general	O
,	O
MT	B
-	I
I	I
regulation	O
follows	O
a	O
similar	O
but	O
less	O
potent	O
response	O
than	O
glial	B
fibrillary	I
acidic	I
protein	I
(	O
GFAP	B
)	O
expression	O
.	O

In	O
contrast	O
to	O
MT	B
-	I
I	I
,	O
MT	B
-	I
III	I
mRNA	O
expression	O
was	O
not	O
significantly	O
altered	O
in	O
any	O
of	O
the	O
models	O
examined	O
suggesting	O
that	O
the	O
various	O
MT	B
isoforms	O
may	O
have	O
different	O
roles	O
in	O
these	O
experimental	O
systems	O
,	O
and	O
perhaps	O
also	O
in	O
human	O
AD	O
.	O

LexA	B
represses	O
CTXphi	O
transcription	O
by	O
blocking	O
access	O
of	O
the	O
alpha	O
C	O
-	O
terminal	O
domain	O
of	O
RNA	B
polymerase	I
to	O
promoter	O
DNA	O
.	O

CTXPhi	O
is	O
a	O
Vibrio	O
cholerae	O
-	O
specific	O
temperate	O
filamentous	O
phage	O
that	O
encodes	O
cholera	B
toxin	I
.	O

CTXPhi	O
lysogens	O
can	O
be	O
induced	O
with	O
DNA	O
damage	O
-	O
inducing	O
agents	O
such	O
as	O
UV	O
light	O
,	O
leading	O
to	O
the	O
release	O
of	O
CTXPhi	O
virions	O
and	O
the	O
rapid	O
dissemination	O
of	O
cholera	B
toxin	I
genes	O
to	O
new	O
V.	O
cholerae	O
hosts	O
.	O

This	O
environmental	O
regulation	O
is	O
directly	O
mediated	O
by	O
LexA	B
,	O
the	O
host	O
-	O
encoded	O
global	O
SOS	O
transcription	B
factor	I
.	O

LexA	B
and	O
a	O
phage	O
-	O
encoded	O
repressor	O
,	O
RstR	B
,	O
both	O
repress	O
transcription	O
from	O
P	O
(	O
rstA	B
)	O
,	O
the	O
primary	O
CTXPhi	O
promoter	O
.	O

Because	O
the	O
LexA	B
binding	O
site	O
is	O
located	O
upstream	O
of	O
the	O
core	O
P	O
(	O
rstA	B
)	O
promoter	O
and	O
overlaps	O
with	O
A	O
-	O
tract	O
sequences	O
,	O
we	O
speculated	O
that	O
LexA	B
represses	O
P	O
(	O
rstA	B
)	O
by	O
occluding	O
a	O
promoter	O
UP	O
element	O
,	O
a	O
binding	O
site	O
for	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	B
subunit	I
of	I
RNA	I
polymerase	I
(	O
RNAP	B
)	O
(	O
alphaCTD	O
)	O
.	O

Using	O
in	O
vitro	O
transcription	O
assays	O
,	O
we	O
have	O
shown	O
that	O
the	O
LexA	B
binding	O
site	O
stimulates	O
maximal	O
rstA	B
transcription	O
in	O
the	O
absence	O
of	O
any	O
added	O
factors	O
.	O

The	O
alphaCTD	O
of	O
RNAP	B
is	O
required	O
for	O
this	O
stimulation	O
,	O
demonstrating	O
that	O
the	O
LexA	B
site	O
contains	O
,	O
or	O
overlaps	O
with	O
,	O
a	O
promoter	O
UP	O
element	O
.	O

LexA	B
represses	O
rstA	B
transcription	O
by	O
normal	O
RNAP	B
but	O
fails	O
to	O
repress	O
rstA	B
transcription	O
catalyzed	O
by	O
RNAP	B
lacking	O
the	O
alphaCTD	O
.	O

DNase	B
I	I
footprint	O
analysis	O
mapped	O
the	O
alphaCTD	O
binding	O
site	O
to	O
the	O
upstream	O
promoter	O
region	O
that	O
includes	O
the	O
LexA	B
binding	O
site	O
.	O

The	O
addition	O
of	O
free	O
alpha	O
subunits	O
blocked	O
the	O
binding	O
of	O
LexA	B
to	O
rstA	B
promoter	O
DNA	O
,	O
indicating	O
that	O
LexA	B
and	O
the	O
alphaCTD	O
directly	O
compete	O
for	O
binding	O
to	O
their	O
respective	O
sites	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
repressor	O
blocking	O
transcription	O
initiation	O
by	O
occluding	O
a	O
promoter	O
UP	O
element	O
.	O

Effects	O
of	O
vasopressin	B
on	O
gene	O
expression	O
in	O
rat	O
inner	O
ear	O
.	O

Vasopressin	B
regulates	O
water	O
excretion	O
from	O
the	O
kidney	O
by	O
increasing	O
water	O
permeability	O
of	O
the	O
collecting	O
duct	O
as	O
a	O
hormone	O
secreted	O
from	O
the	O
posterior	O
pituitary	O
.	O

A	O
clinical	O
study	O
reported	O
that	O
plasma	O
levels	O
of	O
arginine	B
vasopressin	I
were	O
significantly	O
higher	O
in	O
patients	O
suffering	O
from	O
Meniere	O
's	O
disease	O
.	O

It	O
was	O
histologically	O
confirmed	O
that	O
chronic	O
administration	O
of	O
vasopressin	B
induced	O
endolymphatic	O
hydrops	O
in	O
guinea	O
pigs	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
endolymphatic	O
hydrops	O
induced	O
by	O
vasopressin	B
is	O
still	O
unclear	O
.	O

We	O
use	O
cDNA	O
microarray	O
to	O
study	O
the	O
effects	O
of	O
vasopressin	B
on	O
gene	O
expression	O
profiles	O
in	O
rat	O
inner	O
ear	O
to	O
elucidate	O
the	O
possible	O
mechanism	O
of	O
the	O
induced	O
hydrolabyrinth	O
.	O

Wistar	O
rats	O
were	O
intraperitoneally	O
injected	O
with	O
50	O
microg	O
/	O
kg	O
arginine	B
vasopressin	I
once	O
a	O
day	O
for	O
one	O
week	O
.	O

Hydrolabyrinth	O
in	O
rat	O
inner	O
ear	O
induced	O
by	O
administration	O
of	O
vasopressin	B
was	O
detected	O
by	O
HE	O
stain	O
.	O

The	O
bullae	O
were	O
dissected	O
out	O
for	O
total	O
RNA	O
extraction	O
.	O

cDNAs	O
were	O
synthesized	O
by	O
reverse	O
transcription	O
and	O
labeled	O
with	O
Cyanine3	O
(	O
Cy3	O
)	O
or	O
Cyanine5	O
(	O
Cy5	O
)	O
.	O

The	O
BiostarR-40s	O
cDNA	O
microarray	O
was	O
hybridized	O
with	O
the	O
above	O
cDNAs	O
and	O
the	O
changes	O
of	O
mRNA	O
expression	O
intensity	O
were	O
showed	O
by	O
data	O
analysis	O
.	O

Furthermore	O
,	O
the	O
changes	O
of	O
aquaporins	B
expression	O
level	O
were	O
measured	O
by	O
reverse	O
transcription	O
polymerase	B
chain	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Endolymphatic	O
hydrops	O
were	O
present	O
in	O
rats	O
intraperitoneally	O
injected	O
with	O
vasopressin	B
.	O

226	O
known	O
differentially	O
expressed	O
genes	O
were	O
screened	O
out	O
in	O
rat	O
inner	O
ear	O
induced	O
by	O
vasopressin	B
injection	O
.	O

Of	O
the	O
226	O
genes	O
,	O
18	O
transcripts	O
were	O
increased	O
by	O
5	O
-	O
fold	O
or	O
more	O
,	O
and	O
7	O
transcripts	O
were	O
decreased	O
to	O
0.2	O
-	O
fold	O
or	O
less	O
.	O

Ten	O
differentially	O
expressed	O
genes	O
were	O
identified	O
that	O
associate	O
with	O
cell	O
signal	O
transduction	O
,	O
14	O
differentially	O
expressed	O
genes	O
were	O
identified	O
that	O
relate	O
to	O
ion	O
transport	O
,	O
7	O
differentially	O
expressed	O
genes	O
were	O
involved	O
in	O
vesicle	O
-	O
mediated	O
transport	O
,	O
and	O
2	O
differentially	O
expressed	O
genes	O
were	O
aquaporin	B
2	I
(	O
AQP2	B
)	O
and	O
aquaporin	B
7	I
(	O
AQP7	B
)	O
.	O

The	O
expression	O
level	O
of	O
AQP2	B
was	O
significantly	O
higher	O
and	O
AQP7	B
was	O
significantly	O
lower	O
.	O

These	O
results	O
suggest	O
that	O
there	O
are	O
obvious	O
differences	O
in	O
gene	O
expression	O
profiles	O
in	O
inner	O
ear	O
between	O
vasopressin	B
injected	O
rats	O
and	O
normal	O
control	O
rats	O
.	O

Vasopressin	B
may	O
disturb	O
fluid	O
homeostasis	O
in	O
inner	O
ear	O
by	O
way	O
of	O
signal	O
transduction	O
,	O
ion	O
transport	O
,	O
vesicle	O
-	O
mediated	O
transport	O
and	O
aquaporins	B
.	O

It	O
is	O
likely	O
that	O
up	O
-	O
regulated	O
expression	O
of	O
AQP2	B
mRNA	O
and	O
down	O
-	O
regulated	O
expression	O
of	O
AQP7	B
mRNA	O
in	O
the	O
rat	O
inner	O
ear	O
caused	O
by	O
vasopressin	B
induce	O
an	O
increased	O
production	O
and	O
a	O
decreased	O
absorption	O
of	O
endolymph	O
,	O
resulting	O
in	O
endolymphatic	O
hydrops	O
.	O

APOE	B
distribution	O
in	O
world	O
populations	O
with	O
new	O
data	O
from	O
India	O
and	O
the	O
UK	O
.	O

BACKGROUND	O
:	O

The	O
APOE	B
gene	O
and	O
its	O
protein	O
product	O
is	O
associated	O
with	O
a	O
number	O
of	O
plasma	O
proteins	O
like	O
very	B
-	I
low	I
density	I
lipoprotein	I
(	O
VLDL	B
)	O
,	O
high	B
density	I
lipoprotein	I
(	O
HDL	B
)	O
chylomicrons	B
,	O
chylomicron	B
remnants	I
,	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
lipid	O
metabolism	O
.	O

The	O
APOE	B
gene	O
is	O
polymorphic	O
and	O
common	O
alleles	O
(	O
*	O
E2	O
,	O
*	O
E3	O
and	O
*	O
E4	O
)	O
have	O
been	O
associated	O
with	O
a	O
number	O
of	O
common	O
and	O
complex	O
diseases	O
in	O
different	O
populations	O
.	O

Due	O
to	O
their	O
crucial	O
role	O
in	O
metabolism	O
and	O
clinical	O
significance	O
,	O
it	O
is	O
imperative	O
that	O
allelic	O
variation	O
in	O
different	O
populations	O
is	O
analysed	O
to	O
evaluate	O
the	O
usage	O
of	O
APOE	B
in	O
an	O
evolutionary	O
and	O
clinical	O
context	O
.	O

AIM	O
:	O

We	O
report	O
allelic	O
variation	O
at	O
the	O
APOE	B
locus	O
in	O
three	O
European	O
and	O
four	O
Indian	O
populations	O
and	O
evaluate	O
global	O
patterns	O
of	O
genetic	O
variation	O
at	O
this	O
locus	O
.	O

The	O
large	O
,	O
intricate	O
and	O
unexpected	O
heterogeneity	O
of	O
this	O
locus	O
in	O
its	O
global	O
perspective	O
may	O
have	O
insightful	O
consequences	O
,	O
which	O
we	O
have	O
explored	O
in	O
this	O
paper	O
.	O

SUBJECT	O
AND	O
METHODS	O
:	O

Apolipoprotein	B
E	I
genotypes	O
were	O
determined	O
in	O
four	O
population	O
groups	O
(	O
Punjabi	O
Sikhs	O
,	O
Punjabi	O
Hindus	O
,	O
Maria	O
Gonds	O
and	O
Koch	O
,	O
total	O
individuals	O
=	O
497	O
)	O
of	O
India	O
and	O
three	O
regionally	O
sub	O
-	O
divided	O
British	O
populations	O
(	O
Nottinghamshire	O
,	O
East	O
Midlands	O
and	O
West	O
Midlands	O
,	O
total	O
individuals	O
=	O
621	O
)	O
.	O

The	O
extent	O
and	O
distribution	O
of	O
APOE	B
allele	O
frequencies	O
were	O
compared	O
with	O
292	O
populations	O
of	O
the	O
world	O
using	O
a	O
variety	O
of	O
multivariate	O
methods	O
.	O

RESULTS	O
:	O

Three	O
alleles	O
,	O
APOE*E2	B
,	O
APOE*E3	B
and	O
APOE*E4	B
,	O
were	O
observed	O
with	O
contrasting	O
variation	O
,	O
although	O
*	O
E4	O
was	O
absent	O
in	O
the	O
tribal	O
population	O
of	O
Koch	O
.	O

Higher	O
heterozygosities	O
(	O
>	O
43	O
%	O
)	O
in	O
British	O
populations	O
reflected	O
their	O
greater	O
genetic	O
diversity	O
at	O
this	O
locus	O
.	O

The	O
overall	O
pattern	O
of	O
allelic	O
diversity	O
among	O
these	O
populations	O
is	O
comparable	O
to	O
many	O
European	O
and	O
Indian	O
populations	O
.	O
At	O
a	O
global	O
level	O
,	O
higher	O
frequencies	O
of	O
the	O
*	O
E2	O
allele	O
were	O
observed	O
in	O
Africa	O
and	O
Oceania	O
(	O
0.099	O
+	O
/-	O
0.083	O
and	O
0.111	O
+	O
/-	O
0.052	O
,	O
respectively	O
)	O
.	O

Similarly	O
,	O
*	O
E4	O
allele	O
averages	O
were	O
higher	O
in	O
Oceania	O
(	O
0.221	O
+	O
/-	O
0.149	O
)	O
and	O
Africa	O
(	O
0.209	O
+	O
/-	O
0.090	O
)	O
,	O
while	O
Indian	O
and	O
Asian	O
populations	O
showed	O
the	O
highest	O
frequencies	O
of	O
*	O
E3	O
allele	O
.	O

The	O
coefficient	O
of	O
gene	O
differentiation	O
was	O
found	O
to	O
be	O
highest	O
in	O
South	O
America	O
(	O
9.6	O
%	O
)	O
,	O
although	O
the	O
highest	O
genetic	O
diversity	O
was	O
observed	O
in	O
Oceania	O
(	O
48.7	O
%	O
)	O
and	O
Africa	O
(	O
46.3	O
%	O
)	O
.	O

APOE*E2	B
revealed	O
a	O
statistically	O
significant	O
decreasing	O
cline	O
towards	O
the	O
north	O
in	O
Asia	O
(	O
r	O
=	O
-	O
0.407	O
,	O
d.f	O
.	O
=	O
70	O
,	O
p	O
<	O
0.05	O
)	O
,	O
which	O
is	O
not	O
compatible	O
with	O
the	O
coronary	O
heart	O
disease	O
statistics	O
in	O
this	O
continent	O
.	O

APOE*E4	B
showed	O
a	O
significant	O
increasing	O
cline	O
in	O
North	O
European	O
populations	O
.	O

Spatial	O
autocorrelation	O
analysis	O
shows	O
that	O
the	O
variation	O
at	O
this	O
locus	O
is	O
influenced	O
by	O
'	O
isolation	O
by	O
distance	O
'	O
with	O
a	O
strong	O
positive	O
correlation	O
for	O
lower	O
distances	O
up	O
to	O
1313	O
km	O
.	O

CONCLUSION	O
:	O

Overall	O
APOE	B
allelic	O
variation	O
in	O
UK	O
and	O
Indian	O
populations	O
is	O
comparable	O
to	O
previous	O
studies	O
but	O
in	O
tribal	O
populations	O
*	O
E4	O
allele	O
frequency	O
was	O
very	O
low	O
or	O
absent	O
.	O

At	O
a	O
global	O
level	O
allelic	O
variation	O
shows	O
that	O
geography	O
,	O
isolation	O
by	O
distance	O
,	O
genetic	O
drift	O
and	O
possibly	O
pre	O
-	O
historical	O
selection	O
are	O
responsible	O
for	O
shaping	O
the	O
spectrum	O
of	O
genetic	O
variation	O
at	O
the	O
APOE	B
gene	O
.	O

Overall	O
,	O
APOE	B
is	O
a	O
good	O
anthropogenetic	O
and	O
clinical	O
diagnostic	O
marker	O
.	O

Extensive	O
proteolytic	O
processing	O
of	O
the	O
malaria	O
parasite	O
merozoite	B
surface	I
protein	I
7	I
during	O
biosynthesis	O
and	O
parasite	O
release	O
from	O
erythrocytes	O
.	O

In	O
Plasmodium	O
falciparum	O
,	O
merozoite	B
surface	I
protein	I
7	I
(	O
MSP7	B
)	O
was	O
originally	O
identified	O
as	O
a	O
22kDa	O
protein	O
on	O
the	O
merozoite	O
surface	O
and	O
associated	O
with	O
the	O
MSP1	B
complex	I
shed	O
during	O
erythrocyte	O
invasion	O
.	O

MSP7	B
is	O
synthesised	O
in	O
schizonts	O
as	O
a	O
351	O
-	O
amino	O
acid	O
precursor	O
that	O
undergoes	O
proteolytic	O
processing	O
.	O

During	O
biosynthesis	O
the	O
MSP1	B
and	O
MSP7	B
precursors	O
form	O
a	O
complex	O
that	O
is	O
targeted	O
to	O
the	O
surface	O
of	O
developing	O
merozoites	O
.	O

In	O
the	O
sequential	O
proteolytic	O
processing	O
of	O
MSP7	B
,	O
N	O
-	O
and	O
C	O
-	O
terminal	O
20	O
and	O
33kDa	O
products	O
of	O
primary	O
processing	O
,	O
MSP7	B
(	O
20	O
)	O
and	O
MSP7	B
(	O
33	O
)	O
are	O
formed	O
and	O
MSP7	B
(	O
33	O
)	O
remains	O
bound	O
to	O
full	O
length	O
MSP1	B
.	O

Later	O
in	O
the	O
mature	O
schizont	O
,	O
MSP7	B
(	O
20	O
)	O
disappears	O
from	O
the	O
merozoite	O
surface	O
and	O
on	O
merozoite	O
release	O
MSP7	B
(	O
33	O
)	O
undergoes	O
a	O
secondary	O
cleavage	O
yielding	O
the	O
22kDa	O
MSP7	B
(	O
22	O
)	O
associated	O
with	O
MSP1	B
.	O

In	O
free	O
merozoites	O
,	O
both	O
MSP7	B
(	O
22	O
)	O
and	O
a	O
further	O
cleaved	O
product	O
,	O
MSP7	B
(	O
19	O
)	O
present	O
only	O
in	O
some	O
parasite	O
lines	O
,	O
were	O
detected	O
;	O
these	O
two	O
derivatives	O
are	O
shed	O
as	O
part	O
of	O
the	O
protein	O
complex	O
with	O
MSP1	B
fragments	O
during	O
erythrocyte	O
invasion	O
.	O

Primary	O
processing	O
of	O
MSP7	B
is	O
brefeldin	O
A	O
-	O
sensitive	O
while	O
secondary	O
processing	O
is	O
resistant	O
to	O
both	O
calcium	O
chelators	O
and	O
serine	B
protease	I
inhibitors	O
.	O

Primary	O
processing	O
of	O
MSP7	B
occurs	O
prior	O
to	O
that	O
of	O
MSP1	B
in	O
a	O
post	O
-	O
Golgi	O
compartment	O
,	O
whereas	O
the	O
secondary	O
cleavage	O
occurs	O
on	O
the	O
surface	O
of	O
the	O
developing	O
merozoite	O
,	O
possibly	O
at	O
the	O
time	O
of	O
MSP1	B
primary	O
processing	O
and	O
well	O
before	O
the	O
secondary	O
processing	O
of	O
MSP1	B
.	O

Specific	O
interactions	O
by	O
the	O
N	O
-	O
terminal	O
arm	O
inhibit	O
self	O
-	O
association	O
of	O
the	O
AraC	B
dimerization	O
domain	O
.	O

Deletion	O
of	O
the	O
regulatory	O
N	O
-	O
terminal	O
arms	O
of	O
the	O
AraC	B
protein	O
from	O
its	O
dimerization	O
domain	O
fragments	O
increases	O
the	O
susceptibility	O
of	O
the	O
dimerization	O
domain	O
to	O
form	O
a	O
series	O
of	O
higher	O
order	O
polymers	O
by	O
indefinite	O
self	O
-	O
association	O
.	O

We	O
investigated	O
how	O
the	O
normal	O
presence	O
of	O
the	O
arm	O
inhibits	O
this	O
self	O
-	O
association	O
.	O

One	O
possibility	O
is	O
that	O
arms	O
can	O
act	O
as	O
an	O
entropic	O
bristles	O
to	O
interfere	O
with	O
the	O
approach	O
of	O
other	O
macromolecules	O
,	O
thereby	O
decreasing	O
collision	O
frequencies	O
.	O

We	O
examined	O
the	O
repulsive	O
effect	O
of	O
flexible	O
arms	O
by	O
measuring	O
the	O
rate	O
of	O
trypsin	B
cleavage	O
of	O
a	O
specially	O
constructed	O
ubiquitin	B
-	O
arm	O
protein	O
.	O

Adding	O
an	O
arm	O
to	O
ubiquitin	B
or	O
increasing	O
its	O
length	O
produced	O
only	O
a	O
modest	O
repulsive	O
effect	O
.	O

This	O
suggests	O
that	O
arms	O
such	O
as	O
the	O
N	O
-	O
terminal	O
arm	O
of	O
AraC	B
do	O
not	O
reduce	O
self	O
-	O
association	O
by	O
entropic	O
exclusion	O
.	O

We	O
consequently	O
tested	O
the	O
hypothesis	O
that	O
the	O
arm	O
on	O
AraC	B
reduces	O
self	O
-	O
association	O
by	O
binding	O
to	O
the	O
core	O
of	O
the	O
dimerization	O
domain	O
even	O
in	O
the	O
absence	O
of	O
arabinose	O
.	O

The	O
behaviors	O
of	O
dimerization	O
domain	O
mutants	O
containing	O
deletions	O
or	O
alterations	O
in	O
the	O
N	O
-	O
terminal	O
arms	O
substantiate	O
this	O
hypothesis	O
.	O

Apparently	O
,	O
interactions	O
between	O
the	O
N	O
-	O
terminal	O
arm	O
and	O
the	O
dimerization	O
domain	O
core	O
position	O
the	O
arm	O
to	O
interfere	O
with	O
the	O
protein	O
-	O
protein	O
contacts	O
necessary	O
for	O
self	O
-	O
association	O
.	O

Allosteric	O
monofunctional	O
aspartate	B
kinases	I
from	O
Arabidopsis	O
.	O

Plant	O
monofunctional	O
aspartate	B
kinase	I
is	O
unique	O
among	O
all	O
aspartate	B
kinases	I
,	O
showing	O
synergistic	O
inhibition	O
by	O
lysine	O
and	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
(	O
SAM	O
)	O
.	O

The	O
Arabidopsis	O
genome	O
contains	O
three	O
genes	O
for	O
monofunctional	O
aspartate	B
kinases	I
.	O

We	O
show	O
that	O
aspartate	B
kinase	I
2	I
and	O
aspartate	B
kinase	I
3	I
are	O
inhibited	O
only	O
by	O
lysine	O
,	O
and	O
that	O
aspartate	B
kinase	I
1	I
is	O
inhibited	O
in	O
a	O
synergistic	O
manner	O
by	O
lysine	O
and	O
SAM	O
.	O

In	O
the	O
absence	O
of	O
SAM	O
,	O
aspartate	B
kinase	I
1	I
displayed	O
low	O
apparent	O
affinity	O
for	O
lysine	O
compared	O
to	O
aspartate	B
kinase	I
2	I
and	O
aspartate	B
kinase	I
3	I
.	O

In	O
the	O
presence	O
of	O
SAM	O
,	O
the	O
apparent	O
affinity	O
of	O
aspartate	B
kinase	I
1	I
for	O
lysine	O
increased	O
considerably	O
,	O
with	O
K	O
(	O
0.5	O
)	O
values	O
for	O
lysine	O
inhibition	O
similar	O
to	O
those	O
of	O
aspartate	B
kinase	I
2	I
and	O
aspartate	B
kinase	I
3	I
.	O

For	O
all	O
three	O
enzymes	O
,	O
the	O
inhibition	O
resulted	O
from	O
an	O
increase	O
in	O
the	O
apparent	O
K	O
(	O
m	O
)	O
values	O
for	O
the	O
substrates	O
ATP	O
and	O
aspartate	O
.	O

The	O
mechanism	O
of	O
aspartate	B
kinase	I
1	I
synergistic	O
inhibition	O
was	O
characterized	O
.	O

Inhibition	O
by	O
lysine	O
alone	O
was	O
fast	O
,	O
whereas	O
synergistic	O
inhibition	O
by	O
lysine	O
plus	O
SAM	O
was	O
very	O
slow	O
.	O

SAM	O
by	O
itself	O
had	O
no	O
effect	O
on	O
the	O
enzyme	O
activity	O
,	O
in	O
accordance	O
with	O
equilibrium	O
binding	O
analyses	O
indicating	O
that	O
SAM	O
binding	O
to	O
aspartate	B
kinase	I
1	I
requires	O
prior	O
binding	O
of	O
lysine	O
.	O

The	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
aspartate	B
kinase	I
1	I
-	O
Lys	O
-	O
SAM	O
complex	O
has	O
been	O
solved	O
[	O
Mas	O
-	O
Droux	O
C	O
,	O
Curien	O
G	O
,	O
Robert	O
-	O
Genthon	O
M	O
,	O
Laurencin	O
M	O
,	O
Ferrer	O
JL	O
&	O
Dumas	O
R	O
(	O
2006	O
)	O
Plant	O
Cell18	O
,	O
1681	O
-	O
1692	O
]	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
that	O
,	O
upon	O
binding	O
to	O
the	O
inactive	O
aspartate	B
kinase	I
1	I
-	O
Lys	O
complex	O
,	O
SAM	O
promotes	O
a	O
slow	O
conformational	O
transition	O
leading	O
to	O
formation	O
of	O
a	O
stable	O
aspartate	B
kinase	I
1	I
-	O
Lys	O
-	O
SAM	O
complex	O
.	O

The	O
increase	O
in	O
aspartate	B
kinase	I
1	I
apparent	O
affinity	O
for	O
lysine	O
in	O
the	O
presence	O
of	O
SAM	O
thus	O
results	O
from	O
the	O
displacement	O
of	O
the	O
unfavorable	O
equilibrium	O
between	O
aspartate	B
kinase	I
1	I
and	O
aspartate	B
kinase	I
1	I
-	O
Lys	O
towards	O
the	O
inactive	O
form	O
.	O

Immunogenetic	O
factors	O
determining	O
the	O
evolution	O
of	O
T	O
-	O
cell	O
large	O
granular	O
lymphocyte	O
leukaemia	O
and	O
associated	O
cytopenias	O
.	O

T	O
-	O
cell	O
large	O
granular	O
lymphocyte	O
leukaemia	O
(	O
T	O
-	O
LGL	O
)	O
is	O
a	O
chronic	O
clonal	O
proliferation	O
of	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
.	O

T	O
-	O
LGL	O
presents	O
with	O
cytopenias	O
,	O
often	O
accompanied	O
by	O
autoimmune	O
diseases	O
,	O
suggesting	O
clonal	O
transformation	O
arising	O
from	O
an	O
initially	O
polyclonal	O
immune	O
response	O
.	O

Various	O
immunogenetic	O
predisposition	O
factors	O
,	O
previously	O
described	O
for	O
both	O
immune	O
-	O
mediated	O
bone	O
marrow	O
failure	O
and	O
autoimmune	O
conditions	O
,	O
may	O
promote	O
T	O
-	O
LGL	O
evolution	O
and/or	O
development	O
of	O
cytopenias	O
.	O

The	O
association	O
of	O
T	O
-	O
LGL	O
was	O
analysed	O
with	O
a	O
number	O
of	O
immunogenetic	O
factors	O
in	O
66	O
patients	O
,	O
including	O
human	B
leucocyte	I
antigen	I
(	O
HLA	B
)	O
and	O
killer	B
-	I
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genotype	O
,	O
KIR	B
/	O
KIR	B
-	O
L	O
mismatch	O
,	O
CTLA-4	B
(	O
+	O
49	O
A	O
/	O
G	O
)	O
,	O
CD16	B
-	O
158V	O
/	O
F	O
,	O
CD45	B
polymorphisms	O
,	O
cytokine	B
single	O
nucleotide	O
polymorphisms	O
including	O
:	O
TNF	B
-	I
alpha	I
(	O
-308G	O
/	O
A	O
)	O
,	O
TGF	B
-	I
beta1	I
(	O
codons	O
10	O
C	O
/	O
T	O
,	O
25	O
G	O
/	O
C	O
)	O
,	O
IL-10	B
(	O
-	O
1082	O
G	O
/	O
A	O
)	O
,	O
IL-6	B
(	O
-174	O
C	O
/	O
G	O
)	O
,	O
and	O
IFN	B
-	I
gamma	I
(	O
+	O
874	O
T	O
/	O
A	O
)	O
.	O

A	O
statistically	O
significant	O
increase	O
in	O
A	O
/	O
A	O
genotype	O
for	O
TNF	B
-	I
alpha	I
-	O
308	O
,	O
IL-10	B
-	O
1082	O
,	O
andCTLA-4	B
+	O
49	O
was	O
observed	O
in	O
T	O
-	O
LGL	O
patients	O
compared	O
with	O
control	O
,	O
suggesting	O
that	O
the	O
G	O
allele	O
serves	O
a	O
protective	O
role	O
in	O
each	O
case	O
.	O

No	O
association	O
was	O
found	O
between	O
specific	O
KIR	B
/	O
HLA	B
profile	O
and	O
disease	O
.	O

KIR	B
/	O
KIR	B
-	O
L	O
analysis	O
revealed	O
significant	O
mismatches	O
between	O
KIR3DL2	B
and	O
KIR2DS1	B
and	O
their	O
ligands	O
HLA	B
-	I
A3	I
/	O
11	O
and	O
HLA	B
-	I
C	I
group	O
2	O
(	O
P	O
=	O
0.03	O
and	O
0.01	O
respectively	O
)	O
;	O
the	O
biological	O
relevance	O
of	O
this	O
finding	O
is	O
questionable	O
.	O

The	O
significance	O
of	O
additional	O
genetic	O
polymorphisms	O
and	O
their	O
clinical	O
correlation	O
to	O
evolution	O
of	O
T	O
-	O
LGL	O
requires	O
future	O
analysis	O
.	O

Antiviral	O
protein	O
APOBEC3	B
G	I
localizes	O
to	O
ribonucleoprotein	O
complexes	O
found	O
in	O
P	O
bodies	O
and	O
stress	O
granules	O
.	O

Members	O
of	O
the	O
APOBEC	B
(	I
apolipoprotein	I
B	I
mRNA	I
-	I
editing	I
enzyme	I
catalytic	I
polypeptide	I
1	I
-	I
like	I
)	I
family	I
of	I
cytidine	I
deaminases	I
inhibit	O
host	O
cell	O
genome	O
invasion	O
by	O
exogenous	O
retroviruses	O
and	O
endogenous	O
retrotransposons	O
.	O

Because	O
these	O
enzymes	O
can	O
edit	O
DNA	O
or	O
RNA	O
and	O
potentially	O
mutate	O
cellular	O
targets	O
,	O
their	O
activities	O
are	O
presumably	O
regulated	O
;	O
for	O
instance	O
,	O
APOBEC3	B
G	I
(	O
A3	B
G	I
)	O
recruitment	O
into	O
high	O
-	O
molecular	O
-	O
weight	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complexes	O
has	O
been	O
shown	O
to	O
suppress	O
its	O
enzymatic	O
activity	O
.	O

We	O
used	O
tandem	O
affinity	O
purification	O
together	O
with	O
mass	O
spectrometry	O
(	O
MS	O
)	O
to	O
identify	O
protein	O
components	O
within	O
A3	B
G	I
-	O
containing	O
RNPs	O
.	O

We	O
report	O
that	O
numerous	O
cellular	O
RNA	O
-	O
binding	O
proteins	O
with	O
diverse	O
roles	O
in	O
RNA	O
function	O
,	O
metabolism	O
,	O
and	O
fate	O
determination	O
are	O
present	O
in	O
A3	B
G	I
RNPs	O
but	O
that	O
most	O
interactions	O
with	O
A3	B
G	I
are	O
mediated	O
via	O
binding	O
to	O
shared	O
RNAs	O
.	O

Confocal	O
microscopy	O
demonstrated	O
that	O
substantial	O
quantities	O
of	O
A3	B
G	I
localize	O
to	O
cytoplasmic	O
microdomains	O
that	O
are	O
known	O
as	O
P	O
bodies	O
and	O
stress	O
granules	O
(	O
SGs	O
)	O
and	O
are	O
established	O
sites	O
of	O
RNA	O
storage	O
and	O
metabolism	O
.	O

Indeed	O
,	O
subjecting	O
cells	O
to	O
stress	O
induces	O
the	O
rapid	O
redistribution	O
of	O
A3	B
G	I
and	O
a	O
number	O
of	O
P	O
-	O
body	O
proteins	O
to	O
SGs	O
.	O

Among	O
these	O
proteins	O
are	O
Argonaute	B
1	I
(	O
Ago1	B
)	O
and	O
Argonaute	B
2	I
(	O
Ago2	B
)	O
,	O
factors	O
that	O
are	O
important	O
for	O
RNA	O
silencing	O
and	O
whose	O
interactions	O
with	O
A3	B
G	I
are	O
resistant	O
to	O
RNase	B
treatment	O
.	O

Together	O
,	O
these	O
findings	O
reveal	O
that	O
A3	B
G	I
associates	O
with	O
RNPs	O
that	O
are	O
found	O
throughout	O
the	O
cytosol	O
as	O
well	O
as	O
in	O
discrete	O
microdomains	O
.	O

We	O
also	O
speculate	O
that	O
the	O
interplay	O
between	O
A3	B
G	I
,	O
RNA	O
-	O
silencing	O
pathways	O
,	O
and	O
cellular	O
sites	O
of	O
RNA	O
metabolism	O
may	O
contribute	O
to	O
A3	B
G	I
's	I
role	O
as	O
an	O
inhibitor	O
of	O
retroelement	O
mobility	O
and	O
as	O
a	O
possible	O
regulator	O
of	O
cellular	O
RNA	O
function	O
.	O

Functional	O
polymorphism	O
of	O
the	O
KIR3DL1	B
/	I
S1	I
receptor	O
on	O
human	O
NK	O
cells	O
.	O

NK	O
cells	O
express	O
both	O
inhibitory	O
and	O
activatory	O
receptors	O
that	O
allow	O
them	O
to	O
recognize	O
target	O
cells	O
through	O
HLA	B
class	I
I	I
Ag	O
expression	O
.	O

KIR3DL1	B
is	O
a	O
receptor	O
that	O
recognizes	O
the	O
HLA	B
-	I
Bw4	I
public	O
epitope	O
of	O
HLA	B
-	I
B	I
alleles	O
.	O

We	O
demonstrate	O
that	O
polymorphism	O
within	O
the	O
KIR3DL1	B
receptor	O
has	O
functional	O
consequences	O
in	O
terms	O
of	O
NK	O
cell	O
recognition	O
of	O
target	O
.	O

Inhibitory	O
alleles	O
of	O
KIR3DL1	B
differ	O
in	O
their	O
ability	O
to	O
recognize	O
HLA	B
-	I
Bw4	I
ligand	O
,	O
and	O
a	O
consistent	O
hierarchy	O
of	O
ligand	O
reactivity	O
can	O
be	O
defined	O
.	O

KIR3DS1	B
,	O
which	O
segregates	O
as	O
an	O
allele	O
of	O
KIR3DL1	B
,	O
has	O
a	O
short	O
cytoplasmic	O
tail	O
characteristic	O
of	O
activatory	O
receptors	O
.	O

Because	O
it	O
is	O
very	O
similar	O
to	O
KIR3DL1	B
in	O
the	O
extracellular	O
domains	O
,	O
it	O
has	O
been	O
assumed	O
that	O
KIR3DS1	B
will	O
recognize	O
a	O
HLA	B
-	I
Bw4	I
ligand	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
KIR3DS1	B
is	O
expressed	O
as	O
a	O
protein	O
at	O
the	O
cell	O
surface	O
of	O
NK	O
cells	O
,	O
where	O
it	O
is	O
recognized	O
by	O
the	O
Z27	O
Ab	O
.	O

Using	O
this	O
Ab	O
,	O
we	O
found	O
that	O
KIR3DS1	B
is	O
expressed	O
on	O
a	O
higher	O
percentage	O
of	O
NK	O
cells	O
in	O
KIR3DS1	B
homozygous	O
compared	O
with	O
heterozygous	O
donors	O
.	O

In	O
contrast	O
to	O
the	O
inhibitory	O
KIR3DL1	B
allotypes	O
,	O
KIR3DS1	B
did	O
not	O
recognize	O
HLA	B
-	I
Bw4	I
on	O
EBV	O
-	O
transformed	O
cell	O
lines	O
.	O

Binding	O
Characteristics	O
of	O
IFN	B
-	I
alpha	I
Subvariants	O
to	O
IFNAR2	B
-	O
EC	O
and	O
Influence	O
of	O
the	O
6-Histidine	O
Tag	O
.	O

The	O
expression	O
,	O
purification	O
,	O
detection	O
,	O
and	O
assay	O
of	O
recombinant	O
proteins	O
have	O
been	O
made	O
more	O
convenient	O
and	O
rapid	O
by	O
the	O
use	O
of	O
small	O
affinity	O
tags	O
.	O

To	O
facilitate	O
the	O
purification	O
of	O
interferon	B
-	I
alpha2c	I
(	O
IFN	B
-	I
alpha2c	I
)	O
by	O
metal	O
chelate	O
affinity	O
chromatography	O
,	O
N	O
-	O
terminal	O
6	O
-	O
histidine	O
tag	O
was	O
introduced	O
via	O
genetic	O
manipulation	O
.	O

Two	O
preparations	O
of	O
IFN	B
material	O
were	O
purified	O
;	O
one	O
contained	O
IFN	B
-	I
alpha2c	I
with	O
the	O
6-histidine	O
tag	O
,	O
and	O
the	O
other	O
contained	O
IFN	B
-	I
alpha2c	I
without	O
the	O
6-histidine	O
tag	O
.	O

The	O
antigenic	O
properties	O
of	O
the	O
human	O
IFN	B
-	I
alpha2c	I
subvariant	O
with	O
and	O
without	O
the	O
6-histidine	O
tag	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
the	O
N	O
-	O
terminal	O
6	O
-	O
histidine	O
tag	O
on	O
IFN	B
-	I
alpha2c	I
interaction	O
with	O
the	O
extracellular	O
domain	O
of	O
human	O
IFN	B
-	I
alpha	I
receptor	I
chain	I
2	I
(	O
IFNAR2	B
-	O
EC	O
)	O
were	O
examined	O
.	O

For	O
the	O
purposes	O
of	O
this	O
study	O
,	O
IFNs	B
were	O
characterized	O
by	O
Western	O
blots	O
with	O
anti	O
-	O
IFN	B
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
and	O
bioassays	O
.	O

Immunoblot	O
analyses	O
showed	O
differences	O
between	O
IFN	B
-	I
alpha2c	I
-	O
6-histidine	O
tag	O
and	O
IFN	B
-	I
alpha2a	I
,	O
b	O
,	O
c	O
in	O
their	O
interaction	O
with	O
IFNAR2	B
-	O
EC	O
.	O

We	O
also	O
observed	O
differences	O
between	O
IFN	B
-	I
alpha2c	I
-	O
6-histidine	O
tag	O
and	O
IFN	B
-	I
alpha2a	I
,	O
b	O
,	O
c	O
in	O
bioactivities	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
that	O
shows	O
that	O
an	O
N	O
-	O
terminal	O
6	O
-	O
histidine	O
tag	O
on	O
IFN	B
-	I
alpha2c	I
can	O
affect	O
its	O
interaction	O
with	O
receptor	O
and	O
cause	O
a	O
different	O
bioactivity	O
.	O

Helicobacter	O
equorum	O
sp.	O
nov.	O
,	O
a	O
urease	B
-	O
negative	O
Helicobacter	O
species	O
isolated	O
from	O
horse	O
faeces	O
.	O

Gram	O
-	O
negative	O
,	O
curved	O
,	O
motile	O
bacteria	O
(	O
strains	O
EqF1	O
T	O
and	O
EqF2	O
)	O
were	O
isolated	O
from	O
faecal	O
samples	O
from	O
two	O
clinically	O
healthy	O
horses	O
.	O

Both	O
strains	O
possessed	O
a	O
single	O
,	O
monopolar	O
,	O
sheathed	O
flagellum	O
and	O
were	O
urease	B
-	O
negative	O
.	O

The	O
novel	O
strains	O
grew	O
at	O
37	O
degrees	O
C	O
under	O
microaerobic	O
conditions	O
and	O
were	O
positive	O
for	O
oxidase	B
,	O
catalase	B
and	O
alkaline	B
phosphatase	I
activities	O
.	O

The	O
isolates	O
reduced	O
nitrate	O
to	O
nitrite	O
,	O
but	O
gamma	B
-	I
glutamyl	I
transpeptidase	I
activity	O
was	O
not	O
detected	O
.	O

The	O
novel	O
isolates	O
did	O
not	O
grow	O
at	O
42	O
degrees	O
C	O
or	O
on	O
media	O
containing	O
1	O
%	O
glycine	O
.	O

They	O
were	O
resistant	O
to	O
cephalotin	O
and	O
nalidixic	O
acid	O
and	O
susceptible	O
to	O
metronidazole	O
.	O

Analysis	O
of	O
the	O
16S	O
and	O
23S	O
rRNA	O
gene	O
sequences	O
of	O
the	O
two	O
novel	O
strains	O
identified	O
them	O
as	O
representing	O
a	O
single	O
species	O
within	O
the	O
genus	O
Helicobacter	O
.	O

In	O
terms	O
of	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
,	O
Helicobacter	O
pullorum	O
and	O
Helicobacter	O
canadensis	O
were	O
the	O
most	O
closely	O
related	O
species	O
(	O
98	O
%	O
similarity	O
)	O
.	O

23S	O
rRNA	O
gene	O
sequence	O
analysis	O
also	O
classified	O
strains	O
EqF1	O
T	O
and	O
EqF2	O
within	O
the	O
enterohepatic	O
division	O
of	O
the	O
genus	O
Helicobacter	O
,	O
but	O
only	O
94	O
%	O
similarity	O
was	O
detected	O
with	O
H.	O
pullorum	O
and	O
H.	O
canadensis	O
,	O
which	O
are	O
helicobacters	O
with	O
unsheathed	O
flagella	O
.	O

The	O
most	O
closely	O
related	O
species	O
in	O
terms	O
of	O
23S	O
rRNA	O
gene	O
sequence	O
similarity	O
was	O
Helicobacter	O
canis	O
(	O
95	O
%	O
)	O
.	O

Numerical	O
analysis	O
of	O
whole	O
-	O
cell	O
protein	O
extracts	O
by	O
SDS	O
-	O
PAGE	O
was	O
performed	O
and	O
the	O
novel	O
isolates	O
were	O
clearly	O
differentiated	O
from	O
H.	O
pullorum	O
,	O
H.	O
canadensis	O
,	O
H.	O
canis	O
and	O
other	O
species	O
of	O
the	O
genus	O
Helicobacter	O
.	O

This	O
finding	O
was	O
also	O
confirmed	O
by	O
sequence	O
analysis	O
of	O
the	O
hsp60	B
gene	O
.	O

On	O
the	O
basis	O
of	O
these	O
genetic	O
,	O
biochemical	O
and	O
protein	O
data	O
,	O
the	O
isolates	O
are	O
classified	O
as	O
representing	O
a	O
novel	O
species	O
,	O
for	O
which	O
the	O
name	O
Helicobacter	O
equorum	O
sp.	O
nov.	O
is	O
proposed	O
(	O
type	O
strain	O
EqF1	O
T	O
=	O
LMG	O
23362	O
T	O
=	O
CCUG	O
52199	O
T	O
)	O
.	O

Allelic	O
expression	O
patterns	O
of	O
KIR3DS1	B
and	O
3DL1	B
using	O
the	O
Z27	O
and	O
DX9	O
antibodies	O
.	O

KIR3DL1	B
is	O
one	O
of	O
the	O
best	O
-	O
characterised	O
inhibitory	O
NK	O
cell	O
receptors	O
.	O

Unusually	O
,	O
one	O
common	O
allele	O
at	O
the	O
3DL1	B
locus	O
encodes	O
an	O
activating	O
receptor	O
known	O
as	O
3DS1	B
.	O

There	O
is	O
genetic	O
evidence	O
for	O
a	O
protective	O
role	O
of	O
3DS1	B
in	O
certain	O
viral	O
diseases	O
,	O
but	O
there	O
has	O
been	O
uncertainty	O
about	O
expression	O
of	O
the	O
3DS1	B
protein	O
.	O

Using	O
transfection	O
,	O
we	O
show	O
that	O
surface	O
expression	O
of	O
3DS1	B
is	O
reliant	O
on	O
the	O
adaptor	B
protein	I
DNAX	B
-	I
activating	I
protein	I
12	I
(	O
DAP12	B
)	O
.	O

KIR3DS1	B
was	O
recognised	O
by	O
the	O
antibody	O
Z27	O
,	O
a	O
reagent	O
that	O
also	O
detects	O
KIR3DL1	B
but	O
no	O
other	O
killer	B
immunoglobulin	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
molecule	O
.	O

Z27	O
stained	O
3DS1	B
on	O
the	O
surface	O
of	O
fresh	O
circulating	O
NK	O
cells	O
from	O
3DS1	B
/	O
3DS1	B
homozygotes	O
.	O

By	O
double	O
-	O
staining	O
with	O
Z27	O
and	O
DX9	O
,	O
an	O
antibody	O
specific	O
for	O
3DL1	B
,	O
we	O
obtained	O
evidence	O
that	O
in	O
3DS1	B
/	O
3DL1	B
heterozygous	O
donors	O
significant	O
numbers	O
of	O
NK	O
cells	O
express	O
3DS1	B
without	O
co	O
-	O
expressing	O
3DL1	B
and	O
that	O
NK	O
cells	O
expressing	O
both	O
alleles	O
are	O
difficult	O
to	O
detect	O
.	O

Chicken	O
Toll	B
-	I
like	I
Receptor	I
3	I
Recognizes	O
Its	O
Cognate	O
Ligand	O
When	O
Ectopically	O
Expressed	O
in	O
Human	O
Cells	O
.	O

Recognition	O
of	O
pathogens	O
by	O
toll	B
-	I
like	I
receptors	I
(	O
TLRs	B
)	O
causes	O
activation	O
of	O
signaling	O
cascades	O
that	O
trigger	O
cytokine	B
secretion	O
and	O
,	O
ultimately	O
,	O
innate	O
immunity	O
.	O

Genes	O
encoding	O
proteins	O
with	O
substantial	O
homology	O
to	O
mammalian	O
TLR1	B
,	O
TLR2	B
,	O
TLR3	B
,	O
TLR4	B
,	O
TLR5	B
,	O
and	O
TLR7	B
are	O
present	O
in	O
the	O
chicken	O
genome	O
,	O
whereas	O
orthologs	O
of	O
TLR8	B
,	O
TLR9	B
,	O
and	O
TLR10	B
seem	O
to	O
be	O
defective	O
or	O
missing	O
.	O

Except	O
for	O
chicken	O
TLR2	B
(	O
ChTLR2	B
)	O
,	O
which	O
was	O
previously	O
shown	O
to	O
recognize	O
lipopeptides	O
and	O
lipopolysaccharides	O
(	O
LPS	O
)	O
,	O
the	O
ligand	O
specificity	O
of	O
ChTLRs	B
had	O
not	O
been	O
determined	O
.	O

We	O
found	O
that	O
polyI	O
:	O
C	O
,	O
LPS	O
,	O
R848	O
,	O
S-28463	O
,	O
and	O
ODN2006	O
,	O
which	O
are	O
specifically	O
recognized	O
by	O
TLR3	B
,	O
TLR4	B
,	O
TLR7	B
/	I
8	I
,	O
and	O
TLR9	B
in	O
mammals	O
,	O
induced	O
substantial	O
amounts	O
of	O
type	B
I	I
interferon	I
(	O
IFN	B
)	O
and	O
interleukin-6	B
(	O
IL-6	B
)	O
in	O
freshly	O
prepared	O
chicken	O
splenocytes	O
.	O

To	O
determine	O
the	O
ligand	O
specificity	O
of	O
ChTLR3	B
and	O
ChTLR7	B
,	O
we	O
used	O
a	O
standard	O
reporter	O
assay	O
frequently	O
employed	O
for	O
analysis	O
of	O
mammalian	O
TLRs	B
.	O

Neither	O
S-28463	O
nor	O
any	O
other	O
TLR	B
ligand	O
induced	O
reporter	O
activity	O
in	O
human	O
293	O
cells	O
expressing	O
ChTLR7	B
.	O

However	O
,	O
human	O
293	O
cells	O
expressing	O
ChTLR3	B
strongly	O
and	O
specifically	O
responded	O
to	O
polyI	O
:	O
C	O
,	O
demonstrating	O
that	O
this	O
chicken	O
receptor	O
represents	O
a	O
true	O
ortholog	O
of	O
mammalian	O
TLR3	B
.	O

Macrophage	B
Migration	I
Inhibitory	I
Factor	I
Induces	O
MMP-9	B
Expression	O
in	O
Macrophages	O
via	O
The	O
MEK	B
-	O
ERK	B
MAP	B
Kinase	I
Pathway	O
.	O

We	O
have	O
shown	O
previously	O
that	O
macrophage	B
migration	I
inhibitory	I
factor	I
(	O
MIF	B
)	O
may	O
play	O
a	O
role	O
in	O
the	O
destabilization	O
of	O
atherosclerotic	O
plaques	O
by	O
activating	O
matrix	B
metalloproteinase	I
protein-9	I
(	O
MMP-9	B
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
signaling	O
mechanism	O
by	O
which	O
MIF	B
induces	O
MMP-9	B
expression	O
and	O
activation	O
in	O
a	O
murine	O
macrophage	O
line	O
(	O
RAW264.7	O
)	O
.	O

MIF	B
was	O
able	O
to	O
activate	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
1	I
/	I
2	I
(	O
ERK1	B
/	I
2	I
)	O
,	O
to	O
a	O
less	O
extent	O
JNK	B
,	O
but	O
not	O
p38	B
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
,	O
MAP	B
kinase	I
to	O
induce	O
MMP9	B
mRNA	O
and	O
protein	O
expression	O
in	O
RAW264.7	O
murine	O
macrophages	O
.	O

This	O
was	O
confirmed	O
by	O
the	O
findings	O
that	O
addition	O
of	O
an	O
ERK	B
MAP	B
kinase	I
inhibitor	O
(	O
PD98059	O
)	O
but	O
not	O
a	O
p38	B
inhibitor	O
(	O
SB203589	O
)	O
abolished	O
MIF	B
-	O
induced	O
MMP-9	B
expression	O
and	O
activation	O
,	O
whereas	O
addition	O
of	O
a	O
JNK	B
inhibitor	O
(	O
SP600125	O
)	O
produced	O
a	O
partially	O
inhibitory	O
effect	O
.	O

The	O
functional	O
role	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
(	O
MEK	B
)	O
-	O
ERK	B
MAP	B
kinase	I
in	O
MIF	B
-	O
induced	O
MMP-9	B
expression	O
was	O
further	O
confirmed	O
by	O
overexpressing	O
dominant	O
negative	O
MEK	B
(	O
DN	O
-	O
MEK	B
)	O
and	O
DN	O
-	O
ERK	B
MAP	B
kinases	I
.	O

Interestingly	O
,	O
constitutive	O
expression	O
of	O
a	O
wild	O
-	O
type	O
(	O
WT	O
)	O
-	O
MEK	B
alone	O
was	O
also	O
capable	O
of	O
inducing	O
a	O
low	O
,	O
but	O
significant	O
MMP-9	B
mRNA	O
and	O
protein	O
expression	O
but	O
did	O
not	O
cause	O
a	O
further	O
increase	O
in	O
MMP-9	B
in	O
response	O
to	O
MIF	B
.	O

MIF	B
activates	O
the	O
MEK	B
-	O
ERK	B
MAP	B
kinase	I
pathway	O
to	O
induce	O
MMP-9	B
expression	O
by	O
murine	O
macrophages	O
.	O

Activation	O
of	O
this	O
pathway	O
is	O
necessary	O
for	O
MMP-9	B
expression	O
and	O
activation	O
in	O
response	O
to	O
MIF	B
stimulation	O
.	O

Glutamatergic	O
or	O
GABAergic	O
neuron	O
-	O
specific	O
,	O
long	O
-	O
term	O
expression	O
in	O
neocortical	O
neurons	O
from	O
helper	O
virus	O
-	O
free	O
HSV-1	O
vectors	O
containing	O
the	O
phosphate	B
-	I
activated	I
glutaminase	I
,	O
vesicular	B
glutamate	I
transporter-1	I
,	O
or	O
glutamic	B
acid	I
decarboxylase	I
promoter	O
.	O

Many	O
potential	O
uses	O
of	O
direct	O
gene	O
transfer	O
into	O
neurons	O
require	O
restricting	O
expression	O
to	O
one	O
of	O
the	O
two	O
major	O
types	O
of	O
forebrain	O
neurons	O
,	O
glutamatergic	O
or	O
GABAergic	O
neurons	O
.	O

Thus	O
,	O
it	O
is	O
desirable	O
to	O
develop	O
virus	O
vectors	O
that	O
contain	O
either	O
a	O
glutamatergic	O
or	O
GABAergic	O
neuron	O
-	O
specific	O
promoter	O
.	O

The	O
brain	O
/	O
kidney	O
phosphate	B
-	I
activated	I
glutaminase	I
(	O
PAG	B
)	O
,	O
the	O
product	O
of	O
the	O
GLS1	B
gene	O
,	O
produces	O
the	O
majority	O
of	O
the	O
glutamate	O
for	O
release	O
as	O
neurotransmitter	O
,	O
and	O
is	O
a	O
marker	O
for	O
glutamatergic	O
neurons	O
.	O

A	O
PAG	B
promoter	O
was	O
partially	O
characterized	O
using	O
a	O
cultured	O
kidney	O
cell	O
line	O
.	O

The	O
three	O
vesicular	B
glutamate	I
transporters	I
(	O
VGLUTs	B
)	O
are	O
expressed	O
in	O
distinct	O
populations	O
of	O
neurons	O
,	O
and	O
VGLUT1	B
is	O
the	O
predominant	O
VGLUT	B
in	O
the	O
neocortex	O
,	O
hippocampus	O
,	O
and	O
cerebellar	O
cortex	O
.	O

Glutamic	B
acid	I
decarboxylase	I
(	O
GAD	B
)	O
produces	O
GABA	O
;	O
the	O
two	O
molecular	O
forms	O
of	O
the	O
enzyme	O
,	O
GAD65	B
and	O
GAD67	B
,	O
are	O
expressed	O
in	O
distinct	O
,	O
but	O
largely	O
overlapping	O
,	O
groups	O
of	O
neurons	O
,	O
and	O
GAD67	B
is	O
the	O
predominant	O
form	O
in	O
the	O
neocortex	O
.	O

In	O
transgenic	O
mice	O
,	O
an	O
approximately	O
9	O
kb	O
fragment	O
of	O
the	O
GAD67	B
promoter	O
supports	O
expression	O
in	O
most	O
classes	O
of	O
GABAergic	O
neurons	O
.	O

Here	O
,	O
we	O
constructed	O
plasmid	O
(	O
amplicon	O
)	O
Herpes	O
Simplex	O
Virus	O
(	O
HSV-1	O
)	O
vectors	O
that	O
placed	O
the	O
Lac	B
Z	I
gene	O
under	O
the	O
regulation	O
of	O
putative	O
PAG	B
,	O
VGLUT1	B
,	O
or	O
GAD67	B
promoters	O
.	O

Helper	O
virus	O
-	O
free	O
vector	O
stocks	O
were	O
delivered	O
into	O
postrhinal	O
cortex	O
,	O
and	O
the	O
rats	O
were	O
sacrificed	O
4	O
days	O
or	O
2	O
months	O
later	O
.	O

The	O
PAG	B
or	O
VGLUT1	B
promoters	O
supported	O
approximately	O
90	O
%	O
glutamatergic	O
neuron	O
-	O
specific	O
expression	O
.	O

The	O
GAD67	B
promoter	O
supported	O
approximately	O
90	O
%	O
GABAergic	O
neuron	O
-	O
specific	O
expression	O
.	O

Long	O
-	O
term	O
expression	O
was	O
observed	O
using	O
each	O
promoter	O
.	O

Principles	O
for	O
obtaining	O
long	O
-	O
term	O
expression	O
from	O
HSV-1	O
vectors	O
,	O
based	O
on	O
these	O
and	O
other	O
results	O
,	O
are	O
discussed	O
.	O

Long	O
-	O
term	O
glutamatergic	O
or	O
GABAergic	O
neuron	O
-	O
specific	O
expression	O
may	O
benefit	O
specific	O
experiments	O
on	O
learning	O
or	O
specific	O
gene	O
therapy	O
approaches	O
.	O

Of	O
note	O
,	O
promoter	O
analyses	O
might	O
identify	O
regulatory	O
elements	O
that	O
determine	O
a	O
glutamatergic	O
or	O
GABAergic	O
neuron	O
.	O

Pyrin	B
-	I
only	I
protein	I
2	I
modulates	O
NF	B
-	I
kappaB	I
and	O
disrupts	O
ASC	B
:	O
CLR	B
interactions	O
.	O

NF	B
-	I
kappaB	I
is	O
pivotal	O
for	O
transactivation	O
of	O
cell	O
-	O
cycle	O
regulatory	O
,	O
cytokine	B
,	O
and	O
adhesion	B
molecule	I
genes	O
and	O
is	O
dysregulated	O
in	O
many	O
cancers	O
,	O
neurodegenerative	O
disorders	O
,	O
and	O
inflammatory	O
diseases	O
.	O

Proteins	O
with	O
pyrin	O
and/or	O
caspase	B
recruitment	O
domains	O
have	O
roles	O
in	O
apoptosis	O
,	O
innate	O
immunity	O
,	O
and	O
inflammation	O
.	O

Many	O
pyrin	O
domain	O
(	O
PYD	O
)	O
proteins	O
modulate	O
NF	B
-	I
kappaB	I
activity	O
as	O
well	O
as	O
participate	O
in	O
assembling	O
both	O
the	O
perinuclear	O
""""	O
apoptotic	O
speck	O
""""	O
and	O
the	O
pro	O
-	O
IL1beta	B
/	O
IL-18	B
-	O
converting	O
inflammasome	O
complex	O
.	O

""""	O
Pyrin	B
-	I
only	I
""""	I
proteins	I
(	O
POP	B
)	O
are	O
attractive	O
as	O
negative	O
regulators	O
of	O
PYD	O
-	O
mediated	O
functions	O
and	O
one	O
such	O
protein	O
,	O
POP1	B
,	O
has	O
been	O
reported	O
.	O

We	O
report	O
the	O
identification	O
and	O
initial	O
characterization	O
of	O
a	O
second	O
POP	B
.	O

POP2	B
is	O
a	O
294	O
nt	O
single	O
exon	O
gene	O
located	O
on	O
human	O
chromosome	O
3	O
encoding	O
a	O
97	O
-	O
aa	O
protein	O
with	O
sequence	O
and	O
predicted	O
structural	O
similarity	O
to	O
other	O
PYDs	O
.	O

Highly	O
similar	O
to	O
PYDs	O
in	O
CATERPILLER	B
(	I
CLR	I
,	I
NLR	I
,	I
NALP	I
)	I
family	I
proteins	O
,	O
POP2	B
is	O
less	O
like	O
the	O
prototypic	O
pyrin	O
and	O
ASC	B
PYDs	O
.	O

POP2	B
is	O
expressed	O
principally	O
in	O
peripheral	O
blood	O
leukocytes	O
and	O
displays	O
both	O
cytoplasmic	O
and	O
nuclear	O
expression	O
patterns	O
in	O
transfected	O
cells	O
.	O

TNF	B
-	I
alpha	I
-	O
stimulated	O
and	O
p65	B
(	O
RelA	B
)	O
-	O
induced	O
NF	B
-	I
kappaB	I
-	O
dependent	O
gene	O
transcription	O
is	O
inhibited	O
by	O
POP2	B
in	O
vitro	O
by	O
a	O
mechanism	O
involving	O
changes	O
in	O
NF	B
-	I
kappaB	I
nuclear	O
import	O
or	O
distribution	O
.	O

While	O
colocalizing	O
with	O
ASC	B
in	O
perinuclear	O
specks	O
,	O
POP2	B
also	O
inhibits	O
the	O
formation	O
of	O
specks	O
by	O
the	O
CLR	B
protein	O
CIAS1	B
/	O
NALP3	B
.	O

Together	O
,	O
these	O
observations	O
demonstrate	O
that	O
POP2	B
is	O
a	O
negative	O
regulator	O
of	O
NF	B
-	I
kappaB	I
activity	O
that	O
may	O
influence	O
the	O
assembly	O
of	O
PYD	O
-	O
dependent	O
complexes	O
.	O

Expression	O
,	O
purification	O
and	O
characterization	O
of	O
human	O
IFN	B
-	I
lambda1	I
in	O
Pichia	O
pastoris	O
.	O

Interferon	B
-	I
lambda	I
(	O
IFN	B
-	I
lambda	I
)	O
is	O
a	O
newly	O
identified	O
IFN	B
family	I
which	O
belongs	O
to	O
the	O
class	O
II	O
cytokines	B
.	O

The	O
three	O
members	O
of	O
this	O
family	O
represent	O
antiviral	O
activities	O
like	O
other	O
IFNs	B
.	O

In	O
the	O
present	O
study	O
,	O
recombinant	O
human	O
IFN	B
-	I
lambda1	I
(	O
rhIFN	B
-	I
lambda1	I
)	O
was	O
produced	O
by	O
using	O
the	O
methylotrophic	O
yeast	O
Pichia	O
pastoris	O
(	O
P.	O
pastoris	O
)	O
expression	O
system	O
.	O

cDNAs	O
encoding	O
amino	O
acids	O
23	O
-	O
200	O
or	O
20	O
-	O
200	O
of	O
human	O
IFN	B
-	I
lambda1	I
were	O
cloned	O
and	O
joined	O
to	O
sequence	O
encoding	O
the	O
leader	O
region	O
(	O
prepro	O
segment	O
)	O
of	O
the	O
precursor	O
of	O
Saccharomyces	O
cerevisiae	O
alpha	B
-	I
factor	I
.	O

The	O
two	O
hybrid	O
genes	O
were	O
subcloned	O
into	O
yeast	O
integrative	O
vector	O
pAO815	O
separately	O
to	O
construct	O
expression	O
plasmids	O
bearing	O
four	O
tandem	O
copies	O
of	O
IFN	B
-	I
lambda1	I
expression	O
cassettes	O
.	O

The	O
expression	O
plasmids	O
were	O
then	O
used	O
to	O
transform	O
into	O
P.	O
pastoris	O
strain	O
GS115	O
,	O
resulting	O
in	O
recombinant	O
strains	O
GS115	O
/	O
IFNlambda1P	B
and	O
GS115	O
/	O
IFNlambda1	B
G	I
with	O
Mut	O
(	O
+	O
)	O
or	O
Mut	B
(	I
s	I
)	I
phenotype	O
.	O

rhIFN	B
-	I
lambda1	I
was	O
secreted	O
into	O
the	O
medium	O
upon	O
methanol	O
induction	O
.	O

In	O
GS115	O
/	O
IFNlambda1P	B
,	O
however	O
,	O
KEX2	B
cleavage	O
for	O
mature	O
rhIFN	B
-	I
lambda1	I
generation	O
was	O
inhibited	O
by	O
a	O
proline	O
at	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
the	O
products	O
were	O
different	O
from	O
anticipation	O
.	O

GS115	O
/	O
IFNlambda1	B
G	I
strain	O
secreted	O
two	O
forms	O
of	O
mature	O
rhIFN	B
-	I
lambda1	I
with	O
the	O
same	O
N	O
-	O
terminal	O
sequence	O
and	O
different	O
molecular	O
weight	O
.	O

Periodic	O
acid	O
-	O
Schiff	O
(	O
PAS	O
)	O
staining	O
indicated	O
that	O
these	O
proteins	O
were	O
glycosylated	O
.	O

The	O
yield	O
of	O
low	O
-	O
glycosylated	O
rhIFN	B
-	I
lambda1	I
in	O
GS115	O
/	O
IFNlambda1	B
G	I
strain	O
was	O
approximately	O
65	O
mg	O
l	O
(	O
-1	O
)	O
in	O
shaking	O
flasks	O
,	O
representing	O
around	O
57	O
%	O
of	O
the	O
total	O
secreted	O
proteins	O
.	O

rhIFN	B
-	I
lambda1	I
was	O
purified	O
by	O
cation	O
exchange	O
chromatography	O
and	O
gel	O
filtration	O
.	O

The	O
purified	O
rhIFN	B
-	I
lambda1	I
showed	O
specific	O
efficiency	O
to	O
activate	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
1	I
(	O
STAT1	B
)	O
and	O
STAT2	B
that	O
was	O
comparable	O
to	O
that	O
of	O
commercial	O
IFNalpha2a	B
.	O

Crystal	O
structure	O
of	O
the	O
E1	O
component	O
of	O
the	O
Escherichia	O
coli	O
2-oxoglutarate	B
dehydrogenase	I
multienzyme	I
complex	I
.	O

The	O
thiamine	O
-	O
dependent	O
E1o	O
component	O
(	O
EC	B
1.2.4.2	I
)	O
of	O
the	O
2-oxoglutarate	B
dehydrogenase	I
complex	I
catalyses	O
a	O
rate	O
-	O
limiting	O
step	O
of	O
the	O
tricarboxylic	O
acid	O
cycle	O
(	O
TCA	O
)	O
of	O
aerobically	O
respiring	O
organisms	O
.	O

We	O
describe	O
the	O
crystal	O
structure	O
of	O
Escherichia	O
coli	O
E1o	O
in	O
its	O
apo	O
and	O
holo	O
forms	O
at	O
2.6	O
A	O
and	O
3.5	O
A	O
resolution	O
,	O
respectively	O
.	O

The	O
structures	O
reveal	O
the	O
characteristic	O
fold	O
that	O
binds	O
thiamine	O
diphosphate	O
and	O
resemble	O
closely	O
the	O
alpha	O
(	O
2	O
)	O
beta	O
(	O
2	O
)	O
hetero	O
-	O
tetrameric	O
E1	O
components	O
of	O
other	O
2-oxo	B
acid	I
dehydrogenase	I
complexes	I
,	O
except	O
that	O
in	O
E1o	O
,	O
the	O
alpha	O
and	O
beta	O
subunits	O
are	O
fused	O
as	O
a	O
single	O
polypeptide	O
.	O

The	O
extended	O
segment	O
that	O
links	O
the	O
alpha	O
-	O
like	O
and	O
beta	O
-	O
like	O
domains	O
forms	O
a	O
pocket	O
occupied	O
by	O
AMP	O
,	O
which	O
is	O
recognised	O
specifically	O
.	O

Also	O
distinctive	O
to	O
E1o	O
are	O
N	O
-	O
terminal	O
extensions	O
to	O
the	O
core	O
fold	O
,	O
and	O
which	O
may	O
mediate	O
interactions	O
with	O
other	O
components	O
of	O
the	O
2-oxoglutarate	B
dehydrogenase	I
multienzyme	I
complex	I
.	O

The	O
active	O
site	O
pocket	O
contains	O
a	O
group	O
of	O
three	O
histidine	O
residues	O
and	O
one	O
serine	O
that	O
appear	O
to	O
confer	O
substrate	O
specificity	O
and	O
the	O
capacity	O
to	O
accommodate	O
the	O
TCA	O
metabolite	O
oxaloacetate	O
.	O

Oxaloacetate	O
inhibits	O
E1o	O
activity	O
at	O
physiological	O
concentrations	O
,	O
and	O
we	O
suggest	O
that	O
the	O
inhibition	O
may	O
allow	O
coordinated	O
activity	O
within	O
the	O
TCA	O
cycle	O
.	O

We	O
discuss	O
the	O
implications	O
for	O
metabolic	O
control	O
in	O
facultative	O
anaerobes	O
,	O
and	O
for	O
energy	O
homeostasis	O
of	O
the	O
mammalian	O
brain	O
.	O

Expression	O
of	O
the	O
halobacterial	O
transducer	O
protein	O
HtrII	B
from	O
Natronomonas	O
pharaonis	O
in	O
Escherichia	O
coli	O
.	O

Archaeal	O
phototaxis	O
is	O
mediated	O
by	O
sensory	B
rhodopsins	I
which	O
form	O
complexes	O
with	O
their	O
cognate	O
transducers	O
.	O

Whereas	O
the	O
receptors	O
sensory	B
rhodopsin	I
I	I
and	O
sensory	B
rhodopsin	I
II	I
(	O
SRII	B
)	O
have	O
been	O
expressed	O
in	O
Escherichia	O
coli	O
(	O
E.	O
coli	O
)	O
only	O
shortened	O
fragments	O
of	O
HtrII	B
from	O
Natronomonas	O
pharaonis	O
(	O
NpHtrII	B
)	O
are	O
available	O
.	O

Here	O
we	O
describe	O
the	O
heterologous	O
expression	O
of	O
full	O
length	O
NpHtrII	B
which	O
was	O
achieved	O
in	O
yields	O
of	O
up	O
to	O
0.9	O
mg	O
per	O
litre	O
cell	O
culture	O
.	O

Gel	O
filtration	O
analysis	O
reveals	O
the	O
tendency	O
of	O
the	O
transducer	O
to	O
form	O
dimers	O
and	O
higher	O
-	O
order	O
oligomers	O
which	O
was	O
also	O
observed	O
when	O
complexed	O
to	O
NpSRII	B
.	O

A	O
circular	O
dichroism	O
(	O
CD	O
)	O
spectrum	O
of	O
NpHtrII	B
is	O
comparable	O
to	O
those	O
obtained	O
for	O
the	O
E.	O
coli	O
chemoreceptors	B
indicating	O
a	O
similar	O
folding	O
with	O
predominantly	O
alpha	O
-	O
helical	O
structure	O
.	O

NpHtrII	B
dissociates	O
from	O
the	O
NpSRII	B
/	O
HtrII	B
complex	O
with	O
an	O
apparent	O
K	O
(	O
D	O
)	O
of	O
about	O
0.6	O
microM	O
.	O

Photocycle	O
kinetics	O
of	O
the	O
complex	O
is	O
comparable	O
to	O
that	O
obtained	O
for	O
NpSRII	B
in	O
complex	O
with	O
a	O
truncated	O
transducer	O
with	O
slight	O
differences	O
in	O
the	O
M	O
-	O
decay	O
.	O

The	O
data	O
indicate	O
that	O
the	O
heterologously	O
expressed	O
NpHtrII	B
adopt	O
a	O
native	O
like	O
structure	O
,	O
providing	O
the	O
means	O
for	O
elucidating	O
transmembrane	O
signal	O
transduction	O
and	O
activation	O
of	O
microbial	O
signalling	O
cascades	O
.	O

Low	O
molecular	O
weight	O
proteins	O
of	O
outer	O
membrane	O
of	O
Salmonella	O
typhimurium	O
are	O
immunogenic	O
in	O
Salmonella	O
induced	O
reactive	O
arthritis	O
revealed	O
by	O
proteomics	O
.	O

In	O
patients	O
with	O
reactive	O
arthritis	O
(	O
ReA	O
)	O
/	O
undifferentiated	O
spondyloarthropathy	O
(	O
uSpA	O
)	O
,	O
synovial	O
fluid	O
mononuclear	O
cells	O
(	O
SFMC	O
)	O
show	O
proliferation	O
to	O
bacterial	O
antigens	O
that	O
trigger	O
ReA	O
,	O
i.e.	O
Chlamydia	O
,	O
Yersinia	O
,	O
Campylobactor	O
,	O
Shigella	O
and	O
Salmonella	O
species	O
.	O

We	O
have	O
shown	O
previously	O
that	O
SFMC	O
proliferate	O
significantly	O
to	O
outer	O
membrane	O
proteins	O
of	O
S	O
typhimurium	O
in	O
Salmonella	O
induced	O
ReA	O
.	O

In	O
the	O
present	O
study	O
we	O
characterized	O
the	O
immunoreactive	O
fractions	O
of	O
outer	O
membrane	O
protein	O
(	O
Omp	O
)	O
of	O
S	O
typhimurium	O
in	O
Salmonella	O
induced	O
ReA	O
.	O

Omp	O
of	O
Salmonella	O
was	O
isolated	O
and	O
fractionated	O
by	O
continuous	O
elution	O
sodium	O
dodecyl	O
sulphate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
using	O
Prep	O
-	O
Cell	O
into	O
eight	O
Omp	O
fractions	O
based	O
on	O
molecular	O
weight	O
.	O

Twenty	O
-	O
three	O
patients	O
with	O
ReA	O
were	O
screened	O
for	O
the	O
bacterial	O
trigger	O
using	O
the	O
SFMC	O
proliferative	O
response	O
to	O
crude	O
lysates	O
of	O
Y	O
enterocolitica	O
,	O
S	O
flexneri	O
,	O
C	O
jejuni	O
and	O
S	O
typhimurium	O
using	O
thymidine	O
uptake	O
assay	O
.	O

SFMC	O
from	O
patients	O
with	O
salmonella	O
induced	O
ReA	O
were	O
tested	O
against	O
eight	O
fractions	O
.	O

Seven	O
of	O
23	O
patients	O
with	O
ReA	O
had	O
S	O
typhimurium	O
-	O
induced	O
ReA	O
.	O

Of	O
these	O
seven	O
patients	O
,	O
five	O
patients	O
SFMC	O
had	O
a	O
significant	O
stimulation	O
index	O
(	O
SI	O
)	O
against	O
<	O
22	O
,	O
22	O
-	O
26	O
,	O
25	O
-	O
35	O
and	O
28	O
-	O
40	O
kDa	O
fractions	O
of	O
Omp	O
.	O

These	O
fractions	O
were	O
analysed	O
by	O
SDS	O
-	O
PAGE	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometry	O
,	O
which	O
revealed	O
10	O
proteins	O
.	O

These	O
proteins	O
were	O
37	O
kDa	O
OmpA	B
,	O
33	O
kDa	O
TsX	B
,	O
28	O
kDa	O
putative	O
Omp	O
,	O
28	O
kDa	O
Vac	B
J	I
,	O
39	O
kDa	O
OmpD	B
,	O
18	O
kDa	O
OmpX	B
,	O
23	O
kDa	O
OmpW	B
,	O
43	O
kDa	O
OmpS1	B
and	O
19	O
kDa	O
peptidoglycan	O
-	O
associated	O
lipoprotein	O
.	O

In	O
conclusion	O
,	O
for	O
the	O
first	O
time	O
we	O
have	O
identified	O
some	O
low	O
molecular	O
weight	O
proteins	O
in	O
the	O
Omps	O
of	O
Salmonella	O
which	O
are	O
T	O
cells	O
immunoreactive	O
in	O
patients	O
with	O
salmonella	O
induced	O
ReA	O
/	O
uSpA	O
.	O

The	O
Arl4	B
family	I
of	I
small	I
G	I
proteins	I
can	O
recruit	O
the	O
cytohesin	B
Arf6	I
exchange	I
factors	I
to	O
the	O
plasma	O
membrane	O
.	O

The	O
small	B
GTPase	I
Arf6	B
regulates	O
endocytosis	O
,	O
actin	B
dynamics	O
,	O
and	O
cell	O
adhesion	O
,	O
and	O
one	O
of	O
its	O
major	O
activators	O
is	O
the	O
exchange	B
factor	I
Arf	I
nucleotide	I
-	I
binding	I
site	I
opener	I
(	O
ARNO	B
)	O
,	O
also	O
called	O
cytohesin-2	B
[	O
1	O
,	O
2	O
]	O
.	O

ARNO	B
must	O
be	O
recruited	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
in	O
order	O
to	O
activate	O
Arf6	B
,	O
and	O
in	O
addition	O
to	O
a	O
Sec7	B
nucleotide	O
-	O
exchange	O
domain	O
it	O
contains	O
a	O
C	O
-	O
terminal	O
pleckstrin	B
homology	O
(	O
PH	O
)	O
domain	O
that	O
binds	O
phosphoinositides	O
[	O
3	O
,	O
4	O
]	O
.	O

ARNO	B
and	O
its	O
three	O
relatives	O
,	O
cytohesin-1	B
,	O
Grp1	B
/	O
cytohesin	B
-	I
3	I
,	O
and	O
cytohesin	B
-	I
4	I
,	O
are	O
expressed	O
as	O
two	O
splice	O
variants	O
,	O
with	O
either	O
two	O
or	O
three	O
glycines	O
in	O
a	O
loop	O
in	O
the	O
phosphoinositide	O
-	O
binding	O
pocket	O
of	O
the	O
PH	O
domain	O
[	O
5	O
,	O
6	O
]	O
.	O

The	O
diglycine	O
form	O
binds	O
PtdIns	O
(	O
3,4,5	O
)	O
P	O
(	O
3	O
)	O
with	O
high	O
affinity	O
and	O
mediates	O
recruitment	O
of	O
cytohesins	B
to	O
the	O
plasma	O
membrane	O
in	O
response	O
to	O
insulin	B
and	O
growth	B
factors	I
[	O
7	O
,	O
8	O
]	O
.	O

However	O
,	O
the	O
triglycine	O
form	O
has	O
only	O
micromolar	O
affinity	O
for	O
both	O
PtdIns	O
(	O
3,4,5	O
)	O
P	O
(	O
3	O
)	O
and	O
PtdIns	O
(	O
4,5	O
)	O
P	O
(	O
2	O
)	O
,	O
affinities	O
that	O
are	O
insufficient	O
to	O
confer	O
membrane	O
recruitment	O
,	O
raising	O
the	O
question	O
of	O
how	O
the	O
triglycine	O
forms	O
of	O
cytohesins	B
are	O
regulated	O
[	O
5	O
,	O
9	O
]	O
.	O

Here	O
we	O
show	O
that	O
three	O
related	O
Arf	B
-	I
like	I
GTPases	I
of	O
unknown	O
function	O
,	O
Arl4a	B
,	O
Arl4c	B
,	O
and	O
Arl4d	B
,	O
are	O
able	O
to	O
recruit	O
ARNO	B
and	O
other	O
cytohesins	B
to	O
the	O
plasma	O
membrane	O
by	O
binding	O
to	O
their	O
PH	O
domains	O
irrespective	O
of	O
whether	O
they	O
are	O
in	O
the	O
diglycine	O
or	O
triglycine	O
form	O
.	O

The	O
Arl4	B
family	I
thus	O
defines	O
a	O
signal	O
-	O
transduction	O
pathway	O
that	O
can	O
mediate	O
the	O
plasma	O
-	O
membrane	O
recruitment	O
of	O
cytohesins	B
independently	O
of	O
a	O
requirement	O
for	O
the	O
generation	O
of	O
PtdIns	O
(	O
3,4,5	O
)	O
P	O
(	O
3	O
)	O
.	O

Stuck	O
in	O
reverse	O
:	O
loss	O
of	O
LC1	B
in	O
Trypanosoma	O
brucei	O
disrupts	O
outer	O
dynein	B
arms	O
and	O
leads	O
to	O
reverse	O
flagellar	O
beat	O
and	O
backward	O
movement	O
.	O

Axonemal	O
dyneins	B
are	O
multisubunit	O
molecular	O
motors	O
that	O
provide	O
the	O
driving	O
force	O
for	O
flagellar	O
motility	O
.	O

Dynein	B
light	I
chain	I
1	I
(	O
LC1	B
)	O
has	O
been	O
well	O
studied	O
in	O
Chlamydomonas	O
reinhardtii	O
and	O
is	O
unique	O
among	O
all	O
dynein	B
components	O
as	O
the	O
only	O
protein	O
known	O
to	O
bind	O
directly	O
to	O
the	O
catalytic	O
motor	O
domain	O
of	O
the	O
dynein	B
heavy	I
chain	I
.	O

However	O
,	O
the	O
role	O
of	O
LC1	B
in	O
dynein	B
assembly	O
and	O
/	O
or	O
function	O
is	O
unknown	O
because	O
no	O
mutants	O
have	O
previously	O
been	O
available	O
.	O

We	O
identified	O
an	O
LC1	B
homologue	O
(	O
TbLC1	B
)	O
in	O
Trypanosoma	O
brucei	O
and	O
have	O
investigated	O
its	O
role	O
in	O
trypanosome	O
flagellar	O
motility	O
using	O
epitope	O
tagging	O
and	O
RNAi	O
studies	O
.	O

TbLC1	B
is	O
localized	O
along	O
the	O
length	O
of	O
the	O
flagellum	O
and	O
partitions	O
between	O
the	O
axoneme	O
and	O
soluble	O
fractions	O
following	O
detergent	O
and	O
salt	O
extraction	O
.	O

RNAi	O
silencing	O
of	O
TbLC1	B
gene	O
expression	O
results	O
in	O
the	O
complete	O
loss	O
of	O
the	O
dominant	O
tip	O
-	O
to	O
-	O
base	O
beat	O
that	O
is	O
a	O
hallmark	O
of	O
trypanosome	O
flagellar	O
motility	O
and	O
the	O
concomitant	O
emergence	O
of	O
a	O
sustained	O
reverse	O
beat	O
that	O
propagates	O
base	O
-	O
to	O
-	O
tip	O
and	O
drives	O
cell	O
movement	O
in	O
reverse	O
.	O

Ultrastructure	O
analysis	O
revealed	O
that	O
outer	O
arm	O
dyneins	O
are	O
disrupted	O
in	O
TbLC1	O
mutants	O
.	O

Therefore	O
LC1	B
is	O
required	O
for	O
stable	O
dynein	B
assembly	O
and	O
forward	O
motility	O
in	O
T.	O
brucei	O
.	O

Our	O
work	O
provides	O
the	O
first	O
functional	O
analysis	O
of	O
LC1	B
in	O
any	O
organism	O
.	O

Together	O
with	O
the	O
recent	O
findings	O
in	O
T.	O
brucei	O
DNAI1	B
mutants	O
[	O
Branche	O
et	O
al.	O
(	O
2006	O
)	O
.	O
Conserved	O
and	O
specific	O
functions	O
of	O
axoneme	O
components	O
in	O
trypanosome	O
motility	O
.	O
J.	O
Cell	O
Sci	O
.	O
119	O
,	O
3443	O
-	O
3455	O
]	O
,	O
our	O
data	O
indicate	O
functionally	O
specialized	O
roles	O
for	O
outer	O
arm	O
dyneins	O
in	O
T.	O
brucei	O
and	O
C.	O
reinhardtii	O
.	O

Understanding	O
these	O
differences	O
will	O
provide	O
a	O
more	O
robust	O
description	O
of	O
the	O
fundamental	O
mechanisms	O
underlying	O
flagellar	O
motility	O
and	O
will	O
aid	O
efforts	O
to	O
exploit	O
the	O
trypanosome	O
flagellum	O
as	O
a	O
drug	O
target	O
.	O

Requirement	O
for	O
the	O
dynein	B
light	I
chain	I
km23	I
-	I
1	I
in	O
a	O
Smad2	B
-	O
dependent	O
transforming	B
growth	I
factor	I
-	I
beta	I
signaling	O
pathway	O
.	O

We	O
have	O
identified	O
km23	B
-	I
1	I
as	O
a	O
novel	O
transforming	B
growth	I
factor	I
-	I
beta	I
(	I
TGFbeta	I
)	I
receptor	I
(	I
TbetaR	I
)	I
-	O
interacting	O
protein	O
that	O
is	O
also	O
a	O
light	B
chain	I
of	I
the	I
motor	I
protein	I
dynein	I
(	O
dynein	B
light	I
chain	I
)	O
.	O

Herein	O
,	O
we	O
demonstrate	O
by	O
sucrose	O
gradient	O
analyses	O
that	O
,	O
in	O
the	O
presence	O
of	O
TGFbeta	B
but	O
not	O
in	O
the	O
absence	O
,	O
km23	B
-	I
1	I
was	O
present	O
in	O
early	O
endosomes	O
with	O
the	O
TbetaRs	B
.	O

Further	O
,	O
confocal	O
microscopy	O
studies	O
indicate	O
that	O
endogenous	O
km23	B
-	I
1	I
was	O
co	O
-	O
localized	O
with	O
endogenous	O
Smad2	B
at	O
early	O
times	O
after	O
TGFbeta	B
treatment	O
,	O
prior	O
to	O
Smad2	B
translocation	O
to	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
immunoprecipitation	O
/	O
blot	O
analyses	O
showed	O
that	O
TGFbeta	B
regulated	O
the	O
interaction	O
between	O
endogenous	O
km23	B
-	I
1	I
and	O
endogenous	O
Smad2	B
in	O
vivo	O
.	O

Blockade	O
of	O
km23	B
-	I
1	I
using	O
a	O
small	O
interfering	O
RNA	O
approach	O
resulted	O
in	O
a	O
reduction	O
in	O
both	O
total	O
intracellular	O
Smad2	B
levels	O
and	O
in	O
nuclear	O
levels	O
of	O
phosphorylated	O
Smad2	B
after	O
TGFbeta	B
treatment	O
.	O

This	O
decrease	O
was	O
reversed	O
by	O
lactacystin	O
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
26	O
S	O
proteasome	O
,	O
suggesting	O
that	O
knockdown	O
of	O
km23	B
-	I
1	I
causes	O
proteasomal	O
degradation	O
of	O
phosphorylated	O
(	O
i.e.	O
activated	O
)	O
Smad2	B
.	O

Blockade	O
of	O
km23	B
-	I
1	I
also	O
resulted	O
in	O
a	O
reduction	O
in	O
TGFbeta	B
/	O
Smad2	B
-	O
dependent	O
ARE	O
-	O
Lux	B
transcriptional	O
activity	O
,	O
which	O
was	O
rescued	O
by	O
a	O
km23	B
-	I
1	I
small	O
interfering	O
RNA	O
-	O
resistant	O
construct	O
.	O

In	O
contrast	O
,	O
a	O
reduction	O
in	O
TGFbeta	B
/	O
Smad3	B
-	O
dependent	O
SBE2	O
-	O
Luc	B
transcriptional	O
activity	O
did	O
not	O
occur	O
under	O
similar	O
conditions	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
the	O
dynactin	B
subunit	O
dynamitin	B
,	O
which	O
is	O
known	O
to	O
disrupt	O
dynein	B
-	O
mediated	O
intracellular	O
transport	O
,	O
blocked	O
TGFbeta	B
-	O
stimulated	O
nuclear	O
translocation	O
of	O
Smad2	B
.	O

Collectively	O
,	O
our	O
findings	O
indicate	O
for	O
the	O
first	O
time	O
that	O
a	O
dynein	B
light	I
chain	I
is	O
required	O
for	O
a	O
Smad2	B
-	O
dependent	O
TGFbeta	B
signaling	O
pathway	O
.	O

Improved	O
chemical	O
synthesis	O
and	O
demonstration	O
of	O
the	O
relaxin	B
receptor	I
binding	O
affinity	O
and	O
biological	O
activity	O
of	O
mouse	O
relaxin	B
.	O

The	O
primary	O
stored	O
and	O
circulating	O
form	O
of	O
relaxin	B
in	O
humans	O
,	O
human	B
gene	I
-	I
2	I
(	I
H2	I
)	I
relaxin	I
,	O
has	O
potent	O
antifibrotic	O
properties	O
with	O
rapidly	O
occurring	O
efficacy	O
.	O

However	O
,	O
when	O
administered	O
to	O
experimental	O
models	O
of	O
fibrosis	O
,	O
H2	B
relaxin	I
can	O
only	O
be	O
applied	O
over	O
short	O
-	O
term	O
(	O
2	O
-	O
4	O
week	O
)	O
periods	O
,	O
due	O
to	O
rodents	O
mounting	O
an	O
antibody	O
response	O
to	O
the	O
exogenous	O
human	O
relaxin	B
,	O
resulting	O
in	O
delayed	O
clearance	O
and	O
,	O
hence	O
,	O
increased	O
and	O
variable	O
circulating	O
levels	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
the	O
current	O
study	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
mouse	O
relaxin	B
over	O
long	O
-	O
term	O
exposure	O
in	O
vivo	O
.	O

Mouse	O
relaxin	B
is	O
unique	O
among	O
the	O
known	O
relaxins	B
in	O
that	O
it	O
possesses	O
an	O
extra	O
residue	O
within	O
the	O
C	O
-	O
terminal	O
region	O
of	O
its	O
A	O
-	O
chain	O
.	O

To	O
enable	O
a	O
detailed	O
assessment	O
of	O
its	O
receptor	O
interaction	O
and	O
biological	O
properties	O
,	O
it	O
was	O
chemically	O
synthesized	O
in	O
good	O
overall	O
yield	O
by	O
the	O
separate	O
preparation	O
of	O
each	O
of	O
its	O
A	O
-	O
and	O
B	O
-	O
chains	O
followed	O
by	O
regioselective	O
formation	O
of	O
each	O
of	O
the	O
intramolecular	O
and	O
two	O
intermolecular	O
disulfide	O
bonds	O
.	O

Murine	O
relaxin	B
was	O
shown	O
to	O
bind	O
with	O
high	O
affinity	O
to	O
the	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
RXFP1	B
(	O
primary	O
relaxin	B
)	O
receptor	O
but	O
with	O
a	O
slightly	O
lower	O
affinity	O
to	O
that	O
of	O
H2	B
relaxin	I
.	O

When	O
administered	O
to	O
relaxin	B
-	O
deficient	O
mice	O
(	O
which	O
undergo	O
an	O
age	O
-	O
dependent	O
progression	O
of	O
organ	O
fibrosis	O
)	O
over	O
a	O
4	O
month	O
treatment	O
period	O
,	O
mouse	O
relaxin	B
was	O
able	O
to	O
significantly	O
inhibit	O
the	O
progression	O
of	O
collagen	B
accumulation	O
in	O
several	O
organs	O
including	O
the	O
lung	O
,	O
kidney	O
,	O
testis	O
,	O
and	O
skin	O
(	O
all	O
p	O
<	O
0.05	O
vs	O
untreated	O
group	O
)	O
,	O
consistent	O
with	O
the	O
actions	O
of	O
H2	B
relaxin	I
.	O

These	O
combined	O
data	O
demonstrate	O
that	O
mouse	O
relaxin	B
can	O
effectively	O
inhibit	O
collagen	B
deposition	O
and	O
accumulation	O
(	O
fibrosis	O
)	O
over	O
long	O
-	O
term	O
treatment	O
periods	O
.	O

KIRs	B
and	O
autoimmune	O
disease	O
:	O
studies	O
in	O
systemic	O
lupus	O
erythematosus	O
and	O
scleroderma	O
.	O

We	O
investigated	O
killer	B
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIRs	B
)	O
and	O
the	O
human	B
leukocyte	I
antigen	I
(	I
HLA	I
)	I
-	I
C	I
ligands	O
for	O
the	O
corresponding	O
inhibitory	O
KIRs	B
in	O
Caucasian	O
patients	O
,	O
304	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
90	O
with	O
scleroderma	O
[	O
or	O
progressive	O
systemic	O
sclerosis	O
(	O
PSS	O
)	O
]	O
compared	O
with	O
416	O
Caucasian	O
controls	O
.	O

Compared	O
with	O
controls	O
,	O
KIR2DS1	B
in	O
the	O
absence	O
of	O
KIR2DS2	B
was	O
increased	O
in	O
both	O
SLE	O
(	O
P	O
=	O
0.04	O
)	O
and	O
PSS	O
(	O
P	O
=	O
0.02	O
)	O
.	O

Only	O
42	O
%	O
of	O
KIR2DS1	B
-	O
positive	O
PSS	O
patients	O
had	O
the	O
appropriate	O
HLA	B
-	I
C	I
ligand	O
for	O
the	O
corresponding	O
inhibitory	O
KIR	B
compared	O
with	O
61	O
%	O
of	O
KIR2DS1	B
positive	O
controls	O
(	O
P	O
=	O
0.02	O
)	O
.	O

In	O
the	O
PSS	O
group	O
the	O
presence	O
of	O
at	O
least	O
either	O
activating	O
KIR2DS1	B
and/or	O
2DS2	B
was	O
significantly	O
increased	O
in	O
patients	O
when	O
compared	O
with	O
controls	O
(	O
P	O
=	O
0.001	O
)	O
.	O

This	O
suggests	O
that	O
KIR	B
receptors	O
play	O
a	O
role	O
in	O
susceptibility	O
to	O
both	O
PSS	O
and	O
SLE	O
.	O

Increases	O
in	O
expression	O
of	O
14	B
-	I
3	I
-	I
3	I
eta	I
and	O
14	B
-	I
3	I
-	I
3	I
zeta	I
transcripts	O
during	O
neuroprotection	O
induced	O
by	O
delta9	O
-	O
tetrahydrocannabinol	O
in	O
AF5	O
cells	O
.	O

The	O
molecular	O
mechanisms	O
involved	O
in	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
-	O
induced	O
cell	O
death	O
and	O
Delta9	O
-	O
tetrahydrocannabinol	O
(	O
THC	O
)	O
-	O
induced	O
neuroprotection	O
were	O
investigated	O
in	O
vitro	O
with	O
an	O
AF5	O
neural	O
progenitor	O
cell	O
line	O
model	O
.	O

By	O
microarray	O
analysis	O
,	O
Ywhah	B
,	O
CK1	B
,	O
Hsp60	B
,	O
Pdcd	B
4	I
,	O
and	O
Pdcd	B
7	I
were	O
identified	O
as	O
being	O
strongly	O
regulated	O
by	O
both	O
NMDA	O
toxicity	O
and	O
THC	O
neuroprotection	O
.	O

The	O
14	B
-	I
3	I
-	I
3	I
eta	I
(	O
14	B
-	I
3	I
-	I
3eta	I
;	O
gene	O
symbol	O
Ywhah	B
)	O
and	O
14	B
-	I
3	I
-	I
3	I
zeta	I
(	O
14	B
-	I
3	I
-	I
3zeta	I
;	O
gene	O
symbol	O
Ywhaz	B
)	O
transcripts	O
were	O
deceased	O
by	O
NMDA	O
treatment	O
and	O
increased	O
by	O
THC	O
treatment	O
prior	O
to	O
NMDA	O
,	O
as	O
measured	O
by	O
cDNA	O
microarray	O
analysis	O
and	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Other	O
14	B
-	I
3	I
-	I
3	I
isoforms	O
were	O
unchanged	O
.	O

Whereas	O
up	O
-	O
regulation	O
of	O
14	B
-	I
3	I
-	I
3zeta	I
expression	O
was	O
observed	O
30	O
min	O
after	O
treatment	O
with	O
THC	O
plus	O
NMDA	O
,	O
down	O
-	O
regulation	O
by	O
NMDA	O
alone	O
was	O
not	O
seen	O
until	O
16	O
hr	O
after	O
treatment	O
.	O

By	O
Western	O
blotting	O
,	O
THC	O
increased	O
14	B
-	I
3	I
-	I
3	I
protein	I
only	O
in	O
cells	O
that	O
were	O
also	O
treated	O
with	O
NMDA	O
.	O

Overexpression	O
of	O
14	B
-	I
3	I
-	I
3eta	I
or	O
14	B
-	I
3	I
-	I
3zeta	I
by	O
transient	O
plasmid	O
transfection	O
increased	O
14	B
-	I
3	I
-	I
3	I
protein	I
levels	O
and	O
decreased	O
NMDA	O
-	O
induced	O
cell	O
death	O
.	O

These	O
data	O
suggest	O
that	O
increases	O
in	O
14	B
-	I
3	I
-	I
3	I
proteins	I
mediate	O
THC	O
-	O
induced	O
neuroprotection	O
under	O
conditions	O
of	O
NMDA	O
-	O
induced	O
cellular	O
stress	O
.	O

Analysis	O
of	O
KIR	B
gene	O
frequencies	O
in	O
HLA	B
class	I
I	I
characterised	O
bladder	O
,	O
colorectal	O
and	O
laryngeal	O
tumours	O
.	O

Three	O
cohorts	O
of	O
patients	O
with	O
laryngeal	O
,	O
bladder	O
or	O
colorectal	O
tumours	O
were	O
investigated	O
for	O
frequency	O
of	O
killer	B
immunoglobulin	I
-	I
like	I
receptor	I
(	O
KIR	B
)	O
genes	O
compared	O
with	O
a	O
normal	O
control	O
population	O
.	O

The	O
frequency	O
of	O
KIR3DL1	B
and	O
KIR2DS4	B
was	O
significantly	O
increased	O
(	O
but	O
not	O
after	O
correction	O
for	O
number	O
of	O
comparisons	O
made	O
)	O
in	O
patients	O
with	O
bladder	O
tumour	O
compared	O
with	O
controls	O
.	O

No	O
other	O
significant	O
differences	O
were	O
found	O
in	O
gene	O
frequencies	O
or	O
in	O
the	O
frequencies	O
of	O
those	O
KIR	B
genes	O
with	O
and	O
without	O
their	O
human	B
leucocyte	I
antigen	I
(	O
HLA	B
)	O
ligands	O
.	O

Furthermore	O
,	O
no	O
significant	O
differences	O
were	O
found	O
in	O
KIR	B
gene	O
frequencies	O
,	O
taking	O
into	O
consideration	O
the	O
type	O
of	O
loss	O
of	O
HLA	B
expression	O
in	O
the	O
individual	O
tumours	O
.	O

Finally	O
,	O
in	O
the	O
group	O
of	O
colorectal	O
carcinomas	O
,	O
there	O
was	O
an	O
overall	O
significant	O
difference	O
in	O
the	O
frequencies	O
of	O
C	O
group	O
heterozygosity	O
and	O
homozygosity	O
with	O
HLA	B
alterations	O
on	O
the	O
tumour	O
.	O

Laboratory	O
assessment	O
of	O
hypercoagulable	O
state	O
.	O

A	O
study	O
in	O
a	O
group	O
of	O
patients	O
with	O
venous	O
thromboembolism	O
born	O
in	O
Chioggia	O
.	O

AIM	O
:	O

Authors	O
performed	O
a	O
Laboratory	O
assessment	O
for	O
thrombophilia	O
risk	O
factors	O
in	O
a	O
group	O
of	O
patients	O
with	O
previous	O
deep	O
venous	O
thrombosis	O
.	O

METHODS	O
:	O

123	O
consecutive	O
patients	O
were	O
considered	O
.	O

The	O
following	O
parameters	O
were	O
investigated	O
by	O
using	O
commercially	O
available	O
methods	O
:	O
PT	O
,	O
aPTT	O
,	O
TT	O
,	O
Fibrinogen	B
,	O
D	O
-	O
Dimer	O
,	O
Anti	O
thrombin	B
3	O
(	O
AT	O
)	O
,	O
Protein	B
C	I
(	O
PC	B
)	O
,	O
Protein	B
S	I
(	O
PS	B
)	O
,	O
activated	O
C	B
protein	I
(	O
APC	O
)	O
resistance	O
,	O
Lupus	O
anticoagulant	O
(	O
LA	O
)	O
,	O
FV	O
Leiden	O
(	O
G1691a	O
mutation	O
)	O
,	O
Prothrombin	B
G20210A	O
mutation	O
,	O
MTHFR	B
mutation	O
(	O
G677	O
T	O
mutation	O
)	O
,	O
anti	O
Prothrombin	B
auto	O
-	O
antibodies	O
(	O
PR	O
)	O
IgG	B
and	O
IgM	B
,	O
anti	O
Beta	B
2	I
glycoprotein	I
1	I
(	O
B2GP1	B
)	O
auto	O
-	O
antibodies	O
IgG	B
and	O
IgM	B
,	O
anti	O
Cardiolipin	O
(	O
CL	O
)	O
auto	O
-	O
antibodies	O
IgG	B
and	O
IgM	B
,	O
homocysteine	O
.	O

RESULTS	O
:	O

In	O
the	O
123	O
patients	O
considered	O
we	O
observed	O
:	O
two	O
AT	O
deficiency	O
,	O
one	O
PC	B
deficiencies	O
,	O
one	O
PS	B
deficiency	O
,	O
60	O
FV	O
Leiden	O
mutation	O
(	O
six	O
homozygous	O
)	O
,	O
1	O
Prothrombin	B
gene	O
mutations	O
(	O
heterozygous	O
)	O
,	O
71	O
MTHFR	B
mutations	O
(	O
15	O
homozygous	O
)	O
.	O

Study	O
of	O
anti	O
phospholipid	O
auto	O
antibodies	O
showed	O
10	O
patients	O
positive	O
for	O
LA	O
,	O
9	O
for	O
anti	O
CL	O
antibodies	O
(	O
6IgG	O
and	O
3IgM	O
)	O
,	O
10	O
for	O
anti	O
B2GP1	B
antibody	O
(	O
5	O
IgG	B
and	O
5IgM	B
)	O
,	O
3	O
for	O
anti	O
PR	O
antibody	O
(	O
IgG	O
)	O
.	O

Thirty	O
nine	O
patients	O
showed	O
hyper	O
homocysteinemia	O
.	O

CONCLUSION	O
:	O

In	O
our	O
study	O
only	O
19	O
patients	O
were	O
free	O
of	O
demonstrable	O
thrombophilia	O
risk	O
factor	O
.	O

In	O
51	O
subjects	O
a	O
single	O
risk	O
factor	O
was	O
identified	O
and	O
in	O
53	O
multiple	O
(	O
from	O
2	O
to	O
5	O
)	O
risk	O
factors	O
were	O
identified	O
.	O

In	O
our	O
opinion	O
a	O
Laboratory	O
assessment	O
of	O
thrombophilia	O
risk	O
factors	O
after	O
a	O
previous	O
episode	O
of	O
deep	O
venous	O
thrombosis	O
is	O
a	O
diagnostic	O
tool	O
of	O
great	O
importance	O
.	O

As	O
a	O
matter	O
of	O
fact	O
,	O
in	O
our	O
experience	O
,	O
by	O
using	O
a	O
standard	O
analytical	O
panel	O
,	O
it	O
was	O
possible	O
to	O
highlight	O
one	O
or	O
more	O
risk	O
factors	O
in	O
about	O
85	O
%	O
of	O
the	O
patients	O
considered	O
.	O

A	O
novel	O
mutation	O
of	O
gene	O
CBFA1	B
/	O
RUNX2	B
in	O
cleidocranial	O
dysplasia	O
.	O

Cleidocranial	O
dysplasia	O
(	O
CCD	O
)	O
is	O
an	O
autosomal	O
dominant	O
skeletal	O
dysplasia	O
characterised	O
by	O
abnormal	O
clavicles	O
,	O
patent	O
sutures	O
and	O
fontanelles	O
,	O
supernumerary	O
teeth	O
,	O
short	O
stature	O
,	O
and	O
a	O
variety	O
of	O
other	O
skeletal	O
changes	O
.	O

The	O
disease	O
gene	O
is	O
CBFA1	B
/	O
RUNX2	B
,	O
which	O
is	O
mapped	O
to	O
chromosome	O
6p21	O
.	O

Inactivation	O
of	O
the	O
CBFA1	B
/	O
RUNX2	B
gene	O
by	O
mutations	O
is	O
involved	O
in	O
the	O
skeletal	O
defects	O
that	O
occur	O
in	O
patients	O
with	O
CCD	O
.	O

CBFA1	B
/	O
RUNX2	B
controls	O
the	O
differentiation	O
of	O
precursor	O
cells	O
into	O
osteoblasts	O
and	O
is	O
essential	O
for	O
membranous	O
as	O
well	O
as	O
endochondral	O
bone	O
formation	O
.	O

In	O
this	O
study	O
of	O
a	O
14	O
-	O
yr	O
-	O
old	O
boy	O
with	O
typical	O
CCD	O
phenotype	O
,	O
the	O
authors	O
found	O
a	O
novel	O
CBFA1	B
/	O
RUNX2	B
gene	O
mutation	O
.	O

All	O
of	O
the	O
amplified	O
segments	O
from	O
the	O
patient	O
's	O
CBFA1	B
/	O
RUNX2	B
gene	O
were	O
identical	O
to	O
those	O
obtained	O
in	O
controls	O
,	O
except	O
for	O
the	O
one	O
spanning	O
the	O
exon	O
7	O
and	O
intron	O
/	O
exon	O
boundary	O
regions	O
.	O

Direct	O
sequencing	O
of	O
the	O
PCR	O
product	O
showed	O
a	O
heterozygous	O
T	O
-	O
to	O
-	O
A	O
transition	O
mutation	O
at	O
nucleotide	O
1182	O
in	O
exon	O
7	O
,	O
leading	O
to	O
Y394X	O
mutation	O
.	O

The	O
predicted	O
protein	O
product	O
lacks	O
128	O
amino	O
acids	O
,	O
including	O
part	O
of	O
the	O
PST	O
domain	O
.	O

Identification	O
of	O
this	O
novel	O
mutation	O
constitutes	O
a	O
further	O
step	O
in	O
elucidating	O
the	O
pathogenesis	O
of	O
this	O
autosomal	O
disorder	O
.	O

Human	O
adipose	O
tissue	O
macrophages	O
are	O
of	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O
but	O
capable	O
of	O
excessive	O
pro	O
-	O
inflammatory	O
mediator	O
production	O
.	O

OBJECTIVE	O
:	O

Obesity	O
is	O
associated	O
with	O
a	O
chronic	O
low	O
-	O
grade	O
inflammation	O
and	O
an	O
increased	O
abundance	O
of	O
macrophages	O
in	O
adipose	O
tissue	O
.	O

Adipose	O
tissue	O
macrophages	O
(	O
ATMs	O
)	O
are	O
assumed	O
to	O
interfere	O
with	O
adipocyte	O
function	O
leading	O
to	O
insulin	B
resistance	O
,	O
thereby	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Macrophages	O
exist	O
in	O
separate	O
types	O
of	O
differentiation	O
,	O
but	O
the	O
nature	O
of	O
ATMs	O
is	O
largely	O
unknown	O
.	O

DESIGN	O
AND	O
MEASUREMENTS	O
:	O

Stromal	O
vascular	O
cells	O
(	O
SVCs	O
)	O
and	O
ATMs	O
were	O
isolated	O
from	O
human	O
adipose	O
tissues	O
from	O
different	O
locations	O
.	O

We	O
characterized	O
ATMs	O
phenotypically	O
and	O
functionally	O
by	O
flow	O
cytometry	O
,	O
endocytosis	O
assay	O
and	O
determination	O
of	O
secreted	O
cytokines	B
.	O

For	O
comparison	O
,	O
we	O
used	O
macrophages	O
of	O
the	O
'	O
classical	O
'	O
(	O
M1	O
)	O
and	O
the	O
'	O
alternative	O
'	O
,	O
anti	O
-	O
inflammatory	O
(	O
M2	O
)	O
type	O
differentiated	O
in	O
vitro	O
from	O
peripheral	O
blood	O
monocytes	O
.	O

RESULTS	O
:	O

Like	O
prototypic	O
M2	O
macrophages	O
,	O
ATMs	O
expressed	O
considerable	O
amounts	O
of	O
mannose	B
receptor	I
,	O
haemoglobin	B
scavenger	I
receptor	I
CD163	B
and	O
integrin	B
alphavbeta5	I
.	O

The	O
number	O
of	O
cells	O
expressing	O
these	O
molecules	O
correlated	O
significantly	O
with	O
the	O
donors	O
'	O
body	O
mass	O
indices	O
(	O
BMIs	O
)	O
.	O

Notably	O
,	O
SVCs	O
positive	O
for	O
the	O
common	O
monocyte	O
/	O
macrophage	O
marker	O
CD14	B
contained	O
a	O
considerable	O
fraction	O
of	O
blood	O
monocytes	O
,	O
the	O
abundance	O
of	O
which	O
did	O
not	O
correlate	O
with	O
the	O
BMIs	O
,	O
pointing	O
to	O
the	O
requirement	O
of	O
the	O
surface	O
markers	O
identified	O
here	O
for	O
the	O
identification	O
of	O
ATMs	O
.	O

ATMs	O
showed	O
endocytic	O
activities	O
similar	O
to	O
M2	O
macrophages	O
and	O
accordingly	O
secreted	O
high	O
amounts	O
of	O
IL-10	B
and	O
IL-1	B
receptor	I
antagonist	I
.	O

However	O
,	O
basal	O
and	O
induced	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
TNF	B
-	I
alpha	I
,	O
IL-6	B
,	O
IL-1	B
,	O
MCP-1	B
and	O
MIP-1alpha	B
was	O
even	O
higher	O
in	O
ATMs	O
than	O
in	O
pro	O
-	O
inflammatory	O
M1	O
macrophages	O
.	O

CONCLUSION	O
:	O

ATMs	O
comprise	O
a	O
particular	O
macrophage	O
type	O
that	O
is	O
M2	O
-	O
like	O
by	O
surface	O
marker	O
expression	O
,	O
but	O
they	O
are	O
competent	O
to	O
produce	O
extensive	O
amounts	O
of	O
inflammatory	O
cytokines	B
,	O
which	O
could	O
considerably	O
contribute	O
to	O
the	O
development	O
of	O
insulin	B
resistance	O
.	O

Effect	O
of	O
cigarette	O
smoke	O
extract	O
on	O
lipopolysaccha	O
-	O
ride	O
-	O
activated	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
signal	O
transduction	O
pathway	O
in	O
cultured	O
cells	O
.	O

BACKGROUND	O
:	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
forms	O
outer	O
membrane	O
of	O
the	O
wall	O
of	O
Gram	O
-	O
negative	O
cells	O
.	O

LPS	O
can	O
directly	O
cause	O
damage	O
to	O
epithelia	O
of	O
respiratory	O
tract	O
and	O
is	O
the	O
major	O
factor	O
responsible	O
for	O
the	O
chronic	O
inflammation	O
of	O
respiratory	O
passage	O
.	O

The	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
signal	O
transduction	O
pathway	O
of	O
the	O
airway	O
epithelia	O
is	O
intimately	O
associated	O
with	O
the	O
action	O
of	O
LPS	O
.	O

The	O
chronic	O
inflammation	O
of	O
respiratory	O
tract	O
and	O
smoking	O
are	O
interrelated	O
and	O
entwined	O
in	O
the	O
development	O
and	O
progression	O
of	O
chronic	O
lung	O
diseases	O
.	O

This	O
study	O
was	O
designed	O
to	O
examine	O
the	O
effects	O
of	O
cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
and	O
LPS	O
on	O
MAPK	B
signal	O
transduction	O
pathway	O
in	O
order	O
to	O
further	O
understand	O
the	O
roles	O
CSE	O
and	O
LPS	O
play	O
in	O
chronic	O
lung	O
inflammation	O
.	O

METHODS	O
:	O

Cultured	O
primary	O
human	O
epithelial	O
cells	O
of	O
airway	O
were	O
divided	O
into	O
four	O
groups	O
according	O
to	O
the	O
stimulants	O
used	O
:	O
blank	O
control	O
group	O
,	O
LPS	O
-	O
stimulation	O
group	O
,	O
CSE	O
-	O
stimulation	O
group	O
and	O
CSE	O
plus	O
LPS	O
group	O
.	O

Western	O
blotting	O
was	O
employed	O
for	O
the	O
detection	O
of	O
phosphorylation	O
level	O
of	O
extracellular	B
-	I
signal	I
-	I
regulated	I
-	I
kinase	I
(	O
ERK	B
(	I
1	I
/	I
2	I
)	I
)	O
,	O
p38	B
MAPK	I
and	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
.	O

The	O
expression	O
of	O
cytokines	B
of	O
MAPK	B
transduction	O
pathway	O
(	O
granulocyte	B
-	I
macrophage	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
mRNA	O
of	O
IL-8	B
)	O
in	O
the	O
primary	O
epithelial	O
cells	O
of	O
respiratory	O
tract	O
was	O
also	O
determined	O
.	O

RESULTS	O
:	O

Western	O
blotting	O
revealed	O
that	O
the	O
phosphorylation	O
levels	O
of	O
ERK	B
(	I
1	I
/	I
2	I
)	I
,	O
p38	B
MAPK	I
and	O
JNK	B
were	O
low	O
and	O
2	O
hours	O
after	O
the	O
LPS	O
stimulation	O
,	O
the	O
phosphorylation	O
of	O
ERK	B
(	I
1	I
/	I
2	I
)	I
,	O
p38	B
MAPK	I
and	O
JNK	B
were	O
all	O
increased	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
phosphorylation	O
between	O
the	O
LPS	O
-	O
stimulation	O
group	O
and	O
blank	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
;	O
no	O
significant	O
difference	O
was	O
found	O
between	O
CSE	O
-	O
stimulation	O
group	O
and	O
blank	O
control	O
group	O
(	O
P	O
>	O
0.05	O
)	O
;	O
there	O
was	O
a	O
significant	O
difference	O
between	O
CSE	O
+	O
LPS	O
group	O
and	O
blank	O
control	O
group	O
and	O
between	O
CSE	O
+	O
LPS	O
group	O
and	O
LPS	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
phosphorylation	O
of	O
CSE	O
-	O
LPS	O
group	O
was	O
higher	O
than	O
that	O
of	O
blank	O
control	O
group	O
but	O
lower	O
than	O
that	O
of	O
LPS	O
group	O
.	O

In	O
blank	O
control	O
group	O
,	O
the	O
expression	O
of	O
IL	B
-	I
8	I
and	O
GM	B
-	I
CSF	I
mRNA	O
was	O
low	O
in	O
the	O
epithelial	O
cells	O
of	O
airway	O
and	O
the	O
release	O
of	O
IL-8	B
and	O
GM	B
-	I
CSF	I
was	O
also	O
at	O
a	O
low	O
level	O
.	O

One	O
hour	O
after	O
LPS	O
stimulation	O
,	O
the	O
level	O
of	O
IL-8	B
mRNA	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
and	O
reached	O
a	O
peak	O
after	O
2	O
hours	O
.	O

On	O
the	O
other	O
hand	O
,	O
GM	B
-	I
CSF	I
mRNA	O
level	O
increased	O
2	O
hours	O
after	O
the	O
stimulation	O
(	O
P	O
<	O
0.05	O
)	O
and	O
reached	O
the	O
highest	O
level	O
4	O
hours	O
after	O
the	O
stimulation	O
.	O

Two	O
hours	O
after	O
LPS	O
stimulation	O
,	O
IL-8	B
and	O
GM	B
-	I
CSF	I
protein	O
level	O
began	O
to	O
rise	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
the	O
level	O
was	O
the	O
highest	O
8	O
hours	O
after	O
the	O
stimulation	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Stimulation	O
with	O
CSE	O
alone	O
had	O
no	O
effect	O
on	O
the	O
release	O
of	O
IL-8	B
and	O
GM	B
-	I
CSF	I
and	O
expression	O
of	O
IL-8	B
mRNA	O
(	O
P	O
>	O
0.05	O
)	O
,	O
but	O
pre	O
-	O
treatment	O
with	O
CSE	O
could	O
delay	O
the	O
LPS	O
-	O
induced	O
release	O
of	O
IL-8	B
and	O
GM	B
-	I
CSF	I
and	O
the	O
expression	O
of	O
IL-8	B
mRNA	O
and	O
its	O
peak	O
was	O
lower	O
.	O

CONCLUSIONS	O
:	O

LPS	O
stimulation	O
can	O
significantly	O
increase	O
the	O
phosphorylation	O
of	O
ERK	B
(	I
1	I
/	I
2	I
)	I
,	O
p38	B
MAPK	I
and	O
JNK	B
in	O
the	O
epithelial	O
cells	O
of	O
airway	O
and	O
activate	O
the	O
MAPK	B
transduction	O
pathway	O
,	O
thereby	O
can	O
activate	O
the	O
downstream	O
signal	O
transduction	O
pathway	O
,	O
and	O
can	O
ultimately	O
result	O
in	O
the	O
release	O
of	O
cytokines	B
by	O
the	O
epithelial	O
cells	O
of	O
airway	O
.	O

CSE	O
can	O
partially	O
abolish	O
the	O
LPS	O
-	O
induced	O
activation	O
of	O
MAPK	B
signal	O
transduction	O
pathway	O
and	O
the	O
expression	O
of	O
cytokines	B
of	O
the	O
pathway	O
,	O
which	O
might	O
contribute	O
to	O
the	O
development	O
and	O
progression	O
of	O
the	O
inflammatory	O
reactions	O
in	O
COPD	O
patients	O
.	O

Evolutionarily	O
conserved	O
mammalian	O
adenine	B
nucleotide	I
translocase	I
4	I
is	O
essential	O
for	O
spermatogenesis	O
.	O

The	O
adenine	B
nucleotide	I
translocases	I
(	O
Ant	B
)	O
facilitate	O
the	O
transport	O
of	O
ADP	O
and	O
ATP	O
by	O
an	O
antiport	O
mechanism	O
across	O
the	O
inner	O
mitochondrial	O
membrane	O
,	O
thus	O
playing	O
an	O
essential	O
role	O
in	O
cellular	O
energy	O
metabolism	O
.	O

We	O
recently	O
identified	O
a	O
novel	O
member	O
of	O
the	O
Ant	B
family	I
in	O
mouse	O
,	O
Ant4	B
,	O
of	O
which	O
gene	O
configuration	O
as	O
well	O
as	O
amino	O
acid	O
homology	O
is	O
well	O
conserved	O
among	O
mammals	O
.	O

The	O
conservation	O
of	O
Ant4	B
in	O
mammals	O
,	O
along	O
with	O
the	O
absence	O
of	O
Ant4	B
in	O
nonmammalian	O
species	O
,	O
suggests	O
a	O
unique	O
and	O
indispensable	O
role	O
for	O
this	O
ADP	O
/	O
ATP	O
carrier	O
in	O
mammalian	O
development	O
.	O

Of	O
interest	O
,	O
in	O
contrast	O
to	O
its	O
paralog	O
Ant2	B
,	O
which	O
is	O
encoded	O
by	O
the	O
X	O
chromosome	O
and	O
ubiquitously	O
expressed	O
in	O
somatic	O
cells	O
,	O
Ant4	B
is	O
encoded	O
by	O
an	O
autosome	O
and	O
selectively	O
expressed	O
in	O
testicular	O
germ	O
cells	O
.	O

Immunohistochemical	O
examination	O
as	O
well	O
as	O
RNA	O
expression	O
analysis	O
using	O
separated	O
spermatogenic	O
cell	O
types	O
revealed	O
that	O
Ant4	B
expression	O
was	O
particularly	O
high	O
in	O
spermatocytes	O
.	O

When	O
we	O
generated	O
Ant4	B
-	O
deficient	O
mice	O
by	O
targeted	O
disruption	O
,	O
a	O
significant	O
reduction	O
in	O
testicular	O
size	O
was	O
observed	O
without	O
any	O
other	O
distinguishable	O
abnormalities	O
in	O
the	O
mice	O
.	O

Histological	O
examination	O
as	O
well	O
as	O
stage	O
-	O
specific	O
gene	O
expression	O
analysis	O
in	O
adult	O
and	O
neonatal	O
testes	O
revealed	O
a	O
severe	O
reduction	O
of	O
spermatocytes	O
accompanied	O
by	O
increased	O
apoptosis	O
.	O

Subsequently	O
,	O
the	O
Ant4	B
-	O
deficient	O
male	O
mice	O
were	O
infertile	O
.	O

Taken	O
together	O
,	O
these	O
data	O
elucidated	O
the	O
indispensable	O
role	O
of	O
Ant4	B
in	O
murine	O
spermatogenesis	O
.	O

Considering	O
the	O
unique	O
conservation	O
and	O
chromosomal	O
location	O
of	O
the	O
Ant	B
family	I
genes	O
in	O
mammals	O
,	O
the	O
Ant4	B
gene	O
may	O
have	O
arisen	O
in	O
mammalian	O
ancestors	O
and	O
been	O
conserved	O
in	O
mammals	O
to	O
serve	O
as	O
the	O
sole	O
and	O
essential	O
mitochondrial	O
ADP	B
/	I
ATP	I
carrier	I
during	O
spermatogenesis	O
where	O
the	O
sex	O
chromosome	O
-	O
linked	O
Ant2	B
gene	O
is	O
inactivated	O
.	O

Expression	O
and	O
selective	O
up	O
-	O
regulation	O
of	O
toxin	O
-	O
related	O
mono	B
ADP	I
-	I
ribosyltransferases	I
by	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
in	O
alveolar	O
epithelial	O
cells	O
.	O

Mono	B
ADP	I
-	I
ribosyltransferases	I
(	O
ARTs	B
)	O
are	O
a	O
family	O
of	O
enzymes	O
related	O
to	O
bacterial	O
toxins	O
that	O
possess	O
adenosine	B
diphosphate	I
ribosyltransferase	I
activity	O
.	O

We	O
have	O
assessed	O
that	O
A549	O
constitutively	O
expressed	O
ART1	B
on	O
the	O
cell	O
surface	O
and	O
shown	O
that	O
lipotheicoic	O
acid	O
(	O
LTA	O
)	O
and	O
flagellin	B
,	O
but	O
not	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
peptidoglycan	O
(	O
PG	O
)	O
and	O
poly	O
(	O
I	O
:	O
C	O
)	O
,	O
up	O
-	O
regulate	O
ART1	B
in	O
a	O
time	O
and	O
dose	O
dependent	O
manner	O
.	O

These	O
agonists	O
did	O
not	O
alter	O
the	O
expression	O
of	O
ART3	B
and	O
ART5	B
genes	O
.	O

Indeed	O
,	O
LTA	O
and	O
flagellin	B
stimulation	O
increased	O
the	O
level	O
of	O
ART1	B
protein	O
and	O
transcript	O
while	O
ART4	B
gene	O
was	O
activated	O
after	O
stimulation	O
of	O
cells	O
with	O
LPS	O
,	O
LTA	O
,	O
PAM	O
and	O
PG	O
via	O
TLR2	B
and	O
TLR4	B
receptors	O
.	O

These	O
results	O
show	O
that	O
human	O
ARTs	B
possess	O
a	O
differential	O
capacity	O
to	O
respond	O
to	O
bacteria	O
cell	O
wall	O
components	O
and	O
might	O
play	O
a	O
crucial	O
role	O
in	O
innate	O
immune	O
response	O
in	O
airways	O
.	O

Tripodal	O
bis	O
(	O
imidazole	O
)	O
thioether	O
copper	O
(	O
I	O
)	O
complexes	O
:	O
mimics	O
of	O
the	O
Cu	O
(	O
M	O
)	O
site	O
of	O
copper	B
hydroxylase	I
enzymes	O
.	O

Tripodal	O
bis	O
(	O
imidazole	O
)	O
thioether	O
ligands	O
,	O
(	O
N	O
-	O
methyl-4,5-diphenyl-2-imidazolyl	O
)	O
2C	O
(	O
OR	O
)	O
C	O
(	O
CH3	O
)	O
2SR	O
'	O
(	O
BIT	O
(	O
OR	O
,	O
SR	O
'	O
)	O
;	O
R	O
=	O
H	O
,	O
CH3	O
;	O
R	O
'	O
=	O
CH3	O
,	O
C	O
(	O
CH3	O
)	O
3	O
,	O
C	O
(	O
C6H5	O
)	O
3	O
)	O
,	O
have	O
been	O
prepared	O
,	O
offering	O
the	O
same	O
N2S	O
donor	O
atom	O
set	O
as	O
the	O
CuM	O
binding	O
site	O
of	O
the	O
hydroxylase	B
enzymes	O
,	O
dopamine	B
beta	I
hydroxylase	I
and	O
peptidylglycine	B
hydroxylating	I
monooxygenase	I
.	O

Isolable	O
copper	O
(	O
I	O
)	O
complexes	O
of	O
the	O
type	O
[	O
(	O
BIT	O
(	O
OR	O
,	O
SMe	O
)	O
)	O
Cu	O
(	O
CO	O
)	O
]	O
PF6	O
(	O
3a	O
and	O
3b	O
)	O
are	O
produced	O
in	O
reactions	O
of	O
the	O
respective	O
tripodal	O
ligands	O
1a	O
(	O
R	O
=	O
H	O
)	O
and	O
1b	O
(	O
R	O
=	O
Me	O
)	O
with	O
[	O
Cu	O
(	O
CH3CN	O
)	O
4	O
]	O
PF6	O
in	O
CH2Cl2	O
under	O
CO	O
(	O
1	O
atm	O
)	O
;	O
the	O
pyramidal	O
structure	O
of	O
3a	O
has	O
been	O
determined	O
crystallographically	O
.	O

The	O
infrared	O
(	O
IR	O
)	O
nu	O
(	O
CO	O
)	O
's	O
of	O
3a	O
and	O
3b	O
(	O
L	O
=	O
CO	O
)	O
are	O
comparable	O
to	O
those	O
of	O
the	O
Cu	O
(	O
M	O
)	O
-carbonylated	O
enzymes	O
,	O
indicating	O
similar	O
electronic	O
character	O
at	O
the	O
copper	O
centers	O
.	O

The	O
reaction	O
of	O
[	O
(	O
BIT	O
(	O
OH	O
,	O
SMe	O
)	O
)	O
Cu	O
(	O
CH3CN	O
)	O
]	O
PF6	O
(	O
2a	O
)	O
with	O
dioxygen	O
produces	O
[	O
(	O
BIT	O
(	O
O	O
,	O
SOMe	O
)	O
)	O
2Cu2	O
(	O
DMF	O
)	O
2	O
]	O
(	O
PF6	O
)	O
2	O
(	O
4	O
)	O
,	O
whose	O
X	O
-	O
ray	O
structure	O
revealed	O
the	O
presence	O
of	O
bridging	O
BIT	O
-	O
alkoxo	O
ligands	O
and	O
terminal	O
-	O
SOMe	O
groups	O
.	O

In	O
contrast	O
,	O
oxygenation	O
of	O
2b	O
(	O
R	O
=	O
Me	O
)	O
affords	O
crystallographically	O
defined	O
[	O
(	O
BIT	O
(	O
OMe	O
,	O
SMe	O
)	O
)	O
2Cu2	O
(	O
mu	O
-	O
OH	O
)	O
2	O
]	O
(	O
OTf	O
)	O
2	O
(	O
5	O
)	O
,	O
in	O
which	O
the	O
copper	O
centers	O
are	O
oxygenated	O
without	O
accompanying	O
sulfur	O
oxidation	O
.	O

Complex	O
5	O
in	O
DMF	O
is	O
transformed	O
into	O
five	O
-	O
coordinate	O
,	O
mononuclear	O
[	O
CuII	O
(	O
BIT	O
(	O
OMe	O
,	O
SMe	O
)	O
)	O
(	O
DMF	O
)	O
2	O
]	O
(	O
PF6	O
)	O
2	O
(	O
6	O
)	O
.	O

The	O
sterically	O
hindered	O
BIT	O
(	O
OR	O
,	O
SR	O
'	O
)	O
ligands	O
9	O
and	O
10	O
(	O
R	O
'	O
=	O
t	O
-	O
Bu	O
;	O
R	O
=	O
H	O
,	O
Me	O
)	O
and	O
11	O
and	O
12	O
(	O
R	O
'	O
=	O
CPh3	O
;	O
R	O
=	O
H	O
,	O
Me	O
)	O
were	O
also	O
prepared	O
and	O
examined	O
for	O
copper	O
coordination	O
/	O
oxygenation	O
.	O

Oxygenation	O
of	O
copper	O
(	O
I	O
)	O
complex	O
13b	O
derived	O
from	O
the	O
BIT	O
(	O
OMe	O
,	O
SBu	O
-	O
t	O
)	O
ligand	O
is	O
slow	O
,	O
relative	O
to	O
2b	O
,	O
producing	O
a	O
mixture	O
of	O
(	O
BIT	O
(	O
OMe	O
,	O
SBu	O
-	O
t	O
)	O
)	O
2Cu2	O
(	O
mu	O
-	O
OH	O
)	O
2	O
-	O
type	O
complexes	O
14b	O
and	O
15b	O
in	O
which	O
the	O
-	O
SBu	O
-	O
t	O
group	O
is	O
uncoordinated	O
;	O
one	O
of	O
these	O
complexes	O
(	O
15b	O
)	O
has	O
been	O
ortho	O
-	O
oxygenated	O
on	O
a	O
neighboring	O
aryl	O
group	O
according	O
to	O
the	O
X	O
-	O
ray	O
analysis	O
and	O
characterization	O
of	O
the	O
free	O
ligand	O
.	O

Oxygenation	O
of	O
the	O
copper	O
(	O
I	O
)	O
complex	O
derived	O
from	O
BIT	O
(	O
OMe	O
,	O
SCPh3	O
)	O
ligand	O
12	O
produces	O
a	O
novel	O
dinuclear	O
disulfide	O
complex	O
,	O
[	O
(	O
BIT	O
(	O
OMe	O
,	O
S	O
)	O
2Cu2	O
(	O
mu	O
-	O
OH	O
)	O
2	O
]	O
(	O
PF6	O
)	O
2	O
(	O
17	O
)	O
,	O
which	O
is	O
structurally	O
characterized	O
.	O
Reactivity	O
studies	O
under	O
anaerobic	O
conditions	O
in	O
the	O
presence	O
of	O
t	O
-	O
BuNC	O
indicate	O
that	O
17	O
is	O
the	O
result	O
of	O
copper	O
(	O
I	O
)	O
-	O
induced	O
detritylation	O
followed	O
by	O
oxygenation	O
of	O
a	O
highly	O
reactive	O
copper	O
(	O
I	O
)	O
-thiolate	O
complex	O
.	O

MyRIP	B
anchors	O
protein	B
kinase	I
A	I
to	O
the	O
exocyst	O
complex	O
.	O

The	O
movement	O
of	O
signal	O
transduction	O
enzymes	O
in	O
and	O
out	O
of	O
multi	O
-	O
protein	O
complexes	O
coordinates	O
the	O
spatial	O
and	O
temporal	O
resolution	O
of	O
cellular	O
events	O
.	O

Anchoring	O
and	O
scaffolding	O
proteins	O
are	O
key	O
to	O
this	O
process	O
because	O
they	O
sequester	O
protein	B
kinases	I
and	O
phosphatases	B
with	O
a	O
subset	O
of	O
their	O
preferred	O
substrates	O
.	O

The	O
protein	B
kinase	I
A	I
-	I
anchoring	I
family	I
of	I
proteins	I
(	O
AKAPs	B
)	O
,	O
which	O
target	O
the	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
(	O
PKA	B
)	O
and	O
other	O
enzymes	O
to	O
defined	O
subcellular	O
microenvironments	O
,	O
represent	O
a	O
well	O
studied	O
group	O
of	O
these	O
signal	O
-	O
organizing	O
molecules	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
the	O
Rab27a	B
GTPase	B
effector	O
protein	O
MyRIP	B
is	O
a	O
member	O
of	O
the	O
AKAP	B
family	I
.	O

The	O
zebrafish	O
homolog	O
of	O
MyRIP	B
(	O
Ze	O
-	O
AKAP2	B
)	O
was	O
initially	O
detected	O
in	O
a	O
two	O
-	O
hybrid	O
screen	O
for	O
AKAPs	B
.	O

A	O
combination	O
of	O
biochemical	O
,	O
cell	O
-	O
based	O
,	O
and	O
immunofluorescence	O
approaches	O
demonstrate	O
that	O
the	O
mouse	O
MyRIP	B
ortholog	O
targets	O
the	O
type	B
II	I
PKA	I
holoenzyme	O
via	O
an	O
atypical	O
mechanism	O
to	O
a	O
specific	O
perinuclear	O
region	O
of	O
insulin	B
-	O
secreting	O
cells	O
.	O

Similar	O
approaches	O
show	O
that	O
MyRIP	B
interacts	O
with	O
the	O
Sec6	B
and	O
Sec8	B
components	O
of	O
the	O
exocyst	B
complex	I
,	O
an	O
evolutionarily	O
conserved	O
protein	O
unit	O
that	O
controls	O
protein	O
trafficking	O
and	O
exocytosis	O
.	O

These	O
data	O
indicate	O
that	O
MyRIP	B
functions	O
as	O
a	O
scaffolding	O
protein	O
that	O
links	O
PKA	B
to	O
components	O
of	O
the	O
exocytosis	O
machinery	O
.	O

Structurally	O
related	O
TPR	O
subunits	O
contribute	O
differently	O
to	O
the	O
function	O
of	O
the	O
anaphase	B
-	I
promoting	I
complex	I
in	O
Drosophila	O
melanogaster	O
.	O

The	O
anaphase	B
-	I
promoting	I
complex	I
/	O
cyclosome	O
or	O
APC	B
/	I
C	I
is	O
a	O
key	O
regulator	O
of	O
chromosome	O
segregation	O
and	O
mitotic	O
exit	O
in	O
eukaryotes	O
.	O

It	O
contains	O
at	O
least	O
11	O
subunits	O
,	O
most	O
of	O
which	O
are	O
evolutionarily	O
conserved	O
.	O

The	O
most	O
abundant	O
constituents	O
of	O
the	O
vertebrate	O
APC	B
/	I
C	I
are	O
the	O
four	O
structurally	O
related	O
tetratrico	O
-	O
peptide	O
repeat	O
(	O
TPR	O
)	O
subunits	O
,	O
the	O
functions	O
of	O
which	O
are	O
not	O
yet	O
precisely	O
understood	O
.	O

Orthologues	O
of	O
three	O
of	O
the	O
TPR	O
subunits	O
have	O
been	O
identified	O
in	O
Drosophila	O
.	O

We	O
have	O
shown	O
previously	O
that	O
one	O
of	O
the	O
TPR	O
subunits	O
of	O
the	O
Drosophila	O
APC	B
/	I
C	I
,	O
Apc3	B
(	O
also	O
known	O
as	O
Cdc27	B
or	O
MÃ?Â¡kos	B
)	O
,	O
is	O
essential	O
for	O
development	O
,	O
and	O
perturbation	O
of	O
its	O
function	O
results	O
in	O
mitotic	O
cyclin	B
accumulation	O
and	O
metaphase	O
-	O
like	O
arrest	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
the	O
Drosophila	O
APC	B
/	I
C	I
associates	O
with	O
a	O
new	O
TPR	O
protein	O
,	O
a	O
genuine	O
orthologue	O
of	O
the	O
vertebrate	O
Apc7	B
subunit	O
that	O
is	O
not	O
found	O
in	O
yeasts	O
.	O

In	O
addition	O
to	O
this	O
,	O
transgenic	O
flies	O
knocked	O
down	O
for	O
three	O
of	O
the	O
TPR	O
genes	O
Apc6	B
(	O
Cdc16	B
)	O
,	O
Apc7	B
and	O
Apc8	B
(	O
Cdc23	B
)	O
,	O
by	O
RNA	O
interference	O
were	O
established	O
to	O
investigate	O
their	O
function	O
.	O

Whole	O
-	O
body	O
expression	O
of	O
subunit	O
-	O
specific	O
dsRNA	O
efficiently	O
silences	O
these	O
genes	O
resulting	O
in	O
only	O
residual	O
mRNA	O
concentrations	O
.	O

Apc6	B
/	O
Cdc16	B
and	O
Apc8	B
/	O
Cdc23	B
silencing	O
induces	O
developmental	O
delay	O
and	O
causes	O
different	O
pupal	O
lethality	O
.	O

Cytological	O
examination	O
showed	O
that	O
these	O
animals	O
had	O
an	O
elevated	O
level	O
of	O
apoptosis	O
,	O
high	O
mitotic	O
index	O
and	O
delayed	O
or	O
blocked	O
mitosis	O
in	O
a	O
prometaphase	O
-	O
metaphase	O
-	O
like	O
state	O
with	O
overcondensed	O
chromosomes	O
.	O

The	O
arrested	O
neuroblasts	O
contained	O
elevated	O
levels	O
of	O
cyclin	B
B	I
but	O
,	O
surprisingly	O
,	O
cyclin	B
A	I
appeared	O
to	O
be	O
degraded	O
normally	O
.	O

Contrary	O
to	O
the	O
situation	O
for	O
the	O
Apc6	B
/	O
Cdc16	B
and	O
Apc8	B
/	O
Cdc23	B
genes	O
,	O
the	O
apparent	O
loss	O
of	O
Apc7	B
function	O
does	O
not	O
lead	O
to	O
the	O
above	O
abnormalities	O
.	O

Instead	O
,	O
the	O
Apc7	B
knocked	O
down	O
animals	O
and	O
null	O
mutants	O
are	O
viable	O
and	O
fertile	O
,	O
although	O
they	O
display	O
mild	O
chromosome	O
segregation	O
defects	O
and	O
anaphase	O
delay	O
.	O

Nevertheless	O
,	O
the	O
Apc7	B
subunit	O
shows	O
synergistic	O
genetic	O
interaction	O
with	O
Apc8	B
/	O
Cdc23	B
that	O
,	O
together	O
with	O
the	O
phenotypic	O
data	O
,	O
assumes	O
a	O
limited	O
functional	O
role	O
for	O
Apc7	B
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
structurally	O
related	O
TPR	O
subunits	O
contribute	O
differently	O
to	O
the	O
function	O
of	O
the	O
anaphase	B
-	I
promoting	I
complex	I
.	O

[	O
Functional	O
dissociation	O
between	O
apelin	B
receptor	I
signaling	O
and	O
endocytosis	O
:	O
implications	O
for	O
the	O
effects	O
of	O
apelin	B
on	O
arterial	O
blood	O
pressure	O
]	O

Apelin	B
is	O
a	O
peptide	O
involved	O
in	O
the	O
regulation	O
of	O
body	O
fluid	O
homeostasis	O
and	O
cardiovascular	O
functions	O
,	O
that	O
was	O
recently	O
isolated	O
as	O
the	O
endogenous	O
ligand	O
for	O
the	O
human	O
orphan	O
APJ	B
receptor	I
,	O
a	O
G	B
protein	I
-	I
coupled	I
receptor	I
which	O
shares	O
31	O
%	O
amino	O
-	O
acid	O
sequence	O
identity	O
with	O
the	O
angiotensin	B
II	I
type	I
1	I
receptor	I
.	O

The	O
predominant	O
molecular	O
forms	O
of	O
apelin	B
naturally	O
occuring	O
in	O
vivo	O
are	O
apelin	B
36	I
,	O
apelin	B
17	I
(	O
K17F	O
)	O
and	O
the	O
pyroglutamyl	O
form	O
of	O
apelin	B
13	I
(	O
pE13F	O
)	O
.	O

We	O
investigated	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
apelin	B
at	O
the	O
rat	O
apelin	B
receptor	I
,	O
tagged	O
at	O
its	O
C	O
-	O
terminal	O
end	O
with	O
enhanced	O
green	B
fluorescent	I
protein	I
and	O
stably	O
expressed	O
in	O
CHO	O
cells	O
.	O

We	O
compared	O
the	O
abilities	O
of	O
N	O
-	O
and	O
C	O
-	O
terminal	O
deleted	O
fragments	O
of	O
K17F	O
(	O
KFRRQRPRLSHKGPMPF	O
)	O
to	O
bind	O
with	O
high	O
affinity	O
to	O
the	O
apelin	B
receptor	I
,	O
to	O
inhibit	O
cAMP	O
production	O
and	O
to	O
induce	O
apelin	B
receptor	I
internalization	O
.	O

The	O
first	O
five	O
N	O
-	O
terminal	O
and	O
the	O
last	O
two	O
C	O
-	O
terminal	O
amino	O
acids	O
of	O
K17F	O
were	O
not	O
essential	O
for	O
apelin	B
binding	O
or	O
cAMP	O
response	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
the	O
arginine	O
in	O
position	O
6	O
drastically	O
decreased	O
binding	O
and	O
cAMP	O
response	O
.	O

The	O
full	O
-	O
length	O
sequence	O
of	O
K17F	O
was	O
the	O
most	O
potent	O
inducer	O
of	O
apelin	B
receptor	I
internalization	O
because	O
successive	O
N	O
-	O
terminal	O
amino	O
-	O
acid	O
deletions	O
progressively	O
reduced	O
internalization	O
and	O
the	O
removal	O
of	O
a	O
single	O
amino	O
acid	O
,	O
the	O
phenylalanine	O
in	O
position	O
17	O
at	O
the	O
C	O
-	O
terminus	O
of	O
K17F	O
abolished	O
this	O
process	O
.	O

Thus	O
,	O
K16P	O
binds	O
with	O
high	O
affinity	O
to	O
the	O
apelin	B
receptor	I
and	O
strongly	O
inhibits	O
cAMP	O
production	O
,	O
but	O
does	O
not	O
induce	O
apelin	B
receptor	I
endocytosis	O
.	O

These	O
data	O
indicate	O
that	O
apelin	B
receptor	I
signaling	O
(	O
coupling	O
to	O
Gi	B
)	O
and	O
endocytosis	O
are	O
functionally	O
dissociated	O
,	O
possibly	O
reflecting	O
the	O
existence	O
of	O
several	O
conformational	O
states	O
of	O
this	O
receptor	O
,	O
stabilized	O
by	O
the	O
binding	O
of	O
different	O
apelin	B
fragments	O
to	O
the	O
receptor	O
.	O

We	O
then	O
investigated	O
the	O
consequences	O
for	O
biological	O
activity	O
of	O
this	O
functional	O
dissociation	O
by	O
evaluating	O
the	O
effects	O
of	O
various	O
apelin	B
fragments	O
,	O
injected	O
iv	O
,	O
on	O
arterial	O
blood	O
pressure	O
in	O
normotensive	O
Wistar	O
Kyoto	O
rats	O
.	O

We	O
showed	O
that	O
apelin	B
fragments	O
,	O
that	O
did	O
not	O
induce	O
receptor	O
internalization	O
in	O
vitro	O
but	O
kept	O
their	O
ability	O
to	O
activate	O
receptor	O
coupling	O
to	O
Gi	B
,	O
did	O
not	O
decrease	O
arterial	O
blood	O
pressure	O
.	O

Our	O
data	O
showed	O
that	O
hypotensive	O
actions	O
of	O
apelin	B
peptides	O
correlate	O
with	O
the	O
ability	O
of	O
those	O
ligands	O
to	O
internalize	O
.	O

Thus	O
,	O
the	O
depressor	O
response	O
of	O
apelin	B
may	O
be	O
controlled	O
by	O
apelin	B
receptor	I
endocytosis	O
,	O
which	O
is	O
probably	O
required	O
for	O
initiation	O
of	O
a	O
second	O
wave	O
of	O
signal	O
transduction	O
.	O

The	O
development	O
of	O
biaised	O
agonists	O
of	O
the	O
apelin	B
receptor	I
capable	O
of	O
promoting	O
only	O
one	O
specific	O
signal	O
transduction	O
pathway	O
may	O
therefore	O
offer	O
new	O
therapeutic	O
avenues	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
disorders	O
.	O

The	O
transcriptional	O
cycle	O
of	O
HIV-1	O
in	O
real	O
-	O
time	O
and	O
live	O
cells	O
.	O

RNA	B
polymerase	I
II	I
(	O
RNAPII	B
)	O
is	O
a	O
fundamental	O
enzyme	O
,	O
but	O
few	O
studies	O
have	O
analyzed	O
its	O
activity	O
in	O
living	O
cells	O
.	O

Using	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
reporters	O
,	O
we	O
study	O
real	O
-	O
time	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
biogenesis	O
by	O
photobleaching	O
nascent	O
RNAs	O
and	O
RNAPII	B
at	O
specific	O
transcription	O
sites	O
.	O

Through	O
modeling	O
,	O
the	O
use	O
of	O
mutant	O
polymerases	B
,	O
drugs	O
,	O
and	O
quantitative	O
in	O
situ	O
hybridization	O
,	O
we	O
investigate	O
the	O
kinetics	O
of	O
the	O
HIV	O
-	O
1	O
transcription	O
cycle	O
.	O

Initiation	O
appears	O
efficient	O
because	O
most	O
polymerases	B
demonstrate	O
stable	O
gene	O
association	O
.	O

We	O
calculate	O
an	O
elongation	O
rate	O
of	O
approximately	O
1.9	O
kb	O
/	O
min	O
,	O
and	O
,	O
surprisingly	O
,	O
polymerases	B
remain	O
at	O
transcription	O
sites	O
2.5	O
min	O
longer	O
than	O
nascent	O
RNAs	O
.	O

With	O
a	O
total	O
polymerase	B
residency	O
time	O
estimated	O
at	O
333	O
s	O
,	O
114	O
are	O
assigned	O
to	O
elongation	O
,	O
and	O
63	O
are	O
assigned	O
to	O
3	O
'	O
-	O
end	O
processing	O
and	O
/	O
or	O
transcript	O
release	O
.	O

However	O
,	O
mRNAs	O
were	O
released	O
seconds	O
after	O
polyadenylation	O
onset	O
,	O
and	O
analysis	O
of	O
polymerase	B
density	O
by	O
chromatin	O
immunoprecipitation	O
suggests	O
that	O
they	O
pause	O
or	O
lose	O
processivity	O
after	O
passing	O
the	O
polyA	O
site	O
.	O

The	O
strengths	O
and	O
limitations	O
of	O
this	O
kinetic	O
approach	O
to	O
analyze	O
mRNA	O
biogenesis	O
in	O
living	O
cells	O
are	O
discussed	O
.	O

Mutations	O
in	O
the	O
UBIAD1	B
gene	O
on	O
chromosome	O
short	O
arm	O
1	O
,	O
region	O
36	O
,	O
cause	O
Schnyder	O
crystalline	O
corneal	O
dystrophy	O
.	O

PURPOSE	O
:	O

Schnyder	O
crystalline	O
corneal	O
dystrophy	O
(	O
SCCD	O
;	O
MIM	O
121800	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
characterized	O
by	O
an	O
abnormal	O
increase	O
in	O
cholesterol	O
and	O
phospholipid	O
deposition	O
in	O
the	O
cornea	O
,	O
leading	O
to	O
progressive	O
corneal	O
opacification	O
.	O

Although	O
SCCD	O
has	O
been	O
mapped	O
to	O
a	O
genetic	O
interval	O
between	O
markers	O
D1S1160	O
and	O
D1S1635	O
,	O
reclassification	O
of	O
a	O
previously	O
unaffected	O
individual	O
expanded	O
the	O
interval	O
to	O
D1S2667	O
and	O
included	O
nine	O
additional	O
genes	O
.	O

Three	O
candidate	O
genes	O
that	O
may	O
be	O
involved	O
in	O
lipid	O
metabolism	O
and/or	O
are	O
expressed	O
in	O
the	O
cornea	O
were	O
analyzed	O
.	O

METHODS	O
:	O

DNA	O
samples	O
were	O
obtained	O
from	O
six	O
families	O
with	O
clinically	O
confirmed	O
SCCD	O
.	O

Analysis	O
of	O
FRAP1	B
,	O
ANGPTL7	B
,	O
and	O
UBIAD1	B
was	O
performed	O
by	O
PCR	O
-	O
based	O
DNA	O
sequencing	O
,	O
to	O
examine	O
protein	O
-	O
coding	O
regions	O
,	O
RNA	O
splice	O
junctions	O
,	O
and	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
exons	O
.	O

RESULTS	O
:	O

No	O
disease	O
-	O
causing	O
mutations	O
were	O
found	O
in	O
the	O
FRAP1	B
or	O
ANGPTL7	B
gene	O
.	O

A	O
mutation	O
in	O
UBIAD1	B
was	O
identified	O
in	O
all	O
six	O
families	O
:	O
Five	O
families	O
had	O
the	O
same	O
N102S	O
mutation	O
,	O
and	O
one	O
family	O
had	O
a	O
G177R	O
mutation	O
.	O

Predictions	O
of	O
the	O
protein	O
structure	O
indicated	O
that	O
a	O
prenyl	B
-	I
transferase	I
domain	O
and	O
several	O
transmembrane	O
helices	O
are	O
affected	O
by	O
these	O
mutations	O
.	O

Each	O
mutation	O
cosegregated	O
with	O
the	O
disease	O
in	O
four	O
families	O
with	O
DNA	O
samples	O
from	O
both	O
affected	O
and	O
unaffected	O
individuals	O
.	O

Mutations	O
were	O
not	O
observed	O
in	O
100	O
control	O
DNA	O
samples	O
(	O
200	O
chromosomes	O
)	O
.	O

CONCLUSIONS	O
:	O

Nonsynonymous	O
mutations	O
in	O
the	O
UBIAD1	B
gene	O
were	O
detected	O
in	O
six	O
SCCD	O
families	O
,	O
and	O
a	O
potential	O
mutation	O
hot	O
spot	O
was	O
observed	O
at	O
amino	O
acid	O
N102	O
.	O

The	O
mutations	O
are	O
expected	O
to	O
interfere	O
with	O
the	O
function	O
of	O
the	O
UBIAD1	B
protein	O
,	O
since	O
they	O
are	O
located	O
in	O
highly	O
conserved	O
and	O
structurally	O
important	O
domains	O
.	O

Activation	O
of	O
protein	B
kinase	I
C	I
decreases	O
phosphorylation	O
of	O
c	B
-	I
Jun	I
at	O
sites	O
that	O
negatively	O
regulate	O
its	O
DNA	O
-	O
binding	O
activity	O
.	O

In	O
resting	O
human	O
epithelial	O
and	O
fibroblastic	O
cells	O
,	O
c	B
-	I
Jun	I
is	O
phosphorylated	O
on	O
serine	O
and	O
threonine	O
at	O
five	O
sites	O
,	O
three	O
of	O
which	O
are	O
phosphorylated	O
in	O
vitro	O
by	O
glycogen	B
synthase	I
kinase	I
3	I
(	O
GSK-3	B
)	O
.	O

These	O
three	O
sites	O
are	O
nested	O
within	O
a	O
single	O
tryptic	O
peptide	O
located	O
just	O
upstream	O
of	O
the	O
basic	O
region	O
of	O
the	O
c	B
-	I
Jun	I
DNA	O
-	O
binding	O
domain	O
(	O
residues	O
227	O
-	O
252	O
)	O
.	O

Activation	O
of	O
protein	B
kinase	I
C	I
results	O
in	O
rapid	O
,	O
site	O
-	O
specific	O
dephosphorylation	O
of	O
c	B
-	I
Jun	I
at	O
one	O
or	O
more	O
of	O
these	O
three	O
sites	O
and	O
is	O
coincident	O
with	O
increased	O
AP-1	B
-	O
binding	O
activity	O
.	O

Phosphorylation	O
of	O
recombinant	O
human	O
c	B
-	I
Jun	I
proteins	O
in	O
vitro	O
by	O
GSK-3	B
decreases	O
their	O
DNA	O
-	O
binding	O
activity	O
.	O

Mutation	O
of	O
serine	O
243	O
to	O
phenylalanine	O
blocks	O
phosphorylation	O
of	O
all	O
three	O
sites	O
in	O
vivo	O
and	O
increases	O
the	O
inherent	O
trans	O
-	O
activation	O
ability	O
of	O
c	B
-	I
Jun	I
at	O
least	O
10	O
-	O
fold	O
.	O

We	O
propose	O
that	O
c	B
-	I
Jun	I
is	O
present	O
in	O
resting	O
cells	O
in	O
a	O
latent	O
,	O
phosphorylated	O
form	O
that	O
can	O
be	O
activated	O
by	O
site	O
-	O
specific	O
dephosphorylation	O
in	O
response	O
to	O
protein	B
kinase	I
C	I
activation	O
.	O

Effect	O
of	O
promoter	O
mutations	O
and	O
upstream	O
deletions	O
on	O
the	O
expression	O
of	O
genes	O
coding	O
for	O
small	O
,	O
acid	O
-	O
soluble	O
spore	O
proteins	O
of	O
Bacillus	O
subtilis	O
.	O

The	O
sspB	B
and	O
sspE	B
genes	O
code	O
for	O
major	O
small	O
,	O
acid	O
-	O
soluble	O
proteins	O
of	O
Bacillus	O
subtilis	O
spores	O
and	O
are	O
transcribed	O
during	O
sporulation	O
by	O
RNA	B
polymerase	I
containing	O
sigma	B
G	I
.	O

Analysis	O
of	O
the	O
expression	O
in	O
vivo	O
and	O
the	O
sigma	B
G	I
-	O
dependent	O
transcription	O
in	O
vitro	O
of	O
sspB	B
and	O
sspE	B
genes	O
carrying	O
upstream	O
deletions	O
or	O
point	O
mutations	O
in	O
-	O
10	O
and	O
-	O
35	O
promoter	O
regions	O
is	O
consistent	O
with	O
sigma	B
G	I
being	O
the	O
only	O
major	O
transcriptional	O
regulator	O
of	O
these	O
genes	O
.	O

These	O
data	O
also	O
provide	O
information	O
on	O
the	O
residues	O
in	O
-	O
10	O
and	O
-	O
35	O
regions	O
which	O
are	O
most	O
important	O
for	O
sigma	B
G	I
recognition	O
.	O

Control	O
of	O
transcription	O
of	O
the	O
Bacillus	O
subtilis	O
spoIIIG	B
gene	O
,	O
which	O
codes	O
for	O
the	O
forespore	O
-	O
specific	O
transcription	B
factor	I
sigma	B
G	I
.	O

The	O
Bacillus	O
subtilis	O
spoIIIG	B
gene	O
codes	O
for	O
a	O
sigma	B
factor	I
termed	O
sigma	B
G	I
which	O
directs	O
transcription	O
of	O
genes	O
expressed	O
only	O
in	O
the	O
forespore	O
compartment	O
of	O
the	O
sporulating	O
cell	O
.	O

Use	O
of	O
spoIIIG	B
-	O
lacZ	B
transcriptional	O
fusions	O
showed	O
that	O
spoIIIG	B
is	O
cotranscribed	O
with	O
the	O
spoIIG	B
operon	I
beginning	O
at	O
t0.5	O
-	O
1	O
of	O
sporulation	O
.	O

However	O
,	O
this	O
large	O
mRNA	O
produced	O
little	O
if	O
any	O
sigma	B
G	I
,	O
and	O
transferring	O
the	O
spoIIIG	B
gene	O
without	O
the	O
spoIIG	B
promoter	O
into	O
the	O
amyE	B
locus	O
resulted	O
in	O
a	O
Spo	B
+	O
phenotype	O
.	O

Significant	O
translation	O
of	O
spoIIIG	B
began	O
at	O
t2.5	O
-	O
3	O
with	O
use	O
of	O
an	O
mRNA	O
whose	O
5	O
'	O
end	O
is	O
just	O
upstream	O
of	O
the	O
spoIIIG	B
coding	O
sequence	O
.	O

Synthesis	O
of	O
this	O
spoIIIG	B
-	O
specific	O
mRNA	O
was	O
not	O
abolished	O
by	O
a	O
deletion	O
in	O
spoIIIG	B
itself	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
spoIIIG	B
-	O
lacZ	B
translational	O
fusion	O
lacking	O
the	O
spoIIG	B
promoter	O
was	O
integrated	O
at	O
the	O
amyE	B
locus	O
.	O

These	O
data	O
suggest	O
that	O
synthesis	O
of	O
sigma	B
G	I
is	O
dependent	O
neither	O
on	O
transcription	O
from	O
the	O
spoIIG	B
promoter	O
nor	O
on	O
sigma	B
G	I
itself	O
but	O
can	O
be	O
due	O
to	O
another	O
transcription	B
factor	I
.	O

This	O
transcription	B
factor	I
may	O
be	O
sigma	B
F	I
,	O
the	O
product	O
of	O
the	O
spoIIAC	B
locus	O
,	O
since	O
a	O
spoIIAC	B
mutation	O
blocked	O
spoIIIG	B
expression	O
,	O
and	O
sequences	O
upstream	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
spoIIIG	B
-	O
specific	O
mRNA	O
agree	O
well	O
with	O
the	O
recognition	O
sequence	O
for	O
sigma	B
F	I
.	O

RNA	B
polymerase	I
containing	O
sigma	B
F	I
(	O
E	B
sigma	I
F	I
)	O
initiated	O
transcription	O
in	O
vitro	O
on	O
a	O
spoIIIG	B
template	O
at	O
the	O
5	O
'	O
end	O
found	O
in	O
vivo	O
,	O
as	O
did	O
E	B
sigma	I
G	I
.	O

However	O
,	O
E	B
sigma	I
F	I
showed	O
a	O
greater	O
than	O
20	O
-	O
fold	O
preference	O
for	O
spoIIIG	B
over	O
a	O
known	O
sigma	B
G	I
-	O
dependent	O
gene	O
compared	O
with	O
the	O
activity	O
of	O
E	B
sigma	I
G	I
.	O

Phosphorylation	O
of	O
c	B
-	I
jun	I
mediated	O
by	O
MAP	B
kinases	I
.	O

The	O
proto	O
-	O
oncogene	O
c	B
-	I
jun	I
is	O
a	O
component	O
of	O
the	O
AP-1	B
transcription	I
factor	I
family	I
involved	O
in	O
the	O
mediation	O
of	O
nuclear	O
events	O
elicited	O
by	O
extracellular	O
stimuli	O
.	O

The	O
c	B
-	I
jun	I
protein	O
is	O
negatively	O
regulated	O
by	O
phosphorylation	O
of	O
residues	O
near	O
the	O
carboxy	O
terminus	O
which	O
are	O
dephosphorylated	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O

Here	O
we	O
identify	O
two	O
serine	O
residues	O
in	O
the	O
amino	O
terminal	O
A1	O
transactivation	O
domain	O
which	O
are	O
phosphorylated	O
in	O
response	O
to	O
a	O
variety	O
of	O
mitogens	O
,	O
phorbol	O
esters	O
and	O
activated	O
ras	B
.	O

We	O
present	O
evidence	O
that	O
mitogen	B
-	I
activated	I
protein	I
-	I
serine	I
(	I
MAP	I
)	I
kinases	I
(	O
pp54	O
and	O
pp42	O
/	O
44	O
)	O
specifically	O
phosphorylate	O
these	O
sites	O
and	O
that	O
their	O
phosphorylation	O
positively	O
regulates	O
the	O
transacting	O
activity	O
of	O
c	B
-	I
jun	I
.	O

The	O
MAP	B
kinase	I
enzymes	O
pp54	O
and	O
pp42	O
/	O
44	O
are	O
regulated	O
by	O
tyrosine	O
as	O
well	O
as	O
serine	O
/	O
threonine	O
phosphorylation	O
.	O

MAP	B
kinase	I
activation	O
of	O
c	B
-	I
jun	I
may	O
underlie	O
the	O
common	O
stimulation	O
of	O
this	O
transcription	B
factor	I
by	O
mitogens	O
,	O
growth	B
factors	I
and	O
oncogenes	O
.	O

Promoter	O
specificity	O
of	O
sigma	B
G	I
-	O
containing	O
RNA	B
polymerase	I
from	O
sporulating	O
cells	O
of	O
Bacillus	O
subtilis	O
:	O
identification	O
of	O
a	O
group	O
of	O
forespore	O
-	O
specific	O
promoters	O
.	O

During	O
sporulation	O
in	O
Bacillus	O
subtilis	O
,	O
expression	O
of	O
the	O
genes	O
sspA	B
,	O
sspB	B
,	O
sspC	B
,	O
sspD	B
,	O
and	O
sspE	B
,	O
which	O
encode	O
a	O
family	O
of	O
small	O
,	O
acid	O
-	O
soluble	O
spore	O
proteins	O
,	O
as	O
well	O
as	O
of	O
the	O
spoVA	B
and	O
gdh	B
operons	O
is	O
transcriptionally	O
activated	O
at	O
stage	O
III	O
of	O
sporulation	O
only	O
in	O
the	O
forespore	O
compartment	O
.	O

Transcription	O
of	O
these	O
genes	O
is	O
mediated	O
by	O
RNA	B
polymerase	I
containing	O
sigma	B
G	I
(	O
E	B
sigma	I
G	I
)	O
,	O
the	O
product	O
of	O
the	O
sigG	B
gene	O
,	O
which	O
is	O
itself	O
expressed	O
at	O
stage	O
III	O
in	O
the	O
developing	O
forespore	O
.	O

We	O
have	O
determined	O
the	O
5	O
'	O
ends	O
of	O
transcripts	O
generated	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
the	O
action	O
of	O
E	B
sigma	I
G	I
on	O
various	O
genes	O
of	O
B.	O
subtilis	O
and	O
other	O
bacilli	O
.	O

The	O
5	O
'	O
ends	O
of	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
mRNAs	O
were	O
found	O
to	O
coincide	O
and	O
were	O
therefore	O
considered	O
to	O
define	O
the	O
transcription	O
initiation	O
sites	O
for	O
the	O
genes	O
examined	O
.	O

We	O
identified	O
highly	O
homologous	O
DNA	O
sequences	O
centered	O
at	O
35	O
and	O
10	O
base	O
pairs	O
preceding	O
the	O
transcriptional	O
start	O
sites	O
of	O
the	O
genes	O
examined	O
.	O

Consequently	O
,	O
we	O
propose	O
that	O
these	O
sequences	O
define	O
a	O
class	O
of	O
promoters	O
recognized	O
only	O
by	O
E	B
sigma	I
G	I
which	O
allow	O
transcription	O
of	O
genes	O
expressed	O
uniquely	O
at	O
stage	O
III	O
in	O
the	O
developing	O
forespore	O
.	O

Switch	O
protein	O
alters	O
specificity	O
of	O
RNA	B
polymerase	I
containing	O
a	O
compartment	O
-	O
specific	O
sigma	B
factor	I
.	O

During	O
sporulation	O
in	O
Bacillus	O
subtilis	O
,	O
expression	O
of	O
developmental	O
genes	O
spoIVCB	B
and	O
cotD	B
is	O
induced	O
in	O
the	O
mother	O
cell	O
compartment	O
of	O
the	O
sporangium	O
at	O
morphological	O
stages	O
IV	O
and	O
V	O
,	O
respectively	O
.	O

A	O
27	O
-	O
kilodalton	O
RNA	B
polymerase	I
sigma	I
factor	I
called	O
sigma	B
K	I
(	O
or	O
sigma	B
27	I
)	O
has	O
been	O
found	O
that	O
causes	O
weak	O
transcription	O
of	O
spoIVCB	B
and	O
strong	O
transcription	O
of	O
cotD	B
.	O

A	O
14	O
-	O
kD	O
protein	O
was	O
also	O
discovered	O
that	O
changes	O
the	O
specificity	O
of	O
sigma	B
K	I
-	O
containing	O
RNA	B
polymerase	I
,	O
greatly	O
stimulating	O
spoIVCB	B
transcription	O
and	O
markedly	O
repressing	O
cotD	B
transcription	O
.	O

Both	O
sigma	B
K	I
and	O
the	O
14	O
-	O
kD	O
protein	O
are	O
products	O
of	O
genes	O
known	O
to	O
be	O
required	O
for	O
expression	O
of	O
specific	O
genes	O
in	O
the	O
mother	O
cell	O
.	O

Thus	O
,	O
sigma	B
K	I
directs	O
gene	O
expression	O
in	O
the	O
mother	O
cell	O
and	O
it	O
is	O
proposed	O
that	O
inactivation	O
or	O
sequestering	O
of	O
the	O
14	O
-	O
kD	O
protein	O
switches	O
the	O
temporal	O
pattern	O
of	O
gene	O
expression	O
during	O
the	O
transition	O
from	O
stages	O
IV	O
to	O
V	O
of	O
development	O
.	O

Mutation	O
changing	O
the	O
specificity	O
of	O
an	O
RNA	B
polymerase	I
sigma	I
factor	I
.	O

We	O
describe	O
a	O
mutation	O
that	O
changes	O
the	O
fine	O
specificity	O
of	O
promoter	O
selection	O
by	O
a	O
secondary	O
form	O
of	O
RNA	B
polymerase	I
holoenzyme	O
in	O
Bacillus	O
subtilis	O
.	O

The	O
product	O
of	O
regulatory	O
gene	O
spo0H	B
is	O
an	O
RNA	B
polymerase	I
sigma	I
factor	I
called	O
sigma	B
H	I
,	O
which	O
directs	O
transcription	O
of	O
a	O
sporulation	O
gene	O
known	O
as	O
spoVG	B
.	O

We	O
show	O
that	O
the	O
spo0H	B
mutation	O
spo0H81	B
,	O
which	O
blocks	O
transcription	O
from	O
the	O
wild	O
-	O
type	O
spoVG	B
promoter	O
,	O
enhances	O
transcription	O
from	O
a	O
mutant	O
form	O
of	O
the	O
spoVG	B
promoter	O
(	O
spoVG249	B
)	O
bearing	O
a	O
severe	O
down	O
-	O
mutation	O
(	O
a	O
G.C	O
to	O
A.T	O
transition	O
)	O
at	O
position	O
-	O
13	O
in	O
the	O
""""	O
-	O
10	O
region	O
.	O
""""	O

Suppression	O
of	O
the	O
spoVG249	B
mutation	O
is	O
specific	O
in	O
the	O
sense	O
that	O
the	O
transcription	O
from	O
several	O
other	O
spoVG	B
mutant	O
promoters	O
was	O
not	O
restored	O
by	O
the	O
mutant	O
sigma	O
.	O

Evidently	O
,	O
spo0H81	B
is	O
a	O
change	O
-	O
of	O
-	O
specificity	O
mutation	O
that	O
alters	O
sigma	B
H	I
-	O
RNA	B
polymerase	I
in	O
a	O
way	O
that	O
decreases	O
its	O
capacity	O
to	O
use	O
the	O
wild	O
-	O
type	O
spoVG	B
promoter	O
,	O
while	O
increasing	O
its	O
capacity	O
to	O
use	O
the	O
mutant	O
promoter	O
.	O

Transcription	O
experiments	O
in	O
vitro	O
using	O
RNA	B
polymerase	I
containing	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
sigma	O
support	O
this	O
interpretation	O
.	O

The	O
spo0H81	B
mutation	O
causes	O
a	O
threonine	O
(	O
Thr100	O
)	O
to	O
isoleucine	O
substitution	O
in	O
a	O
region	O
of	O
sigma	B
H	I
that	O
is	O
highly	O
homologous	O
among	O
sigma	B
factors	I
of	O
diverse	O
origins	O
.	O

We	O
discuss	O
the	O
possibility	O
that	O
Thr100	O
is	O
an	O
amino	O
acid	O
-	O
base	O
-	O
pair	O
contact	O
site	O
and	O
that	O
sigma	B
factors	I
contact	O
the	O
-	O
10	O
region	O
of	O
their	O
cognate	O
promoters	O
by	O
means	O
of	O
amino	O
acid	O
residues	O
in	O
this	O
highly	O
conserved	O
region	O
.	O

Genetic	O
mapping	O
of	O
rpoD	B
implicates	O
the	O
major	O
sigma	B
factor	I
of	O
Bacillus	O
subtilis	O
RNA	B
polymerase	I
in	O
sporulation	O
initiation	O
.	O

We	O
have	O
mapped	O
the	O
chromosomal	O
locus	O
of	O
rpoD	B
,	O
which	O
encodes	O
the	O
major	O
sigma	B
factor	I
of	O
Bacillus	O
subtilis	O
RNA	B
polymerase	I
.	O

The	O
rpoD	B
locus	O
lay	O
between	O
aroD	B
and	O
lys	B
,	O
tightly	O
linked	O
to	O
dnaE	B
and	O
inseparable	O
from	O
crsA	B
.	O

Marker	O
order	O
in	O
this	O
region	O
was	O
acf	O
-	O
aroD	B
-	O
dnaE	B
-	O
rpoD	B
(	O
crsA	B
)	O
-	O
spoOG	B
-	O
lys	B
.	O

By	O
transformation	O
using	O
cloned	O
donor	O
DNA	O
from	O
the	O
rpoD	B
region	O
,	O
we	O
identified	O
the	O
gene	O
immediately	O
upstream	O
of	O
rpoD	B
as	O
dnaE	B
,	O
which	O
coded	O
for	O
a	O
62,000	O
dalton	O
protein	O
essential	O
for	O
DNA	O
replication	O
.	O

Both	O
dnaE	B
and	O
rpoD	B
were	O
transcribed	O
in	O
the	O
same	O
direction	O
,	O
counterclockwise	O
on	O
the	O
chromosome	O
.	O

The	O
gene	O
functions	O
and	O
organization	O
in	O
the	O
rpoD	B
region	O
are	O
thus	O
similar	O
to	O
those	O
of	O
the	O
E.	O
coli	O
sigma	O
operon	O
.	O

We	O
also	O
used	O
transformation	O
to	O
identify	O
crsA47	O
as	O
a	O
mutation	O
within	O
the	O
sigma	O
coding	O
region	O
itself	O
.	O

The	O
crsA	B
alteration	O
of	O
sigma	O
renders	O
the	O
sporulation	O
process	O
insensitive	O
to	O
glucose	O
catabolite	O
repression	O
,	O
and	O
also	O
restores	O
sporulation	O
ability	O
to	O
strains	O
carrying	O
early	O
-	O
blocked	O
spoOE	B
,	O
spoOF	B
,	O
and	O
spoOK	B
mutations	O
.	O

Thus	O
the	O
major	O
sigma	B
factor	I
and	O
these	O
spoO	B
gene	O
products	O
directly	O
or	O
indirectly	O
affect	O
the	O
same	O
cellular	O
function	O
.	O

Nucleotide	O
sequence	O
and	O
organization	O
of	O
Bacillus	O
subtilis	O
RNA	B
polymerase	I
major	O
sigma	O
(	O
sigma	B
43	I
)	O
operon	O
.	O

The	O
gene	O
coding	O
for	O
Bacillus	O
subtilis	O
RNA	B
polymerase	I
major	O
sigma	B
43	I
,	O
rpoD	B
,	O
was	O
cloned	O
together	O
with	O
its	O
neighboring	O
genes	O
in	O
a	O
7	O
kb	O
EcoRI	B
fragment	O
.	O

The	O
complete	O
nucleotide	O
sequence	O
of	O
a	O
5	O
kb	O
fragment	O
including	O
the	O
entire	O
rpoD	B
gene	O
revealed	O
the	O
presence	O
of	O
two	O
other	O
genes	O
preceding	O
rpoD	B
in	O
the	O
order	O
P23	B
-	O
dnaE	B
-	O
rpoD	B
.	O

The	O
dnaE	B
codes	O
for	O
DNA	B
primase	I
while	O
the	O
function	O
of	O
P23	B
remains	O
unknown	O
.	O

The	O
three	O
genes	O
reside	O
in	O
an	O
operon	O
that	O
is	O
similar	O
in	O
organization	O
to	O
the	O
E.	O
coli	O
RNA	B
polymerase	I
major	O
sigma	B
70	I
operon	O
,	O
which	O
is	O
composed	O
of	O
genes	O
encoding	O
small	B
ribosome	I
protein	I
S21	I
(	O
rpsU	B
)	O
,	O
DNA	B
primase	I
(	O
dnaG	B
)	O
,	O
and	O
RNA	B
polymerase	I
sigma	I
70	I
(	O
rpoD	B
)	O
.	O

There	O
is	O
a	O
relatively	O
high	O
degree	O
of	O
base	O
and	O
amino	O
acid	O
homology	O
between	O
the	O
DNA	B
primase	I
and	O
sigma	O
genes	O
.	O

The	O
most	O
significant	O
differences	O
between	O
the	O
two	O
operons	O
are	O
observed	O
in	O
the	O
molecular	O
size	O
of	O
the	O
first	O
genes	O
(	O
P23	B
and	O
rpsU	B
)	O
,	O
the	O
complete	O
lack	O
of	O
amino	O
acid	O
homology	O
between	O
P23	B
and	O
S21	B
,	O
the	O
molecular	O
weights	O
of	O
the	O
two	O
rpoD	B
genes	O
,	O
the	O
size	O
of	O
the	O
intercistronic	O
region	O
between	O
the	O
first	O
two	O
genes	O
,	O
and	O
the	O
regulatory	O
elements	O
of	O
the	O
operon	O
.	O

Use	O
of	O
a	O
lacZ	B
gene	O
fusion	O
to	O
determine	O
the	O
dependence	O
pattern	O
of	O
sporulation	O
operon	O
spoIIIC	B
in	O
spo	O
mutants	O
of	O
Bacillus	O
subtilis	O
:	O
a	O
branched	O
pathway	O
of	O
expression	O
of	O
sporulation	O
operons	O
.	O

The	O
sporulation	O
gene	O
spoIIIC	B
from	O
Bacillus	O
subtilis	O
was	O
fused	O
to	O
the	O
lacZ	B
gene	O
from	O
Escherichia	O
coli	O
,	O
so	O
that	O
the	O
transcription	O
of	O
the	O
lacZ	B
gene	O
was	O
under	O
the	O
control	O
of	O
the	O
spoIIIC	B
promoter	O
.	O

Production	O
of	O
beta	B
-	I
galactosidase	I
,	O
under	O
conditions	O
of	O
sporulation	O
,	O
was	O
then	O
used	O
as	O
an	O
indicator	O
to	O
study	O
the	O
expression	O
of	O
spoIIIC	B
in	O
relation	O
to	O
other	O
sporulation	O
loci	O
.	O

Expression	O
of	O
spoIIIC	B
,	O
which	O
occurred	O
only	O
in	O
the	O
mother	O
cell	O
compartment	O
,	O
was	O
prevented	O
by	O
mutations	O
in	O
all	O
of	O
the	O
stage	O
0	O
and	O
stage	O
II	O
loci	O
,	O
and	O
also	O
by	O
spoIIID	B
,	O
spoIVA	B
and	O
spoIVB	B
mutations	O
.	O

By	O
contrast	O
,	O
the	O
last	O
three	O
operons	O
are	O
not	O
needed	O
for	O
expression	O
of	O
spoVA	B
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
spore	O
-	O
specific	O
.	O

In	O
consequence	O
,	O
a	O
branched	O
pathway	O
of	O
gene	O
expression	O
is	O
proposed	O
.	O

One	O
branch	O
leads	O
to	O
expression	O
of	O
spoVA	B
within	O
the	O
spore	O
compartment	O
,	O
the	O
other	O
to	O
expression	O
of	O
spoIIIC	B
in	O
the	O
mother	O
cell	O
.	O

Utilization	O
of	O
one	O
promoter	O
by	O
two	O
forms	O
of	O
RNA	B
polymerase	I
from	O
Bacillus	O
subtilis	O
.	O

Bacillus	O
subtilis	O
possesses	O
several	O
forms	O
of	O
RNA	B
polymerase	I
,	O
each	O
differing	O
in	O
its	O
sigma	O
subunit	O
and	O
its	O
specificity	O
of	O
promoter	O
recognition	O
.	O

The	O
sequential	O
appearance	O
of	O
sigma	O
subunits	O
,	O
which	O
change	O
the	O
promoter	O
recognition	O
specificity	O
of	O
RNA	B
polymerase	I
,	O
may	O
have	O
a	O
key	O
role	O
in	O
controlling	O
the	O
temporal	O
pattern	O
of	O
gene	O
expression	O
required	O
for	O
endospore	O
development	O
in	O
B.	O
subtilis	O
.	O

Several	O
genes	O
that	O
are	O
expressed	O
over	O
relatively	O
long	O
periods	O
of	O
time	O
during	O
the	O
developmental	O
cycle	O
are	O
transcribed	O
by	O
more	O
than	O
one	O
form	O
of	O
RNA	B
polymerase	I
,	O
which	O
initiate	O
transcription	O
from	O
either	O
tandem	O
or	O
overlapping	O
promoter	O
.	O

The	O
promoter	O
region	O
for	O
the	O
ctc	B
gene	O
is	O
interesting	O
because	O
transcription	O
is	O
initiated	O
at	O
or	O
near	O
the	O
same	O
position	O
by	O
both	O
sigma	B
37	I
RNA	B
polymerase	I
(	O
E	B
sigma	I
37	I
)	O
,	O
a	O
minor	O
form	O
in	O
growing	O
cells	O
,	O
and	O
sigma	B
29	I
RNA	B
polymerase	I
(	O
E	B
sigma	I
29	I
)	O
,	O
a	O
form	O
which	O
appears	O
approximately	O
2	O
h	O
after	O
the	O
initiation	O
of	O
sproulation	O
.	O

Here	O
we	O
report	O
that	O
several	O
base	O
substitutions	O
in	O
the	O
ctc	O
promoter	O
differentially	O
affect	O
the	O
utilization	O
of	O
the	O
promoter	O
by	O
E	B
sigma	I
37	I
or	O
E	B
sigma	I
29	I
.	O

Evidence	O
that	O
the	O
transcriptional	O
activator	O
Spo0A	B
interacts	O
with	O
two	O
sigma	B
factors	I
in	O
Bacillus	O
subtilis	O
.	O

The	O
transcriptional	O
regulator	O
Spo0A	B
activates	O
transcription	O
from	O
two	O
types	O
of	O
promoters	O
.	O

One	O
type	O
of	O
promoter	O
is	O
used	O
by	O
RNA	B
polymerase	I
containing	O
sigma	B
A	I
,	O
whereas	O
the	O
other	O
type	O
is	O
used	O
by	O
RNA	B
polymerase	I
containing	O
sigma	B
H	I
.	O

There	O
are	O
Spo0A	B
-	O
binding	O
sites	O
near	O
the	O
-	O
35	O
region	O
of	O
both	O
types	O
of	O
promoters	O
.	O

It	O
has	O
been	O
reported	O
that	O
some	O
transcriptional	O
regulators	O
that	O
bind	O
near	O
the	O
-	O
35	O
regions	O
of	O
promoters	O
directly	O
interact	O
with	O
the	O
sigma	O
subunit	O
of	O
RNA	B
polymerase	I
.	O

Therefore	O
,	O
we	O
looked	O
for	O
evidence	O
that	O
Spo0A	B
interacts	O
with	O
both	O
sigma	B
factors	I
by	O
searching	O
for	O
single	O
amino	O
acid	O
substitutions	O
in	O
these	O
factors	O
that	O
specifically	O
prevent	O
expression	O
from	O
Spo0A	B
-	O
dependent	O
promoters	O
,	O
but	O
that	O
do	O
not	O
decrease	O
activity	O
of	O
Spo0A	B
-	O
independent	O
promoters	O
.	O

Two	O
such	O
amino	O
acid	O
substitutions	O
were	O
isolated	O
in	O
sigma	B
A	I
and	O
one	O
was	O
isolated	O
in	O
sigma	B
H	I
.	O

The	O
amino	O
acid	O
substitutions	O
in	O
sigma	B
A	I
prevented	O
expression	O
from	O
the	O
Spo0A	B
-	O
activated	O
promoters	O
,	O
spoIIG	B
and	O
spoIIE	B
,	O
but	O
expression	O
was	O
not	O
impaired	O
from	O
the	O
Spo0A	B
-	O
independent	O
,	O
sigma	B
A	I
-	O
dependent	O
promoter	O
tms	B
or	O
from	O
the	O
Spo0A	B
-	O
activated	O
,	O
sigma	B
H	I
-	O
dependent	O
promoter	O
,	O
spoIIA	B
.	O

The	O
amino	O
acid	O
substitution	O
in	O
sigma	B
H	I
prevented	O
expression	O
from	O
the	O
spoIIA	B
promoter	O
but	O
not	O
from	O
the	O
Spo0A	B
-	O
independent	O
promoter	O
,	O
citGp2	B
,	O
which	O
is	O
used	O
by	O
sigma	B
H	I
-	O
RNA	O
polymerase	O
.	O

All	O
of	O
these	O
amino	O
acid	O
substitutions	O
occur	O
in	O
the	O
carboxyl	O
terminus	O
of	O
the	O
sigma	B
factors	I
.	O

These	O
amino	O
acid	O
substitutions	O
may	O
define	O
the	O
sites	O
of	O
contact	O
between	O
the	O
sigma	B
factors	I
and	O
Spo0A	B
.	O

The	O
ability	O
of	O
response	O
regulators	O
such	O
as	O
Spo0A	B
to	O
interact	O
with	O
multiple	O
sigma	B
factors	I
may	O
increase	O
the	O
variety	O
of	O
responses	O
made	O
by	O
bacteria	O
using	O
a	O
limited	O
number	O
of	O
transcription	B
factors	I
.	O

Expression	O
of	O
the	O
rocDEF	B
operon	I
involved	O
in	O
arginine	O
catabolism	O
in	O
Bacillus	O
subtilis	O
.	O

Three	O
genes	O
called	O
rocD	B
,	O
rocE	B
and	O
rocF	B
were	O
found	O
near	O
the	O
rocR	B
gene	O
in	O
B.	O
subtilis	O
.	O

The	O
product	O
of	O
rocD	B
is	O
similar	O
to	O
eukaryotic	O
ornithine	B
aminotransferases	I
.	O

The	O
product	O
of	O
rocE	B
shares	O
similarity	O
with	O
the	O
product	O
of	O
B.	O
subtilis	O
rocC	B
and	O
with	O
the	O
product	O
of	O
E.	O
coli	O
lysP	B
.	O

The	O
rocE	B
gene	O
may	O
encode	O
an	O
arginine	O
permease	B
.	O

The	O
rocF	B
gene	O
encodes	O
a	O
polypeptide	O
similar	O
to	O
several	O
arginases	B
.	O

Heterologous	O
expression	O
in	O
E.	O
coli	O
indicated	O
that	O
rocD	B
encodes	O
an	O
ornithine	B
aminotransferase	I
and	O
that	O
rocF	B
encodes	O
an	O
arginase	B
.	O

Arginine	O
utilization	O
was	O
abolished	O
in	O
both	O
rocD	B
and	O
rocF	B
mutants	O
of	O
B.	O
subtilis	O
confirming	O
the	O
role	O
of	O
these	O
genes	O
in	O
arginine	O
catabolism	O
.	O

The	O
rocDEF	B
genes	O
form	O
an	O
operon	O
transcribed	O
from	O
a	O
-	O
12	O
,	O
-	O
24	O
promoter	O
almost	O
identical	O
to	O
the	O
-	O
12	O
,	O
-	O
24	O
promoter	O
of	O
the	O
rocABC	B
operon	I
.	O

The	O
expression	O
of	O
the	O
rocDEF	B
operon	I
was	O
induced	O
by	O
the	O
presence	O
of	O
arginine	O
,	O
ornithine	O
or	O
proline	O
in	O
the	O
growth	O
medium	O
and	O
depended	O
on	O
the	O
presence	O
of	O
the	O
sigma	B
factor	I
SigL	B
.	O

Transcription	O
of	O
this	O
operon	O
was	O
also	O
abolished	O
in	O
a	O
B.	O
subtilis	O
strain	O
containing	O
a	O
null	O
mutation	O
in	O
the	O
regulatory	O
gene	O
rocR	B
.	O

Two	O
tandemly	O
repeated	O
upstream	O
activating	O
sequences	O
very	O
similar	O
to	O
those	O
previously	O
identified	O
in	O
the	O
rocABC	B
system	O
were	O
found	O
centered	O
at	O
positions	O
-	O
120	O
and	O
-	O
70	O
,	O
respectively	O
,	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
of	O
rocDEF	B
.	O

Deletion	O
analysis	O
showed	O
that	O
at	O
least	O
one	O
upstream	O
activating	O
sequence	O
is	O
involved	O
in	O
the	O
expression	O
of	O
the	O
rocDEF	B
operon	I
.	O

These	O
sequences	O
are	O
probably	O
the	O
target	O
of	O
RocR	B
.	O

Analysis	O
of	O
a	O
rocR	B
'	O
-	O
'	O
lacZ	B
fusion	O
strain	O
showed	O
that	O
the	O
expression	O
of	O
rocR	B
is	O
not	O
induced	O
by	O
arginine	O
and	O
is	O
negatively	O
autoregulated	O
.	O

The	O
HPr	B
protein	O
of	O
the	O
phosphotransferase	B
system	I
links	O
induction	O
and	O
catabolite	O
repression	O
of	O
the	O
Bacillus	O
subtilis	O
levanase	B
operon	O
.	O

The	O
LevR	B
protein	O
is	O
the	O
activator	O
of	O
expression	O
of	O
the	O
levanase	B
operon	O
of	O
Bacillus	O
subtilis	O
.	O

The	O
promoter	O
of	O
this	O
operon	O
is	O
recognized	O
by	O
RNA	B
polymerase	I
containing	O
the	O
sigma	B
54	I
-	O
like	O
factor	O
sigma	B
L	I
.	O

One	O
domain	O
of	O
the	O
LevR	B
protein	O
is	O
homologous	O
to	O
activators	O
of	O
the	O
NtrC	B
family	I
,	O
and	O
another	O
resembles	O
antiterminator	O
proteins	O
of	O
the	O
BglG	B
family	I
.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
domain	O
which	O
is	O
similar	O
to	O
antiterminators	O
is	O
a	O
target	O
of	O
phosphoenolpyruvate	B
:	I
sugar	I
phosphotransferase	I
system	I
(	O
PTS	B
)	O
-	O
dependent	O
regulation	O
of	O
LevR	B
activity	O
.	O

We	O
show	O
that	O
the	O
LevR	B
protein	O
is	O
not	O
only	O
negatively	O
regulated	O
by	O
the	O
fructose	B
-	I
specific	I
enzyme	I
IIA	I
/	I
B	I
of	O
the	O
phosphotransferase	B
system	I
encoded	O
by	O
the	O
levanase	B
operon	O
(	O
lev	O
-	O
PTS	O
)	O
but	O
also	O
positively	O
controlled	O
by	O
the	O
histidine	B
-	I
containing	I
phosphocarrier	I
protein	I
(	O
HPr	B
)	O
of	O
the	O
PTS	B
.	O

This	O
second	O
type	O
of	O
control	O
of	O
LevR	B
activity	O
depends	O
on	O
phosphoenolpyruvate	O
-	O
dependent	O
phosphorylation	O
of	O
HPr	B
histidine	O
15	O
,	O
as	O
demonstrated	O
with	O
point	O
mutations	O
in	O
the	O
ptsH	B
gene	O
encoding	O
HPr	B
.	O

In	O
vitro	O
phosphorylation	O
of	O
partially	O
purified	O
LevR	B
was	O
obtained	O
in	O
the	O
presence	O
of	O
phosphoenolpyruvate	O
,	O
enzyme	O
I	O
,	O
and	O
HPr	B
.	O

The	O
dependence	O
of	O
truncated	O
LevR	B
polypeptides	O
on	O
stimulation	O
by	O
HPr	B
indicated	O
that	O
the	O
domain	O
homologous	O
to	O
antiterminators	O
is	O
the	O
target	O
of	O
HPr	B
-	O
dependent	O
regulation	O
of	O
LevR	B
activity	O
.	O

This	O
domain	O
appears	O
to	O
be	O
duplicated	O
in	O
the	O
LevR	B
protein	O
.	O

The	O
first	O
antiterminator	O
-	O
like	O
domain	O
seems	O
to	O
be	O
the	O
target	O
of	O
enzyme	O
I	O
and	O
HPr	B
-	O
dependent	O
phosphorylation	O
and	O
the	O
site	O
of	O
LevR	B
activation	O
,	O
whereas	O
the	O
carboxy	O
-	O
terminal	O
antiterminator	O
-	O
like	O
domain	O
could	O
be	O
the	O
target	O
for	O
negative	O
regulation	O
by	O
the	O
lev	O
-	O
PTS	O
.	O

Complete	O
nucleotide	O
sequence	O
of	O
a	O
skin	O
element	O
excised	O
by	O
DNA	O
rearrangement	O
during	O
sporulation	O
in	O
Bacillus	O
subtilis	O
.	O

As	O
part	O
of	O
the	O
Bacillus	O
subtilis	O
genome	O
sequencing	O
project	O
,	O
we	O
have	O
determined	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
a	O
skin	O
element	O
which	O
is	O
located	O
between	O
spoIVCB	B
and	O
spoIIIC	B
.	O

The	O
entire	O
sequence	O
of	O
this	O
element	O
is	O
48	O
,	O
032	O
bp	O
in	O
length	O
,	O
and	O
contains	O
57	O
ORFs	O
with	O
putative	O
ribosome	O
-	O
binding	O
sites	O
.	O

Two	O
of	O
them	O
correspond	O
to	O
previously	O
sequenced	O
and	O
characterized	O
genes	O
,	O
cwIA	B
and	O
spoIVCA	B
.	O

Furthermore	O
,	O
seven	O
ORF	O
products	O
identified	O
in	O
this	O
element	O
show	O
interesting	O
similarities	O
with	O
known	O
proteins	O
present	O
in	O
data	O
banks	O
,	O
including	O
the	O
phi	O
105	O
immunity	B
repressor	I
,	O
the	O
phi	O
105	O
Cro	B
-	O
like	O
protein	O
and	O
the	O
SPP1	O
terminase	B
.	O

These	O
results	O
indicate	O
the	O
possibility	O
that	O
the	O
skin	O
element	O
is	O
a	O
cryptic	O
remnant	O
of	O
an	O
ancestral	O
temperate	O
phage	O
.	O

A	O
gene	O
at	O
333	O
degrees	O
on	O
the	O
Bacillus	O
subtilis	O
chromosome	O
encodes	O
the	O
newly	O
identified	O
sigma	B
B	I
-	O
dependent	O
general	B
stress	I
protein	I
GspA	B
.	O

In	O
Bacillus	O
subtilis	O
,	O
general	B
stress	I
proteins	I
(	O
Gsps	B
)	O
are	O
induced	O
in	O
response	O
to	O
different	O
stresses	O
(	O
heat	O
,	O
salt	O
,	O
or	O
ethanol	O
)	O
or	O
after	O
nutrient	O
starvation	O
.	O

The	O
majority	O
of	O
the	O
genes	O
for	O
the	O
Gsps	B
are	O
organized	O
in	O
a	O
very	O
large	O
stationary	O
-	O
phase	O
or	O
stress	O
regulon	O
which	O
is	O
controlled	O
by	O
alternative	O
sigma	B
factor	I
sigma	B
B	I
.	O

The	O
most	O
striking	O
spots	O
on	O
Coomassie	O
-	O
stained	O
two	O
-	O
dimensional	O
gels	O
belong	O
to	O
GsiB	B
and	O
GspA	B
,	O
which	O
are	O
synthesized	O
at	O
extremely	O
high	O
levels	O
in	O
response	O
to	O
different	O
stresses	O
.	O

Therefore	O
,	O
we	O
determined	O
the	O
N	O
-	O
terminal	O
protein	O
sequence	O
of	O
GspA	B
,	O
which	O
exhibited	O
total	O
identity	O
to	O
a	O
hypothetical	O
33.5	O
-	O
kDa	O
protein	O
of	O
B.	O
subtilis	O
encoded	O
by	O
open	O
reading	O
frame	O
2	O
(	O
ipa-12d	O
)	O
in	O
the	O
sacY	B
-	O
tyrS1	B
intergenic	O
region	O
.	O

The	O
GspA	B
-	O
encoding	O
gene	O
gspA	B
and	O
the	O
upstream	O
and	O
downstream	O
regions	O
were	O
cloned	O
with	O
the	O
aid	O
of	O
the	O
PCR	O
technique	O
.	O

By	O
primer	O
extension	O
experiments	O
,	O
one	O
sigma	B
B	I
-	O
dependent	O
promoter	O
immediately	O
upstream	O
of	O
the	O
coding	O
region	O
was	O
identified	O
.	O

A	O
putative	O
factor	O
-	O
independent	O
terminator	O
closely	O
followed	O
the	O
coding	O
region	O
.	O

By	O
Northern	O
(	O
RNA	O
)	O
blot	O
analysis	O
,	O
a	O
0.95	O
-	O
kb	O
transcript	O
was	O
detected	O
which	O
indicates	O
a	O
monocistronic	O
transcriptional	O
unit	O
.	O

The	O
gspA	B
mRNA	O
was	O
strongly	O
induced	O
by	O
different	O
stimuli	O
like	O
heat	O
or	O
salt	O
stress	O
and	O
starvation	O
for	O
glucose	O
.	O

Analysis	O
of	O
RNA	O
isolated	O
from	O
a	O
sigma	B
B	I
deletion	O
mutant	O
revealed	O
that	O
the	O
transcription	O
of	O
gspA	B
is	O
sigma	B
B	I
dependent	O
.	O

Insertional	O
inactivation	O
of	O
the	O
B.	O
subtilis	O
chromosomal	O
gspA	B
gene	O
confirmed	O
that	O
the	O
gspA	B
gene	O
is	O
not	O
essential	O
for	O
either	O
vegetative	O
growth	O
or	O
growth	O
under	O
the	O
influence	O
of	O
different	O
stresses	O
.	O

In	O
gspA	B
mutant	O
cells	O
,	O
the	O
level	O
of	O
flagellin	B
was	O
increased	O
severalfold	O
over	O
that	O
in	O
wild	O
-	O
type	O
cells	O
.	O

An	O
additional	O
GerE	B
-	O
controlled	O
gene	O
encoding	O
an	O
abundant	O
spore	O
coat	O
protein	O
from	O
Bacillus	O
subtilis	O
.	O

We	O
describe	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
gene	O
,	O
herein	O
designated	O
cotG	B
,	O
encoding	O
an	O
abundant	O
coat	B
protein	I
from	O
the	O
spores	O
of	O
Bacillus	O
subtilis	O
.	O

The	O
cotG	B
open	O
reading	O
frame	O
is	O
195	O
codons	O
in	O
length	O
and	O
is	O
capable	O
of	O
encoding	O
a	O
polypeptide	O
of	O
24	O
kDa	O
that	O
contains	O
nine	O
tandem	O
copies	O
of	O
the	O
13	O
-	O
amino	O
-	O
acid	O
long	O
,	O
approximately	O
repeated	O
sequence	O
H	O
/	O
Y	O
-	O
K	O
-	O
K	O
-	O
S	O
-	O
Y	O
-	O
R	O
/	O
C	O
-	O
S	O
/	O
T	O
-	O
H	O
/	O
Y	O
-	O
K	O
-	O
K	O
-	O
S	O
-	O
R	O
-	O
S	O
.	O

cotG	B
is	O
located	O
at	O
300	O
degrees	O
on	O
the	O
genetic	O
map	O
close	O
to	O
another	O
coat	B
protein	I
gene	O
,	O
cotB	B
.	O

The	O
cotG	B
and	O
cotB	B
genes	O
are	O
in	O
divergent	O
orientation	O
and	O
are	O
separated	O
by	O
1.3	O
kb	O
.	O

Like	O
the	O
promoter	O
for	O
cotB	B
,	O
the	O
cotG	B
promoter	O
is	O
induced	O
at	O
a	O
late	O
stage	O
of	O
sporulation	O
under	O
the	O
control	O
of	O
the	O
RNA	B
polymerase	I
sigma	I
factor	I
sigma	B
K	I
and	O
the	O
DNA	O
-	O
binding	O
protein	O
GerE	B
.	O

The	O
-	O
10	O
and	O
-	O
35	O
nucleotide	O
sequences	O
of	O
the	O
cotG	B
promoter	O
resemble	O
those	O
of	O
other	O
promoters	O
recognized	O
by	O
sigma	B
K	I
-	O
containing	O
RNA	B
polymerase	I
,	O
and	O
centered	O
70	O
bp	O
upstream	O
of	O
the	O
apparent	O
start	O
site	O
is	O
a	O
sequence	O
that	O
matches	O
the	O
consensus	O
binding	O
site	O
for	O
GerE	B
.	O

Spore	O
coat	B
proteins	I
from	O
a	O
newly	O
constructed	O
cotG	B
null	O
mutant	O
lack	O
not	O
only	O
CotG	B
but	O
also	O
CotB	B
,	O
a	O
finding	O
that	O
suggests	O
that	O
CotG	B
may	O
be	O
a	O
morphogenetic	O
protein	O
that	O
is	O
required	O
for	O
the	O
incorporation	O
of	O
CotB	B
into	O
the	O
coat	O
.	O

Effects	O
of	O
Bacillus	O
subtilis	O
sporulation	O
regulatory	O
protein	O
SpoIIID	B
on	O
transcription	O
by	O
sigma	B
K	I
RNA	B
polymerase	I
in	O
vivo	O
and	O
in	O
vitro	O
.	O

SpoIIID	B
is	O
a	O
sequence	O
-	O
specific	O
,	O
DNA	O
-	O
binding	O
protein	O
that	O
activates	O
or	O
represses	O
transcription	O
of	O
different	O
genes	O
by	O
sigma	B
K	I
RNA	B
polymerase	I
in	O
vitro	O
.	O

A	O
Bacillus	O
subtilis	O
strain	O
engineered	O
to	O
produce	O
both	O
sigma	B
K	I
and	O
SpoIIID	B
during	O
growth	O
showed	O
effects	O
of	O
SpoIIID	B
on	O
expression	O
of	O
sigma	B
K	I
-	O
dependent	O
genes	O
that	O
were	O
consistent	O
with	O
the	O
effects	O
of	O
a	O
small	O
amount	O
of	O
SpoIIID	B
on	O
transcription	O
of	O
these	O
genes	O
in	O
vitro	O
,	O
indicating	O
that	O
the	O
strain	O
provides	O
a	O
simple	O
,	O
in	O
vivo	O
method	O
to	O
screen	O
for	O
effects	O
of	O
SpoIIID	B
on	O
transcription	O
of	O
sigma	B
K	I
-	O
dependent	O
genes	O
.	O

Four	O
additional	O
genes	O
in	O
the	O
sigB	B
operon	O
of	O
Bacillus	O
subtilis	O
that	O
control	O
activity	O
of	O
the	O
general	O
stress	O
factor	O
sigma	B
B	I
in	O
response	O
to	O
environmental	O
signals	O
.	O

sigma	B
B	I
of	O
the	O
gram	O
-	O
positive	O
bacterium	O
Bacillus	O
subtilis	O
is	O
an	O
alternative	O
transcription	B
factor	I
activated	O
by	O
a	O
variety	O
of	O
environmental	O
stresses	O
,	O
including	O
the	O
stress	O
imposed	O
upon	O
entry	O
into	O
the	O
stationary	O
growth	O
phase	O
.	O

Previous	O
reports	O
have	O
shown	O
that	O
this	O
stationary	O
-	O
phase	O
activation	O
is	O
enhanced	O
when	O
cells	O
are	O
grown	O
in	O
rich	O
medium	O
containing	O
glucose	O
and	O
glutamine	O
.	O

The	O
sigma	B
B	I
structural	O
gene	O
,	O
sigB	B
,	O
lies	O
in	O
an	O
operon	O
with	O
three	O
other	O
genes	O
whose	O
products	O
have	O
been	O
shown	O
to	O
control	O
sigma	B
B	I
activity	O
in	O
response	O
to	O
environmental	O
stress	O
.	O

However	O
,	O
none	O
of	O
these	O
is	O
sufficient	O
to	O
explain	O
the	O
enhanced	O
stationary	O
-	O
phase	O
activation	O
of	O
sigma	B
B	I
in	O
response	O
to	O
glucose	O
.	O

We	O
show	O
here	O
that	O
the	O
four	O
genes	O
previously	O
identified	O
in	O
the	O
sigB	B
operon	O
constitute	O
the	O
downstream	O
half	O
of	O
an	O
eight	O
-	O
gene	O
operon	O
.	O

The	O
complete	O
sigB	B
operon	O
is	O
preceded	O
by	O
a	O
sigma	B
A	I
-	O
like	O
promoter	O
(	O
PA	O
)	O
and	O
has	O
the	O
order	O
PA	O
-	O
orfR	O
-	O
orfS	O
-	O
orfT	B
-	O
orfU	B
-	O
PB	O
-	O
rsbV	B
-	O
rsbW	B
-	O
sig	B
B	I
-	O
rsbX	B
,	O
where	O
rsb	O
stands	O
for	O
regulator	O
of	O
sigma	O
-	O
B	O
and	O
the	O
previously	O
identified	O
sigma	O
B	O
-	O
dependent	O
promoter	O
(	O
PB	O
)	O
is	O
an	O
internal	O
promoter	O
preceding	O
the	O
downstream	O
four	O
-	O
gene	O
cluster	O
.	O

Although	O
the	O
genes	O
downstream	O
of	O
PB	O
were	O
also	O
transcribed	O
by	O
polymerase	O
activity	O
originating	O
at	O
PA	O
,	O
this	O
transcription	O
into	O
the	O
downstream	O
cluster	O
was	O
not	O
essential	O
for	O
normal	O
induction	O
of	O
a	O
sigma	B
B	I
-	O
dependent	O
ctc	B
-	O
lacZ	B
fusion	O
.	O

However	O
,	O
deletion	O
of	O
all	O
four	O
upstream	O
open	O
reading	O
frames	O
was	O
found	O
to	O
interfere	O
with	O
induction	O
of	O
the	O
ctc	B
-	O
lacZ	B
fusion	O
in	O
response	O
to	O
glucose	O
.	O

Additional	O
deletion	O
analysis	O
and	O
complementation	O
studies	O
showed	O
that	O
orfU	B
was	O
required	O
for	O
full	O
glucose	O
induction	O
of	O
sigma	B
B	I
-	O
dependent	O
genes	O
.	O

orfU	B
encodes	O
a	O
trans	O
-	O
acting	O
,	O
positive	O
factor	O
with	O
significant	O
sequence	O
identity	O
to	O
the	O
RsbX	B
negative	O
regulator	O
of	O
sigma	B
B	I
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
rename	O
orfU	B
as	O
rsbU	B
to	O
symbolize	O
the	O
regulatory	O
role	O
of	O
its	O
product	O
.	O

High	O
-	O
level	O
transcription	O
of	O
the	O
major	O
Bacillus	O
subtilis	O
autolysin	B
operon	O
depends	O
on	O
expression	O
of	O
the	O
sigma	B
D	I
gene	O
and	O
is	O
affected	O
by	O
a	O
sin	B
(	O
flaD	B
)	O
mutation	O
.	O

Transcription	O
of	O
the	O
major	O
Bacillus	O
subtilis	O
autolysin	B
gene	O
(	O
cwlB	B
)	O
was	O
investigated	O
.	O

Deletion	O
of	O
the	O
region	O
upstream	O
of	O
the	O
gene	O
cluster	O
lppX	B
-	O
cwbA	B
-	O
cwlB	B
led	O
to	O
a	O
loss	O
of	O
promoter	O
activity	O
.	O

Primer	O
extension	O
analysis	O
suggested	O
that	O
the	O
cwlB	B
operon	O
is	O
transcribed	O
by	O
E	B
sigma	I
D	I
and	O
E	B
sigma	I
A	I
,	O
the	O
former	O
transcripts	O
being	O
predominants	O
at	O
the	O
exponential	O
growth	O
phase	O
.	O

Expression	O
of	O
the	O
lppX	B
-	O
lacZ	B
fusion	O
gene	O
was	O
reduced	O
by	O
about	O
90	O
%	O
in	O
a	O
sigD	B
-	O
null	O
mutant	O
.	O

A	O
sin	B
(	O
flaD1	B
)	O
mutation	O
caused	O
a	O
severe	O
defect	O
in	O
transcription	O
of	O
the	O
lppX	B
-	O
cwbA	B
-	O
cwlB	B
operon	O
.	O

The	O
sin	B
(	O
flaD1	B
)	O
mutation	O
also	O
reduced	O
expression	O
of	O
a	O
sigD	B
-	O
lacZ	B
fusion	O
gene	O
constructed	O
in	O
the	O
B.	O
subtilis	O
chromosome	O
.	O

Since	O
the	O
sigD	B
-	O
null	O
mutant	O
exhibits	O
motility	O
and	O
autolysin	B
deficiencies	O
and	O
filamentation	O
,	O
similar	O
phenotypes	O
in	O
the	O
sin	B
(	O
flaD1	B
)	O
mutant	O
may	O
be	O
caused	O
by	O
reduction	O
in	O
expression	O
of	O
the	O
sigma	B
D	I
protein	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
acceleration	O
of	O
the	O
neoplastic	O
phenotype	O
of	O
a	O
low	O
-	O
tumorigenicity	O
rat	O
bladder	O
carcinoma	O
cell	O
line	O
by	O
transfected	O
transforming	B
growth	I
factor	I
-	I
alpha	I
.	O

We	O
conducted	O
an	O
experiment	O
to	O
determine	O
whether	O
expression	O
of	O
transforming	B
growth	I
factor	I
-	I
alpha	I
(	O
TGF	B
-	I
alpha	I
)	O
enhances	O
tumorigenicity	O
in	O
a	O
low	O
-	O
tumorigenicity	O
rat	O
bladder	O
carcinoma	O
cell	O
line	O
and	O
whether	O
it	O
is	O
sufficient	O
to	O
induce	O
a	O
tumorigenic	O
phenotype	O
in	O
a	O
nontumorigenic	O
rat	O
bladder	O
cell	O
line	O
.	O

D44c	O
cells	O
(	O
which	O
are	O
nontumorigenic	O
)	O
were	O
derived	O
from	O
a	O
minute	O
nodule	O
from	O
a	O
bladder	O
treated	O
with	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
MNU	O
)	O
;	O
G1	O
-	O
200	O
cl-17	O
cells	O
(	O
which	O
have	O
low	O
tumorigenicity	O
)	O
were	O
isolated	O
from	O
D44c	O
cells	O
exposed	O
to	O
MNU	O
in	O
vitro	O
.	O

Neither	O
cell	O
line	O
expressed	O
TGF	B
-	I
alpha	I
mRNA	O
.	O

The	O
cells	O
were	O
cotransfected	O
with	O
pSV2neo	O
and	O
pSR	O
alpha	O
-	O
rTGF	B
-	I
alpha	I
.	O

The	O
latter	O
plasmid	O
contains	O
the	O
rat	O
TGF	B
-	I
alpha	I
cDNA	O
under	O
the	O
transcriptional	O
control	O
of	O
the	O
SR	O
alpha	O
promoter	O
.	O

In	O
the	O
low	O
-	O
tumorigenicity	O
G1	O
-	O
200	O
cl-17	O
cells	O
,	O
the	O
expression	O
of	O
TGF	B
-	I
alpha	I
mRNA	O
and	O
the	O
subsequent	O
synthesis	O
of	O
TGF	B
-	I
alpha	I
protein	O
activated	O
epidermal	B
growth	I
factor	I
receptors	I
(	O
EGFRs	B
)	O
and	O
markedly	O
enhanced	O
tumorigenicity	O
in	O
nude	O
mice	O
(	O
i.e.	O
,	O
shortened	O
the	O
latency	O
period	O
before	O
tumor	O
appearance	O
,	O
accelerated	O
the	O
rate	O
of	O
growth	O
,	O
and	O
increased	O
the	O
size	O
of	O
the	O
tumors	O
)	O
as	O
well	O
as	O
anchorage	O
-	O
independent	O
growth	O
in	O
vitro	O
.	O

In	O
nontumorigenic	O
D44c	O
cells	O
,	O
however	O
,	O
transfected	O
TGF	B
-	I
alpha	I
did	O
not	O
induce	O
either	O
anchorage	O
-	O
independent	O
growth	O
or	O
tumorigenicity	O
in	O
nude	O
mice	O
,	O
in	O
spite	O
of	O
overexpression	O
of	O
EGFR	B
mRNA	O
and	O
the	O
constitutive	O
expression	O
of	O
c	B
-	I
jun	I
and	O
junB	B
mRNA	O
.	O

These	O
results	O
suggest	O
that	O
the	O
increased	O
signal	O
transduction	O
mediated	O
by	O
TGF	B
-	I
alpha	I
enhanced	O
tumorigenicity	O
in	O
a	O
cell	O
that	O
was	O
already	O
tumorigenic	O
but	O
was	O
not	O
sufficient	O
to	O
induce	O
tumorigenicity	O
in	O
a	O
nontumorigenic	O
cell	O
.	O

Phosphorylation	O
of	O
Spo0A	B
activates	O
its	O
stimulation	O
of	O
in	O
vitro	O
transcription	O
from	O
the	O
Bacillus	O
subtilis	O
spoIIG	B
operon	I
.	O

The	O
spoIIG	B
operon	I
of	O
Bacillus	O
subtilis	O
codes	O
for	O
a	O
sporulation	O
-	O
specific	O
sigma	B
factor	I
,	O
sigma	B
E	I
.	O

In	O
vivo	O
expression	O
of	O
the	O
spoIIG	B
promoter	O
is	O
activated	O
shortly	O
after	O
the	O
onset	O
of	O
sporulation	O
and	O
is	O
dependent	O
on	O
kinA	B
,	O
spo0F	B
,	O
spo0B	B
and	O
spo0A	B
genes	O
.	O

The	O
products	O
of	O
these	O
genes	O
have	O
been	O
shown	O
to	O
participate	O
in	O
a	O
phosphorelay	O
reaction	O
in	O
vitro	O
,	O
culminating	O
in	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
,	O
Spo0A	B
.	O

The	O
effect	O
of	O
Spo0A	B
phosphorylation	O
on	O
in	O
vitro	O
transcription	O
from	O
the	O
spoIIG	B
promoter	O
was	O
determined	O
.	O

Aliquots	O
from	O
phosphorelay	O
reactions	O
enhanced	O
spoIIG	B
promoter	O
activity	O
10	O
-	O
fold	O
in	O
transcription	O
assays	O
and	O
stimulation	O
of	O
transcription	O
was	O
dependent	O
on	O
Spo0A	B
phosphorylation	O
.	O

Our	O
results	O
provide	O
biochemical	O
evidence	O
that	O
Spo0A	B
and	O
the	O
phosphorelay	O
form	O
a	O
signal	O
transduction	O
pathway	O
which	O
activates	O
spoII	O
gene	O
expression	O
in	O
development	O
.	O

The	O
Bacillus	O
subtilis	O
spoVD	B
gene	O
encodes	O
a	O
mother	O
-	O
cell	O
-	O
specific	O
penicillin	O
-	O
binding	O
protein	O
required	O
for	O
spore	O
morphogenesis	O
.	O

The	O
Bacillus	O
subtilis	O
spoVD	B
gene	O
has	O
been	O
cloned	O
and	O
sequenced	O
.	O

It	O
encodes	O
a	O
71	O
,	O
262	O
Da	O
protein	O
with	O
extensive	O
sequence	O
similarity	O
to	O
penicillin	O
-	O
binding	O
proteins	O
from	O
various	O
organisms	O
.	O

The	O
context	O
of	O
this	O
gene	O
in	O
the	O
B.	O
subtilis	O
chromosome	O
,	O
immediately	O
upstream	O
of	O
the	O
mur	B
operon	I
,	O
suggests	O
that	O
it	O
is	O
related	O
to	O
the	O
pbpB	B
gene	O
of	O
Escherichia	O
coli	O
,	O
which	O
is	O
involved	O
in	O
the	O
synthesis	O
of	O
septal	O
peptidoglycan	O
during	O
cell	O
division	O
.	O

Expression	O
of	O
spoVD	B
in	O
E.	O
coli	O
leads	O
to	O
the	O
synthesis	O
of	O
a	O
membrane	O
-	O
associated	O
protein	O
of	O
the	O
size	O
expected	O
for	O
SpoVD	B
,	O
which	O
can	O
bind	O
labelled	O
penicillin	O
.	O

However	O
,	O
insertional	O
disruption	O
of	O
the	O
spoVD	B
gene	O
has	O
no	O
effect	O
on	O
vegetative	O
growth	O
or	O
division	O
:	O
a	O
second	O
pbp	B
-	O
like	O
gene	O
immediately	O
upstream	O
of	O
spoVD	B
is	O
probably	O
the	O
functional	O
homologue	O
of	O
E.	O
coli	O
pbpB	B
.	O

spoVD	B
seems	O
instead	O
to	O
have	O
a	O
specialized	O
role	O
in	O
the	O
morphogenesis	O
of	O
the	O
spore	O
cortex	O
,	O
which	O
is	O
a	O
modified	O
form	O
of	O
peptidoglycan	O
.	O

spoVD	B
transcription	O
appears	O
to	O
occur	O
from	O
a	O
promoter	O
recognized	O
by	O
the	O
sigma	B
E	I
form	O
of	O
RNA	B
polymerase	I
.	O

Analysis	O
of	O
the	O
expression	O
of	O
a	O
spoVD	B
'	O
-	O
lacZ	B
reporter	O
gene	O
supports	O
this	O
notion	O
and	O
indicates	O
that	O
a	O
second	O
level	O
of	O
negative	O
regulation	O
is	O
dependent	O
on	O
the	O
SpoIIID	B
protein	O
.	O

SpoVD	B
synthesis	O
probably	O
occurs	O
only	O
in	O
the	O
mother	O
cell	O
since	O
both	O
sigma	B
E	I
and	O
SpoIIID	B
are	O
thought	O
to	O
be	O
specific	O
to	O
this	O
cell	O
type	O
.	O

Such	O
localization	O
of	O
SpoVD	B
synthesis	O
was	O
supported	O
by	O
the	O
results	O
of	O
a	O
genetic	O
test	O
showing	O
that	O
expression	O
of	O
spoVD	B
only	O
in	O
the	O
mother	O
cell	O
is	O
sufficient	O
for	O
spore	O
formation	O
.	O

The	O
results	O
support	O
the	O
proposition	O
that	O
spore	O
cortex	O
formation	O
is	O
determined	O
primarily	O
by	O
the	O
mother	O
cell	O
.	O

Bacillus	O
subtilis	O
sigma	B
B	I
is	O
regulated	O
by	O
a	O
binding	O
protein	O
(	O
RsbW	B
)	O
that	O
blocks	O
its	O
association	O
with	O
core	O
RNA	B
polymerase	I
.	O

sigma	B
B	I
is	O
a	O
secondary	O
sigma	B
factor	I
of	O
Bacillus	O
subtilis	O
.	O

RNA	B
polymerase	I
containing	O
sigma	B
B	I
transcribes	O
a	O
subset	O
of	O
genes	O
that	O
are	O
expressed	O
after	O
heat	O
shock	O
or	O
the	O
onset	O
of	O
the	O
stationary	O
phase	O
of	O
growth	O
.	O

Three	O
genes	O
(	O
rsbV	B
,	O
rsbW	B
,	O
and	O
rsbX	B
)	O
,	O
cotranscribed	O
with	O
the	O
sigma	B
B	I
structural	O
gene	O
(	O
sigB	B
)	O
,	O
regulate	O
sigma	B
B	I
-	O
dependent	O
gene	O
expression	O
.	O

RsbW	B
is	O
the	O
primary	O
inhibitor	O
of	O
this	O
system	O
with	O
the	O
other	O
gene	O
products	O
acting	O
upstream	O
of	O
RsbW	B
in	O
the	O
sigma	B
B	I
regulatory	O
pathway	O
.	O

Evidence	O
is	O
now	O
presented	O
that	O
RsbW	B
inhibits	O
sigma	B
B	I
-	O
dependent	O
transcription	O
by	O
binding	O
to	O
sigma	B
B	I
and	O
blocking	O
the	O
formation	O
of	O
a	O
sigma	B
B	I
-	O
containing	O
RNA	B
polymerase	I
holoenzyme	O
.	O

Antibodies	O
specific	O
for	O
either	O
RsbW	B
or	O
sigma	B
B	I
will	O
coprecipitate	O
both	O
proteins	O
from	O
crude	O
cell	O
extracts	O
.	O

This	O
is	O
not	O
due	O
to	O
the	O
presence	O
of	O
both	O
proteins	O
on	O
RNA	B
polymerase	I
.	O

Western	O
blot	O
analysis	O
of	O
B.	O
subtilis	O
extracts	O
that	O
had	O
been	O
fractionated	O
by	O
gel	O
-	O
filtration	O
chromatography	O
revealed	O
a	O
single	O
peak	O
of	O
RsbW	B
that	O
did	O
not	O
coelute	O
with	O
RNA	B
polymerase	I
and	O
two	O
peaks	O
of	O
sigma	B
B	I
protein	O
:	O
one	O
that	O
eluted	O
with	O
RNA	B
polymerase	I
and	O
a	O
second	O
that	O
overlapped	O
the	O
fractions	O
that	O
contained	O
RsbW	B
.	O

Reconstitution	O
experiments	O
were	O
performed	O
in	O
which	O
partially	O
purified	O
sigma	B
B	I
and	O
RsbW	B
were	O
added	O
to	O
core	O
RNA	B
polymerase	I
and	O
tested	O
for	O
their	O
ability	O
to	O
influence	O
the	O
transcription	O
of	O
a	O
sigma	B
B	I
-	O
dependent	O
promoter	O
(	O
ctc	B
)	O
in	O
vitro	O
.	O

RsbW	B
efficiently	O
blocked	O
sigma	B
B	I
-	O
dependent	O
transcription	O
but	O
only	O
if	O
it	O
was	O
incubated	O
with	O
sigma	B
B	I
prior	O
to	O
the	O
addition	O
of	O
the	O
core	O
enzyme	O
.	O

Negative	O
signalling	O
via	O
the	O
P58	B
/	O
NKR	O
for	O
HLA.C	B
alleles	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
interaction	O
between	O
HLA	B
class	I
I	I
alleles	O
and	O
specific	O
NK	O
receptors	O
results	O
in	O
negative	O
signals	O
which	O
inhibit	O
NK	O
-	O
mediated	O
cytotoxicity	O
.	O

Such	O
NK	O
receptors	O
have	O
been	O
identified	O
by	O
GL183	B
and	O
EB6	B
mAbs	O
which	O
recognize	O
distinct	O
members	O
of	O
a	O
molecular	O
family	O
involved	O
in	O
the	O
recognition	O
of	O
two	O
groups	O
of	O
HLA.C	B
alleles	O
.	O

Now	O
we	O
describe	O
a	O
new	O
allospecific	O
NK	O
group	O
(	O
group	O
0	O
)	O
which	O
recognize	O
all	O
HLA.C	B
alleles	O
and	O
we	O
demonstrate	O
that	O
,	O
on	O
these	O
clones	O
,	O
the	O
p58	B
molecules	O
EB6	B
and	O
GL183	B
act	O
independently	O
to	O
recognize	O
Cw4	B
(	O
and	O
related	O
alleles	O
)	O
and	O
Cw3	B
(	O
and	O
related	O
alleles	O
)	O
respectively	O
.	O

Finally	O
we	O
investigate	O
whether	O
the	O
inhibitory	O
signal	O
mediated	O
by	O
the	O
NK	O
-	O
receptor	O
for	O
HLA.C	B
induce	O
a	O
temporary	O
turn	O
off	O
on	O
the	O
cytolytic	O
activity	O
.	O

Synthesis	O
of	O
the	O
osmoprotectant	O
glycine	O
betaine	O
in	O
Bacillus	O
subtilis	O
:	O
characterization	O
of	O
the	O
gbsAB	B
genes	O
.	O

Synthesis	O
of	O
the	O
osmoprotectant	O
glycine	O
betaine	O
from	O
the	O
exogenously	O
provided	O
precursor	O
choline	O
or	O
glycine	O
betaine	O
aldehyde	O
confers	O
considerable	O
osmotic	O
stress	O
tolerance	O
to	O
Bacillus	O
subtilis	O
in	O
high	O
-	O
osmolarity	O
media	O
.	O

Using	O
an	O
Escherichia	O
coli	O
mutant	O
(	O
betBA	B
)	O
defective	O
in	O
the	O
glycine	O
betaine	O
synthesis	O
enzymes	O
,	O
we	O
cloned	O
by	O
functional	O
complementation	O
the	O
genes	O
that	O
are	O
required	O
for	O
the	O
synthesis	O
of	O
the	O
osmoprotectant	O
glycine	O
betaine	O
in	O
B.	O
subtilis	O
.	O

The	O
DNA	O
sequence	O
of	O
a	O
4.1	O
-	O
kb	O
segment	O
from	O
the	O
cloned	O
chromosomal	O
B.	O
subtilis	O
DNA	O
was	O
established	O
,	O
and	O
two	O
genes	O
(	O
gbsA	B
and	O
gbsB	B
)	O
whose	O
products	O
were	O
essential	O
for	O
glycine	O
betaine	O
biosynthesis	O
and	O
osmoprotection	O
were	O
identified	O
.	O

The	O
gbsA	B
and	O
gbsB	B
genes	O
are	O
transcribed	O
in	O
the	O
same	O
direction	O
,	O
are	O
separated	O
by	O
a	O
short	O
intergenic	O
region	O
,	O
and	O
are	O
likely	O
to	O
form	O
an	O
operon	O
.	O

The	O
deduced	O
gbsA	B
gene	O
product	O
exhibits	O
strong	O
sequence	O
identity	O
with	O
members	O
of	O
a	O
superfamily	O
of	O
specialized	O
and	O
nonspecialized	O
aldehyde	B
dehydrogenases	I
.	O

This	O
superfamily	O
comprises	O
glycine	B
betaine	I
aldehyde	I
dehydrogenases	I
from	O
bacteria	O
and	O
plants	O
with	O
known	O
involvement	O
in	O
the	O
cellular	O
adaptation	O
to	O
high	O
-	O
osmolarity	O
stress	O
and	O
drought	O
.	O

The	O
deduced	O
gbsB	B
gene	O
product	O
shows	O
significant	O
similarity	O
to	O
the	O
family	O
of	O
type	O
III	O
alcohol	B
dehydrogenases	I
.	O

B.	O
subtilis	O
mutants	O
with	O
defects	O
in	O
the	O
chromosomal	O
gbsAB	B
genes	O
were	O
constructed	O
by	O
marker	O
replacement	O
,	O
and	O
the	O
growth	O
properties	O
of	O
these	O
mutant	O
strains	O
in	O
high	O
-	O
osmolarity	O
medium	O
were	O
analyzed	O
.	O

Deletion	O
of	O
the	O
gbsAB	B
genes	O
destroyed	O
the	O
choline	O
-	O
glycine	O
betaine	O
synthesis	O
pathway	O
and	O
abolished	O
the	O
ability	O
of	O
B.	O
subtilis	O
to	O
deal	O
effectively	O
with	O
high	O
-	O
osmolarity	O
stress	O
in	O
choline	O
-	O
or	O
glycine	O
betaine	O
aldehyde	O
-	O
containing	O
medium	O
.	O

Uptake	O
of	O
radiolabelled	O
choline	O
was	O
unaltered	O
in	O
the	O
gbsAB	B
mutant	O
strain	O
.	O

The	O
continued	O
intracellular	O
accumulation	O
of	O
choline	O
or	O
glycine	O
betaine	O
aldehyde	O
in	O
a	O
strain	O
lacking	O
the	O
glycine	O
betaine	O
-	O
biosynthetic	O
enzymes	O
strongly	O
interfered	O
with	O
the	O
growth	O
of	O
B.	O
subtilis	O
,	O
even	O
in	O
medium	O
of	O
moderate	O
osmolarity	O
.	O

A	O
single	O
transcription	O
initiation	O
site	O
for	O
gbsAB	B
was	O
detected	O
by	O
high	O
-	O
resolution	O
primer	O
extension	O
analysis	O
.	O

gbsAB	B
transcription	O
was	O
initiated	O
from	O
a	O
promoter	O
with	O
close	O
homology	O
to	O
sigma	B
A	I
-	O
dependent	O
promoters	O
and	O
was	O
stimulated	O
by	O
the	O
presence	O
of	O
choline	O
in	O
the	O
growth	O
medium	O
.	O

Human	B
histocompatibility	I
leukocyte	I
antigen	I
(	I
HLA	I
)	I
-	I
G	I
molecules	O
inhibit	O
NKAT3	B
expressing	O
natural	O
killer	O
cells	O
.	O

The	O
crucial	O
immunological	O
function	O
of	O
the	O
classical	B
human	I
major	I
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
I	I
molecules	O
,	O
human	O
histocompatibility	B
leukocyte	I
antigen	I
(	I
HLA	I
)	I
-	I
A	I
,	I
-	I
B	I
,	I
and	I
-	I
C	I
,	O
is	O
the	O
presentation	O
of	O
peptides	O
to	O
T	O
cells	O
.	O

A	O
secondary	O
function	O
is	O
the	O
inhibition	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
mediated	O
by	O
binding	O
of	O
class	O
I	O
molecules	O
to	O
NK	O
receptors	O
.	O

In	O
contrast	O
,	O
the	O
function	O
of	O
the	O
nonclassical	B
human	I
MHC	I
class	I
I	I
molecules	O
,	O
HLA	B
-	I
E	I
,	I
-	I
F	I
,	I
and	I
-	I
G	I
,	O
is	O
still	O
a	O
mystery	O
.	O

The	O
specific	O
expression	O
of	O
HLA	B
-	I
G	I
in	O
placental	O
trophoblast	O
suggests	O
an	O
important	O
role	O
for	O
this	O
molecule	O
in	O
the	O
immunological	O
interaction	O
between	O
mother	O
and	O
child	O
.	O

The	O
fetus	O
,	O
semiallograft	O
by	O
its	O
genotype	O
,	O
escapes	O
maternal	O
allorecognition	O
by	O
downregulation	O
of	O
HLA	B
-	I
A	I
and	O
HLA	B
-	I
B	I
molecules	O
at	O
this	O
interface	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
maternal	O
NK	O
recognition	O
of	O
this	O
downregulation	O
is	O
balanced	O
by	O
the	O
expression	O
of	O
HLA	B
-	I
G	I
,	O
thus	O
preventing	O
damage	O
to	O
the	O
placenta	O
.	O

Here	O
,	O
we	O
describe	O
the	O
partial	O
inhibition	O
of	O
NK	O
lysis	O
of	O
the	O
MHC	B
class	I
I	I
negative	O
cell	O
line	O
LCL721.221	O
upon	O
HLA	B
-	I
G	I
transfection	O
.	O

We	O
present	O
three	O
NK	O
lines	O
that	O
are	O
inhibited	O
via	O
the	O
interaction	O
of	O
their	O
NKAT3	B
receptor	O
with	O
HLA	B
-	I
G	I
and	O
with	O
HLA	B
-	I
Bw4	I
molecules	O
.	O

Inhibition	O
can	O
be	O
blocked	O
by	O
the	O
anti	O
-	O
NKAT3	B
antibody	O
5.133	O
.	O

In	O
conclusion	O
,	O
NK	O
inhibition	O
by	O
HLA	B
-	I
G	I
via	O
NKAT3	B
may	O
contribute	O
to	O
the	O
survival	O
of	O
the	O
fetal	O
semiallograft	O
in	O
the	O
mother	O
during	O
pregnancy	O
.	O

Bacillus	O
subtilis	O
ComK	B
negatively	O
regulates	O
degR	B
gene	O
expression	O
.	O

Exoprotease	B
production	O
in	O
Bacillus	O
subtilis	O
is	O
positively	O
regulated	O
by	O
a	O
two	O
-	O
component	O
regulatory	O
system	O
,	O
DegS	B
-	O
DegU	B
,	O
and	O
,	O
in	O
addition	O
,	O
by	O
several	O
minor	O
factors	O
.	O

The	O
product	O
of	O
the	O
degR	B
gene	O
belongs	O
to	O
the	O
latter	O
group	O
and	O
exerts	O
a	O
positive	O
effect	O
in	O
a	O
DegS	B
-	O
DegU	B
dependent	O
manner	O
.	O

We	O
found	O
that	O
transcription	O
of	O
degR	B
was	O
prevented	O
by	O
disruption	O
of	O
either	O
mecA	B
or	O
mecB	B
but	O
was	O
relieved	O
by	O
further	O
disruption	O
of	O
comK	B
.	O

Disruption	O
of	O
comK	B
alone	O
,	O
however	O
,	O
did	O
not	O
alter	O
degR	B
transcription	O
.	O

We	O
also	O
found	O
that	O
the	O
mecA	B
mutation	O
requires	O
a	O
region	O
around	O
position	O
-	O
52	O
relative	O
to	O
the	O
transcription	O
start	O
point	O
of	O
degR	B
to	O
exert	O
its	O
effect	O
.	O

We	O
have	O
shown	O
previously	O
that	O
the	O
transcription	O
of	O
degR	B
is	O
driven	O
by	O
an	O
alternative	O
sigma	B
factor	I
,	O
sigmaD	B
.	O

When	O
degR	B
expression	O
was	O
directed	O
by	O
an	O
artificially	O
constructed	O
sigmaA	B
-	O
type	O
promoter	O
,	O
disruption	O
of	O
mecA	B
/	I
B	I
did	O
not	O
result	O
in	O
any	O
significant	O
decrease	O
in	O
degR	B
expression	O
,	O
indicating	O
that	O
the	O
negative	O
effect	O
of	O
the	O
mec	O
mutations	O
acts	O
through	O
sigmaD	B
-	O
driven	O
transcription	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
MecA	B
and	O
MecB	B
negatively	O
regulate	O
ComK	B
,	O
and	O
mecA	B
/	I
B	I
null	O
mutations	O
cause	O
enhanced	O
expression	O
of	O
comK	B
.	O

From	O
these	O
results	O
we	O
conclude	O
that	O
ComK	B
negatively	O
regulates	O
degR	B
expression	O
by	O
preventing	O
sigmaD	B
-	O
driven	O
transcription	O
of	O
degR	B
,	O
possibly	O
through	O
interaction	O
with	O
the	O
control	O
region	O
.	O

The	O
Bacillus	O
subtilis	O
sigma	B
(	I
X	I
)	I
protein	O
is	O
an	O
extracytoplasmic	B
function	I
sigma	I
factor	I
contributing	O
to	O
survival	O
at	O
high	O
temperature	O
.	O

The	O
sigX	B
gene	O
,	O
identified	O
as	O
part	O
of	O
the	O
international	O
effort	O
to	O
sequence	O
the	O
Bacillus	O
subtilis	O
genome	O
,	O
has	O
been	O
proposed	O
to	O
encode	O
an	O
alternative	O
sigma	B
factor	I
of	I
the	I
extracytoplasmic	I
function	I
(	I
ECF	I
)	I
subfamily	I
.	O

The	O
sigX	B
gene	O
is	O
cotranscribed	O
with	O
a	O
downstream	O
gene	O
,	O
ypuN	B
,	O
during	O
logarithmic	O
and	O
early	O
stationary	O
phases	O
of	O
growth	O
.	O

We	O
now	O
report	O
that	O
strains	O
lacking	O
sigma	B
(	I
X	I
)	I
are	O
impaired	O
in	O
the	O
ability	O
to	O
survive	O
at	O
high	O
temperature	O
whereas	O
a	O
ypuN	B
mutant	O
has	O
increased	O
thermotolerance	O
.	O

We	O
overproduced	O
and	O
purified	O
sigma	B
(	I
X	I
)	I
from	O
Escherichia	O
coli	O
and	O
demonstrate	O
that	O
in	O
vitro	O
,	O
both	O
sigma	B
(	I
A	I
)	I
and	O
sigma	B
(	I
X	I
)	I
holoenzymes	O
recognize	O
promoter	O
elements	O
within	O
the	O
sigX	B
-	O
ypuN	B
control	O
region	O
.	O

However	O
,	O
they	O
have	O
distinct	O
salt	O
optima	O
such	O
that	O
sigma	B
(	I
A	I
)	I
-	O
dependent	O
transcription	O
predominates	O
at	O
low	O
salt	O
while	O
sigma	B
(	I
X	I
)	I
-	O
dependent	O
transcription	O
predominates	O
at	O
high	O
salt	O
.	O

A	O
54	O
-	O
bp	O
region	O
upstream	O
of	O
sigX	B
suffices	O
as	O
a	O
sigma	B
(	I
X	I
)	I
-	O
dependent	O
promoter	O
in	O
vivo	O
,	O
demonstrating	O
that	O
sigX	B
is	O
at	O
least	O
partially	O
under	O
positive	O
autoregulatory	O
control	O
.	O

Mutation	O
of	O
ypuN	B
increases	O
expression	O
from	O
the	O
sigma	B
(	I
X	I
)	I
-	O
dependent	O
promoter	O
in	O
vivo	O
,	O
suggesting	O
that	O
ypuN	B
may	O
encode	O
a	O
negative	O
regulator	O
of	O
sigma	B
(	I
X	I
)	I
activity	O
.	O

Genomic	O
organization	O
of	O
a	O
human	O
killer	O
cell	O
inhibitory	O
receptor	O
gene	O
.	O

We	O
have	O
cloned	O
a	O
region	O
of	O
human	O
chromosome	O
19q13.4	O
which	O
contains	O
multiple	O
killer	O
cell	O
inhibitory	O
receptor	O
(	O
KIR	B
)	O
loci	O
.	O

By	O
random	O
and	O
directed	O
sequence	O
analysis	O
of	O
these	O
KIR	B
-	O
specific	O
clones	O
,	O
we	O
deduced	O
the	O
genomic	O
structure	O
of	O
KIR	B
genes	O
.	O

A	O
locus	O
encoding	O
a	O
member	O
of	O
the	O
NKAT-2	B
family	I
of	O
KIRs	B
is	O
presented	O
here	O
.	O

The	O
structure	O
of	O
the	O
gene	O
is	O
reminiscent	O
of	O
loci	O
of	O
the	O
Fc	B
receptor	I
gene	I
family	I
,	O
and	O
the	O
two	O
sets	O
of	O
genes	O
may	O
derive	O
from	O
a	O
common	O
ancestor	O
.	O

The	O
KIR	B
gene	O
contains	O
potentially	O
nine	O
exons	O
.	O

The	O
first	O
two	O
exons	O
encode	O
the	O
leader	O
sequence	O
,	O
as	O
in	O
Fc	B
receptor	I
genes	O
.	O

The	O
third	O
exon	O
encodes	O
an	O
untranslated	O
pseudo	O
exon	O
specifying	O
an	O
immunoglobulin	B
domain	O
with	O
an	O
in	O
-	O
frame	O
stop	O
codon	O
.	O

Expressed	O
cDNAs	O
do	O
not	O
contain	O
this	O
exon	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
KIR	B
genes	O
may	O
have	O
been	O
derived	O
from	O
the	O
duplication	O
of	O
a	O
primordial	O
three	O
immunoglobulin	B
domain	O
structure	O
with	O
subsequent	O
skipping	O
of	O
one	O
exon	O
to	O
derive	O
genes	O
with	O
two	O
expressed	O
immunoglobulin	B
domains	O
.	O

Variation	O
in	O
numbers	O
of	O
immunoglobulin	B
domains	O
in	O
different	O
KIR	B
genes	O
is	O
facilitated	O
by	O
conservation	O
of	O
splicing	O
frame	O
in	O
respect	O
to	O
the	O
codon	O
triplet	O
for	O
each	O
immunoglobulin	B
domain	O
.	O

The	O
NAD	B
synthetase	I
NadE	B
(	O
OutB	B
)	O
of	O
Bacillus	O
subtilis	O
is	O
a	O
sigma	B
B	I
-	O
dependent	O
general	O
stress	O
protein	O
.	O

The	O
identification	O
of	O
sigma	B
B	I
-	O
dependent	O
general	O
stress	O
proteins	O
is	O
a	O
useful	O
strategy	O
to	O
understand	O
the	O
physiological	O
role	O
of	O
the	O
unspecific	O
stress	O
response	O
in	O
Bacillus	O
subtilis	O
.	O

By	O
N	O
-	O
terminal	O
sequencing	O
of	O
B.	O
subtilis	O
stress	O
proteins	O
Gsp38	B
was	O
identified	O
as	O
the	O
NAD	B
-	I
synthetase	I
(	O
NadE	B
)	O
.	O

NadE	B
was	O
previously	O
characterized	O
as	O
spore	B
outgrowth	I
factor	I
B	I
(	O
OutB	B
)	O
conferring	O
a	O
temperature	O
-	O
sensitive	O
spore	O
outgrowth	O
defective	O
phenotype	O
.	O

Transcriptional	O
studies	O
showed	O
that	O
nadE	B
is	O
strongly	O
induced	O
in	O
response	O
to	O
heat	O
,	O
ethanol	O
and	O
salt	O
stress	O
or	O
after	O
starvation	O
for	O
glucose	O
in	O
a	O
sigma	B
B	I
-	O
dependent	O
manner	O
.	O

Two	O
promoters	O
are	O
involved	O
in	O
transcriptional	O
initiation	O
,	O
the	O
sigma	B
A	I
-	O
dependent	O
upstream	O
promoter	O
contributes	O
to	O
the	O
basal	O
level	O
during	O
growth	O
,	O
whereas	O
the	O
sigma	B
B	I
-	O
dependent	O
downstream	O
promoter	O
is	O
induced	O
after	O
different	O
stress	O
conditions	O
.	O

Activation	O
of	O
the	O
Bacillus	O
subtilis	O
spoIIG	B
promoter	O
requires	O
interaction	O
of	O
Spo0A	B
and	O
the	O
sigma	B
subunit	I
of	I
RNA	I
polymerase	I
.	O

Bacillus	O
subtilis	O
Spo0A	B
activates	O
transcription	O
from	O
both	O
sigmaA	B
-	O
and	O
sigmaH	B
-	O
dependent	O
promoters	O
.	O

Baldus	O
et	O
al.	O
(	O
2	O
)	O
identified	O
two	O
amino	O
acid	O
substitutions	O
in	O
the	O
carboxyl	O
terminus	O
of	O
sigmaA	B
,	O
K356E	O
and	O
H359R	O
,	O
that	O
specifically	O
impaired	O
Spo0A	B
-	O
activated	O
transcription	O
in	O
vivo	O
.	O

To	O
test	O
the	O
model	O
in	O
which	O
the	O
K356E	O
and	O
H359R	O
substitutions	O
in	O
sigmaA	B
interfere	O
with	O
the	O
interaction	O
of	O
Spo0A	B
and	O
sigmaA	B
,	O
we	O
examined	O
the	O
effects	O
of	O
alanine	O
substitutions	O
at	O
these	O
positions	O
in	O
sigmaA	B
on	O
sigmaA	B
's	O
ability	O
to	O
direct	O
transcription	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

We	O
found	O
that	O
alanine	O
substitutions	O
at	O
these	O
positions	O
specifically	O
reduced	O
expression	O
from	O
the	O
sigmaA	B
-	O
dependent	O
,	O
Spo0A	B
-	O
dependent	O
promoters	O
,	O
spoIIG	B
and	O
spoIIE	B
,	O
in	O
vivo	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
stimulation	O
of	O
spoIIG	B
promoter	O
activity	O
by	O
Spo0A	B
in	O
vitro	O
was	O
reduced	O
by	O
the	O
single	O
substitutions	O
H359A	O
and	O
H359R	O
in	O
sigmaA	B
.	O

Cloning	O
,	O
functional	O
analysis	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
Bacillus	O
subtilis	O
araE	B
gene	O
involved	O
in	O
L	O
-	O
arabinose	O
utilization	O
.	O

The	O
Bacillus	O
subtilis	O
araR	B
locus	O
(	O
mapped	O
at	O
about	O
294	O
degrees	O
on	O
the	O
genetic	O
map	O
)	O
comprises	O
two	O
open	O
reading	O
frames	O
with	O
divergently	O
arranged	O
promoters	O
,	O
the	O
regulatory	O
gene	O
,	O
araR	B
,	O
encoding	O
a	O
repressor	O
,	O
and	O
a	O
partially	O
cloned	O
gene	O
,	O
termed	O
araE	B
by	O
analogy	O
to	O
the	O
Escherichia	O
coli	O
L	B
-	I
arabinose	I
permease	I
gene	O
.	O

Here	O
,	O
we	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
the	O
entire	O
araE	B
gene	O
encoding	O
a	O
50.4	O
-	O
kDa	O
polypeptide	O
.	O

The	O
araE	B
gene	O
is	O
monocistronic	O
(	O
as	O
determined	O
by	O
Northern	O
blot	O
analysis	O
)	O
,	O
and	O
its	O
putative	O
product	O
is	O
very	O
similar	O
to	O
a	O
number	O
of	O
prokaryotic	O
proton	O
-	O
linked	O
monosaccharide	O
transporters	O
(	O
the	O
group	O
I	O
family	O
of	O
membrane	O
transport	O
proteins	O
)	O
.	O

Insertional	O
inactivation	O
of	O
the	O
araE	B
gene	O
leads	O
to	O
a	O
conditional	O
Ara	B
-	O
phenotype	O
dependent	O
on	O
the	O
concentration	O
of	O
L	O
-	O
arabinose	O
in	O
the	O
medium	O
.	O

Therefore	O
,	O
we	O
assume	O
that	O
araE	B
encodes	O
a	O
permease	B
involved	O
in	O
L	O
-	O
arabinose	O
transport	O
into	O
the	O
cell	O
.	O

The	O
araE	B
promoter	O
region	O
contains	O
-	O
10	O
and	O
-	O
35	O
regions	O
(	O
as	O
determined	O
by	O
primer	O
extension	O
analysis	O
)	O
very	O
similar	O
to	O
those	O
recognized	O
by	O
RNA	B
polymerase	I
containing	O
the	O
major	O
vegetative	O
-	O
cell	O
sigma	B
factor	I
sigmaA	B
,	O
and	O
the	O
-	O
35	O
region	O
of	O
the	O
transcription	O
start	O
point	O
for	O
araE	B
is	O
located	O
2	O
bp	O
from	O
the	O
-	O
35	O
region	O
of	O
the	O
araR	B
gene	O
.	O

Transcriptional	O
studies	O
demonstrated	O
that	O
the	O
expression	O
from	O
the	O
araE	B
promoter	O
is	O
induced	O
by	O
L	O
-	O
arabinose	O
,	O
repressed	O
by	O
glucose	O
,	O
and	O
negatively	O
regulated	O
by	O
AraR	B
.	O

These	O
observations	O
are	O
consistent	O
with	O
a	O
model	O
according	O
to	O
which	O
in	O
the	O
absence	O
of	O
L	O
-	O
arabinose	O
,	O
AraR	B
binds	O
to	O
a	O
site	O
(	O
s	O
)	O
within	O
the	O
araE	B
/	O
araR	B
promoter	O
,	O
preventing	O
transcription	O
from	O
the	O
araE	B
promoter	O
and	O
simultaneously	O
limiting	O
the	O
frequency	O
of	O
initiation	O
from	O
its	O
own	O
promoter	O
;	O
the	O
addition	O
of	O
L	O
-	O
arabinose	O
will	O
allow	O
transcription	O
from	O
the	O
araE	B
promoter	O
and	O
increase	O
the	O
frequency	O
of	O
initiation	O
from	O
the	O
araR	B
promoter	O
.	O

Role	O
of	O
amino	O
acid	O
position	O
70	O
in	O
the	O
binding	O
affinity	O
of	O
p50.1	B
and	O
p58.1	B
receptors	O
for	O
HLA	B
-	I
Cw4	I
molecules	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
the	O
amino	O
acid	O
position	O
(	O
s	O
)	O
of	O
the	O
HLA	B
-	I
C	I
-	O
specific	O
p58.1	B
/	O
p50.1	B
natural	O
killer	O
cell	O
receptors	O
that	O
determine	O
the	O
binding	O
affinity	O
for	O
their	O
ligand	O
,	O
we	O
used	O
soluble	O
fusion	O
proteins	O
formed	O
by	O
the	O
ectodomain	O
of	O
either	O
receptor	O
and	O
the	O
Fc	O
portion	O
of	O
human	O
IgG1	B
.	O

We	O
show	O
that	O
the	O
soluble	O
p50.1	B
(	O
activating	O
)	O
receptor	O
binds	O
weakly	O
to	O
221	O
-	O
Cw4	B
transfectants	O
.	O

In	O
contrast	O
,	O
the	O
soluble	O
p58.1	B
(	O
inhibitory	O
)	O
receptor	O
binds	O
with	O
high	O
affinity	O
.	O

A	O
single	O
amino	O
acid	O
mutation	O
at	O
position	O
70	O
,	O
obtained	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
was	O
found	O
to	O
affect	O
the	O
binding	O
affinity	O
of	O
both	O
the	O
p50.1	B
and	O
the	O
p58.1	B
receptors	O
.	O

Thus	O
,	O
substitution	O
in	O
p50.1	B
of	O
lysine	O
70	O
by	O
threonine	O
(	O
typical	O
of	O
the	O
inhibitory	O
p58.1	B
molecule	O
)	O
resulted	O
in	O
a	O
dramatic	O
increase	O
in	O
binding	O
affinity	O
,	O
comparable	O
to	O
that	O
of	O
the	O
p58.1	B
molecule	O
.	O

On	O
the	O
other	O
hand	O
,	O
substitution	O
of	O
threonine	O
70	O
by	O
lysine	O
in	O
p58.1	B
almost	O
abolished	O
binding	O
to	O
221	O
-	O
Cw4	B
cells	O
.	O

Our	O
present	O
data	O
indicate	O
that	O
a	O
single	O
amino	O
acid	O
difference	O
greatly	O
influences	O
the	O
p58.1	B
/	O
p50.1	B
affinity	O
for	O
their	O
HLA	B
-	I
C	I
ligand	O
and	O
suggests	O
a	O
possible	O
role	O
of	O
position	O
70	O
as	O
a	O
contact	O
site	O
in	O
the	O
natural	O
killer	O
cell	O
receptor	O
/	O
major	B
histocompatibility	I
complex	I
class	I
I	I
interaction	O
.	O

The	O
repertoire	O
of	O
HLA	B
-	I
Cw	I
-	O
specific	O
NK	O
cell	O
receptors	O
CD158	B
a	I
/	I
b	I
(	O
EB6	B
and	O
GL183	B
)	O
in	O
individuals	O
with	O
different	O
HLA	B
phenotypes	O
.	O

Over	O
the	O
last	O
few	O
years	O
,	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
have	O
been	O
shown	O
to	O
express	O
major	B
histocompatibility	I
complex	I
(	O
MHC	B
)	O
molecules	O
recognizing	O
receptors	O
that	O
are	O
thought	O
to	O
function	O
primarily	O
as	O
negative	O
signalling	O
receptors	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
NK	O
cell	O
receptors	O
CD158a	B
(	O
EB6	B
)	O
and	O
CD158b	B
(	O
GI	B
183	I
)	O
,	O
which	O
recognize	O
two	O
alternative	O
epitopes	O
on	O
the	O
HLA	B
-	I
Cw	I
locus	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
HLA	B
type	O
affects	O
the	O
CD158a	B
/	I
b	I
repertoire	O
,	O
expressed	O
as	O
percentage	O
positive	O
cells	O
for	O
a	O
particular	O
receptor	O
and	O
mean	O
expression	O
on	O
this	O
population	O
of	O
NK	O
cells	O
,	O
peripheral	O
blood	O
lymphocytes	O
of	O
47	O
HLA	B
-	O
typed	O
donors	O
were	O
examined	O
.	O

Peripheral	O
blood	O
samples	O
were	O
examined	O
by	O
flow	O
cytometric	O
analysis	O
to	O
investigate	O
the	O
expression	O
of	O
CD158a	B
and	O
CD158b	B
receptors	O
on	O
the	O
surface	O
of	O
NK	O
cells	O
.	O

In	O
parallel	O
,	O
we	O
determined	O
each	O
individual	O
's	O
HLA	B
phenotype	O
.	O

There	O
was	O
a	O
great	O
heterogeneity	O
in	O
CD158	B
expression	O
;	O
nevertheless	O
all	O
individuals	O
had	O
NK	O
cells	O
belonging	O
either	O
to	O
the	O
CD158	B
a+b-,a	I
-	I
b+	I
or	I
a	I
-	I
b	I
-	I
populations	O
.	O

No	O
positive	O
or	O
inverse	O
correlations	O
could	O
be	O
shown	O
between	O
either	O
receptor	O
expression	O
intensity	O
or	O
proportion	O
of	O
positive	O
cells	O
,	O
and	O
presence	O
of	O
the	O
appropriate	O
ligand	O
.	O

Thus	O
no	O
association	O
between	O
an	O
individual	O
's	O
NK	O
receptor	O
repertoire	O
and	O
HLA	B
serotype	O
could	O
be	O
demonstrated	O
.	O

It	O
is	O
concluded	O
that	O
CD158	B
is	O
expressed	O
on	O
NK	O
cells	O
in	O
a	O
highly	O
redundant	O
fashion	O
.	O

Our	O
data	O
do	O
not	O
support	O
either	O
a	O
positive	O
selection	O
mechanism	O
or	O
the	O
receptor	O
calibration	O
model	O
.	O

The	O
sigmaD	B
-	O
dependent	O
transcription	O
of	O
the	O
ywcG	B
gene	O
from	O
Bacillus	O
subtilis	O
is	O
dependent	O
on	O
an	O
excess	O
of	O
glucose	O
and	O
glutamate	O
.	O

We	O
investigated	O
the	O
function	O
and	O
transcriptional	O
regulation	O
of	O
ywcG	B
.	O

The	O
protein	O
is	O
essential	O
for	O
Bacillus	O
subtilis	O
.	O

Biochemical	O
characterization	O
of	O
the	O
protein	O
revealed	O
that	O
it	O
is	O
an	O
FMN	O
-	O
containing	O
NADPH	B
oxidase	I
.	O

ywcG	B
is	O
transcribed	O
throughout	O
the	O
whole	O
life	O
cycle	O
of	O
B.	O
subtilis	O
.	O

The	O
start	O
point	O
of	O
transcription	O
is	O
preceded	O
by	O
potential	O
promoter	O
sequences	O
for	O
sigmaA	B
,	O
sigmaB	B
and	O
sigmaD	B
.	O

A	O
boost	O
in	O
transcription	O
occurs	O
at	O
the	O
beginning	O
of	O
stationary	O
phase	O
in	O
complex	O
media	O
containing	O
glutamate	O
and	O
glucose	O
.	O

The	O
induction	O
of	O
transcription	O
at	O
the	O
beginning	O
of	O
stationary	O
phase	O
needs	O
the	O
activity	O
of	O
a	O
different	O
alternative	O
sigma	B
-	I
factor	I
sigmaD	B
.	O

ywcG	B
is	O
,	O
therefore	O
,	O
the	O
first	O
gene	O
with	O
a	O
putative	O
role	O
in	O
energy	O
metabolism	O
from	O
B.	O
subtilis	O
that	O
is	O
transcribed	O
in	O
a	O
sigmaD	B
-	O
dependent	O
fashion	O
,	O
but	O
its	O
regulation	O
is	O
unique	O
and	O
the	O
reverse	O
of	O
that	O
described	O
for	O
all	O
other	O
sigmaD	B
-	O
dependent	O
genes	O
.	O

The	O
katX	B
gene	O
,	O
which	O
codes	O
for	O
the	O
catalase	B
in	O
spores	O
of	O
Bacillus	O
subtilis	O
,	O
is	O
a	O
forespore	O
-	O
specific	O
gene	O
controlled	O
by	O
sigmaF	B
,	O
and	O
KatX	B
is	O
essential	O
for	O
hydrogen	O
peroxide	O
resistance	O
of	O
the	O
germinating	O
spore	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
the	O
katX	B
gene	O
encodes	O
the	O
major	O
catalase	B
in	O
dormant	O
spores	O
of	O
Bacillus	O
subtilis	O
but	O
that	O
this	O
enzyme	O
has	O
no	O
role	O
in	O
dormant	O
spore	O
resistance	O
to	O
hydrogen	O
peroxide	O
.	O

Expression	O
of	O
a	O
katX	B
-	O
lacZ	B
fusion	O
began	O
at	O
approximately	O
h	O
2	O
of	O
sporulation	O
,	O
and	O
>	O
75	O
%	O
of	O
the	O
katX	B
-	O
driven	O
beta	B
-	I
galactosidase	I
was	O
packaged	O
into	O
the	O
mature	O
spore	O
.	O

A	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
the	O
sporulation	O
-	O
specific	O
RNA	B
polymerase	I
sigma	I
factor	I
sigmaF	B
abolished	O
katX	B
-	O
lacZ	B
expression	O
,	O
while	O
mutations	O
in	O
genes	O
encoding	O
sigmaE	B
,	O
sigmaG	B
,	O
and	O
sigmaK	B
did	O
not	O
.	O

Induction	O
of	O
sigmaF	B
synthesis	O
in	O
vegetative	O
cells	O
also	O
resulted	O
in	O
katX	B
-	O
lacZ	B
expression	O
,	O
while	O
induction	O
of	O
sigmaG	B
expression	O
did	O
not	O
;	O
the	O
katX	B
-	O
lacZ	B
fusion	O
was	O
also	O
not	O
induced	O
by	O
hydrogen	O
peroxide	O
.	O

Upstream	O
of	O
the	O
in	O
vivo	O
katX	B
transcription	O
start	O
site	O
there	O
are	O
sequences	O
with	O
good	O
homology	O
to	O
those	O
upstream	O
of	O
known	O
sigmaF	B
-	O
dependent	O
start	O
sites	O
.	O

These	O
data	O
indicate	O
that	O
katX	B
is	O
an	O
additional	O
member	O
of	O
the	O
forespore	O
-	O
specific	O
sigmaF	B
regulon	O
.	O

A	O
mutant	O
in	O
the	O
katA	B
gene	O
,	O
encoding	O
the	O
major	O
catalase	B
in	O
growing	O
cells	O
,	O
was	O
sensitive	O
to	O
hydrogen	O
peroxide	O
during	O
sporulation	O
,	O
while	O
a	O
katX	B
mutant	O
was	O
not	O
.	O

However	O
,	O
outgrowth	O
of	O
katX	B
spores	O
,	O
but	O
not	O
katA	B
spores	O
,	O
was	O
sensitive	O
to	O
hydrogen	O
peroxide	O
.	O

Consequently	O
,	O
a	O
major	O
function	O
for	O
KatX	B
is	O
to	O
protect	O
germinating	O
spores	O
from	O
hydrogen	O
peroxide	O
.	O

Identification	O
of	O
target	O
promoters	O
for	O
the	O
Bacillus	O
subtilis	O
sigma	B
X	I
factor	I
using	O
a	O
consensus	O
-	O
directed	O
search	O
.	O

The	O
promoter	O
selectivity	O
of	O
RNA	B
polymerase	I
(	O
RNAP	B
)	O
can	O
be	O
altered	O
by	O
the	O
association	O
with	O
alternative	O
sigma	O
subunits	O
.	O

Bacillus	O
subtilis	O
hosts	O
a	O
multitude	O
of	O
sigma	B
factors	I
,	O
several	O
of	O
which	O
coordinate	O
the	O
complex	O
developmental	O
program	O
culminating	O
in	O
endospore	O
formation	O
.	O

Genome	O
sequencing	O
has	O
revealed	O
an	O
unanticipated	O
seven	O
new	O
sigma	O
factors	O
of	O
the	O
highly	O
divergent	O
extracytoplasmic	B
function	I
(	I
ECF	I
)	I
sub	I
-	I
family	I
.	O

Virtually	O
nothing	O
is	O
known	O
regarding	O
either	O
the	O
promoter	O
selectivity	O
or	O
the	O
target	O
genes	O
for	O
these	O
newly	O
identified	O
sigma	B
factors	I
.	O

We	O
have	O
used	O
saturation	O
mutagenesis	O
to	O
define	O
a	O
promoter	O
consensus	O
for	O
recognition	O
by	O
one	O
such	O
ECF	B
sigma	I
factor	I
,	O
sigma	B
X	I
.	O

The	O
resulting	O
consensus	O
sequence	O
was	O
used	O
to	O
identify	O
candidate	O
sigma	B
X	I
target	O
sites	O
.	O

Three	O
newly	O
identified	O
sigma	B
X	I
-	O
dependent	O
promoters	O
precede	O
genes	O
encoding	O
regulatory	O
proteins	O
:	O
an	O
AbrB	B
homolog	I
(	O
Abh	B
)	O
,	O
a	O
putative	O
response	B
regulator	I
aspartate	I
phosphatase	I
(	O
RapD	B
)	O
,	O
and	O
a	O
regulator	O
of	O
autolysin	B
expression	O
(	O
LytR	B
)	O
.	O
sigma	B
X	I
also	O
contributes	O
to	O
the	O
expression	O
of	O
CsbB	B
,	O
a	O
putative	O
membrane	O
-	O
bound	O
glucosyl	B
transferase	I
that	O
is	O
partially	O
controlled	O
by	O
the	O
sigma	B
B	I
stress	O
response	O
sigma	B
factor	I
.	O

Since	O
LytR	B
modulates	O
the	O
expression	O
of	O
the	O
major	O
autolytic	O
amidase	B
and	O
CsbB	B
may	O
function	O
in	O
peptidoglycan	O
synthesis	O
or	O
modification	O
,	O
we	O
suggest	O
that	O
sigma	B
X	I
participates	O
in	O
the	O
regulation	O
of	O
peptidoglycan	O
synthesis	O
and	O
turnover	O
.	O

One	O
of	O
two	O
osmC	B
homologs	O
in	O
Bacillus	O
subtilis	O
is	O
part	O
of	O
the	O
sigmaB	B
-	O
dependent	O
general	O
stress	O
regulon	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
identification	O
and	O
analysis	O
of	O
two	O
Bacillus	O
subtilis	O
genes	O
,	O
yklA	B
and	O
ykzA	B
,	O
which	O
are	O
homologous	O
to	O
the	O
partially	O
RpoS	B
-	O
controlled	O
osmC	B
gene	O
from	O
Escherichia	O
coli	O
.	O

The	O
yklA	B
gene	O
is	O
expressed	O
at	O
higher	O
levels	O
in	O
minimal	O
medium	O
than	O
in	O
rich	O
medium	O
and	O
is	O
driven	O
by	O
a	O
putative	O
vegetative	O
promoter	O
.	O

Expression	O
of	O
ykzA	B
is	O
not	O
medium	O
dependent	O
but	O
increases	O
dramatically	O
when	O
cells	O
are	O
exposed	O
to	O
stress	O
and	O
starvation	O
.	O

This	O
stress	O
-	O
induced	O
increase	O
in	O
ykzA	B
expression	O
is	O
absolutely	O
dependent	O
on	O
the	O
alternative	O
sigma	B
factor	I
sigmaB	B
,	O
which	O
controls	O
a	O
large	O
stationary	O
-	O
phase	O
and	O
stress	O
regulon	O
.	O

ykzA	B
is	O
therefore	O
another	O
example	O
of	O
a	O
gene	O
common	O
to	O
the	O
RpoS	B
and	O
sigmaB	B
stress	O
regulons	O
of	O
E.	O
coli	O
and	O
B.	O
subtilis	O
,	O
respectively	O
.	O

The	O
composite	O
complex	O
expression	O
pattern	O
of	O
the	O
two	O
B.	O
subtilis	O
genes	O
is	O
very	O
similar	O
to	O
the	O
expression	O
profile	O
of	O
osmC	B
in	O
E.	O
coli	O
.	O

A	O
molecular	O
switch	O
controlling	O
competence	O
and	O
motility	O
:	O
competence	O
regulatory	O
factors	O
ComS	B
,	O
MecA	B
,	O
and	O
ComK	B
control	O
sigmaD	B
-	O
dependent	O
gene	O
expression	O
in	O
Bacillus	O
subtilis	O
.	O

Bacillus	O
subtilis	O
,	O
like	O
many	O
bacteria	O
,	O
will	O
choose	O
among	O
several	O
response	O
pathways	O
when	O
encountering	O
a	O
stressful	O
environment	O
.	O

Among	O
the	O
processes	O
activated	O
under	O
growth	O
-	O
restricting	O
conditions	O
are	O
sporulation	O
,	O
establishment	O
of	O
motility	O
,	O
and	O
competence	O
development	O
.	O

Recent	O
reports	O
implicate	O
ComK	B
and	O
MecA	B
-	O
ClpC	B
as	O
part	O
of	O
a	O
system	O
that	O
regulates	O
both	O
motility	O
and	O
competence	O
development	O
.	O

MecA	B
,	O
while	O
negatively	O
controlling	O
competence	O
by	O
inhibiting	O
ComK	B
,	O
stimulates	O
sigmaD	B
-	O
dependent	O
transcription	O
of	O
genes	O
that	O
function	O
in	O
motility	O
and	O
autolysin	B
production	O
.	O

Both	O
ComK	B
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
have	O
been	O
proposed	O
for	O
MecA	B
's	O
role	O
in	O
the	O
regulation	O
of	O
motility	O
.	O

Mutations	O
in	O
mecA	B
reduce	O
the	O
transcription	O
of	O
hag	B
.	O

encoding	O
flagellin	B
,	O
and	O
are	O
partially	O
suppressed	O
by	O
comK	B
in	O
both	O
medium	O
promoting	O
motility	O
and	O
medium	O
promoting	O
competence	O
.	O

Reduced	O
sigmaD	B
levels	O
are	O
observed	O
in	O
mecA	B
mutants	O
grown	O
in	O
competence	O
medium	O
,	O
but	O
no	O
change	O
in	O
sigmaD	B
concentration	O
is	O
detected	O
in	O
a	O
comK	B
mutant	O
.	O

The	O
comF	B
operon	I
,	O
transcription	O
of	O
which	O
requires	O
ComK	B
,	O
is	O
located	O
immediately	O
upstream	O
of	O
the	O
operon	O
that	O
contains	O
the	O
flgM	B
gene	O
,	O
encoding	O
the	O
sigmaD	B
-	O
specific	O
antisigma	B
factor	I
.	O

An	O
insertion	O
mutation	O
that	O
disrupts	O
the	O
putative	O
comF	B
-	O
flgM	B
transcription	O
unit	O
confers	O
a	O
phenotype	O
identical	O
to	O
that	O
of	O
the	O
comK	B
mutant	O
with	O
respect	O
to	O
hag	B
-	O
lacZ	B
expression	O
.	O

Expression	O
of	O
a	O
flgM	B
-	O
lacZ	B
operon	O
fusion	O
is	O
reduced	O
in	O
both	O
sigD	B
and	O
comK	B
mutant	O
cells	O
but	O
is	O
abolished	O
in	O
the	O
sigD	B
comK	B
double	O
mutant	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
examination	O
of	O
the	O
comF	B
-	O
flgM	B
transcript	O
indicates	O
that	O
readthrough	O
from	O
comF	B
into	O
the	O
flgM	B
operon	O
is	O
dependent	O
on	O
ComK	B
.	O

ComK	B
negatively	O
controls	O
the	O
transcription	O
of	O
hag	B
by	O
stimulating	O
the	O
transcription	O
of	O
comF	B
-	O
flgM	B
,	O
thereby	O
increasing	O
the	O
production	O
of	O
the	O
FlgM	B
antisigma	B
factor	I
that	O
inhibits	O
sigmaD	B
activity	O
.	O

There	O
likely	O
exists	O
another	O
comK	B
-	O
independent	O
mechanism	O
of	O
hag	B
transcription	O
that	O
requires	O
mecA	B
and	O
possibly	O
affects	O
the	O
sigmaD	B
concentration	O
in	O
cells	O
undergoing	O
competence	O
development	O
.	O

Herpesvirus	B
entry	I
mediator	I
ligand	I
(	O
HVEM	B
-	I
L	I
)	O
,	O
a	O
novel	O
ligand	O
for	O
HVEM	B
/	O
TR2	B
,	O
stimulates	O
proliferation	O
of	O
T	O
cells	O
and	O
inhibits	O
HT29	O
cell	O
growth	O
.	O

Herpesvirus	B
entry	I
mediator	I
(	O
HVEM	B
)	O
,	O
a	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
receptor	I
family	I
,	O
mediates	O
herpesvirus	O
entry	O
into	O
cells	O
during	O
infection	O
.	O

Upon	O
overexpression	O
,	O
HVEM	B
activates	O
NF	B
-	I
kappaB	I
and	O
AP-1	B
through	O
a	O
TNF	B
receptor	I
-	I
associated	I
factor	I
(	O
TRAF	B
)	O
-	O
mediated	O
mechanism	O
.	O

Using	O
an	O
HVEM	B
-	O
Fc	O
fusion	O
protein	O
,	O
we	O
screened	O
soluble	O
forms	O
of	O
novel	O
TNF	B
-	O
related	O
proteins	O
derived	O
from	O
an	O
expressed	O
sequence	O
tag	O
data	O
base	O
.	O

One	O
of	O
these	O
,	O
which	O
we	O
designated	O
HVEM	B
-	I
L	I
,	O
specifically	O
bound	O
to	O
HVEM	B
-	O
Fc	O
with	O
an	O
affinity	O
of	O
44	O
nM	O
.	O

This	O
association	O
was	O
confirmed	O
with	O
soluble	O
and	O
membrane	O
forms	O
of	O
both	O
receptor	O
and	O
ligand	O
.	O

HVEM	B
-	I
L	I
mRNA	O
is	O
expressed	O
in	O
spleen	O
,	O
lymph	O
nodes	O
,	O
macrophages	O
,	O
and	O
T	O
cells	O
and	O
encodes	O
a	O
240	O
-	O
amino	O
acid	O
protein	O
.	O

A	O
soluble	O
,	O
secreted	O
form	O
of	O
the	O
protein	O
stimulates	O
proliferation	O
of	O
T	O
lymphocytes	O
during	O
allogeneic	O
responses	O
,	O
inhibits	O
HT-29	O
cell	O
growth	O
,	O
and	O
weakly	O
stimulates	O
NF	B
-	I
kappaB	I
-	O
dependent	O
transcription	O
.	O

De	O
novo	O
fatty	O
acid	O
synthesis	O
is	O
required	O
for	O
establishment	O
of	O
cell	O
type	O
-	O
specific	O
gene	O
transcription	O
during	O
sporulation	O
in	O
Bacillus	O
subtilis	O
.	O

A	O
hallmark	O
of	O
sporulation	O
of	O
Bacillus	O
subtilis	O
is	O
the	O
formation	O
of	O
two	O
distinct	O
cells	O
by	O
an	O
asymmetric	O
septum	O
.	O

The	O
developmental	O
programme	O
of	O
these	O
two	O
cells	O
involves	O
the	O
compartmentalized	O
activities	O
of	O
sigmaE	B
in	O
the	O
larger	O
mother	O
cell	O
and	O
of	O
sigmaF	B
in	O
the	O
smaller	O
prespore	O
.	O

A	O
potential	O
role	O
of	O
de	O
novo	O
lipid	O
synthesis	O
on	O
development	O
was	O
investigated	O
by	O
treating	O
B.	O
subtilis	O
cells	O
with	O
cerulenin	O
,	O
a	O
specific	O
inhibitor	O
of	O
fatty	O
acid	O
biosynthesis	O
.	O

These	O
experiments	O
demonstrated	O
that	O
spore	O
formation	O
requires	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
at	O
the	O
onset	O
of	O
sporulation	O
.	O

The	O
transcription	O
of	O
the	O
sporulation	O
genes	O
that	O
are	O
induced	O
before	O
the	O
formation	O
of	O
two	O
cell	O
types	O
or	O
that	O
are	O
under	O
the	O
exclusive	O
control	O
of	O
sigmaF	B
occurred	O
in	O
the	O
absence	O
of	O
fatty	O
acid	O
synthesis	O
,	O
as	O
monitored	O
by	O
spo	B
-	O
lacZ	B
fusions	O
.	O

However	O
,	O
expression	O
of	O
lacZ	B
fusions	O
to	O
genes	O
that	O
required	O
activation	O
of	O
sigmaE	B
for	O
transcription	O
was	O
inhibited	O
in	O
the	O
absence	O
of	O
fatty	O
acid	O
synthesis	O
.	O

The	O
block	O
in	O
sigmaE	B
-	O
directed	O
gene	O
expression	O
in	O
cerulenin	O
-	O
treated	O
cells	O
was	O
caused	O
by	O
an	O
inability	O
to	O
process	O
pro	O
-	O
sigmaE	B
to	O
its	O
active	O
form	O
.	O

Electron	O
microscopy	O
revealed	O
that	O
these	O
fatty	O
acid	O
-	O
starved	O
cells	O
initiate	O
abnormal	O
polar	O
septation	O
,	O
suggesting	O
that	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
may	O
be	O
essential	O
to	O
couple	O
the	O
activation	O
of	O
the	O
mother	O
cell	O
transcription	B
factors	I
with	O
the	O
formation	O
of	O
the	O
differentiating	O
cells	O
.	O

Oncoprotein	O
TLS	B
interacts	O
with	O
serine	O
-	O
arginine	O
proteins	O
involved	O
in	O
RNA	O
splicing	O
.	O

The	O
gene	O
encoding	O
the	O
human	O
TLS	B
protein	O
,	O
also	O
termed	O
FUS	B
,	O
is	O
located	O
at	O
the	O
site	O
of	O
chromosomal	O
translocations	O
in	O
human	O
leukemias	O
and	O
sarcomas	O
where	O
it	O
forms	O
a	O
chimeric	O
fusion	O
gene	O
with	O
one	O
of	O
several	O
different	O
genes	O
.	O

To	O
identify	O
interacting	O
partners	O
of	O
TLS	B
,	O
we	O
screened	O
a	O
yeast	O
two	O
-	O
hybrid	O
cDNA	O
library	O
constructed	O
from	O
mouse	O
hematopoietic	O
cells	O
using	O
the	O
C	O
-	O
terminal	O
region	O
of	O
TLS	B
in	O
the	O
bait	O
plasmid	O
.	O

Two	O
cDNAs	O
encoding	O
members	O
of	O
the	O
serine	O
-	O
arginine	O
(	O
SR	O
)	O
family	O
of	O
proteins	O
were	O
isolated	O
.	O

The	O
first	O
SR	O
protein	O
is	O
the	O
mouse	O
homolog	O
of	O
human	O
splicing	B
factor	I
SC35	B
,	O
and	O
the	O
second	O
SR	O
member	O
is	O
a	O
novel	O
183-amino	O
acid	O
protein	O
that	O
we	O
term	O
TASR	B
(	O
TLS	B
-	I
associated	I
serine	I
-	I
arginine	I
protein	I
)	O
.	O

cDNA	O
cloning	O
of	O
human	O
TASR	B
indicated	O
that	O
mouse	O
and	O
human	O
TASR	B
have	O
identical	O
amino	O
acid	O
sequences	O
.	O

The	O
interactions	O
between	O
TLS	B
and	O
these	O
two	O
SR	O
proteins	O
were	O
confirmed	O
by	O
co	O
-	O
transfection	O
and	O
immunoprecipitation	O
studies	O
.	O

In	O
vivo	O
splicing	O
assays	O
indicated	O
that	O
SC35	B
and	O
TASR	B
influence	O
splice	O
site	O
selection	O
of	O
adenovirus	O
E1A	B
pre	O
-	O
mRNA	O
.	O

TLS	B
may	O
recruit	O
SR	O
splicing	O
factors	O
to	O
specific	O
target	O
genes	O
through	O
interaction	O
with	O
its	O
C	O
-	O
terminal	O
region	O
,	O
and	O
chromosomal	O
translocations	O
that	O
truncate	O
the	O
C	O
-	O
terminal	O
region	O
of	O
TLS	B
may	O
prevent	O
this	O
interaction	O
.	O

Thus	O
TLS	B
translocations	O
may	O
alter	O
RNA	O
processing	O
and	O
play	O
a	O
role	O
in	O
malignant	O
transformation	O
.	O

Molecular	O
cloning	O
of	O
the	O
oncofetal	O
isoform	O
of	O
the	O
human	O
pancreatic	O
bile	B
salt	I
-	I
dependent	I
lipase	I
.	O

Specific	O
transcripts	O
for	O
bile	B
salt	I
-	I
dependent	I
lipase	I
(	O
BSDL	B
)	O
,	O
a	O
100	O
-	O
kDa	O
glycoprotein	O
secreted	O
by	O
the	O
human	O
pancreas	O
,	O
were	O
immunodetected	O
in	O
BxPC-3	O
and	O
SOJ-6	O
pancreatic	O
tumoral	O
cell	O
lines	O
.	O

Sequencing	O
of	O
fragments	O
,	O
obtained	O
by	O
mRNA	O
reverse	O
transcription	O
and	O
amplification	O
,	O
confirmed	O
the	O
presence	O
of	O
BSDL	B
transcripts	O
in	O
these	O
cancer	O
cells	O
.	O

The	O
protein	O
was	O
detected	O
in	O
lysates	O
of	O
pancreatic	O
tumoral	O
cells	O
,	O
where	O
it	O
was	O
mainly	O
associated	O
with	O
membranes	O
.	O

Only	O
a	O
minute	O
amount	O
of	O
the	O
enzyme	O
was	O
detected	O
in	O
the	O
culture	O
media	O
.	O

Immunofluorescence	O
studies	O
demonstrated	O
that	O
in	O
SOJ-6	O
cells	O
,	O
BSDL	B
colocates	O
with	O
the	O
p58	O
Golgi	O
protein	O
and	O
suggested	O
that	O
the	O
protein	O
may	O
be	O
sequestrated	O
within	O
the	O
Golgi	O
compartment	O
.	O

These	O
results	O
demonstrated	O
that	O
BSDL	B
is	O
expressed	O
in	O
human	O
pancreatic	O
tumoral	O
cells	O
and	O
can	O
not	O
be	O
secreted	O
(	O
or	O
for	O
the	O
least	O
very	O
poorly	O
)	O
.	O

Subsequently	O
,	O
a	O
cDNA	O
covering	O
the	O
entire	O
sequence	O
of	O
BSDL	B
was	O
obtained	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

The	O
sequence	O
of	O
this	O
cDNA	O
indicated	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
encoded	O
by	O
exons	O
1	O
-	O
10	O
was	O
identical	O
to	O
that	O
of	O
BSDL	B
expressed	O
by	O
the	O
human	O
normal	O
pancreas	O
.	O

However	O
,	O
the	O
sequence	O
corresponding	O
to	O
exon	O
11	O
,	O
which	O
should	O
code	O
for	O
the	O
16	O
tandem	O
-	O
repeated	O
identical	O
mucin	B
-	O
like	O
sequences	O
of	O
BSDL	B
,	O
was	O
deleted	O
by	O
330	O
base	O
pairs	O
(	O
bp	O
)	O
and	O
encoded	O
only	O
6	O
of	O
these	O
repeated	O
sequences	O
.	O

We	O
conclude	O
that	O
this	O
truncated	O
variant	O
of	O
BSDL	B
would	O
be	O
its	O
oncofetal	O
form	O
,	O
referred	O
to	O
as	O
feto	O
-	O
acinar	O
pancreatic	O
protein	O
.	O

We	O
then	O
investigated	O
whether	O
the	O
deletion	O
of	O
330	O
bp	O
affected	O
the	O
secretion	O
of	O
the	O
protein	O
.	O

For	O
this	O
purpose	O
,	O
the	O
cDNA	O
corresponding	O
to	O
the	O
mature	O
form	O
of	O
the	O
BSDL	B
variant	O
expressed	O
in	O
SOJ-6	O
cells	O
was	O
cloned	O
into	O
an	O
expression	O
/	O
secretion	O
vector	O
and	O
transfected	O
into	O
CHO	O
-	O
K1	O
cells	O
.	O

Results	O
indicated	O
that	O
the	O
variant	O
of	O
BSDL	B
isolated	O
from	O
SOJ-6	O
cells	O
was	O
expressed	O
and	O
secreted	O
by	O
transfected	O
cells	O
.	O

However	O
,	O
the	O
level	O
of	O
BSDL	B
secreted	O
by	O
these	O
transfected	O
CHO	O
-	O
K1	O
cells	O
was	O
significantly	O
higher	O
than	O
that	O
observed	O
for	O
SOJ-6	O
cells	O
.	O

Consequently	O
,	O
the	O
retention	O
of	O
the	O
oncofetal	O
variant	O
of	O
BSDL	B
observed	O
in	O
human	O
pancreatic	O
tumoral	O
cells	O
might	O
not	O
result	O
from	O
inherent	O
properties	O
of	O
the	O
protein	O
.	O

Differential	O
binding	O
to	O
HLA	B
-	I
C	I
of	O
p50	B
-	O
activating	O
and	O
p58	B
-	O
inhibitory	O
natural	O
killer	O
cell	O
receptors	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cell	O
cytotoxicity	O
is	O
regulated	O
in	O
large	O
part	O
by	O
the	O
expression	O
of	O
NK	O
cell	O
receptors	O
able	O
to	O
bind	O
class	B
I	I
major	I
histocompatibility	I
complex	I
glycoproteins	I
.	O

The	O
receptors	O
associated	O
with	O
recognition	O
of	O
HLA	B
-	I
C	I
allospecificities	O
are	O
the	O
two	O
-	O
domain	O
Ig	B
-	O
like	O
molecules	O
,	O
p50	B
and	O
p58	B
proteins	O
,	O
with	O
highly	O
homologous	O
extracellular	O
domains	O
but	O
differing	O
in	O
that	O
they	O
have	O
either	O
an	O
activating	O
or	O
inhibitory	O
function	O
,	O
respectively	O
,	O
depending	O
on	O
the	O
transmembrane	O
domain	O
and	O
cytoplasmic	O
tails	O
that	O
they	O
possess	O
.	O

We	O
have	O
compared	O
the	O
binding	O
to	O
HLA	B
-	I
Cw7	I
of	O
an	O
inhibitory	O
p58	B
molecule	O
,	O
NKAT2	B
,	O
the	O
highly	O
homologous	O
activating	O
p50	B
molecule	O
,	O
clone	B
49	I
,	O
and	O
a	O
second	O
activating	O
p50	B
molecule	O
,	O
clone	B
39	I
,	O
which	O
has	O
homologies	O
to	O
both	O
NKAT1	B
and	O
NKAT2	B
.	O

NKAT2	B
binds	O
to	O
HLA	B
-	I
Cw7	I
with	O
very	O
rapid	O
association	O
and	O
dissociation	O
rates	O
.	O

However	O
,	O
the	O
p50	B
receptors	O
bind	O
only	O
very	O
weakly	O
,	O
if	O
at	O
all	O
,	O
to	O
HLA	B
-	I
C	I
.	O

The	O
molecular	O
basis	O
of	O
this	O
difference	O
is	O
analyzed	O
,	O
and	O
the	O
functional	O
significance	O
of	O
these	O
observations	O
is	O
discussed	O
.	O

The	O
first	O
gene	O
of	O
the	O
Bacillus	O
subtilis	O
clpC	B
operon	O
,	O
ctsR	B
,	O
encodes	O
a	O
negative	O
regulator	O
of	O
its	O
own	O
operon	O
and	O
other	O
class	B
III	I
heat	I
shock	I
genes	I
.	O

The	O
Bacillus	O
subtilis	O
clpC	B
operon	O
is	O
regulated	O
by	O
two	O
stress	O
induction	O
pathways	O
relying	O
on	O
either	O
sigmaB	B
or	O
a	O
class	O
III	O
stress	O
induction	O
mechanism	O
acting	O
at	O
a	O
sigmaA	B
-	O
like	O
promoter	O
.	O

When	O
the	O
clpC	B
operon	O
was	O
placed	O
under	O
the	O
control	O
of	O
the	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactopyranoside	O
(	O
IPTG	O
)	O
-	O
inducible	O
Pspac	O
promoter	O
,	O
dramatic	O
repression	O
of	O
the	O
natural	O
clpC	B
promoters	O
fused	O
to	O
a	O
lacZ	B
reporter	O
gene	O
was	O
noticed	O
after	O
IPTG	O
induction	O
.	O

This	O
result	O
strongly	O
indicated	O
negative	O
regulation	O
of	O
the	O
clpC	B
operon	O
by	O
one	O
of	O
its	O
gene	O
products	O
.	O

Indeed	O
,	O
the	O
negative	O
regulator	O
could	O
be	O
identified	O
which	O
is	O
encoded	O
by	O
the	O
first	O
gene	O
of	O
the	O
clpC	B
operon	O
,	O
ctsR	B
,	O
containing	O
a	O
predicted	O
helix	O
-	O
turn	O
-	O
helix	O
DNA	O
-	O
binding	O
motif	O
.	O

Deletion	O
of	O
ctsR	B
abolished	O
the	O
negative	O
regulation	O
and	O
resulted	O
in	O
high	O
expression	O
of	O
both	O
the	O
clpC	B
operon	O
and	O
the	O
clpP	B
gene	O
under	O
nonstressed	O
conditions	O
.	O

Nevertheless	O
,	O
a	O
further	O
increase	O
in	O
clpC	B
and	O
clpP	B
mRNA	O
levels	O
was	O
observed	O
after	O
heat	O
shock	O
,	O
even	O
in	O
the	O
absence	O
of	O
sigmaB	B
,	O
suggesting	O
a	O
second	O
induction	O
mechanism	O
at	O
the	O
vegetative	O
promoter	O
.	O

Two	O
-	O
dimensional	O
gel	O
analysis	O
and	O
mRNA	O
studies	O
showed	O
that	O
the	O
expression	O
of	O
other	O
class	O
III	O
stress	O
genes	O
was	O
at	O
least	O
partially	O
influenced	O
by	O
the	O
ctsR	B
deletion	O
.	O

Studies	O
with	O
different	O
clpC	B
promoter	O
fragments	O
either	O
fused	O
to	O
the	O
reporter	O
gene	O
bgaB	B
or	O
used	O
in	O
gel	O
mobility	O
shift	O
experiments	O
with	O
the	O
purified	O
CtsR	B
protein	O
revealed	O
a	O
possible	O
target	O
region	O
where	O
the	O
repressor	O
seemed	O
to	O
bind	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
CtsR	B
protein	O
acts	O
as	O
a	O
global	O
repressor	O
of	O
the	O
clpC	B
operon	O
,	O
as	O
well	O
as	O
other	O
class	O
III	O
heat	O
shock	O
genes	O
,	O
by	O
preventing	O
unstressed	O
transcription	O
from	O
either	O
the	O
sigmaB	B
-	O
or	O
sigmaA	B
-	O
dependent	O
promoter	O
and	O
might	O
be	O
inactivated	O
or	O
dissociate	O
under	O
inducing	O
stress	O
conditions	O
.	O

Cloning	O
and	O
characterization	O
of	O
RLPK	B
,	O
a	O
novel	O
RSK	B
-	O
related	O
protein	B
kinase	I
.	O

A	O
novel	O
protein	B
kinase	I
whose	O
activity	O
can	O
be	O
stimulated	O
by	O
mitogen	O
in	O
vivo	O
was	O
cloned	O
and	O
characterized	O
.	O

The	O
cDNA	O
of	O
this	O
gene	O
encodes	O
an	O
802-amino	O
acid	O
protein	O
(	O
termed	O
RLPK	B
)	O
with	O
the	O
highest	O
homology	O
(	O
37	O
%	O
identity	O
)	O
to	O
the	O
two	O
protein	B
kinase	I
families	O
,	O
p90	B
(	I
RSK	I
)	I
and	O
p70	B
(	I
RSK	I
)	I
.	O

Like	O
p90	B
(	I
RSR	I
)	I
,	O
but	O
not	O
p70	B
(	I
RSK	I
)	I
,	O
RLPK	B
also	O
contains	O
two	O
complete	O
nonidentical	O
protein	B
kinase	I
domains	O
.	O

RLPK	B
mRNA	O
is	O
widely	O
expressed	O
in	O
all	O
human	O
tissues	O
examined	O
and	O
is	O
enriched	O
in	O
the	O
brain	O
,	O
heart	O
,	O
and	O
placenta	O
.	O

In	O
HeLa	O
cells	O
,	O
transiently	O
expressed	O
epitope	O
-	O
tagged	O
RLPK	B
can	O
be	O
strongly	O
induced	O
by	O
epidermal	B
growth	I
factor	I
,	O
serum	O
,	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
but	O
only	O
moderately	O
up	O
-	O
regulated	O
by	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
other	O
stress	O
-	O
related	O
stimuli	O
.	O

The	O
activity	O
of	O
RLPK	B
stimulated	O
by	O
epidermal	B
growth	I
factor	I
was	O
not	O
inhibited	O
by	O
several	O
known	O
protein	B
kinase	I
C	I
inhibitors	O
nor	O
by	O
rapamycin	O
,	O
a	O
known	O
specific	O
inhibitor	O
for	O
p70	B
(	I
RSK	I
)	I
,	O
but	O
could	O
be	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
tyrosine	B
kinase	I
inhibitor	O
,	O
and	O
partially	O
inhibited	O
by	O
PD98059	O
or	O
SB203580	O
,	O
inhibitors	O
for	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathways	O
.	O

Recombinant	O
RLPK	B
possesses	O
high	O
phosphorylation	O
activity	O
toward	O
histone	B
2B	I
and	O
the	O
S6	O
peptide	O
,	O
RRRLSSLRA	O
.	O

Although	O
purified	O
recombinant	O
RLPK	B
can	O
be	O
phosphorylated	O
by	O
ERK2	B
and	O
p38alpha	B
in	O
vitro	O
,	O
its	O
activity	O
is	O
not	O
affected	O
by	O
this	O
phosphorylation	O
.	O

Moreover	O
,	O
the	O
treatment	O
of	O
RLPK	B
with	O
acid	B
phosphatase	I
did	O
not	O
reduce	O
its	O
in	O
vitro	O
kinase	B
activity	O
.	O

These	O
data	O
suggest	O
that	O
RLPK	B
is	O
structurally	O
similar	O
to	O
previously	O
isolated	O
RSKs	B
,	O
but	O
its	O
regulatory	O
mechanism	O
may	O
be	O
distinct	O
from	O
either	O
p70	B
(	I
RSK	I
)	I
or	O
p90	B
(	I
RSK	I
)	I
s	I
.	O

Multiple	O
transcripts	O
of	O
the	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptor	I
family	I
,	O
KIR3DL1	B
(	O
NKB1	B
)	O
,	O
are	O
expressed	O
by	O
natural	O
killer	O
cells	O
of	O
a	O
single	O
individual	O
.	O

Natural	O
killer	O
(	O
NK	O
)	O
cells	O
express	O
receptors	O
that	O
are	O
ligands	O
for	O
HLA	B
class	I
I	I
molecules	O
.	O

One	O
family	O
of	O
such	O
NK	O
receptors	O
are	O
called	O
killer	B
cell	I
immunoglobulin	I
-	I
like	I
receptors	I
(	O
KIR	B
)	O
.	O

The	O
KIR2DL	B
(	O
inhibiting	O
)	O
and	O
KIR2DS	B
(	O
activating	O
)	O
molecules	O
recognize	O
HLA	B
-	I
Cw	I
antigens	O
,	O
while	O
the	O
KIR3DL	B
(	O
inhibiting	O
)	O
and	O
KIR3DS	B
(	O
activating	O
)	O
molecules	O
interact	O
with	O
HLA	B
-	I
B	I
antigens	O
with	O
the	O
Bw4	B
epitope	O
.	O

No	O
NK	O
receptors	O
have	O
yet	O
been	O
identified	O
for	O
HLA	B
-	I
B	I
antigens	O
with	O
the	O
Bw6	B
epitope	O
.	O

We	O
here	O
report	O
four	O
novel	O
full	O
length	O
cDNA	O
transcripts	O
encoding	O
KIR3DL1	B
-	O
like	O
proteins	O
isolated	O
from	O
mRNA	O
obtained	O
from	O
interleukin-2	B
-	O
activated	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
a	O
donor	O
with	O
two	O
HLA	B
-	I
B	I
antigens	O
expressing	O
the	O
Bw6	B
epitope	O
.	O

These	O
four	O
transcripts	O
belong	O
to	O
a	O
group	O
of	O
closely	O
related	O
KIR3DL1	B
-	O
like	O
molecules	O
initially	O
defined	O
by	O
the	O
cDNA	O
clone	O
NKB1	B
.	O

They	O
differ	O
from	O
NKB1	B
by	O
only	O
2	O
to	O
7	O
nucleotides	O
and	O
have	O
2	O
to	O
4	O
codon	O
changes	O
within	O
the	O
423	O
residues	O
of	O
the	O
mature	O
protein	O
.	O

All	O
transcripts	O
were	O
detected	O
by	O
RT	O
-	O
PCR	O
,	O
together	O
with	O
the	O
previously	O
reported	O
KIR3DL1	B
transcripts	O
,	O
NKB1	B
and	O
KIR3DL1v	B
,	O
in	O
mRNA	O
from	O
NK	O
cells	O
of	O
10	O
of	O
10	O
donors	O
tested	O
,	O
and	O
in	O
seven	O
of	O
eight	O
NK	O
clones	O
derived	O
from	O
one	O
donor	O
.	O

Functionally	O
,	O
the	O
KIR3DL1	B
receptors	O
expressed	O
by	O
five	O
DX9	O
-	O
positive	O
NK	O
clones	O
were	O
not	O
inhibiting	O
NK	O
-	O
mediated	O
cytotoxicity	O
when	O
tested	O
against	O
the	O
721.221	O
B	O
-	O
lymphoblastoid	O
cell	O
line	O
expressing	O
a	O
HLA	B
-	I
B	I
antigen	O
with	O
Bw4	B
epitope	O
.	O

All	O
NK	O
clones	O
were	O
,	O
however	O
,	O
inhibited	O
by	O
721.221	O
cells	O
transfected	O
with	O
a	O
HLA	B
-	I
B	I
antigen	O
carrying	O
the	O
Bw6	B
epitope	O
.	O

A	O
four	O
-	O
dimensional	O
view	O
of	O
assembly	O
of	O
a	O
morphogenetic	O
protein	O
during	O
sporulation	O
in	O
Bacillus	O
subtilis	O
.	O

We	O
report	O
the	O
use	O
of	O
a	O
fusion	O
to	O
the	O
green	B
fluorescent	I
protein	I
to	O
visualize	O
the	O
assembly	O
of	O
the	O
morphogenetic	O
protein	O
SpoIVA	B
around	O
the	O
developing	O
forespore	O
during	O
the	O
process	O
of	O
sporulation	O
in	O
the	O
bacterium	O
Bacillus	O
subtilis	O
.	O

Using	O
a	O
deconvolution	O
algorithm	O
to	O
process	O
digitally	O
-	O
collected	O
optical	O
sections	O
,	O
we	O
show	O
that	O
SpoIVA	B
,	O
which	O
is	O
synthesized	O
in	O
the	O
mother	O
cell	O
chamber	O
of	O
the	O
sporangium	O
,	O
assembled	O
into	O
a	O
spherical	O
shell	O
around	O
the	O
outer	O
surface	O
of	O
the	O
forespore	O
.	O

Time	O
-	O
lapse	O
fluorescence	O
microscopy	O
showed	O
that	O
this	O
assembly	O
process	O
commenced	O
at	O
the	O
time	O
of	O
polar	O
division	O
and	O
seemed	O
to	O
continue	O
after	O
engulfment	O
of	O
the	O
forespore	O
was	O
complete	O
.	O

SpoIVA	B
remained	O
present	O
throughout	O
the	O
late	O
stages	O
of	O
morphogenesis	O
and	O
was	O
present	O
as	O
a	O
component	O
of	O
the	O
fully	O
mature	O
spore	O
.	O

Evidence	O
indicates	O
that	O
assembly	O
of	O
SpoIVA	B
depended	O
on	O
the	O
extreme	O
C	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
and	O
an	O
additional	O
region	O
that	O
directly	O
or	O
indirectly	O
facilitated	O
interaction	O
among	O
SpoIVA	B
molecules	O
.	O

The	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
of	O
SpoIVA	B
,	O
including	O
the	O
extreme	O
C	O
terminus	O
,	O
are	O
highly	O
similar	O
to	O
the	O
corresponding	O
regions	O
of	O
the	O
homologous	O
protein	O
from	O
the	O
distantly	O
related	O
endospore	O
-	O
forming	O
bacterium	O
Clostridium	O
acetobutylicum	O
,	O
attesting	O
to	O
their	O
importance	O
in	O
the	O
function	O
of	O
the	O
protein	O
.	O

Finally	O
,	O
we	O
show	O
that	O
proper	O
localization	O
of	O
SpoIVA	B
required	O
the	O
expression	O
of	O
one	O
or	O
more	O
genes	O
which	O
,	O
like	O
spoIVA	B
,	O
are	O
under	O
the	O
control	O
of	O
the	O
mother	O
cell	O
transcription	B
factor	I
sigmaE	B
.	O

One	O
such	O
gene	O
was	O
spoVM	B
,	O
whose	O
product	O
was	O
required	O
for	O
efficient	O
targeting	O
of	O
SpoIVA	B
to	O
the	O
outer	O
surface	O
of	O
the	O
forespore	O
.	O

